FN Clarivate Analytics Web of Science
VR 1.0
PT S
AU Zou, ZL
   Wang, HJ
   Uquillas, FD
   Wang, XM
   Ding, JR
   Chen, H
AF Zou, Zhiling
   Wang, Huijun
   Uquillas, Federico d'Oleire
   Wang, Xiaomei
   Ding, Jianrui
   Chen, Hong
BE Zhang, X
   Shi, J
   Tao, R
TI Definition of Substance and Non-substance Addiction
SO SUBSTANCE AND NON-SUBSTANCE ADDICTION
SE Advances in Experimental Medicine and Biology
LA English
DT Article; Book Chapter
DE Substance addiction; Drug addiction; Behavioral addiction; Non-substance
   addiction; Pathological gambling; Food addiction; Internet addiction;
   Mobile phone addiction
ID FOOD-ADDICTION; MOBILE PHONE; PRELIMINARY VALIDATION; SMARTPHONE
   ADDICTION; CELLULAR PHONE; DEPENDENCE; PREVALENCE; INTERNET; MODEL;
   SCALE
AB Substance addiction (or drug addiction) is a neuropsychiatric disorder characterized by a recurring desire to continue taking the drug despite harmful consequences. Non-substance addiction (or behavioral addiction) covers pathological gambling, food addiction, internet addiction, and mobile phone addiction. Their definition is similar to drug addiction but they differ from each other in specific domains. This review aims to provide a brief overview of past and current definitions of substance and non-substance addiction, and also touches on the topic of diagnosing drug addiction and non-drug addiction, ultimately aiming to further the understanding of the key concepts needed for a foundation to study the biological and psychological underpinnings of addiction disorders.
C1 [Zou, Zhiling; Wang, Huijun; Wang, Xiaomei; Ding, Jianrui; Chen, Hong] Southwest Univ, Fac Psychol, Chongqing, Peoples R China.
   [Uquillas, Federico d'Oleire] Massachusetts Gen Hosp, Harvard Med Sch, Dept Neurol, Boston, MA USA.
C3 Southwest University - China; Harvard University; Harvard Medical
   School; Massachusetts General Hospital
RP Zou, ZL (通讯作者)，Southwest Univ, Fac Psychol, Chongqing, Peoples R China.
EM zouzl@swu.edu.cn
RI Wang, Hui/HMU-9512-2023; wang, xiao/HZI-9156-2023; wang,
   hao/HSE-7975-2023; wang, huimin/HDM-8421-2022; wang, hui/GRS-4730-2022
OI d'Oleire Uquillas, Federico/0000-0001-9078-9452; Zou,
   Zhiling/0000-0003-4497-2947
CR American Psychiatric Association, 1968, DIAGN STAT MAN MENT, V2nd
   American Psychiatric Association [APA], 2022, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425787]
   Armstrong L, 2001, VIBRANT LIFE, V17, P15
   Association AP, 2000, DIAGNOSTIC STAT MANU, DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]
   Augner C, 2012, INT J PUBLIC HEALTH, V57, P437, DOI 10.1007/s00038-011-0234-z
   Bak-Sosnowska M, 2017, PSYCHIATR POL, V51, P247, DOI 10.12740/PP/OnlineFirst/62824
   Bianchi A, 2005, CYBERPSYCHOL BEHAV, V8, P39, DOI 10.1089/cpb.2005.8.39
   Billieux J, 2016, CURR ADDICT REP, V2, P156
   Billieux J, 2007, APPL COGNITIVE PSYCH, V21, P527, DOI 10.1002/acp.1289
   Billieux J, 2012, COMPR PSYCHIAT, V53, P609, DOI 10.1016/j.comppsych.2011.09.001
   Billieux J, 2008, APPL COGNITIVE PSYCH, V22, P1195, DOI 10.1002/acp.1429
   Bouffard R, 2003, CAN J PSYCHIAT, V48, P546, DOI 10.1177/070674370304800806
   Butt S, 2008, COMPUT HUM BEHAV, V24, P346, DOI 10.1016/j.chb.2007.01.019
   Cagan O, 2014, PROCD SOC BEHV, V114, P831, DOI 10.1016/j.sbspro.2013.12.793
   Cami J, 2003, NEW ENGL J MED, V349, P975, DOI 10.1056/NEJMra023160
   Chen JW, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00511
   Chen S.-H., 2003, CHINESE J PSYCHOL, V45, P279, DOI [10.1037/t44491-000, DOI 10.1037/T44491-000]
   Ching SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139337
   Chiu SI, 2014, COMPUT HUM BEHAV, V34, P49, DOI 10.1016/j.chb.2014.01.024
   Corsica JA, 2010, CURR OPIN GASTROEN, V26, P165, DOI 10.1097/MOG.0b013e328336528d
   Corwin Rebecca L, 2009, J Nutr, V139, P617, DOI 10.3945/jn.108.097691
   DARCIN AE, 2015, EUR PSYCHIAT S1, V30
   Davis RA, 2001, COMPUT HUM BEHAV, V17, P187, DOI 10.1016/S0747-5632(00)00041-8
   de Vries SK, 2016, EUR EAT DISORD REV, V24, P518, DOI 10.1002/erv.2470
   DEMIRCI K, 2014, B CLIN PSYCHOPHARMAC, V24, P226, DOI DOI 10.5455/BCP.20140710040824
   EDDY NB, 1965, B WORLD HEALTH ORGAN, V32, P721
   Eddy NB, 1966, PSYCHOPHARMACOL 0703, V3, P113
   Fainsinger RL, 2006, AM J PSYCHIAT, V163, P2014, DOI 10.1176/appi.ajp.163.11.2014-a
   Fauth-Buhler M, 2017, ADDICT BIOL, V22, P885, DOI 10.1111/adb.12378
   Flint AJ, 2014, AM J CLIN NUTR, V99, P578, DOI 10.3945/ajcn.113.068965
   Fong TW, 2012, PSYCHIAT CLIN N AM, V35, P279, DOI 10.1016/j.psc.2012.03.001
   Gearhardt AN, 2016, PSYCHOL ADDICT BEHAV, V30, P113, DOI 10.1037/adb0000136
   Gearhardt AN, 2013, EAT BEHAV, V14, P508, DOI 10.1016/j.eatbeh.2013.07.002
   Gearhardt Ashley N, 2011, Curr Drug Abuse Rev, V4, P201
   Gearhardt AN, 2009, APPETITE, V52, P430, DOI 10.1016/j.appet.2008.12.003
   Goldberg I., 1996, INTERNET ADDICTION D
   Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Griffiths M, 1996, J Gambl Stud, V12, P471, DOI 10.1007/BF01539190
   Ha JH, 2008, CYBERPSYCHOL BEHAV, V11, P783, DOI 10.1089/cpb.2008.0096
   Haug S, 2015, J BEHAV ADDICT, V4, P299, DOI 10.1556/2006.4.2015.037
   Heather N, 1998, J PSYCHOPHARMACOL, V12, P3, DOI 10.1177/026988119801200101
   Hong FY, 2012, COMPUT HUM BEHAV, V28, P2152, DOI 10.1016/j.chb.2012.06.020
   Hyman SE, 2007, AM J BIOETHICS, V7, P8, DOI 10.1080/15265160601063969
   Imperatori C, 2016, RIV PSICHIATR, V51, P60, DOI 10.1708/2246.24196
   Johansson A, 2010, J PSYCHOSOM RES, V68, P37, DOI 10.1016/j.jpsychores.2009.06.009
   Khang H, 2013, COMPUT HUM BEHAV, V29, P2416, DOI 10.1016/j.chb.2013.05.027
   Kwon M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056936
   Lee U, 2014, 32ND ANNUAL ACM CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS (CHI 2014), P2327, DOI 10.1145/2556288.2557366
   Lepp A, 2014, COMPUT HUM BEHAV, V31, P343, DOI 10.1016/j.chb.2013.10.049
   Leung L, 2008, J CHILD MEDIA, V2, P93, DOI 10.1080/17482790802078565
   Lin Y, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0097838, 10.1371/journal.pone.0098312]
   [刘红 Liu Hong], 2011, [心理科学, Psychological Science], V34, P1453
   Lopez-Fernandez O, 2017, ADDICT BEHAV, V64, P275, DOI 10.1016/j.addbeh.2015.11.013
   MARKS I, 1990, BRIT J ADDICT, V85, P1389
   Merlo LJ, 2009, J ADDICT MED, V3, P26, DOI 10.1097/ADM.0b013e31819638b0
   Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   O'Brien C, 2011, ADDICTION, V106, P866, DOI 10.1111/j.1360-0443.2010.03144.x
   O'Brien CP, 2006, AM J PSYCHIAT, V163, P764, DOI 10.1176/appi.ajp.163.5.764
   Oulasvirta A, 2012, PERS UBIQUIT COMPUT, V16, P105, DOI 10.1007/s00779-011-0412-2
   Pursey KM, 2014, NUTRIENTS, V6, P4552, DOI 10.3390/nu6104552
   RANDOLPH TG, 1956, Q J STUD ALCOHOL, V17, P198
   Robbins TW, 2015, CURR OPIN NEUROBIOL, V30, P66, DOI 10.1016/j.conb.2014.09.005
   Roberts JA, 2015, PERS INDIV DIFFER, V79, P13, DOI 10.1016/j.paid.2015.01.049
   Salehan M, 2013, COMPUT HUM BEHAV, V29, P2632, DOI 10.1016/j.chb.2013.07.003
   Seo DG, 2016, COMPUT HUM BEHAV, V63, P282, DOI 10.1016/j.chb.2016.05.026
   Shaffer HJ, 1999, AM J PUBLIC HEALTH, V89, P1369, DOI 10.2105/AJPH.89.9.1369
   Shapira NA, 2000, J AFFECT DISORDERS, V57, P267, DOI 10.1016/S0165-0327(99)00107-X
   Smetaniuk P, 2014, J BEHAV ADDICT, V3, P41, DOI 10.1556/JBA.3.2014.004
   Strong DR, 2007, ADDICTION, V102, P713, DOI 10.1111/j.1360-0443.2007.01789.x
   Takao M, 2009, CYBERPSYCHOL BEHAV, V12, P501, DOI 10.1089/cpb.2009.0022
   Tan C, 2013, PROCD SOC BEHV, V103, P606, DOI 10.1016/j.sbspro.2013.10.378
   Tao R, 2008, MED J CHIN PEOPLES A, V19, P773, DOI [10.14010/j.cnki.wjyx.2008.09.028, DOI 10.14010/J.CNKI.WJYX.2008.09.028]
   Thomee S, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-66
   Toda M, 2008, SOC BEHAV PERSONAL, V36, P765, DOI 10.2224/sbp.2008.36.6.765
   van Deursen AJAM, 2015, COMPUT HUM BEHAV, V45, P411, DOI 10.1016/j.chb.2014.12.039
   Volkow ND, 2013, OBES REV, V14, P2, DOI 10.1111/j.1467-789X.2012.01031.x
   Volkow Nora D, 2012, Annu Rev Pharmacol Toxicol, V52, P321, DOI 10.1146/annurev-pharmtox-010611-134625
   Walsh SP, 2010, AUST J PSYCHOL, V62, P194, DOI 10.1080/00049530903567229
   Wang Y, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00597
   WHO, 1977, MAN INT STAT CLASS D
   World Health Organization, 2004, ACTA CHIR IUGOSL, V56, P65
   Yang HM, 2008, RES INFLUENCE INTERN
   Yen CF, 2009, J ADOLESCENCE, V32, P863, DOI 10.1016/j.adolescence.2008.10.006
   Young KS, 1996, PSYCHOL REP, V79, P899, DOI 10.2466/pr0.1996.79.3.899
   Young KS, 1997, 105 ANN M AM PSYCH A
   Zheng FZ, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1022
   Ziauddeen H, 2012, NAT REV NEUROSCI, V13, P279, DOI 10.1038/nrn3212
NR 89
TC 65
Z9 70
U1 42
U2 272
PU SPRINGER-VERLAG SINGAPORE PTE LTD
PI SINGAPORE
PA 152 BEACH ROAD, #21-01/04 GATEWAY EAST, SINGAPORE, 189721, SINGAPORE
SN 0065-2598
EI 2214-8019
BN 978-981-10-5562-1; 978-981-10-5561-4
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2017
VL 1010
BP 21
EP 41
DI 10.1007/978-981-10-5562-1_2
D2 10.1007/978-981-10-5562-1
PG 21
WC Substance Abuse; Medicine, Research & Experimental
WE Book Citation Index– Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Substance Abuse; Research & Experimental Medicine
GA BJ9IE
UT WOS:000429224300003
PM 29098666
DA 2023-06-23
ER

PT J
AU Detar, DT
AF Detar, D. Todd
TI Understanding the Disease of Addiction
SO PRIMARY CARE
LA English
DT Article
DE Drug addiction; Dopamine; Prefrontal cortex; cAMP-responsive element
   binding
ID DRUG-ADDICTION; ALCOHOL DEPENDENCE; BRAIN; NEUROBIOLOGY; ABSTINENCE;
   BEHAVIOR; RELAPSE; SUBSTANCE; PATHOLOGY; DOPAMINE
AB Addiction is a chronic brain disease. Drug addiction manifests as a compulsive obsession to use a substance despite serious detrimental and sometimes irreversible consequences. Drug addiction is not the same as drug dependency because dependency may not manifest as an addictive behavior. This problem is fundamental to understanding the disease of addiction. This article discusses the neurobiology and genetics of drug addiction.
C1 Med Univ S Carolina, Dept Family Med, Charleston, SC 29425 USA.
C3 Medical University of South Carolina
RP Detar, DT (通讯作者)，Med Univ S Carolina, Dept Family Med, 295 Calhoun St, Charleston, SC 29425 USA.
EM detardt@musc.edu
CR Baler RD, 2006, TRENDS MOL MED, V12, P559, DOI 10.1016/j.molmed.2006.10.005
   Carlezon WA, 2005, TRENDS NEUROSCI, V28, P436, DOI 10.1016/j.tins.2005.06.005
   Dawson DA, 2007, ALCOHOL CLIN EXP RES, V31, P2036, DOI 10.1111/j.1530-0277.2007.00536.x
   Dick DM, 2004, ALCOHOL CLIN EXP RES, V28, P4, DOI 10.1097/01.ALC.0000108645.54345.98
   Edenberg HJ, 2004, AM J HUM GENET, V74, P705, DOI 10.1086/383283
   Edenberg HJ, 2005, PHARMACOL THERAPEUT, V108, P86, DOI 10.1016/j.pharmthera.2005.06.011
   Enoch MA, 2010, BIOL PSYCHIAT, V67, P20, DOI 10.1016/j.biopsych.2009.08.019
   FLANNERY W, 1694, PRACTITIONER, V251, P99
   Fowler Joanna S, 2007, Sci Pract Perspect, V3, P4
   Gardner EL, 2005, PHARMACOL BIOCHEM BE, V81, P263, DOI 10.1016/j.pbb.2005.01.032
   Grant JE, 2006, CNS SPECTRUMS, V11, P924, DOI 10.1017/S109285290001511X
   Heidbreder C, 2005, EUR J PHARMACOL, V526, P101, DOI 10.1016/j.ejphar.2005.09.038
   Heidbreder CA, 2005, BRAIN RES REV, V49, P77, DOI 10.1016/j.brainresrev.2004.12.033
   Heilig M, 2010, ADDICT BIOL, V15, P169, DOI 10.1111/j.1369-1600.2009.00194.x
   Hester R, 2004, J NEUROSCI, V24, P11017, DOI 10.1523/JNEUROSCI.3321-04.2004
   Hughes JR, 2007, PSYCHOL ADDICT BEHAV, V21, P127, DOI 10.1037/0893-164X.21.2.127
   Hyman SE, 2005, AM J PSYCHIAT, V162, P1414, DOI 10.1176/appi.ajp.162.8.1414
   Hyman SE, 2007, AM J BIOETHICS, V7, P8, DOI 10.1080/15265160601063969
   Impey S, 2007, NEURON, V56, P415, DOI 10.1016/j.neuron.2007.10.029
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564
   Kalivas Peter W, 2007, Dialogues Clin Neurosci, V9, P389
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Kornor H, 2005, DRUG ALCOHOL REV, V24, P267, DOI 10.1080/09595230500170241
   Krystal JH, 2003, ANN NY ACAD SCI, V1003, P176, DOI 10.1196/annals.1300.010
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Moonat S, 2010, CELL MOL LIFE SCI, V67, P73, DOI 10.1007/s00018-009-0135-y
   Nestler EJ, 2004, NEUROPHARMACOLOGY, V47, P24, DOI 10.1016/j.neuropharm.2004.06.031
   Pandey SC, 2004, PHARMACOL THERAPEUT, V104, P47, DOI 10.1016/j.pharmthera.2004.08.002
   Pandey SC, 2008, J NEUROSCI, V28, P3729, DOI 10.1523/JNEUROSCI.5731-07.2008
   Paulus Martin P, 2007, Dialogues Clin Neurosci, V9, P379
   Ross S, 2009, CLIN NEUROPHARMACOL, V32, P269, DOI 10.1097/WNF.0b013e3181a9163c
   Saraceno L, 2009, ADDICTION, V104, P1100, DOI 10.1111/j.1360-0443.2009.02571.x
   Shaham Y, 2005, NAT NEUROSCI, V8, P1437, DOI 10.1038/nn1105-1437
   Spanagel R, 2009, PHYSIOL REV, V89, P649, DOI 10.1152/physrev.00013.2008
   Uhl GR, 2009, J NEUROGENET, V23, P272, DOI 10.1080/01677060802572929
   Uhl GR, 2004, ANN NY ACAD SCI, V1025, P1, DOI 10.1196/annals.1316.001
   Volkow ND, 2003, J CLIN INVEST, V111, P1444, DOI 10.1172/JCI200318533
   Weiss F, 2001, ANN NY ACAD SCI, V937, P1, DOI 10.1111/j.1749-6632.2001.tb03556.x
   Zucker Robert A, 2005, Recent Dev Alcohol, V17, P299, DOI 10.1007/0-306-48626-1_14
NR 41
TC 3
Z9 5
U1 8
U2 71
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0095-4543
EI 1558-299X
J9 PRIMARY CARE
JI Primary Care
PD MAR
PY 2011
VL 38
IS 1
BP 1
EP +
DI 10.1016/j.pop.2010.11.001
PG 8
WC Primary Health Care; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 742VB
UT WOS:000288972300003
PM 21356417
DA 2023-06-23
ER

PT J
AU Pimenta, SN
   Cremasco, MVF
   Lesourd, S
AF Pimenta, Shana Nakoneczny
   Filomena Cremasco, Maria Virginia
   Lesourd, Serge
TI Drug addiction: an expression of melancholia?
SO REVISTA LATINOAMERICANA DE PSICOPATOLOGIA FUNDAMENTAL
LA Portuguese
DT Article
DE Drug addiction; melancholia; psychoanalysis; clinic
AB (Drug addiction: an expression of melancholia?)
   The present article uses psychoanalytic theory to discuss a clinical case that had initially been seen as a question of drug addiction. But during the process of constructing transference, a deep sadness related to melancholia became evident. Theoretical parallels were thus drawn between drug addiction and melancholia, which, in this case, led to the conclusion that drug addiction and melancholia derive from the same metapsychological source.
C1 [Pimenta, Shana Nakoneczny] Univ Strasbourg 1, Estrasburgo, France.
   [Filomena Cremasco, Maria Virginia] Univ Fed Parana, Dept Psicol, BR-80060000 Curitiba, Parana, Brazil.
   [Lesourd, Serge] Univ Estrasburgo, Fac Psicol, Estrasburgo, France.
C3 UDICE-French Research Universities; Universites de Strasbourg
   Etablissements Associes; Universite de Strasbourg; Universidade Federal
   do Parana
RP Pimenta, SN (通讯作者)，Rua Capitao Souza Franco 945-22, BR-80730420 Curitiba, Parana, Brazil.
EM shana_pimenta@yahoo.com.br; virginiacremasco@ufpr.br;
   serge.lesourd@unistra.fr
CR ESCANDE C., 2002, PASSIONS DROGUES FIG
   Fedida P., 1978, ABSENCE
   FREUD S., 1988, AEUVRES COMPLETES, VXIII
   FREUD S., 1992, AEUVRES COMPLETES, VXX
   Lacan J., 1966, ECRITS SELECTION
   LACAN J., 1958, SEMINARIO UNPUB
   LAMBOTTE M.C., 2002, TRAVERSEE MELANCOLIE
   LAMBOTTE M.C., 2003, DISCOURS MELANCOLIQU
   Le Poulichet Sylvie, 1987, TOXICOMANIES PSYCHAN
   PEREIRA M., 1999, PANICO DESAMPARO EST
NR 10
TC 0
Z9 0
U1 1
U2 8
PU ASSOC UNIV PEQUISA PSICOPATOLOGIA FUNDAMENTAL
PI SAO PAOLO SP
PA RUA TUPI, 397-10- CJ 104, SAO PAOLO SP, 01233-001, BRAZIL
SN 1415-4714
J9 REV LATINOAM PSICOPA
JI Rev. Latinoam. Psicopatol. Funda.
PD JUN
PY 2011
VL 14
IS 2
BP 252
EP 267
DI 10.1590/S1415-47142011000200004
PG 16
WC Psychology, Multidisciplinary
WE Social Science Citation Index (SSCI)
SC Psychology
GA 792OL
UT WOS:000292756300004
OA gold, Green Published
DA 2023-06-23
ER

PT J
AU Jones, J
AF Jones, Janet
TI What Do We Mean When We Call Someone a Drug Addict?
SO HEALTH CARE ANALYSIS
LA English
DT Article
DE Addict; Drug addiction; Stigma; Social metaphysics; Harm reduction;
   Linguistic harm
AB When thinking about the harms of drug addiction, there is a tendency to focus on the harms of drug consumption. But not all harms associated with drug addiction are caused by drug consumption. There is at least another dimension of harm worth considering: what I call the linguistic harm of drug addiction. Starting with an analysis of 'drug addict' as it appears in the media, I argue that 'drug addict' is inconsistently applied to people with drug addiction and that this inconsistency reveals two important features of the term. First, being called a 'drug addict' is worse than being described as 'having a drug problem'. Second, being called a drug addict exacerbates the challenges experienced by people with drug addiction. Referencing the 'addict' narrative, I detail how calling someone a drug addict can add to the marginalization of people with drug addiction and argue that to eliminate the linguistic harm of drug addiction, we ought to reduce it first. Using the analysis of 'drug addict' from the first half of the paper, I propose a novel harm reduction strategy that benefits people with drug addiction but calls on people who do not use drugs.
C1 [Jones, Janet] Univ Waterloo, 200 Univ Ave W, Waterloo, ON N2L 3G1, Canada.
C3 University of Waterloo
RP Jones, J (通讯作者)，Univ Waterloo, 200 Univ Ave W, Waterloo, ON N2L 3G1, Canada.
EM janet.jones@uwaterloo.ca
OI Jones, Janet/0000-0003-2170-4675
FU Vanier Canada Graduate Scholarship
FX This paper was supported by the funding provided by the Vanier Canada
   Graduate Scholarship. I am grateful to be a Vanier Scholar. I am also
   grateful to my two anonymous reviewers who provided thoughtful
   suggestions. Finally, I would especially like to thank Shannon Dea, who
   offered me advice on earlier versions of this paper and encouraged me to
   publish it.
CR Brico E, 2019, FILTER
   Canadian Centre on Substance Use and Addiction, 2019, OV STIGM LANG PRIM
   Canale MK, 2005, VISIONS J, V2, P13
   Carlson M, 2018, JOURNALISM STUD, V19, P1879, DOI 10.1080/1461670X.2018.1494513
   Castaneda R, 2017, US NEWS
   Centre for Addiction and Mental Health, 2020, ADDR STIGM
   Cheung YW, 2000, CAN MED ASSOC J, V162, P1697
   Duff C, 2016, INT J DRUG POLICY, V33, P15, DOI 10.1016/j.drugpo.2015.10.003
   Fleming A. R, 2016, RECORD
   Giusti S, BE HUMAN TALKING PEO
   Goodman A, 2018, ROUTLEDGE HDB PHILOS, P415
   Government of Canada, 2010, STIGM SUBST US HLTH
   Gray R., 2010, CONTEMP DRUG PROBL, V37, P685, DOI [https://doi.org/10.1177/009145091003700409, DOI 10.1177/009145091003700409]
   Hill V, 2019, RECORD
   Hughes K, 2007, SOCIOL HEALTH ILL, V29, P673, DOI 10.1111/j.1467-9566.2007.01018.x
   Kelly JF, 2010, INT J DRUG POLICY, V21, P202, DOI 10.1016/j.drugpo.2009.10.010
   Knight K, 2016, J EXP BIOL, V219, P2776, DOI 10.1242/jeb.149047
   Lentinello E, 2017, ACCEPTANCE PROJECT R
   Little J, 2010, J CLIN PSYCHOL, V66, P175, DOI 10.1002/jclp.20673
   Mason R, 2018, ROUTLEDGE ENCY PHILO, DOI [10.4324/9780415249126-N135-1, DOI 10.4324/9780415249126-N135-1]
   Matthews S, 2017, J BIOETHIC INQ, V14, P275, DOI 10.1007/s11673-017-9784-y
   Monteiro L, 2019, RECORD
   Moore D, 2006, SOC SCI MED, V62, P3035, DOI 10.1016/j.socscimed.2005.11.067
   Partnership to End Addiction Staff, 2017, WHY YOU SHOULDNT US
   Paul G, 2020, RECORD
   Paul G, 2019, RECORD
   Ralston M, 2014, END ADDICT
   Region of Waterloo Public Health and Emergency Services, 2018, WAT REG OP RESP PLAN
   Roe Gordon., 2005, CRIT PUBLIC HEALTH, V15, DOI DOI 10.1080/09581590500372188
   Shatterproof, 2020, STIGM RED LANG
   Souleymanov R, 2016, BRIT J SOC WORK, V46, P1429, DOI 10.1093/bjsw/bcv067
   Sveinsdottir A.K., 2017, ROUTLEDGE HDB COLLEC, P290
   Sveinsdottir A, 2015, PHILOS COMPASS, V10, P884, DOI 10.1111/phc3.12265
   Sveinsdottir AK, 2013, HYPATIA, V28, P716, DOI 10.1111/j.1527-2001.2012.01317.x
   Szalavitz M, 2017, ITS TIME STOP CALLIN
   Szalavitz M, 2017, NPR
   Toward the Heart, RED STIGM BCCDC HARM
   U.K. Rehab, 2013, HEROIN USERS USUALLY
   Volkow N., 2020, SCI AM
   Wild TC, 2019, DRUG ALCOHOL DEPEN, V205, DOI 10.1016/j.drugalcdep.2019.107599
   Wilson M, 2018, NY TIMES
NR 41
TC 1
Z9 1
U1 2
U2 23
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1065-3058
EI 1573-3394
J9 HEALTH CARE ANAL
JI Health Care Anal.
PD DEC
PY 2020
VL 28
IS 4
SI SI
BP 391
EP 403
DI 10.1007/s10728-020-00410-0
EA OCT 2020
PG 13
WC Ethics; Health Policy & Services; Social Sciences, Biomedical
WE Social Science Citation Index (SSCI)
SC Social Sciences - Other Topics; Health Care Sciences & Services;
   Biomedical Social Sciences
GA OU0GW
UT WOS:000583982100001
PM 33104912
DA 2023-06-23
ER

PT J
AU Zou, ZL
   Song, HW
   Zhang, YT
   Zhang, XC
AF Zou, Zhiling
   Song, Hongwen
   Zhang, Yuting
   Zhang, Xiaochu
TI Romantic Love vs. Drug Addiction May Inspire a New Treatment for
   Addiction
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Review
DE romantic love; social cognition system; drug addiction; oxytocin;
   resting-state functional connectivity; drug addiction treatment
ID STATE FUNCTIONAL CONNECTIVITY; ANTERIOR CINGULATE CORTEX; DORSAL
   STRIATUM; BRAIN ACTIVITY; NEURAL BASIS; ACCUMBENS DOPAMINE; SOCIAL
   ATTACHMENT; PREFRONTAL CORTEX; COCAINE ADDICTION; SUBSTANCE-ABUSE
AB Drug addiction is a complex neurological dysfunction induced by recurring drug intoxication. Strategies to prevent and treat drug addiction constitute a topic of research interest. Early-stage romantic love is characterized by some characteristics of addiction, which gradually disappear as the love relationship progresses. Therefore, comparison of the concordance and discordance between romantic love and drug addiction may elucidate potential treatments for addiction. This focused review uses the evidences from our recent studies to compare the neural alterations between romantic love and drug addiction, moreover we also compare the behavioral and neurochemical alterations between romantic love and drug addiction. From the behavioral comparisons we find that there are many similarities between the early stage of romantic love and drug addiction, and this stage romantic love is considered as a behavioral addiction, while significant differences exist between the later stage of romantic love and drug addiction, and this stage of romantic love eventually developed into a prosocial behavior. The neuroimaging comparisons suggest that romantic love and drug addiction both display the functional enhancement in reward and emotion regulation network. Except the similar neural changes, romantic love display special function enhancement in social cognition network, while drug addiction display special dysfunction in cognitive control network. The neurochemical comparisons show that there are many similarities in the dopamine (DA) system, while significant differences in oxytocin (OT) system for romantic love and drug addiction. These findings indicate that the functional alterations in reward and emotion regulation network and the DA system may be the neurophysiological basis of romantic love as a behavioral addiction, and the functional alterations in social cognition network and the OT system may be the neurophysiological basis of romantic love as a prosocial behavior. It seems that the OT system is a critical factor for the development of addiction. So we then discuss strategies to treat drug addiction with OT, and suggest that future research should further investigate OT system interventions aiming to improve cognitive control and/or social cognition functions, in order to develop strategies designed to more effectively treat drug addiction.
C1 [Zou, Zhiling; Song, Hongwen] Southwest Univ, Fac Psychol, Chongqing, Peoples R China.
   [Song, Hongwen; Zhang, Xiaochu] Chinese Acad Sci, Hefei Inst Phys Sci, Ctr Med Phys & Technol, Hefei, Peoples R China.
   [Zhang, Yuting; Zhang, Xiaochu] Chinese Acad Sci, Univ Sci & Technol China, Sch Life Sci, Key Lab Brain Funct & Dis, Hefei, Peoples R China.
   [Zhang, Xiaochu] Univ Sci & Technol China, Sch Humanities & Social Sci, Hefei, Peoples R China.
   [Zhang, Xiaochu] Univ Sci & Technol China, Ctr Biomed Engn, Hefei, Peoples R China.
C3 Southwest University - China; Chinese Academy of Sciences; Hefei
   Institutes of Physical Science, CAS; Chinese Academy of Sciences;
   University of Science & Technology of China, CAS; Chinese Academy of
   Sciences; University of Science & Technology of China, CAS; Chinese
   Academy of Sciences; University of Science & Technology of China, CAS
RP Zhang, XC (通讯作者)，Chinese Acad Sci, Hefei Inst Phys Sci, Ctr Med Phys & Technol, Hefei, Peoples R China.; Zhang, XC (通讯作者)，Chinese Acad Sci, Univ Sci & Technol China, Sch Life Sci, Key Lab Brain Funct & Dis, Hefei, Peoples R China.; Zhang, XC (通讯作者)，Univ Sci & Technol China, Sch Humanities & Social Sci, Hefei, Peoples R China.; Zhang, XC (通讯作者)，Univ Sci & Technol China, Ctr Biomed Engn, Hefei, Peoples R China.
EM zxcustc@ustc.edu.cn
RI Zhang, Xiaochu/AEW-0582-2022; Zhang, Xiaochu/AAG-8768-2022; ZHANG,
   YUTING/HOH-4131-2023; Zhang, Xiaochu/O-9592-2014
OI Zhang, Xiaochu/0000-0002-7541-0130; Zou, Zhiling/0000-0003-4497-2947
FU National Natural Science Foundation of China [31230032, 31171083,
   31471071]; Fundamental Research Funds for the Central Universities of
   China [SWU 1509134, WK2070000033]; Chinese Academy of Sciences
   [KJ2070000018]; Hefei Science Center, CAS "User with Potential"
   [2015HSC-UP017]
FX This work was supported by grants from the National Natural Science
   Foundation of China (31230032, 31171083, and 31471071), the Fundamental
   Research Funds for the Central Universities of China (SWU 1509134 and
   WK2070000033), the 100 Talents Program of the Chinese Academy of
   Sciences (KJ2070000018), and Hefei Science Center, CAS "User with
   Potential" (2015HSC-UP017).
CR Acevedo BP, 2012, SOC COGN AFFECT NEUR, V7, P145, DOI 10.1093/scan/nsq092
   Amaro H, 1999, HISPANIC J BEHAV SCI, V21, P266, DOI 10.1177/0739986399213005
   Anderson SM, 2008, NAT NEUROSCI, V11, P344, DOI 10.1038/nn2054
   Aragona BJ, 2006, NAT NEUROSCI, V9, P133, DOI 10.1038/nn1613
   Aron A, 2005, J NEUROPHYSIOL, V94, P327, DOI 10.1152/jn.00838.2004
   Asensio S, 2010, SYNAPSE, V64, P397, DOI 10.1002/syn.20741
   Association A. P., 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596
   Bale TL, 2004, ANNU REV PHARMACOL, V44, P525, DOI 10.1146/annurev.pharmtox.44.101802.121410
   Baler RD, 2006, TRENDS MOL MED, V12, P559, DOI 10.1016/j.molmed.2006.10.005
   Bartels A, 2000, NEUROREPORT, V11, P3829, DOI 10.1097/00001756-200011270-00046
   Bartz JA, 2006, HORM BEHAV, V50, P518, DOI 10.1016/j.yhbeh.2006.06.018
   Bertran-Gonzalez J, 2008, J NEUROSCI, V28, P5671, DOI 10.1523/JNEUROSCI.1039-08.2008
   Bethlehem RAI, 2013, PSYCHONEUROENDOCRINO, V38, P962, DOI 10.1016/j.psyneuen.2012.10.011
   Bosch OJ, 2009, NEUROPSYCHOPHARMACOL, V34, P1406, DOI 10.1038/npp.2008.154
   Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003
   Breiter HC, 1997, NEURON, V19, P591, DOI 10.1016/S0896-6273(00)80374-8
   Burkett JP, 2012, PSYCHOPHARMACOLOGY, V224, P1, DOI 10.1007/s00213-012-2794-x
   Carson DS, 2010, NEUROPHARMACOLOGY, V58, P38, DOI 10.1016/j.neuropharm.2009.06.018
   Cisler JM, 2013, PSYCHIAT RES-NEUROIM, V213, P39, DOI 10.1016/j.pscychresns.2013.02.007
   Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555
   Cui SS, 2001, J NEUROSCI, V21, P9867, DOI 10.1523/JNEUROSCI.21-24-09867.2001
   Davidson RJ, 2000, SCIENCE, V289, P591, DOI 10.1126/science.289.5479.591
   Delgado MR, 2000, J NEUROPHYSIOL, V84, P3072, DOI 10.1152/jn.2000.84.6.3072
   Elliott R, 2003, J NEUROSCI, V23, P303
   Esch T, 2005, NEUROENDOCRINOL LETT, V26, P175
   Everitt BJ, 2013, NEUROSCI BIOBEHAV R, V37, P1946, DOI 10.1016/j.neubiorev.2013.02.010
   Fisher HE, 1998, HUM NATURE-INT BIOS, V9, P23, DOI 10.1007/s12110-998-1010-5
   Fisher HE, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00687
   Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201
   Fox MD, 2010, FRONT SYST NEUROSCI, V4, DOI [10.3389/fnsys.2010.00019, 10.3389/fnsys.2010.0001]
   Fraley R. C., 2000, REV GEN PSYCHOL, V4, P132, DOI [10.1037/1089-2680.4.2.132, DOI 10.1037/1089-2680.4.2.132]
   Frascella J, 2010, ANN NY ACAD SCI, V1187, P294, DOI 10.1111/j.1749-6632.2009.05420.x
   GIBBS DM, 1984, LIFE SCI, V35, P487, DOI 10.1016/0024-3205(84)90241-8
   Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119
   Gordon I, 2013, P NATL ACAD SCI USA, V110, P20953, DOI 10.1073/pnas.1312857110
   Grieder TE, 2012, P NATL ACAD SCI USA, V109, P3101, DOI 10.1073/pnas.1114422109
   Grippo AJ, 2007, PSYCHOSOM MED, V69, P149, DOI 10.1097/PSY.0b013e31802f054b
   Gu H, 2010, NEUROIMAGE, V53, P593, DOI 10.1016/j.neuroimage.2010.06.066
   Hampshire A, 2010, NEUROIMAGE, V50, P1313, DOI 10.1016/j.neuroimage.2009.12.109
   HATFIELD E, 1986, J ADOLESCENCE, V9, P383, DOI 10.1016/S0140-1971(86)80043-4
   HATFIELD E, 1987, ARCH SEX BEHAV, V16, P259, DOI 10.1007/BF01541613
   HAZAN C, 1987, J PERS SOC PSYCHOL, V52, P511, DOI 10.1037/0022-3514.52.3.511
   HENRY DJ, 1995, J NEUROSCI, V15, P6287
   Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.biopsych.2006.05.030
   Jarrett TM, 2006, NEUROPEPTIDES, V40, P161, DOI 10.1016/j.npep.2006.03.002
   Johns JM, 1997, NEUROPEPTIDES, V31, P439, DOI 10.1016/S0143-4179(97)90037-8
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564
   Koob GF, 2008, NEURON, V59, P11, DOI 10.1016/j.neuron.2008.06.012
   Koob GF, 2010, BRAIN RES, V1314, P3, DOI 10.1016/j.brainres.2009.11.008
   Koob GF, 1999, BIOL PSYCHIAT, V46, P1167, DOI 10.1016/S0006-3223(99)00164-X
   KOVACS GL, 1981, NEUROPHARMACOLOGY, V20, P647, DOI 10.1016/0028-3908(81)90111-8
   Kovacs GL, 1998, PSYCHONEUROENDOCRINO, V23, P945
   Liebowitz M. R., 1983, CHEM LOVE
   Light KC, 2004, ADDICT BEHAV, V29, P1541, DOI 10.1016/j.addbeh.2004.02.062
   Liu N, 2015, P NATL ACAD SCI USA, V112, pE3123, DOI 10.1073/pnas.1508097112
   Lv WW, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01335
   Ma N, 2010, NEUROIMAGE, V49, P738, DOI 10.1016/j.neuroimage.2009.08.037
   Maddock RJ, 1999, TRENDS NEUROSCI, V22, P310, DOI 10.1016/S0166-2236(98)01374-5
   Marazziti D, 2004, PSYCHONEUROENDOCRINO, V29, P931, DOI 10.1016/j.psyneuen.2003.08.006
   McGregor IS, 2012, HORM BEHAV, V61, P331, DOI 10.1016/j.yhbeh.2011.12.001
   Melis M, 2005, INT REV NEUROBIOL, V63, P101, DOI 10.1016/S0074-7742(05)63005-X
   Meloy JR, 2005, J FORENSIC SCI, V50, P1472
   MOGENSON GJ, 1980, PROG NEUROBIOL, V14, P69, DOI 10.1016/0301-0082(80)90018-0
   NAKAJIMA S, 1986, PHARMACOL BIOCHEM BE, V24, P919, DOI 10.1016/0091-3057(86)90437-5
   Narendran R, 2005, AM J PSYCHIAT, V162, P2352, DOI 10.1176/appi.ajp.162.12.2352
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   Ortigue S, 2007, J COGNITIVE NEUROSCI, V19, P1218, DOI 10.1162/jocn.2007.19.7.1218
   Panksepp J, 2002, ADDICTION, V97, P459, DOI 10.1046/j.1360-0443.2002.00025.x
   Parker KJ, 2005, PSYCHONEUROENDOCRINO, V30, P924, DOI 10.1016/j.psyneuen.2005.04.002
   Pedersen CA, 2013, ALCOHOL CLIN EXP RES, V37, P484, DOI 10.1111/j.1530-0277.2012.01958.x
   Riem MME, 2013, EUR NEUROPSYCHOPHARM, V23, P1288, DOI 10.1016/j.euroneuro.2013.01.011
   Riem MME, 2011, BIOL PSYCHIAT, V70, P291, DOI 10.1016/j.biopsych.2011.02.006
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Romero-Fernandez W, 2013, MOL PSYCHIATR, V18, P849, DOI 10.1038/mp.2012.103
   SARNYAI Z, 1992, NEUROPHARMACOLOGY, V31, P593, DOI 10.1016/0028-3908(92)90192-R
   Schneiderman I, 2012, PSYCHONEUROENDOCRINO, V37, P1277, DOI 10.1016/j.psyneuen.2011.12.021
   Schultz W, 2000, NAT REV NEUROSCI, V1, P199, DOI 10.1038/35044563
   Song HW, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00071
   Starka L, 2007, Prague Med Rep, V108, P297
   STERNBERG RJ, 1986, PSYCHOL REV, V93, P119, DOI 10.1037/0033-295X.93.2.119
   Sutherland MT, 2012, NEUROIMAGE, V62, P2281, DOI 10.1016/j.neuroimage.2012.01.117
   Tops M, 2014, PHARMACOL BIOCHEM BE, V119, P39, DOI 10.1016/j.pbb.2013.07.015
   van den Heuvel MP, 2010, EUR NEUROPSYCHOPHARM, V20, P519, DOI 10.1016/j.euroneuro.2010.03.008
   Volkow ND, 2003, J CLIN INVEST, V111, P1444, DOI 10.1172/JCI200318533
   Volkow ND, 2008, NEUROIMAGE, V42, P1537, DOI 10.1016/j.neuroimage.2008.06.002
   Volkow ND, 2007, ARCH NEUROL-CHICAGO, V64, P1575, DOI 10.1001/archneur.64.11.1575
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
   Wagner AD, 2001, NEUROIMAGE, V14, P1337, DOI 10.1006/nimg.2001.0936
   Wang Y, 2016, NEUROREPORT, V27, P323, DOI 10.1097/WNR.0000000000000541
   Wei ZD, 2016, SCI REP-UK, V6, DOI 10.1038/srep21778
   Windle RJ, 1997, ENDOCRINOLOGY, V138, P2829, DOI 10.1210/en.138.7.2829
   Windle RJ, 2004, J NEUROSCI, V24, P2974, DOI 10.1523/JNEUROSCI.3432-03.2004
   Winston JS, 2002, NAT NEUROSCI, V5, P277, DOI 10.1038/nn816
   Xu XM, 2011, HUM BRAIN MAPP, V32, P249, DOI 10.1002/hbm.21017
   Zanos P, 2014, NEUROPSYCHOPHARMACOL, V39, P855, DOI 10.1038/npp.2013.285
   Zhang XC, 2011, NEUROIMAGE, V54, P131, DOI 10.1016/j.neuroimage.2010.07.063
   Zhang XC, 2009, HUM BRAIN MAPP, V30, P896, DOI 10.1002/hbm.20552
   Zhang YJ, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00675
   Zorrilla EP, 2001, PSYCHOPHARMACOLOGY, V158, P374, DOI 10.1007/s002130100773
NR 99
TC 8
Z9 8
U1 13
U2 73
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD SEP 22
PY 2016
VL 7
DI 10.3389/fpsyg.2016.01436
PG 12
WC Psychology, Multidisciplinary
WE Social Science Citation Index (SSCI)
SC Psychology
GA DW5EB
UT WOS:000383663900002
PM 27713720
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Zhuo, RR
   Chen, ZC
   Shen, XB
   Yang, HC
   Luo, SL
   Wu, YQ
   Zhu, YX
   Wu, TY
   Feng, ZJ
   Cai, HB
AF Zhuo, Ruirui
   Chen, Zhencai
   Shen, Xunbing
   Yang, Hechen
   Luo, Shuilian
   Wu, Yuanqiang
   Zhu, Yuxiang
   Wu, Tingyun
   Feng, Zhenjun
   Cai, Hengbin
TI The Mediating Roles of Impulsiveness and Maladjustment in the
   Association of Psychological Resilience with Drug Addiction during
   Isolated Detoxification
SO SUBSTANCE USE & MISUSE
LA English
DT Article
DE Psychological resilience; drug addiction; impulsiveness; maladjustment
ID CHINESE VERSION; USE SCALE; ALCOHOL; VALIDATION; ABUSE; PARTICIPANTS;
   DEPRESSION; ANXIETY; REWARD; ADULTS
AB Background: Studies have shown that psychological resilience is a key factor in drug rehabilitation. To explore the feasibility of developing psychological resilience as an addiction treatment intervention, it is essential to explore the role that it plays in drug addiction. Objectives: This study aimed to investigate the relationship between psychological resilience and drug addiction, as well as to examine the underlying mediational roles of maladjustment and impulsiveness in this association. Methods: We used a cross-sectional design that included a sample of 140 male drug addicts in compulsory isolation centers and used questionnaires and scales to ascertain their level of drug addiction, psychological resilience, maladjustment, impulsiveness, social support, and loneliness. Correlation and mediation effect analyses were performed to determine the roles of impulsiveness and maladjustment in the association of psychological resilience with drug addiction. Results: Psychological resilience was an inverse predictor of drug addiction. The results of the mediation effect analysis showed that maladjustment acted as a mediator between resilience and drug addiction and between impulsiveness and drug addiction. Furthermore, impulsiveness and maladjustment jointly mediated the relationship between psychological resilience and drug addiction. Conclusion: These findings highlight the importance of psychological resilience in maladjustment and impulsiveness for drug addicts and suggest that the role of psychological resilience in drug addiction needs to be further explored.
C1 [Zhuo, Ruirui; Chen, Zhencai; Shen, Xunbing; Yang, Hechen; Luo, Shuilian; Wu, Yuanqiang] Jiangxi Univ Chinese Med, Nanchang, Jiangxi, Peoples R China.
   [Zhu, Yuxiang; Wu, Tingyun; Feng, Zhenjun; Cai, Hengbin] Nanchang Compulsory Isolated Detoxificat Ctr, Nanchang, Jiangxi, Peoples R China.
C3 Jiangxi University of Traditional Chinese Medicine
RP Chen, ZC (通讯作者)，Jiangxi Univ Chinese Med, Nanchang, Jiangxi, Peoples R China.
EM zhencai_chen@163.com
RI Shen, Xunbing/AAG-4993-2021; Shen, Xunbing/HHC-0313-2022
OI Shen, Xunbing/0000-0002-3672-273X; 
FU Planed Project of Social Sciences in Jiangxi Province [19JY49]; National
   Natural Science Foundation of China [32000736, 31960180, 31460251];
   Doctoral Research Startup Fund of Jiangxi University of Chinese Medicine
   [2018BSRW001]
FX This study was funded by Planed Project of Social Sciences in Jiangxi
   Province (19JY49) and National Natural Science Foundation of China (No.
   32000736, 31960180, 31460251) and Doctoral Research Startup Fund of
   Jiangxi University of Chinese Medicine (2018BSRW001).
CR Abbott J.-A., 2009, ELECT J APPL PSYCHOL, V5, P89, DOI DOI 10.7790/EJAP.V5I1.145
   Acton GS, 2003, SUBST USE MISUSE, V38, P67, DOI 10.1081/JA-120016566
   Bari A, 2013, PROG NEUROBIOL, V108, P44, DOI 10.1016/j.pneurobio.2013.06.005
   BARRATT ES, 1985, MOTIVATION EMOTION P, P137, DOI DOI 10.1371/JOURNAL.PONE.0129139
   Benetti C, 2006, PERS INDIV DIFFER, V41, P341, DOI 10.1016/j.paid.2006.01.015
   CAMPO AT, 1992, CHILD ABUSE NEGLECT, V16, P429, DOI 10.1016/0145-2134(92)90052-S
   Chen SD, 2016, PSYCHOL HEALTH MED, V21, P460, DOI 10.1080/13548506.2015.1093642
   CHEUNG FM, 1989, PSYCHOL ASSESSMENT J, V1, P230, DOI DOI 10.1037/1040-3590.1.3.230
   Choi JW, 2015, J AFFECT DISORDERS, V170, P172, DOI 10.1016/j.jad.2014.08.056
   Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113
   Dalley JW, 2011, NEURON, V69, P680, DOI 10.1016/j.neuron.2011.01.020
   de Terte I, 2014, STRESS HEALTH, V30, P353, DOI 10.1002/smi.2627
   de Wit H, 2004, NEBR SYM MOTIV, V50, P19
   Fletcher D, 2013, EUR PSYCHOL, V18, P12, DOI 10.1027/1016-9040/a000124
   Franken IHA, 2002, ADDICT BEHAV, V27, P675, DOI 10.1016/S0306-4603(01)00201-5
   Goldstein AL, 2013, CHILD ABUSE NEGLECT, V37, P22, DOI 10.1016/j.chiabu.2012.08.007
   Green KT, 2014, ADDICT BEHAV, V39, P406, DOI 10.1016/j.addbeh.2013.08.024
   Gu J, 2008, ADDICT BEHAV, V33, P725, DOI 10.1016/j.addbeh.2007.12.009
   Hayaki J, 2005, DRUG ALCOHOL DEPEN, V78, P65, DOI 10.1016/j.drugalcdep.2004.09.002
   Herrman H, 2011, CAN J PSYCHIAT, V56, P258, DOI 10.1177/070674371105600504
   Hobkirk AL, 2019, DRUG ALCOHOL DEPEN, V194, P32, DOI 10.1016/j.drugalcdep.2018.09.013
   Hodder RK, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-722
   Huang CY, 2013, J CHIN MED ASSOC, V76, P289, DOI 10.1016/j.jcma.2013.01.005
   Lee D, 2019, PSYCHIAT INVEST, V16, P773, DOI 10.30773/pi.2019.04.02.3
   [李献云 LI XianYun], 2011, [中国心理卫生杂志, Chinese Mental Health Journal], V25, P610
   Lian Z., 2003, CHINESE J PHARMACOEP, V12, P85
   Lopez S. J., 2011, OXFORD HDB POSITIVE, DOI DOI 10.1093/OXFORDHB/9780195187243.001.0001
   Madden GJ, 1997, EXP CLIN PSYCHOPHARM, V5, P256, DOI 10.1037/1064-1297.5.3.256
   McKay JR, 1999, J STUD ALCOHOL, V60, P566, DOI 10.15288/jsa.1999.60.566
   Muthen L. K., 2018, MPLUS COMPREHENSIVE, V5
   Oetting, 2002, RESILIENCE DEV LONGI, P101
   Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1
   Perry JL, 2008, PSYCHOPHARMACOLOGY, V200, P1, DOI 10.1007/s00213-008-1173-0
   [曲如杰 Qu Rujie], 2006, [中国临床心理学杂志, Chinese Journal of Clinical Psychology], V14, P55
   Reynolds BW, 2019, NEUROPSYCHOLOGY, V33, P212, DOI 10.1037/neu0000510
   Riquelme M, 2018, AN PSICOL-SPAIN, V34, P536, DOI 10.6018/analesps.34.3.315201
   Robles E, 2019, REV INT INVESTIGACI, V5, P21, DOI [https://doi.org/10.28931/riiad.2019.2.03, DOI 10.28931/RIIAD.2019.2.03]
   RUSSELL D, 1980, J PERS SOC PSYCHOL, V39, P472, DOI 10.1037/0022-3514.39.3.472
   Sippel LM, 2015, ECOL SOC, V20, DOI 10.5751/ES-07832-200410
   Stanford MS, 2009, PERS INDIV DIFFER, V47, P385, DOI 10.1016/j.paid.2009.04.008
   Sun HQ, 2014, CURR OPIN PSYCHIATR, V27, P251, DOI 10.1097/YCO.0000000000000073
   Wang, 1995, CHINESE J CLIN PSYCH, V3, P23, DOI DOI 10.16128/J.CNKI.1005-3611.1995.01.006
   Wang F, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-326
   Welsh G.S., 1952, M SAN FRANC BAY AR C
   Wingo AP, 2014, J PSYCHIATR RES, V51, P93, DOI 10.1016/j.jpsychires.2014.01.007
   [吴福喜 Wu Fuxi], 2003, [中国行为医学科学, Chinese Journal of Behavioral Medical Science], V12, P49
   Xiong HY, 2019, INT J OFFENDER THER, V63, P1202, DOI 10.1177/0306624X18815243
   Yang CW, 2016, INT J MENT HEALTH AD, V14, P803, DOI 10.1007/s11469-016-9635-9
   Yang X, 2007, J FUJIAN POLICE COLL, V22, P79
   Yang YJ, 2017, ONCOTARGET, V8, P79803, DOI 10.18632/oncotarget.19565
   Yu XN, 2007, SOC BEHAV PERSONAL, V35, P19, DOI 10.2224/sbp.2007.35.1.19
   Zhang Q., 2019, CHINA J HLTH PSYCHOL, V27, P1879, DOI [10.13342/j.cnki.cjhp.2019.12.033, DOI 10.13342/J.CNKI.CJHP.2019.12.033]
   Zhao J-b, 2015, OCCUPATION HLTH, V31, P3114
   ZIMET GD, 1988, J PERS ASSESS, V52, P30, DOI 10.1207/s15327752jpa5201_2
NR 54
TC 1
Z9 1
U1 4
U2 35
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1082-6084
EI 1532-2491
J9 SUBST USE MISUSE
JI Subst. Use Misuse
PD AUG 24
PY 2021
VL 56
IS 10
BP 1457
EP 1466
DI 10.1080/10826084.2021.1936048
EA MAY 2021
PG 10
WC Substance Abuse; Psychiatry; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry; Psychology
GA TM0BJ
UT WOS:000663240100001
PM 34139949
DA 2023-06-23
ER

PT J
AU Mendelevich, VD
   Makushina, OP
AF Mendelevich, V. D.
   Makushina, O. P.
TI The relationship of drug and alcohol addiction in teenagers with the
   character of their relations with parents
SO ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA
LA Russian
DT Article
DE alcoholism; drug addiction; genesis
AB An experimental-psychological study of 62 male teenagers with drug addiction and alcohol addiction revealed that the character of their relations with parents was dependent on the form of addiction. It has been concluded that these types of addictions have different psychological mechanisms of formation.
C1 [Mendelevich, V. D.] Kazan State Med Univ, Kazan, Russia.
   Voronezh State Univ, Voronezh 394693, Russia.
C3 Kazan State Medical University; Voronezh State University
RP Mendelevich, VD (通讯作者)，Kazan State Med Univ, Kazan, Russia.
EM boris.mendelevich@tatar.ru
RI Mendelevich, Vladimir D./O-4908-2016; Mendelevich, Vladimir
   D/HKW-6320-2023
OI Mendelevich, Vladimir D./0000-0001-8489-3130; Mendelevich, Vladimir
   D/0000-0002-8476-6083
CR BRATUS BS, 1984, PSIKHOLOGIYA KLIN PR, P144
   GURYEVA VA, 1994, PSIKHOPATOLOGIYA POD, P310
   KOROLENKO TP, 2000, SOTSIODINAMICHESKAYA, P460
   KOSHKINA EA, 1998, VOPROSY NARKOLOGII, V4, P46
   LICHKO AE, 1991, PODROSTKOVAYA NARKOL, P304
   MAKUSHINA OP, 2011, METODIKA OPREDELENIY
   MAKUSHINA OP, 2011, SOTSIALNAYA PSIKHOLO, V4, P111
   MENDELEVICH CD, 2011, PSIKHICHESKOYE ZDORO, V8, P72
   MENDELEVICH VD, 2007, RUKOVODSTVO ADDIKTOL, P768
   MENDELEVICH VD, 2003, NARKOZAVISIMOST KOMO, P328
   MENDELEVICH VD, 2005, PSIKHOLOGIYA DEVNANT, P445
   Nutt D, 2007, LANCET, V369, P1047, DOI 10.1016/S0140-6736(07)60464-4
   Parashar A, 2007, CNS SPECTRUMS, V12, P257, DOI 10.1017/S109285290002099X
   VALENTIK YV, 2002, SOTSIALNAYA KLIN PSI, V2, P31
NR 14
TC 1
Z9 5
U1 1
U2 10
PU IZDATELSTVO MEDITSINA
PI MOSCOW
PA PETROVERIGSKII PER 6-8, K-142 MOSCOW, RUSSIA
SN 1997-7298
J9 ZH NEVROL PSIKHIATR
JI Z. Nevrol. Psikhiatrii Im S S Korsakova
PY 2013
VL 113
IS 6
SU 2
BP 72
EP 74
PG 3
WC Clinical Neurology; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Psychiatry
GA 197PG
UT WOS:000322862500014
PM 23887473
DA 2023-06-23
ER

PT J
AU Barry, CL
   McGinty, EE
   Pescosolido, BA
   Goldman, HH
AF Barry, Colleen L.
   McGinty, Emma E.
   Pescosolido, Bernice A.
   Goldman, Howard H.
TI Stigma, Discrimination, Treatment Effectiveness, and Policy: Public
   Views About Drug Addiction and Mental Illness
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID ACCESS
AB Objective: Public attitudes about drug addiction and mental illness were compared. Methods: A Web-based national survey (N=709) was conducted to compare attitudes about stigma, discrimination, treatment effectiveness, and policy support in regard to drug addiction and mental illness. Results: Respondents held significantly more negative views toward persons with drug addiction. More respondents were unwilling to have a person with drug addiction many into their family or work closely with them. Respondents were more willing to accept discriminatory practices against persons with drug addiction, more skeptical about the effectiveness of treatments, and more likely to oppose policies aimed at helping them. Conclusions: Drug addiction is often treated as a subcategory of mental illness, and insurance plans group them together under the rubric of "behavioral health." Given starkly different public views about drug addiction and mental illness, advocates may need to adopt differing approaches to reducing stigma and advancing public policy.
C1 [Barry, Colleen L.; McGinty, Emma E.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA.
   [Barry, Colleen L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA.
   [Pescosolido, Bernice A.] Indiana Univ, Schuessler Inst Social Res, Bloomington, IN 47405 USA.
   [Pescosolido, Bernice A.] Indiana Univ, Dept Sociol, Bloomington, IN 47405 USA.
   [Goldman, Howard H.] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA.
C3 Johns Hopkins University; Johns Hopkins Bloomberg School of Public
   Health; Johns Hopkins University; Johns Hopkins Bloomberg School of
   Public Health; Indiana University System; Indiana University
   Bloomington; Indiana University System; Indiana University Bloomington;
   University System of Maryland; University of Maryland Baltimore
RP Barry, CL (通讯作者)，Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA.
EM cbarry@jhu.edu
FU AIG Inc.; National Institute on Drug Abuse [R01 DA026414]; National
   Institute of Mental Health [1R01MH093414-01A1]; National Science
   Foundation [0818839]; College of Arts and Sciences, Indiana University
FX Dr. Barry and Dr. McGinty acknowledge funding from a research grant from
   AIG Inc. (principal investigator, Dr. Barry). Dr. Barry acknowledges
   funding from grant R01 DA026414 from the National Institute on Drug
   Abuse (principal investigator, Dr. Barry). Dr. Barry, Dr. McGinty, and
   Dr. Goldman acknowledge funding from grant 1R01MH093414-01A1 from the
   National Institute of Mental Health (principal investigator, Dr. Barry).
   Data for this study were collected through Time-Sharing Experiments for
   the Social Sciences, National Science Foundation (grant 0818839). Dr.
   Pescosolido acknowledges support from an infrastructure grant from the
   College of Arts and Sciences, Indiana University.
CR Abadia-Barrero CE, 2006, SOC SCI MED, V62, P1219, DOI 10.1016/j.socscimed.2005.07.006
   [Anonymous], 2000, SUMM FIND 2000 NAT H
   Kessler RC, 1996, AM J ORTHOPSYCHIAT, V66, P17, DOI 10.1037/h0080151
   Link BG, 1999, AM J PUBLIC HEALTH, V89, P1328, DOI 10.2105/AJPH.89.9.1328
   Pescosolido BA, 2010, AM J PSYCHIAT, V167, P1321, DOI 10.1176/appi.ajp.2010.09121743
   Wolfe WR, 2008, AM J PUBLIC HEALTH, V98, P1865, DOI 10.2105/AJPH.2007.122044
NR 6
TC 257
Z9 263
U1 4
U2 86
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD OCT
PY 2014
VL 65
IS 10
BP 1269
EP 1272
DI 10.1176/appi.ps.201400140
PG 4
WC Health Policy & Services; Public, Environmental & Occupational Health;
   Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health; Psychiatry
GA AQ0MK
UT WOS:000342477200016
PM 25270497
OA Green Accepted
HC Y
HP N
DA 2023-06-23
ER

PT J
AU He, JZ
   Yan, XY
   Wang, RF
   Zhao, JY
   Liu, J
   Zhou, CW
   Zeng, YM
AF He, Jingzhen
   Yan, Xinyu
   Wang, Rufang
   Zhao, Juyou
   Liu, Jun
   Zhou, Changwei
   Zeng, Yumei
TI Does Childhood Adversity Lead to Drug Addiction in Adulthood? A Study of
   Serial Mediators Based on Resilience and Depression
SO FRONTIERS IN PSYCHIATRY
LA English
DT Article
DE adverse childhood experiences; drug addiction; resilience; depression;
   mediating effect
ID HOUSEHOLD DYSFUNCTION; SUBSTANCE USE; EXPERIENCES; RISK; ABUSE; MODEL;
   BEHAVIORS; CHILDREN
AB Drug addiction is a common problem worldwide. Research has shown adverse childhood experiences (ACEs) to be an important factor related to drug addiction. However, there are few studies on how ACEs lead to drug addiction and the role of resilience and depression in this process. Thus, the main purposes of the study were to determine the proportion of those with adverse childhood experiences who take drugs in adulthood and how resilience and depression affect this relationship. The results showed that (1) greater severity of ACEs made individuals more likely to take drugs; (2) ACEs were positively correlated with depression, and resilience was negatively correlated with ACEs and depression; and (3) ACEs not only affected drug addiction through resilience or depression alone but also through the combined action of resilience and depression, indicating that depression led to drug addiction while resilience weakened the effect of ACEs on depression and drug addiction. Furthermore, in the serial mediation model, abuse, neglect, and family dysfunction were significant predictors of drug addiction. Our results are encouraging in that they provide guidance in understanding the complex relationships among ACEs, resilience, depression, and drug addiction.
EM rufwang@cdutcm.edu.cn
CR Anda RF, 2002, PSYCHIAT SERV, V53, P1001, DOI 10.1176/appi.ps.53.8.1001
   Baker TB, 2004, PSYCHOL REV, V111, P33, DOI 10.1037/0033-295X.111.1.33
   BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004
   Bethell CD, 2017, ACAD PEDIATR, V17, pS51, DOI 10.1016/j.acap.2017.04.161
   Brown SM, 2017, CHILD ABUSE NEGLECT, V63, P211, DOI 10.1016/j.chiabu.2016.11.006
   Campbell JA, 2016, AM J PREV MED, V50, P344, DOI 10.1016/j.amepre.2015.07.022
   Chandler GE, 2015, J AM PSYCHIAT NURSES, V21, P406, DOI 10.1177/1078390315620609
   Chang XN, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211850
   Chapman DP, 2004, J AFFECT DISORDERS, V82, P217, DOI 10.1016/j.jad.2003.12.013
   Cloitre M, 2019, PSYCHOL TRAUMA-US, V11, P82, DOI 10.1037/tra0000374
   Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113
   Davis L, 2008, CURR OPIN PSYCHIATR, V21, P14, DOI 10.1097/YCO.0b013e3282f32408
   De Venter M, 2013, Tijdschr Psychiatr, V55, P259
   Deighton S, 2018, PSYCHIAT RES, V269, P719, DOI 10.1016/j.psychres.2018.08.097
   Dube SR, 2004, CHILD ABUSE NEGLECT, V28, P729, DOI 10.1016/j.chiabu.2003.08.009
   Dube SR, 2003, PEDIATRICS, V111, P564, DOI 10.1542/peds.111.3.564
   Dube SR, 2001, JAMA-J AM MED ASSOC, V286, P3089, DOI 10.1001/jama.286.24.3089
   Duke NN, 2018, AM J HEALTH BEHAV, V42, P85, DOI 10.5993/AJHB.42.5.8
   Farrugia Philippa L, 2011, Ment Health Subst Use, V4, P314
   Feingold D, 2021, ADV EXP MED BIOL, V1264, P67, DOI 10.1007/978-3-030-57369-0_5
   Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8
   Forster M, 2018, ADDICT BEHAV, V76, P298, DOI 10.1016/j.addbeh.2017.08.037
   Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118
   Hustedde C, 2021, PRIMARY CARE, V48, P493, DOI 10.1016/j.pop.2021.05.005
   Jaworska-Andryszewska P, 2019, PHARMACOL REP, V71, P112, DOI 10.1016/j.pharep.2018.10.004
   Jiang LJ, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.786386
   Klika JB, 2013, TRAUMA VIOLENCE ABUS, V14, P222, DOI 10.1177/1524838013487808
   LeMoult J, 2020, J AM ACAD CHILD PSY, V59, P842, DOI 10.1016/j.jaac.2019.10.011
   Luthar SS, 2000, CHILD DEV, V71, P543, DOI 10.1111/1467-8624.00164
   Merrick MT, 2017, CHILD ABUSE NEGLECT, V69, P10, DOI 10.1016/j.chiabu.2017.03.016
   Proitsi P, 2011, NEUROBIOL AGING, V32, P434, DOI 10.1016/j.neurobiolaging.2009.03.005
   Rogers WM, 2004, MULTIVAR BEHAV RES, V39, P379, DOI 10.1207/S15327906MBR3903_1
   Sisto A, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55110745
   Sonu S, 2019, PREV MED, V123, P163, DOI 10.1016/j.ypmed.2019.03.032
   Su S, 2015, CURR CARDIOL REP, V17, DOI 10.1007/s11886-015-0645-1
   Su SY, 2015, CIRCULATION, V131, P1674, DOI 10.1161/CIRCULATIONAHA.114.013104
   Teicher MH, 2016, J CHILD PSYCHOL PSYC, V57, P241, DOI 10.1111/jcpp.12507
   Thurston H, 2018, J PEDIATR NURS, V42, P25, DOI 10.1016/j.pedn.2018.06.008
   Volkow ND, 2004, BIOL PSYCHIAT, V56, P714, DOI 10.1016/j.biopsych.2004.07.007
   Wang ZZ, 2007, BIOMED ENVIRON SCI, V20, P404
   Wingo AP, 2010, J AFFECT DISORDERS, V126, P411, DOI 10.1016/j.jad.2010.04.009
   Wisner B, 2004, AM STAT, DOI [10.1198/tas.2008.s98, DOI 10.1198/TAS.2008.S98]
   [吴艳 Wu Yan], 2011, [心理科学进展, Advances in Psychological Science], V19, P1859
   Xiang XL, 2021, INT J GERIATR PSYCH, V36, P215, DOI 10.1002/gps.5417
   Zhou YY, 2012, J BEHAV THER EXP PSY, V43, P705, DOI 10.1016/j.jbtep.2011.10.004
NR 45
TC 3
Z9 3
U1 5
U2 19
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD APR 18
PY 2022
VL 13
AR 871459
DI 10.3389/fpsyt.2022.871459
PG 9
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA 2B6AM
UT WOS:000810268700001
PM 35509889
OA gold, Green Published
DA 2023-06-23
ER

PT J
AU Isorna, M
   Fernandez-Rios, L
   Souto, A
AF Isorna, Manuel
   Fernandez-Rios, Luis
   Souto, Antonio
TI TREATMENT OF DRUG ADDICTION AND PSYCHOPATHOLOGY: A FIELD STUDY
SO EUROPEAN JOURNAL OF PSYCHOLOGY APPLIED TO LEGAL CONTEXT
LA English
DT Article
DE psychopathology; drug addiction; drug-free programme; antagonists;
   agonists; dual diagnosis
AB Field study to assess the concurrence of the psychopathology of drug addiction, and to evaluate the efficacy of pharmacological treatment versus drug-free treatments for the psychopathology of drug addiction. A total of 261 patients treated for drug addiction, 131 on a drug-free treatment and the remaining 130 patients received a drug regime, of which 113 were, according to the Prochaska and Decrement's Transtheorical Model, in a initial phase of the treatment (from 15 days to 6 months of treatment) and 148 in a maintenance phase in drug treatment (> 6 months), were psychopathologically assessed using the SCL-90-R (Derogatis, 2002). A field study with a 2 X 2 design (treatment: drug-free vs. drug-regime) and (treatment phase: initial phase vs. maintenance in drug treatment) was carried out. The results support the hypothesis of a dual diagnosis, that is, the comorbidity of psychopathology and drug addiction. On the whole, treatment for drug addiction had a significant impact on reducing associated psychopathology. Finally, the results are discussed in the light of the implications for the treatment of drug addiction.
C1 [Isorna, Manuel] Univ Vigo, Fac Ciencias Educ & Deporte, Pontevedra 36005, Spain.
   [Fernandez-Rios, Luis] Univ Santiago de Compostela, Fac Psychol, Santiago De Compostela, Spain.
   [Souto, Antonio] Univ A Coruna, Univ Coll Physiotherapy, La Coruna, Spain.
C3 Universidade de Vigo; Universidade de Santiago de Compostela;
   Universidade da Coruna
RP Isorna, M (通讯作者)，Univ Vigo, Fac Ciencias Educ & Deporte, Campus Xunqueira S-N, Pontevedra 36005, Spain.
EM isorna.catoira@uvigo.es
RI Isorna, Manuel/AAH-3363-2019; Isorna Folgar, Manuel/AAK-9304-2020;
   Souto-Gestal, Antonio/C-7249-2012
OI Isorna, Manuel/0000-0002-3398-8882; Isorna Folgar,
   Manuel/0000-0002-3398-8882; Souto-Gestal, Antonio/0000-0002-7332-1599
CR ABBOTT PJ, 1994, J ADDICT DIS, V13, P1
   Arce R., 2003, ADICCIONES, V15, P221
   Arseneault L, 2002, BRIT MED J, V325, P1212, DOI 10.1136/bmj.325.7374.1212
   Belena M.A., 1993, PSICOLOGIA SOCIAL AP, P145
   Blaszczynski A, 1997, ADDICTION, V92, P75
   Brooner RK, 1997, ARCH GEN PSYCHIAT, V54, P71
   Cacciola JS, 2001, DRUG ALCOHOL DEPEN, V61, P271, DOI 10.1016/S0376-8716(00)00148-4
   Cacciola JS, 1996, J NERV MENT DIS, V184, P234, DOI 10.1097/00005053-199604000-00006
   Calsyn DA, 1996, PSYCHOL ADDICT BEHAV, V10, P3
   Casas M., 1992, TRASTORNOS PSIQUICOS, V1
   Casas M., 1995, ADICCIONES, V7, P411
   Chen CC, 1999, ADDICTION, V94, P825, DOI 10.1046/j.1360-0443.1999.9468256.x
   Darke S, 1997, DRUG ALCOHOL DEPEN, V48, P135, DOI 10.1016/S0376-8716(97)00117-8
   Derogatis L.R., 2002, SCL 90 R MANUAL
   Derogatis LR, 1977, SCL 90 R ADM SCORING
   DICLEMENTE CC, 1982, ADDICT BEHAV, V7, P133, DOI 10.1016/0306-4603(82)90038-7
   DRAKE RE, 1989, HOSP COMMUNITY PSYCH, V40, P1041
   GERSTLEY LJ, 1990, AM J PSYCHIAT, V147, P173
   Goldstein A., 1995, ADICCION
   Gutierrez E., 1998, ADICCIONES, V10, P121
   Horcajadas FA, 1997, ACTAS LUSO-ESP NEUR, V25, P379
   KHANTZIAN EJ, 1985, ARCH GEN PSYCHIAT, V42, P1067
   KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259
   KOSTEN TR, 1989, BIOL PSYCHIAT, V26, P637, DOI 10.1016/0006-3223(89)90090-5
   Krausz M, 1999, EUR ADDICT RES, V5, P55, DOI 10.1159/000018966
   Mateu G, 2005, ADICCIONES, V17, P111
   MCLELLAN AT, 1993, JAMA-J AM MED ASSOC, V269, P1953, DOI 10.1001/jama.269.15.1953
   MEYER RE, 1986, PSYCHOPATHOLOGY ADDI, P3
   Miller N., 1996, ISSUES DIAGNOSIS TRE
   Miller N.S., 1995, ADDICTION PSYCHIAT C
   Miranda JJF, 2001, ACTAS ESP PSIQUIATRI, V29, P228
   PROCHASKA JO, 1982, PSYCHOTHER-THEOR RES, V19, P276, DOI 10.1037/h0088437
   PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102
   Ravndal E, 1998, J SUBST ABUSE TREAT, V15, P135
   REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511
   ROUNSAVILLE BJ, 1982, ARCH GEN PSYCHIAT, V39, P151
   ROUNSAVILLE BJ, 1982, ARCH GEN PSYCHIAT, V39, P161
   ROUNSAVILLE BJ, 1986, PSYCHOPATHOLOGY ADDI, P140
   SANCHEZ E, 1999, ADICCIONES, V11, P221
   Sanchez-Hervas E., 2001, ADICCIONES, V13, P61
   SANNARCISO GI, 1998, ADICCIONES, V10, P7
   Wojnar M, 1997, ALCOHOL CLIN EXP RES, V21, P1351
   WOODY GE, 1990, DRUG ALCOHOL DEPEN, V25, P121, DOI 10.1016/0376-8716(90)90049-K
NR 43
TC 7
Z9 8
U1 0
U2 9
PU SOCIEDAD ESPANOLA PSICOLOGIA JURIDICA FORENSE
PI SANTIAGO
PA UNIV SANTIAGO COMPOSTELA, FACULTAD PSICOLOGIA, SANTIAGO, E-15782, SPAIN
SN 1889-1861
EI 1989-4007
J9 EUR J PSYCHOL APPL L
JI Eur. J. Psychol. Appl. Legal Context
PD JAN
PY 2010
VL 2
IS 1
BP 3
EP 18
PG 16
WC Law; Psychology, Multidisciplinary
WE Social Science Citation Index (SSCI)
SC Government & Law; Psychology
GA V24IF
UT WOS:000208403400002
DA 2023-06-23
ER

PT J
AU Hartogsohn, I
   Vudka, A
AF Hartogsohn, Ido
   Vudka, Amir
TI Technology and addiction: What drugs can teach us about digital media
SO TRANSCULTURAL PSYCHIATRY
LA English
DT Article; Early Access
DE consumer society; drugs; media addiction; psychedelics; set and setting;
   smartphone addiction; sociotechnical imaginaries
ID ENVIRONMENTAL ENRICHMENT; BEHAVIORAL ADDICTIONS; SMARTPHONE USE;
   DEFINITION; DEPRESSION; ANXIETY; NEED
AB Comparisons between digital media and narcotic drugs have become increasingly common in the vigorous discussion on smartphone addiction and technology addiction. Commentators have used evocative terms such as "digital heroin," "electronic cocaine," and "virtual drugs" when discussing users' growing dependence on their devices. This article looks at the spreading discourse comparing digital media with drugs from a set of interdisciplinary perspectives including media studies, political economy, critical theory, science and technology studies, and addiction studies. It engages several key questions: To what extent can heavy smartphone use be considered an addiction, and how is it similar or different from drug addiction? How do the analogies between media and drugs fit within prevalent imaginaries of information technologies, and within the greater cultural themes and preoccupations of late capitalism? And finally, what can drugs teach us about the possible escape routes from our society's current predicament?
C1 [Hartogsohn, Ido] Bar Ilan Univ, Program Sci Technol & Soc, Ramat Gan, Israel.
   [Vudka, Amir] Univ Amsterdam, Film & Media Studies Dept, Amsterdam, Netherlands.
C3 Bar Ilan University; University of Amsterdam
RP Hartogsohn, I (通讯作者)，Bar Ilan Univ, Program Sci Technol & Soc, Ramat Gan, Israel.
EM idohartogsohn@gmail.com
OI Hartogsohn, Ido/0000-0002-7906-3682
CR Alexander B., 2010, GLOBALIZATION ADDICT
   ALEXANDER BK, 1988, CAN PSYCHOL, V29, P151, DOI 10.1037/h0084530
   Alter A, 2017, IRRESISTIBLE RISE AD
   American Psychiatric Association, 2013, DSM 5 TASK FORCE DIA, V5th ed., DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596.744053, 10.1016/B978-0-12-809324-5.05530-9]
   Anderson B., 2016, IMAGINED COMMUNITIES
   Anderson Reaynaldo, 2017, AFROFUTURISM 2 0 RIS
   Barbrook Richard, 1996, SCI CULT-UK, V6, P44, DOI DOI 10.1080/09505439609526455
   Baudrillard J., 2016, CONSUMER SOC MYTHS S
   Becker R, 2016, VERGE 0830
   Bjerg O, 2008, BODY SOC, V14, P1, DOI 10.1177/1357034X08090695
   Blainey MG, 2015, J RELIG HEALTH, V54, P287, DOI 10.1007/s10943-014-9826-2
   Brand Stewart, 1972, ROLLING STONE, P50
   Burroughs W. S., 2013, NAKED LUNCH
   Carhart-Harris RL, 2018, J PSYCHOPHARMACOL, V32, P725, DOI 10.1177/0269881118754710
   Carr N., 2010, SHALLOWS WHAT INTERN
   Carr Nicholas, 2017, WALL STREET J
   Chauvet C, 2012, NEUROPHARMACOLOGY, V63, P635, DOI 10.1016/j.neuropharm.2012.05.014
   Clement J., 2017, SCREEN SCHOOLED 2 VE
   Coambs, 1980, BRIT COLUMBIA MED J, V22, P32
   Colin C, 2013, NEW YORKER
   Collins S.E., 2012, HARM REDUCTION PRAGM, Vsecond, P3
   Common Sense Media, 2016, DEAL DEV PAR TEEN DY
   Courtwright David T., 2002, FORCES HABIT DRUGS M
   Courtwright DT., 2019, AGE ADDICTION BAD HA
   Demirci K, 2015, J BEHAV ADDICT, V4, P85, DOI 10.1556/2006.4.2015.010
   DERY M, 1996, ESCAPE VELOCITY CYBE
   Elhai JD, 2017, J AFFECT DISORDERS, V207, P251, DOI 10.1016/j.jad.2016.08.030
   Elhai JD, 2016, COMPUT HUM BEHAV, V63, P509, DOI 10.1016/j.chb.2016.05.079
   Eyal N., 2014, HOOKED BUILD HABIT F
   Giles P, 2019, J CULT ECON-UK, V12, P612, DOI 10.1080/17530350.2019.1639068
   Gonzalez Robbie, 2018, WIRED
   GOODMAN A, 1990, BRIT J ADDICT, V85, P1403
   Grant JE, 2010, AM J DRUG ALCOHOL AB, V36, P233, DOI 10.3109/00952990.2010.491884
   Gunkell H., 2017, FUTURES FICTIONS ESS
   Hadar AA., 2015, BRAIN STIMUL, V8, P318, DOI [10.1016/j.brs.2015.01.032, DOI 10.1016/J.BRS.2015.01.032]
   Hadar A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180094
   Haraway D.J., 2016, STAYING TROUBLE MAKI, DOI DOI 10.1111/
   Hari J, 2015, CHASING SCREAM 1 LAS
   Harsh A, 2017, HUFFINGTON POST
   Hartogsohn I., 2017, DRUG SCI POLICY LAW, V3, p205032451668332, DOI DOI 10.1177/2050324516683325
   Hawi NS, 2016, COMPUT EDUC, V98, P81, DOI 10.1016/j.compedu.2016.03.007
   Hormes JM, 2014, ADDICTION, V109, P2079, DOI 10.1111/add.12713
   Horvath J, 2020, ADDICT BEHAV, V105, DOI 10.1016/j.addbeh.2020.106334
   Huddleston B., 2016, DIGITAL COCAINE JOUR
   Ifland JR, 2009, MED HYPOTHESES, V72, P518, DOI 10.1016/j.mehy.2008.11.035
   Jameson Fredric, 1996, SEEDS TIME
   Jasanoff S., 2016, DREAMSCAPES MODERNIT
   Jasanoff S, 2004, STATES KNOWLEDGE COP
   Kardaras Nicholas, 2016, GLOW KIDS SCREEN ADD
   Karim R, 2012, J PSYCHOACTIVE DRUGS, V44, P5, DOI 10.1080/02791072.2012.662859
   Koo C, 2011, CYBERPSYCH BEH SOC N, V14, P391, DOI 10.1089/cyber.2009.0331
   Kumar Krishnan, 2005, POSTINDUSTRIAL POSTM
   Labate BC, 2017, VITALITY INDIGEN REL, P1
   Lanier Jaron, 2018, 10 ARGUMENTS DELETIN
   Leary Timothy, 1994, CHAOS CYBER CULTURE
   Leeman RF, 2013, CAN J PSYCHIAT, V58, P260, DOI 10.1177/070674371305800503
   Lenton S, 1998, DRUG ALCOHOL REV, V17, P213, DOI 10.1080/09595239800187011
   Lewis Paul, 2017, GUARDIAN 1006
   Livingstone S, 2018, J CHILD MEDIA, V12, P118, DOI 10.1080/17482798.2017.1417091
   Lucking T, 2015, TECHNOGENIC FLOURISH
   MacDougall R.C., 2012, DRUGS MEDIA NEW PERS, pvii
   Madrigal A. C., 2013, ATLANTIC
   McLuhan M., 1964, NATION, P517
   McLuhan M., 1968, WAR PEACE GLOBAL VIL
   McLuhan M., 2003, UNDERSTANDING MEDIA
   Mod C, 2018, WIRED
   Newport C., 2019, NEW YORKER
   Orford J, 2001, ADDICTION, V96, P15, DOI 10.1046/j.1360-0443.2001.961152.x
   Pellicane A., 2017, CALM COOL CONNECTED
   Petry NM, 2013, ADDICTION, V108, P1186, DOI 10.1111/add.12162
   Phillips T, 2017, GUARDIAN 0828
   Pies Ronald, 2009, Psychiatry (Edgmont), V6, P31
   Price C., 2018, BREAK YOUR PHONE 30
   Przybylski AK, 2013, J SOC PERS RELAT, V30, P237, DOI 10.1177/0265407512453827
   Roberts JA, 2015, PERS INDIV DIFFER, V79, P13, DOI 10.1016/j.paid.2015.01.049
   Roberts JA, 2014, J BEHAV ADDICT, V3, P254, DOI 10.1556/JBA.3.2014.015
   Schmitgen MM, 2020, ADDICT BEHAV, V108, DOI 10.1016/j.addbeh.2020.106422
   Schultes R. E., 1992, PLANTS GODS THEIR SA
   Sellgren K., 2016, BBC NEWS 1006
   Skinner B. F., 1953, SCI HUMAN BEHAV
   Skinner BF., 1966, BEHAV ORGANISMS EXPT
   Stairs DJ, 2006, BEHAV PHARMACOL, V17, P597, DOI 10.1097/01.fbp.0000236271.72300.0e
   Sussman S, 2011, INT J ENV RES PUB HE, V8, P4025, DOI 10.3390/ijerph8104025
   Taylor C, 2002, PUBLIC CULTURE, V14, P91, DOI 10.1215/08992363-14-1-91
   Turel O, 2010, COMMUN ACM, V53, P41, DOI 10.1145/1735223.1735237
   Turkle Sherry., 2011, ALONE TOGETHER WHY W
   Turner Fred, 2008, COUNTERCULTURE CYBER
   Twenge Jean M, 2017, ATLANTIC
   Veissiere SPL, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.00141
   Volkow ND, 2005, NAT NEUROSCI, V8, P555, DOI 10.1038/nn1452
   Ward AF., 2017, J ASSOC CONSUM RES, V2, P140, DOI [DOI 10.1086/691462, 10.1086/691462]
   We Are Plan C., 2014, WE AR ALL VER ANX
   Weber Max., 1905, PROTESTANT ETHIC SPI
   Weil Andrew, 1972, NATURAL MIND INVESTI
   Wheale PR, 2003, TECHNOL ANAL STRATEG, V15, P117, DOI 10.1080/0953732032000046097
   Wheelwright T., 2021, CELL PHONE BEHAV SUR
   Whitaker LR, 2013, NEURON, V77, P335, DOI 10.1016/j.neuron.2012.11.022
   Williams S, 2014, VOA 0825
   Yoon S., 2014, PROC EXTENDED ABSTR, P1735, DOI 10.1145/2559206.2581167
   Zahariades D., 2016, DIGITAL DETOX UNPLUG
NR 100
TC 1
Z9 1
U1 5
U2 17
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1363-4615
EI 1461-7471
J9 TRANSCULT PSYCHIATRY
JI Transcult. Psychiatry
PD 2022 JUL 7
PY 2022
DI 10.1177/13634615221105116
EA JUL 2022
PG 11
WC Anthropology; Psychiatry
WE Social Science Citation Index (SSCI)
SC Anthropology; Psychiatry
GA 2S9EP
UT WOS:000822089000001
PM 35799499
OA hybrid
DA 2023-06-23
ER

PT J
AU Farrugia, A
   Fraser, S
AF Farrugia, Adrian
   Fraser, Suzanne
TI Prehending Addiction: Alcohol and Other Drug Professionals' Encounters
   With "New" Addictions
SO QUALITATIVE HEALTH RESEARCH
LA English
DT Article
DE addiction; prehension; alcohol and other drugs; science communication;
   qualitative research; in-depth interviews; science and technology
   studies; Australia; Canada and Sweden
ID HARM REDUCTION; POLICY; USERS; STIGMATIZATION; STRATEGIES; WORKERS
AB This article investigates the ways new forms of addiction are encountered by professionals working in the area of alcohol and other drugs. Combining interviews with policymakers, service providers, and peer advocates in three countries (Australia, Canada, and Sweden), and Mike Michael's utilization of the notion of prehension for science communication, we track the notions of addiction, drugs, and subjectivity that emerge when alcohol and other drug professionals encounter what Fraser, Moore and Keane call the addicting of nonsubstance-related practices. The analysis has three parts: constituting addiction unity, questioning addiction unity, and conflicting logics of addicting processes. We argue that specific articulations of drugs and health and specific health professional and addiction subjects are made anew in these encounters. These notions of drugs, health, and subjectivity shape how alcohol and other drug professionals engage with substance-related addictions. In concluding, we consider the implications of new addictions for professional practice.
C1 [Farrugia, Adrian] Curtin Univ, Fac Hlth Sci, NDRI, Social Studies Addict Concepts SSAC Res Program, Fitzroy, Vic, Australia.
   [Fraser, Suzanne] Curtin Univ, Fac Hlth Sci, NDRI,Melbourne Off, Social Studies Addict Concepts SSAC Res Program, Fitzroy, Vic, Australia.
C3 Curtin University; Curtin University
RP Farrugia, A (通讯作者)，Curtin Univ, Fac Hlth Sci, Natl Drug Res Inst, Suite 6,19-35 Gertrude St, Fitzroy, Vic 3065, Australia.
EM adrian.farrugia@curtin.edu.au
OI Farrugia, Adrian/0000-0003-3751-9060; Fraser,
   Suzanne/0000-0003-1018-5865
FU Australian Research Council Future Fellowship [FT120100215]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: The
   research reported in this article was funded by an Australian Research
   Council Future Fellowship (FT120100215) awarded to Suzanne Fraser.
CR Barnett AI, 2015, NEUROETHICS-NETH, V8, P271, DOI 10.1007/s12152-015-9236-5
   Bell S, 2014, NEUROETHICS-NETH, V7, P19, DOI 10.1007/s12152-013-9177-9
   Bevir M, 2007, CONSUM PUBLIC LIFE, P1, DOI 10.1057/9780230591363
   Bourgois P, 2003, ADDICT RES THEORY, V11, P31, DOI 10.1080/1606635021000021322
   Campbell Nancy, 2007, DISCOVERING ADDICTIO
   Campbell ND, 2010, BIOSOCIETIES, V5, P89, DOI 10.1057/biosoc.2009.2
   Carr ES, 2011, SCRIPTING ADDICTION
   Courtwright DT, 2010, BIOSOCIETIES, V5, P137, DOI 10.1057/biosoc.2009.3
   CRAWFORD R, 1980, INT J HEALTH SERV, V10, P365, DOI 10.2190/3H2H-3XJN-3KAY-G9NY
   Duff C., 2014, ASSEMBLAGES HLTH DEL
   Dumit J., 2004, PICTURING PERSONHOOD
   Farrugia A, 2017, HEALTH-LONDON, V21, P595, DOI 10.1177/1363459315628042
   Fraser S, 2008, SOC SCI MED, V66, P740, DOI 10.1016/j.socscimed.2007.10.012
   Fraser S, 2018, CRIT POLICY STUD, V12, P61, DOI 10.1080/19460171.2016.1191365
   Fraser S, 2016, INT J DRUG POLICY, V31, P6, DOI 10.1016/j.drugpo.2015.10.014
   Fraser S, 2013, ADDICT RES THEORY, V21, P496, DOI 10.3109/16066359.2012.749868
   Fraser Suzanne, 2014, HABITS REMAKING ADDI
   Harchaoui T., 2003, EC ANAL RES PAPER SE, V11F0027
   Irwin A., 2003, SCI SOCIAL THEORY PU
   Karasaki M, 2013, DRUG ALCOHOL REV, V32, P195, DOI 10.1111/j.1465-3362.2012.00501.x
   Keane H., 2002, WHATS WRONG ADDICTIO
   Lancaster K, 2017, HEALTH-LONDON, V21, P278, DOI 10.1177/1363459316688520
   Metzl Jonathan M., 2010, HLTH HLTH BECAME NEW
   Meurk C, 2016, INT J DRUG POLICY, V32, P34, DOI 10.1016/j.drugpo.2016.03.004
   Michael M, 2002, SCI TECHNOL HUM VAL, V27, P357, DOI 10.1177/016439027003002
   Michael M, 2012, SCI TECHNOL HUM VAL, V37, P528, DOI 10.1177/0162243911428624
   Moore D, 2005, DRUG ALCOHOL REV, V24, P275, DOI 10.1080/09595230500170258
   Moore D, 2013, QUAL HEALTH RES, V23, P916, DOI 10.1177/1049732313487027
   Moore D, 2009, SOC SCI MED, V68, P1161, DOI 10.1016/j.socscimed.2008.12.015
   Olsson B., 2011, NARKOTIKA PROBLEM PO, P15
   ORNBERG JC, 2009, EUROPEANIZATION SWED
   Petersen A, 2010, CRIT PUBLIC HEALTH, V20, P391, DOI 10.1080/09581596.2010.518379
   Reay B. A., 2015, SEX ADDICTION CRITIC
   Redfield J., 2002, HIGH ANXIETIES CULTU
   Rhodes T, 2009, INT J DRUG POLICY, V20, P193, DOI 10.1016/j.drugpo.2008.10.003
   Ritter A., 2011, MONOGRAPH NATL DRUG, V21
   Ritter A, 2006, DRUG ALCOHOL REV, V25, P611, DOI 10.1080/09595230600944529
   Room R., 2003, JANUS HEAD, V6, P221, DOI DOI 10.5840/JH2003628
   Seale CF., 1999, QUALITY QUALITATIVE, DOI DOI 10.4135/9780857020093
   Sedgwick EveKosofsky., 1993, TENDENCIES, DOI DOI 10.1215/9780822381860
   Sendziuk P, 2007, CAN BULL MED HIST, V24, P113, DOI 10.3138/cbmh.24.1.113
   Smith CBR, 2010, SOC SCI MED, V70, P859, DOI 10.1016/j.socscimed.2009.10.033
   Stenius K., 2010, CONTEMP DRUG PROBL, V37, P417, DOI DOI 10.1177/009145091003700304
   TIFFEN R, 2004, AUSTR COMPARES
   UNDP, 2016, HUM DEV EV HUM DEV R
   Valentine K., 2011, DRUG EFFECT HLTH CRI, P137
   Vrecko S, 2010, HIST HUM SCI, V23, P52, DOI 10.1177/0952695110371598
   Whitaker T, 2011, QUAL HEALTH RES, V21, P1086, DOI 10.1177/1049732311404031
   Whitehead A.N., 1929, PROCESS REALITY
   Wolfe D, 2007, INT J DRUG POLICY, V18, P246, DOI 10.1016/j.drugpo.2007.01.012
   Wood E., 2011, CANADIAN MED ASS J, V165, P405
   Zinberg NE, 1984, DRUG SET AND SETTING
NR 52
TC 3
Z9 3
U1 0
U2 12
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1049-7323
EI 1552-7557
J9 QUAL HEALTH RES
JI Qual. Health Res.
PD NOV
PY 2017
VL 27
IS 13
SI SI
BP 2042
EP 2056
DI 10.1177/1049732317731539
PG 15
WC Public, Environmental & Occupational Health; Information Science &
   Library Science; Social Sciences, Interdisciplinary; Social Sciences,
   Biomedical
WE Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health; Information Science &
   Library Science; Social Sciences - Other Topics; Biomedical Social
   Sciences
GA FL5SQ
UT WOS:000414306400013
PM 29088991
DA 2023-06-23
ER

PT J
AU Tang, YL
   Hao, W
AF Tang, Yi-Lang
   Hao, Wei
TI Improving drug addiction treatment in China
SO ADDICTION
LA English
DT Review
DE challenges; China; drug addiction; efficacy; HIV/AIDS; traditional
   Chinese medicine; treatment
ID USE PATTERNS; HIV/AIDS; ILLNESS; YUNNAN; ABUSE
AB Aims To illustrate the current situation and problems of drug addiction in treatment China and propose suggestions. Methods A descriptive study based on literature searched from Medline and the China National Knowledge Infrastructure database (1996-2007) and hand-picked references. Results Since the re-emergence of drug addiction in China in the early 1990s, there has been tremendous progress in drug addiction treatments in China, especially treatments for opiate addiction. However, many problems and challenges remain for improvement, including widespread negative attitudes towards drug abuse and drug-dependent individuals, the lack of evidence-based data on the efficacy of Chinese traditional medicine and the lack of a comprehensive and integrated system to organize all treatment resources and monitor treatment progress. The authors discuss the challenges that impede effective treatments of drug addiction and some suggestions are proposed. Implementing these suggestions can improve the outcome of treatment of drug-dependent individuals and benefit the whole society. Conclusion China faces substantial drug addiction problems that appear to be worsening with time. Although much progress in drug addiction treatment has been made, improvement in many aspects is needed urgently.
C1 Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA.
   Capital Univ Med Sci, Beijing Anding Hosp, Beijing, Peoples R China.
   Cent S Univ, Mental Hlth Inst, Changsha 410083, Hunan, Peoples R China.
   Cent S Univ, Xiangya Hosp 2, WHO Collaborating Ctr Psychosocial Factors Drug A, Changsha 410083, Hunan, Peoples R China.
C3 Emory University; Emory University; Capital Medical University; Central
   South University; Central South University
RP Tang, YL (通讯作者)，Emory Univ, Sch Med, Dept Human Genet, 615 Michael St,Suite 301, Atlanta, GA 30322 USA.
EM weihao57@gmail.com
RI Tang, Yilang/AAH-7164-2020; Hao, Wei/HLX-1665-2023
CR ANGLIN MD, 1990, CRIME JUSTICE, V13, P393, DOI 10.1086/449179
   [Anonymous], 1998, JAMA, V280, P1936
   AO QR, 2004, CHIN J GEN PRACT, V3, P209
   BAI YT, 2001, CPC HIST, V10, P38
   BAUMLER A, 2001, MODERN CHINA OPIUM R
   Cohen J, 2004, SCIENCE, V304, P1430, DOI 10.1126/science.304.5676.1430
   De Leon G, 1988, NIDA Res Monogr, V84, P74
   Deng R, 2007, SOC SCI MED, V64, P1560, DOI 10.1016/j.socscimed.2006.12.011
   DUAN LX, 2003, CHINESE J DRUG ABUSE, V9, P6
   HAN JS, 2001, CHINESE J DRUG DEPEN, V124, P140
   Hao W, 2000, J PSYCHOACTIVE DRUGS, V32, P277, DOI 10.1080/02791072.2000.10400450
   Hao W, 2004, ADDICTION, V99, P1176, DOI 10.1111/j.1360-0443.2004.00830.x
   HAO W, 2004, CHIN J DRUG ABUSE PR, V10, P227
   *INF OFF STAT COUN, 2000, NARC CONTR CHIN
   JIANG Z, 1993, CHINESE J NEUROLOGY, V26, P10
   JIANG ZN, 1999, CHINESE J DRUG DEPEN, V8, P67
   JIANG ZN, 1996, CHINESE J PSYCHIAT, V29, P200
   JIANG ZN, 1995, HEROIN ADDICTION CON
   Li M, 2002, ALTERN THER HEALTH M, V8, P50
   [刘彦红 Liu yanhong], 2004, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V13, P60
   Liu Z. M., 2002, CHINESE J DRUG ABUSE, V8, P27
   Liu ZM, 2006, DRUG ALCOHOL REV, V25, P173, DOI 10.1080/09595230500538835
   LOU J, 2003, CHINESE J DRUG ABUSE, V9, P5
   McCoy A, 2003, POLITICS HEROIN CIA
   McCoy CB, 1997, J DRUG ISSUES, V27, P73, DOI 10.1177/002204269702700105
   McCoy CB, 2001, SUBST USE MISUSE, V36, P49, DOI 10.1081/JA-100000228
   McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689
   McLellan AT, 2004, BIOL PSYCHIAT, V56, P764, DOI 10.1016/j.biopsych.2004.06.018
   *MIN HLTH INF OFF, 2006, CURR SIT HIV AIDS EN
   *MIN HLTH MIN PUBL, 2003, GUID PIL STUD COMM D
   *NNCC, 2005, 5 YEAR NARC CONTR MA
   *OFF CHIN NAT DRUG, 2006, ANN REP DRUG CONTR C
   Shi J, 2006, ACTA PHARMACOL SIN, V27, P1303, DOI 10.1111/j.1745-7254.2006.00431.x
   *STAT COUNC PEOPL, 2000, NARC CONTR CHIN
   [苏中华 Su Zhonghua], 2005, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V14, P122
   Tang YL, 2006, ADDICTION, V101, P657, DOI 10.1111/j.1360-0443.2006.01367.x
   Tang YL, 2005, J SUBST ABUSE TREAT, V29, P215, DOI 10.1016/j.jsat.2005.06.006
   Tang YL, 2001, CHINESE J DRUG DEPEN, V10, P27
   TANG YL, 1997, CHIN B DRUG DEPEND, V6, P73
   TANG YL, 1997, CHINESE B DRUG DEPEN, V6, P31
   Volkow ND, 2001, AM J PSYCHIAT, V158, P1181, DOI 10.1176/appi.ajp.158.8.1181
   WANG XC, 2005, CHINESE J STEREOTACT, V18, P129
   [王雪 Wang Xue], 2004, [中国循证医学杂志, Chinese Journal of Evidence-Based Medicine], V4, P545
   WHO, 2004, NEUR PSYCH SUBST US
   WU JM, 2003, J CHINESE INTEGRATIV, V1, P268
   WU LZ, 1999, J PEKING U HLTH SCI, V31, P123
   [徐国柱 Xu Guozhu], 2002, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V11, P280
   XU GZ, 2002, CHINESE J DRUG ABUSE, V8, P2
   XU GZ, 2000, CHINESE J DRUG DEPEN, V9, P230
   Xu M, 2007, ADDICTION, V102, P282, DOI 10.1111/j.1360-0443.2006.01660.x
   [薛丽燕 Xue Liyan], 2002, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V11, P47
   Yang G, 1996, Zhonghua Yi Xue Za Zhi, V76, P141
   YANG KJ, 2005, CHIN J STEREOTACT FU, V18, P135
   ZHAO M, 2002, DRUG ALCOHOL PROFESS, V2, P10
   Zhao M, 2000, CHIN J DRUG DEPEND, V9, P213
   ZHAO XY, 1997, CHINESE J BEHAV MED, V6, P289
   Zhou Y, 1999, SUBST USE MISUSE, V34, P907, DOI 10.3109/10826089909037248
   Ziedonis DM, 2004, CNS SPECTRUMS, V9, P892, DOI 10.1017/S1092852900009718
   赵苳, 2003, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V12, P246
NR 59
TC 49
Z9 53
U1 4
U2 26
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0965-2140
EI 1360-0443
J9 ADDICTION
JI Addiction
PD JUL
PY 2007
VL 102
IS 7
BP 1057
EP 1063
DI 10.1111/j.1360-0443.2007.01849.x
PG 7
WC Substance Abuse; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry
GA 178MI
UT WOS:000247224400016
PM 17567394
DA 2023-06-23
ER

PT J
AU Chiappini, S
   Schifano, F
   Martinotti, G
AF Chiappini, Stefania
   Schifano, Fabrizio
   Martinotti, Giovanni
TI Editorial: Prescribing Psychotropics: Misuse, Abuse, Dependence,
   Withdrawal and Addiction
SO FRONTIERS IN PSYCHIATRY
LA English
DT Editorial Material
DE drug abuse; drug misuse; prescription drug misuse; pharming; drug
   diversion; addiction; pharmacovigilance
ID PRESCRIPTION; PREGABALIN; DRUGS; NPS
C1 [Chiappini, Stefania; Schifano, Fabrizio; Martinotti, Giovanni] Univ Hertfordshire, Psychopharmacol Drug Misuse & Novel Psychoact Sub, Sch Life & Med Sci, Hatfield, Herts, England.
   [Chiappini, Stefania; Martinotti, Giovanni] Univ G dAnnunzio, Dept Neurosci Imaging & Clin Sci, Chieti, Italy.
C3 University of Hertfordshire; G d'Annunzio University of Chieti-Pescara
RP Chiappini, S (通讯作者)，Univ Hertfordshire, Psychopharmacol Drug Misuse & Novel Psychoact Sub, Sch Life & Med Sci, Hatfield, Herts, England.; Chiappini, S (通讯作者)，Univ G dAnnunzio, Dept Neurosci Imaging & Clin Sci, Chieti, Italy.
EM stefaniachiappini9@gmail.com
RI Martinotti, Giovanni/AAC-7592-2022; CHIAPPINI, STEFANIA/ABC-3831-2020
OI Martinotti, Giovanni/0000-0002-7292-2341; CHIAPPINI,
   STEFANIA/0000-0002-6810-1540; Schifano, Fabrizio/0000-0002-4178-5401
CR Advisory Council on the Misuse of Drugs (ACMD), 2018, ADD ADV ANT DRUGS PR
   Chiappini S., 2020, PHARM J, V305, P7943, DOI [10.1211/PJ.2020.20208538, DOI 10.1211/PJ.2020.20208538]
   Chiappini S, 2021, J PSYCHOPHARMACOL, V35, P681, DOI 10.1177/0269881120959615
   Chiappini S, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10100736
   Chiappini S, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00767
   Chiappini S, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10020105
   Chiappini S, 2016, CNS DRUGS, V30, P647, DOI 10.1007/s40263-016-0359-y
   Clay JM, 2020, LANCET PUBLIC HEALTH, V5, pE259, DOI 10.1016/S2468-2667(20)30088-8
   Dores AR, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.648501
   Festinger DS, 2016, J CHILD ADOLES SUBST, V25, P480, DOI 10.1080/1067828X.2015.1103345
   Lessenger JE, 2008, J AM BOARD FAM MED, V21, P45, DOI 10.3122/jabfm.2008.01.070071
   Levine DA, 2007, CURR OPIN PEDIATR, V19, P270, DOI 10.1097/MOP.0b013e32814b09cf
   Lipari R. N., 2017, WHY DO ADULTS MISUSE
   Martinotti G, 2021, CNS SPECTRUMS, V26, P84, DOI 10.1017/S1092852920001479
   Orsolini L, 2020, CURR NEUROPHARMACOL, V18, P809, DOI 10.2174/1570159X18666200110121333
   Orsolini L, 2017, HUM PSYCHOPHARM CLIN, V32, DOI 10.1002/hup.2573
   Orsolini L, 2015, HUM PSYCHOPHARM CLIN, V30, P302, DOI 10.1002/hup.2466
   Pichini S, 2018, THER DRUG MONIT, V40, P38, DOI 10.1097/FTD.0000000000000465
   Public Health Institute, 2020, DIR IND IMP COVID 19
   Schifano F, 2021, PSYCHOL MED, V51, P30, DOI 10.1017/S0033291719001727
   Schifano F, 2021, EXP NEUROL, V339, DOI 10.1016/j.expneurol.2021.113638
   Schifano F, 2020, PSYCHOTHER PSYCHOSOM, V89, P274, DOI 10.1159/000507897
   Schifano F, 2018, BRAIN SCI, V8, DOI 10.3390/brainsci8120221
   Schifano F, 2018, BRAIN SCI, V8, DOI 10.3390/brainsci8040073
   Schifano F, 2017, CURR TOP BEHAV NEURO, V32, P351, DOI 10.1007/7854_2016_15
   Schifano F, 2014, CNS DRUGS, V28, P491, DOI 10.1007/s40263-014-0164-4
   Schwan S, 2010, EUR J CLIN PHARMACOL, V66, P947, DOI 10.1007/s00228-010-0853-y
   Simeone R, 2017, SUBST ABUS-RES TREAT, V11, DOI 10.1177/1178221817696077
   Stefania C, 2021, CURR NEUROPHARMACOL, V19, P1728, DOI 10.2174/1570159X19666210113151136
   Vickers-Smith R, 2020, DRUG ALCOHOL DEPEN, V206, DOI 10.1016/j.drugalcdep.2019.107709
   WHO, 2014, WHO PERSP MED LOOK P
   Zaami S, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00700
   Zawilska JB, 2019, NEUROTOXICOLOGY, V73, P8, DOI 10.1016/j.neuro.2019.02.015
NR 34
TC 1
Z9 1
U1 0
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD APR 30
PY 2021
VL 12
AR 688434
DI 10.3389/fpsyt.2021.688434
PG 3
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA SB6RH
UT WOS:000650118200001
PM 33995156
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Afzali, R
   Qiomars, YD
   Nosrati, R
AF Afzali, Rasoul
   Qiomars, Yazdanpanah Dero
   Nosrati, Rouhollah
TI Representation of addiction and drugs victims through TV media
SO JOURNAL OF ETHNICITY IN SUBSTANCE ABUSE
LA English
DT Article
DE Addiction; drugs; framing; Iran; representation; victim groups
ID HIGH-SCHOOL; MODEL
AB Misrepresentation of social groups and communities targeted by addiction and drugs in developing countries-where the media are exclusive to the government-has reduced the Media's validity in the prevention control, and treatment of addiction. This study proceeds to scrutinize the demeanor by which the national media of Iran portrays addiction and drugs victim groups to the community, whilst focusing on the prime incentives behind such representations. This is a combinational research design seeking out both qualitative and quantitative factors involved in the study. The findings conjecture that the Iranian national television has, to a large degree, failed to accurately present the social verity of addiction in the community, due to certain errors and omissions in regards to identifying target groups and considering social components of addiction and drugs. the most notable factor behind this misrepresentation is censorship and framing of the subject of addiction in line with political tendencies of the state as regards social problems. The 5 major frames considered by the media as regards victim groups of addiction and drugs and their social characteristics include: frames on "addiction among male adolescents"; "addiction among social degenerates"; "epicurean addiction"; "addiction as the consequence of modern living"; and "law enforcement in drugs". The frame building procedure employed by the Iranian national television for the subject of addiction and drugs entails the curtailment of addiction to exclusive groups of the community, primarily comprised of what the media perceives as disreputable and degrading individuals, so as to allow for society to appear as a separate and somewhat immaculate entity. Such frames have disparaged the authority and influence of the media in controlling the aftermath and damages of drugs and addiction.
C1 [Afzali, Rasoul; Qiomars, Yazdanpanah Dero; Nosrati, Rouhollah] Univ Tehran, Tehran, Iran.
C3 University of Tehran
RP Qiomars, YD (通讯作者)，Univ Tehran, Polit Geog, Tehran, Iran.
EM kyazdanpanah@ut.ac.ir
CR Afzali R., 2018, ADDICTION Q, V12, P31
   Amon JJ, 2014, INT J DRUG POLICY, V25, P13, DOI 10.1016/j.drugpo.2013.05.019
   Anderson P. A., 2011, MULTICHANNEL INTEGRA
   Andrew Dudley, 1976, MAJOR FILM THEORIES
   Assanangkornchai S, 2007, DRUG ALCOHOL DEPEN, V86, P167, DOI 10.1016/j.drugalcdep.2006.06.001
   Ayres TC, 2012, CRIME MEDIA CULT, V8, P315, DOI 10.1177/1741659012443234
   Bagdikian B.H., 2004, NEW MEDIA MONOPOLY
   Baigom-Ghadamgahi M., 2010, HUMANITARIAN GEOGRAP, V2, P117
   BALLROKEACH SJ, 1976, COMMUN RES, V3, P3, DOI 10.1177/009365027600300101
   Barry AE, 2018, SUBST USE MISUSE, V53, P2413, DOI 10.1080/10826084.2018.1482345
   Bastani P, 2019, INT J DRUG POLICY, V63, P90, DOI 10.1016/j.drugpo.2018.11.013
   Baudrillard J., 2016, CONSUMER SOC MYTHS S
   Bhaskar R., 1979, POSSIBILITY NATURALI
   Bolinski R. S., 2018, MEDIA FRAMING DRUG C
   Bouman Z., 1991, MODERNITY AMBIVALENT
   Boydstun Amber E, 2013, IDENTIFYING MEDIA FR
   Broring G., 2008, EMPOWERMENT SELF ORG
   BROSIUS HB, 1995, EUR J COMMUN, V10, P391, DOI 10.1177/0267323195010003005
   Bruno G., 2009, MEDIA LANDSCAPE IRAN
   CHAMBLISS WJ, 1973, SOCIETY, V11, P24, DOI 10.1007/BF03181016
   Chin WW, 1998, MIS QUART, V22, pVII
   Chiricos Theodore, 1996, JUSTICE PREJUDICE RA
   COBB RW, 1972, PARTICIPATION AM POL
   Cobbina J. E., 2008, J CRIMINAL JUSTICE P, V15, P15145
   Collier A., 2000, CRITICAL REALISM INT
   DeFoster R., 2016, CONTEMP DRUG PROBL, V2, P103, DOI [10.1177/0091450916642515, DOI 10.1177/0091450916642515]
   Dehrooyeh M., 2011, CRIME PREVENTION STU, V4, P55
   Denvir D., 2015, STUNNING PARADOX IRA
   Department of Research at University of Tehran, 2016, STUD EFF MED DIR ATT, P409
   ENTMAN RM, 1993, J COMMUN, V43, P51, DOI 10.1111/j.1460-2466.1993.tb01304.x
   Fisk J., 2005, INTRO COMMUNICATION
   Foucault Michel, 1977, DISCIPLINE PUNISH, P192
   Fry D.L., 1986, ANN INT COMMUNICATIO, V9, P443, DOI DOI 10.1080/23808985.1986.11678619
   GAMSON WA, 1989, AM J SOCIOL, V95, P1, DOI 10.1086/229213
   Gans H. J., 1979, DECIDING WHATS NEWS
   Gecer E., 2018, AKAD NCELEMELER DERG, V13, P199, DOI DOI https://doi.org/10.17550/akademikincelemeler.310556
   Ghanbari-Baghestan A., 2010, HUMAN COMMUNICATION, V12, P239
   Ghiabi M, 2018, THIRD WORLD Q, V39, P277, DOI 10.1080/01436597.2017.1350818
   Gramsci A., 2011, PRISON NOTEBOOKS, V1-3
   Habibzadeh-Maleki A., 2009, COMMUNICATIVE RES Q, V16, P95, DOI [10.22082/CR.2009.23844, DOI 10.22082/CR.2009.23844]
   Hallahan K., 1999, J PUBLIC RELAT RES, V11, P205, DOI DOI 10.1207/S1532754XJPRR1103_02
   Henseler J, 2009, ADV INT MARKETING, V20, P277, DOI 10.1108/S1474-7979(2009)0000020014
   Hesse- Biber S. N., 2008, HDB EMERGENT METHODS
   Iran Drug Control Headquarters, 2015, ANN 2015 REP
   Iran Drug Control Headquarters, 2012, ANN 2012 REP
   Iranian Academic Center for Education Culture and Research Department of Humanitarian and Social Sciences., 2012, NAT SURV PREV DRUGS
   Kevin W., 2003, UNDERSTANDING MEDIA
   Khiabany G., 2009, SOCIAL SEMIOTICS, V17, P479, DOI DOI https://doi.org/10.1080/10350330701637064
   Labibi M., 2011, COMMUNICATIVE RES Q, V19, P141
   Lancaster K, 2011, DRUG ALCOHOL REV, V30, P397, DOI 10.1111/j.1465-3362.2010.00239.x
   Lazersfeld Paul F., 1971, PROCESS EFFECTS MASS, P554
   Lee L., 2015, SOCIOLOGICAL IMAGINA, V4, P1
   Legleye S, 2014, INT J DRUG POLICY, V25, P1103, DOI 10.1016/j.drugpo.2014.07.002
   Lippman W., 1921, PUBLIC OPINION
   MENSCH BS, 1988, SOCIOL EDUC, V61, P95, DOI 10.2307/2112267
   Merghati Khoei Effatf, 2018, J Reprod Infertil, V19, P237
   Mirsarood T., 2007, ADDICTS PORTRAYED IR
   Montagne M, 2011, SUBST USE MISUSE, V46, P849, DOI 10.3109/10826084.2011.570609
   Noroozi A, 2018, J PSYCHOACTIVE DRUGS, V50, P214, DOI 10.1080/02791072.2018.1425808
   Norton R., 2007, COMMUNICATION STYLE
   Orsini M. M., 2017, CONTEMP DRUG PROBL, V44, P189, DOI [https://doi.org/10.1177/0091450917722817, DOI 10.1177/0091450917722817]
   Pasztor S. K., 2010, MPSA C
   Price VJ, 2016, MSPHERE, V1, DOI 10.1128/mSphere.00064-16
   Rajabi S., 2011, STRATEGIC STUDIES SP, V27, P21
   Reinarman C., 1997, CRACK AM DEMON DRUGS, P18
   Roshan Pajooh M., 2015, NATL CENSUS PREVALEN
   Samii A. W., 2003, BROWN J WORLD AFFAIR, V9, P283
   Scheufele DA, 1999, J COMMUN, V49, P103, DOI 10.1111/j.1460-2466.1999.tb02784.x
   Semetko HA, 2000, J COMMUN, V50, P93, DOI 10.1093/joc/50.2.93
   Shaditalab Z., 2012, ADDICTED WOMEN LABOR
   Shekarbeygi A., 2014, MILITARY SCI Q, V53, P31
   Shoemaker P. J., 1996, MEDIATING MESSAGE TH
   Soriano CRR, 2021, JOURNALISM, V22, P2386, DOI 10.1177/1464884919867820
   Taylor S, 2008, PROBAT J, V55, P369, DOI 10.1177/0264550508096493
   Tiger Rebecca, 2017, CONTEXTS, P46
   Tuchman G., 1978, MAKING NEWS STUDY CO
   UK Drug Policy Commission (UKDPC), 2010, REPR DRUG US DRUG US
   UNODC, 2013, UNODC COUNTR PROGR I
   Valkov B., 2018, TRAKIA J SCI, V2, P95, DOI [https://doi.org/10.15547/tjs.2018.02.004, DOI 10.15547/tjs.2018.02.004]
   Vreese C. H., 2005, INFORM DESIGN J DOCU, V13, P51, DOI DOI 10.1075/IDJDD.13.1.06VRE
   Werb D, 2011, J EPIDEMIOL COMMUN H, V65, P834, DOI 10.1136/jech.2010.125195
   Yaghoobi H., 2013, NATL SURVEY PREVALEN
   Young Jock, 1981, MANUFACTURE NEWS SOC, P326
   Ziaaddini Hasan, 2013, J Addict, V2013, P297378, DOI 10.1155/2013/297378
NR 84
TC 0
Z9 0
U1 2
U2 15
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1533-2640
EI 1533-2659
J9 J ETHN SUBST ABUSE
JI J. Ethn. Subst. Abuse
PD MAY 2
PY 2022
VL 21
IS 2
BP 585
EP 620
DI 10.1080/15332640.2020.1793863
EA JUL 2020
PG 36
WC Substance Abuse
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse
GA 1A2SD
UT WOS:000551327600001
PM 32701038
DA 2023-06-23
ER

PT J
AU Koshkina, EA
   Kirzhanova, VV
   Babicheva, LP
   Mugantseva, LA
AF Koshkina, E. A.
   Kirzhanova, V. V.
   Babicheva, L. P.
   Mugantseva, L. A.
TI The activity of drug addiction service of the Russian Federation: an
   assessment of statistical parameters and an analysis of results
SO ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA
LA Russian
DT Article
DE epidemiology; narcology; drug addiction service
AB The authors studied changes in the structure of drug addiction services, the dynamics of outpatient and inpatient referrals for drug addiction treatment and effectiveness of drug addiction services in 2011 compared to the preceding period. There was a reduction of availability of drug treatment services due to the reduction of the number of drug addiction units and the depletion of human resource potential. The lack of structural development of rehabilitation sector of drug care services and low rates of its development as well as the decrease in the number of patients seeking treatment are highlighted. It has been concluded that the drug addiction services require reorganization of its regulatory and legal framework and need innovative organizational and management decisions and human resources trained in innovative thinking and technologies.
C1 [Koshkina, E. A.; Kirzhanova, V. V.; Babicheva, L. P.; Mugantseva, L. A.] Minist Publ Hlth Russian Federat, Natl Res Ctr Addict, Moscow, Russia.
RP Koshkina, EA (通讯作者)，Minist Publ Hlth Russian Federat, Natl Res Ctr Addict, Moscow, Russia.
EM epid@list.ru
RI Koshkina, Evgeniya/AFN-4315-2022; Kirzhanova, Valentina/AAI-3529-2020
OI Kirzhanova, Valentina V./0000-0002-3243-1409; Koshkina,
   Evgeniya/0000-0001-7694-8533
CR Box G.E.P., 1976, TIME SERIES ANAL FOR
   KOSHKINA EA, 2008, OSNOVNYE POKAZATELI, P125
   SAFINA N, 2012, NARKOLOGICHESKUYU SL
NR 3
TC 0
Z9 6
U1 0
U2 1
PU IZDATELSTVO MEDITSINA
PI MOSCOW
PA PETROVERIGSKII PER 6-8, K-142 MOSCOW, RUSSIA
SN 1997-7298
J9 ZH NEVROL PSIKHIATR
JI Z. Nevrol. Psikhiatrii Im S S Korsakova
PY 2013
VL 113
IS 6
SU 2
BP 3
EP 8
PG 6
WC Clinical Neurology; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Psychiatry
GA 197PG
UT WOS:000322862500001
PM 23887460
DA 2023-06-23
ER

PT J
AU Chiappini, S
   Schifano, F
   Martinotti, G
AF Chiappini, Stefania
   Schifano, Fabrizio
   Martinotti, Giovanni
TI Editorial: Prescribing psychotropics: Misuse, abuse, dependence,
   withdrawal and addiction, Volume II
SO FRONTIERS IN PSYCHIATRY
LA English
DT Editorial Material
DE drug abuse; drug misuse; prescription drug misuse; pharming; drug
   diversion; addiction; pharmacovigilance
C1 [Chiappini, Stefania; Schifano, Fabrizio; Martinotti, Giovanni] Univ Hertfordshire, Sch Life & Med Sci, Psychopharmacol Drug Misuse & Novel Psychoact Subs, Hatfield, England.
   [Chiappini, Stefania; Martinotti, Giovanni] Univ G dAnnunzio, Dept Neurosci Imaging & Clin Sci, Chieti, Italy.
C3 University of Hertfordshire; G d'Annunzio University of Chieti-Pescara
RP Chiappini, S (通讯作者)，Univ Hertfordshire, Sch Life & Med Sci, Psychopharmacol Drug Misuse & Novel Psychoact Subs, Hatfield, England.; Chiappini, S (通讯作者)，Univ G dAnnunzio, Dept Neurosci Imaging & Clin Sci, Chieti, Italy.
EM stefaniachiappini9@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD OCT 18
PY 2022
VL 13
AR 1053896
DI 10.3389/fpsyt.2022.1053896
PG 4
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA H5CU4
UT WOS:000996148600001
PM 37255962
DA 2023-06-23
ER

PT J
AU Mal'ova, M
AF Mal'ova, Miriam
TI Environment's impact on the emergence of drug addictions of children and
   youth; Possibilities of their prevention
SO NEW EDUCATIONAL REVIEW
LA English
DT Article
DE drug addiction; environment; prevention; toxic addiction of children and
   youth; reasons for emergence of drug addictions; elementary schools.
AB The contribution refers to the participation of environment for the emergence of drug addiction of children and youth. It expounds the origins of drug addiction emergence with special respect to environment's impact. It also presents selected results of the research implemented at elementary schools of the Banska Bystrica district in the Slovak Republic. A part of the research was directed to determine personal experiences with drugs of pupils at the 2(nd) stage of elementary schools.
C1 Matej Bel Univ, Pedagog Fac, Dept Pedagogy, Banska Bystrica 97411, Slovakia.
C3 Matej Bel University
RP Mal'ova, M (通讯作者)，Matej Bel Univ, Pedagog Fac, Dept Pedagogy, Ruzova 13, Banska Bystrica 97411, Slovakia.
EM mmalova@pdf.umb.sk
CR BIELIKOVA M, 2003, PREVENCIA, P13
   BROWN G, 1974, HUMAN TEACHING HUMAN
   EMMEROVA I, 2004, SOCIALNA PATOLOGIA
   EMMEROVA I, 2005, MLADEZ SPOLOCNOST, P48
   HRONCOVA J, 1996, SOCIOLOGIA VYCHOVY
   HRONCOVA J, 2004, SOCIALNA PATOLOGIA
   HRONCOVA J, 2006, PRICINY KRIMINALITY
   MALOVA M, 2005, RIGOROZNA PRACA
   NESPOR K, 2000, NAVYKOV CHOVANI ZAVI
   NOVOTNY I, 1999, PROTIDROGOVA VYCHOVA
   RACKOVA M, 2002, PREVENCIA, P28
   SUPPES MA, 1991, SOCIAL WORK EXPERIEN
   URBAN E, 1974, MLADEZ DROGY
   ZENKE R, 1985, TRAINING APR, P54
   2000, NARODNY PROGRAM PROT
   2006, EUROPSKE MONITOROVAC
NR 16
TC 0
Z9 0
U1 2
U2 18
PU WYDAWNICTWO ADAM MARSZALEK
PI TORUN
PA UL LUBICKA 44, TORUN, 87-100, POLAND
SN 1732-6729
J9 NEW EDUC REV
JI New Educ. Rev.
PY 2007
VL 12
IS 2
BP 63
EP 71
PG 9
WC Education & Educational Research
WE Social Science Citation Index (SSCI)
SC Education & Educational Research
GA 272IC
UT WOS:000253852100007
DA 2023-06-23
ER

PT J
AU Deroche-Gamonet, V
   Piazza, PV
AF Deroche-Gamonet, Veronique
   Piazza, Pier Vincenzo
TI Psychobiology of cocaine addiction: Contribution of a multi-symptomatic
   animal model of loss of control
SO NEUROPHARMACOLOGY
LA English
DT Review
DE Addiction; Animal model; Cocaine
ID SUBSTANCE-USE DISORDERS; SYNAPTIC PLASTICITY; DRUG-USE; PREFRONTAL
   CORTEX; INDIVIDUAL VULNERABILITY; DEPENDENT INDIVIDUALS;
   PERSONALITY-VARIABLES; NUCLEUS-ACCUMBENS; SENSATION-SEEKING;
   MENTAL-DISORDERS
AB Transition to addiction is the shift from controlled to uncontrolled drug use that occurs after prolonged drug intake in a limited number of drug users. A major challenge of addiction research in recent years has been to develop models for studying this pathological transition. Toward this goal, a DSIVI-IV/5-based multi-symptomatic model of cocaine addiction has been developed in the rat. It is based on an operational translation of the main features of the disease. 1. Addiction is not just taking drug; it is a non-adaptive drug use: The procedure models addiction in relation to its clinical definition. 2. All drug users do not face the same individual risk of developing addiction: The model includes an individual-based approach. 3. Addiction develops after protracted periods of controlled drug use: This procedure allows for the study of the long-term shift from controlled drug use to addiction.
   We describe this model in detail and show how it can contribute to our understanding of the pathophysiology of cocaine addiction.
   This article is part of a Special Issue entitled 'NIDA 40th Anniversary Issue'. (C) 2013 Published by Elsevier Ltd.
C1 [Deroche-Gamonet, Veronique; Piazza, Pier Vincenzo] Univ Bordeaux, INSERM, U862, Neuroctr Magendie, F-33077 Bordeaux, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux
RP Deroche-Gamonet, V (通讯作者)，Univ Bordeaux, INSERM, U862, Neuroctr Magendie, 146 Rue Leo Saignat, F-33077 Bordeaux, France.
EM veronique.deroche@inserm.fr; pier-vincenzo.piazza@inserm.fr
RI Deroche-Gamonet, Véronique/E-5728-2010
OI Deroche-Gamonet, Veronique/0000-0002-9704-6624
FU ANR (Neurorelaps, TIMMS); EquipEx OptoPath [ANR-10-EQPX-08]; Labex
   BRAIN; INSERM; Conseil Regional d'Aquitaine; University of Bordeaux 2
FX VDG 82PVP are supported by ANR (Neurorelaps, TIMMS), EquipEx OptoPath
   (ANR-10-EQPX-08) and Labex BRAIN grants, by INSERM, the Conseil Regional
   d'Aquitaine and the University of Bordeaux 2.
CR American Psychiatric Association (APA), 2000, DIAGN STAT MAN MENT, Vfourth
   AUSUBEL DP, 1961, PSYCHIAT QUART, V35, P523, DOI 10.1007/BF01573620
   Ball SA, 1998, J PERS DISORD, V12, P1, DOI 10.1521/pedi.1998.12.1.1
   Bari A, 2008, NAT PROTOC, V3, P759, DOI 10.1038/nprot.2008.41
   Batts K.T., 2005, CONTEXTUAL OTHER FAC
   Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   Belin D, 2011, NEUROPSYCHOPHARMACOL, V36, P569, DOI 10.1038/npp.2010.188
   Belin D, 2009, BIOL PSYCHIAT, V65, P863, DOI 10.1016/j.biopsych.2008.05.031
   Blanchard MM, 2009, NEUROSCI BIOBEHAV R, V33, P1145, DOI 10.1016/j.neubiorev.2009.05.009
   Bornovalova MA, 2005, EXP CLIN PSYCHOPHARM, V13, P311, DOI 10.1037/1064-1297.13.4.311
   Bowers MS, 2010, NEURON, V67, P11, DOI 10.1016/j.neuron.2010.06.004
   BOZARTH MA, 1985, JAMA-J AM MED ASSOC, V254, P81, DOI 10.1001/jama.254.1.81
   Cain ME, 2005, EXP CLIN PSYCHOPHARM, V13, P367, DOI 10.1037/1064-1297.13.4.367
   Chen BT, 2008, NEURON, V59, P288, DOI 10.1016/j.neuron.2008.05.024
   Childress A R, 1988, NIDA Res Monogr, V84, P25
   Clapper R L, 1994, J Subst Abuse, V6, P305, DOI 10.1016/S0899-3289(94)90491-X
   Coffey SF, 2003, EXP CLIN PSYCHOPHARM, V11, P18, DOI 10.1037/1064-1297.11.1.18
   Compton WM, 2013, DRUG ALCOHOL DEPEN, V132, P387, DOI 10.1016/j.drugalcdep.2013.02.036
   Conway KP, 2002, DRUG ALCOHOL DEPEN, V65, P225, DOI 10.1016/S0376-8716(01)00168-5
   Cunha PJ, 2011, AM J ADDICTION, V20, P78, DOI 10.1111/j.1521-0391.2010.00097.x
   Dackis CA, 2001, J SUBST ABUSE TREAT, V21, P111, DOI 10.1016/S0740-5472(01)00192-1
   Dellu F, 1996, NEUROPSYCHOBIOLOGY, V34, P136, DOI 10.1159/000119305
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Deroche-Gamonet V, 2010, ENCYCLOPEDIA OF BEHAVIORAL NEUROSCIENCE, VOL 3: P-Z, P422
   Ersche KD, 2013, BIOL PSYCHIAT, V74, P137, DOI 10.1016/j.biopsych.2012.11.016
   Ferrario CR, 2008, BRAIN RES, V1209, P151, DOI 10.1016/j.brainres.2008.02.081
   Ferrario CR, 2005, BIOL PSYCHIAT, V58, P751, DOI 10.1016/j.biopsych.2005.04.046
   Franques P, 2000, ENCEPHALE, V26, P68
   GAWIN FH, 1991, SCIENCE, V251, P1580, DOI 10.1126/science.2011738
   Gerra G, 2004, SUBST USE MISUSE, V39, P345, DOI 10.1081/JA-120028493
   Goeders NE, 2003, EUR NEUROPSYCHOPHARM, V13, P435, DOI 10.1016/j.euroneuro.2003.08.004
   Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119
   Gorodetzky H, 2011, PSYCHIAT RES, V186, P437, DOI 10.1016/j.psychres.2010.07.024
   GOSSOP M, 1978, DRUG ALCOHOL DEPEN, V3, P359, DOI 10.1016/0376-8716(78)90005-4
   Goto Y, 2010, BIOL PSYCHIAT, V67, P199, DOI 10.1016/j.biopsych.2009.08.026
   GREENE RL, 1993, J PERS ASSESS, V61, P224, DOI 10.1207/s15327752jpa6102_2
   Gunnarsdottir ED, 2000, ADDICT BEHAV, V25, P641, DOI 10.1016/S0306-4603(99)00043-X
   Haney M, 2009, ADDICT BIOL, V14, P9, DOI 10.1111/j.1369-1600.2008.00121.x
   Hutchison KE, 1999, EXP CLIN PSYCHOPHARM, V7, P493, DOI 10.1037/1064-1297.7.4.493
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   JESSOR R, 1980, AM J PUBLIC HEALTH, V70, P604, DOI 10.2105/AJPH.70.6.604
   JOHANSON CE, 1976, PHARMACOL BIOCHEM BE, V4, P45, DOI 10.1016/0091-3057(76)90174-X
   Kasanetz F, 2013, MOL PSYCHIATR, V18, P729, DOI 10.1038/mp.2012.59
   Kasanetz F, 2010, SCIENCE, V328, P1709, DOI 10.1126/science.1187801
   Kessler RC, 1996, AM J ORTHOPSYCHIAT, V66, P17, DOI 10.1037/h0080151
   KHANTZIAN EJ, 1986, AM J DRUG ALCOHOL AB, V12, P213, DOI 10.3109/00952998609007391
   Kreek MJ, 2002, NAT REV DRUG DISCOV, V1, P710, DOI 10.1038/nrd897
   Kreek MJ, 2005, NAT NEUROSCI, V8, P1450, DOI 10.1038/nn1583
   LABOUVIE EW, 1986, J CONSULT CLIN PSYCH, V54, P289, DOI 10.1037/0022-006X.54.3.289
   Le AD, 2002, PHARMACOL THERAPEUT, V94, P137, DOI 10.1016/S0163-7258(02)00200-0
   Lejuez CW, 2008, BEHAV RES THER, V46, P811, DOI 10.1016/j.brat.2008.03.010
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Liu Y, 2005, EUR J NEUROSCI, V22, P195, DOI 10.1111/j.1460-9568.2005.04195.x
   Luscher C, 2011, NEURON, V69, P650, DOI 10.1016/j.neuron.2011.01.017
   Mameli M, 2011, NEUROPHARMACOLOGY, V61, P1052, DOI 10.1016/j.neuropharm.2011.01.036
   Martin M, 2006, NAT NEUROSCI, V9, P868, DOI 10.1038/nn1713
   McLellan AT, 2006, AM J ADDICTION, V15, P113, DOI 10.1080/10550490500528316
   Mihindou C, 2013, BIOL PSYCHIAT, V73, P271, DOI 10.1016/j.biopsych.2012.08.011
   Neiman T, 2013, J NEUROSCI, V33, P1521, DOI 10.1523/JNEUROSCI.2068-12.2013
   Nutt D, 2007, LANCET, V369, P1047, DOI 10.1016/S0140-6736(07)60464-4
   OBRIEN CP, 1992, ANN NY ACAD SCI, V654, P400, DOI 10.1111/j.1749-6632.1992.tb25984.x
   Peer K, 2013, DRUG ALCOHOL DEPEN, V127, P215, DOI 10.1016/j.drugalcdep.2012.07.009
   Pelloux Y, 2007, PSYCHOPHARMACOLOGY, V194, P127, DOI 10.1007/s00213-007-0805-0
   Piazza P. vincenzo, 2013, PSYCHOPHARM IN PRESS
   Piazza PV, 2000, J NEUROSCI, V20, P4226
   PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295
   Piazza PV, 1996, ANNU REV PHARMACOL, V36, P359, DOI 10.1146/annurev.pa.36.040196.002043
   Richardson NR, 1996, J NEUROSCI METH, V66, P1, DOI 10.1016/0165-0270(95)00153-0
   RISNER ME, 1976, BIOL PSYCHIAT, V11, P625
   Russo SJ, 2010, TRENDS NEUROSCI, V33, P267, DOI 10.1016/j.tins.2010.02.002
   Samaha AN, 2005, BIOL PSYCHIAT, V57, P351, DOI 10.1016/j.biopsych.2004.11.040
   Samaha AN, 2005, TRENDS PHARMACOL SCI, V26, P82, DOI 10.1016/j.tips.2004.12.007
   SCHINKA JA, 1994, J PERS ASSESS, V63, P413, DOI 10.1207/s15327752jpa6303_2
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   Shalev U, 2002, PHARMACOL REV, V54, P1, DOI 10.1124/pr.54.1.1
   Sher KJ, 2000, J CONSULT CLIN PSYCH, V68, P818, DOI 10.1037/0022-006X.68.5.818
   Sidhpura N, 2011, NEUROPHARMACOLOGY, V61, P1070, DOI 10.1016/j.neuropharm.2011.05.034
   Skinstad AH, 2001, AM J DRUG ALCOHOL AB, V27, P45, DOI 10.1081/ADA-100103118
   Somaini L, 2011, NEUROSCI BIOBEHAV R, V35, P1771, DOI 10.1016/j.neubiorev.2010.11.008
   Swadi H, 1999, DRUG ALCOHOL DEPEN, V55, P209, DOI 10.1016/S0376-8716(99)00017-4
   Swendsen J, 2011, ANN NY ACAD SCI, V1216, P73, DOI 10.1111/j.1749-6632.2010.05894.x
   Swendsen J, 2010, ADDICTION, V105, P1117, DOI 10.1111/j.1360-0443.2010.02902.x
   Terracciano A, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-22
   Thomas MJ, 2008, BRIT J PHARMACOL, V154, P327, DOI 10.1038/bjp.2008.77
   Vaillant GE, 1996, ALCOHOL HEALTH RES W, V20, P152
   Vaillant GE, 1995, NATURAL HIST ALCOHOL
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Verdejo-Garcia A, 2008, NEUROSCI BIOBEHAV R, V32, P777, DOI 10.1016/j.neubiorev.2007.11.003
   Verdejo-Garcia A, 2006, J INT NEUROPSYCH SOC, V12, P405, DOI 10.1017/S1355617706060486
   Verdejo-Garcia AJ, 2007, ADDICT BEHAV, V32, P950, DOI 10.1016/j.addbeh.2006.06.032
   WHO, 2013, MAN SUBST AB GLOB BU
   WHO, 2013, ICD 10 CM
   Wiessing L., 2009, EUROSURVEILLANCE, V14
   Wolf ME, 2010, NEUROSCI BIOBEHAV R, V35, P185, DOI 10.1016/j.neubiorev.2010.01.013
   WOLFFGRAMM J, 1991, NEUROSCI BIOBEHAV R, V15, P515, DOI 10.1016/S0149-7634(05)80142-3
   Wolffgramm J, 2000, J NEURAL TRANSM, V107, P649, DOI 10.1007/s007020070067
   WOLFFGRAMM J, 1991, PHARMACOL BIOCHEM BE, V38, P389, DOI 10.1016/0091-3057(91)90297-F
   Zuckerman M, 1986, NIDA Res Monogr, V74, P59
   Zuckerman M., 1979, SENSATION SEEKING OP
NR 100
TC 57
Z9 57
U1 3
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3908
EI 1873-7064
J9 NEUROPHARMACOLOGY
JI Neuropharmacology
PD JAN
PY 2014
VL 76
SI SI
BP 437
EP 449
DI 10.1016/j.neuropharm.2013.07.014
PN B
PG 13
WC Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 294YK
UT WOS:000330083600024
PM 23916478
DA 2023-06-23
ER

PT J
AU Hou, HF
   Tian, M
   Zhang, H
AF Hou, Haifeng
   Tian, Mei
   Zhang, Hong
TI Positron Emission Tomography Molecular Imaging of Dopaminergic System in
   Drug Addiction
SO ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY
   BIOLOGY
LA English
DT Article
DE positron emission tomography; dopamine; dopamine receptor; drug
   addiction; heroin
ID MU-OPIOID RECEPTOR; METHADONE-MAINTENANCE TREATMENT; C-11 BETA-CIT;
   NUCLEUS-ACCUMBENS; D2 RECEPTORS; BEHAVIORAL ADDICTIONS; CANNABINOID
   MECHANISM; TRANSPORTER DENSITY; COCAINE ADDICTION; PET EXAMINATION
AB Dopamine (DA) is involved in drug reinforcement, but its role in drug addiction remains unclear. Positron emission tomography (PET) is the first technology used for the direct measurement of components of the dopaminergic system in the living human brain. In this article, we reviewed the major findings of PET imaging studies on the involvement of DA in drug addiction, especially in heroin addiction. Furthermore, we summarized PET radiotracers that have been used to study the role of DA in drug addiction. To investigate presynaptic function in drug addiction, PET tracers have been developed to measure DA synthesis and transport. For the investigation of postsynaptic function, several radioligands targeting dopamine one (D1) receptor and dopamine two (D2) receptor are extensively used in PET imaging studies. Moreover, we also summarized the PET imaging findings of heroin addiction studies, including heroin-induced DA increases and the reinforcement, role of DA in the long-term effects of heroin abuse, DA and vulnerability to heroin abuse and the treatment implications. PET imaging studies have corroborated the role of DA in drug addiction and increase our understanding the mechanism of drug addiction. Anat Rec, 2012. (c) 2012 Wiley Periodicals, Inc.
C1 [Tian, Mei] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Key Lab Med Mol Imaging Zhejiang Prov, Hangzhou 310009, Zhejiang, Peoples R China.
   [Hou, Haifeng; Zhang, Hong] Zhejiang Univ, Sch Med, Dept Nucl Med, Affiliated Hosp 2, Hangzhou 310009, Zhejiang, Peoples R China.
   [Hou, Haifeng; Zhang, Hong] Zhejiang Univ, Med PET Ctr, Hangzhou 310009, Zhejiang, Peoples R China.
   [Hou, Haifeng; Zhang, Hong] Zhejiang Univ, Inst Nucl Med & Mol Imaging, Hangzhou 310009, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang
   University
RP Tian, M (通讯作者)，Zhejiang Univ, Sch Med, Affiliated Hosp 2, Key Lab Med Mol Imaging Zhejiang Prov, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.
EM meitian@gmail.com; hzhang21@gmail.com
RI Tian, Mei/E-3751-2012
FU Zhejiang Provincial Natural Science Foundation of China [Z2110230];
   Health Bureau of Zhejiang Province [2010ZA075, 2011ZDA013]; National
   Science Foundation of China [81101023, 81170306, 81173468]; Ministry of
   Science and Technology of China [2011CB504400]; National Science
   Technology Support Program [2012BAI13B06]
FX Grant sponsor: Zhejiang Provincial Natural Science Foundation of China;
   Grant number: Z2110230; Grant sponsor: Health Bureau of Zhejiang
   Province; Grant numbers: 2010ZA075, 2011ZDA013; Grant sponsor: National
   Science Foundation of China; Grant numbers: 81101023, 81170306,
   81173468; Grant sponsor: Ministry of Science and Technology of China;
   Grant number: 2011CB504400; Grant sponsor: National Science Technology
   Support Program; Grant number: 2012BAI13B06.
CR Aalto S, 2009, EUR J NUCL MED MOL I, V36, P475, DOI 10.1007/s00259-008-0969-9
   Acosta-Garcia J, 2009, NEUROPHARMACOLOGY, V57, P725, DOI 10.1016/j.neuropharm.2009.08.010
   Bancroft J, 2004, J SEX RES, V41, P225, DOI 10.1080/00224490409552230
   Bell KM, 1996, BIOL PSYCHIAT, V39, P360
   Block JJ, 2008, AM J PSYCHIAT, V165, P306, DOI 10.1176/appi.ajp.2007.07101556
   Blum K, 2008, EUR NEUROPSYCHOPHARM
   Brauer LH, 1997, PSYCHOPHARMACOLOGY, V130, P2, DOI 10.1007/s002130050207
   Brodie JD, 2003, SYNAPSE, V50, P261, DOI 10.1002/syn.10278
   Brownell AL, 2010, IFMBE PROC, V27, P27, DOI 10.1007/978-3-642-12020-6_7
   Callier S, 2003, BIOL CELL, V95, P489, DOI 10.1016/S0248-4900(03)00089-3
   Cami J, 2003, NEW ENGL J MED, V349, P975, DOI 10.1056/NEJMra023160
   CANFIELD DR, 1990, SYNAPSE, V6, P189, DOI 10.1002/syn.890060211
   Chen QZ, 2011, EUR J NUCL MED MOL I, V38, P1367, DOI 10.1007/s00259-011-1779-z
   CHRISTMA.DR, 1970, J NUCL MED, V11, P474
   Contet C, 2004, CURR OPIN NEUROBIOL, V14, P370, DOI 10.1016/j.conb.2004.05.005
   Cropley VL, 2006, BIOL PSYCHIAT, V59, P898, DOI 10.1016/j.biopsych.2006.03.004
   Czoty PW, 2007, J ADDICT MED, V1, P33, DOI 10.1097/ADM.0b013e318045c038
   DACKIS CA, 1985, NEUROSCI BIOBEHAV R, V9, P469, DOI 10.1016/0149-7634(85)90022-3
   Dagher A, 2001, SYNAPSE, V42, P48, DOI 10.1002/syn.1098
   Daglish MRC, 2008, BRIT J PSYCHIAT, V193, P65, DOI 10.1192/bjp.bp.107.041228
   De Vries TJ, 2003, PSYCHOPHARMACOLOGY, V168, P164, DOI 10.1007/s00213-003-1422-1
   De Vries TJ, 2001, NAT MED, V7, P1151, DOI 10.1038/nm1001-1151
   DEWEY SL, 1991, SYNAPSE, V7, P324, DOI 10.1002/syn.890070409
   Dewey SL, 1998, SYNAPSE, V30, P119, DOI 10.1002/(SICI)1098-2396(199810)30:2<119::AID-SYN1>3.0.CO;2-F
   DEWIT H, 1977, CAN J PSYCHOL, V31, P195, DOI 10.1037/h0081662
   Dhawan BN, 1996, PHARMACOL REV, V48, P567
   Di Ciano P, 2003, NEUROPSYCHOPHARMACOL, V28, P510, DOI 10.1038/sj.npp.1300088
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Dietis N, 2011, BRIT J ANAESTH, V107, P8, DOI 10.1093/bja/aer115
   Ding YS, 1997, PSYCHOPHARMACOLOGY, V131, P71, DOI 10.1007/s002130050267
   DING YS, 1995, J NUCL MED, V36, P2298
   Dziedzicka-Wasylewska M, 2004, POL J PHARMACOL, V56, P659
   Elsinga PH, 2006, CURR MED CHEM, V13, P2139, DOI 10.2174/092986706777935258
   Fadda P, 2003, SYNAPSE, V50, P1, DOI 10.1002/syn.10238
   FARDE L, 1994, SYNAPSE, V16, P93, DOI 10.1002/syn.890160203
   Fareed A, 2011, J ADDICT DIS, V30, P27, DOI 10.1080/10550887.2010.531672
   Fareed A, 2010, J ADDICT DIS, V29, P1, DOI 10.1080/10550880903436010
   FARRELL M, 1994, BMJ-BRIT MED J, V309, P997, DOI 10.1136/bmj.309.6960.997
   Fattore L, 2003, EUR J NEUROSCI, V17, P1723, DOI 10.1046/j.1460-9568.2003.02607.x
   Fehr C, 2008, AM J PSYCHIAT, V165, P507, DOI 10.1176/appi.ajp.2007.07020352
   FISCHMAN MW, 1991, BRIT J ADDICT, V86, P1563
   Franken IHA, 2005, EUR J PHARMACOL, V526, P199, DOI 10.1016/j.ejphar.2005.09.025
   FROST JJ, 1993, ANN NEUROL, V34, P423, DOI 10.1002/ana.410340331
   GARRIS PA, 1994, J NEUROSCI, V14, P6084
   Gerasimov MR, 1999, SYNAPSE, V34, P11, DOI 10.1002/(SICI)1098-2396(199910)34:1<11::AID-SYN2>3.0.CO;2-5
   Gonzalez G, 2003, ADDICTION, V98, P1625, DOI 10.1046/j.1360-0443.2003.00544.x
   Goodman A, 2008, BIOCHEM PHARMACOL, V75, P266, DOI 10.1016/j.bcp.2007.07.030
   Grant JE, 2010, AM J DRUG ALCOHOL AB, V36, P233, DOI 10.3109/00952990.2010.491884
   Greenwald M, 2007, BIOL PSYCHIAT, V61, P101, DOI 10.1016/j.biopsych.2006.04.043
   Grunder G, 2003, ARCH GEN PSYCHIAT, V60, P974, DOI 10.1001/archpsyc.60.10.974
   Halldin C, 1998, J NUCL MED, V39, P2061
   Hammers A, 2006, NEUROIMAG CLIN N AM, V16, P529, DOI 10.1016/j.nic.2006.06.004
   Heinz A, 2005, AM J PSYCHIAT, V162, P1515, DOI 10.1176/appi.ajp.162.8.1515
   HIETALA J, 1994, PSYCHOPHARMACOLOGY, V116, P285, DOI 10.1007/BF02245330
   Hirvonen J, 2001, J CEREBR BLOOD F MET, V21, P1146, DOI 10.1097/00004647-200110000-00002
   Holden C, 2001, SCIENCE, V294, P980, DOI 10.1126/science.294.5544.980
   Holden C, 2010, SCIENCE, V327, P935, DOI 10.1126/science.327.5968.935
   Johnson BA, 2003, LANCET, V361, P1677, DOI 10.1016/S0140-6736(03)13370-3
   JOHNSON SW, 1992, J NEUROSCI, V12, P483
   Julian MD, 2003, NEUROSCIENCE, V119, P309, DOI 10.1016/S0306-4522(03)00070-8
   KESSLER RM, 1993, BRAIN RES, V609, P237, DOI 10.1016/0006-8993(93)90878-Q
   Kieffer BL, 2002, CELL, V108, P587, DOI 10.1016/S0092-8674(02)00666-9
   Kling MA, 2000, J PHARMACOL EXP THER, V295, P1070
   KOHLER C, 1985, BIOCHEM PHARMACOL, V34, P2251, DOI 10.1016/0006-2952(85)90778-6
   KOOB GF, 1989, NEUROSCI BIOBEHAV R, V13, P135, DOI 10.1016/S0149-7634(89)80022-3
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Kreek MJ, 2002, NAT REV DRUG DISCOV, V1, P710, DOI 10.1038/nrd897
   Kreek MJ, 2000, ANN NY ACAD SCI, V909, P186
   LEDUC PA, 1995, PSYCHOPHARMACOLOGY, V121, P407, DOI 10.1007/BF02246489
   Lee D, 2000, MOL PSYCHIATR, V5, P39, DOI 10.1038/sj.mp.4000601
   Lewis JW, 2004, CURR PHARM DESIGN, V10, P717, DOI 10.2174/1381612043453027
   Linden DEJ, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.049.2009
   Logan J, 1997, SYNAPSE, V27, P347, DOI 10.1002/(SICI)1098-2396(199712)27:4<347::AID-SYN8>3.3.CO;2-D
   Mach RH, 2000, SYNAPSE, V37, P109, DOI 10.1002/1098-2396(200008)37:2<109::AID-SYN5>3.0.CO;2-3
   Maddux JF, 2000, ADDICTION, V95, P661, DOI 10.1046/j.1360-0443.2000.9556611.x
   Maldonado R, 1997, NATURE, V388, P586, DOI 10.1038/41567
   MARKOU A, 1991, NEUROPSYCHOPHARMACOL, V4, P17
   Martin-Soelch C, 2001, EUR J NEUROSCI, V14, P1360, DOI 10.1046/j.0953-816x.2001.01753.x
   Martinez D, 2009, NEUROPSYCHOPHARMACOL, V34, P1774, DOI 10.1038/npp.2008.235
   McCann UD, 1998, J NEUROSCI, V18, P8417
   Melichar JK, 2005, J PHARMACOL EXP THER, V312, P309, DOI 10.1124/jpet.104.072686
   Melichar JK, 2003, ADDICT BIOL, V8, P59, DOI 10.1080/1355621031000069891
   Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189
   Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006
   Morgan CJA, 2012, ADDICTION, V107, P27, DOI 10.1111/j.1360-0443.2011.03576.x
   Nader MA, 2006, NAT NEUROSCI, V9, P1050, DOI 10.1038/nn1737
   Nanni C, 2007, J NUCL MED, V48, P1577, DOI 10.2967/jnumed.107.041947
   Noble EP, 2000, EUR PSYCHIAT, V15, P79, DOI 10.1016/S0924-9338(00)00208-X
   O'Brien C, 2011, ADDICTION, V106, P866, DOI 10.1111/j.1360-0443.2010.03144.x
   OBrien CP, 1996, ALCOHOL, V13, P35, DOI 10.1016/0741-8329(95)02038-1
   PAPP M, 1994, PSYCHOPHARMACOLOGY, V115, P441, DOI 10.1007/BF02245566
   Pelchat ML, 2009, J NUTR, V139, P620, DOI 10.3945/jn.108.097816
   PIAZZA PV, 1991, BRAIN RES, V567, P169, DOI 10.1016/0006-8993(91)91452-7
   Pichler BJ, 2010, J NUCL MED, V51, P333, DOI 10.2967/jnumed.109.061853
   Pichler Bernd J., 2008, V185, P109, DOI 10.1007/978-3-540-72718-7_6
   RAJESWARAN S, 1991, J NEUROSCI METH, V40, P223, DOI 10.1016/0165-0270(91)90071-7
   RINNE JO, 1995, SYNAPSE, V21, P97, DOI 10.1002/syn.890210202
   Saxe R, 2004, ANNU REV PSYCHOL, V55, P87, DOI 10.1146/annurev.psych.55.090902.142044
   Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1
   Seeman P, 2003, SYNAPSE, V47, P250, DOI 10.1002/syn.10171
   Sekine Y, 2001, AM J PSYCHIAT, V158, P1206, DOI 10.1176/appi.ajp.158.8.1206
   Sekine Y, 2003, AM J PSYCHIAT, V160, P1699, DOI 10.1176/appi.ajp.160.9.1699
   Shi J, 2008, EUR J PHARMACOL, V579, P160, DOI 10.1016/j.ejphar.2007.09.042
   SIMANTOV R, 1993, NEUROSCI LETT, V163, P121, DOI 10.1016/0304-3940(93)90360-W
   Slifstein M, 2007, J CEREBR BLOOD F MET, V27, P1733, DOI 10.1038/sj.jcbfm.9600468
   Smythies John, 2005, Int Rev Neurobiol, V64, P123, DOI 10.1016/S0074-7742(05)64002-0
   Tsukada H, 2001, SYNAPSE, V42, P273, DOI 10.1002/syn.10012
   Turjanski N, 1999, NEUROLOGY, V52, P932, DOI 10.1212/WNL.52.5.932
   United Nations Office for Drug Control and Crime Prevention (UNODC), 2010, WORD DRUG REP
   Vallone D, 2000, NEUROSCI BIOBEHAV R, V24, P125, DOI 10.1016/S0149-7634(99)00063-9
   van Harten PN, 1998, J CLIN PSYCHIAT, V59, P128, DOI 10.4088/JCP.v59n0307
   Villemagne V, 1998, J NEUROSCI, V18, P419
   Volkow ND, 2009, NEUROPHARMACOLOGY, V56, P3, DOI 10.1016/j.neuropharm.2008.05.022
   Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI 10.1093/cercor/10.3.318
   Volkow ND, 2004, AM J PSYCHIAT, V161, P1173, DOI 10.1176/appi.ajp.161.7.1173
   Volkow ND, 2004, MOL PSYCHIATR, V9, P557, DOI 10.1038/sj.mp.4001507
   Volkow ND, 2003, SEMIN NUCL MED, V33, P114, DOI 10.1053/snuc.2003.127300
   Volkow ND, 2002, PSYCHIAT RES-NEUROIM, V116, P163, DOI 10.1016/S0925-4927(02)00087-2
   Volkow ND, 2002, SYNAPSE, V44, P175, DOI 10.1002/syn.10075
   Volkow ND, 2002, SYNAPSE, V46, P79, DOI 10.1002/syn.10137
   Volkow ND, 1996, J NUCL MED, V37, P1242
   Volkow ND, 1996, ALCOHOL CLIN EXP RES, V20, P1594, DOI 10.1111/j.1530-0277.1996.tb05936.x
   VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210
   Volkow ND, 2001, AM J PSYCHIAT, V158, P2015, DOI 10.1176/appi.ajp.158.12.2015
   Volkow ND, 1996, NEUROPSYCHOPHARMACOL, V14, P159, DOI 10.1016/0893-133X(95)00073-M
   VOLKOW ND, 1990, AM J PSYCHIAT, V147, P719
   VOLKOW ND, 1995, ARCH GEN PSYCHIAT, V52, P456
   Volkow ND, 2011, P NATL ACAD SCI USA, V108, P15037, DOI 10.1073/pnas.1010654108
   Wallmichrath I, 2002, NEUROSCIENCE, V113, P671, DOI 10.1016/S0306-4522(02)00109-4
   Wang GJ, 1997, NEUROPSYCHOPHARMACOL, V16, P174, DOI 10.1016/S0893-133X(96)00184-4
   Wewers ME, 1998, PSYCHOPHARMACOLOGY, V140, P185, DOI 10.1007/s002130050756
   Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5
   Wise RA, 2009, TRENDS NEUROSCI, V32, P517, DOI 10.1016/j.tins.2009.06.004
   Wu JC, 1997, NEUROPSYCHOPHARMACOL, V17, P402, DOI 10.1016/S0893-133X(97)00089-4
   Yasuno F, 2007, BIOL PSYCHIAT, V61, P1252, DOI 10.1016/j.biopsych.2006.06.028
   Zipursky RB, 2007, CAN J PSYCHIAT, V52, P146, DOI 10.1177/070674370705200303
   Zubieta JK, 2000, NEUROPSYCHOPHARMACOL, V23, P326, DOI 10.1016/S0893-133X(00)00110-X
NR 137
TC 16
Z9 16
U1 2
U2 26
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1932-8486
EI 1932-8494
J9 ANAT REC
JI Anat. Rec.
PD MAY
PY 2012
VL 295
IS 5
BP 722
EP 733
DI 10.1002/ar.22457
PG 12
WC Anatomy & Morphology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Anatomy & Morphology
GA 924PE
UT WOS:000302703000003
PM 22467195
OA Bronze
DA 2023-06-23
ER

PT J
AU Wang, WJ
   Zeng, FC
   Hu, YY
   Li, X
AF Wang, Wenjun
   Zeng, Fancai
   Hu, Yingying
   Li, Xiang
TI A Mini-Review of the Role of Glutamate Transporter in Drug Addiction
SO FRONTIERS IN NEUROLOGY
LA English
DT Review
DE addiction; glutamate transporters; excitatory amino acid transporters;
   vesicular glutamate transporters; glutamate
ID VENTRAL TEGMENTAL AREA; DOPAMINE NEURONS; PREFRONTAL CORTEX; CHOLINERGIC
   MODULATION; SYNAPTIC-TRANSMISSION; INDUCED REINSTATEMENT; QUANTAL SIZE;
   RAT; MORPHINE; VGLUT2
AB Goals: The development of new treatment for drug abuse requires identification of targetable molecular mechanisms. The pathology of glutamate neurotransmission system in the brain reward circuit is related to the relapse of multiple drugs. Glutamate transporter regulates glutamate signaling by removing excess glutamate from the synapse. And the mechanisms between glutamate transporter and drug addiction are still unclear. Methods: A systematic review of the literature searched in Pubmed and reporting drug addiction in relation to glutamate transporter. Studies were screened by title, abstract, and full text. Results: This review is to highlight the effects of drug addiction on glutamate transporter and glutamate uptake, and targeting glutamate transporter as an addictive drug addiction treatment. We focus on the roles of glutamate transporter in different brain regions in drug addiction. More importantly, we suggest the functional roles of glutamate transporter may prove beneficial in the treatment of drug addiction. Conclusion: Overall, understanding how glutamate transporter impacts central nervous system may provide a new insight for treatment of drug addiction.
C1 [Wang, Wenjun] Southwest Med Univ, Inst Canc Med, Luzhou, Peoples R China.
   [Wang, Wenjun] Southwest Med Univ, Sch Basic Med Sci, Luzhou, Peoples R China.
   [Zeng, Fancai; Hu, Yingying; Li, Xiang] Southwest Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Luzhou, Peoples R China.
C3 Southwest Medical University; Southwest Medical University; Southwest
   Medical University
RP Li, X (通讯作者)，Southwest Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Luzhou, Peoples R China.
EM lix2009@126.com
RI Wang, Ji/A-3774-2009; wang, yiran/IAP-0414-2023
OI Wang, Ji/0000-0002-0724-7538; 
FU undergraduate innovation and entrepreneurship training program
   [S201910727096]
FX This work was funded by the undergraduate innovation and
   entrepreneurship training program (S201910727096).
CR Addy NA, 2015, BEHAV BRAIN RES, V288, P54, DOI 10.1016/j.bbr.2015.04.002
   Avena NM, 2012, PHYSIOL BEHAV, V106, P332, DOI 10.1016/j.physbeh.2012.03.020
   Azogu I, 2017, HORM BEHAV, V90, P98, DOI 10.1016/j.yhbeh.2017.02.012
   Birgner C, 2010, P NATL ACAD SCI USA, V107, P389, DOI 10.1073/pnas.0910986107
   Brancato A, 2017, NEUROSCIENCE, V350, P180, DOI 10.1016/j.neuroscience.2017.03.014
   Britt JP, 2012, NEURON, V76, P790, DOI 10.1016/j.neuron.2012.09.040
   Clark JD, 2002, J PAIN SYMPTOM MANAG, V23, P131, DOI 10.1016/S0885-3924(01)00396-7
   Dautan D, 2016, NAT NEUROSCI, V19, P1025, DOI 10.1038/nn.4335
   de Rover M, 2004, EUR J NEUROSCI, V19, P2859, DOI 10.1111/j.0953-816X.2004.03370.x
   El Mestikawy S, 2011, NAT REV NEUROSCI, V12, P204, DOI 10.1038/nrn2969
   Erburu M, 2017, NEUROPHARMACOLOGY, V117, P195, DOI 10.1016/j.neuropharm.2017.01.033
   Everitt BJ, 1999, ANN NY ACAD SCI, V877, P412, DOI 10.1111/j.1749-6632.1999.tb09280.x
   Fang YY, 2018, J NEUROCHEM, V146, P703, DOI 10.1111/jnc.14537
   Farris SP, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00176
   Fattorini G, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00229
   Fremeau RT, 2004, SCIENCE, V304, P1815, DOI 10.1126/science.1097468
   Furuta A, 1997, NEUROSCIENCE, V81, P1031, DOI 10.1016/S0306-4522(97)00252-2
   Gabbott PLA, 2005, J COMP NEUROL, V492, P145, DOI 10.1002/cne.20738
   Gorelova N, 2012, CEREB CORTEX, V22, P327, DOI 10.1093/cercor/bhr107
   Gras C, 2002, J NEUROSCI, V22, P5442
   Gras C, 2008, NAT NEUROSCI, V11, P292, DOI 10.1038/nn2052
   Gretton SK, 2013, J PAIN SYMPTOM MANAG, V45, P670, DOI 10.1016/j.jpainsymman.2012.03.015
   Han S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01088-6
   Hayashi MK, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041177
   He HB, 2012, J NEUROSCI, V32, P15886, DOI 10.1523/JNEUROSCI.4505-11.2012
   HEIMER L, 1991, NEUROSCIENCE, V41, P89, DOI 10.1016/0306-4522(91)90202-Y
   Herman MA, 2014, J NEUROSCI, V34, P11781, DOI 10.1523/JNEUROSCI.1444-14.2014
   Herzog E, 2004, NEUROSCIENCE, V123, P983, DOI 10.1016/j.neuroscience.2003.10.039
   Herzog E, 2006, J NEUROCHEM, V99, P1011, DOI 10.1111/j.1471-4159.2006.04144.x
   Hnasko TS, 2012, J NEUROSCI, V32, P15076, DOI 10.1523/JNEUROSCI.3128-12.2012
   Hoover WB, 2007, BRAIN STRUCT FUNCT, V212, P149, DOI 10.1007/s00429-007-0150-4
   Huang YH, 2011, J NEUROSCI, V31, P18453, DOI 10.1523/JNEUROSCI.3824-11.2011
   Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560
   Jia YF, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00217
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kauer JA, 2007, NAT REV NEUROSCI, V8, P844, DOI 10.1038/nrn2234
   Kawano M, 2006, J COMP NEUROL, V498, P581, DOI 10.1002/cne.21054
   Lammel S, 2015, NEURON, V85, P429, DOI 10.1016/j.neuron.2014.12.036
   Li YJ, 2017, ADDICT BIOL, V22, P435, DOI 10.1111/adb.12343
   Lievens JC, 2000, GLIA, V29, P222, DOI 10.1002/(SICI)1098-1136(20000201)29:3<222::AID-GLIA4>3.0.CO;2-0
   Liu YZ, 2018, NEUROSCIENCE, V382, P59, DOI 10.1016/j.neuroscience.2018.04.032
   MacAskill AF, 2012, NAT NEUROSCI, V15, P1624, DOI 10.1038/nn.3254
   Manchikanti L, 2012, PAIN PHYSICIAN, V15, pS1
   Mao JR, 2002, J NEUROSCI, V22, P8312
   Mark GP, 2011, PHYSIOL BEHAV, V104, P76, DOI 10.1016/j.physbeh.2011.04.052
   McFarland K, 2003, J NEUROSCI, V23, P3531
   Melo CV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053793
   Mennerick S, 1999, J NEUROSCI, V19, P9242
   Meves JM, 2018, EXP NEUROL, V309, P32, DOI 10.1016/j.expneurol.2018.07.013
   Moechars D, 2006, J NEUROSCI, V26, P12055, DOI 10.1523/JNEUROSCI.2556-06.2006
   Navarro D, 2015, FRONT NEUROANAT, V9, DOI 10.3389/fnana.2015.00009
   Neale SA, 2014, NEUROCHEM INT, V73, P159, DOI 10.1016/j.neuint.2013.10.001
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   Ozawa T, 2001, BRAIN RES, V905, P254, DOI 10.1016/S0006-8993(01)02536-7
   Papathanou M, 2018, FRONT NEURAL CIRCUIT, V12, DOI 10.3389/fncir.2018.00064
   Qi CC, 2018, MOL PAIN, V14, DOI 10.1177/1744806918781259
   Rahman S, 2000, J NEUROCHEM, V74, P684, DOI 10.1046/j.1471-4159.2000.740684.x
   Reissner KJ, 2014, NEUROPSYCHOPHARMACOL, V39, P499, DOI 10.1038/npp.2013.223
   Rezayof A, 2003, J PSYCHOPHARMACOL, V17, P415, DOI 10.1177/0269881103174005
   Roccaro-Waldmeyer DM, 2018, FRONT BEHAV NEUROSCI, V12, DOI 10.3389/fnbeh.2018.00146
   Root DH, 2014, J NEUROSCI, V34, P13906, DOI 10.1523/JNEUROSCI.2029-14.2014
   Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0
   Russo SJ, 2013, NAT REV NEUROSCI, V14, P609, DOI 10.1038/nrn3381
   Sakae DY, 2015, MOL PSYCHIATR, V20, P1448, DOI 10.1038/mp.2015.104
   Sari Y, 2009, J NEUROSCI, V29, P9239, DOI 10.1523/JNEUROSCI.1746-09.2009
   Schafer MKH, 2002, J BIOL CHEM, V277, P50734, DOI 10.1074/jbc.M206738200
   Schluter K, 2002, EUR J NEUROSCI, V16, P836, DOI 10.1046/j.1460-9568.2002.02130.x
   Schneider N, 2014, J BIOL CHEM, V289, P1815, DOI 10.1074/jbc.M113.517177
   Sery O, 2015, NEUROCHEM RES, V40, P2461, DOI 10.1007/s11064-015-1605-2
   Sesack SR, 2010, NEUROPSYCHOPHARMACOL, V35, P27, DOI 10.1038/npp.2009.93
   Siksou L, 2013, EUR J NEUROSCI, V37, P1631, DOI 10.1111/ejn.12199
   Sun KL, 2015, CEREBELLUM, V14, P1, DOI [10.1007/s12311-015-0673-9, DOI 10.1007/S12311-015-0673-9]
   Sun X, 2008, J NEUROSCI, V28, P4216, DOI 10.1523/JNEUROSCI.0258-08.2008
   Taepavarapruk P, 2003, PSYCHOPHARMACOLOGY, V168, P99, DOI 10.1007/s00213-002-1337-2
   Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699
   Tecuapetla F, 2010, J NEUROSCI, V30, P7105, DOI 10.1523/JNEUROSCI.0265-10.2010
   Tepper JM, 2004, CURR OPIN NEUROBIOL, V14, P685, DOI 10.1016/j.conb.2004.10.003
   Trotti D, 2001, J BIOL CHEM, V276, P576, DOI 10.1074/jbc.M003779200
   Tukey DS, 2013, MOL BRAIN, V6, DOI 10.1186/1756-6606-6-32
   Untiet V, 2017, GLIA, V65, P388, DOI 10.1002/glia.23098
   Van den Oever MC, 2010, NEUROPSYCHOPHARMACOL, V35, P2120, DOI 10.1038/npp.2010.90
   Vertes RP, 2004, SYNAPSE, V51, P32, DOI 10.1002/syn.10279
   Voglmaier SM, 2006, NEURON, V51, P71, DOI 10.1016/j.neuron.2006.05.027
   Vorwerk CK, 2000, INVEST OPHTH VIS SCI, V41, P3615
   Wan L, 2017, NEUROSCIENCE, V344, P67, DOI 10.1016/j.neuroscience.2016.12.038
   Wang HL, 2015, J NEUROSCI, V35, P15948, DOI 10.1523/JNEUROSCI.3428-15.2015
   Wen ZH, 2015, OSTEOARTHR CARTILAGE, V23, P2009, DOI 10.1016/j.joca.2015.03.017
   Wilson NR, 2005, J NEUROSCI, V25, P6221, DOI 10.1523/JNEUROSCI.3003-04.2005
   Wise R A, 1985, Psychiatr Med, V3, P445
   Wojcik SM, 2004, P NATL ACAD SCI USA, V101, P7158, DOI 10.1073/pnas.0401764101
   Yamaguchi T, 2007, EUR J NEUROSCI, V25, P106, DOI 10.1111/j.1460-9568.2006.05263.x
   Yau HJ, 2016, CELL REP, V16, P2699, DOI 10.1016/j.celrep.2016.08.007
   Yoo JH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13697
   ZAHM DS, 1992, NEUROSCIENCE, V50, P751, DOI 10.1016/0306-4522(92)90202-D
   Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0
NR 95
TC 4
Z9 4
U1 2
U2 23
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD OCT 22
PY 2019
VL 10
AR 1123
DI 10.3389/fneur.2019.01123
PG 8
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA JJ9GW
UT WOS:000494461200001
PM 31695674
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Sattler, S
   Escande, A
   Racine, E
   Goritz, AS
AF Sattler, Sebastian
   Escande, Alice
   Racine, Eric
   Goritz, Anja S.
TI Public Stigma Toward People With Drug Addiction: A Factorial Survey
SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS
LA English
DT Article
ID BIOGENETIC CAUSAL EXPLANATIONS; SUBSTANCE-USE DISORDERS; MENTAL-HEALTH
   PROBLEMS; ALCOHOL DEPENDENCE; UNIVERSITY-STUDENTS; SOCIAL DISTANCE;
   ILLNESS STIGMA; ATTITUDES; POPULATION; SCHIZOPHRENIA
AB Objective: Stigmatizing attitudes toward people with a drug addiction have detrimental effects on the lives of these people. However, the factors that influence stigma toward people with a drug addiction have not yet been thoroughly investigated, compared with the stigma of other mental illnesses. Based on attribution theory, our experiment examined to what extent individual and contextual characteristics of people with a drug addiction influence stigmatizing attitudes toward people with a drug addiction. Moreover, we explored whether respondent characteristics indicative of familiarity with addiction decrease stigma toward people with a drug addiction. Method: We conducted a full factorial survey of 2,857 respondents from a German online access panel who were from all walks of life. We experimentally varied vignettes (2(9)-design) that featured a fictional person with an addiction. Stigmatizing beliefs, such as blame or fear, were assessed using the Attribution Questionnaire (AQ-9). Results: Different attributes of people with a drug addiction and of the characteristics of their addiction modulated stigma in ways that are mostly consistent with attribution theory and related research. For example, female gender and younger age of people with a drug addiction diminished several stigmatizing attitudes; greater duration of addiction and social influence to use drugs increased them. Furthermore, characteristics of respondents modulated stigma: women, younger respondents, and those with higher education expressed less stigmatizing responses than others. Conclusions: The stigmatization of people with a drug addiction is influenced by several factors, including characteristics of the stigmatized person, the addiction, and the person holding stigmatizing attitudes. A better understanding of the underlying mechanisms of these effects is needed to develop evidence-based anti stigma measures.
C1 [Sattler, Sebastian] Univ Cologne, Inst Sociol & Social Psychol, Greinstr 2, D-50939 Cologne, Germany.
   [Sattler, Sebastian; Escande, Alice; Racine, Eric] Inst Rech Clin Montreal, Montreal, PQ, Canada.
   [Escande, Alice; Racine, Eric] McGill Univ, Montreal, PQ, Canada.
   [Racine, Eric] Univ Montreal, Montreal, PQ, Canada.
   [Goritz, Anja S.] Univ Freiburg, Inst Psychol, Freiburg, Germany.
C3 University of Cologne; Institut de Recherche Clinique de Montreal
   (IRCM); Universite de Montreal; McGill University; Universite de
   Montreal; University of Freiburg
RP Sattler, S (通讯作者)，Univ Cologne, Inst Sociol & Social Psychol, Greinstr 2, D-50939 Cologne, Germany.
EM sattler@wiso.uni-koeln.de
RI Göritz, Anja S./HLX-7829-2023; Sattler, Sebastian/Y-3590-2018
OI Göritz, Anja S./0000-0002-4638-0489; Sattler,
   Sebastian/0000-0002-6491-0754
FU Fritz-Thyssen-Foundation; Cologne Graduate School in Management,
   Economics, and Social Sciences; Fonds de recherche du Quebec Sante;
   Social Sciences and Humanities Research Council
FX The work of Sebastian Sattler was funded by a PostDoc Fellowship of the
   Fritz-Thyssen-Foundation and the Cologne Graduate School in Management,
   Economics, and Social Sciences. Eric Racine benefited from a career
   award from the Fonds de recherche du Quebec Sante, and this research was
   supported by the Social Sciences and Humanities Research Council. None
   of the funders influenced any interpretations or forced us to produce
   biased results. The views expressed do not necessarily reflect the
   policies of the funders. These agencies had no further role in study
   design; in the collection, analysis, and interpretation of data; in the
   writing of the report; or in the decision to submit the article for
   publication.
CR Addison SJ, 2004, SOC PSYCH PSYCH EPID, V39, P228, DOI 10.1007/s00127-004-0723-y
   Ali R, 2013, DRUG ALCOHOL DEPEN, V132, P352, DOI 10.1016/j.drugalcdep.2013.03.001
   Angermeyer MC, 2014, SOC SCI MED, V103, P60, DOI 10.1016/j.socscimed.2013.11.014
   Angermeyer MC, 2011, BRIT J PSYCHIAT, V199, P367, DOI 10.1192/bjp.bp.110.085563
   Angermeyer MC, 2005, BRIT J PSYCHIAT, V186, P331, DOI 10.1192/bjp.186.4.331
   Angermeyer MC, 2003, ACTA PSYCHIAT SCAND, V108, P304, DOI 10.1034/j.1600-0447.2003.00150.x
   [Anonymous], [No title captured]
   Barney LJ, 2006, AUST NZ J PSYCHIAT, V40, P51, DOI 10.1080/j.1440-1614.2006.01741.x
   BRISLIN RW, 1970, J CROSS CULT PSYCHOL, V1, P185, DOI 10.1177/135910457000100301
   Buckley P, 2007, ACAD PSYCHIATR, V31, P435, DOI 10.1176/appi.ap.31.6.435
   Cirakoglu OC, 2005, ADDICT BEHAV, V30, P1, DOI 10.1016/j.addbeh.2004.04.003
   Conner KO, 2008, J SOC WORK PRACT ADD, V8, P244, DOI 10.1080/15332560802157065
   Correll Joshua, 2010, SAGE HDB PREJUDICE S, P45, DOI DOI 10.4135/9781446200919.N3
   Corrigan P, 2003, J HEALTH SOC BEHAV, V44, P162, DOI 10.2307/1519806
   Corrigan P., 2012, TOOLKIT EVALUATING P
   Corrigan PW, 2008, J PSYCHOSOC NURS MEN, V46, P42, DOI 10.3928/02793695-20080101-04
   Corrigan PW, 2007, COMMUNITY MENT HLT J, V43, P439, DOI 10.1007/s10597-007-9084-9
   Corrigan PW, 2015, PSYCHIAT RES, V226, P186, DOI 10.1016/j.psychres.2014.12.047
   Corrigan PW, 2012, PSYCHIAT SERV, V63, P963, DOI 10.1176/appi.ps.201100529
   Corrigan PW, 2009, J SOC WORK, V9, P139, DOI 10.1177/1468017308101818
   Corrigan PW, 2003, INT J SOC PSYCHIATR, V49, P142, DOI 10.1177/0020764003049002007
   Corrigan PW, 2001, SCHIZOPHRENIA BULL, V27, P219, DOI 10.1093/oxfordjournals.schbul.a006868
   Corrigan PW, 2000, CLIN PSYCHOL-SCI PR, V7, P48, DOI 10.1093/clipsy/7.1.48
   Couture S., 2003, J MENTAL HLTH, V12, P291, DOI [DOI 10.1080/09638231000118276, 10.1080/09638231000118276]
   CUNNINGHAM JA, 1993, J STUD ALCOHOL, V54, P693, DOI 10.15288/jsa.1993.54.693
   Depla MFIA, 2005, INT J GERIATR PSYCH, V20, P146, DOI 10.1002/gps.1264
   Dietrich S, 2006, INT J SOC PSYCHIATR, V52, P166, DOI 10.1177/0020764006061246
   Ewalds-Kvist B, 2013, NORD J PSYCHIAT, V67, P360, DOI 10.3109/08039488.2012.748827
   Fiske S. T., 2010, SAGE HDB PREJUDICE S, P115, DOI DOI 10.4135/9781446200919.N7
   Flaskerud JH, 1998, NURS RES, V47, P69, DOI 10.1097/00006199-199803000-00005
   Fominaya AW, 2016, PSYCHIAT RES, V241, P159, DOI 10.1016/j.psychres.2016.04.058
   Frankenburg FR., 2014, BRAIN ROBBERS ALCOHO
   Goritz AS, 2014, WILEY SER SURV METH, P154
   Graeff P, 2014, EUR SOCIOL REV, V30, P230, DOI 10.1093/esr/jct036
   Graham JW, 2009, ANNU REV PSYCHOL, V60, P549, DOI 10.1146/annurev.psych.58.110405.085530
   Hartwell S., 2004, CRIMINAL JUSTICE POL, V15, P84, DOI [DOI 10.1177/0887403403255064, 10.1177/0887403403255064]
   Holmes EP, 1999, SCHIZOPHRENIA BULL, V25, P447, DOI 10.1093/oxfordjournals.schbul.a033392
   Holzinger A, 2012, EPIDEMIOL PSYCH SCI, V21, P73, DOI 10.1017/S2045796011000552
   Jasso G, 2006, SOCIOL METHOD RES, V34, P334, DOI 10.1177/0049124105283121
   Kazantzis N, 2009, AUST J REHABIL COUNS, V15, P74, DOI 10.1375/jrc.15.2.74
   LEHTINEN V, 1977, ACTA PSYCHIAT SCAND, V55, P287, DOI 10.1111/j.1600-0447.1977.tb00173.x
   Link BG, 2001, ANNU REV SOCIOL, V27, P363, DOI 10.1146/annurev.soc.27.1.363
   Long J. S., 2001, REGRESSION MODELS CA
   Martin JK, 2000, J HEALTH SOC BEHAV, V41, P208, DOI 10.2307/2676306
   Michaels PJ, 2013, J MENT HEALTH, V22, P218, DOI 10.3109/09638237.2012.734652
   Nelson T. D., 2005, PSYCHOL PREJUDICE
   Olson M. A., 2010, SAGE HDB PREJUDICE S, P367
   Penn DL, 1998, PSYCHIAT QUART, V69, P235, DOI 10.1023/A:1022153327316
   PENN DL, 1994, SCHIZOPHRENIA BULL, V20, P567, DOI 10.1093/schbul/20.3.567
   Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236
   Pescosolido BA, 1999, AM J PUBLIC HEALTH, V89, P1339, DOI 10.2105/AJPH.89.9.1339
   Pescosolido BA, 2013, AM J PUBLIC HEALTH, V103, P853, DOI 10.2105/AJPH.2012.301147
   Pescosolido BA, 2013, J HEALTH SOC BEHAV, V54, P1, DOI 10.1177/0022146512471197
   Pescosolido BA, 2010, AM J PSYCHIAT, V167, P1321, DOI 10.1176/appi.ajp.2010.09121743
   Phelan JC, 2006, PSYCHIAT SERV, V57, P382, DOI 10.1176/appi.ps.57.3.382
   Phelan JC, 2005, J HEALTH SOC BEHAV, V46, P307, DOI 10.1177/002214650504600401
   Pinto MD, 2012, J NURS MEAS, V20, P47, DOI 10.1891/1061-3749.20.1.47
   Power R, 1996, SOCIOL HEALTH ILL, V18, P86, DOI 10.1111/1467-9566.ep10934419
   Racine E, 2015, NEUROETHICS-NETH, V8, P177, DOI 10.1007/s12152-014-9228-x
   Rao H, 2009, J PSYCHIATR MENT HLT, V16, P279, DOI 10.1111/j.1365-2850.2008.01369.x
   Rettinger DA, 2009, RES HIGH EDUC, V50, P293, DOI 10.1007/s11162-008-9116-5
   Schnittker J, 2000, J HEALTH SOC BEHAV, V41, P224, DOI 10.2307/2676307
   Schomerus G, 2012, ACTA PSYCHIAT SCAND, V125, P440, DOI 10.1111/j.1600-0447.2012.01826.x
   Schomerus G, 2011, ALCOHOL ALCOHOLISM, V46, P105, DOI 10.1093/alcalc/agq089
   Schomerus G, 2010, PSYCHIAT PRAX, V37, P111, DOI 10.1055/s-0029-1223438
   SCHWARZER R, 1991, J SOC PERS RELAT, V8, P133, DOI 10.1177/0265407591081007
   Sorsdahl K, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-101
   Statistische Amter des Bundes und der LAnder, 2013, MIKR 2013
   Stuber JP, 2014, PSYCHIAT SERV, V65, P490, DOI 10.1176/appi.ps.201300136
   Thornicroft G, 2008, EPIDEMIOL PSICHIAT S, V17, P14, DOI 10.1017/S1121189X00002621
   van Boekel LC, 2013, DRUG ALCOHOL DEPEN, V131, P23, DOI 10.1016/j.drugalcdep.2013.02.018
   van Veen F, 2016, SOC SCI COMPUT REV, V34, P333, DOI 10.1177/0894439315585074
   Walker I, 2002, PSYCHIATRY, V65, P313, DOI 10.1521/psyc.65.4.313.20238
   WEINER B, 1993, AM PSYCHOL, V48, P957, DOI 10.1037/0003-066X.48.9.957
   WEINER B, 1988, J PERS SOC PSYCHOL, V55, P738, DOI 10.1037/0022-3514.55.5.738
NR 75
TC 52
Z9 53
U1 4
U2 43
PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV
PI PISCATAWAY
PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA
SN 1937-1888
EI 1938-4114
J9 J STUD ALCOHOL DRUGS
JI J. Stud. Alcohol Drugs
PD MAY
PY 2017
VL 78
IS 3
BP 415
EP 425
DI 10.15288/jsad.2017.78.415
PG 11
WC Substance Abuse; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychology
GA EV3SY
UT WOS:000401680600012
PM 28499109
DA 2023-06-23
ER

PT J
AU Piazza, PV
   Deroche-Gamonet, V
AF Piazza, Pier Vincenzo
   Deroche-Gamonet, Veronique
TI A multistep general theory of transition to addiction
SO PSYCHOPHARMACOLOGY
LA English
DT Article
DE Drug addiction; Drug abuse; Drug use; Drug dependence; Drugs of abuse;
   Loss of control; Individual differences; Addiction theory
ID STRESS-INDUCED SENSITIZATION; INDUCED CORTICOSTERONE SECRETION;
   PROGRESSIVE RATIO SCHEDULE; SELF-ADMINISTERED COCAINE;
   RECEPTOR-DEPENDENT MANNER; GOAL-DIRECTED BEHAVIOR; DRUG-ADDICTION;
   NUCLEUS-ACCUMBENS; INDIVIDUAL-DIFFERENCES; SYNAPTIC PLASTICITY
AB Several theories propose alternative explanations for drug addiction.
   We propose a general theory of transition to addiction that synthesizes knowledge generated in the field of addiction into a unitary explanatory frame.
   Transition to addiction results from a sequential three-step interaction between: (1) individual vulnerability; (2) degree/amount of drug exposure. The first step, sporadic recreational drug use is a learning process mediated by overactivation of neurobiological substrates of natural rewards that allows most individuals to perceive drugs as highly rewarding stimuli. The second, intensified, sustained, escalated drug use occurs in some vulnerable individuals who have a hyperactive dopaminergic system and impaired prefrontal cortex function. Sustained and prolonged drug use induces incentive sensitization and an allostatic state that makes drugs strongly wanted and needed. Habit formation can also contribute to stabilizing sustained drug use. The last step, loss of control of drug intake and full addiction, is due to a second vulnerable phenotype. This loss-of-control-prone phenotype is triggered by long-term drug exposure and characterized by long-lasting loss of synaptic plasticity in reward areas in the brain that induce a form of behavioral crystallization resulting in loss of control of drug intake. Because of behavioral crystallization, drugs are now not only wanted and needed but also pathologically mourned when absent.
   This general theory demonstrates that drug addiction is a true psychiatric disease caused by a three-step interaction between vulnerable individuals and amount/duration of drug exposure.
C1 [Piazza, Pier Vincenzo; Deroche-Gamonet, Veronique] INSERM, Neuroctr Magendie, U862, F-33076 Bordeaux, France.
   [Piazza, Pier Vincenzo; Deroche-Gamonet, Veronique] Univ Bordeaux, Neuroctr Magendie, U862, F-33077 Bordeaux, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux; UDICE-French
   Research Universities; Universite de Bordeaux
RP Piazza, PV (通讯作者)，Univ Bordeaux, Neuroctr Magendie, U862, 146 Rue Leo Saignat, F-33077 Bordeaux, France.
EM pier-vincenzo.piazza@inserm.fr; veronique.deroche@inserm.fr
RI Deroche-Gamonet, Véronique/E-5728-2010
OI Deroche-Gamonet, Veronique/0000-0002-9704-6624
FU ANR (Neurorelaps, TIMMS); EquipEx OptoPath [ANR-10-EQPX-08]; Labex
   BRAIN; INSERM; Conseil Regional d'Aquitaine; University of Bordeaux 2
FX We are immeasurably thankful to Drs. David Epstein and Yavin Shaham for
   their insightful and knowlegeable comments and contributions to this
   manuscript. PVP & VDG are supported by ANR (Neurorelaps, TIMMS), EquipEx
   OptoPath (ANR-10-EQPX-08), and Labex BRAIN grants, by INSERM, the
   Conseil Regional d'Aquitaine and the University of Bordeaux 2.
CR Aarts H, 2000, J PERS SOC PSYCHOL, V78, P53, DOI 10.1037/0022-3514.78.1.53
   Aarts H, 2008, SCIENCE, V319, P1639, DOI 10.1126/science.1150432
   Ahmed SH, 2012, NEUROSCIENCE, V211, P107, DOI 10.1016/j.neuroscience.2011.08.014
   Ahmed SH, 2013, CURR OPIN NEUROBIOL, V23, P581, DOI 10.1016/j.conb.2013.01.028
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Ahmed SH, 2003, J NEUROCHEM, V86, P102, DOI 10.1046/j.1471-4159.2003.01833.x
   Ahmed SH, 2002, NAT NEUROSCI, V5, P625, DOI 10.1038/nn872
   Ambroggi F, 2009, NAT NEUROSCI, V12, P247, DOI 10.1038/nn.2282
   American Psychiatric Association, 1994, DSM 4 DIAGN STAT MAN
   Anker JJ, 2009, PHARMACOL BIOCHEM BE, V93, P343, DOI 10.1016/j.pbb.2009.05.013
   APA, 1987, DSM 3 R DIAGN STAT M
   APA, 2000, DSM 4 R DIAGN STAT M
   APA, 2013, DSM 5 DIAGN STAT MAN
   APA American Psychiatric Association, 1980, DSM 3 DIAGN STAT MAN
   Ashby FG, 2010, TRENDS COGN SCI, V14, P208, DOI 10.1016/j.tics.2010.02.001
   Badiani A, 2011, NAT REV NEUROSCI, V12, P685, DOI 10.1038/nrn3104
   Bardo MT, 2013, PHARMACOL REV, V65, P255, DOI 10.1124/pr.111.005124
   Barron Susan, 2005, Alcohol Clin Exp Res, V29, P1720, DOI 10.1097/01.alc.0000179220.79356.e5
   Bassareo V, 1997, J NEUROSCI, V17, P851
   Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584
   Bechara A, 2001, Semin Clin Neuropsychiatry, V6, P205, DOI 10.1053/scnp.2001.22927
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   Belin D, 2008, NEURON, V57, P432, DOI 10.1016/j.neuron.2007.12.019
   Belin D, 2013, CURR OPIN NEUROBIOL, V23, P564, DOI 10.1016/j.conb.2013.01.025
   Belin D, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a011940
   Belin D, 2011, NEUROPSYCHOPHARMACOL, V36, P569, DOI 10.1038/npp.2010.188
   Belin D, 2009, BIOL PSYCHIAT, V65, P863, DOI 10.1016/j.biopsych.2008.05.031
   Belin D, 2009, BEHAV BRAIN RES, V199, P89, DOI 10.1016/j.bbr.2008.09.027
   Belin-Rauscent A, 2012, BIOL PSYCHIAT, V72, P343, DOI 10.1016/j.biopsych.2012.07.001
   Bernard C., 1865, INTRO ETUDE MED EXPT
   Bontempi B, 1999, NATURE, V400, P671, DOI 10.1038/23270
   Bossert JM, 2013, PSYCHOPHARMACOLOGY B
   BOZARTH MA, 1985, JAMA-J AM MED ASSOC, V254, P81, DOI 10.1001/jama.254.1.81
   BRADY JV, 1956, ANN NY ACAD SCI, V64, P632, DOI 10.1111/j.1749-6632.1956.tb36837.x
   Bush DEA, 2007, PSYCHOPHARMACOLOGY, V194, P211, DOI 10.1007/s00213-007-0835-7
   Cabib S, 2000, SCIENCE, V289, P463, DOI 10.1126/science.289.5478.463
   Caspi A, 2006, NAT REV NEUROSCI, V7, P583, DOI 10.1038/nrn1925
   Compton WM, 2013, DRUG ALCOHOL DEPEND
   Crabbe JC, 1999, TRENDS NEUROSCI, V22, P173, DOI 10.1016/S0166-2236(99)01393-4
   Crabbe JC, 2010, BEHAV GENET, V40, P737, DOI 10.1007/s10519-010-9371-z
   de Wit H, 2009, ADDICT BIOL, V14, P22, DOI 10.1111/j.1369-1600.2008.00129.x
   Deroche V, 1999, EUR J NEUROSCI, V11, P2731, DOI 10.1046/j.1460-9568.1999.00696.x
   DEROCHE V, 1992, BRAIN RES, V584, P309, DOI 10.1016/0006-8993(92)90911-R
   Deroche V, 1997, J PHARMACOL EXP THER, V281, P1401
   DEROCHE V, 1995, J NEUROSCI, V15, P7181
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Deroche-Gamonet V, 2010, ENCYCLOPEDIA OF BEHAVIORAL NEUROSCIENCE, VOL 3: P-Z, P422
   Deroche-Gamonet V, 2003, J NEUROSCI, V23, P4785
   Deroche-Gamonet V, NEUROPHARMA IN PRESS
   DEWS PB, 1958, J EXP ANAL BEHAV, V1, P359, DOI 10.1901/jeab.1958.1-359
   DEWS PB, 1955, J PHARMACOL EXP THER, V113, P393
   Di Chiara G, 1998, J PSYCHOPHARMACOL, V12, P54, DOI 10.1177/026988119801200108
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Doremus-Fitzwater TL, 2010, BRAIN COGNITION, V72, P114, DOI 10.1016/j.bandc.2009.08.008
   Ellenbroek BA, 2005, EUR J PHARMACOL, V526, P251, DOI 10.1016/j.ejphar.2005.09.032
   EMCDDA, 2011, COST FIN DRUG TREATM
   Ettenberg A, 2004, NEUROSCI BIOBEHAV R, V27, P721, DOI 10.1016/j.neubiorev.2003.11.009
   Evenden JL, 1999, PSYCHOPHARMACOLOGY, V146, P348, DOI 10.1007/PL00005481
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Everitt BJ, 2002, J NEUROSCI, V22, P3312
   Ferrario CR, 2007, EUR NEUROPSYCHOPHARM, V17, P352, DOI 10.1016/j.euroneuro.2006.08.005
   Foroud T, 2010, ALCOHOL RES HEALTH, V33, P64
   Frankland PW, 2005, NAT REV NEUROSCI, V6, P119, DOI 10.1038/nrn1607
   Goeders NE, 2002, J PHARMACOL EXP THER, V301, P785, DOI 10.1124/jpet.301.3.785
   GOLDBERG SR, 1969, SCIENCE, V166, P1303, DOI 10.1126/science.166.3910.1306
   Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119
   Goto Y, 2010, BIOL PSYCHIAT, V67, P199, DOI 10.1016/j.biopsych.2009.08.026
   Harrison TR, 2011, PRINCIPLES INTERNAL
   Helie S, 2010, J NEUROSCI, V30, P14225, DOI 10.1523/JNEUROSCI.2393-10.2010
   Hogarth L, 2013, ANN NY ACAD SCI, V1282, P12, DOI 10.1111/j.1749-6632.2012.06768.x
   Hogarth L, 2010, PSYCHOPHARMACOLOGY, V208, P337, DOI 10.1007/s00213-009-1735-9
   HOOKS MS, 1992, BRAIN RES, V587, P306
   HOOKS MS, 1991, SYNAPSE, V9, P121, DOI 10.1002/syn.890090206
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483
   Jhou TC, 2013, J NEUROSCI, V33, P7501, DOI 10.1523/JNEUROSCI.3634-12.2013
   JOHANSON CE, 1976, PHARMACOL BIOCHEM BE, V4, P45, DOI 10.1016/0091-3057(76)90174-X
   Jueptner M, 1997, J NEUROPHYSIOL, V77, P1325, DOI 10.1152/jn.1997.77.3.1325
   Kalivas PW, 2009, NAT REV NEUROSCI, V10, P561, DOI 10.1038/nrn2515
   KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U
   Kalivas PW, 2005, NAT NEUROSCI, V8, P1440, DOI 10.1038/nn1105-1440
   Kalivas PW, 2005, NEURON, V45, P647, DOI 10.1016/j.neuron.2005.02.005
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   KARNI A, 1995, NATURE, V377, P155
   Kasanetz F, 2013, MOL PSYCHIATR, V18, P729, DOI 10.1038/mp.2012.59
   Kasanetz F, 2010, SCIENCE, V328, P1709, DOI 10.1126/science.1187801
   Kauer JA, 2007, NAT REV NEUROSCI, V8, P844, DOI 10.1038/nrn2234
   KELLEHER RT, 1958, J EXP ANAL BEHAV, V1, P281, DOI 10.1901/jeab.1958.1-281
   Koehl M, 2002, NEUROTOX RES, V4, P281, DOI 10.1080/1029842021000010866
   Koob GF, 2008, PHILOS T R SOC B, V363, P3113, DOI 10.1098/rstb.2008.0094
   Koob GF, 2008, ANNU REV PSYCHOL, V59, P29, DOI 10.1146/annurev.psych.59.103006.093548
   Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442
   KOOB GF, 1989, NEUROSCI BIOBEHAV R, V13, P135, DOI 10.1016/S0149-7634(89)80022-3
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   LATIES VG, 1966, J PHARMACOL EXP THER, V152, P388
   LEMOAL M, 1979, NATURE, V280, P156
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Lopez-Quintero C, 2011, DRUG ALCOHOL DEPEN, V115, P120, DOI 10.1016/j.drugalcdep.2010.11.004
   Luscher C, 2011, NEURON, V69, P650, DOI 10.1016/j.neuron.2011.01.017
   Mantsch JR, 2004, PSYCHOPHARMACOLOGY, V175, P26, DOI 10.1007/s00213-004-1778-x
   Marinelli M, 2002, EUR J NEUROSCI, V16, P387, DOI 10.1046/j.1460-9568.2002.02089.x
   Marusich JA, 2009, BEHAV PHARMACOL, V20, P447, DOI 10.1097/FBP.0b013e328330ad6d
   Meyer AC, 2010, GENES BRAIN BEHAV, V9, P790, DOI 10.1111/j.1601-183X.2010.00616.x
   Miller G, 2010, SCIENCE, V327, P1437, DOI 10.1126/science.327.5972.1437
   MORSE WH, 1958, J EXP ANAL BEHAV, V1, P103, DOI 10.1901/jeab.1958.1-103
   Neiman T, 2013, J NEUROSCI, V33, P1521, DOI 10.1523/JNEUROSCI.2068-12.2013
   Nestler EJ, 2000, NAT GENET, V26, P277, DOI 10.1038/81570
   Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578
   Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58
   NESTLER EJ, 1994, NEUROPSYCHOPHARMACOL, V11, P77, DOI 10.1038/npp.1994.37
   NESTLER EJ, 1992, J NEUROSCI, V12, P2439
   NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B
   Nutt D, 2007, LANCET, V369, P1047, DOI 10.1016/S0140-6736(07)60464-4
   O'Neill B, 2013, GENES BRAIN BEHAV, V12, P34, DOI 10.1111/j.1601-183X.2012.00872.x
   OBRIEN CP, 1986, BEHAV ANAL DRUG DEPE, P329
   Olmstead MC, 2001, BEHAV NEUROSCI, V115, P394, DOI 10.1037/0735-7044.115.2.394
   Peer K, 2013, DRUG ALCOHOL DEPEN, V127, P215, DOI 10.1016/j.drugalcdep.2012.07.009
   Pelloux Y, 2007, PSYCHOPHARMACOLOGY, V194, P127, DOI 10.1007/s00213-007-0805-0
   Perry JL, 2008, EXP CLIN PSYCHOPHARM, V16, P165, DOI 10.1037/1064-1297.16.2.165
   Perry JL, 2005, PSYCHOPHARMACOLOGY, V178, P193, DOI 10.1007/s00213-004-1994-4
   Piazza P V, 1996, NIDA Res Monogr, V163, P277
   Piazza PV, 2000, J NEUROSCI, V20, P4226
   PIAZZA PV, 1991, P NATL ACAD SCI USA, V88, P2088, DOI 10.1073/pnas.88.6.2088
   Piazza PV, 1997, BRAIN RES REV, V25, P359, DOI 10.1016/S0165-0173(97)00025-8
   PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295
   Piazza PV, 1996, ANNU REV PHARMACOL, V36, P359, DOI 10.1146/annurev.pa.36.040196.002043
   PIAZZA PV, 1991, BRAIN RES, V567, P169, DOI 10.1016/0006-8993(91)91452-7
   Pickens CL, 2011, TRENDS NEUROSCI, V34, P411, DOI 10.1016/j.tins.2011.06.001
   PICKENS R, 1968, J PHARMACOL EXP THER, V161, P122
   Pierre PJ, 1997, PSYCHOPHARMACOLOGY, V129, P277, DOI 10.1007/s002130050191
   RISNER ME, 1976, BIOL PSYCHIAT, V11, P625
   Robbins TW, 2008, ANN NY ACAD SCI, V1141, P1, DOI 10.1196/annals.1441.020
   Robbins TW, 2008, PHILOS T R SOC B, V363, P3109, DOI 10.1098/rstb.2008.0108
   Roberts DCS, 2007, PROG NEURO-PSYCHOPH, V31, P1614, DOI 10.1016/j.pnpbp.2007.08.028
   Roberts DCS, 2002, DRUG ALCOHOL DEPEN, V67, P291, DOI 10.1016/S0376-8716(02)00083-2
   Robinson TE, 2001, ADDICTION, V96, P103, DOI 10.1046/j.1360-0443.2001.9611038.x
   Robinson TE, 2000, ADDICTION, V95, pS91
   Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI 10.1146/annurev.psych.54.101601.145237
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Root DH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007170
   Rouge-Pont F, 1998, EUR J NEUROSCI, V10, P3903, DOI 10.1046/j.1460-9568.1998.00438.x
   ROUGEPONT F, 1995, J NEUROSCI, V15, P7189
   ROUGEPONT F, 1993, BRAIN RES, V602, P169, DOI 10.1016/0006-8993(93)90260-T
   Russo SJ, 2010, TRENDS NEUROSCI, V33, P267, DOI 10.1016/j.tins.2010.02.002
   SALMON DP, 1995, CURR OPIN NEUROBIOL, V5, P184, DOI 10.1016/0959-4388(95)80025-5
   Sanchis-Segura C, 2006, ADDICT BIOL, V11, P2, DOI 10.1111/j.1369-1600.2006.00012.x
   SCHECHTER MD, 1992, PHARMACOL BIOCHEM BE, V43, P1015, DOI 10.1016/0091-3057(92)90475-U
   Schramm-Sapyta NL, 2011, PSYCHOPHARMACOLOGY, V215, P493, DOI 10.1007/s00213-011-2216-5
   Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593
   SELF DW, 1995, ANNU REV NEUROSCI, V18, P463, DOI 10.1146/annurev.ne.18.030195.002335
   Sheeran P, 2005, BRIT J SOC PSYCHOL, V44, P47, DOI 10.1348/014466604X23446
   SIEGEL R. K, 2005, INTOXICATION UNIVERS
   Skinner BF, 1930, P NATL ACAD SCI USA, V16, P433, DOI 10.1073/pnas.16.6.433
   SKINNER BF, 1950, PSYCHOL REV, V57, P193, DOI 10.1037/h0054367
   STEWART J, 1984, PSYCHOL REV, V91, P251, DOI 10.1037/0033-295X.91.2.251
   Suto N, 2003, NEUROPSYCHOPHARMACOL, V28, P629, DOI 10.1038/sj.npp.1300075
   Suto N, 2002, NEUROPSYCHOPHARMACOL, V27, P970, DOI 10.1016/S0893-133X(02)00379-2
   Thomas MJ, 2008, BRIT J PHARMACOL, V154, P327, DOI 10.1038/bjp.2008.77
   THOMPSON T, 1964, PSYCHOPHARMACOLOGIA, V5, P87, DOI 10.1007/BF00413045
   TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147
   Tornatzky W, 2000, PSYCHOPHARMACOLOGY, V148, P289, DOI 10.1007/s002130050053
   Valjent E, 2004, EUR J NEUROSCI, V19, P1826, DOI 10.1111/j.1460-9568.2004.03278.x
   van der Kam EL, 2005, NEUROPHARMACOLOGY, V48, P685, DOI 10.1016/j.neuropharm.2004.12.014
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Vanderschuren LJMJ, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a011932
   Veeneman MMJ, 2012, NEUROPSYCHOPHARMACOL, V37, P487, DOI 10.1038/npp.2011.209
   Vezina P, 1999, PSYCHOPHARMACOLOGY, V147, P125, DOI 10.1007/s002130051152
   Volkow ND, 2011, NEURON, V69, P599, DOI 10.1016/j.neuron.2011.01.027
   Wanat Matthew J, 2009, Curr Drug Abuse Rev, V2, P195
   WEEKS JR, 1962, SCIENCE, V138, P143, DOI 10.1126/science.138.3537.143
   WEISS B, 1964, J PHARMACOL EXP THER, V144, P17
   Wenzel JM, 2011, PSYCHOPHARMACOLOGY, V217, P221, DOI 10.1007/s00213-011-2267-7
   White FJ, 1998, DRUG ALCOHOL DEPEN, V51, P141, DOI 10.1016/S0376-8716(98)00072-6
   WIKLER A, 1967, PSYCHOPHARMACOLOGIA, V10, P255, DOI 10.1007/BF00401386
   WIKLER A, 1971, PSYCHOPHARMACOLOGIA, V20, P103, DOI 10.1007/BF00404365
   Willuhn I, 2012, P NATL ACAD SCI USA, V109, P20703, DOI 10.1073/pnas.1213460109
   Winocur G, 2010, NEUROPSYCHOLOGIA, V48, P2339, DOI 10.1016/j.neuropsychologia.2010.04.016
   Winstanley CA, 2010, ALCOHOL CLIN EXP RES, V34, P1306, DOI 10.1111/j.1530-0277.2010.01215.x
   Wise R A, 1984, NIDA Res Monogr, V50, P15
   Wise R A, 1994, NIDA Res Monogr, V145, P191
   WISE RA, 1982, PHARMACOL BIOCHEM BE, V17, P239, DOI 10.1016/0091-3057(82)90076-4
   WISE RA, 1987, PHARMACOL THERAPEUT, V35, P227, DOI 10.1016/0163-7258(87)90108-2
   WISE RA, 1978, BRAIN RES, V152, P215, DOI 10.1016/0006-8993(78)90253-6
   WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469
   Wolf Marina E, 2002, Mol Interv, V2, P146, DOI 10.1124/mi.2.3.146
   Wolf ME, 2010, NEUROTOX RES, V18, P393, DOI 10.1007/s12640-010-9176-0
   Wolf ME, 2010, TRENDS NEUROSCI, V33, P391, DOI 10.1016/j.tins.2010.06.003
   Wolf ME, 1998, PROG NEUROBIOL, V54, P679, DOI 10.1016/S0301-0082(97)00090-7
   WOLFFGRAMM J, 1991, NEUROSCI BIOBEHAV R, V15, P515, DOI 10.1016/S0149-7634(05)80142-3
   Wolffgramm J, 2000, J NEURAL TRANSM, V107, P649, DOI 10.1007/s007020070067
   WOLFFGRAMM J, 1991, PHARMACOL BIOCHEM BE, V38, P389, DOI 10.1016/0091-3057(91)90297-F
   Wu T, 2008, J PHYSIOL-LONDON, V586, P4295, DOI 10.1113/jphysiol.2008.153445
NR 194
TC 144
Z9 148
U1 2
U2 44
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0033-3158
EI 1432-2072
J9 PSYCHOPHARMACOLOGY
JI Psychopharmacology
PD OCT
PY 2013
VL 229
IS 3
SI SI
BP 387
EP 413
DI 10.1007/s00213-013-3224-4
PG 27
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 214PG
UT WOS:000324145500003
PM 23963530
OA hybrid, Green Published
DA 2023-06-23
ER

PT J
AU Belin-Rauscent, A
   Fouyssac, M
   Bonci, A
   Belin, D
AF Belin-Rauscent, Aude
   Fouyssac, Maxime
   Bonci, Antonello
   Belin, David
TI How Preclinical Models Evolved to Resemble the Diagnostic Criteria of
   Drug Addiction
SO BIOLOGICAL PSYCHIATRY
LA English
DT Review
DE Behavioral models; Cocaine; Compulsive drug seeking; Limbic system;
   Substance use disorders
AB Drug addiction is a complex neuropsychiatric disorder that affects a subset of the individuals who take drugs. It is characterized by maladaptive drug-seeking habits that are maintained despite adverse consequences and intense drug craving. The pathophysiology and etiology of addiction is only partially understood despite extensive research because of the gap between current preclinical models of addiction and the clinical criteria of the disorder. This review presents a brief overview, based on selected methodologies, of how behavioral models have evolved over the last 50 years to the development of recent preclinical models of addiction that more closely mimic diagnostic criteria of addiction. It is hoped that these new models will increase our understanding of the complex neurobiological mechanisms whereby some individuals switch from controlled drug use to compulsive drug-seeking habits and relapse to these maladaptive habits. Additionally, by paving the way to bridge the gap that exists between biobehavioral research on addiction and the human situation, these models may provide new perspectives for the development of novel and effective therapeutic strategies for drug addiction.
C1 [Belin-Rauscent, Aude; Fouyssac, Maxime; Belin, David] Univ Cambridge, Dept Pharmacol, Cambridge CB2 1QJ, England.
   [Belin-Rauscent, Aude; Fouyssac, Maxime; Belin, David] Univ Cambridge, Behav & Clin Neurosci Inst, Cambridge, England.
   [Bonci, Antonello] NIDA, Intramural Res Program, NIH, US Dept HHS, Baltimore, MD 21224 USA.
C3 University of Cambridge; University of Cambridge; National Institutes of
   Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National
   Institute on Drug Abuse (NIDA)
RP Bonci, A (通讯作者)，NIDA, Intramural Res Program, NIH, US Dept HHS, 251 Bayville Blvd, Baltimore, MD 21224 USA.
EM antonello.bonci@nih.gov
RI Belin, David/E-1231-2014
OI Belin, David/0000-0002-7383-372X; Fouyssac, Maxime/0000-0002-9496-5836
FU Agence Nationale de la Recherche [ANR12 SAMA00201]; University of
   Cambridge; Newton Trust; Cambridge Commonwealth; European and
   International Trust; National Institute on Drug Abuse
FX This work was supported by the Agence Nationale de la Recherche Grant
   No. ANR12 SAMA00201 (DB), the University of Cambridge and the Newton
   Trust (DB); the Cambridge Commonwealth, European and International Trust
   (MF), and the National Institute on Drug Abuse (AB).
NR 0
TC 77
Z9 78
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD JAN 1
PY 2016
VL 79
IS 1
BP 39
EP 46
DI 10.1016/j.biopsych.2015.01.004
PG 8
WC Neurosciences; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Psychiatry
GA CW9WX
UT WOS:000365350000008
PM 25747744
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Khan, KT
   Jabeen, T
AF Khan, Khadija Tariq
   Jabeen, Tahira
TI A phenomenological study of addiction recovery at a model drug abuse
   center, Social Welfare Department, Punjab, Pakistan
SO INTERNATIONAL SOCIAL WORK
LA English
DT Article; Early Access
DE Addiction recovery; drug addiction; model drug abuse center; recovery;
   Social Welfare Department; social work
ID SUBSTANCE USE; FAMILY; ECOLOGY; WORKERS; HEALTH; IMPACT
AB This article attempts to provide an insight into the experiences of drug addicts at a rehabilitation center, run by the provincial Social Welfare Department in Lahore, Pakistan, through a qualitative approach. The menace of drugs is increasing worldwide, including Pakistan. Effective treatment and rehabilitative services can lower the prevalence rate of drug addiction. The aim of this research was to understand/explore the experiences of research participants about the phenomenon of drug addiction and rehabilitation services provided in the field of social welfare. This research extends the current knowledge of individuals' drug addiction by revealing the complexities and intricacies of this behavior.
C1 [Khan, Khadija Tariq] Univ Punjab, Lahore, Pakistan.
   [Jabeen, Tahira] Univ Punjab, Dept Social Work, H 111-A Block C Lane 5 PAF Officers Colony, Lahore 54810, Pakistan.
C3 University of Punjab; University of Punjab
RP Khan, KT (通讯作者)，Univ Punjab, Dept Social Work, H 111-A Block C Lane 5 PAF Officers Colony, Lahore 54810, Pakistan.
EM khadija_khan@live.com
CR Arat G, 2017, J TRANSCULT NURS, V28, P573, DOI 10.1177/1043659616668397
   Asad AZ., 2011, DRUGS ANTINARCOTICS, V3, P23
   Ashford RD, 2019, ALCOHOL TREAT Q, V37, P462, DOI 10.1080/07347324.2019.1585216
   Batool S, 2017, E MEDITERR HEALTH J, V23, P168, DOI 10.26719/2017.23.3.168
   Bibi S., 2017, INT J SCI ENG RES, V8, P572
   Blevins CE, 2018, J ADDICT MED, V12, P273, DOI 10.1097/ADM.0000000000000400
   BRONFENBRENNER U, 1977, AM PSYCHOL, V32, P513, DOI 10.1037/0003-066x.32.7.513
   BRONFENBRENNER U, 1986, DEV PSYCHOL, V22, P723, DOI 10.1037/0012-1649.22.6.723
   Creswell J. W., 2018, RES DESIGN QUALITATI, V5th, DOI DOI 10.2307/1523157
   Daley DC, 2013, SOC WORK PUBLIC HLTH, V28, P159, DOI 10.1080/19371918.2013.758960
   de Andrade D, 2019, DRUG ALCOHOL DEPEN, V201, P227, DOI 10.1016/j.drugalcdep.2019.03.031
   DeMarce JM, 2021, SUBST ABUS, V42, P168, DOI 10.1080/08897077.2019.1674238
   Ghazal P, 2019, PUBLIC HEALTH, V167, P34, DOI 10.1016/j.puhe.2018.10.020
   Gomez-Restrepo C, 2017, SUBST ABUSE TREAT PR, V12, DOI 10.1186/s13011-017-0129-y
   Graham JR, 2007, INT SOC WORK, V50, P627, DOI 10.1177/0020872807079920
   Guttmacher S., 2010, COMMUNITY BASED HLTH
   Hafford-Letchfield T., 2018, CONT PRACTICES SOCIA
   Hawkins J, 1987, HDB EVALUATING DRUG
   Hawkins J D, 1985, J Prim Prev, V6, P73, DOI 10.1007/BF01325432
   Higher Education Commission (HEC), 2015, CURR SOC WORK BS MS
   Hughes JM., 2010, CRITICAL SOCIAL THIN, V2, P59
   Jabeen, 2013, THESIS AUSTR NATL U
   Jabeen S, 2017, PAK J ZOOL, V49, P95, DOI 10.17582/journal.pjz/2017.49.1.95
   Jabeen T., 2013, J SOC, V44, P43
   KANDEL DB, 1982, J AM ACAD CHILD PSY, V21, P328, DOI 10.1016/S0002-7138(09)60936-5
   KANDEL DB, 1980, ANNU REV SOCIOL, V6, P235, DOI 10.1146/annurev.so.06.080180.001315
   Kashif A., 2021, THESIS U PUNJAB LAHO
   Kaskutas LA, 2014, J STUD ALCOHOL DRUGS, V75, P999, DOI 10.15288/jsad.2014.75.999
   Khalid S., 2016, J BEHAVIOURAL SCI, V26, P116
   Kourgiantakis T, 2021, J SOC WORK PRACT ADD, V21, P18, DOI 10.1080/1533256X.2020.1870287
   Kumpfer KL., 1985, J CHILDREN CONT SOC, V3/4, P49
   Kumpfer KL., 1987, YOUTH HIGH RISK SUBS, V1537
   Lander L, 2013, SOC WORK PUBLIC HLTH, V28, P194, DOI 10.1080/19371918.2013.759005
   Liddle HA, 2018, J SUBST ABUSE TREAT, V90, P47, DOI 10.1016/j.jsat.2018.04.011
   Mansoori N, 2018, ANN KING EDWARD MED, V24, P932
   Manttari-van der Kuip M, 2016, INT J SOC WELF, V25, P86, DOI 10.1111/ijsw.12163
   Masood S, 2014, HEALTH PSYCHOL BEHAV, V2, P820, DOI 10.1080/21642850.2014.939088
   Moustakas C., 1994, PHENOMENOLOGICAL RES, DOI [10.4135/9781412995658, DOI 10.4135/9781412995658]
   Nasir MJ., 2015, J HUMANITIES SOCIAL, V23, P57
   National Institute on Drug Abuse, 2018, PRINC DRUG ADD TREAT
   O'Sullivan D, 2019, REHABIL COUNS BULL, V62, P209, DOI 10.1177/0034355217730395
   Odgers-Ortiz O, 2021, SOC COMPASS, V68, P430, DOI 10.1177/0037768620974272
   Patton M, 2002, QUALITATIVE RES EVAL, Vthird
   Rea D, 2019, CHILD ADOLESC SOC WO, V36, P329, DOI 10.1007/s10560-019-00603-0
   Rehman S., 2016, PESHAWAR J PSYCHOL B, V2, P59
   RHODES JW, 1988, PREVENTING SUBSTANCE
   Shoaib A., 2018, ANN PIMS SHAHEED ZUL, V14, P123
   Social Welfare Department (SWD) Government of the Punjab (GoP), 2015, MOD DRUG AB CTR
   Social Welfare Department (SWD) Government of the Punjab (GoP), 2015, WELF REH SERV DRUG A
   Substance Abuse and Mental Health Services Administration (SAMSHA), 2019, DRUG ALC US COLL AG
   The Centers for Disease Control and Prevention, 2014, SOC MOD FRAM PREV
   Unguru E, 2019, POSTMOD OPEN, V10, P1, DOI 10.18662/po/79
   United Nations Office on Drugs and Crime, 2013, REPORT DRUG USE PAKI
   Vanderplasschen W, 2013, SCI WORLD J, DOI 10.1155/2013/427817
   Wiercigroch D, 2020, SUBST ABUSE TREAT PR, V15, DOI 10.1186/s13011-019-0250-1
   Wills TA., 1985, Coping Subst. Use, V3, P24
   World Health Organization (WHO), 2014, ECOLOGICAL FRAMEWORK
   Zafar A., 2013, ACAD J INTERDISCIPLI, V2, P287
NR 58
TC 0
Z9 0
U1 2
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0020-8728
EI 1461-7234
J9 INT SOC WORK
JI Int. Soc. Work
PD 2022 SEP 26
PY 2022
DI 10.1177/00208728221124370
EA SEP 2022
PG 20
WC Social Work
WE Social Science Citation Index (SSCI)
SC Social Work
GA 4X6KT
UT WOS:000860949600001
DA 2023-06-23
ER

PT C
AU Li, X
   Lu, H
   Wang, H
   Zhu, PH
   Li, H
AF Li Xia
   Lu Han
   Wang Hui
   Zhu Pan-hua
   Li Hua
BE Tao, MA
TI The Correlation Study on Social Support and Coerced Drug Treatment
SO 2016 23RD ANNUAL INTERNATIONAL CONFERENCE ON MANAGEMENT SCIENCE &
   ENGINEERING, VOLS. I AND II
SE International Conference on Management Science and Engineering-Annual
   Conference Proceedings
LA English
DT Proceedings Paper
CT 23rd Annual International Conference on Management Science and
   Engineering (ICMSE)
CY AUG 18-20, 2016
CL Olten, SWITZERLAND
SP IEEE, Univ Appl Sci & Arts NW Switzerland, Harbin Inst Technol, Sch Management, IEEE Technol Management Council, Harbin Inst Technol
DE drug addiction; drug treatment; legal coerce; social support
ID LEGAL COERCION; MOTIVATION; RETENTION; RELAPSE; DROPOUT
AB The drug treatment is a big challenge for the healthcare workers and researchers as drugs become a global problem. This current study aims at exploring the relationship between social support and drug treatment during the coercion process of drug treatment. 299 coerced drug addicts were tested with a set of measures including demographic information; addiction severity index, and social support rating scale. The results showed the coerced drug addicts had severe drug addiction problem and lower social support. Social support presented negatively correlated with the severity of drug addiction and the effect degree of drug addiction on drug treatment. The subjective social support can significantly predict the awareness of importance of drug treatment, especially the effect of drug addiction on life and work plays an important role in the motivation for treatment. The results of the study provide favorable evidences for the positive role of social support for the coerced drug treatment, and give some implications for healthcare workers. To improve the subjective social support and the awareness of the effect of drug addiction on their life and work is beneficial to the treatment motivation.
C1 [Li Xia; Lu Han; Wang Hui; Zhu Pan-hua] Jiangxi Sci & Technol Normal Univ, Inst Educ, Nanchang 330013, Jiangxi, Peoples R China.
   [Li Hua] Compulsory Isolat Drug Treatment Ctr Fuling, Chongqing 408000, Peoples R China.
C3 Jiangxi Science & Technology Normal University
RP Li, X (通讯作者)，Jiangxi Sci & Technol Normal Univ, Inst Educ, Nanchang 330013, Jiangxi, Peoples R China.
FU National Science of Education Youth Program [CEA130145]
FX Supported by the National Science of Education Youth Program (CEA130145)
CR Brown VL, 2005, AM J DRUG ALCOHOL AB, V31, P203, DOI 10.1081/ADA-200047920
   Cheng G. P., 2014, CHINESE J CLIN PSYCH, V22, P812
   DELEON G, 2000, ADV MED SOC, V7, P103
   El-Bassel N, 1998, SOC SERV REV, V72, P379, DOI 10.1086/515764
   Ellis B, 2004, EVAL PROGRAM PLANN, V27, P213, DOI 10.1016/j.evalprogplan.2004.01.011
   Fang Y. Y., 2010, RES RELATIONSHIP PRE
   Farabee D, 1998, FED PROBAT, V62, P3
   Gregoire TK, 2004, J SUBST ABUSE TREAT, V26, P337, DOI 10.1016/S0740-5472(03)00155-7
   Hiller ML, 1998, CRIM JUSTICE BEHAV, V25, P463, DOI 10.1177/0093854898025004004
   Hough M, 2002, SUBST USE MISUSE, V37, P985, DOI 10.1081/JA-120004162
   Hui Z., 2015, CHINESE J DRUG DEPEN, V24, P262
   Joe GW, 1999, DRUG ALCOHOL DEPEN, V57, P113, DOI 10.1016/S0376-8716(99)00088-5
   Leonhard C, 2000, J SUBST ABUSE TREAT, V18, P129, DOI 10.1016/S0740-5472(99)00025-2
   Lin L., 2009, CHINESE J DRUG DEPEN, V18, P81
   Longshore D, 2006, DRUG ALCOHOL DEPEN, V81, P179, DOI 10.1016/j.drugalcdep.2005.06.011
   MILLER WR, 1985, PSYCHOL BULL, V98, P84, DOI 10.1037/0033-2909.98.1.84
   Panebianco D, 2016, INT J DRUG POLICY, V27, P146, DOI 10.1016/j.drugpo.2015.09.009
   Perron BE, 2008, DRUG ALCOHOL DEPEN, V92, P123, DOI 10.1016/j.drugalcdep.2007.07.011
   REIFMAN A, 1995, ANN BEHAV MED, V17, P124, DOI 10.1007/BF02895061
   SIMPSON DD, 1993, PSYCHOTHER, V30, P357, DOI 10.1037/0033-3204.30.2.357
   Tao L., 2008, RETENTION ITS RELATE
   Tyler KA, 2008, SOC SCI RES, V37, P673, DOI 10.1016/j.ssresearch.2007.09.004
   Xiao S., 1999, CHINESE MENTAL HLTH, P127
   Yang B., 2007, PSYCHOL SCI, V30, P1413, DOI [10.16719/j.cnki.1671-6981.2007.06.037, DOI 10.16719/J.CNKI.1671-6981.2007.06.037]
   [张婷 Zhang Ting], 2013, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V22, P34
NR 25
TC 0
Z9 0
U1 1
U2 3
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
SN 2155-1847
BN 978-1-5090-3604-2
J9 INT C MANAGE SCI ENG
PY 2016
BP 826
EP 831
PG 6
WC Engineering, Multidisciplinary; Management
WE Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)
SC Engineering; Business & Economics
GA BL6GT
UT WOS:000453861200112
DA 2023-06-23
ER

PT J
AU Raz, M
AF Raz, Mical
TI White Market Drugs: Big Pharma and the Hidden History of Addiction in
   America
SO JOURNAL OF THE HISTORY OF MEDICINE AND ALLIED SCIENCES
LA English
DT Book Review
DE Drug history; Addiction; Opioids; Drug Policy; Twentieth-century America
C1 [Raz, Mical] Univ Rochester, New York, NY 14607 USA.
C3 University of Rochester
RP Raz, M (通讯作者)，Univ Rochester, New York, NY 14607 USA.
OI Raz, Mical/0000-0002-8929-6252
CR Herzberg D., 2020, WHITE MARKET DRUGS B
NR 1
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-5045
EI 1468-4373
J9 J HIST MED ALL SCI
JI J. Hist. Med. Allied Sci.
PD FEB 7
PY 2022
VL 77
IS 1
BP 126
EP 128
AR jrab048
DI 10.1093/jhmas/jrab048
EA DEC 2021
PG 3
WC Health Care Sciences & Services; History & Philosophy Of Science
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)
SC Health Care Sciences & Services; History & Philosophy of Science
GA YW0KV
UT WOS:000753111400013
DA 2023-06-23
ER

PT C
AU Ioan, BG
   Hanganu, B
   Chirila, BD
   Coteti, AG
   Neagu, M
AF Ioan, B. G.
   Hanganu, B.
   Chirila, B. D.
   Coteti, A. G.
   Neagu, M.
BE Sandu, A
   Frunza, A
   Ciulei, T
   Gorghiu, G
   Petrovici, A
TI Drug Abuse and Addiction - A Sociological Approach
SO RETHINKING SOCIAL ACTION. CORE VALUES
LA English
DT Proceedings Paper
CT 6th LUMEN International Conference on Rethinking Social Action Core
   Values
CY APR 16-19, 2015
CL Iasi, ROMANIA
SP LUMEN
DE drug abuse; addiction; family; peers; living environment
ID EARLY ADULTHOOD; IMPACT; SOCIALIZATION; DELINQUENCY; ADOLESCENCE;
   MECHANISMS; BEHAVIORS; VARIABLES; ETIOLOGY; DEVIANCE
AB Drug abuse and addiction are important and actual social and public health problems throughout the world. Although considerable progress has been made in identifying the contributing factors of drug abuse, there are still gaps. However it is widely accepted that drug abuse and addiction have a multi-factorial etiology. In this paper the authors analyse the implication of the social factors in the initiation and continuation of drug consumption, abuse and addiction, emphasizing the importance of the family, peer groups and living environment. The authors acknowledge that a thorough knowledge of the causes of drug abuse and addiction allow the creation of effective intervention methods in this field.
C1 [Ioan, B. G.; Hanganu, B.; Chirila, B. D.; Coteti, A. G.; Neagu, M.] Grigore T Popa Univ Med & Pharm, Iasi, Romania.
   [Chirila, B. D.] Socola Clin Hosp, Psychiat, Iasi, Romania.
C3 Grigore T Popa University of Medicine & Pharmacy
RP Ioan, BG (通讯作者)，Grigore T Popa Univ Med & Pharm, Iasi, Romania.
EM ioanbml@yahoo.com; bianca_h_no1@yahoo.com; c_bogdan_d@yahoo.com;
   coteti_alexandru@yahoo.com; mariusneagu87@gmail.com
RI Neagu, Marius/AAT-2551-2021; Neagu, Marius/N-3821-2014; Ioan, Beatrice
   Gabriela/E-9941-2011
OI Neagu, Marius/0000-0003-3659-3154; Neagu, Marius/0000-0003-3659-3154; 
CR AGNEW R, 1993, J RES CRIME DELINQ, V30, P245, DOI 10.1177/0022427893030003001
   Anderson T. L., 1998, SOCIOLOGY CRIME LAW, V1, P233
   [Anonymous], 2001, 32 WHO EXP COMM DRUG
   Bahr Stephen J, 2005, J Prim Prev, V26, P529, DOI 10.1007/s10935-005-0014-8
   BARNES GM, 1986, J STUD ALCOHOL, V47, P53, DOI 10.15288/jsa.1986.47.53
   Barrett AE, 2006, ADDICTION, V101, P109, DOI 10.1111/j.1360-0443.2005.01296.x
   Boardman JD, 2001, J HEALTH SOC BEHAV, V42, P151, DOI 10.2307/3090175
   BROOK JS, 1986, DEV PSYCHOL, V22, P460, DOI 10.1037/0012-1649.22.4.460
   Douglass M., 1995, SOC SCI RES, V24, P352
   HAWKINS JD, 1992, PSYCHOL BULL, V112, P64, DOI 10.1037/0033-2909.112.1.64
   Hirschi T., 1969, CAUSES DELINQUENCY
   Ioan B., 2003, CONSUMUL DROGURI SI
   Ioan B., 2012, ENCY IMMIGRANT HLTH
   Iov J. C., 2012, ENCY IMMIGRANT HLT 4, P1360
   Jing F., 1998, SOC SCI MED, V47, P479
   JOHNSON GM, 1984, ADOLESCENCE, V19, P295
   KANDEL DB, 1987, INT J ADDICT, V22, P319, DOI 10.3109/10826088709027433
   KIRSCHENMAN J, 1991, URBAN UNDERCLASS, P203
   Krivo LJ, 1996, SOC FORCES, V75, P619, DOI 10.2307/2580416
   Lindesmith AR, 1938, AM J SOCIOL, V43, P593, DOI 10.1086/217773
   MARLATT GA, 1988, ANNU REV PSYCHOL, V39, P223, DOI 10.1146/annurev.psych.39.1.223
   NEWCOMB MD, 1988, J RES PERS, V22, P154, DOI 10.1016/0092-6566(88)90012-8
   Oetting ER, 1998, SUBST USE MISUSE, V33, P995, DOI 10.3109/10826089809056252
   Rhodes T, 2009, INT J DRUG POLICY, V20, P193, DOI 10.1016/j.drugpo.2008.10.003
   Sellers C., 2004, CRIMINOLOGICAL THEOR
   Svensson R, 2003, YOUTH SOC, V34, P300, DOI 10.1177/0044118X02250095
   Vitaro F, 2000, J ABNORM CHILD PSYCH, V28, P313, DOI 10.1023/A:1005188108461
   WALLACE JM, 1991, SOC PROBL, V38, P333
NR 28
TC 0
Z9 0
U1 3
U2 20
PU MEDIMOND S R L
PI 40128 BOLOGNA
PA VIA MASERATI 5, 40128 BOLOGNA, 00000, ITALY
BN 978-88-7587-725-5
PY 2015
BP 657
EP 661
PG 5
WC Social Sciences, Interdisciplinary
WE Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)
SC Social Sciences - Other Topics
GA BF0DG
UT WOS:000378560300116
DA 2023-06-23
ER

PT J
AU Winger, G
   Woods, JH
   Galuska, CM
   Wade-Galuska, T
AF Winger, G
   Woods, JH
   Galuska, CM
   Wade-Galuska, T
TI Behavioral perspectives on the neuroscience of drug addiction
SO JOURNAL OF THE EXPERIMENTAL ANALYSIS OF BEHAVIOR
LA English
DT Article
DE drug addiction; neuroscience
ID NEURONAL-ACTIVITY; PREFRONTAL CORTEX; EXPECTED REWARD; COCAINE;
   MECHANISMS; RESPONSES; CIRCUITS; ABUSE; NEUROBIOLOGY; EXPECTATIONS
AB Neuroscientific approaches to drug addiction traditionally have been based on the premise that addiction is a process that results from brain changes that in turn result from chronic administration of drugs of abuse. An alternative approach views drug addiction as a behavioral disorder in which drugs function as preeminent reinforcers. Although there is a fundamental discrepancy between these two approaches, the emerging neuroscience of reinforcement and choice behavior eventually may shed light on the brain mechanisms involved in excessive drug use. Behavioral scientists could assist in this understanding by devoting more attention to the assessment of differences in the reinforcing strength of drugs and by attempting to develop and validate behavioral models of addiction.
C1 Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan
RP Winger, G (通讯作者)，Univ Michigan, Dept Pharmacol, 1302 MSRB 3, Ann Arbor, MI 48109 USA.
EM gwinger@umich.edu
FU NIAAA NIH HHS [AA 013713, R01 AA013713] Funding Source: Medline; NIDA
   NIH HHS [DA 015449, R01 DA015449] Funding Source: Medline
CR Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Ahmed SH, 2000, NEUROPSYCHOPHARMACOL, V22, P413, DOI 10.1016/S0893-133X(99)00133-5
   ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041
   Alheid GF, 2003, ANN NY ACAD SCI, V985, P185
   Bardo MT, 2000, PSYCHOPHARMACOLOGY, V153, P31, DOI 10.1007/s002130000569
   Barraclough DJ, 2004, NAT NEUROSCI, V7, P404, DOI 10.1038/nn1209
   Barrot M, 2002, P NATL ACAD SCI USA, V99, P11435, DOI 10.1073/pnas.172091899
   Benavides DR, 2004, ANN NY ACAD SCI, V1025, P335, DOI 10.1196/annals.1316.041
   Bombard J., 2004, Morbidity and Mortality Weekly Report, V53, P1035
   Cardinal RN, 2004, CURR OPIN NEUROBIOL, V14, P156, DOI 10.1016/j.conb.2004.03.004
   Carelli RM, 2002, PHYSIOL BEHAV, V76, P379, DOI 10.1016/S0031-9384(02)00760-6
   Chang JY, 1998, J NEUROSCI, V18, P3098
   CHEN K, 1995, AM J PUBLIC HEALTH, V85, P41, DOI 10.2105/AJPH.85.1.41
   Colby CL, 1999, ANNU REV NEUROSCI, V22, P319, DOI 10.1146/annurev.neuro.22.1.319
   Colby CR, 2003, J NEUROSCI, V23, P2488
   Cromwell HC, 2003, J NEUROPHYSIOL, V89, P2823, DOI 10.1152/jn.01014.2002
   Davison M, 2000, J EXP ANAL BEHAV, V74, P1, DOI 10.1901/jeab.2000.74-1
   Deadwyler SA, 2004, NEUROSCI BIOBEHAV R, V27, P703, DOI 10.1016/j.neubiorev.2003.11.011
   DENEAU G, 1969, PSYCHOPHARMACOLOGIA, V16, P30, DOI 10.1007/BF00405254
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Glimcher PW, 2003, ANNU REV NEUROSCI, V26, P133, DOI 10.1146/annurev.neuro.26.010302.081134
   Gold JI, 2001, TRENDS COGN SCI, V5, P10, DOI 10.1016/S1364-6613(00)01567-9
   Gold JI, 2002, NEURON, V36, P299, DOI 10.1016/S0896-6273(02)00971-6
   GRIFFITHS RR, 1979, CLIN PHARMACOL THER, V25, P611
   Hassani OK, 2001, J NEUROPHYSIOL, V85, P2477, DOI 10.1152/jn.2001.85.6.2477
   Heimer L, 2003, AM J PSYCHIAT, V160, P1726, DOI 10.1176/appi.ajp.160.10.1726
   HERRNSTEIN RJ, 1961, J EXP ANAL BEHAV, V4, P267, DOI 10.1901/jeab.1961.4-267
   Higgins ST, 2004, ANNU REV PSYCHOL, V55, P431, DOI 10.1146/annurev.psych.55.090902.142033
   HIGGINS ST, 1993, AM J PSYCHIAT, V150, P763
   Horvitz JC, 2000, NEUROSCIENCE, V96, P651, DOI 10.1016/S0306-4522(00)00019-1
   Kalivas P. W., 1993, LIMBIC MOTOR CIRCUIT, P237
   Kalivas Peter W, 2004, Curr Psychiatry Rep, V6, P347, DOI 10.1007/s11920-004-0021-0
   Katz JL, 2003, PSYCHOPHARMACOLOGY, V168, P21, DOI 10.1007/s00213-003-1441-y
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155
   Leon MI, 1999, NEURON, V24, P415, DOI 10.1016/S0896-6273(00)80854-5
   Lubman DI, 2004, ADDICTION, V99, P1491, DOI 10.1111/j.1360-0443.2004.00808.x
   McClung CA, 2003, NAT NEUROSCI, V6, P1208, DOI 10.1038/nn1143
   Nestler EJ, 2004, TRENDS PHARMACOL SCI, V25, P210, DOI 10.1016/j.tips.2004.02.005
   Phillips PEM, 2003, NATURE, V422, P614, DOI 10.1038/nature01566
   Platt ML, 1999, NATURE, V400, P233, DOI 10.1038/22268
   Robbins TW, 1996, CURR OPIN NEUROBIOL, V6, P228, DOI 10.1016/S0959-4388(96)80077-8
   Robins L N, 1994, NIDA Res Monogr, V140, P30
   Robinson R, 2004, HIGH EDUC, V47, P1, DOI 10.1023/B:HIGH.0000009803.70418.9c
   Robinson TE, 2000, ADDICTION, V95, pS91
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Roesch MR, 2003, J NEUROPHYSIOL, V90, P1766, DOI 10.1152/jn.00019.2003
   Roesch MR, 2004, SCIENCE, V304, P307, DOI 10.1126/science.1093223
   Roitman MF, 2004, J NEUROSCI, V24, P1265, DOI 10.1523/JNEUROSCI.3823-03.2004
   Schultz W, 2004, CURR OPIN NEUROBIOL, V14, P139, DOI 10.1016/j.conb.2004.03.017
   Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1
   Skinner B. F., 1974, BEHAVIORISM
   SKINNER BF, 1991, BEHAV ORGANISMS EXPT
   Sugrue LP, 2004, SCIENCE, V304, P1782, DOI 10.1126/science.1094765
   Szumlinski KK, 2004, NEURON, V43, P401, DOI 10.1016/j.neuron.2004.07.019
   Tremblay L, 1999, NATURE, V398, P704, DOI 10.1038/19525
   Watanabe M, 2002, J NEUROSCI, V22, P2391, DOI 10.1523/JNEUROSCI.22-06-02391.2002
   Watanabe M, 2001, EXP BRAIN RES, V140, P511, DOI 10.1007/s002210100856
NR 58
TC 19
Z9 20
U1 10
U2 33
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-5002
EI 1938-3711
J9 J EXP ANAL BEHAV
JI J. Exp. Anal. Behav.
PD NOV
PY 2005
VL 84
IS 3
BP 667
EP 681
DI 10.1901/jeab.2005.101-04
PG 15
WC Psychology, Biological; Behavioral Sciences; Psychology, Experimental
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology; Behavioral Sciences
GA 017KF
UT WOS:000235691800020
PM 16596985
OA Green Published, Green Submitted
DA 2023-06-23
ER

PT J
AU AL-Eitan, LN
   Rababa'h, DM
   Alghamdi, MA
AF AL-Eitan, Laith N.
   Rababa'h, Doaa M.
   Alghamdi, Mansour A.
TI Genetic susceptibility of opioid receptor genes polymorphism to drug
   addiction: A candidate-gene association study
SO BMC PSYCHIATRY
LA English
DT Article
DE Opioids; Polymorphism; Drug addiction; Jordan
AB Background Like other complex diseases including drug addiction, genetic factors can interfere with the disease. In this study, three opioid genes (OPRM1, OPRD1, and OPRK1) were examined for an association with drug addiction among Jordanian males. Methods The study involved 498 addicts, in addition to 496 healthy controls and all from Arab descent. Results The findings in this study showed that rs1799971 of the OPRM1 gene was in association with drug addiction for both alleles and genotypes with P-values = 0.002 and 0.01, respectively. In addition, a significant association between the dominant model (A/A vs G/A-G/G) of rs1799971 (OPRM1) and drug addiction (P-value = 0.003, OR = 1.59 (1.17-2.15)) was detected. Moreover, a genetic haplotype (AGGGCGACCCC) of theOPRM1 gene revealed a significant association with drug addiction (P-value = 0.01, OR = 1.56 (1.15-2.12)). We also found that the age of addicts, smoking, and marital status with genetic variants within OPRM1, OPRD1, and OPRK1 genes may be implicated in drug addiction risk. Conclusion We propose that rs1799971 of the OPRM1gene is a genetic risk factor for drug addiction among Jordanian males.
C1 [AL-Eitan, Laith N.; Rababa'h, Doaa M.] Jordan Univ Sci & Technol, Dept Appl Biol Sci, Irbid 22110, Jordan.
   [AL-Eitan, Laith N.] Jordan Univ Sci & Technol, Dept Biotechnol & Genet Engn, Irbid 22110, Jordan.
   [Alghamdi, Mansour A.] King Khalid Univ, Coll Med, Dept Anat, Abha 61421, Saudi Arabia.
   [Alghamdi, Mansour A.] King Khalid Univ, Coll Med, Enemies & Personalized Med Unit, Abha 61421, Saudi Arabia.
C3 Jordan University of Science & Technology; Jordan University of Science
   & Technology; King Khalid University; King Khalid University
RP AL-Eitan, LN (通讯作者)，Jordan Univ Sci & Technol, Dept Appl Biol Sci, Irbid 22110, Jordan.; AL-Eitan, LN (通讯作者)，Jordan Univ Sci & Technol, Dept Biotechnol & Genet Engn, Irbid 22110, Jordan.
EM lneltan@just.edu.jo
RI Alghamdi, Mansour/AAL-8430-2021
OI Alghamdi, Mansour/0000-0002-6613-1498
FU Scientific Research Support Fund (SRSF) at Jordanian Ministry of Higher
   Education [MPH/1/43/2017]
FX The Scientific Research Support Fund (SRSF) at Jordanian Ministry of
   Higher Education supported this work under grant number MPH/1/43/2017.
CR Agrawal A, 2008, ADDICTION, V103, P1069, DOI 10.1111/j.1360-0443.2008.02213.x
   Ahmed M, 2018, J MOL NEUROSCI, V65, P472, DOI 10.1007/s12031-018-1123-1
   Al-Eitan LN, 2020, GENE, V733, DOI 10.1016/j.gene.2019.144267
   Al-Eitan Laith N., 2016, Current Pharmacogenomics & Personalized Medicine, V14, P7, DOI 10.2174/1875692115666161215103842
   Al-Eitan Laith N., 2014, Current Pharmacogenomics & Personalized Medicine, V12, P167, DOI 10.2174/1875692113666150115221210
   Al-Eitan LN, 2012, PHARMACOGEN PERS MED, V5, P99, DOI 10.2147/PGPM.S33351
   AL-Eitan Laith N., 2012, Current Pharmacogenomics & Personalized Medicine, V10, P293
   Al-Eitan Laith N, 2012, BMC Res Notes, V5, P497, DOI 10.1186/1756-0500-5-497
   Al-Eitan LN, 2014, TOXICOL IND HEALTH, V30, P598, DOI 10.1177/0748233712462446
   Alblooshi H, 2018, ANN GEN PSYCHIATR, V17, DOI 10.1186/s12991-018-0192-4
   American Psychiatric Association DSM-5 Task Force, 2013, DIAGNOSTIC STAT MANU
   Arias AJ, 2012, AM J ADDICTION, V21, P5, DOI 10.1111/j.1521-0391.2011.00195.x
   Bevilacqua L, 2009, CLIN PHARMACOL THER, V85, P359, DOI 10.1038/clpt.2009.6
   Chou WY, 2006, ANESTHESIOLOGY, V105, P334, DOI 10.1097/00000542-200608000-00016
   Colloca L, 2019, PAIN, V160, P1824, DOI 10.1097/j.pain.0000000000001578
   Corley RP, 2008, DRUG ALCOHOL DEPEN, V96, P90, DOI 10.1016/j.drugalcdep.2008.02.004
   Crist RC, 2013, DRUG ALCOHOL DEPEN, V127, P122, DOI 10.1016/j.drugalcdep.2012.06.023
   Crowley JJ, 2003, PSYCHIAT GENET, V13, P169, DOI 10.1097/00041444-200309000-00006
   Gelernter J, 1999, MOL PSYCHIATR, V4, P476, DOI 10.1038/sj.mp.4000556
   Jadidi Nadjme, 2014, J Addict, V2014, P352835, DOI 10.1155/2014/352835
   Li J, 2005, HEREDITY, V95, P221, DOI 10.1038/sj.hdy.6800717
   Mayer P, 1997, NEUROREPORT, V8, P2547, DOI 10.1097/00001756-199707280-00025
   Mistry CJ, 2014, CURR PSYCHIATRY REV, V10, P156, DOI 10.2174/1573400510666140320000928
   Nelson EC, 2014, ADDICT BIOL, V19, P111, DOI 10.1111/j.1369-1600.2012.00445.x
   Ninkovic J, 2013, AMINO ACIDS, V45, P9, DOI 10.1007/s00726-011-1163-0
   Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251
   Oertel BG, 2009, J BIOL CHEM, V284, P6530, DOI 10.1074/jbc.M807030200
   Randesi M, 2020, AM J DRUG ALCOHOL AB, V46, P761, DOI [10.1080/00952990.2020.1797064, 10.1007/978-981-15-6832-9_1]
   Rezaeifar A., 2019, INT J BASIC SCI MED, V4, P143, DOI [10.34172/ijbsm.2019.04, DOI 10.34172/IJBSM.2019.04]
   Wang JC, 2012, ANNU REV GENOM HUM G, V13, P241, DOI 10.1146/annurev-genom-090711-163844
   Wang SC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174294
   Xu K, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.62
   Xuei XL, 2007, AM J MED GENET B, V144B, P877, DOI 10.1002/ajmg.b.30531
   Yuferov V, 2004, PHARMACOGENETICS, V14, P793, DOI 10.1097/00008571-200412000-00002
   Zhang DD, 2007, BIOL PSYCHIAT, V61, P1244, DOI 10.1016/j.biopsych.2006.07.012
   Zhang H, 2008, MOL PSYCHIATR, V13, P531, DOI 10.1038/sj.mp.4002035
NR 36
TC 8
Z9 8
U1 1
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-244X
J9 BMC PSYCHIATRY
JI BMC Psychiatry
PD JAN 5
PY 2021
VL 21
IS 1
AR 5
DI 10.1186/s12888-020-03006-z
PG 14
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Psychiatry
GA PS5VG
UT WOS:000607988200005
PM 33402148
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Al-Kandari, FH
   Yacoub, K
   Omu, FE
AF Al-Kandari, Fatimah H.
   Yacoub, Khawlah
   Omu, Florence E.
TI Effect of drug addiction on the biopsychosocial aspects of persons with
   addiction in Kuwait: Nursing implications
SO JOURNAL OF ADDICTIONS NURSING
LA English
DT Article
DE biopsychosocial perspective; drug addiction; effect on relationships;
   nursing intervention
ID INTIMATE PARTNER VIOLENCE; SUBSTANCE USE; ABUSE; RISK; SPIRITUALITY;
   ADOLESCENTS; DEPRESSION; COMPULSION; EXPOSURE; BRAIN
AB Addiction is often seen as a "family illness" that has biological, psychological, and socio-cultural aspects that should be taken into consideration in order to achieve successful treatment and prevent relapse. The aims of this study are to describe the effect of drug abuse on the biophysical and mental health, family relationships, and job performance of individuals with addiction. The study also investigated drug-associated habits of persons with addiction in an Arabic society. This study was conducted in the Psychological Medicine Hospital, Kuwait. Data were obtained from 237 persons with addiction who were receiving treatment in the addiction center. A self-administered questionnaire designed in Arabic was used for data collection. Pearson and Mantel Hazel tests showed that addiction affects the biophysical, mental, behavioral, and occupational status of individuals with addiction. Also a relationship was found between drug addiction and disrupted family environment. Strategies for nursing intervention focused on family therapy as an important consideration in the management of drug addiction.
C1 Coll Nursing, Publ Author Appl Educ & Training, Safat 13092, Kuwait.
C3 Public Authority for Applied Education & Training (PAAET) - Kuwait
RP Al-Kandari, FH (通讯作者)，Coll Nursing, Publ Author Appl Educ & Training, POB 23167, Safat 13092, Kuwait.
EM fatimah@paaet.edu.kw
CR Abdulkarim AA, 2005, TROP DOCT, V35, P225, DOI 10.1258/004947505774938620
   Adinoff B, 2004, HARVARD REV PSYCHIAT, V12, P305, DOI 10.1080/10673220490910844
   Al-Kandari FH, 2001, J ADV NURS, V34, P78, DOI 10.1046/j.1365-2648.2001.3411731.x
   ALKHAIR B, 2000, OUR EXPT TREATMENT A
   Bechini L, 2003, EUR J AGRON, V19, P1, DOI 10.1016/S1161-0301(02)00013-8
   Bonnot O, 2003, ENCEPHALE, V29, P553
   CHAVEZ N, 2005, SUBSTANCE ABUSE MENT
   *CHILD WELF LEAG A, 2001, ALC OTH DRUGS CHILD
   Claro J de A, 2001, Sao Paulo Med J, V119, P135
   Cook CCH, 2004, ADDICTION, V99, P539, DOI 10.1111/j.1360-0443.2004.00715.x
   Coyer Sharon M, 2003, MCN Am J Matern Child Nurs, V28, P45
   Current Bill, 2002, Occup Health Saf, V71, P34
   Drewe M, 2004, SWISS MED WKLY, V134, P659
   Ebrahim SH, 2003, OBSTET GYNECOL, V101, P374, DOI 10.1016/S0029-7844(02)02588-7
   EID S, 2005, C ASP FOR CLIN CHEM
   Fals-Stewart W, 2003, ADDICT BEHAV, V28, P1555, DOI 10.1016/j.addbeh.2003.08.035
   Goldstein RZ, 2005, PSYCHIAT RES-NEUROIM, V138, P13, DOI 10.1016/j.pscychresns.2004.10.002
   Goldstein RZ, 2001, NEUROREPORT, V12, P2595, DOI 10.1097/00001756-200108080-00060
   GUNDY G, 2005, C ASP FOR CLIN CHEM
   HASSAN T, 2005, C ASP FOR CLIN CHEM
   Hoffmann JP, 2002, DRUG ALCOHOL DEPEN, V66, P255, DOI 10.1016/S0376-8716(02)00005-4
   Huestis MA, 2002, FORENSIC SCI INT, V128, P20, DOI 10.1016/S0379-0738(02)00160-3
   Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560
   JEDIZEJCZAK M, 2005, MIL MED, V170, P688
   Leigh J, 2005, ADDICT BEHAV, V30, P1335, DOI 10.1016/j.addbeh.2005.01.010
   Li ZW, 2006, PAEDIATR PERINAT EP, V20, P43, DOI 10.1111/j.1365-3016.2006.00694.x
   Lineberry TW, 2006, MAYO CLIN PROC, V81, P77, DOI 10.4065/81.1.77
   Lipsky S, 2005, AM J DRUG ALCOHOL AB, V31, P225, DOI 10.1081/ADA-200047923
   Lubman DI, 2004, ADDICTION, V99, P1491, DOI 10.1111/j.1360-0443.2004.00808.x
   Pelchat ML, 2002, PHYSIOL BEHAV, V76, P347, DOI 10.1016/S0031-9384(02)00757-6
   Piko BF, 2004, ADDICT BEHAV, V29, P1095, DOI 10.1016/j.addbeh.2004.03.022
   Radovanovic Z, 2000, J SUBST ABUSE, V12, P363, DOI 10.1016/S0899-3289(01)00057-8
   Scharff JL, 2004, ADDICT BEHAV, V29, P575, DOI 10.1016/j.addbeh.2003.08.028
   Smith PC, 2002, PHLEBOLOGY, V17, P1
   Spanagel R, 2005, ADDICTION, V100, P1813, DOI 10.1111/j.1360-0443.2005.01260.x
   TINSLEY MF, 2004, PITTSBURGH POST 0208, P1
   Welch-Carre Elizabeth, 2005, Adv Neonatal Care, V5, P217, DOI 10.1016/j.adnc.2005.04.007
NR 37
TC 8
Z9 8
U1 0
U2 14
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1088-4602
J9 J ADDICT NURS
JI J. Addict. Nurs.
PY 2007
VL 18
IS 1
BP 31
EP 40
DI 10.1080/10884600600995374
PG 10
WC Substance Abuse; Nursing
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Nursing
GA 156CQ
UT WOS:000245626000005
DA 2023-06-23
ER

PT J
AU Ehrenberg, A
AF Ehrenberg, A
TI From illegal drug addiction to addiction or the two ages of contemporary
   drug
SO M S-MEDECINE SCIENCES
LA French
DT Article
C1 Univ Paris 05, CNRS UMR 8136, CESAMES, Ctr Rech Psychotropes,Santa Mental Soc, F-75270 Paris 06, France.
C3 UDICE-French Research Universities; Universite Paris Cite
RP Ehrenberg, A (通讯作者)，Univ Paris 05, CNRS UMR 8136, CESAMES, Ctr Rech Psychotropes,Santa Mental Soc, 45 Rue St Peres, F-75270 Paris 06, France.
CR BAUDELAIRE C, 1970, PARADIS ARTIFICIELS
   Bergeron H., 1999, ETAT TOXICOMANIE HIS
   CESONI ML, 2000, DOCUMENTS GROUPEMENT
   DECELIS JB, 1992, FALLAIT CREER DELIT
   DEQUINCEY T, 1970, CONFESSIONS MANGEUR
   Ehrenberg A., 1995, INDIVIDU INCERTAIN
   FAUGERON C, 2002, SOC DROGUES ENJEUX L
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   LERT F, 1998, DROGUES MEDICAMENTS
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   *MILDT, 1999, PLAN TRIENN LUTT DRI
   MOREL A, 2001, ALCOOLOGIE ADDICTOLO, V23, P393
   Murard L., 1996, HYGIENE REPUBLIQUE S
   MUSTO D, 1987, AM DIS ORIGINS NARCO
   Ogien A., 2000, DOCUMENTS GROUPEMENT
   RETAILLAUDBAJAC E, 2000, USAGES USAGERS DROGU
   ROQUES B, 1999, DANGEROSITE DROGUES
   Setbon M., 1993, POUVOIRS SIDA
NR 18
TC 0
Z9 0
U1 0
U2 1
PU EDP SCIENCES S A
PI LES ULIS CEDEX A
PA 17, AVE DU HOGGAR, PA COURTABOEUF, BP 112, F-91944 LES ULIS CEDEX A,
   FRANCE
SN 0767-0974
J9 M S-MED SCI
JI M S-Med. Sci.
PD AUG-SEP
PY 2002
VL 18
IS 8-9
BP 905
EP 908
DI 10.1051/medsci/20021889905
PG 4
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 592YG
UT WOS:000177964000023
OA Bronze
DA 2023-06-23
ER

PT J
AU Keramati, M
   Ahmed, SH
   Gutkin, BS
AF Keramati, Mehdi
   Ahmed, Serge H.
   Gutkin, Boris S.
TI Misdeed of the need: towards computational accounts of transition to
   addiction
SO CURRENT OPINION IN NEUROBIOLOGY
LA English
DT Review
ID SUBSTANCE USE DISORDERS; DRUG-ADDICTION; INCENTIVE SALIENCE; COCAINE
   SEEKING; DOPAMINE; REINFORCEMENT; MODEL; NEUROBIOLOGY; PREDICTION; RATS
AB Drug addiction is a complex behavioral and neurobiological disorder which, in an emergent brain-circuit view, reflects a loss of prefrontal top-down control over subcortical circuits governing drug-seeking and drug-taking. We first review previous computational accounts of addiction, focusing on cocaine addiction and on prevalent dopamine-based positive reinforcement and negative-reinforcement computational models. Then, we discuss a recent computational proposal that the progression to addiction is unlikely to result from a complete withdrawal of the goal-oriented decision system in favor the habitual one. Rather, the transition to addiction would arise from a drug-induced alteration in the structure of organismal needs which reorganizes the goal structure, ultimately favoring predominance of drug-oriented goals. Finally, we outline unmet challenges for future computational research on addiction.
C1 [Keramati, Mehdi] UCL, Gatsby Computat Neurosci Unit, London, England.
   [Ahmed, Serge H.] Univ Bordeaux, Inst Malad Neurodegenerat, UMR 5293, 146 Rue Leo Saignat, F-33000 Bordeaux, France.
   [Ahmed, Serge H.] Inst Malad Neurodegenerat, CNRS, UMR 5293, 146 Rue Leo Saignat, F-33000 Bordeaux, France.
   [Gutkin, Boris S.] PSL Res Univ, Grp Neural Theory, Lab Neurosci Cognit, ENS,INSERM, F-75005 Paris, France.
   [Gutkin, Boris S.] NRU Higher Sch Econ, Dept Psychol, Ctr Cognit & Decis Making, Moscow, Russia.
C3 University of London; University College London; Centre National de la
   Recherche Scientifique (CNRS); CNRS - National Institute for Biology
   (INSB); UDICE-French Research Universities; Universite de Bordeaux;
   Centre National de la Recherche Scientifique (CNRS); CNRS - National
   Institute for Biology (INSB); UDICE-French Research Universities;
   Universite de Bordeaux; Institut National de la Sante et de la Recherche
   Medicale (Inserm); UDICE-French Research Universities; Universite PSL;
   Ecole Normale Superieure (ENS); HSE University (National Research
   University Higher School of Economics)
RP Gutkin, BS (通讯作者)，PSL Res Univ, Grp Neural Theory, Lab Neurosci Cognit, ENS,INSERM, F-75005 Paris, France.; Gutkin, BS (通讯作者)，NRU Higher Sch Econ, Dept Psychol, Ctr Cognit & Decis Making, Moscow, Russia.
EM boris.gutkin@ens.fr
RI Gutkin, Boris/ABC-5754-2020
OI Gutkin, Boris/0000-0001-6409-979X; Ahmed, Serge/0000-0002-1225-9234
FU French Research Council (CNRS); Universite de Bordeaux; Fondation pour
   la Recherche Medicale [FRM DPA20140629788]; French National Agency
   [ANR-12-SAMA-003]; INSERM; LABEX [ANR-10-LABX-0087 IEC]; IDEX
   [ANR-10-IDEX-0001-02 PSLa]; RF academic excellence Program [5-100];
   Gatsby Charitable Foundation
FX This work was supported by the French Research Council (CNRS), the
   Universite de Bordeaux, and the Fondation pour la Recherche Medicale
   (FRM DPA20140629788), French National Agency (ANR-12-SAMA-003); INSERM,
   LABEX ANR-10-LABX-0087 IEC, IDEX ANR-10-IDEX-0001-02 PSLa, BSG
   acknowledges support from the RF academic excellence Program 5-100. MK
   was supported by the Gatsby Charitable Foundation.
CR Ahmed SH, 2012, NEUROSCIENCE, V211, P107, DOI 10.1016/j.neuroscience.2011.08.014
   Ahmed SH, 2009, PHARMACOPSYCHIATRY, V42, pS144, DOI 10.1055/s-0029-1216345
   Ahmed SH, 2013, CURR OPIN NEUROBIOL, V23, P581, DOI 10.1016/j.conb.2013.01.028
   Ahmed SH, 2010, NEUROSCI BIOBEHAV R, V35, P172, DOI 10.1016/j.neubiorev.2010.04.005
   Ahmed Serge H, 2007, Drug Alcohol Depend, V90, P304
   Ahmed SH, 2005, PSYCHOPHARMACOLOGY, V180, P473, DOI 10.1007/s00213-005-2180-z
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Ahmed SH, 2004, SCIENCE, V306, P1901, DOI 10.1126/science.1107071
   Arnold JM, 1997, PHARMACOL BIOCHEM BE, V57, P441, DOI 10.1016/S0091-3057(96)00445-5
   Badiani A, 2011, NAT REV NEUROSCI, V12, P685, DOI 10.1038/nrn3104
   Banks ML, 2012, ADV PHARMACOL SCI, V2012, DOI 10.1155/2012/281768
   Baumeister RF, 2015, ADDICT BEHAV, V44, P3, DOI 10.1016/j.addbeh.2014.09.011
   Berridge KC, 2012, EUR J NEUROSCI, V35, P1124, DOI 10.1111/j.1460-9568.2012.07990.x
   Caprioli D, 2015, ADDICT BIOL, V20, P913, DOI 10.1111/adb.12220
   Dezfouli A, 2009, NEURAL COMPUT, V21, P2869, DOI 10.1162/neco.2009.10-08-882
   Everitt BJ, 2016, ANNU REV PSYCHOL, V67, P23, DOI 10.1146/annurev-psych-122414-033457
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Garbusow M, 2016, ADDICT BIOL, V21, P719, DOI 10.1111/adb.12243
   Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119
   Graupner M, 2012, SPR SER COMPUT NEURO, V10, P111, DOI 10.1007/978-1-4614-0751-5_4
   Graupner M, 2009, ACTA PHARMACOL SIN, V30, P681, DOI 10.1038/aps.2009.87
   Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134
   Gutkin BS, 2006, P NATL ACAD SCI USA, V103, P1106, DOI 10.1073/pnas.0510220103
   Hasin DS, 2013, AM J PSYCHIAT, V170, P834, DOI 10.1176/appi.ajp.2013.12060782
   Hemby SE, 1997, PSYCHOPHARMACOLOGY, V133, P7, DOI 10.1007/s002130050365
   Hogarth L, 2015, CURR TOP BEHAV NEURO, V23, P165, DOI 10.1007/978-3-319-13665-3_7
   Huys QJM, 2014, PROG BRAIN RES, V211, P31, DOI 10.1016/B978-0-444-63425-2.00003-9
   Hyman SE, 2007, AM J BIOETHICS, V7, P8, DOI 10.1080/15265160601063969
   Keiflin R, 2015, NEURON, V88, P247, DOI 10.1016/j.neuron.2015.08.037
   Keramati M, 2017, PSYCHOL REV, V124, P130, DOI 10.1037/rev0000046
   Keramati M, 2014, ELIFE, V3, DOI 10.7554/eLife.04811
   Koob GF, 2008, NEURON, V59, P11, DOI 10.1016/j.neuron.2008.06.012
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   LeDoux JE, 2017, MOL PSYCHIATR, V22, P24, DOI 10.1038/mp.2016.166
   Lenoir M, 2013, NEUROPSYCHOPHARMACOL, V38, P1209, DOI 10.1038/npp.2013.17
   Lindesmith A R, 1980, NIDA Res Monogr, V30, P34
   Luscher C, 2006, PLOS MED, V3, P2005, DOI 10.1371/journal.pmed.0030437
   Luscher C, 2016, ANNU REV NEUROSCI, V39, P257, DOI 10.1146/annurev-neuro-070815-013920
   Martin CS, 2008, J ABNORM PSYCHOL, V117, P561, DOI 10.1037/0021-843X.117.3.561
   Mateo Y, 2005, NEUROPSYCHOPHARMACOL, V30, P1455, DOI 10.1038/sj.npp.1300687
   McClure SM, 2003, TRENDS NEUROSCI, V26, P423, DOI 10.1016/S0166-2236(03)00177-2
   Montague PR, 2004, NATURE, V431, P760, DOI 10.1038/nature03015
   Olmstead MC, 2001, BEHAV NEUROSCI, V115, P394, DOI 10.1037/0735-7044.115.2.394
   Panlilio LV, 2003, PSYCHOPHARMACOLOGY, V168, P229, DOI 10.1007/s00213-002-1193-0
   Pascoli V, 2015, NEURON, V88, DOI 10.1016/j.neuron.2015.10.017
   Phillips PEM, 2003, NATURE, V422, P614, DOI 10.1038/nature01566
   Pickard Hanna, 2012, AJOB Neurosci, V3, P40
   Ramsay DS, 2014, PSYCHOL REV, V121, P225, DOI 10.1037/a0035942
   Redish AD, 2004, SCIENCE, V306, P1944, DOI 10.1126/science.1102384
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   SOLOMON RL, 1974, PSYCHOL REV, V81, P119, DOI 10.1037/h0036128
   Takahashi Y, 2008, FRONT NEUROSCI-SWITZ, V2, P86, DOI 10.3389/neuro.01.014.2008
   Takahashi Y, 2007, FRONT INTEGR NEUROSC, V1, DOI 10.3389/neuro.07.011.2007
   Vohs KD, 2009, ADDICT RES THEORY, V17, P231, DOI 10.1080/16066350802567103
   Volkow ND, 2011, NEURON, V69, P599, DOI 10.1016/j.neuron.2011.01.027
   WEEKS JR, 1962, SCIENCE, V138, P143, DOI 10.1126/science.138.3537.143
   Wesley Michael J, 2014, J Addict, V2014, P189853, DOI 10.1155/2014/189853
   Wikler A, 1952, PSYCHIAT QUART, V26, P270, DOI 10.1007/BF01568465
   Willuhn I, 2014, NAT NEUROSCI, V17, P704, DOI 10.1038/nn.3694
   Wise RA, 2014, NEUROPSYCHOPHARMACOL, V39, P254, DOI 10.1038/npp.2013.261
   Zhang J, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000437
NR 61
TC 9
Z9 9
U1 0
U2 5
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0959-4388
EI 1873-6882
J9 CURR OPIN NEUROBIOL
JI Curr. Opin. Neurobiol.
PD OCT
PY 2017
VL 46
BP 142
EP 153
DI 10.1016/j.conb.2017.08.014
PG 12
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology
GA FN7KF
UT WOS:000416196400019
PM 28892737
DA 2023-06-23
ER

PT J
AU Costa, NF
   Fonseca, IB
   Pombo, S
   Monteiro, A
   Dziuba, A
   Costa, T
AF Costa, Nuno F.
   Fonseca, Isabel B.
   Pombo, Samuel
   Monteiro, Ana
   Dziuba, Aleksandra
   Costa, Teresa
TI PSYCHOPHYSIOLOGICAL INDICATORS OF RESPONSE TO DRUG ADDICTION
   REHABILITATION TREATMENT
SO PSYCHOPHYSIOLOGY
LA English
DT Meeting Abstract
CT 49th Annual Meeting of the Society-for-Psychophysiological-Research
CY OCT 21-24, 2009
CL Berlin, GERMANY
SP Soc Psychophysiol Res
DE drug addiction; response to treatment; motivation
C1 [Costa, Nuno F.; Fonseca, Isabel B.; Pombo, Samuel; Monteiro, Ana; Dziuba, Aleksandra; Costa, Teresa] Univ Lisbon, P-1699 Lisbon, Portugal.
C3 Universidade de Lisboa
RI Fonseca, Isabel B/A-7777-2013
OI Fonseca, Isabel B/0000-0002-1965-2207
NR 0
TC 0
Z9 0
U1 0
U2 5
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0048-5772
J9 PSYCHOPHYSIOLOGY
JI Psychophysiology
PD SEP
PY 2009
VL 46
BP S156
EP S156
PG 1
WC Psychology, Biological; Neurosciences; Physiology; Psychology;
   Psychology, Experimental
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology; Neurosciences & Neurology; Physiology
GA 493NR
UT WOS:000269744700888
DA 2023-06-23
ER

PT J
AU Raslan, MA
AF Raslan, Mona A.
TI Natural Products for the Treatment of Drug Addiction: Narrative Review
SO CHEMISTRY & BIODIVERSITY
LA English
DT Review
DE Drug addiction; Tabernanthe iboga; Mitragyna speciosa; Pueraria montana
   var; lobata; Hypericum perforatum; Panax ginseng; Withania somnifera
ID ST-JOHNS-WORT; PERFORMANCE LIQUID-CHROMATOGRAPHY; ALCOHOL-WITHDRAWAL
   SYMPTOMS; RECEIVING FREE-ACCESS; WITHANIA-SOMNIFERA; DOPAMINE RELEASE;
   HYPERICUM-PERFORATUM; MASS-SPECTROMETRY; VOLUNTARY ALCOHOL; HERBAL
   MEDICINE
AB Drug addiction is considered a chronic disorder affecting the individual's life, his/her family and society. Up till now the treatment of drug addiction is considered a problematic issue. Synthetic drugs available for the treatment of drug addiction are few, of limited efficacy and associated with serious side effects. Therefore, there is a continuous search for better therapeutic agents for drug addiction. Natural products represent a promising source for drug addiction treatment. This review summaries drug addiction definition, its mechanism of action, its types, its diagnosis, factors affecting its development and different available approaches for its treatment especially the use of natural products. Six plants were discussed thoroughly in this review, including, Tabernanthe iboga Baill., Mitragyna speciosa Korth., Pueraria montana var. lobata (Willd.) Sanjappa & Pradeep, Hypericum perforatum L., Panax ginseng C.A. Mey., and Withania somnifera (L.) Dunal.
C1 [Raslan, Mona A.] Natl Res Ctr, Pharmaceut & Drug Ind Res Inst, Pharmacognosy Dept, Giza 12622, Egypt.
C3 Egyptian Knowledge Bank (EKB); National Research Centre (NRC)
RP Raslan, MA (通讯作者)，Natl Res Ctr, Pharmaceut & Drug Ind Res Inst, Pharmacognosy Dept, Giza 12622, Egypt.
OI Raslan, Mona/0000-0002-6165-1873
CR Abenavoli L, 2009, PHYTOMEDICINE, V16, P638, DOI 10.1016/j.phymed.2008.12.013
   Afonso R.F., 2016, INNOVATIONS TREATMEN, P193
   Alper K R, 2001, Alkaloids Chem Biol, V56, P1, DOI 10.1016/S0099-9598(01)56005-8
   Alper KR, 2012, J FORENSIC SCI, V57, P398, DOI 10.1111/j.1556-4029.2011.02008.x
   Andrade A., 2016, CHARACTERIZATION SUB, P3
   asam, QUAL CAR DEF ADD
   Attele AS, 1999, BIOCHEM PHARMACOL, V58, P1685, DOI 10.1016/S0006-2952(99)00212-9
   Basiliere S, 2018, J CHROMATOGR B, V1080, P11, DOI 10.1016/j.jchromb.2018.02.010
   Bedendo A., 2016, INNOVATIONS TREATMEN, P17
   Benlhabib E, 2004, J MED FOOD, V7, P180, DOI 10.1089/1096620041224102
   Benlhabib E, 2004, J MED FOOD, V7, P168, DOI 10.1089/1096620041224210
   Bhattacharya SK, 1998, PHARMACOPSYCHIATRY, V31, P22, DOI 10.1055/s-2007-979342
   Bloomfield MAP, 2016, NATURE, V539, P369, DOI 10.1038/nature20153
   Bonci A, 2003, TRENDS PHARMACOL SCI, V24, P172, DOI 10.1016/S0165-6147(03)00068-3
   Brown Thomas Kingsley, 2013, Curr Drug Abuse Rev, V6, P3
   Butterweck V, 2002, BRAIN RES, V930, P21, DOI 10.1016/S0006-8993(01)03394-7
   Candelario M, 2015, J ETHNOPHARMACOL, V171, P264, DOI 10.1016/j.jep.2015.05.058
   Carai MAM, 2000, FITOTERAPIA, V71, pS38, DOI 10.1016/S0367-326X(00)00178-7
   Carlier J, 2015, J CHROMATOGR B, V975, P65, DOI 10.1016/j.jchromb.2014.10.028
   Carlini EA, 2003, PHARMACOL BIOCHEM BE, V75, P501, DOI 10.1016/S0091-3057(03)00112-6
   Cavallaro A, 2017, J BIOL RES-BOLL SOC, V90, P109, DOI 10.4081/jbr.2017.6751
   Chatterjee SS, 1998, LIFE SCI, V63, P499, DOI 10.1016/S0024-3205(98)00299-9
   Corkery JM, 2018, PROG BRAIN RES, V242, P217, DOI 10.1016/bs.pbr.2018.08.005
   Dalley JW, 2007, SCIENCE, V315, P1267, DOI 10.1126/science.1137073
   Darnell D, 2019, PSYCHOL TRAUMA-US, V11, P266, DOI 10.1037/tra0000371
   Davidson C, 2021, AM J DRUG ALCOHOL AB, V47, P74, DOI 10.1080/00952990.2020.1836185
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   drugabuse, ALTERNATIVES
   DWORKIN SI, 1995, PSYCHOPHARMACOLOGY, V117, P257, DOI 10.1007/BF02246099
   Eastlack SC, 2020, PAIN THER, V9, P55, DOI 10.1007/s40122-020-00151-x
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Fainsinger RL, 2006, AM J PSYCHIAT, V163, P2014, DOI 10.1176/appi.ajp.163.11.2014-a
   Feily A, 2009, PHYTOTHER RES, V23, P1549, DOI 10.1002/ptr.2807
   Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8
   Field HL, 2000, INT J PSYCHIAT MED, V30, P203, DOI 10.2190/PBFD-LWB4-U8CG-53C9
   Forsyth B, 2016, J ETHNOPHARMACOL, V189, P10, DOI 10.1016/j.jep.2016.05.022
   Gershman K, 2019, NEW ENGL J MED, V380, P97, DOI 10.1056/NEJMc1811055
   Gilpin NW, 2008, ALCOHOL RES HEALTH, V31, P185
   Gioti EM, 2005, J CHROMATOGR A, V1093, P1, DOI 10.1016/j.chroma.2005.07.038
   Glick S D, 2001, Alkaloids Chem Biol, V56, P39, DOI 10.1016/S0099-9598(01)56006-X
   Glick SD, 1998, ANN NY ACAD SCI, V844, P214, DOI 10.1111/j.1749-6632.1998.tb08237.x
   Glick SD, 1996, BRAIN RES, V719, P29, DOI 10.1016/0006-8993(96)00056-X
   Glick SD, 2000, ANN NY ACAD SCI, V914, P369, DOI 10.1111/j.1749-6632.2000.tb05211.x
   Goncalves J, 2021, MOLECULES, V26, DOI 10.3390/molecules26051397
   Grundmann O, 2017, DRUG ALCOHOL DEPEN, V176, P63, DOI 10.1016/j.drugalcdep.2017.03.007
   Hartley C, 2022, J CLIN PHARMACOL, V62, P577, DOI 10.1002/jcph.2001
   Harun N, 2022, NEUROSCI LETT, V773, DOI 10.1016/j.neulet.2022.136500
   He RH, 2017, ADV EXP MED BIOL, V1010, P295, DOI 10.1007/978-981-10-5562-1_15
   Henningfield JE, 2018, PSYCHOPHARMACOLOGY, V235, P573, DOI 10.1007/s00213-017-4813-4
   Herman MA, 2015, FRONT INTEGR NEUROSC, V9, DOI 10.3389/fnint.2015.00018
   HOMIAK ML, 1991, PHILOS REV, V100, P122, DOI 10.2307/2185521
   Humer E, 2020, METABOLITES, V10, DOI 10.3390/metabo10020072
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Jupp B, 2010, PHARMACOL THERAPEUT, V125, P138, DOI 10.1016/j.pharmthera.2009.11.002
   Kalivas PW, 2007, AM J ADDICTION, V16, P71, DOI 10.1080/10550490601184142
   Keung WM, 1998, P NATL ACAD SCI USA, V95, P2198, DOI 10.1073/pnas.95.5.2198
   KEUNG WM, 1993, P NATL ACAD SCI USA, V90, P1247, DOI 10.1073/pnas.90.4.1247
   KEUNG WM, 1993, P NATL ACAD SCI USA, V90, P10008, DOI 10.1073/pnas.90.21.10008
   Kim HJ, 2013, J GINSENG RES, V37, P8, DOI 10.5142/jgr.2013.37.8
   Kim JH, 2018, J GINSENG RES, V42, P264, DOI 10.1016/j.jgr.2017.10.004
   Kim SE, 2006, NEUROPSYCHOPHARMACOL, V31, P1714, DOI 10.1038/sj.npp.1300945
   Klemow K., 2011, HERBAL MED BIOMOLECU, P211
   Koob GE, 2004, NEBR SYM MOTIV, V50, P1
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Koob GF, 2009, NEUROPHARMACOLOGY, V56, P18, DOI 10.1016/j.neuropharm.2008.07.043
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Kreek MJ, 2002, NAT REV DRUG DISCOV, V1, P710, DOI 10.1038/nrd897
   Kulkarni SK, 2008, PROG NEURO-PSYCHOPH, V32, P1093, DOI 10.1016/j.pnpbp.2007.09.011
   Kulkarni SK, 1997, J ETHNOPHARMACOL, V57, P213, DOI 10.1016/S0378-8741(97)00064-0
   Lee B, 2008, BIOL PHARM BULL, V31, P436, DOI 10.1248/bpb.31.436
   Lee MJ, 2018, ANAL BIOCHEM, V543, P146, DOI 10.1016/j.ab.2017.12.021
   Lee MH, 2014, FOOD FUNCT, V5, P528, DOI 10.1039/c3fo60481k
   Lee RS, 2018, ALCOHOL RES-CURR REV, V39, P147
   Leon F, 2009, NAT PROD COMMUN, V4, P907
   Lesch O.M., 2011, ALCOHOL TOBACCO, P5
   Li P, 2014, NEUROREPORT, V25, P749, DOI 10.1097/WNR.0000000000000166
   Li WK, 2001, J CHROMATOGR B, V765, P99, DOI 10.1016/S0378-4347(01)00404-2
   Lu L, 2009, AM J DRUG ALCOHOL AB, V35, P1, DOI 10.1080/00952990802455469
   Lukas SE, 2013, PSYCHOPHARMACOLOGY, V226, P65, DOI 10.1007/s00213-012-2884-9
   Lukas SE, 2005, ALCOHOL CLIN EXP RES, V29, P756, DOI 10.1097/01.ALC.0000163499.64347.92
   Maculaitis R, 2008, HUM EXP TOXICOL, V27, P181, DOI 10.1177/0960327107087802
   MAISONNEUVE IM, 1995, J PHARMACOL EXP THER, V272, P652
   Maldonado R, 2006, TRENDS NEUROSCI, V29, P225, DOI 10.1016/j.tins.2006.01.008
   Martinez D, 2007, AM J PSYCHIAT, V164, P622, DOI 10.1176/appi.ajp.164.4.622
   Martinez-Delgado G, 2010, CURR NEUROPHARMACOL, V8, P422, DOI 10.2174/157015910793358141
   Matsumoto K, 1996, EUR J PHARMACOL, V317, P75, DOI 10.1016/S0014-2999(96)00714-5
   Matsumoto K, 2005, LIFE SCI, V78, P187, DOI 10.1016/j.lfs.2005.04.042
   Maze I, 2010, SCIENCE, V327, P213, DOI 10.1126/science.1179438
   McGregor NR, 2007, ALCOHOL, V41, P469, DOI 10.1016/j.alcohol.2007.07.009
   Meireles Vania, 2019, Medicines (Basel), V6, DOI 10.3390/medicines6010035
   Mendes F.R., 2012, PLANT BIOACTIVES DRU, P161
   Mendes F.R., 2016, INNOVATIONS TREATMEN, P51, DOI [DOI 10.1007/978-3-319-43172-7_4, 10.1007/978-3-319-43172-7_4]
   Molinari HH, 1996, BRAIN RES, V737, P255, DOI 10.1016/0006-8993(96)00739-1
   Mossadeq WMS, 2009, MED PRIN PRACT, V18, P378, DOI 10.1159/000226292
   Ndasauka Y, 2017, ADV EXP MED BIOL, V1010, P3, DOI 10.1007/978-981-10-5562-1_1
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   nida.nih, PUBL DRUGS BRAINS BE
   OECD, 2019, Health at a Glance 2019:�OECD Indicators, DOI 10.1787/4dd50c09-en
   Overstreet DH, 2003, ALCOHOL CLIN EXP RES, V27, P177, DOI 10.1097/01.ALC.0000051022.26489.CF
   Paskulin R, 2012, J ETHNOPHARMACOL, V143, P319, DOI 10.1016/j.jep.2012.06.039
   Peana AT, 2014, BEHAV PHARMACOL, V25, P618, DOI 10.1097/FBP.0000000000000078
   Penetar DM, 2012, DRUG ALCOHOL DEPEN, V126, P251, DOI 10.1016/j.drugalcdep.2012.04.012
   Perfumi M, 2005, J PSYCHOPHARMACOL, V19, P448, DOI 10.1177/0269881105056519
   Prisinzano TE, 2009, J NAT PROD, V72, P581, DOI 10.1021/np8005748
   Prozialeck WC, 2012, J AM OSTEOPATH ASSOC, V112, P792
   Rancour P, 2017, J HOLIST NURS, V35, P382, DOI 10.1177/0898010116648456
   Rezvani AH, 1999, ALCOHOL ALCOHOLISM, V34, P699, DOI 10.1093/alcalc/34.5.699
   Rezvani AH, 2003, PHARMACOL BIOCHEM BE, V75, P593, DOI 10.1016/S0091-3057(03)00124-2
   Ruiu S, 2013, BEHAV PHARMACOL, V24, P133, DOI 10.1097/FBP.0b013e32835f3d15
   Schenberg EE, 2014, J PSYCHOPHARMACOL, V28, P993, DOI 10.1177/0269881114552713
   Sonar VP, 2019, J NAT PROD, V82, P1250, DOI 10.1021/acs.jnatprod.8b01023
   Sood A, 2010, J ALTERN COMPLEM MED, V16, P761, DOI 10.1089/acm.2009.0445
   Spanagel R, 2017, DIALOGUES CLIN NEURO, V19, P247
   Stein EA, 2017, ADV EXP MED BIOL, V1010, pV
   Subhan F, 2009, PHYTOTHER RES, V23, P564, DOI 10.1002/ptr.2692
   Takayama H, 2004, CHEM PHARM BULL, V52, P916, DOI 10.1248/cpb.52.916
   Tungmunnithum D, 2020, COSMETICS-BASEL, V7, DOI 10.3390/cosmetics7010012
   Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077
   unodc, WORLD DRUG REPORT 20
   unodc, WORLD DRUG REP
   van der Kolk B, 2000, Dialogues Clin Neurosci, V2, P7
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Varadi A, 2016, J MED CHEM, V59, P8381, DOI 10.1021/acs.jmedchem.6b00748
   Vicknasingam B, 2020, YALE J BIOL MED, V93, P229
   Vicknasingam B, 2010, INT J DRUG POLICY, V21, P283, DOI 10.1016/j.drugpo.2009.12.003
   Volkow ND, 1997, NATURE, V386, P830, DOI 10.1038/386830a0
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
   Wallace RJ, 1999, LAW PHILOS, V18, P621
   Wang CZ, 2011, AM J CHINESE MED, V39, P1161, DOI 10.1142/S0192415X11009470
   who, HLTH TOP DRUGS PSYCH
   Wolf Marina E, 2002, Mol Interv, V2, P146, DOI 10.1124/mi.2.3.146
   Xiao LJ, 2017, ADV EXP MED BIOL, V1010, P261, DOI 10.1007/978-981-10-5562-1_13
   Yang L, 2008, J PHARMACOL SCI, V106, P578, DOI 10.1254/jphs.FP0071362
   Zhu WL, 2017, INT REV NEUROBIOL, V135, P279, DOI 10.1016/bs.irn.2017.02.013
   Zirak N, 2019, J CELL PHYSIOL, V234, P8496, DOI 10.1002/jcp.27781
   Zou ZL, 2017, ADV EXP MED BIOL, V1010, P21, DOI 10.1007/978-981-10-5562-1_2
NR 136
TC 0
Z9 0
U1 10
U2 12
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1612-1872
EI 1612-1880
J9 CHEM BIODIVERS
JI Chem. Biodivers.
PD DEC
PY 2022
VL 19
IS 12
DI 10.1002/cbdv.202200702
EA NOV 2022
PG 22
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 8I6QJ
UT WOS:000881630400001
PM 36285806
DA 2023-06-23
ER

PT J
AU Romo-Aviles, N
   Tarrino-Concejero, L
   Pavon-Benitez, L
   Marin-Torres, J
AF Romo-Aviles, Nuria
   Tarrino-Concejero, Lorena
   Pavon-Benitez, Laura
   Marin-Torres, Jesus
TI Addressing Gender-Based Violence in Drug Addiction Treatment: a
   Systematic Mapping Review
SO INTERNATIONAL JOURNAL OF MENTAL HEALTH AND ADDICTION
LA English
DT Review; Early Access
DE Gender-based violence (GBV); Drug addiction treatment; Health; Women;
   Systematic mapping review
ID INTIMATE PARTNER VIOLENCE; SUBSTANCE-ABUSE TREATMENT; CHILDHOOD
   SEXUAL-ABUSE; TREATMENT FACILITIES; DOMESTIC VIOLENCE; HEALTH-CARE;
   WOMEN; DISORDERS; SERVICES; PTSD
AB "Intervention support and treatment" programs are most likely to have been designed for the substances consumed by men, and to cater for men's needs, with little regard to the specific needs of women. Gender-based violence (GBV) has become a key area for addressing the treatment of drug addiction from a gender perspective. In this mapping review covering 32 articles, we examine the strategies used to address gender-based violence in drug addiction treatments that include women. The main topics of analysis were as follows: characteristics of drug addiction treatment, conceptualization of GBV, measurement and approach of GBV in treatment for drug addiction, and effects on health associated with GBV and drug addiction. Only 18.75% of the studies on GBV addressed the area of psycho-social care in the treatment of drug addiction. To avoid inequalities in the healthcare offered, gender-sensitive research and interventions are required which include GBV in the treatment of drug addiction.
C1 [Romo-Aviles, Nuria] Univ Granada, Inst Women & Gender Studies, Dept Social & Cultural Anthropol, Granada, Spain.
   [Tarrino-Concejero, Lorena] Univ Seville, Fac Nursing Physiotherapy & Podiatry, Res Grp CTS 1050: Complex Care Cronoc & Hlth Outco, Seville, Spain.
   [Pavon-Benitez, Laura; Marin-Torres, Jesus] Univ Granada, Res Inst Women & Gender Studies, Granada, Spain.
C3 University of Granada; University of Sevilla; University of Granada
RP Tarrino-Concejero, L (通讯作者)，Univ Seville, Fac Nursing Physiotherapy & Podiatry, Res Grp CTS 1050: Complex Care Cronoc & Hlth Outco, Seville, Spain.
EM nromo@ugr.es; ltarrino@us.es; laurapbenitez@ugr.es; jesusmarin@ugr.es
RI Tarriño-Concejero, Lorena/AAE-6469-2019; Benítez, Laura
   Pavón/GRN-7817-2022; Romo-Aviles, Nuria/H-7668-2015
OI Tarriño-Concejero, Lorena/0000-0003-0158-5744; Benítez, Laura
   Pavón/0000-0001-9786-3555; Romo-Aviles, Nuria/0000-0002-2142-2726
FU FEDER/Junta de Andalucia-Consejeria de Transformacion Economica,
   Industria, Conocimiento y Universidades Project [P20_00296]; University
   of Seville/CBUA
FX This work was funded as a part of the Project "The impact of violence on
   women receiving treatment in the Andalusia Network for Drug Addiction
   Treatment (IMPAVIA)". Funded to the University of Granada by:
   FEDER/Junta de Andalucia-Consejeria de Transformacion Economica,
   Industria, Conocimiento y Universidades Project (P20_00296). Funding for
   Open Access. University of Seville/CBUA.
CR Abdul-Khabir W, 2014, J PSYCHOACTIVE DRUGS, V46, P310, DOI 10.1080/02791072.2014.934978
   Akcayir M, 2022, INT J MENT HEALTH AD, V20, P1516, DOI 10.1007/s11469-020-00459-x
   Amor PJ, 2012, ACCION PSICOL, V9, P3, DOI 10.5944/ap.9.1.204
   Andersson C, 2021, DRUG-EDUC PREV POLIC, V28, P454, DOI 10.1080/09687637.2020.1852180
   Andrews CM, 2011, VIOLENCE AGAINST WOM, V17, P550, DOI 10.1177/1077801211407289
   Balaji D, 2017, AIDS BEHAV, V21, P2093, DOI 10.1007/s10461-016-1529-0
   Bates G., 2017, EFFECTIVENESS INTERV
   Benoit T., 2016, IMPROVING MANAGEMENT
   Bradbury-Jones C, 2019, INT J SOC RES METHOD, V22, P451, DOI 10.1080/13645579.2019.1576328
   Calderone L, 2022, AUST OCCUP THER J, V69, P625, DOI 10.1111/1440-1630.12824
   Capezza NM, 2015, J FAM VIOLENCE, V30, P85, DOI 10.1007/s10896-014-9649-7
   Cheng TC, 2014, INT J HEALTH SERV, V44, P735, DOI 10.2190/HS.44.4.d
   Clark M., 2015, GENDER DIMENSION NON
   Cohen LR, 2013, ADDICT BEHAV, V38, P2325, DOI 10.1016/j.addbeh.2013.03.006
   Cohn A, 2014, PSYCHIAT SERV, V65, P504, DOI 10.1176/appi.ps.201300005
   Cooper ID, 2016, J MED LIBR ASSOC, V104, P76, DOI 10.3163/1536-5050.104.1.013
   Council of Europe, 2011, CONS EUR TREAT SER, V210
   de Dios MA, 2014, SUBST ABUS, V35, P190, DOI 10.1080/08897077.2013.835764
   Delegacion del Gobierno contra la Violencia de Genero, 2020, MACR VIOL MUJ 2019
   Department of Health and Human Services, 2016, FAC ADD AM SURG GEN
   Diez M, 2020, SALUD COLECT, V16, DOI 10.18294/sc.2020.2509
   Dworkin ER, 2017, PSYCHOL TRAUMA-US, V9, P500, DOI 10.1037/tra0000212
   Engstrom M, 2016, SUBST USE MISUSE, V51, P277, DOI 10.3109/10826084.2015.1058823
   Engstrom M, 2012, J SUBST ABUSE TREAT, V43, P366, DOI 10.1016/j.jsat.2012.01.005
   Engstrom M, 2011, AIDS BEHAV, V15, P103, DOI 10.1007/s10461-009-9625-z
   Essex R, 2022, CLIN SIMUL NURS, V73, P48, DOI 10.1016/j.ecns.2022.07.001
   Ferrer-Perez VA, 2019, ANU PSICOL JURID, V29, P69, DOI 10.5093/apj2019a3
   Fonseca F, 2021, CURR ADDICT REP, V8, P89, DOI 10.1007/s40429-021-00357-9
   Gilbert L, 2017, DRUG ALCOHOL REV, V36, P125, DOI 10.1111/dar.12437
   Gilchrist G, 2012, ADV DUAL DIAGN, V5, P46, DOI 10.1108/17570971211241895
   Guthrie JA, 2016, COMMUN Q, V64, P434, DOI 10.1080/01463373.2015.1103296
   Haritavorn N, 2014, INT J DRUG POLICY, V25, P116, DOI 10.1016/j.drugpo.2013.09.008
   Huhn AS, 2020, CURR PSYCHIAT REP, V22, DOI 10.1007/s11920-020-01201-z
   Irfan SD, 2021, INT J DRUG POLICY, V92, DOI 10.1016/j.drugpo.2021.103144
   Ivsins A, 2023, INT J DRUG POLICY, V111, DOI 10.1016/j.drugpo.2022.103910
   Jackson A, 2015, WOMEN HEALTH, V55, P883, DOI 10.1080/03630242.2015.1061090
   James SE, 2004, VIOLENCE AGAINST WOM, V10, P991, DOI 10.1177/1077801204267377
   Jessell L, 2022, VIOLENCE AGAINST WOM, DOI 10.1177/10778012221137921
   Kaufmann VG, 2014, PSYCHOL ADDICT BEHAV, V28, P313, DOI 10.1037/a0034971
   Kraanen FL, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-189
   Lorvick J, 2014, VIOLENCE AGAINST WOM, V20, P1285, DOI 10.1177/1077801214552910
   Lozano-Verduzco I, 2016, SUBST ABUSE TREAT PR, V11, DOI 10.1186/s13011-016-0083-0
   Macy RJ, 2013, VIOLENCE AGAINST WOM, V19, P881, DOI 10.1177/1077801213498208
   Miake-Lye IM, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0204-x
   Mootz JJ, 2022, J SUBST ABUSE TREAT, V137, DOI 10.1016/j.jsat.2021.108694
   Mutatayi C., 2022, IMPLEMENTING GENDER
   Myers US, 2015, J DUAL DIAGN, V11, P238, DOI 10.1080/15504263.2015.1113762
   Noori R, 2019, J SUBST USE, V24, P280, DOI 10.1080/14659891.2018.1562573
   Oertelt-Prigione S, 2020, ECLINICALMEDICINE, V20, DOI 10.1016/j.eclinm.2020.100305
   Ospina-Escobar A., 2020, CULT DROGA, V25, P114, DOI [10.17151/culdr.2020.25.30.6, DOI 10.17151/CULDR.2020.25.30.6]
   Owczarzak J, 2021, SOC SCI MED, V269, DOI 10.1016/j.socscimed.2020.113563
   Pagano Anna, 2014, J Ethn Subst Abuse, V13, P273, DOI 10.1080/15332640.2014.886320
   PRATHER JE, 1978, INT J ADDICT, V13, P863, DOI 10.3109/10826087809039310
   REED BG, 1987, J PSYCHOACTIVE DRUGS, V19, P151, DOI 10.1080/02791072.1987.10472399
   REED BG, 1985, INT J ADDICT, V20, P13, DOI 10.3109/10826088509074828
   Resko SM, 2012, J SOC WORK PRACT ADD, V12, P348, DOI 10.1080/1533256X.2012.728104
   Rhodes KV, 2014, BMC EMERG MED, V14, DOI 10.1186/1471-227X-14-10
   Romo-Aviles N., 2018, Drugs and social context: social perspectives on the use of alcohol and other drugs, P63
   Ruiz-Perez I, 2018, J AFFECT DISORDERS, V229, P69, DOI 10.1016/j.jad.2017.12.032
   Salameh TN, 2021, INT J MENT HEALTH AD, V19, P1569, DOI 10.1007/s11469-020-00247-7
   Schamp J, 2022, FRONT PSYCHIATRY, V13, DOI 10.3389/fpsyt.2022.941384
   Schamp J, 2021, NORD STUD ALCOHOL DR, V38, P175, DOI 10.1177/1455072520964612
   Schiff M, 2015, SOC WORK HEALTH CARE, V54, P687, DOI 10.1080/00981389.2015.1058311
   Schumm JA, 2018, J SUBST ABUSE TREAT, V92, P1, DOI 10.1016/j.jsat.2018.06.004
   Schumm JA, 2011, J STUD ALCOHOL DRUGS, V72, P933, DOI 10.15288/jsad.2011.72.933
   Scicluna P, 2019, J FORENSIC PRACT, V21, P71, DOI 10.1108/JFP-07-2018-0031
   Spangaro J, 2011, VIOLENCE VICTIMS, V26, P130, DOI 10.1891/0886-6708.26.1.130
   Stone R, 2021, J RURAL HEALTH, V37, P35, DOI 10.1111/jrh.12518
   STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733
   Tirado-Munoz J, 2015, ADICCIONES, V27, P168
   Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850
   United Nations, 1995, DECL PLAT ACC BEIJ D
   United Nations Office on Drugs and Crime (UNODC), 2021, WORLD DRUG REPORT 20
   Valencia J, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230886
   Wall K, 2012, INT J RES METHOD EDU, V35, P223, DOI 10.1080/1743727X.2012.723923
   Webb L, 2022, FRONT PSYCHIATRY, V13, DOI 10.3389/fpsyt.2022.1078605
   WELLS DVB, 1992, INT J ADDICT, V27, P571, DOI 10.3109/10826089209063469
NR 77
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1557-1874
EI 1557-1882
J9 INT J MENT HEALTH AD
JI Int. J. Mental Health Addict.
PD 2023 MAY 12
PY 2023
DI 10.1007/s11469-023-01072-4
EA MAY 2023
PG 27
WC Psychology, Clinical; Substance Abuse; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology; Substance Abuse; Psychiatry
GA G0RD0
UT WOS:000986322100001
DA 2023-06-23
ER

PT J
AU Ghitza, UE
AF Ghitza, Udi E.
TI Commentary: Addictions Neuroclinical Assessment: A Neuroscience-Based
   Framework for Addictive Disorders
SO FRONTIERS IN PSYCHIATRY
LA English
DT Editorial Material
DE addiction; addictive disorders; addiction treatment; drug abuse; drug
   abuse treatment; personalized medicine; precision medicine; substance
   abuse
ID RDOC
C1 [Ghitza, Udi E.] NIDA, Ctr Clin Trials Network, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute on
   Drug Abuse (NIDA)
RP Ghitza, UE (通讯作者)，NIDA, Ctr Clin Trials Network, Bethesda, MD 20892 USA.
EM ghitzau@nida.nih.gov
FU Center for the Clinical Trials Network, NIDA
FX UG is a Health Scientist Administrator, Program Official, at the Center
   for the Clinical Trials Network, NIDA, which is the funding agency for
   the National Drug Abuse Treatment Clinical Trials Network. This
   commentary was supported through UG's duties as a Health Scientist
   Administrator.
CR [Anonymous], 2016, PAT REP OUTC MEAS IN
   [Anonymous], 2016, RES DOM CRIT
   [Anonymous], 2016, PREC MED IN
   Conway KP, 2014, DRUG ALCOHOL DEPEN, V141, P153, DOI 10.1016/j.drugalcdep.2014.04.029
   Cuthbert BN, 2014, WORLD PSYCHIATRY, V13, P28, DOI 10.1002/wps.20087
   Cuthbert BN, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-126
   Ghitza UE, 2015, FRONT PSYCHIATRY, V6, DOI 10.3389/fpsyt.2015.00037
   Ghitza UE, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00180
   Kozak MJ, 2016, PSYCHOPHYSIOLOGY, V53, P286, DOI 10.1111/psyp.12518
   Kwako LE, 2016, BIOL PSYCHIAT, V80, P179, DOI 10.1016/j.biopsych.2015.10.024
NR 10
TC 8
Z9 8
U1 3
U2 15
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD JAN 13
PY 2017
VL 8
AR 2
DI 10.3389/fpsyt.2017.00002
PG 3
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA EH5JO
UT WOS:000391809400001
PM 28133452
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Goldstein, R
AF Goldstein, Rita
TI Neuroimaging Recovery in Human Drug Addiction: An Eye Towards
   Intervention Development
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
DE Neuroimaging; drug addiction
C1 [Goldstein, Rita] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai
NR 0
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2022
VL 91
IS 9
SU S
BP S27
EP S27
PG 1
WC Neurosciences; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Psychiatry
GA 0W4TX
UT WOS:000789022200067
DA 2023-06-23
ER

PT J
AU Allain, F
   Minogianis, EA
   Roberts, DCS
   Samaha, AN
AF Allain, Florence
   Minogianis, Ellie-Anna
   Roberts, David C. S.
   Samaha, Anne-Noel
TI How fast and how often: The pharmacokinetics of drug use are decisive in
   addiction
SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
LA English
DT Review
DE Drug addiction; Pharmacokinetics; Cocaine; Route of drug intake; Speed
   of drug delivery; Intermittent drug exposure
ID PROGRESSIVE RATIO SCHEDULE; DOPAMINE NEURON REACTIVITY;
   SELF-ADMINISTERED COCAINE; INDUCED PLACE PREFERENCE; INTRAVENOUS
   COCAINE; NUCLEUS-ACCUMBENS; EXTENDED-ACCESS; BEHAVIORAL SENSITIZATION;
   INCREASED MOTIVATION; MESSENGER-RNA
AB How much, how often and how fast a drug reaches the brain determine the behavioural and neuro-plastic changes associated with the addiction process. Despite the critical nature of these variables, the drug addiction field often ignores pharmacokinetic issues, which we argue can lead to false conclusions. First, we review the clinical data demonstrating the importance of the speed of drug onset and of intermittent patterns of drug intake in psychostimulant drug addiction. This is followed by a review of the preclinical literature demonstrating that pharmacokinetic variables play a decisive role in determining behavioural and neurobiological outcomes in animal models of addiction. This literature includes recent data highlighting the importance of intermittent, 'spiking' brain levels of drug in producing an increase in the motivation to take drug over time. Rapid drug onset and intermittent drug exposure both appear to push the addiction process forward most effectively. This has significant implications for refining animal models of addiction and for better understanding the neuroadaptations that are critical for the disorder. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Allain, Florence; Minogianis, Ellie-Anna; Samaha, Anne-Noel] Univ Montreal, Dept Pharmacol, Fac Med, Montreal, PQ H3C 3J7, Canada.
   [Roberts, David C. S.] Wake Forest Univ Hlth Sci, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA.
   [Samaha, Anne-Noel] Univ Montreal, Fac Med, CNS Res Grp, Montreal, PQ H3C 3J7, Canada.
C3 Universite de Montreal; Wake Forest University; Wake Forest University
   School of Medicine; Universite de Montreal
RP Samaha, AN (通讯作者)，Univ Montreal, Dept Pharmacol, Fac Med, Montreal, PQ H3C 3J7, Canada.
EM Anna.samaha@umontreal.ca
RI Roberts, David C.S./C-8890-2009
OI Roberts, David C.S./0000-0001-7040-0155
FU Fonds de la Recherche en Sante du Quebec [28988, 29651]
FX ANS holds a salary award from the Fonds de la Recherche en Sante du
   Quebec (Grant No. 28988). EAM holds a graduate fellowship from the Fonds
   de la Recherche en Sante du Quebec (Grant No. 29651). ANS wishes to
   warmly thank Dr. Terry E. Robinson for inspiring her to investigate the
   role of kinetic factors in drug addiction.
CR Ahmed SH, 2012, NEUROSCIENCE, V211, P107, DOI 10.1016/j.neuroscience.2011.08.014
   Ahmed SH, 2006, NEUROPSYCHOPHARMACOL, V31, P563, DOI 10.1038/sj.npp.1300834
   Ahmed SH, 2005, PSYCHOPHARMACOLOGY, V180, P473, DOI 10.1007/s00213-005-2180-z
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Ahmed SH, 1999, PSYCHOPHARMACOLOGY, V146, P303, DOI 10.1007/s002130051121
   Ahmed SH, 2002, NAT NEUROSCI, V5, P625, DOI 10.1038/nn872
   Asan E, 1997, CELL TISSUE RES, V288, P449, DOI 10.1007/s004410050832
   Baker LK, 2013, EUR J NEUROSCI, V37, P1004, DOI 10.1111/ejn.12114
   Barrio G, 2001, DRUG ALCOHOL DEPEN, V63, P169, DOI 10.1016/S0376-8716(00)00204-0
   Bass CE, 2010, CHRONOBIOL INT, V27, P535, DOI 10.3109/07420521003664221
   Belin D, 2009, BIOL PSYCHIAT, V65, P863, DOI 10.1016/j.biopsych.2008.05.031
   Ben-Shahar O, 2004, BRAIN RES, V995, P46, DOI 10.1016/j.brainres.2003.09.053
   BENOWITZ NL, 1994, NEW ENGL J MED, V331, P123, DOI 10.1056/NEJM199407143310212
   Berlin I, 2001, INT J NEUROPSYCHOPH, V4, P33, DOI 10.1017/S1461145701002188
   Beveridge T. J., 2012, ANAL HUMAN COCAINE U
   Bouayad-Gervais K, 2014, PSYCHOPHARMACOLOGY, V231, P4241, DOI 10.1007/s00213-014-3576-4
   BRADY KT, 1991, J CLIN PSYCHIAT, V52, P509
   Brebner K, 2000, PSYCHOPHARMACOLOGY, V148, P314, DOI 10.1007/s002130050056
   Brown PL, 2005, PSYCHOPHARMACOLOGY, V181, P299, DOI 10.1007/s00213-005-2244-0
   BUDNEY AJ, 1993, DRUG ALCOHOL DEPEN, V32, P133, DOI 10.1016/0376-8716(93)80006-Z
   Calipari ES, 2014, J PHARMACOL EXP THER, V349, P192, DOI 10.1124/jpet.114.212993
   Calipari ES, 2013, NEUROPSYCHOPHARMACOL, V38, P2385, DOI 10.1038/npp.2013.136
   Carey R, 1998, PHARMACOL BIOCHEM BE, V60, P395, DOI 10.1016/S0091-3057(97)00604-7
   Carpenter MJ, 1998, DRUG ALCOHOL DEPEN, V53, P11, DOI 10.1016/S0376-8716(98)00103-3
   Cohen A, 2012, NEUROPSYCHOPHARMACOL, V37, P2153, DOI 10.1038/npp.2012.67
   Cohen P., 1994, ADDICT RES, V2, P71, DOI DOI 10.3109/16066359409005547
   CONE EJ, 1995, J ANAL TOXICOL, V19, P459, DOI 10.1093/jat/19.6.459
   Cone EJ, 1998, TOXICOL LETT, V103, P97, DOI 10.1016/S0378-4274(98)00292-6
   Connor DF, 2004, CNS DRUGS, V18, P1011, DOI 10.2165/00023210-200418140-00005
   Crombag HS, 2008, PHARMACOL BIOCHEM BE, V90, P797, DOI 10.1016/j.pbb.2008.06.003
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Di Chiara G., 2000, HDB EXPT PHARM
   Downs AW, 1932, J PHARMACOL EXP THER, V46, P199
   EIKELBOOM R, 1982, PSYCHOL REV, V89, P507, DOI 10.1037/0033-295X.89.5.507
   Espana RA, 2010, EUR J NEUROSCI, V31, P336, DOI 10.1111/j.1460-9568.2009.07065.x
   Evans SM, 1996, J PHARMACOL EXP THER, V279, P1345
   Ferrario CR, 2008, BRAIN RES, V1209, P151, DOI 10.1016/j.brainres.2008.02.081
   Ferrario CR, 2007, EUR NEUROPSYCHOPHARM, V17, P352, DOI 10.1016/j.euroneuro.2006.08.005
   Ferrario CR, 2005, BIOL PSYCHIAT, V58, P751, DOI 10.1016/j.biopsych.2005.04.046
   Ferri CP, 1999, ADDICT BEHAV, V24, P815, DOI 10.1016/S0306-4603(99)00036-2
   FITCH TE, 1993, DRUG ALCOHOL DEPEN, V33, P119, DOI 10.1016/0376-8716(93)90053-S
   Fumagalli F, 2007, EUR J NEUROSCI, V26, P2756, DOI 10.1111/j.1460-9568.2007.05918.x
   GAWIN FH, 1991, SCIENCE, V251, P1580, DOI 10.1126/science.2011738
   GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107
   GOSSOP M, 1992, BRIT J ADDICT, V87, P1527
   GOSSOP M, 1994, BRIT J PSYCHIAT, V164, P660, DOI 10.1192/bjp.164.5.660
   Graham DL, 2007, NAT NEUROSCI, V10, P1029, DOI 10.1038/nn1929
   Graham DL, 2009, BIOL PSYCHIAT, V65, P696, DOI 10.1016/j.biopsych.2008.09.032
   Grimm JW, 2003, J NEUROSCI, V23, P742
   Hao Y, 2010, BIOL PSYCHIAT, V68, P240, DOI 10.1016/j.biopsych.2010.02.011
   Hatsukami DK, 1996, JAMA-J AM MED ASSOC, V276, P1580
   HODOS W, 1961, SCIENCE, V134, P943, DOI 10.1126/science.134.3483.943
   Hollander JA, 2005, NEUROPSYCHOPHARMACOL, V30, P1464, DOI 10.1038/sj.npp.1300748
   HOOKS MS, 1994, PSYCHOPHARMACOLOGY, V115, P265
   HORGER BA, 1990, PHARMACOL BIOCHEM BE, V37, P707, DOI 10.1016/0091-3057(90)90552-S
   HUGHES JR, 1989, BIOMED PHARMACOTHER, V43, P11, DOI 10.1016/0753-3322(89)90185-6
   Im HI, 2010, NAT NEUROSCI, V13, P1120, DOI 10.1038/nn.2615
   IZENWASSER S, 1990, BRAIN RES, V531, P338, DOI 10.1016/0006-8993(90)90797-F
   IZENWASSER S, 1992, BRAIN RES, V573, P119, DOI 10.1016/0006-8993(92)90120-X
   JAFFE JH, 1989, PSYCHOPHARMACOLOGY, V97, P59, DOI 10.1007/BF00443414
   JAVAID JI, 1983, BIOPHARM DRUG DISPOS, V4, P9, DOI 10.1002/bdd.2510040104
   JAVAID JI, 1978, SCIENCE, V202, P227, DOI 10.1126/science.694530
   JEFFCOAT AR, 1989, DRUG METAB DISPOS, V17, P153
   Jones R T, 1990, NIDA Res Monogr, V99, P30
   Jones SR, 1996, PSYCHOPHARMACOLOGY, V126, P331, DOI 10.1007/BF02247384
   Jonkman S, 2012, NEUROPSYCHOPHARMACOL, V37, P1612, DOI 10.1038/npp.2012.6
   KATO S, 1987, PHARMACOL BIOCHEM BE, V28, P407
   Kippin TE, 2006, PSYCHOPHARMACOLOGY, V187, P60, DOI 10.1007/s00213-006-0386-3
   Knackstedt LA, 2007, J PHARMACOL EXP THER, V322, P1103, DOI 10.1124/jpet.107.122861
   Kuczenski R., 1988, SENSITIZATION NERVOU, P175
   LETT BT, 1989, PSYCHOPHARMACOLOGY, V98, P357, DOI 10.1007/BF00451687
   Liu Y, 2005, EUR J NEUROSCI, V22, P195, DOI 10.1111/j.1460-9568.2005.04195.x
   Liu Y, 2005, PSYCHOPHARMACOLOGY, V179, P644, DOI 10.1007/s00213-004-2089-y
   LOH EA, 1990, PSYCHOPHARMACOLOGY, V101, P262, DOI 10.1007/BF02244137
   Lorrain DS, 2000, BEHAV BRAIN RES, V107, P9, DOI 10.1016/S0166-4328(99)00109-6
   Mantsch JR, 2004, PSYCHOPHARMACOLOGY, V175, P26, DOI 10.1007/s00213-004-1778-x
   Martin-Garcia E, 2014, NEUROPSYCHOPHARMACOL, V39, P2317, DOI 10.1038/npp.2014.66
   Mendrek A, 1998, PSYCHOPHARMACOLOGY, V135, P416, DOI 10.1007/s002130050530
   Minogianis EA, 2013, NEUROPSYCHOPHARMACOL, V38, P2644, DOI 10.1038/npp.2013.173
   Morgan D, 2006, NEUROPSYCHOPHARMACOL, V31, P121, DOI 10.1038/sj.npp.1300773
   Morgan D, 2005, PSYCHOPHARMACOLOGY, V178, P309, DOI 10.1007/s00213-004-1992-6
   Morgan D, 2004, NEUROSCI BIOBEHAV R, V27, P803, DOI 10.1016/j.neubiorev.2003.11.004
   Morgan D, 2002, BEHAV PHARMACOL, V13, P389, DOI 10.1097/00008877-200209000-00012
   Negus SS, 2015, NEUROPSYCHOPHARMACOL
   Neugebauer NM, 2014, BEHAV BRAIN RES, V260, P155, DOI 10.1016/j.bbr.2013.11.035
   Nicola SM, 2000, J NEUROSCI, V20, P5526, DOI 10.1523/JNEUROSCI.20-14-05526.2000
   NOMIKOS GG, 1988, PSYCHOPHARMACOLOGY, V94, P119, DOI 10.1007/BF00735892
   O'Brien C., 2001, DRUG ADDICTION DRUG
   O'Brien CP, 2008, PHILOS T R SOC B, V363, P3277, DOI 10.1098/rstb.2008.0105
   OBRIEN CP, 1992, ANN NY ACAD SCI, V654, P400, DOI 10.1111/j.1749-6632.1992.tb25984.x
   Oleson EB, 2009, NEUROPSYCHOPHARMACOL, V34, P796, DOI 10.1038/npp.2008.195
   PAN HT, 1991, J NEUROCHEM, V56, P1299, DOI 10.1111/j.1471-4159.1991.tb11425.x
   Paterson NE, 2003, NEUROREPORT, V14, P2229, DOI 10.1097/00001756-200312020-00019
   Phillips AG, 1996, PSYCHOPHARMACOLOGY, V124, P279, DOI 10.1007/BF02246669
   PIAZZA PV, 1990, BRAIN RES, V514, P22, DOI 10.1016/0006-8993(90)90431-A
   PICKENS R, 1968, J PHARMACOL EXP THER, V161, P122
   Pierre PJ, 1997, PSYCHOPHARMACOLOGY, V129, P277, DOI 10.1007/s002130050191
   Pierre PJ, 1998, PSYCHOPHARMACOLOGY, V138, P159, DOI 10.1007/s002130050658
   PORRINO LJ, 1993, PSYCHOPHARMACOLOGY, V112, P343, DOI 10.1007/BF02244931
   POST RM, 1976, NATURE, V260, P731, DOI 10.1038/260731a0
   POST RM, 1980, LIFE SCI, V26, P1275, DOI 10.1016/0024-3205(80)90085-5
   Rawson RA, 2007, AM J ADDICTION, V16, P291, DOI 10.1080/10550490701389864
   REITH MEA, 1987, J PHARMACOL EXP THER, V243, P281
   Richardson NR, 1996, J NEUROSCI METH, V66, P1, DOI 10.1016/0165-0270(95)00153-0
   Roberts DCS, 2013, NEUROSCI BIOBEHAV R, V37, P2026, DOI 10.1016/j.neubiorev.2013.04.017
   ROBERTS DCS, 1989, PHARMACOL BIOCHEM BE, V32, P43, DOI 10.1016/0091-3057(89)90208-6
   ROBERTS DCS, 1994, PHARMACOL BIOCHEM BE, V49, P177, DOI 10.1016/0091-3057(94)90473-1
   ROBERTS DCS, 1989, PSYCHOPHARMACOLOGY, V98, P408, DOI 10.1007/BF00451696
   Roberts DCS, 2002, DRUG ALCOHOL DEPEN, V67, P291, DOI 10.1016/S0376-8716(02)00083-2
   Robinson TE, 2000, ADDICTION, V95, pS91
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   ROBINSON TE, 1986, BRAIN RES REV, V11, P157, DOI 10.1016/0165-0173(86)90002-0
   Roncero C, 2012, ACTAS ESP PSIQUIATRI, V40, P187
   RUSSELL MAH, 1978, DRUG METAB REV, V8, P29, DOI 10.3109/03602537808993776
   Samaha AN, 2004, J NEUROSCI, V24, P6362, DOI 10.1523/JNEUROSCI.1205-04.2004
   Samaha AN, 2005, BIOL PSYCHIAT, V57, P351, DOI 10.1016/j.biopsych.2004.11.040
   Samaha AN, 2002, J NEUROSCI, V22, P3244, DOI 10.1523/JNEUROSCI.22-08-03244.2002
   Schindler CW, 2011, PHARMACOL BIOCHEM BE, V99, P301, DOI 10.1016/j.pbb.2011.05.005
   Schindler CW, 2009, PHARMACOL BIOCHEM BE, V93, P375, DOI 10.1016/j.pbb.2009.05.008
   Segal D. S., 1981, NEUROPHARMACOLOGY, V5, P95, DOI DOI 10.1002/9781444314571.CH11
   Siegel S., 1977, PSYCHOPHARMACOLOGY P
   Sorge RE, 2009, J PHARMACOL EXP THER, V330, P633, DOI 10.1124/jpet.109.154641
   Spencer TJ, 2006, AM J PSYCHIAT, V163, P387, DOI 10.1176/appi.ajp.163.3.387
   SPYRAKI C, 1982, BRAIN RES, V253, P195, DOI 10.1016/0006-8993(82)90686-2
   SPYRAKI C, 1987, BEHAV BRAIN RES, V26, P57, DOI 10.1016/0166-4328(87)90016-7
   STEWART J, 1993, BEHAV PHARMACOL, V4, P289
   Unterwald EM, 2001, BRAIN RES, V900, P103, DOI 10.1016/S0006-8993(01)02269-7
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   VANDYKE C, 1976, SCIENCE, V191, P859, DOI 10.1126/science.56036
   VANDYKE C, 1982, SCI AM, V246, P128, DOI 10.1038/scientificamerican0382-128
   Vezina P, 2007, PROG NEURO-PSYCHOPH, V31, P1625, DOI 10.1016/j.pnpbp.2007.08.038
   Vezina P, 2004, NEUROSCI BIOBEHAV R, V27, P827, DOI 10.1016/j.neubiorev.2003.11.001
   Vezina P, 2002, J NEUROSCI, V22, P4654, DOI 10.1523/JNEUROSCI.22-11-04654.2002
   Volkow ND, 2000, LIFE SCI, V67, pPL1507
   Volkow ND, 2003, AM J PSYCHIAT, V160, P1909, DOI 10.1176/appi.ajp.160.11.1909
   Wakabayashi KT, 2010, J NEUROSCI, V30, P11346, DOI 10.1523/JNEUROSCI.2524-10.2010
   Ward AS, 1997, PSYCHOPHARMACOLOGY, V132, P375, DOI 10.1007/s002130050358
   Wee S, 2008, EUR NEUROPSYCHOPHARM, V18, P303, DOI 10.1016/j.euroneuro.2007.08.003
   Willuhn I, 2014, NAT NEUROSCI, V17, P704, DOI 10.1038/nn.3694
   WILSON MC, 1971, PSYCHOPHARMACOLOGIA, V22, P271, DOI 10.1007/BF00401789
   Winger G, 1992, HDB DRUG ALCOHOL ABU
   WISE RA, 1995, PSYCHOPHARMACOLOGY, V120, P10, DOI 10.1007/BF02246140
   Woolverton WL, 2004, EUR J PHARMACOL, V486, P251, DOI 10.1016/j.ejphar.2004.01.003
   Zernig G., 1997, NIDA RES MONOGR, V178, P218
   Zimmer BA, 2012, NEUROPSYCHOPHARMACOL, V37, P1901, DOI 10.1038/npp.2012.37
NR 145
TC 118
Z9 119
U1 3
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0149-7634
EI 1873-7528
J9 NEUROSCI BIOBEHAV R
JI Neurosci. Biobehav. Rev.
PD SEP
PY 2015
VL 56
BP 166
EP 179
DI 10.1016/j.neubiorev.2015.06.012
PG 14
WC Behavioral Sciences; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Behavioral Sciences; Neurosciences & Neurology
GA CR8CK
UT WOS:000361578500013
PM 26116543
OA Green Submitted
DA 2023-06-23
ER

PT J
AU Chappuy, M
   Peyrat, M
   Lejeune, O
   Duvernay, N
   David, B
   Joubert, P
   Lack, P
AF Chappuy, Mathieu
   Peyrat, Marie
   Lejeune, Olivier
   Duvernay, Nathalie
   David, Brigitte
   Joubert, Philippe
   Lack, Philippe
TI Drug consumption during prolonged lockdown due to Covid-19 as observed
   in French addiction center
SO THERAPIE
LA English
DT Letter
DE COVID19; Coronavirus; Surveys; Drug addiction; Drug dependence
C1 [Chappuy, Mathieu; Peyrat, Marie; Lejeune, Olivier; Duvernay, Nathalie; David, Brigitte; Joubert, Philippe; Lack, Philippe] Hosp Civils Lyon, Croix Rousse Univ Hosp, CSAPA Ctr Support Care & Prevent Addictol, Batiment C-1er,103 Grande Rue Croix Rousse, F-69004 Lyon, France.
   [Chappuy, Mathieu] Hosp Civils Lyon, Edouard Herriot Univ Hosp, CSAPA Ctr Support Care & Prevent Addictol, F-69004 Lyon, France.
   [Chappuy, Mathieu] Le Vinatier Hosp, SUAL Acad Dept Addict Med, F-69678 Bron, France.
C3 CHU Lyon; CHU Lyon
RP Chappuy, M (通讯作者)，Hosp Civils Lyon, Croix Rousse Univ Hosp, CSAPA Ctr Support Care & Prevent Addictol, Batiment C-1er,103 Grande Rue Croix Rousse, F-69004 Lyon, France.; Chappuy, M (通讯作者)，Hosp Civils Lyon, Edouard Herriot Univ Hosp, CSAPA Ctr Support Care & Prevent Addictol, F-69004 Lyon, France.
EM mathieu.chappuy@chu-lyon.fr
OI CHAPPUY, Mathieu/0000-0002-3176-6039
CR Ganesh A, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102120
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Lapeyre-Mestre M, 2020, THERAPIE, V75, P343, DOI 10.1016/j.therap.2020.06.006
   Martiniere M, 2020, MEDIACITES
   Mathew AR, 2011, J COGN PSYCHOTHER, V25, P61, DOI 10.1891/0889-8391.25.1.61
   Palle C., 2016, CSAPA CLIENTS SITUAT CSAPA CLIENTS SITUAT
   Winstock A., GDS SPECIAL EDITION
   World Health Organization (WHO), 2020, MENTAL HLTH COVID 19
NR 8
TC 3
Z9 3
U1 0
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0040-5957
EI 1958-5578
J9 THERAPIE
JI Therapie
PD JUL-AUG
PY 2021
VL 76
IS 4
BP 379
EP 382
DI 10.1016/j.therap.2021.01.053
EA JUL 2021
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA TS0JF
UT WOS:000679342200020
PM 33516544
OA Bronze, Green Published
DA 2023-06-23
ER

PT S
AU Lu, L
   Wang, X
AF Lu, Lin
   Wang, Xi
BE Uhl, GR
TI Drug Addiction in China
SO ADDICTION REVIEWS 2008
SE Annals of the New York Academy of Sciences
LA English
DT Article
DE drug addiction; HIV infection; harm reduction; treatment
ID HEPATITIS-C VIRUS; METHADONE-MAINTENANCE TREATMENT;
   HUMAN-IMMUNODEFICIENCY-VIRUS; SUBSTANCE-ABUSE; GENERAL-POPULATION;
   OPIATE ADDICTION; PASSIVE SMOKING; HARM REDUCTION; HIV-INFECTION;
   HEALTH-STATUS
AB Drug addiction in China began with the importation of Indian opium by the British in the 16th century and brought severe social and health problems. While drug abuse abated following the establishment of People's Republic of China, modernization and Westernization in the 1980s led to the reemergence of this problem. Drug abuse in China became epidemic, facilitating the spread of HIV/AIDS. The Chinese government has made great efforts to address these problems, focusing both on treatments of drug addiction and on harm-reduction programs. Although the new trends of drug addiction in China pose great public health challenges, these government interventions are likely to successfully stern the problem of drug abuse in the future.
C1 [Lu, Lin; Wang, Xi] Peking Univ, Natl Inst Drug Dependence, Beijing 100083, Peoples R China.
C3 Peking University
RP Lu, L (通讯作者)，Peking Univ, Natl Inst Drug Dependence, 38 Xue Yuan Rd, Beijing 100083, Peoples R China.
EM linlu@bjmu.edu.cnc
FU National Basic Research Program of China [2007CB512302, 2003CB 515400];
   National High Technology Research and Development Program of China
   [2006AA02Z4D1]; China-Canada Joint Health Research Program [30611120528]
FX This work was supported in part by the National Basic Research Program
   of China (No: 2007CB512302 and 2003CB 515400), the National High
   Technology Research and Development Program of China (863 Program,
   2006AA02Z4D1) and, the China-Canada Joint Health Research Program (No:
   30611120528).
CR AO T, 2001, LIAONING TAXATION CO, V15, P22
   BAI YT, 2001, CPC HIST, V10, P38
   BELL J, 1990, MED J AUSTRALIA, V153, P274, DOI 10.5694/j.1326-5377.1990.tb136900.x
   *BUR INT NARC LAW, 2003, INT NARC CONTR STRAT
   Carroll KM, 2006, DRUG ALCOHOL DEPEN, V81, P301, DOI 10.1016/j.drugalcdep.2005.08.002
   CHEN C, 2001, WILD PLANT RESOUR, V20, P30
   *CHIN NAT NARC CON, 2007, ANN REP DRUG CONTR C
   *CHIN NAT NARC CON, 2002, ANN REP DRUG CONTR C
   *CHIN NAT NARC CON, 2005, ANN REP DRUG CONTR C
   *CHIN UN THEM GROU, 2001, HIV AIDS CHIN TIT PE
   China State Council AIDS Working Committee Office and UN Theme Group on HIV/AIDS in China, 2007, JOINT ASS HIV AIDS P
   Chinese State Council AIDS Working Committee and UN Theme Group on HIV/AIDS in China, 2004, JOINT ASS HIV AIDS P
   CLEMENTJONES V, 1979, LANCET, V2, P380
   Cochrane J, 2003, ALCOHOL ALCOHOLISM, V38, P537, DOI 10.1093/alcalc/agg111
   *COLL GROUP, 1993, CHINESE J NEUROLOGY, V26, P3
   *COLL RES GROUP AL, 1992, CHINESE J MENTAL HLT, V6, P112
   *COLL RES GROUP AL, 1992, CHIN J MENTAL HLTH, V6, P116
   Collaborative Group of Epidemiological Study of MentalIllness, 1986, CHIN J NEUROPSYCHIAT, V19, P70
   DUAN LX, 2003, CHINESE J DRUG ABUSE, V9, P6
   Fang YX, 2006, ACTA PHARMACOL SIN, V27, P140, DOI 10.1111/j.1745-7254.2006.00270.x
   Freese TE, 2002, J SUBST ABUSE TREAT, V23, P151, DOI 10.1016/S0740-5472(02)00267-2
   Glaser V, 2004, AIDS PATIENT CARE ST, V18, P373
   GOLD M, 1980, DRUG ALCOHOL DEPEN, V6, P201, DOI 10.1016/0376-8716(80)90323-3
   Hagan H, 1998, SUBST USE MISUSE, V33, P1197, DOI 10.3109/10826089809062214
   Hammett TM, 2008, ADDICTION, V103, P137, DOI 10.1111/j.1360-0443.2007.02053.x
   Hao W, 2005, ADDICTION, V100, P737, DOI 10.1111/j.1360-0443.2005.01036.x
   Hao W, 2004, ADDICTION, V99, P1176, DOI 10.1111/j.1360-0443.2004.00830.x
   Hao W, 2004, ALCOHOL ALCOHOLISM, V39, P43, DOI 10.1093/alcalc/agh018
   Hao W, 1999, ADDICTION, V94, P1467, DOI 10.1046/j.1360-0443.1999.941014673.x
   HAO W, 2001, PATTERNS PROBLEMS 7, P116
   Hao W., 2000, J SUBST USE, V5, P71, DOI [DOI 10.3109/14659890009053065, 10.3109/14659890009053065]
   He Y, 1999, CHINESE MED J-PEKING, V112, P3
   Michels II, 2007, ACTA PHARMACOL SIN, V28, P1505, DOI 10.1111/j.1745-7254.2007.00633.x
   JIANG Z, 1993, CHINESE J NEUROLOGY, V26, P10
   JING J, 2002, WROKSH CHANG HLTH NE
   Kaufman J, 2002, SCIENCE, V296, P2339, DOI 10.1126/science.1074479
   Kerr C, 2005, LANCET INFECT DIS, V5, P474, DOI 10.1016/S1473-3099(05)70180-8
   Kleber H., 1981, SUBSTANCE ABUSE CLIN, P317
   KONEFAL J, 1994, J ADDICT DIS, V13, P71
   Kreek MJ, 2002, NAT REV DRUG DISCOV, V1, P710, DOI 10.1038/nrd897
   Lau JTF, 2005, AIDS CARE, V17, P166, DOI 10.1080/09540120512331325662
   LI L, 2003, CHIN MED, V34, P2012
   LIANG Y, 2003, CHIN MAG DRUG ABUSE, V9, P131
   Lin ZH, 2004, J VASC RES, V41, P305, DOI 10.1159/000078928
   Lintzeris N, 2006, NATL CLIN GUIDELINES
   Liu BQ, 1998, BMJ-BRIT MED J, V317, P1411, DOI 10.1136/bmj.317.7170.1411
   [刘彦红 Liu yanhong], 2004, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V13, P60
   Liu ZM, 2003, ACTA PHARMACOL SIN, V24, P448
   Loke AY, 2000, ACTA OBSTET GYN SCAN, V79, P947, DOI 10.1034/j.1600-0412.2000.079011947.x
   LOWINGER P, 1977, AM J DRUG ALCOHOL AB, V4, P165, DOI 10.3109/00952997709002758
   LOWINGER P, 1973, American Journal of Chinese Medicine, V1, P275, DOI 10.1142/S0192415X73000292
   Lu L, 2008, CELL MOL NEUROBIOL, V28, P479, DOI 10.1007/s10571-007-9225-2
   Lu L, 2008, AM J DRUG ALCOHOL AB, V34, P127, DOI 10.1080/00952990701876989
   Lu PK, 2004, ACUPUNCTURE ELECTRO, V29, P187, DOI 10.3727/036012904815901452
   MA Y, 2000, ZHONGGUO XING BING A, V6, P185
   McCoy CB, 1997, J DRUG ISSUES, V27, P73, DOI 10.1177/002204269702700105
   McCoy CB, 2001, SUBST USE MISUSE, V36, P49, DOI 10.1081/JA-100000228
   MICHELS II, 2007, SUCHT, V53, P228
   *MIN HLTH DRUG ADM, 1993, GUID MED OP ADD
   Montazeri Kamran, 2002, Acta Anaesthesiol Sin, V40, P173
   NAIK TN, 1991, AIDS, V5, P117, DOI 10.1097/00002030-199101000-00026
   *NAT I DRUG DEP NA, 2003, REP DRUG SURV 2003
   *NAT I DRUG DEP NA, 2004, REP DRUG SURV 2004
   National Narcotic Control Commission, 2002, ANN REP DRUG CONTR C
   OBRIEN CP, 1994, ADDICTION, V89, P1565, DOI 10.1111/j.1360-0443.1994.tb03759.x
   PAN B, 2006, ACTA TAB SINI, V12, P6
   Peto R, 1996, JAMA-J AM MED ASSOC, V275, P1683, DOI 10.1001/jama.275.21.1683
   POROY II, 1981, INT J MIDDLE E STUD, V13, P191, DOI 10.1017/S002074380005529X
   Qian Han-Zhu, 2006, Harm Reduct J, V3, P4, DOI 10.1186/1477-7517-3-4
   *RAINB COMM CAR CT, 2003, DAYT PREV REC CTR DR
   RAWSON RA, 1998, PSYCHOACTIVE SUSBTAN
   Scherbaum N, 2005, EUR ADDICT RES, V11, P163, DOI 10.1159/000086397
   Shen Y., 1998, ALCOHOL EMERGING MAR, P123
   Shi J, 2007, J ADDICT MED, V1, P186, DOI 10.1097/ADM.0b013e318156cc19
   Shi J, 2006, ACTA PHARMACOL SIN, V27, P1303, DOI 10.1111/j.1745-7254.2006.00431.x
   Shwartz M, 1999, J SUBST ABUSE TREAT, V17, P305, DOI 10.1016/S0740-5472(99)00010-0
   *STAT COUNC PR CHI, 2006, CHIN ACT PLAN RED PR
   *STAT STAT BUR, 1998, CHIN STAT YB
   Sullivan SG, 2007, INT J DRUG POLICY, V18, P118, DOI 10.1016/j.drugpo.2006.11.014
   Tang Y.-L., 1998, HONG KONG J PSYCHIAT, V8, P21
   Tang YL, 2006, ADDICTION, V101, P657, DOI 10.1111/j.1360-0443.2006.01367.x
   Tang YL, 2005, J SUBST ABUSE TREAT, V29, P215, DOI 10.1016/j.jsat.2005.06.006
   TANG YL, 1997, CHINESE B DRUG DEPEN, V6, P31
   Tran GD, 2005, INT J CANCER, V113, P456, DOI 10.1002/ijc.20616
   WALLBANK T, 1992, CIVILIZATIONS PAST P
   Wang ZG, 2002, TRENDS PHARMACOL SCI, V23, P347, DOI 10.1016/S0165-6147(02)02051-5
   Wang ZY, 2006, CELL METAB, V3, P111, DOI 10.1016/j.cmet.2006.01.002
   WASHBURN AM, 1993, J SUBST ABUSE TREAT, V10, P345, DOI 10.1016/0740-5472(93)90019-X
   WASHTON AM, 1980, LANCET, V2, P1297
   WEI H, 1995, ADDICTION, V90, P1448, DOI 10.1111/j.1360-0443.1995.tb02803.x
   Wen WQ, 2006, BMJ-BRIT MED J, V333, P376, DOI 10.1136/bmj.38834.522894.2F
   *WHO, 1999, GLOB STAT REP ALC, P9
   *WHO, 2001, SUMM GLOB STAT REP A
   Woody G E, 1983, NIDA Res Monogr, V43, P59
   World Health Organization, 2002, INT GUID MON ALC CON, P5
   WU JM, 2003, J CHINESE INTEGRATIV, V1, P268
   Wu Z., 2005, INT C RED DRUG REL H
   Wu Z, 2004, 15 INT AIDS C
   XIAO J, 1995, INT HDB ALCOHOL CULT, P116
   [徐国柱 Xu Guozhu], 2002, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V11, P280
   [薛丽燕 Xue Liyan], 2002, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V11, P47
   YANG G, 2004, CHIN SMOKING HLTH, P7
   Yang HM, 2005, SEX TRANSM DIS, V32, P270, DOI 10.1097/01.olq.0000162360.11910.5a
   Yin P, 2007, LANCET, V370, P751, DOI 10.1016/S0140-6736(07)61378-6
   Zhang H, 2003, RESPIROLOGY, V8, P17, DOI 10.1046/j.1440-1843.2003.00433.x
   Zhang H, 2006, J YUNNAN POLICE OFFI, V4, P16
   李超, 1999, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V8, P42
NR 107
TC 45
Z9 49
U1 3
U2 42
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA
SN 0077-8923
BN 978-1-57331-727-6
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2008
VL 1141
BP 304
EP 317
DI 10.1196/annals.1441.025
PG 14
WC Multidisciplinary Sciences; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Neurosciences & Neurology
GA BIM56
UT WOS:000260859100017
PM 18991965
DA 2023-06-23
ER

PT J
AU Itzick, M
   Segal, JN
   Possick, C
AF Itzick, Michal
   Segal, Jenya Neomi
   Possick, Chaya
TI Relationships in the lives of Israeli women coping with drug addiction:
   An ecosystemic perspective
SO JOURNAL OF SOCIAL AND PERSONAL RELATIONSHIPS
LA English
DT Article
DE Drug addiction; drug addiction and trauma; ecosystemic perspective;
   relationships and drug addiction; women; women and drug addiction; women
   and drug rehabilitation
ID SEXUAL-ABUSE; PROSTITUTION; SERVICES
AB This qualitative study explores the experience of relationships in the lives of Israeli women coping with drug addiction, following detoxification. The theoretical foundation of the study is the relational theory of women and drug addiction. The aim of the current study is to use an integrated, ecosystemic framework that contextualizes the women's experiences in relationships. The study is designed according to interpretative phenomenological analysis. The research includes in-depth, loosely structured interviews with 12 women coping with drug addiction, aged 20-33, who have been free of drugs at least 1 year. The interviews were recorded, transcribed, and analyzed by coding meaning units, forming categories, and developing four focal themes: (1) preoccupation with achieving security in relationships with significant others: parents and partners; (2) loneliness and fear resulting from traumatic experiences; (3) the road to recovery as an experience of repeated caring contact by drug rehabilitation staff; and (4) gendered social and cultural stigma by society at large as experienced in relationships with "helping" professionals. The discussion demonstrates how the experiences of women coping with drug addiction who are free of drugs can be divided into three levels, based on the ecosystemic perspective: the internal microsystem of the self, the external mesosystem of relationships with others, and the macrosystem of self and society. Implications for policy practice with women coping with drug addiction are presented based on the gender-mainstreaming approach.
C1 [Itzick, Michal; Segal, Jenya Neomi; Possick, Chaya] Ariel Univ, Ariel, Israel.
C3 Ariel University
RP Possick, C (通讯作者)，Ariel Univ, Sch Social Work, POB 3, IL-40700 Ariel, Israel.
EM chayapossick@gmail.com
OI Possick, Chaya/0000-0002-9518-4134
CR Agrawal A, 2004, BEHAV GENET, V34, P217, DOI 10.1023/B:BEGE.0000017868.07829.45
   Andrews CM, 2011, VIOLENCE AGAINST WOM, V17, P550, DOI 10.1177/1077801211407289
   Bachrach-Cohen R., 2012, THESIS U HAIFA ISRAE
   Becvar D. S., 2006, FAMILY THERAPY SYSTE
   Berkovitch N, 1997, WOMEN STUD INT FORUM, V20, P605, DOI 10.1016/S0277-5395(97)00055-1
   BUCHBINDER E, 2001, THESIS U HAIFA ISRAE
   BYINGTON DB, 1997, GENDER ADDICTIONS ME, P31
   *COUNC EUR, 1998, GEND MAINSTR CONC FR
   Covington S. S., 2007, CLIN PSYCHIAT NEWS, V35, P15
   Covington SS, 2002, HANDBOOK OF ADDICTION TREATMENT FOR WOMEN, P52
   Covington SS, 2008, J PSYCHOACTIVE DRUGS, P377
   CRESWELL WJ, 1998, RES DESIGN QUALITATI
   Crocker J, 2001, PSYCHOL REV, V108, P593, DOI 10.1037//0033-295X.108.3.593
   Fernandez-Montalvo J, 2017, J INTERPERS VIOLENCE, V32, P2046, DOI 10.1177/0886260515591980
   Fletcher A. M., 2013, INSIDE REHAB THE SUR
   Flick U., 2018, INTRO QUALITATIVE RE
   French MT, 2011, HEALTH SERV RES, V46, P877, DOI 10.1111/j.1475-6773.2010.01218.x
   Gavriel-Fried B, 2014, BRIT J SOC WORK, V44, P992, DOI 10.1093/bjsw/bcs176
   Gergen K. J., 2000, SATURATED SELF DILEM
   Germain C. B., 1995, ENCY SOCIAL WORK, P816
   Gilligan Carol, 1982, DIFFERENT VOICE PSYC
   Guarino H, 2012, SUBST ABUSE TREAT PR, V7, DOI 10.1186/1747-597X-7-2
   Gur A., 2008, ADDICTION VIOLENCE S, P93
   Harrison BJ, 2008, P NATL ACAD SCI USA, V105, P9781, DOI 10.1073/pnas.0711791105
   Hashiloni-Dolev Y, 2006, NASHIM, P129, DOI 10.1353/nsh.2006.0021
   Haskell L, 2003, 1 STAGE TRAUMA TREAT
   Inbar I, 2015, MED TREATMENT DRUG A
   Liat Y, 2016, J DRUG ISSUES, V46, P247, DOI 10.1177/0022042616638491
   Lincoln Y.S., 1985, NATURALISTIC INQUIRY, DOI DOI 10.1016/0147-1767(85)90062-8
   Mahapatro M., 2015, VISION, V18, P309, DOI [10.1177/0972262914551663, DOI 10.1177/0972262914551663]
   MILLER BA, 1990, WOMEN CRIMINAL JUSTI, V0001
   MILLER J, 1976, NEW PSYCHOL WOMEN
   Neuliep J. W, 2015, INTERCULTURAL COMMUN
   Patton M. Q., 2015, QUALITATIVE RES EVAL, DOI DOI 10.1002/NUR.4770140111
   Rabinowitz M, 2010, PSYCHOACTIVE DRUG AD
   Sallmann J, 2010, J SOC WORK PRACT ADD, V10, P115, DOI 10.1080/15332561003730155
   Sallmann J, 2010, AFFILIA J WOM SOC WO, V25, P146, DOI 10.1177/0886109910364362
   Sanders JM, 2014, PALGRAVE PIVOT, P1, DOI 10.1057/9781137430496
   Schiff M, 2010, SOC WORK HEALTH CARE, V49, P799, DOI 10.1080/00981381003745103
   Simoni-Wastila L, 2004, SUBST USE MISUSE, V39, P1, DOI 10.1081/JA-120027764
   Smith J.A., 2009, INTERPRETATIVE PHENO
   Strauss E, 1998, CLIN ORTHOP RELAT R, P2
   Tal-Spiro A, 2014, DRUG ABUSE ARAB SECT
   Trute B, 2001, J MARITAL FAM THER, V27, P99, DOI 10.1111/j.1752-0606.2001.tb01142.x
NR 44
TC 2
Z9 2
U1 1
U2 20
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0265-4075
EI 1460-3608
J9 J SOC PERS RELAT
JI J. Soc. Pers. Relatsh.
PD MAR
PY 2019
VL 36
IS 3
BP 741
EP 760
DI 10.1177/0265407517744384
PG 20
WC Communication; Family Studies; Psychology, Social
WE Social Science Citation Index (SSCI)
SC Communication; Family Studies; Psychology
GA HH0CI
UT WOS:000455379700002
DA 2023-06-23
ER

PT J
AU Delic, M
AF Delic, M.
TI Different dimensions of wellness in drug addiction treatment
SO EUROPEAN PSYCHIATRY
LA English
DT Meeting Abstract
DE wellness; well-being; Treatment; drug addiction
C1 [Delic, M.] Univ Psychiat Clin Ljubljana, Ctr Treatment Drug Addict, Ljubljana, Slovenia.
C3 University Medical Centre Ljubljana
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0924-9338
EI 1778-3585
J9 EUR PSYCHIAT
JI Eur. Psychiat.
PD JUN
PY 2022
VL 65
SU 1
SI SI
MA EPV1545
BP S829
EP S829
DI 10.1192/j.eurpsy.2022.2146
PG 1
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA 6Z7QC
UT WOS:000897965702623
OA Green Accepted, gold
DA 2023-06-23
ER

PT J
AU Zeng, XQ
   Tan, CY
AF Zeng, Xiaoqing
   Tan, Chuyi
TI The Relationship between the Family Functioning of Individuals with Drug
   Addiction and Relapse Tendency: A Moderated Mediation Model
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE individuals with drug addiction; family functioning; relapse tendency;
   psychological capital; life history strategy
ID SUBSTANCE USE; SOCIAL INFLUENCES; EARLY ADULTHOOD; MENTAL-HEALTH; COPING
   SKILLS; LIFE; ADOLESCENTS; ATTACHMENT; RESILIENCE; OPTIMISM
AB To explore the relationship between family functioning, psychological capital, life history strategy, and relapse tendency of individuals with drug addiction, 842 individuals with drug addiction completed a questionnaire. The results showed that (1) there was a significant negative correlation between the family functioning of individuals with drug addiction and their relapse tendency; (2) psychological capital played an intermediary role between family functioning and relapse tendency; and (3) life history strategy regulated the mediating effect of psychological capital. The results of this study suggest that family members should collaborate with drug addiction treatment centers and participate in the education and treatment process to help reduce drug relapse tendency. Increasing the psychological capital and self-efficacy of individuals with drug addiction through group psychological counseling and psychological education courses could also reduce drug relapse tendency.
C1 [Zeng, Xiaoqing; Tan, Chuyi] Jiangxi Normal Univ, Sch Psychol, Inst Psychol, Nanchang 330022, Jiangxi, Peoples R China.
C3 Jiangxi Normal University
RP Zeng, XQ (通讯作者)，Jiangxi Normal Univ, Sch Psychol, Inst Psychol, Nanchang 330022, Jiangxi, Peoples R China.
EM zxq3701@163.com; tanchuyi2019@163.com
OI Tan, Chuyi/0000-0002-4209-0943
FU National Social Science Foundation of China [19BGL230]; "13th Five-Year
   Plan" Project of Educational Science in Jiangxi Province [20YB19]
FX This research was funded by grants from the National Social Science
   Foundation of China (19BGL230), and from the "13th Five-Year Plan"
   Project of Educational Science in Jiangxi Province (20YB19).
CR Abdollahi Zahra, 2014, Glob J Health Sci, V6, P138, DOI 10.5539/gjhs.v6n3p138
   Ackerman N. W., 1984, THEORY FAMILY SYSTEM
   Beavers R, 2000, J FAM THER, V22, P128, DOI 10.1111/1467-6427.00143
   Becona Elisardo, 2007, Adicciones, V19, P89
   BOWEN M, 1966, COMPR PSYCHIAT, V7, P345, DOI 10.1016/S0010-440X(66)80065-2
   Brenning K, 2012, J YOUTH ADOLESCENCE, V41, P802, DOI 10.1007/s10964-011-9740-9
   Bronfenbrenner U., 1979, ECOLOGY HUMAN DEV
   Carvajal SC, 1998, J SOC CLIN PSYCHOL, V17, P443, DOI 10.1521/jscp.1998.17.4.443
   Chen MR, 2020, SOC BEHAV PERSONAL, V48, DOI 10.2224/sbp.9334
   Choi Y, 2005, J RES ADOLESCENCE, V15, P505, DOI 10.1111/j.1532-7795.2005.00109.x
   Cohen J., 2003, APPL MULTIPLE REGRES, DOI [https://doi.org/10.4324/9780203774441, DOI 10.1002/0471264385.WEI0219]
   Connelly Thomas W Jr, 2005, MCN Am J Matern Child Nurs, V30, P245, DOI 10.1097/00005721-200507000-00008
   Cordova D, 2014, SUBST USE MISUSE, V49, P1908, DOI 10.3109/10826084.2014.935792
   Duan L, 2009, J YOUTH ADOLESCENCE, V38, P454, DOI 10.1007/s10964-008-9310-y
   EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x
   EPSTEIN NB, 1978, J MARRIAGE FAM COUNS, V4, P19, DOI 10.1111/j.1752-0606.1978.tb00537.x
   Fagan AA, 2011, YOUTH VIOLENCE JUV J, V9, P150, DOI 10.1177/1541204010377748
   Feldman DB, 2005, J SOC CLIN PSYCHOL, V24, P401, DOI 10.1521/jscp.24.3.401.65616
   Fergus S, 2005, ANNU REV PUBL HEALTH, V26, P399, DOI 10.1146/annurev.publhealth.26.021304.144357
   Figueredo AJ, 2005, PERS INDIV DIFFER, V39, P1349, DOI 10.1016/j.paid.2005.06.009
   Gao TT, 2018, J AFFECT DISORDERS, V240, P27, DOI 10.1016/j.jad.2018.07.005
   Gladden PR, 2009, PERS INDIV DIFFER, V46, P270, DOI 10.1016/j.paid.2008.10.010
   Graber R, 2016, BRIT J PSYCHOL, V107, P338, DOI 10.1111/bjop.12135
   Guo XM, 2019, PSYCHOL REP, V122, P506, DOI 10.1177/0033294118765418
   Hayatbakhsh R, 2013, EUR CHILD ADOLES PSY, V22, P693, DOI 10.1007/s00787-013-0464-0
   Hayes A. F., 2013, INTRO MEDIATION MODE
   Heinonen K, 2004, EUR J PERSONALITY, V18, P193, DOI 10.1002/per.508
   Houston R., 2006, THESIS SO METHODIST
   Hummel A, 2013, ADDICTION, V108, P487, DOI 10.1111/add.12055
   Hurst JE, 2017, EVOL HUM BEHAV, V38, P1, DOI 10.1016/j.evolhumbehav.2016.06.001
   Ibrahim F, 2011, SOC SCI, V6, P277, DOI [10.3923/sscience.2011.277.282, DOI 10.3923/SSCIENCE.2011.277.282]
   Irving LM, 1998, J SOC CLIN PSYCHOL, V17, P389, DOI 10.1521/jscp.1998.17.4.389
   Jafari E, 2010, PROCD SOC BEHV, V5, P1376, DOI 10.1016/j.sbspro.2010.07.291
   Jiang X, 2013, PSYCHOL SCHOOLS, V50, P340, DOI 10.1002/pits.21680
   Jorge KO, 2018, CAD SAUDE PUBLICA, V34, DOI [10.1590/0102-311X00144316, 10.1590/0102-311x00144316]
   Krasikova DV, 2015, J LEADERSH ORG STUD, V22, P280, DOI 10.1177/1548051815585853
   Li L, 2013, INT J DRUG POLICY, V24, P545, DOI 10.1016/j.drugpo.2013.06.007
   LOCKE EA, 1987, ACAD MANAGE REV, V12, P169, DOI 10.2307/258004
   LOPEZ JMO, 1989, INT J ADDICT, V24, P1065, DOI 10.3109/10826088909047329
   Luthans F., 2007, PSYCHOL CAPITAL
   Luthans F, 2007, PERS PSYCHOL, V60, P541, DOI 10.1111/j.1744-6570.2007.00083.x
   Luthans F, 2007, J MANAGE, V33, P321, DOI 10.1177/0149206307300814
   Ma H., 1999, HDB MENTAL HLTH ASSE, P82
   Mahmood N.M., 1996, PERANAN DAN PENGLIBA
   Marchegiani V, 2018, PERS INDIV DIFFER, V135, P108, DOI 10.1016/j.paid.2018.07.004
   Mathiesen KS, 2006, EUR J DEV PSYCHOL, V3, P357, DOI 10.1080/17405620600557797
   Meldrum RC, 2012, J YOUTH ADOLESCENCE, V41, P691, DOI 10.1007/s10964-011-9692-0
   Miles OW, 2019, J MOL NEUROSCI, V68, P453, DOI 10.1007/s12031-018-1147-6
   Miller IW, 2000, J FAM THER, V22, P168, DOI 10.1111/1467-6427.00145
   Murphy EL, 2016, J PSYCHOL COUNS SCH, V26, P35, DOI 10.1017/jgc.2015.17
   Mutani V, 2016, UTILIZATION LIB RESO, P1
   Office of the National Drug Control Commission, 2019, REP CHIN DRUG SIT 20
   Parsa N, 2014, ASIAN SOCIAL SCI, V10, P123, DOI DOI 10.5539/ass.v10n8p123
   Podsakoff PM, 2003, J APPL PSYCHOL, V88, P879, DOI 10.1037/0021-9010.88.5.879
   Reitz AK, 2014, DEV PSYCHOL, V50, P754, DOI 10.1037/a0033889
   Rosenblum A, 2005, SUBST USE MISUSE, V40, P581, DOI 10.1081/JA-200030816
   Rueger SY, 2016, PSYCHOL BULL, V142, P1017, DOI 10.1037/bul0000058
   Sahin ZS, 2010, CONTEMP FAM THER, V32, P238, DOI 10.1007/s10591-010-9116-4
   Schofield TJ, 2015, DRUG ALCOHOL DEPEN, V157, P129, DOI 10.1016/j.drugalcdep.2015.10.020
   Shek DTL, 2002, J GENET PSYCHOL, V163, P497, DOI 10.1080/00221320209598698
   Skinner H, 2000, J FAM THER, V22, P190, DOI 10.1111/1467-6427.00146
   Stajduhar KI, 2009, INT J DRUG POLICY, V20, P309, DOI 10.1016/j.drugpo.2008.07.003
   Strouts PH, 2017, PERS INDIV DIFFER, V115, P128, DOI 10.1016/j.paid.2016.03.047
   Szepsenwol O, 2019, CURR OPIN PSYCHOL, V25, P65, DOI 10.1016/j.copsyc.2018.03.005
   Tanaka N, 2008, PSYCHIAT CLIN NEUROS, V62, P65, DOI 10.1111/j.1440-1819.2007.01777.x
   Van Ryzin MJ, 2012, ADDICT BEHAV, V37, P1314, DOI 10.1016/j.addbeh.2012.06.020
   Veselska Z, 2009, ADDICT BEHAV, V34, P287, DOI 10.1016/j.addbeh.2008.11.005
   Weiss JW, 2011, J DRUG EDUC, V41, P79, DOI 10.2190/DE.41.1.e
   [温忠麟 Wen Zhonglin], 2014, [心理学报, Acta Psychologica Sinica], V46, P714
   Zarnaghash M, 2011, PROCD SOC BEHV, V30, DOI 10.1016/j.sbspro.2011.10.481
   Zeng XQ, 2022, J ETHN SUBST ABUSE, V21, P402, DOI 10.1080/15332640.2020.1777608
   Zhang K, 2010, STUDIES PSYCHOL BEHA, V8, P58, DOI DOI 10.3969/J.ISSN.1672-0628.2010.01.011
   朱炜良, 2002, [中国行为医学科学, Chinese Journal of Behavioral Medical Science], V11, P20
NR 73
TC 16
Z9 16
U1 11
U2 38
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD JAN
PY 2021
VL 18
IS 2
AR 625
DI 10.3390/ijerph18020625
PG 12
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA PY2IZ
UT WOS:000611873800001
PM 33451020
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Murphy, J
   Russell, B
AF Murphy, Jennifer
   Russell, Brenda
TI Police Officers' addiction frameworks and policy attitudes
SO ADDICTIVE BEHAVIORS
LA English
DT Article
DE Addiction frameworks; Drug policy; Naloxone; Stigma; Attitudes
ID LAW-ENFORCEMENT OFFICERS; BRAIN DISEASE-MODEL; PUBLIC-OPINION; OPIOID
   OVERDOSE; DRUG-TREATMENT; STIGMA; KNOWLEDGE; DISORDER; SUPPORT; HEALTH
AB Police officers have frequent encounters with people who use drugs, either by making an arrest for a drug-related offense or responding to a drug overdose call. Yet, little is known about how police officers view drug addiction - as a disease, a moral failure, or something else - and how their frameworks for conceptualizing addiction impact their attitudes toward drug policies, including the use of naloxone. This research examined police officers' adherence to a moralistic addiction framework in relation to their support for treatment-oriented drug policies. Officers (N = 618) were surveyed about their beliefs on drug policy and the extent to which drug addiction was a product of one's morals or related to social or biological reasons. Results found that approximately 22% of the variance in drug policy attitudes could be explained by addiction frameworks and control variables. Officers who embraced a biological perspective of addiction were more supportive of policies that expanded treatment, including access to naloxone, and less punitive sanctions. Those with stronger moralistic views were less supportive of expanding treatment initiatives and endorsed expanding punitive sanctions. Officer age and education was positively related with expanding treatment and naloxone use while exposure to overdoses was negatively related to policy support. These results demonstrate that officers' frameworks about drug addiction play an important role in drug policy attitudes and, by extension, how they might interact with people who use drugs.
C1 [Murphy, Jennifer] Penn State Berks, Criminal Justice, POB 7009, Reading, PA 19610 USA.
   [Russell, Brenda] Penn State Berks, Psychol, POB 7009, Reading, PA 19610 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); Pennsylvania State University
RP Murphy, J (通讯作者)，Penn State Berks, Criminal Justice, POB 7009, Reading, PA 19610 USA.
EM jxm1192@psu.edu
CR Adlaf EM, 2009, ADDICT BEHAV, V34, P360, DOI 10.1016/j.addbeh.2008.11.012
   [Anonymous], 2010, ALCOHOLISM DRUG ABUS, V22, P7
   Avery JJ, 2020, AM J ADDICTION, V29, P305, DOI 10.1111/ajad.13023
   Barnett A, 2020, J SUBST ABUSE TREAT, V115, DOI 10.1016/j.jsat.2020.108033
   Barnett AI, 2018, DRUG ALCOHOL REV, V37, P697, DOI 10.1111/dar.12632
   Baumeister RF, 2003, HANDBOOK OF SELF AND IDENTITY, P197
   Baumeister RF, 2015, ADDICT BEHAV, V44, P3, DOI 10.1016/j.addbeh.2014.09.011
   Blendon RJ, 2018, NEW ENGL J MED, V378, P407, DOI 10.1056/NEJMp1714529
   Bradshaw P., 2010, SCOTTISH SOCIAL ATTI
   Broadus AD, 2015, ADDICT RES THEORY, V23, P115, DOI 10.3109/16066359.2014.942296
   Cook A. K., 2019, CRIMINAL JUSTICE POL, V30, P1163, DOI DOI 10.1177/0887403417740186
   Corrigan PW, 2007, COMMUNITY MENT HLT J, V43, P439, DOI 10.1007/s10597-007-9084-9
   Courtwright DT, 2010, BIOSOCIETIES, V5, P137, DOI 10.1057/biosoc.2009.3
   Davis CS, 2014, DRUG ALCOHOL DEPEN, V144, P265, DOI 10.1016/j.drugalcdep.2014.08.007
   Cruz MF, 2007, INT J DRUG POLICY, V18, P54, DOI 10.1016/j.drugpo.2006.12.001
   Foddy B, 2010, PHILOS PSYCHIATR PSY, V17, P1, DOI 10.1353/ppp.0.0282
   Formica SW, 2018, INT J DRUG POLICY, V54, P43, DOI 10.1016/j.drugpo.2018.01.001
   Furnham A, 1996, SOC SCI MED, V43, P29, DOI 10.1016/0277-9536(95)00330-4
   Garland TS, 2012, J ETHN CRIM JUSTICE, V10, P148, DOI 10.1080/15377938.2012.669654
   Giordano VA, 2014, J DRUG ISSUES, V44, P414, DOI 10.1177/0022042614542510
   Gnann C., 2019, MULTIPLE CASE STUDY
   Hall W, 2015, LANCET PSYCHIAT, V2, P105, DOI 10.1016/S2215-0366(14)00126-6
   Hammer Rachel, 2013, AJOB Neurosci, V4, P27
   Heather N, 2017, NEUROETHICS-NETH, V10, P115, DOI 10.1007/s12152-016-9289-0
   Heyman Gene M, 2013, Front Psychiatry, V4, P31, DOI 10.3389/fpsyt.2013.00031
   Heyman Gene M., 2009, ADDICTION DISORDER C, DOI [10.4159/9780674053991, DOI 10.4159/9780674053991]
   Janulis P, 2013, J APPL SOC PSYCHOL, V43, P1065, DOI 10.1111/jasp.12070
   Jones J, 2006, GALLUP POLL
   Jorgensen C, 2018, SAGE OPEN, V8, DOI 10.1177/2158244018805357
   Kennedy-Hendricks A, 2017, PSYCHIAT SERV, V68, P462, DOI 10.1176/appi.ps.201600056
   Knopf A., 2017, ALCOHOLISM DRUG ABUS, V29, P1
   Kruis NE, 2020, J CRIM JUSTICE EDUC, V31, P319, DOI 10.1080/10511253.2020.1736112
   Kulesza M, 2015, SUBST ABUSE TREAT PR, V10, DOI 10.1186/s13011-015-0022-5
   Lancaster K, 2013, YOUNG PEOPLES OPINIO
   Lawrence RE, 2013, AM J ADDICTION, V22, P255, DOI 10.1111/j.1521-0391.2012.00332.x
   Lee RD, 2006, INT J DRUG POLICY, V17, P183, DOI 10.1016/j.drugpo.2006.02.001
   Leshner AI, 2001, ISSUES SCI TECHNOL, V17, P75
   Lewis M, 2017, NEUROETHICS-NETH, V10, P7, DOI 10.1007/s12152-016-9293-4
   Lewis MD, 2011, PERSPECT PSYCHOL SCI, V6, P150, DOI 10.1177/1745691611400235
   Lock ED, 2002, CRIME DELINQUENCY, V48, P380, DOI 10.1177/0011128702048003002
   Lurigio AJ, 2018, VICTIMS OFFENDERS, V13, P1055, DOI 10.1080/15564886.2018.1514552
   Luty J, 2002, J SUBST USE, V7, P93
   Lytle A, 2020, ADDICT RES THEORY, V28, P425, DOI 10.1080/16066359.2019.1680647
   Matheson C, 2014, INT J DRUG POLICY, V25, P407, DOI 10.1016/j.drugpo.2013.11.001
   Meurk C, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0373-x
   Meurk C, 2014, DRUG ALCOHOL REV, V33, P272, DOI 10.1111/dar.12115
   Murphy J, 2015, ILLNESS OR DEVIANCE?: DRUG COURTS, DRUG TREATMENT, AND THE AMBIGUITY OF ADDICTION, P1
   Murphy J., 2017, CONTEMP DRUG PROBL, V44, P232, DOI [DOI 10.1177/0091450917723770, https://doi.org/10.1177/0091450917723770]
   Murphy J, 2020, J DRUG ISSUES, V50, P455, DOI 10.1177/0022042620921363
   Palamar JJ, 2011, SUBST USE MISUSE, V46, P1457, DOI 10.3109/10826084.2011.596606
   Russell C, 2011, J SUBST ABUSE TREAT, V40, P150, DOI 10.1016/j.jsat.2010.09.006
   Saunders E, 2019, DRUG ALCOHOL DEPEN, V204, DOI 10.1016/j.drugalcdep.2019.107555
   Steenbergh TA, 2012, J SUBST ABUSE TREAT, V42, P421, DOI 10.1016/j.jsat.2011.09.015
   Timberlake JM, 2003, POLICY STUD J, V31, P71, DOI 10.1111/1541-0072.00004
   VanderWaal CJ, 2006, J DRUG ISSUES, V36, P619, DOI 10.1177/002204260603600306
   Vederhus JK, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1306-9
   Volkow ND, 2020, NEW ENGL J MED, V382, P1289, DOI 10.1056/NEJMp1917360
   Volkow ND, 2015, LANCET PSYCHIAT, V2, P677, DOI 10.1016/S2215-0366(15)00236-9
   Wagner KD, 2016, DRUG ALCOHOL DEPEN, V165, P22, DOI 10.1016/j.drugalcdep.2016.05.008
   Wiens TK, 2015, ADDICT RES THEORY, V23, P309, DOI 10.3109/16066359.2014.987760
   Wilbanks W., 1989, CRIMINAL JUSTICE POL, V3, P407, DOI DOI 10.1177/088740348900300407
NR 61
TC 3
Z9 3
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4603
EI 1873-6327
J9 ADDICT BEHAV
JI Addict. Behav.
PD NOV
PY 2021
VL 122
AR 107007
DI 10.1016/j.addbeh.2021.107007
EA JUN 2021
PG 7
WC Psychology, Clinical; Substance Abuse
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology; Substance Abuse
GA TT0GU
UT WOS:000680031000012
PM 34146796
OA Green Published
DA 2023-06-23
ER

PT J
AU Messikh, R
   Pelletier, F
   Bizouard, N
   Aubin, F
   Humbert, P
AF Messikh, R.
   Pelletier, F.
   Bizouard, N.
   Aubin, F.
   Humbert, P.
TI Puffy hand syndrome due to drug addiction. Chronic Lymphoedema and
   long-term intravenous drug addiction
SO ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE
LA French
DT Editorial Material
ID COMPLICATIONS
C1 [Messikh, R.; Pelletier, F.; Bizouard, N.; Aubin, F.; Humbert, P.] CHU St Jacques, Serv Dermatol, F-25030 Besancon, France.
   [Messikh, R.; Humbert, P.] Univ Franche Comte, INSERM, U645, F-25030 Besancon, France.
C3 Universite de Franche-Comte; CHU Besancon; Institut National de la Sante
   et de la Recherche Medicale (Inserm); Universite de Franche-Comte
RP Humbert, P (通讯作者)，CHU St Jacques, Serv Dermatol, 2 Pl St Jacques, F-25030 Besancon, France.
EM phumbert@chu-besancon.fr
RI Aubin, François/ABE-1236-2021; Aubin, François/AAB-5824-2022
OI Aubin, François/0000-0002-1421-4996; Aubin, François/0000-0002-1421-4996
CR ABELES H, 1965, NEW ENGL J MED, V273, P1167
   Arrault M, 2006, ANN DERMATOL VENER, V133, P769, DOI 10.1016/S0151-9638(06)71040-7
   del Giudice P, 2004, BRIT J DERMATOL, V150, P1, DOI 10.1111/j.1365-2133.2004.05607.x
   Drinker CK, 1934, AM J PHYSIOL, V108, P509, DOI 10.1152/ajplegacy.1934.108.3.509
   LOURIA DB, 1967, ANN INTERN MED, V67, P1, DOI 10.7326/0003-4819-67-1-1
   NEVIASER RJ, 1972, J BONE JOINT SURG AM, VA 54, P629, DOI 10.2106/00004623-197254030-00016
   RYAN JJ, 1974, PLAST RECONSTR SURG, V53, P445, DOI 10.1097/00006534-197404000-00012
   Simonnet N, 2004, J MAL VASCUL, V29, P201, DOI 10.1016/S0398-0499(04)96748-0
   VOLLUM DI, 1970, BRIT MED J, V2, P647, DOI 10.1136/bmj.2.5710.647
NR 9
TC 3
Z9 3
U1 0
U2 2
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0151-9638
EI 2214-5451
J9 ANN DERMATOL VENER
JI Ann. Dermatol. Venereol.
PD OCT
PY 2009
VL 136
IS 10
BP 756
EP 758
DI 10.1016/j.annder.2009.04.016
PG 3
WC Dermatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dermatology
GA 510NX
UT WOS:000271097400018
PM 19801268
DA 2023-06-23
ER

PT J
AU Latorre, J
   Lopez-Torres, J
   Sanchez-Nunez, T
   Serrano, JP
   Montanes, J
   Escobar, F
AF Latorre, Jose
   Lopez-Torres, Jesus
   Sanchez-Nunez, Trinidad
   Serrano, Juan Pedro
   Montanes, Juan
   Escobar, Francisco
TI Primary care doctors' perception of treatment demand and need for
   training in drug addiction issues
SO PRIMARY CARE & COMMUNITY PSYCHIATRY
LA English
DT Article
DE attitudes; demand perception; drugs addiction; training need
ID ALCOHOL-USE DISORDERS; PRIMARY MEDICAL-CARE; IDENTIFICATION TEST AUDIT;
   SUBSTANCE-ABUSE; PHYSICIAN; EDUCATION; HEALTH; PERSPECTIVES;
   RELIABILITY; EMERGENCY
AB Aim: To learn the opinion of primary care physicians (PCPs) on healthcare provision for the drug addict population and to determine their knowledge and needs as regards to continuing training and their attitudes towards drug addiction.
   Methods: We conducted a cross-sectional survey of 301 PCPs in Castilla-La Mancha, Spain using a questionnaire designed to elicit physician's opinions about drug addiction.
   Results: The response rate was 85.0% (256 cases). 84.2% of the doctors considered that 10% of patient visits to primary care centres were related to drug addiction. The doctors frequently experienced difficulty in: the diagnosis and treatment of organic diseases associated with addiction (18.4%), the assessment of the situation and level of dependence (36.7%), support to treatment of some aspects of drug addiction (51.3%) and, above all, the treatment of these addictions (62.9%). Of all respondents, 53.8% reported they had received some form of postgraduate training in drug addiction issues. Only 28.5% considered they had received sufficient information on specialised. drug addiction services.
   Conclusions: As regards to PCPs' attitudes to drug addiction, we observed a positive attitude regarding the needs of those who abuse drugs, and the development of intervention programmes. PCPs believe that addicts deserve treatment, that there should be more treatment programmes and that primary healthcare centres should establish links with specialised services.
C1 Univ Castilla La Mancha, Dept Psychol, Fac Med, Albacete 02006, Spain.
   Univ Castilla La Mancha, Dept Med Sci, E-13071 Ciudad Real, Spain.
   CRIB, Castilla La Mancha, Spain.
   Castilla La Mancha Hlth Serv, Castilla La Mancha, Spain.
   Univ Castilla La Mancha, Sch Med, E-13071 Ciudad Real, Spain.
C3 Universidad de Castilla-La Mancha; Universidad de Castilla-La Mancha;
   Universidad de Castilla-La Mancha
RP Latorre, J (通讯作者)，Univ Castilla La Mancha, Dept Psychol, Fac Med, C Almansa 14, Albacete 02006, Spain.
EM Jose.Latorre@uclm.es
RI Postigo, José Miguel Latorre/L-2990-2015; Hidalgo, Jesús
   López-Torres/Q-8234-2017
OI Postigo, José Miguel Latorre/0000-0002-6159-5074; Hidalgo, Jesús
   López-Torres/0000-0001-7249-3623
CR Aalto M, 2006, DRUG ALCOHOL DEPEN, V83, P169, DOI 10.1016/j.drugalcdep.2005.11.010
   Aalto M, 2005, ALCOHOL ALCOHOLISM, V40, P520, DOI 10.1093/alcalc/agh219
   Abou-Saleh MT, 2006, J PSYCHOSOM RES, V61, P305, DOI 10.1016/j.jpsychores.2006.06.013
   Anderson P, 2004, ADDICTION, V99, P299, DOI 10.1111/j.1360-0443.2003.00672.x
   CASANOVA J, 1989, DROGODEPENDENCIAS AT
   Coulton S, 2006, BMJ-BRIT MED J, V332, P511, DOI 10.1136/bmj.38743.421574.7C
   CYR MG, 1988, JAMA-J AM MED ASSOC, V259, P51, DOI 10.1001/jama.259.1.51
   *DGPNSD, 2002, IND TRAT URG MORT OB
   Dybek I, 2006, J STUD ALCOHOL, V67, P473, DOI 10.15288/jsa.2006.67.473
   *EMCDDA, 2006, STAT DRUGS PROBL EUR
   Etheridge R M, 1995, J Subst Abuse, V7, P9, DOI 10.1016/0740-5472(95)90003-9
   Friedmann PD, 2006, MED CARE, V44, P8, DOI 10.1097/01.mlr.0000188913.50489.77
   Gache P, 2005, ALCOHOL CLIN EXP RES, V29, P2001, DOI 10.1097/01.alc.0000187034.58955.64
   Klamen DL, 1997, J PSYCHOACTIVE DRUGS, V29, P263
   Klamen DL, 1999, PSYCHIAT CLIN N AM, V22, P471, DOI 10.1016/S0193-953X(05)70087-3
   Larson MJ, 2006, AM J DRUG ALCOHOL AB, V32, P435, DOI 10.1080/00952990600753958
   Latorre Postigo Jm, 2005, Aten Primaria, V36, P85, DOI 10.1157/13076608
   Lawrence S, 2000, DRUG-EDUC PREV POLIC, V7, P279, DOI 10.1080/09687630050109952
   McPherson TL, 2000, J SUBST ABUSE TREAT, V18, P193, DOI 10.1016/S0740-5472(99)00028-8
   MEGIAS E, 2001, ATENCION PRIMARIA SA
   Miller NS, 1999, PSYCHIAT CLIN N AM, V22, P489, DOI 10.1016/S0193-953X(05)70089-7
   Miller NS, 2001, ACAD MED, V76, P410, DOI 10.1097/00001888-200105000-00007
   Room R, 2005, LANCET, V365, P519, DOI 10.1016/S0140-6736(05)70276-2
   Saitz R, 1997, AM J DRUG ALCOHOL AB, V23, P343, DOI 10.3109/00952999709016881
   Saitz R, 2002, J GEN INTERN MED, V17, P373, DOI 10.1007/s11606-002-0043-4
   Samet JH, 2001, ARCH INTERN MED, V161, P85, DOI 10.1001/archinte.161.1.85
   Sandlow LJ, 1997, J PSYCHOACTIVE DRUGS, V29, P275
   SMITH DE, 1990, WESTERN J MED, V152, P500
   Vogt F, 2005, ADDICTION, V100, P1423, DOI 10.1111/j.1360-0443.2005.01221.x
   Weaver MF, 1999, ARCH INTERN MED, V159, P913, DOI 10.1001/archinte.159.9.913
   Weisner C, 2001, JAMA-J AM MED ASSOC, V286, P1715, DOI 10.1001/jama.286.14.1715
   Weisner C, 1995, HEALTH SERV RES, V30, P707
   Willenbring ML, 1999, ARCH INTERN MED, V159, P1946, DOI 10.1001/archinte.159.16.1946
NR 33
TC 0
Z9 1
U1 0
U2 4
PU LIBRAPHARM/INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4 LQ, ENGLAND
SN 1746-8841
J9 PRIMARY CARE COMMUN
JI Prim. Care Community Psychiatry
PY 2007
VL 12
IS 1
BP 33
EP 41
DI 10.1080/09513590701592736
PG 9
WC Medicine, General & Internal; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine; Psychiatry
GA 230IM
UT WOS:000250870200005
DA 2023-06-23
ER

PT J
AU Carter, A
   Mathews, R
   Bell, S
   Lucke, J
   Hall, W
AF Carter, Adrian
   Mathews, Rebecca
   Bell, Stephanie
   Lucke, Jayne
   Hall, Wayne
TI Control and Responsibility in Addicted Individuals: What do Addiction
   Neuroscientists and Clinicians Think?
SO NEUROETHICS
LA English
DT Article
DE Addiction; Drug use; Control; Responsibility; Compulsion; Attitudes;
   Qualitative research
ID DRUG-ADDICTION; CONTINGENCY MANAGEMENT; MOLECULAR-GENETICS;
   NEUROBIOLOGY; BRAIN; ABUSE; VULNERABILITY; DEPENDENCE; BEHAVIOR;
   AUTONOMY
AB Impaired control over drug use is a defining characteristic of addiction in the major diagnostic systems. However there is significant debate about the extent of this impairment. This qualitative study examines the extent to which leading Australian addiction neuroscientists and clinicians believe that addicted individuals have control over their drug use and are responsible for their behaviour. One hour semi-structured interviews were conducted during 2009 and 2010 with 31 Australian addiction neuroscientists and clinicians (10 females and 21 males; 16 with clinical experience and 15 with no clinical experience). Although many addiction neuroscientists and clinicians described uncontrolled or compulsive drug use as characteristic of addiction, most were ambivalent about whether or not addicted people could be said to have no control of their drug use. Most believed that addicted individuals have fluctuating levels of impaired control over their drug use but they nonetheless believed that addicted persons were responsible for their behaviour, including criminal behaviour engaged in to fund their drug use. Addiction was not seen as exculpating criminal behaviour but as a mitigating factor.
C1 [Carter, Adrian; Mathews, Rebecca; Bell, Stephanie; Lucke, Jayne; Hall, Wayne] Univ Queensland, Clin Res Ctr, Brisbane, Qld 4029, Australia.
   [Hall, Wayne] Univ Queensland, Queensland Brain Inst, Brisbane, Qld 4072, Australia.
C3 University of Queensland; University of Queensland
RP Carter, A (通讯作者)，Univ Queensland, Clin Res Ctr, Herston Rd, Brisbane, Qld 4029, Australia.
EM adrian.carter@uq.edu.au
RI Carter, Adrian/AAG-2830-2020; Hall, Wayne D/A-3283-2008; Lucke, Jayne
   C/A-5538-2008
OI Carter, Adrian/0000-0002-3593-0772; Hall, Wayne D/0000-0003-1984-0096;
   Lucke, Jayne C/0000-0002-2885-5292
FU National Health and Medical Research Council [569738, 628935]
FX This work was supported by National Health and Medical Research Council
   fellowships awarded to Wayne Hall and Adrian Carter [grant numbers
   569738 and 628935].
CR American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th
   Baler RD, 2006, TRENDS MOL MED, V12, P559, DOI 10.1016/j.molmed.2006.10.005
   Ball D, 2008, ADDICTION, V103, P360, DOI 10.1111/j.1360-0443.2007.02061.x
   Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584
   Bell S., 2013, NEUROETHICS, P1
   Caplan A, 2008, ADDICTION, V103, P1919, DOI 10.1111/j.1360-0443.2008.02369.x
   Carter A, 2012, ADDICTION NEUROETHICS: THE ETHICS OF ADDICTION NEUROSCIENCE RESEARCH AND TREATMENT, P1
   Carter A., 2012, NEUROSCIENCE RESPONS, P279
   Chandler RK, 2009, JAMA-J AM MED ASSOC, V301, P183, DOI 10.1001/jama.2008.976
   Charland Louis C., 2002, American Journal of Bioethics, V2, P37, DOI 10.1162/152651602317533686
   Cohen PJ, 2002, J LAW MED ETHICS, V30, P73, DOI 10.1111/j.1748-720X.2002.tb00722.x
   Dackis C, 2005, NAT NEUROSCI, V8, P1431, DOI 10.1038/nn1105-1431
   DALRYMPLE T, 2006, ROMANCING OPIATES PH
   DAVIES J. B., 1997, MYTH ADDICTION
   Ersche KD, 2012, SCIENCE, V335, P601, DOI 10.1126/science.1214463
   Foddy B, 2006, BIOETHICS, V20, P1, DOI 10.1111/j.1467-8519.2006.00470.x
   Garavan H., 2007, DRUGS FUTURE BRAIN S, P285
   Goldman D, 2005, NAT REV GENET, V6, P521, DOI 10.1038/nrg1635
   Heyman G.M., 2001, IS ADDICTION CHRONIC, VVolume 13, P81, DOI [10.4159/9780674038622-004, DOI 10.4159/9780674038622-004]
   Heyman Gene M., 2009, ADDICTION DISORDER C, DOI [10.4159/9780674053991, DOI 10.4159/9780674053991]
   Higgins ST, 1999, ALCOHOL RES HEALTH, V23, P122
   Higgins ST, 2006, AM J PSYCHIAT, V163, P1870, DOI 10.1176/appi.ajp.163.11.1870
   JELLINEK EM, 1960, DIS CONCEPT ALCOHOLI
   Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Marlowe DB, 2006, J SUBST ABUSE TREAT, V31, P131, DOI 10.1016/j.jsat.2006.06.005
   McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689
   Peele S., 2004, PSYCHOL TODAY, V37, P43
   Rhodes T, 2010, ADDICTION RESEARCH METHODS, P59, DOI 10.1002/9781444318852.ch5
   Room R., 2007, DRUGS FUTURE BRAIN S, P337
   Satel SL, 1999, PUBLIC INTEREST, P52
   Sullivan MA, 2008, AM J ADDICTION, V17, P36, DOI 10.1080/10550490701756369
   SZASZ T, 1975, CEREMONIAL CHEM RITU
   True WR, 1999, ARCH GEN PSYCHIAT, V56, P655, DOI 10.1001/archpsyc.56.7.655
   Uhl GR, 2008, ANN NY ACAD SCI, V1141, P318, DOI 10.1196/annals.1441.018
   Uhl GR, 2004, NEUROPSYCHOPHARMACOL, V29, pS26
   Volkow N, 2005, NAT NEUROSCI, V8, P1429, DOI 10.1038/nn1105-1429
   Volkow ND, 2005, PHARMACOL THERAPEUT, V108, P3, DOI 10.1016/j.pharmthera.2005.06.021
   Volkow ND, 2004, NAT REV NEUROSCI, V5, P963, DOI 10.1038/nrn1539
   Volkow ND, 2003, J CLIN INVEST, V111, P1444, DOI 10.1172/JCI200318533
NR 40
TC 11
Z9 11
U1 0
U2 21
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1874-5490
EI 1874-5504
J9 NEUROETHICS-NETH
JI Neuroethics
PD AUG
PY 2014
VL 7
IS 2
BP 205
EP 214
DI 10.1007/s12152-013-9196-6
PG 10
WC Ethics; Medical Ethics; Social Sciences, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Social Sciences - Other Topics; Medical Ethics; Biomedical Social
   Sciences
GA AK3QA
UT WOS:000338338600008
DA 2023-06-23
ER

PT J
AU von der Goltz, C
   Kiefer, F
AF von der Goltz, C.
   Kiefer, F.
TI Learning and memory in the pathogenesis of addiction
SO NERVENARZT
LA German
DT Review
DE addiction; learning; memory; neuroplasticity; reconsolidation;
   extinction
ID COCAINE-SEEKING BEHAVIOR; NUCLEUS-ACCUMBENS CORE; SYNAPTIC PLASTICITY;
   PROTEIN-SYNTHESIS; DOPAMINE NEURONS; PLACE PREFERENCE; DRUG-ADDICTION;
   NERVOUS-SYSTEM; NEURAL BASIS; MECHANISMS
AB The persistance of addiction-associated cognitions and behavior is caused, in least part, by long-lasting drug-associated memories. Relapses, triggered by exposure to drug-associated cues, contribute considerably to the maintenance of addiction and are, even after drug-free periods for years, a major challenge in the treatment of addiction. An important advance in understanding the underlying pathophysiology derives from recent research results showing similarities between the process of drug addiction and physiological neural plasticity in learning and memory. In the focus of attention are basic mechanisms involving dopamine, glutamate, and their cellular and molecular targets leading to drug-induced synaptic alterations in the mesolimbic reward system. There is growing evidence from preclinical and clinical studies that specific treatments such as extinction training and cue-exposure therapy are effective. The challenge of future research is to determine which drug-induced adaptations are relevant to the pathophysiology of addiction and to generate more efficient therapies for extinction of addiction-associated cognitions and behavior.
C1 [von der Goltz, C.; Kiefer, F.] Zent Inst Seel Gesundheit, Klin Abhangiges Verhalten & Suchtmed, D-68159 Mannheim, Germany.
C3 Central Institute of Mental Health
RP Kiefer, F (通讯作者)，Zent Inst Seel Gesundheit, Klin Abhangiges Verhalten & Suchtmed, J5, D-68159 Mannheim, Germany.
EM falk.kiefer@zi-mannheim.de
RI Kiefer, Falk/E-8325-2012
CR Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8
   BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273
   Boening JAL, 2001, J NEURAL TRANSM, V108, P755, DOI 10.1007/s007020170050
   Bouton ME, 2004, LEARN MEMORY, V11, P485, DOI 10.1101/lm.78804
   Chklovskii DB, 2004, NATURE, V431, P782, DOI 10.1038/nature03012
   Conklin CA, 2002, ADDICTION, V97, P155, DOI 10.1046/j.1360-0443.2002.00014.x
   Cooke SF, 2006, BRAIN, V129, P1659, DOI 10.1093/brain/awl082
   Dalley JW, 2005, P NATL ACAD SCI USA, V102, P6189, DOI 10.1073/pnas.0502080102
   Day JJ, 2007, NAT NEUROSCI, V10, P1020, DOI 10.1038/nn1923
   Di Ciano P, 2001, NEUROPSYCHOPHARMACOL, V25, P341, DOI 10.1016/S0893-133X(01)00235-4
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Graham DL, 2007, NAT NEUROSCI, V10, P1029, DOI 10.1038/nn1929
   Harris GC, 2003, NEUROPSYCHOPHARMACOL, V28, P73, DOI 10.1038/sj.npp.1300011
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Ito R, 2004, NAT NEUROSCI, V7, P389, DOI 10.1038/nn1217
   Jay TM, 2003, PROG NEUROBIOL, V69, P375, DOI 10.1016/S0301-0082(03)00085-6
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kandel E., 2021, PRINCIPLES NEURAL SC, VSixth Edition6th edition edn
   Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020
   KARLER R, 1989, LIFE SCI, V45, P599, DOI 10.1016/0024-3205(89)90045-3
   Kauer JA, 2004, ANNU REV PHYSIOL, V66, P447, DOI 10.1146/annurev.physiol.66.032102.112534
   Kauer JA, 2007, NAT REV NEUROSCI, V8, P844, DOI 10.1038/nrn2234
   Kelley AE, 2004, NEURON, V44, P161, DOI 10.1016/j.neuron.2004.09.016
   LADEWIG D, 1974, SCHWEIZ MED WSCHR, V104, P545
   Lee JLC, 2005, NEURON, V47, P795, DOI 10.1016/j.neuron.2005.08.007
   Lisman JE, 2005, NEURON, V46, P703, DOI 10.1016/j.neuron.2005.05.002
   Loeber S, 2006, NERVENARZT, V77, P558, DOI 10.1007/s00115-005-2000-z
   Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0
   Malenka RC, 2003, NAT REV NEUROSCI, V4, P923, DOI 10.1038/nrn1258
   McClung CA, 2003, NAT NEUROSCI, V6, P1208, DOI 10.1038/nn1143
   McFarland K, 2003, J NEUROSCI, V23, P3531
   Milner B, 1998, NEURON, V20, P445, DOI 10.1016/S0896-6273(00)80987-3
   MISANIN JR, 1968, SCIENCE, V160, P554, DOI 10.1126/science.160.3827.554
   Montague PR, 2004, NATURE, V431, P760, DOI 10.1038/nature03015
   Nader K, 2000, NATURE, V406, P722, DOI 10.1038/35021052
   Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   Park WK, 2002, J NEUROSCI, V22, P2916, DOI 10.1523/JNEUROSCI.22-07-02916.2002
   Robinson MJF, 2007, BEHAV BRAIN RES, V178, P146, DOI 10.1016/j.bbr.2006.12.013
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-7
   Sanchis-Segura C, 2006, ADDICT BIOL, V11, P2, DOI 10.1111/j.1369-1600.2006.00012.x
   Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593
   Self DW, 2004, LEARN MEMORY, V11, P648, DOI 10.1101/lm.81404
   Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077
   Valjent E, 2006, P NATL ACAD SCI USA, V103, P2932, DOI 10.1073/pnas.0511030103
   White NM, 1996, ADDICTION, V91, P921, DOI 10.1111/j.1360-0443.1996.tb03586.x
   Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406
   Wolf Marina E, 2003, Mol Interv, V3, P248, DOI 10.1124/mi.3.5.248
NR 51
TC 6
Z9 6
U1 1
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0028-2804
EI 1433-0407
J9 NERVENARZT
JI Nervenarzt
PD SEP
PY 2008
VL 79
IS 9
BP 1006
EP +
DI 10.1007/s00115-008-2534-y
PG 8
WC Clinical Neurology; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Psychiatry
GA 347RC
UT WOS:000259157700002
PM 18661117
DA 2023-06-23
ER

PT J
AU Chiappini, S
   Guirguis, A
   John, A
   Corkery, JM
   Schifano, F
AF Chiappini, Stefania
   Guirguis, Amira
   John, Ann
   Corkery, John Martin
   Schifano, Fabrizio
TI COVID-19: The Hidden Impact on Mental Health and Drug Addiction
SO FRONTIERS IN PSYCHIATRY
LA English
DT Editorial Material
DE COVID-19; addiction; mental health; drug abuse; prescription drug misuse
ID EPIDEMIC; SUICIDE; ABUSE
C1 [Chiappini, Stefania; Guirguis, Amira; Corkery, John Martin; Schifano, Fabrizio] Univ Hertfordshire, Sch Life & Med Sci, Psychopharmacol Drug Misuse & Novel Psychoact Sub, Hatfield, Herts, England.
   [Guirguis, Amira; John, Ann] Swansea Univ, Sch Med, Swansea, W Glam, Wales.
C3 University of Hertfordshire; Swansea University
RP Chiappini, S; Guirguis, A (通讯作者)，Univ Hertfordshire, Sch Life & Med Sci, Psychopharmacol Drug Misuse & Novel Psychoact Sub, Hatfield, Herts, England.; Guirguis, A (通讯作者)，Swansea Univ, Sch Med, Swansea, W Glam, Wales.
EM stefaniachiappini9@gmail.com; amira.guirguis@swansea.ac.uk
RI CHIAPPINI, STEFANIA/ABC-3831-2020
OI CHIAPPINI, STEFANIA/0000-0002-6810-1540; Schifano,
   Fabrizio/0000-0002-4178-5401; Corkery, John Martin/0000-0002-3849-817X
CR ACMD, 2020, COVID 19 ACMD ADV PR
   Becker WC, 2020, ANN INTERN MED, V173, P59, DOI 10.7326/M20-1210
   Bhuiyan MAH, 2020, ASIAN J PSYCHIATR, V50, DOI 10.1016/j.ajp.2020.101944
   Centers for Disease Control and Prevention (CDC), 2020, HEALTHC PERS 1 RESP
   Chan SMS, 2006, INT J GERIATR PSYCH, V21, P113, DOI 10.1002/gps.1432
   Chevance A, 2020, ENCEPHALE, V46, P193, DOI 10.1016/j.encep.2020.04.005
   Courtet P, 2020, J CLIN PSYCHIAT, V81, DOI 10.4088/JCP.20com13370
   Drug Enforcement Administration (DEA), 2020, COVID 19 INF PAG
   Dsouza DD, 2020, PSYCHIAT RES, V290, DOI 10.1016/j.psychres.2020.113145
   Epidemiology for public health, 2020, COVID 19 STRESS MAN
   European Monitoring Centre for Drug and Drug Addiction (EMCDDA), 2020, IMPL COVID 19 PEOPL
   GOV.UK, 2020, COVID 19 MENT HLTH C
   Green TC, 2020, SUBST ABUS, V41, P147, DOI 10.1080/08897077.2020.1752351
   Griffiths MD, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.113105
   Gunnell D, 2020, LANCET PSYCHIAT, V7, P468, DOI 10.1016/S2215-0366(20)30171-1
   Hao FY, 2020, BRAIN BEHAV IMMUN, V87, P100, DOI 10.1016/j.bbi.2020.04.069
   Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Kawohl W, 2020, LANCET PSYCHIAT, V7, P389, DOI 10.1016/S2215-0366(20)30141-3
   Klomek AB, 2020, LANCET PSYCHIAT, V7, P390, DOI 10.1016/S2215-0366(20)30142-5
   Levander XA, 2020, COVID 19 WILL WORSEN
   Levine DA, 2007, CURR OPIN PEDIATR, V19, P270, DOI 10.1097/MOP.0b013e32814b09cf
   Luo T.D., 2020, ZHONGHUA LAO DONG WE, V38, DOI 10.3760/cma.j.cn121094-20200219-00063
   Petterson S, 2020, WELL BEING TRUST, V8
   Pfefferbaum B, 2020, NEW ENGL J MED, V383, P510, DOI 10.1056/NEJMp2008017
   Rajkumar RP, 2020, ASIAN J PSYCHIATR, V52, DOI 10.1016/j.ajp.2020.102066
   Reeves RR, 2015, SOUTH MED J, V108, P151, DOI 10.14423/SMJ.0000000000000256
   Reger MA, 2020, JAMA PSYCHIAT, V77, P1093, DOI 10.1001/jamapsychiatry.2020.1060
   SAMHSA, 2020, FAQS PROV METH BUPR
   Schifano F, 2018, BRAIN SCI, V8, DOI 10.3390/brainsci8120221
   Simeone R, 2017, SUBST ABUS-RES TREAT, V11, DOI 10.1177/1178221817696077
   Smith K, 2020, EVID-BASED MENT HEAL, V23, P45, DOI 10.1136/ebmental-2020-300155
   Substance Abuse and Mental Health Services Administration (SAMHSA), 2015, SAMHSA SUPPL RES B
   Thakur V, 2020, BRAIN BEHAV IMMUN, V88, P952, DOI 10.1016/j.bbi.2020.04.062
   United Nations, 2020, COVID 19 CAUS SOM IL
   Volkow ND, 2020, NIH DIRECTORS BLOG D
   Volkow ND, 2020, ANN INTERN MED, V173, P61, DOI 10.7326/M20-1212
   Walton M, 2020, EUR HEART J-ACUTE CA, V9, P241, DOI 10.1177/2048872620922795
   Wand APF, 2020, INT PSYCHOGERIATR, V32, P1225, DOI 10.1017/S1041610220000770
   WHO, 2020, REH CONS COVID 19 OU
   Wu KL, 2020, MED SCI MONIT BASIC, V26, DOI 10.12659/MSMBR.924085
   Zhu S, 2020, BRAIN BEHAV IMMUN, V87, P56, DOI 10.1016/j.bbi.2020.04.045
   Zhuo KM, 2020, GEN PSYCHIAT, V33, DOI 10.1136/gpsych-2020-100260
NR 43
TC 77
Z9 78
U1 4
U2 31
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD JUL 29
PY 2020
VL 11
AR 767
DI 10.3389/fpsyt.2020.00767
PG 4
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA NC8XK
UT WOS:000561495300001
PM 32848937
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Fattore, L
   Melis, M
   Fadda, P
   Fratta, W
AF Fattore, Liana
   Melis, Miriam
   Fadda, Paola
   Fratta, Walter
TI Sex differences in addictive disorders
SO FRONTIERS IN NEUROENDOCRINOLOGY
LA English
DT Review
DE Gender differences; Drug addiction; Pathological gambling; Internet
   addiction; Compulsive sex; Fodd addiction; Excessive exercise; Sex
   hormones; Compulsive buying; Reward
ID GENDER-RELATED DIFFERENCES; IMPULSE CONTROL DISORDERS; NATIONAL
   EPIDEMIOLOGIC SURVEY; MULTILOCUS GENETIC PROFILE;
   ESTROGEN-RECEPTOR-BETA; INDUCED BRAIN ACTIVITY; MENSTRUAL-CYCLE PHASE;
   INTERNET ADDICTION; DRUG-ABUSE; FOOD ADDICTION
AB Gender-dependent differences in the rate of initiation and frequency of misuse of addicting drugs have been widely described. Yet, men and women also differ in their propensity to become addicted to other rewarding stimuli (e.g., sex, food) or activities (e.g., gambling, exercising). The goal of the present review is to summarize current evidence for gender differences not only in drug addiction, but also in other forms of addictive behaviours. Thus, we first reviewed studies showing gender-dependent differences in drug addiction, food addiction, compulsive sexual activity, pathological gambling, Internet addiction and physical exercise addiction. Potential risk factors and underlying brain mechanisms are also examined, with particular emphasis given to the role of sex hormones in modulating addictive behaviours. Investigations on factors allowing the pursuit of non-drug rewards to become pathological in men and women are crucial for designing gender-appropriate treatments of both substance and non-substance addictions. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Fattore, Liana] Cittadella Univ Monserrato, Cagliari Natl Res Council Italy, Inst Neurosci, I-09042 Cagliari, Italy.
   [Fattore, Liana; Melis, Miriam; Fadda, Paola; Fratta, Walter] Univ Cagliari, Ctr Excellence Neurobiol Dependence, Monserrato, Italy.
   [Melis, Miriam; Fadda, Paola; Fratta, Walter] Univ Cagliari, Cittadella Univ Monserrato, Dept Biomed Sci, Div Neurosci & Clin Pharmacol, Monserrato, Italy.
   [Fadda, Paola; Fratta, Walter] Univ Cagliari, Natl Inst Neurosci INN, I-09124 Cagliari, Italy.
C3 University of Cagliari; University of Cagliari; University of Cagliari;
   University of Cagliari
RP Fattore, L (通讯作者)，Cittadella Univ Monserrato, Univ Cagliari, Dept Biomed Sci,Div Neurosci & Clin Pharmacol, Cagliari Natl Res Council Italy,Inst Neurosci, I-09042 Cagliari, Italy.
EM lfattore@in.cnr.it
RI Fattore, Liana/AAC-6996-2021; Melis, Miriam/AAF-3235-2020
OI Melis, Miriam/0000-0001-9631-8651; FADDA, PAOLA/0000-0002-0642-6710;
   FATTORE, LIANA/0000-0002-2663-666X
CR Adams J, 2002, ADDICT RES THEORY, V10, P415, DOI 10.1080/1606635021000032366
   Afifi TO, 2010, PSYCHIAT RES, V178, P395, DOI 10.1016/j.psychres.2009.10.003
   Aidman EV, 2003, PSYCHOL SPORT EXERC, V4, P225, DOI 10.1016/S1469-0292(02)00003-1
   Allegre B, 2006, ADDICT RES THEORY, V14, P631, DOI 10.1080/16066350600903302
   Allen AM, 2010, ADDICT BEHAV, V35, P549, DOI 10.1016/j.addbeh.2010.01.003
   Alyea RA, 2008, J NEUROCHEM, V106, P1525, DOI 10.1111/j.1471-4159.2008.05491.x
   American Psychiatric Association (APA), 2013, DIAGN STAT MAN MENT, V5th
   Andersen SL, 2000, NEUROSCI BIOBEHAV R, V24, P137, DOI 10.1016/S0149-7634(99)00044-5
   Anker JJ, 2011, CURR TOP BEHAV NEURO, V8, P73, DOI 10.1007/7854_2010_93
   ARNOLD AP, 1985, HORM BEHAV, V19, P469, DOI 10.1016/0018-506X(85)90042-X
   Bechara A, 1999, J NEUROSCI, V19, P5473
   Becker JB, 1999, PHARMACOL BIOCHEM BE, V64, P803, DOI 10.1016/S0091-3057(99)00168-9
   Becker JB, 2001, ANN NY ACAD SCI, V937, P172, DOI 10.1111/j.1749-6632.2001.tb03564.x
   Becker JB, 2012, BIOL SEX DIFFER, V3, DOI 10.1186/2042-6410-3-14
   Berg UB, 2006, NEPHROL DIAL TRANSPL, V21, P2577, DOI 10.1093/ndt/gfl227
   Bergevin T, 2006, J GAMBL STUD, V22, P195, DOI 10.1007/s10899-006-9010-z
   Black DW, 2007, CNS SPECTRUMS, V12, P124, DOI 10.1017/S1092852900020630
   Block JJ, 2008, AM J PSYCHIAT, V165, P306, DOI 10.1176/appi.ajp.2007.07101556
   Blum K, 2011, CURR PHARM DESIGN, V17, P1158, DOI 10.2174/138161211795656819
   Boakes RA, 1997, Q J EXP PSYCHOL-B, V50, P129
   Boughton R, 2007, J GAMBL STUD, V23, P323, DOI 10.1007/s10899-007-9056-6
   BOWEN DJ, 1990, PHYSIOL BEHAV, V47, P287, DOI 10.1016/0031-9384(90)90144-S
   Bowman BP, 1999, J PHARMACOL EXP THER, V290, P1316
   Brandt A M, 1996, J Am Med Womens Assoc (1972), V51, P63
   Breiter HC, 2001, NEURON, V30, P619, DOI 10.1016/S0896-6273(01)00303-8
   Bruinsma K, 1999, J AM DIET ASSOC, V99, P1249, DOI 10.1016/S0002-8223(99)00307-7
   Carnes P J, 2000, CNS Spectr, V5, P63
   Carroll ME, 2010, HORM BEHAV, V58, P44, DOI 10.1016/j.yhbeh.2009.10.001
   Carroll ME, 2005, PSYCHOPHARMACOLOGY, V180, P414, DOI 10.1007/s00213-005-2182-x
   Carroll ME, 2004, TRENDS PHARMACOL SCI, V25, P273, DOI 10.1016/j.tips.2004.03.011
   Castelli M.P., 2013, CURR PHARM DES
   Cepeda MS, 2003, ANESTH ANALG, V97, P1464, DOI 10.1213/01.ANE.0000080153.36643.83
   Chambers R Andrew, 2003, J Gambl Stud, V19, P53, DOI 10.1023/A:1021275130071
   Chen ML, 2000, CLIN PHARMACOL THER, V68, P510, DOI 10.1067/mcp.2000.111184
   CHRISTENSON GA, 1994, J CLIN PSYCHIAT, V55, P5
   Cicero TJ, 1996, J PHARMACOL EXP THER, V279, P767
   Clark L, 2013, CURR OPIN NEUROBIOL, V23, P655, DOI 10.1016/j.conb.2013.01.004
   Cooper A, 2002, J SEX MARITAL THER, V28, P105, DOI 10.1080/00926230252851861
   Corsica JA, 2010, CURR OPIN GASTROEN, V26, P165, DOI 10.1097/MOG.0b013e328336528d
   Creutz LM, 2004, J COMP NEUROL, V476, P348, DOI 10.1002/cne.20229
   Creutz LM, 2002, J COMP NEUROL, V446, P288, DOI 10.1002/cne.10207
   Crippens D, 1999, ALCOHOL CLIN EXP RES, V23, P414, DOI 10.1111/j.1530-0277.1999.tb04131.x
   Crockford DN, 2005, BIOL PSYCHIAT, V58, P787, DOI 10.1016/j.biopsych.2005.04.037
   CUNNINGHAM JJ, 1982, AM J CLIN NUTR, V36, P721, DOI 10.1093/ajcn/36.4.721
   Dahan A, 2008, ANESTH ANALG, V107, P83, DOI 10.1213/ane.0b013e31816a66a4
   Daneback K, 2006, SEX ADDICT COMPULS, V13, P53, DOI 10.1080/10720160500529276
   Das A., 1995, Indian Journal of Physiology and Pharmacology, V39, P223
   Davis C, 2013, PHYSIOL BEHAV, V118, P63, DOI 10.1016/j.physbeh.2013.05.014
   Davis C, 2013, ADDICT BEHAV, V38, P2306, DOI 10.1016/j.addbeh.2013.02.012
   Davis C, 2009, APPETITE, V53, P1, DOI 10.1016/j.appet.2009.05.018
   Desai RA, 2008, SOC PSYCH PSYCH EPID, V43, P173, DOI 10.1007/s00127-007-0283-z
   Desai Rani A, 2005, Ann Clin Psychiatry, V17, P249, DOI 10.1080/10401230500295636
   Desai RA, 2006, PSYCHOL ADDICT BEHAV, V20, P145, DOI 10.1037/0893-164X.20.2.145
   Dettling A, 2007, ALCOHOL, V41, P415, DOI 10.1016/j.alcohol.2007.05.003
   Di Leone RJ, 2012, NAT NEUROSCI, V15, P1330, DOI 10.1038/nn.3202
   DiMeo AN, 2006, HORM BEHAV, V49, P519, DOI 10.1016/j.yhbeh.2005.11.003
   Donati MA, 2013, J ADOLESCENCE, V36, P129, DOI 10.1016/j.adolescence.2012.10.001
   Echeburua E, 2011, J GAMBL STUD, V27, P215, DOI 10.1007/s10899-010-9205-1
   European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2005, DIFF PATT DRUG US WO
   Fattore L, 2007, BRIT J PHARMACOL, V152, P795, DOI 10.1038/sj.bjp.0707465
   Fattore L, 2010, BRIT J PHARMACOL, V160, P724, DOI 10.1111/j.1476-5381.2010.00734.x
   Fattore L, 2009, PSYCHONEUROENDOCRI S, V34S, pS227, DOI DOI 10.1016/J.PSYNEUEN.2009.08.008
   Fattore L, 2008, WOMENS HEALTH, V4, P51, DOI 10.2217/17455057.4.1.51
   Fattore L, 2013, DRUG TEST ANAL, V5, P57, DOI 10.1002/dta.1401
   Franconi Flavia, 2012, Handb Exp Pharmacol, P107, DOI 10.1007/978-3-642-30726-3_6
   FURST DM, 1993, PERCEPT MOTOR SKILL, V77, P192, DOI 10.2466/pms.1993.77.1.192
   GAUDRY SE, 1993, CLIN PHARMACOL THER, V54, P23, DOI 10.1038/clpt.1993.104
   Gearhardt AN, 2009, J ADDICT MED, V3, P1, DOI 10.1097/ADM.0b013e318193c993
   Giargiari TD, 2005, ARCH SEX BEHAV, V34, P547, DOI 10.1007/s10508-005-6280-y
   Gillies GE, 2010, PHARMACOL REV, V62, P155, DOI 10.1124/pr.109.002071
   GOODMAN A, 1997, SUBSTANCE ABUSE COMP, P340
   GORDON JH, 1989, PHARMACOL BIOCHEM BE, V33, P123, DOI 10.1016/0091-3057(89)90440-1
   Goudriaan AE, 2010, PSYCHONEUROENDOCRINO, V35, P1416, DOI 10.1016/j.psyneuen.2010.04.005
   Grandi S, 2011, PSYCHIAT RES, V189, P270, DOI 10.1016/j.psychres.2011.02.025
   Grant JE, 2001, J CLIN PSYCHIAT, V62, P957, DOI 10.4088/JCP.v62n1207
   Grant JE, 2012, J PSYCHIATR RES, V46, P1206, DOI 10.1016/j.jpsychires.2012.05.013
   Grant JE, 2009, J PSYCHIATR RES, V43, P380, DOI 10.1016/j.jpsychires.2008.04.005
   Green KL, 1999, PHARMACOL BIOCHEM BE, V64, P379, DOI 10.1016/S0091-3057(99)00057-X
   Greenberg JL, 1999, ADDICT BEHAV, V24, P565, DOI 10.1016/S0306-4603(98)00080-X
   Greenblatt DJ, 2008, J CLIN PHARMACOL, V48, P1350, DOI 10.1177/0091270008323754
   Greenfield SF, 2010, PSYCHIAT CLIN N AM, V33, P339, DOI 10.1016/j.psc.2010.01.004
   GRUNBERG NE, 1991, HEALTH PSYCHOL, V10, P143, DOI 10.1037/0278-6133.10.2.143
   Gupta Rina, 1998, J Gambl Stud, V14, P319, DOI 10.1023/A:1023068925328
   Han DH, 2010, EXP CLIN PSYCHOPHARM, V18, P297, DOI 10.1037/a0020023
   Hashimoto JG, 2008, NEUROPSYCHOPHARMACOL, V33, P1084, DOI 10.1038/sj.npp.1301494
   Hoeft F, 2008, J PSYCHIATR RES, V42, P253, DOI 10.1016/j.jpsychires.2007.11.010
   Hoertel N, 2011, PSYCHIAT RES, V190, P352, DOI 10.1016/j.psychres.2011.05.045
   Hollander E., 1993, OBSESSIVE COMPULSIVE
   Hong SB, 2013, BEHAV BRAIN FUNCT, V9, DOI 10.1186/1744-9081-9-11
   Hu M, 2004, NEUROPSYCHOPHARMACOL, V29, P81, DOI 10.1038/sj.npp.1300301
   Huang GZ, 2012, NEURON, V74, P801, DOI 10.1016/j.neuron.2012.03.035
   Ibanez A, 2003, J CLIN PSYCHIAT, V64, P295, DOI 10.4088/JCP.v64n0311
   Jackson LR, 2006, NEUROPSYCHOPHARMACOL, V31, P129, DOI 10.1038/sj.npp.1300778
   Jacobs DF, 2004, GAMBLING PROBLEMS IN YOUTH: THEORETICAL AND APPLIED PERSPECTIVES, P1
   Jacobs E, 2011, J NEUROSCI, V31, P5286, DOI 10.1523/JNEUROSCI.6394-10.2011
   Jang MH, 2012, J SPEC PEDIATR NURS, V17, P288, DOI 10.1111/j.1744-6155.2012.00344.x
   Johansson A, 2004, SCAND J PSYCHOL, V45, P223, DOI 10.1111/j.1467-9450.2004.00398.x
   Johansson A, 2009, J GAMBL STUD, V25, P67, DOI 10.1007/s10899-008-9088-6
   Kelley AE, 2005, PHYSIOL BEHAV, V86, P11, DOI 10.1016/j.physbeh.2005.06.018
   Kessler RC, 2008, PSYCHOL MED, V38, P1351, DOI 10.1017/S0033291708002900
   Kim J, 2004, NAT NEUROSCI, V7, P697, DOI 10.1038/nn1262
   Kishimoto R, 2002, J NUTR SCI VITAMINOL, V48, P216, DOI 10.3177/jnsv.48.216
   Knutson B, 2007, NEURON, V53, P147, DOI 10.1016/j.neuron.2006.11.010
   Ko CH, 2012, EUR PSYCHIAT, V27, P1, DOI 10.1016/j.eurpsy.2010.04.011
   Ko Chih-Hung, 2005, Kaohsiung Journal of Medical Sciences, V21, P545
   Ko CH, 2013, J PSYCHIATR RES, V47, P486, DOI 10.1016/j.jpsychires.2012.11.008
   Ko CH, 2009, J PSYCHIATR RES, V43, P739, DOI 10.1016/j.jpsychires.2008.09.012
   Koepp MJ, 1998, NATURE, V393, P266, DOI 10.1038/30498
   Koran LM, 2006, AM J PSYCHIAT, V163, P1806, DOI 10.1176/appi.ajp.163.10.1806
   Kritzer MF, 1997, J COMP NEUROL, V379, P247, DOI 10.1002/(SICI)1096-9861(19970310)379:2<247::AID-CNE6>3.0.CO;2-3
   KRYCH R, 1989, ADV CONSUM RES, V16, P745
   LANCASTER FE, 1994, ALCOHOL CLIN EXP RES, V18, P740, DOI 10.1111/j.1530-0277.1994.tb00940.x
   Leeman RF, 2013, CAN J PSYCHIAT, V58, P260, DOI 10.1177/070674371305800503
   Leeman RF, 2011, NEUROPSYCHIATRY-LOND, V1, P133, DOI 10.2217/NPY.11.11
   Lejoyeux M, 1996, AM J PSYCHIAT, V153, P1524
   Lenz B, 2012, PROG NEUROBIOL, V96, P136, DOI 10.1016/j.pneurobio.2011.11.001
   Lesieur H. R., 1991, FEMINIST PERSPECTIVE, P181, DOI DOI 10.5860/CHOICE.29-3595
   LEVINE MP, 1988, J SEX RES, V25, P347, DOI 10.1080/00224498809551467
   LJUNGGREN H, 1957, Acta Endocrinol Suppl (Copenh), V25, P1
   Lukas SE, 1996, PSYCHOPHARMACOLOGY, V125, P346, DOI 10.1007/BF02246017
   Lynch WJ, 2004, ARCH GEN PSYCHIAT, V61, P1116, DOI 10.1001/archpsyc.61.11.1116
   Lynch WJ, 2002, PSYCHOPHARMACOLOGY, V164, P121, DOI 10.1007/s00213-002-1183-2
   MacLaren VV, 2010, ADDICT BEHAV, V35, P252, DOI 10.1016/j.addbeh.2009.09.023
   Mani SK, 2006, NEUROSCIENCE, V138, P773, DOI 10.1016/j.neuroscience.2005.07.034
   MARK ME, 1992, BRIT J ADDICT, V87, P549
   Marshall K., 2004, CANADIAN SOCIAL TREN, V73, P25
   Martins SS, 2008, AM J ADDICTION, V17, P126, DOI 10.1080/10550490701861227
   Matsuda G, 2006, NEUROIMAGE, V29, P706, DOI 10.1016/j.neuroimage.2005.08.019
   Melis M, 2007, EUR J NEUROSCI, V26, P2824, DOI 10.1111/j.1460-9568.2007.05887.x
   Melis M, 2013, ADDICT BIOL
   Melis M, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00093
   Mendelson JH, 1999, NEUROPSYCHOPHARMACOL, V21, P294, DOI 10.1016/S0893-133X(99)00020-2
   Mond JM, 2009, AUST NZ J PSYCHIAT, V43, P227, DOI 10.1080/00048670802653323
   MORISHIMA HO, 1993, J LAB CLIN MED, V122, P157
   MORISSETTE M, 1993, NEUROENDOCRINOLOGY, V58, P16, DOI 10.1159/000126507
   Mozley LH, 2001, AM J PSYCHIAT, V158, P1492, DOI 10.1176/appi.ajp.158.9.1492
   Nasser JA, 2011, PHYSIOL BEHAV, V104, P117, DOI 10.1016/j.physbeh.2011.04.040
   Olsen CM, 2011, NEUROPHARMACOLOGY, V61, P1109, DOI 10.1016/j.neuropharm.2011.03.010
   Panizzon MS, 2013, PSYCHONEUROENDOCRINO, V38, P2163, DOI 10.1016/j.psyneuen.2013.04.003
   Parlesak A, 2002, ALCOHOL ALCOHOLISM, V37, P388, DOI 10.1093/alcalc/37.4.388
   Pelchat ML, 2000, PHYSIOL BEHAV, V68, P353, DOI 10.1016/S0031-9384(99)00190-0
   Perry AN, 2013, HORM BEHAV, V64, P573, DOI 10.1016/j.yhbeh.2013.08.007
   Petry NM, 2005, J CLIN PSYCHIAT, V66, P564, DOI 10.4088/JCP.v66n0504
   Pilver CE, 2013, DRUG ALCOHOL DEPEN, V133, P204, DOI 10.1016/j.drugalcdep.2013.05.002
   Pogun Sakire, 2009, Handb Exp Pharmacol, P261, DOI 10.1007/978-3-540-69248-5_10
   Poletti M, 2013, J CLIN PSYCHOPHARM, V33, P691, DOI 10.1097/JCP.0b013e3182979830
   Poli R, 2012, NORD J PSYCHIAT, V66, P55, DOI 10.3109/08039488.2011.605169
   Porchet RI, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00138
   Potenza MN, 2006, J GAMBL STUD, V22, P41, DOI 10.1007/s10899-005-9002-4
   Potenza MN, 2006, ADDICTION, V101, P142, DOI 10.1111/j.1360-0443.2006.01591.x
   Potenza MN, 2001, AM J PSYCHIAT, V158, P1500, DOI 10.1176/appi.ajp.158.9.1500
   Quinones-Jenab V, 2012, ILAR J, V53, P14, DOI 10.1093/ilar.53.1.14
   Quinones-Jenab V, 2010, HORM BEHAV, V58, P22, DOI 10.1016/j.yhbeh.2009.10.002
   Regan PC, 2006, SOC BEHAV PERSONAL, V34, P95, DOI 10.2224/sbp.2006.34.1.95
   Russo SJ, 2003, NEUROSCIENCE, V120, P523, DOI 10.1016/S0306-4522(03)00317-8
   Santangelo G, 2013, PARKINSONISM RELAT D, V19, P645, DOI 10.1016/j.parkreldis.2013.02.007
   Sarton E, 2000, ANESTHESIOLOGY, V93, P1245, DOI 10.1097/00000542-200011000-00018
   Schaffer S D, 1990, Nurse Pract, V15, P25
   SCHLOSSER S, 1994, GEN HOSP PSYCHIAT, V16, P205, DOI 10.1016/0163-8343(94)90103-1
   Schoenbaum G, 1998, NAT NEUROSCI, V1, P155, DOI 10.1038/407
   Schreglmann SR, 2012, PARKINSONISM RELAT D, V18, P207, DOI 10.1016/j.parkreldis.2011.10.010
   Segarra AC, 2010, HORM BEHAV, V58, P33, DOI 10.1016/j.yhbeh.2009.12.003
   Shek DTL, 2012, SCI WORLD J, DOI 10.1100/2012/104304
   Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6
   SILVAGGIO T, 1994, J OCCUP ENVIRON MED, V36, P849
   Skegg K, 2010, ARCH SEX BEHAV, V39, P968, DOI 10.1007/s10508-009-9504-8
   Slutske WS, 2009, TWIN RES HUM GENET, V12, P425, DOI 10.1375/twin.12.5.425
   Snively TA, 2000, PSYCHONEUROENDOCRINO, V25, P677, DOI 10.1016/S0306-4530(00)00018-4
   Sofuoglu M, 1999, EXP CLIN PSYCHOPHARM, V7, P274, DOI 10.1037/1064-1297.7.3.274
   Soldin OP, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/187103
   Soldin OP, 2009, CLIN PHARMACOKINET, V48, P143, DOI 10.2165/00003088-200948030-00001
   Staley JK, 2001, SYNAPSE, V41, P275, DOI 10.1002/syn.1084
   Stanton SJ, 2011, HORM BEHAV, V59, P252, DOI 10.1016/j.yhbeh.2010.12.003
   Tang DW, 2012, PHYSIOL BEHAV, V106, P317, DOI 10.1016/j.physbeh.2012.03.009
   Tavares H, 2001, J Gambl Stud, V17, P151, DOI 10.1023/A:1016620513381
   Terner JM, 2006, DRUG ALCOHOL DEPEN, V84, P1, DOI 10.1016/j.drugalcdep.2005.12.007
   Thome Jennifer L, 2007, Eat Behav, V8, P334, DOI 10.1016/j.eatbeh.2006.11.009
   THOMPSON TL, 1994, J NEUROCHEM, V62, P1750
   Torresan RC, 2009, COMPR PSYCHIAT, V50, P63, DOI 10.1016/j.comppsych.2008.05.005
   Triemstra JL, 2004, BEHAV BRAIN RES, V154, P221, DOI 10.1016/j.bbr.2004.02.010
   Tschibelu E, 2011, J ADDICT DIS, V30, P81, DOI 10.1080/10550887.2010.531671
   Turner M, 2008, PSYCHIAT CLIN N AM, V31, P713, DOI 10.1016/j.psc.2008.06.004
   Uban KA, 2012, NEUROPSYCHOPHARMACOL, V37, P390, DOI 10.1038/npp.2011.176
   UNODC, 2013, WORLD DRUG REP
   van den Bos R, 2013, BEHAV BRAIN RES, V238, P95, DOI 10.1016/j.bbr.2012.10.002
   van Honk J, 2004, PSYCHONEUROENDOCRINO, V29, P937, DOI 10.1016/j.psyneuen.2003.08.007
   Vansickel AR, 2010, ADDICTION, V105, P727, DOI 10.1111/j.1360-0443.2009.02858.x
   Vasudevan N, 2008, FRONT NEUROENDOCRIN, V29, P238, DOI 10.1016/j.yfrne.2007.08.003
   Volkow ND, 2004, MOL PSYCHIATR, V9, P557, DOI 10.1038/sj.mp.4001507
   Volkow ND, 2002, BEHAV PHARMACOL, V13, P355, DOI 10.1097/00008877-200209000-00008
   Voon V, 2011, ANN NEUROL, V69, P986, DOI 10.1002/ana.22356
   Wang H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019660
   Weiss Howard D, 2012, Neurol Clin Pract, V2, P267
   Welte J, 2001, J STUD ALCOHOL, V62, P706, DOI 10.15288/jsa.2001.62.706
   Welte JW, 2004, J GAMBL STUD, V20, P405, DOI 10.1007/s10899-004-4582-y
   White MA, 2002, OBES RES, V10, P107, DOI 10.1038/oby.2002.17
   Winters J, 2010, ARCH SEX BEHAV, V39, P594, DOI 10.1007/s10508-010-9607-2
   Winters KC, 2002, PSYCHOL ADDICT BEHAV, V16, P3, DOI 10.1037//0893-164X.16.1.3
   Witt ED, 2007, NEUROTOXICOL TERATOL, V29, P81, DOI 10.1016/j.ntt.2006.10.013
   Wolbold R, 2003, HEPATOLOGY, V38, P978, DOI 10.1053/jhep.2003.50393
   Wong G, 2013, J GAMBL STUD, V29, P171, DOI 10.1007/s10899-012-9305-1
   Woolley CS, 2007, ANNU REV PHARMACOL, V47, P657, DOI 10.1146/annurev.pharmtox.47.120505.105219
   World Health Organization, 2010, WHO GLOB INF
   XIAO L, 1994, NEUROSCI LETT, V180, P155, DOI 10.1016/0304-3940(94)90510-X
   Yen JY, 2009, CYBERPSYCHOL BEHAV, V12, P187, DOI 10.1089/cpb.2008.0113
   Ziauddeen H, 2013, OBES REV, V14, P19, DOI 10.1111/j.1467-789X.2012.01046.x
   Zmijewski Christine F, 2003, Eat Behav, V4, P181, DOI 10.1016/S1471-0153(03)00022-9
NR 207
TC 147
Z9 151
U1 4
U2 136
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0091-3022
EI 1095-6808
J9 FRONT NEUROENDOCRIN
JI Front. Neuroendocrinol.
PD AUG
PY 2014
VL 35
IS 3
SI SI
BP 272
EP 284
DI 10.1016/j.yfrne.2014.04.003
PG 13
WC Endocrinology & Metabolism; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA AL2UC
UT WOS:000338980000003
PM 24769267
DA 2023-06-23
ER

PT J
AU Koob, GF
   Zorrilla, EP
AF Koob, George F.
   Zorrilla, Eric P.
TI Neurobiological mechanisms of addiction: Focus on
   corticotropin-releasing factor
SO CURRENT OPINION IN INVESTIGATIONAL DRUGS
LA English
DT Review
DE Addiction; corticotropin-releasing factor; drug relapse; drug
   withdrawal; stress
ID STRESS-INDUCED RELAPSE; ANXIETY-LIKE BEHAVIOR; VENTRAL TEGMENTAL AREA;
   CRF-BINDING-PROTEIN; WITHDRAWAL-INDUCED ANXIETY; ETHANOL WITHDRAWAL;
   FACTOR ANTAGONIST; RECEPTOR ANTAGONISTS; INDUCED INCREASES; COCAINE
   SEEKING
AB Drug addiction is a chronically relapsing disorder that is characterized by a compulsion to take drugs and loss of control in limiting intake. Medications that are on the market for the treatment of drug addiction target either the direct reinforcing effects of abuse (eg, naltrexone) or the consequent protracted abstinence syndrome (eg, acamprosate). Both conceptual and neurobiological advances in research have suggested that brain stress systems contribute to the withdrawal/negative affect and preoccupation/anticipation stages of the addiction cycle that promote the compulsivity of drug-taking in addiction. Validated animal models of the stress component of addiction and improved understanding of the neurocircuitry and neuropharmacological mechanisms involved in perturbations of this component suggest that corticotropin-releasing factor systems are a viable target for the development of future medications for drug addiction.
C1 [Koob, George F.; Zorrilla, Eric P.] Scripps Res Inst, Comm Neurobiol Addict Disorders, La Jolla, CA 92037 USA.
C3 Scripps Research Institute
RP Koob, GF (通讯作者)，Scripps Res Inst, Comm Neurobiol Addict Disorders, 10550 N Torrey Pines Rd,SP30-2400, La Jolla, CA 92037 USA.
EM gkoob@scripps.edu
FU Pearson Center for Alcoholism and Addiction Research; National Institute
   of Diabetes and Digestive and Kidney Diseases [DK26741]; National
   Institute on Alcohol Abuse and Alcoholism [AA06420]
FX This is publication number 20241 from The Scripps Research Institute.
   The authors were each supported by the Pearson Center for Alcoholism and
   Addiction Research, and NIH grants DK26741 from the National Institute
   of Diabetes and Digestive and Kidney Diseases and AA06420 from the
   National Institute on Alcohol Abuse and Alcoholism. The authors thank
   Michael Arends for assistance with the preparation of the manuscript.
CR ALLING C, 1982, ACTA PSYCHIAT SCAND, V66, P384, DOI 10.1111/j.1600-0447.1982.tb06720.x
   ALTSHULER HL, 1980, LIFE SCI, V26, P679, DOI 10.1016/0024-3205(80)90257-X
   Annis HM, 1998, ADDICT BEHAV, V23, P127, DOI 10.1016/S0306-4603(97)00024-5
   Bachteler D, 2005, NEUROPSYCHOPHARMACOL, V30, P1104, DOI 10.1038/sj.npp.1300657
   Bale TL, 2004, ANNU REV PHARMACOL, V44, P525, DOI 10.1146/annurev.pharmtox.44.101802.121410
   Barr CS, 2008, ARCH GEN PSYCHIAT, V65, P934, DOI 10.1001/archpsyc.65.8.934
   Basso AM, 1999, PSYCHOPHARMACOLOGY, V145, P21, DOI 10.1007/s002130051028
   BEHAN DP, 1995, FRONT NEUROENDOCRIN, V16, P362, DOI 10.1006/frne.1995.1013
   Binneman B, 2008, AM J PSYCHIAT, V165, P617, DOI 10.1176/appi.ajp.2008.07071199
   Blomeyer D, 2008, BIOL PSYCHIAT, V63, P146, DOI 10.1016/j.biopsych.2007.04.026
   Brown Z, 2009, PSYCHOPHARMACOLOGY, V203, P121, DOI 10.1007/s00213-008-1376-4
   Bruijnzeel AW, 2007, NEUROPSYCHOPHARMACOL, V32, P955, DOI 10.1038/sj.npp.1301192
   Bruijnzeel AW, 2009, BIOL PSYCHIAT, V66, P110, DOI 10.1016/j.biopsych.2009.01.010
   Bruijnzeel AW, 2005, BRAIN RES REV, V49, P505, DOI 10.1016/j.brainresrev.2005.01.007
   Caberlotto L, 2004, NEUROPSYCHOPHARMACOL, V29, P15, DOI 10.1038/sj.npp.1300296
   CHILDRESS AR, 1994, J SUBST ABUSE TREAT, V11, P17, DOI 10.1016/0740-5472(94)90060-4
   Chu K, 2007, PHARMACOL BIOCHEM BE, V86, P813, DOI 10.1016/j.pbb.2007.03.009
   Contarino A, 2005, P NATL ACAD SCI USA, V102, P18649, DOI 10.1073/pnas.0506999102
   Cooney NL, 1997, J ABNORM PSYCHOL, V106, P243, DOI 10.1037/0021-843X.106.2.243
   deFonseca FR, 1997, SCIENCE, V276, P2050, DOI 10.1126/science.276.5321.2050
   DUNN AJ, 1990, BRAIN RES REV, V15, P71, DOI 10.1016/0165-0173(90)90012-D
   Erb S, 1998, J NEUROSCI, V18, P5529, DOI 10.1523/JNEUROSCI.18-14-05529.1998
   Fekete EM, 2007, FRONT NEUROENDOCRIN, V28, P1, DOI 10.1016/j.yfrne.2006.09.002
   Funk CK, 2007, BIOL PSYCHIAT, V61, P78, DOI 10.1016/j.biopsych.2006.03.063
   Funk CK, 2006, J NEUROSCI, V26, P11324, DOI 10.1523/JNEUROSCI.3096-06.2006
   Gehlert DR, 2007, J NEUROSCI, V27, P2718, DOI 10.1523/JNEUROSCI.4985-06.2007
   George O, 2007, P NATL ACAD SCI USA, V104, P17198, DOI 10.1073/pnas.0707585104
   Ghitza UE, 2006, NEUROPSYCHOPHARMACOL, V31, P2188, DOI 10.1038/sj.npp.1300964
   Gilpin NW, 2008, ALCOHOL CLIN EXP RES, V32, P1535, DOI 10.1111/j.1530-0277.2008.00745.x
   Greenwell TN, 2009, ADDICT BIOL, V14, P130, DOI 10.1111/j.1369-1600.2008.00142.x
   Hahn J, 2009, J NEUROSCI, V29, P6535, DOI 10.1523/JNEUROSCI.4773-08.2009
   Hansson AC, 2006, P NATL ACAD SCI USA, V103, P15236, DOI 10.1073/pnas.0604419103
   Hansson AC, 2007, ADDICT BIOL, V12, P30, DOI 10.1111/j.1369-1600.2007.00050.x
   HEILIG M, 1994, TRENDS NEUROSCI, V17, P80, DOI 10.1016/0166-2236(94)90079-5
   HEIMER L, 1991, ADV EXP MED BIOL, V295, P1
   Heinrichs SC, 2004, J PHARMACOL EXP THER, V311, P427, DOI 10.1124/jpet.103.052092
   HEINRICHS SC, 1994, NEUROPSYCHOPHARMACOL, V11, P179, DOI 10.1038/sj.npp.1380104
   Held K, 2004, J PSYCHIATR RES, V38, P129, DOI 10.1016/S0022-3956(03)00076-1
   HERSHON HI, 1977, J STUD ALCOHOL, V38, P953, DOI 10.15288/jsa.1977.38.953
   Heyser CJ, 2003, NEUROPSYCHOPHARMACOL, V28, P1463, DOI 10.1038/sj.npp.1300175
   Ho SP, 2001, MOL BRAIN RES, V89, P29, DOI 10.1016/S0169-328X(01)00050-X
   Holsboer F, 2008, EUR J PHARMACOL, V583, P350, DOI 10.1016/j.ejphar.2007.12.032
   Ji D, 2008, BEHAV PHARMACOL, V19, P1, DOI 10.1097/FBP.0b013e3282f3cf70
   Knapp DJ, 2004, ALCOHOL, V32, P101, DOI 10.1016/j.alcohol.2003.08.007
   Koob G. F., 2001, INT J COMP PSYCHOL, V14, P90
   Koob G, 2007, AM J PSYCHIAT, V164, P1149, DOI 10.1176/appi.ajp.2007.05030503
   Koob GF, 2008, NEURON, V59, P11, DOI 10.1016/j.neuron.2008.06.012
   Koob GF, 2008, ANNU REV PSYCHOL, V59, P29, DOI 10.1146/annurev.psych.59.103006.093548
   Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442
   Koob GF, 1999, BRAIN RES, V848, P141, DOI 10.1016/S0006-8993(99)01991-5
   KOOB GF, 1994, SEMIN NEUROSCI, V6, P221
   Le AD, 2000, PSYCHOPHARMACOLOGY, V150, P317, DOI 10.1007/s002130000411
   LEMAGNEN J, 1987, ALCOHOL, V4, P97, DOI 10.1016/0741-8329(87)90005-X
   Liu X, 2002, J NEUROSCI, V22, P7856
   Lowman C, 1996, ADDICTION, V91, pS51, DOI 10.1111/j.1360-0443.1996.tb02327.x
   Lu L, 2003, NEUROSCI BIOBEHAV R, V27, P457, DOI 10.1016/S0149-7634(03)00073-3
   Marinelli PW, 2007, PSYCHOPHARMACOLOGY, V195, P345, DOI 10.1007/s00213-007-0905-x
   Marlatt G. A., 1980, BEHAV MED CHANGING H, P410, DOI DOI 10.1037/0022-3514.82.1.112
   MENZAGHI F, 1994, J PHARMACOL EXP THER, V269, P564
   Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006
   Olive MF, 2002, PHARMACOL BIOCHEM BE, V72, P213, DOI 10.1016/S0091-3057(01)00748-1
   Overstreet DH, 2004, PHARMACOL BIOCHEM BE, V77, P405, DOI 10.1016/j.pbb.2003.11.010
   Pelleymounter MA, 2000, J PHARMACOL EXP THER, V293, P799
   PICH EM, 1995, J NEUROSCI, V15, P5439
   Richardson HN, 2008, PHARMACOL BIOCHEM BE, V88, P497, DOI 10.1016/j.pbb.2007.10.008
   Richter RM, 1999, SYNAPSE, V32, P254, DOI 10.1002/(SICI)1098-2396(19990615)32:4<254::AID-SYN2>3.0.CO;2-H
   ROBERTO M, 2010, BIOL PSYCHI IN PRESS
   Sabino V, 2006, PSYCHOPHARMACOLOGY, V189, P175, DOI 10.1007/s00213-006-0546-5
   Sarnyai Z, 2001, PHARMACOL REV, V53, P209
   SARNYAI Z, 1995, BRAIN RES, V675, P89, DOI 10.1016/0006-8993(95)00043-P
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   Shaham Y, 1998, PSYCHOPHARMACOLOGY, V137, P184, DOI 10.1007/s002130050608
   Shaham Y, 1997, J NEUROSCI, V17, P2605
   Simms JA, 2008, ALCOHOL CLIN EXP RES, V32, P1816, DOI 10.1111/j.1530-0277.2008.00753.x
   Sinha R, 2000, PSYCHOPHARMACOLOGY, V152, P140, DOI 10.1007/s002130000499
   Skelton KH, 2007, PSYCHOPHARMACOLOGY, V192, P385, DOI 10.1007/s00213-007-0713-3
   Sommer WH, 2008, BIOL PSYCHIAT, V63, P139, DOI 10.1016/j.biopsych.2007.01.010
   Specio SE, 2008, PSYCHOPHARMACOLOGY, V196, P473, DOI 10.1007/s00213-007-0983-9
   Spina M, 1996, SCIENCE, V273, P1561, DOI 10.1126/science.273.5281.1561
   Spina MG, 2000, NEUROPSYCHOPHARMACOL, V22, P230, DOI 10.1016/S0893-133X(99)00108-6
   Steckler Thomas, 2006, CNS & Neurological Disorders-Drug Targets, V5, P147, DOI 10.2174/187152706776359619
   Stinus L, 2005, NEUROPSYCHOPHARMACOL, V30, P90, DOI 10.1038/sj.npp.1300487
   SWANSON LW, 1983, NEUROENDOCRINOLOGY, V36, P165, DOI 10.1159/000123454
   Tagliaferro P, 2008, J COMP NEUROL, V506, P616, DOI 10.1002/cne.21576
   Takahashi LK, 2001, BRAIN RES, V902, P135, DOI 10.1016/S0006-8993(01)02405-2
   Tucci S, 2003, PSYCHOPHARMACOLOGY, V167, P251, DOI 10.1007/s00213-003-1403-4
   Ungless MA, 2003, NEURON, V39, P401, DOI 10.1016/S0896-6273(03)00461-6
   Valdez GR, 2002, ALCOHOL CLIN EXP RES, V26, P1494, DOI 10.1097/01.ALC.0000033120.51856.F0
   Valdez GR, 2004, ALCOHOL CLIN EXP RES, V28, P865, DOI 10.1097/01.ALC.0000128222.29875.40
   Vanderschuren LJMJ, 2005, EUR J PHARMACOL, V526, P77, DOI 10.1016/j.ejphar.2005.09.037
   Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI 10.1093/cercor/10.3.318
   Wang B, 2005, J NEUROSCI, V25, P5389, DOI 10.1523/JNEUROSCI.0955-05.2005
   Wang B, 2007, PSYCHOPHARMACOLOGY, V193, P283, DOI 10.1007/s00213-007-0782-3
   Weiss F, 2001, ANN NY ACAD SCI, V937, P1, DOI 10.1111/j.1749-6632.2001.tb03556.x
   Zhao Y, 2007, J PHARMACOL EXP THER, V323, P846, DOI 10.1124/jpet.107.123208
   Zobel AW, 2000, J PSYCHIATR RES, V34, P171, DOI 10.1016/S0022-3956(00)00016-9
   Zorrilla EP, 2001, PSYCHOPHARMACOLOGY, V158, P374, DOI 10.1007/s002130100773
   Zorrilla EP, 2004, EXPERT OPIN INV DRUG, V13, P799, DOI 10.1517/13543784.13.7.799
   ZORRILLA EP, 2007, ENCY STRESS, P206
   Zywiak WH, 1996, ADDICTION, V91, pS121, DOI 10.1111/j.1360-0443.1996.tb02332.x
NR 100
TC 96
Z9 105
U1 2
U2 18
PU THOMSON REUTERS (SCIENTIFIC) LTD
PI LONDON
PA 77 HATTON GARDEN, LONDON, EC1N 8JS, ENGLAND
SN 1472-4472
EI 2040-3429
J9 CURR OPIN INVEST DR
JI Curr. Opin. Investig. Drugs
PD JAN
PY 2010
VL 11
IS 1
BP 63
EP 71
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 535OB
UT WOS:000272978900006
PM 20047160
DA 2023-06-23
ER

PT J
AU Jia, SH
   Guo, XT
   Chen, ZX
   Li, SP
   Liu, XA
AF Jia, Shuhui
   Guo, Xuantong
   Chen, Zuxin
   Li, Shupeng
   Liu, Xin-an
TI The roles of the circadian hormone melatonin in drug addiction
SO PHARMACOLOGICAL RESEARCH
LA English
DT Review
DE Melatonin; Drug Addiction; Circadian Rhythms
ID SUBSTANCE USE DISORDERS; METHAMPHETAMINE-INDUCED INHIBITION;
   MORPHINE-TOLERANCE; SUPRACHIASMATIC NUCLEUS; EPIGENETIC MECHANISMS;
   MOUSE HIPPOCAMPUS; OPIATE ADDICTION; COCAINE; SLEEP; RAT
AB Given the devastating social and health consequences of drug addiction and the limitations of current treatments, a new strategy is needed. Circadian system disruptions are frequently associated with drug addiction. Correcting abnormal circadian rhythms and improving sleep quality may thus be beneficial in the treatment of patients with drug addiction. Melatonin, an essential circadian hormone that modulates the biological clock, has anti-inflammatory, analgesic, anti-depressive, and neuroprotective effects via gut microbiota regulation and epigenetic modifications. It has attracted scientists' attention as a potential solution to drug abuse. This review summarized scientific evidence on the roles of melatonin in substance use disorders at the cellular, circuitry, and system levels, and discussed its potential applications as an intervention strategy for drug addiction.
C1 [Jia, Shuhui; Guo, Xuantong; Liu, Xin-an] Chinese Acad Sci, Brain Cognit & Brain Dis Inst BCBDI, Shenzhen Inst Adv Technol, Guangdong Prov Key Lab Brain Connectome & Behav,CA, Shenzhen, Peoples R China.
   [Chen, Zuxin] Brain Cognit & Brain Dis Inst, Shenzhen, Peoples R China.
   [Jia, Shuhui; Guo, Xuantong; Chen, Zuxin; Liu, Xin-an] Shenzhen Fundamental Res Inst, Shenzhen Hong Kong Inst Brain Sci, Shenzhen, Peoples R China.
   [Li, Shupeng] Univ Chinese Acad Sci, Beijing, Peoples R China.
   [Jia, Shuhui; Guo, Xuantong; Chen, Zuxin; Liu, Xin-an] Peking Univ Shenzhen Grad Sch, Sch Chem Biol & Biotechnol, State Key Lab Oncogen, Shenzhen, Peoples R China.
C3 Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology,
   CAS; Chinese Academy of Sciences; University of Chinese Academy of
   Sciences, CAS; Peking University Shenzhen Graduate School
RP Liu, XA (通讯作者)，Chinese Acad Sci, Brain Cognit & Brain Dis Inst BCBDI, Shenzhen Inst Adv Technol, Guangdong Prov Key Lab Brain Connectome & Behav,CA, Shenzhen, Peoples R China.; Chen, ZX (通讯作者)，Brain Cognit & Brain Dis Inst, Shenzhen, Peoples R China.
EM zx.chen3@siat.ac.cn; xa.liu@siat.ac.cn
OI CHEN, ZUXIN/0000-0002-5412-3140
FU National Natural Science Foundation of China (NSFC) [31900728, 32000710,
   U20A2016]; CAS Youth Innovation Fund [Y9G022]; Guangdong Provincial
   Natural Science Foundation [2019A1515110190]; Shenzhen Key Basic
   Research Project [JCYJ20200109115641762 ZC, ZDSYS20190902093601675]; CAS
   Key Laboratory of Brain [2019DP173024]; Guangdong Provincial Key
   Laboratory of Brain Connectome [2017B030301017]
FX This work was funded in part by the financial support from the Na-
   tional Natural Science Foundation of China (NSFC) (31900728 XL, 32000710
   ZC, U20A2016 ZC) , CAS Youth Innovation Fund (Y9G022 XL) , the Guangdong
   Provincial Natural Science Foundation (2019A1515110190 ZC) , Shenzhen
   Key Basic Research Project (JCYJ20200109115641762 ZC) , Shenzhen
   Governmental grant (ZDSYS20190902093601675) , CAS Key Laboratory of
   Brain Con- nectome and Manipulation (2019DP173024) ; Guangdong
   Provincial Key Laboratory of Brain Connectome and Behavior
   (2017B030301017) .
CR Adan A, 2013, J SUBST USE, V18, P171, DOI 10.3109/14659891.2011.632060
   Adan A, 2010, ADICCIONES, V22, P5, DOI 10.20882/adicciones.208
   Alghamdi BS, 2021, FRONT BEHAV NEUROSCI, V15, DOI 10.3389/fnbeh.2021.762297
   Ali T, 2020, FRONT MOL NEUROSCI, V13, DOI 10.3389/fnmol.2020.00096
   Allis CD, 2016, NAT REV GENET, V17, P487, DOI 10.1038/nrg.2016.59
   Alshehri FS, 2021, BRAIN BEHAV, V11, DOI 10.1002/brb3.2397
   Ambler M, 2022, J NEUROSCI, V42, P4267, DOI 10.1523/JNEUROSCI.2102-21.2022
   Anderson G., 2019, MELATONIN RES, V2, P1, DOI [10.32794/mr11250037, DOI 10.32794/MR11250037, 10.32794/mr11250037.]
   Anderson G, 2020, CURR TOP MED CHEM, V20, P524, DOI 10.2174/1568026620666200131094445
   Anderson G, 2020, PROG NEURO-PSYCHOPH, V98, DOI 10.1016/j.pnpbp.2019.109782
   Angarita GA, 2014, DRUG ALCOHOL DEPEN, V134, P343, DOI 10.1016/j.drugalcdep.2013.11.007
   Angoa-Perez M, 2021, PHARMACOL REV, V73, P571, DOI 10.1124/pharmrev.120.000144
   Auty SG, 2022, DRUG ALCOHOL DEPEN, V232, DOI 10.1016/j.drugalcdep.2022.109340
   Bahna SG, 2018, BRIT J PHARMACOL, V175, P3209, DOI 10.1111/bph.14058
   Bahna SG, 2017, EUR NEUROPSYCHOPHARM, V27, P828, DOI 10.1016/j.euroneuro.2017.06.002
   Barbosa-Mendez S, 2020, BRAZ J PSYCHIAT, V42, P295, DOI 10.1590/1516-4446-2018-0400
   Bart G, 2012, J ADDICT DIS, V31, P207, DOI 10.1080/10550887.2012.694598
   Bayraktar G, 2018, NEUROSCIENTIST, V24, P171, DOI 10.1177/1073858417707457
   Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609
   Berson A, 2018, TRENDS NEUROSCI, V41, P587, DOI 10.1016/j.tins.2018.05.005
   Bowman GD, 2015, CHEM REV, V115, P2274, DOI 10.1021/cr500350x
   BRICK J, 1984, ALCOHOL CLIN EXP RES, V8, P204, DOI 10.1111/j.1530-0277.1984.tb05840.x
   Cannella N, 2018, J NEUROSCI, V38, P7516, DOI 10.1523/JNEUROSCI.0600-18.2018
   Cervantes M, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2117113119
   Chavan SS, 2017, IMMUNITY, V46, P927, DOI 10.1016/j.immuni.2017.06.008
   Chen B, 2015, J NEUROSCI, V35, P13300, DOI 10.1523/JNEUROSCI.1065-15.2015
   Chen IJ, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9090780
   Chen YC, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136718
   Cheng WY, 2022, AGEING RES REV, V78, DOI 10.1016/j.arr.2022.101620
   Cheng YC, 2019, INT J MOL MED, V43, P791, DOI 10.3892/ijmm.2018.4030
   Chu C, 2020, IMMUNITY, V52, P464, DOI 10.1016/j.immuni.2020.02.017
   Comai S, 2019, PHARMACOL RES, V144, P343, DOI 10.1016/j.phrs.2019.04.015
   Comai S, 2014, J PSYCHIATR NEUROSCI, V39, P6, DOI 10.1503/jpn.130009
   Cruz-Lebron A, 2021, GUT MICROBES, V13, DOI 10.1080/19490976.2021.1946368
   Doyle SE, 2015, PSYCHOPHARMACOLOGY, V232, P2169, DOI 10.1007/s00213-014-3845-2
   Duan LR, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00866
   Egervari G, 2018, NEUROSCI BIOBEHAV R, V85, P117, DOI 10.1016/j.neubiorev.2017.05.019
   Ekthuwapranee K, 2015, J PINEAL RES, V58, P418, DOI 10.1111/jpi.12225
   Esposito E, 2020, NATURE, V582, P395, DOI 10.1038/s41586-020-2348-z
   Estrada-Reyes R, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082278
   Evely KM, 2016, SYNAPSE, V70, P181, DOI 10.1002/syn.21892
   Falcon E, 2009, NEUROPHARMACOLOGY, V56, P91, DOI 10.1016/j.neuropharm.2008.06.054
   Feng Y, 2020, INT J NEUROSCI, V130, P391, DOI 10.1080/00207454.2019.1692833
   Feng YM, 2013, AUTOPHAGY, V9, P1395, DOI 10.4161/auto.25468
   Forde LA, 2017, J STUD ALCOHOL DRUGS, V78, P645, DOI 10.15288/jsad.2017.78.645
   Friedman J, 2021, AM J PUBLIC HEALTH, V111, P1284, DOI [10.2105/AJPH.2021.306256), 10.2105/AJPH.2021.306256]
   Gao T, 2019, J PINEAL RES, V67, DOI 10.1111/jpi.12574
   Garmabi B, 2016, NEUROSCIENCE, V322, P104, DOI 10.1016/j.neuroscience.2016.02.019
   GELLER I, 1971, SCIENCE, V173, P456, DOI 10.1126/science.173.3995.456
   Gendy MNS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65166-y
   Geoffroy PA, 2020, J PSYCHIATR RES, V124, P34, DOI 10.1016/j.jpsychires.2020.02.018
   Ghaderi A, 2019, ADDICT BIOL, V24, P754, DOI 10.1111/adb.12650
   Golombek DA, 2015, EUR J PHARMACOL, V762, P42, DOI 10.1016/j.ejphar.2015.05.032
   Hablitz LM, 2014, J PHYSIOL-LONDON, V592, P5079, DOI 10.1113/jphysiol.2014.282079
   Hablitz LM, 2015, J NEUROSCI, V35, P14957, DOI 10.1523/JNEUROSCI.1597-15.2015
   Hamilton PJ, 2019, CURR OPIN NEUROBIOL, V59, P128, DOI 10.1016/j.conb.2019.05.005
   Han J, 2008, EUR J PHARMACOL, V594, P125, DOI 10.1016/j.ejphar.2008.07.049
   Hardeland R, 2015, PROG NEUROBIOL, V127, P46, DOI 10.1016/j.pneurobio.2015.02.001
   Hasler BP, 2012, SLEEP MED REV, V16, P67, DOI 10.1016/j.smrv.2011.03.004
   He F, 2021, J MED CHEM, V64, P3794, DOI 10.1021/acs.jmedchem.0c01940
   Heilig M, 2021, NEUROPSYCHOPHARMACOL, V46, P1715, DOI 10.1038/s41386-020-00950-y
   Hemati K, 2021, FUND CLIN PHARMACOL, V35, P25, DOI 10.1111/fcp.12566
   Hirotsu C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32276-7
   Horton WJ, 2015, PSYCHOPHARMACOLOGY, V232, P2519, DOI 10.1007/s00213-015-3886-1
   Huh JR, 2020, NAT REV IMMUNOL, V20, P217, DOI 10.1038/s41577-019-0247-z
   Im HI, 2010, NAT NEUROSCI, V13, P1120, DOI 10.1038/nn.2615
   Jadhav KS, 2018, NEUROPHARMACOLOGY, V141, P249, DOI 10.1016/j.neuropharm.2018.08.026
   Jin CJ, 2016, BRIT J NUTR, V116, P1682, DOI 10.1017/S0007114516004025
   Kim J, 2017, MOL CELLS, V40, P450, DOI 10.14348/molcells.2017.0065
   Kiraly DD, 2016, SCI REP-UK, V6, DOI 10.1038/srep35455
   Klein DC, 2007, J BIOL CHEM, V282, P4233, DOI 10.1074/jbc.R600036200
   Koob GF, 2016, LANCET PSYCHIAT, V3, P760, DOI 10.1016/S2215-0366(16)00104-8
   Kowatch Robert A., 1992, Journal of Addictive Diseases, V11, P21
   Kuhlwein E, 2003, BIOL PSYCHIAT, V54, P1437, DOI 10.1016/S0006-3223(03)00005-2
   Lader M, 2016, CURR PSYCHIAT REP, V18, DOI 10.1007/s11920-015-0642-5
   LaPlant Q, 2010, NAT NEUROSCI, V13, P1137, DOI 10.1038/nn.2619
   Lee K, 2018, NEUROPSYCHOPHARMACOL, V43, P2606, DOI 10.1038/s41386-018-0211-9
   Lee MJ, 2013, J NEURAL TRANSM, V120, P733, DOI 10.1007/s00702-012-0929-1
   Lepack AE, 2020, SCIENCE, V368, P197, DOI 10.1126/science.aaw8806
   Lerner A, 2019, BRAIN COMMUN, V1, DOI 10.1093/braincomms/fcz025
   Levine A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003062
   Li TJ, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12475
   Li X, 2017, NEUROSCIENCE, V364, P45, DOI 10.1016/j.neuroscience.2017.07.064
   Lin SH, 2016, LIFE SCI, V152, P38, DOI 10.1016/j.lfs.2016.03.032
   Liu QJ, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101560
   Liu SP, 2022, J PINEAL RES, V73, DOI 10.1111/jpi.12812
   Liu X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033822
   Logan RW, 2019, NAT REV NEUROSCI, V20, P49, DOI 10.1038/s41583-018-0088-y
   Logan RW, 2018, BIOL PSYCHIAT, V83, P987, DOI 10.1016/j.biopsych.2017.11.035
   Lopez-Otin C, 2021, CELL, V184, P33, DOI 10.1016/j.cell.2020.11.034
   Lwin T, 2021, PROG NEURO-PSYCHOPH, V111, DOI 10.1016/j.pnpbp.2020.110109
   Madsen MT, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1806-x
   Mathews HL, 2019, PSYCHOPHARMACOLOGY, V236, P1335, DOI 10.1007/s00213-018-5139-6
   de Mesquita LSM, 2017, TOXICOL RES-UK, V6, P420, DOI 10.1039/c7tx00009j
   Mohammadghasemi F, 2018, IRAN J BASIC MED SCI, V21, P639, DOI 10.22038/IJBMS.2018.28111.6829
   Molas S, 2017, TRENDS PHARMACOL SCI, V38, P169, DOI 10.1016/j.tips.2016.11.001
   Musiek ES, 2016, SCIENCE, V354, P1004, DOI 10.1126/science.aah4968
   Nestler EJ, 2019, NEURON, V102, P48, DOI 10.1016/j.neuron.2019.01.016
   Nestler EJ, 2014, NEUROPHARMACOLOGY, V76, P259, DOI 10.1016/j.neuropharm.2013.04.004
   Onaolapo OJ, 2018, WORLD J PSYCHIATR, V8, P64, DOI 10.5498/wjp.v8.i2.64
   Pacesova D, 2016, PHYSIOL RES, V65, P517, DOI 10.33549/physiolres.933183
   Palmer RHC, 2021, GENES BRAIN BEHAV, V20, DOI 10.1111/gbb.12738
   Parameyong A, 2015, MITOCHONDRION, V24, P1, DOI 10.1016/j.mito.2015.07.004
   Park G, 2016, J BIOL CHEM, V291, P3531, DOI 10.1074/jbc.M115.675488
   Patke A, 2020, NAT REV MOL CELL BIO, V21, P67, DOI 10.1038/s41580-019-0179-2
   Patterson F, 2019, NICOTINE TOB RES, V21, P139, DOI 10.1093/ntr/ntx236
   Paul R, 2018, LIFE SCI, V192, P238, DOI 10.1016/j.lfs.2017.11.016
   Peres R, 2011, ADDICT BIOL, V16, P580, DOI 10.1111/j.1369-1600.2011.00342.x
   Raghavendra V, 1999, BRAIN RES, V834, P178, DOI 10.1016/S0006-8993(99)01520-6
   Raghavendra V, 2000, EUR J PHARMACOL, V409, P279, DOI 10.1016/S0014-2999(00)00849-9
   Rather ZA, 2015, INDIAN J PHARMACOL, V47, P383, DOI 10.4103/0253-7613.161259
   Reinke H, 2019, NAT REV MOL CELL BIO, V20, P227, DOI 10.1038/s41580-018-0096-9
   Renthal W, 2007, NEURON, V56, P517, DOI 10.1016/j.neuron.2007.09.032
   Renthal W, 2009, NEURON, V62, P335, DOI 10.1016/j.neuron.2009.03.026
   Robison AJ, 2011, NAT REV NEUROSCI, V12, P623, DOI 10.1038/nrn3111
   Roehrs T, 2021, PHARMACOL BIOCHEM BE, V203, DOI 10.1016/j.pbb.2021.173153
   Saad L, 2021, GENES-BASEL, V12, DOI 10.3390/genes12081263
   Saadat Seyedeh Nazanin Seyed, 2014, Interdiscip Toxicol, V7, P41, DOI 10.2478/intox-2014-0007
   Schroeder FA, 2008, NEUROPSYCHOPHARMACOL, V33, P2981, DOI 10.1038/npp.2008.15
   Shen SM, 2020, TOXICOL LETT, V321, P73, DOI 10.1016/j.toxlet.2019.12.020
   Shukla M, 2019, ANN NY ACAD SCI, V1443, P75, DOI 10.1111/nyas.14005
   Singhakumar R, 2015, NEUROSCI LETT, V606, P209, DOI 10.1016/j.neulet.2015.09.011
   Sircar R, 2000, BRAIN RES, V857, P295, DOI 10.1016/S0006-8993(99)02460-9
   Slyepchenko A, 2016, CURR PHARM DESIGN, V22, P6087, DOI 10.2174/1381612822666160922165706
   Song L, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/1471-2253-15-12
   Spadola CE, 2019, SLEEP, V42, DOI 10.1093/sleep/zsz136
   Stephenson-Jones M, 2012, P NATL ACAD SCI USA, V109, pE164, DOI 10.1073/pnas.1119348109
   Stevens L, 2014, J SUBST ABUSE TREAT, V47, P58, DOI 10.1016/j.jsat.2014.01.008
   Stewart AF, 2021, CSH PERSPECT MED, V11, DOI 10.1101/cshperspect.a040253
   Su LY, 2021, MOL NEUROBIOL, DOI 10.1007/s12035-021-02448-0
   Sun LL, 2022, NEURON, V110, P2139, DOI 10.1016/j.neuron.2022.04.010
   Szutorisz H, 2022, NEURON, V110, P1611, DOI 10.1016/j.neuron.2022.03.018
   Takahashi TT, 2017, PSYCHOPHARMACOLOGY, V234, P1741, DOI 10.1007/s00213-017-4576-y
   Tamura EK, 2021, PHARMACOL BIOCHEM BE, V201, DOI 10.1016/j.pbb.2021.173105
   Teichman EM, 2020, CELL METAB, V31, P448, DOI 10.1016/j.cmet.2020.02.008
   Tiffany ST, 2012, ANN NY ACAD SCI, V1248, P1, DOI 10.1111/j.1749-6632.2011.06298.x
   Tunay DL, 2020, BOSNIAN J BASIC MED, V20, P117, DOI 10.17305/bjbms.2019.4379
   Uz T, 2005, NEUROSCIENCE, V134, P1309, DOI 10.1016/j.neuroscience.2005.05.003
   Uz T, 2003, NEUROPSYCHOPHARMACOL, V28, P2117, DOI 10.1038/sj.npp.1300254
   Vargas AM, 2020, MOL IMMUNOL, V121, P159, DOI 10.1016/j.molimm.2020.03.013
   Vengeliene V, 2015, NEUROPSYCHOPHARMACOL, V40, P2897, DOI 10.1038/npp.2015.143
   Vestad B, 2022, J INTERN MED, V291, P801, DOI 10.1111/joim.13458
   Volkow ND, 2015, CELL, V162, P712, DOI 10.1016/j.cell.2015.07.046
   Wang DQ, 2019, BEHAV BRAIN RES, V363, P61, DOI 10.1016/j.bbr.2019.01.035
   Wang N, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.838941
   Wang QQ, 2021, MOL PSYCHIATR, V26, P30, DOI 10.1038/s41380-020-00880-7
   Wang YF, 2018, AGING-US, V10, P463, DOI 10.18632/aging.101405
   Wang YC, 2019, BRAIN RES, V1715, P196, DOI 10.1016/j.brainres.2019.04.002
   Wise RA, 2014, NEUROPSYCHOPHARMACOL, V39, P254, DOI 10.1038/npp.2013.261
   Wongprayoon P, 2015, NEUROTOXICOLOGY, V50, P122, DOI 10.1016/j.neuro.2015.08.008
   Wu JT, 2016, PROG NEURO-PSYCHOPH, V65, DOI 10.1016/j.pnpbp.2015.09.008
   Xin W, 2012, INT J NEUROSCI, V122, P154, DOI 10.3109/00207454.2011.635828
   Xu PF, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12399
   Xu WJ, 2021, PSYCHOPHARMACOLOGY, V238, P2313, DOI 10.1007/s00213-021-05854-3
   Yahyavi-Firouz-Abadi N, 2007, J PINEAL RES, V42, P323, DOI 10.1111/j.1600-079X.2007.00422.x
   Yahyavi-Firouz-Abadi N, 2007, EPILEPSY RES, V75, P138, DOI 10.1016/j.eplepsyres.2007.05.002
   Yamada H, 1998, J NEUROSCI, V18, P4946
   Yan BA, 2017, SCI REP-UK, V7, DOI 10.1038/srep40413
   Yilmaz H, 2018, IRAN J BASIC MED SCI, V21, P787, DOI 10.22038/IJBMS.2018.26705.6539
   Yin J, 2018, J PINEAL RES, V65, DOI 10.1111/jpi.12524
   Yu Chang-Xi, 2000, Shengli Xuebao, V52, P263
   Yuodelis-Flores C, 2015, AM J ADDICTION, V24, P98, DOI 10.1111/ajad.12185
   Zaki NFW, 2018, EUR ARCH PSY CLIN N, V268, P107, DOI 10.1007/s00406-017-0835-5
   Zhang KK, 2022, FOOD CHEM TOXICOL, V166, DOI 10.1016/j.fct.2022.113208
   Zhdanova IV, 2002, BRAIN RES, V956, P323, DOI 10.1016/S0006-8993(02)03565-5
   Zunhammer M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109490
NR 166
TC 2
Z9 2
U1 18
U2 26
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
EI 1096-1186
J9 PHARMACOL RES
JI Pharmacol. Res.
PD SEP
PY 2022
VL 183
AR 106371
DI 10.1016/j.phrs.2022.106371
EA JUL 2022
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 3S2EQ
UT WOS:000839414700002
PM 35907435
DA 2023-06-23
ER

PT J
AU Zheng, F
   Zhan, CG
AF Zheng, Fang
   Zhan, Chang-Guo
TI Are pharmacokinetic approaches feasible for treatment of cocaine
   addiction and overdose?
SO FUTURE MEDICINAL CHEMISTRY
LA English
DT Editorial Material
DE drug abuse; drug addiction; drug metabolism; drug overdose;
   pharmacokinetic agent; therapeutic enzyme
ID HUMAN BUTYRYLCHOLINESTERASE; ABUSE; TOXICITY; ANTIBODY; ESTERASE; RATS
C1 [Zheng, Fang; Zhan, Chang-Guo] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
C3 University of Kentucky
RP Zhan, CG (通讯作者)，Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 789 S Limestone St, Lexington, KY 40536 USA.
EM zhan@uky.edu
RI ZHENG, FANG/HJZ-0472-2023
FU NIDA NIH HHS [R01DA025100, R01 DA025100, R01 DA032910, R01 DA035552, R01
   DA021416, R01 DA013930] Funding Source: Medline
CR BARNETT G, 1981, J ETHNOPHARMACOL, V3, P353, DOI 10.1016/0378-8741(81)90063-5
   Brimijoin S, 2008, NEUROPSYCHOPHARMACOL, V33, P2715, DOI 10.1038/sj.npp.1301666
   Collins GT, 2011, NEUROPSYCHOPHARMACOL, V36, P1047, DOI 10.1038/npp.2010.242
   Columbia University University of Kentucky and University of Michigan, 2008, PCT Int. Appl., Patent No. [WO/2008/008358, 2008008358]
   Fowler JS, 2007, J NUCL MED, V48, P1724, DOI 10.2967/jnumed.107.040279
   Gao DQ, 2009, MOL PHARMACOL, V75, P318, DOI 10.1124/mol.108.049486
   Gao Y, 2009, J PHARMACOL EXP THER, V330, P449, DOI 10.1124/jpet.109.152231
   Gorelick DA, 2004, DRUGS, V64, P1547, DOI 10.2165/00003495-200464140-00004
   Huang XQ, 2009, J PHYS CHEM B, V113, P15057, DOI 10.1021/jp900963n
   Kinsey BM, 2010, EXPERT REV VACCINES, V9, P1109, DOI 10.1586/ERV.10.102
   LANDRY DW, 1993, SCIENCE, V259, P1899, DOI 10.1126/science.8456315
   Moreno AY, 2009, PHARMACOL BIOCHEM BE, V92, P199, DOI 10.1016/j.pbb.2009.01.015
   Norman AB, 2009, J PHARMACOL EXP THER, V328, P873, DOI 10.1124/jpet.108.146407
   Pan YM, 2005, P NATL ACAD SCI USA, V102, P16656, DOI 10.1073/pnas.0507332102
   Schmitt KC, 2010, ANN NY ACAD SCI, V1187, P316, DOI 10.1111/j.1749-6632.2009.05148.x
   Teva Pharmaceutical Industries Ltd, 2011, Patent No. [PCT WO 2011/071926 A1, 2011071926, WO 2011/071926 A1]
   United Nations, 2011, UN PUBL
   University of Kentucky, 2011, [No title captured], Patent No. [US7919082, 7919082]
   University of Kentucky, 2008, [No title captured], Patent No. [US7438904, 7438904]
   University of Kentucky, 2010, [No title captured], Patent No. [US7731957, 7731957]
   Xue L, 2011, MOL PHARMACOL, V79, P290, DOI 10.1124/mol.110.068494
   Zheng F, 2008, J AM CHEM SOC, V130, P12148, DOI 10.1021/ja803646t
NR 22
TC 47
Z9 48
U1 0
U2 7
PU FUTURE SCI LTD
PI LONDON
PA UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND
SN 1756-8919
J9 FUTURE MED CHEM
JI Future Med. Chem.
PD FEB
PY 2012
VL 4
IS 2
BP 125
EP 128
DI 10.4155/FMC.11.171
PG 4
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 911YA
UT WOS:000301759400001
PM 22300091
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Nordstrom, BR
   Williams, AR
AF Nordstrom, Benjamin R.
   Williams, A. R.
TI Drug Treatments in Criminal Justice Settings
SO PSYCHIATRIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Drug addiction; Addiction treatment; Coerced treatment; Drug crime
ID TREATMENT OUTCOME RESEARCH; METHADONE-MAINTENANCE PATIENTS; CONTINGENCY
   MANAGEMENT; FOLLOW-UP; NARCOTIC ADDICTS; RHESUS-MONKEYS; ALTERNATIVE
   REINFORCERS; ABUSE TREATMENT; THERAPEUTIC WORKPLACE; COCAINE DEPENDENCE
AB Studies report that the direct effect of drug-related crime (ie, not including the cost of arrest, prosecution, and incarceration) is the largest single cost related to addiction. Addiction to illicit substances and its connection to people going through the criminal justice system are discussed in this review. Emphasis is on the efficacy of drug treatment in offender populations. Outcomes from large national studies and smaller studies are presented that deal with addiction treatment and criminal offenses; also discussed are operant conditioning in drug addiction, contingency management in a criminal justice context, coercion in the criminal justice setting, and drug courts.
C1 [Nordstrom, Benjamin R.] DHMC, Dartmouth Med Sch, Lebanon, NH 03756 USA.
   [Williams, A. R.] NYU, New York, NY USA.
C3 Dartmouth College; New York University
RP Nordstrom, BR (通讯作者)，DHMC, Dartmouth Med Sch, 1 Med Ctr Dr, Lebanon, NH 03756 USA.
EM benjamins.r.nordstrom@dartmouth.edu
RI Williams, Arthur Robin/H-8511-2019
OI Williams, Arthur Robin/0000-0002-7380-6203
CR ANGLIN MD, 1991, BEHAV SCI LAW, V9, P243, DOI 10.1002/bsl.2370090304
   ANGLIN MD, 1998, OFF NAT DRUG CONTR P
   Anker A L, 1982, NIDA Res Monogr, V41, P452
   Ball J C, 1984, NIDA Res Monogr, V49, P305
   BALL JC, 1983, DRUG ALCOHOL DEPEN, V12, P119, DOI 10.1016/0376-8716(83)90037-6
   BELENKO S, 2001, NATL DRUG COURT I RE, V4, P1
   BELL J, 1992, BRIT J ADDICT, V87, P251
   Bell J, 1997, J SUBST ABUSE, V9, P15, DOI 10.1016/S0899-3289(97)90003-1
   BUDNEY AJ, 1991, J APPL BEHAV ANAL, V24, P657, DOI 10.1901/jaba.1991.24-657
   Budney AJ, 2000, J CONSULT CLIN PSYCH, V68, P1051, DOI 10.1037/0022-006X.68.6.1051
   *BUR JUST STAT, 1998, SUBST AB TREATM AD P
   *BUR JUST STAT, 1999, MENT HLTH TREATM INM
   Burdon WM, 2001, J DRUG ISSUES, V31, P73, DOI 10.1177/002204260103100105
   Bureau of Justice Assistance Office of Justice Programs and US Department of Justice, 2009, BJA DRUG COURT CLEAR
   Bureau of Justice Statistics, 1999, SUBST AB TREATM STAT
   Bureau of Justice Statistics, 2005, SUBST DEP AB TREATM
   Bureau of Justice Statistics, 2006, DRUG US DEP STAT FED
   Campbell UC, 1998, PSYCHOPHARMACOLOGY, V137, P132, DOI 10.1007/s002130050602
   CARROLL ME, 1993, PSYCHOPHARMACOLOGY, V110, P5, DOI 10.1007/BF02246944
   Comer SD, 1997, BEHAV PHARMACOL, V8, P677, DOI 10.1097/00008877-199712000-00002
   Cornish JW, 1997, J SUBST ABUSE TREAT, V14, P529, DOI 10.1016/S0740-5472(97)00020-2
   Crowley T J, 1984, NIDA Res Monogr, V46, P68
   Crowley TJ, 1998, DRUG ALCOHOL DEPEN, V49, P225, DOI 10.1016/S0376-8716(98)00016-7
   Deschenes EP, 1995, JUSTICE SYST J, V18, P55, DOI 10.1080/23277556.1995.10871222
   DOLAN MP, 1985, J CONSULT CLIN PSYCH, V53, P549, DOI 10.1037/0022-006X.53.4.549
   Donny EC, 2004, PSYCHOPHARMACOLOGY, V172, P316, DOI 10.1007/s00213-003-1655-z
   Donny EC, 2003, DRUG ALCOHOL DEPEN, V69, P289, DOI 10.1016/S0376-8716(02)00327-7
   Evans SM, 2003, PHARMACOL BIOCHEM BE, V74, P723, DOI 10.1016/S0091-3057(02)01070-5
   Farabee D, 2001, J ADOLESCENT RES, V16, P679, DOI 10.1177/0743558401166009
   Federal Bureau of Investigation, 2008, UN CRIM REP 2007
   Federal Bureau of Prisons, 2009, QUICK FACTS BUR PRIS
   Flynn PM, 1997, PSYCHOL ADDICT BEHAV, V11, P230, DOI 10.1037/0893-164X.11.4.230
   Foltin FW, 1999, J EXP ANAL BEHAV, V72, P215, DOI 10.1901/jeab.1999.72-215
   Gossop M, 2000, DRUG ALCOHOL DEPEN, V60, P275, DOI 10.1016/S0376-8716(00)00109-5
   Gossop M, 1998, BRIT J PSYCHIAT, V173, P166, DOI 10.1192/bjp.173.2.166
   Gossop M, 2002, ADDICT BEHAV, V27, P155, DOI 10.1016/S0306-4603(00)00174-X
   Gossop M, 2003, ADDICTION, V98, P291, DOI 10.1046/j.1360-0443.2003.00296.x
   Gossop M, 2000, DRUG ALCOHOL DEPEN, V58, P165, DOI 10.1016/S0376-8716(99)00077-0
   Gottfredson D. C., 2003, CRIMINOL PUBLIC POL, V2, P171, DOI DOI 10.1111/J.1745-9133.2003.TB00117.X
   Gottfredson DC, 2005, EVALUATION REV, V29, P42, DOI 10.1177/0193841X04269908
   Gottfredson DC, 2002, J RES CRIME DELINQ, V39, P337, DOI 10.1177/002242780203900304
   GOTTFREDSON DC, 2006, J EXPT CRIMINOLOGY, V2, P67, DOI DOI 10.1007/s11292-005-5128-8
   Grant BF, 1996, J SUBST ABUSE, V8, P195, DOI 10.1016/S0899-3289(96)90249-7
   Griffith JD, 2000, DRUG ALCOHOL DEPEN, V58, P55, DOI 10.1016/S0376-8716(99)00068-X
   GROVE RN, 1974, PHARMACOL BIOCHEM BE, V2, P199, DOI 10.1016/0091-3057(74)90053-7
   HALL W, 1993, DRUG ALCOHOL DEPEN, V31, P123, DOI 10.1016/0376-8716(93)90064-W
   Harrell A., 2003, IMPACT EVALUATION MA
   HARRELL AV, 1998, FINAL REPORT FINDING
   Harrison LD, 2001, CRIME DELINQUENCY, V47, P462, DOI 10.1177/0011128701047003010
   Hart CL, 2000, BEHAV PHARMACOL, V11, P87, DOI 10.1097/00008877-200002000-00010
   Healey A, 1998, BRIT J PSYCHIAT, V173, P160, DOI 10.1192/bjp.173.2.160
   Higgins ST, 2000, EXP CLIN PSYCHOPHARM, V8, P377, DOI 10.1037//1064-1297.8.3.377
   Higgins ST, 1997, PHARMACOL BIOCHEM BE, V57, P419, DOI 10.1016/S0091-3057(96)00446-7
   HIGGINS ST, 1994, LIFE SCI, V55, P179, DOI 10.1016/0024-3205(94)00878-7
   HIGGINS ST, 1994, ARCH GEN PSYCHIAT, V51, P568
   Holloway K., 2008, EFFECTIVENESS TREATM
   IGUCHI MY, 1988, DRUG ALCOHOL DEPEN, V22, P1, DOI 10.1016/0376-8716(88)90030-0
   JOHANSON CE, 1977, PSYCHOPHARMACOLOGY, V53, P277, DOI 10.1007/BF00492364
   Kleiman M, 1997, COERCED ABSTINENCE N
   Kleiman M. A., 2001, DRUG ADDICTION DRUG, P168
   Luchansky B, 2006, AM J ADDICTION, V15, P370, DOI 10.1080/10550490600860171
   MacCoun RJ, 2001, DRUG WAR HERESIES LE
   MCCARTHY JJ, 1985, AM J PSYCHIAT, V142, P1419
   Miller TR, 2006, PREV SCI, V7, P333, DOI 10.1007/s11121-006-0041-6
   Nace EP, 2007, AM J ADDICTION, V16, P15, DOI 10.1080/10550490601077783
   Nader MA, 2001, BEHAV PHARMACOL, V12, P91, DOI 10.1097/00008877-200104000-00002
   National Center on Addiction and Substance Abuse, 1998, BARS SUBST AB AM PRI, V1
   National Institute on Drug Abuse, 2009, PRINC DRUG ADD TREAT
   Negus SS, 2005, PSYCHOPHARMACOLOGY, V181, P244, DOI 10.1007/s00213-005-2266-7
   NIGHTINGALE SL, 1972, INT J ADDICT, V7, P403, DOI 10.3109/10826087209028095
   Nurco D N, 1985, J Subst Abuse Treat, V2, P113, DOI 10.1016/0740-5472(85)90035-2
   NURCO DN, 1984, AM J DRUG ALCOHOL AB, V10, P481, DOI 10.3109/00952998409001486
   NURCO DN, 1986, J NERV MENT DIS, V174, P112, DOI 10.1097/00005053-198602000-00007
   NURCO DN, 1985, J NERV MENT DIS, V173, P94, DOI 10.1097/00005053-198502000-00006
   *OFF NAT DRUG CONT, 2004, EC COSTS DRUG AB US
   Office of National Drug Control Policy, 2000, DRUG REL CRIM
   Petersilia J., 1993, CRIME JUSTICE, V17, P281, DOI DOI 10.1086/449215
   Petry NM, 2002, J SUBST ABUSE TREAT, V23, P81, DOI 10.1016/S0740-5472(02)00251-9
   Piotrowski NA, 1999, EXP CLIN PSYCHOPHARM, V7, P399, DOI 10.1037/1064-1297.7.4.399
   POLING A, 1977, PSYCHOPHARMACOLOGY, V51, P289, DOI 10.1007/BF00431638
   POLING A, 1977, PHARMACOL BIOCHEM BE, V7, P393, DOI 10.1016/0091-3057(77)90236-2
   Prendergast M, 2008, EVALUATION REV, V32, P59, DOI 10.1177/0193841X07308082
   Ritvo JI, 2004, TXB SUBSTANCE ABUSE, P475
   Roll JM, 2005, AM J DRUG ALCOHOL AB, V31, P393, DOI 10.1081/ADA-200056774
   Schuster C. R., 1986, BEHAV ANAL DRUG DEPE, P357
   Shanahan M, 2004, EVALUATION REV, V28, P3, DOI 10.1177/0193841X03257531
   Simpson DD, 2002, ARCH GEN PSYCHIAT, V59, P538, DOI 10.1001/archpsyc.59.6.538
   STITZER ML, 1986, DRUG ALCOHOL DEPEN, V18, P341, DOI 10.1016/0376-8716(86)90097-9
   Stolerman P, 1986, BEHAVIORAL ANAL DRUG, P1
   *SUBST AB MENT HLT, 2008, NSDUH SER H, V34
   Sullivan MA, 2008, AM J ADDICTION, V17, P36, DOI 10.1080/10550490701756369
   Taxman F. S., 1999, PRISON J, V79, P182, DOI DOI 10.1177/0032885599079002004
   U.S. General Accountability Office, 2005, AD DRUG COURTS EV IN
   VAILLANT GE, 1966, AM J PSYCHIAT, V123, P573, DOI 10.1176/ajp.123.5.573
   Wilson David B., 2006, J EXPT CRIMINOLOGY, V2, P459, DOI DOI 10.1007/s11292-006-9019-4
   Wong CJ, 2004, DRUG ALCOHOL DEPEN, V74, P319, DOI 10.1016/j.drugalcdep.2003.12.013
   Wong CJ, 2004, EXP CLIN PSYCHOPHARM, V12, P39, DOI 10.1037/1064-1297.12.1.39
NR 97
TC 4
Z9 4
U1 1
U2 26
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0193-953X
EI 1558-3147
J9 PSYCHIAT CLIN N AM
JI Psychiatr. Clin. North Amer.
PD JUN
PY 2012
VL 35
IS 2
BP 375
EP +
DI 10.1016/j.psc.2012.03.005
PG 18
WC Psychiatry
WE Social Science Citation Index (SSCI)
SC Psychiatry
GA 966OT
UT WOS:000305848000007
PM 22640761
DA 2023-06-23
ER

PT J
AU Zhang, J
   Liu, WL
   Shi, LY
   Liu, X
   Wang, MC
   Li, WT
   Yu, DJ
   Wang, YY
   Zhang, JJ
   Yun, KM
   Yan, JW
AF Zhang, Jun
   Liu, Wenli
   Shi, Linyu
   Liu, Xu
   Wang, Mengchun
   Li, Wanting
   Yu, Daijing
   Wang, Yaya
   Zhang, Jingjing
   Yun, Keming
   Yan, Jiangwei
TI The Effects of Drug Addiction and Detoxification on the Human Oral
   Microbiota
SO MICROBIOLOGY SPECTRUM
LA English
DT Article
DE drug addiction; detoxification; heroin; methylamphetamine; oral
   microbiota
ID HEALTH; COMMUNITY; COMPETITION; DIVERSITY; PACKAGE; DISEASE
AB Drug addiction has serious negative consequences for human health and public security. The evidence indicates that drug abuse can cause poor oral health.
   Drug addiction can powerfully and chronically damage human health. Detoxification contributes to health recovery of the body. It is well established that drug abuse is associated with poor oral health in terms of dental caries and periodontal diseases. We supposed that drug addiction and detoxification might have significant effects on the oral microbiota. To test the hypothesis, we assessed the effects of drug (heroin and methylamphetamine) addiction/detoxification on the oral microbiota based on 16S rRNA gene sequencing by an observational investigation, including 495 saliva samples from participants. The oral microbial compositions differed between non-users, current and former drug users. Lower alpha diversities were observed in current drug users, with no significant differences between non-users and former drug users. Heroin and METH addiction can cause consistent variations in several specific phyla, such as the enrichment of Acidobacteria and depletion of Proteobacteria and Tenericutes. Current drug users had significantly lower relative abundances of Neisseria subflava and Haemophilus parainfluenzae compared to non-users and former drug users. The result of random forest prediction model suggested that the oral microbiota has a powerful classification potential for distinguishing current drug users from non-users and former drug users. A cooccurrence network analysis showed that current drug users had more complex oral microbial networks and lower functional modularity. Overall, our study suggested that drug addiction may damage the balance of the oral microbiota. These results may have benefits for further understanding the effects of addiction-related oral microbiota on the health of drug users and promoting the microbiota to serve as a potential tool for accurate forensic identification.IMPORTANCE Drug addiction has serious negative consequences for human health and public security. The evidence indicates that drug abuse can cause poor oral health. In the current study, we observed that drug addiction caused oral microbial dysbiosis. Detoxication have positive effects on the recovery of oral microbial community structures to some extent. Understanding the effects of drug addiction and detoxification on oral microbial communities will promote a more rational approach for recovering the oral function and health of drug users. Furthermore, specific microbial species might be considered biomarkers that could provide information regarding drug abuse status for saliva left at crime scenes. To the best of our knowledge, this is the first report on the role of the oral microbiota in drug addiction and detoxification. Our findings give new clues to understand the association between drug addiction and oral health.
C1 [Zhang, Jun; Shi, Linyu; Wang, Mengchun; Li, Wanting; Yu, Daijing; Wang, Yaya; Yun, Keming; Yan, Jiangwei] Shanxi Med Univ, Taiyuan, Peoples R China.
   [Liu, Wenli; Liu, Xu; Zhang, Jingjing] Beijing Ctr Phys & Chem Anal, Beijing, Peoples R China.
C3 Shanxi Medical University
RP Yun, KM; Yan, JW (通讯作者)，Shanxi Med Univ, Taiyuan, Peoples R China.
EM yunkeming5142@163.com; yanjw@sxmu.edu.cn
FU National Natural Science Foundation of China [82030058, 82130056,
   82101977]
FX ACKNOWLEDGMENTS This work was supported by the National Natural Science
   Foundation of China (82030058, 82130056 and 82101977). We have no
   conflicts of interest to declare. J.Y., K.Y., and Jun Zhang conceived
   and designed the manuscript. W.L., X.L., Jingjing Zhang, and M.W.
   collected the samples. Jun Zhang, W.L., L.S., W.L., D.Y., and Y.W.
   processed the samples and sequenced the data. Jun Zhang analyzed the
   data and wrote the manuscript. All authors contributed to the article
   and approved the submitted version.
CR American Psychiatric Association D, 2013, DIAGNOSTIC STAT MANU
   Asakawa M, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00332-18
   Assenov Y, 2008, BIOINFORMATICS, V24, P282, DOI 10.1093/bioinformatics/btm554
   Baker JL, 2021, GENOME RES, V31, P64, DOI 10.1101/gr.265645.120
   Baker JL, 2017, TRENDS MICROBIOL, V25, P362, DOI 10.1016/j.tim.2016.12.012
   Belda-Ferre P, 2012, ISME J, V6, P46, DOI 10.1038/ismej.2011.85
   Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324
   Buchanan JB, 2010, BRAIN BEHAV IMMUN, V24, P502, DOI 10.1016/j.bbi.2009.12.008
   Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303
   Casals-Pascual C, 2020, GASTROENTEROLOGY, V158, P1524, DOI 10.1053/j.gastro.2019.11.305
   Chatterjee Shailja, 2019, J Forensic Dent Sci, V11, P1, DOI 10.4103/jfo.jfds_69_18
   Chen C, 2018, ISME J, V12, P1210, DOI 10.1038/s41396-017-0037-1
   Chen T, 2010, DATABASE-OXFORD, DOI 10.1093/database/baq013
   Cossa Federico, 2020, J Clin Exp Dent, V12, pe193, DOI 10.4317/jced.55928
   Coyte KZ, 2019, CURR BIOL, V29, pR538, DOI 10.1016/j.cub.2019.04.017
   Csardi G., 2006, INTERJOURNAL COMPLEX, V1695, P549, DOI 10.1128/jcm.2.6.549-551.1975549-551
   Das SK., 2020, MED TOXICOLOGY
   Deitch D, 2000, J PSYCHOACTIVE DRUGS, V32, P391, DOI 10.1080/02791072.2000.10400241
   Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381
   Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461
   Fan KK, 2018, SOIL BIOL BIOCHEM, V125, P251, DOI 10.1016/j.soilbio.2018.07.022
   Fan XZ, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0448-x
   Fan XZ, 2018, GUT, V67, P120, DOI 10.1136/gutjnl-2016-312580
   Faust Karoline, 2016, F1000Res, V5, P1519
   Flemer B, 2018, GUT, V67, P1454, DOI 10.1136/gutjnl-2017-314814
   Gao C., 2022, IMETA, V1, pe19, DOI [10.1002/imt2.19, DOI 10.1002/IMT2.19]
   Javed S, 2020, COMPUT METH PROG BIO, V186, DOI 10.1016/j.cmpb.2019.105198
   Ju F, 2014, ENVIRON MICROBIOL, V16, P2421, DOI 10.1111/1462-2920.12355
   Kleinstein SE, 2020, J DENT RES, V99, P1131, DOI 10.1177/0022034520926126
   Kosciolek Tomasz, 2021, Brain Behav Immun Health, V15, P100271, DOI 10.1016/j.bbih.2021.100271
   Lee HH, 2021, MBIO, V12, DOI 10.1128/mBio.03534-20
   Ling N, 2016, SOIL BIOL BIOCHEM, V99, P137, DOI 10.1016/j.soilbio.2016.05.005
   Lunardon N, 2014, R J, V6, P79
   Luo ZW, 2021, EBIOMEDICINE, V74, DOI 10.1016/j.ebiom.2021.103701
   Marsh PD, 2017, J CLIN PERIODONTOL, V44, pS12, DOI 10.1111/jcpe.12679
   Matei A., 2006, EUROPEAN C QUALITY S
   Mateos-Moreno MV, 2013, MED ORAL PATOL ORAL, V18, pE671, DOI 10.4317/medoral.18669
   McCann KS, 2000, NATURE, V405, P228, DOI 10.1038/35012234
   Mougeot JLC, 2019, J ORAL MICROBIOL, V11, DOI 10.1080/20002297.2019.1586421
   Nessa A, 2008, Mymensingh Med J, V17, P227
   Newman MEJ, 2006, P NATL ACAD SCI USA, V103, P8577, DOI 10.1073/pnas.0601602103
   Pande S, 2016, ISME J, V10, P1413, DOI 10.1038/ismej.2015.212
   Paniccia JE, 2021, BRAIN BEHAV IMMUN, V91, P315, DOI 10.1016/j.bbi.2020.10.009
   Paradis E, 2004, BIOINFORMATICS, V20, P289, DOI [10.1093/bioinformatics/bty633, 10.1093/bioinformatics/btg412]
   Protrka N, 2013, ACTA CLIN CROAT, V52, P436
   Qudeimat MA, 2021, J DENT, V104, DOI 10.1016/j.jdent.2020.103539
   Ravenel MC, 2012, QUINTESSENCE INT, V43, P229
   Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Robinson PG, 2005, BRIT DENT J, V198, P219, DOI 10.1038/sj.bdj.4812090
   Rognes T, 2016, PEERJ, V4, DOI 10.7717/peerj.2584
   Rook EJ., 2006, BASIC CLIN PHARMACOL, V98, P00
   Saeland M, 2011, BRIT J NUTR, V105, P618, DOI 10.1017/S0007114510003971
   Salamanca SA, 2015, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00445
   Shekarchizadeh H, 2013, IRAN J PUBLIC HEALTH, V42, P929
   Teoh L, 2019, AUST DENT J, V64, P213, DOI 10.1111/adj.12709
   Venturelli OS, 2018, MOL SYST BIOL, V14, DOI 10.15252/msb.20178157
   Violle C, 2010, P NATL ACAD SCI USA, V107, P12925, DOI 10.1073/pnas.1000699107
   Wade WG, 2013, PHARMACOL RES, V69, P137, DOI 10.1016/j.phrs.2012.11.006
   Wang C, 2020, NPJ BIOFILMS MICROBI, V6, DOI 10.1038/s41522-020-0135-0
   Wang X, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01230
   Weaver J, 2014, TOXICOL APPL PHARM, V275, P73, DOI 10.1016/j.taap.2013.12.023
   Wu J, 2016, ISME J, V10, P2435, DOI 10.1038/ismej.2016.37
   Wu ZN, 2021, MICROBIOL SPECTR, V9, DOI 10.1128/Spectrum.00138-21
   Xu X, 2015, ENVIRON MICROBIOL, V17, P699, DOI 10.1111/1462-2920.12502
   Yang F, 2012, ISME J, V6, P1, DOI 10.1038/ismej.2011.71
   Yu GQ, 2017, MICROBIOME, V5, DOI 10.1186/s40168-016-0226-6
   Zarco MF, 2012, ORAL DIS, V18, P109, DOI 10.1111/j.1601-0825.2011.01851.x
   Zhang DX, 2021, MSPHERE, V6, DOI 10.1128/mSphere.01252-20
   Zhang J, 2021, FORENSIC SCI INT-GEN, V52, DOI 10.1016/j.fsigen.2021.102488
NR 70
TC 0
Z9 0
U1 10
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2165-0497
J9 MICROBIOL SPECTR
JI Microbiol. Spectr.
PD APR 13
PY 2023
VL 11
IS 2
DI 10.1128/spectrum.03961-22
EA FEB 2023
PG 16
WC Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Microbiology
GA F8AV3
UT WOS:000921814100001
PM 36722952
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Volkow, ND
   Wang, GJ
   Tomasi, D
   Baler, RD
AF Volkow, Nora D.
   Wang, Gen-Jack
   Tomasi, Dardo
   Baler, Ruben D.
TI Unbalanced neuronal circuits in addiction
SO CURRENT OPINION IN NEUROBIOLOGY
LA English
DT Review
ID NORMALIZES CINGULATE ACTIVITY; VENTRAL TEGMENTAL AREA; SUBTHALAMIC
   NUCLEUS; DRUG-ADDICTION; COCAINE ADDICTION; DOPAMINE-D-2 RECEPTORS;
   LATERAL HABENULA; BINDING-PROTEIN; NMDA RECEPTORS; NEURAL SYSTEMS
AB Through sequential waves of drug-induced neurochemical stimulation, addiction co-opts the brain's neuronal circuits that mediate reward, motivation to behavioral inflexibility and a severe disruption of self-control and compulsive drug intake. Brain imaging technologies have allowed neuroscientists to map out the neural landscape of addiction in the human brain and to understand how drugs modify it.
C1 [Volkow, Nora D.; Baler, Ruben D.] NIDA, NIH, Bethesda, MD 20892 USA.
   [Wang, Gen-Jack; Tomasi, Dardo] Brookhaven Natl Lab, Dept Biosci, Upton, NY 11973 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute on
   Drug Abuse (NIDA); United States Department of Energy (DOE); Brookhaven
   National Laboratory
RP Volkow, ND (通讯作者)，NIDA, NIH, Bethesda, MD 20892 USA.
EM nvokowl@nida.nih.gov
RI Tomasi, Dardo G/J-2127-2015
FU Intramural NIH HHS [Z99 DA999999] Funding Source: Medline
CR Anderson CM, 2006, NEUROPSYCHOPHARMACOL, V31, P1318, DOI 10.1038/sj.npp.1300937
   Baldwin Philip R, 2011, J Addict Res Ther, VS1
   Barnes TD, 2005, NATURE, V437, P1158, DOI 10.1038/nature04053
   Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584
   Belin D, 2009, BEHAV BRAIN RES, V199, P89, DOI 10.1016/j.bbr.2008.09.027
   Bennett DS, 2008, DEV PSYCHOL, V44, P919, DOI 10.1037/0012-1649.44.4.919
   Berglind WJ, 2006, NEUROSCIENCE, V137, P699, DOI 10.1016/j.neuroscience.2005.08.064
   Berridge KC, 2007, PSYCHOPHARMACOLOGY, V191, P391, DOI 10.1007/s00213-006-0578-x
   Blum K, 2012, CURR PHARM DESIGN, V18, P113, DOI 10.2174/138161212798919110
   Bonson KR, 2002, NEUROPSYCHOPHARMACOL, V26, P376, DOI 10.1016/S0893-133X(01)00371-2
   Bromberg-Martin ES, 2010, NEURON, V68, P815, DOI 10.1016/j.neuron.2010.11.022
   Brown RM, 2011, PLOS ONE, V5
   Chabardes S, 2013, WORLD NEURO IN PRESS
   Chang L, 2007, NEUROSCIENTIST, V13, P422, DOI 10.1177/1073858406296601
   Choi JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045938
   Di Chiara G, 1999, EUR J PHARMACOL, V375, P13, DOI 10.1016/S0014-2999(99)00372-6
   Eagle DM, 2011, J NEUROSCI, V31, P7349, DOI 10.1523/JNEUROSCI.6182-10.2011
   Eisenberger NI, 2012, NAT NEUROSCI, V15, P669, DOI 10.1038/nn.3086
   Eluvathingal TJ, 2006, PEDIATRICS, V117, P2093, DOI 10.1542/peds.2005-1727
   Ersche KD, 2012, SCIENCE, V335, P601, DOI 10.1126/science.1214463
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Feil J, 2010, NEUROSCI BIOBEHAV R, V35, P248, DOI 10.1016/j.neubiorev.2010.03.001
   Filbey FM, 2012, NEUROIMAGE, V63, P1800, DOI 10.1016/j.neuroimage.2012.08.073
   Gardini S, 2012, BRAIN RES BULL, V87, P205, DOI 10.1016/j.brainresbull.2011.11.021
   Girault JA, 2012, ADV EXP MED BIOL, V970, P407, DOI 10.1007/978-3-7091-0932-8_18
   Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119
   Goldstein RZ, 2011, NEUROPSYCHOPHARMACOL, V36, P366, DOI 10.1038/npp.2010.145
   Goldstein RZ, 2010, P NATL ACAD SCI USA, V107, P16667, DOI 10.1073/pnas.1011455107
   Goldstein RZ, 2009, TRENDS COGN SCI, V13, P372, DOI 10.1016/j.tics.2009.06.004
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Goudriaan AE, 2010, ADDICT BIOL, V15, P491, DOI 10.1111/j.1369-1600.2010.00242.x
   Graybiel AM, 1998, NEUROBIOL LEARN MEM, V70, P119, DOI 10.1006/nlme.1998.3843
   Graybiel AM, 2008, ANNU REV NEUROSCI, V31, P359, DOI 10.1146/annurev.neuro.29.051605.112851
   IKAI Y, 1994, NEUROSCIENCE, V61, P925, DOI 10.1016/0306-4522(94)90413-8
   Janes AC, 2010, BIOL PSYCHIAT, V67, P722, DOI 10.1016/j.biopsych.2009.12.034
   Janu L, 2012, NEURO ENDOCRINOL LET, P33
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kalivas PW, 2003, PSYCHOPHARMACOLOGY, V168, P44, DOI 10.1007/s00213-003-1393-2
   Kang OS, 2012, PROG NEURO-PSYCHOPH, V38, P285, DOI 10.1016/j.pnpbp.2012.04.013
   Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442
   KOOB GF, 1989, NEUROSCI BIOBEHAV R, V13, P135, DOI 10.1016/S0149-7634(89)80022-3
   Langevin Jean-Philippe, 2012, Surg Neurol Int, V3, pS40, DOI 10.4103/2152-7806.91609
   Laplante DP, 2008, J AM ACAD CHILD PSY, V47, P1063, DOI 10.1097/CHI.0b013e31817eec80
   Luigjes J, 2012, MOL PSYCHIATR, V17, P572, DOI 10.1038/mp.2011.114
   Luo ZC, 2011, J NEUROSCI, V31, P13180, DOI 10.1523/JNEUROSCI.2369-11.2011
   Marsch LA, 2012, PSYCHIAT CLIN N AM, V35, P481, DOI 10.1016/j.psc.2012.03.009
   Matsumoto M, 2007, NATURE, V447, P1111, DOI 10.1038/nature05860
   Matsumoto M, 2009, NAT NEUROSCI, V12, P77, DOI 10.1038/nn.2233
   Moeller SJ, 2012, ADDICT BIOL, V17, P1013, DOI 10.1111/j.1369-1600.2012.00440.x
   Morales M, 2012, ANN NY ACAD SCI, V1248, P71, DOI 10.1111/j.1749-6632.2011.06299.x
   Moussawi K, 2010, EUR J PHARMACOL, V639, P115, DOI 10.1016/j.ejphar.2010.01.030
   Muhammad A, 2012, NEUROSCIENCE, V216, P103, DOI 10.1016/j.neuroscience.2012.04.041
   Naqvi NH, 2007, SCIENCE, V315, P531, DOI 10.1126/science.1135926
   Naqvi NH, 2009, TRENDS NEUROSCI, V32, P56, DOI 10.1016/j.tins.2008.09.009
   Ousdal OT, 2012, NEUROIMAGE, V62, P95, DOI 10.1016/j.neuroimage.2012.04.035
   Padula CB, 2011, ALCOHOL ALCOHOLISM, V46, P547, DOI 10.1093/alcalc/agr066
   Parker JG, 2010, P NATL ACAD SCI USA, V107, P13491, DOI 10.1073/pnas.1007827107
   Parkitna JR, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00089
   Parvaz MA, 2012, PSYCHIAT RES-NEUROIM, V203, P75, DOI 10.1016/j.pscychresns.2012.01.001
   Paulus MP, 2009, PHARMACOL BIOCHEM BE, V94, P1, DOI 10.1016/j.pbb.2009.08.005
   Pelchat ML, 2004, NEUROIMAGE, V23, P1486, DOI 10.1016/j.neuroimage.2004.08.023
   Pickens CL, 2011, TRENDS NEUROSCI, V34, P411, DOI 10.1016/j.tins.2011.06.001
   Redish AD, 2008, BEHAV BRAIN SCI, V31, P415, DOI 10.1017/S0140525X0800472X
   Rosenberg SD, 2007, PSYCHIAT SERV, V58, P245, DOI 10.1176/appi.ps.58.2.245
   Rouaud T, 2010, P NATL ACAD SCI USA, V107, P1196, DOI 10.1073/pnas.0908189107
   Sesack SR, 2010, NEUROPSYCHOPHARMACOL, V35, P27, DOI 10.1038/npp.2009.93
   Shiflett MW, 2011, PROG NEUROBIOL, V95, P1, DOI 10.1016/j.pneurobio.2011.05.007
   St Onge JR, 2011, J NEUROSCI, V31, P8625, DOI 10.1523/JNEUROSCI.1020-11.2011
   Stevenson CW, 2003, EUR J NEUROSCI, V17, P1287, DOI 10.1046/j.1460-9568.2003.02560.x
   Stinson FS, 2006, PSYCHOL MED, V36, P1447, DOI 10.1017/S0033291706008361
   Surmeier DJ, 2007, TRENDS NEUROSCI, V30, P228, DOI 10.1016/j.tins.2007.03.008
   Temel Y, 2005, PROG NEUROBIOL, V76, P393, DOI 10.1016/j.pneurobio.2005.09.005
   Thompson D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011038
   Tomasi D, 2013, CEREB CORTE IN PRESS
   Tomasi D, 2011, CEREB CORTEX, V21, P2003, DOI 10.1093/cercor/bhq268
   Tomasi D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010815
   Ungless MA, 2003, NEURON, V39, P401, DOI 10.1016/S0896-6273(03)00461-6
   van Wouwe NC, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00030
   Verdejo-Garcia A, 2012, NEUROSCI BIOBEHAV R, V36, P1857, DOI 10.1016/j.neubiorev.2012.05.007
   Volkow ND, 2013, OBES REV, V14, P2, DOI 10.1111/j.1467-789X.2012.01031.x
   Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI 10.1093/cercor/10.3.318
   Volkow ND, 2003, J NEUROSCI, V23, P11461
   Volkow ND, 1997, NATURE, V386, P830, DOI 10.1038/386830a0
   VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210
   VOLKOW ND, 1992, SYNAPSE, V11, P184, DOI 10.1002/syn.890110303
   Volkow ND, 2001, AM J PSYCHIAT, V158, P2015, DOI 10.1176/appi.ajp.158.12.2015
   VOLKOW ND, 1990, AM J PSYCHIAT, V147, P719
   Volkow ND, 2007, J NEUROSCI, V27, P12700, DOI 10.1523/JNEUROSCI.3371-07.2007
   Volkow ND, 2006, ARCH GEN PSYCHIAT, V63, P999, DOI 10.1001/archpsyc.63.9.999
   Volkow ND, 2013, NEUROIMAGE, V64, P277, DOI 10.1016/j.neuroimage.2012.08.057
   Wang HL, 2008, J COMP NEUROL, V509, P302, DOI 10.1002/cne.21751
   Wang Z, 2007, J NEUROSCI, V27, P14035, DOI 10.1523/JNEUROSCI.2966-07.2007
   Weiland BJ, 2012, ALCOHOL CLIN EXP RES, V36, P1355, DOI 10.1111/j.1530-0277.2012.01741.x
   Whitmer D, 2012, J NEUROSCI, V32, P8753, DOI 10.1523/JNEUROSCI.1819-12.2012
   Wise RA, 2010, BRAIN RES, V1314, P38, DOI 10.1016/j.brainres.2009.09.101
   Xi ZX, 2012, ADDICT BIOL
   Zaghloul KA, 2012, J NEUROSCI, V32, P2453, DOI 10.1523/JNEUROSCI.5815-11.2012
   Zeki S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015802
   Zeng F, 2012, PLOS ONE, V6
   Zhang FQ, 2005, NEUROSCI LETT, V386, P133, DOI 10.1016/j.neulet.2005.06.008
NR 100
TC 148
Z9 151
U1 2
U2 54
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0959-4388
EI 1873-6882
J9 CURR OPIN NEUROBIOL
JI Curr. Opin. Neurobiol.
PD AUG
PY 2013
VL 23
IS 4
BP 639
EP 648
DI 10.1016/j.conb.2013.01.002
PG 10
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 204XJ
UT WOS:000323404300026
PM 23434063
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Durrant, R
   Adamson, S
   Todd, F
   Sellman, D
AF Durrant, Russil
   Adamson, Simon
   Todd, Fraser
   Sellman, Doug
TI Drug use and addiction: evolutionary perspective
SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
LA English
DT Article
DE addiction; behavioural addictions; drug use; evolution; life history
   theory
ID LIFE-HISTORY THEORY; RISK-TAKING; ORBITOFRONTAL CORTEX; ADOLESCENT
   BRAIN; REWARD SYSTEM; USE DISORDERS; ALCOHOL; BEHAVIOR; ABUSE; MODEL
AB Drug use creates a significant amount of harm in modern societies. From an evolutionary perspective, the pervasive use of drugs and the ongoing risk of drug addiction can be explained in terms of the action of drugs on evolved motivational-emotional systems. Addiction arises through interaction of these evolutionarily ancient systems, designed to promote the pursuit of natural rewards, and contemporary environments where purified and potent forms of drugs are readily available. This evolutionary analysis is extended to account for developmental patterns in problem drug use, and to explain the existence of behavioural addictions, such as problem gambling. The paper concludes by considering some of the clinical and public policy implications of the evolutionary perspective presented.
C1 [Durrant, Russil] Victoria Univ Wellington, Sch Social & Cultural Studies, Inst Criminol, Wellington, New Zealand.
   [Adamson, Simon; Todd, Fraser; Sellman, Doug] Univ Otago, Dept Psychol Med, Natl Addict Ctr Aotearoa New Zealand, Christchurch, New Zealand.
C3 Victoria University Wellington; University of Otago
RP Durrant, R (通讯作者)，Victoria Univ Wellington, Sch Social & Cultural Studies, Inst Criminol, POB 600, Wellington, New Zealand.
EM russil.durrant@vuw.ac.nz
CR Adamson SJ, 2006, AUST NZ J PSYCHIAT, V40, P164, DOI 10.1080/j.1440-1614.2006.01764.x
   Alcaro A, 2007, BRAIN RES REV, V56, P283, DOI 10.1016/j.brainresrev.2007.07.014
   American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th
   Australian Institute of Health and Welfare, 2007, STAT DRUG US AUSTR 2
   BABOR TF, 2003, ALCOHOL NO ORDINARY
   Berridge KC, 2008, PSYCHOPHARMACOLOGY, V199, P457, DOI 10.1007/s00213-008-1099-6
   Booth M., 1996, OPIUM HIST
   Cardinal RN, 2004, CURR OPIN NEUROBIOL, V14, P156, DOI 10.1016/j.conb.2004.03.004
   Casey BJ, 2008, DEV REV, V28, P62, DOI 10.1196/annals.1440.010
   Chambers RA, 2003, AM J PSYCHIAT, V160, P1041, DOI 10.1176/appi.ajp.160.6.1041
   Childress A. R., 2006, RETHINKING SUBSTANCE, P46
   CHISHOLM JS, 1993, CURR ANTHROPOL, V34, P1, DOI 10.1086/204131
   Compton WM, 2007, ARCH GEN PSYCHIAT, V64, P566, DOI 10.1001/archpsyc.64.5.566
   COURTWRIGHT DT, 2001, DRUGS MAKING MODERN
   Crabbe JC, 2002, ANNU REV PSYCHOL, V53, P435, DOI 10.1146/annurev.psych.53.100901.135142
   Dahl RE, 2004, ANN NY ACAD SCI, V1021, P1, DOI 10.1196/annals.1308.001
   De Rios Marlene Dobkin, 1990, HALLUCINOGENS CROSS
   Dudley R, 2002, ADDICTION, V97, P381, DOI 10.1046/j.1360-0443.2002.00002.x
   Dudley R, 2000, Q REV BIOL, V75, P3, DOI 10.1086/393255
   Durrant R., 2003, SUBSTANCE USE ABUSE
   Ernst M, 2006, PSYCHOL MED, V36, P299, DOI 10.1017/S0033291705005891
   ERVIN FR, 1990, PHARMACOL BIOCHEM BE, V36, P367, DOI 10.1016/0091-3057(90)90417-G
   Galvan A, 2006, J NEUROSCI, V26, P6885, DOI 10.1523/JNEUROSCI.1062-06.2006
   GHODSE H, 2003, INT DRUG CONTROL 21
   Glocker ML, 2009, P NATL ACAD SCI USA, V106, P9115, DOI 10.1073/pnas.0811620106
   Grant J.E., 2008, IMPULSE CONTROL DISO
   Grant JE, 2006, AM J PSYCHIAT, V163, P303, DOI 10.1176/appi.ajp.163.2.303
   Hill EM, 2002, ADDICTION, V97, P401, DOI 10.1046/j.1360-0443.2002.00020.x
   Holden C, 2001, SCIENCE, V294, P980, DOI 10.1126/science.294.5544.980
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kaplan HS., 2005, HDB EVOLUTIONARY PSY, P68, DOI DOI 10.1002/9780470939376.CH2
   Katz SG, 1998, J VASC SURG, V28, P23, DOI 10.1016/S0741-5214(98)70196-X
   Kelley AE, 2004, NEURON, V44, P161, DOI 10.1016/j.neuron.2004.09.016
   Kelley AE, 2002, J NEUROSCI, V22, P3306
   Kenny PJ, 2007, TRENDS PHARMACOL SCI, V28, P135, DOI 10.1016/j.tips.2007.01.008
   Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593
   Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550
   Kim SW, 2001, BIOL PSYCHIAT, V49, P914, DOI 10.1016/S0006-3223(01)01079-4
   Klingemann H, 2007, PROMOTING SELF CHANG
   Koob GF, 2008, ANNU REV PSYCHOL, V59, P29, DOI 10.1146/annurev.psych.59.103006.093548
   Lalumiere M. L., 2008, EVOLUTIONARY FORENSI, P139, DOI DOI 10.1093/ACPROF:OSO/9780195325
   Lende D.H., 2008, EVOLUTIONARY MED HLT, P277
   Lende DH, 2002, ADDICTION, V97, P447, DOI 10.1046/j.1360-0443.2002.00022.x
   Miller William E., 1997, Journal of the Lepidopterists' Society, V51, P277
   *MIN HLTH, 2007, DRUG US NZ AN 2003 N
   MOOS R, 2006, RETHINKING SUBSTANCE, P182
   MUESER K. T., 2006, RETHINKING SUBSTANCE, P115
   Musto DF., 1973, AM DIS ORIGINS NARCO
   Nesse RM, 1997, SCIENCE, V278, P63, DOI 10.1126/science.278.5335.63
   NESSE RM, 1994, ETHOL SOCIOBIOL, V15, P339, DOI 10.1016/0162-3095(94)90007-8
   Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578
   O'Doherty JP, 2004, CURR OPIN NEUROBIOL, V14, P769, DOI 10.1016/j.conb.2004.10.016
   Orford J, 2001, ADDICTION, V96, P15, DOI 10.1046/j.1360-0443.2001.961152.x
   Panksepp J, 2002, ADDICTION, V97, P459, DOI 10.1046/j.1360-0443.2002.00025.x
   Phillips A. G., 1992, INT REV STUDIES EMOT, V2, P31
   Picciotto MR, 1998, DRUG ALCOHOL DEPEN, V51, P165, DOI 10.1016/S0376-8716(98)00074-X
   Pomerleau CS, 1997, ADDICTION, V92, P397
   Potenza MN, 2006, ADDICTION, V101, P142, DOI 10.1111/j.1360-0443.2006.01591.x
   Reuter J, 2005, NAT NEUROSCI, V8, P147, DOI 10.1038/nn1378
   Reyna VF, 2006, PSYCHOL SCI, P1, DOI 10.1111/j.1529-1006.2006.00026.x
   ROBINS LN, 1975, ARCH GEN PSYCHIAT, V32, P955
   Robins LN, 2003, ADDICTION, V98, P1053, DOI 10.1046/j.1360-0443.2003.00436.x
   Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI 10.1146/annurev.psych.54.101601.145237
   Rudgley R., 1993, ALCHEMY CULTURE INTO
   SAAH T, 2005, HARM REDUCT J, V2, P1
   Schmitz JM, 2005, SEX ADDICT COMPULS, V12, P149, DOI 10.1080/10720160500203641
   Schoenbaum G, 2006, TRENDS NEUROSCI, V29, P116, DOI 10.1016/j.tins.2005.12.006
   SIEGEL RK, 1984, B PSYCHONOMIC SOC, V22, P49
   Spinella M, 2003, INT J NEUROSCI, V113, P503, DOI 10.1080/00207450390162254
   Steinberg L, 2007, CURR DIR PSYCHOL SCI, V16, P55, DOI 10.1111/j.1467-8721.2007.00475.x
   Sullivan RJ, 2002, ADDICTION, V97, P389, DOI 10.1046/j.1360-0443.2002.00024.x
   Teesson M, 2000, AUST NZ J PSYCHIAT, V34, P206, DOI 10.1080/j.1440-1614.2000.00715.x
   Turner B. L., 2008, EVOLUTIONARY MED HLT, P55
   VONBIBRA E, 1855, PLANT INTOXICANTS
   Wang XT, 2009, EVOL HUM BEHAV, V30, P77, DOI 10.1016/j.evolhumbehav.2008.09.006
   Ward T, 2003, PSYCHOL CRIME LAW, V9, P125, DOI 10.1080/1068316031000116247
   West R, 2001, ADDICTION, V96, P3, DOI 10.1046/j.1360-0443.2001.96131.x
   WILSON M, 1985, ETHOL SOCIOBIOL, V6, P59, DOI 10.1016/0162-3095(85)90041-X
   Wise RA, 1998, DRUG ALCOHOL DEPEN, V51, P13, DOI 10.1016/S0376-8716(98)00063-5
   Yucel M, 2007, AUST NZ J PSYCHIAT, V41, P957, DOI 10.1080/00048670701689444
NR 80
TC 23
Z9 23
U1 2
U2 68
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0004-8674
EI 1440-1614
J9 AUST NZ J PSYCHIAT
JI Aust. N. Z. J. Psych.
PY 2009
VL 43
IS 11
BP 1049
EP 1056
DI 10.3109/00048670903270449
PG 8
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA 514PE
UT WOS:000271406400007
PM 20001400
DA 2023-06-23
ER

PT J
AU Lesscher, HMB
   Vanderschuren, LJMJ
AF Lesscher, Heidi M. B.
   Vanderschuren, Louk J. M. J.
TI Compulsive drug use and its neural substrates
SO REVIEWS IN THE NEUROSCIENCES
LA English
DT Article
DE alcohol; amygdala; animal model; cocaine; drug addiction; striatum
ID CORTICOTROPIN-RELEASING-FACTOR; COCAINE-SEEKING BEHAVIOR;
   NUCLEUS-ACCUMBENS CORE; SUPPRESSES ETHANOL DRINKING; AMINOBUTYRIC-ACID
   RELEASE; CUE-INDUCED REINSTATEMENT; ALCOHOL-PREFERRING RATS;
   ADDICTION-LIKE BEHAVIOR; DEEP BRAIN-STIMULATION; VENTRAL TEGMENTAL AREA
AB Drug addiction is a chronic relapsing brain disease, characterized by compulsive drug use. Despite the fact that drug addiction affects millions of people worldwide, treatments for this disorder are limited in number and efficacy. In our opinion, understanding the neural underpinnings of drug addiction would open new avenues for the development of innovative treatments for this disorder. Based on an awareness that drug use and drug reward do not equal drug addiction, there has been increasing interest in developing animal models of addiction that mimick the loss of control over drug use more closely than existing models aimed at studying drug reward. The present review provides an overview of animal studies of compulsive drug use and the neural mechanisms involved. First, the employed models are summarized, with a particular emphasis on models of escalation of drug use and resistance to punishment. Next, we discuss mechanisms within the (ventral and dorsal) striatum and (central) amygdala that have recently been implicated in the compulsive seeking and taking of alcohol and cocaine. The studies discussed here provide a promising line of research that will advance our knowledge of the neural circuits involved in the self-destructive behavior that characterizes drug addiction.
C1 [Vanderschuren, Louk J. M. J.] Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Dept Neurosci & Pharmacol, NL-3584 CG Utrecht, Netherlands.
   [Lesscher, Heidi M. B.; Vanderschuren, Louk J. M. J.] Univ Utrecht, Dept Anim Sci & Soc, Div Behav Neurosci, Fac Vet Med, NL-3584 CG Utrecht, Netherlands.
C3 Utrecht University; Utrecht University Medical Center; Utrecht
   University
RP Vanderschuren, LJMJ (通讯作者)，Univ Utrecht, Dept Anim Sci & Soc, Div Behav Neurosci, Fac Vet Med, NL-3584 CG Utrecht, Netherlands.
EM l.j.m.j.vanderschuren@uu.nl
RI Vanderschuren, Louk/AAS-4391-2020
OI Vanderschuren, Louk/0000-0002-5379-0363
FU ZonMw (the Netherlands Organisation for Health Research and Development)
   [91207006]; ZonMw (the Netherlands Organisation for Health Research and
   Development)/National Institute on Drug Abuse Collaborative Grant
   [60-60600-97-211]; National Institute on Drug Abuse Grant [R01
   DA022628]; Brain Foundation of the Netherlands Fellowship [H06.08];
   ZonMw (the Netherlands Organization for Health Research and Development)
   VENI grant [91679134]
FX This research was supported by ZonMw (the Netherlands Organisation for
   Health Research and Development) Grant 91207006 (awarded to L.J.M.J.V.,
   P. Voorn and A.B. Smit), ZonMw (the Netherlands Organisation for Health
   Research and Development)/National Institute on Drug Abuse Collaborative
   Grant 60-60600-97-211 (awarded to L.J.M.J. Vanderschuren and R.C.
   Pierce), National Institute on Drug Abuse Grant R01 DA022628
   (L.J.M.J.V.), Brain Foundation of the Netherlands Fellowship H06.08
   (H.M.B.L.) and ZonMw (the Netherlands Organization for Health Research
   and Development) VENI grant 91679134 (H.M.B.L.).
CR Ahmed SH, 2012, NEUROSCIENCE, V211, P107, DOI 10.1016/j.neuroscience.2011.08.014
   Ahmed SH, 2006, NEUROPSYCHOPHARMACOL, V31, P563, DOI 10.1038/sj.npp.1300834
   Ahmed SH, 2005, P NATL ACAD SCI USA, V102, P11533, DOI 10.1073/pnas.0504438102
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Ahmed SH, 1999, PSYCHOPHARMACOLOGY, V146, P303, DOI 10.1007/s002130051121
   Ahmed SH, 2000, NEUROPSYCHOPHARMACOL, V22, P413, DOI 10.1016/S0893-133X(99)00133-5
   American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th
   Bachtell RK, 2005, PSYCHOPHARMACOLOGY, V183, P41, DOI 10.1007/s00213-005-0133-1
   Backstrom P, 2007, PSYCHOPHARMACOLOGY, V192, P571, DOI 10.1007/s00213-007-0753-8
   Bahi A, 2012, PSYCHOPHARMACOLOGY, V222, P141, DOI 10.1007/s00213-011-2630-8
   Bajo M, 2008, P NATL ACAD SCI USA, V105, P8410, DOI 10.1073/pnas.0802302105
   Balleine BW, 2009, BEHAV BRAIN RES, V199, P43, DOI 10.1016/j.bbr.2008.10.034
   Bari AA, 2005, NEUROSCIENCE, V135, P959, DOI 10.1016/j.neuroscience.2005.06.048
   Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584
   Beck A, 2012, ARCH GEN PSYCHIAT, V69, P842, DOI 10.1001/archgenpsychiatry.2011.2026
   Becker HC, 2004, ALCOHOL CLIN EXP RES, V28, P1829, DOI 10.1097/01.ALC.0000149977.95306.3A
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   Belin D, 2008, NEURON, V57, P432, DOI 10.1016/j.neuron.2007.12.019
   Belin D, 2011, NEUROPSYCHOPHARMACOL, V36, P569, DOI 10.1038/npp.2010.188
   Belin D, 2009, BIOL PSYCHIAT, V65, P863, DOI 10.1016/j.biopsych.2008.05.031
   Bell RL, 2006, ALCOHOL, V40, P3, DOI 10.1016/j.alcohol.2006.10.001
   Bell RL, 2009, PHARMACOL BIOCHEM BE, V94, P131, DOI 10.1016/j.pbb.2009.07.019
   Ben-Shahar O, 2008, PROG NEURO-PSYCHOPH, V32, P863, DOI 10.1016/j.pnpbp.2008.01.002
   Besheer J, 2010, BIOL PSYCHIAT, V67, P812, DOI 10.1016/j.biopsych.2009.09.016
   Bossert JM, 2005, EUR J PHARMACOL, V526, P36, DOI 10.1016/j.ejphar.2005.09.030
   Bowers MS, 2008, P NATL ACAD SCI USA, V105, P12533, DOI 10.1073/pnas.0706999105
   BOZARTH MA, 1985, JAMA-J AM MED ASSOC, V254, P81, DOI 10.1001/jama.254.1.81
   Bustamante D, 2008, EUR J PHARMACOL, V591, P153, DOI 10.1016/j.ejphar.2008.06.069
   CAINE SB, 1995, BRAIN RES, V692, P47
   Chen G, 2011, ALCOHOL CLIN EXP RES, V35, P1739, DOI 10.1111/j.1530-0277.2011.01520.x
   Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11
   Ciocchi S, 2010, NATURE, V468, P277, DOI 10.1038/nature09559
   Contet C, 2011, ADDICT BIOL, V16, P615, DOI 10.1111/j.1369-1600.2010.00304.x
   Cooper A, 2007, PSYCHOPHARMACOLOGY, V194, P117, DOI 10.1007/s00213-007-0827-7
   Corbit LH, 2012, BIOL PSYCHIAT, V72, P389, DOI 10.1016/j.biopsych.2012.02.024
   Crabbe JC, 2011, ANN NY ACAD SCI, V1216, P24, DOI 10.1111/j.1749-6632.2010.05895.x
   deFonseca FR, 1997, SCIENCE, V276, P2050, DOI 10.1126/science.276.5321.2050
   DENEAU G, 1969, PSYCHOPHARMACOLOGIA, V16, P30, DOI 10.1007/BF00405254
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Di Ciano P, 2004, J NEUROSCI, V24, P7167, DOI 10.1523/JNEUROSCI.1581-04.2004
   Di Ciano P, 2001, NEUROPSYCHOPHARMACOL, V25, P341, DOI 10.1016/S0893-133X(01)00235-4
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Dickinson A, 2002, Q J EXP PSYCHOL-B, V55, P331, DOI 10.1080/0272499024400016
   Dom G, 2005, BRIT J PSYCHIAT, V187, P209, DOI 10.1192/bjp.187.3.209
   Engleman EA, 2009, ALCOHOL CLIN EXP RES, V33, P2162, DOI 10.1111/j.1530-0277.2009.01055.x
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Everitt BJ, 1999, ANN NY ACAD SCI, V877, P412, DOI 10.1111/j.1749-6632.1999.tb09280.x
   Ferreira JGP, 2008, NEUROSCIENCE, V153, P196, DOI 10.1016/j.neuroscience.2008.02.003
   Fuchs RA, 2004, PSYCHOPHARMACOLOGY, V176, P459, DOI 10.1007/s00213-004-1895-6
   Funk CK, 2007, BIOL PSYCHIAT, V61, P78, DOI 10.1016/j.biopsych.2006.03.063
   Funk CK, 2006, J NEUROSCI, V26, P11324, DOI 10.1523/JNEUROSCI.3096-06.2006
   Garavan H, 2005, TRENDS COGN SCI, V9, P195, DOI 10.1016/j.tics.2005.02.008
   Geisler S, 2007, J NEUROSCI, V27, P5730, DOI 10.1523/JNEUROSCI.0012-07.2007
   Gilpin NW, 2008, ALCOHOL, V42, P541, DOI 10.1016/j.alcohol.2008.07.001
   Gilpin NW, 2008, PHARMACOL BIOCHEM BE, V90, P475, DOI 10.1016/j.pbb.2008.04.006
   Gilpin NW, 2008, PHARMACOL BIOCHEM BE, V90, P470, DOI 10.1016/j.pbb.2008.04.005
   Gilpin NW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031466
   Gilpin NW, 2011, BIOL PSYCHIAT, V69, P1091, DOI 10.1016/j.biopsych.2011.02.004
   GLICK SD, 1978, PSYCHOPHARMACOLOGY, V57, P283, DOI 10.1007/BF00426752
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134
   Haber SN, 2000, J NEUROSCI, V20, P2369
   Han JS, 1997, J NEUROSCI, V17, P3913
   Hao Y, 2010, BIOL PSYCHIAT, V68, P240, DOI 10.1016/j.biopsych.2010.02.011
   HEIMER L, 1991, NEUROSCIENCE, V41, P89, DOI 10.1016/0306-4522(91)90202-Y
   Henderson MB, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.4.FOCUS10105
   Heyne A, 1996, PHARMACOL BIOCHEM BE, V53, P11, DOI 10.1016/0091-3057(95)00193-X
   Hollander JA, 2010, NATURE, V466, P197, DOI 10.1038/nature09202
   Holter SM, 1998, BEHAV PHARMACOL, V9, P41
   Hopf FW, 2010, NEURON, V65, P682, DOI 10.1016/j.neuron.2010.02.015
   Hopf FW, 2010, ALCOHOL CLIN EXP RES, V34, P1565, DOI 10.1111/j.1530-0277.2010.01241.x
   Hoplight BJ, 2006, ALCOHOL, V38, P73, DOI 10.1016/j.alcohol.2006.04.003
   Hwa LS, 2011, ALCOHOL CLIN EXP RES, V35, P1938, DOI 10.1111/j.1530-0277.2011.01545.x
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Ikemoto S, 2004, NEUROPHARMACOLOGY, V47, P190, DOI 10.1016/j.neuropharm.2004.07.012
   Ikemoto S, 2003, J NEUROSCI, V23, P9305
   Im HI, 2010, NAT NEUROSCI, V13, P1120, DOI 10.1038/nn.2615
   Ito R, 2004, NAT NEUROSCI, V7, P389, DOI 10.1038/nn1217
   Ito R, 2002, J NEUROSCI, V22, P6247
   Ito R, 2000, J NEUROSCI, V20, P7489
   Jeanblanc J, 2009, J NEUROSCI, V29, P13494, DOI 10.1523/JNEUROSCI.2243-09.2009
   Jenkins TN, 1926, J COMP PSYCHOL, V6, P361, DOI 10.1037/h0074447
   JOHANSON CE, 1976, PHARMACOL BIOCHEM BE, V4, P45, DOI 10.1016/0091-3057(76)90174-X
   Jonkman S, 2012, NEUROPSYCHOPHARMACOL, V37, P1612, DOI 10.1038/npp.2012.6
   Jonkman S, 2012, J NEUROSCI, V32, P4645, DOI 10.1523/JNEUROSCI.0348-12.2012
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kalivas PW, 2003, PSYCHOPHARMACOLOGY, V168, P44, DOI 10.1007/s00213-003-1393-2
   Karp I, 2005, ANN EPIDEMIOL, V15, P445, DOI 10.1016/j.annepidem.2004.10.002
   Kasanetz F, 2013, MOL PSYCHIATR, V18, P729, DOI 10.1038/mp.2012.59
   Kasanetz F, 2010, SCIENCE, V328, P1709, DOI 10.1126/science.1187801
   Katner SN, 2011, PHARMACOL BIOCHEM BE, V99, P688, DOI 10.1016/j.pbb.2011.06.021
   Katner SN, 2002, ALCOHOL, V28, P29, DOI 10.1016/S0741-8329(02)00235-5
   Kenny PJ, 2007, TRENDS PHARMACOL SCI, V28, P135, DOI 10.1016/j.tips.2007.01.008
   Kenny PJ, 2006, NEUROPSYCHOPHARMACOL, V31, P1203, DOI 10.1038/sj.npp.1300905
   Killcross S, 1997, NATURE, V388, P377, DOI 10.1038/41097
   Kippin TE, 2006, PSYCHOPHARMACOLOGY, V187, P60, DOI 10.1007/s00213-006-0386-3
   Kitamura O, 2006, PSYCHOPHARMACOLOGY, V186, P48, DOI 10.1007/s00213-006-0353-z
   Knackstedt LA, 2007, J PHARMACOL EXP THER, V322, P1103, DOI 10.1124/jpet.107.122861
   Knapp CM, 2009, PHARMACOL BIOCHEM BE, V92, P474, DOI 10.1016/j.pbb.2009.01.017
   Kober H, 2010, P NATL ACAD SCI USA, V107, P14811, DOI 10.1073/pnas.1007779107
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Koob GF, 2003, ALCOHOL CLIN EXP RES, V27, P232, DOI 10.1097/01.ALC.0000057122.36127.C2
   Lenoir M, 2008, NEUROPSYCHOPHARMACOL, V33, P2272, DOI 10.1038/sj.npp.1301602
   Lesscher HMB, 2008, GENES BRAIN BEHAV, V7, P323, DOI 10.1111/j.1601-183X.2007.00356.x
   Lesscher HMB, 2009, GENES BRAIN BEHAV, V8, P493, DOI 10.1111/j.1601-183X.2009.00485.x
   Lesscher HMB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037999
   Lesscher HMB, 2010, ALCOHOL CLIN EXP RES, V34, P1219, DOI 10.1111/j.1530-0277.2010.01199.x
   Lesscher HMB, 2009, PHARMACOGENET GENOM, V19, P719, DOI 10.1097/FPC.0b013e3283311320
   Letchworth SR, 2001, J NEUROSCI, V21, P2799, DOI 10.1523/JNEUROSCI.21-08-02799.2001
   Li YQ, 2008, J NEUROSCI, V28, P13248, DOI 10.1523/JNEUROSCI.3027-08.2008
   Lingawi NW, 2012, J NEUROSCI, V32, P1073, DOI 10.1523/JNEUROSCI.4806-11.2012
   Liu Y, 2005, PSYCHOPHARMACOLOGY, V179, P644, DOI 10.1007/s00213-004-2089-y
   Loi B, 2010, ALCOHOL CLIN EXP RES, V34, P2147, DOI 10.1111/j.1530-0277.2010.01311.x
   Lopez MF, 2005, PSYCHOPHARMACOLOGY, V181, P688, DOI 10.1007/s00213-005-0026-3
   Lu L, 2005, J NEUROCHEM, V94, P161, DOI 10.1111/j.1471-4159.2005.03178.x
   Lu L, 2005, NAT NEUROSCI, V8, P212, DOI 10.1038/nn1383
   LYNESS WH, 1979, PHARMACOL BIOCHEM BE, V11, P553, DOI 10.1016/0091-3057(79)90040-6
   Makris N, 2004, NEURON, V44, P729, DOI 10.1016/j.neuron.2004.10.027
   Makris N, 2008, BIOL PSYCHIAT, V64, P192, DOI 10.1016/j.biopsych.2008.01.018
   Mantsch JR, 2008, PSYCHOPHARMACOLOGY, V195, P591, DOI 10.1007/s00213-007-0950-5
   Mantsch JR, 2004, PSYCHOPHARMACOLOGY, V175, P26, DOI 10.1007/s00213-004-1778-x
   Maren S, 2004, NAT REV NEUROSCI, V5, P844, DOI 10.1038/nrn1535
   McBride WJ, 2010, ALCOHOL, V44, P171, DOI 10.1016/j.alcohol.2009.12.001
   Melendez RI, 2011, ALCOHOL CLIN EXP RES, V35, P652, DOI 10.1111/j.1530-0277.2010.01383.x
   Miles FJ, 2003, BEHAV NEUROSCI, V117, P927, DOI 10.1037/0735-7044.117.5.927
   NAUTA WJH, 1978, NEUROSCIENCE, V3, P385, DOI 10.1016/0306-4522(78)90041-6
   Nelson A, 2006, J NEUROSCI, V26, P3805, DOI 10.1523/JNEUROSCI.4305-05.2006
   Nordquist RE, 2007, EUR NEUROPSYCHOPHARM, V17, P532, DOI 10.1016/j.euroneuro.2006.12.005
   Nutt D, 2007, LANCET, V369, P1047, DOI 10.1016/S0140-6736(07)60464-4
   O'Brien C. P., 2001, GOODMAN GILMANS PHAR, P621
   Oleson EB, 2009, NEUROPSYCHOPHARMACOL, V34, P796, DOI 10.1038/npp.2008.195
   Orio L, 2009, J NEUROSCI, V29, P4846, DOI 10.1523/JNEUROSCI.0563-09.2009
   Pacchioni AM, 2011, BEHAV BRAIN RES, V218, P296, DOI 10.1016/j.bbr.2010.12.014
   Palmer RHC, 2009, DRUG ALCOHOL DEPEN, V102, P78, DOI 10.1016/j.drugalcdep.2009.01.012
   Pandey SC, 2008, J NEUROSCI, V28, P2589, DOI 10.1523/JNEUROSCI.4752-07.2008
   Panlilio LV, 2007, ADDICTION, V102, P1863, DOI 10.1111/j.1360-0443.2007.02011.x
   Paterson NE, 2003, NEUROREPORT, V14, P2229, DOI 10.1097/00001756-200312020-00019
   Paterson NE, 2004, PSYCHOPHARMACOLOGY, V173, P64, DOI 10.1007/s00213-003-1692-7
   Paulus MP, 2005, ARCH GEN PSYCHIAT, V62, P761, DOI 10.1001/archpsyc.62.7.761
   Pelloux Y, 2007, PSYCHOPHARMACOLOGY, V194, P127, DOI 10.1007/s00213-007-0805-0
   Phelps EA, 2005, NEURON, V48, P175, DOI 10.1016/j.neuron.2005.09.025
   PICH EM, 1995, J NEUROSCI, V15, P5439
   Pierce RC, 2010, NEUROSCI BIOBEHAV R, V35, P212, DOI 10.1016/j.neubiorev.2010.01.007
   Pierce RC, 2006, NEUROSCI BIOBEHAV R, V30, P215, DOI 10.1016/j.neubiorev.2005.04.016
   Pitkanen A, 2000, AMYGDALA FUNCTIONAL, P31, DOI DOI 10.1080/713932668
   Porrino LJ, 2004, J NEUROSCI, V24, P3554, DOI 10.1523/JNEUROSCI.5578-03.2004
   Quadros IMH, 2009, PSYCHOPHARMACOLOGY, V206, P109, DOI 10.1007/s00213-009-1584-6
   Rhodes JS, 2005, PHYSIOL BEHAV, V84, P53, DOI 10.1016/j.physbeh.2004.10.007
   Richter RM, 1999, SYNAPSE, V32, P254, DOI 10.1002/(SICI)1098-2396(19990615)32:4<254::AID-SYN2>3.0.CO;2-H
   Robbins TW, 2008, ANN NY ACAD SCI, V1141, P1, DOI 10.1196/annals.1441.020
   Roberto M, 2004, J NEUROSCI, V24, P10159, DOI 10.1523/JNEUROSCI.3004-04.2004
   Roberto M, 2006, P NATL ACAD SCI USA, V103, P9715, DOI 10.1073/pnas.0601899103
   Roberto M, 2010, BIOL PSYCHIAT, V67, P831, DOI 10.1016/j.biopsych.2009.11.007
   Roberts AJ, 2000, NEUROPSYCHOPHARMACOL, V22, P581, DOI 10.1016/S0893-133X(99)00167-0
   ROBERTS DCS, 1977, PHARMACOL BIOCHEM BE, V6, P615, DOI 10.1016/0091-3057(77)90084-3
   Rodd ZA, 2007, PHARMACOGENOMICS J, V7, P222, DOI 10.1038/sj.tpj.6500420
   Rodd ZA, 2003, NEUROPSYCHOPHARMACOL, V28, P1614, DOI 10.1038/sj.npp.1300214
   Rodd-Henricks ZA, 2002, J PHARMACOL EXP THER, V303, P1216, DOI 10.1124/jpet.102.038950
   Rogers RD, 2001, CURR OPIN NEUROBIOL, V11, P250, DOI 10.1016/S0959-4388(00)00204-X
   Roy A, 2002, J PHARMACOL EXP THER, V301, P774, DOI 10.1124/jpet.301.2.774
   Roy A, 2002, ALCOHOL CLIN EXP RES, V26, P796, DOI 10.1111/j.1530-0277.2002.tb02607.x
   Sanna PP, 2002, BRAIN RES, V948, P186, DOI 10.1016/S0006-8993(02)03191-8
   Schneider F, 2001, AM J PSYCHIAT, V158, P1075, DOI 10.1176/appi.ajp.158.7.1075
   See RE, 2005, EUR J PHARMACOL, V526, P140, DOI 10.1016/j.ejphar.2005.09.034
   Sehlmeyer C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005865
   Simms JA, 2008, ALCOHOL CLIN EXP RES, V32, P1816, DOI 10.1111/j.1530-0277.2008.00753.x
   Spanagel R, 1999, ALCOHOL ALCOHOLISM, V34, P231, DOI 10.1093/alcalc/34.2.231
   Spanagel R, 2009, PHYSIOL REV, V89, P649, DOI 10.1152/physrev.00013.2008
   Suto N, 2009, PSYCHOPHARMACOLOGY, V205, P431, DOI 10.1007/s00213-009-1553-0
   THOMPSON T, 1964, PSYCHOPHARMACOLOGIA, V5, P87, DOI 10.1007/BF00413045
   Thorsell A, 2007, BRAIN, V130, P1330, DOI 10.1093/brain/awm033
   TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147
   Tran-Nguyen LTL, 1998, NEUROPSYCHOPHARMACOL, V19, P48
   Uhl GR, 2004, ARCH GEN PSYCHIAT, V61, P223, DOI 10.1001/archpsyc.61.3.223
   Valdez GR, 2002, ALCOHOL CLIN EXP RES, V26, P1494, DOI 10.1097/01.ALC.0000033120.51856.F0
   Van Dongen YC, 2009, ADV BEHAV BIOL, V58, P119, DOI 10.1007/978-1-4419-0340-2_10
   Van Ree JM, 1999, PHARMACOL REV, V51, P341
   Vanderschuren LJMJ, 2005, EUR J PHARMACOL, V526, P77, DOI 10.1016/j.ejphar.2005.09.037
   Vanderschuren LJMJ, 2005, J NEUROSCI, V25, P8665, DOI 10.1523/JNEUROSCI.0925-05.2005
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Vanderschuren LJMJ, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a011932
   Veeneman MMJ, 2012, NEUROPSYCHOPHARMACOL, V37, P487, DOI 10.1038/npp.2011.209
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
   Wang J, 2010, J NEUROSCI, V30, P10187, DOI 10.1523/JNEUROSCI.2268-10.2010
   Watabe-Uchida M, 2012, NEURON, V74, P858, DOI 10.1016/j.neuron.2012.03.017
   Wee S, 2008, EUR NEUROPSYCHOPHARM, V18, P303, DOI 10.1016/j.euroneuro.2007.08.003
   WEEKS JR, 1962, SCIENCE, V138, P143, DOI 10.1126/science.138.3537.143
   Wise RA, 1996, ANNU REV NEUROSCI, V19, P319, DOI 10.1146/annurev.ne.19.030196.001535
   WISE RA, 1973, PSYCHOPHARMACOLOGIA, V29, P203, DOI 10.1007/BF00414034
   Witzmann FA, 2003, PROTEOMICS, V3, P1335, DOI 10.1002/pmic.200300453
   WOLFFGRAMM J, 1991, NEUROSCI BIOBEHAV R, V15, P515, DOI 10.1016/S0149-7634(05)80142-3
   WOLFFGRAMM J, 1995, BEHAV BRAIN RES, V70, P77, DOI 10.1016/0166-4328(95)00131-C
   WOLFFGRAMM J, 1991, PHARMACOL BIOCHEM BE, V38, P389, DOI 10.1016/0091-3057(91)90297-F
   Wong DF, 2006, NEUROPSYCHOPHARMACOL, V31, P2716, DOI 10.1038/sj.npp.1301194
   Wrase J, 2008, AM J PSYCHIAT, V165, P1179, DOI 10.1176/appi.ajp.2008.07121877
   Xue YQ, 2012, EUR J NEUROSCI, V35, P775, DOI 10.1111/j.1460-9568.2012.08000.x
   Zapata A, 2010, J NEUROSCI, V30, P15457, DOI 10.1523/JNEUROSCI.4072-10.2010
   Zhou Y, 2005, NEUROSCIENCE, V134, P1391, DOI 10.1016/j.neuroscience.2005.05.032
   Zhou Y, 2003, MOL BRAIN RES, V114, P73, DOI 10.1016/S0169-328X(03)00139-6
NR 200
TC 39
Z9 39
U1 0
U2 31
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 0334-1763
EI 1607-8470
J9 REV NEUROSCIENCE
JI Rev. Neurosci.
PD NOV
PY 2012
VL 23
IS 5-6
SI SI
BP 731
EP 745
DI 10.1515/revneuro-2012-0066
PG 15
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 083IM
UT WOS:000314456900023
PM 23079511
OA Green Submitted
DA 2023-06-23
ER

PT J
AU Gordon, S
AF Gordon, Sara
TI THE USE AND ABUSE OF MUTUAL-SUPPORT PROGRAMS IN DRUG COURTS
SO UNIVERSITY OF ILLINOIS LAW REVIEW
LA English
DT Article
ID MEDICATION-ASSISTED TREATMENT; SUBSTANCE USE DISORDERS; ADDICTION
   TREATMENT; BARRIERS; ALCOHOL; DISSEMINATION; THERAPY; CARE
AB There is a large gap between what we know about the disease of addiction and its appropriate treatment, and the treatment received by individuals who are ordered into treatment as a condition of participation in drug court. Most medical professionals are not appropriately trained about addiction and most addiction treatment providers do not have the education and training necessary to provide appropriate evidence-based services to individuals who are referred by drug courts for addiction treatment. This disconnect between our understanding of addiction and available addiction treatment has wide reaching impact for individuals who attempt to receive medical care for addiction in this country, as well as for those individuals who are compelled by a drug court to receive that treatment. Instead of receiving evidence-based treatment, most drug court participants are referred to mutual-support groups and programs based largely or entirely on 12-step principles. Mutual-support groups, while well-intentioned and helpful as a supplement to evidence-based addiction treatment, are not a substitute for scientifically valid addiction treatment and should not constitute the primary form of medical assistance received by drug court participants.
   This Article argues that drug and other specialty courts can be part of the transformation of the public perception of addiction, as well as the integration of addiction treatment into mainstream medicine by incorporating and endorsing evidence-based strategies for the treatment of addiction, including psychosocial and pharmacological treatments. Moreover, by adopting these treatments more readily and providing more opportunities for drug court participants to receive evidence-based treatment, drug courts can dramatically improve treatment outcomes for participants.
C1 [Gordon, Sara] Univ Nevada, William S Boyd Sch Law, Law, Las Vegas, NV 89154 USA.
C3 Nevada System of Higher Education (NSHE); University of Nevada Las Vegas
RP Gordon, S (通讯作者)，Univ Nevada, William S Boyd Sch Law, Law, Las Vegas, NV 89154 USA.
CR AM. PSYCHIATRIC ASS'N, 2013, SUBST REL ADD DIS, P1
   AM. Soc'Y ADDICTION MED, 2010, PREF PRACT PATT GUID, P2
   Amato L., 2011, COCHRANE DB SYST REV, V4, P2
   Amato L, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004147.pub4
   American Psychiatric Association [APA], 2022, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425787]
   AMY WINEHOUSE Rehab, 2006, ON REHAB
   [Anonymous], 2014, 12 TRAD ALC AN A
   [Anonymous], 2011, THIS AM LIFE
   Anonymous Alcoholics, 2016, WORLD ENCYCLOPEDIA
   Arias AJ, 2008, ALCOHOL RES HEALTH, V31, P155
   BATTS KATHRYN, 2014, SUBSTANCE ABUSE MEN, P49
   BEATT AVINASH SINGH, 2008, TREAT NOT TREAT EVID, pxi
   BILL W., 2011, ALCOHOLICS ANONYMOUS, P23
   Blum K, 2012, J PSYCHOACTIVE DRUGS, V44, P38, DOI 10.1080/02791072.2012.662112
   Boden MT, 2009, J SUBST ABUSE TREAT, V37, P335, DOI 10.1016/j.jsat.2009.03.012
   Boothroyd RA, 2005, PSYCHIAT SERV, V56, P829, DOI 10.1176/appi.ps.56.7.829
   Brady KT, 2005, AM J PSYCHIAT, V162, P1483, DOI 10.1176/appi.ajp.162.8.1483
   Buchman Daniel Z, 2010, AJOB Neurosci, V1, P36
   Buchman Daniel Z., 2010, AM J BIOETHICS NEURO, V1, P42
   BuFE CHARLES, 1998, ALCOHOLICS ANONYMOUS, P7
   Campbell Mary Aim, 2015, LAW HUMAN BEHAV, V39
   Campbell MA, 2015, LAW HUMAN BEHAV, V39, P489, DOI 10.1037/lhb0000135
   Carroll Kathleen, 2004, ARCH GEN PSYCHIAT, V61, P271
   Carroll KM, 2004, ARCH GEN PSYCHIAT, V61, P264, DOI 10.1001/archpsyc.61.3.264
   Ciccotti G, 2006, LECT NOTES PHYS, V703, P1, DOI [10.1007/3-540-35273-2_0, 10.1007/3-540-35273-2̲0]
   Csete J, 2013, HARM REDUCT J, V10, DOI 10.1186/1477-7517-10-35
   CTR. FOR BEHAVIORAL HEALTH STATISTICS & QUALITY U.S. DEP'T. OF HEALTH & HUMAN SERVS, 2014, RES 2013 NAT SURV DR, V93
   D'Aunno T, 2006, J SUBST ABUSE TREAT, V31, P221, DOI 10.1016/j.jsat.2006.06.016
   D'Aunno Thomas, 2006, J SUBST ABUSE TREAT, V31, P230
   Dackis C, 2005, NAT NEUROSCI, V8, P1431, DOI 10.1038/nn1105-1431
   Department of Agriculture and Co-operation, 2014, STAT PAP OILS, P1
   DODES LANCE, 2014, TRUTH DEBUNKING BAD, V17
   Edgely M, 2014, INT J LAW PSYCHIAT, V37, P572, DOI 10.1016/j.ijlp.2014.02.031
   Edwards T, 2000, WISC LAW REV, P283
   Fortuna JL, 2012, J PSYCHOACTIVE DRUGS, V44, P56, DOI 10.1080/02791072.2012.662092
   Galanter Marc, 2003, RECENT DEV ALCOHOLIS, V16, P149
   Glaser Gabrielle, 2015, ATLANTIC
   Grant JE, 2010, AM J DRUG ALCOHOL AB, V36, P233, DOI 10.3109/00952990.2010.491884
   Grant Jon E., 2013, PSYCHIAT TIMES
   Green LW, 2009, ANNU REV PUBL HEALTH, V30, P151, DOI 10.1146/annurev.publhealth.031308.100049
   Griffiths Mark D., 2016, PSYCHOLOGY
   Hammer Rachel, 2013, AJOB Neurosci, V4, P27
   Hammer Rachel, 2013, AM J BIOETHICS NEURO, V4, P28
   Heckman CJ, 2008, AM J HEALTH BEHAV, V32, P451, DOI 10.5555/ajhb.2008.32.5.451
   Hoffman M, 2000, NC L REV, V78, P1437
   HUDDLESTON WEST, 2011, PAINTING CURRENT PIC, V8
   Humphreys K, 2004, J SUBST ABUSE TREAT, V26, P151, DOI 10.1016/S0740-5472(03)00212-5
   Hyman SE, 2003, SCIENCE, V299, P350, DOI 10.1126/science.1077141
   INST. FOR BEHAV. RES, 2006, DEL NATL TREATM CTR, P6
   INST URBAN, 2011, MULT AD DRUG COURT E, P51
   JUST. POL'Y INST, 2011, ADD COURTS GROW DEP, P2
   Karim R, 2012, J PSYCHOACTIVE DRUGS, V44, P5, DOI 10.1080/02791072.2012.662859
   Kerwin ME, 2006, J SUBST ABUSE TREAT, V30, P173, DOI 10.1016/j.jsat.2005.11.004
   KING RYAN S., 2009, SENTENCING PROJECT D, P1
   Knudsen HK, 2011, EVAL PROGRAM PLANN, V34, P375, DOI 10.1016/j.evalprogplan.2011.02.004
   Knudsen HK, 2010, J ADDICT MED, V4, P99, DOI 10.1097/ADM.0b013e3181b41a32
   KURTZ ERNEST, 1979, NOT GOD HIST ALCOHOL, V17
   Lamb Sara, 1998, BRIDG GAP PRACT RES, P29
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Leshner Alan I., 2001, ISSUES SCI TECH, V17
   Lundgren L, 2011, AM J ADDICTION, V20, P271, DOI 10.1111/j.1521-0391.2011.00127.x
   MANN CINDY, 2014, MED ASS TREATM SUBST, P3
   Markel Howard, 2010, NY TIMES
   MARLOWE DOUGLAS B., 2010, RES UPDATE ADULT DRU, P1
   Matusow H, 2013, J SUBST ABUSE TREAT, V44, P473, DOI 10.1016/j.jsat.2012.10.004
   McCarty D, 2007, PSYCHIAT SERV, V58, P181, DOI 10.1176/appi.ps.58.2.181
   McCarty D, 2009, J BEHAV HEALTH SER R, V36, P52, DOI 10.1007/s11414-008-9108-4
   McCarty Dennis, 2007, PSYCHIAT SERVS, V58, P188
   McHugh RK, 2010, PSYCHIAT CLIN N AM, V33, P511, DOI 10.1016/j.psc.2010.04.012
   McLellan AT, 2004, BIOL PSYCHIAT, V56, P764, DOI 10.1016/j.biopsych.2004.06.018
   Morris ZS, 2011, J ROY SOC MED, V104, P510, DOI 10.1258/jrsm.2011.110180
   NAT'L ASS'N OF DRUG COURT PROF'LS, 2011, REP NAT FOR RES COMM, P2
   NAT'L INST. ON DRUG ABUSE (NIDA), 2006, PRINC DRUG ABUS TREA, P18
   NAT'L QUALITY FORUM, 2005, EV BAS TREATM PRACT, V15
   NAT'L TREATMENT CENTER STUDY, 2004, 809512 DOT HS NAT HI, P22
   NATIONAL TREATMENT CENTER STUDY, 2004, 158 NTC, p[21, 158, 22]
   NIDA. National Institute on Drug Abuse National Institutes of Health. U.S. Department of Health and Human Services, 2012, PRINC DRUG ADD TREAT
   NOLAN JR JAMES L., 2001, REINVENTING JUSTICE, V5
   NTP, 2012, NTP MON HLTH EFF LOW, pi
   Olmstead TA, 2012, DRUG ALCOHOL DEPEN, V120, P149, DOI 10.1016/j.drugalcdep.2011.07.017
   Pace Eric, 1996, NY TIMES
   Pollack HA, 2008, HEALTH SERV RES, V43, P2143, DOI 10.1111/j.1475-6773.2008.00870.x
   Rawson RA, 2000, J PSYCHOACTIVE DRUGS, V32, P371, DOI 10.1080/02791072.2000.10400238
   Rawson Richard A., 2011, J PSYCHOACTIVE DRUGS, V32, P372
   Shaffer HJ, 2004, HARVARD REV PSYCHIAT, V12, P367, DOI 10.1080/10673220490905705
   SULLIVAN ELEANOR, 1997, GUIDE SUBSTANCE ABUS, V66
   Tovino SA, 2016, WASH LAW REV, V91, P1253
   Vocci F, 2005, PHARMACOL THERAPEUT, V108, P94, DOI 10.1016/j.pharmthera.2005.06.010
   Volkow ND, 2005, AM J PSYCHIAT, V162, P1401, DOI 10.1176/appi.ajp.162.8.1401
   WALLACE DAVID FOSTER, 1986, INFINITE JEST, V180
   Weinstein A, 2010, AM J DRUG ALCOHOL AB, V36, P277, DOI 10.3109/00952990.2010.491880
   Westfall JM, 2007, JAMA-J AM MED ASSOC, V297, P403, DOI 10.1001/jama.297.4.403
   Winerman L., 2013, MONITOR PSYCHOL, V44, P30
   Winerman Lea, 2013, MONITOR PSYCHOL, V44, P31
   WORKGROUP ON SUBSTANCE ABUSE SELF-HELP ORGANIZATIONS, 2003, SELF HELP ORG SELF H, P1
   YOKOTE G, 1974, B MED LIBR ASSOC, V62, P251
NR 96
TC 0
Z9 0
U1 0
U2 2
PU UNIV ILLINOIS
PI CHAMPAIGN
PA COLLEGE OF LAW-76 LAW BLDG 504 E PENNSYLVANIA AVE, CHAMPAIGN, IL 61820
   USA
SN 0276-9948
EI 1942-9231
J9 U ILLINOIS LAW REV
JI Univ. Ill. Law Rev.
PY 2017
IS 4
BP 1503
EP 1543
PG 41
WC Law
WE Social Science Citation Index (SSCI)
SC Government & Law
GA FF8QZ
UT WOS:000409284200006
DA 2023-06-23
ER

PT J
AU Lewy, J
AF Lewy, Jonathan
TI The Army Disease: Drug Addiction and the Civil War
SO WAR IN HISTORY
LA English
DT Article
DE Civil war; addiction; opium; morphine; drugs; veterans
AB Since the beginning of the twentieth century, historians and doctors have claimed that the 'army disease' of both the Union and the Confederate armies was morphine addiction. But since drug addiction was not yet fully understood in medical texts of the mid-1860s, addiction as the army disease could have been perceived only in hindsight. Whether addiction was prevalent among veteran troops or not, one thing can be firmly ascertained: after the Civil War, every other war in American history has brought with it a drug problem, whether real or imagined.
C1 [Lewy, Jonathan] Harvard Univ, Cambridge, MA 02138 USA.
C3 Harvard University
RP Lewy, J (通讯作者)，67 Nof Harim St, IL-90805 Mevasseret Zion, Israel.
EM gaeseric@mscc.huji.ac.il
CR Adams George W., 1952, DOCTORS BLUE MED HIS, p[50, 119]
   Allbutt Clifford, 1870, DRUGS AM DOCUMENTARY, P229
   [Anonymous], 1833, BOSTON MED SURG J, VIX, P66
   [Anonymous], 1917, PRIVATE OFFICIAL COR, V2, P263
   [Anonymous], 1863, HERALD HLTH, VII, P188
   [Anonymous], 1865, VINCENNES GAZET 0125
   [Anonymous], 1867, DELAWARE COUNTY 1122
   [Anonymous], 1876, OPIUM EATING AUTOBIO, P55
   [Anonymous], 1877, NY TIMES
   [Anonymous], 1868, DELAWARE COUNTY 0129
   [Anonymous], 1864, PRIVATE OFFICIAL COR, V5, P748
   [Anonymous], 1911, CONFEDERATE SURG LET, P28
   [Anonymous], 1878, NATL REPOSITORY, VIII, P202
   [Anonymous], 1868, FRIENDS INTELLIGENCE, P825
   ANSLINGER HJ, 1953, TRAFFIC NARCOTICS
   Beasley Henry, 1865, BOOK PRESCRIPTIONS, P371
   Bollet Alfred Jay, 2002, CIVIL WAR MED CHALLE, p[240, 247]
   Burnham J. C., 1993, BAD HABITS DRINKING
   Calkins Alonzo, 1871, OPIUM OPIUM APPETITE, P151
   Castleman Alfred Lewis, 1863, ARMY POTOMAC SCENES, P236
   Chardin John, 1720, NEW ACCURATE DESCRIP, P247
   Christison Robert, 1832, LANCET, VXVII, P614
   Cole Rufus, 1918, KENTUCKY MED J, VXVI, P563
   Coonfield Gordon, 2003, THESIS MICHIGAN TECH, P13
   Courtwright David T., 2001, DARK PARADISE HIST O, P9
   Courtwright David T., 2001, FORCES HABIT DRUGS M, P36
   COURTWRIGHT DT, 1983, J SOUTHERN HIST, V49, P57, DOI 10.2307/2209306
   COURTWRIGHT DT, 1978, CIVIL WAR HIST, V24, P101
   Crothers T. D., 1893, DIS INEBRIETY ALCOHO, P170
   Crothers Thomas D., 1902, MORPHINISM NARCOMANI, P25
   Darwin Erasmus, 1803, ZOONOMIA LAWS ORGANI, V1, P23
   Davis Steve, 1998, BLUE GRAY MAGAZI OCT
   Day Horace B., 1868, OPIUM HABIT SUGGESTI, P7
   De Quincey Thomas, 1997, CONFESSIONS ENGLISH
   de Tott Francois, 1786, MEMOIRS BARON TOTT, V1, P141
   Dean Eric T., 1997, SHOOK HELL POSTTRAUM, p[162, 169]
   Douglass Joseph D., 1990, RED COCAINE DRUGGING
   Erlenmeyer Albrecht, 1887, MORPHIUMSUCHT IHRE B, P404
   Fenner E. D., 1861, MED J N CAROLINA, VIII, P659
   Figg Royall W., 1885, MEN ONLY DARE GO STO, P163
   Flannery Michael A., 2004, CIVIL WAR PHARM HIST, p[66, 193]
   Fleming George Thornton, 1919, LIFE LETT A HAYS BRE, P389
   Foxcroft Louise, 2007, USE ABUSE OPIUM 19 C
   Giles Geoffrey J., 2006, CRIMINALS THEIR SCI, P471
   Gordon C. B., 1872, BRIT MED J, VII, P51
   Gross Samuel D., 1861, MANUAL MILITARY SURG, P53
   Gross Samuel D., 1866, SYSTEM SURG, V1, P621
   Harari YN, 2008, ULTIMATE EXPERIENCE: BATTLEFIELD REVELATIONS AND THE MAKING OF MODERN WAR CULTURE, 1450-2000, P1, DOI 10.1057/9780230583887
   Hickman Timothy Alton, 2007, SECRETE LEPROSY MODE, p[8, 16]
   Hosmer James Kendall, 1864, COLOR GUARD BEING CO, p[172, 174]
   Huss M., 1852, CHRONISCHE ALKOHOLSK
   Jaffe Arnold, 1981, ADDICTION REFORM PRO, P27
   Kane H. H., 1882, OPIUM SMOKING AM CHI
   Keeley Leslie E., 1892, OPIUM ITS USE ABUSE, P120
   Kuzmarov J., 2009, MYTH ADDICTED ARMY
   Kuzmarov Jeremy, 2008, J POLICY HIST, V20, P344
   Levinstein E., 1878, MORBID CRAVING MORPH
   Levinstein E., 1877, MORPHIUMSUCHT MONOGR
   Lewy Jonathan, 2010, COMMUNICATION
   Mart G. R., 1832, LANCET, VXVII, P710
   Marten J, 2001, CIVIL WAR HIST, V47, P57, DOI 10.1353/cwh.2001.0011
   Mill John Stuart, 1985, LIBERTY, P148
   Musto DF, 1999, AM DIS, P2
   Oliver F. E., 1872, MASSACHUSETTS STATE, p[162, 168]
   Parrish Joseph, 1869, PROBE INQUIRY USE ST
   QUINONES MA, 1975, INT J ADDICT, V10, P1007, DOI 10.3109/10826087509028357
   Reinegg Jakob, 1785, MED BIBLIO, V2, P370
   Spillane Joseph, 2000, COCAINE MED MARVEL M, P75
   Street Jr James, 1988, CIVIL WAR TIMES  MAY
   Terry Charles E., 1928, OPIUM PROBLEM, P67
   Tracy Sarah W., 2005, ALCOHOLISM AM RECONS, P63
   Valverde Mariana, 1998, DIS WILL ALCOHOL DIL, p[26, 44]
   Velazquez Loreta Janeta, 1876, WOMAN BATTLE NARRATI, P504
   von Bruhl-Cramer C., 1819, UEBER TRUNKSUCHT RAT, p[10, 16]
   VONBRUHLCRAMER C, 1819, TRUNKSUCHT RATIONELL
   Waldorf Dan, 1974, MORPHINE MAINTENANCE, P20
   Warner John Harley, 1986, THERAPEUTIC PERSPECT, P143
   Warner Oliver, 1866, 23 LEG MASS REL REG, P69
   Welch Francis H., 1883, ENTERIC FEVER ITS PR, P4
   Whitman Walt, 1875, MEMORANDA WAR, p[18, 53]
   Wiesemann Claudia, 2000, HEIMLICHE KRANKHEIT, P69
NR 81
TC 6
Z9 6
U1 1
U2 19
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0968-3445
EI 1477-0385
J9 WAR HIST
JI War Hist.
PD JAN
PY 2014
VL 21
IS 1
BP 102
EP 119
DI 10.1177/0968344513504724
PG 18
WC History; International Relations
WE Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)
SC History; International Relations
GA AI9US
UT WOS:000337286300005
DA 2023-06-23
ER

PT J
AU Nestler, EJ
   Landsman, D
AF Nestler, EJ
   Landsman, D
TI Learning about addiction from the genome
SO NATURE
LA English
DT Article
ID MU-OPIOID RECEPTOR; PROTEINS; NEUROSCIENCE; SENSITIVITY; PROGRESS; GENES
AB Drug addiction can be defined as the compulsive seeking and taking of a drug despite adverse consequences. Although addiction involves many psychological and social factors, it also represents a biological process: the effects of repeated drug exposure on a vulnerable brain. The sequencing of the human and other mammalian genomes will help us to understand the biology of addiction by enabling us to identify both genes that contribute to individual risk for addiction and those through which drugs cause addiction. We illustrate this potential impact by searching a draft sequence of the human genome for genes related to desensitization of receptors that mediate the actions of drugs of abuse on the nervous system.
C1 Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75390 USA.
   Natl Lib Med, Natl Ctr Biotechnol Informat, Computat Biol Branch, Bethesda, MD 20892 USA.
C3 University of Texas System; University of Texas Dallas; University of
   Texas Southwestern Medical Center Dallas; National Institutes of Health
   (NIH) - USA; NIH National Library of Medicine (NLM)
RP Nestler, EJ (通讯作者)，Univ Texas, SW Med Ctr, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
RI Landsman, David/C-5923-2009; Landsman, David/GZK-5496-2022
OI Landsman, David/0000-0002-9819-6675; 
CR Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269
   Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086
   Crabbe JC, 1999, TRENDS NEUROSCI, V22, P173, DOI 10.1016/S0166-2236(99)01393-4
   Gaudet R, 1999, MOL CELL, V3, P649, DOI 10.1016/S1097-2765(00)80358-5
   Kandel ER, 1997, J CELL PHYSIOL, V173, P124, DOI 10.1002/(SICI)1097-4652(199711)173:2<124::AID-JCP6>3.3.CO;2-5
   Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7
   Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870
   Nestler EJ, 2000, NAT GENET, V26, P277, DOI 10.1038/81570
   Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58
   PEARSON WR, 1991, GENOMICS, V11, P635, DOI 10.1016/0888-7543(91)90071-L
   Potenza MN, 1999, J PHARMACOL EXP THER, V291, P482
   SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5
   Wise RA, 1998, DRUG ALCOHOL DEPEN, V51, P13, DOI 10.1016/S0376-8716(98)00063-5
   Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157
NR 15
TC 63
Z9 66
U1 0
U2 11
PU MACMILLAN PUBLISHERS LTD
PI LONDON
PA PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD FEB 15
PY 2001
VL 409
IS 6822
BP 834
EP 835
DI 10.1038/35057015
PG 2
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 401QC
UT WOS:000166938800049
PM 11237002
OA Bronze
DA 2023-06-23
ER

PT J
AU Wang, ZY
   Li, WX
   Liu, ZM
AF Wang, Ziyun
   Li, Wei-xiu
   Liu Zhi-min
TI Similarity and Difference in Drug Addiction Process Between Heroin- and
   Methamphetamine-Dependent Users
SO SUBSTANCE USE & MISUSE
LA English
DT Article
DE Drug dependence; drug addiction process; drug use career; heroin;
   methamphetamine
ID OCCASIONAL CANNABIS USE; NEUROCHEMICAL SENSITIZATION; SINGLE EXPOSURE;
   RATS; MICE
AB Objectives: This study aimed to compare the drug addiction process between Chinese heroin- and methamphetamine (MA)- dependent users via a modified 4- stage addiction model (experimentation, occasional use, regular use, and compulsive use). Methods: A descriptive study was conducted among 683 eligible participants. In the statistical analysis, we selected 340 heroin- and 295 MA- dependent userswithout illicit drug use prior to onset of heroin orMAuse. Results: The addiction process of heroindependent userswas shorter than that ofMA- dependent users, with shorter transitions fromthe onset of drug- use to the first drug craving (19.5 vs. 50.0 days), regular use (30.0 vs. 60.0 days), and compulsive use (50.0 vs. 85.0 days). However, no significant differences in the addiction process were observed in frequency of drug administration, except that heroin users reported more administrations of the drug (20.0 vs. 15.0) before progressing to the stage of compulsive drug use. A larger proportion of regular heroin users progressed to use illicit drugs recklessly than did MA users. Most heroin and MA users reported psychological dependence as their primary motivation for compulsive drug use, but more heroin users selected uncomfortable symptoms upon ceasing drug use as further reason to continue. Conclusion: Our results suggest that typical heroin and MA users may experience a similar four- stage addiction process, but MA usersmight undergo a longer addiction process (in days). More research is necessary to further explore factors influencing the drug addiction process.
C1 [Wang, Ziyun] Guizhou Med Univ, Sch Publ Hlth, Guian New Area, Guiyang, Peoples R China.
   [Wang, Ziyun; Li, Wei-xiu] Peking Univ, Sch Publ Hlth, Beijing, Peoples R China.
   [Li, Wei-xiu] Shandong Ctr Dis Control & Prevent, Jinan, Shandong, Peoples R China.
   [Liu Zhi-min] Peking Univ, Natl Inst Drug Dependence, Beijing, Peoples R China.
C3 Guizhou Medical University; Peking University; Peking University
RP Liu, ZM (通讯作者)，Peking Univ, Hlth Sci Ctr, Natl Inst Drug Dependence, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
EM zhiminliu@bjmu.edu.cn
OI ll, li/0000-0001-9925-3021
FU Chinese Ministry of Science and Technology [2012BAI01B07]
FX The study was funded by the Twelfth Five-Year Program of the Chinese
   Ministry of Science and Technology (2012BAI01B07).
CR Bao YP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060544
   Brecht ML, 2004, ADDICT BEHAV, V29, P89, DOI 10.1016/S0306-4603(03)00082-0
   Casa Palmera Staff, 2009, 4 STAG DRUG ADD
   Chauhan H, 2014, INT J MOL SCI, V15, P5884, DOI 10.3390/ijms15045884
   Chein I, 1964, ROAD H NARCOTICS DEL
   China Food and Drug Administration, 2014, NAT DRUG AB MON REP
   China National Narcotic Control Committee, 2015, ANN REP DRUG CONTR C
   Degenhardt L, 2010, BRIT J PSYCHIAT, V196, P290, DOI 10.1192/bjp.bp.108.056952
   Huas C, 2008, EUR J PUBLIC HEALTH, V18, P626, DOI 10.1093/eurpub/ckn065
   Jia S. W, 2013, PSYCHOACTIVE SUBSTAN
   Jing L, 2014, NEUROSCI LETT, V560, P103, DOI 10.1016/j.neulet.2013.12.024
   Larcher A, 1998, NEUROSCIENCE, V84, P583, DOI 10.1016/S0306-4522(97)00556-3
   Li J., 2009, YOUTH STUDIES, P19
   Li JinE, 2011, Occupation and Health, V27, P681
   Lian Z., 2003, VALIDITY RELIABILITY
   Liu Z., 2001, 3 STAGES DRUG ADDICT
   *NAT I DRUG AB, 1999, PRINC DRUG ADD TREAT
   Paul R., 4 STAGES DRUG ABUSE
   Reske M, 2011, J PSYCHIATR RES, V45, P361, DOI 10.1016/j.jpsychires.2010.07.005
   Silva CD, 2014, NEUROTOX RES, V25, P295, DOI 10.1007/s12640-013-9423-2
   Swift W, 2008, ADDICTION, V103, P1361, DOI 10.1111/j.1360-0443.2008.02246.x
   Tulloch I, 2011, NEUROSCIENCE, V193, P162, DOI 10.1016/j.neuroscience.2011.07.020
   United Nations Office on Drugs and Crime (UNODC), 2014, WORLD DRUG REP 2014
   UNODC (United Nations Office on Drugs and Crime), 2013, WORLD DRUG REP 2013
   Vanderschuren LJMJ, 1999, J NEUROSCI, V19, P9579, DOI 10.1523/jneurosci.19-21-09579.1999
   Vanderschuren LJMJ, 2001, EUR J NEUROSCI, V14, P1533, DOI 10.1046/j.0953-816x.2001.01775.x
   Wang X., 2011, CHINESE J SCH HLTH, V32, P546
   [王子云 Wang Ziyun], 2015, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V24, P60
   World Health Organization, 1994, LEX ALC DRUG TERMS
   Yan H., 2010, MED STAT, V2nd
   Zhang W. T., 2011, BASIC TUTORIAL STAT
   [邹海欧 Zou Haiou], 2012, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V21, P459
NR 32
TC 8
Z9 9
U1 0
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1082-6084
EI 1532-2491
J9 SUBST USE MISUSE
JI Subst. Use Misuse
PY 2017
VL 52
IS 4
BP 459
EP 467
DI 10.1080/10826084.2016.1245331
PG 9
WC Substance Abuse; Psychiatry; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry; Psychology
GA EL2EI
UT WOS:000394432500006
PM 28001458
DA 2023-06-23
ER

PT C
AU Naydyonov, A
   Krivenko, I
   Naydyonova, A
AF Naydyonov, Alexey
   Krivenko, Ilya
   Naydyonova, Alina
GP SGEM
TI INFLUENCE OF SOCIAL AND ECONOMIC FACTORS ON A DYNAMIC OF DRUG CRIMES IN
   RUSSIA
SO SGEM 2016, BK 2: POLITICAL SCIENCES, LAW, FINANCE, ECONOMICS AND TOURISM
   CONFERENCE PROCEEDINGS, VOL III
SE International Multidisciplinary Scientific Conferences on Social
   Sciences and Arts
LA English
DT Proceedings Paper
CT 3rd International Multidisciplinary Scientific Conference on Social
   Sciences and Arts, SGEM 2016
CY AUG 24-30, 2016
CL Albena, BULGARIA
SP Bulgarian Acad Sci, Acad Sci Czech Republ, Latvian Acad Sci, Polish Acad Sci, Russian Acad Sci, Serbian Acad Sci & Arts, Slovak Acad Sci, Natl Acad Sci Ukraine, Natl Acad Sci Armenia, Sci Council Japan, World Acad Sci, European Acad Sci, Arts & Letters, Acad Fine Arts Zagreb Croatia, Croatian Acad Sci & Arts, Acad Sci Moldova, Montenegrin Acad Sci & Arts, Georgian Acad Sci, Acad Fine Arts & Design Bratislava, Russian Acad Arts, Turkish Acad Sci, Bulgarian Cultural Inst Vienna
DE drug abuse; drug addiction; economic security; econometric modeling;
   crime
AB The purpose of research is to identify factors of social and economic environment influencing drug addiction and to verify the hypothesis that drug addiction is more economic problem than social or medical.
   The methodology of research is an econometric modeling of drug addiction with regard to the impact of different economic and social factors. We have build linear and logistic models and identified the role poverty, unemployment and other parameters on the level of drug addiction in Russian regions. In order to take into account possible diversity of Russian regions with reference to the patterns of drug addiction we made preliminary clusterization of regions.
   Due to the fact of huge diversification between Russia regions in terms of the typology of drug situation we had made preliminary classification of regions on the basis of their profile in order to provide few econometric models. Classification was made by SVN method and k-means.
   Modeling of the influence of social and economic factors on drugs addiction in Russian regions was made with logistic and linear regression. As a performance criteria we used accuracy value.
   Models obtained show good accuracy and effectiveness. According to the results of modeling we found high priority of economic and social measures in counteraction to drug addiction.
C1 [Naydyonov, Alexey; Krivenko, Ilya] Russian Acad Sci, Inst Econ, Ural Branch, Ekaterinburg, Russia.
   [Naydyonova, Alina] Ural State Univ, Ekaterinburg, Sverdlovsk Obla, Russia.
C3 Institute of Economics of the Ural Branch of the Russian Academy of
   Sciences; Russian Academy of Sciences; Ural Federal University
RP Naydyonov, A (通讯作者)，Russian Acad Sci, Inst Econ, Ural Branch, Ekaterinburg, Russia.
FU Russian Scientific Fund for the Humanities [15-32-01293a2]
FX This research was financially supported by the Russian Scientific Fund
   for the Humanities (project No 15-32-01293a2).
CR Gurban I.A., 2012, EC REGION RUSSIA, P34
   Gurban I. A., 2015, MEDITERRANEAN J SOCI, V6, P197
   Gurban I, 2014, INT MULTIDDISCIP SCI, P209
   Rastvortseva S., 2014, SGEM INT MULT SCI C, V3, P25, DOI [10.5593/sgemsocial2014/B23/S7.003, DOI 10.5593/SGEMSOCIAL2014/B23/S7.003]
   Rastvortseva S., 2014, SGEM INT MULT SCI C, V3, P75, DOI [10.5593/sgemsocial2014/B23/S7.009, DOI 10.5593/SGEMSOCIAL2014/B23/S7.009]
   Sirotin V.P., 2009, EC REGION RUSSIA, P186
NR 6
TC 0
Z9 0
U1 0
U2 0
PU STEF92 TECHNOLOGY LTD
PI SOFIA
PA 1 ANDREY LYAPCHEV BLVD, SOFIA, 1797, BULGARIA
SN 2367-5659
BN 978-619-7105-74-2
J9 INT MULTIDDISCIP SCI
PY 2016
BP 909
EP +
PG 3
WC Business, Finance; Social Sciences, Interdisciplinary
WE Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)
SC Business & Economics; Social Sciences - Other Topics
GA BH0OD
UT WOS:000395727000114
DA 2023-06-23
ER

PT J
AU Prada, OC
   Perali, M
   Giubettini, M
AF Prada, Ozrem Carella
   Perali, Marco
   Giubettini, Maria
TI Considerations about psychopathology of drug addiction
SO RIVISTA DI PSICHIATRIA
LA Italian
DT Review
DE drug addiction; personality
ID PAIN; CANCER
AB In this study, the drug addiction, the physical dependence and the abstinence crisis are explained with analysis of literature and effective psychodynamic interpretation. Drug addiction can be considered similar to a particular procedure of deterioration of pre-existing personality disorder dependent on the environment. The addiction is structured around a dependency for a substance or significant object or behaviour. During the last years many articles have shown the prevalence of this personality disorder that is interpretable as a loss of psychic "feeling of safety". In the event that the psychic mechanisms of defence become inadequate, drug repairs the efficiency of psychic feeling of safety through mimetic splitting and negation mechanism. Physical correlations of drug addiction, physical dependence and abstinence crisis are interpretable as a complex metabolic and neurovegetative syndrome: is therefore likely that behavioural patterns of addiction comes from processes of the central nervous system that support activities instinctual.
C1 [Prada, Ozrem Carella; Perali, Marco; Giubettini, Maria] Univ Roma, Dipartimento Med Legale & Assicuraz Cesare Gerin, Rome, Italy.
C3 Sapienza University Rome
RP Prada, OC (通讯作者)，Univ Roma, Dipartimento Med Legale & Assicuraz Cesare Gerin, Rome, Italy.
EM verbalink@libero.it
CR BLUM K, 1995, PHARMACOGENETICS, V5, P121, DOI 10.1097/00008571-199506000-00001
   BOGDANOFF B, 1972, AM J DIS CHILD, V123, P145, DOI 10.1001/archpedi.1972.02110080123015
   Breivik H, 2001, ACTA ANAESTH SCAND, V45, P1059, DOI 10.1034/j.1399-6576.2001.450902.x
   COLLIN E, 1993, PAIN, V55, P319, DOI 10.1016/0304-3959(93)90007-C
   Compton WM, 2000, AM J ADDICTION, V9, P113
   Cowen DT, 2001, PAIN MED, V2, P193, DOI 10.1046/j.1526-4637.2001.01026.x
   DIGIANNANTONIO M, 1985, B FARMACODIPENDENZE, V8, P230
   Eguchi K, 1980, Nihon Sanka Fujinka Gakkai Zasshi, V32, P663
   GERRA G, SOSTANZE ABUSO
   KERNBERG OF, 1987, J AM PSYCHOANAL ASS, V35, P795, DOI 10.1177/000306518703500401
   Kernberg Otto F., 1975, BORDERLINE CONDITION
   KLEIN GS, 1976, TEORIA PSICOANALITIC
   Lalli N., 1999, MANUALE PSICHIATRIA
   Leary T., 1964, PSYCHEDELIC EXPERIEN
   MANNA V, DISEDONIA RUOLO DISR
   MELZACK R, 1990, SCI AM, V262, P27, DOI 10.1038/scientificamerican0290-27
   PALERMO A, 1980, MEZZOGIORNO SANITARI, V5, P285
   PRADA OC, 1992, GIUSTIZIA PENALE, V97, P6
   PRADA OC, 1991, GIUSTIZIA PENALE, V96, P2
   RAVERA F, 1995, DISTURBI PERSONALITA
   RAVERA F, ASPETTI PSICODINAMIC
   SANDLER S, 2002, OGGETTI INTERNI RIVI
   Schneider K., 1983, PSICOPATOLOGIA CLIN
   SERPILLONI G, MODELLISTICA INTERPR
   VENDRAMIN A, 1996, CLASSIFICAZIONE SOST, P44
   WEISSMAN DE, 1989, PAIN, V36, P363, DOI 10.1016/0304-3959(89)90097-3
   WHO, 2004, NEUR PSYCH SUBST US
   1995, SILVESTRINI MALATI D
NR 28
TC 1
Z9 1
U1 1
U2 14
PU PENSIERO SCIENTIFICO EDITOR
PI ROME
PA VIA BRADANO 3/C, 00199 ROME, ITALY
SN 0035-6484
EI 2038-2502
J9 RIV PSICHIATR
JI Riv. Psichiatr.
PD MAR-APR
PY 2008
VL 43
IS 2
BP 72
EP 78
PG 7
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA 294MW
UT WOS:000255411100002
DA 2023-06-23
ER

PT J
AU Delic, M
   Pregelj, P
AF Delic, Mirjana
   Pregelj, Peter
TI FACTORS ASSOCIATED WITH THE OUTCOME OF DRUG ADDICTION TREATMENT
SO PSYCHIATRIA DANUBINA
LA English
DT Article
DE drug addiction; treatment outcome; substitution therapy; drug abuse
AB Despite different treatment approaches many patients with drug addiction continue to use drugs during and after treatment. Approximately 50 percent of the patients in substance abuse treatment do not complete the first month of treatment, and this is associated with poor outcome. Attempts have been made to improve outcomes of addiction treatment by addressing patient characteristics that predict continued drug use. Appropriate instruments have been developed in order to facilitate assessment and outcome research. It could be concluded that different psychosocial factors could serve as a predictor of drug addiction treatment outcome. However the interplay of these factors is still poorly understood and further research is needed.
C1 [Delic, Mirjana; Pregelj, Peter] Univ Psychiat Hosp Ljubljana, Ljubljana, Slovenia.
   [Pregelj, Peter] Univ Ljubljana, Dept Psychiat, Fac Med, Zaloska 29, SI-1000 Ljubljana, Slovenia.
C3 University Medical Centre Ljubljana; University of Ljubljana
RP Pregelj, P (通讯作者)，Univ Ljubljana, Dept Psychiat, Fac Med, Zaloska 29, SI-1000 Ljubljana, Slovenia.
EM peter.pregelj@psih-klinika.si
RI Pregelj, Peter/P-5079-2015
CR Andrews G., 1994, MEASUREMENT CONSUMER
   Baker S L Jr, 1978, Ann N Y Acad Sci, V311, P253, DOI 10.1111/j.1749-6632.1978.tb16782.x
   Brewer DD, 1998, ADDICTION, V93, P73, DOI 10.1046/j.1360-0443.1998.931738.x
   Clancy CM, 1998, SCIENCE, V282, P245, DOI 10.1126/science.282.5387.245
   Conroy A, 1998, 65 NDARC
   Copeland JR, 2000, NDARC MONOGRAPH, V45
   Gossop M, 2003, ADDICTION, V98, P291, DOI 10.1046/j.1360-0443.2003.00296.x
   Greenfield SF, 2007, DRUG ALCOHOL DEPEN, V86, P1, DOI 10.1016/j.drugalcdep.2006.05.012
   HUBBARD RL, DRUG ABUSE TREATMENT
   Jaffe JH, 1988, NIDA RES MONOGR, V51
   Mandersen J., 2001, ADICCIONES, V13, P217
   Marsden J, 1998, ADDICTION, V93, P1857, DOI 10.1046/j.1360-0443.1998.9312185711.x
   Marsden J, 2009, LANCET, V374, P1262, DOI 10.1016/S0140-6736(09)61420-3
   MCGLOTHLIN WH, 1977, AM J DRUG ALCOHOL AB, V4, P179, DOI 10.3109/00952997709002759
   MCLELLAN AT, 1985, J NERV MENT DIS, V173, P412, DOI 10.1097/00005053-198507000-00005
   MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006
   MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199, DOI 10.1016/0740-5472(92)90062-S
   MCLELLAN AT, 1983, ARCH GEN PSYCHIAT, V40, P620
   O'Brien CP, 1975, NAT I DRUG AB C REST
   Robins L. N., 1974, SPEICAL ACTION OFF A, V2
   SIMPSON DD, 1982, ADV ALCOHOL SUBSTANC, V0002
   Simpson DD, 1990, OVERVIEW 12 YEAR OUT
   STARK MJ, 1992, CLIN PSYCHOL REV, V12, P93, DOI 10.1016/0272-7358(92)90092-M
   Tims FM, 1988, NIDA RES MONOGR, V51
   Toumbourou JW, 1998, ADDICTION, V93, P1051, DOI 10.1046/j.1360-0443.1998.937105110.x
   WELLS EA, 1988, INT J ADDICT, V23, P851, DOI 10.3109/10826088809058843
NR 26
TC 7
Z9 8
U1 1
U2 9
PU MEDICINSKA NAKLADA
PI ZAGREB
PA VLASKA 69, HR-10000 ZAGREB, CROATIA
SN 0353-5053
J9 PSYCHIAT DANUB
JI Psychiatr. Danub.
PY 2013
VL 25
SU 2
BP S337
EP S340
PG 4
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA V45JZ
UT WOS:000209814200058
PM 23995204
DA 2023-06-23
ER

PT J
AU Haller, R
AF Haller, R
TI Do we need new treatments for addictions
SO WIENER KLINISCHE WOCHENSCHRIFT
LA German
DT Editorial Material
DE addiction medicine; drug trends; changes in; drug therapy; substitution
   therapy
C1 Univ Innsbruck, Inst Suchtforsch, A-6800 Feldkirch, Austria.
C3 University of Innsbruck
RP Haller, R (通讯作者)，Univ Innsbruck, Inst Suchtforsch, Postfach 35, A-6800 Feldkirch, Austria.
EM reinhard.haller@suchtforschung.at
CR Caplehorn J., 1996, EUR ADDICT RES, V2, P49
   *EBDD, 2002, DRUGNET EUROPE, V35, P4
   Giacomuzzi SM, 2004, WIEN KLIN WOCHENSCHR, V116, P119, DOI 10.1007/BF03040748
   Grant BF, 1997, J SUBST ABUSE, V9, P103, DOI 10.1016/S0899-3289(97)90009-2
   HALLER R, 2002, OSTERREICHISCHE ARZT, V5, P32
   KANDEL DB, 1992, J STUD ALCOHOL, V53, P447, DOI 10.15288/jsa.1992.53.447
   KLEE J, 2003, SUCHTMED, V5, P71
   LYNSKEY H, 2003, JAMA-J AM MED ASSOC, V4, P427
   Morral AR, 2002, ADDICTION, V97, P1493, DOI 10.1046/j.1360-0443.2002.00280.x
   STEMPEL K, 2003, RAUSCHGIFTLAGE 2002
   THOMASIUS R, 1999, ECTASY WIRKUNG RISIK
NR 11
TC 2
Z9 2
U1 0
U2 2
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0043-5325
J9 WIEN KLIN WOCHENSCHR
JI Wien. Klin. Wochen.
PD FEB 28
PY 2004
VL 116
IS 4
BP 110
EP 111
DI 10.1007/BF03040746
PG 2
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 802QU
UT WOS:000220178800002
PM 15038400
DA 2023-06-23
ER

PT J
AU Nestler, EJ
AF Nestler, EJ
TI From neurobiology to treatment: progress against addiction
SO NATURE NEUROSCIENCE
LA English
DT Review
ID MU-OPIOID RECEPTOR; HEROIN-ADDICTION; COCAINE-SEEKING; WITHDRAWAL;
   DOPAMINE; BEHAVIOR; IMMUNIZATION; MODULATION; TOLERANCE; MORPHINE
AB Most advances in addiction treatment to date have addressed the physical dependence and withdrawal that accompany addiction to some drugs of abuse. In contrast, it has proven more difficult to develop medications that effectively treat drug craving and relapse, the core features of addictive disorders. Current efforts focus on developing medications that prevent a drug from getting to its protein target, that mimic drug action and thereby partially alleviate drug craving, or that affect the addiction process per se. The latter approach is the most speculative, but also the most promising in terms of translating basic knowledge of addiction into clinical progress.
C1 Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA.
C3 University of Texas System; University of Texas Dallas; University of
   Texas Southwestern Medical Center Dallas; University of Texas System;
   University of Texas Dallas; University of Texas Southwestern Medical
   Center Dallas
RP Nestler, EJ (通讯作者)，Univ Texas, SW Med Ctr, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM eric.nestler@utsouthwestern.edu
CR AGHAJANIAN GK, 1978, NATURE, V276, P186, DOI 10.1038/276186a0
   [Anonymous], 1998, JAMA, V280, P1936
   Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086
   Carlezon WA, 2000, J NEUROSCI, V20
   Cohen PJ, 1997, DRUG ALCOHOL DEPEN, V48, P167, DOI 10.1016/S0376-8716(97)00075-6
   Cornish JL, 2001, J ADDICT DIS, V20, P43, DOI 10.1300/J069v20n03_05
   Everitt BJ, 2002, J NEUROSCI, V22, P3312
   GOLD MS, 1978, LANCET, V2, P599
   Hutcheson DM, 2001, NAT NEUROSCI, V4, P943, DOI 10.1038/nn0901-943
   Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560
   Kantak KM, 2001, PSYCHOPHARMACOLOGY, V153, P334, DOI 10.1007/s002130000555
   Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7
   Kreek MJ, 2000, ANN NY ACAD SCI, V909, P186
   Krystal JH, 2001, NEW ENGL J MED, V345, P1734, DOI 10.1056/NEJMoa011127
   Ling W, 1998, ADDICTION, V93, P475, DOI 10.1046/j.1360-0443.1998.9344753.x
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   Nestler EJ, 2001, P NATL ACAD SCI USA, V98, P11042, DOI 10.1073/pnas.191352698
   Nicola SM, 2000, ANNU REV NEUROSCI, V23, P185, DOI 10.1146/annurev.neuro.23.1.185
   OBrien CP, 1997, SCIENCE, V278, P66, DOI 10.1126/science.278.5335.66
   Potenza MN, 1999, J PHARMACOL EXP THER, V291, P482
   PULVIRENTI L, 1994, TRENDS PHARMACOL SCI, V15, P374, DOI 10.1016/0165-6147(94)90158-9
   Self DW, 2002, NEUROPSYCHOPHARMACOL, V26, P14, DOI 10.1016/S0893-133X(01)00373-6
   Self DW, 1996, SCIENCE, V271, P1586, DOI 10.1126/science.271.5255.1586
   Shaham Y, 2000, BRAIN RES REV, V33, P13, DOI 10.1016/S0165-0173(00)00024-2
   Shalev U, 2001, PSYCHOPHARMACOLOGY, V156, P98, DOI 10.1007/s002130100748
   SILAGY C, 2001, COCHRANE DB SYST REV, V3, P146
   Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077
   Wise RA, 1998, DRUG ALCOHOL DEPEN, V51, P13, DOI 10.1016/S0376-8716(98)00063-5
NR 28
TC 89
Z9 92
U1 0
U2 13
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1097-6256
EI 1546-1726
J9 NAT NEUROSCI
JI Nat. Neurosci.
PD NOV
PY 2002
VL 5
SU S
BP 1076
EP 1079
DI 10.1038/nn945
PG 4
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 611WT
UT WOS:000179041300018
PM 12403990
DA 2023-06-23
ER

PT J
AU Nubli, M
   Wahab, A
   Salam, UB
AF Nubli, Muhammad
   Wahab, Abdul
   Salam, Urme Binte
TI Drug Addiction Intervention for Adolescents with Religious Spirituality
   and Biofeedback
SO APPLIED PSYCHOPHYSIOLOGY AND BIOFEEDBACK
LA English
DT Meeting Abstract
DE Spirituality; Biofeedback; Drug addiction; Heart rate variability
EM urmechy@ymail.com
RI Wahab, Abdul Azeez Abdul/E-1455-2018; wahab, nubli/H-8715-2014
OI Wahab, Abdul Azeez Abdul/0000-0002-8906-1365; wahab,
   nubli/0000-0003-3595-4069
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-0586
EI 1573-3270
J9 APPL PSYCHOPHYS BIOF
JI Appl. Psychophysiol. Biofeedback
PD JUN
PY 2014
VL 39
IS 2
BP 151
EP 151
PG 1
WC Psychology, Clinical
WE Social Science Citation Index (SSCI)
SC Psychology
GA AH8KT
UT WOS:000336387400055
DA 2023-06-23
ER

PT J
AU Murphy, J
AF Murphy, Jennifer
TI Drug Court as Both a Legal and Medical Authority
SO DEVIANT BEHAVIOR
LA English
DT Article
AB This article explores how addiction is conceptualized in a drug court program. Through observations and interviews in a drug court in a large northeastern city, the author reveals how the court uses ambiguous and inconsistent medicalized language to describe addiction, extending the label of addiction to behaviors not just associated with using drugs, but with selling drugs as well. Ultimately, drug courts incorporate a medicalized notion of addiction to further their own control over drug-related issues, since they become the authority of both the client's treatment and their punishment.
C1 Calif State Univ Sacramento, Dept Sociol, Sacramento, CA 95819 USA.
C3 California State University System; California State University
   Sacramento
RP Murphy, J (通讯作者)，Calif State Univ Sacramento, Dept Sociol, 6000 J St, Sacramento, CA 95819 USA.
EM murphyj@csus.edu
CR Banks D, 2003, J DRUG ISSUES, V33, P385, DOI 10.1177/002204260303300206
   Burns SL, 2003, SOC PROBL, V50, P416, DOI 10.1525/sp.2003.50.3.416
   COLYER CJ, 2007, CRIMINAL JUSTICE POL, V18, P313
   CONRAD P, 1992, ANNU REV SOCIOL, V18, P209, DOI 10.1146/annurev.so.18.080192.001233
   CONRAD P, 1980, DEVIANCE MEDICALIZAT
   FOX RC, 1989, SOCIOLOGY MED PARTIC
   GOTTFREDSON D, 2003, CRIMINOL PUBLIC POL, V2, P401
   Hora PF, 2002, SUBST USE MISUSE, V37, P1469, DOI 10.1081/JA-120014419
   INCIARDI JA, 1991, TREATMENT ALTERNATIV
   Kalich DM, 2006, DEVIANT BEHAV, V27, P569, DOI 10.1080/01639620600887295
   King R.S., 2008, DISPARITY GEOGRAPHY
   Lemanski M., 2001, HIST ADDICTION RECOV
   Lock ED, 2002, CRIME DELINQUENCY, V48, P380, DOI 10.1177/0011128702048003002
   MARLOWE DB, 2004, DRUG COURT REV, V4, P1
   McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689
   *NADCP, 2007, 13 ANN TRAIN C
   Nolan James, 2001, REINVENTING JUSTICE
   *OFF NAT DRUG CONT, 2008, PRES NAT DRUG CONTR
   Parsons T., 1951, SOCIAL SYSTEM
   ROLIDER A, 1991, J APPL BEHAV ANAL, V24, P763, DOI 10.1901/jaba.1991.24-763
   Roman P. M., 2004, NATL TREATMENT CTR S
   SAMHSA, 2005, NAT SURV SUBST AB TR
   Simmons J Q 3rd, 1969, Curr Psychiatr Ther, V9, P11
   Turner S, 2002, SUBST USE MISUSE, V37, P1489, DOI 10.1081/JA-120014420
   USA Today, 2006, US TODAY        0719
   2007, MEDICALIZATION SOC T
NR 26
TC 10
Z9 10
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0163-9625
J9 DEVIANT BEHAV
JI Deviant Behav.
PY 2011
VL 32
IS 3
BP 257
EP 291
AR PII 934127255
DI 10.1080/01639621003771979
PG 35
WC Criminology & Penology; Psychology, Social; Sociology
WE Social Science Citation Index (SSCI)
SC Criminology & Penology; Psychology; Sociology
GA 726TX
UT WOS:000287750200003
DA 2023-06-23
ER

PT J
AU Olsen, CM
AF Olsen, Christopher M.
TI Natural rewards, neuroplasticity, and non-drug addictions
SO NEUROPHARMACOLOGY
LA English
DT Review
DE Novelty seeking; Addiction; Motivation; Reinforcement; Behavioral
   addiction; Plasticity
ID ADULT HIPPOCAMPAL NEUROGENESIS; CONDITIONED PLACE PREFERENCE; MEDIAL
   PREFRONTAL CORTEX; OPPONENT-PROCESS THEORY; FEMALE SYRIAN-HAMSTERS;
   EXCESSIVE SUGAR INTAKE; CORTICOTROPIN-RELEASING-FACTOR;
   INCENTIVE-SENSITIZATION THEORY; VENTRAL STRIATAL DOPAMINE; CUE-INDUCED
   REINSTATEMENT
AB There is a high degree of overlap between brain regions involved in processing natural rewards and drugs of abuse. "Non-drug" or "behavioral" addictions have become increasingly documented in the clinic, and pathologies include compulsive activities such as shopping, eating, exercising, sexual behavior, and gambling. Like drug addiction, non-drug addictions manifest in symptoms including craving, impaired control over the behavior, tolerance, withdrawal, and high rates of relapse. These alterations in behavior suggest that plasticity may be occurring in brain regions associated with drug addiction. In this review, I summarize data demonstrating that exposure to non-drug rewards can alter neural plasticity in regions of the brain that are affected by drugs of abuse. Research suggests that there are several similarities between neuroplasticity induced by natural and drug rewards and that, depending on the reward, repeated exposure to natural rewards might induce neuroplasticity that either promotes or counteracts addictive behavior. This article is part of a Special Issue entitled 'Synaptic Plasticity and Addiction'. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Olsen, Christopher M.] Vanderbilt Univ, Sch Med, RRB, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.
   [Olsen, Christopher M.] Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Nashville, TN 37232 USA.
   [Olsen, Christopher M.] Vanderbilt Univ, Sch Med, JF Kennedy Ctr Res Human Dev, Nashville, TN 37232 USA.
C3 Vanderbilt University; Vanderbilt University; Vanderbilt University
RP Olsen, CM (通讯作者)，Vanderbilt Univ, Sch Med, RRB, Dept Mol Physiol & Biophys, 23rd & Pierce Ave S,Room 754, Nashville, TN 37232 USA.
EM chris.olsen@vanderbilt.edu
RI Olsen, Christopher/C-3542-2008; Olsen, Christopher/G-9595-2013
OI Olsen, Christopher/0000-0003-2700-0310; Olsen,
   Christopher/0000-0003-2700-0310
FU NIH [DA026994]
FX Financial support was provided by NIH grant DA026994. I would like to
   thank Kelly Conrad, Ph.D. and Tiffany Wills, Ph.D. for constructive
   comments on previous versions of this manuscript.
CR AGHAJANIAN GK, 1978, NATURE, V276, P186, DOI 10.1038/276186a0
   Ahmed SH, 2005, EUR J PHARMACOL, V526, P9, DOI 10.1016/j.ejphar.2005.09.036
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Aiken CB, 2007, J CLIN PSYCHIAT, V68, P1230, DOI 10.4088/JCP.v68n0810
   ALBURGES ME, 1993, SYNAPSE, V14, P314, DOI 10.1002/syn.890140409
   Alcock J., 2005, ANIMAL BEHAV EVOLUTI
   [Anonymous], 2002, NEURON, V36, P189
   ANTELMAN SM, 1980, SCIENCE, V207, P329, DOI 10.1126/science.7188649
   Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244
   Asahina S, 2003, JPN J PHYS FIT SPORT, V52, P159, DOI 10.7600/jspfsm1949.52.159
   Aston-Jones G, 2004, NEUROPHARMACOLOGY, V47, P167, DOI 10.1016/j.neuropharm.2004.06.020
   Avena NA, 2003, PHARMACOL BIOCHEM BE, V74, P635, DOI 10.1016/S0091-3057(02)01050-X
   Avena NM, 2008, NEUROSCI BIOBEHAV R, V32, P20, DOI 10.1016/j.neubiorev.2007.04.019
   Avena NM, 2005, PHYSIOL BEHAV, V84, P359, DOI 10.1016/j.physbeh.2004.12.016
   Avena NM, 2003, NEUROSCIENCE, V122, P17, DOI 10.1016/S0306-4522(03)00502-5
   Balleine BW, 1998, NEUROPHARMACOLOGY, V37, P407, DOI 10.1016/S0028-3908(98)00033-1
   Bardo MT, 2004, NEBR SYM MOTIV, V50, P127
   Bardo MT, 1997, NEUROPHARMACOLOGY, V36, P251, DOI 10.1016/S0028-3908(96)00139-6
   BARDO MT, 1995, PHARMACOL BIOCHEM BE, V51, P397, DOI 10.1016/0091-3057(94)00413-D
   Bardo MT, 2001, PSYCHOPHARMACOLOGY, V155, P278
   BEACH FA, 1956, J COMP PHYSIOL PSYCH, V49, P105, DOI 10.1037/h0046471
   Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584
   Belin D, 2009, BIOL PSYCHIAT, V65, P863, DOI 10.1016/j.biopsych.2008.05.031
   Belke TW, 1998, PSYCHOL REC, V48, P675, DOI 10.1007/BF03395297
   BELKE TW, 1994, ANIM LEARN BEHAV, V22, P267, DOI 10.3758/BF03209834
   Bello NT, 2002, NEUROREPORT, V13, P1575, DOI 10.1097/00001756-200208270-00017
   BENNETT EL, 1969, SCIENCE, V163, P825, DOI 10.1126/science.163.3869.825
   Berthoud HR, 2004, PHYSIOL BEHAV, V81, P781, DOI 10.1016/j.physbeh.2004.04.034
   Besheer J, 1999, BEHAV BRAIN RES, V103, P35, DOI 10.1016/S0166-4328(99)00021-2
   Bevins RA, 2005, NEUROSCI BIOBEHAV R, V29, P707, DOI 10.1016/j.neubiorev.2005.03.013
   Bevins RA, 1999, BEHAV BRAIN RES, V99, P53, DOI 10.1016/S0166-4328(98)00069-2
   Bjornebekk A, 2006, NEUROPSYCHOPHARMACOL, V31, P256, DOI 10.1038/sj.npp.1300820
   Black DW, 2007, CNS SPECTRUMS, V12, P124, DOI 10.1017/S1092852900020630
   Borgland SL, 2004, J NEUROSCI, V24, P7482, DOI 10.1523/JNEUROSCI.1312-04.2004
   Bowman EM, 1996, J NEUROPHYSIOL, V75, P1061, DOI 10.1152/jn.1996.75.3.1061
   Bradley KC, 2005, GENES BRAIN BEHAV, V4, P31, DOI 10.1111/j.1601-183X.2004.00093.x
   Breiter HC, 2001, NEURON, V30, P619, DOI 10.1016/S0896-6273(01)00303-8
   Bruijnzeel AW, 2009, BRAIN RES REV, V62, P127, DOI 10.1016/j.brainresrev.2009.09.008
   Butler S. L, 2005, TRADING DRINK DRUGS
   Butzin CA, 2005, J SUBST ABUSE TREAT, V28, P351, DOI 10.1016/j.jsat.2005.02.009
   CAGGIULA AR, 1966, SCIENCE, V153, P1284, DOI 10.1126/science.153.3741.1284
   Cain ME, 2006, BEHAV PROCESS, V73, P360, DOI 10.1016/j.beproc.2006.08.007
   Cain ME, 2005, EXP CLIN PSYCHOPHARM, V13, P367, DOI 10.1037/1064-1297.13.4.367
   Cantin L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011592
   Cao L, 2010, CELL, V142, P52, DOI 10.1016/j.cell.2010.05.029
   Carelli RM, 2002, PHYSIOL BEHAV, V76, P379, DOI 10.1016/S0031-9384(02)00760-6
   Carelli RM, 2000, J NEUROSCI, V20, P4255
   Carlezon WA, 2009, NEUROPHARMACOLOGY, V56, P122, DOI 10.1016/j.neuropharm.2008.06.075
   CARROLL ME, 1989, PSYCHOPHARMACOLOGY, V97, P23, DOI 10.1007/BF00443407
   CASSENS G, 1981, PSYCHOPHARMACOLOGY, V73, P318, DOI 10.1007/BF00426458
   Chang JY, 1998, J NEUROSCI, V18, P3098
   Chen BT, 2008, NEURON, V59, P288, DOI 10.1016/j.neuron.2008.05.024
   Chen BT, 2010, ANN NY ACAD SCI, V1187, P129, DOI 10.1111/j.1749-6632.2009.05154.x
   Chen HI, 2008, BEHAV BRAIN RES, V187, P185, DOI 10.1016/j.bbr.2007.09.014
   Childress AR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001506
   CHIODO LA, 1980, BRAIN RES, V189, P544, DOI 10.1016/0006-8993(80)90366-2
   CHRISTIE MJ, 1982, LIFE SCI, V30, P1173, DOI 10.1016/0024-3205(82)90659-2
   Clark PJ, 2010, BEHAV BRAIN RES, V213, P246, DOI 10.1016/j.bbr.2010.05.007
   CLONINGER CR, 1987, SCIENCE, V236, P410, DOI 10.1126/science.2882604
   Colantuoni C, 2002, OBES RES, V10, P478, DOI 10.1038/oby.2002.66
   Colantuoni C, 2001, NEUROREPORT, V12, P3549, DOI 10.1097/00001756-200111160-00035
   Conrad KL, 2010, NEUROSCIENCE, V169, P182, DOI 10.1016/j.neuroscience.2010.04.056
   Contet C, 2008, NEUROPHARMACOLOGY, V54, P475, DOI 10.1016/j.neuropharm.2007.10.015
   Corsica JA, 2010, CURR OPIN GASTROEN, V26, P165, DOI 10.1097/MOG.0b013e328336528d
   Cosgrove KP, 2002, PHARMACOL BIOCHEM BE, V73, P663, DOI 10.1016/S0091-3057(02)00853-5
   Cottone P, 2008, NEUROPSYCHOPHARMACOL, V33, P524, DOI 10.1038/sj.npp.1301430
   Covington HE, 2005, PSYCHOPHARMACOLOGY, V183, P331, DOI 10.1007/s00213-005-0190-5
   Covington HE, 2001, PSYCHOPHARMACOLOGY, V158, P388, DOI 10.1007/s002130100858
   CRAWFORD LL, 1993, J EXP ANAL BEHAV, V60, P55, DOI 10.1901/jeab.1993.60-55
   Crombag HS, 2005, CEREB CORTEX, V15, P341, DOI 10.1093/cercor/bhh136
   Cunningham-Williams RM, 2005, J PSYCHIATR RES, V39, P377, DOI 10.1016/j.jpsychires.2004.09.002
   Daniel JZ, 2006, ADDICTION, V101, P1187, DOI 10.1111/j.1360-0443.2006.01457.x
   Davis C, 2009, APPETITE, V53, P1, DOI 10.1016/j.appet.2009.05.018
   Davis JF, 2008, BEHAV NEUROSCI, V122, P1257, DOI 10.1037/a0013111
   Deadwyler SA, 2010, ANN NY ACAD SCI, V1187, P140, DOI 10.1111/j.1749-6632.2009.05155.x
   Deehan GA, 2007, ALCOHOL CLIN EXP RES, V31, P1692, DOI 10.1111/j.1530-0277.2007.00466.x
   Del Arco A, 2009, J NEURAL TRANSM, V116, P941, DOI 10.1007/s00702-009-0243-8
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   DEUTCH AY, 1992, J NEURAL TRANSM-GEN, P61
   Dommett E, 2005, SCIENCE, V307, P1476, DOI 10.1126/science.1107026
   Drewnowski A, 1997, ANNU REV NUTR, V17, P237, DOI 10.1146/annurev.nutr.17.1.237
   Duman RS, 1999, BIOL PSYCHIAT, V46, P1181, DOI 10.1016/S0006-3223(99)00177-8
   Ehringer MA, 2009, ALCOHOL, V43, P443, DOI 10.1016/j.alcohol.2009.06.003
   Epping-Jordan MP, 1998, NATURE, V393, P76, DOI 10.1038/30001
   Ernst C, 2006, J PSYCHIATR NEUROSCI, V31, P84
   ETTENBERG A, 1986, PHARMACOL BIOCHEM BE, V25, P813, DOI 10.1016/0091-3057(86)90392-8
   Evans AH, 2006, ANN NEUROL, V59, P852, DOI 10.1002/ana.20822
   Everitt BJ, 2008, PHILOS T R SOC B, V363, P3125, DOI 10.1098/rstb.2008.0089
   Everitt BJ, 2001, BRAIN RES REV, V36, P129, DOI 10.1016/S0165-0173(01)00088-1
   EVERITT BJ, 1987, J COMP PSYCHOL, V101, P395, DOI 10.1037/0735-7036.101.4.395
   Fiorino D. F., 2003, 2003 ABSTR VIEW LTIN
   Fiorino DF, 1999, J NEUROSCI, V19, P456, DOI 10.1523/JNEUROSCI.19-01-00456.1999
   Foley TE, 2008, NEUROMOL MED, V10, P67, DOI 10.1007/s12017-008-8032-3
   Frascella J, 2010, ANN NY ACAD SCI, V1187, P294, DOI 10.1111/j.1749-6632.2009.05420.x
   FREED CR, 1985, SCIENCE, V229, P62, DOI 10.1126/science.4012312
   Frohmader KS, 2010, NEUROSCIENCE, V166, P771, DOI 10.1016/j.neuroscience.2009.12.070
   Garavan H, 2000, AM J PSYCHIAT, V157, P1789, DOI 10.1176/appi.ajp.157.11.1789
   Girault JA, 2007, CURR OPIN PHARMACOL, V7, P77, DOI 10.1016/j.coph.2006.08.012
   Gold SN, 1998, CLIN PSYCHOL REV, V18, P367, DOI 10.1016/S0272-7358(97)00051-2
   Gomez-Pinilla F, 2002, J NEUROPHYSIOL, V88, P2187, DOI 10.1152/jn.00152.2002
   GOODMAN A, 1992, J SEX MARITAL THER, V18, P303, DOI 10.1080/00926239208412855
   Gosnell BA, 2009, INT J OBESITY, V33, pS54, DOI 10.1038/ijo.2009.73
   Gosnell BA, 2005, BRAIN RES, V1031, P194, DOI 10.1016/j.brainres.2004.10.037
   Grant J E, 2001, Ann Clin Psychiatry, V13, P229, DOI 10.1023/A:1014626102110
   Grant JE, 2006, AM J PSYCHIAT, V163, P303, DOI 10.1176/appi.ajp.163.2.303
   Grant JE, 2006, CNS SPECTRUMS, V11, P924, DOI 10.1017/S109285290001511X
   Grant JE, 2010, AM J DRUG ALCOHOL AB, V36, P233, DOI 10.3109/00952990.2010.491884
   Graybiel AM, 2008, ANNU REV NEUROSCI, V31, P359, DOI 10.1146/annurev.neuro.29.051605.112851
   Green TA, 2003, PSYCHOPHARMACOLOGY, V170, P235, DOI 10.1007/s00213-003-1538-3
   Green TA, 2010, BIOL PSYCHIAT, V67, P28, DOI 10.1016/j.biopsych.2009.06.022
   Greenough W. T., 1988, CEREB CORTEX, P391, DOI DOI 10.1007/978-1-4615-6619-9_11
   Griffiths M. D., 1998, PSYCHOL INTERNET INT, P61
   Grimm JW, 2008, BEHAV PHARMACOL, V19, P777, DOI 10.1097/FBP.0b013e32831c3b18
   Grimm JW, 2005, PHYSIOL BEHAV, V84, P73, DOI 10.1016/j.physbeh.2004.10.011
   Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134
   Grueter BA, 2006, J NEUROSCI, V26, P3210, DOI 10.1523/JNEUROSCI.0170-06.2006
   Haber SN, 2000, J NEUROSCI, V20, P2369
   HAMMER RP, 1989, SYNAPSE, V3, P55, DOI 10.1002/syn.890030108
   HATTORI S, 1994, BRAIN RES BULL, V35, P41, DOI 10.1016/0361-9230(94)90214-3
   He ST, 2004, DRUG ALCOHOL DEPEN, V75, P215, DOI 10.1016/j.drugalcdep.2004.02.010
   Hebb D. O., 1947, AM PSYCHOL, V2, P306, DOI DOI 10.1037/H0028720
   Hedges VL, 2009, GENES BRAIN BEHAV, V8, P442, DOI 10.1111/j.1601-183X.2009.00491.x
   HERMAN JP, 1984, PSYCHOPHARMACOLOGY, V84, P431, DOI 10.1007/BF00555227
   Hoebel B. G., 1989, ANN NEW YORK ACAD SC
   Hoebel BG, 2009, J ADDICT MED, V3, P33, DOI 10.1097/ADM.0b013e31819aa621
   Hoeft F, 2008, J PSYCHIATR RES, V42, P253, DOI 10.1016/j.jpsychires.2007.11.010
   HOFFMANN P, 1987, BEHAV NEURAL BIOL, V47, P346, DOI 10.1016/S0163-1047(87)90461-4
   Holden C, 2001, SCIENCE, V294, P980, DOI 10.1126/science.294.5544.980
   Horvitz JC, 1997, BRAIN RES, V759, P251, DOI 10.1016/S0006-8993(97)00265-5
   Hosseini Mahmoud, 2009, Pathophysiology, V16, P3, DOI 10.1016/j.pathophys.2008.11.001
   Hudson JI, 2007, BIOL PSYCHIAT, V61, P348, DOI 10.1016/j.biopsych.2006.03.040
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Ifland JR, 2009, MED HYPOTHESES, V72, P518, DOI 10.1016/j.mehy.2008.11.035
   Inciardi J. A., 2001, THERAPEUTIC COMMUNIT, P241
   James William, 1981, PRINCIPLES PSYCHOL
   JANAL MN, 1984, PAIN, V19, P13, DOI 10.1016/0304-3959(84)90061-7
   Jentsch JD, 2010, NEUROPSYCHOPHARMACOL, V35, P1797, DOI 10.1038/npp.2010.47
   Johnson PM, 2010, NAT NEUROSCI, V13, P635, DOI 10.1038/nn.2519
   KAAS JH, 1991, ANNU REV NEUROSCI, V14, P137, DOI 10.1146/annurev.neuro.14.1.137
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564
   Kalivas PW, 2009, NEUROPHARMACOLOGY, V56, P169, DOI 10.1016/j.neuropharm.2008.07.011
   KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U
   KALIVAS PW, 1986, BIOL PSYCHIAT, V21, P939, DOI 10.1016/0006-3223(86)90268-4
   KANAREK RB, 1995, PHARMACOL BIOCHEM BE, V51, P725, DOI 10.1016/0091-3057(95)00022-O
   Kanarek RB, 2009, BEHAV NEUROSCI, V123, P905, DOI 10.1037/a0015896
   Kandel E., 2021, PRINCIPLES NEURAL SC, VSixth Edition6th edition edn
   Karama S, 2002, HUM BRAIN MAPP, V16, P1, DOI 10.1002/hbm.10014
   Kasanetz F, 2010, SCIENCE, V328, P1709, DOI 10.1126/science.1187801
   Kauer JA, 2007, NAT REV NEUROSCI, V8, P844, DOI 10.1038/nrn2234
   Kelley AE, 2004, NEUROSCI BIOBEHAV R, V27, P765, DOI 10.1016/j.neubiorev.2003.11.015
   Kelley AE, 2003, EUR J NEUROSCI, V18, P2592, DOI 10.1046/j.1460-9568.2003.02991.x
   Kelley AE, 2002, J NEUROSCI, V22, P3306
   Kelly TH, 2006, PSYCHOPHARMACOLOGY, V189, P17, DOI 10.1007/s00213-006-0487-z
   Kenny PJ, 2007, TRENDS PHARMACOL SCI, V28, P135, DOI 10.1016/j.tips.2007.01.008
   Kim SW, 2001, BIOL PSYCHIAT, V49, P914, DOI 10.1016/S0006-3223(01)01079-4
   Knutson B, 2007, NEURON, V53, P147, DOI 10.1016/j.neuron.2006.11.010
   Koepp MJ, 1998, NATURE, V393, P266, DOI 10.1038/30498
   Kohlert JG, 1999, BEHAV BRAIN RES, V99, P45, DOI 10.1016/S0166-4328(98)00068-0
   Kolb B, 1998, ANNU REV PSYCHOL, V49, P43, DOI 10.1146/annurev.psych.49.1.43
   Komisaruk BR, 2004, BRAIN RES, V1024, P77, DOI 10.1016/j.brainres.2004.07.029
   Koob G, 2007, AM J PSYCHIAT, V164, P1149, DOI 10.1176/appi.ajp.2007.05030503
   Koob GF, 2008, PHILOS T R SOC B, V363, P3113, DOI 10.1098/rstb.2008.0094
   Koob GF, 2010, BRAIN RES, V1314, P3, DOI 10.1016/j.brainres.2009.11.008
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Koob GF, 2009, NAT REV DRUG DISCOV, V8, P500, DOI 10.1038/nrd2828
   KOOB GF, 1989, NEUROSCI BIOBEHAV R, V13, P135, DOI 10.1016/S0149-7634(89)80022-3
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Koya E, 2009, NEUROPHARMACOLOGY, V56, P177, DOI 10.1016/j.neuropharm.2008.04.022
   Lader M, 2008, CNS DRUGS, V22, P407, DOI 10.2165/00023210-200822050-00004
   Laviola G, 2008, NEUROBIOL DIS, V31, P159, DOI 10.1016/j.nbd.2008.05.001
   Lejoyeux M, 2000, EUR PSYCHIAT, V15, P129, DOI 10.1016/S0924-9338(00)00201-7
   Lejoyeux M, 2010, AM J DRUG ALCOHOL AB, V36, P248, DOI 10.3109/00952990.2010.493590
   LEMAGNEN J, 1990, TASTE, EXPERIENCE, AND FEEDING, P241, DOI 10.1037/10075-017
   Lenoir M, 2008, NEUROPSYCHOPHARMACOL, V33, P2272, DOI 10.1038/sj.npp.1301602
   Lenoir M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000698
   Leri F, 2003, NEUROPSYCHOPHARMACOL, V28, P2102, DOI 10.1038/sj.npp.1300284
   Lett BT, 2000, APPETITE, V34, P87, DOI 10.1006/appe.1999.0274
   LETT BT, 1989, PSYCHOPHARMACOLOGY, V98, P357, DOI 10.1007/BF00451687
   Leung KS, 2009, CURR OPIN PSYCHIATR, V22, P69, DOI 10.1097/YCO.0b013e32831575d9
   Lin S, 2000, INT J OBESITY, V24, P639, DOI 10.1038/sj.ijo.0801209
   Lindholm S, 2000, ALCOHOL, V22, P165, DOI 10.1016/S0741-8329(00)00118-X
   Liu X, 2007, PSYCHOPHARMACOLOGY, V194, P463, DOI 10.1007/s00213-007-0863-3
   Lonetti G, 2010, BIOL PSYCHIAT, V67, P657, DOI 10.1016/j.biopsych.2009.12.022
   Lowery EG, 2010, CNS NEUROL DISORD-DR, V9, P77, DOI 10.2174/187152710790966605
   Lu L, 2004, NEUROPHARMACOLOGY, V47, P214, DOI 10.1016/j.neuropharm.2004.06.027
   Lu L, 2006, TRENDS NEUROSCI, V29, P695, DOI 10.1016/j.tins.2006.10.005
   Luscher C, 2008, NAT NEUROSCI, V11, P737, DOI 10.1038/nn0708-737
   Lynch W. J., 2010, BIOL PSYCHIAT
   MACRAE PG, 1987, PSYCHOPHARMACOLOGY, V92, P236
   Maj M, 2003, NEUROPEPTIDES, V37, P105, DOI 10.1016/S0143-4179(03)00021-0
   Majewska M D, 1996, NIDA Res Monogr, V163, P1
   Mameli M., 2011, NAT NEUROSCI
   MARKOU A, 1991, NEUROPSYCHOPHARMACOL, V4, P17
   MARKS I, 1990, BRIT J ADDICT, V85, P1389
   Martinez I, 2001, HORM BEHAV, V40, P510, DOI 10.1006/hbeh.2001.1712
   MARX MH, 1955, J COMP PHYSIOL PSYCH, V48, P73, DOI 10.1037/h0045062
   McBride WJ, 1998, CRIT REV NEUROBIOL, V12, P339, DOI 10.1615/CritRevNeurobiol.v12.i4.40
   McClung CA, 2004, MOL BRAIN RES, V132, P146, DOI 10.1016/j.molbrainres.2004.05.014
   McClung CA, 2008, NEUROPSYCHOPHARMACOL, V33, P3, DOI 10.1038/sj.npp.1301544
   McDaid J, 2006, MOL PHARMACOL, V70, P2064, DOI 10.1124/mol.106.023051
   McDaid J, 2006, NEUROPSYCHOPHARMACOL, V31, P1212, DOI 10.1038/sj.npp.1300854
   McElroy SL, 2007, BIOL PSYCHIAT, V61, P1039, DOI 10.1016/j.biopsych.2006.08.008
   MEISEL RL, 1993, BEHAV BRAIN RES, V55, P151, DOI 10.1016/0166-4328(93)90111-3
   Meisel RL, 2006, BRAIN RES, V1126, P56, DOI 10.1016/j.brainres.2006.08.050
   Mellen J, 2001, ZOO BIOL, V20, P211, DOI 10.1002/zoo.1021
   MERMELSTEIN PG, 1995, BEHAV NEUROSCI, V109, P354, DOI 10.1037/0735-7044.109.2.354
   Meyer A. C., 2010, GENES BRAIN BEHAV
   Molteni R, 2002, EUR J NEUROSCI, V16, P1107, DOI 10.1046/j.1460-9568.2002.02158.x
   Nader MA, 2002, NEUROPSYCHOPHARMACOL, V27, P35, DOI 10.1016/S0893-133X(01)00427-4
   Nair SG, 2009, PROG NEUROBIOL, V89, P18, DOI 10.1016/j.pneurobio.2009.05.003
   Nestler EJ, 1999, BRAIN RES, V835, P10, DOI 10.1016/S0006-8993(98)01191-3
   Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970
   Noonan MA, 2010, J NEUROSCI, V30, P304, DOI 10.1523/JNEUROSCI.4256-09.2010
   O'Brien CP, 2010, ADDICTION, V105, P565
   O'Brien CP, 2005, AM J PSYCHIAT, V162, P1423, DOI 10.1176/appi.ajp.162.8.1423
   O'Brien MS., 2005, NEUROPSYCHOPHARMACOL
   ODONNELL JM, 1980, PSYCHOPHARMACOLOGY, V68, P191, DOI 10.1007/BF00432140
   Olausson P, 2006, J NEUROSCI, V26, P9196, DOI 10.1523/JNEUROSCI.1124-06.2006
   Olsen CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015085
   Olsen CM, 2009, NEUROPSYCHOPHARMACOL, V34, P1685, DOI 10.1038/npp.2008.226
   Olsen CM, 2006, BRAIN RES, V1075, P229, DOI 10.1016/j.brainres.2006.01.003
   Olsen CM, 2001, BRAIN RES, V922, P80, DOI 10.1016/S0006-8993(01)03152-3
   Olsen CM, 2010, J VIS EXP, DOI 10.3791/2292
   Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157
   ORFORD J, 1978, BRIT J ADDICT, V73, P299
   Ostlund Sean B, 2008, Drug Discov Today Dis Models, V5, P235
   Packard MG, 2002, ANNU REV NEUROSCI, V25, P563, DOI 10.1146/annurev.neuro.25.112701.142937
   Paredes RG, 1999, BEHAV BRAIN RES, V105, P117, DOI 10.1016/S0166-4328(99)00087-X
   Petry NM, 2006, ADDICTION, V101, P152, DOI 10.1111/j.1360-0443.2006.01593.x
   PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295
   Pierce K.C, 2010, NEUROSCI BIOBEHAV RE
   Pitchers K.K., 2010, GENES BRAIN BEHAV
   Pitchers KK, 2010, BIOL PSYCHIAT, V67, P872, DOI 10.1016/j.biopsych.2009.09.036
   Porrino LJ, 2004, NEUROSCI BIOBEHAV R, V27, P813, DOI 10.1016/j.neubiorev.2003.11.013
   Porrino LJ, 2004, J NEUROSCI, V24, P3554, DOI 10.1523/JNEUROSCI.5578-03.2004
   Potenza MN, 2006, ADDICTION, V101, P142, DOI 10.1111/j.1360-0443.2006.01591.x
   Potenza MN, 2008, PHILOS T R SOC B, V363, P3181, DOI 10.1098/rstb.2008.0100
   Potenza MN, 2009, NEUROPSYCHOPHARMACOL, V34, P2623, DOI 10.1038/npp.2009.152
   Prochaska JJ, 2008, PREV MED, V47, P215, DOI 10.1016/j.ypmed.2008.05.006
   Rampon C, 2000, NAT NEUROSCI, V3, P238, DOI 10.1038/72945
   Rauschecker JP, 1999, TRENDS NEUROSCI, V22, P74, DOI 10.1016/S0166-2236(98)01303-4
   Rebec GV, 1997, BRAIN RES, V776, P61, DOI 10.1016/S0006-8993(97)01004-4
   Rebec GV, 1997, NEUROSCIENCE, V76, P707, DOI 10.1016/S0306-4522(96)00382-X
   Rivalan M, 2009, BIOL PSYCHIAT, V66, P743, DOI 10.1016/j.biopsych.2009.04.008
   Roberts DCS, 2007, PROG NEURO-PSYCHOPH, V31, P1614, DOI 10.1016/j.pnpbp.2007.08.028
   Robinson DL, 2008, EUR J NEUROSCI, V28, P1887, DOI 10.1111/j.1460-9568.2008.06464.x
   ROBINSON TE, 1982, EUR J PHARMACOL, V85, P253, DOI 10.1016/0014-2999(82)90478-2
   Robinson TE, 2001, ADDICTION, V96, P103, DOI 10.1046/j.1360-0443.2001.9611038.x
   Robinson TE, 2004, NEUROPHARMACOLOGY, V47, P33, DOI 10.1016/j.neuropharm.2004.06.025
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Rogers PJ, 2000, PHARMACOL BIOCHEM BE, V66, P3, DOI 10.1016/S0091-3057(00)00197-0
   ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0
   ROTHWELL NJ, 1984, CLIN ENDOCRINOL META, V13, P437, DOI 10.1016/S0300-595X(84)80032-8
   ROUTTENBERG A, 1967, J COMP PHYSIOL PSYCH, V64, P414, DOI 10.1037/h0025205
   ROUTTENBERG A, 1968, J COMP PHYSIOL PSYCH, V66, P234, DOI 10.1037/h0025977
   Russo SJ, 2010, TRENDS NEUROSCI, V33, P267, DOI 10.1016/j.tins.2010.02.002
   Rylkova D, 2009, PSYCHOPHARMACOLOGY, V203, P629, DOI 10.1007/s00213-008-1409-z
   Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-7
   Sahay A, 2007, NAT NEUROSCI, V10, P1110, DOI 10.1038/nn1969
   Salguero RAT, 2002, ADDICTION, V97, P1601
   Sarnyai Z, 2001, PHARMACOL REV, V53, P209
   Schaffer S D, 1990, Nurse Pract, V15, P25
   Schramm-Sapyta NL, 2006, NEUROPSYCHOPHARMACOL, V31, P1444, DOI 10.1038/sj.npp.1300918
   SCHULTEIS G, 1995, P NATL ACAD SCI USA, V92, P5880, DOI 10.1073/pnas.92.13.5880
   SCHWARZ L, 1992, SPORTS MED, V13, P25, DOI 10.2165/00007256-199213010-00003
   SEGAL DS, 1974, PHARMACOL BIOCHEM BE, V2, P249, DOI 10.1016/0091-3057(74)90060-4
   Segovia G., 2010, J NEURAL TRANSM
   SELF DW, 1995, ANNU REV NEUROSCI, V18, P463, DOI 10.1146/annurev.ne.18.030195.002335
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   Shalev U., 2010, PHYSL BEHAV
   SHIPPENBERG TS, 1995, J PHARMACOL EXP THER, V273, P808
   SIMPSON DM, 1977, PHARMACOL BIOCHEM BE, V7, P59, DOI 10.1016/0091-3057(77)90011-9
   SINCLAIR JD, 1968, Q J STUD ALCOHOL, V29, P863
   Skinner BF, 1930, P NATL ACAD SCI USA, V16, P433, DOI 10.1073/pnas.16.6.433
   Smith GB, 2009, PHILOS T R SOC B, V364, P357, DOI 10.1098/rstb.2008.0198
   Smith MA, 2008, DRUG ALCOHOL DEPEN, V98, P129, DOI 10.1016/j.drugalcdep.2008.05.006
   Solecki W, 2009, BRAIN RES, V1255, P113, DOI 10.1016/j.brainres.2008.12.002
   SOLINAS M, 2010, PROG NEUROBIOL
   Solinas M, 2009, NEUROPSYCHOPHARMACOL, V34, P1102, DOI 10.1038/npp.2008.51
   Solinas M, 2008, P NATL ACAD SCI USA, V105, P17145, DOI 10.1073/pnas.0806889105
   SOLOMON RL, 1974, PSYCHOL REV, V81, P119, DOI 10.1037/h0036128
   SOLOMON RL, 1980, AM PSYCHOL, V35, P691, DOI 10.1037/0003-066X.35.8.691
   Spanagel R, 1999, ALCOHOL ALCOHOLISM, V34, P231, DOI 10.1093/alcalc/34.2.231
   Spangler R, 2003, MOL BRAIN RES, V111, P74, DOI 10.1016/S0169-328X(02)00671-X
   Spangler R, 2004, MOL BRAIN RES, V124, P134, DOI 10.1016/j.molbrainres.2004.02.013
   Spires TL, 2005, FEBS J, V272, P2347, DOI 10.1111/j.1742-4658.2005.04677.x
   St Onge JR, 2009, NEUROPSYCHOPHARMACOL, V34, P681, DOI 10.1038/npp.2008.121
   Stairs DJ, 2009, PHARMACOL BIOCHEM BE, V92, P377, DOI 10.1016/j.pbb.2009.01.016
   Steiner H, 1998, EXP BRAIN RES, V123, P60, DOI 10.1007/s002210050545
   Stewart J, 2000, J PSYCHIATR NEUROSCI, V25, P125
   STEWART J, 1960, J COMP PHYSIOL PSYCH, V53, P187, DOI 10.1037/h0047315
   Stuber GD, 2008, SCIENCE, V321, P1690, DOI 10.1126/science.1160873
   STUBER GD, 2008, ALCOHOL CLIN EXP RES
   Tao R, 2010, ADDICTION, V105, P556, DOI 10.1111/j.1360-0443.2009.02828.x
   Teegarden SL, 2007, BIOL PSYCHIAT, V61, P1021, DOI 10.1016/j.biopsych.2006.09.032
   Thanos PK, 2010, BEHAV BRAIN RES, V215, P77, DOI 10.1016/j.bbr.2010.06.033
   Thibaut F, 2010, AM J DRUG ALCOHOL AB
   Thiel KJ, 2011, PHARMACOL BIOCHEM BE, V97, P595, DOI 10.1016/j.pbb.2010.09.014
   Thiel KJ, 2009, INT J NEUROPSYCHOPH, V12, P1151, DOI 10.1017/S1461145709990472
   Thomas MJ, 2008, BRIT J PHARMACOL, V154, P327, DOI 10.1038/bjp.2008.77
   Turchan J, 1999, NEUROSCIENCE, V91, P971, DOI 10.1016/S0306-4522(98)00637-X
   Tzschentke TM, 2007, ADDICT BIOL, V12, P227, DOI 10.1111/j.1369-1600.2007.00070.x
   Uhlrich DJ, 2005, J NEUROPHYSIOL, V94, P3925, DOI 10.1152/jn.00724.2005
   UNTERWALD EM, 1994, J PHARMACOL EXP THER, V270, P1387
   UNTERWALD EM, 1994, NEUROREPORT, V5, P1613, DOI 10.1097/00001756-199408150-00018
   Valjent E, 2004, EUR J NEUROSCI, V19, P1826, DOI 10.1111/j.1460-9568.2004.03278.x
   Van de Weerd HA, 1998, APPL ANIM BEHAV SCI, V55, P369, DOI 10.1016/S0168-1591(97)00043-9
   Van den Bos R, 2006, BEHAV RES METHODS, V38, P470, DOI 10.3758/BF03192801
   van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427
   van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558
   VEZINA P, 1989, PHARMACOL BIOCHEM BE, V32, P581, DOI 10.1016/0091-3057(89)90201-3
   Volkow ND, 2004, MOL PSYCHIATR, V9, P557, DOI 10.1038/sj.mp.4001507
   Volkow ND, 2005, NAT NEUROSCI, V8, P555, DOI 10.1038/nn1452
   Volkow ND, 1996, ALCOHOL CLIN EXP RES, V20, P1594, DOI 10.1111/j.1530-0277.1996.tb05936.x
   VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210
   VOLKOW ND, 1990, AM J PSYCHIAT, V147, P719
   Vucetic Z, 2010, ENDOCRINOLOGY, V151, P4756, DOI 10.1210/en.2010-0505
   Wallace DL, 2008, J NEUROSCI, V28, P10272, DOI 10.1523/JNEUROSCI.1531-08.2008
   Wanat Matthew J, 2009, Curr Drug Abuse Rev, V2, P195
   Wanat MJ, 2009, BIOL PSYCHIAT, V65, P646, DOI 10.1016/j.biopsych.2008.10.042
   Wang GJ, 2004, J ADDICT DIS, V23, P39, DOI 10.1300/J069v23n03_04
   Wang GJ, 2004, NEUROIMAGE, V21, P1790, DOI 10.1016/j.neuroimage.2003.11.026
   Ward SJ, 2007, NEUROPSYCHOPHARMACOL, V32, P2592, DOI 10.1038/sj.npp.1301384
   Wee S, 2010, PSYCHOPHARMACOLOGY, V210, P121, DOI 10.1007/s00213-010-1825-8
   WEISS F, 1992, BRAIN RES, V593, P314, DOI 10.1016/0006-8993(92)91327-B
   Welte J, 2001, J STUD ALCOHOL, V62, P706, DOI 10.15288/jsa.2001.62.706
   Werme M, 2000, EUR J NEUROSCI, V12, P2967, DOI 10.1046/j.1460-9568.2000.00147.x
   Werme M, 2002, J NEUROSCI, V22, P8133
   Winder Danny G., 2002, Current Molecular Medicine (Hilversum), V2, P667, DOI 10.2174/1566524023361961
   Winstanley CA, 2011, NEUROPSYCHOPHARMACOL
   Winstanley CA, 2007, ANN NY ACAD SCI, V1121, P639, DOI 10.1196/annals.1401.024
   Winstanley CA, 2011, NEUROPSYCHOPHARMACOL, V36, P359, DOI 10.1038/npp.2010.136
   Winstanley CA, 2010, ALCOHOL CLIN EXP RES, V34, P1306, DOI 10.1111/j.1530-0277.2010.01215.x
   WISE RA, 1995, PSYCHOPHARMACOLOGY, V117, P130, DOI 10.1007/BF02245178
   Wise RA, 2008, NEUROTOX RES, V14, P169, DOI 10.1007/BF03033808
   Wojnicki FHE, 2006, PHARMACOL BIOCHEM BE, V84, P197, DOI 10.1016/j.pbb.2006.04.015
   Wood DA, 2004, BEHAV BRAIN RES, V152, P59, DOI 10.1016/j.bbr.2003.09.038
   Young K. S., 2009, CYBERPSYCHOL BEHAV, V11, P237, DOI DOI 10.1089/CPB.1998.1.237
   Zeeb FD, 2009, NEUROPSYCHOPHARMACOL, V34, P2329, DOI 10.1038/npp.2009.62
   Zhu J, 2005, J NEUROCHEM, V93, P1434, DOI 10.1111/j.1471-4159.2005.03130.x
   Zijistra F, 2008, EUR NEUROPSYCHOPHARM, V18, P262, DOI 10.1016/j.euroneuro.2007.11.002
   Zlebnik NE, 2010, PSYCHOPHARMACOLOGY, V209, P113, DOI 10.1007/s00213-010-1776-0
   Zuckerman M, 1986, NIDA Res Monogr, V74, P59
   ZUCKERMAN M, 1991, SELF REGULATORY BEHA, P143
NR 345
TC 168
Z9 169
U1 2
U2 114
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3908
EI 1873-7064
J9 NEUROPHARMACOLOGY
JI Neuropharmacology
PD DEC
PY 2011
VL 61
IS 7
SI SI
BP 1109
EP 1122
DI 10.1016/j.neuropharm.2011.03.010
PG 14
WC Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 834JX
UT WOS:000295956700007
PM 21459101
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Wang, TR
   Moosa, S
   Dallapiazza, RF
   Elias, WJ
   Lynch, WJ
AF Wang, Tony R.
   Moosa, Shayan
   Dallapiazza, Robert F.
   Elias, W. Jeffrey
   Lynch, Wendy J.
TI Deep brain stimulation for the treatment of drug addiction
SO NEUROSURGICAL FOCUS
LA English
DT Article
DE deep brain stimulation; nucleus accumbens; prefrontal cortex;
   neuromodulation; drug addiction
ID DOPAMINE DYSREGULATION SYNDROME; HEROIN-SEEKING BEHAVIORS;
   NUCLEUS-ACCUMBENS; ELECTRICAL-STIMULATION; PARKINSONS-DISEASE; INDUCED
   REINSTATEMENT; ETHANOL-CONSUMPTION; COCAINE SEEKING; REWARD; ALCOHOL
AB Drug addiction represents a significant public health concern that has high rates of relapse despite optimal medical therapy and rehabilitation support. New therapies are needed, and deep brain stimulation (DBS) may be an effective treatment. The past 15 years have seen numerous animal DBS studies for addiction to various drugs of abuse, with most reporting decreases in drug-seeking behavior with stimulation. The most common target for stimulation has been the nucleus accumbens, a key structure in the mesolimbic reward pathway. In addiction, the mesolimbic reward pathway undergoes a series of neuroplastic changes. Chief among them is a relative hypofunctioning of the prefrontal cortex, which is thought to lead to the diminished impulse control that is characteristic of drug addiction. The prefrontal cortex, as well as other targets involved in drug addiction such as the lateral habenula, hypothalamus, insula, and subthalamic nucleus have also been stimulated in animals, with encouraging results. Although animal studies have largely shown promising results, current DBS studies for drug addiction primarily use stimulation during active drug use. More data are needed on the effect of DBS during withdrawal in preventing future relapse. The published human experience for DBS for drug addiction is currently limited to several promising case series or case reports that are not controlled. Further animal and human work is needed to determine what role DBS can play in the treatment of drug addiction.
C1 [Wang, Tony R.; Moosa, Shayan; Elias, W. Jeffrey] Univ Virginia, Dept Neurol Surg, Charlottesville, VA USA.
   [Dallapiazza, Robert F.] Univ Hlth Network, Div Neurosurg, Toronto Western Hosp, Toronto, ON, Canada.
   [Lynch, Wendy J.] Univ Virginia, Dept Psychiat & Neurobehav Sci, Charlottesville, VA USA.
C3 University of Virginia; University of Toronto; University Health Network
   Toronto; University of Virginia
RP Wang, TR (通讯作者)，Univ Virginia, Charlottesville, VA 22904 USA.
EM tw5tf@hscmail.mcc.virginia.edu
FU NIDA NIH HHS [R01 DA039093, R01 DA024716] Funding Source: Medline
CR Abbes M, 2018, J NEUROL NEUROSURG P
   Abdolahi A, 2015, ADDICTION, V110, P1994, DOI 10.1111/add.13061
   Bandini F, 2007, PARKINSONISM RELAT D, V13, P369, DOI 10.1016/j.parkreldis.2006.07.011
   Bari A, 2014, NEUROSURG CLIN N AM, V25, P137, DOI 10.1016/j.nec.2013.08.004
   Batra V, 2017, J NEUROSURG, V126, P1339, DOI 10.3171/2016.4.JNS152524
   BENABID AL, 1987, APPL NEUROPHYSIOL, V50, P344
   Bonci A, 2006, ANN NEUROL, V59, P733, DOI 10.1002/ana.20878
   Creed M, 2015, SCIENCE, V347, P659, DOI 10.1126/science.1260776
   Everitt BJ, 2002, J NEUROSCI, V22, P3312
   Fein G, 2008, DRUG ALCOHOL DEPEN, V92, P141, DOI 10.1016/j.drugalcdep.2007.07.017
   Follett KA, 2000, ANNU REV MED, V51, P135, DOI 10.1146/annurev.med.51.1.135
   Forman SD, 2004, BIOL PSYCHIAT, V55, P531, DOI 10.1016/j.biopsych.2003.09.011
   Friedman A, 2010, NEUROPHARMACOLOGY, V59, P452, DOI 10.1016/j.neuropharm.2010.06.008
   Goncalves-Ferreira A, 2016, BIOL PSYCHIAT, V79, pE87, DOI 10.1016/j.biopsych.2015.06.023
   Grant BF, 2017, JAMA PSYCHIAT, V74, P911, DOI 10.1001/jamapsychiatry.2017.2161
   Greenberg BD, 2006, NEUROPSYCHOPHARMACOL, V31, P2384, DOI 10.1038/sj.npp.1301165
   Guercio LA, 2015, BEHAV BRAIN RES, V281, P125, DOI 10.1016/j.bbr.2014.12.025
   Guo LM, 2013, DRUG ALCOHOL DEPEN, V129, P70, DOI 10.1016/j.drugalcdep.2012.09.012
   Hamilton J, 2015, BRAIN STIMUL, V8, P57, DOI 10.1016/j.brs.2014.09.018
   Han B, 2017, ANN INTERN MED, V167, P293, DOI 10.7326/M17-0865
   Heinze HJ, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.022.2009
   Heldmann M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036572
   Henderson MB, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.4.FOCUS10105
   Hu WH, 2011, MED SCI MONITOR, V17, pBR153, DOI 10.12659/MSM.881802
   Jha P, 2013, NEW ENGL J MED, V368, P341, DOI 10.1056/NEJMsa1211128
   Johansen-Berg H, 2008, CEREB CORTEX, V18, P1374, DOI 10.1093/cercor/bhm167
   Knapp CM, 2009, PHARMACOL BIOCHEM BE, V92, P474, DOI 10.1016/j.pbb.2009.01.017
   Knobel D, 2008, COGN BEHAV NEUROL, V21, P187, DOI 10.1097/WNN.0b013e318185e6e2
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Kuhn J, 2014, MOL PSYCHIATR, V19, P145, DOI 10.1038/mp.2012.196
   Kuhn J, 2009, EUR ADDICT RES, V15, P196, DOI 10.1159/000228930
   Kuhn J, 2007, J NEUROL NEUROSUR PS, V78, P1152, DOI 10.1136/jnnp.2006.113092
   Kuhn J, 2011, ADDICT BIOL, V16, P620, DOI 10.1111/j.1369-1600.2011.00337.x
   Langleben DD, 2008, AM J PSYCHIAT, V165, P390, DOI 10.1176/appi.ajp.2007.07010070
   Lawrence AD, 2003, LANCET NEUROL, V2, P595, DOI 10.1016/S1474-4422(03)00529-5
   Leiphart JW, 2010, J NEUROSURG, V113, P1204, DOI 10.3171/2010.5.JNS091277
   Levy D, 2007, J NEUROSCI, V27, P14179, DOI 10.1523/JNEUROSCI.4477-07.2007
   Lim SY, 2009, J CLIN NEUROSCI, V16, P1148, DOI 10.1016/j.jocn.2008.12.010
   Liu HY, 2008, ADDICT BIOL, V13, P40, DOI 10.1111/j.1369-1600.2007.00088.x
   Luigjes J, 2012, MOL PSYCHIATR, V17, P572, DOI 10.1038/mp.2011.114
   Lynch WJ, 2018, PHARMACOL BIOCHEM BE, V164, P50, DOI 10.1016/j.pbb.2017.06.006
   Ma Y, 2013, CHINESE MED J-PEKING, V126, P1939, DOI 10.3760/cma.j.issn.0366-6999.20130088
   MacAskill AF, 2014, NAT NEUROSCI, V17, P1198, DOI 10.1038/nn.3783
   MAISONNEUVE IM, 1995, J PHARMACOL EXP THER, V272, P652
   Mantione M, 2010, NEUROSURGERY, V66, P218, DOI 10.1227/01.NEU.0000360570.40339.64
   Martinez-Rivera FJ, 2016, BIOL PSYCHIAT, V80, P682, DOI 10.1016/j.biopsych.2016.05.015
   Muller UJ, 2009, PHARMACOPSYCHIATRY, V42, P288, DOI 10.1055/s-0029-1233489
   Muller UJ, 2013, ANN NY ACAD SCI, V1282, P119, DOI 10.1111/j.1749-6632.2012.06834.x
   Naqvi NH, 2007, SCIENCE, V315, P531, DOI 10.1126/science.1135926
   OBrien CP, 1996, LANCET, V347, P237, DOI 10.1016/S0140-6736(96)90409-2
   Pascoli V, 2014, NATURE, V509, P459, DOI 10.1038/nature13257
   Pascoli V, 2012, NATURE, V481, P71, DOI 10.1038/nature10709
   Porta M, 2009, NEUROLOGY, V73, P1375, DOI 10.1212/WNL.0b013e3181bd809b
   Pushparaj A, 2013, NEUROPSYCHOPHARMACOL, V38, P690, DOI 10.1038/npp.2012.235
   Ramoa CP, 2014, BIOL PSYCHIAT, V76, P8, DOI 10.1016/j.biopsych.2013.09.028
   Rouaud T, 2010, P NATL ACAD SCI USA, V107, P1196, DOI 10.1073/pnas.0908189107
   Smeding HMM, 2007, J NEUROL NEUROSUR PS, V78, P517, DOI 10.1136/jnnp.2006.102061
   Stelten BML, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC/2008/25/7/E5
   Valencia-Alfonso CE, 2012, BIOL PSYCHIAT, V71, pE35, DOI 10.1016/j.biopsych.2011.12.013
   Vassoler FM, 2008, J NEUROSCI, V28, P8735, DOI 10.1523/JNEUROSCI.5277-07.2008
   Vassoler FM, 2013, J NEUROSCI, V33, P14446, DOI 10.1523/JNEUROSCI.4804-12.2013
   Voges J, 2013, WORLD NEUROSURG, V80, DOI 10.1016/j.wneu.2012.07.011
   Volkow ND, 2003, J CLIN INVEST, V111, P1444, DOI 10.1172/JCI200318533
   Volkow ND, 1997, NATURE, V386, P830, DOI 10.1038/386830a0
   Wade CL, 2017, NEUROPSYCHOPHARMACOL, V42, P1850, DOI 10.1038/npp.2016.270
   Warren N, 2017, J NEUROL NEUROSUR PS, V88, P1060, DOI 10.1136/jnnp-2017-315985
   WEISS F, 1992, BRAIN RES, V593, P314, DOI 10.1016/0006-8993(92)91327-B
   Wilden JA, 2014, J NEUROSURG, V120, P997, DOI 10.3171/2013.12.JNS13205
   Wind JJ, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.12.E11
   Witjas T, 2005, MOVEMENT DISORD, V20, P1052, DOI 10.1002/mds.20501
   Wolf Marina E, 2002, Mol Interv, V2, P146, DOI 10.1124/mi.2.3.146
   Zahm DS, 2000, NEUROSCI BIOBEHAV R, V24, P85, DOI 10.1016/S0149-7634(99)00065-2
   Zhou HY, 2011, BIOL PSYCHIAT, V69, pE41, DOI 10.1016/j.biopsych.2011.02.012
NR 75
TC 41
Z9 43
U1 7
U2 42
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 1092-0684
J9 NEUROSURG FOCUS
JI Neurosurg. Focus
PD AUG
PY 2018
VL 45
IS 2
AR E11
DI 10.3171/2018.5.FOCUS18163
PG 10
WC Clinical Neurology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Surgery
GA GP0HC
UT WOS:000440488900011
PM 30064320
OA Green Accepted, gold
DA 2023-06-23
ER

PT J
AU Spanagel, R
AF Spanagel, Rainer
TI A CALL FOR SYSTEMS APPROACHES IN ADDICTION RESEARCH
SO ADDICTION
LA English
DT Editorial Material
DE Allostatic shift; drug reinforcement; optogenetics; systems approach
ID DRUG-ADDICTION; REWARD
C1 Univ Heidelberg, Dept Psychopharmacol, Cent Inst Mental Hlth ZI, D-68159 Mannheim, Germany.
C3 Central Institute of Mental Health; Ruprecht Karls University Heidelberg
RP Spanagel, R (通讯作者)，Univ Heidelberg, Dept Psychopharmacol, Cent Inst Mental Hlth ZI, J5, D-68159 Mannheim, Germany.
EM rainer.spanagel@zi-mannheim.de
CR Ahmed SH, 2009, PHARMACOPSYCHIATRY, V42, pS144, DOI 10.1055/s-0029-1216345
   Ahmed SH, 2005, PSYCHOPHARMACOLOGY, V180, P473, DOI 10.1007/s00213-005-2180-z
   Airan RD, 2009, NATURE, V458, P1025, DOI 10.1038/nature07926
   Gebicke-Haerter PJ, 2008, ADDICT BIOL, V13, P449, DOI 10.1111/j.1369-1600.2008.00137.x
   Kalant H, 2010, ADDICTION, V105, P780, DOI 10.1111/j.1360-0443.2009.02739.x
   OLDS J, 1954, J COMP PHYSIOL PSYCH, V47, P419, DOI 10.1037/h0058775
   Spanagel R, 2009, PHYSIOL REV, V89, P649, DOI 10.1152/physrev.00013.2008
   Tsai HC, 2009, SCIENCE, V324, P1080, DOI 10.1126/science.1168878
   Tzschentke TM, 2007, ADDICT BIOL, V12, P227, DOI 10.1111/j.1369-1600.2007.00070.x
   Zhang F, 2006, NAT METHODS, V3, P785, DOI 10.1038/nmeth936
NR 10
TC 5
Z9 7
U1 0
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0965-2140
J9 ADDICTION
JI Addiction
PD MAY
PY 2010
VL 105
IS 5
BP 791
EP 792
PG 2
WC Substance Abuse; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry
GA 581IN
UT WOS:000276516000005
PM 20402968
OA Bronze
DA 2023-06-23
ER

PT C
AU Sani, MN
AF Sani, Mahbuba Naznin
BE Hacifazlioglu, O
   Halat, MM
TI Drug addiction among undergraduate students of private universities in
   Bangladesh
SO WCPCG 2010
SE Procedia Social and Behavioral Sciences
LA English
DT Proceedings Paper
CT World Conference on Psychology, Counselling and Guidance (WCPCG 2010)
CY APR 22-25, 2010
CL Antalya, TURKEY
DE Drug addiction; undergraduate students; treatment taking attitude
AB The present study was conducted to get an idea of drug addiction in undergraduate students of private universities in Bangladesh. Researcher also exposed the causes of drug addiction, types of drugs they mainly used and their treatment taking attitude. Sample was selected on the basis of purposive sampling technique. Researcher met them individually to collect the data by using questionnaire. For this purpose 160 samples were selected from different private universities. Age range of the subjects was from 15 to 25 years. Result revealed that 38.75% respondents were addicted because of influenced by friends and 31.88% respondents involved in drug addiction of just trying to do something new. 86.87% respondents were taking ganja which was the highest among different drugs, 86.87% respondents were aware of treatment for drug addiction though the rate of taking treatment for drug addiction was less. Among them 41.93% respondents were involved with drugs again after taking treatment. In conclusion it can be said that students mainly took drugs to have fun or just for the sake of curiosity though their treatment taking attitude was in very low stage. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Sani, Mahbuba Naznin] BRAC Univ, Dept Econ & Social Sci, Dhaka, Bangladesh.
C3 Bangladesh Rural Advancement Committee BRAC; BRAC University
EM sani@bracu.ac.bd
CR Cepulkauskaite I., 1998, DRUG ADDICTION PREVE, P141
   Gerstein R., 1996, NATL TREATMENT IMPRO, P83
   Hogue A, 2008, J SUBST ABUSE TREAT, V35, P137, DOI 10.1016/j.jsat.2007.09.002
NR 3
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1877-0428
J9 PROCD SOC BEHV
PY 2010
VL 5
BP 498
EP 501
DI 10.1016/j.sbspro.2010.07.131
PG 4
WC Psychology, Multidisciplinary; Social Sciences, Interdisciplinary
WE Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)
SC Psychology; Social Sciences - Other Topics
GA BTK33
UT WOS:000287160900091
OA gold
DA 2023-06-23
ER

PT J
AU El Rawas, R
   Venniro, M
AF El Rawas, Rana
   Venniro, Marco
TI Editorial: The Double Facets of Social Behavior in Drug Addiction
SO FRONTIERS IN BEHAVIORAL NEUROSCIENCE
LA English
DT Editorial Material
DE social interaction; drug addiction; stress; social support; reward
C1 [El Rawas, Rana] Med Univ Innsbruck, Dept Psychiat, Div Psychiatry1, Psychotherapy, Innsbruck, Austria.
   [Venniro, Marco] Univ Maryland Sch Med, Dept Anat & Neurobiol, Baltimore, MD USA.
C3 Medical University of Innsbruck; University System of Maryland;
   University of Maryland Baltimore
RP El Rawas, R (通讯作者)，Med Univ Innsbruck, Dept Psychiat, Div Psychiatry1, Psychotherapy, Innsbruck, Austria.; Venniro, M (通讯作者)，Univ Maryland Sch Med, Dept Anat & Neurobiol, Baltimore, MD USA.
EM rana.el-rawas@i-med.ac.at; marco.venniro@som.umaryland.edu
OI El Rawas, Rana/0000-0002-8068-4507
NR 0
TC 0
Z9 0
U1 0
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1662-5153
J9 FRONT BEHAV NEUROSCI
JI Front. Behav. Neurosci.
PD MAY 5
PY 2022
VL 16
AR 907327
DI 10.3389/fnbeh.2022.907327
PG 2
WC Behavioral Sciences; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Behavioral Sciences; Neurosciences & Neurology
GA 1J8WK
UT WOS:000798193800001
PM 35600986
OA gold, Green Published
DA 2023-06-23
ER

PT J
AU Utkin, YA
   Tsukanov, RN
   Lan, IL
AF Utkin, Yu. A.
   Tsukanov, R. N.
   Lan, I. L.
TI Organization of drug addiction aid for chronic alcoholic patients in the
   Penza Region
SO ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA
LA Russian
DT Article
DE chronic alcoholism; drug addiction aid
C1 [Utkin, Yu. A.; Tsukanov, R. N.; Lan, I. L.] Penza Reg Narcol Hosp, Minist Hlth & Social Dev Penza Reg, Penza, Russia.
RP Utkin, YA (通讯作者)，Penza Reg Narcol Hosp, Minist Hlth & Social Dev Penza Reg, Penza, Russia.
EM onborgmetod@yndex.ru
NR 0
TC 0
Z9 0
U1 0
U2 0
PU IZDATELSTVO MEDITSINA
PI MOSCOW
PA PETROVERIGSKII PER 6-8, K-142 MOSCOW, RUSSIA
SN 1997-7298
J9 ZH NEVROL PSIKHIATR
JI Z. Nevrol. Psikhiatrii Im S S Korsakova
PY 2012
VL 112
IS 5
SU 2
BP 58
EP 61
PG 4
WC Clinical Neurology; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Psychiatry
GA 979YV
UT WOS:000306861700011
PM 22951800
DA 2023-06-23
ER

PT J
AU Vanderschuren, LJMJ
   Ahmed, SH
AF Vanderschuren, Louk J. M. J.
   Ahmed, Serge H.
TI Animal Studies of Addictive Behavior
SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LA English
DT Article
ID SELF-ADMINISTERED COCAINE; EXTENDED-ACCESS; DRUG-ADDICTION; INDUCED
   REINSTATEMENT; RHESUS-MONKEYS; IMPULSIVITY PREDICTS; INCREASED
   MOTIVATION; DECISION-MAKING; D-AMPHETAMINE; RESPONSE-INHIBITION
AB It is increasingly recognized that studying drug taking in laboratory animals does not equate to studying genuine addiction, characterized by loss of control over drug use. This has inspired recent work aimed at capturing genuine addiction-like behavior in animals. In this work, we summarize empirical evidence for the occurrence of several DSM-IV-like symptoms of addiction in animals after extended drug use. These symptoms include escalation of drug use, neurocognitive deficits, resistance to extinction, increased motivation for drugs, preference for drugs over nondrug rewards, and resistance to punishment. The fact that addiction-like behavior can occur and be studied in animals gives us the exciting opportunity to investigate the neural and genetic background of drug addiction, which we hope will ultimately lead to the development of more effective treatments for this devastating disorder.
C1 [Vanderschuren, Louk J. M. J.] Univ Utrecht, Fac Vet Med, Div Behav Neurosci, Dept Anim Sci & Soc, NL-3584 CG Utrecht, Netherlands.
   [Vanderschuren, Louk J. M. J.] Univ Med Ctr Utrecht, Dept Neurosci & Pharmacol, Rudolf Magnus Inst Neurosci, NL-3584 CG Utrecht, Netherlands.
   [Ahmed, Serge H.] Univ Bordeaux, Inst Malad Neurodegenerat, CNRS UMR 5293, F-33000 Bordeaux, France.
C3 Utrecht University; Utrecht University; Utrecht University Medical
   Center; Centre National de la Recherche Scientifique (CNRS); CNRS -
   National Institute for Biology (INSB); UDICE-French Research
   Universities; Universite de Bordeaux
RP Vanderschuren, LJMJ (通讯作者)，Univ Utrecht, Fac Vet Med, Div Behav Neurosci, Dept Anim Sci & Soc, NL-3584 CG Utrecht, Netherlands.
EM l.j.m.j.vanderschuren@uu.nl
RI Vanderschuren, Louk/AAS-4391-2020; AHMED, Serge H/D-5236-2014
OI Vanderschuren, Louk/0000-0002-5379-0363; Ahmed,
   Serge/0000-0002-1225-9234
FU ZonMw (the Netherlands Organisation for Health Research and Development)
   [91207006]; ZonMw (the Netherlands Organisation for Health Research and
   Development)/National Institute on Drug Abuse (NIDA) [60-60600-97-211];
   French Research Council (CNRS); National Research Agency (ANR);
   University of Bordeaux-Segalen; Conseil Regional d'Aquitaine (CRA)
FX L.J.M.J.V. is supported by ZonMw (the Netherlands Organisation for
   Health Research and Development) Grant 91207006 (awarded to L.J.M.J.V.,
   P. Voorn, and A.B. Smit), ZonMw (the Netherlands Organisation for Health
   Research and Development)/National Institute on Drug Abuse (NIDA)
   Collaborative Grant 60-60600-97-211 (awarded to L.J.M.J.V. and R. C.
   Pierce). S.H.A. is supported by the French Research Council (CNRS), the
   National Research Agency (ANR), the University of Bordeaux-Segalen, and
   the Conseil Regional d'Aquitaine (CRA).
CR Ahmed SH, 2012, NEUROSCIENCE, V211, P107, DOI 10.1016/j.neuroscience.2011.08.014
   Ahmed SH, 2011, ILAR J, V52, P309, DOI 10.1093/ilar.52.3.309
   Ahmed SH, 2011, NEUROMETHODS, V53, P267, DOI 10.1007/978-1-60761-934-5_10
   Ahmed SH, 2010, NEUROSCI BIOBEHAV R, V35, P172, DOI 10.1016/j.neubiorev.2010.04.005
   Ahmed SH, 2006, NEUROPSYCHOPHARMACOL, V31, P563, DOI 10.1038/sj.npp.1300834
   Ahmed SH, 2005, EUR J PHARMACOL, V526, P9, DOI 10.1016/j.ejphar.2005.09.036
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Ahmed SH, 1999, PSYCHOPHARMACOLOGY, V146, P303, DOI 10.1007/s002130051121
   Ahmed SH, 2000, NEUROPSYCHOPHARMACOL, V22, P413, DOI 10.1016/S0893-133X(99)00133-5
   AIGNER TG, 1978, SCIENCE, V201, P534, DOI 10.1126/science.96531
   Allen RM, 2007, PSYCHOPHARMACOLOGY, V191, P341, DOI 10.1007/s00213-006-0661-3
   American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th
   Anker JJ, 2011, CURR TOP BEHAV NEURO, V8, P73, DOI 10.1007/7854_2010_93
   Anker JJ, 2009, PHARMACOL BIOCHEM BE, V93, P343, DOI 10.1016/j.pbb.2009.05.013
   Audrain-McGovern J, 2009, DRUG ALCOHOL DEPEN, V103, P99, DOI 10.1016/j.drugalcdep.2008.12.019
   Augier E, 2012, ADDICT BIOL, V17, P378, DOI 10.1111/j.1369-1600.2011.00368.x
   Badiani A, 2011, NAT REV NEUROSCI, V12, P685, DOI 10.1038/nrn3104
   Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   Belin D, 2009, BIOL PSYCHIAT, V65, P863, DOI 10.1016/j.biopsych.2008.05.031
   Ben-Shahar O, 2008, PROG NEURO-PSYCHOPH, V32, P863, DOI 10.1016/j.pnpbp.2008.01.002
   BERGMAN J, 1981, PHARMACOL BIOCHEM BE, V14, P423, DOI 10.1016/0091-3057(81)90413-5
   Bowden-Jones H, 2005, J NEUROPSYCH CLIN N, V17, P417, DOI 10.1176/appi.neuropsych.17.3.417
   Briand LA, 2008, NEUROPSYCHOPHARMACOL, V33, P2969, DOI 10.1038/npp.2008.18
   Calu DJ, 2007, LEARN MEMORY, V14, P325, DOI 10.1101/lm.534807
   Cantin L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011592
   Caprioli D, 2009, BIOL PSYCHIAT, V65, P893, DOI 10.1016/j.biopsych.2008.12.009
   CARROLL ME, 1989, PSYCHOPHARMACOLOGY, V97, P23, DOI 10.1007/BF00443407
   CARROLL ME, 1993, PSYCHOPHARMACOLOGY, V110, P5, DOI 10.1007/BF02246944
   Chambers CD, 2009, NEUROSCI BIOBEHAV R, V33, P631, DOI 10.1016/j.neubiorev.2008.08.016
   Charney DA, 2010, J SUBST ABUSE TREAT, V38, P42, DOI 10.1016/j.jsat.2009.06.002
   Christensen CJ, 2008, PSYCHOPHARMACOLOGY, V198, P221, DOI 10.1007/s00213-008-1120-0
   Cooper A, 2007, PSYCHOPHARMACOLOGY, V194, P117, DOI 10.1007/s00213-007-0827-7
   Dalley JW, 2007, SCIENCE, V315, P1267, DOI 10.1126/science.1137073
   Dalley JW, 2007, NEUROPSYCHOPHARMACOL, V32, P1195, DOI 10.1038/sj.npp.1301220
   Dalley JW, 2005, PSYCHOPHARMACOLOGY, V182, P579, DOI 10.1007/s00213-005-0107-3
   Del Olmo N, 2007, PSYCHOPHARMACOLOGY, V195, P19, DOI 10.1007/s00213-007-0873-1
   Deroche V, 1999, EUR J NEUROSCI, V11, P2731, DOI 10.1046/j.1460-9568.1999.00696.x
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Dickinson A, 2002, Q J EXP PSYCHOL-B, V55, P331, DOI 10.1080/0272499024400016
   DICKINSON A, 1985, PHILOS T ROY SOC B, V308, P67, DOI 10.1098/rstb.1985.0010
   Diergaarde L, 2008, BIOL PSYCHIAT, V63, P301, DOI 10.1016/j.biopsych.2007.07.011
   Doherty J, 2009, PHARMACOL BIOCHEM BE, V92, P164, DOI 10.1016/j.pbb.2008.11.009
   Domingos AI, 2011, NAT NEUROSCI, V14, P1562, DOI 10.1038/nn.2977
   Ferrario CR, 2005, BIOL PSYCHIAT, V58, P751, DOI 10.1016/j.biopsych.2005.04.046
   Galli G, 2004, DRUG ALCOHOL DEPEN, V73, P51, DOI 10.1016/j.drugalcdep.2003.09.003
   Galli G, 2011, BEHAV BRAIN RES, V217, P261, DOI 10.1016/j.bbr.2010.10.011
   Garavan H, 2005, TRENDS COGN SCI, V9, P195, DOI 10.1016/j.tics.2005.02.008
   George O, 2008, NEUROPSYCHOPHARMACOL, V33, P2474, DOI 10.1038/sj.npp.1301626
   Gipson CD, 2009, PSYCHOPHARMACOLOGY, V207, P391, DOI 10.1007/s00213-009-1667-4
   Goldstein RZ, 2009, TRENDS COGN SCI, V13, P372, DOI 10.1016/j.tics.2009.06.004
   Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134
   GROVE RN, 1974, PHARMACOL BIOCHEM BE, V2, P199, DOI 10.1016/0091-3057(74)90053-7
   Hao Y, 2010, BIOL PSYCHIAT, V68, P240, DOI 10.1016/j.biopsych.2010.02.011
   Heyne A, 1996, PHARMACOL BIOCHEM BE, V53, P11, DOI 10.1016/0091-3057(95)00193-X
   Heyne A, 1998, PSYCHOPHARMACOLOGY, V140, P510, DOI 10.1007/s002130050796
   HODOS W, 1961, SCIENCE, V134, P943, DOI 10.1126/science.134.3483.943
   Hollander JA, 2010, NATURE, V466, P197, DOI 10.1038/nature09202
   Holter SM, 1998, BEHAV PHARMACOL, V9, P41
   Hopf FW, 2010, ALCOHOL CLIN EXP RES, V34, P1565, DOI 10.1111/j.1530-0277.2010.01241.x
   Im HI, 2010, NAT NEUROSCI, V13, P1120, DOI 10.1038/nn.2615
   Jenkins TN, 1926, J COMP PSYCHOL, V6, P361, DOI 10.1037/h0074447
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564
   Kasanetz F, 2010, SCIENCE, V328, P1709, DOI 10.1126/science.1187801
   Kearns David N, 2011, Curr Drug Abuse Rev, V4, P261
   Kearns DN, 2002, DRUG ALCOHOL DEPEN, V65, P253, DOI 10.1016/S0376-8716(01)00167-3
   Kenny PJ, 2007, TRENDS PHARMACOL SCI, V28, P135, DOI 10.1016/j.tips.2007.01.008
   Kenny PJ, 2006, NEUROPSYCHOPHARMACOL, V31, P1203, DOI 10.1038/sj.npp.1300905
   KERSTETTER KA, 2010, NEUR M PLANN
   Kippin TE, 2006, PSYCHOPHARMACOLOGY, V187, P60, DOI 10.1007/s00213-006-0386-3
   Kitamura O, 2006, PSYCHOPHARMACOLOGY, V186, P48, DOI 10.1007/s00213-006-0353-z
   Knackstedt LA, 2007, J PHARMACOL EXP THER, V322, P1103, DOI 10.1124/jpet.107.122861
   Koffarnus MN, 2013, ADDICT BIOL, V18, P8, DOI 10.1111/j.1369-1600.2011.00361.x
   Koob GF, 2009, NAT REV DRUG DISCOV, V8, P500, DOI 10.1038/nrd2828
   Larson EB, 2007, EXP CLIN PSYCHOPHARM, V15, P461, DOI 10.1037/1064-1297.15.5.461
   Lenoir M, 2008, NEUROPSYCHOPHARMACOL, V33, P2272, DOI 10.1038/sj.npp.1301602
   Lenoir M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000698
   Lenoir M, 2007, NEUROPSYCHOPHARMACOL, V32, P616, DOI 10.1038/sj.npp.1301083
   Lenoir M, 2012, ADDICT BIOL, V17, P964, DOI 10.1111/j.1369-1600.2011.00385.x
   LeSage M, 2009, PSYCHOPHARMACOLOGY, V203, P13, DOI 10.1007/s00213-008-1362-x
   Lesscher HMB, 2009, GENES BRAIN BEHAV, V8, P493, DOI 10.1111/j.1601-183X.2009.00485.x
   Lesscher HMB, 2010, ALCOHOL CLIN EXP RES, V34, P1219, DOI 10.1111/j.1530-0277.2010.01199.x
   Liu Y, 2005, EUR J NEUROSCI, V22, P195, DOI 10.1111/j.1460-9568.2005.04195.x
   Liu Y, 2005, PSYCHOPHARMACOLOGY, V179, P644, DOI 10.1007/s00213-004-2089-y
   Liu Y, 2007, PSYCHOPHARMACOLOGY, V195, P369, DOI 10.1007/s00213-007-0909-6
   Lu L, 2004, NEUROPHARMACOLOGY, V47, P214, DOI 10.1016/j.neuropharm.2004.06.027
   Mantsch JR, 2008, PSYCHOPHARMACOLOGY, V195, P591, DOI 10.1007/s00213-007-0950-5
   Mantsch JR, 2004, PSYCHOPHARMACOLOGY, V175, P26, DOI 10.1007/s00213-004-1778-x
   Marusich JA, 2010, EXP CLIN PSYCHOPHARM, V18, P257, DOI 10.1037/a0019814
   McNamara R, 2010, PSYCHOPHARMACOLOGY, V212, P453, DOI 10.1007/s00213-010-1974-9
   Mendez IA, 2010, BEHAV NEUROSCI, V124, P470, DOI 10.1037/a0020458
   Miles FJ, 2003, BEHAV NEUROSCI, V117, P927, DOI 10.1037/0735-7044.117.5.927
   Moeller FG, 2001, J SUBST ABUSE TREAT, V21, P193, DOI 10.1016/S0740-5472(01)00202-1
   Morgan D, 2006, NEUROPSYCHOPHARMACOL, V31, P121, DOI 10.1038/sj.npp.1300773
   Morgan D, 2005, PSYCHOPHARMACOLOGY, V178, P309, DOI 10.1007/s00213-004-1992-6
   Morgan D, 2002, NAT NEUROSCI, V5, P169, DOI 10.1038/nn798
   NADER MA, 1991, PSYCHOPHARMACOLOGY, V105, P169, DOI 10.1007/BF02244304
   Negus SS, 2006, J PHARMACOL EXP THER, V317, P711, DOI 10.1124/jpet.105.095380
   Negus SS, 2003, NEUROPSYCHOPHARMACOL, V28, P919, DOI 10.1038/sj.npp.1300096
   Nigg JT, 2006, J AM ACAD CHILD PSY, V45, P468, DOI 10.1097/01.chi.0000199028.76452.a9
   NORMAN N, 2011, 14 EBPS BIENN M AMST
   O'Brien CP, 2008, PHILOS T R SOC B, V363, P3277, DOI 10.1098/rstb.2008.0105
   O'Connor EC, 2011, NEUROSCI BIOBEHAV R, V35, P912, DOI 10.1016/j.neubiorev.2010.10.012
   Oleson EB, 2009, NEUROPSYCHOPHARMACOL, V34, P796, DOI 10.1038/npp.2008.195
   Olmstead MC, 2001, BEHAV NEUROSCI, V115, P394, DOI 10.1037/0735-7044.115.2.394
   Orio L, 2009, J NEUROSCI, V29, P4846, DOI 10.1523/JNEUROSCI.0563-09.2009
   Pacchioni AM, 2011, BEHAV BRAIN RES, V218, P296, DOI 10.1016/j.bbr.2010.12.014
   Paronis CA, 2002, PSYCHOPHARMACOLOGY, V163, P283, DOI 10.1007/s00213-002-1180-5
   Parsegian A, 2011, BIOL PSYCHIAT, V69, P253, DOI 10.1016/j.biopsych.2010.09.003
   Paterson NE, 2003, NEUROREPORT, V14, P2229, DOI 10.1097/00001756-200312020-00019
   Paterson NE, 2004, PSYCHOPHARMACOLOGY, V173, P64, DOI 10.1007/s00213-003-1692-7
   Paulus MP, 2007, SCIENCE, V318, P602, DOI 10.1126/science.1142997
   Pelloux Y, 2007, PSYCHOPHARMACOLOGY, V194, P127, DOI 10.1007/s00213-007-0805-0
   PERRY AN, 2011, NEUR M PLANN
   Perry JL, 2005, PSYCHOPHARMACOLOGY, V178, P193, DOI 10.1007/s00213-004-1994-4
   Pickens CL, 2011, TRENDS NEUROSCI, V34, P411, DOI 10.1016/j.tins.2011.06.001
   Pierce RC, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a012880
   Porter JN, 2011, J NEUROSCI, V31, P4926, DOI 10.1523/JNEUROSCI.5426-10.2011
   Poulos CX, 1995, BEHAV PHARMACOL, V6, P810
   Quadros IMH, 2009, PSYCHOPHARMACOLOGY, V206, P109, DOI 10.1007/s00213-009-1584-6
   Richardson NR, 1996, J NEUROSCI METH, V66, P1, DOI 10.1016/0165-0270(95)00153-0
   Robbins TW, 2008, ANN NY ACAD SCI, V1141, P1, DOI 10.1196/annals.1441.020
   Rodd ZA, 2003, NEUROPSYCHOPHARMACOL, V28, P1614, DOI 10.1038/sj.npp.1300214
   Rogers JL, 2008, PSYCHOPHARMACOLOGY, V199, P615, DOI 10.1007/s00213-008-1187-7
   Schenk S, 2011, J PSYCHOPHARMACOL, V25, P1043, DOI 10.1177/0269881110389213
   Schippers MC, 2012, PSYCHOPHARMACOLOGY, V219, P443, DOI 10.1007/s00213-011-2444-8
   Solinas M, 2010, PROG NEUROBIOL, V92, P572, DOI 10.1016/j.pneurobio.2010.08.002
   Sorge RE, 2005, PSYCHOPHARMACOLOGY, V183, P210, DOI 10.1007/s00213-005-0160-y
   Spanagel R, 1999, ALCOHOL ALCOHOLISM, V34, P231, DOI 10.1093/alcalc/34.2.231
   SPRAGG S. D. S., 1940, COMPAR PSYCHOL MONOGR, V15, P1
   Tzschentke TM, 2007, ADDICT BIOL, V12, P227, DOI 10.1111/j.1369-1600.2007.00070.x
   Uhl GR, 2004, ARCH GEN PSYCHIAT, V61, P223, DOI 10.1001/archpsyc.61.3.223
   VANDENBRINK W, 2011, CURRENT DRUG ABUSE R, V5, P3
   Vanderschuren LJMJ, 2005, EUR J PHARMACOL, V526, P77, DOI 10.1016/j.ejphar.2005.09.037
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Ward SJ, 2006, PSYCHOPHARMACOLOGY, V185, P150, DOI 10.1007/s00213-005-0288-9
   Wee S, 2008, EUR NEUROPSYCHOPHARM, V18, P303, DOI 10.1016/j.euroneuro.2007.08.003
   Wee S, 2007, NEUROPSYCHOPHARMACOL, V32, P2238, DOI 10.1038/sj.npp.1301353
   Wee S, 2009, PSYCHOPHARMACOLOGY, V205, P565, DOI 10.1007/s00213-009-1563-y
   Winstanley CA, 2009, CEREB CORTEX, V19, P435, DOI 10.1093/cercor/bhn094
   Wise RA, 1996, ANNU REV NEUROSCI, V19, P319, DOI 10.1146/annurev.ne.19.030196.001535
   WISE RA, 1973, PSYCHOPHARMACOLOGIA, V29, P203, DOI 10.1007/BF00414034
   WOLFFGRAMM J, 1991, NEUROSCI BIOBEHAV R, V15, P515, DOI 10.1016/S0149-7634(05)80142-3
   WOLFFGRAMM J, 1995, BEHAV BRAIN RES, V70, P77, DOI 10.1016/0166-4328(95)00131-C
   WOLFFGRAMM J, 1991, PHARMACOL BIOCHEM BE, V38, P389, DOI 10.1016/0091-3057(91)90297-F
   Zapata A, 2010, J NEUROSCI, V30, P15457, DOI 10.1523/JNEUROSCI.4072-10.2010
   Zhou WH, 2009, PSYCHOPHARMACOLOGY, V203, P677, DOI 10.1007/s00213-008-1414-2
NR 147
TC 45
Z9 46
U1 1
U2 12
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 2157-1422
J9 CSH PERSPECT MED
JI Cold Spring Harb. Perspect. Med.
PD APR
PY 2013
VL 3
IS 4
AR a011932
DI 10.1101/cshperspect.a011932
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 187ZK
UT WOS:000322160300003
PM 23249442
OA Green Published, Bronze
DA 2023-06-23
ER

PT J
AU Li, CL
   Zhu, N
   Li, YH
   Meng, XL
   Gao, J
   Sui, N
AF Li Chun-Lu
   Zhu Ning
   Li Yong-Hui
   Meng Xiao-Lu
   Gao Jun
   Sui Nan
TI The Role of Interoception and Insular Cortex in Addiction
SO PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS
LA Chinese
DT Article
DE interoception; insular cortex; addiction
ID TAKING DECISION-MAKING; FUNCTIONAL CONNECTIVITY; NUCLEUS-ACCUMBENS;
   VISCERAL CORTEX; DRUG-ADDICTION; RAT; ACTIVATION; BRAIN; RISK; STOP
AB Interoception is the sense of the physiological condition of the body. Recent studies suggested that interoception is involved in drug addiction and insular cortex is a key anatomical position. The neural mechanisms underlying such phenomena attract growing attention. In an effort to develop working hypotheses for future investigation, the article first reviewed the evidence of interoceptive regulation of addiction, and subsequently presented human and animal data that suggest a central role of the insular cortex in mediating interoception and addiction. On this basis, we proposed potential neurobiological mechanisms through which insular cortex may mediate drug addiction. Further, possible functional roles of neurotransmitters in the insular cortex are discussed in the context of drug addiction.
C1 [Li Chun-Lu; Zhu Ning; Li Yong-Hui; Meng Xiao-Lu; Gao Jun; Sui Nan] Chinese Acad Sci, Inst Psychol, Key Lab Mental Hlth, Beijing 100101, Peoples R China.
   [Li Chun-Lu; Meng Xiao-Lu; Gao Jun] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
C3 Chinese Academy of Sciences; Institute of Psychology, CAS; Chinese
   Academy of Sciences; University of Chinese Academy of Sciences, CAS
RP Sui, N (通讯作者)，Chinese Acad Sci, Inst Psychol, Key Lab Mental Hlth, Beijing 100101, Peoples R China.
EM suin@psych.ac.cn
RI Li, Yonghui/G-8539-2012
FU National Natural Science Foundation of China [31070911, 31170988];
   National Basic Research Program of China [2009CB522002]
FX This work was supported by grants from The National Natural Science
   Foundation of China (31070911, 31170988), National Basic Research
   Program of China (2009CB522002).
CR Accolla R, 2008, P NATL ACAD SCI USA, V105, P4010, DOI 10.1073/pnas.0708927105
   ALLEN GV, 1991, J COMP NEUROL, V311, P1, DOI 10.1002/cne.903110102
   Bechara A, 2001, Semin Clin Neuropsychiatry, V6, P205, DOI 10.1053/scnp.2001.22927
   Bencherif B, 2005, J NUCL MED, V46, P1349
   BERTHIER M, 1988, ANN NEUROL, V24, P41, DOI 10.1002/ana.410240109
   Bienkowski P, 2010, NEUROSCI LETT, V478, P161, DOI 10.1016/j.neulet.2010.05.008
   Bossaerts P, 2010, BRAIN STRUCT FUNCT, V214, P645, DOI 10.1007/s00429-010-0253-1
   Brass M, 2010, BRAIN STRUCT FUNCT, V214, P603, DOI 10.1007/s00429-010-0269-6
   Brody AL, 2007, BIOL PSYCHIAT, V62, P642, DOI 10.1016/j.biopsych.2006.10.026
   Burkey AR, 1996, J NEUROSCI, V16, P6612
   Campbell-Meiklejohn DK, 2008, BIOL PSYCHIAT, V63, P293, DOI 10.1016/j.biopsych.2007.05.014
   Chaudhry AM, 2009, EUR J NEUROSCI, V29, P1047, DOI 10.1111/j.1460-9568.2009.06646.x
   Chen H, 2004, BEHAV BRAIN RES, V154, P557, DOI 10.1016/j.bbr.2004.03.024
   Chikama M, 1997, J NEUROSCI, V17, P9686
   Chikazoe J, 2009, J NEUROSCI, V29, P15870, DOI 10.1523/JNEUROSCI.3645-09.2009
   CHRISTIE MJ, 1987, NEUROSCIENCE, V22, P425, DOI 10.1016/0306-4522(87)90345-9
   Chumakova YA, 2011, B EXP BIOL MED+, V150, P398, DOI 10.1007/s10517-011-1151-0
   Contreras M, 2007, SCIENCE, V318, P655, DOI 10.1126/science.1145590
   Critchley HD, 2004, NAT NEUROSCI, V7, P189, DOI 10.1038/nn1176
   Critchley HD, 2001, NAT NEUROSCI, V4, P207, DOI 10.1038/84048
   Critchley HD, 2005, J COMP NEUROL, V493, P154, DOI 10.1002/cne.20749
   Damasio AR, 2000, NAT NEUROSCI, V3, P1049, DOI 10.1038/79871
   Di Martino A, 2009, AM J PSYCHIAT, V166, P891, DOI 10.1176/appi.ajp.2009.08121894
   Di Pietro NC, 2008, PSYCHOPHARMACOLOGY, V200, P81, DOI 10.1007/s00213-008-1149-0
   Ersche KD, 2012, SCIENCE, V335, P601, DOI 10.1126/science.1214463
   Escobar ML, 2000, BRAIN RES, V852, P208, DOI 10.1016/S0006-8993(99)02134-4
   Evans JM, 2007, J COMP NEUROL, V500, P530, DOI 10.1002/cne.21197
   Feltenstein MW, 2008, BRIT J PHARMACOL, V154, P261, DOI 10.1038/bjp.2008.51
   Forget B, 2010, BIOL PSYCHIAT, V68, P265, DOI 10.1016/j.biopsych.2010.01.029
   Gabbott PLA, 2003, BRAIN RES, V993, P59, DOI 10.1016/j.brainres.2003.08.056
   Grant JE, 2008, J CLIN PSYCHIAT, V69, P783, DOI 10.4088/JCP.v69n0511
   Gray MA, 2007, NEURON, V54, P183, DOI 10.1016/j.neuron.2007.03.024
   GRIFFITHS M, 2011, INT J MENT HEALTH AD, V9, P1, DOI DOI 10.1007/s11469-009-9246-9
   Gu H, 2010, NEUROIMAGE, V53, P593, DOI 10.1016/j.neuroimage.2010.06.066
   Hamlin AS, 2006, NEUROSCIENCE, V143, P25, DOI 10.1016/j.neuroscience.2006.07.035
   Hanamori T, 1998, J NEUROPHYSIOL, V79, P2535, DOI 10.1152/jn.1998.79.5.2535
   Hollander JA, 2008, P NATL ACAD SCI USA, V105, P19480, DOI 10.1073/pnas.0808023105
   Jasmin L, 2003, NATURE, V424, P316, DOI 10.1038/nature01808
   KRUSHEL LA, 1988, J COMP NEUROL, V270, P39, DOI 10.1002/cne.902700105
   Kufahl PR, 2009, SYNAPSE, V63, P823, DOI 10.1002/syn.20666
   Ma N, 2010, NEUROIMAGE, V49, P738, DOI 10.1016/j.neuroimage.2009.08.037
   MANARA L, 1985, ANNU REV PHARMACOL, V25, P249, DOI 10.1146/annurev.pa.25.040185.001341
   Matthews SC, 2004, NEUROREPORT, V15, P2123, DOI 10.1097/00001756-200409150-00025
   Meriau K, 2009, BRAIN COGNITION, V69, P73, DOI 10.1016/j.bandc.2008.05.006
   Naqvi N, 2010, BRAIN STRUCTURE FUNC, V214, P1
   Naqvi NH, 2007, SCIENCE, V315, P531, DOI 10.1126/science.1135926
   Ohara PT, 2003, J NEUROCYTOL, V32, P131, DOI 10.1023/B:NEUR.0000005598.09647.7f
   Paulus MP, 2005, ARCH GEN PSYCHIAT, V62, P761, DOI 10.1001/archpsyc.62.7.761
   Paulus MP, 2003, NEUROIMAGE, V19, P1439, DOI 10.1016/S1053-8119(03)00251-9
   Ploghaus A, 1999, SCIENCE, V284, P1979, DOI 10.1126/science.284.5422.1979
   Potenza MN, 2008, PHILOS T R SOC B, V363, P3181, DOI 10.1098/rstb.2008.0100
   Preuschoff K, 2008, J NEUROSCI, V28, P2745, DOI 10.1523/JNEUROSCI.4286-07.2008
   Proskuryakova TV, 2009, B EXP BIOL MED+, V148, P357
   Ramautar JR, 2006, BRAIN RES, V1105, P143, DOI 10.1016/j.brainres.2006.02.091
   Sudakov SK, 2010, B EXP BIOL MED+, V149, P273, DOI 10.1007/s10517-010-0925-0
   Sudakov SK, 2010, B EXP BIOL MED+, V149, P167, DOI 10.1007/s10517-010-0898-z
   Tian YM, 2008, NEUROSCIENCE, V153, P634, DOI 10.1016/j.neuroscience.2008.02.033
   Wei CG, 2010, PROG BIOCHEM BIOPHYS, V37, P713, DOI 10.3724/SP.J.1206.2010.00047
   Wise RA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002846
   Wittert G, 1996, BIOCHEM BIOPH RES CO, V218, P877, DOI 10.1006/bbrc.1996.0156
   ZITO KA, 1988, PHARMACOL BIOCHEM BE, V30, P693, DOI 10.1016/0091-3057(88)90086-X
NR 61
TC 0
Z9 0
U1 3
U2 32
PU CHINESE ACAD SCIENCES, INST BIOPHYSICS
PI BEIJING
PA 15 DATUN RD, CHAOYAND DISTRICT, BEIJING, 100101, PEOPLES R CHINA
SN 1000-3282
J9 PROG BIOCHEM BIOPHYS
JI Prog. Biochem. Biophys.
PD JAN
PY 2013
VL 40
IS 1
BP 15
EP 21
DI 10.3724/SP.J.1206.2012.00116
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 077BO
UT WOS:000314003100002
OA Bronze
DA 2023-06-23
ER

PT J
AU Zhao, Y
   Qin, F
   Han, S
   Li, S
   Zhao, Y
   Wang, HB
   Tian, JW
   Cen, XB
AF Zhao, Yue
   Qin, Feng
   Han, Shuang
   Li, Shu
   Zhao, Ying
   Wang, Hongbo
   Tian, Jingwei
   Cen, Xiaobo
TI MicroRNAs in drug addiction: Current status and future perspectives
SO PHARMACOLOGY & THERAPEUTICS
LA English
DT Review
DE microRNAs (miRNAs); Drug addiction; Neuroadaptation; Biomarker
ID MU-OPIOID RECEPTOR; MEDIATED DOWN-REGULATION; POSTTRANSCRIPTIONAL
   REGULATION; ALCOHOL EXPOSURE; BDNF EXPRESSION; GABAERGIC
   NEUROTRANSMISSION; GLUCOCORTICOID-RECEPTOR; EXTRACELLULAR VESICLES;
   ALZHEIMERS-DISEASE; ADULT NEUROGENESIS
AB Drug addiction is a chronic and relapsing brain disorder characterized by compulsive drug seeking and continued drug use despite adverse consequences. The high prevalence and social burden of addiction is indisputable; however, the available intervention is insufficient. Abnormal gene expression is observed in reward-related brain regions in animal models of addiction. The modulation of gene expression and aberrant adaptation of neural networks attribute to the changes in brain function under repeated exposure to addictive drugs. The emerging recognition of the role of microRNA (miRNA) provides new insights into many biological and pathological processes in the central nervous system. Considerable studies have demonstrated that miRNAs are strong modulators of posttranscriptional gene expression in drug addiction. Here, we provide an overview of miRNAs, followed by evidence for aberrant miRNA expression and regulatory roles of miRNAs in drug addiction as well as neuroadaptation. We concluded by providing our perspectives that miRNAs have the potential as novel therapeutic targets for drug addiction. (c) 2022 Published by Elsevier Inc.
C1 [Zhao, Yue; Qin, Feng; Han, Shuang; Li, Shu; Zhao, Ying; Cen, Xiaobo] Sichuan Univ, Natl Chengdu Ctr Safety Evaluat Drugs, West China Hosp, State Key Lab Biotherapy, Keyuan Rd 4,Gaopeng St, Chengdu 610041, Peoples R China.
   [Zhao, Yue; Qin, Feng; Han, Shuang; Li, Shu; Zhao, Ying; Cen, Xiaobo] Sichuan Univ, Canc Ctr, West China Hosp, Keyuan Rd 4,Gaopeng St, Chengdu 610041, Peoples R China.
   [Zhao, Yue; Qin, Feng; Han, Shuang; Li, Shu; Zhao, Ying; Cen, Xiaobo] Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Peoples R China.
   [Wang, Hongbo; Tian, Jingwei] Yantai Univ, Collaborat Innovat Ctr Adv Drug Delivery Syst & B, Minist Educ, Yantai 264005, Peoples R China.
C3 Sichuan University; Sichuan University; Yantai University
RP Cen, XB (通讯作者)，Sichuan Univ, Natl Chengdu Ctr Safety Evaluat Drugs, West China Hosp, State Key Lab Biotherapy, Keyuan Rd 4,Gaopeng St, Chengdu 610041, Peoples R China.; Cen, XB (通讯作者)，Sichuan Univ, Canc Ctr, West China Hosp, Keyuan Rd 4,Gaopeng St, Chengdu 610041, Peoples R China.; Tian, JW (通讯作者)，Yantai Univ, Collaborat Innovat Ctr Adv Drug Delivery Syst & B, Minist Educ, Yantai 264005, Peoples R China.
EM Tianjingwei618@163.com; xbcen@scu.edu.cn
RI Tian, Jingwei/GPJ-9819-2022
OI Qin, Feng/0000-0001-9521-7146
FU National Natural Science Foundation of China [82071494, 81871043,
   32000719, 81272459]; 1.3.5 Project for Disciplines of Excellence, West
   China Hospital, Sichuan University [ZYGD18024]
FX This work was supported by the National Natural Science Foundation of
   China (Grants 82071494, 81871043, 32000719, 81272459), and "1.3.5
   Project for Disciplines of Excellence (ZYGD18024), West China Hospital,
   Sichuan University".
CR Abrimian A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073779
   Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
   Alhaddad H, 2020, NEUROSCIENCE, V437, P107, DOI 10.1016/j.neuroscience.2020.04.033
   Ali MM, 2014, CHEM SOC REV, V43, P3324, DOI 10.1039/c3cs60439j
   Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810
   Bahi A, 2020, EUR NEUROPSYCHOPHARM, V37, P70, DOI 10.1016/j.euroneuro.2020.06.011
   Bahi A, 2013, EUR J NEUROSCI, V38, P2328, DOI 10.1111/ejn.12228
   Bai Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep35642
   Balaraman S, 2017, ALCOHOL, V60, P159, DOI 10.1016/j.alcohol.2016.12.006
   Balaraman S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165081
   Balaraman S, 2014, ALCOHOL CLIN EXP RES, V38, P1390, DOI 10.1111/acer.12378
   Balaraman S, 2012, ALCOHOL CLIN EXP RES, V36, P1669, DOI 10.1111/j.1530-0277.2012.01793.x
   Barreto-Valer K, 2013, NEUROSCIENCE, V231, P258, DOI 10.1016/j.neuroscience.2012.11.052
   Barreto-Valer K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052701
   Bastle RM, 2018, MOL PSYCHIATR, V23, P434, DOI 10.1038/mp.2016.238
   Bekdash RA, 2015, BRAIN BEHAV, V5, DOI 10.1002/brb3.355
   Benatti RO, 2014, BRIT J NUTR, V111, P2112, DOI 10.1017/S0007114514000579
   Bian S, 2013, CURR OPIN NEUROBIOL, V23, P928, DOI 10.1016/j.conb.2013.08.002
   Bin Wei Y, 2016, INT J NEUROPSYCHOPH, V19, DOI 10.1093/ijnp/pyw069
   Bosch PJ, 2015, BMC NEUROSCI, V16, DOI 10.1186/s12868-015-0186-y
   Brennan GP, 2020, NAT REV NEUROL, V16, P506, DOI 10.1038/s41582-020-0369-8
   Brites D, 2020, GLIA, V68, P1631, DOI 10.1002/glia.23846
   Browne CJ, 2020, BIOL PSYCHIAT, V87, P22, DOI 10.1016/j.biopsych.2019.06.027
   Burgos K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094839
   Cameron HA, 2015, ANNU REV PSYCHOL, V66, P53, DOI 10.1146/annurev-psych-010814-015006
   Cami J, 2003, NEW ENGL J MED, V349, P975, DOI 10.1056/NEJMra023160
   Carlezon WA, 2005, TRENDS NEUROSCI, V28, P436, DOI 10.1016/j.tins.2005.06.005
   Casserly AP, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57907-w
   Chahrour M, 2008, SCIENCE, V320, P1224, DOI 10.1126/science.1153252
   Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137
   Chand S, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12177
   Chandrasekar V, 2011, NEUROPSYCHOPHARMACOL, V36, P1149, DOI 10.1038/npp.2010.250
   Chandrasekar V, 2009, MOL CELL NEUROSCI, V42, P350, DOI 10.1016/j.mcn.2009.08.009
   Chang L, 2020, NUCLEIC ACIDS RES, V48, pW244, DOI 10.1093/nar/gkaa467
   Chavoshi H, 2020, J CHEM NEUROANAT, V109, DOI 10.1016/j.jchemneu.2020.101854
   Chefer VI, 2011, NEUROPSYCHOPHARMACOL, V36, P2018, DOI 10.1038/npp.2011.89
   Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178
   Chen CL, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-96
   Chen D, 2018, CELL PHYSIOL BIOCHEM, V47, P2319, DOI 10.1159/000491543
   Chen HX, 2007, J NEUROSCI, V27, P8378, DOI 10.1523/JNEUROSCI.0872-07.2007
   Chen L, 2019, BRIEF BIOINFORM, V20, P1836, DOI 10.1093/bib/bby054
   Cheng MHY, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00134
   Cho S, 2013, NUCLEIC ACIDS RES, V41, pD252, DOI 10.1093/nar/gks1168
   Choi KH, 2006, NEUROSCIENCE, V137, P373, DOI 10.1016/j.neuroscience.2005.10.049
   Choi MR, 2020, BIOL SEX DIFFER, V11, DOI 10.1186/s13293-020-00342-3
   Coleman LG, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0799-4
   Contet C, 2004, CURR OPIN NEUROBIOL, V14, P370, DOI 10.1016/j.conb.2004.05.005
   Cooper S, 2017, NEUROTHERAPEUTICS, V14, P687, DOI 10.1007/s13311-017-0525-z
   Darcq E, 2015, MOL PSYCHIATR, V20, P1240, DOI 10.1038/mp.2014.120
   Degliangeli F, 2014, J AM CHEM SOC, V136, P2264, DOI 10.1021/ja412152x
   Demirel G, 2019, IRAN J PHARM RES, V18, P1989, DOI 10.22037/ijpr.2019.15097.12874
   Deroche-Gamonet V, 2019, MOL PSYCHIATR, V24, P312, DOI 10.1038/s41380-018-0038-0
   Dhir A, 2015, NAT STRUCT MOL BIOL, V22, P319, DOI 10.1038/nsmb.2982
   Dong HF, 2013, CHEM REV, V113, P6207, DOI 10.1021/cr300362f
   Dreyer JL, 2010, GENOME MED, V2, DOI 10.1186/gm213
   Du HY, 2016, NEUROSCI LETT, V611, P21, DOI 10.1016/j.neulet.2015.11.016
   Du LF, 2019, TOXICOL LETT, V301, P53, DOI 10.1016/j.toxlet.2018.10.020
   Ehinger Y, 2021, ADDICT BIOL, V26, DOI 10.1111/adb.12890
   Eipper-Mains JE, 2011, RNA, V17, P1529, DOI 10.1261/rna.2775511
   Eisch AJ, 2004, AM J PSYCHIAT, V161, P426, DOI 10.1176/appi.ajp.161.3.426
   Epelbaum J, 2005, M S-MED SCI, V21, P1117
   Everitt BJ, 2016, ANNU REV PSYCHOL, V67, P23, DOI 10.1146/annurev-psych-122414-033457
   Filipow S, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00169
   Formisano L, 2007, P NATL ACAD SCI USA, V104, P4170, DOI 10.1073/pnas.0611704104
   Garcia-Concejo A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157806
   Garcia-Perez D, 2015, ADDICT BIOL, V20, P104, DOI 10.1111/adb.12083
   Gaur A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698
   Gedik H, 2015, DNA CELL BIOL, V34, P220, DOI 10.1089/dna.2014.2549
   Goh SY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225649
   Gong S, 2021, NEURON, V109, P3421, DOI 10.1016/j.neuron.2021.08.012
   Gorini G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082565
   Groc L, 2020, SCIENCE, V368, P1204, DOI 10.1126/science.aay4631
   Gu WJ, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109918
   Gu X, 2018, J CELL PHYSIOL, V233, P673, DOI 10.1002/jcp.25927
   Guil S, 2015, TRENDS BIOCHEM SCI, V40, P248, DOI 10.1016/j.tibs.2015.03.001
   Guo ML, 2016, EPIGENETICS-US, V11, P819, DOI 10.1080/15592294.2016.1232233
   Gupta S, 2016, J BIOMED SEMANT, V7, DOI 10.1186/s13326-015-0044-y
   Hamilton PJ, 2019, CURR OPIN NEUROBIOL, V59, P128, DOI 10.1016/j.conb.2019.05.005
   He Ying, 2012, Frontiers in Genetics, V3, P110, DOI 10.3389/fgene.2012.00110
   He Y, 2010, J NEUROSCI, V30, P10251, DOI 10.1523/JNEUROSCI.2419-10.2010
   Henry M, 2009, AM J PHYSIOL-REG I, V297, pR783, DOI 10.1152/ajpregu.00226.2009
   Hollander JA, 2010, NATURE, V466, P197, DOI 10.1038/nature09202
   Horvath PM, 2018, TRENDS NEUROSCI, V41, P72, DOI 10.1016/j.tins.2017.11.005
   Hsu CW, 2019, J CLIN MED, V8, DOI 10.3390/jcm8081105
   Hsu SD, 2008, NUCLEIC ACIDS RES, V36, pD165, DOI 10.1093/nar/gkm1012
   Hu XQ, 2017, HYPERTENSION, V70, P601, DOI 10.1161/HYPERTENSIONAHA.117.09864
   Hu Y, 2017, METHODS MOL BIOL, V1617, P169, DOI 10.1007/978-1-4939-7046-9_12
   Huang HY, 2020, NUCLEIC ACIDS RES, V48, pD148, DOI 10.1093/nar/gkz896
   Huang WY, 2019, BRAIN RES BULL, V149, P231, DOI 10.1016/j.brainresbull.2019.04.013
   Huang WH, 2009, BIOL PSYCHIAT, V65, P702, DOI 10.1016/j.biopsych.2008.11.024
   Huang Z, 2019, NUCLEIC ACIDS RES, V47, pD1013, DOI 10.1093/nar/gky1010
   Hwang JY, 2017, NAT REV NEUROSCI, V18, P347, DOI 10.1038/nrn.2017.46
   Ignacio C, 2015, BMC NEUROSCI, V16, DOI 10.1186/s12868-015-0195-x
   Im HI, 2012, TRENDS NEUROSCI, V35, P325, DOI 10.1016/j.tins.2012.01.004
   Im HI, 2010, NAT NEUROSCI, V13, P1120, DOI 10.1038/nn.2615
   Iwaki J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069496
   Jeggari A, 2012, BIOINFORMATICS, V28, P2062, DOI 10.1093/bioinformatics/bts344
   Jet T, 2021, CHEM SOC REV, V50, P4141, DOI 10.1039/d0cs00609b
   Jia M, 2022, ADDICT BIOL, V27, DOI 10.1111/adb.13086
   Jia M, 2019, NEUROSCI BULL, V35, P486, DOI 10.1007/s12264-019-00338-z
   John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363
   Jurcevic S, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935-014-0088-6
   Kawahara H, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00030
   Kazemi T, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88221-8
   Kazemi T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71875-1
   Kazenwadel J, 2010, BLOOD, V116, P2395, DOI 10.1182/blood-2009-12-256297
   Kehl T, 2020, NUCLEIC ACIDS RES, V48, pD142, DOI 10.1093/nar/gkz1022
   Keiflin R, 2015, NEURON, V88, P247, DOI 10.1016/j.neuron.2015.08.037
   Kenny PJ, 2007, TRENDS PHARMACOL SCI, V28, P135, DOI 10.1016/j.tips.2007.01.008
   Kim B, 2022, ACTA PHARM SIN B, V12, P3281, DOI 10.1016/j.apsb.2022.02.030
   Kim B, 2022, PSYCHOPHARMACOLOGY, V239, P831, DOI 10.1007/s00213-022-06074-z
   Kim J, 2018, NEURAL REGEN RES, V13, P77, DOI 10.4103/1673-5374.224374
   Koob GF, 2016, LANCET PSYCHIAT, V3, P760, DOI 10.1016/S2215-0366(16)00104-8
   Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Krol J, 2004, J BIOL CHEM, V279, P42230, DOI 10.1074/jbc.M404931200
   Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843
   Krutzfeldt J, 2006, CELL METAB, V4, P9, DOI 10.1016/j.cmet.2006.05.009
   Kumar A, 2021, EBIOMEDICINE, V63, DOI 10.1016/j.ebiom.2020.103192
   Lammel S, 2014, NEUROPHARMACOLOGY, V76, P351, DOI 10.1016/j.neuropharm.2013.03.019
   Latorre R, 2017, PHYSIOL REV, V97, P39, DOI 10.1152/physrev.00001.2016
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Lee S, 2015, SCI REP-UK, V5, DOI 10.1038/srep12909
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Lewohl JM, 2011, ALCOHOL CLIN EXP RES, V35, P1928, DOI 10.1111/j.1530-0277.2011.01544.x
   Li C, 2020, HUM MUTAT, V41, P1123, DOI 10.1002/humu.24020
   Li CP, 2011, CHEM COMMUN, V47, P2595, DOI 10.1039/c0cc03957h
   Li HC, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/8025062
   Li H, 2009, J CLIN INVEST, V119, P3666, DOI 10.1172/JCI39832
   Li JY, 2013, EMBO MOL MED, V5, P1402, DOI 10.1002/emmm.201201900
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248
   Li MD, 2011, MOL PSYCHIATR, V16, P1159, DOI 10.1038/mp.2011.58
   Li X, 2015, BEHAV BRAIN RES, V279, P240, DOI 10.1016/j.bbr.2014.11.018
   Liang Y, 2016, MOL PAIN, V12, DOI 10.1177/1744806916641679
   Liao K, 2020, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12027
   Lim Y, 2021, TRANSL PSYCHIAT, V11, DOI 10.1038/s41398-021-01635-w
   Liu BL, 2019, INT J CARDIOL, V281, P82, DOI 10.1016/j.ijcard.2019.01.099
   Liu D, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.708034
   Liu HX, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.679206
   Liu PK, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929-016-0294-8
   Liu PC, 2018, METHODS MOL BIOL, V1783, P171, DOI 10.1007/978-1-4939-7834-2_8
   Loera-Valencia R, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221810139
   Loher P, 2012, BIOINFORMATICS, V28, P3322, DOI 10.1093/bioinformatics/bts615
   Lou DN, 2019, MOL CELL PROBE, V48, DOI 10.1016/j.mcp.2019.101470
   Lu ZG, 2014, MOL PHARMACOL, V85, P368, DOI 10.1124/mol.113.089292
   Luscher C, 2020, NAT REV NEUROSCI, V21, P247, DOI 10.1038/s41583-020-0289-z
   Ma YH, 2018, CURR NEUROPHARMACOL, V16, P37, DOI 10.2174/1570159X15666170703102410
   Sanchez-Simon FM, 2010, MOL PHARMACOL, V78, P935, DOI 10.1124/mol.110.066837
   Magill ST, 2010, P NATL ACAD SCI USA, V107, P20382, DOI 10.1073/pnas.1015691107
   Mahnke AH, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80734-y
   Martinez M, 2019, TOXICOL RES-UK, V8, P842, DOI 10.1039/c9tx00069k
   Maselli V, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-457
   Matsuda T, 2019, NEURON, V101, P472, DOI 10.1016/j.neuron.2018.12.010
   Mavrikaki M, 2019, INT J NEUROPSYCHOPH, V22, P383, DOI 10.1093/ijnp/pyz015
   Metzker Michael L, 2010, Nat Rev Genet, V11, P31, DOI 10.1038/nrg2626
   Miguel-Hidalgo Jose Javier, 2009, Curr Drug Abuse Rev, V2, P76
   Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189
   Miyamoto Y, 2004, EUR J NEUROSCI, V19, P151, DOI 10.1111/j.1460-9568.2004.03086.x
   Moon JM, 2013, J CEREBR BLOOD F MET, V33, P1976, DOI 10.1038/jcbfm.2013.157
   Moore LD, 2013, NEUROPSYCHOPHARMACOL, V38, P23, DOI 10.1038/npp.2012.112
   Mori MA, 2019, CELL METAB, V30, P656, DOI 10.1016/j.cmet.2019.07.011
   Morita S, 2013, INT J MOL SCI, V14, P14647, DOI 10.3390/ijms140714647
   Most D, 2019, ADDICT BIOL, V24, P604, DOI 10.1111/adb.12625
   Muller M, 2016, MOL NEUROBIOL, V53, P2894, DOI 10.1007/s12035-015-9156-8
   Mutlu AS, 2021, DEV CELL, V56, P1394, DOI 10.1016/j.devcel.2021.03.034
   Nampoothiri SS, 2017, MOL NEUROBIOL, V54, P2003, DOI 10.1007/s12035-016-9797-2
   Nazmara Z, 2019, UROL J, V16, P289, DOI 10.22037/uj.v0i0.4321
   Nestler EJ, 2019, NEURON, V102, P48, DOI 10.1016/j.neuron.2019.01.016
   Niedzielska-Andres E, 2021, PHARMACOL THERAPEUT, V221, DOI 10.1016/j.pharmthera.2020.107797
   Nielsen DA, 2008, MOL PSYCHIATR, V13, P417, DOI 10.1038/sj.mp.4002147
   Nunez YO, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-725
   Paraskevopoulou MD, 2013, NUCLEIC ACIDS RES, V41, pW169, DOI 10.1093/nar/gkt393
   Peng H, 2017, ALCOHOL, V62, P29, DOI 10.1016/j.alcohol.2017.02.175
   Perdikopanis N, 2021, NUCLEIC ACIDS RES, V49, pD151, DOI 10.1093/nar/gkaa1060
   Periyasamy P, 2018, MOL NEUROBIOL, V55, P3196, DOI 10.1007/s12035-017-0584-5
   Perkins DO, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r27
   Pietrzykowski AZ, 2008, NEURON, V59, P274, DOI 10.1016/j.neuron.2008.05.032
   Pin JP, 2016, NATURE, V540, P60, DOI 10.1038/nature20566
   Prins SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083166
   Pritchard CC, 2012, NAT REV GENET, V13, P358, DOI 10.1038/nrg3198
   Qian HY, 2021, PSYCHOPHARMACOLOGY, V238, P3207, DOI 10.1007/s00213-021-05936-2
   Quinn RK, 2018, ADDICT BIOL, V23, P631, DOI 10.1111/adb.12520
   Ramirez CM, 2011, ARTERIOSCL THROM VAS, V31, P2707, DOI 10.1161/ATVBAHA.111.232066
   Refeat MM, 2021, J GENET ENG BIOTECHN, V19, DOI 10.1186/s43141-021-00246-8
   Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604
   Roberts BM, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10030709
   Rosato AJ, 2019, EPIGENOMICS-UK, V11, P739, DOI 10.2217/epi-2018-0177
   Ru YB, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku631
   Saba R, 2012, MOL CELL BIOL, V32, P619, DOI 10.1128/MCB.05896-11
   Saliminejad K, 2019, J CELL PHYSIOL, V234, P5451, DOI 10.1002/jcp.27486
   Sambo DO, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02087-x
   Samuel P, 2016, TUMOR BIOL, V37, P2565, DOI 10.1007/s13277-015-4081-z
   Sandau US, 2020, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12028
   Schaefer A, 2010, J EXP MED, V207, P1843, DOI 10.1084/jem.20100451
   Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367
   Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228
   Self DW, 1996, SCIENCE, V271, P1586, DOI 10.1126/science.271.5255.1586
   Sengupta JN, 2013, PAIN, V154, P59, DOI 10.1016/j.pain.2012.09.002
   Sequeira-Cordero A, 2021, EUR J PHARMACOL, V904, DOI 10.1016/j.ejphar.2021.174148
   Shah P, 2014, ANALYST, V139, P2158, DOI 10.1039/c3an02150e
   Shah R, 2018, NEW ENGL J MED, V379, P958, DOI 10.1056/NEJMra1704286
   Shaham Y, 2005, NAT NEUROSCI, V8, P1437, DOI 10.1038/nn1105-1437
   Shi JJ, 2019, METAB BRAIN DIS, V34, P1029, DOI 10.1007/s11011-019-00430-3
   Shi R, 2005, BIOTECHNIQUES, V39, P519, DOI 10.2144/000112010
   Shi YH, 2010, J NEUROSCI, V30, P14931, DOI 10.1523/JNEUROSCI.4280-10.2010
   Sim MS, 2017, METAB BRAIN DIS, V32, P1767, DOI 10.1007/s11011-017-0061-x
   Smaga I, 2020, NEUROSCIENCE, V451, P99, DOI 10.1016/j.neuroscience.2020.10.001
   Soares-Cunha C, 2020, MOL PSYCHIATR, V25, P3241, DOI 10.1038/s41380-019-0484-3
   Solinas M, 2019, J NEURAL TRANSM, V126, P481, DOI 10.1007/s00702-018-1957-2
   Sticht C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206239
   Su H, 2019, NEUROPHARMACOLOGY, V148, P160, DOI 10.1016/j.neuropharm.2019.01.007
   Swan GE, 2007, NEUROPSYCHOL REV, V17, P259, DOI 10.1007/s11065-007-9035-9
   Taki FA, 2014, SCI REP-UK, V4, DOI 10.1038/srep07513
   Taniguchi M, 2012, NEURON, V73, P108, DOI 10.1016/j.neuron.2011.10.032
   Tapocik JD, 2013, PHARMACOGENOMICS J, V13, P286, DOI 10.1038/tpj.2012.17
   Tapocik JD, 2014, J NEUROSCI, V34, P4581, DOI 10.1523/JNEUROSCI.0445-14.2014
   Tapocik JD, 2013, ADDICT BIOL, V18, P480, DOI 10.1111/j.1369-1600.2012.00470.x
   Tatro ET, 2013, J NEUROIMMUNE PHARM, V8, P1210, DOI 10.1007/s11481-013-9446-8
   Thadani R, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S5-S20
   Thatcher DL, 2008, ALCOHOL RES HEALTH, V31, P168
   Thomas JD, 2010, BIRTH DEFECTS RES A, V88, P827, DOI 10.1002/bdra.20713
   Tian T, 2015, ORG BIOMOL CHEM, V13, P2226, DOI 10.1039/c4ob02104e
   Tian ZQ, 2015, LUNG, V193, P583, DOI 10.1007/s00408-015-9726-6
   Tobon KE, 2015, EUR J NEUROSCI, V42, P1849, DOI 10.1111/ejn.12933
   Tokar T, 2018, NUCLEIC ACIDS RES, V46, pD360, DOI 10.1093/nar/gkx1144
   Tong Z, 2019, NUCLEIC ACIDS RES, V47, pD253, DOI 10.1093/nar/gky1023
   Traynelis SF, 2010, PHARMACOL REV, V62, P405, DOI 10.1124/pr.109.002451
   Treistman SN, 2009, TRENDS NEUROSCI, V32, P629, DOI 10.1016/j.tins.2009.08.001
   Tsai PC, 2014, BIOL OPEN, V3, P741, DOI 10.1242/bio.20147765
   Tzoumakis S, 2018, CRIM BEHAV MENT HEAL, V28, P397, DOI 10.1002/cbm.2089
   Upadhya R, 2021, AGING DIS, V12, P1438, DOI 10.14336/AD.2021.0516
   Vannan A, 2021, DRUG ALCOHOL DEPEN, V221, DOI 10.1016/j.drugalcdep.2021.108585
   Vejnar CE, 2013, NUCLEIC ACIDS RES, V41, pW165, DOI 10.1093/nar/gkt430
   Vergoulis T, 2012, NUCLEIC ACIDS RES, V40, pD222, DOI 10.1093/nar/gkr1161
   Vinciguerra A, 2014, MOL THER, V22, P1829, DOI 10.1038/mt.2014.113
   Viola TW, 2019, J PSYCHIATR RES, V114, P48, DOI 10.1016/j.jpsychires.2019.03.028
   Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pW460, DOI 10.1093/nar/gkv403
   Vo N, 2005, P NATL ACAD SCI USA, V102, P16426, DOI 10.1073/pnas.0508448102
   Volkow ND, 2019, PHYSIOL REV, V99, P2115, DOI 10.1152/physrev.00014.2018
   Volkow ND, 2017, NAT REV NEUROSCI, V18, P741, DOI 10.1038/nrn.2017.130
   Volkow ND, 2015, CELL, V162, P712, DOI 10.1016/j.cell.2015.07.046
   Wada R, 2010, INT J CANCER, V127, P1106, DOI 10.1002/ijc.25126
   Wang CS, 2022, CELL, V185, P62, DOI 10.1016/j.cell.2021.12.003
   Wang Fan, 2013, J Addict Res Ther, V4
   Wang JS, 2021, BIOL PSYCHIAT, V89, P386, DOI 10.1016/j.biopsych.2020.08.012
   Wang L, 2020, FRONT MOL NEUROSCI, V13, DOI 10.3389/fnmol.2020.00053
   Wang SY, 2019, AM J PHYSIOL-ENDOC M, V317, pE911, DOI 10.1152/ajpendo.00190.2019
   Wang WX, 2008, J NEUROSCI, V28, P1213, DOI 10.1523/JNEUROSCI.5065-07.2008
   Wang YJ, 2021, FRONT MOL NEUROSCI, V14, DOI 10.3389/fnmol.2021.667725
   Wegman DW, 2011, ANGEW CHEM INT EDIT, V50, P10335, DOI 10.1002/anie.201104693
   WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4
   Wiklund ED, 2010, EPIGENOMICS-UK, V2, P823, DOI 10.2217/EPI.10.51
   Wong N, 2015, NUCLEIC ACIDS RES, V43, pD146, DOI 10.1093/nar/gku1104
   Wu BB, 2018, NEUROSCI LETT, V662, P115, DOI 10.1016/j.neulet.2017.10.011
   Wu QF, 2013, FASEB J, V27, P522, DOI 10.1096/fj.12-213439
   Wu QF, 2008, FASEB J, V22, P4085, DOI 10.1096/fj.08-108175
   Wu X, 2020, ARTIF CELL NANOMED B, V48, P276, DOI 10.1080/21691401.2019.1703729
   Xiao FF, 2009, NUCLEIC ACIDS RES, V37, pD105, DOI 10.1093/nar/gkn851
   Xu C, 2014, STEM CELLS, V32, P2961, DOI 10.1002/stem.1774
   Xu WJ, 2021, PSYCHOPHARMACOLOGY, V238, P2313, DOI 10.1007/s00213-021-05854-3
   Xu WJ, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23486
   Xu X, 2021, FOOD CHEM TOXICOL, V149, DOI 10.1016/j.fct.2021.111970
   Xu X, 2019, J PHARMACOL EXP THER, V369, P244, DOI 10.1124/jpet.118.255729
   Yan BA, 2017, SCI REP-UK, V7, DOI 10.1038/srep40413
   Yan JL, 2013, TALANTA, V110, P190, DOI 10.1016/j.talanta.2013.02.028
   Yang J, 2020, PHARM BIOL, V58, P797, DOI 10.1080/13880209.2020.1803366
   Yorgason JT, 2022, ADDICT BIOL, V27, DOI 10.1111/adb.13108
   Zeng YP, 2014, CHEM COMMUN, V50, P7160, DOI 10.1039/c4cc02034k
   Zhang K, 2016, SCI REP-UK, V6, DOI 10.1038/srep35691
   Zhang S, 2021, DRUG DES DEV THER, V15, P721, DOI 10.2147/DDDT.S288859
   Zhang Y, 2016, AUTOPHAGY, V12, P1538, DOI 10.1080/15548627.2016.1191723
   Zhao Chunling, 2012, BMC Res Notes, V5, P91, DOI 10.1186/1756-0500-5-91
   Zhao CN, 2013, SCI REP-UK, V3, DOI 10.1038/srep01329
   Zhao Y, 2016, J NEUROIMMUNE PHARM, V11, P542, DOI 10.1007/s11481-016-9671-z
   Zhao YF, 2017, BMC BIOL, V15, DOI 10.1186/s12915-017-0467-2
   Zheng H, 2010, J NEUROSCI, V30, P8102, DOI 10.1523/JNEUROSCI.6069-09.2010
   Zheng H, 2010, MOL PHARMACOL, V77, P102, DOI 10.1124/mol.109.060848
   Zhu L, 2016, SCI REP-UK, V6, DOI 10.1038/srep36993
   Zou ZL, 2017, ADV EXP MED BIOL, V1010, P21, DOI 10.1007/978-981-10-5562-1_2
NR 279
TC 3
Z9 3
U1 12
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0163-7258
EI 1879-016X
J9 PHARMACOL THERAPEUT
JI Pharmacol. Ther.
PD AUG
PY 2022
VL 236
AR 108215
DI 10.1016/j.pharmthera.2022.108215
PG 19
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 8A8SB
UT WOS:000916504100001
PM 35609719
DA 2023-06-23
ER

PT J
AU Edwards, S
   Koob, GF
AF Edwards, Scott
   Koob, George F.
TI Escalation of drug self-administration as a hallmark of persistent
   addiction liability
SO BEHAVIOURAL PHARMACOLOGY
LA English
DT Review
DE addiction; alcohol; cocaine; escalation; heroin; self-administration
ID CORTICOTROPIN-RELEASING-FACTOR; COCAINE-SEEKING BEHAVIOR;
   ETHANOL-DEPENDENT RATS; NUCLEUS-ACCUMBENS SHELL; KAPPA-OPIOID RECEPTORS;
   ANXIETY-LIKE BEHAVIOR; CENTRAL AMYGDALA; EXTENDED-ACCESS; INDIVIDUAL
   VULNERABILITY; PROTRACTED ABSTINENCE
AB Drug addiction is a progressive, relapsing disease comprised of interlocking stages of disordered motivation. Numerous animal models describing various stages of the addiction process have been developed over the past few decades, providing considerable advantages for the modeling of drug addiction compared with other complex psychiatric disease states. Escalation of drug self-administration has emerged as a widely accepted operant conditioning model of excessive drug intake. We further argue here that drug-escalated animals represent a comprehensive model of addiction according to the manifestations of behavioral neuroadaptations resulting directly or indirectly from excessive drug consumption. In particular, drug-escalated animals exhibit a host of symptoms in line with multiple Diagnostic and Statistical Manual of Mental Disorders criteria for substance dependence, which can be summarized as an emergence of uncontrollable drug-taking and drug-seeking behaviors as a consequence of within-circuit and between-circuit neuroadaptations. Such a transition from impulsive drug sampling to compulsive intake represents a highly valid conceptualization of the addiction timeline in humans, and further investigation of persistent or near-permanent (e.g. epigenetic) neuroadaptations generated by operant drug intake escalation models will continue to provide mechanisms and therapeutic interventions for reversing the aberrant neuroplasticity underlying addiction.
C1 [Edwards, Scott; Koob, George F.] Scripps Res Inst, Comm Neurobiol Addict Disorders, La Jolla, CA 92037 USA.
C3 Scripps Research Institute
RP Edwards, S (通讯作者)，Scripps Res Inst, Comm Neurobiol Addict Disorders, 10550 North Torrey Pines Rd,SP30-2400, La Jolla, CA 92037 USA.
EM edwards@scripps.edu
FU National Institutes of Health [AA020839, AA006420]; National Institute
   on Alcohol Abuse and Alcoholism [AA020608, AA008459]; National Institute
   on Drug Abuse [DA010072, DA004043, DA023597, DA004398]; Pearson Center
   for Alcoholism and Addiction Research
FX This work was supported by grants AA020839 (S.E.) and AA006420 from the
   National Institutes of Health, AA020608, and AA008459 (G.F.K.) from the
   National Institute on Alcohol Abuse and Alcoholism, and DA010072,
   DA004043, DA023597, and DA004398 (G.F.K.) from the National Institute on
   Drug Abuse, as well as by the Pearson Center for Alcoholism and
   Addiction Research.
CR Ahmed SH, 2012, NEUROSCIENCE, V211, P107, DOI 10.1016/j.neuroscience.2011.08.014
   Ahmed SH, 2010, NEUROSCI BIOBEHAV R, V35, P172, DOI 10.1016/j.neubiorev.2010.04.005
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Ahmed SH, 2002, NAT NEUROSCI, V5, P625, DOI 10.1038/nn872
   Ahmed SH, 2000, NEUROPSYCHOPHARMACOL, V22, P413, DOI 10.1016/S0893-133X(99)00133-5
   American Psychiatric Association, DIAGN STAT MAN MENT
   Anker JJ, 2009, PHARMACOL BIOCHEM BE, V93, P343, DOI 10.1016/j.pbb.2009.05.013
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   Ben-Shahar O, 2008, PROG NEURO-PSYCHOPH, V32, P863, DOI 10.1016/j.pnpbp.2008.01.002
   Breese GR, 2005, NEUROPSYCHOPHARMACOL, V30, P1662, DOI 10.1038/sj.npp.1300706
   Bruchas MR, 2010, BRAIN RES, V1314, P44, DOI 10.1016/j.brainres.2009.08.062
   Carlezon WA, 1998, SCIENCE, V282, P2272, DOI 10.1126/science.282.5397.2272
   Chartoff E, 2012, NEUROPHARMACOLOGY, V62, P167, DOI 10.1016/j.neuropharm.2011.06.014
   Choi KH, 2006, NEUROSCIENCE, V137, P373, DOI 10.1016/j.neuroscience.2005.10.049
   Conrad KL, 2008, NATURE, V454, P118, DOI 10.1038/nature06995
   Dalley JW, 2007, SCIENCE, V315, P1267, DOI 10.1126/science.1137073
   Deroche V, 1999, EUR J NEUROSCI, V11, P2731, DOI 10.1046/j.1460-9568.1999.00696.x
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   DICHIARA G, 1988, J PHARMACOL EXP THER, V244, P1067
   Edwards S, 2011, ADDICT BIOL, V16, P450, DOI 10.1111/j.1369-1600.2010.00296.x
   Edwards S, 2012, ADDICT BIOL, V17, P76, DOI 10.1111/j.1369-1600.2010.00291.x
   Edwards S, 2012, METHODS MOL BIOL, V829, P31, DOI 10.1007/978-1-61779-458-2_2
   Edwards S, 2010, FUTUR NEUROL, V5, P393, DOI 10.2217/FNL.10.14
   GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107
   George O, 2012, PHYSIOL BEHAV, V106, P58, DOI 10.1016/j.physbeh.2011.11.004
   George O, 2010, NEUROSCI BIOBEHAV R, V35, P232, DOI 10.1016/j.neubiorev.2010.05.002
   Grimm JW, 2003, J NEUROSCI, V23, P742
   Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134
   Heilig M, 2007, TRENDS NEUROSCI, V30, P399, DOI 10.1016/j.tins.2007.06.006
   Heilig M, 2006, PHARMACOL THERAPEUT, V111, P855, DOI 10.1016/j.pharmthera.2006.02.001
   Heilig M, 2010, ADDICT BIOL, V15, P169, DOI 10.1111/j.1369-1600.2009.00194.x
   Hjelmstad GO, 2001, J NEUROPHYSIOL, V85, P1153, DOI 10.1152/jn.2001.85.3.1153
   Huang MM, 2010, J PHARMACOL EXP THER, V332, P298, DOI 10.1124/jpet.109.159186
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Jang CG, 2013, PSYCHOPHARMACOLOGY, V225, P753, DOI 10.1007/s00213-012-2864-0
   Jonkman S, 2012, NEUROPSYCHOPHARMACOL, V37, P1612, DOI 10.1038/npp.2012.6
   Kalivas PW, 2005, NAT NEUROSCI, V8, P1440, DOI 10.1038/nn1105-1440
   Kenny PJ, 2006, J NEUROSCI, V26, P5894, DOI 10.1523/JNEUROSCI.0740-06.2006
   Kippin TE, 2006, PSYCHOPHARMACOLOGY, V187, P60, DOI 10.1007/s00213-006-0386-3
   Kitamura O, 2006, PSYCHOPHARMACOLOGY, V186, P48, DOI 10.1007/s00213-006-0353-z
   Koob GF, 2008, NEURON, V59, P11, DOI 10.1016/j.neuron.2008.06.012
   Koob GF, 2008, ANNU REV PSYCHOL, V59, P29, DOI 10.1146/annurev.psych.59.103006.093548
   Koob GF, 2009, NEUROPHARMACOLOGY, V56, P18, DOI 10.1016/j.neuropharm.2008.07.043
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550
   Larson EB, 2011, J NEUROSCI, V31, P16447, DOI 10.1523/JNEUROSCI.3070-11.2011
   Li YQ, 2008, J NEUROSCI, V28, P13248, DOI 10.1523/JNEUROSCI.3027-08.2008
   Logrip ML, 2011, CNS DRUGS, V25, P271, DOI 10.2165/11587790-000000000-00000
   Lu L, 2005, J NEUROCHEM, V94, P161, DOI 10.1111/j.1471-4159.2005.03178.x
   Lu L, 2004, NEUROPHARMACOLOGY, V47, P214, DOI 10.1016/j.neuropharm.2004.06.027
   Lu L, 2003, J NEUROCHEM, V85, P1604, DOI 10.1046/j.1471-4159.2003.01824.x
   Lu L, 2005, NAT NEUROSCI, V8, P212, DOI 10.1038/nn1383
   Mantsch JR, 2008, PSYCHOPHARMACOLOGY, V195, P591, DOI 10.1007/s00213-007-0950-5
   Mantsch JR, 2004, PSYCHOPHARMACOLOGY, V175, P26, DOI 10.1007/s00213-004-1778-x
   Mantsch JR, 2001, PSYCHOPHARMACOLOGY, V157, P31, DOI 10.1007/s002130100744
   Martin-Fardon R, 2010, BRAIN RES, V1314, P145, DOI 10.1016/j.brainres.2009.12.027
   Nealey KA, 2011, NEUROPHARMACOLOGY, V61, P35, DOI 10.1016/j.neuropharm.2011.02.012
   Nestler EJ, 2006, BIOL PSYCHIAT, V59, P1151, DOI 10.1016/j.biopsych.2005.09.018
   O'Dell LE, 2007, J PHARMACOL EXP THER, V320, P180, DOI 10.1124/jpet.106.105270
   Pandey SC, 2008, J NEUROSCI, V28, P3729, DOI 10.1523/JNEUROSCI.5731-07.2008
   Paterson NE, 2003, NEUROREPORT, V14, P2229, DOI 10.1097/00001756-200312020-00019
   Pelloux Y, 2007, PSYCHOPHARMACOLOGY, V194, P127, DOI 10.1007/s00213-007-0805-0
   Perry JL, 2008, EXP CLIN PSYCHOPHARM, V16, P165, DOI 10.1037/1064-1297.16.2.165
   Perry JL, 2005, PSYCHOPHARMACOLOGY, V178, P193, DOI 10.1007/s00213-004-1994-4
   Piazza PV, 2000, J NEUROSCI, V20, P4226
   PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295
   Pliakas AM, 2001, J NEUROSCI, V21, P7397, DOI 10.1523/JNEUROSCI.21-18-07397.2001
   POULOS CX, 1991, PSYCHOL REV, V98, P390, DOI 10.1037/0033-295X.98.3.390
   Renthal W, 2007, NEURON, V56, P517, DOI 10.1016/j.neuron.2007.09.032
   Roberts AJ, 2000, NEUROPSYCHOPHARMACOL, V22, P581, DOI 10.1016/S0893-133X(99)00167-0
   Roberts DCS, 2007, PROG NEURO-PSYCHOPH, V31, P1614, DOI 10.1016/j.pnpbp.2007.08.028
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Robison AJ, 2011, NAT REV NEUROSCI, V12, P623, DOI 10.1038/nrn3111
   Schank JR, 2012, NEURON, V76, P192, DOI 10.1016/j.neuron.2012.09.026
   Schlosburg JE, 2011, NEUR M PLANN
   Self DW, 1998, DRUG ALCOHOL DEPEN, V51, P49, DOI 10.1016/S0376-8716(98)00065-9
   Shaham Y, 2005, NAT NEUROSCI, V8, P1437, DOI 10.1038/nn1105-1437
   Siegmund KD, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000895
   Sinha R, 2007, DRUG ALCOHOL REV, V26, P25, DOI 10.1080/09595230601036960
   SOLOMON RL, 1974, PSYCHOL REV, V81, P119, DOI 10.1037/h0036128
   Starkman BG, 2012, ALCOHOL RES-CURR REV, V34, P293
   Sutton MA, 2000, NEUROPSYCHOPHARMACOL, V22, P626, DOI 10.1016/S0893-133X(99)00160-8
   Swendsen J, 2011, ANN NY ACAD SCI, V1216, P73, DOI 10.1111/j.1749-6632.2010.05894.x
   Tran-Nguyen LTL, 1998, NEUROPSYCHOPHARMACOL, V19, P48
   Tsankova N, 2007, NAT REV NEUROSCI, V8, P355, DOI 10.1038/nrn2132
   Valdez GR, 2002, ALCOHOL CLIN EXP RES, V26, P1494, DOI 10.1097/01.ALC.0000033120.51856.F0
   Valdez GR, 2003, ALCOHOL, V29, P55, DOI 10.1016/S0741-8329(03)00020-X
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Vendruscolo LF, 2012, J NEUROSCI, V32, P7563, DOI 10.1523/JNEUROSCI.0069-12.2012
   Virdee K, 2012, NEUROSCI BIOBEHAV R, V36, P1188, DOI 10.1016/j.neubiorev.2012.01.009
   Volkow ND, 2011, NEURON, V69, P599, DOI 10.1016/j.neuron.2011.01.027
   Walker BM, 2007, ALCOHOL CLIN EXP RES, V31, P11, DOI 10.1111/j.1530-0277.2006.00259.x
   Wee S, 2008, EUR NEUROPSYCHOPHARM, V18, P303, DOI 10.1016/j.euroneuro.2007.08.003
   Wee S, 2010, PSYCHOPHARMACOLOGY, V210, P121, DOI 10.1007/s00213-010-1825-8
   Whitfield Jr TW, 2011, NEUR M PLANN
   Wolf ME, 2010, NEUROSCI BIOBEHAV R, V35, P185, DOI 10.1016/j.neubiorev.2010.01.013
   Zhou Y, 2008, NEUROPSYCHOPHARMACOL, V33, P226, DOI 10.1038/sj.npp.1301419
NR 97
TC 96
Z9 96
U1 1
U2 25
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0955-8810
J9 BEHAV PHARMACOL
JI Behav. Pharmacol.
PD SEP
PY 2013
VL 24
IS 5-6
BP 356
EP 362
DI 10.1097/FBP.0b013e3283644d15
PG 7
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA 202NX
UT WOS:000323225500004
PM 23839030
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Wang, L
   Bai, M
   Jin, TB
   Zheng, JW
   Wang, YH
   He, YJ
   Yuan, DY
   He, X
AF Wang, Li
   Bai, Mei
   Jin, Tianbo
   Zheng, Jianwen
   Wang, Yuhe
   He, Yongjun
   Yuan, Dongya
   He, Xue
TI Effects of CYP3A4 Polymorphisms on Drug Addiction Risk Among the Chinese
   Han Population
SO FRONTIERS IN PUBLIC HEALTH
LA English
DT Article
DE drug addiction; case-control study; polymorphisms; Chinese Han
   population
ID GENETIC POLYMORPHISMS; SEVERITY INDEX; USE DISORDER; OPIOID USE;
   METABOLISM; METHADONE; ALCOHOL
AB Background: Cytochrome P450 3A4 (CYP3A4) regulates pharmacokinetic and pharmacodynamic interactions during the process of drug absorption and metabolism, suggesting CYP3A4 plays an important role in drug addiction. However, the association between CYP3A4 polymorphisms and drug addiction risk is still not clear. Methods: This case-control study included 504 drug addicts and 501 healthy controls from Xi'an, China. Four single nucleotide polymorphisms (SNP) in CYP3A4 (rs3735451, rs4646440, rs35564277, and rs4646437) were genotyped by Agena MassARRAY platform. After adjusting by age and gender, we calculated odd ratios (OR) and 95% confidence intervals (CI) by logistic regression to estimate the association between CYP3A4 polymorphisms and drug addiction risk. Results: We found rs4646440 and rs4646437 were associated with decreased risk of drug addiction in codominant (rs4646440: OR = 0.41, 95%CI = 0.19-0.92, p = 0.030; rs4646437: OR = 0.19, 95%CI = 0.04-0.87, p = 0.032) and recessive (rs4646440: OR = 0.41, 95%CI = 0.19-0.91, p = 0.028; rs4646437: OR = 0.20, 95%CI = 0.04-0.90, p = 0.036) models. Rs3735451 and rs4646437 were associated with drug addiction risk in the subgroup of middle-aged people (44 < age <= 59) and elderly people (age >= 60), individually. For men, rs3735451, rs4646440, and rs4646437 had strong relationship with decreased risk of drug addiction (p < 0.05). The effects of rs3735451 on drug addiction risk were related to drug-using time (p < 0.05). We also observed one block (rs4646440 and rs35564277) in haplotype analysis. Conclusion: CYP3A4 polymorphisms were associated with drug addiction risk among the Chinese Han population.
C1 [Wang, Li; Bai, Mei; Jin, Tianbo; Zheng, Jianwen; Wang, Yuhe; He, Yongjun; Yuan, Dongya; He, Xue] Xizang Minzu Univ, Key Lab Mol Mech & Intervent Res Plateau Dis Tibe, Sch Med, Xianyang, Peoples R China.
   [Wang, Li; Bai, Mei; Jin, Tianbo; He, Yongjun; Yuan, Dongya; He, Xue] Xizang Minzu Univ, Sch Basic Med Sci, Xianyang, Peoples R China.
   [Zheng, Jianwen] Xizang Minzu Univ, Affiliated Hosp, Dept Neurol, Xianyang, Peoples R China.
   [Wang, Yuhe] Xizang Minzu Univ, Affiliated Hosp, Dept Clin Lab, Xianyang, Peoples R China.
C3 Xizang Minzu University; Xizang Minzu University; Xizang Minzu
   University; Xizang Minzu University
RP He, X (通讯作者)，Xizang Minzu Univ, Key Lab Mol Mech & Intervent Res Plateau Dis Tibe, Sch Med, Xianyang, Peoples R China.; He, X (通讯作者)，Xizang Minzu Univ, Sch Basic Med Sci, Xianyang, Peoples R China.
EM hexue@xzmu.edu.com
FU Major Science and Technology Research Projects of Xizang (Tibet)
   Autonomous Region [2015XZ01G23]
FX This work was supported by Major Science and Technology Research
   Projects of Xizang (Tibet) Autonomous Region (2015XZ01G23).
CR Bobzean SAM, 2014, EXP NEUROL, V259, P64, DOI 10.1016/j.expneurol.2014.01.022
   Burns L, 2014, DRUG ALCOHOL REV, V33, P216, DOI 10.1111/dar.12110
   Cacciola JS, 2011, ADDICTION, V106, P1588, DOI 10.1111/j.1360-0443.2011.03482.x
   Carew AM, 2018, DRUG ALCOHOL DEPEN, V182, P48, DOI 10.1016/j.drugalcdep.2017.10.007
   Caruso A, 2014, PHARMACOGN PERS MED, V7, P117, DOI 10.2147/PGPM.S55548
   Chang Y, 2011, BASIC CLIN PHARMACOL, V108, P55, DOI 10.1111/j.1742-7843.2010.00628.x
   Chau CH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126672
   Chen CH, 2011, PHARMACOGENOMICS, V12, P1397, DOI [10.2217/pgs.11.103, 10.2217/PGS.11.103]
   de Almeida TB, 2018, J ANTIMICROB CHEMOTH, V73, P2460, DOI 10.1093/jac/dky190
   Denis C, 2016, SUBST ABUS, V37, P168, DOI 10.1080/08897077.2015.1036334
   Depaz IMB, 2013, DRUG METAB DISPOS, V41, P1187, DOI 10.1124/dmd.113.051359
   Diekstra M, 2017, PHARMACOGENOMICS J, V17, P42, DOI 10.1038/tpj.2015.100
   Ding YP, 2015, INT J CLIN EXP PATHO, V8, P13201
   He HR, 2015, EUR J CLIN MICROBIOL, V34, P811, DOI 10.1007/s10096-014-2294-5
   Jin TB, 2016, INT J CLIN EXP PATHO, V9, P3717
   Johnson JL, 1999, PEDIATRICS, V103, P1085
   Kendler KS, 2003, AM J PSYCHIAT, V160, P687, DOI 10.1176/appi.ajp.160.4.687
   Krishna DR, 2005, METHOD FIND EXP CLIN, V27, P559, DOI 10.1358/mf.2005.27.8.928310
   KRISHNA DR, 1994, CLIN PHARMACOKINET, V26, P144, DOI 10.2165/00003088-199426020-00007
   Li CJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086206
   Li S, 2019, J STROKE CEREBROVASC, V28, P1860, DOI 10.1016/j.jstrokecerebrovasdis.2019.04.013
   Marienfeld C, 2016, LANCET PSYCHIAT, V3, P799, DOI 10.1016/S2215-0366(16)30130-4
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   Pal D, 2011, LIFE SCI, V88, P959, DOI 10.1016/j.lfs.2010.09.012
   Palamar JJ, 2016, DRUG ALCOHOL DEPEN, V158, P132, DOI 10.1016/j.drugalcdep.2015.11.005
   Statistics CfBH Quality, 2016, HHS PUBL
   Sychev Dmitry A., 2017, Drug Metabolism and Personalized Therapy, V32, P129, DOI 10.1515/dmpt-2017-0021
   Wakefield JC, 2015, ACTA PSYCHIAT SCAND, V132, P327, DOI 10.1111/acps.12446
   Wang A, 2005, EUR J CLIN PHARMACOL, V60, P843, DOI 10.1007/s00228-004-0848-7
   Wang J, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190296
   Watkins PB, 1997, ADV DRUG DELIVER REV, V27, P161, DOI 10.1016/S0169-409X(97)00041-0
   Zhang C, 2017, ONCOTARGET, V8, P8597, DOI 10.18632/oncotarget.14354
   Zhang DD, 2007, BIOL PSYCHIAT, V61, P1244, DOI 10.1016/j.biopsych.2006.07.012
   Zhang HX, 2016, J GENE MED, V18, P147, DOI 10.1002/jgm.2887
   Zhou YH, 2016, FRONT NEUROENDOCRIN, V40, P24, DOI 10.1016/j.yfrne.2015.07.001
NR 35
TC 4
Z9 4
U1 1
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-2565
J9 FRONT PUBLIC HEALTH
JI Front. Public Health
PD NOV 19
PY 2019
VL 7
AR 315
DI 10.3389/fpubh.2019.00315
PG 7
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA JT9DF
UT WOS:000501281200001
PM 31799230
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Mahmoudi, M
   Pakpour, S
   Perry, G
AF Mahmoudi, Morteza
   Pakpour, Sepideh
   Perry, George
TI Drug-Abuse Nanotechnology: Opportunities and Challenges
SO ACS CHEMICAL NEUROSCIENCE
LA English
DT Article
DE Opioid drug abuse; dependence/addiction; nanoparticle; nanotechnology;
   early detection; therapeutics
ID ENHANCED RAMAN-SPECTROSCOPY; MU-OPIOID RECEPTOR; ENABLED BLOOD-TEST;
   PROTEIN CORONA; GUT MICROBIOTA; PLASMA-PROTEINS; BIOLOGICAL IDENTITY;
   LATENT FINGERPRINTS; BIG DATA; NANOPARTICLES
AB Opioid drug abuse and dependence/addiction are complex disorders regulated by a wide range of interacting networks of genes and pathways that control a variety of phenotypes. Although the field has been extensively progressed since the birth of the National Institute on Drug Abuse in 1974, the fundamental knowledge and involved mechanisms that lead to drug dependence/addiction are poorly understood, and thus, there has been limited success in the prevention of drug addiction and development of therapeutics for definitive treatment and cure of addiction disease. The lack of success in both identification of addiction in at-risk populations and the development of efficient drugs has resulted in a serious social and economic burden from opioid drug abuse with global increasing rate of mortality from drug overdoses. This perspective aims to draw the attention of scientists to the potential role of nanotechnologies, which might pave the way for the development of more practical platforms for either drug development or identification and screening of patients who may be vulnerable to addiction after using opioid drugs.
C1 [Mahmoudi, Morteza] Harvard Med Sch, Brigham & Womens Hosp, Dept Anesthesiol, Boston, MA 02115 USA.
   [Pakpour, Sepideh] Brd Inst, Infect Dis & Microbiome, Cambridge, MA 02142 USA.
   [Pakpour, Sepideh] Univ British Columbia, Sch Engn, Kelowna, BC V1V 1V7, Canada.
   [Perry, George] Univ Texas San Antonio, Neurosci Inst, San Antonio, TX 78249 USA.
   [Perry, George] Univ Texas San Antonio, Dept Biol, Coll Sci, San Antonio, TX 78249 USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard Medical School;
   University of British Columbia; University of Texas System; University
   of Texas at San Antonio (UTSA); University of Texas System; University
   of Texas at San Antonio (UTSA)
RP Mahmoudi, M (通讯作者)，Harvard Med Sch, Brigham & Womens Hosp, Dept Anesthesiol, Boston, MA 02115 USA.
EM mmahmoudi@bwh.harvard.edu
RI Mahmoudi, Morteza/F-3432-2011; Perry, George/A-8611-2009
OI Mahmoudi, Morteza/0000-0002-2575-9684; Perry, George/0000-0002-6547-0172
CR Acharya SS, 2008, HAEMOPHILIA, V14, P1151, DOI 10.1111/j.1365-2516.2008.01831.x
   Acosta-Martinez V, 2008, SOIL BIOL BIOCHEM, V40, P2762, DOI 10.1016/j.soilbio.2008.07.022
   Akbarali HI, 2017, CURR OPIN PHARMACOL, V37, P126, DOI 10.1016/j.coph.2017.10.012
   Andreou C, 2013, ACS NANO, V7, P7157, DOI 10.1021/nn402563f
   Babrowski T, 2012, ANN SURG, V255, P386, DOI 10.1097/SLA.0b013e3182331870
   Beger RD, 2010, TOXICOL APPL PHARM, V243, P154, DOI 10.1016/j.taap.2009.11.019
   Blennow K, 2010, NAT REV NEUROL, V6, P131, DOI 10.1038/nrneurol.2010.4
   Bonoiu AC, 2009, P NATL ACAD SCI USA, V106, P5546, DOI 10.1073/pnas.0901715106
   Bowen DJ, 2002, J CLIN PATHOL-MOL PA, V55, P1, DOI 10.1136/mp.55.1.1
   Bravo JA, 2011, P NATL ACAD SCI USA, V108, P16050, DOI 10.1073/pnas.1102999108
   Brigger I, 2012, ADV DRUG DELIVER REV, V64, P24, DOI 10.1016/j.addr.2012.09.006
   Brosnahan AJ, 2014, PATHOGENS, V3, P249, DOI 10.3390/pathogens3020249
   Calabresi P, 2000, J NEUROSCI, V20, P8443, DOI 10.1523/JNEUROSCI.20-22-08443.2000
   Caputo D, 2017, NANOSCALE, V9, P349, DOI 10.1039/c6nr05609a
   Caracciolo G, 2017, TRENDS BIOTECHNOL, V35, P257, DOI 10.1016/j.tibtech.2016.08.011
   Carmichael AN, 2016, SUBST ABUSE REHABIL, V7, P71, DOI 10.2147/SAR.S85409
   Chen W, 2009, BIOSENS BIOELECTRON, V24, P2051, DOI 10.1016/j.bios.2008.10.015
   Choi H, 2016, EUR J NANOMED, V8, P71, DOI 10.1515/ejnm-2015-0052
   Christo PJ, 2011, PAIN PHYSICIAN, V14, P123
   Clarke G, 2013, MOL PSYCHIATR, V18, P666, DOI 10.1038/mp.2012.77
   Clarke G, 2014, MOL ENDOCRINOL, V28, P1221, DOI 10.1210/me.2014-1108
   Cohen JD, 2018, SCIENCE, V359, P926, DOI 10.1126/science.aar3247
   Colapicchioni V, 2016, INT J BIOCHEM CELL B, V75, P180, DOI 10.1016/j.biocel.2015.09.002
   Corbo C, 2017, BIOMATER SCI-UK, V5, P378, DOI 10.1039/c6bm00921b
   Crist RC, 2013, NEUROPSYCHOPHARMACOL, V38, P2003, DOI 10.1038/npp.2013.99
   Crowley JJ, 2003, PSYCHIAT GENET, V13, P169, DOI 10.1097/00041444-200309000-00006
   Daglish MRC, 2001, AM J PSYCHIAT, V158, P1680, DOI 10.1176/appi.ajp.158.10.1680
   David LA, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-7-r89
   Davis BD, 1943, J CLIN INVEST, V22, P753, DOI 10.1172/JCI101448
   de la Fuente-Nunez C, 2018, ACS CHEM NEUROSCI, V9, P141, DOI 10.1021/acschemneuro.7b00373
   Deo RC, 2015, CIRCULATION, V132, P1920, DOI 10.1161/CIRCULATIONAHA.115.001593
   Desbonnet L, 2008, J PSYCHIATR RES, V43, P164, DOI 10.1016/j.jpsychires.2008.03.009
   Distler U, 2017, ACS NANO, V11, P11768, DOI 10.1021/acsnano.7b07363
   Dong RL, 2015, ANAL CHEM, V87, P2937, DOI 10.1021/acs.analchem.5b00137
   Du Y, 2011, ANALYST, V136, P493, DOI 10.1039/c0an00557f
   Eisenstein TK, 2011, BRIT J PHARMACOL, V164, P1826, DOI 10.1111/j.1476-5381.2011.01513.x
   El-Agnaf OMA, 2006, FASEB J, V20, P419, DOI 10.1096/fj.03-1449com
   Ellgren M, 2007, NEUROPSYCHOPHARMACOL, V32, P607, DOI 10.1038/sj.npp.1301127
   Engstrom G, 2002, CIRCULATION, V105, P2632, DOI 10.1161/01.CIR.0000017327.69909.FF
   Fallon MS, 2004, J PHARMACOKINET PHAR, V31, P381, DOI 10.1007/s10928-004-8322-9
   Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m
   Farquharson Stuart, 2011, Pharmaceutics, V3, P425, DOI 10.3390/pharmaceutics3030425
   Fiala M, 1998, ADV EXP MED BIOL, V437, P199
   Forsythe P, 2014, ADV EXP MED BIOL, V817, P115, DOI 10.1007/978-1-4939-0897-4_5
   Frohlich EE, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040509
   Fukuda S, 2014, SEMIN IMMUNOPATHOL, V36, P103, DOI 10.1007/s00281-013-0399-z
   Gerard P, 2014, PATHOGENS, V3, P14, DOI 10.3390/pathogens3010014
   Goldber D. E., 1988, Machine Learning, V3, P95, DOI 10.1023/A:1022602019183
   GOLDSTEIN A, 1949, PHARMACOL REV, V1, P102
   Gould TD, 2005, P NATL ACAD SCI USA, V102, P253, DOI 10.1073/pnas.0408700102
   Gourlay DL, 2010, URINE DRUG TESTING C
   Green-Sadan T, 2005, EXP NEUROL, V194, P97, DOI 10.1016/j.expneurol.2005.01.020
   Hajipour MJ, 2014, BIOMATER SCI-UK, V2, P1210, DOI 10.1039/c4bm00131a
   Hajipour MJ, 2017, TRENDS BIOTECHNOL, V35, P937, DOI 10.1016/j.tibtech.2017.06.002
   Hajipour MJ, 2015, NANOSCALE, V7, P8978, DOI 10.1039/c5nr00520e
   Han ZZ, 2015, ANAL CHEM, V87, P4821, DOI 10.1021/acs.analchem.5b00176
   Hanash SM, 2008, NATURE, V452, P571, DOI 10.1038/nature06916
   Harari Y, 2006, SURGERY, V139, P54, DOI 10.1016/j.surg.2005.07.009
   Hazarika P, 2008, ANGEW CHEM INT EDIT, V47, P10167, DOI 10.1002/anie.200804348
   He MY, 2016, ANAL CHEM, V88, P1530, DOI 10.1021/acs.analchem.5b04863
   Hilburger ME, 1997, J INFECT DIS, V176, P183, DOI 10.1086/514021
   Hoehe MR, 2000, HUM MOL GENET, V9, P2895, DOI 10.1093/hmg/9.19.2895
   Hsiao EY, 2013, CELL, V155, P1451, DOI 10.1016/j.cell.2013.11.024
   Ignatowski TA, 2015, J NEUROIMMUNE PHARM, V10, P136, DOI 10.1007/s11481-015-9585-1
   Inscore F, 2011, APPL SPECTROSC, V65, P1004, DOI 10.1366/11-06310
   Jangi S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12015
   Javurek AB, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02880-0
   Jin J, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-33
   Jose PA, 2015, CURR OPIN NEPHROL HY, V24, P403, DOI 10.1097/MNH.0000000000000149
   Kahan M, 2006, CAN FAM PHYSICIAN, V52, P1081
   Kaminsky YG, 2012, B EXP BIOL MED+, V153, P170, DOI 10.1007/s10517-012-1668-x
   Katz NP, 2003, ANESTH ANALG, V97, P1097, DOI 10.1213/01.ANE.0000080159.83342.B5
   Kelly-Spratt KS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019721
   Kennedy L., 1982, DIABETES, V31, P52, DOI DOI 10.2337/DIAB.31.3.S52
   Kennedy PJ, 2017, NEUROPHARMACOLOGY, V112, P399, DOI 10.1016/j.neuropharm.2016.07.002
   Keshishian H, 2017, NAT PROTOC, V12, P1683, DOI 10.1038/nprot.2017.054
   Kharazian B, 2016, INT J BIOCHEM CELL B, V75, P162, DOI 10.1016/j.biocel.2016.02.008
   Kim BYS, 2010, NEW ENGL J MED, V363, P2434, DOI 10.1056/NEJMra0912273
   Kinross JM, 2011, GENOME MED, V3, DOI 10.1186/gm228
   Kiraly DD, 2016, SCI REP-UK, V6, DOI 10.1038/srep35455
   Koob G.F., 2011, FOCUS MADISON, V9, P55, DOI [DOI 10.1176/FOC.9.1.FOC55, 10.1176/foc.9.1.foc55]
   KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J
   Krishnan S, 2015, CURR OPIN BIOTECH, V36, P137, DOI 10.1016/j.copbio.2015.08.015
   Krol S, 2013, CHEM REV, V113, P1877, DOI 10.1021/cr200472g
   LAPCHAK PA, 1989, NEUROSCIENCE, V31, P313, DOI 10.1016/0306-4522(89)90376-X
   Laurent S, 2011, ADV COLLOID INTERFAC, V166, P8, DOI 10.1016/j.cis.2011.04.003
   LaVan DA, 2003, NAT BIOTECHNOL, V21, P1184, DOI 10.1038/nbt876
   Law WC, 2012, THERANOSTICS, V2, P695, DOI 10.7150/thno.3459
   Le Merrer J, 2009, PHYSIOL REV, V89, P1379, DOI 10.1152/physrev.00005.2009
   Leclercq S, 2014, BIOL PSYCHIAT, V76, P725, DOI 10.1016/j.biopsych.2014.02.003
   Leggett R., 2007, ANGEW CHEM, V119, P4178, DOI DOI 10.1002/ANGE.200700217
   Lin YP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040232
   Lundqvist M, 2008, P NATL ACAD SCI USA, V105, P14265, DOI 10.1073/pnas.0805135105
   MacFarlane AS, 2000, J INFECT DIS, V181, P1350, DOI 10.1086/315403
   Mahmoudi M, 2018, TRENDS BIOTECHNOL, V36, P755, DOI 10.1016/j.tibtech.2018.02.014
   Mahmoudi M, 2017, NAT NANOTECHNOL, V12, P845, DOI [10.1038/nnano.2017.167, 10.1038/NNANO.2017.167]
   Mahmoudi M, 2013, ACS NANO, V7, P6555, DOI 10.1021/nn305337c
   Mahmoudi M, 2012, CHEM REV, V112, P2323, DOI 10.1021/cr2002596
   Mahmoudi M, 2011, CHEM REV, V111, P5610, DOI 10.1021/cr100440g
   Mahmoudi M, 2011, ADV DRUG DELIVER REV, V63, P24, DOI 10.1016/j.addr.2010.05.006
   Mahmoudi M, 2011, CHEM REV, V111, P253, DOI 10.1021/cr1001832
   MARTIN BK, 1965, NATURE, V207, P274, DOI 10.1038/207274a0
   Matsumoto M, 2012, SCI REP-UK, V2, DOI 10.1038/srep00233
   McAfee A, 2012, HARVARD BUS REV, V90, P60
   Monopoli MP, 2012, NAT NANOTECHNOL, V7, P779, DOI [10.1038/NNANO.2012.207, 10.1038/nnano.2012.207]
   Muller LK, 2018, BIOMACROMOLECULES, V19, P374, DOI 10.1021/acs.biomac.7b01472
   Murdoch TB, 2013, JAMA-J AM MED ASSOC, V309, P1351, DOI 10.1001/jama.2013.393
   National Institute on Drug Abuse, CHART EV BAS SCREEN
   Nel AE, 2009, NAT MATER, V8, P543, DOI [10.1038/nmat2442, 10.1038/NMAT2442]
   Nestler EJ, 2004, TRENDS PHARMACOL SCI, V25, P210, DOI 10.1016/j.tips.2004.02.005
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   O'Mahony SM, 2015, BEHAV BRAIN RES, V277, P32, DOI 10.1016/j.bbr.2014.07.027
   Oslin DW, 2003, NEUROPSYCHOPHARMACOL, V28, P1546, DOI 10.1038/sj.npp.1300219
   Park SM, 2017, NAT REV MATER, V2, DOI 10.1038/natrevmats.2017.14
   Partty A, 2015, PEDIATR RES, V77, P823, DOI 10.1038/pr.2015.51
   Postler TS, 2017, CELL METAB, V26, P110, DOI 10.1016/j.cmet.2017.05.008
   Rao Pss, 2015, J Pers Nanomed, V1, P3
   Ribeiro JA, 2016, TALANTA, V160, P653, DOI 10.1016/j.talanta.2016.06.066
   Ridker P. M., 2004, CIRCULATION, V109
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Sacerdote P, 2006, PALLIATIVE MED, V20, pS9, DOI 10.1191/0269216306pm1124oa
   Sagar V, 2016, MOL BRAIN, V9, DOI 10.1186/s13041-016-0236-0
   Sagar V, 2015, J BIOMED NANOTECHNOL, V11, P1722, DOI 10.1166/jbn.2015.2108
   Saha K, 2012, CHEM REV, V112, P2739, DOI 10.1021/cr2001178
   SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605
   Sampson TR, 2016, CELL, V167, P1469, DOI 10.1016/j.cell.2016.11.018
   Scheperjans F, 2015, MOVEMENT DISORD, V30, P350, DOI 10.1002/mds.26069
   Schulzke JD, 2009, ANN NY ACAD SCI, V1165, P294, DOI 10.1111/j.1749-6632.2009.04062.x
   Serpooshan V, 2018, ACS NANO, V12, P2253, DOI 10.1021/acsnano.7b06212
   Shankaran DR, 2007, SENSOR ACTUAT B-CHEM, V121, P158, DOI 10.1016/j.snb.2006.09.014
   Sharifi S, 2015, CONTRAST MEDIA MOL I, V10, P329, DOI 10.1002/cmmi.1638
   Shi JJ, 2017, NAT REV CANCER, V17, P20, DOI 10.1038/nrc.2016.108
   Shi JJ, 2010, NANO LETT, V10, P3223, DOI 10.1021/nl102184c
   Strojan K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169552
   Tavakol M, 2018, NANOSCALE, V10, P7108, DOI 10.1039/c7nr09502c
   Taylor A., 2018, J PAIN, V19, P1
   Temko JE, 2017, ALCOHOL ALCOHOLISM, V52, P403, DOI 10.1093/alcalc/agx024
   Tillisch K, 2013, GASTROENTEROLOGY, V144, P1394, DOI 10.1053/j.gastro.2013.02.043
   Umezaki Y, 2015, BIOMATERIALS, V45, P115, DOI 10.1016/j.biomaterials.2014.12.032
   Vaglienti Richard M, 2003, W V Med J, V99, P67
   Valjent E, 2005, M S-MED SCI, V21, P453, DOI 10.1051/medsci/2005215453
   Valjent E, 2005, P NATL ACAD SCI USA, V102, P491, DOI 10.1073/pnas.0408305102
   van den Brule S, 2016, PART FIBRE TOXICOL, V13, DOI 10.1186/s12989-016-0149-1
   Vilaseca P, 2013, SOFT MATTER, V9, P6978, DOI 10.1039/c3sm50220a
   Vlasova M, 2017, ADV MED TECH CLIN PR, P1, DOI 10.4018/978-1-5225-0754-3.ch001
   Wang FY, 2017, TOXICOL PATHOL, V45, P150, DOI 10.1177/0192623316679898
   Wang WY, 2017, ACS NANO, V11, P12641, DOI 10.1021/acsnano.7b07093
   Wei Juan, 2011, Chin J Cancer, V30, P407
   Wikoff WR, 2009, P NATL ACAD SCI USA, V106, P3698, DOI 10.1073/pnas.0812874106
   Williams K, 2015, NANOTOXICOLOGY, V9, P279, DOI 10.3109/17435390.2014.921346
   Wolfheis OS, 2009, ANGEW CHEM INT EDIT, V48, P2268, DOI 10.1002/anie.200805765
   Yan J, 2018, CALCIFIED TISSUE INT, V102, P406, DOI 10.1007/s00223-018-0395-3
   Zanganeh S, 2016, NAT NANOTECHNOL, V11, P986, DOI [10.1038/nnano.2016.168, 10.1038/NNANO.2016.168]
   Zheng TY, 2017, ACS INFECT DIS, V3, P866, DOI 10.1021/acsinfecdis.7b00137
   Zheng TY, 2015, ACS APPL MATER INTER, V7, P6819, DOI 10.1021/acsami.5b00371
NR 155
TC 5
Z9 6
U1 2
U2 32
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-7193
J9 ACS CHEM NEUROSCI
JI ACS Chem. Neurosci.
PD OCT
PY 2018
VL 9
IS 10
SI SI
BP 2288
EP 2298
DI 10.1021/acschemneuro.8b00127
PG 21
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences
   & Neurology
GA GX7LS
UT WOS:000447954300002
PM 29851334
DA 2023-06-23
ER

PT J
AU Ogai, Y
   Senoo, E
   Sugaya, N
   Morita, N
   Ikeda, K
AF Ogai, Y.
   Senoo, E.
   Sugaya, N.
   Morita, N.
   Ikeda, K.
TI THE RELATIONSHIP BETWEEN VICTIMIZATION AND SEVERITY OF DRUG ADDICTION
   MEASURED WITH ADDICTION SEVERITY INDEX IN JAPANESE DRUG-DEPENDENT
   PATIENTS
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 16th World Congress of the
   International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY SEP 09-12, 2012
CL Sapporo, JAPAN
SP Int Soc Biomed Res Alcoholism (ISBRA), Japanese Med Soc Alcohol & Drug Studies (JMSAS), Sci Council Japan
C1 [Ogai, Y.; Senoo, E.; Sugaya, N.; Morita, N.; Ikeda, K.] Univ Tsukuba, Tsukuba, Ibaraki 3058577, Japan.
C3 University of Tsukuba
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD SEP
PY 2012
VL 36
SU 2
SI SI
BP 107A
EP 107A
PG 1
WC Substance Abuse
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Substance Abuse
GA 000OS
UT WOS:000308396700368
DA 2023-06-23
ER

PT J
AU Hemmingson, M
AF Hemmingson, Michael
TI Tijuana and Tramadol: Border Reflections on Addiction to an
   Over-The-Counter Drug
SO LIFE WRITING
LA English
DT Article
DE addiction; drugs; Tijuana; Tramadol; pharmacies
CR BURROUGHS W, 1953, JUNKIE
   Carrol J., 1978, BASKETBALL DIARIES
   Chopra D, 1997, OVERCOMING ADDICTION
   Dodes L., 1996, HEART ADDICTION
   Domaldson J., SEROTONIN NOREPINEPH
   Drugs, TRAM
   KARP D, 2006, IS IT ME MY MEDS
   Labate A, 2005, MED J AUSTRALIA, V182, P42, DOI 10.5694/j.1326-5377.2005.tb06556.x
   Ronell Avital, 1992, CRACK WARS
   Tramadol, TRAM
NR 10
TC 0
Z9 0
U1 0
U2 1
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1448-4528
J9 LIFE WRIT
JI Life Writ.
PY 2010
VL 7
IS 2
SI SI
BP 211
EP 220
DI 10.1080/14484520902931040
PG 10
WC Literature
WE Arts &amp; Humanities Citation Index (A&amp;HCI)
SC Literature
GA V21KZ
UT WOS:000208207800010
DA 2023-06-23
ER

PT J
AU Robles, JS
AF Robles, Jessica S.
TI Managing moral category implications of former drug addiction
SO DISCOURSE & SOCIETY
LA English
DT Article
DE Accounts; addiction; categorization; discourse; epistemics; identity;
   interaction; morality; normalization; stigma
ID MEMBERSHIP CATEGORIZATION; STIGMA; LANGUAGE; TALK; USER
AB This project examines how meanings of drug addiction are negotiated through analysis of situated social actions in a telephone conversation. This paper uses interactional analysis to show how a former heroin user's identity is constructed and moralized in the process of providing accounts through descriptions of drug addiction and its consequences. This case shows how social actions in interpersonal conversation provide insights into judgment and addiction, and how participants manage the complex moral hierarchies associated with drug use and drug user identities. The analysis contributes to enriching an area of empirical research that needs more data and more attention to interaction, while also contributing to theories of categorization, normalization, stigma, and morality of drug addiction.
C1 [Robles, Jessica S.] Loughborough Univ, Discourse & Rhetor Grp DARG, Loughborough, Leics, England.
C3 Loughborough University
RP Robles, JS (通讯作者)，Loughborough Univ, Margaret Keay Rd,Brockington Bldg, Loughborough LE11 3TU, Leics, England.
EM j.j.robles@lboro.ac.uk
CR Beach WA, 2019, HEALTH COMMUN, V34, P1697, DOI 10.1080/10410236.2018.1536945
   Benwell B., 2010, SAGE HDB IDENTITIES
   Bergen C, 2013, J HEALTH SOC BEHAV, V54, P220, DOI 10.1177/0022146513487379
   Coker, 2012, LANGUAGE DISCOURSE S, V1, P138
   Denvir P, 2014, COMMUNITY MED, V11, P263, DOI [10.1558/cam.v11i3.17876, DOI 10.1558/CAM.V11I3.17876]
   Denvir PM, 2012, SOC SCI MED, V75, P1650, DOI 10.1016/j.socscimed.2012.06.021
   Denvir PM., 2009, PHYS PATIENT COMMUNI
   Dingle GA, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01795
   EDWARDS D, 1995, RES LANG SOC INTERAC, V28, P319, DOI 10.1207/s15327973rlsi2804_1
   EDWARDS D, 1991, THEOR PSYCHOL, V1, P515, DOI 10.1177/0959354391014007
   Edwards D, 2017, DISCOURSE STUD, V19, P497, DOI 10.1177/1461445617715171
   Fitzgerald R., 2015, INT ENCY LANGUAGE SO, P1, DOI DOI 10.1002/9781118611463.WBIELSI018
   GARFINKEL H, 1956, AM J SOCIOL, V61, P420, DOI 10.1086/221800
   GARFINKEL H, 1967, STUDIES ETHNOMETHODO
   Goffman, 1981, FORMS TALK
   Goffman E., 1963, STIGMA NOTES MANAGEM
   Heritage J, 2005, SOC PSYCHOL QUART, V68, P15, DOI 10.1177/019027250506800103
   Hester S., 1997, CULTURE ACTION STUDI
   HOFFMANN HC, 2003, CONTEMP DRUG PROBL, V30, P647, DOI DOI 10.1177/009145090303000306
   Housley W, 2009, DISCOURSE SOC, V20, P345, DOI 10.1177/0957926509102405
   Hughes K, 2007, SOCIOL HEALTH ILL, V29, P673, DOI 10.1111/j.1467-9566.2007.01018.x
   Jayyusi L, 2013, CATEGORIZATION MORAL
   JEFFERSON G, 1988, SOC PROBL, V35, P418, DOI 10.1525/sp.1988.35.4.03a00070
   Jefferson G., 1984, STRUCTURES SOCIAL AC, pix, DOI DOI 10.1017/CBO9780511665868
   Juhila K., 2004, QUALITATIVE SOCIAL W, V3, P259, DOI DOI 10.1177/1473325004045665
   Kusow AM, 2004, SYMB INTERACT, V27, P179, DOI 10.1525/si.2004.27.2.179
   Morris J, 2019, PSYCHOLOGIST, V32, P36
   Nettleton S, 2013, HEALTH-LONDON, V17, P174, DOI 10.1177/1363459312451182
   Nikander P, 2000, J AGING STUD, V14, P335, DOI 10.1016/S0890-4065(00)80001-8
   Pillet-Shore D., 2021, YOURE PART OPIOID CR
   Pino, 2020, LANGUAGE SOC, V50, P695
   Pino M., 2014, COMMUNICATING CERTAI, P201
   POMERANTZ A, 1978, SOCIOLOGY, V12, P115, DOI 10.1177/003803857801200107
   Pomerantz A, 1984, STRUCTURES SOCIAL AC, P57, DOI DOI 10.1017/CBO9780511665868.008
   Radburn B, 2011, J GAMBL ISSUES, P30, DOI 10.4309/jgi.2011.26.4
   Radcliffe P, 2011, SOC SCI MED, V72, P984, DOI 10.1016/j.socscimed.2011.01.017
   Rapley M, 2003, BRIT J SOC PSYCHOL, V42, P427, DOI 10.1348/014466603322438242
   Robles JS., 2019, CADAAD J, V9, P5
   Rodner S, 2005, ADDICT RES THEORY, V13, P333, DOI 10.1080/16066350500136276
   Ruusuvuori Johanna, 2012, HDB CONVERSATION ANA, P330, DOI [DOI 10.1002/9781118325001.CH16, DOI 10.1002/9781118325001]
   SACKS H, 1992, LECT CONVERSATION
   Scheff TJ, 2003, SYMB INTERACT, V26, P239, DOI 10.1525/si.2003.26.2.239
   SCHEGLOFF EA, 1987, SOC PSYCHOL QUART, V50, P101, DOI 10.2307/2786745
   Schubert SJ, 2009, DISCOURSE SOC, V20, P499, DOI 10.1177/0957926509104025
   Sidnell J, 2010, CONVERSATION ANAL IN
   Stokoe E., 2018, TALK SCI CONVERSATIO
   Stokoe EH, 2003, FEM PSYCHOL, V13, P317, DOI 10.1177/0959353503013003006
   Stokoe E, 2012, DISCOURSE STUD, V14, P277, DOI 10.1177/1461445612441534
   Stommel W, 2011, GLOB HEALTH PROMOT, V18, P18, DOI 10.1177/1757975911404764
   Thurnell-Read T, 2013, SOCIOL RES ONLINE, V18, DOI 10.5153/sro.3000
   Tracy K, 2004, J COMMUN, V54, P788, DOI 10.1093/joc/54.4.788
   Tracy Karen, 2013, EVERYDAY TALK BUILDI
   Tsui Amy B. M., 1991, TEXT, V11, P607, DOI DOI 10.1515/TEXT.1.1991.11.4.607
   Weinberg D, 2000, SOC PROBL, V47, P606, DOI 10.1525/sp.2000.47.4.03x0310x
   WHALEN J, 1988, SOC PROBL, V35, P335, DOI 10.1525/sp.1988.35.4.03a00030
   Yang LH, 2017, CURR OPIN PSYCHIATR, V30, P378, DOI 10.1097/YCO.0000000000000351
   YEARLEY S, 1989, HUM STUD, V12, P97, DOI 10.1007/BF00142841
NR 57
TC 0
Z9 0
U1 2
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0957-9265
EI 1460-3624
J9 DISCOURSE SOC
JI niscl. Soc.
PD JUL
PY 2022
VL 33
IS 4
BP 519
EP 538
AR 09579265221088130
DI 10.1177/09579265221088130
EA APR 2022
PG 20
WC Communication; Psychology, Multidisciplinary; Sociology
WE Social Science Citation Index (SSCI)
SC Communication; Psychology; Sociology
GA 3E5CU
UT WOS:000783224600001
OA Green Published
DA 2023-06-23
ER

PT J
AU Kalivas, PW
   O'Brien, C
AF Kalivas, Peter W.
   O'Brien, Charles
TI Drug addiction as a pathology of staged neuroplasticity
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Review
DE addiction; neuroplasticity; motivational circuitry; glutamate; dopamine
ID COCAINE-INDUCED REINSTATEMENT; ELEMENT-BINDING PROTEIN; MESOLIMBIC
   DOPAMINE SYSTEM; MEDIAL PREFRONTAL CORTEX; D-3 RECEPTOR EXPRESSION;
   VENTRAL TEGMENTAL AREA; NUCLEUS-ACCUMBENS; SYNAPTIC PLASTICITY; SEEKING
   BEHAVIOR; DELTA-FOSB
AB Using addictive drugs can evolve from controlled social use into the compulsive relapsing disorder that characterizes addiction. This transition to addiction results from genetic, developmental, and sociological vulnerabilities, combined with pharmacologically induced plasticity in brain circuitry that strengthens learned drug-associated behaviors at the expense of adaptive responding for natural rewards. Advances over the last decade have identified the brain circuits most vulnerable to drug-induced changes, as well as many associated molecular and morphological underpinnings. This growing knowledge has contributed to an expanded understanding of how drugs usurp normal learning circuitry to create the pathology of addiction, as evidenced by involuntary activation of reward circuits in response to drug-associated cues and simultaneous reports of drug craving. This new understanding provides unprecedented potential opportunities for novel pharmacotherapeutic targets in treating addiction. There appears to be plasticity associated with the addiction phenomenon in general as well as changes produced by addiction to a specific class of addicting drugs. These findings also provide the basis for the current understanding of addiction as a chronic, relapsing disease of the brain with changes that persist long after the last use of the drug. Here, we describe the neuroplasticity in brain circuits and cell function induced by addictive drugs that is thought to underlie the compulsions to resume drug-taking, and discuss how this knowledge is impelling exploration and testing of novel addiction therapies.
C1 Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
   Univ Penn, Philadelphia VA Med Ctr, Dept Psychiat, Philadelphia, PA 19104 USA.
C3 Medical University of South Carolina; University of Pennsylvania;
   Pennsylvania Medicine; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); Philadelphia Veterans Affairs Medical
   Center
RP Kalivas, PW (通讯作者)，Med Univ S Carolina, Dept Neurosci, 173 Ashley Ave,BSB 10, Charleston, SC 29425 USA.
EM kalivasp@musc.edu
FU NIDA NIH HHS [P50 DA015369, P60 DA01586] Funding Source: Medline
CR Altar CA, 1997, NATURE, V389, P856, DOI 10.1038/39885
   Baker DA, 2003, NAT NEUROSCI, V6, P743, DOI 10.1038/nn1069
   Baptista MAS, 2004, J NEUROSCI, V24, P4723, DOI 10.1523/JNEUROSCI.0176-04.2004
   Barnes TD, 2005, NATURE, V437, P1158, DOI 10.1038/nature04053
   Barrot M, 2002, P NATL ACAD SCI USA, V99, P11435, DOI 10.1073/pnas.172091899
   Benavides DR, 2004, ANN NY ACAD SCI, V1025, P335, DOI 10.1196/annals.1316.041
   Berglind WJ, 2007, EUR J NEUROSCI, V26, P757, DOI 10.1111/j.1460-9568.2007.05692.x
   Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9
   Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8
   Blanpied TA, 2004, BIOL PSYCHIAT, V55, P1121, DOI 10.1016/j.biopsych.2003.10.006
   Blumer JB, 2003, RECEPTOR CHANNEL, V9, P195, DOI 10.1080/10606820390203839
   Borgland SL, 2006, NEURON, V49, P589, DOI 10.1016/j.neuron.2006.01.016
   Boudreau AC, 2005, J NEUROSCI, V25, P9144, DOI 10.1523/JNEUROSCI.2252-05.2005
   Bowers MS, 2004, NEURON, V42, P269, DOI 10.1016/S0896-6273(04)00159-X
   Bramham CR, 2005, PROG NEUROBIOL, V76, P99, DOI 10.1016/j.pneurobio.2005.06.003
   Caille S, 2004, EUR J NEUROSCI, V20, P593, DOI 10.1111/j.1460-9568.2004.03497.x
   Capriles N, 2003, PSYCHOPHARMACOLOGY, V168, P66, DOI 10.1007/s00213-002-1283-z
   Cardinal RN, 2004, CURR OPIN NEUROBIOL, V14, P156, DOI 10.1016/j.conb.2004.03.004
   Carlezon WA, 1998, SCIENCE, V282, P2272, DOI 10.1126/science.282.5397.2272
   Centonze D, 2005, MOL NEUROBIOL, V32, P123, DOI 10.1385/MN:32:2:123
   Cha XY, 1997, J NEUROSCI, V17, P6864
   Chefer VI, 2000, NEUROSCIENCE, V101, P619, DOI 10.1016/S0306-4522(00)00417-6
   Chick A., 1997, J SUSTAINABLE PRODUC, V1, P5
   Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11
   CHILDRESS AR, 2007, COLL PROBL DRUG DEP
   Choi KH, 2006, NEUROSCIENCE, V137, P373, DOI 10.1016/j.neuroscience.2005.10.049
   Colby CR, 2003, J NEUROSCI, V23, P2488
   Cornish JL, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-15-j0006.2000
   Cubells Joseph F, 2006, Curr Psychiatry Rep, V8, P130, DOI 10.1007/s11920-006-0011-5
   Dackis CA, 2005, NEUROPSYCHOPHARMACOL, V30, P205, DOI 10.1038/sj.npp.1300600
   Dackis Charles A, 2004, Curr Psychiatry Rep, V6, P323, DOI 10.1007/s11920-004-0018-8
   DAUNAIS JB, 1994, SYNAPSE, V18, P35, DOI 10.1002/syn.890180106
   DAVIS WM, 1974, BIOL PSYCHIAT, V9, P181
   Daws LC, 2002, BIOCHEM BIOPH RES CO, V290, P1545, DOI 10.1006/bbrc.2002.6384
   DEUTCH AY, 1990, PROG BRAIN RES, V85, P367
   Di Ciano P, 2001, NEUROPSYCHOPHARMACOL, V25, P341, DOI 10.1016/S0893-133X(01)00235-4
   Dong Y, 2005, J NEUROSCI, V25, P936, DOI 10.1523/JNEUROSCI.4715-04.2005
   ELGHUNDI M, 2007, IN PRESS REV NEUROSC
   Epstein DH, 2006, PSYCHOPHARMACOLOGY, V189, P1, DOI 10.1007/s00213-006-0529-6
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Filip M, 2006, BRAIN RES, V1071, P218, DOI 10.1016/j.brainres.2005.11.099
   Franklin TR, 2002, BIOL PSYCHIAT, V51, P134, DOI 10.1016/S0006-3223(01)01269-0
   Fuchs RA, 2006, J NEUROSCI, V26, P3584, DOI 10.1523/JNEUROSCI.5146-05.2006
   Garavan H, 2000, AM J PSYCHIAT, V157, P1789, DOI 10.1176/appi.ajp.157.11.1789
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Gonzales RA, 1998, J NEUROSCI, V18, P10663
   Graham DL, 2007, NAT NEUROSCI, V10, P1029, DOI 10.1038/nn1929
   Grimm JW, 2003, J NEUROSCI, V23, P742
   Guillin O, 2001, NATURE, V411, P86, DOI 10.1038/35075076
   HART CL, 2007, NEUROPSYCHOPHAR 0613
   Horger BA, 1999, J NEUROSCI, V19, P4110
   HURD YL, 1993, SYNAPSE, V13, P357, DOI 10.1002/syn.890130408
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Jay TM, 2003, PROG NEUROBIOL, V69, P375, DOI 10.1016/S0301-0082(03)00085-6
   Jedynak JP, 2007, EUR J NEUROSCI, V25, P847, DOI 10.1111/j.1460-9568.2007.05316.x
   Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483
   Jin SH, 2005, NEUROSCIENCE, V133, P647, DOI 10.1016/j.neuroscience.2005.03.017
   Jones S, 2005, CURR OPIN PHARMACOL, V5, P20, DOI 10.1016/j.coph.2004.08.011
   Kalivas PW, 2006, TRENDS NEUROSCI, V29, P610, DOI 10.1016/j.tins.2006.08.008
   Kalivas PW, 2005, NEURON, V45, P647, DOI 10.1016/j.neuron.2005.02.005
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kampman KM, 2004, DRUG ALCOHOL DEPEN, V75, P233, DOI 10.1016/j.drugalcdep.2004.03.008
   Kasai H, 2003, TRENDS NEUROSCI, V26, P360, DOI 10.1016/S0166-2236(03)00162-0
   Kelley AE, 2004, NEURON, V44, P161, DOI 10.1016/j.neuron.2004.09.016
   Kelz MB, 1999, NATURE, V401, P272, DOI 10.1038/45790
   Kolb B, 2004, BRAIN COGNITION, V55, P104, DOI 10.1016/s0278-2626(03)00278-1
   Kourrich S, 2007, J NEUROSCI, V27, P7921, DOI 10.1523/JNEUROSCI.1859-07.2007
   LALUMIERE R, 2006, NEUROBIOLOGY MEMORY, P459
   LaRowe SD, 2007, AM J PSYCHIAT, V164, P1115, DOI 10.1176/appi.ajp.164.7.1115
   Laviolette SR, 2004, NAT REV NEUROSCI, V5, P55, DOI 10.1038/nrn1298
   Le Foll B, 2005, NEUROREPORT, V16, P175, DOI 10.1097/00001756-200502080-00022
   Lippman J, 2005, J NEUROBIOL, V64, P47, DOI 10.1002/neu.20149
   Lisman J, 2003, NEURON, V38, P361, DOI 10.1016/S0896-6273(03)00257-5
   Lu L, 2004, J NEUROSCI, V24, P1604, DOI 10.1523/JNEUROSCI.5124-03.2004
   Lu L, 2004, NEUROPHARMACOLOGY, V47, P214, DOI 10.1016/j.neuropharm.2004.06.027
   Lu L, 2003, J NEUROCHEM, V85, P1604, DOI 10.1046/j.1471-4159.2003.01824.x
   Mackler SA, 2000, J NEUROSCI, V20, P6210, DOI 10.1523/JNEUROSCI.20-16-06210.2000
   Malcolm R, 2006, AM J DRUG ALCOHOL AB, V32, P577, DOI 10.1080/00952990600920425
   Mangiavacchi S, 2004, J NEUROCHEM, V88, P1261, DOI 10.1046/j.1471-4159.2003.02248.x
   Mansvelder HD, 2000, NEURON, V27, P349, DOI 10.1016/S0896-6273(00)00042-8
   Martin M, 2006, NAT NEUROSCI, V9, P868, DOI 10.1038/nn1713
   Martinez D, 2007, AM J PSYCHIAT, V164, P622, DOI 10.1176/appi.ajp.164.4.622
   Matus A, 2005, CURR OPIN NEUROBIOL, V15, P67, DOI 10.1016/j.conb.2005.01.015
   McBean GJ, 2002, TRENDS PHARMACOL SCI, V23, P299, DOI 10.1016/S0165-6147(02)02060-6
   McClung CA, 2003, NAT NEUROSCI, V6, P1208, DOI 10.1038/nn1143
   McFarland K, 2004, J NEUROSCI, V24, P1551, DOI 10.1523/JNEUROSCI.4177-03.2004
   McFarland K, 2003, J NEUROSCI, V23, P3531
   McFarland K, 2001, J NEUROSCI, V21, P8655
   McGinty JF, 2007, PROG BRAIN RES, V160, P273, DOI 10.1016/S0079-6123(06)60016-2
   Meng YH, 2002, NEURON, V35, P121, DOI 10.1016/S0896-6273(02)00758-4
   Moran MM, 2005, J NEUROSCI, V25, P6389, DOI 10.1523/JNEUROSCI.1007-05.2005
   Moratalla R, 1996, NEURON, V17, P147, DOI 10.1016/S0896-6273(00)80288-3
   Myrick Hugh, 2004, Curr Psychiatry Rep, V6, P332, DOI 10.1007/s11920-004-0019-7
   Nader K, 1997, J NEUROSCI, V17, P383, DOI 10.1523/JNEUROSCI.17-01-00383.1997
   Nader MA, 2005, AM J PSYCHIAT, V162, P1473, DOI 10.1176/appi.ajp.162.8.1473
   Neisewander JL, 2004, NEUROPSYCHOPHARMACOL, V29, P1479, DOI 10.1038/sj.npp.1300456
   Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   Nestler EJ, 2001, P NATL ACAD SCI USA, V98, P11042, DOI 10.1073/pnas.191352698
   Nicola SM, 2000, ANNU REV NEUROSCI, V23, P185, DOI 10.1146/annurev.neuro.23.1.185
   Nogueira L, 2006, J NEUROSCI, V26, P12308, DOI 10.1523/JNEUROSCI.3206-06.2006
   Norrholm SD, 2003, NEUROSCIENCE, V116, P19, DOI 10.1016/S0306-4522(02)00560-2
   O'Brien CP, 2006, AM J PSYCHIAT, V163, P764, DOI 10.1176/appi.ajp.163.5.764
   O'Brien CP, 2003, AM J ADDICTION, V12, pS36, DOI 10.1080/10550490390210092
   O'Brien CP, 2005, AM J PSYCHIAT, V162, P1423, DOI 10.1176/appi.ajp.162.8.1423
   OBRIEN CP, 1975, PHARMACOL REV, V27, P533
   OBRIEN CP, 1977, SCIENCE, V195, P1000, DOI 10.1126/science.841320
   Pandey SC, 2004, J NEUROSCI, V24, P5022, DOI 10.1523/JNEUROSCI.5557-03.2004
   Peters J, 2006, PSYCHOPHARMACOLOGY, V186, P143, DOI 10.1007/s00213-006-0372-9
   Pierce RC, 1997, BRAIN RES REV, V25, P192, DOI 10.1016/S0165-0173(97)00021-0
   Pierce RC, 2006, NEUROSCI BIOBEHAV R, V30, P215, DOI 10.1016/j.neubiorev.2005.04.016
   Pu L, 2006, NAT NEUROSCI, V9, P605, DOI 10.1038/nn1687
   Rao A, 2000, HIPPOCAMPUS, V10, P527, DOI 10.1002/1098-1063(2000)10:5<527::AID-HIPO3>3.0.CO;2-B
   Richards DA, 2005, P NATL ACAD SCI USA, V102, P6166, DOI 10.1073/pnas.0501881102
   Rilling JK, 2002, NEURON, V35, P395, DOI 10.1016/S0896-6273(02)00755-9
   Robinson R, 2004, HIGH EDUC, V47, P1, DOI 10.1023/B:HIGH.0000009803.70418.9c
   Robinson TE, 1999, SYNAPSE, V33, P160
   Schultz W, 2004, CURR OPIN NEUROBIOL, V14, P139, DOI 10.1016/j.conb.2004.03.017
   SCHULTZ W, 1998, AM J PHYSIOL, V80, P1
   See RE, 2002, PHARMACOL BIOCHEM BE, V71, P517, DOI 10.1016/S0091-3057(01)00682-7
   SEIDEN LS, 1993, ANNU REV PHARMACOL, V33, P639, DOI 10.1146/annurev.pharmtox.33.1.639
   Sierra-Mercado D, 2006, EUR J NEUROSCI, V24, P1751, DOI 10.1111/j.1460-9568.2006.05014.x
   Soosairajah J, 2005, EMBO J, V24, P473, DOI 10.1038/sj.emboj.7600543
   Steward O, 2001, P NATL ACAD SCI USA, V98, P7062, DOI 10.1073/pnas.131146398
   Sun WL, 2005, PSYCHOPHARMACOLOGY, V177, P315, DOI 10.1007/s00213-004-1956-x
   Sun X, 2005, J NEUROSCI, V25, P7342, DOI 10.1523/JNEUROSCI.4603-04.2005
   Sutton MA, 2003, NATURE, V421, P70, DOI 10.1038/nature01249
   Szumlinski KK, 2006, NEUROPSYCHOPHARMACOL, V31, P768, DOI 10.1038/sj.npp.1300890
   Tang XC, 2005, J NEUROSCI, V25, P4512, DOI 10.1523/JNEUROSCI.0685-05.2005
   Toda S, 2006, J NEUROSCI, V26, P1579, DOI 10.1523/JNEUROSCI.4132-05.2006
   Todtenkopf MS, 2006, J NEUROSCI, V26, P11665, DOI 10.1523/JNEUROSCI.3070-06.2006
   Trantham H, 2002, NEUROSCIENCE, V113, P749, DOI 10.1016/S0306-4522(02)00246-4
   Vocci F, 2005, PHARMACOL THERAPEUT, V108, P94, DOI 10.1016/j.pharmthera.2005.06.010
   Volkow ND, 2005, J NEUROSCI, V25, P3932, DOI 10.1523/JNEUROSCI.0433-05.2005
   Volkow ND, 2004, MOL PSYCHIATR, V9, P557, DOI 10.1038/sj.mp.4001507
   Volkow ND, 2002, SYNAPSE, V46, P79, DOI 10.1002/syn.10137
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
   VOLPICELLI JR, 1995, AM J PSYCHIAT, V152, P613
   Walters CL, 2005, NEURON, V46, P933, DOI 10.1016/j.neuron.2005.05.005
   Wilson SJ, 2004, NAT NEUROSCI, V7, P211, DOI 10.1038/nn1200
   Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406
   Wolf ME, 2004, NEUROPHARMACOLOGY, V47, P61, DOI 10.1016/j.neuropharm.2004.07.006
   Xi ZX, 2006, NEUROPSYCHOPHARMACOL, V31, P1393, DOI 10.1038/sj.npp.1300912
   Xi ZX, 2002, J PHARMACOL EXP THER, V303, P608, DOI 10.1124/jpet.102.039735
   Yao L, 2005, P NATL ACAD SCI USA, V102, P8746, DOI 10.1073/pnas.0503419102
   Zachariou V, 2006, NAT NEUROSCI, V9, P205, DOI 10.1038/nn1636
   Zhang XF, 1998, J NEUROSCI, V18, P488
NR 147
TC 515
Z9 543
U1 0
U2 62
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
EI 1740-634X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD JAN
PY 2008
VL 33
IS 1
BP 166
EP 180
DI 10.1038/sj.npp.1301564
PG 15
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 235XH
UT WOS:000251267100013
PM 17805308
OA Bronze
DA 2023-06-23
ER

PT J
AU Dezfouli, A
   Piray, P
   Keramati, MM
   Ekhtiari, H
   Lucas, C
   Mokri, A
AF Dezfouli, Amir
   Piray, Payam
   Keramati, Mohammad Mahdi
   Ekhtiari, Hamed
   Lucas, Caro
   Mokri, Azarakhsh
TI A Neurocomputational Model for Cocaine Addiction
SO NEURAL COMPUTATION
LA English
DT Article
ID DOPAMINE SYSTEM REGULATION; DRUG-ADDICTION; NEURONS ENCODE; BASAL
   GANGLIA; SELF-CONTROL; REWARD; REINFORCEMENT; RATS; MOTIVATION;
   FRAMEWORK
AB Based on the dopamine hypotheses of cocaine addiction and the assumption of decrement of brain reward system sensitivity after long-term drug exposure, we propose a computational model for cocaine addiction. Utilizing average reward temporal difference reinforcement learning, we incorporate the elevation of basal reward threshold after long-term drug exposure into the model of drug addiction proposed by Redish. Our model is consistent with the animal models of drug seeking under punishment. In the case of nondrug reward, the model explains increased impulsivity after long-term drug exposure. Furthermore, the existence of a blocking effect for cocaine is predicted by our model.
C1 [Dezfouli, Amir; Piray, Payam; Lucas, Caro] Univ Tehran, Control & Intelligent Proc Ctr Excellence, Sch Elect & Comp Engn, Tehran, Iran.
   [Keramati, Mohammad Mahdi] Sharif Univ Technol, Sch Management & Econ, Tehran, Iran.
   [Ekhtiari, Hamed] Iranian Natl Ctr Addict Studies, Neurocognit Lab, Tehran, Iran.
   [Mokri, Azarakhsh] Iranian Natl Ctr Addict Studies, Dept Clin Sci, Tehran, Iran.
   [Mokri, Azarakhsh] Univ Tehran Med Sci, Dept Psychiat, Tehran, Iran.
C3 University of Tehran; Sharif University of Technology; Tehran University
   of Medical Sciences
RP Dezfouli, A (通讯作者)，Univ Tehran, Control & Intelligent Proc Ctr Excellence, Sch Elect & Comp Engn, Tehran, Iran.
EM a.dezfouli@ut.ac.ir; piray@ut.ac.ir; mm_keramati@gsme.sharif.edu;
   h_ekhtiari@razi.tums.ac.ir; lucas@ut.ac.ir; mokriazr@sina.tums.ac.ir
RI Ekhtiari, Hamed/L-3639-2013; Piray, Payam/F-6620-2013
OI Ekhtiari, Hamed/0000-0001-6902-8798; Piray, Payam/0000-0002-8100-6628
CR Ahmed SH, 2005, PSYCHOPHARMACOLOGY, V180, P473, DOI 10.1007/s00213-005-2180-z
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Ahmed SH, 1999, PSYCHOPHARMACOLOGY, V146, P303, DOI 10.1007/s002130051121
   Ahmed SH, 2004, SCIENCE, V306, P1901, DOI 10.1126/science.1107071
   American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th
   Aragona BJ, 2008, J NEUROSCI, V28, P8821, DOI 10.1523/JNEUROSCI.2225-08.2008
   Chen R, 2006, P NATL ACAD SCI USA, V103, P9333, DOI 10.1073/pnas.0600905103
   Daruna J. H., 1993, IMPULSIVE CLIENT THE, P23, DOI [DOI 10.1037/10500-002, 10.1037/10500-002]
   Das TK, 1999, MANAGE SCI, V45, P560, DOI 10.1287/mnsc.45.4.560
   Daw N., 2003, THESIS CARNEGIE MELL
   Daw ND, 2006, NATURE, V441, P876, DOI 10.1038/nature04766
   Daw ND, 2006, CURR OPIN NEUROBIOL, V16, P199, DOI 10.1016/j.conb.2006.03.006
   Daw ND, 2005, NAT NEUROSCI, V8, P1704, DOI 10.1038/nn1560
   Daw ND, 2002, NEURAL COMPUT, V14, P2567, DOI 10.1162/089976602760407973
   Daw ND, 2002, NEURAL NETWORKS, V15, P603, DOI 10.1016/S0893-6080(02)00052-7
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Doya K, 1999, NEURAL NETWORKS, V12, P961, DOI 10.1016/S0893-6080(99)00046-5
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Garavan H, 2000, AM J PSYCHIAT, V157, P1789, DOI 10.1176/appi.ajp.157.11.1789
   Goldstein RZ, 2007, AM J PSYCHIAT, V164, P43, DOI 10.1176/appi.ajp.164.1.43
   Grace AA, 2000, ADDICTION, V95, pS119
   GRACE AA, 1995, DRUG ALCOHOL DEPEN, V37, P111, DOI 10.1016/0376-8716(94)01066-T
   Gutkin BS, 2006, P NATL ACAD SCI USA, V103, P1106, DOI 10.1073/pnas.0510220103
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kamin L.J., 1969, PUNISHMENT AVERSIVE, P279, DOI DOI 10.2105/AJPH.2006.090910
   Kauer JA, 2007, NAT REV NEUROSCI, V8, P844, DOI 10.1038/nrn2234
   Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442
   LOGUE AW, 1992, PSYCHOPHARMACOLOGY, V109, P245, DOI 10.1007/BF02245509
   Mahadevan S, 1996, MACH LEARN, V22, P159, DOI 10.1007/BF00114727
   Mantsch JR, 2001, PSYCHOPHARMACOLOGY, V157, P31, DOI 10.1007/s002130100744
   Mateo Y, 2005, NEUROPSYCHOPHARMACOL, V30, P1455, DOI 10.1038/sj.npp.1300687
   Melo FS, 2007, LECT NOTES COMPUT SC, V4539, P308, DOI 10.1007/978-3-540-72927-3_23
   Montague PR, 1996, J NEUROSCI, V16, P1936, DOI 10.1523/jneurosci.16-05-01936.1996
   Morris G, 2006, NAT NEUROSCI, V9, P1057, DOI 10.1038/nn1743
   Nader MA, 2006, NAT NEUROSCI, V9, P1050, DOI 10.1038/nn1737
   Niv Y, 2007, PSYCHOPHARMACOLOGY, V191, P507, DOI 10.1007/s00213-006-0502-4
   Norman AB, 2006, BRAIN RES, V1116, P143, DOI 10.1016/j.brainres.2006.07.092
   Paine TA, 2003, BEHAV BRAIN RES, V147, P135, DOI 10.1016/S0166-4328(03)00156-6
   Panlilio LV, 2007, PHARMACOL BIOCHEM BE, V86, P774, DOI 10.1016/j.pbb.2007.03.005
   Paterson NE, 2003, NEUROREPORT, V14, P2229, DOI 10.1097/00001756-200312020-00019
   Pelloux Y, 2007, PSYCHOPHARMACOLOGY, V194, P127, DOI 10.1007/s00213-007-0805-0
   Rangel A, 2008, NAT REV NEUROSCI, V9, P545, DOI 10.1038/nrn2357
   Redish AD, 2008, BEHAV BRAIN SCI, V31, P415, DOI 10.1017/S0140525X0800472X
   Redish AD, 2007, PSYCHOL REV, V114, P784, DOI 10.1037/0033-295X.114.3.784
   Redish AD, 2004, SCIENCE, V306, P1944, DOI 10.1126/science.1102384
   Roesch MR, 2007, NAT NEUROSCI, V10, P1615, DOI 10.1038/nn2013
   Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593
   Simon NW, 2007, BEHAV NEUROSCI, V121, P543, DOI 10.1037/0735-7044.121.3.543
   Stuber GD, 2005, NEURON, V46, P661, DOI 10.1016/j.neuron.2005.04.036
   Sutton R. S., 1998, REINFORCEMENT LEARNI
   Tilley MR, 2009, NEUROREPORT, V20, P9, DOI 10.1097/WNR.0b013e32831b9ce4
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Volkow ND, 2004, MOL PSYCHIATR, V9, P557, DOI 10.1038/sj.mp.4001507
   Volkow ND, 1997, NATURE, V386, P830, DOI 10.1038/386830a0
   Volkow ND, 2007, ARCH NEUROL-CHICAGO, V64, P1575, DOI 10.1001/archneur.64.11.1575
   Watkins, 1989, THESIS KINGS COLL CA
NR 57
TC 32
Z9 33
U1 3
U2 17
PU MIT PRESS
PI CAMBRIDGE
PA ONE ROGERS ST, CAMBRIDGE, MA 02142-1209 USA
SN 0899-7667
EI 1530-888X
J9 NEURAL COMPUT
JI Neural Comput.
PD OCT
PY 2009
VL 21
IS 10
BP 2869
EP 2893
DI 10.1162/neco.2009.10-08-882
PG 25
WC Computer Science, Artificial Intelligence; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Neurosciences & Neurology
GA 494RN
UT WOS:000269833200006
PM 19635010
DA 2023-06-23
ER

PT J
AU Pickard, H
AF Pickard, Hanna
TI What We're Not Talking about When We Talk about Addiction
SO HASTINGS CENTER REPORT
LA English
DT Article
DE addiction; disease; choice; compulsion; moralism; value
ID BRAIN DISEASE; COCAINE; SENSITIZATION; ALCOHOL; HISTORY; MARKER
AB The landscape of addiction is dominated by two rival models: a moral model and a model that characterizes addiction as a neurobiological disease of compulsion. Against both, I offer a scientifically and clinically informed alternative. Addiction is a highly heterogenous condition that is ill-characterized as involving compulsive use. On the whole, drug consumption in addiction remains goal directed: people take drugs because drugs have tremendous value. This view has potential implications for the claim that addiction is, in all cases, a brain disease. But more importantly, it has implications for clinical and policy interventions. To help someone overcome addiction, you need to understand and address why they persist in using drugs despite negative consequences. If they are not compelled, then the explanation must advert to the value of drugs for them as an individual. What blocks us from acknowledging this reality is not science but fear: that it will ignite moralism about drugs and condemnation of drug users. The solution is not to cleave to the concept of compulsion but to fight moralism directly.
C1 [Pickard, Hanna] Johns Hopkins Univ, Philosophy & Bioeth, Baltimore, MD 21218 USA.
C3 Johns Hopkins University
RP Pickard, H (通讯作者)，Johns Hopkins Univ, Philosophy & Bioeth, Baltimore, MD 21218 USA.
OI Pickard, Hanna/0000-0001-5926-1377
CR Ahmed SH, 2020, NEUROSCI BIOBEHAV R, V110, P3, DOI 10.1016/j.neubiorev.2018.08.015
   Ahmed SH, 2013, CURR OPIN NEUROBIOL, V23, P581, DOI 10.1016/j.conb.2013.01.028
   Ainslie G, 2000, LAW PHILOS, V19, P77
   Ainslie G., 2018, PHILOS SCI ADDICTION, P22
   American Psychiatric Association [APA], 2022, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425787]
   [Anonymous], 2015, ADD IS DIS FREE WILL
   Bartlett E, 1997, NEUROPSYCHOPHARMACOL, V16, P77, DOI 10.1016/S0893-133X(96)00164-9
   Becker Howard S., 1963, OUTSIDERS STUDIES SO
   Belser AB, 2017, J HUMANIST PSYCHOL, V57, P354, DOI 10.1177/0022167817706884
   Bickel WK, 2014, NEUROPHARMACOLOGY, V76, P518, DOI 10.1016/j.neuropharm.2013.06.013
   BOORSE C, 1977, PHILOS SCI, V44, P542, DOI 10.1086/288768
   Bornstein AM, 2020, NEUROPSYCHOPHARMACOL, V45, P907, DOI 10.1038/s41386-019-0594-2
   Bornstein and Pickard, CHASING 1 HIGH
   Compton, PREVALENCE CORRELATE
   Compton WM, 2007, ARCH GEN PSYCHIAT, V64, P566, DOI 10.1001/archpsyc.64.5.566
   Courtwright, NIDA BRAIN DIS PAR
   Courtwright DT, 2010, BIOSOCIETIES, V5, P137, DOI 10.1057/biosoc.2009.3
   DOLE VP, 1965, J AMER MED ASSOC, V193, P646, DOI 10.1001/jama.1965.03090080008002
   Epstein DH, TRANSLATIONAL NEUROS
   Everitt BJ, 2016, ANNU REV PSYCHOL, V67, P23, DOI 10.1146/annurev-psych-122414-033457
   Girardeau P, 2019, NEUROPHARMACOLOGY, V155, P185, DOI 10.1016/j.neuropharm.2019.05.036
   Hart CL, 2000, BEHAV PHARMACOL, V11, P87, DOI 10.1097/00008877-200002000-00010
   Hart CL., 2018, PHILOS SCI ADDICTION, P511
   Hawken A., 2009, MANAGING DRUG INVOLV, P233
   Heilig Epstein and Shaham, TIME CONNECT
   Heilig M, 2016, NAT REV NEUROSCI, V17, P592, DOI 10.1038/nrn.2016.67
   Heyman, ADDICTION
   Heyman, ADDICTION
   Heyman Gene M., 2009, ADDICTION DISORDER C, DOI [10.4159/9780674053991, DOI 10.4159/9780674053991]
   Hogarth L, 2018, PSYCHOL HABIT, P325, DOI [10.1007/978-3-319-97529-0_18, DOI 10.1007/978-3-319-97529-0_18]
   Holton and Berridge, ADDICTION COMPULSION
   Holton R, 2013, ADDICTION SELF CONTR, P239, DOI [10.1093/acprof:oso/9780199862580.003.0012, DOI 10.1093/ACPROF:OSO/9780199862580.003.0012]
   Husak Douglas, 2002, LEGALIZE THIS CASE D
   James W., 1890, PRINCIPLES PSYCHOL, P543
   Leshner, ADDICTION IS BRAIN D
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Mate, REALM HUNGRY GHOSTS
   McGinty EE, 2018, PREV MED, V111, P73, DOI 10.1016/j.ypmed.2018.02.026
   Mehta S, 1997, J SOC CLIN PSYCHOL, V16, P405, DOI 10.1521/jscp.1997.16.4.405
   Muller and Schumann, DRUGS INSTR
   Muller C., 2011, BEHAV BRAIN SCI, V34
   National Institute on Drug Abuse, 2017, TRENDS STAT
   Nutt D., 2012, DRUGS HOT AIR
   Peele S., 1975, LOVE AND ADDICTION
   Perscosolido, 2015, CURRENT DIRECTIONS P, V24, P399
   Pescosolido BA, 2010, AM J PSYCHIAT, V167, P1321, DOI 10.1176/appi.ajp.2010.09121743
   Pickard, ADDICTION SELF
   Pickard, RESPONSIBILITY BLAME
   Pickard and Pearce, ADDICTION CONTEXT
   Pickard H., 2013, ADDICTION SELF CONTR, P165
   Pickard H, 2018, PHILOS SCI ADDICTION, P29
   Pickard H, 2021, NOUS, V55, P737, DOI 10.1111/nous.12328
   Pickard H, 2017, NEUROETHICS-NETH, V10, P169, DOI 10.1007/s12152-016-9295-2
   Pickard H, 2016, MIND LANG, V31, P277, DOI 10.1111/mila.12106
   Pickard Hanna, 2012, AJOB Neurosci, V3, P40
   Preston KL, 2009, PSYCHOPHARMACOLOGY, V207, P291, DOI 10.1007/s00213-009-1655-8
   Reed SC, 2009, DRUG ALCOHOL DEPEN, V102, P102, DOI 10.1016/j.drugalcdep.2009.02.004
   Regier, COMORBIDITY MENTAL D
   Robinson and Berridge, NEURAL BASIS DRUG CR
   Robinson MJF, 2018, PHILOS SCI ADDICTION, P351
   Robinson Robinson and Berridge, CURRENT STATUS INCEN
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Serre F, 2015, DRUG ALCOHOL DEPEN, V148, P1, DOI 10.1016/j.drugalcdep.2014.12.024
   Shenhav A, 2013, NEURON, V79, P217, DOI 10.1016/j.neuron.2013.07.007
   Silverman Kenneth, 2016, Transl Issues Psychol Sci, V2, P203
   Sinha R, 2006, ARCH GEN PSYCHIAT, V63, P324, DOI 10.1001/archpsyc.63.3.324
   Small AC, 2009, SUBST USE MISUSE, V44, P1888, DOI 10.3109/10826080902961179
   Sripada C, 2018, J PHILOS, V115, P569, DOI 10.5840/jphil20181151133
   Substance Abuse and Mental Health Services Administration, 2020, 2018 NAT SURV DRUG U
   Tiffany ST, 1998, J PSYCHOPHARMACOL, V12, P23, DOI 10.1177/026988119801200104
   U. S. Department of Health and Human Services; National Institutes of Health & National Institute of Drug Abuse, 2009, PRINC DRUG ADD TREAT
   Venniro M, 2018, NAT NEUROSCI, V21, P1520, DOI 10.1038/s41593-018-0246-6
   Verdejo-Garcia A, 2018, PHILOS SCI ADDICTION, P339, DOI DOI 10.4324/9781315689197-28
   Volkow Koob and McLellan, NEUROBIOLOGIC ADV BR
   Wachtel SR, 1999, BEHAV PHARMACOL, V10, P271, DOI 10.1097/00008877-199905000-00004
   Waldorf D, 1992, COCAINE CHANGES EXPE
   WHO, 2004, NEUR PSYCH SUBST US
   Zajac Alessi and Petry, CONTINGENCY MANAGEME
   Zajac K, 2018, PHILOS SCI ADDICTION, P455
   Zinberg, DRUG SET AND SETTING
   ZINBERG NE, 1976, AM J PSYCHIAT, V133, P37
   Zinberg NE., 1984, DRUG SET SETTING BAS
NR 82
TC 11
Z9 11
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0093-0334
EI 1552-146X
J9 HASTINGS CENT REP
JI Hastings Cent. Rep.
PD JUL
PY 2020
VL 50
IS 4
BP 37
EP 46
DI 10.1002/hast.1172
PG 10
WC Ethics; Health Care Sciences & Services; Medical Ethics; Social
   Sciences, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Social Sciences - Other Topics; Health Care Sciences & Services; Medical
   Ethics; Biomedical Social Sciences
GA NG3JM
UT WOS:000563881900011
PM 33448417
DA 2023-06-23
ER

PT J
AU Muller, CP
AF Mueller, Christian P.
TI Animal models of psychoactive drug use and addiction - Present problems
   and future needs for translational approaches
SO BEHAVIOURAL BRAIN RESEARCH
LA English
DT Article
DE Drug instrumentalization; Addiction; Animal models; Theories of
   addiction; Translational gap
ID BRAIN DISEASE-MODEL; CONDITIONED PLACE PREFERENCE; ALCOHOL DEPENDENCE;
   SELF-MEDICATION; RODENT MODELS; COCAINE; REWARD; MEMORY; MECHANISMS;
   DRINKING
AB Drug addiction is a psychiatric disorder based on a dysfunction of the brain. It frequently develops from a controlled drug consumption and drug instrumentalization (DI). Thereby, DI is the use of a drug to improve specific non-drug related behaviors, beyond the drug's direct positive or negative reinforcing effects. Currently available pharmacotherapies for drug addiction show low effect size and rather limited long-term efficacy, which suggests that current theories on addiction are still insufficient in how they capture the phenomenon and how they allow predictions for highly efficient treatments. This opinion review attempts a critical analysis of some aspects of current addiction neuroscience using animal models. As a result, (1) animal models that cover previously neglected types of drug memories in controlled drug use are suggested. (2) Animal models for drug instrumentalization are warranted. Animal models of drug addiction should consider that addiction develops predominantly in individuals with mental and/or environmental challenges. It is suggested (3) to preferentially use animal models with similar mental and environmental challenges to model the transition of controlled to compulsive drug use. (4) Animal models should in the future also capture the important aspect of the motivation to self-medicate in order to ameliorate a negative emotional/physical state. Potential pharmaco-treatments of addiction, in order to later achieve compliance in humans, should be tested for their systemic self-administration in order to self-medicate a drug-induced aversive state. This may allow a better understanding of the fundamental differences between an organism that shows controlled psychoactive drug consumption as an integral part of a 'normal' behavioral repertoire and one in a pathological condition with compulsive drug abuse.
C1 [Mueller, Christian P.] Friedrich Alexander Univ Erlangen Nuremberg, Sect Addict Med, Dept Psychiat & Psychotherapy, Univ Clin, Schwabachanlage 6, D-91054 Erlangen, Germany.
C3 University of Erlangen Nuremberg
RP Muller, CP (通讯作者)，Friedrich Alexander Univ Erlangen Nuremberg, Sect Addict Med, Dept Psychiat & Psychotherapy, Univ Clin, Schwabachanlage 6, D-91054 Erlangen, Germany.
EM Christian.Mueller@uk-erlangen.de
FU DFG [MU 2789/8-1]; Interdisciplinary Center for Clinical Research (IZKF)
   Erlangen, Project E22
FX This work was supported by funding from DFG grant MU 2789/8-1 and by
   funding from the Interdisciplinary Center for Clinical Research (IZKF)
   Erlangen, Project E22.
CR Abel EL., 1980, MARIHUANA 1 12000 YE
   Ahmed SH, 2012, NEUROSCIENCE, V211, P107, DOI 10.1016/j.neuroscience.2011.08.014
   Ahmed SH, 2010, NEUROSCI BIOBEHAV R, V35, P172, DOI 10.1016/j.neubiorev.2010.04.005
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   [Anonymous], EATING WILD SIDE PHA
   [Anonymous], 2000, DRINK OCC COMP PERSP
   Bardo MT, 2000, PSYCHOPHARMACOLOGY, V153, P31, DOI 10.1007/s002130000569
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   Belin D, 2009, BEHAV BRAIN RES, V199, P89, DOI 10.1016/j.bbr.2008.09.027
   Bierut LJ, 1998, ARCH GEN PSYCHIAT, V55, P982, DOI 10.1001/archpsyc.55.11.982
   Blomeyer D, 2008, BIOL PSYCHIAT, V63, P146, DOI 10.1016/j.biopsych.2007.04.026
   Boyd CJ, 2009, J ADDICT DIS, V28, P232, DOI 10.1080/10550880903028452
   Boyer EW, 2007, AM J ADDICTION, V16, DOI 10.1080/10550490701525368
   Boys A, 2003, ADDICTION, V98, P951, DOI 10.1046/j.1360-0443.2003.00394.x
   Bradizza CM, 1999, J STUD ALCOHOL, V60, P491, DOI 10.15288/jsa.1999.60.491
   Brand R, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01226
   Callahan PM, 1997, NEUROPHARMACOLOGY, V36, P373, DOI 10.1016/S0028-3908(97)00010-5
   Carey RJ, 2008, PROG BRAIN RES, V172, P347, DOI 10.1016/S0079-6123(08)00917-5
   Chen CY, 2004, PSYCHOPHARMACOLOGY, V172, P78, DOI 10.1007/s00213-003-1624-6
   Clarke TK, 2008, ADDICT BIOL, V13, P1, DOI 10.1111/j.1369-1600.2007.00084.x
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Dong L, 2011, AM J PSYCHIAT, V168, P1090, DOI 10.1176/appi.ajp.2011.10111579
   Dudley R, 2002, ADDICTION, V97, P381, DOI 10.1046/j.1360-0443.2002.00002.x
   EMCDDA, 2016, EUR DRUG REP 2016 TR
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Gable RS, 2004, ADDICTION, V99, P686, DOI 10.1111/j.1360-0443.2004.00744.x
   Hall W, 2015, LANCET PSYCHIAT, V2, P105, DOI 10.1016/S2215-0366(14)00126-6
   Harper C, 2007, HUM EXP TOXICOL, V26, P251, DOI 10.1177/0960327107070499
   Heilig M, 2007, TRENDS NEUROSCI, V30, P399, DOI 10.1016/j.tins.2007.06.006
   Heyman G. M., 1996, RESOLVING CONTRADICT, P561
   Higgins GA, 2012, NEUROPSYCHOPHARMACOL, V37, P1177, DOI 10.1038/npp.2011.303
   Hopf FW, 2014, ALCOHOL, V48, P253, DOI 10.1016/j.alcohol.2014.03.001
   Huffman MA, 2003, P NUTR SOC, V62, P371, DOI 10.1079/PNS2003257
   Huston JP, 2013, TRENDS PHARMACOL SCI, V34, P162, DOI 10.1016/j.tips.2013.01.004
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Johnson BA, 2008, BIOCHEM PHARMACOL, V75, P34, DOI 10.1016/j.bcp.2007.08.005
   Karch, 2017, SAGE HDB DRUGS ALCOH, P411
   Kelley AE, 2004, NEURON, V44, P161, DOI 10.1016/j.neuron.2004.09.016
   Koob GF, 2016, ANNU REV PHARMACOL, V56, P299, DOI 10.1146/annurev-pharmtox-010715-103143
   Koob GF, 2004, NEUROSCI BIOBEHAV R, V27, P739, DOI 10.1016/j.neubiorev.2003.11.007
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7
   Koukouli F, 2017, NAT MED, V23, P347, DOI 10.1038/nm.4274
   Kuntsche E, 2005, CLIN PSYCHOL REV, V25, P841, DOI 10.1016/j.cpr.2005.06.002
   Le Foll B, 2006, PSYCHOPHARMACOLOGY, V184, P367, DOI 10.1007/s00213-005-0155-8
   Lee JLC, 2005, NEURON, V47, P795, DOI 10.1016/j.neuron.2005.08.007
   Lende DH, 2007, ADDICT RES THEORY, V15, P465, DOI 10.1080/16066350701284552
   Lenz B, 2017, ACTA PSYCHIAT SCAND, V136, P96, DOI 10.1111/acps.12725
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Lesscher HMB, 2010, ALCOHOL CLIN EXP RES, V34, P1219, DOI 10.1111/j.1530-0277.2010.01199.x
   Lisonbee LD, 2009, BEHAV PROCESS, V82, P184, DOI 10.1016/j.beproc.2009.06.009
   Litten RZ, 2012, ADDICT BIOL, V17, P513, DOI 10.1111/j.1369-1600.2012.00454.x
   Lozano GA, 1998, ADV STUD BEHAV, V27, P291
   McCreary AC, 2015, INT REV NEUROBIOL, V120, P41, DOI 10.1016/bs.irn.2015.02.008
   MELLO NK, 1972, BIOL ALCOHOL, P210
   Meyer PJ, 2012, PSYCHOPHARMACOLOGY, V219, P999, DOI 10.1007/s00213-011-2429-7
   Mielenz D, 2018, MOL PSYCHIATR, V23, P1303, DOI 10.1038/mp.2017.63
   Miller PM, 2011, INT J PSYCHIAT MED, V42, P227, DOI 10.2190/PM.42.3.b
   Milton AL, 2010, EUR J NEUROSCI, V31, P2308, DOI 10.1111/j.1460-9568.2010.07249.x
   Muller CP, 2017, TRENDS PHARMACOL SCI, V38, P501, DOI 10.1016/j.tips.2017.03.005
   Muller CP, 2017, ACTA NEUROPATHOL, V133, P463, DOI 10.1007/s00401-016-1658-6
   Muller CP, 2015, BEHAV BRAIN RES, V277, P146, DOI 10.1016/j.bbr.2014.04.007
   Muller CP, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00034
   Muller CP, 2011, BEHAV BRAIN SCI, V34, P328, DOI 10.1017/S0140525X1100135X
   Muller CP, 2011, BEHAV BRAIN SCI, V34, P293, DOI 10.1017/S0140525X11000057
   Muller CP, 2006, TRENDS PHARMACOL SCI, V27, P105, DOI 10.1016/j.tips.2005.12.003
   Muller CP, 2002, BEHAV BRAIN RES, V134, P337, DOI 10.1016/S0166-4328(02)00042-6
   NATHANSON JA, 1993, P NATL ACAD SCI USA, V90, P9645, DOI 10.1073/pnas.90.20.9645
   Nestler EJ, 2002, NEUROBIOL LEARN MEM, V78, P637, DOI 10.1006/nlme.2002.4084
   Olmstead MC, 2006, Q J EXP PSYCHOL, V59, P625, DOI 10.1080/17470210500356308
   PAGE JE, 1992, PHYTOCHEMISTRY, V31, P3437, DOI 10.1016/0031-9422(92)83702-Z
   Patrick ME, 2008, J ADOLESCENCE, V31, P307, DOI 10.1016/j.adolescence.2007.06.002
   PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295
   Prus A. J., 2009, METHODS BEHAV ANAL N
   Rehm J, 2009, LANCET, V373, P2223, DOI 10.1016/S0140-6736(09)60746-7
   Ripley TL, 2011, BRIT J PHARMACOL, V164, P1335, DOI 10.1111/j.1476-5381.2011.01406.x
   Robbins TW, 2008, ANN NY ACAD SCI, V1141, P1, DOI 10.1196/annals.1441.020
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   ROBLES M, 1995, PLANTA MED, V61, P199, DOI 10.1055/s-2006-958055
   RODRIGUEZ E, 1985, EXPERIENTIA, V41, P419, DOI 10.1007/BF02004537
   RODRIGUEZ E, 1993, RECENT ADV PHYTOCHEM, V27, P89
   SAMHSA, 2015, NAT SURV DRUG US HLT
   Sanchis-Segura C, 2006, ADDICT BIOL, V11, P2, DOI 10.1111/j.1369-1600.2006.00012.x
   Schuckit MA, 2007, J STUD ALCOHOL DRUGS, V68, P805, DOI 10.15288/jsad.2007.68.805
   Seif T, 2013, NAT NEUROSCI, V16, P1094, DOI 10.1038/nn.3445
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   Spanagel R, 2008, TRENDS PHARMACOL SCI, V29, P109, DOI 10.1016/j.tips.2007.12.005
   Spanagel R, 2009, PHYSIOL REV, V89, P649, DOI 10.1152/physrev.00013.2008
   SPEALMAN RD, 1978, ANNU REV PHARMACOL, V18, P313, DOI 10.1146/annurev.pa.18.040178.001525
   Streatfeild D., 2001, COCAINE UNAUTHORIZED
   Sullivan RJ, 2008, P ROY SOC B-BIOL SCI, V275, P1231, DOI 10.1098/rspb.2007.1673
   Tzschentke TM, 2007, ADDICT BIOL, V12, P227, DOI 10.1111/j.1369-1600.2007.00070.x
   van den Brink W, 2014, J PSYCHOPHARMACOL, V28, P733, DOI 10.1177/0269881114527362
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Vargo EJ, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00779
   Villalba JJ, 2010, J ANIM SCI, V88, P2189, DOI 10.2527/jas.2009-2272
   Volkow ND, 2016, NEW ENGL J MED, V374, P363, DOI 10.1056/NEJMra1511480
   Volkow ND, 2015, CELL, V162, P712, DOI 10.1016/j.cell.2015.07.046
   Volkow ND, 2015, LANCET PSYCHIAT, V2, P677, DOI 10.1016/S2215-0366(15)00236-9
   Wagner FA, 2002, NEUROPSYCHOPHARMACOL, V26, P479, DOI 10.1016/S0893-133X(01)00367-0
   Waldorf D., 1991, COCAINE CHANGES EXPE
   Weinshenker D, 2007, NEUROPSYCHOPHARMACOL, V32, P1433, DOI 10.1038/sj.npp.1301263
   Wells BE, 2010, AM J DRUG ALCOHOL AB, V36, P39, DOI 10.3109/00952990903544836
   White NM, 1996, ADDICTION, V91, P921, DOI 10.1111/j.1360-0443.1996.tb03586.x
   Whiteford HA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116820
   Whiteford HA, 2013, LANCET, V382, P1575, DOI 10.1016/S0140-6736(13)61611-6
   Wiegel C, 2016, ANXIETY STRESS COPIN, V29, P100, DOI 10.1080/10615806.2015.1025764
   Wise RA, 2002, NEURON, V36, P229, DOI 10.1016/S0896-6273(02)00965-0
   Wittchen HU, 2011, EUR NEUROPSYCHOPHARM, V21, P655, DOI 10.1016/j.euroneuro.2011.07.018
   WRANGHAM R W, 1983, Primates, V24, P276, DOI 10.1007/BF02381090
   Yardley MM, 2017, ADDICT BIOL, V22, P581, DOI 10.1111/adb.12349
   Zuckerman M, 1996, NEUROPSYCHOBIOLOGY, V34, P125, DOI 10.1159/000119303
NR 112
TC 29
Z9 31
U1 4
U2 36
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-4328
EI 1872-7549
J9 BEHAV BRAIN RES
JI Behav. Brain Res.
PD OCT 15
PY 2018
VL 352
SI SI
BP 109
EP 115
DI 10.1016/j.bbr.2017.06.028
PG 7
WC Behavioral Sciences; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Behavioral Sciences; Neurosciences & Neurology
GA GR8MB
UT WOS:000442976900013
PM 28641965
DA 2023-06-23
ER

PT J
AU Saitz, R
AF Saitz, Richard
TI Treatment of alcohol and other drug dependence
SO LIVER TRANSPLANTATION
LA English
DT Article
ID OFFICE-BASED TREATMENT; EFFICACY
AB Addiction (e.g., alcohol or drugs) is a chronic disease. Specific behavioral and pharmacological treatments have proven efficacy.
   Addressing addiction includes intervention for risky and problem use.
   Clinicians who are not addiction specialists can play important roles in addressing addiction.
C1 Boston Univ, Med Ctr, Youth Alcohol Prevent Ctr, Dept Med,Clin Addict Res & Educ Unit,Sect Gen I, Boston, MA 02118 USA.
   Boston Univ, Med Ctr, Youth Alcohol Prevent Ctr, Dept Epidemiol,Clin Addict Res & Educ Unit, Boston, MA 02118 USA.
C3 Boston University; Boston University
RP Saitz, R (通讯作者)，Boston Univ, Med Ctr, Youth Alcohol Prevent Ctr, Dept Med,Clin Addict Res & Educ Unit,Sect Gen I, 91 E Concord St 200, Boston, MA 02118 USA.
EM rsaitz@bu.edu
OI /0000-0002-2535-1427
CR Anton RF, 2006, JAMA-J AM MED ASSOC, V295, P2003, DOI 10.1001/jama.295.17.2003
   BALL JC, 1991, EFFECTIVENESS METHAD
   Berg AO, 2004, ANN INTERN MED, V140, P554, DOI 10.7326/0003-4819-140-7-200404060-00016
   Bernstein J, 2005, DRUG ALCOHOL DEPEN, V77, P49, DOI 10.1016/j.drugalcdep.2004.07.006
   Carmen B, 2004, ADDICTION, V99, P811, DOI 10.1111/j.1360-0443.2004.00763.x
   DOLE VP, 1965, JAMA-J AM MED ASSOC, V193, P80
   Fiellin DA, 2004, J SUBST ABUSE TREAT, V27, P153, DOI 10.1016/j.jsat.2004.06.005
   Fiellin DA, 2002, NEW ENGL J MED, V347, P817, DOI 10.1056/NEJMcp013579
   Fiellin DA, 2002, ANN INTERN MED, V137, P688, DOI 10.7326/0003-4819-137-8-200210150-00014
   Friedmann PD, 1998, JAMA-J AM MED ASSOC, V279, P1227, DOI 10.1001/jama.279.15.1227
   Garbutt JC, 2005, JAMA-J AM MED ASSOC, V293, P1617, DOI 10.1001/jama.293.13.1617
   Kaner EFS, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004148.pub3, 10.1002/14651858.CD004148.pub4]
   McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689
   MCLELLAN AT, 2002, ADDICTION, V88, P106
   Miller WR, 2001, J STUD ALCOHOL, V62, P211, DOI 10.15288/jsa.2001.62.211
   *NAT I DRUG AB, 1999, NIH PUBL
   O'Connor PG, 2000, ANN INTERN MED, V133, P40, DOI 10.7326/0003-4819-133-1-200007040-00008
   Saitz R, 2005, NEW ENGL J MED, V352, P596, DOI 10.1056/NEJMcp042262
NR 18
TC 8
Z9 9
U1 1
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD NOV
PY 2007
VL 13
IS 11
SU 2
BP S59
EP S64
DI 10.1002/lt.21339
PG 6
WC Gastroenterology & Hepatology; Surgery; Transplantation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 230ZD
UT WOS:000250914400011
PM 17969089
DA 2023-06-23
ER

PT J
AU Horseman, C
   Meyer, A
AF Horseman, Casia
   Meyer, Avery
TI Neurobiology of Addiction
SO CLINICAL OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE human behavior; compulsion; negative affect; neurobiology
AB Drugs of abuse can cause changes in the brain leading to addiction. Current scientific focus has been on how these drugs interact with the brain and the changes they cause, how those changes affect human behavior and how they may last beyond termination of drug use. Compulsiveness in seeking the drug, impulsiveness in consuming the drug, and negative affect when the drug is withheld are characteristic of addiction. Each of these characteristics has a root in neurobiology and understanding their mechanisms helps us to understand addiction and see potential targets for treatment.
C1 [Horseman, Casia; Meyer, Avery] Ohio State Univ, Dept Psychiat & Behav Hlth, Columbus, OH 43210 USA.
C3 University System of Ohio; Ohio State University
RP Horseman, C (通讯作者)，1670 Upham Dr, Columbus, OH 43210 USA.
EM casia.horseman@osumc.edu
OI Meyer, Avery/0000-0002-9015-1309
CR American Psychiatric Association [APA], 2022, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425787]
   Begun A, 2014, CLIN WORK SUBSTANCE, P39
   Beveridge TJR, 2014, ASAM PRINCIPLES ADDI, P36
   Goodman A, 2008, BIOCHEM PHARMACOL, V75, P266, DOI 10.1016/j.bcp.2007.07.030
   Gorelick DA, 2014, ASAM PRINCIPLES ADDI, P151
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   National Institute on Drug Abuse (NIDA), 2016, MED GUID
   Simkin DR, 2014, ASAM PRINCIPLES ADDI, P1580
   Tetrault J, 2014, ASAM PRINCIPLES ADDI, P668
   Volkow ND, 2014, PRINCIPLES ADDICTION, P3
NR 11
TC 5
Z9 6
U1 5
U2 30
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-9201
EI 1532-5520
J9 CLIN OBSTET GYNECOL
JI Clin. Obstet. Gynecol.
PD MAR
PY 2019
VL 62
IS 1
BP 118
EP 127
DI 10.1097/GRF.0000000000000416
PG 10
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology
GA HU6WB
UT WOS:000465421300013
PM 30628917
DA 2023-06-23
ER

PT J
AU Akindipe, T
   Abiodun, L
   Adebajo, S
   Lawal, R
   Rataemane, S
AF Akindipe, Taiwo
   Abiodun, Lolade
   Adebajo, Sylvia
   Lawal, Rahman
   Rataemane, Solomon
TI From Addiction to Infection: Managing Drug Abuse in the Context of
   HIV/AIDS in Africa
SO AFRICAN JOURNAL OF REPRODUCTIVE HEALTH
LA English
DT Review
DE Drug users; Drug addiction; Substance use; HIV infection; Africa
ID HIV DISEASE PROGRESSION; ANTIRETROVIRAL THERAPY; VIRAL SUPPRESSION;
   SUBSTANCE-ABUSE; CARE SERVICES; MORPHINE; USERS; ADHERENCE; HEALTH;
   COHORT
AB People who use drugs are at higher risk of HIV: directly through the sharing of injecting equipment, indirectly through associated risk behavior, and physiologically through the substances' impact on the immune system. Drug users, especially people who inject drugs (PWID) are a bridge to the general population. The treatment of drug addiction and provision of harm reduction interventions have impact on HIV transmission and incidence. Addiction treatment reduces the frequency of drug-related risky behaviors and enhances access and adherence to HIV treatment, resulting in fewer new infections. However, the drug policies of many African countries are punitive and hostile to harm reduction programs. These fuel criminalization of drug use and discrimination against the drug user thereby preventing individuals with drug addiction from accessing treatment programs. There is need to formulate policies aimed at protecting the rights of people with drug addiction and address the ethical aspects of treatment.
C1 [Akindipe, Taiwo; Lawal, Rahman] Fed Neuropsychiat Hosp Yaba, Drug Unit, Lagos, Nigeria.
   [Abiodun, Lolade; Adebajo, Sylvia] Populat Council, Abuja, Nigeria.
   [Rataemane, Solomon] Univ Limpopo MEDUNSA, Pretoria, South Africa.
C3 Sefako Makgatho Health Sciences University; University of Limpopo
RP Akindipe, T (通讯作者)，Fed Neuropsychiat Hosp Yaba, Drug Unit, Lagos, Nigeria.
EM taiwo.akindipe@gmail.com
CR Adinoff B, 2004, HARVARD REV PSYCHIAT, V12, P305, DOI 10.1080/10673220490910844
   Ansari AA, 2004, J NEUROIMMUNOL, V147, P9, DOI 10.1016/j.jneuroim.2003.10.006
   Antoniou T, 2002, ANN PHARMACOTHER, V36, P1598, DOI 10.1345/aph.1A447
   Arnsten JH, 2002, J GEN INTERN MED, V17, P377, DOI 10.1046/j.1525-1497.2002.10644.x
   Baum MK, 2009, JAIDS-J ACQ IMM DEF, V50, P93, DOI 10.1097/QAI.0b013e3181900129
   Calsyn DA, 2010, AM J ADDICTION, V19, P119, DOI 10.1111/j.1521-0391.2009.00022.x
   Chander G, 2009, AIDS CARE, V21, P655, DOI 10.1080/09540120802459762
   Comm Pediat AIDS, 2006, PEDIATRICS, V117, P566, DOI 10.1542/peds.2005-2750
   de Jong BC, 2005, JAIDS-J ACQ IMM DEF, V38, P43, DOI 10.1097/00126334-200501010-00008
   Degenhardt L, 2012, LANCET, V379, P55, DOI 10.1016/S0140-6736(11)61138-0
   Dewing S, 2006, DRUG-EDUC PREV POLIC, V13, P121, DOI 10.1080/09687630500480228
   Flexner CW, 2001, AIDS PATIENT CARE ST, V15, P57, DOI 10.1089/108729101300003636
   Gatch MB, 2013, NEUROPSYCHOPHARMACOL, V38, P2373, DOI 10.1038/npp.2013.135
   Glasel JA, 2000, PROG DRUG RES, V55, P33
   Goumon Y, 2002, ANN NY ACAD SCI, V971, P542, DOI 10.1111/j.1749-6632.2002.tb04523.x
   Grelotti DJ, 2014, AIDS BEHAV, V18, P511, DOI 10.1007/s10461-013-0575-0
   Grelotti DJ, 2013, LANCET INFECT DIS, V13, P10, DOI 10.1016/S1473-3099(12)70294-3
   Harm Reduction International, GLOB STAT HARM RED 2
   Harrington RD, 1999, ARCH INTERN MED, V159, P2221, DOI 10.1001/archinte.159.18.2221
   Henry JA, 1998, LANCET, V352, P1751, DOI 10.1016/S0140-6736(05)79824-X
   Hilton BA, 2001, J ADV NURS, V33, P357, DOI 10.1046/j.1365-2648.2001.01672.x
   IRIN, INJ DRUG US HIV TRAN
   Joint United Nations Programme on HIV/AIDS (UNAIDS), THE GAP REP 2014
   Kapadia F, 2005, CLIN INFECT DIS, V41, P1027, DOI 10.1086/433175
   Kim SG, 2013, J LEUKOCYTE BIOL, V94, P835, DOI 10.1189/jlb.1112566
   Kohli R, 2005, CLIN INFECT DIS, V41, P864, DOI 10.1086/432883
   Kosel BW, 2002, AIDS, V16, P543, DOI 10.1097/00002030-200203080-00005
   Krusi A, 2010, INT J DRUG POLICY, V21, P4, DOI 10.1016/j.drugpo.2009.08.003
   Larkan F, 2010, AFR SOCIOL REV, V14, P62
   McCarthy L, 2001, DRUG ALCOHOL DEPEN, V62, P111, DOI 10.1016/S0376-8716(00)00181-2
   McCurdy SA, 2010, ADDICTION, V105, P1062, DOI 10.1111/j.1360-0443.2010.02908.x
   Metzger DS, 2010, JAIDS-J ACQ IMM DEF, V55, pS32, DOI 10.1097/QAI.0b013e3181f9c10b
   Nair MPN, 2009, J NEUROIMMUNE PHARM, V4, P129, DOI 10.1007/s11481-008-9128-0
   Napuri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083682
   NARHS, NAT HIV AIDS REPR HL
   National Institute on Drug Abuse (NIDA), 2012, SCI DRUG AB ADD 2012
   Neale J, 2008, HEALTH SOC CARE COMM, V16, P147, DOI 10.1111/j.1365-2524.2007.00739.x
   Pechansky F, 2006, DRUG ALCOHOL DEPEN, V82, pS109, DOI 10.1016/S0376-8716(06)80017-7
   PETERSON PK, 1990, AIDS, V4, P869, DOI 10.1097/00002030-199009000-00006
   PRB, WORLD POP DAT SHEET
   Reid SR, 2009, HARM REDUCT J, V6, DOI 10.1186/1477-7517-6-24
   Roy S, 1996, NEUROCHEM RES, V21, P1375, DOI 10.1007/BF02532379
   Singhal PC, 1998, J IMMUNOL, V160, P1886
   Sohler NL, 2007, AIDS PATIENT CARE ST, V21, pS68, DOI 10.1089/apc.2007.9985
   Sorensen JL, 2000, DRUG ALCOHOL DEPEN, V59, P17, DOI 10.1016/S0376-8716(99)00104-0
   The International HIV/AIDS Alliance (IHAA), 2010, WHO AR VULN MOST AT
   Tucker JS, 2003, AM J MED, V114, P573, DOI 10.1016/S0002-9343(03)00093-7
   Ugen KE, 2006, SPRINGER SEMIN IMMUN, V28, P281, DOI 10.1007/s00281-006-0045-0
   UNAIDS, GUID EST SIZ POP MOS
   UNAIDS, GLOB REP UNAIDS REP
   UNODC (United Nations Office on Drugs and Crime), 2008, RED ADV HLTH SOC CON
   van Sighem AI, 2003, AIDS, V17, P2227, DOI 10.1097/00002030-200310170-00011
   Vittinghoff E, 2001, J ACQ IMMUN DEF SYND, V27, P308, DOI 10.1097/00126334-200107010-00015
   Wodak A, 2008, AIDS, V22, pS81, DOI 10.1097/01.aids.0000327439.20914.33
   Wolfe D, 2010, ADDICTION, V105, P1859, DOI 10.1111/j.1360-0443.2010.03114.x
NR 55
TC 3
Z9 4
U1 0
U2 5
PU WOMENS HEALTH & ACTION RESEARCH CENTRE
PI BENIN CITY
PA IGUE-IHEYA VILLAGE, BENIN-LAGOS EXPRESS RD, PO BOX 10231, UGBOWO, BENIN
   CITY, EDO STATE 00000, NIGERIA
SN 1118-4841
EI 2141-3606
J9 AFR J REPROD HEALTH
JI Afr. J. Reprod. Health
PD SEP
PY 2014
VL 18
IS 3
SI SI
BP 47
EP 54
PG 8
WC Public, Environmental & Occupational Health
WE Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA CA5KQ
UT WOS:000348947700006
PM 26050376
DA 2023-06-23
ER

PT J
AU Zheng, F
   Zhan, CG
AF Zheng, Fang
   Zhan, Chang-Guo
TI Enzyme-therapy approaches for the treatment of drug overdose and
   addiction
SO FUTURE MEDICINAL CHEMISTRY
LA English
DT Editorial Material
DE drug abuse; drug addiction; drug metabolism; drug overdose; rational
   drug design; therapeutic enzyme
ID ENERGY PERTURBATION SIMULATION; HIGH-ACTIVITY MUTANTS; HUMAN
   BUTYRYLCHOLINESTERASE; COCAINE HYDROLYSIS; TRANSITION-STATES;
   REACTION-MECHANISM; DESIGN; DOPAMINE; ESTERASE; PROTECTION
C1 [Zheng, Fang; Zhan, Chang-Guo] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
C3 University of Kentucky
RP Zhan, CG (通讯作者)，Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 789 S Limestone St, Lexington, KY 40536 USA.
EM zhan@uky.edu
RI ZHENG, FANG/HJZ-0472-2023
FU NIDA NIH HHS [R01 DA025100, R01 DA032910, R01 DA013930, R01 DA021416]
   Funding Source: Medline
CR Beuming T, 2008, NAT NEUROSCI, V11, P780, DOI 10.1038/nn.2146
   Bhattacharyya S, 2009, CURR PHARM DESIGN, V15, P2603, DOI 10.2174/138161209788957465
   Brim RL, 2010, MOL PHARMACOL, V77, P593, DOI 10.1124/mol.109.060806
   Brimijoin S, 2008, NEUROPSYCHOPHARMACOL, V33, P2715, DOI 10.1038/sj.npp.1301666
   Collins GT, 2009, J PHARMACOL EXP THER, V331, P445, DOI 10.1124/jpet.108.150029
   Cooper ZD, 2006, MOL PHARMACOL, V70, P1885, DOI 10.1124/mol.106.025999
   Flatscher-Bader T, 2009, NUTR RES REV, V22, P148, DOI 10.1017/S0954422409990114
   Gao DQ, 2009, MOL PHARMACOL, V75, P318, DOI 10.1124/mol.108.049486
   Gao DQ, 2006, ANGEW CHEM INT EDIT, V45, P653, DOI 10.1002/anie.200503025
   Gao DQ, 2005, J PHYS CHEM B, V109, P23070, DOI 10.1021/jp053736x
   Gorelick David A, 2008, Expert Rev Clin Pharmacol, V1, P277, DOI 10.1586/17512433.1.2.277
   Hamza A, 2005, J PHYS CHEM B, V109, P4776, DOI 10.1021/jp0447136
   Huang X, 2007, BIOPHYS J, V93, P3627, DOI 10.1529/biophysj.107.110924
   Huang XQ, 2009, J PHYS CHEM B, V113, P15057, DOI 10.1021/jp900963n
   Hubbard JJ, 2011, J PHARMACOL EXP THER, V336, P414, DOI 10.1124/jpet.110.175083
   Kinsey BM, 2010, EXPERT REV VACCINES, V9, P1109, DOI 10.1586/ERV.10.102
   Ko MC, 2007, J PHARMACOL EXP THER, V320, P926, DOI 10.1124/jpet.106.114223
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   LANDRY DW, 1993, SCIENCE, V259, P1899, DOI 10.1126/science.8456315
   Leader AE, 2010, NICOTINE TOB RES, V12, P390, DOI 10.1093/ntr/ntq015
   Moreno AY, 2010, MOL PHARMACEUT, V7, P431, DOI 10.1021/mp900213u
   Moreno AY, 2009, PHARMACOL BIOCHEM BE, V92, P199, DOI 10.1016/j.pbb.2009.01.015
   Narasimhan D, 2010, PROTEIN ENG DES SEL, V23, P537, DOI 10.1093/protein/gzq025
   *NIDA, NAT I DRUG AB NIDA F
   Norman AB, 2011, J NEUROSCI METH, V194, P252, DOI 10.1016/j.jneumeth.2010.10.017
   Novak G, 2010, INT J NEUROSCI, V120, P691, DOI 10.3109/00207454.2010.513462
   Novak M, 2010, J NEUROSCI, V30, P11973, DOI 10.1523/JNEUROSCI.2550-10.2010
   Pan YM, 2005, P NATL ACAD SCI USA, V102, P16656, DOI 10.1073/pnas.0507332102
   Pan YM, 2008, J AM CHEM SOC, V130, P5140, DOI 10.1021/ja077972s
   Pan YM, 2007, J AM CHEM SOC, V129, P13537, DOI 10.1021/ja073724k
   Park JB, 2010, J CONTROL RELEASE, V142, P174, DOI 10.1016/j.jconrel.2009.10.015
   Redish AD, 2004, SCIENCE, V306, P1944, DOI 10.1126/science.1102384
   Sun H, 2002, MOL PHARMACOL, V62, P220, DOI 10.1124/mol.62.2.220
   UNODC, 2010, WORLD DRUG REPORT 20
   Wood SK, 2010, DRUG ALCOHOL DEPEN, V106, P219, DOI 10.1016/j.drugalcdep.2009.09.001
   Xue L, 2011, MOL PHARMACOL, V79, P290, DOI 10.1124/mol.110.068494
   Yang WC, 2010, CHEM-BIOL INTERACT, V187, P148, DOI 10.1016/j.cbi.2010.01.004
   Yang WC, 2010, J PHYS CHEM B, V114, P10889, DOI 10.1021/jp104989b
   Yang WC, 2009, BIOPHYS J, V96, P1931, DOI 10.1016/j.bpj.2008.11.051
   Zhan CG, 2005, BIOPHYS J, V89, P3863, DOI 10.1529/biophysj.105.070276
   Zhan CG, 2003, J AM CHEM SOC, V125, P2462, DOI 10.1021/ja020850+
   Zhan CG, 2006, TOP HETEROCYCLIC CHE, V4, P107, DOI 10.1007/7081_024
   Zheng F, 2008, J COMPUT AID MOL DES, V22, P661, DOI 10.1007/s10822-007-9144-9
   Zheng F, 2008, J AM CHEM SOC, V130, P12148, DOI 10.1021/ja803646t
   Zheng F, 2008, ORG BIOMOL CHEM, V6, P836, DOI 10.1039/b716268e
   Zheng F, 2010, BIOCHEMISTRY-US, V49, P9113, DOI 10.1021/bi1011628
   Zheng F, 2009, FUTURE MED CHEM, V1, P515, DOI 10.4155/FMC.09.20
NR 47
TC 26
Z9 27
U1 1
U2 7
PU FUTURE SCI LTD
PI LONDON
PA UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND
SN 1756-8919
EI 1756-8927
J9 FUTURE MED CHEM
JI Future Med. Chem.
PD JAN
PY 2011
VL 3
IS 1
BP 9
EP 13
DI 10.4155/FMC.10.275
PG 5
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 728QE
UT WOS:000287887900009
PM 21428822
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Caceres, CF
AF Fernandez Caceres, C.
TI Dual disorders in drug users served in a network of specialized
   addiction care
SO HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS
LA English
DT Meeting Abstract
DE Dual Disorders; Drug Users; Specialized Addiction Care
C1 [Fernandez Caceres, C.] Ctr Integrac Juvenil AC CIJ, Mexico City, DF, Mexico.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU PACINI EDITORE
PI PISA
PA VIA DELLA GHERARDESCA-ZONA INDUSTRIALE OSPEDALETTO, 56121 PISA, ITALY
SN 1592-1638
J9 HEROIN ADDICT REL CL
JI Heroin Addict. Relat. Clin. Probl.
PD OCT
PY 2018
VL 20
SU 2
MA S08-1
BP 32
EP 32
PG 1
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA HD4XH
UT WOS:000452531200037
DA 2023-06-23
ER

PT J
AU Liu, JF
   Li, JX
AF Liu, Jian-feng
   Li, Jun-xu
TI Drug addiction: a curable mental disorder?
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Review
DE drug addiction; pharmacological targets; behavioral treatment; brain
   stimulation; gene therapy
ID COGNITIVE-BEHAVIORAL THERAPY; COMPUTER-ASSISTED DELIVERY;
   N-ACETYLCYSTEINE; BRAIN-STIMULATION; SYNAPTIC PLASTICITY;
   COCAINE-SEEKING; GENE-EXPRESSION; NEURAL CIRCUITS; IMMUNE-SYSTEM;
   RECEPTOR
AB Drug addiction is a chronic, relapsing brain disorder. Multiple neural networks in the brain including the reward system (e.g., the mesocorticolimbic system), the anti-reward/stress system (e.g., the extended amygdala), and the central immune system, are involved in the development of drug addiction and relapse after withdrawal from drugs of abuse. Preclinical and clinical studies have demonstrated that it is promising to control drug addiction by pharmacologically targeting the addiction-related systems in the brain. Here we review the pharmacological targets within the dopamine system, glutamate system, trace amine system, antire-ward system, and central immune system, which are of clinical interests. Furthermore, we discuss other potential therapies, e.g., brain stimulation, behavioral treatments, and therapeutic gene modulation, which could be effective to treat drug addiction. We conclude that, although drug addiction is a complex disorder that involves complicated neural mechanisms and psychological processes, this mental disorder is treatable and may be curable by therapies such as gene modulation in the future.
C1 [Liu, Jian-feng; Li, Jun-xu] SUNY Buffalo, Dept Pharmacol & Toxicol, Univ Buffalo, Buffalo, NY 14203 USA.
C3 State University of New York (SUNY) System; State University of New York
   (SUNY) Buffalo
RP Liu, JF; Li, JX (通讯作者)，SUNY Buffalo, Dept Pharmacol & Toxicol, Univ Buffalo, Buffalo, NY 14203 USA.
EM jliu66@buffalo.edu; junxuli@buffalo.edu
RI Li, Jun-Xu/K-9192-2013
OI Li, Jun-Xu/0000-0003-4749-0767; Liu, Jianfeng/0000-0002-3464-6462
FU National Institutes of Health National Institute on Drug Abuse
   [R21DA040777]
FX This work was supported by the National Institutes of Health National
   Institute on Drug Abuse [Grant R21DA040777]. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health.
CR Akhtar H, 2016, NEUROSCI BULL, V32, P115, DOI 10.1007/s12264-015-0009-2
   Anker JJ, 2012, BIOL PSYCHIAT, V71, P700, DOI 10.1016/j.biopsych.2011.11.014
   [Anonymous], 2014, NICOTINE REPLACEMENT
   Bachtell RK, 2017, DRUG ALCOHOL DEPEN, V180, P156, DOI 10.1016/j.drugalcdep.2017.08.003
   Baik JH, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00152
   Bonhomme J, 2012, J NATL MED ASSOC, V104, P342, DOI 10.1016/S0027-9684(15)30175-9
   Britt JP, 2013, CURR OPIN NEUROBIOL, V23, P539, DOI 10.1016/j.conb.2013.01.010
   Brown KT, 2018, BRAIN BEHAV IMMUN, V67, P130, DOI 10.1016/j.bbi.2017.08.012
   Carroll KM, 2008, AM J PSYCHIAT, V165, P881, DOI 10.1176/appi.ajp.2008.07111835
   Carroll KM, 2014, ANN NY ACAD SCI, V1327, P94, DOI 10.1111/nyas.12501
   Carroll KM, 2014, AM J PSYCHIAT, V171, P436, DOI 10.1176/appi.ajp.2013.13070987
   Chen YH, 2013, CURR GENE THER, V13, P39, DOI 10.2174/156652313804806552
   Coles AS, 2018, AM J ADDICTION, V27, P71, DOI 10.1111/ajad.12674
   Creed M, 2015, SCIENCE, V347, P659, DOI 10.1126/science.1260776
   Cui SZ, 2011, ACTA PHARMACOL SIN, V32, P175, DOI 10.1038/aps.2010.199
   Dakwar E, 2017, MOL PSYCHIATR, V22, P76, DOI 10.1038/mp.2016.39
   Dakwar E, 2014, BIOL PSYCHIAT, V76, P40, DOI 10.1016/j.biopsych.2013.08.009
   Deisseroth K, 2015, NAT NEUROSCI, V18, P1213, DOI 10.1038/nn.4091
   Dong Y, 2017, J NEUROSCI, V37, P10867, DOI 10.1523/JNEUROSCI.1821-17.2017
   Du SH, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00409
   Ducci F, 2012, PSYCHIAT CLIN N AM, V35, P495, DOI 10.1016/j.psc.2012.03.010
   Duman RS, 2012, SCIENCE, V338, P68, DOI 10.1126/science.1222939
   Dunbar CE, 2018, SCIENCE, V359, P175, DOI 10.1126/science.aan4672
   Dunlop K, 2017, ANN NY ACAD SCI, V1394, P31, DOI 10.1111/nyas.12985
   Ebbert JO, 2015, JAMA-J AM MED ASSOC, V313, P687, DOI 10.1001/jama.2015.280
   Eidson LN, 2013, J NEUROSCI, V33, P15952, DOI 10.1523/JNEUROSCI.1609-13.2013
   Fuehrlein BS, 2017, BIOL PSYCHIAT, V81, pE43, DOI 10.1016/j.biopsych.2017.01.014
   Gong YX, 2010, ACTA PHARMACOL SIN, V31, P1431, DOI 10.1038/aps.2010.136
   Grandy DK, 2007, PHARMACOL THERAPEUT, V116, P355, DOI 10.1016/j.pharmthera.2007.06.007
   Hamilton KL, 2013, BRAIN RES, V1538, P73, DOI 10.1016/j.brainres.2013.09.026
   Han Y, 2016, NEUROSCI BULL, V32, P569, DOI 10.1007/s12264-016-0051-8
   Hanlon CA, 2018, PHARMACOL REV, V70, P661, DOI 10.1124/pr.116.013649
   Huang XD, 2017, NEUROSCI BULL, V33, P357, DOI 10.1007/s12264-017-0121-6
   Hutchinson MR, 2012, J NEUROSCI, V32, P11187, DOI 10.1523/JNEUROSCI.0684-12.2012
   Hutchinson MR, 2011, PHARMACOL REV, V63, P772, DOI 10.1124/pr.110.004135
   Iversen SD, 2007, TRENDS NEUROSCI, V30, P188, DOI 10.1016/j.tins.2007.03.002
   Jacobsen JHW, 2016, CURR OPIN PHARMACOL, V26, P131, DOI 10.1016/j.coph.2015.10.010
   Jastrzebska J, 2016, PSYCHOPHARMACOLOGY, V233, P3437, DOI 10.1007/s00213-016-4388-5
   Jia XJ, 2016, NEUROSCI BULL, V32, P512, DOI 10.1007/s12264-016-0061-6
   Jiang HF, 2016, NEUROSCI BULL, V32, P538, DOI 10.1007/s12264-016-0059-0
   Jones KA, 2013, MOL CELL NEUROSCI, V53, P52, DOI 10.1016/j.mcn.2012.10.002
   Ju YY, 2015, ACTA PHARMACOL SIN, V36, P1437, DOI 10.1038/aps.2015.94
   Kalivas PW, 2011, MOL PSYCHIATR, V16, P974, DOI 10.1038/mp.2011.46
   Kashima DT, 2017, P NATL ACAD SCI USA, V114, P8865, DOI 10.1073/pnas.1705974114
   Klenowski PM, 2018, ADDICT BEHAV, V77, P102, DOI 10.1016/j.addbeh.2017.09.024
   Knackstedt LA, 2009, CURR OPIN PHARMACOL, V9, P59, DOI 10.1016/j.coph.2008.12.003
   Koob GF, 2017, PSYCHOPHARMACOLOGY, V234, P1315, DOI 10.1007/s00213-016-4484-6
   Koob GF, 2014, NEUROPHARMACOLOGY, V76, P370, DOI 10.1016/j.neuropharm.2013.05.024
   Koob George F, 2013, Front Psychiatry, V4, P72, DOI 10.3389/fpsyt.2013.00072
   KOSAROV D, 1975, Electromyography and Clinical Neurophysiology, V15, P453
   Kruepunga N, 2018, BIOCH BIOPHYS ACTA M
   Lareau CA, 2018, NAT METHODS, V15, P238, DOI [10.1038/nmeth.4541, 10.1038/NMETH.4541]
   Larney S, 2014, DRUG ALCOHOL REV, V33, P115, DOI 10.1111/dar.12095
   LaRowe SD, 2013, AM J ADDICTION, V22, P443, DOI 10.1111/j.1521-0391.2013.12034.x
   Lee JLC, 2005, NEURON, V47, P795, DOI 10.1016/j.neuron.2005.08.007
   Leff-Gelman P, 2016, NEUROSCI BULL, V32, P398, DOI 10.1007/s12264-016-0048-3
   Li NX, 2010, SCIENCE, V329, P959, DOI 10.1126/science.1190287
   Lin XJ, 2016, NEUROSCI BULL, V32, P177, DOI 10.1007/s12264-016-0018-9
   Liu JF, 2019, EUR J NEUROSCI, V50, P2503, DOI 10.1111/ejn.14072
   Liu JF, 2018, NEUROPSYCHOPHARMACOL, V43, P2435, DOI 10.1038/s41386-018-0017-9
   Liu JF, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00279
   Lou ZZ, 2014, ACTA PHARMACOL SIN, V35, P1485, DOI 10.1038/aps.2014.93
   Lupi M, 2017, J ECT, V33, P203, DOI 10.1097/YCT.0000000000000401
   Luscher C, 2016, ANNU REV NEUROSCI, V39, P257, DOI 10.1146/annurev-neuro-070815-013920
   Mardikian PN, 2007, PROG NEURO-PSYCHOPH, V31, P389, DOI 10.1016/j.pnpbp.2006.10.001
   Mellentin AI, 2017, CLIN PSYCHOL REV, V57, P195, DOI 10.1016/j.cpr.2017.07.006
   Murphy A, 2017, NEUROPSYCHOPHARMACOL, V42, P1049, DOI 10.1038/npp.2016.289
   Murthy V, 2014, VACCINE, V32, P4155, DOI 10.1016/j.vaccine.2014.05.067
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   Newman AH, 2012, BIOCHEM PHARMACOL, V84, P882, DOI 10.1016/j.bcp.2012.06.023
   Ng E, 2017, AM J DRUG ALCOHOL AB, V43, P456, DOI 10.1080/00952990.2016.1183020
   Nishi A, 2017, EXPERT OPIN THER TAR, V21, P259, DOI 10.1080/14728222.2017.1279149
   Echevarria MA, 2017, PSYCHIAT RES, V251, P197, DOI 10.1016/j.psychres.2017.02.024
   Olive M Foster, 2009, Curr Drug Abuse Rev, V2, P83
   Pei Y, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00148
   Pierce RC, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a012021
   Rhodes JS, 2005, CURR OPIN PHARMACOL, V5, P26, DOI 10.1016/j.coph.2004.12.001
   Rimmele TS, 2016, NEUROCHEM INT, V98, P19, DOI 10.1016/j.neuint.2016.04.010
   Roberts-Wolfe DJ, 2015, CNS NEUROL DISORD-DR, V14, P745, DOI 10.2174/1871527314666150529144655
   Rushworth GF, 2014, PHARMACOL THERAPEUT, V141, P150, DOI 10.1016/j.pharmthera.2013.09.006
   Salling MC, 2016, NEUROPSYCHOPHARMACOL, V41, P2798, DOI 10.1038/npp.2016.80
   Schmaal L, 2012, NEUROPSYCHOPHARMACOL, V37, P2143, DOI 10.1038/npp.2012.66
   Schwandt ML, 2016, NEUROPSYCHOPHARMACOL, V41, P2818, DOI 10.1038/npp.2016.61
   Shafran R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201226
   Smith ACW, 2018, GENES BRAIN BEHAV, V17, DOI 10.1111/gbb.12424
   Spencer S, 2017, INT J NEUROPSYCHOPH, V20, P797, DOI 10.1093/ijnp/pyx050
   Stefan E, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1605
   Sun L, 2016, ACTA PHARMACOL SIN, V37, P157, DOI 10.1038/aps.2015.96
   Sunitha K, 2013, FREE RADICAL RES, V47, P357, DOI 10.3109/10715762.2013.781595
   Swiech L, 2015, NAT BIOTECHNOL, V33, P102, DOI 10.1038/nbt.3055
   Tanda G, 2016, NEUROPSYCHOPHARMACOL, V41, P2772, DOI 10.1038/npp.2016.91
   Theberge FR, 2013, BIOL PSYCHIAT, V73, P729, DOI 10.1016/j.biopsych.2012.12.019
   Verdejo-Garcia A, 2015, BRIT J PSYCHIAT, V207, P158, DOI 10.1192/bjp.bp.114.152223
   Volkow ND, 2009, NEUROPHARMACOLOGY, V56, P3, DOI 10.1016/j.neuropharm.2008.05.022
   Walker Deena M, 2018, Handb Clin Neurol, V148, P747, DOI 10.1016/B978-0-444-64076-5.00048-X
   Wang BF, 2016, NEUROSCI BULL, V32, P531, DOI 10.1007/s12264-016-0066-1
   Wang F, 2016, NEUROSCI BULL, V32, P545, DOI 10.1007/s12264-016-0074-1
   Wang J, 2013, ACTA PHARMACOL SIN, V34, P811, DOI 10.1038/aps.2013.3
   Wang XF, 2016, NEUROSCI BULL, V32, P523, DOI 10.1007/s12264-016-0031-z
   Wang XH, 2012, P NATL ACAD SCI USA, V109, P6325, DOI 10.1073/pnas.1200130109
   Wolf ME, 2016, NAT REV NEUROSCI, V17, P351, DOI 10.1038/nrn.2016.39
   Yang JY, 2010, ACTA PHARMACOL SIN, V31, P1071, DOI 10.1038/aps.2010.140
   Yang LZ, 2016, NEUROSCI BULL, V32, P550, DOI 10.1007/s12264-016-0056-3
   Yuan K, 2016, NEUROSCI BULL, V32, P565, DOI 10.1007/s12264-016-0082-1
   Zhao HC, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00685
   Zhou ZF, 2014, INT REV NEUROBIOL, V116, P251, DOI 10.1016/B978-0-12-801105-8.00010-2
   Zhu HQ, 2017, NEUROSCI BULL, V33, P396, DOI 10.1007/s12264-017-0140-3
   Zhu WL, 2016, NEUROSCI BULL, V32, P557, DOI 10.1007/s12264-016-0081-2
   Zilverstand A, 2016, PROG BRAIN RES, V224, P285, DOI 10.1016/bs.pbr.2015.07.019
NR 109
TC 23
Z9 26
U1 5
U2 76
PU ACTA PHARMACOLOGICA SINICA
PI SHANGHAI
PA 294 TAI-YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1671-4083
EI 1745-7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD DEC
PY 2018
VL 39
IS 12
BP 1823
EP 1829
DI 10.1038/s41401-018-0180-x
PG 7
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA HG2DU
UT WOS:000454773800001
PM 30382181
OA Green Published, Bronze
DA 2023-06-23
ER

PT J
AU Ruisoto, P
   Contador, I
AF Ruisoto, Pablo
   Contador, Israel
TI The role of stress in drug addiction. An integrative review
SO PHYSIOLOGY & BEHAVIOR
LA English
DT Review
DE Stress; Drug-addiction; Hippocampus; Craving; Amygdala; Prefrontal
   cortex
ID CORTICOTROPIN-RELEASING-FACTOR; PREFRONTAL CORTEX; SOCIAL MEDICINE;
   BRAIN-DISEASE; DARK SIDE; EPIGENETIC MECHANISMS; DECISION-MAKING;
   REWARD; DOPAMINE; NEUROBIOLOGY
AB Background: The high prevalence and burden to society of drug abuse and addiction is undisputed. However, its conceptualisation as a brain disease is controversial, and available interventions insufficient. Research on the role of stress in drug addiction may bridge positions and develop more effective interventions.
   Aim: The aim of this paper is to integrate the most influential literature to date on the role of stress in drug addiction.
   Methods: A literature search was conducted of the core collections of Web of Science and Semantic Scholar on the topic of stress and addiction from a neurobiological perspective in humans. The most frequently cited articles and related references published in the last decade were finally redrafted into a narrative review based on 130 full-text articles.
   Results and discussion: First, a brief overview of the neurobiology of stress and drug addiction is provided. Then, the role of stress in drug addiction is described. Stress is conceptualised as a major source of allostatic load, which result in progressive long-term changes in the brain, leading to a drug-prone state characterized by craving and increased risk of relapse. The effects of stress on drug addiction are mainly mediated by the action of corticotropin-releasing factor and other stress hormones, which weaken the hippocampus and prefrontal cortex and strengthen the amygdala, leading to a negative emotional state, craving and lack of executive control, increasing the risk of relapse. Both, drugs and stress result in an allostatic overload responsible for neuroadaptations involved in most of the key features of addiction: reward anticipation/craving, negative affect, and impaired executive functions, involved in three stages of addiction and relapse.
   Conclusion: This review elucidates the crucial role of stress in drug addiction and highlights the need to incorporate the social context where brain-behaviour relationships unfold into the current model of addition.
C1 [Ruisoto, Pablo; Contador, Israel] Univ Salamanca, Fac Psychol, Dept Psychobiol Methodol & Behav Sci, Ave De la Merced 109-131, E-37008 Salamanca, Spain.
C3 University of Salamanca
RP Ruisoto, P (通讯作者)，Univ Salamanca, Fac Psychol, Dept Psychobiol Methodol & Behav Sci, Ave De la Merced 109-131, E-37008 Salamanca, Spain.
EM ruisoto@usal.es
RI Contador, Israel/Z-4641-2019; Ruisoto, Pablo/J-3170-2019
OI Ruisoto, Pablo/0000-0003-1252-0479; Contador, Israel/0000-0002-7841-1307
CR Ahmed SH, 2013, CURR OPIN NEUROBIOL, V23, P581, DOI 10.1016/j.conb.2013.01.028
   al'Absi M, 2018, PSYCHOSOM MED, V80, P2, DOI 10.1097/PSY.0000000000000520
   Anthes E, 2014, NATURE, V515, P185, DOI 10.1038/515185a
   Arnsten AFT, 2009, NAT REV NEUROSCI, V10, P410, DOI 10.1038/nrn2648
   Barker JM, 2015, BRAIN RES, V1628, P68, DOI 10.1016/j.brainres.2014.10.058
   Bazov I, 2013, ADDICT BIOL, V18, P161, DOI 10.1111/j.1369-1600.2011.00366.x
   Becker J. B., 2018, NEUROPSYCHOPHARMACOL, V1, P1
   Becker JB, 2017, J NEUROSCI RES, V95, P136, DOI 10.1002/jnr.23963
   Belin D, 2013, CURR OPIN NEUROBIOL, V23, P564, DOI 10.1016/j.conb.2013.01.025
   Belujon P, 2011, ANN NY ACAD SCI, V1216, P114, DOI 10.1111/j.1749-6632.2010.05896.x
   Berridge CW, 2010, BRAIN RES, V1314, P91, DOI 10.1016/j.brainres.2009.09.019
   Bourzac K., 2015, NATURE, V522, P50
   Boutrel B, 2008, PHYSIOL BEHAV, V93, P947, DOI 10.1016/j.physbeh.2007.11.022
   Bowen S, 2014, JAMA PSYCHIAT, V71, P547, DOI 10.1001/jamapsychiatry.2013.4546
   Boyce WT, 2012, P NATL ACAD SCI USA, V109, P17143, DOI 10.1073/pnas.1121264109
   Bradley EH, 2017, QJM-INT J MED, V110, P61, DOI 10.1093/qjmed/hcw187
   Braveman P, 2011, ANNU REV PUBL HEALTH, V32, P381, DOI 10.1146/annurev-publhealth-031210-101218
   Bryce CA, 2016, NEUROPSYCHOPHARMACOL, V41, P2147, DOI 10.1038/npp.2016.15
   Buchanan TW, 2019, CURR OPIN PSYCHOL, V27, P72, DOI 10.1016/j.copsyc.2018.09.005
   Cacioppo JT, 2015, ANNU REV PSYCHOL, V66, P733, DOI 10.1146/annurev-psych-010814-015240
   Cadet JL, 2016, MOL NEUROBIOL, V53, P545, DOI 10.1007/s12035-014-9040-y
   Campos-Melo D, 2013, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00044
   Ch'ng S, 2018, PROG NEURO-PSYCHOPH, V87, P108, DOI 10.1016/j.pnpbp.2018.01.005
   Chavkin C, 2016, NEUROPSYCHOPHARMACOL, V41, P373, DOI 10.1038/npp.2015.258
   Cohen S, 2007, JAMA-J AM MED ASSOC, V298, P1685, DOI 10.1001/jama.298.14.1685
   Cohen S, 2016, PERSPECT PSYCHOL SCI, V11, P456, DOI 10.1177/1745691616646305
   Creswell JD, 2017, ANNU REV PSYCHOL, V68, P491, DOI 10.1146/annurev-psych-042716-051139
   Danese A, 2017, EUR J PSYCHOTRAUMATO, V8, DOI 10.1080/20008198.2017.1375840
   Danese A, 2017, NEUROPSYCHOPHARMACOL, V42, P99, DOI 10.1038/npp.2016.198
   Darcq E, 2018, NAT REV NEUROSCI, V19, P499, DOI 10.1038/s41583-018-0028-x
   Daughters SB, 2009, DRUG ALCOHOL DEPEN, V105, P202, DOI 10.1016/j.drugalcdep.2009.06.026
   Dedic N, 2018, CURR MOL PHARMACOL, V11, P4, DOI 10.2174/1874467210666170302104053
   Diamond A, 2013, ANNU REV PSYCHOL, V64, P135, DOI 10.1146/annurev-psych-113011-143750
   Diana Marco, 2011, Front Psychiatry, V2, P64, DOI 10.3389/fpsyt.2011.00064
   Duffing Tiffany M, 2014, Curr Top Behav Neurosci, V18, P237, DOI 10.1007/7854_2014_276
   Echouffo-Tcheugui J. B., 2018, NEUROLOGY, V91
   Edwards S, 2010, FUTUR NEUROL, V5, P393, DOI 10.2217/FNL.10.14
   Everitt BJ, 2013, NEUROSCI BIOBEHAV R, V37, P1946, DOI 10.1016/j.neubiorev.2013.02.010
   Feltenstein MW, 2008, BRIT J PHARMACOL, V154, P261, DOI 10.1038/bjp.2008.51
   Garland EL, 2018, ADDICT SCI CLIN PRAC, V13, DOI 10.1186/s13722-018-0115-3
   Gass J T, 2013, Front Psychiatry, V4, P46, DOI 10.3389/fpsyt.2013.00046
   George O, 2014, PSYCHOPHARMACOLOGY, V231, P3911, DOI 10.1007/s00213-014-3623-1
   George O, 2012, PHYSIOL BEHAV, V106, P58, DOI 10.1016/j.physbeh.2011.11.004
   Ghosh S, 2013, J NEUROSCI, V33, P7234, DOI 10.1523/JNEUROSCI.0638-13.2013
   Giardino WJ, 2014, CURR OPIN NEUROBIOL, V29, P103, DOI 10.1016/j.conb.2014.07.006
   Gilpin NW, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00079
   Gilpin NW, 2011, BIOL PSYCHIAT, V69, P1091, DOI 10.1016/j.biopsych.2011.02.004
   Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119
   Goncalves J, 2016, ADDICT BIOL, V21, P755, DOI 10.1111/adb.12250
   Goodman A, 2008, BIOCHEM PHARMACOL, V75, P266, DOI 10.1016/j.bcp.2007.07.030
   Grant JE, 2010, AM J DRUG ALCOHOL AB, V36, P233, DOI 10.3109/00952990.2010.491884
   Greene JA, 2017, NEW ENGL J MED, V377, P2493, DOI 10.1056/NEJMms1706744
   Greenwald MK, 2018, NEUROBIOL STRESS, V9, P84, DOI 10.1016/j.ynstr.2018.08.003
   Haass-Koffler CL, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00091
   Hanson JL, 2015, BIOL PSYCHIAT, V77, P314, DOI 10.1016/j.biopsych.2014.04.020
   Hassanbeigi A, 2013, PROCD SOC BEHV, V84, P1333, DOI 10.1016/j.sbspro.2013.06.752
   Heilig M, 2016, NAT REV NEUROSCI, V17, P592, DOI 10.1038/nrn.2016.67
   Henckens MJAG, 2009, J NEUROSCI, V29, P10111, DOI 10.1523/JNEUROSCI.1184-09.2009
   Herman AI, 2012, SUBST ABUSE REHABIL, V3, P49, DOI 10.2147/SAR.S25864
   Hildebrandt T, 2013, PSYCHONEUROENDOCRINO, V38, P1923, DOI 10.1016/j.psyneuen.2013.06.017
   Hiser J, 2018, BIOL PSYCHIAT, V83, P638, DOI 10.1016/j.biopsych.2017.10.030
   Holzel BK, 2010, SOC COGN AFFECT NEUR, V5, P11, DOI 10.1093/scan/nsp034
   Johnson B, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00545
   Kalivas PW, 2009, NEUROPHARMACOLOGY, V56, P169, DOI 10.1016/j.neuropharm.2008.07.011
   Karoly HC, 2013, ANN NY ACAD SCI, V1282, P71, DOI 10.1111/nyas.12074
   Kaye JT, 2017, J STUD ALCOHOL DRUGS, V78, P353, DOI 10.15288/jsad.2017.78.353
   Kertes DA, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0367-x
   Kim HS, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00406
   Koob G. F., 2018, NEUROSCI BIOBEHAV R, DOI [10.1016/j.neubiorev.2018.09, DOI 10.1016/J.NEUBIOREV.2018.09]
   Koob GF, 2008, NEURON, V59, P11, DOI 10.1016/j.neuron.2008.06.012
   Koob GF, 2008, ANNU REV PSYCHOL, V59, P29, DOI 10.1146/annurev.psych.59.103006.093548
   Koob GF, 2017, PSYCHOPHARMACOLOGY, V234, P1315, DOI 10.1007/s00213-016-4484-6
   Koob GF, 2016, LANCET PSYCHIAT, V3, P760, DOI 10.1016/S2215-0366(16)00104-8
   Koob GF, 2015, EUR J PHARMACOL, V753, P73, DOI 10.1016/j.ejphar.2014.11.044
   Koob GF, 2014, NEUROPHARMACOLOGY, V76, P370, DOI 10.1016/j.neuropharm.2013.05.024
   Koob George F, 2013, Front Psychiatry, V4, P72, DOI 10.3389/fpsyt.2013.00072
   Koob GF, 2010, BRAIN RES, V1314, P3, DOI 10.1016/j.brainres.2009.11.008
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Koob GF, 2009, BRAIN RES, V1293, P61, DOI 10.1016/j.brainres.2009.03.038
   Koob GF, 2009, NAT REV DRUG DISCOV, V8, P500, DOI 10.1038/nrd2828
   Krishnan HR, 2014, INT REV NEUROBIOL, V115, P75, DOI 10.1016/B978-0-12-801311-3.00003-2
   Kruse O, 2018, NEUROIMAGE, V171, P15, DOI 10.1016/j.neuroimage.2017.12.076
   Kuss D. J., 2017, INT J ENV RES PUB HE, V14, P13
   Kwako LE, 2017, CHRONIC STRESS, V1
   Lammel S, 2014, NEUROPHARMACOLOGY, V76, P351, DOI 10.1016/j.neuropharm.2013.03.019
   Leonard KE, 2015, NATURE, V522, pS56, DOI 10.1038/522S56a
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Levy Neil, 2013, Front Psychiatry, V4, P24, DOI 10.3389/fpsyt.2013.00024
   Lewis M, 2017, NEUROETHICS-NETH, V10, P7, DOI 10.1007/s12152-016-9293-4
   Li MD, 2009, NAT REV GENET, V10, P225, DOI 10.1038/nrg2536
   Manzanares J, 2018, BIOCHEM PHARMACOL, V157, P108, DOI 10.1016/j.bcp.2018.09.013
   Mate G., 2012, J RESTORATIVE MED, V1, P56, DOI DOI 10.14200/JRM.2012.1.1005
   Mather M, 2012, CURR DIR PSYCHOL SCI, V21, P36, DOI 10.1177/0963721411429452
   Maze I, 2011, ANN NY ACAD SCI, V1216, P99, DOI 10.1111/j.1749-6632.2010.05893.x
   McEwen BS, 2013, PERSPECT PSYCHOL SCI, V8, P673, DOI 10.1177/1745691613506907
   McEwen BS, 2011, ANNU REV MED, V62, P431, DOI 10.1146/annurev-med-052209-100430
   McGowan PO, 2009, NAT NEUROSCI, V12, P342, DOI 10.1038/nn.2270
   Mechoulam R, 2013, ANNU REV PSYCHOL, V64, P21, DOI 10.1146/annurev-psych-113011-143739
   Mitchell MR, 2015, FRONT PSYCHIATRY, V6, DOI 10.3389/fpsyt.2015.00024
   Moraes L. J., 2017, PSYCHOL HEALTH MED, V20, P1
   Myers B, 2014, PSYCHOL ADDICT BEHAV, V28, P1117, DOI 10.1037/a0037459
   Naqvi NH, 2009, TRENDS NEUROSCI, V32, P56, DOI 10.1016/j.tins.2008.09.009
   Niehaus JL, 2009, AM J ADDICTION, V18, P259, DOI 10.1080/10550490902925946
   Nutt DJ, 2015, NAT REV NEUROSCI, V16, P305, DOI 10.1038/nrn3939
   Pandey SC, 2017, NEUROPHARMACOLOGY, V122, P74, DOI 10.1016/j.neuropharm.2017.02.002
   Parsons LH, 2015, NAT REV NEUROSCI, V16, P579, DOI 10.1038/nrn4004
   Peters J, 2009, LEARN MEMORY, V16, P279, DOI 10.1101/lm.1041309
   Petry NM, 2011, PSYCHIATR BULL, V35, P161, DOI 10.1192/pb.bp.110.031831
   Porter D, 2006, PLOS MED, V3, P1667, DOI 10.1371/journal.pmed.0030399
   Preston KL, 2018, NEUROPSYCHOPHARMACOL, V43, P859, DOI 10.1038/npp.2017.275
   Probst C, 2014, INT J EPIDEMIOL, V43, P1314, DOI 10.1093/ije/dyu043
   Quaedflieg CWEM, 2018, MEMORY, V26, P364, DOI 10.1080/09658211.2017.1338299
   Racz I, 2014, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00056
   Renthal W, 2008, TRENDS MOL MED, V14, P341, DOI 10.1016/j.molmed.2008.06.004
   Robinson TE, 2004, NEUROPHARMACOLOGY, V47, P33, DOI 10.1016/j.neuropharm.2004.06.025
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Robison AJ, 2011, NAT REV NEUROSCI, V12, P623, DOI 10.1038/nrn3111
   Roozendaal B, 2009, NAT REV NEUROSCI, V10, P423, DOI 10.1038/nrn2651
   Russo SJ, 2010, TRENDS NEUROSCI, V33, P267, DOI 10.1016/j.tins.2010.02.002
   Sakano E, 2014, BRAZ J OTORHINOLAR, V80, P1, DOI 10.1002/0471142700.nc0909s57
   Sancho M, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00095
   Satel S, 2014, FRONT PSYCHIATRY, V4, DOI 10.3389/fpsyt.2013.00141
   Schumann G, 2010, MOL PSYCHIATR, V15, P1128, DOI 10.1038/mp.2010.4
   Serrano A, 2011, PHARMACOL THERAPEUT, V132, P215, DOI 10.1016/j.pharmthera.2011.06.005
   Silberman Yuval, 2013, Front Psychiatry, V4, P42, DOI 10.3389/fpsyt.2013.00042
   Sinha R, 2008, ANN NY ACAD SCI, V1141, P105, DOI 10.1196/annals.1441.030
   Slavich GM, 2013, CLIN PSYCHOL SCI, V1, P331, DOI 10.1177/2167702613478594
   Smith RJ, 2018, PROG NEURO-PSYCHOPH, V87, P11, DOI 10.1016/j.pnpbp.2017.09.003
   Srinivasan S., 2013, FRONT PSYCHIATRY, V4, P68, DOI DOI 10.3389/FPSYT.2013.00068
   Stonington SD, 2018, NEW ENGL J MED, V379, P1958, DOI 10.1056/NEJMms1814262
   Thorsell A, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00178
   Trifilieff Pierre, 2013, Front Psychiatry, V4, P44, DOI 10.3389/fpsyt.2013.00044
   van Dijk W, 2016, INT J HEALTH POLICY, V5, P619, DOI 10.15171/ijhpm.2016.121
   Venniro M, 2018, NAT NEUROSCI, V21, P1520, DOI 10.1038/s41593-018-0246-6
   Verplaetse TL, 2017, J STUD ALCOHOL DRUGS, V78, P372, DOI 10.15288/jsad.2017.78.372
   Verplaetse TL, 2015, NICOTINE TOB RES, V17, P486, DOI 10.1093/ntr/ntu280
   Volkow ND, 2009, NEUROPHARMACOLOGY, V56, P3, DOI 10.1016/j.neuropharm.2008.05.022
   Volkow ND., 2011, PRINCIPLES DRUG ADDI
   Volkow ND, 2016, NEW ENGL J MED, V374, P363, DOI 10.1056/NEJMra1511480
   Volkow ND, 2015, CELL, V162, P712, DOI 10.1016/j.cell.2015.07.046
   Volkow ND, 2011, P NATL ACAD SCI USA, V108, P15037, DOI 10.1073/pnas.1010654108
   Wand G, 2008, ALCOHOL RES HEALTH, V31, P119
   Wee S, 2010, PSYCHOPHARMACOLOGY, V210, P121, DOI 10.1007/s00213-010-1825-8
   Wenzel JM, 2018, NEUROPSYCHOPHARMACOL, V43, P103, DOI 10.1038/npp.2017.126
   Wilcox CE, 2016, AM J PSYCHIAT, V173, P344, DOI 10.1176/appi.ajp.2015.15060710
   Wise RA, 2014, NEUROPSYCHOPHARMACOL, V39, P254, DOI 10.1038/npp.2013.261
   Wolf A. F., 2017, BEHAV PUBLIC POLICY
   World Health Organization, 2018, AIR POLL CHILD HLTH
   Yoshimasu K., 2013, J ADDICT RES THEORY, V6, P6
   Zanos P, 2018, BRIT J PHARMACOL, V175, P2809, DOI 10.1111/bph.13757
   Zhou Y, 2016, PROG BRAIN RES, V223, P237, DOI 10.1016/bs.pbr.2015.09.001
   Zorrilla EP, 2014, FRONT NEUROENDOCRIN, V35, P234, DOI 10.1016/j.yfrne.2014.01.001
NR 152
TC 41
Z9 43
U1 4
U2 61
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0031-9384
J9 PHYSIOL BEHAV
JI Physiol. Behav.
PD APR 1
PY 2019
VL 202
BP 62
EP 68
DI 10.1016/j.physbeh.2019.01.022
PG 7
WC Psychology, Biological; Behavioral Sciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology; Behavioral Sciences
GA HO5UB
UT WOS:000460992200008
PM 30711532
OA Green Published
DA 2023-06-23
ER

PT J
AU Sellman, JD
   Baker, MP
   Adamson, SJ
   Geering, LG
AF Sellman, John D.
   Baker, Michael P.
   Adamson, Simon J.
   Geering, Lloyd G.
TI Future of God in recovery from drug addiction
SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
LA English
DT Review
DE drug addiction; entheogens; God; higher power; spirituality
ID ALCOHOL; DEPENDENCE; RELIGION; SPIRITUALITY; PSYCHIATRY; NALTREXONE;
   OUTCOMES; MODEL; LSD
AB The purpose of the present paper was to explore the concept and experience of God in relation to recovery from drug addiction from a scientific perspective. Examination of a diverse literature was undertaken, including five key threads: the universality of the experience of God; the induction of spiritual experiences of God through hallucinogenic drugs; the nature of drug addiction from an evolutionary neurobiological perspective; the 12 Step movement as the prototype for the place of God in recovery from drug addiction; and identified ingredients for successful recovery from addiction. The diverse threads of literature examined can be integrated around the concept of higher power as an important factor in recovery from drug addiction. Higher power can be manifested in individuals in diverse ways: religious, ethnic, spiritual including the use of entheogens, as well as cognitive behavioural development, but a common final pathway for all is the strengthening of executive functions (the brain's 'higher power'). Practical implications for assisting people with drug addiction to achieve recovery through their own experience of God/ development of higher power are outlined.
C1 Univ Otago, Natl Addict Ctr, Christchurch, New Zealand.
   Univ Victoria, Wellington, New Zealand.
C3 University of Otago; Victoria University Wellington
RP Sellman, JD (通讯作者)，Univ Otago, Natl Addict Ctr, POB 4345,Christchurch Mail Ctr 8140, Christchurch, New Zealand.
EM doug.seliman@chmeds.ac.nz
CR American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th
   ARTHUR S, 2007, NARRATIVE TIMELINE A
   AUXIER JW, 1995, DISS ABSTR INT B SCI, V55, P2995
   Benson H, 2006, AM HEART J, V151, P934, DOI 10.1016/j.ahj.2005.05.028
   BOWKER J, 2002, GOD BRIEF HIST HUMAN
   CARROLL S, 1993, J STUD ALCOHOL, V54, P297, DOI 10.15288/jsa.1993.54.297
   CLONINGER CR, 1993, ARCH GEN PSYCHIAT, V50, P975, DOI 10.1001/archpsyc.1993.01820240059008
   Cummings K Michael, 2006, Curr Oncol Rep, V8, P475, DOI 10.1007/s11912-006-0077-6
   DARVIN C, 1874, DESCENT MAN
   Darwin C., 1859, ORIGINS SPECIES
   Davis DR, 1998, SOC WORK, V43, P169, DOI 10.1093/sw/43.2.169
   Dawkins Richard, 2006, GOD DELUSION
   de Rios MD, 2002, J PSYCHOACTIVE DRUGS, V34, P239, DOI 10.1080/02791072.2002.10399960
   Ellis A., 1962, REASON EMOTION PSYCH
   GALANTER M, 1993, AM J DRUG ALCOHOL AB, V19, P499, DOI 10.3109/00952999309001638
   Geering, 1999, WORLD COME CHRISTIAN
   Gentry John R, 2002, Ann Clin Psychiatry, V14, P233, DOI 10.1023/A:1021921118070
   GOLD MS, 1992, PSYCHIAT ANN, V22, P430, DOI 10.3928/0048-5713-19920801-09
   Green LL, 1998, J SUBST ABUSE TREAT, V15, P325, DOI 10.1016/S0740-5472(97)00211-0
   Griffiths RR, 2006, PSYCHOPHARMACOLOGY, V187, P268, DOI 10.1007/s00213-006-0457-5
   HAMER D, 2004, GOD GENE FAITH HARDW
   HAMMER RP, 2002, BRAIN CIRCUITRY SIGN, P99
   Hart CL, 2005, DRUG ALCOHOL DEPEN, V80, P147, DOI 10.1016/j.drugalcdep.2005.03.027
   Hawking Stephen, 2005, BRIEFER HIST TIME
   Huriwai T, 2000, SUBST USE MISUSE, V35, P281, DOI 10.3109/10826080009147697
   HUXLEY A, 2002, ISLAND
   Hyman SE, 2005, AM J PSYCHIAT, V162, P1414, DOI 10.1176/appi.ajp.162.8.1414
   JAMES W, 1902, VARIETIES RELIGIOUS
   JOHNSON FG, 1969, AM J PSYCHIAT, V126, P481, DOI 10.1176/ajp.126.4.481
   Jung C. G., 1964, MAN HIS SYMBOLS
   Krupitsky E, 2002, J SUBST ABUSE TREAT, V23, P273, DOI 10.1016/S0740-5472(02)00275-1
   Kurtz Ernest, 1979, NOT GOD HIST ALCOHOL
   Levi MS, 2002, CURR MED CHEM, V9, P1807, DOI 10.2174/0929867023368980
   LEWIN L, 1921, PHANTASTICA NARCOTIC
   McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689
   Miller W.R., 1999, INTEGRATING SPIRITUA, P3, DOI DOI 10.1037/10327-001
   MORROW D, 1993, J COUNS DEV, V71, P452, DOI 10.1002/j.1556-6676.1993.tb02664.x
   MOTTIN JL, 1973, Q J STUD ALCOHOL, V34, P444
   NIETZSCHE F, 1882, GAY SCI PRELUDE GERM
   OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881
   PAHNKE WN, 1970, J AMER MED ASSOC, V212, P1856, DOI 10.1001/jama.212.11.1856
   Pettinati Helen M, 2006, Curr Psychiatry Rep, V8, P383, DOI 10.1007/s11920-006-0040-0
   Previc FH, 2006, CONSCIOUS COGN, V15, P500, DOI 10.1016/j.concog.2005.09.009
   Project Match Res Grp, 1998, J STUD ALCOHOL, V59, P631
   *RAT REC SYST, 2004, STRUCT MOD ADD 1996
   Roberts L, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000368.pub2
   Robinson TE, 2001, ADDICTION, V96, P103, DOI 10.1046/j.1360-0443.2001.9611038.x
   RUCK CAP, 1979, J PSYCHEDEL DRUG, V11, P145, DOI 10.1080/02791072.1979.10472098
   Sessa B, 2005, BRIT J PSYCHIAT, V186, P457, DOI 10.1192/bjp.186.6.457
   SMART RC, 1967, BROOKSIDE MONOGRAPH, V6
   *SMART REC, 2006, SELF MAN REC TRAIN
   Sofuoglu Mehmet, 2006, Expert Opin Emerg Drugs, V11, P91, DOI 10.1517/14728214.11.1.91
   SOSKIN RA, 1970, Q J STUD ALCOHOL, V31, P920
   STALL R, 1986, INT J ADDICT, V21, P1
   Steigerwald F, 1999, J SUBST ABUSE TREAT, V16, P321, DOI 10.1016/S0740-5472(98)00052-X
   TRIMPEY J, 1988, SMALL BOOK
   Turbott J, 1996, AUST NZ J PSYCHIAT, V30, P720, DOI 10.3109/00048679609065037
   Vaillant GE, 2005, AUST NZ J PSYCHIAT, V39, P431, DOI 10.1080/j.1440-1614.2005.01600.x
   VAILLANT GE, 1988, BRIT J ADDICT, V83, P1147
   VANDUSEN W, 1967, Q J STUD ALCOHOL, V28, P295
   VASTAG B, 2002, JAMA-J AM MED ASSOC, V288, P3099
   VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876
   White JM, 2007, EXPERT OPIN PHARMACO, V8, P1, DOI 10.1517/14656566.8.1.1
   White WL, 2004, J CLIN PSYCHOL, V60, P461, DOI 10.1002/jclp.20001
   *WIK, 2008, SALV ARM
   Worthington EL, 1996, PSYCHOL BULL, V119, P448, DOI 10.1037/0033-2909.119.3.448
   Worthington EL, 2001, PSYCHOTHERAPY, V38, P473
   ZUCKERMAN P, 2004, SKEPTICAL INQUIR MAR
   HEALING OUR SPIRIT W
NR 69
TC 11
Z9 11
U1 1
U2 16
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0004-8674
EI 1440-1614
J9 AUST NZ J PSYCHIAT
JI Aust. N. Z. J. Psych.
PD OCT
PY 2007
VL 41
IS 10
BP 800
EP 808
DI 10.1080/00048670701579074
PG 9
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA 226JX
UT WOS:000250586400005
PM 17828653
DA 2023-06-23
ER

PT J
AU Cornelis, MC
   Flint, A
   Field, AE
   Kraft, P
   Han, J
   Rimm, EB
   van Dam, RM
AF Cornelis, Marilyn C.
   Flint, Alan
   Field, Alison E.
   Kraft, Peter
   Han, Jiali
   Rimm, Eric B.
   van Dam, Rob M.
TI A genome-wide investigation of food addiction
SO OBESITY
LA English
DT Article
ID ASSOCIATION; OBESITY; SUSCEPTIBILITY; METAANALYSIS; LOCI
AB ObjectiveEvidence of parallels between drug addiction and eating behavior continues to accumulate. Genetic studies of addictive substances have yielded a number of susceptibility loci that point to common higher order genetic pathways underlying addiction. It was hypothesized that a genome-wide association study (GWAS) of food addiction would yield significant enrichment in genes and pathways linked to addiction.
   MethodsA GWAS of food addiction, determined by the modified Yale Food Addiction Scale (mYFAS), was conducted among 9,314 women of European ancestry, and results for enrichment of single-nucleotide polymorphisms (SNPs) (n=44), genes (n=238), and pathways (n=11) implicated in drug addiction were examined.
   ResultsTwo loci met GW-significance (P<2.5 x 10(-8)) mapping to 17q21.31 and 11q13.4 that harbor genes with no obvious roles in eating behavior. GW results were significantly enriched for gene members of the MAPK signaling pathway (P=0.02). No candidate SNP or gene for drug addiction was significantly associated with food addiction after correction for multiple testing.
   ConclusionsIn the first GWAS of mYFAS, suggestive loci worthy of further follow-up were identified, but limited support was provided for shared genetic underpinnings of food addiction and drug addiction. The latter might be due to limited study power and knowledge of the genetics of drug addiction.
C1 [Cornelis, Marilyn C.] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Flint, Alan; Rimm, Eric B.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
   [Flint, Alan; Field, Alison E.; Kraft, Peter; Rimm, Eric B.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Kraft, Peter] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [Han, Jiali] Indiana Univ, Simon Canc Ctr, Dept Epidemiol, Richard M Fairbanks Sch Publ Hlth, Indianapolis, IN 46204 USA.
   [Rimm, Eric B.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.
   [van Dam, Rob M.] Natl Univ Singapore, Yong Loo Lin Sch Med, Saw Swee Hock Sch Publ Hlth, Singapore 117595, Singapore.
   [van Dam, Rob M.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 117595, Singapore.
   [van Dam, Rob M.] Natl Univ Hlth Syst, Singapore, Singapore.
C3 Northwestern University; Feinberg School of Medicine; Harvard
   University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard T.H. Chan School of Public Health; Indiana
   University System; Indiana University-Purdue University Indianapolis;
   Harvard University; Brigham & Women's Hospital; National University of
   Singapore; National University of Singapore; National University of
   Singapore
RP Cornelis, MC (通讯作者)，Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA.
EM marilyn.cornelis@northwestern.edu
RI Field, Alison/AAA-4508-2021; Kraft, Peter/GQH-8448-2022; van Dam, Rob
   M/F-9674-2010
OI van Dam, Rob M/0000-0002-7354-8734; Kraft, Peter/0000-0002-4472-8103
FU National Institute on Deafness and Other Communication Disorders
   [R03DC01337301A1]; National Cancer Institute (NCI) [UM1 CA186107, R01
   CA49449, UM1 CA176726, R01 CA67262]
FX This study was supported by the National Institute on Deafness and Other
   Communication Disorders (R03DC01337301A1 to MCC). Both cohorts are
   supported by the National Cancer Institute (NCI) (UM1 CA186107, R01
   CA49449, UM1 CA176726, R01 CA67262). Additional support was provided by
   the NCI, National Institute of Diabetes and Digestive and Kidney
   Diseases (NIDDK), National Human Genome Research Institute (NHGRI), and
   Merck/Rosetta Research Laboratories (North Wales, PA) for the collection
   and management of genetic data: R01 CA40356, U01 CA98233, U01 HG004399,
   U01 HG004728, 5P01 DK070756, U01 CA137088, R01 CA059045.
CR Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Bajo M, 2015, BRAIN BEHAV IMMUN, V45, P189, DOI 10.1016/j.bbi.2014.11.011
   Carlier N, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0634-5
   Chen RS, 2007, CELL BIOCHEM BIOPHYS, V47, P178, DOI 10.1007/s12013-007-0002-0
   Colditz GA, 2005, NAT REV CANCER, V5, P388, DOI 10.1038/nrc1608
   Cornelis MC, 2014, OBESITY, V22, pE135, DOI 10.1002/oby.20592
   Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323
   Dagher A, 2009, INT J OBESITY, V33, pS30, DOI 10.1038/ijo.2009.69
   Davis C, 2013, PHYSIOL BEHAV, V118, P63, DOI 10.1016/j.physbeh.2013.05.014
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Flint AJ, 2014, AM J CLIN NUTR, V99, P578, DOI 10.3945/ajcn.113.068965
   Fox CS, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002695
   Gearhardt AN, 2009, J ADDICT MED, V3, P1, DOI 10.1097/ADM.0b013e318193c993
   Gearhardt AN, 2009, APPETITE, V52, P430, DOI 10.1016/j.appet.2008.12.003
   Hindorf L, 2015, NHGRI EBI CATALOG PU
   HIROSE T, 1995, BIOCHEM BIOPH RES CO, V211, P83, DOI 10.1006/bbrc.1995.1781
   Ioannidis JPA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000841
   Li CY, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.0040002
   Li CY, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-508
   Li MD, 2009, NAT REV GENET, V10, P225, DOI 10.1038/nrg2536
   Liu CT, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003681
   Liu JZ, 2010, AM J HUM GENET, V87, P139, DOI 10.1016/j.ajhg.2010.06.009
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   McAdams MA, 2007, OBESITY, V15, P188, DOI 10.1038/oby.2007.504
   McGue M, 2013, BEHAV GENET, V43, P363, DOI 10.1007/s10519-013-9606-x
   Murphy A, 2009, AM J HUM GENET, V85, P87, DOI 10.1016/j.ajhg.2009.06.011
   Pan Y, 2011, PROG NEURO-PSYCHOPH, V35, P154, DOI 10.1016/j.pnpbp.2010.10.016
   Pe'er I, 2008, GENET EPIDEMIOL, V32, P381, DOI 10.1002/gepi.20303
   Roadmap Epigenomics Consortium, 2015, Nature, V518, P317, DOI 10.1038/nature14248
   Rockhill B, 1998, J NATL CANCER I, V90, P1155, DOI 10.1093/jnci/90.15.1155
   Segre AV, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001058
   Speliotes EK, 2010, NAT GENET, V42, P937, DOI 10.1038/ng.686
   Stutzmann F, 2009, INT J OBESITY, V33, P373, DOI 10.1038/ijo.2008.279
   Thorgeirsson TE, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.81
   Thorgeirsson TE, 2010, NAT GENET, V42, P448, DOI 10.1038/ng.573
   Uhl GR, 2009, J NEUROGENET, V23, P272, DOI 10.1080/01677060802572929
   Volkow ND, 2013, OBES REV, V14, P2, DOI 10.1111/j.1467-789X.2012.01031.x
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
   Wu MC, 2010, AM J HUM GENET, V86, P929, DOI 10.1016/j.ajhg.2010.05.002
NR 39
TC 35
Z9 35
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1930-7381
EI 1930-739X
J9 OBESITY
JI Obesity
PD JUN
PY 2016
VL 24
IS 6
BP 1336
EP 1341
DI 10.1002/oby.21476
PG 6
WC Endocrinology & Metabolism; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA DO1EK
UT WOS:000377521100023
PM 27106561
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Laque, A
   Wagner, GE
   Matzeu, A
   De Ness, GL
   Kerr, TM
   Carroll, AM
   De Guglielmo, G
   Nedelescu, H
   Buczynski, MW
   Gregus, AM
   Jhou, TC
   Zorrilla, EP
   Martin-Fardon, R
   Koya, E
   Ritter, RC
   Weiss, F
   Suto, N
AF Laque, Amanda
   Wagner, Grant E.
   Matzeu, Alessandra
   De Ness, Genna L.
   Kerr, Tony M.
   Carroll, Ayla M.
   de Guglielmo, Giordano
   Nedelescu, Hermina
   Buczynski, Matthew W.
   Gregus, Ann M.
   Jhou, Thomas C.
   Zorrilla, Eric P.
   Martin-Fardon, Remi
   Koya, Eisuke
   Ritter, Robert C.
   Weiss, Friedbert
   Suto, Nobuyoshi
TI Linking drug and food addiction via compulsive appetite
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE eating disorders; food addiction; substance use disorders
ID HELPS INFORM; HIGH-FAT; COCAINE; BEHAVIOR; SEEKING; RATS; SENSITIZATION;
   NEUROBIOLOGY; WITHDRAWAL; DISEASE
AB Background and Purpose 'Food addiction' is the subject of intense public and research interest. However, this nosology based on neurobehavioural similarities among obese individuals, patients with eating disorders and those with substance use disorders (drug addiction) remains controversial. We thus sought to determine which aspects of disordered eating are causally linked to preclinical models of drug addiction. We hypothesized that extensive drug histories, known to cause addiction-like brain changes and drug motivation in rats, would also cause addiction-like food motivation. Experimental Approach Rats underwent extensive cocaine, alcohol, caffeine or obesogenic diet histories and were subsequently tested for punishment-resistant food self-administration or 'compulsive appetite', as a measure of addiction-like food motivation. Key Results Extensive cocaine and alcohol (but not caffeine) histories caused compulsive appetite that persisted long after the last drug exposure. Extensive obesogenic diet histories also caused compulsive appetite, although neither cocaine nor alcohol histories caused excess calorie intake and bodyweight during abstinence. Hence, compulsive appetite and obesity appear to be dissociable, with the former sharing common mechanisms with preclinical drug addiction models. Conclusion and Implications Compulsive appetite, as seen in subsets of obese individuals and patients with binge-eating disorder and bulimia nervosa (eating disorders that do not necessarily result in obesity), appears to epitomize 'food addiction'. Because different drug and obesogenic diet histories caused compulsive appetite, overlapping dysregulations in the reward circuits, which control drug and food motivation independently of energy homeostasis, may offer common therapeutic targets for treating addictive behaviours across drug addiction, eating disorders and obesity.
C1 [Laque, Amanda; Wagner, Grant E.; De Ness, Genna L.; Kerr, Tony M.; Carroll, Ayla M.; de Guglielmo, Giordano; Nedelescu, Hermina; Buczynski, Matthew W.; Weiss, Friedbert; Suto, Nobuyoshi] Scripps Res Inst, Dept Neurosci, La Jolla, CA 92037 USA.
   [Matzeu, Alessandra; Zorrilla, Eric P.; Martin-Fardon, Remi] Scripps Res Inst, Dept Mol Med, La Jolla, CA USA.
   [Kerr, Tony M.] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA.
   [de Guglielmo, Giordano] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
   [Buczynski, Matthew W.; Gregus, Ann M.] Virginia Polytech Inst & State Univ, Sch Neurosci, Blacksburg, VA 24061 USA.
   [Jhou, Thomas C.] Med Univ South Carolina, Dept Neurosci, Charleston, SC 29425 USA.
   [Koya, Eisuke] Univ Sussex, Sch Psychol, Sussex Neurosci, Falmer, England.
   [Ritter, Robert C.] Washington State Univ, Dept Integrat Physiol & Neurosci, Pullman, WA 99164 USA.
C3 Scripps Research Institute; Scripps Research Institute; University of
   Texas System; University of Texas Austin; University of California
   System; University of California San Diego; Virginia Polytechnic
   Institute & State University; Medical University of South Carolina;
   University of Sussex; Washington State University
RP Weiss, F; Suto, N (通讯作者)，Scripps Res Inst, Dept Neurosci, La Jolla, CA 92037 USA.
EM bweiss@scripps.edu; nsuto@scripps.edu
RI de Guglielmo, Giordano/AAX-6289-2021
OI de Guglielmo, Giordano/0000-0002-4782-7430; Nedelescu,
   Hermina/0000-0003-1300-672X; Carroll, Ayla/0000-0001-8068-9693; Matzeu,
   Alessandra/0000-0002-7654-4149; Kerr, Tony/0000-0002-8962-6215; Koya,
   Eisuke/0000-0002-5039-4875; Gregus, Ann/0000-0001-6851-1382
FU National Institute on Drug Abuse [K99/R00DA035865, R01DA037294,
   R01DA08467]; National Institute on Alcohol Abuse and Alcoholism
   [R01AA021549, R01AA023183, T32AA007456]
FX National Institute on Drug Abuse, Grant/Award Numbers: K99/R00DA035865,
   R01DA037294, R01DA08467; National Institute on Alcohol Abuse and
   Alcoholism, Grant/Award Numbers: R01AA021549, R01AA023183, T32AA007456
CR Ahmed SH, 2012, NEUROSCIENCE, V211, P107, DOI 10.1016/j.neuroscience.2011.08.014
   Alaux-Cantin S, 2021, ADDICT BIOL, V26, DOI 10.1111/adb.13023
   Alexander SPH, 2019, BRIT J PHARMACOL, V176, pS1, DOI 10.1111/bph.14747
   American Psychiatric Association [APA], 2022, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425787]
   Avena Nicole M, 2011, Curr Drug Abuse Rev, V4, P133
   Berthoud HR, 2006, OBESITY, V14, P197
   Billing L, 2015, AM J DRUG ALCOHOL AB, V41, P115, DOI 10.3109/00952990.2014.966196
   Boswell RG, 2021, CLIN THER, V43, P50, DOI 10.1016/j.clinthera.2020.10.014
   Chao AM, 2016, EAT BEHAV, V21, P41, DOI 10.1016/j.eatbeh.2015.12.007
   Clemens KJ, 2018, PROG NEURO-PSYCHOPH, V87, P48, DOI 10.1016/j.pnpbp.2017.11.011
   Cowan J, 2008, APPETITE, V50, P33, DOI 10.1016/j.appet.2007.05.006
   Curtis MJ, 2018, BRIT J PHARMACOL, V175, P987, DOI 10.1111/bph.14153
   de Araujo IE, 2020, ANNU REV PSYCHOL, V71, P139, DOI 10.1146/annurev-psych-122216-011643
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Desai U, 2007, P NATL ACAD SCI USA, V104, P11766, DOI 10.1073/pnas.0705041104
   du Sert NP, 2020, BRIT J PHARMACOL, V177, P3617, DOI 10.1111/bph.15193
   Edwards S, 2012, NEUROPHARMACOLOGY, V62, P1142, DOI 10.1016/j.neuropharm.2011.11.006
   Ersche KD, 2013, APPETITE, V71, P75, DOI 10.1016/j.appet.2013.07.011
   Everitt BJ, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2017.0027
   Fletcher PC, 2018, NEUROPSYCHOPHARMACOL, V43, P2506, DOI 10.1038/s41386-018-0203-9
   Gearhardt AN, 2021, AM J CLIN NUTR, V113, P263, DOI 10.1093/ajcn/nqaa343
   Gearhardt AN, 2021, AM J CLIN NUTR, V113, P274, DOI 10.1093/ajcn/nqaa345
   Gearhardt AN, 2016, PSYCHOL ADDICT BEHAV, V30, P113, DOI 10.1037/adb0000136
   Gearhardt Ashley N, 2011, Curr Drug Abuse Rev, V4, P201
   Heckman MA, 2010, J FOOD SCI, V75, pR77, DOI 10.1111/j.1750-3841.2010.01561.x
   Heyne A, 2009, ADDICT BIOL, V14, P373, DOI 10.1111/j.1369-1600.2009.00175.x
   Hodgkins Candace, 2007, J Addict Dis, V26 Suppl 1, P41, DOI 10.1300/J069v26S01_05
   Holtrup B, 2017, ADIPOCYTE, V6, P224, DOI 10.1080/21623945.2017.1349042
   HORSAGER C, 2021, EAT WEIGHT DISORD-ST
   Jean-Richard-Dit-Bressel P, 2021, ELIFE, V10, DOI 10.7554/eLife.69594
   Jean-Richard-dit-Bressel P, 2019, ELIFE, V8, DOI 10.7554/eLife.52765
   Jimenez-Murcia S, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112633
   Johnson PM, 2010, NAT NEUROSCI, V13, P635, DOI 10.1038/nn.2519
   Kirpich IA, 2011, J NUTR BIOCHEM, V22, P38, DOI 10.1016/j.jnutbio.2009.11.009
   Klein ED, 2007, LEARN MOTIV, V38, P44, DOI 10.1016/j.lmot.2006.07.004
   Laque A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11799-1
   LeSage MG, 2006, PHARMACOL BIOCHEM BE, V83, P585, DOI 10.1016/j.pbb.2006.03.021
   Li YY, 2017, PSYCHOPHARMACOLOGY, V234, P1277, DOI 10.1007/s00213-017-4565-1
   Li YL, 2004, EUR J NEUROSCI, V20, P1647, DOI 10.1111/j.1460-9568.2004.03612.x
   Lilley E, 2020, BRIT J PHARMACOL, V177, P3611, DOI 10.1111/bph.15178
   Lucantonio F, 2014, NAT NEUROSCI, V17, P1092, DOI 10.1038/nn.3763
   McBride WJ, 1998, CRIT REV NEUROBIOL, V12, P339, DOI 10.1615/CritRevNeurobiol.v12.i4.40
   Minhas M, 2021, ADDICTION, V116, P2870, DOI 10.1111/add.15446
   Munn-Chernoff MA, 2021, ADDICT BIOL, V26, DOI 10.1111/adb.12880
   Pelloux Y, 2007, PSYCHOPHARMACOLOGY, V194, P127, DOI 10.1007/s00213-007-0805-0
   Richardson NR, 1996, J NEUROSCI METH, V66, P1, DOI 10.1016/0165-0270(95)00153-0
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Rossetti C, 2014, ADDICT BIOL, V19, P975, DOI 10.1111/adb.12065
   Schoenbaum G, 2005, CEREB CORTEX, V15, P1162, DOI 10.1093/cercor/bhh216
   Schoenbaum G, 2004, EUR J NEUROSCI, V19, P1997, DOI 10.1111/j.1460-9568.2004.03274.x
   Serafine KM, 2021, NEUROPHARMACOLOGY, V196, DOI 10.1016/j.neuropharm.2021.108556
   Serrano A, 2018, NEUROPSYCHOPHARMACOL, V43, P1840, DOI 10.1038/s41386-018-0055-3
   Shoaib M, 1999, PSYCHOPHARMACOLOGY, V142, P327, DOI 10.1007/s002130050896
   Singer BF, 2018, J NEUROSCI, V38, P60, DOI 10.1523/JNEUROSCI.2458-17.2017
   Small DM, 2019, SCIENCE, V363, P346, DOI 10.1126/science.aav0556
   Spierling S, 2020, NEUROPSYCHOPHARMACOL, V45, P579, DOI 10.1038/s41386-019-0538-x
   Udo T, 2018, BIOL PSYCHIAT, V84, P345, DOI 10.1016/j.biopsych.2018.03.014
   Uriarte G, 2013, J PHYSIOL BIOCHEM, V69, P601, DOI 10.1007/s13105-012-0231-6
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Vanderschuren LJMJ, 2021, CSH PERSPECT MED, V11, DOI 10.1101/cshperspect.a040287
   Volkow ND, 2005, NAT NEUROSCI, V8, P555, DOI 10.1038/nn1452
   Volkow ND, 2016, NEW ENGL J MED, V374, P363, DOI 10.1056/NEJMra1511480
   Whiteford HA, 2013, LANCET, V382, P1575, DOI 10.1016/S0140-6736(13)61611-6
   Wiss DA, 2017, APPETITE, V115, P19, DOI 10.1016/j.appet.2016.12.019
NR 64
TC 1
Z9 1
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD JUN
PY 2022
VL 179
IS 11
BP 2589
EP 2609
DI 10.1111/bph.15797
EA MAR 2022
PG 21
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Pharmacology & Pharmacy
GA 0Z1ED
UT WOS:000765273500001
PM 35023154
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Proudfoot, J
AF Proudfoot, Jesse
TI Drugs, addiction, and the social bond
SO GEOGRAPHY COMPASS
LA English
DT Article
ID SPACES; GEOGRAPHIES; ALCOHOL; CONSUMPTION; HOMELESSNESS; DRINKING;
   VIOLENCE; HEROIN; POLICY
AB This article contributes towards the project of critically theorizing drug addiction by drawing on insights from psychoanalysis, anthropology, and geography. I argue that social bondsthat is, people's relationships to other people and to societyare central to the phenomenon of drug addiction, and I present three accounts of drug addiction and the social bond. The first is the classical psychoanalytic account of addiction, which holds that drug use is essentially masturbatory: a solitary pleasure that involves a turning away from the pleasure of being with others towards the pleasure of the drug. The second, which is associated with ethnographies of drug users, insists on the enduring sociality of drug use, demonstrating how even the most marginalized of drug addicts inhabits a social world of mores, obligations, and kinship relations. Third, I present an alternative psychoanalytic account of addiction, one which views addiction as a symptom that is meaningfulas an act or message that is addressed to the other. Each of these readings provides a different way of understanding the relationship between drug use, the social bond, and their respective geographies. I conclude by reviewing recent post-structuralist work on drug use by geographers and argue that the psychoanalytic concept of the symptom provides a productive way forward in thinking about addictionone that maintains a relational account of drug use while also providing us with a language for examining the place of drug-using subject and the meanings that addiction plays for them.
C1 [Proudfoot, Jesse] Univ Durham, Dept Geog, South Rd, Durham DH1 3LE, England.
C3 N8 Research Partnership; Durham University
RP Proudfoot, J (通讯作者)，Univ Durham, Dept Geog, South Rd, Durham DH1 3LE, England.
EM jesse.proudfoot@durham.ac.uk
OI Proudfoot, Jesse/0000-0002-5828-2341
CR Aitken SC, 2012, SOC CULT GEOGR, V13, P127, DOI 10.1080/14649365.2012.655767
   Alexander B., 2010, GLOBALIZATION ADDICT
   American Psychiatric Association [APA], 2022, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425787]
   Aronofsky D., 2001, REQUIEM FOR A DREAM
   Blomley N, 2009, URBAN GEOGR, V30, P577, DOI 10.2747/0272-3638.30.6.577
   Blum V, 2011, ENVIRON PLANN D, V29, P1030, DOI 10.1068/d11910
   Bourgois P, 1998, SUBST USE MISUSE, V33, P2323, DOI 10.3109/10826089809056260
   Bourgois P., 2009, RIGHTEOUS DOPEFIEND
   Braunstein N., 2003, CAMBRIDGE COMPANION, P102
   Dean J., 2006, ZIEKS POLITICS
   Dean Tim, 2009, UNLIMITED INTIMACY R
   DeVerteuil G, 2009, GEOGR COMPASS, V3, P478, DOI 10.1111/j.1749-8198.2008.00204.x
   Dodes Lance., 2014, SOBER TRUTH DEBUNKIN
   Dor Joel, 1997, INTRO READING LACAN
   Duff C, 2008, INT J DRUG POLICY, V19, P384, DOI 10.1016/j.drugpo.2007.07.003
   Duff C, 2015, J SOCIOL, V51, P81, DOI 10.1177/1440783314562502
   Duff C, 2012, SOC CULT GEOGR, V13, P145, DOI 10.1080/14649365.2012.655765
   Evans Dylan, 1996, INTRO DICT LACANIAN
   Evans J, 2012, SOC CULT GEOGR, V13, P185, DOI 10.1080/14649365.2012.655769
   Evening Standard, 2011, ES AUB IS GETT US HA
   Fink B., 2014, UNDERSTANDING, V1, P5
   Fink B., 2014, UNDERSTANDING, V1, P158
   Fink Bruce, 1995, LACANIAN SUBJECT LAN
   Freud S., 2001, STANDARD EDITION COM, V20, P77
   Freud S, 2001, STANDARD EDITION COM, VXVIII, P1
   Freud S., 2001, STANDARD EDITION COM, V14, P141
   Freud S., 1954, ORIGINS PSYCHOANALYS, P238
   Garcia A, 2010, PASTORAL CLIN ADDICT
   GESLER WM, 1992, SOC SCI MED, V34, P735, DOI 10.1016/0277-9536(92)90360-3
   Hari J, 2015, CHASING SCREAM 1 LAS
   Hollway W., 2000, DOING QUALITATIVE RE, DOI [10.4135/9781849209007, DOI 10.4135/9781849209007]
   Hook D., 2012, CRITICAL PSYCHOL POS
   Jayne M, 2008, PROG HUM GEOG, V32, P247, DOI 10.1177/0309132507087649
   Jayne M, 2006, PROG HUM GEOG, V30, P451, DOI 10.1191/0309132506ph618oa
   KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259
   Kingsbury P, 2014, PSYCHOANALYTIC GEOGRAPHIES, P1
   Kingsbury P, 2007, SOC CULT GEOGR, V8, P235, DOI 10.1080/14649360701360196
   Kingsbury P, 2010, PROF GEOGR, V62, P519, DOI 10.1080/00330124.2010.501272
   Kneale J, 2008, DRUG-EDUC PREV POLIC, V15, P233, DOI 10.1080/09687630801920690
   LACAN J, 2006, ECRITS, P671
   LACAN J, 1988, SEMINAR J LACAN BOOK
   Lacan Jacques., 1997, SEMINAR JACQUES LACA
   Lang L, 2004, I MISS YOU HEROIN
   LAPLANCHE J, 1973, LANGUAGE PSYCHOANALY
   Layton L, 2008, PSYCHOANALYSIS CULTU, V13
   Levi-Strauss Claude, 1969, ELEMENTARY STRUCTURE
   Lewis M, 2016, BIOL DESIRE WHY ADDI
   LOOSE R, 2002, SUBJECT ADDICTION PS
   Loose R., 2011, LACAN ADDICTION ANTH, P1
   Malins P, 2004, JANUS HEAD, V7, P84
   Malins P, 2006, GENDER PLACE CULT, V13, P509, DOI 10.1080/09663690600858895
   Martin L, 2014, PROG HUM GEOG, V38, P420, DOI 10.1177/0309132513508209
   Mate G., 2009, REALM HUNGRY GHOSTS
   McCann E, 2015, HEALTH PLACE, V31, P216, DOI 10.1016/j.healthplace.2014.12.009
   McCann EJ, 2008, ENVIRON PLANN A, V40, P885, DOI 10.1068/a38456
   Mimica J., 2007, EXPLORATIONS PSYCHOA
   Moreno CM, 2009, GEOJOURNAL, V74, P219, DOI 10.1007/s10708-008-9223-z
   Moreno CM, 2012, SOC CULT GEOGR, V13, P161, DOI 10.1080/14649365.2012.655768
   Peele S., 1985, MEANING ADDICTION CO
   Pickard Hanna, 2012, AJOB Neurosci, V3, P40
   Proudfoot J., 2011, ANXIOUS ENJOYMENT PO
   Raikhel E., 2013, ADDICTION TRAJECTORI
   Rhodes T., 2002, INT J DRUG POLICY, V13, P85
   Rhodes T, 2009, INT J DRUG POLICY, V20, P193, DOI 10.1016/j.drugpo.2008.10.003
   Saldanha A., 2007, PSYCHEDELIC WHITE GO
   Schull N. D., 2012, ADDICTION DESIGN MAC, DOI DOI 10.2307/J.CTT12F4D0
   Shaw R, 2010, GEOGR COMPASS, V4, DOI 10.1111/j.1749-8198.2010.00345.x
   Valverde M., 1998, DIS WILL ALCOHOL DIL
   VERHAEGHE P, 1999, LOVE TIME LONELINESS
   Volkow N. D., 2012, PRINCIPLES DRUG ADDI
   WALDRON J, 1991, UCLA LAW REV, V39, P295
   Wilton R., 2007, THERAPEUTIC LANDSCAP, P77
   Wilton R, 2012, SOC CULT GEOGR, V13, P99, DOI 10.1080/14649365.2012.670505
NR 73
TC 3
Z9 3
U1 1
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1749-8198
J9 GEOGR COMPASS
JI Geogr. Compass
PD JUL
PY 2017
VL 11
IS 7
AR e12320
DI 10.1111/gec3.12320
PG 11
WC Geography
WE Social Science Citation Index (SSCI)
SC Geography
GA FA6IS
UT WOS:000405547300002
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Martinelli, TF
   Vander Laenen, F
   Nagelhout, GE
   van de Mheen, DH
AF Martinelli, Thomas F.
   Vander Laenen, Freya
   Nagelhout, Gera E.
   van de Mheen, Dike H.
TI Addiction and Recovery in Dutch Governmental and Practice-Level Drug
   Policy: What's the Problem Represented to be?
SO JOURNAL OF DRUG ISSUES
LA English
DT Article
DE addiction recovery; drug policy; practice-level policy;
   problematization; bacchi; Netherlands
ID UK; PRAGMATISM; STIGMA; CRIME; MODEL
AB Around 2009, 'recovery' was introduced in the Netherlands as a new approach to drug addiction and addiction services. Recovery is now featured in practice-level policy but is absent in governmental drug policy. To investigate whether the Dutch recovery vision is coherent with governmental drug policy, we apply Bacchi's What's the problem represented to be? approach to analyse problematizations of 'drug addiction'. We analysed two influential practice-level policy documents and one governmental drug policy document. We found that governmental policy addresses the harms and public nuisance of drug addiction, whilst practice-level policy addresses the wellbeing of persons with addiction. Despite these different starting points, the Dutch recovery vision seems coherent with both problematizations. Its adoption in the Netherlands was less subject to political debate compared to other countries. This may be a result of recovery being driven by bottom-up efforts without government intervention, leading to constructive ambiguity between government- and practice-level policies.
C1 [Martinelli, Thomas F.; Nagelhout, Gera E.] IVO Res Inst, Koningin Julianapl 10, NL-2595 AA The Hague, Netherlands.
   [Martinelli, Thomas F.; van de Mheen, Dike H.] Tilburg Univ, Tranzo Sci Ctr Care & Wellbeing, Sch Social & Behav Sci, Tilburg, Netherlands.
   [Vander Laenen, Freya] Univ Ghent, Fac Law & Criminol, Dept Criminol Penal Law & Social Law, Ghent, Belgium.
   [Nagelhout, Gera E.] Maastricht Univ, CAPHRI, Dept Hlth Promot, Maastricht, Netherlands.
C3 Tilburg University; Ghent University; Maastricht University; Maastricht
   University Medical Centre (MUMC)
RP Martinelli, TF (通讯作者)，IVO Res Inst, Koningin Julianapl 10, NL-2595 AA The Hague, Netherlands.
EM martinelli@ivo.nl
OI Nagelhout, Gera/0000-0001-7748-5059; Martinelli,
   Thomas/0000-0003-0055-5631
FU European Research Area Network on Illicit Drugs (ERANID); Netherlands
   Organisation for Health Research and Development (ZonMW) [63200000105];
   Research Foundation Flanders (FWO, Belgium); Belgian Science Policy
   Office (BELSPO)
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship and/or publication of this article: This
   research was supported by the European Research Area Network on Illicit
   Drugs (ERANID). It is funded in the Netherlands by The Netherlands
   Organisation for Health Research and Development (ZonMW), (63200000105)
   and in Belgium by the Research Foundation Flanders (FWO, Belgium) and
   the Belgian Science Policy Office (BELSPO).
CR Andrews DA, 2010, PSYCHOL PUBLIC POL L, V16, P39, DOI 10.1037/a0018362
   Anthony W. A., 1993, PSYCHOSOC REHABIL, V16, P11, DOI DOI 10.1037/H0095655
   Bacchi C., 2016, POSTSTRUCTURAL POLIC, DOI [10.1057/978-1-137-52546-8, DOI 10.1057/978-1-137-52546-8, 10.1057/978-1-137-52546-8.]
   Bacchi C., 2009, ANAL POLICY WHATS PR
   Bakkum F., 2020, MANIFEST REALISTISCH
   Bellaert L, 2021, DRUG-EDUC PREV POLIC, V28, P399, DOI 10.1080/09687637.2021.1915250
   Berg J, 2021, CRIT PUBLIC HEALTH, V31, P101, DOI 10.1080/09581596.2019.1680803
   Best D, 2021, FRONT PSYCHOL, V12, DOI 10.3389/fpsyg.2021.663447
   Best D, 2018, ALCOHOL TREAT Q, V36, P517, DOI 10.1080/07347324.2018.1488550
   Best D, 2010, J GROUPS ADDICT RECO, V5, P264, DOI 10.1080/1556035X.2010.523362
   Blok G., 2011, ZIEK ZWAK GESCHIEDEN
   Braslow JT, 2013, ANNU REV CLIN PSYCHO, V9, P781, DOI 10.1146/annurev-clinpsy-050212-185642
   Brewer M.D., 2015, POLARIZATION POLITIC
   Cameron D., 2010, BIG SOC SPEECH
   Clarke A, 2019, CRIT POLICY STUD, V13, P190, DOI 10.1080/19460171.2017.1414619
   Csete J, 2012, INT J DRUG POLICY, V23, P82, DOI 10.1016/j.drugpo.2011.07.011
   Davidson L, 2007, J MENTAL HLTH, V16, P459, DOI DOI 10.1080/09638230701482394
   Davidson Larry, 2007, J Behav Health Serv Res, V34, P109
   De Kort M, 1999, J DRUG ISSUES, V29, P473, DOI 10.1177/002204269902900303
   Deegan P. E, 1988, PSYCHOSOC REHABIL, V11, P11, DOI DOI 10.1037/H0099565
   DELSEN L, 2000, EXIT POLDERMODEL SOC
   Duke K, 2013, J DRUG ISSUES, V43, P39, DOI 10.1177/0022042612466614
   ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460
   Expertise Center Forensic Psychiatry, 2020, ZORGPR FOR VERSL
   Fomiatti R., 2017, HOPE CHOICE IMPROVAB
   Fomiatti R, 2020, INT J DRUG POLICY, V80, DOI 10.1016/j.drugpo.2019.04.007
   Fomiatti R, 2017, INT J DRUG POLICY, V44, P174, DOI 10.1016/j.drugpo.2017.04.001
   Foucault M., 1988, M FOUCAULT POLITICS
   GGZ Nederland, 2013, VIS VERSL VERSL FOC
   GGZ Nederland, 2009, NAAR HERST GEL BURG
   Gilman M., 2011, FOUNDING FATHERS CON, P12
   Granfield R, 2001, SUBST USE MISUSE, V36, P1543, DOI 10.1081/JA-100106963
   Grund J.-P.C., 2018, DRUG POLICY NETHERLA, P128, DOI [10.4324/9781315690384-10, DOI 10.4324/9781315690384-10]
   Heather N, 2018, ADDICT RES THEORY, V26, P249, DOI 10.1080/16066359.2017.1399659
   Houborg E, 2020, INT J DRUG POLICY, V80, DOI 10.1016/j.drugpo.2020.102779
   Humphreys K, 2014, DRUG ALCOHOL REV, V33, P13, DOI 10.1111/dar.12092
   Humphreys K, 2010, PSYCHOL SERV, V7, P275, DOI 10.1037/a0020390
   Jellinek EM., 1960, DIS CONCEPT ALCOHOLI, DOI [10.1037/14090-000, DOI 10.1037/14090-000]
   Kaskutas LA, 2014, J STUD ALCOHOL DRUGS, V75, P999, DOI 10.15288/jsad.2014.75.999
   Kuipers S., 2015, BEGIN MODERNE NEDERL
   Lancaster K, 2015, INT J DRUG POLICY, V26, P617, DOI 10.1016/j.drugpo.2015.04.006
   LEVINE HG, 1978, J STUD ALCOHOL, V39, P143, DOI 10.15288/jsa.1978.39.143
   Martinelli TF, 2021, DRUG-EDUC PREV POLIC, V28, P389, DOI 10.1080/09687637.2020.1844638
   Martinelli TF, 2020, DRUG-EDUC PREV POLIC, V27, P387, DOI 10.1080/09687637.2020.1779182
   Mayock P, 2021, INT J DRUG POLICY, V90, DOI 10.1016/j.drugpo.2020.103092
   Mol R., 1991, INT J DRUG POLICY, V2, P16, DOI [10.1177/002204269502500307, DOI 10.1177/002204269502500307]
   National Institute on Drug Abuse, 2021, WHAT IS DRUG ADD
   Neale J, 2014, DRUG-EDUC PREV POLIC, V21, P310, DOI 10.3109/09687637.2014.918089
   Nutt D, 2007, LANCET, V369, P1047, DOI 10.1016/S0140-6736(07)60464-4
   Nutt DJ, 2010, LANCET, V376, P1558, DOI 10.1016/S0140-6736(10)61462-6
   O'Mahony S., 2019, IRISH J SOCIOLOGY, V27, P153, DOI [https://doi.org/10.1177/0791603519835437, DOI 10.1177/0791603519835437]
   Parker H., 1995, DRUGS FUTURES CHANGI
   Pieters G., 1995, REHABILITATIE CHRONI
   Rabinow P., 2009, ANTHROPOS TODAY, DOI [10.1515/9781400825905, DOI 10.1515/9781400825905]
   Ritter A., 2005, DPMP MONOGRAPH SERIE
   Room R, 2005, DRUG ALCOHOL REV, V24, P143, DOI 10.1080/09595230500102434
   Seddon T., 2009, HIST DRUGS, DOI [10.4324/9780203880838, DOI 10.4324/9780203880838]
   Seear K, 2014, INT J DRUG POLICY, V25, P826, DOI 10.1016/j.drugpo.2014.02.016
   Shiner M, 1997, SOCIOLOGY, V31, P511, DOI 10.1177/0038038597031003008
   SIEGLER M, 1968, INT J ADDICT, V3, P3, DOI 10.3109/10826086809042880
   Single Convention on Narcotic Drugs 1961 as amended by the 1972 Protocol Amending the Single Convention on Narcotic Drugs, 1961, TESTIMONY UN
   Spruit IP, 2001, SUBST USE MISUSE, V36, P23, DOI 10.1081/JA-100000227
   Thomas N, 2019, INT J DRUG POLICY, V73, P72, DOI 10.1016/j.drugpo.2019.07.013
   Tops D., 2006, DRUG USERS SPACES LE
   Tran M., 2009, GUARDIAN
   Uitermark J, 2004, J DRUG ISSUES, V34, P511, DOI 10.1177/002204260403400303
   UK Drug Policy Commission, 2008, VIS REC POL REP
   United Nations, 1988, UNESCO COURRIER, P1
   van der Stel J., 2014, HERSTEL BINNEN VERSL, P1, DOI [10.1007/978-90-368-0794-4_1, DOI 10.1007/978-90-368-0794-4_1]
   van Laar M., 2009, EVALUATIE NEDERLANDS
   van Weeghel J, 2019, PSYCHIATR REHABIL J, V42, P169, DOI 10.1037/prj0000356
   Vanderplasschen W., 2017, NAAR HERSTELONDERSTE
   Wakeman SE, 2018, SUBST USE MISUSE, V53, P330, DOI 10.1080/10826084.2017.1363238
   Ward T, 2003, PROF PSYCHOL-RES PR, V34, P353, DOI 10.1037/0735-7028.34.4.353
   White WL, 2007, J SUBST ABUSE TREAT, V33, P229, DOI 10.1016/j.jsat.2007.04.015
   White William L., 1998, SLAYING DRAGON HIST
   Zorgverzekeringswet, 2006, TESTIMONY RIJKSOVERH
NR 77
TC 0
Z9 0
U1 3
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022-0426
EI 1945-1369
J9 J DRUG ISSUES
JI J. Drug Issues
PD OCT
PY 2022
VL 52
IS 4
BP 547
EP 567
AR 00220426221087590
DI 10.1177/00220426221087590
EA APR 2022
PG 21
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA 4F8MG
UT WOS:000783238500001
OA Green Published
DA 2023-06-23
ER

PT J
AU Babic, R
   Babic, D
   Martinac, M
   Pavlovic, M
   Vasilj, I
   Miljko, M
   Vasilj, M
AF Babic, Romana
   Babic, Dragan
   Martinac, Marko
   Pavlovic, Marko
   Vasilj, Ivan
   Miljko, Miro
   Vasilj, Marina
TI ADDICTIONS WITHOUT DRUGS: CONTEMPORARY ADDICTIONS OR WAY OF LIFE?
SO PSYCHIATRIA DANUBINA
LA English
DT Article
DE contemporary; addictive; sick; style
ID INTERNET ADDICTION; DIAGNOSIS
AB In the five thousand years of recorded history there is written evidence of various types of addiction. In recent decades scientists focus their attention on addictions without the immediate introduction of psychoactive substances into the organism or the so-called "addictions without drugs". Studies have revealed a number of similarities between drug addictions and addictions without drugs that also carry biological, psychological and social consequences in the form of addictive activity carvings, adrenaline alarm, dopamine and serotonin secretion, tolerance and abstinence syndrome same as classical forms of addiction. Although the physiological effect of addiction without drugs on the brain and nervous system is not yet sufficiently explored, scientists have found equivalent effects on addicts suffering from one or the other type of addiction. These addicts are almost generally dysfunctional persons who become prisoners of their own passions, and the consequences are numerous technological advantages offered by modern times and in some respects a punishment due to the civilization for forgetting the man himself. Considering that most people, so and many psychiatrist, often accept these addictions as a lifestyle and without any delay and awareness of the potential dangers they may pose, we can with certainty say that the so-called "addictions without drugs" are the scourge of the 21st century. With pathological gambling, which is as old as human civilization, in recent decades we meet the growing problems of internet addiction, gambling games, which are classified for the first time at DSM V in addictive disorder, uncontrolled shopping, food cravings, addiction to sex, weight loss, sports, work and many more, which are mostly true addictions, and not only the way of life.
   The aim of this paper is to point to the growing problem of addiction without drugs, which is becoming an increasing problem within our community.
C1 [Babic, Romana; Babic, Dragan; Pavlovic, Marko] Univ Clin Hosp Mostar, Dept Psychiat, Mostar, Bosnia & Herceg.
   [Babic, Romana; Babic, Dragan; Martinac, Marko; Pavlovic, Marko; Vasilj, Ivan; Miljko, Miro; Vasilj, Marina] Univ Mostar, Sch Med, Mostar, Bosnia & Herceg.
   [Babic, Romana; Babic, Dragan; Martinac, Marko; Pavlovic, Marko; Vasilj, Ivan; Miljko, Miro; Vasilj, Marina] Univ Mostar, Fac Hlth Studies, Mostar, Bosnia & Herceg.
   [Martinac, Marko] Hlth Ctr Mostar, Mostar, Bosnia & Herceg.
   [Vasilj, Marina] Univ Clin Hosp Mostar, Dept Lab Med, Mostar, Bosnia & Herceg.
C3 University of Mostar; University of Mostar; University of Mostar;
   University of Mostar; University of Mostar
RP Babic, R (通讯作者)，Univ Clin Hosp Mostar, Mostar 88000, Bosnia & Herceg.
EM romana.babic@gmail.com
CR Ajtlbez L, 2016, HLTH B, V2, P72
   American Psychiatric Association, 1996, DSM 4 DIAGN STAT MAN
   [Anonymous], 2004, GROUP AUTHORS CROATI
   Babi D, 2016, PSYCHOACTIVE SUBSTAN
   Birouste J, 1999, REV SPORT PSYCHOL, V10, P367
   Brlas S, 2010, IT IS IMPORTANT NOT
   Carrier C, 2000, ANN MED INTERNE, V151, pA60
   Clark L, 2014, DISORDERED GAMBLING
   Cought J, 2000, NET RECOGNIZE SINGS
   Dimitrijevic I, 2015, PSYCHIAT DANUB, V27, P101
   Dordevic V, 2016, LOST SOULS ZAGREBS I
   Duarte Garcia F, 2010, AM J DRUG ALCOHOL AB, V5, P254
   Evren C, 2014, PSYCHIAT DANUB, V26, P330
   Farre JM, 2015, COMPR PSYCHIAT, V56, P59, DOI 10.1016/j.comppsych.2014.10.002
   Foddy B, 2011, ADDICTION, V106, P25, DOI 10.1111/j.1360-0443.2010.03158.x
   Hinic D, 2011, PSYCHIAT DANUB, V23, P145
   Jakovljevic M, 2016, ZDRAVSTVENI GLASNIK, V1, P65
   Kecmanovi D, 2008, OFFICIAL B BEOGRAD
   Lipovetsky G, 2008, SOC DECEPTION, V127
   Martinac M, 2007, PAEDIATR CROAT, V51, P5
   Mihajlovic G, 2008, PSYCHIAT DANUB, V20, P6
   Paucic Kirincic E, 2003, PEDIAT CROATICA, V47, P191
   Sartorius N, 2010, FIGHTING MENTAL HLTH
   Sartorius N, 2014, MENTAL HLTH CULTURE
   Senormanci O, 2014, PSYCHIAT DANUB, V26, P39
   Sissa J, 1997, PLAISIR MAL ODILE JA
   Vasilj I, 2016, PSYCHOACTIVE SUBSTAN
   World Health Organisation, 1993, CLIN DESCR DIAGN GUI
   World Health Organisation, 2009, HLTH YOUTH
   Zuckerman IZ, 2010, ADDICTIONS MODERN AG
   Zuckerman IZ, 2004, PEDAGOGICAL RES, V1, P231
NR 31
TC 1
Z9 1
U1 1
U2 21
PU MEDICINSKA NAKLADA
PI ZAGREB
PA VLASKA 69, HR-10000 ZAGREB, CROATIA
SN 0353-5053
J9 PSYCHIAT DANUB
JI Psychiatr. Danub.
PY 2018
VL 30
SU 6
BP S371
EP S379
PG 9
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA GU8VK
UT WOS:000445620800006
DA 2023-06-23
ER

PT J
AU Kreek, MJ
   Nielsen, DA
   LaForge, KS
AF Kreek, MJ
   Nielsen, DA
   LaForge, KS
TI Genes associated with addiction - Alcoholism, opiate, and cocaine
   addiction
SO NEUROMOLECULAR MEDICINE
LA English
DT Review
DE addiction; alcohol; cocaine; genetics; genotype; opiate; physiogenetics;
   physiogenomics; polymorphism; single nucleoticle polymorphism
ID OPIOID-RECEPTOR GENE; CATECHOL-O-METHYLTRANSFERASE;
   DOPAMINE-BETA-HYDROXYLASE; ALDEHYDE DEHYDROGENASE GENOTYPES;
   MONOAMINE-OXIDASE-A; CONTROLLING MORPHINE PREFERENCE; NEUROPEPTIDE-Y
   POLYMORPHISM; CYTOCHROME-P450 CYP2D LOCUS; AMERICAN MISSION INDIANS;
   ACID AMIDE HYDROLASE
AB Drug addiction is a complex disorder that has a large spectrum of causes. Vulnerability to addiction has been shown in twin studies to have a robust genetic component. This genetic basis for addiction has general and specific components for each drug abused. Although many genes have been implicated in drug addiction, only a handful have either been replicated to have an association or to have an identified functional mechanism related to specific effects of abused drugs. A few selected genetic variants that currently look promising for the study of alcohol, opiate, and cocaine addiction are discussed in this article.
C1 Rockefeller Univ, Lab Biol & Addict Dis, New York, NY 10021 USA.
C3 Rockefeller University
RP Kreek, MJ (通讯作者)，Rockefeller Univ, Lab Biol & Addict Dis, 1230 York Ave, New York, NY 10021 USA.
EM kreek@rockefeller.edu
RI Nielsen, David A/B-4655-2009; Nielsen, David/HJI-9825-2023
FU NCRR NIH HHS [M01-RR00102] Funding Source: Medline; NIDA NIH HHS
   [P60-DA05130, R01-DA12848, R01-DA09444, K05-DA00049] Funding Source:
   Medline
CR Alexander RC, 1996, PSYCHIATR GENET, V6, P29, DOI 10.1097/00041444-199621000-00006
   ALVAN G, 1990, EUR J CLIN PHARMACOL, V39, P533, DOI 10.1007/BF00316090
   ASGHARI V, 1995, J NEUROCHEM, V65, P1157, DOI 10.1046/j.1471-4159.1995.65031157.x
   Aubert R, 2000, INT J OBESITY, V24, P920, DOI 10.1038/sj.ijo.0801253
   Barnard EA, 1998, PHARMACOL REV, V50, P291
   Becker A, 2002, N-S ARCH PHARMACOL, V365, P296, DOI 10.1007/s00210-002-0533-2
   Becker A, 2000, N-S ARCH PHARMACOL, V361, P584, DOI 10.1007/s002100000244
   Befort K, 2001, J BIOL CHEM, V276, P3130, DOI 10.1074/jbc.M006352200
   BELKNAP JK, 1992, ANN NY ACAD SCI, V654, P311, DOI 10.1111/j.1749-6632.1992.tb25977.x
   Bergen AW, 1997, MOL PSYCHIATR, V2, P490, DOI 10.1038/sj.mp.4000331
   Berrettini WH, 1997, ADDICT BIOL, V2, P303, DOI 10.1080/13556219772598
   BERRETTINI WH, 1994, NAT GENET, V7, P54, DOI 10.1038/ng0594-54
   Bierut LJ, 1998, ARCH GEN PSYCHIAT, V55, P982, DOI 10.1001/archpsyc.55.11.982
   Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608
   BOSRON WF, 1993, SEMIN LIVER DIS, V13, P126, DOI 10.1055/s-2007-1007344
   BOYLE AE, 1993, PHARMACOL BIOCHEM BE, V46, P179, DOI 10.1016/0091-3057(93)90338-T
   BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186
   Carr LG, 2002, AM J MED GENET, V112, P138, DOI 10.1002/ajmg.10674
   CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602
   Chang YT, 2002, MOL PSYCHIATR, V7, P828, DOI 10.1038/sj.mp.4001110
   Chen ACH, 2002, AM J MED GENET, V114, P429, DOI 10.1002/ajmg.10362
   Chen WJ, 1996, BRIT J PSYCHIAT, V168, P762, DOI 10.1192/bjp.168.6.762
   Claye LH, 1997, NIDA RES MONOGR, V174, P113
   CLONINGER CR, 1981, ARCH GEN PSYCHIAT, V38, P861
   Comings DE, 1999, AM J MED GENET, V88, P358, DOI 10.1002/(SICI)1096-8628(19990820)88:4<358::AID-AJMG13>3.0.CO;2-G
   CRABB DW, 1989, J CLIN INVEST, V83, P314, DOI 10.1172/JCI113875
   CRABB DW, 1993, J LAB CLIN MED, V122, P234
   Crabbe JC, 1996, NAT GENET, V14, P98, DOI 10.1038/ng0996-98
   Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698
   Cubells JF, 1998, HUM GENET, V102, P533, DOI 10.1007/s004390050736
   Cubells JF, 2000, MOL PSYCHIATR, V5, P56, DOI 10.1038/sj.mp.4000657
   Dalen P, 1997, THER DRUG MONIT, V19, P543, DOI 10.1097/00007691-199710000-00011
   Daly AK, 1996, PHARMACOGENETICS, V6, P193, DOI 10.1097/00008571-199606000-00001
   Edenberg HJ, 2002, ALCOHOL RES HEALTH, V26, P214
   Ehlers CL, 2003, J STUD ALCOHOL, V64, P176, DOI 10.15288/jsa.2003.64.176
   Ehlers CL, 2001, ALCOHOL CLIN EXP RES, V25, P1773
   Ekelund J, 1999, AM J PSYCHIAT, V156, P1453
   Fehr C, 2000, PSYCHIAT RES, V97, P1, DOI 10.1016/S0165-1781(00)00215-8
   Fernandes LC, 2002, J CLIN PSYCHOPHARM, V22, P326, DOI 10.1097/00004714-200206000-00014
   Foroud T, 2000, ALCOHOL CLIN EXP RES, V24, P933, DOI 10.1097/00000374-200007000-00001
   Franke P, 2000, MOL PSYCHIATR, V5, P101, DOI 10.1038/sj.mp.4000583
   Franklin A, 2001, FOLK MUSIC J, V8, P114
   Fuke S., 2001, Pharmacogenomics Journal, V1, P152
   GAEDIGK A, 1991, AM J HUM GENET, V48, P943
   Gelernter J, 1999, MOL PSYCHIATR, V4, P476, DOI 10.1038/sj.mp.4000556
   Gelernter J, 1997, AM J HUM GENET, V61, P1144, DOI 10.1086/301595
   GEORGE SR, 1993, BIOCHEM BIOPH RES CO, V196, P107, DOI 10.1006/bbrc.1993.2222
   Glatt SJ, 2003, AM J PSYCHIAT, V160, P469, DOI 10.1176/appi.ajp.160.3.469
   GOUGH AC, 1990, NATURE, V347, P773, DOI 10.1038/347773a0
   Grobin AC, 1998, PSYCHOPHARMACOLOGY, V139, P2, DOI 10.1007/s002130050685
   Hall FS, 2001, PSYCHOPHARMACOLOGY, V154, P43, DOI 10.1007/s002130000622
   HARADA S, 1982, LANCET, V2, P827, DOI 10.1016/s0140-6736(82)92722-2
   HARADA S, 1980, AM J HUM GENET, V32, P8
   Hernandez-Avila CA, 2003, AM J MED GENET B, V118B, P60, DOI 10.1002/ajmg.b.10054
   HIGUCHI S, 1992, J STUD ALCOHOL, V53, P170, DOI 10.15288/jsa.1992.53.170
   Higuchi S, 1996, ALCOHOL CLIN EXP RES, V20, P493, DOI 10.1111/j.1530-0277.1996.tb01080.x
   Hoehe MR, 2000, HUM MOL GENET, V9, P2895, DOI 10.1093/hmg/9.19.2895
   Holmes A, 2002, PSYCHOPHARMACOLOGY, V161, P160, DOI 10.1007/s00213-002-1024-3
   HORIKAWA S, 1983, NATURE, V306, P611, DOI 10.1038/306611a0
   Hsu YPP, 1998, MOL PSYCHIATR, V3, P213, DOI 10.1038/sj.mp.4000371
   Hsu YPP, 1996, AM J PSYCHIAT, V153, P1209
   Huang YY, 1999, NEUROPSYCHOPHARMACOL, V21, P238, DOI 10.1016/S0893-133X(99)00030-5
   Hutchison KE, 2002, HEALTH PSYCHOL, V21, P139, DOI 10.1037//0278-6133.21.2.139
   IKAWA M, 1983, J BIOL CHEM, V258, P6282
   Ilveskoski E, 2001, ALCOHOL CLIN EXP RES, V25, P1420, DOI 10.1097/00000374-200110000-00003
   Ishiguro H, 1999, J NEURAL TRANSM, V106, P1017, DOI 10.1007/s007020050220
   JOHANSSON I, 1993, P NATL ACAD SCI USA, V90, P11825, DOI 10.1073/pnas.90.24.11825
   Jonsson EG, 1997, EUR ARCH PSY CLIN N, V247, P297, DOI 10.1007/BF02922258
   Joober R, 2002, ARCH GEN PSYCHIAT, V59, P662, DOI 10.1001/archpsyc.59.7.662
   KAGIMOTO M, 1990, J BIOL CHEM, V265, P17209
   Kaij L., 1960, ALCOHOLISM TWINS STU
   Karvonen MK, 1998, NAT MED, V4, P1434, DOI 10.1038/4027
   Kathiramalainathan K, 2000, J CLIN PSYCHOPHARM, V20, P435, DOI 10.1097/00004714-200008000-00008
   Kauhanen J, 2000, ALCOHOL CLIN EXP RES, V24, P135, DOI 10.1111/j.1530-0277.2000.tb04582.x
   Kauhanen J, 2000, AM J MED GENET, V93, P117, DOI 10.1002/1096-8628(20000717)93:2<117::AID-AJMG7>3.0.CO;2-#
   Kendler KS, 2003, AM J PSYCHIAT, V160, P687, DOI 10.1176/appi.ajp.160.4.687
   Kitanaka N, 1998, EUR J PHARMACOL, V355, pR1, DOI 10.1016/S0014-2999(98)00516-0
   Koch T, 2000, MOL PHARMACOL, V58, P328, DOI 10.1124/mol.58.2.328
   Kotler M, 1997, MOL PSYCHIATR, V2, P251, DOI 10.1038/sj.mp.4000248
   KOZAK CA, 1994, GENOMICS, V21, P659, DOI 10.1006/geno.1994.1331
   Kranzler H, 2002, ALCOHOL CLIN EXP RES, V26, P1330, DOI 10.1097/01ALC.0000030840.48315.40
   Kreek MJ, 2002, NAT REV DRUG DISCOV, V1, P710, DOI 10.1038/nrd897
   Kreek MJ, 1996, NEUROCHEM RES, V21, P1469, DOI 10.1007/BF02532387
   KREEK MJ, 2002, GENOMIC REVOLUTION U, P97
   KREEK MJ, 2000, DHHS PUB, V180, P3
   LaForge KS, 2000, EUR J PHARMACOL, V410, P249, DOI 10.1016/S0014-2999(00)00819-0
   Lappalainen J, 1998, ARCH GEN PSYCHIAT, V55, P989, DOI 10.1001/archpsyc.55.11.989
   Lappalainen J, 2002, ARCH GEN PSYCHIAT, V59, P825, DOI 10.1001/archpsyc.59.9.825
   Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527
   Li T, 2000, ADDICT BIOL, V5, P181, DOI 10.1080/13556210050003775
   Li T, 1997, MOL PSYCHIATR, V2, P413, DOI 10.1038/sj.mp.4000310
   Long JC, 1998, AM J MED GENET, V81, P216, DOI 10.1002/(SICI)1096-8628(19980508)81:3<216::AID-AJMG2>3.0.CO;2-U
   Lotsch J, 2002, PHARMACOGENETICS, V12, P3, DOI 10.1097/00008571-200201000-00002
   Mattay VS, 2003, P NATL ACAD SCI USA, V100, P6186, DOI 10.1073/pnas.0931309100
   Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0
   McCreadie RG, 2002, BRIT J PSYCHIAT, V181, P321, DOI 10.1192/bjp.181.4.321
   Merikangas KR, 1998, ARCH GEN PSYCHIAT, V55, P973, DOI 10.1001/archpsyc.55.11.973
   MEROZ Y, 2001, ANESTHESIOLOGY, V95, pA1358
   MIZOI Y, 1983, PHARMACOL BIOCHEM BE, V18, P127, DOI 10.1016/0091-3057(83)90159-4
   MURAMATSU T, 1995, BIOCHEM BIOPH RES CO, V211, P28, DOI 10.1006/bbrc.1995.1773
   Muramatsu T, 1996, J MED GENET, V33, P113, DOI 10.1136/jmg.33.2.113
   Nakamura K, 1996, ALCOHOL CLIN EXP RES, V20, P52, DOI 10.1111/j.1530-0277.1996.tb01043.x
   Nestler EJ, 2000, NAT GENET, V26, P277, DOI 10.1038/81570
   Nielsen DA, 1998, ARCH GEN PSYCHIAT, V55, P593, DOI 10.1001/archpsyc.55.7.593
   NIELSEN DA, 1992, AM J HUM GENET, V51, P1366
   NIELSEN DA, 1994, ARCH GEN PSYCHIAT, V51, P34
   O'Malley SS, 2002, PSYCHOPHARMACOLOGY, V160, P19, DOI 10.1007/s002130100919
   Ono H, 2002, MOL PSYCHIATR, V7, P1127, DOI 10.1038/sj.mp.4001150
   Oscarson M, 1997, MOL PHARMACOL, V52, P1034, DOI 10.1124/mol.52.6.1034
   Osier M, 1999, AM J HUM GENET, V64, P1147, DOI 10.1086/302317
   Oslin DW, 2003, NEUROPSYCHOPHARMACOL, V28, P1546, DOI 10.1038/sj.npp.1300219
   OXENSTIERNA G, 1986, J PSYCHIAT RES, V20, P19, DOI 10.1016/0022-3956(86)90020-8
   Palmatier MA, 1999, BIOL PSYCHIAT, V46, P557, DOI 10.1016/S0006-3223(99)00098-0
   Parsian A, 2003, AM J MED GENET B, V117B, P46, DOI 10.1002/ajmg.b.10017
   Parsian A, 1999, AM J MED GENET, V88, P533, DOI 10.1002/(SICI)1096-8628(19991015)88:5<533::AID-AJMG18>3.0.CO;2-C
   PARTANEN J, 1966, INHERITANCE DRINKING
   Poulsen L, 1996, EUR J CLIN PHARMACOL, V51, P289, DOI 10.1007/s002280050200
   Reich T, 1998, AM J MED GENET, V81, P207, DOI 10.1002/(SICI)1096-8628(19980508)81:3<207::AID-AJMG1>3.3.CO;2-X
   Roberts AJ, 2000, J PHARMACOL EXP THER, V293, P1002
   Romach MK, 2000, J CLIN PSYCHOPHARM, V20, P43, DOI 10.1097/00004714-200002000-00008
   Sabol SZ, 1998, HUM GENET, V103, P273, DOI 10.1007/s004390050816
   Samochowiec J, 1999, PSYCHIAT RES, V86, P67, DOI 10.1016/S0165-1781(99)00020-7
   Sander T, 1999, PSYCHIAT GENET, V9, P69, DOI 10.1097/00041444-199906000-00004
   Schinka JA, 2002, MOL PSYCHIATR, V7, P224, DOI 10.1038/sj.mp.4000951
   Schluger JH, 1998, ALCOHOL CLIN EXP RES, V22, P1430, DOI 10.1111/j.1530-0277.1998.tb03931.x
   Shea SH, 2001, BEHAV GENET, V31, P231, DOI 10.1023/A:1010261713092
   Shen YC, 1997, ALCOHOL CLIN EXP RES, V21, P1272, DOI 10.1097/00000374-199710000-00017
   Shi JX, 2002, HUM MUTAT, V19, DOI 10.1002/humu.9026
   Silva AP, 2002, CLIN CHIM ACTA, V326, P3, DOI 10.1016/S0009-8981(02)00301-7
   SINDRUP SH, 1990, CLIN PHARMACOL THER, V48, P686, DOI 10.1038/clpt.1990.212
   Sipe JC, 2002, P NATL ACAD SCI USA, V99, P8394, DOI 10.1073/pnas.082235799
   Skarke C, 2003, CLIN PHARMACOL THER, V73, P107, DOI 10.1067/mcp.2003.5
   Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544
   SPIELMAN RS, 1981, AM J MED GENET, V10, P279, DOI 10.1002/ajmg.1320100311
   Stallings MC, 2003, DRUG ALCOHOL DEPEN, V70, P295, DOI 10.1016/S0376-8716(03)00031-0
   Szeto CYK, 2001, NEUROREPORT, V12, P1103, DOI 10.1097/00001756-200105080-00011
   TAKESHITA T, 1994, HUM GENET, V94, P217
   Tan EC, 2003, NEUROREPORT, V14, P569, DOI 10.1097/00001756-200303240-00008
   Thiele TE, 1998, NATURE, V396, P366, DOI 10.1038/24614
   THOMASSON HR, 1993, BEHAV GENET, V23, P131, DOI 10.1007/BF01067417
   THOMASSON HR, 1994, ALCOHOL CLIN EXP RES, V18, P640, DOI 10.1111/j.1530-0277.1994.tb00923.x
   THOMASSON HR, 1991, AM J HUM GENET, V48, P677
   Thorsell A, 2002, NEUROSCI LETT, V332, P1, DOI 10.1016/S0304-3940(02)00904-7
   Tiihonen J, 1999, MOL PSYCHIATR, V4, P286, DOI 10.1038/sj.mp.4000509
   Town T, 1999, AM J MED GENET, V88, P458, DOI 10.1002/(SICI)1096-8628(19991015)88:5<458::AID-AJMG3>3.0.CO;2-S
   Tsuang MT, 1998, ARCH GEN PSYCHIAT, V55, P967, DOI 10.1001/archpsyc.55.11.967
   Tyndale RF, 1997, PHARMACOGENETICS, V7, P375, DOI 10.1097/00008571-199710000-00006
   Tyndale RF, 2003, ANN MED, V35, P94, DOI 10.1080/07853890310010014
   Ueno S, 1999, MOL PSYCHIATR, V4, P552, DOI 10.1038/sj.mp.4000562
   Uhl GR, 2001, AM J HUM GENET, V69, P1290, DOI 10.1086/324467
   Vandenbergh DJ, 2000, AM J MED GENET, V96, P678, DOI 10.1002/1096-8628(20001009)96:5<678::AID-AJMG15>3.0.CO;2-8
   VANTOL HHM, 1992, NATURE, V358, P149
   VANYUKOV MM, 1995, AM J MED GENET, V60, P122, DOI 10.1002/ajmg.1320600207
   Wall TL, 1996, ALCOHOL CLIN EXP RES, V20, P1159, DOI 10.1111/j.1530-0277.1996.tb01105.x
   Wall TL, 2003, AM J PSYCHIAT, V160, P41, DOI 10.1176/appi.ajp.160.1.41
   Wand GS, 2002, NEUROPSYCHOPHARMACOL, V26, P106, DOI 10.1016/S0893-133X(01)00294-9
   Wang DX, 2001, J BIOL CHEM, V276, P34624, DOI 10.1074/jbc.M104083200
   Wang T, 2001, MOL PSYCHIATR, V6, P109, DOI 10.1038/sj.mp.4000803
   Wei J, 1997, HUM GENET, V99, P52
   WEINSHILBOUM RM, 1977, AM J HUM GENET, V29, P125
   WEINSHILBOUM RM, 1974, PHARMACOL REV, V30, P133
   Wendel B, 1998, J MOL MED-JMM, V76, P525, DOI 10.1007/s001090050246
   Whitfield JB, 1997, ALCOHOL ALCOHOLISM, V32, P613
   WILSON AF, 1988, AM J HUM GENET, V42, P160
   YASUNAMI M, 1990, GENOMICS, V7, P152, DOI 10.1016/0888-7543(90)90535-3
   YOSHIDA A, 1991, PROG NUCLEIC ACID RE, V40, P255
   YOSHIDA A, 1984, P NATL ACAD SCI-BIOL, V81, P258, DOI 10.1073/pnas.81.1.258
   Zabetian CP, 2001, AM J HUM GENET, V68, P515, DOI 10.1086/318198
   Zhang Y, 2003, SYNAPSE, V50, P191, DOI 10.1002/syn.10251
   Zhu GS, 2003, ALCOHOL CLIN EXP RES, V27, P19, DOI 10.1097/01.ALC.0000050642-62233.44
   Zimprich A, 2000, J NEUROCHEM, V74, P472, DOI 10.1046/j.1471-4159.2000.740472.x
   1999, GENET EPIDEMIOL S1, V17
NR 172
TC 92
Z9 98
U1 5
U2 70
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1535-1084
EI 1559-1174
J9 NEUROMOL MED
JI Neuromol. Med.
PY 2004
VL 5
IS 1
BP 85
EP 108
DI 10.1385/NMM:5:1:085
PG 24
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology
GA 804WK
UT WOS:000220328600008
PM 15001815
DA 2023-06-23
ER

PT J
AU Tamura, EK
   Oliveira-Silva, KS
   Ferreira-Moraes, FA
   Marinho, EAV
   Guerrero-Vargas, NN
AF Tamura, Eduardo K.
   Oliveira-Silva, Kallyane S.
   Ferreira-Moraes, Felipe A.
   Marinho, Eduardo A. V.
   Guerrero-Vargas, Natali N.
TI Circadian rhythms and substance use disorders: A bidirectional
   relationship
SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
LA English
DT Review
DE Addiction; Circadian rhythms; Circadian system; Chronodisruption; Clock
   genes; Drug abuse
AB The circadian system organizes circadian rhythms (biological cycles that occur around 24 h) that couple environmental cues (zeitgebers) with internal functions of the organism. The misalignment between circadian rhythms and external cues is known as chronodisruption and contributes to the development of mental, metabolic and other disorders, including cancer, cardiovascular diseases and addictive disorders. Drug addiction represents a global public health concern and affects the health and well-being of individuals, families and communities. In this manuscript, we reviewed evidence indicating a bidirectional relationship between the circadian system and the development of addictive disorders. We provide information on the interaction between the circadian system and drug addiction for each drug or drug class (alcohol, cannabis, hallucinogens, psychostimulants and opioids). We also describe evidence showing that drug use follows a circadian pattern, which changes with the progression of addiction. Furthermore, clock gene expression is also altered during the development of drug addiction in many brain areas related to drug reward, drug seeking and relapse. The regulation of the glutamatergic and dopaminergic neurocircuitry by clock genes is postulated to be the main circadian mechanism underlying the escalation of drug addiction. The bidirectional interaction between the circadian system and drug addiction seems to be mediated by the effects caused by each drug or class of drugs of abuse. These studies provide new insights on the development of successful strategies aimed at restoring/stabilizing circadian rhythms to reduce the risk for addiction development and relapse.
C1 [Tamura, Eduardo K.; Oliveira-Silva, Kallyane S.; Ferreira-Moraes, Felipe A.; Marinho, Eduardo A. V.] Univ Estadual Santa Cruz, Dept Hlth Sci, BR-415,Rodovia Ilheus Itabuna,Km 16, BR-45662000 Ilheus, BA, Brazil.
   [Guerrero-Vargas, Natali N.] Univ Nacl Autonoma Mexico, Fac Med, Dept Anat, Ave Univ 3000,Ciudad Univ, Mexico City 04510, DF, Mexico.
C3 Universidade Estadual de Santa Cruz; Universidad Nacional Autonoma de
   Mexico
RP Tamura, EK (通讯作者)，Univ Estadual Santa Cruz, Dept Hlth Sci, BR-415,Rodovia Ilheus Itabuna,Km 16, BR-45662000 Ilheus, BA, Brazil.
EM ektamura@yahoo.com.br
RI Tamura, Eduardo Koji/L-4360-2019; Tamura, Eduardo Koji/F-7068-2012;
   Guerrero-Vargas, Natali N/ISA-8332-2023; Marinho, Eduardo/AGK-8589-2022;
   Marinho, Eduardo Ary Villela/D-7223-2013
OI Tamura, Eduardo Koji/0000-0002-6105-7452; Tamura, Eduardo
   Koji/0000-0002-6105-7452; Guerrero-Vargas, Natali N/0000-0002-6048-7047;
   Marinho, Eduardo/0000-0002-3179-2819; Marinho, Eduardo Ary
   Villela/0000-0002-3179-2819
FU DGAPA-PAPIIT (Mexico) [IA206620]; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (PROICCNPQ; Brazil); Programa Institucional de
   Bolsas de Extensao da Universidade Estadual de Santa Cruz (PROBEX/UESC,
   Brazil); PROIC-CNPQ (Brazil)
FX Dr. Natali N Guerrero-Vargas was supported by DGAPA-PAPIIT IA206620
   (Mexico). Kallyane S. Oliveira-Silva was supported by Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico (PROICCNPQ; Brazil) and
   Programa Institucional de Bolsas de Extensao da Universidade Estadual de
   Santa Cruz (PROBEX/UESC, Brazil), Felipe A. Ferreira-Moraes was
   supported by PROIC-CNPQ (Brazil).
CR Abarca C, 2002, P NATL ACAD SCI USA, V99, P9026, DOI 10.1073/pnas.142039099
   ABEL EL, 1970, NATURE, V227, P1151, DOI 10.1038/2271151b0
   Acuna-Goycolea C, 2010, J NEUROSCI, V30, P10061, DOI 10.1523/JNEUROSCI.5838-09.2010
   ADAN A, 1994, ADDICTION, V89, P455, DOI 10.1111/j.1360-0443.1994.tb00926.x
   Adan A, 2012, CHRONOBIOL INT, V29, P1153, DOI 10.3109/07420528.2012.719971
   Akhisaroglu M, 2004, PHARMACOL BIOCHEM BE, V79, P37, DOI 10.1016/j.pbb.2004.06.014
   Albrecht U, 2012, NEURON, V74, P246, DOI 10.1016/j.neuron.2012.04.006
   Antle MC, 2012, NEUROPSYCHOPHARMACOL, V37, P2446, DOI 10.1038/npp.2012.103
   Antony JM, 2020, TRANSL NEUROSCI, V11, P4, DOI 10.1515/tnsci-2020-0002
   Baird AL, 2013, BRAIN RES, V1513, P61, DOI 10.1016/j.brainres.2013.03.038
   Baird TJ, 2000, PHARMACOL BIOCHEM BE, V65, P289, DOI 10.1016/S0091-3057(99)00207-5
   Baltazar RM, 2014, NEUROSCIENCE, V258, P204, DOI 10.1016/j.neuroscience.2013.11.013
   Banach E, 2018, J AFFECT DISORDERS, V241, P142, DOI 10.1016/j.jad.2018.07.080
   Bass CE, 2010, CHRONOBIOL INT, V27, P535, DOI 10.3109/07420521003664221
   Beaule C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007476
   Berridge KC, 2009, CURR OPIN PHARMACOL, V9, P65, DOI 10.1016/j.coph.2008.12.014
   Brager AJ, 2013, BEHAV BRAIN RES, V243, P255, DOI 10.1016/j.bbr.2013.01.014
   Brager AJ, 2010, ALCOHOL CLIN EXP RES, V34, P1266, DOI 10.1111/j.1530-0277.2010.01204.x
   Brancaccio M, 2017, NEURON, V93, P1420, DOI 10.1016/j.neuron.2017.02.030
   Brower KJ, 2012, SLEEP, V35, P571, DOI 10.5665/sleep.1748
   Brower KJ, 2003, SLEEP MED REV, V7, P523, DOI 10.1016/S1087-0792(03)90005-0
   Bullock B, 2019, YALE J BIOL MED, V92, P359
   Calle PA, 2006, ACTA CLIN BELG, V61, P188, DOI 10.1179/acb.2006.033
   CARLINI EA, 1970, PHARMACOLOGY, V4, P359, DOI 10.1159/000136165
   Chen CP, 2004, J NEUROCHEM, V88, P1547, DOI 10.1046/j.1471-4159.2003.02300.x
   Choi DS, 2004, NAT NEUROSCI, V7, P855, DOI 10.1038/nn1288
   Coffey AA, 2018, PSYCHOPHARMACOLOGY, V235, P3005, DOI 10.1007/s00213-018-4990-9
   CONE EJ, 1988, J ANAL TOXICOL, V12, P169, DOI 10.1093/jat/12.4.169
   Daan S, 2010, PROTEIN REV, V12, P1, DOI 10.1007/978-1-4419-1262-6_1
   Dahchour A, 1999, ALCOHOL CLIN EXP RES, V23, P1698, DOI 10.1111/j.1530-0277.1999.tb04063.x
   Damaggio AS, 2014, BEHAV NEUROSCI, V128, P371, DOI 10.1037/a0036408
   Danel T, 2003, CHRONOBIOL INT, V20, P1093, DOI 10.1081/CBI-120025533
   Danel T, 2006, ALCOHOL ALCOHOLISM, V41, P386, DOI 10.1093/alcalc/agl036
   Darcq E, 2018, NAT REV NEUROSCI, V19, P499, DOI 10.1038/s41583-018-0028-x
   Davies J A, 1972, Prog Brain Res, V36, P79
   De Bundel D, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00152
   Depoy LM, 2017, NEURAL PLAST, V2017, DOI 10.1155/2017/5720842
   Di Chiara G, 1999, EUR J PHARMACOL, V375, P13, DOI 10.1016/S0014-2999(99)00372-6
   Di Milia L, 2013, CHRONOBIOL INT, V30, P1261, DOI 10.3109/07420528.2013.817415
   Dibner C, 2010, ANNU REV PHYSIOL, V72, P517, DOI 10.1146/annurev-physiol-021909-135821
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Dietis N, 2011, BRIT J ANAESTH, V107, P8, DOI 10.1093/bja/aer115
   Dodd PR, 2000, NEUROCHEM INT, V37, P509, DOI 10.1016/S0197-0186(00)00061-9
   Drummond SPA, 1998, ALCOHOL CLIN EXP RES, V22, P1796, DOI 10.1097/00000374-199811000-00026
   Erickson TB, 1998, AM J EMERG MED, V16, P568, DOI 10.1016/S0735-6757(98)90220-0
   Escobar C, 2011, PHYSIOL BEHAV, V104, P555, DOI 10.1016/j.physbeh.2011.05.001
   FACCHINETTI F, 1985, DRUG ALCOHOL DEPEN, V15, P361, DOI 10.1016/0376-8716(85)90014-6
   Falcon E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066438
   Favrod-Coune T, 2010, PHARMACEUTICALS-BASE, V3, P2333, DOI 10.3390/ph3072333
   FITCH TE, 1993, DRUG ALCOHOL DEPEN, V33, P119, DOI 10.1016/0376-8716(93)90053-S
   Foster RG, 2014, EXP PHYSIOL, V99, P599, DOI 10.1113/expphysiol.2012.071118
   Fox HC, 2008, PSYCHOPHARMACOLOGY, V195, P527, DOI 10.1007/s00213-007-0936-3
   Freyberg Z, 2018, CURR OPIN PHYSIOL, V5, P80, DOI 10.1016/j.cophys.2018.08.004
   Gallerani M, 2001, CRIT CARE MED, V29, P96, DOI 10.1097/00003246-200101000-00021
   Garmabi B, 2016, NEUROSCIENCE, V322, P104, DOI 10.1016/j.neuroscience.2016.02.019
   Gass JT, 2008, BIOCHEM PHARMACOL, V75, P218, DOI 10.1016/j.bcp.2007.06.039
   Gau SSF, 2007, J BIOL RHYTHM, V22, P268, DOI 10.1177/0748730406298447
   Gaytan O, 2000, BRAIN RES, V864, P24, DOI 10.1016/S0006-8993(00)02117-X
   Gaytan O, 1999, EUR J PHARMACOL, V374, P1, DOI 10.1016/S0014-2999(99)00243-5
   Gibson S, 2013, NUTR J, V12, DOI 10.1186/1475-2891-12-9
   Gillman AG, 2019, BEHAV PROCESS, V165, P23, DOI 10.1016/j.beproc.2019.05.017
   Giorgetti M, 2000, BRAIN RES, V877, P170, DOI 10.1016/S0006-8993(00)02671-8
   Glaser AM, 2012, PHARMACOL BIOCHEM BE, V101, P544, DOI 10.1016/j.pbb.2012.02.015
   Glass JD, 2012, AM J PHYSIOL-REG I, V302, pR740, DOI 10.1152/ajpregu.00602.2011
   Golombek DA, 2010, PHYSIOL REV, V90, P1063, DOI 10.1152/physrev.00009.2009
   Gorelick DA, 2013, AM J ADDICTION, V22, P510, DOI 10.1111/j.1521-0391.2013.12003.x
   Grippo RM, 2019, YALE J BIOL MED, V92, P271
   Gulick D, 2018, PHARMACOL THERAPEUT, V188, P124, DOI 10.1016/j.pharmthera.2018.03.003
   Hagenauer MH, 2012, FRONT NEUROENDOCRIN, V33, P211, DOI 10.1016/j.yfrne.2012.04.003
   Halbout B, 2011, BEHAV PHARMACOL, V22, P76, DOI 10.1097/FBP.0b013e328341e9ca
   Hannibal J, 2002, CELL TISSUE RES, V309, P73, DOI 10.1007/s00441-002-0574-3
   Hasler BP, 2015, ALCOHOL, V49, P377, DOI 10.1016/j.alcohol.2014.06.010
   Hasler BP, 2013, ALCOHOL CLIN EXP RES, V37, P558, DOI 10.1111/acer.12003
   Hastings MH, 2003, NAT REV NEUROSCI, V4, P649, DOI 10.1038/nrn1177
   HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991
   HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932
   HONMA K, 1987, PHYSIOL BEHAV, V40, P767, DOI 10.1016/0031-9384(87)90281-2
   Honma S, 2008, J BIOL RHYTHM, V23, P91, DOI 10.1177/0748730407311124
   Hood S, 2011, NEUROSCIENCE, V186, P65, DOI 10.1016/j.neuroscience.2011.04.045
   HOWLETT AC, 1995, ANNU REV PHARMACOL, V35, P607, DOI 10.1146/annurev.pa.35.040195.003135
   Huang MC, 2010, ALCOHOL CLIN EXP RES, V34, P1899, DOI 10.1111/j.1530-0277.2010.01278.x
   Irwin MR, 2007, J PHARMACOL EXP THER, V320, P507, DOI 10.1124/jpet.106.112797
   Isir AB, 2016, J MOL NEUROSCI, V58, P456, DOI 10.1007/s12031-016-0721-z
   Jackson FR, 2011, GLIA, V59, P1341, DOI 10.1002/glia.21097
   Jansen HT, 2012, CHRONOBIOL INT, V29, P454, DOI 10.3109/07420528.2012.667467
   Kalivas Peter W, 2007, Dialogues Clin Neurosci, V9, P389
   Kennaway DJ, 1998, BRAIN RES, V806, P257, DOI 10.1016/S0006-8993(98)00746-X
   Kim JH, 2018, SLEEP MED CLIN, V13, P39, DOI 10.1016/j.jsmc.2017.09.004
   Kondoh D, 2014, BIOL PHARM BULL, V37, P1422, DOI 10.1248/bpb.b14-00229
   Koob GF, 2008, ANNU REV PSYCHOL, V59, P29, DOI 10.1146/annurev.psych.59.103006.093548
   Koob GF, 2016, LANCET PSYCHIAT, V3, P760, DOI 10.1016/S2215-0366(16)00104-8
   Koob GF, 2015, EUR J PHARMACOL, V753, P73, DOI 10.1016/j.ejphar.2014.11.044
   Koob George F, 2008, Drug Discov Today Dis Models, V5, P207
   Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442
   Kosobud Ann E K, 2007, ScientificWorldJournal, V7, P203
   Krystal JH, 2003, PHARMACOL THERAPEUT, V99, P79, DOI 10.1016/S0163-7258(03)00054-8
   Kurtuncu M, 2004, EUR J PHARMACOL, V489, P203, DOI 10.1016/j.ejphar.2004.03.010
   Lafaye G, 2019, ADDICT BIOL, V24, P921, DOI 10.1111/adb.12660
   Levandovski Rosa, 2013, Trends Psychiatry Psychother., V35, P3
   Levandovski R, 2011, CHRONOBIOL INT, V28, P771, DOI 10.3109/07420528.2011.602445
   Levran O, 2014, PHARMACOGENOMICS, V15, P2001, DOI [10.2217/PGS.14.145, 10.2217/pgs.14.145]
   Li SX, 2010, J NEUROCHEM, V115, P353, DOI 10.1111/j.1471-4159.2010.06941.x
   Li SX, 2009, J NEUROCHEM, V109, P1668, DOI 10.1111/j.1471-4159.2009.06086.x
   Li SX, 2009, BIOL PSYCHIAT, V65, P905, DOI 10.1016/j.biopsych.2008.11.025
   Liakoni E, 2016, BMC PHARMACOL TOXICO, V17, DOI 10.1186/s40360-016-0068-7
   Lindberg D, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00009
   Lisboa SF, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00005
   Liu C, 2000, NEURON, V25, P123, DOI 10.1016/S0896-6273(00)80876-4
   Liu Y, 2007, NEUROSCIENCE, V146, P265, DOI 10.1016/j.neuroscience.2007.01.009
   Logan RW, 2014, BEHAV NEUROSCI, V128, P387, DOI 10.1037/a0036268
   Luo AH, 2009, EUR J NEUROSCI, V29, P748, DOI 10.1111/j.1460-9568.2008.06606.x
   Lynch WJ, 2008, BRAIN RES, V1213, P166, DOI 10.1016/j.brainres.2008.02.106
   Malison RT, 2006, PSYCHIAT GENET, V16, P245, DOI 10.1097/01.ypg.0000242198.59020.ca
   Mantsch JR, 2000, J PHARMACOL EXP THER, V294, P239
   Marchant EG, 1995, NEUROREPORT, V7, P209, DOI 10.1097/00001756-199512000-00050
   Montero-Moraga JM, 2020, INT J DRUG POLICY, V81, DOI 10.1016/j.drugpo.2020.102772
   Marpegan L, 2011, J NEUROSCI, V31, P8342, DOI 10.1523/JNEUROSCI.6537-10.2011
   MARTINIVERSON MT, 1989, PHARMACOL BIOCHEM BE, V34, P465, DOI 10.1016/0091-3057(89)90542-X
   Masubuchi S, 2000, EUR J NEUROSCI, V12, P4206, DOI 10.1111/j.1460-9568.2000.01313.x
   McCarthy MJ, 2013, ALCOHOL CLIN EXP RES, V37, P1304, DOI 10.1111/acer.12106
   McClung CA, 2005, P NATL ACAD SCI USA, V102, P9377, DOI 10.1073/pnas.0503584102
   McDevitt DS, 2019, ENEURO, V6, DOI 10.1523/ENEURO.0377-19.2019
   Mendoza J, 2014, NEUROSCIENCE, V282, P230, DOI 10.1016/j.neuroscience.2014.07.081
   Meyrel M, 2020, PROG NEURO-PSYCHOPH, V99, DOI 10.1016/j.pnpbp.2019.109831
   Miyakawa K, 2007, NEUROPHARMACOLOGY, V52, P1055, DOI 10.1016/j.neuropharm.2006.11.003
   Mohawk JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062463
   Mohawk JA, 2012, ANNU REV NEUROSCI, V35, P445, DOI 10.1146/annurev-neuro-060909-153128
   Mohawk JA, 2009, P NATL ACAD SCI USA, V106, P3519, DOI 10.1073/pnas.0813366106
   Morgan Peter T, 2007, ScientificWorldJournal, V7, P223
   MORIMASA T, 1987, PHYSIOL BEHAV, V39, P699, DOI 10.1016/0031-9384(87)90253-8
   Mukherjee S, 2009, BEHAV BRAIN RES, V198, P113, DOI 10.1016/j.bbr.2008.10.026
   Nagayama H, 1996, PSYCHOPHARMACOLOGY, V127, P113, DOI 10.1007/BF02805983
   Nam HW, 2011, BIOL PSYCHIAT, V69, P1043, DOI 10.1016/j.biopsych.2011.02.013
   Negriff S, 2011, PSYCHIAT RES, V185, P408, DOI 10.1016/j.psychres.2010.07.006
   Nicholson AN, 2004, J CLIN PSYCHOPHARM, V24, P305, DOI 10.1097/01.jcp.0000125688.05091.8f
   Nikaido T, 2001, MOL PHARMACOL, V59, P894, DOI 10.1124/mol.59.4.894
   O'Brien Erin M, 2005, Behav Sleep Med, V3, P113, DOI 10.1207/s15402010bsm0303_1
   Ono M, 1996, NEUROSCIENCE, V72, P213, DOI 10.1016/0306-4522(95)00500-5
   OZAKI N, 1991, J NEURAL TRANSM-GEN, V86, P175, DOI 10.1007/BF01250703
   Ozburn AR, 2012, PSYCHOPHARMACOLOGY, V223, P169, DOI 10.1007/s00213-012-2704-2
   Parekh PK, 2015, ALCOHOL, V49, P341, DOI 10.1016/j.alcohol.2014.09.034
   Pasch KE, 2010, AM J HEALTH BEHAV, V34, P237
   Perreau-Lenz S, 2015, ALCOHOL, V49, P351, DOI 10.1016/j.alcohol.2015.04.003
   Perreau-Lenz S, 2010, EUR NEUROPSYCHOPHARM, V20, P509, DOI 10.1016/j.euroneuro.2010.03.006
   Perron RR, 2001, NEUROREPORT, V12, P3791, DOI 10.1097/00001756-200112040-00038
   Pierce RC, 2006, NEUROSCI BIOBEHAV R, V30, P215, DOI 10.1016/j.neubiorev.2005.04.016
   Pieters S, 2010, ALCOHOL CLIN EXP RES, V34, P1512, DOI 10.1111/j.1530-0277.2010.01235.x
   Prat G, 2013, CHRONOBIOL INT, V30, P942, DOI 10.3109/07420528.2013.790044
   Prosser RA, 2014, NEUROSCIENCE, V275, P184, DOI 10.1016/j.neuroscience.2014.06.012
   Raehal KM, 2011, NEUROPHARMACOLOGY, V60, P58, DOI 10.1016/j.neuropharm.2010.08.003
   RAYMOND RC, 1992, J TOXICOL-CLIN TOXIC, V30, P467
   Refinetti R, 2012, COMPR PHYSIOL, V2, P1213, DOI 10.1002/cphy.c100088
   Reinberg A, 2015, CHRONOBIOL INT, V32, P1005, DOI 10.3109/07420528.2015.1053911
   Ren ZY, 2009, PHARMACOL BIOCHEM BE, V91, P468, DOI 10.1016/j.pbb.2008.08.023
   Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965
   Resendiz-Flores M, 2019, ADDICT BIOL, V24, P1179, DOI 10.1111/adb.12674
   Roberts DCS, 2002, DRUG ALCOHOL DEPEN, V67, P291, DOI 10.1016/S0376-8716(02)00083-2
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Roenneberg T, 2003, J BIOL RHYTHM, V18, P80, DOI 10.1177/0748730402239679
   Roenneberg T, 2007, SLEEP MED REV, V11, P429, DOI 10.1016/j.smrv.2007.07.005
   Roenneberg T, 2012, CURR BIOL, V22, P939, DOI 10.1016/j.cub.2012.03.038
   Rosenwasser AM, 2015, PHYSIOL BEHAV, V147, P342, DOI 10.1016/j.physbeh.2015.05.011
   Rosenwasser AM, 2013, PHYSIOL BEHAV, V110, P140, DOI 10.1016/j.physbeh.2013.01.001
   ROSSETTI ZL, 1995, EUR J PHARMACOL, V283, P177, DOI 10.1016/0014-2999(95)00344-K
   Roy K, 2018, NEUROSCI LETT, V685, P24, DOI 10.1016/j.neulet.2018.07.023
   Roybal K, 2007, P NATL ACAD SCI USA, V104, P6406, DOI 10.1073/pnas.0609625104
   Ruby CL, 2009, AM J PHYSIOL-REG I, V296, pR411, DOI 10.1152/ajpregu.90782.2008
   Rutters F, 2014, J BIOL RHYTHM, V29, P377, DOI 10.1177/0748730414550199
   Saffroy R, 2019, CHRONOBIOL INT, V36, P122, DOI 10.1080/07420528.2018.1523797
   Salgado-Delgado R, 2008, NEUROSCIENCE, V154, P922, DOI 10.1016/j.neuroscience.2008.03.066
   Saxvig IW, 2012, SLEEP MED, V13, P193, DOI 10.1016/j.sleep.2011.10.024
   SHIBATA S, 1995, J PHARMACOL EXP THER, V274, P688
   Shirakawa T, 2000, EUR J NEUROSCI, V12, P2833, DOI 10.1046/j.1460-9568.2000.00170.x
   Shumay E, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.11
   Sircar R, 2000, BRAIN RES, V857, P295, DOI 10.1016/S0006-8993(99)02460-9
   Sjoholm Louise K, 2010, J Circadian Rhythms, V8, P1, DOI 10.1186/1740-3391-8-1
   Sleipness EP, 2007, PHYSIOL BEHAV, V91, P523, DOI 10.1016/j.physbeh.2007.02.013
   Spanagel R, 2005, NAT MED, V11, P35, DOI 10.1038/nm1163
   Spanagel R, 2005, ALCOHOL CLIN EXP RES, V29, P1550, DOI 10.1097/01.alc.0000175074.70807.fd
   Srinivasan V, 2010, ADV THER, V27, P796, DOI 10.1007/s12325-010-0065-y
   Stevens RG, 2011, OCCUP ENVIRON MED, V68, P154, DOI 10.1136/oem.2009.053512
   Stowie AC, 2015, NEUROSCIENCE, V284, P171, DOI 10.1016/j.neuroscience.2014.08.057
   Summa KC, 2015, ALCOHOL CLIN EXP RES, V39, P1917, DOI 10.1111/acer.12834
   Summa KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067102
   Tahsili-Fahadan P, 2005, NEUROREPORT, V16, P2051, DOI 10.1097/00001756-200512190-00017
   TAKAHASHI JS, 1992, SCIENCE, V258, P238, DOI 10.1126/science.1384127
   Takahashi TT, 2017, PSYCHOPHARMACOLOGY, V234, P1741, DOI 10.1007/s00213-017-4576-y
   Tataroglu O, 2006, J BIOL RHYTHM, V21, P185, DOI 10.1177/0748730406287529
   Tavernier R, 2014, CHRONOBIOL INT, V31, P232, DOI 10.3109/07420528.2013.843541
   TAYLOR DA, 1977, EUR J PHARMACOL, V46, P93, DOI 10.1016/0014-2999(77)90244-8
   TINKLENBERG JR, 1976, PSYCHOPHARMACOLOGY, V49, P275, DOI 10.1007/BF00426830
   Touitou Y, 2017, LIFE SCI, V173, P94, DOI 10.1016/j.lfs.2017.02.008
   Touitou Y, 2013, J PHYSIOL-PARIS, V107, P323, DOI 10.1016/j.jphysparis.2013.03.008
   Tsai GC, 1998, ANNU REV MED, V49, P173
   UNODC, 2020, BJM B STDLER
   Urban R, 2011, CHRONOBIOL INT, V28, P238, DOI 10.3109/07420528.2010.549599
   Uz T, 2005, NEUROSCIENCE, V134, P1309, DOI 10.1016/j.neuroscience.2005.05.003
   Uz T, 2003, NEUROPSYCHOPHARMACOL, V28, P2117, DOI 10.1038/sj.npp.1300254
   Uz T, 2002, LIFE SCI, V70, P3069, DOI 10.1016/S0024-3205(02)01559-X
   Vansteensel MJ, 2005, EUR J NEUROSCI, V21, P2958, DOI 10.1111/j.1460-9568.2005.04131.x
   VESCOVI PP, 1992, HORM RES, V37, P221, DOI 10.1159/000182316
   Vetter C, 2020, EUR J NEUROSCI, V51, P531, DOI 10.1111/ejn.14255
   Vivanco P, 2013, NEUROSCIENCE, V254, P98, DOI 10.1016/j.neuroscience.2013.09.025
   Wang DQ, 2019, BEHAV BRAIN RES, V363, P61, DOI 10.1016/j.bbr.2019.01.035
   Webb IC, 2015, PHYSIOL BEHAV, V143, P58, DOI 10.1016/j.physbeh.2015.02.034
   WISE RA, 1988, J ABNORM PSYCHOL, V97, P118, DOI 10.1037/0021-843X.97.2.118
   Wittmann M, 2006, CHRONOBIOL INT, V23, P497, DOI 10.1080/07420520500545979
   Wongchitrat P, 2013, NEUROSCI LETT, V542, P126, DOI 10.1016/j.neulet.2013.03.009
   Wu JH, 2011, BIOCHEM BIOPH RES CO, V406, P47, DOI 10.1016/j.bbrc.2011.01.104
   Yan LL, 2002, EUR J NEUROSCI, V15, P1153, DOI 10.1046/j.1460-9568.2002.01955.x
   Yuferov V, 2005, NAT MED, V11, P23, DOI 10.1038/nm0105-23
   Yuferov V, 2003, SYNAPSE, V48, P157, DOI 10.1002/syn.10198
NR 212
TC 17
Z9 17
U1 4
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0091-3057
EI 1873-5177
J9 PHARMACOL BIOCHEM BE
JI Pharmacol. Biochem. Behav.
PD FEB
PY 2021
VL 201
AR 173105
DI 10.1016/j.pbb.2021.173105
EA JAN 2021
PG 14
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA QB2UD
UT WOS:000613995900003
PM 33444601
DA 2023-06-23
ER

PT J
AU Heilig, M
   Epstein, DH
   Nader, MA
   Shaham, Y
AF Heilig, Markus
   Epstein, David H.
   Nader, Michael A.
   Shaham, Yavin
TI Time to connect: bringing social context into addiction neuroscience
SO NATURE REVIEWS NEUROSCIENCE
LA English
DT Review
ID CORTICOTROPIN-RELEASING-FACTOR; PLACEBO-CONTROLLED TRIAL; RECEPTOR GENE
   OPRM1; DRUG-ADDICTION; ANIMAL-MODELS; DOUBLE-BLIND; ATTACHMENT BEHAVIOR;
   REINSTATEMENT MODEL; INTRAVENOUS HEROIN; ALCOHOL-DEPENDENCE
AB Research on the neural substrates of drug reward, withdrawal and relapse has yet to be translated into significant advances in the treatment of addiction. One potential reason is that this research has not captured a common feature of human addiction: progressive social exclusion and marginalization. We propose that research aimed at understanding the neural mechanisms that link these processes to drug seeking and drug taking would help to make addiction neuroscience research more clinically relevant.
C1 [Heilig, Markus] Linkoping Univ, Ctr Social & Affect Neurosci, Dept Clin & Expt Med IKE, SE-58183 Linkoping, Sweden.
   [Epstein, David H.; Shaham, Yavin] NIDA, Intramural Res Program, NIH, Baltimore, MD 21044 USA.
   [Nader, Michael A.] Wake Forest Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA.
C3 Linkoping University; National Institutes of Health (NIH) - USA; NIH
   National Institute on Aging (NIA); NIH National Institute on Drug Abuse
   (NIDA); Wake Forest University
RP Heilig, M (通讯作者)，Linkoping Univ, Ctr Social & Affect Neurosci, Dept Clin & Expt Med IKE, SE-58183 Linkoping, Sweden.
EM markus.heilig@liu.se
RI shaham, yavin/G-1306-2014
FU Swedish Research Council; Intramural Research Program of the US National
   Institutes of Health; US National Institute on Drug Abuse [DA010584,
   DA017763]
FX The writing of this article was supported in part by a grant from the
   Swedish Research Council (M.H.), the Intramural Research Program of the
   US National Institutes of Health and the US National Institute on Drug
   Abuse (D.H.E. and Y.S.) and grants DA010584 and DA017763 (M.A.N.). The
   authors are grateful to S. N. Haber at the University of Rochester, New
   York, USA, and her co-workers for producing and providing Figure 3. The
   authors apologize to their many friends and colleagues for not citing
   many reviews and empirical papers relevant to the topic of their paper,
   owing to format restrictions.
CR Ahmed SH, 2010, NEUROSCI BIOBEHAV R, V35, P172, DOI 10.1016/j.neubiorev.2010.04.005
   ALEXANDER BK, 1978, PSYCHOPHARMACOLOGY, V58, P175, DOI 10.1007/BF00426903
   Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244
   Anton RF, 2008, J CLIN PSYCHOPHARM, V28, P5, DOI 10.1097/jcp.0b013e3181602fd4
   Badiani A, 2011, NAT REV NEUROSCI, V12, P685, DOI 10.1038/nrn3104
   Bardo MT, 2013, PHARMACOL REV, V65, P255, DOI 10.1124/pr.111.005124
   Barr CS, 2008, P NATL ACAD SCI USA, V105, P5277, DOI 10.1073/pnas.0710225105
   Baumgartner U, 2006, NEUROIMAGE, V30, P692, DOI 10.1016/j.neuroimage.2005.10.033
   Bedi G, 2011, BIOL PSYCHIAT, V69, P708, DOI 10.1016/j.biopsych.2010.07.014
   Berkman LF, 2000, SOCIAL EPIDEMIOLOGY
   Bickel WK, 2001, ADDICTION, V96, P73, DOI 10.1046/j.1360-0443.2001.961736.x
   Binneman B, 2008, AM J PSYCHIAT, V165, P617, DOI 10.1176/appi.ajp.2008.07071199
   BLANCHARD DC, 1990, NEUROSCI BIOBEHAV R, V14, P455, DOI 10.1016/S0149-7634(05)80068-5
   BLANCHARD RJ, 1987, PHARMACOL BIOCHEM BE, V28, P437, DOI 10.1016/0091-3057(87)90502-8
   Bossert JM, 2013, PSYCHOPHARMACOLOGY, V229, P453, DOI 10.1007/s00213-013-3120-y
   BOZARTH MA, 1989, PHARMACOL BIOCHEM BE, V33, P903, DOI 10.1016/0091-3057(89)90490-5
   BOZARTH MA, 1985, JAMA-J AM MED ASSOC, V254, P81, DOI 10.1001/jama.254.1.81
   Bradberry CW, 2007, PSYCHOPHARMACOLOGY, V191, P705, DOI 10.1007/s00213-006-0561-6
   BRADY JV, 1991, NEUROSCI BIOBEHAV R, V15, P35, DOI 10.1016/S0149-7634(05)80089-2
   BROWNELL KD, 1986, AM PSYCHOL, V41, P765, DOI 10.1037/0003-066X.41.7.765
   Bruchas MR, 2010, BRAIN RES, V1314, P44, DOI 10.1016/j.brainres.2009.08.062
   Butti C, 2013, CORTEX, V49, P312, DOI 10.1016/j.cortex.2011.10.004
   Cahill L, 2010, PROG BRAIN RES, V186, P29, DOI 10.1016/B978-0-444-53630-3.00003-8
   Cantin L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011592
   Caprioli D, 2015, BIOL PSYCHIAT, V78, P463, DOI 10.1016/j.biopsych.2015.02.018
   Caprioli D, 2009, BIOL PSYCHIAT, V65, P893, DOI 10.1016/j.biopsych.2008.12.009
   Chikama M, 1997, J NEUROSCI, V17, P9686
   Cho YT, 2013, J NEUROSCI, V33, P14017, DOI 10.1523/JNEUROSCI.0170-13.2013
   Copeland WE, 2011, NEUROPSYCHOPHARMACOL, V36, P1165, DOI 10.1038/npp.2010.251
   Coric V, 2010, DEPRESS ANXIETY, V27, P417, DOI 10.1002/da.20695
   Cunningham KA, 1996, BEHAV BRAIN RES, V73, P93
   Czoty PW, 2015, NEUROPSYCHOPHARMACOL, V40, P1072, DOI 10.1038/npp.2014.300
   de Wit H, 2009, ADDICT BIOL, V14, P22, DOI 10.1111/j.1369-1600.2008.00129.x
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Dinur-Klein L, 2014, BIOL PSYCHIAT, V76, P742, DOI 10.1016/j.biopsych.2014.05.020
   DOLE VP, 1965, J AMER MED ASSOC, V193, P646, DOI 10.1001/jama.1965.03090080008002
   Eisenberger NI, 2012, NAT REV NEUROSCI, V13, P421, DOI 10.1038/nrn3231
   Eisenberger NI, 2003, SCIENCE, V302, P290, DOI 10.1126/science.1089134
   Epstein DH, 2006, PSYCHOPHARMACOLOGY, V189, P1, DOI 10.1007/s00213-006-0529-6
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   FABRENYS C, 1982, PHARMACOL BIOCHEM BE, V16, P653, DOI 10.1016/0091-3057(82)90432-4
   Garavan H, 2010, BRAIN STRUCT FUNCT, V214, P593, DOI 10.1007/s00429-010-0259-8
   Gowin JL, 2014, NEUROPSYCHOPHARMACOL, V39, P1379, DOI 10.1038/npp.2013.333
   Grillon C, 2015, NEUROPSYCHOPHARMACOL, V40, P1064, DOI 10.1038/npp.2014.316
   Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134
   HAVASSY BE, 1991, ADDICT BEHAV, V16, P235, DOI 10.1016/0306-4603(91)90016-B
   Heilig M, 2007, TRENDS NEUROSCI, V30, P399, DOI 10.1016/j.tins.2007.06.006
   Helms CM, 2012, PSYCHOPHARMACOLOGY, V224, P133, DOI 10.1007/s00213-012-2707-z
   Heyne A, 1996, PHARMACOL BIOCHEM BE, V53, P11, DOI 10.1016/0091-3057(95)00193-X
   HIGGINS ST, 1991, AM J PSYCHIAT, V148, P1218
   Hsu DT, 2013, MOL PSYCHIATR, V18, P1211, DOI [10.1038/mp.2013.96, 10.1038/mp.2013.139]
   JASINSKI DR, 1978, ARCH GEN PSYCHIAT, V35, P501
   Jobes ML, 2011, PSYCHOPHARMACOLOGY, V218, P83, DOI 10.1007/s00213-011-2230-7
   JOHANSON CE, 1976, PHARMACOL BIOCHEM BE, V4, P45, DOI 10.1016/0091-3057(76)90174-X
   Jupp B, 2016, PSYCHOPHARMACOLOGY, V233, P579, DOI 10.1007/s00213-015-4122-8
   Kalant H, 2010, ADDICTION, V105, P780, DOI 10.1111/j.1360-0443.2009.02739.x
   Kalivas PW, 2009, NAT REV NEUROSCI, V10, P561, DOI 10.1038/nrn2515
   Kendler KS, 2012, NAT NEUROSCI, V15, P181, DOI 10.1038/nn.3018
   Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550
   Koob GF, 2008, ANNU REV PSYCHOL, V59, P29, DOI 10.1146/annurev.psych.59.103006.093548
   Kowalczyk WJ, 2015, AM J PSYCHIAT, V172, P760, DOI 10.1176/appi.ajp.2014.14081014
   Krasnova IN, 2014, NEUROPSYCHOPHARMACOL, V39, P2008, DOI 10.1038/npp.2014.50
   Kwako LE, 2015, NEUROPSYCHOPHARMACOL, V40, P1053, DOI 10.1038/npp.2014.306
   LaRowe SD, 2013, AM J ADDICTION, V22, P443, DOI 10.1111/j.1521-0391.2013.12034.x
   Le AD, 2002, J NEUROSCI, V22, P7844
   Leong JK, 2016, NEURON, V89, P63, DOI 10.1016/j.neuron.2015.12.015
   Lopez-Quintero C, 2011, DRUG ALCOHOL DEPEN, V115, P120, DOI 10.1016/j.drugalcdep.2010.11.004
   Lu L, 2003, NEUROSCI BIOBEHAV R, V27, P457, DOI 10.1016/S0149-7634(03)00073-3
   Lucantonio F, 2012, NAT NEUROSCI, V15, P358, DOI 10.1038/nn.3014
   Lutz PE, 2013, CURR OPIN NEUROBIOL, V23, P473, DOI 10.1016/j.conb.2013.02.005
   Machin AJ, 2011, BEHAVIOUR, V148, P985, DOI 10.1163/000579511X596624
   MacKillop J, 2011, PSYCHOPHARMACOLOGY, V216, P305, DOI 10.1007/s00213-011-2229-0
   Mantsch JR, 2016, NEUROPSYCHOPHARMACOL, V41, P335, DOI 10.1038/npp.2015.142
   MARLATT GA, 1988, ANNU REV PSYCHOL, V39, P223, DOI 10.1146/annurev.psych.39.1.223
   Martinez D, 2010, BIOL PSYCHIAT, V67, P275, DOI 10.1016/j.biopsych.2009.07.037
   Maurage P, 2012, NEUROPSYCHOPHARMACOL, V37, P2067, DOI 10.1038/npp.2012.54
   Meisch RA., 1987, METHODS ASSESSING RE, P143, DOI DOI 10.1007/978
   Mick I, 2016, NEUROPSYCHOPHARMACOL, V41, P1742, DOI 10.1038/npp.2015.340
   Miczek KA, 2008, PHARMACOL THERAPEUT, V120, P102, DOI 10.1016/j.pharmthera.2008.07.006
   Mitchell JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002902
   Moles A, 2004, SCIENCE, V304, P1983, DOI 10.1126/science.1095943
   Morgan D, 2002, NAT NEUROSCI, V5, P169, DOI 10.1038/nn798
   Mullainathan S., 2013, SCARCITY WHY HAVING
   NADER MA, 1991, PSYCHOPHARMACOLOGY, V105, P169, DOI 10.1007/BF02244304
   Nader MA, 2008, PHILOS T R SOC B, V363, P3223, DOI 10.1098/rstb.2008.0092
   Nader MA, 2014, NEUROPHARMACOLOGY, V76, P510, DOI 10.1016/j.neuropharm.2013.05.044
   Nader MA, 2012, BIOL PSYCHIAT, V72, P414, DOI 10.1016/j.biopsych.2012.03.002
   Naqvi NH, 2007, SCIENCE, V315, P531, DOI 10.1126/science.1135926
   Naqvi NH, 2014, ANN NY ACAD SCI, V1316, P53, DOI 10.1111/nyas.12415
   Neisewander JL, 2012, PSYCHOPHARMACOLOGY, V224, P33, DOI 10.1007/s00213-012-2853-3
   Nieuwenhuys R, 2012, PROG BRAIN RES, V195, P123, DOI 10.1016/B978-0-444-53860-4.00007-6
   North CS, 2004, AM J PUBLIC HEALTH, V94, P103, DOI 10.2105/AJPH.94.1.103
   Nutt DJ, 2015, NAT REV NEUROSCI, V16, P305, DOI 10.1038/nrn3939
   Orban C, 2013, AM J DRUG ALCOHOL AB, V39, P433, DOI 10.3109/00952990.2013.846348
   PANKSEPP J, 1978, BIOL PSYCHIAT, V13, P607
   PANKSEPP J, 1980, NEUROSCI BIOBEHAV R, V4, P473, DOI 10.1016/0149-7634(80)90036-6
   Piazza PV, 2013, PSYCHOPHARMACOLOGY, V229, P387, DOI 10.1007/s00213-013-3224-4
   Preller KH, 2014, ADDICT BIOL, V19, P452, DOI 10.1111/adb.12070
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Robison AJ, 2011, NAT REV NEUROSCI, V12, P623, DOI 10.1038/nrn3111
   Satel S, 2014, FRONT PSYCHIATRY, V4, DOI 10.3389/fpsyt.2013.00141
   Schmitz JM, 2001, DRUG ALCOHOL DEPEN, V63, P207, DOI 10.1016/S0376-8716(00)00208-8
   SCHUSTER CR, 1969, ANNU REV PHARMACOLOG, V9, P483, DOI 10.1146/annurev.pa.09.040169.002411
   Schwandt M. L., 2016, NEUROPSYCHOPHARMACOL
   Senatorov VV, 2015, BRAIN, V138, P69, DOI 10.1093/brain/awu305
   Shaham Y, 2000, BRAIN RES REV, V33, P13, DOI 10.1016/S0165-0173(00)00024-2
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   Singer T, 2009, TRENDS COGN SCI, V13, P334, DOI 10.1016/j.tics.2009.05.001
   Sinha R, 2011, PSYCHOPHARMACOLOGY, V218, P69, DOI 10.1007/s00213-011-2263-y
   Solinas M, 2010, PROG NEUROBIOL, V92, P572, DOI 10.1016/j.pneurobio.2010.08.002
   Sullivan EV, 2013, BIOL PSYCHIAT, V74, P547, DOI 10.1016/j.biopsych.2013.02.026
   Thomas MJ, 2008, BRIT J PHARMACOL, V154, P327, DOI 10.1038/bjp.2008.77
   Tiihonen J, 2007, AM J PSYCHIAT, V164, P160, DOI 10.1176/appi.ajp.164.1.160
   Uddin LQ, 2015, NAT REV NEUROSCI, V16, P55, DOI 10.1038/nrn3857
   Uekermann J, 2008, ADDICTION, V103, P726, DOI 10.1111/j.1360-0443.2008.02157.x
   Vendruscolo LF, 2015, J CLIN INVEST, V125, P3193, DOI 10.1172/JCI79828
   Vendruscolo LF, 2012, J NEUROSCI, V32, P7563, DOI 10.1523/JNEUROSCI.0069-12.2012
   Volkow ND, 2004, MOL PSYCHIATR, V9, P557, DOI 10.1038/sj.mp.4001507
   Volkow ND, 2007, ARCH NEUROL-CHICAGO, V64, P1575, DOI 10.1001/archneur.64.11.1575
   Wager TD, 2013, NEW ENGL J MED, V368, P1388, DOI 10.1056/NEJMoa1204471
   Way BM, 2009, P NATL ACAD SCI USA, V106, P15079, DOI 10.1073/pnas.0812612106
   Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406
   WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469
   Wolf ME, 2010, NEUROSCI BIOBEHAV R, V35, P185, DOI 10.1016/j.neubiorev.2010.01.013
   WOLFFGRAMM J, 1995, BEHAV BRAIN RES, V70, P77, DOI 10.1016/0166-4328(95)00131-C
   WOLFFGRAMM J, 1991, PHARMACOL BIOCHEM BE, V38, P389, DOI 10.1016/0091-3057(91)90297-F
   Xue YX, 2012, SCIENCE, V336, P241, DOI 10.1126/science.1215070
NR 127
TC 157
Z9 158
U1 2
U2 50
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-003X
EI 1471-0048
J9 NAT REV NEUROSCI
JI Nat. Rev. Neurosci.
PD SEP
PY 2016
VL 17
IS 9
BP 592
EP 599
DI 10.1038/nrn.2016.67
PG 8
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology
GA DU5MK
UT WOS:000382255600012
PM 27277868
OA Green Accepted
DA 2023-06-23
ER

PT S
AU Xiao, LJ
   Tao, R
AF Xiao, Li-Jun
   Tao, Ran
BE Zhang, X
   Shi, J
   Tao, R
TI Nutrition Support Therapy
SO SUBSTANCE AND NON-SUBSTANCE ADDICTION
SE Advances in Experimental Medicine and Biology
LA English
DT Article; Book Chapter
DE Nutrition intervention; Dietary behaviors; Nutritional deficiency; Omega
   3 fatty acids; Nutrition education; Metabolic systems; Disorders of
   eating; Nutrition assessment
ID SUBSTANCE-ABUSERS; SEROTONERGIC DYSFUNCTION; METABOLIC SYNDROME;
   ADDICTION; OUTCOMES; ANXIETY; ACID; FOOD; DRUG
AB In most addictions, serious nutritional deficiencies of major proteins, fats, vitamins and minerals exist which prevent their capability to digest carbohydrates efficiently. This review aims to point out some treatment approaches in nutrition management for alcohol addiction, drug addiction, food addiction, Internet addiction and sex addiction, according to existing literatures.
C1 [Xiao, Li-Jun; Tao, Ran] PLA Army Gen Hosp, Dept Psychol Med, Beijing 100700, Peoples R China.
RP Xiao, LJ (通讯作者)，PLA Army Gen Hosp, Dept Psychol Med, Beijing 100700, Peoples R China.
EM bjptaoran@126.com
CR American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors and Clinical Practice Committee, 2012, DEF TERMS STYL CONV
   Brewerton TD, 2014, EATING DISORDERS ADD
   Buydens-Branchey L, 2003, DRUG ALCOHOL DEPEN, V71, P319, DOI 10.1016/S0376-8716(03)00168-6
   Buydens-Branchey L, 2008, PROG NEURO-PSYCHOPH, V32, P568, DOI 10.1016/j.pnpbp.2007.10.020
   Buydens-Branchey L, 2006, J CLIN PSYCHOPHARM, V26, P661, DOI 10.1097/01.jcp.0000246214.49271.f1
   Buydens-Branchey L, 2009, AM J ADDICTION, V18, P73, DOI 10.1080/10550490802544003
   Cowan JA, 2013, J NUTR EDUC BEHAV, V45, P154, DOI 10.1016/j.jneb.2011.10.011
   Daniel EL, 1991, EMPL ASSIST Q, V7, P1
   Doheny K, 2012, GROUP PROGRAMS WEIGH
   Grant LP, 2004, J AM DIET ASSOC, V104, P604, DOI 10.1016/j.jada.2004.01.008
   Heinz A, 2001, ALCOHOL CLIN EXP RES, V25, P487
   Hoebel BG, 2009, J ADDICT MED, V3, P33, DOI 10.1097/ADM.0b013e31819aa621
   Islam SKN, 2001, EUR J CLIN NUTR, V55, P1022, DOI 10.1038/sj.ejcn.1601263
   Kohen D, 2004, BRIT J PSYCHIAT, V184, pS64, DOI 10.1192/bjp.184.47.s64
   Lyle MH, 2006, LETHBRIDGE UNDERGRAD, V1, P1
   Maurer HH, 2004, THER DRUG MONIT, V26, P127, DOI 10.1097/00007691-200404000-00007
   Paulvanna N. M., 2010, 2010 7 INT C WIRELES, P1
   SANTOLARIAFERNANDEZ FJ, 1995, DRUG ALCOHOL DEPEN, V38, P11, DOI 10.1016/0376-8716(94)01088-3
   Schroeder RD, 2017, SUBST USE MISUSE, V52, P10, DOI 10.1080/10826084.2016.1212603
   Shriner R, 2014, NUTRIENTS, V6, P5370, DOI 10.3390/nu6115370
   Shriner RL, 2011, CURR PHARM DESIGN, V17, P1198, DOI 10.2174/138161211795656710
   Timar O, 2000, CAN J CARDIOL, V16, P779
   Tony D, 2016, INT J ENV RES PUB HE, V13, P1
   Ukleja A, 2010, NUTR CLIN PRACT, V25, P403, DOI 10.1177/0884533610374200
   United Nations Office on Drugs and Crime, 2010, WORLD DRUG REP
   Volkow N D, 2012, Curr Top Behav Neurosci, V11, P1, DOI 10.1007/7854_2011_169
   Weitzman M, 2005, CIRCULATION, V112, P862, DOI 10.1161/CIRCULATIONAHA.104.520650
   Wrase J, 2006, COGN AFFECT BEHAV NE, V6, P53, DOI 10.3758/CABN.6.1.53
NR 28
TC 1
Z9 3
U1 0
U2 4
PU SPRINGER-VERLAG SINGAPORE PTE LTD
PI SINGAPORE
PA SINGAPORE, SINGAPORE
SN 0065-2598
EI 2214-8019
BN 978-981-10-5562-1; 978-981-10-5561-4
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2017
VL 1010
BP 281
EP 293
DI 10.1007/978-981-10-5562-1_14
D2 10.1007/978-981-10-5562-1
PG 13
WC Substance Abuse; Medicine, Research & Experimental
WE Book Citation Index– Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Substance Abuse; Research & Experimental Medicine
GA BJ9IE
UT WOS:000429224300015
PM 29098678
DA 2023-06-23
ER

PT J
AU Wasserman, D
AF Wasserman, D
TI Addiction and disability: Moral and policy issues
SO SUBSTANCE USE & MISUSE
LA English
DT Article
DE addiction; disability; distributive justice; impairment; discrimination
ID DISEASE
AB This article discusses the conceptual, ethical, and policy issues raised by the legal classification of drug addiction,as an impairment, and of some nonusing drug addicts as people with disabilities. It focuses on the questions of (1) what moral judgments, if any, underlie the classification of addiction as an impairment; (2) whether it makes sense to apportion the burdens of drug addiction between chemical, biological, social, political, and other causes; (3) how considerations of distributive justice may compel or constrain measures to ease the burdens of drug addiction; and (4) whether it is justifiable to deny the current users of illegal substances legal protections available to the current users of legal substances.
C1 Univ Maryland, Sch Publ Affairs, Inst Philosophy & Publ Policy, College Pk, MD 20742 USA.
C3 University System of Maryland; University of Maryland College Park
RP Wasserman, D (通讯作者)，Univ Maryland, Sch Publ Affairs, Inst Philosophy & Publ Policy, 3111 Van Munching Hall, College Pk, MD 20742 USA.
EM dwasserm@umd.edu
RI Stevens, David/F-4683-2015
CR ALBRECHT GL, 1982, SOC SCI MED, V16, P1319, DOI 10.1016/0277-9536(82)90027-2
   ALTMAN BM, 2001, HDB DISABILITY STUDI, P97, DOI DOI 10.4135/9781412976251.N4
   AMEY R, 2002, E COMMUNICATION 0708
   AMUNDSON R, 2000, STUDIES HIST PHILOS, V31
   AMUNDSON R, 1992, J SOCIAL PHILOS, V23
   Bickenbach Jerome, 1993, PHYS DISABILITY SOCI
   Bickenbach Jerome E, 2000, AM DISABILITIES EXPL
   BOORSE C, 1977, PHILOS SCI, V44, P542, DOI 10.1086/288768
   BOORSE C, 1975, PHILOS PUBLIC AFF, V5, P49
   BOORSE C, 1995, HLTH CARE ETHICS INT, P359
   BUCHANAN A, 1996, SOCIAL PHILOS POLICY, V13
   DOLNICK E, 1993, ATLANTIC MONTHLY SEP, P38
   EDWARDS G, 1994, ALCOHOL POLICY PUBLI
   Elster J., 1999, GETTING HOOKED RATIO
   Engelhardt H., 1986, FDN BIOETHICS
   Galston WA, 1996, PUBLIC INTEREST, P58
   Gardner EL, 1999, ADDICTION, P57
   HACKING I, 2001, GENETICS CRIMINAL BE
   HENNEN A, 1997, LAW INEQ, V15, P157
   KOBLER J, 1973, ARDENT SPIRITS RISE
   Kramer PE, 1993, LISTENING PROZAC
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   MacCallum DE, 2002, MOL BIOL CELL, V13, P25, DOI 10.1091/mbc.01-09-0441
   MACCOUN R, 2001, DRUG WAR HERESIES LE, P385
   MILLS C, 2002, ONE PILL MAKES YOU S, P257
   Vanko KJ, 1996, U ILLINOIS LAW REV, P1257
   VASSEL RA, 1994, J L COM, V13, P397
   WACHBROIT R, 1992, PHILOS SCI, V61, P579
   WACHBROIT R, 1998, CONCEPTS ENCY APPL E, V2, P533
   WASSERMAN D, 2000, AM DISABILITIES
   WATSON G, 2001, EXCUSING ADDICTION L, P589
   WIKLER D, 1979, PHILOS PUBLIC AFF, V8, P63
   Williams G., 2001, HDB DISABILITY STUDI, P123, DOI DOI 10.4135/9781412976251.N5
   Wilson E.O., 1984, BIOPHILIA
   YAFFE G, 2002, RECENT WORK ADDICTIO, V30, P178
NR 35
TC 1
Z9 1
U1 2
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1082-6084
EI 1532-2491
J9 SUBST USE MISUSE
JI Subst. Use Misuse
PY 2004
VL 39
IS 3
BP 461
EP 488
DI 10.1081/JA-120029986
PG 28
WC Substance Abuse; Psychiatry; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry; Psychology
GA 809BZ
UT WOS:000220613500005
PM 15088810
DA 2023-06-23
ER

PT J
AU Du, XJ
   Xu, WQ
   Li, XX
   Zhou, DS
   Han, CL
AF Du, Xiangju
   Xu, Weiqian
   Li, Xingxing
   Zhou, Dongsheng
   Han, Cuilan
TI Sleep Disorder in Drug Addiction: Treatment With Transcranial Magnetic
   Stimulation
SO FRONTIERS IN PSYCHIATRY
LA English
DT Editorial Material
DE TMS (Transcranial Magnetic Stimulation); sleep disorder; drug; addiction
   disorders; treatment
ID DORSOLATERAL PREFRONTAL CORTEX; RTMS
C1 [Du, Xiangju; Li, Xingxing; Zhou, Dongsheng; Han, Cuilan] Ningbo Kangning Hosp, Psychiat Dept, Ningbo, Zhejiang, Peoples R China.
   [Xu, Weiqian] Taizhou 2nd Peoples Hosp, Ctr Sleep Med, Taizhou, Peoples R China.
RP Zhou, DS; Han, CL (通讯作者)，Ningbo Kangning Hosp, Psychiat Dept, Ningbo, Zhejiang, Peoples R China.
EM wyzhouds@sina.com; hancuilannb@163.com
FU Zhejiang medical and health science and technology program [2018KY182];
   Medical Science and Technology Project in Ningbo [2017A10]; Ningbo
   municipal innovation team of life science and health [2015C110026]
FX The study was supported by the Zhejiang medical and health science and
   technology program (2018KY182), the Medical Science and Technology
   Project in Ningbo (2017A10), and Ningbo municipal innovation team of
   life science and health (2015C110026).
CR Bajbouj M, 2005, EXP NEUROL, V196, P332, DOI 10.1016/j.expneurol.2005.08.008
   BARKER AT, 1985, LANCET, V1, P1106
   Bolloni C, 2018, SUBST ABUSE REHABIL, V9, P11, DOI 10.2147/SAR.S161206
   DuPont RL, 2017, J ADDICT MED, V11, P84, DOI 10.1097/ADM.0000000000000291
   Ekhtiari H, 2019, NEUROSCI BIOBEHAV R, V104, P118, DOI 10.1016/j.neubiorev.2019.06.007
   Fitzgerald PB, 2006, AM J PSYCHIAT, V163, P88, DOI 10.1176/appi.ajp.163.1.88
   Gordon Harold W, 2019, J Addict Res (OPAST Group), V3, DOI 10.33140/JAR.03.02.01
   Hallett M, 2000, NATURE, V406, P147, DOI 10.1038/35018000
   Herrmann ES, 2017, DRUG ALCOHOL DEPEN, V178, P291, DOI 10.1016/j.drugalcdep.2017.05.013
   Hodges SE, 2017, SLEEP, V40, DOI 10.1093/sleep/zsw069
   Huang ZY, 2018, BRAIN STIMUL, V11, P1103, DOI 10.1016/j.brs.2018.05.016
   Irwin MR, 2016, ADDICTION, V111, P1084, DOI 10.1111/add.13300
   Lanza G, 2018, THER ADV NEUROL DISO, V11, DOI [10.1177/1756285618759973, 10.1177/1756286418759973]
   Lee EK, 2010, CAN J PSYCHIAT, V55, P403, DOI 10.1177/070674371005500703
   Lefaucheur JP, 2006, NEUROPHYSIOL CLIN, V36, P117, DOI 10.1016/j.neucli.2006.08.002
   Leo RJ, 2007, J PAIN, V8, P453, DOI 10.1016/j.jpain.2007.01.009
   Liang Y, 2018, JAMA PSYCHIAT, V75, P1199, DOI 10.1001/jamapsychiatry.2018.2383
   Liao YH, 2011, AM J DRUG ALCOHOL AB, V37, P179, DOI 10.3109/00952990.2010.535580
   Lin J, 2019, SLEEP MED, V58, P7, DOI 10.1016/j.sleep.2019.01.052
   Liu QM, 2017, AM J ADDICTION, V26, P776, DOI 10.1111/ajad.12638
   Logan RW, 2018, BIOL PSYCHIAT, V83, P987, DOI 10.1016/j.biopsych.2017.11.035
   Mahfoud Youssef, 2009, Psychiatry (Edgmont), V6, P38
   Massimini M, 2007, P NATL ACAD SCI USA, V104, P8496, DOI 10.1073/pnas.0702495104
   Melo-Silva CA, 2013, EXP PHYSIOL, V98, P946, DOI 10.1113/expphysiol.2012.070359
   Mensen A, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00420
   Miller MB, 2016, ADDICT BEHAV, V63, P23, DOI 10.1016/j.addbeh.2016.05.005
   Neu Peter, 2018, J Addict, V2018, P9492453, DOI 10.1155/2018/9492453
   O'Reardon JP, 2010, BIOL PSYCHIAT, V67, pE15, DOI 10.1016/j.biopsych.2009.06.027
   Park EJ, 2014, KOREAN J PAIN, V27, P285, DOI 10.3344/kjp.2014.27.3.285
   Pettorruso M, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00621
   Putnins SI, 2012, J CLIN PSYCHIAT, V73, P703, DOI 10.4088/JCP.11m07007
   Sanchez-Escandon O, 2016, SLEEP MED, V20, P37, DOI 10.1016/j.sleep.2015.11.022
   Shen Y, 2016, BIOL PSYCHIAT, V80, pE13, DOI 10.1016/j.biopsych.2016.02.006
   Song PH, 2019, SLEEP MED, V56, P157, DOI 10.1016/j.sleep.2019.01.007
   Tang JS, 2015, BMC PSYCHIATRY, V15, DOI 10.1186/s12888-015-0409-x
   Terraneo A, 2016, EUR NEUROPSYCHOPHARM, V26, P37, DOI 10.1016/j.euroneuro.2015.11.011
NR 36
TC 2
Z9 2
U1 1
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD NOV 19
PY 2019
VL 10
AR 848
DI 10.3389/fpsyt.2019.00848
PG 3
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA JT4OH
UT WOS:000500970100001
PM 31798482
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Levran, O
   Peles, E
   Randesi, M
   da Rosa, JC
   Ott, J
   Rotrosen, J
   Adelson, M
   Kreek, MJ
AF Levran, Orna
   Peles, Einat
   Randesi, Matthew
   da Rosa, Joel Correa
   Ott, Jurg
   Rotrosen, John
   Adelson, Miriam
   Kreek, Mary Jeanne
TI Glutamatergic and GABAergic susceptibility loci for heroin and cocaine
   addiction in subjects of African and European ancestry
SO PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Addiction; African Americans; Cocaine; GAD1, glutamate, GABA; Heroin
ID GAMMA-AMINOBUTYRIC-ACID; DRUG-ADDICTION; PHYSIOLOGICAL FUNCTIONS;
   GENETIC SUSCEPTIBILITY; SUBSTANCE USE; ASSOCIATION; RECEPTOR;
   DEPENDENCE; GABA; POPULATION
AB Background: Drug addiction, a leading health problem, is a chronic brain disease with a significant genetic component. Animal models and clinical studies established the involvement of glutamate and GABA neurotransmission in drug addiction. This study was designed to assess if 258 variants in 27 genes of these systems contribute to the vulnerability to develop drug addiction.
   Methods: Four independent analyses were conducted in a sample of 1860 subjects divided according to drug of abuse (heroin or cocaine) and ancestry (African and European).
   Results: A total of 11 SNPs in eight genes showed nominally significant associations (P < 0.01) with heroin and/or cocaine addiction in one or both ancestral groups but the associations did not survive correction for multiple testing. Of these SNPs, the GAD1 upstream SNP rs1978340 is potentially functional as it was shown to affect GABA concentrations in the cingulate cortex. In addition, SNPs GABRB3 rs7165224; DBI rs12613135; GAD1 SNPs rs2058725, rs1978340, rs2241164; and GRIN2A rs1650420 were previously reported in associations with drug addiction or related phenotypes.
   Conclusions: The study supports the involvement of genetic variation in the glutamatergic and GABAergic systems in drug addiction with partial overlap in susceptibility loci between cocaine and heroin addiction. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Levran, Orna; Randesi, Matthew; Adelson, Miriam; Kreek, Mary Jeanne] Rockefeller Univ, Lab Biol Addict Dis, New York, NY 10021 USA.
   [Peles, Einat; Adelson, Miriam] Tel Aviv Elias Sourasky Med Ctr, Dr Miriam & Sheldon G Adelson Clin Drug Abuse Tre, Tel Aviv, Israel.
   [Peles, Einat] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
   [da Rosa, Joel Correa] Rockefeller Univ, Ctr Clin & Translat Sci, New York, NY 10021 USA.
   [Ott, Jurg] Chinese Acad Sci, Inst Psychol, Beijing 100101, Peoples R China.
   [Ott, Jurg] Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA.
   [Rotrosen, John] VA New York Harbor Healthcare Syst, New York, NY USA.
   [Rotrosen, John] NYU, Sch Med, New York, NY USA.
   [Adelson, Miriam] Dr Miriam & Sheldon G Adelson Clin Drug Abuse Tre, Las Vegas, NV USA.
C3 Rockefeller University; Tel Aviv University; Sackler Faculty of
   Medicine; Tel Aviv University; Sackler Faculty of Medicine; Rockefeller
   University; Chinese Academy of Sciences; Institute of Psychology, CAS;
   Rockefeller University; New York University
RP Levran, O (通讯作者)，Rockefeller Univ, Lab Biol Addict Dis, 1230 York Ave, New York, NY 10021 USA.
EM levrano@rockefeller.edu
RI Da Rosa, Joel/AAU-1238-2020; Correa da Rosa, Joel/Q-4753-2017; Levran,
   Orna/H-2772-2019
OI Da Rosa, Joel/0000-0003-4221-1976; Correa da Rosa,
   Joel/0000-0003-4221-1976; 
FU Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; National
   Center for Advancing Translational Sciences of the National Institutes
   of Health [UL1RR024143]; Chinese Government [31470070]
FX This work was supported by the Dr. Miriam and Sheldon G. Adelson Medical
   Research Foundation, the Clinical and Translational Science Award
   UL1RR024143 from the National Center for Advancing Translational
   Sciences of the National Institutes of Health (B. Coller) and NSFC grant
   31470070 from the Chinese Government (J. Ott).
CR Addolorato G, 2012, NEUROPSYCHOPHARMACOL, V37, P163, DOI 10.1038/npp.2011.216
   Ary AW, 2013, J NEUROSCI, V33, P8101, DOI 10.1523/JNEUROSCI.1727-12.2013
   Atzmon G, 2010, AM J HUM GENET, V86, P850, DOI 10.1016/j.ajhg.2010.04.015
   Bauer LO, 2007, ALCOHOL CLIN EXP RES, V31, P1780, DOI 10.1111/j.1530-0277.2007.00517.x
   Benes FM, 2007, P NATL ACAD SCI USA, V104, P10164, DOI 10.1073/pnas.0703806104
   Chen CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102227
   Dahl JR, 2005, PSYCHIAT GENET, V15, P277, DOI 10.1097/00041444-200512000-00010
   de Bartolomeis A, 2012, MOL NEUROBIOL, V46, P275, DOI 10.1007/s12035-012-8293-6
   Di Chiara G, 2004, NEUROPHARMACOLOGY, V47, P227, DOI 10.1016/j.neuropharm.2004.06.032
   DILTS RP, 1989, BRAIN RES, V488, P311, DOI 10.1016/0006-8993(89)90723-3
   Ducci F, 2009, AM J PSYCHIAT, V166, P1031, DOI 10.1176/appi.ajp.2009.08071068
   Easton AC, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.97
   Enoch MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029369
   Enoch MA, 2010, BIOL PSYCHIAT, V67, P20, DOI 10.1016/j.biopsych.2009.08.019
   Ferraguti F, 2008, PHARMACOL REV, V60, P536, DOI 10.1124/pr.108.000166
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Giese KP, 2013, LEARN MEMORY, V20, P540, DOI 10.1101/lm.028449.112
   Gipson CD, 2014, NEUROPHARMACOLOGY, V76, P276, DOI 10.1016/j.neuropharm.2013.04.032
   Herman JP, 2004, ANN NY ACAD SCI, V1018, P35, DOI 10.1196/annals.1296.004
   Hodgkinson CA, 2008, ALCOHOL ALCOHOLISM, V43, P505, DOI 10.1093/alcalc/agn032
   Jacobs MM, 2013, MOL PSYCHIATR, V18, P1205, DOI 10.1038/mp.2012.140
   JOHNSON SW, 1992, J NEUROSCI, V12, P483
   Kalivas PW, 2009, NAT REV NEUROSCI, V10, P561, DOI 10.1038/nrn2515
   Kellogg SH, 2003, DRUG ALCOHOL DEPEN, V69, P137, DOI 10.1016/S0376-8716(02)00308-3
   Kendler KS, 2000, ARCH GEN PSYCHIAT, V57, P261, DOI 10.1001/archpsyc.57.3.261
   Kennedy PJ, 2013, NAT NEUROSCI, V16, P434, DOI 10.1038/nn.3354
   Kim JH, 2006, NEUROSCI RES, V56, P220, DOI 10.1016/j.neures.2006.06.013
   Kranzler HR, 2009, ALCOHOL CLIN EXP RES, V33, P925, DOI 10.1111/j.1530-0277.2009.00913.x
   Kreek MJ, 2012, J CLIN INVEST, V122, P3387, DOI 10.1172/JCI60390
   Kuo PH, 2009, DRUG ALCOHOL DEPEN, V101, P80, DOI 10.1016/j.drugalcdep.2008.11.009
   Levran O, 2008, GENES BRAIN BEHAV, V7, P720, DOI 10.1111/j.1601-183X.2008.00410.x
   Levran O, 2014, PSYCHONEUROENDOCRINO, V45, P67, DOI 10.1016/j.psyneuen.2014.03.017
   Levran O, 2009, GENES BRAIN BEHAV, V8, P531, DOI 10.1111/j.1601-183X.2009.00501.x
   Levran O, 2015, ANN HUM GENET, V79, P188, DOI 10.1111/ahg.12104
   Levran O, 2014, PHARMACOGENOMICS, V15, P2001, DOI [10.2217/PGS.14.145, 10.2217/pgs.14.145]
   Levran O, 2014, ANN HUM GENET, V78, P290, DOI 10.1111/ahg.12064
   Li DW, 2014, NEUROPSYCHOPHARMACOL, V39, P907, DOI 10.1038/npp.2013.291
   Loh EW, 2007, AM J MED GENET B, V144B, P439, DOI 10.1002/ajmg.b.30429
   Marenco S, 2010, NEUROPSYCHOPHARMACOL, V35, P1708, DOI 10.1038/npp.2010.35
   MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199, DOI 10.1016/0740-5472(92)90062-S
   Miguens M, 2013, ADDICT BIOL, V18, P623, DOI 10.1111/j.1369-1600.2011.00404.x
   Olive MF, 2012, PHARMACOL BIOCHEM BE, V100, P801, DOI 10.1016/j.pbb.2011.04.015
   Olsen RW, 2009, NEUROPHARMACOLOGY, V56, P141, DOI 10.1016/j.neuropharm.2008.07.045
   Pinard A, 2010, ADV PHARMACOL, V58, P231, DOI 10.1016/S1054-3589(10)58010-4
   Pinheiro PS, 2008, NAT REV NEUROSCI, V9, P423, DOI 10.1038/nrn2379
   Schlussman SD, 2013, BRAIN RES, V1523, P49, DOI 10.1016/j.brainres.2013.05.040
   Szumlinski KK, 2006, CURR OPIN NEUROBIOL, V16, P251, DOI 10.1016/j.conb.2006.05.002
   Tian C, 2009, MOL MED, V15, P371, DOI 10.2119/molmed.2009.00094
   Wu W, 2012, BIOCHEM BIOPH RES CO, V422, P91, DOI 10.1016/j.bbrc.2012.04.112
   Xi ZX, 2000, J PHARMACOL EXP THER, V294, P613
   Yang Yaxian, 2014, Yichuan, V36, P888, DOI 10.3724/SP.J.1005.2014.0888
   Zhao B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070817
   Zhong HJ, 2014, GENET MOL RES, V13, P8714, DOI 10.4238/2014.October.27.12
   Zintzaras E, 2012, PSYCHIAT GENET, V22, P189, DOI 10.1097/YPG.0b013e328353ae53
NR 54
TC 11
Z9 14
U1 1
U2 84
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-5846
EI 1878-4216
J9 PROG NEURO-PSYCHOPH
JI Prog. Neuro-Psychopharmacol. Biol. Psychiatry
PD JAN 4
PY 2016
VL 64
BP 118
EP 123
DI 10.1016/j.pnpbp.2015.08.003
PG 6
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA CQ9GN
UT WOS:000360921600015
PM 26277529
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Jabeen, S
   Raja, MS
   Saeed, S
   Zafar, MM
   Ghani, RA
   Mahmood, A
   Fiaz, M
   Shiaq, PA
   Baig, SM
   Naqvi, SMS
   Raja, GK
AF Jabeen, Shagufta
   Raja, Muhammad Saglain
   Saeed, Sadia
   Zafar, Muhammad Mobeen
   Ghani, Rizwana Abdul
   Mahmood, Abid
   Fiaz, Muhammad
   Shiaq, Pakeeza Arzoo
   Baig, Shahid Mahmood
   Naqvi, S. M. Saglan
   Raja, Ghazala Kaukab
TI Factors Influencing Vulnerability Towards Heroin Addiction in a
   Pakistani Cohort
SO PAKISTAN JOURNAL OF ZOOLOGY
LA English
DT Article
ID ADOLESCENT SUBSTANCE-ABUSE; ILLICIT OPIOID USE; RISK-FACTORS; DRUG-USE;
   OVERDOSE; USERS; TRANSITIONS; DEPENDENCE; AUSTRALIA
AB Addiction to opioids including other illicit drugs is a chronic, relapsing multifactorial disorder of brain and, if left untreated, major medical, social, and economic problems arise. Drug addiction is among major health issues faced by the World includmg Pakistan with an alarming annual increase in herom addicts The study was designed to identify the socio-demographic risk factors contributing to increasing susceptibility to heroin addiction in Pakistani populations In this epidemiological study subjects were interviewed through a comprehensive questionnaire consisting of open and closed-ended questions Data regarding key factors such as age and ethnicity, communal domain, education level, employment status and demographic factors (drug route, drug dose) have bearing upon heroin addiction was collected Descriptive and inferential statistics were used for data analysis. Early age of addiction onset, low literacy rate, peer pressure, occupation type, and stress are among risk factors increasing susceptibility towards heroin addiction in our studied cohort Drug abuse initiated at an early age seems to trigger transition to heroin addiction under the influence of environmental risk factors.
C1 [Jabeen, Shagufta; Raja, Muhammad Saglain; Saeed, Sadia; Zafar, Muhammad Mobeen; Ghani, Rizwana Abdul; Mahmood, Abid; Shiaq, Pakeeza Arzoo; Naqvi, S. M. Saglan; Raja, Ghazala Kaukab] PMAS Arid Agr Univ, Dept Biochem, Rawalpindi, Pakistan.
   [Fiaz, Muhammad] Shaheed Zulfiqar Ali Bhutto Med Univ, Dept Med, Islamabad, Pakistan.
   [Baig, Shahid Mahmood] Natl Inst Biotechnol & Genet Engn, Faisalabad, Pakistan.
C3 Arid Agriculture University; Pakistan Institute of Engineering & Applied
   Science
RP Raja, GK (通讯作者)，PMAS Arid Agr Univ, Dept Biochem, Rawalpindi, Pakistan.
EM ghazala@uaar.edu.pk
RI Raja, Ghazala/X-8561-2019; BAig, Shahid Mahmood/AAS-8365-2020; Shaiq,
   Pakeeza/HOH-8357-2023
OI Raja, Ghazala/0000-0002-8362-7137; 
FU Higher Education Commission Pakistan
FX We are thankful to Higher Education Commission Pakistan for funds for
   this study under 5000 Indigenous Scholarship Scheme. We are also
   thankful to all the drug rehabilitation centers and hospitals enrolled
   and assessed subjects for this study.
CR Adriani W, 2003, J NEUROSCI, V23, P4712
   Aslam N., 2015, J ALCOHOL DRUG DEPEN, V3, P201
   Aslam N, 2011, JCPSP-J COLL PHYSICI, V21, P125, DOI 02.2011/JCPSP.125126
   Buster MCA, 2002, ADDICTION, V97, P993, DOI 10.1046/j.1360-0443.2002.00179.x
   Darke S, 2000, DRUG ALCOHOL DEPEN, V60, P141, DOI 10.1016/S0376-8716(99)00147-7
   Darke S, 2003, J URBAN HEALTH, V80, P189, DOI 10.1093/jurban/jtg022
   Darke S., 2016, ADDICTION, V111
   Fischer B, 2006, CAN MED ASSOC J, V175, P1385, DOI 10.1503/cmaj.060729
   Fischer B, 2006, CAN J PSYCHIAT, V51, P624, DOI 10.1177/070674370605101002
   Fornasari D, 2012, CLIN DRUG INVEST, V32, P45, DOI 10.2165/11630070-000000000-00000
   Gossop M, 1996, BRIT MED J, V313, P402
   Kilpatrick DG, 2000, J CONSULT CLIN PSYCH, V68, P19, DOI 10.1037/0022-006X.68.1.19
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Kosten Thomas R, 2002, Sci Pract Perspect, V1, P13
   Krantz MJ, 2004, ARCH INTERN MED, V164, P277, DOI 10.1001/archinte.164.3.277
   Kreek MJ, 2012, J CLIN INVEST, V122, P3387, DOI 10.1172/JCI60390
   Malik A., 2011, PAK J COMMER SOC SCI, V5, P155
   Mehdi S., 2014, J PHARM ALTER MED, V3, P1
   Mubeen C., 2007, J AGR SOCIAL SCI, V3, P101
   Neaigus A, 2001, ADDICTION, V96, P847, DOI 10.1046/j.1360-0443.2001.9668476.x
   NIDA, 2014, DRUGS BRAINS BEHAV S
   Nizami S, 2011, J PAK MED ASSOC, V61, P198
   Rehab-International, 2016, GET FACTS
   Ronel N, 2011, SUBST USE MISUSE, V46, P608, DOI 10.3109/10826084.2010.527417
   Rudd RA, 2016, AM J TRANSPLANT, V16, P1323, DOI 10.1111/ajt.13776
   Schepis TS, 2008, AM J ADDICTION, V17, P6, DOI 10.1080/10550490701756146
   Sinha R, 2008, ANN NY ACAD SCI, V1141, P105, DOI 10.1196/annals.1441.030
   Smart R.G., 1982, WHO OFFSET PUBLICATI, V60, P58
   Swartzwelder HS, 1998, ALCOHOL, V15, P311, DOI 10.1016/S0741-8329(97)00135-3
   Swift W, 1999, ADDICTION, V94, P71, DOI 10.1046/j.1360-0443.1999.941714.x
   Tsuang MT, 1999, BEHAV GENET, V29, P473, DOI 10.1023/A:1021635223370
   UNODC, 2013, DRUG US PASK
   Weinberg NZ, 2001, J LEARN DISABIL-US, V34, P343, DOI 10.1177/002221940103400409
   Zapata JT, 1998, ADOLESCENCE, V33, P391
NR 34
TC 4
Z9 4
U1 1
U2 4
PU ZOOLOGICAL SOC PAKISTAN
PI LAHORE
PA UNIV PUNJAB, NEW CAMPUS, C/O DEPT ZOOLOGY, LAHORE, PAKISTAN
SN 0030-9923
J9 PAK J ZOOL
JI Pak. J. Zool.
PD FEB
PY 2017
VL 49
IS 1
BP 95
EP 99
DI 10.17582/journal.pjz/2017.49.1.95
PG 5
WC Zoology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Zoology
GA ER5YS
UT WOS:000398881500014
DA 2023-06-23
ER

PT J
AU Marilov, VV
   Yashin, NA
AF Marilov, V. V.
   Yashin, N. A.
TI Peculiarities of psychoactive drug addiction in psychopathic patients at
   the of conscription
SO ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA
LA Russian
DT Article
AB Male adolescents (n=193) at the age of conscription (from 17 to 27 years) underwent a military medical examination due to pathological behavior complicated with psychoactive drug addiction. A diagnosis of psychopathy (personal disorders) was confirmed in all cases. Statistically significant correlations were found between different types of psychopathy (excitable, hysteric, hyperthymic, unstable, schizoid) and peculiarities of the development of alcohol and drug addiction. it has been shown that the beginning of psychoactive drug addiction suggests the psychopathy decompensation.
RI Baltutyte, Gerda/AGH-5630-2022
CR BEREZIN SV, 1997, PSIKHOLOGIYA RANNEY
   IVANETS NN, 2000, GEROINOVAYA NARKOMAN
   KOSHKINA YA, 2000, NARKOMANIYA MOSKVA F, V13, P32
NR 3
TC 0
Z9 0
U1 0
U2 0
PU IZDATELSTVO MEDITSINA
PI MOSCOW
PA PETROVERIGSKII PER 6-8, K-142 MOSCOW, RUSSIA
SN 0044-4588
J9 ZH NEVROL PSIKHIATR
JI Z. Nevrol. Psikhiatrii Im S S Korsakova
PY 2007
VL 107
IS 9
BP 17
EP 19
PG 3
WC Clinical Neurology; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Psychiatry
GA 231ED
UT WOS:000250928400003
PM 18379457
DA 2023-06-23
ER

PT J
AU Fattore, L
   Melis, M
AF Fattore, Liana
   Melis, Miriam
TI Editorial: Exploring Gender and Sex differences in Behavioral
   dyscontrol: From drug addiction to impulse Control disorders
SO FRONTIERS IN PSYCHIATRY
LA English
DT Editorial Material
DE gender differences; sex differences; behavioral addictions; drug
   addiction; impulse control disorders; sex hormones; sexual brain
   dimorphism
ID RANDOMIZED CONTROLLED-TRIAL; ENDOCANNABINOID SYSTEM; OVARIAN HORMONES;
   HUMAN BRAIN
C1 [Fattore, Liana] CNR, CNR Neurosci Inst, Cagliari, Italy.
   [Melis, Miriam] Univ Cagliari, Dept Biomed Sci, Cagliari, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); University of Cagliari
RP Fattore, L (通讯作者)，CNR, CNR Neurosci Inst, Cagliari, Italy.
EM lfattore@in.cnr.it
RI Melis, Miriam/AAF-3235-2020; Fattore, Liana/AAC-6996-2021
OI Melis, Miriam/0000-0001-9631-8651; FATTORE, LIANA/0000-0002-2663-666X
CR Becker JB, 2016, PHARMACOL REV, V68, P242, DOI 10.1124/pr.115.011163
   Becker JB, 2012, BIOL SEX DIFFER, V3, DOI 10.1186/2042-6410-3-14
   Becker JB, 2009, HORM BEHAV, V55, P646, DOI 10.1016/j.yhbeh.2009.03.014
   Castelli MP, 2014, CURR PHARM DESIGN, V20, P2100, DOI 10.2174/13816128113199990430
   Ceylan-Isik AF, 2010, LIFE SCI, V87, P133, DOI 10.1016/j.lfs.2010.06.002
   Craft RM, 2013, LIFE SCI, V92, P476, DOI 10.1016/j.lfs.2012.06.009
   Fattore L, 2010, BRIT J PHARMACOL, V160, P724, DOI 10.1111/j.1476-5381.2010.00734.x
   Fattore L, 2008, WOMENS HEALTH, V4, P51, DOI 10.2217/17455057.4.1.51
   Fattore L, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00329
   Fattore L, 2014, FRONT NEUROENDOCRIN, V35, P272, DOI 10.1016/j.yfrne.2014.04.003
   Fattore L, 2013, DRUG TEST ANAL, V5, P57, DOI 10.1002/dta.1401
   Garbutt JC, 2005, JAMA-J AM MED ASSOC, V293, P1617, DOI 10.1001/jama.293.13.1617
   Goel N, 2014, COMPR PHYSIOL, V4, P1121, DOI 10.1002/cphy.c130054
   Goldstein JM, 2001, CEREB CORTEX, V11, P490, DOI 10.1093/cercor/11.6.490
   Gur RE, 2004, BIOL PSYCHIAT, V55, P512, DOI 10.1016/j.biopsych.2003.10.009
   Ingalhalikar M, 2014, P NATL ACAD SCI USA, V111, P823, DOI 10.1073/pnas.1316909110
   Joel D, 2015, P NATL ACAD SCI USA, V112, P15468, DOI 10.1073/pnas.1509654112
   Lopez HH, 2010, HORM BEHAV, V58, P100, DOI 10.1016/j.yhbeh.2009.10.005
   Melis M, ADDICT BIOL IN PRESS
   Melis M, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00093
   Minami H, 2014, EXP CLIN PSYCHOPHARM, V22, P392, DOI 10.1037/a0037156
   O'Malley SS, 2007, ALCOHOL CLIN EXP RES, V31, P625, DOI 10.1111/j.1530-0277.2007.00347.x
   Viveros MP, 2012, J PSYCHOPHARMACOL, V26, P164, DOI 10.1177/0269881111408956
NR 23
TC 8
Z9 8
U1 1
U2 14
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD FEB 22
PY 2016
VL 7
AR 19
DI 10.3389/fpsyt.2016.00019
PG 3
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA DE3GX
UT WOS:000370516800001
PM 26941657
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Tiako, MJN
   Hong, S
   Bin Mahmood, SU
   Mori, M
   Mangi, A
   Yun, J
   Juthani-Mehta, M
   Geirsson, A
AF Tiako, Max Jordan Nguemeni
   Hong, Seong
   Bin Mahmood, Syed Usman
   Mori, Makoto
   Mangi, Abeel
   Yun, James
   Juthani-Mehta, Manisha
   Geirsson, Arnar
TI Inconsistent Addiction Treatment for Patients Undergoing Cardiac Surgery
   for Injection Drug Use-associated Infective Endocarditis
SO JOURNAL OF ADDICTION MEDICINE
LA English
DT Article
DE addiction treatment; cardiac surgery; infective endocarditis; injection
   drug use
ID VALVE-REPLACEMENT; OPIOID DEPENDENCE; OUTCOMES
AB Introduction: Cases of surgical injection drug use-associated infective endocarditis (IDU-IE) are on the rise, amid the US opioid epidemic. We aimed to describe nature of perioperative addiction treatment for these patients.
   Methods: This is a retrospective review of 56 surgical IDU-IE from 2011 to 2016 at a tertiary care center. Data collected included substances used, documented psychosocial consultations (social work or psychiatry), medications for addiction and evidence of enrollment in a drug rehabilitation program after discharge.
   Among patients with active drug use (ADU), we compared the 24-month survival of those who received comprehensive addiction treatment, defined as both psychosocial consultation and medications for opioid use disorder to that of those who received partial or no treatment.
   Results: Out of 56 patients, 42 (75%, n = 56) received a psychosocial consultation, 23 (41.1%, n = 56) received medications for opioid use disorder and 15 (26.8% n = 56) attended a drug rehabilitation program.
   Forty-two patients had ADU. Among those, 20 (47.6%, n = 42) received comprehensive addiction treatment, while 28 (52.4%, n = 42) received partial or no treatment, and 10 (23.8%, n = 42) attended drug rehabilitation. Most patients with ADU who attended drug rehabilitation (9, 90%) had received comprehensive addiction treatment. All patients with ADU who received comprehensive addiction treatment were alive after 24-months, while 7 patients (25%, n = 28) who received partial or no treatment were not.
   Conclusion: Addiction treatment was inconsistent for surgical IDU-IE patients. Comprehensive addiction treatment predicted drug rehabilitation attendance, and was protective against 24-month mortality. Implementing protocols for comprehensive perioperative addiction treatment in IDU-IE patients is of the utmost importance.
C1 [Tiako, Max Jordan Nguemeni; Hong, Seong; Bin Mahmood, Syed Usman; Mori, Makoto; Mangi, Abeel; Geirsson, Arnar] Yale Univ, Sch Med, Dept Surg, Sect Cardiac Surg, New Haven, CT 06510 USA.
   [Yun, James] Cleveland Clin, Dept Thorac & Cardiovasc Surg, Cleveland, OH 44106 USA.
   [Juthani-Mehta, Manisha] Yale Univ, Sch Med, Dept Internal Med, Sect Infect Dis, New Haven, CT 06510 USA.
   [Juthani-Mehta, Manisha] Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA.
C3 Yale University; Cleveland Clinic Foundation; Yale University; Yale
   University
RP Tiako, MJN (通讯作者)，Yale Sch Med, 367 Cedar St, New Haven, CT 06511 USA.
EM max.tiako@yale.edu
RI Geirsson, Arnar/S-4735-2019; Nguemeni Tiako, Max Jordan/AAZ-7373-2020
OI Nguemeni Tiako, Max Jordan/0000-0002-5468-8926
FU Horace Stansel Jr Research Fund; Yale School of Medicine Department of
   Surgery
FX Funded by Horace Stansel Jr Research Fund, Yale School of Medicine
   Department of Surgery.
CR Baddour LM, 2015, CIRCULATION, V132, P1435, DOI 10.1161/CIR.0000000000000296
   Bernstein SL, 2017, ADDICT SCI CLIN PRAC, V12, DOI 10.1186/s13722-017-0083-z
   Clark RE, 1994, DEFINITIONS TERMS SO
   D'Onofrio G, 2017, J GEN INTERN MED, V32, P660, DOI 10.1007/s11606-017-3993-2
   D'Onofrio G, 2015, JAMA-J AM MED ASSOC, V313, P1636, DOI 10.1001/jama.2015.3474
   Fedoruk LM, 2009, J THORAC CARDIOV SUR, V137, P326, DOI 10.1016/j.jtcvs.2008.08.024
   Gray ME, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3408-y
   HIRATZKA LF, 1979, J THORAC CARDIOV SUR, V77, P355
   Hull SC, 2014, ANN THORAC SURG, V97, P1486, DOI 10.1016/j.athoracsur.2014.02.010
   Hussain ST, 2017, J THORAC CARDIOV SUR, V154, P2002, DOI 10.1016/j.jtcvs.2017.08.004
   Jewell C, 2013, J ADDICT MED, V7, P271, DOI 10.1097/ADM.0b013e318294b1eb
   Keeshin SW, 2016, AM J MED SCI, V352, P609, DOI 10.1016/j.amjms.2016.10.002
   Leahey PA, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz089
   Mennander AA, 2020, J THORAC CARDIOV SUR, V159, P1271, DOI 10.1016/j.jtcvs.2019.06.081
   Moller LF, 2010, PUBLIC HEALTH, V124, P637, DOI 10.1016/j.puhe.2010.08.012
   Mori M, 2019, J THORAC CARDIOVASC, V159, p1262e2
   Mori M, 2018, EUR J CARDIO-THORAC, V54, P1067, DOI 10.1093/ejcts/ezy191
   Muhuri PK, 2013, ASS NONMEDICAL PAIN
   Protos AN, 2018, ANN THORAC SURG, V106, P664, DOI [10.1016/j.athoracsur.2018.04.051, 10.1016/]
   Rabkin DG, 2012, ANN THORAC SURG, V93, P51, DOI 10.1016/j.athoracsur.2011.08.016
   Ribeiro IB, 2018, ANN THORAC SURG, V106, P664
   Rosenthal ES, 2016, AM J MED, V129, P481, DOI 10.1016/j.amjmed.2015.09.024
   Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3
   Schranz AJ, 2019, ANN INTERN MED, V170, P31, DOI 10.7326/M18-2124
   Shrestha NK, 2015, ANN THORAC SURG, V100, P875, DOI 10.1016/j.athoracsur.2015.03.019
   Slaughter MS, 2019, J THORAC CARDIOVASC, DOI 10.1016/j.jtcvs.2019.10.124
   Suzuki J, 2016, AM J ADDICTION, V25, P191, DOI 10.1111/ajad.12349
   Wakeman SE, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2019.20622
   Weimer M, 2019, CURR ADDICT REP, V6, P339
   Wurcel AG, 2017, J THORAC CARDIOV SUR, V154, P2002, DOI 10.1016/j.jtcvs.2017.07.020
   Wurcel AG, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw157
NR 31
TC 10
Z9 10
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1932-0620
EI 1935-3227
J9 J ADDICT MED
JI J. Addict. Med.
PD DEC
PY 2020
VL 14
IS 6
BP E350
EP E354
DI 10.1097/ADM.0000000000000710
PG 5
WC Substance Abuse
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Substance Abuse
GA OQ0MN
UT WOS:000588486800014
PM 32732685
OA Green Submitted
DA 2023-06-23
ER

PT J
AU Halim, NS
AF Halim, NS
TI New approaches to drug addiction therapy
SO SCIENTIST
LA English
DT Editorial Material
AB Drug addiction therapy: Monoclonal antibodies and small-molecule medications may offer the means for drug addicts to not only kick the habit, but also stay clean.
C1 The Scientist, Philadelphia, PA 19104 USA.
RP Halim, NS (通讯作者)，The Scientist, 3600 Market St,Suite 450, Philadelphia, PA 19104 USA.
CR Carroll FI, 1999, J MED CHEM, V42, P2721, DOI 10.1021/jm9706729
   Hardin JS, 1998, J PHARMACOL EXP THER, V285, P1113
   Koob GF, 1999, NAT MED, V5, P993, DOI 10.1038/12429
   Renshaw PF, 1999, PSYCHOPHARMACOLOGY, V142, P132, DOI 10.1007/s002130050871
NR 4
TC 0
Z9 0
U1 0
U2 1
PU SCIENTIST INC
PI PHILADELPHIA
PA 3600 MARKET ST SUITE 450, PHILADELPHIA, PA 19104 USA
SN 0890-3670
J9 SCIENTIST
JI Scientist
PD SEP 27
PY 1999
VL 13
IS 19
BP 12
EP 13
PG 2
WC Information Science & Library Science; Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Information Science & Library Science; Science & Technology - Other
   Topics
GA 243ML
UT WOS:000083001800012
DA 2023-06-23
ER

PT J
AU Jarvis, M
   Williams, J
   Hurford, M
   Lindsay, D
   Lincoln, P
   Giles, L
   Luongo, P
   Safarian, T
AF Jarvis, Margaret
   Williams, Jessica
   Hurford, Matthew
   Lindsay, Dawn
   Lincoln, Piper
   Giles, Leila
   Luongo, Peter
   Safarian, Taleen
TI Appropriate Use of Drug Testing in Clinical Addiction Medicine
SO JOURNAL OF ADDICTION MEDICINE
LA English
DT Article
DE addiction identification; addiction treatment; American Society of
   Addiction Medicine; drug testing; medication monitoring; opioid
   treatment services; substance use disorder
AB Biological drug testing is a tool that provides information about an individual's recent substance use. Like any tool, its value depends on using it correctly; that is, on selecting the right test for the right person at the right time. This document is intended to clarify appropriate clinical use of drug testing in addiction medicine and aid providers in their decisions about drug testing for the identification, diagnosis, treatment, and recovery of patients with, or at risk for, addiction. The RAND Corporation (RAND)/University of California, Los Angeles (UCLA) Appropriateness Method (RAM) process for combining scientific evidence with the collective judgment of experts was used to identify appropriate clinical practices and highlight areas where research is needed. Although consensus panels and expert groups have offered guidance on the use of drug testing for patients with addiction, very few addressed considerations for patients across settings and in different levels of care. This document will focus primarily on patients in addiction treatment and recovery, where drug testing is used to assess patients for a substance use disorder, monitor the effectiveness of a treatment plan, and support recovery. Inasmuch as the scope includes the recognition of addiction, which often occurs in general healthcare settings, selected special populations at risk for addiction visiting these settings are briefly included.
C1 [Jarvis, Margaret; Safarian, Taleen] Amer Soc Addict Med, 11400 Rockville Pike,Suite 200, Rockville, MD 20852 USA.
   [Williams, Jessica; Lindsay, Dawn; Lincoln, Piper; Giles, Leila; Luongo, Peter] Inst Res Educ & Training Addict, Pittsburgh, PA USA.
   [Hurford, Matthew] Community Care Behav Hlth Org, Pittsburgh, PA USA.
RP Jarvis, M (通讯作者)，Amer Soc Addict Med, 11400 Rockville Pike,Suite 200, Rockville, MD 20852 USA.
EM mjarvis@geisinger.edu
CR Center for Substance Abuse Treatment, 2007, TREATMENT IMPROVEMEN, V40
   Center for Substance Abuse Treatment, 2012, TREATMENT IMPROVEMEN, V43
   Center for Substance Abuse Treatment, 2012, HHS PUBL
   Center for Substance Abuse Treatment, 2007, HHS PUBL
   Fitch K, 2001, RAND UCLA APPROPRIAT
NR 5
TC 66
Z9 68
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1932-0620
EI 1935-3227
J9 J ADDICT MED
JI J. Addict. Med.
PD MAY-JUN
PY 2017
VL 11
IS 3
BP 163
EP 173
DI 10.1097/ADM.0000000000000323
PG 11
WC Substance Abuse
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Substance Abuse
GA EW5HT
UT WOS:000402537100002
PM 28557958
DA 2023-06-23
ER

PT J
AU Deroche-Gamonet, V
AF Deroche-Gamonet, Veronique
TI The relevance of animal models of addiction
SO ADDICTION
LA English
DT Editorial Material
DE Adverse consequences; animal model; choice; drug addiction; maladaptive
   behavior; pathological threshold
ID DRUG; VULNERABILITY; TRANSITION; PUNISHMENT; COCAINE
C1 [Deroche-Gamonet, Veronique] Neuroctr Magendie, Inserm U1215, Psychobiol Drug Addict, Bordeaux, France.
   [Deroche-Gamonet, Veronique] Univ Bordeaux, Psychobiol Drug Addict, Bordeaux, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux
RP Deroche-Gamonet, V (通讯作者)，Neuroctr Magendie, Inserm U1215, Psychobiol Drug Addict, Bordeaux, France.; Deroche-Gamonet, V (通讯作者)，Univ Bordeaux, Psychobiol Drug Addict, Bordeaux, France.
OI Deroche-Gamonet, Veronique/0000-0002-9704-6624
CR Bale TL, 2019, NEUROPSYCHOPHARMACOL, V44, P1349, DOI 10.1038/s41386-019-0405-9
   Belin D, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a011940
   Belin-Rauscent A, 2016, BIOL PSYCHIAT, V79, P39, DOI 10.1016/j.biopsych.2015.01.004
   Belsky DW, 2013, JAMA PSYCHIAT, V70, P534, DOI 10.1001/jamapsychiatry.2013.736
   Caspi A, 2006, NAT REV NEUROSCI, V7, P583, DOI 10.1038/nrn1925
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Deroche-Gamonet V., TRANSLATION NEUROSCI
   Deroche-Gamonet V, 2014, NEUROPHARMACOLOGY, V76, P437, DOI 10.1016/j.neuropharm.2013.07.014
   Field M, 2020, ADDICTION, V115, P6, DOI 10.1111/add.14764
   Heather N, 2018, ADDICT RES THEORY, V26, P249, DOI 10.1080/16066359.2017.1399659
   Kasanetz F, 2013, MOL PSYCHIATR, V18, P729, DOI 10.1038/mp.2012.59
   Kasanetz F, 2010, SCIENCE, V328, P1709, DOI 10.1126/science.1187801
   Pelloux Y, 2007, PSYCHOPHARMACOLOGY, V194, P127, DOI 10.1007/s00213-007-0805-0
   Pelloux Y, 2015, PSYCHOPHARMACOLOGY, V232, P125, DOI 10.1007/s00213-014-3648-5
   Piazza PV, 2013, PSYCHOPHARMACOLOGY, V229, P387, DOI 10.1007/s00213-013-3224-4
   Swendsen J, 2011, ANN NY ACAD SCI, V1216, P73, DOI 10.1111/j.1749-6632.2010.05894.x
   Troisi A, 2019, BEHAV BRAIN SCI, V42, DOI 10.1017/S0140525X1800119X
   Vandaele Y, 2016, NEUROPSYCHOPHARMACOL, V41, P646, DOI 10.1038/npp.2015.195
   Venniro M, 2018, NAT NEUROSCI, V21, P1520, DOI 10.1038/s41593-018-0246-6
NR 19
TC 7
Z9 7
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0965-2140
EI 1360-0443
J9 ADDICTION
JI Addiction
PD JAN
PY 2020
VL 115
IS 1
BP 16
EP 17
DI 10.1111/add.14821
EA NOV 2019
PG 2
WC Substance Abuse; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry
GA JZ6VI
UT WOS:000494949800001
PM 31701597
OA Bronze
DA 2023-06-23
ER

PT J
AU Prangnell, A
   Daly-Grafstein, B
   Dong, HR
   Nolan, S
   Milloy, MJ
   Wood, E
   Kerr, T
   Hayashi, K
AF Prangnell, Amy
   Daly-Grafstein, Ben
   Dong, Huiru
   Nolan, Seonaid
   Milloy, M-J
   Wood, Evan
   Kerr, Thomas
   Hayashi, Kanna
TI Factors associated with inability to access addiction treatment among
   people who inject drugs in Vancouver, Canada
SO SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY
LA English
DT Article
DE Injection drug use; Addiction treatment; Homelessness; Drug or alcohol
   treatment; Binge drug use; Violence
ID METHADONE TREATMENT; OPIOID DEPENDENCE; PARTNER VIOLENCE; MENTAL-HEALTH;
   FOLLOW-UP; USERS; BARRIERS; ABUSE; HIV; SEROCONVERSION
AB Background: Addiction treatment is an effective strategy used to reduce drug-related harm. In the wake of recent developments in novel addiction treatment modalities, we conducted a longitudinal data analysis to examine factors associated with inability to access addiction treatment among a prospective cohort of persons who inject drugs (PWID).
   Methods: Data were derived from two prospective cohorts of PWID in Vancouver, Canada, between December 2005 and November 2013. Using multivariate generalized estimating equations, we examined factors associated with reporting an inability to access addiction treatment.
   Results: In total, 1142 PWID who had not accessed any addiction treatment during the six months prior to interview were eligible for this study, including 364 women (31.9 %). Overall, 188 (16.5 %) reported having sought but were ultimately unsuccessful in accessing addiction treatment at least once during the study period. In multivariate analysis, factors independently and positively associated with reporting inability to access addiction treatment included: binge drug use (Adjusted Odds Ratio [AOR] = 1.65), being a victim of violence (AOR = 1.77), homelessness (AOR = 1.99), and having ever accessed addiction treatment (AOR = 2.33); while length of time injecting was negatively and independently associated (AOR = 0.98) (all p < 0.05).
   Conclusions: These findings suggest that sub-populations of PWID were more likely to report experiencing difficulty accessing addiction treatment, including those who may be entrenched in severe drug addiction and vulnerable to violence. It is imperative that additional resources go into ensuring treatment options are readily available when requested for these target populations.
C1 [Prangnell, Amy; Dong, Huiru; Nolan, Seonaid; Milloy, M-J; Wood, Evan; Kerr, Thomas; Hayashi, Kanna] St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
   [Daly-Grafstein, Ben] Univ Toronto, Human Biol Program, Wetmore Hall,Room 105,300 Huron St, Toronto, ON M5S 3J6, Canada.
   [Nolan, Seonaid; Milloy, M-J; Wood, Evan; Kerr, Thomas; Hayashi, Kanna] Univ British Columbia, Dept Med, St Pauls Hosp, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
C3 B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University
   of Toronto; St. Paul's Hospital; University of British Columbia
RP Hayashi, K (通讯作者)，St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.; Hayashi, K (通讯作者)，Univ British Columbia, Dept Med, St Pauls Hosp, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
EM khayashi@cfenet.ubc.ca
RI Milloy, M-J/AAY-3618-2020
FU US National Institutes of Health [U01DA038886, R01DA021525]; Canada
   Research Chairs program through a Canada Research Chair in Inner City
   Medicine; Canadian Institutes of Health Research New Investigator Award
   [MSH-141971]; United States National Institutes of Health [R01DA021525]
FX The authors thank the study participants for their contribution to the
   research, as well as current and past researchers and staff. The study
   was supported by the US National Institutes of Health (U01DA038886,
   R01DA021525). This research was undertaken, in part, thanks to funding
   from the Canada Research Chairs program through a Tier 1 Canada Research
   Chair in Inner City Medicine which supports Dr. Evan Wood. Dr. Kanna
   Hayashi is supported by the Canadian Institutes of Health Research New
   Investigator Award (MSH-141971). Dr. Milloy is supported in part by the
   United States National Institutes of Health (R01DA021525).
CR ALLEN K, 1995, J NATL MED ASSOC, V87, P751
   Bobrova N, 2006, DRUG ALCOHOL DEPEN, V82, pS57, DOI 10.1016/S0376-8716(06)80010-4
   Cohen JB, 2003, AM J ADDICTION, V12, P377, DOI 10.1080/10550490390240701
   Coker AL, 2002, AM J PREV MED, V23, P260, DOI 10.1016/S0749-3797(02)00514-7
   Darke S, 1998, DRUG ALCOHOL DEPEN, V51, P253, DOI 10.1016/S0376-8716(98)00028-3
   DeBeck K, 2007, DRUG ALCOHOL DEPEN, V91, P50, DOI 10.1016/j.drugalcdep.2007.05.003
   DeBeck K, 2011, DRUG ALCOHOL DEPEN, V113, P172, DOI 10.1016/j.drugalcdep.2010.07.023
   Degenhardt L, 2012, LANCET, V379, P55, DOI 10.1016/S0140-6736(11)61138-0
   Digiusto E, 2007, ADDICTION, V102, P958, DOI 10.1111/j.1360-0443.2007.01842.x
   El-Bassel N, 2001, VIOLENCE AGAINST WOM, V7, P246, DOI 10.1177/10778010122182433
   French Michael T., 2000, Subst Abus, V21, P95, DOI 10.1023/A:1007763129628
   Gossop M, 2000, DRUG ALCOHOL DEPEN, V58, P165, DOI 10.1016/S0376-8716(99)00077-0
   Hser YI, 2001, ARCH GEN PSYCHIAT, V58, P503, DOI 10.1001/archpsyc.58.5.503
   Krahn G, 2006, J SUBST ABUSE TREAT, V31, P375, DOI 10.1016/j.jsat.2006.05.011
   Krupitsky E, 2011, LANCET, V377, P1506, DOI 10.1016/S0140-6736(11)60358-9
   Li X, 2007, ADDICT BEHAV, V32, P1043, DOI 10.1016/j.addbeh.2006.07.012
   Lundgren LM, 2013, J DUAL DIAGN, V9, P47, DOI 10.1080/15504263.2012.749830
   Luty J, 2003, ADV PSYCHIAT TREAT, V9, P280, DOI DOI 10.1192/APT.9.4.280
   Maldonado JR, 2014, ALCOHOL, V48, P375, DOI 10.1016/j.alcohol.2014.01.004
   Marsh DC, 2006, INT J DRUG POLICY, V17, P137, DOI 10.1016/j.drugpo.2005.12.006
   Marshall BDL, 2008, DRUG ALCOHOL DEPEN, V97, P237, DOI 10.1016/j.drugalcdep.2008.03.028
   Mathers BM, 2008, LANCET, V372, P1733, DOI 10.1016/S0140-6736(08)61311-2
   Metzger DS, 2010, JAIDS-J ACQ IMM DEF, V55, pS32, DOI 10.1097/QAI.0b013e3181f9c10b
   METZGER DS, 1993, J ACQ IMMUN DEF SYND, V6, P1049
   Miller CL, 2006, SUBST USE MISUSE, V41, P199, DOI 10.1080/10826080500391795
   Milloy MJS, 2010, J PUBLIC HEALTH-UK, V32, P342, DOI 10.1093/pubmed/fdp089
   Nordt C, 2015, J CLIN EPIDEMIOL, V68, P1346, DOI 10.1016/j.jclinepi.2015.05.002
   Nosyk B, 2010, J SUBST ABUSE TREAT, V39, P22, DOI 10.1016/j.jsat.2010.03.008
   Palepu A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011697
   Pan W, 2001, BIOMETRICS, V57, P120, DOI 10.1111/j.0006-341X.2001.00120.x
   Rapp RC, 2006, J SUBST ABUSE TREAT, V30, P227, DOI 10.1016/j.jsat.2006.01.002
   Redko C, 2006, J DRUG ISSUES, V36, P831, DOI 10.1177/002204260603600404
   Ross J, 2005, DRUG ALCOHOL REV, V24, P411, DOI 10.1080/09595230500286039
   Sambamoorthi U, 2000, DRUG ALCOHOL DEPEN, V60, P77
   Sigmon SC, 2014, JAMA PSYCHIAT, V71, P359, DOI 10.1001/jamapsychiatry.2013.4450
   Sittambalam CD, 2014, J COMMUNITY HOSP INT, V4, DOI 10.3402/jchimp.v4.22902
   Tyndall MW, 2003, AIDS, V17, P887, DOI 10.1097/00002030-200304110-00014
   Weiner MD, 2005, ADDICT BEHAV, V30, P1261, DOI 10.1016/j.addbeh.2004.12.007
   Wood E, 2006, INT J DRUG POLICY, V17, P55, DOI 10.1016/j.drugpo.2005.12.007
   Wood E, 2005, SUBST USE MISUSE, V40, P1153, DOI 10.1081/JA-200042287
NR 40
TC 13
Z9 13
U1 1
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1747-597X
J9 SUBST ABUSE TREAT PR
JI Subst/ Abus. Treatment Prev. Pol.
PD FEB 25
PY 2016
VL 11
AR 9
DI 10.1186/s13011-016-0053-6
PG 8
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA DE9JQ
UT WOS:000370953200001
PM 26916425
OA gold, Green Published
DA 2023-06-23
ER

PT S
AU Lax, E
   Szyf, M
AF Lax, Elad
   Szyf, Moshe
BE Grayson, DR
TI The Role of DNA Methylation in Drug Addiction: Implications for
   Diagnostic and Therapeutics
SO EPIGENETICS AND PSYCHIATRIC DISEASE
SE Progress in Molecular Biology and Translational Science
LA English
DT Review; Book Chapter
ID ALCOHOL-USE DISORDER; EPIGENETIC MECHANISMS; PREFRONTAL CORTEX; GENE
   PROMOTER; NUCLEUS-ACCUMBENS; COCAINE-SEEKING; RHESUS MACAQUE; NEURAL
   BASIS; GENOME; SENSITIZATION
AB Drug addiction is a devastating health problem that is a very heavy burden on the individual affected and the society in general. Recent research defines addiction as a neurobehavioral disorder. Underpinning biological mechanisms of drug addiction are abnormal neuronal and brain activity following acute and repeated drug exposure. Abnormal gene expression is found in reward and decision-making brain regions of addicts and in animal models and is possibly responsible for changes in brain function. DNA methylation is an epigenetic modification that regulates gene expression. Global and site-specific changes in DNA methylation are observed in addiction. Here, we discuss recent findings on the involvement of DNA methylation in drug addiction from animal and human studies. We also propose future directions for utilizing DNA methylation-based approaches for diagnosis, therapeutics, and evaluation of response to therapy in drug addiction.
C1 [Lax, Elad; Szyf, Moshe] McGill Univ, Sch Med, Dept Pharmacol & Therapeut, Montreal, PQ, Canada.
C3 McGill University
RP Szyf, M (通讯作者)，McGill Univ, Sch Med, Dept Pharmacol & Therapeut, Montreal, PQ, Canada.
EM moshe.szyf@mcgill.ca
RI Lax, Elad/AAF-4993-2020
OI Lax, Elad/0000-0002-0310-0520
FU Canadian Institute of Health Research [MOP-42411] Funding Source:
   Medline
CR Alaghband Y, 2016, NEUROSCI LETT, V625, P40, DOI 10.1016/j.neulet.2016.01.023
   American Psychiatric Association, 2013, SUBST REL ADD DIS DI
   Anier K, 2013, INT J NEUROPSYCHOPH, V16, P2053, DOI 10.1017/S1461145713000394
   Anier K, 2010, NEUROPSYCHOPHARMACOL, V35, P2450, DOI 10.1038/npp.2010.128
   Barbier E, 2015, J NEUROSCI, V35, P6153, DOI 10.1523/JNEUROSCI.4571-14.2015
   Bernstein BE, 2010, NAT BIOTECHNOL, V28, P1045, DOI 10.1038/nbt1010-1045
   Bleich S, 2006, ALCOHOL CLIN EXP RES, V30, P587, DOI 10.1111/j.1530-0277.2006.00068.x
   Bonsch D, 2004, J NEURAL TRANSM, V111, P1611, DOI 10.1007/s00702-004-0232-x
   Bossert JM, 2005, EUR J PHARMACOL, V526, P36, DOI 10.1016/j.ejphar.2005.09.030
   Bruckmann C, 2016, EPIGENETICS-US, V11, P456, DOI 10.1080/15592294.2016.1179411
   Brueckner B, 2005, CANCER RES, V65, P6305, DOI 10.1158/0008-5472.CAN-04-2957
   CEDAR H, 1990, BIOCHIM BIOPHYS ACTA, V1049, P1, DOI 10.1016/0167-4781(90)90076-E
   Cheishvili D, 2017, EPIGENOMICS-UK, V9, P611, DOI 10.2217/epi-2016-0141
   Cheng MC, 2015, BRAIN RES, V1629, P126, DOI 10.1016/j.brainres.2015.10.021
   Chorbov Vesselin M, 2011, J Opioid Manag, V7, P258
   Day JJ, 2015, ANNU REV PHARMACOL, V55, P591, DOI 10.1146/annurev-pharmtox-010814-124527
   Ebrahimi G, 2018, AM J DRUG ALCOHOL AB, V44, P193, DOI 10.1080/00952990.2016.1275659
   Edgar RD, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.171
   Fan W, 2016, SCI REP-UK, V6, DOI 10.1038/srep19430
   Feng J, 2013, CURR OPIN NEUROBIOL, V23, P521, DOI 10.1016/j.conb.2013.01.001
   Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134
   Hagerty SL, 2016, ALCOHOL CLIN EXP RES, V40, P1633, DOI 10.1111/acer.13138
   Hannon E, 2015, EPIGENETICS-US, V10, P1024, DOI 10.1080/15592294.2015.1100786
   Heberlein A, 2015, EUR NEUROPSYCHOPHARM, V25, P1892, DOI 10.1016/j.euroneuro.2015.08.018
   Hillemacher T, 2015, PSYCHONEUROENDOCRINO, V51, P371, DOI 10.1016/j.psyneuen.2014.10.014
   Itzhak Y, 2015, MOL PSYCHIATR, V20, P252, DOI 10.1038/mp.2014.7
   Jayanthi S, 2017, MOL NEUROBIOL, DOI [10.1007/s12035-017-075-09, DOI 10.1007/S12035017-07509]
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kalivas PW, 1998, J PSYCHOPHARMACOL, V12, P49, DOI 10.1177/026988119801200107
   Kozlenkov A, 2017, GENES-BASEL, V8, DOI 10.3390/genes8060152
   Kreek MJ, 2002, NAT REV DRUG DISCOV, V1, P710, DOI 10.1038/nrd897
   Lan J, 2010, ACTA BIOCH BIOPH SIN, V42, P243, DOI 10.1093/abbs/gmq015
   LaPlant Q, 2010, NAT NEUROSCI, V13, P1137, DOI 10.1038/nn.2619
   Li X, 2015, ADDICT BIOL, V20, P872, DOI 10.1111/adb.12205
   Liu C, 2018, MOL PSYCHIATR, V23, P422, DOI 10.1038/mp.2016.192
   Lohoff FW, 2018, MOL PSYCHIATR, V23, DOI 10.1038/mp.2017.168
   Ludwig AK, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00115
   MacDonald JL, 2009, PROG NEUROBIOL, V88, P170, DOI 10.1016/j.pneurobio.2009.04.002
   Marie-Claire C, 2016, EPIGENOMICS-UK, V8, P181, DOI 10.2217/epi.15.110
   Massart R, 2014, NEUROSCIENCE, V268, P139, DOI 10.1016/j.neuroscience.2014.03.021
   Massart R, 2016, SCI REP-UK, V6, DOI 10.1038/srep19615
   Massart R, 2015, J NEUROSCI, V35, P8042, DOI 10.1523/JNEUROSCI.3053-14.2015
   Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0
   Mendelson JH, 1996, NEW ENGL J MED, V334, P965, DOI 10.1056/NEJM199604113341507
   Moore LD, 2013, NEUROPSYCHOPHARMACOL, V38, P23, DOI 10.1038/npp.2012.112
   Muschler MAN, 2010, J NEURAL TRANSM, V117, P513, DOI 10.1007/s00702-010-0378-7
   Nader MA, 2016, PROG BRAIN RES, V224, P3, DOI 10.1016/bs.pbr.2015.07.012
   Nan XS, 1998, CIBA F SYMP, V214, P6
   Nemoda Z, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.32
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   Nestler EJ, 2014, NEUROPHARMACOLOGY, V76, P259, DOI 10.1016/j.neuropharm.2013.04.004
   Nielsen DA, 2009, NEUROPSYCHOPHARMACOL, V34, P867, DOI 10.1038/npp.2008.108
   Nieratschker V, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.75
   Philibert RA, 2014, EPIGENETICS-US, V9, P1212, DOI 10.4161/epi.32252
   Ponomarev I, 2012, J NEUROSCI, V32, P1884, DOI 10.1523/JNEUROSCI.3136-11.2012
   Provencal N, 2012, J NEUROSCI, V32, P15626, DOI 10.1523/JNEUROSCI.1470-12.2012
   RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Robison AJ, 2011, NAT REV NEUROSCI, V12, P623, DOI 10.1038/nrn3111
   Roost MS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01077-3
   Ruggeri B, 2015, AM J PSYCHIAT, V172, P543, DOI 10.1176/appi.ajp.2014.14030382
   Sartor GC, 2014, NEUROPSYCHOPHARMACOL, V39, P1059, DOI 10.1038/npp.2013.323
   Skinner BF., 1966, BEHAV ORGANISMS EXPT
   Stresemann C, 2008, INT J CANCER, V123, P8, DOI 10.1002/ijc.23607
   Szyf M, 2016, EPIGENOMICS-UK, V8, P1539, DOI 10.2217/epi-2016-0076
   Tian WP, 2016, SCI REP-UK, V6, DOI 10.1038/srep22087
   Tian WP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033435
   Tuesta LM, 2014, EMBO J, V33, P1091, DOI 10.1002/embj.201488106
   Tzschentke TM, 2007, ADDICT BIOL, V12, P227, DOI 10.1111/j.1369-1600.2007.00070.x
   van der Knaap LJ, 2014, GENES BRAIN BEHAV, V13, P618, DOI 10.1111/gbb.12147
   Venniro M, 2016, PROG BRAIN RES, V224, P25, DOI 10.1016/bs.pbr.2015.08.004
   Watson CT, 2015, NEUROPSYCHOPHARMACOL, V40, P2993, DOI 10.1038/npp.2015.155
   Wright KN, 2015, J NEUROSCI, V35, P8948, DOI 10.1523/JNEUROSCI.5227-14.2015
   Zhang HP, 2013, ALCOHOL CLIN EXP RES, V37, pE108, DOI 10.1111/j.1530-0277.2012.01928.x
   Zhu J, 2017, J NEUROSCI RES, V95, P1459, DOI 10.1002/jnr.23913
NR 75
TC 12
Z9 12
U1 1
U2 8
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1877-1173
BN 978-0-12-813565-5
J9 PROG MOL BIOL TRANSL
JI Prog. Molec. Biol. Transl. Sci.
PY 2018
VL 157
BP 93
EP 104
DI 10.1016/bs.pmbts.2018.01.003
PG 12
WC Biochemistry & Molecular Biology; Neurosciences
WE Book Citation Index– Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA BL5NM
UT WOS:000452371300006
PM 29933958
DA 2023-06-23
ER

PT J
AU Olmstead, MC
AF Olmstead, MC
TI Animal models of drug addiction: Where do we go from here?
SO QUARTERLY JOURNAL OF EXPERIMENTAL PSYCHOLOGY
LA English
DT Review
ID PRENATAL ETHANOL EXPOSURE; VENTROMEDIAL PREFRONTAL CORTEX; EARLY SOCIAL
   DEPRIVATION; SELF-ADMINISTER COCAINE; ISOLATION-REARED RATS; DOSE-BINGE
   PATTERN; NUCLEUS-ACCUMBENS; D-AMPHETAMINE; IMPULSIVE BEHAVIOR; DOPAMINE
   RELEASE
AB Compulsion and impulsivity are both primary features of drug addiction. Based on decades of animal research, we have a detailed understanding of the factors (both environmental and physiological) that influence compulsive drug use, but still know relatively little about the impulsive aspects of drug addiction. This review outlines our current knowledge of the relationship between impulsivity and drug addiction, focusing on cognitive and motor impulsivity, which are particularly relevant to this disorder. Topics to be discussed include the influence of chronic drug administration on impulsivity, the mechanisms that may explain drug-induced impulsivity, and the role of individual differences in the development of impulsive drug use. In addition, the manner in which contemporary theories of drug addiction conceptualize the relationship between impulsivity and compulsion is examined. Most importantly, this review emphasizes a critical role for animal research in understanding the role of impulsivity in the development and maintenance of drug addiction.
C1 Queens Univ, Dept Psychol, Kingston, ON K7L 3N6, Canada.
C3 Queens University - Canada
RP Olmstead, MC (通讯作者)，Queens Univ, Dept Psychol, 62 Arch St, Kingston, ON K7L 3N6, Canada.
EM olmstead@post.queensu.ca
CR ABDOLLAH S, 1993, CAN J PHYSIOL PHARM, V71, P776, DOI 10.1139/y93-116
   ABEL EL, 1982, ALCOHOLISM CLIN EXPT, V6, P376
   Adriani W, 2004, NEUROPSYCHOPHARMACOL, V29, P869, DOI 10.1038/sj.npp.1300366
   Adriani W, 2003, BEHAV NEUROSCI, V117, P695, DOI 10.1037/0735-7044.117.4.695
   ALEXANDER BK, 1978, PSYCHOPHARMACOLOGY, V58, P175, DOI 10.1007/BF00426903
   Andersen SL, 2003, NEUROSCI BIOBEHAV R, V27, P3, DOI 10.1016/S0149-7634(03)00005-8
   Andersen SL, 2002, BEHAV BRAIN RES, V130, P197, DOI 10.1016/S0166-4328(01)00417-X
   ANDERSEN SL, 2005, NAT NEUROSCI, V5, P13
   BABE KS, 1996, PHARMACOL BASIS THER, P581
   Baer JS, 2003, ARCH GEN PSYCHIAT, V60, P377, DOI 10.1001/archpsyc.60.4.377
   BAGLENOVA J, 2004, BEHAV BRAIN RES, V150, P159
   BARRATT ES, 1983, BIOL BASES SENSATION, P77
   Bates ME, 2002, EXP CLIN PSYCHOPHARM, V10, P193, DOI 10.1037//1064-1297.10.3.193
   BAUMANN MH, 1993, SYNAPSE, V14, P40, DOI 10.1002/syn.890140107
   BEATTY WW, 1995, DRUG ALCOHOL DEPEN, V37, P247, DOI 10.1016/0376-8716(94)01072-S
   Bechara A, 2001, NEUROPSYCHOLOGIA, V39, P376, DOI 10.1016/S0028-3932(00)00136-6
   Bechara A, 2002, NEUROPSYCHOLOGIA, V40, P1690, DOI 10.1016/S0028-3932(02)00016-7
   Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189
   Belej T, 1996, BRAIN RES, V736, P287, DOI 10.1016/0006-8993(96)00713-5
   Bennett AJ, 2002, MOL PSYCHIATR, V7, P118, DOI 10.1038/sj/mp/4000949
   Bickel WK, 2001, ADDICTION, V96, P73, DOI 10.1046/j.1360-0443.2001.961736.x
   Birrell JM, 2000, J NEUROSCI, V20, P4320
   Bizot JC, 1999, PSYCHOPHARMACOLOGY, V146, P400, DOI 10.1007/PL00005485
   Blanchard RJ, 1998, NEUROSCI BIOBEHAV R, V23, P179, DOI 10.1016/S0149-7634(98)00019-0
   Block RI, 2002, PHARMACOL BIOCHEM BE, V73, P491, DOI 10.1016/S0091-3057(02)00816-X
   Bolla KI, 2000, NEUROLOGY, V54, P2285, DOI 10.1212/WNL.54.12.2285
   Bowden SC, 2001, ALCOHOL CLIN EXP RES, V25, P317, DOI 10.1111/j.1530-0277.2001.tb02215.x
   BOYLE AE, 2001, PHARM BIOCH BEHAV, V39, P269
   BOZARTH MA, 1989, PHARMACOL BIOCHEM BE, V33, P903, DOI 10.1016/0091-3057(89)90490-5
   BOZARTH MA, 1985, JAMA-J AM MED ASSOC, V254, P81, DOI 10.1001/jama.254.1.81
   Brodsky BS, 2001, AM J PSYCHIAT, V158, P1871, DOI 10.1176/appi.ajp.158.11.1871
   Brooks SP, 2002, NEUROPHARMACOLOGY, V42, P577, DOI 10.1016/S0028-3908(02)00006-0
   Brunner D, 1997, ANN NY ACAD SCI, V836, P81, DOI 10.1111/j.1749-6632.1997.tb52356.x
   Buka SL, 2003, AM J PSYCHIAT, V160, P1978, DOI 10.1176/appi.ajp.160.11.1978
   Burchett SA, 1997, MOL BRAIN RES, V49, P95, DOI 10.1016/S0169-328X(97)00131-9
   Cardinal RN, 2000, PSYCHOPHARMACOLOGY, V152, P362, DOI 10.1007/s002130000536
   Cardinal RN, 2001, SCIENCE, V292, P2499, DOI 10.1126/science.1060818
   Carlezon WA, 2002, TRENDS NEUROSCI, V25, P610, DOI 10.1016/S0166-2236(02)02289-0
   Chambers R Andrew, 2003, J Gambl Stud, V19, P53, DOI 10.1023/A:1021275130071
   Chen K, 2002, DRUG ALCOHOL DEPEN, V68, P65, DOI 10.1016/S0376-8716(02)00086-8
   Chen WJA, 1997, NEUROTOXICOL TERATOL, V19, P39, DOI 10.1016/S0892-0362(96)00188-2
   Choong K, 2004, NEUROSCIENCE, V126, P1083, DOI 10.1016/j.neuroscience.2004.04.041
   CHOW TW, 2000, CURRENT PSYCHIAT REP, V12, P446
   Chudasama Y, 2001, BEHAV NEUROSCI, V115, P417, DOI 10.1037/0735-7044.115.2.417
   Chudasama Y, 2001, EUR J NEUROSCI, V14, P1009, DOI 10.1046/j.0953-816x.2001.01607.x
   CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408
   CLONINGER CR, 1993, ARCH GEN PSYCHIAT, V50, P975, DOI 10.1001/archpsyc.1993.01820240059008
   COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45
   COLE BJ, 1987, BEHAV NEUROSCI, V101, P476, DOI 10.1037/0735-7044.101.4.476
   Collins SL, 2004, NEUROPHARMACOLOGY, V46, P349, DOI 10.1016/j.neuropharm.2003.09.024
   Collins SL, 2002, DEV BRAIN RES, V138, P27, DOI 10.1016/S0165-3806(02)00471-6
   Crabbe JC, 1999, TRENDS NEUROSCI, V22, P173, DOI 10.1016/S0166-2236(99)01393-4
   CREESE I, 1974, PSYCHOPHARMACOLOGIA, V39, P345, DOI 10.1007/BF00422974
   CUNNINGHAM KA, 1992, SYNAPSE, V11, P112, DOI 10.1002/syn.890110204
   Dalley JW, 2002, PSYCHOPHARMACOLOGY, V164, P329, DOI 10.1007/s00213-002-1215-y
   Dalley JW, 2002, NEUROPSYCHOPHARMACOL, V26, P716, DOI 10.1016/S0893-133X(01)00412-2
   de Wit H, 2000, BEHAV NEUROSCI, V114, P830, DOI 10.1037//0735-7044.114.4.830
   de Wit H, 2002, NEUROPSYCHOPHARMACOL, V27, P813, DOI 10.1016/S0893-133X(02)00343-3
   DEATHERAGE G, 1972, Physiology and Behavior, V9, P55, DOI 10.1016/0031-9384(72)90264-8
   DeLeon KR, 2002, BEHAV BRAIN RES, V133, P211, DOI 10.1016/S0166-4328(02)00004-9
   DEVENPORT LD, 1983, PSYCHOPHARMACOLOGY, V79, P21, DOI 10.1007/BF00433010
   DiCiano P, 1996, BEHAV PHARMACOL, V7, P714
   DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7
   DOTY P, 1995, PSYCHOPHARMACOLOGY, V118, P19, DOI 10.1007/BF02245245
   DRISCOLL CD, 1990, NEUROTOXICOL TERATOL, V12, P231, DOI 10.1016/0892-0362(90)90094-S
   DWORKIN SI, 1995, BRAIN RES, V682, P116, DOI 10.1016/0006-8993(95)00327-M
   Evenden J, 1999, J PSYCHOPHARMACOL, V13, P180, DOI 10.1177/026988119901300211
   Evenden JL, 1998, PSYCHOPHARMACOLOGY, V140, P319, DOI 10.1007/s002130050773
   Evenden JL, 1996, PSYCHOPHARMACOLOGY, V128, P161, DOI 10.1007/s002130050121
   Evenden JL, 1999, PSYCHOPHARMACOLOGY, V146, P413, DOI 10.1007/PL00005486
   Everitt BJ, 2001, BRAIN RES REV, V36, P129, DOI 10.1016/S0165-0173(01)00088-1
   Everitt BJ, 2000, PSYCHOPHARMACOLOGY, V153, P17, DOI 10.1007/s002130000566
   Everitt BJ, 1999, ANN NY ACAD SCI, V877, P412, DOI 10.1111/j.1749-6632.1999.tb09280.x
   Everitt BJ, 2002, J NEUROSCI, V22, P3312
   Fein G, 2002, DRUG ALCOHOL DEPEN, V68, P87, DOI 10.1016/S0376-8716(02)00110-2
   Feola TW, 2000, BEHAV NEUROSCI, V114, P838, DOI 10.1037/0735-7044.114.4.838
   Fillmore MT, 2002, EXP CLIN PSYCHOPHARM, V10, P417, DOI 10.1037//1064-1297.10.4.417
   Fillmore MT, 2002, DRUG ALCOHOL DEPEN, V66, P265, DOI 10.1016/S0376-8716(01)00206-X
   Finn PR, 1999, PSYCHOPHARMACOLOGY, V146, P465, DOI 10.1007/PL00005492
   Fleckenstein AE, 1999, EUR J PHARMACOL, V382, P45, DOI 10.1016/S0014-2999(99)00588-9
   FLETCHER PJ, 1993, BEHAV BRAIN RES, V54, P187, DOI 10.1016/0166-4328(93)90078-5
   Franklin TR, 2002, BIOL PSYCHIAT, V51, P134, DOI 10.1016/S0006-3223(01)01269-0
   Garcia-Moreno LM, 2002, PROG NEURO-PSYCHOPH, V26, P831, DOI 10.1016/S0278-5846(01)00327-X
   GAWIN FH, 1988, NEW ENGL J MED, V318, P1173, DOI 10.1056/NEJM198805053181806
   Gendle MH, 2003, DEV BRAIN RES, V147, P85, DOI 10.1016/j.devbrainres.2003.10.002
   GERBING DW, 1987, MULTIVAR BEHAV RES, V22, P357, DOI 10.1207/s15327906mbr2203_6
   Glatt SJ, 2004, SYNAPSE, V53, P74, DOI 10.1002/syn.20036
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Grant S, 2000, NEUROPSYCHOLOGIA, V38, P1180, DOI 10.1016/S0028-3932(99)00158-X
   Hall FS, 1998, PSYCHOPHARMACOLOGY, V139, P210, DOI 10.1007/s002130050706
   Hall FS, 1998, CRIT REV NEUROBIOL, V12, P129, DOI 10.1615/CritRevNeurobiol.v12.i1-2.50
   Hall FS, 1998, PSYCHOPHARMACOLOGY, V139, P203, DOI 10.1007/s002130050705
   Harrison AA, 1997, PSYCHOPHARMACOLOGY, V133, P329, DOI 10.1007/s002130050410
   Harrison PA, 1997, CHILD ABUSE NEGLECT, V21, P529, DOI 10.1016/S0145-2134(97)00013-6
   Harrison PA, 1998, AM J PSYCHIAT, V155, P486, DOI 10.1176/ajp.155.4.486
   Harvey JA, 2004, NEUROSCI BIOBEHAV R, V27, P751, DOI 10.1016/j.neubiorev.2003.11.006
   Hayward ML, 2004, J PHARMACOL EXP THER, V308, P644, DOI 10.1124/jpet.103.059261
   Heinz A, 2001, ALCOHOL CLIN EXP RES, V25, P487
   Hellemans KGC, 2005, BEHAV BRAIN RES, V159, P207, DOI 10.1016/j.bbr.2004.10.018
   Hellemans KGC, 2002, CAN J EXP PSYCHOL, V56, P241, DOI 10.1037/h0087400
   Hellstrom-Lindahl E, 2002, RESPIRATION, V69, P289, DOI 10.1159/000063261
   Higley J D, 1997, Recent Dev Alcohol, V13, P191
   HILL SY, 1976, PHARMACOL BIOCHEM BE, V5, P701, DOI 10.1016/0091-3057(76)90315-4
   Hoaken PNS, 1998, J STUD ALCOHOL, V59, P599, DOI 10.15288/jsa.1998.59.599
   Hobbs W. R., 1996, GOODMAN GILMANS PHAR, P361
   Homberg JR, 2002, EUR J NEUROSCI, V15, P1542, DOI 10.1046/j.1460-9568.2002.01976.x
   Hommer D, 1997, J NEUROSCI, V17, P2796
   Howes SR, 2000, PSYCHOPHARMACOLOGY, V151, P55, DOI 10.1007/s002130000451
   Hutcheson DM, 2001, NAT NEUROSCI, V4, P943, DOI 10.1038/nn0901-943
   Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560
   Iqbal U, 2004, BEHAV BRAIN RES, V150, P117, DOI 10.1016/S0166-4328(03)00246-8
   Jacobs EH, 2003, TRENDS PHARMACOL SCI, V24, P566, DOI 10.1016/j.tips.2003.09.006
   Jacobsen LK, 2000, AM J PSYCHIAT, V157, P1134, DOI 10.1176/appi.ajp.157.7.1134
   Jentsch JD, 2002, NEUROPSYCHOPHARMACOL, V26, P183, DOI 10.1016/S0893-133X(01)00355-4
   Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483
   Jentsch JD, 2003, BEHAV NEUROSCI, V117, P76, DOI 10.1037/0735-7044.117.1.76
   JOHNSON RG, 1993, PHARMACOL BIOCHEM BE, V46, P289, DOI 10.1016/0091-3057(93)90355-W
   KALIVAS PW, 1993, BEHAV PHARMACOL, V4, P315
   KANDEL DB, 1992, J STUD ALCOHOL, V53, P447, DOI 10.15288/jsa.1992.53.447
   Kane VB, 2004, J PHARMACOL EXP THER, V308, P521, DOI 10.1124/jpet.103.059899
   KAZMAIER K, 1973, Q J STUD ALCOHOL, V34, P520
   Keller RW, 1996, NEUROSCI LETT, V205, P153, DOI 10.1016/0304-3940(96)12409-5
   Kelley AE, 2002, J NEUROSCI, V22, P3306
   KILBEY MM, 1977, ADV BEHAV BIOL, P409
   Kirby KN, 1999, J EXP PSYCHOL GEN, V128, P78, DOI 10.1037/0096-3445.128.1.78
   Kish SJ, 2002, PHARMACOL BIOCHEM BE, V71, P845, DOI 10.1016/S0091-3057(01)00708-0
   KLEVEN MS, 1988, BRAIN RES BULL, V21, P233, DOI 10.1016/0361-9230(88)90236-5
   Klitzman RL, 2000, AM J PSYCHIAT, V157, P1162, DOI 10.1176/appi.ajp.157.7.1162
   Kodituwakku PW, 2001, NEUROPSYCHOLOGIA, V39, P699, DOI 10.1016/S0028-3932(01)00002-1
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Kuczenski R, 1997, J NEUROSCI, V17, P4441
   LAU MA, 1995, J ABNORM PSYCHOL, V104, P150, DOI 10.1037/0021-843X.104.1.150
   Laviola G, 2003, NEUROSCI BIOBEHAV R, V27, P19, DOI 10.1016/S0149-7634(03)00006-X
   LAVIOLA G, 1995, J PHARMACOL EXP THER, V275, P345
   Lesch KP, 2000, BEHAV SCI LAW, V18, P581, DOI 10.1002/1099-0798(200010)18:5<581::AID-BSL411>3.0.CO;2-L
   Leshner AI, 2000, AM J MED GENET, V96, P590, DOI 10.1002/1096-8628(20001009)96:5<590::AID-AJMG2>3.0.CO;2-2
   Lindholm S, 2001, BRAIN RES, V915, P176, DOI 10.1016/S0006-8993(01)02847-5
   Little KY, 1996, AM J PSYCHIAT, V153, P1216
   Little KY, 1998, AM J PSYCHIAT, V155, P207
   London ED, 2000, CEREB CORTEX, V10, P334, DOI 10.1093/cercor/10.3.334
   Lovinger DR, 1999, NEUROCHEM INT, V35, P125, DOI 10.1016/S0197-0186(99)00054-6
   MacDonald TK, 2000, J PERS SOC PSYCHOL, V78, P605, DOI 10.1037/0022-3514.78.4.605
   MacDonald TK, 1996, PERS SOC PSYCHOL B, V22, P763, DOI 10.1177/0146167296228001
   Madden GJ, 1997, EXP CLIN PSYCHOPHARM, V5, P256, DOI 10.1037/1064-1297.5.3.256
   MAISONNEUVE IM, 1994, J PHARMACOL EXP THER, V268, P916
   Marinelli M, 2002, EUR J NEUROSCI, V16, P387, DOI 10.1046/j.1460-9568.2002.02089.x
   MARKOU A, 1993, PSYCHOPHARMACOLOGY, V112, P163, DOI 10.1007/BF02244907
   Markou A, 1998, NEUROPSYCHOPHARMACOL, V18, P135, DOI 10.1016/S0893-133X(97)00113-9
   MARTENSSON L, 1984, EUR J OBSTET GYN R B, V18, P169, DOI 10.1016/0028-2243(84)90016-9
   Mattson SN, 1998, ALCOHOL CLIN EXP RES, V22, P279, DOI 10.1111/j.1530-0277.1998.tb03651.x
   Mattson SN, 2001, ALCOHOL RES HEALTH, V25, P185
   McCann UD, 1997, NEUROPSYCHOPHARMACOL, V16, P229, DOI 10.1016/S0893-133X(96)00197-2
   McClure GYH, 1997, J PHARMACOL EXP THER, V281, P1368
   Melega WP, 1996, SYNAPSE, V22, P63, DOI 10.1002/(SICI)1098-2396(199601)22:1<63::AID-SYN7>3.3.CO;2-J
   MILLER LA, 1992, NEUROPSYCHOLOGIA, V30, P69, DOI 10.1016/0028-3932(92)90015-E
   Mitchell SH, 1999, PSYCHOPHARMACOLOGY, V146, P455, DOI 10.1007/PL00005491
   Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006
   Moeller FG, 2002, DRUG ALCOHOL DEPEN, V68, P105
   Morgan MJ, 2000, PSYCHOPHARMACOLOGY, V152, P230, DOI 10.1007/s002130000545
   Morgan MJ, 1998, NEUROPSYCHOPHARMACOL, V19, P252, DOI 10.1016/S0893-133X(98)00012-8
   Morral AR, 2002, ADDICTION, V97, P1493, DOI 10.1046/j.1360-0443.2002.00280.x
   Nadal R, 2002, PSYCHOPHARMACOLOGY, V162, P333, DOI 10.1007/s00213-002-1091-5
   NANSON JL, 1990, ALCOHOL CLIN EXP RES, V14, P656, DOI 10.1111/j.1530-0277.1990.tb01223.x
   Neddens J, 2002, J NEURAL TRANSM, V109, P141, DOI 10.1007/s007020200010
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   OBOYLE M, 1993, PERS INDIV DIFFER, V14, P609, DOI 10.1016/0191-8869(93)90156-W
   Olmstead MC, 2000, PSYCHOPHARMACOLOGY, V152, P123, DOI 10.1007/s002130000498
   Olmstead MC, 2001, BEHAV NEUROSCI, V115, P394, DOI 10.1037/0735-7044.115.2.394
   OLMSTEAD MC, IN PRESS PSYCHOPHARM
   Ornstein TJ, 2000, NEUROPSYCHOPHARMACOL, V23, P113, DOI 10.1016/S0893-133X(00)00097-X
   Ortner CNM, 2003, ALCOHOL ALCOHOLISM, V38, P151, DOI 10.1093/alcalc/agg041
   Paine TA, 2004, PSYCHOPHARMACOLOGY, V175, P443, DOI 10.1007/s00213-004-1845-3
   Paine TA, 2003, BEHAV BRAIN RES, V147, P135, DOI 10.1016/S0166-4328(03)00156-6
   PAINE TA, 2004, SOC NEUR ABSTR
   Paus T, 2005, TRENDS COGN SCI, V9, P60, DOI 10.1016/j.tics.2004.12.008
   Paus T, 1999, SCIENCE, V283, P1908, DOI 10.1126/science.283.5409.1908
   Petry NM, 2001, DRUG ALCOHOL DEPEN, V63, P29, DOI 10.1016/S0376-8716(00)00188-5
   PHILLIPS GD, 1994, PSYCHOPHARMACOLOGY, V115, P419, DOI 10.1007/BF02245085
   PHILLIPS GD, 1994, PSYCHOPHARMACOLOGY, V115, P407, DOI 10.1007/BF02245084
   Piazza PV, 1996, ANNU REV PHARMACOL, V36, P359, DOI 10.1146/annurev.pa.36.040196.002043
   PITMAN RK, 1989, BIOL PSYCHIAT, V26, P189, DOI 10.1016/0006-3223(89)90022-X
   Poulos CX, 1996, BEHAV PHARMACOL, V7, P395, DOI 10.1097/00008877-199608000-00011
   Poulos CX, 1998, BEHAV NEUROSCI, V112, P1247, DOI 10.1037/0735-7044.112.5.1247
   RAMSEY NF, 1993, DRUG ALCOHOL DEPEN, V33, P41, DOI 10.1016/0376-8716(93)90032-L
   RANDRUP A, 1966, J PHARM PHARMACOL, V18, P752, DOI 10.1111/j.2042-7158.1966.tb07799.x
   RAPOPORT JL, 1990, PSYCHOL MED, V20, P465, DOI 10.1017/S0033291700016962
   Reneman L, 2000, PSYCHOPHARMACOLOGY, V148, P322, DOI 10.1007/s002130050057
   Reneman L, 2001, BIOL PSYCHIAT, V50, P550, DOI 10.1016/S0006-3223(01)01177-5
   Richards JB, 1999, PSYCHOPHARMACOLOGY, V146, P432, DOI 10.1007/PL00005488
   Richards JB, 1999, J EXP ANAL BEHAV, V71, P121, DOI 10.1901/jeab.1999.71-121
   Richardson DP, 2002, EUR J NEUROSCI, V16, P1593, DOI 10.1046/j.1460-9568.2002.02214.x
   RIDLEY RM, 1980, PSYCHOPHARMACOLOGY, V67, P241, DOI 10.1007/BF00431263
   RILEY EP, 1980, PHYSIOL PSYCHOL, V8, P47
   RILEY EP, 1979, PSYCHOPHARMACOLOGY, V41, P652
   Robbins TW, 1996, J PSYCHOPHARMACOL, V10, P39, DOI 10.1177/026988119601000107
   ROBERTS DCS, 1994, PHARMACOL BIOCHEM BE, V49, P177, DOI 10.1016/0091-3057(94)90473-1
   Robinson TE, 1999, EUR J NEUROSCI, V11, P1598, DOI 10.1046/j.1460-9568.1999.00576.x
   Robinson TE, 2001, SYNAPSE, V39, P257
   Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI 10.1146/annurev.psych.54.101601.145237
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Rocha BA, 2002, PSYCHOPHARMACOLOGY, V163, P221, DOI 10.1007/s00213-002-1140-0
   ROCKMAN GE, 1988, BEHAV NEURAL BIOL, V49, P184, DOI 10.1016/S0163-1047(88)90506-7
   Rogers RD, 1999, NEUROPSYCHOPHARMACOL, V20, P322, DOI 10.1016/S0893-133X(98)00091-8
   Rossetti ZL, 2002, ALCOHOL CLIN EXP RES, V26, P181, DOI 10.1111/j.1530-0277.2002.tb02523.x
   RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817
   Ruotsalainen S, 2000, PSYCHOPHARMACOLOGY, V148, P111, DOI 10.1007/s002130050032
   RYAN LJ, 1990, BRAIN RES, V518, P67, DOI 10.1016/0006-8993(90)90955-B
   SABOL KE, 1995, PSYCHOPHARMACOLOGY, V121, P57, DOI 10.1007/BF02245591
   SAHAKIAN BJ, 1975, BRAIN RES, V84, P195, DOI 10.1016/0006-8993(75)90975-0
   Salvatore MF, 2004, NEUROSCIENCE, V123, P481, DOI 10.1016/j.neuroscience.2003.10.002
   SCHENK S, 1987, NEUROSCI LETT, V81, P227, DOI 10.1016/0304-3940(87)91003-2
   SCHENK S, 1990, ALCOHOL, V7, P321, DOI 10.1016/0741-8329(90)90090-Y
   SCHENK S, 1988, PHARMACOL BIOCHEM BE, V31, P59, DOI 10.1016/0091-3057(88)90311-5
   Schrijver NCA, 2001, BEHAV NEUROSCI, V115, P437, DOI 10.1037/0735-7044.115.2.437
   SCHWARTZ AS, 1974, NATURE, V248, P257, DOI 10.1038/248257a0
   Scourfield J, 1996, COMPR PSYCHIAT, V37, P384, DOI 10.1016/S0010-440X(96)90021-8
   Segal DS, 1997, J PHARMACOL EXP THER, V282, P561
   Segal DS, 1999, PSYCHOPHARMACOLOGY, V142, P182, DOI 10.1007/s002130050878
   Segal DS, 1997, BEHAV BRAIN RES, V88, P251, DOI 10.1016/S0166-4328(97)00067-3
   SHAHMAN Y, 2000, BRAIN RES REV, V1
   Shen RY, 1999, ALCOHOL CLIN EXP RES, V23, P1801, DOI 10.1111/j.1530-0277.1999.tb04076.x
   Singer LT, 2004, JAMA-J AM MED ASSOC, V291, P2448, DOI 10.1001/jama.291.20.2448
   Smith AM, 2004, NEUROTOXICOL TERATOL, V26, P533, DOI 10.1016/j.ntt.2004.04.004
   Smith RF, 2003, NEUROTOXICOL TERATOL, V25, P291, DOI 10.1016/S0892-0362(02)00349-5
   SOKOLOWSKI JD, 1994, BRAIN RES, V642, P20, DOI 10.1016/0006-8993(94)90901-6
   Sowell ER, 2001, J NEUROSCI, V21, P8819, DOI 10.1523/JNEUROSCI.21-22-08819.2001
   SPEAR LP, 1983, DEV PSYCHOBIOL, V16, P83, DOI 10.1002/dev.420160203
   STAPLETON JM, 1995, NEUROPSYCHOPHARMACOL, V13, P21, DOI 10.1038/sj.npp.1380272
   STEELE CM, 1990, AM PSYCHOL, V45, P921, DOI 10.1037/0003-066X.45.8.921
   STEWART J, 1993, BEHAV PHARMACOL, V4, P289
   STREISSGUTH AP, 1984, DEV PSYCHOL, V20, P533, DOI 10.1037/0012-1649.20.4.533
   SZECHTMAN H, 2003, PSYCHOL REV, V10, P1
   SZECHTMAN H, 2001, BIOMEDICAL CTR NEURO, V2, P1471
   Taylor JR, 2001, BIOL PSYCHIAT, V50, P137, DOI 10.1016/S0006-3223(01)01106-4
   TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147
   Tornatzky W, 1999, PSYCHOPHARMACOLOGY, V145, P144, DOI 10.1007/s002130051043
   Tornatzky W, 2000, PSYCHOPHARMACOLOGY, V148, P289, DOI 10.1007/s002130050053
   UNTERWALD EM, 1994, J PHARMACOL EXP THER, V270, P1387
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI 10.1093/cercor/10.3.318
   VONKNORRING L, 1987, J STUD ALCOHOL, V48, P523, DOI 10.15288/jsa.1987.48.523
   Vuchinich RE, 1998, EXP CLIN PSYCHOPHARM, V6, P292, DOI 10.1037/1064-1297.6.3.292
   Wade TR, 2000, PSYCHOPHARMACOLOGY, V150, P90
   Weissenborn R, 1997, PSYCHOPHARMACOLOGY, V134, P242, DOI 10.1007/s002130050447
   WENGER GR, 1990, PHARMACOL BIOCHEM BE, V35, P595, DOI 10.1016/0091-3057(90)90296-T
   White AM, 2000, ALCOHOL CLIN EXP RES, V24, P1251, DOI 10.1097/00000374-200008000-00017
   White NM, 1996, ADDICTION, V91, P921, DOI 10.1111/j.1360-0443.1996.tb03586.x
   WILCOTT RC, 1982, PHYSIOL PSYCHOL, V10, P371, DOI 10.3758/BF03332967
   Williams BR, 1999, DEV PSYCHOL, V35, P205, DOI 10.1037/0012-1649.35.1.205
   Wilmouth CE, 2004, ANN NY ACAD SCI, V1021, P462, DOI 10.1196/annals.1308.065
   WILSON JM, 1994, BRAIN RES, V668, P39, DOI 10.1016/0006-8993(94)90508-8
   WISE RA, 1988, J ABNORM PSYCHOL, V97, P118, DOI 10.1037/0021-843X.97.2.118
   Wise RA, 1996, CURR OPIN NEUROBIOL, V6, P243, DOI 10.1016/S0959-4388(96)80079-1
   Wise RA, 1999, PSYCHOBIOLOGY, V27, P300
   WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469
   Wise Roy A., 2000, Neuron, V26, P27, DOI 10.1016/S0896-6273(00)81134-4
   WOOLVERTON WL, 1978, PHARMACOL BIOCHEM BE, V9, P327, DOI 10.1016/0091-3057(78)90293-9
   Yin HH, 2004, EUR J NEUROSCI, V19, P181, DOI 10.1111/j.1460-9568.2004.03095.x
   Zhang Y, 2001, BRAIN RES, V923, P172, DOI 10.1016/S0006-8993(01)03032-3
NR 259
TC 70
Z9 72
U1 0
U2 17
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1747-0218
EI 1747-0226
J9 Q J EXP PSYCHOL
JI Q. J. Exp. Psychol.
PD APR
PY 2006
VL 59
IS 4
BP 625
EP 653
DI 10.1080/17470210500356308
PG 29
WC Psychology, Biological; Physiology; Psychology; Psychology, Experimental
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology; Physiology
GA 036IE
UT WOS:000237064000001
PM 16707354
OA Green Submitted
DA 2023-06-23
ER

PT J
AU Lee, MY
   Lee, BH
   Kim, HY
   Yang, CH
AF Lee, Mi Young
   Lee, Bong Hyo
   Kim, Hee Young
   Yang, Chae Ha
TI Bidirectional role of acupuncture in the treatment of drug addiction
SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
LA English
DT Article
DE Acupuncture; Bidirectional regulation; Drug-seeking behavior; Mesolimbic
   dopamine pathway; Neurotransmitters; Somatosensory afferent mechanism
ID ANXIETY-LIKE BEHAVIOR; CORTICOTROPIN-RELEASING-FACTOR; VENTRAL TEGMENTAL
   AREA; INCENTIVE-SENSITIZATION THEORY; DOPAMINE NEURON REACTIVITY; MEDIAL
   PREFRONTAL CORTEX; KAPPA-OPIOID RECEPTORS; PITUITARY-ADRENAL AXIS; RAT
   NUCLEUS-ACCUMBENS; MORPHINE-INDUCED CPP
AB Drug addiction is a chronically relapsing disorder, affecting people from all walks of life. Studies of acupuncture effects on drug addiction are intriguing in light of the fact that acupuncture can be used as a convenient therapeutic intervention for treating drug addiction by direct activation of brain pathway. The current review aims to discuss the neurobiological mechanisms underlying acupuncture's effectiveness in the treatment of drug addiction, on the basis of two different theories (the incentive sensitization theory and the opponent process theory) that have seemingly opposite view on the role of the mesolimbic reward pathways in mediating compulsive drug-seeking behavior. This review provides evidence that acupuncture may reduce relapse to drugseeking behavior by regulating neurotransmitters involved in drug craving modulation via somatosensory afferent mechanisms. Also, acupuncture normalizes hyper-reactivity or hypoactivity of the mesolimbic dopamine system in these opposed processes in drug addiction, suggesting bidirectional role of acupuncture in regulation of drug addiction. This proposes that acupuncture may reduce drug craving by correcting both dysfunctions of the mesolimbic dopamine pathway.
C1 [Lee, Mi Young] Daegu Haany Univ, Coll Biomed Sci, Gyongsan, Gyeongsangbuk D, South Korea.
   [Lee, Bong Hyo; Kim, Hee Young; Yang, Chae Ha] Daegu Haany Univ, Coll Korean Med, 136 Sincheondong Ro, Daegu, South Korea.
C3 Daegu Haany University; Daegu Haany University
RP Yang, CH (通讯作者)，Daegu Haany Univ, Coll Korean Med, 136 Sincheondong Ro, Daegu, South Korea.
EM chyang@dhu.ac.kr
FU National Research Foundation of Korea (NRF) - Korea government (MSIT)
   [2018R1A5A2025272, 2020R1A2C1006559]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MSIT) (No. 2018R1A5A2025272)
   (No. 2020R1A2C1006559) . We thank Sungwon Kim for checking the English
   in the manuscript.
CR Aguilar MA, 2009, BRAIN RES REV, V59, P253, DOI 10.1016/j.brainresrev.2008.08.002
   Allain F, 2021, NEUROPSYCHOPHARMACOL, V46, P305, DOI 10.1038/s41386-020-0773-1
   Allain F, 2017, NEUROPHARMACOLOGY, V117, P227, DOI 10.1016/j.neuropharm.2017.01.026
   Anderson SM, 2005, PHARMACOL THERAPEUT, V106, P389, DOI 10.1016/j.pharmthera.2004.12.004
   ANDERSSON S, 1995, MED HYPOTHESES, V45, P271, DOI 10.1016/0306-9877(95)90117-5
   Avery MC, 2017, FRONT NEURAL CIRCUIT, V11, DOI 10.3389/fncir.2017.00108
   Backes EN, 2008, NEUROCHEM RES, V33, P459, DOI 10.1007/s11064-007-9454-2
   Barroso AR, 2019, EUR NEUROPSYCHOPHARM, V29, P1213, DOI 10.1016/j.euroneuro.2019.08.298
   Becker HC, 2008, ALCOHOL RES HEALTH, V31, P348
   Bills KB, 2020, BRAIN STIMUL, V13, P403, DOI 10.1016/j.brs.2019.11.012
   Bocklisch C, 2013, SCIENCE, V341, P1521, DOI 10.1126/science.1237059
   Breiter HC, 1997, NEURON, V19, P591, DOI 10.1016/S0896-6273(00)80374-8
   Brody AL, 2002, ARCH GEN PSYCHIAT, V59, P1162, DOI 10.1001/archpsyc.59.12.1162
   Brudzynski SM, 2009, ILAR J, V50, P43, DOI 10.1093/ilar.50.1.43
   BUCKINGHAM JC, 1986, NEUROENDOCRINOLOGY, V42, P148, DOI 10.1159/000124266
   Buckner RL, 2009, J NEUROSCI, V29, P1860, DOI 10.1523/JNEUROSCI.5062-08.2009
   Cai XH, 2012, NEURAL REGEN RES, V7, P2607, DOI 10.3969/j.issn.1673-5374.2012.33.006
   Calipari ES, 2013, NEUROPSYCHOPHARMACOL, V38, P2385, DOI 10.1038/npp.2013.136
   Carr CC, 2020, PSYCHOPHARMACOLOGY, V237, P1795, DOI 10.1007/s00213-020-05500-4
   Ceccherelli F, 2001, ACUPUNCTURE ELECTRO, V26, P229, DOI 10.3727/036012901816355938
   Chae Y, 2008, NEUROSCI LETT, V430, P98, DOI 10.1016/j.neulet.2007.10.026
   Chae YY, 2004, NEUROSCI LETT, V358, P87, DOI 10.1016/j.neulet.2003.12.121
   Chang S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax1342
   Chang SC, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00928
   Chang S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05681-7
   Chefer VI, 2003, J NEUROSCI, V23, P3076
   Chen L, 2019, PHYSIOL RES, V68, P835, DOI 10.33549/physiolres.934106
   Chen Pei, 2018, Int J Physiol Pathophysiol Pharmacol, V10, P60
   CHEN XH, 1992, BEHAV BRAIN RES, V47, P143, DOI 10.1016/S0166-4328(05)80120-2
   Chen YI, 2008, NEUROSCI LETT, V431, P231, DOI 10.1016/j.neulet.2007.11.063
   Chen YI, 2012, SYNAPSE, V66, P331, DOI 10.1002/syn.21516
   Chu NN, 2007, BRAIN RES, V1182, P90, DOI 10.1016/j.brainres.2007.08.086
   Crombag HS, 2008, PHILOS T R SOC B, V363, P3233, DOI 10.1098/rstb.2008.0090
   Cui CL, 2008, NEUROCHEM RES, V33, P2013, DOI 10.1007/s11064-008-9784-8
   DIANA M, 1993, P NATL ACAD SCI USA, V90, P7966, DOI 10.1073/pnas.90.17.7966
   Due DL, 2002, AM J PSYCHIAT, V159, P954, DOI 10.1176/appi.ajp.159.6.954
   Duvauchelle CL, 2000, BEHAV NEUROSCI, V114, P1156, DOI 10.1037/0735-7044.114.6.1156
   Ebner SR, 2010, PSYCHOPHARMACOLOGY, V210, P241, DOI 10.1007/s00213-010-1836-5
   Edwards S, 2010, FUTUR NEUROL, V5, P393, DOI 10.2217/FNL.10.14
   Ersche KD, 2013, CURR OPIN NEUROBIOL, V23, P615, DOI 10.1016/j.conb.2013.02.017
   Eshkevari L, 2015, ENDOCRINOLOGY, V156, P3649, DOI 10.1210/EN.2015-1018
   Eshkevari L, 2013, J ENDOCRINOL, V217, P95, DOI 10.1530/JOE-12-0404
   Fang JL, 2009, HUM BRAIN MAPP, V30, P1196, DOI 10.1002/hbm.20583
   George O, 2012, PHYSIOL BEHAV, V106, P58, DOI 10.1016/j.physbeh.2011.11.004
   Grant S, 2016, DRUG ALCOHOL DEPEN, V163, P1, DOI 10.1016/j.drugalcdep.2016.02.034
   GRAY TS, 1984, BRAIN RES, V306, P354, DOI 10.1016/0006-8993(84)90386-X
   Graziane NM, 2013, NEURON, V77, P942, DOI 10.1016/j.neuron.2012.12.034
   Grusser SM, 2004, PSYCHOPHARMACOLOGY, V175, P296, DOI 10.1007/s00213-004-1828-4
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   HAN JS, 1982, ANNU REV PHARMACOL, V22, P193, DOI 10.1146/annurev.pa.22.040182.001205
   Havermans RC, 2003, ADDICT BEHAV, V28, P989, DOI 10.1016/S0306-4603(01)00289-1
   He F, 2018, ACUPUNCT MED, V36, P394, DOI 10.1136/acupmed-2017-011450
   He T, 2015, AUTON NEUROSCI-BASIC, V190, P1, DOI 10.1016/j.autneu.2015.03.006
   Heinrichs SC, 2010, BEHAV BRAIN RES, V207, P353, DOI 10.1016/j.bbr.2009.10.013
   Ho TJ, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/5642708
   Hoover WB, 2007, BRAIN STRUCT FUNCT, V212, P149, DOI 10.1007/s00429-007-0150-4
   Hsieh CW, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/951258
   Hu AR, 2013, NEUROSCI LETT, V534, P252, DOI 10.1016/j.neulet.2012.12.021
   Hu L, 2009, ADDICT BIOL, V14, P431, DOI 10.1111/j.1369-1600.2009.00163.x
   Hui KKS, 2009, BRAIN RES, V1287, P84, DOI 10.1016/j.brainres.2009.06.061
   Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037
   Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F
   Itoh K, 2011, CHIN MED-UK, V6, DOI 10.1186/1749-8546-6-24
   Jasinska AJ, 2014, NEUROSCI BIOBEHAV R, V38, P1, DOI 10.1016/j.neubiorev.2013.10.013
   Jin W, 2018, ADDICT BIOL, V23, P165, DOI 10.1111/adb.12499
   JOHNSON SW, 1992, J NEUROSCI, V12, P483
   Johnston A L, 1988, J Psychopharmacol, V2, P33, DOI 10.1177/026988118800200106
   Kang OS, 2013, PSYCHOPHARMACOLOGY, V228, P119, DOI 10.1007/s00213-013-3015-y
   Kawa AB, 2019, EUR J NEUROSCI, V50, P2663, DOI 10.1111/ejn.14418
   Kawa AB, 2016, PSYCHOPHARMACOLOGY, V233, P3587, DOI 10.1007/s00213-016-4393-8
   Kelz MB, 1999, NATURE, V401, P272, DOI 10.1038/45790
   Kim MR, 2005, NEUROSCI LETT, V387, P17, DOI 10.1016/j.neulet.2005.07.007
   Kim SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081018
   Kim U, 2012, EUR J NEUROSCI, V35, P1253, DOI 10.1111/j.1460-9568.2012.08030.x
   Kim YH, 2020, NEUROREPORT, V31, P352, DOI 10.1097/WNR.0000000000001412
   Kober H, 2014, NEUROPSYCHOPHARMACOL, V39, P2288, DOI 10.1038/npp.2014.82
   Koob GF, 2008, PHILOS T R SOC B, V363, P3113, DOI 10.1098/rstb.2008.0094
   Koob GF, 2008, ANNU REV PSYCHOL, V59, P29, DOI 10.1146/annurev.psych.59.103006.093548
   Koob GF, 2020, BIOL PSYCHIAT, V87, P44, DOI 10.1016/j.biopsych.2019.05.023
   Koob GF, 2016, LANCET PSYCHIAT, V3, P760, DOI 10.1016/S2215-0366(16)00104-8
   Koob GF, 2015, EUR J PHARMACOL, V753, P73, DOI 10.1016/j.ejphar.2014.11.044
   Koob GF, 2009, BRAIN RES, V1293, P61, DOI 10.1016/j.brainres.2009.03.038
   KOOB GF, 1994, EXS, V71, P103
   KOOB GF, 1992, ANN NY ACAD SCI, V654, P171, DOI 10.1111/j.1749-6632.1992.tb25966.x
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Kosten, 1993, AM J ADDICTIONS, V2, P194
   Kravets JL, 2015, BRAIN STRUCT FUNCT, V220, P541, DOI 10.1007/s00429-013-0674-8
   Kuhn S, 2011, EUR J NEUROSCI, V33, P1318, DOI 10.1111/j.1460-9568.2010.07590.x
   Lee B, 2009, NEUROSCI LETT, V449, P128, DOI 10.1016/j.neulet.2008.10.089
   Lee BH, 2008, NEUROSCI LETT, V443, P213, DOI 10.1016/j.neulet.2008.07.069
   Lee BH, 2015, J ACUPUNCT MERIDIAN, V8, P175, DOI 10.1016/j.jams.2015.04.001
   Lee BH, 2014, NEUROSCI LETT, V576, P34, DOI 10.1016/j.neulet.2014.05.050
   Lee BH, 2012, NEUROSCI LETT, V529, P23, DOI 10.1016/j.neulet.2012.09.020
   Leite-Morris KA, 2014, BEHAV BRAIN RES, V263, P51, DOI 10.1016/j.bbr.2013.12.041
   Leung L, 2012, J ACUPUNCT MERIDIAN, V5, P261, DOI 10.1016/j.jams.2012.07.017
   Li AH, 2004, BRAIN RES, V1012, P154, DOI 10.1016/j.brainres.2004.04.009
   Liang J, 2010, NEUROPHARMACOLOGY, V58, P233, DOI 10.1016/j.neuropharm.2009.07.007
   Lin JG, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/739045
   Liu S, 2007, NEUROSCI LETT, V421, P203, DOI 10.1016/j.neulet.2007.04.078
   Liu S, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/286404
   Logan RW, 2015, ALCOHOL CLIN EXP RES, V39, P146, DOI 10.1111/acer.12611
   Ma YY, 2008, BRAIN RES, V1212, P63, DOI 10.1016/j.brainres.2008.03.044
   Ma YY, 2009, BEHAV BRAIN RES, V204, P192, DOI 10.1016/j.bbr.2009.06.017
   MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8
   Mantsch JR, 2016, NEUROPSYCHOPHARMACOL, V41, P335, DOI 10.1038/npp.2015.142
   Mathon DS, 2005, NEUROSCIENCE, V130, P359, DOI 10.1016/j.neuroscience.2004.10.002
   MAYER DJ, 1977, BRAIN RES, V121, P368, DOI 10.1016/0006-8993(77)90161-5
   Motlagh FE, 2016, CHIN MED-UK, V11, DOI 10.1186/s13020-016-0088-7
   Myrick H, 2004, NEUROPSYCHOPHARMACOL, V29, P393, DOI 10.1038/sj.npp.1300295
   Nakai T, 2002, PHARMACOL RES, V45, P407, DOI 10.1006/phrs.2002.0962
   Namba MD, 2018, FRONT BEHAV NEUROSCI, V12, DOI 10.3389/fnbeh.2018.00017
   Negus SS, 2018, PHARMACOL BIOCHEM BE, V164, P32, DOI 10.1016/j.pbb.2017.04.006
   Nentwig TB, 2019, ADDICT BIOL, V24, P447, DOI 10.1111/adb.12610
   Neugebauer V, 2020, NEUROPHARMACOLOGY, V170, DOI 10.1016/j.neuropharm.2020.108052
   Oh JY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30337-5
   Overstreet DH, 2008, NEUROCHEM RES, V33, P2166, DOI 10.1007/s11064-008-9791-9
   Pan B, 2008, J NEUROSCI, V28, P1385, DOI 10.1523/JNEUROSCI.4033-07.2008
   Pan Wei-Xing, 2019, Zhen Ci Yan Jiu, V44, P843, DOI 10.13702/j.1000-0607.190260
   Peuker Elmar, 2003, Acupunct Med, V21, P122
   Pierre PJ, 1998, PSYCHOPHARMACOLOGY, V138, P159, DOI 10.1007/s002130050658
   Pilkington K, 2013, INT REV NEUROBIOL, V111, P197, DOI 10.1016/B978-0-12-411545-3.00010-9
   PLOTSKY PM, 1986, REGUL PEPTIDES, V16, P235, DOI 10.1016/0167-0115(86)90022-4
   PORRINO LJ, 1993, PSYCHOPHARMACOLOGY, V112, P343, DOI 10.1007/BF02244931
   Purves D, 2001, NEUROSCIENCE
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Ray L. A., 2018, CURR ADDICT REP, V5, P102, DOI [10.1007/s40429-018-0202-2, DOI 10.1007/S40429-018-0202-2]
   Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI 10.1146/annurev.psych.54.101601.145237
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Roh HS, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/5367864
   Rossetti ZL, 1999, NEUROPHARMACOLOGY, V38, P1361, DOI 10.1016/S0028-3908(99)00039-8
   Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-7
   Sanchis-Segura C, 2006, ADDICT BIOL, V11, P2, DOI 10.1111/j.1369-1600.2006.00012.x
   Self DW, 2004, NEUROPHARMACOLOGY, V47, P242, DOI 10.1016/j.neuropharm.2004.07.005
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   Sher L, 2003, PSYCHOPHARMACOLOGY, V165, P202, DOI 10.1007/s00213-002-1308-7
   Shi XD, 2004, MOL BRAIN RES, V130, P124, DOI 10.1016/j.molbrainres.2004.07.016
   Shi XD, 2003, BRAIN RES, V981, P23, DOI 10.1016/S0006-8993(03)02798-7
   SHIPPENBERG TS, 1995, J PHARMACOL EXP THER, V273, P808
   Smolka MN, 2006, PSYCHOPHARMACOLOGY, V184, P577, DOI 10.1007/s00213-005-0080-x
   SPANAGEL R, 1990, J NEUROCHEM, V55, P1734, DOI 10.1111/j.1471-4159.1990.tb04963.x
   SPANAGEL R, 1992, P NATL ACAD SCI USA, V89, P2046, DOI 10.1073/pnas.89.6.2046
   SPANAGEL R, 1991, PSYCHOPHARMACOLOGY, V104, P51, DOI 10.1007/BF02244553
   Spanagel R, 2017, DIALOGUES CLIN NEURO, V19, P247
   Steffensen SC, 2009, PHARMACOL BIOCHEM BE, V92, P68, DOI 10.1016/j.pbb.2008.10.012
   Steketee JD, 2011, PHARMACOL REV, V63, P348, DOI 10.1124/pr.109.001933
   Stux G, 2003, BASICS ACUPUNCTURE
   SUDA T, 1992, ENDOCRINOLOGY, V130, P1325, DOI 10.1210/en.130.3.1325
   Sun YM, 2018, JOVE-J VIS EXP, DOI 10.3791/58384
   Sunsay C, 2014, BEHAV NEUROSCI, V128, P579, DOI 10.1037/bne0000012
   Svingos AL, 2001, SYNAPSE, V42, P185, DOI 10.1002/syn.10005
   Valdez GR, 2002, ALCOHOL CLIN EXP RES, V26, P1494, DOI 10.1097/01.ALC.0000033120.51856.F0
   Valdez GR, 2004, ALCOHOL CLIN EXP RES, V28, P865, DOI 10.1097/01.ALC.0000128222.29875.40
   Vanderschuren LJMJ, 2010, CURR TOP BEHAV NEURO, V3, P179, DOI 10.1007/7854_2009_21
   Velasquez KM, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00174
   Vezina P, 2004, NEUROSCI BIOBEHAV R, V27, P827, DOI 10.1016/j.neubiorev.2003.11.001
   Vezina P, 2002, J NEUROSCI, V22, P4654, DOI 10.1523/JNEUROSCI.22-11-04654.2002
   WANG Q, 1990, BRAIN RES, V513, P60, DOI 10.1016/0006-8993(90)91088-X
   WANG Q, 1990, BRAIN RES, V518, P40, DOI 10.1016/0006-8993(90)90951-7
   Wang YY, 2019, QUANT IMAG MED SURG, V9, P1118, DOI 10.21037/qims.2019.06.07
   Watabe-Uchida M, 2012, NEURON, V74, P858, DOI 10.1016/j.neuron.2012.03.017
   Weiss F, 1996, J NEUROSCI, V16, P3474
   WHO Regional Office for the Western Pacific, 2008, WHO STD AC POINT LOC
   Wise RA, 2010, BRAIN RES, V1314, P38, DOI 10.1016/j.brainres.2009.09.101
   Yamamoto H, 2011, AUTON NEUROSCI-BASIC, V160, P27, DOI 10.1016/j.autneu.2010.11.004
   Yang CH, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/2850124
   Yang CH, 2010, ALCOHOL CLIN EXP RES, V34, P2137, DOI 10.1111/j.1530-0277.2010.01310.x
   Yoon SS, 2012, PSYCHOPHARMACOLOGY, V222, P303, DOI 10.1007/s00213-012-2683-3
   Yoon SS, 2010, BRAIN RES BULL, V81, P625, DOI 10.1016/j.brainresbull.2009.12.011
   Yoon SS, 2004, NEUROSCI LETT, V369, P234, DOI 10.1016/j.neulet.2004.07.095
   Yoshimoto K, 2001, ALCOHOL CLIN EXP RES, V25, p63S
   Yue N, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00149
   Zhang ZH, 2000, BRAIN RES, V861, P241, DOI 10.1016/S0006-8993(00)01990-9
   Zhang ZJ, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429412
   Zhao RJ, 2006, NEUROSCI LETT, V395, P28, DOI 10.1016/j.neulet.2005.10.043
   Zhao ZL, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq045
   Zhao ZL, 2015, NEUROSCI LETT, V597, P143, DOI 10.1016/j.neulet.2015.04.045
   Zhao ZL, 2013, J ACUPUNCT MERIDIAN, V6, P234, DOI 10.1016/j.jams.2013.01.017
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zhong F, 2006, ADDICT BIOL, V11, P184, DOI 10.1111/j.1369-1600.2006.00020.x
   Zhou W, 2014, J ACUPUNCT MERIDIAN, V7, P186, DOI 10.1016/j.jams.2014.02.008
   Zijlstra F, 2009, DRUG ALCOHOL DEPEN, V99, P183, DOI 10.1016/j.drugalcdep.2008.07.012
NR 182
TC 11
Z9 11
U1 5
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0149-7634
EI 1873-7528
J9 NEUROSCI BIOBEHAV R
JI Neurosci. Biobehav. Rev.
PD JUL
PY 2021
VL 126
BP 382
EP 397
DI 10.1016/j.neubiorev.2021.04.004
EA APR 2021
PG 16
WC Behavioral Sciences; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Behavioral Sciences; Neurosciences & Neurology
GA SK5IR
UT WOS:000656249400014
PM 33839169
OA hybrid
DA 2023-06-23
ER

PT J
AU Heyman, GM
AF Heyman, Gene M.
TI Received Wisdom Regarding the Roles of Craving and Dopamine in
   Addiction: A Response to Lewis's Critique of Addiction: A Disorder of
   Choice
SO PERSPECTIVES ON PSYCHOLOGICAL SCIENCE
LA English
DT Article
DE addiction; remission rates; craving; dopamine; treatment seeking; drug
   dependence; recovery
ID UNITED-STATES; DRUG-USE; COMORBIDITY; ALCOHOL; DEPENDENCE; PREVALENCE
AB Lewis's review of my book (2011, this issue) repeats widely shared understandings of the nature of addiction and the role that dopamine plays in the persistence of self-destructive drug use. These accounts depict addiction as a chronic relapsing disease and claim that drug-induced changes in dopamine function explain the transition from drug experimentation to compulsive drug use. In my book, I test the idea that addiction is a chronic, persistent state. Lewis fails to mention the results of the various tests, although they provide a handy test for his account of addiction and are surprising in light of the common verbal formula "addiction is a chronic, relapsing disease." Consequently, I review a few of the key findings in this response. Lewis faults me for not giving enough attention to dopamine. In my book, I conclude that there is more to the biology of addiction than dopamine, and in this response, I describe research that tests the idea that drug-induced increases in dopamine markedly reduce an individual's capacity to choose nondrug reinforcers. In one experiment, rats readily gave up cocaine for saccharin, even when they had been consuming massive amounts of the drug for weeks. Put more generally, well-established research results call for a revision of currently accepted understandings of addiction and the role that dopamine plays in drug use.
C1 [Heyman, Gene M.] Boston Coll, Dept Psychol, Chestnut Hill, MA 02467 USA.
   [Heyman, Gene M.] McLean Hosp, Behav Psychopharmacol Res Lab, Belmont, MA 02178 USA.
C3 Boston College; Harvard University; McLean Hospital
RP Heyman, GM (通讯作者)，Boston Coll, Dept Psychol, Chestnut Hill, MA 02467 USA.
EM heymang@bc.edu
CR Ainslie G., 1992, PICOECONOMICS STRATE
   ANTHONY JC, 1991, PSYCHIAT DISORDERS A, P116
   Berridge KC, 2008, SOC COGNITION, V26, P621, DOI 10.1521/soco.2008.26.5.621
   BRECHER EM, 1972, LICIT ILLICIT DRUGS
   Carter BL, 2001, EXP CLIN PSYCHOPHARM, V9, P183, DOI 10.1037//1064-1297.9.2.183
   Heyman GM, 1997, PSYCHOPHARMACOLOGY, V129, P72, DOI 10.1007/s002130050164
   Higgins ST, 1995, EXP CLIN PSYCHOPHARM, V3, P205, DOI 10.1037/1064-1297.3.2.205
   Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593
   KOZLOWSKI LT, 1987, BRIT J ADDICT, V82, P31
   Lenoir M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000698
   Lewis MD, 2011, PERSPECT PSYCHOL SCI, V6, P150, DOI 10.1177/1745691611400235
   Meyer R. E., 1979, HEROIN STIMULUS IMPL
   Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006
   NADER MA, 1991, PSYCHOPHARMACOLOGY, V105, P169, DOI 10.1007/BF02244304
   ROBINS LN, 1975, ARCH GEN PSYCHIAT, V32, P955
   ROBINS LN, 1991, PSYCHIAT DISORDERS A
   Shiffman S, 1997, J ABNORM PSYCHOL, V106, P104, DOI 10.1037/0021-843X.106.1.104
   Stinson FS, 2005, DRUG ALCOHOL DEPEN, V80, P105, DOI 10.1016/j.drugalcdep.2005.03.009
   Waldorf D., 1991, COCAINE CHANGES EXPE
   WARNER LA, 1995, ARCH GEN PSYCHIAT, V52, P219
NR 20
TC 1
Z9 2
U1 0
U2 28
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1745-6916
EI 1745-6924
J9 PERSPECT PSYCHOL SCI
JI Perspect. Psychol. Sci.
PD MAR
PY 2011
VL 6
IS 2
BP 156
EP 160
DI 10.1177/1745691611400243
PG 5
WC Psychology, Multidisciplinary
WE Social Science Citation Index (SSCI)
SC Psychology
GA 745MH
UT WOS:000289169000006
PM 26162133
DA 2023-06-23
ER

PT J
AU Chang, R
   Peng, JH
   Chen, YF
   Liao, HL
   Zhao, SZ
   Zou, J
   Tan, SJ
AF Chang, Rui
   Peng, Jionghong
   Chen, Yunfan
   Liao, Hailin
   Zhao, Size
   Zou, Ju
   Tan, Sijie
TI Deep Brain Stimulation in Drug Addiction Treatment: Research Progress
   and Perspective
SO FRONTIERS IN PSYCHIATRY
LA English
DT Review
DE drug addiction; deep brain stimulation; nucleus accumbens; substantia
   nigra pars reticulata; opioids
ID HEROIN-SEEKING BEHAVIORS; NUCLEUS-ACCUMBENS; INDUCED REINSTATEMENT;
   COCAINE; MECHANISMS; RELAPSE
AB Drug addiction is a chronic psychiatric disorder characterized by compulsive drug-seeking and drug-using behavior, and a tremendous socioeconomic burden to society. Current pharmacological and psychosocial methods have shown limited treatment effects for substance abuse. Deep Brain Stimulation (DBS) is a novel treatment for psychiatric disease and has gradually gained popularity in the treatment of addiction. Addiction is characterized by neuroplastic changes in the nucleus accumbens (NAc), a key structure in the brain reward system, and DBS in this region has shown promising treatment effects. In this paper, the research progress on DBS for drug addiction has been reviewed. Specifically, we discuss the mechanism of NAc DBS for addiction treatment and summarize the results of clinical trials on DBS treatment for addiction to psychoactive substances such as nicotine, alcohol, cocaine, opioids and methamphetamine/amphetamine. In addition, the treatment effects of DBS in other brain regions, such as the substantia nigra pars reticulata (SNr) and insula are discussed.
C1 [Chang, Rui; Peng, Jionghong; Chen, Yunfan; Liao, Hailin; Zhao, Size; Zou, Ju; Tan, Sijie] Univ South China, Hengyang Med Coll, Sch Basic Med, Dept Histol & Embryol, Hengyang, Peoples R China.
C3 University of South China
RP Zou, J; Tan, SJ (通讯作者)，Univ South China, Hengyang Med Coll, Sch Basic Med, Dept Histol & Embryol, Hengyang, Peoples R China.
EM Juliana_zou11@126.com; sjtan@usc.edu.cn
OI tan, Sijie/0000-0002-8389-7372
FU Research Project of Hunan Education Department [21C0312]; Hunan
   Provincial Natural Science Foundation [2019JJ40250]
FX Funding This work was supported by grants from the National Science
   Foundation of China (NSFC 81301144) and Research Learning and Innovative
   Experiment Project for University Students of University of South China
   (210XCX486, 210XCX510, and 200XCX322).
CR Bari A, 2018, NEUROSCI BIOBEHAV R, V95, P33, DOI 10.1016/j.neubiorev.2018.09.013
   Battle Dolores Elaine, 2013, CoDAS, V25, P190
   Beier KT, 2017, NATURE, V549, P345, DOI 10.1038/nature23888
   BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638
   Bjerknes S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105288
   Brandon TH, 2007, ANNU REV CLIN PSYCHO, V3, P257, DOI 10.1146/annurev.clinpsy.3.022806.091455
   Chakravarty MM, 2016, NEUROIMAGE, V125, P422, DOI 10.1016/j.neuroimage.2015.10.049
   Creed M, 2015, SCIENCE, V347, P659, DOI 10.1126/science.1260776
   Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281
   Dorval AD, 2008, J NEUROPHYSIOL, V100, P2807, DOI 10.1152/jn.90763.2008
   Dostrovsky JO, 2002, MOVEMENT DISORD, V17, pS63, DOI 10.1002/mds.10143
   Drobisz D, 2019, BEHAV BRAIN RES, V359, P266, DOI 10.1016/j.bbr.2018.11.004
   Eitan S, 2017, NEUROSCI BIOBEHAV R, V83, P697, DOI 10.1016/j.neubiorev.2017.05.017
   Fakhrieh-Asl G, 2020, ADDICT BIOL, V25, DOI 10.1111/adb.12780
   Feuerstein TJ, 2011, N-S ARCH PHARMACOL, V384, P1, DOI 10.1007/s00210-011-0644-8
   Galaj E, 2020, J NEUROSCI, V40, P8853, DOI 10.1523/JNEUROSCI.0988-20.2020
   Ge SN, 2019, WORLD NEUROSURG, V122, P512, DOI 10.1016/j.wneu.2018.11.056
   Goncalves-Ferreira A, 2016, BIOL PSYCHIAT, V79, pE87, DOI 10.1016/j.biopsych.2015.06.023
   Greenberg BD, 2010, MOL PSYCHIATR, V15, P64, DOI 10.1038/mp.2008.55
   Guercio LA, 2020, BRAIN RES, V1746, DOI 10.1016/j.brainres.2020.147011
   Guercio LA, 2015, BEHAV BRAIN RES, V281, P125, DOI 10.1016/j.bbr.2014.12.025
   Guo LM, 2013, DRUG ALCOHOL DEPEN, V129, P70, DOI 10.1016/j.drugalcdep.2012.09.012
   Hamilton J, 2015, BRAIN STIMUL, V8, P57, DOI 10.1016/j.brs.2014.09.018
   Hammond C, 2008, MOVEMENT DISORD, V23, P2111, DOI 10.1002/mds.22120
   Hashimoto T, 2003, J NEUROSCI, V23, P1916
   Ibrahim C, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00720
   Jakobs M, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809575
   Kallupi M, 2022, BRAIN STIMUL, V15, P13, DOI 10.1016/j.brs.2021.11.003
   Koob GF, 2016, LANCET PSYCHIAT, V3, P760, DOI 10.1016/S2215-0366(16)00104-8
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Kosten Thomas R, 2002, Sci Pract Perspect, V1, P13
   Kuhn J, 2014, MOL PSYCHIATR, V19, P145, DOI 10.1038/mp.2012.196
   Kuhn J, 2009, EUR ADDICT RES, V15, P196, DOI 10.1159/000228930
   Kuhn Jens, 2013, Handb Clin Neurol, V116, P259, DOI 10.1016/B978-0-444-53497-2.00021-8
   Kuhn J, 2011, ADDICT BIOL, V16, P620, DOI 10.1111/j.1369-1600.2011.00337.x
   LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4
   Lozano AM, 2019, NAT REV NEUROL, V15, P148, DOI 10.1038/s41582-018-0128-2
   Luigjes J, 2012, MOL PSYCHIATR, V17, P572, DOI 10.1038/mp.2011.114
   Luigjes J, 2019, NEUROPSYCHOL REV, V29, P116, DOI 10.1007/s11065-018-9393-5
   Mahoney JJ, 2020, J NEUROL SCI, V418, DOI 10.1016/j.jns.2020.117149
   Mantione M, 2015, J PSYCHIATR NEUROSCI, V40, P378, DOI 10.1503/jpn.140210
   McCracken CB, 2007, J NEUROSCI, V27, P12601, DOI 10.1523/JNEUROSCI.3750-07.2007
   McCracken CB, 2009, J NEUROSCI, V29, P5354, DOI 10.1523/JNEUROSCI.0131-09.2009
   McIntyre CC, 2004, CLIN NEUROPHYSIOL, V115, P1239, DOI 10.1016/j.clinph.2003.12.024
   Milad MR, 2012, TRENDS COGN SCI, V16, P43, DOI 10.1016/j.tics.2011.11.003
   Miocinovic S, 2013, JAMA NEUROL, V70, P163, DOI 10.1001/2013.jamaneurol.45
   Montgomery EB, 2000, NEUROL RES, V22, P259
   Muller UJ, 2016, PHARMACOPSYCHIATRY, V49, P170, DOI 10.1055/s-0042-104507
   Naassila M, 2018, PRESSE MED, V47, P554, DOI 10.1016/j.lpm.2017.12.001
   Niu LL, 2020, SCI CHINA LIFE SCI, V63, P1328, DOI 10.1007/s11427-019-1616-6
   Rodriguez-Romaguera J, 2012, P NATL ACAD SCI USA, V109, P8764, DOI 10.1073/pnas.1200782109
   Roth GA, 2018, LANCET, V392, P1736, DOI [10.1016/S0140-6736(18)32203-7, 10.1016/s0140-6736(18)32203-7]
   Sankar T, 2011, INT REV NEUROBIOL, V98, P151, DOI 10.1016/B978-0-12-381328-2.00006-7
   Shen Y, 2016, BIOL PSYCHIAT, V80, pE13, DOI 10.1016/j.biopsych.2016.02.006
   Sinha R, 2011, CURR PSYCHIAT REP, V13, P398, DOI 10.1007/s11920-011-0224-0
   Sobstyl M, 2021, NEUROL NEUROCHIR POL, V55, P440, DOI 10.5603/PJNNS.a2021.0065
   Tierney TS, 2011, PROG BRAIN RES, V194, P83, DOI 10.1016/B978-0-444-53815-4.00015-7
   Tseng PT, 2022, ADDICTION, V117, P1830, DOI 10.1111/add.15624
   Urbano FJ, 2008, J NEUROIMMUNOL, V201, P136, DOI 10.1016/j.jneuroim.2008.06.031
   Valencia-Alfonso CE, 2012, BIOL PSYCHIAT, V71, pE35, DOI 10.1016/j.biopsych.2011.12.013
   Vassoler FM, 2008, J NEUROSCI, V28, P8735, DOI 10.1523/JNEUROSCI.5277-07.2008
   Vassoler FM, 2013, J NEUROSCI, V33, P14446, DOI 10.1523/JNEUROSCI.4804-12.2013
   Voges J, 2013, WORLD NEUROSURG, V80, DOI 10.1016/j.wneu.2012.07.011
   Volkow ND, 2019, JAMA PSYCHIAT, V76, P208, DOI 10.1001/jamapsychiatry.2018.3126
   Volkow ND, 2011, JAMA-J AM MED ASSOC, V305, P1299, DOI 10.1001/jama.2011.401
   Wang TR, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.5.FOCUS18163
   Wilden JA, 2014, J NEUROSURG, V120, P997, DOI 10.3171/2013.12.JNS13205
   Xiao LJ, 2017, ADV EXP MED BIOL, V1010, P247, DOI 10.1007/978-981-10-5562-1_12
   Xu L, 2020, FRONT NEURAL CIRCUIT, V14, DOI 10.3389/fncir.2020.00037
   Xu WY, 2020, TRANSL NEURODEGENER, V9, DOI 10.1186/s40035-020-0183-7
   Yuan JJ, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.0910
   Zhang CC, 2019, BRAIN STIMUL, V12, P1055, DOI 10.1016/j.brs.2019.02.023
   Zhang LB, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.705813
   Zhou HY, 2011, BIOL PSYCHIAT, V69, pE41, DOI 10.1016/j.biopsych.2011.02.012
   Zhu R, 2020, STEREOT FUNCT NEUROS, V98, P345, DOI 10.1159/000509313
   Zou ZL, 2017, ADV EXP MED BIOL, V1010, P21, DOI 10.1007/978-981-10-5562-1_2
NR 76
TC 5
Z9 5
U1 12
U2 19
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD APR 7
PY 2022
VL 13
AR 858638
DI 10.3389/fpsyt.2022.858638
PG 8
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA 1Y8GA
UT WOS:000808375400001
PM 35463506
OA gold, Green Published
DA 2023-06-23
ER

PT J
AU Chitaman, JM
   Fraser, P
   Feng, J
AF Chitaman, Javed M.
   Fraser, Peter
   Feng, Jian
TI Three-dimensional chromosome architecture and drug addiction
SO CURRENT OPINION IN NEUROBIOLOGY
LA English
DT Article
ID CHROMATIN ARCHITECTURE; GENOME ARCHITECTURE; ORGANIZATION; MECHANISMS;
   GENE; IDENTIFICATION; TRANSCRIPTION; TECHNOLOGIES; EXPRESSION;
   PRINCIPLES
AB Aberrant gene expression underlies drug addiction. Therefore, studying the regulation of gene expression in drug addiction may provide mechanistic insights into this disease, for which there are still only limited treatments. Recently, the three-dimensional (3D) organization of linear DNA in the nucleus has been recognized as having a major influence on gene transcription. Here, we review its roles in both basic brain function and neuropsychiatric disorders, while also highlighting its emerging implications in drug addiction. Unraveling the 3D architecture of chromosomes in drug addiction is adding to our understanding of this disease and has the potential to trigger novel approaches for better diagnosis and therapy.
C1 [Chitaman, Javed M.; Fraser, Peter; Feng, Jian] Florida State Univ, Dept Biol Sci, 319 Stadium Dr, Tallahassee, FL 32306 USA.
   [Chitaman, Javed M.; Feng, Jian] Florida State Univ, Program Neurosci, Tallahassee, FL 32306 USA.
C3 State University System of Florida; Florida State University; State
   University System of Florida; Florida State University
RP Feng, J (通讯作者)，Florida State Univ, Dept Biol Sci, 319 Stadium Dr, Tallahassee, FL 32306 USA.; Feng, J (通讯作者)，Florida State Univ, Program Neurosci, Tallahassee, FL 32306 USA.
EM feng@bio.fsu.edu
FU National Institutes of Health [5DP1DA046587, 1R01DA046720]; Legacy
   Fellowship; Florida State University
FX We thank all our lab members for help and advice. Preparation of this
   review was supported by National Institutes of Health grants
   5DP1DA046587 and 1R01DA046720 (JF). JMC is supported by a Legacy
   Fellowship and a Neuroscience Fellowship from Florida State University.
   The authors apologize to any colleagues whose work was not referenced
   due to space limitations.
CR Armelin-Correa LM, 2014, P NATL ACAD SCI USA, V111, P2782, DOI 10.1073/pnas.1317036111
   BARR ML, 1949, NATURE, V163, P676, DOI 10.1038/163676a0
   BARR ML, 1951, J ANAT, V85, P171
   Bharadwaj R, 2014, NEURON, V84, P997, DOI 10.1016/j.neuron.2014.10.032
   Bharadwaj R, 2013, J NEUROSCI, V33, P11839, DOI 10.1523/JNEUROSCI.1252-13.2013
   Bonev B, 2016, NAT REV GENET, V17, P661, DOI 10.1038/nrg.2016.112
   Cattoni DI, 2015, TRENDS GENET, V31, P454, DOI 10.1016/j.tig.2015.05.011
   Clowney EJ, 2012, CELL, V151, P724, DOI 10.1016/j.cell.2012.09.043
   Cremer T, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003889
   Dekker J, 2017, NATURE, V549, P219, DOI 10.1038/nature23884
   Denker A, 2016, GENE DEV, V30, P1357, DOI 10.1101/gad.281964.116
   Dixon JR, 2012, NATURE, V485, P376, DOI 10.1038/nature11082
   Engmann O, 2017, BIOL PSYCHIAT, V82, P794, DOI 10.1016/j.biopsych.2017.04.013
   Feng J., 2013, CURR OPIN NEUROBIOL
   Feng J, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-4-r65
   Fujita Y, 2018, NEUROCHEM INT, V119, P49, DOI 10.1016/j.neuint.2017.06.014
   Furlan-Magaril M, 2015, CURR OPIN GENET DEV, V31, P36, DOI 10.1016/j.gde.2015.04.004
   Girdhar K, 2018, NAT NEUROSCI, V21, P1126, DOI 10.1038/s41593-018-0187-0
   Gregor A, 2013, AM J HUM GENET, V93, P124, DOI 10.1016/j.ajhg.2013.05.007
   Guelen L, 2008, NATURE, V453, P948, DOI 10.1038/nature06947
   Hancock DB, 2018, CURR PSYCHIAT REP, V20, DOI 10.1007/s11920-018-0873-3
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Ito S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5450
   Javierre BM, 2016, CELL, V167, P1369, DOI 10.1016/j.cell.2016.09.037
   Jiang Y, 2017, NAT GENET, V49, P1239, DOI 10.1038/ng.3906
   Jiang Y, 2010, J NEUROSCI, V30, P7152, DOI 10.1523/JNEUROSCI.1314-10.2010
   Joo JY, 2016, NAT NEUROSCI, V19, P75, DOI 10.1038/nn.4170
   Kim TK, 2010, NATURE, V465, P182, DOI 10.1038/nature09033
   Koob GF, 2016, LANCET PSYCHIAT, V3, P760, DOI 10.1016/S2215-0366(16)00104-8
   Krantz ID, 2004, NAT GENET, V36, P631, DOI 10.1038/ng1364
   Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369
   Magklara A, 2011, CELL, V145, P555, DOI 10.1016/j.cell.2011.03.040
   Malik AN, 2014, NAT NEUROSCI, V17, P1330, DOI 10.1038/nn.3808
   Markenscoff-Papadimitriou E, 2014, CELL, V159, P543, DOI 10.1016/j.cell.2014.09.033
   Medrano-Fernandez A, 2016, MOL BRAIN, V9, DOI 10.1186/s13041-016-0263-x
   Mitchell AC, 2018, MOL PSYCHIATR, V23, P123, DOI 10.1038/mp.2016.254
   Monahan K, 2019, NATURE, V565, P448, DOI 10.1038/s41586-018-0845-0
   Nagano T, 2013, NATURE, V502, P59, DOI 10.1038/nature12593
   Pasman JA, 2018, NAT NEUROSCI, V21, P1161, DOI 10.1038/s41593-018-0206-1
   Peric-Hupkes D, 2010, MOL CELL, V38, P603, DOI 10.1016/j.molcel.2010.03.016
   Rajarajan P, 2018, SCIENCE, V362, P1269, DOI 10.1126/science.aat4311
   Rajarajan P, 2016, NAT REV NEUROSCI, V17, P681, DOI 10.1038/nrn.2016.124
   Rao SSP, 2014, CELL, V159, P1665, DOI 10.1016/j.cell.2014.11.021
   Robison AJ, 2011, NAT REV NEUROSCI, V12, P623, DOI 10.1038/nrn3111
   Salery M, 2017, BIOL PSYCHIAT, V81, P573, DOI 10.1016/j.biopsych.2016.05.025
   Schaukowitch K, 2014, MOL CELL, V56, P29, DOI 10.1016/j.molcel.2014.08.023
   Schmitt AD, 2016, NAT REV MOL CELL BIO, V17, P743, DOI 10.1038/nrm.2016.104
   Schoenfelder S, 2018, J VIS EXP, V136
   Shen Y, 2012, NATURE, V488, P116, DOI 10.1038/nature11243
   Solovei I, 2009, CELL, V137, P356, DOI 10.1016/j.cell.2009.01.052
   Su YJ, 2017, NAT NEUROSCI, V20, P476, DOI 10.1038/nn.4494
   Sun HS, 2016, J NEUROSCI, V36, P3954, DOI 10.1523/JNEUROSCI.3254-15.2016
   Sun JH, 2018, CELL, V175, P224, DOI 10.1016/j.cell.2018.08.005
   Tan LZ, 2019, NAT STRUCT MOL BIOL, V26, P297, DOI 10.1038/s41594-019-0205-2
   Tonkin ET, 2004, NAT GENET, V36, P636, DOI 10.1038/ng1363
   Tsai SYA, 2015, P NATL ACAD SCI USA, V112, pE6562, DOI 10.1073/pnas.1518894112
   Vermunt MW, 2014, CELL REP, V9, P767, DOI 10.1016/j.celrep.2014.09.023
   Vogel-Ciernia A, 2013, NAT NEUROSCI, V16, P552, DOI 10.1038/nn.3359
   Walczak A, 2013, J NEUROSCI, V33, P2507, DOI 10.1523/JNEUROSCI.1085-12.2013
   Watson LA, 2017, CURR OPIN NEUROBIOL, V43, P48, DOI 10.1016/j.conb.2016.12.002
   Wilczynski GM, 2014, NEUROPHARMACOLOGY, V80, P28, DOI 10.1016/j.neuropharm.2014.01.016
   Won HJ, 2016, NATURE, V538, P523, DOI 10.1038/nature19847
   Yoon KH, 2015, P NATL ACAD SCI USA, V112, pE2403, DOI 10.1073/pnas.1506058112
NR 63
TC 1
Z9 1
U1 0
U2 7
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0959-4388
EI 1873-6882
J9 CURR OPIN NEUROBIOL
JI Curr. Opin. Neurobiol.
PD DEC
PY 2019
VL 59
BP 137
EP 145
DI 10.1016/j.conb.2019.05.009
PG 9
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA JW5KF
UT WOS:000503090100017
PM 31276935
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Zhou, YH
   Zhou, CL
   Li, RN
AF Zhou, Yuehui
   Zhou, Chenglin
   Li, Rena
TI Sex differences in exercise and drug addiction: A mini review of animal
   studies
SO JOURNAL OF SPORT AND HEALTH SCIENCE
LA English
DT Review
DE Animal studies; Drug addiction; Exercise; Sex difference
ID CONDITIONED PLACE PREFERENCE; ADULT HIPPOCAMPAL NEUROGENESIS; SUBSEQUENT
   NICOTINE-SEEKING; CUE-INDUCED REINSTATEMENT; VOLUNTARY EXERCISE;
   COCAINE-SEEKING; ENVIRONMENTAL ENRICHMENT; EPIGENETIC MECHANISMS;
   LOCOMOTOR-ACTIVITY; GENDER-DIFFERENCES
AB Growing literature has demonstrated that exercise may be an effective prevention and treatment option for drug addiction. In the past few years, many studies have suggested that there were sex differences in all phases of drug addiction. However, very limited research has investigated sex differences in the effectiveness of exercise intervention in drug addiction and rehabilitation. In this mini review, we summarize the effect of sex on the results of using exercise to prevent and treat drug addiction. The studies we consider span various animal models and use multiple types of exercise to examine the effectiveness of exercise on the neurobiological mechanism of exercise rehabilitation. We believe that exercise as an adjuvant intervention strategy can be applied better in drug addiction prevention and recovery. Copyright (C) 2014, Shanghai University of Sport. Production and hosting by Elsevier B.V. All rights reserved.
C1 [Zhou, Yuehui; Zhou, Chenglin; Li, Rena] Shanghai Univ Sport, Sch Sport Sci, Dept Sport Psychol, Shanghai 200438, Peoples R China.
   [Li, Rena] Roskamp Inst, Ctr Hormone Adv Sci & Educ, Sarasota, FL 34243 USA.
C3 Shanghai University of Sport
RP Zhou, CL (通讯作者)，Shanghai Univ Sport, Sch Sport Sci, Dept Sport Psychol, Shanghai 200438, Peoples R China.
EM Chenglin_600@126.com
FU Shanghai Science and Technology Commission [13490503600]; National
   Natural Science Foundation of China [31171004]
FX This work was supported by grants from the Shanghai Science and
   Technology Commission (NO. 13490503600) and National Natural Science
   Foundation of China (NO. 31171004).
CR Abadi THN, 2013, ALCOHOL, V47, P309, DOI 10.1016/j.alcohol.2013.01.008
   Alaei H, 2006, EUR J PHARMACOL, V536, P138, DOI 10.1016/j.ejphar.2006.02.025
   Anker JJ, 2011, PSYCHOPHARMACOLOGY, V215, P785, DOI 10.1007/s00213-011-2181-z
   Becker JB, 2008, FRONT NEUROENDOCRIN, V29, P36, DOI 10.1016/j.yfrne.2007.07.003
   Becker JB, 2012, BIOL SEX DIFFER, V3, DOI 10.1186/2042-6410-3-14
   Belke TW, 2005, BEHAV PROCESS, V68, P165, DOI 10.1016/j.beproc.2004.12.006
   Berchtold NC, 2001, EUR J NEUROSCI, V14, P1992, DOI 10.1046/j.0953-816x.2001.01825.x
   BIRREN JE, 1958, J GERONTOL, V13, P374, DOI 10.1093/geronj/13.4.374
   Bobzean SAM, 2014, EXP NEUROL, V259, P64, DOI 10.1016/j.expneurol.2014.01.022
   Bobzean SAM, 2010, BRAIN RES BULL, V83, P331, DOI 10.1016/j.brainresbull.2010.09.003
   Brager AJ, 2012, PHYSIOL BEHAV, V107, P418, DOI 10.1016/j.physbeh.2012.09.011
   Brene S, 2007, PHYSIOL BEHAV, V92, P136, DOI 10.1016/j.physbeh.2007.05.015
   Brotto LA, 2000, EUR J PHARMACOL, V402, P87, DOI 10.1016/S0014-2999(00)00491-X
   Brown DA, 2007, J APPL PHYSIOL, V103, P1979, DOI 10.1152/japplphysiol.00706.2007
   Carroll ME, 2010, HORM BEHAV, V58, P44, DOI 10.1016/j.yhbeh.2009.10.001
   Chauvet C, 2011, NEUROSCIENCE, V184, P88, DOI 10.1016/j.neuroscience.2011.03.068
   Chauvet C, 2012, NEUROPHARMACOLOGY, V63, P635, DOI 10.1016/j.neuropharm.2012.05.014
   Chen HI, 2008, BEHAV BRAIN RES, V187, P185, DOI 10.1016/j.bbr.2007.09.014
   Chen WC, 2014, MED SCI SPORT EXER, V46, P1517, DOI 10.1249/MSS.0000000000000272
   Chow C, 2013, PSYCHONEUROENDOCRINO, V38, P1236, DOI 10.1016/j.psyneuen.2012.11.007
   Cicero TJ, 2000, PHARMACOL BIOCHEM BE, V65, P91, DOI 10.1016/S0091-3057(99)00174-4
   Connell S, 2004, DEV BRAIN RES, V151, P187, DOI 10.1016/j.devbrainres.2004.03.008
   Cosgrove KP, 2002, PHARMACOL BIOCHEM BE, V73, P663, DOI 10.1016/S0091-3057(02)00853-5
   Darlington TM, 2014, BEHAV BRAIN RES, V259, P313, DOI 10.1016/j.bbr.2013.11.011
   Doran N, 2014, AM J ADDICTION, V23, P211, DOI 10.1111/j.1521-0391.2014.12094.x
   Ehringer MA, 2009, ALCOHOL, V43, P443, DOI 10.1016/j.alcohol.2009.06.003
   EIKELBOOM R, 1988, PHYSIOL BEHAV, V43, P625, DOI 10.1016/0031-9384(88)90217-X
   Eisenstein SA, 2007, PHARMACOL BIOCHEM BE, V86, P607, DOI 10.1016/j.pbb.2007.02.002
   El Rawas R, 2009, PSYCHOPHARMACOLOGY, V203, P561, DOI 10.1007/s00213-008-1402-6
   Engelmann AJ, 2014, BRAIN STRUCT FUNCT, V219, P657, DOI 10.1007/s00429-013-0525-7
   Fattore L, 2007, BRIT J PHARMACOL, V152, P795, DOI 10.1038/sj.bjp.0707465
   Fattore L, 2008, WOMENS HEALTH, V4, P51, DOI 10.2217/17455057.4.1.51
   Fattore Liana, 2009, Psychoneuroendocrinology, V34 Suppl 1, pS227, DOI 10.1016/j.psyneuen.2009.08.008
   Festa ED, 2004, NEUROPHARMACOLOGY, V46, P672, DOI 10.1016/j.neuropharm.2003.11.017
   Fontes-Ribeiro CA, 2011, CURR NEUROPHARMACOL, V9, P45, DOI 10.2174/157015911795017380
   Fox HC, 2009, HARVARD REV PSYCHIAT, V17, P103, DOI 10.1080/10673220902899680
   Geuzaine A, 2014, BEHAV BRAIN RES, V262, P57, DOI 10.1016/j.bbr.2014.01.002
   Gimenez-Llort L., 2010, INT J ALZHEIMERS DIS
   Gorton LM, 2010, BEHAV BRAIN RES, V213, P253, DOI 10.1016/j.bbr.2010.05.009
   Greenwood BN, 2011, BEHAV BRAIN RES, V217, P354, DOI 10.1016/j.bbr.2010.11.005
   Hammer SB, 2010, ALCOHOL CLIN EXP RES, V34, P1651, DOI 10.1111/j.1530-0277.2010.01251.x
   Hosseini Mahmoud, 2009, Pathophysiology, V16, P3, DOI 10.1016/j.pathophys.2008.11.001
   Hu M, 2004, NEUROPSYCHOPHARMACOL, V29, P81, DOI 10.1038/sj.npp.1300301
   Jessen HM, 2011, EPIGENETICS-US, V6, P857, DOI 10.4161/epi.6.7.16517
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564
   Kanarek RB, 2009, BEHAV NEUROSCI, V123, P905, DOI 10.1037/a0015896
   Karami M, 2008, EUR J PHARMACOL, V582, P78, DOI 10.1016/j.ejphar.2007.12.010
   KAY H, 1958, J GERONTOL, V13, P378, DOI 10.1093/geronj/13.4.378
   Kennedy AP, 2013, DRUG ALCOHOL DEPEN, V132, P29, DOI 10.1016/j.drugalcdep.2012.12.025
   Kerstetter KA, 2012, NEUROPSYCHOPHARMACOL, V37, P2605, DOI 10.1038/npp.2012.99
   Kissin WB, 2014, J SUBST ABUSE TREAT, V46, P332, DOI 10.1016/j.jsat.2013.09.005
   Larson EB, 2005, PHARMACOL BIOCHEM BE, V82, P590, DOI 10.1016/j.pbb.2005.10.015
   Leasure JL, 2008, NEUROSCIENCE, V156, P456, DOI 10.1016/j.neuroscience.2008.07.041
   Leasure JL, 2010, ALCOHOL CLIN EXP RES, V34, P404, DOI 10.1111/j.1530-0277.2009.01105.x
   Lee SJ, 2004, NEUROSCIENCE, V124, P549, DOI 10.1016/j.neuroscience.2003.11.035
   Lee TTY, 2014, HIPPOCAMPUS, V24, P280, DOI 10.1002/hipo.22221
   Lett BT, 2002, PHARMACOL BIOCHEM BE, V72, P101, DOI 10.1016/S0091-3057(01)00722-5
   Lett BT, 2001, LEARN MOTIV, V32, P129, DOI 10.1006/lmot.2000.1073
   Levy Neil, 2013, Front Psychiatry, V4, P24, DOI 10.3389/fpsyt.2013.00024
   Lightfoot JT, 2008, INT J BIOL SCI, V4, P126
   Lynch WJ, 2007, PSYCHOPHARMACOLOGY, V191, P263, DOI 10.1007/s00213-006-0656-0
   Lynch WJ, 2013, NEUROSCI BIOBEHAV R, V37, P1622, DOI 10.1016/j.neubiorev.2013.06.011
   Lynch WJ, 2010, BIOL PSYCHIAT, V68, P774, DOI 10.1016/j.biopsych.2010.06.022
   Lynch WJ, 2006, EXP CLIN PSYCHOPHARM, V14, P34, DOI 10.1037/1064-1297.14.1.34
   Lynch WJ, 2002, PSYCHOPHARMACOLOGY, V164, P121, DOI 10.1007/s00213-002-1183-2
   Masaki T, 2005, PHYSIOL BEHAV, V84, P9, DOI 10.1016/j.physbeh.2004.09.022
   Mathews IZ, 2007, BEHAV PHARMACOL, V18, P641, DOI 10.1097/FBP.0b013e3282effbf5
   Miladi-Gorji H, 2014, NEUROSCIENCE, V256, P83, DOI 10.1016/j.neuroscience.2013.09.056
   Miladi-Gorji H, 2012, PHYSIOL BEHAV, V105, P195, DOI 10.1016/j.physbeh.2011.08.010
   Miladi-Gorji H, 2011, NEUROBIOL LEARN MEM, V96, P479, DOI 10.1016/j.nlm.2011.08.001
   Miller ML, 2012, DRUG ALCOHOL DEPEN, V121, P90, DOI 10.1016/j.drugalcdep.2011.08.013
   Moeller FG, 2012, AM J PSYCHIAT, V169, P351, DOI 10.1176/appi.ajp.2012.12010041
   Mustroph ML, 2011, EUR J NEUROSCI, V34, P1161, DOI 10.1111/j.1460-9568.2011.07828.x
   Nakajima S, 2004, INTEGR PHYS BEH SCI, V39, P95, DOI 10.1007/BF02734275
   Nazarian A, 2009, PSYCHOPHARMACOLOGY, V203, P641, DOI 10.1007/s00213-008-1411-5
   Nestler EJ, 2004, NEUROPHARMACOLOGY, V47, P24, DOI 10.1016/j.neuropharm.2004.06.031
   Noonan MA, 2010, J NEUROSCI, V30, P304, DOI 10.1523/JNEUROSCI.4256-09.2010
   O'Dell SJ, 2012, SYNAPSE, V66, P71, DOI 10.1002/syn.20989
   Perry RI, 2013, DRUG ALCOHOL DEPEN, V133, P222, DOI 10.1016/j.drugalcdep.2013.04.032
   Peterson AB, 2014, PSYCHOPHARMACOLOGY, V231, P2661, DOI 10.1007/s00213-014-3437-1
   Peterson AB, 2014, PSYCHOPHARMACOLOGY, V231, P1305, DOI 10.1007/s00213-013-3321-4
   Petit-Demouliere B, 2005, PSYCHOPHARMACOLOGY, V177, P245, DOI 10.1007/s00213-004-2048-7
   Pollitzer E, 2013, NATURE, V500, P23, DOI 10.1038/500023a
   Randall CK, 1998, PHARMACOL BIOCHEM BE, V60, P217, DOI 10.1016/S0091-3057(97)00585-6
   Renthal W, 2008, TRENDS MOL MED, V14, P341, DOI 10.1016/j.molmed.2008.06.004
   Rhodes JS, 2003, PSYCHOPHARMACOLOGY, V167, P242, DOI 10.1007/s00213-003-1399-9
   Rhodes JS, 2001, PSYCHOPHARMACOLOGY, V158, P120
   Roth ME, 2004, NEUROSCI BIOBEHAV R, V28, P533, DOI 10.1016/j.neubiorev.2004.08.001
   Rozeske RR, 2011, BEHAV BRAIN RES, V219, P378, DOI 10.1016/j.bbr.2011.01.030
   Russo SJ, 2003, NEUROSCIENCE, V120, P523, DOI 10.1016/S0306-4522(03)00317-8
   Russo SJ, 2003, BRAIN RES, V970, P214, DOI 10.1016/S0006-8993(03)02346-1
   Sanchez V, 2014, PSYCHOPHARMACOLOGY, V231, P1753, DOI 10.1007/s00213-013-3359-3
   Sanchez V, 2013, PSYCHOPHARMACOLOGY, V227, P403, DOI 10.1007/s00213-012-2964-x
   Schindler CW, 2002, EUR J PHARMACOL, V442, P231, DOI 10.1016/S0014-2999(02)01550-9
   Segat HJ, 2014, BEHAV BRAIN RES, V262, P94, DOI 10.1016/j.bbr.2014.01.005
   Siddiqui A, 1997, DEV BRAIN RES, V98, P247, DOI 10.1016/S0165-3806(96)00171-X
   Smith MA, 2008, DRUG ALCOHOL DEPEN, V98, P129, DOI 10.1016/j.drugalcdep.2008.05.006
   Smith MA, 2008, PHARMACOL REP, V60, P561
   Smith MA, 2012, EXP CLIN PSYCHOPHARM, V20, P437, DOI 10.1037/a0029724
   Smith MA, 2012, PHARMACOL REP, V64, P960, DOI 10.1016/S1734-1140(12)70891-5
   Smith MA, 2012, DRUG ALCOHOL DEPEN, V121, P54, DOI 10.1016/j.drugalcdep.2011.08.006
   Smith MA, 2011, PSYCHOPHARMACOLOGY, V218, P357, DOI 10.1007/s00213-011-2321-5
   Smith MA, 2011, PHARMACOL BIOCHEM BE, V100, P237, DOI 10.1016/j.pbb.2011.08.025
   Smith M, 2011, POSTHUMANITIES, V16, P1
   Solinas M, 2009, NEUROPSYCHOPHARMACOL, V34, P1102, DOI 10.1038/npp.2008.51
   Solinas M, 2008, P NATL ACAD SCI USA, V105, P17145, DOI 10.1073/pnas.0806889105
   Thanos PK, 2013, BEHAV BRAIN RES, V239, P8, DOI 10.1016/j.bbr.2012.10.035
   Thanos PK, 2010, BEHAV BRAIN RES, V215, P77, DOI 10.1016/j.bbr.2010.06.033
   Thiel KJ, 2010, NEUROSCIENCE, V171, P1187, DOI 10.1016/j.neuroscience.2010.10.001
   Thiel KJ, 2011, PHARMACOL BIOCHEM BE, V97, P595, DOI 10.1016/j.pbb.2010.09.014
   Toborek M, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-22
   Tomkins DM, 2001, CAN MED ASSOC J, V164, P817
   Van Swearingen AED, 2013, PSYCHOPHARMACOLOGY, V225, P707, DOI 10.1007/s00213-012-2860-4
   Walker QD, 2006, NEUROPSYCHOPHARMACOL, V31, P1193, DOI 10.1038/sj.npp.1300915
   Werme M, 2002, BEHAV BRAIN RES, V133, P301, DOI 10.1016/S0166-4328(02)00027-X
   Wissman AM, 2011, NEUROPHARMACOLOGY, V61, P217, DOI 10.1016/j.neuropharm.2011.04.002
   Xu ZW, 2007, EXP NEUROL, V204, P714, DOI 10.1016/j.expneurol.2006.12.027
   Yararbas G, 2010, NEUROPHARMACOLOGY, V58, P374, DOI 10.1016/j.neuropharm.2009.10.001
   Zakharova E, 2009, PHARMACOL BIOCHEM BE, V92, P131, DOI 10.1016/j.pbb.2008.11.002
   Zlebnik NE, 2014, BEHAV BRAIN RES, V261, P71, DOI 10.1016/j.bbr.2013.12.012
   Zlebnik NE, 2012, PSYCHOPHARMACOLOGY, V224, P387, DOI 10.1007/s00213-012-2760-7
   Zlebnik NE, 2010, PSYCHOPHARMACOLOGY, V209, P113, DOI 10.1007/s00213-010-1776-0
   Zschucke Elisabeth, 2013, J Prev Med Public Health, V46 Suppl 1, pS12, DOI 10.3961/jpmph.2013.46.S.S12
NR 123
TC 11
Z9 12
U1 4
U2 38
PU SHANGHAI UNIV SPORT
PI SHANGHAI
PA EDITORIAL BOARD, 650 QINGYUANHUAN RD, SHANGHAI, 200438, PEOPLES R CHINA
SN 2095-2546
EI 2213-2961
J9 J SPORT HEALTH SCI
JI J. Sport Health Sci.
PD SEP
PY 2014
VL 3
IS 3
BP 163
EP 169
DI 10.1016/j.jshs.2014.04.005
PG 7
WC Hospitality, Leisure, Sport & Tourism; Sport Sciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Social Sciences - Other Topics; Sport Sciences
GA AY8LK
UT WOS:000347804900003
OA gold
DA 2023-06-23
ER

PT J
AU Zhou, YH
   Zhao, M
   Zhou, CL
   Li, RN
AF Zhou, Yuehui
   Zhao, Min
   Zhou, Chenglin
   Li, Rena
TI Sex differences in drug addiction and response to exercise intervention:
   From human to animal studies
SO FRONTIERS IN NEUROENDOCRINOLOGY
LA English
DT Review
DE Sex differences; Drug addiction; Exercise; Animal and human studies;
   Neurobiological mechanisms
ID CONDITIONED PLACE PREFERENCE; CUE-INDUCED REINSTATEMENT; COCAINE-SEEKING
   BEHAVIOR; ADULT HIPPOCAMPAL NEUROGENESIS; SUBSEQUENT NICOTINE-SEEKING;
   MODERATE-INTENSITY EXERCISE; SUBSTANCE-ABUSE TREATMENT; TIME-DEPENDENT
   INCREASES; OPIOID PEPTIDE LEVELS; PHYSICAL-ACTIVITY
AB Accumulated research supports the idea that exercise could be an option of potential prevention and treatment for drug addiction. During the past few years, there has been increased interest in investigating of sex differences in exercise and drug addiction. This demonstrates that sex-specific exercise intervention strategies may be important for preventing and treating drug addiction in men and women. However, little is known about how and why sex differences are found when doing exercise-induced interventions for drug addiction. In this review, we included both animal and human that pulled subjects from a varied age demographic, as well as neurobiological mechanisms that may highlight the sex-related differences in these potential to assess the impact of sex-specific roles in drug addiction and exercise therapies. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Zhou, Yuehui; Zhao, Min; Zhou, Chenglin; Li, Rena] Shanghai Univ Sport, Sch Sport Sci, Dept Sport Psychol, Shanghai 200438, Peoples R China.
   [Zhao, Min] Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Shanghai 200030, Peoples R China.
   [Li, Rena] Roskamp Inst, Ctr Hormone Adv Sci & Educ, Sarasota, FL 34243 USA.
C3 Shanghai University of Sport; Shanghai Jiao Tong University
RP Zhou, CL (通讯作者)，Shanghai Univ Sport, Sch Sport Sci, Dept Sport Psychol, Shanghai 200438, Peoples R China.; Li, RN (通讯作者)，Roskamp Inst, Ctr Hormone Adv Sci & Educ, Sarasota, FL 34243 USA.
EM Chenglin_600@126.com; rli@rfdn.org
FU Shanghai Science and Technology Commission - China [13490503600-C];
   National Natural Science Foundation of China - China [31171004-C];
   American Health Assistance Foundation - United States [G2006-118-R];
   National Institutes of Health - United States [R01AG032441-01-R]
FX This work was supported by grants from the Shanghai Science and
   Technology Commission - China (NO. 13490503600-C Zhou), also National
   Natural Science Foundation of China - China (NO. 31171004-C Zhou), the
   American Health Assistance Foundation - United States (G2006-118-R Li),
   and the National Institutes of Health - United States (R01AG032441-01-R
   Li). We also thank Juliet Shen for editing and proofreading.
CR AARON DJ, 1995, MED SCI SPORT EXER, V27, P1639
   Abadi THN, 2013, ALCOHOL, V47, P309, DOI 10.1016/j.alcohol.2013.01.008
   Aizawa K, 2008, J APPL PHYSIOL, V104, P67, DOI 10.1152/japplphysiol.00558.2007
   Alaei H, 2006, EUR J PHARMACOL, V536, P138, DOI 10.1016/j.ejphar.2006.02.025
   An L, 2013, BEHAV BRAIN RES, V256, P564, DOI 10.1016/j.bbr.2013.09.017
   Anker JJ, 2011, CURR TOP BEHAV NEURO, V8, P73, DOI 10.1007/7854_2010_93
   Anker JJ, 2011, PSYCHOPHARMACOLOGY, V215, P785, DOI 10.1007/s00213-011-2181-z
   Back SE, 2011, ADDICT BEHAV, V36, P829, DOI 10.1016/j.addbeh.2011.03.013
   Bailey CP, 2014, EXPERT OPIN DRUG DIS, V9, P1333, DOI 10.1517/17460441.2014.964203
   Baler RD, 2006, TRENDS MOL MED, V12, P559, DOI 10.1016/j.molmed.2006.10.005
   Bardo MT, 2000, PSYCHOPHARMACOLOGY, V153, P31, DOI 10.1007/s002130000569
   Barker JM, 2008, NEUROSCIENCE, V152, P888, DOI 10.1016/j.neuroscience.2007.10.071
   Barry D, 2009, ADDICT BEHAV, V34, P51, DOI 10.1016/j.addbeh.2008.08.008
   Barth C, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00037
   Bawor M, 2014, SYST REV-LONDON, V3, DOI 10.1186/2046-4053-3-45
   Becker JB, 1999, PHARMACOL BIOCHEM BE, V64, P803, DOI 10.1016/S0091-3057(99)00168-9
   Becker JB, 2008, FRONT NEUROENDOCRIN, V29, P36, DOI 10.1016/j.yfrne.2007.07.003
   Becker JB, 2012, BIOL SEX DIFFER, V3, DOI 10.1186/2042-6410-3-14
   Beery AK, 2011, NEUROSCI BIOBEHAV R, V35, P565, DOI 10.1016/j.neubiorev.2010.07.002
   Belke TW, 2005, BEHAV PROCESS, V68, P165, DOI 10.1016/j.beproc.2004.12.006
   Ben J, 2010, NEUROBIOL LEARN MEM, V94, P312, DOI 10.1016/j.nlm.2010.07.003
   Berchtold NC, 2001, EUR J NEUROSCI, V14, P1992, DOI 10.1046/j.0953-816x.2001.01825.x
   Biedermann S, 2012, NEUROIMAGE, V61, P1206, DOI 10.1016/j.neuroimage.2012.04.010
   Bilbao A, 2013, ADDICT BIOL, V18, P904, DOI 10.1111/adb.12115
   Birdee GS, 2013, J ALTERN COMPLEM MED, V19, P550, DOI 10.1089/acm.2012.0223
   BIRREN JE, 1958, J GERONTOL, V13, P374, DOI 10.1093/geronj/13.4.374
   Bobzean SAM, 2014, EXP NEUROL, V259, P64, DOI 10.1016/j.expneurol.2014.01.022
   Bobzean SAM, 2010, BRAIN RES BULL, V83, P331, DOI 10.1016/j.brainresbull.2010.09.003
   Bock BC, 1999, ADDICT BEHAV, V24, P399, DOI 10.1016/S0306-4603(98)00088-4
   Bock BC, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-14
   Bowers J Michael, 2010, Biol Sex Differ, V1, P8, DOI 10.1186/2042-6410-1-8
   Brager AJ, 2012, PHYSIOL BEHAV, V107, P418, DOI 10.1016/j.physbeh.2012.09.011
   Brandt N, 2013, INT J DEV BIOL, V57, P351, DOI 10.1387/ijdb.120217gr
   Brene S, 2007, PHYSIOL BEHAV, V92, P136, DOI 10.1016/j.physbeh.2007.05.015
   Brenhouse HC, 2008, J NEUROSCI, V28, P2375, DOI 10.1523/JNEUROSCI.5064-07.2008
   Brocardo PS, 2012, NEUROPHARMACOLOGY, V62, P1607, DOI 10.1016/j.neuropharm.2011.10.006
   Brotto LA, 2000, EUR J PHARMACOL, V402, P87, DOI 10.1016/S0014-2999(00)00491-X
   Brown DA, 2007, J APPL PHYSIOL, V103, P1979, DOI 10.1152/japplphysiol.00706.2007
   Burling T A, 1992, J Subst Abuse, V4, P407, DOI 10.1016/0899-3289(92)90047-2
   Carbone DL, 2013, NEUROSCIENCE, V239, P295, DOI 10.1016/j.neuroscience.2012.10.073
   Carroll ME, 2010, HORM BEHAV, V58, P44, DOI 10.1016/j.yhbeh.2009.10.001
   Castelli MP, 2014, CURR PHARM DESIGN, V20, P2100, DOI 10.2174/13816128113199990430
   Charilaou M, 2009, NICOTINE TOB RES, V11, P969, DOI 10.1093/ntr/ntp096
   Chauvet C, 2011, NEUROSCIENCE, V184, P88, DOI 10.1016/j.neuroscience.2011.03.068
   Chauvet C, 2012, NEUROPHARMACOLOGY, V63, P635, DOI 10.1016/j.neuropharm.2012.05.014
   Chaya M S, 2006, BMC Complement Altern Med, V6, P28, DOI 10.1186/1472-6882-6-28
   Chen HH, 2003, CHINESE J PHYSIOL, V46, P169
   Chen HI, 2008, BEHAV BRAIN RES, V187, P185, DOI 10.1016/j.bbr.2007.09.014
   Chen JX, 2007, CELL MOL NEUROBIOL, V27, P1, DOI 10.1007/s10571-006-9110-4
   Chen KW, 2010, J ALTERN COMPLEM MED, V16, P875, DOI 10.1089/acm.2009.0443
   Chen MJ, 2005, MOL BRAIN RES, V135, P181, DOI 10.1016/j.molbrainres.2004.12.001
   Chen XQ, 2009, EUR J NEUROSCI, V29, P768, DOI 10.1111/j.1460-9568.2009.06610.x
   Cheong RY, 2012, ENDOCRINOLOGY, V153, P3792, DOI 10.1210/en.2012-1232
   Chow C, 2013, PSYCHONEUROENDOCRINO, V38, P1236, DOI 10.1016/j.psyneuen.2012.11.007
   Collingwood TR, 2000, J DRUG EDUC, V30, P435, DOI 10.2190/RVUE-9XW7-TYRQ-EJR8
   Correia CJ, 2005, ADDICT BEHAV, V30, P19, DOI 10.1016/j.addbeh.2004.04.006
   Cosgrove KP, 2002, PHARMACOL BIOCHEM BE, V73, P663, DOI 10.1016/S0091-3057(02)00853-5
   Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011
   Craft RM, 2013, LIFE SCI, V92, P476, DOI 10.1016/j.lfs.2012.06.009
   Cummins ED, 2013, BEHAV BRAIN RES, V257, P215, DOI 10.1016/j.bbr.2013.09.036
   Darlington TM, 2014, BEHAV BRAIN RES, V259, P313, DOI 10.1016/j.bbr.2013.11.011
   De Chiara V, 2010, NEUROPSYCHOPHARMACOL, V35, P374, DOI 10.1038/npp.2009.141
   Deaner RO, 2013, CROSS-CULT RES, V47, P268, DOI 10.1177/1069397112463687
   Deaner RO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049168
   Devaud LL, 2012, PHARMACOL BIOCHEM BE, V103, P18, DOI 10.1016/j.pbb.2012.07.012
   Devaud LL, 2004, ALCOHOL CLIN EXP RES, V28, P957, DOI 10.1097/01.ALC.0000128225.83916.40
   Diaz LR, 2013, BEHAV BRAIN RES, V237, P82, DOI 10.1016/j.bbr.2012.09.014
   Diaz SL, 2006, SYNAPSE, V60, P132, DOI 10.1002/syn.20279
   Dietrich A, 2004, BRIT J SPORT MED, V38, P536, DOI 10.1136/bjsm.2004.011718
   Dolezal BA, 2013, J ADDICT MED, V7, P122, DOI 10.1097/ADM.0b013e318282475e
   Doran N, 2014, AM J ADDICTION, V23, P211, DOI 10.1111/j.1521-0391.2014.12094.x
   Duchesne A, 2009, PROG NEURO-PSYCHOPH, V33, P251, DOI 10.1016/j.pnpbp.2008.11.012
   Ehringer MA, 2009, ALCOHOL, V43, P443, DOI 10.1016/j.alcohol.2009.06.003
   EIKELBOOM R, 1988, PHYSIOL BEHAV, V43, P625, DOI 10.1016/0031-9384(88)90217-X
   Eisenstein SA, 2007, PHARMACOL BIOCHEM BE, V86, P607, DOI 10.1016/j.pbb.2007.02.002
   El Rawas R, 2009, PSYCHOPHARMACOLOGY, V203, P561, DOI 10.1007/s00213-008-1402-6
   Engelmann AJ, 2014, BRAIN STRUCT FUNCT, V219, P657, DOI 10.1007/s00429-013-0525-7
   English AW, 2011, ANN ANAT, V193, P354, DOI 10.1016/j.aanat.2011.02.013
   ESCOBEDO LG, 1993, JAMA-J AM MED ASSOC, V269, P1391, DOI 10.1001/jama.269.11.1391
   Evans SM, 2010, HORM BEHAV, V58, P13, DOI 10.1016/j.yhbeh.2009.08.010
   Fadaei A, 2015, EUR J PHARMACOL, V747, P88, DOI 10.1016/j.ejphar.2014.11.042
   Farmer J, 2004, NEUROSCIENCE, V124, P71, DOI 10.1016/j.neuroscience.2003.09.029
   Fattore L, 2007, BRIT J PHARMACOL, V152, P795, DOI 10.1038/sj.bjp.0707465
   Fattore L, 2010, BRIT J PHARMACOL, V160, P724, DOI 10.1111/j.1476-5381.2010.00734.x
   Fattore L, 2009, PSYCHONEUROENDOCRI S, V34S, pS227, DOI DOI 10.1016/J.PSYNEUEN.2009.08.008
   Fattore L, 2008, WOMENS HEALTH, V4, P51, DOI 10.2217/17455057.4.1.51
   Fattore L, 2010, BRIT J PHARMACOL, V160, P544, DOI 10.1111/j.1476-5381.2010.00776.x
   Feltenstein MW, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a011916
   Ferreira-Vieira TH, 2014, HIPPOCAMPUS, V24, P79, DOI 10.1002/hipo.22206
   Festa ED, 2004, NEUROPHARMACOLOGY, V46, P672, DOI 10.1016/j.neuropharm.2003.11.017
   Foley TE, 2008, NEUROMOL MED, V10, P67, DOI 10.1007/s12017-008-8032-3
   Fontes-Ribeiro CA, 2011, CURR NEUROPHARMACOL, V9, P45, DOI 10.2174/157015911795017380
   Forlano PM, 2010, J COMP NEUROL, V518, P1330, DOI 10.1002/cne.22279
   Fox HC, 2009, HARVARD REV PSYCHIAT, V17, P103, DOI 10.1080/10673220902899680
   Franconi Flavia, 2012, Handb Exp Pharmacol, P107, DOI 10.1007/978-3-642-30726-3_6
   Friemel CM, 2014, NEUROPSYCHOPHARMACOL, V39, P2387, DOI 10.1038/npp.2014.86
   Galea LAM, 2014, J NEUROENDOCRINOL, V26, P641, DOI 10.1111/jne.12177
   Galea LAM, 2013, J NEUROENDOCRINOL, V25, P1039, DOI 10.1111/jne.12070
   Galea LAM, 2008, BRAIN RES REV, V57, P332, DOI 10.1016/j.brainresrev.2007.05.008
   Geuzaine A, 2014, BEHAV BRAIN RES, V262, P57, DOI 10.1016/j.bbr.2014.01.002
   Ghitza UE, 2010, NEUROSCI BIOBEHAV R, V35, P157, DOI 10.1016/j.neubiorev.2009.11.009
   Giannakopoulou M, 2001, NEUROENDOCRINOLOGY, V73, P387, DOI 10.1159/000054657
   Gioiosa L, 2008, HORM BEHAV, V53, P124, DOI 10.1016/j.yhbeh.2007.09.003
   Gomez-Pinilla F, 2011, EUR J NEUROSCI, V33, P383, DOI 10.1111/j.1460-9568.2010.07508.x
   Gomez-Pinilla F, 2013, COMPR PHYSIOL, V3, P403, DOI 10.1002/cphy.c110063
   Gorton LM, 2010, BEHAV BRAIN RES, V213, P253, DOI 10.1016/j.bbr.2010.05.009
   Gothe NP, 2014, J GERONTOL A-BIOL, V69, P1109, DOI 10.1093/gerona/glu095
   Greenfield SF, 2007, DRUG ALCOHOL DEPEN, V86, P1, DOI 10.1016/j.drugalcdep.2006.05.012
   Greenwood BN, 2011, BEHAV BRAIN RES, V217, P354, DOI 10.1016/j.bbr.2010.11.005
   Grimm JW, 2003, J NEUROSCI, V23, P742
   Gross NB, 2009, NEUROSCIENCE, V161, P1114, DOI 10.1016/j.neuroscience.2009.04.023
   Guezennec CY, 1998, INT J SPORTS MED, V19, P323, DOI 10.1055/s-2007-971925
   Hallgren M, 2014, COMPLEMENT THER MED, V22, P441, DOI 10.1016/j.ctim.2014.03.003
   Hammer SB, 2010, ALCOHOL CLIN EXP RES, V34, P1651, DOI 10.1111/j.1530-0277.2010.01251.x
   HANDA RJ, 1994, HORM BEHAV, V28, P464, DOI 10.1006/hbeh.1994.1044
   Harris RC, 2012, AMINO ACIDS, V43, P5, DOI 10.1007/s00726-012-1233-y
   Henchoz Y, 2014, QUAL LIFE RES, V23, P2225, DOI 10.1007/s11136-014-0665-0
   Henchoz Y, 2014, PREV MED, V64, P27, DOI 10.1016/j.ypmed.2014.03.022
   HENNINGFIELD JE, 1991, BRIT J ADDICT, V86, P1571
   Hernandez-Avila CA, 2004, DRUG ALCOHOL DEPEN, V74, P265, DOI 10.1016/j.drugalcdep.2004.02.001
   Heyman E, 2012, PSYCHONEUROENDOCRINO, V37, P844, DOI 10.1016/j.psyneuen.2011.09.017
   Hicks A L, 2001, Exerc Sport Sci Rev, V29, P109, DOI 10.1097/00003677-200107000-00004
   Hilderbrand ER, 2014, NEUROREPORT, V25, P105, DOI 10.1097/WNR.0000000000000053
   Hill DW, 2014, J SPORT MED PHYS FIT, V54, P255
   Hill D W, 1993, Br J Sports Med, V27, P45
   Hill MN, 2010, HIPPOCAMPUS, V20, P513, DOI 10.1002/hipo.20647
   Horn K, 2011, PEDIATRICS, V128, pE801, DOI 10.1542/peds.2010-2599
   Hosseini Mahmoud, 2009, Pathophysiology, V16, P3, DOI 10.1016/j.pathophys.2008.11.001
   Howden E.J., 2015, J APPL PHYSL
   Ignjatova L, 2009, BRATISL MED J, V110, P285
   Ikemoto S, 2014, NEUROPHARMACOLOGY, V76, P329, DOI 10.1016/j.neuropharm.2013.04.031
   Jackson LR, 2006, NEUROPSYCHOPHARMACOL, V31, P129, DOI 10.1038/sj.npp.1300778
   Jacobs E, 2011, J NEUROSCI, V31, P5286, DOI 10.1523/JNEUROSCI.6394-10.2011
   Ji JF, 2014, BIOCHEM BIOPH RES CO, V443, P646, DOI 10.1016/j.bbrc.2013.12.031
   Jia LL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085481
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564
   Kanarek RB, 2009, BEHAV NEUROSCI, V123, P905, DOI 10.1037/a0015896
   Kauer JA, 2007, NAT REV NEUROSCI, V8, P844, DOI 10.1038/nrn2234
   KAY H, 1958, J GERONTOL, V13, P378, DOI 10.1093/geronj/13.4.378
   Keeney BK, 2012, PHARMACOL BIOCHEM BE, V101, P528, DOI 10.1016/j.pbb.2012.02.017
   Kennedy AP, 2013, DRUG ALCOHOL DEPEN, V132, P29, DOI 10.1016/j.drugalcdep.2012.12.025
   Kerstetter KA, 2008, PSYCHOPHARMACOLOGY, V198, P63, DOI 10.1007/s00213-008-1089-8
   Kinnunen T, 2008, NICOTINE TOB RES, V10, P689, DOI 10.1080/14622200801979043
   Kirchengast S, 2014, ANTHROPOL ANZ, V71, P123, DOI 10.1127/0003-5548/2014/0376
   Kissin WB, 2014, J SUBST ABUSE TREAT, V46, P332, DOI 10.1016/j.jsat.2013.09.005
   Konhilas JP, 2004, AM J PHYSIOL-HEART C, V287, pH2768, DOI 10.1152/ajpheart.00292.2004
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Korhonen T, 2011, J WOMENS HEALTH, V20, P1051, DOI 10.1089/jwh.2010.2075
   Korhonen T, 2009, TWIN RES HUM GENET, V12, P261, DOI 10.1375/twin.12.3.261
   Kuipers SD, 2013, NEUROPHARMACOLOGY, V75, P426, DOI 10.1016/j.neuropharm.2013.08.018
   Kulig K, 2003, ARCH PEDIAT ADOL MED, V157, P905, DOI 10.1001/archpedi.157.9.905
   Larson EB, 2005, PHARMACOL BIOCHEM BE, V82, P590, DOI 10.1016/j.pbb.2005.10.015
   Leasure JL, 2008, NEUROSCIENCE, V156, P456, DOI 10.1016/j.neuroscience.2008.07.041
   Leasure JL, 2010, ALCOHOL CLIN EXP RES, V34, P404, DOI 10.1111/j.1530-0277.2009.01105.x
   Lee TTY, 2014, HIPPOCAMPUS, V24, P280, DOI 10.1002/hipo.22221
   Lenoir M, 2015, PHARMACOL BIOCHEM BE, V132, P56, DOI 10.1016/j.pbb.2015.02.019
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Lett BT, 2002, PHARMACOL BIOCHEM BE, V72, P101, DOI 10.1016/S0091-3057(01)00722-5
   Levy Neil, 2013, Front Psychiatry, V4, P24, DOI 10.3389/fpsyt.2013.00024
   Leyton M, 2014, TRENDS PHARMACOL SCI, V35, P268, DOI 10.1016/j.tips.2014.04.002
   Li DX, 2013, AM J CHINESE MED, V41, P43, DOI 10.1142/S0192415X13500043
   Li J, 2011, J CEREBR BLOOD F MET, V31, P413, DOI 10.1038/jcbfm.2010.181
   Li M, 2002, ALTERN THER HEALTH M, V8, P50
   Lightfoot JT, 2008, INT J BIOL SCI, V4, P126
   Lin SK, 2003, PHARMACOGENOMICS J, V3, P349, DOI 10.1038/sj.tpj.6500203
   Linke Sarah E, 2012, Ment Health Phys Act, V5, P85
   Llorente-Berzal A, 2013, PHARMACOL RES, V74, P23, DOI 10.1016/j.phrs.2013.05.001
   Lopez HH, 2010, HORM BEHAV, V58, P100, DOI 10.1016/j.yhbeh.2009.10.005
   Lu JQ, 2014, NEUROSCI LETT, V573, P13, DOI 10.1016/j.neulet.2014.04.053
   Luscher C, 2011, NEURON, V69, P650, DOI 10.1016/j.neuron.2011.01.017
   Luine V, 2013, NEUROSCIENCE, V239, P34, DOI 10.1016/j.neuroscience.2012.10.019
   Lynch WJ, 2013, NEUROSCI BIOBEHAV R, V37, P1622, DOI 10.1016/j.neubiorev.2013.06.011
   Lynch WJ, 2010, BIOL PSYCHIAT, V68, P774, DOI 10.1016/j.biopsych.2010.06.022
   Lynch WJ, 2006, EXP CLIN PSYCHOPHARM, V14, P34, DOI 10.1037/1064-1297.14.1.34
   Lynch WJ, 1999, PSYCHOPHARMACOLOGY, V144, P77, DOI 10.1007/s002130050979
   Lynch WJ, 2000, PSYCHOPHARMACOLOGY, V148, P196, DOI 10.1007/s002130050042
   Lynch WJ, 2002, PSYCHOPHARMACOLOGY, V164, P121, DOI 10.1007/s00213-002-1183-2
   Ma Qiang, 2008, Neurosci Bull, V24, P265, DOI 10.1007/s12264-008-0402-1
   Ma XX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036048
   Maldonado R, 2006, TRENDS NEUROSCI, V29, P225, DOI 10.1016/j.tins.2006.01.008
   Maldonado R, 2013, CURR OPIN NEUROBIOL, V23, P480, DOI 10.1016/j.conb.2013.02.004
   Man DWK, 2010, J ALTERN COMPLEM MED, V16, P1259, DOI 10.1089/acm.2009.0462
   Mandyam CD, 2007, J NEUROSCI, V27, P11442, DOI 10.1523/JNEUROSCI.2505-07.2007
   Mandyam CD, 2012, TRENDS NEUROSCI, V35, P250, DOI 10.1016/j.tins.2011.12.005
   Marcus BH, 1999, ARCH INTERN MED, V159, P1229, DOI 10.1001/archinte.159.11.1229
   MARCUS BH, 1995, ADDICT BEHAV, V20, P87, DOI 10.1016/0306-4603(94)00048-4
   Marcus BH, 2005, NICOTINE TOB RES, V7, P871, DOI 10.1080/14622200500266056
   Marghmaleki V. Saedi, 2013, IRAN J BASIC MED SCI, V16
   Martinez LA, 2014, BEHAV BRAIN RES, V271, P39, DOI 10.1016/j.bbr.2014.05.052
   Mathews IZ, 2007, BEHAV PHARMACOL, V18, P641, DOI 10.1097/FBP.0b013e3282effbf5
   Mattila VM, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-230
   Maynard ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076644
   McArthur S, 2007, NEUROPSYCHOPHARMACOL, V32, P1462, DOI 10.1038/sj.npp.1301277
   McClung CA, 2004, MOL BRAIN RES, V132, P146, DOI 10.1016/j.molbrainres.2004.05.014
   McCulley WD, 2012, PHARMACOL BIOCHEM BE, V100, P485, DOI 10.1016/j.pbb.2011.10.009
   McHugh RK, 2013, J SUBST ABUSE TREAT, V45, P38, DOI 10.1016/j.jsat.2012.12.007
   Menendez-Delmestre R, 2011, PHYSIOL BEHAV, V102, P96, DOI 10.1016/j.physbeh.2010.09.025
   Mereu M, 2015, ADDICT BIOL, V20, P91, DOI 10.1111/adb.12080
   Miladi-Gorji H, 2014, NEUROSCIENCE, V256, P83, DOI 10.1016/j.neuroscience.2013.09.056
   Miladi-Gorji H, 2012, PHYSIOL BEHAV, V105, P195, DOI 10.1016/j.physbeh.2011.08.010
   Miladi-Gorji H, 2011, NEUROBIOL LEARN MEM, V96, P479, DOI 10.1016/j.nlm.2011.08.001
   Miller ML, 2012, DRUG ALCOHOL DEPEN, V121, P90, DOI 10.1016/j.drugalcdep.2011.08.013
   Mirbaha H, 2009, PHARMACOL BIOCHEM BE, V92, P399, DOI 10.1016/j.pbb.2009.01.009
   Moeller FG, 2012, AM J PSYCHIAT, V169, P351, DOI 10.1176/appi.ajp.2012.12010041
   Monteggia LM, 2007, BIOL PSYCHIAT, V61, P187, DOI 10.1016/j.biopsych.2006.03.021
   Moore MJ, 2005, J ADOLESCENT HEALTH, V36, P486, DOI 10.1016/j.jadohealth.2004.02.031
   Morita N, 2013, CIRC J, V77, P646, DOI 10.1253/circj.CJ-12-0607
   Mustroph ML, 2011, EUR J NEUROSCI, V34, P1161, DOI 10.1111/j.1460-9568.2011.07828.x
   Nakajima S, 2004, INTEGR PHYS BEH SCI, V39, P95, DOI 10.1007/BF02734275
   Napier TC, 2013, NEUROSCI BIOBEHAV R, V37, P2081, DOI 10.1016/j.neubiorev.2013.05.002
   Nazarian A, 2009, PSYCHOPHARMACOLOGY, V203, P641, DOI 10.1007/s00213-008-1411-5
   Nestler EJ, 2004, NEUROPHARMACOLOGY, V47, P24, DOI 10.1016/j.neuropharm.2004.06.031
   Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578
   Nestler EJ, 2008, PHILOS T R SOC B, V363, P3245, DOI 10.1098/rstb.2008.0067
   Nilsen J, 2000, J NEUROBIOL, V43, P64, DOI 10.1002/(SICI)1097-4695(200004)43:1<64::AID-NEU6>3.0.CO;2-7
   Noonan MA, 2010, J NEUROSCI, V30, P304, DOI 10.1523/JNEUROSCI.4256-09.2010
   Nygard SK, 2013, BRAIN RES, V1520, P121, DOI 10.1016/j.brainres.2013.04.060
   O'Dell SJ, 2012, SYNAPSE, V66, P71, DOI 10.1002/syn.20989
   Olesen KM, 2005, J NEUROENDOCRINOL, V17, P255, DOI 10.1111/j.1365-2826.2005.01302.x
   Panlilio LV, 2007, ADDICTION, V102, P1863, DOI 10.1111/j.1360-0443.2007.02011.x
   Parada M, 2012, HORM BEHAV, V62, P442, DOI 10.1016/j.yhbeh.2012.07.012
   Pate RR, 1996, AM J PUBLIC HEALTH, V86, P1577, DOI 10.2105/AJPH.86.11.1577
   Pate RR, 2000, ARCH PEDIAT ADOL MED, V154, P904, DOI 10.1001/archpedi.154.9.904
   Pendergast JS, 2008, J NEUROENDOCRINOL, V20, P1155, DOI 10.1111/j.1365-2826.2008.01776.x
   Perry RI, 2013, DRUG ALCOHOL DEPEN, V133, P222, DOI 10.1016/j.drugalcdep.2013.04.032
   Peterson AB, 2014, PSYCHOPHARMACOLOGY, V231, P2661, DOI 10.1007/s00213-014-3437-1
   Peterson AB, 2014, PSYCHOPHARMACOLOGY, V231, P1305, DOI 10.1007/s00213-013-3321-4
   Pickering RP, 2011, J CLIN PSYCHIAT, V72, P1494, DOI 10.4088/JCP.10m06077gry
   Pierce GL, 2011, CLIN SCI, V120, P13, DOI 10.1042/CS20100174
   Pina IL, 2014, JACC-HEART FAIL, V2, P180, DOI 10.1016/j.jchf.2013.10.007
   Pluchino N, 2013, NEUROSCIENCE, V239, P271, DOI 10.1016/j.neuroscience.2013.01.025
   Pohjalainen T, 1998, AM J PSYCHIAT, V155, P768
   Pollitzer E, 2013, NATURE, V500, P23, DOI 10.1038/500023a
   Prapavessis H, 2007, ADDICT BEHAV, V32, P1416, DOI 10.1016/j.addbeh.2006.10.005
   Quinones-Jenab V, 2010, HORM BEHAV, V58, P22, DOI 10.1016/j.yhbeh.2009.10.002
   Raichlen DA, 2013, EUR J APPL PHYSIOL, V113, P869, DOI 10.1007/s00421-012-2495-5
   Randall CK, 1998, PHARMACOL BIOCHEM BE, V60, P217, DOI 10.1016/S0091-3057(97)00585-6
   Reich CG, 2009, BEHAV BRAIN RES, V203, P264, DOI 10.1016/j.bbr.2009.05.013
   Reichel CM, 2012, PSYCHOPHARMACOLOGY, V223, P371, DOI 10.1007/s00213-012-2727-8
   Revilla S, 2014, NEUROPHARMACOLOGY, V81, P55, DOI 10.1016/j.neuropharm.2014.01.037
   Rezende EL, 2006, PHYSIOL BIOCHEM ZOOL, V79, P83, DOI 10.1086/498187
   Riebe CJN, 2010, PSYCHONEUROENDOCRINO, V35, P1265, DOI 10.1016/j.psyneuen.2010.02.008
   Roberts MD, 2012, PHYSIOL BEHAV, V105, P661, DOI 10.1016/j.physbeh.2011.09.024
   de Oliveira MSR, 2010, BRAIN RES BULL, V83, P278, DOI 10.1016/j.brainresbull.2010.07.009
   Garcia PLR, 2014, ARCH ARGENT PEDIATR, V112, P12, DOI [10.5546/aap.2014.eng.12, 10.5546/aap.2014.e12]
   Roger-Sanchez C, 2012, NEUROTOXICOL TERATOL, V34, P108, DOI 10.1016/j.ntt.2011.07.011
   Roman E, 2006, NEUROPEPTIDES, V40, P195, DOI 10.1016/j.npep.2006.01.004
   Roth ME, 2004, PHARMACOL BIOCHEM BE, V78, P199, DOI 10.1016/j.pbb.2004.03.018
   Roth ME, 2002, PHARMACOL BIOCHEM BE, V72, P313, DOI 10.1016/S0091-3057(01)00777-8
   Russo SJ, 2010, TRENDS NEUROSCI, V33, P267, DOI 10.1016/j.tins.2010.02.002
   Russo SJ, 2003, NEUROSCIENCE, V120, P523, DOI 10.1016/S0306-4522(03)00317-8
   Russo SJ, 2003, BRAIN RES, V970, P214, DOI 10.1016/S0006-8993(03)02346-1
   Saleh MC, 2013, NEUROSCI LETT, V548, P217, DOI 10.1016/j.neulet.2013.05.057
   Sanchez V, 2014, PSYCHOPHARMACOLOGY, V231, P1753, DOI 10.1007/s00213-013-3359-3
   Sanchez V, 2013, PSYCHOPHARMACOLOGY, V227, P403, DOI 10.1007/s00213-012-2964-x
   Sanchis-Segura C, 2006, ADDICT BIOL, V11, P2, DOI 10.1111/j.1369-1600.2006.00012.x
   Scarduzio M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080792
   Schindler CW, 2002, EUR J PHARMACOL, V442, P231, DOI 10.1016/S0014-2999(02)01550-9
   Schlauch RC, 2013, J PSYCHOPATHOL BEHAV, V35, P45, DOI 10.1007/s10862-012-9313-6
   Schmidt-Kassow M, 2012, NEUROREPORT, V23, P889, DOI 10.1097/WNR.0b013e32835946ca
   Segarra AC, 2010, HORM BEHAV, V58, P33, DOI 10.1016/j.yhbeh.2009.12.003
   Segat HJ, 2014, BEHAV BRAIN RES, V262, P94, DOI 10.1016/j.bbr.2014.01.005
   Sinha R, 2008, ANN NY ACAD SCI, V1141, P105, DOI 10.1196/annals.1441.030
   SINYOR D, 1982, J STUD ALCOHOL, V43, P380, DOI 10.15288/jsa.1982.43.380
   Smelson D, 2013, J ALTERN COMPLEM MED, V19, P97, DOI 10.1089/acm.2012.0052
   Smith MA, 2003, PSYCHOPHARMACOLOGY, V168, P426, DOI 10.1007/s00213-003-1471-5
   Smith MA, 2008, DRUG ALCOHOL DEPEN, V98, P129, DOI 10.1016/j.drugalcdep.2008.05.006
   Smith MA, 2008, PHARMACOL REP, V60, P561
   Smith MA, 2012, EXP CLIN PSYCHOPHARM, V20, P437, DOI 10.1037/a0029724
   Smith MA, 2012, PHARMACOL REP, V64, P960, DOI 10.1016/S1734-1140(12)70891-5
   Smith Mark A, 2011, Front Psychiatry, V2, P82, DOI 10.3389/fpsyt.2011.00082
   Smith MA, 2012, DRUG ALCOHOL DEPEN, V121, P54, DOI 10.1016/j.drugalcdep.2011.08.006
   Smith MA, 2011, PSYCHOPHARMACOLOGY, V218, P357, DOI 10.1007/s00213-011-2321-5
   Smith MA, 2011, PHARMACOL BIOCHEM BE, V100, P237, DOI 10.1016/j.pbb.2011.08.025
   Smits JAJ, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-207
   Sobieraj JC, 2014, BRAIN STRUCT FUNCT
   Solinas M, 2009, NEUROPSYCHOPHARMACOL, V34, P1102, DOI 10.1038/npp.2008.51
   Solinas M, 2008, P NATL ACAD SCI USA, V105, P17145, DOI 10.1073/pnas.0806889105
   Sparling PB, 2003, NEUROREPORT, V14, P2209, DOI 10.1097/00001756-200312020-00015
   Stapleton JN, 2014, ARCH PHYS MED REHAB, V95, P1787, DOI 10.1016/j.apmr.2014.03.021
   Storey A, 2012, SPORTS MED, V42, P769, DOI 10.2165/11633000-000000000-00000
   Strohle A, 2007, PSYCHOL MED, V37, P1657, DOI 10.1017/S003329170700089X
   Suzuki S, 2007, J COMP NEUROL, V500, P1064, DOI 10.1002/cne.21240
   Tantimonaco M, 2014, CELL MOL LIFE SCI, V71, P2681, DOI 10.1007/s00018-014-1575-6
   Tatar C, 2013, GLIA, V61, P192, DOI 10.1002/glia.22426
   Temfemo A, 2011, CARDIOL J, V18, P632, DOI 10.5603/CJ.2011.0026
   Terry-McElrath YM, 2011, ADDICTION, V106, P1855, DOI 10.1111/j.1360-0443.2011.03489.x
   Terry-McElrath YM, 2011, AM J PREV MED, V40, P530, DOI 10.1016/j.amepre.2010.12.021
   Thanos PK, 2013, BEHAV BRAIN RES, V239, P8, DOI 10.1016/j.bbr.2012.10.035
   Thanos PK, 2010, BEHAV BRAIN RES, V215, P77, DOI 10.1016/j.bbr.2010.06.033
   Thiel KJ, 2010, NEUROSCIENCE, V171, P1187, DOI 10.1016/j.neuroscience.2010.10.001
   Thiel KJ, 2011, PHARMACOL BIOCHEM BE, V97, P595, DOI 10.1016/j.pbb.2010.09.014
   Torres OV, 2009, PSYCHOPHARMACOLOGY, V206, P303, DOI 10.1007/s00213-009-1607-3
   Torres-Reveron A, 2009, NEUROSCIENCE, V159, P204, DOI 10.1016/j.neuroscience.2008.12.023
   Torres-Reveron A, 2008, BRAIN RES, V1232, P70, DOI 10.1016/j.brainres.2008.07.058
   Torres-Reveron A, 2007, NEUROSCI LETT, V421, P213, DOI 10.1016/j.neulet.2007.05.001
   Toy WA, 2014, NEUROBIOL DIS, V63, P201, DOI 10.1016/j.nbd.2013.11.017
   Trigo JM, 2010, DRUG ALCOHOL DEPEN, V108, P183, DOI 10.1016/j.drugalcdep.2009.10.011
   Tzeng WY, 2014, PSYCHONEUROENDOCRINO, V42, P24, DOI 10.1016/j.psyneuen.2014.01.003
   Uth N, 2005, INT J SPORTS MED, V26, P763, DOI 10.1055/s-2005-837443
   Van Kempen TA, 2013, NEUROSCI LETT, V552, P66, DOI 10.1016/j.neulet.2013.07.048
   Vaynman S, 2003, NEUROSCIENCE, V122, P647, DOI 10.1016/j.neuroscience.2003.08.001
   Vera-Villarroel P, 2014, SUBST ABUSE TREAT PR, V9, DOI 10.1186/1747-597X-9-1
   Vickers KS, 2009, NICOTINE TOB RES, V11, P985, DOI 10.1093/ntr/ntp101
   Vlachou S, 2014, CURR PHARM DESIGN, V20, P2072, DOI 10.2174/13816128113199990433
   Volkow ND, 2007, ARCH NEUROL-CHICAGO, V64, P1575, DOI 10.1001/archneur.64.11.1575
   Wakefield JC, 2015, ACTA PSYCHIAT SCAND
   Walker QD, 2006, NEUROPSYCHOPHARMACOL, V31, P1193, DOI 10.1038/sj.npp.1300915
   Wang JS, 2013, NEUROPSYCHOPHARMACOL, V38, P2286, DOI 10.1038/npp.2013.130
   Werch CC, 2005, PREV SCI, V6, P213, DOI 10.1007/s11121-005-0012-3
   Werme M, 2000, EUR J NEUROSCI, V12, P2967, DOI 10.1046/j.1460-9568.2000.00147.x
   Werme M, 2002, BEHAV BRAIN RES, V133, P301, DOI 10.1016/S0166-4328(02)00027-X
   Werme M, 2002, J NEUROSCI, V22, P8133
   Wetherington CL, 2010, HORM BEHAV, V58, P2, DOI 10.1016/j.yhbeh.2010.03.004
   Williams DM, 2011, ADDICT BEHAV, V36, P894, DOI 10.1016/j.addbeh.2011.04.001
   Williams DM, 2010, PSYCHOL ADDICT BEHAV, V24, P349, DOI 10.1037/a0018332
   Winsley RJ, 2009, J SCI MED SPORT, V12, P647, DOI 10.1016/j.jsams.2008.05.006
   Winters KC, 2014, ADOLESC HEALTH MED T, V5, P199, DOI 10.2147/AHMT.S48053
   Wissman AM, 2011, NEUROPHARMACOLOGY, V61, P217, DOI 10.1016/j.neuropharm.2011.04.002
   Wong SYS, 2008, J SPORT SCI, V26, P295, DOI 10.1080/02640410701552658
   Wu A, 2008, NEUROSCIENCE, V155, P751, DOI 10.1016/j.neuroscience.2008.05.061
   Xu ZW, 2007, EXP NEUROL, V204, P714, DOI 10.1016/j.expneurol.2006.12.027
   Yau SY, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/403120
   Zakharova E, 2009, PHARMACOL BIOCHEM BE, V92, P131, DOI 10.1016/j.pbb.2008.11.002
   Zhang F, 2010, INT J MOL SCI, V11, P2658, DOI 10.3390/ijms11072658
   Zhou YH, 2014, J SPORT HEALTH SCI, V3, P163, DOI 10.1016/j.jshs.2014.04.005
   Zlebnik NE, 2014, PSYCHOPHARMACOLOGY, V231, P3787, DOI 10.1007/s00213-014-3513-6
   Zlebnik NE, 2014, BEHAV BRAIN RES, V261, P71, DOI 10.1016/j.bbr.2013.12.012
   Zlebnik NE, 2012, PSYCHOPHARMACOLOGY, V224, P387, DOI 10.1007/s00213-012-2760-7
   Zlebnik NE, 2010, PSYCHOPHARMACOLOGY, V209, P113, DOI 10.1007/s00213-010-1776-0
   Zschucke E, 2012, SCI WORLD J, DOI 10.1100/2012/901741
   Zuloaga DG, 2014, J NEUROCHEM, V129, P495, DOI 10.1111/jnc.12651
NR 332
TC 43
Z9 51
U1 6
U2 77
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0091-3022
EI 1095-6808
J9 FRONT NEUROENDOCRIN
JI Front. Neuroendocrinol.
PD JAN
PY 2016
VL 40
BP 24
EP 41
DI 10.1016/j.yfrne.2015.07.001
PG 18
WC Endocrinology & Metabolism; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA DM6OW
UT WOS:000376473300002
PM 26182835
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Rasekh, B
   Saw, YM
   Azimi, S
   Kariya, T
   Yamamoto, E
   Hamajima, N
AF Rasekh, Bakhtar
   Saw, Yu Mon
   Azimi, Sayed
   Kariya, Tetsuyoshi
   Yamamoto, Eiko
   Hamajima, Nobuyuki
TI Associations of treatment completion against drug addiction with
   motivational interviewing and related factors in Afghanistan
SO NAGOYA JOURNAL OF MEDICAL SCIENCE
LA English
DT Article
DE drug addiction; drug treatment; motivational interviewing; Afghanistan
ID SUBSTANCE USE
AB Despite the increase in the number of drug treatment centers, patients with drug addicts have been increasing without the improvement of treatment in Afghanistan. This study aimed to examine the associations of the completion of drug addiction treatment with motivational interviewing (MI) and other factors among male drug users in Afghanistan. Subjects were patients admitted to Jangalak Hospital in Kabul, Afghanistan in 2014 and 2015. Systematic sampling and supplementary sampling were applied. The records of 327 males aged 18 to 54 years were collected from those of 3,373 male inpatients. Completion of treatment was defined as presence and receiving treatment in the hospital for at least 45 days. Multiple logistic regression models were applied to estimate the adjusted odds ratio (AOR) and 95% confidence interval (CI) for the completion of drug addiction treatment. Among the patients, heroin was the most commonly used drug, followed by opium, crystal, hashish, and other drugs. Patients with treatment history for drug addiction (AOR 2.46; 95% CI 1.14-5.30), those attended MI before admission (AOR 43.98; 95% CI 17.21-112.39), and those used heroin (AOR 4.74; 95% CI 1.32-16.97) were more likely to complete the drug addiction treatment. Among the factors examined in this study, attending MI was most strongly associated with the completion of drug addiction treatment. Amendments to policies to include compulsory MI in standard operational procedures of drug addiction treatment before hospitalization may be recommended.
C1 [Rasekh, Bakhtar] Minist Publ Hlth, Drug Demand Reduct Dept, Kabul, Afghanistan.
   [Saw, Yu Mon; Kariya, Tetsuyoshi; Yamamoto, Eiko; Hamajima, Nobuyuki] Nagoya Univ, Dept Healthcare Adm, Grad Sch Med, Nagoya, Aichi, Japan.
   [Azimi, Sayed] Minist Publ Hlth, Mental Hlth Dept, Kabul, Afghanistan.
C3 Nagoya University
RP Rasekh, B (通讯作者)，Minist Publ Hlth, Drug Demand Reduct Dept, Kabul, Afghanistan.
EM dibakhter@gmail.com
RI Saw, Yu Mon/M-7946-2019; KARIYA, TETSUYOSHI/L-4750-2017
OI KARIYA, TETSUYOSHI/0000-0002-7757-4251; Mon, Saw Yu/0000-0002-5038-0043
CR Baker A, 2002, ADDICTION, V97, P1329, DOI 10.1046/j.1360-0443.2002.00178.x
   Barnett E, 2012, ADDICT BEHAV, V37, P1325, DOI 10.1016/j.addbeh.2012.07.001
   Bjelica J, 2015, HOMELESS UNWANTED KA
   Brown S., 2017, RISING ADDICTION RAT
   Carroll KM, 2006, DRUG ALCOHOL DEPEN, V81, P301, DOI 10.1016/j.drugalcdep.2005.08.002
   Catherine S, 2005, HARM REDUCT J, V2, P1
   Davis KC, 2010, INT J ENV RES PUB HE, V7, P4152, DOI 10.3390/ijerph7124152
   Hall WD, 2014, LANCET GLOB HEALTH, V2, pE557, DOI 10.1016/S2214-109X(14)70299-2
   Hedden SL, 2015, BEHAV HLTH TRENDS US, P4
   Henkel Dieter, 2011, Curr Drug Abuse Rev, V4, P4
   Jhanjee Sonali, 2014, Indian J Psychol Med, V36, P112, DOI 10.4103/0253-7176.130960
   Labrie JW, 2007, J STUD ALCOHOL DRUGS, V68, P393, DOI 10.15288/jsad.2007.68.393
   Marhe R, 2013, J CONSULT CLIN PSYCH, V81, P1, DOI 10.1037/a0030754
   McKillip R., 2015, SCI CONS PREV DRUG U, P30
   Ministry of Counter Narcotics, 2012, NAT DRUG DEM RED POL, P23
   Palmeri Josephine M., 2011, PEER PRESSURE ALCOHO
   SGI Global LLC, 2015, AFGH NAT DRUG US SUR
   Sheer VC, 2017, SUBST USE MISUSE, V52, P866, DOI 10.1080/10826084.2016.1264972
   Substance Abuse and Mental Health Services Administration, 2012, RES 2011 NAT SURV DR
   United Nations Office on Drugs and Crime, 2016, WORLD DRUG REP
   United Nations Office on Drugs and Crime, 2003, COMM DRUG PROF NO 5
   United Nations Office on Drugs and Crime, 2010, UNODC REP MAJ GROW D
   United Nations Office on Drugs and Crime, 2015, AFGH DRUG REP
NR 23
TC 4
Z9 4
U1 0
U2 7
PU NAGOYA UNIV, SCH MED
PI NAGOYA
PA EDITORIAL OFF, NAGOYA UNIV MED LIB, SCH MED, 65 TSURUMAI-CHO SHOWA- KU,
   NAGOYA, 466-8550, JAPAN
SN 2186-3326
EI 0027-7622
J9 NAGOYA J MED SCI
JI Nagoya J. Med. Sci.
PD AUG
PY 2018
VL 80
IS 3
BP 329
EP 340
DI 10.18999/nagjms.80.3.329
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GR1HI
UT WOS:000442282900005
PM 30214082
DA 2023-06-23
ER

PT J
AU Delpont, B
   Lhommee, E
   Klinger, H
   Schmitt, E
   Bichon, A
   Fraix, V
   Castrioto, A
   Quesada, JL
   Pelissier, P
   Kistner, A
   Carnicella, S
   Luscher, C
   Broussolle, E
   Pollak, P
   Thobois, S
   Krack, P
AF Delpont, Benoit
   Lhommee, Eugenie
   Klinger, Helene
   Schmitt, Emmanuelle
   Bichon, Amelie
   Fraix, Valerie
   Castrioto, Anna
   Quesada, Jean-Louis
   Pelissier, Pierre
   Kistner, Andrea
   Carnicella, Sebastien
   Luescher, Christian
   Broussolle, Emmanuel
   Pollak, Pierre
   Thobois, Stephane
   Krack, Paul
TI Psychostimulant Effect of Dopaminergic Treatment and Addictions in
   Parkinson's Disease
SO MOVEMENT DISORDERS
LA English
DT Article
DE Parkinson's disease; nonmotor fluctuations; addictions; dopamine
   dysregulation syndrome; impulsive control disorders
ID IMPULSE CONTROL DISORDERS; SUBTHALAMIC NUCLEUS STIMULATION; COMPULSIVE
   BEHAVIORS; WITHDRAWAL SYNDROME; NONMOTOR SYMPTOMS; DRUG-USE; LEVODOPA;
   SCALE; MOOD; DYSREGULATION
AB Background: Dopamine replacement therapy in PD has been associated with both behavioral addictions and dopamine addiction
   Objectives: To investigate potential association between l-dopa induced neuropsychiatric fluctuations and addictions in PD.
   Methods: A cohort of 102 patients with PD suffering from motor complications of l-dopa treatment was prospectively analyzed. We evaluated dopamine addiction, behavioral addictions, and neuropsychiatric fluctuations using the Ardouin scale of behavior in PD.
   Results: Patients with (n=51) or without (n=51) neuropsychiatric fluctuations did not differ in age, disease duration, medication, or UPDRS III motor score during on and off drug condition. Patients with neuropsychiatric fluctuations had a higher H & Y stage in off-drug condition. A multivariate model showed that dopamine addiction (odds ratio: 8.9; P=0.02) and behavioral addictions (odds ratio: 3.76; P=0.033) were more frequent in the presence of neuropsychiatric fluctuations. Behavioral addictions and dopamine addiction were more frequent in the presence than in the absence of on-drug euphoria (46% vs. 13.9%; P<0.001 and 27% vs 6.2 %; P=0.003), while conversely, no association emerged between dopamine or behavioral addictions and presence of off-drug dysphoria. Patients with neuropsychiatric fluctuations had a poorer quality of life and a more frequent history of anxiety disorder.
   Conclusions: The psychostimulant effects of dopamine treatment during on-drug euphoria, rather than avoidance of off-drug dysphoria, appear to drive both behavioral addictions and abuse of medication. (C) 2017 International Parkinson and Movement Disorder Society
C1 [Delpont, Benoit; Lhommee, Eugenie; Schmitt, Emmanuelle; Bichon, Amelie; Fraix, Valerie; Castrioto, Anna; Pelissier, Pierre; Kistner, Andrea; Krack, Paul] CHU Grenoble Alpes, Neurol Dept, Movement Disorders Unit, Grenoble, France.
   [Delpont, Benoit; Lhommee, Eugenie; Schmitt, Emmanuelle; Bichon, Amelie; Fraix, Valerie; Castrioto, Anna; Pelissier, Pierre; Kistner, Andrea; Krack, Paul] Univ Grenoble Alpes, Grenoble, France.
   [Lhommee, Eugenie; Schmitt, Emmanuelle; Bichon, Amelie; Fraix, Valerie; Castrioto, Anna; Carnicella, Sebastien; Krack, Paul] INSERM, Grenoble Inst Neurosci, U1216, Grenoble, France.
   [Klinger, Helene; Broussolle, Emmanuel; Thobois, Stephane] Univ Lyon 1, Hosp Civils Lyon, Serv Neurol C, Hop Neurol Pierre Wertheimer, Lyon, France.
   [Klinger, Helene; Broussolle, Emmanuel; Thobois, Stephane] CNRS, Ctr Neurosci Cognit, UMR 5229, Lyon, France.
   [Quesada, Jean-Louis] DRCI, Unite Sci, Grenoble, France.
   [Quesada, Jean-Louis] CHU Grenoble, Ctr Invest Clin, Grenoble, France.
   [Luescher, Christian; Pollak, Pierre; Krack, Paul] Univ Geneva, Med Fac, Dept Basic Neurosci, Geneva, Switzerland.
   [Luescher, Christian; Pollak, Pierre; Krack, Paul] Geneva Univ Hosp, Dept Clin Neurosci, Clin Neurol, Geneva, Switzerland.
C3 CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French
   Research Universities; Universite Grenoble Alpes (UGA); Institut
   National de la Sante et de la Recherche Medicale (Inserm); UDICE-French
   Research Universities; Communaute Universite Grenoble Alpes; Universite
   Grenoble Alpes (UGA); CHU Lyon; UDICE-French Research Universities;
   Universite Claude Bernard Lyon 1; Centre National de la Recherche
   Scientifique (CNRS); CNRS - National Institute for Biology (INSB);
   UDICE-French Research Universities; Universite Claude Bernard Lyon 1;
   CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French
   Research Universities; Universite Grenoble Alpes (UGA); Institut
   National de la Sante et de la Recherche Medicale (Inserm); University of
   Geneva; University of Geneva
RP Krack, P (通讯作者)，Hop Univ Geneve, Serv Neurol, CH-1211 Geneva, Switzerland.
EM paul.krack@hcuge.ch
RI FRAIX, VALERIE/AAC-3616-2019; Lüscher, Christian/A-2496-2011;
   Carnicella, Sebastien/B-2003-2017; Kistner, Andrea/AAE-8812-2020
OI Lüscher, Christian/0000-0001-7917-4596; Carnicella,
   Sebastien/0000-0003-1043-8631; Krack, Paul/0000-0002-3508-7295
FU ROGER DE SPOELBERCH foundation
FX We thank C. Dalmolin for English corrections. P.K. thanks the ROGER DE
   SPOELBERCH foundation for their funding of the ROGER DE SPOELBERCH
   professorship in neurostimulation, University of Geneva.
CR Ardouin C, 2009, REV NEUROL-FRANCE, V165, P845, DOI 10.1016/j.neurol.2009.06.003
   Chaudhuri KR, 2009, LANCET NEUROL, V8, P464, DOI 10.1016/S1474-4422(09)70068-7
   Cilia R, 2011, BRAIN STRUCT FUNCT, V216, P289, DOI 10.1007/s00429-011-0314-0
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Drui G, 2014, MOL PSYCHIATR, V19, P358, DOI 10.1038/mp.2013.3
   Engeln M, 2013, ANN NEUROL, V74, P140, DOI 10.1002/ana.23881
   Eusebio A, 2013, J NEUROL NEUROSUR PS, V84, P868, DOI 10.1136/jnnp-2012-302387
   Evans AH, 2006, ANN NEUROL, V59, P852, DOI 10.1002/ana.20822
   Evans AH, 2005, NEUROLOGY, V65, P1570, DOI 10.1212/01.wnl.0000184487.72289.f0
   Evans AH, 2010, MOVEMENT DISORD, V25, P867, DOI 10.1002/mds.22898
   Fasano A, 2011, J NEUROL, V258, P656, DOI 10.1007/s00415-010-5817-8
   Funkiewiez A, 2003, MOVEMENT DISORD, V18, P524, DOI 10.1002/mds.10441
   Giovannoni G, 2000, J NEUROL NEUROSUR PS, V68, P423, DOI 10.1136/jnnp.68.4.423
   Grace AA, 2007, TRENDS NEUROSCI, V30, P220, DOI 10.1016/j.tins.2007.03.003
   Holden C, 2001, SCIENCE, V294, P980, DOI 10.1126/science.294.5544.980
   Koob GF, 2013, CURR OPIN NEUROBIOL, V23, P559, DOI 10.1016/j.conb.2013.03.011
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Lamberti VMJ, 2016, J PARKINSON DIS, V6, P133, DOI 10.3233/JPD-150698
   Leyton M, 2014, TRENDS PHARMACOL SCI, V35, P268, DOI 10.1016/j.tips.2014.04.002
   Lhommee E, 2012, BRAIN, V135, P1463, DOI 10.1093/brain/aws078
   Luscher C, 2011, NEURON, V69, P650, DOI 10.1016/j.neuron.2011.01.017
   Maricle RA, 1998, NEUROLOGY, V50, P1890, DOI 10.1212/WNL.50.6.1890
   MARICLE RA, 1995, NEUROLOGY, V45, P1757, DOI 10.1212/WNL.45.9.1757
   Martinez-Fernandez R, 2016, MOVEMENT DISORD, V31, P1080, DOI 10.1002/mds.26731
   Martinez-Fernandez R, 2016, J NEUROL NEUROSUR PS, V87, P311, DOI 10.1136/jnnp-2014-310189
   Martinez-Martin P, 2009, NEUROLOGY, V73, P1584, DOI 10.1212/WNL.0b013e3181c0d416
   Nutt JG, 1996, ANN NEUROL, V39, P561, DOI 10.1002/ana.410390504
   O'Sullivan SS, 2011, BRAIN, V134, P969, DOI 10.1093/brain/awr003
   O'Sullivan SS, 2009, CNS DRUGS, V23, P157, DOI 10.2165/00023210-200923020-00005
   Okai D, 2016, MOV DISORD CLIN PRAC, V3, P494, DOI 10.1002/mdc3.12316
   Potenza MN, 2011, NEURON, V69, P695, DOI 10.1016/j.neuron.2011.02.009
   Rabinak CA, 2010, ARCH NEUROL-CHICAGO, V67, P58, DOI 10.1001/archneurol.2009.294
   Racette BA, 2002, J NEUROPSYCH CLIN N, V14, P438, DOI 10.1176/appi.neuropsych.14.4.438
   Rieu I, 2015, MOVEMENT DISORD, V30, P705, DOI 10.1002/mds.26223
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Schrag A, 2015, LANCET NEUROL, V14, P57, DOI 10.1016/S1474-4422(14)70287-X
   Sierra M, 2015, J PARKINSON DIS, V5, P625, DOI 10.3233/JPD-150535
   Smith KM, 2016, J NEUROL NEUROSUR PS, V87, P864, DOI 10.1136/jnnp-2015-311827
   Thobois S, 2010, BRAIN, V133, P1111, DOI 10.1093/brain/awq032
   Volkow ND, 2016, NEW ENGL J MED, V374, P363, DOI 10.1056/NEJMra1511480
   Voon V, 2007, ARCH NEUROL-CHICAGO, V64, P1089, DOI 10.1001/archneur.64.8.1089
   Voon V, 2011, ANN NEUROL, V69, P986, DOI 10.1002/ana.22356
   Vriend C, 2014, MOVEMENT DISORD, V29, P904, DOI 10.1002/mds.25886
   Weintraub D, 2012, MOVEMENT DISORD, V27, P242, DOI 10.1002/mds.24023
   Weintraub D, 2010, ARCH NEUROL-CHICAGO, V67, P589, DOI 10.1001/archneurol.2010.65
NR 45
TC 14
Z9 14
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD NOV
PY 2017
VL 32
IS 11
BP 1566
EP 1573
DI 10.1002/mds.27101
PG 8
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA FM3XA
UT WOS:000414942700009
PM 28737225
DA 2023-06-23
ER

PT C
AU Chicos, O
AF Chicos, O.
GP Titu Maiorescu, Univ of Bucharest
TI THE IMPACT OF PSYCHOACTIVE SUBSTANCES ON YOUTH
SO LAW BETWEEN MODERNIZATION AND TRADITION - IMPLICATIONS FOR THE LEGAL,
   POLITICAL, ADMINISTRATIVE AND PUBLIC ORDER ORGANIZATION
LA English
DT Proceedings Paper
CT International Conference on Law between Modernization and Tradition -
   Implications for the Legal, Political, Administrative and Public Order
   Organization
CY APR 21-23, 2015
CL Bucharest, ROMANIA
SP European Union, Romanian Govt, AMPOSDRU, European Social Fund, Struct Instruments, Minist Natl Educ, Titu Maiorescu Univ Bucharest, Alexandru Ioan Cuza Univ Iasi, Univ Craiova
DE drug; drug addiction; drug trafficking; addiction; ethnobotanical plants
AB The drug contaminates, corrupts, morally destroys individuals and societies, breaking innocent lives. Drug addiction is a sad and painful phenomenon of the world we live in whose real size you cannot really know. Drug addiction is an old and destructive legacy which went in humanity from generation to generation, overcoming time and amplifying dangerously against the evolution of human society.
   Drug trafficking was and remains the predominant activity of criminal organizations and also their financial backbone. It is that reference offense, extremely profitable, which most oft en intertwines with acts of money laundering, arms trafficking, corruption and many other criminal activities.
C1 Titu Maiorescu Univ Bucharest, Fac Law, Bucharest, Romania.
C3 Titu Maiorescu University
RP Chicos, O (通讯作者)，Titu Maiorescu Univ Bucharest, Fac Law, Bucharest, Romania.
EM oana.chicos@ugal.ro
CR Pop S., 2008, ANTIDRUG GUIDE U LUC
   Tical G., 2005, PAST PRESENT
   Toader T., 2014, NEW CRIMINAL CODE CO
   Tone C., 2009, KILLING TEMPTATIONS
NR 4
TC 0
Z9 0
U1 0
U2 2
PU HAMANGIU
PI BUCHAREST
PA STR COLONEL CORNELIUS POPE, NR 36, SECT 5, BUCHAREST, 00000, ROMANIA
BN 978-606-27-0222-9
PY 2015
BP 904
EP 909
PG 6
WC Law
WE Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)
SC Government & Law
GA BD6RB
UT WOS:000362509800117
DA 2023-06-23
ER

PT J
AU Robinson, TE
   Berridge, KC
AF Robinson, TE
   Berridge, KC
TI Addiction
SO ANNUAL REVIEW OF PSYCHOLOGY
LA English
DT Review
DE sensitization; learning; nucleus accumbens; dopamine; drug abuse
ID MESSENGER-RNA EXPRESSION; COCAINE-SEEKING BEHAVIOR; D-AMPHETAMINE
   CHALLENGE; STRESS-INDUCED RELAPSE; NUCLEUS-ACCUMBENS; PREFRONTAL CORTEX;
   DRUG-ADDICTION; DECISION-MAKING; INCENTIVE-SENSITIZATION; INTRAACCUMBENS
   AMPHETAMINE
AB The development of addiction involves a transition from casual to compulsive patterns of drug use. This transition to addiction is accompanied by many drug-induced changes in the brain and associated changes in psychological functions. In this article we present a critical analysis of the major theoretical explanations of how drug-induced alterations in psychological function might cause a transition to addiction. These include: (a) the traditional hedonic view that drug pleasure and subsequent unpleasant withdrawal symptoms are the chief causes of addiction; (b) the view that addiction is due to aberrant learning, especially the development of strong stimulus-response habits; (c) our incentive-sensitization view, which suggests that sensitization of a neural system that attributes incentive salience causes compulsive motivation or "wanting" to take addictive drugs; and (d) the idea that dysfunction of frontal cortical systems, which normally regulate decision making and inhibitory control over behavior, leads to impaired judgment and impulsivity in addicts.
C1 Univ Michigan, Dept Psychol, Biopsychol Program, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan
RP Robinson, TE (通讯作者)，Univ Michigan, Dept Psychol, Biopsychol Program, 580 Union Dr, Ann Arbor, MI 48109 USA.
EM ter@umich.edu; berridge@umich.edu
RI Strang, John/H-5460-2011; Berridge, Kent/C-1525-2009; Farrell, Michael
   P/A-4769-2012
OI Strang, John/0000-0002-5413-2725; Berridge, Kent/0000-0002-6031-2626;
   Farrell, Michael P/0000-0001-7008-8130
CR Anagnostaras SG, 2002, NEUROPSYCHOPHARMACOL, V26, P703, DOI 10.1016/S0893-133X(01)00402-X
   Anagnostaras SG, 1996, BEHAV NEUROSCI, V110, P1397, DOI 10.1037/0735-7044.110.6.1397
   [Anonymous], 1997, CONSCIOUSNESS LOST F
   Anteinaan S. M., 1983, STIMULANTS NEUROCHEM, P269
   ANTELMAN SM, 1980, SCIENCE, V207, P329, DOI 10.1126/science.7188649
   Badiani A, 1999, BEHAV BRAIN RES, V103, P203, DOI 10.1016/S0166-4328(99)00041-8
   Badiani A, 2000, PSYCHOPHARMACOLOGY, V151, P273, DOI 10.1007/s002130000447
   BADIANI A, 1995, BRAIN RES, V674, P291, DOI 10.1016/0006-8993(95)00028-O
   BADIANI A, 1995, PSYCHOPHARMACOLOGY, V117, P443, DOI 10.1007/BF02246217
   Badiani A, 1998, J NEUROSCI, V18, P10579
   Balleine BW, 1998, NEUROPHARMACOLOGY, V37, P407, DOI 10.1016/S0028-3908(98)00033-1
   Balleine BW, 2000, J NEUROSCI, V20, P8954
   Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295
   Bechara A, 2002, NEUROPSYCHOLOGIA, V40, P1675, DOI 10.1016/S0028-3932(02)00015-5
   Bechara A, 2002, NEUROPSYCHOLOGIA, V40, P1690, DOI 10.1016/S0028-3932(02)00016-7
   Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9
   Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8
   BERRIDGE KC, 1995, CURR DIR PSYCHOL SCI, V4, P71, DOI 10.1111/1467-8721.ep10772316
   Berridge KC, 2000, NEUROSCI BIOBEHAV R, V24, P173, DOI 10.1016/S0149-7634(99)00072-X
   BERRIDGE KC, 2002, IN PRESS BRAIN COGN
   BERRIDGE KC, 2002, IN PRESS COGN EMOT
   BERRIDGE KC, 1999, WELL BEING FDN HEDON, P527
   Biggins CA, 1997, BIOL PSYCHIAT, V42, P472, DOI 10.1016/S0006-3223(96)00425-8
   Bolla KI, 1998, J NEUROPSYCH CLIN N, V10, P280, DOI 10.1176/jnp.10.3.280
   Cardinal RN, 2002, NEUROSCI BIOBEHAV R, V26, P321, DOI 10.1016/S0149-7634(02)00007-6
   Carlsson A, 2001, ANNU REV PHARMACOL, V41, P237, DOI 10.1146/annurev.pharmtox.41.1.237
   Castner SA, 1999, NEUROPSYCHOPHARMACOL, V20, P10, DOI 10.1016/S0893-133X(98)00050-5
   Childress A R, 1988, NIDA Res Monogr, V84, P25
   Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11
   Covington HE, 2001, PSYCHOPHARMACOLOGY, V158, P388, DOI 10.1007/s002130100858
   Crombag HS, 2001, NEUROPSYCHOPHARMACOL, V24, P680, DOI 10.1016/S0893-133X(00)00238-4
   Crombag HS, 2000, BEHAV BRAIN RES, V116, P1, DOI 10.1016/S0166-4328(00)00243-6
   Davidson RJ, 2000, PSYCHOL BULL, V126, P890, DOI 10.1037/0033-2909.126.6.890
   de Borchgrave R, 2002, EXP BRAIN RES, V144, P50, DOI 10.1007/s00221-002-1031-y
   De Vries TJ, 2002, NEUROPSYCHOPHARMACOL, V26, P18, DOI 10.1016/S0893-133X(01)00293-7
   De Vries TJ, 2002, J NEUROSCI, V22, P3321
   De Vries TJ, 1998, EUR J NEUROSCI, V10, P3565, DOI 10.1046/j.1460-9568.1998.00368.x
   Deroche V, 1999, EUR J NEUROSCI, V11, P2731, DOI 10.1046/j.1460-9568.1999.00696.x
   Di Chiara G, 1999, EUR J PHARMACOL, V375, P13, DOI 10.1016/S0014-2999(99)00372-6
   Dickinson A, 2000, BEHAV NEUROSCI, V114, P468, DOI 10.1037/0735-7044.114.3.468
   DICKINSON A, 1994, ANIM LEARN BEHAV, V22, P1, DOI 10.3758/BF03199951
   EDWARDS G, 1981, B WORLD HEALTH ORGAN, V59, P225
   Elster J., 1999, STRONG FEELINGS EMOT
   Everitt BJ, 2001, BRAIN RES REV, V36, P129, DOI 10.1016/S0165-0173(01)00088-1
   Everitt BJ, 2002, J NEUROSCI, V22, P3312
   Fiorino DF, 1999, J NEUROSCI, V19, P456, DOI 10.1523/JNEUROSCI.19-01-00456.1999
   Fiorino DF, 1999, PSYCHOPHARMACOLOGY, V142, P200, DOI 10.1007/s002130050880
   FISCHMAN MW, 1992, CIBA F SYMP, V166, P165
   Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134
   Harmer CJ, 1998, BEHAV PHARMACOL, V9, P299
   Harmer CJ, 1999, PSYCHOPHARMACOLOGY, V142, P120, DOI 10.1007/s002130050870
   HORGER BA, 1992, PSYCHOPHARMACOLOGY, V107, P271, DOI 10.1007/BF02245147
   HORGER BA, 1990, PHARMACOL BIOCHEM BE, V37, P707, DOI 10.1016/0091-3057(90)90552-S
   Hurvich LM, 1981, COLOR VISION
   Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560
   Jackson ME, 2001, J NEUROCHEM, V78, P920, DOI 10.1046/j.1471-4159.2001.00499.x
   Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483
   JOHNSTON LD, 2001, NIH PUBL, V4925
   Kelley AE, 1999, PSYCHOBIOLOGY, V27, P198
   Kelley AE, 2002, J NEUROSCI, V22, P3306
   Klebaur JE, 2002, BRAIN RES, V930, P30, DOI 10.1016/S0006-8993(01)03400-X
   Knutson B, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-16-j0002.2001
   Koob GF, 1997, PHARMACOL BIOCHEM BE, V57, P513, DOI 10.1016/S0091-3057(96)00438-8
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   LAMB RJ, 1991, J PHARMACOL EXP THER, V259, P1165
   LETT BT, 1989, PSYCHOPHARMACOLOGY, V98, P357, DOI 10.1007/BF00451687
   Liu X, 1998, NEUROPSYCHOPHARMACOL, V18, P243
   Lorrain DS, 2000, BEHAV BRAIN RES, V107, P9, DOI 10.1016/S0166-4328(99)00109-6
   MCAULIFFE WE, 1982, INT J ADDICT, V17, P19, DOI 10.3109/10826088209054607
   Mendrek A, 1998, PSYCHOPHARMACOLOGY, V135, P416, DOI 10.1007/s002130050530
   Meyer-Lindenberg A, 2002, NAT NEUROSCI, V5, P267, DOI 10.1038/nn804
   NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B
   Nocjar C, 2002, BEHAV BRAIN RES, V128, P189, DOI 10.1016/S0166-4328(01)00321-7
   O'Brien C P, 1988, NIDA Res Monogr, V84, P44
   OBRIEN CP, 1992, RES P ARNMD, V70, P157
   Park WK, 2002, J NEUROSCI, V22, P2916, DOI 10.1523/JNEUROSCI.22-07-02916.2002
   PAULSON PE, 1991, PSYCHOPHARMACOLOGY, V103, P480, DOI 10.1007/BF02244248
   PERT A, 1990, NIDA RES MG, V97, P208
   PIAZZA PV, 1991, MESOLIMBIC DOPAMINE SYSTEM : FROM MOTIVATION TO ACTION, P473
   PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295
   PIAZZA PV, 1990, BRAIN RES, V514, P22, DOI 10.1016/0006-8993(90)90431-A
   Pierce RC, 1997, BRAIN RES REV, V25, P192, DOI 10.1016/S0165-0173(97)00021-0
   Pierre PJ, 1998, PSYCHOPHARMACOLOGY, V138, P159, DOI 10.1007/s002130050658
   Ramsay DS, 1997, PSYCHOL REV, V104, P170, DOI 10.1037/0033-295X.104.1.170
   RESCORLA RA, 1967, PSYCHOL REV, V74, P151, DOI 10.1037/h0024475
   Robbins TW, 1999, NATURE, V398, P567, DOI 10.1038/19208
   Robbins TW, 1999, PSYCHOL SCI, V10, P199, DOI 10.1111/1467-9280.00134
   Robbins TW, 1996, CURR OPIN NEUROBIOL, V6, P228, DOI 10.1016/S0959-4388(96)80077-8
   Robinson T. E., 1988, SENSITIZATION NERVOU, P145
   Robinson TE, 1999, EUR J NEUROSCI, V11, P1598, DOI 10.1046/j.1460-9568.1999.00576.x
   Robinson TE, 1997, J NEUROSCI, V17, P8491
   Robinson TE, 1999, SYNAPSE, V33, P160
   Robinson TE, 2001, SYNAPSE, V39, P257
   Robinson TE, 2000, ADDICTION, V95, pS91
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   ROBINSON TE, 1986, BRAIN RES REV, V11, P157, DOI 10.1016/0165-0173(86)90002-0
   Robinson TE, 1998, NEUROSCI BIOBEHAV R, V22, P347, DOI 10.1016/S0149-7634(97)00020-1
   Rogers RD, 1999, NEUROPSYCHOPHARMACOL, V20, P322, DOI 10.1016/S0893-133X(98)00091-8
   Samaha AN, 2002, J NEUROSCI, V22, P3244, DOI 10.1523/JNEUROSCI.22-08-03244.2002
   Schacter Daniel, 1996, SEARCHING FOR MEMORY
   SCHULL J, 1979, PSYCHOL LEARN MOTIV, P57
   Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1
   Schultz W, 2000, NAT REV NEUROSCI, V1, P199, DOI 10.1038/35044563
   Shaham Y, 2000, BRAIN RES REV, V33, P13, DOI 10.1016/S0165-0173(00)00024-2
   Shalev U, 2002, PHARMACOL REV, V54, P1, DOI 10.1124/pr.54.1.1
   Shalev U, 2001, PSYCHOPHARMACOLOGY, V156, P98, DOI 10.1007/s002130100748
   Shippenberg TS, 1996, EUR J PHARMACOL, V299, P33, DOI 10.1016/0014-2999(95)00852-7
   SHIPPENBERG TS, 1995, J PHARMACOL EXP THER, V273, P808
   Siegel S, 1998, PSYCHOL BULL, V124, P230, DOI 10.1037/0033-2909.124.2.230
   Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657
   Solomon R.L, 1977, PSYCHOPATHOLOGY EXPT, P66
   SOLOMON RL, 1973, J ABNORM PSYCHOL, V81, P158, DOI 10.1037/h0034534
   Stewart J, 2000, J PSYCHIATR NEUROSCI, V25, P125
   STEWART J, 1993, BEHAV PHARMACOL, V4, P289
   STEWART J, 1992, PSYCHOPHARMACOLOGY, V108, P79, DOI 10.1007/BF02245289
   STEWART J, 1991, BEHAV PHARMACOL, V2, P65
   Strakowski SM, 1998, BIOL PSYCHIAT, V44, P1171, DOI 10.1016/S0006-3223(97)00454-X
   Strakowski SM, 1996, BIOL PSYCHIAT, V40, P872, DOI 10.1016/0006-3223(95)00497-1
   Taylor JR, 1999, PSYCHOPHARMACOLOGY, V142, P31, DOI 10.1007/s002130050859
   TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147
   Uslaner J, 2001, EUR J NEUROSCI, V13, P1977, DOI 10.1046/j.0953-816x.2001.01574.x
   VALADEZ A, 1994, PHARMACOL BIOCHEM BE, V47, P203, DOI 10.1016/0091-3057(94)90132-5
   Vanderschuren LJMJ, 2000, PSYCHOPHARMACOLOGY, V151, P99, DOI 10.1007/s002130000493
   VOLKOW ND, 1991, AM J PSYCHIAT, V148, P621
   VOLKOW ND, 1992, SYNAPSE, V11, P184, DOI 10.1002/syn.890110303
   Wagner FA, 2002, NEUROPSYCHOPHARMACOL, V26, P479, DOI 10.1016/S0893-133X(01)00367-0
   Washton A M, 1993, NIDA Res Monogr, V135, P15
   White FJ, 1998, DRUG ALCOHOL DEPEN, V51, P141, DOI 10.1016/S0376-8716(98)00072-6
   White NM, 1996, ADDICTION, V91, P921, DOI 10.1111/j.1360-0443.1996.tb03586.x
   WIKLER A, 1948, AM J PSYCHIAT, V105, P329, DOI 10.1176/ajp.105.5.329
   WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469
   WISE RA, 1989, NEUROPHARMACOLOGICAL, P377
   Wolf ME, 1998, PROG NEUROBIOL, V54, P679, DOI 10.1016/S0301-0082(97)00090-7
   Wyvell CL, 2001, J NEUROSCI, V21, P7831, DOI 10.1523/JNEUROSCI.21-19-07831.2001
   Wyvell CL, 2000, J NEUROSCI, V20, P8122
NR 136
TC 1283
Z9 1334
U1 5
U2 371
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA
SN 0066-4308
EI 1545-2085
J9 ANNU REV PSYCHOL
JI Annu. Rev. Psychol.
PY 2003
VL 54
BP 25
EP 53
DI 10.1146/annurev.psych.54.101601.145237
PG 29
WC Psychology; Psychology, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology
GA 653KU
UT WOS:000181435000003
PM 12185211
DA 2023-06-23
ER

PT J
AU Gould, TJ
AF Gould, Thomas J.
TI Nicotine and hippocampus-dependent learning - Implications for addiction
SO MOLECULAR NEUROBIOLOGY
LA English
DT Review
DE learning; addiction; acetylcholine; nicotine; hippocampus; contextual
   fear conditioning; CREB; MAPK; withdrawal; plasticity
ID CONDITIONED PLACE PREFERENCE; LONG-TERM POTENTIATION; NEURONAL
   ACETYLCHOLINE-RECEPTORS; PROTEIN-KINASE-A; CONTEXTUAL FEAR;
   NUCLEUS-ACCUMBENS; C57BL/6 MICE; SYNAPTIC-TRANSMISSION;
   ALPHA-BUNGAROTOXIN; COCAINE-SEEKING
AB Addiction is a complex disorder because many factors contribute to the development and maintenance of addiction. One factor is learning. For example, drug-context associations that develop during drug use could facilitate drug craving upon re-exposure to contexts previously associated with drugs. Additionally, deficits in cognitive processes associated with withdrawal could precipitate relapse in attempts to ameliorate those deficits. Because addiction and learning involve common neural areas and cell signaling cascades, addiction-related changes in processes underlying plasticity may contribute to addiction. This article examines similarities between addiction and learning at the behavioral, neural, and cellular levels, with emphasis on the neural substrates underlying the effects of acute nicotine, chronic nicotine, and withdrawal from chronic nicotine on hippocampus-dependent contextual learning.
C1 Temple Univ, Dept Psychol, Philadelphia, PA 19122 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple
   University
RP Gould, TJ (通讯作者)，Temple Univ, Dept Psychol, Philadelphia, PA 19122 USA.
EM tgould@temple.edu
FU NIDA NIH HHS [R01 DA017949, R01 DA017949-01A2, DA017949] Funding Source:
   Medline
CR Abel T, 2001, CURR OPIN NEUROBIOL, V11, P180, DOI 10.1016/S0959-4388(00)00194-X
   Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2
   Adams JP, 2002, ANNU REV PHARMACOL, V42, P135, DOI 10.1146/annurev.pharmtox.42.082701.145401
   Adler LE, 1998, SCHIZOPHRENIA BULL, V24, P189, DOI 10.1093/oxfordjournals.schbul.a033320
   Alkondon M, 1998, BRAIN RES, V810, P257, DOI 10.1016/S0006-8993(98)00880-4
   Alkondon M, 2003, J NEUROPHYSIOL, V90, P1613, DOI 10.1152/jn.00214.2003
   Alonso M, 2003, NEUROREPORT, V14, P1989, DOI 10.1097/00001756-200310270-00022
   Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836
   Baker TB, 2004, ANNU REV PSYCHOL, V55, P463, DOI 10.1146/annurev.psych.55.090902.142054
   Balfour DJK, 2000, BEHAV BRAIN RES, V113, P73, DOI 10.1016/S0166-4328(00)00202-3
   BARRANTES GE, 1994, BIOCHEM SOC T, V22, pS294, DOI 10.1042/bst022294s
   BARRANTES GE, 1995, NEUROSCI LETT, V196, P101, DOI 10.1016/0304-3940(95)11859-U
   Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584
   Bell S L, 1999, Nicotine Tob Res, V1, P45, DOI 10.1080/14622299050011141
   Belluzzi JD, 2004, PSYCHOPHARMACOLOGY, V174, P389, DOI 10.1007/s00213-003-1758-6
   BENOWITZ NL, 1989, PROG BRAIN RES, V79, P279
   Berg DK, 2002, J NEUROBIOL, V53, P512, DOI 10.1002/neu.10116
   Blum S, 2006, NEUROREPORT, V17, P341, DOI 10.1097/01.wnr.0000201509.53750.bc
   Broide RS, 1999, MOL NEUROBIOL, V20, P1, DOI 10.1007/BF02741361
   Brunzell DH, 2003, J NEUROCHEM, V84, P1431, DOI 10.1046/j.1471-4159.2003.01640.x
   Caggiula AR, 2001, PHARMACOL BIOCHEM BE, V70, P515, DOI 10.1016/S0091-3057(01)00676-1
   Caggiula AR, 2002, PHYSIOL BEHAV, V77, P683, DOI 10.1016/S0031-9384(02)00918-6
   Caggiula AR, 2002, PSYCHOPHARMACOLOGY, V163, P230, DOI 10.1007/s00213-002-1156-5
   Caldarone BJ, 2000, NEUROPHARMACOLOGY, V39, P2779, DOI 10.1016/S0028-3908(00)00137-4
   Cammarota M, 2002, CELL MOL NEUROBIOL, V22, P259, DOI 10.1023/A:1020763716886
   Carlezon WA, 1998, SCIENCE, V282, P2272, DOI 10.1126/science.282.5397.2272
   Carlezon WA, 2005, TRENDS NEUROSCI, V28, P436, DOI 10.1016/j.tins.2005.06.005
   Chang KT, 2001, NEURON, V32, P855, DOI 10.1016/S0896-6273(01)00516-5
   Chaudhri N, 2005, PSYCHOPHARMACOLOGY, V180, P258, DOI 10.1007/s00213-005-2152-3
   Chaudhri N, 2006, PSYCHOPHARMACOLOGY, V184, P353, DOI 10.1007/s00213-005-0178-1
   Chavez-Noriega LE, 2000, NEUROPHARMACOLOGY, V39, P2543, DOI 10.1016/S0028-3908(00)00134-9
   Chen Y, 2003, NEUROPHARMACOLOGY, V45, P334, DOI 10.1016/S0028-3908(03)00189-8
   Chu ZG, 2000, BRAIN RES, V887, P399, DOI 10.1016/S0006-8993(00)03076-6
   Cohen C, 2005, NEUROPSYCHOPHARMACOL, V30, P145, DOI 10.1038/sj.npp.1300541
   Cordero-Erausquin M, 2000, TRENDS PHARMACOL SCI, V21, P211, DOI 10.1016/S0165-6147(00)01489-9
   Cornish JL, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-15-j0006.2000
   Corrigall W A, 1999, Nicotine Tob Res, V1, P11, DOI 10.1080/14622299050011121
   Dajas-Bailador FA, 2002, J NEUROCHEM, V81, P606, DOI 10.1046/j.1471-4159.2002.00846.x
   Dajas-Bailador FA, 2002, J NEUROCHEM, V80, P520, DOI 10.1046/j.0022-3042.2001.00725.x
   Damaj MI, 2003, J PHARMACOL EXP THER, V307, P526, DOI 10.1124/jpet.103.054908
   Davis JA, 2006, PSYCHOPHARMACOLOGY, V184, P345, DOI 10.1007/s00213-005-0047-y
   Davis JA, 2005, J NEUROSCI, V25, P8708, DOI 10.1523/JNEUROSCI.2853-05.2005
   Di Chiara G, 1999, ANN NY ACAD SCI, V877, P461
   Di Ciano P, 2001, NEUROPSYCHOPHARMACOL, V25, P341, DOI 10.1016/S0893-133X(01)00235-4
   Domino Edward F, 2002, Nicotine Tob Res, V4, P71, DOI 10.1080/14622200110098400
   Eichenbaum H, 1997, ANNU REV PSYCHOL, V48, P547, DOI 10.1146/annurev.psych.48.1.547
   Eichenbaum H, 1999, BEHAV BRAIN RES, V103, P123, DOI 10.1016/S0166-4328(99)00044-3
   Eilers H, 1997, MOL PHARMACOL, V52, P1105, DOI 10.1124/mol.52.6.1105
   Epping-Jordan MP, 1998, NATURE, V393, P76, DOI 10.1038/30001
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Fabian-Fine R, 2001, J NEUROSCI, V21, P7993, DOI 10.1523/JNEUROSCI.21-20-07993.2001
   FANSELOW MS, 1994, BEHAV NEUROSCI, V108, P210, DOI 10.1037/0735-7044.108.1.210
   FANSELOW MS, 1994, BEHAV NEUROSCI, V108, P235, DOI 10.1037/0735-7044.108.2.235
   Feiro O, 2005, PHARMACOL BIOCHEM BE, V80, P251, DOI 10.1016/j.pbb.2004.11.005
   Fenster CP, 1997, J NEUROSCI, V17, P5747
   Fisher JL, 2000, NEUROPHARMACOLOGY, V39, P2756, DOI 10.1016/S0028-3908(00)00102-7
   Frazier CJ, 1998, J NEUROSCI, V18, P8228
   Fuchs RA, 2005, NEUROPSYCHOPHARMACOL, V30, P296, DOI 10.1038/sj.npp.1300579
   Fujii S, 2000, NEUROSCI LETT, V286, P134, DOI 10.1016/S0304-3940(00)01076-4
   Fujii S, 2000, BRAIN RES, V863, P259, DOI 10.1016/S0006-8993(00)02119-3
   Fujii S, 2001, BRAIN RES, V894, P340, DOI 10.1016/S0006-8993(01)02058-3
   Fujii S, 2001, BRAIN RES, V894, P347, DOI 10.1016/S0006-8993(01)02057-1
   Gentry CL, 2003, J PHARMACOL EXP THER, V304, P206, DOI 10.1124/jpet.102.041756
   Gould TJ, 1999, BEHAV BRAIN RES, V102, P31, DOI 10.1016/S0166-4328(98)00157-0
   Gould TJ, 2005, LEARN MEMORY, V12, P389, DOI 10.1101/lm.89105
   Gould TJ, 2004, BEHAV BRAIN RES, V155, P167, DOI 10.1016/j.bbr.2004.04.009
   Gould TJ, 2003, BEHAV NEUROSCI, V117, P1276, DOI 10.1037/0735-7044.117.6.1276
   Gould TJ, 2003, INTEGR PHYS BEH SCI, V38, P124, DOI 10.1007/BF02688830
   Gould TJ, 2002, BEHAV PHARMACOL, V13, P287, DOI 10.1097/00008877-200207000-00005
   Gould TJ, 2003, NEUROBIOL LEARN MEM, V80, P147, DOI 10.1016/S1074-7427(03)00057-1
   Grabus SD, 2006, PSYCHOPHARMACOLOGY, V184, P456, DOI 10.1007/s00213-006-0305-7
   Grillner P, 2000, SYNAPSE, V38, P1
   Grottick AJ, 2000, BEHAV BRAIN RES, V117, P197, DOI 10.1016/S0166-4328(00)00305-3
   Hefft S, 1999, J PHYSIOL-LONDON, V515, P769, DOI 10.1111/j.1469-7793.1999.769ab.x
   HENNINGFIELD JE, 1993, J CONSULT CLIN PSYCH, V61, P743, DOI 10.1037/0022-006X.61.5.743
   Horan B, 1997, SYNAPSE, V26, P93
   Hou JM, 2004, J NEUROBIOL, V60, P249, DOI 10.1002/neu.20021
   HUGHES JR, 1991, ARCH GEN PSYCHIAT, V48, P52
   Ji D, 2001, NEURON, V31, P131, DOI 10.1016/S0896-6273(01)00332-4
   Jonkman S, 2005, EUR J PHARMACOL, V516, P40, DOI 10.1016/j.ejphar.2005.04.032
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Karadsheh MS, 2004, J NEUROCHEM, V91, P1138, DOI 10.1111/j.1471-4159.2004.02801.x
   KIM JJ, 1991, BEHAV NEUROSCI, V105, P126, DOI 10.1037/0735-7044.105.1.126
   KLEINMAN KM, 1973, PSYCHOL REP, V32, P963, DOI 10.2466/pr0.1973.32.3.963
   Konu O, 2001, BRAIN RES, V909, P194, DOI 10.1016/S0006-8993(01)02685-3
   KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J
   KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550
   Kreek MJ, 2005, NAT NEUROSCI, V8, P1450, DOI 10.1038/nn1583
   Kumari V, 1999, PSYCHOPHARMACOLOGY, V141, P11, DOI 10.1007/s002130050800
   Le Foll B, 2005, PSYCHOPHARMACOLOGY, V178, P481, DOI 10.1007/s00213-004-2021-5
   Le Novere N, 2002, P NATL ACAD SCI USA, V99, P3210, DOI 10.1073/pnas.042699699
   Lena C, 1998, J PHYSIOL-PARIS, V92, P63, DOI 10.1016/S0928-4257(98)80140-X
   Lerman C, 2002, ONCOGENE, V21, P7412, DOI 10.1038/sj.onc.1205801
   LEVIN ED, 1991, BRAIN RES BULL, V27, P125, DOI 10.1016/0361-9230(91)90293-S
   Levy RB, 2002, J NEUROSCI, V22, P5001, DOI 10.1523/JNEUROSCI.22-12-05001.2002
   Logue SE, 1997, BEHAV NEUROSCI, V111, P104, DOI 10.1037/0735-7044.111.1.104
   London ED, 2000, CEREB CORTEX, V10, P334, DOI 10.1093/cercor/10.3.334
   Lu L, 2005, NAT NEUROSCI, V8, P212, DOI 10.1038/nn1383
   Lynch WJ, 2005, EUR J NEUROSCI, V22, P1214, DOI 10.1111/j.1460-9568.2005.04305.x
   MALIN DH, 1992, PHARMACOL BIOCHEM BE, V43, P779, DOI 10.1016/0091-3057(92)90408-8
   Maren S, 2001, ANNU REV NEUROSCI, V24, P897, DOI 10.1146/annurev.neuro.24.1.897
   Marks MJ, 2004, NEUROPHARMACOLOGY, V46, P1141, DOI 10.1016/j.neuropharm.2004.02.009
   MARKS MJ, 1993, J PHARMACOL EXP THER, V266, P1268
   MARKS MJ, 1983, J PHARMACOL EXP THER, V226, P291
   Mathieu-Kia AM, 2002, PSYCHOPHARMACOLOGY, V162, P102, DOI 10.1007/s00213-002-1096-0
   Matsubayashi H, 2004, BRAIN RES, V1005, P1, DOI 10.1016/j.brainres.2004.01.040
   Matsubayashi H, 2004, MOL BRAIN RES, V129, P1, DOI 10.1016/j.molbrainres.2004.06.040
   McCallum S, 2006, PSYCHOPHARMACOLOGY, V184, P314, DOI 10.1007/s00213-005-0076-6
   Mukhin AG, 2000, MOL PHARMACOL, V57, P642, DOI 10.1124/mol.57.3.642
   Nakayama H, 2001, J NEUROCHEM, V79, P489, DOI 10.1046/j.1471-4159.2001.00602.x
   Nestler EJ, 2002, NEUROBIOL LEARN MEM, V78, P637, DOI 10.1006/nlme.2002.4084
   Nomikos GG, 2000, BEHAV BRAIN RES, V113, P97, DOI 10.1016/S0166-4328(00)00204-7
   Olale F, 1997, J PHARMACOL EXP THER, V283, P675
   OrrUrtreger A, 1997, J NEUROSCI, V17, P9165
   Pandey SC, 2001, J NEUROCHEM, V77, P943, DOI 10.1046/j.1471-4159.2001.00309.x
   Papke RL, 2001, J PHARMACOL EXP THER, V297, P646
   Paylor R, 1998, LEARN MEMORY, V5, P302
   Pelletier JG, 2004, BIOL PSYCHIAT, V55, P559, DOI 10.1016/j.biopsych.2003.08.019
   Peng X, 1997, MOL PHARMACOL, V51, P776, DOI 10.1124/mol.51.5.776
   Perry DC, 2002, J NEUROCHEM, V82, P468, DOI 10.1046/j.1471-4159.2002.00951.x
   Peto R, 1996, BRIT MED BULL, V52, P12, DOI 10.1093/oxfordjournals.bmb.a011519
   PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274
   Picciotto MR, 2000, NEUROPSYCHOPHARMACOL, V22, P451, DOI 10.1016/S0893-133X(99)00146-3
   Pierce RC, 1998, J PHARMACOL EXP THER, V286, P1171
   Pierce RC, 1999, J NEUROSCI, V19, P8685
   Pittenger C, 2002, NEURON, V34, P447, DOI 10.1016/S0896-6273(02)00684-0
   Pluzarev O, 2004, J NEUROSCI RES, V77, P884, DOI 10.1002/jnr.20216
   Pomerleau CS, 2003, ADDICT BEHAV, V28, P1149, DOI 10.1016/S0306-4603(02)00223-X
   Porter JT, 1999, J NEUROSCI, V19, P5228
   Postma P, 2001, PSYCHOPHARMACOLOGY, V156, P360, DOI 10.1007/s002130100829
   Radcliffe KA, 1999, ANN NY ACAD SCI, V868, P591, DOI 10.1111/j.1749-6632.1999.tb11332.x
   Radcliffe KA, 1998, J NEUROSCI, V18, P7075
   RISINGER FO, 1995, PHARMACOL BIOCHEM BE, V51, P457, DOI 10.1016/0091-3057(95)00007-J
   Robbins TW, 2002, NEUROBIOL LEARN MEM, V78, P625, DOI 10.1006/nlme.2002.4103
   Roerig B, 1997, J NEUROSCI, V17, P8353
   Rose JE, 1997, PSYCHOPHARMACOLOGY, V130, P28, DOI 10.1007/s002130050209
   Rossi L, 2003, BIOTECHNOL INTELL UN, V6, P1
   Rush R, 2002, MOL PHARMACOL, V61, P1416, DOI 10.1124/mol.61.6.1416
   Sabban EL, 2002, ANN NY ACAD SCI, V971, P39, DOI 10.1111/j.1749-6632.2002.tb04430.x
   Sanna PP, 2002, BRAIN RES, V948, P186, DOI 10.1016/S0006-8993(02)03191-8
   Schafe GE, 2000, J NEUROSCI, V20, P8177
   SCHWARTZ RD, 1985, J NEUROCHEM, V45, P427, DOI 10.1111/j.1471-4159.1985.tb04005.x
   See RE, 2002, PHARMACOL BIOCHEM BE, V71, P517, DOI 10.1016/S0091-3057(01)00682-7
   Selcher JC, 2002, NEUROSCIENTIST, V8, P122, DOI 10.1177/107385840200800208
   Selcher JC, 1999, LEARN MEMORY, V6, P478, DOI 10.1101/lm.6.5.478
   Self DW, 1998, J NEUROSCI, V18, P1848
   Semenova S, 2003, EUR J PHARMACOL, V472, P99, DOI 10.1016/S0014-2999(03)01904-6
   Setlow B, 1997, J NEUROSCI RES, V49, P515
   Shalin SC, 2004, J NEUROSCI RES, V75, P760, DOI 10.1002/jnr.20052
   Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127
   SNYDER FR, 1989, PSYCHOPHARMACOLOGY, V97, P17, DOI 10.1007/BF00443406
   Sorenson EM, 1998, NEUROSCIENCE, V87, P659, DOI 10.1016/S0306-4522(98)00064-5
   Stiedl O, 2000, BEHAV BRAIN RES, V116, P157, DOI 10.1016/S0166-4328(00)00269-2
   Takashima A, 2006, P NATL ACAD SCI USA, V103, P756, DOI 10.1073/pnas.0507774103
   Tzavara ET, 2002, EUR J NEUROSCI, V16, P149, DOI 10.1046/j.1460-9568.2002.02061.x
   Valjent E, 2004, EUR J NEUROSCI, V19, P1826, DOI 10.1111/j.1460-9568.2004.03278.x
   Vastola BJ, 2002, PHYSIOL BEHAV, V77, P107, DOI 10.1016/S0031-9384(02)00818-1
   Vorel SR, 2001, SCIENCE, V292, P1175, DOI 10.1126/science.1058043
   Waltereit R, 2003, MOL NEUROBIOL, V27, P99, DOI 10.1385/MN:27:1:99
   Wehner JM, 2004, NEUROSCIENCE, V129, P11, DOI 10.1016/j.neuroscience.2004.07.016
   White NM, 1996, ADDICTION, V91, P921, DOI 10.1111/j.1360-0443.1996.tb03586.x
   Widnell KL, 1996, J PHARMACOL EXP THER, V276, P306
   Wonnacott S, 1997, TRENDS NEUROSCI, V20, P92, DOI 10.1016/S0166-2236(96)10073-4
   Wooltorton JRA, 2003, J NEUROSCI, V23, P3176
   Wu M, 2003, EUR J NEUROSCI, V18, P1155, DOI 10.1046/j.1460-9568.2003.02847.x
   Zhang SL, 2001, PHYSIOL GENOMICS, V5, P187, DOI 10.1152/physiolgenomics.2001.5.4.187
   Zhang ZW, 1996, NEURON, V17, P1231, DOI 10.1016/S0896-6273(00)80253-6
NR 167
TC 51
Z9 51
U1 1
U2 13
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0893-7648
EI 1559-1182
J9 MOL NEUROBIOL
JI Mol. Neurobiol.
PD OCT
PY 2006
VL 34
IS 2
BP 93
EP 107
DI 10.1385/MN:34:2:93
PG 15
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 219WT
UT WOS:000250119600002
PM 17220532
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Wu, PH
   Schulz, KM
AF Wu, Peter H.
   Schulz, Kalynn M.
TI Advancing Addiction Treatment: What Can We Learn from Animal Studies?
SO ILAR JOURNAL
LA English
DT Article
DE addiction; dependence; drug abuse; memory; reinforcement; reward; rodent
   model
ID CONDITIONED PLACE PREFERENCE; VENTRAL TEGMENTAL AREA; ACUTE FUNCTIONAL
   TOLERANCE; CRANICAL SELF-STIMULATION; OPIOID-RECEPTOR-AGONIST;
   ALCOHOL-PREFERRING P; ANA RAT LINES; NUCLEUS-ACCUMBENS; DOPAMINE
   RELEASE; COCAINE REWARD
AB Substance addiction is a maladaptive behavior characterized by compulsive and uncontrolled self-administration of a substance (drug). Years of research indicate that addictive behavior is the result of complex interactions between the drug, the user, and the environment in which the drug is used; therefore, addiction cannot simply be attributed to the neurobiological actions of a drug. However, despite the obvious complexity of addictive behavior, animal models have both advanced understanding of addiction and contributed importantly to the development of medications to treat this disease. We briefly review recent animal models used to study drug addiction and the contribution of data generated by these animal models for the clinical treatment of addictive disorders.
C1 [Wu, Peter H.; Schulz, Kalynn M.] Univ Colorado, Dept Psychiat, Aurora, CO 80045 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus
RP Wu, PH (通讯作者)，Univ Colorado, Dept Psychiat, Anschutz Med Campus,Res Complex 1 N,Mail Stop 834, Aurora, CO 80045 USA.
EM peter.wu@ucdenver.edu
RI Schulz, Kalynn M/O-6740-2018
OI Schulz, Kalynn M/0000-0001-5001-3721
FU National Institutes of Health National Institute on Alcohol Abuse and
   Alcoholism (NIH-NIAAA) [AA018328]; Veterans Administration Career
   Development Award; Developmental Psychobiology Research Group at the
   University of Colorado Anschutz Medical Campus
FX This work is supported in part by National Institutes of Health National
   Institute on Alcohol Abuse and Alcoholism (NIH-NIAAA) grant AA018328
   (Wu), a Veterans Administration Career Development Award (Schulz), and
   the Developmental Psychobiology Research Group (Schulz) at the
   University of Colorado Anschutz Medical Campus. We thank Dr. Karen
   Stevens, Dr. Kristin Andrud, and April Mattson for their helpful
   comments on this manuscript.
CR Addolorato G, 2009, EXPERT OPIN INV DRUG, V18, P675, DOI [10.1517/13543780902905855 , 10.1517/13543780902905855]
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Ahmed SH, 2000, NEUROPSYCHOPHARMACOL, V22, P413, DOI 10.1016/S0893-133X(99)00133-5
   Anton RF, 2008, NEW ENGL J MED, V359, P715, DOI 10.1056/NEJMct0801733
   Beguin C, 2008, J PHARMACOL EXP THER, V324, P188, DOI 10.1124/jpet.107.129023
   Bell RL, 2006, ADDICT BIOL, V11, P270, DOI 10.1111/j.1369-1600.2005.00029.x
   Bhatia KS, 2011, BEHAV BRAIN RES, V223, P227, DOI 10.1016/j.bbr.2011.04.045
   Bird M K, 2009, Curr Mol Pharmacol, V2, P83
   Boehm SL, 2006, ADV PHARMACOL, V54, P171, DOI 10.1016/S1054-3589(06)54008-6
   BOZARTH MA, 1980, PHARMACOL BIOCHEM BE, V13, P245, DOI 10.1016/S0091-3057(80)80037-2
   Brodie MS, 1999, ALCOHOL CLIN EXP RES, V23, P1848, DOI 10.1111/j.1530-0277.1999.tb04082.x
   BROEKKAMP CLE, 1975, PSYCHOPHARMACOLOGIA, V42, P179, DOI 10.1007/BF00429550
   Brown TE, 2008, LEARN MEMORY, V15, P857, DOI 10.1101/lm.1152808
   Budygin EA, 2004, P NATL ACAD SCI USA, V101, P7781, DOI 10.1073/pnas.0401418101
   Carlezon WA, 2006, J PHARMACOL EXP THER, V316, P440, DOI 10.1124/jpet.105.092304
   Changeux JP, 2010, NAT REV NEUROSCI, V11, P389, DOI 10.1038/nrn2849
   Chefer VI, 2005, J NEUROSCI, V25, P5029, DOI 10.1523/JNEUROSCI.0854-05.2005
   Chen R, 2006, P NATL ACAD SCI USA, V103, P9333, DOI 10.1073/pnas.0600905103
   Ciccocioppo R, 1998, PHARMACOL BIOCHEM BE, V61, P459, DOI 10.1016/S0091-3057(98)00090-2
   Ciccocioppo R, 2006, ADDICT BIOL, V11, P339, DOI 10.1111/j.1369-1600.2006.00032.x
   COLLE LM, 1988, BRAIN RES, V459, P361, DOI 10.1016/0006-8993(88)90653-1
   Colombo G, 1997, ALCOHOL ALCOHOLISM, V32, P443
   CORBETT D, 1980, BRAIN RES, V185, P1, DOI 10.1016/0006-8993(80)90666-6
   CRABBE JC, 1990, ANN MED, V22, P259, DOI 10.3109/07853899009148937
   Crabbe JC, 2011, ANN NY ACAD SCI, V1216, P24, DOI 10.1111/j.1749-6632.2010.05895.x
   DEVINE DP, 1994, J NEUROSCI, V14, P1978
   DEVINE DP, 1993, J PHARMACOL EXP THER, V266, P1236
   Dhonnchadha BAN, 2011, PHARMACOL BIOCHEM BE, V99, P229, DOI 10.1016/j.pbb.2011.01.018
   Donovan DM, 1999, MOL BRAIN RES, V73, P37, DOI 10.1016/S0169-328X(99)00235-1
   Doremus TL, 2005, ALCOHOL CLIN EXP RES, V29, P1796, DOI 10.1097/01.alc.0000183007.65998.aa
   Enoch MA, 2011, PSYCHOPHARMACOLOGY, V214, P17, DOI 10.1007/s00213-010-1916-6
   Erwin VG, 1996, J PHARMACOL EXP THER, V279, P1310
   FALK JL, 1972, SCIENCE, V177, P811, DOI 10.1126/science.177.4051.811
   Filip M, 2010, ADDICT BIOL, V15, P227, DOI 10.1111/j.1369-1600.2010.00214.x
   Fiore MC, 2008, JAMA-J AM MED ASSOC, V299, P2083, DOI 10.1001/jama.299.17.2083
   Garbutt JC, 2010, CURR PHARM DESIGN, V16, P2091
   Gilpin NW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031466
   Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0
   Goldman D, 2005, NAT REV GENET, V6, P521, DOI 10.1038/nrg1635
   Goldstein D B, 1977, Adv Exp Med Biol, V85B, P539
   GOSSOP M, 1989, BRIT J PSYCHIAT, V154, P360, DOI 10.1192/bjp.154.3.360
   GOSSOP M, 1988, DRUG ALCOHOL DEPEN, V21, P253, DOI 10.1016/0376-8716(88)90078-6
   Gowing L, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002025.pub4
   Gudelsky GA, 2008, PHARMACOL BIOCHEM BE, V90, P198, DOI 10.1016/j.pbb.2007.10.003
   Haile CN, 2008, AM J DRUG ALCOHOL AB, V34, P355, DOI 10.1080/00952990802122564
   Hasin D, 2006, ADDICTION, V101, P59, DOI 10.1111/j.1360-0443.2006.01584.x
   Hernandez PJ, 2005, NEURON, V47, P772, DOI 10.1016/j.neuron.2005.09.001
   Hingson RW, 2006, ARCH PEDIAT ADOL MED, V160, P739, DOI 10.1001/archpedi.160.7.739
   Hirose N, 2005, NEUROSCIENCE, V135, P213, DOI 10.1016/j.neuroscience.2005.03.065
   Hnasko TS, 2007, J NEUROSCI, V27, P12484, DOI 10.1523/JNEUROSCI.3133-07.2007
   Huddleston HG, 2008, FERTIL STERIL, V90, P1259, DOI 10.1016/j.fertnstert.2007.07.1383
   Hutcheson DM, 2001, EUR J NEUROSCI, V13, P153, DOI 10.1046/j.1460-9568.2001.01363.x
   JOHNSON SW, 1992, J NEUROSCI, V12, P483
   JOSSELYN SA, 1993, PHARMACOL BIOCHEM BE, V46, P543, DOI 10.1016/0091-3057(93)90542-2
   Kalivas PW, 2011, MOL PSYCHIATR, V16, P974, DOI 10.1038/mp.2011.46
   Kelley AE, 2004, NEURON, V44, P161, DOI 10.1016/j.neuron.2004.09.016
   KIIANMAA K, 1991, ALCOHOL ALCOHOLISM, P115
   Klink R, 2001, J NEUROSCI, V21, P1452, DOI 10.1523/JNEUROSCI.21-05-01452.2001
   KNAPP CM, 1994, PHARMACOL BIOCHEM BE, V49, P901, DOI 10.1016/0091-3057(94)90241-0
   Land BB, 2008, J NEUROSCI, V28, P407, DOI 10.1523/JNEUROSCI.4458-07.2008
   Lee JLC, 2006, J NEUROSCI, V26, P5881, DOI 10.1523/JNEUROSCI.0323-06.2006
   Li T K, 1987, Alcohol Alcohol Suppl, V1, P91
   Lobmaier P, 2010, EUR J CLIN PHARMACOL, V66, P537, DOI 10.1007/s00228-010-0793-6
   Loi B, 2010, ALCOHOL CLIN EXP RES, V34, P2147, DOI 10.1111/j.1530-0277.2010.01311.x
   Lynch WJ, 2010, COMPARATIVE MED, V60, P177
   Maldonado-Devincci AM, 2010, PHARMACOL BIOCHEM BE, V96, P476, DOI 10.1016/j.pbb.2010.07.008
   Mann K, 2008, ALCOHOL CLIN EXP RES, V32, P1105, DOI 10.1111/j.1530-0277.2008.00690.x
   McBride WJ, 1998, CRIT REV NEUROBIOL, V12, P339, DOI 10.1615/CritRevNeurobiol.v12.i4.40
   MCCLEARN GE, 1972, ANN NY ACAD SCI, V197, P26, DOI 10.1111/j.1749-6632.1972.tb28114.x
   Metten P, 2011, PHARMACOL BIOCHEM BE, V98, P279, DOI 10.1016/j.pbb.2011.01.003
   Mihalek RM, 2001, ALCOHOL CLIN EXP RES, V25, P1708, DOI 10.1111/j.1530-0277.2001.tb02179.x
   Miller CA, 2005, NEURON, V47, P873, DOI 10.1016/j.neuron.2005.08.006
   Milton AL, 2012, PSYCHOPHARMACOLOGY, V219, P751, DOI 10.1007/s00213-011-2399-9
   Milton AL, 2010, EUR J NEUROSCI, V31, P2308, DOI 10.1111/j.1460-9568.2010.07249.x
   Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189
   Montoya ID, 2002, AM J DRUG ALCOHOL AB, V28, P189, DOI 10.1081/ADA-120001288
   Moussawi K, 2010, EUR J PHARMACOL, V639, P115, DOI 10.1016/j.ejphar.2010.01.030
   MUCHA RF, 1982, BRAIN RES, V243, P91, DOI 10.1016/0006-8993(82)91123-4
   MYERS RD, 1968, SCIENCE, V160, P1469, DOI 10.1126/science.160.3835.1469
   Newton PM, 2007, BEHAV NEUROSCI, V121, P439, DOI 10.1037/0735-7044.121.2.439
   NIAAA Newsletter, 2004, NIAAA NEWSLETTER
   O'Brien C, 2011, ADDICTION, V106, P866, DOI 10.1111/j.1360-0443.2010.03144.x
   O'Brien CP, 2011, AM J ADDICTION, V20, P106, DOI 10.1111/j.1521-0391.2010.00107.x
   OLDS J, 1954, J COMP PHYSIOL PSYCH, V47, P419, DOI 10.1037/h0058775
   Olive MF, 2012, PHARMACOL BIOCHEM BE, V100, P801, DOI 10.1016/j.pbb.2011.04.015
   Olmstead MC, 1997, BEHAV NEUROSCI, V111, P1324, DOI 10.1037/0735-7044.111.6.1324
   Peng XQ, 2010, NEUROPSYCHOPHARMACOL, V35, P2564, DOI 10.1038/npp.2010.133
   PENN PE, 1978, PHARMACOL BIOCHEM BE, V8, P475, DOI 10.1016/0091-3057(78)90087-4
   PHILLIPS AG, 1980, PHARMACOL BIOCHEM BE, V12, P965, DOI 10.1016/0091-3057(80)90460-8
   Polosa R, 2011, TRENDS PHARMACOL SCI, V32, P281, DOI 10.1016/j.tips.2010.12.008
   Pons S, 2008, J NEUROSCI, V28, P12318, DOI 10.1523/JNEUROSCI.3918-08.2008
   Rhodes JS, 2005, PHYSIOL BEHAV, V84, P53, DOI 10.1016/j.physbeh.2004.10.007
   Ripley TL, 2011, BRIT J PHARMACOL, V164, P1335, DOI 10.1111/j.1476-5381.2011.01406.x
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Rocha BA, 1998, NAT NEUROSCI, V1, P132, DOI 10.1038/381
   Rosner S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001867.pub3
   Sager JJ, 2011, BIOCHEMISTRY-US, V50, P7295, DOI 10.1021/bi200405c
   Schenk S, 2011, BRIT J PHARMACOL, V162, P1770, DOI 10.1111/j.1476-5381.2010.01193.x
   Schenk S, 2011, NEUROSCI BIOBEHAV R, V35, P1203, DOI 10.1016/j.neubiorev.2010.12.010
   Schildein S, 1998, BRAIN RES, V790, P185, DOI 10.1016/S0006-8993(98)00062-6
   Schultz W, 2010, BEHAV BRAIN FUNCT, V6, DOI 10.1186/1744-9081-6-24
   Seger D, 2010, CLIN TOXICOL, V48, P695, DOI 10.3109/15563650.2010.516263
   SEIDEN LS, 1993, ANNU REV PHARMACOL, V33, P639, DOI 10.1146/annurev.pharmtox.33.1.639
   SINCLAIR JD, 1989, EXPERIENTIA, V45, P798, DOI 10.1007/BF01954055
   Somaini Lorenzo, 2011, Recent Pat CNS Drug Discov, V6, P146
   Song R, 2012, ADDICT BIOL, V17, P259, DOI 10.1111/j.1369-1600.2011.00317.x
   Soyka M, 2010, EXPERT OPIN INV DRUG, V19, P1451, DOI 10.1517/13543784.2010.522990
   Steffensen SC, 2011, SYNAPSE, V65, P695, DOI 10.1002/syn.20885
   Stephens DN, 2005, EUR J PHARMACOL, V526, P240, DOI 10.1016/j.ejphar.2005.09.031
   STEWART J, 1984, PSYCHOL REV, V91, P251, DOI 10.1037/0033-295X.91.2.251
   STEWART RB, 1993, ALCOHOL, V10, P1, DOI 10.1016/0741-8329(93)90046-Q
   Stewart RB, 1996, PHARMACOL BIOCHEM BE, V53, P487, DOI 10.1016/0091-3057(95)02102-7
   STRANG J, 1990, ADDICT BEHAV, V15, P541, DOI 10.1016/0306-4603(90)90054-2
   Strong MN, 2010, HORM BEHAV, V58, P82, DOI 10.1016/j.yhbeh.2009.10.008
   Sulzer D, 2005, PROG NEUROBIOL, V75, P406, DOI 10.1016/j.pneurobio.2005.04.003
   Taly A, 2009, NAT REV DRUG DISCOV, V8, P733, DOI 10.1038/nrd2927
   TAMPIER L, 1984, ALCOHOL ALCOHOLISM, V19, P203
   Taylor JR, 2009, NEUROPHARMACOLOGY, V56, P186, DOI 10.1016/j.neuropharm.2008.07.027
   Thomsen M, 2009, J PHARMACOL EXP THER, V331, P204, DOI 10.1124/jpet.109.156265
   Thomsen M, 2009, J NEUROSCI, V29, P1087, DOI 10.1523/JNEUROSCI.4037-08.2009
   Tilley MR, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-42
   TOLLIVER GA, 1991, PHARMACOL BIOCHEM BE, V38, P575, DOI 10.1016/0091-3057(91)90016-U
   Truxell EM, 2007, ALCOHOL CLIN EXP RES, V31, P755, DOI 10.1111/j.1530-0277.2007.00358.x
   USHIJIMA I, 1995, PHARMACOL BIOCHEM BE, V52, P737, DOI 10.1016/0091-3057(95)00167-U
   Veilleux JC, 2010, CLIN PSYCHOL REV, V30, P155, DOI 10.1016/j.cpr.2009.10.006
   Vetter CS, 2007, ALCOHOL CLIN EXP RES, V31, P1159, DOI 10.1111/j.1530-0277.2007.00417.x
   Wallace MJ, 2007, NEUROPSYCHOPHARMACOL, V32, P127, DOI 10.1038/sj.npp.1301059
   Weiss F, 2001, NEUROPSYCHOPHARMACOL, V25, P361, DOI 10.1016/S0893-133X(01)00238-X
   Weiss F, 2010, FRONT NEUROSCI, P1
   Weissenborn R, 1996, PSYCHOPHARMACOLOGY, V126, P311
   WISE RA, 1981, BRAIN RES, V213, P190, DOI 10.1016/0006-8993(81)91260-9
   Wise RA, 1996, ANNU REV NEUROSCI, V19, P319, DOI 10.1146/annurev.ne.19.030196.001535
   Wise RA, 2008, NEUROTOX RES, V14, P169, DOI 10.1007/BF03033808
   WITHERS NW, 1995, J CLIN PSYCHOPHARM, V15, P63, DOI 10.1097/00004714-199502000-00010
   Yoshida Y, 1999, NEUROSCIENCE, V92, P1357, DOI 10.1016/S0306-4522(99)00046-9
NR 135
TC 2
Z9 2
U1 3
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1084-2020
EI 1930-6180
J9 ILAR J
JI ILAR J.
PY 2012
VL 53
IS 1
BP 4
EP 13
DI 10.1093/ilar.53.1.4
PG 10
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Veterinary Sciences
GA 084NP
UT WOS:000314546600011
PM 23520595
OA Bronze, Green Accepted
DA 2023-06-23
ER

PT J
AU Iorga, M
   Stankovszky, LZ
AF Iorga, Magdalena
   Stankovszky, Laszlo-Zoltan
TI SPIRITUALITY AND RELIGION IN THE RECOVERY OF ADDICTED PERSONS
SO EUROPEAN JOURNAL OF SCIENCE AND THEOLOGY
LA English
DT Article
DE addiction; drug; spirituality; religion; treatment
ID SUBSTANCE-ABUSE; DRUG; SMOKING
AB Addiction is a persistent, compulsive dependence on a certain behaviour (ex. gambling, eating) or substance (alcohol, drug abuse and smoking). Studies proved that addiction is seen in different ways: pleasure, disease, moral condition, neuropsychiatric disorder. The study presents a literature review on addiction, the profile of an addicted person, methods of intervention, treatments and guiding lines for health and educational policies.
C1 [Iorga, Magdalena] Tech Univ Iasi, Dept Teacher Training, Iasi, Romania.
   [Iorga, Magdalena; Stankovszky, Laszlo-Zoltan] Univ Med & Pharm Gr T Popa, Iasi 700483, Romania.
C3 Grigore T Popa University of Medicine & Pharmacy
RP Iorga, M (通讯作者)，Tech Univ Iasi, Dept Teacher Training, Bd D Mangeron 71, Iasi, Romania.
EM magdaiorga@yahoo.com
RI IORGA, Magdalena/D-1125-2015; Iorga, Magda/AAS-6406-2021
OI IORGA, Magdalena/0000-0002-7074-959X; 
CR Bliss DL, 2013, ALCOHOL TREAT Q, V31, P25, DOI 10.1080/07347324.2013.746625
   Charlton JP, 2013, INFORM COMMUN SOC, V16, P1619, DOI 10.1080/1369118X.2012.735251
   Ciuhodaru T, 2013, EUR J SCI THEOL, V9, P195
   Cohen PJ, 2007, AM J BIOETHICS, V7, P21, DOI 10.1080/15265160601064090
   Fallot RD, 2001, INT REV PSYCHIATR, V13, P110, DOI 10.1080/09540260125657
   Fifield M., 2005, AM J PASTORAL COUNSE, V8, P67
   Fitchett G., 1993, ASSESSING SPIRITUAL
   Foddy B, 2006, BIOETHICS, V20, P1, DOI 10.1111/j.1467-8519.2006.00470.x
   HAWKINS JD, 1992, PSYCHOL BULL, V112, P64, DOI 10.1037/0033-2909.112.1.64
   Highet G, 2011, ETHNIC HEALTH, V16, P519, DOI 10.1080/13557858.2011.578734
   Hodgkins CC, 2004, J ADDICT DIS, V23, P55, DOI 10.1300/J069v23n03_05
   Holford N. L., 1982, DISS ABSTR INT, V43
   Hyman SE, 2007, AM J BIOETHICS, V7, P8, DOI 10.1080/15265160601063969
   Jarusiewicz B., 2000, ALCOHOLISM TREATMENT, V18, P99, DOI DOI 10.1300/J020V18N04_08
   Kleftaras G, 2012, J SPIRITUAL MENT HE, V14, P268, DOI 10.1080/19349637.2012.730469
   Koval J, 2006, AM J HEALTH EDUC, V37, P344, DOI 10.1080/19325037.2006.10598925
   Lantz J., 2007, SHORT TERM EXISTENTI
   Laudet AB, 2006, ALCOHOL TREAT Q, V24, P33, DOI 10.1300/J020v24n01_04
   LESHNER A, 2001, ISSUES SCI TECHNOLOG
   Lyter L. L., 2003, J SOCIAL WORK PRACTI, V3, P3
   MORGAN M, 1994, IRISH J PSYCHOL, V15, P179, DOI 10.1080/03033910.1994.10558002
   Morse Stephen J, 2004, Cerebrum, V6, P81
   Nicolaus M, 2012, J GROUPS ADDICT RECO, V7, P118, DOI 10.1080/1556035X.2012.705653
   Orr-Brown DE, 2007, J SOC WORK PRACT ADD, V7, P5, DOI 10.1300/J160v07n03_02
   Osman MM., 2002, J SOC WORK PRACT ADD, V2, P97, DOI [10.1300/J160v02n03_07, DOI 10.1300/J160V02N03_07]
   ROSS LE, 1994, SOCIOL SPECTRUM, V14, P65, DOI 10.1080/02732173.1994.9982052
   Russinova Z, 2009, J NERV MENT DIS, V197, P69, DOI 10.1097/NMD.0b013e31819251fe
   Sanders Jolene M, 2011, J Ethn Subst Abuse, V10, P48, DOI 10.1080/15332640.2011.547798
   Satel SL, 1999, PSYCHIAT SERV, V50, P861, DOI 10.1176/ps.50.7.861
   Stewart C., 2004, AM J PASTORAL COUNSE, V7, P71, DOI DOI 10.1300/J062V7N04_05
   Stewart C, 2007, J SOC WORK PRACT ADD, V7, P75, DOI 10.1300/J160v07n04_05
   Stewart C, 2008, J RELIG SPIRITUAL SO, V27, P385, DOI 10.1080/15426430802347313
   SULLIVAN WP, 1993, PSYCHOSOC REHABIL, V16, P125, DOI DOI 10.1037/h0095669
   Vedoy TF, 2013, ETHNIC HEALTH, V18, P190, DOI 10.1080/13557858.2012.700917
   WALDRON I, 1990, WOMEN HEALTH, V16, P23, DOI 10.1300/J013v16n03_03
   Walsh J, 2012, J SPIRITUAL MENT HE, V14, P229, DOI 10.1080/19349637.2012.730462
NR 36
TC 3
Z9 3
U1 0
U2 26
PU ACAD ORGANISATION ENVIRONMENTAL ENGINEERING & SUSTAINABLE DEV
PI IASI
PA MANGERON BLVD NO 71A, PO 10, BOX 2111, IASI, 700050, ROMANIA
SN 1841-0464
EI 1842-8517
J9 EUR J SCI THEOL
JI Eur. J. Sci. Theol.
PD AUG
PY 2013
VL 9
IS 4
BP 201
EP 210
PG 10
WC Religion
WE Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)
SC Religion
GA 178UQ
UT WOS:000321473300016
DA 2023-06-23
ER

PT J
AU Waters, RP
   Moorman, DE
   Young, AB
   Feltenstein, MW
   See, RE
AF Waters, R. Parrish
   Moorman, David E.
   Young, Amy B.
   Feltenstein, Matthew W.
   See, Ronald E.
TI Assessment of a proposed "three-criteria" cocaine addiction model for
   use in reinstatement studies with rats
SO PSYCHOPHARMACOLOGY
LA English
DT Article
DE Addiction; Cocaine; Phenotype; Punished reward; Reinstatement
ID CUE-INDUCED REINSTATEMENT; CONDITIONED PLACE PREFERENCE; DRUG-SEEKING;
   FEMALE RATS; BASOLATERAL AMYGDALA; ANIMAL-MODEL; RELAPSE; STRESS;
   YOHIMBINE; POTENTIATION
AB Relapse is a primary obstacle in the treatment of addiction disorders, and as such, understanding this phenomenon is a major effort of clinical and preclinical studies of cocaine addiction.
   A recently developed protocol uses laboratory rats to model cocaine addiction by examining three criteria of addiction-like behaviors (persistent seeking in the absence of drug, high motivation for drug, and resistance to punishment during drug seeking) to detect subjects that possess an addiction phenotype. We closely followed this protocol in order to detect rats possessing this addiction phenotype, with the goal of utilizing this model in future studies investigating potential therapies for relapse in human cocaine addicts.
   The majority of the rats used in this study exhibited multiple characteristics thought to be associated with addiction-like behavior in rats, including robust reinstatement to multiple stimuli and high motivation to obtain cocaine. However, no rats displayed the complete addiction phenotype as previously described, due to a complete lack of addiction-like behavior in all subjects on two of the three addiction criteria (drug seeking in the absence of drug and resistance to punishment).
   Our data highlight the independence of behavioral aspects of a rat addiction-like phenotype and suggest that some of these behavioral criteria may be altogether absent in some rat populations. Furthermore, our results suggest a closer review and analysis of some parameters used in this protocol and its global utility.
C1 [Waters, R. Parrish] Charite, NeuroCure Cluster Excellence, D-10117 Berlin, Germany.
   [Moorman, David E.; Young, Amy B.; See, Ronald E.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
   [Feltenstein, Matthew W.] Noldus Informat Technol Inc, Leesburg, VA 20176 USA.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Medical University of South Carolina
RP Waters, RP (通讯作者)，Charite, NeuroCure Cluster Excellence, Charite Pl 1, D-10117 Berlin, Germany.
EM robert-parrish.waters@charite.de
OI Moorman, David/0000-0002-5755-0789
FU National Institute on Drug Abuse [DA10462, DA015369]; NIH [C06 RR015455]
FX This research was supported by National Institute on Drug Abuse grants
   DA10462 and DA015369 and NIH grant C06 RR015455. The authors have no
   conflict of interest to declare. We thank our technicians, especially
   Shannon Ghee and Clifford Chan for assistance with conducting these
   studies, and to Rachel Smith for help with data analysis.
CR Ahmed SH, 2012, NEUROSCIENCE, V211, P107, DOI 10.1016/j.neuroscience.2011.08.014
   American Psychiatric Association (APA), 2000, DIAGN STAT MAN MENT, Vfourth
   Anker JJ, 2010, PSYCHOPHARMACOLOGY, V208, P211, DOI 10.1007/s00213-009-1721-2
   Baker DA, 1998, SYNAPSE, V30, P181, DOI 10.1002/(SICI)1098-2396(199810)30:2<181::AID-SYN8>3.3.CO;2-N
   Banna KM, 2010, BEHAV BRAIN RES, V208, P144, DOI 10.1016/j.bbr.2009.11.030
   Belin D, 2012, COLD SPRING HARBOR P, V2, P1, DOI DOI 10.1101/CSHPERSPECTA011940
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   Belin D, 2011, NEUROPSYCHOPHARMACOL, V36, P569, DOI 10.1038/npp.2010.188
   Belin D, 2009, BIOL PSYCHIAT, V65, P863, DOI 10.1016/j.biopsych.2008.05.031
   Bongiovanni M, 2008, PHARMACOL BIOCHEM BE, V89, P227, DOI 10.1016/j.pbb.2007.12.019
   Boyson CO, 2011, PSYCHOPHARMACOLOGY, V218, P257, DOI 10.1007/s00213-011-2266-8
   Brimijoin S, 2011, CNS NEUROL DISORD-DR, V10, P880, DOI 10.2174/187152711799219398
   Buffalari DM, 2012, PHYSIOL BEHAV, V105, P209, DOI 10.1016/j.physbeh.2011.08.020
   Buffalari DM, 2011, PSYCHOPHARMACOLOGY, V213, P19, DOI 10.1007/s00213-010-2008-3
   Burke AR, 2013, PSYCHOPHARM IN PRESS
   Cason AM, 2010, PHYSIOL BEHAV, V100, P419, DOI 10.1016/j.physbeh.2010.03.009
   Comer SD, 1996, PSYCHOPHARMACOLOGY, V125, P355, DOI 10.1007/BF02246018
   Crombag HS, 2008, PHILOS T R SOC B, V363, P3233, DOI 10.1098/rstb.2008.0090
   Dackis CA, 2001, J SUBST ABUSE TREAT, V21, P111, DOI 10.1016/S0740-5472(01)00192-1
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Feltenstein MW, 2007, BIOL PSYCHIAT, V61, P582, DOI 10.1016/j.biopsych.2006.04.010
   Feltenstein MW, 2006, BEHAV BRAIN RES, V174, P1, DOI 10.1016/j.bbr.2006.06.039
   Feltenstein MW, 2012, DRUG ALCOHOL DEPEN, V121, P240, DOI 10.1016/j.drugalcdep.2011.09.001
   Feltenstein MW, 2013, COLD SPRING HARBOR P, V3, P1
   Goeders NE, 2003, EUR NEUROPSYCHOPHARM, V13, P435, DOI 10.1016/j.euroneuro.2003.08.004
   Kalivas PW, 2011, MOL PSYCHIATR, V16, P974, DOI 10.1038/mp.2011.46
   Kasanetz F, 2013, MOL PSYCHIATR, V18, P729, DOI 10.1038/mp.2012.59
   Kasanetz F, 2010, SCIENCE, V328, P1709, DOI 10.1126/science.1187801
   Kippin TE, 2005, PSYCHOPHARMACOLOGY, V182, P245, DOI 10.1007/s00213-005-0071-y
   Kippin TE, 2006, PSYCHOPHARMACOLOGY, V187, P60, DOI 10.1007/s00213-006-0386-3
   McGinty JF, 2010, BRAIN RES, V1314, P183, DOI 10.1016/j.brainres.2009.08.078
   National Research Council (US) Institute for Laboratory Animal Research, 1996, GUIDE CARE USE LAB A
   O'Brien C P, 1992, Recent Dev Alcohol, V10, P303
   Parker LA, 2006, PSYCHOPHARMACOLOGY, V187, P133, DOI 10.1007/s00213-006-0422-3
   Pelloux Y, 2007, PSYCHOPHARMACOLOGY, V194, P127, DOI 10.1007/s00213-007-0805-0
   Peters J, 2008, PSYCHOPHARMACOLOGY, V197, P319, DOI 10.1007/s00213-007-1034-2
   Piazza PV, 2013, PSYCHOPHARMACOLOGY, V229, P387, DOI 10.1007/s00213-013-3224-4
   Reichel CM, 2012, INT J NEUROPSYCHOPH, V15, P919, DOI 10.1017/S1461145711000988
   Roberts DCS, 2007, PROG NEURO-PSYCHOPH, V31, P1614, DOI 10.1016/j.pnpbp.2007.08.028
   See RE, 2011, AM J TRANSL RES, V3, P81
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   Shaham Y, 2005, NAT NEUROSCI, V8, P1437, DOI 10.1038/nn1105-1437
   Sinha R, 2001, PSYCHOPHARMACOLOGY, V158, P343, DOI 10.1007/s002130100917
   Somaini Lorenzo, 2011, Recent Pat CNS Drug Discov, V6, P146
   Sun WL, 2014, ADDICT BIOL, V19, P77, DOI 10.1111/adb.12043
   TAYLOR WA, 1990, WESTERN J MED, V152, P573
   Theberge FRM, 2010, LEARN MEMORY, V17, P444, DOI 10.1101/lm.1757410
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   WARNER EA, 1995, POSTGRAD MED, V98, P173, DOI 10.1080/00325481.1995.11946036
   WASHTON AM, 1990, J PSYCHOACTIVE DRUGS, V22, P135, DOI 10.1080/02791072.1990.10472539
   Wee S, 2007, J PHARMACOL EXP THER, V320, P1134, DOI 10.1124/jpet.106.113340
   Yahyavi-Firouz-Abadi N, 2009, PHARMACOL THERAPEUT, V124, P235, DOI 10.1016/j.pharmthera.2009.06.014
   Zheng D, 2012, PHARMACOL BIOCHEM BE, V100, P538, DOI 10.1016/j.pbb.2011.10.021
NR 53
TC 10
Z9 10
U1 2
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0033-3158
EI 1432-2072
J9 PSYCHOPHARMACOLOGY
JI Psychopharmacology
PD AUG
PY 2014
VL 231
IS 16
BP 3197
EP 3205
DI 10.1007/s00213-014-3497-2
PG 9
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA AM5MP
UT WOS:000339904200012
PM 24615055
DA 2023-06-23
ER

PT J
AU Rataemane, S
AF Rataemane, S.
TI Biological basis of addiction (alcohol and drug addiction)
SO SOUTH AFRICAN JOURNAL OF PSYCHIATRY
LA English
DT Meeting Abstract
C1 [Rataemane, S.] Univ Limpopo, Med Univ South Africa, Turfloop, South Africa.
C3 Sefako Makgatho Health Sciences University; University of Limpopo
EM srataema@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SA MEDICAL ASSOC HEALTH & MEDICAL PUBL GROUP
PI CLAREMONT
PA 21 DREYER ST, 4TH FLOOR, SANCLARE BLDG, CLAREMONT, 7700, SOUTH AFRICA
SN 1608-9685
J9 SAJP-S AFR J PSYCHI
JI SAJP
PD AUG
PY 2013
VL 19
IS 3
BP 105
EP 106
PG 2
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA 228ZO
UT WOS:000325231800052
DA 2023-06-23
ER

PT J
AU de Jong, JW
   Vanderschuren, LJMJ
   Adan, RAH
AF de Jong, Johannes W.
   Vanderschuren, Louk J. M. J.
   Adan, Roger A. H.
TI Towards an Animal Model of Food Addiction
SO OBESITY FACTS
LA English
DT Review
DE Animal models; Food; Motivation; Psychiatric aspects; Obesity; Addiction
ID SUBSTANCE USE DISORDERS; EXCESSIVE SUGAR INTAKE; BINGE-EATING DISORDER;
   GENETICALLY SELECTED RATS; IMPULSIVITY PREDICTS; DRUG-ADDICTION;
   PALATABLE FOOD; INCREASED MOTIVATION; COCAINE WITHDRAWAL; PREFRONTAL
   CORTEX
AB The dramatically increasing prevalence of obesity, associated with potentially life-threatening health problems, including cardiovascular diseases and type II diabetes, poses an enormous public health problem. It has been proposed that the obesity epidemic can be explained by the concept of 'food addiction'. In this review we focus on possible similarities between binge eating disorder (BED), which is highly prevalent in the obese population, and drug addiction. Indeed, both behavioral and neural similarities between addiction and BED have been demonstrated. Behavioral similarities are reflected in the overlap in DSM-IV criteria for drug addiction with the (suggested) criteria for BED and by food addiction-like behavior in animals after prolonged intermittent access to palatable food. Neural similarities include the overlap in brain regions involved in food and drug craving. Decreased dopamine D2 receptor availability in the striatum has been found in animal models of binge eating, after cocaine self-administration in animals as well as in drug addiction and obesity in humans. To further explore the neurobiological basis of food addiction, it is essential to have an animal model to test the addictive potential of palatable food. A recently developed animal model for drug addiction involves three behavioral characteristics that are based on the DSM-IV criteria: i) extremely high motivation to obtain the drug, ii) difficulty in limiting drug seeking even in periods of explicit non-availability, iii) continuation of drug-seeking despite negative consequences. Indeed, it has been shown that a subgroup of rats, after prolonged cocaine self-administration, scores positive on these three criteria. If food possesses addictive properties, then food-addicted rats should also meet these criteria while searching for and consuming food. In this review we discuss evidence from literature regarding food addiction-like behavior. We also suggest future experiments that could further contribute to our understanding of behavioral and neural commonalities and differences between obesity and drug addiction. Copyright (C) 2012 S. Karger GmbH, Freiburg
C1 [de Jong, Johannes W.; Vanderschuren, Louk J. M. J.; Adan, Roger A. H.] Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Dept Neurosci & Pharmacol, NL-3584 CG Utrecht, Netherlands.
   [Vanderschuren, Louk J. M. J.] Univ Utrecht, Dept Anim Sci & Soc, Div Behav Neurosci, Fac Vet Med, Utrecht, Netherlands.
C3 Utrecht University; Utrecht University Medical Center; Utrecht
   University
RP Adan, RAH (通讯作者)，Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Dept Neurosci & Pharmacol, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.
EM r.a.h.adan@umcutrecht.nl
RI de Jong, Johannes/AAM-4842-2020; Vanderschuren, Louk/AAS-4391-2020
OI de Jong, Johannes/0000-0002-0788-9282; Vanderschuren,
   Louk/0000-0002-5379-0363
FU NeuroFAST Foundation; European Union [245009]
FX The current work has been supported and funded by the NeuroFAST
   Foundation (the integrated neurobiology of food intake, addiction and
   stress). NeuroFAST is funded by the European Union Seventh Framework
   Programme (FP7/2007-2013) under grant agreement no 245009.
CR Ahmed SH, 1997, PSYCHOPHARMACOLOGY, V132, P289, DOI 10.1007/s002130050347
   Angeles-Castellanos M, 2007, NEUROSCIENCE, V144, P344, DOI 10.1016/j.neuroscience.2006.08.064
   Association the American Psychiatric, 2000, DSM 4 TR DIAGN STAT
   Audrain-McGovern J, 2009, DRUG ALCOHOL DEPEN, V103, P99, DOI 10.1016/j.drugalcdep.2008.12.019
   Avena NM, 2008, NEUROSCI BIOBEHAV R, V32, P20, DOI 10.1016/j.neubiorev.2007.04.019
   Avena NM, 2003, NEUROSCIENCE, V122, P17, DOI 10.1016/S0306-4522(03)00502-5
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   Belin D, 2009, BIOL PSYCHIAT, V65, P863, DOI 10.1016/j.biopsych.2008.05.031
   Bello NT, 2002, NEUROREPORT, V13, P1575, DOI 10.1097/00001756-200208270-00017
   Boggiano MM, 2009, INT J OBESITY, V33, P693, DOI 10.1038/ijo.2009.57
   Bossert JM, 2005, EUR J PHARMACOL, V526, P36, DOI 10.1016/j.ejphar.2005.09.030
   Bowden-Jones H, 2005, J NEUROPSYCH CLIN N, V17, P417, DOI 10.1176/appi.neuropsych.17.3.417
   Braet C, 2007, EUR CHILD ADOLES PSY, V16, P473, DOI 10.1007/s00787-007-0623-2
   Buczek Y, 1999, PSYCHOPHARMACOLOGY, V144, P183, DOI 10.1007/s002130050992
   Cantin L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011592
   Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11
   Cifani C, 2009, PSYCHOPHARMACOLOGY, V204, P113, DOI 10.1007/s00213-008-1442-y
   COHEN E, 1984, PHYSIOL BEHAV, V32, P1041, DOI 10.1016/0031-9384(84)90300-7
   Colantuoni C, 2002, OBES RES, V10, P478, DOI 10.1038/oby.2002.66
   Colantuoni C, 2001, NEUROREPORT, V12, P3549, DOI 10.1097/00001756-200111160-00035
   Cooper Z, 2003, INT J EAT DISORDER, V34, pS89, DOI 10.1002/eat.10208
   Corsica JA, 2010, CURR OPIN GASTROEN, V26, P165, DOI 10.1097/MOG.0b013e328336528d
   Corwin RL, 2009, J NUTR, V139, P617, DOI 10.3945/jn.108.097691
   Cottone P, 2009, P NATL ACAD SCI USA, V106, P20016, DOI 10.1073/pnas.0908789106
   Dalley JW, 2007, SCIENCE, V315, P1267, DOI 10.1126/science.1137073
   Dalley JW, 2011, NEURON, V69, P680, DOI 10.1016/j.neuron.2011.01.020
   Dallman MF, 2010, TRENDS ENDOCRIN MET, V21, P159, DOI 10.1016/j.tem.2009.10.004
   Davis C, 1998, ADDICT BEHAV, V23, P463, DOI 10.1016/S0306-4603(98)00009-4
   Davis C, 2011, APPETITE, V57, P711, DOI 10.1016/j.appet.2011.08.017
   Davis C, 2009, APPETITE, V53, P1, DOI 10.1016/j.appet.2009.05.018
   Davis CA, 2009, OBESITY, V17, P1220, DOI 10.1038/oby.2009.52
   Davis L, 2008, CURR OPIN PSYCHIATR, V21, P14, DOI 10.1097/YCO.0b013e3282f32408
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Dickinson A, 2002, Q J EXP PSYCHOL-B, V55, P331, DOI 10.1080/0272499024400016
   Diergaarde L, 2008, BIOL PSYCHIAT, V63, P301, DOI 10.1016/j.biopsych.2007.07.011
   Diergaarde L, 2009, BEHAV NEUROSCI, V123, P794, DOI 10.1037/a0016504
   DREWNOWSKI A, 1995, AM J CLIN NUTR, V61, P1206, DOI 10.1093/ajcn/61.6.1206
   Duarte C, 2003, PSYCHOPHARMACOLOGY, V166, P19, DOI 10.1007/s00213-002-1310-0
   ESPOSITO RU, 1978, PHARMACOL BIOCHEM BE, V8, P437, DOI 10.1016/0091-3057(78)90082-5
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Fairburn CG, 2011, BRIT J PSYCHIAT, V198, P8, DOI 10.1192/bjp.bp.110.083881
   Filbey FM, 2009, P NATL ACAD SCI USA, V106, P13016, DOI 10.1073/pnas.0903863106
   Flegal KM, 2010, JAMA-J AM MED ASSOC, V303, P235, DOI 10.1001/jama.2009.2014
   Frodl T, 2010, J ATTEN DISORD, V14, P109, DOI 10.1177/1087054710365054
   Garavan H, 2000, AM J PSYCHIAT, V157, P1789, DOI 10.1176/appi.ajp.157.11.1789
   Gearhardt AN, 2011, ARCH GEN PSYCHIAT, V68, P808, DOI 10.1001/archgenpsychiatry.2011.32
   Gearhardt AN, 2009, APPETITE, V52, P430, DOI 10.1016/j.appet.2008.12.003
   Ghitza UE, 2006, NEUROPSYCHOPHARMACOL, V31, P2188, DOI 10.1038/sj.npp.1300964
   Hagan MM, 1997, INT J EAT DISORDER, V22, P411, DOI 10.1002/(SICI)1098-108X(199712)22:4&lt;411::AID-EAT6&gt;3.0.CO;2-P
   Hagan MM, 2003, INT J EAT DISORDER, V34, P183, DOI 10.1002/eat.10168
   Hagan MM, 2002, BEHAV MED, V28, P99, DOI 10.1080/08964280209596048
   Hagan MM, 2002, PHYSIOL BEHAV, V77, P45, DOI 10.1016/S0031-9384(02)00809-0
   Hasin D, 2002, ARCH GEN PSYCHIAT, V59, P375, DOI 10.1001/archpsyc.59.4.375
   Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140-6736(05)67483-1
   Heyne A, 2009, ADDICT BIOL, V14, P373, DOI 10.1111/j.1369-1600.2009.00175.x
   Hopf FW, 2010, ALCOHOL CLIN EXP RES, V34, P1565, DOI 10.1111/j.1530-0277.2010.01241.x
   Hudson JI, 2007, BIOL PSYCHIAT, V61, P348, DOI 10.1016/j.biopsych.2006.03.040
   Hudson JI, 2006, ARCH GEN PSYCHIAT, V63, P313, DOI 10.1001/archpsyc.63.3.313
   Jansen A, 1998, BEHAV RES THER, V36, P257, DOI 10.1016/S0005-7967(98)00055-2
   Jentsch J David, 2008, Drug Discov Today Dis Models, V5, P247
   Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483
   Johnson PM, 2010, NAT NEUROSCI, V13, P635, DOI 10.1038/nn.2519
   Kasanetz F, 2010, SCIENCE, V328, P1709, DOI 10.1126/science.1187801
   Kelley AE, 2002, PHYSIOL BEHAV, V76, P365, DOI 10.1016/S0031-9384(02)00751-5
   Kilts CD, 2001, ARCH GEN PSYCHIAT, V58, P334, DOI 10.1001/archpsyc.58.4.334
   KNAPP CM, 1994, PHARMACOL BIOCHEM BE, V49, P901, DOI 10.1016/0091-3057(94)90241-0
   Kober H, 2010, P NATL ACAD SCI USA, V107, P14811, DOI 10.1073/pnas.1007779107
   Koob GF, 2008, NEURON, V59, P11, DOI 10.1016/j.neuron.2008.06.012
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Kreek MJ, 2005, NAT NEUROSCI, V8, P1450, DOI 10.1038/nn1583
   Krishnan-Sarin S, 2007, DRUG ALCOHOL DEPEN, V88, P79, DOI 10.1016/j.drugalcdep.2006.09.006
   la Fleur SE, 2007, INT J OBESITY, V31, P1286, DOI 10.1038/sj.ijo.0803570
   la Fleur SE, 2010, INT J OBESITY, V34, P537, DOI 10.1038/ijo.2009.257
   Latagliata EC, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-15
   Lenoir M, 2008, NEUROPSYCHOPHARMACOL, V33, P2272, DOI 10.1038/sj.npp.1301602
   Lenoir M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000698
   Lenoir M, 2007, NEUROPSYCHOPHARMACOL, V32, P616, DOI 10.1038/sj.npp.1301083
   Lesscher HMB, 2010, ALCOHOL CLIN EXP RES, V34, P1219, DOI 10.1111/j.1530-0277.2010.01199.x
   LIEBLICH I, 1983, SCIENCE, V221, P871, DOI 10.1126/science.6879185
   Liu Y, 2005, PSYCHOPHARMACOLOGY, V179, P644, DOI 10.1007/s00213-004-2089-y
   MARKOU A, 1991, NEUROPSYCHOPHARMACOL, V4, P17
   MARKOU A, 1992, NEUROPSYCHOPHARMACOL, V7, P213
   McNamara R, 2010, PSYCHOPHARMACOLOGY, V212, P453, DOI 10.1007/s00213-010-1974-9
   Miles FJ, 2003, BEHAV NEUROSCI, V117, P927, DOI 10.1037/0735-7044.117.5.927
   Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167
   Mitchell SH, 1999, PSYCHOPHARMACOLOGY, V146, P455, DOI 10.1007/PL00005491
   Moeller FG, 2001, J SUBST ABUSE TREAT, V21, P193, DOI 10.1016/S0740-5472(01)00202-1
   Molander AC, 2011, PSYCHOPHARMACOLOGY, V215, P721, DOI 10.1007/s00213-011-2167-x
   Morgan D, 2006, NEUROPSYCHOPHARMACOL, V31, P121, DOI 10.1038/sj.npp.1300773
   Morgan D, 2002, NAT NEUROSCI, V5, P169, DOI 10.1038/nn798
   Nader MA, 2002, NEUROPSYCHOPHARMACOL, V27, P35, DOI 10.1016/S0893-133X(01)00427-4
   Nair SG, 2009, PROG NEUROBIOL, V89, P18, DOI 10.1016/j.pneurobio.2009.05.003
   Nederkoorn C, 2007, BEHAV RES THER, V45, P1071, DOI 10.1016/j.brat.2006.05.009
   Nederkoorn Chantal, 2006, Eat Behav, V7, P315, DOI 10.1016/j.eatbeh.2005.11.005
   Nederkoorn C, 2006, APPETITE, V47, P253, DOI 10.1016/j.appet.2006.05.008
   Nigg JT, 2006, J AM ACAD CHILD PSY, V45, P468, DOI 10.1097/01.chi.0000199028.76452.a9
   Noble EP, 2003, AM J MED GENET B, V116B, P103, DOI 10.1002/ajmg.b.10005
   Orio L, 2009, J NEUROSCI, V29, P4846, DOI 10.1523/JNEUROSCI.0563-09.2009
   Oswald KD, 2011, INT J EAT DISORDER, V44, P203, DOI 10.1002/eat.20808
   Pankevich DE, 2010, J NEUROSCI, V30, P16399, DOI 10.1523/JNEUROSCI.1955-10.2010
   Panlilio LV, 2007, ADDICTION, V102, P1863, DOI 10.1111/j.1360-0443.2007.02011.x
   Parylak SL, 2011, PHYSIOL BEHAV, V104, P149, DOI 10.1016/j.physbeh.2011.04.063
   Paterson NE, 2003, NEUROREPORT, V14, P2229, DOI 10.1097/00001756-200312020-00019
   Paulus MP, 2005, ARCH GEN PSYCHIAT, V62, P761, DOI 10.1001/archpsyc.62.7.761
   Pecina S, 2010, PHARMACOL BIOCHEM BE, V97, P34, DOI 10.1016/j.pbb.2010.05.016
   Pelchat ML, 2009, J NUTR, V139, P620, DOI 10.3945/jn.108.097816
   Pelchat ML, 2004, NEUROIMAGE, V23, P1486, DOI 10.1016/j.neuroimage.2004.08.023
   Pelchat ML, 2002, PHYSIOL BEHAV, V76, P347, DOI 10.1016/S0031-9384(02)00757-6
   Pelloux Y, 2007, PSYCHOPHARMACOLOGY, V194, P127, DOI 10.1007/s00213-007-0805-0
   Perry JL, 2008, PSYCHOPHARMACOLOGY, V200, P1, DOI 10.1007/s00213-008-1173-0
   Perry JL, 2005, PSYCHOPHARMACOLOGY, V178, P193, DOI 10.1007/s00213-004-1994-4
   Piazza PV, 2000, J NEUROSCI, V20, P4226
   PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295
   Pierce RC, 2010, NEUROSCI BIOBEHAV R, V35, P212, DOI 10.1016/j.neubiorev.2010.01.007
   Porrino LJ, 2004, NEUROSCI BIOBEHAV R, V27, P813, DOI 10.1016/j.neubiorev.2003.11.013
   Porrino LJ, 2004, J NEUROSCI, V24, P3554, DOI 10.1523/JNEUROSCI.5578-03.2004
   Poulos CX, 1995, BEHAV PHARMACOL, V6, P810
   Reboussin BA, 2006, NEUROPSYCHOPHARMACOL, V31, P2055, DOI 10.1038/sj.npp.1301037
   Richardson NR, 1996, J NEUROSCI METH, V66, P1, DOI 10.1016/0165-0270(95)00153-0
   Rolls ET, 2007, EUR J NEUROSCI, V26, P1067, DOI 10.1111/j.1460-9568.2007.05724.x
   SARNYAI Z, 1995, BRAIN RES, V675, P89, DOI 10.1016/0006-8993(95)00043-P
   Schippers MC, 2012, PSYCHOPHARMACOLOGY, V219, P443, DOI 10.1007/s00213-011-2444-8
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   Stice E, 2008, SCIENCE, V322, P449, DOI 10.1126/science.1161550
   Tossmann P, 2001, EUR ADDICT RES, V7, P2, DOI 10.1159/000050709
   Trigo JM, 2010, DRUG ALCOHOL DEPEN, V108, P183, DOI 10.1016/j.drugalcdep.2009.10.011
   Van den Eynde F, 2010, BIOL PSYCHIAT, V67, P793, DOI 10.1016/j.biopsych.2009.11.023
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Volkow ND, 1999, AM J PSYCHIAT, V156, P1440
   Volkow ND, 2005, J NEUROSCI, V25, P3932, DOI 10.1523/JNEUROSCI.0433-05.2005
   Volkow ND, 2005, NAT NEUROSCI, V8, P555, DOI 10.1038/nn1452
   Volkow ND, 2002, SYNAPSE, V46, P79, DOI 10.1002/syn.10137
   Volkow ND, 2008, PHILOS T R SOC B, V363, P3191, DOI 10.1098/rstb.2008.0107
   Volkow ND, 2008, NEUROIMAGE, V42, P1537, DOI 10.1016/j.neuroimage.2008.06.002
   Volkow ND, 2007, AM J PSYCHIAT, V164, P708, DOI 10.1176/appi.ajp.164.5.708
   Wang GJ, 2001, LANCET, V357, P354, DOI 10.1016/S0140-6736(00)03643-6
   Wee S, 2008, EUR NEUROPSYCHOPHARM, V18, P303, DOI 10.1016/j.euroneuro.2007.08.003
   WEINGARTEN HP, 1983, SCIENCE, V220, P431, DOI 10.1126/science.6836286
   Wilens TE, 1997, J NERV MENT DIS, V185, P475, DOI 10.1097/00005053-199708000-00001
   Wilens TE, 2004, PSYCHIAT CLIN N AM, V27, P283, DOI 10.1016/S0193-953X(03)00113-8
   Wilson GT, 2010, EUR EAT DISORD REV, V18, P341, DOI 10.1002/erv.1048
   Wise RA, 1996, ANNU REV NEUROSCI, V19, P319, DOI 10.1146/annurev.ne.19.030196.001535
   Wojnicki FHE, 2006, PHARMACOL BIOCHEM BE, V84, P197, DOI 10.1016/j.pbb.2006.04.015
   WOLFFGRAMM J, 1991, NEUROSCI BIOBEHAV R, V15, P515, DOI 10.1016/S0149-7634(05)80142-3
   WOLFFGRAMM J, 1995, BEHAV BRAIN RES, V70, P77, DOI 10.1016/0166-4328(95)00131-C
   Yeomans MR, 1997, PHYSIOL BEHAV, V62, P15, DOI 10.1016/S0031-9384(97)00101-7
NR 146
TC 22
Z9 22
U1 3
U2 45
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1662-4025
J9 OBESITY FACTS
JI Obes. Facts
PD APR
PY 2012
VL 5
IS 2
BP 180
EP 195
DI 10.1159/000338292
PG 16
WC Endocrinology & Metabolism; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 934IM
UT WOS:000303437800003
PM 22647301
OA Green Published, Bronze
DA 2023-06-23
ER

PT J
AU Hamilton, PJ
   Nestler, EJ
AF Hamilton, Peter J.
   Nestler, Eric J.
TI Epigenetics and addiction
SO CURRENT OPINION IN NEUROBIOLOGY
LA English
DT Article
ID NUCLEUS-ACCUMBENS; DELTA-FOSB; HISTONE ACETYLATION; DNA METHYLATION;
   GENE-REGULATION; CHROMATIN REGULATION; COCAINE REWARD; GENOME; BINDING;
   TRANSCRIPTION
AB As an individual becomes addicted to a drug of abuse, nerve cells within the brain's reward circuitry adapt at the epigenetic level during the course of repeated drug exposure. These drug-induced epigenetic adaptations mediate enduring changes in brain function which contribute to life-long, drug-related behavioral abnormalities that define addiction. Targeting these epigenetic alterations will enhance our understanding of the biological basis of addiction and might even yield more effective anti-addiction therapies. However, the complexity of the neuroepigenetic landscape makes it difficult to determine which drug-induced epigenetic changes causally contribute to the pathogenic mechanisms of drug addiction. In this review, we highlight the evidence that epigenetic modifications, specifically histone modifications, within key brain reward regions are correlated with addiction. We then discuss the emerging field of locus-specific neuroepigenetic editing, which is a promising method for determining the causal epigenetic molecular mechanisms that drive an addicted state. Such approaches will substantially increase the field's ability to establish the precise epigenetic mechanisms underlying drug addiction, and could lead to novel treatments for addictive disorders.
C1 [Hamilton, Peter J.; Nestler, Eric J.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, Nash Family Dept Neurosci, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai
RP Nestler, EJ (通讯作者)，Icahn Sch Med Mt Sinai, Friedman Brain Inst, Nash Family Dept Neurosci, New York, NY 10029 USA.
EM eric.nestler@mssm.edu
OI Hamilton, Peter/0000-0002-6819-8346
FU National Institute on Drug Abuse [K99 DA045795, R01 DA07359]
FX The preparation of this review was supported in part by funding from
   National Institute on Drug Abuse: K99 DA045795 to P.J.H and R01 DA07359
   to E.J.N.
CR Aleyasin H, 2018, J NEUROSCI, V38, P5913, DOI 10.1523/JNEUROSCI.0296-18.2018
   Allis CD, 2016, NAT REV GENET, V17, P487, DOI 10.1038/nrg.2016.59
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Barrett RM, 2008, LEARN MEMORY, V15, P460, DOI 10.1101/lm.917508
   Barrot M, 2002, P NATL ACAD SCI USA, V99, P11435, DOI 10.1073/pnas.172091899
   Black JB, 2016, CELL STEM CELL, V19, P406, DOI 10.1016/j.stem.2016.07.001
   Boch J, 2009, SCIENCE, V326, P1509, DOI 10.1126/science.1178811
   Botia B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047527
   Bowman GD, 2015, CHEM REV, V115, P2274, DOI 10.1021/cr500350x
   Cano-Rodriguez D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12284
   Carlezon WA, 1998, SCIENCE, V282, P2272, DOI 10.1126/science.282.5397.2272
   Chen LF, 2019, CELL REP, V26, P1174, DOI 10.1016/j.celrep.2019.01.032
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Cong L, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1962
   Crocker J, 2013, NAT METHODS, V10, P762, DOI [10.1038/NMETH.2543, 10.1038/nmeth.2543]
   Diana Marco, 2011, Front Psychiatry, V2, P64, DOI 10.3389/fpsyt.2011.00064
   Egervari G, 2018, NEUROSCI BIOBEHAV R, V85, P117, DOI 10.1016/j.neubiorev.2017.05.019
   Feng J, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-4-r65
   Ferguson D, 2015, J NEUROSCI, V35, P3100, DOI 10.1523/JNEUROSCI.4012-14.2015
   Ferguson D, 2013, J NEUROSCI, V33, P16088, DOI 10.1523/JNEUROSCI.1284-13.2013
   Gersbach CA, 2014, ACCOUNTS CHEM RES, V47, P2309, DOI 10.1021/ar500039w
   Gilbert LA, 2013, CELL, V154, P442, DOI 10.1016/j.cell.2013.06.044
   Groner AC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000869
   Grueter BA, 2013, P NATL ACAD SCI USA, V110, P1923, DOI 10.1073/pnas.1221742110
   Hall DB, 2002, J BIOL CHEM, V277, P46043, DOI 10.1074/jbc.M208911200
   Hamilton PJ, 2018, METHODS MOL BIOL, V1767, P113, DOI 10.1007/978-1-4939-7774-1_5
   Hamilton PJ, 2018, NEUROPSYCHOPHARMACOL, V43, P272, DOI 10.1038/npp.2017.88
   Heller EA, 2016, J NEUROSCI, V36, P4690, DOI 10.1523/JNEUROSCI.0013-16.2016
   Heller EA, 2014, NAT NEUROSCI, V17, P1720, DOI 10.1038/nn.3871
   Hilton IB, 2015, NAT BIOTECHNOL, V33, P510, DOI 10.1038/nbt.3199
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0
   Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829
   Kearns NA, 2015, NAT METHODS, V12, P401, DOI 10.1038/nmeth.3325
   Kelley AE, 2002, J NEUROSCI, V22, P3306
   Kennedy PJ, 2015, CNS NEUROL DISORD-DR, V14, P764, DOI 10.2174/1871527314666150529144804
   Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299
   Klug A, 2010, ANNU REV BIOCHEM, V79, P213, DOI 10.1146/annurev-biochem-010909-095056
   Konermann S, 2015, NATURE, V517, P583, DOI 10.1038/nature14136
   Konermann S, 2013, NATURE, V500, P472, DOI 10.1038/nature12466
   Koob G, 2007, AM J PSYCHIAT, V164, P1149, DOI 10.1176/appi.ajp.2007.05030503
   Koob GF, 2016, LANCET PSYCHIAT, V3, P760, DOI 10.1016/S2215-0366(16)00104-8
   Kumar A, 2005, NEURON, V48, P303, DOI 10.1016/j.neuron.2005.09.023
   Kwon DY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15315
   LaPlant Q, 2010, NAT NEUROSCI, V13, P1137, DOI 10.1038/nn.2619
   Lei Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16026
   Levine AA, 2005, P NATL ACAD SCI USA, V102, P19186, DOI 10.1073/pnas.0509735102
   Levine A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003062
   Li X, 2018, BIOL PSYCHIAT, V84, P213, DOI 10.1016/j.biopsych.2017.12.008
   Liao HK, 2017, CELL, V171, P1495, DOI 10.1016/j.cell.2017.10.025
   Lino CA, 2018, DRUG DELIV, V25, P1234, DOI 10.1080/10717544.2018.1474964
   Liu XS, 2018, CELL, V172, P979, DOI 10.1016/j.cell.2018.01.012
   Liu XS, 2016, CELL, V167, P233, DOI 10.1016/j.cell.2016.08.056
   Lorsch ZS, 2019, NAT NEUROSCI
   Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033
   Malvaez M, 2011, J NEUROSCI, V31, P16941, DOI 10.1523/JNEUROSCI.2747-11.2011
   Maze I, 2010, SCIENCE, V327, P213, DOI 10.1126/science.1179438
   Moscou MJ, 2009, SCIENCE, V326, P1501, DOI 10.1126/science.1178817
   Pandey SC, 2008, J NEUROSCI, V28, P3729, DOI 10.1523/JNEUROSCI.5731-07.2008
   Polstein LR, 2015, GENOME RES, V25, P1158, DOI 10.1101/gr.179044.114
   Qi LS, 2013, CELL, V152, P1173, DOI 10.1016/j.cell.2013.02.022
   Ran FA, 2015, NATURE, V520, P186, DOI 10.1038/nature14299
   Renthal W, 2008, J NEUROSCI, V28, P7344, DOI 10.1523/JNEUROSCI.1043-08.2008
   Renthal W, 2007, NEURON, V56, P517, DOI 10.1016/j.neuron.2007.09.032
   Renthal W, 2009, NEURON, V62, P335, DOI 10.1016/j.neuron.2009.03.026
   Robison AJ, 2011, NAT REV NEUROSCI, V12, P623, DOI 10.1038/nrn3111
   Rogge GA, 2013, NEUROPSYCHOPHARMACOL, V38, P94, DOI 10.1038/npp.2012.154
   Sander JD, 2014, NAT BIOTECHNOL, V32, P347, DOI 10.1038/nbt.2842
   Sase AS, 2019, BIOL PSYCHIAT, V85, P623, DOI 10.1016/j.biopsych.2018.11.022
   Savell KE, 2017, YALE J BIOL MED, V90, P567
   Schroeder FA, 2008, NEUROPSYCHOPHARMACOL, V33, P2981, DOI 10.1038/npp.2008.15
   Shen HY, 2008, NEUROSCIENCE, V157, P644, DOI 10.1016/j.neuroscience.2008.09.019
   Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000
   Snowden AW, 2002, CURR BIOL, V12, P2159, DOI 10.1016/S0960-9822(02)01391-X
   Stege JT, 2002, PLANT J, V32, P1077, DOI 10.1046/j.1365-313X.2002.01492.x
   Stepper P, 2017, NUCLEIC ACIDS RES, V45, P1703, DOI 10.1093/nar/gkw1112
   Sun HS, 2016, J NEUROSCI, V36, P3954, DOI 10.1523/JNEUROSCI.3254-15.2016
   Tanenbaum ME, 2014, CELL, V159, P635, DOI 10.1016/j.cell.2014.09.039
   Taniguchi M, 2012, NEURON, V73, P108, DOI 10.1016/j.neuron.2011.10.032
   Vojta A, 2016, NUCLEIC ACIDS RES, V44, P5615, DOI 10.1093/nar/gkw159
   Wang L, 2010, NEUROPSYCHOPHARMACOL, V35, P913, DOI 10.1038/npp.2009.193
   Yang Marty G., 2016, Yale Journal of Biology and Medicine, V89, P457
   Zachariou V, 2006, NAT NEUROSCI, V9, P205, DOI 10.1038/nn1636
   Zheng Y, 2018, NAT NEUROSCI, V21, P447, DOI 10.1038/s41593-018-0077-5
   Zhou HB, 2018, NAT NEUROSCI, V21, P440, DOI 10.1038/s41593-017-0060-6
NR 85
TC 44
Z9 45
U1 2
U2 29
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0959-4388
EI 1873-6882
J9 CURR OPIN NEUROBIOL
JI Curr. Opin. Neurobiol.
PD DEC
PY 2019
VL 59
BP 128
EP 136
DI 10.1016/j.conb.2019.05.005
PG 9
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA JW5KF
UT WOS:000503090100016
PM 31255844
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Haracz, JL
AF Haracz, John L.
TI Money Addiction as a Potential Diagnostic Category Among Behavioral
   Addictions: Imbalanced Brain Valuation and Control Networks as a
   Candidate Etiology
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
DE Behavioral addiction; Drug addiction; Neuroimaging; RDoC;
   Substance-related disorders
C1 [Haracz, John L.] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN USA.
C3 Indiana University System; Indiana University Bloomington
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2016
VL 79
IS 9
SU S
MA 768
BP 274S
EP 275S
PG 2
WC Neurosciences; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Psychiatry
GA VC2BP
UT WOS:000432440803179
DA 2023-06-23
ER

PT S
AU Ma, YY
   Cepeda, C
   Cui, CL
AF Ma, Yao-Ying
   Cepeda, Carlos
   Cui, Cai-Lian
BE Lu, XH
TI THE ROLE OF STRIATAL NMDA RECEPTORS IN DRUG ADDICTION
SO NOVEL APPROACHES TO STUDYING BASAL GANGLIA AND RELATED NEUROPSYCHIATRIC
   DISODERS
SE International Review of Neurobiology
LA English
DT Review; Book Chapter
ID SIGNAL-REGULATED KINASE; SUBUNIT MESSENGER-RNAS; VENTRAL TEGMENTAL AREA;
   RAT NUCLEUS-ACCUMBENS; GLUTAMATE RECEPTORS; MOLECULAR-BIOLOGY; TYROSINE
   KINASE; BASAL GANGLIA; NR2B SUBUNIT; BEHAVIORAL SENSITIZATION
AB The past decade has witnessed an impressive accumulation of evidence indicating that the excitatory amino acid glutamate and its receptors, in particular the N-methyl-D-aspartate (NMDA) receptor subtype, play ail important role in drug addiction. Various lines of research using animal models of drug addiction have demonstrated that drug-induced craving is accompanied by significant upregulation of NR2B subunit expression. Furthermore, selective blockade of NR2B-containing NMDA receptors in the striatum, especially in the nucleus accumbens (NAc) call inhibit drug craving and reinstatement. The purpose of this review is to examine the role of striatal NMDA receptors in drug addiction. After a brief description of glutamatergic innervation and NMDA receptor subunit distribution ill the striatum, we discuss potential mechanisms to explain the role of striatal NMDA receptors in drug addiction by elucidating signaling cascades involved in the regulation of subunit expression and redistribution, phosphorylation of receptor subunits, as well as activation of intracellular signals triggered by drug experience. Understanding the mechanisms regulating striatal NMDA receptor changes in drug addiction will provide more specific and rational targets to counteract the deleterious effects of drug addiction.
C1 [Ma, Yao-Ying] Univ Calif Los Angeles, Stefan & Shirley Hatos Ctr Neuropharmacol, Los Angeles, CA 90095 USA.
   [Cepeda, Carlos] Univ Calif Los Angeles, Mental Retardat Res Ctr, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA.
   [Cui, Cai-Lian] Peking Univ, Hlth Sci Ctr, Neurosci Res Inst, Beijing, Peoples R China.
   [Cui, Cai-Lian] Peking Univ, Hlth Sci Ctr, Dept Neurobiol, Beijing, Peoples R China.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   Peking University; Peking University
RP Ma, YY (通讯作者)，Univ Calif Los Angeles, Stefan & Shirley Hatos Ctr Neuropharmacol, Los Angeles, CA 90095 USA.
FU NCCIH NIH HHS [P01 AT-002038-01A1] Funding Source: Medline; NIDA NIH HHS
   [DA05010] Funding Source: Medline
CR AFIFI AK, 1994, J CHILD NEUROL, V9, P352, DOI 10.1177/088307389400900403
   Aguilar MA, 2009, BRAIN RES, V1288, P95, DOI 10.1016/j.brainres.2009.06.100
   Bevins RA, 2002, BEHAV BRAIN RES, V129, P41, DOI 10.1016/S0166-4328(01)00326-6
   Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251
   Bonuccelli U, 2006, NEUROLOGY, V67, pS30, DOI 10.1212/WNL.67.7_suppl_2.S30
   CEPEDA C, 1993, P NATL ACAD SCI USA, V90, P9576, DOI 10.1073/pnas.90.20.9576
   Cepeda C, 1998, J NEUROPHYSIOL, V79, P82, DOI 10.1152/jn.1998.79.1.82
   Cepeda C, 1998, DEV NEUROSCI-BASEL, V20, P1, DOI 10.1159/000017294
   Cervo L, 1996, BRAIN RES, V731, P31, DOI 10.1016/0006-8993(96)00455-6
   Chao J, 2004, ANNU REV MED, V55, P113, DOI 10.1146/annurev.med.55.091902.103730
   Chapman DE, 2003, J NEUROPHYSIOL, V89, P69, DOI 10.1152/jn.00342.2002
   Chergui K, 1999, NEUROPHARMACOLOGY, V38, P223, DOI 10.1016/S0028-3908(98)00187-7
   Comer SD, 2007, PSYCHOPHARMACOLOGY, V193, P235, DOI 10.1007/s00213-007-0775-2
   Cowan CM, 2008, J NEUROSCI, V28, P12725, DOI 10.1523/JNEUROSCI.4619-08.2008
   Crespo JA, 2002, ANN NY ACAD SCI, V965, P78
   DARLISON MG, 1992, TRENDS NEUROSCI, V15, P469, DOI 10.1016/0166-2236(92)90091-L
   De Kock MF, 2007, BEST PRACT RES-CLIN, V21, P85, DOI 10.1016/j.bpa.2006.12.006
   Dingledine R, 1999, PHARMACOL REV, V51, P7
   Dudman JT, 2003, J NEUROCHEM, V87, P922, DOI 10.1046/j.1471-4159.2003.02067.x
   Dunah AW, 2003, J NEUROCHEM, V85, P935, DOI 10.1046/j.1471-4159.2003.01744.x
   Dunah AW, 2004, MOL PHARMACOL, V65, P121, DOI 10.1124/mol.65.1.121
   Estrada-Sanchez AM, 2009, NEUROBIOL DIS, V34, P78, DOI 10.1016/j.nbd.2008.12.017
   Fan MMY, 2007, J NEUROSCI, V27, P3768, DOI 10.1523/JNEUROSCI.4356-06.2007
   Gerfen CR, 2000, TRENDS NEUROSCI, V23, pS64, DOI 10.1016/S1471-1931(00)00019-7
   GERFEN CR, 1984, NATURE, V311, P461, DOI 10.1038/311461a0
   Ghasemzadeh MB, 2009, NEUROSCIENCE, V159, P414, DOI 10.1016/j.neuroscience.2008.10.027
   Hall RA, 1997, J BIOL CHEM, V272, P4135, DOI 10.1074/jbc.272.7.4135
   Hallett PJ, 2006, J NEUROSCI, V26, P4690, DOI 10.1523/JNEUROSCI.0792-06.2006
   Hammerman C, 1998, CLIN PERINATOL, V25, P757, DOI 10.1016/S0095-5108(18)30110-6
   Harvey J, 1997, J NEUROSCI, V17, P5271
   Huang YHH, 2009, NEURON, V63, P40, DOI 10.1016/j.neuron.2009.06.007
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Kato Hideaki, 2007, Japanese Journal of Alcohol Studies & Drug Dependence, V42, P13
   Kerdsan W, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/329631
   Kim JA, 2004, P NATL ACAD SCI USA, V101, P5664, DOI 10.1073/pnas.0401373101
   Kreitzer AC, 2008, NEURON, V60, P543, DOI 10.1016/j.neuron.2008.11.005
   Kuppenbender KD, 2000, J COMP NEUROL, V419, P407, DOI 10.1002/(SICI)1096-9861(20000417)419:4<407::AID-CNE1>3.0.CO;2-I
   KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0
   Lee DK, 2008, EUR J PHARMACOL, V590, P157, DOI 10.1016/j.ejphar.2008.06.048
   Liu XY, 2006, NEURON, V52, P897, DOI 10.1016/j.neuron.2006.10.011
   Liu ZG, 2004, J COMP NEUROL, V474, P393, DOI 10.1002/cne.20136
   Loftis JM, 2002, PSYCHOPHARMACOLOGY, V164, P349, DOI 10.1007/s00213-002-1209-9
   Lu WX, 1999, EUR J NEUROSCI, V11, P3167, DOI 10.1046/j.1460-9568.1999.00736.x
   Ma YY, 2007, EXP NEUROL, V203, P309, DOI 10.1016/j.expneurol.2006.08.014
   Ma YY, 2006, EXP NEUROL, V200, P343, DOI 10.1016/j.expneurol.2006.02.117
   Marino MJ, 2002, CNS NEUROL DISORD-DR, V1, P1, DOI 10.2174/1568007023339544
   Meredith GE, 2008, BRAIN STRUCT FUNCT, V213, P17, DOI 10.1007/s00429-008-0175-3
   Michaelis EK, 1998, PROG NEUROBIOL, V54, P369, DOI 10.1016/S0301-0082(97)00055-5
   MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0
   MORI H, 1995, NEUROPHARMACOLOGY, V34, P1219, DOI 10.1016/0028-3908(95)00109-J
   Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200
   Narita M, 2000, NEUROSCIENCE, V101, P601, DOI 10.1016/S0306-4522(00)00405-X
   Nelson CL, 2009, J NEUROCHEM, V109, P35, DOI 10.1111/j.1471-4159.2009.05911.x
   Nestler EJ, 2004, TRENDS PHARMACOL SCI, V25, P210, DOI 10.1016/j.tips.2004.02.005
   Nestler EJ, 2004, NEUROPHARMACOLOGY, V47, P24, DOI 10.1016/j.neuropharm.2004.06.031
   Ozaki S, 2004, J NEUROCHEM, V88, P1389, DOI 10.1046/j.1471-4159.2003.02272.x
   Reynolds JNJ, 2002, NEURAL NETWORKS, V15, P507, DOI 10.1016/S0893-6080(02)00045-X
   Sanchez-Blazquez P, 2009, CELL SIGNAL, V21, P1444, DOI 10.1016/j.cellsig.2009.05.003
   Scheggi S, 2004, J NEUROCHEM, V90, P792, DOI 10.1111/j.1471-4159.2004.02510.x
   Scheggi S, 2002, NEUROSCIENCE, V109, P267, DOI 10.1016/S0306-4522(01)00483-3
   SCHOEPFER R, 1994, PROG NEUROBIOL, V42, P353, DOI 10.1016/0301-0082(94)90076-0
   Schumann J, 2009, J NEUROSCI, V29, P6955, DOI 10.1523/JNEUROSCI.1329-09.2009
   SESACK SR, 2009, NEUROPSYCHOPHARMACOL
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   Simoes PF, 2007, NEUROSCIENCE, V150, P433, DOI 10.1016/j.neuroscience.2007.09.044
   Smith Y, 2008, MOVEMENT DISORD, V23, pS534, DOI 10.1002/mds.22027
   Standaert DG, 1996, MOL BRAIN RES, V42, P89, DOI 10.1016/S0169-328X(96)00117-9
   Stipanovich A, 2008, NATURE, V453, P879, DOI 10.1038/nature06994
   Sun X, 2008, J NEUROSCI, V28, P4216, DOI 10.1523/JNEUROSCI.0258-08.2008
   SUZUKI T, 1995, BIOCHEM BIOPH RES CO, V216, P582, DOI 10.1006/bbrc.1995.2662
   Svenningsson P, 2004, ANNU REV PHARMACOL, V44, P269, DOI 10.1146/annurev.pharmtox.44.101802.121415
   Thomas GM, 2004, NAT REV NEUROSCI, V5, P173, DOI 10.1038/nrn1346
   Tzschentke TM, 2002, AMINO ACIDS, V23, P147, DOI 10.1007/s00726-001-0120-8
   Valjent E, 2000, J NEUROSCI, V20, P8701
   Valjent E, 2005, P NATL ACAD SCI USA, V102, P491, DOI 10.1073/pnas.0408305102
   Valjent E, 2006, P NATL ACAD SCI USA, V103, P2932, DOI 10.1073/pnas.0511030103
   Voorn P, 2004, TRENDS NEUROSCI, V27, P468, DOI 10.1016/j.tins.2004.06.006
   Wang JQ, 2006, J NEUROSCI RES, V84, P1621, DOI 10.1002/jnr.21050
   WATANABE M, 1993, J COMP NEUROL, V338, P377, DOI 10.1002/cne.903380305
   WATANABE M, 1994, J COMP NEUROL, V343, P513, DOI 10.1002/cne.903430402
   Zheng F, 1998, NAT NEUROSCI, V1, P185, DOI 10.1038/634
NR 81
TC 26
Z9 28
U1 0
U2 4
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0074-7742
BN 978-0-12-374894-2
J9 INT REV NEUROBIOL
JI Int. Rev. Neurobiol.
PY 2009
VL 89
BP 131
EP 146
DI 10.1016/S0074-7742(09)89006-5
PG 16
WC Neurosciences
WE Book Citation Index– Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA BMI36
UT WOS:000272436500007
PM 19900618
DA 2023-06-23
ER

PT J
AU Sun, JC
   Huang, LC
   Xu, H
   Zhao, ZM
AF Sun, Jingchun
   Huang, Liang-Chin
   Xu, Hua
   Zhao, Zhongming
TI Network-Assisted Prediction of Potential Drugs for Addiction
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID TEMAZEPAM; ABUSE; BUPRENORPHINE; DRONABINOL; PARADIGM; DATABASE; TARGETS
AB Drug addiction is a chronic and complex brain disease, adding much burden on the community. Though numerous efforts have been made to identify the effective treatment, it is necessary to find more novel therapeutics for this complex disease. As network pharmacology has become a promising approach for drug repurposing, we proposed to apply the approach to drug addiction, which might provide new clues for the development of effective addiction treatment drugs. We first extracted 44 addictive drugs from the NIDA and their targets from DrugBank. Then, we constructed two networks: an addictive drug-target network and an expanded addictive drug-target network by adding other drugs that have at least one common target with these addictive drugs. By performing network analyses, we found that those addictive drugs with similar actions tended to cluster together. Additionally, we predicted 94 nonaddictive drugs with potential pharmacological functions to the addictive drugs. By examining the PubMed data, 51 drugs significantly cooccurred with addictive keywords than expected. Thus, the network analyses provide a list of candidate drugs for further investigation of their potential in addiction treatment or risk.
C1 [Sun, Jingchun; Huang, Liang-Chin; Xu, Hua] Univ Texas Hlth Sci Ctr Houston, Sch Biomed Informat, Houston, TX 77030 USA.
   [Zhao, Zhongming] Vanderbilt Univ, Sch Med, Dept Psychiat, Nashville, TN 37212 USA.
   [Zhao, Zhongming] Vanderbilt Univ, Sch Med, Dept Biomed Informat, Nashville, TN 37203 USA.
   [Zhao, Zhongming] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA.
C3 University of Texas System; University of Texas Health Science Center
   Houston; Vanderbilt University; Vanderbilt University; Vanderbilt
   University
RP Zhao, ZM (通讯作者)，Vanderbilt Univ, Sch Med, Dept Psychiat, Nashville, TN 37212 USA.
EM zhongming.zhao@vanderbilt.edu
FU Brain and Behavior Research Foundation
FX The authors thank Ms. Rebecca Hiller Posey for critically reading an
   early version of this paper. This work was partially supported by The
   Brain and Behavior Research Foundation under a 2010 NARSAD Young
   Investigator Award to JS.
CR AGRAWAL A, 2012, TRANSL PSYCHIAT, V2
   Arrell DK, 2010, CLIN PHARMACOL THER, V88, P120, DOI 10.1038/clpt.2010.91
   Assenov Y, 2008, BIOINFORMATICS, V24, P282, DOI 10.1093/bioinformatics/btm554
   Atreya RV, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-S4-S1
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Boone C, 2007, NAT REV GENET, V8, P437, DOI 10.1038/nrg2085
   Calhoun SR, 1998, J PSYCHOACTIVE DRUGS, V30, P187
   Cline MS, 2007, NAT PROTOC, V2, P2366, DOI 10.1038/nprot.2007.324
   Cowley MJ, 2012, NUCLEIC ACIDS RES, V40, pD862, DOI 10.1093/nar/gkr967
   Crabbe JC, 2002, ANNU REV PSYCHOL, V53, P435, DOI 10.1146/annurev.psych.53.100901.135142
   Emig D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060618
   HAMMERSLEY R, 1990, BRIT J ADDICT, V85, P301
   Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118
   Hwang WC, 2008, CLIN PHARMACOL THER, V84, P563, DOI 10.1038/clpt.2008.129
   Knowles J, 2003, NAT REV DRUG DISCOV, V2, P63, DOI 10.1038/nrd986
   Knox C, 2011, NUCLEIC ACIDS RES, V39, pD1035, DOI 10.1093/nar/gkq1126
   Kreek MJ, 2010, J ADDICT DIS, V29, P200, DOI 10.1080/10550881003684798
   Kreek MJ, 2001, ANN NY ACAD SCI, V937, P27
   Leshner AI, 1999, JAMA-J AM MED ASSOC, V282, P1314, DOI 10.1001/jama.282.14.1314
   Levin FR, 2011, DRUG ALCOHOL DEPEN, V116, P142, DOI 10.1016/j.drugalcdep.2010.12.010
   Li CY, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-508
   Li HL, 2006, NUCLEIC ACIDS RES, V34, pW219, DOI 10.1093/nar/gkl114
   Liu TQ, 2007, NUCLEIC ACIDS RES, V35, pD198, DOI 10.1093/nar/gkl999
   Mansie D T, 1995, Aust Fam Physician, V24, P2146
   Meulenbeek PAM, 2000, J SUBST ABUSE TREAT, V19, P171, DOI 10.1016/S0740-5472(00)00116-1
   RALSTON GE, 1993, ADDICTION, V88, P423, DOI 10.1111/j.1360-0443.1993.tb00832.x
   Robison AJ, 2011, NAT REV NEUROSCI, V12, P623, DOI 10.1038/nrn3111
   SAKOL MS, 1989, BRIT J ADDICT, V84, P439
   STARK C, 1987, LANCET, V2, P802
   Sun JC, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/458989
   Sun JC, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S9-S7
   Sun JC, 2012, CHEM BIODIVERS, V9, P900, DOI 10.1002/cbdv.201100356
   Sun JC, 2009, BIOINFORMATICS, V25, P2595, DOI 10.1093/bioinformatics/btp428
   Uhl GR, 2004, NEUROPHARMACOLOGY, V47, P140, DOI 10.1016/j.neuropharm.2004.07.029
   Wang J, 2013, NUCLEIC ACIDS RES, V41, pW77, DOI 10.1093/nar/gkt439
   Wu ZK, 2013, MOL BIOSYST, V9, P1268, DOI 10.1039/c3mb25382a
   Xu JZ, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-S8-S2
   Yu HY, 2004, TRENDS GENET, V20, P227, DOI 10.1016/j.tig.2004.04.008
   Zhu F, 2012, NUCLEIC ACIDS RES, V40, pD1128, DOI 10.1093/nar/gkr797
NR 39
TC 10
Z9 9
U1 1
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
VL 2014
AR 258784
DI 10.1155/2014/258784
PG 9
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AB4CR
UT WOS:000331737300001
PM 24689033
OA Green Submitted, Green Published, gold
DA 2023-06-23
ER

PT J
AU Smith, D
AF Smith, Dana
TI Beating the odds of addiction
SO PSYCHOLOGIST
LA English
DT Book Review
ID PROTECTIVE FACTORS; DRUG-ADDICTION
C1 Univ Cambridge, Dept Psychol, Cambridge CB2 1TN, England.
C3 RLUK- Research Libraries UK; University of Cambridge
RP Smith, D (通讯作者)，Univ Cambridge, Dept Psychol, Cambridge CB2 1TN, England.
EM ds555@cam.ac.uk
CR [Anonymous], 2012, SYDNEY MORNING HERAL
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   Best D, 2005, DRUG ALCOHOL REV, V24, P483, DOI 10.1080/09595230500292920
   djo C.M., 2002, PEDIATR CLIN N AM, V49, P257
   Ersche KD, 2013, BIOL PSYCHIAT, V74, P137, DOI 10.1016/j.biopsych.2012.11.016
   Ersche KD, 2012, SCIENCE, V335, P601, DOI 10.1126/science.1214463
   Ersche KD, 2010, BIOL PSYCHIAT, V68, P770, DOI 10.1016/j.biopsych.2010.06.015
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Friedman I, 2000, J NERV MENT DIS, V188, P155, DOI 10.1097/00005053-200003000-00005
   George O, 2010, NEUROSCI BIOBEHAV R, V35, P232, DOI 10.1016/j.neubiorev.2010.05.002
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Kirby KN, 1999, J EXP PSYCHOL GEN, V128, P78, DOI 10.1037/0096-3445.128.1.78
   McCanna S., 2007, SALON
   Piko BF, 2010, ADDICT BEHAV, V35, P53, DOI 10.1016/j.addbeh.2009.08.004
   ROBINS LN, 1993, ADDICTION, V88, P1041, DOI 10.1111/j.1360-0443.1993.tb02123.x
   Shewan D, 2005, BRIT J HEALTH PSYCH, V10, P33, DOI 10.1348/135910704X14582
   SMITH D, BEATING ODDS ADDICTI
   United Nations Office on Drugs and Crime, 2012, WORLD DRUG REP 2012
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
NR 19
TC 0
Z9 0
U1 0
U2 3
PU BRITISH PSYCHOLOGICAL SOC
PI LEICESTER
PA ST ANDREWS HOUSE, 48 PRINCESS RD EAST, LEICESTER LE1 7DR, LEICS, ENGLAND
SN 0952-8229
J9 PSYCHOLOGIST
JI Psychologist
PD AUG
PY 2013
VL 26
IS 8
BP 610
EP 611
PG 2
WC Psychology, Multidisciplinary
WE Social Science Citation Index (SSCI)
SC Psychology
GA 198TN
UT WOS:000322945300037
DA 2023-06-23
ER

PT J
AU Carroll, ME
   Smethells, JR
AF Carroll, Marilyn E.
   Smethells, John R.
TI Sex Differences in Behavioral Dyscontrol: Role in Drug Addiction and
   Novel Treatments
SO FRONTIERS IN PSYCHIATRY
LA English
DT Review
DE animal models; behavioral dyscontrol; drug addiction; food addiction;
   impulsivity; sweet intake; sex differences; novel treatments
ID COCAINE-SEEKING BEHAVIOR; MENSTRUAL-CYCLE PHASE; SELF-ADMINISTERED
   COCAINE; CUE-INDUCED REINSTATEMENT; CIGARETTE-SMOKING STATUS; SUBSTANCE
   USE DISORDERS; FEMALE RATS; INTRAVENOUS COCAINE; ENVIRONMENTAL
   ENRICHMENT; PHYSICAL-ACTIVITY
AB The purpose of this review is to discuss recent findings related to sex differences in behavioral dyscontrol that lead to drug addiction, and clinical implications for humans are discussed. This review includes research conducted in animals and humans that reveals fundamental aspects of behavioral dyscontrol. The importance of sex differences in aspects of behavioral dyscontrol, such as impulsivity and compulsivity, is discussed as major determinants of drug addiction. Behavioral dyscontrol during adolescence is also an important consideration, as this is the time of onset for drug addiction. These vulnerability factors additively increase drug-abuse vulnerability, and they are integral aspects of addiction that covary and interact with sex differences. Sex differences in treatments for drug addiction are also reviewed in terms of their ability to modify the behavioral dyscontrol that underlies addictive behavior. Customized treatments to reduce behavioral dyscontrol are discussed, such as (1) using natural consequences such as non-drug rewards (e.g., exercise) to maintain abstinence, or using punishment as a consequence for drug use, (2) targeting factors that underlie behavioral dyscontrol, such as impulsivity or anxiety, by repurposing medications to relieve these underlying conditions, and (3) combining two or more novel behavioral or pharmacological treatments to produce additive reductions in drug seeking. Recent published work has indicated that factors contributing to behavioral dyscontrol are an important target for advancing our knowledge on the etiology of drug abuse, intervening with the drug addiction process and developing novel treatments.
C1 [Carroll, Marilyn E.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA.
   [Smethells, John R.] Univ Minnesota, Dept Psychiat, Program PharmacoNeuroImmunol, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities
RP Carroll, ME (通讯作者)，Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA.
EM mcarroll@umn.edu
RI Smethells, John R./AAT-5001-2021
OI Smethells, John R./0000-0002-8761-5416
FU NIDA NIH HHS [T32 DA007097, P50 DA033942, R01 DA003240, R01 DA019942,
   R01 DA002486] Funding Source: Medline
CR Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Ahmed SH, 1999, PSYCHOPHARMACOLOGY, V146, P303, DOI 10.1007/s002130051121
   AINSLIE GW, 1974, J EXP ANAL BEHAV, V21, P485, DOI 10.1901/jeab.1974.21-485
   *AM PSYCH ASS, 2013, DIAGN STAST MAN MENT
   Andrade LF, 2012, PSYCHOPHARMACOLOGY, V219, P491, DOI 10.1007/s00213-011-2508-9
   Anker JJ, 2008, BEHAV PHARMACOL, V19, P615, DOI 10.1097/FBP.0b013e32830dc0ae
   Anker JJ, 2007, EXP CLIN PSYCHOPHARM, V15, P472, DOI 10.1037/1064-1297.15.5.472
   Anker JJ, 2011, DRUG ALCOHOL DEPEN, V118, P68, DOI 10.1016/j.drugalcdep.2011.02.016
   Anker JJ, 2011, CURR TOP BEHAV NEURO, V8, P73, DOI 10.1007/7854_2010_93
   Anker JJ, 2010, NEUROSCI BIOBEHAV R, V35, P315, DOI 10.1016/j.neubiorev.2010.04.003
   Anker JJ, 2010, PSYCHOPHARMACOLOGY, V208, P211, DOI 10.1007/s00213-009-1721-2
   Anker JJ, 2009, PHARMACOL BIOCHEM BE, V93, P343, DOI 10.1016/j.pbb.2009.05.013
   [Anonymous], 2010, PREVALENCE OVERWEIGH
   [Anonymous], 2004, SURG GEN REP
   Avena N.M., 2013, ANIMAL MODELS EATING
   Avena NM, 2003, NEUROSCIENCE, V122, P17, DOI 10.1016/S0306-4522(03)00502-5
   Baarendse PJJ, 2012, PSYCHOPHARMACOLOGY, V219, P313, DOI 10.1007/s00213-011-2576-x
   Bardo MT, 2015, DRUG ALCOHOL DEPEN, V153, P3, DOI 10.1016/j.drugalcdep.2015.05.037
   Bardo MT, 2001, PSYCHOPHARMACOLOGY, V155, P278
   Baumeister SE, 2005, EUR ADDICT RES, V11, P92, DOI 10.1159/000083038
   Bayless DW, 2012, BEHAV BRAIN RES, V235, P48, DOI 10.1016/j.bbr.2012.07.028
   Beck RC, 2009, EXP CLIN PSYCHOPHARM, V17, P345, DOI 10.1037/a0017078
   Becker JB, 2008, FRONT NEUROENDOCRIN, V29, P36, DOI 10.1016/j.yfrne.2007.07.003
   Becker JB, 2012, BIOL SEX DIFFER, V3, DOI 10.1186/2042-6410-3-14
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   BELL SM, 1994, ALCOHOL, V11, P141, DOI 10.1016/0741-8329(94)90055-8
   Benegal V, 2013, ASIAN J PSYCHIATR, V6, P544, DOI 10.1016/j.ajp.2013.07.007
   Berger SS, 2013, ANIMAL MODELS EATING, P3
   Bizot JC, 2011, NEUROSCI LETT, V489, P20, DOI 10.1016/j.neulet.2010.11.058
   Bjork JM, 2004, ALCOHOL, V34, P133, DOI 10.1016/j.alcohol.2004.06.012
   BLANCHARD BA, 1993, ALCOHOL CLIN EXP RES, V17, P968, DOI 10.1111/j.1530-0277.1993.tb05650.x
   Bossert JM, 2013, PSYCHOPHARMACOLOGY, V229, P453, DOI 10.1007/s00213-013-3120-y
   Brasser SM, 2002, BEHAV NEUROSCI, V116, P305, DOI 10.1037//0735-7044.116.2.305
   Broadwater M, 2011, ALCOHOL CLIN EXP RES, V35, P1392, DOI 10.1111/j.1530-0277.2011.01474.x
   Broos N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036781
   Broos N, 2012, NEUROPSYCHOPHARMACOL, V37, P1377, DOI 10.1038/npp.2011.323
   Brown HE, 2013, SPORTS MED, V43, P195, DOI 10.1007/s40279-012-0015-8
   Brown SA, 2004, ANN NY ACAD SCI, V1021, P234, DOI 10.1196/annals.1308.028
   Burton CL, 2012, BEHAV BRAIN RES, V230, P21, DOI 10.1016/j.bbr.2012.01.046
   Bymaster FP, 2002, NEUROPSYCHOPHARMACOL, V27, P699, DOI 10.1016/S0893-133X(02)00346-9
   Campbell UC, 2000, PSYCHOPHARMACOLOGY, V147, P418, DOI 10.1007/s002130050011
   Campbell UC, 2002, DRUG ALCOHOL DEPEN, V66, P61, DOI 10.1016/S0376-8716(01)00185-5
   Carroll M. E., 2001, ANIMAL RES HUMAN PSY, P139, DOI [10.1037/10441-010, DOI 10.1037/10441-000]
   Carroll M. E., 2013, ANIMAL MODELS EATING, P201
   Carroll M. E., 2010, IMPULSIVITY BEHAV NE, P243, DOI DOI 10.1037/12069-009
   Carroll ME, 2008, BEHAV PHARMACOL, V19, P435, DOI 10.1097/FBP.0b013e32830c3632
   Carroll ME, 2007, PHARMACOL BIOCHEM BE, V88, P94, DOI 10.1016/j.pbb.2007.07.010
   Carroll ME, 2010, HORM BEHAV, V58, P44, DOI 10.1016/j.yhbeh.2009.10.001
   Carroll ME, 2009, PSYCHOPHARMACOLOGY, V207, P85, DOI 10.1007/s00213-009-1636-y
   Carroll ME, 2009, DRUG ALCOHOL DEPEN, V104, pS70, DOI 10.1016/j.drugalcdep.2008.11.011
   CARROLL ME, 1979, SCIENCE, V205, P319, DOI 10.1126/science.36665
   Carroll ME, 2005, PSYCHOPHARMACOLOGY, V180, P414, DOI 10.1007/s00213-005-2182-x
   Carroll ME, 2002, PSYCHOPHARMACOLOGY, V161, P304, DOI 10.1007/s00213-002-1030-5
   Carroll ME, 2001, EXP CLIN PSYCHOPHARM, V9, P307, DOI 10.1037//1064-1297.9.3.307
   Carroll ME, 2000, PSYCHOPHARMACOLOGY, V149, P401, DOI 10.1007/s002130000389
   Carroll ME, 2016, ADDICT BIOL IN PRESS
   Carruthers MN, 2015, ANN RHEUM DIS, V74, P14, DOI 10.1136/annrheumdis-2013-204907
   Cason AM, 2013, PHYSIOL BEHAV, V112, P96, DOI 10.1016/j.physbeh.2013.02.017
   Centers for Disease Control and Prevention, 2009, PREV OB US CDC NCHS
   Chauvet C, 2012, NEUROPHARMACOLOGY, V63, P635, DOI 10.1016/j.neuropharm.2012.05.014
   Chester JA, 2003, ALCOHOL CLIN EXP RES, V27, P377, DOI 10.1097/01.ALC.0000056619.98553.50
   Claus ED, 2011, ALCOHOL CLIN EXP RES, V35, P1209, DOI 10.1111/j.1530-0277.2011.01455.x
   Clayton JA, 2014, NATURE, V509, P282, DOI 10.1038/509282a
   Colzato LS, 2010, NEUROSCIENCE, V167, P709, DOI 10.1016/j.neuroscience.2010.02.029
   Cooper ZD, 2013, HORM BEHAV, V63, P105, DOI 10.1016/j.yhbeh.2012.10.008
   Corsica JA, 2010, CURR OPIN GASTROEN, V26, P165, DOI 10.1097/MOG.0b013e328336528d
   Cosgrove KP, 2004, EXP CLIN PSYCHOPHARM, V12, P111, DOI 10.1037/1064-1297.12.2.111
   Cosgrove KP, 2003, PSYCHOPHARMACOLOGY, V170, P9, DOI 10.1007/s00213-003-1487-x
   Cosgrove KP, 2002, PHARMACOL BIOCHEM BE, V73, P663, DOI 10.1016/S0091-3057(02)00853-5
   Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011
   Crews FT, 2009, PHARMACOL BIOCHEM BE, V93, P237, DOI 10.1016/j.pbb.2009.04.018
   Crosbie J, 2013, J ABNORM CHILD PSYCH, V41, P497, DOI 10.1007/s10802-012-9693-9
   Dahan A, 2008, ANESTH ANALG, V107, P83, DOI 10.1213/ane.0b013e31816a66a4
   Dalley JW, 2007, SCIENCE, V315, P1267, DOI 10.1126/science.1137073
   Davis C, 2009, APPETITE, V53, P1, DOI 10.1016/j.appet.2009.05.018
   Davis JA, 2007, NEUROPSYCHOPHARMACOL, V32, P2011, DOI 10.1038/sj.npp.1301315
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Deroche-Gamonet V, 2014, NEUROPHARMACOLOGY, V76, P437, DOI 10.1016/j.neuropharm.2013.07.014
   DeSantis SM, 2009, DRUG ALCOHOL DEPEN, V105, P227, DOI 10.1016/j.drugalcdep.2009.07.008
   DESOR JA, 1987, PHYSIOL BEHAV, V39, P639, DOI 10.1016/0031-9384(87)90166-1
   DeSousa NJ, 2000, PSYCHOPHARMACOLOGY, V148, P52, DOI 10.1007/s002130050024
   Dess NK, 2005, ALCOHOL, V37, P9, DOI 10.1016/j.alcohol.2005.09.006
   Dess NK, 1998, ALCOHOL, V16, P275, DOI 10.1016/S0741-8329(98)00010-X
   Dess NK, 1996, ANIM LEARN BEHAV, V24, P105, DOI 10.3758/BF03198958
   Dess NK, 2000, INT J COMP PSYCHOL, V13:, P34
   DeVito EE, 2014, NEUROPSYCHOPHARMACOL, V39, P1431, DOI 10.1038/npp.2013.339
   Di Leone RJ, 2012, NAT NEUROSCI, V15, P1330, DOI 10.1038/nn.3202
   Diergaarde L, 2008, BIOL PSYCHIAT, V63, P301, DOI 10.1016/j.biopsych.2007.07.011
   Dolezal BA, 2013, J ADDICT MED, V7, P122, DOI 10.1097/ADM.0b013e318282475e
   Dolezal BA, 2014, MED SCI SPORT EXER, V46, P1057, DOI 10.1249/MSS.0000000000000201
   Dom G, 2006, ADDICTION, V101, P50, DOI 10.1111/j.1360-0443.2005.01270.x
   Doremus TL, 2005, ALCOHOL CLIN EXP RES, V29, P1796, DOI 10.1097/01.alc.0000183007.65998.aa
   Doremus TL, 2003, PHARMACOL BIOCHEM BE, V75, P411, DOI 10.1016/S0091-3057(03)00134-5
   Doremus-Fitzwater TL, 2010, PHARMACOL BIOCHEM BE, V96, P198, DOI 10.1016/j.pbb.2010.05.005
   Economidou D, 2011, BIOL PSYCHIAT, V69, P266, DOI 10.1016/j.biopsych.2010.09.040
   Economidou D, 2009, BIOL PSYCHIAT, V65, P851, DOI 10.1016/j.biopsych.2008.12.008
   Ehringer MA, 2009, ALCOHOL, V43, P443, DOI 10.1016/j.alcohol.2009.06.003
   Engelmann AJ, 2014, BRAIN STRUCT FUNCT, V219, P657, DOI 10.1007/s00429-013-0525-7
   Evans SE, 2006, EXP CLIN PSYCHOPHARM, V14, P121, DOI 10.1037/1064-1297.14.2.121
   Evans SM, 2006, NEUROPSYCHOPHARMACOL, V31, P659, DOI 10.1038/sj.npp.1300887
   Evans SM, 2002, PSYCHOPHARMACOLOGY, V159, P397, DOI 10.1007/s00213-001-0944-7
   Evans SM, 2010, HORM BEHAV, V58, P13, DOI 10.1016/j.yhbeh.2009.08.010
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Fattore L, 2009, PSYCHONEUROENDOCRI S, V34S, pS227, DOI DOI 10.1016/J.PSYNEUEN.2009.08.008
   Fattore L, 2014, FRONT NEUROENDOCRIN, V35, P272, DOI 10.1016/j.yfrne.2014.04.003
   Feltenstein MW, 2007, DRUG ALCOHOL DEPEN, V89, P183, DOI 10.1016/j.drugalcdep.2006.12.017
   Fernie G, 2010, DRUG ALCOHOL DEPEN, V112, P54, DOI 10.1016/j.drugalcdep.2010.05.011
   Field M, 2007, ADDICTION, V102, P579, DOI 10.1111/j.1360-0443.2007.01743.x
   Fields S, 2009, BEHAV PHARMACOL, V20, P455, DOI 10.1097/FBP.0b013e328330dcff
   Fox HC, 2013, PSYCHONEUROENDOCRINO, V38, P1532, DOI 10.1016/j.psyneuen.2012.12.022
   Friemel CM, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00039
   Gahtan E, 1996, PHARMACOL BIOCHEM BE, V53, P919, DOI 10.1016/0091-3057(95)02148-5
   Garber Andrea K, 2011, Curr Drug Abuse Rev, V4, P146
   Gearhardt Ashley N, 2011, Curr Drug Abuse Rev, V4, P201
   GOSNELL BA, 1995, PSYCHOPHARMACOLOGY, V117, P248, DOI 10.1007/BF02245194
   Gosnell BA, 2000, PSYCHOPHARMACOLOGY, V149, P286, DOI 10.1007/s002130000375
   Goudriaan AE, 2007, ALCOHOL CLIN EXP RES, V31, P928, DOI 10.1111/j.1530-0277.2007.00378.x
   Green TA, 2002, PSYCHOPHARMACOLOGY, V162, P373, DOI 10.1007/s00213-002-1134-y
   Greenfield SF, 2007, DRUG ALCOHOL DEPEN, V86, P1, DOI 10.1016/j.drugalcdep.2006.05.012
   Greenfield SF, 2010, ALCOHOL CLIN EXP RES, V34, P1803, DOI 10.1111/j.1530-0277.2010.01267.x
   Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134
   Gundersen C, 2013, ADV NUTR, V4, P36, DOI 10.3945/an.112.003244
   Hashimoto JG, 2008, NEUROPSYCHOPHARMACOL, V33, P1084, DOI 10.1038/sj.npp.1301494
   Hasson R, 2012, J ATTEN DISORD, V16, P190, DOI 10.1177/1087054711427398
   Hecht GS, 1999, DEV PSYCHOBIOL, V35, P136
   Heyman GM, 2006, BEHAV PHARMACOL, V17, P669, DOI 10.1097/FBP.0b013e3280116cfe
   Higgins S. T., 2008, CONTINGENCY MANAGEME
   Holley J, 2011, BRIT J CLIN PSYCHOL, V50, P84, DOI 10.1348/014466510X496220
   Holtz NA, 2015, ANIMAL MODELS BEHAV
   Holtz NA, 2015, BEHAV PHARMACOL, V26, P393, DOI 10.1097/FBP.0000000000000136
   Holtz NA, 2013, PHYSIOL BEHAV, V122, P32, DOI 10.1016/j.physbeh.2013.08.004
   Holtz NA, 2012, DRUG ALCOHOL DEPEN, V120, P233, DOI 10.1016/j.drugalcdep.2011.07.010
   Holtz NA, 2011, PHARMACOL BIOCHEM BE, V100, P275, DOI 10.1016/j.pbb.2011.08.028
   Hopf FW, 2010, ALCOHOL CLIN EXP RES, V34, P1565, DOI 10.1111/j.1530-0277.2010.01241.x
   Horn K, 2011, PEDIATRICS, V128, pE801, DOI 10.1542/peds.2010-2599
   Jackson LR, 2006, NEUROPSYCHOPHARMACOL, V31, P129, DOI 10.1038/sj.npp.1300778
   Jentsch JD, 2003, BEHAV NEUROSCI, V117, P76, DOI 10.1037/0735-7044.117.1.76
   Johnson CA, 2008, NEUROPSYCHOLOGIA, V46, P714, DOI 10.1016/j.neuropsychologia.2007.09.012
   Kerstetter KA, 2007, PSYCHOPHARMACOLOGY, V194, P403, DOI 10.1007/s00213-007-0852-6
   Kirby KN, 1996, PSYCHON B REV, V3, P100, DOI 10.3758/BF03210748
   Kirby KN, 2004, ADDICTION, V99, P461, DOI 10.1111/j.1360-0443.2003.00669.x
   Kirby KN, 2002, J ECON PSYCHOL, V23, P291, DOI 10.1016/S0167-4870(02)00078-8
   Koelch M, 2008, CURR OPIN PSYCHIATR, V21, P598, DOI 10.1097/YCO.0b013e328314b776
   Koot S, 2009, BEHAV BRAIN RES, V200, P134, DOI 10.1016/j.bbr.2009.01.006
   Kornetsky C., 2007, DRUG ALCOHOL DEPEN, V88, P96, DOI [10.1016/j.drugalcdep.2006.11.018, DOI 10.1016/J.DRUGALCDEP.2006.11.018]
   Larson EB, 2007, EXP CLIN PSYCHOPHARM, V15, P461, DOI 10.1037/1064-1297.15.5.461
   Leventhal AM, 2007, EXP CLIN PSYCHOPHARM, V15, P21, DOI 10.1037/1064-1297.15.1.21
   Levin FR, 2009, J DUAL DIAGN, V5, P41, DOI 10.1080/15504260802628767
   Linke SE, 2015, AM J DRUG ALCOHOL AB, V41, P7, DOI 10.3109/00952990.2014.976708
   Linke SE, 2013, WOMENS HEALTH, V9, P69, DOI [10.2217/whe.12.63, 10.2217/WHE.12.63]
   Liu TR, 2013, NEUROREPORT, V24, P126, DOI 10.1097/WNR.0b013e32835d846b
   Llaneza DC, 2009, PHARMACOL BIOCHEM BE, V93, P337, DOI 10.1016/j.pbb.2009.05.003
   Logue AW, 2001, PSYCHOL SCI, V12, P276, DOI 10.1111/1467-9280.00351
   Lukas SE, 1996, PSYCHOPHARMACOLOGY, V125, P346, DOI 10.1007/BF02246017
   Lussier JP, 2006, ADDICTION, V101, P192, DOI 10.1111/j.1360-0443.2006.01311.x
   Lynch WJ, 2008, PSYCHOPHARMACOLOGY, V197, P237, DOI 10.1007/s00213-007-1028-0
   Lynch WJ, 2010, BIOL PSYCHIAT, V68, P774, DOI 10.1016/j.biopsych.2010.06.022
   Lynch WJ, 2000, PSYCHOPHARMACOLOGY, V152, P132, DOI 10.1007/s002130000488
   Lynch WJ, 2002, PSYCHOPHARMACOLOGY, V164, P121, DOI 10.1007/s00213-002-1183-2
   MacKillop J, 2011, PSYCHOPHARMACOLOGY, V216, P305, DOI 10.1007/s00213-011-2229-0
   Madden G. J., 2010, IMPULSIVITY BEHAV NE
   Marchant NJ, 2013, CURR OPIN NEUROBIOL, V23, P675, DOI 10.1016/j.conb.2013.01.003
   Marcus BH, 1999, ARCH INTERN MED, V159, P1229, DOI 10.1001/archinte.159.11.1229
   Mcvoy M, 2009, PSYCHIAT CLIN N AM, V32, P111, DOI 10.1016/j.psc.2008.11.002
   Mello NK, 2007, NEUROPSYCHOPHARMACOL, V32, P1956, DOI 10.1038/sj.npp.1301314
   Mello NK, 2011, NEUROPSYCHOPHARMACOL, V36, P2187, DOI 10.1038/npp.2011.130
   Merritt PS, 2012, EXP CLIN PSYCHOPHARM, V20, P258, DOI 10.1037/a0027414
   Miller ML, 2012, DRUG ALCOHOL DEPEN, V121, P90, DOI 10.1016/j.drugalcdep.2011.08.013
   Myers CS, 2008, NEUROPSYCHOPHARMACOL, V33, P588, DOI 10.1038/sj.npp.1301425
   Naimi TS, 2003, JAMA-J AM MED ASSOC, V289, P70, DOI 10.1001/jama.289.1.70
   Nasrallah NA, 2011, P NATL ACAD SCI USA, V108, P5466, DOI 10.1073/pnas.1017732108
   Nasrallah NA, 2009, P NATL ACAD SCI USA, V106, P17600, DOI 10.1073/pnas.0906629106
   Nederkoorn C, 2009, PHARMACOL BIOCHEM BE, V93, P331, DOI 10.1016/j.pbb.2009.04.015
   NETTER P, 1994, CLIN INVESTIGATOR, V72, P512
   NEWMAN JP, 1985, J PERS SOC PSYCHOL, V48, P1316, DOI 10.1037/0022-3514.48.5.1316
   NIH, 2016, NIH GUID NO IN PRESS
   Nyberg S, 2004, PSYCHONEUROENDOCRINO, V29, P767, DOI 10.1016/S0306-4530(03)00121-5
   O'Dell LE, 2006, PSYCHOPHARMACOLOGY, V186, P612, DOI 10.1007/s00213-006-0383-6
   Olsen CM, 2011, NEUROPHARMACOLOGY, V61, P1109, DOI 10.1016/j.neuropharm.2011.03.010
   Papaleo F, 2012, P NATL ACAD SCI USA, V109, P20160, DOI 10.1073/pnas.1214397109
   Perkins Kenneth A, 2009, Handb Exp Pharmacol, P369, DOI 10.1007/978-3-540-69248-5_13
   Perry JL, 2008, PSYCHOPHARMACOLOGY, V200, P1, DOI 10.1007/s00213-008-1173-0
   Perry JL, 2008, EXP CLIN PSYCHOPHARM, V16, P165, DOI 10.1037/1064-1297.16.2.165
   Perry JL, 2007, PHARMACOL BIOCHEM BE, V86, P822, DOI 10.1016/j.pbb.2007.03.012
   Perry JL, 2007, PHYSIOL BEHAV, V91, P126, DOI 10.1016/j.physbeh.2007.02.001
   Perry JL, 2006, PSYCHOPHARMACOLOGY, V186, P235, DOI 10.1007/s00213-006-0371-x
   Perry JL, 2006, EXP CLIN PSYCHOPHARM, V14, P68, DOI 10.1037/1064-1297.14.1.68
   Perry JL, 2005, PSYCHOPHARMACOLOGY, V178, P193, DOI 10.1007/s00213-004-1994-4
   Peterson AB, 2014, PSYCHOPHARMACOLOGY, V231, P2661, DOI 10.1007/s00213-014-3437-1
   Petry NM, 2001, PSYCHOPHARMACOLOGY, V154, P243, DOI 10.1007/s002130000638
   Pogun Sakire, 2009, Handb Exp Pharmacol, P261, DOI 10.1007/978-3-540-69248-5_10
   Poulos CX, 1995, BEHAV PHARMACOL, V6, P810
   Price KL, 2010, BEHAV RES THER, V48, P860, DOI 10.1016/j.brat.2010.05.010
   Qin L, 2010, EUR J EPIDEMIOL, V25, P5, DOI 10.1007/s10654-009-9395-y
   Quinones-Jenab V, 2012, ILAR J, V53, P14, DOI 10.1093/ilar.53.1.14
   Radke AK, 2016, BEHAV PHARMACOL, V27, P133, DOI 10.1097/FBP.0000000000000182
   Radke AK, 2015, BEHAV PHARMACOL, V26, P485, DOI 10.1097/FBP.0000000000000151
   Rawson RA, 2015, DRUG ALCOHOL DEPEN, V156, P21, DOI 10.1016/j.drugalcdep.2015.08.029
   Regier PS, 2014, DRUG ALCOHOL DEPEN, V143, P58, DOI 10.1016/j.drugalcdep.2014.07.001
   Reichel CM, 2007, EXP CLIN PSYCHOPHARM, V15, P501, DOI 10.1037/1064-1297.15.5.501
   Reynolds B, 2006, PERS INDIV DIFFER, V40, P305, DOI 10.1016/j.paid.2005.03.024
   Reynolds B, 2004, BEHAV PROCESS, V65, P35, DOI 10.1016/S0376-6357(03)00109-8
   Reynolds B, 2003, BEHAV PROCESS, V64, P333, DOI 10.1016/S0376-6357(03)00168-2
   Riley AL, 2011, PHYSIOL BEHAV, V103, P69, DOI 10.1016/j.physbeh.2010.11.021
   RITZ MC, 1990, LIFE SCI, V46, P635, DOI 10.1016/0024-3205(90)90132-B
   ROBERTS DCS, 1989, PSYCHOPHARMACOLOGY, V98, P408, DOI 10.1007/BF00451696
   Robinson ESJ, 2009, BEHAV BRAIN RES, V196, P310, DOI 10.1016/j.bbr.2008.09.021
   Robinson ESJ, 2008, NEUROPSYCHOPHARMACOL, V33, P1028, DOI 10.1038/sj.npp.1301487
   Roth ME, 2004, PHARMACOL BIOCHEM BE, V78, P199, DOI 10.1016/j.pbb.2004.03.018
   Rush CR, 2011, PHARMACOL BIOCHEM BE, V100, P40, DOI 10.1016/j.pbb.2011.06.024
   Saladin ME, 2015, NICOTINE TOB RES, V17, P398, DOI 10.1093/ntr/ntu262
   Sanchez V, 2015, DRUG ALCOHOL DEPEN, V156, P193, DOI 10.1016/j.drugalcdep.2015.09.022
   Sanchez V, 2014, PSYCHOPHARMACOLOGY, V231, P1753, DOI 10.1007/s00213-013-3359-3
   Saunders BT, 2011, NEUROPSYCHOPHARMACOL, V36, P1668, DOI 10.1038/npp.2011.48
   Schiller CE, 2012, EXP CLIN PSYCHOPHARM, V20, P251, DOI 10.1037/a0027759
   Schneider T, 2007, PSYCHONEUROENDOCRINO, V32, P651, DOI 10.1016/j.psyneuen.2007.04.003
   Schramm-Sapyta NL, 2011, PSYCHOPHARMACOLOGY, V215, P493, DOI 10.1007/s00213-011-2216-5
   Seif T, 2013, NAT NEUROSCI, V16, P1094, DOI 10.1038/nn.3445
   Sershen H, 1998, BRAIN RES, V801, P67, DOI 10.1016/S0006-8993(98)00546-0
   Shahbazi M, 2008, PSYCHOPHARMACOLOGY, V196, P71, DOI 10.1007/s00213-007-0933-6
   Silveri MM, 1998, ALCOHOL CLIN EXP RES, V22, P670, DOI 10.1111/j.1530-0277.1998.tb04310.x
   Silveri MM, 2000, ALCOHOL, V20, P45, DOI 10.1016/S0741-8329(99)00055-5
   Sinha R, 2007, EXP CLIN PSYCHOPHARM, V15, P445, DOI 10.1037/1064-1297.15.5.445
   Smethells JR, 2015, PSYCHOPHARMACOLOGY, V232, P2455, DOI 10.1007/s00213-015-3874-5
   Smith MA, 2008, DRUG ALCOHOL DEPEN, V98, P129, DOI 10.1016/j.drugalcdep.2008.05.006
   Smith MA, 2012, PHARMACOL REP, V64, P960, DOI 10.1016/S1734-1140(12)70891-5
   Smith MA, 2012, DRUG ALCOHOL DEPEN, V121, P54, DOI 10.1016/j.drugalcdep.2011.08.006
   Smith MA, 2011, PSYCHOPHARMACOLOGY, V218, P357, DOI 10.1007/s00213-011-2321-5
   Smith MA, 2011, PHARMACOL BIOCHEM BE, V100, P237, DOI 10.1016/j.pbb.2011.08.025
   Sobieraj JC, 2016, BRAIN STRUCT FUNCT, V221, P261, DOI 10.1007/s00429-014-0905-7
   Sofuoglu M, 2004, PHARMACOL BIOCHEM BE, V78, P699, DOI 10.1016/j.pbb.2004.05.004
   Sofuoglu M, 2002, PHARMACOL BIOCHEM BE, V72, P431, DOI 10.1016/S0091-3057(02)00716-5
   Sofuoglu M, 2009, EXP CLIN PSYCHOPHARM, V17, P63, DOI 10.1037/a0015297
   Somaini Lorenzo, 2011, Recent Pat CNS Drug Discov, V6, P146
   Spear LP, 2014, NEUROSCI BIOBEHAV R, V45, P1, DOI 10.1016/j.neubiorev.2014.04.012
   Spear LP, 2011, DEV COGN NEUROS-NETH, V1, P390, DOI 10.1016/j.dcn.2011.08.001
   Spear LP, 2009, DEV PSYCHOPATHOL, V21, P87, DOI 10.1017/S0954579409000066
   Stairs DJ, 2009, PHARMACOL BIOCHEM BE, V92, P377, DOI 10.1016/j.pbb.2009.01.016
   Stevens L, 2014, J SUBST ABUSE TREAT, V47, P58, DOI 10.1016/j.jsat.2014.01.008
   Stoops WW, 2014, EXPERT REV CLIN PHAR, V7, P363, DOI 10.1586/17512433.2014.909283
   Strohle A, 2009, J NEURAL TRANSM, V116, P777, DOI 10.1007/s00702-008-0092-x
   Terner JM, 2006, DRUG ALCOHOL DEPEN, V84, P1, DOI 10.1016/j.drugalcdep.2005.12.007
   Terry-McElrath YM, 2011, AM J PREV MED, V40, P530, DOI 10.1016/j.amepre.2010.12.021
   Thanos PK, 2010, BEHAV BRAIN RES, V215, P77, DOI 10.1016/j.bbr.2010.06.033
   Townshend JM, 2005, ALCOHOL CLIN EXP RES, V29, P317, DOI 10.1097/01.ALC.0000156453.05028.F5
   Truxell EM, 2007, ALCOHOL CLIN EXP RES, V31, P755, DOI 10.1111/j.1530-0277.2007.00358.x
   UNODC (United Nations Office on Drugs and Crime), 2013, WORLD DRUG REP 2013
   Vaidya JG, 2004, ANN NY ACAD SCI, V1021, P395, DOI 10.1196/annals.1308.051
   van der Plas EAA, 2009, J CLIN EXP NEUROPSYC, V31, P706, DOI 10.1080/13803390802484797
   VANHAAREN F, 1988, J EXP ANAL BEHAV, V49, P201, DOI 10.1901/jeab.1988.49-201
   Vansickel AR, 2010, ADDICTION, V105, P727, DOI 10.1111/j.1360-0443.2009.02858.x
   Varlinskaya EI, 2002, ALCOHOL CLIN EXP RES, V26, P1502, DOI 10.1097/01.ALC.0000034033.95701.E3
   Volkow ND, 2013, OBES REV, V14, P2, DOI 10.1111/j.1467-789X.2012.01031.x
   Vuchinich RE, 1998, EXP CLIN PSYCHOPHARM, V6, P292, DOI 10.1037/1064-1297.6.3.292
   Walker BM, 2009, PHARMACOL BIOCHEM BE, V91, P560, DOI 10.1016/j.pbb.2008.09.017
   Walsh SL, 2013, DRUG ALCOHOL DEPEN, V130, P150, DOI 10.1016/j.drugalcdep.2012.10.024
   Weafer J, 2014, ADDICT BEHAV, V39, P1573, DOI 10.1016/j.addbeh.2013.10.033
   Wee S, 2004, DRUG ALCOHOL DEPEN, V75, P271, DOI 10.1016/j.drugalcdep.2004.03.010
   Weinberger AH, 2015, NICOTINE TOB RES, V17, P407, DOI 10.1093/ntr/ntu249
   Weinstock J, 2008, ADDICT BEHAV, V33, P1072, DOI 10.1016/j.addbeh.2008.03.011
   WEISS G, 1982, INT J ADDICT, V17, P905, DOI 10.3109/10826088209056337
   Wetherington CL, 2010, HORM BEHAV, V58, P2, DOI 10.1016/j.yhbeh.2010.03.004
   White AM, 2002, PHARMACOL BIOCHEM BE, V73, P673, DOI 10.1016/S0091-3057(02)00860-2
   Wilens TE, 2011, CURR MED RES OPIN, V27, P2309, DOI 10.1185/03007995.2011.628648
   Witt ED, 2007, NEUROTOXICOL TERATOL, V29, P81, DOI 10.1016/j.ntt.2006.10.013
   Wood DA, 2006, PHYSIOL BEHAV, V88, P132, DOI 10.1016/j.physbeh.2006.03.024
   World Health Organization, 2010, WHO GLOB INF
   Wronski M, 2007, ALCOHOL ALCOHOLISM, V42, P75, DOI 10.1093/alcalc/agl097
   Yakovenko V, 2011, APPETITE, V57, P397, DOI 10.1016/j.appet.2011.06.002
   Yonkers KA, 2014, LANCET PSYCHIAT, V1, P360, DOI 10.1016/S2215-0366(14)70333-5
   Yoon JH, 2007, EXP CLIN PSYCHOPHARM, V15, P176, DOI 10.1037/1064-1297.15.2.186
   Zhou YH, 2016, FRONT NEUROENDOCRIN, V40, P24, DOI 10.1016/j.yfrne.2015.07.001
   Zhou YH, 2014, J SPORT HEALTH SCI, V3, P163, DOI 10.1016/j.jshs.2014.04.005
   Zlebnik NE, 2015, PSYCHOPHARMACOLOGY, V232, P3507, DOI 10.1007/s00213-015-3999-6
   Zlebnik NE, 2015, PSYCHOPHARMACOLOGY, V232, P1049, DOI 10.1007/s00213-014-3744-6
   Zlebnik NE, 2014, PSYCHOPHARMACOLOGY, V231, P3787, DOI 10.1007/s00213-014-3513-6
   Zlebnik NE, 2014, BEHAV BRAIN RES, V261, P71, DOI 10.1016/j.bbr.2013.12.012
   Zlebnik NE, 2012, PSYCHOPHARMACOLOGY, V224, P387, DOI 10.1007/s00213-012-2760-7
   Zlebnik NE, 2010, PSYCHOPHARMACOLOGY, V209, P113, DOI 10.1007/s00213-010-1776-0
NR 279
TC 34
Z9 36
U1 2
U2 33
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD FEB 8
PY 2016
VL 6
AR 175
DI 10.3389/fpsyt.2015.00175
PG 20
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA DD6UQ
UT WOS:000370060400001
PM 26903885
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Solinas, M
   Chauvet, C
   Thiriet, N
   El Rawas, R
   Jaber, M
AF Solinas, Marcello
   Chauvet, Claudia
   Thiriet, Nathalie
   El Rawas, Rana
   Jaber, Mohamed
TI Reversal of cocaine addiction by environmental enrichment
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE dopamine; drug abuse; environment; stress; treatment
ID CONDITIONED PLACE PREFERENCE; DRUG-SEEKING BEHAVIOR; INDUCED
   REINSTATEMENT; RATS; RELAPSE; EXPRESSION; MICE; EXTINCTION; DISORDERS;
   FOS
AB Environmental conditions can dramatically influence the behavioral and neurochemical effects of drugs of abuse. For example, stress increases the reinforcing effects of drugs and plays an important role in determining the vulnerability to develop drug addiction. On the other hand, positive conditions, such as environmental enrichment, can reduce the reinforcing effects of psychostimulants and may provide protection against the development of drug addiction. However, whether environmental enrichment can be used to "treat" drug addiction has not been investigated. In this study, we first exposed mice to drugs and induced addiction-related behaviors and only afterward exposed them to enriched environments. We found that 30 days of environmental enrichment completely eliminates behavioral sensitization and conditioned place preference to cocaine. In addition, housing mice in enriched environments after the development of conditioned place preference prevents cocaine-induced reinstatement of conditioned place preference and reduces activation of the brain circuitry involved in cocaine-induced reinstatement. Altogether, these results demonstrate that environmental enrichment can eliminate already established addiction-related behaviors in mice and suggest that environmental stimulation may be a fundamental factor in facilitating abstinence and preventing relapse to cocaine addiction.
C1 [Solinas, Marcello; Chauvet, Claudia; Thiriet, Nathalie; El Rawas, Rana; Jaber, Mohamed] Univ Poitiers, Inst Physiol & Biol Cellulaires, CNRS, F-86022 Poitiers, France.
C3 Centre National de la Recherche Scientifique (CNRS); Universite de
   Poitiers
RP Solinas, M (通讯作者)，Univ Poitiers, Inst Physiol & Biol Cellulaires, CNRS, F-86022 Poitiers, France.
EM marcello.solinas@univ-poitiers.fr
RI Solinas, Marcello/M-3500-2016; Rawas, Rana El/AAR-7062-2020; JABER,
   Mohamed/IQW-5358-2023
OI Solinas, Marcello/0000-0002-0664-5964; JABER,
   Mohamed/0000-0003-2536-1913; THIRIET, Nathalie/0000-0002-0076-4946; El
   Rawas, Rana/0000-0002-8068-4507
FU Centre National de la Recherche Scientifique (CNRS) [BDI-PED,
   2005-2008]; University of Poitiers; Mission Interministerielle de Lutte
   contre la Drogue et la Toxicomanie, and Region Poitou-Charentes
FX We thank S.R. Goldberg, F. Becq, and D. Belin for comments on the paper,
   A. Gaillard for help with immunohistochemistry procedures, and V.
   Lardeux for technical assistance. This work was supported by Centre
   National de la Recherche Scientifique (CNRS), University of Poitiers,
   Mission Interministerielle de Lutte contre la Drogue et la Toxicomanie,
   and Region Poitou-Charentes. R.E.R. is a recipient of a CNRS Ph.D.
   fellowship (BDI-PED, 2005-2008).
CR Anderson SM, 2003, PSYCHOPHARMACOLOGY, V168, P132, DOI 10.1007/s00213-002-1298-5
   Bardo MT, 2001, PSYCHOPHARMACOLOGY, V155, P278
   Bezard E, 2003, J NEUROSCI, V23, P10999
   Bossert JM, 2005, EUR J PHARMACOL, V526, P36, DOI 10.1016/j.ejphar.2005.09.030
   Carroll KM, 2005, AM J PSYCHIAT, V162, P1452, DOI 10.1176/appi.ajp.162.8.1452
   Compton WM, 2005, AM J PSYCHIAT, V162, P1494, DOI 10.1176/appi.ajp.162.8.1494
   Crombag HS, 2002, BEHAV BRAIN RES, V136, P455, DOI 10.1016/S0166-4328(02)00196-1
   Cunningham CL, 2006, NAT PROTOC, V1, P1662, DOI 10.1038/nprot.2006.279
   Epstein DH, 2006, PSYCHOPHARMACOLOGY, V189, P1, DOI 10.1007/s00213-006-0529-6
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Fischer A, 2007, NATURE, V447, P178, DOI 10.1038/nature05772
   Frankland PW, 2005, NAT REV NEUROSCI, V6, P119, DOI 10.1038/nrn1607
   Goeders NE, 2002, J PHARMACOL EXP THER, V301, P785, DOI 10.1124/jpet.301.3.785
   Hall FS, 1998, CRIT REV NEUROBIOL, V12, P129, DOI 10.1615/CritRevNeurobiol.v12.i1-2.50
   Hamlin AS, 2008, NEUROSCIENCE, V151, P659, DOI 10.1016/j.neuroscience.2007.11.018
   Hyman SE, 2005, AM J PSYCHIAT, V162, P1414, DOI 10.1176/appi.ajp.162.8.1414
   Itzhak Y, 2002, NEUROPSYCHOPHARMACOL, V26, P130, DOI 10.1016/S0893-133X(01)00303-7
   Kalivas PW, 2003, PSYCHOPHARMACOLOGY, V168, P44, DOI 10.1007/s00213-003-1393-2
   Kodjo CM, 2002, PEDIATR CLIN N AM, V49, P257, DOI 10.1016/S0031-3955(01)00003-7
   Laviola G, 2008, NEUROBIOL DIS, V31, P159, DOI 10.1016/j.nbd.2008.05.001
   Lu L, 2003, NEUROSCI BIOBEHAV R, V27, P457, DOI 10.1016/S0149-7634(03)00073-3
   Marinelli M, 2002, EUR J NEUROSCI, V16, P387, DOI 10.1046/j.1460-9568.2002.02089.x
   McFarland K, 2001, J NEUROSCI, V21, P8655
   Mueller D, 2000, BEHAV BRAIN RES, V115, P39, DOI 10.1016/S0166-4328(00)00239-4
   Neisewander JL, 2000, J NEUROSCI, V20, P798, DOI 10.1523/JNEUROSCI.20-02-00798.2000
   Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970
   O'Brien CP, 2005, AM J PSYCHIAT, V162, P1423, DOI 10.1176/appi.ajp.162.8.1423
   Peters J, 2008, J NEUROSCI, V28, P6046, DOI 10.1523/JNEUROSCI.1045-08.2008
   Pizzorusso T, 2007, NEURON, V54, P508, DOI 10.1016/j.neuron.2007.05.003
   ROSENZWE.MR, 1966, AM PSYCHOL, V21, P321, DOI 10.1037/h0023555
   See RE, 2005, EUR J PHARMACOL, V526, P140, DOI 10.1016/j.ejphar.2005.09.034
   Shalev U, 2002, PHARMACOL REV, V54, P1, DOI 10.1124/pr.54.1.1
   Solinas M, 2009, NEUROPSYCHOPHARMACOL, V34, P1102, DOI 10.1038/npp.2008.51
   Szumlinski KK, 2002, BEHAV BRAIN RES, V136, P151, DOI 10.1016/S0166-4328(02)00102-X
   Thiriet N, 2008, BRAIN RES, V1222, P31, DOI 10.1016/j.brainres.2008.05.030
   van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558
   Vanderschuren LJMJ, 2000, PSYCHOPHARMACOLOGY, V151, P99, DOI 10.1007/s002130000493
   Zavala AR, 2007, NEUROSCIENCE, V145, P438, DOI 10.1016/j.neuroscience.2006.12.038
NR 38
TC 193
Z9 195
U1 0
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 4
PY 2008
VL 105
IS 44
BP 17145
EP 17150
DI 10.1073/pnas.0806889105
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 372PP
UT WOS:000260913800063
PM 18955698
OA Bronze, Green Published
DA 2023-06-23
ER

PT J
AU Wang, L
   Wu, N
   Zhao, TY
   Li, J
AF Wang, Lv
   Wu, Ning
   Zhao, Tai-Yun
   Li, Jin
TI The potential biomarkers of drug addiction: proteomic and metabolomics
   challenges
SO BIOMARKERS
LA English
DT Review
DE Biomarkers; drug addiction; metabolomics; proteomics
ID CONDITIONED PLACE PREFERENCE; NUCLEUS-ACCUMBENS; WITHDRAWAL
   INTERVENTION; GENE-EXPRESSION; PLEIOTROPHIN KNOCKOUT; INDUCED
   NEUROTOXICITY; METABONOMIC ANALYSIS; MORPHINE-DEPENDENCE;
   RHESUS-MONKEYS; BLOOD-PLASMA
AB Drug addiction places a significant burden on society and individuals. Proteomics and metabolomics approaches pave the road for searching potential biomarkers to assist the diagnosis and treatment. This review summarized putative drug addiction-related biomarkers in proteomics and metabolomics studies and discussed challenges and prospects in future studies. Alterations of several hundred proteins and metabolites were reported when exposure to abused drug, which enriched in energy metabolism, oxidative stress response, protein modification and degradation, synaptic function and neurotrasmission, etc. Hsp70, peroxiredoxin-6 and alpha- and beta-synuclein, as well as n-methylserotonin and purine metabolites, were promising as potential biomarker for drug addiction.
C1 [Wang, Lv; Wu, Ning; Zhao, Tai-Yun; Li, Jin] Beijing Inst Pharmacol & Toxicol, Beijing Key Lab Neuropsychopharmacol, State Key Lab Toxicol & Med Countermeasures, 27th Taiping Rd, Beijing, Peoples R China.
C3 Academy of Military Medical Sciences - China
RP Li, J (通讯作者)，Beijing Inst Pharmacol & Toxicol, Beijing Key Lab Neuropsychopharmacol, State Key Lab Toxicol & Med Countermeasures, 27th Taiping Rd, Beijing, Peoples R China.
EM jinli9802@163.com
FU Project of National Science and Technology Support Program in China
   [2012BAI01B07]; National Basic Research Program of China [2015CB553504];
   China Postdoctoral Science Foundation [54, 2013M542511]
FX This study was funded by Project of National Science and Technology
   Support Program in China [2012BAI01B07], National Basic Research Program
   of China [2015CB553504] and No.54 China Postdoctoral Science Foundation
   Funded Project [2013M542511].
CR Adkins DE, 2013, GENES BRAIN BEHAV, V12, P780, DOI 10.1111/gbb.12081
   Blanchet L, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-254
   Bu Q, 2013, NEUROTOXICOLOGY, V36, P17, DOI 10.1016/j.neuro.2013.02.007
   Bu Q, 2012, J PROTEOMICS, V75, P1330, DOI 10.1016/j.jprot.2011.11.008
   Craft GE, 2013, METHODS, V61, P186, DOI 10.1016/j.ymeth.2013.04.008
   Deng Y, 2012, J NEUROSCI RES, V90, P2154, DOI 10.1002/jnr.23109
   Diaz SO, 2011, J PROTEOME RES, V10, P3732, DOI 10.1021/pr200352m
   Dominy SS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089366
   Estevez JFDF, 2004, EUR J CLIN NUTR, V58, P449, DOI 10.1038/sj.ejcn.1601827
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Ezquerra L, 2008, GROWTH FACTORS, V26, P44, DOI 10.1080/08977190801987711
   Filipeanu CM, 2011, J NEUROCHEM, V118, P1101, DOI 10.1111/j.1471-4159.2011.07391.x
   Gika HG, 2014, BIOANALYSIS, V6, P59, DOI [10.4155/BIO.13.301, 10.4155/bio.13.301]
   Gorini G, 2014, NEUROPSYCHOPHARMACOL, V39, P104, DOI 10.1038/npp.2013.182
   Gramage E, 2013, TOXICOLOGY, V306, P147, DOI 10.1016/j.tox.2013.02.013
   Gruber MP, 2006, AM J RESP CELL MOL, V35, P65, DOI 10.1165/rcmb.2004-0261OC
   Hu ZT, 2012, BEHAV BRAIN RES, V231, P11, DOI 10.1016/j.bbr.2012.02.026
   Iwazaki T, 2008, NEUROSCI LETT, V435, P113, DOI 10.1016/j.neulet.2008.02.025
   Kaddurah-Daouk R, 2009, NEUROPSYCHOPHARMACOL, V34, P173, DOI 10.1038/npp.2008.174
   Kendler KS, 2007, ARCH GEN PSYCHIAT, V64, P1313, DOI 10.1001/archpsyc.64.11.1313
   Krapfenbauer K, 2003, BRAIN RES, V967, P152, DOI 10.1016/S0006-8993(02)04243-9
   Krastanov A, 2010, BIOTECHNOL BIOTEC EQ, V24, P1537, DOI 10.2478/V10133-010-0001-Y
   Le Greves P, 2005, BRAIN RES BULL, V65, P529, DOI 10.1016/j.brainresbull.2005.03.010
   Li Y, 2012, NEUROSCIENCE, V218, P196, DOI 10.1016/j.neuroscience.2012.05.019
   Lichti CF, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00246
   Lin X, 2011, BEHAV BRAIN RES, V221, P197, DOI 10.1016/j.bbr.2011.03.002
   Ling YS, 2014, MOL BIOSYST, V10, P1918, DOI 10.1039/c4mb00090k
   Lull ME, 2010, DRUG ALCOHOL DEPEN, V107, P11, DOI 10.1016/j.drugalcdep.2009.10.001
   MAILLEUX P, 1994, NEUROSCI LETT, V175, P25, DOI 10.1016/0304-3940(94)91069-3
   Makris N, 2004, NEURON, V44, P729, DOI 10.1016/j.neuron.2004.10.027
   Mannelli P, 2009, HUM PSYCHOPHARM CLIN, V24, P666, DOI 10.1002/hup.1068
   Martins-De-Souza D, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-17
   McClay JL, 2013, METABOLOMICS, V9, P392, DOI 10.1007/s11306-012-0456-y
   Meng JR, 2012, ANAL CHIM ACTA, V710, P125, DOI 10.1016/j.aca.2011.09.033
   Naylor S, 2003, EXPERT REV MOL DIAGN, V3, P525, DOI 10.1586/14737159.3.5.525
   Nestler EJ, 2004, NEUROPHARMACOLOGY, V47, P24, DOI 10.1016/j.neuropharm.2004.06.031
   Nordstrom A, 2010, J NEUROIMMUNE PHARM, V5, P4, DOI 10.1007/s11481-009-9156-4
   Patkar AA, 2009, PSYCHOPHARMACOLOGY, V206, P479, DOI 10.1007/s00213-009-1625-1
   Potenza MN, 2011, NEURON, V69, P695, DOI 10.1016/j.neuron.2011.02.009
   Pottiez G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031031
   Power JHT, 2008, ACTA NEUROPATHOL, V115, P611, DOI 10.1007/s00401-008-0373-3
   Robison AJ, 2011, NAT REV NEUROSCI, V12, P623, DOI 10.1038/nrn3111
   Shi WL, 2012, NEUROSCI LETT, V525, P23, DOI 10.1016/j.neulet.2012.07.026
   Shima N, 2011, TOXICOLOGY, V287, P29, DOI 10.1016/j.tox.2011.05.012
   Stockton SD, 2014, NEUROPSYCHOPHARMACOL, V39, P88, DOI 10.1038/npp.2013.227
   Taurines R, 2011, J PSYCHOPHARMACOL, V25, P151, DOI 10.1177/0269881109106931
   Vicente-Rodriguez M, 2013, TOXICOLOGY, V314, P166, DOI 10.1016/j.tox.2013.09.014
   Wang J, 2011, MOL NEUROBIOL, V44, P269, DOI 10.1007/s12035-011-8202-4
   Wang-Sattler R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003863
   Yao JK, 2011, ANTIOXID REDOX SIGN, V15, P1999, DOI 10.1089/ars.2010.3646
   Zaitsu K, 2014, ANAL BIOANAL CHEM, V406, P1339, DOI 10.1007/s00216-013-7234-1
   Zhao YY, 2014, CHEM-BIOL INTERACT, V215, P7, DOI 10.1016/j.cbi.2014.02.014
   Zheng T, 2014, MOL BIOSYST, V10, P1968, DOI 10.1039/c4mb00158c
   Zheng T, 2013, DRUG ALCOHOL DEPEN, V127, P177, DOI 10.1016/j.drugalcdep.2012.06.031
   Zill P, 2011, EUR ARCH PSY CLIN N, V261, P121, DOI 10.1007/s00406-010-0129-7
NR 55
TC 13
Z9 13
U1 2
U2 27
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354-750X
EI 1366-5804
J9 BIOMARKERS
JI Biomarkers
PY 2016
VL 21
IS 8
BP 678
EP 685
DI 10.1080/1354750X.2016.1201530
PG 8
WC Biotechnology & Applied Microbiology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Toxicology
GA EA1GA
UT WOS:000386339300002
PM 27328859
DA 2023-06-23
ER

PT J
AU Reid, A
AF Reid, Alastair
TI Drug addiction finds its own niche
SO BEHAVIORAL AND BRAIN SCIENCES
LA English
DT Editorial Material
AB The evolutionary framework suggested by Muller & Schumann (M&S) can be extended further by considering drug-taking in terms of Niche Construction Theory (NCT). It is suggested here that genetic and environmental components of addiction are modified by cultural acceptance of the advantages of non-addicted drug taking and the legitimate supply of performance-enhancing drugs. This may then reduce the prevalence of addiction.
C1 Oxford Hlth NHS Fdn Trust, Specialist Community Addict Serv, Valley Ctr, High Wycombe HP13 6EQ, Bucks, England.
RP Reid, A (通讯作者)，Oxford Hlth NHS Fdn Trust, Specialist Community Addict Serv, Valley Ctr, High Wycombe HP13 6EQ, Bucks, England.
EM alastair.reid@oxfordhealth.nhs.uk
CR Kendal J, 2011, PHILOS T R SOC B, V366, P785, DOI 10.1098/rstb.2010.0306
   Lingford-Hughes A, 2010, BRIT MED BULL, V96, P93, DOI 10.1093/bmb/ldq032
NR 2
TC 0
Z9 0
U1 0
U2 6
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0140-525X
EI 1469-1825
J9 BEHAV BRAIN SCI
JI Behav. Brain Sci.
PD DEC
PY 2011
VL 34
IS 6
BP 321
EP 322
DI 10.1017/S0140525X11000781
PG 2
WC Psychology, Biological; Behavioral Sciences; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology; Behavioral Sciences; Neurosciences & Neurology
GA 857UT
UT WOS:000297748500013
PM 22074974
DA 2023-06-23
ER

PT J
AU Hogarth, L
   Field, M
AF Hogarth, Lee
   Field, Matt
TI Relative expected value of drugs versus competing rewards underpins
   vulnerability to and recovery from addiction
SO BEHAVIOURAL BRAIN RESEARCH
LA English
DT Review
DE Concurent drug choice tasks; Relative value; Economic decision theory;
   Addiction
ID NEGATIVE MOOD INDUCTION; SUBSTANCE USE; BEHAVIORAL ECONOMICS; CUE
   REACTIVITY; ALTERNATIVE REINFORCERS; COPING MOTIVES; INSTRUMENTAL
   TRANSFER; COCAINE-SEEKING; ALCOHOL-SEEKING; USE DISORDER
AB Behavioural economic theories of addiction contend that greater expected value of drug relative to alternative non-drug rewards is the core mechanism underpinning vulnerability to and recovery from addiction. To evaluate this claim, we exhaustively review studies with human drug users that have measured concurrent choice between drugs vs. alternative rewards, and explored individual differences. These studies show that drug choice can be modulated by drug cues, drug devaluation, imposition of costs/punishment and negative mood induction. Regarding individual differences, dependence severity was reliably associated with overall drug preference, and self-reported drug use to cope with negative affect was reliably associated with greater sensitivity to mood induced increases in drug choice. By contrast, there were no reliable individual differences in sensitivity to the effect of drug cues, drug devaluation or punishment on drug choice. These findings provide insight into the mechanisms that underpin vulnerability to dependence: vulnerability is conferred by greater relative value ascribed to drugs, and relative drug value is further augmented by negative affective states in those who report drug use coping motives. However, dependence does not appear to be characterised by abnormal cue-reactivity, habit learning or compulsion. We then briefly review emerging literature which demonstrates that therapeutic interventions and recovery from addiction might be attributed to changes in the expected relative value of drug versus alternative rewards. Finally, we outline a speculative computational account of the distortions in decision-making that precede action selection in addiction, and we explain how this account provides a blueprint for future research on the determinants of drug choice, and mechanisms of treatment and recovery from addiction. We conclude that a unified economic decision-making account of addiction has great promise in reconciling diverse addiction theories, and neuropsychological evaluation of the underlying decision mechanisms is a fruitful area for future research and treatment.
C1 [Hogarth, Lee] Univ Exeter, Sch Psychol, Washington Singer Bldg,Perry Rd, Exeter EX4 4QG, Devon, England.
   [Field, Matt] Univ Sheffield, Dept Psychol, Sheffield, S Yorkshire, England.
C3 University of Exeter; N8 Research Partnership; White Rose University
   Consortium; University of Sheffield
RP Hogarth, L (通讯作者)，Univ Exeter, Sch Psychol, Washington Singer Bldg,Perry Rd, Exeter EX4 4QG, Devon, England.
EM L.Hogarth@exeter.ac.uk
RI Field, Matt/AAQ-1056-2020
OI Field, Matt/0000-0002-7790-5559; Hogarth, Lee/0000-0002-0299-5748
FU Alcohol Change UK [RS17/03]; Medical Research Council (UK, MRC)
   Confidence in Global Mental Health pump priming award
   [MC_PC_MR/R019991/1]; MRC [MC_PC_MR/R019991/1] Funding Source: UKRI
FX The research was supported by an Alcohol Change UK grant (RS17/03) to
   Lee Hogarth, and a Medical Research Council (UK, MRC) Confidence in
   Global Mental Health pump priming award (MC_PC_MR/R019991/1) to Hogarth.
   Funders had no role in the study design, collection, analysis or
   interpretation of the data, writing the manuscript, or the decision to
   submit the paper for publication.
CR Acuff S.F., 2020, ALCOHOLISM CLIN EXPT
   Acuff SF, 2020, ADDICTION, V115, P817, DOI 10.1111/add.14865
   Acuff SF, 2019, CLIN PSYCHOL REV, V70, P79, DOI 10.1016/j.cpr.2019.04.003
   Aguirre CG, 2015, J ABNORM PSYCHOL, V124, P623, DOI 10.1037/abn0000060
   Ahmed SH, 2018, PROG NEURO-PSYCHOPH, V87, P3, DOI 10.1016/j.pnpbp.2017.09.027
   Anker JJ, 2017, J ABNORM PSYCHOL, V126, P325, DOI 10.1037/abn0000257
   [Anonymous], [No title captured]
   Bickel WK, 1995, EXP CLIN PSYCHOPHARM, V3, P467, DOI 10.1037/1064-1297.3.4.467
   Bickel WK, 2017, NEBR SYM MOTIV, V64, P227, DOI 10.1007/978-3-319-51721-6_8
   Bickel WK, 2014, ANNU REV CLIN PSYCHO, V10, P641, DOI 10.1146/annurev-clinpsy-032813-153724
   Bravo AJ, 2017, ADDICT BEHAV, V73, P94, DOI 10.1016/j.addbeh.2017.05.001
   Bujarski S, 2012, EXP CLIN PSYCHOPHARM, V20, P181, DOI 10.1037/a0027379
   Busemeyer J. R., 2019, TRENDS COGN SCI
   Carter BL, 2001, EXP CLIN PSYCHOPHARM, V9, P183, DOI 10.1037//1064-1297.9.2.183
   Carter C, 2015, EUR POL RES UN SER, P1
   Cassidy RN, 2015, NICOTINE TOB RES, V17, P1449, DOI 10.1093/ntr/ntv033
   Chase HW, 2013, PSYCHOPHARMACOLOGY, V226, P371, DOI 10.1007/s00213-012-2911-x
   Comer SD, 2013, BEHAV PHARMACOL, V24, P504, DOI 10.1097/FBP.0b013e328363d1c4
   Cooney NL, 1997, J ABNORM PSYCHOL, V106, P243, DOI 10.1037/0021-843X.106.2.243
   Copeland Amber, 2020, Addict Behav Rep, V11, P100258, DOI 10.1016/j.abrep.2020.100258
   Daughters SB, 2018, ADDICTION, V113, P535, DOI 10.1111/add.14049
   Dennhardt AA, 2015, J EXP ANAL BEHAV, V103, P125, DOI 10.1002/jeab.121
   Dickinson A, 2002, Q J EXP PSYCHOL-B, V55, P331, DOI 10.1080/0272499024400016
   Dutra L, 2008, AM J PSYCHIAT, V165, P179, DOI 10.1176/appi.ajp.2007.06111851
   Dyer ML, 2020, J PSYCHOPHARMACOL, V34, P1237, DOI 10.1177/0269881120940913
   Ersche KD, 2008, PSYCHOPHARMACOLOGY, V197, P421, DOI 10.1007/s00213-007-1051-1
   Everitt BJ, 2016, ANNU REV PSYCHOL, V67, P23, DOI 10.1146/annurev-psych-122414-033457
   Fazzino TL, 2019, J SUBST ABUSE TREAT, V104, P83, DOI 10.1016/j.jsat.2019.06.016
   Field M, 2020, PSYCHOL ADDICT BEHAV, V34, P182, DOI 10.1037/adb0000518
   Field M, 2016, HEALTH PSYCHOL, V35, P767, DOI 10.1037/hea0000405
   FitzGerald THB, 2009, J NEUROSCI, V29, P8388, DOI 10.1523/JNEUROSCI.0717-09.2009
   Freese L, 2018, PHARMACOL BIOCHEM BE, V173, P65, DOI 10.1016/j.pbb.2018.07.010
   Fucito LM, 2009, PSYCHOL ADDICT BEHAV, V23, P546, DOI 10.1037/a0016529
   Garland EL, 2016, BEHAV RES THER, V77, P7, DOI 10.1016/j.brat.2015.11.012
   Goelz PM, 2014, DRUG ALCOHOL DEPEN, V138, P67, DOI 10.1016/j.drugalcdep.2014.02.007
   Gonzalez-Roz A, 2019, ADDICTION, V114, P1926, DOI 10.1111/add.14736
   GREEN L, 1993, J EXP ANAL BEHAV, V60, P141, DOI 10.1901/jeab.1993.60-141
   Guillem K, 2018, ADDICT BIOL, V23, P880, DOI 10.1111/adb.12536
   Hardy L, 2018, BEHAV PHARMACOL, V29, P716, DOI 10.1097/FBP.0000000000000421
   Hardy L, 2017, EXP CLIN PSYCHOPHARM, V25, P448, DOI 10.1037/pha0000155
   Hardy L, 2017, PSYCHOPHARMACOLOGY, V234, P1977, DOI 10.1007/s00213-017-4605-x
   Hart C., 2013, HIGH PRICE NEUROSCIE
   Hart CL, 2000, BEHAV PHARMACOL, V11, P87, DOI 10.1097/00008877-200002000-00010
   HARTMANNBOYCE J, 2018, COCHRANE DATABASE SY, V2018
   Hatsukami DK, 1994, EXP CLIN PSYCHOPHARM, V2, P115
   Heather Nick, 2017, Addict Behav Rep, V6, P15, DOI 10.1016/j.abrep.2017.05.002
   Herrnstein RJ, 1970, J EXP ANAL BEHAV, V13, P243, DOI 10.1901/jeab.1970.13-243
   Heyman GM, 2013, ANNU REV CLIN PSYCHO, V9, P29, DOI 10.1146/annurev-clinpsy-032511-143041
   Heyman Gene M., 2009, ADDICTION DISORDER C, DOI [10.4159/9780674053991, DOI 10.4159/9780674053991]
   HIGGINS ST, 1994, LIFE SCI, V55, P179, DOI 10.1016/0024-3205(94)00878-7
   Hogarth L., INDIVIDUL DIFF UNPUB
   Hogarth L, 2007, J EXP PSYCHOL ANIM B, V33, P484, DOI 10.1037/0097-7403.33.4.484
   Hogarth L, 2020, NEUROPSYCHOPHARMACOL, V45, P720, DOI 10.1038/s41386-020-0600-8
   Hogarth L, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00274
   Hogarth L, 2019, DRUG ALCOHOL DEPEN, V194, P69, DOI 10.1016/j.drugalcdep.2018.10.009
   Hogarth L, 2019, EUR J NEUROSCI, V50, P2513, DOI 10.1111/ejn.13961
   Hogarth L, 2018, PSYCHOPHARMACOLOGY, V235, P2257, DOI 10.1007/s00213-018-4922-8
   Hogarth L, 2018, EXP CLIN PSYCHOPHARM, V26, P138, DOI 10.1037/pha0000177
   Hogarth L, 2018, PSYCHOPHARMACOLOGY, V235, P269, DOI 10.1007/s00213-017-4765-8
   Hogarth L, 2017, DRUG ALCOHOL DEPEN, V176, P1, DOI 10.1016/j.drugalcdep.2017.02.009
   Hogarth L, 2015, PSYCHOPHARMACOLOGY, V232, P3235, DOI 10.1007/s00213-015-3977-z
   Hogarth L, 2015, ADDICTION, V110, P174, DOI 10.1111/add.12756
   Hogarth L, 2014, BEHAV RES THER, V59, P61, DOI 10.1016/j.brat.2014.06.001
   Hogarth L, 2012, J EXP PSYCHOL-ANIM B, V38, P266, DOI 10.1037/a0028914
   Hogarth L, 2012, EXP CLIN PSYCHOPHARM, V20, P213, DOI 10.1037/a0027203
   Hogarth L, 2011, J EXP PSYCHOL-ANIM B, V37, P261, DOI 10.1037/a0022913
   Hogarth L, 2011, PSYCHOPHARMACOLOGY, V215, P567, DOI 10.1007/s00213-011-2172-0
   Hutcheson DM, 2001, NAT NEUROSCI, V4, P943, DOI 10.1038/nn0901-943
   Joyner KJ, 2019, ALCOHOL CLIN EXP RES, V43, P2607, DOI 10.1111/acer.14206
   Kelly JF, 2017, ADDICTION, V112, P929, DOI 10.1111/add.13590
   Lamb RJ, 2018, PHARMACOL BIOCHEM BE, V164, P62, DOI 10.1016/j.pbb.2017.05.002
   Lile JA, 2016, DRUG ALCOHOL DEPEN, V165, P111, DOI 10.1016/j.drugalcdep.2016.05.022
   Lingford-Hughes AR, 2012, J PSYCHOPHARMACOL, V26, P899, DOI 10.1177/0269881112444324
   Lubman DI, 2009, ARCH GEN PSYCHIAT, V66, P205, DOI 10.1001/archgenpsychiatry.2008.522
   Lussier JP, 2006, ADDICTION, V101, P192, DOI 10.1111/j.1360-0443.2006.01311.x
   MacKillop J, 2016, ALCOHOL CLIN EXP RES, V40, P672, DOI 10.1111/acer.13004
   Magill M, 2013, ADDICTION, V108, P874, DOI 10.1111/add.12013
   Martinetti MP, 2019, ALCOHOL CLIN EXP RES, V43, P531, DOI 10.1111/acer.13954
   Mathew AR, 2017, ADDICTION, V112, P401, DOI 10.1111/add.13604
   McIntosh J, 2000, SOC SCI MED, V50, P1501, DOI 10.1016/S0277-9536(99)00409-8
   Miele Andrew, 2018, J Addict, V2018, P2438161, DOI 10.1155/2018/2438161
   Moeller SJ, 2015, PHARMACOL BIOCHEM BE, V138, P133, DOI 10.1016/j.pbb.2015.09.020
   Moeller SJ, 2013, DRUG ALCOHOL DEPEN, V130, P178, DOI 10.1016/j.drugalcdep.2012.11.001
   Moeller SJ, 2010, BRAIN, V133, P1484, DOI 10.1093/brain/awq066
   Moeller SJ, 2009, BIOL PSYCHIAT, V66, P169, DOI 10.1016/j.biopsych.2009.02.015
   Murphy JG, 2019, J CONSULT CLIN PSYCH, V87, P657, DOI 10.1037/ccp0000412
   Murphy JG, 2014, J STUD ALCOHOL DRUGS, V75, P653, DOI 10.15288/jsad.2014.75.653
   Olmstead MC, 2001, BEHAV NEUROSCI, V115, P394, DOI 10.1037/0735-7044.115.2.394
   Panlilio LV, 1996, PSYCHOPHARMACOLOGY, V125, P202, DOI 10.1007/BF02247329
   Perkins KA, 2002, HEALTH PSYCHOL, V21, P332, DOI 10.1037/0278-6133.21.4.332
   Perkins KA, 2009, ADDICTION, V104, P1610, DOI 10.1111/j.1360-0443.2009.02550.x
   Polania R, 2014, NEURON, V82, P709, DOI 10.1016/j.neuron.2014.03.014
   Ratcliff R, 2016, TRENDS COGN SCI, V20, P260, DOI 10.1016/j.tics.2016.01.007
   Redish AD, 2008, BEHAV BRAIN SCI, V31, P415, DOI 10.1017/S0140525X0800472X
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Rogers RE, 2008, PSYCHOL ADDICT BEHAV, V22, P544, DOI 10.1037/0893-164X.22.4.544
   Roos CR, 2017, ADDICTION, V112, P1547, DOI 10.1111/add.13841
   Rose AK, 2018, PSYCHOPHARMACOLOGY, V235, P1233, DOI 10.1007/s00213-018-4839-2
   Schnoll RA, 2016, DRUG ALCOHOL DEPEN, V165, P245, DOI 10.1016/j.drugalcdep.2016.06.017
   Seabrooke T, 2017, J EXP PSYCHOL-ANIM L, V43, P377, DOI 10.1037/xan0000147
   Seabrooke T, 2016, Q J EXP PSYCHOL, V69, P2452, DOI 10.1080/17470218.2015.1115885
   Shiffman S, 2015, DRUG ALCOHOL DEPEN, V155, P163, DOI 10.1016/j.drugalcdep.2015.07.673
   Shuai R., 2020, ADDICT BEHAV, V102, P106
   Sinha R, 2011, ARCH GEN PSYCHIAT, V68, P942, DOI 10.1001/archgenpsychiatry.2011.49
   Stitzer M, 2006, ANNU REV CLIN PSYCHO, V2, P411, DOI 10.1146/annurev.clinpsy.2.022305.095219
   Stoops WW, 2012, PROG NEURO-PSYCHOPH, V36, P189, DOI 10.1016/j.pnpbp.2011.10.003
   Strickland JC, 2018, PSYCHOPHARMACOLOGY, V235, P2871, DOI 10.1007/s00213-018-4978-5
   Takahashi TT, 2019, FRONT BEHAV NEUROSCI, V13, DOI 10.3389/fnbeh.2019.00129
   Teeters JB, 2015, ALCOHOL CLIN EXP RES, V39, P896, DOI 10.1111/acer.12695
   TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147
   TUCKER JA, 1994, J STUD ALCOHOL, V55, P401, DOI 10.15288/jsa.1994.55.401
   Tucker JA, 2002, EXP CLIN PSYCHOPHARM, V10, P248, DOI 10.1037//1064-1297.10.3.248
   Tucker JA, 1995, EXP CLIN PSYCHOPHARM, V3, P195, DOI 10.1037/1064-1297.3.2.195
   van Timmeren T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61892-5
   Verdejo-Garcia A, 2019, NEUROPSYCHOL REV, V29, P79, DOI 10.1007/s11065-018-9384-6
   Vlaev I, 2011, TRENDS COGN SCI, V15, P546, DOI 10.1016/j.tics.2011.09.008
   Volkow ND, 2004, NEUROPHARMACOLOGY, V47, P3, DOI 10.1016/j.neuropharm.2004.07.019
   Wise RA, 2014, NEUROPSYCHOPHARMACOL, V39, P254, DOI 10.1038/npp.2013.261
   Witkiewitz K, 2013, PSYCHOL ADDICT BEHAV, V27, P351, DOI 10.1037/a0029258
   Zvorsky I, 2019, PREV MED, V128, DOI 10.1016/j.ypmed.2019.105789
NR 120
TC 32
Z9 32
U1 0
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-4328
EI 1872-7549
J9 BEHAV BRAIN RES
JI Behav. Brain Res.
PD SEP 15
PY 2020
VL 394
AR 112815
DI 10.1016/j.bbr.2020.112815
PG 12
WC Behavioral Sciences; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Behavioral Sciences; Neurosciences & Neurology
GA NP3KS
UT WOS:000570078600006
PM 32707138
OA Green Submitted, hybrid, Green Published
DA 2023-06-23
ER

PT J
AU Panlilio, LV
   Goldberg, SR
AF Panlilio, Leigh V.
   Goldberg, Steven R.
TI Self-administration of drugs in animals and humans as a model and an
   investigative tool
SO ADDICTION
LA English
DT Article
DE abuse liability; addiction; animal models; escalation; operant behavior;
   reinforcement; self-administration; translational research
ID 2ND-ORDER SCHEDULES; COCAINE-SEEKING; D-AMPHETAMINE; RATS; BEHAVIOR;
   REINFORCEMENT; REINSTATEMENT; MORPHINE; HEROIN; ADDICTION
AB Aims To review briefly the methods, assumptions, models, accomplishments, drawbacks and future directions of research using drug self-administration in animals and humans. Background The use of drug self-administration to study addiction is based on the assumption that drugs reinforce the behavior that results in their delivery. A wide range of drug self-administration techniques have been developed to model specific aspects of addiction. These techniques are highly amenable to being combined with a wide variety of neuroscience techniques. Conclusions The identification of drug use as behavior that is reinforced by drugs has contributed greatly to the understanding and treatment of addiction. As part of a program of pre-clinical research that also involves screening with a variety of simpler behavioral techniques, drug self-administration procedures can provide an important last step in testing potential treatments for addiction. There is currently a concerted effort to develop self-administration procedures that model the extreme nature of the behavior engendered by addiction. As advances continue to be made in neuroscience techniques, self-administration should continue to provide a means of applying these techniques within a sophisticated and valid model of human drug addiction.
C1 Natl Inst Drug Abuse, Preclin Pharmacol Sect, Behav Neurosci Res Branch, Intramural Res Program,NIH DHHS, Baltimore, MD 21224 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute on
   Drug Abuse (NIDA)
RP Goldberg, SR (通讯作者)，Natl Inst Drug Abuse, Preclin Pharmacol Sect, Behav Neurosci Res Branch, Intramural Res Program,NIH DHHS, 5500 Nathan Shoch Dr, Baltimore, MD 21224 USA.
EM sgoldber@intra.nida.nih.gov
FU Intramural NIH HHS [Z99 DA999999, Z01 DA000001-23] Funding Source:
   Medline
CR ADAMS CD, 1982, Q J EXP PSYCHOL-B, V34, P77, DOI 10.1080/14640748208400878
   ADLER MW, 1995, DRUG ALCOHOL DEPEN, V37, P167
   Ahmed SH, 2000, NEUROPSYCHOPHARMACOL, V22, P413, DOI 10.1016/S0893-133X(99)00133-5
   Arnold JM, 1997, PHARMACOL BIOCHEM BE, V57, P441, DOI 10.1016/S0091-3057(96)00445-5
   BALSTER RL, 1973, J EXP ANAL BEHAV, V20, P119, DOI 10.1901/jeab.1973.20-119
   BICKEL WK, 1993, DRUG ALCOHOL DEPEN, V33, P173, DOI 10.1016/0376-8716(93)90059-Y
   BOZARTH MA, 1985, JAMA-J AM MED ASSOC, V254, P81, DOI 10.1001/jama.254.1.81
   DENEAU G, 1969, PSYCHOPHARMACOLOGIA, V16, P30, DOI 10.1007/BF00405254
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Dickinson A, 2002, Q J EXP PSYCHOL-B, V55, P331, DOI 10.1080/0272499024400016
   Everitt BJ, 2000, PSYCHOPHARMACOLOGY, V153, P17, DOI 10.1007/s002130000566
   GOLDBERG SR, 1975, FED PROC, V34, P1771
   GOLDBERG SR, 1981, SCIENCE, V214, P573
   Kippin TE, 2006, PSYCHOPHARMACOLOGY, V187, P60, DOI 10.1007/s00213-006-0386-3
   Ko MC, 2002, J PHARMACOL EXP THER, V301, P698, DOI 10.1124/jpet.301.2.698
   Koob GF, 2004, NEUROSCI BIOBEHAV R, V27, P739, DOI 10.1016/j.neubiorev.2003.11.007
   LAMB RJ, 1991, J PHARMACOL EXP THER, V259, P1165
   Lenoir M, 2007, NEUROPSYCHOPHARMACOL, V32, P616, DOI 10.1038/sj.npp.1301083
   Liu Y, 2005, PSYCHOPHARMACOLOGY, V179, P644, DOI 10.1007/s00213-004-2089-y
   Lynch WJ, 2001, EXP CLIN PSYCHOPHARM, V9, P131, DOI 10.1037//1064-1297.9.2.131
   Martinez D, 2007, AM J PSYCHIAT, V164, P622, DOI 10.1176/appi.ajp.164.4.622
   Miles FJ, 2003, BEHAV NEUROSCI, V117, P927, DOI 10.1037/0735-7044.117.5.927
   Negus SS, 2003, NEUROPSYCHOPHARMACOL, V28, P919, DOI 10.1038/sj.npp.1300096
   Olmstead MC, 2000, PSYCHOPHARMACOLOGY, V152, P123, DOI 10.1007/s002130000498
   Panlilio LV, 2005, PSYCHOPHARMACOLOGY, V179, P374, DOI 10.1007/s00213-004-2040-2
   Panlilio LV, 2005, NEUROPSYCHOPHARMACOL, V30, P433, DOI 10.1038/sj.npp.1300599
   Panlilio LV, 2003, PSYCHOPHARMACOLOGY, V168, P229, DOI 10.1007/s00213-002-1193-0
   Panlilio LV, 1996, PSYCHOPHARMACOLOGY, V125, P202, DOI 10.1007/BF02247329
   Perry JL, 2006, PSYCHOPHARMACOLOGY, V186, P235, DOI 10.1007/s00213-006-0371-x
   Rawson RA, 2006, ADDICTION, V101, P267, DOI 10.1111/j.1360-0443.2006.01312.x
   Schindler CW, 2002, PSYCHOPHARMACOLOGY, V163, P327, DOI 10.1007/s00213-002-1157-4
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   Spanagel R, 2005, ADDICTION, V100, P1813, DOI 10.1111/j.1360-0443.2005.01260.x
   Sughondhabirom A, 2005, PSYCHOPHARMACOLOGY, V180, P436, DOI 10.1007/s00213-005-2192-8
   THOMPSON T, 1964, PSYCHOPHARMACOLOGIA, V5, P87, DOI 10.1007/BF00413045
   Thomsen M, 2007, BEHAV GENET, V37, P101, DOI 10.1007/s10519-006-9097-0
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   WEEKS JR, 1964, PSYCHOPHARMACOLOGIA, V6, P267, DOI 10.1007/BF00413156
   WISE RA, 1995, PSYCHOPHARMACOLOGY, V120, P10, DOI 10.1007/BF02246140
   Yasar S, 2006, PSYCHOPHARMACOLOGY, V183, P413, DOI 10.1007/s00213-005-0200-7
NR 40
TC 178
Z9 178
U1 0
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0965-2140
EI 1360-0443
J9 ADDICTION
JI Addiction
PD DEC
PY 2007
VL 102
IS 12
BP 1863
EP 1870
DI 10.1111/j.1360-0443.2007.02011.x
PG 8
WC Substance Abuse; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry
GA 234ST
UT WOS:000251185000003
PM 18031422
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Afaq, MYM
   Rehna, T
   Akhtar, Z
AF Afaq, Muhammad Yasir Masood
   Rehna, Tasnim
   Akhtar, Zubaa
TI The journey from drug addiction to drug recovery; a case report of an
   inpatient rehabilitation
SO JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION
LA English
DT Article
DE Illicit Drugs; Substance-related Disorders; Mental Health Recovery; Case
   report; Pakistan
ID MODEL
AB In Pakistan, 64% of the total population is under the age of 30 and unfortunately, the increasing number of young addicts in Pakistan is estimated at the distressing rate of 40,000 per year. By considering the alarming situation and scarcity of literature, this research aims to investigate the recovery phase of drug addiction by introducing a case that highlights drug addiction, recovery, and relapse in the Pakistani context. We designed a case study approach in which face-to-face interviews were used. The case under consideration is a 38 years old patient with a history of chronic addiction with episodes of recovery and relapses. The shift of approaches from the extreme end of the addiction continuum to full recovery poses an opportunity for drug rehabilitation professionals to learn factors associated with drug addiction, the recovery process, and first-hand comments on recovering interventions in
C1 [Afaq, Muhammad Yasir Masood; Rehna, Tasnim] Natl Univ Modern Languages, Dept Appl Psychol, Islamabad, Pakistan.
   [Akhtar, Zubaa] Natl Univ Sci & Technol, NUST Business Sch, Islamabad, Pakistan.
C3 National University of Sciences & Technology - Pakistan
RP Afaq, MYM (通讯作者)，Natl Univ Modern Languages, Dept Appl Psychol, Islamabad, Pakistan.
EM yasir@houseofwellness.pk
RI Rehna, Tasnim/GPX-8215-2022
OI Akhtar, Zuba'a/0000-0002-0246-7160
CR Abolmagd S, 2018, ADDICT DISORD TREAT, V17, P168, DOI 10.1097/ADT.0000000000000137
   Aslam N., 2019, PAK J MED RES, V58, P44
   Batool S, 2017, E MEDITERR HEALTH J, V23, P168, DOI 10.26719/2017.23.3.168
   Becona E, 2018, PSICOTHEMA, V30, P270, DOI 10.7334/psicothema2017.303
   De Avila C, 2020, CHILD ABUSE NEGLECT, V109, DOI 10.1016/j.chiabu.2020.104696
   Degenhardt L, 2018, LANCET PSYCHIAT, V5, P987, DOI 10.1016/S2215-0366(18)30337-7
   Hennessy EA, 2019, ADDICT RES THEORY, V27, P429, DOI 10.1080/16066359.2018.1540694
   June DL, 2017, TOUGH LOVE OVERPOWER, P153
   Kayani A, P 22 INT COUNCIL ALC
   Khattak N., 2019, THE DAILY TIMES
   Morgan J., 2019, SUSPENDED SENTENCE M
   Muzaffar N, 2017, J ED HLTH COMMUNITY, V6, P46
   Skewes MC, 2013, PRINCIPLES OF ADDICTION: COMPREHENSIVE ADDICTIVE BEHAVIORS AND DISORDERS, VOL 1, P61, DOI 10.1016/B978-0-12-398336-7.00006-1
   UNODC, 2018, WORLD DRUG REP UN OF
NR 14
TC 0
Z9 0
U1 0
U2 3
PU PAKISTAN MEDICAL ASSOC
PI KARACHI
PA PMA HOUSE, AGA KHAN III RD, KARACHI, 00000, PAKISTAN
SN 0030-9982
J9 J PAK MED ASSOC
JI J. Pak. Med. Assoc.
PD JUL
PY 2022
VL 72
IS 7
BP 1435
EP 1437
DI 10.47391/JPMA.2419
PG 3
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA 2C6OW
UT WOS:000810986300034
PM 36156576
OA gold
DA 2023-06-23
ER

PT J
AU Shen, XY
   Orson, FM
   Kosten, TR
AF Shen, X. Y.
   Orson, F. M.
   Kosten, T. R.
TI Vaccines Against Drug Abuse
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Review
ID ANTI-(+)-METHAMPHETAMINE MONOCLONAL-ANTIBODY; MONOPHOSPHORYL-LIPID-A;
   ACTIVE IMMUNIZATION; COCAINE DEPENDENCE; SMOKING-CESSATION; CONJUGATE
   VACCINE; HEROIN-ADDICTION; PREVENT COCAINE; UNITED-STATES;
   METHAMPHETAMINE
AB The currently available medications for the treatment of drug abuse have had only limited success. Anti-addiction vaccines, aimed at eliciting antibodies that block the pharmacological effects of drugs, have great potential for treating drug abuse. We review the status of two vaccines that are undergoing clinical trials (for cocaine and nicotine addiction) and two that are still in preclinical development (for methamphetamine and heroin addiction). We also outline the challenges and ethical concerns associated with the development of anti-addiction vaccines and their use as future therapeutics.
C1 [Orson, F. M.; Kosten, T. R.] Vet Affairs Med Ctr, Houston, TX 77030 USA.
   [Shen, X. Y.; Orson, F. M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
   [Kosten, T. R.] Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA.
C3 Baylor College of Medicine; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); Baylor College of Medicine; Baylor College
   of Medicine
RP Kosten, TR (通讯作者)，Vet Affairs Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM kosten@bcm.edu
RI Kosten, Thomas/AAI-5998-2021
FU Department of Veterans Affairs (VA); VISN 16 Mental Illness Research,
   Education and Clinical Center (MIRECC); VA National Substance Use
   Disorders Quality Enhancement Research Initiative (QUERI); National
   Institute on Drug Abuse [K05 DA 0454, P50-DA18197, 5R01DA030338,
   1X02DA032939, R01DA026859]
FX This work was supported by the Department of Veterans Affairs (VA) Merit
   Review Program and the VISN 16 Mental Illness Research, Education and
   Clinical Center (MIRECC), the VA National Substance Use Disorders
   Quality Enhancement Research Initiative (QUERI), and National Institute
   on Drug Abuse grants K05 DA 0454 (T.R.K.), P50-DA18197 (T.R.K.),
   5R01DA030338 (F.M.O.), 1X02DA032939 (T.R.K., F.M.O., and X.Y.S.), and
   R01DA026859 (F.M.O. and X.Y.S.).
CR Akbarzadeh A, 1999, BIOTECHNOL APPL BIOC, V30, P139
   [Anonymous], PHASE 2 DOUBLE BLIND
   Anton B, 2006, VACCINE, V24, P3232, DOI 10.1016/j.vaccine.2006.01.047
   Aubin HJ, 2011, CURR PHARM DESIGN, V17, P1343, DOI 10.2174/138161211796150837
   BAGASRA O, 1992, IMMUNOPHARMACOLOGY, V23, P173, DOI 10.1016/0162-3109(92)90023-6
   Banzhoff A, 2008, INFLUENZA OTHER RESP, V2, P243, DOI 10.1111/j.1750-2659.2008.00059.x
   BERKOWITZ B, 1972, SCIENCE, V178, P1290, DOI 10.1126/science.178.4067.1290
   BONESE KF, 1974, NATURE, V252, P708, DOI 10.1038/252708a0
   Brown MJ, 2009, NAT REV CARDIOL, V6, P639, DOI 10.1038/nrcardio.2009.156
   Byrnes-Blake KA, 2005, EUR J PHARMACOL, V521, P86, DOI 10.1016/j.ejphar.2005.08.016
   Byrnes-Blake KA, 2001, INT IMMUNOPHARMACOL, V1, P329, DOI 10.1016/S1567-5769(00)00019-9
   Casella CR, 2008, CELL MOL LIFE SCI, V65, P3231, DOI 10.1007/s00018-008-8228-6
   Centers for Disease Control and Prevention, 2004, HLTH CONS SMOK
   Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002
   Cornuz J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002547
   *CYT BIOT, 2006, CYT002 NIC QB NOV VA
   Daniels JR, 2006, PSYCHOPHARMACOLOGY, V185, P36, DOI 10.1007/s00213-005-0299-6
   Darke S, 2008, DRUG ALCOHOL REV, V27, P253, DOI 10.1080/09595230801923702
   Dekimpe MG, 1998, MANAGE SCI, V44, P1478, DOI 10.1287/mnsc.44.11.1478
   Deng SX, 2002, J IMMUNOL METHODS, V269, P299, DOI 10.1016/S0022-1759(02)00237-5
   deWit H, 1996, EXP CLIN PSYCHOPHARM, V4, P5, DOI 10.1037/1064-1297.4.1.5
   Didierlaurent AM, 2009, J IMMUNOL, V183, P6186, DOI 10.4049/jimmunol.0901474
   DONNELLY JJ, 1990, J IMMUNOL, V145, P3071
   Esson L, 2004, MILLENNIUM DEV GOALS
   Ettinger RH, 1997, PHARMACOL BIOCHEM BE, V58, P215, DOI 10.1016/S0091-3057(97)00005-1
   Fowler JS, 2007, J NUCL MED, V48, P1724, DOI 10.2967/jnumed.107.040279
   Fowler JS, 2008, NEUROIMAGE, V43, P756, DOI 10.1016/j.neuroimage.2008.07.020
   Fox BS, 1996, NAT MED, V2, P1129, DOI 10.1038/nm1096-1129
   Gavin AL, 2006, SCIENCE, V314, P1936, DOI 10.1126/science.1135299
   Gentry WB, 2006, INT IMMUNOPHARMACOL, V6, P968, DOI 10.1016/j.intimp.2006.01.008
   Gonzales R, 2010, ANNU REV PUBL HEALTH, V31, P385, DOI 10.1146/annurev.publhealth.012809.103600
   Gossop M, 2002, ADDICTION, V97, P1259, DOI 10.1046/j.1360-0443.2002.00227.x
   Hall W, 2004, J MED ETHICS, V30, P337, DOI 10.1136/jme.2003.004739
   Hall W, 2011, CURR OPIN PSYCHIATR, V24, P191, DOI 10.1097/YCO.0b013e328345922b
   Haney Margaret, 2004, Expert Rev Vaccines, V3, P11, DOI 10.1586/14760584.3.1.11
   Haney M, 2010, BIOL PSYCHIAT, V67, P59, DOI 10.1016/j.biopsych.2009.08.031
   Harwood HJ., 2004, NEW TREATMENTS ADDIC
   Hatsukami DK, 2011, CLIN PHARMACOL THER, V89, P392, DOI 10.1038/clpt.2010.317
   Hatsukami DK, 2005, CLIN PHARMACOL THER, V78, P456, DOI 10.1016/j.clpt.2005.08.007
   Hays JT, 2010, DRUGS, V70, P2357, DOI 10.2165/11538190-000000000-00000
   Hieda Y, 2000, INT J IMMUNOPHARMACO, V22, P809, DOI 10.1016/S0192-0561(00)00042-4
   Hieda Y, 1997, J PHARMACOL EXP THER, V283, P1076
   INTURRISI CE, 1983, LIFE SCI, V33, P773, DOI 10.1016/0024-3205(83)90616-1
   Kahan M, 2011, CAN FAM PHYSICIAN, V57, P281
   Karila L, 2008, INT J NEUROPSYCHOPH, V11, P425, DOI 10.1017/S1461145707008097
   KOIDA M, 1974, JPN J PHARMACOL, V24, P165, DOI 10.1254/jjp.24.165
   Kosten Thomas R, 2002, Expert Rev Vaccines, V1, P363
   Kreek MJ, 2010, J ADDICT DIS, V29, P200, DOI 10.1080/10550881003684798
   Laurenzana EM, 2009, VACCINE, V27, P7011, DOI 10.1016/j.vaccine.2009.09.072
   Laurenzana EM, 2003, DRUG METAB DISPOS, V31, P1320, DOI 10.1124/dmd.31.11.1320
   Lindroth K, 2004, IMMUNOLOGY, V112, P413, DOI 10.1111/j.1365-2567.2004.01894.x
   Ma Li-xia, 2006, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V22, P368
   Mark TL, 2001, DRUG ALCOHOL DEPEN, V61, P195, DOI 10.1016/S0376-8716(00)00162-9
   Martell BA, 2005, BIOL PSYCHIAT, V58, P158, DOI 10.1016/j.biopsych.2005.04.032
   Martell BA, 2009, ARCH GEN PSYCHIAT, V66, P1116, DOI 10.1001/archgenpsychiatry.2009.128
   Mata-Haro V, 2007, SCIENCE, V316, P1628, DOI 10.1126/science.1138963
   Maurer P, 2007, EXPERT OPIN INV DRUG, V16, P1775, DOI 10.1517/13543784.16.11.1775
   Maxwell S, 2002, J ADDICT DIS, V21, P1, DOI 10.1300/J069v21n03_01
   Mbow ML, 2010, CURR OPIN IMMUNOL, V22, P411, DOI 10.1016/j.coi.2010.04.004
   Mcketin R, 2008, DRUG ALCOHOL REV, V27, P220, DOI 10.1080/09595230801923710
   McMillan DE, 2004, J PHARMACOL EXP THER, V309, P1248, DOI 10.1124/jpet.103.061762
   Meijler Michael M, 2004, Curr Drug Discov Technol, V1, P77, DOI 10.2174/1570163043484851
   Minozzi S, 2011, COCHRANE DATABASE SY
   Moreno AY, 2011, J AM CHEM SOC, V133, P6587, DOI 10.1021/ja108807j
   *NSDUH, 2006, OFF APPL STUD NSDU H, V30
   Orson FM, 2008, ANN NY ACAD SCI, V1141, P257, DOI 10.1196/annals.1441.027
   Orson FM, 2009, HUM VACCINES, V5, P194, DOI 10.4161/hv.5.4.7457
   Ott G, 1995, Pharm Biotechnol, V6, P277
   Peterson EC, 2007, J PHARMACOL EXP THER, V322, P30, DOI 10.1124/jpet.106.117150
   Polosa R, 2011, TRENDS PHARMACOL SCI, V32, P281, DOI 10.1016/j.tips.2010.12.008
   Rook EJ, 2006, BASIC CLIN PHARMACOL, V98, P86, DOI 10.1111/j.1742-7843.2006.pto_233.x
   *SAMHSA, OFF APPL STUD RES 20
   Schijns VEJC, 2011, EXPERT REV VACCINES, V10, P539, DOI [10.1586/erv.11.21, 10.1586/ERV.11.21]
   Schwarz TF, 2009, ADV THER, V26, P983, DOI 10.1007/s12325-009-0079-5
   SHEN XY, 2011, COLL PROBL DRUG DEP, P648
   SHEN XY, 2011, WORLD VACC C, P341
   Spooner C, 2001, DRUG ALCOHOL REV, V20, P281
   STEWART DJ, 1979, CLIN PHARMACOL THER, V25, P464
   Stotts AL, 2009, EXPERT OPIN PHARMACO, V10, P1727, DOI 10.1517/14656560903037168
   Stowe GN, 2011, J MED CHEM, V54, P5195, DOI 10.1021/jm200461m
   Tang YL, 2006, ADDICTION, V101, P657, DOI 10.1111/j.1360-0443.2006.01367.x
   Tobacco Free Initiative (TFI), 2005, WHY IS TOB PUBL HLTH
   United Nations Office on Drugs and Crime, WORLD DRUG REP 2010
   VANVUNAKIS H, 1972, J PHARMACOL EXP THER, V180, P514
   Volkow ND, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015269
   WAINER BH, 1973, J IMMUNOL, V110, P667
   Williams RH, 2000, J ANAL TOXICOL, V24, P478, DOI 10.1093/jat/24.7.478
   CLINICAL TRIALS NICV
NR 88
TC 77
Z9 79
U1 0
U2 39
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD JAN
PY 2012
VL 91
IS 1
BP 60
EP 70
DI 10.1038/clpt.2011.281
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Pharmacology & Pharmacy
GA 865UO
UT WOS:000298336600012
PM 22130115
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Kasanetz, F
   Deroche-Gamonet, V
   Berson, N
   Balado, E
   Lafourcade, M
   Manzoni, O
   Piazza, PV
AF Kasanetz, Fernando
   Deroche-Gamonet, Veronique
   Berson, Nadege
   Balado, Eric
   Lafourcade, Mathieu
   Manzoni, Olivier
   Piazza, Pier Vincenzo
TI Transition to Addiction Is Associated with a Persistent Impairment in
   Synaptic Plasticity
SO SCIENCE
LA English
DT Article
ID LONG-TERM DEPRESSION; DRUG-SEEKING; COCAINE ADDICTION; NEURAL
   MECHANISMS; NUCLEUS-ACCUMBENS; BEHAVIOR; LTD; VTA
AB Chronic exposure to drugs of abuse induces countless modifications in brain physiology. However, the neurobiological adaptations specifically associated with the transition to addiction are unknown. Cocaine self-administration rapidly suppresses long-term depression (LTD), an important form of synaptic plasticity in the nucleus accumbens. Using a rat model of addiction, we found that animals that progressively develop the behavioral hallmarks of addiction have permanently impaired LTD, whereas LTD is progressively recovered in nonaddicted rats maintaining a controlled drug intake. By making drug seeking consistently resistant to modulation by environmental contingencies and consequently more and more inflexible, a persistently impaired LTD could mediate the transition to addiction.
C1 [Kasanetz, Fernando; Deroche-Gamonet, Veronique; Berson, Nadege; Balado, Eric; Lafourcade, Mathieu; Manzoni, Olivier; Piazza, Pier Vincenzo] INSERM, U862, NeuroCtr Magendie, F-33077 Bordeaux, France.
   [Kasanetz, Fernando; Deroche-Gamonet, Veronique; Berson, Nadege; Balado, Eric; Lafourcade, Mathieu; Manzoni, Olivier; Piazza, Pier Vincenzo] Univ Bordeaux, F-33077 Bordeaux, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux; UDICE-French
   Research Universities; Universite de Bordeaux
RP Manzoni, O (通讯作者)，INSERM, U862, NeuroCtr Magendie, 147 Rue Leo Saignat, F-33077 Bordeaux, France.
EM olivier.manzoni@inserm.fr; pier-vincenzo.piazza@inserm.fr
RI Manzoni, Olivier/M-7899-2016; Deroche-Gamonet, Véronique/E-5728-2010;
   Lafourcade, Mathieu/GQZ-7267-2022
OI Manzoni, Olivier/0000-0002-5579-6208; Lafourcade,
   Mathieu/0000-0001-6117-1194; Kasanetz, Fernando/0000-0003-4585-2314;
   Deroche-Gamonet, Veronique/0000-0002-9704-6624
FU ANR [2005]; EU-STREPPheCOMP; MILDT/INCa/Inserm [2008]
FX Supported by ANR (2005), EU-STREPPheCOMP (FP6), MILDT/INCa/Inserm (2008)
   grants to P. V. P., O.M., and V. D.-G. The authors report no conflict of
   interest.
CR Belin D, 2009, BIOL PSYCHIAT, V65, P863, DOI 10.1016/j.biopsych.2008.05.031
   Bellone C, 2006, NAT NEUROSCI, V9, P636, DOI 10.1038/nn1682
   Chen BT, 2008, NEURON, V59, P288, DOI 10.1016/j.neuron.2008.05.024
   Conrad KL, 2008, NATURE, V454, P118, DOI 10.1038/nature06995
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Everitt BJ, 2008, PHILOS T R SOC B, V363, P3125, DOI 10.1098/rstb.2008.0089
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Kalivas PW, 2009, NAT REV NEUROSCI, V10, P561, DOI 10.1038/nrn2515
   Kalivas PW, 2005, NAT NEUROSCI, V8, P1440, DOI 10.1038/nn1105-1440
   Kalivas PW, 2005, NEURON, V45, P647, DOI 10.1016/j.neuron.2005.02.005
   Kauer JA, 2007, NAT REV NEUROSCI, V8, P844, DOI 10.1038/nrn2234
   Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442
   Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012
   Mameli M, 2009, NAT NEUROSCI, V12, P1036, DOI 10.1038/nn.2367
   Martin M, 2006, NAT NEUROSCI, V9, P868, DOI 10.1038/nn1713
   Maze I, 2010, SCIENCE, V327, P213, DOI 10.1126/science.1179438
   Moussawi K, 2009, NAT NEUROSCI, V12, P182, DOI 10.1038/nn.2250
   Nestler EJ, 2008, PHILOS T R SOC B, V363, P3245, DOI 10.1098/rstb.2008.0067
   OBrien CP, 1997, SCIENCE, V278, P66, DOI 10.1126/science.278.5335.66
   Panlilio LV, 2007, ADDICTION, V102, P1863, DOI 10.1111/j.1360-0443.2007.02011.x
   Robbe D, 2002, J NEUROSCI, V22, P4346, DOI 10.1523/JNEUROSCI.22-11-04346.2002
   Robinson TE, 2004, NEUROPHARMACOLOGY, V47, P33, DOI 10.1016/j.neuropharm.2004.06.025
   Sanchis-Segura C, 2006, ADDICT BIOL, V11, P2, DOI 10.1111/j.1369-1600.2006.00012.x
   Shaham Y, 2005, NAT NEUROSCI, V8, P1437, DOI 10.1038/nn1105-1437
   Stuber GD, 2008, SCIENCE, V321, P1690, DOI 10.1126/science.1160873
   Thomas MJ, 2008, BRIT J PHARMACOL, V154, P327, DOI 10.1038/bjp.2008.77
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   WARNER LA, 1995, ARCH GEN PSYCHIAT, V52, P219
   Wolf ME, 2004, NEUROPHARMACOLOGY, V47, P61, DOI 10.1016/j.neuropharm.2004.07.006
   Yin HH, 2009, NAT NEUROSCI, V12, P333, DOI 10.1038/nn.2261
NR 30
TC 272
Z9 277
U1 0
U2 39
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD JUN 25
PY 2010
VL 328
IS 5986
BP 1709
EP 1712
DI 10.1126/science.1187801
PG 4
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 615BY
UT WOS:000279107400048
PM 20576893
DA 2023-06-23
ER

PT J
AU Kim, HJ
   Lee, JH
   Yun, K
   Kim, JH
AF Kim, Hyun Jin
   Lee, Joo Han
   Yun, Kyunghwa
   Kim, Joung-Hun
TI Alterations in Striatal Circuits Underlying Addiction-Like Behaviors
SO MOLECULES AND CELLS
LA English
DT Review
DE addiction-like behaviors; circuit-specific modulation; drug addiction;
   striatal circuits
ID MEDIAL PREFRONTAL CORTEX; CONDITIONED PLACE PREFERENCE; COCAINE-SEEKING
   BEHAVIOR; VENTRAL TEGMENTAL AREA; NUCLEUS-ACCUMBENS; CHOLINERGIC
   INTERNEURONS; BASOLATERAL AMYGDALA; BASAL GANGLIA; STRIATOPALLIDAL
   NEURONS; SILENT SYNAPSES
AB Drug addiction is a severe psychiatric disorder characterized by the compulsive pursuit of drugs of abuse despite potential adverse consequences. Although several decades of studies have revealed that psychostimulant use can result in extensive alterations of neural circuits and physiology, no effective therapeutic strategies or medicines for drug addiction currently exist. Changes in neuronal connectivity and regulation occurring after repeated drug exposure contribute to addiction-like behaviors in animal models. Among the involved brain areas, including those of the reward system, the striatum is the major area of convergence for glutamate, GABA, and dopamine transmission, and this brain region potentially determines stereotyped behaviors. Although the physiological consequences of striatal neurons after drug exposure have been relatively well documented, it remains to be clarified how changes in striatal connectivity underlie and modulate the expression of addiction-like behaviors. Understanding how striatal circuits contribute to addiction-like behaviors may lead to the development of strategies that successfully attenuate drug-induced behavioral changes. In this review, we summarize the results of recent studies that have examined striatal circuitry and pathway-specific alterations leading to addiction-like behaviors to provide an updated framework for future investigations.
C1 [Kim, Hyun Jin; Lee, Joo Han; Yun, Kyunghwa; Kim, Joung-Hun] Pohang Univ Sci & Technol POSTECH, Dept Life Sci, Pohang 37673, South Korea.
C3 Pohang University of Science & Technology (POSTECH)
RP Kim, JH (通讯作者)，Pohang Univ Sci & Technol POSTECH, Dept Life Sci, Pohang 37673, South Korea.
EM joungkim@postech.ac.kr
OI Kim, Hyun Jin/0000-0001-9108-151X
FU National Research Foundation of Korea [2014051826, NRF-2017R1A2B2004122]
FX This work was supported by grants from the National Research Foundation
   of Korea (2014051826 and NRF-2017R1A2B2004122) to J.-H.K.
CR Adamantidis AR, 2011, J NEUROSCI, V31, P10829, DOI 10.1523/JNEUROSCI.2246-11.2011
   Alcantara AA, 2003, BRAIN RES, V986, P22, DOI 10.1016/S0006-8993(03)03165-2
   ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041
   AMALRIC M, 1993, PROG BRAIN RES, V99, P209
   Bock R, 2013, NAT NEUROSCI, V16, P632, DOI 10.1038/nn.3369
   Bolam JP, 2000, J ANAT, V196, P527, DOI 10.1046/j.1469-7580.2000.19640527.x
   Borgland SL, 2004, J NEUROSCI, V24, P7482, DOI 10.1523/JNEUROSCI.1312-04.2004
   Bossert JM, 2011, NAT NEUROSCI, V14, P420, DOI 10.1038/nn.2758
   Britt JP, 2012, NEURON, V76, P790, DOI 10.1016/j.neuron.2012.09.040
   Brown MTC, 2012, NATURE, V492, P452, DOI 10.1038/nature11657
   Brown TE, 2011, J NEUROSCI, V31, P8163, DOI 10.1523/JNEUROSCI.0016-11.2011
   Cachope R, 2012, CELL REP, V2, P33, DOI 10.1016/j.celrep.2012.05.011
   Caine SB, 2007, J NEUROSCI, V27, P13140, DOI 10.1523/JNEUROSCI.2284-07.2007
   Caine SB, 2002, J NEUROSCI, V22, P2977, DOI 10.1523/JNEUROSCI.22-07-02977.2002
   Caine SB, 2001, BEHAV NEUROSCI, V115, P880, DOI 10.1037//0735-7044.115.4.880
   Creed M, 2016, NEURON, V92, P214, DOI 10.1016/j.neuron.2016.09.001
   Crittenden JR, 2011, FRONT NEUROANAT, V5, DOI 10.3389/fnana.2011.00059
   Dalley JW, 2004, NEUROSCI BIOBEHAV R, V28, P771, DOI 10.1016/j.neubiorev.2004.09.006
   Dobbs LK, 2016, NEURON, V90, P1100, DOI 10.1016/j.neuron.2016.04.031
   Durieux PF, 2009, NAT NEUROSCI, V12, P393, DOI 10.1038/nn.2286
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Farrell MS, 2013, NEUROPSYCHOPHARMACOL, V38, P854, DOI 10.1038/npp.2012.251
   Ferguson SM, 2015, CURR OPIN BEHAV SCI, V2, P69, DOI 10.1016/j.cobeha.2014.09.004
   Ferguson SM, 2011, NAT NEUROSCI, V14, P22, DOI 10.1038/nn.2703
   FREUND TF, 1984, NEUROSCIENCE, V13, P1189, DOI 10.1016/0306-4522(84)90294-X
   Fuchs RA, 2002, BRAIN RES, V929, P15, DOI 10.1016/S0006-8993(01)03366-2
   Fuchs RA, 2007, EUR J NEUROSCI, V26, P487, DOI 10.1111/j.1460-9568.2007.05674.x
   Gerfen CR, 2011, ANNU REV NEUROSCI, V34, P441, DOI 10.1146/annurev-neuro-061010-113641
   GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780
   Giorgetti M, 2001, J NEUROSCI, V21, P6362, DOI 10.1523/JNEUROSCI.21-16-06362.2001
   Haber SN, 2003, J CHEM NEUROANAT, V26, P317, DOI 10.1016/j.jchemneu.2003.10.003
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Ishikawa M, 2013, J NEUROSCI, V33, P6759, DOI 10.1523/JNEUROSCI.4694-12.2013
   Kalivas PW, 2009, NAT REV NEUROSCI, V10, P561, DOI 10.1038/nrn2515
   KALIVAS PW, 1993, J NEUROSCI, V13, P266
   Kalivas PW, 2003, PSYCHOPHARMACOLOGY, V168, P44, DOI 10.1007/s00213-003-1393-2
   Killcross S, 2003, CEREB CORTEX, V13, P400, DOI 10.1093/cercor/13.4.400
   Kim J, 2016, NAT NEUROSCI, V19, P1636, DOI 10.1038/nn.4414
   Kincaid AE, 1998, J NEUROSCI, V18, P4722, DOI 10.1523/jneurosci.18-12-04722.1998
   Koya E, 2012, NAT NEUROSCI, V15, P1556, DOI 10.1038/nn.3232
   Koya E, 2009, NEUROPHARMACOLOGY, V56, P177, DOI 10.1016/j.neuropharm.2008.04.022
   Kravitz AV, 2012, NAT NEUROSCI, V15, P816, DOI 10.1038/nn.3100
   Lee BR, 2013, NAT NEUROSCI, V16, P1644, DOI 10.1038/nn.3533
   Lobo MK, 2010, SCIENCE, V330, P385, DOI 10.1126/science.1188472
   Luscher C, 2015, CURR OPIN NEUROBIOL, V35, P95, DOI 10.1016/j.conb.2015.07.005
   Ma YY, 2014, NEURON, V83, P1453, DOI 10.1016/j.neuron.2014.08.023
   MacAskill AF, 2014, NAT NEUROSCI, V17, P1198, DOI 10.1038/nn.3783
   Neve KA, 2004, J RECEPT SIG TRANSD, V24, P165, DOI 10.1081/LRST-200029981
   Ostlund SB, 2005, J NEUROSCI, V25, P7763, DOI 10.1523/JNEUROSCI.1921-05.2005
   Pascoli V, 2015, NEURON, V88, DOI 10.1016/j.neuron.2015.10.017
   Pascoli V, 2014, NATURE, V509, P459, DOI 10.1038/nature13257
   Paton JJ, 2006, NATURE, V439, P865, DOI 10.1038/nature04490
   Peters J, 2008, PSYCHOPHARMACOLOGY, V197, P319, DOI 10.1007/s00213-007-1034-2
   Rogers JL, 2007, NEUROBIOL LEARN MEM, V87, P688, DOI 10.1016/j.nlm.2007.01.003
   Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-7
   Shaham Y, 2000, BRAIN RES REV, V33, P13, DOI 10.1016/S0165-0173(00)00024-2
   Shukla A, 2017, EMBO J, V36, P458, DOI 10.15252/embj.201695465
   SMITH Y, 1994, J COMP NEUROL, V344, P1, DOI 10.1002/cne.903440102
   Stefanik MT, 2013, ADDICT BIOL, V18, P50, DOI 10.1111/j.1369-1600.2012.00479.x
   Steinberg EE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094771
   Stuber GD, 2011, NATURE, V475, P377, DOI 10.1038/nature10194
   Tsai HC, 2009, SCIENCE, V324, P1080, DOI 10.1126/science.1168878
   Tye KM, 2012, NAT REV NEUROSCI, V13, P251, DOI 10.1038/nrn3171
   Tzschentke TM, 1998, PROG NEUROBIOL, V56, P613, DOI 10.1016/S0301-0082(98)00060-4
   Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077
   Walsh JJ, 2014, NAT NEUROSCI, V17, P27, DOI 10.1038/nn.3591
   Warner-Schmidt JL, 2012, P NATL ACAD SCI USA, V109, P11360, DOI 10.1073/pnas.1209293109
   Whitelaw RB, 1996, PSYCHOPHARMACOLOGY, V127, P213, DOI 10.1007/BF02805996
   Wise RA, 1998, DRUG ALCOHOL DEPEN, V51, P13, DOI 10.1016/S0376-8716(98)00063-5
   Wise RA, 2014, NEUROPSYCHOPHARMACOL, V39, P254, DOI 10.1038/npp.2013.261
   Witten IB, 2011, NEURON, V72, P721, DOI 10.1016/j.neuron.2011.10.028
   Yin HH, 2006, NAT REV NEUROSCI, V7, P464, DOI 10.1038/nrn1919
   Yorgason JT, 2017, J NEUROSCI, V37, P2086, DOI 10.1523/JNEUROSCI.3064-16.2017
   Zhu YJ, 2016, NATURE, V530, P219, DOI 10.1038/nature16954
NR 74
TC 21
Z9 23
U1 2
U2 14
PU KOREAN SOC MOLECULAR & CELLULAR  BIOLOGY
PI SEOUL
PA 635-4, YUCKSAM-DONG, GANGNAM-GU, SEOUL 135-703, SOUTH KOREA
SN 1016-8478
EI 0219-1032
J9 MOL CELLS
JI Mol. Cells
PD JUN
PY 2017
VL 40
IS 6
BP 379
EP 385
DI 10.14348/molcells.2017.0088
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA FJ7PS
UT WOS:000412951800001
PM 28724279
OA Green Published, hybrid, Green Submitted
DA 2023-06-23
ER

PT J
AU Navone, S
   Carollo, G
AF Navone, Stefano
   Carollo, Giovanni
TI Extremely fragile: playing with care! A study on music therapy's
   application with young patients suffering from drug addiction
SO NORDIC JOURNAL OF MUSIC THERAPY
LA English
DT Meeting Abstract
DE Drug addiction; emotional states; intersubjectivity; affect attunement
C1 [Navone, Stefano; Carollo, Giovanni] Therapeut Community Ca Ore, Breganze, Italy.
EM musicoterapia@istitutomusicaleveneto.it
NR 0
TC 0
Z9 0
U1 0
U2 5
PU GRIEG ACADEMY
PI BERGEN
PA UNIV BERGEN, DEPT MUSIC, LARS HILLES GATE 3, BERGEN, N-5015, NORWAY
SN 0809-8131
EI 1944-8260
J9 NORD J MUSIC THER
JI Nord. J. Music Ther.
PY 2016
VL 25
SU 1
BP 52
EP 53
DI 10.1080/08098131.2016.1179962
PG 2
WC Rehabilitation
WE Social Science Citation Index (SSCI)
SC Rehabilitation
GA DO0GQ
UT WOS:000377457800087
OA Bronze
DA 2023-06-23
ER

PT J
AU Winter, JJ
   Rodriguez-Acevedo, KL
   Dittrich, M
   Heller, EA
AF Winter, Julia J.
   Rodriguez-Acevedo, Kiara L.
   Dittrich, Mia
   Heller, Elizabeth A.
TI Early life adversity: Epigenetic regulation underlying drug addiction
   susceptibility
SO MOLECULAR AND CELLULAR NEUROSCIENCE
LA English
DT Article
DE Neuroepigenetics; Drug addiction; Sex differences; Early life adversity
ID MATERNAL SEPARATION; STRESS EXPOSURE; SEX-DIFFERENCES; THC EXPOSURE;
   COCAINE; BRAIN; VULNERABILITY; ADOLESCENCE; IMPAIRMENTS; ACQUISITION
AB Drug addiction is a leading cause of disability worldwide, with more than 70,000 Americans dying from drug overdose in 2019 alone. While only a small percentage of chronic drug users escalate to drug addiction, little is understood on the precise mechanisms of this susceptibility. Early life adversity is causally relevant to adult psychiatric disease and may contribute to the risk of addiction. Here we review recent pre-clinical evidence showing that early life exposure to stress and/or drugs regulates changes in behavior, gene expression, and the epigenome that persist into adulthood. We summarize the major findings and gaps in the preclinical literature, highlighting studies that demonstrate the often profound differences between female and male subjects.
C1 [Winter, Julia J.; Rodriguez-Acevedo, Kiara L.; Dittrich, Mia; Heller, Elizabeth A.] Univ Penn, Philadelphia, PA 19106 USA.
C3 University of Pennsylvania
RP Heller, EA (通讯作者)，Univ Penn, Philadelphia, PA 19106 USA.
EM eheller@pennmedicine.upenn.edu
FU NIH-NIDA Avenir Director's Pioneer Award [DP1DA044250]; NIDA Research
   Project Grant [R01DA052465, R01MH126027]; National Science Foundation
   Graduate Research Fellowship [DGE-1845298]
FX The authors acknowledge Yuan Li for pencil artwork in Fig. 1. Financial
   support was provided by NIH-NIDA Avenir Director's Pioneer Award (E.A.H,
   DP1DA044250), NIDA Research Project Grant (E.A.H, R01DA052465,
   R01MH126027), and the National Science Foundation Graduate Research
   Fellowship under Grant No. DGE-1845298 (K.L.R.).
CR Altshuler RD, 2021, FRONT BEHAV NEUROSCI, V15, DOI 10.3389/fnbeh.2021.697509
   Alves RL, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70242-4
   Anderson EM, 2019, NEUROPSYCHOPHARMACOL, V44, P1370, DOI 10.1038/s41386-018-0305-4
   Trujillo CA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225384
   Areal LB, 2020, NEUROCHEM INT, V137, DOI 10.1016/j.neuint.2020.104747
   Bagot RC, 2014, DIALOGUES CLIN NEURO, V16, P281
   Bangasser DA, 2019, NEUROPSYCHOPHARMACOL, V44, P129, DOI 10.1038/s41386-018-0137-2
   Bangasser DA, 2017, J NEUROSCI RES, V95, P75, DOI 10.1002/jnr.23812
   Baracz SJ, 2022, NEUROPSYCHOPHARMACOL, V47, P1561, DOI 10.1038/s41386-022-01336-y
   Baratta AM, 2021, INT REV NEUROBIOL, V156, P217, DOI 10.1016/bs.irn.2020.08.003
   Becker J., 2018, SEX DIFFERENCES BRAI
   Becker JB, 2019, NEUROPSYCHOPHARMACOL, V44, P166, DOI 10.1038/s41386-018-0125-6
   Becker JB, 2016, DIALOGUES CLIN NEURO, V18, P395
   Birn RM, 2017, P NATL ACAD SCI USA, V114, P13549, DOI 10.1073/pnas.1708791114
   Bis-Humbert C, 2021, PSYCHOPHARMACOLOGY, V238, P3399, DOI 10.1007/s00213-021-05955-z
   Blanco C, 2018, AM J ADDICTION, V27, P477, DOI 10.1111/ajad.12764
   Bohnsack JP, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abn2748
   Bohnsack JP, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0367-z
   Browne CJ, 2020, BIOL PSYCHIAT, V87, P22, DOI 10.1016/j.biopsych.2019.06.027
   Bryant DJ, 2020, PSYCHOL TRAUMA-US, V12, pS193, DOI 10.1037/tra0000711
   Brynildsen JK, 2020, BEHAV BRAIN RES, V395, DOI 10.1016/j.bbr.2020.112842
   Butelman ER, 2020, EXP CLIN PSYCHOPHARM, V28, P317, DOI 10.1037/pha0000314
   Cabana-Dominguez J, 2019, PROG NEURO-PSYCHOPH, V94, DOI 10.1016/j.pnpbp.2019.109667
   Caffino L., 2021, EFFECTS PCOCAINE EXP, DOI [10.1111/bph.v179.17/issuetoc, DOI 10.1111/BPH.V179.17/ISSUETOC]
   Carpenter MD, 2021, ADDICT BIOL, V26, DOI 10.1111/adb.12994
   Carr CC, 2020, PSYCHOPHARMACOLOGY, V237, P1795, DOI 10.1007/s00213-020-05500-4
   Castro-Zavala A, 2020, EUR NEUROPSYCHOPHARM, V32, P12, DOI 10.1016/j.euroneuro.2019.12.112
   Cisse YM, 2020, PLACENTA, V100, P164, DOI 10.1016/j.placenta.2020.06.019
   DePoy LM, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.150
   Dufford AJ, 2020, INT REV NEUROBIOL, V150, P77, DOI 10.1016/bs.irn.2019.12.001
   Dulman RS, 2020, CURR PATHOBIOL REP, V8, P61, DOI 10.1007/s40139-020-00210-0
   Eck SR, 2020, NEUROSCI BIOBEHAV R, V119, P86, DOI 10.1016/j.neubiorev.2020.09.014
   Fernandez-Castillo N, 2022, MOL PSYCHIATR, V27, P624, DOI 10.1038/s41380-021-01256-1
   Flagel SB, 2016, P NATL ACAD SCI USA, V113, pE2861, DOI 10.1073/pnas.1520491113
   Fosnocht AQ, 2019, BEHAV BRAIN RES, V359, P589, DOI 10.1016/j.bbr.2018.10.007
   Garcia-Cabrerizo R, 2019, J PSYCHOPHARMACOL, V33, P154, DOI 10.1177/0269881118812353
   Gerra MC, 2021, GENES-BASEL, V12, DOI 10.3390/genes12081226
   Goodwill HL, 2019, NEUROPSYCHOPHARMACOL, V44, P711, DOI 10.1038/s41386-018-0195-5
   Guadagno A, 2021, FRONT HUM NEUROSCI, V15, DOI 10.3389/fnhum.2021.669120
   Guarino H, 2021, FRONT SOCIOL, V6, DOI 10.3389/fsoc.2021.620395
   Guarino H, 2018, ADDICT BEHAV, V86, P118, DOI 10.1016/j.addbeh.2018.04.017
   Hamidullah S, 2020, FRONT HUM NEUROSCI, V14, DOI 10.3389/fnhum.2020.00298
   Hanson JL, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.744690
   Hay EA, 2019, PSYCHONEUROENDOCRINO, V109, DOI 10.1016/j.psyneuen.2019.104407
   Heck AL, 2019, NEUROPSYCHOPHARMACOL, V44, P45, DOI 10.1038/s41386-018-0167-9
   Jaric I, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10704-0
   Jaric I, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00074
   Jastrzebska J, 2015, BEHAV BRAIN RES, V293, P62, DOI 10.1016/j.bbr.2015.06.040
   Kaplan G, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.806685
   Kember RL, 2012, BRAIN BEHAV, V2, P455, DOI 10.1002/brb3.69
   Kharas N, 2019, BEHAV BRAIN RES, V362, P36, DOI 10.1016/j.bbr.2018.12.018
   Kronman H, 2021, NAT NEUROSCI, V24, P667, DOI 10.1038/s41593-021-00814-8
   Kundakovic M, 2022, FRONT NEUROENDOCRIN, V66, DOI 10.1016/j.yfrne.2022.101010
   Kyzar EJ, 2019, BIOL PSYCHIAT, V85, P904, DOI 10.1016/j.biopsych.2018.12.021
   Lacy RT, 2018, EXP CLIN PSYCHOPHARM, V26, P18, DOI 10.1037/pha0000164
   Lepack AE, 2020, SCIENCE, V368, P197, DOI 10.1126/science.aaw8806
   Levis SC, 2022, EUR J NEUROSCI, V55, P2170, DOI 10.1111/ejn.15223
   Lewis CR, 2014, BEHAV PHARMACOL, V25, P341, DOI 10.1097/FBP.0000000000000057
   Leza L, 2021, DRUG ALCOHOL DEPEN, V221, DOI 10.1016/j.drugalcdep.2021.108563
   Lopez AJ, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02358-w
   Maldonado R, 2021, AM J MED GENET B, V186, P128, DOI 10.1002/ajmg.b.32843
   Malvaez M, 2018, CURR OPIN BEHAV SCI, V20, P67, DOI 10.1016/j.cobeha.2017.11.005
   Matosin N, 2018, BIOL PSYCHIAT, V83, P821, DOI 10.1016/j.biopsych.2018.01.021
   McCabe SE, 2019, DRUG ALCOHOL DEPEN, V194, P377, DOI 10.1016/j.drugalcdep.2018.10.027
   McEwen C.A., 2017, SOCIAL STRUCTURE ADV, V29, DOI [10.1146/annurev-soc-060116, DOI 10.1146/ANNUREV-SOC-060116]
   McHugh RK, 2018, CLIN PSYCHOL REV, V66, P12, DOI 10.1016/j.cpr.2017.10.012
   Moreno-Lopez L, 2020, BIOL PSYCHIAT-COGN N, V5, P392, DOI 10.1016/j.bpsc.2019.12.008
   Murphy MD, 2022, TRENDS NEUROSCI, V45, P955, DOI 10.1016/j.tins.2022.10.001
   Nam H, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00109
   National Institute on Drug Abuse, 2020, SUBST US WOM RES REP
   Nestler EJ, 2019, NEURON, V102, P48, DOI 10.1016/j.neuron.2019.01.016
   Novick AM, 2018, J PSYCHIATR RES, V101, P80, DOI 10.1016/j.jpsychires.2018.02.002
   Orihuel J, 2021, INT J NEUROPSYCHOPH, V24, P920, DOI 10.1093/ijnp/pyab058
   Parsegian A, 2022, FRONT PSYCHIATRY, V13, DOI 10.3389/fpsyt.2022.1024617
   Pena CJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13085-6
   Peter CJ, 2016, BIOL PSYCHIAT, V80, P765, DOI 10.1016/j.biopsych.2016.03.2100
   Petruccelli K, 2019, CHILD ABUSE NEGLECT, V97, DOI 10.1016/j.chiabu.2019.104127
   Policarpi C, 2021, BIOESSAYS, V43, DOI 10.1002/bies.202000316
   Prini P, 2018, J PSYCHIATR NEUROSCI, V43, P87, DOI 10.1503/jpn.170082
   Quigley JA, 2021, NEUROPHARMACOLOGY, V187, DOI 10.1016/j.neuropharm.2021.108491
   Rana S, 2015, NEUROSCI LETT, V584, P146, DOI 10.1016/j.neulet.2014.10.011
   Reed B, 2021, CSH PERSPECT MED, V11, DOI 10.1101/cshperspect.a039735
   Rocks D, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-30961-w
   Russo AM, 2019, BEHAV BRAIN RES, V359, P918, DOI 10.1016/j.bbr.2018.06.019
   Sakharkar AJ, 2016, BRAIN STRUCT FUNCT, V221, P4691, DOI 10.1007/s00429-016-1196-y
   Salmanzadeh H, 2020, BRAIN RES BULL, V156, P105, DOI 10.1016/j.brainresbull.2020.01.007
   Sanchez EO, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2020173118
   Scherma M., 2020, P NATL ACAD SCI
   Schmidt MV, 2011, PSYCHOPHARMACOLOGY, V214, P131, DOI 10.1007/s00213-010-2096-0
   Schrott R, 2022, EPIGENET CHROMATIN, V15, DOI 10.1186/s13072-022-00466-3
   Shepard RD, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.588476
   Shepard RD, 2018, EXP NEUROL, V309, P160, DOI 10.1016/j.expneurol.2018.08.002
   Sheridan MA, 2022, DEV COGN NEUROS-NETH, V54, DOI 10.1016/j.dcn.2022.101082
   Shlomi S, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23094945
   Shu GH, 2018, LEARN MEMORY, V25, P109, DOI 10.1101/lm.046920.117
   Silberman DM, 2016, PHARMACOL RES, V109, P64, DOI 10.1016/j.phrs.2015.12.033
   Smith KE, 2020, J NEURODEV DISORD, V12, DOI 10.1186/s11689-020-09337-y
   Spear L.P., 2016, CURR ADDICT REP, V3, P50, DOI [10.1007/S40429-016-0088-9/TABLES/2, DOI 10.1007/S40429-016-0088-9]
   Stead JDH, 2006, BEHAV GENET, V36, P697, DOI 10.1007/s10519-006-9058-7
   Stedenfeld KA, 2011, PHYSIOL BEHAV, V103, P210, DOI 10.1016/j.physbeh.2011.02.001
   Stein MD, 2017, DRUG ALCOHOL DEPEN, V179, P325, DOI 10.1016/j.drugalcdep.2017.07.007
   Substance Abuse and Mental Health Services Administration, 2020, KEY SUBSTANCE USE ME
   Swalve N, 2016, PSYCHOPHARMACOLOGY, V233, P1005, DOI 10.1007/s00213-015-4183-8
   Szutorisz H, 2022, NEURON, V110, P1611, DOI 10.1016/j.neuron.2022.03.018
   Szutorisz H, 2016, NEUROTOXICOL TERATOL, V58, P107, DOI 10.1016/j.ntt.2016.05.005
   Targum Steven D, 2019, Innov Clin Neurosci, V16, P35
   Torres-Berrio A, 2019, DIALOGUES CLIN NEURO, V21, P341, DOI 10.31887/DCNS.2019.21.4/enestler
   Tschetter KE, 2021, INT REV NEUROBIOL, V161, P277, DOI 10.1016/bs.irn.2021.08.007
   Tsuchimine S, 2020, BIOCHEM BIOPH RES CO, V525, P33, DOI 10.1016/j.bbrc.2020.02.073
   Usui N, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.754198
   Vassoler FM, 2020, NEUROPHARMACOLOGY, V162, DOI 10.1016/j.neuropharm.2019.107852
   Vassoler FM, 2019, PSYCHOPHARMACOLOGY, V236, P1261, DOI 10.1007/s00213-018-5132-0
   Veliz P, 2022, AM J ADDICTION, V31, P180, DOI 10.1111/ajad.13281
   Walker CD, 2017, STRESS, V20, P421, DOI 10.1080/10253890.2017.1343296
   Walker DM, 2020, bioRxiv, DOI [10.1101/2020.02.18.955187, 10.1101/ 2020.02.18.955187, DOI 10.1101/2020.02.18.955187]
   Watson CT, 2015, NEUROPSYCHOPHARMACOL, V40, P2993, DOI 10.1038/npp.2015.155
   Williams AR, 2020, J LAW MED ETHICS, V48, P268, DOI 10.1177/1073110520935338
   Windisch KA, 2020, PHARMACOL BIOCHEM BE, V198, DOI 10.1016/j.pbb.2020.173022
   Xu SJ, 2021, NEURON, V109, P2943, DOI 10.1016/j.neuron.2021.08.008
   Zuo YN, 2022, NEUROPSYCHOPHARMACOL, V47, P2071, DOI 10.1038/s41386-022-01413-2
NR 120
TC 0
Z9 0
U1 1
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1044-7431
EI 1095-9327
J9 MOL CELL NEUROSCI
JI Mol. Cell. Neurosci.
PD JUN
PY 2023
VL 125
AR 103825
DI 10.1016/j.mcn.2023.103825
EA MAR 2023
PG 8
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA G9FE7
UT WOS:000992121100001
PM 36842544
OA hybrid
DA 2023-06-23
ER

PT J
AU Keramati, M
   Durand, A
   Girardeau, P
   Gutkin, B
   Ahmed, SH
AF Keramati, Mehdi
   Durand, Audrey
   Girardeau, Paul
   Gutkin, Boris
   Ahmed, Serge H.
TI Cocaine Addiction as a Homeostatic Reinforcement Learning Disorder
SO PSYCHOLOGICAL REVIEW
LA English
DT Article
DE drug addiction; homeostatic regulation; reinforcement learning;
   goal-directed planning; escalation
ID NUCLEUS-ACCUMBENS NEURONS; DOSE-RESPONSE FUNCTIONS; SUBSTANCE USE
   DISORDERS; DOPAMINE D2 RECEPTORS; MEDIUM SPINY NEURONS; DRUG-ADDICTION;
   RHESUS-MONKEYS; DISCRIMINATIVE STIMULUS; GLUTAMATE HOMEOSTASIS;
   DECISION-MAKING
AB Drug addiction implicates both reward learning and homeostatic regulation mechanisms of the brain. This has stimulated 2 partially successful theoretical perspectives on addiction. Many important aspects of addiction, however, remain to be explained within a single, unified framework that integrates the 2 mechanisms. Building upon a recently developed homeostatic reinforcement learning theory, the authors focus on a key transition stage of addiction that is well modeled in animals, escalation of drug use, and propose a computational theory of cocaine addiction where cocaine reinforces behavior due to its rapid homeostatic corrective effect, whereas its chronic use induces slow and long-lasting changes in homeostatic setpoint. Simulations show that our new theory accounts for key behavioral and neurobiological features of addiction, most notably, escalation of cocaine use, drug-primed craving and relapse, individual differences underlying dose-response curves, and dopamine D2-receptor downregulation in addicts. The theory also generates unique predictions about cocaine self-administration behavior in rats that are confirmed by new experimental results. Viewing addiction as a homeostatic reinforcement learning disorder coherently explains many behavioral and neurobiological aspects of the transition to cocaine addiction, and suggests a new perspective toward understanding addiction.
C1 [Keramati, Mehdi] UCL, Gatsby Computat Neurosci Unit, 25 Howland St, London W1T 4JG, England.
   [Keramati, Mehdi; Gutkin, Boris] PSL Res Univ, Ecole Normale Super, Dept Etud Cognit, Grp Neural Theory,INSERM U960, Paris, France.
   [Durand, Audrey; Girardeau, Paul; Ahmed, Serge H.] Univ Bordeaux, Inst Malad Neurodegenerat, Bordeaux, France.
   [Durand, Audrey; Girardeau, Paul; Ahmed, Serge H.] CNRS, Inst Malad Neurodegenerat, Bordeaux, France.
   [Gutkin, Boris] Natl Res Univ, Higher Sch Econ, Ctr Cognit & Decis Making, Moscow, Russia.
C3 University of London; University College London; Institut National de la
   Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Universite PSL; Ecole Normale Superieure (ENS);
   UDICE-French Research Universities; Universite de Bordeaux; Centre
   National de la Recherche Scientifique (CNRS); HSE University (National
   Research University Higher School of Economics)
RP Keramati, M (通讯作者)，UCL, Gatsby Computat Neurosci Unit, 25 Howland St, London W1T 4JG, England.; Ahmed, SH (通讯作者)，Univ Bordeaux, Inst Malad Neurodegenerat, UMR CNRS 5293, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
EM mehdi@gatsby.ucl.ac.uk; serge.ahmed@u-bordeaux.fr
RI Gutkin, Boris/ABC-5754-2020
OI Gutkin, Boris/0000-0001-6409-979X; Ahmed, Serge/0000-0002-1225-9234
FU Frontiers du Vivant; French MESR; CNRS; INSERM; ANR; ENP; NERF; French
   Research Council (CNRS); Universite de Bordeaux; French National Agency
   (ANR) [ANR2010-BLAN-1404-01]; Conseil Regional d'Aquitaine
   [CRA20101301022, CRA11004375/11004699]; LabEX BRAIN [ANR-10-LABX-43];
   Russian Academic Excellence Project '5-100'
FX Mehdi Keramati and Boris Gutkin are supported by grants from Frontiers
   du Vivant, the French MESR, CNRS, INSERM, ANR, ENP and NERF. Serge H.
   Ahmed is supported by the French Research Council (CNRS), the Universite
   de Bordeaux, the French National Agency (ANR, ANR2010-BLAN-1404-01), the
   Conseil Regional d'Aquitaine (CRA20101301022; CRA11004375/11004699) and
   the LabEX BRAIN (ANR-10-LABX-43). Boris Gutkin also acknowledges support
   from the Russian Academic Excellence Project '5-100.' We thank Peter
   Dayan for critical discussions.
CR Ahmed SH, 2012, NEUROSCIENCE, V211, P107, DOI 10.1016/j.neuroscience.2011.08.014
   Ahmed SH, 2011, BEHAV BRAIN SCI, V34, P310, DOI 10.1017/S0140525X11000677
   Ahmed SH, 2006, NEUROPSYCHOPHARMACOL, V31, P563, DOI 10.1038/sj.npp.1300834
   Ahmed SH, 2005, EUR J PHARMACOL, V526, P9, DOI 10.1016/j.ejphar.2005.09.036
   Ahmed SH, 2005, PSYCHOPHARMACOLOGY, V180, P473, DOI 10.1007/s00213-005-2180-z
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Ahmed SH, 1999, PSYCHOPHARMACOLOGY, V146, P303, DOI 10.1007/s002130051121
   Ahmed SH, 2004, PSYCHOPHARMACOLOGY, V172, P450, DOI 10.1007/s00213-003-1682-9
   Ahmed SH, 2003, J NEUROCHEM, V86, P102, DOI 10.1046/j.1471-4159.2003.01833.x
   ALEXANDER BK, 1981, PHARMACOL BIOCHEM BE, V15, P571, DOI 10.1016/0091-3057(81)90211-2
   ALEXANDER BK, 1982, PSYCHOL BULL, V92, P367, DOI 10.1037/0033-2909.92.2.367
   Altman J, 1996, PSYCHOPHARMACOLOGY, V125, P285, DOI 10.1007/BF02246016
   Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244
   Anthony JC, 2005, CLIN NEUROSCI RES, V5, P55, DOI 10.1016/j.cnr.2005.08.002
   Bachtell RK, 2005, PSYCHOPHARMACOLOGY, V183, P41, DOI 10.1007/s00213-005-0133-1
   Badiani A, 2011, NAT REV NEUROSCI, V12, P685, DOI 10.1038/nrn3104
   Baker DA, 2003, NAT NEUROSCI, V6, P743, DOI 10.1038/nn1069
   Bardo MT, 2001, PSYCHOPHARMACOLOGY, V155, P278
   Bari AA, 2005, NEUROSCIENCE, V135, P959, DOI 10.1016/j.neuroscience.2005.06.048
   Baumeister RF, 2015, ADDICT BEHAV, V44, P3, DOI 10.1016/j.addbeh.2014.09.011
   Ben-Shahar O, 2007, BRAIN RES, V1131, P220, DOI 10.1016/j.brainres.2006.10.069
   Ben-Shahar OM, 2012, ADDICT BIOL, V17, P746, DOI 10.1111/j.1369-1600.2011.00428.x
   Bertran-Gonzalez J, 2013, J NEUROSCI, V33, P16060, DOI 10.1523/JNEUROSCI.1927-13.2013
   Bock R, 2013, NAT NEUROSCI, V16, P632, DOI 10.1038/nn.3369
   Briand LA, 2008, NEUROPSYCHOPHARMACOL, V33, P2969, DOI 10.1038/npp.2008.18
   CAINE SB, 1995, BRAIN RES, V692, P47
   Calipari ES, 2016, P NATL ACAD SCI USA, V113, P2726, DOI 10.1073/pnas.1521238113
   Carlezon WA, 2009, NEUROPHARMACOLOGY, V56, P122, DOI 10.1016/j.neuropharm.2008.06.075
   CARROLL ME, 1989, PSYCHOPHARMACOLOGY, V97, P23, DOI 10.1007/BF00443407
   CARROLL ME, 1993, PSYCHOPHARMACOLOGY, V110, P5, DOI 10.1007/BF02246944
   Carroll ME, 1997, PSYCHOPHARMACOLOGY, V129, P206, DOI 10.1007/s002130050182
   Chandra R, 2013, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00013
   Conklin CA, 2002, ADDICTION, V97, P155, DOI 10.1046/j.1360-0443.2002.00014.x
   Conrad KL, 2010, NEUROSCIENCE, V169, P182, DOI 10.1016/j.neuroscience.2010.04.056
   Daw ND, 2005, NAT NEUROSCI, V8, P1704, DOI 10.1038/nn1560
   de Wit H, 2012, NEUROSCI BIOBEHAV R, V36, P1565, DOI 10.1016/j.neubiorev.2012.04.005
   Desai RI, 2010, J PHARMACOL EXP THER, V333, P834, DOI 10.1124/jpet.110.165746
   Dezfouli A, 2009, NEURAL COMPUT, V21, P2869, DOI 10.1162/neco.2009.10-08-882
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   DICLEMENTE CC, 2006, ADDICTION CHANGE ADD
   Dobbs LK, 2016, NEURON, V90, P1100, DOI 10.1016/j.neuron.2016.04.031
   Doyle SE, 2014, BIOL PSYCHIAT, V76, P810, DOI 10.1016/j.biopsych.2014.02.005
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Faupel C. E., 2009, SOCIOLOGY AM DRUG US
   Frantz KJ, 2007, NEUROPSYCHOPHARMACOL, V32, P625, DOI 10.1038/sj.npp.1301130
   Gerfen CR, 2011, ANNU REV NEUROSCI, V34, P441, DOI 10.1146/annurev-neuro-061010-113641
   Gershman SJ, 2010, PSYCHOL REV, V117, P197, DOI 10.1037/a0017808
   Glantz M. D., 1992, VULNERABILITY DRUG A
   Green TA, 2002, PSYCHOPHARMACOLOGY, V162, P373, DOI 10.1007/s00213-002-1134-y
   Guillem K, 2014, BIOL PSYCHIAT, V76, P31, DOI 10.1016/j.biopsych.2013.08.032
   Heilig M, 2016, NAT REV NEUROSCI, V17, P592, DOI 10.1038/nrn.2016.67
   Heyman GM, 2013, ANNU REV CLIN PSYCHO, V9, P29, DOI 10.1146/annurev-clinpsy-032511-143041
   Higgins ST, 2004, ANNU REV PSYCHOL, V55, P431, DOI 10.1146/annurev.psych.55.090902.142033
   Hikida T, 2010, NEURON, V66, P896, DOI 10.1016/j.neuron.2010.05.011
   Hogarth L, 2015, CURR TOP BEHAV NEURO, V23, P165, DOI 10.1007/978-3-319-13665-3_7
   Howes SR, 2000, PSYCHOPHARMACOLOGY, V151, P55, DOI 10.1007/s002130000451
   Hser YI, 2008, ADDICT BEHAV, V33, P1581, DOI 10.1016/j.addbeh.2008.07.024
   JAFFE JH, 1989, PSYCHOPHARMACOLOGY, V97, P59, DOI 10.1007/BF00443414
   Kalivas PW, 2009, NAT REV NEUROSCI, V10, P561, DOI 10.1038/nrn2515
   Keiflin R, 2008, PSYCHOPHARMACOLOGY, V197, P649, DOI 10.1007/s00213-008-1083-1
   Kendler KS, 2012, NAT NEUROSCI, V15, P181, DOI 10.1038/nn.3018
   Keramati M, 2014, ELIFE, V3, DOI 10.7554/eLife.04811
   Keramati M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061489
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Kourrich S, 2015, NAT REV NEUROSCI, V16, P173, DOI 10.1038/nrn3877
   Lamas X, 1998, PHARMACOL BIOCHEM BE, V60, P357, DOI 10.1016/S0091-3057(98)00021-5
   Lenoir M, 2008, NEUROPSYCHOPHARMACOL, V33, P2272, DOI 10.1038/sj.npp.1301602
   Lenoir M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000698
   Lobo MK, 2011, FRONT NEUROANAT, V5, DOI 10.3389/fnana.2011.00041
   Lobo MK, 2010, SCIENCE, V330, P385, DOI 10.1126/science.1188472
   Luscher C, 2011, NEURON, V69, P650, DOI 10.1016/j.neuron.2011.01.017
   Luo ZC, 2011, J NEUROSCI, V31, P13180, DOI 10.1523/JNEUROSCI.2369-11.2011
   Lynch WJ, 2006, PSYCHOPHARMACOLOGY, V185, P306, DOI 10.1007/s00213-006-0323-5
   Mahoney JJ, 2007, PROG NEURO-PSYCHOPH, V31, P593, DOI 10.1016/j.pnpbp.2006.12.004
   Mantsch JR, 1998, PSYCHOPHARMACOLOGY, V135, P423, DOI 10.1007/s002130050531
   Martinez D, 2009, NEUROPSYCHOPHARMACOL, V34, P1774, DOI 10.1038/npp.2008.235
   Mihindou C, 2011, BIOL PSYCHIAT, V70, P593, DOI 10.1016/j.biopsych.2011.03.036
   Morgan D, 2002, NAT NEUROSCI, V5, P169, DOI 10.1038/nn798
   NADER MA, 1992, BEHAV PHARMACOL, V3, P635
   NADER MA, 1991, PSYCHOPHARMACOLOGY, V105, P169, DOI 10.1007/BF02244304
   Nader MA, 2002, NEUROPSYCHOPHARMACOL, V27, P35, DOI 10.1016/S0893-133X(01)00427-4
   Nader MA, 2008, PHILOS T R SOC B, V363, P3223, DOI 10.1098/rstb.2008.0092
   Nader MA, 2006, NAT NEUROSCI, V9, P1050, DOI 10.1038/nn1737
   Negus SS, 2003, NEUROPSYCHOPHARMACOL, V28, P919, DOI 10.1038/sj.npp.1300096
   Newlin DB, 2012, SPR SER COMPUT NEURO, V10, P57, DOI 10.1007/978-1-4614-0751-5_3
   Park K, 2013, J NEUROSCI, V33, P15827, DOI 10.1523/JNEUROSCI.1935-13.2013
   Pascoli V, 2014, NATURE, V509, P459, DOI 10.1038/nature13257
   Peoples L L, 2007, ScientificWorldJournal, V7, P22
   Peoples LL, 2007, NEUROPSYCHOPHARMACOL, V32, P1141, DOI 10.1038/sj.npp.1301203
   Peoples LL, 1999, BRAIN RES, V822, P231, DOI 10.1016/S0006-8993(98)01271-2
   Peoples LL, 2003, J NEUROPHYSIOL, V90, P993, DOI 10.1152/jn.00849.2002
   Peoples LL, 1998, J NEUROSCI, V18, P7588
   PETTIT HO, 1989, PHARMACOL BIOCHEM BE, V34, P899, DOI 10.1016/0091-3057(89)90291-8
   Piazza PV, 2000, J NEUROSCI, V20, P4226
   Pickard Hanna, 2012, AJOB Neurosci, V3, P40
   PICKENS R, 1968, J PHARMACOL EXP THER, V161, P122
   Rangel A, 2008, NAT REV NEUROSCI, V9, P545, DOI 10.1038/nrn2357
   Rangel A, 2013, NAT NEUROSCI, V16, P1717, DOI 10.1038/nn.3561
   Redish AD, 2007, PSYCHOL REV, V114, P784, DOI 10.1037/0033-295X.114.3.784
   Redish AD, 2004, SCIENCE, V306, P1944, DOI 10.1126/science.1102384
   Root DH, 2015, PROG NEUROBIOL, V130, P29, DOI 10.1016/j.pneurobio.2015.03.005
   SCHENK S, 1987, NEUROSCI LETT, V81, P227, DOI 10.1016/0304-3940(87)91003-2
   Scofield MD, 2016, PHARMACOL REV, V68, P816, DOI 10.1124/pr.116.012484
   Self D. W., 2014, BIOL PSYCHIAT
   Shaffer HJ, 2002, ADDICTION, V97, P543, DOI 10.1046/j.1360-0443.2002.00114.x
   Siegel R K, 1984, NIDA Res Monogr, V50, P92
   Smith KS, 2009, BEHAV BRAIN RES, V196, P155, DOI 10.1016/j.bbr.2008.09.038
   Smith RJ, 2013, CURR OPIN NEUROBIOL, V23, P546, DOI 10.1016/j.conb.2013.01.026
   Soares-Cunha C, 2016, NEUROSCI BIOBEHAV R, V68, P370, DOI 10.1016/j.neubiorev.2016.05.021
   Sughondhabirom A, 2005, PSYCHOPHARMACOLOGY, V180, P436, DOI 10.1007/s00213-005-2192-8
   Suto N, 2011, J NEUROSCI, V31, P17917, DOI 10.1523/JNEUROSCI.1903-11.2011
   Suto N, 2009, PSYCHOPHARMACOLOGY, V205, P431, DOI 10.1007/s00213-009-1553-0
   Sutton R. S., 1998, REINFORCEMENT LEARNI
   Terrier J, 2016, NEUROPSYCHOPHARMACOL, V41, P1779, DOI 10.1038/npp.2015.345
   Thanos PK, 2008, SYNAPSE, V62, P481, DOI 10.1002/syn.20523
   Tsibulsky VL, 1999, BRAIN RES, V839, P85, DOI 10.1016/S0006-8993(99)01717-5
   Volkow ND, 1999, AM J PSYCHIAT, V156, P1440
   Volkow ND, 1997, NATURE, V386, P830, DOI 10.1038/386830a0
   VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
   Volkow ND, 2015, CELL, V162, P712, DOI 10.1016/j.cell.2015.07.046
   WEE S, 2006, THE JOURNAL OF PHARM, V320, P1134, DOI DOI 10.1124/JPET.106.113340
   Wheeler RA, 2009, NEUROPHARMACOLOGY, V56, P149, DOI 10.1016/j.neuropharm.2008.06.028
   WISE RA, 1995, PSYCHOPHARMACOLOGY, V120, P10, DOI 10.1007/BF02246140
   Wise RA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002846
   Wolf ME, 2016, NAT REV NEUROSCI, V17, P351, DOI 10.1038/nrn.2016.39
   Yager LM, 2015, NEUROSCIENCE, V301, P529, DOI 10.1016/j.neuroscience.2015.06.033
   Zahm DS, 2000, NEUROSCI BIOBEHAV R, V24, P85, DOI 10.1016/S0149-7634(99)00065-2
   Zittel-Lazarini A, 2007, PSYCHOPHARMACOLOGY, V192, P337, DOI 10.1007/s00213-007-0724-0
NR 129
TC 26
Z9 26
U1 2
U2 34
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0033-295X
EI 1939-1471
J9 PSYCHOL REV
JI Psychol. Rev.
PD MAR
PY 2017
VL 124
IS 2
BP 130
EP 153
DI 10.1037/rev0000046
PG 24
WC Psychology; Psychology, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology
GA EN2UI
UT WOS:000395865300002
PM 28095003
OA Green Accepted, Green Submitted
DA 2023-06-23
ER

PT J
AU Hyman, SE
   Malenka, RC
   Nestler, EJ
AF Hyman, Steven E.
   Malenka, Robert C.
   Nestler, Eric J.
TI Neural mechanisms of addiction: The role of reward-related learning and
   memory
SO ANNUAL REVIEW OF NEUROSCIENCE
SE Annual Review of Neuroscience
LA English
DT Article; Book Chapter
DE associative memory; dopamine; plasticity; drug; reward
AB Addiction is a state of compulsive drug use; despite treatment and other attempts to control drug taking, addiction tends to persist. Clinical and laboratory observations have converged on the hypothesis that addiction represents the pathological usurpation of neural processes that normally serve reward-related learning. The major substrates of persistent compulsive drug use are hypothesized to be molecular and cellular mechanisms that underlie long-term associative memories in several forebrain circuits (involving the ventral and dorsal striatum and prefrontal cortex) that receive input from midbrain dopamine neurons. Here we review progress in identifying candidate mechanisms of addiction.
C1 Harvard Univ, Off Provost, Cambridge, MA 02138 USA.
   Stanford Univ, Nancy Pritzker Lab, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA.
   Univ Texas, Dept Psychiat, SW Med Ctr, Dallas, TX 75390 USA.
   Univ Texas, Ctr Basic Neurosci, SW Med Ctr, Dallas, TX 75390 USA.
C3 Harvard University; Stanford University; University of Texas System;
   University of Texas Dallas; University of Texas Southwestern Medical
   Center Dallas; University of Texas System; University of Texas Dallas;
   University of Texas Southwestern Medical Center Dallas
RP Hyman, SE (通讯作者)，Harvard Univ, Off Provost, Cambridge, MA 02138 USA.
EM seh@harvard.edu; malenka@stanford.edu; Eric.Nestler@UTSouthwestern.edu
NR 0
TC 1816
Z9 1866
U1 4
U2 372
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA
SN 0147-006X
EI 1545-4126
J9 ANNU REV NEUROSCI
JI Annu. Rev. Neurosci.
PY 2006
VL 29
BP 565
EP 598
DI 10.1146/annurev.neuro.29.051605.113009
PG 34
WC Neurosciences
WE Book Citation Index– Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 074JF
UT WOS:000239807800020
PM 16776597
DA 2023-06-23
ER

PT J
AU Goldstein, RZ
   Volkow, ND
AF Goldstein, RZ
   Volkow, ND
TI Drug addiction and its underlying neurobiological basis: Neuroimaging
   evidence for the involvement of the frontal cortex
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Review
ID CEREBRAL BLOOD-FLOW; BRAIN GLUCOSE-METABOLISM; FUNCTIONAL
   MAGNETIC-RESONANCE; POSITRON EMISSION TOMOGRAPHY; PROGRESSIVE RATIO
   SCHEDULE; ANTERIOR CINGULATE CORTEX; PREFRONTAL CORTEX; ORBITOFRONTAL
   CORTEX; NUCLEUS-ACCUMBENS; COCAINE ABUSERS
AB Objective: Studies of the neurobiological processes underlying drug addiction primarily have focused on limbic subcortical structures. Here the authors evaluated the role of frontal cortical structures in drug addiction.
   Method: An integrated model of drug addiction that encompasses intoxication, bingeing, withdrawal, and craving is proposed. This model and findings from neuroirnaging studies on the behavioral, cognitive, and emotional processes that are at the core of drug addiction were used to analyze the involvement of frontal structures in drug addiction.
   Results: The orbitofrontal cortex and the anterior cingulate gyrus, which are regions neuroanatomically connected with limbic structures, are the frontal cortical areas most frequently implicated in drug addiction. They are activated in addicted subjects during intoxication, craving, and bingeing, and they are deactivated during withdrawal. These regions are also involved in higher-order cognitive and motivational functions, such as the ability to track, update, and modulate the salience of a reinforcer as a function of context and expectation and the ability to control and inhibit prepotent responses.
   Conclusions: These results imply that addiction connotes cortically regulated cognitive and emotional processes, which result in the overvaluing of drug reinforcers, the undervaluing of alternative reinforcers, and deficits in inhibitory control for drug responses. These changes in addiction, which the authors call I-RISA (impaired response inhibition and salience attribution), expand the traditional concepts of drug dependence that emphasize limbic-regulated responses to pleasure and reward.
C1 Brookhaven Natl Lab, Upton, NY 11973 USA.
C3 United States Department of Energy (DOE); Brookhaven National Laboratory
RP Goldstein, RZ (通讯作者)，Brookhaven Natl Lab, Bldg 490,30 Bell Ave, Upton, NY 11973 USA.
FU NIAAA NIH HHS [AA 09481, R01 AA009481] Funding Source: Medline; NIDA NIH
   HHS [R01 DA006891, K23 DA015517, DA 06891] Funding Source: Medline
CR Barr AM, 1999, PHARMACOL BIOCHEM BE, V64, P597, DOI 10.1016/S0091-3057(99)00156-2
   Barr AM, 1999, PSYCHOPHARMACOLOGY, V141, P99, DOI 10.1007/s002130050812
   Berns GS, 2001, J NEUROSCI, V21, P2793, DOI 10.1523/JNEUROSCI.21-08-02793.2001
   Blair RJR, 1999, BRAIN, V122, P883, DOI 10.1093/brain/122.5.883
   Blum K, 2000, J PSYCHOACTIVE DR S1, V32, P1, DOI [DOI 10.1080/02791072.2000.10736099, 10.1080/02791072, DOI 10.1080/02791072]
   Breiter HC, 2001, NEURON, V30, P619, DOI 10.1016/S0896-6273(01)00303-8
   Breiter HC, 1997, NEURON, V19, P591, DOI 10.1016/S0896-6273(00)80374-8
   BROWN EE, 1993, PSYCHOPHARMACOLOGY, V113, P123, DOI 10.1007/BF02244344
   Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747
   Carter CS, 2000, P NATL ACAD SCI USA, V97, P1944, DOI 10.1073/pnas.97.4.1944
   Casey BJ, 1997, J COGNITIVE NEUROSCI, V9, P835, DOI 10.1162/jocn.1997.9.6.835
   CASSENS G, 1981, PSYCHOPHARMACOLOGY, V73, P318, DOI 10.1007/BF00426458
   Catafau AM, 1999, J NUCL MED, V40, P19
   Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11
   Chua P, 1999, NEUROIMAGE, V9, P563, DOI 10.1006/nimg.1999.0407
   Cornish JL, 1999, NEUROSCIENCE, V93, P1359, DOI 10.1016/S0306-4522(99)00214-6
   DEWIT H, 1990, ALCOHOL CLIN EXP RES, V14, P482
   Di Chiara G, 1999, EUR J PHARMACOL, V375, P13, DOI 10.1016/S0014-2999(99)00372-6
   Elliott R, 1997, NEUROPSYCHOLOGIA, V35, P1395, DOI 10.1016/S0028-3932(97)00055-9
   Elliott R, 1998, PSYCHOL MED, V28, P559, DOI 10.1017/S0033291798006709
   Elliott R, 2000, NEUROREPORT, V11, P1739, DOI 10.1097/00001756-200006050-00028
   Elliott R, 1999, NEUROPSYCHOLOGIA, V37, P403, DOI 10.1016/S0028-3932(98)00107-9
   FISCHMAN MW, 1985, J PHARMACOL EXP THER, V235, P677
   Francis S, 1999, NEUROREPORT, V10, P453, DOI 10.1097/00001756-199902250-00003
   Franklin TR, 2000, EUR J NEUROSCI, V12, P2097, DOI 10.1046/j.1460-9568.2000.00071.x
   Franklin TR, 2002, BIOL PSYCHIAT, V51, P134, DOI 10.1016/S0006-3223(01)01269-0
   Garavan H, 2000, AM J PSYCHIAT, V157, P1789, DOI 10.1176/appi.ajp.157.11.1789
   GEORGE MS, 1993, J NEUROPSYCH CLIN N, V5, P384
   GOEDERS NE, 1986, PHARMACOL BIOCHEM BE, V25, P191, DOI 10.1016/0091-3057(86)90252-2
   Goldstein RZ, 2001, NEUROREPORT, V12, P2595, DOI 10.1097/00001756-200108080-00060
   Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040
   GRANT SJ, 1999, ABSTR SOC NEUROSCI, V25, P1551
   Hickie I, 1999, PSYCHIAT RES-NEUROIM, V92, P75, DOI 10.1016/S0925-4927(99)00038-4
   HODGINS DC, 1995, J CONSULT CLIN PSYCH, V63, P400, DOI 10.1037/0022-006X.63.3.400
   Hommer D, 1997, J NEUROSCI, V17, P2796
   HUGDAHL K, 1995, NEUROREPORT, V6, P1723, DOI 10.1097/00001756-199509000-00005
   HURD YL, 1989, SYNAPSE, V3, P48, DOI 10.1002/syn.890030107
   Ingvar M, 1998, J STUD ALCOHOL, V59, P258, DOI 10.15288/jsa.1998.59.258
   Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483
   JERNIGAN TL, 1991, NEUROPSYCHOPHARMACOL, V4, P175
   JERNIGAN TL, 1991, ALCOHOL CLIN EXP RES, V15, P418, DOI 10.1111/j.1530-0277.1991.tb00540.x
   JOHANSON CE, 1989, PHARMACOL REV, V41, P3
   Karreman M, 1996, J NEUROCHEM, V66, P589
   Kiehl KA, 2000, PSYCHOPHYSIOLOGY, V37, P216, DOI 10.1017/S0048577200990231
   Kiyatkin EA, 1996, J NEUROPHYSIOL, V75, P142, DOI 10.1152/jn.1996.75.1.142
   Koob G F, 1994, NIDA Res Monogr, V145, P1
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Krams M, 1998, EXP BRAIN RES, V120, P386, DOI 10.1007/s002210050412
   Lane RD, 1997, NEUROREPORT, V8, P3969, DOI 10.1097/00001756-199712220-00024
   Liu X, 1998, NEUROPSYCHOPHARMACOL, V18, P243
   LOH EA, 1990, PSYCHOPHARMACOLOGY, V101, P262, DOI 10.1007/BF02244137
   LONDON ED, 1990, ARCH GEN PSYCHIAT, V47, P73
   LONDON ED, 1990, ARCH GEN PSYCHIAT, V47, P567
   Maas LC, 1998, AM J PSYCHIAT, V155, P124, DOI 10.1176/ajp.155.1.124
   MATHEW RJ, 1992, J CEREBR BLOOD F MET, V12, P750, DOI 10.1038/jcbfm.1992.106
   Mayberg HS, 1999, AM J PSYCHIAT, V156, P675
   Meil WM, 1997, BEHAV BRAIN RES, V87, P139, DOI 10.1016/S0166-4328(96)02270-X
   Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167
   Nakamura Hironori, 2000, Keio Journal of Medicine, V49, pA122
   Nobre AC, 1999, NAT NEUROSCI, V2, P11, DOI 10.1038/4513
   OBBINS TW, 1992, HDB AFFECTIVE DISORD, P289
   PARDO JV, 1993, AM J PSYCHIAT, V150, P713
   Pfefferbaum A, 1997, ALCOHOL CLIN EXP RES, V21, P521, DOI 10.1111/j.1530-0277.1997.tb03798.x
   Ploghaus A, 1999, SCIENCE, V284, P1979, DOI 10.1126/science.284.5422.1979
   Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968
   RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058
   Robinson TE, 2001, SYNAPSE, V39, P257
   Rogers RD, 1999, J NEUROSCI, V19, P9029, DOI 10.1523/JNEUROSCI.19-20-09029.1999
   Rosenkranz JA, 2001, J NEUROSCI, V21, P4090, DOI 10.1523/JNEUROSCI.21-11-04090.2001
   Rubia K, 2000, NEUROSCI BIOBEHAV R, V24, P13, DOI 10.1016/S0149-7634(99)00055-X
   Schultz W, 2000, CEREB CORTEX, V10, P272, DOI 10.1093/cercor/10.3.272
   Sprengelmeyer R, 1998, P ROY SOC B-BIOL SCI, V265, P1927, DOI 10.1098/rspb.1998.0522
   Stein EA, 1998, AM J PSYCHIAT, V155, P1009, DOI 10.1176/ajp.155.8.1009
   Teneback CC, 1999, J NEUROPSYCH CLIN N, V11, P426
   Thanos PK, 2001, J NEUROCHEM, V78, P1094, DOI 10.1046/j.1471-4159.2001.00492.x
   Thut G, 1997, NEUROREPORT, V8, P1225, DOI 10.1097/00001756-199703240-00033
   TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147
   TIIHONEN J, 1994, AM J PSYCHIAT, V151, P1505
   Vaidya CJ, 1998, P NATL ACAD SCI USA, V95, P14494, DOI 10.1073/pnas.95.24.14494
   Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI 10.1093/cercor/10.3.318
   Volkow ND, 1999, AM J PSYCHIAT, V156, P1440
   Volkow ND, 2001, AM J PSYCHIAT, V158, P377, DOI 10.1176/appi.ajp.158.3.377
   Volkow ND, 1997, ALCOHOL CLIN EXP RES, V21, P1278, DOI 10.1111/j.1530-0277.1997.tb04449.x
   VOLKOW ND, 1993, AM J PSYCHIAT, V150, P417
   VOLKOW ND, 1988, BRIT J PSYCHIAT, V152, P641, DOI 10.1192/bjp.152.5.641
   VOLKOW ND, 1990, PSYCHIAT RES-NEUROIM, V35, P39, DOI 10.1016/0925-4927(90)90007-S
   Volkow ND, 1996, PSYCHIAT RES-NEUROIM, V67, P29, DOI 10.1016/0925-4927(96)02817-X
   Volkow ND, 1997, NATURE, V386, P830, DOI 10.1038/386830a0
   Volkow ND, 1996, ALCOHOL CLIN EXP RES, V20, P1594, DOI 10.1111/j.1530-0277.1996.tb05936.x
   VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210
   VOLKOW ND, 1991, AM J PSYCHIAT, V148, P621
   VOLKOW ND, 1992, AM J PSYCHIAT, V149, P1016
   VOLKOW ND, 1994, AM J PSYCHIAT, V151, P178
   VOLKOW ND, 1992, SYNAPSE, V11, P184, DOI 10.1002/syn.890110303
   Volkow ND, 1999, AM J PSYCHIAT, V156, P19, DOI 10.1176/ajp.156.1.19
   Volkow ND, 2001, AM J PSYCHIAT, V158, P2015, DOI 10.1176/appi.ajp.158.12.2015
   VOLKOW ND, 1988, PSYCHIAT RES, V24, P201, DOI 10.1016/0165-1781(88)90063-7
   VOLKOW ND, 1990, AM J PSYCHIAT, V147, P719
   Wallace EA, 1996, PSYCHOPHARMACOLOGY, V128, P17, DOI 10.1007/s002130050104
   Wang GJ, 1999, LIFE SCI, V64, P775, DOI 10.1016/S0024-3205(98)00619-5
   Wang GJ, 1997, NEUROPSYCHOPHARMACOL, V16, P174, DOI 10.1016/S0893-133X(96)00184-4
   Wexler BE, 2001, AM J PSYCHIAT, V158, P86, DOI 10.1176/appi.ajp.158.1.86
   WILLNER P, 1992, NEUROSCI BIOBEHAV R, V16, P525, DOI 10.1016/S0149-7634(05)80194-0
NR 103
TC 1811
Z9 1868
U1 5
U2 297
PU AMER PSYCHIATRIC PRESS, INC
PI WASHINGTON
PA 1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA
SN 0002-953X
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD OCT
PY 2002
VL 159
IS 10
BP 1642
EP 1652
DI 10.1176/appi.ajp.159.10.1642
PG 11
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA 600GR
UT WOS:000178382700005
PM 12359667
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Kuhar, MJ
AF Kuhar, Michael J.
TI Contributions of basic science to understanding addiction
SO BIOSOCIETIES
LA English
DT Article
DE drug addiction; drug self-administration; genetics; treatment
ID GENETIC INFLUENCES; ANIMAL-MODELS; DOPAMINE; COCAINE; DEPENDENCE; DRUGS;
   VULNERABILITY; RECEPTORS; ALCOHOL; SYSTEMS
AB Discoveries in basic science have helped us understand the drug abuse/dependence/addiction brain disorder. One can view this brain disorder as a long-lasting, relapsing pattern of drug seeking and taking with adverse consequences. Drug self-administration studies in animals have revealed brain circuits and neurotransmitters that underlie drug-induced reward and reinforcement. Moreover, studies of effects of drugs on receptors have shown us how drugs can change gene expression and how drugs can change the biochemical makeup of the brain. Drug-induced changes in the brain are very long lasting, which presumably can explain why drug addiction is a chronic and relapsing disease. Also, drugs exert their actions at least partly through evolved brain circuits that serve functions critical for survival such as feeding and sex. Thus, drugs can harness our strongest instincts and the desire to use them can become very powerful. These findings should influence research, treatment and policy towards the disorder of drug addiction and abuse. BioSocieties (2010) 5, 25-35. doi:10.1057/biosoc.2009.5
C1 Emory Univ, Yerkes Reg Primate Res Ctr, Atlanta, GA 30322 USA.
C3 Emory University
RP Kuhar, MJ (通讯作者)，Emory Univ, Yerkes Reg Primate Res Ctr, 954 Gatewood Rd NE, Atlanta, GA 30322 USA.
EM mkuhar@emory.edu
CR Agrawal A, 2008, ADDICTION, V103, P1069, DOI 10.1111/j.1360-0443.2008.02213.x
   Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244
   Barr AM, 2005, NEUROSCI BIOBEHAV R, V29, P675, DOI 10.1016/j.neubiorev.2005.03.012
   Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584
   Belknap JK, 2008, TRENDS PHARMACOL SCI, V29, P537, DOI 10.1016/j.tips.2008.07.010
   Beveridge TJR, 2008, PHILOS T R SOC B, V363, P3257, DOI 10.1098/rstb.2008.0102
   Bocher M, 2001, NEUROIMAGE, V14, P105, DOI 10.1006/nimg.2001.0794
   Bonci A, 2003, TRENDS PHARMACOL SCI, V24, P172, DOI 10.1016/S0165-6147(03)00068-3
   Carroll FI, 2006, AAPS J, V8, pE196, DOI 10.1208/aapsj080124
   Dew B, 2007, J RURAL HEALTH, V23, P16, DOI 10.1111/j.1748-0361.2007.00119.x
   Dominguez JM, 2005, PHYSIOL BEHAV, V86, P356, DOI 10.1016/j.physbeh.2005.08.006
   Glennon RA, 2003, PRINCIPLES ADDICTION, P275
   Jamner Larry D, 2003, Nicotine Tob Res, V5 Suppl 1, pS71
   Joslyn G, 2008, P NATL ACAD SCI USA, V105, P20368, DOI 10.1073/pnas.0810970105
   Kendler KS, 1999, BRIT J PSYCHIAT, V175, P351, DOI 10.1192/bjp.175.4.351
   Kuhar MJ, 2002, NAT NEUROSCI, V5, P88, DOI 10.1038/nn0202-88
   KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G
   Malin David H, 2009, Handb Exp Pharmacol, P401, DOI 10.1007/978-3-540-69248-5_14
   Meaney MJ, 2002, PSYCHONEUROENDOCRINO, V27, P127, DOI 10.1016/S0306-4530(01)00040-3
   Morgan D, 2002, NAT NEUROSCI, V5, P169, DOI 10.1038/nn798
   Nader MA, 2005, AM J PSYCHIAT, V162, P1473, DOI 10.1176/appi.ajp.162.8.1473
   Nestler EJ., 2015, MOL NEUROPHARMACOLOG
   Palmiter RD, 2007, TRENDS NEUROSCI, V30, P375, DOI 10.1016/j.tins.2007.06.004
   PETTIT HO, 1991, BRAIN RES, V539, P94, DOI 10.1016/0006-8993(91)90690-W
   Redish AD, 2008, BEHAV BRAIN SCI, V31, P415, DOI 10.1017/S0140525X0800472X
   Schierenbeck T, 2008, SLEEP MED REV, V12, P381, DOI 10.1016/j.smrv.2007.12.004
   Siegel G.J., 1999, BASIC NEUROCHEMISTRY
   Spiga S, 2008, ANN NY ACAD SCI, V1139, P299, DOI 10.1196/annals.1432.008
   Uhl GR, 2008, ANN NY ACAD SCI, V1141, P318, DOI 10.1196/annals.1441.018
   VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210
   Volkow ND, 2008, PHILOS T R SOC B, V363, P3191, DOI 10.1098/rstb.2008.0107
   Wagner FA, 2007, DRUG ALCOHOL DEPEN, V86, P191, DOI 10.1016/j.drugalcdep.2006.06.003
   WHITE NM, 1986, NEUROSCI BIOBEHAV R, V10, P15, DOI 10.1016/0149-7634(86)90030-8
   Wise RA, 2005, J COMP NEUROL, V493, P115, DOI 10.1002/cne.20689
   WOOLVERTON WL, 1983, PHARMACOL REV, V35, P33
NR 35
TC 10
Z9 13
U1 1
U2 5
PU PALGRAVE MACMILLAN LTD
PI BASINGSTOKE
PA BRUNEL RD BLDG, HOUNDMILLS, BASINGSTOKE RG21 6XS, HANTS, ENGLAND
SN 1745-8552
EI 1745-8560
J9 BIOSOCIETIES
JI BioSocieties
PD MAR
PY 2010
VL 5
IS 1
SI SI
BP 25
EP 35
DI 10.1057/biosoc.2009.5
PG 11
WC Social Sciences, Biomedical
WE Social Science Citation Index (SSCI)
SC Biomedical Social Sciences
GA 688TX
UT WOS:000284877900004
DA 2023-06-23
ER

PT J
AU Weaver, M
   Schnoll, S
AF Weaver, M
   Schnoll, S
TI Abuse liability in opioid therapy for pain treatment in patients with an
   addiction history
SO CLINICAL JOURNAL OF PAIN
LA English
DT Article
DE addiction; drug-seeking behavior; medication misuse/abuse;
   pseudoaddiction
ID DRUG-ABUSE; DEPENDENCE; MANAGEMENT
AB Patients may present to physicians with complaints of acute or chronic pain. Some of these patients will have a history of addiction to drugs or alcohol, and a few will have active addiction. Controlled-substance prescriptions, especially opioid pain medications, can be very beneficial for treatment of pain in patients. There are clear differences between physical dependence on medication, active addiction, addiction in remission, and pseudoaddiction. A search of the medical literature revealed different rates of addiction in patients with chronic pain because different criteria were used to define addiction and the types of chronic pain. It appears that rates of addiction in patient populations with chronic pain are no different than rates of addiction in the general population, according to some recent studies. "Drug-seeking behavior" may be seen with either active addiction or pseudoaddiction. A way to distinguish between these conditions is by giving the patient more pain medication and observing the patient's pattern of behavior. Some patients may be at higher risk to abuse prescription opioids, and some types of drug-seeking behavior may be more predictive of active addiction than pseudoaddiction. General guidelines can improve physicians' comfort level in prescribing opioids for patients with chronic pain, even those with a history of addiction. These include using a medication agreement or contract, setting appropriate goals with the patient, giving appropriate amounts of pain medication, monitoring with drug screens and pill counts, and documenting the case carefully. Even patients with a history of addiction can benefit from opioid pain medications if the patients are monitored appropriately.
C1 Virginia Commonwealth Univ, Med Coll Virginia, Div Gen Med & Primary Care, Richmond, VA 23298 USA.
   Purdue Pharma LP, Stamford, CT USA.
C3 Virginia Commonwealth University; Purdue Pharma L.P.
RP Weaver, M (通讯作者)，Virginia Commonwealth Univ, Med Coll Virginia, Div Gen Med & Primary Care, POB 980109, Richmond, VA 23298 USA.
OI Jamison, Robert/0000-0003-1768-0906
CR [Anonymous], 2001, DEF REL US OP TREATM
   BUCKLEY FP, 1986, PAIN, V26, P153, DOI 10.1016/0304-3959(86)90071-0
   EVANS PJD, 1981, ANAESTHESIA, V36, P597, DOI 10.1111/j.1365-2044.1981.tb10323.x
   FINLAYSON RE, 1986, PAIN, V26, P167, DOI 10.1016/0304-3959(86)90072-2
   FISHBAIN DA, 1992, CLIN J PAIN, V8, P77, DOI 10.1097/00002508-199206000-00003
   KHATAMI M, 1979, COMPR PSYCHIAT, V20, P55, DOI 10.1016/0010-440X(79)90059-2
   KISSEN B, 1997, TREATMENT REHABILITA
   Kouyanou K, 1997, J PSYCHOSOM RES, V43, P497, DOI 10.1016/S0022-3999(97)00171-2
   MARUTA T, 1979, MAYO CLIN PROC, V54, P241
   MELZACK R, 1990, SCI AM, V262, P27, DOI 10.1038/scientificamerican0290-27
   Miotto K, 1996, PSYCHOSOMATICS, V37, P223, DOI 10.1016/S0033-3182(96)71561-X
   Portenoy R., 1994, PHARM APPROACHES TRE, V1
   READY LB, 1982, PAIN, V12, P285, DOI 10.1016/0304-3959(82)90160-9
   REGIER DA, 1984, ARCH GEN PSYCHIAT, V41, P934
   SAVAGE SR, 1993, J PAIN SYMPTOM MANAG, V8, P265, DOI 10.1016/0885-3924(93)90155-O
   SCHNOLL SH, 1994, J LAW MED ETHICS, V22, P252, DOI 10.1111/j.1748-720X.1994.tb01303.x
   TURNER JA, 1982, PAIN, V12, P357, DOI 10.1016/0304-3959(82)90180-4
   Weaver MF, 1999, ARCH INTERN MED, V159, P913, DOI 10.1001/archinte.159.9.913
   WEISSMAN DE, 1989, PAIN, V36, P363, DOI 10.1016/0304-3959(89)90097-3
NR 19
TC 67
Z9 70
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0749-8047
J9 CLIN J PAIN
JI Clin. J. Pain
PD JUL-AUG
PY 2002
VL 18
IS 4
SU S
BP S61
EP S69
DI 10.1097/00002508-200207001-00007
PG 9
WC Anesthesiology; Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Anesthesiology; Neurosciences & Neurology
GA 579ML
UT WOS:000177181700007
PM 12479255
DA 2023-06-23
ER

PT J
AU Mendrek, A
AF Mendrek, Adrianna
TI Is it important to consider sex and gender in neurocognitive studies?
SO FRONTIERS IN PSYCHIATRY
LA English
DT Article
DE sex differences; gender; cognition and emotion; schizophrenia; drug
   addiction
ID DRUG-ADDICTION; BRAIN; WOMEN; HORMONES; MEMORY
C1 Bishops Univ, Dept Psychol, Sherbrooke, PQ, Canada.
C3 Bishops University
RP Mendrek, A (通讯作者)，Bishops Univ, Dept Psychol, Sherbrooke, PQ, Canada.
EM adrianna.mendrek@ubishops.ca
CR Abel KM, 2010, INT REV PSYCHIATR, V22, P417, DOI 10.3109/09540261.2010.515205
   Bao AM, 2010, NEUROSCIENTIST, V16, P550, DOI 10.1177/1073858410377005
   Becker JB, 2008, FRONT NEUROENDOCRIN, V29, P36, DOI 10.1016/j.yfrne.2007.07.003
   Becker JB, 2012, BIOL SEX DIFFER, V3, DOI 10.1186/2042-6410-3-14
   Belfi AM, 2014, DEV NEUROPSYCHOL, V39, P25, DOI 10.1080/87565641.2013.839681
   BEM SL, 1981, PSYCHOL REV, V88, P354, DOI 10.1037/0033-295X.88.4.354
   BLEULER E, 1911, DEMENTIA PRAECOX GRO
   Cahill L, 2004, CONSCIOUS COGN, V13, P391, DOI 10.1016/j.concog.2003.11.003
   Cahill L, 2012, ENDOCRINOLOGY, V153, P2541, DOI 10.1210/en.2011-2167
   Champagne J, 2012, SCHIZOPHR RES TREAT, V2012, DOI 10.1155/2012/917901
   Chevalier N, 2015, DIABETES METAB, V41, P107, DOI 10.1016/j.diabet.2014.09.005
   Chilet-Rosell E, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25484
   Cotto JH, 2010, GENDER MED, V7, P402, DOI 10.1016/j.genm.2010.09.004
   Eagly AH, 2014, AM PSYCHOL, V69, P685, DOI 10.1037/a0037372
   Eagly AH, 2012, AM PSYCHOL, V67, P211, DOI 10.1037/a0027260
   Fattore L, 2008, WOMENS HEALTH, V4, P51, DOI 10.2217/17455057.4.1.51
   Fattore L, 2014, FRONT NEUROENDOCRIN, V35, P272, DOI 10.1016/j.yfrne.2014.04.003
   Frye CA, 2014, VITAM HORM, V94, P41, DOI 10.1016/B978-0-12-800095-3.00003-1
   Goldstein JM, 2002, ARCH GEN PSYCHIAT, V59, P154, DOI 10.1001/archpsyc.59.2.154
   Gopman S, 2014, OBSTET GYN CLIN N AM, V41, P213, DOI 10.1016/j.ogc.2014.02.004
   Gur RE, 2004, BIOL PSYCHIAT, V55, P512, DOI 10.1016/j.biopsych.2003.10.009
   Jimenez JA, 2010, SCHIZOPHR RES, V122, P53, DOI 10.1016/j.schres.2010.03.011
   Kandall SR, 2010, J ADDICT DIS, V29, P117, DOI 10.1080/10550881003684491
   KRAEPELIN E, 1971, DEMENTIA PRAECOX PAR
   Kulkarni J, 2013, INT J ENDOCRINOL MET, V11, P129, DOI 10.5812/ijem.6615
   Kulkarni J, 2012, CURR OPIN PSYCHIATR, V25, P89, DOI 10.1097/YCO.0b013e328350360e
   Lakis N, 2011, PSYCHIAT RES-NEUROIM, V194, P245, DOI 10.1016/j.pscychresns.2011.05.010
   Leung A, 2000, ACTA PSYCHIAT SCAND, V101, P3
   Leventhal AM, 2007, EXP CLIN PSYCHOPHARM, V15, P21, DOI 10.1037/1064-1297.15.1.21
   Lynch WJ, 2006, EXP CLIN PSYCHOPHARM, V14, P34, DOI 10.1037/1064-1297.14.1.34
   McCarthy MM, 2012, J NEUROSCI, V32, P2241, DOI 10.1523/JNEUROSCI.5372-11.2012
   Mendrek A., 2014, PSYCHIAT J U OTTAWA, V2014, P1, DOI DOI 10.1155/2014/723632
   Mendrek Adrianna, 2012, ISRN Psychiatry, V2012, P656274, DOI 10.5402/2012/656274
   Moran-Santa Maria Megan M, 2014, Curr Psychiatry Rep, V16, P511, DOI 10.1007/s11920-014-0511-7
   Poon R, 2013, J WOMENS HEALTH, V22, P604, DOI 10.1089/jwh.2012.3753
   Potenza MN, 2012, AM J PSYCHIAT, V169, P406, DOI 10.1176/appi.ajp.2011.11020289
   Lombardi EMS, 2011, J BRAS PNEUMOL, V37, P118, DOI 10.1590/S1806-37132011000100017
   Wood JL, 2008, CEREB CORTEX, V18, P534, DOI 10.1093/cercor/bhm079
   Xu JS, 2008, NICOTINE TOB RES, V10, P1653, DOI 10.1080/14622200802412929
NR 39
TC 17
Z9 18
U1 2
U2 13
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD JUN 2
PY 2015
VL 6
AR 83
DI 10.3389/fpsyt.2015.00083
PG 4
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA CV7OO
UT WOS:000364463800001
PM 26082728
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Rosenthal, ES
   Karchmer, AW
   Theisen-Toupal, J
   Castillo, RA
   Rowley, CF
AF Rosenthal, Elana S.
   Karchmer, Adolf W.
   Theisen-Toupal, Jesse
   Castillo, Roger Araujo
   Rowley, Chris F.
TI Suboptimal Addiction Interventions for Patients Hospitalized with
   Injection Drug Use-Associated Infective Endocarditis
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Article
DE Harm reduction; Infective endocarditis; Injection drug use;
   Medication-assisted treatment; Substance use disorder
ID MANAGEMENT; NALOXONE
AB BACKGROUND: Infective endocarditis is a serious infection, often resulting from injection drug use. Inpatient treatment regularly focuses on management of infection without attention to the underlying addiction. We aimed to determine the addiction interventions done in patients hospitalized with injection drug use-associated infective endocarditis.
   METHODS: This is a retrospective review of patients hospitalized with injection drug use-associated infective endocarditis from January, 2004 through August, 2014 at a large academic tertiary care center in Boston, Massachusetts. For the initial and subsequent admissions, data were collected regarding addiction interventions, including consultation by social work, addiction clinical nurse and psychiatry, documentation of addiction in the discharge summary plan, plan for medication-assisted treatment and naloxone provision.
   RESULTS: There were 102 patients admitted with injection drug use-associated infective endocarditis, 50 patients ( 49.0%) were readmitted and 28 (27.5%) patients had ongoing injection drug use at readmission. At initial admission, 86.4% of patients had social work consultation, 23.7% had addiction consultation, and 24.0% had psychiatry consultation. Addiction was mentioned in 55.9% of discharge summary plans, 7.8% of patients had a plan for medication-assisted treatment, and naloxone was never prescribed. Of 102 patients, 26 (25.5%) are deceased. The median age at death was 40.9 years (interquartile range 28.7-48.7).
   CONCLUSIONS: We found that patients hospitalized with injection drug use-associated infective endocarditis had high rates of readmission, recurrent infective endocarditis and death. Despite this, addiction interventions were suboptimal. Improved addiction interventions are imperative in the treatment of injection drug use-associated infective endocarditis. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Rosenthal, Elana S.; Karchmer, Adolf W.; Castillo, Roger Araujo; Rowley, Chris F.] Beth Israel Deaconess Med Ctr, Dept Med, Div Infect Dis, Lowry Bldg,Suite GB,110 Francis St, Boston, MA 02215 USA.
   [Rosenthal, Elana S.; Karchmer, Adolf W.; Theisen-Toupal, Jesse; Castillo, Roger Araujo; Rowley, Chris F.] Harvard Univ, Sch Med, Boston, MA USA.
   [Theisen-Toupal, Jesse] Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, Boston, MA 02215 USA.
   [Rowley, Chris F.] Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.
C3 Harvard University; Beth Israel Deaconess Medical Center; Harvard
   University; Harvard Medical School; Harvard University; Beth Israel
   Deaconess Medical Center; Harvard University; Harvard T.H. Chan School
   of Public Health
RP Rosenthal, ES (通讯作者)，Beth Israel Deaconess Med Ctr, Dept Med, Div Infect Dis, Lowry Bldg,Suite GB,110 Francis St, Boston, MA 02215 USA.
EM elana.rosenthal@gmail.com
OI Araujo Castillo, Roger V/0000-0002-3740-1962; Rosenthal,
   Elana/0000-0001-7234-4871
FU National Institute on Drug Abuse [R25DA013582]
FX This study was supported, in part, through the Fellow Immersion Training
   (FIT) Program in Addiction Medicine under the CARE grant, R25DA013582,
   form the National Institute on Drug Abuse.
CR Cami J, 2003, NEW ENGL J MED, V349, P975, DOI 10.1056/NEJMra023160
   de Sa DDC, 2010, MAYO CLIN PROC, V85, P422, DOI 10.4065/mcp.2009.0585
   DOLE VP, 1965, J AMER MED ASSOC, V193, P646, DOI 10.1001/jama.1965.03090080008002
   Haber PS, 2009, LANCET, V374, P1284, DOI 10.1016/S0140-6736(09)61036-9
   Hedegaard H., 2015, DRUG POISONING DEATH
   HUBBELL G, 1981, AM HEART J, V102, P85, DOI 10.1016/0002-8703(81)90418-X
   Jones CM, 2015, AM J PUBLIC HEALTH, V105, pE55, DOI 10.2105/AJPH.2015.302664
   Kakko J, 2003, LANCET, V361, P662, DOI 10.1016/S0140-6736(03)12600-1
   Kleber HD, 2008, JAMA-J AM MED ASSOC, V300, P2303, DOI 10.1001/jama.2008.648
   Lagu T, 2006, J SUBST ABUSE TREAT, V30, P129, DOI 10.1016/j.jsat.2005.05.010
   Li JS, 2000, CLIN INFECT DIS, V30, P633, DOI 10.1086/313753
   Mathers BM, 2008, LANCET, V372, P1733, DOI 10.1016/S0140-6736(08)61311-2
   Mattick RP, 2014, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002207.pub4, 10.1002/14651858.CD002207.pub3]
   Merralll ELC, 2013, ADDICTION, V108, P377, DOI 10.1111/j.1360-0443.2012.04066.x
   Miller NS, 2001, ACAD MED, V76, P410, DOI 10.1097/00001888-200105000-00007
   Olsen Y, 2014, JAMA-J AM MED ASSOC, V311, P1393, DOI 10.1001/jama.2014.2147
   Rachlis BS, 2009, HARM REDUCT J, V6, DOI 10.1186/1477-7517-6-19
   Walley Alexander Y, 2013, BMJ, V346, pf174, DOI 10.1136/bmj.f174
   Weber E., 2010, J HLTH CARE LAW POLI, V13, P49
   Wilson LE, 2002, J INFECT DIS, V185, P1761, DOI 10.1086/340827
NR 20
TC 191
Z9 192
U1 1
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9343
EI 1555-7162
J9 AM J MED
JI Am. J. Med.
PD MAY
PY 2016
VL 129
IS 5
BP 481
EP 485
DI 10.1016/j.amjmed.2015.09.024
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine
GA DK7YZ
UT WOS:000375144600026
PM 26597670
OA Bronze
HC Y
HP N
DA 2023-06-23
ER

PT J
AU Westwater, ML
   Fletcher, PC
   Ziauddeen, H
AF Westwater, Margaret L.
   Fletcher, Paul C.
   Ziauddeen, Hisham
TI Sugar addiction: the state of the science
SO EUROPEAN JOURNAL OF NUTRITION
LA English
DT Review
DE Sugar addiction; Obesity; Binge eating; Animal neuroscience; Drug
   addiction
ID CONDITIONED PLACE PREFERENCE; COCAINE-SEEKING BEHAVIOR; DOPAMINE D2
   RECEPTORS; NUCLEUS-ACCUMBENS CORE; MU-OPIOID RECEPTORS; FOOD ADDICTION;
   DRUG-ADDICTION; DORSAL STRIATUM; ORBITOFRONTAL CORTEX; REINFORCING
   EFFICACY
AB Purpose As obesity rates continue to climb, the notion that overconsumption reflects an underlying 'food addiction' (FA) has become increasingly influential. An increasingly popular theory is that sugar acts as an addictive agent, eliciting neurobiological changes similar to those seen in drug addiction. In this paper, we review the evidence in support of sugar addiction.
   Methods We reviewed the literature on food and sugar addiction and considered the evidence suggesting the addictiveness of highly processed foods, particularly those with high sugar content. We then examined the addictive potential of sugar by contrasting evidence from the animal and human neuroscience literature on drug and sugar addiction.
   Results We find little evidence to support sugar addiction in humans, and findings from the animal literature suggest that addiction-like behaviours, such as bingeing, occur only in the context of intermittent access to sugar. These behaviours likely arise from intermittent access to sweet tasting or highly palatable foods, not the neurochemical effects of sugar.
   Conclusion Given the lack of evidence supporting it, we argue against a premature incorporation of sugar addiction into the scientific literature and public policy recommendations.
C1 [Westwater, Margaret L.] Univ Cambridge, Dept Psychiat, Brain Mapping Unit, Cambridge CB2 3EB, England.
   [Westwater, Margaret L.; Fletcher, Paul C.; Ziauddeen, Hisham] Univ Cambridge, Addenbrookes Hosp, Dept Psychiat, Herchel Smith Bldg, Cambridge CB2 0SZ, England.
   [Fletcher, Paul C.; Ziauddeen, Hisham] Univ Cambridge, Wellcome Trust MRC Inst Metab Sci, Cambridge Biomed Campus, Cambridge CB2 0QQ, England.
   [Fletcher, Paul C.; Ziauddeen, Hisham] Cambridgeshire & Peterborough Fdn Trust, Cambridge CB21 5EF, England.
   [Ziauddeen, Hisham] Box 189,Herchel Smith Bldg,West Forvie Site, Cambridge CB21 5DS, England.
C3 University of Cambridge; Cambridge University Hospitals NHS Foundation
   Trust; Addenbrooke's Hospital; University of Cambridge; University of
   Cambridge
RP Ziauddeen, H (通讯作者)，Univ Cambridge, Addenbrookes Hosp, Dept Psychiat, Herchel Smith Bldg, Cambridge CB2 0SZ, England.; Ziauddeen, H (通讯作者)，Univ Cambridge, Wellcome Trust MRC Inst Metab Sci, Cambridge Biomed Campus, Cambridge CB2 0QQ, England.; Ziauddeen, H (通讯作者)，Cambridgeshire & Peterborough Fdn Trust, Cambridge CB21 5EF, England.; Ziauddeen, H (通讯作者)，Box 189,Herchel Smith Bldg,West Forvie Site, Cambridge CB21 5DS, England.
EM hz238@cam.ac.uk
RI Fletcher, Paul/HZK-7358-2023
OI Westwater, Margaret/0000-0002-2918-0979
FU Wellcome Trust; Bernard Wolfe Health Neuroscience Fund; Medical Research
   Council [MC_UU_12012/5/B] Funding Source: researchfish
FX PCF is supported by a Wellcome Trust Senior Fellowship award. PCF and HZ
   are supported by the Bernard Wolfe Health Neuroscience Fund.
CR Ahmed SH, 2000, NEUROPSYCHOPHARMACOL, V22, P413, DOI 10.1016/S0893-133X(99)00133-5
   Alderson HL, 2001, BRAIN RES BULL, V56, P599, DOI 10.1016/S0361-9230(01)00733-X
   American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th
   Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244
   Avena NM, 2008, NEUROSCIENCE, V156, P865, DOI 10.1016/j.neuroscience.2008.08.017
   Avena NM, 2006, NEUROSCIENCE, V139, P813, DOI 10.1016/j.neuroscience.2005.12.037
   Avena NA, 2004, ALCOHOL, V34, P203, DOI 10.1016/j.alcohol.2004.09.006
   Avena NM, 2008, PHYSIOL BEHAV, V94, P309, DOI 10.1016/j.physbeh.2008.01.008
   Avena NM, 2008, NEUROSCI BIOBEHAV R, V32, P20, DOI 10.1016/j.neubiorev.2007.04.019
   Avena NM, 2005, PHYSIOL BEHAV, V84, P359, DOI 10.1016/j.physbeh.2004.12.016
   Avena NM, 2003, NEUROSCIENCE, V122, P17, DOI 10.1016/S0306-4522(03)00502-5
   Benton D, 2010, CLIN NUTR, V29, P288, DOI 10.1016/j.clnu.2009.12.001
   Bocarsly ME, 2011, PHYSIOL BEHAV, V104, P865, DOI 10.1016/j.physbeh.2011.05.018
   CAINE SB, 1995, BRAIN RES, V692, P47
   Carelli RM, 2003, J NEUROSCI, V23, P11214
   Colantuoni C, 2002, OBES RES, V10, P478, DOI 10.1038/oby.2002.66
   Colantuoni C, 2001, NEUROREPORT, V12, P3549, DOI 10.1097/00001756-200111160-00035
   Corwin RLW, 2012, ILAR J, V53, P23, DOI 10.1093/ilar.53.1.23
   Corwin Rebecca L W, 2011, Curr Drug Abuse Rev, V4, P174
   DAI S, 1989, PHARMACOL BIOCHEM BE, V32, P1009, DOI 10.1016/0091-3057(89)90074-9
   Davis C, 2013, PHYSIOL BEHAV, V118, P63, DOI 10.1016/j.physbeh.2013.05.014
   Davis C, 2009, APPETITE, V53, P1, DOI 10.1016/j.appet.2009.05.018
   Davis CA, 2009, OBESITY, V17, P1220, DOI 10.1038/oby.2009.52
   DAVIS WM, 1975, PHARMACOL BIOCHEM BE, V3, P477, DOI 10.1016/0091-3057(75)90059-3
   Delamater AR, 2000, PHARMACOL BIOCHEM BE, V65, P697, DOI 10.1016/S0091-3057(99)00251-8
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Di Chiara G, 2005, PHYSIOL BEHAV, V86, P9, DOI 10.1016/j.physbeh.2005.06.020
   Di Chiara G, 2007, CURR OPIN PHARMACOL, V7, P69, DOI 10.1016/j.coph.2006.11.003
   Di Leone RJ, 2012, NAT NEUROSCI, V15, P1330, DOI 10.1038/nn.3202
   Domingos AI, 2013, ELIFE, V2, DOI 10.7554/eLife.01462
   Donohoe RT, 1999, PSYCHOPHARMACOLOGY, V145, P378, DOI 10.1007/s002130051071
   Eichen DM, 2013, APPETITE, V67, P22, DOI 10.1016/j.appet.2013.03.008
   Elmer GI, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-10-j0004.2002
   Everitt BJ, 2008, PHILOS T R SOC B, V363, P3125, DOI 10.1098/rstb.2008.0089
   Everitt BJ, 2014, EUR J NEUROSCI, V40, P2163, DOI 10.1111/ejn.12644
   Everitt BJ, 2001, BRAIN RES REV, V36, P129, DOI 10.1016/S0165-0173(01)00088-1
   Everitt BJ, 2000, PSYCHOPHARMACOLOGY, V153, P17, DOI 10.1007/s002130000566
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Fowler L, 2014, EAT BEHAV, V15, P505, DOI 10.1016/j.eatbeh.2014.06.009
   Fuchs RA, 1998, PSYCHOPHARMACOLOGY, V135, P151, DOI 10.1007/s002130050496
   Gearhardt A, 2013, J LAW MED ETHICS, V41, P46, DOI 10.1111/jlme.12038
   Gearhardt AN, 2016, PSYCHOL ADDICT BEHAV, V30, P113, DOI 10.1037/adb0000136
   Gearhardt AN, 2014, EAT BEHAV, V15, P427, DOI 10.1016/j.eatbeh.2014.05.001
   Gearhardt Ashley N, 2011, Curr Drug Abuse Rev, V4, P140
   Gearhardt AN, 2011, ARCH GEN PSYCHIAT, V68, P808, DOI 10.1001/archgenpsychiatry.2011.32
   Gearhardt AN, 2011, ADDICTION, V106, P1208, DOI 10.1111/j.1360-0443.2010.03301.x
   Gearhardt AN, 2009, APPETITE, V52, P430, DOI 10.1016/j.appet.2008.12.003
   Hebebrand J, 2014, NEUROSCI BIOBEHAV R, V47, P295, DOI 10.1016/j.neubiorev.2014.08.016
   Hoebel BG, 2009, J ADDICT MED, V3, P33, DOI 10.1097/ADM.0b013e31819aa621
   HUBNER CB, 1990, BRAIN RES, V508, P20, DOI 10.1016/0006-8993(90)91112-T
   Ito R, 2004, NAT NEUROSCI, V7, P389, DOI 10.1038/nn1217
   Ito R, 2000, J NEUROSCI, V20, P7489
   Jedynak JP, 2007, EUR J NEUROSCI, V25, P847, DOI 10.1111/j.1460-9568.2007.05316.x
   Johnson PM, 2010, NAT NEUROSCI, V13, P635, DOI 10.1038/nn.2519
   Kawasaki H, 2011, BIOSCI BIOTECH BIOCH, V75, P2288, DOI 10.1271/bbb.110388
   KEUL J, 1982, AKTUEL ERNAHRUNGSMED, V7, P7
   Koob GF, 2006, ADDICTION, V101, P23, DOI 10.1111/j.1360-0443.2006.01586.x
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442
   KOOB GF, 1989, NEUROSCI BIOBEHAV R, V13, P135, DOI 10.1016/S0149-7634(89)80022-3
   Koob GF, 1996, NEURON, V16, P893, DOI 10.1016/S0896-6273(00)80109-9
   Laulin JP, 1998, EUR J NEUROSCI, V10, P782, DOI 10.1046/j.1460-9568.1998.00083.x
   Lennerz BS, 2013, AM J CLIN NUTR, V98, P641, DOI 10.3945/ajcn.113.064113
   Lenoir M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000698
   Levy A, 2013, ADDICT BIOL, V18, P763, DOI 10.1111/j.1369-1600.2011.00433.x
   Liu Y, 2005, EUR J NEUROSCI, V22, P195, DOI 10.1111/j.1460-9568.2005.04195.x
   Liu Y, 2005, PSYCHOPHARMACOLOGY, V179, P644, DOI 10.1007/s00213-004-2089-y
   Long CG, 2015, OBESITY FACTS, V8, P386, DOI 10.1159/000442403
   Lynch WJ, 2010, COMPARATIVE MED, V60, P177
   Maher CE, 2005, LIFE SCI, V77, P1140, DOI 10.1016/j.lfs.2005.03.004
   Mangabeira V, 2015, PHYSIOL BEHAV, V139, P468, DOI 10.1016/j.physbeh.2014.09.017
   Martin S, 1999, BRAIN RES, V821, P350, DOI 10.1016/S0006-8993(99)01122-1
   Meule Adrian, 2015, Yale Journal of Biology and Medicine, V88, P295
   Meule A, 2014, EUR EAT DISORD REV, V22, P331, DOI 10.1002/erv.2306
   Meule A, 2012, EAT BEHAV, V13, P252, DOI 10.1016/j.eatbeh.2012.02.001
   Miles FJ, 2003, BEHAV NEUROSCI, V117, P927, DOI 10.1037/0735-7044.117.5.927
   Morgan D, 2005, PSYCHOPHARMACOLOGY, V178, P309, DOI 10.1007/s00213-004-1992-6
   Morgan D, 2002, BEHAV PHARMACOL, V13, P389, DOI 10.1097/00008877-200209000-00012
   Mueller D, 2000, BEHAV BRAIN RES, V115, P39, DOI 10.1016/S0166-4328(00)00239-4
   Nader MA, 2002, NEUROPSYCHOPHARMACOL, V27, P35, DOI 10.1016/S0893-133X(01)00427-4
   Nader MA, 2006, NAT NEUROSCI, V9, P1050, DOI 10.1038/nn1737
   Ng M, 2014, LANCET, V384, P766, DOI 10.1016/S0140-6736(14)60460-8
   Park PE, 2015, ADDICT BIOL, V20, P275, DOI 10.1111/adb.12120
   Parker LA, 2000, PHARMACOL BIOCHEM BE, V66, P559, DOI 10.1016/S0091-3057(00)00222-7
   Perry JL, 2006, PSYCHOPHARMACOLOGY, V186, P235, DOI 10.1007/s00213-006-0371-x
   Phillips PEM, 2003, NATURE, V422, P614, DOI 10.1038/nature01566
   Pontieri FE, 1995, P NATL ACAD SCI USA, V92, P12304, DOI 10.1073/pnas.92.26.12304
   Pursey Kirrilly M, 2015, Addict Behav Rep, V2, P41, DOI 10.1016/j.abrep.2015.05.007
   Rada P, 2005, NEUROSCIENCE, V134, P737, DOI 10.1016/j.neuroscience.2005.04.043
   RANDOLPH TG, 1956, Q J STUD ALCOHOL, V17, P198
   Roberts DCS, 2007, PROG NEURO-PSYCHOPH, V31, P1614, DOI 10.1016/j.pnpbp.2007.08.028
   Roberts DCS, 2002, DRUG ALCOHOL DEPEN, V67, P291, DOI 10.1016/S0376-8716(02)00083-2
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Rogers PJ, 2000, PHARMACOL BIOCHEM BE, V66, P3, DOI 10.1016/S0091-3057(00)00197-0
   Roitman MF, 2004, J NEUROSCI, V24, P1265, DOI 10.1523/JNEUROSCI.3823-03.2004
   Schulte EM, 2016, CLIN PSYCHOL REV, V44, P125, DOI 10.1016/j.cpr.2016.02.001
   Schulte EM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117959
   Seip-Cammack KM, 2013, PSYCHOPHARMACOLOGY, V225, P127, DOI 10.1007/s00213-012-2801-2
   Shalev U, 2002, PHARMACOL REV, V54, P1, DOI 10.1124/pr.54.1.1
   Sonnenburg ED, 2015, NATURE, V528, P484, DOI 10.1038/528484a
   Sora I, 2001, P NATL ACAD SCI USA, V98, P5300, DOI 10.1073/pnas.091039298
   SPECKER SM, 1994, PHARMACOL BIOCHEM BE, V48, P1025, DOI 10.1016/0091-3057(94)90215-1
   Steffen KJ, 2015, EUR EAT DISORD REV, V23, P442, DOI 10.1002/erv.2399
   Sun X, 2014, PHYSIOL BEHAV, V136, P63, DOI 10.1016/j.physbeh.2014.04.017
   Tellez LA, 2016, NAT NEUROSCI, V19, P465, DOI 10.1038/nn.4224
   Thanos PK, 2007, PHARMACOL BIOCHEM BE, V87, P426, DOI 10.1016/j.pbb.2007.05.020
   Tornatzky W, 2000, PSYCHOPHARMACOLOGY, V148, P289, DOI 10.1007/s002130050053
   Trogdon JG, 2008, OBES REV, V9, P489, DOI 10.1111/j.1467-789X.2008.00472.x
   Vanderschuren LJMJ, 2005, J NEUROSCI, V25, P8665, DOI 10.1523/JNEUROSCI.0925-05.2005
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Velazquez-Sanchez C, 2015, BEHAV NEUROSCI, V129, P219, DOI 10.1037/bne0000042
   Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI 10.1093/cercor/10.3.318
   Volkow ND, 2005, NAT NEUROSCI, V8, P555, DOI 10.1038/nn1452
   Volkow ND, 2001, AM J PSYCHIAT, V158, P2015, DOI 10.1176/appi.ajp.158.12.2015
   Wagner FA, 2002, NEUROPSYCHOPHARMACOL, V26, P479, DOI 10.1016/S0893-133X(01)00367-0
   WARNER LA, 1995, ARCH GEN PSYCHIAT, V52, P219
   Weissenborn R, 1997, PSYCHOPHARMACOLOGY, V134, P242, DOI 10.1007/s002130050447
   Woolley JD, 2006, NEUROSCIENCE, V143, P309, DOI 10.1016/j.neuroscience.2006.06.067
   Xi ZX, 1999, J PHARMACOL EXP THER, V290, P1369
   Zeevi D, 2015, CELL, V163, P1079, DOI 10.1016/j.cell.2015.11.001
   Zhang M, 2002, PSYCHOPHARMACOLOGY, V159, P415, DOI 10.1007/s00213-001-0932-y
   Zhang M, 2003, BEHAV NEUROSCI, V117, P202, DOI 10.1037/0735-7044.117.2.202
   Ziauddeen H, 2013, OBES REV, V14, P19, DOI 10.1111/j.1467-789X.2012.01046.x
   Ziauddeen H, 2015, ADV NUTR, V6, P474, DOI 10.3945/an.115.008268
   Ziauddeen H, 2012, NAT REV NEUROSCI, V13, P279, DOI 10.1038/nrn3212
NR 125
TC 60
Z9 61
U1 12
U2 103
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1436-6207
EI 1436-6215
J9 EUR J NUTR
JI Eur. J. Nutr.
PD NOV
PY 2016
VL 55
SU 2
BP S55
EP S69
DI 10.1007/s00394-016-1229-6
PG 15
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Nutrition & Dietetics
GA EK8IQ
UT WOS:000394167500005
PM 27372453
OA Green Published
DA 2023-06-23
ER

PT J
AU Lucas, CJ
   Patel, J
   Martin, JH
AF Lucas, Catherine J.
   Patel, Joanne
   Martin, Jennifer H.
TI Predicting drug interactions in addiction treatment
SO INTERNAL MEDICINE JOURNAL
LA English
DT Article
DE drug interaction; pharmacokinetic; pharmacodynamic; addiction; drug
   abuse; comorbidity
ID SMOKING-CESSATION; MEDICATIONS; DISULFIRAM; BUPRENORPHINE; WARFARIN
AB It is not uncommon to be treating people with addiction who also have significant other health problems, including heart, renal or liver failure, diabetes and vascular disease. These conditions require regular medications to be taken. This can be a problem for people living with addiction and difficult social circumstances affecting compliance, among other issues. Our perspective provides a summary of general pharmacological factors affecting medicine taking in people with addiction problems, to provide a guide for hospital doctors in this setting.
C1 [Lucas, Catherine J.; Patel, Joanne; Martin, Jennifer H.] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW, Australia.
   [Lucas, Catherine J.; Patel, Joanne; Martin, Jennifer H.] Calvary Mater Hosp, Newcastle, NSW, Australia.
   [Lucas, Catherine J.; Patel, Joanne; Martin, Jennifer H.] John Hunter Hosp, Newcastle, NSW, Australia.
C3 University of Newcastle; Calvary Mater Newcastle Hospital; John Hunter
   Hospital
RP Lucas, CJ (通讯作者)，Univ Newcastle, Sch Med & Publ Hlth, Calvary Mater Hosp, Level 5,New Med 2 Bldg, Waratah, NSW 2298, Australia.
EM catherine.lucas@newcastle.edu.au
RI martin, jen/O-5029-2019
OI martin, jen/0000-0002-8614-0199
CR Back DJ, 2015, GASTROENTEROLOGY, V149, P1315, DOI 10.1053/j.gastro.2015.09.031
   Badri PS, 2016, ANTIMICROB AGENTS CH, V60, P105, DOI 10.1128/AAC.01778-15
   Begg EJ, 2008, INSTANT CLIN PHARM
   Blanch B, 2014, BRIT J CLIN PHARMACO, V78, P1159, DOI 10.1111/bcp.12446
   Bruce RD, 2013, EXPERT REV CLIN PHAR, V6, P249, DOI [10.1586/ECP.13.18, 10.1586/ecp.13.18]
   Dasgupta N, 2016, PAIN MED, V17, P85, DOI 10.1111/pme.12907
   Desai HD, 2001, CNS DRUGS, V15, P469, DOI 10.2165/00023210-200115060-00005
   Doogue M, 2009, AUST PRESCR, V32, P120
   Faber MS, 2004, CLIN PHARMACOL THER, V76, P178, DOI 10.1016/j.clpt.2004.04.003
   Fagerstrom Karl, 2008, Neuropsychiatr Dis Treat, V4, P353
   FDA, 2020, DRUG DEV DRUG INT TA
   Gowing L, 2014, NAT GUIDELINES MEDIC
   Grebely J, 2016, CLIN INFECT DIS, V63, P1479, DOI 10.1093/cid/ciw579
   Holbrook AM, 2005, ARCH INTERN MED, V165, P1095, DOI 10.1001/archinte.165.10.1095
   Lee SC, 2014, DRUG ALCOHOL DEPEN, V138, P118, DOI 10.1016/j.drugalcdep.2014.02.014
   Lucas CJ, 2013, AUST PRESCR, V36, P98
   Luykx JJ, 2013, J CLIN PSYCHOPHARM, V33, P136, DOI 10.1097/01.jcp.0000426185.68487.9a
   MACLEOD SM, 1978, CLIN PHARMACOL THER, V24, P583
   Maisel NC, 2013, ADDICTION, V108, P275, DOI 10.1111/j.1360-0443.2012.04054.x
   McCance-Katz EF, 2014, AM J ADDICTION, V23, P137, DOI 10.1111/j.1521-0391.2013.12081.x
   McCance-Katz EF, 2010, AM J ADDICTION, V19, P4, DOI 10.1111/j.1521-0391.2009.00005.x
   Menon RM, 2015, J HEPATOL, V63, P20, DOI 10.1016/j.jhep.2015.01.026
   Meyer JM, 2001, J CLIN PSYCHOPHARM, V21, P569, DOI 10.1097/00004714-200112000-00005
   Nathisuwan S, 2011, CHEST, V139, P1130, DOI 10.1378/chest.10-0777
   Ogawa R, 2010, CLIN PHARMACOKINET, V49, P509, DOI 10.2165/11531320-000000000-00000
   OREILLY RA, 1981, CLIN PHARMACOL THER, V29, P332, DOI 10.1038/clpt.1981.45
   Overholser Brian R, 2011, Am J Manag Care, V17 Suppl 11, pS276
   Pani PP, 2013, COCHRANE DB SYST REV, V6
   Perucca E, 2006, BRIT J CLIN PHARMACO, V61, P246, DOI 10.1111/j.1365-2125.2005.02529.x
   Richelson E, 1997, MAYO CLIN PROC, V72, P835, DOI 10.4065/72.9.835
   Rosner S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004332.pub2
   Rossi S, 2012, AUSTR MED HDB 2012
   Schaffer SD, 2009, J CLIN NURS, V18, P1533, DOI 10.1111/j.1365-2702.2008.02724.x
   Smith HS, 2009, MAYO CLIN PROC, V84, P613, DOI 10.1016/S0025-6196(11)60750-7
   Stafford J., 2016, AUSTR DRUG TRENDS 20
   Sun EC, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j760
   Therapeutic Guidelines Limited, 2013, ETG COMPL
   Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133
   U. S. Food and Drug Administration, 2005, CAMPRAL AC CAL DEL R
   U. S. Food and Drug Administration, 2011, WELLB BUPR HYDR PRES
   Verbeeck RK, 2008, EUR J CLIN PHARMACOL, V64, P1147, DOI 10.1007/s00228-008-0553-z
   Washio I, 2011, DRUG METAB DISPOS, V39, P1, DOI 10.1124/dmd.110.034504
   WHO, 2009, GUID PSYCH ASS PHARM
   Zakhari S, 2006, ALCOHOL RES HEALTH, V29, P245
   Zhou SF, 2009, AAPS J, V11, P481, DOI 10.1208/s12248-009-9127-y
NR 45
TC 1
Z9 1
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1444-0903
EI 1445-5994
J9 INTERN MED J
JI Intern. Med. J.
PD AUG
PY 2017
VL 47
IS 8
BP 872
EP 878
DI 10.1111/imj.13500
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine
GA FD0KY
UT WOS:000407229400005
PM 28782217
OA Green Submitted
DA 2023-06-23
ER

PT J
AU Koob, GF
AF Koob, George F.
TI Negative reinforcement in drug addiction: the darkness within
SO CURRENT OPINION IN NEUROBIOLOGY
LA English
DT Review
ID KAPPA-OPIOID RECEPTOR; DOPAMINERGIC NEURONAL-ACTIVITY; EXTENDED-ACCESS;
   STRESS; WITHDRAWAL; BRAIN; ANTAGONISTS; ACTIVATION; NUCLEUS; REWARD
AB Drug seeking is associated with the activation of reward neural circuitry, but I argue that drug addiction also involves another major source of reinforcement, specifically negative reinforcement driven by the 'dark side' (i.e., a decrease in the function of normal reward-related neurocircuitry and persistent recruitment of the brain stress systems). This combination forms the antireward system or 'darkness within.' Understanding the neuroplasticity of the neurocircuitry that comprises the negative reinforcement associated with addiction is the key to understanding the vulnerability to the transition to addiction, misery of addiction, and persistence of addiction.
C1 Scripps Res Inst, Comm Neurobiol Addict Disorders, La Jolla, CA 92037 USA.
C3 Scripps Research Institute
RP Koob, GF (通讯作者)，Scripps Res Inst, Comm Neurobiol Addict Disorders, La Jolla, CA 92037 USA.
EM gkoob@scripps.edu
CR Ahmed SH, 2002, NAT NEUROSCI, V5, P625, DOI 10.1038/nn872
   Aston-Jones G, 1999, ANN NY ACAD SCI, V877, P486, DOI 10.1111/j.1749-6632.1999.tb09284.x
   Briand LA, 2008, NEUROSCIENCE, V155, P1, DOI 10.1016/j.neuroscience.2008.06.004
   Briand LA, 2008, NEUROPSYCHOPHARMACOL, V33, P2969, DOI 10.1038/npp.2008.18
   Carlezon WA, 1998, SCIENCE, V282, P2272, DOI 10.1126/science.282.5397.2272
   Chartoff E, 2012, NEUROPHARMACOLOGY, V62, P167, DOI 10.1016/j.neuropharm.2011.06.014
   Daruna J. H., 1993, IMPULSIVE CLIENT THE, P23, DOI [DOI 10.1037/10500-002, 10.1037/10500-002]
   DIANA M, 1993, P NATL ACAD SCI USA, V90, P7966, DOI 10.1073/pnas.90.17.7966
   DIANA M, 1995, J PHARMACOL EXP THER, V272, P781
   George O, 2008, NEUROPSYCHOPHARMACOL, V33, P2474, DOI 10.1038/sj.npp.1301626
   Jang CG, 2013, PSYCHOPHARMACOLOGY, V225, P753, DOI 10.1007/s00213-012-2864-0
   Kenny PJ, 2006, J NEUROSCI, V26, P5894, DOI 10.1523/JNEUROSCI.0740-06.2006
   Knoll AT, 2007, J PHARMACOL EXP THER, V323, P838, DOI 10.1124/jpet.107.127415
   Koob GF, 2008, ANNU REV PSYCHOL, V59, P29, DOI 10.1146/annurev.psych.59.103006.093548
   Koob GF, 2009, NEUROPHARMACOLOGY, V56, P18, DOI 10.1016/j.neuropharm.2008.07.043
   Koob GF, 2003, ALCOHOL CLIN EXP RES, V27, P232, DOI 10.1097/01.ALC.0000057122.36127.C2
   KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Land BB, 2008, J NEUROSCI, V28, P407, DOI 10.1523/JNEUROSCI.4458-07.2008
   Land BB, 2009, P NATL ACAD SCI USA, V106, P19168, DOI 10.1073/pnas.0910705106
   Le Moal Michel, 1995, P283
   Mague SD, 2003, J PHARMACOL EXP THER, V305, P323, DOI 10.1124/jpet.102.046433
   McLaughlin JP, 2006, NEUROPSYCHOPHARMACOL, V31, P1241, DOI 10.1038/sj.npp.1300872
   McLaughlin JP, 2003, J NEUROSCI, V23, P5674, DOI 10.1523/jneurosci.23-13-05674.2003
   Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006
   Nealey KA, 2011, NEUROPHARMACOLOGY, V61, P35, DOI 10.1016/j.neuropharm.2011.02.012
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   Redila VA, 2008, PSYCHOPHARMACOLOGY, V200, P59, DOI 10.1007/s00213-008-1122-y
   Schindler AG, 2010, NEUROPSYCHOPHARMACOL, V35, P1932, DOI 10.1038/npp.2010.67
   Schlosburg JE, 2011, SOC NEUR ABSTR
   Shurman J, 2010, PAIN MED, V11, P1092, DOI 10.1111/j.1526-4637.2010.00881.x
   Volkow ND, 2003, J CLIN INVEST, V111, P1444, DOI 10.1172/JCI200318533
   Walker BM, 2011, ADDICT BIOL, V16, P116, DOI 10.1111/j.1369-1600.2010.00226.x
   Wee S, 2009, PSYCHOPHARMACOLOGY, V205, P565, DOI 10.1007/s00213-009-1563-y
   Weiss F, 1996, J NEUROSCI, V16, P3474
   Whitfield T. W. Jr., 2011, Society for Neuroscience Abstract Viewer and Itinerary Planner, V41
NR 36
TC 188
Z9 197
U1 5
U2 42
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0959-4388
EI 1873-6882
J9 CURR OPIN NEUROBIOL
JI Curr. Opin. Neurobiol.
PD AUG
PY 2013
VL 23
IS 4
BP 559
EP 563
DI 10.1016/j.conb.2013.03.011
PG 5
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 204XJ
UT WOS:000323404300016
PM 23628232
DA 2023-06-23
ER

PT J
AU Chuang, CWI
   Sussman, S
   Stone, MD
   Pang, RD
   Chou, CP
   Leventhal, AM
   Kirkpatrick, MG
AF Chuang, Cheng-Wei I.
   Sussman, Steve
   Stone, Matthew D.
   Pang, Raina D.
   Chou, Chih-Ping
   Leventhal, Adam M.
   Kirkpatrick, Matthew G.
TI Impulsivity and history of behavioral addictions are associated with
   drug use in adolescents
SO ADDICTIVE BEHAVIORS
LA English
DT Article
DE Impulsivity; Behavioral addiction; Marijuana; Tobacco; Alcohol;
   Adolescents
ID SUBSTANCE USE; CROSS-SENSITIZATION; PREVALENCE; SMOKING; COOCCURRENCE;
   PREDICTORS; ABUSE; YOUTH; RATS
AB Background: Previous literature suggests that trait impulsivity and engagement in non-drug-related behavioral addictions (e.g., Internet addiction, food addiction) are two risk factors for drug use. Here we further investigated the potential impact of having one or both of these risk factors on drug use in Los Angeles area adolescents.
   Method: High school students (N = 1612; Mean age = 14.1) completed self-report surveys measuring two potential risk factors (impulsivity, lifetime history of several behavioral addictions), and past 6-month use of tobacco, alcohol and marijuana. Participants who reported never using drugs completed questionnaires assessing their susceptibility for future use.
   Results: In general, adolescents who endorsed either impulsivity alone or at least two behavioral addictions alone were more likely to have used tobacco, alcohol, or marijuana compared to individuals who had neither risk factor (OR = 2.50-4.13), and individuals who endorsed both impulsivity and three or more behavioral addictions were the most likely to have used these drugs (OR = 9.40-10.13). Similarly, among those who had never tried a drug, individuals with this combined set of risk factors were the most likely to be susceptible to future drug use (OR = 3.37-5.04).
   Discussion: These results indicate that the combination of trait impulsivity and a history of behavioral addictions increases the risk for current and future drug use in adolescents, to a greater extent than either risk factor alone. It may be useful for drug prevention efforts to target impulsive adolescents who also actively engage in other non-drug-related addictive behaviors.
C1 [Chuang, Cheng-Wei I.; Sussman, Steve; Stone, Matthew D.; Pang, Raina D.; Chou, Chih-Ping; Leventhal, Adam M.; Kirkpatrick, Matthew G.] Univ Southern Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
   [Sussman, Steve; Leventhal, Adam M.] Univ Southern Calif, Dept Psychol, Los Angeles, CA 90089 USA.
   [Sussman, Steve; Chou, Chih-Ping] Univ Southern Calif, Sch Social Work, Los Angeles, CA 90089 USA.
C3 University of Southern California; University of Southern California;
   University of Southern California
RP Kirkpatrick, MG (通讯作者)，Univ Southern Calif, Dept Prevent Med, 2001 North Soto St, Los Angeles, CA 90032 USA.
EM mgkirkpa@usc.edu
FU National Institute on Drug Abuse [R01-DA033296]
FX Funding for this study was provided by National Institute on Drug Abuse
   grant R01-DA033296 (PI: Leventhal). NIDA had no role in the study
   design, collection, analysis or interpretation of the data, writing the
   manuscript, or the decision to submit the paper for publication.
CR [Anonymous], 2012, PRACTICAL ASSESSMENT, DOI [10.7275/n560-j767, DOI 10.7275/N560-J767]
   Avena NA, 2003, PHARMACOL BIOCHEM BE, V74, P635, DOI 10.1016/S0091-3057(02)01050-X
   Avena NM, 2003, NEUROSCIENCE, V122, P17, DOI 10.1016/S0306-4522(03)00502-5
   Bachman J. G., 2011, MONITORING FUTURE PR
   Bahr Stephen J, 2005, J Prim Prev, V26, P529, DOI 10.1007/s10935-005-0014-8
   Chambers R Andrew, 2003, J Gambl Stud, V19, P53, DOI 10.1023/A:1021275130071
   Chamorro J, 2012, J PSYCHIATR RES, V46, P994, DOI 10.1016/j.jpsychires.2012.04.023
   Cloninger C.R., 1994, TEMPERAMENT CHARACTE
   Davis C, 2011, APPETITE, V57, P711, DOI 10.1016/j.appet.2011.08.017
   Demetrovics Z, 2012, J BEHAV ADDICT, V1, P1, DOI 10.1556/JBA.1.2012.1.0
   Eaton Danice K., 2010, Morbidity and Mortality Weekly Report, V59, P1
   Fernie G, 2013, ADDICTION, V108, P1916, DOI 10.1111/add.12283
   Fiorino DF, 1999, J NEUROSCI, V19, P456, DOI 10.1523/JNEUROSCI.19-01-00456.1999
   Fischer S, 2008, PERS INDIV DIFFER, V44, P789, DOI 10.1016/j.paid.2007.10.008
   Gibbons FX, 1998, J PERS SOC PSYCHOL, V74, P1164, DOI 10.1037/0022-3514.74.5.1164
   Gil AG, 2004, AM J PUBLIC HEALTH, V94, P1603, DOI 10.2105/AJPH.94.9.1603
   Grant JE, 2006, CNS SPECTRUMS, V11, P924, DOI 10.1017/S109285290001511X
   Grant JE, 2014, ADDICT BEHAV, V39, P1632, DOI 10.1016/j.addbeh.2014.04.022
   Johnston L. D., 2010, NIH PUBLICATION
   Kollins SH, 2003, ADDICT BEHAV, V28, P1167, DOI 10.1016/S0306-4603(02)00220-4
   Krishnan-Sarin S, 2007, DRUG ALCOHOL DEPEN, V88, P79, DOI 10.1016/j.drugalcdep.2006.09.006
   Lee YS, 2013, ADDICT BEHAV, V38, P2022, DOI 10.1016/j.addbeh.2012.12.024
   Leventhal AM, 2015, JAMA-J AM MED ASSOC, V314, P700, DOI 10.1001/jama.2015.8950
   Moss HB, 2014, DRUG ALCOHOL DEPEN, V136, P51, DOI 10.1016/j.drugalcdep.2013.12.011
   Mottram AJ, 2009, CYBERPSYCHOL BEHAV, V12, P319, DOI 10.1089/cpb.2007.0170
   Perry JL, 2008, PSYCHOPHARMACOLOGY, V200, P1, DOI 10.1007/s00213-008-1173-0
   Pierce JP, 2005, ADDICT BEHAV, V30, P685, DOI 10.1016/j.addbeh.2004.08.014
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Strong DR, 2015, NICOTINE TOB RES, V17, P862, DOI 10.1093/ntr/ntu254
   Sussman S, 2002, AM J HEALTH BEHAV, V26, P354, DOI 10.5993/AJHB.26.5.4
   Sussman S, 2008, DRUG ABUSE: CONCEPTS, PREVENTION, AND CESSATION, P1
   Sussman S., 2017, SUBSTANCE BEHAV ADDI
   Sussman S, 2015, J BEHAV ADDICT, V4, P189, DOI 10.1556/2006.4.2015.027
   Sussman S, 2014, J BEHAV ADDICT, V3, P33, DOI 10.1556/JBA.3.2014.005
   Sussman S, 2011, EVAL HEALTH PROF, V34, P3, DOI 10.1177/0163278710380124
   Unger JB, 2009, J IMMIGR MINOR HEALT, V11, P149, DOI 10.1007/s10903-007-9083-5
   United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics and Quality. National Survey on Drug Use and Health, 2014, SUBST AB MENT HLTH S
   Vitaro F, 1998, PSYCHOL ADDICT BEHAV, V12, P185, DOI 10.1037/0893-164X.12.3.185
   Vitaro F, 1999, ADDICTION, V94, P565, DOI 10.1046/j.1360-0443.1999.94456511.x
   Wallace John M Jr, 2007, Soc Work Public Health, V23, P193, DOI 10.1080/19371910802152059
   Weafer Jessica, 2014, Curr Addict Rep, V1, P289
   Weiss JW, 2011, J ADOLESCENT HEALTH, V48, P591, DOI 10.1016/j.jadohealth.2010.09.012
   Zack M, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00036
NR 43
TC 25
Z9 26
U1 1
U2 59
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4603
EI 1873-6327
J9 ADDICT BEHAV
JI Addict. Behav.
PD NOV
PY 2017
VL 74
BP 41
EP 47
DI 10.1016/j.addbeh.2017.05.021
PG 7
WC Psychology, Clinical; Substance Abuse
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology; Substance Abuse
GA FD4XS
UT WOS:000407536100007
PM 28570913
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Polonsky, M
   Rozanova, J
   Azbel, L
   Bachireddy, C
   Izenberg, J
   Kiriazova, T
   Dvoryak, S
   Altice, FL
AF Polonsky, Maxim
   Rozanova, Julia
   Azbel, Lyuba
   Bachireddy, Chethan
   Izenberg, Jacob
   Kiriazova, Tetiana
   Dvoryak, Sergii
   Altice, Frederick L.
TI Attitudes Toward Addiction, Methadone Treatment, and Recovery Among
   HIV-Infected Ukrainian Prisoners Who Inject Drugs: Incarceration Effects
   and Exploration of Mediators
SO AIDS AND BEHAVIOR
LA English
DT Article
DE Methadone; HIV; Prisoners; Opioid Agonist Therapies; Addiction; Ukraine;
   Structural Equation Modeling
ID OPIOID SUBSTITUTION THERAPY; RANDOMIZED CONTROLLED-TRIAL; SUBSTANCE USE
   DISORDERS; MAINTENANCE TREATMENT; CRIMINAL-JUSTICE; HARM REDUCTION;
   ANTIRETROVIRAL THERAPY; MULTIDIMENSIONAL SCALE; RISK-FACTORS;
   HEPATITIS-C
AB In this study, we use data from a survey conducted in Ukraine among 196 HIV-infected people who inject drugs, to explore attitudes toward drug addiction and methadone maintenance therapy (MMT), and intentions to change drug use during incarceration and after release from prison. Two groups were recruited: Group 1 (n = 99) was currently incarcerated and Group 2 (n = 97) had been recently released from prison. This paper's key finding is that MMT treatment and addiction recovery were predominantly viewed as mutually exclusive processes. Group comparisons showed that participants in Group 1 (pre-release) exhibited higher optimism about changing their drug use, were less likely to endorse methadone, and reported higher intention to recover from their addiction. Group 2 participants (post-release), however, reported higher rates of HIV stigma. Structural equation modeling revealed that in both groups, optimism about recovery and awareness of addiction mediated the effect of drug addiction severity on intentions to recover from their addiction.
C1 [Polonsky, Maxim; Rozanova, Julia; Altice, Frederick L.] Yale Univ, Infect Dis Sect, Sch Med, 135 Coll St Suite 323, New Haven, CT 06510 USA.
   [Azbel, Lyuba] London Sch Hyg & Trop Med, London, England.
   [Bachireddy, Chethan] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA USA.
   [Izenberg, Jacob] Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA USA.
   [Kiriazova, Tetiana; Dvoryak, Sergii] Ukrainian Inst Publ Hlth Policy, Kiev, Ukraine.
   [Altice, Frederick L.] Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA.
   [Altice, Frederick L.] Univ Malaya, Ctr Excellence Res AIDS CERiA, Kuala Lumpur, Malaysia.
C3 Yale University; University of London; London School of Hygiene &
   Tropical Medicine; Harvard University; Brigham & Women's Hospital;
   Harvard Medical School; University of California System; University of
   California San Francisco; Ukrainian Institute on Public Health Policy;
   Yale University; Universiti Malaya
RP Polonsky, M (通讯作者)，Yale Univ, Infect Dis Sect, Sch Med, 135 Coll St Suite 323, New Haven, CT 06510 USA.
EM maxim.polonsky@yale.edu
RI Altice, Frederick L/A-9095-2009
OI dvoryak, sergii/0000-0002-0032-5417; Altice, Frederick
   L/0000-0002-7860-693X; Bachireddy, Chethan/0000-0002-8855-5769
FU National Institute on Drug Abuse [R01 DA029910, R01 DA033679, K24
   DA017072]; Yale University School of Medicine's Office of Student
   Research; Yale University Global Health Initiative; International
   Renaissance Foundation; NIH Fogarty Research Training Grant [R25
   TW009338]
FX This research received funding from the National Institute on Drug Abuse
   for research (R01 DA029910 and R01 DA033679) and career development (K24
   DA017072), the Yale University School of Medicine's Office of Student
   Research, the Yale University Global Health Initiative, the
   International Renaissance Foundation, and the NIH Fogarty Research
   Training Grant (R25 TW009338). No funding source had any role in study
   design, collection or analysis of data, writing or review of the
   manuscript, or decision to submit this paper for publication.
CR Alistar SS, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000423
   Altice FL, 2001, J ACQ IMMUN DEF SYND, V28, P47, DOI 10.1097/00042560-200109010-00008
   Altice FL, 2010, LANCET, V376, P367, DOI 10.1016/S0140-6736(10)60829-X
   Amato L, 2005, J SUBST ABUSE TREAT, V28, P321, DOI 10.1016/j.jsat.2005.02.007
   American Psychiatric Association (APA), 2013, DIAGN STAT MAN MENT, V5th
   Azbel L, 2015, DRUG ALCOHOL DEPEN, V151, P68, DOI 10.1016/j.drugalcdep.2015.02.034
   Azbel L, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.19005
   Azbel L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059643
   Berger BE, 2001, RES NURS HEALTH, V24, P518, DOI 10.1002/nur.10011
   Binswanger IA, 2007, NEW ENGL J MED, V356, P157, DOI 10.1056/NEJMsa064115
   Binswanger IA, 2013, ANN INTERN MED, V159, P592, DOI 10.7326/0003-4819-159-9-201311050-00005
   Bobrovskyy O., 2012, UKRAINE HARMONIZED A
   Bojko MJ, 2015, DRUG-EDUC PREV POLIC, V22, P255, DOI 10.3109/09687637.2015.1016397
   Bojko MJ, 2013, ADDICTION, V108, P1697, DOI 10.1111/add.12243
   BOLLEN KA, 1992, SOCIOL METHOD RES, V21, P205, DOI 10.1177/0049124192021002004
   BRISLIN RW, 1970, J CROSS CULT PSYCHOL, V1, P185, DOI 10.1177/135910457000100301
   Bruce RD, 2007, INT J DRUG POLICY, V18, P326, DOI 10.1016/j.drugpo.2006.12.011
   Bryan A, 2007, AIDS BEHAV, V11, P365, DOI 10.1007/s10461-006-9150-2
   Bullinger M, 1998, J CLIN EPIDEMIOL, V51, P913, DOI 10.1016/S0895-4356(98)00082-1
   Cakalo JI, 2015, AIDS BEHAV, V19, P1938, DOI 10.1007/s10461-015-1112-0
   Canty-Mitchell J, 2000, AM J COMMUN PSYCHOL, V28, P391, DOI 10.1023/A:1005109522457
   Choi P, 2010, INT J STD AIDS, V21, P416, DOI 10.1258/ijsa.2009.009180
   Comfort Megan, 2009, DOING TIME TOGETHER
   Culbert GJ, 2015, J ASSOC NURSE AIDS C, V26, P743, DOI 10.1016/j.jana.2015.07.006
   Culbert GJ, 2014, INT J PRISON HEALTH, V10, P94, DOI 10.1108/IJPH-05-2013-0020
   Culbert GJ, 2015, AIDS BEHAV, P1
   Degenhardt L, 2014, INT J DRUG POLICY, V25, P53, DOI 10.1016/j.drugpo.2013.08.004
   Dhami MK, 2006, LAW HUMAN BEHAV, V30, P631, DOI 10.1007/s10979-006-9040-1
   Di Paola A, 2014, CONTEMP CLIN TRIALS, V39, P256, DOI 10.1016/j.cct.2014.09.002
   Dolan KA, 2005, ADDICTION, V100, P820, DOI 10.1111/j.1360-0443.2005.01050.x
   Dolan KA, 2003, DRUG ALCOHOL DEPEN, V72, P59, DOI 10.1016/S0376-8716(03)00187-X
   Epley N, 2006, J BEHAV DECIS MAKING, V19, P213, DOI 10.1002/bdm.519
   European Centre for Disease Prevention and Control/WHO, 2013, HIV AIDS SURV EUR 20
   Festinger L, 1954, HUM RELAT, V7, P117, DOI 10.1177/001872675400700202
   Forste R, 2011, INT J OFFENDER THER, V55, P430, DOI 10.1177/0306624X09359649
   Goffman E., 1963, STIGMA NOTES MANAGEM
   Gordon MS, 2014, DRUG ALCOHOL DEPEN, V142, P33, DOI 10.1016/j.drugalcdep.2014.05.011
   Gordon MS, 2011, BEHAV SCI LAW, V29, P829, DOI 10.1002/bsl.1015
   Harding DJ, 2014, J POLICY ANAL MANAG, V33, P440, DOI 10.1002/pam.21741
   Hedrich D, 2012, ADDICTION, V107, P501, DOI 10.1111/j.1360-0443.2011.03676.x
   Izenberg JM, 2014, INT J DRUG POLICY, V25, P845, DOI 10.1016/j.drugpo.2014.02.010
   Izenberg JM, 2013, DRUG ALCOHOL DEPEN, V133, P154, DOI 10.1016/j.drugalcdep.2013.05.018
   Izenberg JM, 2010, ADDICTION, V105, P569, DOI 10.1111/j.1360-0443.2009.02881.x
   Johnson BT, 1999, PSYCHOL BULL, V106, P290
   Jurgens R, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-26
   Jurgens R, 2009, LANCET INFECT DIS, V9, P57, DOI 10.1016/S1473-3099(08)70305-0
   Kim SW, 2014, COST EFFECT RESOUR A, V12, DOI 10.1186/1478-7547-12-25
   Kinlock TW, 2008, CRIM JUSTICE BEHAV, V35, P34, DOI 10.1177/0093854807309111
   Kinlock TW, 2009, J SUBST ABUSE TREAT, V37, P277, DOI 10.1016/j.jsat.2009.03.002
   KRAUS SJ, 1995, PERS SOC PSYCHOL B, V21, P58, DOI 10.1177/0146167295211007
   Kunoe N, 2010, DRUG ALCOHOL DEPEN, V111, P166, DOI 10.1016/j.drugalcdep.2010.03.021
   Livingston JD, 2012, ADDICTION, V107, P39, DOI 10.1111/j.1360-0443.2011.03601.x
   Lobmaier PP, 2010, EUR ADDICT RES, V16, P139, DOI 10.1159/000313336
   MacArthur GJ, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5945
   MacArthur GJ, 2014, INT J DRUG POLICY, V25, P34, DOI 10.1016/j.drugpo.2013.07.001
   Mattick RP, 2008, COCHRANE DB SYST REV, V2008
   MCKEE KJ, 1995, AIDS CARE, V7, P159, DOI 10.1080/09540129550126687
   McKenzie Michelle, 2009, J Opioid Manag, V5, P219
   Merrall ELC, 2010, ADDICTION, V105, P1545, DOI 10.1111/j.1360-0443.2010.02990.x
   Meyer JP, 2015, AM J PUBLIC HEALTH, V105, P1901, DOI 10.2105/AJPH.2015.302687
   Ministry of Health of Ukraine, 2012, UKR HARM AIDS RESP P
   Minozzi S, 2011, ORAL NALTREXONE MAIN
   Morozova O, 2013, INT J PRISON HEALTH, V9, P5, DOI 10.1108/17449201311310760
   Nilssen O, 2005, INT J EPIDEMIOL, V34, P781, DOI 10.1093/ije/dyi078
   Nunn A, 2009, DRUG ALCOHOL DEPEN, V105, P83, DOI 10.1016/j.drugalcdep.2009.06.015
   Oser CB, 2009, DRUG ALCOHOL DEPEN, V103, pS73, DOI 10.1016/j.drugalcdep.2008.11.005
   Petersen Z, 2013, HARM REDUCT J, V10, DOI 10.1186/1477-7517-10-13
   Polonsky M, 2016, INT J DRUG POLICY, V29, P91, DOI 10.1016/j.drugpo.2015.12.016
   Polonsky M, 2015, DRUG ALCOHOL DEPEN, V148, P47, DOI 10.1016/j.drugalcdep.2014.12.008
   Pomery EA, 2009, PERS SOC PSYCHOL B, V35, P894, DOI 10.1177/0146167209335166
   Preacher KJ, 2007, MULTIVAR BEHAV RES, V42, P185, DOI 10.1080/00273170701341316
   Rich JD, 2015, LANCET, V386, P350, DOI 10.1016/S0140-6736(14)62338-2
   Sarang A, 2007, INT J DRUG POLICY, V18, P129, DOI 10.1016/j.drugpo.2006.11.007
   Schwartz RP, 2011, DRUG ALCOHOL DEPEN, V115, P23, DOI 10.1016/j.drugalcdep.2010.10.016
   Springer SA, 2015, JAIDS-J ACQ IMM DEF, V69, pS155, DOI 10.1097/QAI.0000000000000637
   Springer SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038335
   Springer Sandra A, 2008, J Opioid Manag, V4, P81
   Stangl AL, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.3.18734
   Stover H., 2006, HIV AIDS PREVENTION
   Taxman FS, 2008, BEHAV SCI LAW, V26, P435, DOI 10.1002/bsl.830
   Taxman FS, 2009, DRUG ALCOHOL DEPEN, V103, pS1, DOI 10.1016/j.drugalcdep.2009.03.003
   Torrens M, 2013, B WORLD HEALTH ORGAN, V91, P136, DOI 10.2471/BLT.12.111054
   UNAIDS, 2014, UKR COUNTR PROGR REP
   UNAIDS, 2015, REL LEAD FAITH BAS O
   United Nations Office on Drugs and Crime (UNODC), 2012, GLOH43 UNODC TREATNE
   Uuskula A, 2012, AIDS CARE, V24, P1470, DOI 10.1080/09540121.2012.672724
   WHO, 2015, HIV PRIS
   Wickersham JA, 2015, J CORRECT HEALTH CAR, V21, P12, DOI 10.1177/1078345814557513
   Wickersham JA, 2013, DRUG ALCOHOL DEPEN, V132, P378, DOI 10.1016/j.drugalcdep.2013.01.005
   Wickersham JA, 2013, B WORLD HEALTH ORGAN, V91, P124, DOI 10.2471/BLT.12.109132
   Wolfe D, 2011, LANCET, V377, P1468, DOI 10.1016/S0140-6736(10)62056-9
   World Health Organization, 2015, TOOL SET MON TARG HI
   Zaller N, 2015, INT J DRUG POLICY, V26, P37, DOI 10.1016/j.drugpo.2014.09.004
   ZIMET GD, 1990, J PERS ASSESS, V55, P610, DOI 10.1207/s15327752jpa5503&4_17
NR 94
TC 26
Z9 26
U1 1
U2 16
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD DEC
PY 2016
VL 20
IS 12
BP 2950
EP 2960
DI 10.1007/s10461-016-1375-0
PG 11
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
WE Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA ED1AF
UT WOS:000388575100016
PM 27011378
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Girczys-Poledniok, K
   Pudlo, R
   Jarzab, M
   Szymlak, A
AF Girczys-Poledniok, Katarzyna
   Pudlo, Robert
   Jarzab, Magdalena
   Szymlak, Agnieszka
TI COCAINE - CHARACTERISTICS AND ADDICTION
SO MEDYCYNA PRACY
LA Polish
DT Article
DE psychoactive substances; cocaine; drug use; addictions; crack; harm
   reduction
ID DRUG-USE; PATTERNS; HEROIN; USERS; CRACK; RISK
AB Cocaine use leads to health, social and legal problems. The aim of this paper is to discuss cocaine action, addicts characteristics, use patterns and consequences, as well as addiction treatment methods. A literature review was based on the Medline, PubMed, Polish Medical Bibliography databases and the Silesian Library resources. The Police and Central Statistical Office statistics, as well as the World Health Organization, the European Monitoring Centre for Drugs and Drug Addiction and the National Office for Combating Drug Addiction reports were used. Cocaine leads to mood improvement, appetite decrease, physical and intellectual activity enhancement, euphoria, inflated self-esteem, social networking ease and increased sexual desire. Cocaine hydrochloride is mainly used intranasaly, but also as intravenous and subcutaneous injections. Cocaine use and first addiction treatment fall in later age compared to other psychoactive substances. There is a high men to women ratio among addicts. There is a relationship between cocaine addiction, the presence of other disorders and genetic predisposition to addiction development. Polish reports indicate higher popularity of cocaine among people with a high economic and social status. Although Poland is a country with the low percentage of cocaine use, its popularity is growing. The consequences of cocaine use concern somatic and mental health problems, socioeconomic and legal conditions. The drug plays a role in crimes and traffic accidents. Because of the risks associated with cocaine use, it has been listed in a register of drugs attached to the Act on Counteracting Drug Addiction. Addiction treatment includes psychological, pharmacological and harm reduction strategies.
C1 [Girczys-Poledniok, Katarzyna; Pudlo, Robert; Jarzab, Magdalena] Med Univ Silesia, Sch Med, Wydzial Lekarski,Oddzialem Lekarsko Dent Zabrzu, Div Dent Zabrze,Dept Psychiat,Katedra & Oddzial K, Katowice, Poland.
   [Szymlak, Agnieszka] Med Univ Silesia, Sch Med, Wydzial Lekarski,Oddzialem Lekarsko Dent Zabrzu, Div Dent Zabrze,Dept Pediat,Katedra & Klin Pediat, Katowice, Poland.
C3 Medical University Silesia; Medical University Silesia
RP Girczys-Poledniok, K (通讯作者)，Slaski Uniwersytet Med, Wydzial Lekarski, Oddzialem Lekarsko Dent Zabrzu, Katedra & Oddzial Klin Psychiat, Ul Pyskowicka 47-51, PL-42612 Tarnowskie Gory, Poland.
EM girgiz@o2.pl
RI Pudlo, Robert/HKF-1660-2023
OI Pudlo, Robert/0000-0002-5748-0063
CR Anand Jacek Sein, 2009, Przegl Lek, V66, P330
   Aps JKM, 2005, FORENSIC SCI INT, V150, P119, DOI 10.1016/j.forsciint.2004.10.026
   Belin-Rauscent A, 2016, BIOL PSYCHIAT, V79, P39, DOI 10.1016/j.biopsych.2015.01.004
   Benzaquen BS, 2001, AM HEART J, V142, P402, DOI 10.1067/mhj.2001.117607
   Bourgois P, 2003, ADDICT RES THEORY, V11, P31, DOI 10.1080/1606635021000021322
   Brugal MT, 2009, EUR ADDICT RES, V15, P171, DOI 10.1159/000220345
   Bukowska B., 2013, KRAJOWE BIURO DS PRZ, V1
   Cruz M, 2014, SUBST ABUSE TREAT PR, V9, DOI 10.1186/1747-597X-9-2
   Europejskie Centrum Monitorowania Narkotykow i Narkomanii, 2010, SPRAW ROCZN 2010 STA
   Falck RS, 2008, DRUG ALCOHOL DEPEN, V98, P24, DOI 10.1016/j.drugalcdep.2008.04.004
   FREIMARK D, 1994, J HEART LUNG TRANSPL, V13, P1138
   Glowny Urzad Statystyczny, 2014, ROCZN STAT RZECZ POL
   Godwod-Sikorska C., 1989, ALCOHOLISM OTHER DEP, P25
   Haasen Christian, 2005, World Psychiatry, V4, P173
   Habrat B., 2011, PSYCHIAT KLIN, V2, P157
   Hser YI, 2008, J ADDICT DIS, V27, P13, DOI 10.1080/10550880802122554
   Inciardi JA, 2006, J PSYCHOACTIVE DRUGS, V38, P305, DOI 10.1080/02791072.2006.10399856
   Instytut Transportu Samochodowego, 2010, DRIV INFL DRUGS ALC
   Isaza C, 2013, COLOMB MEDICA, V44, P19
   Kessler RC, 1996, AM J ORTHOPSYCHIAT, V66, P17, DOI 10.1037/h0080151
   Kidawa M., 2016, UZYWANIE KOKAINY EUR
   Maj Z., 2009, MLODZIEZ NARKOTYKI P
   Majsterek M., 2013, WIAD STAT, P76
   Malczewski A., 2007, SIN, V4, P5
   Malczewski A., 2006, SIN, V3, P8
   Measham F, 2009, CRIMINOL CRIM JUSTIC, V9, P437, DOI 10.1177/1748895809343406
   Minozzi S., 2015, COCHRANE DB SYST REV, P4
   Moura HF, 2014, CLINICS, V69, P497, DOI 10.6061/clinics/2014(07)10
   Palczak K., 2007, STYLE ZYCIA UZYTKOWN
   Pani P.P., 2010, COCHRANE DATABASE SY, V20
   Policja. Statystyka, PRZEST NARK STAT POL
   Roberts M., 2005, 6 BECKL FDN DRUG POL
   Robson P., 1997, NARKOTYKI WYDAWNICTW
   Roy E, 2012, DRUG ALCOHOL REV, V31, P72, DOI 10.1111/j.1465-3362.2011.00299.x
   Sieroslawski J., 1996, ALKOHOL NARKOM, V4, P487
   Sofuoglu M, 2005, CNS DRUGS, V19, P13, DOI 10.2165/00023210-200519010-00002
   Steinbarth-Chmielewska K., 2008, FARMAKOTER PSYCHIAT, V1, P33
   Szukalski B., 2005, NARKOTYKI KOMPENDIUM
   Szukalski B., 2006, PROBLEMY KRYMINALIST, V252, P5
   United Nations Office on Drugs and Crime, 2012, WORLD DRUG REP 2012
   van Ameijden EJC, 2001, J EPIDEMIOL COMMUN H, V55, P356, DOI 10.1136/jech.55.5.356
   van der Poel A, 2009, INT J DRUG POLICY, V20, P143, DOI 10.1016/j.drugpo.2008.02.005
   Vetulani J, 2001, POL J PHARMACOL, V53, P201
   Vetulani J., 2001, WSZECHSWIAT, V102, P37
   Wagner FA, 2002, NEUROPSYCHOPHARMACOL, V26, P479, DOI 10.1016/S0893-133X(01)00367-0
   Winstock A., 2005, SEDNO PSYCHIAT, P453
   Woronowicz BT, 2009, UZALEZNIENIA GENEZA
NR 47
TC 4
Z9 5
U1 14
U2 41
PU NOFER INST OCCUPATIONAL MEDICINE, POLAND
PI LODZ
PA SW TERESY 8, LODZ, 91-348, POLAND
SN 0465-5893
EI 2353-1339
J9 MED PR
JI Med. Pr.
PY 2016
VL 67
IS 4
BP 537
EP 544
DI 10.13075/mp.5893.00291
PG 8
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA DX5WI
UT WOS:000384453000011
PM 27623834
OA gold
DA 2023-06-23
ER

PT J
AU MacCoun, RJ
AF MacCoun, Robert J.
TI Bridging the gap between science and drug policy: From "what" and "how"
   to "whom" and "when"
SO BEHAVIORAL AND BRAIN SCIENCES
LA English
DT Editorial Material
ID ADDICTION
AB For all its problems, the microeconomic "rational addiction" theory had the appeal of making clear predictions about the effects of various drug policies. The emerging picture of the "what" and "how" of addiction is far more complex. Addiction scientists might help bridge the science-policy gap by devoting more attention to the "whom" and "when" of addiction.
C1 [MacCoun, Robert J.] Univ Calif Berkeley, Goldman Sch Publ Policy, Berkeley, CA 94720 USA.
   [MacCoun, Robert J.] Univ Calif Berkeley, Boalt Hall Sch Law, Berkeley, CA 94720 USA.
C3 University of California System; University of California Berkeley;
   University of California System; University of California Berkeley
RP MacCoun, RJ (通讯作者)，Univ Calif Berkeley, Goldman Sch Publ Policy, Berkeley, CA 94720 USA.
EM maccoun@berkeley.edu
RI MacCoun, Robert/N-1765-2019; MacCoun, Robert/D-1702-2011
OI MacCoun, Robert/0000-0003-0929-4423; 
CR Auld MC, 2004, J HEALTH ECON, V23, P1117, DOI 10.1016/j.jhealeco.2004.02.003
   BECKER GS, 2004, W10976 NBER
   BICKEL WK, 1995, PSYCHOPHARMACOLOGY, V118, P250, DOI 10.1007/BF02245952
   Gruber J, 2001, Q J ECON, V116, P1261, DOI 10.1162/003355301753265570
   Kleiman M., 2001, DRUG ADDICTION DRUG
   MacCoun R, 2003, CHOICE, BEHAVIOURAL ECONOMICS AND ADDICTION, P383, DOI 10.1016/B978-008044056-9/50055-5
   MACCOUN RJ, 2001, DRUG WAR HERESIES LE
   Manski CF, 2001, INFORM AM POLICY ILL
   OBrien CP, 1996, LANCET, V347, P237, DOI 10.1016/S0140-6736(96)90409-2
   Skog OJ, 2006, ADDICTION, V101, P1444, DOI 10.1111/j.1360-0443.2006.01551.x
   Vuchinich R. E., 2003, CHOICE BEHAV EC ADDI
NR 11
TC 0
Z9 0
U1 0
U2 2
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0140-525X
J9 BEHAV BRAIN SCI
JI Behav. Brain Sci.
PD AUG
PY 2008
VL 31
IS 4
BP 454
EP +
DI 10.1017/S0140525X08004901
PG 20
WC Psychology, Biological; Behavioral Sciences; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology; Behavioral Sciences; Neurosciences & Neurology
GA 370SP
UT WOS:000260783700045
DA 2023-06-23
ER

PT J
AU Boshears, P
   Boeri, M
   Harbry, L
AF Boshears, Paul
   Boeri, Miriam
   Harbry, Liam
TI Addiction and sociality: Perspectives from methamphetamine users in
   suburban USA
SO ADDICTION RESEARCH & THEORY
LA English
DT Article
DE methamphetamine; addiction; sociality; qualitative research
ID DRUG-ABUSE TREATMENT; SCIENCE; CONSTRUCTION; NEUROBIOLOGY; IDENTITIES;
   CONTEXT; SOCIETY; MONKEYS; COCAINE; CHOICE
AB This article contributes to a growing body of literature that emphasizes the social nature of drug use, abuse and addiction. Current discourses of addiction tend to focus on the individual while limiting attention on the social environment and the role of sociality. We seek to contribute a more intuitive, insiders'' perspective of the drug trajectory and a broader conceptualization of addiction. Drawing from our qualitative study on 100 current and former methamphetamine users in the suburbs of Atlanta, Georgia (USA), we examined the trajectories of methamphetamine use to provide greater insight on what influences drug initiation, progression, cessation and relapse from the users'' perspective. Findings show that the entire drug trajectory is intertwined with, and impacted by, sociality for the majority of drug users in our sample. Moreover, the findings of our study increase our understanding of multiple routes to recovery. We join the call for greater attention to drug use and addiction as a social behavior and future research that focuses more on the role of sociality among drug users.</.
C1 [Boshears, Paul; Boeri, Miriam; Harbry, Liam] Kennesaw State Univ, Dept Sociol & Criminal Justice, Kennesaw, GA 30144 USA.
C3 University System of Georgia; Kennesaw State University
RP Boeri, M (通讯作者)，Kennesaw State Univ, Dept Sociol & Criminal Justice, 1000 Chastain Rd,MD2204, Kennesaw, GA 30144 USA.
EM mboeri@kennesaw.edu
RI Boshears, Paul F/D-8184-2016
OI Boshears, Paul F/0000-0002-7485-0564; Boeri, Miriam/0000-0002-7118-0040
CR Acker CJ, 2010, BIOSOCIETIES, V5, P70, DOI 10.1057/biosoc.2009.1
   Adams P., 2008, FRAGMENTED INTIMACY
   AKERS RL, 1991, J DRUG ISSUES, V21, P777, DOI 10.1177/002204269102100407
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5th ed., DOI DOI 10.1176/APPI.BOOKS.9780890425596
   Bailey L, 2005, ADDICT RES THEORY, V13, P535, DOI 10.1080/16066350500338195
   BECKER H, 1953, BECOMING MARIJUANA U
   Biernacki P, 1986, PATHWAYS HEROIN ADDI
   Boeri M. W., 2007, J APPL SOCIAL SCI, V1, P48
   Bourgois Philippe, 2007, Ethnography, V8, P7
   Campbell ND, 2010, BIOSOCIETIES, V5, P89, DOI 10.1057/biosoc.2009.2
   Carlson R G, 1995, NIDA Res Monogr, V157, P6
   CHARMAZ K, 2001, CONT FIELD RES PERSP, P335
   Cloud W., 2004, NAD PUBLICATION, V44, P185
   Cohen PDA, 2000, ADDICT RES, V8, P589, DOI 10.3109/16066350008998990
   Czoty PW, 2005, J PHARMACOL EXP THER, V312, P96, DOI 10.1124/jpet.104.073411
   Davies JB, 1998, PHARMACOL THERAPEUT, V80, P265, DOI 10.1016/S0163-7258(98)00031-X
   DOLE VP, 1980, SCI AM, V243, P138, DOI 10.1038/scientificamerican1280-138
   Dunbar D, 2010, BIOSOCIETIES, V5, P2, DOI 10.1057/biosoc.2009.10
   FAUPEL CE, 1991, SHOOTING DOPE CAREER
   Foddy B, 2007, AM J BIOETHICS, V7, P29, DOI 10.1080/15265160601064157
   Gibson B, 2004, SOCIOL HEALTH ILL, V26, P597, DOI 10.1111/j.0141-9889.2004.00407.x
   Giele JZ, 1998, METHODS LIFE COURSE, DOI DOI 10.4135/9781483348919
   Graham MD, 2008, ADDICT RES THEORY, V16, P121, DOI 10.1080/16066350701794543
   Granfield R, 2001, SUBST USE MISUSE, V36, P1543, DOI 10.1081/JA-100106963
   GRANFIELD R, 2004, NORDIC STUDIES ALCOH, V44, P27
   Halkitis PN, 2006, ADDICT BEHAV, V31, P549, DOI 10.1016/j.addbeh.2005.05.040
   Hammersley R, 2002, ADDICT RES THEORY, V10, P7, DOI 10.1080/16066350290001687
   Hughes K, 2007, SOCIOL HEALTH ILL, V29, P673, DOI 10.1111/j.1467-9566.2007.01018.x
   Kuhar MJ, 2010, BIOSOCIETIES, V5, P25, DOI 10.1057/biosoc.2009.5
   Lash S, 2009, EUR J SOC THEORY, V12, P175, DOI 10.1177/1368431008099646
   Laub J.H., 2003, SHARED BEGINNINGS DI
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Lindesmith AR, 1938, AM J SOCIOL, V43, P593, DOI 10.1086/217773
   LYONS T, 2010, PRACTICING ANTHR, V32, P41, DOI DOI 10.17730/PRAA.32.2.FT047XW4K8U27525
   Malterud K, 2001, LANCET, V358, P397, DOI 10.1016/S0140-6736(01)05548-9
   Matto H, 2007, ADDICT BEHAV, V32, P1826, DOI 10.1016/j.addbeh.2006.12.015
   May C, 2001, SOCIOLOGY, V35, P385, DOI 10.1017/S0038038501000189
   Milkman H, 1995, AM DRUG SCENE ANTHOL, P12
   Miller N.S., 1995, ADDICTION PSYCHIAT C
   Morgan D, 2002, NAT NEUROSCI, V5, P169, DOI 10.1038/nn798
   NADELMANN EA, 2004, CRIMINOL PUBLIC POL, V3, P441, DOI DOI 10.1111/j.1745-9133.2004.tb00052.x
   *NIH, 2005, NIH PUBL, V1
   Pilkington H, 2007, SOCIOL REV, V55, P373, DOI 10.1111/j.1467-954X.2007.00710.x
   PREBLE E, 1969, INT J ADDICT, V4, P1, DOI 10.3109/10826086909061998
   Reinarman C, 2005, ADDICT RES THEORY, V13, P307, DOI 10.1080/16066350500077728
   REINARMAN C, 1997, CRACK AM DEMON DRUGS
   Robinson TE, 2000, ADDICTION, V95, pS91
   Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1
   Sexton RL, 2008, J PSYCHOACTIVE DRUGS, V40, P121, DOI 10.1080/02791072.2008.10400621
   STEPHENS RC, 1991, STREET ADDICT ROLE T
   Stockwell T, 1997, ADDICT RES, V5, P1, DOI 10.3109/16066359709005577
   Strauss E, 1998, CLIN ORTHOP RELAT R, P2
   Vanderstaay SL, 2005, J CONTEMP ETHNOGR, V34, P371, DOI 10.1177/0891241605275478
   Volkow ND, 2004, NAT REV NEUROSCI, V5, P963, DOI 10.1038/nrn1539
   WARD NJ, 2008, SOCIOLOGY HLTH ILLNE, V30, P1007
   WATTERS JK, 1989, SOC PROBL, V36, P416, DOI 10.1525/sp.1989.36.4.03a00070
   Weinberg D, 2000, SOC PROBL, V47, P606, DOI 10.1525/sp.2000.47.4.03x0310x
   WILLIAMS C, 2006, ATLANTA J CONST 0320
   WINICK C, 1962, B NARCOTICS, V14, P1
NR 59
TC 24
Z9 24
U1 1
U2 13
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1606-6359
EI 1476-7392
J9 ADDICT RES THEORY
JI Addict. Res. Theory
PY 2011
VL 19
IS 4
BP 289
EP 301
DI 10.3109/16066359.2011.566654
PG 13
WC Substance Abuse; Social Issues
WE Social Science Citation Index (SSCI)
SC Substance Abuse; Social Issues
GA 779VI
UT WOS:000291809900001
PM 21887124
OA Green Accepted, Green Submitted
DA 2023-06-23
ER

PT J
AU Zaveri, NT
AF Zaveri, Nurulain T.
TI The Nociceptin/Orphanin FQ Receptor (NOP) as a Target for Drug Abuse
   Medications
SO CURRENT TOPICS IN MEDICINAL CHEMISTRY
LA English
DT Review
DE Nociceptin receptor ligands; NOP ligands; NOP receptor; mixed-action
   opioids; NOP/opioid ligands; drug addiction; polydrug addiction
ID CONDITIONED PLACE PREFERENCE; ORPHANIN FQ/NOCICEPTIN RECEPTOR; INDUCED
   DOPAMINE RELEASE; ALCOHOL-PREFERRING RATS; CENTRAL-NERVOUS-SYSTEM;
   MORPHINE-TOLERANCE; NUCLEUS-ACCUMBENS; CENTRAL AMYGDALA; ORL1 RECEPTOR;
   GABAERGIC TRANSMISSION
AB Several studies show that the nociceptin receptor NOP plays a role in the regulation of reward and motivation pathways related to substance abuse. Administration of the NOP's natural peptide ligand, Nociceptin/Orphanin FQ (N/OFQ) or synthetic agonist Ro 64-6198 has been shown to block rewarding effects of cocaine, morphine, amphetamines and alcohol, in various behavioral models of drug reward and reinforcement, such as conditioned place preference and drug self-administration. Administration of N/OFQ has been shown to reduce drug-stimulated levels of dopamine in mesolimbic pathways. The NOP-N/OFQ system has been particularly well examined in the development of alcohol abuse in animal models. Furthermore, the efficacy of the mixed-action opioid buprenorphine, in attenuating alcohol consumption in human addicts and in alcohol-preferring animal models, at higher doses, has been attributed to its partial agonist activity at the NOP receptor. These studies suggest that NOP receptor agonists may have potential as drug abuse medications. However, the pathophysiology of addiction is complex and drug addiction pharmacotherapy needs to address the various phases of substance addiction (craving, withdrawal, relapse). Further studies are needed to clearly establish how NOP agonists may attenuate the drug addiction process and provide therapeutic benefit. Addiction to multiple abused drugs (polydrug addiction) is now commonplace and presents a treatment challenge, given the limited pharmacotherapies currently approved. Polydrug addiction may not be adequately treated by a single agent with a single mechanism of action. As with the case of buprenorphine, a mixed-action profile of NOP/opioid activity may provide a more effective drug to treat addiction to various abused substances and/or polydrug addiction.
C1 Astraea Therapeut LLC, Mountain View, CA 94043 USA.
RP Zaveri, NT (通讯作者)，Astraea Therapeut LLC, 320 Logue Ave,Suite 142, Mountain View, CA 94043 USA.
EM nurulain@astraeatherapeutics.com
FU NIDA [DA 14026]
FX Support by a grant from NIDA (DA 14026, N.Z.) is gratefully
   acknowledged. The author would like to thank her colleagues, Lawrence
   Toll, Taline Khroyan, Faming Jiang, Cris Olsen, and Willma Polgar for
   helpful discussions.
CR Bloms-Funke P, 2000, PEPTIDES, V21, P1141, DOI 10.1016/S0196-9781(00)00252-7
   Boothby LA, 2007, AM J HEALTH-SYST PH, V64, P266, DOI 10.2146/ajhp060403
   BUNZOW JR, 1994, FEBS LETT, V347, P284, DOI 10.1016/0014-5793(94)00561-3
   Carra G, 2005, J PHARMACOL EXP THER, V312, P1114, DOI 10.1124/jpet.104.077339
   CARROLL ME, 1992, J PHARMACOL EXP THER, V261, P26
   Chung SJ, 2006, J PHARMACOL EXP THER, V318, P262, DOI 10.1124/jpet.106.103960
   Ciccocioppo R, 2004, PSYCHOPHARMACOLOGY, V172, P170, DOI 10.1007/s00213-003-1645-1
   Ciccocioppo R, 1999, PSYCHOPHARMACOLOGY, V141, P220, DOI 10.1007/s002130050828
   Ciccocioppo R, 2000, EUR J PHARMACOL, V404, P153, DOI 10.1016/S0014-2999(00)00590-2
   Ciccocioppo R, 2004, PHYSIOL BEHAV, V82, P63, DOI 10.1016/j.physbeh.2004.04.035
   Ciccocioppo R, 2001, NEUROREPORT, V12, P1145, DOI 10.1097/00001756-200105080-00019
   Ciccocioppo R, 2007, BIOL PSYCHIAT, V61, P4, DOI 10.1016/j.biopsych.2006.01.006
   Ciccocioppo R, 2006, ADDICT BIOL, V11, P339, DOI 10.1111/j.1369-1600.2006.00032.x
   COWAN A, 1977, BRIT J PHARMACOL, V60, P537, DOI 10.1111/j.1476-5381.1977.tb07532.x
   Di Giannuario A, 2000, PEPTIDES, V21, P1125, DOI 10.1016/S0196-9781(00)00250-3
   Di Giannuario A, 1999, NEUROSCI LETT, V272, P183, DOI 10.1016/S0304-3940(99)00579-0
   Economidou D, 2006, PEPTIDES, V27, P3299, DOI 10.1016/j.peptides.2006.09.007
   Economidou D, 2008, BIOL PSYCHIAT, V64, P211, DOI 10.1016/j.biopsych.2008.02.004
   Fioravanti B, 2008, CURR TOP MED CHEM, V8, P1442, DOI 10.2174/156802608786264227
   FRANCE CP, 1990, J PHARMACOL EXP THER, V254, P626
   Gintzler AR, 1997, EUR J PHARMACOL, V325, P29, DOI 10.1016/S0014-2999(97)00103-9
   Griebel G, 1999, BRAIN RES, V836, P221, DOI 10.1016/S0006-8993(99)01684-4
   Higgins GA, 2001, NEUROPHARMACOLOGY, V41, P97, DOI 10.1016/S0028-3908(01)00048-X
   Huang P, 2001, J PHARMACOL EXP THER, V297, P688
   ISHIYAMA K, 2003, Patent No. 1275657
   Jenck F, 1997, P NATL ACAD SCI USA, V94, P14854, DOI 10.1073/pnas.94.26.14854
   Jenck F, 2000, P NATL ACAD SCI USA, V97, P4938, DOI 10.1073/pnas.090514397
   Kenna GA, 2007, CNS DRUGS, V21, P213, DOI 10.2165/00023210-200721030-00003
   Kest B, 2001, NEUROSCIENCE, V104, P217, DOI 10.1016/S0306-4522(01)00037-9
   Khroyan TV, 2007, J PHARMACOL EXP THER, V320, P934, DOI 10.1124/jpet.106.111997
   Koizumi M, 2004, J NEUROCHEM, V89, P257, DOI 10.1111/j.1471-4159.2003.02322.x
   KOSTEN TR, 1992, PSYCHOPHARMACOL BULL, V28, P15
   Kotlinska J, 2003, EUR J PHARMACOL, V474, P233, DOI 10.1016/S0014-2999(03)02081-8
   Kotlinska J, 2003, NEUROREPORT, V14, P601, DOI 10.1097/00001756-200303240-00015
   Kotlinska J, 2002, BEHAV PHARMACOL, V13, P229, DOI 10.1097/00008877-200205000-00006
   Kuzmin A, 2003, J PHARMACOL EXP THER, V304, P310, DOI 10.1124/jpet.102.041350
   Kuzmin A, 2007, NEUROPSYCHOPHARMACOL, V32, P902, DOI 10.1038/sj.npp.1301169
   Lambert DG, 2008, NAT REV DRUG DISCOV, V7, P694, DOI 10.1038/nrd2572
   Lukas S E, 1983, NIDA Res Monogr, V43, P178
   Lutfy K, 2003, J NEUROSCI, V23, P10331
   Lutfy K, 2001, BRIT J PHARMACOL, V134, P529, DOI 10.1038/sj.bjp.0704279
   Lutfy K, 2001, PSYCHOPHARMACOLOGY, V154, P1, DOI 10.1007/s002130000609
   Maidment Nigel T., 2002, Neuroreport, V13, P1137, DOI 10.1097/00001756-200207020-00013
   Mamiya T, 2001, J NEURAL TRANSM, V108, P1349, DOI 10.1007/s007020100012
   Marquez P, 2008, NEUROSCIENCE, V155, P597, DOI 10.1016/j.neuroscience.2008.06.027
   Marquez P, 2008, NEUROPHARMACOLOGY, V54, P564, DOI 10.1016/j.neuropharm.2007.11.003
   Martin-Fardon R, 2000, NEUROREPORT, V11, P1939, DOI 10.1097/00001756-200006260-00026
   Mello N K, 1989, NIDA Res Monogr, V95, P333
   MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0
   Mogil JS, 1996, NEUROSCIENCE, V75, P333, DOI 10.1016/0306-4522(96)00338-7
   Mogil JS, 2001, PHARMACOL REV, V53, P381
   Mogil JS, 1996, NEUROSCI LETT, V214, P131, DOI 10.1016/0304-3940(96)12917-7
   MOLLEREAU C, 1994, FEBS LETT, V341, P338
   Montoya ID, 2004, CLIN PHARMACOL THER, V75, P34, DOI 10.1016/j.clpt.2003.09.004
   Murphy NP, 1996, NEUROSCIENCE, V75, P1, DOI 10.1016/0306-4522(96)00322-3
   Murphy NP, 1999, J NEUROCHEM, V73, P179, DOI 10.1046/j.1471-4159.1999.0730179.x
   Murphy NP, 1999, BRAIN RES, V832, P168, DOI 10.1016/S0006-8993(99)01425-0
   Nava F, 2008, PROG NEURO-PSYCHOPH, V32, P1867, DOI 10.1016/j.pnpbp.2008.08.019
   Neal CR, 1999, J COMP NEUROL, V406, P503
   Neal CR, 1999, J COMP NEUROL, V412, P563
   REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792
   Rizzi A, 2007, PEPTIDES, V28, P1240, DOI 10.1016/j.peptides.2007.04.020
   Roberto M, 2004, J NEUROSCI, V24, P10159, DOI 10.1523/JNEUROSCI.3004-04.2004
   Roberto M, 2003, P NATL ACAD SCI USA, V100, P2053, DOI 10.1073/pnas.0437926100
   Roberto M, 2006, P NATL ACAD SCI USA, V103, P9715, DOI 10.1073/pnas.0601899103
   Rover S, 2000, J MED CHEM, V43, P1329, DOI 10.1021/jm991129q
   SADEE W, 1982, J PHARMACOL EXP THER, V223, P157
   Sakoori K, 2004, PSYCHOPHARMACOLOGY, V172, P129, DOI 10.1007/s00213-003-1643-3
   Sakoori K, 2008, NEUROPSYCHOPHARMACOL, V33, P877, DOI 10.1038/sj.npp.1301459
   SCHOTTENFELD RS, 1993, BIOL PSYCHIAT, V34, P66, DOI 10.1016/0006-3223(93)90258-F
   Shoblock JR, 2005, NEUROPHARMACOLOGY, V49, P439, DOI 10.1016/j.neuropharm.2005.04.008
   Varty GB, 2005, PSYCHOPHARMACOLOGY, V182, P132, DOI 10.1007/s00213-005-0041-4
   Varty GB, 2008, J PHARMACOL EXP THER, V326, P672, DOI 10.1124/jpet.108.136937
   Walker JR, 1998, NEUROREPORT, V9, P2243, DOI 10.1097/00001756-199807130-00017
   WANG JB, 1994, FEBS LETT, V348, P75, DOI 10.1016/0014-5793(94)00557-5
   Wichmann J, 1999, BIOORG MED CHEM LETT, V9, P2343, DOI 10.1016/S0960-894X(99)00385-6
   Wnendt S, 1999, MOL PHARMACOL, V56, P334, DOI 10.1124/mol.56.2.334
   YOUNG AM, 1984, J PHARMACOL EXP THER, V229, P118
   Zaveri N, 2003, LIFE SCI, V73, P663, DOI 10.1016/S0024-3205(03)00387-4
   Zaveri N, 2001, EUR J PHARMACOL, V428, P29, DOI 10.1016/S0014-2999(01)01282-1
   Zeilhofer HU, 2003, J PHARMACOL EXP THER, V306, P423, DOI 10.1124/jpet.102.046979
   Zhao RJ, 2003, NEUROREPORT, V14, P2383, DOI 10.1097/00001756-200312190-00019
NR 82
TC 57
Z9 60
U1 0
U2 11
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0266
J9 CURR TOP MED CHEM
JI Curr. Top. Med. Chem.
PD MAY
PY 2011
VL 11
IS 9
BP 1151
EP 1156
PG 6
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 764UD
UT WOS:000290658400004
PM 21050175
DA 2023-06-23
ER

PT J
AU Potenza, MN
AF Potenza, Marc N.
TI How might food addiction relate to drug and behavioral addictions?
SO JOURNAL OF BEHAVIORAL ADDICTIONS
LA English
DT Meeting Abstract
C1 [Potenza, Marc N.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
   [Potenza, Marc N.] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA.
   [Potenza, Marc N.] Yale Univ, Sch Med, Dept Child Study, New Haven, CT USA.
C3 Yale University; Yale University; Yale University
EM marc.potenza@yale.edu
NR 0
TC 0
Z9 0
U1 0
U2 6
PU AKADEMIAI KIADO RT
PI BUDAPEST
PA PRIELLE K U 19, PO BOX 245,, H-1117 BUDAPEST, HUNGARY
SN 2062-5871
EI 2063-5303
J9 J BEHAV ADDICT
JI J. Behav. Addict.
PY 2013
VL 2
SU 1
MA PL-08
BP 4
EP 4
PG 1
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA AK3JD
UT WOS:000338318500009
DA 2023-06-23
ER

PT J
AU Jimenez-Gonzalez, A
   Gomez-Acevedo, C
   Ochoa-Aguilar, A
   Chavarria, A
AF Jimenez-Gonzalez, Ariadna
   Gomez-Acevedo, Claudia
   Ochoa-Aguilar, Abraham
   Chavarria, Anahi
TI The Role of Glia in Addiction: Dopamine as a Modulator of Glial
   Responses in Addiction
SO CELLULAR AND MOLECULAR NEUROBIOLOGY
LA English
DT Review
DE Addiction; Dopamine; Dopamine receptors; Glial activation; Glial
   interactions; Reward system; TLR4
ID FIBRILLARY ACIDIC PROTEIN; TOLL-LIKE RECEPTORS; PREFRONTAL CORTEX; D2
   RECEPTORS; MICROGLIAL ACTIVATION; PROSTAGLANDIN E-2; OXIDATIVE STRESS;
   DRUG-ADDICTION; BRAIN-INJURY; TNF-ALPHA
AB Addiction is a chronic and potentially deadly disease considered a global health problem. Nevertheless, there is still no ideal treatment for its management. The alterations in the reward system are the most known pathophysiological mechanisms. Dopamine is the pivotal neurotransmitter involved in neuronal drug reward mechanisms and its neuronal mechanisms have been intensely investigated in recent years. However, neuroglial interactions and their relation to drug addiction development and maintenance of drug addiction have been understudied. Many reports have found that most neuroglial cells express dopamine receptors and that dopamine activity may induce neuroimmunomodulatory effects. Furthermore, current research has also shown that pro- and anti-inflammatory molecules modulate dopaminergic neuron activity. Thus, studying the immune mechanisms of dopamine associated with drug abuse is vital in researching new pathophysiological mechanisms and new therapeutic targets for addiction management.
C1 [Jimenez-Gonzalez, Ariadna; Gomez-Acevedo, Claudia] Univ Nacl Autonoma Mexico, Lab Biomembranas, Dept Farmacol, Fac Med, Mexico City, DF, Mexico.
   [Ochoa-Aguilar, Abraham] Univ Nacl Autonoma Mexico, Plan Estudios Combinados Med, Fac Med, Mexico City, DF, Mexico.
   [Chavarria, Anahi] Univ Nacl Autonoma Mexico, Unidad Invest Med Expt, Fac Med, Mexico City, DF, Mexico.
C3 Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma
   de Mexico; Universidad Nacional Autonoma de Mexico
RP Chavarria, A (通讯作者)，Univ Nacl Autonoma Mexico, Unidad Invest Med Expt, Fac Med, Mexico City, DF, Mexico.
EM anahi.chavarria@facmed.unam.mx
RI Chavarria, Anahi/AAD-6636-2019
OI Chavarria, Anahi/0000-0002-6412-0461; Ochoa-Aguilar,
   Abraham/0000-0002-5800-144X
FU Facultad de Medicina, Universidad Nacional Autonoma de Mexico (UNAM);
   PAPIIT [IN207918, IN214821]; CONACYT Ciencia de Frontera 2019 [1783];
   CONACYT [889179]
FX The Facultad de Medicina, Universidad Nacional Autonoma de Mexico
   (UNAM), PAPIIT (IN207918, IN214821), and CONACYT Ciencia de Frontera
   2019 (1783) provided the funding for this study. Ariadna
   Jimenez-Gonzalez is a doctoral student from Programa de Doctorado en
   Ciencias Biomedicas, UNAM and received the fellowship 889179 from
   CONACYT. The authors are grateful to Jesus Enrique Gil de Maria y Campos
   for his artwork assistance.
CR Aghaie CI, 2020, ALCOHOL CLIN EXP RES, V44, P435, DOI 10.1111/acer.14275
   ALONSO R, 1993, J NEUROCHEM, V61, P1284, DOI 10.1111/j.1471-4159.1993.tb13620.x
   Armstrong V, 2004, EUR J PHARMACOL, V488, P111, DOI 10.1016/j.ejphar.2004.02.001
   Aurelian L, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.72
   Banisadr G, 2002, J NEUROCHEM, V81, P257, DOI 10.1046/j.1471-4159.2002.00809.x
   Barron AB, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00163
   Basu S, 2000, J NEUROIMMUNOL, V102, P113, DOI 10.1016/S0165-5728(99)00176-9
   Beaulieu JM, 2015, BRIT J PHARMACOL, V172, P1, DOI 10.1111/bph.12906
   Beaulieu JM, 2011, PHARMACOL REV, V63, P182, DOI 10.1124/pr.110.002642
   Beeler JA, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00170
   Lopez-Rodriguez AB, 2014, BRIT J PHARMACOL, V171, P1435, DOI 10.1111/bph.12519
   Berridge KC, 2015, NEURON, V86, P646, DOI 10.1016/j.neuron.2015.02.018
   Bland ST, 2009, BRAIN BEHAV IMMUN, V23, P492, DOI 10.1016/j.bbi.2009.01.014
   Bloomfield MAP, 2016, NATURE, V539, P369, DOI 10.1038/nature20153
   Boileau I, 2003, SYNAPSE, V49, P226, DOI 10.1002/syn.10226
   BOYSON SJ, 1986, J NEUROSCI, V6, P3177
   Bressan RA, 2005, ACTA PSYCHIAT SCAND, V111, P14, DOI 10.1111/j.1600-0447.2005.00540.x
   Bruinsma K, 1999, J AM DIET ASSOC, V99, P1249, DOI 10.1016/S0002-8223(99)00307-7
   Chen JX, 2017, BEHAV BRAIN RES, V335, P151, DOI 10.1016/j.bbr.2017.08.022
   Coller JK, 2012, PHARMACOL THERAPEUT, V134, P219, DOI 10.1016/j.pharmthera.2012.01.008
   Cooper S, 2017, NEUROTHERAPEUTICS, V14, P687, DOI 10.1007/s13311-017-0525-z
   Cosentino M, 2004, FREE RADICAL BIO MED, V36, P1233, DOI 10.1016/j.freeradbiomed.2004.02.065
   Dalcik H, 2009, INT J NEUROSCI, V119, P1303, DOI 10.1080/00207450802333672
   Daubner SC, 2011, ARCH BIOCHEM BIOPHYS, V508, P1, DOI 10.1016/j.abb.2010.12.017
   Degenhardt L, 2014, ADDICTION, V109, P1320, DOI 10.1111/add.12551
   Degraaf AJ, 2014, AM J RESP CELL MOL, V51, P242, DOI 10.1165/rcmb.2013-0495OC
   di Volo M, 2019, EUR J NEUROSCI, V50, P2282, DOI 10.1111/ejn.14147
   Ding SD, 2016, MOL NEUROBIOL, V53, P5324, DOI 10.1007/s12035-015-9445-2
   Dominguez-Meijide A, 2017, BRAIN BEHAV IMMUN, V62, P277, DOI 10.1016/j.bbi.2017.02.013
   Fan Y, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00309
   Farber K, 2005, MOL CELL NEUROSCI, V29, P128, DOI 10.1016/j.mcn.2005.01.003
   Felger JC, 2012, FRONT NEUROENDOCRIN, V33, P315, DOI 10.1016/j.yfrne.2012.09.003
   Ferre S, 1997, TRENDS NEUROSCI, V20, P482, DOI 10.1016/S0166-2236(97)01096-5
   Fields RD, 2002, SCIENCE, V298, P556, DOI 10.1126/science.298.5593.556
   Fleckenstein AE, 2007, ANNU REV PHARMACOL, V47, P681, DOI 10.1146/annurev.pharmtox.47.120505.105140
   Franco R, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9020109
   Gessa GL, 1998, EUR J PHARMACOL, V355, P119, DOI 10.1016/S0014-2999(98)00486-5
   Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119
   Grace AA, 2000, ADDICTION, V95, pS119
   Granado N, 2011, NEUROBIOL DIS, V42, P391, DOI 10.1016/j.nbd.2011.01.033
   Guillot TS, 2008, NEUROPEPTIDES, V42, P423, DOI 10.1016/j.npep.2008.04.003
   Guyon A, 2009, NEUROSCIENCE, V162, P1072, DOI 10.1016/j.neuroscience.2009.05.048
   Hamid AA, 2016, NAT NEUROSCI, V19, P117, DOI 10.1038/nn.4173
   Hamilton NB, 2010, NAT REV NEUROSCI, V11, P227, DOI 10.1038/nrn2803
   Hawkins JL, 2015, NEUROSCIENCE, V290, P115, DOI 10.1016/j.neuroscience.2015.01.034
   Ho A, 1998, J NEUROSCI, V18, P5614
   Huck JHJ, 2015, J CEREBR BLOOD F MET, V35, P1804, DOI 10.1038/jcbfm.2015.128
   Hutchinson MR, 2010, BRAIN BEHAV IMMUN, V24, P83, DOI 10.1016/j.bbi.2009.08.004
   Hutchinson MR, 2009, BRAIN BEHAV IMMUN, V23, P240, DOI 10.1016/j.bbi.2008.09.012
   Jacobsen JHW, 2016, CURR OPIN PHARMACOL, V26, P131, DOI 10.1016/j.coph.2015.10.010
   Jacobsen JHW, 2014, INT REV NEUROBIOL, V118, P129, DOI 10.1016/B978-0-12-801284-0.00006-3
   Jennings A, 2016, OPERA MED PHYSL, V2, P34, DOI [DOI 10.20388/0MP2016.001.0017, 10.20388/OMP2016.001.0017]
   JOHNSON SW, 1992, J NEUROSCI, V12, P483
   Kim J, 2016, MOL CELLS, V39, P645, DOI 10.14348/molcells.2016.0137
   Koga M, 2019, TISSUE CELL, V60, P14, DOI 10.1016/j.tice.2019.07.006
   Koga S, 2014, NEUROSCI LETT, V571, P11, DOI 10.1016/j.neulet.2014.04.028
   Koob GF, 2016, LANCET PSYCHIAT, V3, P760, DOI 10.1016/S2215-0366(16)00104-8
   Kopec A., 2017, MICROGILAL ELIMINATI, V269
   Kupchik YM, 2015, NAT NEUROSCI, V18, P1230, DOI 10.1038/nn.4068
   Kuzmich NN, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5040034
   la Cour CM, 2011, MOL PHARMACOL, V79, P91, DOI 10.1124/mol.110.065409
   Lacagnina MJ, 2017, NEUROPSYCHOPHARMACOL, V42, P156, DOI 10.1038/npp.2016.121
   Lathia JD, 2008, J NEUROSCI, V28, P13978, DOI 10.1523/JNEUROSCI.2140-08.2008
   Lee MS, 2007, ANNU REV BIOCHEM, V76, P447, DOI 10.1146/annurev.biochem.76.060605.122847
   LEMOAL M, 1991, PHYSIOL REV, V71, P155, DOI 10.1152/physrev.1991.71.1.155
   Levite M, 2012, NERVE-DRIVEN IMMUNITY: NEUROTRANSMITTERS AND NEUROPEPTIDES IN THE IMMUNE SYSTEM, P1, DOI 10.1007/978-3-7091-0888-8_1
   Lewitus GM, 2016, NEURON, V90, P483, DOI 10.1016/j.neuron.2016.03.030
   Linker KE, 2019, EUR J NEUROSCI, V50, P2574, DOI 10.1111/ejn.14163
   Little KY, 2009, PSYCHIAT RES, V168, P173, DOI 10.1016/j.psychres.2008.10.034
   Liu AM, 2019, ANN CLIN LAB SCI, V49, P353
   Lourbopoulos A, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00054
   MacNicol B, 2017, CAN J ANESTH, V64, P141, DOI 10.1007/s12630-016-0771-2
   Marie-Claire C, 2004, NEUROPSYCHOPHARMACOL, V29, P2208, DOI 10.1038/sj.npp.1300513
   Mastroeni D, 2009, NEUROBIOL AGING, V30, P1805, DOI 10.1016/j.neurobiolaging.2008.01.001
   Matt SM, 2020, J NEUROIMMUNE PHARM, V15, P114, DOI 10.1007/s11481-019-09851-4
   McNamara CG, 2014, NAT NEUROSCI, V17, P1658, DOI 10.1038/nn.3843
   MEREU G, 1987, EUR J PHARMACOL, V141, P395, DOI 10.1016/0014-2999(87)90556-5
   Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189
   Miyazaki I, 2004, BRAIN RES, V1029, P120, DOI 10.1016/j.brainres.2004.09.014
   Montoya A, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1652-8
   Nakanishi S, 2014, NEUROSCIENCE, V282, P49, DOI 10.1016/j.neuroscience.2014.04.026
   Nolan R A, 2020, Brain Behav Immun Health, V2, DOI 10.1016/j.bbih.2019.100030
   Nolan RA, 2019, J NEUROIMMUNE PHARM, V14, P134, DOI 10.1007/s11481-018-9825-2
   Northcutt AL, 2015, MOL PSYCHIATR, V20, P1525, DOI 10.1038/mp.2014.177
   Okun E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047522
   Okun E, 2011, TRENDS NEUROSCI, V34, P269, DOI 10.1016/j.tins.2011.02.005
   Okun E, 2010, J NEUROCHEM, V114, P462, DOI 10.1111/j.1471-4159.2010.06778.x
   Partilla JS, 2006, J PHARMACOL EXP THER, V319, P237, DOI 10.1124/jpet.106.103622
   Perry VH, 2014, NAT REV NEUROL, V10, P217, DOI 10.1038/nrneurol.2014.38
   Pocock JM, 2007, TRENDS NEUROSCI, V30, P527, DOI 10.1016/j.tins.2007.07.007
   Porter JT, 1997, PROG NEUROBIOL, V51, P439, DOI 10.1016/S0301-0082(96)00068-8
   Qiu J, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0739-8
   Ray LA, 2017, NEUROPSYCHOPHARMACOL, V42, P1776, DOI 10.1038/npp.2017.10
   RICHFIELD EK, 1989, NEUROSCIENCE, V30, P767, DOI 10.1016/0306-4522(89)90168-1
   RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058
   Robinson Donita L, 2011, Front Psychiatry, V2, P23, DOI 10.3389/fpsyt.2011.00023
   Rolls A, 2007, NAT CELL BIOL, V9, P1081, DOI 10.1038/ncb1629
   Saika F, 2018, NEUROSCI LETT, V665, P33, DOI 10.1016/j.neulet.2017.11.042
   Salter MW, 2014, CELL, V158, P15, DOI 10.1016/j.cell.2014.06.008
   Sarkar C, 2010, BRAIN BEHAV IMMUN, V24, P525, DOI 10.1016/j.bbi.2009.10.015
   Schottenfeld RS, 2016, JAMA PSYCHIAT, V73, P437, DOI 10.1001/jamapsychiatry.2016.0139
   Schultz W, 2002, NEURON, V36, P241, DOI 10.1016/S0896-6273(02)00967-4
   Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1
   Schwarz JM, 2011, J NEUROSCI, V31, P17835, DOI 10.1523/JNEUROSCI.3297-11.2011
   Sekine Y, 2008, J NEUROSCI, V28, P5756, DOI 10.1523/JNEUROSCI.1179-08.2008
   Selemon LD, 1999, BIOL PSYCHIAT, V46, P161, DOI 10.1016/S0006-3223(99)00113-4
   Shao W, 2013, NATURE, V494, P90, DOI 10.1038/nature11748
   SHINTANI F, 1993, J NEUROSCI, V13, P3574
   Skrzydelski D, 2007, J NEUROCHEM, V102, P1175, DOI 10.1111/j.1471-4159.2007.04639.x
   Soares-Cunha C, 2016, NEUROSCI BIOBEHAV R, V68, P370, DOI 10.1016/j.neubiorev.2016.05.021
   Solinas M, 2002, J NEUROSCI, V22, P6321
   Sulzer D, 2011, NEURON, V69, P628, DOI 10.1016/j.neuron.2011.02.010
   Tanaka K, 2012, J NEUROSCI, V32, P4319, DOI 10.1523/JNEUROSCI.5952-11.2012
   Tang SC, 2007, P NATL ACAD SCI USA, V104, P13798, DOI 10.1073/pnas.0702553104
   Trinchieri G, 2007, NAT REV IMMUNOL, V7, P179, DOI 10.1038/nri2038
   Vitkovic L, 2000, J NEUROCHEM, V74, P457, DOI 10.1046/j.1471-4159.2000.740457.x
   Volkow ND, 2009, NEUROPHARMACOLOGY, V56, P3, DOI 10.1016/j.neuropharm.2008.05.022
   Volkow ND, 2002, NEUROBIOL LEARN MEM, V78, P610, DOI 10.1006/nlme.2002.4099
   Volkow ND, 2015, CELL, V162, P712, DOI 10.1016/j.cell.2015.07.046
   Volkow ND, 2011, TRENDS COGN SCI, V15, P37, DOI 10.1016/j.tics.2010.11.001
   Wang B, 2019, NEUROCHEM RES, V44, P947, DOI 10.1007/s11064-019-02730-7
   Weiss F, 2010, FRONT NEUROSCI, P1
   World Drug Report, 2018, WORLD DRUG REP
   Wu RY, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.603445
   ZALCMAN S, 1994, BRAIN RES, V643, P40, DOI 10.1016/0006-8993(94)90006-X
   Zalcman S, 1999, BRAIN RES, V847, P276, DOI 10.1016/S0006-8993(99)02063-6
   Zhang J, 2001, J NEUROCHEM, V76, P855, DOI 10.1046/j.1471-4159.2001.00080.x
NR 127
TC 3
Z9 3
U1 5
U2 31
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0272-4340
EI 1573-6830
J9 CELL MOL NEUROBIOL
JI Cell. Mol. Neurobiol.
PD OCT
PY 2022
VL 42
IS 7
BP 2109
EP 2120
DI 10.1007/s10571-021-01105-3
EA MAY 2021
PG 12
WC Cell Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Neurosciences & Neurology
GA 4A4LT
UT WOS:000656421400001
PM 34057683
DA 2023-06-23
ER

PT J
AU Vadivelu, N
   Lumermann, L
   Zhu, R
   Kodumudi, G
   Elhassan, AO
   Kaye, AD
AF Vadivelu, Nalini
   Lumermann, Leandro
   Zhu, Richard
   Kodumudi, Gopal
   Elhassan, Amir O.
   Kaye, Alan David
TI Pain Control in the Presence of Drug Addiction
SO CURRENT PAIN AND HEADACHE REPORTS
LA English
DT Review
DE Prescription drug abuse; Illicit drug abuse; Analgesia; Abuse deterrent
   formulation; Opioid; Addiction; Tolerance
ID OPIOID THERAPY; MANAGEMENT; COCAINE; ABUSE; METHADONE; HEROIN; RISK
AB Drug addiction is present in a significant proportion of the population in the USA and worldwide. Drug addiction can occur with the abuse of many types of substances including cocaine, marijuana, stimulants, alcohol, opioids, and tranquilizers. There is a high likelihood that clinicians will encounter patients with substance abuse disorders on a regular basis with the prevalence of the use of illicit substances and the high rate of abuse of prescription drugs. The use of abuse deterrent formulations of prescription opioid agents, pill counts, and urine drug abuse screenings are all useful strategies. Optimum pain management of patients with addiction in the outpatient and inpatient setting is essential to minimize pain states. Careful selection of medications and appropriate oversight, including drug agreements, can reduce drug induced impairments, including sleep deficits and diminished physical, social, and sexual functioning. This review, therefore, discusses the prevalence of illicit and prescription drug addiction, the challenges of achieving optimum pain control, and the therapeutic approaches to be considered in this challenging population. More research is warranted to develop improved therapies and routes of treatments for optimum pain relief and to prevent the development of central sensitization, chronic pain, and impaired physical and social functioning in patients with drug addiction.
C1 [Vadivelu, Nalini] Yale Univ, Sch Med, Dept Anesthesiol, 333 Cedar St, New Haven, CT 06520 USA.
   [Lumermann, Leandro; Zhu, Richard] Yale Univ, Sch Med, 333 Cedar St, New Haven, CT 06520 USA.
   [Kodumudi, Gopal] Calif North State Univ, Coll Med, 9700 W Taron, Elk Grove, CA 95757 USA.
   [Elhassan, Amir O.; Kaye, Alan David] LSU Sch Med, Dept Anesthesiol, New Orleans, LA USA.
C3 Yale University; Yale University; Louisiana State University System;
   Louisiana State University
RP Vadivelu, N (通讯作者)，Yale Univ, Sch Med, Dept Anesthesiol, 333 Cedar St, New Haven, CT 06520 USA.
EM Nalini.vadivelu@yale.edu
CR Alford DP, 2006, ANN INTERN MED, V144, P127, DOI 10.7326/0003-4819-144-2-200601170-00010
   American Academy of Pain Medicine the American Pain Society and the American Society of Addition Medicine, 2001, WMJ, V100, P28
   [Anonymous], 1998, J ADDICT DIS, V17, P129
   [Anonymous], 2015, NSDUH SERIES H, VH-50
   Asbridge M, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e536
   Badila E, 2015, ROM J INTERN MED, V53, P218, DOI 10.1515/rjim-2015-0029
   Baron Michael J, 2006, J Opioid Manag, V2, P277
   Bingham CR, 2005, ALCOHOL CLIN EXP RES, V29, P2170, DOI 10.1097/01.alc.0000191763.56873.c4
   Brown R L, 1995, Wis Med J, V94, P135
   BUCHSBAUM DG, 1991, ANN INTERN MED, V115, P774, DOI 10.7326/0003-4819-115-10-774
   Center for Behavioral Health Statistics and Quality, 2015, HHS PUBLICATION
   Cicero TJ, 2015, NEW ENGL J MED, V373, P1789, DOI 10.1056/NEJMc1505541
   Conroy DA, 2016, J ADDICT DIS, P0
   DeMaria S, 2011, INT ANESTHESIOL CLIN, V49, P79, DOI 10.1097/AIA.0b013e3181ffc0cb
   Doverty M, 2001, PAIN, V93, P155, DOI 10.1016/S0304-3959(01)00306-2
   Dowling K, 2006, CLIN J PAIN, V22, P776, DOI 10.1097/01.ajp.0000210926.41406.2c
   Dunham CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047999
   ERICKSON T, 1994, AM J EMERG MED, V12, P126, DOI 10.1016/0735-6757(94)90227-5
   Fishman SM, 1999, J PAIN SYMPTOM MANAG, V18, P27, DOI 10.1016/S0885-3924(99)00035-4
   Fishman SM, 2002, CLIN J PAIN, V18, pS70, DOI 10.1097/00002508-200207001-00008
   Foltin RW, 2003, DRUG ALCOHOL DEPEN, V70, P149, DOI 10.1016/S0376-8716(02)00343-5
   Ghuran A, 2000, HEART, V83, P627, DOI 10.1136/heart.83.6.627
   Gordon S, 1996, PEDIATR EMERG CARE, V12, P36, DOI 10.1097/00006565-199602000-00010
   Gourlay DL, 2005, PAIN MED, V6, P107, DOI 10.1111/j.1526-4637.2005.05031.x
   Gourlay DL, 2008, J ADDICT DIS, V27, P23, DOI 10.1080/10550880802122570
   Heit HA, 2001, EUR J PAIN-LONDON, V5, P27, DOI 10.1053/eujp.2001.0276
   Irwin MR, 2016, ADDICTION
   Jamison Robert N, 2014, J Opioid Manag, V10, P375, DOI 10.5055/jom.2014.0234
   Karasz A, 2004, J PAIN SYMPTOM MANAG, V28, P517, DOI 10.1016/j.jpainsymman.2004.02.025
   Laroche F, 2012, JOINT BONE SPINE, V79, P446, DOI 10.1016/j.jbspin.2012.01.007
   Lee M, 2011, PAIN PHYSICIAN, V14, P145
   Manchikanti L, 2001, Pain Physician, V4, P358
   Manchikanti Laxmaiah, 2006, Pain Physician, V9, P215
   Manchikanti Laxmaiah, 2003, Pain Physician, V6, P173
   McNicol E, 2003, J PAIN, V4, P231, DOI 10.1016/S1526-5900(03)00556-X
   Mehta V, 2006, ANAESTHESIA, V61, P269, DOI 10.1111/j.1365-2044.2005.04503.x
   Miotto K, 2012, PSYCHIAT CLIN N AM, V35, P393, DOI 10.1016/j.psc.2012.03.006
   Moran S, 2015, SURG CLIN N AM, V95, P417, DOI 10.1016/j.suc.2014.11.001
   Pavarin R, 2011, EUR J EMERG MED, V18, P208, DOI 10.1097/MEJ.0b013e3283440f25
   Peppin JF, 2012, PAIN MED, V13, P886, DOI 10.1111/j.1526-4637.2012.01414.x
   Prater Christopher D., 2002, Prim Care Companion J Clin Psychiatry, V4, P125
   Rezaei F, 2016, FUNDAM CLIN PHARM
   Rosenblatt Aaron B, 2005, Pain Pract, V5, P2, DOI 10.1111/j.1533-2500.2005.05102.x
   SAMHSA Administration, 2014, SAMHSAS CONC TRAUM G
   Seyit M, 2015, IRAN RED CRESCENT ME, V17, DOI 10.5812/ircmj.17(5)2015.18780
   Sinatra R, 2010, PAIN MED, V11, P1859, DOI 10.1111/j.1526-4637.2010.00983.x
   Substance Abuse and Mental Health Services Administration, 2014, BHSIS SER S, V72
   Tang YL, 2014, J DUAL DIAGN, V10, P98, DOI 10.1080/15504263.2014.906133
   Vadivelu N, 2014, BEST PRACT RES-CLIN, V28, P91, DOI 10.1016/j.bpa.2014.02.003
   Weaver M, 2002, CLIN J PAIN, V18, pS61, DOI 10.1097/00002508-200207001-00007
   WEISSMAN DE, 1989, PAIN, V36, P363, DOI 10.1016/0304-3959(89)90097-3
   WHITBY LG, 1960, NATURE, V187, P604, DOI 10.1038/187604a0
   Won S, 2013, CLIN CARDIOL, V36, P737, DOI 10.1002/clc.22195
NR 53
TC 14
Z9 15
U1 2
U2 25
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1531-3433
EI 1534-3081
J9 CURR PAIN HEADACHE R
JI Curr. Pain Headache Rep.
PD MAY
PY 2016
VL 20
IS 5
DI 10.1007/s11916-016-0561-0
PG 8
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology
GA DK1JB
UT WOS:000374667200004
PM 27068665
DA 2023-06-23
ER

PT J
AU White, WL
AF White, William L.
TI Further reflections on the loss of addiction libraries and databases
SO ADDICTION
LA English
DT Letter
DE Addiction; Addiction libraries; alcohol-drugs; bibliographic databases;
   grey literature; information infrastructure; internet
C1 [White, William L.] Chestnut Hlth Syst, Bloomington, IL USA.
   [White, William L.] Chestnut Hlth Syst, Punta Gorda, FL 33955 USA.
RP White, WL (通讯作者)，Chestnut Hlth Syst, Bloomington, IL USA.
EM bwhite@chestnut.org
CR Mitchell AL, 2012, ADDICTION, V107, P1367, DOI 10.1111/j.1360-0443.2012.03813.x
   White William L., 1998, SLAYING DRAGON HIST
NR 2
TC 1
Z9 1
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0965-2140
J9 ADDICTION
JI Addiction
PD FEB
PY 2013
VL 108
IS 2
BP 435
EP 436
DI 10.1111/add.12030
PG 2
WC Substance Abuse; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry
GA 073MD
UT WOS:000313746200036
PM 23331892
DA 2023-06-23
ER

PT J
AU Carlezon, WA
   Chartoff, EH
AF Carlezon, William A., Jr.
   Chartoff, Elena H.
TI Extreme chipping: Addiction to a high-fat diet?
SO BIOLOGICAL PSYCHIATRY
LA English
DT Editorial Material
ID DRUG-ADDICTION; STRESS
C1 Harvard Univ, Behav Genet Lab, Sch Med, McLean Hosp, Belmont, MA 02478 USA.
C3 Harvard University; McLean Hospital
RP Carlezon, WA (通讯作者)，Harvard Univ, Behav Genet Lab, Sch Med, McLean Hosp, 115 Mill St, Belmont, MA 02478 USA.
OI /0000-0002-4162-3947
CR Chartoff EH, 2006, J NEUROSCI, V26, P6450, DOI 10.1523/JNEUROSCI.0491-06.2006
   Kelley AE, 2002, J NEUROSCI, V22, P3306
   Koob GF, 1999, ANN NY ACAD SCI, V897, P27, DOI 10.1111/j.1749-6632.1999.tb07876.x
   LEVINS PC, 1983, LANCET, V2, P166
   McLaughlin JP, 2003, J NEUROSCI, V23, P5674, DOI 10.1523/jneurosci.23-13-05674.2003
   Nestler EJ, 2004, NEUROPHARMACOLOGY, V47, P24, DOI 10.1016/j.neuropharm.2004.06.031
   Nestler EJ, 2006, BIOL PSYCHIAT, V59, P1151, DOI 10.1016/j.biopsych.2005.09.018
   Pfaus JG, 1999, CURR OPIN NEUROBIOL, V9, P751, DOI 10.1016/S0959-4388(99)00034-3
   Teegarden SL, 2007, BIOL PSYCHIAT, V61, P1021, DOI 10.1016/j.biopsych.2006.09.032
   WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469
   Zachariou V, 2006, NAT NEUROSCI, V9, P205, DOI 10.1038/nn1636
NR 11
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2007
VL 61
IS 9
BP 1019
EP 1020
DI 10.1016/j.biopsych.2007.03.004
PG 2
WC Neurosciences; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Psychiatry
GA 160VK
UT WOS:000245970200002
PM 17434011
DA 2023-06-23
ER

PT J
AU Grech, G
AF Grech, G.
TI An existential model of addiction
SO EUROPEAN PSYCHIATRY
LA English
DT Meeting Abstract
DE authenticity; being-with-drug; Addiction; existentialism
C1 [Grech, G.] Mt Carmel Hosp, Psychiat, Attard, Malta.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0924-9338
EI 1778-3585
J9 EUR PSYCHIAT
JI Eur. Psychiat.
PD APR
PY 2021
VL 64
SU 1
SI SI
MA EPP1100
BP S495
EP S495
DI 10.1192/j.eurpsy.2021.1323
PG 1
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA UM9UD
UT WOS:000693668500413
OA Green Accepted, gold
DA 2023-06-23
ER

PT J
AU Zimic, JI
   Jukic, V
AF Zimic, Jadranka Ivandic
   Jukic, Vlado
TI Familial Risk Factors Favoring Drug Addiction Onset
SO JOURNAL OF PSYCHOACTIVE DRUGS
LA English
DT Article
DE drug addiction; family; risk factors
ID CHILDREN; DISORDER
AB This study, primarily aimed at identification of familial risk factors favoring drug addiction onset, was carried out throughout 2008 and 2009. The study comprised a total of 146 addicts and 134 control subjects. Based on the study outcome, it can be concluded that in the families the addicts were born into, familial risk factors capable of influencing their psychosocial development and favoring drug addiction onset had been statistically more frequently encountered during childhood and adolescence as compared to the controls. The results also indicated the need for further research into familial interrelations and the structure of the families addicts were born into, as well as the need for the implementation of family-based approaches to both drug addiction prevention and therapy.
C1 [Zimic, Jadranka Ivandic] Govt Republ Croatia, Off Combating Drug Abuse, Zagreb 10000, Croatia.
   [Jukic, Vlado] Psychiat Hosp Vrapce, Zagreb, Croatia.
RP Zimic, JI (通讯作者)，Govt Republ Croatia, Off Combating Drug Abuse, Preobrazenska 4-11, Zagreb 10000, Croatia.
EM jadranka.ivandic@uredzadroge.hr
CR Berger Sather M, 2007, PARENTING CONT EUROP
   Bouillet D, 2004, P C STRUGGL ADD STRU
   Bry B.H., 1998, NIDA RES MONOGRAPH, V177
   Cernkovich S.A., 1987, CRIMINOLOGY, V25, P401
   Chilcoat HD, 1998, ARCH GEN PSYCHIAT, V55, P913, DOI 10.1001/archpsyc.55.10.913
   Coleman S.B, 1978, J MARITAL FAMILY THE, V21, P79
   Cudina-Obradovic M., 2002, REV SOCIAL POLITICS, V10, P45
   Etz K.E., 1998, NIDA RES MONOGRAPH
   Farrington K., 1993, SOURCEBOOK FAMILY TH
   Feric Slean M, 2004, CROATIAN REV REHABIL, V45, P88
   Georgas J, 2006, FAMILIES FAMILY CHAN
   Glavak R., 2003, CROAT MED J, V44, P206
   HADDAD JD, 1991, J CLIN CHILD PSYCHOL, V20, P152, DOI 10.1207/s15374424jccp2002_6
   Haine RA, 2008, PROF PSYCHOL-RES PR, V39, P113, DOI 10.1037/0735-7028.39.2.113
   HARBIN HT, 1975, FAM PROCESS, V14, P411, DOI 10.1111/j.1545-5300.1975.00411.x
   Hill H, 1980, NIDA RES MONOGRAPH, V30
   Jankovic J, 1994, REV SOCIAL POLITICS, V3, P277
   Janson S, 2007, PARENTING CONT EUROP
   Kerr M., 2003, HDB PSYCHOL, V6
   Klarin M, 2002, SOC RES, V4, P805
   Klein E, 1992, WAR PSYCHOL PSYCHIAT
   Kusevic V, 1987, DRUG ABUSE
   Lamb M. E., 2004, ROLE FAT HER CHILD D
   Milkman H.B, 2005, CRIMINAL CONDUCT SUB
   National Institute of Drug Abuse (NIDA), 2003, NIH PUBL
   National Institute of Drug Abuse (NIDA), 1999, 6 NIDA
   Nikolic S, 1991, PSYCHIAT CHILDHOOD A
   Nikolic S, 1993, PROTECTION MENTAL HL
   Nikolic S., 1990, MED PSYCHOL BASICS
   Oslen A.O, 2004, SCANDINAVIAN PSYCHOA, V27, P34
   Perasovic B, 2000, NAPREDAK, V141, P411
   Plunkett S, 2011, SYMBOLIC INTERACTION
   Rudan V, 1995, THESIS SCH MED ZAGRE
   STANTON MD, 1978, AM J DRUG ALCOHOL AB, V5, P125, DOI 10.3109/00952997809027993
   Stattin H, 2000, CHILD DEV, V71, P1072, DOI 10.1111/1467-8624.00210
   Tamis-LeMonda CS, 2004, CHILD DEV, V75, P1806, DOI 10.1111/j.1467-8624.2004.00818.x
   Tokic A, 2008, DRUS ISTRAZ, V17, P1133
   UNODC (United Nations Office on Drugs and Crime), 2009, WORLD DRUGS REP, VE.09.XI.12
   Vitaro F, 1999, CAN J PSYCHIAT, V44, P901, DOI 10.1177/070674379904400906
   Vuksic-Mihaljevic Z, 2004, SOC RES, V6, P1099
   Werner MJ, 1999, PEDIATRICS, V103, P1099
   Williams Jill Schlabig, 2003, NIDA NOTES
NR 42
TC 21
Z9 23
U1 4
U2 27
PU HAIGHT-ASHBURY PUBL
PI SAN FRANCISCO
PA 409 CLAYTON ST, SAN FRANCISCO, CA 94117 USA
SN 0279-1072
J9 J PSYCHOACTIVE DRUGS
JI J. Psychoact. Drugs
PD APR-JUN
PY 2012
VL 44
IS 2
BP 173
EP 185
DI 10.1080/02791072.2012.685408
PG 13
WC Psychology, Clinical; Substance Abuse
WE Social Science Citation Index (SSCI)
SC Psychology; Substance Abuse
GA 970SH
UT WOS:000306152100011
PM 22880546
DA 2023-06-23
ER

PT J
AU Ferguson, S
   O'Neal, T
   Richardson, J
AF Ferguson, Susan
   O'Neal, Tim
   Richardson, Jordyn
TI Chemogenetic Modulation of Direct and Indirect Pathway Striatal Medium
   Spiny Neurons Alters Drug-Seeking in a Rat Model of Heroin Addiction
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Meeting Abstract
DE Heroin Self-Administration; Drug Addiction; Nucleus Accumbens
C1 [Ferguson, Susan; O'Neal, Tim; Richardson, Jordyn] Univ Washington, Seattle Childrens Res Inst, Seattle, WA 98195 USA.
C3 Seattle Children's Hospital; University of Washington; University of
   Washington Seattle
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
EI 1740-634X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD DEC
PY 2018
VL 43
SU S
MA T282
BP S379
EP S380
PG 2
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA VI6YX
UT WOS:000509546600698
DA 2023-06-23
ER

PT J
AU Steele, VR
AF Steele, Vaughn R.
TI Transcranial Magnetic Stimulation as an Interventional Tool for
   Addiction
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Editorial Material
DE addiction; rTMS; iTBS; cTBS; known unknowns
ID DRUG-ADDICTION; DOPAMINE RELEASE; IDENTIFICATION; SUBSTRATE; MEMORY;
   BRAIN
C1 [Steele, Vaughn R.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
C3 Yale University
RP Steele, VR (通讯作者)，Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
EM vaughn.steele@yale.edu
FU National Institute on Drug Abuse (NIDA) [K12 DA000167]
FX VRS was partially funded by the National Institute on Drug Abuse (NIDA)
   Grant No. K12 DA000167 (Multiple PI: Potenza & O'Malley).
CR Cermak S, 2020, J NEUROSCI METH, V339, DOI 10.1016/j.jneumeth.2020.108709
   Chen BT, 2013, NATURE, V496, P359, DOI 10.1038/nature12024
   Diana M, 2017, NAT REV NEUROSCI, V18, P685, DOI 10.1038/nrn.2017.113
   Ekhtiari H, 2019, NEUROSCI BIOBEHAV R, V104, P118, DOI 10.1016/j.neubiorev.2019.06.007
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Fox MD, 2012, BIOL PSYCHIAT, V72, P595, DOI 10.1016/j.biopsych.2012.04.028
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Goodkind M, 2015, JAMA PSYCHIAT, V72, P305, DOI 10.1001/jamapsychiatry.2014.2206
   Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033
   Jay TM, 2003, PROG NEUROBIOL, V69, P375, DOI 10.1016/S0301-0082(03)00085-6
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564
   Kelley AE, 2004, NEURON, V44, P161, DOI 10.1016/j.neuron.2004.09.016
   Liu XL, 2020, EBIOMEDICINE, V56, DOI 10.1016/j.ebiom.2020.102809
   Ma TY, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01095
   McTeague LM, 2017, AM J PSYCHIAT, V174, P676, DOI 10.1176/appi.ajp.2017.16040400
   Meng QL, 2018, BRAIN STIMUL, V11, P663, DOI 10.1016/j.brs.2018.02.018
   Moretti J, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00137
   Nardone R, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01237
   Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578
   Pascual-Leone A, 1998, J CLIN NEUROPHYSIOL, V15, P333, DOI 10.1097/00004691-199807000-00005
   Sanna A, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00765
   Schluter RS, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01257
   Spagnolo PA, 2020, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01385
   Steele VR, 2020, EBIOMEDICINE, V57, DOI 10.1016/j.ebiom.2020.102839
   Steele VR, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01147
   Strafella AP, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-15-j0003.2001
   Strafella AP, 2003, BRAIN, V126, P2609, DOI 10.1093/brain/awg268
   Stramba-Badiale C, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00720
   Volkow ND, 2016, NEW ENGL J MED, V374, P363, DOI 10.1056/NEJMra1511480
   Zhao D, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00208
   Zhou LJ, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00876
   Zilverstand A, 2018, NEURON, V98, P886, DOI 10.1016/j.neuron.2018.03.048
   Zucchella C, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00729
NR 33
TC 4
Z9 4
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD OCT 22
PY 2020
VL 14
AR 592343
DI 10.3389/fnins.2020.592343
PG 4
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA OL2OY
UT WOS:000585182500001
PM 33192278
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Zhang, C
   Ding, H
   Cheng, YJ
   Chen, WL
   Li, Q
   Li, Q
   Dai, R
   Luo, ML
AF Zhang, Chan
   Ding, Heng
   Cheng, Yujing
   Chen, Wanlu
   Li, Qi
   Li, Qing
   Dai, Run
   Luo, Manlin
TI Genetic polymorphisms in ALDH2 are associated with drug addiction in a
   Chinese Han population
SO ONCOTARGET
LA English
DT Article
DE drug addiction; ALDH2; single nucleotide polymorphisms (SNPs);
   case-control study; association study
ID ALCOHOL-CONSUMPTION; ALDEHYDE DEHYDROGENASE-2; GLU504LYS POLYMORPHISM;
   CANCER; SENSITIVITY; DEPENDENCE; RS886205; RISK
AB We investigated the association between single nucleotide polymorphisms (SNPs) in ALDH2, which has been associated with alcohol dependence and several types of diseases, and the risk of drug addiction in a Chinese Han population. In a case-control study that included 692 cases and 700 healthy controls, eight SNPs in ALDH2 were selected and genotyped using the Sequenom MassARRAY platform. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using unconditional logistic regression after adjusting for age and gender. We determined that rs671 is significantly associated with a 1.551-fold increased drug addiction risk (95% CI = 1.263-1.903; p < 0.001). In the genetic model analysis, we found that rs671 is associated with an increased risk of drug addiction under additive, dominant and recessive models (p < 0.001), while rs886205, rs441 and rs4646778 displayed a decreased drug addiction risk under additive and recessive model, respectively (p < 0.05). SNP rs671 remained significant after Bonferroni correction (p < 0.00125). Additionally, we observed that haplotype "GTCAC" was associated with increased drug addiction risk (OR = 1.668; 95% CI, 1.328-2.094, p < 0.001); in contrast, "ATCGC" was a protective haplotype for drug addiction risk (OR = 0.444; 95% CI, 0.281-0.704, p < 0.001). Our findings showed that ALDH2 polymorphisms are significantly associated with the risk of drug addiction in the Chinese Han population.
C1 [Zhang, Chan; Cheng, Yujing; Chen, Wanlu; Li, Qi; Li, Qing; Dai, Run] Kunming Univ Sci & Technol, Affiliated Hosp, Peoples Hosp Yunnan Prov 1, Dept Blood Transfus, Kunming 650032, Yunnan, Peoples R China.
   [Ding, Heng] Honghe Ctr Blood Stn, Mengzi 661100, Yunnan, Peoples R China.
   [Luo, Manlin] Second Peoples Hosp Yunnan Prov, Dept Blood Transfus, Kunming 650032, Yunnan, Peoples R China.
C3 Kunming University of Science & Technology
RP Luo, ML (通讯作者)，Second Peoples Hosp Yunnan Prov, Dept Blood Transfus, Kunming 650032, Yunnan, Peoples R China.
EM drmanlinluo@163.com
RI Luo, Man/GWQ-4789-2022; luo, man/HGC-7868-2022
FU Foundation of Educational Commission of Yunnan Province [2014Z038]
FX This work is supported by the Foundation of Educational Commission of
   Yunnan Province (2014Z038).
CR ADAMEC C, 1964, Cesk Zdrav, V12, P613
   Bland JM, 2000, BRIT MED J, V320, P1468, DOI 10.1136/bmj.320.7247.1468
   Bye H, 2011, CARCINOGENESIS, V32, P1855, DOI 10.1093/carcin/bgr211
   Chang YC, 2012, BMC CARDIOVASC DISOR, V12, DOI 10.1186/1471-2261-12-58
   CRABB DW, 1989, J CLIN INVEST, V83, P314, DOI 10.1172/JCI113875
   Dickson PA, 2006, ALCOHOL CLIN EXP RES, V30, P1093, DOI 10.1111/j.1530-0277.2006.00128.x
   Gabriel S, 2009, CURRENT PROTOCOLS HU
   Guo YJ, 2010, ATHEROSCLEROSIS, V211, P545, DOI 10.1016/j.atherosclerosis.2010.03.030
   Hira A, 2013, BLOOD, V122, P3206, DOI 10.1182/blood-2013-06-507962
   Johnson JL, 1999, PEDIATRICS, V103, P1085
   KENDLER KS, 2003, THE AMERICAN JOURNAL, V160, P687
   Matsuo K, 2001, CARCINOGENESIS, V22, P913, DOI 10.1093/carcin/22.6.913
   Matsuo K, 2006, CANCER EPIDEM BIOMAR, V15, P1009, DOI 10.1158/1055-9965.EPI-05-0911
   Nassab MH, 2016, EUR ADDICT RES, V22, P59, DOI 10.1159/000381018
   Nassab MH, 2015, PSYCHIAT GENET, V25, P41, DOI 10.1097/YPG.0000000000000073
   Oze I, 2010, CANCER SCI, V101, P1875, DOI 10.1111/j.1349-7006.2010.01599.x
   Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236
   Reynolds E. K, 2010, YOUNG ADULT MENTAL H, P40
   Shi YY, 2005, CELL RES, V15, P97, DOI 10.1038/sj.cr.7290272
   Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975
   Tian JN, GENETIC POLYMORPHISM
   Yang H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109634
   Yang H, 2009, CANCER EPIDEM BIOMAR, V18, P2522, DOI 10.1158/1055-9965.EPI-09-0398
   Yokoyama A, 1998, CARCINOGENESIS, V19, P1383, DOI 10.1093/carcin/19.8.1383
   YOSHIDA A, 1984, P NATL ACAD SCI-BIOL, V81, P258, DOI 10.1073/pnas.81.1.258
NR 25
TC 2
Z9 2
U1 0
U2 1
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 31
PY 2017
VL 8
IS 5
BP 8597
EP 8603
DI 10.18632/oncotarget.14354
PG 7
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EJ5YP
UT WOS:000393295500118
PM 28052001
OA Green Published, gold, Green Submitted
DA 2023-06-23
ER

PT J
AU Hamilton, HA
   Mann, RE
   Noh, S
AF Hamilton, Hayley A.
   Mann, Robert E.
   Noh, Samuel
TI Adolescent immigrant generation and stigmatizing attitudes toward drug
   addiction
SO ADDICTION RESEARCH & THEORY
LA English
DT Article
DE Drug addiction; drug use; stigma; adolescents; immigrants
ID MENTAL-ILLNESS; PUBLIC-HEALTH; SUBSTANCE USE; SCHIZOPHRENIA; EXPERIENCE;
   BEHAVIOR; CHILDREN; ALCOHOL; PEOPLE; USERS
AB This study examined differences in stigmatizing attitudes toward individuals addicted to drugs among three immigrant generations of youth, and the role of adolescent drug use and friends'' drug use on the association. Data were derived from the 2005 cycle of the Ontario Student Drug Use Survey administered to students in grades 7--12 in the province of Ontario, Canada. A sample of 4078 students completed questionnaires that included a measure of stigma toward drug addiction. Results indicated some immigrant generational differences in negative attitudes toward individuals addicted to drugs, but much of this difference was explained by adolescents'' individual drug use and friendships with individuals who use drugs. The difference between second-generation immigrant youth and their third- and later-generation counterparts was not fully explained. This study highlights the need for greater research on adolescent stigma toward drug addiction given that stigma may reduce drug usage but also may reduce help-seeking among individuals with an addiction.</.
C1 [Hamilton, Hayley A.; Noh, Samuel] Ctr Addict & Mental Hlth, Dept Social & Epidemiol Res, Toronto, ON M5S 2G8, Canada.
   [Mann, Robert E.] Ctr Addict & Mental Hlth, Dept Social & Epidemiol Res, Toronto, ON M5S 2S1, Canada.
C3 University of Toronto; Centre for Addiction & Mental Health - Canada;
   University of Toronto; Centre for Addiction & Mental Health - Canada
RP Hamilton, HA (通讯作者)，Ctr Addict & Mental Hlth, Dept Social & Epidemiol Res, 455 Spadina Ave, Toronto, ON M5S 2G8, Canada.
EM hayley_hamilton@camh.net
CR Adlaf EM, 2009, ADDICT BEHAV, V34, P360, DOI 10.1016/j.addbeh.2008.11.012
   ADLAF EM, 2005, 16 CAMH
   ADLAF EM, 2007, SERIES CAMH, V21
   Ahern J, 2007, DRUG ALCOHOL DEPEN, V88, P188, DOI 10.1016/j.drugalcdep.2006.10.014
   Aiken L. S., 1991, MULTIPLE REGRESSION
   Bayer R, 2006, AM J PUBLIC HEALTH, V96, P47, DOI 10.2105/AJPH.2005.071886
   Bayer R, 2008, SOC SCI MED, V67, P463, DOI 10.1016/j.socscimed.2008.03.017
   Blake SM, 2001, AM J PUBLIC HEALTH, V91, P794, DOI 10.2105/AJPH.91.5.794
   Burlew K., 2000, J BLACK PSYCHOL, V26, P402, DOI [10.1177/0095798400026004004, DOI 10.1177/0095798400026004004]
   Canadian Council on Social Development, 2007, IMM YOUTH CAN
   Chui T., 2007, IMMIGRATION CANADA P
   Corrigan PW, 2007, COMMUNITY MENT HLT J, V43, P439, DOI 10.1007/s10597-007-9084-9
   Corrigan PW, 2005, PSYCHIAT SERV, V56, P544, DOI 10.1176/appi.ps.56.5.544
   Farmer PE, 1992, AIDS AND ACCUSATION
   Gordon Milton, 1964, ASSIMILATION AM LIFE
   Hamilton HA, 2009, CAN J PUBLIC HEALTH, V100, P221, DOI 10.1007/BF03405545
   Hinshaw SP, 2005, J CHILD PSYCHOL PSYC, V46, P714, DOI 10.1111/j.1469-7610.2005.01456.x
   Hollingshead A. B., 1958, SOCIAL CLASS MENTAL
   Hussey Jon M, 2007, J Immigr Minor Health, V9, P85
   JOHNSTON LD, 2005, NIH PUB
   Link BG, 1999, AM J PUBLIC HEALTH, V89, P1328, DOI 10.2105/AJPH.89.9.1328
   Link BG, 1997, J HEALTH SOC BEHAV, V38, P177, DOI 10.2307/2955424
   Pena JB, 2008, PREV SCI, V9, P299, DOI 10.1007/s11121-008-0105-x
   Phelan JC, 1998, SCHIZOPHRENIA BULL, V24, P115, DOI 10.1093/oxfordjournals.schbul.a033304
   Phillips MR, 2002, BRIT J PSYCHIAT, V181, P488, DOI 10.1192/bjp.181.6.488
   Plancherel B, 2005, J DRUG EDUC, V35, P131, DOI 10.2190/DMDW-X35X-P6AV-6F4L
   Portes A., 1995, CALIFORNIAS IMMIGRAN, P71
   Power R, 1996, DRUG-EDUC PREV POLIC, V3, P71, DOI 10.3109/09687639609019312
   Schulze B, 2003, ACTA PSYCHIAT SCAND, V107, P142, DOI 10.1034/j.1600-0447.2003.02444.x
   Shell Marc, 2005, POLIO ITS AFTERMATH
   StataCorp, 2003, STAT STAT SOFTW REL
   United States Public Health Service, 1999, MENT HLTH REP SURG G
   VEGA WA, 1993, AM J PUBLIC HEALTH, V83, P257, DOI 10.2105/AJPH.83.2.257
   Wahl OF, 1999, SCHIZOPHRENIA BULL, V25, P467, DOI 10.1093/oxfordjournals.schbul.a033394
   *WORLD PSYCH ASS, 1999, WORLD PSYCH ASS PROG, V3
   Yang LH, 2007, SOC SCI MED, V64, P1524, DOI 10.1016/j.socscimed.2006.11.013
   Yang LH, 2002, J FAM THER, V24, P233
   ZASTOWNY TR, 1993, J PSYCHOACTIVE DRUGS, V25, P223, DOI 10.1080/02791072.1993.10472273
NR 38
TC 2
Z9 2
U1 9
U2 27
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1606-6359
J9 ADDICT RES THEORY
JI Addict. Res. Theory
PY 2011
VL 19
IS 4
BP 344
EP 351
DI 10.3109/16066359.2010.530713
PG 8
WC Substance Abuse; Social Issues
WE Social Science Citation Index (SSCI)
SC Substance Abuse; Social Issues
GA 779VI
UT WOS:000291809900006
DA 2023-06-23
ER

PT J
AU Betz, C
   Mihalic, D
   Pinto, ME
   Raffa, RB
AF Betz, C
   Mihalic, D
   Pinto, ME
   Raffa, RB
TI Could a common biochemical mechanism underlie addictions?
SO JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
LA English
DT Review
ID TRANSPORTER KNOCKOUT MICE; BRAIN REWARD PATHWAYS; DOPAMINE-TRANSPORTER;
   NUCLEUS-ACCUMBENS; CANNABINOID RECEPTOR; MESOLIMBIC DOPAMINE; UPTAKE
   INHIBITORS; DRUG-ABUSE; INTRAVENOUS COCAINE; ALCOHOL DEPENDENCE
AB The subject of 'drug addiction' is multifaceted and many aspects of it (even some of the definitions) are controversial. Collateral medical problems include the spread of HIV and hepatitis C virus secondary to i.v. drug abuse and effects on prenatal brain development (1). Progress in the understanding of the causes of addictions and its treatment has been impeded by the lack of a unifying biochemical theory. However, recent evidence suggests that some common mechanism might underlie addictions to otherwise apparently unrelated drugs. A major hypothesis has emerged suggesting that the neurotransmitter dopamine (DA) might play a central role in the molecular mechanisms of at least some addictions. If so, it would represent an important target for discovery of effective pharmacotherapy and revolutionize the pharmacist's role in treating addictions. This short overview outlines the status of the theory of a common biochemical mechanism of drug addiction.
C1 Temple Univ, Sch Pharm, Philadelphia, PA 19104 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple
   University
RP Raffa, RB (通讯作者)，Temple Univ, Sch Pharm, 3307 N Broad St, Philadelphia, PA 19104 USA.
EM rraffa@nimbus.temple.edu
RI Betz, Christopher/AAH-7019-2021
CR Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Akil H, 1998, DRUG ALCOHOL DEPEN, V51, P127, DOI 10.1016/S0376-8716(98)00071-4
   Altman J, 1996, MOL MED TODAY, V2, P237, DOI 10.1016/1357-4310(96)88804-6
   Amara SG, 1998, DRUG ALCOHOL DEPEN, V51, P87, DOI 10.1016/S0376-8716(98)00068-4
   Balster RL, 1998, DRUG ALCOHOL DEPEN, V51, P207, DOI 10.1016/S0376-8716(98)00078-7
   Balter M, 1996, SCIENCE, V271, P909, DOI 10.1126/science.271.5251.909
   BENWELL MEM, 1994, CLIN INVESTIGATOR, V72, P233
   CARLEZON WA, 1995, PSYCHOPHARMACOLOGY, V122, P194, DOI 10.1007/BF02246095
   CARON MG, 1997, NEURON, V19, P1285
   CORRIGALL WA, 1992, PSYCHOPHARMACOLOGY, V107, P285, DOI 10.1007/BF02245149
   Crabbe JC, 1998, DRUG ALCOHOL DEPEN, V51, P61, DOI 10.1016/S0376-8716(98)00066-0
   Daly JW, 1998, DRUG ALCOHOL DEPEN, V51, P199, DOI 10.1016/S0376-8716(98)00077-5
   DEVANE WA, 1988, MOL PHARMACOL, V34, P605
   DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919
   DEVINE DP, 1993, J PHARMACOL EXP THER, V266, P1236
   DEWIT H, 1977, CAN J PSYCHOL, V31, P195, DOI 10.1037/h0081662
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Drago J, 1998, DEV NEUROSCI-BASEL, V20, P188, DOI 10.1159/000017313
   Dworkin S I, 1986, NIDA Res Monogr, V67, P242
   Edwards G, 1976, DRUGS DRUG DEPENDENC, P182
   Garris PA, 1999, NATURE, V398, P67, DOI 10.1038/18019
   Gatley SJ, 1998, DRUG ALCOHOL DEPEN, V51, P97, DOI 10.1016/S0376-8716(98)00069-6
   GAWIN FH, 1991, SCIENCE, V251, P1580, DOI 10.1126/science.2011738
   Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0
   Gordis E, 1998, DRUG ALCOHOL DEPEN, V51, P9, DOI 10.1016/S0376-8716(98)00062-3
   Harris RA, 1998, DRUG ALCOHOL DEPEN, V51, P155, DOI 10.1016/S0376-8716(98)00073-8
   Hartmann PM, 1997, AM FAM PHYSICIAN, V55, P1877
   HEIKKILA RE, 1975, J PHARMACOL EXP THER, V194, P47
   Herz A, 1998, CAN J PHYSIOL PHARM, V76, P252, DOI 10.1139/cjpp-76-3-252
   HOEBEL BG, 1983, PSYCHOPHARMACOLOGY, V81, P158, DOI 10.1007/BF00429012
   HUBNER CB, 1991, PSYCHOPHARMACOLOGY, V105, P151, DOI 10.1007/BF02244301
   IMPERATO A, 1986, EUR J PHARMACOL, V132, P337, DOI 10.1016/0014-2999(86)90629-1
   JONES RT, 1979, ENDOGENOUS EXOGENOUS, P557
   Jones SR, 1998, J NEUROSCI, V18, P1979
   JORENBY DE, 1997, HOSP PRACTICE    APR, P17
   KARCH SB, 1996, PATHOLOGY DRUG ABUSE, P1
   KLEVEN MS, 1993, DRUG ALCOHOL DEPEN, V31, P149, DOI 10.1016/0376-8716(93)90067-Z
   KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   KOOB GF, 1997, HOSP PRACT SPECIAL R, P12
   KOSTEN TR, 1998, BASIC CLIN PHARM, P516
   Kreek MJ, 1998, DRUG ALCOHOL DEPEN, V51, P23, DOI 10.1016/S0376-8716(98)00064-7
   LACOSTA S, 1993, PHARMACOL BIOCHEM BE, V44, P161, DOI 10.1016/0091-3057(93)90295-5
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   LESHNER AI, 1997, HOSP PRACT OFF ED SP, P2
   Levitt P, 1998, DRUG ALCOHOL DEPEN, V51, P109, DOI 10.1016/S0376-8716(98)00070-2
   Litten RZ, 1999, J SUBST ABUSE TREAT, V16, P105, DOI 10.1016/S0740-5472(98)00028-2
   LYNESS WH, 1979, PHARMACOL BIOCHEM BE, V11, P553, DOI 10.1016/0091-3057(79)90040-6
   MARKS MJ, 1986, MOL PHARMACOL, V30, P427
   MASTERS SB, 1998, BASIC CLIN PHARM, P372
   MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0
   MELZACK R, 1990, SCI AM, V262, P27, DOI 10.1038/scientificamerican0290-27
   Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738
   Mirenowicz J, 1996, NATURE, V379, P449, DOI 10.1038/379449a0
   Nash J. M., 1997, TIME            0505, P69
   Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58
   Noble E, 1996, SCI AM SCI MED, V3, P52
   Nutt DJ, 1996, LANCET, V347, P31, DOI 10.1016/S0140-6736(96)91561-5
   OBrien CP, 1997, SCIENCE, V278, P66, DOI 10.1126/science.278.5335.66
   OLDS J, 1954, J COMP PHYSIOL PSYCH, V47, P419, DOI 10.1037/h0058775
   OMalley SS, 1996, ALCOHOL ALCOHOLISM, V31, P77
   Perrine D. M., 1996, CHEM MIND ALTERING D
   Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3
   Picciotto MR, 1998, DRUG ALCOHOL DEPEN, V51, P165, DOI 10.1016/S0376-8716(98)00074-X
   Pich EM, 1998, ANN MED, V30, P390, DOI 10.3109/07853899809029939
   Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0
   Robbins TW, 1999, NATURE, V398, P567, DOI 10.1038/19208
   ROBERTS DCS, 1977, PHARMACOL BIOCHEM BE, V6, P615, DOI 10.1016/0091-3057(77)90084-3
   ROBERTS DCS, 1980, PHARMACOL BIOCHEM BE, V12, P781, DOI 10.1016/0091-3057(80)90166-5
   Rocha BA, 1998, NAT NEUROSCI, V1, P132, DOI 10.1038/381
   Self DW, 1998, DRUG ALCOHOL DEPEN, V51, P49, DOI 10.1016/S0376-8716(98)00065-9
   SELF DW, 1997, HOSP PRACT SPECIAL R, P5
   SIMANTOV R, 1993, NEUROSCI LETT, V163, P121, DOI 10.1016/0304-3940(93)90360-W
   SNYDER SH, 1981, P NATL ACAD SCI-BIOL, V78, P3260, DOI 10.1073/pnas.78.5.3260
   Sora I, 1998, P NATL ACAD SCI USA, V95, P7699, DOI 10.1073/pnas.95.13.7699
   SORA I, 1998, NIDA RES MONOGR, V179, P138
   Spanagel R, 1997, TRENDS PHARMACOL SCI, V18, P54, DOI 10.1016/S0165-6147(97)89800-8
   SPEALMAN RD, 1993, PSYCHOPHARMACOLOGY, V112, P93, DOI 10.1007/BF02247368
   Takahashi N, 1997, P NATL ACAD SCI USA, V94, P9938, DOI 10.1073/pnas.94.18.9938
   Tanda G, 1997, SCIENCE, V276, P2048, DOI 10.1126/science.276.5321.2048
   TON JMNC, 1988, BRAIN RES, V451, P59, DOI 10.1016/0006-8993(88)90749-4
   Uhl GR, 1996, CURR BIOL, V6, P935, DOI 10.1016/S0960-9822(02)00630-9
   VOLKOW ND, 1997, HOSP PRACTICE    APR, P22
   VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876
   WALSH SL, 1994, J CLIN PSYCHOPHARM, V14, P396
   Warner EA, 1997, MED CLIN N AM, V81, P909, DOI 10.1016/S0025-7125(05)70555-1
   Weinrieb RM, 1997, ANNU REV MED, V48, P477
   WISE RA, 1988, J ABNORM PSYCHOL, V97, P118, DOI 10.1037/0021-843X.97.2.118
   WISE RA, 1980, PHARMACOL BIOCHEM BE, V13, P213, DOI 10.1016/S0091-3057(80)80033-5
   Wise RA, 1996, ANNU REV NEUROSCI, V19, P319, DOI 10.1146/annurev.ne.19.030196.001535
   Wise RA, 1998, DRUG ALCOHOL DEPEN, V51, P13, DOI 10.1016/S0376-8716(98)00063-5
   YOKEL RA, 1975, SCIENCE, V187, P547, DOI 10.1126/science.1114313
   [No title captured]
NR 93
TC 22
Z9 22
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-4727
EI 1365-2710
J9 J CLIN PHARM THER
JI J. Clin. Pharm. Ther.
PD FEB
PY 2000
VL 25
IS 1
BP 11
EP 20
DI 10.1046/j.1365-2710.2000.00260.x
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 301CC
UT WOS:000086289700002
PM 10771460
OA gold
DA 2023-06-23
ER

PT J
AU Volkow, ND
   Wang, GJ
   Fowler, JS
   Tomasi, D
   Telang, F
   Baler, R
AF Volkow, Nora D.
   Wang, Gene-Jack
   Fowler, Joanna S.
   Tomasi, Dardo
   Telang, Frank
   Baler, Ruben
TI Addiction: Decreased reward sensitivity and increased expectation
   sensitivity conspire to overwhelm the brain's control circuit
SO BIOESSAYS
LA English
DT Review
DE addiction; brain disease; dopamine; reward circuit
ID STRIATAL DOPAMINE RELEASE; DRUG-ADDICTION; COCAINE; METHYLPHENIDATE;
   RECEPTORS; PHARMACOKINETICS; METHAMPHETAMINE; ASSOCIATION; IMPULSIVITY;
   DISRUPTION
AB Based on brain imaging findings, we present a model according to which addiction emerges as an imbalance in the information processing and integration among various brain circuits and functions. The dysfunctions reflect (a) decreased sensitivity of reward circuits, (b) enhanced sensitivity of memory circuits to conditioned expectations to drugs and drug cues, stress reactivity, and (c) negative mood, and a weakened control circuit. Although initial experimentation with a drug of abuse is largely a voluntary behavior, continued drug use can eventually impair neuronal circuits in the brain that are involved in free will, turning drug use into an automatic compulsive behavior. The ability of addictive drugs to co-opt neurotransmitter signals between neurons (including dopamine, glutamate, and GABA) modifies the function of different neuronal circuits, which begin to falter at different stages of an addiction trajectory. Upon exposure to the drug, drug cues or stress this results in unrestrained hyperactivation of the motivation/drive circuit that results in the compulsive drug intake that characterizes addiction.
C1 [Volkow, Nora D.; Baler, Ruben] Natl Inst Drug Abuse, NIH, Bethesda, MD USA.
   [Wang, Gene-Jack; Fowler, Joanna S.; Tomasi, Dardo; Telang, Frank] Brookhaven Natl Lab, Dept Med, Upton, NY 11973 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute on
   Drug Abuse (NIDA); United States Department of Energy (DOE); Brookhaven
   National Laboratory
RP Volkow, ND (通讯作者)，Natl Inst Drug Abuse, NIH, Bethesda, MD USA.
EM nvolkow@nida.nih.gov
RI Tomasi, Dardo G/J-2127-2015
FU Intramural NIH HHS [ZIA AA000550-06] Funding Source: Medline
CR BALSTER RL, 1973, J EXP ANAL BEHAV, V20, P119, DOI 10.1901/jeab.1973.20-119
   Barr AM, 2005, NEUROSCI BIOBEHAV R, V29, P675, DOI 10.1016/j.neubiorev.2005.03.012
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   Boileau I, 2003, SYNAPSE, V49, P226, DOI 10.1002/syn.10226
   Brody AL, 2009, NEUROPSYCHOPHARMACOL, V34, P282, DOI 10.1038/npp.2008.87
   CHAIT LD, 1994, BEHAV PHARMACOL, V5, P281, DOI 10.1097/00008877-199406000-00005
   Dalley JW, 2007, SCIENCE, V315, P1267, DOI 10.1126/science.1137073
   Di Chiara G, 2005, PHYSIOL BEHAV, V86, P9, DOI 10.1016/j.physbeh.2005.06.020
   Di Chiara G, 2004, NEUROPHARMACOLOGY, V47, P227, DOI 10.1016/j.neuropharm.2004.06.032
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Dong Y, 2004, P NATL ACAD SCI USA, V101, P14282, DOI 10.1073/pnas.0401553101
   Drevets WC, 2001, BIOL PSYCHIAT, V49, P81, DOI 10.1016/S0006-3223(00)01038-6
   Fowler JS, 2008, NEUROIMAGE, V43, P756, DOI 10.1016/j.neuroimage.2008.07.020
   Goldstein RZ, 2009, TRENDS COGN SCI, V13, P372, DOI 10.1016/j.tics.2009.06.004
   Grace AA, 2006, NEUROTOX RES, V10, P93, DOI 10.1007/BF03033238
   HEMBY SE, 1997, NEUROBIOLOGICAL BASI
   Horvitz JC, 2000, NEUROSCIENCE, V96, P651, DOI 10.1016/S0306-4522(00)00019-1
   Kalivas PW, 2004, CURR OPIN PHARMACOL, V4, P23, DOI 10.1016/j.coph.2003.11.002
   Kauer JA, 2007, NAT REV NEUROSCI, V8, P844, DOI 10.1038/nrn2234
   Kenny PJ, 2005, J NEUROSCI, V25, P6208, DOI 10.1523/JNEUROSCI.4785-04.2005
   Koob GF, 2010, BRAIN RES, V1314, P3, DOI 10.1016/j.brainres.2009.11.008
   KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550
   Lane DA, 2008, J NEUROSCI, V28, P9670, DOI 10.1523/JNEUROSCI.2151-08.2008
   Lee B, 2009, J NEUROSCI, V29, P14734, DOI 10.1523/JNEUROSCI.3765-09.2009
   McClure SM, 2003, TRENDS NEUROSCI, V26, P423, DOI 10.1016/S0166-2236(03)00177-2
   Parasrampuria DA, 2007, J CLIN PHARMACOL, V47, P1476, DOI 10.1177/0091270007308615
   Phillips PEM, 2003, NATURE, V422, P614, DOI 10.1038/nature01566
   Schultz W, 2000, CEREB CORTEX, V10, P272, DOI 10.1093/cercor/10.3.272
   Stoops WW, 2007, PHARMACOL BIOCHEM BE, V87, P20, DOI 10.1016/j.pbb.2007.03.016
   Thanos PK, 2008, SYNAPSE, V62, P481, DOI 10.1002/syn.20523
   Thanos PK, 2004, ALCOHOL CLIN EXP RES, V28, P720, DOI 10.1097/01.ALC.0000125270.30501.08
   Tobler PN, 2007, J NEUROPHYSIOL, V97, P1621, DOI 10.1152/jn.00745.2006
   Villemagne VL, 1999, SYNAPSE, V33, P268, DOI 10.1002/(SICI)1098-2396(19990915)33:4<268::AID-SYN3>3.3.CO;2-N
   Volkow ND, 2000, LIFE SCI, V67, pPL1507
   Volkow ND, 2002, NEUROBIOL LEARN MEM, V78, P610, DOI 10.1006/nlme.2002.4099
   Volkow ND, 1996, P NATL ACAD SCI USA, V93, P10388, DOI 10.1073/pnas.93.19.10388
   Volkow ND, 2001, AM J PSYCHIAT, V158, P377, DOI 10.1176/appi.ajp.158.3.377
   Volkow ND, 2003, J NEUROSCI, V23, P11461
   Volkow ND, 2003, J CLIN INVEST, V111, P1444, DOI 10.1172/JCI200318533
   Volkow ND, 1998, AM J PSYCHIAT, V155, P1325, DOI 10.1176/ajp.155.10.1325
   VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210
   Volkow ND, 1999, AM J PSYCHIAT, V156, P19, DOI 10.1176/ajp.156.1.19
   Volkow ND, 1999, J PHARMACOL EXP THER, V291, P409
   Volkow ND, 1996, NEUROPSYCHOPHARMACOL, V14, P159, DOI 10.1016/0893-133X(95)00073-M
   VOLKOW ND, 1995, ARCH GEN PSYCHIAT, V52, P456
   VOLKOW ND, 2001, J NEUROSCI, V21, P121
   Volkow ND, 2007, J NEUROSCI, V27, P12700, DOI 10.1523/JNEUROSCI.3371-07.2007
   Volkow ND, 2006, ARCH GEN PSYCHIAT, V63, P999, DOI 10.1001/archpsyc.63.9.999
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
   Volkow ND, 2010, NEUROIMAGE, V49, P2536, DOI 10.1016/j.neuroimage.2009.10.088
   Waelti P, 2001, NATURE, V412, P43, DOI 10.1038/35083500
   Wong DF, 2006, NEUROPSYCHOPHARMACOL, V31, P2716, DOI 10.1038/sj.npp.1301194
   Zink CF, 2003, J NEUROSCI, V23, P8092
   Zweifel LS, 2009, P NATL ACAD SCI USA, V106, P7281, DOI 10.1073/pnas.0813415106
NR 54
TC 306
Z9 320
U1 6
U2 61
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0265-9247
EI 1521-1878
J9 BIOESSAYS
JI Bioessays
PD SEP
PY 2010
VL 32
IS 9
BP 748
EP 755
DI 10.1002/bies.201000042
PG 8
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA 647NK
UT WOS:000281625000005
PM 20730946
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Venniro, M
   Zhang, M
   Caprioli, D
   Hoots, JK
   Golden, SA
   Heins, C
   Morales, M
   Epstein, DH
   Shaham, Y
AF Venniro, Marco
   Zhang, Michelle
   Caprioli, Daniele
   Hoots, Jennifer K.
   Golden, Sam A.
   Heins, Conor
   Morales, Marisela
   Epstein, David H.
   Shaham, Yavin
TI Volitional social interaction prevents drug addiction in rat models
SO NATURE NEUROSCIENCE
LA English
DT Article
ID CONTEXT-INDUCED RELAPSE; ENVIRONMENTAL ENRICHMENT; REINSTATEMENT MODEL;
   COCAINE SEEKING; INCUBATION; METHAMPHETAMINE; MECHANISMS; REINFORCEMENT;
   NEUROBIOLOGY; ABSTINENCE
AB Addiction treatment has not been appreciably improved by neuroscientific research. One problem is that mechanistic studies using rodent models do not incorporate volitional social factors, which play a critical role in human addiction. Here, using rats, we introduce an operant model of choice between drugs and social interaction. Independent of sex, drug class, drug dose, training conditions, abstinence duration, social housing, or addiction score in Diagnostic & Statistical Manual IV-based and intermittent access models, operant social reward prevented drug self-administration. This protection was lessened by delay or punishment of the social reward but neither measure was correlated with the addiction score. Social-choice-induced abstinence also prevented incubation of methamphetamine craving. This protective effect was associated with activation of central amygdala PKC delta-expressing inhibitory neurons and inhibition of anterior insular cortex activity. These findings highlight the need for incorporating social factors into neuroscience-based addiction research and support the wider implantation of socially based addiction treatments.
C1 [Venniro, Marco; Zhang, Michelle; Hoots, Jennifer K.; Golden, Sam A.; Heins, Conor; Morales, Marisela; Epstein, David H.; Shaham, Yavin] NIDA, Intramural Res Program, NIH, Baltimore, MD 21224 USA.
   [Caprioli, Daniele] Sapienza Univ Rome, Dept Physiol & Pharmacol Vittorio Erspamer, Rome, Italy.
   [Caprioli, Daniele] Santa Lucia Fdn, IRCCS Fdn Santa Lucia, Rome, Italy.
C3 National Institutes of Health (NIH) - USA; NIH National Institute on
   Aging (NIA); NIH National Institute on Drug Abuse (NIDA); Sapienza
   University Rome; IRCCS Santa Lucia
RP Venniro, M; Shaham, Y (通讯作者)，NIDA, Intramural Res Program, NIH, Baltimore, MD 21224 USA.
EM venniro.marco@nih.gov; yshaham@intra.nida.nih.gov
RI Venniro, Marco/AAU-5988-2021; Caprioli, Daniele/AAA-7536-2019; Venniro,
   Marco/AAX-7686-2020; shaham, yavin/G-1306-2014
OI Caprioli, Daniele/0000-0001-6198-0776; Golden, Sam/0000-0002-2104-2272;
   shaham, yavin/0000-0002-8242-3319; Venniro, Marco/0000-0001-7653-957X
FU Intramural Research Program of NIDA; NIH Center on Compulsive Behaviors;
   NARSAD Distinguished Investigator Grant Award
FX We thank M. Jin, A. Minier Toribio, and O. Lofaro for their help during
   the experiments. The research was supported by the Intramural Research
   Program of NIDA, a fellowship from the NIH Center on Compulsive
   Behaviors (M.V.), and NARSAD Distinguished Investigator Grant Award
   (Y.S.).
CR Ahmed SH, 2018, PROG NEURO-PSYCHOPH, V87, P3, DOI 10.1016/j.pnpbp.2017.09.027
   Ahmed SH, 2013, CURR OPIN NEUROBIOL, V23, P581, DOI 10.1016/j.conb.2013.01.028
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Augier E, 2018, SCIENCE, V360, P1321, DOI 10.1126/science.aao1157
   Azrin NH, 1996, BEHAV RES THER, V34, P41, DOI 10.1016/0005-7967(95)00049-4
   Balleine BW, 1998, NEUROPHARMACOLOGY, V37, P407, DOI 10.1016/S0028-3908(98)00033-1
   Banks ML, 2017, TRENDS PHARMACOL SCI, V38, P181, DOI 10.1016/j.tips.2016.11.002
   Bardo MT, 2013, PHARMACOL REV, V65, P255, DOI 10.1124/pr.111.005124
   Bossert JM, 2013, PSYCHOPHARMACOLOGY, V229, P453, DOI 10.1007/s00213-013-3120-y
   Calu DJ, 2014, NEUROPHARMACOLOGY, V76, P395, DOI 10.1016/j.neuropharm.2013.04.030
   Caprioli D, 2017, J NEUROSCI, V37, P1014, DOI 10.1523/JNEUROSCI.3091-16.2016
   Caprioli D, 2015, ADDICT BIOL, V20, P913, DOI 10.1111/adb.12220
   Caprioli D, 2015, BIOL PSYCHIAT, V78, P463, DOI 10.1016/j.biopsych.2015.02.018
   Chauvet C, 2012, NEUROPHARMACOLOGY, V63, P635, DOI 10.1016/j.neuropharm.2012.05.014
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Dong Y, 2017, J NEUROSCI, V37, P10867, DOI 10.1523/JNEUROSCI.1821-17.2017
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Fritz M, 2011, ADDICT BIOL, V16, P273, DOI 10.1111/j.1369-1600.2010.00285.x
   Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134
   Grundemann J, 2015, CURR OPIN NEUROBIOL, V35, P200, DOI 10.1016/j.conb.2015.10.005
   Heilig M, 2016, NAT REV NEUROSCI, V17, P592, DOI 10.1038/nrn.2016.67
   Heyman Gene M, 2013, Front Psychiatry, V4, P31, DOI 10.3389/fpsyt.2013.00031
   Higgins ST, 2003, ARCH GEN PSYCHIAT, V60, P1043, DOI 10.1001/archpsyc.60.9.1043
   Insel TR, 2017, JAMA-J AM MED ASSOC, V318, P1215, DOI 10.1001/jama.2017.11295
   Kawa AB, 2016, PSYCHOPHARMACOLOGY, V233, P3587, DOI 10.1007/s00213-016-4393-8
   Kim J, 2017, NEURON, V93, P1464, DOI 10.1016/j.neuron.2017.02.034
   Krasnova IN, 2014, NEUROPSYCHOPHARMACOL, V39, P2008, DOI 10.1038/npp.2014.50
   Lash SJ, 2004, ADDICT BEHAV, V29, P337, DOI 10.1016/j.addbeh.2003.08.008
   Li X, 2015, J NEUROSCI, V35, P8232, DOI 10.1523/JNEUROSCI.1022-15.2015
   Li X, 2015, NEUROPSYCHOPHARMACOL, V40, P1297, DOI 10.1038/npp.2014.320
   Marchant NJ, 2013, BIOL PSYCHIAT, V73, P256, DOI 10.1016/j.biopsych.2012.07.007
   MARLATT GA, 1988, ANNU REV PSYCHOL, V39, P223, DOI 10.1146/annurev.psych.39.1.223
   Miczek KA, 2008, PHARMACOL THERAPEUT, V120, P102, DOI 10.1016/j.pharmthera.2008.07.006
   Monterosso J, 2007, DRUG ALCOHOL DEPEN, V90, pS100, DOI 10.1016/j.drugalcdep.2006.09.004
   Nader MA, 2014, NEUROPHARMACOLOGY, V76, P510, DOI 10.1016/j.neuropharm.2013.05.044
   Nestler EJ, 2014, NEUROPHARMACOLOGY, V76, P259, DOI 10.1016/j.neuropharm.2013.04.004
   PAXINOS G, 2008, RAT BRAIN STREOTAXIC
   Pelloux Y, 2018, ADDICT BIOL, V23, P699, DOI 10.1111/adb.12527
   Piazza PV, 2013, PSYCHOPHARMACOLOGY, V229, P387, DOI 10.1007/s00213-013-3224-4
   Pickens CL, 2011, TRENDS NEUROSCI, V34, P411, DOI 10.1016/j.tins.2011.06.001
   Richardson NR, 1996, J NEUROSCI METH, V66, P1, DOI 10.1016/0165-0270(95)00153-0
   Schoenbaum G, 2016, NEUROPSYCHOPHARMACOL, V41, P2966, DOI 10.1038/npp.2016.147
   Smith MA, 2012, PSYCHOPHARMACOLOGY, V224, P81, DOI 10.1007/s00213-012-2737-6
   Solinas M, 2008, P NATL ACAD SCI USA, V105, P17145, DOI 10.1073/pnas.0806889105
   Solinas M, 2010, PROG NEUROBIOL, V92, P572, DOI 10.1016/j.pneurobio.2010.08.002
   Strickland JC, 2014, EXP CLIN PSYCHOPHARM, V22, P23, DOI 10.1037/a0034669
   Theberge FR, 2013, BIOL PSYCHIAT, V73, P729, DOI 10.1016/j.biopsych.2012.12.019
   Thiel KJ, 2012, ADDICT BIOL, V17, P365, DOI 10.1111/j.1369-1600.2011.00358.x
   Tourigny SC, 1998, QUAL HEALTH RES, V8, P149, DOI 10.1177/104973239800800202
   Vanderschuren LJMJ, 2016, NEUROSCI BIOBEHAV R, V70, P86, DOI 10.1016/j.neubiorev.2016.07.025
   Venniro M, 2017, NEURON, V96, P414, DOI 10.1016/j.neuron.2017.09.024
   Venniro M, 2017, NEUROPSYCHOPHARMACOL, V42, P1126, DOI 10.1038/npp.2016.287
   Venniro M, 2016, PROG BRAIN RES, V224, P25, DOI 10.1016/bs.pbr.2015.08.004
   Waldorf D., 1991, COCAINE CHANGES EXPE
   Wise RA, 2014, NEUROPSYCHOPHARMACOL, V39, P254, DOI 10.1038/npp.2013.261
   Wolf ME, 2016, NAT REV NEUROSCI, V17, P351, DOI 10.1038/nrn.2016.39
   Wong C, 2011, HDB MOTIVATIONAL COU
   Zernig Gerald, 2013, Front Psychiatry, V4, P100, DOI 10.3389/fpsyt.2013.00100
   Zimmer BA, 2012, NEUROPSYCHOPHARMACOL, V37, P1901, DOI 10.1038/npp.2012.37
   Zlebnik NE, 2015, PSYCHOPHARMACOLOGY, V232, P3507, DOI 10.1007/s00213-015-3999-6
NR 60
TC 174
Z9 175
U1 9
U2 75
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1097-6256
EI 1546-1726
J9 NAT NEUROSCI
JI Nat. Neurosci.
PD NOV
PY 2018
VL 21
IS 11
BP 1520
EP +
DI 10.1038/s41593-018-0246-6
PG 16
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology
GA GY1UT
UT WOS:000448319500006
PM 30323276
OA Green Accepted
HC Y
HP N
DA 2023-06-23
ER

PT J
AU Belin, D
   Berson, N
   Balado, E
   Piazza, PV
   Deroche-Gamonet, V
AF Belin, David
   Berson, Nadege
   Balado, Eric
   Piazza, Pier Vincenzo
   Deroche-Gamonet, Veronique
TI High-Novelty-Preference Rats are Predisposed to Compulsive Cocaine
   Self-administration
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE addiction; cocaine; compulsivity; distributions; novelty; locomotor
   reactivity
ID SENSATION-SEEKING TRAIT; ADDICTION-LIKE BEHAVIOR;
   INDIVIDUAL-DIFFERENCES; SUBSTANCE USE; GENE-EXPRESSION; RISK APPRAISAL;
   DRUG SEEKING; AMPHETAMINE; STRESS; PREDICT
AB Sensation/novelty-seeking is amongst the best markers of cocaine addiction in humans. However, its implication in the vulnerability to cocaine addiction is still a matter of debate, as it is unclear whether this trait precedes or follows the development of addiction. Sensation/novelty-seeking trait has been identified in rats on the basis of either novelty-induced locomotor activity (high-responder (HR) trait) or novelty-induced place preference (high-novelty-preference trait (HNP)). HR and HNP traits have been associated with differential sensitivity to psychostimulants. However, it has recently been demonstrated that HR rats do not develop compulsive cocaine self-administration (SA) after protracted exposure to the drug, thereby suggesting that at least one dimension of sensation/novelty seeking in the rat is dissociable from the vulnerability to switch from controlled to compulsive cocaine SA. We therefore investigated whether HNP, as measured as the propensity to choose a new environment in a free choice procedure, as opposed to novelty-induced locomotor activity, predicts the vulnerability to, and the severity of, addiction-like behavior for cocaine. For this, we identified HR/LR rats and HNP/LNP rats before any exposure to cocaine. After 60 days of cocaine SA, each rat was given an addiction score based on three addiction-like behaviors (persistence of responding when the drug is signaled as not available, high breakpoint under progressive ratio schedule and resistance to punishment) that resemble the clinical features of drug addiction, namely inability to refrain from drug seeking, high motivation for the drug and compulsive drug use despite adverse consequences. We show that, as opposed to HR rats, HNP rats represent a sub-population predisposed to compulsive cocaine intake, displaying higher addiction scores than LNP rats. This study thereby provides new insights into the factors predisposing to cocaine addiction, supporting the hypothesis that addiction is sustained by two vulnerable phenotypes: a 'drug use prone' phenotype such as HR which brings an individual to develop drug use and an 'addiction prone' phenotype, such as HNP, which facilitates the shift from sustained to compulsive drug intake and addiction. Neuropsychopharmacology (2011) 36, 569-579; doi:10.1038/npp.2010.188; published online 27 October 2010
C1 [Belin, David] Univ Poitiers, INSERM AVENIR Team Psychobiol Compuls Disorders, CNRS, UMR 6187, Poitiers, France.
   [Belin, David; Berson, Nadege; Balado, Eric; Piazza, Pier Vincenzo; Deroche-Gamonet, Veronique] Univ Bordeaux, Bordeaux, France.
   [Belin, David; Berson, Nadege; Balado, Eric; Piazza, Pier Vincenzo; Deroche-Gamonet, Veronique] NeuroCtr Magendie, INSERM, U862, Bordeaux, France.
C3 Centre National de la Recherche Scientifique (CNRS); Institut National
   de la Sante et de la Recherche Medicale (Inserm); Universite de
   Poitiers; UDICE-French Research Universities; Universite de Bordeaux;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux
RP Belin, D (通讯作者)，Univ Poitiers, INSERM AVENIR Team Psychobiol Compuls Disorders, CNRS, UMR 6187, Poitiers, France.
EM david.belin@inserm.fr
RI Deroche-Gamonet, Véronique/E-5728-2010; Belin, David/E-1231-2014
OI Belin, David/0000-0002-7383-372X; Deroche-Gamonet,
   Veronique/0000-0002-9704-6624
FU ANR; INSERM; Region Aquitaine; MILDT/INSERM/Inca; INSERM AVENIR
FX This work was supported by the ANR (2005), INSERM, Region Aquitaine,
   MILDT/INSERM/Inca 2008 grants to PVP and VDG. DB is supported by an
   INSERM AVENIR grant. The authors thank Dr Ruth McNamara for careful
   review of the manuscript.
CR Abreu-Villaca Y, 2006, BEHAV BRAIN RES, V167, P175, DOI 10.1016/j.bbr.2005.09.003
   Adriani W, 2009, NEUROSCIENCE, V159, P47, DOI 10.1016/j.neuroscience.2008.11.042
   Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244
   ARNETT J, 1994, PERS INDIV DIFFER, V16, P289, DOI 10.1016/0191-8869(94)90165-1
   Ballaz SJ, 2008, NEUROPEPTIDES, V42, P245, DOI 10.1016/j.npep.2008.03.001
   Ballaz SJ, 2007, NEUROSCI LETT, V428, P27, DOI 10.1016/j.neulet.2007.09.035
   Bardo MT, 1993, EXP CLIN PSYCHOPHARM, V1, P101, DOI 10.1037/1064-1297.1.1-4.101
   BARDO MT, 1990, PHARMACOL BIOCHEM BE, V37, P89, DOI 10.1016/0091-3057(90)90046-K
   Bardo MT, 1996, BEHAV BRAIN RES, V77, P23, DOI 10.1016/0166-4328(95)00203-0
   BARDO MT, 1989, PHARMACOL BIOCHEM BE, V32, P683, DOI 10.1016/0091-3057(89)90018-X
   BECKMANN JS, 2010, BEHAV BRAIN RES
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   Belin D, 2009, BIOL PSYCHIAT, V65, P863, DOI 10.1016/j.biopsych.2008.05.031
   Bevins RA, 1997, BEHAV PHARMACOL, V8, P113
   Blanchard MM, 2009, NEUROSCI BIOBEHAV R, V33, P1145, DOI 10.1016/j.neubiorev.2009.05.009
   Bossert JM, 2005, EUR J PHARMACOL, V526, P36, DOI 10.1016/j.ejphar.2005.09.030
   Buckman JF, 2009, J STUD ALCOHOL DRUGS, V70, P919, DOI 10.15288/jsad.2009.70.919
   Cain ME, 2005, EXP CLIN PSYCHOPHARM, V13, P367, DOI 10.1037/1064-1297.13.4.367
   Cain ME, 2004, PSYCHOPHARMACOLOGY, V176, P129, DOI 10.1007/s00213-004-1870-2
   CLONINGER CR, 1988, PSYCHIAT DEV, V6, P83
   Darnaudery M, 2002, BRAIN RES, V951, P237, DOI 10.1016/S0006-8993(02)03166-9
   Dellu F, 1996, PSYCHONEUROENDOCRINO, V21, P441, DOI 10.1016/0306-4530(96)00017-0
   DELLU F, 1993, PERS INDIV DIFFER, V15, P411, DOI 10.1016/0191-8869(93)90069-F
   Dellu F, 1996, NEUROPSYCHOBIOLOGY, V34, P136, DOI 10.1159/000119305
   DEMINIERE JM, 1992, BRAIN RES, V586, P135, DOI 10.1016/0006-8993(92)91383-P
   DEROCHE V, 1993, BRAIN RES, V623, P341, DOI 10.1016/0006-8993(93)91451-W
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Deroche-Gamonet V, 2010, ENCYCLOPEDIA OF BEHAVIORAL NEUROSCIENCE, VOL 3: P-Z, P422
   Dieckmann U, 1999, NATURE, V400, P354, DOI 10.1038/22521
   Economidou D, 2009, BIOL PSYCHIAT, V65, P851, DOI 10.1016/j.biopsych.2008.12.008
   Ellenbroek BA, 2002, BEHAV GENET, V32, P349, DOI 10.1023/A:1020214322065
   Franques P, 2003, DRUG ALCOHOL DEPEN, V69, P121, DOI 10.1016/S0376-8716(02)00309-5
   Franques P, 2000, ENCEPHALE, V26, P68
   Hasegawa M, 2006, J PLANT RES, V119, P63, DOI 10.1007/s10265-005-0241-3
   HOOKS MS, 1995, NEUROSCIENCE, V64, P587, DOI 10.1016/0306-4522(94)00409-X
   HORVATH P, 1993, PERS INDIV DIFFER, V14, P41, DOI 10.1016/0191-8869(93)90173-Z
   Jonah BA, 1997, ACCIDENT ANAL PREV, V29, P651, DOI 10.1016/S0001-4575(97)00017-1
   Kabbaj M, 2000, J NEUROSCI, V20, P6983, DOI 10.1523/JNEUROSCI.20-18-06983.2000
   KALICHMAN SC, 1994, J PERS ASSESS, V62, P385, DOI 10.1207/s15327752jpa6203_1
   Klebaur JE, 1999, PHARMACOL BIOCHEM BE, V63, P131, DOI 10.1016/S0091-3057(98)00258-5
   Klebaur JE, 2001, BEHAV PHARMACOL, V12, P267, DOI 10.1097/00008877-200107000-00005
   Koob G. F., 2005, NEUROBIOLOGY ADDICTI
   Kreek MJ, 2005, NAT NEUROSCI, V8, P1450, DOI 10.1038/nn1583
   Limpert E, 2001, BIOSCIENCE, V51, P341, DOI 10.1641/0006-3568(2001)051[0341:LNDATS]2.0.CO;2
   MISSLIN R, 1982, PSYCHONEUROENDOCRINO, V7, P217, DOI 10.1016/0306-4530(82)90015-4
   Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006
   Nesse RM, 1997, SCIENCE, V278, P63, DOI 10.1126/science.278.5335.63
   Pelloux Y, 2004, PSYCHOPHARMACOLOGY, V171, P277, DOI 10.1007/s00213-003-1584-x
   Pelloux Y, 2007, PSYCHOPHARMACOLOGY, V194, P127, DOI 10.1007/s00213-007-0805-0
   Piazza P.V., 1990, Behav Pharmacol, V1, P339
   Piazza PV, 1998, TRENDS PHARMACOL SCI, V19, P67, DOI 10.1016/S0165-6147(97)01115-2
   Piazza PV, 2000, J NEUROSCI, V20, P4226
   PIAZZA PV, 1991, P NATL ACAD SCI USA, V88, P2088, DOI 10.1073/pnas.88.6.2088
   PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295
   Rouge-Pont F, 1998, EUR J NEUROSCI, V10, P3903, DOI 10.1046/j.1460-9568.1998.00438.x
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   Shaw P.J.A., 2003, MULTIVARIATE STAT EN
   Sher KJ, 2000, J CONSULT CLIN PSYCH, V68, P818, DOI 10.1037/0022-006X.68.5.818
   Swendsen J, 2010, ADDICTION, V105, P1117, DOI 10.1111/j.1360-0443.2010.02902.x
   Tomie A, 2008, BRAIN RES REV, V58, P121, DOI 10.1016/j.brainresrev.2007.12.003
   Turner CA, 2008, NEUROSCI LETT, V446, P105, DOI 10.1016/j.neulet.2008.09.037
   Uhl GR, 2004, ARCH GEN PSYCHIAT, V61, P223, DOI 10.1001/archpsyc.61.3.223
   Wills T A, 1994, J Subst Abuse, V6, P1, DOI 10.1016/S0899-3289(94)90039-6
   WOHLWILL JF, 1984, BEHAV BRAIN SCI, V7, P453, DOI 10.1017/S0140525X00019178
   Woicik PA, 2009, ADDICT BEHAV, V34, P1042, DOI 10.1016/j.addbeh.2009.07.001
   ZUCKERMAN M, 1990, ADDICT BEHAV, V15, P209, DOI 10.1016/0306-4603(90)90064-5
   Zuckerman M, 2000, J PERS, V68, P999, DOI 10.1111/1467-6494.00124
   ZUCKERMAN M, 1978, J CONSULT CLIN PSYCH, V46, P139, DOI 10.1037/0022-006X.46.1.139
   Zuckerman M, 1986, NIDA Res Monogr, V74, P59
   ZUCKERMAN M, 1979, PSYCHIAT RES, V1, P255, DOI 10.1016/0165-1781(79)90007-6
NR 70
TC 181
Z9 183
U1 3
U2 24
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0893-133X
EI 1740-634X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD FEB
PY 2011
VL 36
IS 3
BP 569
EP 579
DI 10.1038/npp.2010.188
PG 11
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 705YM
UT WOS:000286176700003
PM 20980989
OA Green Submitted, Green Published, Bronze
DA 2023-06-23
ER

PT J
AU Manna, V
AF Manna, Vincenzo
TI Stress, drug abuse and addiction: neurobiological and behavioral aspects
SO RIVISTA DI PSICHIATRIA
LA Italian
DT Review
DE drug abuse; addiction; stress; dopamine; CRE
ID CORTICOTROPIN-RELEASING-FACTOR; FREELY MOVING RATS; EXTRACELLULAR
   DOPAMINE LEVELS; COCAINE-SEEKING BEHAVIOR; NUCLEUS-ACCUMBENS; PROLONGED
   EXTINCTION; HEROIN-ADDICTS; ETHANOL INTOXICATION; INTRAVENOUS COCAINE;
   OLFACTORY STIMULI
AB The onset and the development of drug addiction and vulnerability to relapse following withdrawal are thought to be the result of neuro-adaptive processes within the central nervous system. The long-lasting effects of abused drugs lead to impairment of the mechanisms mediating positive reinforcement but also to the emergence of affective changes such as anxiety, dysphoria and depression during withdrawal. A growing body of evidence suggests the involvement of a cyclic dysregulation of the endocrine and non-endocrine stress control system as a common factor in the development of drug addiction and vulnerability to relapse following withdrawal. A critical element contributing to the chronic relapsing nature of drug addiction are the learned responses to drug-related stimuli.
C1 ASL RM H, Ctr Salute Mental Genzano Roma, Dept Salute Mentale, Rome, Italy.
RP Manna, V (通讯作者)，ASL RM H, Ctr Salute Mental Genzano Roma, Dept Salute Mentale, Rome, Italy.
EM vi.manna@tiscali.it
CR ACQUAS E, 1989, PSYCHOPHARMACOLOGY, V99, P151, DOI 10.1007/BF00442800
   Ahmed SH, 1997, PSYCHOPHARMACOLOGY, V132, P289, DOI 10.1007/s002130050347
   ALLOLIO B, 1987, ACTA ENDOCRINOL-COP, V114, P509, DOI 10.1530/acta.0.1140509
   Ambrosio E, 1997, SYNAPSE, V25, P272, DOI 10.1002/(SICI)1098-2396(199703)25:3<272::AID-SYN6>3.0.CO;2-8
   BANKI CM, 1987, PSYCHONEUROENDOCRINO, V12, P3, DOI 10.1016/0306-4530(87)90016-3
   BAUMMEISTER RF, 1994, LOSING CONTROL WHY P
   BENINGER RJ, 1983, BRAIN RES REV, V6, P173, DOI 10.1016/0165-0173(83)90038-3
   BENOWITZ NL, 1976, J CLIN ENDOCR METAB, V42, P938, DOI 10.1210/jcem-42-5-938
   BROWN SA, 1995, J STUD ALCOHOL, V56, P538, DOI 10.15288/jsa.1995.56.538
   CARBONI E, 1989, NEUROSCIENCE, V28, P653, DOI 10.1016/0306-4522(89)90012-2
   CARNICER JO, 1981, MED CLIN-BARCELONA, V76, P206
   CARR A, 1989, NEURO PHARM BASIS RE
   Childress A, 1988, NIDA Res Monogr, V81, P74
   CICCOCIOPPO R, 1999, ALCOHOL CLIN EXPT S, V23, P52
   CLOUET D, 1988, MECHANISMS COCAIRNE
   CONE EJ, 1986, PHARMACOL BIOCHEM BE, V24, P1749, DOI 10.1016/0091-3057(86)90515-0
   CRUICKSHANK EK, 1976, ANN NY ACAD SCI, V282, P162, DOI 10.1111/j.1749-6632.1976.tb49895.x
   DACKIS CA, 1982, LANCET, V2, P1167
   Dani JA, 1996, NEURON, V16, P905, DOI 10.1016/S0896-6273(00)80112-9
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   DICHIARA G, 1988, J PHARMACOL EXP THER, V244, P1067
   DICHIARA G, 1991, MESOLIMBIC DOPAMINE
   DUNN AJ, 1990, BRAIN RES REV, V15, P71, DOI 10.1016/0165-0173(90)90012-D
   EIKELBOOM R, 1982, PSYCHOL REV, V89, P507, DOI 10.1037/0033-295X.89.5.507
   ELLIS FW, 1996, J PHARMACOL EXP THER, V153, P121
   Erb S, 1996, PSYCHOPHARMACOLOGY, V128, P408, DOI 10.1007/s002130050150
   FACCHINETTI F, 1984, ACTA ENDOCRINOL-COP, V105, P149, DOI 10.1530/acta.0.1050149
   FITZGERALD LW, 1995, CLIN NEUROSCI, V3, P165
   GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107
   GESSA GL, 1985, BRIAN RES, V34, P210
   Gracy KN, 2000, PHARMACOL BIOCHEM BE, V65, P489, DOI 10.1016/S0091-3057(99)00234-8
   HANEY M, 1995, BRAIN RES, V698, P46, DOI 10.1016/0006-8993(95)00788-R
   HASSEN AH, 1982, LIFE SCI, V31, P2193, DOI 10.1016/0024-3205(82)90116-3
   HEINRICHS SC, 1992, BRAIN RES, V581, P190, DOI 10.1016/0006-8993(92)90708-H
   HEINRICHS SC, 1995, BEHAV PHARMACOL, V6, P74
   HIGLEY JD, 1991, P NATL ACAD SCI USA, V88, P7261, DOI 10.1073/pnas.88.16.7261
   KAKIHANA R, 1976, PSYCHOPHARMACOLOGIA, V46, P301, DOI 10.1007/BF00421118
   KANNER AD, 1978, J HUM STRESS, V4, P33, DOI 10.1080/0097840X.1978.10545984
   Katner SN, 1999, NEUROPSYCHOPHARMACOL, V20, P471, DOI 10.1016/S0893-133X(98)00084-0
   Katner SN, 1999, ALCOHOL CLIN EXP RES, V23, P1751, DOI 10.1097/00000374-199911000-00007
   Koob GF, 1999, ANN NY ACAD SCI, V897, P27, DOI 10.1111/j.1749-6632.1999.tb07876.x
   KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   KOOB GF, 1987, NEUROSCI LETT, V79, P315, DOI 10.1016/0304-3940(87)90451-4
   KOOB GF, 1994, SEMIN NEUROSCI, V6, P221
   Kreek MJ, 1987, PSYCHOPHARMACOLOGY 3, P1597
   Le AD, 1998, PSYCHOPHARMACOLOGY, V135, P169, DOI 10.1007/s002130050498
   Levi L, 1971, SOC STRESS DIS
   LIBERMAN JM, 1989, NEURO PHARM BASIS RE
   LINKOLA J, 1978, ACTA PHYSIOL SCAND, V104, P180, DOI 10.1111/j.1748-1716.1978.tb06265.x
   MACEDO T, 1995, MOL NEUROBIOL, V11, P21, DOI 10.1007/BF02740681
   Macey D. J., 1997, Society for Neuroscience Abstracts, V23, P521
   Manna V, 1990, PSICHIAT E TERRITORI, VVII, P63
   Manna V, 2003, GIORNALE ITALIANO PS, V9, P71
   MANNA V, 1996, GAZZETTA SANITARIA D, V46, P72
   MANNA V, 2004, TRATTATO COMPLETO AB, V4, P1313
   MANNA V, 1990, SALUTE PREVENZIONE, V1, P63
   Manna V., 2006, GIORNALE ITALIANO PS, V12, P72
   Manna V, 2001, RIV PSICHIATR, V36, P1
   MANNA V, 2002, MINERVA PSICHIAT, V43, P29
   MANNA V, 2002, DIFESA SOC, V1, P63
   MANNA V, 1998, G IT PSICOPATOL, V2, P209
   Manna V., 1997, NEUROL PSICHIATR SCI, V17, P367
   MANNA V, 2006, IMPULSIVIO COMPULSIV
   MANNA V, 2002, GIORNALE ITALIANO PS, V8, P36
   MARKOU A, 1992, PHYSIOL BEHAV, V51, P111, DOI 10.1016/0031-9384(92)90211-J
   MARKOU A, 1991, NEUROPSYCHOPHARMACOL, V4, P17
   MARLATT GA, 1985, RELAPSE PREVENTION M
   MARTIN WR, 1969, J PSYCHIAT RES, V7, P9, DOI 10.1016/0022-3956(69)90007-7
   MCDONALD RK, 1959, J PHARMACOL EXP THER, V125, P241
   MCKAY JR, 1995, DRUG ALCOHOL DEPEN, V38, P35, DOI 10.1016/0376-8716(95)01098-J
   MENDELSO.JH, 1966, PSYCHOSOM MED, V28, P1
   MENDELSON JH, 1971, PSYCHOSOM MED, V33, P145, DOI 10.1097/00006842-197103000-00006
   Mendoza H, 1998, An Med Interna, V15, P172
   MEREU G, 1987, EUR J PHARMACOL, V141, P395, DOI 10.1016/0014-2999(87)90556-5
   Miller N S, 1994, Ann Clin Psychiatry, V6, P99, DOI 10.3109/10401239409148988
   MOLLENAUER S, 1993, PHARMACOL BIOCHEM BE, V46, P35, DOI 10.1016/0091-3057(93)90313-I
   MUCHA RF, 1987, BRAIN RES, V418, P214, DOI 10.1016/0006-8993(87)90088-6
   Murakawa T, 1989, Masui, V38, P625
   MUTTI A, 1992, CURRENT ISSUES NEURO
   NASH JF, 1988, PROG NEURO-PSYCHOPH, V12, P653, DOI 10.1016/0278-5846(88)90010-3
   OBrien C. P., 1986, BEHAV ANAL DRUG DEPE
   OEDERS NE, 1994, PSYCOPHARMACOLOGY, V114, P63
   Palm S, 1997, METHOD FIND EXP CLIN, V19, P269
   PANCHERI P, 1982, STRESS PSICHIATRIA E
   PANCHERI P, 1979, STRESS ANXIETY
   PARSONS LH, 1995, J PHARMACOL EXP THER, V274, P1182
   PEREZREYES M, 1976, ANN NY ACAD SCI, V282, P173, DOI 10.1111/j.1749-6632.1976.tb49897.x
   PERIS J, 1990, J PHARMACOL EXP THER, V253, P38
   PFEIFFER A, 1986, HORM METAB RES, V18, P842, DOI 10.1055/s-2007-1012453
   PHILLIPS AG, 1991, MESOLIMBIC DOPAMINE
   PICH EM, 1995, J NEUROSCI, V15, P5439
   PICH EM, 1994, ALCOHOL CLIN EXP RES, V18, P522
   PICH EMM, 1995, NEUROSCIENCE, V55, P695
   POHORECKY LA, 1974, PHARMACOLOGY, V12, P340, DOI 10.1159/000136557
   RAMSEY NF, 1993, BRAIN RES, V608, P216, DOI 10.1016/0006-8993(93)91461-Z
   Rasheed Azmat, 1995, Polish Journal of Pharmacology, V47, P441
   RASSNICK S, 1993, BRAIN RES, V605, P25, DOI 10.1016/0006-8993(93)91352-S
   Richter RM, 1999, SYNAPSE, V32, P254, DOI 10.1002/(SICI)1098-2396(19990615)32:4<254::AID-SYN2>3.0.CO;2-H
   Roberts AJ, 1996, ALCOHOL CLIN EXP RES, V20, P1289, DOI 10.1111/j.1530-0277.1996.tb01125.x
   SARNYAI Z, 1995, BRAIN RES, V675, P89, DOI 10.1016/0006-8993(95)00043-P
   Seyle H, 1976, STRESS LIFE
   SEYLE H, 1936, NATURE, V32, P138
   SHAHAM Y, 1994, PSYCHOPHARMACOLOGY, V114, P523, DOI 10.1007/BF02249346
   SHAHAM Y, 1995, PSYCHOPHARMACOLOGY, V119, P334, DOI 10.1007/BF02246300
   SHIPPENBERG TS, 1987, BRAIN RES, V436, P169, DOI 10.1016/0006-8993(87)91571-X
   STINUS L, 1990, NEUROSCIENCE, V37, P767, DOI 10.1016/0306-4522(90)90106-E
   STORMARK KM, 1995, ADDICT BEHAV, V20, P571, DOI 10.1016/0306-4603(95)00017-7
   SWIERGIEL AH, 1993, BRAIN RES, V623, P229, DOI 10.1016/0006-8993(93)91432-R
   TAYLOR JR, 1984, PSYCHOPHARMACOLOGY, V84, P405, DOI 10.1007/BF00555222
   TENNANT F, 1991, J PSYCHOACTIVE DRUGS, V23, P135, DOI 10.1080/02791072.1991.10472232
   THACKRAY RI, 1981, PSYCHOSOM MED, V43, P165, DOI 10.1097/00006842-198104000-00008
   Tiffany ST, 1998, J PSYCHOPHARMACOL, V12, P23, DOI 10.1177/026988119801200104
   TSAGARAKIS S, 1979, CLIN PROSPECTIVES EN
   VALDEZ GR, 2000, SOC NEUR ABSTR, V26, P1821
   VESCOVI PP, 1989, ACTA ENDOCRINOL-COP, V121, P484, DOI 10.1530/acta.0.1210484
   WALLACE BC, 1989, J SUBST ABUSE TREAT, V6, P95, DOI 10.1016/0740-5472(89)90036-6
   WALTMAN C, 1993, CLIN ENDOCRINOLOGIC, V77, P18
   Weiss F, 2000, P NATL ACAD SCI USA, V97, P4321, DOI 10.1073/pnas.97.8.4321
   WEISS F, 1992, BRAIN RES, V593, P314, DOI 10.1016/0006-8993(92)91327-B
   Weiss F, 2001, ANN NY ACAD SCI, V937, P1, DOI 10.1111/j.1749-6632.2001.tb03556.x
   Weiss I, 1999, J MATH IMAGING VIS, V10, P175, DOI 10.1023/A:1008383224450
   WIKLER A, 1967, PSYCHOPHARMACOLOGIA, V10, P255, DOI 10.1007/BF00401386
   WIKLER A, 1948, AM J PSYCHIAT, V105, P329, DOI 10.1176/ajp.105.5.329
   Wilkins J N, 1992, Recent Dev Alcohol, V10, P57
   WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469
   YANG XM, 1992, PHARMACOL BIOCHEM BE, V41, P643, DOI 10.1016/0091-3057(92)90386-T
   Zhou Y, 1996, J PHARMACOL EXP THER, V279, P351
NR 128
TC 2
Z9 2
U1 2
U2 10
PU PENSIERO SCIENTIFICO EDITOR
PI ROME
PA VIA BRADANO 3/C, 00199 ROME, ITALY
SN 0035-6484
EI 2038-2502
J9 RIV PSICHIATR
JI Riv. Psichiatr.
PD SEP-OCT
PY 2007
VL 42
IS 5
BP 308
EP 319
PG 12
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA 271SW
UT WOS:000253810000003
DA 2023-06-23
ER

PT J
AU Okaliova, D
   Soucova, D
   Luha, J
AF Okaliova, D
   Soucova, D
   Luha, J
TI Drugs in the Slovak Republic - Spread and public opinion (trends
   1994-2000)
SO STUDIA PSYCHOLOGICA
LA English
DT Article; Proceedings Paper
CT International Conference on Quantity Versus Quality within the Context
   of Preventing Drug Addiction
CY JUN 24-26, 2001
CL LIPTOVSKY JAN, SLOVAKIA
SP Secretariat Gen Council, Minist Drug Addict & Drug Control, Govt Off Slovak Republic
DE feeling of menace; prevalence of drug addiction; one's own experience
   with drug abuse; family background; connection with use of legalized
   drugs; willingness to take drugs; attitudes toward drug abuse; opinions
   on the state's anti-drug policy; opinions on drug legalization
AB The paper presents a picture of the prevailing epidemiological situation as regards abuse of illegal drug in Slovakia and public opinion on drug addiction in a comparable form since 1994. The research was carried out on three representative samples of respondents, viz. a group of Adult Citizens of Slovakia, one of Slovak Youth and the third of Bratislava' Youth the last two aged 15 to 29 years. Prevalence of drug addiction was followed with the aid of several indicators: occurrence of drug addiction in the respondent's close milieu (family, residence, workplace, friends), the respondents' own experience with illegal drugs, his/her attitude toward drug abuse.
C1 Stat Off Slovak Republ, Inst Publ Opin, Bratislava 84000, Slovakia.
RP Okaliova, D (通讯作者)，Stat Off Slovak Republ, Inst Publ Opin, Dubravska Cesta 3,POB 18, Bratislava 84000, Slovakia.
CR *I PUBL OP RES STA, 2000, SPREAD DRUG AB SLOV
   *I PUBL OP RES STA, 1997, SPREAD DRUG AB SOLV
   *I PUBL OP RES STA, 1998, SPREAD DRUG AB SLOV
   NOCIAR A, 2000, NATL REPORT DRUG SIT
   NOCIAR A, 1998, NATL REPORT DRUG SIT
   OKALIOVA D, 1995, DROGOVY PROBLEM NASE
   SIMON R, 1995, 23 M EXP EP DRUG PRO
NR 7
TC 0
Z9 0
U1 0
U2 2
PU SLOVAK ACAD SCIENCES INST EXPERIMENTAL PSYCHOLOGY
PI BRATISLAVA
PA DUBRAVSKA CESTA 9, BRATISLAVA, SLOVAK REPUBLIC
SN 0039-3320
J9 STUD PSYCHOL
JI Studia Psychol.
PY 2001
VL 43
IS 3
BP 171
EP 180
PG 10
WC Psychology, Multidisciplinary
WE Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Social Science Citation Index (SSCI)
SC Psychology
GA 493KM
UT WOS:000172221800001
DA 2023-06-23
ER

PT J
AU Chatterjee, B
   Agarwal, A
   Singh, RKL
   Adarkar, S
   Ambekar, A
   Rao, R
   Khandelwal, SK
AF Chatterjee, Biswadip
   Agarwal, Alok
   Singh, Raj Kumar Lenin
   Adarkar, Shilpa
   Ambekar, Atul
   Rao, Ravindra
   Khandelwal, Sudhir K.
TI "Drug Treatment Clinics": A Government of India Scheme to Promote
   Affordable, Accessible and Quality Addiction Treatment Services in India
SO INDIAN JOURNAL OF PSYCHIATRY
LA English
DT Meeting Abstract
DE DTC; RRTC; Drug treatment Clinic; DDAP; de-addiction treatment
C1 [Chatterjee, Biswadip] All India Inst Med Sci, NDDTC, New Delhi, India.
   [Chatterjee, Biswadip] All India Inst Med Sci, Dept Psychiat, New Delhi, India.
C3 All India Institute of Medical Sciences (AIIMS) New Delhi; National Drug
   Dependence Treatment Centre (NDDTC); All India Institute of Medical
   Sciences (AIIMS) New Delhi
EM biswadip.c@gmail.com
RI CHATTERJEE, BISWADIP/D-2917-2013
OI CHATTERJEE, BISWADIP/0000-0002-3812-9147
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0019-5545
EI 1998-3794
J9 INDIAN J PSYCHIAT
JI Indian J. Psychiatry
PD JAN
PY 2016
VL 58
IS 5
SU S
BP S29
EP S29
PG 1
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA EH9PR
UT WOS:000392103800094
DA 2023-06-23
ER

PT S
AU Kreek, MJ
AF Kreek, MJ
BE QuinonesJenab, V
TI Drug addictions - Molecular and cellular endpoints
SO BIOLOGICAL BASIS OF COCAINE ADDICTION
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT Seminar on Frontiers in Drug Abuse Research: Molecular and Cellular
   Adaptations to Cocaine
CY 2000
CL NEW YORK, NY
SP Natl Inst Hlth, City Univ New York, Grad Ctr & Biopsychol Doc Program
DE addiction; alcohol; cocaine; drug addiction; neurobiology; opioid
   receptors
ID MU-OPIOID RECEPTOR; MESSENGER-RNA LEVELS; POSITRON-EMISSION-TOMOGRAPHY;
   NALTREXONE MAINTENANCE TREATMENT; ACUTE INTERMITTENT MORPHINE; IN-VIVO
   MICRODIALYSIS; CHRONIC BINGE COCAINE; RAT CAUDATE-PUTAMEN; EX-OPIATE
   ADDICTS; BETA-ENDORPHIN
AB Addiction to alcohol, tobacco, and illicit drugs of abuse continues to be one of the most significant medical, social, and economic problems facing our society. Since the mid-1960s, addictions have been recognized as diseases. We have hypothesized that three domains of factors contribute to the development and persistence of addictions: inherited or genetic differences in individual physiology, alterations in physiology induced by drugs or alcohol, and environmental or developmental factors. Neurochemical alterations in the brain caused by addictive drugs have a cellular and molecular basis and, in the setting of repeated self-exposure, which can lead to addiction, these changes may be persistent or even permanent. Such altered molecular, cellular, and neurophysiological "set points" in the brain, in turn, contribute to alterations in behavior with implications for the specific addictive diseases.
C1 Rockefeller Univ Hosp, New York, NY 10021 USA.
   Lab Biol Addict Dis, New York, NY USA.
C3 Rockefeller University
RP Kreek, MJ (通讯作者)，Rockefeller Univ Hosp, 1230 York Ave, New York, NY 10021 USA.
EM kreek@rockvax.rockefeller.edu
FU NCRR NIH HHS [M01-RR00102] Funding Source: Medline; NIDA NIH HHS
   [P50-DA05130, KO5-DA00049, R01-DA09444, R01-DA12848] Funding Source:
   Medline
CR Berrettini WH, 1997, ADDICT BIOL, V2, P303, DOI 10.1080/13556219772598
   Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608
   Borg L, 1999, J ADDICT DIS, V18, P63, DOI 10.1300/J069v18n04_06
   BORG L, 1998, PROBLEMS DRUG DEPEND, V178, P167
   BRANCH AD, 1992, MOL BRAIN RES, V14, P231, DOI 10.1016/0169-328X(92)90178-E
   Centers for Disease Control (CDC), 1984, MMWR Morb Mortal Wkly Rep, V33, P377
   CHEN Y, 1993, MOL PHARMACOL, V44, P8
   CHEN Y, 1993, BIOCHEM J, V295, P625, DOI 10.1042/bj2950625
   Claye LH, 1996, J PHARMACOL EXP THER, V277, P359
   CLAYE LH, 1997, PROBLEMS DRUG DEPEND, V174, P113
   CulpepperMorgan JA, 1997, METABOLISM, V46, P130, DOI 10.1016/S0026-0495(97)90289-4
   CULPEPPERMORGAN JA, 1992, CLIN PHARMACOL THER, V52, P90, DOI 10.1038/clpt.1992.106
   CUSHMAN P, 1974, NEW YORK STATE J MED, V74, P1970
   DAUNAIS JB, 1993, NEUROREPORT, V4, P543, DOI 10.1097/00001756-199305000-00020
   DESJARLAIS DC, 1989, JAMA-J AM MED ASSOC, V261, P1008, DOI 10.1001/jama.261.7.1008
   *DHHS, 1998, SAMHSA NAT HOUS SURV
   DOLE VP, 1966, ARCH INTERN MED, V118, P304, DOI 10.1001/archinte.118.4.304
   DOLE VP, 1970, ANNU REV BIOCHEM, V39, P821, DOI 10.1146/annurev.bi.39.070170.004133
   EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167
   GOLDSTEIN A, 1971, P NATL ACAD SCI USA, V68, P1742, DOI 10.1073/pnas.68.8.1742
   HACHEY DL, 1977, J PHARM SCI, V24, P1579
   INGOGLIA NA, 1970, J PHARMACOL EXP THER, V175, P84
   INTURRISI CE, 1972, CLIN PHARMACOL THER, V13, P633
   INTURRISI CE, 1984, NEW ENGL J MED, V310, P1213, DOI 10.1056/NEJM198405103101902
   INTURRISI CE, 1972, J CHROMATOGR, V65, P361, DOI 10.1016/S0021-9673(00)92558-5
   Judd LL, 1998, JAMA-J AM MED ASSOC, V280, P1936
   KENNEDY JA, 1990, BRIT J ADDICT, V85, P1133
   KIEFFER BL, 1994, P NATL ACAD SCI USA, V91, P1193, DOI 10.1073/pnas.91.3.1193b
   KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048
   King AC, 1999, DRUG ALCOHOL DEPEN, V54, P87, DOI 10.1016/S0376-8716(98)00150-1
   KOSTEN TR, 1986, LIFE SCI, V39, P55, DOI 10.1016/0024-3205(86)90437-6
   KOSTEN TR, 1986, BIOL PSYCHIAT, V21, P217, DOI 10.1016/0006-3223(86)90150-2
   KOSTEN TR, 1992, BIOL PSYCHIAT, V32, P523, DOI 10.1016/0006-3223(92)90220-T
   Kreek M J, 1978, Ann N Y Acad Sci, V311, P110, DOI 10.1111/j.1749-6632.1978.tb16769.x
   Kreek M J, 1991, NIDA Res Monogr, V106, P245
   Kreek M. J., 1987, PSYCHOPHARMACOLOGY 3, P1597
   KREEK MJ, 1982, ANN NY ACAD SCI, V398, P151, DOI 10.1111/j.1749-6632.1982.tb39489.x
   KREEK MJ, 1973, NEW YORK STATE J MED, V73, P2773
   KREEK MJ, 1984, NEUROPEPTIDES, V5, P277, DOI 10.1016/0143-4179(84)90081-7
   Kreek MJ, 1996, NEUROCHEM RES, V21, P1469, DOI 10.1007/BF02532387
   KREEK MJ, 1973, JAMA-J AM MED ASSOC, V223, P665, DOI 10.1001/jama.223.6.665
   KREEK MJ, 1979, LIFE SCI, V24, P925, DOI 10.1016/0024-3205(79)90343-6
   KREEK MJ, 1992, RES P ARNMD, V70, P205
   KREEK MJ, 1983, LANCET, V1, P261, DOI 10.1016/S0140-6736(83)91684-7
   Kreek MJ, 1996, MOL PSYCHIATR, V1, P232
   KREEK MJ, 1983, LIFE SCI, V33, P409, DOI 10.1016/0024-3205(83)90529-5
   Kreek MJ, 1999, J PHARMACOL EXP THER, V288, P260
   Kreek MJ, 1974, NARCOTIC HYPOTHALAMU, P161
   KREEK MJ, 1995, FEDERAL REGULATION M, P37
   Kreek MJ, 1981, ADV ENDOGENOUS EXOGE, P364
   Kreek MJ, 1972, P 4 NAT C METH TREAT, P171, DOI [DOI 10.1001/JAMA.223.6.665, 10.1001/jama.223.6.665]
   KREEK MJ, 2000, PROBLEMS DRUG DEPEND, V180, P3
   KREEK MJ, 1973, METHADONE TREATMENT, P85
   KREEK MJ, 1990, P 3 INT C ETH MED NO, P181
   Kreek MJ, 1984, INT C SERIES, V652, P845
   LaForge KS, 2000, AM J MED GENET, V96, P604, DOI 10.1002/1096-8628(20001009)96:5<604::AID-AJMG5>3.0.CO;2-F
   LAFORGE KS, 2000, PROBLEMS DRUG DEPEND, V180, P47
   Maggos CE, 1998, NEUROPSYCHOPHARMACOL, V19, P146, DOI 10.1016/S0893-133X(98)00009-8
   MAISONNEUVE IM, 1995, J PHARMACOL EXP THER, V272, P652
   MAISONNEUVE IM, 1994, J PHARMACOL EXP THER, V268, P916
   Nakamura K, 1982, J PHARM SCI, V71, P39
   Novick D M, 1986, NIDA Res Monogr, V67, P318
   NOVICK DM, 1986, B NARCOTICS, V38, P15
   NOVICK DM, 1988, J INFECT DIS, V158, P795, DOI 10.1093/infdis/158.4.795
   PERT CB, 1973, P NATL ACAD SCI USA, V70, P2243, DOI 10.1073/pnas.70.8.2243
   Portenoy RK, 1999, CLIN DRUG INVEST, V17, P33, DOI 10.2165/00044011-199917010-00004
   RAGAVAN VV, 1983, NEUROENDOCRINOLOGY, V37, P266, DOI 10.1159/000123556
   ROSEN MI, 1995, AM J DRUG ALCOHOL AB, V21, P453, DOI 10.3109/00952999509002710
   SCHLUGER J, 1998, PROBLEMS DRUG DEPEND, V178, P105
   Schluger JH, 1998, ALCOHOL CLIN EXP RES, V22, P1430, DOI 10.1111/j.1530-0277.1998.tb03931.x
   SIMON EJ, 1973, P NATL ACAD SCI USA, V70, P1947, DOI 10.1073/pnas.70.7.1947
   Spangler R, 1996, NEUROREPORT, V7, P2196, DOI 10.1097/00001756-199609020-00028
   Spangler R, 1997, MOL BRAIN RES, V44, P139, DOI 10.1016/S0169-328X(96)00249-5
   Spangler R, 1996, MOL BRAIN RES, V38, P71, DOI 10.1016/0169-328X(95)00319-N
   SPANGLER R, 1993, MOL BRAIN RES, V19, P323, DOI 10.1016/0169-328X(93)90133-A
   Spangler R, 1997, BEHAV BRAIN RES, V86, P201, DOI 10.1016/S0166-4328(96)02257-7
   Specker S, 1998, PSYCHOPHARMACOLOGY, V137, P326, DOI 10.1007/s002130050626
   Stimmel B, 1975, HEROIN DEPENDENCY ME, P71
   Stimmel B, 1975, HEROIN DEPENDENCY ME, P88
   TERENIUS L, 1973, ACTA PHARMACOL TOX, V32, P317
   Tsuang MT, 1998, ARCH GEN PSYCHIAT, V55, P967, DOI 10.1001/archpsyc.55.11.967
   Tsukada H, 1996, J NEUROSCI, V16, P7670
   UNTERWALD EM, 1994, J PHARMACOL EXP THER, V270, P1387
   UNTERWALD EM, 1995, MOL BRAIN RES, V33, P351, DOI 10.1016/0169-328X(95)00143-G
   UNTERWALD EM, 1992, BRAIN RES, V584, P314, DOI 10.1016/0006-8993(92)90912-S
   UNTERWALD EM, 1994, NEUROREPORT, V5, P1613, DOI 10.1097/00001756-199408150-00018
   Unterwald EM, 1997, BRAIN RES, V775, P183, DOI 10.1016/S0006-8993(97)00931-1
   WANG JB, 1993, P NATL ACAD SCI USA, V90, P10230, DOI 10.1073/pnas.90.21.10230
   Wang XM, 1999, MOL BRAIN RES, V66, P184, DOI 10.1016/S0169-328X(99)00021-2
   Yuferov V, 1999, BRAIN RES BULL, V48, P109, DOI 10.1016/S0361-9230(98)00155-5
   Zhou Y, 1999, J ENDOCRINOL, V163, P261, DOI 10.1677/joe.0.1630261
   Zhou Y, 1999, NEUROENDOCRINOLOGY, V70, P196, DOI 10.1159/000054476
   Zhou Y, 1996, J PHARMACOL EXP THER, V279, P351
NR 93
TC 69
Z9 71
U1 6
U2 35
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA
SN 0077-8923
BN 1-57331-303-3
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2001
VL 937
BP 27
EP 49
PG 23
WC Substance Abuse; Multidisciplinary Sciences
WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Substance Abuse; Science & Technology - Other Topics
GA BT11P
UT WOS:000172010800002
PM 11458539
DA 2023-06-23
ER

PT J
AU Hou, HF
   Wang, CY
   Jia, SW
   Hu, S
   Tian, M
AF Hou, Haifeng
   Wang, Chunyan
   Jia, Shaowei
   Hu, Shu
   Tian, Mei
TI Brain dopaminergic system changes in drug addiction: a review of
   positron emission tomography findings
SO NEUROSCIENCE BULLETIN
LA English
DT Review
DE dopamine; dopaminergic system; drug addiction; positron emission
   tomography
ID MONOAMINE TRANSPORTER BINDING; C-11 BETA-CIT; RECEPTOR AVAILABILITY;
   METHAMPHETAMINE ABUSERS; BEHAVIORAL ADDICTIONS; PARKINSONS-DISEASE;
   COCAINE ABUSERS; BABOON BRAIN; DSM-V; ABSTINENT METHAMPHETAMINE
AB Dopamine (DA) is considered crucial for the rewarding effects of drugs of abuse, but its role in addiction remains unclear. Positron emission tomography (PET) is the first technology used for in vivo measurement of components of the dopaminergic system in the human brain. In this article, we review the major findings from PET imaging studies on the involvement of DA in drug addiction, including presynaptic DA synthesis, vesicular monoamine transporter 2, the DA transporter, and postsynaptic DA receptors. These results have corroborated the role of DA in addiction and increased the understanding of its underlying mechanisms.
C1 [Hou, Haifeng; Tian, Mei] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Nucl Med, Hangzhou 310009, Zhejiang, Peoples R China.
   [Hou, Haifeng; Tian, Mei] Zhejiang Univ, Med PET Ctr, Hangzhou 310009, Zhejiang, Peoples R China.
   [Hou, Haifeng; Tian, Mei] Zhejiang Univ, Inst Nucl Med & Mol Imaging, Hangzhou 310009, Zhejiang, Peoples R China.
   [Hou, Haifeng; Tian, Mei] Key Lab Med Mol Imaging Zhejiang Prov, Hangzhou 310009, Zhejiang, Peoples R China.
   [Wang, Chunyan] Beijing 307 Hosp, Beijing 100071, Peoples R China.
   [Jia, Shaowei; Hu, Shu] Peking Univ, Shenzhen Hosp, Dept Nucl Med, Shenzhen 518036, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang University; Fifth
   Medical Center of Chinese PLA General Hospital; Peking University
RP Tian, M (通讯作者)，Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Nucl Med, Hangzhou 310009, Zhejiang, Peoples R China.
EM meitian@gmail.com
FU National Basic Research Development Program of China [2013CB329506];
   National Natural Science Foundation of China [81301243, 81271601];
   Research Fund for the Doctoral Program of Higher Education of China
   [20120101120031, 20130101110015]; Health Bureau of Zhejiang Province
   [2014KYA095, WKJ2013-2-016]; Scientific Research Foundation for Doctors
   of Second Affiliated Hospital of Zhejiang University School of Medicine
   [Y560252013]; Natural Science Foundation of Zhejiang Province, China
   [LR13H180001]
FX This review was partly sponsored by the National Basic Research
   Development Program of China (2013CB329506), the National Natural
   Science Foundation of China (81301243 and 81271601), the Research Fund
   for the Doctoral Program of Higher Education of China (20120101120031
   and 20130101110015), grants from the Health Bureau of Zhejiang Province
   (2014KYA095, and WKJ2013-2-016), the Scientific Research Foundation for
   Doctors of Second Affiliated Hospital of Zhejiang University School of
   Medicine (Y560252013), and the Natural Science Foundation of Zhejiang
   Province, China (LR13H180001).
CR ARNETT CD, 1985, LIFE SCI, V36, P1359, DOI 10.1016/0024-3205(85)90041-4
   Bancroft J, 2004, J SEX RES, V41, P225, DOI 10.1080/00224490409552230
   Block JJ, 2008, AM J PSYCHIAT, V165, P306, DOI 10.1176/appi.ajp.2007.07101556
   Boileau I, 2008, J NEUROSCI, V28, P9850, DOI 10.1523/JNEUROSCI.3008-08.2008
   Boileau I, 2010, SYNAPSE, V64, P417, DOI 10.1002/syn.20743
   Callier S, 2003, BIOL CELL, V95, P489, DOI 10.1016/S0248-4900(03)00089-3
   Cami J, 2003, NEW ENGL J MED, V349, P975, DOI 10.1056/NEJMra023160
   CANFIELD DR, 1990, SYNAPSE, V6, P189, DOI 10.1002/syn.890060211
   CHRISTMA.DR, 1970, J NUCL MED, V11, P474
   Czoty PW, 2007, J ADDICT MED, V1, P33, DOI 10.1097/ADM.0b013e318045c038
   DACKIS CA, 1985, NEUROSCI BIOBEHAV R, V9, P469, DOI 10.1016/0149-7634(85)90022-3
   Dagher A, 2001, SYNAPSE, V42, P48, DOI 10.1002/syn.1098
   DEJESUS OT, 1986, APPL RADIAT ISOTOPES, V37, P719, DOI 10.1016/0883-2889(86)90266-2
   DEWEY SL, 1991, SYNAPSE, V7, P324, DOI 10.1002/syn.890070409
   Ding YS, 1997, PSYCHOPHARMACOLOGY, V131, P71, DOI 10.1007/s002130050267
   DING YS, 1995, J NUCL MED, V36, P2298
   Eiden LE, 2011, ANN NY ACAD SCI, V1216, P86, DOI 10.1111/j.1749-6632.2010.05906.x
   FARDE L, 1994, SYNAPSE, V16, P93, DOI 10.1002/syn.890160203
   Fehr C, 2008, AM J PSYCHIAT, V165, P507, DOI 10.1176/appi.ajp.2007.07020352
   FISCHMAN MW, 1991, BRIT J ADDICT, V86, P1563
   Fowler JS, 2001, NUCL MED BIOL, V28, P561, DOI 10.1016/S0969-8051(01)00211-6
   Franken IHA, 2005, EUR J PHARMACOL, V526, P199, DOI 10.1016/j.ejphar.2005.09.025
   FROST JJ, 1993, ANN NEUROL, V34, P423, DOI 10.1002/ana.410340331
   GARRIS PA, 1994, J NEUROSCI, V14, P6084
   Goodman A, 2008, BIOCHEM PHARMACOL, V75, P266, DOI 10.1016/j.bcp.2007.07.030
   Grant JE, 2010, AM J DRUG ALCOHOL AB, V36, P233, DOI 10.3109/00952990.2010.491884
   Halldin C, 1998, J NUCL MED, V39, P2061
   Heinz A, 2005, AM J PSYCHIAT, V162, P1515, DOI 10.1176/appi.ajp.162.8.1515
   HIETALA J, 1994, PSYCHOPHARMACOLOGY, V116, P285, DOI 10.1007/BF02245330
   Hirvonen J, 2001, J CEREBR BLOOD F MET, V21, P1146, DOI 10.1097/00004647-200110000-00002
   Holden C, 2001, SCIENCE, V294, P980, DOI 10.1126/science.294.5544.980
   Holden C, 2010, SCIENCE, V327, P935, DOI 10.1126/science.327.5968.935
   Hou HF, 2012, ANAT REC, V295, P722, DOI 10.1002/ar.22457
   HURD YL, 1993, SYNAPSE, V13, P357, DOI 10.1002/syn.890130408
   Johanson CE, 2006, PSYCHOPHARMACOLOGY, V185, P327, DOI 10.1007/s00213-006-0330-6
   Kienast T, 2013, PHARMACOPSYCHIATRY, V46, P130, DOI 10.1055/s-0032-1331747
   Kilbourn MR, 2010, NUCL MED BIOL, V37, P3, DOI 10.1016/j.nucmedbio.2009.08.013
   Klongpanichapak S, 2006, NEUROCHEM RES, V31, P303, DOI 10.1007/s11064-005-9025-3
   KOOB GF, 1989, NEUROSCI BIOBEHAV R, V13, P135, DOI 10.1016/S0149-7634(89)80022-3
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Lee D, 2000, MOL PSYCHIATR, V5, P39, DOI 10.1038/sj.mp.4000601
   Little KY, 1999, AM J PSYCHIAT, V156, P238
   Mach RH, 1997, PHARMACOL BIOCHEM BE, V57, P477, DOI 10.1016/S0091-3057(96)00449-2
   Mach RH, 2000, SYNAPSE, V37, P109, DOI 10.1002/1098-2396(200008)37:2<109::AID-SYN5>3.0.CO;2-3
   Maddux JF, 2000, ADDICTION, V95, P661, DOI 10.1046/j.1360-0443.2000.9556611.x
   Mansi L, 2014, EUR J NUCL MED MOL I, V41, P1385, DOI 10.1007/s00259-014-2765-z
   MARKOU A, 1991, NEUROPSYCHOPHARMACOL, V4, P17
   Martin WR, 2008, ANN NEUROL, V63, P388, DOI 10.1002/ana.21320
   Martinez D, 2009, NEUROPSYCHOPHARMACOL, V34, P1774, DOI 10.1038/npp.2008.235
   McCann UD, 1998, J NEUROSCI, V18, P8417
   Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189
   Nader MA, 2006, NAT NEUROSCI, V9, P1050, DOI 10.1038/nn1737
   Nanni C, 2007, J NUCL MED, V48, P1577, DOI 10.2967/jnumed.107.041947
   Narendran R, 2012, AM J PSYCHIAT, V169, P55, DOI 10.1176/appi.ajp.2011.11010126
   O'Brien C, 2011, ADDICTION, V106, P866, DOI 10.1111/j.1360-0443.2010.03144.x
   Pelchat ML, 2009, J NUTR, V139, P620, DOI 10.3945/jn.108.097816
   Pichler BJ, 2010, J NUCL MED, V51, P333, DOI 10.2967/jnumed.109.061853
   Pichler Bernd J., 2008, V185, P109, DOI 10.1007/978-3-540-72718-7_6
   RINNE JO, 1995, SYNAPSE, V21, P97, DOI 10.1002/syn.890210202
   Salokangas RKR, 2000, AM J PSYCHIAT, V157, P632, DOI 10.1176/appi.ajp.157.4.632
   Schiffer WK, 2005, DRUG DISCOV TODAY, V10, P547, DOI 10.1016/S1359-6446(05)03412-4
   Schlaepfer TE, 1997, AM J PSYCHIAT, V154, P1209
   Sekine Y, 2001, AM J PSYCHIAT, V158, P1206, DOI 10.1176/appi.ajp.158.8.1206
   Sekine Y, 2003, AM J PSYCHIAT, V160, P1699, DOI 10.1176/appi.ajp.160.9.1699
   Shi J, 2008, EUR J PHARMACOL, V579, P160, DOI 10.1016/j.ejphar.2007.09.042
   Slifstein M, 2007, J CEREBR BLOOD F MET, V27, P1733, DOI 10.1038/sj.jcbfm.9600468
   Smythies John, 2005, Int Rev Neurobiol, V64, P123, DOI 10.1016/S0074-7742(05)64002-0
   Tai YF, 2011, NEUROPSYCHOPHARMACOL, V36, P735, DOI 10.1038/npp.2010.201
   Tian M, 2014, EUR J NUCL MED MOL I, V41, P1388, DOI 10.1007/s00259-014-2708-8
   Tiihonen J, 1998, MOL PSYCHIATR, V3, P156, DOI 10.1038/sj.mp.4000365
   Turjanski N, 1999, NEUROLOGY, V52, P932, DOI 10.1212/WNL.52.5.932
   Urban NBL, 2012, PSYCHIAT CLIN N AM, V35, P521, DOI 10.1016/j.psc.2012.03.011
   Vallone D, 2000, NEUROSCI BIOBEHAV R, V24, P125, DOI 10.1016/S0149-7634(99)00063-9
   Villemagne V, 1998, J NEUROSCI, V18, P419
   Volkow ND, 2009, NEUROPHARMACOLOGY, V56, P3, DOI 10.1016/j.neuropharm.2008.05.022
   Volkow ND, 2004, MOL PSYCHIATR, V9, P557, DOI 10.1038/sj.mp.4001507
   Volkow ND, 2003, SEMIN NUCL MED, V33, P114, DOI 10.1053/snuc.2003.127300
   Volkow ND, 2002, PSYCHIAT RES-NEUROIM, V116, P163, DOI 10.1016/S0925-4927(02)00087-2
   Volkow ND, 2001, J NEUROSCI, V21, P9414, DOI 10.1523/JNEUROSCI.21-23-09414.2001
   Volkow ND, 1996, ALCOHOL CLIN EXP RES, V20, P1594, DOI 10.1111/j.1530-0277.1996.tb05936.x
   VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210
   Volkow ND, 2001, AM J PSYCHIAT, V158, P2015, DOI 10.1176/appi.ajp.158.12.2015
   Volkow ND, 1996, NEUROPSYCHOPHARMACOL, V14, P159, DOI 10.1016/0893-133X(95)00073-M
   VOLKOW ND, 1990, AM J PSYCHIAT, V147, P719
   VOLKOW ND, 1995, ARCH GEN PSYCHIAT, V52, P456
   Volkow ND, 2011, P NATL ACAD SCI USA, V108, P15037, DOI 10.1073/pnas.1010654108
   Wang GJ, 1997, NEUROPSYCHOPHARMACOL, V16, P174, DOI 10.1016/S0893-133X(96)00184-4
   WELCH MJ, 1984, ANN NEUROL, V15, pS77
   Wise RA, 2009, TRENDS NEUROSCI, V32, P517, DOI 10.1016/j.tins.2009.06.004
   Wu JC, 1997, NEUROPSYCHOPHARMACOL, V17, P402, DOI 10.1016/S0893-133X(97)00089-4
   Yasuno F, 2007, BIOL PSYCHIAT, V61, P1252, DOI 10.1016/j.biopsych.2006.06.028
NR 91
TC 21
Z9 21
U1 6
U2 68
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1673-7067
EI 1995-8218
J9 NEUROSCI BULL
JI Neurosci. Bull.
PD OCT
PY 2014
VL 30
IS 5
SI SI
BP 765
EP 776
DI 10.1007/s12264-014-1469-5
PG 12
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA AQ1PV
UT WOS:000342554200005
PM 25260796
OA Green Published
DA 2023-06-23
ER

PT J
AU el-Guebaly, N
AF el-Guebaly, Nady
TI A Canadian Perspective on Addiction Treatment
SO SUBSTANCE ABUSE
LA English
DT Article
DE Addiction treatment; Canada; drug strategy
AB This paper presents a synopsis of addiction treatment in Canada, along with some available comparative figures with other North American countries. Within the framework of Canada's Medicare, a largely single-payer system, addiction and psychiatric disorders are insured on par with other medical disorders. Canada's strategy recognizes the four pillars of prevention, treatment, harm reduction, and enforcement. The Canadian Alcohol and Drug Use Monitoring Survey is the yearly main source of data on alcohol and illicit drug use. The main features of the Canadian addiction treatment network are identified as a "top 10" list, outlining early identification and intervention, assessment, and referral; detoxification; ambulatory care/day treatment programs; residential care; hospitals; concurrent disorders networks and regionalization; drug specific strategies; mutual help; behavioral addictions; and training, qualification, and research.
C1 [el-Guebaly, Nady] Univ Calgary, Addict Div, Calgary, AB, Canada.
C3 University of Calgary
RP el-Guebaly, N (通讯作者)，Foothills Prov Gen Hosp, Addict Ctr, 1403 29th St NW, Calgary, AB T2N 2T9, Canada.
EM nady.el-guebaly@albertahealthservices.ca
CR Alberta Health Services, 2013, EV DOOR IS RIGHT DOO
   Canadian Centre on Substance Abuse, 2010, BEH COMP CAN SUBST A
   Canadian Centre on Substance Abuse, DAT ADD ORG CAN
   Canadian Society of Addiction Medicine, 2012, MED US CANN PERSP PO
   Centre for Addiction and Mental Health, 2010, BEST PRACT CONC MENT
   Collin C., 2006, SUBSTANCE ABUSE ISSU
   Crockford DN, 2009, APPROACHES POSTGRADU, P167
   el-Guebaly N, 2007, ISSUES SUBSTANCE 200
   El-Guebaly N, 2008, CURR OPIN PSYCHIATR, V21, P116, DOI 10.1097/YCO.0b013e3282f57dec
   el-Guebaly N, 2012, J ADDICT MED, V6, P1, DOI 10.1097/ADM.0b013e31823ae540
   el-Guebaly N, 2011, SUBST ABUS, V32, P93, DOI 10.1080/08897077.2011.555705
   Health Canada, 2011, CAN ALC DRUG US MON
   Health Canada, MAR MED PURP REG
   Kahan M, 2011, CSAM POSITION STATEM
   Kates N, 2011, CAN J PSYCHIAT, V56, pB1
   Luce J, 2011, CANADIAN EXECUTIVE C
   Midner D, 2002, ANN R COLL PHYS S S1, V35, P1
   Mudry TE, 2011, CURR PSYCHIATRY REV, V7, P138, DOI 10.2174/157340011796391201
   Oviedo-Joekes E, 2009, NEW ENGL J MED, V361, P777, DOI 10.1056/NEJMoa0810635
   Substance Abuse and Mental Health Services Administration (SAMHSA)-Center for Integrated Health Solutions Department of Health and Human Services, 2014, SBIRT SCREEN BRIEF I
   SULLIVAN JT, 1989, BRIT J ADDICT, V84, P1353
   Tyhurst J. S., 1963, MORE MIND STUDY PSYC
   Wood E, 2006, NEW ENGL J MED, V354, P2512, DOI 10.1056/NEJMc052939
NR 23
TC 4
Z9 4
U1 1
U2 12
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0889-7077
EI 1547-0164
J9 SUBST ABUS
JI Subst. Abus.
PY 2014
VL 35
IS 3
BP 298
EP 303
DI 10.1080/08897077.2014.923362
PG 6
WC Substance Abuse
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse
GA AP7VA
UT WOS:000342284200014
PM 24857633
DA 2023-06-23
ER

PT J
AU Diana, M
   Fattore, L
AF Diana, Marco
   Fattore, Liana
TI Editorial: The Therapeutic Potential of Transcranial Magnetic
   Stimulation in Addiction
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Editorial Material
DE drug addiction; gambling; neuromodulation; food addiction; TMS
   (repetitive transcranial magnetic stimulation); virtual reality
C1 [Diana, Marco] Univ Sassari, Dept Chem & Pharm, G Minardi Lab Cognit Neurosci, Sassari, Italy.
   [Fattore, Liana] CNR, CNR Inst Neurosci Cagliari, Rome, Italy.
C3 University of Sassari; Consiglio Nazionale delle Ricerche (CNR);
   Istituto di Neuroscienze (IN-CNR)
RP Diana, M (通讯作者)，Univ Sassari, Dept Chem & Pharm, G Minardi Lab Cognit Neurosci, Sassari, Italy.
EM dsfdiana@uniss.it
CR [Anonymous], 2020, WORLD DRUG REP
   Diana M, 2017, NAT REV NEUROSCI, V18, P685, DOI 10.1038/nrn.2017.113
   Fattore L, 2016, NEUROSCI BIOBEHAV R, V65, P341, DOI 10.1016/j.neubiorev.2016.04.006
   Lyden J, 2019, SEMIN PERINATOL, V43, P123, DOI 10.1053/j.semperi.2019.01.001
   Peele Stanton, 2016, Addict Behav Rep, V4, P97, DOI 10.1016/j.abrep.2016.05.003
   Quoilin C, 2018, NEUROPSYCHOPHARMACOL, V43, P1851, DOI 10.1038/s41386-018-0074-0
   Ritter A, 2006, DRUG ALCOHOL REV, V25, P611, DOI 10.1080/09595230600944529
   Weinstein AM, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00156
NR 8
TC 1
Z9 1
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD NOV 23
PY 2020
VL 14
AR 614642
DI 10.3389/fnins.2020.614642
PG 2
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA PB7HS
UT WOS:000596488400001
PM 33328878
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Schnoll, SH
AF Schnoll, Sidney H.
TI REFLECTIONS OF AN ACADEMIC CLINICAL RESEARCHER ON THE PAST 40 YEARS OF
   ADDICTION DEVELOPMENT
SO JOURNAL OF DRUG ISSUES
LA English
DT Article
AB This paper reflects on three areas of addiction: prescription drug abuse, perinatal addiction, and the clinical fields of addiction medicine and addiction psychiatry. The concerns about the abuse and misuse of prescription drugs date back over a century with numerous laws passed to address these problems. Despite these laws, there has been increasing concern over the past decade about the increases in the nonmedical use and abuse of prescription drugs. This begs the question of whether the passing of laws addressing the supply side of the problem is the correct approach. Abuse of licit and illicit drugs by pregnant women creates concern because of the effects of drugs and alcohol on the fetus and future development of the child. Most of the studies have addressed newborn development without adequate studies of the effects of the drugs and withdrawal on pregnancy and the fetus. In addition, studies of long-term effects on the development of the child are needed. The only way to adequately address these important clinical issues will be to have well-trained clinicians and clinical investigators in addiction medicine and addiction psychiatry.
C1 [Schnoll, Sidney H.] Virginia Commonwealth Univ, Sch Med, Internal Med & Psychiat, Richmond, VA 23284 USA.
C3 Virginia Commonwealth University
CR BRITT GC, 1999, SOURCEBOOK SUBSTANCE, P75
   Courtwright D. T., 1982, DARK PARADISE HIST O
   FINNEGAN LP, 2008, TXB SUBSTANCE ABUSE, P565
   Mandel Jerry, MYTHICAL ROOTS US DR
   MARKS J, 1915, CURSE NARCOTISM AM, P315
   Musto D., 1973, AM DIS
   *SAMHSA, 2008, TYP ILL DRUG US LIF
   *SAMHSA, 2008, ANN NUMB NEW US MAR
   SEES KL, 1993, J PAIN SYMPTOM MANAG, V8, P257, DOI 10.1016/0885-3924(93)90154-N
   STARKEY G, 1971, DRUG DEPENDENCE ABUS, P482
NR 10
TC 0
Z9 0
U1 0
U2 0
PU J DRUG ISSUES INC
PI TALLAHASSEE
PA FLORIDA STATE UNIV, SCHOOL CRIMINOLOGY CRIMINAL JUSTICE, PO BOX 66696,
   TALLAHASSEE, FL 32313-6696 USA
SN 0022-0426
J9 J DRUG ISSUES
JI J. Drug Issues
PD WIN
PY 2009
VL 39
IS 1
BP 21
EP 28
DI 10.1177/002204260903900103
PG 8
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA 451ZH
UT WOS:000266508900004
DA 2023-06-23
ER

PT J
AU Farrugia, A
   Fraser, S
AF Farrugia, Adrian
   Fraser, Suzanne
TI Young brains at risk: Co-constituting youth and addiction in
   neuroscience-informed Australian drug education
SO BIOSOCIETIES
LA English
DT Article
DE addiction; youth; drug education; neuroscience; Bruno Latour; Annemarie
   Mol and John Law
ID ADOLESCENT BRAIN; ONTOLOGICAL POLITICS; PREVENTION PROGRAMS; PUBLIC
   DISCOURSE; HEPATITIS-C; SAY KNOW; SCIENCE; RESISTANCE; INCREASES;
   ACCOUNTS
AB This article explores the developing relationship between neuroscientific under-standings of 'addiction' and 'youth'. Drawing on science and technology studies theory and social scientific analyses of both these concepts, it identifies a co-constitutive relationship between notions of addiction as a brain disease and of youth as a stage of brain development. These two concepts are then tracked in a series of drug education documents concerned with alcohol and other drug (AOD) use and addiction among young people, and their implications and effects and analysed together. The aim is to investigate the impact on drug education of neuroscientific approaches to youth and addiction. Are new concepts and directions for harm reduction created in the encounters between neuroscience, youth and addiction, or do they simply reinstate and reinforce existing assumptions and judgments? Is drug education shaped by these concepts likely to achieve its aim, that is, to increase young people's sensitivity to harm and safety? The article begins by introducing neuroscientific accounts of youth and addiction, arguing that the two concepts share three key assumptions. First, both emphasise biology and sideline social context in the making of drug use practices and outcomes. Second, both reproduce uncritical treatments of brain scans (PET and fMRI images) as windows into minds and subjects. Third, both understand the brain as ontologically separate from its environment. These assumptions and their implications are then tracked through an analysis of Australian drug education resources, focusing on how drug education constitutes youthfulness and addiction as pathological disorders. In its reliance on neuroscientific understandings of youth and addiction, we conclude, drug education is unlikely to achieve its goal of reducing drug-related harm.
C1 [Farrugia, Adrian; Fraser, Suzanne] Curtin Univ, Natl Drug Res Inst, Suite 6,19-35 Gertrude St, Fitzroy, Vic 3065, Australia.
C3 Curtin University
RP Farrugia, A (通讯作者)，Curtin Univ, Natl Drug Res Inst, Suite 6,19-35 Gertrude St, Fitzroy, Vic 3065, Australia.
EM adrian.farrugia@curtin.edu.au
OI Fraser, Suzanne/0000-0003-1018-5865; Farrugia,
   Adrian/0000-0003-3751-9060
FU Australian Government under the Substance Misuse Prevention and Service
   Improvement Grants Fund; Australian Research Council Future Fellowship
   [FT120100215]
FX The National Drug Research Institute at Curtin University is supported
   by funding from the Australian Government under the Substance Misuse
   Prevention and Service Improvement Grants Fund. Suzanne Fraser's
   research is supported by Australian Research Council Future Fellowship
   (FT120100215). The authors state that this manuscript comprises original
   material that is not under review elsewhere, and that the study on which
   the research is based has been subject to appropriate ethical review.
CR Alcohol and Drug Foundation (formally the Australian Drug Foundation), 2008, TEEN DRINK FACTS ISS
   Alexander B.K., 2008, GLOBALIZATION ADDICT
   AYMANNOLLEY S, 2000, J YOUTH STUD, V3, P35, DOI DOI 10.1080/136762600113022
   Barad K., 2007, M UNIVERSE HALFWAY Q
   Beck J, 1998, EVALUATION REV, V22, P15, DOI 10.1177/0193841X9802200102
   Bessant J, 2012, CONTEMP SOC SCI, V7, P181, DOI 10.1080/21582041.2012.691541
   Bessant J, 2008, J YOUTH STUD, V11, P347, DOI 10.1080/13676260801948387
   Blackman S., 2004, CHILLING OUT CULTURA
   Brown R, 2012, CONTINUUM-J MEDIA CU, V26, P357, DOI 10.1080/10304312.2012.665834
   Butler J., 1999, GENDER TROUBLE FEMIN
   Campbell Nancy, 2007, DISCOVERING ADDICTIO
   Campbell ND, 2010, BIOSOCIETIES, V5, P89, DOI 10.1057/biosoc.2009.2
   Campbell ND, 2012, CRIT PERSPECT ADDICT, V14, P3, DOI DOI 10.1108/S1057-6290(2012)0000014005
   Carhart-Harris RL, 2016, P NATL ACAD SCI USA, V113, P4853, DOI 10.1073/pnas.1518377113
   Courtwright DT, 2010, BIOSOCIETIES, V5, P137, DOI 10.1057/biosoc.2009.3
   Department of Education and Early Childhood Development (DEECD) Victoria, 2013, GET READ
   Department of Health and Ageing Commonwealth of Australia, DRUGS REAL FACTS
   Duff C, 2015, J SOCIOL, V51, P81, DOI 10.1177/1440783314562502
   Dumit J, 2012, CRITICAL NEUROSCIENCE: A HANDBOOK OF THE SOCIAL AND CULTURAL CONTEXTS OF NEUROSCIENCE, P195
   Dwyer R, 2013, INT J DRUG POLICY, V24, P203, DOI 10.1016/j.drugpo.2013.03.003
   Farrugia A, 2016, HLTH INTERDISCIPLINA
   Farrugia A., 2015, CONTEMP DRUG PROBL, V42, P240, DOI DOI 10.1177/0091450915601520
   Farrugia A, 2017, GENDER EDUC, V29, P281, DOI 10.1080/09540253.2016.1156655
   Farrugia A, 2014, INT J DRUG POLICY, V25, P663, DOI 10.1016/j.drugpo.2014.04.019
   Fitzgerald J, 2015, FRAMING DRUG USE SPA
   Fraser S, 2011, DRUG EFFECT HLTH CRI
   Fraser S, 2008, SOC SCI MED, V66, P740, DOI 10.1016/j.socscimed.2007.10.012
   Fraser S, 2013, INT J DRUG POLICY, V24, P212, DOI 10.1016/j.drugpo.2013.03.009
   Fraser S, 2010, HEALTH SOCIOL REV, V19, P230, DOI 10.5172/hesr.2010.19.2.230
   Fraser Suzanne, 2014, HABITS REMAKING ADDI
   Gabriel F, 2013, DECONSTRUCTING YOUTH
   Gaten M, 1996, IMAGINARY BODIES ETH
   Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119
   Gomart E, 2002, SOC STUD SCI, V32, P93, DOI 10.1177/0306312702032001005
   Grosbras MH, 2007, J NEUROSCI, V27, P8040, DOI 10.1523/JNEUROSCI.1360-07.2007
   Grosz Elizabeth, 1994, VOLATILE BODIES CORP
   Hall S., 1904, ADOLESCENCE ITS PSYC
   Hart A., 2014, CONTEMP DRUG PROBL, V41, P393, DOI DOI 10.1177/009145091404100306
   Hyman SE, 2005, AM J PSYCHIAT, V162, P1414, DOI 10.1176/appi.ajp.162.8.1414
   IGCD, 2015, NAT DRUG STRAT 2016, P1
   Keane H., 2002, WHATS WRONG ADDICTIO
   Kelly P, 2012, J YOUTH STUD, V15, P944, DOI 10.1080/13676261.2012.693596
   Latour Bruno, 2004, BODY SOC, V2, P205, DOI [10.1177/1357034X04042943, DOI 10.1177/1357034X04042943]
   Law J., 2004, METHOD MESS SOCIAL S
   Law John, 2011, POLITICS KNOWLEDGE, P156
   Lesko N., 2012, ACT YOUR AGE CULTURA
   MacLean KA, 2011, J PSYCHOPHARMACOL, V25, P1453, DOI 10.1177/0269881111420188
   Males M, 2009, J ADOLESCENT RES, V24, P3, DOI 10.1177/0743558408326913
   McLeod K., 2014, CONTEMP DRUG PROBL, V41, P109, DOI DOI 10.1177/009145091404100106
   Midford R, 2010, ADDICTION, V105, P1688, DOI 10.1111/j.1360-0443.2009.02790.x
   Mol A, 1999, ACTOR NETWORK THEORY AND AFTER, P74, DOI 10.1111/j.1467-954X.1999.tb03483.x
   Mol A., 2002, BODY MULTIPLE ONTOLO
   Mol Annemarie, 2002, COMPLEXITIES SOCIAL
   National Cannabis Prevention and Information Centre (NCPIC), 2011, CANN CONS 2
   National Cannabis Prevention and Information Centre (NCPIC), 2012, MAK LINK PROM HELP S
   National Drug and Alcohol Research Centre, 2014, CLIMATE SCH ONL PREV
   New South Wales Department of Health, 2006, DRUG SMART
   Nicholson T, 2013, J SUBST USE, V18, P431, DOI 10.3109/14659891.2012.689922
   Osorio FD, 2015, REV BRAS PSIQUIATR, V37, P13, DOI 10.1590/1516-4446-2014-1496
   Pennay A., 2012, CONTEMP DRUG PROBL, V39, P397, DOI DOI 10.1177/009145091203900304
   Race K, 2015, SEXUALITIES, V18, P253, DOI 10.1177/1363460714550913
   Sedgwick E.K., 1993, TENDENCIES
   Sercombe H, 2010, J ADOLESCENT RES, V25, P31, DOI 10.1177/0743558409353065
   Soler J, 2016, PSYCHOPHARMACOLOGY, V233, P823, DOI 10.1007/s00213-015-4162-0
   Steinberg L, 2009, AM PSYCHOL, V64, P739, DOI 10.1037/0003-066X.64.8.739
   Teesson M, 2012, DRUG ALCOHOL REV, V31, P731, DOI 10.1111/j.1465-3362.2012.00420.x
   Tupper K., 2003, J DRUG ED AWARENESS, V1, P145
   Tupper KW, 2008, TEACH TEACH EDUC, V24, P356, DOI 10.1016/j.tate.2007.08.007
   Tupper KW, 2014, CRIT PUBLIC HEALTH, V24, P115, DOI 10.1080/09581596.2013.862517
   Volkow ND, 2004, NAT REV NEUROSCI, V5, P963, DOI 10.1038/nrn1539
   Vrecko S, 2010, BIOSOCIETIES, V5, P36, DOI 10.1057/biosoc.2009.8
   Wyn J., 1997, RETHINKING YOUTH, P8
   Zinberg NE., 1984, DRUG SET SETTING BAS
NR 73
TC 6
Z9 6
U1 1
U2 10
PU PALGRAVE MACMILLAN LTD
PI BASINGSTOKE
PA BRUNEL RD BLDG, HOUNDMILLS, BASINGSTOKE RG21 6XS, HANTS, ENGLAND
SN 1745-8552
EI 1745-8560
J9 BIOSOCIETIES
JI BioSocieties
PD DEC
PY 2017
VL 12
IS 4
BP 588
EP 610
DI 10.1057/s41292-017-0047-2
PG 23
WC Social Sciences, Biomedical
WE Social Science Citation Index (SSCI)
SC Biomedical Social Sciences
GA FS0FF
UT WOS:000419448600006
DA 2023-06-23
ER

PT J
AU Verdejo-Garcia, A
   Chong, TTJ
AF Verdejo-Garcia, Antonio
   Chong, Trevor T. -J.
TI Targeting goal-based decision-making for addiction recovery
SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
LA English
DT Editorial Material
DE Addiction; Decision-making; Neurocognitive mechanisms; Recovery; Goals;
   Reinforcement learning
ID DRUG-ADDICTION; DOPAMINE; REINFORCEMENT; HUMANS; ABUSE
C1 [Verdejo-Garcia, Antonio] Monash Univ, Sch Psychol Sci, Clayton, Vic 3800, Australia.
   Monash Univ, Turner Inst Brain & Mental Hlth, Clayton, Vic 3800, Australia.
C3 Monash University; Monash University
RP Verdejo-Garcia, A (通讯作者)，Monash Univ, Sch Psychol Sci, Clayton, Vic 3800, Australia.
EM antonio.verdejo@monash.edu
FU Australian Medical Research Future Fund [MRF1141214]; Australian
   Research Council [DP 180102383, DE 180100389]
FX AVG was supported by the Australian Medical Research Future Fund
   (MRF1141214). TC was supported by the Australian Research Council (DP
   180102383, DE 180100389).
CR ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L
   Balleine BW, 2007, ANN NY ACAD SCI, V1104, P147, DOI 10.1196/annals.1390.006
   Bolivar HA, 2021, JAMA PSYCHIAT, V78, P1092, DOI 10.1001/jamapsychiatry.2021.1969
   Chau BKH, 2018, BEHAV PHARMACOL, V29, P569, DOI 10.1097/FBP.0000000000000424
   Chong TTJ, 2018, CURR OPIN BEHAV SCI, V22, P35, DOI 10.1016/j.cobeha.2017.12.010
   Colaizzi JM, 2020, NEUROSCI BIOBEHAV R, V111, P84, DOI 10.1016/j.neubiorev.2020.01.018
   Daw ND, 2011, NEURON, V69, P1204, DOI 10.1016/j.neuron.2011.02.027
   Dayan P, 2009, PHARMACOPSYCHIATRY, V42, pS56, DOI 10.1055/s-0028-1124107
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Fernandez-Serrano MJ, 2011, NEUROSCI BIOBEHAV R, V35, P377, DOI 10.1016/j.neubiorev.2010.04.008
   Forster SE, 2018, DRUG ALCOHOL DEPEN, V185, P93, DOI 10.1016/j.drugalcdep.2017.12.009
   Groman SM, 2019, BIOL PSYCHIAT, V85, P936, DOI 10.1016/j.biopsych.2018.12.017
   Haber SN, 2010, NEUROPSYCHOPHARMACOL, V35, P4, DOI 10.1038/npp.2009.129
   Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483
   Lucantonio F, 2014, NEUROPHARMACOLOGY, V76, P407, DOI 10.1016/j.neuropharm.2013.05.033
   McKay JR, 2017, ADDICTION, V112, P751, DOI 10.1111/add.13502
   Moeller SJ, 2015, PHARMACOL BIOCHEM BE, V138, P133, DOI 10.1016/j.pbb.2015.09.020
   Oluwoye O, 2020, PSYCHOL ADDICT BEHAV, V34, P99, DOI 10.1037/adb0000487
   Paulus MP, 2020, JAMA PSYCHIAT, V77, P959, DOI 10.1001/jamapsychiatry.2020.0246
   Redish AD, 2008, BEHAV BRAIN SCI, V31, P415, DOI 10.1017/S0140525X0800472X
   Robinson AH, 2021, ADDICT BIOL, V26, DOI 10.1111/adb.12999
   Schultz W, 2016, DIALOGUES CLIN NEURO, V18, P23
   Smith R, 2020, DRUG ALCOHOL DEPEN, V215, DOI 10.1016/j.drugalcdep.2020.108208
   Stalnaker TA, 2009, NEUROPHARMACOLOGY, V56, P63, DOI 10.1016/j.neuropharm.2008.07.019
   Verdejo-Garcia A, 2018, PHARMACOL BIOCHEM BE, V164, P99, DOI 10.1016/j.pbb.2017.02.003
   VerdejoGarcia A, 2021, DEV GOAL MANAGEMENT, DOI [10.1101/2021.08.01.21261454, DOI 10.1101/2021.08.01.21261454]
   Zilverstand A, 2018, NEURON, V98, P886, DOI 10.1016/j.neuron.2018.03.048
NR 27
TC 1
Z9 1
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0091-3057
EI 1873-5177
J9 PHARMACOL BIOCHEM BE
JI Pharmacol. Biochem. Behav.
PD NOV
PY 2021
VL 210
AR 173275
DI 10.1016/j.pbb.2021.173275
EA SEP 2021
PG 3
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA WC6EE
UT WOS:000704348500004
PM 34547354
DA 2023-06-23
ER

PT J
AU Ahmed, SH
AF Ahmed, SH
TI Neuroscience - Addiction as compulsive reward prediction
SO SCIENCE
LA English
DT Editorial Material
ID RATIONAL ADDICTION; DRUG-ABUSE; DOPAMINE; SUBSTRATE
C1 Univ Bordeaux 2, CNRS, UMR 5541, F-33076 Bordeaux, France.
C3 Centre National de la Recherche Scientifique (CNRS); UDICE-French
   Research Universities; Universite de Bordeaux
RP Ahmed, SH (通讯作者)，Univ Bordeaux 2, CNRS, UMR 5541, F-33076 Bordeaux, France.
EM sahmed@lnpb.u-bordeaux2.fr
RI AHMED, Serge H/D-5236-2014
OI Ahmed, Serge/0000-0002-1225-9234
CR Ahmed SH, 1998, BEHAV NEUROSCI, V112, P1167
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Ahmed SH, 2002, NAT NEUROSCI, V5, P625, DOI 10.1038/nn872
   AINSLIE G, 1975, PSYCHOL BULL, V82, P463, DOI 10.1037/h0076860
   BECKER GS, 1988, J POLIT ECON, V96, P675, DOI 10.1086/261558
   Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9
   Bickel WK, 2001, ADDICTION, V96, P73, DOI 10.1046/j.1360-0443.2001.961736.x
   Bridges JFP, 2001, EUR ADDICT RES, V7, P78, DOI 10.1159/000050720
   Di Chiara G, 1999, EUR J PHARMACOL, V375, P13, DOI 10.1016/S0014-2999(99)00372-6
   Egelman DM, 1998, J COGNITIVE NEUROSCI, V10, P623, DOI 10.1162/089892998563022
   Garavan H, 2000, AM J PSYCHIAT, V157, P1789, DOI 10.1176/appi.ajp.157.11.1789
   HERMSTEIN RJ, 1991, J ECON PERSPECT, V5, P137
   Heyman GM, 1996, BEHAV BRAIN SCI, V19, P561, DOI 10.1017/S0140525X00042990
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   McClure SM, 2003, TRENDS NEUROSCI, V26, P423, DOI 10.1016/S0166-2236(03)00177-2
   Montague PR, 1996, J NEUROSCI, V16, P1936, DOI 10.1523/jneurosci.16-05-01936.1996
   Redish AD, 2004, SCIENCE, V306, P1944, DOI 10.1126/science.1102384
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593
   Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1
   STIGLER GJ, 1977, AM ECON REV, V67, P78
   Volkow ND, 2004, MOL PSYCHIATR, V9, P557, DOI 10.1038/sj.mp.4001507
NR 22
TC 28
Z9 28
U1 0
U2 10
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD DEC 10
PY 2004
VL 306
IS 5703
BP 1901
EP 1902
DI 10.1126/science.1107071
PG 2
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 879DC
UT WOS:000225695600033
PM 15591193
DA 2023-06-23
ER

PT J
AU Bailey, JA
   Hurley, RW
   Gold, MS
AF Bailey, John A.
   Hurley, Robert W.
   Gold, Mark S.
TI Crossroads of Pain and Addiction
SO PAIN MEDICINE
LA English
DT Review
DE Pain Training Programs; Drug Abuse; Addiction; Chronic Pain
ID SUBSTANCE USE DISORDERS; CHILDHOOD SEXUAL-ABUSE; PRESCRIPTION DRUGS;
   DEPENDENT PATIENTS; NONMALIGNANT PAIN; REWARD CIRCUITRY; OPIOID THERAPY;
   ALCOHOL; STRESS; OPIATE
AB Background.
   Despite the fact that chronic pain and addiction often coexist, few pain training programs offer significant experiential and didactic training in drug abuse and addiction. Similarly, addiction medicine programs often offer little training in pain management. What follows is a review of the intersection between these two specialties from the perspective of clinicians that practice both.
   Objective.
   The objective of this study was to review the historical backdrop, terminology, vulnerability, and neurobiology of addiction; explore the effects of drug, delivery system, timing, and environment on drug self-administration; and review strategies used in managing patients with coexisting addiction and chronic pain.
   Setting.
   The University of Florida has training programs in both pain management and addiction medicine. The collaboration of these two subspecialties has led to the development of a successful pain management clinic that manages difficult patients based on the strategies that are discussed.
   Conclusions.
   It is possible to successfully manage patients with coexisting chronic pain and addictive disorders. Addiction medicine and pain management training programs should offer didactic and experiential training in both subspecialties.
C1 [Bailey, John A.] Univ Florida, Springhill Hlth Ctr, Div Addict Med, Dept Psychiat, Gainesville, FL 32606 USA.
   [Hurley, Robert W.] Univ Florida, Div Pain, Dept Anesthesiol, Gainesville, FL 32611 USA.
   [Gold, Mark S.] McKnight Brain Inst, Dept Psychiat, Gainesville, FL USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida
RP Bailey, JA (通讯作者)，Univ Florida, Springhill Hlth Ctr, Div Addict Med, Dept Psychiat, 8491 NW 39th Ave, Gainesville, FL 32606 USA.
EM baileyjo@ufl.edu
RI MD/PhD, Robert W. Hurley/V-6619-2019
OI Hurley, Robert/0000-0001-6591-9390
CR Adams LL, 2004, J PAIN SYMPTOM MANAG, V27, P440, DOI 10.1016/j.jpainsymman.2003.10.009
   Agrawal A, 2006, PREV MED, V43, P125, DOI 10.1016/j.ypmed.2006.03.022
   Akbik H, 2006, J PAIN SYMPTOM MANAG, V32, P287, DOI 10.1016/j.jpainsymman.2006.03.010
   *ALC AN WORLD SERV, AA MEMB MED OTH DRUG
   Alcoholics Anonymous, 2001, ALC AN
   *AM AC PAIN MED, CLIN RES CONTR SUSBS
   Atluri S, 2002, PAIN PHYSICIAN, V5, P447
   Atluri Sairam L, 2004, Pain Physician, V7, P333
   BAILEY J, 2009, PARADIGM, V21, P22
   BALLANTYNE J, 2006, AM SOC ANESTH REV, V3, P34
   Becerra L, 2001, NEURON, V32, P927, DOI 10.1016/S0896-6273(01)00533-5
   Blum K, 2008, THEOR BIOL MED MODEL, V5, DOI 10.1186/1742-4682-5-24
   BOZARTH MA, 1984, SCIENCE, V224, P516, DOI 10.1126/science.6324347
   Brady KT, 2005, AM J PSYCHIAT, V162, P1483, DOI 10.1176/appi.ajp.162.8.1483
   Bremner JD, 1997, AM J PSYCHIAT, V154, P624
   Bruijnzeel AW, 2004, PSYCHIAT CLIN N AM, V27, P661, DOI 10.1016/j.psc.2004.06.005
   Bulik CM, 2001, BRIT J PSYCHIAT, V179, P444, DOI 10.1192/bjp.179.5.444
   Canive JM, 1997, ANN NY ACAD SCI, V821, P512, DOI 10.1111/j.1749-6632.1997.tb48318.x
   Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P33
   Chakroun N, 2004, ENCEPHALE, V30, P564
   Chappel JN, 1999, PSYCHIAT CLIN N AM, V22, P425, DOI 10.1016/S0193-953X(05)70085-X
   Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008
   Comings DE, 2000, PROG BRAIN RES, V126, P325
   COMPTON MA, 1994, J PAIN SYMPTOM MANAG, V9, P462, DOI 10.1016/0885-3924(94)90203-8
   Compton P, 1998, J PAIN SYMPTOM MANAG, V16, P355, DOI 10.1016/S0885-3924(98)00110-9
   Compton P, 2001, DRUG ALCOHOL DEPEN, V63, P139, DOI 10.1016/S0376-8716(00)00200-3
   Compton WA, 2006, DRUG ALCOHOL DEPEN, V83, pS4, DOI 10.1016/j.drugalcdep.2005.10.020
   Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009
   Courtwright DT, 2004, DRUG ALCOHOL DEPEN, V76, P9, DOI 10.1016/j.drugalcdep.2004.04.012
   Courtwright DT., 2001, DARK PARADISE HIST O, VEnl. ed., pxiii, 326
   *CTR DRUG FREE LIV, FAQS
   Dackis C, 2005, NAT NEUROSCI, V8, P1431, DOI 10.1038/nn1105-1431
   DACKIS C, 1990, ADV ALCOHOL SUB ABUS, P9
   Dalley JW, 2007, SCIENCE, V315, P1267, DOI 10.1126/science.1137073
   Daniell HW, 2002, J PAIN, V3, P377, DOI 10.1054/jpai.2002.126790
   Devulder J, 2005, CURR MED RES OPIN, V21, P1555, DOI 10.1185/030079905X65321
   DOWEIKO H, 2008, CONCEPTS CHEM DEPEND, P41
   DUPONT R, 2009, PRINCIPLES ADDICTION, P1502
   DUPONT R, 2005, DRUG TESTING TREATME
   DuPont Robert L, 2007, J Addict Dis, V26 Suppl 1, P13, DOI 10.1300/J069v26S01_03
   Ellgren M, 2007, NEUROPSYCHOPHARMACOL, V32, P607, DOI 10.1038/sj.npp.1301127
   *FIRSTL, FIRSTL REP ETG ETS E
   *FIRSTL, ETH GLUC
   FISHBAIN DA, 1992, CLIN J PAIN, V8, P77, DOI 10.1097/00002508-199206000-00003
   Fishbain DA, 2008, PAIN MED, V9, P444, DOI 10.1111/j.1526-4637.2007.00370.x
   Fishman SM, 1999, J PAIN SYMPTOM MANAG, V18, P27, DOI 10.1016/S0885-3924(99)00035-4
   Flugsrud-Breckenridge MR, 2007, CURR OPIN ANESTHESIO, V20, P319, DOI 10.1097/ACO.0b013e32814b1626
   FRANCIS H, 2001, BIOGRAPHY ALCOHOLICS
   FREYE E, 2008, OPIOIDS MED COMPREHE, P420
   Friedman R, 2003, PAIN MED, V4, P182, DOI 10.1046/j.1526-4637.2003.03017.x
   GARDNER E, 2008, PAIN CHEM DEPENDENCY, P432
   Gardner EL, 2000, AM J ADDICTION, V9, P285, DOI 10.1080/105504900750047355
   Gardner EL, 1999, ADDICTION, P57
   GAWIN FH, 1991, SCIENCE, V251, P1580, DOI 10.1126/science.2011738
   Goldenbaum DM, 2008, PAIN MED, V9, P737, DOI 10.1111/j.1526-4637.2008.00482.x
   Gonzalez LA, 2009, J PHARMACOL EXP THER, V329, P827, DOI 10.1124/jpet.109.151142
   GORSKI TT, 1986, STAYING SOBER GUIDE
   Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168
   Gracely RH, 2002, ARTHRITIS RHEUM-US, V46, P1333, DOI 10.1002/art.10225
   Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI 10.1001/archpsyc.61.8.807
   Hakamata Y, 2007, NEUROSCI RES, V59, P383, DOI 10.1016/j.neures.2007.08.012
   Heit HA, 2004, PAIN MED, V5, P303, DOI 10.1111/j.1526-4637.2004.04044.x
   Heit HA, 2001, EUR J PAIN-LONDON, V5, P27, DOI 10.1053/eujp.2001.0276
   HOHENSTEIN K, 2001, J SUPREME COURT HIST, V26, P23
   Hull MJ, 2008, J ANAL TOXICOL, V32, P516, DOI 10.1093/jat/32.7.516
   Humphreys K, 2004, J SUBST ABUSE TREAT, V26, P151, DOI 10.1016/S0740-5472(03)00212-5
   *I DRUG AB, PRINC DRUG ADD TREAT
   Isaacson JH, 2000, J STUD ALCOHOL, V61, P912, DOI 10.15288/jsa.2000.61.912
   Jaffee WB, 2008, PSYCHIAT SERV, V59, P140, DOI 10.1176/ps.2008.59.2.140
   Jung B, 2007, PAIN MED, V8, P433, DOI 10.1111/j.1526-4637.2007.00315.x
   Kahan M, 2006, CAN FAM PHYSICIAN, V52, P1081
   Kaiko RF, 1996, CLIN PHARMACOL THER, V59, P52, DOI 10.1016/S0009-9236(96)90024-7
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kelley AE, 2002, J NEUROSCI, V22, P3306
   Kendler KS, 2000, ARCH GEN PSYCHIAT, V57, P953, DOI 10.1001/archpsyc.57.10.953
   Khazaal Y, 2007, ANN PHARMACOTHER, V41, P359, DOI 10.1345/aph.1H504
   KINTZ P, 2006, ANAL PRACTICAL ASPEC, P28
   Kirsh KL, 2002, CLIN J PAIN, V18, pS52, DOI 10.1097/00002508-200207001-00006
   KOENIGS M, 2009, NEUROSCIENTST S, V6683, P373
   Koob G, 2003, EUR NEUROPSYCHOPHARM, V13, pS7, DOI 10.1016/S0924-977X(03)90005-8
   Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442
   LOGAN D, 2009, ADD MED SPEC U FLOR
   MALLINOFF H, 2005, AM J THER, V12, P379
   Manchikanti Laxmaiah, 2006, Pain Physician, V9, P57
   MARKEL H, 2003, NY TIMES
   Martell BA, 2007, ANN INTERN MED, V146, P116, DOI 10.7326/0003-4819-146-2-200701160-00006
   MENDELSON JH, 1975, J PHARMACOL EXP THER, V195, P296
   Michna E, 2004, J PAIN SYMPTOM MANAG, V28, P250, DOI 10.1016/j.jpainsymman.2004.04.007
   Miller NS, 2001, ACAD MED, V76, P410, DOI 10.1097/00001888-200105000-00007
   Miotto K, 1996, PSYCHOSOMATICS, V37, P223, DOI 10.1016/S0033-3182(96)71561-X
   Modesto-Lowe V, 2007, AM J ADDICTION, V16, DOI 10.1080/10550490701525566
   Musshoff F, 2006, FORENSIC SCI INT, V156, P118, DOI 10.1016/j.forsciint.2004.07.024
   Myrick Hugh, 2004, Ann Clin Psychiatry, V16, P101, DOI 10.1080/10401230490453743
   Nafziger AN, 2009, CLIN J PAIN, V25, P73, DOI 10.1097/AJP.0b013e31817e13cc
   *NIDA, NIDA INF TREATM APPR
   Passik SD, 2006, PAIN MED, V7, P363, DOI 10.1111/j.1526-4637.2006.00189.x
   Passik Steven D, 2005, J Support Oncol, V3, P83
   Paterson S, 2006, J ANAL TOXICOL, V30, P267, DOI 10.1093/jat/30.4.267
   PIAZZA PV, 1998, PRINCIPLES ADDICTION, P83
   Polydorou Soteri, 2008, Curr Psychiatry Rep, V10, P399, DOI 10.1007/s11920-008-0064-8
   PORRINO L, 2004, J NEUROSCI, V24, P4560
   PORTENOY RK, 1986, PAIN, V25, P171, DOI 10.1016/0304-3959(86)90091-6
   PORTER J, 1980, NEW ENGL J MED, V302, P123
   Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x
   Reeves RR, 2007, SOUTH MED J, V100, P834, DOI 10.1097/SMJ.0b013e3180f62d53
   REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511
   Reisfield Gary M, 2007, J Opioid Manag, V3, P80
   Reisfield GM, 2009, BIOANALYSIS, V1, P937, DOI 10.4155/BIO.09.81
   RONALD T, 2005, TREATING DOCTORS DRU
   Rosenblum A, 2003, JAMA-J AM MED ASSOC, V289, P2370, DOI 10.1001/jama.289.18.2370
   Samaha AN, 2005, TRENDS PHARMACOL SCI, V26, P82, DOI 10.1016/j.tips.2004.12.007
   *SAMHSA, 2004, HHS MAND GUID
   Sapolsky RM, 1996, SCIENCE, V273, P749, DOI 10.1126/science.273.5276.749
   SAVAGE S, 1994, PRINCIPLES ADDICTION, P1406
   Savage SR, 2003, J PAIN SYMPTOM MANAG, V26, P655, DOI 10.1016/S0885-3924(03)00219-7
   Savage SR, 2002, CLIN J PAIN, V18, pS28, DOI 10.1097/00002508-200207001-00004
   Schmahl C, 2009, J PSYCHIATR NEUROSCI, V34
   Segman RH, 2002, MOL PSYCHIATR, V7, P903, DOI 10.1038/sj.mp.4001085
   Sell LA, 1999, EUR J NEUROSCI, V11, P1042, DOI 10.1046/j.1460-9568.1999.00522.x
   Simoni-Wastila L, 2004, SUBST USE MISUSE, V39, P1, DOI 10.1081/JA-120027764
   Singh ME, 2006, NEUROPSYCHOPHARMACOL, V31, P58, DOI 10.1038/sj.npp.1300770
   SOUTHWICK SM, 1993, ARCH GEN PSYCHIAT, V50, P266
   Sullivan MD, 2005, PAIN, V119, P95, DOI 10.1016/j.pain.2005.09.020
   Svetlov SI, 2007, J ADDICT DIS, V26, P1, DOI 10.1300/J069v26n04_01
   Thevis M, 2003, J ANAL TOXICOL, V27, P53, DOI 10.1093/jat/27.1.53
   Trescot Andrea M, 2006, Pain Physician, V9, P1
   Turk DC, 2008, CLIN J PAIN, V24, P497, DOI 10.1097/AJP.0b013e31816b1070
   *US SUBST TREATM P, 2004, MOD POL US CONTR
   VoltaireCarlsson A, 1996, ALCOHOL, V13, P415, DOI 10.1016/0741-8329(96)81678-8
   Walsh SL, 2003, DRUG ALCOHOL DEPEN, V70, pS13, DOI 10.1016/S0376-8716(03)00056-5
   WARFIELD C, 2004, PRINCIPLES PRACTICE, P58
   Wasan AD, 2005, REGION ANESTH PAIN M, V30, P184, DOI 10.1016/j.rapm.2004.11.005
   Watanabe KI, 2001, ADDICT BIOL, V6, P163, DOI 10.1080/13556210020040244
   Weaver M, 2002, CLIN J PAIN, V18, pS61, DOI 10.1097/00002508-200207001-00007
   Weaver M, 2007, J ADDICT MED, V1, P2, DOI 10.1097/ADM.0b013e3180473bec
   Webster L, 2003, PAIN MED, V4, P135, DOI 10.1046/j.1526-4637.2003.03014.x
   Webster LR, 2005, PAIN MED, V6, P432, DOI 10.1111/j.1526-4637.2005.00072.x
   YOUNG S, BALANCING CLIN RISK
   Zajecka J, 1997, J CLIN PSYCHIAT, V58, P291, DOI 10.4088/JCP.v58n0702
   Ziegler SJ, 2003, J LAW MED ETHICS, V31, P75, DOI 10.1111/j.1748-720X.2003.tb00060.x
   DRUG TESTING
   2003, JAMA, V290, P2492
   SUBOXONE PRODUCT INF
NR 143
TC 28
Z9 28
U1 1
U2 15
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1526-2375
EI 1526-4637
J9 PAIN MED
JI Pain Med.
PY 2010
VL 11
IS 12
BP 1803
EP 1818
DI 10.1111/j.1526-4637.2010.00982.x
PG 16
WC Anesthesiology; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Anesthesiology; General & Internal Medicine
GA 691FQ
UT WOS:000285066100012
PM 21040437
OA Bronze
DA 2023-06-23
ER

PT J
AU Lu, L
   Wang, X
   Kosten, TR
AF Lu, Lin
   Wang, Xi
   Kosten, Thomas R.
TI Stereotactic Neurosurgical Treatment of Drug Addiction
SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE
LA English
DT Article
DE addiction; deep brain stimulation; stereotactic surgery
ID DEEP BRAIN-STIMULATION; NUCLEUS-ACCUMBENS; SURGERY; ALCOHOL
AB Background: Stereotactic neurosurgery is a well-developed and accepted treatment for movement disorders like Parkinson's disease. Objective: Review use of this neurosurgical intervention to treat drug addiction since the 1960s. Methods: Literature review of case and series reports. Results: Stereotactic neurosurgery has shown promising results in reducing drug addiction, but it has also caused severe side effects. Thus, surgeons have sought to refine the stereotactic lesion procedure and its target over the past 50 years. Conclusions and Significance: Recent developments in stereotactic technique and deep brain stimulation (DBS) may make stereotactic neurosurgery a viable and reversible treatment for drug addiction.
C1 [Lu, Lin; Wang, Xi] Peking Univ, Natl Inst Drug Dependence, Beijing 100083, Peoples R China.
   [Kosten, Thomas R.] Baylor Coll Med, Div Alcohol & Addict Disorders, Houston, TX 77030 USA.
C3 Peking University; Baylor College of Medicine
RP Lu, L (通讯作者)，Peking Univ, Natl Inst Drug Dependence, 38 Xue Yuan Rd, Beijing 100083, Peoples R China.
EM linlu@bjmu.edu.cn
RI Kosten, Thomas/AAI-5998-2021
CR ARMITAGE C, 2004, AUSTRALIAN      0529, P14
   Balasubramaniam V, 1973, Neurol India, V21, P63
   DIECKMANN G, 1978, APPL NEUROPHYSIOL, V41, P93
   Gao GD, 2003, STEREOT FUNCT NEUROS, V81, P96, DOI 10.1159/000075111
   HASSLER R, 1960, BRAIN, V83, P337, DOI 10.1093/brain/83.2.337
   KANAKA TS, 1978, APPL NEUROPHYSIOL, V41, P86
   Kennedy Sidney H, 2007, Ann Clin Psychiatry, V19, P279, DOI 10.1080/10401230701675222
   Knight G, 1969, Nurs Times, V65, P583
   Kopell BH, 2008, NEUROSCI BIOBEHAV R, V32, P408, DOI 10.1016/j.neubiorev.2007.07.004
   Kuhn J, 2007, J NEUROL NEUROSUR PS, V78, P1152, DOI 10.1136/jnnp.2006.113092
   Limousin P, 2008, NEUROTHERAPEUTICS, V5, P309, DOI 10.1016/j.nurt.2008.01.006
   Medvedev S. V., 2003, Fiziologiya Cheloveka, V29, P117
   Orellana C, 2002, LANCET NEUROL, V1, P333, DOI 10.1016/S1474-4422(02)00175-8
   Walsh N. P., 2002, GUARDIAN        0809, P12
   Yu H, 2008, NEUROTHERAPEUTICS, V5, P26, DOI 10.1016/j.nurt.2007.10.072
NR 15
TC 19
Z9 20
U1 0
U2 7
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0095-2990
J9 AM J DRUG ALCOHOL AB
JI Am. J. Drug Alcohol Abuse
PD NOV
PY 2009
VL 35
IS 6
BP 391
EP 393
DI 10.3109/00952990903312478
PG 3
WC Psychology, Clinical; Substance Abuse
WE Social Science Citation Index (SSCI)
SC Psychology; Substance Abuse
GA 697UU
UT WOS:000285545100001
PM 20014906
DA 2023-06-23
ER

PT J
AU Earnshaw, V
   Smith, L
   Copenhaver, M
AF Earnshaw, Valerie
   Smith, Laramie
   Copenhaver, Michael
TI Drug Addiction Stigma in the Context of Methadone Maintenance Therapy:
   An Investigation into Understudied Sources of Stigma
SO INTERNATIONAL JOURNAL OF MENTAL HEALTH AND ADDICTION
LA English
DT Article
DE Methadone; Stigma; Prejudice; Stereotypes; Discrimination; Drug
   Addiction
ID HEPATITIS-C; HEALTH-CARE; USERS; DISCRIMINATION; PREJUDICE; ATTITUDES;
   PROGRAMS
AB Experiences of stigma from others among people with a history of drug addiction are understudied in comparison to the strength of stigma associated with drug addiction. Work that has studied these experiences has primarily focused on stigma experienced from healthcare workers specifically even though stigma is often experienced from other sources as well. Because stigma has important implications for the mental health and recovery efforts of people in treatment, it is critical to better understand these experiences of stigma. Therefore, we characterize drug addiction stigma from multiple sources using qualitative methodology to advance understandings of how drug addiction stigma is experienced among methadone maintenance therapy patients and from whom. Results demonstrate that methadone maintenance therapy patients experience prejudice, stereotypes, and discrimination from friends and family, coworkers and employers, healthcare workers, and others. Discussion highlights similarities and differences in stigma experienced from these sources.
C1 [Earnshaw, Valerie; Smith, Laramie; Copenhaver, Michael] Yale Univ, New Haven, CT USA.
C3 Yale University
RP Earnshaw, V (通讯作者)，Yale Univ, New Haven, CT USA.
EM valerie.earnshaw@gmail.com; laramie.smith@uconn.edu;
   michael.copenhaver@uconn.edu
FU NIDA NIH HHS [K02 DA033139, R01 DA022122] Funding Source: Medline; NIMH
   NIH HHS [F31 MH093264, P30 MH062294] Funding Source: Medline
CR Ahern J, 2007, DRUG ALCOHOL DEPEN, V88, P188, DOI 10.1016/j.drugalcdep.2006.10.014
   Baldwin ML, 2010, DRUG ALCOHOL DEPEN, V110, P1, DOI 10.1016/j.drugalcdep.2010.01.018
   Beatty PC, 2007, PUBLIC OPIN QUART, V71, P287, DOI 10.1093/poq/nfm006
   Ben Natan M, 2009, INT J NURS PRACT, V15, P566, DOI 10.1111/j.1440-172X.2009.01799.x
   Bernard H. R., 2011, RES METHODS ANTHR QU, V5th
   Beyrer C, 2010, LANCET, V376, P208, DOI 10.1016/S0140-6736(10)61005-7
   Brener L, 2008, SUBST USE MISUSE, V43, P295, DOI 10.1080/10826080701202627
   Brener L, 2007, INT J DRUG POLICY, V18, P381, DOI 10.1016/j.drugpo.2007.01.006
   Brener L, 2010, SUBST USE MISUSE, V45, P1007, DOI 10.3109/10826081003659543
   DelRio M, 1997, ADDICTION, V92, P1353
   Earnshaw VA, 2012, CHRONIC ILLN, V8, P79, DOI 10.1177/1742395311429393
   Earnshaw VA, 2012, J HEALTH PSYCHOL, V17, P157, DOI 10.1177/1359105311414952
   Earnshaw VA, 2009, AIDS BEHAV, V13, P1160, DOI 10.1007/s10461-009-9593-3
   Gerra G, 2003, J SUBST ABUSE TREAT, V25, P1, DOI 10.1016/S0740-5472(03)00031-X
   Goffman E., 1963, STIGMA NOTES MANAGEM
   Gyarmathy VA, 2008, SUBST USE MISUSE, V43, P1865, DOI 10.1080/10826080802293038
   Interian A, 2010, PSYCHIAT SERV, V61, P373, DOI 10.1176/ps.2010.61.4.373
   JARLAIS DCD, 1995, AM J PUBLIC HEALTH, V85, P1577
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Mak WWS, 2007, SOC SCI MED, V65, P245, DOI 10.1016/j.socscimed.2007.03.015
   Pascoe E. A., 2009, PSYCHOL BULL, DOI [10.1037/a0016059.supp, DOI 10.1037/A0016059.SUPP]
   Smith CBR, 2010, SOC SCI MED, V70, P859, DOI 10.1016/j.socscimed.2009.10.033
   Tempalski B, 2007, GEOFORUM, V38, P1250, DOI 10.1016/j.geoforum.2007.03.012
   Vanable PA, 2006, AIDS BEHAV, V10, P473, DOI 10.1007/s10461-006-9099-1
   von Hippel W, 2008, PSYCHOL SCI, V19, P7, DOI 10.1111/j.1467-9280.2008.02037.x
NR 25
TC 148
Z9 149
U1 3
U2 58
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1874
EI 1557-1882
J9 INT J MENT HEALTH AD
JI Int. J. Mental Health Addict.
PD FEB
PY 2013
VL 11
IS 1
BP 110
EP 122
DI 10.1007/s11469-012-9402-5
PG 13
WC Psychology, Clinical; Substance Abuse; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology; Substance Abuse; Psychiatry
GA 077WE
UT WOS:000314059300008
PM 23956702
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Humphreys, K
   Marsden, J
AF Humphreys, Keith
   Marsden, John
TI Synthesizing advice to the United States from other nations that have
   experienced drug epidemics
SO ADDICTION
LA English
DT Editorial Material
DE drug deaths; epidemic of addiction; opiates; opioid epidemic; opioids;
   overdose crisis
ID ADDICTION; LESSONS; COULD
C1 [Humphreys, Keith] Vet Affairs, Palo Alto, CA 94304 USA.
   [Humphreys, Keith] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA.
   [Marsden, John] Kings Coll London, London, England.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   VA Palo Alto Health Care System; Stanford University; RLUK- Research
   Libraries UK; University of London; King's College London
RP Humphreys, K (通讯作者)，Vet Affairs, Palo Alto, CA 94304 USA.; Humphreys, K (通讯作者)，Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA.
EM knh@stanford.edu
RI Marsden, John/B-4745-2012
OI Marsden, John/0000-0002-1307-2498
CR Abel-Ollo K, 2022, ADDICTION, V117, P1188, DOI 10.1111/add.15833
   Bergeron H, 2022, ADDICTION, V117, P1191, DOI 10.1111/add.15826
   Clausen T, 2022, ADDICTION, V117, P1192, DOI 10.1111/add.15845
   Fagan A. A., 2019, COMMUNITIES CARE BUI
   Frank RG, 2022, ADDICTION, V117, P1198, DOI 10.1111/add.15827
   Fugelstad A, 2022, ADDICTION, V117, P1189, DOI 10.1111/add.15847
   Humphreys K, 2019, WE CANT FIGHT OPIOID
   Humphreys K, 2022, LANCET, V399, P555, DOI 10.1016/S0140-6736(21)02252-2
   Jalal H, 2022, ADDICTION, V117, P1200, DOI 10.1111/add.15841
   Kolla G, 2022, ADDICTION, V117, P1194, DOI 10.1111/add.15844
   Teesson M, 2020, LANCET DIGIT HEALTH, V2, pE74, DOI 10.1016/S2589-7500(19)30213-4
   van den Brink W, 2022, ADDICTION, V117, P1197, DOI 10.1111/add.15839
NR 12
TC 0
Z9 0
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0965-2140
EI 1360-0443
J9 ADDICTION
JI Addiction
PD MAY
PY 2022
VL 117
IS 5
BP 1202
EP 1203
DI 10.1111/add.15863
PG 2
WC Substance Abuse; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry
GA 0G0KD
UT WOS:000777742400011
PM 35373483
DA 2023-06-23
ER

PT J
AU Sattler, S
   Zolala, F
   Baneshi, MR
   Ghasemi, J
   Googhari, SA
AF Sattler, Sebastian
   Zolala, Farzaneh
   Baneshi, Mohammad Reza
   Ghasemi, Javad
   Amirzadeh Googhari, Saber
TI Public Stigma Toward Female and Male Opium and Heroin Users. An
   Experimental Test of Attribution Theory and the Familiarity Hypothesis
SO FRONTIERS IN PUBLIC HEALTH
LA English
DT Article
DE public stigma; attribution theory; substance abuse; gender; opium;
   heroin; familiarity hypothesis; addiction
ID NETWORK SCALE-UP; MENTAL-ILLNESS; DRUG-USE; SOCIAL DESIRABILITY; ALCOHOL
   DEPENDENCE; HARM REDUCTION; USE DISORDERS; OPIOID USE; HEALTH; ATTITUDES
AB Drug abuse and addiction exist around the world. People addicted to drugs such as opium or heroin often encounter dehumanizing discriminatory behaviors and health-care systems that are reluctant to provide services. Experiencing discrimination often serves as a barrier to receiving help or finding a home or work. Therefore, it is important to better understand the mechanisms that lead to the stigmatization of drug addiction and who is more prone to stigmatizing behaviors. There is also a dearth of research on whether different patterns of stigma exist in men and women. Therefore, this study investigated factors affecting gender-specific stigmatization in the context of drug addiction. In our vignette study (N-Mensample = 320 and N-Womensample = 320) in Iran, we experimentally varied signals and signaling events regarding a person with drug addiction (i.e., N-Vignettes = 32 per sample), based on Attribution Theory, before assessing stigmatizing cognitions (e.g., blameworthiness), affective responses (e.g., anger), and discriminatory inclinations (e.g., segregation) with the Attribution Questionnaire. We also tested assumptions from the Familiarity Hypothesis by assessing indicators of respondents' familiarity with drug addiction (e.g., knowledge about addiction). Results, for example, show higher stigma if the person used "harder" drugs, displayed aggressive behavior, or had a less controllable drug urge. Self-attributed knowledge about addiction or prior drug use increased some forms of stigma, but diminished others. These findings only partially converged between men and women. We suggest that anti-stigma initiatives should consider information about the stigmatized person, conditions of the addiction, and characteristics of stigmatizers.
C1 [Sattler, Sebastian] Univ Cologne, Inst Sociol & Social Psychol, Cologne, Germany.
   [Sattler, Sebastian] Inst Rech Clin Montreal, Montreal, PQ, Canada.
   [Zolala, Farzaneh; Ghasemi, Javad; Amirzadeh Googhari, Saber] Kerman Univ Med Sci, Inst Futures Studies Hlth, Social Determinants Hlth Res Ctr, Kerman, Iran.
   [Zolala, Farzaneh; Amirzadeh Googhari, Saber] Kerman Univ Med Sci, Inst Futures Studies Hlth, WHO Collaborating Ctr HIV Surveillance, HIV STI Surveillance Res Ctr, Kerman, Iran.
   [Baneshi, Mohammad Reza] Kerman Univ Med Sci, Inst Futures Studies Hlth, Modeling Hlth Res Ctr, Kerman, Iran.
C3 University of Cologne; Institut de Recherche Clinique de Montreal
   (IRCM); Universite de Montreal; Kerman University of Medical Sciences;
   Kerman University of Medical Sciences; World Health Organization; Kerman
   University of Medical Sciences
RP Googhari, SA (通讯作者)，Kerman Univ Med Sci, Inst Futures Studies Hlth, Social Determinants Hlth Res Ctr, Kerman, Iran.; Googhari, SA (通讯作者)，Kerman Univ Med Sci, Inst Futures Studies Hlth, WHO Collaborating Ctr HIV Surveillance, HIV STI Surveillance Res Ctr, Kerman, Iran.
EM s.amirzadeh@kmu.ac.ir
RI Zolala, Farzaneh/S-7088-2016; Sattler, Sebastian/Y-3590-2018
OI Zolala, Farzaneh/0000-0002-1848-183X; Sattler,
   Sebastian/0000-0002-6491-0754
FU HIV/STI Surveillance Research Center [97001059]
FX The work was supported by the HIV/STI Surveillance Research Center under
   [grant number: 97001059].
CR Addison SJ, 2004, SOC PSYCH PSYCH EPID, V39, P228, DOI 10.1007/s00127-004-0723-y
   Aguinis H, 2014, ORGAN RES METHODS, V17, P351, DOI 10.1177/1094428114547952
   Ahmadinejad Mehdi, 2019, Addict Health, V11, P11, DOI 10.22122/ahj.v11i1.220
   Alam-mehrjerdi Z, 2015, ASIAN J PSYCHIATR, V16, P78, DOI 10.1016/j.ajp.2015.06.002
   ALEXANDER CS, 1978, PUBLIC OPIN QUART, V42, P93, DOI 10.1086/268432
   Amin-Esmaeili M, 2016, ADDICTION, V111, P1836, DOI 10.1111/add.13453
   Angermeyer MC, 2005, BRIT J PSYCHIAT, V186, P331, DOI 10.1192/bjp.186.4.331
   Auspurg K., 2015, FACTORIAL SURVEY EXP, DOI [10.4135/9781483398075, DOI 10.4135/9781483398075]
   Barry CL, 2014, PSYCHIAT SERV, V65, P1269, DOI 10.1176/appi.ps.201400140
   BROCKINGTON IF, 1993, BRIT J PSYCHIAT, V162, P93, DOI 10.1192/bjp.162.1.93
   Broome D., 1991, INT J DRUG POLICY, V2, P25
   CDC, 2020, NATL CTR HLTH STAT C
   Conner KO, 2008, J SOC WORK PRACT ADD, V8, P244, DOI 10.1080/15332560802157065
   Corrigan P, 2003, J HEALTH SOC BEHAV, V44, P162, DOI 10.2307/1519806
   Corrigan P., 2012, TOOLKIT EVALUATING P
   Corrigan PW, 2008, J PSYCHOSOC NURS MEN, V46, P42, DOI 10.3928/02793695-20080101-04
   Corrigan PW, 2007, COMMUNITY MENT HLT J, V43, P439, DOI 10.1007/s10597-007-9084-9
   Corrigan PW, 2006, J SOC CLIN PSYCHOL, V25, P875, DOI 10.1521/jscp.2006.25.8.875
   Corrigan PW, 2019, CLIN PSYCHOL REV, V70, P40, DOI 10.1016/j.cpr.2019.02.001
   Corrigan PW, 2009, J SOC WORK, V9, P139, DOI 10.1177/1468017308101818
   Corrigan PW, 2003, INT J SOC PSYCHIATR, V49, P142, DOI 10.1177/0020764003049002007
   Corrigan PW, 2000, CLIN PSYCHOL-SCI PR, V7, P48, DOI 10.1093/clipsy/7.1.48
   Couture S., 2003, J MENTAL HLTH, V12, P291, DOI [DOI 10.1080/09638231000118276, 10.1080/09638231000118276]
   Cowan G, 1998, PSYCHOL WOMEN QUART, V22, P267, DOI 10.1111/j.1471-6402.1998.tb00154.x
   Crutzen R, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-720
   CUNNINGHAM JA, 1993, J STUD ALCOHOL, V54, P693, DOI 10.15288/jsa.1993.54.693
   Davies JB, 2004, ALCOHOL ALCOHOLISM, V39, P346, DOI 10.1093/alcalc/agh066
   Dentith AM, 2015, ADULT LEARN, V26, P28, DOI 10.1177/1045159514558409
   Depla MFIA, 2005, INT J GERIATR PSYCH, V20, P146, DOI 10.1002/gps.1264
   Dong YR, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-222
   Ellemers N, 2004, BRIT J SOC PSYCHOL, V43, P315, DOI 10.1348/0144666042037999
   Engel U., 2015, IMPROVING SURVEY MET
   ERICKSON PG, 1989, AM J DRUG ALCOHOL AB, V15, P135, DOI 10.3109/00952998909092717
   Eskandari Narges, 2016, Glob J Health Sci, V8, P52667, DOI 10.5539/gjhs.v8n9p139
   Etesam F, 2014, ARCH IRAN MED, V17, P108, DOI 014172/AIM.005
   Ewalds-Kvist B, 2013, NORD J PSYCHIAT, V67, P360, DOI 10.3109/08039488.2012.748827
   Flaskerud JH, 1998, NURS RES, V47, P69, DOI 10.1097/00006199-199803000-00005
   Fominaya AW, 2016, PSYCHIAT RES, V241, P159, DOI 10.1016/j.psychres.2016.04.058
   Fooladi Marjaneh M, 2003, J Transcult Nurs, V14, P32, DOI 10.1177/1043659602238348
   Frankenburg FR., 2014, BRAIN ROBBERS ALCOHO
   Ghane T, 2018, B WORLD HEALTH ORGAN, V96, P165, DOI 10.2471/BLT.17.196287
   Goodyear K, 2018, DRUG ALCOHOL DEPEN, V185, P339, DOI 10.1016/j.drugalcdep.2017.12.037
   Graeff P, 2014, EUR SOCIOL REV, V30, P230, DOI 10.1093/esr/jct036
   Graham JW, 2009, ANNU REV PSYCHOL, V60, P549, DOI 10.1146/annurev.psych.58.110405.085530
   Gunn AJ, 2015, DRUG-EDUC PREV POLIC, V22, P281, DOI 10.3109/09687637.2015.1021241
   Hedegaard Holly, 2017, NCHS Data Brief, P1
   Heydari Z, 2019, INT J DRUG POLICY, V73, P36, DOI 10.1016/j.drugpo.2019.07.022
   Himmich H, 2016, INT J DRUG POLICY, V31, P184, DOI 10.1016/j.drugpo.2016.02.013
   Holmes EP, 1999, SCHIZOPHRENIA BULL, V25, P447, DOI 10.1093/oxfordjournals.schbul.a033392
   HOX JJ, 1991, SOCIOL METHOD RES, V19, P493, DOI 10.1177/0049124191019004003
   Inglehart RF, 2016, MODERNIZATION EXISTE
   Inglehart RF, 2017, SOC FORCES, V95, P1313, DOI 10.1093/sf/sox008
   Kazantzis N, 2009, AUST J REHABIL COUNS, V15, P74, DOI 10.1375/jrc.15.2.74
   Kennedy-Hendricks A, 2017, PSYCHIAT SERV, V68, P462, DOI 10.1176/appi.ps.201600056
   KERRICK JS, 1969, GENET PSYCHOL MONOGR, V79, P191
   Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957
   Kreuter F, 2008, PUBLIC OPIN QUART, V72, P847, DOI 10.1093/poq/nfn063
   Krumpal I, 2013, QUAL QUANT, V47, P2025, DOI 10.1007/s11135-011-9640-9
   Link BG, 1999, AM J PUBLIC HEALTH, V89, P1328, DOI 10.2105/AJPH.89.9.1328
   Link BG, 2001, ANNU REV SOCIOL, V27, P363, DOI 10.1146/annurev.soc.27.1.363
   LINK BG, 1987, AM J SOCIOL, V92, P1461, DOI 10.1086/228672
   Long J. S., 2001, REGRESSION MODELS CA
   Lyndon AE, 2019, J MENT HEALTH, V28, P255, DOI 10.1080/09638237.2016.1244722
   Martin JK, 2000, J HEALTH SOC BEHAV, V41, P208, DOI 10.2307/2676306
   Michaels PJ, 2013, J MENT HEALTH, V22, P218, DOI 10.3109/09638237.2012.734652
   Jimenez AM, 2014, PROCD SOC BEHV, V132, P92, DOI 10.1016/j.sbspro.2014.04.283
   Monk RL, 2011, PSYCHOL ADDICT BEHAV, V25, P645, DOI 10.1037/a0025685
   Nasirian M, 2018, INT J HEALTH POLICY, V7, P738, DOI 10.15171/ijhpm.2018.18
   Nieweglowski K, 2019, ADDICT RES THEORY, V27, P156, DOI 10.1080/16066359.2018.1474205
   Nieweglowski K, 2018, ADDICT RES THEORY, V26, P323, DOI 10.1080/16066359.2017.1409890
   OETTING ER, 1987, J COUNS PSYCHOL, V34, P205, DOI 10.1037/0022-0167.34.2.205
   Penn DL, 1998, PSYCHIAT QUART, V69, P235, DOI 10.1023/A:1022153327316
   PENN DL, 1994, SCHIZOPHRENIA BULL, V20, P567, DOI 10.1093/schbul/20.3.567
   Pescosolido BA, 1999, AM J PUBLIC HEALTH, V89, P1339, DOI 10.2105/AJPH.89.9.1339
   Pescosolido BA, 2013, AM J PUBLIC HEALTH, V103, P853, DOI 10.2105/AJPH.2012.301147
   Pescosolido BA, 2013, J HEALTH SOC BEHAV, V54, P1, DOI 10.1177/0022146512471197
   Power R, 1996, SOCIOL HEALTH ILL, V18, P86, DOI 10.1111/1467-9566.ep10934419
   Rasouli F., 2011, RES ADDICT, V4, P7
   Rettinger DA, 2009, RES HIGH EDUC, V50, P293, DOI 10.1007/s11162-008-9116-5
   Robertson LH, 2018, AM J MENS HEALTH, V12, P1118, DOI 10.1177/1557988318763661
   Saberi Zafarghandi Mohammad Bagher, 2015, Int J High Risk Behav Addict, V4, pe22863, DOI 10.5812/ijhrba.22863
   Sattler S, 2017, J STUD ALCOHOL DRUGS, V78, P415, DOI 10.15288/jsad.2017.78.415
   Sauer C., 2011, J HEALTH SOC BEHAV, V5, P83, DOI [10.18148/srm/2011.v5i3.4625, DOI 10.18148/SRM/2011.V5I3.4625]
   Schomerus G, 2012, ACTA PSYCHIAT SCAND, V125, P440, DOI 10.1111/j.1600-0447.2012.01826.x
   Schomerus G, 2011, ALCOHOL ALCOHOLISM, V46, P105, DOI 10.1093/alcalc/agq089
   Schomerus G, 2010, PSYCHIAT PRAX, V37, P111, DOI 10.1055/s-0029-1223438
   SCHWARZER R, 1991, J SOC PERS RELAT, V8, P133, DOI 10.1177/0265407591081007
   Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550
   Sorsdahl K, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-101
   Steiner P.M., 2017, J METHODS MEASUREMEN, V7, P43, DOI [DOI 10.2458/V7I2.20321, 10.2458/v7i2.20321]
   Strauser DR, 2009, INT J REHABIL RES, V32, P41, DOI 10.1097/MRR.0b013e328307f5b0
   Stuber JP, 2014, PSYCHIAT SERV, V65, P490, DOI 10.1176/appi.ps.201300136
   Toner P, 2008, DRUG-EDUC PREV POLIC, V15, P93, DOI 10.1080/09687630601157816
   US Dept of Health and Human Services, ANN SURVEILLANCE REP
   Vaghee S., 2016, EVID BASED CARE, V6, P37, DOI [10.22038/EBCJ.2016.6725, DOI 10.22038/EBCJ.2016.6725]
   Wason K. D., 2002, AUSTRALAS MARK J, V10, P41, DOI DOI 10.1016/S1441-3582(02)70157-2
   WEINER B, 1993, AM PSYCHOL, V48, P957, DOI 10.1037/0003-066X.48.9.957
   WEINER B, 1988, J PERS SOC PSYCHOL, V55, P738, DOI 10.1037/0022-3514.55.5.738
   WHO, 2010, ATLAS SUBST US RES P
   Witte TH, 2019, SUBST USE MISUSE, V54, P1115, DOI 10.1080/10826084.2018.1560469
   Wood E, 2020, SUBST USE MISUSE, V55, P818, DOI 10.1080/10826084.2019.1703750
   WORLD HEALTH ORGANIZATION, GUID PSYCH ASS PHARM
   Zahedi R, 2018, J RES HEALTH SCI, V18
   Zamanian M, 2019, INT J FERTIL STERIL, V13, P209, DOI 10.22074/ijfs.2019.5721
   Zargham M, 2002, P NAT C ADD ZANJ IR
   Zarghami M, 2015, IRAN J PSYCHIATR BEH, V9, DOI 10.17795/ijpbs2074
   Ziaaddini Hasan, 2013, J Addict, V2013, P297378, DOI 10.1155/2013/297378
   Zolala Farzaneh, 2016, Int J High Risk Behav Addict, V5, pe22320, DOI 10.5812/ijhrba.22320
NR 108
TC 6
Z9 6
U1 4
U2 14
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-2565
J9 FRONT PUBLIC HEALTH
JI Front. Public Health
PD APR 20
PY 2021
VL 9
AR 652876
DI 10.3389/fpubh.2021.652876
PG 13
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA RW5ZN
UT WOS:000646601800001
PM 33959582
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Ahmed, SH
   Lenoir, M
   Guillem, K
AF Ahmed, Serge H.
   Lenoir, Magalie
   Guillem, Karine
TI Neurobiology of addiction versus drug use driven by lack of choice
SO CURRENT OPINION IN NEUROBIOLOGY
LA English
DT Review
ID NUCLEUS-ACCUMBENS; RHESUS-MONKEYS; COCAINE; REWARD; DOPAMINE; FOOD;
   MECHANISMS; ABSTINENCE; FRAMEWORK; NEURONS
AB Research on the neurobiology of addiction often involves nonhuman animals that are given ready access to drugs for self-administration but without other choices. Here we argue using cocaine as an example that this standard setting may no longer be sufficient and can even lead to the formulation of unrealistic views about the neurobiology of addiction. Addiction as a psychiatric disorder is defined as resulting from brain dysfunctions that affect normal choice-making, not as an expectable response to lack of alternative choices. We encourage neurobiologists involved in addiction research to increase animals' choice during drug access, preferably by supplying alternative rewarding pursuits. Only animals that continue to take and prefer drugs despite and at the expense of other available choices may be considered as having developed an addiction-like behavior in comparison to those that remain able to stop drug use for other pursuits, even after extended drug use. The systematic comparison of these two individual behaviors Should reveal new insights about the neurobiology of drug choice and addiction. More generally, this research should also shed a unique light on how the brain 'chooses' among qualitatively different kinds of pursuits.
C1 [Ahmed, Serge H.; Lenoir, Magalie; Guillem, Karine] Univ Bordeaux, Inst Malad Neurodegenerat, UMR 5293, F-33000 Bordeaux, France.
   [Ahmed, Serge H.; Lenoir, Magalie; Guillem, Karine] CNRS, Inst Malad Neurodegenerat, UMR 5293, F-33000 Bordeaux, France.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS - National
   Institute for Biology (INSB); UDICE-French Research Universities;
   Universite de Bordeaux; Centre National de la Recherche Scientifique
   (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French
   Research Universities; Universite de Bordeaux
RP Ahmed, SH (通讯作者)，Univ Bordeaux, Inst Malad Neurodegenerat, UMR 5293, 146 Rue Leo Saignat, F-33000 Bordeaux, France.
EM sahmed@u-bordeaux2.f
RI AHMED, Serge H/D-5236-2014; Lenoir, Magalie/E-5797-2019; Guillem,
   Karine/D-8705-2014
OI Lenoir, Magalie/0000-0001-7983-1824; Guillem,
   Karine/0000-0002-9623-3698; Ahmed, Serge/0000-0002-1225-9234
FU French Research Council (CNRS); French National Agency (ANR); Fondation
   NRJ; Universite Bordeaux-Segalen; Conseil Regional d'Aquitaine
FX This work is supported by the French Research Council (CNRS), the French
   National Agency (ANR), the Fondation NRJ, the Universite
   Bordeaux-Segalen and the Conseil Regional d'Aquitaine.
CR Adamantidis AR, 2011, J NEUROSCI, V31, P10829, DOI 10.1523/JNEUROSCI.2246-11.2011
   Ahmed SH, 2012, NEUROSCIENCE, V211, P107, DOI 10.1016/j.neuroscience.2011.08.014
   Ahmed SH, 2011, NEUROMETHODS, V53, P267, DOI 10.1007/978-1-60761-934-5_10
   Ahmed SH, 2010, NEUROSCI BIOBEHAV R, V35, P172, DOI 10.1016/j.neubiorev.2010.04.005
   Ahmed SH, 2005, EUR J PHARMACOL, V526, P9, DOI 10.1016/j.ejphar.2005.09.036
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   AIGNER TG, 1978, SCIENCE, V201, P534, DOI 10.1126/science.96531
   Alexander B., 2010, GLOBALIZATION ADDICT
   ALEXANDER BK, 1981, PHARMACOL BIOCHEM BE, V15, P571, DOI 10.1016/0091-3057(81)90211-2
   ANTHONY JC, 2002, NEUROPSYCHOPHARMACOL, P1557
   Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P224
   Augier E, 2012, ADDICT BIOL, V17, P378, DOI 10.1111/j.1369-1600.2011.00368.x
   Avena NM, 2008, NEUROSCI BIOBEHAV R, V32, P20, DOI 10.1016/j.neubiorev.2007.04.019
   Berridge KC, 2007, PSYCHOPHARMACOLOGY, V191, P391, DOI 10.1007/s00213-006-0578-x
   Berridge KC, 2010, BRAIN RES, V1350, P43, DOI 10.1016/j.brainres.2010.04.003
   Berthoud HR, 2011, CURR OPIN NEUROBIOL, V21, P888, DOI 10.1016/j.conb.2011.09.004
   Bowman EM, 1996, J NEUROPHYSIOL, V75, P1061, DOI 10.1152/jn.1996.75.3.1061
   Cacciapaglia F, 2011, J NEUROSCI, V31, P13860, DOI 10.1523/JNEUROSCI.1340-11.2011
   Cameron CM, 2012, EUR J NEUROSCI, V35, P940, DOI 10.1111/j.1460-9568.2012.08024.x
   Cantin L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011592
   Cardinal RN, 2004, CURR OPIN NEUROBIOL, V14, P156, DOI 10.1016/j.conb.2004.03.004
   CARROLL ME, 1989, PSYCHOPHARMACOLOGY, V97, P23, DOI 10.1007/BF00443407
   CARROLL ME, 1993, PSYCHOPHARMACOLOGY, V110, P5, DOI 10.1007/BF02246944
   Carroll ME, 1997, PSYCHOPHARMACOLOGY, V129, P206, DOI 10.1007/s002130050182
   Day JJ, 2007, NAT NEUROSCI, V10, P1020, DOI 10.1038/nn1923
   Degenhardt L, 2008, DRUG ALCOHOL DEPEN, V93, P227, DOI 10.1016/j.drugalcdep.2007.09.024
   Dennett Daniel C., 2003, FREEDOM EVOLVES
   Di Chiara G, 1999, EUR J PHARMACOL, V375, P13, DOI 10.1016/S0014-2999(99)00372-6
   Di Leone RJ, 2012, NAT NEUROSCI, V15, P1330, DOI 10.1038/nn.3202
   Domingos AI, 2011, NAT NEUROSCI, V14, P1562, DOI 10.1038/nn.2977
   Dutra L, 2008, AM J PSYCHIAT, V165, P179, DOI 10.1176/appi.ajp.2007.06111851
   Gearhardt AN, 2011, ADDICTION, V106, P1208, DOI 10.1111/j.1360-0443.2010.03301.x
   Heyman Gene M., 2009, ADDICTION DISORDER C, DOI [10.4159/9780674053991, DOI 10.4159/9780674053991]
   HIGGINS ST, 1994, ARCH GEN PSYCHIAT, V51, P568
   Hyman SE, 2005, AM J PSYCHIAT, V162, P1414, DOI 10.1176/appi.ajp.162.8.1414
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564
   Kane R., 1998, SIGNIFICANCE FREE WI
   Kenny PJ, 2011, NEURON, V69, P664, DOI 10.1016/j.neuron.2011.02.016
   Kerstetter KA, 2012, NEUROPSYCHOPHARMACOL, V37, P2605, DOI 10.1038/npp.2012.99
   Kim KM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033612
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J
   LEMOAL M, 1991, PHYSIOL REV, V71, P155, DOI 10.1152/physrev.1991.71.1.155
   Lenoir M, NEUROPSYCHO IN PRESS
   Lenoir M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000698
   LeSage M, 2009, PSYCHOPHARMACOLOGY, V203, P13, DOI 10.1007/s00213-008-1362-x
   Levy DJ, 2012, CURR OPIN NEUROBIOL, V22, P1027, DOI 10.1016/j.conb.2012.06.001
   Maia TV, 2011, NAT NEUROSCI, V14, P154, DOI 10.1038/nn.2723
   Martin CS, 2008, J ABNORM PSYCHOL, V117, P561, DOI 10.1037/0021-843X.117.3.561
   Mele AR, 1995, AUTONOMOUS AGENTS
   Miller W.R., 2011, TREATING ADDICTION
   Mirenowicz J, 1996, NATURE, V379, P449, DOI 10.1038/379449a0
   Montague PR, 2004, NATURE, V431, P760, DOI 10.1038/nature03015
   Montague PR, 1996, J NEUROSCI, V16, P1936, DOI 10.1523/jneurosci.16-05-01936.1996
   NADER MA, 1991, PSYCHOPHARMACOLOGY, V105, P169, DOI 10.1007/BF02244304
   Negus SS, 2003, NEUROPSYCHOPHARMACOL, V28, P919, DOI 10.1038/sj.npp.1300096
   O'Brien MS, 2005, NEUROPSYCHOPHARMACOL, V30, P1006, DOI 10.1038/sj.npp.1300681
   Opris I, 2009, NEUROSCIENCE, V163, P40, DOI 10.1016/j.neuroscience.2009.06.002
   Pan WX, 2005, J NEUROSCI, V25, P6235, DOI 10.1523/JNEUROSCI.1478-05.2005
   Paronis CA, 2002, PSYCHOPHARMACOLOGY, V163, P283, DOI 10.1007/s00213-002-1180-5
   Potenza MN, 2011, NEURON, V69, P695, DOI 10.1016/j.neuron.2011.02.009
   Rangel A, 2008, NAT REV NEUROSCI, V9, P545, DOI 10.1038/nrn2357
   Redish AD, 2008, BEHAV BRAIN SCI, V31, P415, DOI 10.1017/S0140525X0800472X
   Redish AD, 2008, BEHAV BRAIN SCI, P437, DOI DOI 10.1017/S0110525X0100472X
   Reynolds JNJ, 2001, NATURE, V413, P67, DOI 10.1038/35092560
   Robbins TW, 1999, NATURE, V398, P567, DOI 10.1038/19208
   ROBERTS DCS, 1977, PHARMACOL BIOCHEM BE, V6, P615, DOI 10.1016/0091-3057(77)90084-3
   ROBERTS DCS, 1980, PHARMACOL BIOCHEM BE, V12, P781, DOI 10.1016/0091-3057(80)90166-5
   Robinson DL, 2008, EUR J NEUROSCI, V28, P1887, DOI 10.1111/j.1460-9568.2008.06464.x
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Roitman MF, 2004, J NEUROSCI, V24, P1265, DOI 10.1523/JNEUROSCI.3823-03.2004
   Salamone JD, 2012, BIOL PSYCHI IN PRESS
   Salamone JD, 2012, NEURON, V76, P470, DOI 10.1016/j.neuron.2012.10.021
   Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593
   Schultz W, 2011, NEURON, V69, P603, DOI 10.1016/j.neuron.2011.02.014
   Searle J. R., 2007, FREEDOM NEUROBIOLOGY
   Seddon T., 2010, HIST DRUGS DRUGS FRE
   Solinas M, 2010, PROG NEUROBIOL, V92, P572, DOI 10.1016/j.pneurobio.2010.08.002
   SPRAGG S. D. S., 1940, COMPAR PSYCHOL MONOGR, V15, P1
   Stairs DJ, 2009, PHARMACOL BIOCHEM BE, V92, P377, DOI 10.1016/j.pbb.2009.01.016
   Stein DJ, 2010, PSYCHOL MED, V40, P1759, DOI 10.1017/S0033291709992261
   Thomsen M, 2009, J PHARMACOL EXP THER, V331, P204, DOI 10.1124/jpet.109.156265
   TREIT D, 1990, PHARMACOL BIOCHEM BE, V37, P451, DOI 10.1016/0091-3057(90)90011-6
   Tsai HC, 2009, SCIENCE, V324, P1080, DOI 10.1126/science.1168878
   Volkow ND, 2005, NAT NEUROSCI, V8, P555, DOI 10.1038/nn1452
   Volkow ND, 2011, NEURON, V69, P599, DOI 10.1016/j.neuron.2011.01.027
   Volkow ND, 2011, TRENDS COGN SCI, V15, P37, DOI 10.1016/j.tics.2010.11.001
   Ziauddeen H, 2012, NAT REV NEUROSCI, V13, P279, DOI 10.1038/nrn3212
NR 88
TC 80
Z9 80
U1 2
U2 38
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0959-4388
EI 1873-6882
J9 CURR OPIN NEUROBIOL
JI Curr. Opin. Neurobiol.
PD AUG
PY 2013
VL 23
IS 4
BP 581
EP 587
DI 10.1016/j.conb.2013.01.028
PG 7
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 204XJ
UT WOS:000323404300019
PM 23428657
DA 2023-06-23
ER

PT J
AU von der Goltz, C
   Kiefer, F
AF von der Goltz, Christoph
   Kiefer, Falk
TI Learning and memory in the aetiopathogenesis of addiction: future
   implications for therapy?
SO EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
LA English
DT Article
DE Addiction; Drugs; Alcohol; Learning; Memory; Reconsolidation; Extinction
ID COCAINE-SEEKING BEHAVIOR; CONDITIONED PLACE PREFERENCE;
   NUCLEUS-ACCUMBENS CORE; CUE-EXPOSURE; SYNAPTIC PLASTICITY; ALCOHOL
   DEPENDENCE; PROTEIN-SYNTHESIS; DOPAMINE NEURONS; DRUG-ADDICTION; NEURAL
   BASIS
AB Addiction is a chronic relapsing disorder. Even after long periods of abstinence from drugs, the risk of relapse, often precipitated by drug-associated cues, remains high. Especially learning processes have been shown to play a major role in the maintenance of addictive behaviour. Humans and animals rapidly learn cues and contexts that predict the availability of addictive drugs. Once learned, these cues and contexts initiate drug seeking, craving and relapse in both animal models and clinical studies. These observations have converged on the hypothesis that addiction represents the pathological usurpation of neural processes that normally serve reward-related learning. In this context, a substantial body of evidence suggests that several types of neuroadaptation occur, including synapse-specific adaptations of the type thought to underlie specific long-term associative memory. Consequently, understanding learning and memory processes in the brain in addiction is an important key for understanding the persistence of addiction, and it is reasonable to hypothesize that the disruption of drug-related memories may help to prevent relapses.
C1 [von der Goltz, Christoph; Kiefer, Falk] Heidelberg Univ, CIMH, Dept Addict Behav & Addict Med, D-68159 Mannheim, Germany.
C3 Central Institute of Mental Health; Ruprecht Karls University Heidelberg
RP Kiefer, F (通讯作者)，Heidelberg Univ, CIMH, Dept Addict Behav & Addict Med, J5, D-68159 Mannheim, Germany.
EM falk.kiefer@zi-mannheim.de
RI Kiefer, Falk/E-8325-2012
FU Deutsche Forschungsgemeinschaft (DFG)
FX The authors' research and the preparation of the manuscript were
   supported by the Deutsche Forschungsgemeinschaft (DFG; SFB 636, D6).
CR Bernardi RE, 2007, BEHAV NEUROSCI, V121, P156, DOI 10.1037/0735-7044.121.1.156
   Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8
   BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273
   Boening JAL, 2001, J NEURAL TRANSM, V108, P755, DOI 10.1007/s007020170050
   Chklovskii DB, 2004, NATURE, V431, P782, DOI 10.1038/nature03012
   Conklin CA, 2002, ADDICTION, V97, P155, DOI 10.1046/j.1360-0443.2002.00014.x
   Cooke SF, 2006, BRAIN, V129, P1659, DOI 10.1093/brain/awl082
   Dalley JW, 2005, P NATL ACAD SCI USA, V102, P6189, DOI 10.1073/pnas.0502080102
   Di Ciano P, 2001, NEUROPSYCHOPHARMACOL, V25, P341, DOI 10.1016/S0893-133X(01)00235-4
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   DRUMMOND DC, 1990, BRIT J ADDICT, V85, P725
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Harris GC, 2003, NEUROPSYCHOPHARMACOL, V28, P73, DOI 10.1038/sj.npp.1300011
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Ito R, 2004, NAT NEUROSCI, V7, P389, DOI 10.1038/nn1217
   Jay TM, 2003, PROG NEUROBIOL, V69, P375, DOI 10.1016/S0301-0082(03)00085-6
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kandel E., 2021, PRINCIPLES NEURAL SC, VSixth Edition6th edition edn
   KARLER R, 1989, LIFE SCI, V45, P599, DOI 10.1016/0024-3205(89)90045-3
   Kauer JA, 2004, ANNU REV PHYSIOL, V66, P447, DOI 10.1146/annurev.physiol.66.032102.112534
   Kauer JA, 2007, NAT REV NEUROSCI, V8, P844, DOI 10.1038/nrn2234
   LADEWIG D, 1974, SCHWEIZ MED WSCHR, V104, P545
   Lee JLC, 2005, NEURON, V47, P795, DOI 10.1016/j.neuron.2005.08.007
   Lisman JE, 2005, NEURON, V46, P703, DOI 10.1016/j.neuron.2005.05.002
   Loeber S, 2006, NERVENARZT, V77, P558, DOI 10.1007/s00115-005-2000-z
   Malenka RC, 2003, NAT REV NEUROSCI, V4, P923, DOI 10.1038/nrn1258
   McFarland K, 2003, J NEUROSCI, V23, P3531
   Milekic MH, 2006, J NEUROSCI, V26, P3010, DOI 10.1523/JNEUROSCI.4818-05.2006
   MISANIN JR, 1968, SCIENCE, V160, P554, DOI 10.1126/science.160.3827.554
   Montague PR, 2004, NATURE, V431, P760, DOI 10.1038/nature03015
   MONTI PM, 1993, J CONSULT CLIN PSYCH, V61, P1011, DOI 10.1037/0022-006X.61.6.1011
   Nader K, 2000, NATURE, V406, P722, DOI 10.1038/35021052
   Park WK, 2002, J NEUROSCI, V22, P2916, DOI 10.1523/JNEUROSCI.22-07-02916.2002
   Robinson MJF, 2007, BEHAV BRAIN RES, V178, P146, DOI 10.1016/j.bbr.2006.12.013
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Rohsenow DJ, 2001, ADDICTION, V96, P1161, DOI 10.1046/j.1360-0443.2001.96811619.x
   Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-7
   Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593
   Sitharthan T, 1997, J CONSULT CLIN PSYCH, V65, P878, DOI 10.1037/0022-006X.65.5.878
   Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077
   Valjent E, 2006, P NATL ACAD SCI USA, V103, P2932, DOI 10.1073/pnas.0511030103
   von der Goltz C, 2009, PSYCHOPHARMACOLOGY, V205, P389, DOI 10.1007/s00213-009-1544-1
   White NM, 1996, ADDICTION, V91, P921, DOI 10.1111/j.1360-0443.1996.tb03586.x
   Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406
NR 45
TC 25
Z9 25
U1 1
U2 11
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0940-1334
EI 1433-8491
J9 EUR ARCH PSY CLIN N
JI Eur. Arch. Psych. Clin. Neurosci.
PD NOV
PY 2009
VL 259
SU 2
BP 183
EP 187
DI 10.1007/s00406-009-0057-6
PG 5
WC Clinical Neurology; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology; Psychiatry
GA 513FD
UT WOS:000271307000012
PM 19876677
DA 2023-06-23
ER

PT J
AU Fouyssac, M
   Puaud, M
   Ducret, E
   Marti-Prats, L
   Vanhille, N
   Ansquer, S
   Zhang, XX
   Belin-Rauscent, A
   Giuliano, C
   Houeto, JL
   Everitt, BJ
   Belin, D
AF Fouyssac, Maxime
   Puaud, Mickael
   Ducret, Eric
   Marti-Prats, Lucia
   Vanhille, Nathalie
   Ansquer, Solene
   Zhang, Xinxuan
   Belin-Rauscent, Aude
   Giuliano, Chiara
   Houeto, Jean-Luc
   Everitt, Barry. J.
   Belin, David
TI Environment-dependent behavioral traits and experiential factors shape
   addiction vulnerability
SO EUROPEAN JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE alcohol; cocaine; compulsivity; environmental enrichment;
   schedule-induced polydipsia
ID SCHEDULE-INDUCED-POLYDIPSIA; VOLUNTARY ETHANOL INTAKE;
   SENSATION-SEEKING; INDIVIDUAL-DIFFERENCES; NUCLEUS-ACCUMBENS;
   DRUG-ADDICTION; MALE-RATS; COCAINE; ALCOHOL; ENRICHMENT
AB The transition from controlled drug use to drug addiction depends on an interaction between a vulnerable individual, their environment and a drug. Here we tested the hypothesis that conditions under which individuals live influence behavioral vulnerability traits and experiential factors operating in the drug taking environment to determine the vulnerability to addiction. The role of behavioral vulnerability traits in mediating the influence of housing conditions on the tendency to acquire cocaine self-administration was characterized in 48 rats housed in either an enriched (EE) or a standard (SE) environment. Then, the influence of these housing conditions on the individual vulnerability to develop addiction-like behavior for cocaine or alcohol was measured in 72 EE or SE rats after several months of cocaine self-administration or intermittent alcohol drinking, respectively. The determining role of negative experiential factors in the drug taking context was further investigated in 48 SE rats that acquired alcohol drinking to self-medicate distress in a schedule-induced polydipsia procedure. The environment influenced the acquisition of drug intake through its effect on behavioral markers of resilience to addiction. In contrast, the initiation of drug taking as a coping strategy or in a negative state occasioned by the contrast between enriched housing conditions and a relatively impoverished drug taking setting, facilitated the development of compulsive cocaine and alcohol intake. These data indicate that addiction vulnerability depends on environmentally determined experiential factors, and suggest that initiating drug use through negative reinforcement-based self-medication facilitates the development of addiction in vulnerable individuals.
   Significance statement: The factors that underlie an individual's vulnerability to switch from controlled, recreational drug use to addiction are not well understood. We showed that in individuals housed in enriched conditions, the experience of drugs in the relative social and sensory impoverishment of the drug taking context, and the associated change in behavioral traits of resilience to addiction, exacerbate the vulnerability to develop compulsive drug intake. We further demonstrated that the acquisition of alcohol drinking as a mechanism to cope with distress increases the vulnerability to develop compulsive alcohol intake. Together these results demonstrate that experiential factors in the drug taking context shape the vulnerability to addiction.
C1 [Fouyssac, Maxime; Puaud, Mickael; Marti-Prats, Lucia; Zhang, Xinxuan; Belin-Rauscent, Aude; Giuliano, Chiara; Everitt, Barry. J.; Belin, David] Univ Cambridge, Dept Psychol, Cambridge, England.
   [Ducret, Eric] Univ Poitiers, Fac Pharm, Poitiers, France.
   [Vanhille, Nathalie; Ansquer, Solene; Houeto, Jean-Luc] CHU Poitiers, INSERM CIC 1402, Poitiers, France.
   [Houeto, Jean-Luc] Univ Limoges, Neuroepidemiol Trop, INSERM UMR S 1094, Limoges, France.
C3 University of Cambridge; Universite de Poitiers; CHU Poitiers; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Universite de
   Poitiers; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite de Limoges
RP Belin, D (通讯作者)，Univ Cambridge, Dept Psychol, Cambridge, England.
EM jlhoueto@orange.fr; bdb26@cam.ac.uk
OI Zhang, Xinxuan/0000-0001-8301-4552
FU Medical Research Council [MR/N02530X/1]; Leverhulme Trust
   [RPG-2016-117]; Leverhulme Trust Early Career Fellowship [ECF-2018-713];
   MRC [MR/N02530X/1] Funding Source: UKRI
FX Medical Research Council, Grant/Award Number: MR/N02530X/1; Leverhulme
   Trust, Grant/Award Number: RPG-2016-117; Leverhulme Trust Early Career
   Fellowship, Grant/Award Number: ECF-2018-713
CR Ahmed SH, 2020, NEUROSCI BIOBEHAV R, V110, P3, DOI 10.1016/j.neubiorev.2018.08.015
   Alvers KM, 2012, BEHAV PHARMACOL, V23, P650, DOI 10.1097/FBP.0b013e3283584765
   American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4th, DOI [DOI 10.1176/DSM10.1176/APPI.BOOKS.9780890420249.DSM-IV-TR, DOI 10.1016/B978-1-4377-2242-0.00016-X]
   American Psychiatric Association [APA], 2022, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425787]
   Ansquer S, 2014, BIOL PSYCHIAT, V75, P825, DOI 10.1016/j.biopsych.2013.09.031
   Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244
   Augier E, 2018, SCIENCE, V360, P1321, DOI 10.1126/science.aao1157
   Bardo MT, 2001, PSYCHOPHARMACOLOGY, V155, P278
   Beckmann JS, 2012, BEHAV BRAIN RES, V226, P331, DOI 10.1016/j.bbr.2011.09.021
   Belin D, 2016, GENES BRAIN BEHAV, V15, P74, DOI 10.1111/gbb.12265
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   Belin D, 2013, CURR OPIN NEUROBIOL, V23, P564, DOI 10.1016/j.conb.2013.01.025
   Belin D, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a011940
   Belin D, 2011, NEUROPSYCHOPHARMACOL, V36, P569, DOI 10.1038/npp.2010.188
   Belin D, 2009, BIOL PSYCHIAT, V65, P863, DOI 10.1016/j.biopsych.2008.05.031
   Belin-Rauscent A, 2016, MOL PSYCHIATR, V21, P491, DOI [10.1038/mp.2015.140, 10.1038/mp.2016.32]
   BRETT LP, 1979, J COMP PHYSIOL PSYCH, V93, P946, DOI 10.1037/h0077619
   Burke AR, 2017, NEUROSCI BIOBEHAV R, V76, P280, DOI 10.1016/j.neubiorev.2017.01.018
   CAMPFIELD LA, 1986, AM J PHYSIOL, V251, pR63, DOI 10.1152/ajpregu.1986.251.1.R63
   Caprioli D, 2009, BIOL PSYCHIAT, V65, P893, DOI 10.1016/j.biopsych.2008.12.009
   Carnicella S, 2014, ALCOHOL, V48, P243, DOI 10.1016/j.alcohol.2014.01.006
   Chen BT, 2013, NATURE, V496, P359, DOI 10.1038/nature12024
   Collins SE, 2016, ALCOHOL RES-CURR REV, V38, P83
   Comeau N, 2001, ADDICT BEHAV, V26, P803, DOI 10.1016/S0306-4603(01)00238-6
   Dal Mas DE, 2017, CORTEX, V92, P57, DOI 10.1016/j.cortex.2017.03.008
   DANTZER R, 1988, PHYSIOL BEHAV, V43, P269, DOI 10.1016/0031-9384(88)90186-2
   DANTZER R, 1981, HORM BEHAV, V15, P386, DOI 10.1016/0018-506X(81)90003-9
   DANTZER R, 1988, PHYSIOL BEHAV, V43, P275, DOI 10.1016/0031-9384(88)90187-4
   Dellu F, 1996, PSYCHONEUROENDOCRINO, V21, P441, DOI 10.1016/0306-4530(96)00017-0
   Dellu F, 1996, NEUROPSYCHOBIOLOGY, V34, P136, DOI 10.1159/000119305
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Desrichard O, 2005, ADDICT BEHAV, V30, P1449, DOI 10.1016/j.addbeh.2005.01.011
   Dilleen R, 2012, PSYCHOPHARMACOLOGY, V222, P89, DOI 10.1007/s00213-011-2626-4
   Doremus TL, 2006, PHARMACOL BIOCHEM BE, V83, P570, DOI 10.1016/j.pbb.2006.03.019
   Ducret E, 2016, BIOL PSYCHIAT, V80, P226, DOI 10.1016/j.biopsych.2015.09.019
   Ersche KD, 2013, BIOL PSYCHIAT, V74, P137, DOI 10.1016/j.biopsych.2012.11.016
   Everitt B. J., 2008, DOPAMINE HDB
   FALK JL, 1961, SCIENCE, V133, P195, DOI 10.1126/science.133.3447.195
   FALK JL, 1966, J EXP ANAL BEHAV, V9, P19, DOI 10.1901/jeab.1966.9-19
   Franques P, 2000, ENCEPHALE, V26, P68
   Gipson CD, 2011, PSYCHOPHARMACOLOGY, V214, P557, DOI 10.1007/s00213-010-2060-z
   Giuliano C, 2019, J NEUROSCI, V39, P1744, DOI 10.1523/JNEUROSCI.2615-18.2018
   Giuliano C, 2018, NEUROPSYCHOPHARMACOL, V43, P728, DOI 10.1038/npp.2017.105
   GOSNELL BA, 1992, ALCOHOL, V9, P203, DOI 10.1016/0741-8329(92)90054-E
   HADAWAY PF, 1979, PSYCHOPHARMACOLOGY, V66, P87, DOI 10.1007/BF00431995
   Havermans RC, 2015, APPETITE, V85, P52, DOI 10.1016/j.appet.2014.11.007
   Holtz NA, 2013, PSYCHOPHARMACOLOGY, V227, P243, DOI 10.1007/s00213-012-2958-8
   Hopf FW, 2014, ALCOHOL, V48, P253, DOI 10.1016/j.alcohol.2014.03.001
   Hopf FW, 2010, ALCOHOL CLIN EXP RES, V34, P1565, DOI 10.1111/j.1530-0277.2010.01241.x
   Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560
   Ipser JC, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007505.pub2
   JONES GH, 1989, PHYSIOL BEHAV, V45, P71, DOI 10.1016/0031-9384(89)90167-4
   Joyner KJ, 2019, CLIN PSYCHOL SCI, V7, P1109, DOI 10.1177/2167702619838480
   Karkhanis AN, 2014, ALCOHOL CLIN EXP RES, V38, P2770, DOI 10.1111/acer.12555
   Kasanetz F, 2010, SCIENCE, V328, P1709, DOI 10.1126/science.1187801
   Khantzian EJ, 2013, ADDICTION, V108, P668, DOI 10.1111/add.12004
   Koob GF, 2009, PHARMACOPSYCHIATRY, V42, pS32, DOI 10.1055/s-0029-1216356
   Koob GF, 2015, EUR J PHARMACOL, V753, P73, DOI 10.1016/j.ejphar.2014.11.044
   Koob GF, 2013, CURR OPIN NEUROBIOL, V23, P559, DOI 10.1016/j.conb.2013.03.011
   Kreek MJ, 2005, NAT NEUROSCI, V8, P1450, DOI 10.1038/nn1583
   Laviola G, 2008, NEUROBIOL DIS, V31, P159, DOI 10.1016/j.nbd.2008.05.001
   Lechner WV, 2020, ADDICT BEHAV, V110, DOI 10.1016/j.addbeh.2020.106527
   Luthar SS, 2018, DEV PSYCHOPATHOL, V30, P315, DOI 10.1017/S0954579417000645
   Marti-Prats L., 2020, BACLOFEN DECREASES C
   Meiss H R, 1984, Adv Alcohol Subst Abuse, V4, P97
   Mitsushima D, 2003, PSYCHONEUROENDOCRINO, V28, P574, DOI 10.1016/S0306-4530(02)00043-4
   Murray JE, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10088
   Naeem M, 2016, BEHAV NEUROSCI, V130, P376, DOI 10.1037/bne0000154
   Pellon R, 2011, BEHAV BRAIN RES, V217, P195, DOI 10.1016/j.bbr.2010.10.010
   PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295
   Platt B., 2008, CURRENT PROTOCOLS NE, V43
   Puhl MD, 2012, BEHAV PHARMACOL, V23, P43, DOI 10.1097/FBP.0b013e32834eb060
   Radwanska K, 2012, ADDICT BIOL, V17, P601, DOI 10.1111/j.1369-1600.2011.00394.x
   Ravenelle R, 2014, NEUROSCIENCE, V270, P76, DOI 10.1016/j.neuroscience.2014.03.060
   ROCKMAN GE, 1989, PHARMACOL BIOCHEM BE, V34, P487, DOI 10.1016/0091-3057(89)90545-5
   Rouge-Pont F, 1998, EUR J NEUROSCI, V10, P3903, DOI 10.1046/j.1460-9568.1998.00438.x
   Shiels MS, 2019, LANCET PUBLIC HEALTH, V4, pE97, DOI 10.1016/S2468-2667(18)30208-1
   Siciliano CA, 2019, SCIENCE, V366, P1008, DOI 10.1126/science.aay1186
   Singhal G, 2019, BEHAV BRAIN RES, V368, P110, DOI 10.1016/j.bbr.2019.111917
   SIREVAAG AM, 1991, EXP NEUROL, V111, P74, DOI 10.1016/0014-4886(91)90052-E
   Smith MA, 2009, BEHAV PHARMACOL, V20, P312, DOI 10.1097/FBP.0b013e32832ec568
   Suh JJ, 2008, PSYCHOANAL PSYCHOL, V25, P518, DOI 10.1037/0736-9735.25.3.518
   TOMIE A, 1989, CONT LEARNING THEORI, P191
   Um M, 2020, BRAIN IMAGING BEHAV, V14, P1921, DOI 10.1007/s11682-019-00136-1
   Valentino RJ, 2010, BRAIN RES, V1314, P29, DOI 10.1016/j.brainres.2009.09.100
   Vanhille N, 2015, NEUROPSYCHOPHARMACOL, V40, P577, DOI 10.1038/npp.2014.204
   VODANOVICH SJ, 1991, PSYCHOL REP, V69, P1139, DOI 10.2466/PR0.69.8.1139-1146
   Wang XM, 2019, PSYCHOPHARMACOLOGY, V236, P1999, DOI 10.1007/s00213-019-5187-6
   WISE RA, 1973, PSYCHOPHARMACOLOGIA, V29, P203, DOI 10.1007/BF00414034
   WOLFFGRAMM J, 1995, BEHAV BRAIN RES, V70, P77, DOI 10.1016/0166-4328(95)00131-C
NR 90
TC 9
Z9 9
U1 2
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0953-816X
EI 1460-9568
J9 EUR J NEUROSCI
JI Eur. J. Neurosci.
PD MAR
PY 2021
VL 53
IS 6
BP 1794
EP 1808
DI 10.1111/ejn.15087
EA JAN 2021
PG 15
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology
GA RG7GJ
UT WOS:000607142100001
PM 33332672
OA Green Submitted
DA 2023-06-23
ER

PT J
AU Moeller, S
   Kundu, P
   Bachi, K
   Maloney, T
   Malaker, P
   Parvaz, M
   Alia-Klein, N
   London, E
   Goldstein, R
AF Moeller, Scott
   Kundu, Prantik
   Bachi, Keren
   Maloney, Thomas
   Malaker, Pias
   Parvaz, Muhammad
   Alia-Klein, Nelly
   London, Edythe
   Goldstein, Rita
TI Neurocircuitry Underlying Self-Awareness of the Need to Change
   Problematic Drug Use: A New fMRI Task Assessing Insight in Addiction
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Meeting Abstract
DE Self-Referential; fMRI; Drug Addiction; Insight; Anterior Cingulate
   Cortex
C1 [Moeller, Scott; Kundu, Prantik; Bachi, Keren; Maloney, Thomas; Malaker, Pias; Parvaz, Muhammad; Alia-Klein, Nelly; London, Edythe; Goldstein, Rita] SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA.
C3 State University of New York (SUNY) System; State University of New York
   (SUNY) Stony Brook
RI Bachi, Keren/O-9024-2017; Moeller, Scott J/AAV-1861-2021; Parvaz,
   Muhammad/GPF-9163-2022
OI Bachi, Keren/0000-0001-9817-5957; 
NR 0
TC 0
Z9 0
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
EI 1740-634X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD DEC
PY 2018
VL 43
SU S
MA W269
BP S520
EP S520
PG 1
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA VI6YX
UT WOS:000509546600944
DA 2023-06-23
ER

PT J
AU Simoneau, H
   Menard, JM
   Blanchette-Martin, N
AF Simoneau, Helene
   Menard, Jean-Marc
   Blanchette-Martin, Nadine
TI Addiction Severity and Suicidal Behaviors Among Persons Entering
   Treatment
SO ARCHIVES OF SUICIDE RESEARCH
LA English
DT Article
DE alcohol addiction; drug addiction; substance use disorder; suicidal
   behaviors; treatment
ID SUBSTANCE USE DISORDERS; RISK-FACTORS; COMPLETED SUICIDE; HEROIN USERS;
   DRUG-ABUSE; ALCOHOL; DEPENDENCE; PREDICTORS; DRINKING; INDEX
AB The aim of this study was three-fold: to compare the rates for suicidal behaviors based on the problem substance, to look at the association between addiction severity and suicidal behaviors, and to identify the components of addiction severity associated with suicidal behaviors. Addiction Severity Index databases from three public rehabilitation centers were merged for analyses, yielding 6,551 evaluations. The rates for suicidal behaviors among those who have a problem with both alcohol and a drug are higher than for those who have a problem with any single substance. The effect of addiction severity on suicidal behaviors persists even when other problem areas are taken into account. Thus, clinicians must pay closer attention to persons with both alcohol and drug problem.
C1 [Simoneau, Helene] Ctr Integre Univ Sante & Serv Soc Ctr Est de Ile, 950 Louvain St East, Montreal, PQ H2M 2E8, Canada.
   [Menard, Jean-Marc] Ctr Integre Univ Sante & Serv Soc Mauricie & Ctr, Trois Rivieres, PQ, Canada.
   [Blanchette-Martin, Nadine] Ctr Integre Sante & Serv, Quebec City, PQ, Canada.
   [Blanchette-Martin, Nadine] Ctr Integre Univ Sante & Serv Soc Capitale Natl, Ctr Serv Readaptat Dependance Quebec, Quebec City, PQ, Canada.
   [Blanchette-Martin, Nadine] Ctr Integre Sante & Serv Soc Chaudiere Appalaches, Programme Dependance, Levis, PQ, Canada.
C3 Centre Integre de Sante et de Services Sociaux de Laval
RP Simoneau, H (通讯作者)，Ctr Integre Univ Sante & Serv Soc Ctr Est de Ile, 950 Louvain St East, Montreal, PQ H2M 2E8, Canada.
EM helene.simoneau.cdc@ssss.gouv.qc.ca
CR Bergeron J., 1992, VALIDATION INSTRUMEN
   Bergeron J, 1998, EVALUATION CLIENTELE, P31
   Bohnert ASB, 2010, DRUG ALCOHOL DEPEN, V110, P183, DOI 10.1016/j.drugalcdep.2010.03.010
   Borges G, 2000, AM J EPIDEMIOL, V151, P781
   Bradvik L, 2003, SUICIDE LIFE-THREAT, V33, P186, DOI 10.1521/suli.33.2.186.22773
   Cho H, 2007, ADDICT BEHAV, V32, P1628, DOI 10.1016/j.addbeh.2006.11.017
   Conner KR, 2012, DRUG ALCOHOL DEPEN, V120, P155, DOI 10.1016/j.drugalcdep.2011.07.013
   Conner KR, 2011, ALCOHOL CLIN EXP RES, V35, P60, DOI 10.1111/j.1530-0277.2010.01322.x
   Conner KR, 2004, ALCOHOL CLIN EXP RES, V28, p6S, DOI 10.1097/01.ALC.0000127410.84505.2A
   Darke S, 2005, DRUG ALCOHOL DEPEN, V78, P177, DOI 10.1016/j.drugalcdep.2004.10.009
   Darke S, 2004, DRUG ALCOHOL DEPEN, V73, P1, DOI 10.1016/j.drugalcdep.2003.08.008
   Darke S, 2002, ADDICTION, V97, P1383, DOI 10.1046/j.1360-0443.2002.00214.x
   Delisle J. M, 2009, ALCOOLOGIE ADDICTOLO, V31, P57
   Duhamel D, 2007, TOXICOMANIE PHENOMEN
   Erinoff L, 2004, DRUG ALCOHOL DEPEN, V76, pS3, DOI 10.1016/j.drugalcdep.2004.08.002
   Erinoff L, 2004, DRUG ALCOHOL DEPEN, V76, pS1, DOI 10.1016/j.drugalcdep.2004.08.001
   Glasner-Edwards S, 2008, AM J ADDICTION, V17, P24, DOI 10.1080/10550490701756070
   Goldston DB, 2004, DRUG ALCOHOL DEPEN, V76, pS79, DOI 10.1016/j.drugalcdep.2004.08.009
   Gonzalez VM, 2012, ADDICT BEHAV, V37, P994, DOI 10.1016/j.addbeh.2012.03.027
   Hufford MR, 2001, CLIN PSYCHOL REV, V21, P797, DOI 10.1016/S0272-7358(00)00070-2
   Ilgen MA, 2007, ALCOHOL CLIN EXP RES, V31, P635, DOI 10.1111/j.1530-0277.2007.00348.x
   Landheim AS, 2006, EUR ADDICT RES, V12, P102, DOI 10.1159/000090430
   MCLELLAN AT, 1985, J NERV MENT DIS, V173, P412, DOI 10.1097/00005053-198507000-00005
   MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199, DOI 10.1016/0740-5472(92)90062-S
   Miller M, 2011, DRUG ALCOHOL DEPEN, V113, P110, DOI 10.1016/j.drugalcdep.2010.07.016
   MILLER N S, 1991, Journal of Addictive Diseases, V10, P49, DOI 10.1300/J069v10n03_06
   Mino A, 1999, Crisis, V20, P28, DOI 10.1027//0227-5910.20.1.28
   Preuss UW, 2003, AM J PSYCHIAT, V160, P56, DOI 10.1176/appi.ajp.160.1.56
   Preuss UW, 2002, ALCOHOL CLIN EXP RES, V26, P471, DOI 10.1111/j.1530-0277.2002.tb02563.x
   ROY A, 1993, ALCOHOL HEALTH RES W, V17, P133
   Schneider B, 2009, ARCH SUICIDE RES, V13, P303, DOI 10.1080/13811110903263191
   Sher L, 2006, ACTA PSYCHIAT SCAND, V113, P13, DOI 10.1111/j.1600-0447.2005.00643.x
   Tiet QQ, 2006, ALCOHOL CLIN EXP RES, V30, P998, DOI 10.1111/j.1530-0277.2006.00114.x
   Vijayakumar L, 2011, CURR OPIN PSYCHIATR, V24, P197, DOI 10.1097/YCO.0b013e3283459242
   Wilcox HC, 2004, DRUG ALCOHOL DEPEN, V76, pS11, DOI 10.1016/j.drugalcdep.2004.08.003
   Wines JD, 2004, DRUG ALCOHOL DEPEN, V76, pS21, DOI 10.1016/j.drugalcdep.2004.08.004
   Yuodelis-Flores C, 2015, AM J ADDICTION, V24, P98, DOI 10.1111/ajad.12185
NR 37
TC 5
Z9 5
U1 0
U2 11
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1381-1118
EI 1543-6136
J9 ARCH SUICIDE RES
JI Arch. Suicide Res.
PY 2017
VL 21
IS 2
BP 341
EP 353
DI 10.1080/13811118.2016.1182093
PG 13
WC Psychiatry; Psychology; Psychology, Multidisciplinary
WE Social Science Citation Index (SSCI)
SC Psychiatry; Psychology
GA ES5NM
UT WOS:000399587300009
PM 27135975
DA 2023-06-23
ER

PT J
AU Sy, MP
   Reyes, RCD
   Roraldo, MPNR
   Ohshima, N
AF Sy, Michael P.
   Delos Reyes, Rod Charlie
   Roraldo, Ma Patricia Nicole R.
   Ohshima, Nobuo
TI Uncovering the lived experiences of Filipino drug recoverees towards
   occupational participation and justice through an interpretative
   phenomenological analysis
SO SCANDINAVIAN JOURNAL OF OCCUPATIONAL THERAPY
LA English
DT Article
DE Drug addiction; occupational therapy; phenomenology
ID ADDICTION; DISORDERS; FRAMEWORK
AB Background: The drug using crisis entails participation and justice issues making it a pressing health and social concern in the Philippines today. Aim: This study explored the lived experiences of Filipinos recovering from drug addiction and sought to understand the occupational justice determinants of drug addiction to better develop substance addiction rehabilitation programs in the Philippines. Method: Using a qualitative approach, we conducted in-depth interviews guided by the Occupational Justice Health Questionnaire to 24 participants. Data were analyzed using interpretative phenomenological analysis. Results: We found four emerging themes: living with drugs, living around rules, living for the future, and living amidst the war on drugs. Each theme represented a "period of participation" exposing occupational injustices that activated the first enablement skill "raise consciousness of occupational injustice" from the Participatory Occupational Justice Framework.
C1 [Sy, Michael P.; Ohshima, Nobuo] Tokyo Metropolitan Univ, Dept Occupat Therapy, Tokyo, Japan.
   [Sy, Michael P.] Angeles Univ Fdn, Dept Occupat Therapy, Angeles City, Philippines.
   [Delos Reyes, Rod Charlie] Philippine Acad Occupat Therapists Inc, Makati, Philippines.
   [Roraldo, Ma Patricia Nicole R.] Mariveles Mental Hosp, Dept Occupat Therapy, Bataan, Philippines.
C3 Tokyo Metropolitan University; Angeles University Foundation
RP Sy, MP (通讯作者)，Tokyo Metropolitan Univ, Dept Occupat Therapy, Tokyo, Japan.; Sy, MP (通讯作者)，Angeles Univ Fdn, Dept Occupat Therapy, Angeles City, Philippines.
EM sy-michael-palapa@ed.tmu.ac.jp
RI Sy, Michael/AAC-6509-2019
OI Sy, Michael/0000-0003-0849-2874; Delos Reyes, Rod
   Charlie/0000-0003-0305-3960
FU Tokyo Metropolitan University Urban Diplomatic Personnel Grant Fund
FX This work was supported by Tokyo Metropolitan University Urban
   Diplomatic Personnel Grant Fund.
CR Benjamin-Thomas TE, 2018, AUST OCCUP THER J, V65, P3, DOI 10.1111/1440-1630.12428
   Chapman AR, 2017, J STUD ALCOHOL DRUGS, V78, P491, DOI 10.15288/jsad.2017.78.491
   Dangerous Drug Board, 2013, TREATM REH
   Durocher E, 2014, J OCCUP SCI, V21, P431, DOI 10.1080/14427591.2013.775693
   Elo S, 2014, SAGE OPEN, V4, DOI 10.1177/2158244014522633
   Frank G, 2012, J OCCUP SCI, V19, P25, DOI 10.1080/14427591.2011.607792
   Friese S, 2013, 1CD ROM COLOR 4 ACCO
   Go JRR, 2017, PHILIPP POLIT SCI J, V38, P48, DOI 10.1080/01154451.2017.1330022
   Godoy-Vieira A, 2018, CAN J OCCUP THER, V85, P307, DOI 10.1177/0008417418796868
   Gupta J, 2016, OTJR-OCCUP THER J RE, V36, P179, DOI 10.1177/1539449216672171
   Hammell KRW, 2017, CAN J OCCUP THER, V84, P47, DOI 10.1177/0008417416654501
   Hechanova MRM, 2017, J PAC RIM PSYCHOL, V12, P1
   Hitch D, 2014, OCCUP THER HEALTH CA, V28, P247, DOI 10.3109/07380577.2014.898115
   Hocking C, 2017, J OCCUP SCI, V24, P29, DOI 10.1080/14427591.2017.1294016
   Jones J, 2016, J STUDY SPIRITUAL, V6, P38, DOI 10.1080/20440243.2016.1158455
   Kiepek N., 2016, LICIT ILLICIT PRESCR
   Kiepek N, 2018, J OCC SCI, V3, P341, DOI DOI 10.1080/14427591.2018.1499123
   Kiepek N, 2011, J OCCUP SCI, V18, P254, DOI 10.1080/14427591.2011.581628
   Kronenberg F., 2005, OCCUPATIONAL THERAPY, P58
   Lim KH, 2011, OCCUPATIONAL THERAPI, V2, P103
   Olivares-Aising D, 2018, J OCCUP SCI, V25, P474, DOI 10.1080/14427591.2018.1513780
   Rettie H, 2018, NURSE RES, V26, P46, DOI 10.7748/nr.2018.e1589
   Ryan G. W., 2003, FIELD METHOD, V15, P85, DOI [10.1177/1525822X02239569, DOI 10.1177/1525822X02239569]
   Malfitano APS, 2016, OTJR-OCCUP PART HEAL, V36, P167, DOI 10.1177/1539449216669133
   Simangan D, 2017, J GENOCIDE RES, V1, P1
   Simbulan N, 2019, ANN GLOB HEALTH, V85, DOI 10.5334/aogh.28
   Smith J.A., 2009, INTERPRETATIVE PHENO
   Sy MP, 2018, OCCUP THER MENT HEAL, V34, P367, DOI 10.1080/0164212X.2018.1446206
   Sy MP, 2018, WORLD FED OCCUP THER, V75, P59
   Townsend Elizabeth, 2004, Can J Occup Ther, V71, P75
   Townsend E, 2013, CAD TER OCUP UFSCAR, V21, P215, DOI 10.4322/cto.2013.025
   Twinley R, 2013, AUST OCCUP THER J, V60, P301, DOI 10.1111/1440-1630.12026
   Wasmuth S, 2016, J SUBST ABUSE TREAT, V62, P1, DOI 10.1016/j.jsat.2015.11.011
   Wasmuth S, 2014, BRIT J OCCUP THER, V77, P605, DOI 10.4276/030802214X14176260335264
   Whiteford G, 2011, OCCUPATIONAL THERAPI, P65
   Whiteford G, 2018, J OCCUP SCI, V25, P497, DOI 10.1080/14427591.2018.1504607
   Wilcock A. A., 2014, WILLARD SPACKMANS OC, P541
   Wilcock AA, 2007, J OCCUP SCI, V14, P3, DOI 10.1080/14427591.2007.9686577
   Youngstrom MJ, 2002, AM J OCCUP THER, V56, P609, DOI 10.5014/ajot.2020.74S2001
NR 39
TC 5
Z9 5
U1 1
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1103-8128
EI 1651-2014
J9 SCAND J OCCUP THER
JI Scand. J. Occup. Ther.
PD AUG 18
PY 2021
VL 28
IS 6
BP 457
EP 470
DI 10.1080/11038128.2019.1642380
EA JUL 2019
PG 14
WC Rehabilitation
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Rehabilitation
GA UD2LK
UT WOS:000478207800001
PM 31322976
DA 2023-06-23
ER

PT J
AU De Brucq, H
   Vital, I
AF De Brucq, Helene
   Vital, Isabelle
TI Addictions and aging
SO PSYCHOLOGIE & NEUROPSYCHIATRIE DU VIEILLISSEMENT
LA French
DT Article
DE addictions; psychopathology; aging; alcohol; drugs
AB The most frequent addictions observed in the elderly are alcoholism and therapeutic drug abuse, due to the psychic and physical vulnerability associated with age. First, the impact of aging to addiction is presented from epidemiologic data. Somatic and neuropsychiatric complications, interaction between addiction and mental illnesses, and therapeutic approach are detailed. In the second part, the psychopathological basis likely to support the addictive conduit occurring in old age is explored.
C1 [De Brucq, Helene; Vital, Isabelle] Unite Psychogeriatrie Sud Loire, Nantes, France.
RP De Brucq, H (通讯作者)，Unite Psychogeriatrie Sud Loire, Nantes, France.
EM helene.debrucq@ch-montbert.fr
CR Ades J, 1994, Rev Prat, V44, P1439
   BARR J, 2006, QUELLE APPROCHE ADOP, P32
   BAYLE FJ, 1994, NEUROPSY, V9, P9
   CHAMBONET JY, 2006, REV FRANCOPHONE GERI, V13, P10
   CLEMENT JP, 1999, PSYCHIAT SUJET AGE, P257
   DEBERTRAND N, 2008, SOINS PSYCHIAT, V255, P7
   DIVINE A, 2007, ADDICTIONS PERSONNES
   Fernandez L, 2001, ENCEPHALE, V27, P459
   Guelfi JD, 1987, PSYCHIATRIE
   LACOSTE L, 2006, NEUROLOGIE PSYCHIAT, V6, P29
   Menecier P, 2006, REV GERIATR, V31, P11
   VERMETTE G, 1999, VIS A VIE, V9, P27
   VIGNE C, 2003, REV GERIATR, V28, P741
NR 13
TC 3
Z9 3
U1 2
U2 6
PU JOHN LIBBEY EUROTEXT LTD
PI MONTROUGE
PA 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE
SN 1760-1703
J9 PSYCHOL NEUROPSYCHIA
JI Psychol. NeuroPsychiatr. Vieil.
PD SEP
PY 2008
VL 6
IS 3
BP 177
EP 182
DI 10.1684/pnv.2008.0134
PG 6
WC Psychiatry; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Psychiatry; Psychology
GA 364FF
UT WOS:000260320900003
PM 18786876
DA 2023-06-23
ER

PT J
AU Xu, M
   Zhang, JH
AF Xu, M
   Zhang, JH
TI Molecular genetic probing of dopamine receptors in drug addiction
SO CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT
LA English
DT Review
DE addiction; cocaine; dopamine receptor; gene targeting; mechanism; mutant
   mice
ID CONDITIONED PLACE PREFERENCE; INDUCED LOCOMOTOR-ACTIVITY; MICE LACKING;
   MUTANT MICE; DEFICIENT MICE; D1 RECEPTOR; KNOCKOUT MICE; D2 RECEPTORS;
   BEHAVIORAL-RESPONSES; D-3 RECEPTOR
AB Drug addiction is a brain disease with complex genetic, psychological and social factors. The dopaminergic system of the brain plays a central role in natural reward and motivation and is the main neural substrate for the actions of abusive drugs. The analysis of mice with mutations in their dopamine receptor genes has provided new information regarding the influence of individual dopamine receptors on drug actions. The use of genetic manipulation of dopamine receptors, and related intracellular signaling molecules, in mice will help to enhance our understanding of the molecular and cellular mechanisms underlying compulsive drug-seeking and drug-taking behaviors, reasons for relapse into drug addiction and persistent neuronal changes in response to repeated drug use. These studies will provide new insights for improved therapeutic strategies for the prevention and treatment of drug addiction.
C1 Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA.
C3 University System of Ohio; University of Cincinnati
RP Xu, M (通讯作者)，Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, 3125 Eden Ave, Cincinnati, OH 45267 USA.
EM ming.xu@uc.edu
RI zhang, jianhua/D-3404-2009
OI Zhang, Jianhua/0000-0002-2128-9574
CR Accili D, 1996, P NATL ACAD SCI USA, V93, P1945, DOI 10.1073/pnas.93.5.1945
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   BAIK JH, 1995, NATURE, V377, P424, DOI 10.1038/377424a0
   Betancur C, 2001, NEUROPSYCHOPHARMACOL, V24, P170, DOI 10.1016/S0893-133X(00)00179-2
   Bowers MS, 2004, NEURON, V42, P269, DOI 10.1016/S0896-6273(04)00159-X
   Caine S. B., 2002, Drug and Alcohol Dependence, V66, pS25
   Caine SB, 2002, J NEUROSCI, V22, P2977, DOI 10.1523/JNEUROSCI.22-07-02977.2002
   Caine SB, 1999, PSYCHOPHARMACOLOGY, V147, P22, DOI 10.1007/s002130051134
   Capecchi MR, 2001, NAT MED, V7, P1086, DOI 10.1038/nm1001-1086
   Carta AR, 2000, NEUROREPORT, V11, P2395, DOI 10.1097/00001756-200008030-00012
   Chausmer AL, 2002, PSYCHOPHARMACOLOGY, V163, P54, DOI 10.1007/s00213-002-1142-y
   Colby CR, 2003, J NEUROSCI, V23, P2488
   Colpaert FC, 1999, PHARMACOL BIOCHEM BE, V64, P337, DOI 10.1016/S0091-3057(99)00047-7
   Crawford CA, 1997, NEUROREPORT, V8, P2523, DOI 10.1097/00001756-199707280-00021
   Cunningham CL, 2000, PHARMACOL BIOCHEM BE, V67, P693, DOI 10.1016/S0091-3057(00)00414-7
   Dockstader CL, 2001, EUR J NEUROSCI, V13, P995, DOI 10.1046/j.1460-9568.2001.01455.x
   DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0
   DRAGO J, 1994, P NATL ACAD SCI USA, V91, P12564, DOI 10.1073/pnas.91.26.12564
   Drago J, 1996, NEUROSCIENCE, V74, P813, DOI 10.1016/0306-4522(96)00145-5
   Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129
   El-Ghundi M, 1998, EUR J PHARMACOL, V353, P149, DOI 10.1016/S0014-2999(98)00414-2
   Elliot EE, 2003, PSYCHOPHARMACOLOGY, V169, P161, DOI 10.1007/s00213-003-1494-y
   Elmer GI, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-10-j0004.2002
   Evans MJ, 2001, NAT MED, V7, P1081, DOI 10.1038/nm1001-1081
   Gerlai R, 1996, TRENDS NEUROSCI, V19, P177, DOI 10.1016/S0166-2236(96)20020-7
   Glickstein SB, 2001, PHARMACOL THERAPEUT, V91, P63, DOI 10.1016/S0163-7258(01)00145-0
   Hollon TR, 2002, J NEUROSCI, V22, P10801, DOI 10.1523/jneurosci.22-24-10801.2002
   Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560
   Joseph JD, 2002, NEUROSCIENCE, V112, P39, DOI 10.1016/S0306-4522(02)00067-2
   Jung MY, 1999, NEUROSCIENCE, V91, P911, DOI 10.1016/S0306-4522(98)00705-2
   Kalivas PW, 1998, J PSYCHOPHARMACOL, V12, P49, DOI 10.1177/026988119801200107
   Karper PE, 2002, PSYCHOPHARMACOLOGY, V159, P407, DOI 10.1007/s00213-001-0936-7
   Katz JL, 2003, PSYCHOPHARMACOLOGY, V170, P108, DOI 10.1007/s00213-003-1513-z
   Kelly MA, 1998, J NEUROSCI, V18, P3470
   Kelz MB, 1999, NATURE, V401, P272, DOI 10.1038/45790
   KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J
   Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7
   Laakso A, 2002, NEURON, V36, P213, DOI 10.1016/S0896-6273(02)00972-8
   Lathe R, 1996, TRENDS NEUROSCI, V19, P183, DOI 10.1016/S0166-2236(96)20022-0
   Le Foll B, 2002, EUR J NEUROSCI, V15, P2016, DOI 10.1046/j.1460-9568.2002.02049.x
   Lewandoski M, 2001, NAT REV GENET, V2, P743, DOI 10.1038/35093537
   Maldonado R, 1997, NATURE, V388, P586, DOI 10.1038/41567
   McClung CA, 2003, NAT NEUROSCI, V6, P1208, DOI 10.1038/nn1143
   McNamara FN, 2003, NEUROPSYCHOPHARMACOL, V28, P86, DOI 10.1038/sj.npp.1300008
   Miner LL, 1995, NEUROREPORT, V6, P2314, DOI 10.1097/00001756-199511270-00011
   Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189
   Moratalla R, 1996, P NATL ACAD SCI USA, V93, P14928, DOI 10.1073/pnas.93.25.14928
   Narita M, 2003, J NEUROSCI, V23, P1006
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   Risinger FO, 2000, PSYCHOPHARMACOLOGY, V152, P343, DOI 10.1007/s002130000548
   Robinson TE, 2000, ADDICTION, V95, pS91
   Rouge-Pont F, 2002, J NEUROSCI, V22, P3293, DOI 10.1523/JNEUROSCI.22-08-03293.2002
   Rubinstein M, 1997, CELL, V90, P991, DOI 10.1016/S0092-8674(00)80365-7
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   Sibley DR, 1999, ANNU REV PHARMACOL, V39, P313, DOI 10.1146/annurev.pharmtox.39.1.313
   Smith JW, 2002, NEUROSCIENCE, V113, P755, DOI 10.1016/S0306-4522(02)00257-9
   Smithies O, 2001, NAT MED, V7, P1083, DOI 10.1038/nm1001-1083
   THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5
   Tzschentke TM, 1998, PROG NEUROBIOL, V56, P613, DOI 10.1016/S0301-0082(98)00060-4
   Usiello A, 2000, NATURE, V408, P199, DOI 10.1038/35041572
   Wang YY, 2000, J NEUROSCI, V20, P8305, DOI 10.1523/JNEUROSCI.20-22-08305.2000
   Weiss B, 1997, NEUROCHEM INT, V31, P321, DOI 10.1016/S0197-0186(96)00105-2
   White FJ, 1998, DRUG ALCOHOL DEPEN, V51, P141, DOI 10.1016/S0376-8716(98)00072-6
   Wise Roy A., 2000, Neuron, V26, P27, DOI 10.1016/S0896-6273(00)81134-4
   XU M, 1994, CELL, V79, P945, DOI 10.1016/0092-8674(94)90026-4
   Xu M, 1997, NEURON, V19, P837, DOI 10.1016/S0896-6273(00)80965-4
   Xu M, 2000, BRAIN RES, V852, P198, DOI 10.1016/S0006-8993(99)02258-1
   XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6
   Yao WD, 2004, NEURON, V41, P625, DOI 10.1016/S0896-6273(04)00048-0
   Zhang DS, 2002, J NEUROCHEM, V82, P1453, DOI 10.1046/j.1471-4159.2002.01089.x
   Zhang L, 2004, J NEUROSCI, V24, P3344, DOI 10.1523/JNEUROSCI.0060-04.2004
NR 71
TC 4
Z9 4
U1 2
U2 6
PU THOMSON REUTERS (SCIENTIFIC) LTD
PI LONDON
PA 77 HATTON GARDEN, LONDON, EC1N 8JS, ENGLAND
SN 1367-6733
EI 2040-3437
J9 CURR OPIN DRUG DISC
JI Curr. Opin. Drug Discov. Dev.
PD SEP
PY 2004
VL 7
IS 5
BP 703
EP 708
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 869MF
UT WOS:000224986900012
PM 15503872
DA 2023-06-23
ER

PT J
AU Filbey, FM
AF Filbey, Francesca M.
TI An introduction to "The addiction connectome: brain connectivity in drug
   and alcohol addiction''
SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE
LA English
DT Editorial Material
C1 Univ Texas Dallas, Sch Behav & Brain Sci, Ctr BrainHlth, Dallas, TX 75235 USA.
C3 University of Texas System; University of Texas Dallas
RP Filbey, FM (通讯作者)，Univ Texas Dallas, Sch Behav & Brain Sci, Ctr BrainHlth, Dallas, TX 75235 USA.
EM Francesca.Filbey@utdallas.edu
RI Filbey, Francesca/V-1366-2019; Filbey, Francesca M./J-5163-2014
OI Filbey, Francesca/0000-0002-7466-4796; 
FU NIDA NIH HHS [R01 DA030344] Funding Source: Medline
NR 0
TC 5
Z9 5
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0095-2990
EI 1097-9891
J9 AM J DRUG ALCOHOL AB
JI Am. J. Drug Alcohol Abuse
PD NOV
PY 2013
VL 39
IS 6
SI SI
BP 341
EP 342
DI 10.3109/00952990.2013.856661
PG 2
WC Psychology, Clinical; Substance Abuse
WE Social Science Citation Index (SSCI)
SC Psychology; Substance Abuse
GA 251YE
UT WOS:000326969600001
PM 24200202
DA 2023-06-23
ER

PT J
AU Zhu, ZL
   Dou, BZ
   Cao, YK
   Jiang, J
   Zhu, YY
   Chen, D
   Feng, HS
   Liu, J
   Zhang, BG
   Zhou, TS
   Wei, GW
AF Zhu, Zailiang
   Dou, Bozheng
   Cao, Yukang
   Jiang, Jian
   Zhu, Yueying
   Chen, Dong
   Feng, Hongsong
   Liu, Jie
   Zhang, Bengong
   Zhou, Tianshou
   Wei, Guo-Wei
TI TIDAL: Topology-Inferred Drug Addiction Learning
SO JOURNAL OF CHEMICAL INFORMATION AND MODELING
LA English
DT Article
ID RECEPTORS; IBOGAINE; LANGUAGE; SYSTEM
AB Drug addiction is a global public health crisis, and the design of antiaddiction drugs remains a major challenge due to intricate mechanisms. Since experimental drug screening and optimization are too time-consuming and expensive, there is urgent need to develop innovative artificial intelligence (AI) methods for addressing the challenge. We tackle this challenge by topology-inferred drug addiction learning (TIDAL) built from integrating multiscale topological Laplacians, deep bidirectional transformer, and ensemble-assisted neural networks (EANNs). Multiscale topological Laplacians are a novel class of algebraic topology tools that embed molecular topological invariants and algebraic invariants into its harmonic spectra and nonharmonic spectra, respectively. These invariants complement sequence information extracted from a bidirectional transformer. We validate the proposed TIDAL framework on 22 drug addiction related, 4 hERG, and 12 DAT data sets, which suggests that the proposed TIDAL is a state-of-the-art framework for the modeling and analysis of drug addiction data. We carry out cross-target analysis of the current drug addiction candidates to alert their side effects and identify their repurposing potentials. Our analysis reveals drug-mediated linear and bilinear target correlations. Finally, TIDAL is applied to shed light on relative efficacy, repurposing potential, and potential side effects of 12 existing antiaddiction medications. Our results suggest that TIDAL provides a new computational strategy for pressingly needed antisubstance addiction drug development.
C1 [Zhu, Zailiang; Cao, Yukang] Wuhan Text Univ, Sch Comp Sci & Artificial Intelligence, Wuhan 430200, Peoples R China.
   [Dou, Bozheng; Jiang, Jian; Zhu, Yueying; Liu, Jie; Zhang, Bengong] Wuhan Text Univ, Res Ctr Nonlinear Sci, Sch Math & Phys Sci, Wuhan 430200, Peoples R China.
   [Jiang, Jian; Chen, Dong; Feng, Hongsong; Wei, Guo-Wei] Michigan State Univ, Dept Math, E Lansing, MI 48824 USA.
   [Zhou, Tianshou] Sun Yat Sen Univ, Key Lab Computat Math, Guangzhou 510006, Guangdong, Peoples R China.
   [Zhou, Tianshou] Sun Yat Sen Univ, Sch Math, Guangzhou 510006, Peoples R China.
   [Wei, Guo-Wei] Michigan State Univ, Dept Elect & Comp Engn, E Lansing, MI 48824 USA.
   [Wei, Guo-Wei] Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.
C3 Wuhan Textile University; Wuhan Textile University; Michigan State
   University; Sun Yat Sen University; Sun Yat Sen University; Michigan
   State University; Michigan State University
RP Jiang, J (通讯作者)，Wuhan Text Univ, Res Ctr Nonlinear Sci, Sch Math & Phys Sci, Wuhan 430200, Peoples R China.; Jiang, J; Wei, GW (通讯作者)，Michigan State Univ, Dept Math, E Lansing, MI 48824 USA.; Wei, GW (通讯作者)，Michigan State Univ, Dept Elect & Comp Engn, E Lansing, MI 48824 USA.; Wei, GW (通讯作者)，Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.
EM jjiang@wtu.edu.cn; weig@msu.edu
RI Feng, Hongsong/HZK-3238-2023; Zhang, Ben-gong/D-6488-2013
OI Feng, Hongsong/0000-0001-8039-3059; Zhang, Ben-gong/0000-0002-2766-6502
FU National Natural Science Foundation of China [11971367, 11972266]; NIH
   [R01GM126189, R01AI164266]; NSF [DMS-1721024, DMS-1761320, IIS1900473];
   NASA [80NSSC21M0023]; Bristol Myers Squibb; MSU Foundation; Pfizer
FX The work of Zailiang Zhu, Jian Jiang, and Bengong Zhang was supported by
   the National Natural Science Foundation of China under Grant No.
   11971367 and No.11972266. The work of Dong Chen and Guo-Wei Wei was
   supported in part by NIH grants R01GM126189 and R01AI164266, NSF Grants
   DMS-1721024, DMS-1761320, and IIS1900473, NASA grant 80NSSC21M0023,
   Bristol Myers Squibb, Pfizer, and MSU Foundation. All authors appreciate
   the technology assistance from Rui Wang.
CR Blondel A, 1996, J COMPUT CHEM, V17, P1132, DOI 10.1002/(SICI)1096-987X(19960715)17:9<1132::AID-JCC5>3.0.CO;2-T
   Bruice PY., 2014, ORGANIC CHEM, V7 International
   Cang ZX, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005690
   Cao DN, 2021, BRIT J PHARMACOL, P1
   Carney T, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012254.pub2
   Chen D, 2021, J PHYS CHEM LETT, V12, P10793, DOI 10.1021/acs.jpclett.1c03058
   Chen D, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23720-w
   Chen JH, 2021, DISCRETE CONT DYN-B, V26, P3785, DOI 10.3934/dcdsb.2020257
   Chi ZX, 2010, J HAZARD MATER, V180, P741, DOI 10.1016/j.jhazmat.2010.04.110
   Ciocanel MV, 2021, B MATH BIOL, V83, DOI 10.1007/s11538-020-00847-3
   Czarnecki WM, 2015, J CHEMINFORMATICS, V7, DOI 10.1186/s13321-015-0088-0
   Devlin J, 2019, Arxiv, DOI [arXiv:1810.04805, DOI 10.48550/ARXIV.1810.04805]
   Nguyen DD, 2019, J CHEM INF MODEL, V59, P3291, DOI 10.1021/acs.jcim.9b00334
   Nguyen DD, 2019, INT J NUMER METH BIO, V35, DOI 10.1002/cnm.3179
   Dydyk AM., 2021, STATPEARLS
   Edelsbrunner H, 2008, CONTEMP MATH, V453, P257
   Efange SMN, 1998, J MED CHEM, V41, P4486, DOI 10.1021/jm980156y
   Feng HS, 2022, J CHEM THEORY COMPUT, V18, P2703, DOI 10.1021/acs.jctc.2c00002
   Gao KF, 2021, J PHYS CHEM LETT, V12, P11122, DOI 10.1021/acs.jpclett.1c03133
   Gao KF, 2020, J CHEM INF MODEL, V60, P5682, DOI 10.1021/acs.jcim.0c00599
   Gao KF, 2020, PHYS CHEM CHEM PHYS, V22, P8373, DOI 10.1039/d0cp00305k
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   Hozumi Y., 2022, PREPRINT, DOI DOI 10.48550/ARXIV.2206.04189
   Jiang J, 2020, J CHEM INF MODEL, V60, P1235, DOI 10.1021/acs.jcim.9b01184
   KAMBER FW, 1987, MATH ANN, V277, P415, DOI 10.1007/BF01458323
   Khanna IK, 2015, J PAIN RES, V8, DOI 10.2147/JPR.S85951
   Koenig X, 2015, MOLECULES, V20, P2208, DOI 10.3390/molecules20022208
   Lee KH, 2021, J CHEM INF MODEL, V61, P4266, DOI 10.1021/acs.jcim.1c00856
   Li H, 2018, NATL SCI REV, V5, P24, DOI 10.1093/nsr/nwx110
   McInnes Leland, 2020, Arxiv, DOI [arXiv:1802.03426, 10.21105/joss.00861, DOI 10.21105/JOSS.00861]
   Meng ZY, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-55660-3
   Mischaikow K, 2013, DISCRETE COMPUT GEOM, V50, P330, DOI 10.1007/s00454-013-9529-6
   Newman AH, 2021, ANNU REV PHARMACOL, V61, P609, DOI 10.1146/annurev-pharmtox-030220-124205
   RAYNOR K, 1994, MOL PHARMACOL, V45, P330
   Robinson ESJ, 2008, NEUROPSYCHOPHARMACOL, V33, P2398, DOI 10.1038/sj.npp.1301636
   Singh J, 2021, J CHEM INF MODEL, V61, P2610, DOI 10.1021/acs.jcim.1c00153
   Smieja M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146666
   Smusz S, 2015, J CHEM INF MODEL, V55, P823, DOI 10.1021/ci500564b
   Trifilieff P., 2013, EFFECTS DRUG ABUSE H, DOI [10.1016/B978-0-12-418679-8.00005-8, DOI 10.1016/B978-0-12-418679-8.00005-8]
   Vaswani A., 2018, ADV NEURAL INFORM PR, P5998
   Veilleux JC, 2010, CLIN PSYCHOL REV, V30, P155, DOI 10.1016/j.cpr.2009.10.006
   Verma J, 2010, CURR TOP MED CHEM, V10, P95, DOI 10.2174/156802610790232260
   Wang R, 2020, INT J NUMER METH BIO, V36, DOI 10.1002/cnm.3376
   Wang S, 2019, ACM-BCB'19: PROCEEDINGS OF THE 10TH ACM INTERNATIONAL CONFERENCE ON BIOINFORMATICS, COMPUTATIONAL BIOLOGY AND HEALTH INFORMATICS, P429, DOI 10.1145/3307339.3342186
   Warszycki D, 2021, J CHEM INF MODEL, V61, P5054, DOI 10.1021/acs.jcim.1c00589
   WEININGER D, 1988, J CHEM INF COMP SCI, V28, P31, DOI 10.1021/ci00057a005
   Yuan L, 2021, Arxiv, DOI [arXiv:2101.11986, DOI 10.48550/ARXIV.2101.11986]
   Zhao RD, 2020, B MATH BIOL, V82, DOI 10.1007/s11538-020-00783-2
   Zomorodian A, 2005, DISCRETE COMPUT GEOM, V33, P249, DOI 10.1007/s00454-004-1146-y
NR 49
TC 0
Z9 0
U1 1
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1549-9596
EI 1549-960X
J9 J CHEM INF MODEL
JI J. Chem Inf. Model.
PD MAR 13
PY 2023
VL 63
IS 5
BP 1472
EP 1489
DI 10.1021/acs.jcim.3c00046
PG 18
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Computer Science,
   Information Systems; Computer Science, Interdisciplinary Applications
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Chemistry; Computer Science
GA A2FT3
UT WOS:000953348400001
PM 36826415
OA Green Submitted
DA 2023-06-23
ER

PT J
AU Koob, G
AF Koob, George
TI Drug Addiction: The Gain in the Brain is in the Pain
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 73rd Annual Scientific Convention and Meeting of the
   Society-of-Biological-Psychiatry (SOBP)
CY MAY 10-12, 2018
CL New York, NY
SP Soc Biol Psychiat
DE Addiction
C1 [Koob, George] NIAAA, NIH, Bethesda, MD USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute on
   Alcohol Abuse & Alcoholism (NIAAA)
NR 0
TC 1
Z9 1
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2018
VL 83
IS 9
SU S
MA 181
BP S72
EP S73
DI 10.1016/j.biopsych.2018.02.200
PG 2
WC Neurosciences; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Neurosciences & Neurology; Psychiatry
GA GG1SD
UT WOS:000432466300182
DA 2023-06-23
ER

PT J
AU Groenewald, C
   Essack, Z
AF Groenewald, Candice
   Essack, Zaynab
TI "I started that day and continued for 2 years": A case report on
   adolescent 'whoonga' addiction
SO JOURNAL OF SUBSTANCE USE
LA English
DT Article
DE Adolescent drug abuse; addiction; lived experience; phenomenology; South
   Africa
AB Background: 'Whoonga' is a new craze drug that young people in South Africa are increasingly using. It consists of a cocktail of drugs and is considered to be highly addictive. Yet, there is a paucity of research that describes young people's experiences of using this drug. Method: Using an interpretative phenomenological approach, this case report describes the highly addictive and destructive nature of adolescent whoonga addiction. Results: The adolescent's narrative revealed that initial experimentation with 'whoonga' has the potential to rapidly escalate into full addiction over a short period of time. Whoonga addiction was also associated with involvement in criminal activities to support the adolescent's high drug use demands. Conclusion: Whoonga is a dangerous street drug that requires immediate attention is South Africa.
C1 [Groenewald, Candice] Human Sci Res Council, Durban Reg Off, Human & Social Dev Unit, Berea, South Africa.
   [Essack, Zaynab] Human Sci Res Council, Human & Social Dev Unit, Pietermaritzburg, South Africa.
   [Essack, Zaynab] Univ KwaZulu Natal, Sch Law, Pietermaritzburg, South Africa.
C3 University of Kwazulu Natal
RP Groenewald, C (通讯作者)，Human Sci Res Council, Human & Social Dev Unit, Durban Reg Off, 5th Floor,430 Peter Mokaba Ridge, ZA-4001 Durban, Kwazulu Natal, South Africa.
EM cgroenewald@hsrc.ac.za
RI Essack, Zaynab/P-3253-2019; Groenewald, Candice/AAF-3106-2020
OI Essack, Zaynab/0000-0002-8867-3415; Groenewald,
   Candice/0000-0003-2731-1370
CR Balyoi P., 2018, SERVAMUS, V111, P50
   Dada S., 2018, S AFRICAN COMMUNITY
   Department of Basic Education, 2013, NAT STRAT PREV MAN A
   Department of Health & Department of Basic Education, 2012, INT SCH HLTH POL, DOI [10.1094/PDIS-11-11-0999-PDN, DOI 10.1094/PDIS-11-11-0999-PDN]
   Fernandes L, 2016, S AFR FAM PRACT, V58, P153, DOI 10.1080/20786190.2016.1223794
   Groenewald C, 2018, J SUBST USE, V23, P667, DOI 10.1080/14659891.2018.1459902
   Khine AA., 2016, AFRICAN J DRUG ALCOH, V15, P91
   Mokwena K.E., 2015, AFR J DRUG ALCOHOL S, V14, P49
   Mokwena KE., 2015, PULA BOTSWANA J AFRI, V28, P41
   Mokwena K, 2016, HEALTH SA GESONDHEID, V21, DOI 10.1016/j.hsag.2015.09.001
   Smith JA, 2007, QUALITATIVE PSYCHOL, P53
NR 11
TC 2
Z9 2
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1465-9891
EI 1475-9942
J9 J SUBST USE
JI J. Subst. Use
PY 2019
VL 24
IS 6
BP 578
EP 580
DI 10.1080/14659891.2019.1642408
EA JUL 2019
PG 3
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA MA9KT
UT WOS:000476268200001
DA 2023-06-23
ER

PT J
AU Heidbreder, CA
   Hagan, JJ
AF Heidbreder, CA
   Hagan, JJ
TI Novel pharmacotherapeutic approaches for the treatment of drug addiction
   and craving
SO CURRENT OPINION IN PHARMACOLOGY
LA English
DT Review
ID TREATING COCAINE ADDICTION; RECEPTOR AGONIST LY379268; SELECTIVE
   ANTAGONISM; GLUTAMATE RECEPTORS; SEEKING BEHAVIOR; BRAIN REWARD;
   DOPAMINE; RELAPSE; RATS; WITHDRAWAL
AB Pharmacological agents have shown limited efficacy and consistency in the treatment of drug addiction. Hence, the development of new medications with improved long-term efficacy and reduced side effects should be given a high priority given the costs to society associated with drug abuse and drug-related pathologies. Neurochemical systems can be significantly altered by repeated exposure to drugs of abuse. These long-term molecular and neurochemical changes might, in turn, explain the core features of addiction - the compulsive seeking and taking of the drug - as well as the risk of relapse.
C1 GlaxoSmithKline, Dept Biol, Ctr Excellence Drug Discovery Psychiat, I-37135 Verona, Italy.
C3 GlaxoSmithKline
RP Heidbreder, CA (通讯作者)，GlaxoSmithKline, Dept Biol, Ctr Excellence Drug Discovery Psychiat, Via A Fleming 4, I-37135 Verona, Italy.
EM Christian_A_Heidbreder@gsk.com
OI Heidbreder, Christian/0000-0001-8937-003X
CR Andreoli M, 2003, NEUROPSYCHOPHARMACOL, V28, P1272, DOI 10.1038/sj.npp.1300183
   Andreoli M, 2003, EUR NEUROPSYCHOPHARM, V13, pS17, DOI 10.1016/S0924-977X(03)90011-3
   Ashby CR, 2003, SYNAPSE, V48, P154, DOI 10.1002/syn.10188
   Baker DA, 2003, NAT NEUROSCI, V6, P743, DOI 10.1038/nn1069
   Baptista MAS, 2004, J NEUROSCI, V24, P4723, DOI 10.1523/JNEUROSCI.0176-04.2004
   Barth F, 1999, CURR MED CHEM, V6, P745
   Basile AS, 2002, P NATL ACAD SCI USA, V99, P11452, DOI 10.1073/pnas.162371899
   Brodie JD, 2003, SYNAPSE, V50, P261, DOI 10.1002/syn.10278
   Carrera MRA, 2004, P NATL ACAD SCI USA, V101, P10416, DOI 10.1073/pnas.0403795101
   Chaperon F, 1998, PSYCHOPHARMACOLOGY, V135, P324, DOI 10.1007/s002130050518
   Chiamulera C, 2001, NAT NEUROSCI, V4, P873, DOI 10.1038/nn0901-873
   Cohen C, 2002, BEHAV PHARMACOL, V13, P451, DOI 10.1097/00008877-200209000-00018
   De Vries TJ, 2001, NAT MED, V7, P1151, DOI 10.1038/nm1001-1151
   Deroche V, 1997, J PHARMACOL EXP THER, V281, P1401
   Deroche-Gamonet V, 2003, J NEUROSCI, V23, P4785
   Di Ciano P, 2003, NEUROPSYCHOPHARMACOL, V28, P329, DOI 10.1038/sj.npp.1300148
   Fink-Jensen A, 2003, J NEUROSCI RES, V74, P91, DOI 10.1002/jnr.10728
   Forster GL, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-01-j0001.2002
   Freedland CS, 2001, ALCOHOL CLIN EXP RES, V25, P277, DOI 10.1097/00000374-200102000-00017
   Gonzalez G, 2003, ADDICTION, V98, P1625, DOI 10.1046/j.1360-0443.2003.00544.x
   Haney M, 2001, PSYCHOPHARMACOLOGY, V155, P330, DOI 10.1007/s002130100725
   Harrison AA, 2001, NEUROPSYCHOPHARMACOL, V25, P55, DOI 10.1016/S0893-133X(00)00237-2
   Higgins GA, 2003, EUR J PHARMACOL, V480, P151, DOI 10.1016/j.ejphar.2003.08.102
   Hogg RC, 2004, CNS NEUROL DISORD-DR, V3, P123, DOI 10.2174/1568007043482507
   Kantak KM, 2003, DRUGS, V63, P341, DOI 10.2165/00003495-200363040-00001
   Kenny PJ, 2004, TRENDS PHARMACOL SCI, V25, P265, DOI 10.1016/j.tips.2004.03.009
   Kim JH, 2002, PHARMACOL BIOCHEM BE, V73, P333, DOI 10.1016/S0091-3057(02)00827-4
   Kosten Thomas R, 2002, Expert Rev Vaccines, V1, P363
   Krystal JH, 2003, PHARMACOL THERAPEUT, V99, P79, DOI 10.1016/S0163-7258(03)00054-8
   Le Foll B, 2003, SYNAPSE, V47, P176, DOI 10.1002/syn.10170
   Lu L, 2004, TRENDS NEUROSCI, V27, P74, DOI 10.1016/j.tins.2003.11.007
   Martinez-Raga J, 2004, PROG NEURO-PSYCHOPH, V28, P599, DOI 10.1016/j.pnpbp.2003.11.020
   McCance-Katz EF, 2001, PSYCHOPHARMACOLOGY, V155, P327, DOI 10.1007/s002130100745
   McDonagh J, 2003, NEUROLOGY, V61, P1690, DOI 10.1212/01.WNL.0000098938.80082.25
   Nagy J, 2004, NEUROCHEM INT, V44, P17, DOI 10.1016/S0197-0186(03)00100-1
   Nann-Vernotica E, 2001, PSYCHOPHARMACOLOGY, V155, P338, DOI 10.1007/s002130100724
   *NAT HOUS SURV DRU, 2002, SURV NAT FIND, V1, P25
   Navarro M, 2001, J NEUROSCI, V21, P5344, DOI 10.1523/JNEUROSCI.21-14-05344.2001
   Nie ZG, 2004, SCIENCE, V303, P1512, DOI 10.1126/science.1092550
   Raby WN, 2004, J CLIN PSYCHIAT, V65, P84
   Reavill C, 2000, J PHARMACOL EXP THER, V294, P1154
   RIVERA SN, 2003, SOC NEUR ABSTR, V29
   Sarnyai Z, 2001, PHARMACOL REV, V53, P209
   Shaham Y, 1998, PSYCHOPHARMACOLOGY, V137, P184, DOI 10.1007/s002130050608
   Smith MA, 2004, PSYCHOPHARMACOLOGY, V173, P105, DOI 10.1007/s00213-003-1706-5
   Spangler R, 2003, MOL BRAIN RES, V111, P74, DOI 10.1016/S0169-328X(02)00671-X
   Staley JK, 1996, J NEUROSCI, V16, P6100
   Stewart J, 2003, AM J ADDICTION, V12, P1, DOI 10.1080/10550490390143330
   Suzuki M, 1998, BRAIN RES, V779, P58, DOI 10.1016/S0006-8993(97)01078-0
   Tanda G, 1997, SCIENCE, V276, P2048, DOI 10.1126/science.276.5321.2048
   Urwyler S, 2003, J PHARMACOL EXP THER, V307, P322, DOI 10.1124/jpet.103.053074
   Vorel SR, 2002, J NEUROSCI, V22, P9595
   Weiss F, 2001, ANN NY ACAD SCI, V937, P1, DOI 10.1111/j.1749-6632.2001.tb03556.x
   Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406
   Xi ZX, 2002, J PHARMACOL EXP THER, V303, P608, DOI 10.1124/jpet.102.039735
NR 55
TC 47
Z9 55
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4892
EI 1471-4973
J9 CURR OPIN PHARMACOL
JI Curr. Opin. Pharmacol.
PD FEB
PY 2005
VL 5
IS 1
BP 107
EP 118
DI 10.1016/j.coph.2004.08.013
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 896TU
UT WOS:000226957400017
PM 15661634
DA 2023-06-23
ER

PT J
AU Heyer, MP
   Kenny, PJ
AF Heyer, Mary P.
   Kenny, Paul J.
TI Corticostriatal microRNAs in addiction
SO BRAIN RESEARCH
LA English
DT Review
DE MicroRNA; Addiction; Plasticity
ID LONG-TERM POTENTIATION; POSTTRANSCRIPTIONAL REGULATION; NONCODING RNAS;
   DRUG-ADDICTION; SYNAPTIC PLASTICITY; BDNF EXPRESSION; EPIGENETIC
   MECHANISMS; NEUROTROPHIC FACTOR; TARGET RECOGNITION; PREFRONTAL CORTEX
AB Addiction is a chronically relapsing disorder characterized by compulsive drug use in spite of adverse consequences. Currently, there are very few effective treatments for addiction; in order to develop novel therapies, a clearer understanding of mechanisms underlying addiction is needed. Drugs of abuse induce lasting adaptations in corticostriatal and mesolimbic brain reward circuitry due to long-term alterations in gene expression. microRNAs, a class of non-coding RNAs, are powerful regulators of gene expression that bind to target mRNAs, thereby inhibiting their translation and/or causing degradation. miRNAs are increasingly implicated in gene expression changes underlying normal neuronal function as well as dysfunctions such as addiction and psychiatric disorders. This review summarizes plasticity- and drug-related miRNA expression patterns and functions in the context of corticostriatal circuitry, while proposing future directions that may reveal miRNA-mediated mechanisms regulating addiction-related behaviors in vivo.
   This article is part of a Special Issue entitled SI:Addiction circuits. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Heyer, Mary P.; Kenny, Paul J.] Icahn Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai
RP Kenny, PJ (通讯作者)，Icahn Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, One Gustave L Levy Pl, New York, NY 10029 USA.
EM paul.kenny@mssm.edu
FU National Institute on Drug Abuse (NIDA) [DA025983]
FX This work was supported by a grant from the National Institute on Drug
   Abuse (NIDA) to P.J.K. (DA025983).
CR Argilli E, 2008, J NEUROSCI, V28, P9092, DOI 10.1523/JNEUROSCI.1001-08.2008
   Ashraf SI, 2006, CELL, V124, P191, DOI 10.1016/j.cell.2005.12.017
   Bahi A, 2013, EUR J NEUROSCI, V38, P2328, DOI 10.1111/ejn.12228
   Bak M, 2008, RNA, V14, P432, DOI 10.1261/rna.783108
   Bali Purva, 2013, Frontiers in Genetics, V4, P43, DOI 10.3389/fgene.2013.00043
   Barry G, 2014, MOL PSYCHIATR, V19, P410, DOI 10.1038/mp.2013.196
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bateup HS, 2008, NAT NEUROSCI, V11, P932, DOI 10.1038/nn.2153
   Bateup HS, 2010, P NATL ACAD SCI USA, V107, P14845, DOI 10.1073/pnas.1009874107
   Beitzinger M., 2007, RNA BIOL, P4
   Berezikov E, 2006, NAT GENET, V38, P1375, DOI 10.1038/ng1914
   Berezikov E, 2006, GENOME RES, V16, P1289, DOI 10.1101/gr.5159906
   Bicker S., 2014, CELL MOL LIFE SCI
   Brodersen P, 2009, NAT REV MOL CELL BIO, V10, P141, DOI 10.1038/nrm2619
   Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406
   Cao XW, 2006, ANNU REV NEUROSCI, V29, P77, DOI 10.1146/annurev.neuro.29.051605.112839
   Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035
   Chandrasekar V, 2011, NEUROPSYCHOPHARMACOL, V36, P1149, DOI 10.1038/npp.2010.250
   Chandrasekar V, 2009, MOL CELL NEUROSCI, V42, P350, DOI 10.1016/j.mcn.2009.08.009
   Chang TC, 2007, ANNU REV GENOM HUM G, V8, P215, DOI 10.1146/annurev.genom.8.080706.092351
   Cheng HYM, 2007, NEURON, V54, P813, DOI 10.1016/j.neuron.2007.05.017
   Chi SW, 2009, NATURE, V460, P479, DOI 10.1038/nature08170
   Cho William, 2012, Frontiers in Genetics, V3, P271, DOI 10.3389/fgene.2012.00271
   Cuellar TL, 2008, P NATL ACAD SCI USA, V105, P5614, DOI 10.1073/pnas.0801689105
   Cui GH, 2013, NATURE, V494, P238, DOI 10.1038/nature11846
   Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002
   Davis TH, 2008, J NEUROSCI, V28, P4322, DOI 10.1523/JNEUROSCI.4815-07.2008
   Di Filippo M, 2009, BEHAV BRAIN RES, V199, P108, DOI 10.1016/j.bbr.2008.09.025
   DiNieri JA, 2009, J NEUROSCI, V29, P1855, DOI 10.1523/JNEUROSCI.5104-08.2009
   Dong Y, 2006, NAT NEUROSCI, V9, P475, DOI 10.1038/nn1661
   Dreyer JL, 2010, GENOME MED, V2, DOI 10.1186/gm213
   Durieux PF, 2011, FRONT NEUROANAT, V5, DOI 10.3389/fnana.2011.00040
   Durieux PF, 2009, NAT NEUROSCI, V12, P393, DOI 10.1038/nn.2286
   Edbauer D, 2010, NEURON, V65, P373, DOI 10.1016/j.neuron.2010.01.005
   Edwards S, 2013, BEHAV PHARMACOL, V24, P356, DOI 10.1097/FBP.0b013e3283644d15
   Eipper-Mains Jodi E., 2012, Frontiers in Genetics, V3, P109, DOI 10.3389/fgene.2012.00109
   Eipper-Mains JE, 2011, RNA, V17, P1529, DOI 10.1261/rna.2775511
   Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103
   Fasano S, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.029.2009
   Fenelon K, 2011, P NATL ACAD SCI USA, V108, P4447, DOI 10.1073/pnas.1101219108
   Feng J, 2013, CURR OPIN NEUROBIOL, V23, P521, DOI 10.1016/j.conb.2013.01.001
   Fields R.D., 2011, P NATL ACAD SCI US
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   Fineberg SK, 2009, NEURON, V64, P303, DOI 10.1016/j.neuron.2009.10.020
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Forero DA, 2010, HUM MUTAT, V31, P1195, DOI 10.1002/humu.21344
   Freeze BS, 2013, J NEUROSCI, V33, P18531, DOI 10.1523/JNEUROSCI.1278-13.2013
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Gao FB, 2008, TRENDS NEUROSCI, V31, P20, DOI 10.1016/j.tins.2007.10.004
   Garcia-Perez D, 2015, ADDICT BIOL, V20, P104, DOI 10.1111/adb.12083
   Gerfen CR, 2011, ANNU REV NEUROSCI, V34, P441, DOI 10.1146/annurev-neuro-061010-113641
   Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119
   Goodman R.H., 2012, P NATL ACAD SCI
   Gorini G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082565
   Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952
   Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017
   Grueter BA, 2012, CURR OPIN NEUROBIOL, V22, P545, DOI 10.1016/j.conb.2011.09.009
   Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267
   Hansen KF, 2013, BRAIN STRUCT FUNCT, V218, P817, DOI 10.1007/s00429-012-0431-4
   Hansen KF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015497
   He M, 2012, NEURON, V73, P35, DOI 10.1016/j.neuron.2011.11.010
   He Ying, 2012, Frontiers in Genetics, V3, P110, DOI 10.3389/fgene.2012.00110
   He Y, 2010, J NEUROSCI, V30, P10251, DOI 10.1523/JNEUROSCI.2419-10.2010
   Hebert SS, 2010, HUM MOL GENET, V19, P3959, DOI 10.1093/hmg/ddq311
   Hollander JA, 2010, NATURE, V466, P197, DOI 10.1038/nature09202
   Hu HY, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002327
   Huang WH, 2009, INT J NEUROPSYCHOPH, V12, P537, DOI 10.1017/S1461145708009528
   Huang WH, 2009, BIOL PSYCHIAT, V65, P702, DOI 10.1016/j.biopsych.2008.11.024
   Huntzinger E, 2011, NAT REV GENET, V12, P99, DOI 10.1038/nrg2936
   Hwang YY, 2006, PROTEOMICS, V6, P3138, DOI 10.1002/pmic.200500745
   Im HI, 2010, NAT NEUROSCI, V13, P1120, DOI 10.1038/nn.2615
   Impey S, 2010, MOL CELL NEUROSCI, V43, P146, DOI 10.1016/j.mcn.2009.10.005
   Joe KH, 2007, ALCOHOL CLIN EXP RES, V31, P1833, DOI 10.1111/j.1530-0277.2007.00507.x
   Jonkman S, 2013, NEUROPSYCHOPHARMACOL, V38, P198, DOI 10.1038/npp.2012.120
   Kalivas PW, 2008, NEUROTOX RES, V14, P185, DOI 10.1007/BF03033809
   Kim YK, 2010, CELL, V143, P703, DOI 10.1016/j.cell.2010.11.018
   Klein ME, 2007, NAT NEUROSCI, V10, P1513, DOI 10.1038/nn2010
   Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009
   Konopka W, 2010, J NEUROSCI, V30, P14835, DOI 10.1523/JNEUROSCI.3030-10.2010
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Koob GF, 2009, NAT REV DRUG DISCOV, V8, P500, DOI 10.1038/nrd2828
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Kosik KS, 2006, NAT REV NEUROSCI, V7, P911, DOI 10.1038/nrn2037
   Kosik KS, 2005, NEURON, V47, P779, DOI 10.1016/j.neuron.2005.08.019
   Kozomara A, 2011, NUCLEIC ACIDS RES, V39, pD152, DOI 10.1093/nar/gkq1027
   Kravitz AV, 2012, PHYSIOLOGY, V27, P167, DOI 10.1152/physiol.00004.2012
   Kravitz AV, 2012, NAT NEUROSCI, V15, P816, DOI 10.1038/nn.3100
   Krichevsky AM, 2003, RNA, V9, P1274, DOI 10.1261/rna.5980303
   Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843
   Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6
   Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921
   Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040
   Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062
   Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Lerman C, 2007, NAT REV DRUG DISCOV, V6, P746, DOI 10.1038/nrd2361
   Lesscher HMB, 2012, REV NEUROSCIENCE, V23, P731, DOI 10.1515/revneuro-2012-0066
   Leung AKL, 2007, CELL, V130, P581, DOI 10.1016/j.cell.2007.08.010
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Lewohl JM, 2011, ALCOHOL CLIN EXP RES, V35, P1928, DOI 10.1111/j.1530-0277.2011.01544.x
   Li JY, 2013, EMBO MOL MED, V5, P1402, DOI 10.1002/emmm.201201900
   Li MD, 2011, MOL PSYCHIATR, V16, P1159, DOI 10.1038/mp.2011.58
   Lippi G, 2011, J CELL BIOL, V194, P889, DOI 10.1083/jcb.201103006
   Lobo MK, 2011, FRONT NEUROANAT, V5, DOI 10.3389/fnana.2011.00041
   Loebrich S, 2009, PHYSIOL REV, V89, P1079, DOI 10.1152/physrev.00013.2009
   Lu M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003420
   Luscher C, 2011, NEURON, V69, P650, DOI 10.1016/j.neuron.2011.01.017
   Lugli G, 2005, J NEUROCHEM, V94, P896, DOI 10.1111/j.1471-4159.2005.03224.x
   Lugli G, 2008, J NEUROCHEM, V106, P650, DOI 10.1111/j.1471-4159.2008.05413.x
   Magill ST, 2010, P NATL ACAD SCI USA, V107, P20382, DOI 10.1073/pnas.1015691107
   Man HY, 2011, CURR OPIN NEUROBIOL, V21, P291, DOI 10.1016/j.conb.2011.01.001
   Maze I, 2011, ANN NY ACAD SCI, V1216, P99, DOI 10.1111/j.1749-6632.2010.05893.x
   McGough NNH, 2004, J NEUROSCI, V24, P10542, DOI 10.1523/JNEUROSCI.3714-04.2004
   Meerson A, 2010, J MOL NEUROSCI, V40, P47, DOI 10.1007/s12031-009-9252-1
   Mehler MF, 2007, PHYSIOL REV, V87, P799, DOI 10.1152/physrev.00036.2006
   Mellios N, 2011, NAT NEUROSCI, V14, P1240, DOI 10.1038/nn.2909
   Mendelson JH, 1996, NEW ENGL J MED, V334, P965, DOI 10.1056/NEJM199604113341507
   Miller BH, 2010, BRAIN RES, V1338, P89, DOI 10.1016/j.brainres.2010.03.035
   Mulligan Megan K., 2013, Frontiers in Genetics, V4, P126, DOI 10.3389/fgene.2013.00126
   Nunez YO, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-725
   Nunez Yury O., 2012, Frontiers in Genetics, V3, P43, DOI 10.3389/fgene.2012.00043
   O'Carroll Donal, 2013, Neuropsychopharmacology, V38, P39, DOI 10.1038/npp.2012.87
   Obernosterer G, 2006, RNA, V12, P1161, DOI 10.1261/rna.2322506
   Olsen L., 2009, PLOS ONE, P4
   Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001
   Orom UA, 2007, METHODS, V43, P162, DOI 10.1016/j.ymeth.2007.04.007
   Park CY, 2012, CELL REP, V1, P385, DOI 10.1016/j.celrep.2012.02.008
   Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556
   Pathak M., 2012, Proceedings of the 2012 4th International Conference on Intelligent Human Computer Interaction (IHCI), DOI 10.1109/IHCI.2012.6481858
   Pierce RC, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a012880
   Pietrzykowski AZ, 2008, NEURON, V59, P274, DOI 10.1016/j.neuron.2008.05.032
   Qureshi IA, 2013, NEUROTHERAPEUTICS, V10, P632, DOI 10.1007/s13311-013-0199-0
   Qureshi IA, 2012, NAT REV NEUROSCI, V13, P528, DOI 10.1038/nrn3234
   Qureshi IA, 2011, TRENDS MOL MED, V17, P337, DOI 10.1016/j.molmed.2011.02.002
   Rao P, 2013, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00039
   Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607
   Remenyi J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062509
   Richter JD, 2009, GENE DEV, V23, P1, DOI 10.1101/gad.1735809
   Robison AJ, 2011, NAT REV NEUROSCI, V12, P623, DOI 10.1038/nrn3111
   Rodriguez Raquel E., 2012, Frontiers in Genetics, V3, P223, DOI 10.3389/fgene.2012.00223
   Roush S, 2008, TRENDS CELL BIOL, V18, P505, DOI 10.1016/j.tcb.2008.07.007
   Ruby JG, 2006, CELL, V127, P1193, DOI 10.1016/j.cell.2006.10.040
   Russo SJ, 2010, TRENDS NEUROSCI, V33, P267, DOI 10.1016/j.tins.2010.02.002
   Saba R., 2011, MOL CELL BIOL, P49
   Saba R, 2010, BRAIN RES, V1338, P3, DOI 10.1016/j.brainres.2010.03.107
   Saj A., 2011, CURR OPIN GENET DEV
   Sartor Gregory C., 2012, Frontiers in Genetics, V3, P106, DOI 10.3389/fgene.2012.00106
   Sayed D, 2011, PHYSIOL REV, V91, P827, DOI 10.1152/physrev.00006.2010
   Schaefer A, 2010, J EXP MED, V207, P1843, DOI 10.1084/jem.20100451
   Schmidt HD, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a012047
   Schratt G., 2014, PHILOS T R SOC LON B, P369
   Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367
   Sethupathy P, 2008, TRENDS GENET, V24, P489, DOI 10.1016/j.tig.2008.07.004
   Sethupathy P, 2006, NAT METHODS, V3, P881, DOI 10.1038/NMETH954
   Shaltiel G, 2013, BRAIN STRUCT FUNCT, V218, P59, DOI 10.1007/s00429-011-0376-z
   Shepherd GMG, 2013, NAT REV NEUROSCI, V14, P278, DOI 10.1038/nrn3469
   Siegel G., 2011, CURR OPIN GENET DEV
   Smith LN, 2014, NEURON, V82, P645, DOI 10.1016/j.neuron.2014.03.028
   Soifer HS, 2007, MOL THER, V15, P2070, DOI 10.1038/sj.mt.6300311
   Stefanik MT, 2013, J NEUROSCI, V33, P13654, DOI 10.1523/JNEUROSCI.1570-13.2013
   Sun KL, 2013, NAT REV GENET, V14, P535, DOI 10.1038/nrg3471
   Tapocik JD, 2014, J NEUROSCI, V34, P4581, DOI 10.1523/JNEUROSCI.0445-14.2014
   Tapocik JD, 2013, ADDICT BIOL, V18, P480, DOI 10.1111/j.1369-1600.2012.00470.x
   Tognini P, 2011, NAT NEUROSCI, V14, P1237, DOI 10.1038/nn.2920
   Tonelli DD, 2008, DEVELOPMENT, V135, P3911, DOI 10.1242/dev.025080
   Tritsch NX, 2012, NEURON, V76, P33, DOI 10.1016/j.neuron.2012.09.023
   Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077
   Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460
   Vasudevan S, 2007, CELL, V128, P1105, DOI 10.1016/j.cell.2007.01.038
   Vo N, 2005, P NATL ACAD SCI USA, V102, P16426, DOI 10.1073/pnas.0508448102
   Vo NK, 2010, P NATL ACAD SCI USA, V107, P19231, DOI 10.1073/pnas.1013162107
   Vo NK, 2010, CURR OPIN NEUROBIOL, V20, P457, DOI 10.1016/j.conb.2010.04.002
   Wayman GA, 2008, P NATL ACAD SCI USA, V105, P9093, DOI 10.1073/pnas.0803072105
   West A., 2011, COLD SPRING HARB PER
   WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4
   Wu QF, 2008, FASEB J, V22, P4085, DOI 10.1096/fj.08-108175
   Yadav S, 2011, J BIOL CHEM, V286, P37347, DOI 10.1074/jbc.M111.235531
NR 177
TC 19
Z9 22
U1 0
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0006-8993
EI 1872-6240
J9 BRAIN RES
JI Brain Res.
PD DEC 2
PY 2015
VL 1628
SI SI
BP 2
EP 16
DI 10.1016/j.brainres.2015.07.047
PN A
PG 15
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA CZ9IV
UT WOS:000367412200002
PM 26253823
DA 2023-06-23
ER

PT J
AU Goforth, HW
   Murtaugh, R
   Fernandez, F
AF Goforth, Harold W.
   Murtaugh, Reed
   Fernandez, Francisco
TI Neurologic Aspects of Drug Abuse
SO NEUROLOGIC CLINICS
LA English
DT Article
DE Addiction; Neurobiology; Neurotoxicity; Epidemiology
ID COCAINE USE; ALCOHOL DEPENDENCE; EFFICACY; METHAMPHETAMINE;
   DETOXIFICATION; DISULFIRAM; METHADONE; STROKE; PHARMACOTHERAPIES;
   BUPRENORPHINE
AB Neurologic aspects of drug abuse vary. This article explains the general nature of drug abuse, identifies the physiologic effects of certain drugs, and briefly describes the neurobiology of addiction. This article also reviews available treatment options for those addicted to substances of abuse, and clarifies common misconceptions, including the differences between tolerance, abuse, and addiction.
C1 [Goforth, Harold W.] Duke Univ, Med Ctr, Durham, NC 27705 USA.
   [Goforth, Harold W.] Durham Vet Affairs Med Ctr, Consultat Liaison Psychiat Serv, Durham, NC 27705 USA.
   [Goforth, Harold W.] Durham Vet Affairs Med Ctr, GRECC, Durham, NC 27705 USA.
   [Murtaugh, Reed; Fernandez, Francisco] Univ S Florida, Tampa, FL 33612 USA.
C3 Duke University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Durham VA Medical Center; Geriatric Research
   Education & Clinical Center; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); Durham VA Medical Center; State University
   System of Florida; University of South Florida
RP Goforth, HW (通讯作者)，Duke Univ, Med Ctr, Durham, NC 27705 USA.
EM harold.goforth@duke.edu
CR Adams IB, 1996, ADDICTION, V91, P1585, DOI 10.1111/j.1360-0443.1996.tb02264.x
   Anderson AL, 2009, DRUG ALCOHOL DEPEN, V104, P133, DOI 10.1016/j.drugalcdep.2009.04.015
   ANGRIST B, 1974, J PSYCHIAT RES, V11, P13, DOI 10.1016/0022-3956(74)90064-8
   Anton RF, 2008, NEW ENGL J MED, V359, P715, DOI 10.1056/NEJMct0801733
   Anton RF, 2006, JAMA-J AM MED ASSOC, V295, P2003, DOI 10.1001/jama.295.17.2003
   Association AP, 2000, DIAGN STAT MAN MENT
   BALFOUR DJK, 1982, PHARMACOL THERAPEUT, V16, P269, DOI 10.1016/0163-7258(82)90058-4
   Barnett PG, 2001, ADDICTION, V96, P683, DOI 10.1046/j.1360-0443.2001.9656834.x
   Bergman J, 2008, EXP CLIN PSYCHOPHARM, V16, P475, DOI 10.1037/a0014398
   Besson J, 1998, ALCOHOL CLIN EXP RES, V22, P573, DOI 10.1111/j.1530-0277.1998.tb04295.x
   CARLEN PL, 1994, ALCOHOL CLIN EXP RES, V18, P1330, DOI 10.1111/j.1530-0277.1994.tb01432.x
   Carroll KM, 2004, ARCH GEN PSYCHIAT, V61, P264, DOI 10.1001/archpsyc.61.3.264
   De Witte P, 2005, CNS DRUGS, V19, P517, DOI 10.2165/00023210-200519060-00004
   Elkashef AM, 2008, NEUROPSYCHOPHARMACOL, V33, P1162, DOI 10.1038/sj.npp.1301481
   FITZGERALD JL, 1990, EUR J PHARMACOL, V191, P217, DOI 10.1016/0014-2999(90)94150-V
   FLANAGAN RJ, 1990, DRUG SAFETY, V5, P359, DOI 10.2165/00002018-199005050-00005
   FULLER RK, 1986, JAMA-J AM MED ASSOC, V256, P1449, DOI 10.1001/jama.256.11.1449
   GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046
   Garbutt JC, 2005, JAMA-J AM MED ASSOC, V293, P1617, DOI 10.1001/jama.293.13.1617
   George DT, 1999, ALCOHOL CLIN EXP RES, V23, P272, DOI 10.1097/00000374-199902000-00012
   GOLD MS, 1978, LANCET, V1, P929
   GOLD MS, 1992, SUBSTANCE ABUSE COMP
   Grabowski J, 1997, J CLIN PSYCHOPHARM, V17, P485, DOI 10.1097/00004714-199712000-00008
   Grabowski J, 2001, J CLIN PSYCHOPHARM, V21, P522, DOI 10.1097/00004714-200110000-00010
   Hingson RW, 2009, J STUD ALCOHOL DRUGS, P12, DOI 10.15288/jsads.2009.s16.12
   Johnson BA, 2000, ALCOHOL CLIN EXP RES, V24, P737, DOI 10.1111/j.1530-0277.2000.tb02048.x
   Johnson BA, 2008, ARCH INTERN MED, V168, P1188, DOI 10.1001/archinte.168.11.1188
   Kalivas PW, 2003, PSYCHOPHARMACOLOGY, V168, P44, DOI 10.1007/s00213-003-1393-2
   KLEBER HD, 1985, ARCH GEN PSYCHIAT, V42, P391
   KLIEGMAN RM, 1994, J PEDIATR-US, V124, P751, DOI 10.1016/S0022-3476(05)81370-8
   Kollins SH, 2001, PHARMACOL BIOCHEM BE, V68, P611, DOI 10.1016/S0091-3057(01)00464-6
   Kongsakon R, 2005, INT CLIN PSYCHOPHARM, V20, P253, DOI 10.1097/01.yic.0000166815.83017.d8
   Koob GF, 2009, NAT REV DRUG DISCOV, V8, P500, DOI 10.1038/nrd2828
   KOSTEN TR, 1993, J NERV MENT DIS, V181, P358, DOI 10.1097/00005053-199306000-00004
   KOSTEN TR, 2002, NEUROPSYCHOPHARMACOL, P1461
   Lejoyeux M, 1996, ALCOHOL ALCOHOLISM, V31, P69
   LIPMAN AG, 2004, PRINCIPLES PRACTICE, P583
   Martin Billy R, 2004, J Support Oncol, V2, P305
   MARTIN BR, 2004, J SUPPORT ONCOL, V2, P314
   Mason B. J., 2006, FOCUS, V4, P505
   MATTICK RP, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002207.PUB3
   Nanda A, 2006, ACTA NEUROCHIR SUPPL, V96, P91
   Nestler EJ, 2001, AM J ADDICTION, V10, P201, DOI 10.1080/105504901750532094
   Newton TF, 2008, INT J NEUROPSYCHOPH, V11, P1037, DOI 10.1017/S1461145708009097
   *NID, 2008, P COMM EP WORK GROUP
   OConnor PG, 1997, ANN INTERN MED, V127, P526, DOI 10.7326/0003-4819-127-7-199710010-00004
   Qureshi AI, 2001, CIRCULATION, V103, P502, DOI 10.1161/01.CIR.103.4.502
   Reichel CM, 2009, DRUG ALCOHOL DEPEN, V100, P54, DOI 10.1016/j.drugalcdep.2008.09.006
   Sampson PD, 1997, TERATOLOGY, V56, P317, DOI 10.1002/(SICI)1096-9926(199711)56:5<317::AID-TERA5>3.0.CO;2-U
   SELLERS EM, 1994, ALCOHOL CLIN EXP RES, V18, P879, DOI 10.1111/j.1530-0277.1994.tb00054.x
   SINGER L, 1994, ARCH PEDIAT ADOL MED, V148, P959, DOI 10.1001/archpedi.1994.02170090073014
   SNYDER SH, 1976, AM J PSYCHIAT, V133, P197
   Sokol RJ, 2003, JAMA-J AM MED ASSOC, V290, P2996, DOI 10.1001/jama.290.22.2996
   STRATTON K, 1996, FETAL ALCOHOL SYNDRO
   Swift R, 2007, AM J HEALTH-SYST PH, V64, pS12, DOI 10.2146/ajhp060644
   TABAKOFF B, 1992, SUBSTANCE ABUSE COMP
   TORVIK A, 1991, ALCOHOL ALCOHOLISM, P381
   UNGERLEIDER TJ, 1992, SUBSTANCE ABUSE COMP
   *US DEP HHS, 2000, HER AB ADD
   Westover AN, 2007, ARCH GEN PSYCHIAT, V64, P495, DOI 10.1001/archpsyc.64.4.495
   ZUKIN SR, 1992, SUBSTANCE ABUSE COMP
NR 61
TC 7
Z9 7
U1 0
U2 15
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0733-8619
EI 1557-9875
J9 NEUROL CLIN
JI Neurol. Clin.
PD FEB
PY 2010
VL 28
IS 1
BP 199
EP +
DI 10.1016/j.ncl.2009.09.010
PG 19
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 617CL
UT WOS:000279258300012
PM 19932382
DA 2023-06-23
ER

PT J
AU Bentzley, BS
   Jhou, TC
   Aston-Jones, G
AF Bentzley, Brandon S.
   Jhou, Thomas C.
   Aston-Jones, Gary
TI Economic demand predicts addiction-like behavior and therapeutic
   efficacy of oxytocin in the rat
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE behavioral economics; reinstatement; extinction; long access; punished
   responding
ID METHAMPHETAMINE-SEEKING; DRUG-ADDICTION; ALCOHOL DEMAND; COCAINE;
   MOTIVATION; HISTORY; REINFORCEMENT; REINSTATEMENT; WITHDRAWAL; PATHOLOGY
AB Development of new treatments for drug addiction will depend on high-throughput screening in animal models. However, an addiction biomarker fit for rapid testing, and useful in both humans and animals, is not currently available. Economic models are promising candidates. They offer a structured quantitative approach to modeling behavior that is mathematically identical across species, and accruing evidence indicates economic-based descriptors of human behavior may be particularly useful biomarkers of addiction severity. However, economic demand has not yet been established as a biomarker of addiction-like behavior in animals, an essential final step in linking animal and human studies of addiction through economic models. We recently developed a mathematical approach for rapidly modeling economic demand in rats trained to self-administer cocaine. We show here that economic demand, as both a spontaneous trait and induced state, predicts addiction-like behavior, including relapse propensity, drug seeking in abstinence, and compulsive (punished) drug taking. These findings confirm economic demand as a biomarker of addiction-like behavior in rats. They also support the view that excessive motivation plays an important role in addiction while extending the idea that drug dependence represents a shift from initially recreational to compulsive drug use. Finally, we found that economic demand for cocaine predicted the efficacy of a promising pharmacotherapy (oxytocin) in attenuating cocaine-seeking behaviors across individuals, demonstrating that economic measures may be used to rapidly identify the clinical utility of prospective addiction treatments.
C1 [Bentzley, Brandon S.; Jhou, Thomas C.; Aston-Jones, Gary] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
C3 Medical University of South Carolina
RP Aston-Jones, G (通讯作者)，Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
EM astong@musc.edu
RI Bentzley, Brandon Stephen/AAH-3582-2020
OI Bentzley, Brandon Stephen/0000-0001-6014-4514
FU US Public Health Service Grants [R37 DA006214, P50 DA016511, T32
   GM008716, T32 DA007288, C06 RR015455, R21 DA032898, F30 DA035065]
FX We thank our colleagues Kimberly Fender and Jennifer Osborne for their
   assistance with behavioral testing. This work was supported by US Public
   Health Service Grants R37 DA006214, P50 DA016511, T32 GM008716, T32
   DA007288, C06 RR015455, R21 DA032898, and F30 DA035065.
CR Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Ahmed SH, 1999, PSYCHOPHARMACOLOGY, V146, P303, DOI 10.1007/s002130051121
   American Psychiatric Association [APA], 2022, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425787]
   Becker RE, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000446
   Bentzley BS, 2013, PSYCHOPHARMACOLOGY, V226, P113, DOI 10.1007/s00213-012-2899-2
   Bickel WK, 2014, ANNU REV CLIN PSYCHO, V10, P641, DOI 10.1146/annurev-clinpsy-032813-153724
   Bruner NR, 2014, PSYCHOPHARMACOLOGY, V231, P889, DOI 10.1007/s00213-013-3312-5
   Carson DS, 2013, J PSYCHOPHARMACOL, V27, P231, DOI 10.1177/0269881112473788
   Carson DS, 2010, ADDICT BIOL, V15, P448, DOI 10.1111/j.1369-1600.2010.00247.x
   Carson DS, 2010, NEUROPHARMACOLOGY, V58, P38, DOI 10.1016/j.neuropharm.2009.06.018
   Chase HW, 2013, PSYCHOPHARMACOLOGY, V226, P371, DOI 10.1007/s00213-012-2911-x
   Chen BT, 2013, NATURE, V496, P359, DOI 10.1038/nature12024
   Christensen CJ, 2008, PHARMACOL BIOCHEM BE, V91, P209, DOI 10.1016/j.pbb.2008.07.009
   Cox BM, 2013, PSYCHONEUROENDOCRINO, V38, P2343, DOI 10.1016/j.psyneuen.2013.05.005
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Everitt BJ, 2013, NEUROSCI BIOBEHAV R, V37, P1946, DOI 10.1016/j.neubiorev.2013.02.010
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Galuska CM, 2011, BEHAV PHARMACOL, V22, P312, DOI 10.1097/FBP.0b013e3283473be4
   Gray JC, 2014, PSYCHOL ADDICT BEHAV, V28, P282, DOI 10.1037/a0032766
   Groblewski PA, 2015, ADDICT BIOL, V20, P297, DOI 10.1111/adb.12123
   Haney M, 2008, PSYCHOPHARMACOLOGY, V199, P403, DOI 10.1007/s00213-008-1079-x
   Hart CL, 2000, BEHAV PHARMACOL, V11, P87, DOI 10.1097/00008877-200002000-00010
   Heinz Adrienne J, 2012, Curr Drug Abuse Rev, V5, P257
   Hursh SR, 2008, PSYCHOL REV, V115, P186, DOI 10.1037/0033-295X.115.1.186
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kirkpatrick MG, 2012, ADDICTION, V107, P783, DOI 10.1111/j.1360-0443.2011.03706.x
   MacKillop J, 2007, DRUG ALCOHOL DEPEN, V89, P227, DOI 10.1016/j.drugalcdep.2007.01.002
   MacKillop J, 2012, NICOTINE TOB RES, V14, P1426, DOI 10.1093/ntr/nts006
   MacKillop J, 2010, ADDICTION, V105, P1599, DOI 10.1111/j.1360-0443.2010.03004.x
   MacKillop J, 2010, J ABNORM PSYCHOL, V119, P106, DOI 10.1037/a0017513
   Markou A, 2009, NEUROPSYCHOPHARMACOL, V34, P74, DOI 10.1038/npp.2008.173
   McClure EA, 2013, NICOTINE TOB RES, V15, P139, DOI 10.1093/ntr/nts101
   McRae-Clark AL, 2013, PSYCHOPHARMACOLOGY, V228, P623, DOI 10.1007/s00213-013-3062-4
   Murphy JG, 2011, DRUG ALCOHOL DEPEN, V113, P207, DOI 10.1016/j.drugalcdep.2010.08.004
   Murphy JG, 2009, EXP CLIN PSYCHOPHARM, V17, P396, DOI 10.1037/a0017684
   O'Brien CP, 2008, PHILOS T R SOC B, V363, P3277, DOI 10.1098/rstb.2008.0105
   Oleson EB, 2011, PSYCHOPHARMACOLOGY, V214, P567, DOI 10.1007/s00213-010-2058-6
   Pedersen CA, 2013, ALCOHOL CLIN EXP RES, V37, P484, DOI 10.1111/j.1530-0277.2012.01958.x
   Petry NM, 2001, DRUG ALCOHOL DEPEN, V62, P31, DOI 10.1016/S0376-8716(00)00157-5
   Pierce RC, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a012880
   Sarnyai Z, 2014, PHARMACOL BIOCHEM BE, V119, P3, DOI 10.1016/j.pbb.2013.11.019
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   SOLOMON RL, 1980, AM PSYCHOL, V35, P691, DOI 10.1037/0003-066X.35.8.691
   Stafford D, 1998, PSYCHOPHARMACOLOGY, V139, P169, DOI 10.1007/s002130050702
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Volkow ND, 2011, NEURON, V69, P599, DOI 10.1016/j.neuron.2011.01.027
   Zimmer BA, 2012, NEUROPSYCHOPHARMACOL, V37, P1901, DOI 10.1038/npp.2012.37
NR 48
TC 102
Z9 102
U1 0
U2 16
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
EI 1091-6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 12
PY 2014
VL 111
IS 32
BP 11822
EP 11827
DI 10.1073/pnas.1406324111
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AM8CQ
UT WOS:000340097900059
PM 25071176
OA Green Published, Bronze
DA 2023-06-23
ER

PT J
AU Chen, W
   Nong, ZH
   Li, YX
   Huang, JP
   Chen, CX
   Huang, LY
AF Chen, Wan
   Nong, Zhihuan
   Li, Yaoxuan
   Huang, Jianping
   Chen, Chunxia
   Huang, Luying
TI Role of Dopamine Signaling in Drug Addiction
SO CURRENT TOPICS IN MEDICINAL CHEMISTRY
LA English
DT Review
DE Dopamine; Addiction; Dopamine receptors; Brain regions; Perforental
   cortex; PA receptor
ID CONDITIONED PLACE PREFERENCE; VENTRAL TEGMENTAL AREA; COCAINE-SEEKING
   BEHAVIOR; PSEUDO NUCLEOTIDE COMPOSITION; MORPHINE-DEPENDENT RATS;
   RECEPTOR KNOCKOUT MICE; PROTEIN-BIOMOLECULE INTERACTIONS; RECOGNITION
   SEQUENCE PEPTIDES; STRIATAL SYNAPTIC PLASTICITY; LYSINE SUCCINYLATION
   SITES
AB Addiction is a chronic, relapsing disease of the brain that includes drug-induced compulsive seeking behavior and consumption of drugs. Dopamine (DA) is considered to be critical in drug addiction due to reward mechanisms in the midbrain. In this article, we review the major animal models in addictive drug experiments in vivo and in vitro. We discuss the relevance of the structure and pharmacological function of DA receptors. To improve the understanding of the role of DA receptors in reward pathways, specific brain regions, including the Ventral tegmental area, Nucleus accumbens, Prefrontal cortex, and Habenula, are highlighted. These factors contribute to the development of novel therapeutic targets that act at DA receptors. In addiction, the development of neuro imaging method will increase our understanding of the mechanisms underlying drug addiction.
C1 [Chen, Wan] Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Emergency, Nanning 530021, Guangxi, Peoples R China.
   [Nong, Zhihuan] Guangxi Inst Chinese Med & Pharmaceut Sci, Dept Pharmacol, Nanning 530022, Peoples R China.
   [Li, Yaoxuan] Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Neurol, Nanning 530021, Guangxi, Peoples R China.
   [Huang, Jianping; Chen, Chunxia] Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Hyperbar Oxygen, Nanning 530021, Guangxi, Peoples R China.
   [Huang, Luying] Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Resp Med, Nanning 530021, Guangxi, Peoples R China.
RP Chen, CX (通讯作者)，Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Hyperbar Oxygen, 6 Taoyuan Rd, Nanning 530021, Guangxi Zhuang, Peoples R China.; Huang, LY (通讯作者)，Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Resp Med, 6 Taoyuan Rd, Nanning 530021, Guangxi Zhuang, Peoples R China.
EM chunxia251401@126.com; huangluying2601@vip.sina.com
FU Guangxi Sanitation and Family Planning Committee Project [Z2016582]
FX This work was supported by the Guangxi Sanitation and Family Planning
   Committee Project (No. Z2016582).
CR Airan RD, 2009, NATURE, V458, P1025, DOI 10.1038/nature07926
   ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X
   [Anonymous], 2010, WORLD DRUG REPORT 20
   ASGHARI V, 1994, MOL PHARMACOL, V46, P364
   Baker DA, 1998, SYNAPSE, V30, P181, DOI 10.1002/(SICI)1098-2396(199810)30:2<181::AID-SYN8>3.3.CO;2-N
   Beaulieu JM, 2015, BRIT J PHARMACOL, V172, P1, DOI 10.1111/bph.12906
   Belliotti TR, 1999, J MED CHEM, V42, P5181, DOI 10.1021/jm990277d
   Bello EP, 2011, NAT NEUROSCI, V14, P1033, DOI 10.1038/nn.2862
   Bellucci A, 2008, J NEUROCHEM, V106, P560, DOI 10.1111/j.1471-4159.2008.05406.x
   Beyer CE, 2002, CEREB CORTEX, V12, P526, DOI 10.1093/cercor/12.5.526
   Bezard E, 2001, NAT REV NEUROSCI, V2, P577, DOI 10.1038/35086062
   Bjorklund A, 2007, TRENDS NEUROSCI, V30, P194, DOI 10.1016/j.tins.2007.03.006
   Boyaci H, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002464
   Britt JP, 2013, CURR OPIN NEUROBIOL, V23, P539, DOI 10.1016/j.conb.2013.01.010
   Britt JP, 2012, NEURON, V76, P790, DOI 10.1016/j.neuron.2012.09.040
   Bromberg-Martin ES, 2010, NEURON, V68, P815, DOI 10.1016/j.neuron.2010.11.022
   Brown RM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015889
   Buttner A, 2011, NEUROPATH APPL NEURO, V37, P118, DOI 10.1111/j.1365-2990.2010.01131.x
   Cacciapaglia F, 2011, J NEUROSCI, V31, P13860, DOI 10.1523/JNEUROSCI.1340-11.2011
   Cai YD, 2008, INT CONF BIOMED, P158, DOI 10.1109/BMEI.2008.11
   Caine SB, 2007, J NEUROSCI, V27, P13140, DOI 10.1523/JNEUROSCI.2284-07.2007
   Caine SB, 2002, J NEUROSCI, V22, P2977, DOI 10.1523/JNEUROSCI.22-07-02977.2002
   Centonze D, 2003, J NEUROSCI, V23, P8506, DOI 10.1523/jneurosci.23-24-08506.2003
   CERVO L, 1995, BRAIN RES, V673, P242, DOI 10.1016/0006-8993(94)01420-M
   Chartoff EH, 2009, PSYCHOPHARMACOLOGY, V204, P227, DOI 10.1007/s00213-008-1454-7
   Chausmer AL, 2002, PSYCHOPHARMACOLOGY, V163, P54, DOI 10.1007/s00213-002-1142-y
   Chen BT, 2008, NEURON, V59, P288, DOI 10.1016/j.neuron.2008.05.024
   Chen CX, 2014, NEUROSCI LETT, V570, P63, DOI 10.1016/j.neulet.2014.04.006
   Chen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035254
   Chen W, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.37
   Chen W, 2015, ANAL BIOCHEM, V490, P26, DOI 10.1016/j.ab.2015.08.021
   Chen W, 2015, MOL BIOSYST, V11, P2620, DOI 10.1039/c5mb00155b
   Chen W, 2015, BIOINFORMATICS, V31, P119, DOI 10.1093/bioinformatics/btu602
   Chen W, 2014, ANAL BIOCHEM, V456, P53, DOI 10.1016/j.ab.2014.04.001
   Chien EYT, 2010, SCIENCE, V330, P1091, DOI 10.1126/science.1197410
   Chou K.-C., 2011, NAT SCI, V3, P862, DOI DOI 10.4236/NS.2011.310111
   Chou KC, 2004, CURR MED CHEM, V11, P2105, DOI 10.2174/0929867043364667
   Chou KC, 2001, PEPTIDES, V22, P1973, DOI 10.1016/S0196-9781(01)00540-X
   Chou KC, 2001, PROTEINS, V43, P246, DOI 10.1002/prot.1035
   Chou KC, 2007, BIOCHEM BIOPH RES CO, V357, P633, DOI 10.1016/j.bbrc.2007.03.162
   Chou KC, 2012, MOL BIOSYST, V8, P629, DOI 10.1039/c1mb05420a
   Chou KC, 2015, MED CHEM, V11, P218, DOI 10.2174/1573406411666141229162834
   Chou KC, 2013, MOL BIOSYST, V9, P1092, DOI 10.1039/c3mb25555g
   Chou KC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018258
   Chou KC, 2010, CURR DRUG METAB, V11, P369, DOI 10.2174/138920010791514261
   Chou KC, 2009, CURR PROTEOMICS, V6, P262, DOI 10.2174/157016409789973707
   Clausen B, 2011, BEHAV BRAIN RES, V223, P241, DOI 10.1016/j.bbr.2011.03.069
   Cohen JY, 2012, NATURE, V482, P85, DOI 10.1038/nature10754
   Collo G, 2008, EUR J NEUROSCI, V28, P1231, DOI 10.1111/j.1460-9568.2008.06423.x
   Collo G, 2012, J NEUROCHEM, V120, P765, DOI 10.1111/j.1471-4159.2011.07618.x
   CORNWALL J, 1990, BRAIN RES BULL, V25, P271, DOI 10.1016/0361-9230(90)90072-8
   da Silva WCN, 2012, NEUROBIOL LEARN MEM, V97, P271, DOI 10.1016/j.nlm.2012.01.005
   De Vries TJ, 2002, NEUROPSYCHOPHARMACOL, V26, P18, DOI 10.1016/S0893-133X(01)00293-7
   Dea-Ayuela MA, 2008, BIOORGAN MED CHEM, V16, P7770, DOI 10.1016/j.bmc.2008.07.023
   Di Chiara G, 2007, CURR OPIN PHARMACOL, V7, P69, DOI 10.1016/j.coph.2006.11.003
   DRAGO J, 1994, P NATL ACAD SCI USA, V91, P12564, DOI 10.1073/pnas.91.26.12564
   Du F, 2005, EUR J NEUROSCI, V22, P2422, DOI 10.1111/j.1460-9568.2005.04438.x
   El-Ghundi M, 1999, EUR J PHARMACOL, V383, P95, DOI 10.1016/S0014-2999(99)00573-7
   Elliot EE, 2003, PSYCHOPHARMACOLOGY, V169, P161, DOI 10.1007/s00213-003-1494-y
   Ettenberg A, 1999, PHARMACOL BIOCHEM BE, V64, P507, DOI 10.1016/S0091-3057(99)00109-4
   Fan YN, 2014, INT J MOL SCI, V15, P4915, DOI 10.3390/ijms15034915
   FERGUSON KM, 1986, J BIOL CHEM, V261, P7393
   Fields HL, 2007, ANNU REV NEUROSCI, V30, P289, DOI 10.1146/annurev.neuro.30.051606.094341
   Fiorentini C, 2008, MOL PHARMACOL, V74, P59, DOI 10.1124/mol.107.043885
   Fiorentini C, 2010, CURR OPIN PHARMACOL, V10, P87, DOI 10.1016/j.coph.2009.09.008
   Friedman A, 2010, NEUROPHARMACOLOGY, V59, P452, DOI 10.1016/j.neuropharm.2010.06.008
   Fuchs RA, 2002, PHARMACOL BIOCHEM BE, V72, P623, DOI 10.1016/S0091-3057(02)00731-1
   GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0
   GLICK SD, 1978, PSYCHOPHARMACOLOGY, V57, P283, DOI 10.1007/BF00426752
   Glickstein SB, 2001, PHARMACOL THERAPEUT, V91, P63, DOI 10.1016/S0163-7258(01)00145-0
   GOEDERS NE, 1983, SCIENCE, V221, P773, DOI 10.1126/science.6879176
   Goldman-Rakic PS, 2004, PSYCHOPHARMACOLOGY, V174, P3, DOI 10.1007/s00213-004-1793-y
   Good CH, 2013, J NEUROSCI, V 33, P16853, DOI 10.1523/JNEUROSCI.1844-13.2013
   Groenewegen HJ, 2000, PROG BRAIN RES, V126, P3
   Guitart X, 2014, MOL PHARMACOL, V86, P417, DOI 10.1124/mol.114.093096
   Hasbi A, 2010, CURR OPIN PHARMACOL, V10, P93, DOI 10.1016/j.coph.2009.09.011
   HEMBY SE, 1992, PSYCHOPHARMACOLOGY, V106, P330, DOI 10.1007/BF02245413
   HENRY DJ, 1989, J PHARMACOL EXP THER, V251, P833
   Higley AE, 2011, EUR J PHARMACOL, V659, P187, DOI 10.1016/j.ejphar.2011.02.046
   Holmes A, 2001, BEHAV NEUROSCI, V115, P1129, DOI 10.1037//0735-7044.115.5.1129
   Hong S, 2011, J NEUROSCI, V31, P11457, DOI 10.1523/JNEUROSCI.1384-11.2011
   Hopkins E, 2004, BRAIN RES, V1014, P244, DOI 10.1016/j.brainres.2004.03.056
   Ikemoto S, 2007, BRAIN RES REV, V56, P27, DOI 10.1016/j.brainresrev.2007.05.004
   Jalabert M, 2011, P NATL ACAD SCI USA, V108, P16446, DOI 10.1073/pnas.1105418108
   Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V142, P78, DOI 10.1007/s002130050865
   Jhou TC, 2013, J NEUROSCI, V33, P7501, DOI 10.1523/JNEUROSCI.3634-12.2013
   Jhou TC, 2009, NEURON, V61, P786, DOI 10.1016/j.neuron.2009.02.001
   Jia JH, 2016, J THEOR BIOL, V394, P223, DOI 10.1016/j.jtbi.2016.01.020
   Jia JH, 2016, ANAL BIOCHEM, V497, P48, DOI 10.1016/j.ab.2015.12.009
   Jiao DL, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00162
   JOHNSON SM, 1978, J PHARMACOL EXP THER, V204, P54
   Joyce JN, 2007, CURR OPIN PHARMACOL, V7, P100, DOI 10.1016/j.coph.2006.11.004
   Kalani MYS, 2004, P NATL ACAD SCI USA, V101, P3815, DOI 10.1073/pnas.0400100101
   KALIVAS PW, 1993, BRAIN RES REV, V18, P75, DOI 10.1016/0165-0173(93)90008-N
   Karasinska JM, 2000, EUR J PHARMACOL, V399, P171, DOI 10.1016/S0014-2999(00)00347-2
   Karasinska JM, 2005, EUR J NEUROSCI, V22, P1741, DOI 10.1111/j.1460-9568.2005.04353.x
   Karlsson RM, 2008, PSYCHOPHARMACOLOGY, V200, P117, DOI 10.1007/s00213-008-1165-0
   Kaufling J, 2010, BRIT J PHARMACOL, V161, P1677, DOI 10.1111/j.1476-5381.2010.00984.x
   Kerr JND, 2001, J NEUROPHYSIOL, V85, P117, DOI 10.1152/jn.2001.85.1.117
   Khroyan TV, 2003, PSYCHOPHARMACOLOGY, V168, P124, DOI 10.1007/s00213-002-1365-y
   Khroyan TV, 2000, J PHARMACOL EXP THER, V294, P680
   Kim SY, 2006, J NEUROSCI, V26, P4567, DOI 10.1523/JNEUROSCI.5236-05.2006
   Kobayashi M, 2004, P NATL ACAD SCI USA, V101, P11465, DOI 10.1073/pnas.0402028101
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Kowski AB, 2009, NEUROSCIENCE, V161, P1154, DOI 10.1016/j.neuroscience.2009.04.026
   Kudwa AE, 2005, PSYCHOPHARMACOLOGY, V180, P206, DOI 10.1007/s00213-005-2150-5
   Lammel S, 2012, NATURE, V491, P212, DOI 10.1038/nature11527
   Le Foll B, 2002, EUR J NEUROSCI, V15, P2016, DOI 10.1046/j.1460-9568.2002.02049.x
   LEEDHAM JA, 1991, J PHARMACOL EXP THER, V259, P295
   LeMoine C, 1996, NEUROSCIENCE, V73, P131, DOI 10.1016/0306-4522(96)00029-2
   Lex A, 2008, LEARN MEMORY, V15, P483, DOI 10.1101/lm.978708
   Li ZJ, 2016, ACTA CRYSTALLOGR F, V72, P782, DOI 10.1107/S2053230X16014278
   [李志杰 Li Zhijie], 2010, [生物物理学报, Acta Biophysica Sinica], V26, P37
   Li ZJ, 2010, ACTA CRYSTALLOGR F, V66, P426, DOI 10.1107/S1744309110005002
   Lin H, 2014, NUCLEIC ACIDS RES, V42, P12961, DOI 10.1093/nar/gku1019
   Lin WZ, 2013, MOL BIOSYST, V9, P634, DOI 10.1039/c3mb25466f
   Liu B, 2016, BIOINFORMATICS, V32, P2411, DOI 10.1093/bioinformatics/btw186
   Liu B, 2016, BIOINFORMATICS, V32, P362, DOI [10.1093/bioinformatics/btv604, 10.1093/bioinformatics/btw539]
   Liu B, 2016, MOL GENET GENOMICS, V291, P473, DOI 10.1007/s00438-015-1078-7
   Liu B, 2015, NUCLEIC ACIDS RES, V43, pW65, DOI 10.1093/nar/gkv458
   Liu B, 2015, BIOINFORMATICS, V31, P1307, DOI 10.1093/bioinformatics/btu820
   Liu Z, 2016, ANAL BIOCHEM, V497, P60, DOI 10.1016/j.ab.2015.12.017
   Liu Z, 2015, ANAL BIOCHEM, V474, P69, DOI 10.1016/j.ab.2014.12.009
   LIVAK KJ, 1995, P NATL ACAD SCI USA, V92, P427, DOI 10.1073/pnas.92.2.427
   Lobo MK, 2010, SCIENCE, V330, P385, DOI 10.1126/science.1188472
   Lu L, 2000, EUR J NEUROSCI, V12, P4398
   Ma DKK, 2015, CELL, V161, P1152, DOI 10.1016/j.cell.2015.04.026
   Maguma H, 2010, BIOCHEM PHARMACOL, V80, P522, DOI 10.1016/j.bcp.2010.05.005
   Mantsch JR, 2010, NEUROPSYCHOPHARMACOL, V35, P2165, DOI 10.1038/npp.2010.86
   Mao GT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10198
   Marcellino D, 2008, J BIOL CHEM, V283, P26016, DOI 10.1074/jbc.M710349200
   Matsumoto M, 2007, NATURE, V447, P1111, DOI 10.1038/nature05860
   Mattioli L, 2012, PSYCHOPHARMACOLOGY, V221, P183, DOI 10.1007/s00213-012-2686-0
   Mattioli L, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/741925
   MEADORWOODRUFF JH, 1991, PROG NEURO-PSYCHOPH, V15, P885, DOI 10.1016/0278-5846(91)90016-T
   Meng JZ, 1997, J PHARMACOL EXP THER, V281, P41
   Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228
   Min JL, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/701317
   Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189
   Morgan D, 2002, NAT NEUROSCI, V5, P169, DOI 10.1038/nn798
   Nader K, 1997, J NEUROSCI, V17, P383, DOI 10.1523/JNEUROSCI.17-01-00383.1997
   Nair-Roberts RG, 2008, NEUROSCIENCE, V152, P1024, DOI 10.1016/j.neuroscience.2008.01.046
   Nakajima S, 2013, EUR NEUROPSYCHOPHARM, V23, P799, DOI 10.1016/j.euroneuro.2013.05.006
   Nazarian A, 2004, BRAIN RES BULL, V63, P295, DOI 10.1016/j.brainresbull.2004.03.004
   Neisewander JL, 2004, NEUROPSYCHOPHARMACOL, V29, P1479, DOI 10.1038/sj.npp.1300456
   Neugebauer NM, 2013, PHARMACOL BIOCHEM BE, V109, P77, DOI 10.1016/j.pbb.2013.04.015
   O'Sullivan GJ, 2005, SYNAPSE, V55, P201, DOI 10.1002/syn.20107
   Overton PG, 1997, BRAIN RES REV, V25, P312, DOI 10.1016/S0165-0173(97)00039-8
   Pascoli V, 2012, NATURE, V481, P71, DOI 10.1038/nature10709
   Paxinos G, 1997, RAT BRAIN STEREOTAXI
   Prado C, 2012, J IMMUNOL, V188, P3062, DOI 10.4049/jimmunol.1103096
   Prado-Prado FJ, 2008, BIOORGAN MED CHEM, V16, P5871, DOI 10.1016/j.bmc.2008.04.068
   Prado-Prado FJ, 2009, BIOORGAN MED CHEM, V17, P569, DOI 10.1016/j.bmc.2008.11.075
   Qiu WR, 2016, ONCOTARGET, V7, P51270, DOI 10.18632/oncotarget.9987
   Qiu WR, 2015, J BIOMOL STRUCT DYN, V33, P1731, DOI 10.1080/07391102.2014.968875
   Qiu WR, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/947416
   RASMUSSEN K, 1990, J NEUROSCI, V10, P2308
   Rondou P, 2010, CELL MOL LIFE SCI, V67, P1971, DOI 10.1007/s00018-010-0293-y
   RUBINSTEIN M, 1988, N-S ARCH PHARMACOL, V337, P115
   Rubinstein M, 1997, CELL, V90, P991, DOI 10.1016/S0092-8674(00)80365-7
   Saddoris MP, 2011, EUR J NEUROSCI, V33, P2274, DOI 10.1111/j.1460-9568.2011.07683.x
   SanMartinClark O, 1996, PSYCHOPHARMACOLOGY, V123, P297, DOI 10.1007/BF02246584
   SEEMAN P, 1994, TRENDS PHARMACOL SCI, V15, P264, DOI 10.1016/0165-6147(94)90323-9
   Self DW, 1996, SCIENCE, V271, P1586, DOI 10.1126/science.271.5255.1586
   SEMBA K, 1992, J COMP NEUROL, V323, P387, DOI 10.1002/cne.903230307
   SESACK SR, 1992, J COMP NEUROL, V320, P145, DOI 10.1002/cne.903200202
   Sesack SR, 2010, NEUROPSYCHOPHARMACOL, V35, P27, DOI 10.1038/npp.2009.93
   Sharma AK, 2008, J BIOL CHEM, V283, P32860, DOI 10.1074/jbc.M804916200
   Shen HB, 2007, BIOCHEM BIOPH RES CO, V363, P297, DOI 10.1016/j.bbrc.2007.08.140
   Shen WX, 2008, SCIENCE, V321, P848, DOI 10.1126/science.1160575
   Shen XF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034323
   SHIPPENBERG TS, 1995, J PHARMACOL EXP THER, V273, P808
   SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2
   Sim H, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2598
   Smith DR, 1998, NEUROSCIENCE, V86, P135, DOI 10.1016/S0306-4522(97)00608-8
   Smythies John, 2005, Int Rev Neurobiol, V64, P123, DOI 10.1016/S0074-7742(05)64002-0
   Steinberg EE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094771
   Stewart D, 2000, EUR ADDICT RES, V6, P106, DOI 10.1159/000019022
   STEWART J, 1988, BRAIN RES, V457, P287, DOI 10.1016/0006-8993(88)90698-1
   Stuber GD, 2011, NATURE, V475, P377, DOI 10.1038/nature10194
   SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0
   Tepper JM, 2004, CURR OPIN NEUROBIOL, V14, P685, DOI 10.1016/j.conb.2004.10.003
   Thanos PK, 2010, J PSYCHOPHARMACOL, V24, P897, DOI 10.1177/0269881109102613
   TIBERI M, 1991, P NATL ACAD SCI USA, V88, P7491, DOI 10.1073/pnas.88.17.7491
   Tran AH, 2008, J NEUROSCI, V28, P13390, DOI 10.1523/JNEUROSCI.2680-08.2008
   Tritsch NX, 2012, NEURON, V76, P33, DOI 10.1016/j.neuron.2012.09.023
   Tsai HC, 2009, SCIENCE, V324, P1080, DOI 10.1126/science.1168878
   Tzschentke TM, 2001, PROG NEUROBIOL, V63, P241, DOI 10.1016/S0301-0082(00)00033-2
   Usiello A, 2000, NATURE, V408, P199, DOI 10.1038/35041572
   Vaidehi N, 2002, P NATL ACAD SCI USA, V99, P12622, DOI 10.1073/pnas.122357199
   van Huijstee AN, 2015, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00466
   Ventura R, 2005, CEREB CORTEX, V15, P1877, DOI 10.1093/cercor/bhi066
   Volkow ND, 1996, J ADDICT DIS, V15, P55, DOI 10.1300/J069v15n04_04
   Volkow ND, 2012, ANNU REV PHARMACOL, V52, P321, DOI 10.1146/annurev-pharmtox-010611-134625
   Waddington JL, 1993, D1 D2 DOPAMINE RECEP, V1st
   Wall VZ, 2011, MOL CELL NEUROSCI, V46, P21, DOI 10.1016/j.mcn.2010.09.011
   Wang B, 2000, NEUROREPORT, V11, P2781, DOI 10.1097/00001756-200008210-00034
   Wang JH, 2012, ADDICT BIOL, V17, P539, DOI 10.1111/j.1369-1600.2010.00289.x
   Wang P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023505
   WEI E, 1973, PSYCHOPHARMACOLOGIA, V28, P35, DOI 10.1007/BF00413955
   White FJ, 1998, NEUROPSYCHOPHARMACOL, V18, P26
   WISE RA, 1989, NEUROSCI BIOBEHAV R, V13, P129, DOI 10.1016/S0149-7634(89)80021-1
   WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469
   Woolley ML, 2008, BEHAV PHARMACOL, V19, P765, DOI 10.1097/FBP.0b013e32831c3b06
   Wu ZC, 2012, PROTEIN PEPTIDE LETT, V19, P4, DOI 10.2174/092986612798472839
   Wu ZC, 2011, MOL BIOSYST, V7, P3287, DOI 10.1039/c1mb05232b
   Xiao X, 2016, ONCOTARGET, V7, P34180, DOI 10.18632/oncotarget.9057
   Xiao X, 2015, J BIOMOL STRUCT DYN, V33, P2221, DOI 10.1080/07391102.2014.998710
   Xiao X, 2013, J THEOR BIOL, V337, P71, DOI 10.1016/j.jtbi.2013.08.013
   Xiao X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072234
   Xiao X, 2013, ANAL BIOCHEM, V436, P168, DOI 10.1016/j.ab.2013.01.019
   Xiao X, 2011, J THEOR BIOL, V284, P42, DOI 10.1016/j.jtbi.2011.06.005
   Xiao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020592
   XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6
   Xu TX, 2009, J NEUROSCI, V29, P14086, DOI 10.1523/JNEUROSCI.0974-09.2009
   Xu Y., 2014, PLOS ONE, V9
   Xu Y, 2016, CURR TOP MED CHEM, V16, P591, DOI 10.2174/1568026615666150819110421
   Xu Y, 2013, PEERJ, V1, DOI 10.7717/peerj.171
   Xu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055844
   Yan SM, 2013, VIRULENCE, V4, P716, DOI 10.4161/viru.26612
   Yan T, 2015, FRONT BEHAV NEUROSCI, V9, DOI [10.3389/fnbeh.2015.00273, 10.3389/fnbeh.2015,00273]
   Yang HY, 2009, EUR J PHARMACOL, V609, P51, DOI 10.1016/j.ejphar.2009.03.028
   Yoon S, 2013, J BIOL CHEM, V288, P28435, DOI 10.1074/jbc.M113.461202
   Yoon S, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.188078
   Zeng Chunyu, 2007, Cardiovascular & Hematological Agents in Medicinal Chemistry, V5, P241
   Zhang CJ, 2016, ONCOTARGET, V7, P69783, DOI 10.18632/oncotarget.11975
   Zhang FQ, 2005, NEUROSCI LETT, V386, P133, DOI 10.1016/j.neulet.2005.06.008
   Zhang FP, 2007, ANAL SCI, V23, P1325, DOI 10.2116/analsci.23.1325
   Zhou GP, 2004, BLOOD, V104, p963A, DOI 10.1182/blood.V104.11.3539.3539
   Zhou GP, 2005, CURR PROTEIN PEPT SC, V6, P399, DOI 10.2174/138920305774329377
   Zhou GP, 2003, GLYCOBIOLOGY, V13, P51, DOI 10.1093/glycob/cwg008
   Zhou GP, 2016, CURR TOP MED CHEM, V16, P579, DOI 10.2174/1568026616999150918145955
   Zhou GP, 2016, CURR TOP MED CHEM, V16, P581, DOI 10.2174/1568026615666150819104617
   Zhou GP, 2015, MED CHEM, V11, P216, DOI 10.2174/1573406411666141229162618
   Zhou GP, 2015, PROTEIN PEPTIDE LETT, V22, P137, DOI 10.2174/0929866521666141019192221
   Zhou GP, 2013, VIRULENCE, V4, P669, DOI 10.4161/viru.27136
   Zhou GP, 2013, CURR TOP MED CHEM, V13, P1152, DOI 10.2174/15680266113139990003
   Zhou GP, 2011, PROTEIN PEPTIDE LETT, V18, P966, DOI 10.2174/0929866511107010966
   Zhou GP, 2011, J THEOR BIOL, V284, P142, DOI 10.1016/j.jtbi.2011.06.006
NR 239
TC 22
Z9 23
U1 15
U2 93
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0266
EI 1873-5294
J9 CURR TOP MED CHEM
JI Curr. Top. Med. Chem.
PY 2017
VL 17
IS 21
BP 2440
EP 2455
DI 10.2174/1568026617666170504100642
PG 16
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Pharmacology & Pharmacy
GA FB7CJ
UT WOS:000406298400010
PM 28474551
DA 2023-06-23
ER

PT J
AU Nechifor, M
AF Nechifor, Mihai
TI Magnesium in addiction - a general view
SO MAGNESIUM RESEARCH
LA English
DT Article
DE magnesium deficit; addiction; stress; trauma; heroin; nicotine; cocaine
ID CONDITIONED PLACE PREFERENCE; NITRIC-OXIDE; DRUG-ADDICTION; SUBSTANCE-P;
   DOPAMINE RELEASE; MORPHINE; NMDA; HIPPOCAMPUS; ALCOHOL; CALCIUM
AB Addiction is a dysregulation of brain reward systems that progressively increases, resulting in compulsive drug use and loss of control over drug-taking. Addiction is a brain disease. There is evidence that magnesium deficit is involved in addiction to various addictive substances (heroin, morphine, cocaine, nicotine, alcohol, caffeine, and others). Magnesium is involved in all the stages of addiction. Magnesium deficit enhances the vulnerability to psychoactive substance addiction. Stress and trauma reduce the brain magnesium level and at the same time favor addiction development. In experimental studies, administration of magnesium while inducing morphine dependence in rats reduced the dependence intensity. Magnesium reduces the NMDA receptor activity and the glutamatergic activity. Because stress and trauma induce hypomagnesemia with increased vulnerability to addiction, magnesium intake by people who are under prolonged stress could be away to reduce this vulnerability and the development of addiction to different psychoactive substances. Anxiety and depression appear to be associated with increases in drug-related harm and addictive substance use. Magnesium anxiolytic effect could be important for the antiaddictive action. Addiction is characterized by relapses. Magnesium deficiency may be a contributing factor to these relapses.
C1 [Nechifor, Mihai] Gr T Popa Univ Med & Pharm, Dept Pharmacol, Univ 16, Iasi 700115, Romania.
C3 Grigore T Popa University of Medicine & Pharmacy
RP Nechifor, M (通讯作者)，Gr T Popa Univ Med & Pharm, Dept Pharmacol, Univ 16, Iasi 700115, Romania.
EM mihainechif@yahoo.com
RI nechifor, mihai/GQO-9715-2022
CR Abdel-Zaher AO, 2013, EUR J PHARMACOL, V702, P62, DOI 10.1016/j.ejphar.2013.01.036
   Akbarabadi A, 2018, PHYSIOL BEHAV, V184, P143, DOI 10.1016/j.physbeh.2017.11.024
   Alburges ME, 2000, EUR J PHARMACOL, V390, P119, DOI 10.1016/S0014-2999(99)00919-X
   Amri J, 2018, AM J DRUG ALCOHOL AB, V44, P95, DOI 10.1080/00952990.2017.1348509
   Bayer R, 2015, DRUG ALCOHOL DEPEN, V156, P139, DOI 10.1016/j.drugalcdep.2015.09.005
   Biala G, 2006, EUR J PHARMACOL, V537, P85, DOI 10.1016/j.ejphar.2006.03.017
   Boden JM, 2011, ADDICTION, V106, P906, DOI 10.1111/j.1360-0443.2010.03351.x
   Broccoli L, 2018, PSYCHOPHARMACOLOGY, V235, P1821, DOI 10.1007/s00213-018-4908-6
   Chambers RA, 2013, DRUG ALCOHOL DEPEN, V130, P1, DOI 10.1016/j.drugalcdep.2012.12.005
   Commons KG, 2010, BRAIN RES, V1314, P175, DOI 10.1016/j.brainres.2009.11.014
   CORR L, 1991, J MOL CELL CARDIOL, V23, P231, DOI 10.1016/0022-2828(91)90059-U
   deBeun R, 1996, BEHAV PHARMACOL, V7, P346, DOI 10.1097/00008877-199608000-00006
   Di Chiara G, 2004, NEUROPHARMACOLOGY, V47, P227, DOI 10.1016/j.neuropharm.2004.06.032
   Dickerman Barbra, 2011, Top Clin Nutr, V26, P257, DOI 10.1097/TIN.0b013e3182260d86
   Dyuizen I, 2009, J CHEM NEUROANAT, V37, P65, DOI 10.1016/j.jchemneu.2008.10.005
   Ezquerra-Romano II, 2018, NEUROPHARMACOLOGY, V142, P72, DOI 10.1016/j.neuropharm.2018.01.017
   Ferre S, 2010, BBA-MOL BASIS DIS, V1802, P952, DOI 10.1016/j.bbadis.2010.06.016
   Flores-Bastias O, 2018, NEUROPHARMACOLOGY, V128, P401, DOI 10.1016/j.neuropharm.2017.11.003
   Gabach LA, 2013, PSYCHOPHARMACOLOGY, V229, P41, DOI 10.1007/s00213-013-3084-y
   Gardner EL, 2011, ADV PSYCHOSOM MED, V30, P22, DOI 10.1159/000324065
   Gholami A, 2003, EUR J PHARMACOL, V458, P119, DOI 10.1016/S0014-2999(02)02696-1
   Hatzigiakoumis Daniele Stavros, 2011, Front Psychiatry, V2, P10, DOI 10.3389/fpsyt.2011.00010
   Huang Y, 2018, CNS NEUROSCI THER, V24, P70, DOI 10.1111/cns.12775
   Jia SS, 2016, J CELL PHYSIOL, V231, P1903, DOI 10.1002/jcp.25306
   Jung KI, 2010, BIOL TRACE ELEM RES, V133, P153, DOI 10.1007/s12011-009-8421-y
   Karakiewicz B, 2007, MAGNESIUM RES, V20, P53
   Khan MI, 2018, PROG NEURO-PSYCHOPH, V82, P39, DOI 10.1016/j.pnpbp.2017.12.002
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   L'hirondel M, 1999, EUR J NEUROSCI, V11, P1292, DOI 10.1046/j.1460-9568.1999.00534.x
   Lam MP, 2011, PSYCHOPHARMACOLOGY, V218, P229, DOI 10.1007/s00213-011-2337-x
   LAWLEY SI, 1990, PHARMACOL BIOCHEM BE, V36, P539, DOI 10.1016/0091-3057(90)90253-E
   Lee US, 2010, TRENDS NEUROSCI, V33, P415, DOI 10.1016/j.tins.2010.06.004
   Li W, 2014, MOL BRAIN, V7, DOI 10.1186/s13041-014-0065-y
   Ma P, 2014, NEUROREPORT, V25, P641, DOI 10.1097/WNR.0000000000000146
   Mantsch JR, 2016, NEUROPSYCHOPHARMACOL, V41, P335, DOI 10.1038/npp.2015.142
   Margolin A, 2003, J ADDICT DIS, V22, P49, DOI 10.1300/J069v22n02_04
   Marrero HG, 2015, ALCOHOL CLIN EXP RES, V39, P1671, DOI 10.1111/acer.12821
   Martin G, 1999, J NEUROSCI, V19, P9081, DOI 10.1523/JNEUROSCI.19-20-09081.1999
   McBride WJ, 1999, BEHAV BRAIN RES, V101, P129, DOI 10.1016/S0166-4328(99)00022-4
   Miliano C, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00153
   Miyamoto Y, 2004, EUR J NEUROSCI, V19, P151, DOI 10.1111/j.1460-9568.2004.03086.x
   Moykkynen T, 2001, NEUROREPORT, V12, P2175
   Nechifor M, 2004, MAGNESIUM RES, V17, P176
   Nechifor M, 2004, J AM COLL NUTR, V23, p549S, DOI 10.1080/07315724.2004.10719401
   Nechifor M, 2004, MAGNESIUM RES, V17, P7
   Nechifor M, 2010, MAGNESIUM RES, V23, P41, DOI 10.1684/mrh.2010.0199
   Nennig SE, 2017, ALCOHOL ALCOHOLISM, V52, P172, DOI 10.1093/alcalc/agw098
   O'Connor RM, 2015, NEUROPHARMACOLOGY, V99, P168, DOI 10.1016/j.neuropharm.2015.07.012
   Orso R, 2017, NEUROSCI LETT, V658, P27, DOI 10.1016/j.neulet.2017.08.032
   Parker D, 1998, J NEUROSCI, V18, P4800
   Romani AMP, 2008, MAGNESIUM RES, V21, P197
   Sartori SB, 2012, NEUROPHARMACOLOGY, V62, P304, DOI 10.1016/j.neuropharm.2011.07.027
   Shane S R, 1991, Magnes Trace Elem, V10, P263
   Sharain K, 2015, AM J MED, V128, pE17, DOI 10.1016/j.amjmed.2015.06.051
   Starcevic V, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00053
   Sutoo D, 2000, NEUROSCI LETT, V294, P5, DOI 10.1016/S0304-3940(00)01537-8
   Tan SE, 2008, BRAIN RES BULL, V77, P412, DOI 10.1016/j.brainresbull.2008.09.007
   Thorsell A, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00178
   Wakida N, 2014, J PHARMACOL SCI, V125, P68, DOI 10.1254/jphs.14032FP
   Yang JQ, 2013, J GEN PHYSIOL, V141, P217, DOI 10.1085/jgp.201210794
   Yuan CJ, 2011, PHARMACOL BIOCHEM BE, V100, P98, DOI 10.1016/j.pbb.2011.08.004
   Zhao ZG, 2017, MOL MED REP, V16, P3627, DOI 10.3892/mmr.2017.6993
   ZHU XZ, 1992, J NEUROCHEM, V59, P932, DOI 10.1111/j.1471-4159.1992.tb08332.x
NR 63
TC 3
Z9 3
U1 0
U2 5
PU JOHN LIBBEY EUROTEXT LTD
PI MONTROUGE
PA 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE
SN 0953-1424
EI 1952-4021
J9 MAGNESIUM RES
JI Magnes. Res.
PD JUL-SEP
PY 2018
VL 31
IS 3
BP 90
EP 98
DI 10.1684/mrh.2018.0443
PG 9
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA HT4IE
UT WOS:000464526400003
PM 30714574
DA 2023-06-23
ER

PT J
AU Redish, AD
AF Redish, AD
TI Addiction as a computational process gone awry
SO SCIENCE
LA English
DT Article
ID REINFORCED BEHAVIOR; RATIONAL ADDICTION; DOPAMINE NEURONS;
   DRUG-ADDICTION; COCAINE; REWARD; RECEPTORS; NICOTINE; MAINTENANCE;
   ACQUISITION
AB Addictive drugs have been hypothesized to access the same neurophysiological mechanisms as natural learning systems. These natural learning systems can be modeled through temporal-difference reinforcement learning (TDRL), which requires a reward-error signal that has been hypothesized to be carried by dopamine. TDRL learns to predict reward by driving that reward-error signal to zero. By adding a noncompensable drug-induced dopamine increase to a TDRL model, a computational model of addiction is constructed that over-selects actions leading to drug receipt. The model provides an explanation for important aspects of the addiction literature and provides a theoretic viewpoint with which to address other aspects.
C1 Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities
RP Redish, AD (通讯作者)，Univ Minnesota, Dept Neurosci, 6-145 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.
EM redish@ahc.umn.edu
CR Ainslie G., 1992, PICOECONOMICS
   BECKER GS, 1988, J POLIT ECON, V96, P675, DOI 10.1086/261558
   Bickel WK, 2001, ADDICTION, V96, P73, DOI 10.1046/j.1360-0443.2001.961736.x
   Bouton ME, 2002, BIOL PSYCHIAT, V52, P976, DOI 10.1016/S0006-3223(02)01546-9
   Bradberry CW, 2002, NEUROSCIENTIST, V8, P315, DOI 10.1177/107385840200800407
   CARROLL ME, 1993, DRUG ALCOHOL DEPEN, V33, P201, DOI 10.1016/0376-8716(93)90061-T
   CARROLL ME, 1989, PSYCHOPHARMACOLOGY, V97, P23, DOI 10.1007/BF00443407
   Daw N., 2003, THESIS CARNEGIE MELL
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Di Chiara G, 1999, EUR J PHARMACOL, V375, P13, DOI 10.1016/S0014-2999(99)00372-6
   Dickinson A, 1980, CONT ANIMAL LEARNING
   Everitt BJ, 2001, BRAIN RES REV, V36, P129, DOI 10.1016/S0165-0173(01)00088-1
   Grossman M, 1998, J HEALTH ECON, V17, P427, DOI 10.1016/S0167-6296(97)00046-5
   Higgins ST, 2004, ANNU REV PSYCHOL, V55, P431, DOI 10.1146/annurev.psych.55.090902.142033
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Laviolette SR, 2004, NAT NEUROSCI, V7, P160, DOI 10.1038/nn1182
   Letchworth SR, 2001, J NEUROSCI, V21, P2799, DOI 10.1523/JNEUROSCI.21-08-02799.2001
   LOWINSON JH, 1997, SUBSTANCE ABUSE COMP
   Mazur JE, 2001, PSYCHOL REV, V108, P96, DOI 10.1037//0033-295X.108.1.96
   McClure SM, 2003, TRENDS NEUROSCI, V26, P423, DOI 10.1016/S0166-2236(03)00177-2
   Montague PR, 1996, J NEUROSCI, V16, P1936, DOI 10.1523/jneurosci.16-05-01936.1996
   NADER MA, 1991, PSYCHOPHARMACOLOGY, V105, P169, DOI 10.1007/BF02244304
   Phillips PEM, 2003, NATURE, V422, P614, DOI 10.1038/nature01566
   Picciotto MR, 1998, DRUG ALCOHOL DEPEN, V51, P165, DOI 10.1016/S0376-8716(98)00074-X
   Pidoplichko VI, 1997, NATURE, V390, P401, DOI 10.1038/37120
   Rescorla R.A., 1972, CLASSICAL CONDITION, P64, DOI DOI 10.1101/GR.110528.110
   RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058
   Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI 10.1146/annurev.psych.54.101601.145237
   Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593
   Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1
   Suri RE, 1999, NEUROSCIENCE, V91, P871, DOI 10.1016/S0306-4522(98)00697-6
   Sutton R. S., 1998, REINFORCEMENT LEARNI
   Tanaka SC, 2004, NAT NEUROSCI, V7, P887, DOI 10.1038/nn1279
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Volkow ND, 2002, BEHAV PHARMACOL, V13, P355, DOI 10.1097/00008877-200209000-00008
   Waelti P, 2001, NATURE, V412, P43, DOI 10.1038/35083500
   White FJ, 1998, DRUG ALCOHOL DEPEN, V51, P141, DOI 10.1016/S0376-8716(98)00072-6
   Wolf ME, 2003, ANN NY ACAD SCI, V1003, P241, DOI 10.1196/annals.1300.015
   WOODWARD M, 1993, ADDICTION, V88, P821, DOI 10.1111/j.1360-0443.1993.tb02096.x
NR 39
TC 335
Z9 340
U1 2
U2 29
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD DEC 10
PY 2004
VL 306
IS 5703
BP 1944
EP 1947
DI 10.1126/science.1102384
PG 4
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 879DC
UT WOS:000225695600047
PM 15591205
DA 2023-06-23
ER

PT J
AU Maldonado, R
   Robledo, P
   Berrendero, F
AF Maldonado, Rafael
   Robledo, Patricia
   Berrendero, Fernando
TI Endocannabinoid system and drug addiction: new insights from mutant mice
   approaches
SO CURRENT OPINION IN NEUROBIOLOGY
LA English
DT Review
ID CONDITIONED PLACE PREFERENCE; AMIDE HYDROLASE INHIBITION;
   NUCLEUS-ACCUMBENS DOPAMINE; ALCOHOL-CONSUMPTION; RECEPTOR; COCAINE;
   MORPHINE; DEPENDENCE; 2-ARACHIDONOYLGLYCEROL; RESPONSES
AB The involvement of the endocannabinoid system in drug addiction was initially studied by the use of compounds with different affinities for each cannabinoid receptor or for the proteins involved in endocannabinoids inactivation. The generation of genetically modified mice with selective mutations in these endocannabinoid system components has now provided important advances in establishing their specific contribution to drug addiction. These genetic tools have identified the particular interest of CB1, cannabinoid receptor and endogenous anandamide as potential targets for drug addiction treatment. Novel genetic tools will allow determining if the modulation of CB2 cannabinoid receptor activity and 2-arachidonoylglycerol tone can also have an important therapeutic relevance for drug addiction.
C1 [Maldonado, Rafael; Robledo, Patricia; Berrendero, Fernando] Univ Pompeu Fabra, Fac Hlth & Life Sci, Neuropharmacol Lab, Barcelona 08003, Spain.
   [Robledo, Patricia] IMIM Hosp Mar Med Res Inst, Neurosci Res Program, Human Pharmacol & Clin Neurosci Res Grp, Barcelona 08003, Spain.
C3 Pompeu Fabra University; Institut Hospital del Mar d'Investigacions
   Mediques (IMIM)
RP Maldonado, R (通讯作者)，Univ Pompeu Fabra, Fac Hlth & Life Sci, Neuropharmacol Lab, C Dr Aiguader 88, Barcelona 08003, Spain.
EM rafael.maldonado@upf.edu
RI Berrendero, Fernando/AAZ-2892-2021; Maldonado, Rafael/F-5657-2014;
   Robledo, P/H-8512-2014; Berrendero, F/G-2208-2014
OI Berrendero, Fernando/0000-0003-3502-9439; Maldonado,
   Rafael/0000-0002-4359-8773; Robledo, P/0000-0002-7941-0939; Berrendero,
   F/0000-0003-3502-9439
FU Spanish 'Ministerio de Ciencia e Innovacion' [SAF2007-64062,
   SAF2011-29864]; 'Instituo de Salud Carlos III' (RETICS Red de Trastomos
   Adictivos-Redes Tematicas de Investigacion Cooperativa en Salud)
   [RD06/0001/0001, RD06/0001/1004]; Plan Nacional Sobre Drogas (PNSD)
   [2009/026]; Catalan Government [SGR2009-00131]; ICREA Foundation; 
   [10/00316];  [10/01708]
FX This work was supported by the Spanish 'Ministerio de Ciencia e
   Innovacion' (#SAF2007-64062 and SAF2011-29864), 'Instituo de Salud
   Carlos III' (RETICS Red de Trastomos Adictivos-Redes Tematicas de
   Investigacion Cooperativa en Salud: RD06/0001/0001 and RD06/0001/1004),
   grants #10/00316 and #10/01708, Plan Nacional Sobre Drogas (PNSD
   #2009/026), the Catalan Government (SGR2009-00131) and the ICREA
   Foundation (ICREA Academia-2008). Important contributions from several
   authors could not be included due to space limitations. We thank Neus
   Morgui and Cristina Fernandez for expert technical assistance.
CR Adamczyk P, 2009, J PHYSIOL PHARMACOL, V60, P119
   Aracil-Fernandez A, 2012, NEUROPSYCHOPHARMACOL, V37, P1749, DOI 10.1038/npp.2012.22
   Basavarajappa BS, 2006, NEUROPHARMACOLOGY, V50, P834, DOI 10.1016/j.neuropharm.2005.12.005
   Bellocchio L, 2010, NAT NEUROSCI, V13, P281, DOI 10.1038/nn.2494
   Blednov YA, 2007, NEUROPSYCHOPHARMACOL, V32, P1570, DOI 10.1038/sj.npp.1301274
   Busquets-Garcia A, 2011, BIOL PSYCHIAT, V70, P479, DOI 10.1016/j.biopsych.2011.04.022
   Caille S, 2003, EUR J NEUROSCI, V18, P3145, DOI 10.1111/j.1460-9568.2003.02961.x
   Castane A, 2002, NEUROPHARMACOLOGY, V43, P857, DOI 10.1016/S0028-3908(02)00118-1
   Castillo PE, 2012, NEURON, V76, P70, DOI 10.1016/j.neuron.2012.09.020
   Cippitelli A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028142
   Clapper JR, 2009, NEUROPHARMACOLOGY, V56, P235, DOI 10.1016/j.neuropharm.2008.07.018
   Cossu G, 2001, BEHAV BRAIN RES, V118, P61, DOI 10.1016/S0166-4328(00)00311-9
   Forget B, 2009, PSYCHOPHARMACOLOGY, V205, P613, DOI 10.1007/s00213-009-1569-5
   Gamaleddin I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029900
   Houchi H, 2005, NEUROPSYCHOPHARMACOL, V30, P339, DOI 10.1038/sj.npp.1300568
   Hungund BL, 2003, J NEUROCHEM, V84, P698, DOI 10.1046/j.1471-4159.2003.01576.x
   Ishiguro H, 2007, PHARMACOGENOMICS J, V7, P380, DOI 10.1038/sj.tpj.6500431
   Jung KM, 2012, CELL METAB, V15, P299, DOI 10.1016/j.cmet.2012.01.021
   Justinova Z, 2005, J NEUROSCI, V25, P5645, DOI 10.1523/JNEUROSCI.0951-05.2005
   Justinova Z, 2011, J NEUROSCI, V31, P7043, DOI 10.1523/JNEUROSCI.6058-10.2011
   Justinova Z, 2008, BIOL PSYCHIAT, V64, P930, DOI 10.1016/j.biopsych.2008.08.008
   Katona I, 2006, J NEUROSCI, V26, P5628, DOI 10.1523/JNEUROSCI.0309-06.2006
   Kenny PJ, 2011, NAT NEUROSCI, V14, P1100, DOI 10.1038/nn.2912
   Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401
   Li X, 2009, PSYCHOPHARMACOLOGY, V204, P1, DOI 10.1007/s00213-008-1432-0
   Long JZ, 2009, NAT CHEM BIOL, V5, P37, DOI 10.1038/nchembio.129
   Luchicchi A, 2012, MOL NEUROBIOL, V46, P374, DOI 10.1007/s12035-012-8299-0
   Maldonado R, 2006, TRENDS NEUROSCI, V29, P225, DOI 10.1016/j.tins.2006.01.008
   Martin M, 2000, EUR J NEUROSCI, V12, P4038, DOI 10.1046/j.1460-9568.2000.00287.x
   Mascia MS, 1999, EUR J PHARMACOL, V383, pR1, DOI 10.1016/S0014-2999(99)00656-1
   Mechoulam R, 2012, ANN REV PSYCHOL, V64, P61
   Merritt LL, 2008, J PHARMACOL EXP THER, V326, P483, DOI 10.1124/jpet.108.138321
   Pava MJ, 2012, ALCOHOL, V46, P185, DOI 10.1016/j.alcohol.2012.01.002
   Racz I, 2003, J NEUROSCI, V23, P2453
   Ramesh D, 2011, J PHARMACOL EXP THER, V339, P173, DOI 10.1124/jpet.111.181370
   Rice OV, 2002, BRAIN RES, V945, P135, DOI 10.1016/S0006-8993(02)02890-1
   Schlosburg JE, 2010, NAT NEUROSCI, V13, P1113, DOI 10.1038/nn.2616
   Serrano A, 2011, PHARMACOL THERAPEUT, V132, P215, DOI 10.1016/j.pharmthera.2011.06.005
   Shahidi S, 2011, BRAIN RES BULL, V86, P118, DOI 10.1016/j.brainresbull.2011.06.019
   Shoaib M, 2008, NEUROPHARMACOLOGY, V54, P438, DOI 10.1016/j.neuropharm.2007.10.011
   Soria G, 2005, NEUROPSYCHOPHARMACOL, V30, P1670, DOI 10.1038/sj.npp.1300707
   Thanos PK, 2005, BEHAV BRAIN RES, V164, P206, DOI 10.1016/j.bbr.2005.06.021
   Tourino C, 2008, BIOL PSYCHIAT, V63, P1030, DOI 10.1016/j.biopsych.2007.09.003
   Van Sickle MD, 2005, SCIENCE, V310, P329, DOI 10.1126/science.1115740
   Vinod KY, 2008, J NEUROCHEM, V104, P233, DOI 10.1111/j.1471-4159.2007.04956.x
   Xi ZX, 2011, NAT NEUROSCI, V14, P1160, DOI 10.1038/nn.2874
NR 46
TC 12
Z9 12
U1 0
U2 22
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0959-4388
EI 1873-6882
J9 CURR OPIN NEUROBIOL
JI Curr. Opin. Neurobiol.
PD AUG
PY 2013
VL 23
IS 4
BP 480
EP 486
DI 10.1016/j.conb.2013.02.004
PG 7
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 204XJ
UT WOS:000323404300004
PM 23490550
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Zhao, J
   Du, XY
   Chen, MZ
   Zhu, SM
AF Zhao, Jing
   Du, Xinyu
   Chen, Mingzhu
   Zhu, Shimin
TI Growth Hormone Secretagogue Receptor 1A Antagonist JMV2959 Effectively
   Prevents Morphine Memory Reconsolidation and Relapse
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE conditioned place preference; morphine relapse; addiction; ghrelin
   antagonism; JMV2959
ID SIGNALING PATHWAY; PROTEIN-SYNTHESIS; GHRELIN; INHIBITION; INCUBATION;
   COCAINE; NEUROBIOLOGY; PLASTICITY; MECHANISMS; ADDICTION
AB Relapse to drug seeking after prolonged abstinence is a major problem in the clinical treatment of drug addiction. The use of pharmacological interventions to disrupt established drug reward memories is a promising strategy for the treatment of drug addiction. A growth hormone secretagogue receptor 1 A antagonist, JMV2959, has been shown to reduce morphine-induced conditioned place preference (CPP) in rats within hours of intervention; thus, JMV2959 is a potential candidate for drug addiction treatment. However, the effect of JMV2959 on reconsolidation to disrupt drug seeking remains unknown. In this study, we assessed the effect of JMV2959 on morphine induced memory reconsolidation to inhibit drug seeking after drug withdrawal. Our results showed that the administration of JMV2959 (6 mg/kg) significantly reduced environmental cue induced CPP, which suggested a preventive effect of JMV2959 on morphine induced memory reconsolidation. Additionally, JMV2959 administration significantly altered the locomotor activity and food and water intake but did not significantly alter the natural reward preference. We concluded that JMV2959 may be an effective candidate to treat drug addiction.
C1 [Zhao, Jing] Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Anesthesiol, Shanghai, Peoples R China.
   [Du, Xinyu; Chen, Mingzhu; Zhu, Shimin] Wuhan Univ, Key Lab Combinatorial Biosynthesis & Drug Discove, Minist Educ, Wuhan, Peoples R China.
   [Du, Xinyu; Chen, Mingzhu; Zhu, Shimin] Wuhan Univ, Sch Pharmaceut Sci, Wuhan, Peoples R China.
C3 Shanghai Jiao Tong University; Wuhan University; Wuhan University
RP Zhao, J (通讯作者)，Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Anesthesiol, Shanghai, Peoples R China.
EM zhaojing@shsmu.edu.cn
FU Shanghai Municipal Planning Commission of Science and Research Fund
   [2015ZB0103]
FX This work was supported by the Shanghai Municipal Planning Commission of
   Science and Research Fund (grant number 2015ZB0103).
CR Abizaid A, 2006, J CLIN INVEST, V116, P3229, DOI 10.1172/JCI29867
   Abizaid A, 2020, TRENDS ENDOCRIN MET, V31, P107, DOI 10.1016/j.tem.2019.09.006
   Casadio A, 1999, CELL, V99, P221, DOI 10.1016/S0092-8674(00)81653-0
   DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518
   Engel JA, 2015, EUR NEUROPSYCHOPHARM, V25, P2364, DOI 10.1016/j.euroneuro.2015.10.004
   Ferrini F, 2009, CURR NEUROPHARMACOL, V7, P37, DOI 10.2174/157015909787602779
   Ge XC, 2018, CELL METAB, V27, P461, DOI 10.1016/j.cmet.2017.10.016
   Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134
   Havlickova T, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102925
   Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Jerabek P, 2017, NEUROCHEM INT, V110, P101, DOI 10.1016/j.neuint.2017.09.013
   Kern A, 2015, CELL, V163, P1176, DOI 10.1016/j.cell.2015.10.062
   Landgren S, 2011, BEHAV BRAIN RES, V221, P182, DOI 10.1016/j.bbr.2011.03.003
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Li YQ, 2008, PSYCHOPHARMACOLOGY, V199, P245, DOI 10.1007/s00213-008-1169-9
   Li YQ, 2011, J NEUROSCI, V31, P5436, DOI 10.1523/JNEUROSCI.5884-10.2011
   Li YQ, 2008, J NEUROSCI, V28, P13248, DOI 10.1523/JNEUROSCI.3027-08.2008
   Lin J, 2014, INT J NEUROPSYCHOPH, V17, P127, DOI 10.1017/S1461145713001156
   Lu L, 2005, NAT NEUROSCI, V8, P212, DOI 10.1038/nn1383
   McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248
   Milekic MH, 2006, J NEUROSCI, V26, P3010, DOI 10.1523/JNEUROSCI.4818-05.2006
   Millan EZ, 2013, NEUROBIOL LEARN MEM, V101, P26, DOI 10.1016/j.nlm.2012.12.010
   Nestler EJ, 2001, SCIENCE, V292, P2266, DOI 10.1126/science.1063024
   OBrien CP, 1996, LANCET, V347, P237, DOI 10.1016/S0140-6736(96)90409-2
   Robinson MJF, 2007, BEHAV BRAIN RES, V178, P146, DOI 10.1016/j.bbr.2006.12.013
   Sara SJ, 2000, LEARN MEMORY, V7, P73, DOI 10.1101/lm.7.2.73
   Skibicka KP, 2011, NEUROSCIENCE, V180, P129, DOI 10.1016/j.neuroscience.2011.02.016
   Stoica L, 2011, P NATL ACAD SCI USA, V108, P3791, DOI 10.1073/pnas.1014715108
   Sustkova-Fiserova M, 2020, ADDICT BIOL, V25, DOI 10.1111/adb.12845
   Tronson NC, 2007, NAT REV NEUROSCI, V8, P262, DOI 10.1038/nrn2090
   Tronson NC, 2006, NAT NEUROSCI, V9, P167, DOI 10.1038/nn1628
   Valjent E, 2006, P NATL ACAD SCI USA, V103, P2932, DOI 10.1073/pnas.0511030103
   Wu B, 2019, BRAIN RES BULL, V146, P112, DOI 10.1016/j.brainresbull.2018.12.016
NR 34
TC 3
Z9 3
U1 1
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 29
PY 2021
VL 12
AR 718615
DI 10.3389/fphar.2021.718615
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Pharmacology & Pharmacy
GA XQ7BV
UT WOS:000731700700001
PM 34912212
OA gold, Green Published
DA 2023-06-23
ER

PT J
AU Adrian, M
AF Adrian, M
TI How can sociological theory help our understanding of addictions?
SO SUBSTANCE USE & MISUSE
LA English
DT Article; Proceedings Paper
CT Middle Eastern Mediterranean Summer Institute on Drug Use Meeting
CY MAY 23-26, 2001
CL PAVIA, ITALY
SP Middle Eastern Mediterranean Summer Inst
DE addiction; problem deflation; problem inflation; sociological theory and
   addictions; sociology
ID SUBSTANCE USE; ALCOHOL; MULTICULTURALISM; DRINKING
AB Those who work in the addiction field usually use the pharmacological or medical model, psychological theories of behavior, or operate within the confines of a criminal justice perspective. Contributions from the field of sociology are limited to use of the methods of sociological investigations, primarily population surveys, which, typically, are used to identify groups at-risk for specific types of drug use. Surveys have identified illicit drug use as, predominantly, a problem of young males, whereas prescription drug use is predominantly a problem of middle-aged and older women in industrialized countries.
   Experts in addiction have accused sociologists who study addiction of being "a theoretical." Paradoxically, in the sociology field, the most highly cited article is Merton's theory of addiction. This article will examine the contributions of sociological theory to our understanding of addiction, including social definitions of "the problem of addiction" and mechanisms to account for individual drug use within a social context that defines it as problematic.
C1 Univ Guelph, Dept Econ, Guelph, ON N1G 2W1, Canada.
   Nova SE Univ, Coll Osteopath Med, Ft Lauderdale, FL 33314 USA.
C3 University of Guelph; Nova Southeastern University
RP Adrian, M (通讯作者)，Univ Guelph, Dept Econ, Guelph, ON N1G 2W1, Canada.
EM madrian@the-beach.net
CR Adler P., 2000, CONSTRUCTIONS DEVIAN
   Adler P., 1993, WHEELING DEALING ETH
   Adrian M, 2002, SUBST USE MISUSE, V37, P853, DOI 10.1081/JA-120004157
   Adrian M, 2001, SUBST USE MISUSE, V36, P1923, DOI 10.1081/JA-100108433
   Adrian M, 1996, SUBST USE MISUSE, V31, P1459, DOI 10.3109/10826089609063988
   ADRIAN M, 1988, CAN J PUBLIC HEALTH, V79, P316
   ADRIAN M, 1991, INT J ADDICT, V25, P731, DOI 10.3109/10826089109077268
   ADRIAN M, 1991, JOURNAL, V20, P7
   ADRIAN M, 1989, STAT ALCOHOL DRUG US, V2
   ADRIAN M, 1999, SOC POPULATION HLTH, V2
   AKERS RL, 1977, DEVIANT BEHAV SOCIAL
   ALEXANDER JC, 1987, MICRO MACRO LINK
   Bandura A, 1986, SOCIAL FUNCTIONS THO
   Becker Howard S, 1973, OUTSIDERS STUDIES SO
   BLUMER H, 2000, SOCIAL THOUGHT RES, V23, P87
   Bulmer Martin, 1986, CHICAGO SCH SOCIOLOG
   Buscema M, 1998, SUBST USE MISUSE, V33, P1
   CAREY JJ, 1968, CONT SOCIAL PROBLEMS, P185
   CHEIN I, 1964, DEVIANT BEHAV
   Chomsky N, 1968, LANGUAGE MIND
   CLOWARD R, 1960, DELINQUENCY OPPORTUN
   COHEN AJ, 1966, AM SOCIOL REV, V30, P5
   COHEN AK, 1959, ANOMIE DEVIANT BEHAV, P158
   COHEN P, 1968, MODERN SOCIAL THEORY
   CONRAD P, 1980, DEVIANCE MEDICALIZAI
   Cooley C. H., 1902, SELF SOCIAL ORG
   DEDOBBELEER N, IN PRESS SOCIAL SCI
   DERIOS D, 1984, HALLUCINOGENS CROSS
   Durkheim E., 1897, SUICIDE STUDY SOCIOL
   Durkheim E., 1964, DIVISION LABOR SOC
   Durkheim Emile, 1995, ELEMENTARY FORMS REL
   Engels F., 1845, CONDITION WORKING CL
   ERICKSON PG, 1980, CANNABIS CRIMINALS S
   Erikson K., 1966, WAYWARD PURITANS STU
   *EXP COMM ADD PROD, 1965, 7 REP WORLD HLTH ORG, V116
   FIELD P, 1962, SOC CULTURE DRINKING
   FINESTONE H, 1957, ANOMIE DEVIANT BEHAV, P158
   Freud S., 2010, EGO ID
   GARFINKEL H, 1994, IMAGES DEVIANCE SOCI, V61, P420
   Gerstein Dean R., 1987, MICROMACRO LINK, P86
   GLASER D, 1971, IMAGES DEVIANCE SOCI, P510
   Goffman E., 1963, STIGMA NOTES MANAGEM
   GORDON AJ, 1978, MED ANTHROPOLOGY, P147
   GRAMSCI A, 1973, LETT PRISON ANTONIO
   Greenfield TK, 2000, J SUBST ABUSE, V12, P33, DOI 10.1016/S0899-3289(00)00039-0
   GROENEVELD J, 1989, DRUG USE VICTIMS PHY
   Halls W. D., 1982, RULES SOCIOLOGICAL M
   HORTON D, 1943, Q J STUDIES ALCOHOL
   HORTON D, 1945, ALCOHOL SCI SOC, P153
   Hyams Peter, 1981, OUTLAND
   INCIARDI JA, 1992, WAR DRUGS, V2
   Ivis FJ, 1997, J STUD ALCOHOL, V58, P622, DOI 10.15288/jsa.1997.58.622
   KENISTON K, 1968, CONT SOCIAL PROBLEMS, P185
   LEDERMANN S, 1956, ALCOOL ALCOOLISME AL, V29
   LEWIS M, 1970, CRIME CITY
   Lindesmith AR, 1938, AM J SOCIOL, V43, P593, DOI 10.1086/217773
   Lindesmith AR., 1968, ADDICTION OPIATES
   Lukes S., 1973, E DURKHEIM HIS LIFE
   MARX K, 2001, MANIFESTO COMMUNIST
   Marx Karl, 1852, 18 BRUMAIRE LOUIS NA
   MARZA D, 1969, DELINQUENCY DRIFT
   Mead George H., 1934, MIND SELF SOC
   MERTON RK, 1968, SOCIAL THEOYR SOCIAL
   Merton RK, 1938, AM SOCIOL REV, V3, P672, DOI 10.2307/2084686
   *NEW YORK LAW PUBL, 2003, LAWY MAK BILL EXP SI
   Pacula RL, 2001, SUBST USE MISUSE, V36, P1901, DOI 10.1081/JA-100108432
   Parker BL, 1998, FOREST SCI, V44, P414
   Parsons T., 1951, SOCIAL SYSTEM
   QUINNEY R, 1974, CRIMINAL JUSTICE AM
   RITZER G, 1992, SOCIOLOGICAL THEORY
   ROOM R, 1984, CURR ANTHROPOL, V25, P169, DOI 10.1086/203107
   RUBINGTON E, 1977, STUDY SOCIAL PROBLEM, P4
   Schur E., 1965, CRIMES VICTIMS DEVIA
   SHAIN M, 1991, DOMESTIC VIOLENCE SU
   Smart R G, 1990, Bull Pan Am Health Organ, V24, P22
   SMART RG, 1982, TRENDS ALCOHOL DRUG
   SPECTOR M, 1987, CONSTRUCTING SOCIAL, P23
   SPRADLEY JP, 1979, YOU OWE YOURSELF DRU
   Sutherland E., 1934, PRINCIPLES CRIMINOLO
   SWANBECK J, 2000, BIG KAHUNA
   Sykes G. M., 1957, AM SOCIOLOGICAL REV, V22
   TERRY C, 1928, OPIUM PROBLEM
   THIO A, 1995, DEVIANT BEHAVIOR
   Turner Jonathan H., 1979, FUNCTIONALISM
   WELSH I, 1996, TRAINSPOTTING
   [No title captured]
NR 86
TC 6
Z9 7
U1 1
U2 19
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1082-6084
EI 1532-2491
J9 SUBST USE MISUSE
JI Subst. Use Misuse
PY 2003
VL 38
IS 10
BP 1385
EP 1423
DI 10.1081/JA-120023391
PG 39
WC Substance Abuse; Psychiatry; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)
SC Substance Abuse; Psychiatry; Psychology
GA 722BE
UT WOS:000185353800002
PM 14509544
DA 2023-06-23
ER

PT J
AU Nencini, P
AF Nencini, P
TI The Shaman and the rave party: Social pharmacology of ecstasy
SO SUBSTANCE USE & MISUSE
LA English
DT Article
DE addiction; psychoactive drugs; ritual use; hedonic use
ID POPPY DERIVATIVES; ANCIENT-WORLD; DRUG-USE; SUBSTANCE USE; RULES; WINE;
   ADDICTION; RELIGION; IMPACT; DANCE
AB Current psychobiological models of drug addiction are focused on the capability of drugs to cause a pathological exploitation of the neural rewarding system. This approach has emphasized the role of hedonistic factors in the etiology of drug addiction. Comparing primitive and modern settings of intoxication, such as shamanic rituals and rave parties, it is possible to confute this assumption. The archaic way of perceiving and elaborating drug effects mainly determined their use as being for supernatural purposes and excluded recreational purposes. Only after a completely profane setting of drug use was developed, did psychoactive drugs express all their hedonistic potentialities. This development, however, has been a slow process.
C1 Univ Roma La Sapienza, Inst Med Pharmacol, I-00185 Rome, Italy.
   Univ Roma La Sapienza, Serv Speciale Antidroga, I-00185 Rome, Italy.
C3 Sapienza University Rome; Sapienza University Rome
RP Nencini, P (通讯作者)，Univ Roma La Sapienza, Inst Med Pharmacol, P le A Moro 5, I-00185 Rome, Italy.
RI Nencini, Paolo/D-5062-2009
OI Nencini, Paolo/0000-0001-9712-5421
CR Altman J, 1996, PSYCHOPHARMACOLOGY, V125, P285, DOI 10.1007/BF02246016
   Amey CH, 1996, SUBST USE MISUSE, V31, P1311, DOI 10.3109/10826089609063979
   BELARDI W, 1995, DROGA SACRA NELL EUR, P19
   Boyer L. Bryce, 1973, HALLUCINOGENS SHAMAN, P53
   BRAUDEL F, 1993, CIVILISATION MAT ECO, P206
   BROWNSTEIN MJ, 1993, P NATL ACAD SCI USA, V90, P5391, DOI 10.1073/pnas.90.12.5391
   BURKERT W, 1996, CREATION SACRED, P191
   BURKERT W, 1987, STRUCTURE HIST GREEK, P141
   Cook CCH, 1997, DRUG ALCOHOL DEPEN, V46, P9, DOI 10.1016/S0376-8716(97)00036-7
   De Martino Ernesto, 1997, MONDO MAGICO
   Dobkin de Rios M., 1973, HALLUCINOGENS SHAMAN, P67
   DODDS ER, 1986, GREEKS IRRATIONAL
   ELIADE M, 1995, YOGA IMMORTALITE LIB, P109
   Eliade Mircea, 1964, SHAMANISM ARCHAIC TE
   Forsyth AJM, 1996, ADDICTION, V91, P511, DOI 10.1111/j.1360-0443.1996.tb02309.x
   Francis LJ, 1997, DRUG ALCOHOL DEPEN, V44, P95, DOI 10.1016/S0376-8716(96)01325-7
   GODLEY AD, 1950, HERODOTUS, V2, P273
   GODLEY AD, 1946, HERODOTUS, V1, P255
   GREEN AR, 1995, PSYCHOPHARMACOLOGY, V119, P247, DOI 10.1007/BF02246288
   GUERRA F, 1974, BRIT J ADDICT, V69, P269
   Harner M., 1973, HALLUCINOGENS SHAMAN, P125
   HARNER MJ, 1973, HALLUCINOGENS SHAMAN, P6
   HARNER MJ, 1973, HALLUCINOGENS SHAMAN, P160
   HENRY JA, 1992, BRIT MED J, V305, P5, DOI 10.1136/bmj.305.6844.5
   HENRY JA, 1992, LANCET, V340, P384, DOI 10.1016/0140-6736(92)91469-O
   JONES HL, 1924, STRABO GEOGRAPHY 7 3, V3
   KARAGEORGHIS VA, 1976, ANTIQUITY, V198, P125
   Kendler KS, 1997, AM J PSYCHIAT, V154, P322
   KRAMER JC, 1979, BRIT J ADDICT, V74, P377
   KRITIKOS PG, 1967, B NARCOTICS, V19, P17
   La Barre W., 1972, FLESH GODS RITUAL US
   LABARRE W, 1970, GHOST DANCE ORIGINS, P468
   LEVISTRAUSS C, 1970, MIEL CENDRES
   LEWIN L, 1964, PHANTASTICA NARCOTIC, P1
   LYTTLE T, 1992, INT J ADDICT, V27, P1159, DOI 10.3109/10826089209047341
   Mathee Rudi, 1995, DRUGS NARCOTICS HIST, P24
   Montanari Enrico, 1988, IDENTITA CULTURALE C
   NEHAR A, 1961, ELECTROEN CLIN NEURO, V13, P449
   NEHER A, 1962, HUM BIOL, V34, P151
   Nencini P, 1978, Clin Ter, V85, P223
   Nencini P, 1997, SUBST USE MISUSE, V32, P361, DOI 10.3109/10826089709055857
   Nencini P, 1997, SUBST USE MISUSE, V32, P757, DOI 10.3109/10826089709039375
   Nencini P, 1997, SUBST USE MISUSE, V32, P1405, DOI 10.3109/10826089709039386
   Nencini P, 1997, SUBST USE MISUSE, V32, P475, DOI 10.3109/10826089709039366
   Nencini P, 1997, SUBST USE MISUSE, V32, P89, DOI 10.3109/10826089709027300
   Nencini P, 1997, SUBST USE MISUSE, V32, P629, DOI 10.3109/10826089709027317
   Nencini P, 1997, SUBST USE MISUSE, V32, P1581, DOI 10.3109/10826089709055880
   NENCINI P, 1997, CONCLUSIONS SUBSTANC, V32, P1
   NENCINI P, 1997, SUBST USE MISUSE, V32, P213
   Nesse RM, 1997, SCIENCE, V278, P63, DOI 10.1126/science.278.5335.63
   Portenoy R K, 1997, J Pain Symptom Manage, V14, pS27, DOI 10.1016/S0885-3924(97)00168-1
   PORTER J, 1980, NEW ENGL J MED, V302, P123
   Sherratt A, 1991, OXFORD U COMMITTEE A, P50
   STRASSMAN RJ, 1994, ARCH GEN PSYCHIAT, V51, P98
   TAGI S, 1969, B STUP, V21, P321
   WEST ML, 1983, ORPHIC POEMS, P143
   WILBERT J, 1991, J ETHNOPHARMACOL, V32, P179, DOI 10.1016/0378-8741(91)90115-T
   WOODS JH, 1992, PHARMACOL REV, V44, P151
NR 58
TC 10
Z9 10
U1 0
U2 13
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016 USA
SN 1082-6084
J9 SUBST USE MISUSE
JI Subst. Use Misuse
PY 2002
VL 37
IS 8-10
BP 923
EP 939
DI 10.1081/JA-120004159
PG 17
WC Substance Abuse; Psychiatry; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry; Psychology
GA 581XG
UT WOS:000177319400004
PM 12180571
DA 2023-06-23
ER

PT J
AU Muller, CP
   Kornhuber, J
AF Mueller, Christian P.
   Kornhuber, Johannes
TI Biological Evidence for Paradoxical Improvement of Psychiatric Disorder
   Symptoms by Addictive Drugs
SO TRENDS IN PHARMACOLOGICAL SCIENCES
LA English
DT Editorial Material
ID ACID SPHINGOMYELINASE; SUBSTANCE USE; ALCOHOL
AB Addiction biology has focused on the mechanisms of the positive and negative reinforcing actions of addictive drugs but neglected potential benefits. Two new studies provide the first insights into a neurobiology of psychoactive drug instrumentalization. This may help us design better models for addiction neuroscience and opens a new dimension for the development of personalized pharmacotherapy of drug addiction.
C1 [Mueller, Christian P.; Kornhuber, Johannes] Friedrich Alexander Univ Erlangen Nuremberg, Univ Clin, Dept Psychiat & Psychotherapy, Schwabachanlage 6, D-91054 Erlangen, Germany.
C3 University of Erlangen Nuremberg
RP Muller, CP (通讯作者)，Friedrich Alexander Univ Erlangen Nuremberg, Univ Clin, Dept Psychiat & Psychotherapy, Schwabachanlage 6, D-91054 Erlangen, Germany.
EM Christian.Mueller@uk-erlangen.de
RI Kornhuber, Johannes/B-9613-2014
OI Kornhuber, Johannes/0000-0002-8096-3987
CR Caprioli D, 2009, BIOL PSYCHIAT, V65, P893, DOI 10.1016/j.biopsych.2008.12.009
   Gulbins E, 2013, NAT MED, V19, P934, DOI 10.1038/nm.3214
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Jay M., 2010, HIGH SOC MIND ALTERI
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550
   Koukouli F, 2017, NAT MED, V23, P347, DOI 10.1038/nm.4274
   Muller CP, 2017, ACTA NEUROPATHOL, V133, P463, DOI 10.1007/s00401-016-1658-6
   Muller CP, 2016, TRENDS PHARMACOL SCI, V37, P153, DOI 10.1016/j.tips.2015.11.001
   Muller CP, 2011, BEHAV BRAIN SCI, V34, P293, DOI 10.1017/S0140525X11000057
   Ripke S, 2014, NATURE, V511, P421, DOI 10.1038/nature13595
   Schuckit MA, 2013, J STUD ALCOHOL DRUGS, V74, P271, DOI 10.15288/jsad.2013.74.271
NR 12
TC 22
Z9 22
U1 0
U2 11
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0165-6147
EI 1873-3735
J9 TRENDS PHARMACOL SCI
JI Trends Pharmacol. Sci.
PD JUN
PY 2017
VL 38
IS 6
BP 501
EP 502
DI 10.1016/j.tips.2017.03.005
PG 2
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Pharmacology & Pharmacy
GA EV1OS
UT WOS:000401516500001
PM 28389130
DA 2023-06-23
ER

PT J
AU Kalivas, PW
AF Kalivas, PW
TI How do we determine which drug-induced neuroplastic changes are
   important?
SO NATURE NEUROSCIENCE
LA English
DT Editorial Material
ID SYNAPTIC PLASTICITY; DELTA-FOSB; ADDICTION; COCAINE; MOTIVATION;
   MECHANISMS; SENSITIZATION; PATHOLOGY; ABUSE
AB Although many drug-induced neural changes are known, progress has been slow in identifying the ones that actually mediate addiction. Identifying changes that are specific to particular elements of the transition from initial to habitual to relapsing drug use may be a fruitful strategy for pinpointing which forms of drug-induced plasticity are critical for addiction.
C1 Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
C3 Medical University of South Carolina
RP Kalivas, PW (通讯作者)，Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
EM kalivasp@musc.edu
CR Ahmed SH, 2002, NAT NEUROSCI, V5, P625, DOI 10.1038/nn872
   Baker DA, 2003, NAT NEUROSCI, V6, P743, DOI 10.1038/nn1069
   Baptista MAS, 2004, J NEUROSCI, V24, P4723, DOI 10.1523/JNEUROSCI.0176-04.2004
   Canales JJ, 2005, NEUROBIOL LEARN MEM, V83, P93, DOI 10.1016/j.nlm.2004.10.006
   Carlezon WA, 2002, TRENDS NEUROSCI, V25, P610, DOI 10.1016/S0166-2236(02)02289-0
   Jones S, 2005, CURR OPIN PHARMACOL, V5, P20, DOI 10.1016/j.coph.2004.08.011
   Kalivas PW, 2005, NEURON, V45, P647, DOI 10.1016/j.neuron.2005.02.005
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kauer JA, 2004, ANNU REV PHYSIOL, V66, P447, DOI 10.1146/annurev.physiol.66.032102.112534
   Keitz M., 2003, Neural Plasticity, V10, P121, DOI 10.1155/NP.2003.121
   Kelley AE, 2004, NEURON, V44, P161, DOI 10.1016/j.neuron.2004.09.016
   Koob GF, 2004, NEUROSCI BIOBEHAV R, V27, P739, DOI 10.1016/j.neubiorev.2003.11.007
   Lu L, 2005, NAT NEUROSCI, V8, P212, DOI 10.1038/nn1383
   Mackler SA, 2000, J NEUROSCI, V20, P6210, DOI 10.1523/JNEUROSCI.20-16-06210.2000
   McClung CA, 2003, NAT NEUROSCI, V6, P1208, DOI 10.1038/nn1143
   Nestler EJ, 2001, P NATL ACAD SCI USA, V98, P11042, DOI 10.1073/pnas.191352698
   Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI 10.1146/annurev.psych.54.101601.145237
   SZUMLINSKI KK, 2005, NEUROPSYCHOPHAR 0914
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406
NR 20
TC 56
Z9 57
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA
SN 1097-6256
J9 NAT NEUROSCI
JI Nat. Neurosci.
PD NOV
PY 2005
VL 8
IS 11
BP 1440
EP 1441
DI 10.1038/nn1105-1440
PG 2
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 979TB
UT WOS:000232966600012
PM 16251984
DA 2023-06-23
ER

PT J
AU Luo, YX
   Xue, YX
   Shen, HW
   Lu, L
AF Luo, Yi-Xiao
   Xue, Yan-Xue
   Shen, Hao-Wei
   Lu, Lin
TI Role of amygdala in drug memory
SO NEUROBIOLOGY OF LEARNING AND MEMORY
LA English
DT Article
DE Addiction; Relapse; Amygdala; Drug memory
ID CONDITIONED PLACE PREFERENCE; COCAINE-SEEKING BEHAVIOR; ROSTRAL
   BASOLATERAL AMYGDALA; STRESS-INDUCED REINSTATEMENT; NUCLEUS-ACCUMBENS
   CORE; C-FOS EXPRESSION; MGLUR(2/3) AGONIST LY379268; OPIATE-WITHDRAWAL
   MEMORIES; GAMMA-AMINOBUTYRIC-ACID; STIMULUS-REWARD MEMORY
AB Drug addiction is a chronic brain disorder with the hallmark of a high rate of relapse to compulsive drug seeking and drug taking even after long-term abstinence. Addiction has been considered as an aberrant memory that has been termed "addiction memory." Drug-related memory plays a critical role in the maintenance of learned addictive behaviors and emergence of relapse. Disrupting these long-lasting memories by administering amnestic agents or other manipulations during specific phases of drug memory is a promising strategy for relapse prevention. Recent studies on the processes of drug addiction and relapse have demonstrated that the amygdala is involved in associative drug addiction learning processes. In this review, we focus on preclinical studies that used conditioned place preference and self-administration models to investigate the differential roles of the amygdala in each phase of drug-related memory, including acquisition, consolidation, retrieval, reconsolidation, and extinction. These studies indicate that the amygdala plays a critical role in both cue-associative learning and the expression of cue-induced relapse to drug-seeking behavior. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Luo, Yi-Xiao; Xue, Yan-Xue; Shen, Hao-Wei; Lu, Lin] Peking Univ, Natl Inst Drug Dependence, Beijing 100191, Peoples R China.
C3 Peking University
RP Lu, L (通讯作者)，Peking Univ, Natl Inst Drug Dependence, Beijing 100191, Peoples R China.
EM linlu@bjmu.edu.cn
RI Xue, Yan-Xue/B-7245-2011
OI Shen, Hao-wei/0000-0002-2766-5139
FU Natural Science Foundation of China [31230033, 81221002, 91132716]
FX The authors thank Dr. Ping Wu, Ms. Jia-Hui Deng, and Shi-Qiu Meng for
   assistance with the manuscript. This work was supported in part by the
   Natural Science Foundation of China (Nos. 31230033, 81221002, and
   91132716). The authors declare that they do not have any conflicts of
   interest (financial or otherwise).
CR AANTAA R, 1990, ANESTHESIOLOGY, V73, P230, DOI 10.1097/00000542-199008000-00007
   Abrari K, 2008, NEUROBIOL LEARN MEM, V89, P178, DOI 10.1016/j.nlm.2007.07.005
   Alderson HL, 2000, PSYCHOPHARMACOLOGY, V153, P111, DOI 10.1007/s002130000527
   Alen F, 2009, NEUROSCIENCE, V158, P465, DOI 10.1016/j.neuroscience.2008.10.002
   Allen CD, 2011, BRAIN BEHAV IMMUN, V25, pS50, DOI 10.1016/j.bbi.2011.01.016
   Alvarez-Jaimes L, 2008, NEUROPSYCHOPHARMACOL, V33, P2483, DOI 10.1038/sj.npp.1301630
   Amaral DG, 2003, ANN NY ACAD SCI, V1000, P337, DOI 10.1196/annals.1280.015
   BERGMAN J, 1989, J PHARMACOL EXP THER, V251, P150
   Bernardi RE, 2006, NEUROREPORT, V17, P1443, DOI 10.1097/01.wnr.0000233098.20655.26
   Bernardi RE, 2009, LEARN MEMORY, V16, P777, DOI 10.1101/lm.1648509
   Bie B, 2009, NEUROSCIENCE, V160, P348, DOI 10.1016/j.neuroscience.2009.02.049
   Bienkowski P, 2004, EUR NEUROPSYCHOPHARM, V14, P355, DOI 10.1016/j.euroneuro.2003.10.005
   Bishop SF, 2011, CEREB CORTEX, V21, P68, DOI 10.1093/cercor/bhq060
   Boening JAL, 2001, ALCOHOL CLIN EXP RES, V25, p127S, DOI 10.1111/j.1530-0277.2001.tb02386.x
   Bonson KR, 2002, NEUROPSYCHOPHARMACOL, V26, P376, DOI 10.1016/S0893-133X(01)00371-2
   BORLONGAN CV, 1994, PHARMACOL BIOCHEM BE, V48, P677, DOI 10.1016/0091-3057(94)90331-X
   Botreau F, 2006, BEHAV BRAIN RES, V172, P173, DOI 10.1016/j.bbr.2006.05.012
   Breiter HC, 1997, NEURON, V19, P591, DOI 10.1016/S0896-6273(00)80374-8
   BROG JS, 1993, J COMP NEUROL, V338, P255, DOI 10.1002/cne.903380209
   BROWN EE, 1993, PSYCHOPHARMACOLOGY, V113, P123, DOI 10.1007/BF02244344
   Cannady R, 2011, NEUROPSYCHOPHARMACOL, V36, P2328, DOI 10.1038/npp.2011.121
   Carlson JN, 2006, ALCOHOL CLIN EXP RES, V30, P1678, DOI 10.1111/j.1530-0277.2006.00203.x
   Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11
   Christian DT, 2012, NEUROPHARMACOLOGY, V62, P2430, DOI 10.1016/j.neuropharm.2012.02.017
   Ciccocioppo R, 2003, PSYCHOPHARMACOLOGY, V168, P208, DOI 10.1007/s00213-002-1380-z
   Ciccocioppo R, 2002, NEUROPSYCHOPHARMACOL, V27, P391, DOI 10.1016/S0893-133X(02)00302-0
   Ciccocioppo R, 2001, ALCOHOL CLIN EXP RES, V25, P1414, DOI 10.1111/j.1530-0277.2001.tb02141.x
   Contet C, 2004, CURR OPIN NEUROBIOL, V14, P370, DOI 10.1016/j.conb.2004.05.005
   Dackis CA, 2001, J SUBST ABUSE TREAT, V21, P111, DOI 10.1016/S0740-5472(01)00192-1
   Davis M, 2002, BIOL PSYCHIAT, V52, P998, DOI 10.1016/S0006-3223(02)01507-X
   Dayas CV, 2007, BIOL PSYCHIAT, V61, P979, DOI 10.1016/j.biopsych.2006.07.034
   Debiec J, 2004, NEUROSCIENCE, V129, P267, DOI 10.1016/j.neuroscience.2004.08.018
   Di Ciano P, 2008, BEHAV NEUROSCI, V122, P129, DOI 10.1037/0735-7044.122.1.129
   Diergaarde L, 2006, BEHAV BRAIN RES, V170, P333, DOI 10.1016/j.bbr.2006.02.014
   EDWARDS G, 1976, BRIT MED J, V1, P1058, DOI 10.1136/bmj.1.6017.1058
   Edwards S, 2012, ADDICT BIOL, V17, P76, DOI 10.1111/j.1369-1600.2010.00291.x
   Edwards S, 2009, SYNAPSE, V63, P224, DOI 10.1002/syn.20601
   Everitt BJ, 2000, PSYCHOPHARMACOLOGY, V153, P17, DOI 10.1007/s002130000566
   Everitt BJ, 2003, ANN NY ACAD SCI, V985, P233
   EVERITT BJ, 1991, NEUROSCIENCE, V42, P1, DOI 10.1016/0306-4522(91)90145-E
   Feltenstein MW, 2007, NEUROBIOL LEARN MEM, V88, P435, DOI 10.1016/j.nlm.2007.05.006
   Flor H, 1997, PAIN, V73, P413, DOI 10.1016/S0304-3959(97)00137-1
   Frenois F, 2005, J NEUROSCI, V25, P1366, DOI 10.1523/JNEUROSCI.3090-04.2005
   Fricks-Gleason AN, 2008, LEARN MEMORY, V15, P643, DOI 10.1101/lm.1054608
   Fuchs RA, 2002, BRAIN RES, V929, P15, DOI 10.1016/S0006-8993(01)03366-2
   Fuchs RA, 2002, PSYCHOPHARMACOLOGY, V160, P425, DOI 10.1007/s00213-001-0997-7
   Fuchs RA, 2007, EUR J NEUROSCI, V26, P487, DOI 10.1111/j.1460-9568.2007.05674.x
   Fuchs RA, 2006, EUR J NEUROSCI, V23, P2809, DOI 10.1111/j.1460-9568.2006.04806.x
   Gabriele A, 2010, EUR J NEUROSCI, V32, P1024, DOI 10.1111/j.1460-9568.2010.07394.x
   Gadd CA, 2003, J NEUROSCI, V23, P8271, DOI 10.1523/jneurosci.23-23-08271.2003
   Gass JT, 2011, ADDICT BIOL, V16, P215, DOI 10.1111/j.1369-1600.2010.00262.x
   GAWIN FH, 1991, SCIENCE, V251, P1580, DOI 10.1126/science.2011738
   Ghashghaei H, 2007, NEUROIMAGE, V34, P905, DOI 10.1016/j.neuroimage.2006.09.046
   Ghashghaei HT, 2002, NEUROSCIENCE, V115, P1261, DOI 10.1016/S0306-4522(02)00446-3
   Gilpin NW, 2011, BIOL PSYCHIAT, V69, P1091, DOI 10.1016/j.biopsych.2011.02.004
   Goldberg S R, 1981, NIDA Res Monogr, V37, P241
   Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040
   Gremel CM, 2008, J NEUROSCI, V28, P1076, DOI 10.1523/JNEUROSCI.4520-07.2008
   Gremel CM, 2009, NEUROPSYCHOPHARMACOL, V34, P1443, DOI 10.1038/npp.2008.179
   Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134
   GROENEWEGEN HJ, 1990, PROG BRAIN RES, V85, P95
   Guo N, 2008, BEHAV NEUROSCI, V122, P1078, DOI 10.1037/a0012595
   He YY, 2011, NEUROPSYCHOPHARMACOL, V36, P1972, DOI 10.1038/npp.2011.63
   Hearing MC, 2008, BRAIN STRUCT FUNCT, V213, P215, DOI 10.1007/s00429-008-0182-4
   Hellemans KGC, 2006, J NEUROSCI, V26, P12694, DOI 10.1523/JNEUROSCI.3101-06.2006
   Heyne A, 2000, J NEURAL TRANSM, V107, P613, DOI 10.1007/s007020070065
   HIROI N, 1991, J NEUROSCI, V11, P2107
   Hsu EH, 2002, BEHAV BRAIN RES, V129, P93, DOI 10.1016/S0166-4328(01)00376-X
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kantak KM, 2002, J NEUROSCI, V22, P1126, DOI 10.1523/JNEUROSCI.22-03-01126.2002
   KILTS CD, 1987, BRAIN RES, V416, P402, DOI 10.1016/0006-8993(87)90926-7
   Kilts CD, 2001, ARCH GEN PSYCHIAT, V58, P334, DOI 10.1001/archpsyc.58.4.334
   Kodas E, 2007, PSYCHOPHARMACOLOGY, V194, P161, DOI 10.1007/s00213-007-0813-0
   Koob GF, 2009, BRAIN RES, V1293, P61, DOI 10.1016/j.brainres.2009.03.038
   Koob GF, 2004, BIOCHEM PHARMACOL, V68, P1515, DOI 10.1016/j.bcp.2004.07.031
   KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J
   Koya E, 2006, J NEUROCHEM, V98, P905, DOI 10.1111/j.1471-4159.2006.03917.x
   KRANK MD, 1990, BEHAV NEUROSCI, V104, P725, DOI 10.1037/0735-7044.104.5.725
   Krishnan B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025639
   Kruzich PJ, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-14-j0002.2001
   Kufahl PR, 2011, NEUROPSYCHOPHARMACOL, V36, P2762, DOI 10.1038/npp.2011.174
   Kufahl PR, 2009, SYNAPSE, V63, P823, DOI 10.1002/syn.20666
   Lai YT, 2008, NEUROBIOL LEARN MEM, V90, P164, DOI 10.1016/j.nlm.2008.03.006
   Langleben DD, 2008, AM J PSYCHIAT, V165, P390, DOI 10.1176/appi.ajp.2007.07010070
   LeDoux J, 2003, CELL MOL NEUROBIOL, V23, P727, DOI 10.1023/A:1025048802629
   LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155
   Lee JLC, 2006, J NEUROSCI, V26, P5881, DOI 10.1523/JNEUROSCI.0323-06.2006
   Lee JLC, 2005, NEURON, V47, P795, DOI 10.1016/j.neuron.2005.08.007
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Li FQ, 2010, J NEUROSCI, V30, P10351, DOI 10.1523/JNEUROSCI.2112-10.2010
   Li YQ, 2011, J NEUROSCI, V31, P5436, DOI 10.1523/JNEUROSCI.5884-10.2011
   Li YQ, 2008, J NEUROSCI, V28, P13248, DOI 10.1523/JNEUROSCI.3027-08.2008
   Liddie S, 2012, J PSYCHOPHARMACOL, V26, P1375, DOI 10.1177/0269881112447991
   Lintas A, 2012, EUR J NEUROSCI, V35, P279, DOI 10.1111/j.1460-9568.2011.07943.x
   Lintas A, 2011, J NEUROSCI, V31, P11172, DOI 10.1523/JNEUROSCI.1781-11.2011
   Liu Y, 2012, J NEUROSCI, V32, P12005, DOI 10.1523/JNEUROSCI.0871-12.2012
   Logrip ML, 2012, ADDICT BIOL, V17, P920, DOI 10.1111/j.1369-1600.2012.00460.x
   Lu L, 2000, NEUROSCI LETT, V291, P191, DOI 10.1016/S0304-3940(00)01352-5
   Lu L, 2004, PSYCHOPHARMACOLOGY, V176, P101, DOI 10.1007/s00213-004-1860-4
   Lu L, 2003, NEUROSCI BIOBEHAV R, V27, P457, DOI 10.1016/S0149-7634(03)00073-3
   Lu L, 2005, NAT NEUROSCI, V8, P212, DOI 10.1038/nn1383
   Lu L, 2007, BIOL PSYCHIAT, V61, P591, DOI 10.1016/j.biopsych.2006.04.011
   Lucas M, 2012, NEUROBIOL LEARN MEM, V97, P47, DOI 10.1016/j.nlm.2011.09.002
   Marinelli PW, 2007, EUR J NEUROSCI, V26, P2815, DOI 10.1111/j.1460-9568.2007.05898.x
   Marinelli PW, 2010, BEHAV BRAIN RES, V211, P58, DOI 10.1016/j.bbr.2010.03.008
   Markou A, 2008, PHILOS T R SOC B, V363, P3159, DOI 10.1098/rstb.2008.0095
   Mashhoon Y, 2010, PHARMACOL BIOCHEM BE, V96, P347, DOI 10.1016/j.pbb.2010.06.005
   Mashhoon Y, 2009, EUR J NEUROSCI, V29, P1641, DOI 10.1111/j.1460-9568.2009.06705.x
   Miller CA, 2005, NEURON, V47, P873, DOI 10.1016/j.neuron.2005.08.006
   Miller CA, 2005, EUR J NEUROSCI, V21, P1385, DOI 10.1111/j.1460-9568.2005.03974.x
   Milton AL, 2008, J NEUROSCI, V28, P8230, DOI 10.1523/JNEUROSCI.1723-08.2008
   Mueller D, 2000, BEHAV BRAIN RES, V115, P39, DOI 10.1016/S0166-4328(00)00239-4
   Neisewander JL, 2000, J NEUROSCI, V20, P798, DOI 10.1523/JNEUROSCI.20-02-00798.2000
   Nestler EJ, 2001, AM J ADDICTION, V10, P201, DOI 10.1080/105504901750532094
   Nie H, 2003, PSYCHOPHARMACOLOGY, V168, P222, DOI 10.1007/s00213-003-1468-0
   O'Brien CP, 1998, J PSYCHOPHARMACOL, V12, P15, DOI 10.1177/026988119801200103
   O'Dell LE, 1999, NEUROPSYCHOPHARMACOL, V20, P591, DOI 10.1016/S0893-133X(98)00083-9
   OBRIEN CP, 1992, RES P ARNMD, V70, P157
   Ozburn AR, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-130
   Paolone G, 2009, PSYCHOPHARMACOLOGY, V202, P403, DOI 10.1007/s00213-008-1280-y
   Pare D, 2004, J NEUROPHYSIOL, V92, P1, DOI 10.1152/jn.00153.2004
   Parker LA, 2000, PHARMACOL BIOCHEM BE, V66, P559, DOI 10.1016/S0091-3057(00)00222-7
   Przybyslawski J, 1999, J NEUROSCI, V19, P6623
   Rademacher DJ, 2010, J NEUROSCI, V30, P4676, DOI 10.1523/JNEUROSCI.6165-09.2010
   Radwanska K, 2008, NEUROPSYCHOPHARMACOL, V33, P1835, DOI 10.1038/sj.npp.1301567
   Rezayof A, 2002, PHARMACOL BIOCHEM BE, V74, P187, DOI 10.1016/S0091-3057(02)00989-9
   Rezayof A, 2007, BRAIN RES, V1133, P34, DOI 10.1016/j.brainres.2006.11.049
   Rezayof A, 2012, PHYSIOL BEHAV, V107, P301, DOI 10.1016/j.physbeh.2012.08.009
   Robbins TW, 2008, ANN NY ACAD SCI, V1141, P1, DOI 10.1196/annals.1441.020
   Robinson MJF, 2007, BEHAV BRAIN RES, V182, P129, DOI 10.1016/j.bbr.2007.05.023
   Sanchez H, 2010, J NEUROSCI, V30, P4401, DOI 10.1523/JNEUROSCI.3149-09.2010
   Schroeder JP, 2002, BEHAV NEUROSCI, V116, P922, DOI 10.1037//0735-7044.116.5.922
   Schroeder JP, 2004, LEARN MEMORY, V11, P641, DOI 10.1101/lm.78504
   See RE, 2001, PSYCHOPHARMACOLOGY, V154, P301, DOI 10.1007/s002130000636
   Shalev U, 2002, PHARMACOL REV, V54, P1, DOI 10.1124/pr.54.1.1
   Shalev U, 2001, PSYCHOPHARMACOLOGY, V156, P98, DOI 10.1007/s002130100748
   Shepard JD, 2004, BIOL PSYCHIAT, V55, P1082, DOI 10.1016/j.biopsych.2004.02.032
   Simms JA, 2012, NEUROPSYCHOPHARMACOL, V37, P906, DOI 10.1038/npp.2011.268
   Sinclair CM, 2012, PHARMACOL BIOCHEM BE, V101, P329, DOI 10.1016/j.pbb.2012.01.014
   STRETCH R, 1971, CAN J PHYSIOL PHARM, V49, P581, DOI 10.1139/y71-075
   Sun NL, 2012, PSYCHOPHARMACOLOGY, V222, P645, DOI 10.1007/s00213-012-2665-5
   Szalay JJ, 2011, EUR J NEUROSCI, V33, P1299, DOI 10.1111/j.1460-9568.2010.07581.x
   Szegedi A, 2000, J NEURAL TRANSM, V107, P721, DOI 10.1007/s007020070073
   Theberge FRM, 2010, LEARN MEMORY, V17, P444, DOI 10.1101/lm.1757410
   Thiel KJ, 2010, BEHAV BRAIN RES, V214, P386, DOI 10.1016/j.bbr.2010.06.021
   Tzeng WY, 2012, NEUROBIOL LEARN MEM, V97, P241, DOI 10.1016/j.nlm.2012.01.001
   Vendruscolo LF, 2012, J NEUROSCI, V32, P7563, DOI 10.1523/JNEUROSCI.0069-12.2012
   Walker BM, 2012, ALCOHOL, V46, P339, DOI 10.1016/j.alcohol.2012.01.001
   Walker BM, 2012, ALCOHOL, V46, P359, DOI 10.1016/j.alcohol.2011.10.006
   Wang B, 2002, BRAIN RES, V950, P1, DOI 10.1016/S0006-8993(02)02980-3
   Wang XY, 2008, J NEUROSCI, V28, P5602, DOI 10.1523/JNEUROSCI.0750-08.2008
   Wells A. M., 2012, NEUROPSYCHOPHARMACOL
   Wells AM, 2011, LEARN MEMORY, V18, P693, DOI 10.1101/lm.2273111
   Whitelaw RB, 1996, PSYCHOPHARMACOLOGY, V127, P213, DOI 10.1007/BF02805996
   Wise SP, 2008, TRENDS NEUROSCI, V31, P599, DOI 10.1016/j.tins.2008.08.008
   WOLFFGRAMM J, 1995, BEHAV BRAIN RES, V70, P77, DOI 10.1016/0166-4328(95)00131-C
   Woodward DJ, 1999, ANN NY ACAD SCI, V877, P91, DOI 10.1111/j.1749-6632.1999.tb09263.x
   Wu P, 2011, J NEUROCHEM, V118, P113, DOI 10.1111/j.1471-4159.2011.07277.x
   Wu Y., 2012, ADDICTION BIOL
   Xu YL, 2004, NEURON, V43, P487, DOI 10.1016/j.neuron.2004.08.005
   Xue YX, 2012, SCIENCE, V336, P241, DOI 10.1126/science.1215070
   Yamada H, 2011, NEUROPHARMACOLOGY, V60, P303, DOI 10.1016/j.neuropharm.2010.09.013
   Zarrindast MR, 2010, NEUROSCIENCE, V168, P505, DOI 10.1016/j.neuroscience.2010.03.019
   Zarrindast MR, 2005, PHARMACOL BIOCHEM BE, V82, P1, DOI 10.1016/j.pbb.2005.02.018
   Zarrindast MR, 2004, BRAIN RES, V1006, P49, DOI 10.1016/j.brainres.2003.12.048
   Zarrindast MR, 2003, BRAIN RES, V965, P212, DOI 10.1016/S0006-8993(02)04201-4
   Zavala AR, 2008, EUR NEUROPSYCHOPHARM, V18, P600, DOI 10.1016/j.euroneuro.2008.04.010
   Zhao Y, 2006, J NEUROSCI, V26, P9967, DOI 10.1523/JNEUROSCI.2384-06.2006
   Zhou Y, 2008, NEUROPSYCHOPHARMACOL, V33, P226, DOI 10.1038/sj.npp.1301419
   Zhu W, 2007, J NEUROSCI, V27, P289, DOI 10.1523/JNEUROSCI.3912-06.2007
   Zironi I, 2006, BEHAV BRAIN RES, V167, P150, DOI 10.1016/j.bbr.2005.09.007
NR 172
TC 27
Z9 28
U1 2
U2 53
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1074-7427
EI 1095-9564
J9 NEUROBIOL LEARN MEM
JI Neurobiol. Learn. Mem.
PD OCT
PY 2013
VL 105
SI SI
BP 159
EP 173
DI 10.1016/j.nlm.2013.06.017
PG 15
WC Behavioral Sciences; Neurosciences; Psychology; Psychology,
   Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Behavioral Sciences; Neurosciences & Neurology; Psychology
GA 219LP
UT WOS:000324508800017
PM 23831499
DA 2023-06-23
ER

PT J
AU West, R
AF West, R
TI Theories of addiction
SO ADDICTION
LA English
DT Editorial Material
ID SUBSTANCE USE DISORDERS; DSM-III-R; PREDICTING SMOKING CESSATION;
   DRUG-ADDICTION; ALCOHOL-CONSUMPTION; REINFORCEMENT PROCESSES;
   METHADONE-MAINTENANCE; COCAINE DEPENDENCE; DRINKING BEHAVIOR; OPIATE
   ADDICTION
C1 St George Hosp, Sch Med, London SW17 0RE, England.
C3 St Georges University London
RP West, R (通讯作者)，St George Hosp, Sch Med, Cranmer Terrace, London SW17 0RE, England.
EM r.west@sghms.ac.uk
RI West, Robert/B-5414-2009; West, Robert/B-5414-2009
OI West, Robert/0000-0002-0291-5760; West, Robert/0000-0001-6398-0921
CR ACKER CJ, 1993, J PSYCHOACTIVE DRUGS, V25, P193, DOI 10.1080/02791072.1993.10472271
   Alterman AI, 1998, DRUG ALCOHOL DEPEN, V49, P217, DOI 10.1016/S0376-8716(98)00015-5
   Angres D H, 1985, Psychiatr Med, V3, P369
   ANNIS HM, 1990, J PSYCHOACTIVE DRUGS, V22, P117, DOI 10.1080/02791072.1990.10472537
   ANNIS HM, 1991, ALCOHOL ALCOHOLISM, P527
   Beechem MH, 1996, J DRUG EDUC, V26, P183, DOI 10.2190/0GXH-9Q2Y-9NUG-UQ24
   BEJEROT N, 1972, AM J PSYCHIAT, V128, P842, DOI 10.1176/ajp.128.7.842
   Bejerot N, 1980, NIDA Res Monogr, V30, P246
   Betz C, 2000, J CLIN PHARM THER, V25, P11, DOI 10.1046/j.1365-2710.2000.00260.x
   BOZARTH MA, 1994, ADDICTION, V89, P1425, DOI 10.1111/j.1360-0443.1994.tb03739.x
   BRADIZZA CM, 1994, J BEHAV THER EXP PSY, V25, P15, DOI 10.1016/0005-7916(94)90058-2
   BRESLIN FC, 1995, J STUD ALCOHOL, V56, P546, DOI 10.15288/jsa.1995.56.546
   BRILL L, 1977, AM J PSYCHIAT, V134, P157
   BRISMAN J, 1984, Journal of Substance Abuse Treatment, V1, P113, DOI 10.1016/0740-5472(84)90034-5
   Buck KJ, 2001, ADDICTION, V96, P139, DOI 10.1046/j.1360-0443.2001.96113910.x
   CARROLL JFX, 1975, COMMUNITY MENT HLT J, V11, P418, DOI 10.1007/BF01419665
   Castellani B, 1997, ADDICT BEHAV, V22, P139, DOI 10.1016/S0306-4603(96)00026-3
   Cheng LSC, 2000, ADDICTION, V95, P427, DOI 10.1046/j.1360-0443.2000.95342713.x
   CLAPPER RL, 1995, INT J ADDICT, V30, P507, DOI 10.3109/10826089509048741
   COLLIER MR, 1993, INT J ADDICT, V28, P175, DOI 10.3109/10826089309039622
   Connors GJ, 1996, ADDICTION, V91, pS173, DOI 10.1111/j.1360-0443.1996.tb02337.x
   Connors GJ, 1996, ADDICTION, V91, pS5, DOI 10.1111/j.1360-0443.1996.tb02323.x
   Cornish JL, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-15-j0006.2000
   COTTLER LB, 1993, ADDICTION, V88, P689, DOI 10.1111/j.1360-0443.1993.tb02082.x
   CUNNINGHAM CL, 1992, PSYCHOPHARMACOLOGY, V107, P385, DOI 10.1007/BF02245166
   DAVIS JR, 1991, INT J ADDICT, V25, P805, DOI 10.3109/10826089109071025
   DEANGELIS GG, 1976, AM J OCCUP THER, V30, P87
   DEFEUDIS FV, 1978, GEN PHARMACOL, V9, P303, DOI 10.1016/0306-3623(78)90065-4
   Delaney W, 1998, ADDICTION, V93, P399, DOI 10.1046/j.1360-0443.1998.9333998.x
   DELEON G, 1995, INT J ADDICT, V30, P1603
   Dickerson Mark, 1989, INT REV PSYCHIATR, V1, P157, DOI DOI 10.3109/09540268909110392
   Dodes LM, 1996, J AM PSYCHOANAL ASS, V44, P815, DOI 10.1177/000306519604400307
   DRUMMOND DC, 1990, BRIT J ADDICT, V85, P725
   Drummond DC, 2001, ADDICTION, V96, P33, DOI 10.1046/j.1360-0443.2001.961333.x
   EDWARDS G, 1981, B WORLD HEALTH ORGAN, V59, P225
   Egleton RD, 1998, J PHARM SCI-US, V87, P1433, DOI 10.1021/js980062b
   ELGUEBALY N, 1993, ADDICTION, V88, P1405, DOI 10.1111/j.1360-0443.1993.tb02027.x
   Everitt BJ, 1999, ANN NY ACAD SCI, V877, P412, DOI 10.1111/j.1749-6632.1999.tb09280.x
   Farkas AJ, 1996, ADDICTION, V91, P1271, DOI 10.1046/j.1360-0443.1996.91912713.x
   Fattinger K, 1997, J PHARMACOL EXP THER, V281, P1238
   FAZEY C, 1973, SOCIOL REV, V21, P417, DOI 10.1111/j.1467-954X.1973.tb00231.x
   FEINGOLD A, 1995, ADDICTION, V90, P1661, DOI 10.1111/j.1360-0443.1995.tb02836.x
   Ferrence R, 2001, ADDICTION, V96, P165, DOI 10.1046/j.1360-0443.2001.96116512.x
   Ferrence R, 1996, CAN J PUBLIC HEALTH, V87, pS24
   FINNEY JW, 1995, ADDICTION, V90, P1223, DOI 10.1111/j.1360-0443.1995.tb01092.x
   Fisher LA, 1998, ALCOHOL CLIN EXP RES, V22, P1041, DOI 10.1111/j.1530-0277.1998.tb03696.x
   Flagler S, 1997, J Obstet Gynecol Neonatal Nurs, V26, P441, DOI 10.1111/j.1552-6909.1997.tb02726.x
   Fowler JS, 1998, J ADDICT DIS, V17, P23, DOI 10.1300/J069v17n01_03
   Fulkerson JA, 1999, ADDICTION, V94, P495, DOI 10.1046/j.1360-0443.1999.9444955.x
   GALANTER M, 1976, AM J PSYCHIAT, V133, P930
   GLASS IB, 1991, INT HDB ADDICTION BE
   GOODMAN A, 1990, BRIT J ADDICT, V85, P1403
   GORDON WW, 1971, AM J PSYCHOTHER, V25, P394, DOI 10.1176/appi.psychotherapy.1971.25.3.394
   Grant S, 2000, NEUROPSYCHOLOGIA, V38, P1180, DOI 10.1016/S0028-3932(99)00158-X
   Grun L, 2000, ADDICTION, V95, P959, DOI 10.1046/j.1360-0443.2000.95695912.x
   Hajema KJ, 1998, ADDICTION, V93, P1717, DOI 10.1046/j.1360-0443.1998.931117179.x
   Heather N, 1998, J PSYCHOPHARMACOL, V12, P3, DOI 10.1177/026988119801200101
   Herz A, 1997, PSYCHOPHARMACOLOGY, V129, P99, DOI 10.1007/s002130050169
   Heyne A, 1998, PSYCHOPHARMACOLOGY, V140, P510, DOI 10.1007/s002130050796
   HOFFMAN JA, 1994, J PSYCHOACTIVE DRUGS, V26, P181, DOI 10.1080/02791072.1994.10472266
   Hofler DZ, 1996, J SUBST ABUSE TREAT, V13, P511, DOI 10.1016/S0740-5472(96)00156-0
   Hopper E, 1995, INT J PSYCHOANAL, V76, P1121
   HUGHES TL, 1989, NURS CLIN N AM, V24, P1
   Ilyina AD, 1998, BIOSYSTEMS, V45, P67, DOI 10.1016/S0303-2647(97)00063-4
   Jaeger E, 2000, ADDICTION, V95, P267, DOI 10.1046/j.1360-0443.2000.95226713.x
   JANSEN A, 1989, BEHAV RES THER, V27, P247, DOI 10.1016/0005-7967(89)90043-0
   Johnson EO, 1996, ADDICTION, V91, P583, DOI 10.1111/j.1360-0443.1996.tb02315.x
   Johnson PB, 1998, ADDICTION, V93, P583, DOI 10.1046/j.1360-0443.1998.93458313.x
   JONAS S, 1973, NEW ENGL J MED, V288, P421
   Jones BT, 2001, ADDICTION, V96, P57, DOI 10.1046/j.1360-0443.2001.961575.x
   Jones BT, 1996, ADDICTION, V91, P89, DOI 10.1111/j.1360-0443.1996.tb03164.x
   Kalivas PW, 1998, J PSYCHOPHARMACOL, V12, P49, DOI 10.1177/026988119801200107
   KAPLAN CD, 1978, AM J PSYCHOANAL, V38, P317, DOI 10.1007/BF01253588
   Kearney MH, 1998, QUAL HEALTH RES, V8, P495, DOI 10.1177/104973239800800405
   KEELER TE, 1993, J HEALTH ECON, V12, P1, DOI 10.1016/0167-6296(93)90037-F
   KELLER LE, 1992, B MENNINGER CLIN, V56, P221
   Kenkel D, 2001, ADDICTION, V96, P151, DOI 10.1046/j.1360-0443.2001.96115111.x
   KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259
   KOFOED L, 1987, Pediatrician, V14, P39
   Koob GF, 1997, PHARMACOL BIOCHEM BE, V57, P513, DOI 10.1016/S0091-3057(96)00438-8
   Koob GF, 1998, J PSYCHOPHARMACOL, V12, P39, DOI 10.1177/026988119801200106
   Kreek MJ, 1996, J ADDICT DIS, V15, P73, DOI 10.1300/J069v15n04_05
   KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G
   LEWIS CE, 1984, PSYCHIAT DEV, V2, P223
   Littleton J, 2001, ADDICTION, V96, P87, DOI 10.1046/j.1360-0443.2001.961877.x
   Liu JL, 1999, J HEALTH ECON, V18, P795, DOI 10.1016/S0167-6296(99)00023-5
   LOGAN FA, 1993, PSYCHOL REP, V73, P291, DOI 10.2466/pr0.1993.73.1.291
   LONGABAUGH R, 1994, J STUD ALCOHOL, P46, DOI 10.15288/jsas.1994.s12.46
   Lowman C, 2000, ADDICTION, V95, pS45
   Lowman C, 1996, ADDICTION, V91, pS51, DOI 10.1111/j.1360-0443.1996.tb02327.x
   Lyvers M, 1998, EXP CLIN PSYCHOPHARM, V6, P107
   Marlatt GA, 1996, ADDICTION, V91, pS37, DOI 10.1111/j.1360-0443.1996.tb02326.x
   Martin GW, 1998, ADDICTION, V93, P1703, DOI 10.1046/j.1360-0443.1998.931117038.x
   McAuliffe W E, 1980, NIDA Res Monogr, V30, P137
   MCAULIFFE WE, 1991, INT J ADDICT, V25, P1141, DOI 10.3109/10826089109081040
   McCusker CG, 2001, ADDICTION, V96, P47, DOI 10.1046/j.1360-0443.2001.961474.x
   McCusker CG, 1997, BRIT J CLIN PSYCHOL, V36, P543, DOI 10.1111/j.2044-8260.1997.tb01259.x
   Miller CS, 1997, ENVIRON HEALTH PERSP, V105, P445, DOI 10.2307/3433351
   MILLER L, 1991, J SUBST ABUSE TREAT, V8, P277, DOI 10.1016/0740-5472(91)90051-B
   MILLER NS, 1990, J PSYCHOACTIVE DRUGS, V22, P83, DOI 10.1080/02791072.1990.10472201
   Miller WR, 1996, ADDICTION, V91, pS155, DOI 10.1046/j.1360-0443.91.12s1.7.x
   Modesto-Lowe V, 1999, ADDICTION, V94, P1639, DOI 10.1046/j.1360-0443.1999.941116393.x
   MUTHEN BO, 1993, ADDICTION, V88, P1079, DOI 10.1111/j.1360-0443.1993.tb02127.x
   Nardi D, 1998, ARCH PSYCHIAT NURS, V12, P81, DOI 10.1016/S0883-9417(98)80057-5
   Nelson CB, 1999, ADDICTION, V94, P843, DOI 10.1046/j.1360-0443.1999.9468438.x
   NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B
   Newlin DB, 1999, TOXICOL IND HEALTH, V15, P313
   OBRIEN CP, 1992, RES P ARNMD, V70, P157
   OCONNOR LE, 1993, J PSYCHOACTIVE DRUGS, V25, P283, DOI 10.1080/02791072.1993.10472285
   Orford J, 2001, ADDICTION, V96, P15, DOI 10.1046/j.1360-0443.2001.961152.x
   ORFORD J, 1992, EXCESSIVE APPETITIE
   Pacula RL, 1997, HEALTH ECON, V6, P521, DOI 10.1002/(SICI)1099-1050(199709)6:5<521::AID-HEC301>3.0.CO;2-6
   PARSSINEN TM, 1980, MED HIST, V24, P275, DOI 10.1017/S0025727300040321
   Peele S, 1980, NIDA Res Monogr, V30, P142
   Peteet JR, 1998, GEN HOSP PSYCHIAT, V20, P267, DOI 10.1016/S0163-8343(98)00033-4
   Phillips TJ, 1996, INT REV NEUROBIOL, V39, P243, DOI 10.1016/S0074-7742(08)60669-8
   Pich EM, 1998, J PHYSIOLOGY-PARIS, V92, P225, DOI 10.1016/S0928-4257(98)80015-6
   Pierce JP, 1998, ADDICTION, V93, P277, DOI 10.1046/j.1360-0443.1998.93227711.x
   PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102
   Prochaska JO, 1996, ADDICTION, V91, P1281, DOI 10.1111/j.1360-0443.1996.tb03609.x
   Reid D, 1996, BRIT MED BULL, V52, P108, DOI 10.1093/oxfordjournals.bmb.a011518
   RICHMAN A, 1976, DRUG ALCOHOL DEPEN, V1, P383, DOI 10.1016/0376-8716(76)90003-X
   Robinson TE, 2001, ADDICTION, V96, P103, DOI 10.1046/j.1360-0443.2001.9611038.x
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Romelsjo A, 1996, ADDICTION, V91, P1307
   ROUNSAVILLE BJ, 1993, ADDICTION, V88, P337, DOI 10.1111/j.1360-0443.1993.tb00821.x
   Saunders B, 1996, ADDICT BEHAV, V21, P843, DOI 10.1016/0306-4603(96)00043-3
   Schulteis G, 1996, NEUROCHEM RES, V21, P1437, DOI 10.1007/BF02532385
   SHOHAM SG, 1984, DRUG ALCOHOL DEPEN, V13, P297, DOI 10.1016/0376-8716(84)90069-3
   Siegel S, 1988, NIDA Res Monogr, V84, P1
   Silvia L Y, 1988, J Subst Abuse, V1, P55, DOI 10.1016/S0899-3289(88)80008-7
   SKOG OJ, 1985, BRIT J ADDICT, V80, P83
   SOLOMON KE, 1990, BRIT J ADDICT, V85, P659
   Speri L, 1998, SUBST USE MISUSE, V33, P555, DOI 10.3109/10826089809115886
   STANTON MD, 1978, AM J DRUG ALCOHOL AB, V5, P125, DOI 10.3109/00952997809027993
   Stewart J, 2000, J PSYCHIATR NEUROSCI, V25, P125
   STOLERMAN IP, 1993, BIOCHEM SOC SYMP, P1
   Sutton S, 2001, ADDICTION, V96, P175, DOI 10.1046/j.1360-0443.2001.96117513.x
   TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147
   True WR, 1997, ADDICTION, V92, P1277, DOI 10.1111/j.1360-0443.1997.tb02847.x
   Vasse RM, 1998, ADDICTION, V93, P231, DOI 10.1046/j.1360-0443.1998.9322317.x
   Verheul R, 1999, ALCOHOL ALCOHOLISM, V34, P197, DOI 10.1093/alcalc/34.2.197
   Verheul R, 1998, ADDICT BEHAV, V23, P869, DOI 10.1016/S0306-4603(98)00065-3
   Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI 10.1093/cercor/10.3.318
   Weiner S, 1998, J CLIN PSYCHOL, V54, P163, DOI 10.1002/(SICI)1097-4679(199802)54:2<163::AID-JCLP5>3.0.CO;2-T
   WHITEHEAD CC, 1974, PSYCHOSOM MED, V36, P189, DOI 10.1097/00006842-197405000-00001
   WILSON A, 1989, J NERV MENT DIS, V177, P390, DOI 10.1097/00005053-198907000-00002
   Winters KC, 2000, ADDICTION, V95, P601, DOI 10.1046/j.1360-0443.2000.95460111.x
   WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469
   Wolf ME, 1998, PROG NEUROBIOL, V54, P679, DOI 10.1016/S0301-0082(97)00090-7
   WOLFFGRAMM J, 1995, BEHAV BRAIN RES, V70, P77, DOI 10.1016/0166-4328(95)00131-C
   ZWEBEN JE, 1994, J PSYCHOACTIVE DRUGS, V26, P327, DOI 10.1080/02791072.1994.10472453
NR 152
TC 77
Z9 80
U1 1
U2 50
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0965-2140
EI 1360-0443
J9 ADDICTION
JI Addiction
PD JAN
PY 2001
VL 96
IS 1
SI SI
BP 3
EP 13
DI 10.1046/j.1360-0443.2001.96131.x
PG 11
WC Substance Abuse; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry
GA 394JV
UT WOS:000166521700001
PM 11177516
DA 2023-06-23
ER

PT J
AU Kenny, PJ
AF Kenny, Paul J.
TI Epigenetics, microRNA, and addiction
SO DIALOGUES IN CLINICAL NEUROSCIENCE
LA English
DT Article
DE addiction; cocaine; nicotine; opiate; amphetamine; MeCP2; BDNF; miR-212
ID COCAINE-INDUCED PLASTICITY; DOPAMINE D2 RECEPTORS; NEUROTROPHIC FACTOR;
   NUCLEUS-ACCUMBENS; MESSENGER-RNA; BDNF EXPRESSION; DRUG-ADDICTION;
   SYNAPTIC PLASTICITY; MENTAL-RETARDATION; MAMMALIAN BRAIN
AB Drug addiction is characterized by uncontrolled drug consumption and high rates of relapse to drug taking during periods of attempted abstinence. Addiction is now largely considered a disorder of experience-dependent neuroplasticity, driven by remodeling of synapses in reward and motivation relevant brain circuits in response to a history of prolonged drug intake. Alterations in gene expression play a central role in addiction-relevant neuroplasticity, but the mechanisms by which additive drugs remodel brain motivation circuits remains unclear. MicroRNAs (miRNAs) are a class of noncoding RNA that can regulate the expression of large numbers of protein-coding mRNA transcripts by binding to the 3' untranslated region (3' UTR) of target transcripts and blocking their translation into the encoded protein or triggering their destabilization and degradation. Emerging evidence has implicated miRNAs in regulating addiction-relevant neuroplasticity in the brain, and in controlling the motivational properties of cocaine and other drugs of abuse. Here, the role for miRNAs in regulating basic aspects of neuronal function is reviewed. The involvement of miRNAs in controlling the motivational properties of addictive drugs is also summarized. Finally, mechanisms by which miRNAs exert their actions on drug intake, when known, are considered. (C) 2014, AICH - Servier Research Group
C1 [Kenny, Paul J.] Icahn Sch Med Mt Sinai, Lab Behav & Mol Neurosci, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai
RP Kenny, PJ (通讯作者)，Icahn Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, 1470 Madison Ave, New York, NY 10029 USA.
EM paul.kenny@mssm.edu
FU National Institute on Drug Abuse [DA025983]
FX This work was supported by a grant from the National Institute on Drug
   Abuse (DA025983). PJK is a consultant for Pfizer, Inc. and is a
   shareholder in Eolas Therapeutics, Inc
CR Acar M, 2005, NATURE, V435, P228, DOI 10.1038/nature03524
   Ahmed SH, 2005, EUR J PHARMACOL, V526, P9, DOI 10.1016/j.ejphar.2005.09.036
   Ahmed SH, 2005, PSYCHOPHARMACOLOGY, V180, P473, DOI 10.1007/s00213-005-2180-z
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Ahmed SH, 2002, NAT NEUROSCI, V5, P625, DOI 10.1038/nn872
   Ahmed SH, 2000, NEUROPSYCHOPHARMACOL, V22, P413, DOI 10.1016/S0893-133X(99)00133-5
   Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810
   Ashraf SI, 2006, CURR OPIN NEUROBIOL, V16, P535, DOI 10.1016/j.conb.2006.08.007
   Ashraf SI, 2006, CELL, V124, P191, DOI 10.1016/j.cell.2005.12.017
   Autry AE, 2012, PHARMACOL REV, V64, P238, DOI 10.1124/pr.111.005108
   Axtell MJ, 2005, PLANT CELL, V17, P1658, DOI 10.1105/tpc.105.032185
   Bahi A, 2013, EUR J NEUROSCI, V38, P2328, DOI 10.1111/ejn.12228
   Ball D, 2008, ADDICTION, V103, P360, DOI 10.1111/j.1360-0443.2007.02061.x
   Benavides DR, 2007, J NEUROSCI, V27, P12967, DOI 10.1523/JNEUROSCI.4061-07.2007
   Bilen J, 2006, CELL CYCLE, V5, P2835, DOI 10.4161/cc.5.24.3579
   CAINE SB, 1995, BRAIN RES, V692, P47
   Carlezon WA, 1998, SCIENCE, V282, P2272, DOI 10.1126/science.282.5397.2272
   Chandrasekar V, 2011, NEUROPSYCHOPHARMACOL, V36, P1149, DOI 10.1038/npp.2010.250
   Chandrasekar V, 2009, MOL CELL NEUROSCI, V42, P350, DOI 10.1016/j.mcn.2009.08.009
   CHEN JS, 1995, MOL PHARMACOL, V48, P880
   Covington HE, 2011, NEURON, V71, P656, DOI 10.1016/j.neuron.2011.06.007
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   DiNieri JA, 2009, J NEUROSCI, V29, P1855, DOI 10.1523/JNEUROSCI.5104-08.2009
   Duan Ranhui, 2006, V342, P267, DOI 10.1385/1-59745-123-1:267
   Edbauer D, 2010, NEURON, V65, P373, DOI 10.1016/j.neuron.2010.01.005
   Eipper-Mains JE, 2011, RNA, V17, P1529, DOI 10.1261/rna.2775511
   Ferri CP, 2001, SUBST USE MISUSE, V36, P237, DOI 10.1081/JA-100102624
   Fuchs RA, 2004, PSYCHOPHARMACOLOGY, V176, P459, DOI 10.1007/s00213-004-1895-6
   Gao J, 2010, NATURE, V466, P1105, DOI 10.1038/nature09271
   GAWIN FH, 1989, ANNU REV MED, V40, P149
   George O, 2007, P NATL ACAD SCI USA, V104, P17198, DOI 10.1073/pnas.0707585104
   Gillespie NA, 2007, PSYCHOL MED, V37, P947, DOI 10.1017/S0033291707009920
   Giraldez AJ, 2005, SCIENCE, V308, P833, DOI 10.1126/science.1109020
   Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0
   Gong X, 2013, BIOCHEM BIOPH RES CO, V439, P493, DOI 10.1016/j.bbrc.2013.08.096
   Gonon F, 1997, J NEUROSCI, V17, P5972
   GOODWIN DW, 1977, ARCH GEN PSYCHIAT, V34, P1005
   GOODWIN DW, 1974, ARCH GEN PSYCHIAT, V31, P164
   Grimm JW, 2003, J NEUROSCI, V23, P742
   GUZE SB, 1986, COMPR PSYCHIAT, V27, P501, DOI 10.1016/0010-440X(86)90054-4
   Hollander JA, 2010, NATURE, V466, P197, DOI 10.1038/nature09202
   HOPE BT, 1994, NEURON, V13, P1235, DOI 10.1016/0896-6273(94)90061-2
   Hyman SE, 2005, AM J PSYCHIAT, V162, P1414, DOI 10.1176/appi.ajp.162.8.1414
   Ikemoto S, 2003, J NEUROSCI, V23, P9305
   Im HI, 2012, TRENDS NEUROSCI, V35, P325, DOI 10.1016/j.tins.2012.01.004
   Im HI, 2010, NAT NEUROSCI, V13, P1120, DOI 10.1038/nn.2615
   Impey S, 2007, NEURON, V56, P415, DOI 10.1016/j.neuron.2007.10.029
   Ito R, 2004, NAT NEUROSCI, V7, P389, DOI 10.1038/nn1217
   Jones S, 2005, CURR OPIN PHARMACOL, V5, P20, DOI 10.1016/j.coph.2004.08.011
   Jones-Rhoades MW, 2006, ANNU REV PLANT BIOL, V57, P19, DOI 10.1146/annurev.arplant.57.032905.105218
   Jonkman S, 2013, NEUROPSYCHOPHARMACOL, V38, P198, DOI 10.1038/npp.2012.120
   Jonkman S, 2012, J NEUROSCI, V32, P4645, DOI 10.1523/JNEUROSCI.0348-12.2012
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564
   Kalivas PW, 2005, NAT NEUROSCI, V8, P1440, DOI 10.1038/nn1105-1440
   Kapsimali M, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r173
   Karres JS, 2007, CELL, V131, P136, DOI 10.1016/j.cell.2007.09.020
   Kauer JA, 2007, NAT REV NEUROSCI, V8, P844, DOI 10.1038/nrn2234
   Kendler KS, 2007, ARCH GEN PSYCHIAT, V64, P1313, DOI 10.1001/archpsyc.64.11.1313
   Kennedy PJ, 2013, NAT NEUROSCI, V16, P434, DOI 10.1038/nn.3354
   Kenny PJ, 2007, TRENDS PHARMACOL SCI, V28, P135, DOI 10.1016/j.tips.2007.01.008
   Kenny PJ, 2013, CURR OPIN NEUROBIOL, V23, P535, DOI 10.1016/j.conb.2013.04.012
   Kiebler MA, 2000, NEURON, V25, P19, DOI 10.1016/S0896-6273(00)80868-5
   Kitamura O, 2006, PSYCHOPHARMACOLOGY, V186, P48, DOI 10.1007/s00213-006-0353-z
   Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442
   Koob GF, 2004, NEUROSCI BIOBEHAV R, V27, P739, DOI 10.1016/j.neubiorev.2003.11.007
   KRAMER JC, 1967, J AMER MED ASSOC, V201, P305, DOI 10.1001/jama.201.5.305
   Krichevsky AM, 2003, RNA, V9, P1274, DOI 10.1261/rna.5980303
   Kumar A, 2005, NEURON, V48, P303, DOI 10.1016/j.neuron.2005.09.023
   Kye MJ, 2007, RNA, V13, P1224, DOI 10.1261/rna.480407
   Lai EC, 2005, CURR BIOL, V15, pR458, DOI 10.1016/j.cub.2005.06.015
   Lai EC, 2003, CURR BIOL, V13, pR925, DOI 10.1016/j.cub.2003.11.017
   LaPlant Q, 2010, NAT NEUROSCI, V13, P1137, DOI 10.1038/nn.2619
   Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062
   Lee ST, 2012, ANN NEUROL, V72, P269, DOI 10.1002/ana.23588
   Li JY, 2013, EMBO MOL MED, V5, P1402, DOI 10.1002/emmm.201201900
   Li MD, 2011, MOL PSYCHIATR, V16, P1159, DOI 10.1038/mp.2011.58
   Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372
   Lin Q, 2011, NAT NEUROSCI, V14, P1115, DOI 10.1038/nn.2891
   Lu L, 2006, TRENDS NEUROSCI, V29, P695, DOI 10.1016/j.tins.2006.10.005
   Makeyev EV, 2007, MOL CELL, V27, P435, DOI 10.1016/j.molcel.2007.07.015
   Maze I, 2011, P NATL ACAD SCI USA, V108, P3035, DOI 10.1073/pnas.1015483108
   Maze I, 2010, SCIENCE, V327, P213, DOI 10.1126/science.1179438
   McClung CA, 2003, NAT NEUROSCI, V6, P1208, DOI 10.1038/nn1143
   McClung CA, 2004, MOL BRAIN RES, V132, P146, DOI 10.1016/j.molbrainres.2004.05.014
   McNeill E, 2012, NEURON, V75, P363, DOI 10.1016/j.neuron.2012.07.005
   Mellios N, 2011, NAT NEUROSCI, V14, P1240, DOI 10.1038/nn.2909
   Merikangas KR, 1998, ARCH GEN PSYCHIAT, V55, P973, DOI 10.1001/archpsyc.55.11.973
   Miska EA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r68
   Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006
   Miura P, 2012, J NEUROCHEM, V120, P230, DOI 10.1111/j.1471-4159.2011.07583.x
   Moghaddam B, 2008, NEUROPSYCHOPHARMACOL, V33, P42, DOI 10.1038/sj.npp.1301554
   Muddashetty RS, 2011, MOL CELL, V42, P673, DOI 10.1016/j.molcel.2011.05.006
   Mulholland Patrick J, 2007, ScientificWorldJournal, V7, P9
   Nader MA, 2005, AM J PSYCHIAT, V162, P1473, DOI 10.1176/appi.ajp.162.8.1473
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Nestler EJ, 2008, PHILOS T R SOC B, V363, P3245, DOI 10.1098/rstb.2008.0067
   Nestler EJ, 2014, NEUROPHARMACOLOGY, V76, P259, DOI 10.1016/j.neuropharm.2013.04.004
   Pietrzykowski AZ, 2010, INT REV NEUROBIOL, V91, P1, DOI 10.1016/S0074-7742(10)91001-5
   Plante I, 2006, J BIOMED BIOTECHNOL, V2006
   Pontieri FE, 1995, P NATL ACAD SCI USA, V92, P12304, DOI 10.1073/pnas.92.26.12304
   Radzikinas K, 2011, J NEUROSCI, V31, P15407, DOI 10.1523/JNEUROSCI.2745-11.2011
   Rajagopalan R, 2006, GENE DEV, V20, P3407, DOI 10.1101/gad.1476406
   Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607
   Renthal W, 2007, NEURON, V56, P517, DOI 10.1016/j.neuron.2007.09.032
   Rodriguez Raquel E., 2012, Frontiers in Genetics, V3, P223, DOI 10.3389/fgene.2012.00223
   Ruby JG, 2006, CELL, V127, P1193, DOI 10.1016/j.cell.2006.10.040
   Sartor Gregory C., 2012, Frontiers in Genetics, V3, P106, DOI 10.3389/fgene.2012.00106
   Schaefer A, 2007, J EXP MED, V204, P1553, DOI 10.1084/jem.20070823
   Schaefer A, 2010, J EXP MED, V207, P1843, DOI 10.1084/jem.20100451
   Siegel R K, 1984, NIDA Res Monogr, V50, P92
   Sim SE, 2014, MOL CELLS, V37, P511, DOI 10.14348/molcells.2014.0132
   Sosanya NM, 2013, J CELL BIOL, V202, P53, DOI 10.1083/jcb.201212089
   Sudhakaran IP, 2014, P NATL ACAD SCI USA, V111, pE99, DOI 10.1073/pnas.1309543111
   Suto N, 2011, J NEUROSCI, V31, P17917, DOI 10.1523/JNEUROSCI.1903-11.2011
   Suto N, 2009, PSYCHOPHARMACOLOGY, V205, P431, DOI 10.1007/s00213-009-1553-0
   Tapocik JD, 2014, J NEUROSCI, V34, P4581, DOI 10.1523/JNEUROSCI.0445-14.2014
   Taylor JR, 2007, P NATL ACAD SCI USA, V104, P4147, DOI 10.1073/pnas.0610288104
   Tian N, 2014, NEUROSCI BULL, V30, P191, DOI 10.1007/s12264-013-1419-7
   Townley-Tilson WHD, 2010, INT J BIOCHEM CELL B, V42, P1252, DOI 10.1016/j.biocel.2009.03.002
   Tsang J, 2007, MOL CELL, V26, P753, DOI 10.1016/j.molcel.2007.05.018
   Uhl GR, 2008, BIOCHEM PHARMACOL, V75, P98, DOI 10.1016/j.bcp.2007.06.042
   Uhl George R., 1995, P1793
   Van Esch H, 2005, AM J HUM GENET, V77, P442, DOI 10.1086/444549
   Vanderschuren LJMJ, 2005, J NEUROSCI, V25, P8665, DOI 10.1523/JNEUROSCI.0925-05.2005
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Varga EV, 2002, EUR J PHARMACOL, V451, P101, DOI 10.1016/S0014-2999(02)02220-3
   Vetere G, HIPPOCAMPUS IN PRESS
   Vo N, 2005, P NATL ACAD SCI USA, V102, P16426, DOI 10.1073/pnas.0508448102
   Volman Susan F, 2007, ScientificWorldJournal, V7, P4
   Wayman GA, 2008, P NATL ACAD SCI USA, V105, P9093, DOI 10.1073/pnas.0803072105
   Wikler A, 1952, PSYCHIAT QUART, V26, P270, DOI 10.1007/BF01568465
   Wright D, 2005, NSDUH SER H, V26
   Xu XL, 2011, J NEUROSCI, V31, P13705, DOI 10.1523/JNEUROSCI.2827-11.2011
   Zalfa F, 2005, CELL MOL LIFE SCI, V62, P251, DOI 10.1007/s00018-004-4521-1
   Zapata A, 2010, J NEUROSCI, V30, P15457, DOI 10.1523/JNEUROSCI.4072-10.2010
NR 136
TC 57
Z9 58
U1 0
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1294-8322
EI 1958-5969
J9 DIALOGUES CLIN NEURO
JI Dialogues Clin. Neurosci.
PD SEP
PY 2014
VL 16
IS 3
BP 335
EP 344
PG 10
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA V45QR
UT WOS:000209831600006
PM 25364284
DA 2023-06-23
ER

PT C
AU Sarwirini
   Kurniawan, RA
AF Sarwirini
   Kurniawan, Riza Alifianto
BE Junita, F
TI Rehabilitation of Narcotics Addicts as the Rights to Health
SO PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON LAW, GOVERNANCE AND
   GLOBALIZATION 2017 (ICLGG 2017)
SE Advances in Social Science Education and Humanities Research
LA English
DT Proceedings Paper
CT International Conference on Law, Governance and Globalization (ICLGG)
CY NOV 15-16, 2017
CL Univ Airlangga, Fac Law, Surabaya, INDONESIA
HO Univ Airlangga, Fac Law
DE Drug Addiction; Rights of Health
AB Illegal Narcotic addiction can be qualified as commiting crime. The punishment for illegal drug offender and place them to prison is far from success to reduce the rate of illegal narcotics consumtion. The offenders tend to come back to their addiction and turn them to commit crime related with illegal drug trafficking. The objective by punished the illegal drug offenders could not meet its goal and should be amendment. One of alteration strategy to release the offender from addiction is rehabilitation program. This program will treat the offenders recover from the addiction and reduce the negative impact of punishment. Furthermore rehabilitation would cohere with the rights for health.
C1 [Sarwirini; Kurniawan, Riza Alifianto] Airlangga Univ, Fac Law, Surabaya, Indonesia.
C3 Airlangga University
RP Sarwirini (通讯作者)，Airlangga Univ, Fac Law, Surabaya, Indonesia.
EM Sarwirini.rini@gmail.com; alifriza@fh.unair.ac.id
CR Adi Kusno, 2009, CRIMINAL POLICY ILLE
   Adi Kusno, 2009, DIVERSI SEBAGAI UPAY
   Albanjary Syaefurrahman, 2005, TACKLING ILLICIT NAR
   Arief Barda Nawawi, 1996, GROUP ARTICLE CRIMIN
   Arif Barda Nawawi, 2001, LAW ENFORCEMENT PROB
   Dolan K., 2007, PRISONS DRUGS GLOBAL
   Dwidja Priyatno, 2006, SISTEM PELAKSANAAN P
   Hadisuprapto Paulus, 2008, JUVENILE DELIQUENCY
   Kaligis O. C, 2002, NARKOBA DAN PERADILA
   Kurniawan Riza Alifianto, 2008, ULTIMUM REMIDIUM PRI
   Leukefeld Carl G., 1992, NIDA RES MONOGR, V118
   Makarao Taufik, 2003, TINDAK PIDANA NARKOB
   Makaro Taufik, 2003, NARCOTIC CRIMES INDO
   Musa M., RESTORATIVE JUSTICE
   Nasional Badan Narkotika, 2007, KUMP HAS HAS PEN PEN
   Newburn Tim, 2007, CRIMINOLOGY
   Rasul Abdul, 2003, JURNAL STUDI KEPOLIS
   Roger Harley, 2001, AM J CRIMINAL JUSTIC, V26
   Sunarso Siswanto, 2004, LAW ENFORCEMENT PSYC
   Sunarso Siswantoro, 2004, PENEGAKAN HUKUM PSIK
   Togar Sianipar M., 2003, POLICE J
NR 21
TC 0
Z9 0
U1 0
U2 1
PU ATLANTIS PRESS
PI PARIS
PA 29 AVENUE LAVMIERE, PARIS, 75019, FRANCE
SN 2352-5398
BN 978-94-6252-567-2
J9 ADV SOC SCI EDUC HUM
PY 2017
VL 131
BP 250
EP 263
PG 14
WC Law; Political Science; Social Sciences, Interdisciplinary
WE Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)
SC Government & Law; Social Sciences - Other Topics
GA BK9WN
UT WOS:000445100100034
DA 2023-06-23
ER

PT J
AU Lyvers, M
AF Lyvers, M
TI Drug addiction as a physical disease: The role of physical dependence
   and other chronic drug-induced neurophysiological changes in compulsive
   drug self-administration
SO EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY
LA English
DT Review
ID CONDITIONED PLACE PREFERENCE; VENTRAL TEGMENTAL AREA; OPIATE WITHDRAWAL
   SYNDROME; SUBSTANCE USE DISORDERS; IV FIELD TRIAL; ALCOHOL-WITHDRAWAL;
   COCAINE ABUSE; BENZODIAZEPINE DEPENDENCE; ETHANOL DEPENDENCE; RATS
AB Physical-dependence-based theories of addiction regard compulsive drug taking as the behavioral manifestation of a desperate need to relieve aversive autonomic withdrawal symptoms. In the present article, the withdrawal-relief paradigm, or opiate model of addiction, is critically examined in the light of recent experimental and clinical evidence for various addictive drugs. It is concluded that contrary to the opiate model, the constellation of pathological behaviors defining addiction (compulsive drug use, craving, loss of control, and a persistent tendency to relapse) does not primarily reflect a need to relieve actual or conditioned autonomic withdrawal symptoms. Recent theories of addiction emphasize the positive reinforcing properties of drugs and sensitization of brain dopamine systems rather than negative reinforcement or drug-opposing neuroadaptations. Despite the failure of the opiate model, recent evidence suggests that persistent drug-induced changes in the physical brain may underlie addictive behavior, consistent with the general notion of addiction as a physical disease.
C1 Bond Univ, Dept Psychiat, Sch Humanities & Social Sci, Gold Coast, Qld 4229, Australia.
C3 Bond University
RP Lyvers, M (通讯作者)，Bond Univ, Dept Psychiat, Sch Humanities & Social Sci, Gold Coast, Qld 4229, Australia.
EM mike_lyvers@bond.edu.au
OI Lyvers, Michael/0000-0002-8355-3182
CR ABRAHAMSEN GC, 1995, PHARMACOL BIOCHEM BE, V51, P407, DOI 10.1016/0091-3057(94)00415-F
   American Psychiatric Association, 1987, DIAGNOSTIC STAT MANU, V3rd
   American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3rd ed.
   [Anonymous], [No title captured]
   ASHTON H, 1994, ADDICTION, V89, P1535, DOI 10.1111/j.1360-0443.1994.tb03755.x
   ASIN KE, 1985, PHARMACOL BIOCHEM BE, V22, P169, DOI 10.1016/0091-3057(85)90372-7
   AYD FJ, 1983, J PSYCHOACTIVE DRUGS, V15, P67, DOI 10.1080/02791072.1983.10472125
   BALFOUR DJK, 1994, ADDICTION, V89, P1419, DOI 10.1111/j.1360-0443.1994.tb03738.x
   BALSTER RT, 1977, COCAINE OTHER STIMUL, P571
   Begleiter H, 1996, PHARM ALCOHOL ALCOHO
   BERMAN RF, 1984, DRUG ALCOHOL DEPEN, V13, P245, DOI 10.1016/0376-8716(84)90065-6
   Bickel WK, 1995, EXP CLIN PSYCHOPHARM, V3, P477, DOI 10.1037/1064-1297.3.4.477
   BOZARTH MA, 1983, PROG NEURO-PSYCHOPH, V7, P569, DOI 10.1016/0278-5846(83)90027-1
   BOZARTH MA, 1985, JAMA-J AM MED ASSOC, V254, P81, DOI 10.1001/jama.254.1.81
   BOZARTH MA, 1994, ADDICTION, V89, P1425, DOI 10.1111/j.1360-0443.1994.tb03739.x
   BOZARTH MA, 1984, SCIENCE, V224, P516, DOI 10.1126/science.6324347
   Brady J V, 1983, NIDA Res Monogr, V43, P99
   BRADY JV, 1984, NIDA RES MONORAPH SE, V52, P153
   Brauer LH, 1995, EXP CLIN PSYCHOPHARM, V3, P371, DOI 10.1037/1064-1297.3.4.371
   BURGLASS ME, 1984, ADV ALCOHOL SUBSTANC, V3, P19
   CAPPELL H, 1987, PSYCHOPHARMACOLOGY, V91, P154
   CAPPELL H, 1983, PATHOGENESIS ALCOHOL, P359
   Carroll ME, 1996, EXP CLIN PSYCHOPHARM, V4, P11
   CHAPMAN CR, 1989, CANCER, V63, P1636
   Childress A R, 1988, NIDA Res Monogr, V84, P25
   CHILDRESS AR, 1985, NATIONAL I DRUG ABUS, V55, P202
   Chutuape MAD, 1994, EXP CLIN PSYCHOPHARM, V2, P310, DOI 10.1037/1064-1297.2.4.310
   CIRAULO DA, 1988, J CLIN PSYCHIAT, V49, P333
   COHEN AJ, 1983, DRUG ALCOHOL DEPEN, V12, P167, DOI 10.1016/0376-8716(83)90041-8
   COHEN S, 1984, PSYCHIAT ANN, V14, P747, DOI 10.3928/0048-5713-19841001-10
   COOPER SJ, 1983, NEUROPHARMACOLOGY, V22, P535, DOI 10.1016/0028-3908(83)90174-0
   CORRIGALL WA, 1988, PHARMACOL BIOCHEM BE, V30, P443, DOI 10.1016/0091-3057(88)90478-9
   CORRIGALL WA, 1992, PSYCHOPHARMACOLOGY, V107, P285, DOI 10.1007/BF02245149
   COTTLER LB, 1995, DRUG ALCOHOL DEPEN, V38, P59, DOI 10.1016/0376-8716(94)01091-X
   CROWELL CR, 1981, PSYCHOPHARMACOLOGY, V73, P51, DOI 10.1007/BF00431101
   CUMMINGS C, 1980, ADDICT BEHAV, P291
   CUSHMAN P, 1985, ALCOHOL CLIN EXP RES, V9, P103, DOI 10.1111/j.1530-0277.1985.tb05527.x
   DAR M S, 1984, Alcohol, V1, P453, DOI 10.1016/0741-8329(84)90021-1
   Deitrich RA, 1996, PHARM ALCOHOL ALCOHO, P431
   DENEAU G, 1969, PSYCHOPHARMACOLOGIA, V16, P30, DOI 10.1007/BF00405254
   deWit H, 1983, NIDA Res Monogr, V43, P251
   DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175
   deWit H, 1996, EXP CLIN PSYCHOPHARM, V4, P5, DOI 10.1037/1064-1297.4.1.5
   DEWIT H, 1984, DRUG ALCOHOL DEPEN, V13, P31, DOI 10.1016/0376-8716(84)90030-9
   DEWITTE P, 1984, NEUROPSYCHOBIOLOGY, V12, P73, DOI 10.1159/000118113
   DIANA M, 1993, P NATL ACAD SCI USA, V90, P7966, DOI 10.1073/pnas.90.17.7966
   DICHIARA G, 1995, DRUG ALCOHOL DEPEN, V38, P95, DOI 10.1016/0376-8716(95)01118-I
   EIKELBOOM R, 1982, PSYCHOL REV, V89, P507, DOI 10.1037/0033-295X.89.5.507
   ERIKSEN L, 1984, INT J ADDICT, V19, P287, DOI 10.3109/10826088409057182
   EWING JA, 1983, ALCOHOL CLIN EXP RES, V7, P271, DOI 10.1111/j.1530-0277.1983.tb05458.x
   FALK JL, 1983, PHARMACOL BIOCHEM BE, V19, P385, DOI 10.1016/0091-3057(83)90106-5
   FALK JL, 1972, SCIENCE, V177, P811, DOI 10.1126/science.177.4051.811
   FUDALA PJ, 1985, PHARMACOL BIOCHEM BE, V22, P237, DOI 10.1016/0091-3057(85)90384-3
   GABE J, 1994, ADDICTION, V89, P1497, DOI 10.1111/j.1360-0443.1994.tb03749.x
   GESSA GL, 1985, BRAIN RES, V348, P201, DOI 10.1016/0006-8993(85)90381-6
   GINZBURG HM, 1983, NIDA TREATMENT RES M, P174
   GOEDERS NE, 1985, NIDA RES MONOGR, V55, P132
   GOLD MS, 1995, PSYCHIAT ANN, V25, P146, DOI 10.3928/0048-5713-19950301-06
   GOLD MS, 1984, PSYCHIAT ANN, V14, P714, DOI 10.3928/0048-5713-19841001-06
   GOLD MS, 1983, ADV SUBSTANC ABUSE, V3, P157
   Goleman D., 1996, NY TIMES, pB5
   GOLEMAN D, 1996, NY TIMES        0813, pB8
   GOSSOP M, 1995, ADDICTION, V90, P607, DOI 10.1046/j.1360-0443.1995.9056072.x
   GOSSOP M, 1988, DRUG ALCOHOL DEPEN, V21, P253, DOI 10.1016/0376-8716(88)90078-6
   GOSSOP M, 1984, DRUG ALCOHOL DEPEN, V13, P191, DOI 10.1016/0376-8716(84)90058-9
   GRIFFITHS RR, 1985, NEUROSCI BIOBEHAV R, V9, P133, DOI 10.1016/0149-7634(85)90039-9
   GRIFFITHS RR, 1978, NIDA RES MONOGR, V20, P24
   Grinspoon L., 1985, COCAINE DRUG ITS SOC
   HARRIS GC, 1994, NATURE, V371, P155, DOI 10.1038/371155a0
   HAWLEY RJ, 1985, ARCH GEN PSYCHIAT, V42, P1056
   HERNING RI, 1983, PSYCHOPHYSIOLOGY, V20, P507, DOI 10.1111/j.1469-8986.1983.tb03004.x
   HUGHES JR, 1994, ADDICTION, V89, P1461, DOI 10.1111/j.1360-0443.1994.tb03744.x
   HUNT DE, 1984, DRUG ALCOHOL DEPEN, V13, P375, DOI 10.1016/0376-8716(84)90005-X
   INSEL TR, 1992, ARCH GEN PSYCHIAT, V49, P739
   JAFFE JH, 1989, PSYCHOPHARMACOLOGY, V97, P59, DOI 10.1007/BF00443414
   JAFFE JH, 1995, PSYCHIAT ANN, V25, P369, DOI 10.3928/0048-5713-19950601-09
   JAFFE JH, 1992, RES P ARNMD, V70, P1
   JARVIS MJ, 1994, ADDICTION, V89, P1371, DOI 10.1111/j.1360-0443.1994.tb03732.x
   JASINSKI DR, 1985, ARCH GEN PSYCHIAT, V42, P1063
   JELLINEK EM, 1952, Q J STUD ALCOHOL, V13, P673, DOI 10.15288/QJSA.1952.13.673
   JELLINEK EM, 1960, DIS CONCEPT ALCOHOLI
   JOHNS A, 1994, ADDICTION, V89, P1551, DOI 10.1111/j.1360-0443.1994.tb03757.x
   JONES RT, 1992, RES P ARNMD, V70, P109
   KANOF PD, 1992, J PHARMACOL EXP THER, V260, P355
   Kaplan R F, 1983, NIDA Res Monogr, V43, P273
   KAPLAN RF, 1983, BRIT J ADDICT, V78, P259
   KAUFMAN JF, 1984, ADV ALCOHOL SUBSTANC, V3, P7
   KHANTZIAN EJ, 1984, PSYCHIAT ANN, V14, P753, DOI 10.3928/0048-5713-19841001-11
   KING MB, 1994, ADDICTION, V89, P1367, DOI 10.1111/j.1360-0443.1994.tb03731.x
   Kirsch MM, 1986, DESIGNER DRUGS
   KLEBER HD, 1985, ARCH GEN PSYCHIAT, V42, P391
   KLEBER HD, 1995, CLIN NEUROPHARMACOL, V18, pS96
   KLEBER HD, 1984, J CLIN PSYCHIAT, V45, P18
   KLEBER HD, 1983, NIDA TREATMENT RES M, P212
   KNOBLICH G, 1992, BIOL PSYCHIAT, V32, P96, DOI 10.1016/0006-3223(92)90146-Q
   KOOB GF, 1992, RES P ARNMD, V70, P79
   KORNETSKY C, 1992, RES P ARNMD, V70, P59
   KOZLOWSKI LT, 1987, BRIT J ADDICT, V82, P31
   KOZLOWSKI LT, 1989, JAMA-J AM MED ASSOC, V261, P898
   KREEK MJ, 1992, RES P ARNMD, V70, P205
   LADER M, 1994, ADDICTION, V89, P1413, DOI 10.1111/j.1360-0443.1994.tb03737.x
   LAGO JA, 1994, ADDICTION, V89, P1477, DOI 10.1111/j.1360-0443.1994.tb03746.x
   LAMB RJ, 1991, J PHARMACOL EXP THER, V259, P1165
   LE AD, 1979, SCIENCE, V206, P1109, DOI 10.1126/science.493999
   le Magnen J, 1984, Alcohol, V1, P359, DOI 10.1016/0741-8329(84)90003-X
   Le Magnen J, 1984, Alcohol, V1, P269, DOI 10.1016/0741-8329(84)90048-X
   LEWIS JW, 1985, DRUG ALCOHOL DEPEN, V14, P363, DOI 10.1016/0376-8716(85)90067-5
   LITMAN GK, 1983, BRIT J ADDICT, V78, P381
   LITTLETON J, 1994, ADDICTION, V89, P1397, DOI 10.1111/j.1360-0443.1994.tb03736.x
   LUDWIG AM, 1974, Q J STUD ALCOHOL, V35, P108
   LUDWIG AM, 1974, Q J STUD ALCOHOL, V35, P899
   LUDWIG AM, 1974, ARCH GEN PSYCHIAT, V30, P539
   Lukas S E, 1983, NIDA Res Monogr, V43, P178
   LYVERS M, 1988, PSYCHOPHYSIOLOGY, V25, P408, DOI 10.1111/j.1469-8986.1988.tb01878.x
   LYVERS M, 1993, PSYCHOPHYSIOLOGY, V30, P231, DOI 10.1111/j.1469-8986.1993.tb03348.x
   Lyvers M, 1994, EXP CLIN PSYCHOPHARM, V2, P283, DOI 10.1037/1064-1297.2.3.283
   MALTZMAN I, 1994, J PSYCHOACTIVE DRUGS, V26, P13, DOI 10.1080/02791072.1994.10472598
   Maltzman I., 1979, ORIENTING REFLEX HUM, P323
   Maltzman I, 1996, PHARM ALCOHOL ALCOHO, P248
   MANHEM P, 1985, ALCOHOL CLIN EXP RES, V9, P238, DOI 10.1111/j.1530-0277.1985.tb05743.x
   MANSFIELD JG, 1980, J COMP PHYSIOL PSYCH, V94, P962, DOI 10.1037/h0077824
   MARFAINGJALLAT P, 1982, PHARMACOL BIOCHEM BE, V17, P609, DOI 10.1016/0091-3057(82)90331-8
   MARFAINGJALLAT P, 1983, PHARMACOL BIOCHEM BE, V18, P537, DOI 10.1016/0091-3057(83)90232-0
   MARFAINGJALLAT P, 1985, PHARMACOL BIOCHEM BE, V22, P19, DOI 10.1016/0091-3057(85)90479-4
   MARLATT GA, 1973, J ABNORM PSYCHOL, V81, P233, DOI 10.1037/h0034532
   MARTIN SD, 1989, BIOL PSYCHIAT, V26, P356, DOI 10.1016/0006-3223(89)90051-6
   MCAULIFFE WE, 1982, INT J ADDICT, V17, P19, DOI 10.3109/10826088209054607
   MCAULIFFE WE, 1974, AM J SOCIOL, V79, P795, DOI 10.1086/225628
   MCAULIFFE WE, 1985, J DRUG ISSUES, V15, P203, DOI 10.1177/002204268501500204
   MCMILLAN DE, 1976, J PHARMACOL EXP THER, V196, P269
   Mello N K, 1984, NIDA Res Monogr, V49, P172
   MELLO NK, 1983, SCIENCE, V221, P677, DOI 10.1126/science.6867739
   MELLO NK, 1985, DRUG ALCOHOL DEPEN, V14, P283, DOI 10.1016/0376-8716(85)90062-6
   MELLO NK, 1972, PSYCHOSOM MED, V34, P139, DOI 10.1097/00006842-197203000-00007
   MELLO NK, 1983, PATHOGENESIS ALCOHOL, P133
   MELLO NK, 1983, ADV SUBSTANC ABUSE, V3, P271
   Meyer R. E., 1979, HEROIN STIMULUS IMPL
   Miller N S, 1994, Ann Clin Psychiatry, V6, P99, DOI 10.3109/10401239409148988
   MILLER NS, 1995, PSYCHIAT ANN, V25, P166, DOI 10.3928/0048-5713-19950301-10
   MILLER NS, 1995, PSYCHIAT ANN, V25, P149, DOI 10.3928/0048-5713-19950301-07
   MILLER NS, 1995, J ADDICT DIS, V14, P23, DOI 10.1300/J069v14n01_04
   MODELL JG, 1993, ALCOHOL CLIN EXP RES, V17, P234, DOI 10.1111/j.1530-0277.1993.tb00755.x
   MODELL JG, 1995, J NEUROPSYCH CLIN N, V7, P15
   MULE SJ, 1984, PSYCHIAT ANN, V14, P724, DOI 10.3928/0048-5713-19841001-07
   NEWLIN DB, 1990, PSYCHOL BULL, V108, P383, DOI 10.1037/0033-2909.108.3.383
   NUMAN R, 1984, PHARMACOL BIOCHEM BE, V21, P609, DOI 10.1016/S0091-3057(84)80046-5
   O'Brien C P, 1984, NIDA Res Monogr, V49, P35
   OBRIEN CP, 1992, RES P ARNMD, V70, P157
   OBRIEN CP, 1984, J CLIN PSYCHIAT, V45, P53
   OBRIEN CP, 1994, ADDICTION, V89, P1565, DOI 10.1111/j.1360-0443.1994.tb03759.x
   Orford J., 1985, EXCESSIVE APPETITES
   PACHTER IJ, 1985, DRUG ALCOHOL DEPEN, V14, P325, DOI 10.1016/0376-8716(85)90065-1
   PARRAN TV, 1994, AM J ADDICTION, V3, P306
   PORTER J, 1980, NEW ENGL J MED, V302, P123
   POWELL J, 1992, BRIT J ADDICT, V87, P1133
   Rawson R A, 1984, Adv Alcohol Subst Abuse, V3, P41
   Rawson R A, 1984, NIDA Res Monogr, V49, P289
   RAY O, 1993, DRUGS SOC HUMAN BEHA
   REID LD, 1985, PHARMACOL BIOCHEM BE, V22, P483, DOI 10.1016/0091-3057(85)90051-6
   ROACHE JD, 1995, PSYCHIAT ANN, V25, P153, DOI 10.3928/0048-5713-19950301-08
   ROBERTS DCS, 1982, PHARMACOL BIOCHEM BE, V17, P901, DOI 10.1016/0091-3057(82)90469-5
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   ROSENBERG HC, 1985, NEUROSCI BIOBEHAV R, V9, P123, DOI 10.1016/0149-7634(85)90038-7
   ROUNSAVILLE BJ, 1985, J NERV MENT DIS, V173, P103, DOI 10.1097/00005053-198502000-00007
   ROUNSAVILLE BJ, 1995, DRUG ALCOHOL DEPEN, V38, P79, DOI 10.1016/0376-8716(94)01094-2
   Sarkar M, 1995, EXP CLIN PSYCHOPHARM, V3, P118, DOI 10.1037/1064-1297.3.2.118
   Schuster CR, 1995, EXP CLIN PSYCHOPHARM, V3, P424, DOI 10.1037/1064-1297.3.4.424
   SCHUSTER CR, 1968, INT J ADDICT, V3, P223, DOI 10.3109/10826086809042897
   SCHUSTER CR, 1968, PSYCHOPHARMACOLOGY R, P811
   SELF DW, 1995, ANNU REV NEUROSCI, V18, P463, DOI 10.1146/annurev.ne.18.030195.002335
   SELLMAN JD, 1995, DRUG ALCOHOL REV, V14, P109, DOI 10.1080/09595239500185111
   SIEGEL RK, 1984, PSYCHIAT ANN, V14, P728, DOI 10.3928/0048-5713-19841001-08
   SIEGEL RK, 1982, J PSYCHOACTIVE DRUGS, V14, P271
   SIEGEL S, 1977, J EXP PSYCHOL ANIM B, V3, P1, DOI 10.1037/0097-7403.3.1.1
   SLIFER BL, 1985, PHARMACOL BIOCHEM BE, V22, P61, DOI 10.1016/0091-3057(85)90487-3
   SPOTTS JV, 1984, INT J ADDICT, V19, P119, DOI 10.3109/10826088409057173
   STEWART J, 1983, PROG NEURO-PSYCHOPH, V7, P591, DOI 10.1016/0278-5846(83)90030-1
   STEWART J, 1992, PSYCHOPHARMACOLOGY, V108, P79, DOI 10.1007/BF02245289
   STEWART J, 1984, PSYCHOL REV, V91, P251, DOI 10.1037/0033-295X.91.2.251
   STEWART J, 1984, PHARMACOL BIOCHEM BE, V20, P917, DOI 10.1016/0091-3057(84)90017-0
   STOCKWELL T, 1994, ADDICTION, V89, P1447, DOI 10.1111/j.1360-0443.1994.tb03742.x
   STOCKWELL TR, 1982, BEHAV RES THER, V20, P513, DOI 10.1016/0005-7967(82)90072-9
   STRAIN EC, 1994, PSYCHOPHARMACOLOGY, V116, P401, DOI 10.1007/BF02247469
   SUZUKI T, 1995, LIFE SCI, V57, pPL247, DOI 10.1016/0024-3205(95)02139-A
   Tang M, 1984, Alcohol, V1, P55, DOI 10.1016/0741-8329(84)90037-5
   TENNANT FS, 1983, DRUG ALCOHOL DEPEN, V11, P111, DOI 10.1016/0376-8716(83)90106-0
   TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147
   *US DEP HHS, 1988, DHHS PUBL
   VAILLANT GE, 1992, RES P ARNMD, V70, P41
   VANDYKE C, 1982, SCI AM, V246, P128, DOI 10.1038/scientificamerican0382-128
   VOLICER L, 1984, DRUG ALCOHOL DEPEN, V13, P215, DOI 10.1016/0376-8716(84)90062-0
   VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876
   VOLPICELLI JR, 1994, ALCOHOL HEALTH RES W, V18, P272
   WADE TC, 1995, ALCOHOLISM TREATMENT, V12, P113
   WALDORF D, 1983, J DRUG ISSUES, V13, P237, DOI 10.1177/002204268301300205
   WALSH SL, 1995, PSYCHOPHARMACOLOGY, V119, P268, DOI 10.1007/BF02246290
   Washton A M, 1984, NIDA Res Monogr, V49, P247
   WASHTON AM, 1984, PSYCHIAT ANN, V14, P733, DOI 10.3928/0048-5713-19841001-09
   WEISS RD, 1995, AM J DRUG ALCOHOL AB, V21, P289, DOI 10.3109/00952999509002698
   WEST R, 1994, ADDICTION, V89, P1483, DOI 10.1111/j.1360-0443.1994.tb03747.x
   *WHO, 1993, INT CLASS DIS REL HL
   WIKLER A, 1977, J NERV MENT DIS, V165, P29, DOI 10.1097/00005053-197707000-00002
   Wikler A., 1980, OPIOID DEPENDENCE
   WINGARD JA, 1980, ACTA PSYCHOL, V46, P153, DOI 10.1016/0001-6918(80)90007-4
   WINGER G, 1988, DRUG ALCOHOL DEPEN, V22, P235, DOI 10.1016/0376-8716(88)90023-3
   WINGER G, 1983, PATHOGENESIS ALCOHOL, P107
   WINGER GD, 1973, ANN NY ACAD SCI, V215, P162, DOI 10.1111/j.1749-6632.1973.tb28263.x
   WISE RA, 1995, PSYCHOPHARMACOLOGY, V117, P130, DOI 10.1007/BF02245178
   WISE RA, 1989, ANNU REV PSYCHOL, V40, P191, DOI 10.1146/annurev.ps.40.020189.001203
   WISE RA, 1993, BEHAV BRAIN RES, V55, P195, DOI 10.1016/0166-4328(93)90115-7
   WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469
   WISEMAN EJ, 1995, AM J ADDICTION, V4, P261, DOI 10.3109/10550499509038111
   WITHERS NW, 1995, J CLIN PSYCHOPHARM, V15, P63, DOI 10.1097/00004714-199502000-00010
   WOLFFGRAMM J, 1995, BEHAV BRAIN RES, V70, P77, DOI 10.1016/0166-4328(95)00131-C
   WOODS JH, 1985, DRUG ALCOHOL DEPEN, V14, P233, DOI 10.1016/0376-8716(85)90059-6
   WOODS JH, 1983, J PSYCHOACTIVE DRUGS, V15, P61, DOI 10.1080/02791072.1983.10472124
   YOUNG AM, 1980, PSYCHOPHARMACOLOGY, V70, P263, DOI 10.1007/BF00427883
NR 217
TC 30
Z9 32
U1 1
U2 21
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1064-1297
EI 1936-2293
J9 EXP CLIN PSYCHOPHARM
JI Exp. Clin. Psychopharmacol.
PD FEB
PY 1998
VL 6
IS 1
BP 107
EP 125
PG 19
WC Psychology, Biological; Psychology, Clinical; Pharmacology & Pharmacy;
   Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology; Pharmacology & Pharmacy; Psychiatry
GA ZC056
UT WOS:000072535100011
PM 9526151
DA 2023-06-23
ER

PT J
AU Tasic, JK
   Sapic, R
   Valkanou, M
AF Tasic, J. Knezevic
   Sapic, R.
   Valkanou, M.
TI WHERE IS "I" IN ADDICTION? (A LINK BETWEEN PERSONALITY DISORDERS AND
   DRUG ADDICTION)
SO EUROPEAN PSYCHIATRY
LA English
DT Meeting Abstract
C1 [Tasic, J. Knezevic; Sapic, R.; Valkanou, M.] Lorijen Hosp, Clin Addict & Other Psychiat Disorders, Belgrade, Serbia.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0924-9338
J9 EUR PSYCHIAT
JI Eur. Psychiat.
PY 2011
VL 26
SU 1
MA P01-118
PG 1
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA V27VS
UT WOS:000208641300119
DA 2023-06-23
ER

PT J
AU Vicol, MC
   Bulgaru-Iliescu, D
   Astarastoae, V
AF Vicol, Mihaela-Catalina
   Bulgaru-Iliescu, Diana
   Astarastoae, Vasile
TI INFORMED CONSENT IN THE TREATMENT OF DRUG-ADDICTION
SO REVISTA ROMANA DE BIOETICA
LA English
DT Article
DE informed consent; drug addicts; competence; volunteer participation
ID BRAIN
AB As a general rule of the medical therapy, no competent patient can be treated without being informed in prior on the diagnosis, on the development stage of disease with/without treatment, on complications, therapeutic alternatives, on the prognostic and before acquiring the patient's consent. Nevertheless, in the case of drug-addicted patients, this aspect faces several issues. Could drug-addicts be considered fully competent in order to authorize the commencement of a treatment? Is the subscription to a specialized drug-addiction treatment program filly voluntarily? Are coercive therapy methods ethical? This article aims at approaching the complexity of informed consent in drug-addiction treatment, starting from these dilemmas, by the presentation of a research made on drug addicts within a specific drug-addiction therapy program.
C1 [Vicol, Mihaela-Catalina; Astarastoae, Vasile] UMF Gr T Popa Iasi, Iasi, Romania.
   [Bulgaru-Iliescu, Diana] Inst Legal Med, Iasi, Romania.
C3 Grigore T Popa University of Medicine & Pharmacy
RP Vicol, MC (通讯作者)，UMF Gr T Popa Iasi, Iasi, Romania.
EM mihavicol@yahoo.com; bulgarudiana@yahoo.com
RI Bulgaru Iliescu, Diana/B-8626-2017
OI Bulgaru Iliescu, Diana/0000-0002-0847-8055
CR APPELBAUM PS, 1995, LAW HUMAN BEHAV, V19, P105, DOI 10.1007/BF01499321
   BISBING SB, 2004, LEGAL MED, P37
   Charland Louis C., 2002, American Journal of Bioethics, V2, P37, DOI 10.1162/152651602317533686
   CHEIN I, 1964, BASIC BOOKS
   Elliott C, 1991, J Clin Ethics, V2, P167
   Elliott C., 1996, RULES INSANITY MORAL
   Garner B. A., 1999, BLACKS LAW DICT
   HOWE EG, 1996, J CLIN ETHICS, V7
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   *NAT BIOETH ADV CO, 1998, REP REC NAT BIOETH A, V1
   Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58
   Post S.G., 2004, ENCY BIOETHICS
   Powledge TM, 1999, BIOSCIENCE, V49, P513, DOI 10.2307/1313471
   Roberts Laura Weiss, 2002, American Journal of Bioethics, V2, P58
   ROBERTS LW, 2002, AM J PSYCHIAT
   VICOL MC, REV ROMANA IN PRESS
   VICOL MC, 2008, RRB, V6
NR 18
TC 1
Z9 1
U1 0
U2 3
PU COLEGIUL MEDICILOR IASI
PI IASI
PA STR CAROL I, NR. 3-5, IASI, 00000, ROMANIA
SN 1583-5170
J9 REV ROM BIOET
JI Rev. Rom. Bioet.
PD JUL-SEP
PY 2009
VL 7
IS 3
BP 165
EP 173
PG 9
WC Ethics; Medical Ethics; Social Sciences, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Social Sciences - Other Topics; Medical Ethics; Biomedical Social
   Sciences
GA 515KA
UT WOS:000271467400011
DA 2023-06-23
ER

PT J
AU Fan, C
   Cheng, Y
   Gou, HX
   Liu, C
   Deng, SL
   Liu, CL
   Chen, XW
   Bu, JJ
   Zhang, XC
AF Fan, Chuan
   Cheng, Yan
   Gou, Huixing
   Liu, Chang
   Deng, Shengliang
   Liu, Chialun
   Chen, Xianwen
   Bu, Junjie
   Zhang, Xiaochu
TI Neuroimaging and intervening in memory reconsolidation of human drug
   addiction
SO SCIENCE CHINA-INFORMATION SCIENCES
LA English
DT Review
DE memory reconsolidation; human neuroimaging; drug addiction;
   retrieval-extinction
ID VENTROMEDIAL PREFRONTAL CORTEX; POSTTRAUMATIC-STRESS-DISORDER;
   NONINVASIVE BRAIN-STIMULATION; FEAR MEMORY; MODULATING RECONSOLIDATION;
   INCENTIVE-SENSITIZATION; EMOTIONAL MEMORIES; PROTEIN-SYNTHESIS; EPISODIC
   MEMORY; HUMAN AMYGDALA
AB Reconsolidation refers to memory reprocessing when consolidated memory is being recalled and restored. Importantly, as memory is being recalled, it could further modify past memories. Memory reconsolidation has been identified as a critical role in various types of mental disorders, in particular drug addiction. In this review, we first review earlier studies related to reconsolidation. Secondly, we characterize memory reconsolidation processing in human brain via neuroimaging studies. Then we focus on the role of reconsolidation and reconsolidation-based interventions in drug addiction. Finally, we highlight the potentials of combining reconsolidation-based interventions and neuroimaging techniques as a therapeutic tool in drug addiction.
C1 [Fan, Chuan] Anhui Med Univ, Affiliated Hosp 1, Dept Psychiat, Hefei 230022, Peoples R China.
   [Fan, Chuan; Cheng, Yan; Gou, Huixing; Liu, Chang; Deng, Shengliang; Liu, Chialun; Zhang, Xiaochu] Univ Sci & Technol China, Sch Life Sci, Div Life Sci & Med, Hefei 230026, Peoples R China.
   [Chen, Xianwen] Anhui Med Univ, Affiliated Hosp 1, Dept Neurol, Hefei 230022, Peoples R China.
   [Bu, Junjie] Anhui Med Univ, Sch Biomed Engn, Hefei 230032, Peoples R China.
   [Zhang, Xiaochu] Univ Sci & Technol China, CAS Key Lab Brain Funct & Dis, Hefei 230026, Peoples R China.
C3 Anhui Medical University; Chinese Academy of Sciences; University of
   Science & Technology of China, CAS; Anhui Medical University; Anhui
   Medical University; Chinese Academy of Sciences; University of Science &
   Technology of China, CAS
RP Zhang, XC (通讯作者)，Univ Sci & Technol China, Sch Life Sci, Div Life Sci & Med, Hefei 230026, Peoples R China.; Bu, JJ (通讯作者)，Anhui Med Univ, Sch Biomed Engn, Hefei 230032, Peoples R China.; Zhang, XC (通讯作者)，Univ Sci & Technol China, CAS Key Lab Brain Funct & Dis, Hefei 230026, Peoples R China.
EM bujunjie@ahmu.edu.cn; zxcustc@ustc.edu.cn
RI Zhang, Xiaochu/AEW-0582-2022; Zhang, Xiaochu/AAG-8768-2022; Zhang,
   Xiaochu/O-9592-2014
OI Gou, Huixing/0000-0002-2938-519X; Zhang, Xiaochu/0000-0002-7541-0130
FU National Key Basic Research Program [2016YFA0400900, 2018YFC0831101];
   National Natural Science Foundation of China [71942003, 31771221,
   61773360, 71874170]; School Foundation of Anhui Medical University
   [2019xkj016, XJ201907]; National Science Foundation for Young Scientists
   of China [31900766]; Major Project of Philosophy and Social Science
   Research, Ministry of Education of China [19JZD010]; Fundamental
   Research Funds for the Central Universities of China
FX This work was supported by National Key Basic Research Program (Grant
   Nos. 2016YFA0400900, 2018YFC0831101), National Natural Science
   Foundation of China (Grant Nos. 71942003, 31771221, 61773360, 71874170),
   School Foundation of Anhui Medical University (Grant Nos. 2019xkj016,
   XJ201907), National Science Foundation for Young Scientists of China
   (Grant No. 31900766), Major Project of Philosophy and Social Science
   Research, Ministry of Education of China (Grant No. 19JZD010),
   Fundamental Research Funds for the Central Universities of China. A
   portion of the numerical calculations in this study were performed with
   the supercomputing system at the Supercomputing Centre of USTC.
CR Addis DR, 2007, NEUROPSYCHOLOGIA, V45, P1363, DOI 10.1016/j.neuropsychologia.2006.10.016
   Agren T, 2012, SCIENCE, V337, P1550, DOI 10.1126/science.1223006
   Alaghband Y, 2014, NEUROBIOL LEARN MEM, V116, P79, DOI 10.1016/j.nlm.2014.09.001
   Bjorkstrand J, 2017, BEHAV BRAIN RES, V324, P125, DOI 10.1016/j.bbr.2017.02.016
   Bouton ME, 2004, LEARN MEMORY, V11, P485, DOI 10.1101/lm.78804
   Cadet JL, 2014, ACTA NEUROPATHOL, V127, P91, DOI 10.1007/s00401-013-1221-7
   Censor N, 2014, CORTEX, V58, P281, DOI 10.1016/j.cortex.2013.05.013
   Censor N, 2010, CURR BIOL, V20, P1545, DOI 10.1016/j.cub.2010.07.047
   Cheng DT, 2007, LEARN MEMORY, V14, P485, DOI 10.1101/lm.632007
   Chiu CQ, 2010, J NEUROSCI, V30, P7236, DOI 10.1523/JNEUROSCI.0736-10.2010
   Costanzi M, 2011, LEARN MEMORY, V18, P508, DOI 10.1101/lm.2175811
   Dayan E, 2013, NAT NEUROSCI, V16, P838, DOI 10.1038/nn.3422
   Debiec J, 2002, NEURON, V36, P527, DOI 10.1016/S0896-6273(02)01001-2
   Drevets WC, 2001, BIOL PSYCHIAT, V49, P81, DOI 10.1016/S0006-3223(00)01038-6
   Dudai Y, 2015, NEURON, V88, P20, DOI 10.1016/j.neuron.2015.09.004
   Elsey JWB, 2018, PSYCHOL BULL, V144, P797, DOI 10.1037/bul0000152
   Fan HY, 2010, BEHAV BRAIN RES, V208, P522, DOI 10.1016/j.bbr.2009.12.034
   Feng P, 2016, SOC COGN AFFECT NEUR, V11, P991, DOI 10.1093/scan/nsw031
   Feng P, 2015, SCI REP-UK, V5, DOI 10.1038/srep16701
   Finnie PSB, 2012, NEUROSCI BIOBEHAV R, V36, P1667, DOI 10.1016/j.neubiorev.2012.03.008
   Forcato C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151381
   Gagnon G, 2011, NEUROSCI LETT, V488, P138, DOI 10.1016/j.neulet.2010.11.016
   Gagnon G, 2010, BRAIN RES, V1344, P148, DOI 10.1016/j.brainres.2010.04.041
   Germeroth LJ, 2017, JAMA PSYCHIAT, V74, P214, DOI 10.1001/jamapsychiatry.2016.3148
   Goense J, 2012, NEURON, V76, P629, DOI 10.1016/j.neuron.2012.09.019
   Grossman N, 2017, CELL, V169, P1029, DOI 10.1016/j.cell.2017.05.024
   Han JH, 2009, SCIENCE, V323, P1492, DOI 10.1126/science.1164139
   Hellemans KGC, 2006, J NEUROSCI, V26, P12694, DOI 10.1523/JNEUROSCI.3101-06.2006
   Hu JC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27252-0
   Ishii D, 2012, NEUROSCI LETT, V523, P76, DOI 10.1016/j.neulet.2012.06.048
   Isserles M, 2013, BRAIN STIMUL, V6, P377, DOI 10.1016/j.brs.2012.07.008
   Javadi AH, 2013, BRAIN STIMUL, V6, P668, DOI 10.1016/j.brs.2012.10.007
   Javadi AH, 2012, BRAIN STIMUL, V5, P231, DOI 10.1016/j.brs.2011.06.007
   Jones CE, 2013, LEARN MEMORY, V20, P674, DOI 10.1101/lm.031740.113
   Kandel ER, 2014, CELL, V157, P163, DOI 10.1016/j.cell.2014.03.001
   Kaneta T, 2020, JPN J RADIOL, V38, P343, DOI 10.1007/s11604-019-00901-8
   Kenny PJ, 2006, J NEUROSCI, V26, P5894, DOI 10.1523/JNEUROSCI.0740-06.2006
   Khalaf O, 2018, SCIENCE, V360, P1239, DOI 10.1126/science.aas9875
   Kindt M, 2009, NAT NEUROSCI, V12, P256, DOI 10.1038/nn.2271
   Knight DC, 2005, NEUROIMAGE, V26, P1193, DOI 10.1016/j.neuroimage.2005.03.020
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Lee JLC, 2017, TRENDS COGN SCI, V21, P531, DOI 10.1016/j.tics.2017.04.006
   Lewis D J, 1973, J Comp Physiol Psychol, V85, P421, DOI 10.1037/h0035020
   LEWIS DJ, 1972, J COMP PHYSIOL PSYCH, V81, P243, DOI 10.1037/h0033524
   Lv XF, 2015, INT J NEUROPSYCHOPH, V18, DOI 10.1093/ijnp/pyv030
   Mahabir M, 2015, J ANXIETY DISORD, V36, P127, DOI 10.1016/j.janxdis.2015.10.004
   Manenti R, 2012, BRAIN STIMUL, V5, P103, DOI 10.1016/j.brs.2012.03.004
   Merlo E, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/687175
   Milad MR, 2007, BIOL PSYCHIAT, V62, P446, DOI 10.1016/j.biopsych.2006.10.011
   Milton AL, 2010, EUR J NEUROSCI, V31, P2308, DOI 10.1111/j.1460-9568.2010.07249.x
   MISANIN JR, 1968, SCIENCE, V160, P554, DOI 10.1126/science.160.3827.554
   Monfils MH, 2018, LANCET PSYCHIAT, V5, P1032, DOI 10.1016/S2215-0366(18)30270-0
   Monfils MH, 2009, SCIENCE, V324, P951, DOI 10.1126/science.1167975
   Nader K, 2000, NATURE, V406, P722, DOI 10.1038/35021052
   Nader K, 2009, NAT REV NEUROSCI, V10, P224, DOI 10.1038/nrn2590
   OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951
   Pan YF, 2019, BRAIN TOPOGR, V32, P998, DOI 10.1007/s10548-019-00740-w
   Pare D, 2012, CURR OPIN NEUROBIOL, V22, P717, DOI 10.1016/j.conb.2012.02.014
   Pavlov IP, 2010, ANN NEUROSCI, V17, P136, DOI 10.5214/ans.0972-7531.1017309
   Przybyslawski J, 1999, J NEUROSCI, V19, P6623
   Richardson MP, 2004, NAT NEUROSCI, V7, P278, DOI 10.1038/nn1190
   Robinson TE, 2001, ADDICTION, V96, P103, DOI 10.1046/j.1360-0443.2001.9611038.x
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   RODRIGUEZ WA, 1993, BEHAV BRAIN RES, V59, P125, DOI 10.1016/0166-4328(93)90158-M
   Rose JK, 2006, J NEUROSCI, V26, P11582, DOI 10.1523/JNEUROSCI.2049-06.2006
   Sandrini M, 2003, J COGNITIVE NEUROSCI, V15, P855, DOI 10.1162/089892903322370771
   Sandrini M, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.01430
   Sandrini M, 2015, TRENDS COGN SCI, V19, P475, DOI 10.1016/j.tics.2015.06.002
   Sandrini M, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00289
   Sandrini M, 2013, CURR BIOL, V23, P2181, DOI 10.1016/j.cub.2013.08.045
   Schiller D, 2013, P NATL ACAD SCI USA, V110, P20040, DOI 10.1073/pnas.1320322110
   Schiller D, 2010, NATURE, V463, P49, DOI 10.1038/nature08637
   SCHNEIDER AM, 1968, SCIENCE, V159, P219, DOI 10.1126/science.159.3811.219
   Schwabe L, 2014, BIOL PSYCHIAT, V76, P274, DOI 10.1016/j.biopsych.2014.03.008
   Schwabe L, 2012, BIOL PSYCHIAT, V71, P380, DOI 10.1016/j.biopsych.2011.10.028
   Shin LM, 2005, ARCH GEN PSYCHIAT, V62, P273, DOI 10.1001/archpsyc.62.3.273
   Somer E, 2020, J COGNITIVE NEUROSCI, V3, P1
   Song PH, 2020, BRAIN RES BULL, V155, P155, DOI 10.1016/j.brainresbull.2019.12.007
   Sorg BA, 2012, NEUROSCI BIOBEHAV R, V36, P1400, DOI 10.1016/j.neubiorev.2012.02.004
   Sotres-Bayon F, 2010, CURR OPIN NEUROBIOL, V20, P231, DOI 10.1016/j.conb.2010.02.005
   Tronson NC, 2007, NAT REV NEUROSCI, V8, P262, DOI 10.1038/nrn2090
   Visser R. M., 2018, PHILOS T R SOC B, V373, P1742
   Walker MP, 2003, NATURE, V425, P616, DOI 10.1038/nature01930
   Wang WG, 2012, J PHYSIOL-LONDON, V590, P3743, DOI 10.1113/jphysiol.2012.235200
   Wirkner J, 2015, NEUROBIOL LEARN MEM, V119, P63, DOI 10.1016/j.nlm.2015.01.006
   Xue YX, 2012, SCIENCE, V336, P241, DOI 10.1126/science.1215070
NR 86
TC 4
Z9 4
U1 4
U2 32
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 1674-733X
EI 1869-1919
J9 SCI CHINA INFORM SCI
JI Sci. China-Inf. Sci.
PD MAY 29
PY 2020
VL 63
IS 7
AR 170103
DI 10.1007/s11432-019-2847-8
PG 11
WC Computer Science, Information Systems; Engineering, Electrical &
   Electronic
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Computer Science; Engineering
GA LW6LD
UT WOS:000539254800001
DA 2023-06-23
ER

PT J
AU Di Nucci, E
AF Di Nucci, Ezio
TI Addiction, Compulsion, and Agency
SO NEUROETHICS
LA English
DT Article
DE Addiction; Compulsion; Agency; Freedom; Alternative possibilities;
   Causalism
ID FRANKFURT; OMISSIONS; CAUSALISM; REASONS
AB I show that Pickard's argument against the irresistibility of addiction fails because her proposed dilemma, according to which either drug-seeking does not count as action or addiction is resistible, is flawed; and that is the case whether or not one endorses Pickard's controversial definition of action. Briefly, we can easily imagine cases in which drug-seeking meets Pickard's conditions for agency without thereby implying that the addiction was not irresistible, as when the drug addict may take more than one route to go meet her dealer.
C1 Univ Duisburg Essen, Essen, Germany.
C3 University of Duisburg Essen
RP Di Nucci, E (通讯作者)，Univ Duisburg Essen, Essen, Germany.
EM ezio.dinucci@uni-due.de
OI Di Nucci, Ezio/0000-0002-5734-6622
CR Alvarez M., 2010, KINDS REASONS
   Anscombe G.E.M., 1957, INTENTION
   BRATMAN M, 1984, PHILOS REV, V93, P375, DOI 10.2307/2184542
   Bratman M., 1986, INTENTION PLANS PRAC
   Collins AW, 1997, RATIO, V10, P108, DOI 10.1111/1467-9329.00033
   Dancy J., 2000, PRACTICAL REALITY
   DAVIDSON D, 1963, J PHILOS, V60, P685, DOI 10.2307/2023177
   Davidson D., 1973, ESSAYS FREEDOM ACTIO, P137
   DAVIDSON D, 1978, PHILOS HIST ACTION
   Davidson D., 1971, AGENT ACTION REASON
   Di Nucci E, 2008, MIND OUT ACTION
   Di Nucci E., 2013, MINDLESSNESS
   Di Nucci E., 2011, RATIONALITY MARKETS, V2, P179
   Di Nucci E, 2012, INT J PHILOS STUD, V20, P725, DOI 10.1080/09672559.2012.713376
   Di Nucci E, 2011, PHILOS EXPLOR, V14, P117, DOI 10.1080/13869795.2011.544233
   Di Nucci E, 2011, ANALYSIS-UK, V71, P102, DOI 10.1093/analys/anq110
   Di Nucci E, 2010, ETHICAL THEORY MORAL, V13, P207, DOI 10.1007/s10677-009-9188-0
   Di Nucci E, 2009, ANALYSIS, V69, P69, DOI 10.1093/analys/ann011
   Dreyfus H. L., 1988, AI SOC, V2, P99, DOI [10.1007/bf01891374, DOI 10.1007/BF01891374]
   Fischer J. M., 1994, METAPHYSICS FREE WIL
   FRANKFURT HG, 1969, J PHILOS, V66, P829, DOI 10.2307/2023833
   FRANKFURT HG, 1978, AM PHILOS QUART, V15, P157
   Goldie P, 2000, MIND, V109, P25, DOI 10.1093/mind/109.433.25
   HAMPSHIRE S, 1959, THOUGHT ACTION
   HURSTHOUSE R, 1991, J PHILOS, V88, P57, DOI 10.2307/2026906
   MELDEN AI, 1961, FREE ACTION
   MELE AR, 1994, NOUS, V28, P39, DOI 10.2307/2215919
   Pickard Hanna, 2012, AJOB Neurosci, V3, P40
   Pollard B, 2006, AM PHILOS QUART, V43, P57
   Pollard B., 2003, ETHICAL THEORY MORAL, V6, P411, DOI [https://doi.org/10.1023/B:ETTA.0000004561.34480.d4, DOI 10.1023/B:ETTA.0000004561.34480.D4]
   Sartorio C, 2005, NOUS, V39, P460, DOI 10.1111/j.0029-4624.2005.00509.x
   Sartorio C, 2009, NOUS, V43, P513, DOI 10.1111/j.1468-0068.2009.00716.x
   STOUT R, 1996, THINGS HAPPEN THEY S
   van Inwagen P., 1983, ESSAY FREE WILL
   Von Wright G. H., 1971, EXPLANATION UNDERSTA
   Zhu J, 2004, PHILOS STUD, V119, P295, DOI 10.1023/B:PHIL.0000030433.41964.14
NR 36
TC 1
Z9 1
U1 0
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1874-5490
EI 1874-5504
J9 NEUROETHICS-NETH
JI Neuroethics
PD APR
PY 2014
VL 7
IS 1
BP 105
EP 107
DI 10.1007/s12152-013-9184-x
PG 3
WC Ethics; Medical Ethics; Social Sciences, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Social Sciences - Other Topics; Medical Ethics; Biomedical Social
   Sciences
GA AB7WM
UT WOS:000332001700010
OA Green Submitted
DA 2023-06-23
ER

PT J
AU Kozlov, AA
   Rokhlina, ML
AF Kozlov, AA
   Rokhlina, ML
TI Dependence of the formation of the addictive personality on the
   predisposing factors
SO ZHURNAL NEVROPATOLOGII I PSIKHIATRII IMENI S S KORSAKOVA
LA Russian
DT Article
AB During observation of 100 patients with consequences of different types of drug-addictions (heroin, opium, poly-drug, pervitine-ephedrine) a complex of social and biological factors was analyzed: heredity, premorbid personality, somatic diseases, nurture, age of the onset of drug-addiction, duration of drug abuse, asocial behavior. influence of these factors was studied according to the following parameters: alterations of personality; degree of the moral-ethic decline and of the intellectual-mnestic disorders; somatic complications; the presence of the suicidal trends; frequency of self-damages; a professional level; family interrelations; frequency of the delinquencies (including conviction). On the basis of the correlation analysis it was established that the most significant unfavorable prognostic factors, which had determined a rate of the formation of the addictive personality were the following (in order of the decrease of significance): perinatal pathology; family history of alcoholism, drug-addiction and other mental diseases; personality deviations in premorbid period; an early age of the onset of drug addiction; a type of the drug; education; alcoholic abuse before the addiction; duration of the addiction.
C1 Minist Publ Hlth Russia, Hlth narcol Res Inst, Moscow, Russia.
RP Kozlov, AA (通讯作者)，Minist Publ Hlth Russia, Hlth narcol Res Inst, Moscow, Russia.
RI Kozlov, Alexander A/C-7311-2013
CR CHIRKO VV, 2000, 13 SEZD PSIKHIATROV, P276
   EGOROV VF, 1998, NARKOLOGICHESKAYA SI, P109
   GABLE RS, 1993, AM J DRUG ALCOHOL AB, V19, P263, DOI 10.3109/00952999309001618
   GRECHANAYHA TB, 1995, 12 SEZD PSIKH ROSS M, P705
   GROUGHAN JZ, 1982, J CLIN PSYCHIAT, V43, P225
   KOSHKINA EA, 1997, VOPR NARKOL, V4, P64
   KOSHKINA EA, 1997, METODY IZUCHENIYA PO
   KOZLOV A, 2000, 6 WORLD C INN PSYCH, P16
   Kozlov AA, 2000, ZH NEVROPATOL PSIKH, V100, P23
   Kozlov AA, 1999, ZH NEVROPATOL PSIKH, V99, P14
   Kozlov AA, 2000, EUR PSYCHIAT, V15, p342S, DOI 10.1016/S0924-9338(00)94489-4
   KUREK NS, 1991, ZH NEVROPATOL PSIKH, V91, P64
   PELIPAS VE, 1991, VOPR NARKOL, V1, P31
   ROKHLINA ML, 1998, VOPR NARKOL, V1, P11
   ROKHLINAML, 2000, VOPR NARKOL, V3, P29
   Shufman N. E., 1994, Harefuah, V127, P52
   Tchistyakova LA, 2000, EUR PSYCHIAT, V15, p341S, DOI 10.1016/S0924-9338(00)94486-9
   TRAININA EG, 1984, THESIS MOSCOW
   TSELINSKII BP, 1996, VOPR NARKOL, V3, P10
   URAKOV IG, 1976, KLIN PSIKHIATRIYA UZ, P104
NR 20
TC 2
Z9 3
U1 0
U2 5
PU IZDATELSTVO MEDITSINA
PI MOSCOW
PA PETROVERIGSKII PER 6-8, K-142 MOSCOW, RUSSIA
SN 0044-4588
J9 ZH NEVROPATOL PSIKH
JI Zhurnal Nevropatol. Psikhiatrii Im. S S Korsakova
PY 2001
VL 101
IS 5
BP 16
EP 20
PG 5
WC Clinical Neurology; Pathology; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology; Pathology; Psychiatry
GA 471QP
UT WOS:000170940300004
PM 11505909
DA 2023-06-23
ER

PT C
AU Munteanu, CN
   Muraru, ID
   Iorga, M
AF Munteanu, Catalina Nicoleta
   Muraru, Iulia-Diana
   Iorga, Magdalena
BE Ioan, BG
TI Factors that Influence Addiction among Medical Students
SO PROCEEDINGS OF THE XIIITH NATIONAL CONFERENCE ON BIOETHICS WITH
   INTERNATIONAL PARTICIPATION
LA English
DT Proceedings Paper
CT 13th National Conference on Bioethics
CY NOV 08-10, 2018
CL Iasi, ROMANIA
SP Romanian Soc Bioeth, Iasi Dermatologists Union, Natl Author Qual Management Hlth, Romanian Coll Phys, Univ Med & Pharm, UNESCO Chair Bioeth Grigore T Popa
DE addiction; alcohol; tobacco; drugs; medical students
ID MOBILE PHONE ADDICTION; ALCOHOL; UNIVERSITY; TOBACCO; SMOKING
AB Addiction among medical students is one of the major factors that can affect learning ability as well as aspects of the student's social life. Studies dealing with addiction problems among medical students related to the students' origin in a certain continent have been analyzed. Different types of addiction (such as drugs, nicotine, caffeine, alcohol, social networking) can adversely affect both the intellectual abilities of the future physician (in the case of drug or alcohol use) or distract them (engaging in the use of social media). Reporting addiction cases and its variety of forms among students presents a major factor of concern in terms of the evolution of this aspect over time and of the subsequent effects.
C1 [Munteanu, Catalina Nicoleta; Muraru, Iulia-Diana; Iorga, Magdalena] Grigore T Popa Univ Med & Pharm, Iasi, Romania.
C3 Grigore T Popa University of Medicine & Pharmacy
RP Iorga, M (通讯作者)，Grigore T Popa Univ Med & Pharm, Iasi, Romania.
EM catalinanicoletamunteanu@yahoo.com; iuliadianamuraru@gmail.com;
   magdalena.iorga@umfiasi.ro
CR Abbasi-Ghahramanloo Abbas, 2015, Int J High Risk Behav Addict, V4, pe21945, DOI 10.5812/ijhrba.21945
   Akvardar Y, 2003, DRUG ALCOHOL DEPEN, V72, P117, DOI 10.1016/S0376-8716(03)00192-3
   American Psychiatric Association:, 2013, DIAGN STAT MAN MENT, V5th
   American Society of Addiction Medicine (ASAM), PUBL POL STAT DEF AD
   Babadi-Akashe Zahra, 2014, Addict Health, V6, P93
   Boland M, 2006, DRUG ALCOHOL DEPEN, V85, P123, DOI 10.1016/j.drugalcdep.2006.03.016
   Carinci AJ, 2009, PAIN PHYSICIAN, V12, P487
   Choliz M, 2010, ADDICTION, V105, P373, DOI 10.1111/j.1360-0443.2009.02854.x
   Dumitrascu CI, 2014, MSRJ, V3, P26
   Dyrbye LN, 2005, MAYO CLIN PROC, V80, P1613, DOI 10.4065/80.12.1613
   Ezoe S., 2013, Open Journal of Preventive Medicine, V3, P407
   Galea S, 2004, EPIDEMIOL REV, V26, P36, DOI 10.1093/epirev/mxh007
   Gezgin D. M., 2018, INT J RES ED SCI, V4, P215, DOI [10.21890/ijres.383153, DOI 10.21890/IJRES.383153]
   Goel N, 2015, CENT ASIAN J GLOB HE, V4, DOI 10.5195/cajgh.2015.187
   Haque M, 2016, PSYCHOL RES BEHAV MA, V9, P297, DOI 10.2147/PRBM.S119275
   Igarashi T, 2005, J SOC PERS RELAT, V22, P691, DOI 10.1177/0265407505056492
   Jackson ER, 2016, ACAD MED, V91, P1251, DOI 10.1097/ACM.0000000000001138
   Jalilian F, 2015, J RES HEALTH SCI, V15, P42
   La Torre G, 2012, PUBLIC HEALTH, V126, P159, DOI 10.1016/j.puhe.2011.10.009
   Liang J., 2019, SUBSTANCE ABUSE ADDI, P321
   Melani AS, 2000, EUR J EPIDEMIOL, V16, P607, DOI 10.1023/A:1007697126844
   Newbury-Birch D, 2000, DRUG ALCOHOL DEPEN, V59, P125, DOI 10.1016/S0376-8716(99)00108-8
   Pavithra MB, 2015, NATL J COMMUNITY MED, V6, P340
   Rettie R, 2008, MOBILITIES-UK, V3, P291, DOI 10.1080/17450100802095346
   Roberts JA, 2014, J BEHAV ADDICT, V3, P254, DOI 10.1556/JBA.3.2014.015
   Sahin S, 2013, PAK J MED SCI, V29, P913, DOI 10.12669/pjms.294.3686
   Sanchez-Martinez M, 2009, CYBERPSYCHOL BEHAV, V12, P131, DOI 10.1089/cpb.2008.0164
   Toda M., 2013, Open Journal of Preventive Medicine, V3, P99
   Tsimtsiou Z, 2015, ACAD PSYCHIATR, V39, P300, DOI 10.1007/s40596-014-0273-x
   Vakeflliu Y, 2002, PREV MED, V34, P370, DOI 10.1006/pmed.2001.0994
   Yen CF, 2009, J ADOLESCENCE, V32, P863, DOI 10.1016/j.adolescence.2008.10.006
NR 31
TC 0
Z9 0
U1 0
U2 1
PU FILODIRITTO PUBLISHER
PI BOLOGNA
PA INFOROMATICA SRL, VIA CASTIGLIONE, 81, BOLOGNA, 40124, ITALY
BN 978-88-85813-58-8
PY 2019
BP 265
EP 270
PG 6
WC Medical Ethics; Social Sciences, Biomedical
WE Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)
SC Medical Ethics; Biomedical Social Sciences
GA BR6BL
UT WOS:000659436700050
DA 2023-06-23
ER

PT J
AU Carter, A
   Hall, W
AF Carter, Adrian
   Hall, Wayne
TI THE ISSUE OF CONSENT IN RESEARCH THAT ADMINISTERS DRUGS OF ADDICTION TO
   ADDICTED PERSONS
SO ACCOUNTABILITY IN RESEARCH-POLICIES AND QUALITY ASSURANCE
LA English
DT Article
DE addiction; addiction research; informed consent; neuroethics; research
   ethics
ID INFORMED-CONSENT; OPIOID DEPENDENCE; DECISION-MAKING; SUBSTANCE-ABUSE;
   ALCOHOL; CAPACITY; USERS; INDIVIDUALS; DYSFUNCTION; DOPAMINE
AB In addiction, impaired control over drug use raises questions about the capacity of addicted persons to consent to participate in research studies in which they are given their drug of addiction. We review the case for doing such research, and the arguments that addiction does, and does not, prevent addicted persons from consenting to such research. We argue for a more nuanced view that acknowledges that while in some situations addiction impairs decision-making capacity, it does not eliminate such capacity. We conclude with some suggestions for recruiting addicted subjects and designing experiments in ways to obtain free and informed consent.
C1 [Carter, Adrian] Univ Queensland, Queensland Brain Inst, Brisbane, Qld 4072, Australia.
   [Carter, Adrian] Univ Queensland, Dept Philosophy, Brisbane, Qld 4072, Australia.
   [Hall, Wayne] Univ Queensland, Sch Populat Hlth, Brisbane, Qld 4072, Australia.
C3 University of Queensland; University of Queensland; University of
   Queensland
RP Carter, A (通讯作者)，Univ Queensland, Queensland Brain Inst, Brisbane, Qld 4072, Australia.
EM adrian.carter@uq.edu.au
RI Hall, Wayne D/A-3283-2008; Carter, Adrian N/A-1282-2008; Carter,
   Adrian/AAG-2830-2020
OI Hall, Wayne D/0000-0003-1984-0096; Carter, Adrian N/0000-0002-3593-0772;
   Carter, Adrian/0000-0002-3593-0772
CR ADLER MW, 1995, DRUG ALCOHOL DEPEN, V37, P167
   Baumeister RF, 2003, ALCOHOL CLIN EXP RES, V27, P281, DOI 10.1097/01.ALC.0000060879.61384.A4
   Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584
   Bechara A, 2001, NEUROPSYCHOLOGIA, V39, P376, DOI 10.1016/S0028-3932(00)00136-6
   Bigelow G. E., 1994, PROBL DRUG DEP P 56, V2, P354
   Cairns R, 2005, BRIT J PSYCHIAT, V187, P379, DOI 10.1192/bjp.187.4.379
   Carter A, 2008, INT J DRUG POLICY, V19, P79, DOI 10.1016/j.drugpo.2007.09.007
   Charland Louis C., 2002, American Journal of Bioethics, V2, P37, DOI 10.1162/152651602317533686
   Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11
   Cohen PJ, 2002, J LAW MED ETHICS, V30, P73, DOI 10.1111/j.1748-720X.2002.tb00722.x
   CURRAN HV, 1991, PSYCHOPHARMACOLOGY, V105, P1
   Curran HV, 2001, PSYCHOPHARMACOLOGY, V154, P153, DOI 10.1007/s002130000628
   DALRYMPLE T, 2006, ROMANCING OPIATES PH
   Dunn LB, 2006, AM J PSYCHIAT, V163, P1323, DOI 10.1176/appi.ajp.163.8.1323
   Dunn LB, 2001, NEUROPSYCHOPHARMACOL, V24, P595, DOI 10.1016/S0893-133X(00)00218-9
   Elliott Carl, 2002, American Journal of Bioethics, V2, P48, DOI 10.1162/152651602317533695
   Elster J., 1999, GETTING HOOKED RATIO
   Epstein DH, 2006, PSYCHOPHARMACOLOGY, V189, P1, DOI 10.1007/s00213-006-0529-6
   Faden R., 1986, HIST THEORY INFORM C
   FAILLACE LA, 1972, Q J STUD ALCOHOL, V33, P85
   Fillmore Mark T, 2003, Behav Cogn Neurosci Rev, V2, P179, DOI 10.1177/1534582303257007
   Finnigan F., 1992, HDB HUMAN PERFORMANC, V1, P73
   Fisch GS, 2007, BEHAV GENET, V37, P1, DOI 10.1007/s10519-006-9117-0
   Foddy B, 2006, BIOETHICS, V20, P1, DOI 10.1111/j.1467-8519.2006.00470.x
   Fry C, 2001, ADDICTION, V96, P1319, DOI 10.1046/j.1360-0443.2001.969131911.x
   Fureman I, 1997, AIDS EDUC PREV, V9, P330
   Garavan H., 2007, DRUGS FUTURE BRAIN S, P285
   GERSTEIN D, 1990, TREATING DRUG PROBLE, V1
   Geyer Mark A., 1995, P787
   Grant S, 2000, NEUROPSYCHOLOGIA, V38, P1180, DOI 10.1016/S0028-3932(99)00158-X
   Hall W, 2003, ADDICTION, V98, P867, DOI 10.1046/j.1360-0443.2003.00400.x
   Hall WD, 2008, ADDICTION, V103, P350, DOI 10.1111/j.1360-0443.2007.02070.x
   HARRISON K, 1995, J ACQ IMMUN DEF SYND, V10, P386
   Hazelton LD, 2003, GEN HOSP PSYCHIAT, V25, P130, DOI 10.1016/S0163-8343(03)00005-7
   Hester R, 2004, J NEUROSCI, V24, P11017, DOI 10.1523/JNEUROSCI.3321-04.2004
   Hotopf M, 2005, CLIN MED, V5, P580, DOI 10.7861/clinmedicine.5-6-580
   Iverson L., 2007, DRUGS FUTURE BRAIN S, P169
   Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483
   Koob GF, 2006, NEUR ADD
   KRANZLER HR, 1990, BRIT J ADDICT, V85, P119
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Levy N, 2006, CAN J PHILOS, V36, P427, DOI 10.1353/cjp.2006.0018
   Lubman D. I., 2008, J PSYCHOPHA IN PRESS
   Lyvers M, 2003, ADDICT BEHAV, V28, P605, DOI 10.1016/S0306-4603(01)00253-2
   Mintzer MZ, 2005, DRUG ALCOHOL DEPEN, V78, P225, DOI 10.1016/j.drugalcdep.2004.10.008
   Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006
   MODELL JG, 1993, ALCOHOL ALCOHOLISM, V28, P189
   MONTOYA ID, 1994, J ADDICT DIS, V13, P89, DOI 10.1300/J069v13n02_08
   National Advisory Council on Alcohol Abuse and Alcoholism, 1989, REC COUNC GUID ETH A
   National Bioethics Advisory Commission, 1999, RES INV PERS MENT DI
   Nutt D., 2007, DRUGS FUTURE BRAIN S
   Perneger TV, 1998, BMJ-BRIT MED J, V317, P13, DOI 10.1136/bmj.317.7150.13
   Rapeli P, 2006, BMC PSYCHIATRY, V6, DOI 10.1186/1471-244X-6-9
   Roberts LW, 2002, AM J PSYCHIAT, V159, P705, DOI 10.1176/appi.ajp.159.5.705
   Smith KL, 2006, DRUG ALCOHOL DEPEN, V82, P231, DOI 10.1016/j.drugalcdep.2005.09.012
   Sugarman J, 1999, Hastings Cent Rep, V29, pS1, DOI 10.2307/3528546
   Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI 10.1093/cercor/10.3.318
   Volkow ND, 2005, PHARMACOL THERAPEUT, V108, P3, DOI 10.1016/j.pharmthera.2005.06.021
   Volkow ND, 2004, NAT REV NEUROSCI, V5, P963, DOI 10.1038/nrn1539
   Volkow ND, 2004, MOL PSYCHIATR, V9, P557, DOI 10.1038/sj.mp.4001507
   Volkow ND, 2003, J CLIN INVEST, V111, P1444, DOI 10.1172/JCI200318533
   Volkow ND, 2007, ARCH NEUROL-CHICAGO, V64, P1575, DOI 10.1001/archneur.64.11.1575
   Walker R, 2005, J SUBST ABUSE TREAT, V29, P241, DOI 10.1016/j.jsat.2005.08.001
   Walker T, 2008, BIOETHICS, V22, P314, DOI 10.1111/j.1467-8519.2008.00647.x
   WHO, 1993, ICD 10 CLASS MENT BE
NR 65
TC 18
Z9 18
U1 1
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0898-9621
EI 1545-5815
J9 ACCOUNT RES
JI Account. Res.
PY 2008
VL 15
IS 4
BP 209
EP 225
DI 10.1080/08989620802388689
PG 17
WC Medical Ethics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Ethics
GA V18AL
UT WOS:000207977600002
PM 18972263
DA 2023-06-23
ER

PT J
AU Gunawan, T
   Ziausyte, U
   Kim, H
   Melen-Dez, C
   Morris, J
   Parida, K
   Manor, B
   Luk, J
   Schwandt, M
   Kwako, L
   Vinson, T
   Horneffer, Y
   George, D
   Koob, G
   Diazgranados, N
   Ramchandani, V
   Goldman, D
AF Gunawan, Tommy
   Ziausyte, Ugne
   Kim, Hannah
   Melen-Dez, Carlos
   Morris, James
   Parida, Kurren
   Manor, Brandon
   Luk, Jeremy
   Schwandt, Melanie
   Kwako, Laura
   Vinson, Tonette
   Horneffer, Yvonne
   George, David
   Koob, George
   Diazgranados, Nancy
   Ramchandani, Vijay
   Goldman, David
TI Latent Structure of the Addictions Neuroclinical Assessment: Differences
   Between Individuals With and Without Alcohol Use Disorder
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Meeting Abstract
DE Addiction Phenotypes; Alcohol Use Disorder and Drug Addiction;
   Neurocognitive Functioning
C1 [Gunawan, Tommy; Ziausyte, Ugne; Kim, Hannah; Melen-Dez, Carlos; Morris, James; Parida, Kurren; Manor, Brandon; Luk, Jeremy; Schwandt, Melanie; Kwako, Laura; Vinson, Tonette; Horneffer, Yvonne; George, David; Koob, George; Diazgranados, Nancy; Ramchandani, Vijay; Goldman, David] NIAAA, Bethesda, MD USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute on
   Alcohol Abuse & Alcoholism (NIAAA)
RI Gunawan, Tommy/AFR-7801-2022; Ramchandani, Vijay A./N-5081-2018
OI Ramchandani, Vijay A./0000-0003-2474-2183
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0893-133X
EI 1740-634X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD DEC
PY 2021
VL 46
IS SUPPL 1
SU 1
MA P687
BP 443
EP 443
PG 1
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA XH5ZD
UT WOS:000725511401392
DA 2023-06-23
ER

PT J
AU Feltenstein, MW
   See, RE
AF Feltenstein, M. W.
   See, R. E.
TI The neurocircuitry of addiction: an overview
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Review
DE abuse; addiction; animal models; dopamine; glutamate; mesocorticolimbic;
   neurobiology; relapse
ID COCAINE-SEEKING BEHAVIOR; VENTRAL TEGMENTAL AREA;
   CORTICOTROPIN-RELEASING-FACTOR; STRESS-INDUCED REINSTATEMENT; RAT
   NUCLEUS-ACCUMBENS; CUE-INDUCED REINSTATEMENT; DORSOMEDIAL PREFRONTAL
   CORTEX; VOLUNTARY ETHANOL-CONSUMPTION; EXTRACELLULAR DOPAMINE LEVELS;
   CONDITIONED PLACE PREFERENCE
AB Drug addiction presents as a chronic relapsing disorder characterized by persistent drug-seeking and drug-taking behaviours. Given the significant detrimental effects of this disease both socially and economically, a considerable amount of research has been dedicated to understanding a number of issues in addiction, including behavioural and neuropharmacological factors that contribute to the development, loss of control and persistence of compulsive addictive behaviours. In this review, we will give a broad overview of various theories of addiction, animal models of addiction and relapse, drugs of abuse, and the neurobiology of drug dependence and relapse. Although drugs of abuse possess diverse neuropharmacological profiles, activation of the mesocorticolimbic system, particularly the ventral tegmental area, nucleus accumbens, amygdala and prefrontal cortex via dopaminergic and glutamatergic pathways, constitutes a common pathway by which various drugs of abuse mediate their acute reinforcing effects. However, long-term neuroadaptations in this circuitry likely underlie the transition to drug dependence and cycles of relapse. As further elucidated in more comprehensive reviews of various subtopics on addiction in later sections of this special issue, it is anticipated that continued basic neuroscience research will aid in the development of effective therapeutic interventions for the long-term treatment of drug-dependent individuals.
C1 [Feltenstein, M. W.; See, R. E.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
C3 Medical University of South Carolina
RP Feltenstein, MW (通讯作者)，Med Univ S Carolina, Dept Neurosci, 173 Ashley Ave, Charleston, SC 29425 USA.
EM feltens@musc.edu
CR ALTSHULER HL, 1980, LIFE SCI, V26, P679, DOI 10.1016/0024-3205(80)90257-X
   Anagnostaras SG, 1996, BEHAV NEUROSCI, V110, P1397, DOI 10.1037/0735-7044.110.6.1397
   Anderson SM, 2003, PSYCHOPHARMACOLOGY, V168, P132, DOI 10.1007/s00213-002-1298-5
   ANDERSON WW, 1974, PHARMACOL BIOCHEM BE, V2, P447, DOI 10.1016/0091-3057(74)90002-1
   Anonymous, 2006, P243
   ATOR NA, 1983, PHARMACOL BIOCHEM BE, V19, P993, DOI 10.1016/0091-3057(83)90406-9
   Backstrom P, 2007, PSYCHOPHARMACOLOGY, V192, P571, DOI 10.1007/s00213-007-0753-8
   BALSTER RL, 1976, PSYCHOPHARMACOLOGIA, V46, P229, DOI 10.1007/BF00421107
   BALSTER RL, 1985, DRUG ALCOHOL DEPEN, V14, P249, DOI 10.1016/0376-8716(85)90060-2
   BALSTER RL, 1991, BRIT J ADDICT, V86, P1549
   Bardo MT, 2000, PSYCHOPHARMACOLOGY, V153, P31, DOI 10.1007/s002130000569
   BARTOLETTI M, 1983, NEUROPHARMACOLOGY, V22, P1193, DOI 10.1016/0028-3908(83)90080-1
   Benowitz NL, 1996, ANNU REV PHARMACOL, V36, P597, DOI 10.1146/annurev.pa.36.040196.003121
   Berglind WJ, 2006, NEUROSCIENCE, V137, P699, DOI 10.1016/j.neuroscience.2005.08.064
   Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9
   BERRIDGE KC, 1995, CURR DIR PSYCHOL SCI, V4, P71, DOI 10.1111/1467-8721.ep10772316
   Berridge KC, 2007, PSYCHOPHARMACOLOGY, V191, P391, DOI 10.1007/s00213-006-0578-x
   BLAKESLEY BC, 1972, BRIT J PHARMACOL, V45, pP181
   Bonson KR, 2002, NEUROPSYCHOPHARMACOL, V26, P376, DOI 10.1016/S0893-133X(01)00371-2
   Bossert JM, 2007, J NEUROSCI, V27, P12655, DOI 10.1523/JNEUROSCI.3926-07.2007
   Boutrel B, 2005, P NATL ACAD SCI USA, V102, P19168, DOI 10.1073/pnas.0507480102
   Bozarth M A, 1982, NIDA Res Monogr, V41, P158
   BOZARTH MA, 1983, PROG NEURO-PSYCHOPH, V7, P569, DOI 10.1016/0278-5846(83)90027-1
   BOZARTH MA, 1981, LIFE SCI, V28, P551, DOI 10.1016/0024-3205(81)90148-X
   Bozarth MA, 1987, METHODS ASSESSING RE, P173, DOI DOI 10.1007/978-1-4612-4812-5_9
   Caille S, 2003, EUR J NEUROSCI, V18, P3145, DOI 10.1111/j.1460-9568.2003.02961.x
   Cami J, 2003, NEW ENGL J MED, V349, P975, DOI 10.1056/NEJMra023160
   Capriles N, 2003, PSYCHOPHARMACOLOGY, V168, P66, DOI 10.1007/s00213-002-1283-z
   CARBONI E, 2001, J NEUROSCI, V141, P1
   Carr G.D., 1989, TOPICS EXPT PSYCHOPH, P264
   CHARNEY DS, 1983, LIFE SCI, V33, P19, DOI 10.1016/0024-3205(83)90707-5
   Cheer JF, 2007, NEURON, V54, P237, DOI 10.1016/j.neuron.2007.03.021
   Chefer VI, 2002, NEUROSCIENCE, V112, P907, DOI 10.1016/S0306-4522(02)00099-4
   Chevrette J, 2002, PHARMACOL BIOCHEM BE, V71, P501, DOI 10.1016/S0091-3057(01)00686-4
   Childress A R, 1993, NIDA Res Monogr, V137, P73
   Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11
   Ciccocioppo R, 2001, P NATL ACAD SCI USA, V98, P1976, DOI 10.1073/pnas.98.4.1976
   Clark D, 1998, ADDICT BIOL, V3, P109, DOI 10.1080/13556219872191
   COLLINS RJ, 1984, PSYCHOPHARMACOLOGY, V82, P6
   COLOMBO G, 1984, PHARM BIOCH BEHAV, V81, P369
   Contarino A, 2002, EUR J PHARMACOL, V446, P103, DOI 10.1016/S0014-2999(02)01812-5
   Cornish JL, 1999, NEUROSCIENCE, V93, P1359, DOI 10.1016/S0306-4522(99)00214-6
   Cornish JL, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-15-j0006.2000
   CORRIGALL WA, 1988, PHARMACOL BIOCHEM BE, V30, P443, DOI 10.1016/0091-3057(88)90478-9
   CORRIGALL WA, 1994, BRAIN RES, V653, P278, DOI 10.1016/0006-8993(94)90401-4
   CORRIGALL WA, 1989, PSYCHOPHARMACOLOGY, V99, P473, DOI 10.1007/BF00589894
   Dackis CA, 2001, J SUBST ABUSE TREAT, V21, P111, DOI 10.1016/S0740-5472(01)00192-1
   Dahchour A, 2000, PHARMACOL BIOCHEM BE, V65, P345, DOI 10.1016/S0091-3057(99)00197-5
   DAVIS M, 1979, PSYCHOPHARMACOLOGY, V65, P111, DOI 10.1007/BF00433036
   Dayas CV, 2007, BIOL PSYCHIAT, V61, P979, DOI 10.1016/j.biopsych.2006.07.034
   DENEAU G, 1969, PSYCHOPHARMACOLOGIA, V16, P30, DOI 10.1007/BF00405254
   Di Chiara G, 2002, BEHAV BRAIN RES, V137, P75, DOI 10.1016/S0166-4328(02)00286-3
   Di Chiara G, 1999, EUR J PHARMACOL, V375, P13, DOI 10.1016/S0014-2999(99)00372-6
   Di Ciano P, 2004, J NEUROSCI, V24, P7167, DOI 10.1523/JNEUROSCI.1581-04.2004
   Di Ciano P, 2004, EUR J NEUROSCI, V19, P1661, DOI 10.1111/j.1460-9568.2004.03232.x
   Di Ciano P, 2001, NEUROPSYCHOPHARMACOL, V25, P341, DOI 10.1016/S0893-133X(01)00235-4
   Di Pietro NC, 2006, EUR J NEUROSCI, V24, P3285, DOI 10.1111/j.1460-9568.2006.05193.x
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   DICIANO P, 1995, BEHAV PHARMACOL, V6, P311
   DICIANO P, 2008, NEUROPSYCHOPHARMACOL
   DWORKIN SI, 1988, PHARMACOL BIOCHEM BE, V30, P1051, DOI 10.1016/0091-3057(88)90138-4
   DWORKIN SI, 1988, PHARMACOL BIOCHEM BE, V29, P175, DOI 10.1016/0091-3057(88)90292-4
   Erb S, 1999, J NEUROSCI, V19, part. no., DOI 10.1523/JNEUROSCI.19-20-j0006.1999
   Erb S, 2000, NEUROPSYCHOPHARMACOL, V23, P138, DOI 10.1016/S0893-133X(99)00158-X
   Erb S, 1996, PSYCHOPHARMACOLOGY, V128, P408, DOI 10.1007/s002130050150
   Erb S, 1998, J NEUROSCI, V18, P5529, DOI 10.1523/JNEUROSCI.18-14-05529.1998
   ETTENBERG A, 1982, PSYCHOPHARMACOLOGY, V78, P204, DOI 10.1007/BF00428151
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   FADDA F, 1991, ALCOHOL ALCOHOLISM, V26, P107, DOI 10.1093/oxfordjournals.alcalc.a045088
   Fadda P, 2006, NEUROREPORT, V17, P1629, DOI 10.1097/01.wnr.0000236853.40221.8e
   Feltenstein MW, 2007, NEUROBIOL LEARN MEM, V88, P435, DOI 10.1016/j.nlm.2007.05.006
   Feltenstein MW, 2006, BEHAV BRAIN RES, V174, P1, DOI 10.1016/j.bbr.2006.06.039
   FISCHMAN MW, 1982, FED PROC, V41, P241
   Franklin TR, 2000, EUR J NEUROSCI, V12, P2097, DOI 10.1046/j.1460-9568.2000.00071.x
   Franklin TR, 2002, BIOL PSYCHIAT, V51, P134, DOI 10.1016/S0006-3223(01)01269-0
   Fuchs RA, 2004, J NEUROSCI, V24, P6600, DOI 10.1523/JNEUROSCI.1924-04.2004
   Fuchs RA, 2006, J NEUROSCI, V26, P3584, DOI 10.1523/JNEUROSCI.5146-05.2006
   Fuchs RA, 2005, NEUROPSYCHOPHARMACOL, V30, P296, DOI 10.1038/sj.npp.1300579
   Fuchs RA, 2004, PSYCHOPHARMACOLOGY, V176, P459, DOI 10.1007/s00213-004-1895-6
   Fuchs RA, 2002, PSYCHOPHARMACOLOGY, V160, P425, DOI 10.1007/s00213-001-0997-7
   Fuchs RA, 2007, EUR J NEUROSCI, V26, P487, DOI 10.1111/j.1460-9568.2007.05674.x
   Fuchs RA, 2006, EUR J NEUROSCI, V23, P2809, DOI 10.1111/j.1460-9568.2006.04806.x
   GALLISTEL CR, 1983, PHYSL BASIS MEMORY, P73
   GATTO GJ, 1994, ALCOHOL, V11, P557, DOI 10.1016/0741-8329(94)90083-3
   GILL K, 1988, ALCOHOL, V5, P349, DOI 10.1016/0741-8329(88)90019-5
   GOLDBERG SR, 1976, J EXP ANAL BEHAV, V25, P93, DOI 10.1901/jeab.1976.25-93
   GOLDBERG SR, 1971, J PHARMACOL EXP THER, V176, P464
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040
   GRIFFITHS RR, 1978, NIDA RES MONOGR, V20, P24
   Grimm JW, 2000, PSYCHOBIOLOGY, V28, P383
   Grimm JW, 2000, NEUROPSYCHOPHARMACOL, V22, P473, DOI 10.1016/S0893-133X(99)00157-8
   HANSMANN I, 1979, CYTOGENET CELL GENET, V23, P70, DOI 10.1159/000131304
   Harris GC, 2005, NATURE, V437, P556, DOI 10.1038/nature04071
   HEMBY SE, 1995, J PHARMACOL EXP THER, V273, P591
   HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991
   HIGGINS RL, 1975, J ABNORM PSYCHOL, V84, P644, DOI 10.1037/0021-843X.84.6.644
   Highfield D, 2001, NEUROPSYCHOPHARMACOL, V25, P320, DOI 10.1016/S0893-133X(01)00227-5
   HOEBEL BG, 1983, PSYCHOPHARMACOLOGY, V81, P158, DOI 10.1007/BF00429012
   HOLMBERG G, 1961, PSYCHOPHARMACOLOGIA, V2, P93, DOI 10.1007/BF00592678
   HUBNER CB, 1990, BRAIN RES, V508, P20, DOI 10.1016/0006-8993(90)91112-T
   Hungund BL, 2003, J NEUROCHEM, V84, P698, DOI 10.1046/j.1471-4159.2003.01576.x
   HURD YL, 1989, BRAIN RES, V498, P199, DOI 10.1016/0006-8993(89)90422-8
   Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560
   JAFFE JH, 1989, PSYCHOPHARMACOLOGY, V97, P59, DOI 10.1007/BF00443414
   Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483
   JOHNSON SW, 1992, J NEUROSCI, V12, P483
   Justinova Z, 2003, PSYCHOPHARMACOLOGY, V169, P135, DOI 10.1007/s00213-003-1484-0
   KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kalivas PW, 2003, PSYCHOPHARMACOLOGY, V168, P44, DOI 10.1007/s00213-003-1393-2
   Kalivas PW, 1998, J PSYCHOPHARMACOL, V12, P49, DOI 10.1177/026988119801200107
   Kilts CD, 2004, AM J PSYCHIAT, V161, P233, DOI 10.1176/appi.ajp.161.2.233
   Kilts CD, 2001, ARCH GEN PSYCHIAT, V58, P334, DOI 10.1001/archpsyc.58.4.334
   KOLTA MG, 1985, NEUROPHARMACOLOGY, V24, P823, DOI 10.1016/0028-3908(85)90032-2
   Koob G, 2007, AM J PSYCHIAT, V164, P1149, DOI 10.1176/appi.ajp.2007.05030503
   Koob GF, 1999, ANN NY ACAD SCI, V897, P27, DOI 10.1111/j.1749-6632.1999.tb07876.x
   KOOB GF, 1984, J PHARMACOL EXP THER, V229, P481
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   KOOB GF, 1992, TRENDS NEUROSCI, V15, P186, DOI 10.1016/0166-2236(92)90171-4
   KORNETSKY C, 1979, ARCH GEN PSYCHIAT, V36, P289
   Kornetsky C, 1990, TESTING EVALUATION D, P211
   Koya E, 2006, J NEUROCHEM, V98, P905, DOI 10.1111/j.1471-4159.2006.03917.x
   Kreek MJ, 1998, DRUG ALCOHOL DEPEN, V51, P23, DOI 10.1016/S0376-8716(98)00064-7
   Kuczenski R, 1994, PSYCHOPHARMACOLOGY T, P81
   KUZICH PJ, 2001, J NEUROSCI, V21, pRC155
   LANG WJ, 1963, ARCH INT PHARMACOD T, V142, P457
   Lawrence AJ, 2006, BRIT J PHARMACOL, V148, P752, DOI 10.1038/sj.bjp.0706789
   Le AD, 2005, PSYCHOPHARMACOLOGY, V179, P366, DOI 10.1007/s00213-004-2036-y
   Le AD, 2000, PSYCHOPHARMACOLOGY, V150, P317, DOI 10.1007/s002130000411
   Lecca D, 2006, PSYCHOPHARMACOLOGY, V184, P435, DOI 10.1007/s00213-005-0280-4
   Lecca D, 2006, PSYCHOPHARMACOLOGY, V188, P63, DOI 10.1007/s00213-006-0475-3
   Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401
   Ledford CC, 2003, NEUROPSYCHOPHARMACOL, V28, P1721, DOI 10.1038/sj.npp.1300249
   Lee B, 2004, NEUROPSYCHOPHARMACOL, V29, P686, DOI 10.1038/sj.npp.1300391
   Leri F, 2002, J NEUROSCI, V22, P5713
   Levin ED, 1998, PSYCHOPHARMACOLOGY, V140, P135, DOI 10.1007/s002130050750
   LYNESS WH, 1979, PHARMACOL BIOCHEM BE, V11, P553, DOI 10.1016/0091-3057(79)90040-6
   MARKOU A, 1991, NEUROPSYCHOPHARMACOL, V4, P17
   MARKOU A, 1993, PSYCHOPHARMACOLOGY, V112, P163, DOI 10.1007/BF02244907
   MASUR J, 1980, PHARMACOL BIOCHEM BE, V13, P777, DOI 10.1016/0091-3057(80)90206-3
   Mateo Y, 2004, P NATL ACAD SCI USA, V101, P372, DOI 10.1073/pnas.0207805101
   McFarland K, 2004, J NEUROSCI, V24, P1551, DOI 10.1523/JNEUROSCI.4177-03.2004
   McFarland K, 2003, J NEUROSCI, V23, P3531
   McFarland K, 2001, J NEUROSCI, V21, P8655
   McLaughlin J, 2003, PSYCHOPHARMACOLOGY, V168, P57, DOI 10.1007/s00213-002-1196-x
   Meil WM, 1997, BEHAV BRAIN RES, V87, P139, DOI 10.1016/S0166-4328(96)02270-X
   MEIL WM, 1995, PSYCHOPHARMACOLOGY, V118, P338, DOI 10.1007/BF02245964
   Melendez RI, 2002, ALCOHOL CLIN EXP RES, V26, P318
   Meyer RE, 1996, LANCET, V347, P162, DOI 10.1016/S0140-6736(96)90345-1
   Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006
   Monaco AP, 1981, NEUROBIOLOGY NUCLEUS, P338
   Mugnaini M, 2006, NEUROSCIENCE, V137, P565, DOI 10.1016/j.neuroscience.2005.09.008
   MYERS RD, 1974, HDB DRUG CHEM STIMUL
   Neisewander JL, 2000, J NEUROSCI, V20, P798, DOI 10.1523/JNEUROSCI.20-02-00798.2000
   NESBITT PD, 1973, J PERS SOC PSYCHOL, V25, P137, DOI 10.1037/h0034256
   Nesse RM, 1997, SCIENCE, V278, P63, DOI 10.1126/science.278.5335.63
   OLDS ME, 1982, BRAIN RES, V237, P429, DOI 10.1016/0006-8993(82)90454-1
   Panagis G, 2000, PSYCHOPHARMACOLOGY, V149, P388, DOI 10.1007/s002130000384
   Park WK, 2002, J NEUROSCI, V22, P2916, DOI 10.1523/JNEUROSCI.22-07-02916.2002
   PETTIT HO, 1984, PSYCHOPHARMACOLOGY, V84, P167, DOI 10.1007/BF00427441
   PETTIT HO, 1989, PHARMACOL BIOCHEM BE, V34, P899, DOI 10.1016/0091-3057(89)90291-8
   PHILLIPS AG, 1981, NEUROSCI LETT, V24, P81, DOI 10.1016/0304-3940(81)90363-3
   Piazza PV, 1998, TRENDS PHARMACOL SCI, V19, P67, DOI 10.1016/S0165-6147(97)01115-2
   PICKENS R, 1968, PSYCHOPHARMACOLOGIA, V12, P158, DOI 10.1007/BF00401545
   PICKENS R, 1968, J PHARMACOL EXP THER, V161, P122
   PICKENS R, 1968, PSYCHOL REP, V23, P1267, DOI 10.2466/pr0.1968.23.3f.1267
   PICKENS R, 1967, PSYCHON SCI, V8, P371
   Pontieri FE, 1995, P NATL ACAD SCI USA, V92, P12304, DOI 10.1073/pnas.92.26.12304
   Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0
   RASSNICK S, 1993, ALCOHOL CLIN EXP RES, V17, P124, DOI 10.1111/j.1530-0277.1993.tb00736.x
   RASSNICK S, 1993, BRAIN RES, V623, P16, DOI 10.1016/0006-8993(93)90004-7
   RASSNICK S, 1992, PSYCHOPHARMACOLOGY, V109, P92, DOI 10.1007/BF02245485
   RICHARDSON NR, 1994, DRUG ALCOHOL DEPEN, V36, P23, DOI 10.1016/0376-8716(94)90005-1
   RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058
   RITZ MC, 1989, J PHARMACOL EXP THER, V248, P1010
   Robbins TW, 1996, CURR OPIN NEUROBIOL, V6, P228, DOI 10.1016/S0959-4388(96)80077-8
   ROBERTS DCS, 1977, PHARMACOL BIOCHEM BE, V6, P615, DOI 10.1016/0091-3057(77)90084-3
   ROBERTS DCS, 1980, PHARMACOL BIOCHEM BE, V12, P781, DOI 10.1016/0091-3057(80)90166-5
   ROBERTS DCS, 1982, PHARMACOL BIOCHEM BE, V17, P901, DOI 10.1016/0091-3057(82)90469-5
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Rocha BA, 1998, NAT NEUROSCI, V1, P132, DOI 10.1038/381
   Rodd ZA, 2005, J PHARMACOL EXP THER, V313, P134, DOI 10.1124/jpet.104.075952
   Rodd ZA, 2004, ALCOHOL CLIN EXP RES, V28, P1212, DOI 10.1097/01.ALC.0000134401.30394.7F
   Rodd ZA, 2004, J NEUROSCI, V24, P1050, DOI 10.1523/JNEUROSCI.1319-03.2004
   Rodd-Henricks ZA, 2002, J PHARMACOL EXP THER, V303, P1216, DOI 10.1124/jpet.102.038950
   Rogers JL, 2008, NEUROSCIENCE, V151, P579, DOI 10.1016/j.neuroscience.2007.10.012
   Rogers JL, 2007, NEUROBIOL LEARN MEM, V87, P688, DOI 10.1016/j.nlm.2007.01.003
   RUSSELL JA, 1975, J STUD ALCOHOL, V36, P1508, DOI 10.15288/jsa.1975.36.1508
   *SAMHSA, 2007, DHHS PUBL
   SAMSON HH, 1985, PHARMACOL BIOCHEM BE, V22, P91, DOI 10.1016/0091-3057(85)90491-5
   SCHULTEIS G, 1995, P NATL ACAD SCI USA, V92, P5880, DOI 10.1073/pnas.92.13.5880
   SCHULTEIS G, 1994, J PHARMACOL EXP THER, V271, P1391
   Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593
   SCHUSTER CR, 1969, ANNU REV PHARMACOLOG, V9, P483, DOI 10.1146/annurev.pa.09.040169.002411
   See RE, 2007, PSYCHOPHARMACOLOGY, V194, P321, DOI 10.1007/s00213-007-0850-8
   See RE, 2003, NEUROSCIENCE, V117, P477, DOI 10.1016/S0306-4522(02)00665-6
   See RE, 2005, EUR J PHARMACOL, V526, P140, DOI 10.1016/j.ejphar.2005.09.034
   See RE, 2002, PHARMACOL BIOCHEM BE, V71, P517, DOI 10.1016/S0091-3057(01)00682-7
   See RE, 2001, PSYCHOPHARMACOLOGY, V154, P301, DOI 10.1007/s002130000636
   SEIDEN LS, 1993, ANNU REV PHARMACOL, V33, P639, DOI 10.1146/annurev.pharmtox.33.1.639
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   Shaham Y, 1996, PSYCHOPHARMACOLOGY, V125, P385, DOI 10.1007/BF02246022
   Shaham Y, 1997, J NEUROSCI, V17, P2605
   Shaham Y, 2000, EUR J NEUROSCI, V12, P292, DOI 10.1046/j.1460-9568.2000.00899.x
   Shepard JD, 2004, BIOL PSYCHIAT, V55, P1082, DOI 10.1016/j.biopsych.2004.02.032
   Sinha R, 1999, PSYCHOPHARMACOLOGY, V142, P343, DOI 10.1007/s002130050898
   SMITH GM, 1959, JAMA-J AM MED ASSOC, V170, P542, DOI 10.1001/jama.1959.63010050001008
   SMITH SG, 1975, METHODS NARCOTICS RE, P3
   SPEALMAN RD, 1978, ANNU REV PHARMACOL, V18, P313, DOI 10.1146/annurev.pa.18.040178.001525
   Stewart J, 2000, J PSYCHIATR NEUROSCI, V25, P125
   Stine SM, 2002, BIOL PSYCHIAT, V51, P642, DOI 10.1016/S0006-3223(01)01292-6
   STRETCH R, 1970, CAN J PHYSIOL PHARM, V48, P575, DOI 10.1139/y70-088
   SWERDLOW NR, 1989, PSYCHOPHARMACOLOGY, P399
   TAKAHASHI RN, 1979, PHARMACOL BIOCHEM BE, V11, P737, DOI 10.1016/0091-3057(79)90274-0
   Tobler PN, 2003, J NEUROSCI, V23, P10402
   Tsou K, 1998, NEUROSCIENCE, V83, P393, DOI 10.1016/S0306-4522(97)00436-3
   Tzschentke TM, 1998, PROG NEUROBIOL, V56, P613, DOI 10.1016/S0301-0082(98)00060-4
   Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077
   VACCARINO FJ, 1985, PSYCHOPHARMACOLOGY, V86, P37, DOI 10.1007/BF00431681
   van Erp AMM, 2007, PSYCHOPHARMACOLOGY, V191, P679, DOI 10.1007/s00213-006-0637-3
   Van Ree JM, 1999, PHARMACOL REV, V51, P341
   Vanderschuren LJMJ, 2005, J NEUROSCI, V25, P8665, DOI 10.1523/JNEUROSCI.0925-05.2005
   Vanderschuren LJMJ, 2000, PSYCHOPHARMACOLOGY, V151, P99, DOI 10.1007/s002130000493
   VANREE JM, 1980, PHARMACOL BIOCHEM BE, V13, P257, DOI 10.1016/S0091-3057(80)80039-6
   Volkow ND, 2003, J CLIN INVEST, V111, P1444, DOI 10.1172/JCI200318533
   VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210
   Volkow ND, 1997, NATURE, V386, P827, DOI 10.1038/386827a0
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
   Vorel SR, 2002, J NEUROSCI, V22, P9595
   Wagner FA, 2002, NEUROPSYCHOPHARMACOL, V26, P479, DOI 10.1016/S0893-133X(01)00367-0
   Watkins SS, 1999, PHARMACOL BIOCHEM BE, V62, P743, DOI 10.1016/S0091-3057(98)00226-3
   WEEKS J R, 1972, P155
   WEEKS JR, 1962, SCIENCE, V138, P143, DOI 10.1126/science.138.3537.143
   WEEKS JR, 1976, PROSTAGLANDINS, V193, P1262
   Weiss F, 2000, P NATL ACAD SCI USA, V97, P4321, DOI 10.1073/pnas.97.8.4321
   WEISS F, 1992, BRAIN RES, V593, P314, DOI 10.1016/0006-8993(92)91327-B
   WEISS F, 1993, J PHARMACOL EXP THER, V267, P250
   Weiss F, 2001, ANN NY ACAD SCI, V937, P1, DOI 10.1111/j.1749-6632.2001.tb03556.x
   WESNES K, 1983, NEUROPSYCHOBIOLOGY, V9, P41, DOI 10.1159/000117935
   Whitelaw RB, 1996, PSYCHOPHARMACOLOGY, V127, P213, DOI 10.1007/BF02805996
   Wiegmann DA, 1996, INT J AVIAT PSYCHOL, V6, P379
   WIKLER A, 1973, ARCH GEN PSYCHIAT, V28, P611
   WILSON MC, 1974, PHARMACOL BIOCHEM BE, V2, P563, DOI 10.1016/0091-3057(74)90021-5
   WISE RA, 1980, PHARMACOL BIOCHEM BE, V13, P213, DOI 10.1016/S0091-3057(80)80033-5
   Wise RA, 1996, CURR OPIN NEUROBIOL, V6, P243, DOI 10.1016/S0959-4388(96)80079-1
   WISE RA, 1995, PSYCHOPHARMACOLOGY, V120, P10, DOI 10.1007/BF02246140
   WISE RA, 1995, SYNAPSE, V21, P140, DOI 10.1002/syn.890210207
   Wise RA, 2002, NEURON, V36, P229, DOI 10.1016/S0896-6273(02)00965-0
   Wong DF, 2006, NEUROPSYCHOPHARMACOL, V31, P2716, DOI 10.1038/sj.npp.1301194
   Woods J. H., 1971, BIOL ASPECTS ALCOHOL, P371
   WOOLVERTON WL, 1986, PHARMACOL BIOCHEM BE, V24, P531, DOI 10.1016/0091-3057(86)90553-8
   WOOLVERTON WL, 1992, TRENDS PHARMACOL SCI, V13, P193, DOI 10.1016/0165-6147(92)90063-C
   YANAURA S, 1980, JPN J PHARMACOL, V30, P258, DOI 10.1254/jjp.30.258
   YOKEL RA, 1975, SCIENCE, V187, P547, DOI 10.1126/science.1114313
   YOUNES M, 1986, DRUG CHEM TOXICOL, V9, P67, DOI 10.3109/01480548609042831
   Zhou W, 2007, NEUROSCIENCE, V144, P1209, DOI 10.1016/j.neuroscience.2006.11.013
   ZITO KA, 1985, PHARMACOL BIOCHEM BE, V23, P1029, DOI 10.1016/0091-3057(85)90110-8
NR 260
TC 266
Z9 277
U1 0
U2 48
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD MAY
PY 2008
VL 154
IS 2
BP 261
EP 274
DI 10.1038/bjp.2008.51
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 299LA
UT WOS:000255755900002
PM 18311189
OA Green Published
DA 2023-06-23
ER

PT J
AU Popescu, D
   Popescu, G
   Lupu, G
   Panus, V
   Neagu-Sadoveanu, S
   Buda, O
AF Popescu, Daniel
   Popescu, Gabriela
   Lupu, George
   Panus, Victor
   Neagu-Sadoveanu, Sebastian
   Buda, Octavian
TI Drugs effects on the central nervous system. Forensic implications
SO ROMANIAN JOURNAL OF LEGAL MEDICINE
LA English
DT Article
DE Addiction; Neural mechanisms; Forensic evaluation
ID COCAINE; PSYCHOSIS
AB Addiction is a wide spread term used in our days. Some of the habits due to routine conditioning are called dependences, i.e.: eating shopping etc. These are fundamentally different of those due to chronic alcohol intake, drugs medicines (chemicals), with euphoric effect. For this reason some physicians prefer the term of addiction to drug. Unlike the benign addiction, by conditioning, drugs addiction initiates very fast (after 1 or 2 intakes), had a big resistance at treatment and show the phenomena of sever disturbance in withdrawal. In this paper we refer mainly at this kind of dependency. Nervous disturbances that are produced during drugs and even alcohol intakes refer to psychical affective and cognitive processes. The prevailing factor of these processes is the hedonist one.
C1 [Popescu, Daniel] UMF Carol Davila, Dept Publ Hlth Bucharest, Dept Anat, Bucharest, Romania.
   [Neagu-Sadoveanu, Sebastian] Serban Voda Policlin, Dept Neuropsychiat, Bucharest, Romania.
   [Buda, Octavian] Natl Inst Legal Med Mina Minovici, Dept Forens Psychiat, Bucharest 042122, Romania.
C3 Carol Davila University of Medicine & Pharmacy
RP Popescu, D (通讯作者)，UMF Carol Davila, Dept Publ Hlth Bucharest, Dept Anat, Bucharest, Romania.
EM popescu3dan@yahoo.com
OI Buda, Octavian/0000-0002-1455-8246
CR ARSENI C, 1980, TRATAT NEUROLOGIE
   BAKER TE, 2010, ADDICT BIOL     0823
   BERTHIER M, 1987, ACTA NEUROL BELG, V87, P125
   BOUVENOT G, 2001, PATOLOGIE MED, V6
   BOZARTH MA, 1991, MESOLIMBIC DOPAMINE SYSTEM : FROM MOTIVATION TO ACTION, P301
   BOZARTH MA, 1989, CAN J PHYSIOL PHARM, V67, P1158, DOI 10.1139/y89-185
   BOZARTH MA, 1987, METHODS ASSESSING RE
   Bozarth MA, 1990, ADDICTION CONTROVERS, P112
   Bozarth MA, 1987, BRAIN REWARD SYSTEMS, P1
   CHIU HFK, 1995, BRIT J CLIN PRACT, V49, P277
   CONSTANTIN D, 2000, BOLI PSIHOSOMATICE P
   GELDER M, 1994, TXB PSYCHIAT
   HAMILTON ME, 1988, LIFE SCI, V43, P941, DOI 10.1016/0024-3205(88)90271-8
   Heath RG, 1964, ROLE PLEASURE BEHAVI, P219
   Kish SJ, 1999, MOL PSYCHIATR, V4, P26, DOI 10.1038/sj.mp.4000462
   KONRAD M, 1993, IMAGING BRAIN PSYCHI
   Lishman A, 1987, ORGANIC PSYCHIAT
   OLDS J, 1956, SCI AM           OCT
   Xu JS, 2010, NEUROPSYCHOPHARMACOL, V35, P1541, DOI 10.1038/npp.2010.25
NR 19
TC 1
Z9 1
U1 0
U2 7
PU ROMANIAN LEGAL MED SOC
PI BUCHAREST
PA SOS VITAN-BIRZESTI 9, BUCHAREST, 75669, ROMANIA
SN 1221-8618
J9 ROM J LEG MED
JI Rom. J. Leg. Med.
PD SEP
PY 2010
VL 18
IS 3
BP 231
EP 236
DI 10.4323/rjlm.2010.231
PG 6
WC Medicine, Legal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Legal Medicine
GA 660OC
UT WOS:000282651900014
DA 2023-06-23
ER

PT J
AU Van Bockstaele, EJ
AF Van Bockstaele, Elisabeth J.
TI The Neurobiology of Addiction-like Behaviors
SO ILAR JOURNAL
LA English
DT Editorial Material
ID NEURAL MECHANISMS; DRUG-ADDICTION; ANIMAL-MODELS; PLASTICITY; INCREASE
C1 [Van Bockstaele, Elisabeth J.] Thomas Jefferson Univ, Dept Neurosci, Farber Inst Neurosci, Philadelphia, PA 19107 USA.
   [Van Bockstaele, Elisabeth J.] Thomas Jefferson Univ, Grad Program Neurosci, Farber Inst Neurosci, Philadelphia, PA 19107 USA.
C3 Jefferson University; Jefferson University
RP Van Bockstaele, EJ (通讯作者)，Thomas Jefferson Univ, 900 Walnut St,Suite 400, Philadelphia, PA 19107 USA.
EM elisabeth.vanbockstaele@jefferson.edu
FU NIDA NIH HHS [R01 DA020129, R01 DA009082] Funding Source: Medline
CR American Psychiatric Association (APA), 2000, DIAGN STAT MAN MENT, Vfourth
   Barson JR, 2012, ILAR J, V53, P35, DOI 10.1093/ilar.53.1.35
   Corwin RLW, 2012, ILAR J, V53, P23, DOI 10.1093/ilar.53.1.23
   Cunha-Oliveira T, 2008, BRAIN RES REV, V58, P192, DOI 10.1016/j.brainresrev.2008.03.002
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Fitzgerald LW, 1996, J NEUROSCI, V16, P274
   Goto Y, 2005, NEURON, V47, P255, DOI 10.1016/j.neuron.2005.06.017
   Hughes-Moore DE, 2012, ILAR J, V53, P69, DOI 10.1093/ilar.53.1.69
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Kalivas PW, 2006, MOL INTERV, V6, P339, DOI 10.1124/mi.6.6.7
   Kalivas PW, 2009, NEUROPHARMACOLOGY, V56, P169, DOI 10.1016/j.neuropharm.2008.07.011
   Knackstedt LA, 2009, CURR OPIN PHARMACOL, V9, P59, DOI 10.1016/j.coph.2008.12.003
   KOOB GF, 1992, ANN NY ACAD SCI, V654, P171, DOI 10.1111/j.1749-6632.1992.tb25966.x
   Koob GF, 2003, EUR NEUROPSYCHOPHARM, V13, P442, DOI 10.1016/j.euroneuro.2003.08.005
   Koob GF, 2006, NEUR ADD
   Luscher C, 2011, NEURON, V69, P650, DOI 10.1016/j.neuron.2011.01.017
   Maze I, 2011, ANN NY ACAD SCI, V1216, P99, DOI 10.1111/j.1749-6632.2010.05893.x
   Michaelides M, 2012, ILAR J, V53, P59, DOI 10.1093/ilar.53.1.59
   Quinones-Jenab V, 2012, ILAR J, V53, P14, DOI 10.1093/ilar.53.1.14
   Volkow ND, 2004, NAT REV NEUROSCI, V5, P963, DOI 10.1038/nrn1539
   Willuhn I, 2010, CURR TOP BEHAV NEURO, V3, P29, DOI 10.1007/7854_2009_27
   Wu PH, 2012, ILAR J, V53, P4, DOI 10.1093/ilar.53.1.4
NR 22
TC 0
Z9 0
U1 0
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1084-2020
EI 1930-6180
J9 ILAR J
JI ILAR J.
PY 2012
VL 53
IS 1
BP 1
EP 3
DI 10.1093/ilar.53.1.1a
PG 3
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Veterinary Sciences
GA 084NP
UT WOS:000314546600010
PM 23520594
OA Green Accepted, Bronze
DA 2023-06-23
ER

PT J
AU Dores, AR
   Carvalho, I
   Burkauskas, J
   Beretta, V
   Ioannidis, K
   Simonato, P
   Gomez, A
   Demetrovics, Z
   Fujiwara, H
   Chamberlain, S
   Fineberg, N
   Barbosa, F
   Corazza, O
AF Dores, A. R.
   Carvalho, I.
   Burkauskas, J.
   Beretta, V.
   Ioannidis, K.
   Simonato, P.
   Gomez, A.
   Demetrovics, Z.
   Fujiwara, H.
   Chamberlain, S.
   Fineberg, N.
   Barbosa, F.
   Corazza, O.
TI Exercise addiction, body dysmorphic disorder, and use of enhancement
   drugs during the COVID-19 pandemic confinement period: A transcultural
   study
SO EUROPEAN PSYCHIATRY
LA English
DT Meeting Abstract
DE COVID-19; Exercise Addiction; body dysmorphic disorder; Use of
   Enhancement Drugs
C1 [Dores, A. R.; Beretta, V.] Polytech Porto, Sch Hlth, Ctr Rehabil Res Ess Pporto, Porto, Portugal.
   [Dores, A. R.] Lab Neuropsychophysiol Fpceup, Porto, Portugal.
   [Dores, A. R.] Ctr Rehabil Res Ess pporto, Fac Psychol & Educ Sci, Porto, Portugal.
   [Dores, A. R.] Polytech Porto, Sch Hlth, Porto, Portugal.
   [Carvalho, I.] Univ Porto, Sch Med, Clin Neurosci & Mental Hlth & Cintesis, Porto, Portugal.
   [Burkauskas, J.] Neuromokslu Inst Palangos Klin, Palanga, Lithuania.
   [Ioannidis, K.; Chamberlain, S.; Fineberg, N.] Univ Cambridge, Dept Psychiat, Cambridge, England.
   [Simonato, P.] Parco Tigli Casa Cura Parco Tigli, Teolo, Italy.
   [Gomez, A.] Pontifical Univ Salamanca, Salamanca, Spain.
   [Demetrovics, Z.] Eotvos Lorand Univ, Inst Psychol, Budapest, Hungary.
   [Fujiwara, H.] Kyoto Univ, Kyoto, Japan.
   [Barbosa, F.] Univ Porto, Fac Psychol & Educ Sci, Lab Neuropsychophysiol, Porto, Portugal.
   [Corazza, O.] Univ Hertfordshire, Dept Clin & Pharmaceut Sci, Hatfield, Herts, England.
C3 Polytechnic Institute of Porto; Universidade do Porto; Polytechnic
   Institute of Porto; Universidade do Porto; University of Cambridge;
   Pontifical University of Salamanca; Eotvos Lorand University; Kyoto
   University; Universidade do Porto; University of Hertfordshire
RI Barbosa, Fernando/L-3836-2014; Burkauskas, Julius/HKO-7051-2023;
   Carvalho, Irene Palmares/L-8031-2013; Demetrovics, Zsolt/F-8613-2010;
   Burkauskas, Julius/I-9718-2019
OI Barbosa, Fernando/0000-0002-3310-5613; Burkauskas,
   Julius/0000-0002-3928-2151; Carvalho, Irene
   Palmares/0000-0001-7981-4442; Demetrovics, Zsolt/0000-0001-5604-7551;
   Burkauskas, Julius/0000-0002-3928-2151
NR 0
TC 1
Z9 1
U1 1
U2 8
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0924-9338
EI 1778-3585
J9 EUR PSYCHIAT
JI Eur. Psychiat.
PD APR
PY 2021
VL 64
SU 1
SI SI
MA EPP0401
BP S290
EP S291
DI 10.1192/j.eurpsy.2021.779
PG 2
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA UM9TU
UT WOS:000693667600331
OA Green Accepted, Green Submitted, gold
DA 2023-06-23
ER

PT J
AU McGinty, EE
   Goldman, HH
   Pescosolido, B
   Barry, CL
AF McGinty, Emma E.
   Goldman, Howard H.
   Pescosolido, Bernice
   Barry, Colleen L.
TI Portraying mental illness and drug addiction as treatable health
   conditions: Effects of a randomized experiment on stigma and
   discrimination
SO SOCIAL SCIENCE & MEDICINE
LA English
DT Article
DE Mental illness; Addiction; Substance use; Stigma; Discrimination
ID ANTIPSYCHOTIC ADHERENCE; PUBLIC CONCEPTIONS; SCHIZOPHRENIA; MEDICATION;
   DISORDERS; ACCESS; LABELS; POLICY; NEWS
AB Despite significant advances in treatment, stigma and discrimination toward persons with mental illness and drug addiction have remained constant in past decades. Prior work suggests that portraying other stigmatized health conditions (i.e., HIV/AIDS) as treatable can improve public attitudes toward those affected. Our study compared the effects of vignettes portraying persons with untreated and symptomatic versus successfully treated and asymptomatic mental illness and drug addiction on several dimensions of public attitudes about these conditions. We conducted a survey-embedded randomized experiment using a national sample (N = 3940) from an online panel. Respondents were randomly assigned to read one of ten vignettes. Vignette one was a control vignette, vignettes 2-5 portrayed individuals with untreated schizophrenia, depression, prescription pain medication addiction and heroin addiction, and vignettes 6-10 portrayed successfully treated individuals with the same conditions. After reading the randomly assigned vignette, respondents answered questions about their attitudes related to mental illness or drug addiction. Portrayals of untreated and symptomatic schizophrenia, depression, and heroin addiction heightened negative public attitudes toward persons with mental illness and drug addiction. In contrast, portrayals of successfully treated schizophrenia, prescription painkiller addiction, and heroin addiction led to less desire for social distance, greater belief in the effectiveness of treatment, and less willingness to discriminate against persons with these conditions. Portrayal of persons with successfully treated mental illness and drug addiction is a promising strategy for reducing stigma and discrimination toward persons with these conditions and improving public perceptions of treatment effectiveness. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [McGinty, Emma E.; Barry, Colleen L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA.
   [Goldman, Howard H.] Univ Maryland, Sch Med, Dept Psychiat, College Pk, MD USA.
   [Pescosolido, Bernice] Indiana Univ, Dept Sociol, Bloomington, IN 47405 USA.
   [Barry, Colleen L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins Bloomberg School of Public
   Health; University System of Maryland; University of Maryland College
   Park; Indiana University System; Indiana University Bloomington; Johns
   Hopkins University; Johns Hopkins Bloomberg School of Public Health
RP McGinty, EE (通讯作者)，Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 624 N Broadway,Room 359, Baltimore, MD 21205 USA.
EM emcginty@jhsph.edu; hh.goldman@verizon.net; pescosol@indiana.edu;
   cbarry@jhsph.edu
FU AIG Inc.; NIMH [1R01MH093414-01A1]; National Science Foundation
   [0818839]; College of Arts and Sciences, Indiana University; Direct For
   Social, Behav & Economic Scie; Divn Of Social and Economic Sciences
   [0818839] Funding Source: National Science Foundation
FX Drs. McGinty, Goldman, Pescosolido, and Barry have no financial
   disclosures. Drs. Barry and McGinty gratefully acknowledge funding from
   AIG Inc. (PI: Barry), and Drs. Barry, McGinty and Goldman gratefully
   acknowledge funding from NIMH 1R01MH093414-01A1 (PI: Barry). The data
   for this study were collected through Time-Sharing Experiments for the
   Social Sciences (TESS), National Science Foundation (grant 0818839). Dr.
   Pescosolido's participation was supported by an infrastructure grant
   from the College of Arts and Sciences, Indiana University.
CR Abadia-Barrero CE, 2006, SOC SCI MED, V62, P1219, DOI 10.1016/j.socscimed.2005.07.006
   Babor Thomas F, 2007, Subst Abus, V28, P7, DOI 10.1300/J465v28n03_03
   Baker L, 2003, JAMA-J AM MED ASSOC, V289, P2400, DOI 10.1001/jama.289.18.2400
   Barry CL, 2013, NEW ENGL J MED, V368, P1077, DOI 10.1056/NEJMp1300512
   Barry CL, 2011, NEW ENGL J MED, V365, P973, DOI 10.1056/NEJMp1108649
   Busch SH, 2013, PSYCHIAT SERV, V64, P520, DOI 10.1176/appi.ps.201200011
   Corrigan PW, 2012, PSYCHIAT SERV, V63, P963, DOI 10.1176/appi.ps.201100529
   Evans-Lacko S, 2012, PSYCHOL MED, V42, P1741, DOI 10.1017/S0033291711002558
   Frank RG, 2006, BETTER NOT WELL MENT
   Garfield RL, 2011, AM J PSYCHIAT, V168, P486, DOI 10.1176/appi.ajp.2010.10060792
   Gaudiano B.A., 2012, INT J SOC PSYCHIAT
   Gilmer TP, 2004, AM J PSYCHIAT, V161, P692, DOI 10.1176/appi.ajp.161.4.692
   Goldman HH, 2010, AM J PSYCHIAT, V167, P1289, DOI 10.1176/appi.ajp.2010.10081174
   Griffiths KM, 2006, BMC PSYCHIATRY, V6, DOI 10.1186/1471-244X-6-21
   Gross K, 2008, POLIT PSYCHOL, V29, P169, DOI 10.1111/j.1467-9221.2008.00622.x
   HAMILL R, 1980, J PERS SOC PSYCHOL, V39, P578, DOI 10.1037/0022-3514.39.4.578
   IYENGAR S, 1990, POLITICAL BEHAV, V0012
   Iyengar S, 1996, ANN AM ACAD POLIT SS, V546, P59, DOI 10.1177/0002716296546001006
   JACOBY WG, 1994, AM J POLIT SCI, V38, P336, DOI 10.2307/2111407
   Kessler R.C., 2011, ARCH GEN PSYCHIAT, pE1
   Knowledge Networks, 2010, KNOWL PAN DES SUMM
   Link BG, 1999, AM J PUBLIC HEALTH, V89, P1328, DOI 10.2105/AJPH.89.9.1328
   LINK BG, 1987, AM J SOCIOL, V92, P1461, DOI 10.1086/228672
   LINK BG, 1986, J HEALTH SOC BEHAV, V27, P289, DOI 10.2307/2136945
   McAfee T, 2013, LANCET, V382, P2003, DOI 10.1016/S0140-6736(13)61686-4
   McGinty EE, 2014, AM J PUBLIC HEALTH, V104, P406, DOI 10.2105/AJPH.2013.301557
   McSween JL, 2002, J HEALTH POLIT POLIC, V27, P773, DOI 10.1215/03616878-27-5-773
   Mojtabai R., 2007, PSYCHIAT SERV, V58
   Mojtabai R, 2010, SOC PSYCH PSYCH EPID, V45, P705, DOI 10.1007/s00127-009-0109-2
   Mueser KT, 2004, LANCET, V363, P2063, DOI 10.1016/S0140-6736(04)16458-1
   Mutz DC, 2011, POPULATION-BASED SURVEY EXPERIMENTS, P1
   Olafsdottir S., 2011, SAGE HDB MENTAL HLTH, P239
   Pescosolido BA, 2013, AM J PUBLIC HEALTH, V103, P853, DOI 10.2105/AJPH.2012.301147
   Pescosolido BA, 2010, AM J PSYCHIAT, V167, P1321, DOI 10.1176/appi.ajp.2010.09121743
   Phelan JC, 2000, J HEALTH SOC BEHAV, V41, P188, DOI 10.2307/2676305
   Rudolph TJ, 2005, AM J POLIT SCI, V49, P660, DOI 10.1111/j.1540-5907.2005.00148.x
   Sartorius N, 2005, REDUCING STIGMA MENT
   SCHNEIDER A, 1993, AM POLIT SCI REV, V87, P334, DOI 10.2307/2939044
   Sirey JA, 2001, AM J PSYCHIAT, V158, P479, DOI 10.1176/appi.ajp.158.3.479
   Slattery K, 2001, J BROADCAST ELECTRON, V45, P290, DOI 10.1207/s15506878jobem4502_6
   Thornicroft G, 2009, LANCET, V373, P408, DOI 10.1016/S0140-6736(08)61817-6
   Valenstein M, 2004, SCHIZOPHRENIA BULL, V30, P255, DOI 10.1093/oxfordjournals.schbul.a007076
   Valenstein M, 2006, J CLIN PSYCHIAT, V67, P1542, DOI 10.4088/JCP.v67n1008
   Wahl O, 2003, J COMMUNITY PSYCHOL, V31, P553, DOI 10.1002/jcop.10072
   Wahl O.F., 1995, MEDIA MADNESS IMAGES
   Wahl O. F., 2002, PSYCHIATR REHABIL J, V6, P9, DOI [10.1080/10973430208408417, DOI 10.1080/10973430208408417]
   Wahl OF, 2003, AM BEHAV SCI, V46, P1594, DOI 10.1177/0002764203254615
   WAHL OF, 1992, J COMMUNITY PSYCHOL, V20, P343, DOI 10.1002/1520-6629(199210)20:4<343::AID-JCOP2290200408>3.0.CO;2-2
   Wahlbeck K., 2011, PSYCHIAT FENNICA, V42, P87
   Wolfe WR, 2008, AM J PUBLIC HEALTH, V98, P1865, DOI 10.2105/AJPH.2007.122044
   Yankelovich D.Y., 1990, RW JOHNSON FDN UNPUB
   Young JL, 1999, J AM ACAD PSYCHIATRY, V27, P426
   Zillmann D., 2000, EXEMPLIFICATION COMM
NR 53
TC 139
Z9 140
U1 2
U2 84
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0277-9536
J9 SOC SCI MED
JI Soc. Sci. Med.
PD FEB
PY 2015
VL 126
BP 73
EP 85
DI 10.1016/j.socscimed.2014.12.010
PG 13
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA CB2AM
UT WOS:000349429100009
PM 25528557
DA 2023-06-23
ER

PT J
AU Karasaki, M
   Fraser, S
   Moore, D
   Dietze, P
AF Karasaki, Mutsumi
   Fraser, Suzanne
   Moore, David
   Dietze, Paul
TI The place of volition in addiction: Differing approaches and their
   implications for policy and service provision
SO DRUG AND ALCOHOL REVIEW
LA English
DT Article
DE addiction; volition; policy; qualitative research; Australia
ID SUBSTANCE-ABUSE; DRUG-ADDICTION; RESPONSIBILITY; ALCOHOL; VIEWS;
   NARRATIVES; RECOVERY; MODELS
AB Introduction. Addiction' is an ambiguous concept. Its meaning, and how it is used in drug policy and treatment, depends on how it is conceptualised. While the disease' model of addiction is prevalent in Australia, differing, sometimes contradictory, interpretations of this model are mobilised. Methods. Drawing on 20 semi-structured interviews conducted with professionals working in the area of drug use in Victoria, Australia, this paper develops a typology delineating different approaches to addiction. Results. Five domains of meaning related to addiction were identified in the data. These were: (i) the sign of craving; (ii) susceptibility; (iii) social and psychological issues producing addiction; (iv) self-concept; and (v) social functions of addiction. These domains are further divided into two subtypes based on how the participants understood the role of a key notion in addiction: volition, that is, whether or not an addict' has control over drug use and other aspects of life. Discussion. By systematically mapping different conceptualisations of addiction, this typology identifies the ambiguities and contradictions in the models currently in use, especially with respect to the notion of volition. While a homogeneous approach to these issues is neither practical nor desirable, there is a need to consider the implications of this lack of coherence. Conclusions. Service providers, medical practitioners and policy makers need to reflect on their assumptions, and consider the implications of their different approaches for clients, some of whom encounter more than one approach when undergoing treatment for drug use. [Karasaki M, Fraser S, Moore D, Dietze P. The place of volition in addiction: Differing approaches and their implications for policy and service provision. Drug Alcohol Rev 2013; 32: 195-204]
C1 [Karasaki, Mutsumi] Monash Univ, Sch Polit & Social Inquiry, Fac Arts, Melbourne, Vic 3004, Australia.
   [Fraser, Suzanne] Monash Univ, Ctr Womens Studies & Gender Res, Sch Polit & Social Inquiry, Fac Arts, Melbourne, Vic 3004, Australia.
   [Moore, David] Curtin Univ Technol, Natl Drug Res Inst, Melbourne, Vic, Australia.
   [Dietze, Paul] Burnet Inst, Ctr Populat Hlth, Melbourne, Vic, Australia.
C3 Monash University; Monash University; Curtin University; Burnet
   Institute
RP Fraser, S (通讯作者)，Monash Univ, Ctr Womens Studies & Gender Res, Sch Polit & Social Inquiry, Fac Arts, Wellington Rd, Clayton, Vic 3800, Australia.
EM Suzanne.fraser@monash.edu
OI Fraser, Suzanne/0000-0003-1018-5865; Dietze, Paul/0000-0001-7871-6234;
   Moore, David/0000-0002-5860-3109
CR ALEXANDER BK, 1988, CAN PSYCHOL, V29, P151, DOI 10.1037/h0084530
   Allsop SJ, 2002, DRUG ALCOHOL REV, V21, P215, DOI 10.1080/0959523021000002660
   Berends L., 2010, DEFINING ALCOHOL OTH
   Bonnie RJ, 2002, J AM ACAD PSYCHIATRY, V30, P405
   BRADIZZA CM, 1994, J BEHAV THER EXP PSY, V25, P15, DOI 10.1016/0005-7916(94)90058-2
   BRICKMAN P, 1982, AM PSYCHOL, V37, P368, DOI 10.1037//0003-066X.37.4.368
   Bright SJ, 2008, ADDICT RES THEORY, V16, P135, DOI 10.1080/16066350701794972
   Burke AC, 1997, SOC WORK, V42, P552, DOI 10.1093/sw/42.6.552
   Burns SL, 2003, SOC PROBL, V50, P416, DOI 10.1525/sp.2003.50.3.416
   Davies J. B., 1992, MYTH ADDICTION APPL
   Davies JB, 1998, PHARMACOL THERAPEUT, V80, P265, DOI 10.1016/S0163-7258(98)00031-X
   Department of Health, 2010, SYST PERF AN ALC OTH
   DIETZE P, 2003, TREATMENT UTILISATIO
   Fitzroy Legal Service, 2010, SERV DIR DRUG ALC US
   GOLDBERG T, 1999, DEMYSTIFYING DRUGS P
   Griffiths M. D., 2005, J SUBST USE, V10, P191, DOI [10.1080/14659890500114359, DOI 10.1080/14659890500114359]
   Hammersley R, 2002, ADDICT RES THEORY, V10, P7, DOI 10.1080/16066350290001687
   Hanninen V, 1999, ADDICTION, V94, P1837, DOI 10.1046/j.1360-0443.1999.941218379.x
   Heale P, 2001, DRUG ALCOHOL REV, V20, P223
   Hopper E, 1995, INT J PSYCHOANAL, V76, P1121
   Kalant H, 2010, ADDICTION, V105, P780, DOI 10.1111/j.1360-0443.2009.02739.x
   Keane H., 2002, WHATS WRONG ADDICTIO
   Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550
   Koski-Jannes A, 2012, SUBST USE MISUSE, V47, P296, DOI 10.3109/10826084.2011.629708
   Leshner AI, 1999, JAMA-J AM MED ASSOC, V282, P1314, DOI 10.1001/jama.282.14.1314
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Ling W, 2011, ADDICTION, V106, P872, DOI 10.1111/j.1360-0443.2010.03343.x
   Moore D, 2006, SOC SCI MED, V62, P3035, DOI 10.1016/j.socscimed.2005.11.067
   Newton TF, 2009, AM J ADDICTION, V18, P294, DOI 10.1080/10550490902925920
   O'Brien CP, 2006, AM J PSYCHIAT, V163, P764, DOI 10.1176/appi.ajp.163.5.764
   Palm J, 2004, ADDICT RES THEORY, V12, P413, DOI 10.1080/16066350412331302103
   Rickwood D., 2005, PERSPECTIVES PSYCHOL
   Roche AM, 1998, DRUG-EDUC PREV POLIC, V5, P85, DOI 10.3109/09687639809035774
   Schulteis G, 1996, NEUROCHEM RES, V21, P1437, DOI 10.1007/BF02532385
   Seale CF., 1999, QUALITY QUALITATIVE, DOI DOI 10.4135/9780857020093
   Seddon T, 2007, ADDICT RES THEORY, V15, P333, DOI 10.1080/16066350701350262
   Seear K, 2010, CRIT PUBLIC HEALTH, V20, P439, DOI 10.1080/09581591003653132
   Shaffer HJ, 1997, SUBST USE MISUSE, V32, P1573, DOI 10.3109/10826089709055879
   Taxman FS, 2003, J SUBST ABUSE TREAT, V25, P75, DOI 10.1016/S0740-5472(03)00115-6
   Treloar C, 2006, DRUG-EDUC PREV POLIC, V13, P367, DOI 10.1080/09687630600761444
   Victorian Auditor-General's Office, 2011, MAN DRUG ALC PREV TR
   West R, 2001, ADDICTION, V96, P3, DOI 10.1046/j.1360-0443.2001.96131.x
   West R., 2006, THEORY ADDICTION
   WURMSER L, 1984, INT J PSYCHOANAL PSY, V10, P227
   Zinberg NE., 1984, DRUG SET SETTING
NR 45
TC 43
Z9 44
U1 1
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0959-5236
EI 1465-3362
J9 DRUG ALCOHOL REV
JI Drug Alcohol Rev.
PD MAR
PY 2013
VL 32
IS 2
BP 195
EP 204
DI 10.1111/j.1465-3362.2012.00501.x
PG 10
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA 102OG
UT WOS:000315853300012
PM 22963577
DA 2023-06-23
ER

PT J
AU Oksanen, A
AF Oksanen, Atte
TI Female rock stars and addiction in autobiographies
SO NORDIC STUDIES ON ALCOHOL AND DRUGS
LA English
DT Article
DE Gender; addiction; drugs; alcoholism; popular culture
ID DRUG-USE; DRINKING; GENDER; RECOVERY; WOMENS; MAGAZINES; BEHAVIORS;
   ALCOHOL; MUSIC; ROLES
AB AIM - This article analyses addiction and rehabilitation as described in the autobiographies, memoirs and diaries of famous female rock artists. The article shows how female artists portray rock culture, addiction and causes to addiction. MATERIAL - The data includes 16 autobiographical books published between 1982 and 2010. These books were published first in English. Female rock artists are marked as the first authors, and all of the books use first-person narration. METHOD - The analysis relies on thematic qualitative analysis and narratology. Data were encoded for addiction, object of addiction, rehabilitation and type of recovery from addiction. Gender was analysed as a separate category. In addition, narrative strategies used in the books were analysed. RESULTS - Addictions and rehabilitation are prevalent themes in autobiographical rock books written by female authors. Many authors write about their personal experiences of addiction and rehabilitation. Those authors who do not portray their personal problems with alcohol or drugs write about staying sober as a way of coping in the male-dominated rock world. CONCLUSIONS - Rock 'n' roll mythology is changing. Rock artists no longer celebrate their excesses, but rather write about their negative experiences with alcohol and drugs. Rock narratives by female stars portray social and gendered settings which lead to addiction.
C1 Finnish Youth Res Network, Helsinki, Finland.
RP Oksanen, A (通讯作者)，Finnish Youth Res Network, Helsinki, Finland.
EM atte.oksanen@uta.fi
RI Oksanen, Atte/AAA-6682-2019
OI Oksanen, Atte/0000-0003-4143-5580
CR [Anonymous], 2003, ROLLING STONE
   [Anonymous], 2010, BODY READER ESSENTIA
   Atkinson A., 2011, YOUNG PEOPLE ALCOHOL
   Auslander Philip, 2004, POP MUSIC, V23, P1, DOI DOI 10.1017/S0261143004000030
   Benatar P., 2010, HEART ROCK PLACE MEM
   Bernhardsson J, 2012, FEM MEDIA STUD, V12, P1, DOI 10.1080/14680777.2011.558344
   Bogren A, 2008, ADDICT RES THEORY, V16, P95, DOI 10.1080/16066350701668895
   Bogren A, 2011, J GENDER STUD, V20, P155, DOI 10.1080/09589236.2011.565196
   Bogren A, 2011, FEM MEDIA STUD, V11, P197, DOI 10.1080/14680777.2010.521627
   Boyatzis R.E., 1998, TRANSFORMING QUALITA
   Brady K.T., 2009, WOMEN ADDICTION COMP
   Clawson MA, 1999, GENDER SOC, V13, P193, DOI 10.1177/089124399013002003
   CURTIS D, 1995, TOUCHING DISTANCE
   Demant J, 2011, SUBST USE MISUSE, V46, P1244, DOI 10.3109/10826084.2011.569965
   DESBARRES P, 1987, IM BAND CONFESSIONS
   Elster J, 1999, ADDICTION, P239
   ETHERIDGE M, 2001, TRUTH IS MY LIFE LOV
   Faithfull Marianne, 1994, FAITHFULL AUTOBIOGRA
   Frith Simon, 1990, RECORD ROCK POP WRIT
   Furedi F, 2004, THERAPY CULTURE CULT
   Gaar G.G., 2002, SHES REBEL HIST WOME
   Gilmore L, 2010, BIOGRAPHY, V33, P657, DOI 10.1353/bio.2010.1006
   Gilmore Leigh, 2001, LIMITS AUTOBIOGRAPHY
   Goode I, 2010, ASHG POP FOLK MUSIC, P27
   Gottleib Joanne, 1994, MICROPHONE FIENDS YO, P250
   Gubrium J. F., 2009, ANAL NARRATIVE REALI
   Hanninen V, 1999, ADDICTION, V94, P1837, DOI 10.1046/j.1360-0443.1999.941218379.x
   Hellman Matilda, 2010, CONSTRUING DEFINING
   Holmila M, 2005, ADDICTION, V100, P1763, DOI 10.1111/j.1360-0443.2005.01249.x
   Huggins Richard, 2006, BODY EMBODIMENT SYMB, P165
   Hunt Geoffrey, 2010, YOUTH DRUGS NIGHTLIF
   Jackson Buzzy, 2005, BAD WOMAN FEELING GO
   Jarvinen M, 2004, NARRAT INQ, V14, P45, DOI 10.1075/ni.14.1.03jar
   Jarvinen M, 2001, SYMB INTERACT, V24, P263, DOI 10.1525/si.2001.24.3.263
   Keane Helen, 2002, CONTEMP DRUG PROBL, V28, P567
   Koski-Jannes A, 2002, ADDICT RES THEORY, V10, P183, DOI 10.1080/16066350290017266
   LIPMANBLUMEN J, 1976, SIGNS, V1, P15, DOI 10.1086/493272
   Lyons AC, 2006, J HEALTH PSYCHOL, V11, P223, DOI 10.1177/1359105306061183
   Markert J, 2001, SOCIOL INQ, V71, P194, DOI 10.1111/j.1475-682X.2001.tb01108.x
   Maunu A., 2007, NAT NORDIC STUDIES A, V24, P177, DOI DOI 10.1177/145507250702400212
   Mayhew Emma, 1999, J INTERDISCIPLINARY, V4, P63
   McLeod Kembrew, 2002, POP MUSIC PRESS, P93
   Oksanen A, 2011, NORD STUD ALCOHOL DR, V28, P357, DOI 10.2478/v10199-011-0030-3
   Oksanen A, 2013, DRUG ALCOHOL REV, V32, P53, DOI 10.1111/j.1465-3362.2012.00474.x
   Oksanen A, 2012, SUBST USE MISUSE, V47, P143, DOI 10.3109/10826084.2012.637441
   Orford J., 2001, EXCESSIVE APPETITES
   Rhodes LL, 2005, ELECTRIC LADYLAND: WOMEN AND ROCK CULTURE, P1
   Riessman C. K., 2008, NARRATIVE METHODS HU
   Room R, 1996, J SUBST ABUSE, V8, P227, DOI 10.1016/S0899-3289(96)90271-0
   Shaw RL, 2010, HEALTH RISK SOC, V12, P575, DOI 10.1080/13698575.2010.515736
   Smith P., 2010, JUST KIDS
   Spector Ronnie, 1990, BE MY BABY I SURVIVE
   Strong C, 2011, J POP CULT, V44, P398, DOI 10.1111/j.1540-5931.2011.00839.x
   Swiss Thomas, 2005, POP MUSIC, V24, P287, DOI DOI 10.1017/S0261143005000504
   Torronen J, 2011, NORD STUD ALCOHOL DR, V28, P251, DOI 10.2478/v10199-011-0023-2
   Warhol Robyn R., 2002, HIGH ANXIETIES CULTU, P97
   Weiland Mary Forsberg, 2009, FALL PIECES MEMOIR D
   White W. L., 2006, COUNSELOR, V7, P46
   Whiteley Sheila, 1997, SEXING GROOVE POPULA
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
NR 83
TC 6
Z9 7
U1 0
U2 11
PU VERSITA
PI WARSAW
PA SOLIPSKA 14A-1, 02-482 WARSAW, POLAND
SN 1455-0725
J9 NORD STUD ALCOHOL DR
JI Nord. Stud. Alcohol Drugs
PD FEB
PY 2013
VL 30
IS 1-2
BP 123
EP 140
DI 10.2478/nsad-2013-0009
PG 18
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA 137FE
UT WOS:000318420100009
DA 2023-06-23
ER

PT J
AU Li, JX
AF Li, Jun-Xu
TI Trace Amines and Cocaine Abuse
SO ACS CHEMICAL NEUROSCIENCE
LA English
DT Editorial Material
DE Trace amine associated receptor 1; cocaine addiction; drug target;
   preclinical
AB Cocaine addiction remains a clinical challenge with no effective pharmacotherapy available. Trace amine associated receptor (TAAR) 1 represents a promising drug target for the modulation of dopaminergic system and stimulant abuse. This Viewpoint discusses the emerging data which strongly suggest that TAAR 1 functions as a molecular "brake" that controls the addiction-related effects of cocaine and could be a novel drug target for the development of efficacious pharmacotherapy to treat cocaine addiction.
C1 SUNY Buffalo, Dept Pharmacol & Toxicol, Buffalo, NY 14214 USA.
C3 State University of New York (SUNY) System; State University of New York
   (SUNY) Buffalo
RP Li, JX (通讯作者)，SUNY Buffalo, Dept Pharmacol & Toxicol, Buffalo, NY 14214 USA.
EM junxuli@buffalo.edu
RI Li, Jun-Xu/K-9192-2013
OI Li, Jun-Xu/0000-0003-4749-0767
FU NIDA NIH HHS [DA034806, DA033426, R01 DA034806] Funding Source: Medline
CR Pei Y, 2014, NEUROPSYCHOPHARMACOL, V39, P2299, DOI 10.1038/npp.2014.88
   Revel FG, 2013, MOL PSYCHIATR, V18, P543, DOI 10.1038/mp.2012.57
   Revel FG, 2012, BIOL PSYCHIAT, V72, P934, DOI 10.1016/j.biopsych.2012.05.014
   Thorn DA, 2014, NEUROPSYCHOPHARMACOL, V39, P2309, DOI 10.1038/npp.2014.91
   Xie Z., 2009, PHARMACOLOGY, V78, P1095
NR 5
TC 5
Z9 5
U1 0
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-7193
J9 ACS CHEM NEUROSCI
JI ACS Chem. Neurosci.
PD JUL
PY 2014
VL 5
IS 7
BP 497
EP 498
DI 10.1021/cn500104s
PG 2
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences
   & Neurology
GA AL6ET
UT WOS:000339226100003
PM 24849494
OA Green Published, hybrid
DA 2023-06-23
ER

PT J
AU Moustafa, AA
   Parkes, D
   Fitzgerald, L
   Underhill, D
   Garami, J
   Levy-Gigi, E
   Stramecki, F
   Valikhani, A
   Frydecka, D
   Misiak, B
AF Moustafa, Ahmed A.
   Parkes, Denise
   Fitzgerald, Louise
   Underhill, Dylan
   Garami, Julia
   Levy-Gigi, Einat
   Stramecki, Filip
   Valikhani, Ahmad
   Frydecka, Dorota
   Misiak, Blazej
TI The relationship between childhood trauma, early-life stress, and
   alcohol and drug use, abuse, and addiction: An integrative review
SO CURRENT PSYCHOLOGY
LA English
DT Review
DE Stress; trauma; PTSD; Addiction; Types of stress; trauma; Learned
   helplessness; Neural studies
AB In this review, we discuss the relationship between childhood trauma, early-life stress, and substance use, abuse, and addiction. We further provide theories and neural studies to explain this relationship as well as potential treatment strategies for alcohol and drug abuse and addiction based on understanding types of early-life stressors that lead to both drug use and relapse.
C1 [Moustafa, Ahmed A.; Parkes, Denise; Fitzgerald, Louise; Underhill, Dylan; Garami, Julia] Western Sydney Univ, Sch Social Sci & Psychol, Sydney, NSW, Australia.
   [Moustafa, Ahmed A.] Western Sydney Univ, Marcs Inst Brain & Behav & Dev, Sydney, NSW, Australia.
   [Levy-Gigi, Einat] Bar Ilan Univ, Sch Educ, Ramat Gan, Israel.
   [Levy-Gigi, Einat] Bar Ilan Univ, Multidisciplinary Brain Res Ctr, Ramat Gan, Israel.
   [Stramecki, Filip; Valikhani, Ahmad] Shiraz Univ, Sch Educ & Psychol, Dept Clin Psychol, Shiraz, Iran.
   [Frydecka, Dorota; Misiak, Blazej] Wroclaw Med Univ, Dept & Clin Psychiat, Wroclaw, Poland.
   [Misiak, Blazej] Wroclaw Med Univ, Dept Genet, Wroclaw, Poland.
C3 Western Sydney University; Western Sydney University; Bar Ilan
   University; Bar Ilan University; Shiraz University; Wroclaw Medical
   University; Wroclaw Medical University
RP Moustafa, AA (通讯作者)，Western Sydney Univ, Sch Social Sci & Psychol, Sydney, NSW, Australia.; Moustafa, AA (通讯作者)，Western Sydney Univ, Marcs Inst Brain & Behav & Dev, Sydney, NSW, Australia.
EM a.moustafa@westernsydney.edu.au
RI Moustafa, Ahmed/AAM-2836-2021; Frydecka, Dorota/ABD-8176-2021;
   Stramecki, Filip/N-7599-2017; Misiak, Błażej/ABA-2657-2021; Valikhani,
   Ahmad/AAF-7161-2020
OI Frydecka, Dorota/0000-0001-8582-9958; Stramecki,
   Filip/0000-0002-5326-8778; Levy-Gigi, Einat/0000-0001-5759-6480; Misiak,
   Blazej/0000-0002-5392-6398
CR Anda RF, 2006, EUR ARCH PSY CLIN N, V256, P174, DOI 10.1007/s00406-005-0624-4
   Boardman JD, 2001, J HEALTH SOC BEHAV, V42, P151, DOI 10.2307/3090175
   Bunce SC, 2015, J ADDICT MED, V9, P53, DOI 10.1097/ADM.0000000000000087
   Burke AR, 2014, PSYCHOPHARMACOLOGY, V231, P1557, DOI 10.1007/s00213-013-3369-1
   Caldji C, 2003, NEUROPSYCHOPHARMACOL, V28, P1950, DOI 10.1038/sj.npp.1300237
   Carliner H, 2016, J AM ACAD CHILD PSY, V55, P701, DOI 10.1016/j.jaac.2016.05.010
   Cuomo C, 2008, AM J DRUG ALCOHOL AB, V34, P339, DOI 10.1080/00952990802010884
   Dom G, 2007, COMPR PSYCHIAT, V48, P178, DOI 10.1016/j.comppsych.2006.08.004
   Dube S. R., 2006, Journal of Adolescent Health, V38, DOI 10.1016/j.jadohealth.2005.06.006
   Enoch MA, 2011, PSYCHOPHARMACOLOGY, V214, P17, DOI 10.1007/s00213-010-1916-6
   Evren C, 2009, J PSYCHOACTIVE DRUGS, V41, P85, DOI 10.1080/02791072.2009.10400677
   Gerra G, 2008, ADDICT BIOL, V13, P95, DOI 10.1111/j.1369-1600.2007.00086.x
   Goldman D, 2005, NAT REV GENET, V6, P521, DOI 10.1038/nrg1635
   Gowing LR, 2015, ADDICTION, V110, P904, DOI 10.1111/add.12899
   Greenfield SF, 2002, DRUG ALCOHOL DEPEN, V67, P227, DOI 10.1016/S0376-8716(02)00072-8
   GRICE DE, 1995, AM J ADDICTION, V4, P297
   Huang S, 2011, ADDICT BEHAV, V36, P95, DOI 10.1016/j.addbeh.2010.09.001
   Hulme PA, 2011, WESTERN J NURS RES, V33, P1069, DOI 10.1177/0193945910388949
   Hyman SM, 2006, AM J DRUG ALCOHOL AB, V32, P655, DOI 10.1080/10623320600919193
   Jaremko KM, 2015, J SUBST ABUSE TREAT, V48, P117, DOI 10.1016/j.jsat.2014.08.006
   Keiflin R, 2015, NEURON, V88, P247, DOI 10.1016/j.neuron.2015.08.037
   Khoury L, 2010, DEPRESS ANXIETY, V27, P1077, DOI 10.1002/da.20751
   KREEK MJ, 1973, JAMA-J AM MED ASSOC, V223, P665, DOI 10.1001/jama.223.6.665
   Kreek MJ, 2005, NAT NEUROSCI, V8, P1450, DOI 10.1038/nn1583
   Kuhlman KR, 2015, J TRAUMA STRESS, V28, P572, DOI 10.1002/jts.22054
   Levran O, 2012, HUM GENET, V131, P823, DOI 10.1007/s00439-012-1172-4
   Lotzin A, 2016, ALCOHOL CLIN EXP RES, V40, P543, DOI 10.1111/acer.12990
   Low NCP, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-116
   Medrano MA, 1999, AM J DRUG ALCOHOL AB, V25, P449, DOI 10.1081/ADA-100101872
   Pena CJ, 2014, EUR J NEUROSCI, V39, P946, DOI 10.1111/ejn.12479
   Pilowsky DJ, 2009, AM J PUBLIC HEALTH, V99, P258, DOI 10.2105/AJPH.2008.139006
   Pruessner JC, 2004, J NEUROSCI, V24, P2825, DOI 10.1523/JNEUROSCI.3422-03.2004
   Ruggiero J, 1999, PSYCHIAT ANN, V29, P713, DOI 10.3928/0048-5713-19991201-12
   Schwandt ML, 2013, ALCOHOL CLIN EXP RES, V37, P984, DOI 10.1111/acer.12053
   Shand FL, 2011, ADDICTION, V106, P590, DOI 10.1111/j.1360-0443.2010.03217.x
   Sinha R, 2006, ARCH GEN PSYCHIAT, V63, P324, DOI 10.1001/archpsyc.63.3.324
   Tavolacci MP, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-724
   Thompson MP, 2004, AM J PUBLIC HEALTH, V94, P599, DOI 10.2105/AJPH.94.4.599
   Ullman SE, 2013, ADDICT BEHAV, V38, P2219, DOI 10.1016/j.addbeh.2013.01.027
   United Nations Office on Drugs and Crime, 2012, WORLD DRUG REP
   Walitzer KS, 2006, CLIN PSYCHOL REV, V26, P128, DOI 10.1016/j.cpr.2005.11.003
   Widom Cathy Spatz, 2007, Arch Gen Psychiatry, V64, P49
   Widom CS, 2006, PSYCHOL ADDICT BEHAV, V20, P394, DOI 10.1037/0893-164X.20.4.394
   WIDOM CS, 1995, J STUD ALCOHOL, V56, P207, DOI 10.15288/jsa.1995.56.207
   Wu NS, 2010, ADDICT BEHAV, V35, P68, DOI 10.1016/j.addbeh.2009.09.003
   Zhang XL, 2011, AM J PSYCHIAT, V168, P610, DOI 10.1176/appi.ajp.2010.10040499
   Zhou Y, 1996, J PHARMACOL EXP THER, V279, P351
NR 47
TC 38
Z9 38
U1 10
U2 111
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1046-1310
EI 1936-4733
J9 CURR PSYCHOL
JI Curr. Psychol.
PD FEB
PY 2021
VL 40
IS 2
BP 579
EP 584
DI 10.1007/s12144-018-9973-9
PG 6
WC Psychology, Multidisciplinary
WE Social Science Citation Index (SSCI)
SC Psychology
GA QM0IJ
UT WOS:000621462000011
DA 2023-06-23
ER

PT J
AU Nubukpo, P
   Clement, JP
AF Nubukpo, Philippe
   Clement, Jean-Pierre
TI Medical drug abuse and aging
SO GERIATRIE ET PSYCHOLOGIE NEUROPSYCHIATRIE DE VIEILLISSEMENT
LA French
DT Article
DE addictions; drugs; elderly; epidemiology; clinic; prevention; care
ID OLDER-ADULTS; SUBSTANCE-ABUSE; BENZODIAZEPINES; PREVALENCE
AB Drug addiction is often underestimated among the aged. Opiate drugs (mostly pain killers) are the most frequently implicated in drug addiction after benzodiazepines (BZD) in the aged. The subjects aged of 65 years or more are the most represented among the BZD users in France. Frequency of BZD use varies according to various studies from 39 to 55% in this age group. Leading a lonely life is associated with the use of psychotropic drugs among retired people (OR = 1.7). Vulnerability at this age must take into account not only polypathology, but also the faster aging of a minority of the population under opiate drugs substitution treatment (OST), more subjects to drugs interaction. Drug addiction among elderly often reflects the drift of "lawful" doctor's instructions that leads to an increase in drugs use. The difficulty has to do with a lack of specificity of diagnosis of addiction at this age, but perhaps also with physicans' instructions in the aged. Some authors suggest that continued and prolonged use should be considered the main criterion for BZD addiction at this age, with or without increase in doses and failed attempt at cessation. Besides, the prescription of BZD increases after retirement and loneliness.
C1 [Nubukpo, Philippe] Ctr Hosp Esquirol, Limoges, France.
   [Nubukpo, Philippe] Ctr Hosp La Valette, St Vaury, France.
   [Clement, Jean-Pierre] Ctr Hosp Esquirol, Pole Univ Psychiat Adulte & Personne Agee, Limoges, France.
   [Nubukpo, Philippe; Clement, Jean-Pierre] CHU Limoges, Fac Med, UMR Inserm NET 1094, Limoges, France.
   [Nubukpo, Philippe; Clement, Jean-Pierre] Ctr Hosp Esquirol, Ctr Memoire Ressources & Rech Limousin, Limoges, France.
C3 CHU Limoges; Institut National de la Sante et de la Recherche Medicale
   (Inserm)
RP Nubukpo, P (通讯作者)，Ctr Hosp Esquirol, Limoges, France.
EM philippe.nubukpo@9online.fr
CR Beaujouan L, 2005, ANN FR ANESTH, V24, P471, DOI 10.1016/j.annfar.2005.02.023
   Broers B., 2008, COMMUNICATION ORALE
   BUSTO U, 1986, BRIT J ADDICT, V81, P87
   Colliver JD, 2006, ANN EPIDEMIOL, V16, P257, DOI 10.1016/j.annepidem.2005.08.003
   Egan M, 2000, J AM GERIATR SOC, V48, P811, DOI 10.1111/j.1532-5415.2000.tb04758.x
   Fernandez L, 2001, ENCEPHALE, V27, P459
   Fourrier A, 1996, REV GERIATRIE, V21, P447
   Gfroerer J, 2003, DRUG ALCOHOL DEPEN, V69, P127, DOI 10.1016/S0376-8716(02)00307-1
   Guillou-Landreat M, 2011, REV GERIATR, V36, P369
   Haute autorite de sante (HAS), 2007, MODALITES DARRET DES
   Le Nezet O, 2009, TENDANCES, P67
   LIR-ESSEC Business school, 2013, SYNTHESE DE LETUDE E
   Manchikanti L, 2008, PAIN PHYSICIAN SUPPL, V11, pS33
   Nomine P, 1987, CONFRONTATIONS PSYCH, V20, P9
   OFDT, 2010, NOTE NO 2010 12
   Pelissolo A., 1996, SYNAPSE, V131, P37
   Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x
   Petrovic M, 2003, ACTA CLIN BELG, V58, P27, DOI 10.1179/acb.2003.58.1.004
   Petrovic M, 2002, INT J GERIATR PSYCH, V17, P733, DOI 10.1002/gps.677
   Rosen D, 2008, AM J GERIAT PSYCHIAT, V16, P488, DOI 10.1097/JGP.0b013e31816ff35a
   Rouleau Annick, 2003, Sante Ment Que, V28, P149
   Sacco P, 2013, DRUG ALCOHOL DEPEN, V131, P157, DOI 10.1016/j.drugalcdep.2012.10.008
   Simoni-Wastila Linda, 2006, Am J Geriatr Pharmacother, V4, P380, DOI 10.1016/j.amjopharm.2006.10.002
   TAMBLYN RM, 1994, CAN MED ASSOC J, V150, P1801
   Venisse JL, 2007, RAPPORT POUR LA MILD
   Wu LT, 2011, J AGING HEALTH, V23, P481, DOI 10.1177/0898264310386224
NR 26
TC 3
Z9 3
U1 3
U2 18
PU JOHN LIBBEY EUROTEXT LTD
PI MONTROUGE
PA 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE
SN 2115-8789
EI 2115-7863
J9 GERIATR PSYCHOL NEUR
JI Geriatr. Psychol. Neuropsychiat. Vieil.
PD SEP
PY 2013
VL 11
IS 3
BP 305
EP 315
DI 10.1684/pnv.2013.0415
PG 11
WC Psychiatry; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Psychiatry; Psychology
GA 228DG
UT WOS:000325164900009
PM 24026133
DA 2023-06-23
ER

PT J
AU Flensburg, OL
   Richert, T
   Fritz, MV
AF Flensburg, Olivia Liahaugen
   Richert, Torkel
   Fritz, Marie Vafors
TI Parents of adult children with drug addiction dealing with shame and
   courtesy stigma
SO DRUGS-EDUCATION PREVENTION AND POLICY
LA English
DT Article; Early Access
DE Alienation; courtesy stigma; drug addiction; parents; selective
   openness; shame
ID MENTAL-ILLNESS; FAMILY BURDEN; EXPERIENCES; ABUSE; ADOLESCENTS; IMPACT;
   SELF
AB The study aims to provide insight into the lives of parents to adult children with drug addiction. We focus on how the parents' social life and interactions were affected by feelings of guilt and shame, and how they dealt with the stigma that often accompanies drug addiction. 32 semi-structured interviews were conducted with parents (age 46-70) of adult children (age 18-47) with drug addiction in Sweden. Three themes emerged (1) Experiences of guilt, shame, and courtesy stigma, (2) Impact on social life and relationships and, (3) Strategies to reduce guilt and shame. Guilt, shame, and courtesy stigma complicated and restricted the parents' social interactions. Many parents applied a selective openness, carried experiences of alienation and in some cases isolated themselves. At the same time, several parents described that they were open about their child's addiction in certain contexts. For some parents, this meant a relief from guilt and shame and an opportunity for increased social interaction. Both informal and professional support for family members of individuals with drug addiction is vital to reduce experiences of guilt, shame, and courtesy stigma.
C1 [Flensburg, Olivia Liahaugen; Richert, Torkel] Malmo Univ, Dept Social Work, S-20506 Malmo, Sweden.
   [Fritz, Marie Vafors] Malmo Univ, Dept Criminol, Malmo, Sweden.
C3 Malmo University; Malmo University
RP Flensburg, OL (通讯作者)，Malmo Univ, Dept Social Work, S-20506 Malmo, Sweden.
EM Olivia.liahaugen@mau.se
OI Richert, Torkel/0000-0003-0653-0849; Liahaugen Flensburg,
   Olivia/0000-0002-2339-2647
CR BARKER JC, 2006, INT J DRUG POLICY, V15, P347, DOI DOI 10.1016/J.DRUGPO.2004.07.002
   Barnard M., 2005, DRUGS FAMILY IMPACT
   Black BP, 2002, JOGNN-J OBST GYN NEO, V31, P688, DOI 10.1177/0884217502239211
   Bryant A., 2007, SAGE HDB GROUNDED TH, P31, DOI DOI 10.4135/9781848607941.N1
   Burns VF., 2021, CONTEMP DRUG PROBL, V48, P223, DOI [10.1177/00914509211031092, DOI 10.1177/00914509211031092]
   Butler R, 2005, DRUG-EDUC PREV POLIC, V12, P35, DOI 10.1080/0968763042000275308
   Charmaz, 2014, CONSTRUCTING GROUNDE
   Choate PW, 2015, BEHAV SCI-BASEL, V5, P461, DOI 10.3390/bs5040461
   Choate PW, 2011, PROCD SOC BEHV, V30, DOI 10.1016/j.sbspro.2011.10.263
   Corrigan PW, 2006, J FAM PSYCHOL, V20, P239, DOI 10.1037/0893-3200.20.2.239
   Corrigan PW, 2015, PSYCHIAT RES, V229, P148, DOI 10.1016/j.psychres.2015.07.053
   Devaney E, 2017, DRUG-EDUC PREV POLIC, V24, P359, DOI 10.1080/09687637.2017.1340433
   Dube SR, 2003, PEDIATRICS, V111, P564, DOI 10.1542/peds.111.3.564
   Francis AA, 2012, J CONTEMP ETHNOGR, V41, P371, DOI 10.1177/0891241611426142
   Goffman E., 1963, STIGMA NOTES MANAGEM, P168
   Groenewald C, 2016, INT J MENT HEALTH AD, V14, P646, DOI 10.1007/s11469-015-9605-7
   Hlungwani Evelyn N., 2020, Curationis, V43, P1, DOI 10.4102/curationis.v43i1.2139
   Hojer I., 2012, TO RAISE FAMILY TXB, P88
   Holstein J. A., 2016, QUAL RES, P67
   Jackson Debra, 2006, Contemp Nurse, V23, P321
   Jackson Debra, 2003, Contemp Nurse, V14, P169
   Jackson I.C., 2018, UNIVERSAL J PSYCHOL, V6, P19, DOI [https://doi.org/10.13189/ujp.2018.060103, DOI 10.13189/UJP.2018.060103]
   Flensburg OL, 2022, DRUG-EDUC PREV POLIC, V29, P255, DOI 10.1080/09687637.2021.1897525
   Lind J., 2016, DOING GOOD PARENTHOO, P1
   Lloyd C, 2013, DRUG-EDUC PREV POLIC, V20, P85, DOI 10.3109/09687637.2012.743506
   Mafa P., 2019, GENDER BEHAV, V17, P14116
   Mafa P, 2020, PERTANIKA J SOC SCI, V28, P1925
   Mathibela F, 2021, J SUBST ABUSE TREAT, V120, DOI 10.1016/j.jsat.2020.108178
   McCann TV, 2018, INT J MENT HEALTH NU, V27, P693, DOI 10.1111/inm.12355
   McDonagh D., 2019, CHILD CARE PRACT, V25, P175, DOI DOI 10.1080/13575279.2018.1448258
   Morse J.M., 2010, SAGE HDB GROUNDED TH, P229, DOI DOI 10.4135/9781848607941.N11
   Nordgren J, 2020, J FAM ISSUES, V41, P567, DOI 10.1177/0192513X19879200
   Oreo A, 2007, ADDICT RES THEORY, V15, P71, DOI 10.1080/16066350601036169
   Orford J, 2013, SOC SCI MED, V78, P70, DOI 10.1016/j.socscimed.2012.11.036
   Orford J, 2010, DRUG-EDUC PREV POLIC, V17, P44, DOI 10.3109/09687637.2010.514192
   Richert T, 2021, J SOC SOC WORK RES, V12, P677, DOI 10.1086/712894
   Richert T, 2018, J FAM ISSUES, V39, P2311, DOI 10.1177/0192513X17748695
   Sales E, 2003, QUAL LIFE RES, V12, P33, DOI 10.1023/A:1023513218433
   SCHEFF T, 1990, MICROSOCIOLOGY DISCO
   Scheff TJ, 2000, SOCIOL THEOR, V18, P84, DOI 10.1111/0735-2751.00089
   Scheff TJ, 2003, SYMB INTERACT, V26, P239, DOI 10.1525/si.2003.26.2.239
   SCHENE AH, 1990, SOC PSYCH PSYCH EPID, V25, P289, DOI 10.1007/BF00782883
   Smith JM, 2014, J FAM NURS, V20, P415, DOI 10.1177/1074840714554397
   Sturges JE, 2004, QUAL RES, V4, P107, DOI DOI 10.1177/1468794104041110
   Usher K, 2007, INT J MENT HEALTH NU, V16, P422, DOI 10.1111/j.1447-0349.2007.00497.x
NR 45
TC 0
Z9 0
U1 2
U2 12
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0968-7637
EI 1465-3370
J9 DRUG-EDUC PREV POLIC
JI Drug-Educ. Prev. Policy
PD 2022 JUL 18
PY 2022
DI 10.1080/09687637.2022.2099249
EA JUL 2022
PG 10
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA 3A8EC
UT WOS:000827486300001
OA hybrid, Green Published
DA 2023-06-23
ER

PT J
AU Pacini, M
   Maremmani, I
AF Pacini, Matteo
   Maremmani, Icro
TI Malleus maleficarum ... the superstition of psychosocially centred
   intervention in addictive diseases. Heroin Addiction as case study
SO HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS
LA English
DT Article
DE addiction treatment philosophy; psychosocially centred interventions;
   drug addiction; heroin addiction
ID OPIOID MAINTENANCE TREATMENT; CURRENT STATE; DEPENDENCE; TOLERANCE;
   OUTCOMES; ABUSE
AB The meaning of psychosocial features in drug addiction is often misunderstood. They are often regarded as the core of the disease, or as independent indicators of global severity, instead of being interpreted as possible expressions and consequences of addictive psychopathology. Furthermore, evidence about the psychosocial impairment of drug addicts is treated as if it were directly dependent on the theory and practice of psychosocially based treatment of such patients. Thus, we have become familiar with the paradox according to which psychosocial requirements or engagement are employed as therapeutic instruments in treating a condition characterized by the disruption and neutralization of psychosocial resources. We have tried to analyse the role of psychosocial factors in the diagnosis and treatment of drug addiction, with the aim of distinguishing between the possible frontiers of psychosocially assisted treatment and the counterproductive psychosocial engagement of untreated drug addicts. We have also tried to classify those factors and psychosocial treatments by applying the criterion of consistency with the main aims and known dynamics of drug addiction treatment.
C1 [Maremmani, Icro] Univ Pisa, Santa Chiara Univ Hosp, Vincent P Dole Dual Diag Unit, Dept Neurosci, I-56100 Pisa, Italy.
   [Pacini, Matteo; Maremmani, Icro] G De Lisio Inst Behav Sci Pisa, Pisa, Italy.
   [Maremmani, Icro] Assoc Applicat Neurosci Knowledge Social Aims AU, Lucca, Italy.
C3 University of Pisa
RP Maremmani, I (通讯作者)，Univ Pisa, Santa Chiara Univ Hosp, Vincent P Dole Dual Diag Unit, Dept Neurosci, Via Roma 67, I-56100 Pisa, Italy.
EM maremman@med.unipi.it
RI Pacini, Matteo/AAC-6832-2021
OI Pacini, Matteo/0000-0002-8195-9963
CR A.P.A, 2000, DSM 4 TR DIAGN STAT
   Apostolova I, 2010, PSYCHIAT RES-NEUROIM, V184, P105, DOI 10.1016/j.pscychresns.2010.08.012
   Arria AM, 2012, SUBST USE MISUSE, V47, P1041, DOI 10.3109/10826084.2012.663273
   Ausebel D. P., 1958, DRUG ADDICTION PHYSL
   Benyamina A, 2012, HEROIN ADDICT REL CL, V14, P65
   Bergen Kommune, 2012, LEG REH LAR
   CritsChristoph P, 1996, ARCH GEN PSYCHIAT, V53, P749
   Dale-Perera A, 2012, HEROIN ADDICT REL CL, V14, P23
   DOLE VP, 1980, SCI AM, V243, P138, DOI 10.1038/scientificamerican1280-138
   Fischer G, 2012, HEROIN ADDICT REL CL, V14, P5
   GOLDBERG SR, 1986, BEHAV ANAL DRUG DEPE
   Goulao J, 2012, HEROIN ADDICT REL CL, V14, P7
   Isaacs D, 1999, BRIT MED J, V319, P1618, DOI 10.1136/bmj.319.7225.1618
   Italian Governement Presidenza Del Consiglio Dei Ministri Dipartimento Poliche Antidroga, 2012, REL ANN PARL STAT TO
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kantchelov A., 2009, PRINCIPLES PRACTICE, P233
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Lovrecic M., 2002, HEROIN ADDICT REL CL, V4, P5
   Maremmani I., 2009, PRINCIPLES PRACTICE, P21
   Maremmani I., 2003, HEROIN ADDICT RELAT, V5, P5
   Maremmani I., 2009, PRINCIPLES PRACTICE, P87
   Maremmani I., 2006, MED TOSSICODIPENDENZ, V48-49, P61
   Maremmani I., 2008, HEROIN ADDICT REL CL, V10, P41
   Maremmani I., 1995, DRUG ADDICTION RELAT, P225
   Maremmani I, 2007, J SUBST ABUSE TREAT, V33, P91, DOI 10.1016/j.jsat.2006.11.009
   Maremmani I, 2011, HEROIN ADDICT REL CL, V13, P5
   Martin W. R, 1972, DRUG ABUSE, P153
   MARTIN WR, 1969, J PSYCHIAT RES, V7, P9, DOI 10.1016/0022-3956(69)90007-7
   Mayet S, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004330.pub2
   MCLELLAN AT, 1993, JAMA-J AM MED ASSOC, V269, P1953, DOI 10.1001/jama.269.15.1953
   McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689
   Pacini M., 2008, B FARMACODIPENDENZE, VXXXI, P247
   PAYTE JT, 2004, HEROIN ADDICT REL CL, V6, P37
   Quilici C., 2007, HEROIN ADDICT RELAT, V9, P35
   Rovai L., 2013, RIV PSICHIATRIA, V48
   Simioni N, 2012, MED HYPOTHESES, V79, P894, DOI 10.1016/j.mehy.2012.09.021
   Steckler T, 2012, NEUROPHARMACOLOGY, V62, P617, DOI 10.1016/j.neuropharm.2011.06.012
   Stover H, 2012, HEROIN ADDICT REL CL, V14, P51
   Strang J, 2003, BMJ-BRIT MED J, V326, P959, DOI 10.1136/bmj.326.7396.959
   Volkow ND, 2004, NAT REV NEUROSCI, V5, P963, DOI 10.1038/nrn1539
NR 40
TC 3
Z9 3
U1 0
U2 2
PU PACINI EDITORE
PI PISA
PA VIA DELLA GHERARDESCA-ZONA INDUSTRIALE OSPEDALETTO, 56121 PISA, ITALY
SN 1592-1638
J9 HEROIN ADDICT REL CL
JI Heroin Addict. Relat. Clin. Probl.
PD SEP
PY 2013
VL 15
IS 3
BP 9
EP 18
PG 10
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA AL6GK
UT WOS:000339230400002
DA 2023-06-23
ER

PT J
AU Maze, I
   Lepack, A
   Farrelly, L
   Werner, C
   Smith, A
   Lyu, Y
   Thompson, R
   O'Connor, R
   Bastle, R
   Muirt, T
   Dietz, D
   Kenny, P
AF Maze, Ian
   Lepack, Ashley
   Farrelly, Lorna
   Werner, Craig
   Smith, Alexander
   Lyu, Yang
   Thompson, Robert
   O'Connor, Richard
   Bastle, Ryan
   Muirt, Tom
   Dietz, David
   Kenny, Paul
TI Deciphering Roles for Aberrant Histone Dopaminylation in Drug Addiction
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Meeting Abstract
DE Epigenetics; Dopamine; Cocaine Addiction; Histone
C1 [Maze, Ian; Lepack, Ashley; Farrelly, Lorna; Werner, Craig; Smith, Alexander; Lyu, Yang; Thompson, Robert; O'Connor, Richard; Bastle, Ryan; Muirt, Tom; Dietz, David; Kenny, Paul] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai
RI Dietz, David/AAW-4574-2021
OI Dietz, David/0000-0002-6927-9236
NR 0
TC 0
Z9 0
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
EI 1740-634X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD DEC
PY 2018
VL 43
SU S
MA W242
BP S504
EP S505
PG 2
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA VI6YX
UT WOS:000509546600918
DA 2023-06-23
ER

PT J
AU Templeman, D
   Shelling, J
AF Templeman, David
   Shelling, Jane
TI Addiction libraries in Australia: collective amnesia threat
SO ADDICTION
LA English
DT Letter
DE ADCA; addiction; alcohol-drugs; librarians; libraries; SALIS
C1 [Templeman, David; Shelling, Jane] Alcohol & Other Drugs Council Australia, Natl Drugs Sect Informat Serv, Canberra, ACT, Australia.
RP Templeman, D (通讯作者)，Alcohol & Other Drugs Council Australia, Natl Drugs Sect Informat Serv, Canberra, ACT, Australia.
EM jane.shelling@adca.org.au
CR Curtis+Cartwright Consulting Limited, 2011, VAL LIB RES RES
   Douglas B., 2012, 2 AUSTRALIA21 ROUNDT
   Mitchell AL, 2012, ADDICTION, V107, P1367, DOI 10.1111/j.1360-0443.2012.03813.x
   Reinarman C, 2005, INT J DRUG POLICY, V16, P1, DOI 10.1016/j.drugpo.2004.12.001
   Shelling J, 2012, AUST ACAD RES LIBR, V43, P135, DOI 10.1080/00048623.2012.10722266
   Sun HC, 2011, NEW LIB WORLD, V112, P321, DOI 10.1108/03074801111150459
NR 6
TC 0
Z9 0
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0965-2140
EI 1360-0443
J9 ADDICTION
JI Addiction
PD FEB
PY 2013
VL 108
IS 2
BP 436
EP 436
DI 10.1111/add.12029
PG 1
WC Substance Abuse; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry
GA 073MD
UT WOS:000313746200037
PM 23331893
OA Bronze
DA 2023-06-23
ER

PT C
AU Borjkhani, M
   Mahdavi, A
   Bahrami, F
AF Borjkhani, Mehdi
   Mahdavi, Ali
   Bahrami, Fariba
GP IEEE
TI A mathematical model for neuron astrocytes interactions in hippocampus
   during addiction
SO 2014 21th Iranian Conference on Biomedical Engineering (ICBME)
LA English
DT Proceedings Paper
CT 21th Iranian Conference on Biomedical Engineering
CY NOV 26-28, 2014
CL Tehran, IRAN
SP IEEE
DE mathematical modeling; Addiction; tripartite synapse
ID LONG-TERM POTENTIATION; SYNAPTIC PLASTICITY; PYRAMIDAL NEURONS;
   GLUTAMATE; NICOTINE; RELEASE; DYNAMICS; OPIATES; CALCIUM
AB Addiction is a chronic disorder whereby addicted individuals compulsively engage in drug seeking despite its negative consequences. Hippocampus has unavoidable role in addiction because of its importance in learning and memory. Any modification of hippocampal cells alters dopamine levels in NAc and firing rates of VTA dopaminergic cells. In order to have a better understanding of the addiction in cellular level, we present a mathematical model of a tripartite synapse in hippocampus. The proposed model can show some functions of synapses under addiction that may contribute to drug seeking and relapse behaviors. The model is based on glutamate alterations in synaptic cleft during drug abuse.
   Experimental studies suggest that during drug abuse, NMDAR dependent synaptic transmission is increased. According to our simulation results, dysfunction of astrocyte has a significant role in initiating addiction. Since healthy astrocytes has a comprehensive control over synaptic interactions it may use to treat addicted related behaviors. Also, we may conclude that addiction causes abnormalities on postsynaptic signaling such as NMDA currents. Furthermore, we may suggest that drug induced D-serine enhancement in synaptic cleft potentiate post synaptic calcium influx and LTP.
C1 [Borjkhani, Mehdi; Mahdavi, Ali; Bahrami, Fariba] Univ Tehran, Mot Control & Computat Neurosci Lab, Control & Intelligent Proc Ctr Excellence, Sch Elect & Comp Engn,Coll Engn, Tehran, Iran.
C3 University of Tehran
RP Borjkhani, M (通讯作者)，Univ Tehran, Mot Control & Computat Neurosci Lab, Control & Intelligent Proc Ctr Excellence, Sch Elect & Comp Engn,Coll Engn, Tehran, Iran.
EM m.borjkhani@ut.ac.ir
CR Caffino L, 2014, PHARMACOL REP, V66, P198, DOI 10.1016/j.pharep.2013.09.002
   Dani JA, 2001, NEURON, V31, P349, DOI 10.1016/S0896-6273(01)00379-8
   De Pitta M, 2009, J BIOL PHYS, V35, P383, DOI 10.1007/s10867-009-9155-y
   Eisch AJ, 2006, HIPPOCAMPUS, V16, P271, DOI 10.1002/hipo.20161
   Gass JT, 2008, BIOCHEM PHARMACOL, V75, P218, DOI 10.1016/j.bcp.2007.06.039
   Golomb D, 2006, J NEUROPHYSIOL, V96, P1912, DOI 10.1152/jn.00205.2006
   Kauer JA, 2007, NAT REV NEUROSCI, V8, P844, DOI 10.1038/nrn2234
   Kelley AE, 2003, ANN NY ACAD SCI, V1003, P159, DOI 10.1196/annals.1300.061
   Kenney JW, 2008, MOL NEUROBIOL, V38, P101, DOI 10.1007/s12035-008-8037-9
   Koch C., 1998, METHODS NEURONAL MOD
   Lopez-Hidalgo M., 2012, BIOM ENG ICBME 2013, V7
   Lopez-Hidalgo M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049998
   Nadkarni S, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000088
   Nakauchi S, 2007, EUR J NEUROSCI, V25, P2666, DOI 10.1111/j.1460-9568.2007.05513.x
   Nowacki J, 2011, PROG BIOPHYS MOL BIO, V105, P34, DOI 10.1016/j.pbiomolbio.2010.09.020
   Parpura V, 2000, P NATL ACAD SCI USA, V97, P8629, DOI 10.1073/pnas.97.15.8629
   Placzek AN, 2009, ACTA PHARMACOL SIN, V30, P752, DOI 10.1038/aps.2009.39
   Pu L, 2002, J NEUROSCI, V22, P1914, DOI 10.1523/JNEUROSCI.22-05-01914.2002
   Rosato-Siri M, 2006, J PHYSIOL-LONDON, V576, P361, DOI 10.1113/jphysiol.2006.114587
   Schmidt HD, 2010, ANN NY ACAD SCI, V1187, P35, DOI 10.1111/j.1749-6632.2009.05144.x
   Scofield MD, 2014, NEUROSCIENTIST
   Shuai JW, 2002, BIOPHYS J, V83, P87, DOI 10.1016/S0006-3495(02)75151-5
   Szabo SI, 2008, HIPPOCAMPUS, V18, P376, DOI 10.1002/hipo.20401
   Tewari SG, 2012, J BIOL PHYS, V38, P465, DOI 10.1007/s10867-012-9267-7
   Tsodyks MV, 1997, P NATL ACAD SCI USA, V94, P719, DOI 10.1073/pnas.94.2.719
   Uys JD, 2008, CNS NEUROL DISORD-DR, V7, P482, DOI 10.2174/187152708786927868
   Wang H. L., 2006, EUROPEAN J NEUROSCIE, V23, P1111
NR 27
TC 0
Z9 0
U1 1
U2 4
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 978-1-4799-7418-4
PY 2014
BP 303
EP 308
PG 6
WC Engineering, Biomedical
WE Conference Proceedings Citation Index - Science (CPCI-S)
SC Engineering
GA BF3KK
UT WOS:000380551500058
DA 2023-06-23
ER

PT J
AU Hadad, NA
   Knackstedt, LA
AF Hadad, Natalie A.
   Knackstedt, Lori A.
TI Addicted to palatable foods: comparing the neurobiology of Bulimia
   Nervosa to that of drug addiction
SO PSYCHOPHARMACOLOGY
LA English
DT Review
DE Bulimia nervosa; Addiction; Neurobiology; Dopamine; Glutamate; Opioid;
   Palatable food; Bingeing; Sugar; Sucrose
ID VENTRAL TEGMENTAL AREA; TRANSPORTER MESSENGER-RNA; MESOLIMBIC DOPAMINE
   TRANSMISSION; DIFFERENTIALLY AFFECT INTAKE; CUE-INDUCED REINSTATEMENT;
   MEDIAL PREFRONTAL CORTEX; SELF-REGULATORY CONTROL; BINGE-EATING
   DISORDER; RAT NUCLEUS-ACCUMBENS; DELTA-FOSB
AB Bulimia nervosa (BN) is highly comorbid with substance abuse and shares common phenotypic and genetic predispositions with drug addiction. Although treatments for the two disorders are similar, controversy remains about whether BN should be classified as addiction.
   Here, we review the animal and human literature with the goal of assessing whether BN and drug addiction share a common neurobiology.
   Similar neurobiological features are present following administration of drugs and bingeing on palatable food, especially sugar. Specifically, both disorders involve increases in extracellular dopamine (DA), D1 binding, D3 messenger RNA (mRNA), and Delta FosB in the nucleus accumbens (NAc). Animal models of BN reveal increases in ventral tegmental area (VTA) DA and enzymes involved in DA synthesis that resemble changes observed after exposure to addictive drugs. Additionally, alterations in the expression of glutamate receptors and prefrontal cortex activity present in human BN or following sugar bingeing in animals are comparable to the effects of addictive drugs. The two disorders differ in regards to alterations in NAc D2 binding, VTA DAT mRNA expression, and the efficacy of drugs targeting glutamate to treat these disorders.
   Although additional empirical studies are necessary, the synthesis of the two bodies of research presented here suggests that BN shares many neurobiological features with drug addiction. While few Food and Drug Administration-approved options currently exist for the treatment of drug addiction, pharmacotherapies developed in the future, which target the glutamate, DA, and opioid systems, may be beneficial for the treatment of both BN and drug addiction.
C1 [Hadad, Natalie A.; Knackstedt, Lori A.] Univ Florida, Dept Psychol, Gainesville, FL 32611 USA.
C3 State University System of Florida; University of Florida
RP Knackstedt, LA (通讯作者)，Univ Florida, Dept Psychol, POB 112250, Gainesville, FL 32611 USA.
EM knack@ufl.edu
RI Knackstedt, Lori A/K-1956-2014
CR ACQUAS E, 1992, J NEUROCHEM, V58, P1620, DOI 10.1111/j.1471-4159.1992.tb10033.x
   Alen F, 2008, EUR J NEUROSCI, V27, P3292, DOI 10.1111/j.1460-9568.2008.06302.x
   American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4th, DOI [DOI 10.1176/DSM10.1176/APPI.BOOKS.9780890420249.DSM-IV-TR, DOI 10.1016/B978-1-4377-2242-0.00016-X]
   American Psychiatric Association [APA], 2022, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425787]
   Avena NM, 2008, NEUROSCIENCE, V156, P865, DOI 10.1016/j.neuroscience.2008.08.017
   Avena NM, 2006, NEUROSCIENCE, V139, P813, DOI 10.1016/j.neuroscience.2005.12.037
   Avena NM, 2008, PHYSIOL BEHAV, V94, P309, DOI 10.1016/j.physbeh.2008.01.008
   Avena NM, 2012, NEUROPHARMACOLOGY, V63, P87, DOI 10.1016/j.neuropharm.2011.11.010
   Avena NM, 2006, CURR PROTOC NEUROSCI
   Backstrom P, 2006, NEUROPSYCHOPHARMACOL, V31, P778, DOI 10.1038/sj.npp.1300845
   Bahk JY, 2002, PROG NEURO-PSYCHOPH, V26, P1095, DOI 10.1016/S0278-5846(02)00243-9
   Barak S, 2011, J NEUROSCI, V31, P9885, DOI 10.1523/JNEUROSCI.1750-11.2011
   Beckstead MJ, 2004, NEURON, V42, P939, DOI 10.1016/j.neuron.2004.05.019
   BEITNERJOHNSON D, 1991, J NEUROCHEM, V57, P344, DOI 10.1111/j.1471-4159.1991.tb02133.x
   Bello NT, 2003, AM J PHYSIOL-REG I, V284, pR1260, DOI 10.1152/ajpregu.00716.2002
   Bello NT, 2002, NEUROREPORT, V13, P1575, DOI 10.1097/00001756-200208270-00017
   Ben-Shahar O, 2007, BRAIN RES, V1131, P220, DOI 10.1016/j.brainres.2006.10.069
   Ben-Shahar O, 2006, BRAIN RES, V1095, P148, DOI 10.1016/j.brainres.2006.04.002
   Berggren U, 2006, ALCOHOL ALCOHOLISM, V41, P479, DOI 10.1093/alcalc/agl043
   Berglind WJ, 2006, NEUROSCIENCE, V137, P699, DOI 10.1016/j.neuroscience.2005.08.064
   BERNARDINI GL, 1991, J NEURAL TRANSM-GEN, V84, P183, DOI 10.1007/BF01244969
   Berner LA, 2011, CURR PHARM DESIGN, V17, P1180, DOI 10.2174/138161211795656774
   Bisaga A, 2001, PSYCHOPHARMACOLOGY, V157, P1, DOI 10.1007/s002130100739
   Bisaga A, 2008, EUR NEUROPSYCHOPHARM, V18, P794, DOI 10.1016/j.euroneuro.2008.05.004
   Bocarsly ME, 2011, PHYSIOL BEHAV, V104, P865, DOI 10.1016/j.physbeh.2011.05.018
   BRADBERRY CW, 1989, NEUROSCI LETT, V103, P97, DOI 10.1016/0304-3940(89)90492-8
   Brennan BP, 2008, INT J EAT DISORDER, V41, P520, DOI 10.1002/eat.20541
   BRISMAN J, 1984, Journal of Substance Abuse Treatment, V1, P113, DOI 10.1016/0740-5472(84)90034-5
   Broft AI, 2011, PHYSIOL BEHAV, V104, P122, DOI 10.1016/j.physbeh.2011.04.028
   Bromberg-Martin ES, 2010, NEURON, V68, P815, DOI 10.1016/j.neuron.2010.11.022
   Brown RM, 2012, DRUG ALCOHOL DEPEN, V123, P264, DOI 10.1016/j.drugalcdep.2011.11.002
   Carbaugh RJ, 2010, J MENTAL HLTH COUNSE, V32, P125, DOI DOI 10.17744/MEHC.32.2.J72865M4159P1420
   Casper RC, 2008, PSYCHOPHARMACOLOGY, V199, P313, DOI 10.1007/s00213-008-1102-2
   CERRUTI C, 1994, MOL BRAIN RES, V22, P132, DOI 10.1016/0169-328X(94)90040-X
   Colantuoni C, 2002, OBES RES, V10, P478, DOI 10.1038/oby.2002.66
   Colantuoni C, 2001, NEUROREPORT, V12, P3549, DOI 10.1097/00001756-200111160-00035
   Colby CR, 2003, J NEUROSCI, V23, P2488
   Conason Alexis H, 2006, Int J Adolesc Med Health, V18, P31
   Connor JP, 2008, PSYCHIAT RES, V160, P94, DOI 10.1016/j.psychres.2007.06.030
   Conrad KL, 2010, NEUROSCIENCE, V169, P182, DOI 10.1016/j.neuroscience.2010.04.056
   Conrad KL, 2008, NATURE, V454, P118, DOI 10.1038/nature06995
   Corwin R.L., 2006, CURR PROTOC NEUROSCI, DOI [10.1002/0471142301.ns0923bs36, DOI 10.1002/0471142301.NS0923BS36]
   Corwin RL, 2009, BEHAV PHARMACOL, V20, P537, DOI 10.1097/FBP.0b013e3283313168
   Cragg SJ, 1997, J NEUROSCI, V17, P5738
   Crego A, 2010, DRUG ALCOHOL DEPEN, V109, P45, DOI 10.1016/j.drugalcdep.2009.11.020
   Crombag HS, 2002, NEUROPSYCHOPHARMACOL, V27, P1006, DOI 10.1016/S0893-133X(02)00356-1
   Di Bella D, 2000, MOL PSYCHIATR, V5, P233, DOI 10.1038/sj.mp.4000689
   Di Leone RJ, 2012, NAT NEUROSCI, V15, P1330, DOI 10.1038/nn.3202
   Diana M, 1998, P NATL ACAD SCI USA, V95, P10269, DOI 10.1073/pnas.95.17.10269
   Diana M, 1999, EUR J NEUROSCI, V11, P1037, DOI 10.1046/j.1460-9568.1999.00488.x
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   El-Ghundi M, 2007, REV NEUROSCIENCE, V18, P37
   Evans SM, 2007, ALCOHOL CLIN EXP RES, V31, P775, DOI 10.1111/j.1530-0277.2007.00360.x
   Fattore L, 2007, EUR J NEUROSCI, V25, P2191, DOI 10.1111/j.1460-9568.2007.05470.x
   Ferrari R, 2002, EUR J NEUROSCI, V15, P1810, DOI 10.1046/j.1460-9568.2001.02009.x
   Ferrario CR, 2011, NEUROPHARMACOLOGY, V61, P1141, DOI 10.1016/j.neuropharm.2011.01.021
   Fitzgibbon ML, 2000, INT J EAT DISORDER, V27, P238, DOI 10.1002/(SICI)1098-108X(200003)27:2&lt;238::AID-EAT12&gt;3.0.CO;2-Q
   Gaddnas H, 2002, NEUROSCI LETT, V330, P219, DOI 10.1016/S0304-3940(02)00734-6
   Gass JT, 2011, ADDICT BIOL, V16, P215, DOI 10.1111/j.1369-1600.2010.00262.x
   Gearhardt Ashley N, 2011, Curr Drug Abuse Rev, V4, P201
   George MS, 2001, ARCH GEN PSYCHIAT, V58, P345, DOI 10.1001/archpsyc.58.4.345
   German CL, 2012, J NEUROCHEM, V123, P288, DOI 10.1111/j.1471-4159.2012.07875.x
   Gervasini G, 2012, J CLIN PSYCHOPHARM, V32, P426, DOI 10.1097/JCP.0b013e3182539f2b
   Giuliano C, 2012, NEUROPSYCHOPHARMACOL, V37, P2643, DOI 10.1038/npp.2012.128
   Goldstein RZ, 2007, AM J PSYCHIAT, V164, P43, DOI 10.1176/appi.ajp.164.1.43
   Goodman A, 2008, BIOCHEM PHARMACOL, V75, P266, DOI 10.1016/j.bcp.2007.07.030
   Grant JE, 2010, PSYCHOPHARMACOLOGY, V212, P603, DOI 10.1007/s00213-010-1994-5
   Grusser SM, 2004, PSYCHOPHARMACOLOGY, V175, P296, DOI 10.1007/s00213-004-1828-4
   Hagan MM, 1997, INT J EAT DISORDER, V22, P411, DOI 10.1002/(SICI)1098-108X(199712)22:4&lt;411::AID-EAT6&gt;3.0.CO;2-P
   Hagan MM, 2002, PHYSIOL BEHAV, V77, P45, DOI 10.1016/S0031-9384(02)00809-0
   HAGAN MM, 1991, PHARMACOL BIOCHEM BE, V39, P421, DOI 10.1016/0091-3057(91)90201-C
   Henry DJ, 1998, PSYCHOPHARMACOLOGY, V140, P233, DOI 10.1007/s002130050762
   Inoue K, 1998, BIOL PSYCHIAT, V44, P1329, DOI 10.1016/S0006-3223(97)00518-0
   JONAS JM, 1986, INT J PSYCHIAT MED, V16, P305
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564
   KALIVAS PW, 1991, J NEUROCHEM, V56, P961, DOI 10.1111/j.1471-4159.1991.tb02015.x
   Kelz MB, 1999, NATURE, V401, P272, DOI 10.1038/45790
   Kim YT, 2011, NMR BIOMED, V24, P1392, DOI 10.1002/nbm.1702
   Klein DA, 2013, ANIMAL MODELS EATING, P155
   Kohl RR, 1998, PSYCHOPHARMACOLOGY, V139, P79, DOI 10.1007/s002130050692
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Krupitsky EM, 2007, ALCOHOL CLIN EXP RES, V31, P604, DOI 10.1111/j.1530-0277.2007.00344.x
   Krupitsky EM, 2006, J SUBST ABUSE TREAT, V31, P319, DOI 10.1016/j.jsat.2006.05.005
   Kumaresan V, 2009, BEHAV BRAIN RES, V202, P238, DOI 10.1016/j.bbr.2009.03.039
   LaLumiere RT, 2008, J NEUROSCI, V28, P3170, DOI 10.1523/JNEUROSCI.5129-07.2008
   Le Cozannet Romain, 2013, Tropical Medicine & International Health, V18, P3487, DOI 10.1111/ejn.12361
   Le Foll B, 2003, SYNAPSE, V47, P176, DOI 10.1002/syn.10170
   Lee JH, 2005, APPL PSYCHOPHYS BIOF, V30, P195, DOI 10.1007/s10484-005-6377-z
   Li SP, 2004, NEUROSCI LETT, V363, P29, DOI 10.1016/j.neulet.2004.03.053
   Lindblom J, 2006, EUR J NEUROSCI, V23, P180, DOI 10.1111/j.1460-9568.2005.04531.x
   Liu X, 2002, J PHARMACOL EXP THER, V300, P882, DOI 10.1124/jpet.300.3.882
   LJUNGBERG T, 1992, J NEUROPHYSIOL, V67, P145, DOI 10.1152/jn.1992.67.1.145
   Lominac KD, 2012, NEUROPSYCHOPHARMACOL, V37, P707, DOI 10.1038/npp.2011.248
   Lu WX, 1997, MOL BRAIN RES, V49, P137, DOI 10.1016/S0169-328X(97)00136-8
   Maremmani I, 1996, EUR PSYCHIAT, V11, P322, DOI 10.1016/S0924-9338(96)89902-0
   MARRAZZI MA, 1995, INT CLIN PSYCHOPHARM, V10, P163, DOI 10.1097/00004850-199510030-00005
   Marsh R, 2011, AM J PSYCHIAT, V168, P1210, DOI 10.1176/appi.ajp.2011.11010094
   Marsh R, 2009, ARCH GEN PSYCHIAT, V66, P51, DOI 10.1001/archgenpsychiatry.2008.504
   Martin-Fardon R, 2009, J PHARMACOL EXP THER, V329, P1084, DOI 10.1124/jpet.109.151357
   Mateo Y, 2005, NEUROPSYCHOPHARMACOL, V30, P1455, DOI 10.1038/sj.npp.1300687
   Maurage P, 2012, NEUROPSYCHOPHARMACOL, V37, P2067, DOI 10.1038/npp.2012.54
   McFarland K, 2003, J NEUROSCI, V23, P3531
   McHugh RK, 2010, DRUG ALCOHOL DEPEN, V108, P1, DOI 10.1016/j.drugalcdep.2009.11.017
   Metaxas A, 2010, ADDICT BIOL, V15, P464, DOI 10.1111/j.1369-1600.2010.00246.x
   MIRENOWICZ J, 1994, J NEUROPHYSIOL, V72, P1024, DOI 10.1152/jn.1994.72.2.1024
   MITCHELL JE, 1989, J CLIN PSYCHOPHARM, V9, P94, DOI 10.1097/00004714-198904000-00004
   Miyake Y, 2010, NEUROIMAGE, V50, P1333, DOI 10.1016/j.neuroimage.2009.12.095
   Mukda S, 2009, DEV NEUROSCI-BASEL, V31, P193, DOI 10.1159/000193395
   Nakagawa T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024865
   Natividad LA, 2010, SYNAPSE, V64, P136, DOI 10.1002/syn.20713
   Nestler EJ, 2001, P NATL ACAD SCI USA, V98, P11042, DOI 10.1073/pnas.191352698
   Nestor LJ, 2011, PSYCHIAT RES-NEUROIM, V194, P287, DOI 10.1016/j.pscychresns.2011.04.010
   Neville MJ, 2004, HUM MUTAT, V23, P540, DOI 10.1002/humu.20039
   Nisoli E, 2007, EAT WEIGHT DISORD-ST, V12, P91, DOI 10.1007/BF03327583
   Nokleby H, 2012, NORD STUD ALCOHOL DR, V29, P303, DOI 10.2478/v10199-012-0024-9
   Osborne MPH, 2008, ANN NY ACAD SCI, V1139, P206, DOI 10.1196/annals.1432.034
   Patterson TA, 1998, NEUROENDOCRINOLOGY, V68, P11, DOI 10.1159/000054345
   Peng XX, 2011, SYNAPSE, V65, P1024, DOI 10.1002/syn.20931
   Popik P, 2011, AMINO ACIDS, V40, P477, DOI 10.1007/s00726-010-0659-3
   POTHOS E, 1991, BRAIN RES, V566, P348, DOI 10.1016/0006-8993(91)91724-F
   Purgianto A, 2013, NEUROPSYCHOPHARMACOL, V38, P1789, DOI 10.1038/npp.2013.78
   Rada P, 2005, NEUROSCIENCE, V134, P737, DOI 10.1016/j.neuroscience.2005.04.043
   Rada P, 2001, PSYCHOPHARMACOLOGY, V157, P105, DOI 10.1007/s002130100781
   Rahman S, 2004, NEUROSCIENCE, V129, P415, DOI 10.1016/j.neuroscience.2004.08.010
   Ramoa CP, 2013, BIOL PSYCHIAT
   Ramoz N, 2007, EXPERT OPIN PHARMACO, V8, P2029, DOI 10.1517/14656566.8.13.2029
   Rao RE, 2008, PHARMACOL BIOCHEM BE, V89, P581, DOI 10.1016/j.pbb.2008.02.013
   Reith MEA, 1997, PSYCHOPHARMACOLOGY, V134, P309, DOI 10.1007/s002130050454
   Salo R, 2009, BIOL PSYCHIAT, V65, P706, DOI 10.1016/j.biopsych.2008.11.026
   Sari Y, 2006, ALCOHOL CLIN EXP RES, V30, P46, DOI 10.1111/j.1530-0277.2006.00010.x
   Schultz W, 2004, CURR OPIN NEUROBIOL, V14, P139, DOI 10.1016/j.conb.2004.03.017
   SEE RE, 1991, NEUROPHARMACOLOGY, V30, P1269, DOI 10.1016/0028-3908(91)90022-4
   Shaham Y, 1996, PSYCHOPHARMACOLOGY, V125, P385, DOI 10.1007/BF02246022
   Shilling PD, 1997, NEUROSCI LETT, V236, P131, DOI 10.1016/S0304-3940(97)00768-4
   Shishido T, 1997, MOL BRAIN RES, V52, P146, DOI 10.1016/S0169-328X(97)00266-0
   Sidhpura N, 2010, BIOL PSYCHIAT, V67, P804, DOI 10.1016/j.biopsych.2010.01.005
   Smink FRE, 2012, CURR PSYCHIAT REP, V14, P406, DOI 10.1007/s11920-012-0282-y
   Sorge RE, 2009, J PHARMACOL EXP THER, V330, P633, DOI 10.1124/jpet.109.154641
   Spangler DL, 2012, INT J EAT DISORDER, V45, P17, DOI 10.1002/eat.20899
   Spangler R, 2004, MOL BRAIN RES, V124, P134, DOI 10.1016/j.molbrainres.2004.02.013
   Stairs DJ, 2010, BEHAV PHARMACOL, V21, P182, DOI 10.1097/FBP.0b013e32833a5c9e
   Stamp JA, 2008, BRAIN RES, V1204, P94, DOI 10.1016/j.brainres.2008.02.019
   Tanda G, 1997, SCIENCE, V276, P2048, DOI 10.1126/science.276.5321.2048
   Tapert SF, 2004, ADDICT BEHAV, V29, P33, DOI 10.1016/j.addbeh.2003.07.003
   Tobin S, 2009, INT J NEUROPSYCHOPH, V12, P217, DOI 10.1017/S1461145708008778
   Trotzky Arthur S, 2002, Int J Adolesc Med Health, V14, P269
   Uher R, 2004, AM J PSYCHIAT, V161, P1238, DOI 10.1176/appi.ajp.161.7.1238
   Unterwald EM, 2001, BRAIN RES, V900, P103, DOI 10.1016/S0006-8993(01)02269-7
   Vialou V, 2011, BIOL PSYCHIAT, V70, P204, DOI 10.1016/j.biopsych.2010.11.027
   Volkow ND, 2013, OBES REV, V14, P2, DOI 10.1111/j.1467-789X.2012.01031.x
   VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210
   Volkow ND, 2001, AM J PSYCHIAT, V158, P2015, DOI 10.1176/appi.ajp.158.12.2015
   WANG RY, 1981, BRAIN RES REV, V3, P153, DOI 10.1016/0165-0173(81)90004-7
   Wang XS, 2013, ADDICT BIOL, V18, P40, DOI 10.1111/j.1369-1600.2011.00432.x
   WEISS F, 1992, BRAIN RES, V593, P314, DOI 10.1016/0006-8993(92)91327-B
   Weissenborn R, 1996, PSYCHOPHARMACOLOGY, V126, P311
   WHITE FJ, 1984, LIFE SCI, V34, P1161, DOI 10.1016/0024-3205(84)90088-2
   Wilcox CE, 2011, DRUG ALCOHOL DEPEN, V115, P137, DOI 10.1016/j.drugalcdep.2011.01.009
   Wilson GT, 1995, J MENTAL HLTH, V4, P451
   Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406
   Wolf ME, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00072
   Wong KJ, 2009, PHARMACOL BIOCHEM BE, V92, P528, DOI 10.1016/j.pbb.2009.02.002
   YOSHIDA M, 1992, NEUROSCI LETT, V139, P73, DOI 10.1016/0304-3940(92)90861-Z
   Young KA, 2011, BRAIN RES, V1367, P213, DOI 10.1016/j.brainres.2010.09.109
   Zachariou V, 2006, NAT NEUROSCI, V9, P205, DOI 10.1038/nn1636
   ZHANG HL, 1994, BRAIN RES, V656, P59, DOI 10.1016/0006-8993(94)91366-8
   Zhang LF, 2012, BIOL PSYCHIAT, V71, P184, DOI 10.1016/j.biopsych.2011.07.024
   Zhang Y, 2001, ANN NY ACAD SCI, V937, P93
NR 168
TC 26
Z9 27
U1 1
U2 54
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0033-3158
EI 1432-2072
J9 PSYCHOPHARMACOLOGY
JI Psychopharmacology
PD MAY
PY 2014
VL 231
IS 9
BP 1897
EP 1912
DI 10.1007/s00213-014-3461-1
PG 16
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA AF2AE
UT WOS:000334514200003
PM 24500676
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Sosnin, VA
AF Sosnin, V. A.
TI PSYCHOLOGICAL ASPECTS OF COUNTERACTION TO NON-MEDICAL USE OF DRUGS:
   CONTEMPORARY PROBLEMS AND TENDENCIES
SO PSIKHOLOGICHESKII ZHURNAL
LA Russian
DT Article
DE drugs; addiction; personality; medical sciences; psychological aspects;
   national policy; social psychology; education; mass communications;
   motivations
ID ADDICTION; DOPAMINE; ABUSE; RATS
AB The problem of drug addiction is analyzed from the viewpoint of different sciences; its complex character is stressed. Contemporary approaches to anti-drug propaganda by means of psychological principles and information policy (popularization of morality and healthy way of life, creation conditions for development of motivation for healthy life and possibility of psychological work with drug addicts) are examined. Conclusions regarding anti-drug policy in Russia are drawn.
C1 Inst Psychol RAS, Fed State Financed Inst, Lab Social & Econ Psychol, Moscow, Russia.
C3 Institute of Psychology of Russian Academy of Sciences; Russian Academy
   of Sciences
RP Sosnin, VA (通讯作者)，Inst Psychol RAS, Fed State Financed Inst, Lab Social & Econ Psychol, Moscow, Russia.
CR Adolphs R, 2003, NAT REV NEUROSCI, V4, P165, DOI 10.1038/nrn1056
   Altman J, 1996, PSYCHOPHARMACOLOGY, V125, P285, DOI 10.1007/BF02246016
   ANDERSON TL, 1994, SOCIOL QUART, V35, P159, DOI 10.1111/j.1533-8525.1994.tb00404.x
   [Anonymous], 2004, ANT BEH ORD PEN NOT
   Arseneault L, 2004, BRIT J PSYCHIAT, V184, P110, DOI 10.1192/bjp.184.2.110
   BABOR TF, 2003, ALCOHOL NO ORDINARY
   Bellinger FP, 2002, DEV BRAIN RES, V136, P77, DOI 10.1016/S0165-3806(02)00363-2
   BRIK L, 2008, VESTNIK MGTU, P175
   Chisholm D, 2004, J STUD ALCOHOL, V65, P782, DOI 10.15288/jsa.2004.65.782
   Curran V., 2007, DRUGS FUTURE BRAIN S, P209
   *EUR MON CTR DRUGS, 2005, DIFF PATT DRUG US ME
   Felrdman R. S., 1997, PRINCIPLES NEUROPSYC
   Gassman RA, 2005, J SOC WORK PRACT ADD, V5, P101, DOI 10.1300/J160v05n04_07
   Graham MD, 2008, ADDICT RES THEORY, V16, P121, DOI 10.1080/16066350701794543
   Hawkins EH, 2009, ANNU REV PSYCHOL, V60, P197, DOI 10.1146/annurev.psych.60.110707.163456
   HAY G, 2005, ESTIMATING NATL LOCA
   Heidbreder CA, 2001, PSYCHOPHARMACOLOGY, V156, P338, DOI 10.1007/s002130100760
   Howes SR, 2000, PSYCHOPHARMACOLOGY, V151, P55, DOI 10.1007/s002130000451
   Jha P, 2000, TOBACCO CONTROL DEV, P449
   Luoma JB, 2010, SUBST USE MISUSE, V45, P47, DOI 10.3109/10826080902864712
   MacCoun R., 2001, DRUG WAR HERESIES LE, P113
   MacDonald Z, 2004, J ECON SURV, V18, P113, DOI 10.1111/j.0950-0804.2004.00002.x
   McKeganey N, 2004, DRUG-EDUC PREV POLIC, V11, P315, DOI 10.1080/09687630410001687888
   Mitchell SH, 2003, CHOICE, BEHAVIOURAL ECONOMICS AND ADDICTION, P339, DOI 10.1016/B978-008044056-9/50053-1
   Nice G, 2006, HDB SUBSTANCE MISUSE
   Nitt D. J., 2007, DRUGS FUTURES 2025, P1
   Nitt D. J., 2007, DRUGS FUTURE BRAIN S, P12
   OBrien CP, 1996, LANCET, V347, P237, DOI 10.1016/S0140-6736(96)90409-2
   Ochsner KN, 2001, AM PSYCHOL, V56, P717, DOI 10.1037//0003-066X.56.9.717
   OLEYNIK I, 2005, TOTALITARNAYA SEKTA
   Ornstein TJ, 2000, NEUROPSYCHOPHARMACOL, V23, P113, DOI 10.1016/S0893-133X(00)00097-X
   Piazza PV, 2000, J NEUROSCI, V20, P4226
   PUTYATINA T, 2007, DIS KAND SOTSIOL NAU
   ROBBINS TW, 1994, DEMENTIA, V5, P266, DOI 10.1159/000106735
   Room R, 2004, ADDICTION, V99, P1092, DOI 10.1111/j.1360-0443.2004.00870.x
   SEMENOV V, 2008, CHTO MI DUMAEM NARKO, P367
   SEMENOV VE, 2011, PSIKHOLOGICHESKIE IS, P60
   SOSNIN V, 2008, SOVREMENNYIY TERRORI, P177
   SOSNIN V, 2010, PSIHOLOGIYA NRAVSTVE
   SUHAREV A, 2008, ETNOFUNKTSIONALNAYA
   [Цветкова Лариса Александровна Ts v e t k o v a L.A.], 2010, [Вестник Московского университета. Серия 14: Психология, Vestnik Moskovskogo universiteta. Seriya 14: Psikhologiya], P142
   TSVETKOVA L, 2011, SOTSIALNAYA PSIHOLOG
   TSVETKOVA L, 2011, VESTNIK TGU GR DERZH, P91
   TSVETKOVA L, 2011, SOVREMENNYIE PROBLEM, P17
   Volkov N.D., 2004, J CLIN INVEST, V111, P1444
NR 45
TC 0
Z9 0
U1 0
U2 2
PU MEZHDUNARODNAYA KNIGA
PI MOSCOW
PA 39 DIMITROVA UL., MOSCOW, 113095, RUSSIA
SN 0205-9592
J9 PSIKHOL ZH
JI Psikhologicheskii Zhurnal
PD JAN-FEB
PY 2013
VL 34
IS 1
BP 132
EP 144
PG 13
WC Psychology, Multidisciplinary
WE Social Science Citation Index (SSCI)
SC Psychology
GA AO3IX
UT WOS:000341224000012
DA 2023-06-23
ER

PT J
AU Volkow, ND
   Li, TK
AF Volkow, ND
   Li, TK
TI Science and society - Drug addiction: the neurobiology of behaviour gone
   awry
SO NATURE REVIEWS NEUROSCIENCE
LA English
DT Review
ID PLACEBO-CONTROLLED TRIAL; ALCOHOL DEPENDENCE; NUCLEUS-ACCUMBENS;
   MONOAMINE-OXIDASE; DOUBLE-BLIND; IN-VIVO; COCAINE; BRAIN; DOPAMINE;
   INVOLVEMENT
AB Drug addiction manifests as a compulsive drive to take a drug despite serious adverse consequences. This aberrant behaviour has traditionally been viewed as bad 'choices' that are made voluntarily by the addict. However, recent studies have shown that repeated drug use leads to long-lasting changes in the brain that undermine voluntary control. This, combined with new knowledge of how environmental, genetic and developmental factors contribute to addiction, should bring about changes in our approach to the prevention and treatment of addiction.
C1 NIDA, Bethesda, MD 20892 USA.
   NIAAA, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute on
   Drug Abuse (NIDA); National Institutes of Health (NIH) - USA; NIH
   National Institute on Alcohol Abuse & Alcoholism (NIAAA)
RP Volkow, ND (通讯作者)，NIDA, Bethesda, MD 20892 USA.
EM nvolkow@nida.nih.gov
CR Addolorato G, 2002, ALCOHOL ALCOHOLISM, V37, P504, DOI 10.1093/alcalc/37.5.504
   Adriani W, 2003, J NEUROSCI, V23, P4712
   Anton RF, 2001, J CLIN PSYCHIAT, V62, P11
   Block LG, 2002, AM J PUBLIC HEALTH, V92, P1346, DOI 10.2105/AJPH.92.8.1346
   Brodie JD, 2003, SYNAPSE, V50, P261, DOI 10.1002/syn.10278
   Brook DW, 2002, ARCH GEN PSYCHIAT, V59, P1039, DOI 10.1001/archpsyc.59.11.1039
   Butzin CA, 2002, J SUBST ABUSE TREAT, V22, P63, DOI 10.1016/S0740-5472(01)00216-1
   Carroll KM, 2004, ARCH GEN PSYCHIAT, V61, P264, DOI 10.1001/archpsyc.61.3.264
   Chen CC, 1999, AM J HUM GENET, V65, P795, DOI 10.1086/302540
   Dackis C, 2003, ANN NY ACAD SCI, V1003, P328, DOI 10.1196/annals.1300.021
   Di Chiara G, 2002, BEHAV BRAIN RES, V137, P75, DOI 10.1016/S0166-4328(02)00286-3
   Dick DM, 2004, ALCOHOL CLIN EXP RES, V28, P4, DOI 10.1097/01.ALC.0000108645.54345.98
   Edenberg HJ, 2004, AM J HUM GENET, V74, P705, DOI 10.1086/383283
   Fernandez Jose R, 2004, Curr Opin Investig Drugs, V5, P430
   Fielding JE, 2002, J SUBST ABUSE TREAT, V23, P217, DOI 10.1016/S0740-5472(02)00262-3
   Flynn BS, 1997, PREV MED, V26, P389, DOI 10.1006/pmed.1997.0159
   Fowler JS, 2003, P NATL ACAD SCI USA, V100, P11600, DOI 10.1073/pnas.1833106100
   Fowler JS, 2003, NEUROTOXICOLOGY, V24, P75, DOI 10.1016/S0161-813X(02)00109-2
   Fraser C, 2002, NEURON, V34, P831, DOI 10.1016/S0896-6273(02)00705-5
   Fulco C.E., 1995, DEV MED TREATMENT OP
   George TP, 2004, TRENDS PHARMACOL SCI, V25, P42, DOI 10.1016/j.tips.2003.11.003
   George TP, 2003, BIOL PSYCHIAT, V53, P136, DOI 10.1016/S0006-3223(02)01454-3
   Gfroerer J. C, 2002, ANAL SERIES A, V17
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Gonzalez G, 2003, ADDICTION, V98, P1625, DOI 10.1046/j.1360-0443.2003.00544.x
   Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI 10.1001/archpsyc.61.8.807
   Grant BF, 2001, J SUBST ABUSE, V13, P493, DOI 10.1016/S0899-3289(01)00096-7
   Gruber AJ, 2002, PEDIATR CLIN N AM, V49, P389, DOI 10.1016/S0031-3955(01)00011-6
   Hiller ML, 1999, ADDICTION, V94, P833, DOI 10.1046/j.1360-0443.1999.9468337.x
   Horvitz JC, 2000, NEUROSCIENCE, V96, P651, DOI 10.1016/S0306-4522(00)00019-1
   Ito R, 2000, J NEUROSCI, V20, P7489
   Johnson BA, 2000, JAMA-J AM MED ASSOC, V284, P963, DOI 10.1001/jama.284.8.963
   Johnson BA, 2003, LANCET, V361, P1677, DOI 10.1016/S0140-6736(03)13370-3
   JOHNSTON LD, 2003, NIH PUBLICATION
   JOHNSTON LD, 2004, NIH PUBLICATION, P1
   Kampman KM, 2004, DRUG ALCOHOL DEPEN, V75, P233, DOI 10.1016/j.drugalcdep.2004.03.008
   Kandel D B, 2000, Nicotine Tob Res, V2, P263
   Kathiramalainathan K, 2000, J CLIN PSYCHOPHARM, V20, P435, DOI 10.1097/00004714-200008000-00008
   Kelley MS, 2004, SOC SCI MED, V58, P2083, DOI 10.1016/j.socscimed.2003.08.006
   Koob GF, 1999, ANN NY ACAD SCI, V897, P27, DOI 10.1111/j.1749-6632.1999.tb07876.x
   KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550
   Kosten Thomas R, 2002, Expert Rev Vaccines, V1, P363
   Kreek MJ, 2002, NAT REV DRUG DISCOV, V1, P710, DOI 10.1038/nrd897
   Krupitsky EM, 2004, J SUBST ABUSE TREAT, V26, P285, DOI 10.1016/j.jsat.2004.02.002
   Kujala T, 2001, P NATL ACAD SCI USA, V98, P10509, DOI 10.1073/pnas.181589198
   Laakso A, 2002, NEURON, V36, P213, DOI 10.1016/S0896-6273(02)00972-8
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Lu L, 2003, J NEUROCHEM, V85, P1604, DOI 10.1046/j.1471-4159.2003.01824.x
   MADRAS BK, 1989, J PHARMACOL EXP THER, V251, P131
   Markou A, 1998, NEUROPSYCHOPHARMACOL, V18, P135, DOI 10.1016/S0893-133X(97)00113-9
   Martin-Soelch C, 2001, EUR J NEUROSCI, V14, P1360, DOI 10.1046/j.0953-816x.2001.01753.x
   Mason BJ, 1999, ARCH GEN PSYCHIAT, V56, P719, DOI 10.1001/archpsyc.56.8.719
   McClure SM, 2003, TRENDS NEUROSCI, V26, P423, DOI 10.1016/S0166-2236(03)00177-2
   McFarland K, 2004, J NEUROSCI, V24, P1551, DOI 10.1523/JNEUROSCI.4177-03.2004
   McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689
   Morgan D, 2002, NAT NEUROSCI, V5, P169, DOI 10.1038/nn798
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   Porrino LJ, 2004, J NEUROSCI, V24, P3554, DOI 10.1523/JNEUROSCI.5578-03.2004
   Raby WN, 2004, J CLIN PSYCHIAT, V65, P84
   Rao YS, 2000, MOL PHARMACOL, V58, P747, DOI 10.1124/mol.58.4.747
   Robinson TE, 2001, SYNAPSE, V39, P257
   SALLOUM IM, IN PRESS ARCH GEN PS
   Schaffer DV, 2004, NEUROMOL MED, V5, P1, DOI 10.1385/NMM:5:1:001
   Schultz W, 2001, NEUROSCIENTIST, V7, P293, DOI 10.1177/107385840100700406
   Schultz W, 2000, CEREB CORTEX, V10, P272, DOI 10.1093/cercor/10.3.272
   Sellers EM, 2003, NICOTINE TOB RES, V5, P891, DOI 10.1080/14622200310001615231
   Shoptaw S, 2003, J CLIN PSYCHIAT, V64, P1440, DOI 10.4088/JCP.v64n1207
   Slawecki CJ, 2004, ALCOHOL CLIN EXP RES, V28, P598, DOI 10.1097/01.ALC.0000122767.69206.1B
   Sowell ER, 2003, NAT NEUROSCI, V6, P309, DOI 10.1038/nn1008
   Spear LP, 2000, NEUROSCI BIOBEHAV R, V24, P417, DOI 10.1016/S0149-7634(00)00014-2
   Thanos PK, 2001, J NEUROCHEM, V78, P1094, DOI 10.1046/j.1471-4159.2001.00492.x
   Uhl GR, 2004, ARCH GEN PSYCHIAT, V61, P223, DOI 10.1001/archpsyc.61.3.223
   Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI 10.1093/cercor/10.3.318
   Volkow ND, 2004, MOL PSYCHIATR, V9, P557, DOI 10.1038/sj.mp.4001507
   Volkow ND, 2003, J CLIN INVEST, V111, P1444, DOI 10.1172/JCI200318533
   Wagner FA, 2002, NEUROPSYCHOPHARMACOL, V26, P479, DOI 10.1016/S0893-133X(01)00367-0
   Webster EL, 1996, ENDOCRINOLOGY, V137, P5747, DOI 10.1210/en.137.12.5747
   Wise RA, 2002, NEURON, V36, P229, DOI 10.1016/S0896-6273(02)00965-0
   2003, AIDS ALERT, V18, P118
NR 79
TC 386
Z9 395
U1 2
U2 59
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-003X
EI 1471-0048
J9 NAT REV NEUROSCI
JI Nat. Rev. Neurosci.
PD DEC
PY 2004
VL 5
IS 12
BP 963
EP 970
DI 10.1038/nrn1539
PG 8
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology
GA 875YO
UT WOS:000225459300018
PM 15550951
DA 2023-06-23
ER

PT C
AU Razzhivin, OA
   Volkova, KR
AF Razzhivin, O. A.
   Volkova, K. R.
BE Gaol, FL
   Kadry, S
   Taylor, M
   Li, PS
TI Pedagogical determinants of drug prevention in the Russian secondary
   school
SO RECENT TRENDS IN SOCIAL AND BEHAVIOUR SCIENCES
LA English
DT Proceedings Paper
CT 2nd International Congress on Interdisciplinary Behavior and Social
   Science (ICIBSoS)
CY NOV 04-05, 2013
CL Jakarta, INDONESIA
AB The spread of drug addiction in the school environment is a serious danger to society. The work aiming at prevention students' drug addiction causes a search for complex methods in preventive anti-drug activities in the educational process. A pedagogical approach to the problem of drug addiction brings out the school teaching staff potential to resist the process of secondary school students' drug abuse. This article provides such a pedagogical approach and investigates a secondary school potential to be used in opposition to the expansion of drug addiction among secondary school students. We define measures to prevent students' drug abuse as a specially organized process aimed at eliminating or weakening to the least possible degree the factors inducing students to try and abuse drugs. Our study examines various directions of anti-drug measures, which can compensate for the negative features of schoolchildren's life.
C1 [Razzhivin, O. A.; Volkova, K. R.] Kazan Fed Univ, Tatarstan, Russia.
C3 Kazan Federal University
RI Volkova, Kadriya/O-2800-2016
OI Volkova, Kadriya/0000-0003-2840-5387
CR Botvin GJ, 2007, INT REV PSYCHIATR, V19, P607, DOI 10.1080/09540260701797753
   Drozdova I.G., 2007, GEOGRAPHY SCH, V5, P67
   Eremenko V.V., 2006, SOCIAL STUDIES HUMAN, V3, P127
   Getman V.A., 2009, B U RUSSIAN ACAD ED, V1, P150
   Griffin K.W., 2009, PRINCIPLES ADDICTION, V4, P1375
   Griffin K.W., 2011, ESSENTIALS ADDICTION, P549
   Lisetsky K. S., 2008, PSYCHOL PREVENTION D
   Lisova E. V., 2008, SOCIAL STUDIES HUMAN, V3, P125
   Lowe SR, 2013, J DRUG ISSUES, V43, P103, DOI 10.1177/0022042612462221
   Makeyeva A. G., 2005, FINDING ANSWERS DIFF
   Orlova I. A., 2009, B KOSTROMA NA NEKRAS, V15, P434
   Pavlenok P. D., 2010, ACTIVITIES PREVENT C
   Rozhkov M. I., 2004, PREVENTION DRUG ABUS
   Shakurov R. K., 2005, PUBLIC ED, V7, P143
   Shakurov R. K., 2002, PSYCHOLOGICAL BASIS
   Shirvanyan T. A., 2009, B MOSCOW U TEACHER E, V3, P73
   Weiner E. N., 2011, FUNDAMENTALS LIFE SA, V2, P25
   Yasaveyev I. G., 2004, CONSTRUCTION SOCIAL
   Zaretsky V. V., 2011, SOCIAL PEDAGOGY, V5, P20
   Zheleznyakova O., 2007, ED SCH CHILDREN, V7, P53
NR 20
TC 0
Z9 0
U1 1
U2 2
PU CRC PRESS-TAYLOR & FRANCIS GROUP
PI BOCA RATON
PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA
BN 978-1-315-77553-1; 978-1-138-00121-3
PY 2014
BP 431
EP 436
PG 6
WC Social Sciences, Interdisciplinary
WE Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)
SC Social Sciences - Other Topics
GA BA9MK
UT WOS:000339555100076
DA 2023-06-23
ER

PT J
AU Philibin, SD
   Hernandez, A
   Self, DW
   Bibb, JA
AF Philibin, Scott D.
   Hernandez, Adan
   Self, David W.
   Bibb, James A.
TI Striatal signal transduction and drug addiction
SO FRONTIERS IN NEUROANATOMY
LA English
DT Review
DE addiction; signaling; plasticity; spines; dopamine; glutamate;
   phosphorylation
ID COCAINE-SEEKING BEHAVIOR; DEPENDENT PROTEIN-KINASE; NUCLEUS-ACCUMBENS
   SHELL; GLUTAMATE-RECEPTOR SUBUNITS; CAUDATE-PUTAMEN LESIONS; VENTRAL
   TEGMENTAL AREA; DELTA-FOSB INDUCTION; DOPAMINE-RECEPTOR; SYNAPTIC
   PLASTICITY; GENE-EXPRESSION
AB Drug addiction is a severe neuropsychiatric disorder characterized by loss of control over motivated behavior. The need for effective treatments mandates a greater understanding of the causes and identification of new therapeutic targets for drug development. Drugs of abuse subjugate normal reward-related behavior to uncontrollable drug-seeking and -taking. Contributions of brain reward circuitry are being mapped with increasing precision.The role of synaptic plasticity in addiction and underlying molecular mechanisms contributing to the formation of the addicted state are being delineated. Thus we may now consider the role of striatal signal transduction in addiction from a more integrative neurobiological perspective. Drugs of abuse alter dopaminergic and glutamatergic neurotransmission in medium spiny neurons of the striatum. Dopamine receptors important for reward serve as principle targets of drugs abuse, which interact with glutamate receptor signaling critical for reward learning. Complex networks of intracellular signal transduction mechanisms underlying these receptors are strongly stimulated by addictive drugs. Through these mechanisms, repeated drug exposure alters functional and structural neuroplasticity, resulting in transition to the addicted biological state and behavioral outcomes that typify addiction. Ca2+ and cAMP represent key second messengers that initiate signaling cascades, which regulate synaptic strength and neuronal excitability. Protein phosphorylation and dephosphorylation are fundamental mechanisms underlying synaptic plasticity that are dysregulated by drugs of abuse. Increased understanding of the regulatory mechanisms by which protein kinases and phosphatases exert their effects during normal reward learning and the addiction process may lead to novel targets and pharmacotherapeutics with increased efficacy in promoting abstinence and decreased side effects, such as interference with natural reward, for drug addiction.
C1 [Philibin, Scott D.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Lab Dr James A Bibb, Dallas, TX 75390 USA.
   [Bibb, James A.] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center Dallas; University of Texas System; University of Texas
   Southwestern Medical Center Dallas
RP Philibin, SD (通讯作者)，Univ Texas SW Med Ctr Dallas, Dept Psychiat, Lab Dr James A Bibb, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM scott.philibin@utsouthwestern.edu
OI Hernandez-Cortes, Adan/0000-0002-7098-870X
FU NARSAD; National Institute of Drug Abuse [DA026482, DA010460, DA008227,
   DA16672]; National Institute of Mental health [MH079710, MH083711]
FX This work was supported by a NARSAD Young Investigator Award (to Scott
   D. Philibin); National Institute of Drug Abuse grants DA026482,
   DA010460, DA008227 (to David W. Self), DA16672 (to James A. Bibb); and
   National Institute of Mental health grants MH079710 and MH083711 (to
   James A. Bibb).
CR Ahn JH, 2007, P NATL ACAD SCI USA, V104, P9876, DOI 10.1073/pnas.0703589104
   Ahn JH, 2007, P NATL ACAD SCI USA, V104, P2979, DOI 10.1073/pnas.0611532104
   Akiyama K, 2000, ANN NY ACAD SCI, V914, P263, DOI 10.1111/j.1749-6632.2000.tb05201.x
   Alleweireldt AT, 2003, PSYCHOPHARMACOLOGY, V168, P109, DOI 10.1007/s00213-002-1305-x
   Angelo M, 2006, J NEUROCHEM, V99, P353, DOI 10.1111/j.1471-4159.2006.04040.x
   Bachtell RK, 2005, PSYCHOPHARMACOLOGY, V183, P41, DOI 10.1007/s00213-005-0133-1
   Bachtell RK, 2008, EUR J NEUROSCI, V27, P2229, DOI 10.1111/j.1460-9568.2008.06199.x
   Backstrom P, 2007, PSYCHOPHARMACOLOGY, V192, P571, DOI 10.1007/s00213-007-0753-8
   Barnett DGS, 2011, BRAIN RES BULL, V85, P9, DOI 10.1016/j.brainresbull.2010.11.016
   Barrot M, 2002, P NATL ACAD SCI USA, V99, P11435, DOI 10.1073/pnas.172091899
   Bassareo V, 2002, J NEUROSCI, V22, P4709, DOI 10.1523/JNEUROSCI.22-11-04709.2002
   Bassareo V, 2011, PSYCHOPHARMACOLOGY, V214, P687, DOI 10.1007/s00213-010-2072-8
   Benavides DR, 2007, J NEUROSCI, V27, P12967, DOI 10.1523/JNEUROSCI.4061-07.2007
   Beninger RJ, 2003, PSYCHOPHARMACOLOGY, V170, P23, DOI 10.1007/s00213-003-1510-2
   Berglind WJ, 2007, EUR J NEUROSCI, V26, P757, DOI 10.1111/j.1460-9568.2007.05692.x
   Berglind WJ, 2009, J NEUROSCI, V29, P3715, DOI 10.1523/JNEUROSCI.5457-08.2009
   Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8
   Berridge KC, 2009, CURR OPIN PHARMACOL, V9, P65, DOI 10.1016/j.coph.2008.12.014
   Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251
   Bibb JA, 2001, NATURE, V410, P376, DOI 10.1038/35066591
   Bibb JA, 2010, J NEUROSCI, V30, P14987, DOI 10.1523/JNEUROSCI.4419-10.2010
   Blumer JB, 2005, TRENDS PHARMACOL SCI, V26, P470, DOI 10.1016/j.tips.2005.07.003
   Blumer JB, 2003, RECEPTOR CHANNEL, V9, P195, DOI 10.1080/10606820390203839
   Boehm J, 2006, NEURON, V51, P213, DOI 10.1016/j.neuron.2006.06.013
   Borgland SL, 2004, J NEUROSCI, V24, P7482, DOI 10.1523/JNEUROSCI.1312-04.2004
   BOWER G, 1964, J EXP ANAL BEHAV, V7, P401, DOI 10.1901/jeab.1964.7-401
   Bowers BJ, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-21-j0004.2001
   Bowers MS, 2008, P NATL ACAD SCI USA, V105, P12533, DOI 10.1073/pnas.0706999105
   Bowers MS, 2010, NEURON, V67, P11, DOI 10.1016/j.neuron.2010.06.004
   Bowers MS, 2010, BEHAV PHARMACOL, V21, P500, DOI 10.1097/FBP.0b013e32833dcfa5
   Bowers MS, 2004, NEURON, V42, P269, DOI 10.1016/S0896-6273(04)00159-X
   Brami-Cherrier K, 2005, J NEUROSCI, V25, P11444, DOI 10.1523/JNEUROSCI.1711-05.2005
   Burchett SA, 1998, J NEUROCHEM, V70, P2216
   Cadoni C, 2000, EUR J PHARMACOL, V387, pR23, DOI 10.1016/S0014-2999(99)00843-2
   Cadoni C, 2000, EUR J PHARMACOL, V388, P69, DOI 10.1016/S0014-2999(99)00824-9
   Cadoni C, 1999, NEUROSCIENCE, V90, P447, DOI 10.1016/S0306-4522(98)00466-7
   Caine SB, 2007, J NEUROSCI, V27, P13140, DOI 10.1523/JNEUROSCI.2284-07.2007
   Carlezon WA, 1998, SCIENCE, V282, P2272, DOI 10.1126/science.282.5397.2272
   Carlezon WA, 2005, TRENDS NEUROSCI, V28, P436, DOI 10.1016/j.tins.2005.06.005
   CHEN JS, 1995, MOL PHARMACOL, V48, P880
   Chen JS, 1997, J NEUROSCI, V17, P4933
   Chen R, 2009, J PHARMACOL EXP THER, V328, P912, DOI 10.1124/jpet.108.147959
   Choe ES, 2002, NEUROREPORT, V13, P1013, DOI 10.1097/00001756-200206120-00006
   Choe ES, 2002, NEUROPSYCHOPHARMACOL, V27, P565
   Choe ES, 2001, NEUROSCI LETT, V313, P129, DOI 10.1016/S0304-3940(01)02258-3
   Colby CR, 2003, J NEUROSCI, V23, P2488
   COLE RL, 1995, NEURON, V14, P813, DOI 10.1016/0896-6273(95)90225-2
   Compton WA, 2006, DRUG ALCOHOL DEPEN, V83, pS4, DOI 10.1016/j.drugalcdep.2005.10.020
   Crabbe JC, 2002, ANNU REV PSYCHOL, V53, P435, DOI 10.1146/annurev.psych.53.100901.135142
   Cui SZ, 2011, ACTA PHARMACOL SIN, V32, P175, DOI 10.1038/aps.2010.199
   Das S, 1997, SYNAPSE, V25, P227
   Derkach VA, 2007, NAT REV NEUROSCI, V8, P101, DOI 10.1038/nrn2055
   Dias C, 2004, PSYCHOPHARMACOLOGY, V175, P414, DOI 10.1007/s00213-004-1839-1
   Drevets WC, 2001, BIOL PSYCHIAT, V49, P81, DOI 10.1016/S0006-3223(00)01038-6
   Dudman JT, 2003, J NEUROCHEM, V87, P922, DOI 10.1046/j.1471-4159.2003.02067.x
   Edwards S, 2007, NEUROPSYCHOPHARMACOL, V32, P354, DOI 10.1038/sj.npp.1301062
   Engelhardt S, 2007, CIRC RES, V100, P1109, DOI 10.1161/01.RES.0000266971.15127.e8
   Epstein DH, 2006, PSYCHOPHARMACOLOGY, V189, P1, DOI 10.1007/s00213-006-0529-6
   ETTENBERG A, 1990, PHARMACOL BIOCHEM BE, V36, P635, DOI 10.1016/0091-3057(90)90268-M
   Ferguson SM, 2006, NEUROPSYCHOPHARMACOL, V31, P2660, DOI 10.1038/sj.npp.1301014
   Fog JU, 2006, NEURON, V51, P417, DOI 10.1016/j.neuron.2006.06.028
   Garcia DE, 1998, J NEUROSCI, V18, P2834
   Garzon Javier, 2008, Curr Drug Abuse Rev, V1, P222
   Gerdeman GL, 2003, TRENDS NEUROSCI, V26, P184, DOI 10.1016/S0166-2236(03)00065-1
   Gerdjikov TV, 2004, BEHAV NEUROSCI, V118, P740, DOI 10.1037/0735-7044.118.4.740
   Ghasemzadeh MB, 2009, NEUROSCIENCE, V159, P414, DOI 10.1016/j.neuroscience.2008.10.027
   Girault JA, 2007, CURR OPIN PHARMACOL, V7, P77, DOI 10.1016/j.coph.2006.08.012
   Gold SJ, 1997, J NEUROSCI, V17, P8024
   GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5
   Grafstein-Dunn E, 2001, MOL BRAIN RES, V88, P113, DOI 10.1016/S0169-328X(01)00038-9
   Greengard P, 1999, NEURON, V23, P435, DOI 10.1016/S0896-6273(00)80798-9
   Greenstein R, 2007, SYNAPSE, V61, P827, DOI 10.1002/syn.20429
   Guire ES, 2008, J NEUROSCI, V28, P6000, DOI 10.1523/JNEUROSCI.0384-08.2008
   HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947
   Hemby SE, 2005, J NEUROCHEM, V95, P1785, DOI 10.1111/j.1471-4159.2005.03517.x
   Hemby SE, 2005, BRAIN RES, V1064, P75, DOI 10.1016/j.brainres.2005.09.051
   Hemby SE, 1997, PSYCHOPHARMACOLOGY, V133, P7, DOI 10.1007/s002130050365
   HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0
   Hiroi N, 1997, P NATL ACAD SCI USA, V94, P10397, DOI 10.1073/pnas.94.19.10397
   Hisanaga S, 2010, J NEUROCHEM, V115, P1309, DOI 10.1111/j.1471-4159.2010.07050.x
   Hodge CW, 2002, J CLIN INVEST, V110, P1003, DOI 10.1172/JCI200215903
   Hodge CW, 1999, NAT NEUROSCI, V2, P997, DOI 10.1038/14795
   Hodgkinson CA, 2008, ALCOHOL ALCOHOLISM, V43, P505, DOI 10.1093/alcalc/agn032
   Hooks SB, 2008, BIOCHEM PHARMACOL, V75, P76, DOI 10.1016/j.bcp.2007.07.045
   HUANG KP, 1993, ARCH BIOCHEM BIOPHYS, V305, P570, DOI 10.1006/abbi.1993.1463
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Ikemoto S, 1997, J NEUROSCI, V17, P8580
   Ikemoto S, 2003, J NEUROSCI, V23, P9305
   Iwata SI, 1997, J PHARMACOL EXP THER, V283, P1445
   Jacobs EH, 2005, ADDICT BIOL, V10, P91, DOI 10.1080/13556210412331284748
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Karasawa JI, 2006, NEUROSCI LETT, V393, P127, DOI 10.1016/j.neulet.2005.09.058
   Kasanetz F, 2010, SCIENCE, V328, P1709, DOI 10.1126/science.1187801
   Kauer JA, 2007, NAT REV NEUROSCI, V8, P844, DOI 10.1038/nrn2234
   Kelley AE, 2004, NEURON, V42, P181, DOI 10.1016/S0896-6273(04)00223-5
   Kelz MB, 1999, NATURE, V401, P272, DOI 10.1038/45790
   Kim Y, 2006, NATURE, V442, P814, DOI 10.1038/nature04976
   Koeltzow TE, 2005, BEHAV BRAIN RES, V160, P250, DOI 10.1016/j.bbr.2004.12.005
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289
   LaLumiere RT, 2008, J NEUROSCI, V28, P3170, DOI 10.1523/JNEUROSCI.5129-07.2008
   Lee KW, 2006, P NATL ACAD SCI USA, V103, P3399, DOI 10.1073/pnas.0511244103
   LI DL, 1995, AM J PHYSIOL-RENAL, V269, pF673, DOI 10.1152/ajprenal.1995.269.5.F673
   Li T, 2010, NEUROSCI LETT, V468, P348, DOI 10.1016/j.neulet.2009.11.030
   Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753
   Liu QS, 2005, NATURE, V437, P1027, DOI 10.1038/nature04050
   Liu XY, 2009, NEURON, V61, P425, DOI 10.1016/j.neuron.2008.12.015
   Lopes JP, 2011, PROG NEUROBIOL, V94, P49, DOI 10.1016/j.pneurobio.2011.03.006
   Lu L, 2003, J NEUROCHEM, V85, P1604, DOI 10.1046/j.1471-4159.2003.01824.x
   Lu L, 2006, TRENDS NEUROSCI, V29, P695, DOI 10.1016/j.tins.2006.10.005
   Luscher C, 2006, PLOS MED, V3, P2005, DOI 10.1371/journal.pmed.0030437
   Madayag A, 2007, J NEUROSCI, V27, P13968, DOI 10.1523/JNEUROSCI.2808-07.2007
   Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758
   Martin M, 2006, NAT NEUROSCI, V9, P868, DOI 10.1038/nn1713
   Mattson BJ, 2005, J NEUROCHEM, V95, P1481, DOI 10.1111/j.1471-4159.2005.03500.x
   Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068
   Mazzucchelli C, 2002, NEURON, V34, P807, DOI 10.1016/S0896-6273(02)00716-X
   McClung CA, 2003, NAT NEUROSCI, V6, P1208, DOI 10.1038/nn1143
   McFarland K, 2004, J NEUROSCI, V24, P1551, DOI 10.1523/JNEUROSCI.4177-03.2004
   McGinty JF, 2010, BRAIN RES, V1314, P183, DOI 10.1016/j.brainres.2009.08.078
   Meyer DA, 2008, P NATL ACAD SCI USA, V105, P18561, DOI 10.1073/pnas.0806078105
   Miller CA, 2005, NEURON, V47, P873, DOI 10.1016/j.neuron.2005.08.006
   Milton AL, 2010, EUR J NEUROSCI, V31, P2308, DOI 10.1111/j.1460-9568.2010.07249.x
   MITCHELL JA, 1985, BEHAV NEUROSCI, V99, P1074, DOI 10.1037/0735-7044.99.6.1074
   MITCHELL JA, 1988, BEHAV NEUROSCI, V102, P504, DOI 10.1037/0735-7044.102.4.504
   Mizoguchi H, 2004, MOL PHARMACOL, V65, P1293, DOI 10.1124/mol.65.5.1293
   Moratalla R, 1996, NEURON, V17, P147, DOI 10.1016/S0896-6273(00)80288-3
   MORGAN JI, 1995, TRENDS NEUROSCI, V18, P66
   Moussawi K, 2010, EUR J PHARMACOL, V639, P115, DOI 10.1016/j.ejphar.2010.01.030
   Muller DL, 2005, J PHARMACOL EXP THER, V314, P148, DOI 10.1124/jpet.105.083410
   Nagerl UV, 2004, NEURON, V44, P759, DOI 10.1016/j.neuron.2004.11.016
   Nagy G, 2002, J NEUROSCI, V22, P9278
   Namkung Y, 2004, J BIOL CHEM, V279, P49533, DOI 10.1074/jbc.M408319200
   Narita M, 2001, NEUROSCIENCE, V103, P309, DOI 10.1016/S0306-4522(00)00572-8
   Natochin M, 2000, J BIOL CHEM, V275, P40981, DOI 10.1074/jbc.M006478200
   Neve KA, 2004, J RECEPT SIG TRANSD, V24, P165, DOI 10.1081/LRST-200029981
   Newton PM, 2007, GENES BRAIN BEHAV, V6, P329, DOI 10.1111/j.1601-183X.2006.00261.x
   Newton PM, 2007, BEHAV NEUROSCI, V121, P439, DOI 10.1037/0735-7044.121.2.439
   Nomoto S, 1997, BIOCHEM BIOPH RES CO, V241, P281, DOI 10.1006/bbrc.1997.7802
   Norrholm SD, 2003, NEUROSCIENCE, V116, P19, DOI 10.1016/S0306-4522(02)00560-2
   Nye HE, 1995, J PHARMACOL EXP THER, V275, P1671
   Oehrlein SA, 1996, BIOCHEM J, V317, P219, DOI 10.1042/bj3170219
   Okamoto KI, 2004, NAT NEUROSCI, V7, P1104, DOI 10.1038/nn1311
   Olive MF, 2000, EUR J NEUROSCI, V12, P4131, DOI 10.1046/j.1460-9568.2000.00297.x
   Olive MF, 2010, BEHAV PHARMACOL, V21, P493, DOI 10.1097/FBP.0b013e32833d8bb7
   Ouimet CC, 1998, BRAIN RES, V808, P8, DOI 10.1016/S0006-8993(98)00724-0
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822
   Penela P, 2003, CELL SIGNAL, V15, P973, DOI 10.1016/S0898-6568(03)00099-8
   Perrotti LI, 2008, SYNAPSE, V62, P358, DOI 10.1002/syn.20500
   Phillips PEM, 2003, NATURE, V422, P614, DOI 10.1038/nature01566
   Pierce RC, 2010, NEUROSCI BIOBEHAV R, V35, P212, DOI 10.1016/j.neubiorev.2010.01.007
   Ping AS, 2008, BRAIN RES, V1215, P173, DOI 10.1016/j.brainres.2008.03.088
   Pollock VV, 2007, J NEUROCHEM, V103, P456, DOI 10.1111/j.1471-4159.2007.04853.x
   Porrino LJ, 2007, PROG NEURO-PSYCHOPH, V31, P1593, DOI 10.1016/j.pnpbp.2007.08.040
   Prus A. J., 2009, METHODS BEHAV ANAL N
   Psifogeorgou K, 2007, J NEUROCHEM, V103, P617, DOI 10.1111/j.1471-4159.2007.04812.x
   Pulipparacharuvil S, 2008, NEURON, V59, P621, DOI 10.1016/j.neuron.2008.06.020
   Qi ZH, 2007, J BIOL CHEM, V282, P33052, DOI 10.1074/jbc.M707233200
   Rahman Z, 1999, J NEUROSCI, V19, P2016
   Richards G, 2005, J COMP NEUROL, V487, P15, DOI 10.1002/cne.20538
   Robbins TW, 2008, ANN NY ACAD SCI, V1141, P1, DOI 10.1196/annals.1441.020
   Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-7
   Salzmann J, 2003, BRIT J PHARMACOL, V140, P831, DOI 10.1038/sj.bjp.0705506
   Schmidt HD, 2006, EUR J NEUROSCI, V23, P219, DOI 10.1111/j.1460-9568.2005.04524.x
   Schmidt HD, 2005, EUR J PHARMACOL, V526, P65, DOI 10.1016/j.ejphar.2005.09.068
   Schultz W, 2000, CEREB CORTEX, V10, P272, DOI 10.1093/cercor/10.3.272
   Schumann J, 2009, J NEUROSCI, V29, P6955, DOI 10.1523/JNEUROSCI.1329-09.2009
   SELF DW, 1992, BRAIN RES, V582, P349, DOI 10.1016/0006-8993(92)90155-3
   Self DW, 1996, SCIENCE, V271, P1586, DOI 10.1126/science.271.5255.1586
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   Shaw-Lutchman TZ, 2002, J NEUROSCI, V22, P3663
   Shiflett MW, 2011, PROG NEUROBIOL, V95, P1, DOI 10.1016/j.pneurobio.2011.05.007
   Shiflett MW, 2011, BEHAV BRAIN RES, V218, P240, DOI 10.1016/j.bbr.2010.12.010
   Shippenberg TS, 1997, PHARMACOL BIOCHEM BE, V57, P449, DOI 10.1016/S0091-3057(96)00450-9
   Sung JY, 2008, P NATL ACAD SCI USA, V105, P3112, DOI 10.1073/pnas.0712180105
   Surmeier DJ, 2007, TRENDS NEUROSCI, V30, P228, DOI 10.1016/j.tins.2007.03.008
   SURMEIER DJ, 1995, NEURON, V14, P385, DOI 10.1016/0896-6273(95)90294-5
   Sutton MA, 2000, BEHAV PHARMACOL, V11, P365, DOI 10.1097/00008877-200008000-00002
   Svenningsson P, 2005, AAPS J, V7, DOI 10.1208/aapsj070235
   Svenningsson P, 2004, ANNU REV PHARMACOL, V44, P269, DOI 10.1146/annurev.pharmtox.44.101802.121415
   Taylor JR, 2007, P NATL ACAD SCI USA, V104, P4147, DOI 10.1073/pnas.0610288104
   Taymans JM, 2002, NEUROSCIENCE, V114, P39, DOI 10.1016/S0306-4522(02)00260-9
   Tepper JM, 2007, PROG BRAIN RES, V160, P3, DOI 10.1016/S0079-6123(06)60001-0
   Thomas EA, 1998, J NEUROSCI RES, V52, P118, DOI 10.1002/(SICI)1097-4547(19980401)52:1<118::AID-JNR11>3.0.CO;2-6
   Thomas MJ, 2008, BRIT J PHARMACOL, V154, P327, DOI 10.1038/bjp.2008.77
   Thomas MJ, 2001, NAT NEUROSCI, V4, P1217, DOI 10.1038/nn757
   Torregrossa M.M., 2011, NEUROBIOL LEARN MEM
   Traynor J, 2010, ANN NY ACAD SCI, V1187, P341, DOI 10.1111/j.1749-6632.2009.05150.x
   Turgeon SM, 1997, BRAIN RES, V749, P120, DOI 10.1016/S0006-8993(96)01316-9
   Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077
   Valjent E, 2000, J NEUROSCI, V20, P8701
   Valjent E, 2005, P NATL ACAD SCI USA, V102, P491, DOI 10.1073/pnas.0408305102
   Valjent E, 2004, EUR J NEUROSCI, V19, P1826, DOI 10.1111/j.1460-9568.2004.03278.x
   Valjent E, 2001, EUR J NEUROSCI, V14, P342, DOI 10.1046/j.0953-816x.2001.01652.x
   Valjent E, 2006, P NATL ACAD SCI USA, V103, P2932, DOI 10.1073/pnas.0511030103
   Volkow ND, 1996, P NATL ACAD SCI USA, V93, P10388, DOI 10.1073/pnas.93.19.10388
   Volkow ND, 2005, AM J PSYCHIAT, V162, P1401, DOI 10.1176/appi.ajp.162.8.1401
   Walters CL, 2001, J NEUROSCI, V21, P9438, DOI 10.1523/JNEUROSCI.21-23-09438.2001
   Wayman GA, 2008, NEURON, V59, P914, DOI 10.1016/j.neuron.2008.08.021
   WEED MR, 1993, PSYCHOPHARMACOLOGY, V113, P51, DOI 10.1007/BF02244333
   Wei FY, 2005, J NEUROCHEM, V93, P502, DOI 10.1111/j.1471-4159.2005.03058.x
   Weiss F, 2010, FRONT NEUROSCI, P1
   WISE RA, 1989, ANNU REV PSYCHOL, V40, P191, DOI 10.1146/annurev.ps.40.020189.001203
   WISE RA, 1995, PSYCHOPHARMACOLOGY, V120, P10, DOI 10.1007/BF02246140
   WISE RA, 1995, SYNAPSE, V21, P140, DOI 10.1002/syn.890210207
   Wolf ME, 2010, NEUROTOX RES, V18, P393, DOI 10.1007/s12640-010-9176-0
   WOOLVERTON WL, 1984, J PHARMACOL EXP THER, V230, P678
   Xi ZX, 2010, NEUROPHARMACOLOGY, V58, P304, DOI 10.1016/j.neuropharm.2009.06.016
   Xi ZX, 2002, J PHARMACOL EXP THER, V303, P608, DOI 10.1124/jpet.102.039735
   Xie GQ, 2009, ALCOHOL CLIN EXP RES, V33, P121, DOI 10.1111/j.1530-0277.2008.00818.x
   Yan JZ, 2011, J BIOL CHEM, V286, P25187, DOI 10.1074/jbc.M110.192708
   YOKEL RA, 1978, PSYCHOPHARMACOLOGY, V58, P289, DOI 10.1007/BF00427393
   Zachariou V, 2006, NAT NEUROSCI, V9, P205, DOI 10.1038/nn1636
   Zachariou V, 2003, P NATL ACAD SCI USA, V100, P13656, DOI 10.1073/pnas.2232594100
   Zhang L, 2004, J NEUROSCI, V24, P3344, DOI 10.1523/JNEUROSCI.0060-04.2004
   Zheng Z, 2008, NEUROSCIENCE, V156, P872, DOI 10.1016/j.neuroscience.2008.08.042
NR 218
TC 23
Z9 24
U1 1
U2 17
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1662-5129
J9 FRONT NEUROANAT
JI Front. Neuroanat.
PD SEP 20
PY 2011
VL 5
DI 10.3389/fnana.2011.00060
PG 15
WC Anatomy & Morphology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Anatomy & Morphology; Neurosciences & Neurology
GA 886RN
UT WOS:000299871700001
PM 21960960
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Rogues, BP
AF Rogues, BP
TI Comparison of drug toxicity: neurobiological mechanisms of drug
   addiction and therapeutic approaches
SO M S-MEDECINE SCIENCES
LA French
DT Article
ID MICE; INHIBITION; RECEPTORS; NEURONS; PAIN
AB In humans as in animals, individual differences in the response to drug of abuse and in the proneness to self-administer these compounds have been observed. Many factors, such as genetics, history of drug use, stress and life events likely contribute to drug-addiction. Gene deletion was largely use in association with inhibitors of neuropeptide inactivating enzyme to Investigate the neurochemical basis of drug addiction. The mesolimbic dopamine system has been clearly demonstrated to be critically involved in rewarding effects of all drugs of abuse. Addiction could be a dopamine-dependent associative learning disorder. In contrast to natural rewards, drugs of abuse have nonhabituating effects leading to sensitization of the DA systems and overestimation of the expected drug-induced sensation of pleasure. Numerous results emphasize the important role of endogenous opioids in the mechanism of drug addiction which could be related to the imbalance between stimulation of mu vs delta receptors and/or defects in the equilibrium between rewarding (opioid) and counteracting (CCK, SP...) systems. The identity in the mechanism subtaining the abuse of illicits as well as licits (ex. alcohol) drugs has been taken into account to extend the role of the French organization against drug abuse.
C1 UFR Sci Pharmaceut & Biol, CNRS UMR 8600, Inserm U 266, F-75270 Paris 06, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite Paris Cite
RP Rogues, BP (通讯作者)，UFR Sci Pharmaceut & Biol, CNRS UMR 8600, Inserm U 266, 4 Ave Observ, F-75270 Paris 06, France.
CR Antelman S. M., 1988, SENSITIZATION NERVOU, P227
   BAAMONDE A, 1992, EUR J PHARMACOL, V216, P157, DOI 10.1016/0014-2999(92)90356-9
   Bertrand E, 1997, NEUROSCIENCE, V80, P17
   DELLU F, 1996, NEUROPSYCHOBIOLOGY, V34, P145
   DEMINIERE JM, 1992, BRAIN RES, V586, P135, DOI 10.1016/0006-8993(92)91383-P
   Di Chiara G, 1999, EUR J PHARMACOL, V375, P13, DOI 10.1016/S0014-2999(99)00372-6
   Filliol D, 2000, NAT GENET, V25, P195, DOI 10.1038/76061
   Flynn PM, 1996, J PERS DISORD, V10, P56, DOI 10.1521/pedi.1996.10.1.56
   HIGHLEY JD, 1991, P NATL ACAD SCI USA, V88, P7261
   KENDLER K, 1998, BRIT J PSYCHIAT, V55, P967
   Konig M, 1996, NATURE, V383, P535, DOI 10.1038/383535a0
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401
   Maldonado R, 1997, NATURE, V388, P586, DOI 10.1038/41567
   Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0
   McCann UD, 1998, LANCET, V352, P1433, DOI 10.1016/S0140-6736(98)04329-3
   Murtra P, 2000, NATURE, V405, P180, DOI 10.1038/35012069
   OLDS J, 1958, SCIENCE, V127, P315, DOI 10.1126/science.127.3294.315
   Phillips TJ, 1998, NAT NEUROSCI, V1, P610, DOI 10.1038/2843
   PIAZZA PV, 1991, P NATL ACAD SCI USA, V88, P2088, DOI 10.1073/pnas.88.6.2088
   Pilla M, 1999, NATURE, V400, P371, DOI 10.1038/43944
   Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6
   ROQUES B, 1999, DANGEROSITE DROGUES
   ROQUES BP, 1993, PHARMACOL REV, V45, P87
   ROQUES BP, 1996, NEUROCHEM RES, V21, P1395
   RUIZGAYO R, 1999, BRIT J PHARMACOL, V119, P174
   SCHULTZ W, 1997, SCIENCE, V275, P1597
   Sebret A, 1999, J NEUROSCI, V19, P7230, DOI 10.1523/JNEUROSCI.19-16-07230.1999
   SOLOMON RL, 1980, AM PSYCHOL, V35, P691, DOI 10.1037/0003-066X.35.8.691
   Spanagel R, 1999, TRENDS NEUROSCI, V22, P521, DOI 10.1016/S0166-2236(99)01447-2
   Spielewoy C, 2000, EUR J NEUROSCI, V12, P1827, DOI 10.1046/j.1460-9568.2000.00063.x
   Swan N., 1998, NIDA NOTES, V13, P1
   Van Ree JM, 1999, PHARMACOL REV, V51, P341
NR 33
TC 0
Z9 0
U1 0
U2 0
PU MASSON EDITEUR
PI PARIS 06
PA 120 BLVD SAINT-GERMAIN, 75280 PARIS 06, FRANCE
SN 0767-0974
J9 M S-MED SCI
JI M S-Med. Sci.
PD DEC
PY 2000
VL 16
IS 12
BP 1346
EP 1354
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 383LZ
UT WOS:000165885300008
DA 2023-06-23
ER

PT C
AU Eshleman, R
   Jha, D
   Singh, R
AF Eshleman, Ryan
   Jha, Deeptanshu
   Singh, Rahul
BE Hu, XH
   Shyu, CR
   Bromberg, Y
   Gao, J
   Gong, Y
   Korkin, D
   Yoo, I
   Zheng, JH
TI Identifying Individuals Amenable to Drug Recovery Interventions through
   Computational Analysis of Addiction Content in Social Media
SO 2017 IEEE INTERNATIONAL CONFERENCE ON BIOINFORMATICS AND BIOMEDICINE
   (BIBM)
SE IEEE International Conference on Bioinformatics and Biomedicine-BIBM
LA English
DT Proceedings Paper
CT Biological Ontologies and Knowledge Bases Workshop at IEEE International
   Conference on Bioinformatics and Biomedicine (IEEE BIBM)
CY NOV 13-16, 2017
CL Kansas City, MI
SP IEEE, IEEE Comp Soc, IEEE Tech Comm Computat Life Sci
DE Computational epidemiology; drug addiction; opioid addiction; addiction
   analysis; social media
ID UNITED-STATES; INTERNET; ABUSE
AB Drug abuse and addiction is a growing epidemic at the forefront of public health. Within this remit, the illicit use of opioid analgesics alone has emerged as one of the fastest growing forms of drug abuse in the U.S. and the death rate from this epidemic are drawing comparison to the US AIDS epidemic. Traditional methods of epidemiology based on explicit reporting of indicator-based data from patient records or data collected through surveys is often found wanting in modeling and designing effective interventions for addiction. In addition to the non-real time nature of the aforementioned methods, this is also due to a number of reasons including the continual penetration of novel biological/chemical entities into the abuse-cycle, the complex etiology of addiction which includes among others social factors, and the multistage nature of the addiction process.
   The recent advent of social media presents an intriguing information resource that is free from some of the above deficiencies and may be leveraged to model the addiction process and offer perspectives that are unavailable through traditional methods of epidemiology. In this paper, we use addiction related social media content to design a computational epidemiological approach for predicting a user's propensity for seeking drug recovery interventions. Solving this problem is crucial for designing effective interventions, identifying cohorts who would be most amenable to recovery, and planning resource allocations. Our method characterizes the evolving language of drug use, identifies the interactions that influence a drug user's actions, and using machine learning techniques predicts the extent to which a user is likely to participate in addiction recovery communities. Experimental assessments on real-world data from the social media platforms Reddit and Twitter indicate the proposed method can identify users who are amenable to addiction recovery intervention with high precision, recall, and F1 values.
C1 [Eshleman, Ryan; Jha, Deeptanshu; Singh, Rahul] San Francisco State Univ, Dept Comp Sci, San Francisco, CA 94132 USA.
   [Singh, Rahul] Univ Calif San Diego, Ctr Discovery & Innovat Parasit Dis, San Diego, CA 92103 USA.
C3 California State University System; San Francisco State University;
   University of California System; University of California San Diego
RP Eshleman, R (通讯作者)，San Francisco State Univ, Dept Comp Sci, San Francisco, CA 94132 USA.
CR Boyer EW, 2005, PEDIATRICS, V115, P302, DOI 10.1542/peds.2004-1199
   Boyer EW, 2001, NEW ENGL J MED, V345, P469, DOI 10.1056/NEJM200108093450619
   Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324
   Cameron D, 2013, J BIOMED INFORM, V46, P985, DOI 10.1016/j.jbi.2013.07.007
   Chan B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135072
   De Choudhury M, 2016, 34TH ANNUAL CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, CHI 2016, P2098, DOI 10.1145/2858036.2858207
   Deluca P, 2007, AM J ADDICTION, V16, P479, DOI 10.1080/10550490701641181
   Hanson CL, 2013, J MED INTERNET RES, V15, P256, DOI 10.2196/jmir.2741
   Kluger Y, 2003, GENOME RES, V13, P703, DOI 10.1101/gr.648603
   Mikolov T., 2013, ADV NEURAL INFORM PR, P3111, DOI DOI 10.1162/JMLR.2003.3.4-5.951
   Miller PG, 2010, ADDICTION, V105, P1557, DOI 10.1111/j.1360-0443.2010.02992.x
   Paulozzi LJ, 2008, PHARMACOEPIDEM DR S, V17, P997, DOI 10.1002/pds.1626
   Pedregosa F, 2011, J MACH LEARN RES, V12, P2825
   President Commission on the Opioid Crisis, 2017, INT REP
   Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3
   SALTON G, 1988, INFORM PROCESS MANAG, V24, P513, DOI 10.1016/0306-4573(88)90021-0
   Schifano F, 2010, RIV PSICHIATR, V45, P88
NR 17
TC 7
Z9 7
U1 0
U2 8
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
SN 2156-1125
EI 2156-1133
BN 978-1-5090-3050-7
J9 IEEE INT C BIOINFORM
PY 2017
BP 849
EP 854
PG 6
WC Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
WE Conference Proceedings Citation Index - Science (CPCI-S)
SC Computer Science; Engineering; Mathematical & Computational Biology
GA BJ6DG
UT WOS:000426504100158
DA 2023-06-23
ER

PT J
AU Denomme, W
   Shane, M
   Simard, I
AF Denomme, William
   Shane, Matthew
   Simard, Isabelle
TI Psychopathic Traits and Stimulus-Processing in Addiction: How
   Psychopathy and Addiction Interact to Influence Drug and Food Processing
   in the Brain
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 73rd Annual Scientific Convention and Meeting of the
   Society-of-Biological-Psychiatry (SOBP)
CY MAY 10-12, 2017
CL New York, NY
SP Soc Biol Psychiat
DE Addiction; Psychopathy; BOLD fMRI; Craving; Reward
C1 [Denomme, William; Shane, Matthew; Simard, Isabelle] Univ Ontario Inst Technol, Oshawa, ON, Canada.
C3 Ontario Tech University
FU  [RO1DA026932]
FX Supported By: RO1DA026932
NR 0
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2018
VL 83
IS 9
SU S
MA T267
BP S233
EP S233
DI 10.1016/j.biopsych.2018.02.604
PG 1
WC Neurosciences; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Neurosciences & Neurology; Psychiatry
GA GG9DU
UT WOS:000433001900003
DA 2023-06-23
ER

PT J
AU Takahashi, TT
   Ornello, R
   Quatrosi, G
   Torrente, A
   Albanese, M
   Vigneri, S
   Guglielmetti, M
   De Marco, CM
   Dutordoir, C
   Colangeli, E
   Fuccaro, M
   Di Lenola, D
   Spuntarelli, V
   Pilati, L
   Di Marco, S
   Van Dycke, A
   Abdullahi, RA
   van den Brink, AM
   Martelletti, P
AF Takahashi, Tatiane Teru
   Ornello, Raffaele
   Quatrosi, Giuseppe
   Torrente, Angelo
   Albanese, Maria
   Vigneri, Simone
   Guglielmetti, Martina
   De Marco, Cristiano Maria
   Dutordoir, Camille
   Colangeli, Enrico
   Fuccaro, Matteo
   Di Lenola, Davide
   Spuntarelli, Valerio
   Pilati, Laura
   Di Marco, Salvatore
   Van Dycke, Annelies
   Abdullahi, Ramla Abuukar
   van den Brink, Antoinette Maassen
   Martelletti, Paolo
CA European Headache Federation Sch
TI Medication overuse and drug addiction: a narrative review from addiction
   perspective (vol 22, 32, 2021)
SO JOURNAL OF HEADACHE AND PAIN
LA English
DT Correction
C1 [Takahashi, Tatiane Teru; Abdullahi, Ramla Abuukar] Kings Coll London, Inst Psychiat Psychol & Neurosci, Wolfson CARD, Headache Res, 20 Newcomen St, London SE1 1YR, England.
   [Takahashi, Tatiane Teru; Colangeli, Enrico] Med Discovery Catapult, Block 35,Mereside,Alderley Pk, Macclesfield, Cheshire, England.
   [Ornello, Raffaele] Univ Aquila, Via Vetoio 1, Laquila 67100, Coppito, Italy.
   [Quatrosi, Giuseppe] Univ Palermo, Dept Hlth Promot, Mother & Child Care Internal Med & Med Specialtie, Piazza Cliniche 2, Palermo 90127, Italy.
   [Torrente, Angelo; Pilati, Laura; Di Marco, Salvatore] Univ Palermo, Dept Biomed Neurosci & Diagnost, Via Vespro 129, Palermo 90127, Italy.
   [Albanese, Maria] Univ Roma Tor Vergata, Tor Vergata Hosp, Dept Syst Med, Viale Oxford 81, Rome 00133, Italy.
   [Vigneri, Simone] Univ Palermo, Dept Expt Biomed & Clin Neurosci, Via Vespro,129, Palermo 90127, Italy.
   [Vigneri, Simone] Santa Maria Maddalena Hosp, Pain Med Unit, Occhiobello, Italy.
   [Guglielmetti, Martina; De Marco, Cristiano Maria; Martelletti, Paolo] Sant Andrea Hosp, Reg Headache Referral Ctr, Via Grottarossa 1039, Rome 00189, Italy.
   [Guglielmetti, Martina] Univ Sassari, Dept Med Surg & Expt Sci, Piazza Univ 21, Sassari 07100, Italy.
   [Dutordoir, Camille] Univ Hosp Ghent, Dept Neurol, Corneel Heymanslaan 10, Ghent 9000, Belgium.
   [Fuccaro, Matteo] Conegliano Hosp, Dept Neurol, Via Brigata Bisagno 2, Conegliano 31015, Italy.
   [Di Lenola, Davide] Sapienza Univ Rome, Dept Med Surg Sci & Biotechnol, Polo Pontino,Viale XXIV Maggio 7, Latina 04100, Italy.
   [Spuntarelli, Valerio] Erasmus MC Univ Med Ctr Rotterdam, Dept Internal Med, Div Pharmacol, Wytemaweg 80, Rotterdam 3015CN, Netherlands.
   [Van Dycke, Annelies; van den Brink, Antoinette Maassen] AZ Sint Jan Brugge, Dept Neurol, Ruddershove 10, Brugge 8000, Belgium.
   [Abdullahi, Ramla Abuukar] Guys & St Thomas NHS Trust, Headache Ctr, London, England.
   [Martelletti, Paolo] Sapienza Univ Rome, Dept Clin & Mol Med, Via Grottarossa 1039, Rome 00189, Italy.
C3 University of London; King's College London; University of L'Aquila;
   University of Palermo; University of Palermo; University of Rome Tor
   Vergata; Policlin Tor Vergata; University of Palermo; Sapienza
   University Rome; Azienda Ospedaliera Sant'Andrea; University of Sassari;
   Ghent University; Ghent University Hospital; ULSS 2 Marca TV; Ospedale
   Conegliano; Sapienza University Rome; Guy's & St Thomas' NHS Foundation
   Trust; Sapienza University Rome
RP Takahashi, TT (通讯作者)，Kings Coll London, Inst Psychiat Psychol & Neurosci, Wolfson CARD, Headache Res, 20 Newcomen St, London SE1 1YR, England.; Takahashi, TT (通讯作者)，Med Discovery Catapult, Block 35,Mereside,Alderley Pk, Macclesfield, Cheshire, England.
EM tati.pharmacy@gmail.com
RI Albanese, Maria/K-7232-2016; Vigneri, Simone/GSN-9512-2022; Colangeli,
   Enrico/AIC-7367-2022
OI Vigneri, Simone/0000-0002-6511-3490; TORRENTE,
   Angelo/0000-0002-0585-8351; Colangeli, Enrico/0000-0002-8696-9407
CR Takahashi TT, 2021, J HEADACHE PAIN, V22, DOI 10.1186/s10194-021-01224-8
NR 1
TC 0
Z9 0
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1129-2369
EI 1129-2377
J9 J HEADACHE PAIN
JI J. Headache Pain
PD DEC
PY 2021
VL 22
IS 1
AR 64
DI 10.1186/s10194-021-01275-x
PG 1
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA TE2SS
UT WOS:000669866400001
PM 34225669
OA gold, Green Published
DA 2023-06-23
ER

PT J
AU Rokhlina, ML
   Boginskaya, DD
   Usmanova, NN
   Mokhnachev, SO
AF Rokhlina, M. L.
   Boginskaya, D. D.
   Usmanova, N. N.
   Mokhnachev, S. O.
TI Abusing with pharmacy drugs
SO ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA
LA Russian
DT Article
DE drug addiction; derivatives of pharmacy drugs
C1 [Rokhlina, M. L.; Boginskaya, D. D.; Usmanova, N. N.; Mokhnachev, S. O.] Natl Res Ctr Addict, Moscow, Russia.
RP Rokhlina, ML (通讯作者)，Natl Res Ctr Addict, Moscow, Russia.
EM rokhlina@inbox.ru
CR BABAYAN EA, 1987, NARKOLOGIYA, P366
   BOGINSKAYA DD, 2012, NARKOLOGIYA, V3, P32
   Guillem E, 2003, ENCEPHALE, V29, P456
   IVANOV VI, 1978, TSIKLODOLOVAYA TOKSI, P15
   KOSHELEVA TS, 2005, AVTOREF DIS KAND MED, P31
   KRUPITSKY EM, 2007, NARKOLOGIYA, V1, P73
   MOKHANCHEV SO, 2008, VOPROSY NARKOLOGII, V5, P102
   NADEZHDIN AV, VOPROSY NARKOLOGII, V1, P45
   NAYDENOVA NG, VOPROSY NARKOLOGII, V200, P16
   NOSATOVSKY IA, 2007, AVTOREF DIS D RA MED, P42
   PETRYUK PT, 2001, ZH PSIKHIAT MED PSIK, V1, P65
   ROKHLINA ML, 2010, NARKOMANY TOKSIMANY, P151
   RYBTSEVA AA, 2008, NARKOLOGIYA, V1, P49
   Saatcioglu O, 2006, TURK PSIKIYATR DERG, V17, P72
   SHEVTSOVA YB, 2008, NARKOLOGIYA, V2, P56
   STUPIN VA, 2008, NARKOLOGIYA, V3, P49
   TUZIKOVA YB, 2000, VOPROSY NARKOLOGII, V1, P49
NR 17
TC 0
Z9 4
U1 0
U2 1
PU IZDATELSTVO MEDITSINA
PI MOSCOW
PA PETROVERIGSKII PER 6-8, K-142 MOSCOW, RUSSIA
SN 1997-7298
J9 ZH NEVROL PSIKHIATR
JI Z. Nevrol. Psikhiatrii Im S S Korsakova
PY 2013
VL 113
IS 7
BP 55
EP 59
PG 5
WC Clinical Neurology; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Psychiatry
GA 304NU
UT WOS:000330754400012
PM 23994923
DA 2023-06-23
ER

PT J
AU Avery, JA
   Burrows, K
   Kerr', KL
   Bodurka, J
   Khalsa, S
   Paulus, MP
   Simmons, WK
AF Avery, Jason A.
   Burrows, Kaiping
   Kerr', Kara L.
   Bodurka, Jerzy
   Khalsa, Sahib
   Paulus, Martin P.
   Simmons, W. Kyle
TI The Neural Basis of Positive Alliesthesia in Nicotine Addiction
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
DE Interoception; Insula; Drug Craving; Addiction; fMRI
C1 [Avery, Jason A.; Burrows, Kaiping; Kerr', Kara L.; Bodurka, Jerzy; Khalsa, Sahib; Paulus, Martin P.; Simmons, W. Kyle] LIBR, Tulsa, OK USA.
   [Kerr', Kara L.] Univ Tulsa, Dept Psychol, Tulsa, OK 74104 USA.
   [Bodurka, Jerzy] Univ Oklahoma, Coll Engn, Tulsa, OK USA.
   [Khalsa, Sahib; Simmons, W. Kyle] Univ Tulsa, Sch Community Med, Tulsa, OK 74104 USA.
C3 Laureate Institute for Brain Research, Inc.; University of Tulsa;
   University of Oklahoma System; University of Oklahoma - Tulsa;
   University of Tulsa
RI Simmons, W. Kyle/V-6846-2019; Khalsa, Sahib S./ABA-8359-2020; Khalsa,
   Sahib S. S/Q-1434-2018
OI Simmons, W. Kyle/0000-0002-0399-9003; Khalsa, Sahib
   S./0000-0003-2124-8585; Khalsa, Sahib S. S/0000-0003-2124-8585
FU Oklahoma Tobacco Research Center; William K. Warren Foundation
FX Supported by: Oklahoma Tobacco Research Center grant to WKS; The William
   K. Warren Foundation
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2016
VL 79
IS 9
SU S
MA 913
BP 305S
EP 305S
PG 1
WC Neurosciences; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Psychiatry
GA VC2BP
UT WOS:000432440804063
DA 2023-06-23
ER

PT J
AU Rahman, S
AF Rahman, Shafiqur
TI Nicotinic Receptors as Therapeutic Targets for Drug Addictive Disorders
SO CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS
LA English
DT Article
DE Drug addiction; nicotinic receptors; nicotine addiction; alcoholism;
   cocaine; opioids; pharmacotherapy; drug development
ID VENTRAL TEGMENTAL AREA; SOMATODENDRITIC DOPAMINE RELEASE; VOLUNTARY
   ETHANOL INTAKE; NUCLEUS-ACCUMBENS SHELL; ACETYLCHOLINE-RECEPTORS;
   PARTIAL AGONIST; EXTRACELLULAR DOPAMINE; SAZETIDINE-A;
   N,N'-DODECANE-1,12-DIYL-BIS-3-PICOLINIUM DIBROMIDE; PHYSIOLOGICAL
   DIVERSITY
AB Drug addiction is a chronic neuropsychiatric disorder which is characterized by a compulsion to take drugs and loss of control in limiting intake. The worldwide impact of drug addiction on morbidity and mortality is very high. Evidence from preclinical and clinical studies suggests that brain nicotinic acetylcholine receptors (nAChRs), play a critical role in various addictive disorders, including nicotine addiction and alcoholism. Thus, there is an increasing impetus in developing new therapeutics for addictive disorders by targeting brain nAChRs. This review highlights the important preclinical findings involving nAChR ligands in regulating nicotine, alcohol and other addictive drug-induced neurobiological changes in animal models and humans. A number of partial agonists or antagonists targeting nAChRs have shown therapeutic benefit in nicotine addiction and alcohol use disorders are also discussed. Furthermore, the role of nAChRs in other addictive disorders is reviewed. Overall, novel pharmacological agents that target brain nAChRs for future drug development are discussed.
C1 S Dakota State Univ, Coll Pharm, Dept Pharmaceut Sci, Brookings, SD 57007 USA.
C3 South Dakota State University
RP Rahman, S (通讯作者)，S Dakota State Univ, Coll Pharm, Dept Pharmaceut Sci, Box 2202C,SAV 265, Brookings, SD 57007 USA.
EM shafiqur.rahman@sdstate.edu
RI Rahman, Shafiqur/P-6206-2018
OI Rahman, Shafiqur/0000-0002-6289-5386
FU American Foundation for Pharmaceutical Education; South Dakota State
   University Research Foundation
FX The author wish to acknowledge grant support from The American
   Foundation for Pharmaceutical Education and South Dakota State
   University Research Foundation.
CR Albuquerque EX, 2009, PHYSIOL REV, V89, P73, DOI 10.1152/physrev.00015.2008
   Balfour DJK, 2004, NICOTINE TOB RES, V6, P899, DOI 10.1080/14622200412331324965
   Bell RL, 2009, ALCOHOL, V43, P581, DOI 10.1016/j.alcohol.2009.09.027
   Benowitz NL, 2009, ANNU REV PHARMACOL, V49, P57, DOI 10.1146/annurev.pharmtox.48.113006.094742
   BENWELL MEM, 1992, BRIT J PHARMACOL, V105, P849, DOI 10.1111/j.1476-5381.1992.tb09067.x
   BENWELL MEM, 1995, BRIT J PHARMACOL, V114, P454, DOI 10.1111/j.1476-5381.1995.tb13248.x
   Biala G, 2010, PHARMACOL BIOCHEM BE, V96, P141, DOI 10.1016/j.pbb.2010.04.022
   Bito-Onon JJ, 2011, ADDICT BIOL, V16, P440, DOI 10.1111/j.1369-1600.2010.00309.x
   BLOMQVIST O, 1993, EUR J PHARMACOL, V249, P207, DOI 10.1016/0014-2999(93)90434-J
   Blomqvist O, 1996, EUR J PHARMACOL, V314, P257, DOI 10.1016/S0014-2999(96)00583-3
   Blomqvist O, 2002, ALCOHOL CLIN EXP RES, V26, P326, DOI 10.1097/00000374-200203000-00004
   Champtiaux N, 2006, BEHAV BRAIN RES, V168, P120, DOI 10.1016/j.bbr.2005.10.017
   Champtiaux N, 2003, J NEUROSCI, V23, P7820
   Changeux JP, 2010, NAT REV NEUROSCI, V11, P389, DOI 10.1038/nrn2849
   Chatterjee S, 2011, NEUROPSYCHOPHARMACOL, V36, P603, DOI [10.1038/npp.2010.191, 10.1038/npp.2011.268]
   Chi H, 2003, ALCOHOL CLIN EXP RES, V27, P780, DOI 10.1097/01.ALC.0000065435.12068.24
   Coe JW, 2005, J MED CHEM, V48, P3474, DOI 10.1021/jm050069n
   CORRIGALL WA, 1994, BRAIN RES, V653, P278, DOI 10.1016/0006-8993(94)90401-4
   CORRIGALL WA, 1992, PSYCHOPHARMACOLOGY, V107, P285, DOI 10.1007/BF02245149
   Crunelle CL, 2010, EUR NEUROPSYCHOPHARM, V20, P69, DOI 10.1016/j.euroneuro.2009.11.001
   Cui RJ, 2009, EUR J PHARMACOL, V609, P74, DOI 10.1016/j.ejphar.2008.12.051
   Dajas-Bailador F, 2004, TRENDS PHARMACOL SCI, V25, P317, DOI 10.1016/j.tips.2004.04.006
   Damaj MI, 1997, J PHARMACOL EXP THER, V282, P410
   Dani JA, 2007, ANNU REV PHARMACOL, V47, P699, DOI 10.1146/annurev.pharmtox.47.120505.105214
   Di Chiara G, 2004, NEUROPHARMACOLOGY, V47, P227, DOI 10.1016/j.neuropharm.2004.06.032
   Drenan RM, 2010, J NEUROSCI, V30, P9877, DOI 10.1523/JNEUROSCI.2056-10.2010
   Dwoskin LP, 2009, BIOCHEM PHARMACOL, V78, P732, DOI 10.1016/j.bcp.2009.06.002
   Ericson M, 1998, EUR J PHARMACOL, V358, P189, DOI 10.1016/S0014-2999(98)00602-5
   Ericson M, 2009, J PHARMACOL EXP THER, V329, P225, DOI 10.1124/jpet.108.147058
   Falk DE, 2006, ALCOHOL RES HEALTH, V29, P162
   Farook JM, 2009, PHYSIOL BEHAV, V97, P503, DOI 10.1016/j.physbeh.2009.02.031
   Feduccia A.A., 2012, CNS NEUROL DISORD-DR, V5, P1
   Feng B, 2011, BEHAV BRAIN RES, V220, P100, DOI 10.1016/j.bbr.2011.01.040
   Fowler CD, 2008, BEHAV PHARMACOL, V19, P461, DOI 10.1097/FBP.0b013e32830c360e
   Fu Y, 2000, NEUROSCIENCE, V101, P369, DOI 10.1016/S0306-4522(00)00371-7
   Glick S.D., BRAIN
   Glick SD, 2002, EUR J PHARMACOL, V438, P99, DOI 10.1016/S0014-2999(02)01284-0
   Gotti C, 2007, BIOCHEM PHARMACOL, V74, P1102, DOI 10.1016/j.bcp.2007.05.023
   Gotti C, 2010, J NEUROSCI, V30, P5311, DOI 10.1523/JNEUROSCI.5095-09.2010
   Gotti C, 2009, BIOCHEM PHARMACOL, V78, P703, DOI 10.1016/j.bcp.2009.05.024
   Gould RW, 2011, J PHARMACOL EXP THER, V339, P678, DOI 10.1124/jpet.111.185538
   Grady SR, 1997, J PHARMACOL EXP THER, V282, P32
   Guillem K, 2010, BEHAV PHARMACOL, V21, P96, DOI 10.1097/FBP.0b013e328336e9c5
   Hall BJ, 2011, NEUROPHARMACOLOGY, V61, P798, DOI 10.1016/j.neuropharm.2011.05.026
   Hansen ST, 2007, PSYCHOPHARMACOLOGY, V194, P53, DOI 10.1007/s00213-007-0822-z
   Hart N, 2010, J PSYCHOPHARMACOL, V24, P51, DOI 10.1177/0269881108092119
   Hauser SR, 2012, ALCOHOL CLIN EXP RES, V36, P43, DOI 10.1111/j.1530-0277.2011.01579.x
   Hendrickson LM, 2009, PSYCHOPHARMACOLOGY, V204, P563, DOI 10.1007/s00213-009-1488-5
   Henningfield JE, 2009, PHARMACOL THERAPEUT, V123, P1, DOI 10.1016/j.pharmthera.2009.03.011
   Hogg RC, 2003, REV PHYSIOL BIOCH P, V147, P1, DOI 10.1007/s10254-003-0005-1
   IMPERATO A, 1986, EUR J PHARMACOL, V132, P337, DOI 10.1016/0014-2999(86)90629-1
   Jackson KJ, 2009, J PHARMACOL EXP THER, V331, P547, DOI 10.1124/jpet.109.155457
   Jones IW, 2004, J NEUROSCI, V24, P11244, DOI 10.1523/JNEUROSCI.3009-04.2004
   Kalivas PW, 2011, MOL PSYCHIATR, V16, P974, DOI 10.1038/mp.2011.46
   Kamens HM, 2010, PSYCHOPHARMACOLOGY, V208, P613, DOI 10.1007/s00213-009-1759-1
   Klink R, 2001, J NEUROSCI, V21, P1452, DOI 10.1523/JNEUROSCI.21-05-01452.2001
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Larsson A, 2004, NEUROSCI BIOBEHAV R, V27, P713, DOI 10.1016/j.neubiorev.2003.11.010
   Le AD, 2000, ALCOHOL CLIN EXP RES, V24, P155, DOI 10.1111/j.1530-0277.2000.tb04585.x
   Le AD, 2003, PSYCHOPHARMACOLOGY, V168, P216, DOI 10.1007/s00213-002-1330-9
   Lecca D, 2006, PSYCHOPHARMACOLOGY, V184, P435, DOI 10.1007/s00213-005-0280-4
   LeNovere N, 1996, EUR J NEUROSCI, V8, P2428
   Levin ED, 2000, PHYSIOL BEHAV, V71, P565, DOI 10.1016/S0031-9384(00)00382-6
   Levin ED, 2010, J PHARMACOL EXP THER, V332, P933, DOI 10.1124/jpet.109.162073
   Litten RZ, 2012, ADDICT BIOL, V17, P513, DOI 10.1111/j.1369-1600.2012.00454.x
   Livingstone PD, 2009, BIOCHEM PHARMACOL, V78, P744, DOI 10.1016/j.bcp.2009.06.004
   Lundahl LH, 2000, PHARMACOL BIOCHEM BE, V66, P637, DOI 10.1016/S0091-3057(00)00252-5
   Mansvelder HD, 2002, NEURON, V33, P905, DOI 10.1016/S0896-6273(02)00625-6
   Mao DY, 2010, J MOL NEUROSCI, V40, P154, DOI 10.1007/s12031-009-9230-7
   Marshall DL, 1997, J NEUROCHEM, V68, P1511
   MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513
   McKee SA, 2009, BIOL PSYCHIAT, V66, P185, DOI 10.1016/j.biopsych.2009.01.029
   Mihalak KB, 2006, MOL PHARMACOL, V70, P801, DOI 10.1124/mol.106.025130
   Mineur YS, 2008, BIOCHEM PHARMACOL, V75, P323, DOI 10.1016/j.bcp.2007.06.010
   Morgan G, 2010, AM J HEALTH BEHAV, V34, P267, DOI 10.5993/AJHB.34.3.2
   Neugebauer NM, 2006, PSYCHOPHARMACOLOGY, V184, P426, DOI 10.1007/s00213-005-0163-8
   NISELL M, 1994, SYNAPSE, V16, P36, DOI 10.1002/syn.890160105
   Panchal V, 2005, EUR J PHARMACOL, V525, P98, DOI 10.1016/j.ejphar.2005.09.060
   PAPKE RL, 1994, MOL PHARMACOL, V45, P142
   Papke RL, 2007, J NEUROCHEM, V101, P160, DOI 10.1111/j.1471-4159.2006.04355.x
   Picciotto MR, 2008, PROG NEUROBIOL, V84, P329, DOI 10.1016/j.pneurobio.2007.12.005
   Picciotto MR, 1998, NATURE, V391, P173, DOI 10.1038/34413
   Pidoplichko VI, 2004, LEARN MEMORY, V11, P60, DOI 10.1101/lm.70004
   Plebani JG, 2012, DRUG ALCOHOL DEPEN, V121, P163, DOI 10.1016/j.drugalcdep.2011.08.025
   Rahman S, 2008, BRIT J PHARMACOL, V153, P792, DOI 10.1038/sj.bjp.0707612
   Rahman S, 2004, NEUROSCIENCE, V129, P415, DOI 10.1016/j.neuroscience.2004.08.010
   Rahman S, 2004, NEUROCHEM RES, V29, P1687, DOI 10.1023/B:NERE.0000035803.64724.17
   Rahman S, 2003, NEUROSCI LETT, V348, P61, DOI 10.1016/S0304-3940(03)00723-7
   Rahman S, 2007, NEUROPHARMACOLOGY, V52, P755, DOI 10.1016/j.neuropharm.2006.09.012
   Rahman Shafiqur, 2012, Recent Pat CNS Drug Discov, V7, P145
   Reus VI, 2007, DRUG TODAY, V43, P65, DOI 10.1358/dot.2007.43.2.1069956
   Rezvani AH, 2010, PSYCHOPHARMACOLOGY, V211, P161, DOI 10.1007/s00213-010-1878-8
   Rollema H, 2007, NEUROPHARMACOLOGY, V52, P985, DOI 10.1016/j.neuropharm.2006.10.016
   Rollema H, 2010, BRIT J PHARMACOL, V160, P334, DOI 10.1111/j.1476-5381.2010.00682.x
   Rose JE, 2004, NICOTINE TOB RES, V6, P133, DOI 10.1080/14622200310001656957
   Sajja RK, 2012, PHARMACOL BIOCHEM BE, V102, P36, DOI 10.1016/j.pbb.2012.03.017
   Sajja RK, 2011, PROG NEURO-PSYCHOPH, V35, P257, DOI 10.1016/j.pnpbp.2010.11.020
   Sajja RK, 2010, PHARMACOLOGY, V86, P168, DOI 10.1159/000317063
   Schnoll Robert A, 2006, Expert Opin Emerg Drugs, V11, P429, DOI 10.1517/14728214.11.3.429
   Smith BR, 1999, PSYCHOPHARMACOLOGY, V142, P408, DOI 10.1007/s002130050906
   Soderpalm B, 2000, BEHAV BRAIN RES, V113, P85, DOI 10.1016/S0166-4328(00)00203-5
   Soderpalm B, 2009, PHARMACOPSYCHIATRY, V42, pS87, DOI 10.1055/s-0029-1220690
   Solinas M, 2007, J NEUROSCI, V27, P5615, DOI 10.1523/JNEUROSCI.0027-07.2007
   Steensland P, 2007, P NATL ACAD SCI USA, V104, P12518, DOI 10.1073/pnas.0705368104
   Sziraki I, 2002, NEUROCHEM RES, V27, P253, DOI 10.1023/A:1014844823534
   Taraschenko OD, 2007, SYNAPSE, V61, P547, DOI 10.1002/syn.20396
   Tizabi Y, 2007, ALCOHOL ALCOHOLISM, V42, P413, DOI 10.1093/alcalc/agm057
   Tobey KM, 2012, PSYCHOPHARMACOLOGY, V223, P159, DOI 10.1007/s00213-012-2703-3
   Toll L, 2012, NEUROPSYCHOPHARMACOL, V37, P1367, DOI 10.1038/npp.2011.322
   Tuesta LM, 2011, BIOCHEM PHARMACOL, V82, P984, DOI 10.1016/j.bcp.2011.06.026
   Tutka P, 2006, PHARMACOL REP, V58, P777
   Volkow ND, 2012, NEUROPSYCHOPHARMACOL, V37, P290, DOI 10.1038/npp.2011.84
   Xiao YX, 2006, MOL PHARMACOL, V70, P1454, DOI 10.1124/mol.106.027318
   Young EM, 2005, ALCOHOL CLIN EXP RES, V29, P58, DOI 10.1097/01.ALC.0000150007.34702.16
   Zachariou V, 2001, NEUROPSYCHOPHARMACOL, V24, P576, DOI 10.1016/S0893-133X(00)00224-4
   Zanetti L, 2006, PSYCHOPHARMACOLOGY, V187, P181, DOI 10.1007/s00213-006-0419-y
   Zoli M, 2002, J NEUROSCI, V22, P8785
NR 117
TC 19
Z9 20
U1 0
U2 13
PU BENTHAM SCIENCE PUBL
PI BUSUM
PA PO BOX 294, BUSUM, 1400 AG, NETHERLANDS
SN 1871-5273
EI 1996-3181
J9 CNS NEUROL DISORD-DR
JI CNS Neurol. Disord.-Drug Targets
PD AUG
PY 2013
VL 12
IS 5
BP 633
EP 640
PG 8
WC Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 188OK
UT WOS:000322202100011
PM 23574176
DA 2023-06-23
ER

PT S
AU Yamada, K
   Nabeshima, T
AF Yamada, K
   Nabeshima, T
BE Ali, SF
   Nabeshima, T
   Yanagita, T
TI Pro- and anti-addictive neurotrophic factors and cytokines in
   psychostimulant addiction: Mini review
SO CURRENT STATUS OF DRUG DEPENDENCE / ABUSE STUDIES: CELLULAR AND
   MOLECULAR MECHANISMS OF DRUGS OF ABUSE AND NEUROTOXICITY
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT Conference on Current Status of Depedence and Abuse Studies
CY JUL 30-AUG 01, 2003
CL Kyoto, JAPAN
SP Int Soc Neurochem, Japanese Pharmacol Soc, Japanese Med Soc Alcohol& Drug Studies, Japanese Soc Neurochem, Japanese Soc Neuropsychopharmocol, Minist Educ, Culture, Sports, Sci & Technol, Nagoya Univ Fdn, Uehara Memorial Fdn, Sigma-Tau Hlth Sci, Natl Inst Drug Abuse, Natl Ctr Toxicol Res, US FDA
DE cocaine; amphetamine; methamphetamine; synaptic plasticity
ID TUMOR-NECROSIS-FACTOR; FIBROBLAST-GROWTH-FACTOR; KAPPA-B-BINDING;
   FACTOR-ALPHA; TARGETED DELETION; NUCLEUS-ACCUMBENS; TRANSGENIC MICE;
   MESSENGER-RNA; BRAIN; COCAINE
AB Drug addiction is defined as a chronically relapsing disorder that is characterized by compulsive drug taking, inability to limit the intake, and intense drug craving. While the positive reinforcing effects of psychostimulants such as cocaine and amphetamines depend on the mesocorticolimbic dopamine system innervating nucleus accumbens, chronic drug exposure causes stable changes in the structure and function of the brain that may underlie the long-lived behavioral abnormalities in drug addiction. Recent evidence has suggested that various neurotrophic factors and cytokines are involved in the effects of psychomotor stimulants, suggesting that these factors play a role in drug addiction. In this article, a role of neurotrophic factors and cytokines in psycho-stimulant addiction is discussed.
C1 Nagoya Univ, Grad Sch Med, Dept Neuropsychopharmacol, Nagoya, Aichi 4668560, Japan.
   Nagoya Univ, Grad Sch Med, Hosp Pharm, Nagoya, Aichi 4668560, Japan.
   Kanazawa Univ, Fac Pharmaceut Sci, Lab Neuropsychopharmacol, Kanazawa, Ishikawa 9200934, Japan.
C3 Nagoya University; Nagoya University; Kanazawa University
RP Nabeshima, T (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Neuropsychopharmacol, Nagoya, Aichi 4668560, Japan.
EM tnabeshi@med.nagoya-u.ac.jp
RI Sokabe, Masahiro/I-1565-2012; Yamada, Kiyofumi/I-7487-2014
OI Yamada, Kiyofumi/0000-0002-5280-5180
CR Aloe L, 1997, NEUROSCI LETT, V238, P65, DOI 10.1016/S0304-3940(97)00850-1
   BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328
   Berhow MT, 1996, J NEUROSCI, V16, P8019
   Boulanger L, 1999, SCIENCE, V284, P1982, DOI 10.1126/science.284.5422.1982
   BRENNEMAN DE, 1992, J NEUROCHEM, V58, P454, DOI 10.1111/j.1471-4159.1992.tb09743.x
   Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788
   Connor B, 1998, BRAIN RES REV, V27, P1, DOI 10.1016/S0165-0173(98)00004-6
   DENICOFF KD, 1987, ANN INTERN MED, V107, P293, DOI 10.7326/0003-4819-107-2-293
   Dluzen DE, 2001, EXP NEUROL, V170, P121, DOI 10.1006/exnr.2001.7698
   Flora G, 2002, NEUROMOL MED, V2, P71
   Flores C, 2000, J NEUROSCI, V20
   Flores C, 1998, J NEUROSCI, V18, P9547
   Freeman AY, 2002, SYNAPSE, V46, P57, DOI 10.1002/syn.10123
   GIULIAN D, 1988, J NEUROSCI, V8, P709
   GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213
   Grimm JW, 2003, J NEUROSCI, V23, P742
   Hall FS, 2003, NEUROPSYCHOPHARMACOL, V28, P1485, DOI 10.1038/sj.npp.1300192
   HAMA T, 1989, NEUROSCI LETT, V104, P340, DOI 10.1016/0304-3940(89)90600-9
   HO BT, 1994, CYTOKINE, V6, P365, DOI 10.1016/1043-4666(94)90059-0
   Horger BA, 1999, J NEUROSCI, V19, P4110
   Iida R, 2000, FASEB J, V14, P1023, DOI 10.1096/fasebj.14.7.1023
   Kirik D, 2001, EUR J NEUROSCI, V13, P1589, DOI 10.1046/j.0953-816x.2001.01534.x
   KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J
   Kubera M, 2002, J PHYSIOL PHARMACOL, V53, P233
   Ladenheim B, 2000, MOL PHARMACOL, V58, P1247, DOI 10.1124/mol.58.6.1247
   Lee YW, 2001, J NEUROSCI RES, V66, P583, DOI 10.1002/jnr.1248
   Maier SF, 1998, PSYCHOL REV, V105, P83, DOI 10.1037/0033-295X.105.1.83
   MCDONALD EM, 1987, LANCET, V2, P1175
   Meredith GE, 2002, BRAIN RES, V949, P218, DOI 10.1016/S0006-8993(02)03160-8
   Messer CJ, 2000, NEURON, V26, P247, DOI 10.1016/S0896-6273(00)81154-X
   Nakajima A, 2004, J NEUROSCI, V24, P2212, DOI 10.1523/JNEUROSCI.4847-03.2004
   Nakajima A, 2002, FREE RADICAL BIO MED, V32, P1324, DOI 10.1016/S0891-5849(02)00845-6
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002
   PAMAMOORTHY S, 1995, BIOCHEM BIOPH RES CO, V216, P560
   Pierce RC, 1999, J NEUROSCI, V19, P8685
   RIECKMANN P, 1995, ANN NEUROL, V37, P82, DOI 10.1002/ana.410370115
   Robbins TW, 1999, NATURE, V398, P567, DOI 10.1038/19208
   Robinson TE, 1999, EUR J NEUROSCI, V11, P1598, DOI 10.1046/j.1460-9568.1999.00576.x
   Robinson TE, 1997, J NEUROSCI, V17, P8491
   Rofael HZ, 2003, TOXICOLOGY, V188, P101, DOI 10.1016/S0300-483X(03)00081-7
   Yamada K, 2000, J NEUROIMMUNOL, V111, P131, DOI 10.1016/S0165-5728(00)00375-1
   Yamada K, 1997, BRAIN RES BULL, V43, P573, DOI 10.1016/S0361-9230(96)00336-X
   YAMADA K, 2001, B JPN SOC NEUROCHEM, V40, P254
   YAMAGUCHI T, 1991, NEUROSCI RES, V12, P432, DOI 10.1016/0168-0102(91)90074-9
   Zalcman S, 1999, BRAIN RES, V847, P276, DOI 10.1016/S0006-8993(99)02063-6
   Zalcman SS, 2001, BRAIN RES, V899, P1, DOI 10.1016/S0006-8993(01)02090-X
NR 47
TC 28
Z9 32
U1 0
U2 4
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA
SN 0077-8923
BN 1-57331-522-2
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2004
VL 1025
BP 198
EP 204
DI 10.1196/annals.1316.025
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Substance Abuse;
   Multidisciplinary Sciences; Neurosciences
WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Substance Abuse; Science
   & Technology - Other Topics; Neurosciences & Neurology
GA BBP90
UT WOS:000226975200025
PM 15542718
DA 2023-06-23
ER

PT J
AU Silverman, K
   Roll, JM
   Higgins, ST
AF Silverman, Kenneth
   Roll, John M.
   Higgins, Stephen T.
TI INTRODUCTION TO THE SPECIAL ISSUE ON THE BEHAVIOR ANALYSIS AND TREATMENT
   OF DRUG ADDICTION
SO JOURNAL OF APPLIED BEHAVIOR ANALYSIS
LA English
DT Article
DE abstinence reinforcement; contingency management; drug abuse; drug
   addiction; operant conditioning
ID SUBSTANCE USE DISORDERS; CLINICAL-TRIALS NETWORK; CONTINGENCY
   MANAGEMENT; PSYCHOSOCIAL INTERVENTIONS; RANDOMIZED-TRIAL; ABSTINENCE;
   OUTCOMES; COCAINE; METAANALYSIS; FEASIBILITY
AB Extensive evidence from the laboratory and the clinic suggests that drug addiction can be viewed as operant behavior and effectively treated through the application of principles of operant conditioning. Contingency management interventions that arrange for the direct reinforcement of drug abstinence or of other therapeutically important target behaviors (e.g., regular use of drug abuse treatment medications) are among the most studied type of operant treatments. Behavior analysts have contributed to the substantial and rapidly growing literature on operant treatments for drug addiction, but the Publications of this work usually appear in medical, clinical psychology, or drug abuse journals. This special issue of the Journal of Applied Behavior Analysis represents an effort to bring this important work to the attention of the behavior-analytic community. The articles in this special issue illustrate both the enormous potential of contingency management interventions to address the Serious and seemingly intractable problem of drug addiction as well as the real challenges involved in attempting to develop and disseminate treatments that will produce substantial and lasting changes in the lives of individuals plagued by the chronic problem of drug addiction.
C1 [Silverman, Kenneth] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21224 USA.
   [Roll, John M.] Washington State Univ, Pullman, WA 99164 USA.
   [Higgins, Stephen T.] Univ Vermont, Burlington, VT 05405 USA.
C3 Johns Hopkins University; Washington State University; University of
   Vermont
RP Silverman, K (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, 5200 Eastern Ave,Suite 142 W, Baltimore, MD 21224 USA.
EM ksilverm@jhmi.edu
RI Higgins, Stephen/HPG-5751-2023; /ABG-5735-2021
OI Silverman, Kenneth/0000-0003-2724-1413
FU NIDA NIH HHS [R01 DA009378, DA022476, R01 DA017407, DA023864, R01
   DA014028, DA09378, R01 DA023864, DA019497, DA14028, R01 DA022476,
   DA019386, R01 DA013107, DA017407, R01 DA019497, DA013107, R01 DA008076,
   DA14871, R37 DA009378, DA08076, R01 DA019386] Funding Source: Medline
CR Alessi SM, 2008, J APPL BEHAV ANAL, V41, P617, DOI 10.1901/jaba.2008.41-617
   Bigelow G. E., 1999, MOTIVATING BEHAV CHA, P15, DOI DOI 10.1037/10321-001
   Chivers LL, 2008, J APPL BEHAV ANAL, V41, P481, DOI 10.1901/jaba.2008.41-481
   Dallery J, 2005, J APPL BEHAV ANAL, V38, P349, DOI 10.1901/jaba.2005.150-04
   Dallery J, 2008, J APPL BEHAV ANAL, V41, P609, DOI 10.1901/jaba.2008.41-609
   Donlin WD, 2008, J APPL BEHAV ANAL, V41, P499, DOI 10.1901/jaba.2008.41-499
   Dunn KE, 2008, J APPL BEHAV ANAL, V41, P527, DOI 10.1901/jaba.2008.41-527
   Dutra L, 2008, AM J PSYCHIAT, V165, P179, DOI 10.1176/appi.ajp.2007.06111851
   EPSTEIN DH, 2008, CONTINGENCY MANAGEME, P42
   Garica-Rodriguez O, 2008, J APPL BEHAV ANAL, V41, P623, DOI 10.1901/jaba.2008.41-623
   GHIRZA UE, 2008, J APPL BEHAV ANAL, V41, P539
   Ghitza UE, 2007, J CONSULT CLIN PSYCH, V75, P765, DOI 10.1037/0022-006X.75.5.765
   Greenwald MK, 2008, J APPL BEHAV ANAL, V41, P603, DOI 10.1901/jaba.2008.41-603
   Higgins S. T., 2008, CONTINGENCY MANAGEME
   HIGGINS ST, 1991, AM J PSYCHIAT, V148, P1218
   Hubbard RL, 2003, J SUBST ABUSE TREAT, V25, P125, DOI 10.1016/S0740-5472(03)00130-2
   Husky MM, 2008, J APPL BEHAV ANAL, V41, P635, DOI 10.1901/jaba.2008.41-635
   Kirby KC, 2008, J APPL BEHAV ANAL, V41, P579, DOI 10.1901/jaba.2008.41-579
   Ledgerwood DM, 2008, J APPL BEHAV ANAL, V41, P517, DOI 10.1901/jaba.2008.41-517
   Lussier JP, 2006, ADDICTION, V101, P192, DOI 10.1111/j.1360-0443.2006.01311.x
   Madden GJ, 2008, J APPL BEHAV ANAL, V41, P645, DOI 10.1901/jaba.2008.41-645
   Marlowe DB, 2008, J APPL BEHAV ANAL, V41, P565, DOI 10.1901/jaba.2008.41-565
   McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689
   Peirce JM, 2006, ARCH GEN PSYCHIAT, V63, P201, DOI 10.1001/archpsyc.63.2.201
   Petry NM, 2007, J CONSULT CLIN PSYCH, V75, P983, DOI 10.1037/0022-006X.75.6.983
   Petry NM, 2005, J CONSULT CLIN PSYCH, V73, P1005, DOI 10.1037/0022-006X.73.6.1005
   Petry NM, 2005, ARCH GEN PSYCHIAT, V62, P1148, DOI 10.1001/archpsyc.62.10.1148
   Pilling S, 2007, BRIT MED J, V335, P203, DOI 10.1136/bmj.39265.639641.AD
   Prendergast M, 2006, ADDICTION, V101, P1546, DOI 10.1111/j.1360-0443.2006.01581.x
   Preston KL, 2008, J APPL BEHAV ANAL, V41, P551, DOI 10.1901/jaba.2008.41-551
   Reynolds B, 2008, J APPL BEHAV ANAL, V41, P597, DOI 10.1901/jaba.2008.41-597
   Roll JM, 2005, J APPL BEHAV ANAL, V38, P463, DOI 10.1901/jaba.2005.114-04
   Roll JM, 2008, J APPL BEHAV ANAL, V41, P629, DOI 10.1901/jaba.2008.41-629
   Silverman K, 2004, BEHAV ANALYST, V27, P209, DOI 10.1007/BF03393181
   Simpson DD, 1999, ARCH GEN PSYCHIAT, V56, P507, DOI 10.1001/archpsyc.56.6.507
   *US OFF NAT DRUG C, 2004, 207303 US OFF NAT DR
NR 36
TC 18
Z9 18
U1 1
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-8855
EI 1938-3703
J9 J APPL BEHAV ANAL
JI J. Appl. Behav. Anal.
PD WIN
PY 2008
VL 41
IS 4
BP 471
EP 480
DI 10.1901/jaba.2008.41-471
PG 10
WC Psychology, Clinical
WE Social Science Citation Index (SSCI)
SC Psychology
GA 390LH
UT WOS:000262165300001
PM 19192853
OA Green Published
DA 2023-06-23
ER

PT J
AU Scheibein, F
   Stowe, MJ
   Arya, S
   Morgan, N
   Shirasaka, T
   Grandinetti, P
   Saad, NA
   Ghosh, A
   Vadivel, R
   Ratta-apha, W
   Pant, SB
   Ransing, R
   Ramalho, R
   Bruschi, A
   Maiti, T
   Ha, AY
   Delic, M
   Jain, S
   Peyron, E
   Siste, K
   Onoria, J
   Boujraf, S
   Dannatt, L
   Schellekens, A
   Calvey, T
AF Scheibein, Florian
   Stowe, M. J.
   Arya, Sidharth
   Morgan, Nirvana
   Shirasaka, Tomohiro
   Grandinetti, Paolo
   Saad, Noha Ahmed
   Ghosh, Abhishek
   Vadivel, Ramyadarshni
   Ratta-apha, Woraphat
   Pant, Sagun Ballav
   Ransing, Ramdas
   Ramalho, Rodrigo
   Bruschi, Angelo
   Maiti, Tanay
   Ha, Anne Yee
   Delic, Mirjana
   Jain, Shobhit
   Peyron, Eric
   Siste, Kristiana
   Onoria, Joy
   Boujraf, Said
   Dannatt, Lisa
   Schellekens, Arnt
   Calvey, Tanya
TI Responding to COVID-19: Emerging Practices in Addiction Medicine in 17
   Countries
SO FRONTIERS IN PSYCHIATRY
LA English
DT Editorial Material
DE COVID-19; drug policy; addiction medicine; substance use; behaviourial
   addictions; best practice; guidelines
ID SERVICES; PEOPLE
C1 [Scheibein, Florian] Waterford Inst Technol, Sch Hlth Sci, Waterford, Ireland.
   [Stowe, M. J.] Univ Pretoria, Sch Med, Dept Family Med, Fac Hlth Sci, Pretoria, South Africa.
   [Arya, Sidharth] Pt Bhagwat Dayal Sharma Univ Hlth Sci, Inst Mental Hlth, State Drug Dependence Treatment Ctr, Rohtak, Haryana, India.
   [Morgan, Nirvana] Univ Witwatersrand, Johannesburg, South Africa.
   [Shirasaka, Tomohiro] Teine Keijinkai Med Ctr, Dept Psychiat, Sapporo, Hokkaido, Japan.
   [Grandinetti, Paolo] ASL Teramo, Dept Terr Serv, Addict Serv SerD, Teramo, Italy.
   [Saad, Noha Ahmed] Ain Shams Univ, Dept Psychiat, Cairo, Egypt.
   [Ghosh, Abhishek] Postgrad Inst Med Educ & Res, Drug Deaddict & Treatment Ctr, Chandigarh, India.
   [Vadivel, Ramyadarshni] Waikato Dist Hlth Board, Waikato, New Zealand.
   [Ratta-apha, Woraphat] Mahidol Univ, Fac Med, Siriraj Hosp, Salaya, Nakhon Pathom, Thailand.
   [Pant, Sagun Ballav] Tribhuvan Univ, Inst Med, Dept Psychiat & Mental Hlth, Kathmandu, Nepal.
   [Ransing, Ramdas] BKL Walawalkar Rural Med Coll, Dept Psychiat, Ratnagiri, India.
   [Ramalho, Rodrigo] Univ Auckland, Sch Populat Hlth, Dept Social & Community Hlth, Auckland, New Zealand.
   [Bruschi, Angelo] ASL Viterbo, Dept Mental Hlth, Viterbo, Italy.
   [Maiti, Tanay] AIIMS, Dept Psychiat, New Delhi, India.
   [Ha, Anne Yee] Univ Malaya, Ctr Addict Sci, Dept Psychol Med, Fac Med, Kuala Lumpur, Malaysia.
   [Delic, Mirjana] Univ Psychiat Clin Ljubljana, Ctr Treatment Drug Addict, Ljubljana, Slovenia.
   [Jain, Shobhit] HIMS, Dept Psychiat, Varanasi, Uttar Pradesh, India.
   [Peyron, Eric] AddiPsy, Lyon, France.
   [Siste, Kristiana] Univ Indonesia, Dept Psychiat, Fac Med, Ciptomangunkusumo Hosp, Jakarta, Indonesia.
   [Onoria, Joy] Makerere Univ, Dept Psychiat, Coll Hlth Sci, Kampala, Uganda.
   [Boujraf, Said] Sidi Mohamed Ben Abdellah Univ Fez, Fac Med & Pharm, Fes, Morocco.
   [Dannatt, Lisa] Univ Cape Town, Dept Psychiat & Mental Hlth, Fac Hlth Sci, Cape Town, South Africa.
   [Schellekens, Arnt] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands.
   [Calvey, Tanya] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa.
C3 South East Technological University (SETU); University of Pretoria;
   University of Witwatersrand; Egyptian Knowledge Bank (EKB); Ain Shams
   University; Post Graduate Institute of Medical Education & Research
   (PGIMER), Chandigarh; Mahidol University; Tribhuvan University;
   Institute of Medicine (IoM) - Nepal; University of Auckland; All India
   Institute of Medical Sciences (AIIMS) New Delhi; Universiti Malaya;
   University Medical Centre Ljubljana; University of Indonesia; Makerere
   University; Sidi Mohamed Ben Abdellah University of Fez; University of
   Cape Town; Radboud University Nijmegen; University of Witwatersrand
RP Calvey, T (通讯作者)，Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa.
EM tanyac@polka.co.za
RI Jain, Shobhit/AAY-6369-2021; Schellekens, Arnt F.A./G-5611-2013;
   Ratta-apha, Woraphat/AAS-6737-2021; Ramalho, Rodrigo/ADL-2819-2022; Hway
   Ann, Yee/D-7968-2012; siste, kristiana/GOE-4849-2022; RANSING, RAMDAS
   Sarjerao/H-4776-2014
OI Schellekens, Arnt F.A./0000-0002-7715-5209; Ratta-apha,
   Woraphat/0000-0001-8776-2427; Ramalho, Rodrigo/0000-0002-2372-6854; Hway
   Ann, Yee/0000-0002-9835-6798; RANSING, RAMDAS
   Sarjerao/0000-0002-5040-5570; Calvey, Tanya/0000-0002-7540-2130; Morgan,
   Nirvana/0000-0003-1950-8720; Vadivel, Ramyadarshni/0000-0002-7055-5250
FU South African Medical Research Council
FX This research was funded by the South African Medical Research Council
   grant held by TC.
CR [Anonymous], 2020, POLICY BRIEF COVID 1
   [Anonymous], 2020, FEDERAZIONE ITALIANA
   Association Marocain d'Addictologie, 2020, REC ASS MAR ADD AMA
   Basu D, 2020, INDIAN J PSYCHIAT, V62, P322, DOI 10.4103/psychiatry.IndianJPsychiatry_295_20
   Calvey T, 2020, J ADDICT MED, V14, pE284, DOI 10.1097/ADM.0000000000000735
   Dunlop A, 2020, HARM REDUCT J, V17, DOI 10.1186/s12954-020-00370-7
   European Monitoring Centre for Drugs and Drug Addiction, 2020, EMCDDA UPD IMPL COVI
   Federazione Italiana Operatori Dipartimenti e Servizi Dipendenze, 2020, STRUM TERAP INN SERO
   Health Service Executive, 2020, EX SOP EM IND OST CO
   Health Service Executive, 2020, CONT PLANN PEOPL WHO
   Health Service Executive, 2020, COVID 19 PHARM SOP C
   Health Service Executive, 2020, NEEDLE EXCHANGE PROV
   Indian Psychiatric Society, 2020, IND PSYCH SOC POS ST
   Indian Psychiatric Society, 2020, IPS INT GUID OP SUB
   Indian Psychiatric Society and National Institute of Mental Health and NeuroSciences, 2020, MENTAL HLTH CHALLENG
   Indonesian Ministry of Health, 2020, PROT PELAKS LAYAN HI
   Japanese Medical Society of Alcohol and Addiction Studies, 2020, WORR NEW COR PROBL
   Japanese Ministry of Health, 2020, LABOUR WELFARE POLIC
   Japansese Ministry of Health, LAB WELF POL PREV CO
   Lintzeris N., 2020, INTERIM GUIDANCE DEL
   Malaysian Ministry of Health, 2020, RAW MET SEP PER KAW
   Ministeres des Solidarites et de la Sante, REC APPL ORG PRIS CH
   Ministry of Health, 2020, PROT PEL LAYAN HIV A
   Ministry of Health, 2020, PSYC MENT WELLB REC
   Ministry of Health and Population and National Center of AIDS & STD Control, 2020, INT GUID MAN PLHV HA
   Ministry of Public Health, 2020, **DROPPED REF**
   New Zealand Ministry of Health, 2020, GUID MENT HLTH ADD R
   New Zealand Ministry of Health, 2020, GUID SPEC MENT HLTH
   Royal College of Psychiatrists of Thailand, 2020, REC ALC WITHDR PHYS
   Stowe MJ, 2020, J ADDICT MED, V14, pE287, DOI 10.1097/ADM.0000000000000753
   United Nations Office on Drugs and Crime, 2020, PUBLICO IPSILON
   Vahidi M., 2020, REORGANIZATION SUBST
   WHO, 2020, COVID 19 DISR MENT H
NR 33
TC 5
Z9 5
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD MAR 12
PY 2021
VL 12
AR 634309
DI 10.3389/fpsyt.2021.634309
PG 6
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA RF5ON
UT WOS:000634887700001
PM 33796034
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Cleck, JN
   Blendy, JA
AF Cleck, Jessica N.
   Blendy, Julie A.
TI Making a bad thing worse: adverse effects of stress on drug addiction
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Review
ID CORTICOTROPIN-RELEASING-FACTOR; PITUITARY-ADRENAL AXIS; CRF1 RECEPTOR
   ANTAGONIST; HYPOTHALAMIC NORADRENERGIC ACTIVITY; CONDITIONED PLACE
   PREFERENCE; DOPAMINE-DEPENDENT RESPONSES; INDUCED REINSTATEMENT;
   NUCLEUS-ACCUMBENS; INDUCED RELAPSE; INTRAVENOUS COCAINE
AB Sustained exposure to various psychological stressors can exacerbate neuropsychiatric disorders, including drug addiction. Addiction is a chronic brain disease in which individuals cannot control their need for drugs, despite negative health and social consequences. The brains of addicted individuals are altered and respond very differently to stress than those of individuals who are not addicted. In this Review, we highlight some of the common effects of stress and drugs of abuse throughout the addiction cycle. We also discuss both animal and human studies that suggest treating the stress-related aspects of drug addiction is likely to be an important contributing factor to a long-lasting recovery from this disorder.
C1 [Cleck, Jessica N.; Blendy, Julie A.] Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Blendy, JA (通讯作者)，Univ Penn, Sch Med, Dept Pharmacol, 125 S 31st St, Philadelphia, PA 19104 USA.
EM blendy@mail.med.upenn.edu
FU NIDA NIH HHS [DA116-49-01A2] Funding Source: Medline
CR al'Absi M, 2006, INT J PSYCHOPHYSIOL, V59, P218, DOI 10.1016/j.ijpsycho.2005.10.010
   ALLOLIO B, 1987, ACTA ENDOCRINOL-COP, V114, P509, DOI 10.1530/acta.0.1140509
   Ballon JS, 2006, J CLIN PSYCHIAT, V67, P554, DOI 10.4088/JCP.v67n0406
   Barrot M, 2002, P NATL ACAD SCI USA, V99, P11435, DOI 10.1073/pnas.172091899
   Barrot M, 2000, EUR J NEUROSCI, V12, P973, DOI 10.1046/j.1460-9568.2000.00996.x
   BAUMANN MH, 1995, BIOL PSYCHIAT, V38, P751, DOI 10.1016/0006-3223(95)00083-6
   BENWELL MEM, 1979, PSYCHOPHARMACOLOGY, V63, P7, DOI 10.1007/BF00426913
   Bilang-Bleuel A, 2002, EUR J NEUROSCI, V15, P1048, DOI 10.1046/j.1460-9568.2002.01934.x
   BOROWSKY B, 1991, BRAIN RES, V543, P301, DOI 10.1016/0006-8993(91)90041-S
   Buczek Y, 1999, PSYCHOPHARMACOLOGY, V144, P183, DOI 10.1007/s002130050992
   Campbell J, 2003, AM J ADDICTION, V12, P122, DOI 10.1080/10550490390201380
   COX S, 1995, LANCET, V345, P1385, DOI 10.1016/S0140-6736(95)92593-7
   Deroche-Gamonet V, 2003, J NEUROSCI, V23, P4785
   Di Chiara G, 2000, EUR J PHARMACOL, V393, P295, DOI 10.1016/S0014-2999(00)00122-9
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Duncan E, 2007, AM J ADDICTION, V16, P174, DOI 10.1080/10550490701375285
   Dwoskin LP, 2006, CNS DRUG REV, V12, P178, DOI 10.1111/j.1527-3458.2006.00178.x
   Erb S, 1999, J NEUROSCI, V19, part. no., DOI 10.1523/JNEUROSCI.19-20-j0006.1999
   Erb S, 2000, NEUROPSYCHOPHARMACOL, V23, P138, DOI 10.1016/S0893-133X(99)00158-X
   Erb S, 2001, PSYCHOPHARMACOLOGY, V158, P360, DOI 10.1007/s002130000642
   Erb S, 1998, J NEUROSCI, V18, P5529, DOI 10.1523/JNEUROSCI.18-14-05529.1998
   Fox HC, 2008, NEUROPSYCHOPHARMACOL, V33, P796, DOI 10.1038/sj.npp.1301470
   FRIEDMAN AJ, 1987, FERTIL STERIL, V47, P398
   Funk CK, 2007, BIOL PSYCHIAT, V61, P78, DOI 10.1016/j.biopsych.2006.03.063
   Gass JT, 2007, ALCOHOL CLIN EXP RES, V31, P1441, DOI 10.1111/j.1530-0277.2007.00480.x
   George O, 2007, P NATL ACAD SCI USA, V104, P17198, DOI 10.1073/pnas.0707585104
   Glover ED, 2007, EXPERT OPIN PHARMACO, V8, P1757, DOI 10.1517/14656566.8.11.1757
   Goeders NE, 1996, NEUROENDOCRINOLOGY, V64, P337, DOI 10.1159/000127137
   Goeders NE, 1996, BRAIN RES, V722, P145, DOI 10.1016/0006-8993(96)00206-5
   Goeders NE, 2002, J PHARMACOL EXP THER, V301, P785, DOI 10.1124/jpet.301.3.785
   GOEDERS NE, 1994, PSYCHOPHARMACOLOGY, V114, P63, DOI 10.1007/BF02245445
   Gonzales D, 2006, JAMA-J AM MED ASSOC, V296, P47, DOI 10.1001/jama.296.1.47
   GOSSELIN RE, 1983, ENDOCRINOLOGY, V112, P2168, DOI 10.1210/endo-112-6-2168
   Graham DL, 2007, NAT NEUROSCI, V10, P1029, DOI 10.1038/nn1929
   Green TA, 2006, J NEUROSCI, V26, P8235, DOI 10.1523/JNEUROSCI.0880-06.2006
   Grimm JW, 2003, J NEUROSCI, V23, P742
   Habib KE, 2000, P NATL ACAD SCI USA, V97, P6079, DOI 10.1073/pnas.97.11.6079
   HARFSTRAND A, 1986, P NATL ACAD SCI USA, V83, P9779, DOI 10.1073/pnas.83.24.9779
   Harrison PA, 1997, CHILD ABUSE NEGLECT, V21, P529, DOI 10.1016/S0145-2134(97)00013-6
   HEESCH CM, 1995, AM J MED SCI, V310, P61, DOI 10.1097/00000441-199508000-00004
   Hyman SM, 2007, EXP CLIN PSYCHOPHARM, V15, P134, DOI 10.1037/1064-1297.15.2.134
   Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560
   Hyman SE, 1996, NEURON, V16, P901, DOI 10.1016/S0896-6273(00)80111-7
   IGNAR DM, 1990, J PHARMACOL EXP THER, V255, P1287
   Ising M, 2007, NEUROPSYCHOPHARMACOL, V32, P1941, DOI 10.1038/sj.npp.1301328
   KALIVAS PW, 1995, BRAIN RES, V675, P325, DOI 10.1016/0006-8993(95)00013-G
   KANT GJ, 1985, PHARMACOL BIOCHEM BE, V22, P631
   KANT GJ, 1983, PHARMACOL BIOCHEM BE, V18, P967, DOI 10.1016/S0091-3057(83)80022-7
   KIRSCHBAUM C, 1992, LIFE SCI, V50, P435, DOI 10.1016/0024-3205(92)90378-3
   Koob G, 2007, AM J PSYCHIAT, V164, P1149, DOI 10.1176/appi.ajp.2007.05030503
   KOSTEN T, 1992, NEUROPSYCHOPHARMACOL, V7, P169
   Kosten TA, 2000, BRAIN RES, V875, P44, DOI 10.1016/S0006-8993(00)02595-6
   KREEK MJ, 1984, NEUROPEPTIDES, V5, P277, DOI 10.1016/0143-4179(84)90081-7
   Kreek MJ, 1998, DRUG ALCOHOL DEPEN, V51, P23, DOI 10.1016/S0376-8716(98)00064-7
   Kreek MJ, 2000, ANN NY ACAD SCI, V909, P186
   Kreibich AS, 2004, J NEUROSCI, V24, P6686, DOI 10.1523/JNEUROSCI.1706-04.2004
   Kunzel HE, 2003, J PSYCHIATR RES, V37, P525, DOI 10.1016/S0022-3956(03)00070-0
   Leri F, 2002, J NEUROSCI, V22, P5713
   Liston C, 2006, J NEUROSCI, V26, P7870, DOI 10.1523/JNEUROSCI.1184-06.2006
   Liu X, 2002, J NEUROSCI, V22, P7856
   Lo CC, 2007, AM J DRUG ALCOHOL AB, V33, P139, DOI 10.1080/00952990601091119
   Lu L, 2003, J NEUROCHEM, V84, P1378, DOI 10.1046/j.1471-4159.2003.01635.x
   Lu L, 2001, EUR J PHARMACOL, V415, P203, DOI 10.1016/S0014-2999(01)00840-8
   MADDAHIAN E, 1988, ADDICT BEHAV, V13, P191, DOI 10.1016/0306-4603(88)90011-1
   Mann K, 2004, ALCOHOL CLIN EXP RES, V28, P51, DOI 10.1097/01.ALC.0000108656.81563.05
   Mantsch JR, 2007, NEUROSCI LETT, V415, P269, DOI 10.1016/j.neulet.2007.01.036
   Mantsch JR, 1998, J PHARMACOL EXP THER, V287, P72
   Marinelli M, 1998, P NATL ACAD SCI USA, V95, P7742, DOI 10.1073/pnas.95.13.7742
   MARKOU A, 1992, PSYCHOPHARMACOLOGY, V109, P305, DOI 10.1007/BF02245878
   Matta SG, 1997, BRAIN RES, V759, P259, DOI 10.1016/S0006-8993(97)00266-7
   McLaughlin JP, 2003, J NEUROSCI, V23, P5674, DOI 10.1523/jneurosci.23-13-05674.2003
   MENDELSON JH, 1971, PSYCHOSOM MED, V33, P145, DOI 10.1097/00006842-197103000-00006
   Milanes MV, 1998, J PHARMACOL EXP THER, V285, P700
   Milanes MV, 1997, N-S ARCH PHARMACOL, V356, P603, DOI 10.1007/PL00005096
   Morgan M, 2002, QUALITATIVE RES, V2, P5, DOI DOI 10.1177/1468794102002001636
   Nestler EJ, 2001, P NATL ACAD SCI USA, V98, P11042, DOI 10.1073/pnas.191352698
   O'Brien CP, 2005, AM J PSYCHIAT, V162, P1423, DOI 10.1176/appi.ajp.162.8.1423
   Ogilvie KM, 1997, BRAIN RES, V766, P19, DOI 10.1016/S0006-8993(97)00525-8
   Oswald LM, 2007, NEUROIMAGE, V36, P153, DOI 10.1016/j.neuroimage.2007.01.055
   Perrotti LI, 2004, J NEUROSCI, V24, P10594, DOI 10.1523/JNEUROSCI.2542-04.2004
   PIAZZA PV, 1991, P NATL ACAD SCI USA, V88, P2088, DOI 10.1073/pnas.88.6.2088
   PIAZZA PV, 1990, BRAIN RES, V514, P22, DOI 10.1016/0006-8993(90)90431-A
   Przegalinski E, 2005, NEUROPEPTIDES, V39, P525, DOI 10.1016/j.npep.2005.07.002
   RASSNICK S, 1993, BRAIN RES, V605, P25, DOI 10.1016/0006-8993(93)91352-S
   RIVIER C, 1994, MOL CELL NEUROSCI, V5, P189, DOI 10.1006/mcne.1994.1021
   Robinson TE, 1999, EUR J NEUROSCI, V11, P1598, DOI 10.1046/j.1460-9568.1999.00576.x
   Robinson TE, 1999, SYNAPSE, V33, P160
   Rohleder N, 2006, INT J PSYCHOPHYSIOL, V59, P236, DOI 10.1016/j.ijpsycho.2005.10.012
   Rollema H, 2007, NEUROPHARMACOLOGY, V52, P985, DOI 10.1016/j.neuropharm.2006.10.016
   Rouge-Pont F, 1998, EUR J NEUROSCI, V10, P3903, DOI 10.1046/j.1460-9568.1998.00438.x
   Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-7
   Sarnyai Z, 2001, PHARMACOL REV, V53, P209
   SARNYAI Z, 1995, BRAIN RES, V675, P89, DOI 10.1016/0006-8993(95)00043-P
   SARNYAI Z, 1993, BRAIN RES, V616, P315, DOI 10.1016/0006-8993(93)90224-B
   Schluger JH, 2001, NEUROPSYCHOPHARMACOL, V24, P568, DOI 10.1016/S0893-133X(00)00222-0
   Semba J, 2004, PSYCHONEUROENDOCRINO, V29, P215, DOI 10.1016/S0306-4530(03)00024-6
   Shaham Y, 1998, PSYCHOPHARMACOLOGY, V137, P184, DOI 10.1007/s002130050608
   Shaham Y, 1997, J NEUROSCI, V17, P2605
   Shaham Y, 2000, EUR J NEUROSCI, V12, P292, DOI 10.1046/j.1460-9568.2000.00899.x
   Shalev U, 2006, PSYCHOPHARMACOLOGY, V187, P376, DOI 10.1007/s00213-006-0427-y
   Shippenberg TS, 2007, PHARMACOL THERAPEUT, V116, P306, DOI 10.1016/j.pharmthera.2007.06.011
   Sinha R, 2000, PSYCHOPHARMACOLOGY, V152, P140, DOI 10.1007/s002130000499
   Sinha Rajita, 2007, Curr Psychiatry Rep, V9, P388, DOI 10.1007/s11920-007-0050-6
   Sinha R, 2007, PSYCHOPHARMACOLOGY, V190, P569, DOI 10.1007/s00213-006-0640-8
   Skelton KH, 2007, EUR J PHARMACOL, V571, P17, DOI 10.1016/j.ejphar.2007.05.041
   Slemmer JE, 2000, J PHARMACOL EXP THER, V295, P321
   Spanagel R, 1999, TRENDS NEUROSCI, V22, P521, DOI 10.1016/S0166-2236(99)01447-2
   SPENCER RL, 1990, NEUROENDOCRINOLOGY, V52, P481, DOI 10.1159/000125632
   Steensland P, 2007, P NATL ACAD SCI USA, V104, P12518, DOI 10.1073/pnas.0705368104
   SUEMARU S, 1985, ACTA MED OKAYAMA, V39, P463
   Tsai ST, 2007, CLIN THER, V29, P1027, DOI 10.1016/j.clinthera.2007.06.011
   Ussher M, 2006, PSYCHOSOM MED, V68, P299, DOI 10.1097/01.psy.0000204926.27215.a1
   VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876
   Walters CL, 2005, NEURON, V46, P933, DOI 10.1016/j.neuron.2005.05.005
   Walters CL, 2003, J NEUROCHEM, V87, P1237, DOI 10.1046/j.1471-4159.2003.02090.x
   Wang B, 2005, J NEUROSCI, V25, P5389, DOI 10.1523/JNEUROSCI.0955-05.2005
   Wang B, 2007, PSYCHOPHARMACOLOGY, V193, P283, DOI 10.1007/s00213-007-0782-3
   Wang JS, 2006, PSYCHOPHARMACOLOGY, V185, P19, DOI 10.1007/s00213-005-0262-6
   Weinshenker D, 2007, NEUROPSYCHOPHARMACOL, V32, P1433, DOI 10.1038/sj.npp.1301263
   Wing VC, 2007, PSYCHOPHARMACOLOGY, V195, P303, DOI 10.1007/s00213-007-0902-0
   Zhou Y, 1996, J PHARMACOL EXP THER, V279, P351
   Zislis G, 2007, NEUROPHARMACOLOGY, V53, P958, DOI 10.1016/j.neuropharm.2007.09.007
   Zobel AW, 2000, J PSYCHIATR RES, V34, P171, DOI 10.1016/S0022-3956(00)00016-9
   Zorrilla EP, 2001, PSYCHOPHARMACOLOGY, V158, P374, DOI 10.1007/s002130100773
   Zoumakis E, 2006, ANN NY ACAD SCI, V1083, P239, DOI 10.1196/annals.1367.021
NR 125
TC 79
Z9 80
U1 0
U2 22
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD FEB
PY 2008
VL 118
IS 2
BP 454
EP 461
DI 10.1172/JCI33946
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 257CS
UT WOS:000252777400011
PM 18246196
OA Bronze, Green Published
DA 2023-06-23
ER

PT J
AU Li, ZH
   Liu, YF
   Li, KN
   DuanMu, HZ
   Chang, ZQ
   Li, ZQ
   Zhang, SZ
   Xu, Y
AF Li, Zi-hui
   Liu, Yu-feng
   Li, Ke-ning
   DuanMu, Hui-zi
   Chang, Zhi-qiang
   Li, Zhen-qi
   Zhang, Shan-zhen
   Xu, Yan
TI Analysis of functional and pathway association of differential
   co-expressed genes: A case study in drug addiction
SO JOURNAL OF BIOMEDICAL INFORMATICS
LA English
DT Article
DE Drug addiction; Gene co-expression meta-analysis; Functional
   association; Pathway association
ID ELECTRON-TRANSPORT; FETAL ALCOHOL; COCAINE; BRAIN; INHIBITION;
   GLYCOLYSIS; ACTIVATION; MICROARRAY; PLASTICITY; RECEPTOR
AB Drug addiction has been considered as a kind of chronic relapsing brain disease influenced by both genetic and environmental factors. At present, many causative genes and pathways related to diverse kinds of drug addiction have been discovered, while less attention has been paid to common mechanisms shared by different drugs underlying addiction. By applying a co-expression meta-analysis method to mRNA expression profiles of alcohol, cocaine, heroin addicted and normal samples, we identified significant gene co-expression pairs. As co-expression networks of drug group and control group constructed, associated function term pairs and pathway pairs reflected by co-expression pattern changes were discovered by integrating functional and pathway information respectively. The results indicated that respiratory electron transport chain, synaptic transmission, mitochondrial electron transport, signal transduction, locomotory behavior, response to amphetamine, negative regulation of cell migration, glucose regulation of insulin secretion, signaling by NGF, diabetes pathways, integration of energy metabolism, dopamine receptors may play an important role in drug addiction. In addition, the results can provide theory support for studies of addiction mechanisms. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Li, Zi-hui; Liu, Yu-feng; Li, Ke-ning; DuanMu, Hui-zi; Chang, Zhi-qiang; Li, Zhen-qi; Zhang, Shan-zhen; Xu, Yan] Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin 150081, Peoples R China.
C3 Harbin Medical University
RP Xu, Y (通讯作者)，Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin 150081, Peoples R China.
EM xuyanls@yahoo.com.cn
CR Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   BERHOW MT, 1995, NEUROSCIENCE, V68, P969, DOI 10.1016/0306-4522(95)00207-Y
   Bonate PL, 1997, PHARMACOL BIOCHEM BE, V57, P665, DOI 10.1016/S0091-3057(96)00387-5
   Chiriboga CA, 2003, NEUROLOGIST, V9, P267, DOI 10.1097/01.nrl.0000094941.96358.d1
   Chiu SL, 2008, NEURON, V58, P708, DOI 10.1016/j.neuron.2008.04.014
   Choi JK, 2003, BIOINFORMATICS, V19, pi84, DOI 10.1093/bioinformatics/btg1010
   Crandall JE, 2004, CEREB CORTEX, V14, P665, DOI 10.1093/cercor/bhh027
   Fernie AR, 2004, CURR OPIN PLANT BIOL, V7, P254, DOI 10.1016/j.pbi.2004.03.007
   Goossens V, 1999, ANTIOXID REDOX SIGN, V1, P285, DOI 10.1089/ars.1999.1.3-285
   Hannila SS, 2005, J COMP NEUROL, V486, P331, DOI 10.1002/cne.20537
   He L, 2006, J BIOL CHEM, V281, P11126, DOI 10.1074/jbc.M510724200
   Herlenius E, 2004, EXP NEUROL, V190, pS8, DOI 10.1016/j.expneurol.2004.03.027
   Kimpel MW, 2007, ALCOHOL, V41, P95, DOI 10.1016/j.alcohol.2007.03.003
   Kuntz-Melcavage KL, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-95
   Li CY, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.0040002
   Mayr BM, 2001, P NATL ACAD SCI USA, V98, P10936, DOI 10.1073/pnas.191152098
   MCGEHEE DS, 1995, SCIENCE, V269, P1692, DOI 10.1126/science.7569895
   Nestler EJ, 1999, BIOL PSYCHIAT, V46, P1131, DOI 10.1016/S0006-3223(99)00158-4
   Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   Schaefer CF, 2009, NUCLEIC ACIDS RES, V37, pD674, DOI 10.1093/nar/gkn653
   SLOTKIN TA, 1980, LIFE SCI, V26, P861, DOI 10.1016/0024-3205(80)90348-3
   Uhl GR, 2004, NEUROPHARMACOLOGY, V47, P140, DOI 10.1016/j.neuropharm.2004.07.029
   Virmani A, 2002, ANN NY ACAD SCI, V965, P225
   Warnat P, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-265
   Xu RH, 2005, CANCER RES, V65, P613
   Zhou FC, 2005, ALCOHOL CLIN EXP RES, V29, P141, DOI 10.1097/01.ALC.0000150636.19677.6F
   Zima T, 2005, ALCOHOL CLIN EXP RES, V29, p110S, DOI 10.1097/01.alc.0000189288.30358.4b
NR 28
TC 28
Z9 29
U1 0
U2 12
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1532-0464
J9 J BIOMED INFORM
JI J. Biomed. Inform.
PD FEB
PY 2012
VL 45
IS 1
BP 30
EP 36
DI 10.1016/j.jbi.2011.08.014
PG 7
WC Computer Science, Interdisciplinary Applications; Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Medical Informatics
GA 895EK
UT WOS:000300478800003
PM 21907308
OA Bronze
DA 2023-06-23
ER

PT J
AU Ahmed, B
   Yousaf, FN
   Saud, M
   Ahmad, A
AF Ahmed, Bilal
   Yousaf, Farhan Navid
   Saud, Muhammad
   Ahmad, Akhlaq
TI Youth at risk: The alarming issue of drug addiction in academic
   institutions in Pakistan
SO CHILDREN AND YOUTH SERVICES REVIEW
LA English
DT Article
DE Drug addiction; Social problem; Youth addiction; Academic institutions;
   Social Work for youth
ID SUBSTANCE; STUDENTS; SMOKING; ABUSE
AB A rapid increase in drug addiction among students of academic institutions has emerged as a serious social problem confronting the contemporary Pakistani society that constitutes one of the highest proportions of young people in the world. This study was designed to explore the processes that lead to drug addiction among students of higher education institutions and how it affects their everyday activities. To gain insights to the phenomenon, the study deployed the qualitative research approach involving in-depth interviews with drug addict students from three public-sector universities in Pakistan. The data were analysed through narrations and thematic analysis. The results unveil that students consume drugs in the universities without much restriction and risks as the academic institutions have not taken serious steps to address the issue in their premises. There is an urgent need for Pakistan to develop a comprehensive strategy to address the alarming problem of drug addiction in academic institutions involving all the stakeholders to interrupt the supply chain and punish those who are involved in the heinous crime of trading illicit drugs.
C1 [Ahmed, Bilal; Ahmad, Akhlaq] Int Islamic Univ, Fac Social Sci, Dept Sociol, Main Campus, Islamabad, Pakistan.
   [Yousaf, Farhan Navid] Univ Punjab, Inst Social & Cultural Studies, Lahore, Pakistan.
   [Saud, Muhammad] Univ Airlangga, Fac Social & Polit Sci, Dept Sociol, Surabaya, Indonesia.
C3 International Islamic University, Pakistan; University of Punjab;
   Airlangga University
RP Saud, M (通讯作者)，Univ Airlangga, Fac Social & Polit Sci, Dept Sociol, Surabaya, Indonesia.
EM bilal.phdsoc51@iiu.edu.pk; drfarhan.iscs@pu.edu.pk;
   muhhammad.saud@gmail.com; akhlaq.ahmad@iiu.edu.pk
RI Ahmad, Akhlaq/GVS-1598-2022; Ahmed, Bilal/X-4555-2019; Saud,
   Muhammad/GQR-0264-2022
OI Ahmed, Bilal/0000-0003-0039-2131; Saud, Muhammad/0000-0001-5739-7238;
   Ahmad, Akhlaq/0000-0002-3764-2985
CR A Reporter, 2018, DAWN
   Abbasi K., 2016, DAWN
   Anti-Narcotics Force, 2000, DRUG AB ASS STUD PAK
   Anwar-ul-Haq, 1979, DRUG ADDICTION REHAB, P218
   Badr HE, 2018, ASIAN J PSYCHIATR, V37, P51, DOI 10.1016/j.ajp.2018.08.004
   Banken JA, 2004, ANN NY ACAD SCI, V1025, P465, DOI 10.1196/annals.1316.057
   BEMAN DS, 1995, ADOLESCENCE, V30, P201
   Chander V, 2016, J XENOBIOTICS, V6, P1, DOI 10.4081/xeno.2016.5774
   Erskine HE, 2015, PSYCHOL MED, V45, P1551, DOI 10.1017/S0033291714002888
   Farhud DD, 2015, IRAN J PUBLIC HEALTH, V44, P1442
   Hamilton HA, 2011, ADDICT RES THEORY, V19, P344, DOI 10.3109/16066359.2010.530713
   Khattak M., 2012, INTERDISCIPLINARY J, V4, P1
   Kuria MW, 1996, E AFR MED J, V73, P339
   MASOOD A, 1979, B NARCOTICS, V31, P59
   Maxwell S, 2006, J ADDICT DIS, V25, P89, DOI 10.1300/J069v25n03_11
   National Institute of Drug Abuse, 2014, US SOC MED BETT UND
   Ngesu L. M., 2008, ACAD J, V3, P304
   Omu FE, 2017, J ADDICT NURS, V28, P55, DOI 10.1097/JAN.0000000000000166
   Pakistan Bureau of Statistics, 2017, PAK STAT YB 2017
   PLANT M, 1992, RISK TAKERS ALCOHOL
   Quigley J., 2014, PAKISTAN J SOCIAL SC, V34, P9
   Raza R., 2011, EXPRESS TRIBUNE 0626
   Roncero C, 2014, J ADDICT DIS, V33, P277, DOI 10.1080/10550887.2014.969600
   Ruangkanchanasetr S, 2005, J ADOLESCENT HEALTH, V36, P227, DOI 10.1016/j.jadohealth.2004.01.013
   Sabri B., 2018, ISLAMABAD STUDENTS H
   Saud M, 2020, J HUM BEHAV SOC ENVI, V30, P760, DOI 10.1080/10911359.2020.1745112
   Sheffield FD, 2005, J AM COLL HEALTH, V54, P137, DOI 10.3200/JACH.54.3.137-142
   Sherouse, 1985, J ADOLESCENT HLTH CA, V8, P239
   SIEGEL RA, 1989, ADOLESCENCE, V24, P925
   United Nations, 2018, UN WORLD YOUTH REP W
   United Nations Office on Drugs and Crime, 2019, WORLD DRUG REPORT 20
   United Nations Office on Drugs and Crime, 2013, REPORT DRUG USE PAKI
   United NationsOffice on Drugs and Crime, 1983, NAT SURV DRUG AB PAK
   Zaman M., 2015, PAKISTAN J PHARM RES, V01, P6
NR 34
TC 3
Z9 3
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0190-7409
EI 1873-7765
J9 CHILD YOUTH SERV REV
JI Child. Youth Serv. Rev.
PD NOV
PY 2020
VL 118
AR 105385
DI 10.1016/j.childyouth.2020.105385
PG 6
WC Family Studies; Social Work
WE Social Science Citation Index (SSCI)
SC Family Studies; Social Work
GA OD7TK
UT WOS:000580051200137
DA 2023-06-23
ER

PT J
AU Lavack, A
AF Lavack, Anne
TI Using social marketing to de-stigmatize addictions: A review
SO ADDICTION RESEARCH & THEORY
LA English
DT Review
DE stigma; de-stigmatization; social marketing; addictions; drugs; alcohol
ID DRUG; ALCOHOL; WOMEN
AB Persons with addictions face a significant social stigma. Fear of being stigmatized often results in persons with addictions or substance abuse issues not seeking the help they require for fear of societal disapproval. This article examines how social marketing has been used, and can be used, to de-stigmatize addictions. Previous de-stigmatization campaigns are reviewed and discussed, and recommendations for future social marketing campaigns are provided.
C1 Univ Regina, Fac Business Adm, Regina, SK S4S 0A2, Canada.
C3 University of Regina
RP Lavack, A (通讯作者)，Univ Regina, Fac Business Adm, 3737 Wascana Pkwy, Regina, SK S4S 0A2, Canada.
EM anne.lavack@uregina.ca
RI Lavack, Anne M/H-2794-2012
OI Lavack, Anne M/0000-0002-5043-8663
CR ACKER CJ, 1993, J PSYCHOACTIVE DRUGS, V25, P193, DOI 10.1080/02791072.1993.10472271
   ANDERSON TL, 1996, SOCIOLOGICAL ABSTR, V20, P25
   BARGER MD, 1985, EMPLOYEE ASSISTANCE, V1, P101
   *BC PARTN MENT HLT, 2005, STIGM DISCR MENT DIS
   BLOOM PN, 1981, J MARKETING, V45, P79, DOI 10.2307/1251667
   BLUME SB, 1991, ALCOHOL HEALTH RES W, V15, P139
   Cape GS, 2003, ACTA PSYCHIAT SCAND, V107, P163, DOI 10.1034/j.1600-0447.2003.00075.x
   *CENTR E ADD TECHN, 2000, ADD STIG RED TOOLK I
   Crocker J., 1998, HDB SOCIAL PSYCHOL, P504, DOI DOI 10.1002/9780470561119
   *CTR ADD MENT HLTH, 2000, PROJ ADDR STIGM ADD
   CUNNINGHAM JA, 1993, J STUD ALCOHOL, V54, P693, DOI 10.15288/jsa.1993.54.693
   DAVIS JL, 2004, FACES VOICES RECOVER
   DEAN JC, 1984, INT J ADDICT, V19, P859, DOI 10.3109/10826088409061991
   *DRUG PREV NETW AM, 2004, EX ADD CANT KICK STI
   ERICKSON C, 2003, ADDICTION DIS ADDICT
   Erickson Patricia G, 2005, Can J Commun Ment Health, V24, P99
   Fortney J, 2004, J BEHAV HEALTH SER R, V31, P418
   Franken IHA, 2003, PROG NEURO-PSYCHOPH, V27, P563, DOI 10.1016/S0278-5846(03)00081-2
   FUNK CE, 1950, THEREBY HANGS TALE S
   Goffman E., 1963, STIGMA NOTES MANAGEM
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Gourlay J, 2005, SUBST USE MISUSE, V40, P1875, DOI 10.1080/10826080500259497
   Haghighat R, 2001, BRIT J PSYCHIAT, V178, P207, DOI 10.1192/bjp.178.3.207
   *HAZ FDN, 2003, 1 4 CO IS LESS LIK H
   Jones EE., 1984, SOCIAL STIGMA PSYCHO
   Joseph H, 2000, MT SINAI J MED, V67, P347
   Klamen DL, 1997, J PSYCHOACTIVE DRUGS, V29, P263
   KOTLER P, 1971, J MARKETING, V35, P3, DOI 10.2307/1249783
   KOTLER P., 2002, STRATEGIC MARKETING
   Kurzban R, 2001, PSYCHOL BULL, V127, P187, DOI 10.1037//0033-2909.127.2.187
   LESHNER AI, 1997, SCIENCE, V280, P807
   Lewis DC, 1999, J ADDICT DIS, V18, P5, DOI 10.1300/J069v18n02_02
   LUCK DJ, 1974, J MARKETING, V38, P70, DOI 10.2307/1250395
   *MAN COMM GROUP, 2004, BUILD MOM PUBL CAMP
   Miller NS, 1999, PSYCHIAT CLIN N AM, V22, P489, DOI 10.1016/S0193-953X(05)70089-7
   Miller NS, 2001, ACAD MED, V76, P410, DOI 10.1097/00001888-200105000-00007
   *NAT GOV ASS, 2006, STIGM MENT ILLN ADD
   O'Hear MM, 2004, VANDERBILT LAW REV, V57, P783
   *PD HART RES ASS, 2004, FAC VOIC REC PUBL SU
   Perlick DA, 2001, PSYCHIAT SERV, V52, P1613, DOI 10.1176/appi.ps.52.12.1613
   Pryor JB, 2004, J PERS SOC PSYCHOL, V87, P436, DOI 10.1037/0022-3514.87.4.436
   Ritson EB, 1999, INT J CLIN PRACT, V53, P549
   Roberts LW, 2003, OBSTET GYN CLIN N AM, V30, P559, DOI 10.1016/S0889-8545(03)00071-8
   Roche AM, 1997, DRUG ALCOHOL REV, V16, P157, DOI 10.1080/09595239700186451
   Room R, 2005, DRUG ALCOHOL REV, V24, P143, DOI 10.1080/09595230500102434
   *ROYAL COLL PSYCH, 2003, DRUGS ALC WHOS PROBL
   *SAMHSA, 2002, NAT REV MONTH HELPS
   SCHUCKIT MA, 1987, J FAM PRACTICE, V25, P225
   SCHWARZER R, 1991, J SOC PERS RELAT, V8, P133, DOI 10.1177/0265407591081007
   Shih M, 2004, ANN AM ACAD POLIT SS, V591, P175, DOI 10.1177/0002716203260099
   SOBELL LC, 1992, SELF CONTROL ADDICTI
   STAFFORD RA, 1977, J STUD ALCOHOL, V38, P2109, DOI 10.15288/jsa.1977.38.2109
   THOM B, 1986, BRIT J ADDICT, V81, P777
   TOOTLE DM, 1987, J DRUG ISSUES, V17, P273, DOI 10.1177/002204268701700304
   WEINER B, 1988, J PERS SOC PSYCHOL, V55, P738, DOI 10.1037/0022-3514.55.5.738
   WEINER B, 1996, JUDGMENTS RESPONSIBI
   WEINREICH NK, 1999, HANDS THOUSANDS OAKS
   Woods J, 2001, MT SINAI J MED, V68, P75
NR 58
TC 13
Z9 13
U1 1
U2 16
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1606-6359
EI 1476-7392
J9 ADDICT RES THEORY
JI Addict. Res. Theory
PD OCT
PY 2007
VL 15
IS 5
BP 479
EP 492
DI 10.1080/16066350601176957
PG 14
WC Substance Abuse; Social Issues
WE Social Science Citation Index (SSCI)
SC Substance Abuse; Social Issues
GA 230SP
UT WOS:000250896500005
DA 2023-06-23
ER

PT J
AU Schmidt, WJ
AF Schmidt, WJ
TI Glutamatergic mechanisms in addiction
SO NEUROLOGY PSYCHIATRY AND BRAIN RESEARCH
LA English
DT Article
DE addiction; withdrawal; craving; glutamate; reward-system; sensitization
ID EXCITATORY AMINO-ACIDS; COCAINE-SEEKING BEHAVIOR; MEDIAL PREFRONTAL
   CORTEX; RECEPTOR ANTAGONIST; NUCLEUS-ACCUMBENS; DOPAMINE RELEASE;
   DEPENDENT SENSITIZATION; DRUG-ADDICTION; NMDA RECEPTORS; MK-801
AB Glutamate plays a role in various aspects of addiction: Glutamatergic pathways, especially the projection from the prefrontal cortex to the midbrain dopamine neurons and to the nucleus accumbens, are integral parts of the brain reward system. The temporal and spatial pattern of dopamine activity in these nuclei is shaped by glutamate. Experimental interference with glutamatergic mechanisms alters the rewarding effects of addictive drugs. Most importantly, glutamatergic mechanisms mediate the plastic changes that characterize the transition from controlled drug-intake to addiction. A process of sensitization may underly this transition since sensitization renders the brain re-ward system hyperreactive to addictive drugs. Similar to addiction sensitization is build up gradually and is very stable, nearly inextinguishable; it is therefore considered to play a major role in the formation of an "addiction memory". In withdrawal states glutamatergic activity is assumed to be increased. Reports of reinstatement of drug-seeking behaviour by glutamate-agonists in rats fit to this view as well as the therapeutical efficacy of the anticraving drug acamprosate which is a NMDA receptor-antagonist.
C1 Univ Tubingen, Inst Zool, Abt Neuropharmakol, D-72074 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen
EM werner.schmidt@uni-tuebingen.de
CR Baldo BA, 1999, PSYCHOPHARMACOLOGY, V141, P135, DOI 10.1007/s002130050817
   Bespalov AY, 2000, BEHAV PHARMACOL, V11, P37, DOI 10.1097/00008877-200002000-00004
   Cador M., 1999, BEHAV PHARMACOL, V10, pS14
   CARLEZON WA, 1995, SYNAPSE, V20, P1, DOI 10.1002/syn.890200102
   Carlezon WA, 1996, J NEUROSCI, V16, P3112
   Carr DB, 2000, J NEUROSCI, V20, P3864, DOI 10.1523/JNEUROSCI.20-10-03864.2000
   Cheramy A, 1998, AMINO ACIDS, V14, P63, DOI 10.1007/BF01345244
   Danysz W., 1995, Drug News Perspect, V8, P261
   De Vries TJ, 1998, EUR J NEUROSCI, V10, P3565, DOI 10.1046/j.1460-9568.1998.00368.x
   DICHIARA G, 1992, TRENDS PHARMACOL SCI, V13, P185
   GERRITS MAF, 1998, NEUROPSYCHOPHARMAC S, V1, pS60
   Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040
   Heyne A, 2000, J NEURAL TRANSM, V107, P613, DOI 10.1007/s007020070065
   IMPERATO A, 1990, EUR J PHARMACOL, V187, P555, DOI 10.1016/0014-2999(90)90387-L
   IMPERATO A, 1990, BRAIN RES, V530, P223, DOI 10.1016/0006-8993(90)91286-P
   Jog MS, 1999, SCIENCE, V286, P1745, DOI 10.1126/science.286.5445.1745
   KALIVAS PW, 1995, DRUG ALCOHOL DEPEN, V37, P95, DOI 10.1016/0376-8716(94)01063-Q
   KALIVAS PW, 1999, BEHAV PHARMACOL, V10, pS51
   KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J
   Kratzer U, 1998, NEUROSCI LETT, V252, P53, DOI 10.1016/S0304-3940(98)00550-3
   Kretschmer BD, 1999, J NEUROCHEM, V73, P839, DOI 10.1046/j.1471-4159.1999.0730839.x
   LEVIEL V, 1990, NEUROSCIENCE, V39, P305, DOI 10.1016/0306-4522(90)90269-A
   LIN NL, 1995, BRAIN RES BULL, V36, P421, DOI 10.1016/0361-9230(94)00215-M
   Nakamura M, 1999, PSYCHOBIOLOGY, V27, P287
   OLDS J, 1954, J COMP PHYSIOL PSYCH, V47, P419, DOI 10.1037/h0058775
   PAULSON PE, 1995, SYNAPSE, V19, P56, DOI 10.1002/syn.890190108
   Ranaldi R, 1997, BRAIN RES, V760, P231, DOI 10.1016/S0006-8993(97)00288-6
   Robbins TW, 1999, NATURE, V398, P567, DOI 10.1038/19208
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   SCHENK S, 1993, BEHAV PHARMACOL, V4, P652
   Schenk S, 1997, BRAIN RES, V769, P225, DOI 10.1016/S0006-8993(97)00712-9
   Schmidt WJ, 1999, EUR J NEUROSCI, V11, P3365, DOI 10.1046/j.1460-9568.1999.00794.x
   Schmidt WJ, 1998, NEUROL PSYCHIAT BR, V6, P155
   Spanagel R, 1997, TRENDS PHARMACOL SCI, V18, P54, DOI 10.1016/S0165-6147(97)89800-8
   Spanagel R, 1999, TRENDS NEUROSCI, V22, P521, DOI 10.1016/S0166-2236(99)01447-2
   Stephens DN, 2000, BEHAV PHARMACOL, V11, P161, DOI 10.1097/00008877-200004000-00008
   STEWART J, 1993, BEHAV PHARMACOL, V4, P289
   Tzschentke TM, 1999, TRENDS PHARMACOL SCI, V20, P189, DOI 10.1016/S0165-6147(99)01317-6
   Tzschentke TM, 2000, CEREB CORTEX, V10, P488, DOI 10.1093/cercor/10.5.488
   Tzschentke TM, 1998, TRENDS PHARMACOL SCI, V19, P447, DOI 10.1016/S0165-6147(98)01255-3
   Tzschentke TM, 1998, BEHAV BRAIN RES, V97, P115, DOI 10.1016/S0166-4328(98)00034-5
   Vanderschuren LJMJ, 2000, PSYCHOPHARMACOLOGY, V151, P99, DOI 10.1007/s002130000493
   White NM, 1997, CURR OPIN NEUROBIOL, V7, P164, DOI 10.1016/S0959-4388(97)80004-9
   Wise RA, 1996, CURR OPIN NEUROBIOL, V6, P243, DOI 10.1016/S0959-4388(96)80079-1
   Wolf ME, 1998, PROG NEUROBIOL, V54, P679, DOI 10.1016/S0301-0082(97)00090-7
   WOLF ME, 1993, BEHAV PHARMACOL, V4, P429
   WOLFFGRAMM J, 1995, BEHAV BRAIN RES, V70, P77, DOI 10.1016/0166-4328(95)00131-C
   Zigmond MJ, 1998, AMINO ACIDS, V14, P57, DOI 10.1007/BF01345243
   Zoli M, 1999, TRENDS PHARMACOL SCI, V20, P142, DOI 10.1016/S0165-6147(99)01343-7
NR 49
TC 1
Z9 1
U1 0
U2 4
PU UNIVERSITATSVERLAG ULM GMBH
PI ULM
PA BAHNHOFSTRASSE 20, D-89073 ULM, GERMANY
SN 0941-9500
J9 NEUROL PSYCHIAT BR
JI Neurol. Psychiatr. Brain Res.
PY 2000
VL 8
IS 2
BP 75
EP 80
PG 6
WC Neurosciences; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Psychiatry
GA 401JT
UT WOS:000166925000004
DA 2023-06-23
ER

PT J
AU Nestler, EJ
AF Nestler, EJ
TI Historical review: Molecular and cellular mechanisms of opiate and
   cocaine addiction
SO TRENDS IN PHARMACOLOGICAL SCIENCES
LA English
DT Review
ID ELEMENT-BINDING PROTEIN; LOCUS-CERULEUS NEURONS; FOS-RELATED ANTIGENS;
   NUCLEUS-ACCUMBENS; DELTA-FOSB; CHRONIC MORPHINE; BEHAVIORAL
   SENSITIZATION; MEDIATED TRANSCRIPTION; REINFORCING PROPERTIES; OPPOSITE
   MODULATION
AB The National Institute on Drug Abuse was founded in 1974, and since that time there have been significant advances in understanding the processes by which drugs of abuse cause addiction. The initial protein targets for almost all drugs of abuse are now known. Animal models that replicate key features of addiction are available, and these models have made it possible to characterize the brain regions that are important for addiction and other drug effects, such as physical dependence. A large number of drug-induced changes at the molecular and cellular levels have been identified in these brain areas and rapid progress is being made in relating individual changes to specific behavioral abnormalities in animal models of addiction. The current challenges are to translate this increasingly impressive knowledge of the basic neurobiology of addiction to human addicts, and to identify the specific genes that make some individuals either particularly vulnerable or resistant to addiction. In this article, I present a historical review of basic research on opiate and cocaine addiction.
C1 Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA.
C3 University of Texas System; University of Texas Dallas; University of
   Texas Southwestern Medical Center Dallas; University of Texas System;
   University of Texas Dallas; University of Texas Southwestern Medical
   Center Dallas
RP Nestler, EJ (通讯作者)，Univ Texas, SW Med Ctr, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM eric.nestler@utsouthwestern.edu
CR AGHAJANIAN GK, 1978, NATURE, V276, P186, DOI 10.1038/276186a0
   ALREJA M, 1991, BRAIN RES, V556, P339, DOI 10.1016/0006-8993(91)90327-R
   American Psychiatric Association, 2000, DIAGN STAT
   Asher O, 2002, J PHARMACOL EXP THER, V301, P66, DOI 10.1124/jpet.301.1.66
   AstonJones G, 1997, BRAIN RES, V765, P331, DOI 10.1016/S0006-8993(97)00682-3
   Baker DA, 2003, NAT NEUROSCI, V6, P743, DOI 10.1038/nn1069
   Barrot M, 2002, P NATL ACAD SCI USA, V99, P11435, DOI 10.1073/pnas.172091899
   Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9
   Bibb JA, 2001, NATURE, V410, P376, DOI 10.1038/35066591
   Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086
   Bonci A, 1997, J NEUROSCI, V17, P796
   Burns LH, 1996, BEHAV NEUROSCI, V110, P60, DOI 10.1037/0735-7044.110.1.60
   Butelman ER, 2001, J PHARMACOL EXP THER, V298, P1049
   Carlezon WA, 1998, SCIENCE, V282, P2272, DOI 10.1126/science.282.5397.2272
   Carlezon WA, 2002, TRENDS NEUROSCI, V25, P610, DOI 10.1016/S0166-2236(02)02289-0
   CHEN JS, 1995, MOL PHARMACOL, V48, P880
   Chen JS, 1997, J NEUROSCI, V17, P4933
   Christie MJ, 1997, TRENDS PHARMACOL SCI, V18, P134, DOI 10.1016/S0165-6147(97)01045-6
   Colby CR, 2003, J NEUROSCI, V23, P2488
   COLE RL, 1995, NEURON, V14, P813, DOI 10.1016/0896-6273(95)90225-2
   COLLIER HOJ, 1975, NATURE, V255, P159, DOI 10.1038/255159b0
   Delfs JM, 2000, NATURE, V403, P430, DOI 10.1038/35000212
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   DUMAN RS, 1988, J PHARMACOL EXP THER, V246, P1033
   Everitt BJ, 2002, J NEUROSCI, V22, P3312
   Fitzgerald LW, 1996, J NEUROSCI, V16, P274
   Gainetdinov RR, 2003, ANNU REV PHARMACOL, V43, P261, DOI 10.1146/annurev.pharmtox.43.050802.112309
   GOLD MS, 1978, LANCET, V2, P599
   GRAYBIEL AM, 1990, P NATL ACAD SCI USA, V87, P6912, DOI 10.1073/pnas.87.17.6912
   GUITART X, 1989, J NEUROSCI, V9, P4371
   GUITART X, 1992, J NEUROCHEM, V58, P1168, DOI 10.1111/j.1471-4159.1992.tb09377.x
   HAN MH, 2003, SOC NEUR ABSTR, V29, P644
   HANSON GR, 1992, ANN NY ACAD SCI, V668, P165, DOI 10.1111/j.1749-6632.1992.tb27348.x
   Hiroi N, 1997, P NATL ACAD SCI USA, V94, P10397, DOI 10.1073/pnas.94.19.10397
   HOPE B, 1992, P NATL ACAD SCI USA, V89, P5764, DOI 10.1073/pnas.89.13.5764
   HOPE BT, 1994, NEURON, V13, P1235, DOI 10.1016/0896-6273(94)90061-2
   Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560
   Jentsch JD, 2002, BIOL PSYCHIAT, V52, P111, DOI 10.1016/S0006-3223(02)01358-6
   Jones S, 2000, J NEUROSCI, V20, P5575, DOI 10.1523/JNEUROSCI.20-15-05575.2000
   Kalivas PW, 1999, CURR OPIN NEUROBIOL, V9, P223, DOI 10.1016/S0959-4388(99)80031-2
   Kelley AE, 2002, J NEUROSCI, V22, P3306
   Kelz MB, 1999, NATURE, V401, P272, DOI 10.1038/45790
   KOGAN JH, 1992, EUR J PHARMACOL, V211, P47, DOI 10.1016/0014-2999(92)90261-2
   KOOB GF, 1992, TRENDS NEUROSCI, V15, P186, DOI 10.1016/0166-2236(92)90171-4
   Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7
   KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G
   LaneLadd SB, 1997, J NEUROSCI, V17, P7890
   Maldonado R, 1996, SCIENCE, V273, P657, DOI 10.1126/science.273.5275.657
   MALDONADO R, 1993, BRAIN RES, V605, P128, DOI 10.1016/0006-8993(93)91364-X
   MALDONADO R, 1995, N-S ARCH PHARMACOL, V352, P565
   MARKOU A, 1993, PSYCHOPHARMACOLOGY, V112, P163, DOI 10.1007/BF02244907
   MATSUOKA I, 1994, EUR J PHARM-MOLEC PH, V268, P215, DOI 10.1016/0922-4106(94)90191-0
   McClung C, 1998, CURR BIOL, V8, P109, DOI 10.1016/S0960-9822(98)70041-7
   McClung CA, 2003, NAT NEUROSCI, V6, P1208, DOI 10.1038/nn1143
   Moratalla R, 1996, NEURON, V17, P147, DOI 10.1016/S0896-6273(00)80288-3
   Nestler E. J., 1984, PROTEIN PHOSPHORYLAT
   Nestler EJ, 2002, NEUROBIOL LEARN MEM, V78, P637, DOI 10.1006/nlme.2002.4084
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58
   Nestler EJ, 2002, NEURON, V34, P13, DOI 10.1016/S0896-6273(02)00653-0
   Nestler EJ, 2001, P NATL ACAD SCI USA, V98, P11042, DOI 10.1073/pnas.191352698
   NESTLER EJ, 1992, J NEUROSCI, V12, P2439
   NESTLER EJ, 1988, MOL PHARMACOL, V33, P127
   Newton SS, 2002, J NEUROSCI, V22, P10883
   Norrholm SD, 2003, NEUROSCIENCE, V116, P19, DOI 10.1016/S0306-4522(02)00560-2
   Nye HE, 1995, J PHARMACOL EXP THER, V275, P1671
   Nye HE, 1996, MOL PHARMACOL, V49, P636
   OLAUSSON P, 2002, SOC NEUR ABSTR, V28, P502
   OLDS ME, 1982, BRAIN RES, V237, P429, DOI 10.1016/0006-8993(82)90454-1
   ORTIZ J, 1995, SYNAPSE, V21, P289, DOI 10.1002/syn.890210403
   Peakman MC, 2003, BRAIN RES, V970, P73, DOI 10.1016/S0006-8993(03)02230-3
   Pich EM, 1997, SCIENCE, V275, P83
   Pliakas AM, 2001, J NEUROSCI, V21, P7397, DOI 10.1523/JNEUROSCI.21-18-07397.2001
   Punch LJ, 1997, J NEUROSCI, V17, P8520
   RASMUSSEN K, 1990, J NEUROSCI, V10, P2308
   Robinson TE, 1997, J NEUROSCI, V17, P8491
   Robinson TE, 1999, SYNAPSE, V33, P160
   Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-7
   Sawin ER, 2000, NEURON, V26, P619, DOI 10.1016/S0896-6273(00)81199-X
   Self DW, 1998, J NEUROSCI, V18, P1848
   Self DW, 1996, SCIENCE, V271, P1586, DOI 10.1126/science.271.5255.1586
   Shaham Y, 2000, BRAIN RES REV, V33, P13, DOI 10.1016/S0165-0173(00)00024-2
   SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092
   Shaw-Lutchman TZ, 2003, SYNAPSE, V48, P10, DOI 10.1002/syn.10172
   Shaw-Lutchman TZ, 2002, J NEUROSCI, V22, P3663
   Shippenberg TS, 1997, PHARMACOL BIOCHEM BE, V57, P449, DOI 10.1016/S0091-3057(96)00450-9
   SklairTavron L, 1996, P NATL ACAD SCI USA, V93, P11202, DOI 10.1073/pnas.93.20.11202
   Snyder SH, 2003, TRENDS PHARMACOL SCI, V24, P198, DOI 10.1016/S0165-6147(03)00066-X
   STRIPLIN CD, 1992, BRAIN RES, V579, P181, DOI 10.1016/0006-8993(92)90049-F
   TAYLOR JR, 1988, PSYCHOPHARMACOLOGY, V96, P121, DOI 10.1007/BF02431544
   TERWILLIGER RZ, 1991, BRAIN RES, V548, P100, DOI 10.1016/0006-8993(91)91111-D
   Thomas MJ, 2001, NAT NEUROSCI, V4, P1217, DOI 10.1038/nn757
   Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI 10.1093/cercor/10.3.318
   Walters CL, 2001, J NEUROSCI, V21, P9438, DOI 10.1523/JNEUROSCI.21-23-09438.2001
   Werme M, 2002, J NEUROSCI, V22, P8133
   Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5
   White FJ, 1998, DRUG ALCOHOL DEPEN, V51, P141, DOI 10.1016/S0376-8716(98)00072-6
   WIDNELL KL, 1994, P NATL ACAD SCI USA, V91, P10947, DOI 10.1073/pnas.91.23.10947
   Wise RA, 1998, DRUG ALCOHOL DEPEN, V51, P13, DOI 10.1016/S0376-8716(98)00063-5
   YOUNG ST, 1991, P NATL ACAD SCI USA, V88, P1291, DOI 10.1073/pnas.88.4.1291
   ZACHARIOU V, 2003, SOC NEUR ABSTR, V29
NR 101
TC 316
Z9 341
U1 3
U2 54
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0165-6147
EI 1873-3735
J9 TRENDS PHARMACOL SCI
JI Trends Pharmacol. Sci.
PD APR
PY 2004
VL 25
IS 4
BP 210
EP 218
DI 10.1016/j.tips.2004.02.005
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 815OL
UT WOS:000221051500011
PM 15063085
DA 2023-06-23
ER

PT S
AU Van den Oever, MC
   Spijker, S
   Smit, AB
AF Van den Oever, Michel C.
   Spijker, Sabine
   Smit, August B.
BE Kreutz, MR
   Sala, C
TI The Synaptic Pathology of Drug Addiction
SO SYNAPTIC PLASTICITY: DYNAMICS, DEVELOPMENT AND DISEASE
SE Advances in Experimental Medicine and Biology
LA English
DT Article; Book Chapter
DE Animal models; Dopamine; Drug induced neuroplasticity; Nucleus
   accumbens; Ventral tegmental area
ID COCAINE-SEEKING BEHAVIOR; MEDIAL PREFRONTAL CORTEX; VENTRAL TEGMENTAL
   AREA; NUCLEUS-ACCUMBENS SHELL; LONG-TERM POTENTIATION;
   CORTICOTROPIN-RELEASING-FACTOR; CONTEXT-INDUCED RELAPSE; PRIMING-INDUCED
   REINSTATEMENT; CONDITIONED PLACE PREFERENCE; GLUTAMATE-RECEPTOR SUBUNITS
AB A hallmark of drug addiction is the uncontrollable desire to consume drugs at the expense of severe negative consequences. Moreover, addicts that successfully refrain from drug use have a high vulnerability to relapse even after months or years of abstinence. In this chapter, we will discuss the current understanding of drug-induced neuroplasticity within the mesocorticolimbic brain system that contributes to the development of addiction and the persistence of relapse to drug seeking. I particular, we will focus at animal models that can be translated to human addiction. Although dopaminergic transmission is important for the acute effects of drug intake, the long-lived behavioral abnormalities associated with addiction are thought to arise from pathological plasticity in glutamatergic neurotransmission. The nature of changes in excitatory synaptic plasticity depends on several factors, including the type of drug, the brain area, and the time-point studied in the transition of drug exposure to withdrawal and relapse to drug seeking. Identification of drug-induced neuroplasticity is crucial to understand how molecular and cellular adaptations contribute to the end stage of addiction, which from a clinical perspective, is a time-point where pharmacotherapy may be most effectively employed.
C1 [Van den Oever, Michel C.; Spijker, Sabine; Smit, August B.] Vrije Univ Amsterdam, Dept Mol & Cellular Neurobiol, Ctr Neurogen & Cognit Res, NL-1081 HV Amsterdam, Netherlands.
C3 Vrije Universiteit Amsterdam
RP Smit, AB (通讯作者)，Vrije Univ Amsterdam, Dept Mol & Cellular Neurobiol, Ctr Neurogen & Cognit Res, Neurosci Campus Amsterdam,Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands.
EM guus.smit@cncr.vu.nl
RI van den Oever, Michel C/A-2180-2015; van den Oever,
   Michel/GNW-3560-2022; Spijker, Sabine/F-2300-2011
OI van den Oever, Michel C/0000-0001-5523-8612; van den Oever,
   Michel/0000-0001-5523-8612; Spijker, Sabine/0000-0002-6814-2019
CR Abraham WC, 2008, NAT REV NEUROSCI, V9, P387, DOI 10.1038/nrn2356
   Aguilar MA, 2009, BRAIN RES REV, V59, P253, DOI 10.1016/j.brainresrev.2008.08.002
   Anderson SM, 2008, NAT NEUROSCI, V11, P344, DOI 10.1038/nn2054
   Anderson SM, 2006, NEUROPSYCHOPHARMACOL, V31, P1452, DOI 10.1038/sj.npp.1300922
   Anderson SM, 2003, PSYCHOPHARMACOLOGY, V168, P132, DOI 10.1007/s00213-002-1298-5
   Argilli E, 2008, J NEUROSCI, V28, P9092, DOI 10.1523/JNEUROSCI.1001-08.2008
   Bachtell RK, 2005, PSYCHOPHARMACOLOGY, V183, P41, DOI 10.1007/s00213-005-0133-1
   Baker DA, 2003, NAT NEUROSCI, V6, P743, DOI 10.1038/nn1069
   Bardo MT, 2000, PSYCHOPHARMACOLOGY, V153, P31, DOI 10.1007/s002130000569
   Bell K, 1996, PSYCHOPHARMACOLOGY, V127, P377, DOI 10.1007/BF02806018
   Bellone C, 2006, NAT NEUROSCI, V9, P636, DOI 10.1038/nn1682
   Ben-Shahar O, 2009, SYNAPSE, V63, P598, DOI 10.1002/syn.20640
   Borgland SL, 2004, J NEUROSCI, V24, P7482, DOI 10.1523/JNEUROSCI.1312-04.2004
   Bossert JM, 2007, J NEUROSCI, V27, P12655, DOI 10.1523/JNEUROSCI.3926-07.2007
   Bossert JM, 2006, NEUROPSYCHOPHARMACOL, V31, P2197, DOI 10.1038/sj.npp.1300977
   Bossert JM, 2011, NAT NEUROSCI, V14, P420, DOI 10.1038/nn.2758
   Boudreau AC, 2005, J NEUROSCI, V25, P9144, DOI 10.1523/JNEUROSCI.2252-05.2005
   Boudreau AC, 2007, J NEUROSCI, V27, P10621, DOI 10.1523/JNEUROSCI.2163-07.2007
   Boudreau AC, 2009, J NEUROCHEM, V110, P363, DOI 10.1111/j.1471-4159.2009.06140.x
   Brebner K, 2005, SCIENCE, V310, P1340, DOI 10.1126/science.1116894
   Buffalari DM, 2010, CURR TOP BEHAV NEURO, V3, P73, DOI 10.1007/7854_2009_18
   Chen BT, 2008, NEURON, V59, P288, DOI 10.1016/j.neuron.2008.05.024
   Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11
   Churchill L, 1999, J NEUROCHEM, V72, P2397, DOI 10.1046/j.1471-4159.1999.0722397.x
   Conrad KL, 2008, NATURE, V454, P118, DOI 10.1038/nature06995
   Cornish JL, 1999, NEUROSCIENCE, V93, P1359, DOI 10.1016/S0306-4522(99)00214-6
   Cornish JL, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-15-j0006.2000
   Crombag HS, 2008, PHILOS T R SOC B, V363, P3233, DOI 10.1098/rstb.2008.0090
   Di Ciano P, 2001, NEUROPSYCHOPHARMACOL, V25, P341, DOI 10.1016/S0893-133X(01)00235-4
   DICHIARA G, 1992, TRENDS PHARMACOL SCI, V13, P185
   Engblom D, 2008, NEURON, V59, P497, DOI 10.1016/j.neuron.2008.07.010
   Epstein DH, 2006, PSYCHOPHARMACOLOGY, V189, P1, DOI 10.1007/s00213-006-0529-6
   Erb S, 1998, J NEUROSCI, V18, P5529, DOI 10.1523/JNEUROSCI.18-14-05529.1998
   Famous KR, 2008, J NEUROSCI, V28, P11061, DOI 10.1523/JNEUROSCI.1221-08.2008
   Fitzgerald LW, 1996, J NEUROSCI, V16, P274
   Fu Y, 2007, J NEUROPHYSIOL, V97, P937, DOI 10.1152/jn.00349.2006
   Fuchs RA, 2005, NEUROPSYCHOPHARMACOL, V30, P296, DOI 10.1038/sj.npp.1300579
   Fuchs RA, 2002, PSYCHOPHARMACOLOGY, V160, P425, DOI 10.1007/s00213-001-0997-7
   Fuchs RA, 2008, PSYCHOPHARMACOLOGY, V200, P545, DOI 10.1007/s00213-008-1234-4
   Gabriele A, 2010, EUR J NEUROSCI, V32, P1024, DOI 10.1111/j.1460-9568.2010.07394.x
   Gardner EL, 2000, AM J ADDICTION, V9, P285, DOI 10.1080/105504900750047355
   Geisler S, 2008, REV NEUROSCIENCE, V19, P227
   Gerdjikov TV, 2004, BEHAV NEUROSCI, V118, P740, DOI 10.1037/0735-7044.118.4.740
   Ghasemzadeh MB, 1999, J NEUROCHEM, V72, P157, DOI 10.1046/j.1471-4159.1999.0720157.x
   Goeders NE, 2003, EUR NEUROPSYCHOPHARM, V13, P435, DOI 10.1016/j.euroneuro.2003.08.004
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Goussakov I, 2006, EUR J NEUROSCI, V23, P239, DOI 10.1111/j.1460-9568.2005.04538.x
   GYSLING K, 1983, BRAIN RES, V277, P119, DOI 10.1016/0006-8993(83)90913-7
   Heidbreder CA, 2003, NEUROSCI BIOBEHAV R, V27, P555, DOI 10.1016/j.neubiorev.2003.09.003
   Hyman SE, 2005, AM J PSYCHIAT, V162, P1414, DOI 10.1176/appi.ajp.162.8.1414
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Isaac JTR, 2007, NEURON, V54, P859, DOI 10.1016/j.neuron.2007.06.001
   Kalivas PW, 2009, NAT REV NEUROSCI, V10, P561, DOI 10.1038/nrn2515
   Kalivas PW, 2005, NEURON, V45, P647, DOI 10.1016/j.neuron.2005.02.005
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kasanetz F, 2010, SCIENCE, V328, P1709, DOI 10.1126/science.1187801
   Knackstedt LA, 2010, BIOL PSYCHIAT, V67, P81, DOI 10.1016/j.biopsych.2009.07.018
   Knackstedt LA, 2009, BIOL PSYCHIAT, V65, P841, DOI 10.1016/j.biopsych.2008.10.040
   Kourrich S, 2007, J NEUROSCI, V27, P7921, DOI 10.1523/JNEUROSCI.1859-07.2007
   Koya E, 2009, NEUROPHARMACOLOGY, V56, P177, DOI 10.1016/j.neuropharm.2008.04.022
   Krishnan B, 2010, EUR J NEUROSCI, V31, P1027, DOI 10.1111/j.1460-9568.2010.07148.x
   Kruzich PJ, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-14-j0002.2001
   Kruzich PJ, 2001, BEHAV NEUROSCI, V115, P1086, DOI 10.1037//0735-7044.115.5.1086
   LaLumiere RT, 2008, J NEUROSCI, V28, P3170, DOI 10.1523/JNEUROSCI.5129-07.2008
   LaRowe SD, 2007, AM J PSYCHIAT, V164, P1115, DOI 10.1176/appi.ajp.164.7.1115
   Lobo MK, 2010, SCIENCE, V330, P385, DOI 10.1126/science.1188472
   Lu H, 2010, NEURON, V67, P821, DOI 10.1016/j.neuron.2010.08.012
   Lu L, 2005, J NEUROCHEM, V94, P161, DOI 10.1111/j.1471-4159.2005.03178.x
   Lu L, 2003, J NEUROCHEM, V85, P1604, DOI 10.1046/j.1471-4159.2003.01824.x
   Lu L, 2005, NAT NEUROSCI, V8, P212, DOI 10.1038/nn1383
   Mameli M, 2007, SCIENCE, V317, P530, DOI 10.1126/science.1142365
   Mameli M, 2009, NAT NEUROSCI, V12, P1036, DOI 10.1038/nn.2367
   Mardikian PN, 2007, PROG NEURO-PSYCHOPH, V31, P389, DOI 10.1016/j.pnpbp.2006.10.001
   Martin M, 2006, NAT NEUROSCI, V9, P868, DOI 10.1038/nn1713
   McFarland K, 2004, J NEUROSCI, V24, P1551, DOI 10.1523/JNEUROSCI.4177-03.2004
   McFarland K, 2003, J NEUROSCI, V23, P3531
   McFarland K, 2001, J NEUROSCI, V21, P8655
   McLaughlin J, 2003, PSYCHOPHARMACOLOGY, V168, P57, DOI 10.1007/s00213-002-1196-x
   Meredith GE, 2008, BRAIN STRUCT FUNCT, V213, P17, DOI 10.1007/s00429-008-0175-3
   MEREU G, 1987, EUR J PHARMACOL, V141, P395, DOI 10.1016/0014-2999(87)90556-5
   Miguens M, 2008, PSYCHOPHARMACOLOGY, V196, P303, DOI 10.1007/s00213-007-0958-x
   Millan EZ, 2011, BEHAV BRAIN RES, V217, P454, DOI 10.1016/j.bbr.2010.10.037
   Miller CA, 2005, NEURON, V47, P873, DOI 10.1016/j.neuron.2005.08.006
   Moran MM, 2005, J NEUROSCI, V25, P6389, DOI 10.1523/JNEUROSCI.1007-05.2005
   Moussawi K, 2011, P NATL ACAD SCI USA, V108, P385, DOI 10.1073/pnas.1011265108
   Moussawi K, 2009, NAT NEUROSCI, V12, P182, DOI 10.1038/nn.2250
   OBRIEN CP, 1986, CLASSICAL CONDITIONI
   Park WK, 2002, J NEUROSCI, V22, P2916, DOI 10.1523/JNEUROSCI.22-07-02916.2002
   Peters J, 2008, J NEUROSCI, V28, P6046, DOI 10.1523/JNEUROSCI.1045-08.2008
   Peters J, 2006, PSYCHOPHARMACOLOGY, V186, P143, DOI 10.1007/s00213-006-0372-9
   Peters J, 2009, LEARN MEMORY, V16, P279, DOI 10.1101/lm.1041309
   Pierce RC, 1996, J NEUROSCI, V16, P1550
   Ping AS, 2008, BRAIN RES, V1215, P173, DOI 10.1016/j.brainres.2008.03.088
   Pollandt S, 2006, EUR J NEUROSCI, V24, P1733, DOI 10.1111/j.1460-9568.2006.05049.x
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Rogers JL, 2008, NEUROSCIENCE, V151, P579, DOI 10.1016/j.neuroscience.2007.10.012
   Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-7
   SARNYAI Z, 1992, LIFE SCI, V51, P2019, DOI 10.1016/0024-3205(92)90151-E
   SCHENK S, 1991, BRAIN RES, V543, P227, DOI 10.1016/0006-8993(91)90032-Q
   Schmidt HD, 2006, NEUROSCIENCE, V142, P451, DOI 10.1016/j.neuroscience.2006.06.004
   Schramm-Sapyta NL, 2006, NEUROPSYCHOPHARMACOL, V31, P1444, DOI 10.1038/sj.npp.1300918
   Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1
   Schultz W, 2007, ANNU REV NEUROSCI, V30, P259, DOI 10.1146/annurev.neuro.28.061604.135722
   Sesack SR, 2003, ANN NY ACAD SCI, V1003, P36, DOI 10.1196/annals.1300.066
   SESACK SR, 1989, J COMP NEUROL, V290, P213, DOI 10.1002/cne.902900205
   Shaham Y, 1998, PSYCHOPHARMACOLOGY, V137, P184, DOI 10.1007/s002130050608
   STEWART J, 1993, BEHAV PHARMACOL, V4, P289
   Stuber GD, 2008, SCIENCE, V321, P1690, DOI 10.1126/science.1160873
   Sutton MA, 2003, NATURE, V421, P70, DOI 10.1038/nature01249
   Tang WX, 2004, J NEUROCHEM, V89, P1021, DOI 10.1111/j.1471-4159.2004.02392.x
   Thomas MJ, 2001, NAT NEUROSCI, V4, P1217, DOI 10.1038/nn757
   Tsai HC, 2009, SCIENCE, V324, P1080, DOI 10.1126/science.1168878
   Tye KM, 2008, NATURE, V453, P1253, DOI 10.1038/nature06963
   Tzschentke TM, 2001, PROG NEUROBIOL, V63, P241, DOI 10.1016/S0301-0082(00)00033-2
   Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077
   Van den Oever MC, 2008, NAT NEUROSCI, V11, P1053, DOI 10.1038/nn.2165
   Van den Oever MC, 2010, NEUROSCI BIOBEHAV R, V35, P276, DOI 10.1016/j.neubiorev.2009.11.016
   Van den Oever MC, 2010, NEUROPSYCHOPHARMACOL, V35, P2120, DOI 10.1038/npp.2010.90
   van der Staay FJ, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-11
   Vanderschuren LJMJ, 1997, PSYCHOPHARMACOLOGY, V131, P115, DOI 10.1007/s002130050273
   Vezina P, 2004, NEUROSCI BIOBEHAV R, V27, P827, DOI 10.1016/j.neubiorev.2003.11.001
   Voorn P, 2004, TRENDS NEUROSCI, V27, P468, DOI 10.1016/j.tins.2004.06.006
   Weissenborn R, 1997, PSYCHOPHARMACOLOGY, V134, P242, DOI 10.1007/s002130050447
   White FJ, 1996, ANNU REV NEUROSCI, V19, P405, DOI 10.1146/annurev.ne.19.030196.002201
   WHITE FJ, 1995, J PHARMACOL EXP THER, V273, P445
   Williams JM, 2006, HANDB EXP PHARM, V175, P215
   Witten IB, 2010, SCIENCE, V330, P1677, DOI 10.1126/science.1193771
   Xi ZX, 2004, PSYCHOPHARMACOLOGY, V176, P57, DOI 10.1007/s00213-004-1858-y
   Zahm DS, 1999, ANN NY ACAD SCI, V877, P113, DOI 10.1111/j.1749-6632.1999.tb09264.x
   Zhou WH, 2008, BIOL PSYCHIAT, V63, P338, DOI 10.1016/j.biopsych.2007.06.008
   Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8
   Zweifel LS, 2008, NEURON, V59, P486, DOI 10.1016/j.neuron.2008.05.028
NR 132
TC 27
Z9 27
U1 0
U2 37
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0065-2598
EI 2214-8019
BN 978-3-7091-0931-1
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2012
VL 970
BP 469
EP 491
DI 10.1007/978-3-7091-0932-8_21
D2 10.1007/978-3-7091-0932-8
PG 23
WC Biology; Medicine, Research & Experimental; Neurosciences
WE Book Citation Index– Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine; Neurosciences & Neurology
GA BAA81
UT WOS:000303541700021
PM 22351069
DA 2023-06-23
ER

PT J
AU Zhou, KK
   Zhu, YJ
AF Zhou, Kuikui
   Zhu, Yingjie
TI The paraventricular thalamic nucleus: A key hub of neural circuits
   underlying drug addiction
SO PHARMACOLOGICAL RESEARCH
LA English
DT Review
DE The paraventricular thalamic nucleus; Drug addiction; Neural circuits;
   Synaptic plasticity; Neuromodulation
ID RECEPTOR MESSENGER-RNA; CONDITIONED PLACE PREFERENCE; COCAINE-PAIRED
   ENVIRONMENT; AUTORADIOGRAPHIC LOCALIZATION; STRIA TERMINALIS; BED
   NUCLEUS; RAT-BRAIN; SLOW AFTERHYPERPOLARIZATION; INDUCED REINSTATEMENT;
   HORMONE RECEPTORS
AB Drug addiction is a chronic relapsing brain disease characterized by compulsive, out-of-control drug use and the appearance of negative somatic and emotional consequences when drug access is prevented. The limited efficacy of treatment urges researchers toward a deeper understanding of the neural mechanism of drug addiction. Brain circuits that regulate reward and motivation are considered to be the neural substrate of drug addiction. An increasing body of literature indicates that the paraventricular thalamic nucleus (PVT) could serve as a key node in the neurocircuits that control goal-directed behaviors. In this review, we summarize the anatomical and functional evidence that the PVT regulates drug-related behaviors. The PVT receives extensive inputs from the brainstem and hypothalamus, and is reciprocally connected with the limbic system. Neurons in the PVT are recruited by drug exposure as well as cues and context associated with drug taking. Pathway-specific perturbation studies have begun to decipher the precise role of PVT circuits in drug-related behaviors. We also highlight recent findings about the involvement of neural plasticity of the PVT pathways in drug addiction and provide perspectives on future studies.
C1 [Zhou, Kuikui; Zhu, Yingjie] Chinese Acad Sci, Shenzhen Inst Adv Technol, Brain Cognit & Brain Dis Inst, Guangdong Prov Key Lab Brain Connectome & Behav, Shenzhen 518055, Peoples R China.
C3 Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology,
   CAS
RP Zhu, YJ (通讯作者)，Chinese Acad Sci, Shenzhen Inst Adv Technol, Brain Cognit & Brain Dis Inst, Guangdong Prov Key Lab Brain Connectome & Behav, Shenzhen 518055, Peoples R China.
EM yj.zhu1@siat.ac.cn
OI Zhu, Yingjie/0000-0002-0783-0897
FU Shenzhen governmental grants [JCYJ20170818163217196,
   JCYJ20170818162613877]; National Natural Science Foundation of China
   [31741058]; Thousand Youth Talents Plan
FX This work was supported by Shenzhen governmental grants
   JCYJ20170818163217196, JCYJ20170818162613877, the National Natural
   Science Foundation of China grant 31741058, and the Thousand Youth
   Talents Plan.
CR Atasoy D, 2012, NATURE, V488, P172, DOI 10.1038/nature11270
   Baker TB, 2004, PSYCHOL REV, V111, P33, DOI 10.1037/0033-295X.111.1.33
   Barson JR, 2017, ADDICT BIOL, V22, P58, DOI 10.1111/adb.12288
   Barson JR, 2015, ADDICT BIOL, V20, P469, DOI 10.1111/adb.12139
   Bayer L, 2002, J NEUROSCI, V22, P7835
   Beas BS, 2018, NAT NEUROSCI, V21, P963, DOI 10.1038/s41593-018-0167-4
   BENTIVOGLIO M, 1991, PROG BRAIN RES, V87, P53
   BERENDSE HW, 1991, NEUROSCIENCE, V42, P73, DOI 10.1016/0306-4522(91)90151-D
   Betley JN, 2013, CELL, V155, P1337, DOI 10.1016/j.cell.2013.11.002
   Bora E, 2012, ADDICT BIOL, V17, P141, DOI 10.1111/j.1369-1600.2010.00266.x
   BROWN EE, 1992, J NEUROSCI, V12, P4112
   Browning JR, 2014, DRUG ALCOHOL DEPEN, V134, P387, DOI 10.1016/j.drugalcdep.2013.09.021
   Bruchas MR, 2010, BRAIN RES, V1314, P44, DOI 10.1016/j.brainres.2009.08.062
   Brunton J, 1998, J NEUROSCI, V18, P1671
   Bubser M, 1999, SYNAPSE, V32, P13, DOI 10.1002/(SICI)1098-2396(199904)32:1<13::AID-SYN2>3.0.CO;2-R
   Bubser M, 1998, BRAIN RES, V787, P304, DOI 10.1016/S0006-8993(97)01373-5
   Chen ZH, 2015, NEUROPHARMACOLOGY, V97, P259, DOI 10.1016/j.neuropharm.2015.05.030
   CHRISTIE MJ, 1987, NEUROSCIENCE, V22, P425, DOI 10.1016/0306-4522(87)90345-9
   Clark AM, 2017, ENEURO, V4, DOI 10.1523/ENEURO.0227-17.2017
   CORNWALL J, 1988, BRAIN RES BULL, V21, P147, DOI 10.1016/0361-9230(88)90227-4
   Dayas CV, 2008, BIOL PSYCHIAT, V63, P152, DOI 10.1016/j.biopsych.2007.02.002
   Deutch AY, 1998, J NEUROSCI, V18, P10680
   Do-Monte FH, 2017, NEURON, V94, P388, DOI 10.1016/j.neuron.2017.03.036
   Do-Monte FH, 2015, NATURE, V519, P460, DOI 10.1038/nature14030
   Dong XW, 2017, BRAIN STRUCT FUNCT, V222, P3927, DOI 10.1007/s00429-017-1445-8
   Erb S, 2010, PROG NEURO-PSYCHOPH, V34, P798, DOI 10.1016/j.pnpbp.2009.11.025
   Franklin TR, 2000, EUR J NEUROSCI, V12, P2097, DOI 10.1046/j.1460-9568.2000.00071.x
   Frassoni C, 1997, EXP BRAIN RES, V115, P95, DOI 10.1007/PL00005689
   GARCIA MM, 1995, BRAIN RES, V692, P23, DOI 10.1016/0006-8993(95)00625-Z
   Gass J T, 2013, Front Psychiatry, V4, P46, DOI 10.3389/fpsyt.2013.00046
   George O, 2017, NEUROPHARMACOLOGY, V122, P107, DOI 10.1016/j.neuropharm.2017.04.031
   GERFEN CR, 1992, ANNU REV NEUROSCI, V15, P285, DOI 10.1146/annurev.neuro.15.1.285
   Goaillard JM, 2002, J PHYSIOL-LONDON, V541, P453, DOI 10.1113/jphysiol.2001.013896
   Graziane NM, 2016, NAT NEUROSCI, V19, P915, DOI 10.1038/nn.4313
   GROENEWEGEN HJ, 1994, TRENDS NEUROSCI, V17, P52, DOI 10.1016/0166-2236(94)90074-4
   Gutstein HB, 1998, CAN J PHYSIOL PHARM, V76, P294, DOI 10.1139/cjpp-76-3-294
   HADFIELD MG, 1992, PHARMACOL BIOCHEM BE, V43, P395, DOI 10.1016/0091-3057(92)90168-F
   Hamlin AS, 2009, EUR J NEUROSCI, V29, P802, DOI 10.1111/j.1460-9568.2009.06623.x
   Heilbronner U, 2004, CELL MOL NEUROBIOL, V24, P815, DOI 10.1007/s10571-004-6921-z
   Heydendael W, 2012, BRAIN RES BULL, V89, P203, DOI 10.1016/j.brainresbull.2012.09.002
   Heydendael W, 2011, ENDOCRINOLOGY, V152, P4738, DOI 10.1210/en.2011-1652
   Hsu DT, 2007, J COMP NEUROL, V504, P89, DOI 10.1002/cne.21440
   Hsu DT, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00073
   Hsu DT, 2009, J COMP NEUROL, V512, P825, DOI 10.1002/cne.21934
   Huang AS, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2017.0028
   Ishibashi M, 2005, PEPTIDES, V26, P471, DOI 10.1016/j.peptides.2004.10.014
   James MH, 2011, NEUROSCIENCE, V199, P235, DOI 10.1016/j.neuroscience.2011.09.047
   James MH, 2017, CURR TOP BEHAV NEURO, V33, P247, DOI 10.1007/7854_2016_57
   James MH, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00018
   James MH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012980
   Janak PH, 2015, NATURE, V517, P284, DOI 10.1038/nature14188
   Kelley AE, 2005, J COMP NEUROL, V493, P72, DOI 10.1002/cne.20769
   Kirouac GJ, 2006, J COMP NEUROL, V497, P155, DOI 10.1002/cne.20971
   Kirouac GJ, 2015, NEUROSCI BIOBEHAV R, V56, P315, DOI 10.1016/j.neubiorev.2015.08.005
   Kirouac GJ, 2005, BRAIN RES, V1059, P179, DOI 10.1016/j.brainres.2005.08.035
   Kolaj M, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00132
   Koob GF, 2016, LANCET PSYCHIAT, V3, P760, DOI 10.1016/S2215-0366(16)00104-8
   Koob GF, 2014, NEUROPHARMACOLOGY, V76, P370, DOI 10.1016/j.neuropharm.2013.05.024
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Krout KE, 2000, J COMP NEUROL, V424, P111, DOI 10.1002/1096-9861(20000814)424:1<111::AID-CNE9>3.0.CO;2-3
   Krout KE, 2000, J COMP NEUROL, V428, P475, DOI 10.1002/1096-9861(20001218)428:3<475::AID-CNE6>3.0.CO;2-9
   Kukkonen JP, 2014, BIOCHIMIE, V96, P158, DOI 10.1016/j.biochi.2013.06.015
   Lebow MA, 2016, MOL PSYCHIATR, V21, P450, DOI 10.1038/mp.2016.1
   Lee JS, 2015, BRAIN RES, V1598, P97, DOI 10.1016/j.brainres.2014.12.029
   LEVEY AI, 1994, NEUROSCIENCE, V63, P207, DOI 10.1016/0306-4522(94)90017-5
   Li S, 2008, J COMP NEUROL, V506, P263, DOI 10.1002/cne.21502
   Li S, 2014, FRONT NEUROANAT, V8, DOI 10.3389/fnana.2014.00136
   Li S, 2012, BRAIN STRUCT FUNCT, V217, P257, DOI 10.1007/s00429-011-0360-7
   Li YH, 2011, PHYSIOL BEHAV, V102, P42, DOI 10.1016/j.physbeh.2010.10.006
   Li YH, 2010, PSYCHOPHARMACOLOGY, V212, P251, DOI 10.1007/s00213-010-1948-y
   Li YH, 2010, PHARMACOL BIOCHEM BE, V95, P121, DOI 10.1016/j.pbb.2009.12.016
   Lobo MK, 2010, SCIENCE, V330, P385, DOI 10.1126/science.1188472
   Luscher C, 2011, NEURON, V69, P650, DOI 10.1016/j.neuron.2011.01.017
   MacAskill AF, 2012, NAT NEUROSCI, V15, P1624, DOI 10.1038/nn.3254
   MANAKER S, 1985, NEUROLOGY, V35, P1650, DOI 10.1212/WNL.35.11.1650
   MANAKER S, 1985, J NEUROSCI, V5, P167
   MANSOUR A, 1994, MOL CELL NEUROSCI, V5, P124, DOI 10.1006/mcne.1994.1015
   MANSOUR A, 1994, J COMP NEUROL, V350, P412, DOI 10.1002/cne.903500307
   Mantsch JR, 2016, NEUROPSYCHOPHARMACOL, V41, P335, DOI 10.1038/npp.2015.142
   Marchant NJ, 2010, J NEUROSCI, V30, P14102, DOI 10.1523/JNEUROSCI.4079-10.2010
   Martin-Fardon R, 2018, ADDICT BIOL, V23, P6, DOI 10.1111/adb.12441
   Martin-Fardon R, 2012, FRONT BEHAV NEUROSCI, V6, DOI 10.3389/fnbeh.2012.00075
   MASH DC, 1986, NEUROSCIENCE, V19, P551, DOI 10.1016/0306-4522(86)90280-0
   Matyas F, 2018, NAT NEUROSCI, V21, P1551, DOI 10.1038/s41593-018-0251-9
   Matzeu A, 2018, NEUROPSYCHOPHARMACOL, V43, P1010, DOI 10.1038/npp.2017.250
   Matzeu A, 2017, ADDICT BIOL, V22, P70, DOI 10.1111/adb.12280
   Matzeu A, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00117
   McCall NM, 2017, NEUROPSYCHOPHARMACOL, V42, P707, DOI 10.1038/npp.2016.138
   MEREDITH GE, 1990, J COMP NEUROL, V296, P204, DOI 10.1002/cne.902960203
   Millan EZ, 2017, PROG BRAIN RES, V235, P113, DOI 10.1016/bs.pbr.2017.07.006
   MOGA MM, 1995, J COMP NEUROL, V359, P221, DOI 10.1002/cne.903590204
   Moutsimilli L, 2008, NEUROPHARMACOLOGY, V54, P497, DOI 10.1016/j.neuropharm.2007.10.022
   Naqvi NH, 2014, ANN NY ACAD SCI, V1316, P53, DOI 10.1111/nyas.12415
   Neumann PA, 2016, NEUROPSYCHOPHARMACOL, V41, P2399, DOI 10.1038/npp.2016.52
   Otake K, 2005, NEUROSCI RES, V51, P383, DOI 10.1016/j.neures.2004.12.009
   Pandey S, 2019, ADDICT BIOL, V24, P3, DOI 10.1111/adb.12546
   Panlilio LV, 2007, ADDICTION, V102, P1863, DOI 10.1111/j.1360-0443.2007.02011.x
   Parsons MP, 2007, J COMP NEUROL, V500, P1050, DOI 10.1002/cne.21224
   Pascoli V, 2014, NATURE, V509, P459, DOI 10.1038/nature13257
   Pasumarthi RK, 2008, BRAIN RES BULL, V77, P367, DOI 10.1016/j.brainresbull.2008.09.014
   Peng ZC, 2004, J NEUROCYTOL, V33, P101, DOI 10.1023/B:NEUR.0000029651.51195.f9
   Penzo MA, 2015, NATURE, V519, P455, DOI 10.1038/nature13978
   Penzo MA, 2014, J NEUROSCI, V34, P2432, DOI 10.1523/JNEUROSCI.4166-13.2014
   Perry CJ, 2013, EUR J NEUROSCI, V38, P2762, DOI 10.1111/ejn.12283
   PIERIBONE VA, 1994, J NEUROSCI, V14, P4252
   Pinto A, 2003, J COMP NEUROL, V459, P142, DOI 10.1002/cne.10596
   RAINBOW TC, 1984, P NATL ACAD SCI-BIOL, V81, P1585, DOI 10.1073/pnas.81.5.1585
   Ren SC, 2018, SCIENCE, V362, P429, DOI 10.1126/science.aat2512
   REN T, 1992, BRAIN RES BULL, V29, P589, DOI 10.1016/0361-9230(92)90127-J
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Ruggiero DA, 1998, BRAIN RES, V799, P159, DOI 10.1016/S0006-8993(98)00442-9
   Ryabinin AE, 1998, PSYCHOPHARMACOLOGY, V139, P34, DOI 10.1007/s002130050687
   Saito Y, 2001, J COMP NEUROL, V435, P26, DOI 10.1002/cne.1191
   Salti A, 2018, FRONT BEHAV NEUROSCI, V12, DOI 10.3389/fnbeh.2018.00224
   Sargin D., 2018, NEUROPHARMACOLOGY, DOI [10.1016/neuropharm.2018.09.034, DOI 10.1016/NEUROPHARM.2018.09.034]
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   SHIPPENBERG TS, 1993, J PHARMACOL EXP THER, V265, P53
   SU HS, 1990, J COMP NEUROL, V297, P582, DOI 10.1002/cne.902970410
   TAKADA M, 1990, NEUROSCI LETT, V115, P33, DOI 10.1016/0304-3940(90)90513-9
   Tye KM, 2012, NEURON, V76, P671, DOI 10.1016/j.neuron.2012.11.008
   Tzschentke TM, 2007, ADDICT BIOL, V12, P227, DOI 10.1111/j.1369-1600.2007.00070.x
   Unzai T, 2017, CEREB CORTEX, V27, P1164, DOI 10.1093/cercor/bhv295
   Uroz V, 2004, SYNAPSE, V51, P173, DOI 10.1002/syn.10298
   Venniro M, 2016, PROG BRAIN RES, V224, P25, DOI 10.1016/bs.pbr.2015.08.004
   Vertes RP, 2008, J COMP NEUROL, V508, P212, DOI 10.1002/cne.21679
   Volkow ND, 2015, CELL, V162, P712, DOI 10.1016/j.cell.2015.07.046
   Vranjkovic O, 2017, NEUROPHARMACOLOGY, V122, P100, DOI 10.1016/j.neuropharm.2017.03.028
   Wedzony K, 2003, N-S ARCH PHARMACOL, V368, P331, DOI 10.1007/s00210-003-0811-7
   Wee S, 2010, PSYCHOPHARMACOLOGY, V210, P121, DOI 10.1007/s00213-010-1825-8
   Winrow CJ, 2010, NEUROPHARMACOLOGY, V58, P185, DOI 10.1016/j.neuropharm.2009.07.008
   Yeoh JW, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00280
   Yeoh JW, 2012, J PHYSIOL-LONDON, V590, P3677, DOI 10.1113/jphysiol.2012.230268
   Young CD, 1998, PHARMACOL BIOCHEM BE, V60, P753, DOI 10.1016/S0091-3057(98)00051-3
   Zhang L, 2009, J NEUROPHYSIOL, V101, P2741, DOI 10.1152/jn.91183.2008
   Zhang XB, 2017, SCIENCE, V356, P853, DOI 10.1126/science.aam7100
   Zhu YJ, 2018, SCIENCE, V362, P423, DOI 10.1126/science.aat0481
   Zhu YJ, 2016, NATURE, V530, P219, DOI 10.1038/nature16954
NR 137
TC 31
Z9 32
U1 5
U2 34
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD APR
PY 2019
VL 142
BP 70
EP 76
DI 10.1016/j.phrs.2019.02.014
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HT3TU
UT WOS:000464486900007
PM 30772461
DA 2023-06-23
ER

PT J
AU Markou, A
AF Markou, Athina
TI The role of metabotropic glutamate receptors in drug reward, motivation
   and dependence
SO DRUG NEWS & PERSPECTIVES
LA English
DT Article
ID COCAINE-INDUCED REINSTATEMENT; CUE-INDUCED REINSTATEMENT; ANTAGONIST
   MPEP; CONDITIONED REWARD; AGONIST LY379268; NICOTINE; SEEKING;
   ADDICTION; DOPAMINE; ANXIETY
AB Addiction to drugs of abuse is a disorder that involves dysfunctions in motivational processes. Both the primary rewarding effects of drugs, as well as the acquired motivational properties of stimuli associated with drug-seeking and -taking, contribute to the perpetuation of dependence on drugs of abuse. Metabotropic glutamate (mGlu) receptors, which mediate slow glutamate neurotransmission, are located throughout limbic and cortical brain sites implicated in drug addiction. Preclinical evidence suggests that mGlu receptors play a crucial role in regulating behavioral effects of drugs of abuse relevant to drug addiction. Specifically, antagonists at excitatory postsynaptic mGlu5 receptors decrease drug self-administration without affecting motor behaviors, cognition or the reward value of natural rewards, while agonists at inhibitory presynaptic mGlu2/3 receptor agonists prevent reinstatement to drug-seeking and -taking after a period of abstinence. These findings have increased our understanding of the neuropathological processes associated with aspects of dependence on drugs of abuse and have provided new targets for pharmacological approaches to the treatment of dysfunctions in motivational processes characterizing the various phases of drug addiction. (c) 2007 Prous Science. All rights reserved.
C1 Univ Calif San Diego, Dept Psychiat, Sch Med, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego
RP Markou, A (通讯作者)，Univ Calif San Diego, Dept Psychiat, Sch Med, M-C 0603,9500 Gilman Dr, La Jolla, CA 92093 USA.
EM amarkou@ucsd.edu
CR Aoki T, 2004, EUR J NEUROSCI, V20, P1633, DOI 10.1111/j.1460-9568.2004.03609.x
   Backstrom P, 2004, NEUROPSYCHOPHARMACOL, V29, P921, DOI 10.1038/sj.npp.1300381
   Backstrom P, 2006, NEUROPSYCHOPHARMACOL, V31, P778, DOI 10.1038/sj.npp.1300845
   Baker DA, 2003, NAT NEUROSCI, V6, P743, DOI 10.1038/nn1069
   Ballard TM, 2005, PSYCHOPHARMACOLOGY, V179, P218, DOI 10.1007/s00213-005-2211-9
   Baptista MAS, 2004, J NEUROSCI, V24, P4723, DOI 10.1523/JNEUROSCI.0176-04.2004
   Bespalov AY, 2005, NEUROPHARMACOLOGY, V49, P167, DOI 10.1016/j.neuropharm.2005.06.007
   Bossert JM, 2005, NEUROREPORT, V16, P1013, DOI 10.1097/00001756-200506210-00026
   Chiamulera C, 2001, NAT NEUROSCI, V4, P873, DOI 10.1038/nn0901-873
   Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Herzig V, 2005, ADDICT BIOL, V10, P243, DOI 10.1080/13556210500223272
   Herzig V, 2004, NEUROPHARMACOLOGY, V47, P973, DOI 10.1016/j.neuropharm.2004.07.037
   Kalivas PW, 2005, NEURON, V45, P647, DOI 10.1016/j.neuron.2005.02.005
   Kenny PJ, 2005, PSYCHOPHARMACOLOGY, V179, P247, DOI 10.1007/s00213-004-2069-2
   Kenny PJ, 2004, TRENDS PHARMACOL SCI, V25, P265, DOI 10.1016/j.tips.2004.03.009
   Kenny PJ, 2003, J PHARMACOL EXP THER, V306, P1068, DOI 10.1124/jpet.103.052027
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Markou A, 1998, NEUROPSYCHOPHARMACOL, V18, P135, DOI 10.1016/S0893-133X(97)00113-9
   Markou Athina, 2004, Discov Med, V4, P246
   Markou A, 2007, BIOL PSYCHIAT, V61, P17, DOI 10.1016/j.biopsych.2006.03.053
   McFarland K, 2003, J NEUROSCI, V23, P3531
   McFarland K, 2001, J NEUROSCI, V21, P8655
   McGeehan AJ, 2003, SYNAPSE, V47, P240, DOI 10.1002/syn.10166
   Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006
   Miyatake M, 2005, EUR J NEUROSCI, V22, P1476, DOI 10.1111/j.1460-9568.2005.04325.x
   Moran MM, 2005, J NEUROSCI, V25, P6389, DOI 10.1523/JNEUROSCI.1007-05.2005
   Paterson NE, 2003, PSYCHOPHARMACOLOGY, V167, P257, DOI 10.1007/s00213-003-1432-z
   Paterson NE, 2005, PSYCHOPHARMACOLOGY, V179, P255, DOI 10.1007/s00213-004-2070-9
   Paterson NE, 2005, NEUROPSYCHOPHARMACOL, V30, P119, DOI 10.1038/sj.npp.1300524
   Popik P, 2002, NEUROPHARMACOLOGY, V43, P1210, DOI 10.1016/S0028-3908(02)00309-X
   Schroeder JP, 2005, PSYCHOPHARMACOLOGY, V179, P262, DOI 10.1007/s00213-005-2175-9
   Sutton MA, 2003, NATURE, V421, P70, DOI 10.1038/nature01249
   Swanson CJ, 2005, NAT REV DRUG DISCOV, V4, P131, DOI 10.1038/nrd1630
   Tessari M, 2004, EUR J PHARMACOL, V499, P121, DOI 10.1016/j.ejphar.2004.07.056
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
   WANG F, 2006, IN PRESS NEUROPSYCHO
   WHITE FJ, 1995, J PHARMACOL EXP THER, V273, P445
NR 38
TC 12
Z9 28
U1 0
U2 4
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0214-0934
EI 2013-0139
J9 DRUG NEWS PERSPECT
JI Drug News Perspect.
PD MAR
PY 2007
VL 20
IS 2
BP 103
EP 108
DI 10.1358/dnp.2007.20.2.1083435
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 164MZ
UT WOS:000246239500004
PM 17440633
DA 2023-06-23
ER

PT J
AU Mandyam, CD
   Koob, GF
AF Mandyam, Chitra D.
   Koob, George F.
TI The addicted brain craves new neurons: putative role for adult-born
   progenitors in promoting recovery
SO TRENDS IN NEUROSCIENCES
LA English
DT Review
DE Prefrontal cortex; Gliogenesis; Hippocampus; Neurogenesis; Addiction
ID MEDIAL PREFRONTAL CORTEX; INCREASES CELL-PROLIFERATION; VENTRAL
   TEGMENTAL AREA; HIPPOCAMPAL STEM-CELLS; DENTATE GYRUS; COCAINE-SEEKING;
   ALCOHOL DEPENDENCE; AEROBIC EXERCISE; DRUG-ADDICTION; RAT HIPPOCAMPUS
AB Addiction is a chronic relapsing disorder associated with compulsive drug taking, drug seeking and a loss of control in limiting intake, reflected in three stages of a recurrent cycle: binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation ("craving"). This review discusses the role of adult-born neural and glial progenitors in drug seeking associated with the different stages of the addiction cycle. A review of the current literature suggests that the loss of newly born progenitors, particularly in hippocampal and cortical regions, plays a role in determining vulnerability to relapse in rodent models of drug addiction. The normalization of drug-impaired neurogenesis or gliogenesis may help reverse neuroplasticity during abstinence and, thus, may help reduce the vulnerability to relapse and aid recovery.
C1 [Mandyam, Chitra D.; Koob, George F.] Scripps Res Inst, Comm Neurobiol Addict Disorders, La Jolla, CA 92037 USA.
C3 Scripps Research Institute
RP Mandyam, CD (通讯作者)，Scripps Res Inst, Comm Neurobiol Addict Disorders, La Jolla, CA 92037 USA.
EM cmandyam@scripps.edu
RI mandyam, chitra D/C-9189-2013
OI mandyam, chitra D/0000-0002-7354-205X
FU National Institute on Drug Abuse [DA022473, DA004398, DA023597,
   DA010072]; National Institute on Alcohol Abuse and Alcoholism [AA008459,
   AA006420]; Pearson Center for Alcoholism and Addiction Research
FX Preparation of this review was supported by funds from the National
   Institute on Drug Abuse (DA022473 to C.D.M. and DA004398, DA023597, and
   DA010072 to G.F.K.), National Institute on Alcohol Abuse and Alcoholism
   (AA008459 and AA006420 to G.F.K) and Pearson Center for Alcoholism and
   Addiction Research (to G.F.K.). We appreciate the editorial assistance
   of Michael Arends. This is publication number 21090 from The Scripps
   Research Institute.
CR Ables JL, 2010, J NEUROSCI, V30, P10484, DOI 10.1523/JNEUROSCI.4721-09.2010
   Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003
   Abrous DN, 2002, J NEUROSCI, V22, P3656
   Aimone JB, 2006, NAT NEUROSCI, V9, P723, DOI 10.1038/nn1707
   Aimone JB, 2011, NEURON, V70, P589, DOI 10.1016/j.neuron.2011.05.010
   Alexson TO, 2006, DEV NEUROSCI-BASEL, V28, P34, DOI 10.1159/000090751
   ALTMAN J, 1969, J COMP NEUROL, V136, P269, DOI 10.1002/cne.901360303
   Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4
   Alvarez-Buylla A, 2000, Prog Brain Res, V127, P1
   Baker DA, 2003, NAT NEUROSCI, V6, P743, DOI 10.1038/nn1069
   Banasr M, 2007, BIOL PSYCHIAT, V62, P496, DOI 10.1016/j.biopsych.2007.02.006
   Barkho BZ, 2006, STEM CELLS DEV, V15, P407, DOI 10.1089/scd.2006.15.407
   Benarroch EE, 2005, MAYO CLIN PROC, V80, P1326, DOI 10.4065/80.10.1326
   Berglind WJ, 2007, EUR J NEUROSCI, V26, P757, DOI 10.1111/j.1460-9568.2007.05692.x
   Black YD, 2004, BEHAV BRAIN RES, V151, P225, DOI 10.1016/j.bbr.2003.08.020
   Breunig JJ, 2007, P NATL ACAD SCI USA, V104, P20558, DOI 10.1073/pnas.0710156104
   Brown RA, 2009, BEHAV MODIF, V33, P220, DOI 10.1177/0145445508329112
   Brown TE, 2010, NEUROSCI LETT, V481, P41, DOI 10.1016/j.neulet.2010.06.048
   Burmeister JJ, 2003, PSYCHOPHARMACOLOGY, V168, P146, DOI 10.1007/s00213-002-1307-8
   Burns KA, 2009, GLIA, V57, P1115, DOI 10.1002/glia.20835
   Caine S.B., 1993, INTRAVENOUS DRUG SEL
   Cameron H, 1996, J COMP NEUROL, V369, P56, DOI 10.1002/(SICI)1096-9861(19960520)369:1<56::AID-CNE4>3.0.CO;2-J
   CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D
   Canales JJ, 2007, EUR ARCH PSY CLIN N, V257, P261, DOI 10.1007/s00406-007-0730-6
   Canales JJ, 2010, BEHAV PHARMACOL, V21, P379, DOI 10.1097/FBP.0b013e32833e16b6
   Castilla-Ortega E, 2011, REV NEUROSCIENCE, V22, P267, DOI 10.1515/RNS.2011.027
   Catlow BJ, 2010, EUR J PHARMACOL, V628, P96, DOI 10.1016/j.ejphar.2009.11.017
   Chehrehasa F, 2009, J NEUROSCI METH, V177, P122, DOI 10.1016/j.jneumeth.2008.10.006
   Chung W.S., 2011, CURR OPIN NEUROBIOL, DOI S0959-4388(11)00158-9
   Churchwell JC, 2010, NEUROBIOL LEARN MEM, V93, P415, DOI 10.1016/j.nlm.2009.12.008
   Cosgrove KP, 2002, PHARMACOL BIOCHEM BE, V73, P663, DOI 10.1016/S0091-3057(02)00853-5
   Crews FT, 2004, ALCOHOL, V33, P63, DOI 10.1016/j.alcohol.2004.04.005
   Crews FT, 2009, ALCOHOL ALCOHOLISM, V44, P115, DOI 10.1093/alcalc/agn079
   Czeh B, 2007, NEUROPSYCHOPHARMACOL, V32, P1490, DOI 10.1038/sj.npp.1301275
   D'Ambrosio R, 1998, J NEUROSCI, V18, P4425
   Davis BA, 2008, PHARMACOL BIOCHEM BE, V90, P331, DOI 10.1016/j.pbb.2008.03.008
   Dayer AG, 2005, J CELL BIOL, V168, P415, DOI 10.1083/jcb.200407053
   Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822
   Duan X, 2007, CELL, V130, P1146, DOI 10.1016/j.cell.2007.07.010
   Eisch AJ, 2006, HIPPOCAMPUS, V16, P271, DOI 10.1002/hipo.20161
   Eisch AJ, 2000, P NATL ACAD SCI USA, V97, P7579, DOI 10.1073/pnas.120552597
   Eisch AJ, 2007, CURR PHARM BIOTECHNO, V8, P147
   Enomoto A, 2009, NEURON, V63, P774, DOI 10.1016/j.neuron.2009.08.015
   Flagel SB, 2010, NEUROPSYCHOPHARMACOL, V35, P388, DOI 10.1038/npp.2009.142
   Floresco SB, 2001, J NEUROSCI, V21, P4915, DOI 10.1523/JNEUROSCI.21-13-04915.2001
   Fuchs RA, 2005, NEUROPSYCHOPHARMACOL, V30, P296, DOI 10.1038/sj.npp.1300579
   Gabbott PLA, 2005, J COMP NEUROL, V492, P145, DOI 10.1002/cne.20738
   Garcia-Fuster MJ, 2010, EUR J NEUROSCI, V31, P79, DOI 10.1111/j.1460-9568.2009.07045.x
   Ge WP, 2006, SCIENCE, V312, P1533, DOI 10.1126/science.1124669
   GORDON AS, 1990, ARCH OTOLARYNGOL, V116, P1415
   Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365
   Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548
   Hansson AC, 2010, INT J NEUROPSYCHOPH, V13, P583, DOI 10.1017/S1461145710000246
   Hernandez-Rabaza V, 2008, NEUROBIOL LEARN MEM, V90, P553, DOI 10.1016/j.nlm.2008.06.008
   Herrera DG, 2003, P NATL ACAD SCI USA, V100, P7919, DOI 10.1073/pnas.1230907100
   Hiranita T, 2006, P NATL ACAD SCI USA, V103, P8523, DOI 10.1073/pnas.0600347103
   Hoehn BD, 2005, STROKE, V36, P2718, DOI 10.1161/01.STR.0000190020.30282.cc
   Hoglinger GU, 2004, NAT NEUROSCI, V7, P726, DOI 10.1038/nn1265
   Hsieh J, 2010, NEUROBIOL DIS, V39, P73, DOI 10.1016/j.nbd.2010.01.008
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Jessberger S, 2009, LEARN MEMORY, V16, P147, DOI 10.1101/lm.1172609
   Jessberger S, 2008, PLOS BIOL, V6, P2465, DOI 10.1371/journal.pbio.0060272
   Johnson MA, 2009, BMB REP, V42, P245, DOI 10.5483/BMBRep.2009.42.5.245
   Garcia-Fuster MJ, 2011, NEUROPSYCHOPHARMACOL, V36, P2303, DOI 10.1038/npp.2011.119
   Kalivas PW, 2011, MOL PSYCHIATR, V16, P974, DOI 10.1038/mp.2011.46
   KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941
   Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013
   Kim W.R., 2011, BEHAV BRAIN RES, DOI S0166-4328(11)00528-6
   Kippin TE, 2008, NEUROPSYCHOPHARMACOL, V33, P769, DOI 10.1038/sj.npp.1301447
   Knackstedt LA, 2009, CURR OPIN PHARMACOL, V9, P59, DOI 10.1016/j.coph.2008.12.003
   Kodamo M, 2004, BIOL PSYCHIAT, V56, P570, DOI 10.1016/j.biopsych.2004.07.008
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Koob GF, 1999, ANN NY ACAD SCI, V897, P27, DOI 10.1111/j.1749-6632.1999.tb07876.x
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Koya E, 2009, NEUROPHARMACOLOGY, V56, P177, DOI 10.1016/j.neuropharm.2008.04.022
   Lagace DC, 2008, P NATL ACAD SCI USA, V105, P18567, DOI 10.1073/pnas.0810137105
   Leasure JL, 2010, ALCOHOL CLIN EXP RES, V34, P404, DOI 10.1111/j.1530-0277.2009.01105.x
   Lemaire V, 2000, P NATL ACAD SCI USA, V97, P11032, DOI 10.1073/pnas.97.20.11032
   Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108
   Luo AH, 2011, SCIENCE, V333, P353, DOI 10.1126/science.1204622
   Lynch WJ, 2010, BIOL PSYCHIAT, V68, P774, DOI 10.1016/j.biopsych.2010.06.022
   Madsen TM, 2005, NEUROPSYCHOPHARMACOL, V30, P27, DOI 10.1038/sj.npp.1300565
   Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083
   Mandyam CD, 2007, J NEUROSCI, V27, P11442, DOI 10.1523/JNEUROSCI.2505-07.2007
   Mandyam CD, 2008, BIOL PSYCHIAT, V64, P958, DOI 10.1016/j.biopsych.2008.04.010
   Mandyam CD, 2008, DEV NEUROBIOL, V68, P575, DOI 10.1002/dneu.20600
   Maslov AY, 2004, J NEUROSCI, V24, P1726, DOI 10.1523/JNEUROSCI.4608-03.2004
   MCDONALD RJ, 1993, BEHAV NEUROSCI, V107, P3, DOI 10.1037/0735-7044.107.1.3
   McFarland K, 2001, J NEUROSCI, V21, P8655
   MCMILLAN DE, 1995, DRUG ALCOHOL DEPEN, V40, P1, DOI 10.1016/0376-8716(95)01162-5
   Miller M.L., 2011, DRUG ALCOHOL DEPEND, DOI S0376-8716(11)00358-9
   MIYAKE T, 1992, BRAIN RES, V590, P300, DOI 10.1016/0006-8993(92)91109-R
   Mu YL, 2011, J NEUROSCI, V31, P4113, DOI 10.1523/JNEUROSCI.4913-10.2011
   Nishiyama A, 2005, J ANAT, V207, P687, DOI 10.1111/j.1469-7580.2005.00489.x
   Nixon K, 2008, NEUROBIOL DIS, V31, P218, DOI 10.1016/j.nbd.2008.04.009
   Nixon K, 2006, HIPPOCAMPUS, V16, P287, DOI 10.1002/hipo.20162
   Nixon K, 2004, J NEUROSCI, V24, P9714, DOI 10.1523/JNEUROSCI.3063-04.2004
   Noonan MA, 2008, J NEUROSCI, V28, P2516, DOI 10.1523/JNEUROSCI.4661-07.2008
   Noonan MA, 2010, J NEUROSCI, V30, P304, DOI 10.1523/JNEUROSCI.4256-09.2010
   Ongur D, 2007, BIOL PSYCHIAT, V62, P505, DOI 10.1016/j.biopsych.2006.11.014
   Potter H, 1979, Curr Alcohol, V7, P261
   Pow DV, 2001, GLIA, V34, P27, DOI 10.1002/glia.1037
   Rhodes JS, 2005, BEHAV NEUROSCI, V119, P759, DOI 10.1037/0735-7044.119.3.759
   Richardson HN, 2009, NEUROBIOL DIS, V36, P1, DOI 10.1016/j.nbd.2009.05.021
   ROSSI NA, 1976, PHYSIOL PSYCHOL, V4, P269
   Rupp CI, 2006, ALCOHOL CLIN EXP RES, V30, P1355, DOI 10.1111/j.1530-0277.2006.00162.x
   Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   Shors TJ, 2002, HIPPOCAMPUS, V12, P578, DOI 10.1002/hipo.10103
   Simons JS, 2003, NAT REV NEUROSCI, V4, P637, DOI 10.1038/nrn1178
   Smith M.A., 2011, DRUG ALCOHOL DEPEND, DOI S0376-8716(11)00350-4
   Smith MA, 2008, DRUG ALCOHOL DEPEN, V98, P129, DOI 10.1016/j.drugalcdep.2008.05.006
   Smith MA, 2011, PSYCHOPHARMACOLOGY, V218, P357, DOI 10.1007/s00213-011-2321-5
   Smith MA, 2011, PHARMACOL BIOCHEM BE, V100, P237, DOI 10.1016/j.pbb.2011.08.025
   Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a
   SONTHEIMER H, 1993, J NEUROPHYSIOL, V70, P1863, DOI 10.1152/jn.1993.70.5.1863
   Steiner B, 2006, GLIA, V54, P805, DOI 10.1002/glia.20407
   Stewart CV, 2006, J NEUROSCI, V26, P8148, DOI 10.1523/JNEUROSCI.0723-06.2006
   Sudai E, 2011, ADDICT BIOL, V16, P251, DOI 10.1111/j.1369-1600.2010.00241.x
   Taepavarapruk P, 2000, PSYCHOPHARMACOLOGY, V151, P242, DOI 10.1007/s002130000376
   Taffe MA, 2010, P NATL ACAD SCI USA, V107, P11104, DOI 10.1073/pnas.0912810107
   Taylor AH, 2007, ADDICTION, V102, P534, DOI 10.1111/j.1360-0443.2006.01739.x
   Taylor AH, 2005, PSYCHOPHARMACOLOGY, V181, P1, DOI 10.1007/s00213-005-2216-4
   Thiel KJ, 2009, INT J NEUROPSYCHOPH, V12, P1151, DOI 10.1017/S1461145709990472
   Ussher MH, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002295.pub3
   van Praag H, 2008, NEUROMOL MED, V10, P128, DOI 10.1007/s12017-008-8028-z
   Vorel SR, 2001, SCIENCE, V292, P1175, DOI 10.1126/science.1058043
   Wigley R, 2007, J ANAT, V210, P661, DOI 10.1111/j.1469-7580.2007.00729.x
   Yuan XQ, 1998, DEVELOPMENT, V125, P2901
   Zlebnik NE, 2010, PSYCHOPHARMACOLOGY, V209, P113, DOI 10.1007/s00213-010-1776-0
NR 130
TC 96
Z9 96
U1 1
U2 24
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0166-2236
EI 1878-108X
J9 TRENDS NEUROSCI
JI Trends Neurosci.
PD APR
PY 2012
VL 35
IS 4
BP 250
EP 260
DI 10.1016/j.tins.2011.12.005
PG 11
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 928GT
UT WOS:000302971900005
PM 22265158
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Pickard, H
   Ahmed, SH
   Foddy, B
AF Pickard, Hanna
   Ahmed, Serge H.
   Foddy, Bennett
TI Alternative models of addiction
SO FRONTIERS IN PSYCHIATRY
LA English
DT Editorial Material
DE drugs; addiction; disease; choice; compulsion; self-control; substance
   abuse; substance dependence
C1 [Pickard, Hanna] Univ Birmingham, Birmingham, W Midlands, England.
   [Ahmed, Serge H.] Univ Bordeaux, IMN CNRS UMR 5293, Bordeaux, France.
   [Foddy, Bennett] NYU, New York, NY USA.
C3 University of Birmingham; Centre National de la Recherche Scientifique
   (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French
   Research Universities; Universite de Bordeaux; New York University
RP Pickard, H (通讯作者)，Univ Birmingham, Birmingham, W Midlands, England.
EM h.pickard@gmail.com
OI Ahmed, Serge/0000-0002-1225-9234; Pickard, Hanna/0000-0001-5926-1377
CR Ainslie George, 2013, Front Psychiatry, V4, P63, DOI 10.3389/fpsyt.2013.00063
   Dill Brendan, 2014, Front Psychiatry, V5, P139, DOI 10.3389/fpsyt.2014.00139
   Flanagan Owen, 2013, Front Psychiatry, V4, P120, DOI 10.3389/fpsyt.2013.00120
   Hagen EH, 2013, FRONT PSYCHIATRY, V4, DOI 10.3389/fpsyt.2013.00142
   Henden Edmund, 2013, Front Psychiatry, V4, P77, DOI 10.3389/fpsyt.2013.00077
   Heyman GM, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00070
   Heyman Gene M, 2013, Front Psychiatry, V4, P31, DOI 10.3389/fpsyt.2013.00031
   Levy Neil, 2013, Front Psychiatry, V4, P24, DOI 10.3389/fpsyt.2013.00024
   Satel S, 2014, FRONT PSYCHIATRY, V4, DOI 10.3389/fpsyt.2013.00141
   Wakefield JC, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00010
   Zernig Gerald, 2013, Front Psychiatry, V4, P100, DOI 10.3389/fpsyt.2013.00100
NR 11
TC 12
Z9 13
U1 3
U2 16
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD FEB 13
PY 2015
VL 6
AR 20
DI 10.3389/fpsyt.2015.00020
PG 2
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA CV3YY
UT WOS:000364203800001
PM 25741288
OA gold, Green Published
DA 2023-06-23
ER

PT J
AU Loganathan, K
   Ho, ETW
AF Loganathan, Kavinash
   Ho, Eric Tatt Wei
TI Value, drug addiction and the brain
SO ADDICTIVE BEHAVIORS
LA English
DT Review
DE Drug addiction; Valuation; Neuroimaging; Neurobiology; Cycle of
   Addiction
ID INCENTIVE-SENSITIZATION THEORY; RANDOMIZED CONTROLLED-TRIAL; COGNITIVE
   BIAS MODIFICATION; WORKING-MEMORY; DECISION-MAKING; PREFRONTAL CORTEX;
   ATTENTIONAL BIAS; TOP-DOWN; ALTERNATIVE REINFORCER; VALUATION NETWORKS
AB Over the years, various models have been proposed to explain the psychology and biology of drug addiction, built primarily around the habit and compulsion models. Recent research indicates drug addiction may be goal directed, motivated by excessive valuation of drugs. Drug consumption may initially occur for the sake of pleasure but may transition to a means of escaping withdrawal, stress and negative emotions. In this hypothetical paper, we propose a value-based neurobiological model for drug addiction. We posit that during dependency, the value-based decision-making system in the brain is not inactive but has instead prioritized drugs as the reward of choice. In support of this model, we consider the role of valuation in choice, its influence on pleasure and punishment, and how valuation is contrasted in impulsive and compulsive behaviours. We then discuss the neurobiology of value, beginning with the dopaminergic system and its relationship with incentive salience before moving to brain-wide networks involved in valuation, control and prospection. These value-based neurobiological components are then integrated into the cycle of addiction as we consider the development of drug dependency from a valuation perspective. We conclude with a discussion of cognitive interventions utilizing value-based decision-making, highlighting not just advances in recalibrating the valuation system to focus on non-drug rewards, but also areas for improvement in refining this approach.
C1 [Loganathan, Kavinash; Ho, Eric Tatt Wei] Univ Teknol Petronas, Ctr Intelligent Signal & Imaging, Bandar Seri Iskandar 32610, Perak, Malaysia.
   [Ho, Eric Tatt Wei] Univ Teknol Petronas, Dept Elect & Elect Engn, Perak, Malaysia.
C3 Universiti Teknologi Petronas; Universiti Teknologi Petronas
RP Loganathan, K (通讯作者)，Univ Teknol Petronas, Ctr Intelligent Signal & Imaging, Bandar Seri Iskandar 32610, Perak, Malaysia.
EM kavinash@gmail.com
OI Ho, Eric Tatt Wei/0000-0002-7590-1028
FU IBRO-APRC; Yayasan Universiti Teknologi PETRONAS (YUTP); Ministry of
   Higher Education, Malaysia through the Higher Institution Center of
   Excellence (HI-CoE) program; YUTP-Fundamental Research Grant award
FX Kavinash Loganathan is grateful to IBRO-APRC and Yayasan Universiti
   Teknologi PETRONAS (YUTP) for funding to undertake this study. Eric Tatt
   Wei Ho gratefully acknowledges the Ministry of Higher Education,
   Malaysia, for funding through the Higher Institution Center of
   Excellence (HI-CoE) program awarded to the Center for Intelligent Signal
   & Imaging Research, Universiti Teknologi PETRONAS, and the
   YUTP-Fundamental Research Grant award.
CR Addicott MA, 2012, PSYCHOPHARMACOLOGY, V219, P563, DOI 10.1007/s00213-011-2404-3
   Aguirre CG, 2015, J ABNORM PSYCHOL, V124, P623, DOI 10.1037/abn0000060
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   AINSLIE G, 1975, PSYCHOL BULL, V82, P463, DOI 10.1037/h0076860
   Alfonso JP, 2011, DRUG ALCOHOL DEPEN, V117, P78, DOI 10.1016/j.drugalcdep.2010.12.025
   Aloi J, 2021, ADDICT BIOL, V26, DOI 10.1111/adb.12885
   Anderson N. D., 2000, OXFORD HDB MEMORY
   Anselme P, 2016, NEUROSCI BIOBEHAV R, V65, P1, DOI 10.1016/j.neubiorev.2016.03.014
   Argyriou E, 2018, PHARMACOL BIOCHEM BE, V164, P106, DOI 10.1016/j.pbb.2017.07.013
   Ashby FG, 2011, J MATH PSYCHOL, V55, P273, DOI 10.1016/j.jmp.2011.04.003
   Augier E, 2018, SCIENCE, V360, P1321, DOI 10.1126/science.aao1157
   Awh E, 2012, TRENDS COGN SCI, V16, P437, DOI 10.1016/j.tics.2012.06.010
   Bai YJ, 2019, PSYCHOPHARMACOLOGY, V236, P3197, DOI 10.1007/s00213-019-05272-6
   Barlow RL, 2018, INT J NEUROPSYCHOPH, V21, P705, DOI 10.1093/ijnp/pyy030
   Bauml JG, 2019, BIOL PSYCHIAT-COGN N, V4, P333, DOI 10.1016/j.bpsc.2018.11.005
   Bechara A, 2019, PSYCHOL SCI PUBL INT, V20, P96, DOI 10.1177/1529100619860513
   Beck AT, 2002, CLINICAL ADVANCES IN COGNITIVE PSYCHOTHERAPY: THEORY AND APPLICATION, P29
   Beckmann JS, 2015, LEARN MEMORY, V22, P116, DOI 10.1101/lm.037382.114
   Bedi G, 2015, NEUROPSYCHOPHARMACOL, V40, P2657, DOI 10.1038/npp.2015.135
   Belin D, 2011, NEUROPSYCHOPHARMACOL, V36, P569, DOI 10.1038/npp.2010.188
   Bentzley BS, 2014, P NATL ACAD SCI USA, V111, P11822, DOI 10.1073/pnas.1406324111
   Bernosky-Smith KA, 2018, BEHAV BRAIN RES, V341, P129, DOI 10.1016/j.bbr.2017.12.029
   Berridge K., 2002, PSYCHOL EC DECISIONS, V1, P17
   Berridge KC, 2008, SOC COGNITION, V26, P621, DOI 10.1521/soco.2008.26.5.621
   Berridge KC, 2016, AM PSYCHOL, V71, P670, DOI 10.1037/amp0000059
   Berridge KC, 2015, NEURON, V86, P646, DOI 10.1016/j.neuron.2015.02.018
   Berridge KC, 2012, EUR J NEUROSCI, V35, P1124, DOI 10.1111/j.1460-9568.2012.07990.x
   Betts JM, 2019, DRUG ALCOHOL DEPEN, V204, DOI 10.1016/j.drugalcdep.2019.04.040
   Bickel WK, 2012, PHARMACOL THERAPEUT, V134, P287, DOI 10.1016/j.pharmthera.2012.02.004
   Bickel WK, 2011, BIOL PSYCHIAT, V69, P260, DOI 10.1016/j.biopsych.2010.08.017
   Boileau I, 2006, ARCH GEN PSYCHIAT, V63, P1386, DOI 10.1001/archpsyc.63.12.1386
   Brandon TH, 2007, ANNU REV CLIN PSYCHO, V3, P257, DOI 10.1146/annurev.clinpsy.3.022806.091455
   Breiter HC, 1997, NEURON, V19, P591, DOI 10.1016/S0896-6273(00)80374-8
   Brevers D, 2015, BEHAV BRAIN RES, V278, P262, DOI 10.1016/j.bbr.2014.09.026
   Brevers D, 2014, ADDICT BEHAV, V39, P1533, DOI 10.1016/j.addbeh.2014.06.004
   Brooks SJ, 2017, PROG BRAIN RES, V235, P177, DOI 10.1016/bs.pbr.2017.08.002
   Cabanac M, 2010, PLEASURES BRAIN, P113
   Castrellon JJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56858-1
   Castrellon JJ, 2019, J NEUROSCI, V39, P321, DOI 10.1523/JNEUROSCI.1984-18.2018
   Chamberlain SR, 2006, AM J PSYCHIAT, V163, P1282, DOI 10.1176/appi.ajp.163.7.1282
   Christensen CJ, 2008, PHARMACOL BIOCHEM BE, V91, P209, DOI 10.1016/j.pbb.2008.07.009
   Claus ED, 2011, NEUROPSYCHOPHARMACOL, V36, P2086, DOI 10.1038/npp.2011.99
   Clerkin EM, 2016, BEHAV RES THER, V87, P58, DOI 10.1016/j.brat.2016.08.010
   Collins AGE, 2012, EUR J NEUROSCI, V35, P1024, DOI 10.1111/j.1460-9568.2011.07980.x
   Cuthbert BN, 2000, BIOL PSYCHOL, V52, P95, DOI 10.1016/S0301-0511(99)00044-7
   Dalley JW, 2011, NEURON, V69, P680, DOI 10.1016/j.neuron.2011.01.020
   Dang LC, 2018, COGN AFFECT BEHAV NE, V18, P739, DOI 10.3758/s13415-018-0601-9
   Davis M, 2010, NEUROPSYCHOPHARMACOL, V35, P105, DOI 10.1038/npp.2009.109
   de Lisle SM, 2012, J GAMBL STUD, V28, P719, DOI 10.1007/s10899-011-9284-7
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Dickinson A, 2002, Q J EXP PSYCHOL-B, V55, P331, DOI 10.1080/0272499024400016
   Dissabandara LO, 2014, ADDICT BEHAV, V39, P71, DOI 10.1016/j.addbeh.2013.06.009
   Dunning JP, 2011, EUR J NEUROSCI, V33, P1716, DOI 10.1111/j.1460-9568.2011.07663.x
   Egecioglu E, 2011, REV ENDOCR METAB DIS, V12, P141, DOI 10.1007/s11154-011-9166-4
   Everitt BJ, 2016, ANNU REV PSYCHOL, V67, P23, DOI 10.1146/annurev-psych-122414-033457
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Ewing SWF, 2011, J STUD ALCOHOL DRUGS, V72, P903, DOI 10.15288/jsad.2011.72.903
   Fiabane E, 2017, NEUROPSYCH DIS TREAT, V13, P2497, DOI 10.2147/NDT.S137766
   Field M, 2020, PSYCHOL ADDICT BEHAV, V34, P182, DOI 10.1037/adb0000518
   Fisher NR, 2017, APPETITE, V118, P41, DOI 10.1016/j.appet.2017.07.019
   Foltin RW, 2019, PHARMACOL BIOCHEM BE, V177, P20, DOI 10.1016/j.pbb.2018.12.008
   Foti D, 2009, PSYCHOPHYSIOLOGY, V46, P521, DOI 10.1111/j.1469-8986.2009.00796.x
   Gardner EL, 2011, ADV PSYCHOSOM MED, V30, P22, DOI 10.1159/000324065
   Garland EL, 2018, ADDICT SCI CLIN PRAC, V13, DOI 10.1186/s13722-018-0115-3
   Genauck A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16433-y
   Gladwin TE, 2017, CURR OPIN BEHAV SCI, V13, P19, DOI 10.1016/j.cobeha.2016.08.001
   Goldstein RZ, 2009, P NATL ACAD SCI USA, V106, P9453, DOI 10.1073/pnas.0900491106
   Gonzalez-Roz A, 2019, ADDICTION, V114, P1926, DOI 10.1111/add.14736
   Gonzalez-Roz A, 2020, NICOTINE TOB RES, V22, P74, DOI 10.1093/ntr/nty236
   Gray JC, 2017, SCI REP-UK, V7, DOI 10.1038/srep41930
   Gray JC, 2014, PSYCHOL ADDICT BEHAV, V28, P282, DOI 10.1037/a0032766
   Haber SN, 2003, J CHEM NEUROANAT, V26, P317, DOI 10.1016/j.jchemneu.2003.10.003
   Hagele C, 2015, PSYCHOPHARMACOLOGY, V232, P331, DOI 10.1007/s00213-014-3662-7
   Halcomb ME, 2019, PSYCHIAT RES-NEUROIM, V284, P21, DOI 10.1016/j.pscychresns.2018.12.016
   Hardy L, 2017, PSYCHOPHARMACOLOGY, V234, P1977, DOI 10.1007/s00213-017-4605-x
   Harkness JH, 2010, PSYCHOPHARMACOLOGY, V208, P521, DOI 10.1007/s00213-009-1755-5
   Harricharan R, 2017, PROG BRAIN RES, V235, P65, DOI 10.1016/bs.pbr.2017.07.012
   Helie S, 2017, ANN NY ACAD SCI, V1395, P33, DOI 10.1111/nyas.13327
   Hellberg SN, 2019, COGN AFFECT BEHAV NE, V19, P737, DOI 10.3758/s13415-018-00662-3
   Heyman Gene M., 2009, ADDICTION DISORDER C, DOI [10.4159/9780674053991, DOI 10.4159/9780674053991]
   HIGGINS ST, 1994, LIFE SCI, V55, P179, DOI 10.1016/0024-3205(94)00878-7
   Hogarth L, 2020, BEHAV BRAIN RES, V394, DOI 10.1016/j.bbr.2020.112815
   Hogarth L, 2020, NEUROPSYCHOPHARMACOL, V45, P720, DOI 10.1038/s41386-020-0600-8
   Hogarth L, 2018, PSYCHOPHARMACOLOGY, V235, P2257, DOI 10.1007/s00213-018-4922-8
   Hogarth L, 2015, PSYCHOPHARMACOLOGY, V232, P3235, DOI 10.1007/s00213-015-3977-z
   Huys QJM, 2017, BIOL PSYCHIAT, V82, P413, DOI 10.1016/j.biopsych.2017.07.003
   Huys QJM, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002028
   Hyatt CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034917
   Izard CE, 2007, PERSPECT PSYCHOL SCI, V2, P260, DOI [10.1111/j.1745-6916.2007.00044.x, 10.1111/j.1745-6916.2007.00053.x]
   Jackson KJ, 2013, PSYCHOPHARMACOLOGY, V226, P763, DOI 10.1007/s00213-012-2716-y
   James MH, 2019, EUR J NEUROSCI, V50, P2602, DOI 10.1111/ejn.14166
   Janes AC, 2010, NEUROPSYCHOPHARMACOL, V35, P2339, DOI 10.1038/npp.2010.103
   Jasinska AJ, 2014, NEUROSCI BIOBEHAV R, V38, P1, DOI 10.1016/j.neubiorev.2013.10.013
   Jennings JH, 2013, NATURE, V496, P224, DOI 10.1038/nature12041
   Jocham G, 2011, J NEUROSCI, V31, P1606, DOI 10.1523/JNEUROSCI.3904-10.2011
   Jones S, 2020, NUTR RES, V79, P1, DOI 10.1016/j.nutres.2020.05.001
   Kable JW, 2007, NAT NEUROSCI, V10, P1625, DOI 10.1038/nn2007
   Kable JW, 2010, J NEUROPHYSIOL, V103, P2513, DOI 10.1152/jn.00177.2009
   Kable JW, 2009, NEURON, V63, P733, DOI 10.1016/j.neuron.2009.09.003
   Kakade S, 2002, NEURAL NETWORKS, V15, P549, DOI 10.1016/S0893-6080(02)00048-5
   Kasanetz F, 2010, SCIENCE, V328, P1709, DOI 10.1126/science.1187801
   Kearns DN, 2017, ADDICT BIOL, V22, P1501, DOI 10.1111/adb.12450
   Kim S, 2009, NEURAL NETWORKS, V22, P294, DOI 10.1016/j.neunet.2009.03.010
   Kober H, 2016, NEUROPSYCHOPHARMACOL, V41, P628, DOI 10.1038/npp.2015.193
   Koob GF, 2017, PSYCHOPHARMACOLOGY, V234, P1315, DOI 10.1007/s00213-016-4484-6
   Koob GF, 2015, EUR J PHARMACOL, V753, P73, DOI 10.1016/j.ejphar.2014.11.044
   Koob GF, 2014, NEUROPHARMACOLOGY, V76, P370, DOI 10.1016/j.neuropharm.2013.05.024
   Koob GF, 1999, ANN NY ACAD SCI, V877, P445, DOI 10.1111/j.1749-6632.1999.tb09282.x
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Kufahl PR, 2005, NEUROIMAGE, V28, P904, DOI 10.1016/j.neuroimage.2005.06.039
   Kuhn S, 2011, EUR J NEUROSCI, V33, P1318, DOI 10.1111/j.1460-9568.2010.07590.x
   Laibson D, 1997, Q J ECON, V112, P443, DOI 10.1162/003355397555253
   Lang PJ, 2013, EMOT REV, V5, P230, DOI 10.1177/1754073913477511
   Langenecker SA, 2020, DRUG ALCOHOL DEPEN, V206, DOI 10.1016/j.drugalcdep.2019.107725
   Laurent V, 2015, BRIT J PHARMACOL, V172, P449, DOI 10.1111/bph.12818
   Lawn W, 2020, ADDICT BIOL, V25, DOI 10.1111/adb.12802
   Leknes S, 2008, NAT REV NEUROSCI, V9, P314, DOI 10.1038/nrn2333
   Lempert KM, 2019, PSYCHOL MED, V49, P190, DOI 10.1017/S0033291718001770
   Levine B, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00009
   Levy DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053978
   Levy DJ, 2012, CURR OPIN NEUROBIOL, V22, P1027, DOI 10.1016/j.conb.2012.06.001
   Leyton M, 2014, TRENDS PHARMACOL SCI, V35, P268, DOI 10.1016/j.tips.2014.04.002
   Li JA, 2020, NAT HUM BEHAV, V4, P294, DOI 10.1038/s41562-019-0804-2
   Li Jing, 2019, Int J Physiol Pathophysiol Pharmacol, V11, P163
   Li Q, 2015, ADDICT BIOL, V20, P968, DOI 10.1111/adb.12182
   Liang CW, 2014, ADDICTION, V109, P1355, DOI 10.1111/add.12591
   Liu L, 2019, BRAIN RES, V1704, P59, DOI 10.1016/j.brainres.2018.09.024
   Lu L, 2004, NEUROPHARMACOLOGY, V47, P214, DOI 10.1016/j.neuropharm.2004.06.027
   Lubman DI, 2008, J PSYCHOPHARMACOL, V22, P836, DOI 10.1177/0269881107083846
   Luo R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04784-7
   Lynch KS, 2020, INTEGR COMP BIOL, V60, P712, DOI 10.1093/icb/icaa054
   MacKillop J, 2016, ALCOHOL CLIN EXP RES, V40, P672, DOI 10.1111/acer.13004
   Mathews A, 2005, ANNU REV CLIN PSYCHO, V1, P167, DOI 10.1146/annurev.clinpsy.1.102803.143916
   McClure SM, 2007, J NEUROSCI, V27, P5796, DOI 10.1523/JNEUROSCI.4246-06.2007
   Mcclure SM, 2004, NEUROSCIENTIST, V10, P260, DOI 10.1177/1073858404263526
   Medic N, 2014, J NEUROSCI, V34, P16856, DOI 10.1523/JNEUROSCI.2051-14.2014
   Miendlarzewska EA, 2016, NEUROSCI BIOBEHAV R, V61, P156, DOI 10.1016/j.neubiorev.2015.11.015
   Mo C, 2018, J NEUROSCI, V38, P149, DOI 10.1523/JNEUROSCI.1206-17.2017
   Moeller FG, 2001, AM J PSYCHIAT, V158, P1783, DOI 10.1176/appi.ajp.158.11.1783
   Monem R, 2019, PSYCHOL ADDICT BEHAV, V33, P677, DOI 10.1037/adb0000522
   Monterosso J, 2012, BIOL PSYCHIAT, V72, P107, DOI 10.1016/j.biopsych.2012.03.012
   Moors A, 2013, EMOT REV, V5, P119, DOI 10.1177/1754073912468165
   Moschak TM, 2017, ENEURO, V4, DOI 10.1523/ENEURO.0119-17.2017
   Moustafa AA, 2007, COGN SYST RES, V8, P262, DOI 10.1016/j.cogsys.2007.02.001
   Navarro-Zaragoza J, 2010, MOL PHARMACOL, V77, P864, DOI 10.1124/mol.109.062463
   Nestor L, 2018, ADDICT BIOL, V23, P369, DOI 10.1111/adb.12484
   Niv Y, 2009, NEUROECONOMICS: DECISION MAKING AND THE BRAIN, P331, DOI 10.1016/B978-0-12-374176-9.00022-1
   Noel X, 2013, CURR OPIN NEUROBIOL, V23, P632, DOI 10.1016/j.conb.2013.01.018
   Nutt DJ, 2015, NAT REV NEUROSCI, V16, P305, DOI 10.1038/nrn3939
   Oleson EB, 2019, BRAIN RES, V1713, P32, DOI 10.1016/j.brainres.2018.11.043
   Oleson EB, 2012, J NEUROSCI, V32, P14804, DOI 10.1523/JNEUROSCI.3087-12.2012
   Opsal A, 2019, SUBST ABUSE TREAT PR, V14, DOI 10.1186/s13011-019-0237-y
   Owens MM, 2019, PSYCHOL BULL, V145, P141, DOI 10.1037/bul0000181
   Ozker M, 2018, ELIFE, V7, DOI 10.7554/eLife.30387
   Paulus MP, 2014, NEUROPHARMACOLOGY, V76, P342, DOI 10.1016/j.neuropharm.2013.07.002
   Paulus MP, 2005, ARCH GEN PSYCHIAT, V62, P761, DOI 10.1001/archpsyc.62.7.761
   Pelloux Y, 2007, PSYCHOPHARMACOLOGY, V194, P127, DOI 10.1007/s00213-007-0805-0
   Pelloux Y, 2015, PSYCHOPHARMACOLOGY, V232, P125, DOI 10.1007/s00213-014-3648-5
   Pessiglione M, 2006, NATURE, V442, P1042, DOI 10.1038/nature05051
   Peters J, 2010, BEHAV BRAIN RES, V213, P135, DOI 10.1016/j.bbr.2010.04.031
   Peters J, 2011, TRENDS COGN SCI, V15, P227, DOI 10.1016/j.tics.2011.03.002
   Peters J, 2010, NEURON, V66, P138, DOI 10.1016/j.neuron.2010.03.026
   Porreca F, 2017, PAIN, V158, pS43, DOI 10.1097/j.pain.0000000000000798
   Prisciandaro JJ, 2014, ADDICTION, V109, P2062, DOI 10.1111/add.12666
   Pultorak K. J., 2018, ENEURO SOC NEUROSCIE, V5
   Raichle ME, 2015, ANNU REV NEUROSCI, V38, P433, DOI 10.1146/annurev-neuro-071013-014030
   Rass O, 2015, DRUG ALCOHOL DEPEN, V156, P38, DOI 10.1016/j.drugalcdep.2015.08.012
   Redish AD, 2008, BEHAV BRAIN SCI, V31, P415, DOI 10.1017/S0140525X0800472X
   Reeves SJ, 2012, PSYCHIAT RES-NEUROIM, V202, P60, DOI 10.1016/j.pscychresns.2011.09.011
   Rinck M, 2018, J CONSULT CLIN PSYCH, V86, P1005, DOI 10.1037/ccp0000321
   Robbins TW, 2012, TRENDS COGN SCI, V16, P81, DOI 10.1016/j.tics.2011.11.009
   Roberts W, 2015, PSYCHOL ADDICT BEHAV, V29, P63, DOI 10.1037/adb0000005
   Robinson MJF, 2013, CURR BIOL, V23, P282, DOI 10.1016/j.cub.2013.01.016
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Schacter DL, 2007, NAT REV NEUROSCI, V8, P657, DOI 10.1038/nrn2213
   Schroll H, 2012, NEURAL NETWORKS, V26, P59, DOI 10.1016/j.neunet.2011.10.008
   Schultz W, 2015, PHYSIOL REV, V95, P853, DOI 10.1152/physrev.00023.2014
   Seabrooke T, 2016, Q J EXP PSYCHOL, V69, P2452, DOI 10.1080/17470218.2015.1115885
   Shoptaw S, 2014, ADDICTION, V109, P248, DOI 10.1111/add.12442
   Shorey RC, 2017, J ADDICT DIS, V36, P151, DOI 10.1080/10550887.2017.1302661
   Siegel S., 1989, PSYCHOACTIVE DRUGS T, P115
   Small DM, 2001, BRAIN, V124, P1720, DOI 10.1093/brain/124.9.1720
   Solinas M, 2019, J NEURAL TRANSM, V126, P481, DOI 10.1007/s00702-018-1957-2
   SOLOMON RL, 1974, PSYCHOL REV, V81, P119, DOI 10.1037/h0036128
   Sprague TC, 2013, NAT NEUROSCI, V16, P1879, DOI 10.1038/nn.3574
   Stein EA, 1998, AM J PSYCHIAT, V155, P1009, DOI 10.1176/ajp.155.8.1009
   Steketee JD, 2011, PHARMACOL REV, V63, P348, DOI 10.1124/pr.109.001933
   STEWART J, 1984, PHARMACOL BIOCHEM BE, V20, P917, DOI 10.1016/0091-3057(84)90017-0
   Sutton LP, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000477
   Sutton R.S., 1998, INTRO REINFORCEMENT, VVolume 2
   Sutton RS, 2018, ADAPT COMPUT MACH LE, P1
   Symmonds M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011090
   Tang YY, 2017, FRONT SYST NEUROSCI, V11, DOI 10.3389/fnsys.2017.00006
   Tau GZ, 2014, NEUROPSYCHOPHARMACOL, V39, P545, DOI 10.1038/npp.2013.189
   Tavakolian E, 2016, ARCH PSYCHIATR PSYCH, V18, P14
   Tersakyan A., 2016, PLEASANT AVERSIVE BR
   Thompson LL, 2012, DRUG ALCOHOL DEPEN, V123, P84, DOI 10.1016/j.drugalcdep.2011.10.017
   TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147
   Tobler PN, 2005, SCIENCE, V307, P1642, DOI 10.1126/science.1105370
   Trifilieff P, 2014, NEUROPHARMACOLOGY, V76, P498, DOI 10.1016/j.neuropharm.2013.06.031
   Valls-Serrano C, 2016, DRUG ALCOHOL DEPEN, V165, P9, DOI 10.1016/j.drugalcdep.2016.04.040
   van den Bos W, 2013, J EXP ANAL BEHAV, V99, P58, DOI 10.1002/jeab.6
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Vengeliene V, 2009, ADDICT BIOL, V14, P384, DOI 10.1111/j.1369-1600.2009.00177.x
   Verdejo-Garcia A, 2019, NEUROPSYCHOL REV, V29, P79, DOI 10.1007/s11065-018-9384-6
   Verdejo-Garcia A, 2009, NEUROPHARMACOLOGY, V56, P48, DOI 10.1016/j.neuropharm.2008.07.035
   Viola TW, 2020, J ADDICT MED, V14, pE37, DOI 10.1097/ADM.0000000000000599
   Volkow ND, 2005, J NEUROSCI, V25, P3932, DOI 10.1523/JNEUROSCI.0433-05.2005
   Volkow ND, 2008, NEUROIMAGE, V39, P1266, DOI 10.1016/j.neuroimage.2007.09.059
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
   Volkow ND, 2016, NEW ENGL J MED, V374, P363, DOI 10.1056/NEJMra1511480
   Weafer J, 2013, PSYCHOL ADDICT BEHAV, V27, P32, DOI 10.1037/a0028991
   Wenzel JM, 2018, CURR BIOL, V28, P1392, DOI 10.1016/j.cub.2018.03.037
   Wesley MJ, 2014, BIOL PSYCHIAT, V75, P435, DOI 10.1016/j.biopsych.2013.08.008
   Wiers CE, 2015, AM J PSYCHIAT, V172, P335, DOI 10.1176/appi.ajp.2014.13111495
   Wiers RW, 2011, PSYCHOL SCI, V22, P490, DOI 10.1177/0956797611400615
   Wikler A., 1984, J SUBST ABUSE TREAT, V1, P279, DOI [10.1016/0740-5472(84)90008-4, DOI 10.1016/0740-5472(84)90008-4]
   Wise RA, 2014, NEUROPSYCHOPHARMACOL, V39, P254, DOI 10.1038/npp.2013.261
   Wolf ME, 2016, NAT REV NEUROSCI, V17, P351, DOI 10.1038/nrn.2016.39
   Wong DF, 2006, NEUROPSYCHOPHARMACOL, V31, P2716, DOI 10.1038/sj.npp.1301194
   Wood W, 2016, ANNU REV PSYCHOL, V67, P289, DOI 10.1146/annurev-psych-122414-033417
   Wrase J, 2007, NEUROIMAGE, V35, P787, DOI 10.1016/j.neuroimage.2006.11.043
   Xie C, 2014, MOL PSYCHIATR, V19, P10, DOI 10.1038/mp.2012.169
   Xie CM, 2011, BEHAV BRAIN RES, V216, P639, DOI 10.1016/j.bbr.2010.09.004
   Young KS, 2020, Q J EXP PSYCHOL, V73, P1066, DOI 10.1177/1747021819890289
   Zellner MR, 2011, NEUROSCI BIOBEHAV R, V35, P2000, DOI 10.1016/j.neubiorev.2011.01.003
   Zhai TY, 2014, BEHAV BRAIN RES, V272, P209, DOI 10.1016/j.bbr.2014.06.054
   Zhai TY, 2015, NEUROIMAGE, V115, P76, DOI 10.1016/j.neuroimage.2015.04.060
   Zhang RY, 2020, APPETITE, V150, DOI 10.1016/j.appet.2020.104660
   Zhang SY, 2016, NAT NEUROSCI, V19, P1733, DOI 10.1038/nn.4417
   Zilverstand A, 2018, NEURON, V98, P886, DOI 10.1016/j.neuron.2018.03.048
   Zvorsky I, 2019, PREV MED, V128, DOI 10.1016/j.ypmed.2019.105789
NR 232
TC 4
Z9 4
U1 15
U2 73
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4603
EI 1873-6327
J9 ADDICT BEHAV
JI Addict. Behav.
PD MAY
PY 2021
VL 116
AR 106816
DI 10.1016/j.addbeh.2021.106816
EA JAN 2021
PG 11
WC Psychology, Clinical; Substance Abuse
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology; Substance Abuse
GA TI1RG
UT WOS:000672561700018
PM 33453587
DA 2023-06-23
ER

PT J
AU Batra, A
AF Batra, Anil
TI Research Award of the German Society for Drug Addiction Research and
   Addiction Therapy (DG-Sucht)
SO SUCHTTHERAPIE
LA German
DT Editorial Material
C1 Univ Klin Psychiat & Psychotherapie, Sekt Suchtforsch & Med, DG Sucht, D-72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital
RP Batra, A (通讯作者)，Univ Klin Psychiat & Psychotherapie, Sekt Suchtforsch & Med, DG Sucht, Calwer Str 14, D-72076 Tubingen, Germany.
EM sucht@med.uni-tuebingen.de
NR 0
TC 0
Z9 0
U1 0
U2 1
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 1439-9903
J9 SUCHTTHERAPIE
JI Suchttherapie
PD MAY
PY 2012
VL 13
IS 2
BP 53
EP 53
PG 1
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Psychiatry
GA 966QR
UT WOS:000305853000003
DA 2023-06-23
ER

PT J
AU Lynch, WJ
AF Lynch, Wendy J.
TI Modeling the development of drug addiction in male and female animals
SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
LA English
DT Review
DE Addicted phenotype; Animal models; Extended access; Substance use
   disorder; Sex differences
ID COCAINE-SEEKING BEHAVIOR; NUCLEUS-ACCUMBENS CORE; ADMINISTRATION
   PRODUCES SENSITIZATION; SUBSEQUENT NICOTINE-SEEKING; EXTENDED-ACCESS
   CONDITIONS; SELF-ADMINISTERED COCAINE; GLUTAMATE-RECEPTOR 5;
   SEX-DIFFERENCES; INDUCED REINSTATEMENT; SUBSTANCE-ABUSE
AB An increasing emphasis has been placed on the development and use of animal models of addiction that capture defining features of human drug addiction, including escalation/binge drug use, enhanced motivation for the drug, preference for the drug over other reward options, use despite negative consequences, and enhanced drug-seeking/relapse vulnerability. The need to examine behavior in both males and females has also become apparent given evidence demonstrating that the addiction process occurs differently in males and females. This review discusses the procedures that are used to model features of addiction in animals, as well as factors that influence their development. Individual differences are also discussed, with a particular focus on sex differences. While no one procedure consistently produces all characteristics, different models have been developed to focus on certain characteristics. A history of escalating/binge patterns of use appears to be critical for producing other features characteristic of addiction, including an enhanced motivation for the drug, enhanced drug seeking, and use despite negative consequences. These characteristics tend to emerge over abstinence, and appear to increase rather than decrease in magnitude over time. In females, these characteristics develop sooner during abstinence and/or following less drug exposure as compared to males, and for psychostimulant addiction, may require estradiol. Although preference for the drug over other reward options has been demonstrated in non-human primates, it has been more difficult to establish in rats. Future research is needed to define the parameters that optimally induce each of these features of addiction in the majority of animals. Such models are essential for advancing our understanding of human drug addiction and its treatment in men and women.
C1 [Lynch, Wendy J.] Univ Virginia, Dept Psychiat & Neurobehav Sci, Charlottesville, VA 22904 USA.
C3 University of Virginia
RP Lynch, WJ (通讯作者)，Univ Virginia, Dept Psychiat & Neurobehav Sci, Charlottesville, VA 22904 USA.
EM wlynch@virginia.edu
FU National Institute on Drug Abuse [R01DA024716, R01DA039093]
FX The research reviewed here was supported by the National Institute on
   Drug Abuse [grants R01DA024716 and R01DA039093].
CR Ahmed SH, 2012, NEUROSCIENCE, V211, P107, DOI 10.1016/j.neuroscience.2011.08.014
   Ahmed SH, 2013, CURR OPIN NEUROBIOL, V23, P581, DOI 10.1016/j.conb.2013.01.028
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Ahmed SH, 2000, NEUROPSYCHOPHARMACOL, V22, P413, DOI 10.1016/S0893-133X(99)00133-5
   Ahmed SH, 2009, NEUROMETHODS ANIMAL
   AIGNER TG, 1978, SCIENCE, V201, P534, DOI 10.1126/science.96531
   ALEXANDER BK, 1981, PHARMACOL BIOCHEM BE, V15, P571, DOI 10.1016/0091-3057(81)90211-2
   Allain F, 2017, NEUROPHARMACOLOGY, V117, P227, DOI 10.1016/j.neuropharm.2017.01.026
   Allain F, 2015, NEUROSCI BIOBEHAV R, V56, P166, DOI 10.1016/j.neubiorev.2015.06.012
   Allen RM, 2014, DRUG ALCOHOL DEPEN, V134, P38, DOI 10.1016/j.drugalcdep.2013.09.005
   American Psychiatric Association [APA], 2022, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425787]
   ANGLIN MD, 1987, AM J DRUG ALCOHOL AB, V13, P59, DOI 10.3109/00952998709001500
   Anker JJ, 2012, DRUG ALCOHOL DEPEN, V124, P149, DOI 10.1016/j.drugalcdep.2012.01.004
   Anker JJ, 2011, CURR TOP BEHAV NEURO, V8, P73, DOI 10.1007/7854_2010_93
   Anker JJ, 2009, PHARMACOL BIOCHEM BE, V93, P343, DOI 10.1016/j.pbb.2009.05.013
   Arnold JM, 1997, PHARMACOL BIOCHEM BE, V57, P441, DOI 10.1016/S0091-3057(96)00445-5
   BALSTER RL, 1982, FED PROC, V41, P211
   Banks Matthew L, 2015, Curr Treat Options Psychiatry, V2, P136
   Banks ML, 2012, ADV PHARMACOL SCI, V2012, DOI 10.1155/2012/281768
   Barros HMT, 1996, PSYCHOPHARMACOLOGY, V125, P379
   Becker HC, 2014, ALCOHOL, V48, P205, DOI 10.1016/j.alcohol.2014.04.001
   Becker JB, 2017, J NEUROSCI RES, V95, P136, DOI 10.1002/jnr.23963
   Becker JB, 2016, PHARMACOL REV, V68, P242, DOI 10.1124/pr.115.011163
   Beiter RM, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.58
   Belin D, 2012, COLD SPRING HARB PER, V2
   Belin D, 2011, NEUROPSYCHOPHARMACOL, V36, P569, DOI 10.1038/npp.2010.188
   Belin-Rauscent A, 2016, BIOL PSYCHIAT, V79, P39, DOI 10.1016/j.biopsych.2015.01.004
   Ben-Shahar O, 2007, BRAIN RES, V1131, P220, DOI 10.1016/j.brainres.2006.10.069
   Bentzley BS, 2013, PSYCHOPHARMACOLOGY, V226, P113, DOI 10.1007/s00213-012-2899-2
   BERGMAN J, 1981, PHARMACOL BIOCHEM BE, V14, P423, DOI 10.1016/0091-3057(81)90413-5
   Bobzean SAM, 2014, EXP NEUROL, V259, P64, DOI 10.1016/j.expneurol.2014.01.022
   Bossert JM, 2013, PSYCHOPHARMACOLOGY, V229, P453, DOI 10.1007/s00213-013-3120-y
   BOZARTH MA, 1989, PHARMACOL BIOCHEM BE, V33, P903, DOI 10.1016/0091-3057(89)90490-5
   BOZARTH MA, 1985, JAMA-J AM MED ASSOC, V254, P81, DOI 10.1001/jama.254.1.81
   Brady KT, 1999, PSYCHIAT CLIN N AM, V22, P241, DOI 10.1016/S0193-953X(05)70074-5
   Briand LA, 2008, NEUROPSYCHOPHARMACOL, V33, P2969, DOI 10.1038/npp.2008.18
   Burke AR, 2015, PSYCHOPHARMACOLOGY, V232, P3067, DOI 10.1007/s00213-015-3947-5
   Calipari ES, 2015, NEUROPSYCHOPHARMACOL, V40, P728, DOI 10.1038/npp.2014.238
   Calipari ES, 2014, NEUROPHARMACOLOGY, V82, P1, DOI 10.1016/j.neuropharm.2014.02.021
   Calipari ES, 2014, J PHARMACOL EXP THER, V349, P192, DOI 10.1124/jpet.114.212993
   Calipari ES, 2014, J NEUROCHEM, V128, P224, DOI 10.1111/jnc.12452
   Calipari ES, 2013, NEUROPSYCHOPHARMACOL, V38, P2385, DOI 10.1038/npp.2013.136
   Campbell UC, 2000, EXP CLIN PSYCHOPHARM, V8, P312, DOI 10.1037//1064-1297.8.3.312
   Cantin L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011592
   Caprioli D, 2015, ADDICT BIOL, V20, P913, DOI 10.1111/adb.12220
   Caprioli D, 2015, BIOL PSYCHIAT, V78, P463, DOI 10.1016/j.biopsych.2015.02.018
   Arenas MC, 2016, CURR NEUROPHARMACOL, V14, P87, DOI 10.2174/1570159X13666150921112841
   Carnicella S, 2014, ALCOHOL, V48, P243, DOI 10.1016/j.alcohol.2014.01.006
   Carroll ME, 2016, ADDICT BIOL, V21, P1007, DOI 10.1111/adb.12400
   Carroll ME, 2016, FRONT PSYCHIATRY, V6, DOI 10.3389/fpsyt.2015.00175
   Carroll ME, 2005, PSYCHOPHARMACOLOGY, V180, P414, DOI 10.1007/s00213-005-2182-x
   Carroll ME, 2004, TRENDS PHARMACOL SCI, V25, P273, DOI 10.1016/j.tips.2004.03.011
   Carroll ME, 1997, PSYCHOPHARMACOLOGY, V129, P206, DOI 10.1007/s002130050182
   Cohen A, 2015, PSYCHOPHARMACOLOGY, V232, P453, DOI 10.1007/s00213-014-3685-0
   Cohen A, 2012, NEUROPSYCHOPHARMACOL, V37, P2153, DOI 10.1038/npp.2012.67
   Comer SD, 2008, DRUG ALCOHOL DEPEN, V96, P1, DOI 10.1016/j.drugalcdep.2008.03.001
   Conrad KL, 2008, NATURE, V454, P118, DOI 10.1038/nature06995
   Crawford JT, 2013, DRUG ALCOHOL DEPEN, V132, P414, DOI 10.1016/j.drugalcdep.2013.07.024
   Czoty PW, 2012, PSYCHOPHARMACOLOGY, V224, P69, DOI 10.1007/s00213-011-2562-3
   Dalley JW, 2011, NEURON, V69, P680, DOI 10.1016/j.neuron.2011.01.020
   de Wit H, 2012, NEUROSCI BIOBEHAV R, V36, P1565, DOI 10.1016/j.neubiorev.2012.04.005
   DEMINIERE JM, 1989, NEUROSCI BIOBEHAV R, V13, P141, DOI 10.1016/S0149-7634(89)80023-5
   DENEAU G, 1969, PSYCHOPHARMACOLOGIA, V16, P30, DOI 10.1007/BF00405254
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Deroche-Gamonet V, 2014, NEUROPHARMACOLOGY, V76, P437, DOI 10.1016/j.neuropharm.2013.07.014
   DEWIT H, 1983, PSYCHOPHARMACOLOGY, V79, P29, DOI 10.1007/BF00433012
   DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175
   Dobrin CV, 2012, METHODS MOL BIOL, V829, P291, DOI 10.1007/978-1-61779-458-2_19
   Doyle SE, 2014, BIOL PSYCHIAT, V76, P810, DOI 10.1016/j.biopsych.2014.02.005
   Ducret E, 2016, BIOL PSYCHIAT, V80, P226, DOI 10.1016/j.biopsych.2015.09.019
   Edwards S, 2013, BEHAV PHARMACOL, V24, P356, DOI 10.1097/FBP.0b013e3283644d15
   Elton A., 2010, WOMEN ADDICTION COMP, P147
   Ettenberg A, 2015, PSYCHOPHARMACOLOGY, V232, P2363, DOI 10.1007/s00213-015-3873-6
   Fattore L, 2010, BRIT J PHARMACOL, V160, P724, DOI 10.1111/j.1476-5381.2010.00734.x
   Fattore L, 2008, WOMENS HEALTH, V4, P51, DOI 10.2217/17455057.4.1.51
   Ferland J. N., 2016, ADDICT BIOL
   Fischer KD, 2013, J NEUROSCI, V33, P9319, DOI 10.1523/JNEUROSCI.3278-12.2013
   Fischer-Smith KD, 2012, NEUROSCIENCE, V210, P333, DOI 10.1016/j.neuroscience.2012.02.049
   FITCH TE, 1993, DRUG ALCOHOL DEPEN, V33, P119, DOI 10.1016/0376-8716(93)90053-S
   Flores RJ, 2016, BEHAV BRAIN RES, V307, P258, DOI 10.1016/j.bbr.2016.04.004
   Ford MM, 2004, ALCOHOL CLIN EXP RES, V28, P20, DOI 10.1097/01.ALC.0000108647.62718.5A
   Ford MM, 2002, ALCOHOL, V26, P103, DOI 10.1016/S0741-8329(01)00203-8
   Freeman KB, 2014, PSYCHOPHARMACOLOGY, V231, P2751, DOI 10.1007/s00213-014-3436-2
   Galli G, 2004, DRUG ALCOHOL DEPEN, V73, P51, DOI 10.1016/j.drugalcdep.2003.09.003
   Galli G, 2011, BEHAV BRAIN RES, V217, P261, DOI 10.1016/j.bbr.2010.10.011
   Gallop RJ, 2007, J CONSULT CLIN PSYCH, V75, P95, DOI 10.1037/0022-006X.75.1.95
   Gancarz-Kausch AM, 2014, SCI REP-UK, V4, DOI 10.1038/srep06876
   Gardner EL, 2000, AM J ADDICTION, V9, P285, DOI 10.1080/105504900750047355
   George O, 2008, NEUROPSYCHOPHARMACOL, V33, P2474, DOI 10.1038/sj.npp.1301626
   Gipson CD, 2011, PSYCHOPHARMACOLOGY, V214, P557, DOI 10.1007/s00213-010-2060-z
   Gould RW, 2017, NEUROPSYCHOPHARMACOL, V42, P1093, DOI 10.1038/npp.2016.285
   Greenfield SF, 2010, PSYCHIAT CLIN N AM, V33, P339, DOI 10.1016/j.psc.2010.01.004
   Greenwell TN, 2009, ADDICT BIOL, V14, P130, DOI 10.1111/j.1369-1600.2008.00142.x
   GRIFFIN ML, 1989, ARCH GEN PSYCHIAT, V46, P122
   Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134
   Haas AL, 2000, J SUBST ABUSE, V12, P241, DOI 10.1016/S0899-3289(00)00053-5
   Hao Y, 2010, BIOL PSYCHIAT, V68, P240, DOI 10.1016/j.biopsych.2010.02.011
   Henry PK, 2009, PSYCHOPHARMACOLOGY, V204, P523, DOI 10.1007/s00213-009-1485-8
   Hernandez-Avila CA, 2004, DRUG ALCOHOL DEPEN, V74, P265, DOI 10.1016/j.drugalcdep.2004.02.001
   Heyne A, 1996, PHARMACOL BIOCHEM BE, V53, P11, DOI 10.1016/0091-3057(95)00193-X
   Heyne A, 1998, PSYCHOPHARMACOLOGY, V140, P510, DOI 10.1007/s002130050796
   Hitchcock LN, 2014, PROG MOL BIOL TRANSL, V128, P51, DOI 10.1016/B978-0-12-800977-2.00003-6
   Holtz NA, 2015, BEHAV PHARMACOL, V26, P393, DOI 10.1097/FBP.0000000000000136
   Holtz NA, 2013, PHYSIOL BEHAV, V122, P32, DOI 10.1016/j.physbeh.2013.08.004
   Holtz NA, 2013, PSYCHOPHARMACOLOGY, V227, P243, DOI 10.1007/s00213-012-2958-8
   Hutsell BA, 2016, DRUG ALCOHOL DEPEN, V168, P36, DOI 10.1016/j.drugalcdep.2016.08.637
   Hutsell BA, 2016, ADDICT BIOL, V21, P360, DOI 10.1111/adb.12206
   Huynh C, 2017, ADDICT BIOL, V22, P142, DOI 10.1111/adb.12306
   Imperio CG, 2015, BEHAV NEUROSCI, V129, P380, DOI 10.1037/bne0000069
   Jackson LR, 2006, NEUROPSYCHOPHARMACOL, V31, P129, DOI 10.1038/sj.npp.1300778
   JOHANSON CE, 1976, PHARMACOL BIOCHEM BE, V4, P45, DOI 10.1016/0091-3057(76)90174-X
   JOHANSON CE, 1977, PSYCHOPHARMACOLOGY, V53, P277, DOI 10.1007/BF00492364
   Jones JD, 2013, BEHAV PHARMACOL, V24, P384, DOI 10.1097/FBP.0b013e3283641c3d
   Jonkman S, 2012, NEUROPSYCHOPHARMACOL, V37, P1612, DOI 10.1038/npp.2012.6
   Katz JL, 2003, PSYCHOPHARMACOLOGY, V168, P21, DOI 10.1007/s00213-003-1441-y
   Kawa AB, 2016, PSYCHOPHARMACOLOGY, V233, P3587, DOI 10.1007/s00213-016-4393-8
   Kelamangalath L, 2010, NEUROSCIENCE, V169, P1127, DOI 10.1016/j.neuroscience.2010.06.006
   Kerstetter K. A., 2011, J ADDICT RES THER S, VS4
   Kerstetter KA, 2008, PSYCHOPHARMACOLOGY, V198, P63, DOI 10.1007/s00213-008-1089-8
   Kerstetter KA, 2012, NEUROPSYCHOPHARMACOL, V37, P2605, DOI 10.1038/npp.2012.99
   Kippin TE, 2006, PSYCHOPHARMACOLOGY, V187, P60, DOI 10.1007/s00213-006-0386-3
   Kitamura O, 2006, PSYCHOPHARMACOLOGY, V186, P48, DOI 10.1007/s00213-006-0353-z
   Koob G, 2007, AM J PSYCHIAT, V164, P1149, DOI 10.1176/appi.ajp.2007.05030503
   Koob GF, 2016, LANCET PSYCHIAT, V3, P760, DOI 10.1016/S2215-0366(16)00104-8
   Koob GF, 2016, ANNU REV PHARMACOL, V56, P299, DOI 10.1146/annurev-pharmtox-010715-103143
   Koob George F, 2014, Handb Clin Neurol, V125, P33, DOI 10.1016/B978-0-444-62619-6.00003-3
   Koskela M, 2017, NEUROBIOL DIS, V97, P189, DOI 10.1016/j.nbd.2016.05.010
   Kucerova J, 2009, NEUROENDOCRINOL LETT, V30, P663
   Lacy RT, 2016, PSYCHOPHARMACOLOGY, V233, P3201, DOI 10.1007/s00213-016-4368-9
   Larson EB, 2007, EXP CLIN PSYCHOPHARM, V15, P461, DOI 10.1037/1064-1297.15.5.461
   Le AD, 2002, PHARMACOL THERAPEUT, V94, P137, DOI 10.1016/S0163-7258(02)00200-0
   Le Cozannet R, 2013, EUR J NEUROSCI, V38, P3487, DOI 10.1111/ejn.12361
   Lenoir M, 2013, EXTENDED HEROIN ACCE
   Lenoir M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000698
   Lenoir M, 2007, NEUROPSYCHOPHARMACOL, V32, P616, DOI 10.1038/sj.npp.1301083
   Lenoir Magalie, 2013, Curr Protoc Neurosci, VChapter 9, DOI 10.1002/0471142301.ns0944s64
   Li X, 2015, ADDICT BIOL, V20, P872, DOI 10.1111/adb.12205
   Liu Y, 2005, PSYCHOPHARMACOLOGY, V179, P644, DOI 10.1007/s00213-004-2089-y
   Lopez MF, 2017, ALCOHOL, V58, P73, DOI 10.1016/j.alcohol.2016.09.003
   Lynch W. J., 2010, WOMEN ADDICTION COMP, P407
   Lynch W. J., 2010, ADDICTION MED SCI PR
   Lynch WJ, 2013, NEUROSCI BIOBEHAV R, V37, P1622, DOI 10.1016/j.neubiorev.2013.06.011
   Lynch WJ, 2010, EXP CLIN PSYCHOPHARM, V18, P451, DOI 10.1037/a0021265
   Lynch WJ, 2006, EXP CLIN PSYCHOPHARM, V14, P34, DOI 10.1037/1064-1297.14.1.34
   Lynch WJ, 2005, NEUROPSYCHOPHARMACOL, V30, P927, DOI 10.1038/sj.npp.1300656
   Lynch WJ, 2005, NEUROPSYCHOPHARMACOL, V30, P322, DOI 10.1038/sj.npp.1300594
   Lynch WJ, 2004, NEUROPSYCHOPHARMACOL, V29, P943, DOI 10.1038/sj.npp.1300389
   Lynch WJ, 2001, PHARMACOL BIOCHEM BE, V68, P641, DOI 10.1016/S0091-3057(01)00455-5
   Lynch WJ, 2001, EXP CLIN PSYCHOPHARM, V9, P131, DOI 10.1037//1064-1297.9.2.131
   Madsen HB, 2015, ADDICT BIOL, V20, P433, DOI 10.1111/adb.12134
   Mandt BH, 2015, DRUG ALCOHOL DEPEN, V149, P166, DOI 10.1016/j.drugalcdep.2015.01.039
   Mantsch JR, 2016, NEUROPSYCHOPHARMACOL, V41, P335, DOI 10.1038/npp.2015.142
   Mantsch JR, 2004, PSYCHOPHARMACOLOGY, V175, P26, DOI 10.1007/s00213-004-1778-x
   Mantsch JR, 2001, PSYCHOPHARMACOLOGY, V157, P31, DOI 10.1007/s002130100744
   Marchant NJ, 2013, CURR OPIN NEUROBIOL, V23, P675, DOI 10.1016/j.conb.2013.01.003
   Martin TJ, 2006, DRUG ALCOHOL DEPEN, V82, P282, DOI 10.1016/j.drugalcdep.2005.11.018
   Martinez LA, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0140-16.2016
   Mateo Y, 2005, NEUROPSYCHOPHARMACOL, V30, P1455, DOI 10.1038/sj.npp.1300687
   McBride WJ, 2014, ALCOHOL, V48, P209, DOI 10.1016/j.alcohol.2013.09.044
   McCance-Katz EF, 1999, AM J ADDICTION, V8, P300
   McKay JR, 1996, J NERV MENT DIS, V184, P616, DOI 10.1097/00005053-199610000-00006
   McNamara R, 2010, PSYCHOPHARMACOLOGY, V212, P453, DOI 10.1007/s00213-010-1974-9
   Meisch RA, 2001, ALCOHOL, V24, P117, DOI 10.1016/S0741-8329(01)00149-5
   Mello NK, 2011, NEUROPSYCHOPHARMACOL, V36, P2187, DOI 10.1038/npp.2011.130
   Miller BW, 2017, ADDICT BIOL, V22, P629, DOI 10.1111/adb.12354
   Moeller SJ, 2015, PHARMACOL BIOCHEM BE, V138, P133, DOI 10.1016/j.pbb.2015.09.020
   Morgan D, 2005, PSYCHOPHARMACOLOGY, V178, P309, DOI 10.1007/s00213-004-1992-6
   Morgan D, 2004, NEUROSCI BIOBEHAV R, V27, P803, DOI 10.1016/j.neubiorev.2003.11.004
   Morgan D, 2002, BEHAV PHARMACOL, V13, P389, DOI 10.1097/00008877-200209000-00012
   Nader MA, 2014, NEUROPHARMACOLOGY, V76, P510, DOI 10.1016/j.neuropharm.2013.05.044
   Negus SS, 2003, NEUROPSYCHOPHARMACOL, V28, P919, DOI 10.1038/sj.npp.1300096
   Nguyen J. D., 2017, ADDICT BIOL
   O'Brien CP, 1998, J PSYCHOPHARMACOL, V12, P15, DOI 10.1177/026988119801200103
   Oleson EB, 2012, METHODS MOL BIOL, V829, P303, DOI 10.1007/978-1-61779-458-2_20
   Oleson Erik B, 2008, Drug Discov Today Dis Models, V5, P217
   Oleson EB, 2009, NEUROPSYCHOPHARMACOL, V34, P796, DOI 10.1038/npp.2008.195
   Pacchioni AM, 2011, BEHAV BRAIN RES, V218, P296, DOI 10.1016/j.bbr.2010.12.014
   Panlilio LV, 2007, ADDICTION, V102, P1863, DOI 10.1111/j.1360-0443.2007.02011.x
   Parkitna JR, 2013, BIOL PSYCHIAT, V73, P263, DOI 10.1016/j.biopsych.2012.07.019
   Paronis CA, 2002, PSYCHOPHARMACOLOGY, V163, P283, DOI 10.1007/s00213-002-1180-5
   Paronis CA, 2013, BEHAV PHARMACOL, V24, P486, DOI 10.1097/FBP.0b013e328364c006
   Pascoli V, 2015, NEURON, V88, DOI 10.1016/j.neuron.2015.10.017
   Paterson NE, 2003, NEUROREPORT, V14, P2229, DOI 10.1097/00001756-200312020-00019
   Pelloux Y, 2015, PSYCHOPHARMACOLOGY, V232, P125, DOI 10.1007/s00213-014-3648-5
   Peoples LL, 1997, BRAIN RES, V757, P280, DOI 10.1016/S0006-8993(97)00299-0
   Perry AN, 2015, NEUROPSYCHOPHARMACOL, V40, P2696, DOI 10.1038/npp.2015.116
   Perry AN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079465
   Peterson AB, 2014, PSYCHOPHARMACOLOGY, V231, P2661, DOI 10.1007/s00213-014-3437-1
   Peterson AB, 2014, PSYCHOPHARMACOLOGY, V231, P1305, DOI 10.1007/s00213-013-3321-4
   Picetti R, 2012, PSYCHOPHARMACOLOGY, V220, P163, DOI 10.1007/s00213-011-2464-4
   Pickens CL, 2011, TRENDS NEUROSCI, V34, P411, DOI 10.1016/j.tins.2011.06.001
   Pitchers KK, 2017, BEHAV BRAIN RES, V320, P302, DOI 10.1016/j.bbr.2016.11.024
   Pomierny-Chamiolo L, 2014, PHARMACOL THERAPEUT, V142, P281, DOI 10.1016/j.pharmthera.2013.12.012
   Radwanska K, 2012, ADDICT BIOL, V17, P601, DOI 10.1111/j.1369-1600.2011.00394.x
   Ramoa CP, 2014, BIOL PSYCHIAT, V76, P8, DOI 10.1016/j.biopsych.2013.09.028
   Ramoa CP, 2013, NEUROPSYCHOPHARMACOL, V38, P1698, DOI 10.1038/npp.2013.68
   Recinto P, 2012, NEUROPSYCHOPHARMACOL, V37, P1275, DOI 10.1038/npp.2011.315
   Reichel CM, 2012, PSYCHOPHARMACOLOGY, V223, P371, DOI 10.1007/s00213-012-2727-8
   Reichel Carmela M, 2009, Curr Drug Abuse Rev, V2, P184
   Roberts DCS, 2007, PROG NEURO-PSYCHOPH, V31, P1614, DOI 10.1016/j.pnpbp.2007.08.028
   Roberts DCS, 2002, DRUG ALCOHOL DEPEN, V67, P291, DOI 10.1016/S0376-8716(02)00083-2
   Rogers JL, 2008, PSYCHOPHARMACOLOGY, V199, P615, DOI 10.1007/s00213-008-1187-7
   Roth ME, 2004, PHARMACOL BIOCHEM BE, V78, P199, DOI 10.1016/j.pbb.2004.03.018
   Roth ME, 2002, PHARMACOL BIOCHEM BE, V72, P313, DOI 10.1016/S0091-3057(01)00777-8
   Ruda-Kucerova J, 2015, FRONT PSYCHIATRY, V6, DOI 10.3389/fpsyt.2015.00091
   Sanchez V, 2014, PSYCHOPHARMACOLOGY, V231, P1753, DOI 10.1007/s00213-013-3359-3
   Sanchez V, 2013, PSYCHOPHARMACOLOGY, V227, P403, DOI 10.1007/s00213-012-2964-x
   Schmeichel BE, 2015, NEUROPSYCHOPHARMACOL, V40, P1123, DOI 10.1038/npp.2014.293
   Sedki F, 2015, PSYCHOPHARMACOLOGY, V232, P3773, DOI 10.1007/s00213-015-4037-4
   Shalev U, 2002, PHARMACOL REV, V54, P1, DOI 10.1124/pr.54.1.1
   Sinha R, 2011, PSYCHOPHARMACOLOGY, V218, P69, DOI 10.1007/s00213-011-2263-y
   Smith MA, 2017, NEUROPSYCHOPHARMACOL, V42, P364, DOI 10.1038/npp.2016.218
   Smith MA, 2016, FRONT BEHAV NEUROSCI, V10, DOI 10.3389/fnbeh.2016.00217
   Smith MA, 2011, PSYCHOPHARMACOLOGY, V218, P357, DOI 10.1007/s00213-011-2321-5
   Sobieraj JC, 2016, BRAIN STRUCT FUNCT, V221, P261, DOI 10.1007/s00429-014-0905-7
   Sokoloff P, 2017, EUR J NEUROSCI, V45, P2, DOI 10.1111/ejn.13390
   SPRAGG S. D. S., 1940, COMPAR PSYCHOL MONOGR, V15, P1
   Stewart J, 1996, PSYCHOBIOLOGY, V24, P154
   Strickland JC, 2015, PHARMACOL BIOCHEM BE, V136, P47, DOI 10.1016/j.pbb.2015.06.013
   Suh JJ, 2006, J CLIN PSYCHOPHARM, V26, P290, DOI 10.1097/01.jcp.0000222512.25649.08
   Thiel KJ, 2011, PHARMACOL BIOCHEM BE, V97, P595, DOI 10.1016/j.pbb.2010.09.014
   Thomsen M, 2008, PSYCHOPHARMACOLOGY, V201, P43, DOI 10.1007/s00213-008-1245-1
   Thomsen M, 2013, J EXP ANAL BEHAV, V99, P211, DOI 10.1002/jeab.15
   Tornatzky W, 2000, PSYCHOPHARMACOLOGY, V148, P289, DOI 10.1007/s002130050053
   Tunstall BJ, 2015, BEHAV BRAIN RES, V281, P222, DOI 10.1016/j.bbr.2014.12.034
   Tunstall BJ, 2014, EXP CLIN PSYCHOPHARM, V22, P364, DOI 10.1037/a0037019
   Valentine JD, 1997, PSYCHOPHARMACOLOGY, V133, P300, DOI 10.1007/s002130050405
   Vandaele Y, 2016, NEUROPSYCHOPHARMACOL, V41, P646, DOI 10.1038/npp.2015.195
   Vanderschuren LJMJ, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a011932
   Venniro M, 2016, PROG BRAIN RES, V224, P25, DOI 10.1016/bs.pbr.2015.08.004
   Wade CL, 2015, NEUROPSYCHOPHARMACOL, V40, P421, DOI 10.1038/npp.2014.188
   Wakabayashi KT, 2010, J NEUROSCI, V30, P11346, DOI 10.1523/JNEUROSCI.2524-10.2010
   Ward SJ, 2006, PSYCHOPHARMACOLOGY, V185, P150, DOI 10.1007/s00213-005-0288-9
   Waters RP, 2014, PSYCHOPHARMACOLOGY, V231, P3197, DOI 10.1007/s00213-014-3497-2
   Wee S, 2008, EUR NEUROPSYCHOPHARM, V18, P303, DOI 10.1016/j.euroneuro.2007.08.003
   Westermeyer J, 2000, AM J DRUG ALCOHOL AB, V26, P523, DOI 10.1081/ADA-100101893
   Wetherill Reagan R, 2016, Curr Addict Rep, V3, P1
   Whitfield TW, 2015, J NEUROSCI, V35, P4296, DOI 10.1523/JNEUROSCI.1978-13.2015
   WISE RA, 1981, PROG NEURO-PSYCHOPHA, V5, P467, DOI 10.1016/0364-7722(81)90028-X
   Wise RA, 2014, NEUROPSYCHOPHARMACOL, V39, P254, DOI 10.1038/npp.2013.261
   Wolf ME, 2016, NAT REV NEUROSCI, V17, P351, DOI 10.1038/nrn.2016.39
   Wolf ME, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00072
   WOLFFGRAMM J, 1995, BEHAV BRAIN RES, V70, P77, DOI 10.1016/0166-4328(95)00131-C
   WOLFFGRAMM J, 1991, PHARMACOL BIOCHEM BE, V38, P389, DOI 10.1016/0091-3057(91)90297-F
   Yahyavi-Firouz-Abadi N, 2009, PHARMACOL THERAPEUT, V124, P235, DOI 10.1016/j.pharmthera.2009.06.014
   Zakiniaeiz Yasmin, 2016, Yale Journal of Biology and Medicine, V89, P255
   Zhang Y, 2014, PSYCHOPHARMACOLOGY, V231, P1277, DOI 10.1007/s00213-013-3306-3
   Zilberman M, 2003, J ADDICT DIS, V22, P61, DOI 10.1300/J069v22n04_06
   Zimmer BA, 2012, NEUROPSYCHOPHARMACOL, V37, P1901, DOI 10.1038/npp.2012.37
   Zlebnik N. E., 2014, EFFECTS COMBINED EXE
   Zorrilla EP, 2012, ADDICT BIOL, V17, P300, DOI 10.1111/j.1369-1600.2011.00329.x
NR 251
TC 38
Z9 38
U1 1
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0091-3057
EI 1873-5177
J9 PHARMACOL BIOCHEM BE
JI Pharmacol. Biochem. Behav.
PD JAN
PY 2018
VL 164
SI SI
BP 50
EP 61
DI 10.1016/j.pbb.2017.06.006
PG 12
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA FU1VN
UT WOS:000423637700006
PM 28624586
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Noonan, MA
   Bulin, SE
   Fuller, DC
   Eisch, AJ
AF Noonan, Michele A.
   Bulin, Sarah E.
   Fuller, Dwain C.
   Eisch, Amelia J.
TI Reduction of Adult Hippocampal Neurogenesis Confers Vulnerability in an
   Animal Model of Cocaine Addiction
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID PROGRESSIVE-RATIO SCHEDULES; DOSE-RESPONSE FUNCTIONS; DENTATE GYRUS;
   NUCLEUS-ACCUMBENS; SEEKING BEHAVIOR; ENVIRONMENTAL ENRICHMENT; SYNAPTIC
   PLASTICITY; CELL-PROLIFERATION; DORSAL HIPPOCAMPUS; VENTRAL SUBICULUM
AB Drugs of abuse dynamically regulate adult neurogenesis, which appears important for some types of learning and memory. Interestingly, a major site of adult neurogenesis, the hippocampus, is important in the formation of drug-context associations and in the mediation of drug-taking and drug-seeking behaviors in animal models of addiction. Correlative evidence suggests an inverse relationship between hippocampal neurogenesis and drug-taking or drug-seeking behaviors, but the lack of a causative link has made the relationship between adult-generated neurons and addiction unclear. We used rat intravenous cocaine self-administration in rodents, a clinically relevant animal model of addiction, to test the hypothesis that suppression of adult hippocampal neurogenesis enhances vulnerability to addiction and relapse. Suppression of adult hippocampal neurogenesis via cranial irradiation before drug-taking significantly increased cocaine self-administration on both fixed-ratio and progressive-ratio schedules, as well as induced a vertical shift in the dose-response curve. This was not a general enhancement of learning, motivation, or locomotion, because sucrose self-administration and locomotor activity were unchanged in irradiated rats. Suppression of adult hippocampal neurogenesis after drug-taking significantly enhanced resistance to extinction of drug-seeking behavior. These studies identify reduced adult hippocampal neurogenesis as a novel risk factor for addiction-related behaviors in an animal model of cocaine addiction. Furthermore, they suggest that therapeutics to specifically increase or stabilize adult hippocampal neurogenesis could aid in preventing initial addiction as well as future relapse.
C1 [Noonan, Michele A.; Bulin, Sarah E.; Eisch, Amelia J.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA.
   [Fuller, Dwain C.] Vet Affairs N Texas Hlth Ctr, Dept Pathol & Lab Med Toxicol, Dallas, TX 75216 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center Dallas; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA North Texas Health Care System
RP Eisch, AJ (通讯作者)，Univ Texas SW Med Ctr Dallas, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM amelia.eisch@utsouthwestern.edu
OI Eisch, Amelia/0000-0001-6476-5385
FU National Institute of Drug Abuse [F31DA021045, K02DA023555,
   R01DA01676505]
FX This work was supported by National Institute of Drug Abuse Grants
   F31DA021045 (M.A.N.) and K02DA023555 and R01DA01676505 (A.J.E.). We
   thank Chandana Ravikumar for excellent technical assistance, Dr. Erin
   Larson for excellent advice, and Amy Arguello, Nathan DeCarolis, and
   Drs. Diane Lagace and Madeleine Johnson for very helpful discussions of
   this paper. We are grateful to National Institute on Drug Abuse for
   providing the cocaine used in these studies.
CR Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003
   Abrous DN, 2002, J NEUROSCI, V22, P3656
   Airan RD, 2007, SCIENCE, V317, P819, DOI 10.1126/science.1144400
   Baker DA, 2001, PSYCHOPHARMACOLOGY, V155, P18, DOI 10.1007/s002130000676
   Borders AS, 2007, J COMP NEUROL, V501, P206, DOI 10.1002/cne.21252
   Brown J, 2003, EUR J NEUROSCI, V17, P2042, DOI 10.1046/j.1460-9568.2003.02647.x
   Buczek Y, 1999, PSYCHOPHARMACOLOGY, V144, P183, DOI 10.1007/s002130050992
   Caine SB, 2001, BEHAV NEUROSCI, V115, P880, DOI 10.1037//0735-7044.115.4.880
   Cammarota M, 2005, CELL MOL NEUROBIOL, V25, P465, DOI 10.1007/s10571-005-4009-z
   Chambers RA, 2002, NEUROPSYCHOPHARMACOL, V27, P889, DOI 10.1016/S0893-133X(02)00365-2
   Corcoran KA, 2005, J NEUROSCI, V25, P8978, DOI 10.1523/JNEUROSCI.2246-05.2005
   Covington HE, 2005, PSYCHOPHARMACOLOGY, V183, P331, DOI 10.1007/s00213-005-0190-5
   Deng W, 2009, J NEUROSCI, V29, P13532, DOI 10.1523/JNEUROSCI.3362-09.2009
   Deroche V, 1997, J PHARMACOL EXP THER, V281, P1401
   Dupret D, 2005, EUR J NEUROSCI, V22, P778, DOI 10.1111/j.1460-9568.2005.04262.x
   Dupret D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001959
   Dupret D, 2007, PLOS BIOL, V5, P1683, DOI 10.1371/journal.pbio.0050214
   Edwards S, 2007, NEUROPSYCHOPHARMACOL, V32, P354, DOI 10.1038/sj.npp.1301062
   Eisch AJ, 2002, PROG BRAIN RES, V138, P315, DOI 10.1016/S0079-6123(02)38085-3
   Eisch AJ, 2000, P NATL ACAD SCI USA, V97, P7579, DOI 10.1073/pnas.120552597
   EMERICH DF, 1990, PHARMACOL BIOCHEM BE, V37, P149, DOI 10.1016/0091-3057(90)90055-M
   Erb S, 1996, PSYCHOPHARMACOLOGY, V128, P408, DOI 10.1007/s002130050150
   Erb S, 1998, J NEUROSCI, V18, P5529, DOI 10.1523/JNEUROSCI.18-14-05529.1998
   Floresco SB, 2001, J NEUROSCI, V21, P4915, DOI 10.1523/JNEUROSCI.21-13-04915.2001
   Fuchs RA, 2005, NEUROPSYCHOPHARMACOL, V30, P296, DOI 10.1038/sj.npp.1300579
   Graham DL, 2007, NAT NEUROSCI, V10, P1029, DOI 10.1038/nn1929
   Green TA, 2002, PSYCHOPHARMACOLOGY, V162, P373, DOI 10.1007/s00213-002-1134-y
   Herman JP, 2006, BEHAV BRAIN RES, V174, P215, DOI 10.1016/j.bbr.2006.05.035
   Hernandez-Rabaza V, 2008, NEUROBIOL LEARN MEM, V90, P553, DOI 10.1016/j.nlm.2008.06.008
   Holmes PV, 2002, SYNAPSE, V46, P4, DOI 10.1002/syn.10105
   Hsu D, 2007, PROG BRAIN RES, V163, P601, DOI 10.1016/S0079-6123(07)63032-5
   Hubbard R L, 1986, NIDA Res Monogr, V72, P157
   Imayoshi I, 2008, NAT NEUROSCI, V11, P1153, DOI 10.1038/nn.2185
   Ji JZ, 2007, HIPPOCAMPUS, V17, P749, DOI 10.1002/hipo.20331
   KANAREK RB, 1995, PHARMACOL BIOCHEM BE, V51, P725, DOI 10.1016/0091-3057(95)00022-O
   Keiflin R, 2008, PSYCHOPHARMACOLOGY, V197, P247, DOI 10.1007/s00213-007-1026-2
   KELLEY AE, 1982, NEUROSCIENCE, V7, P2321, DOI 10.1016/0306-4522(82)90198-1
   Kempermann G, 2008, TRENDS NEUROSCI, V31, P163, DOI 10.1016/j.tins.2008.01.002
   Ko HG, 2009, MOL BRAIN, V2, DOI 10.1186/1756-6606-2-1
   Kohl Z, 2007, BRAIN RES, V1155, P24, DOI 10.1016/j.brainres.2007.04.039
   Laplagne DA, 2006, PLOS BIOL, V4, P2349, DOI 10.1371/journal.pbio.0040409
   Lodge DJ, 2008, J NEUROSCI, V28, P7876, DOI 10.1523/JNEUROSCI.1582-08.2008
   Lu L, 2003, NEUROSCI BIOBEHAV R, V27, P457, DOI 10.1016/S0149-7634(03)00073-3
   Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000
   Mandyam CD, 2008, BIOL PSYCHIAT, V64, P958, DOI 10.1016/j.biopsych.2008.04.010
   Meyers RA, 2006, BEHAV NEUROSCI, V120, P401, DOI 10.1037/0735-7044.120.2.401
   Miczek KA, 1996, PSYCHOPHARMACOLOGY, V128, P256, DOI 10.1007/s002130050133
   Mirescu C, 2006, HIPPOCAMPUS, V16, P233, DOI 10.1002/hipo.20155
   Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578
   Noonan MA, 2008, J NEUROSCI, V28, P2516, DOI 10.1523/JNEUROSCI.4661-07.2008
   Paxinos G, 1997, RAT BRAIN STEREOTAXI
   Piazza PV, 2000, J NEUROSCI, V20, P4226
   Pitkanen A, 2000, ANN NY ACAD SCI, V911, P369
   Quirk GJ, 2008, NEUROPSYCHOPHARMACOL, V33, P56, DOI 10.1038/sj.npp.1301555
   RABE A, 1968, EXP BRAIN RES, V5, P259
   Reif A, 2006, MOL PSYCHIATR, V11, P514, DOI 10.1038/sj.mp.4001791
   Richardson NR, 1996, J NEUROSCI METH, V66, P1, DOI 10.1016/0165-0270(95)00153-0
   Rogers JL, 2007, NEUROBIOL LEARN MEM, V87, P688, DOI 10.1016/j.nlm.2007.01.003
   Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034
   Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328
   Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103
   Schmelzeis MC, 1996, BEHAV NEUROSCI, V110, P1049
   Shen F, 2006, J NEUROSCI, V26, P11041, DOI 10.1523/JNEUROSCI.2898-06.2006
   Slattery DA, 2007, PSYCHOPHARMACOLOGY, V190, P555, DOI 10.1007/s00213-006-0630-x
   Smith MA, 2008, DRUG ALCOHOL DEPEN, V98, P129, DOI 10.1016/j.drugalcdep.2008.05.006
   Snyder JS, 2001, J NEUROPHYSIOL, V85, P2423, DOI 10.1152/jn.2001.85.6.2423
   Snyder JS, 2005, NEUROSCIENCE, V130, P843, DOI 10.1016/j.neuroscience.2004.10.009
   Specio SE, 2008, PSYCHOPHARMACOLOGY, V196, P473, DOI 10.1007/s00213-007-0983-9
   Stairs DJ, 2006, BEHAV PHARMACOL, V17, P597, DOI 10.1097/01.fbp.0000236271.72300.0e
   Surget A, 2008, BIOL PSYCHIAT, V64, P293, DOI 10.1016/j.biopsych.2008.02.022
   Sutton MA, 2003, NATURE, V421, P70, DOI 10.1038/nature01249
   Sutton MA, 2000, NEUROPSYCHOPHARMACOL, V22, P626, DOI 10.1016/S0893-133X(99)00160-8
   Tani K, 2001, BRIT J PHARMACOL, V134, P1411, DOI 10.1038/sj.bjp.0704370
   Tornatzky W, 2000, PSYCHOPHARMACOLOGY, V148, P289, DOI 10.1007/s002130050053
   van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368
   Vorel SR, 2001, SCIENCE, V292, P1175, DOI 10.1126/science.1058043
   Winocur G, 2006, HIPPOCAMPUS, V16, P296, DOI 10.1002/hipo.20163
   Wojtowicz JM, 2008, EUR J NEUROSCI, V27, P1494, DOI 10.1111/j.1460-9568.2008.06128.x
   Wojtowicz JM, 2006, NAT PROTOC, V1, P1399, DOI 10.1038/nprot.2006.224
   Wojtowicz JM, 2006, HIPPOCAMPUS, V16, P261, DOI 10.1002/hipo.20158
NR 80
TC 156
Z9 162
U1 0
U2 15
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD JAN 6
PY 2010
VL 30
IS 1
BP 304
EP 315
DI 10.1523/JNEUROSCI.4256-09.2010
PG 12
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 540PN
UT WOS:000273347300030
PM 20053911
OA hybrid, Green Accepted, Green Published
DA 2023-06-23
ER

PT J
AU Belin, D
   Deroche-Gamonet, V
AF Belin, David
   Deroche-Gamonet, Veronique
TI Responses to Novelty and Vulnerability to Cocaine Addiction:
   Contribution of a Multi-Symptomatic Animal Model
SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LA English
DT Article
ID SUBSTANCE-USE DISORDERS; GENE-ENVIRONMENT INTERACTIONS; SELF-MEDICATION
   HYPOTHESIS; SENSATION-SEEKING TRAIT; HIGHER DISCOUNT RATES;
   DECISION-MAKING; INDIVIDUAL-DIFFERENCES; DEPENDENT INDIVIDUALS;
   DRUG-ADDICTION; SEVERITY INDEX
AB Epidemiological studies have revealed striking associations between several distinct behavioral/personality traits and drug addiction, with a large emphasis on the sensation-seeking trait and the associated impulsive dimension of personality. However, in human studies, it is difficult to identify whether personality/behavioral traits actually contribute to increased vulnerability to drug addiction or reflect psychobiological adaptations to chronic drug exposure. Here we show how animal models, including the first multi-symptomatic model of addiction in the rat, have contributed to a better understanding of the relationships between different subdimensions of the sensation-seeking trait and different stages of the development of cocaine addiction, from vulnerability to initiation of cocaine self-administration to the transition to compulsive drug intake. We argue that sensation seeking predicts vulnerability to use cocaine, whereas novelty seeking, akin to high impulsivity, predicts instead vulnerability to shift from controlled to compulsive cocaine use, that is, addiction.
C1 [Belin, David] Univ Poitiers, Associated European Lab Psychobiol Compuls Habits, INSERM,Lab Neurosci Expt & Clin, Grp Psychobiol Compul Disorders,U1084, F-86022 Poitiers, France.
   [Deroche-Gamonet, Veronique] Univ Bordeaux, Grp Psychobiol Addict, INSERM, Neuroctr Magendie,Team Pathophysiol Addict,U862, F-33077 Bordeaux, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Poitiers; Institut National de la Sante et de la Recherche
   Medicale (Inserm); UDICE-French Research Universities; Universite de
   Bordeaux
RP Deroche-Gamonet, V (通讯作者)，Univ Bordeaux, Grp Psychobiol Addict, INSERM, Neuroctr Magendie,Team Pathophysiol Addict,U862, F-33077 Bordeaux, France.
EM veronique.deroche@inserm.fr
RI Belin, David/E-1231-2014; Deroche-Gamonet, Véronique/E-5728-2010
OI Belin, David/0000-0002-7383-372X; Deroche-Gamonet,
   Veronique/0000-0002-9704-6624
FU INSERM AVENIR grant; foundation Fyssen; IREB; FRM; ANR (Neurorelaps,
   TIMMS) by INSERM; EquipEx (OptoPath) by INSERM; Conseil Regional
   d'Aquitaine; University of Bordeaux
FX D.B. is supported by an INSERM AVENIR grant, the foundation Fyssen, the
   IREB, and the FRM. V.D.-G. is supported by ANR (Neurorelaps, TIMMS) and
   EquipEx (OptoPath) grants, by INSERM, the Conseil Regional d'Aquitaine,
   and the University of Bordeaux 2.
CR Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   ALLCOCK CC, 1988, AUST NZ J PSYCHIAT, V22, P307, DOI 10.3109/00048678809161212
   Alterman AI, 2007, PSYCHOL ASSESSMENT, V19, P119, DOI 10.1037/1040-3590.19.1.119
   Ambroggi F, 2009, NAT NEUROSCI, V12, P247, DOI 10.1038/nn.2282
   American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th
   Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244
   ARNETT J, 1994, PERS INDIV DIFFER, V16, P289, DOI 10.1016/0191-8869(94)90165-1
   AUSUBEL DP, 1961, PSYCHIAT QUART, V35, P523, DOI 10.1007/BF01573620
   Badiani A, 2011, NAT REV NEUROSCI, V12, P685, DOI 10.1038/nrn3104
   Baler RD, 2006, TRENDS MOL MED, V12, P559, DOI 10.1016/j.molmed.2006.10.005
   Ball SA, 1998, J PERS DISORD, V12, P1, DOI 10.1521/pedi.1998.12.1.1
   Bardo MT, 1996, BEHAV BRAIN RES, V77, P23, DOI 10.1016/0166-4328(95)00203-0
   Bari A, 2008, NAT PROTOC, V3, P759, DOI 10.1038/nprot.2008.41
   Batts K.T., 2005, CONTEXTUAL OTHER FAC
   Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584
   Bechara A, 2002, NEUROPSYCHOLOGIA, V40, P1675, DOI 10.1016/S0028-3932(02)00015-5
   Belin D, 2012, DRUG ABUSE IN PRESS
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   Belin D, 2008, NEURON, V57, P432, DOI 10.1016/j.neuron.2007.12.019
   Belin D, 2011, NEUROMETHODS, V53, P337, DOI 10.1007/978-1-60761-934-5_13
   Belin D, 2011, NEUROPSYCHOPHARMACOL, V36, P569, DOI 10.1038/npp.2010.188
   Belin D, 2010, HBK BEHAV NEUROSCI, V20, P571
   Belin D, 2009, BIOL PSYCHIAT, V65, P863, DOI 10.1016/j.biopsych.2008.05.031
   Belin D, 2009, BEHAV BRAIN RES, V199, P89, DOI 10.1016/j.bbr.2008.09.027
   Blanchard MM, 2009, NEUROSCI BIOBEHAV R, V33, P1145, DOI 10.1016/j.neubiorev.2009.05.009
   Bornovalova MA, 2005, EXP CLIN PSYCHOPHARM, V13, P311, DOI 10.1037/1064-1297.13.4.311
   Bornovalova MA, 2005, CLIN PSYCHOL REV, V25, P790, DOI 10.1016/j.cpr.2005.05.005
   Cacciola J S, 1997, NIDA Res Monogr, V175, P182
   Cain ME, 2005, EXP CLIN PSYCHOPHARM, V13, P367, DOI 10.1037/1064-1297.13.4.367
   Caspi A, 2006, NAT REV NEUROSCI, V7, P583, DOI 10.1038/nrn1925
   CASTELLANI B, 1995, INT J ADDICT, V30, P275, DOI 10.3109/10826089509048726
   Childress A R, 1988, NIDA Res Monogr, V84, P25
   Clapper R L, 1994, J Subst Abuse, V6, P305, DOI 10.1016/S0899-3289(94)90491-X
   Clark L, 2006, BIOL PSYCHIAT, V60, P515, DOI 10.1016/j.biopsych.2005.11.007
   Coffey SF, 2003, EXP CLIN PSYCHOPHARM, V11, P18, DOI 10.1037/1064-1297.11.1.18
   Comeau N, 2001, ADDICT BEHAV, V26, P803, DOI 10.1016/S0306-4603(01)00238-6
   Conway KP, 2002, DRUG ALCOHOL DEPEN, V65, P225, DOI 10.1016/S0376-8716(01)00168-5
   Crews FT, 2009, PHARMACOL BIOCHEM BE, V93, P237, DOI 10.1016/j.pbb.2009.04.018
   Cunha PJ, 2011, AM J ADDICTION, V20, P78, DOI 10.1111/j.1521-0391.2010.00097.x
   Dalley JW, 2007, SCIENCE, V315, P1267, DOI 10.1126/science.1137073
   Dalley JW, 2011, NEURON, V69, P680, DOI 10.1016/j.neuron.2011.01.020
   Dalley JW, 2005, NEUROPSYCHOPHARMACOL, V30, P525, DOI 10.1038/sj.npp.1300590
   DELLU F, 1993, PERS INDIV DIFFER, V15, P411, DOI 10.1016/0191-8869(93)90069-F
   Dellu F, 1996, NEUROPSYCHOBIOLOGY, V34, P136, DOI 10.1159/000119305
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Deroche-Gamonet V, 2010, ENCYCLOPEDIA OF BEHAVIORAL NEUROSCIENCE, VOL 3: P-Z, P422
   Deroche-Gamonet V, 2003, J NEUROSCI, V23, P4785
   Dom G, 2006, ADDICTION, V101, P50, DOI 10.1111/j.1360-0443.2005.01270.x
   EMCDDA, 2009, ANN REPORT
   Ersche KD, 2008, PSYCHOPHARMACOLOGY, V197, P421, DOI 10.1007/s00213-007-1051-1
   Ersche KD, 2012, SCIENCE, V335, P601, DOI 10.1126/science.1214463
   Ersche KD, 2011, BRAIN, V134, P2013, DOI 10.1093/brain/awr138
   Ersche KD, 2010, BIOL PSYCHIAT, V68, P770, DOI 10.1016/j.biopsych.2010.06.015
   Ersche KD, 2005, PSYCHOPHARMACOLOGY, V180, P612, DOI 10.1007/s00213-005-2205-7
   Evenden JL, 1999, PSYCHOPHARMACOLOGY, V146, P348, DOI 10.1007/PL00005481
   Eysenck HJ., 1985, PERSONALITY INDIVIDU, DOI [10.1007/978-1-4613-2413-3, 13877]
   Franques P, 2003, DRUG ALCOHOL DEPEN, V69, P121, DOI 10.1016/S0376-8716(02)00309-5
   Franques P, 2000, ENCEPHALE, V26, P68
   Gerra G, 2008, SUBST USE MISUSE, V43, P317, DOI 10.1080/10826080701202726
   Gerra G, 2004, SUBST USE MISUSE, V39, P345, DOI 10.1081/JA-120028493
   Geyer Mark A., 1995, P787
   Goeders NE, 2003, EUR NEUROPSYCHOPHARM, V13, P435, DOI 10.1016/j.euroneuro.2003.08.004
   Goldstein RZ, 2009, TRENDS COGN SCI, V13, P372, DOI 10.1016/j.tics.2009.06.004
   Gorodetzky H, 2011, PSYCHIAT RES, V186, P437, DOI 10.1016/j.psychres.2010.07.024
   GOSSOP M, 1978, DRUG ALCOHOL DEPEN, V3, P359, DOI 10.1016/0376-8716(78)90005-4
   Grant S, 2000, NEUROPSYCHOLOGIA, V38, P1180, DOI 10.1016/S0028-3932(99)00158-X
   GREENE RL, 1993, J PERS ASSESS, V61, P224, DOI 10.1207/s15327752jpa6102_2
   Gum Amber M, 2008, Curr Psychiatry Rep, V10, P23, DOI 10.1007/s11920-008-0006-5
   Gunnarsdottir ED, 2000, ADDICT BEHAV, V25, P641, DOI 10.1016/S0306-4603(99)00043-X
   Hester R, 2004, J NEUROSCI, V24, P11017, DOI 10.1523/JNEUROSCI.3321-04.2004
   HOOKS MS, 1992, PHARMACOL BIOCHEM BE, V43, P815, DOI 10.1016/0091-3057(92)90413-A
   HOOKS MS, 1991, PHARMACOL BIOCHEM BE, V38, P467, DOI 10.1016/0091-3057(91)90308-O
   HOOKS MS, 1991, SYNAPSE, V9, P121, DOI 10.1002/syn.890090206
   Jessor R, 1980, NIDA Res Monogr, V30, P102
   JESSOR R, 1980, AM J PUBLIC HEALTH, V70, P604, DOI 10.2105/AJPH.70.6.604
   Fernandez-Serrano MJ, 2010, EUR J PHARMACOL, V626, P104, DOI 10.1016/j.ejphar.2009.10.019
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kampman KM, 1998, ADDICT BEHAV, V23, P449, DOI 10.1016/S0306-4603(98)00011-2
   Kasanetz F, 2010, SCIENCE, V328, P1709, DOI 10.1126/science.1187801
   Kessler RC, 1996, AM J ORTHOPSYCHIAT, V66, P17, DOI 10.1037/h0080151
   Khantzian E J, 1991, NIDA Res Monogr, V110, P211
   KHANTZIAN EJ, 1985, JAMA-J AM MED ASSOC, V254, P249, DOI 10.1001/jama.254.2.249
   KHANTZIAN EJ, 1974, AM J PSYCHIAT, V131, P160, DOI 10.1176/ajp.131.2.160
   Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550
   KHANTZIAN EJ, 1986, AM J DRUG ALCOHOL AB, V12, P213, DOI 10.3109/00952998609007391
   KHANTZIAN EJ, 1989, J SUBST ABUSE TREAT, V6, P75
   KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259
   KHANTZIAN EJ, 1980, NEW ENGL J MED, V302, P869
   Kirby KN, 1999, J EXP PSYCHOL GEN, V128, P78, DOI 10.1037/0096-3445.128.1.78
   Kirby KN, 2004, ADDICTION, V99, P461, DOI 10.1111/j.1360-0443.2003.00669.x
   Klebaur JE, 2001, BEHAV PHARMACOL, V12, P267, DOI 10.1097/00008877-200107000-00005
   Koob G. F., 2005, NEUROBIOLOGY ADDICTI
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Kreek MJ, 2002, NAT REV DRUG DISCOV, V1, P710, DOI 10.1038/nrd897
   Kreek MJ, 2005, NAT NEUROSCI, V8, P1450, DOI 10.1038/nn1583
   LABOUVIE EW, 1986, J CONSULT CLIN PSYCH, V54, P289, DOI 10.1037/0022-006X.54.3.289
   Le AD, 2002, PHARMACOL THERAPEUT, V94, P137, DOI 10.1016/S0163-7258(02)00200-0
   Lejuez CW, 2008, BEHAV RES THER, V46, P811, DOI 10.1016/j.brat.2008.03.010
   Lejuez CW, 2006, BEHAV RES THER, V44, P667, DOI 10.1016/j.brat.2005.04.006
   Lejuez CW, 2005, DRUG ALCOHOL DEPEN, V77, P169, DOI 10.1016/j.drugalcdep.2004.08.013
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Madden GJ, 1997, EXP CLIN PSYCHOPHARM, V5, P256, DOI 10.1037/1064-1297.5.3.256
   Maremmani I, 2009, J AFFECT DISORDERS, V117, P186, DOI 10.1016/j.jad.2009.01.007
   Marinelli M, 2002, EUR J NEUROSCI, V16, P387, DOI 10.1046/j.1460-9568.2002.02089.x
   MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006
   MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199, DOI 10.1016/0740-5472(92)90062-S
   McNamara R, 2010, PSYCHOPHARMACOLOGY, V212, P453, DOI 10.1007/s00213-010-1974-9
   Meda SA, 2009, BEHAV PHARMACOL, V20, P390, DOI 10.1097/FBP.0b013e32833113a3
   Mitchell JM, 2005, ALCOHOL CLIN EXP RES, V29, P2158, DOI 10.1097/01.alc.0000191755.63639.4a
   Molander AC, 2011, PSYCHOPHARMACOLOGY, V215, P721, DOI 10.1007/s00213-011-2167-x
   Monterosso J, 2001, ADDICTION, V96, P1825, DOI 10.1046/j.1360-0443.2001.9612182512.x
   Naqvi NH, 2010, BRAIN STRUCT FUNCT, V214, P435, DOI 10.1007/s00429-010-0268-7
   Nutt D, 2007, LANCET, V369, P1047, DOI 10.1016/S0140-6736(07)60464-4
   OBrien CP, 1997, SCIENCE, V278, P66, DOI 10.1126/science.278.5335.66
   Patkar AA, 2004, J ADDICT DIS, V23, P109, DOI 10.1300/J069v23n02_08
   Patkar AA, 2003, AM J ADDICTION, V12, P432, DOI 10.1080/10550490390240800
   Patkar AA, 2002, PSYCHIAT RES, V110, P103, DOI 10.1016/S0165-1781(02)00098-7
   Pelloux Y, 2007, PSYCHOPHARMACOLOGY, V194, P127, DOI 10.1007/s00213-007-0805-0
   Piazza P V, 1998, NIDA Res Monogr, V169, P105
   Piazza PV, 2000, J NEUROSCI, V20, P4226
   PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295
   Piazza PV, 1996, ANNU REV PHARMACOL, V36, P359, DOI 10.1146/annurev.pa.36.040196.002043
   PIAZZA PV, 1991, BRAIN RES, V567, P169, DOI 10.1016/0006-8993(91)91452-7
   Richardson NR, 1996, J NEUROSCI METH, V66, P1, DOI 10.1016/0165-0270(95)00153-0
   Rikoon SH, 2006, J SUBST ABUSE TREAT, V31, P17, DOI 10.1016/j.jsat.2006.03.003
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Salgado JV, 2009, REV BRAS PSIQUIATR, V31, P4, DOI 10.1590/S1516-44462009000100003
   SCHINKA JA, 1994, J PERS ASSESS, V63, P413, DOI 10.1207/s15327752jpa6303_2
   Shalev U, 2002, PHARMACOL REV, V54, P1, DOI 10.1124/pr.54.1.1
   Sher KJ, 2000, J CONSULT CLIN PSYCH, V68, P818, DOI 10.1037/0022-006X.68.5.818
   Skinstad AH, 2001, AM J DRUG ALCOHOL AB, V27, P45, DOI 10.1081/ADA-100103118
   Somaini L, 2011, NEUROSCI BIOBEHAV R, V35, P1771, DOI 10.1016/j.neubiorev.2010.11.008
   Swadi H, 1999, DRUG ALCOHOL DEPEN, V55, P209, DOI 10.1016/S0376-8716(99)00017-4
   Swendsen J, 2011, ANN NY ACAD SCI, V1216, P73, DOI 10.1111/j.1749-6632.2010.05894.x
   TEICHMAN M, 1989, BRIT J ADDICT, V84, P181
   Terracciano A, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-22
   van der Veen R, 2007, PSYCHOPHARMACOLOGY, V193, P179, DOI 10.1007/s00213-007-0777-0
   van der Veen R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002245
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Verdejo-Garcia A, 2008, NEUROSCI BIOBEHAV R, V32, P777, DOI 10.1016/j.neubiorev.2007.11.003
   Verdejo-Garcia A, 2007, DRUG ALCOHOL DEPEN, V91, P213, DOI 10.1016/j.drugalcdep.2007.05.025
   Verdejo-Garcia A, 2006, J INT NEUROPSYCH SOC, V12, P405, DOI 10.1017/S1355617706060486
   Verdejo-Garcia A, 2009, NEUROPHARMACOLOGY, V56, P48, DOI 10.1016/j.neuropharm.2008.07.035
   Verdejo-Garcia AJ, 2007, ADDICT BEHAV, V32, P950, DOI 10.1016/j.addbeh.2006.06.032
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
   Volkow ND, 2010, BIOESSAYS, V32, P748, DOI 10.1002/bies.201000042
   VONKNORRING L, 1984, PSYCHIAT RES, V12, P11, DOI 10.1016/0165-1781(84)90134-3
   WEEKS JR, 1962, SCIENCE, V138, P143, DOI 10.1126/science.138.3537.143
   WHO, 2004, NEUR PSYCH SUBST US
   Wiessing L, 2009, EUROSURVEILLANCE, V14, P25
   WOHLWILL JF, 1984, BEHAV BRAIN SCI, V7, P453, DOI 10.1017/S0140525X00019178
   Yalachkov Y, 2010, BEHAV BRAIN RES, V207, P215, DOI 10.1016/j.bbr.2009.09.015
   ZUCKERMAN M, 1993, NEUROPSYCHOBIOLOGY, V28, P30, DOI 10.1159/000118996
   Zuckerman M, 1986, NIDA Res Monogr, V74, P59
NR 154
TC 74
Z9 74
U1 0
U2 15
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 2157-1422
J9 CSH PERSPECT MED
JI Cold Spring Harb. Perspect. Med.
PD NOV
PY 2012
VL 2
IS 11
AR a011940
DI 10.1101/cshperspect.a011940
PG 20
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 080ZB
UT WOS:000314282300005
PM 23125204
OA Green Published, Bronze
DA 2023-06-23
ER

PT J
AU Feltenstein, MW
   See, RE
   Fuchs, RA
AF Feltenstein, Matthew W.
   See, Ronald E.
   Fuchs, Rita A.
TI Neural Substrates and Circuits of Drug Addiction
SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LA English
DT Article
ID COCAINE-SEEKING BEHAVIOR; VENTRAL TEGMENTAL AREA; NUCLEUS-ACCUMBENS
   CORE; STRESS-INDUCED REINSTATEMENT; CORTICOTROPIN-RELEASING-FACTOR;
   CUE-INDUCED REINSTATEMENT; CONDITIONED PLACE PREFERENCE;
   INCENTIVE-SENSITIZATION THEORY; DORSOMEDIAL PREFRONTAL CORTEX;
   CONTEXT-INDUCED REINSTATEMENT
AB Drug addiction is a chronic relapsing disorder, and a significant amount of research has been devoted to understand the factors that contribute to the development, loss of control, and persistence of compulsive addictive behaviors. In this review, we provide an overview of various theories of addiction to drugs of abuse and the neurobiology involved in elements of the addiction cycle. Specific focus is devoted to the role of the mesolimbic pathway in acute drug reinforcement and occasional drug use, the role of the mesocortical pathway and associated areas (e.g., the dorsal striatum) in escalation/dependence, and the contribution of these pathways and associated circuits to conditioned responses, drug craving, and loss of behavioral control that may underlie drug relapse. By enhancing the understanding of the neurobiological factors that mediate drug addiction, continued preclinical and clinical research will aid in the development of novel therapeutic interventions that can serve as effective long-term treatment strategies for drug-dependent individuals.
C1 [Feltenstein, Matthew W.; See, Ronald E.] Med Univ South Carolina, Dept Neurosci, Charleston, SC 29425 USA.
   [See, Ronald E.] Westmont Coll, Dept Psychol, Santa Barbara, CA 93108 USA.
   [Fuchs, Rita A.] Washington State Univ, Integrat Physiol & Neurosci, Coll Vet Med, Pullman, WA 99164 USA.
C3 Medical University of South Carolina; Washington State University
RP Fuchs, RA (通讯作者)，Washington State Univ, Integrat Physiol & Neurosci, Coll Vet Med, Pullman, WA 99164 USA.
EM rita.fuchs@wsu.edu
RI Fuchs, Rita A/I-4419-2013
FU National Institutes of Health [P50 DA015369, P50 DA016511, P20 DA022658,
   R01 DA010462, R01 DA021690, R01 DA025646]
FX The work of the authors was supported by National Institutes of Health
   Grant Nos. P50 DA015369, P50 DA016511, P20 DA022658, R01 DA010462, R01
   DA021690, and R01 DA025646.
CR Alderson HL, 2006, EUR J NEUROSCI, V23, P2169, DOI 10.1111/j.1460-9568.2006.04737.x
   ALTSHULER HL, 1980, LIFE SCI, V26, P679, DOI 10.1016/0024-3205(80)90257-X
   American Psychiatric Association [APA], 2022, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425787]
   Anderson SM, 2003, PSYCHOPHARMACOLOGY, V168, P132, DOI 10.1007/s00213-002-1298-5
   Aragona BJ, 2009, EUR J NEUROSCI, V30, P1889, DOI 10.1111/j.1460-9568.2009.07027.x
   Arguello AA, 2017, NEUROPSYCHOPHARMACOL, V42, P727, DOI 10.1038/npp.2016.157
   Atkins AL, 2008, PHARMACOL BIOCHEM BE, V90, P481, DOI 10.1016/j.pbb.2008.04.007
   Augur IF, 2016, J NEUROSCI, V36, P10174, DOI 10.1523/JNEUROSCI.0773-16.2016
   Backstrom P, 2007, PSYCHOPHARMACOLOGY, V192, P571, DOI 10.1007/s00213-007-0753-8
   Belin D, 2008, NEURON, V57, P432, DOI 10.1016/j.neuron.2007.12.019
   Berglind WJ, 2006, NEUROSCIENCE, V137, P699, DOI 10.1016/j.neuroscience.2005.08.064
   Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9
   BERRIDGE KC, 1995, CURR DIR PSYCHOL SCI, V4, P71, DOI 10.1111/1467-8721.ep10772316
   Berridge KC, 2007, PSYCHOPHARMACOLOGY, V191, P391, DOI 10.1007/s00213-006-0578-x
   Berridge KC, 2016, AM PSYCHOL, V71, P670, DOI 10.1037/amp0000059
   Blouin AM, 2019, ADDICT BIOL, V24, P958, DOI 10.1111/adb.12666
   Bolla KI, 2003, NEUROIMAGE, V19, P1085, DOI 10.1016/S1053-8119(03)00113-7
   Bonson KR, 2002, NEUROPSYCHOPHARMACOL, V26, P376, DOI 10.1016/S0893-133X(01)00371-2
   Bossert JM, 2007, J NEUROSCI, V27, P12655, DOI 10.1523/JNEUROSCI.3926-07.2007
   Boutrel B, 2005, P NATL ACAD SCI USA, V102, P19168, DOI 10.1073/pnas.0507480102
   Bozarth M A, 1982, NIDA Res Monogr, V41, P158
   BOZARTH MA, 1983, PROG NEURO-PSYCHOPH, V7, P569, DOI 10.1016/0278-5846(83)90027-1
   BOZARTH MA, 1981, LIFE SCI, V28, P551, DOI 10.1016/0024-3205(81)90148-X
   Bozarth MA, 1987, METHODS ASSESSING RE, P173, DOI DOI 10.1007/978-1-4612-4812-5_9
   Buffalari DM, 2012, PHYSIOL BEHAV, V105, P209, DOI 10.1016/j.physbeh.2011.08.020
   Buffalari DM, 2009, PHYSIOL BEHAV, V98, P614, DOI 10.1016/j.physbeh.2009.09.013
   BURNS LH, 1993, BEHAV BRAIN RES, V55, P167, DOI 10.1016/0166-4328(93)90113-5
   Caille S, 2003, EUR J NEUROSCI, V18, P3145, DOI 10.1111/j.1460-9568.2003.02961.x
   Calipari ES, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13877
   Calu DJ, 2007, LEARN MEMORY, V14, P325, DOI 10.1101/lm.534807
   Cami J, 2003, NEW ENGL J MED, V349, P975, DOI 10.1056/NEJMra023160
   Canales JJ, 2005, NEUROBIOL LEARN MEM, V83, P93, DOI 10.1016/j.nlm.2004.10.006
   Capriles N, 2003, PSYCHOPHARMACOLOGY, V168, P66, DOI 10.1007/s00213-002-1283-z
   Carelli RM, 2014, NEUROPHARMACOLOGY, V76, P360, DOI 10.1016/j.neuropharm.2013.04.025
   Centers for Disease Control and Prevention, 2018, CDC VIT OP OV TREAT
   Charbogne P, 2014, NEUROPHARMACOLOGY, V76, P204, DOI 10.1016/j.neuropharm.2013.08.028
   Chen WS, 2016, NEUROSCI LETT, V612, P126, DOI 10.1016/j.neulet.2015.11.024
   Chevrette J, 2002, PHARMACOL BIOCHEM BE, V71, P501, DOI 10.1016/S0091-3057(01)00686-4
   Childress A R, 1993, NIDA Res Monogr, V137, P73
   Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11
   Ciccocioppo R, 2001, P NATL ACAD SCI USA, V98, P1976, DOI 10.1073/pnas.98.4.1976
   Clark D, 1998, ADDICT BIOL, V3, P109, DOI 10.1080/13556219872191
   Colombo G, 2005, PHARMACOL BIOCHEM BE, V81, P369, DOI 10.1016/j.pbb.2005.01.022
   Cooper A, 2007, PSYCHOPHARMACOLOGY, V194, P117, DOI 10.1007/s00213-007-0827-7
   Cornish JL, 1999, NEUROSCIENCE, V93, P1359, DOI 10.1016/S0306-4522(99)00214-6
   Cornish JL, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-15-j0006.2000
   CORRIGALL WA, 1988, PHARMACOL BIOCHEM BE, V30, P443, DOI 10.1016/0091-3057(88)90478-9
   Corrigall WA, 2002, PSYCHOPHARMACOLOGY, V160, P198, DOI 10.1007/s00213-001-0965-2
   CORRIGALL WA, 1991, PSYCHOPHARMACOLOGY, V104, P171, DOI 10.1007/BF02244174
   CORRIGALL WA, 1992, PSYCHOPHARMACOLOGY, V107, P285, DOI 10.1007/BF02245149
   Corrigall WA, 2001, PSYCHOPHARMACOLOGY, V158, P190, DOI 10.1007/s002130100869
   Cossu G, 2001, BEHAV BRAIN RES, V118, P61, DOI 10.1016/S0166-4328(00)00311-9
   Cox BM, 2017, BIOL PSYCHIAT, V81, P949, DOI 10.1016/j.biopsych.2016.11.011
   Crombag HS, 2005, CEREB CORTEX, V15, P341, DOI 10.1093/cercor/bhh136
   Dackis CA, 2001, J SUBST ABUSE TREAT, V21, P111, DOI 10.1016/S0740-5472(01)00192-1
   Dalley JW, 2004, NEUROSCI BIOBEHAV R, V28, P771, DOI 10.1016/j.neubiorev.2004.09.006
   Dayas CV, 2007, BIOL PSYCHIAT, V61, P979, DOI 10.1016/j.biopsych.2006.07.034
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175
   Di Chiara G, 2002, BEHAV BRAIN RES, V137, P75, DOI 10.1016/S0166-4328(02)00286-3
   Di Chiara G, 1999, EUR J PHARMACOL, V375, P13, DOI 10.1016/S0014-2999(99)00372-6
   Di Ciano P, 2004, J NEUROSCI, V24, P7167, DOI 10.1523/JNEUROSCI.1581-04.2004
   Di Ciano P, 2004, EUR J NEUROSCI, V19, P1661, DOI 10.1111/j.1460-9568.2004.03232.x
   Di Ciano P, 2001, NEUROPSYCHOPHARMACOL, V25, P341, DOI 10.1016/S0893-133X(01)00235-4
   Di Ciano P, 2008, NEUROPSYCHOPHARMACOL, V33, P1413, DOI 10.1038/sj.npp.1301522
   Di Pietro NC, 2006, EUR J NEUROSCI, V24, P3285, DOI 10.1111/j.1460-9568.2006.05193.x
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   DICIANO P, 1995, BEHAV PHARMACOL, V6, P311
   DWORKIN SI, 1988, PHARMACOL BIOCHEM BE, V30, P1051, DOI 10.1016/0091-3057(88)90138-4
   DWORKIN SI, 1988, PHARMACOL BIOCHEM BE, V29, P175, DOI 10.1016/0091-3057(88)90292-4
   Erb S, 1999, J NEUROSCI, V19, part. no., DOI 10.1523/JNEUROSCI.19-20-j0006.1999
   Erb S, 2000, NEUROPSYCHOPHARMACOL, V23, P138, DOI 10.1016/S0893-133X(99)00158-X
   Erb S, 2001, PSYCHOPHARMACOLOGY, V158, P360, DOI 10.1007/s002130000642
   Erb S, 1996, PSYCHOPHARMACOLOGY, V128, P408, DOI 10.1007/s002130050150
   Erb S, 1998, J NEUROSCI, V18, P5529, DOI 10.1523/JNEUROSCI.18-14-05529.1998
   Ersche KD, 2011, BRAIN, V134, P2013, DOI 10.1093/brain/awr138
   ETTENBERG A, 1982, PSYCHOPHARMACOLOGY, V78, P204, DOI 10.1007/BF00428151
   Everitt BJ, 2008, PHILOS T R SOC B, V363, P3125, DOI 10.1098/rstb.2008.0089
   Everitt BJ, 2007, ANN NY ACAD SCI, V1121, P576, DOI 10.1196/annals.1401.022
   Everitt BJ, 2001, BRAIN RES REV, V36, P129, DOI 10.1016/S0165-0173(01)00088-1
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Everitt BJ, 2018, PHILOS T R SOC LON B, V19, P373
   Ewald VAM, 2019, PSYCHOPHARMACOLOGY, V236, P479, DOI 10.1007/s00213-018-4964-y
   Fadda P, 2006, NEUROREPORT, V17, P1629, DOI 10.1097/01.wnr.0000236853.40221.8e
   Feltenstein MW, 2007, NEUROBIOL LEARN MEM, V88, P435, DOI 10.1016/j.nlm.2007.05.006
   Franklin TR, 2007, NEUROPSYCHOPHARMACOL, V32, P2301, DOI 10.1038/sj.npp.1301371
   Franklin TR, 2000, EUR J NEUROSCI, V12, P2097, DOI 10.1046/j.1460-9568.2000.00071.x
   Franklin TR, 2002, BIOL PSYCHIAT, V51, P134, DOI 10.1016/S0006-3223(01)01269-0
   Fuchs R A, 2008, Drug Discov Today Dis Models, V5, P251
   Fuchs RA, 2004, J NEUROSCI, V24, P6600, DOI 10.1523/JNEUROSCI.1924-04.2004
   Fuchs RA, 2006, J NEUROSCI, V26, P3584, DOI 10.1523/JNEUROSCI.5146-05.2006
   Fuchs RA, 2005, NEUROPSYCHOPHARMACOL, V30, P296, DOI 10.1038/sj.npp.1300579
   Fuchs RA, 2004, PSYCHOPHARMACOLOGY, V176, P459, DOI 10.1007/s00213-004-1895-6
   Fuchs RA, 2002, PSYCHOPHARMACOLOGY, V160, P425, DOI 10.1007/s00213-001-0997-7
   Fuchs RA, 2007, EUR J NEUROSCI, V26, P487, DOI 10.1111/j.1460-9568.2007.05674.x
   Fuchs RA, 2006, EUR J NEUROSCI, V23, P2809, DOI 10.1111/j.1460-9568.2006.04806.x
   Fuchs RA, 2019, NEURAL MECHANISMS OF ADDICTION, P3, DOI 10.1016/B978-0-12-812202-0.00002-6
   Fuchs RA, 2009, EUR J NEUROSCI, V30, P889, DOI 10.1111/j.1460-9568.2009.06888.x
   Gabriele A, 2011, BRAIN RES, V1417, P27, DOI 10.1016/j.brainres.2011.08.030
   Gabriele A, 2010, EUR J NEUROSCI, V32, P1024, DOI 10.1111/j.1460-9568.2010.07394.x
   Gallagher M, 1999, J NEUROSCI, V19, P6610
   Gao J, 2013, J PSYCHOPHARMACOL, V27, P181, DOI 10.1177/0269881112466181
   GATTO GJ, 1994, ALCOHOL, V11, P557, DOI 10.1016/0741-8329(94)90083-3
   George MS, 2001, ARCH GEN PSYCHIAT, V58, P345, DOI 10.1001/archpsyc.58.4.345
   GERRITS MAFM, 1994, PSYCHOPHARMACOLOGY, V114, P486, DOI 10.1007/BF02249340
   Glover EJ, 2019, NEUROPSYCHOPHARMACOL, V44, P1896, DOI 10.1038/s41386-019-0406-8
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Graf EN, 2013, J NEUROSCI, V33, P11800, DOI 10.1523/JNEUROSCI.1969-13.2013
   Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040
   Grimm JW, 2000, NEUROPSYCHOPHARMACOL, V22, P473, DOI 10.1016/S0893-133X(99)00157-8
   Haber SN, 2000, J NEUROSCI, V20, P2369
   Heinsbroek JA, 2017, J NEUROSCI, V37, P757, DOI 10.1523/JNEUROSCI.2659-16.2016
   HEMBY SE, 1995, J PHARMACOL EXP THER, V273, P591
   Hester R, 2004, J NEUROSCI, V24, P11017, DOI 10.1523/JNEUROSCI.3321-04.2004
   HIGGINS RL, 1975, J ABNORM PSYCHOL, V84, P644, DOI 10.1037/0021-843X.84.6.644
   Highfield D, 2001, NEUROPSYCHOPHARMACOL, V25, P320, DOI 10.1016/S0893-133X(01)00227-5
   Hiranita T, 2006, P NATL ACAD SCI USA, V103, P8523, DOI 10.1073/pnas.0600347103
   Hnasko TS, 2007, J NEUROSCI, V27, P12484, DOI 10.1523/JNEUROSCI.3133-07.2007
   Hnasko TS, 2005, NATURE, V438, P854, DOI 10.1038/nature04172
   Hodebourg R, 2019, EUR J NEUROSCI, V50, P2036, DOI 10.1111/ejn.13894
   HOEBEL BG, 1983, PSYCHOPHARMACOLOGY, V81, P158, DOI 10.1007/BF00429012
   Hungund BL, 2003, J NEUROCHEM, V84, P698, DOI 10.1046/j.1471-4159.2003.01576.x
   HURD YL, 1989, BRAIN RES, V498, P199, DOI 10.1016/0006-8993(89)90422-8
   Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560
   Ikemoto S, 2007, BRAIN RES REV, V56, P27, DOI 10.1016/j.brainresrev.2007.05.004
   Ito R, 2002, J NEUROSCI, V22, P6247
   Ito R, 2000, J NEUROSCI, V20, P7489
   Izquierdo A, 2010, NEUROPSYCHOPHARMACOL, V35, P505, DOI 10.1038/npp.2009.155
   JAFFE JH, 1989, PSYCHOPHARMACOLOGY, V97, P59, DOI 10.1007/BF00443414
   Jalabert M, 2011, P NATL ACAD SCI USA, V108, P16446, DOI 10.1073/pnas.1105418108
   James MH, 2019, BIOL PSYCHIAT, V85, P925, DOI 10.1016/j.biopsych.2018.07.022
   James MH, 2017, CURR TOP BEHAV NEURO, V33, P247, DOI 10.1007/7854_2016_57
   Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483
   Jhou TC, 2009, NEURON, V61, P786, DOI 10.1016/j.neuron.2009.02.001
   Jog MS, 1999, SCIENCE, V286, P1745, DOI 10.1126/science.286.5445.1745
   JOHNSON SW, 1992, J NEUROSCI, V12, P483
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kalivas PW, 2003, PSYCHOPHARMACOLOGY, V168, P44, DOI 10.1007/s00213-003-1393-2
   Kaufling J, 2015, J NEUROSCI, V35, P10290, DOI 10.1523/JNEUROSCI.0715-15.2015
   Kaufling J, 2009, J COMP NEUROL, V513, P597, DOI 10.1002/cne.21983
   Kaufman JN, 2003, J NEUROSCI, V23, P7839
   Kilts CD, 2004, AM J PSYCHIAT, V161, P233, DOI 10.1176/appi.ajp.161.2.233
   Kilts CD, 2001, ARCH GEN PSYCHIAT, V58, P334, DOI 10.1001/archpsyc.58.4.334
   Kolb B, 2004, BRAIN COGNITION, V55, P104, DOI 10.1016/s0278-2626(03)00278-1
   Koob GE, 2004, NEBR SYM MOTIV, V50, P1
   Koob GF, 2016, LANCET PSYCHIAT, V3, P760, DOI 10.1016/S2215-0366(16)00104-8
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J
   KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Koob GF, 2006, NEUR ADD
   KORNETSKY C, 1979, ARCH GEN PSYCHIAT, V36, P289
   Kornetsky C, 1990, TESTING EVALUATION D, P211
   Koya E, 2006, J NEUROCHEM, V98, P905, DOI 10.1111/j.1471-4159.2006.03917.x
   Koya E, 2009, NEUROPHARMACOLOGY, V56, P177, DOI 10.1016/j.neuropharm.2008.04.022
   Kruzich PJ, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-14-j0002.2001
   Kufahl PR, 2009, SYNAPSE, V63, P823, DOI 10.1002/syn.20666
   LaLumiere RT, 2008, J NEUROSCI, V28, P3170, DOI 10.1523/JNEUROSCI.5129-07.2008
   Lanca AJ, 2000, NEUROSCIENCE, V96, P735, DOI 10.1016/S0306-4522(99)00607-7
   Larson EB, 2015, J NEUROSCI, V35, P3537, DOI 10.1523/JNEUROSCI.1524-14.2015
   Lasseter HC, 2010, NEUROSCIENCE, V171, P830, DOI 10.1016/j.neuroscience.2010.09.032
   Lasseter HC, 2011, NEUROPSYCHOPHARMACOL, V36, P711, DOI 10.1038/npp.2010.209
   Lasseter HC, 2010, CURR TOP BEHAV NEURO, V3, P101, DOI 10.1007/7854_2009_19
   Lasseter HC, 2009, EUR J NEUROSCI, V30, P1370, DOI 10.1111/j.1460-9568.2009.06906.x
   Lavezzi HN, 2011, BASAL GANGLIA, V1, P191, DOI 10.1016/j.baga.2011.08.003
   Lawrence AJ, 2006, BRIT J PHARMACOL, V148, P752, DOI 10.1038/sj.bjp.0706789
   Le AD, 2005, PSYCHOPHARMACOLOGY, V179, P366, DOI 10.1007/s00213-004-2036-y
   Le AD, 2000, PSYCHOPHARMACOLOGY, V150, P317, DOI 10.1007/s002130000411
   Lecca D, 2006, PSYCHOPHARMACOLOGY, V184, P435, DOI 10.1007/s00213-005-0280-4
   Lecca D, 2006, PSYCHOPHARMACOLOGY, V188, P63, DOI 10.1007/s00213-006-0475-3
   Lecca S, 2011, NEUROPSYCHOPHARMACOL, V36, P589, DOI 10.1038/npp.2010.190
   Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401
   Lee B, 2004, NEUROPSYCHOPHARMACOL, V29, P686, DOI 10.1038/sj.npp.1300391
   Leong KC, 2018, INT REV NEUROBIOL, V140, P201, DOI 10.1016/bs.irn.2018.07.007
   Leri F, 2002, J NEUROSCI, V22, P5713
   Letchworth SR, 2001, J NEUROSCI, V21, P2799, DOI 10.1523/JNEUROSCI.21-08-02799.2001
   Lichtenberg NT, 2017, J NEUROSCI, V37, P8374, DOI 10.1523/JNEUROSCI.0486-17.2017
   London ED, 1999, CRIT REV NEUROBIOL, V13, P227, DOI 10.1615/CritRevNeurobiol.v13.i3.10
   Lucantonio F, 2012, NAT NEUROSCI, V15, P358, DOI 10.1038/nn.3014
   LYNESS WH, 1979, PHARMACOL BIOCHEM BE, V11, P553, DOI 10.1016/0091-3057(79)90040-6
   LYNESS WH, 1992, PHARMACOL BIOCHEM BE, V42, P187, DOI 10.1016/0091-3057(92)90465-R
   Maas LC, 1998, AM J PSYCHIAT, V155, P124, DOI 10.1176/ajp.155.1.124
   Marchant NJ, 2016, J NEUROSCI, V36, P3281, DOI 10.1523/JNEUROSCI.4299-15.2016
   Mark GP, 2011, PHYSIOL BEHAV, V104, P76, DOI 10.1016/j.physbeh.2011.04.052
   Maskos U, 2008, BRIT J PHARMACOL, V153, pS438, DOI 10.1038/bjp.2008.5
   Matochik JA, 2003, NEUROIMAGE, V19, P1095, DOI 10.1016/S1053-8119(03)00244-1
   McFarland K, 2004, J NEUROSCI, V24, P1551, DOI 10.1523/JNEUROSCI.4177-03.2004
   McFarland K, 2003, J NEUROSCI, V23, P3531
   McFarland K, 2001, J NEUROSCI, V21, P8655
   McLaughlin J, 2003, PSYCHOPHARMACOLOGY, V168, P57, DOI 10.1007/s00213-002-1196-x
   McReynolds JR, 2017, NEUROPSYCHOPHARMACOL, V42, P757, DOI 10.1038/npp.2016.187
   McReynolds JR, 2016, PSYCHOPHARMACOLOGY, V233, P99, DOI 10.1007/s00213-015-4092-x
   Meil WM, 1997, BEHAV BRAIN RES, V87, P139, DOI 10.1016/S0166-4328(96)02270-X
   MEIL WM, 1995, PSYCHOPHARMACOLOGY, V118, P338, DOI 10.1007/BF02245964
   Melendez RI, 2002, ALCOHOL CLIN EXP RES, V26, P318
   Meyer RE, 1996, LANCET, V347, P162, DOI 10.1016/S0140-6736(96)90345-1
   Meyers RA, 2006, BEHAV NEUROSCI, V120, P401, DOI 10.1037/0735-7044.120.2.401
   Monaco AP, 1981, NEUROBIOLOGY NUCLEUS, P338
   Moorman DE, 2018, PSYCHOPHARMACOLOGY, V235, P1663, DOI 10.1007/s00213-018-4871-2
   MYERS RD, 1974, HDB DRUG CHEM STIMUL
   Nader MA, 2002, NEUROPSYCHOPHARMACOL, V27, P35, DOI 10.1016/S0893-133X(01)00427-4
   Neisewander JL, 2000, J NEUROSCI, V20, P798, DOI 10.1523/JNEUROSCI.20-02-00798.2000
   Nesse RM, 1997, SCIENCE, V278, P63, DOI 10.1126/science.278.5335.63
   Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578
   Olausson P, 2007, ANN NY ACAD SCI, V1121, P610, DOI 10.1196/annals.1401.016
   OLDS J, 1954, J COMP PHYSIOL PSYCH, V47, P419, DOI 10.1037/h0058775
   OLDS ME, 1982, BRAIN RES, V237, P429, DOI 10.1016/0006-8993(82)90454-1
   Panlilio LV, 2003, PSYCHOPHARMACOLOGY, V168, P229, DOI 10.1007/s00213-002-1193-0
   Park WK, 2002, J NEUROSCI, V22, P2916, DOI 10.1523/JNEUROSCI.22-07-02916.2002
   Parsegian A, 2011, BIOL PSYCHIAT, V69, P253, DOI 10.1016/j.biopsych.2010.09.003
   Peters J, 2008, J NEUROSCI, V28, P6046, DOI 10.1523/JNEUROSCI.1045-08.2008
   PETTIT HO, 1984, PSYCHOPHARMACOLOGY, V84, P167, DOI 10.1007/BF00427441
   PETTIT HO, 1989, PHARMACOL BIOCHEM BE, V34, P899, DOI 10.1016/0091-3057(89)90291-8
   PICKENS R, 1968, PSYCHOL REP, V23, P1267, DOI 10.2466/pr0.1968.23.3f.1267
   Pitchers KK, 2017, EUR J NEUROSCI, V46, P2768, DOI 10.1111/ejn.13741
   Plaza-Zabala A, 2010, J NEUROSCI, V30, P2300, DOI 10.1523/JNEUROSCI.5724-09.2010
   Polter AM, 2014, BIOL PSYCHIAT, V76, P785, DOI 10.1016/j.biopsych.2014.04.019
   Pontieri FE, 1995, P NATL ACAD SCI USA, V92, P12304, DOI 10.1073/pnas.92.26.12304
   Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0
   Porrino LJ, 2004, J NEUROSCI, V24, P3554, DOI 10.1523/JNEUROSCI.5578-03.2004
   Porter JN, 2011, J NEUROSCI, V31, P4926, DOI 10.1523/JNEUROSCI.5426-10.2011
   Ramirez DR, 2009, EUR J NEUROSCI, V30, P901, DOI 10.1111/j.1460-9568.2009.06889.x
   RASSNICK S, 1993, BRAIN RES, V623, P16, DOI 10.1016/0006-8993(93)90004-7
   RASSNICK S, 1992, PSYCHOPHARMACOLOGY, V109, P92, DOI 10.1007/BF02245485
   Ray S, 2010, ALCOHOL ALCOHOLISM, V45, P444, DOI 10.1093/alcalc/agq043
   Richards JK, 2008, PSYCHOPHARMACOLOGY, V199, P109, DOI 10.1007/s00213-008-1136-5
   RICHARDSON NR, 1994, DRUG ALCOHOL DEPEN, V36, P23, DOI 10.1016/0376-8716(94)90005-1
   Robbins TW, 1996, CURR OPIN NEUROBIOL, V6, P228, DOI 10.1016/S0959-4388(96)80077-8
   ROBERTS DCS, 1977, PHARMACOL BIOCHEM BE, V6, P615, DOI 10.1016/0091-3057(77)90084-3
   ROBERTS DCS, 1980, PHARMACOL BIOCHEM BE, V12, P781, DOI 10.1016/0091-3057(80)90166-5
   ROBERTS DCS, 1982, PHARMACOL BIOCHEM BE, V17, P901, DOI 10.1016/0091-3057(82)90469-5
   Roberts DCS, 1992, COCAINE PHARM PHYSL, P73
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Rodd ZA, 2005, J PHARMACOL EXP THER, V313, P134, DOI 10.1124/jpet.104.075952
   Rodd ZA, 2004, ALCOHOL CLIN EXP RES, V28, P1212, DOI 10.1097/01.ALC.0000134401.30394.7F
   Rodd ZA, 2004, J NEUROSCI, V24, P1050, DOI 10.1523/JNEUROSCI.1319-03.2004
   Rodd-Henricks ZA, 2002, J PHARMACOL EXP THER, V303, P1216, DOI 10.1124/jpet.102.038950
   Roesch MR, 2007, J NEUROSCI, V27, P245, DOI 10.1523/JNEUROSCI.4080-06.2007
   Rogers JL, 2008, NEUROSCIENCE, V151, P579, DOI 10.1016/j.neuroscience.2007.10.012
   Rogers JL, 2007, NEUROBIOL LEARN MEM, V87, P688, DOI 10.1016/j.nlm.2007.01.003
   Rogers RD, 1999, NEUROPSYCHOPHARMACOL, V20, P322, DOI 10.1016/S0893-133X(98)00091-8
   RUSSELL JA, 1975, J STUD ALCOHOL, V36, P1508, DOI 10.15288/jsa.1975.36.1508
   SAMSON HH, 1985, PHARMACOL BIOCHEM BE, V22, P91, DOI 10.1016/0091-3057(85)90491-5
   Sanchez CJ, 2003, NEUROSCIENCE, V119, P497, DOI 10.1016/S0306-4522(03)00078-2
   Schindler CW, 2016, NEUROPSYCHOPHARMACOL, V41, P2283, DOI 10.1038/npp.2016.27
   Schmeichel BE, 2015, NEUROPSYCHOPHARMACOL, V40, P1123, DOI 10.1038/npp.2014.293
   Schoenbaum G, 2006, TRENDS NEUROSCI, V29, P116, DOI 10.1016/j.tins.2005.12.006
   See RE, 2007, PSYCHOPHARMACOLOGY, V194, P321, DOI 10.1007/s00213-007-0850-8
   See RE, 2003, NEUROSCIENCE, V117, P477, DOI 10.1016/S0306-4522(02)00665-6
   See RE, 2005, EUR J PHARMACOL, V526, P140, DOI 10.1016/j.ejphar.2005.09.034
   See RE, 2001, PSYCHOPHARMACOLOGY, V154, P301, DOI 10.1007/s002130000636
   Shaham Y, 2000, BRAIN RES REV, V33, P13, DOI 10.1016/S0165-0173(00)00024-2
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   Shaham Y, 1997, J NEUROSCI, V17, P2605
   Shaham Y, 2000, EUR J NEUROSCI, V12, P292, DOI 10.1046/j.1460-9568.2000.00899.x
   Shepard JD, 2004, BIOL PSYCHIAT, V55, P1082, DOI 10.1016/j.biopsych.2004.02.032
   Shoblock JR, 2011, PSYCHOPHARMACOLOGY, V215, P191, DOI 10.1007/s00213-010-2127-x
   Simon NW, 2007, BEHAV NEUROSCI, V121, P543, DOI 10.1037/0735-7044.121.3.543
   Singer BF, 2018, J NEUROSCI, V38, P60, DOI 10.1523/JNEUROSCI.2458-17.2017
   Sinha R, 1999, PSYCHOPHARMACOLOGY, V142, P343, DOI 10.1007/s002130050898
   SMITH JE, 1985, PHARMACOL BIOCHEM BE, V23, P843, DOI 10.1016/0091-3057(85)90080-2
   Smith RJ, 2012, EUR J NEUROSCI, V35, P798, DOI 10.1111/j.1460-9568.2012.08013.x
   Smith RJ, 2010, NEUROPHARMACOLOGY, V58, P179, DOI 10.1016/j.neuropharm.2009.06.042
   Smith RJ, 2009, EUR J NEUROSCI, V30, P493, DOI 10.1111/j.1460-9568.2009.06844.x
   Sorg BA, 2012, NEUROSCI BIOBEHAV R, V36, P1400, DOI 10.1016/j.neubiorev.2012.02.004
   Soria G, 2005, NEUROPSYCHOPHARMACOL, V30, P1670, DOI 10.1038/sj.npp.1300707
   Stefanik MT, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00213
   Stefanik MT, 2013, J NEUROSCI, V33, P13654, DOI 10.1523/JNEUROSCI.1570-13.2013
   Stewart J, 2000, J PSYCHIATR NEUROSCI, V25, P125
   Stringfield SJ, 2016, INT J NEUROPSYCHOPH, V19, DOI 10.1093/ijnp/pyw073
   Substance Abuse and Mental Health Services Administration, 2013, DAWN REPORT EMERGENC
   Substance Abuse and Mental Health Services Administration, 2019, KEY SUBSTANCE USE ME
   Sun WL, 2005, PSYCHOPHARMACOLOGY, V177, P315, DOI 10.1007/s00213-004-1956-x
   Suto N, 2011, NEUROSCI LETT, V493, P29, DOI 10.1016/j.neulet.2011.02.011
   Taylor JR, 2009, NEUROPHARMACOLOGY, V56, P186, DOI 10.1016/j.neuropharm.2008.07.027
   Thanos PK, 2005, BEHAV BRAIN RES, V164, P206, DOI 10.1016/j.bbr.2005.06.021
   Thompson PM, 2004, J NEUROSCI, V24, P6028, DOI 10.1523/JNEUROSCI.0713-04.2004
   van Erp AMM, 2007, PSYCHOPHARMACOLOGY, V191, P679, DOI 10.1007/s00213-006-0637-3
   Van Ree JM, 1999, PHARMACOL REV, V51, P341
   Vanderschuren LJMJ, 2005, J NEUROSCI, V25, P8665, DOI 10.1523/JNEUROSCI.0925-05.2005
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   VANREE JM, 1980, PHARMACOL BIOCHEM BE, V13, P257, DOI 10.1016/S0091-3057(80)80039-6
   Venniro M, 2019, NEUROPSYCHOPHARMACOL, V44, P234, DOI 10.1038/s41386-018-0196-4
   Venniro M, 2016, PROG BRAIN RES, V224, P25, DOI 10.1016/bs.pbr.2015.08.004
   Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI 10.1093/cercor/10.3.318
   Volkow ND, 2003, J CLIN INVEST, V111, P1444, DOI 10.1172/JCI200318533
   VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
   Volkow ND, 2019, PHYSIOL REV, V99, P2115, DOI 10.1152/physrev.00014.2018
   Wagner FA, 2002, NEUROPSYCHOPHARMACOL, V26, P479, DOI 10.1016/S0893-133X(01)00367-0
   Warren BL, 2019, J NEUROSCI, V39, P7394, DOI 10.1523/JNEUROSCI.0918-19.2019
   Weiss F, 2000, P NATL ACAD SCI USA, V97, P4321, DOI 10.1073/pnas.97.8.4321
   WEISS F, 1992, ANN NY ACAD SCI, V654, P220, DOI 10.1111/j.1749-6632.1992.tb25970.x
   WEISS F, 1993, J PHARMACOL EXP THER, V267, P250
   Weissenborn R, 1997, PSYCHOPHARMACOLOGY, V134, P242, DOI 10.1007/s002130050447
   Wells AM, 2011, LEARN MEMORY, V18, P693, DOI 10.1101/lm.2273111
   Whitelaw RB, 1996, PSYCHOPHARMACOLOGY, V127, P213, DOI 10.1007/BF02805996
   WIKLER A, 1973, ARCH GEN PSYCHIAT, V28, P611
   WILSON MC, 1974, PHARMACOL BIOCHEM BE, V2, P563, DOI 10.1016/0091-3057(74)90021-5
   Winstanley CA, 2007, J NEUROSCI, V27, P10497, DOI 10.1523/JNEUROSCI.2566-07.2007
   WISE RA, 1980, PHARMACOL BIOCHEM BE, V13, P213, DOI 10.1016/S0091-3057(80)80033-5
   WISE RA, 1995, PSYCHOPHARMACOLOGY, V120, P10, DOI 10.1007/BF02246140
   WISE RA, 1995, SYNAPSE, V21, P140, DOI 10.1002/syn.890210207
   Wise RA, 2002, NEURON, V36, P229, DOI 10.1016/S0896-6273(02)00965-0
   WOLFFGRAMM J, 1995, BEHAV BRAIN RES, V70, P77, DOI 10.1016/0166-4328(95)00131-C
   Wong DF, 2006, NEUROPSYCHOPHARMACOL, V31, P2716, DOI 10.1038/sj.npp.1301194
   WOOLVERTON WL, 1986, PHARMACOL BIOCHEM BE, V24, P531, DOI 10.1016/0091-3057(86)90553-8
   Xi ZX, 2008, NEUROPSYCHOPHARMACOL, V33, P1735, DOI 10.1038/sj.npp.1301552
   Xie XH, 2010, PSYCHOPHARMACOLOGY, V208, P1, DOI 10.1007/s00213-009-1700-7
   YOKEL RA, 1975, SCIENCE, V187, P547, DOI 10.1126/science.1114313
   Zanos P, 2018, BRIT J PHARMACOL, V175, P2809, DOI 10.1111/bph.13757
   Zapata A, 2010, J NEUROSCI, V30, P15457, DOI 10.1523/JNEUROSCI.4072-10.2010
   Zavala AR, 2003, BRAIN RES, V990, P157, DOI 10.1016/S0006-8993(03)03452-8
   Zavala AR, 2008, SYNAPSE, V62, P421, DOI 10.1002/syn.20502
   Zhou LY, 2012, J PHARMACOL EXP THER, V340, P801, DOI 10.1124/jpet.111.187567
   Zhou W, 2007, NEUROSCIENCE, V144, P1209, DOI 10.1016/j.neuroscience.2006.11.013
   ZITO KA, 1985, PHARMACOL BIOCHEM BE, V23, P1029, DOI 10.1016/0091-3057(85)90110-8
NR 319
TC 18
Z9 18
U1 2
U2 22
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 2157-1422
J9 CSH PERSPECT MED
JI Cold Spring Harb. Perspect. Med.
PD APR
PY 2021
VL 11
IS 4
AR a039628
DI 10.1101/cshperspect.a039628
PG 24
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Research & Experimental Medicine
GA RI4WM
UT WOS:000636909600007
PM 32205414
OA Bronze, Green Published
DA 2023-06-23
ER

PT J
AU Schiffer, WK
   Lee, DE
   Brodie, JD
   Dewey, SL
AF Schiffer, WK
   Lee, DE
   Brodie, JD
   Dewey, SL
TI Imaging addiction with PET: is insight in sight?
SO DRUG DISCOVERY TODAY
LA English
DT Review
ID GAMMA-VINYL-GABA; POSITRON-EMISSION-TOMOGRAPHY; DOPAMINE-D-2
   RECEPTOR-BINDING; CEREBRAL-BLOOD-FLOW; MEASURED IN-VIVO; HUMAN-BRAIN;
   TRANSAMINASE INHIBITION; IRREVERSIBLE INHIBITOR; ANTIEPILEPTIC DRUGS;
   GLUCOSE-METABOLISM
AB Neurochemical imaging studies can identify molecular targets of abused drugs and link them to the underlying pathology associated with behaviors such as drug dependence, addiction and withdrawal. positron emission tomography (PET) is opening new avenues for the investigation of the neurochemical disturbances underlying drug abuse and addiction and the in vivo mechanisms by which medications might ameliorate these conditions. PET can identify vulnerable human populations, treatment strategies and monitor treatment efficacy. Thus, with this tool and the knowledge it provides, the potential for developing novel drugs and treatment strategies for drug addiction is now close at hand.
C1 SUNY Stony Brook, Dept Neurobiol & Behav, Stony Brook, NY 11794 USA.
   Brookhaven Natl Lab, Dept Chem, Upton, NY 11973 USA.
   NYU, Sch Med, New York, NY 10016 USA.
C3 State University of New York (SUNY) System; State University of New York
   (SUNY) Stony Brook; United States Department of Energy (DOE); Brookhaven
   National Laboratory; New York University
RP Schiffer, WK (通讯作者)，SUNY Stony Brook, Dept Neurobiol & Behav, Stony Brook, NY 11794 USA.
EM wynne@bnl.gov
OI Brodie, Jonathan/0000-0002-2254-8654
FU NIDA NIH HHS [F31-DA15874, DA015874] Funding Source: Medline
CR Aalto S, 2002, PSYCHOPHARMACOLOGY, V164, P401, DOI 10.1007/s00213-002-1236-6
   Abadie P, 1996, EUR J PHARMACOL, V295, P35, DOI 10.1016/0014-2999(95)00633-8
   ABE M, 1983, NEUROCHEM RES, V8, P563, DOI 10.1007/BF00964697
   Abi-Dargham A, 2000, P NATL ACAD SCI USA, V97, P8104, DOI 10.1073/pnas.97.14.8104
   AGMO A, 1985, PSYCHOPHARMACOLOGY, V87, P51, DOI 10.1007/BF00431777
   ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H
   Balster RL, 2003, DRUG ALCOHOL DEPEN, V70, pS13, DOI 10.1016/S0376-8716(03)00097-8
   BEARDSLEY PM, 1990, J PHARMACOL EXP THER, V252, P953
   BENMENACHEM E, 1991, J CHILD NEUROL, V6, pS11, DOI 10.1177/0883073891006002041
   Beran RG, 1999, NEUROLOGY, V52, pA249
   Bialer M, 2001, EPILEPSY RES, V43, P11, DOI 10.1016/S0920-1211(00)00171-6
   Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101
   Boileau I, 2003, SYNAPSE, V49, P226, DOI 10.1002/syn.10226
   Brodie JD, 2005, SYNAPSE, V55, P122, DOI 10.1002/syn.20097
   Brodie JD, 2003, SYNAPSE, V50, P261, DOI 10.1002/syn.10278
   Castner SA, 2000, SCIENCE, V287, P2020, DOI 10.1126/science.287.5460.2020
   CHARALAMBOUS A, 1991, PHARMACOL BIOCHEM BE, V40, P503, DOI 10.1016/0091-3057(91)90354-5
   Collins ED, 2003, PHARMACOL BIOCHEM BE, V76, P401, DOI 10.1016/j.pbb.2003.08.013
   Cooper JR, 1996, BIOCH BASIS NEUROPHA
   Cumming P, 2003, NEUROIMAGE, V19, P1127, DOI 10.1016/S1053-8119(03)00079-X
   DEWEY SL, 1993, P NATL ACAD SCI USA, V90, P11816, DOI 10.1073/pnas.90.24.11816
   Dewey SL, 1999, SYNAPSE, V31, P76
   DEWEY SL, 1992, J NEUROSCI, V12, P3773
   DEWEY SL, 1991, SYNAPSE, V7, P324, DOI 10.1002/syn.890070409
   Dewey SL, 1998, SYNAPSE, V30, P119, DOI 10.1002/(SICI)1098-2396(199810)30:2<119::AID-SYN1>3.0.CO;2-F
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Drevets WC, 2001, BIOL PSYCHIAT, V49, P81, DOI 10.1016/S0006-3223(00)01038-6
   Edling C, 1997, INT ARCH OCC ENV HEA, V70, P180, DOI 10.1007/s004200050204
   Eke T, 1997, BRIT MED J, V314, P180, DOI 10.1136/bmj.314.7075.180
   FECHTNER RD, INVEST OPHTHALMOL VI
   FOWLER JS, 1989, SYNAPSE, V4, P371, DOI 10.1002/syn.890040412
   Gardner EL, 2002, SYNAPSE, V46, P240, DOI 10.1002/syn.10138
   GARDNER EL, 1991, PHARMACOL BIOCHEM BE, V40, P571, DOI 10.1016/0091-3057(91)90365-9
   Gasior M, 1999, J PHARMACOL EXP THER, V290, P1148
   Gerasimov MR, 1999, SYNAPSE, V34, P11, DOI 10.1002/(SICI)1098-2396(199910)34:1<11::AID-SYN2>3.0.CO;2-5
   Gerasimov MR, 2002, LIFE SCI, V70, P2811, DOI 10.1016/S0024-3205(02)01542-4
   Gulyas B, 2002, NUCL MED BIOL, V29, P753, DOI 10.1016/S0969-8051(02)00319-0
   Hagelberg N, 2002, SYNAPSE, V45, P25, DOI 10.1002/syn.10078
   Hageman G, 1999, J NEUROL, V246, P198, DOI 10.1007/s004150050334
   HAMMERS A, 2004, NEURORECEPTOR MAPP O, V28
   Haney Margaret, 2004, Expert Rev Vaccines, V3, P11, DOI 10.1586/14760584.3.1.11
   Hayase T, 2004, J APPL TOXICOL, V24, P15, DOI 10.1002/jat.939
   Hietala J, 1997, PSYCHOPHARMACOLOGY, V132, P361, DOI 10.1007/s002130050356
   HOLTHOFF VA, 1991, J CEREBR BLOOD F MET, V11, P745, DOI 10.1038/jcbfm.1991.131
   JAVITT DC, 1991, AM J PSYCHIAT, V148, P1301
   JOLKKONEN J, 1992, EUR J PHARMACOL, V229, P269, DOI 10.1016/0014-2999(92)90566-M
   JUNG MJ, 1977, J NEUROCHEM, V29, P797, DOI 10.1111/j.1471-4159.1977.tb10721.x
   KALIVAS PW, 1993, BRAIN RES REV, V18, P75, DOI 10.1016/0165-0173(93)90008-N
   Kalviainen R, 1999, NEUROLOGY, V53, P922, DOI 10.1212/WNL.53.5.922
   Koob GF, 1996, MOL PSYCHIATR, V1, P186
   Kosten TR, 2002, VACCINE, V20, P1196, DOI 10.1016/S0264-410X(01)00425-X
   Kosten TR, 1998, AM J ADDICTION, V7, P205
   Kreek MJ, 2002, NAT REV DRUG DISCOV, V1, P710, DOI 10.1038/nrd897
   Kushner S. A., 1997, Society for Neuroscience Abstracts, V23, P1942
   Kushner SA, 1997, PSYCHOPHARMACOLOGY, V133, P383, DOI 10.1007/s002130050418
   Lee DE, 2004, SYNAPSE, V54, P183, DOI 10.1002/syn.20072
   Ling W, 1998, NEUROPSYCHOPHARMACOL, V18, P403
   Lingford-Hughes A, 2003, BRIT MED BULL, V65, P209, DOI 10.1093/bmb/65.1.209
   LONDON ED, 1990, CIBA F SYMP, V152, P131
   LONDON ED, 1990, ARCH GEN PSYCHIAT, V47, P73
   LONDON ED, 1990, ARCH GEN PSYCHIAT, V47, P567
   Manuchehri K, 2000, BRIT MED J, V320, P1403
   Manuchehri K, 2000, BRIT J OPHTHALMOL, V84, P499, DOI 10.1136/bjo.84.5.499
   Mathew RJ, 2002, PSYCHIAT RES-NEUROIM, V116, P173, DOI 10.1016/S0925-4927(02)00069-0
   MATTHEW E, 1995, P NATL ACAD SCI USA, V92, P2775, DOI 10.1073/pnas.92.7.2775
   Melichar JK, 2005, J PHARMACOL EXP THER, V312, P309, DOI 10.1124/jpet.104.072686
   Meltzer PC, 2002, BIOORGAN MED CHEM, V10, P3583, DOI 10.1016/S0968-0896(02)00244-4
   Munzar P, 2000, EUR J PHARMACOL, V408, P169, DOI 10.1016/S0014-2999(00)00772-X
   Muzic RF, 1998, J NUCL MED, V39, P2048
   Nakamura H, 1997, NUCL MED BIOL, V24, P165, DOI 10.1016/S0969-8051(96)00204-1
   NYBACK H, 1994, PSYCHOPHARMACOLOGY, V115, P31, DOI 10.1007/BF02244748
   OBRIEN C, 2002, NEUROPSYCHOPHARMACOL, P1355
   OBrien CP, 1997, SCIENCE, V278, P66, DOI 10.1126/science.278.5335.66
   Paul M, 2001, SYNAPSE, V41, P219, DOI 10.1002/syn.1078
   Petroff OAC, 1998, MOL NEUROBIOL, V16, P97, DOI 10.1007/BF02740605
   Pilla M, 1999, NATURE, V400, P371, DOI 10.1038/43944
   Pouletty P, 2002, NAT REV DRUG DISCOV, V1, P731, DOI 10.1038/nrd896
   Richerson GB, 2003, J NEUROPHYSIOL, V90, P1363, DOI 10.1152/jn.00317.2003
   ROBERTS DCS, 1977, PHARMACOL BIOCHEM BE, V6, P615, DOI 10.1016/0091-3057(77)90084-3
   Roberts DCS, 2000, ANN NY ACAD SCI, V909, P145
   Scanziani M, 1997, NATURE, V385, P630, DOI 10.1038/385630a0
   Schiffer WK, 2003, NEUROPSYCHOPHARMACOL, V28, P2192, DOI 10.1038/sj.npp.1300258
   Schiffer WK, 2003, PSYCHOPHARMACOLOGY, V168, P339, DOI 10.1007/s00213-003-1446-6
   Schiffer WK, 2000, LIFE SCI, V66, pPL169, DOI 10.1016/S0024-3205(00)00432-X
   Schlaepfer TE, 1997, AM J PSYCHIAT, V154, P1209
   SEEMAN P, 1989, SYNAPSE, V3, P96, DOI 10.1002/syn.890030113
   SHIUE CY, 1995, NUCL MED BIOL, V22, P321, DOI 10.1016/0969-8051(94)00104-R
   Smith G. S., 1993, Society for Neuroscience Abstracts, V19, P302
   Smith GS, 1997, AM J PSYCHIAT, V154, P490
   Smith GS, 1998, NEUROPSYCHOPHARMACOL, V18, P18
   Spanaki MV, 1999, NEUROLOGY, V53, P1518, DOI 10.1212/WNL.53.7.1518
   Stromberg MF, 2001, PHARMACOL BIOCHEM BE, V68, P291, DOI 10.1016/S0091-3057(00)00456-1
   SWERDLOW NR, 1986, PHARMACOL BIOCHEM BE, V25, P233, DOI 10.1016/0091-3057(86)90261-3
   Tsukada H, 2002, SYNAPSE, V45, P207, DOI 10.1002/syn.10102
   Tzschentke TM, 1998, PROG NEUROBIOL, V56, P613, DOI 10.1016/S0301-0082(98)00060-4
   Vocci F, 1995, NIDA Res Monogr, V149, P4
   Volkow ND, 1999, J PSYCHOPHARMACOL, V13, P337, DOI 10.1177/026988119901300406
   Volkow ND, 2001, AM J PSYCHIAT, V158, P377, DOI 10.1176/appi.ajp.158.3.377
   VOLKOW ND, 1995, NEUROPSYCHOPHARMACOL, V12, P123, DOI 10.1038/sj.npp.1380246
   Volkow ND, 1996, PSYCHIAT RES-NEUROIM, V67, P29, DOI 10.1016/0925-4927(96)02817-X
   Volkow ND, 1997, ANN NY ACAD SCI, V820, P41, DOI 10.1111/j.1749-6632.1997.tb46188.x
   Volkow ND, 1996, NEUROPSYCHOPHARMACOL, V14, P159, DOI 10.1016/0893-133X(95)00073-M
   Vollenweider FX, 1998, PSYCHIAT RES-NEUROIM, V83, P149, DOI 10.1016/S0925-4927(98)00033-X
   Vollenweider FX, 1999, NEUROPSYCHOPHARMACOL, V20, P424, DOI 10.1016/S0893-133X(98)00108-0
   Wang GJ, 2004, AM J PSYCHIAT, V161, P242, DOI 10.1176/appi.ajp.161.2.242
   Wang GJ, 1997, NEUROPSYCHOPHARMACOL, V16, P174, DOI 10.1016/S0893-133X(96)00184-4
   Wang GJ, 2000, ALCOHOL CLIN EXP RES, V24, P822, DOI 10.1111/j.1530-0277.2000.tb02061.x
   Weiss F, 2001, ANN NY ACAD SCI, V937, P1, DOI 10.1111/j.1749-6632.2001.tb03556.x
   Wolf ME, 1998, PROG NEUROBIOL, V54, P679, DOI 10.1016/S0301-0082(97)00090-7
   Wu J C, 1991, Yakubutsu Seishin Kodo, V11, P47
   Wu JC, 1997, NEUROPSYCHOPHARMACOL, V17, P402, DOI 10.1016/S0893-133X(97)00089-4
   Wu YM, 2001, J NEUROSCI, V21, P2630, DOI 10.1523/JNEUROSCI.21-08-02630.2001
   Yu RCT, 1999, CARCINOGENESIS, V20, P1193, DOI 10.1093/carcin/20.7.1193
   ZITO KA, 1985, PHARMACOL BIOCHEM BE, V23, P1029, DOI 10.1016/0091-3057(85)90110-8
   Zubieta JK, 1996, NAT MED, V2, P1225, DOI 10.1038/nm1196-1225
NR 115
TC 12
Z9 12
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6446
EI 1878-5832
J9 DRUG DISCOV TODAY
JI Drug Discov. Today
PD APR 15
PY 2005
VL 10
IS 8
BP 547
EP 562
AR PII S1359-6446(05)03412-4
DI 10.1016/S1359-6446(05)03412-4
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 912PM
UT WOS:000228091600008
PM 15837598
DA 2023-06-23
ER

PT J
AU Konova, AB
   Parvaz, MA
   Bernstein, V
   Schneider, KE
   Moeller, SJ
   Goldstein, RZ
AF Konova, Anna B.
   Parvaz, Muhammad A.
   Bernstein, Vladimir
   Schneider, Kristin E.
   Moeller, Scott J.
   Goldstein, Rita Z.
TI Extinguishing Drug Cue Associations in Addiction: Role of the VMPFC
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 69th Annual Scientific Convention and Meeting of the
   Society-of-Biological-Psychiatry
CY 2014
CL New York, NY
SP Soc Biol Psychiat
DE Extinction learning; Cocaine; Addiction; fMRI
C1 [Konova, Anna B.; Parvaz, Muhammad A.; Bernstein, Vladimir; Schneider, Kristin E.; Moeller, Scott J.; Goldstein, Rita Z.] Icahn Sch Med Mt Sinai, Dept Psychiat & Neurosci, New York, NY USA.
   [Konova, Anna B.] SUNY Stony Brook, Dept Psychol, Stony Brook, NY 11794 USA.
C3 Icahn School of Medicine at Mount Sinai; State University of New York
   (SUNY) System; State University of New York (SUNY) Stony Brook
RI Moeller, Scott J/AAV-1861-2021; Konova, Anna/AAX-5209-2020; Parvaz,
   Muhammad/GPF-9163-2022
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2014
VL 75
IS 9
SU S
MA 722
BP 207S
EP 208S
PG 2
WC Neurosciences; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Neurosciences & Neurology; Psychiatry
GA AE6KS
UT WOS:000334101801222
DA 2023-06-23
ER

PT J
AU Dong, Y
   Nestler, EJ
AF Dong, Yan
   Nestler, Eric J.
TI The neural rejuvenation hypothesis of cocaine addiction
SO TRENDS IN PHARMACOLOGICAL SCIENCES
LA English
DT Review
DE cocaine; addiction; silent synapse; NMDA receptor; synaptic plasticity;
   CREB; dendritic spine
ID RECEPTOR SUBUNIT COMPOSITION; EVOKED SYNAPTIC PLASTICITY;
   NUCLEUS-ACCUMBENS NEURONS; ELEMENT-BINDING PROTEIN; LONG-TERM
   POTENTIATION; AMPA-SILENT SYNAPSES; VISUAL-CORTEX; IN-VIVO; BASOLATERAL
   AMYGDALA; DENDRITIC SPINES
AB A leading hypothesis guiding current molecular and cellular research into drug addiction conceptualizes key aspects of addiction as a form of memory in which common neuroplasticity mechanisms that mediate normal learning and memory processes are 'hijacked' by exposure to drugs of abuse to produce pathologic addiction-related memories. Such addiction-related memories are particularly robust and long-lasting and once formed are less amenable to updating. Here we propose a neural rejuvenation hypothesis of cocaine addiction. According to this hypothesis, repeated exposure to drugs of abuse induces some plasticity mechanisms normally associated with brain development within the reward circuitry that mediate the highly efficient and unusually stable memory abnormalities that characterize addiction.
C1 [Dong, Yan] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15260 USA.
   [Nestler, Eric J.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA.
   [Nestler, Eric J.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Icahn School of Medicine at Mount Sinai; Icahn School of
   Medicine at Mount Sinai
RP Dong, Y (通讯作者)，Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15260 USA.
EM yandong@pitt.edu; eric.nestler@mssm.edu
RI Dong, Yan/A-4154-2016
OI Dong, Yan/0000-0003-0016-9028
FU NIH [DA023206, DA030379, DA034856];  [DA008227];  [DA014133]
FX Related work by the authors was supported by grants NIH DA023206,
   DA030379, and DA034856 to Y.D., and grants DA008227 and DA014133 to
   E.J.N.
CR Abdolahi A, 2010, EUR J NEUROSCI, V31, P733, DOI 10.1111/j.1460-9568.2010.07114.x
   Aguado F, 2003, DEVELOPMENT, V130, P1267, DOI 10.1242/dev.00351
   Aguado F, 2009, J NEUROSCI, V29, P328, DOI 10.1523/JNEUROSCI.5252-08.2009
   Albertson DN, 2006, NEUROPSYCHOPHARMACOL, V31, P2304, DOI 10.1038/sj.npp.1301089
   ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404
   Ambroggi F, 2008, NEURON, V59, P648, DOI 10.1016/j.neuron.2008.07.004
   Arthur JSC, 2004, J NEUROSCI, V24, P4324, DOI 10.1523/JNEUROSCI.5227-03.2004
   BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145
   Barria A, 2002, NEURON, V35, P345, DOI 10.1016/S0896-6273(02)00776-6
   Bienkowski P, 2004, EUR NEUROPSYCHOPHARM, V14, P355, DOI 10.1016/j.euroneuro.2003.10.005
   Boudreau AC, 2005, J NEUROSCI, V25, P9144, DOI 10.1523/JNEUROSCI.2252-05.2005
   Brown TE, 2011, J NEUROSCI, V31, P8163, DOI 10.1523/JNEUROSCI.0016-11.2011
   CADOR M, 1989, NEUROSCIENCE, V30, P77, DOI 10.1016/0306-4522(89)90354-0
   Carlezon WA, 1998, SCIENCE, V282, P2272, DOI 10.1126/science.282.5397.2272
   Chao J, 2004, ANNU REV MED, V55, P113, DOI 10.1146/annurev.med.55.091902.103730
   CHARPIER S, 1995, P NATL ACAD SCI USA, V92, P117, DOI 10.1073/pnas.92.1.117
   Chen X, 2005, NEURON, V46, P13, DOI 10.1016/j.neuron.2005.03.009
   COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0
   Conrad KL, 2008, NATURE, V454, P118, DOI 10.1038/nature06995
   Creed MC, 2013, CURR OPIN NEUROBIOL, V23, P553, DOI 10.1016/j.conb.2013.03.005
   DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0
   Dingledine R, 1999, PHARMACOL REV, V51, P7
   Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0
   Ehrlich ME, 2002, J NEUROSCI, V22, P9155
   Eisch AJ, 2000, P NATL ACAD SCI USA, V97, P7579, DOI 10.1073/pnas.120552597
   Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Filip M, 2006, BRAIN RES, V1071, P218, DOI 10.1016/j.brainres.2005.11.099
   Friedman HV, 2000, NEURON, V27, P57, DOI 10.1016/S0896-6273(00)00009-X
   FRITSCHY JM, 1994, J NEUROSCI, V14, P5302
   Fumagalli F, 2007, EUR J NEUROSCI, V26, P2756, DOI 10.1111/j.1460-9568.2007.05918.x
   Gambrill AC, 2011, P NATL ACAD SCI USA, V108, P5855, DOI 10.1073/pnas.1012676108
   GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107
   Gipson CD, 2014, NEUROPHARMACOLOGY, V76, P276, DOI 10.1016/j.neuropharm.2013.04.032
   Gipson CD, 2013, P NATL ACAD SCI USA, V110, P9124, DOI 10.1073/pnas.1220591110
   Gipson CD, 2013, NEURON, V77, P867, DOI 10.1016/j.neuron.2013.01.005
   Graham DL, 2007, NAT NEUROSCI, V10, P1029, DOI 10.1038/nn1929
   Gray JA, 2011, NEURON, V71, P1085, DOI 10.1016/j.neuron.2011.08.007
   Grimm JW, 2005, PHYSIOL BEHAV, V84, P73, DOI 10.1016/j.physbeh.2004.10.011
   Grimm JW, 2003, J NEUROSCI, V23, P742
   Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134
   Groc L, 2006, TRENDS NEUROSCI, V29, P132, DOI 10.1016/j.tins.2006.01.005
   Grueter BA, 2013, P NATL ACAD SCI USA, V110, P1923, DOI 10.1073/pnas.1221742110
   Guez-Barber D, 2011, J NEUROSCI, V31, P4251, DOI 10.1523/JNEUROSCI.6195-10.2011
   Hall BJ, 2008, TRENDS NEUROSCI, V31, P82, DOI 10.1016/j.tins.2007.11.010
   Halt AR, 2012, EMBO J, V31, P1203, DOI 10.1038/emboj.2011.482
   Hanse E, 2013, NAT REV NEUROSCI, V14, P839, DOI 10.1038/nrn3642
   HOLT EB, 1931, ANIMAL DRIVE LEARNIN
   Horch HW, 1999, NEURON, V23, P353
   Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677
   Huang YH, 2008, J BIOL CHEM, V283, P2751, DOI 10.1074/jbc.M706578200
   Huang YH, 2013, NEURON, V80, P835, DOI 10.1016/j.neuron.2013.11.001
   Huang YHH, 2009, NEURON, V63, P40, DOI 10.1016/j.neuron.2009.06.007
   Impey S, 2004, CELL, V119, P1041, DOI 10.1016/S0092-8674(04)01159-6
   Isaac JTR, 1999, CAN J PHYSIOL PHARM, V77, P735, DOI 10.1139/cjpp-77-9-735
   ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2
   Ji YY, 2010, NAT NEUROSCI, V13, P302, DOI 10.1038/nn.2505
   Kalivas PW, 2005, NAT NEUROSCI, V8, P1440, DOI 10.1038/nn1105-1440
   Kennedy PJ, 2013, NAT NEUROSCI, V16, P434, DOI 10.1038/nn.3354
   Kerchner GA, 2008, NAT REV NEUROSCI, V9, P813, DOI 10.1038/nrn2501
   Kirkwood A, 1996, NATURE, V381, P526, DOI 10.1038/381526a0
   Kleim JA, 1996, J NEUROSCI, V16, P4529
   Klein M, 1998, GENE, V208, P259, DOI 10.1016/S0378-1119(98)00005-5
   Knott GW, 2002, NEURON, V34, P265, DOI 10.1016/S0896-6273(02)00663-3
   Kolb B, 2003, P NATL ACAD SCI USA, V100, P10523, DOI 10.1073/pnas.1834271100
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   KOOB GF, 1976, SCIENCE, V194, P637, DOI 10.1126/science.982032
   Lee BR, 2013, NAT NEUROSCI, V16, P1644, DOI 10.1038/nn.3533
   Lee BR, 2011, NEUROPHARMACOLOGY, V61, P1060, DOI 10.1016/j.neuropharm.2010.12.033
   Lee HK, 2005, NAT NEUROSCI, V8, P1657, DOI 10.1038/nn1586
   LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0
   LIN JW, 1988, J NEUROSCI, V8, P1313
   Liu NY, 2007, CHINESE MED J-PEKING, V120, P910, DOI 10.1097/00029330-200705020-00011
   Lobo MK, 2010, SCIENCE, V330, P385, DOI 10.1126/science.1188472
   Lonze BE, 2002, NEURON, V34, P371, DOI 10.1016/S0896-6273(02)00686-4
   Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0
   Lu B, 2013, NAT REV NEUROSCI, V14, P401, DOI 10.1038/nrn3505
   Maffei A, 2008, PROG BRAIN RES, V169, P211, DOI 10.1016/S0079-6123(07)00012-X
   Malenka RC, 1997, NEURON, V19, P473, DOI 10.1016/S0896-6273(00)80362-1
   Mandyam CD, 2012, TRENDS NEUROSCI, V35, P250, DOI 10.1016/j.tins.2011.12.005
   Manganas LN, 2007, SCIENCE, V318, P980, DOI 10.1126/science.1147851
   Marie H, 2005, NEURON, V45, P741, DOI 10.1016/j.neuron.2005.01.039
   Matsuzaki M, 2001, NAT NEUROSCI, V4, P1086, DOI 10.1038/nn736
   Maze I, 2010, SCIENCE, V327, P213, DOI 10.1126/science.1179438
   MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X
   McClung CA, 2003, NAT NEUROSCI, V6, P1208, DOI 10.1038/nn1143
   McCutcheon JE, 2011, J NEUROSCI, V31, P5737, DOI 10.1523/JNEUROSCI.0350-11.2011
   MERRILL EG, 1972, J PHYSIOL-LONDON, V226, P825, DOI 10.1113/jphysiol.1972.sp010012
   Merz K, 2011, EUR J NEUROSCI, V33, P1078, DOI 10.1111/j.1460-9568.2011.07606.x
   MESSIER B, 1960, AM J ANAT, V106, P247, DOI 10.1002/aja.1001060305
   Minichiello L, 1999, NEURON, V24, P401, DOI 10.1016/S0896-6273(00)80853-3
   MOGENSON GJ, 1980, PROG NEUROBIOL, V14, P69, DOI 10.1016/0301-0082(80)90018-0
   Murphy DD, 1997, P NATL ACAD SCI USA, V94, P1482, DOI 10.1073/pnas.94.4.1482
   Neisewander JL, 2000, J NEUROSCI, V20, P798, DOI 10.1523/JNEUROSCI.20-02-00798.2000
   Nestler EJ, 2002, NEUROBIOL LEARN MEM, V78, P637, DOI 10.1006/nlme.2002.4084
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   Noguchi J, 2005, NEURON, V46, P609, DOI 10.1016/j.neuron.2005.03.015
   O'Dell LE, 1999, NEUROPSYCHOPHARMACOL, V20, P591, DOI 10.1016/S0893-133X(98)00083-9
   OLDS J, 1954, J COMP PHYSIOL PSYCH, V47, P419, DOI 10.1037/h0058775
   Petralia RS, 1999, NAT NEUROSCI, V2, P31, DOI 10.1038/4532
   Philpot BD, 2003, J NEUROSCI, V23, P5583
   Philpot BD, 2007, NEURON, V53, P495, DOI 10.1016/j.neuron.2007.01.027
   Philpot BD, 2010, NEURON, V66, P814, DOI 10.1016/j.neuron.2010.06.014
   Pickens CL, 2011, TRENDS NEUROSCI, V34, P411, DOI 10.1016/j.tins.2011.06.001
   Quinlan EM, 1999, P NATL ACAD SCI USA, V96, P12876, DOI 10.1073/pnas.96.22.12876
   Quinlan EM, 1999, NAT NEUROSCI, V2, P352, DOI 10.1038/7263
   Roberts AC, 2009, NEURON, V63, P342, DOI 10.1016/j.neuron.2009.06.016
   Robinson TE, 2004, NEUROPHARMACOLOGY, V47, P33, DOI 10.1016/j.neuropharm.2004.06.025
   Robison AJ, 2013, J NEUROSCI, V33, P4295, DOI 10.1523/JNEUROSCI.5192-12.2013
   Robison AJ, 2011, NAT REV NEUROSCI, V12, P623, DOI 10.1038/nrn3111
   Russo SJ, 2010, TRENDS NEUROSCI, V33, P267, DOI 10.1016/j.tins.2010.02.002
   Russo SJ, 2009, J NEUROSCI, V29, P3529, DOI 10.1523/JNEUROSCI.6173-08.2009
   Schumann J, 2009, J NEUROSCI, V29, P6955, DOI 10.1523/JNEUROSCI.1329-09.2009
   See RE, 2001, PSYCHOPHARMACOLOGY, V154, P301, DOI 10.1007/s002130000636
   Setlow B, 2002, BEHAV NEUROSCI, V116, P267, DOI 10.1037//0735-7044.116.2.267
   Shaham Y, 2005, NAT NEUROSCI, V8, P1437, DOI 10.1038/nn1105-1437
   Shen HW, 2011, P NATL ACAD SCI USA, V108, P19407, DOI 10.1073/pnas.1112052108
   Shepard JD, 2004, BIOL PSYCHIAT, V55, P1082, DOI 10.1016/j.biopsych.2004.02.032
   Shepherd JD, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00049
   Shiflett MW, 2010, EUR J NEUROSCI, V32, P1735, DOI 10.1111/j.1460-9568.2010.07439.x
   Sobczyk A, 2005, J NEUROSCI, V25, P6037, DOI 10.1523/JNEUROSCI.1221-05.2005
   Stuber GD, 2011, NATURE, V475, P377, DOI 10.1038/nature10194
   Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7
   Tartaglia N, 2001, J BIOL CHEM, V276, P37585, DOI 10.1074/jbc.M101683200
   Thomas MJ, 2001, NAT NEUROSCI, V4, P1217, DOI 10.1038/nn757
   Tyler WJ, 2003, J PHYSIOL-LONDON, V553, P497, DOI 10.1113/jphysiol.2003.052639
   van Zundert B, 2004, TRENDS NEUROSCI, V27, P428, DOI 10.1016/j.tins.2004.05.010
   Waites CL, 2005, ANNU REV NEUROSCI, V28, P251, DOI 10.1146/annurev.neuro.27.070203.144336
   Washbourne P, 2002, NAT NEUROSCI, V5, P751, DOI 10.1038/nn883
   WISDEN W, 1992, J NEUROSCI, V12, P1040
   WISE RA, 1987, PHARMACOL THERAPEUT, V35, P227, DOI 10.1016/0163-7258(87)90108-2
   Wolf ME, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00072
   Wolf ME, 2010, TRENDS NEUROSCI, V33, P391, DOI 10.1016/j.tins.2010.06.003
   Wong HK, 2002, J COMP NEUROL, V450, P303, DOI 10.1002/cne.10314
   Wong WC, 2013, J NEUROSCI, V33, P4913, DOI 10.1523/JNEUROSCI.1371-12.2013
   Xiao MY, 2004, NAT NEUROSCI, V7, P236, DOI 10.1038/nn1196
   Yao WD, 2004, NEURON, V41, P625, DOI 10.1016/S0896-6273(04)00048-0
   Yasuda H, 2003, NAT NEUROSCI, V6, P15, DOI 10.1038/nn985
   Yuan TF, 2013, NEURON, V80, P1025, DOI 10.1016/j.neuron.2013.07.050
   Zito K, 2009, NEURON, V61, P247, DOI 10.1016/j.neuron.2008.10.054
NR 140
TC 106
Z9 110
U1 4
U2 50
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0165-6147
EI 1873-3735
J9 TRENDS PHARMACOL SCI
JI Trends Pharmacol. Sci.
PD AUG
PY 2014
VL 35
IS 8
BP 374
EP 383
DI 10.1016/j.tips.2014.05.005
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AN1KQ
UT WOS:000340341600003
PM 24958329
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Nestler, EJ
AF Nestler, EJ
TI Genes and addiction
SO NATURE GENETICS
LA English
DT Article
ID RECEPTOR KNOCKOUT MICE; INBRED MOUSE STRAINS; DOPAMINE-TRANSPORTER;
   ALCOHOL DEPENDENCE; RECENT PROGRESS; COCAINE; REWARD; LACKING;
   SENSITIZATION; CREB
AB Drug addiction, like all psychiatric disorders, is defined solely in behavioural terms. For example, addiction can be considered a loss of control over drug-taking, or compulsive drug-seeking and -taking despite horrendous consequences. Abnormal behaviours are a consequence of aberrant brain function, which means that it is a tangible goal to identify the biological underpinnings of addiction. The genetic basis of addiction encompasses two broad areas of enquiry. One of these is the identification of genetic variation in humans that partly determines susceptibility to addiction. The other is the use of animal models to investigate the role of specific genes in mediating the development of addiction. Whereas recent advances in this latter effort are heartening, a major challenge remains: to understand how the many genes implicated in rodent models interact to yield as complex a phenotype as addiction.
C1 Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75235 USA.
   Univ Texas, SW Med Ctr, Ctr Neurosci, Dallas, TX USA.
C3 University of Texas System; University of Texas Dallas; University of
   Texas Southwestern Medical Center Dallas; University of Texas System;
   University of Texas Dallas; University of Texas Southwestern Medical
   Center Dallas
RP Nestler, EJ (通讯作者)，Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75235 USA.
CR Andretic R, 1999, SCIENCE, V285, P1066, DOI 10.1126/science.285.5430.1066
   Bainton RJ, 2000, CURR BIOL, V10, P187, DOI 10.1016/S0960-9822(00)00336-5
   BERRETTINI WH, 1994, NAT GENET, V7, P54, DOI 10.1038/ng0594-54
   Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8
   Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495
   Brodkin ES, 1998, BRAIN RES, V805, P55, DOI 10.1016/S0006-8993(98)00663-5
   Burmeister M, 1999, BIOL PSYCHIAT, V45, P522, DOI 10.1016/S0006-3223(98)00316-3
   Carlezon WA, 1998, SCIENCE, V282, P2272, DOI 10.1126/science.282.5397.2272
   CHEN JS, IN PRESS J NEUROSCI
   Chen YC, 1999, ALCOHOL CLIN EXP RES, V23, P1853, DOI 10.1111/j.1530-0277.1999.tb04083.x
   Crabbe JC, 1996, NAT GENET, V14, P98, DOI 10.1038/ng0996-98
   Crabbe JC, 1999, TRENDS NEUROSCI, V22, P173, DOI 10.1016/S0166-2236(99)01393-4
   Crawley JN, 1997, PSYCHOPHARMACOLOGY, V132, P107, DOI 10.1007/s002130050327
   Everitt BJ, 1999, ANN NY ACAD SCI, V877, P412, DOI 10.1111/j.1749-6632.1999.tb09280.x
   Gerlai R, 1996, SEMIN NEUROSCI, V8, P153, DOI 10.1006/smns.1996.0020
   Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0
   Horger BA, 1999, J NEUROSCI, V19, P4110
   Kalivas PW, 1999, CURR OPIN NEUROBIOL, V9, P223, DOI 10.1016/S0959-4388(99)80031-2
   Kalivas PW, 1999, SYNAPSE, V33, P153, DOI 10.1002/(SICI)1098-2396(199908)33:2<153::AID-SYN5>3.0.CO;2-N
   Kelz MB, 1999, NATURE, V401, P272, DOI 10.1038/45790
   KELZ MB, IN PRESS CURR OPIN N
   KENDLER KS, 1994, AM J PSYCHIAT, V151, P707
   Kendler KS, 2000, ARCH GEN PSYCHIAT, V57, P261, DOI 10.1001/archpsyc.57.3.261
   Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7
   Kuhar MJ, 1999, TRENDS NEUROSCI, V22, P316, DOI 10.1016/S0166-2236(98)01377-0
   LaneLadd SB, 1997, J NEUROSCI, V17, P7890
   Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401
   Long JC, 1998, AM J MED GENET, V81, P216, DOI 10.1002/(SICI)1096-8628(19980508)81:3<216::AID-AJMG2>3.0.CO;2-U
   Maldonado R, 1996, SCIENCE, V273, P657, DOI 10.1126/science.273.5275.657
   Maldonado R, 1997, NATURE, V388, P586, DOI 10.1038/41567
   Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0
   McBride WJ, 1998, CRIT REV NEUROBIOL, V12, P339, DOI 10.1615/CritRevNeurobiol.v12.i4.40
   McClung C, 1999, CURR BIOL, V9, P853, DOI 10.1016/S0960-9822(99)80389-3
   Messer CJ, 2000, NEURON, V26, P247, DOI 10.1016/S0896-6273(00)81154-X
   Mogil JS, 1996, P NATL ACAD SCI USA, V93, P3048, DOI 10.1073/pnas.93.7.3048
   Murtra P, 2000, NATURE, V405, P180, DOI 10.1038/35012069
   Nestler EJ, 1996, MOL PSYCHIATR, V1, P190
   Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58
   Reich T, 1998, AM J MED GENET, V81, P207, DOI 10.1002/(SICI)1096-8628(19980508)81:3<207::AID-AJMG1>3.3.CO;2-X
   Rocha BA, 1998, NAT NEUROSCI, V1, P132, DOI 10.1038/381
   Rocha BA, 1998, NATURE, V393, P175, DOI 10.1038/30259
   Shaham Y, 2000, BRAIN RES REV, V33, P13, DOI 10.1016/S0165-0173(00)00024-2
   Thiele TE, 1998, NATURE, V396, P366, DOI 10.1038/24614
   THOMASSON HR, 1991, AM J HUM GENET, V48, P677
   Tsuang MT, 1998, ARCH GEN PSYCHIAT, V55, P967, DOI 10.1001/archpsyc.55.11.967
   Tzschentke TM, 1998, PROG NEUROBIOL, V56, P613, DOI 10.1016/S0301-0082(98)00060-4
   Weiss KM, 2000, NAT GENET, V26, P151, DOI 10.1038/79866
   Whisler K., 1999, Society for Neuroscience Abstracts, V25, P811
   Wise RA, 1998, DRUG ALCOHOL DEPEN, V51, P13, DOI 10.1016/S0376-8716(98)00063-5
   Wolf ME, 1998, PROG NEUROBIOL, V54, P679, DOI 10.1016/S0301-0082(97)00090-7
   Wurbel H, 2000, NAT GENET, V26, P263, DOI 10.1038/81541
   ZACHARIOU V, IN PRESS NEUROPSYCHO
   Zhu YX, 1999, NEURON, V24, P243, DOI 10.1016/S0896-6273(00)80836-3
NR 53
TC 159
Z9 166
U1 2
U2 20
PU NATURE AMERICA INC
PI NEW YORK
PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA
SN 1061-4036
J9 NAT GENET
JI Nature Genet.
PD NOV
PY 2000
VL 26
IS 3
BP 277
EP 281
DI 10.1038/81570
PG 5
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 371JU
UT WOS:000165176500014
PM 11062465
DA 2023-06-23
ER

PT J
AU Robbins, TW
AF Robbins, T. W.
TI Commentary on Bechara et al.'s "A Neurobehavioral Approach to Addiction:
   Implications for the Opioid Epidemic and the Psychology of Addiction"
SO PSYCHOLOGICAL SCIENCE IN THE PUBLIC INTEREST
LA English
DT Editorial Material
ID DRUG-ADDICTION; NUCLEUS-ACCUMBENS; REINFORCEMENT; HABITS; IMPULSIVITY
C1 [Robbins, T. W.] Univ Cambridge, Dept Psychol, Cambridge CB2 3EB, England.
C3 RLUK- Research Libraries UK; University of Cambridge
RP Robbins, TW (通讯作者)，Univ Cambridge, Dept Psychol, Cambridge CB2 3EB, England.
EM twr2@cam.ac.uk
RI Robbins, Trevor W/A-7551-2008
CR American Psychiatric Association [APA], 2022, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425787]
   Balleine BW, 2010, NEUROPSYCHOPHARMACOL, V35, P48, DOI 10.1038/npp.2009.131
   Bechara A, 2019, PSYCHOL SCI PUBL INT, V20, P96, DOI 10.1177/1529100619860513
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   Belin-Rauscent A, 2016, MOL PSYCHIATR, V21, P491, DOI [10.1038/mp.2015.140, 10.1038/mp.2016.32]
   Clark LA, 2017, PSYCHOL SCI PUBL INT, V18, P72, DOI 10.1177/1529100617727266
   Coutureau E, 2003, BEHAV BRAIN RES, V146, P167, DOI 10.1016/j.bbr.2003.09.025
   Dalley JW, 2007, SCIENCE, V315, P1267, DOI 10.1126/science.1137073
   Ersche KD, 2016, SCIENCE, V352, P1468, DOI 10.1126/science.aaf3700
   Everitt BJ, 2016, ANNU REV PSYCHOL, V67, P23, DOI 10.1146/annurev-psych-122414-033457
   Everitt BJ, 2000, PSYCHOPHARMACOLOGY, V153, P17, DOI 10.1007/s002130000566
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   GOLDBERG SR, 1967, J EXP ANAL BEHAV, V10, P235, DOI 10.1901/jeab.1967.10-235
   Holland PC, 2004, J EXP PSYCHOL-ANIM B, V30, P104, DOI 10.1037/0097-7403.30.2.104
   Kenny PJ, 2006, J NEUROSCI, V26, P5894, DOI 10.1523/JNEUROSCI.0740-06.2006
   Luigjes J, 2012, MOL PSYCHIATR, V17, P572, DOI 10.1038/mp.2011.114
   McNamara R, 2010, PSYCHOPHARMACOLOGY, V212, P453, DOI 10.1007/s00213-010-1974-9
   National Institute of Mental Health, 2016, AD BRAIN COGN DEV AB
   Parkinson JA, 2005, Q J EXP PSYCHOL-B, V58, P19, DOI 10.1080/02724990444000023
   Robbins TW, 1999, NATURE, V398, P567, DOI 10.1038/19208
   Schwabe L, 2009, J NEUROSCI, V29, P7191, DOI 10.1523/JNEUROSCI.0979-09.2009
   TAYLOR JR, 1986, PSYCHOPHARMACOLOGY, V90, P390
   TAYLOR JR, 1984, PSYCHOPHARMACOLOGY, V84, P405, DOI 10.1007/BF00555222
   Voon V, 2015, MOL PSYCHIATR, V20, P345, DOI 10.1038/mp.2014.44
NR 24
TC 4
Z9 4
U1 0
U2 16
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1529-1006
EI 1539-6053
J9 PSYCHOL SCI PUBL INT
JI Psychol. Sci. Public Interest
PD OCT
PY 2019
VL 20
IS 2
BP 91
EP 95
DI 10.1177/1529100619862034
PG 5
WC Psychology, Multidisciplinary
WE Social Science Citation Index (SSCI)
SC Psychology
GA JC3IG
UT WOS:000489171800001
PM 31591937
DA 2023-06-23
ER

PT J
AU Barnett, A
   Hall, W
   Fry, CL
   Dilkes-Frayne, E
   Carter, A
AF Barnett, Anthony
   Hall, Wayne
   Fry, Craig L.
   Dilkes-Frayne, Ella
   Carter, Adrian
TI Implications of treatment providers' varying conceptions of the disease
   model of addiction: A response
SO DRUG AND ALCOHOL REVIEW
LA English
DT Editorial Material
DE addiction; attitudes of health personnel; brain disease; medicalisation;
   treatment
ID DRUG-ADDICTION; BRAIN DISEASE; ALCOHOL
C1 [Barnett, Anthony; Carter, Adrian] Monash Univ, Monash Inst Cognit & Clin Neurosci, Melbourne, Vic, Australia.
   [Barnett, Anthony; Carter, Adrian] Monash Univ, Sch Psychol Sci, Melbourne, Vic, Australia.
   [Hall, Wayne] Univ Queensland, Ctr Youth Subst Abuse Res, Brisbane, Qld, Australia.
   [Hall, Wayne] Kings Coll London, Inst Psychiat Psychol & Neurosci, Natl Addict Ctr, London, England.
   [Fry, Craig L.] Victoria Univ, Coll Hlth & Biomed, Melbourne, Vic, Australia.
   [Dilkes-Frayne, Ella] Australian Natl Univ, Sch Sociol, Res Sch Social Sci, Canberra, ACT, Australia.
   [Carter, Adrian] Univ Queensland, Clin Res Ctr, Brisbane, Qld, Australia.
C3 Monash University; Monash University; University of Queensland; RLUK-
   Research Libraries UK; University of London; King's College London;
   Victoria University; Australian National University; University of
   Queensland
RP Barnett, A (通讯作者)，Monash Univ, Monash Inst Cognit & Clin Neurosci, Melbourne, Vic, Australia.; Barnett, A (通讯作者)，Monash Univ, Sch Psychol Sci, Melbourne, Vic, Australia.
EM anthony.barnett@monash.edu
RI Carter, Adrian/AAG-2830-2020; Hall, Wayne D/A-3283-2008
OI Carter, Adrian/0000-0002-3593-0772; Hall, Wayne D/0000-0003-1984-0096;
   Barnett, Anthony/0000-0003-2804-4585
CR Barnett AI, 2017, DRUG ALCOHOL REV
   Best D, 2016, ADDICT RES THEORY, V24, P111, DOI 10.3109/16066359.2015.1075980
   Best DW, 2012, AUST FAM PHYSICIAN, V41, P593
   BRICKMAN P, 1982, AM PSYCHOL, V37, P368, DOI 10.1037//0003-066X.37.4.368
   CASSWELL S, 1983, J STUD ALCOHOL, V44, P342, DOI 10.15288/jsa.1983.44.342
   Hshieh S., 1997, ALCOHOLISM TREATMENT, V15, P63
   Karasaki M, 2013, DRUG ALCOHOL REV, V32, P195, DOI 10.1111/j.1465-3362.2012.00501.x
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   LEVINE H G, 1985, Journal of Substance Abuse Treatment, V2, P43, DOI 10.1016/0740-5472(85)90022-4
   Moyers T. B., 1993, PSYCHOL ADDICT BEHAV, V7, P238, DOI DOI 10.1037/0893-164X.7.4.238
   Palm J, 2004, ADDICT RES THEORY, V12, P413, DOI 10.1080/16066350412331302103
   Savic M, 2018, DRUG ALCOHOL REV
   Schmidt L, 2018, DRUG ALCOHOL REV
   SCHMIDT LA, 1995, J STUD ALCOHOL, V56, P110, DOI 10.15288/jsa.1995.56.110
   Storbjork J, 2018, DRUG ALCOHOL REV
   Volkow ND, 2016, NEW ENGL J MED, V374, P363, DOI 10.1056/NEJMra1511480
   Winter K., 2016, CONTEMP DRUG PROBL, V43, P25, DOI DOI 10.1177/0091450916636896
NR 17
TC 4
Z9 4
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0959-5236
EI 1465-3362
J9 DRUG ALCOHOL REV
JI Drug Alcohol Rev.
PD SEP
PY 2018
VL 37
IS 6
BP 729
EP 730
DI 10.1111/dar.12844
PG 2
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA GS2MP
UT WOS:000443384300006
PM 29998464
OA Green Published
DA 2023-06-23
ER

PT J
AU Chen, G
   Gueta, K
AF Chen, Gila
   Gueta, Keren
TI Child abuse, drug addiction and mental health problems of incarcerated
   women in Israel
SO INTERNATIONAL JOURNAL OF LAW AND PSYCHIATRY
LA English
DT Article
DE Incarcerated women; Childhood abuse; Drug addiction; Mental health
   problems; Depression; Family risk factors
ID POSTTRAUMATIC-STRESS-DISORDER; ADOLESCENT SUBSTANCE USE; PHYSICAL
   VICTIMIZATION; PSYCHIATRIC-DISORDERS; SEXUAL VICTIMIZATION; FAMILY
   RELATIONSHIPS; GENDER-DIFFERENCES; ENVIRONMENT; PREVALENCE; INMATES
AB The mental health problems and pathways to drug addiction and crime among female inmates have long been of interest to researchers and practitioners. The purpose of the current study was to examine the possible association between multiple types of childhood abuse, mental health problems, and drug addiction and the incarceration of 50 Israeli women in prison. The findings indicated that female inmates come from risky families with a high prevalence of family mental health problems, parental drug addiction and crime, and sibling drug addiction and crime. Furthermore, they revealed that incarcerated women from risky families were victims of multiple types of childhood abuse and neglect by their parents, as well as their siblings. Overall, the results suggest that the adverse consequences of a family's mental health problems are much more dramatic than we assumed to date, and that women are more likely than men to be the victims of multiple types of childhood abuse and neglect, as well as suffering more severe psychiatric problems, depression, and drug addiction. The implications of these findings are discussed. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Chen, Gila] Ashkelon Acad Coll, Dept Criminol, IL-78109 Ashqelon, Israel.
   [Gueta, Keren] Bar Ilan Univ, Dept Criminol, IL-52100 Ramat Gan, Israel.
C3 Bar Ilan University
RP Chen, G (通讯作者)，Ashkelon Acad Coll, Dept Criminol, 12 Ben Tzvi St, IL-78109 Ashqelon, Israel.
EM chengila6@gmail.com
RI Chen, Gila/I-7934-2019; Wilson, Gregory/AAA-9035-2021
OI Chen, Gila/0000-0003-4283-3361; 
CR Alexander, 1987, BIOL MORAL SYSTEMS
   ALEXANDER PC, 1992, J CONSULT CLIN PSYCH, V60, P185, DOI 10.1037/0022-006X.60.2.185
   American Psychiatric Association [APA], 2022, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425787]
   Bandura A, 1973, AGGRESSION SOCIAL LE
   Beck A. T, 1996, MANUAL BECK DEPRESSI, DOI DOI 10.1037/T00742-000
   Belknap J., 2006, FEM CRIMINOL, V1, P48, DOI DOI 10.1177/1557085105282897
   BERNSTEIN DP, 1994, AM J PSYCHIAT, V151, P1132, DOI 10.1176/ajp.151.8.1132
   Blitz CL, 2008, INT J LAW PSYCHIAT, V31, P385, DOI 10.1016/j.ijlp.2008.08.005
   Bloom B, 1996, TRIPLE JEOPARDY RACE
   BLOOM B, 1994, WOMEN CALIFORNIA PRI
   Bradley RG, 2002, PSYCHOL WOMEN QUART, V26, P351, DOI 10.1111/1471-6402.t01-2-00074
   Bradley RH, 2001, CHILD DEV, V72, P1844, DOI 10.1111/1467-8624.t01-1-00382
   Brems C, 2004, AM J DRUG ALCOHOL AB, V30, P799, DOI 10.1081/ADA-200037546
   Browne A, 1999, INT J LAW PSYCHIAT, V22, P301, DOI 10.1016/S0160-2527(99)00011-4
   Button DM, 2010, J FAM VIOLENCE, V25, P131, DOI 10.1007/s10896-009-9276-x
   Byrd PM, 2009, J INTERPERS VIOLENCE, V24, P379, DOI 10.1177/0886260508316475
   CHASSIN L, 1993, J ABNORM PSYCHOL, V102, P3, DOI 10.1037/0021-843X.102.1.3
   Chen G, 2009, ASIAN J CRIMINOL, V4, P47, DOI 10.1007/s11417-008-9055-2
   Clements-Nolle K, 2009, WOMEN HEALTH ISS, V19, P185, DOI 10.1016/j.whi.2009.02.002
   CONTE JR, 1987, CHILD ABUSE NEGLECT, V11, P201, DOI 10.1016/0145-2134(87)90059-7
   CONTE JR, 1988, LASTING EFFECTS CHIL, P157
   Covington S., 2003, PRISONERS ONCE REMOV, P67
   Covington SS, 2000, ASSESSMENT TO ASSISTANCE: PROGRAMS FOR WOMEN IN COMMUNITY CORRECTIONS, P171
   Daly K., 1992, SO CALIFORNIA REV LA, V2, P11, DOI DOI 10.4135/9781412959193.N69
   Drapalski AL, 2009, CRIM BEHAV MENT HEAL, V19, P193, DOI 10.1002/cbm.733
   Emery RE, 1998, AM PSYCHOL, V53, P121, DOI 10.1037/0003-066X.53.2.121
   Fagan A A, 2001, Violence Vict, V16, P457
   Faith K., 1993, UNRULY WOMEN POLITIC
   Feiring C, 1996, CHILD ABUSE NEGLECT, V20, P767, DOI 10.1016/0145-2134(96)00064-6
   Finkelhor D., 2008, SEXUALLY ASSAULTED C
   Foster H, 2012, J CRIM JUST, V40, P221, DOI 10.1016/j.jcrimjus.2012.01.005
   Fujiwara T, 2010, CHILD ABUSE NEGLECT, V34, P267, DOI 10.1016/j.chiabu.2009.07.007
   Gilligan Carol, 1982, DIFFERENT VOICE
   Girshick L, 1999, NO SAFE HAVEN STORIE
   Girshick L. B., 2003, WOMEN PRISON GENDER, P95
   GOVE WR, 1982, SOCIOL QUART, V23, P301, DOI 10.1111/j.1533-8525.1982.tb01014.x
   Grella CE, 2006, PRISON J, V86, P89, DOI 10.1177/0032885505283925
   Haller DL, 2003, J INTERPERS VIOLENCE, V18, P760, DOI 10.1177/0886260503253239
   Hanlon TE, 2005, AM J DRUG ALCOHOL AB, V31, P59, DOI 10.1081/ADA-200037564
   Haseltine F P, 2000, J Womens Health Gend Based Med, V9, P579, DOI 10.1089/15246090050118080
   HELZER JE, 1981, ARCH GEN PSYCHIAT, V38, P393
   HOLSINGER K, 2000, WOMEN CRIMINAL JUSTI, V12, P23, DOI DOI 10.1300/J012V12N01_03
   Horwitz AV, 2001, J HEALTH SOC BEHAV, V42, P184, DOI 10.2307/3090177
   Islam-Zwart KA, 2004, CRIM JUSTICE BEHAV, V31, P521, DOI 10.1177/0093854804267091
   Israel Prison Service (IPS), 2013, DRUGS ALC US ISR PRI
   Israel Prison Service (IPS), 2006, ANN REPORT
   JACOB T, 1986, J STUD ALCOHOL, V47, P373, DOI 10.15288/jsa.1986.47.373
   JOHNSON JL, 1991, ALCOHOL HEALTH RES W, V15, P33
   Jordan BK, 1996, ARCH GEN PSYCHIAT, V53, P513
   Karberg J. C., 2007, DRUG USE DEPENDENCE
   KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012
   Kim-Cohen J, 2006, MOL PSYCHIATR, V11, P903, DOI 10.1038/sj.mp.4001851
   Langan NP, 2001, J SUBST ABUSE, V13, P291, DOI 10.1016/S0899-3289(01)00083-9
   LORD E, 2002, ACTING OUT MALADAPTI, P363
   Makkai T., 2004, WOMENS EXPERIENCE MA
   McClellan DS, 1997, CRIM JUSTICE BEHAV, V24, P455, DOI 10.1177/0093854897024004004
   McDaniels-Wilson C, 2008, VIOLENCE AGAINST WOM, V14, P1090, DOI 10.1177/1077801208323160
   MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199, DOI 10.1016/0740-5472(92)90062-S
   McLeod JD, 1996, J HEALTH SOC BEHAV, V37, P207, DOI 10.2307/2137292
   McLoyd VC, 1998, AM PSYCHOL, V53, P185, DOI 10.1037/0003-066X.53.2.185
   Miller J.B., 1988, WORKING PAPER SERIES
   MILLER JB, 1986, NEW PSYCHOL WOMEN
   Moloney KP, 2009, PUBLIC HEALTH, V123, P426, DOI 10.1016/j.puhe.2009.04.002
   MYERS HF, 1992, AM J COMMUN PSYCHOL, V20, P557
   Reid J., 1999, NO SAFE HAVEN CHILDR
   Repetti R.L, 2010, PSYCHOL BULL, V128, P330
   Rosenbaum Jill Leslie, 1987, JUSTICE Q, V4, P117, DOI DOI 10.1080/07418828700089221.
   Rosenman S, 2004, SOC PSYCH PSYCH EPID, V39, P695, DOI 10.1007/s00127-004-0802-0
   ROWAN AB, 1993, J TRAUMA STRESS, V6, P3, DOI 10.1002/jts.2490060103
   Salisbury EJ, 2009, CRIM JUSTICE BEHAV, V36, P541, DOI 10.1177/0093854809334076
   SEILHAMER RA, 1990, CHILDREN ALCOHOLICS, P168
   Silberman M, 2010, INT J OFFENDER THER, V54, P783, DOI 10.1177/0306624X09340011
   Simpson TL, 2002, CLIN PSYCHOL REV, V22, P27, DOI 10.1016/S0272-7358(00)00088-X
   SINGER MI, 1995, SOC WORK, V40, P103
   SMALL SA, 1994, J MARRIAGE FAM, V56, P181, DOI 10.2307/352712
   SPACCARELLI S, 1995, CHILD ABUSE NEGLECT, V19, P1171, DOI 10.1016/0145-2134(95)00077-L
   Su SS, 1997, J DRUG ISSUES, V27, P851, DOI 10.1177/002204269702700412
   Sykes G. M, 1958, SOC CAPTIVES STUDY M
   Teplin LA, 1996, ARCH GEN PSYCHIAT, V53, P505
   Thompson KM, 2009, J FAM VIOLENCE, V24, P531, DOI 10.1007/s10896-009-9251-6
   Thompson MP, 2002, J INTERPERS VIOLENCE, V17, P1115, DOI 10.1177/088626002236663
   Tripodi SJ, 2013, INT J LAW PSYCHIAT, V36, P30, DOI 10.1016/j.ijlp.2012.11.005
   Van Voorhis P, 2010, CRIM JUSTICE BEHAV, V37, P261, DOI 10.1177/0093854809357442
   Veigh M., 2003, AUSTR SOCIAL WORK, V56, P116, DOI DOI 10.1046/J.0312-407X.2003.00062.X
   Wagner BM, 1997, PSYCHOL BULL, V121, P246, DOI 10.1037/0033-2909.121.2.246
   WAHLER RG, 1990, J SOC CLIN PSYCHOL, V9, P43, DOI 10.1521/jscp.1990.9.1.43
   Weich S, 2009, BRIT J PSYCHIAT, V194, P392, DOI 10.1192/bjp.bp.107.042515
   Westermeyer J, 2000, AM J DRUG ALCOHOL AB, V26, P523, DOI 10.1081/ADA-100101893
   Widom Cathy Spatz, 2006, Violence Vict, V21, P675, DOI 10.1891/vv-v21i6a001
   Wilsnack S., 1991, PSYCHOL ADDICT BEHAV, V4, P46
   Wolff N., 2008, WOMENS MENTAL HLTH I, P226
   Wolff N, 2007, PSYCHIAT SERV, V58, P1087, DOI 10.1176/appi.ps.58.8.1087
   Wolff N, 2012, J ANXIETY DISORD, V26, P703, DOI 10.1016/j.janxdis.2012.06.001
   Wolff N, 2009, PRISON J, V89, P172, DOI 10.1177/0032885509334754
   Wolff N, 2009, JUSTICE Q, V26, P445, DOI 10.1080/07418820802427858
   Zlotnick C, 1997, J NERV MENT DIS, V185, P761, DOI 10.1097/00005053-199712000-00007
   Zucker R. A., 2000, CHILDREN ADDICTION R, P174
NR 97
TC 15
Z9 15
U1 3
U2 38
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0160-2527
EI 1873-6386
J9 INT J LAW PSYCHIAT
JI Int. J. Law Psychiatr.
PD MAR-APR
PY 2015
VL 39
BP 36
EP 45
DI 10.1016/j.ijlp.2015.01.019
PG 10
WC Law; Psychiatry
WE Social Science Citation Index (SSCI)
SC Government & Law; Psychiatry
GA CH2LJ
UT WOS:000353856400006
PM 25660063
DA 2023-06-23
ER

PT J
AU Wolf, ME
AF Wolf, ME
TI Cocaine addiction: Clues from Drosophila on drugs
SO CURRENT BIOLOGY
LA English
DT Article
ID SENSITIZATION
AB Recent studies have shown that the fruitfly Drosophila exhibits behavioral sensitization in response to repeated exposure to cocaine; the exploitation of this genetically tractable model system for studying cocaine addiction is already providing new clues that may help understand the process of drug addiction in man.
C1 Finch Univ Hlth Sci Chicago Med Sch, Dept Neurosci, N Chicago, IL 60064 USA.
C3 Chicago Medical School
RP Wolf, ME (通讯作者)，Finch Univ Hlth Sci Chicago Med Sch, Dept Neurosci, 3333 Green Bay Rd, N Chicago, IL 60064 USA.
CR Andretic R, 1999, SCIENCE, V285, P1066, DOI 10.1126/science.285.5430.1066
   Berke JD, 1998, J NEUROSCI, V18, P5301, DOI 10.1523/JNEUROSCI.18-14-05301.1998
   DANIELSON TJ, 1976, LIFE SCI, V18, P1237, DOI 10.1016/0024-3205(76)90200-9
   Gaytan O, 1999, EUR J PHARMACOL, V374, P1, DOI 10.1016/S0014-2999(99)00243-5
   McClung C, 1999, CURR BIOL, V9, P853, DOI 10.1016/S0960-9822(99)80389-3
   McClung C, 1998, CURR BIOL, V8, P109, DOI 10.1016/S0960-9822(98)70041-7
   Reale V, 1997, J NEUROSCI, V17, P6545
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Wolf ME, 1998, PROG NEUROBIOL, V54, P679, DOI 10.1016/S0301-0082(97)00090-7
   Yellman C, 1997, P NATL ACAD SCI USA, V94, P4131, DOI 10.1073/pnas.94.8.4131
NR 10
TC 19
Z9 20
U1 2
U2 9
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0960-9822
J9 CURR BIOL
JI Curr. Biol.
PD OCT 21
PY 1999
VL 9
IS 20
BP R770
EP R772
DI 10.1016/S0960-9822(00)80009-3
PG 3
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 248RM
UT WOS:000083289200008
PM 10531026
OA Bronze
DA 2023-06-23
ER

PT J
AU Venniro, M
   Shaham, Y
AF Venniro, Marco
   Shaham, Yavin
TI An operant social self-administration and choice model in rats
SO NATURE PROTOCOLS
LA English
DT Article
ID COMMUNITY-REINFORCEMENT APPROACH; COCAINE ADDICTION; PEER INFLUENCES;
   DRUG; INCUBATION; MECHANISMS; METHAMPHETAMINE; NEUROBIOLOGY; PREFERENCE;
   REVERSAL
AB It is difficult to translate results from animal research on addiction to an understanding of the behavior of human drug users. Despite decades of basic research on neurobiological mechanisms of drug addiction, treatment options remain largely unchanged. A potential reason for this is that mechanistic studies using rodent models do not incorporate a critical facet of human addiction: volitional choices between drug use and non-drug social rewards (e.g., employment and family). Recently, we developed an operant model in which rats press a lever for rewarding social interaction with a peer and then choose between an addictive drug (heroin or methamphetamine) and social interaction. Using this model, we showed that rewarding social interaction suppresses drug self-administration, relapse to drug seeking, and brain responses to drug-associated cues. Here, we describe a protocol for operant social interaction using a discrete-trial choice between drugs and social interaction that causes voluntary abstinence from the drug and tests for incubation of drug craving (the time-dependent increase in drug seeking during abstinence). This protocol is flexible but generally requires 8-9 weeks for completion. We also provide a detailed description of the technical requirements and procedures for building the social self-administration and choice apparatus. Our protocol provides a reliable way to study the role of operant social reward in addiction and addiction vulnerability in the context of choices. We propose that this protocol can be used to study brain mechanisms of operant social reward and potentially impairments in social reward in animal models of psychiatric disorders and pain.
   In this operant model, rats press a lever to obtain addictive drugs or rewarding social interaction with a peer. The model can thus be used to study the role of operant social reward in addiction and addiction vulnerability in the context of choices.
C1 [Venniro, Marco; Shaham, Yavin] NIDA, Behav Neurosci Res Branch, Intramural Res Program, NIH, Baltimore, MD 21224 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute on
   Aging (NIA); NIH National Institute on Drug Abuse (NIDA)
RP Venniro, M; Shaham, Y (通讯作者)，NIDA, Behav Neurosci Res Branch, Intramural Res Program, NIH, Baltimore, MD 21224 USA.
EM venniro.marco@nih.gov; Yshaham@intra.nida.nih.gov
RI Venniro, Marco/AAU-5988-2021; Venniro, Marco/AAX-7686-2020; shaham,
   yavin/G-1306-2014
OI Venniro, Marco/0000-0001-7653-957X; shaham, yavin/0000-0002-8242-3319
FU Intramural Research Program of NIDA; NIH Center on Compulsive Behaviors;
   NARSAD Distinguished Investigator Grant Award; NATIONAL INSTITUTE ON
   DRUG ABUSE [ZIADA000434] Funding Source: NIH RePORTER
FX We thank T.I. Russell for her help during the experiments and D. Harvey
   for proofreading and editorial comments on the original version of the
   manuscript. The research was supported by the Intramural Research
   Program of NIDA, a fellowship from the NIH Center on Compulsive
   Behaviors (M.V.), and a NARSAD Distinguished Investigator Grant Award
   (Y.S.).
CR Ahmed SH, 2018, PROG NEURO-PSYCHOPH, V87, P3, DOI 10.1016/j.pnpbp.2017.09.027
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Aklin WM, 2014, J SUBST ABUSE TREAT, V47, P329, DOI 10.1016/j.jsat.2014.06.013
   Azrin NH, 1996, BEHAV RES THER, V34, P41, DOI 10.1016/0005-7967(95)00049-4
   AZRIN NH, 1976, BEHAV RES THER, V14, P339, DOI 10.1016/0005-7967(76)90021-8
   Banks ML, 2017, TRENDS PHARMACOL SCI, V38, P181, DOI 10.1016/j.tips.2016.11.002
   Bardo MT, 2013, PHARMACOL REV, V65, P255, DOI 10.1124/pr.111.005124
   Caprioli D, 2017, J NEUROSCI, V37, P1014, DOI 10.1523/JNEUROSCI.3091-16.2016
   Caprioli D, 2015, BIOL PSYCHIAT, V78, P463, DOI 10.1016/j.biopsych.2015.02.018
   de Wit H, 2018, NEUROPSYCHOPHARMACOL, V43, P1985, DOI 10.1038/s41386-018-0095-8
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Dong Y, 2017, J NEUROSCI, V37, P10867, DOI 10.1523/JNEUROSCI.1821-17.2017
   Fritz M, 2011, ADDICT BIOL, V16, P273, DOI 10.1111/j.1369-1600.2010.00285.x
   Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134
   Heilig M, 2016, NAT REV NEUROSCI, V17, P592, DOI 10.1038/nrn.2016.67
   Heyman Gene M, 2013, Front Psychiatry, V4, P31, DOI 10.3389/fpsyt.2013.00031
   HUNT GM, 1973, BEHAV RES THER, V11, P91, DOI 10.1016/0005-7967(73)90072-7
   Jonkman S, 2013, NEUROPSYCHOPHARMACOL, V38, P198, DOI 10.1038/npp.2012.120
   Lash SJ, 2004, ADDICT BEHAV, V29, P337, DOI 10.1016/j.addbeh.2003.08.008
   Lenoir M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000698
   Monterosso J, 2007, DRUG ALCOHOL DEPEN, V90, pS100, DOI 10.1016/j.drugalcdep.2006.09.004
   Nader M A, 1990, NIDA Res Monogr, V105, P621
   Nestler EJ, 2014, NEUROPHARMACOLOGY, V76, P259, DOI 10.1016/j.neuropharm.2013.04.004
   Peitz GW, 2013, BEHAV PHARMACOL, V24, P114, DOI 10.1097/FBP.0b013e32835f1719
   Richardson NR, 1996, J NEUROSCI METH, V66, P1, DOI 10.1016/0165-0270(95)00153-0
   Roozen HG, 2004, DRUG ALCOHOL DEPEN, V74, P1, DOI 10.1016/j.drugalcdep.2003.12.006
   Shalev U, 2002, PHARMACOL REV, V54, P1, DOI 10.1124/pr.54.1.1
   Silverman K, 2012, PREV MED, V55, pS46, DOI 10.1016/j.ypmed.2012.03.013
   Smith MA, 2015, BEHAV PHARMACOL, V26, P631, DOI 10.1097/FBP.0000000000000139
   Smith MA, 2014, DRUG ALCOHOL DEPEN, V135, P140, DOI 10.1016/j.drugalcdep.2013.12.001
   Smith MA, 2012, PSYCHOPHARMACOLOGY, V224, P81, DOI 10.1007/s00213-012-2737-6
   Solinas M, 2008, P NATL ACAD SCI USA, V105, P17145, DOI 10.1073/pnas.0806889105
   Spragg SDS., 1940, COMP PSYCHOL MONOGR, V15, P132
   Stitzer M. L., 2011, HDB MOTIVATIONAL COU
   Stitzer M, 2006, ANNU REV CLIN PSYCHO, V2, P411, DOI 10.1146/annurev.clinpsy.2.022305.095219
   Strickland JC, 2015, PHARMACOL BIOCHEM BE, V136, P47, DOI 10.1016/j.pbb.2015.06.013
   Vanderschuren LJMJ, 2016, NEUROSCI BIOBEHAV R, V70, P86, DOI 10.1016/j.neubiorev.2016.07.025
   Venniro M, 2019, BIOL PSYCHIAT, V86, P848, DOI 10.1016/j.biopsych.2019.05.018
   Venniro M, 2018, NAT NEUROSCI, V21, P1520, DOI 10.1038/s41593-018-0246-6
   Venniro M, 2019, NEUROPSYCHOPHARMACOL, V44, P234, DOI 10.1038/s41386-018-0196-4
   Venniro M, 2017, NEURON, V96, P414, DOI 10.1016/j.neuron.2017.09.024
   Venniro M, 2017, NEUROPSYCHOPHARMACOL, V42, P1126, DOI 10.1038/npp.2016.287
   Venniro M, 2016, PROG BRAIN RES, V224, P25, DOI 10.1016/bs.pbr.2015.08.004
   Zernig Gerald, 2013, Front Psychiatry, V4, P100, DOI 10.3389/fpsyt.2013.00100
   Zimmer BA, 2012, NEUROPSYCHOPHARMACOL, V37, P1901, DOI 10.1038/npp.2012.37
   Zlebnik NE, 2015, PSYCHOPHARMACOLOGY, V232, P3507, DOI 10.1007/s00213-015-3999-6
NR 46
TC 42
Z9 42
U1 0
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1754-2189
EI 1750-2799
J9 NAT PROTOC
JI Nat. Protoc.
PD APR
PY 2020
VL 15
IS 4
BP 1542
EP 1559
DI 10.1038/s41596-020-0296-6
EA MAR 2020
PG 18
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA KZ1EJ
UT WOS:000520825800001
PM 32203485
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Gordon, EL
   Lent, MR
   Merlo, LJ
AF Gordon, Eliza L.
   Lent, Michelle R.
   Merlo, Lisa J.
TI The Effect of Food Composition and Behavior on Neurobiological Response
   to Food: a Review of Recent Research
SO CURRENT NUTRITION REPORTS
LA English
DT Review
DE Food addiction; Addictive disorders; Neuroimaging; Highly palatable
   foods; Highly processed foods; Binge eating; Neurobiological effects;
   Nutrition; Eating behavior; Compulsive eating; Reward; Craving
ID FUNCTIONAL CONNECTIVITY; INGESTIVE BEHAVIOR; INHIBITORY CONTROL;
   DRUG-ADDICTION; BRAIN RESPONSE; OSCILLATIONS; ACTIVATION; MOTIVATION;
   REGIONS; PEOPLE
AB Purpose of Review Controversy surrounds the construct of food addiction. The current review examines neurobiological evidence for the existence of food addiction as a valid diagnosis.
   Recent Findings Recent neuroimaging studies suggest significant overlap in the areas of the brain that are activated in relation to both food and drug addiction. Specifically, areas of the brain implicated in executive functioning (e.g., attention, planning, decision-making, inhibition), pleasure and the experience of reward, and sensory input and motor functioning display increased activation among individuals with symptoms of both food and drug addiction.
   Summary Proposed symptoms of food addiction mirror those comprising other substance use disorder diagnoses, with similar psychological and behavioral sequelae. Results of neuroimaging studies suggest significant overlap in the areas of the brain that are activated in relation to both food and drug addiction, providing support for continued research into the construct of food addiction.
C1 [Gordon, Eliza L.] Univ Florida, Dept Clin & Hlth Psychol, POB 100165, Gainesville, FL 32610 USA.
   [Lent, Michelle R.] Philadelphia Coll Osteopath Med, Sch Profess & Appl Psychol, Rowland Hall 532a,4190 City Ave, Philadelphia, PA 19131 USA.
   [Merlo, Lisa J.] Univ Florida, McKnight Brain Inst, Dept Psychiat, Coll Med, L4-100K,POB 100256, Gainesville, FL 32611 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida
RP Merlo, LJ (通讯作者)，Univ Florida, McKnight Brain Inst, Dept Psychiat, Coll Med, L4-100K,POB 100256, Gainesville, FL 32611 USA.
EM egordon2@geisinger.edu; michellele@pcom.edu; lmerlo@ufl.edu
RI Merlo, Lisa J./AAU-9179-2020; Gordon, Eliza L./L-7697-2018
OI Merlo, Lisa J./0000-0003-3613-7853; Gordon, Eliza
   L./0000-0001-8206-3387; Lent, Michelle/0000-0001-7892-1879
CR American Psychiatric Association [APA], 2022, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425787]
   American Psychiatric Association (APA), 2000, TEXT, V4th ed., DOI [DOI 10.1176/APPI.BOOKS.9780890423349, 10.1176/appi.books.9780890423349]
   Batterink L, 2010, NEUROIMAGE, V52, P1696, DOI 10.1016/j.neuroimage.2010.05.059
   Boutelle KN, 2015, INT J OBESITY, V39, P620, DOI 10.1038/ijo.2014.206
   Crews FT, 2009, PHARMACOL BIOCHEM BE, V93, P237, DOI 10.1016/j.pbb.2009.04.018
   De Ridder D, 2016, SCI REP-UK, V6, DOI 10.1038/srep34122
   du Boisgueheneuc F, 2006, BRAIN, V129, P3315, DOI 10.1093/brain/awl244
   Eisenstein SA, 2015, SCI REP-UK, V5, DOI 10.1038/srep11283
   Ewing SWF, 2017, BRAIN IMAGING BEHAV, V11, P925, DOI 10.1007/s11682-016-9564-z
   Garavan H, 2000, AM J PSYCHIAT, V157, P1789, DOI 10.1176/appi.ajp.157.11.1789
   Garcia-Garcia I, 2014, OBES REV, V15, P853, DOI 10.1111/obr.12221
   Gearhardt AN, 2011, ARCH GEN PSYCHIAT, V68, P808, DOI 10.1001/archgenpsychiatry.2011.32
   Gearhardt AN, 2009, APPETITE, V52, P430, DOI 10.1016/j.appet.2008.12.003
   Geliebter A, 2016, APPETITE, V96, P195, DOI 10.1016/j.appet.2015.08.009
   Gordon EL, 2018, NUTRIENTS, V10, DOI 10.3390/nu10040477
   Guzzardi MA, 2018, EUR EAT DISORD REV, V26, P657, DOI 10.1002/erv.2652
   Hanlon CA, 2014, DRUG ALCOHOL DEPEN, V143, P206, DOI 10.1016/j.drugalcdep.2014.07.028
   He QH, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00350
   Imperatori C, 2015, BRAIN IMAGING BEHAV, V9, P703, DOI 10.1007/s11682-014-9324-x
   Jastreboff AM, 2016, DIABETES, V65, P1929, DOI 10.2337/db15-1216
   Kahathuduwa CN, 2016, APPETITE, V107, P348, DOI 10.1016/j.appet.2016.08.112
   Kahathuduwa CN, 2018, APPETITE, V120, P431, DOI 10.1016/j.appet.2017.09.025
   Kelley AE, 2004, NEUROSCI BIOBEHAV R, V27, P765, DOI 10.1016/j.neubiorev.2003.11.015
   Kilpatrick LA, 2014, GASTROENTEROLOGY, V146, P1212, DOI 10.1053/j.gastro.2014.01.023
   Knyazev GG, 2007, NEUROSCI BIOBEHAV R, V31, P377, DOI 10.1016/j.neubiorev.2006.10.004
   Knyazev GG, 2012, NEUROSCI BIOBEHAV R, V36, P677, DOI 10.1016/j.neubiorev.2011.10.002
   Koechlin E, 2011, TRENDS COGN SCI, V15, P241, DOI 10.1016/j.tics.2011.04.005
   Kroemer NB, 2016, NEUROIMAGE, V128, P273, DOI 10.1016/j.neuroimage.2015.12.031
   Luckmann HC, 2014, PROG NEUROBIOL, V116, P66, DOI 10.1016/j.pneurobio.2014.02.002
   Naqvi NH, 2010, BRAIN STRUCT FUNCT, V214, P435, DOI 10.1007/s00429-010-0268-7
   Parvaz MA, 2011, REV NEUROSCIENCE, V22, P609, DOI 10.1515/RNS.2011.055
   Pursey K.M., 2017, CURR ADDICT REP, V4, P142, DOI [10.1007/s40429-017-0139-x, DOI 10.1007/S40429-017-0139-X]
   Reid MS, 2003, CLIN ELECTROENCEPHAL, V34, P110, DOI 10.1177/155005940303400305
   Schoenberg MR, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P1, DOI 10.1007/978-0-387-76978-3
   Schulte EM, 2019, PHYSIOL BEHAV, V208, DOI 10.1016/j.physbeh.2019.112574
   Shenhav A, 2013, NEURON, V79, P217, DOI 10.1016/j.neuron.2013.07.007
   Simon JJ, 2016, SOC COGN AFFECT NEUR, V11, P1393, DOI 10.1093/scan/nsw049
   Smith R, 2018, BRAIN IMAGING BEHAV, V12, P685, DOI 10.1007/s11682-017-9726-7
   Stice E, 2010, NEUROIMAGE, V50, P1618, DOI 10.1016/j.neuroimage.2010.01.081
   Wexler BE, 2001, AM J PSYCHIAT, V158, P86, DOI 10.1176/appi.ajp.158.1.86
   World Health Organization, 2019, INT STAT CLASS DIS R
NR 41
TC 9
Z9 10
U1 3
U2 9
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
EI 2161-3311
J9 CURR NUTR REP
JI Curr. Nutr. Rep.
PD JUN
PY 2020
VL 9
IS 2
BP 75
EP 82
DI 10.1007/s13668-020-00305-5
PG 8
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA SD3OD
UT WOS:000651283600003
PM 32157660
DA 2023-06-23
ER

PT J
AU Muller, CP
AF Mueller, Christian P.
TI Lasting translation: how to improve animal models for addiction
   treatment
SO ADDICTION
LA English
DT Editorial Material
DE Addiction; animal models; drug abuse; translation
C1 [Mueller, Christian P.] Friedrich Alexander Univ Erlangen Nuremberg, Univ Clin, Dept Psychiat & Psychotherapy, Erlangen, Germany.
C3 University of Erlangen Nuremberg
RP Muller, CP (通讯作者)，Friedrich Alexander Univ Erlangen Nuremberg, Univ Clin, Dept Psychiat & Psychotherapy, Erlangen, Germany.
EM christian.mueller@uk-erlangen.de
OI Muller, Christian/0000-0002-5325-9900
FU Deutsche Forschungsgemeinschaft (DFG) [Mu 2789/8-2]; Bundesministerium
   fur Bildung und Forschung (BMBF), project Target-OXY; Interdisciplinary
   Center for Clinical Research (IZKF) Erlangen, Project E22
FX The work of the author is supported by the Deutsche
   Forschungsgemeinschaft (DFG) grant Mu 2789/8-2, the Bundesministerium
   fur Bildung und Forschung (BMBF), project Target-OXY, and by the
   Interdisciplinary Center for Clinical Research (IZKF) Erlangen, Project
   E22.
CR Ahmed SH, 2020, NEUROSCI BIOBEHAV R, V110, P3, DOI 10.1016/j.neubiorev.2018.08.015
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Field M, 2020, ADDICTION, V115, P6, DOI 10.1111/add.14764
   Karch, 2017, SAGE HDB DRUGS ALCOH, P411
   Koukouli F, 2017, NAT MED, V23, P347, DOI 10.1038/nm.4274
   McCreary AC, 2015, INT REV NEUROBIOL, V120, P41, DOI 10.1016/bs.irn.2015.02.008
   Muller CP, 2018, BEHAV BRAIN RES, V352, P109, DOI 10.1016/j.bbr.2017.06.028
   Muller CP, 2017, TRENDS PHARMACOL SCI, V38, P501, DOI 10.1016/j.tips.2017.03.005
   Muller CP, 2017, ACTA NEUROPATHOL, V133, P463, DOI 10.1007/s00401-016-1658-6
   Muller CP, 2015, BEHAV BRAIN RES, V277, P146, DOI 10.1016/j.bbr.2014.04.007
   Muller CP, 2011, BEHAV BRAIN SCI, V34, P328, DOI 10.1017/S0140525X1100135X
   Muller CP, 2011, BEHAV BRAIN SCI, V34, P293, DOI 10.1017/S0140525X11000057
   Robbins TW, 1999, NATURE, V398, P567, DOI 10.1038/19208
   Schumann G, 2014, EUR NEUROPSYCHOPHARM, V24, P5, DOI 10.1016/j.euroneuro.2013.09.010
   Spanagel R, 2009, PHYSIOL REV, V89, P649, DOI 10.1152/physrev.00013.2008
NR 15
TC 4
Z9 4
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0965-2140
EI 1360-0443
J9 ADDICTION
JI Addiction
PD JAN
PY 2020
VL 115
IS 1
BP 13
EP 14
DI 10.1111/add.14788
EA OCT 2019
PG 2
WC Substance Abuse; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry
GA JZ6VI
UT WOS:000491198200001
PM 31576616
OA hybrid
DA 2023-06-23
ER

PT J
AU Antonio, N
   Diehl, A
   Niel, M
   Pillon, S
   Ratto, L
   Pinheiro, MC
   Silveira, D
   Otani, TZ
   Otani, V
   Cordeiro, Q
   Ushida, R
AF Antonio, Nelson
   Diehl, Alessandra
   Niel, Marcelo
   Pillon, Sandra
   Ratto, Lilian
   Pinheiro, Maria Carolina
   Silveira, Dartiu
   Otani, Thais Zelia
   Otani, Victor
   Cordeiro, Quirino
   Ushida, Ricardo
TI Sexual addiction in drug addicts: The impact of drug of choice and
   poly-addiction
SO REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
LA English
DT Article
DE substance-related disorders; sexual behavior; observational study as
   topic
ID HYPERSEXUAL DISORDER; SAO-PAULO; BEHAVIOR; ALCOHOL
AB Objective: To compare the risk of comorbid sexual addiction in a sample of individuals with a diagnosis of substance dependence, stratifying the sample by drug of choice as well as by mono versus polysubstance addiction.
   Method: All data were collected at Santa Casa de Sao Paulo, Brazil. The study sample comprised all alcohol or drug dependents admitted to the Addiction Treatment Unit between November 2013 and August 2014. A generalized linear model with a binomial distribution was performed to compare the odds of having a Sexual Addiction Screening Test (SAST) score greater than 6 points in the subgroups analyzed.
   Results: A total of 133 participants were included in our analysis, all reporting cocaine/crack and/or alcohol as drug of choice. Polysubstance addicts had a significant higher risk of a positive screening for sexual addiction compared to monosubstance addicts, age-sex adjusted odds ratios of sexual addiction being respectively 2.72 (95CI 1.1-6.71) and 0.37 (95CI 0.15-0.91). The odds of a SAST score greater than 6 was not statistically different between the cocaine/crack and alcohol groups, respectively 0.38 (95CI 0.14-1.02) and 2.67 (95CI 0.98-7.25). We found a significant relation between stronger drug addiction and greater levels of sexual addiction in the cocaine/crack group (p=0.0012), but not in the alcohol group.
   Conclusion: Our study reinforces the importance of assessing sexual behavior of drug addicts in clinical practice, especially considering users of multiple substances or with severe dependence.
C1 [Antonio, Nelson; Niel, Marcelo; Ratto, Lilian; Pinheiro, Maria Carolina; Otani, Thais Zelia; Otani, Victor; Cordeiro, Quirino; Ushida, Ricardo] FCMSCSP, Ctr Integrated Mental Hlth CAISM, Sao Paulo, SP, Brazil.
   [Diehl, Alessandra] Univ Fed Sao Paulo Unifesp, Psychiat Dept, Sexual Studies Grp Gesex, Sao Paulo, SP, Brazil.
   [Pillon, Sandra] Univ Sao Paulo, Escola Enfermagem Ribeirao Preto, Psychiat Nursing & Social Sci Dept, Ribeirao Preto, SP, Brazil.
   [Silveira, Dartiu] Univ Fed Sao Paulo, Psychiat Dept, Sao Paulo, SP, Brazil.
C3 Faculdade de Ciencias Medicas Santa Casa de Sao Paulo; Universidade
   Federal de Sao Paulo (UNIFESP); Universidade de Sao Paulo; Universidade
   Federal de Sao Paulo (UNIFESP)
RP Antonio, N (通讯作者)，CAISM Santa Casa Sao Paulo, R Major Maragliano 241, BR-04017030 Sao Paulo, SP, Brazil.
EM nelsonpsiq@gmail.com
RI Pillon, Sandra Cristina/C-6908-2012
OI Pillon, Sandra Cristina/0000-0001-8902-7549
CR American Psychiatric Association, 2000, DSM IV TR
   [Anonymous], 2016, CURR ADDICT REP
   [Anonymous], MEDITERRANEAN J CLIN
   [Anonymous], VISUALIZATION IMPUTE
   [Anonymous], REV ENFERM UERJ
   [Anonymous], ATENCION PRIMARIA
   Blum K, 2012, J PSYCHOACTIVE DRUGS, V44, P38, DOI 10.1080/02791072.2012.662112
   Carnes P, 1991, Tenn Nurse, V54, P29
   Carnes P., 2013, CLIN MANAGEMENT SEX
   Derbyshire KL, 2015, J BEHAV ADDICT, V4, P37, DOI 10.1556/2006.4.2015.003
   Gilder DA, 2016, DRUG ALCOHOL DEPEN, V161, P222, DOI 10.1016/j.drugalcdep.2016.02.006
   Hartman LI, 2012, SEX ADDICT COMPULS, V19, P284, DOI 10.1080/10720162.2012.735515
   Karila L, 2014, CURR PHARM DESIGN, V20, P4012, DOI 10.2174/13816128113199990619
   Koller G, 2015, J ADDICT MED, V9, P257, DOI 10.1097/ADM.0000000000000126
   Kopetz CE, 2010, EXP CLIN PSYCHOPHARM, V18, P214, DOI 10.1037/a0019635
   Kor A, 2013, SEX ADDICT COMPULS, V20, P27, DOI 10.1080/10720162.2013.768132
   Kraus SW, 2016, ADDICTION, V111, P2097, DOI 10.1111/add.13297
   Kuhn M., 2018, APPL PREDICTIVE MODE, DOI DOI 10.1007/978-1-4614-6849-3
   Martinotti G, 2009, ADDICT BEHAV, V34, P790, DOI 10.1016/j.addbeh.2009.04.012
   Nappo SA, 2011, SUBST USE MISUSE, V46, P476, DOI 10.3109/10826084.2010.503480
   Odlaug BL, 2013, ANN CLIN PSYCHIATRY, V25, P193
   PAATERO P, 1994, ENVIRONMETRICS, V5, P111, DOI 10.1002/env.3170050203
   Peugh J, 2001, J PSYCHOACTIVE DRUGS, V33, P223, DOI 10.1080/02791072.2001.10400569
   R Core Team, 2018, R LANG ENV STAT COMP, DOI DOI 10.1007/978-3-540-74686-7
   Race K, 2017, SEX HEALTH, V14, P42, DOI 10.1071/SH16080
   Reshef DN, 2011, SCIENCE, V334, P1518, DOI 10.1126/science.1205438
   Rosa-Oliveira LQ, 2011, REV BRAS PSIQUIATR, V33, P68, DOI 10.1590/S1516-44462010005000020
   Salom CL, 2016, ADDICTION, V111, P156, DOI 10.1111/add.13058
   Scanavino MD, 2013, PSYCHIAT RES, V209, P518, DOI 10.1016/j.psychres.2013.01.021
   Shoptaw S, 2013, JAIDS-J ACQ IMM DEF, V63, pS174, DOI 10.1097/QAI.0b013e3182987028
   Silveira Dartiu X., 2000, Revista Brasileira de Psiquiatria, V22, P4, DOI 10.1590/S1516-44462000000100003
   SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3
   Stavro K, 2013, SEX ADDICT COMPULS, V20, P210, DOI 10.1080/10720162.2013.787379
   von Elm E, 2007, PREV MED, V45, P247, DOI 10.1016/j.ypmed.2007.08.012
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3
   Yoon I. S., 2016, CURR ADDICT REP, V3, P387, DOI [10.1007/s40429-016-0121-z, DOI 10.1007/S40429-016-0121-Z]
   Yudko E, 2007, J SUBST ABUSE TREAT, V32, P189, DOI 10.1016/j.jsat.2006.08.002
   Zaazaa A, 2013, ENDOCRIN METAB CLIN, V42, P585, DOI 10.1016/j.ecl.2013.06.003
NR 39
TC 9
Z9 9
U1 1
U2 9
PU ASSOC MEDICA BRASILEIRA
PI SAO PAULO
PA RUA SAO CARLOS DO PINHAL 324, CAIXA POSTAL 8904, SAO PAULO, SP, BRAZIL
SN 0104-4230
EI 1806-9282
J9 REV ASSOC MED BRAS
JI Rev. Assoc. Med. Bras.
PD MAY
PY 2017
VL 63
IS 5
BP 414
EP 421
DI 10.1590/1806-9282.63.05.414
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FB2CG
UT WOS:000405950400007
PM 28724038
OA Green Published, Green Submitted, gold
DA 2023-06-23
ER

PT J
AU Garcia-Pardo, MP
   Roger-Sanchez, C
   Rodriguez-Arias, M
   Minarro, J
   Aguilar, MA
AF Pilar Garcia-Pardo, Maria
   Roger-Sanchez, Concepcion
   Rodriguez-Arias, Marta
   Minarro, Jose
   Asuncion Aguilar, Maria
TI Pharmacological modulation of protein kinases as a new approach to treat
   addiction to cocaine and opiates
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Review
DE Cocaine; Opiate; Drug addiction; Memory; Intracellular signalling;
   Protein kinases
ID CONDITIONED PLACE PREFERENCE; NUCLEUS-ACCUMBENS CORE; SIGNAL-REGULATED
   KINASE; MU-OPIOID RECEPTOR; MEDIAL PREFRONTAL CORTEX; DOPAMINE D3
   RECEPTORS; PRECIPITATED MORPHINE-WITHDRAWAL; ELEMENT-BINDING PROTEIN;
   DELTA-FOSB EXPRESSION; N-TERMINAL KINASE
AB Drug addiction shares brain mechanisms and molecular substrates with learning and memory processes, such as the stimulation of glutamate receptors and their downstream signalling pathways. In the present work we provide an up-to-date review of studies that have demonstrated the implication of the main memory-related calcium-dependent protein kinases in opiate and cocaine addiction. The effects of these drugs of abuse in different animal models of drug reward, dependence and addiction are altered by manipulation of the mitogen-activated protein kinase (MAPK) family, particularly extracellular signal regulated kinase (ERK), calcium/calmodulin-dependent kinase II (CaMKII), the protein kinase C (PKC) family (including PKM zeta), cAMP-dependent protein kinase A (PIGS), cGMP-dependent protein kinase G (PKG), the phosphatidylinositol 3-kinase (PI3K) pathway and its downstream target mammalian target of Rapamycin (mTOR), cyclin-dependent kinase 5 (Cdk5), heat-shock proteins (Hsp) and other enzymes and proteins. Research suggests that drugs of abuse induce dependence and addiction by modifying the signalling pathways that involve these memory-related protein kinases, and supports the idea that drug addiction is an excessive aberrant learning disorder in which the maladaptive memory of drug-associated cues maintains compulsive drug use and contributes to relapse. Moreover, the studies we review offer new pharmacological strategies to treat opiate and cocaine dependence based on the manipulation of these protein kinases. In particular, disruption of reconsolidation of drug-related memories may have a high therapeutic value in the treatment of drug addiction. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Pilar Garcia-Pardo, Maria; Roger-Sanchez, Concepcion; Rodriguez-Arias, Marta; Minarro, Jose; Asuncion Aguilar, Maria] Univ Valencia, Fac Psicol, Dept Psicobiol, Unidad Invest Psicobiol Drogodependencias, Avda Blasco Ibanez 21, Valencia 46010, Spain.
C3 University of Valencia
RP Aguilar, MA (通讯作者)，Univ Valencia, Fac Psicol, Dept Psicobiol, Unidad Invest Psicobiol Drogodependencias, Avda Blasco Ibanez 21, Valencia 46010, Spain.
EM asuncion.aguilar@uv.es
RI Aguilar, Maria A/D-3416-2011; Rodriguez-Arias, Marta/B-5163-2011;
   Roger-Sánchez, Concepción/I-7657-2012; PARDO, MARIA PILAR
   GARCIA/B-3352-2017
OI Aguilar, Maria A/0000-0002-1935-6619; Rodriguez-Arias,
   Marta/0000-0002-1121-8879; Roger-Sánchez,
   Concepción/0000-0002-1442-9751; PARDO, MARIA PILAR
   GARCIA/0000-0003-2730-0145
FU Ministerio de Economia y Competitividad (MINECO), Direccion General de
   Investigacion [PSI2011-24762, PSI2014-51847-R]; Institute de Salud
   Carlos III, Red de Trastornos Adictivos (RTA) [RD12/0028/0005]; Union
   Europea, Fondos FEDER "una manera de hacer Europa"
FX This work was supported by the following grants: Ministerio de Economia
   y Competitividad (MINECO), Direccion General de Investigacion,
   PSI2011-24762 and PSI2014-51847-R; Institute de Salud Carlos III, Red de
   Trastornos Adictivos (RTA) RD12/0028/0005 and Union Europea, Fondos
   FEDER "una manera de hacer Europa". Ministerio de Sanidad, Servicios
   Sociales e Igualdad. Delegacion del Gobierno para el Plan Nacional Sobre
   Drogas, Proyectos de Investigacion sobre Drogodependencias, 2014I007.
   Generalitat Valenciana, Conselleria de Educacion, PROMETEOII/2014/063,
   Val+id (for MP G-P), Spain.
CR Aguilar MA, 2009, BRAIN RES REV, V59, P253, DOI 10.1016/j.brainresrev.2008.08.002
   Alvaro-Bartolome M, 2013, NEUROSCIENCE, V247, P294, DOI 10.1016/j.neuroscience.2013.05.035
   Anderson SM, 2008, NAT NEUROSCI, V11, P344, DOI 10.1038/nn2054
   Arguello AA, 2014, PSYCHOPHARMACOLOGY, V231, P55, DOI 10.1007/s00213-013-3203-9
   Arias-Carrion Oscar, 2014, Int Arch Med, V7, P29, DOI 10.1186/1755-7682-7-29
   Bailey CP, 2009, EUR J NEUROSCI, V29, P307, DOI 10.1111/j.1460-9568.2008.06573.x
   Bailey J, 2012, ADDICT BIOL, V17, P248, DOI 10.1111/j.1369-1600.2010.00311.x
   Bardo MT, 2000, PSYCHOPHARMACOLOGY, V153, P31, DOI 10.1007/s002130000569
   Barker J. M., 2014, BRAIN RES
   Belin D, 2013, CURR OPIN NEUROBIOL, V23, P564, DOI 10.1016/j.conb.2013.01.025
   Berta T, 2013, NEUROSCIENCE, V247, P376, DOI 10.1016/j.neuroscience.2013.05.018
   Besnard A, 2011, J NEUROSCI, V31, P14296, DOI 10.1523/JNEUROSCI.2890-11.2011
   Bilbao A, 2008, P NATL ACAD SCI USA, V105, P17549, DOI 10.1073/pnas.0803959105
   Bilecki W, 2009, EUR J NEUROSCI, V30, P1101, DOI 10.1111/j.1460-9568.2009.06886.x
   Boudreau AC, 2009, J NEUROCHEM, V110, P363, DOI 10.1111/j.1471-4159.2009.06140.x
   Bruchas MR, 2011, NEURON, V71, P498, DOI 10.1016/j.neuron.2011.06.011
   Caffino L, 2014, INT J NEUROPSYCHOPH, V17, P323, DOI 10.1017/S1461145713000916
   Cahill E, 2014, MOL PSYCHIATR, V19, P1295, DOI 10.1038/mp.2014.73
   Cates HM, 2014, J NEUROSCI, V34, P11461, DOI 10.1523/JNEUROSCI.1611-14.2014
   Chandra R, 2015, J NEUROSCI, V35, P7927, DOI 10.1523/JNEUROSCI.0548-15.2015
   Chauvet C, 2011, NEUROSCIENCE, V184, P88, DOI 10.1016/j.neuroscience.2011.03.068
   Chen HJ, 2012, NEUROSCI BULL, V28, P182, DOI 10.1007/s12264-012-1216-8
   Chen LP, 2010, J NEUROCHEM, V114, P530, DOI 10.1111/j.1471-4159.2010.06775.x
   Chen Meng-Ling, 2012, Shengli Xuebao, V64, P365
   Chen Y, 2010, J NEUROSCI, V30, P38, DOI 10.1523/JNEUROSCI.4346-09.2010
   Chen Y, 2009, MOL NEUROBIOL, V40, P101, DOI 10.1007/s12035-009-8074-z
   Ciccarelli A, 2014, NEUROPHARMACOLOGY, V80, P34, DOI 10.1016/j.neuropharm.2014.01.039
   Ciccarelli A, 2013, NEUROPHARMACOLOGY, V70, P168, DOI 10.1016/j.neuropharm.2012.12.010
   Cleva RM, 2010, CURR NEUROPHARMACOL, V8, P394, DOI 10.2174/157015910793358169
   Contet C, 2008, NEUROPHARMACOLOGY, V54, P475, DOI 10.1016/j.neuropharm.2007.10.015
   Cui Y, 2010, NEUROSCIENCE, V171, P134, DOI 10.1016/j.neuroscience.2010.08.064
   Deb I, 2010, J NEUROCHEM, V112, P486, DOI 10.1111/j.1471-4159.2009.06472.x
   Deschatrettes E, 2013, INT J NEUROPSYCHOPH, V16, P1587, DOI 10.1017/S1461145712001630
   Edwards S, 2011, ADDICT BIOL, V16, P450, DOI 10.1111/j.1369-1600.2010.00296.x
   Edwards S, 2009, SYNAPSE, V63, P224, DOI 10.1002/syn.20601
   Everitt BJ, 2014, EUR J NEUROSCI, V40, P2163, DOI 10.1111/ejn.12644
   Fan PD, 2009, MOL PHARMACOL, V76, P526, DOI 10.1124/mol.109.057802
   Fasano S, 2009, BIOL PSYCHIAT, V66, P758, DOI 10.1016/j.biopsych.2009.03.014
   Ferrario CR, 2011, NEUROPHARMACOLOGY, V61, P1141, DOI 10.1016/j.neuropharm.2011.01.021
   Freeman WM, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-29
   Fricks-Gleason AN, 2011, NEUROPSYCHOPHARMACOL, V36, P434, DOI 10.1038/npp.2010.174
   Fujita-Hamabe W, 2011, EUR J PHARMACOL, V672, P77, DOI 10.1016/j.ejphar.2011.04.029
   Gabach LA, 2013, PSYCHOPHARMACOLOGY, V229, P41, DOI 10.1007/s00213-013-3084-y
   Gabra BH, 2008, BRAIN RES, V1217, P70, DOI 10.1016/j.brainres.2008.04.036
   Garzon Javier, 2012, Curr Drug Abuse Rev, V5, P199
   Giese KP, 2013, LEARN MEMORY, V20, P540, DOI 10.1101/lm.028449.112
   Go BS, 2010, NEUROPHARMACOLOGY, V59, P100, DOI 10.1016/j.neuropharm.2010.04.009
   Guo ML, 2010, NEUROSCI BULL, V26, P163, DOI 10.1007/s12264-010-1016-y
   He YY, 2011, NEUROPSYCHOPHARMACOL, V36, P1972, DOI 10.1038/npp.2011.63
   Hearing MC, 2011, INT J NEUROPSYCHOPH, V14, P784, DOI 10.1017/S1461145710001173
   Hervera A, 2012, EUR J PHARMACOL, V685, P42, DOI 10.1016/j.ejphar.2012.04.009
   Ho SY, 2012, BIOL PSYCHIAT, V71, P706, DOI 10.1016/j.biopsych.2011.10.031
   Hong YG, 2010, J NEUROSCI, V30, P12508, DOI 10.1523/JNEUROSCI.0306-10.2010
   Hoot MR, 2013, BEHAV PHARMACOL, V24, P144, DOI 10.1097/FBP.0b013e32835f3d2f
   Hu ZZ, 2015, KOREAN J PHYSIOL PHA, V19, P89, DOI 10.4196/kjpp.2015.19.2.89
   Hull LC, 2010, J PHARMACOL EXP THER, V332, P1127, DOI 10.1124/jpet.109.161455
   Iniguez SD, 2010, BEHAV BRAIN RES, V214, P460, DOI 10.1016/j.bbr.2010.05.040
   James MH, 2014, NEUROPSYCHOPHARMACOL, V39, P1694, DOI 10.1038/npp.2014.16
   Janes AC, 2009, PSYCHOPHARMACOLOGY, V206, P177, DOI 10.1007/s00213-009-1594-4
   Jia W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066111
   Jian M, 2014, J NEUROSCI, V34, P10010, DOI 10.1523/JNEUROSCI.0934-14.2014
   Jin WY, 2010, ACS CHEM NEUROSCI, V1, P122, DOI 10.1021/cn900005d
   Johnson MM, 2012, J FORENSIC SCI, V57, P1519, DOI 10.1111/j.1556-4029.2012.02212.x
   Kadivar M, 2014, BEHAV BRAIN RES, V267, P74, DOI 10.1016/j.bbr.2014.03.035
   Kalivas PW, 2009, NEUROPHARMACOLOGY, V56, P169, DOI 10.1016/j.neuropharm.2008.07.011
   Kaplan GB, 2011, PHARMACOL BIOCHEM BE, V97, P619, DOI 10.1016/j.pbb.2010.08.004
   Keifer J, 2010, EUR J NEUROSCI, V32, P269, DOI 10.1111/j.1460-9568.2010.07339.x
   Kiefer F, 2013, CURR TOP BEHAV NEURO, V13, P671, DOI 10.1007/7854_2011_147
   Kim S, 2011, KOREAN J PHYSIOL PHA, V15, P389, DOI 10.4196/kjpp.2011.15.6.389
   Kong H, 2011, NEUROSCIENCE, V176, P152, DOI 10.1016/j.neuroscience.2010.12.008
   Kourrich S, 2012, J NEUROSCI, V32, P6578, DOI 10.1523/JNEUROSCI.6391-11.2012
   Koya E, 2009, NEUROPHARMACOLOGY, V56, P177, DOI 10.1016/j.neuropharm.2008.04.022
   Krishnan B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025639
   Kuhar JR, 2015, CELL SIGNAL, V27, P1799, DOI 10.1016/j.cellsig.2015.05.019
   Lai MJ, 2014, INT J NEUROPSYCHOPH, V17, P1397, DOI 10.1017/S1461145714000595
   Lai YT, 2008, NEUROBIOL LEARN MEM, V90, P164, DOI 10.1016/j.nlm.2008.03.006
   Lee AM, 2008, ANN NY ACAD SCI, V1141, P22, DOI 10.1196/annals.1441.022
   Lee DK, 2013, NEUROCHEM RES, V38, P1424, DOI 10.1007/s11064-013-1040-1
   Lee DK, 2013, NEUROSCI LETT, V541, P120, DOI 10.1016/j.neulet.2013.02.014
   Li F, 2011, NEUROTOX RES, V20, P362, DOI 10.1007/s12640-011-9250-2
   Li FQ, 2010, J NEUROSCI, V30, P10351, DOI 10.1523/JNEUROSCI.2112-10.2010
   Li T, 2010, NEUROSCI LETT, V468, P348, DOI 10.1016/j.neulet.2009.11.030
   Li YQ, 2011, J NEUROSCI, V31, P5436, DOI 10.1523/JNEUROSCI.5884-10.2011
   Lichti CF, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00246
   Liddie S., 2014, ADDICT BIOL
   Liddie S, 2012, J PSYCHOPHARMACOL, V26, P1375, DOI 10.1177/0269881112447991
   Lin J, 2014, INT J NEUROPSYCHOPH, V17, P127, DOI 10.1017/S1461145713001156
   Liu XY, 2009, NEURON, V61, P425, DOI 10.1016/j.neuron.2008.12.015
   Liu XJ, 2014, NEUROPSYCHOPHARMACOL, V39, P989, DOI 10.1038/npp.2013.299
   Liu X, 2015, P NATL ACAD SCI USA, V112, P4483, DOI 10.1073/pnas.1421758112
   Liu Z, 2012, NEUROSCI LETT, V526, P39, DOI 10.1016/j.neulet.2012.07.042
   Liu Z, 2012, NEUROSCI LETT, V518, P167, DOI 10.1016/j.neulet.2012.05.003
   Lu GY, 2011, NEUROSCI LETT, V503, P196, DOI 10.1016/j.neulet.2011.08.034
   Lu W, 2010, P NATL ACAD SCI USA, V107, P22266, DOI 10.1073/pnas.1016289107
   Lull ME, 2009, PROTEOM CLIN APPL, V3, P462, DOI 10.1002/prca.200800055
   Luo FC, 2012, FREE RADICAL BIO MED, V52, P1218, DOI 10.1016/j.freeradbiomed.2012.01.004
   Luo YX, 2013, NEUROBIOL LEARN MEM, V105, P159, DOI 10.1016/j.nlm.2013.06.017
   Lv XF, 2015, INT J NEUROPSYCHOPH, V18, DOI 10.1093/ijnp/pyv030
   Lyons D, 2013, J NEUROSCI, V33, P14693, DOI 10.1523/JNEUROSCI.1226-13.2013
   Macey TA, 2009, J PHARMACOL EXP THER, V331, P412, DOI 10.1124/jpet.109.152157
   Mannangatti P, 2015, J BIOL CHEM, V290, P10814, DOI 10.1074/jbc.M114.612192
   Marin MT, 2009, EUR J NEUROSCI, V30, P1931, DOI 10.1111/j.1460-9568.2009.06982.x
   Martin F, 2011, BRIT J PHARMACOL, V163, P857, DOI 10.1111/j.1476-5381.2011.01287.x
   Martinez-Laorden E, 2014, BRIT J PHARMACOL, V171, P688, DOI 10.1111/bph.12511
   Massaly N, 2013, NEUROPSYCHOPHARMACOL, V38, P596, DOI 10.1038/npp.2012.217
   Massart R, 2015, J NEUROSCI, V35, P8042, DOI 10.1523/JNEUROSCI.3053-14.2015
   McGinty JF, 2010, BRAIN RES, V1314, P183, DOI 10.1016/j.brainres.2009.08.078
   McGinty JP, 2014, BRAIN RES
   Medvedev IO, 2013, J NEUROSCI, V33, P18125, DOI 10.1523/JNEUROSCI.2382-13.2013
   Miller CA, 2005, NEURON, V47, P873, DOI 10.1016/j.neuron.2005.08.006
   Miszkiel J, 2014, PHARMACOL REP, V66, P630, DOI 10.1016/j.pharep.2014.02.001
   Morgenstern J, 2013, PSYCHOL ADDICT BEHAV, V27, P336, DOI 10.1037/a0032435
   Morris RGM, 2013, NEUROPHARMACOLOGY, V74, P32, DOI 10.1016/j.neuropharm.2013.04.014
   Mu Y, 2014, MOL BRAIN, V7, DOI 10.1186/s13041-014-0070-1
   Mukherjee S, 2013, NEUROPHARMACOLOGY, V66, P65, DOI 10.1016/j.neuropharm.2012.06.005
   Navarro-Zaragoza J, 2014, TOXICOL APPL PHARM, V275, P28, DOI 10.1016/j.taap.2013.12.021
   Navidhamidi M, 2012, BEHAV BRAIN RES, V226, P440, DOI 10.1016/j.bbr.2011.09.043
   Nazarian A, 2009, PSYCHOPHARMACOLOGY, V203, P641, DOI 10.1007/s00213-008-1411-5
   Neasta J, 2014, J NEUROCHEM, V130, P172, DOI 10.1111/jnc.12725
   Nemoto W, 2013, NEUROPEPTIDES, V47, P187, DOI 10.1016/j.npep.2012.11.002
   Nestler Eric J, 2013, Dialogues Clin Neurosci, V15, P431
   Nestler EJ, 2014, NEUROPHARMACOLOGY, V76, P259, DOI 10.1016/j.neuropharm.2013.04.004
   Nygard SK, 2015, NEUROSCIENCE, V287, P1, DOI 10.1016/j.neuroscience.2014.12.010
   Nygard SK, 2013, BRAIN RES, V1520, P121, DOI 10.1016/j.brainres.2013.04.060
   Oh JH, 2015, EXP BRAIN RES, V233, P1511, DOI 10.1007/s00221-015-4228-6
   Ortinski PI, 2015, NEUROPHARMACOLOGY, V92, P80, DOI 10.1016/j.neuropharm.2015.01.002
   Pan B, 2011, J NEUROSCI, V31, P11244, DOI 10.1523/JNEUROSCI.1040-11.2011
   Park JM, 2013, CELL, V154, P637, DOI 10.1016/j.cell.2013.07.001
   Pascoli V, 2012, NATURE, V481, P71, DOI 10.1038/nature10709
   Pascoli V, 2011, BIOL PSYCHIAT, V69, P218, DOI 10.1016/j.biopsych.2010.08.031
   Peregud DI, 2012, B EXP BIOL MED+, V153, P836, DOI 10.1007/s10517-012-1838-x
   Perez MF, 2011, SYNAPSE, V65, P168, DOI 10.1002/syn.20831
   Peters J, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a012088
   Ping XJ, 2012, NEUROPHARMACOLOGY, V62, P959, DOI 10.1016/j.neuropharm.2011.10.001
   Pomierny-Chamiolo L, 2014, PHARMACOL THERAPEUT, V142, P281, DOI 10.1016/j.pharmthera.2013.12.012
   Potenza MN, 2011, NEURON, V69, P695, DOI 10.1016/j.neuron.2011.02.009
   Ramos-Miguel A, 2012, NEUROSCIENCE, V215, P17, DOI 10.1016/j.neuroscience.2012.04.035
   Ramos-Miguel A, 2009, NEUROSCIENCE, V161, P23, DOI 10.1016/j.neuroscience.2009.03.028
   Rehni AK, 2013, NEUROPHARMACOLOGY, V71, P19, DOI 10.1016/j.neuropharm.2013.01.022
   Reissner KJ, 2011, J NEUROSCI, V31, P5648, DOI 10.1523/JNEUROSCI.3452-10.2011
   Ren Z, 2010, NEUROSCIENCE, V168, P48, DOI 10.1016/j.neuroscience.2010.03.034
   Ren ZY, 2013, NEUROPSYCHOPHARMACOL, V38, P778, DOI 10.1038/npp.2012.243
   Robison AJ, 2013, J NEUROSCI, V33, P4295, DOI 10.1523/JNEUROSCI.5192-12.2013
   Rudy JW, 2014, NEUROBIOLOGY OF LEARNING AND MEMORY, SECOND EDITION, P1
   Ruffle JK, 2014, AM J DRUG ALCOHOL AB, V40, P428, DOI 10.3109/00952990.2014.933840
   Salas E, 2013, NEUROSCIENCE, V230, P151, DOI 10.1016/j.neuroscience.2012.11.001
   Salas E, 2011, BEHAV BRAIN RES, V225, P71, DOI 10.1016/j.bbr.2011.06.034
   Sanchez H, 2010, J NEUROSCI, V30, P4401, DOI 10.1523/JNEUROSCI.3149-09.2010
   Sanchez-Blazquez P, 2013, EUR J PHARMACOL, V716, P94, DOI 10.1016/j.ejphar.2013.01.066
   Schierberl K, 2011, J NEUROSCI, V31, P13562, DOI 10.1523/JNEUROSCI.2315-11.2011
   Schindler AG, 2012, J NEUROSCI, V32, P17582, DOI 10.1523/JNEUROSCI.3220-12.2012
   Schmidt HD, 2015, ADDICT BIOL, V20, P285, DOI 10.1111/adb.12122
   Schmidt HD, 2013, J NEUROSCI, V33, P14160, DOI 10.1523/JNEUROSCI.2284-13.2013
   Seo SY, 2013, NEUROSCI LETT, V544, P147, DOI 10.1016/j.neulet.2013.04.003
   Seyedi SY, 2014, FUND CLIN PHARMACOL, V28, P445, DOI 10.1111/fcp.12045
   Shabashov D, 2012, J MOL NEUROSCI, V47, P546, DOI 10.1007/s12031-011-9671-7
   Shen F, 2014, BEHAV NEUROSCI, V128, P446, DOI 10.1037/a0036964
   Shen F, 2012, NEUROBIOL LEARN MEM, V98, P130, DOI 10.1016/j.nlm.2012.07.005
   Shepherd JD, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00049
   Shi XD, 2014, PSYCHOPHARMACOLOGY, V231, P3109, DOI 10.1007/s00213-014-3491-8
   Shibasaki M, 2011, EUR J PHARMACOL, V651, P137, DOI 10.1016/j.ejphar.2010.11.013
   Slaker M, 2015, J NEUROSCI, V35, P4190, DOI 10.1523/JNEUROSCI.3592-14.2015
   Solinas M, 2010, PROG NEUROBIOL, V92, P572, DOI 10.1016/j.pneurobio.2010.08.002
   Song L, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/1471-2253-15-12
   Song ZB, 2010, J GENE MED, V12, P873, DOI 10.1002/jgm.1514
   Stein IS, 2010, EMBO J, V29, P1943, DOI 10.1038/emboj.2010.105
   Sun WL, 2014, ADDICT BIOL, V19, P77, DOI 10.1111/adb.12043
   Sun WL, 2013, PSYCHOPHARMACOLOGY, V229, P603, DOI 10.1007/s00213-013-3118-5
   Tan-No K, 2010, NEUROPEPTIDES, V44, P279, DOI 10.1016/j.npep.2010.02.001
   Tronson NC, 2013, CURR OPIN NEUROBIOL, V23, P573, DOI 10.1016/j.conb.2013.01.022
   Tropea TF, 2008, J NEUROCHEM, V106, P1780, DOI 10.1111/j.1471-4159.2008.05518.x
   Tumati S, 2011, J NEUROSCI METH, V199, P62, DOI 10.1016/j.jneumeth.2011.04.036
   Tzschentke TM, 2007, ADDICT BIOL, V12, P227, DOI 10.1111/j.1369-1600.2007.00070.x
   Tzschentke TM, 1998, PROG NEUROBIOL, V56, P613, DOI 10.1016/S0301-0082(98)00060-4
   Walker DM, 2015, CURR OPIN NEUROBIOL, V30, P112, DOI 10.1016/j.conb.2014.11.002
   Wan X., 2014, PLOS ONE, V26
   Wang L, 2010, NEUROPSYCHOPHARMACOL, V35, P913, DOI 10.1038/npp.2009.193
   Wang WS, 2015, BRIT J PHARMACOL, V172, P482, DOI 10.1111/bph.12671
   Wang WS, 2012, J NEUROSCI, V32, P13763, DOI 10.1523/JNEUROSCI.1991-12.2012
   Wang X, 2010, J NEUROSCI, V30, P12632, DOI 10.1523/JNEUROSCI.1264-10.2010
   Wang YT, 2014, INT J NEUROPSYCHOPH, V17, P469, DOI 10.1017/S1461145713001429
   Wang ZY, 2010, PAIN, V151, P194, DOI 10.1016/j.pain.2010.07.006
   Weiner J, 2009, NEUROSCIENCE, V161, P865, DOI 10.1016/j.neuroscience.2009.03.071
   Wells AM, 2013, NEUROPSYCHOPHARMACOL, V38, P753, DOI 10.1038/npp.2012.238
   Werner C.T., 2015, NEUROPSYCHOPHARMACOL
   White SL, 2013, NEUROSCI LETT, V537, P71, DOI 10.1016/j.neulet.2013.01.017
   Whitfield TW, 2011, J NEUROSCI, V31, P834, DOI 10.1523/JNEUROSCI.4986-10.2011
   Wu J, 2011, NEUROSCIENCE, V172, P104, DOI 10.1016/j.neuroscience.2010.10.041
   Wu Q, 2012, BEHAV BRAIN RES, V233, P217, DOI 10.1016/j.bbr.2012.04.026
   Xie WY, 2009, J NEUROSCI, V29, P3551, DOI 10.1523/JNEUROSCI.0415-09.2009
   Xin W, 2012, INT J NEUROSCI, V122, P154, DOI 10.3109/00207454.2011.635828
   Xu T, 2012, EUR J PHARMACOL, V683, P78, DOI 10.1016/j.ejphar.2012.02.046
   Xu Y, 2012, BRAIN RES BULL, V89, P22, DOI 10.1016/j.brainresbull.2012.06.012
   Xue B, 2012, BRAIN RES, V1435, P146, DOI 10.1016/j.brainres.2011.11.024
   Yan Y, 2014, NEUROSCIENCE, V278, P154, DOI 10.1016/j.neuroscience.2014.08.008
   Yan Y, 2013, NEUROSCIENCE, V241, P32, DOI 10.1016/j.neuroscience.2013.03.005
   Yang HY, 2014, ANTIOXID REDOX SIGN, V20, P31, DOI 10.1089/ars.2012.5119
   Yang JL, 2011, BEHAV BRAIN RES, V216, P592, DOI 10.1016/j.bbr.2010.08.047
   Yap JJ, 2015, PSYCHOPHARMACOLOGY, V232, P1555, DOI 10.1007/s00213-014-3796-7
   Zamora-Martinez ER, 2014, FRONT INTEGR NEUROSC, V8, DOI 10.3389/fnint.2014.00024
   Zhang L, 2012, NEUROSIGNALS, V20, P15, DOI 10.1159/000330743
   Zhang XQ, 2012, BRAIN BEHAV IMMUN, V26, P318, DOI 10.1016/j.bbi.2011.09.017
   Zhang XQ, 2011, BEHAV BRAIN RES, V218, P184, DOI 10.1016/j.bbr.2010.11.049
   Zhao YL, 2012, J BIOL CHEM, V287, P25073, DOI 10.1074/jbc.M112.378737
   Zhong P, 2012, NEUROPSYCHOPHARMACOL, V37, P2377, DOI 10.1038/npp.2012.93
NR 205
TC 27
Z9 28
U1 2
U2 52
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD JUN 15
PY 2016
VL 781
BP 10
EP 24
DI 10.1016/j.ejphar.2016.03.065
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA DL1UB
UT WOS:000375417000002
PM 27056740
DA 2023-06-23
ER

PT S
AU Konrath, EL
   Arbo, MD
   Arbo, BD
   Hort, MA
   Elisabetsky, E
   Leal, MB
AF Konrath, Eduardo Luis
   Arbo, Marcelo Dutra
   Arbo, Bruno Dutra
   Hort, Mariana Appel
   Elisabetsky, Elaine
   Leal, Mirna Bainy
BE Barreto, GE
   Sahebkar, A
TI Plants with Anti-Addictive Potential
SO PHARMACOLOGICAL PROPERTIES OF PLANT-DERIVED NATURAL PRODUCTS AND
   IMPLICATIONS FOR HUMAN HEALTH
SE Advances in Experimental Medicine and Biology
LA English
DT Article; Book Chapter
DE Addiction; Drug dependence; Natural products; Substance abuse; Opioid
   dependence
ID CONDITIONED PLACE PREFERENCE; PASSIFLORA-INCARNATA LINNEAUS; NICOTINE
   LOCOMOTOR SENSITIZATION; NITRIC-OXIDE OVERPRODUCTION; REDUCE
   MORPHINE-WITHDRAWAL; NIGELLA-SATIVA OIL; BENZOFLAVONE MOIETY; ALCOHOL
   INTAKE; SALVIA-MILTIORRHIZA; WITHANIA-SOMNIFERA
AB Drug addiction is prevalent among individuals of modern society, being a major cause of disability and premature loss of life. Although the drug addiction have profound social, economical and health impact in the world population, its management remains a challenge as available pharmacological treatments remains ineffective for most people. The limited efficacy and adverse effects have led to a search for alternative therapies to treat drug addiction. In this context, natural products are an important source for new chemical substances with a potential therapeutic applicability. Therefore, this chapter will present data obtained after an extensive literature search regarding the use of medicinal plants as a pharmacological alternative for drug addiction treatment.
C1 [Konrath, Eduardo Luis; Arbo, Marcelo Dutra] Univ Fed Rio Grande Sul UFRGS, Fac Farm, Porto Alegre, RS, Brazil.
   [Arbo, Bruno Dutra; Leal, Mirna Bainy] Univ Fed Rio Grande Sul UFRGS, Inst Ciencias Basicas Saude, Dept Farmacol, Porto Alegre, RS, Brazil.
   [Hort, Mariana Appel] Univ Fed Rio Grande FURG, Inst Ciencias Biol, Rio Grande, RS, Brazil.
   [Elisabetsky, Elaine] Univ Fed Rio Grande Sul UFRGS, Inst Ciencias Basicas Saude ICBS, Dept Bioquim, Porto Alegre, RS, Brazil.
C3 Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio
   Grande do Sul; Universidade Federal do Rio Grande; Universidade Federal
   do Rio Grande do Sul
RP Leal, MB (通讯作者)，Univ Fed Rio Grande Sul UFRGS, Inst Ciencias Basicas Saude, Dept Farmacol, Porto Alegre, RS, Brazil.
EM mirnablufrgs@gmail.com
RI Hort, Mariana/T-7377-2019; Leal, Mirna/AAE-8222-2022; Konrath, Eduardo
   Luis/P-7524-2018; Elisabetsky, Elaine/K-3444-2012
OI Hort, Mariana/0000-0001-5877-3506; Konrath, Eduardo
   Luis/0000-0003-1838-4228; Arbo, Bruno/0000-0001-7929-1688; Elisabetsky,
   Elaine/0000-0002-9922-2863
CR Abdel-Zaher AO, 2011, NEUROTOXICOLOGY, V32, P725, DOI 10.1016/j.neuro.2011.08.001
   Abdel-Zaher AO, 2010, NEUROCHEM RES, V35, P1557, DOI 10.1007/s11064-010-0215-2
   ACETO MD, 1978, EUR J PHARMACOL, V50, P203, DOI 10.1016/0014-2999(78)90352-7
   Adkins JE, 2011, CURR TOP MED CHEM, V11, P1165
   Ahmad H, 2018, BIOORG CHEM, V78, P427, DOI 10.1016/j.bioorg.2018.04.008
   Akhondzadeh S, 2001, J CLIN PHARM THER, V26, P369, DOI 10.1046/j.1365-2710.2001.00366.x
   Alemy S, 2012, EUR REV MED PHARMACO, V16, P38
   Alper KR, 1999, AM J ADDICTION, V8, P234
   Schunck RVA, 2017, PHYTOTHER RES, V31, P1199, DOI 10.1002/ptr.5839
   Anvari M, 2012, ANC SCI LIFE, V32, P82, DOI 10.4103/0257-7941.118537
   Assanangkornchai S, 2007, SUBST USE MISUSE, V42, P2145, DOI 10.1080/10826080701205869
   Association AP, 2000, DIAGNOSTIC STAT MANU, DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]
   Bassareo V, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00545
   Baumann MH, 2001, J PHARMACOL EXP THER, V297, P531
   Bedell S, 2019, PHARM BIOL, V57, P8, DOI 10.1080/13880209.2018.1561725
   BHARGAVA HN, 1991, GEN PHARMACOL, V22, P521, DOI 10.1016/0306-3623(91)90017-Z
   Bracci A, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/482976
   Breivogel C, 2012, PHARM BIOL, V50, P1310, DOI 10.3109/13880209.2012.674535
   Brunetti G, 2003, J ETHNOPHARMACOL, V85, P93, DOI 10.1016/S0378-8741(02)00363-X
   Calixto JR, 2019, AN ACAD BRAS CIENC, V91, DOI 10.1590/0001-3765201920190105
   Capasso A, 1997, PLANTA MED, V63, P326, DOI 10.1055/s-2006-957693
   Capasso A, 2006, CURR MED CHEM, V13, P807, DOI 10.2174/092986706776055616
   Capasso A, 2003, PHYTOTHER RES, V17, P826, DOI 10.1002/ptr.1218
   Capasso A, 2003, PHYTOTHER RES, V17, P774, DOI 10.1002/ptr.1234
   Capasso A, 2009, CURR DRUG SAF, V4, P97, DOI 10.2174/157488609788173035
   CAPPENDIJK SLT, 1993, EUR J PHARMACOL, V241, P261, DOI 10.1016/0014-2999(93)90212-Z
   Caputi FF, 2019, PHARMACOL RES, V139, P422, DOI 10.1016/j.phrs.2018.11.033
   Caputi FF, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-017-2065-9
   Carlini Elisaldo A., 2006, Rev. bras. farmacogn., V16, P690, DOI 10.1590/S0102-695X2006000500016
   Cheaha D, 2017, J ETHNOPHARMACOL, V208, P129, DOI 10.1016/j.jep.2017.07.008
   Chen CX, 2018, NEUROCHEM RES, V43, P918, DOI 10.1007/s11064-018-2497-8
   Chen CX, 2014, NEUROSCI LETT, V570, P63, DOI 10.1016/j.neulet.2014.04.006
   COLLIER HOJ, 1974, NATURE, V249, P471, DOI 10.1038/249471a0
   Colombo G, 2006, ALCOHOL CLIN EXP RES, V30, P754, DOI 10.1111/j.1530-0277.2006.00088.x
   Corkery JM, 2018, PROG BRAIN RES, V242, P217, DOI 10.1016/bs.pbr.2018.08.005
   Cragg GM, 2013, BBA-GEN SUBJECTS, V1830, P3670, DOI 10.1016/j.bbagen.2013.02.008
   Daneshfard B, 2019, COMPLEMENT THER MED, V46, P29, DOI 10.1016/j.ctim.2019.05.027
   Dar NJ, 2015, CELL MOL LIFE SCI, V72, P4445, DOI 10.1007/s00018-015-2012-1
   Darvishzadeh-Mahani F, 2012, J ETHNOPHARMACOL, V141, P901, DOI 10.1016/j.jep.2012.03.030
   De Vry J, 1999, EUR NEUROPSYCHOPHARM, V9, P461, DOI 10.1016/S0924-977X(99)00005-X
   Dewick P. M., 2009, MED NATURAL PRODUCTS, P187
   Dhawan K, 2003, J PHARM PHARM SCI, V6, P215
   Dhawan K, 2002, J ETHNOPHARMACOL, V81, P239, DOI 10.1016/S0378-8741(02)00086-7
   Dhawan K, 2002, J PHARM PHARMACOL, V54, P875, DOI 10.1211/0022357021779069
   Dhawan K, 2002, ADDICT BIOL, V7, P435, DOI 10.1080/1355621021000006044
   dos Santos RG, 2011, J CLIN PSYCHOPHARM, V31, P717, DOI 10.1097/JCP.0b013e31823607f6
   Egashira N, 2006, J ETHNOPHARMACOL, V104, P193, DOI 10.1016/j.jep.2005.08.056
   Elisabetsky Elaine, 1997, Ciencia e Cultura (Sao Paulo), V49, P378
   FARNSWORTH NR, 1994, CIBA F SYMP, V185, P42
   Ghaderi A, 2019, PHYTOTHER RES, V33, P2714, DOI 10.1002/ptr.6445
   Ghannadi A, 2012, RES PHARM SCI, V7, P127
   Gilani AH, 2005, J ETHNOPHARMACOL, V100, P43, DOI 10.1016/j.jep.2005.06.001
   Giri S, 2006, CHEM RES TOXICOL, V19, P818, DOI 10.1021/tx0600402
   GLICK SD, 1991, EUR J PHARMACOL, V195, P341, DOI 10.1016/0014-2999(91)90474-5
   Glick SD, 2000, ANN NY ACAD SCI, V914, P369, DOI 10.1111/j.1749-6632.2000.tb05211.x
   Gomaa A, 2003, J PHARMACOL SCI, V92, P50, DOI 10.1254/jphs.92.50
   GOTTLIEB OR, 1982, J ETHNOPHARMACOL, V6, P227, DOI 10.1016/0378-8741(82)90005-8
   Gupta AK, 2020, REGUL TOXICOL PHARM, V110, DOI 10.1016/j.yrtph.2019.104548
   Habtemariam S, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104722
   Haghparast A, 2008, NEUROSCI LETT, V440, P134, DOI 10.1016/j.neulet.2008.05.060
   Halbsguth C, 2003, PLANTA MED, V69, P305, DOI 10.1055/s-2003-38869
   Hamill J, 2019, CURR NEUROPHARMACOL, V17, P108, DOI 10.2174/1570159X16666180125095902
   Hasanein P, 2015, AM J DRUG ALCOHOL AB, V41, P405, DOI 10.3109/00952990.2015.1062893
   Helsley S, 1998, PHARMACOL BIOCHEM BE, V59, P419, DOI 10.1016/S0091-3057(97)00451-6
   Hidese S, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102362
   Hidese S, 2017, ACTA NEUROPSYCHIATR, V29, P72, DOI 10.1017/neu.2016.33
   Horak M, 2016, SBORNIK PRISPEVKU Z MEZINARODNI VEDECKE KONFERENCE: REGION V ROZVOJI SPOLECNOSTI 2016, P276
   Horenstein NA, 2019, NICOTINE TOB RES, V21, P805, DOI 10.1093/ntr/ntx187
   Hosseinzadeh H, 2000, PHYTOTHER RES, V14, P384, DOI 10.1002/1099-1573(200008)14:5&lt;384::AID-PTR641&gt;3.0.CO;2-F
   Hosseinzadeh H, 2003, PHYTOTHER RES, V17, P938, DOI 10.1002/ptr.1311
   Hosseinzadeh H, 2007, J MED PLANTS, V6, P48
   Hosseinzadeh H, 2016, AVICENNA J PHYTOMEDI, V6, P55
   Hosseinzadeh Hossein, 2002, BMC Pharmacol, V2, P7
   Hosseinzadeh H, 2010, PHYTOTHER RES, V24, P726, DOI 10.1002/ptr.3011
   Imanshahidi M, 2006, PHYTOTHER RES, V20, P427, DOI 10.1002/ptr.1898
   Jenks CW, 2002, NAT PROD LETT, V16, P71, DOI 10.1080/1057563029001/4881
   Kakuda T, 2000, BIOSCI BIOTECH BIOCH, V64, P287, DOI 10.1271/bbb.64.287
   Kakuda T, 2002, BIOSCI BIOTECH BIOCH, V66, P2683, DOI 10.1271/bbb.66.2683
   Karami M, 2013, ADV PHARM BULL, V3, P457, DOI 10.5681/apb.2013.075
   Kasture S, 2009, NEUROTOX RES, V16, P343, DOI 10.1007/s12640-009-9069-2
   KEUNG WM, 1993, P NATL ACAD SCI USA, V90, P1247, DOI 10.1073/pnas.90.4.1247
   Khalatbari-mohseni A, 2019, SUBST ABUSE TREAT PR, V14, DOI 10.1186/s13011-019-0198-1
   Khalili M, 2001, EUR J PHARMACOL, V412, P239, DOI 10.1016/S0014-2999(01)00718-X
   Khan Y, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00352
   Khodayar MJ, 2014, JUNDISHAPUR J NAT PH, V9, DOI 10.17795/jjnpp-9959
   Kim HC, 2005, ARCH PHARM RES, V28, P995, DOI 10.1007/BF02977391
   Kim HS, 1999, BEHAV BRAIN RES, V103, P55, DOI 10.1016/S0166-4328(99)00030-3
   Kim HS, 1998, J ETHNOPHARMACOL, V60, P33, DOI 10.1016/S0378-8741(97)00131-1
   Kim SE, 2006, NEUROPSYCHOPHARMACOL, V31, P1714, DOI 10.1038/sj.npp.1300945
   KIMURA R, 1971, CHEM PHARM BULL, V19, P1257
   Koenig X, 2013, TOXICOL APPL PHARM, V273, P259, DOI 10.1016/j.taap.2013.05.012
   Koob GF, 2016, LANCET PSYCHIAT, V3, P760, DOI 10.1016/S2215-0366(16)00104-8
   Kulkarni SK, 1997, J ETHNOPHARMACOL, V57, P213, DOI 10.1016/S0378-8741(97)00064-0
   Kumarnsit E, 2005, FITOTERAPIA, V76, P534, DOI 10.1016/j.fitote.2005.04.015
   Kushner Steven, 2013, J Addict Res Ther, V4
   Kwon SH, 2008, BIOMOL THER, V16, P113, DOI 10.4062/biomolther.2008.16.2.113
   Leal MB, 2003, PROG NEURO-PSYCHOPH, V27, P781, DOI 10.1016/S0278-5846(03)00109-X
   Lee B, 2012, KOREAN J PHYSIOL PHA, V16, P379, DOI 10.4196/kjpp.2012.16.6.379
   Lee B, 2011, J MICROBIOL BIOTECHN, V21, P1088, DOI 10.4014/jmb.1106.06027
   Lee HS, 2012, PHYTOTHER RES, V26, P1753, DOI 10.1002/ptr.4630
   Lee SY, 2003, ARCH PHARM RES, V26, P540, DOI 10.1007/BF02976878
   Liester MB, 2012, J PSYCHOACTIVE DRUGS, V44, P200, DOI 10.1080/02791072.2012.704590
   Lin CC, 2017, SUBST USE MISUSE, V52, P646, DOI 10.1080/10826084.2016.1246572
   Lin RC, 1996, ALCOHOL CLIN EXP RES, V20, P659, DOI 10.1111/j.1530-0277.1996.tb01668.x
   LIU GQ, 1982, ARCH INT PHARMACOD T, V258, P39
   Liu JF, 2018, ACTA PHARMACOL SIN, V39, P1823, DOI 10.1038/s41401-018-0180-x
   Lowe ED, 2008, J MED CHEM, V51, P4482, DOI 10.1021/jm800488j
   Lu L, 2009, AM J DRUG ALCOHOL AB, V35, P1, DOI 10.1080/00952990802455469
   Lukas SE, 2013, PSYCHOPHARMACOLOGY, V226, P65, DOI 10.1007/s00213-012-2884-9
   Maccioni P, 2014, ALCOHOL, V48, P587, DOI 10.1016/j.alcohol.2014.06.002
   Maculaitis R, 2008, HUM EXP TOXICOL, V27, P181, DOI 10.1177/0960327107087802
   Mannucci C, 2007, PHYTOMEDICINE, V14, P645, DOI 10.1016/j.phymed.2007.06.005
   Mannucci C, 2012, PHYTOMEDICINE, V19, P1117, DOI 10.1016/j.phymed.2012.07.001
   MARCENAC F, 1986, PSYCHOPHARMACOLOGY, V89, P89
   Fabregas JM, 2010, DRUG ALCOHOL DEPEN, V111, P257, DOI 10.1016/j.drugalcdep.2010.03.024
   Mash DC, 2016, J PSYCHOPHARMACOL, V30, P688, DOI 10.1177/0269881116641331
   Matsuda N, 2015, IEEE INT CONF COMPUT
   Matsumoto K, 2005, LIFE SCI, V78, P2, DOI 10.1016/j.lfs.2004.10.086
   Matsumoto K, 2006, EUR J PHARMACOL, V549, P63, DOI 10.1016/j.ejphar.2006.08.013
   Mattioli L, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/741925
   Mattioli L, 2011, J PSYCHOPHARMACOL, V25, P411, DOI 10.1177/0269881109359096
   Mattioli L, 2011, J PSYCHOPHARMACOL, V25, P402, DOI 10.1177/0269881109348166
   McCallum SE, 2009, NEUROSCI LETT, V458, P57, DOI 10.1016/j.neulet.2009.04.019
   McKenna DJ, 1998, HEFFTER REV PSYCHEDE, V1, P10
   Meireles Vania, 2019, Medicines (Basel), V6, DOI 10.3390/medicines6010035
   Mo Zhi-xian, 2006, Nan Fang Yi Ke Da Xue Xue Bao, V26, P1709
   Mostallino MC, 2004, EUR J PHARMACOL, V494, P83, DOI 10.1016/j.ejphar.2004.04.021
   Mykhailenko O, 2019, PHYTOCHEMISTRY, V162, P56, DOI 10.1016/j.phytochem.2019.02.004
   Nagappan A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010265
   Nah SY, 2009, BRAIN RES, V1248, P184, DOI 10.1016/j.brainres.2008.10.064
   Narasingam M, 2016, EXP ANIM TOKYO, V65, P157, DOI 10.1538/expanim.15-0088
   National Institute on Drug Abuse (NIDA), 2020, 2016 2020 NIDA STRAT
   Nestler EJ, 2019, NEURON, V102, P48, DOI 10.1016/j.neuron.2019.01.016
   Nolli LM, 2020, ALCOHOL, V84, P67, DOI 10.1016/j.alcohol.2019.10.005
   Nunes AA, 2016, J PSYCHOACTIVE DRUGS, V48, P195, DOI 10.1080/02791072.2016.1188225
   Oliveira-Lima AJ, 2015, PHYSIOL BEHAV, V142, P28, DOI 10.1016/j.physbeh.2015.01.032
   Overstreet DH, 2003, PHARMACOL BIOCHEM BE, V75, P619, DOI 10.1016/S0091-3057(03)00114-X
   Panchal V, 2005, EUR J PHARMACOL, V525, P98, DOI 10.1016/j.ejphar.2005.09.060
   Pandy V, 2018, BIOMED PHARMACOTHER, V107, P368, DOI 10.1016/j.biopha.2018.08.008
   Peacock A, 2018, ADDICTION, V113, P1905, DOI 10.1111/add.14234
   Peana AT, 2014, BEHAV PHARMACOL, V25, P618, DOI 10.1097/FBP.0000000000000078
   Penetar DM, 2015, DRUG ALCOHOL DEPEN, V153, P194, DOI 10.1016/j.drugalcdep.2015.05.025
   Peng B, 2021, JAMIA OPEN, V4, DOI [10.1093/jamiaopen/ooaa074, 10.1155/2014/139030]
   Peng W, 2015, J ETHNOPHARMACOL, V164, P340, DOI 10.1016/j.jep.2015.02.010
   Perfumi M, 2005, ALCOHOL ALCOHOLISM, V40, P291, DOI 10.1093/alcalc/agh133
   Perfumi M, 2003, ALCOHOL CLIN EXP RES, V27, P1554, DOI 10.1097/01.ALC.0000092062.60924.56
   Pourmotabbed A, 2004, J ETHNOPHARMACOL, V95, P431, DOI 10.1016/j.jep.2004.08.022
   Qi D, 2009, J PSYCHOPHARMACOL, V23, P74, DOI 10.1177/0269881107082950
   Rahman Syed, 2002, BMC Complement Altern Med, V2, P6, DOI 10.1186/1472-6882-2-6
   Rahmati B, 2017, J ETHNOPHARMACOL, V199, P39, DOI 10.1016/j.jep.2017.01.032
   Rauf K, 2014, PHYTOTHER RES, V28, P937, DOI 10.1002/ptr.5081
   Rauf K, 2012, PHYTOTHER RES, V26, P758, DOI 10.1002/ptr.3631
   Rauf K, 2011, PHYTOMEDICINE, V18, P836, DOI 10.1016/j.phymed.2011.01.023
   REZVANI AH, 1995, PHARMACOL BIOCHEM BE, V52, P615, DOI 10.1016/0091-3057(95)00152-M
   Rezvani AH, 2003, PHARMACOL BIOCHEM BE, V75, P593, DOI 10.1016/S0091-3057(03)00124-2
   Rezvani AH, 2016, PHARMACOL BIOCHEM BE, V150, P153, DOI 10.1016/j.pbb.2016.10.010
   Riba J, 2001, PSYCHOPHARMACOLOGY, V154, P85, DOI 10.1007/s002130000606
   Roach JJ, 2018, BIOORG MED CHEM LETT, V28, P1436, DOI 10.1016/j.bmcl.2018.03.029
   Teves MR, 2015, J ETHNOPHARMACOL, V161, P170, DOI 10.1016/j.jep.2014.12.019
   Ruiu S, 2013, BEHAV PHARMACOL, V24, P133, DOI 10.1097/FBP.0b013e32835f3d15
   Safakhah HA, 2020, PHARMACOL REP, V72, P305, DOI 10.1007/s43440-020-00071-9
   Sahraei H, 2006, J ETHNOPHARMACOL, V103, P420, DOI 10.1016/j.jep.2005.08.022
   Sahraei H, 2002, J ETHNOPHARMACOL, V80, P43, DOI 10.1016/S0378-8741(02)00012-0
   Sayyah M, 2002, PHARM BIOL, V40, P478, DOI 10.1076/phbi.40.6.478.8446
   Shahid M, 2017, PAK J PHARM SCI, V30, P2067
   Shi J, 2006, ACTA PHARMACOL SIN, V27, P1303, DOI 10.1111/j.1745-7254.2006.00431.x
   Shi X, 2018, TOXICOL APPL PHARM, V350, P21, DOI 10.1016/j.taap.2018.04.036
   Shim I, 2000, PLANTA MED, V66, P705, DOI 10.1055/s-2000-9777
   Shin EJ, 2004, LIFE SCI, V75, P2751, DOI 10.1016/j.lfs.2004.04.045
   Sood A, 2010, J ALTERN COMPLEM MED, V16, P761, DOI 10.1089/acm.2009.0445
   Subhan F, 2009, PHYTOTHER RES, V23, P564, DOI 10.1002/ptr.2692
   Tabatabai SM, 2014, PHYTOTHER RES, V28, P811, DOI 10.1002/ptr.5073
   Teves MR, 2015, J ETHNOPHARMACOL, V174, P11, DOI 10.1016/j.jep.2015.07.046
   The United Nations Office on Drugs and Crime, 2019, WORLD DRUG REPORT 20, P1, DOI 10.18356/BDC264F4--EN
   Thomas Gerald, 2013, Curr Drug Abuse Rev, V6, P30
   Thongpradichote S, 1998, LIFE SCI, V62, P1371, DOI 10.1016/S0024-3205(98)00075-7
   Titomanlio F, 2014, PSYCHOPHARMACOLOGY, V231, P2077, DOI 10.1007/s00213-013-3351-y
   Titomanlio F, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/697632
   Tokuyama S, 1996, PHARMACOL BIOCHEM BE, V54, P671, DOI 10.1016/0091-3057(96)00021-4
   Vacca G, 2003, PHYTOTHER RES, V17, P537, DOI 10.1002/ptr.1203
   Veltri C, 2019, SUBST ABUSE REHABIL, V10, P23, DOI 10.2147/SAR.S164261
   Vijeepallam K, 2019, METAB BRAIN DIS, V34, P1713, DOI 10.1007/s11011-019-00477-2
   Volkow ND, 2019, PHYSIOL REV, V99, P2115, DOI 10.1152/physrev.00014.2018
   Volkow ND, 2015, CELL, V162, P712, DOI 10.1016/j.cell.2015.07.046
   Wang JB, 2012, FUTURE MED CHEM, V4, P177, DOI [10.4155/FMC.11.166, 10.4155/fmc.11.166]
   Ward J, 2011, CNS DRUGS, V25, P999, DOI 10.2165/11596830-000000000-00000
   White CM, 2018, AM J HEALTH-SYST PH, V75, P261, DOI 10.2146/ajhp161035
   Wise LE, 2012, PHARMACOL BIOCHEM BE, V103, P245, DOI 10.1016/j.pbb.2012.08.008
   Xu M, 2007, ADDICTION, V102, P282, DOI 10.1111/j.1360-0443.2006.01660.x
   Xu ZJ, 2000, TOXICOL SCI, V57, P95, DOI 10.1093/toxsci/57.1.95
   Yang Z, 2008, ACTA PHARMACOL SIN, V29, P781, DOI 10.1111/j.1745-7254.2008.00817.x
   Yayeh T, 2016, J GINSENG RES, V40, P445, DOI 10.1016/j.jgr.2016.08.006
   Yokogoshi H, 1998, NEUROCHEM RES, V23, P667, DOI 10.1023/A:1022490806093
   Yun J, 2014, PHARM BIOL, V52, P1382, DOI 10.3109/13880209.2014.892514
   Yun J, 2014, PHYTOMEDICINE, V21, P1287, DOI 10.1016/j.phymed.2014.07.003
   Yusoff NHM, 2017, BEHAV BRAIN RES, V332, P1, DOI 10.1016/j.bbr.2017.05.059
   Zafar S, 2002, FITOTERAPIA, V73, P553, DOI 10.1016/S0367-326X(02)00223-X
   Zafar S, 2001, J ETHNOPHARMACOL, V78, P95, DOI 10.1016/S0378-8741(01)00317-8
   Zou ZL, 2017, ADV EXP MED BIOL, V1010, P21, DOI 10.1007/978-981-10-5562-1_2
   Zubaran C, 1999, NEUROPSYCHOPHARMACOL, V21, P119, DOI 10.1016/S0893-133X(99)00003-2
NR 200
TC 2
Z9 2
U1 0
U2 4
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 0065-2598
EI 2214-8019
BN 978-3-030-64872-5; 978-3-030-64871-8
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2021
VL 1308
BP 185
EP 215
DI 10.1007/978-3-030-64872-5_14
D2 10.1007/978-3-030-64872-5
PG 31
WC Chemistry, Medicinal; Medicine, Research & Experimental; Pharmacology &
   Pharmacy
WE Book Citation Index– Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Research & Experimental Medicine
GA BR3MG
UT WOS:000647701200014
PM 33861445
DA 2023-06-23
ER

PT J
AU Battista, NA
   Pearcy, LB
   Strickland, WC
AF Battista, Nicholas A.
   Pearcy, Leigh B.
   Strickland, W. Christopher
TI Modeling the Prescription Opioid Epidemic
SO BULLETIN OF MATHEMATICAL BIOLOGY
LA English
DT Article
DE Population biology; Dynamical systems; Epidemiology; Compartmental
   model; Mathematical biology; Prescription drug addiction
ID UNITED-STATES; CHRONIC PAIN; HEROIN; RISK; ADDICTION; MISUSE; ABUSE;
   INCREASES; METHADONE; DEATHS
AB Opioid addiction has become a global epidemic and a national health crisis in recent years, with the number of opioid overdose fatalities steadily increasing since the 1990s. In contrast to the dynamics of a typical illicit drug or disease epidemic, opioid addiction has its roots in legal, prescription medication-a fact which greatly increases the exposed population and provides additional drug accessibility for addicts. In this paper, we present a mathematical model for prescription drug addiction and treatment with parameters and validation based on data from the opioid epidemic. Key dynamics considered include addiction through prescription, addiction from illicit sources, and treatment. Through mathematical analysis, we show that no addiction-free equilibrium can exist without stringent control over how opioids are administered and prescribed, in which case we estimate that the epidemic would cease to be self-sustaining. Numerical sensitivity analysis suggests that relatively low states of endemic addiction can be obtained by primarily focusing on medical prevention followed by aggressive treatment of remaining cases-even when the probability of relapse from treatment remains high. Further empirical study focused on understanding the rate of illicit drug dependence versus overdose risk, along with the current and changing rates of opioid prescription and treatment, would shed significant light on optimal control efforts and feasible outcomes for this epidemic and drug epidemics in general.
C1 [Battista, Nicholas A.] Coll New Jersey, Dept Math & Stat, 2000 Pennington Rd, Ewing, NJ 08628 USA.
   [Pearcy, Leigh B.] Univ N Carolina, Dept Math, CB 3250, Chapel Hill, NC 27599 USA.
   [Pearcy, Leigh B.; Strickland, W. Christopher] Univ Tennessee, Dept Math, 1403 Circle Dr, Knoxville, TN 37996 USA.
C3 College of New Jersey; University of North Carolina; University of North
   Carolina Chapel Hill; University of Tennessee System; University of
   Tennessee Knoxville
RP Strickland, WC (通讯作者)，Univ Tennessee, Dept Math, 1403 Circle Dr, Knoxville, TN 37996 USA.
EM battistn@tcnj.edu; lpearcy1@vols.utk.edu; cstric12@utk.edu
OI Battista, Nicholas/0000-0003-2437-0383; Strickland,
   Christopher/0000-0002-5424-2086
CR ANDERSON RM, 1979, NATURE, V280, P361, DOI 10.1038/280361a0
   Bailey GL, 2013, J SUBST ABUSE TREAT, V45, P302, DOI 10.1016/j.jsat.2013.04.002
   Battista NA, 2009, COMP HEROIN EPIDEMIC
   Baumblatt JAG, 2014, JAMA INTERN MED, V174, P796, DOI 10.1001/jamainternmed.2013.12711
   Bicket MC, 2017, JAMA SURG, V152, P1066, DOI 10.1001/jamasurg.2017.0831
   Boscarino JA, 2010, ADDICTION, V105, P1776, DOI 10.1111/j.1360-0443.2010.03052.x
   Boudreau D, 2009, PHARMACOEPIDEM DR S, V18, P1166, DOI 10.1002/pds.1833
   Campbell CI, 2010, AM J PUBLIC HEALTH, V100, P2541, DOI 10.2105/AJPH.2009.180646
   Castillo-Chavez C, 2004, MATH BIOSCI ENG, V1, P361, DOI 10.3934/mbe.2004.1.361
   Centers for Disease Control and Prevention (CDC), 2017, 1 CDC DEP HLTH HUM S
   Centers for Disease Control and Prevention (CDC), 2014, VIT SIGNS OP PAINK P
   Diekmann O, 2010, J R SOC INTERFACE, V7, P873, DOI 10.1098/rsif.2009.0386
   Diekmann O., 1990, J MATH BIOL, V35, P503
   Fang B, 2015, J SYST SCI COMPLEX, V28, P1243, DOI 10.1007/s11424-015-3243-9
   Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2
   GOSSOP M, 1987, ADDICT BEHAV, V12, P1, DOI 10.1016/0306-4603(87)90002-5
   Han B, 2017, ANN INTERN MED, V167, P293, DOI 10.7326/M17-0865
   Heffernan JM, 2005, J R SOC INTERFACE, V2, P281, DOI 10.1098/rsif.2005.0042
   Hirschfeld Davis Julie, 2017, NEW YORK TIMES
   Huang G, 2013, APPL MATH LETT, V26, P687, DOI 10.1016/j.aml.2013.01.010
   Hughes A, 2016, NSDUH DATA REV
   HUGHES PH, 1972, AM J PUBLIC HEALTH N, V62, P995, DOI 10.2105/AJPH.62.7.995
   Jones CM, 2013, DRUG ALCOHOL DEPEN, V132, P95, DOI 10.1016/j.drugalcdep.2013.01.007
   Kermack WO, 1927, P R SOC LOND A-CONTA, V115, P700, DOI 10.1098/rspa.1927.0118
   Keyes KM, 2014, AM J PUBLIC HEALTH, V104, pE52, DOI 10.2105/AJPH.2013.301709
   Kochanek KD, 2016, NCHS DATA BRIEF, V293, P1
   Lankenau SE, 2012, INT J DRUG POLICY, V23, P37, DOI 10.1016/j.drugpo.2011.05.014
   Ma MJ, 2017, NONLINEAR DYNAM, V88, P555, DOI 10.1007/s11071-016-3260-9
   MACKINTOSH DR, 1979, J EPIDEMIOL COMMUN H, V33, P299, DOI 10.1136/jech.33.4.299
   Mandell BF, 2016, CLEV CLIN J MED, V83, P400, DOI 10.3949/ccjm.83b.06016
   Miao H, 2013, ABSTR APPL ANAL, DOI 10.1155/2013/163484
   Muhuri Pradip K, 2013, TECHNICAL REPORT
   Njagarah HJB, 2013, J BIOL SYST, V21, DOI 10.1142/S0218339013500010
   Nyabadza F, 2010, MATH BIOSCI, V225, P132, DOI 10.1016/j.mbs.2010.03.002
   O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P897, DOI 10.15585/mmwr.mm6634a2
   Office of the Surgeon General, TECHNICAL REPORT
   PERRY S, 1982, PAIN, V13, P267, DOI 10.1016/0304-3959(82)90016-1
   Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3
   Pezalla EJ, 2017, J PAIN RES, V10, DOI 10.2147/JPR.S129553
   PORTER J, 1980, NEW ENGL J MED, V302, P123
   Saltelli A, 2002, COMPUT PHYS COMMUN, V145, P280, DOI 10.1016/S0010-4655(02)00280-1
   Saltelli A, 2010, COMPUT PHYS COMMUN, V181, P259, DOI 10.1016/j.cpc.2009.09.018
   Samanta GP, 2011, J APPL MATHE COMPUT, V35, P161, DOI 10.1007/s12190-009-0349-z
   SCHUG SA, 1992, J PAIN SYMPTOM MANAG, V7, P259, DOI 10.1016/0885-3924(92)90059-Q
   Scully RE, 2018, JAMA SURG, V153, P37, DOI 10.1001/jamasurg.2017.3132
   Seth P, 2018, AM J PUBLIC HEALTH, V108, P500, DOI 10.2105/AJPH.2017.304265
   Shah A, 2017, MMWR-MORBID MORTAL W, V66, P265, DOI 10.15585/mmwr.mm6610a1
   Smyth B P, 2010, Ir Med J, V103, P176
   Sobol IM, 2001, MATH COMPUT SIMULAT, V55, P271, DOI 10.1016/S0378-4754(00)00270-6
   Substance Abuse and Mental health Services Administration, 2016, HHS PUBL, VSMA 16-4984
   Substance Abuse and Mental Health Services Administration, 2016, BHSIS SER S, V84
   Twombly EC, 2008, J PRIM PREV, V29, P503, DOI 10.1007/s10935-008-0157-5
   U. S. Census Bureau: International Database, INT DAT POP TOT
   U.S. Food and Drug Administration, 2018, TECHNICAL REPORT
   van den Driessche P, 2002, MATH BIOSCI, V180, P29, DOI 10.1016/S0025-5564(02)00108-6
   Volkow ND, 2016, NEW ENGL J MED, V374, P1253, DOI 10.1056/NEJMra1507771
   Vowles KE, 2015, PAIN, V156, P569, DOI 10.1097/01.j.pain.0000460357.01998.f1
   Watkins KE, 2017, DRUG ALCOHOL DEPEN, V177, P307, DOI 10.1016/j.drugalcdep.2017.03.033
   Weiss RD, 2017, DRUG ALCOHOL DEPEN, V173, pS48, DOI 10.1016/j.drugalcdep.2016.12.001
   White E, 2007, MATH BIOSCI, V208, P312, DOI 10.1016/j.mbs.2006.10.008
   Zee AV, 2009, AM J PUBLIC HEALTH, V99, P221, DOI 10.2105/AJPH.2007.131714
NR 61
TC 20
Z9 20
U1 1
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0092-8240
EI 1522-9602
J9 B MATH BIOL
JI Bull. Math. Biol.
PD JUL
PY 2019
VL 81
IS 7
BP 2258
EP 2289
DI 10.1007/s11538-019-00605-0
PG 32
WC Biology; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA IH5ZL
UT WOS:000474571900009
PM 31012032
OA Green Submitted
DA 2023-06-23
ER

PT J
AU Happel, HV
   Korkel, J
   Becker, G
   Lipsmeier, G
AF Happel, H. -V.
   Koerkel, J.
   Becker, G.
   Lipsmeier, G.
TI Successfully Cutting Down Ones Drug Consumption: A Pyrrhic Victory? An
   Empirical Test of the Substitution Hypothesis
SO SUCHTTHERAPIE
LA German
DT Article
DE Suchtverlagerung; Drogenabhangigkeit; Konsumreduktionsprogramm;
   substitute addictions; drug addiction; behavioral self-control training
ID ALCOHOL-USE
AB Aim: To test the hypothesis that drug addicts that participate in a program aiming at self-controlled drug consumption (German acronym "KISS") develop substitute addictions.
   Method: Drug consumption of N=59 DSM-IV drug addicts was assessed by (urine validated) timeline-followback interviews before and after KISS participation. Pre-post-comparisons were calculated for the main substances (crack, heroin, benzodiazepines, cannabis, alcohol, cocaine).
   Results: Instead of a substitution effect a carry-over effect emerged: Decreases in heroin, cocaine, and cannabis use (not significantly for crack, benzodiazepines, and alcohol) went along with significant decreases in the consumption of other drugs.
   Conclusion: KISS is an effective behavioral self-control training for drug addicts with no substitute addictions to be expected.
C1 [Happel, H. -V.] Frankfurt Univ Appl Sci, D-60318 Frankfurt, Germany.
   [Koerkel, J.] Evangel Hsch Nurnberg, Inst Innovat Suchtbehandlung & Suchtforsch ISS, Nurnberg, Germany.
   [Happel, H. -V.; Becker, G.; Lipsmeier, G.] Integrat Drogenhilfe eV Frankfurt M, Frankfurt, Germany.
RP Happel, HV (通讯作者)，Frankfurt Univ Appl Sci, FB Soziale Arbeit & Gesundheit 4, Nibelungenpl 1, D-60318 Frankfurt, Germany.
EM happel@idh-frankfurt.de
CR [Anonymous], 2001, DOK 3 EV BEH ABH SUC, V47
   Baker A, 2005, ADDICTION, V100, P367, DOI 10.1111/j.1360-0443.2005.01002.x
   Darke S, 2006, DRUG ALCOHOL DEPEN, V84, P201, DOI 10.1016/j.drugalcdep.2006.03.004
   Gossop M, 2003, J SUBST ABUSE TREAT, V25, P135, DOI 10.1016/S0740-5472(03)00129-6
   Hester R. K., 2003, HDB ALCOHOLISM TREAT, P152
   Korkel J., 2014, SUCHTTHERAPIE, V15, P165
   Korkel J., 2011, SELBSTKONTROLLIERTE
   Korkel J, 2010, TEILNEHMERHANDBUCH T
   Mann K., 2013, PSYCHOPHARMAKOTHERAP, V20, P193
   Metrik J, 2011, DRUG ALCOHOL DEPEN, V119, P194, DOI 10.1016/j.drugalcdep.2011.06.004
   Nutt D, 2007, LANCET, V369, P1047, DOI 10.1016/S0140-6736(07)60464-4
   SIMPSON DD, 1978, AM J DRUG ALCOHOL AB, V5, P1, DOI 10.3109/00952997809029257
   SOBELL LC, 1992, MEASURING ALCOHOL CONSUMPTION, P41, DOI 10.1007/978-1-4612-0357-5_3
   Staiger PK, 2013, ADDICTION, V108, P1188, DOI 10.1111/j.1360-0443.2012.04075.x
   Sussman S, 2008, J DRUG EDUC, V38, P167, DOI 10.2190/DE.38.2.e
   WITTCHEN HU, 1997, SKID 1 STRUKTURIERTE
NR 16
TC 0
Z9 0
U1 0
U2 3
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 1439-9903
EI 1439-989X
J9 SUCHTTHERAPIE
JI Suchttherapie
PD NOV
PY 2014
VL 15
IS 4
BP 187
EP 190
DI 10.1055/s-0034-1390480
PG 4
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Psychiatry
GA AT8ZT
UT WOS:000345218200010
DA 2023-06-23
ER

PT S
AU Naqvi, NH
   Gaznick, N
   Tranel, D
   Bechara, A
AF Naqvi, Nasir H.
   Gaznick, Natassia
   Tranel, Daniel
   Bechara, Antoine
BE Kingstone, A
   Miller, MB
TI The insula: a critical neural substrate for craving and drug seeking
   under conflict and risk
SO YEAR IN COGNITIVE NEUROSCIENCE
SE Annals of the New York Academy of Sciences
LA English
DT Article; Book Chapter
DE insula; addiction; risk; craving; drug seeking
ID TRANSCRANIAL MAGNETIC STIMULATION; ANTERIOR CINGULATE CORTEX; PREFRONTAL
   CORTEX; DECISION-MAKING; FUNCTIONAL CONNECTIVITY; ORBITOFRONTAL CORTEX;
   SMOKING-CESSATION; BRAIN REACTIVITY; CUE REACTIVITY; ADDICTION
AB Drug addiction is characterized by the inability to control drug use when it results in negative consequences or conflicts with more adaptive goals. Our previous work showed that damage to the insula disrupted addiction to cigarette smoking-the first time that the insula was shown to be a critical neural substrate for addiction. Here, we review those findings, as well as more recent studies that corroborate and extend them, demonstrating the role of the insula in (1) incentive motivational processes that drive addictive behavior, (2) control processes that moderate or inhibit addictive behavior, and (3) interoceptive processes that represent bodily states associated with drug use. We then describe a theoretical framework that attempts to integrate these seemingly disparate findings. In this framework, the insula functions in the recall of interoceptive drug effects during craving and drug seeking under specific conditions where drug taking is perceived as risky and/or where there is conflict between drug taking and more adaptive goals. We describe this framework in an evolutionary context and discuss its implications for understanding the mechanisms of behavior change in addiction treatments.
C1 [Naqvi, Nasir H.] Columbia Univ, Dept Psychiat, Div Substance Abuse, New York, NY USA.
   [Naqvi, Nasir H.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA.
   [Gaznick, Natassia; Tranel, Daniel; Bechara, Antoine] Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA.
   [Tranel, Daniel] Univ Iowa, Dept Psychol, Iowa City, IA 52242 USA.
   [Bechara, Antoine] Univ So Calif, Brain & Creat Inst, Los Angeles, CA 90089 USA.
   [Bechara, Antoine] Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA.
C3 Columbia University; New York State Psychiatry Institute; University of
   Iowa; University of Iowa; University of Southern California; University
   of Southern California
RP Bechara, A (通讯作者)，Univ So Calif, Brain & Creat Inst, HNB B26, Los Angeles, CA 90089 USA.
EM bechara@usc.edu
RI Naqvi, Nasir/AAW-7933-2021
OI Bechara, Antoine/0000-0001-5127-2549; Tranel, Daniel/0000-0002-1338-1389
FU NIAAA NIH HHS [K23 AA022771] Funding Source: Medline; NIDA NIH HHS [R01
   DA16708, R21 DA016708, T32 DA007294, F30 DA016847] Funding Source:
   Medline; NIGMS NIH HHS [T32 GM007337] Funding Source: Medline; NIMH NIH
   HHS [T32 MH020004] Funding Source: Medline
CR Albrecht J, 2009, HUM BRAIN MAPP, V30, P699, DOI 10.1002/hbm.20535
   Allman JM, 2010, BRAIN STRUCT FUNCT, V214, P495, DOI 10.1007/s00429-010-0254-0
   Wikler A, 1984, J Subst Abuse Treat, V1, P277
   Augustine JR, 1996, BRAIN RES REV, V22, P229, DOI 10.1016/S0165-0173(96)00011-2
   Balleine BW, 2010, NEUROPSYCHOPHARMACOL, V35, P48, DOI 10.1038/npp.2009.131
   Balleine BW, 2000, J NEUROSCI, V20, P8954
   Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584
   Bednarski B., 2008, CURRENT STATUS TOBAC
   Berridge KC, 2003, TRENDS NEUROSCI, V26, P507, DOI 10.1016/S0166-2236(03)00233-9
   Bienkowski P, 2010, NEUROSCI LETT, V478, P161, DOI 10.1016/j.neulet.2010.05.008
   Blaine S, 2013, ALCOHOL CLIN EXP RES, V37, pE125, DOI 10.1111/j.1530-0277.2012.01923.x
   Bonthius DJ, 2005, J NEUROPATH EXP NEUR, V64, P910, DOI 10.1097/01.jnen.0000182983.87106.d1
   Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003
   Carpenter CM, 2007, ADDICTION, V102, P136, DOI 10.1111/j.1360-0443.2006.01649.x
   Castro N., 2012, THESIS SAN DIEGO STA
   Chanraud S, 2007, NEUROPSYCHOPHARMACOL, V32, P429, DOI 10.1038/sj.npp.1301219
   Chase HW, 2011, BIOL PSYCHIAT, V70, P785, DOI 10.1016/j.biopsych.2011.05.025
   Chikama M, 1997, J NEUROSCI, V17, P9686
   Cisler JM, 2013, PSYCHIAT RES-NEUROIM, V213, P39, DOI 10.1016/j.pscychresns.2013.02.007
   Clark L, 2008, BRAIN, V131, P1311, DOI 10.1093/brain/awn066
   Claus ED, 2013, NEUROPSYCHOPHARMACOL, V38, P2363, DOI 10.1038/npp.2013.134
   Claus ED, 2011, NEUROPSYCHOPHARMACOL, V36, P2086, DOI 10.1038/npp.2011.99
   Claus ED, 2011, ALCOHOL CLIN EXP RES, V35, P1209, DOI 10.1111/j.1530-0277.2011.01455.x
   Contreras M, 2007, SCIENCE, V318, P655, DOI 10.1126/science.1145590
   Contreras M, 2012, NEUROPSYCHOPHARMACOL, V37, P2101, DOI 10.1038/npp.2012.59
   Craig AD, 2010, BRAIN STRUCT FUNCT, V214, P563, DOI 10.1007/s00429-010-0248-y
   Craig AD, 2002, NAT REV NEUROSCI, V3, P655, DOI 10.1038/nrn894
   Damasio A., 1999, FEELING WHAT HAPPENS
   Damasio A. R., 2000, DESCARTES ERROR EMOT
   Damasio A, 2013, CEREB CORTEX, V23, P833, DOI 10.1093/cercor/bhs077
   DeVito EE, 2013, NEUROPSYCHOPHARMACOL, V38, P1854, DOI 10.1038/npp.2013.92
   Engelmann JM, 2012, NEUROIMAGE, V60, P252, DOI 10.1016/j.neuroimage.2011.12.024
   Ersche KD, 2012, SCIENCE, V335, P601, DOI 10.1126/science.1214463
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Everitt BJ, 1999, ANN NY ACAD SCI, V877, P412, DOI 10.1111/j.1749-6632.1999.tb09280.x
   Fagerstrom K, 2001, LUNG CANCER-J IASLC, V32, P1, DOI 10.1016/S0169-5002(00)00203-8
   Filbey FM, 2008, ALCOHOL CLIN EXP RES, V32, P1113, DOI 10.1111/j.1530-0277.2008.00692.x
   Filbey FM, 2008, NEUROPSYCHOPHARMACOL, V33, P1391, DOI 10.1038/sj.npp.1301513
   Forget B, 2010, BIOL PSYCHIAT, V68, P265, DOI 10.1016/j.biopsych.2010.01.029
   Franklin TR, 2011, DRUG ALCOHOL DEPEN, V117, P176, DOI 10.1016/j.drugalcdep.2011.01.015
   Franklin TR, 2002, BIOL PSYCHIAT, V51, P134, DOI 10.1016/S0006-3223(01)01269-0
   Fudge JL, 2002, NEUROSCIENCE, V110, P257, DOI 10.1016/S0306-4522(01)00546-2
   Gardini S, 2012, BRAIN RES BULL, V87, P205, DOI 10.1016/j.brainresbull.2011.11.021
   Gaznick N, 2014, NICOTINE TOB RES, V16, P445, DOI 10.1093/ntr/ntt172
   Georgiadis JR, 2005, J COMP NEUROL, V493, P33, DOI 10.1002/cne.20735
   Goldstein RZ, 2009, TRENDS COGN SCI, V13, P372, DOI 10.1016/j.tics.2009.06.004
   Goldstein RZ, 2004, NEUROPSYCHOLOGIA, V42, P1447, DOI 10.1016/j.neuropsychologia.2004.04.002
   Gottfried JA, 2003, SCIENCE, V301, P1104, DOI 10.1126/science.1087919
   Gray's Anatomy, 2008, GRAYS ANATOMY ANATOM
   Hollander JA, 2008, P NATL ACAD SCI USA, V105, P19480, DOI 10.1073/pnas.0808023105
   Ikemoto S, 1999, BRAIN RES REV, V31, P6, DOI 10.1016/S0165-0173(99)00023-5
   Ishii H, 2012, J NEUROSCI, V32, P16031, DOI 10.1523/JNEUROSCI.2278-12.2012
   Janes AC, 2012, DRUG ALCOHOL DEPEN, V120, P7, DOI 10.1016/j.drugalcdep.2011.06.009
   Janes AC, 2010, BIOL PSYCHIAT, V67, P722, DOI 10.1016/j.biopsych.2009.12.034
   Jentsch JD, 2014, NEUROPHARMACOLOGY, V76, P479, DOI 10.1016/j.neuropharm.2013.05.022
   Kelley AE, 1999, PSYCHOBIOLOGY, V27, P198
   Khalsa SS, 2009, NAT NEUROSCI, V12, P1494, DOI 10.1038/nn.2411
   Klein TA, 2013, FRONT HUM NEUROSCI, V7, DOI [10.3389/fnhum.2013.00014, 10.3389/fnins.2013.00113]
   Kohno M, 2015, CEREB CORTEX, V25, P236, DOI 10.1093/cercor/bht218
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Kringelbach ML, 2005, NAT REV NEUROSCI, V6, P691, DOI 10.1038/nrn1747
   Kuhn S, 2011, EUR J NEUROSCI, V33, P1318, DOI 10.1111/j.1460-9568.2010.07590.x
   Kuhnen CM, 2005, NEURON, V47, P763, DOI 10.1016/j.neuron.2005.08.008
   Li XB, 2013, BIOL PSYCHIAT, V73, P714, DOI 10.1016/j.biopsych.2013.01.003
   Liu X, 1998, NEUROPSYCHOPHARMACOL, V18, P243
   Lovero KL, 2009, NEUROIMAGE, V45, P976, DOI 10.1016/j.neuroimage.2008.12.070
   Luigjes J, 2012, MOL PSYCHIATR, V17, P572, DOI 10.1038/mp.2011.114
   Makris N, 2008, BIOL PSYCHIAT, V64, P192, DOI 10.1016/j.biopsych.2008.01.018
   MARLATT GA, 1985, RELAPSE PREVENTION
   Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0
   MESULAM MM, 1982, J COMP NEUROL, V212, P38, DOI 10.1002/cne.902120104
   Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167
   Miller JM, 2006, AM J PSYCHIAT, V163, P786, DOI 10.1176/appi.ajp.163.5.786
   Miller W.R., 2013, MOTIVATIONAL INTERVI, V3rd
   Mizuhiki T, 2012, J NEUROPHYSIOL, V107, P2996, DOI 10.1152/jn.00282.2011
   Mohr PNC, 2010, J NEUROSCI, V30, P6613, DOI 10.1523/JNEUROSCI.0003-10.2010
   Morales AM, 2012, DRUG ALCOHOL DEPEN, V125, P230, DOI 10.1016/j.drugalcdep.2012.02.017
   Moreno-Lopez L, 2012, DRUG ALCOHOL DEPEN, V125, P208, DOI 10.1016/j.drugalcdep.2012.02.012
   Morrison I, 2011, J NEUROSCI, V31, P9554, DOI 10.1523/JNEUROSCI.0397-11.2011
   Naqvi NH, 2007, SCIENCE, V315, P531, DOI 10.1126/science.1135926
   Naqvi NH, 2006, INT J PSYCHOPHYSIOL, V61, P77, DOI 10.1016/j.ijpsycho.2005.10.018
   Naqvi NH, 2010, BRAIN STRUCT FUNCT, V214, P435, DOI 10.1007/s00429-010-0268-7
   Naqvi NH, 2009, TRENDS NEUROSCI, V32, P56, DOI 10.1016/j.tins.2008.09.009
   Naqvi NH, 2005, PHARMACOL BIOCHEM BE, V81, P821, DOI 10.1016/j.pbb.2005.06.005
   National Institute on Drug Abuse, 2012, PRINC DRUG ADD TREAT
   OBRIEN CP, 1975, DRUG ALCOHOL DEPEN, V1, P115, DOI 10.1016/0376-8716(75)90013-7
   Olausson H, 2002, NAT NEUROSCI, V5, P900, DOI 10.1038/nn896
   Paulus MP, 2008, BIOL PSYCHIAT, V63, P1054, DOI 10.1016/j.biopsych.2007.09.007
   Paulus MP, 2009, PHARMACOL BIOCHEM BE, V94, P1, DOI 10.1016/j.pbb.2009.08.005
   Paulus MP, 2005, ARCH GEN PSYCHIAT, V62, P761, DOI 10.1001/archpsyc.62.7.761
   Philippi CL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038413
   Pickens CL, 2003, J NEUROSCI, V23, P11078
   Potenza MN, 2011, NEURON, V69, P695, DOI 10.1016/j.neuron.2011.02.009
   Preuschoff K, 2008, J NEUROSCI, V28, P2745, DOI 10.1523/JNEUROSCI.4286-07.2008
   Reynolds SM, 2005, J NEUROSCI, V25, P11757, DOI 10.1523/JNEUROSCI.3432-05.2005
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Rogers RD, 1999, NEUROPSYCHOPHARMACOL, V20, P322, DOI 10.1016/S0893-133X(98)00091-8
   Rose JE, 2006, PSYCHOPHARMACOLOGY, V184, P274, DOI 10.1007/s00213-005-0250-x
   Rose JE, 2011, BIOL PSYCHIAT, V70, P794, DOI 10.1016/j.biopsych.2011.05.031
   Schacht JP, 2013, ADDICT BIOL, V18, P121, DOI 10.1111/j.1369-1600.2012.00464.x
   Scott D, 2011, BIOL PSYCHIAT, V69, P1052, DOI 10.1016/j.biopsych.2011.01.023
   Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007
   Seif T, 2013, NAT NEUROSCI, V16, P1094, DOI 10.1038/nn.3445
   Sieminska A, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-274
   Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535
   Small DM, 2010, BRAIN STRUCT FUNCT, V214, P551, DOI 10.1007/s00429-010-0266-9
   Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105
   Stefanacci L, 2002, J COMP NEUROL, V451, P301, DOI 10.1002/cne.10339
   Sullivan EV, 2013, BIOL PSYCHIAT, V74, P547, DOI 10.1016/j.biopsych.2013.02.026
   Suner-Soler R, 2012, STROKE, V43, P131, DOI 10.1161/STROKEAHA.111.630004
   Sutherland M.T., 2013, BIOL PSYCHIAT
   Sutherland MT, 2012, NEUROIMAGE, V62, P2281, DOI 10.1016/j.neuroimage.2012.01.117
   Tiffany ST, 2000, ADDICTION, V95, pS145, DOI 10.1046/j.1360-0443.95.8s2.3.x
   Verdejo-Garcia A, 2009, NEUROPHARMACOLOGY, V56, P48, DOI 10.1016/j.neuropharm.2008.07.035
   Villafuerte S, 2012, MOL PSYCHIATR, V17, P511, DOI 10.1038/mp.2011.33
   Vorel S.R, 2007, INSULA DAMAGE QUITTI
   Vorel SR, 2007, SCIENCE, V317, P318
   Wise RA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002846
   Xue G, 2010, NEUROIMAGE, V50, P709, DOI 10.1016/j.neuroimage.2009.12.097
   Yan YJ, 2012, NEUROPSYCHOPHARMACOL, V37, P685, DOI 10.1038/npp.2011.245
   Zangen A, 2005, CLIN NEUROPHYSIOL, V116, P775, DOI 10.1016/j.clinph.2004.11.008
   Zhang XC, 2011, NEUROIMAGE, V54, P42, DOI 10.1016/j.neuroimage.2010.08.008
NR 122
TC 221
Z9 224
U1 3
U2 37
PU BLACKWELL SCIENCE PUBL
PI OXFORD
PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND
SN 0077-8923
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2014
VL 1316
BP 53
EP 70
DI 10.1111/nyas.12415
PG 18
WC Psychology, Biological; Neurosciences; Psychology
WE Book Citation Index– Social Sciences & Humanities (BKCI-SSH); Book Citation Index– Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Psychology; Neurosciences & Neurology
GA BA6SA
UT WOS:000337269000004
PM 24690001
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Samecki, J
   Traynor, R
   Clune, M
AF Samecki, John
   Traynor, Rebecca
   Clune, Michael
TI Cue fascination: A new vulnerability in drug addiction
SO BEHAVIORAL AND BRAIN SCIENCES
LA English
DT Editorial Material
ID INCENTIVE-SENSITIZATION; DOPAMINE; NEURONS; REWARD
AB Redish et al. propose a constellation of vulnerabilities inherent in the brain's decision-making system. They allow over-attention to cues a minor role in drug addiction. We think this is inadequate. Using the established links among drug, cues, dopamine, and novelty, we propose a fuller account of this key feature of addiction, which we call the phenomenon of cue fascination.
C1 [Samecki, John; Traynor, Rebecca] Univ Toledo, Dept Philosophy, Toledo, OH 43606 USA.
   [Clune, Michael] Univ S Florida, Dept English, Tampa, FL 33620 USA.
C3 University System of Ohio; University of Toledo; State University System
   of Florida; University of South Florida
RP Samecki, J (通讯作者)，Univ Toledo, Dept Philosophy, 2801 W Bancroft St, Toledo, OH 43606 USA.
EM john.sarnecki@utoledo.edu; rebecca.traynor@utoledo.edu;
   mclune@cas.usf.edu
CR Berridge KC, 2003, TRENDS NEUROSCI, V26, P507, DOI 10.1016/S0166-2236(03)00233-9
   Carter BL, 1999, ADDICTION, V94, P327, DOI 10.1046/j.1360-0443.1999.9433273.x
   FREEMAN AS, 1985, LIFE SCI, V36, P1983, DOI 10.1016/0024-3205(85)90448-5
   Garris PA, 1999, NATURE, V398, P67, DOI 10.1038/18019
   Kapur S, 2005, SCHIZOPHR RES, V79, P59, DOI 10.1016/j.schres.2005.01.003
   Kotler M, 1997, MOL PSYCHIATR, V2, P251, DOI 10.1038/sj.mp.4000248
   Robinson TE, 2004, PSYCHOPHARMACOLOGY, V171, P352, DOI 10.1007/s00213-003-1602-z
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   ROSSE RB, 1993, AM J PSYCHIAT, V150, P155
   Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1
   Zinberg NE., 1984, DRUG SET SETTING BAS
NR 11
TC 0
Z9 0
U1 0
U2 1
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0140-525X
J9 BEHAV BRAIN SCI
JI Behav. Brain Sci.
PD AUG
PY 2008
VL 31
IS 4
BP 458
EP +
DI 10.1017/S0140525X08004949
PG 20
WC Psychology, Biological; Behavioral Sciences; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology; Behavioral Sciences; Neurosciences & Neurology
GA 370SP
UT WOS:000260783700049
DA 2023-06-23
ER

PT C
AU Vorotilkina, I
   Bazhenov, R
   Prokopeva, M
   Bogachenko, N
   Schetinina, S
AF Vorotilkina, Irina
   Bazhenov, Ruslan
   Prokopeva, Maria
   Bogachenko, Natalia
   Schetinina, Svetlana
BE Chinakhov, DA
TI The Spread of Psychoactive Substance Use among the Population of the
   Jewish Autonomous Region
SO PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON THE THEORY AND PRACTICE
   OF PERSONALITY FORMATION IN MODERN SOCIETY (ICTPPFMS 2018)
SE Advances in Social Science Education and Humanities Research
LA English
DT Proceedings Paper
CT International Conference on the Theory and Practice of Personality
   Formation in Modern Society (ICTPPFMS)
CY SEP 20-22, 2018
CL Tomsk Polytechn Univ, Yurga Inst Technol, Yurga, RUSSIA
HO Tomsk Polytechn Univ, Yurga Inst Technol
DE drug addiction; narcotisation; psychoactive substances; drug control
ID DRUG-USE; ADOLESCENT MARIJUANA; CONSUMPTION; ADDICTION; EPIDEMIOLOGY;
   INITIATION; ALCOHOL; RISK
AB One of the most complicated problems of modern Russian society is the spread and use of drugs. The aim of the study is to reveal an attitude of the population of the Jewish Autonomous region to problems of drug addiction. The study was conducted in 2012, 2013 and involved 1,000 respondents per year. We used a technique developed by the State Anti-Drugs Committee of the Russian Federation. The results make it possible to conclude that respondents have an adequate understanding of a real danger of drugs and narcotisation, as well as the process of addiction to psychoactive substances. The major reason for taking or expressing a wish to take drugs is interest or curiosity.
C1 [Vorotilkina, Irina] Sholom Aleichem Priamursky State Univ, Dept Serv Advertising & Social Work, Birobidzhan, Russia.
   [Bazhenov, Ruslan] Sholom Aleichem Priamursky State Univ, Dept Informat Syst Math & Legal Informat, Birobidzhan, Russia.
   [Prokopeva, Maria] MK Ammosov North Eastern Fed Univ, Dept Age & Pedag Pschol, Yakutsk, Russia.
   [Bogachenko, Natalia] Sholom Aleichem Priamursky State Univ, Fac Philol Hist & Journalism, Birobidzhan, Russia.
   [Schetinina, Svetlana] Pacific Natl Univ, Dept Phys Culture & Sport, Khabarovsk, Russia.
C3 North-Eastern Federal University in Yakutsk; Pacific National University
RP Vorotilkina, I (通讯作者)，Sholom Aleichem Priamursky State Univ, Dept Serv Advertising & Social Work, Birobidzhan, Russia.
EM btb-irina@rambler.ru; r-i-bazhenov@yandex.ru; prokmary@mail.ru;
   nataliya-bogachenko@yandex.ru; Shetinina65@mail.ru
RI Bogachenko, Natalia/ABF-3012-2020; Bazhenov, Ruslan I/M-9720-2015
OI Bazhenov, Ruslan I/0000-0003-2668-1142
CR Abramove A. Yu., 2015, THESIS
   Acuda W, 2011, AM J ADDICTION, V20, P87, DOI 10.1111/j.1521-0391.2010.00111.x
   Bobrova N, 2006, DRUG ALCOHOL DEPEN, V82, pS57, DOI 10.1016/S0376-8716(06)80010-4
   Brook JS, 1999, AM J PUBLIC HEALTH, V89, P1549, DOI 10.2105/AJPH.89.10.1549
   Canedo M, 2017, INT J DRUG POLICY, V49, P102, DOI 10.1016/j.drugpo.2017.08.002
   Clark DB, 2005, DRUG ALCOHOL DEPEN, V77, P13, DOI 10.1016/j.drugalcdep.2004.06.008
   Degenhardt L., 2010, AUSTR BRIT J PSYCHIA, V196, P290
   DISHION TJ, 1985, AM J DRUG ALCOHOL AB, V11, P11, DOI 10.3109/00952998509016846
   Hibell. B., 2000, NON TRADITIONAL REF
   Janin J. B., 2001, ANPASSEN AUSWEICHEN, P347
   Kikura-Hanajiri R, 2011, LEGAL MED-TOKYO, V13, P109, DOI 10.1016/j.legalmed.2011.02.003
   Koshkina E A, 2000, Zh Mikrobiol Epidemiol Immunobiol, P15
   Kufner H, 2010, BUNDESGESUNDHEITSBLA, V53, P271, DOI 10.1007/s00103-010-1041-z
   Lander I, 2015, BRIT J CRIMINOL, V55, P270, DOI 10.1093/bjc/azu099
   Lu L, 2008, ANN NY ACAD SCI, V1141, P304, DOI 10.1196/annals.1441.025
   Ma MJ, 2017, COMMUN NONLINEAR SCI, V50, P169, DOI 10.1016/j.cnsns.2017.03.002
   Melo JS, 2018, DRUG ALCOHOL DEPEN, V182, P67, DOI 10.1016/j.drugalcdep.2017.10.009
   Muza GM, 1997, REV SAUDE PUBL, V31, P21, DOI 10.1590/S0034-89101997000100005
   Nilson M., 2010, NARCOLOGY, V9, P20
   Ossiander EM, 2015, AM J DRUG ALCOHOL AB, V41, P30, DOI 10.3109/00952990.2014.956110
   Pakesch G, 1989, Med Law, V8, P63
   PANDINA RJ, 1990, J STUD ALCOHOL, V51, P278, DOI 10.15288/jsa.1990.51.278
   Potapchik Elena, 2014, Value Health Reg Issues, V4, P1, DOI 10.1016/j.vhri.2014.03.004
   Rivera B, 2017, INT J DRUG POLICY, V44, P92, DOI 10.1016/j.drugpo.2017.03.012
   Silva CC, 2014, CIENC SAUDE COLETIVA, V19, P737, DOI 10.1590/1413-81232014193.15922013
   Simoni-Wastila Linda, 2006, Am J Geriatr Pharmacother, V4, P380, DOI 10.1016/j.amjopharm.2006.10.002
   Vuong T, 2012, INT J DRUG POLICY, V23, P319, DOI 10.1016/j.drugpo.2011.11.005
   Voigt K, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-219
   Zahnow R, 2018, INT J DRUG POLICY, V56, P81, DOI 10.1016/j.drugpo.2018.03.018
NR 29
TC 0
Z9 0
U1 0
U2 4
PU ATLANTIS PRESS
PI PARIS
PA 29 AVENUE LAVMIERE, PARIS, 75019, FRANCE
SN 2352-5398
BN 978-94-6252-577-1
J9 ADV SOC SCI EDUC HUM
PY 2018
VL 198
BP 280
EP 285
PG 6
WC Psychology, Developmental; Social Sciences, Interdisciplinary
WE Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)
SC Psychology; Social Sciences - Other Topics
GA BL1SH
UT WOS:000448272100050
DA 2023-06-23
ER

PT J
AU Torregrossa, MM
   Taylor, JR
AF Torregrossa, Mary M.
   Taylor, Jane R.
TI Learning to forget: manipulating extinction and reconsolidation
   processes to treat addiction
SO PSYCHOPHARMACOLOGY
LA English
DT Review
DE Addiction; Extinction; Reconsolidation; Cue; Reinstatement; Memory;
   Neuroadaptation
ID CONDITIONED PLACE PREFERENCE; COCAINE-SEEKING BEHAVIOR;
   LONG-TERM-MEMORY; CYCLOSERINE FACILITATES EXTINCTION; MK-801 DISRUPTS
   RECONSOLIDATION; POST-RETRIEVAL PROPRANOLOL; BETA-ADRENERGIC-RECEPTORS;
   NUCLEUS-ACCUMBENS SHELL; STIMULUS-REWARD MEMORY; CUE-EXPOSURE THERAPY
AB Finding effective long-lasting treatments for drug addiction has been an elusive goal. Consequently, researchers are beginning to investigate novel treatment strategies including manipulations of drug-associated memories. When environmental stimuli (cues) become associated with drug use, they become powerful motivators of continued drug use and relapse after abstinence. Reducing the strength of these cue-drug memories could decrease the number of factors that induce craving and relapse to aid in the treatment of addiction. Enhancing the consolidation of extinction learning and/or disrupting cue-drug memory reconsolidation are two strategies that have been proposed to reduce the strength of cues in motivating drug-seeking and drug-taking behavior. Here, we review the latest basic and clinical research elucidating the mechanisms underlying consolidation of extinction and reconsolidation of cue-drug memories in the hopes of developing pharmacological tools that exploit these signaling systems to treat addiction.
C1 [Torregrossa, Mary M.; Taylor, Jane R.] Yale Univ, Sch Med, Dept Psychiat,Ribicoff Res Labs, Div Mol Psychiat,Connecticut Mental Hlth Ctr, New Haven, CT 06508 USA.
   [Taylor, Jane R.] Yale Univ, Dept Psychol, New Haven, CT 06520 USA.
C3 Yale University; Yale University
RP Torregrossa, MM (通讯作者)，Yale Univ, Sch Med, Dept Psychiat,Ribicoff Res Labs, Div Mol Psychiat,Connecticut Mental Hlth Ctr, S301,34 Pk St, New Haven, CT 06508 USA.
EM mtorregrossa@gmail.com
RI Torregrossa, Mary/AAW-6740-2020; Torregrossa, Mary/N-6053-2017
OI Torregrossa, Mary/0000-0003-2083-0231; Torregrossa,
   Mary/0000-0003-2083-0231
CR Alberini CM, 2005, TRENDS NEUROSCI, V28, P51, DOI 10.1016/j.tins.2004.11.001
   Ana EJS, 2009, DRUG ALCOHOL DEPEN, V104, P220, DOI 10.1016/j.drugalcdep.2009.04.023
   Bassareo V, 2002, J NEUROSCI, V22, P4709, DOI 10.1523/JNEUROSCI.22-11-04709.2002
   Bassareo V, 1999, EUR J NEUROSCI, V11, P4389, DOI 10.1046/j.1460-9568.1999.00843.x
   Bernardi RE, 2006, NEUROREPORT, V17, P1443, DOI 10.1097/01.wnr.0000233098.20655.26
   Botreau F, 2006, BEHAV BRAIN RES, V172, P173, DOI 10.1016/j.bbr.2006.05.012
   BOUTON ME, 1979, J EXP PSYCHOL ANIM B, V5, P368, DOI 10.1037/0097-7403.5.4.368
   Bouton ME, 2004, LEARN MEMORY, V11, P485, DOI 10.1101/lm.78804
   Bouton ME, 2002, BIOL PSYCHIAT, V52, P976, DOI 10.1016/S0006-3223(02)01546-9
   Bozon B, 2003, NEURON, V40, P695, DOI 10.1016/S0896-6273(03)00674-3
   Brown Travis E, 2007, Learn Mem, V14, P214, DOI 10.1101/lm.476207
   Brown TE, 2008, LEARN MEMORY, V15, P857, DOI 10.1101/lm.1152808
   Brunet A, 2008, J PSYCHIATR RES, V42, P503, DOI 10.1016/j.jpsychires.2007.05.006
   Brunet A, 2011, J CLIN PSYCHOPHARM, V31, P547, DOI 10.1097/JCP.0b013e318222f360
   Carter BL, 1999, ADDICTION, V94, P327, DOI 10.1046/j.1360-0443.1999.9433273.x
   Chan Wan Yee Macy, 2010, Learn Mem, V17, P512, DOI 10.1101/lm.1912510
   Chaudhri N, 2008, BIOL PSYCHIAT, V64, P203, DOI 10.1016/j.biopsych.2008.03.007
   Clem RL, 2010, SCIENCE, V330, P1108, DOI 10.1126/science.1195298
   Conklin CA, 2002, ADDICTION, V97, P155, DOI 10.1046/j.1360-0443.2002.00014.x
   Corcoran KA, 2004, LEARN MEMORY, V11, P598, DOI 10.1101/lm.78704
   Corcoran KA, 2001, J NEUROSCI, V21, P1720, DOI 10.1523/JNEUROSCI.21-05-01720.2001
   de la Fuente V, 2011, J NEUROSCI, V31, P5562, DOI 10.1523/JNEUROSCI.6066-10.2011
   De Quervain DJF, 2007, PROG BRAIN RES, V167, P239, DOI 10.1016/S0079-6123(07)67017-4
   de Quervain DJF, 2008, EUR J PHARMACOL, V583, P365, DOI 10.1016/j.ejphar.2007.11.068
   Debiec J, 2006, P NATL ACAD SCI USA, V103, P3428, DOI 10.1073/pnas.0507168103
   Debiec J, 2006, ANN NY ACAD SCI, V1071, P521, DOI 10.1196/annals.1364.056
   Debiec J, 2011, DEPRESS ANXIETY, V28, P186, DOI 10.1002/da.20803
   Debiec J, 2010, NAT NEUROSCI, V13, P536, DOI 10.1038/nn.2520
   Dhonnchadha BAN, 2010, NEUROPSYCHOPHARMACOL, V35, P357, DOI 10.1038/npp.2009.139
   Di Chiara G, 2002, BEHAV BRAIN RES, V137, P75, DOI 10.1016/S0166-4328(02)00286-3
   Di Ciano P, 2004, NEUROPHARMACOLOGY, V47, P202, DOI 10.1016/j.neuropharm.2004.06.005
   Doyere V, 2007, NAT NEUROSCI, V10, P414, DOI 10.1038/nn1871
   Drummond DC, 2000, ADDICTION, V95, pS129, DOI 10.1046/j.1360-0443.95.8s2.2.x
   DRUMMOND DC, 1994, J CONSULT CLIN PSYCH, V62, P809, DOI 10.1037/0022-006X.62.4.809
   Dudai Y, 2004, ANNU REV PSYCHOL, V55, P51, DOI 10.1146/annurev.psych.55.090902.142050
   Eisenberg M, 2004, EUR J NEUROSCI, V20, P3397, DOI 10.1111/j.1460-9568.2004.03818.x
   Eisenberg M, 2003, SCIENCE, V301, P1102, DOI 10.1126/science.1086881
   Eisenhardt D, 2007, NEUROBIOL LEARN MEM, V87, P167, DOI 10.1016/j.nlm.2006.09.005
   Feltenstein MW, 2007, NEUROBIOL LEARN MEM, V88, P435, DOI 10.1016/j.nlm.2007.05.006
   Field M, 2002, PSYCHOPHARMACOLOGY, V159, P325, DOI 10.1007/s00213-001-0923-z
   Flavell CR, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1515
   Foltin RW, 2000, PSYCHOPHARMACOLOGY, V149, P24, DOI 10.1007/s002139900340
   Font L, 2012, PHARMACOL BIOCHEM BE, V101, P222, DOI 10.1016/j.pbb.2012.01.009
   Franken IHA, 1999, J SUBST ABUSE TREAT, V16, P81, DOI 10.1016/S0740-5472(98)00004-X
   Freeman TP, 2012, PSYCHOL MED, V42, P161, DOI [10.1017/S0033291711001139, 10.1017/S0033291712000475]
   Fuchs RA, 2006, EUR J NEUROSCI, V23, P2809, DOI 10.1111/j.1460-9568.2006.04806.x
   Fuchs RA, 2009, EUR J NEUROSCI, V30, P889, DOI 10.1111/j.1460-9568.2009.06888.x
   Hamlin AS, 2008, NEUROSCIENCE, V151, P659, DOI 10.1016/j.neuroscience.2007.11.018
   Hobin JA, 2006, HIPPOCAMPUS, V16, P174, DOI 10.1002/hipo.20144
   Hofmann SG, 2012, AM J DRUG ALCOHOL AB, V38, P101, DOI 10.3109/00952990.2011.600396
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Inda MC, 2011, J NEUROSCI, V31, P1635, DOI 10.1523/JNEUROSCI.4736-10.2011
   Itzhak Y, 2007, SYNAPSE, V61, P1002, DOI 10.1002/syn.20446
   Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483
   Kalivas PW, 2006, MOL INTERV, V6, P339, DOI 10.1124/mi.6.6.7
   Kamboj SK, 2012, PSYCHOPHARMACOLOGY, V221, P273, DOI 10.1007/s00213-011-2571-2
   Kamboj SK, 2011, PSYCHOPHARMACOLOGY, V217, P25, DOI 10.1007/s00213-011-2254-z
   Kearns DN, 2007, DRUG ALCOHOL DEPEN, V90, P193, DOI 10.1016/j.drugalcdep.2007.03.006
   Kelamangalath L, 2009, NEUROBIOL LEARN MEM, V92, P544, DOI 10.1016/j.nlm.2009.07.004
   Kelley JB, 2007, NEUROREPORT, V18, P777, DOI 10.1097/WNR.0b013e3280c1e2e7
   Kida S, 2002, NAT NEUROSCI, V5, P348, DOI 10.1038/nn819
   Kindt M, 2013, BIOL PSYCHOL, V92, P43, DOI 10.1016/j.biopsycho.2011.09.016
   Kindt M, 2009, NAT NEUROSCI, V12, P256, DOI 10.1038/nn.2271
   Koya E, 2009, NEUROPHARMACOLOGY, V56, P177, DOI 10.1016/j.neuropharm.2008.04.022
   Kuntze MF, 2001, CYBERPSYCHOL BEHAV, V4, P497, DOI 10.1089/109493101750527051
   Ledgerwood L, 2004, BEHAV NEUROSCI, V118, P505, DOI 10.1037/0735-7044.118.3.505
   Ledgerwood L, 2003, BEHAV NEUROSCI, V117, P341, DOI 10.1037/0735-7044.117.2.341
   Lee JH, 2007, CYBERPSYCHOL BEHAV, V10, P617, DOI 10.1089/cpb.2007.9978
   Lee JLC, 2006, J NEUROSCI, V26, P5881, DOI 10.1523/JNEUROSCI.0323-06.2006
   Lee JLC, 2005, NEURON, V47, P795, DOI 10.1016/j.neuron.2005.08.007
   Lee JLC, 2008, NAT NEUROSCI, V11, P1264, DOI 10.1038/nn.2205
   Lee JLC, 2009, LEARN MEMORY, V16, P82, DOI 10.1101/lm.1186609
   Leri F, 2002, EXP CLIN PSYCHOPHARM, V10, P339, DOI 10.1037//1064-1297.10.4.339
   Li FQ, 2010, J NEUROSCI, V30, P10351, DOI 10.1523/JNEUROSCI.2112-10.2010
   Li YQ, 2011, J NEUROSCI, V31, P5436, DOI 10.1523/JNEUROSCI.5884-10.2011
   Lindgren JL, 2003, EUR J NEUROSCI, V17, P160, DOI 10.1046/j.1460-9568.2003.02421.x
   Lynch WJ, 2005, EUR J NEUROSCI, V22, P1214, DOI 10.1111/j.1460-9568.2005.04305.x
   Ma X, 2012, PSYCHOPHARMACOLOGY, V221, P19, DOI 10.1007/s00213-011-2545-4
   Marissen MAE, 2007, PSYCHOTHER PSYCHOSOM, V76, P97, DOI 10.1159/000097968
   McCleery JM, 2004, J TRAUMA STRESS, V17, P485, DOI 10.1007/s10960-004-5797-5
   McLaughlin J, 2003, PSYCHOPHARMACOLOGY, V168, P57, DOI 10.1007/s00213-002-1196-x
   Meil WM, 1997, BEHAV BRAIN RES, V87, P139, DOI 10.1016/S0166-4328(96)02270-X
   Merlo E, 2005, LEARN MEMORY, V12, P23, DOI 10.1101/lm.82705
   Merlo E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003687
   Mihindou C, 2011, BIOL PSYCHIAT, V70, P593, DOI 10.1016/j.biopsych.2011.03.036
   Miller CA, 2005, NEURON, V47, P873, DOI 10.1016/j.neuron.2005.08.006
   Milton AL, 2008, J NEUROSCI, V28, P8230, DOI 10.1523/JNEUROSCI.1723-08.2008
   Milton AL, 2008, LEARN MEMORY, V15, P88, DOI 10.1101/lm.825008
   Milton AL, 2012, PSYCHOPHARMACOLOGY, V219, P751, DOI 10.1007/s00213-011-2399-9
   Monfils MH, 2009, SCIENCE, V324, P951, DOI 10.1126/science.1167975
   Muller J, 1997, BEHAV NEUROSCI, V111, P683, DOI 10.1037/0735-7044.111.4.683
   Muravieva EV, 2010, LEARN MEMORY, V17, P306, DOI 10.1101/lm.1794710
   Nader K, 2000, NATURE, V406, P722, DOI 10.1038/35021052
   Nestler EJ, 2004, NEUROPHARMACOLOGY, V47, P24, DOI 10.1016/j.neuropharm.2004.06.031
   OBRIEN CP, 1990, ADDICT BEHAV, V15, P355, DOI 10.1016/0306-4603(90)90045-Y
   Otis JM, 2011, NEUROPSYCHOPHARMACOL, V36, P1912, DOI 10.1038/npp.2011.77
   Paolone G, 2009, PSYCHOPHARMACOLOGY, V202, P403, DOI 10.1007/s00213-008-1280-y
   Parker LA, 2006, PSYCHOPHARMACOLOGY, V187, P133, DOI 10.1007/s00213-006-0422-3
   Pedreira ME, 2003, NEURON, V38, P863, DOI 10.1016/S0896-6273(03)00352-0
   Peters J, 2008, J NEUROSCI, V28, P6046, DOI 10.1523/JNEUROSCI.1045-08.2008
   Peters J, 2010, SCIENCE, V328, P1288, DOI 10.1126/science.1186909
   Peters J, 2009, LEARN MEMORY, V16, P279, DOI 10.1101/lm.1041309
   Pollandt S, 2006, EUR J NEUROSCI, V24, P1733, DOI 10.1111/j.1460-9568.2006.05049.x
   Power AE, 2006, LEARN MEMORY, V13, P27, DOI 10.1101/lm.91206
   Price KL, 2013, PSYCHOPHARMACOLOGY, V226, P739, DOI 10.1007/s00213-011-2592-x
   Ramirez DR, 2009, EUR J NEUROSCI, V30, P901, DOI 10.1111/j.1460-9568.2009.06889.x
   Ressler KJ, 2004, ARCH GEN PSYCHIAT, V61, P1136, DOI 10.1001/archpsyc.61.11.1136
   Robbins TW, 2002, NEUROBIOL LEARN MEM, V78, P625, DOI 10.1006/nlme.2002.4103
   Robinson MJF, 2007, BEHAV BRAIN RES, V182, P129, DOI 10.1016/j.bbr.2007.05.023
   Robinson MJF, 2011, BEHAV BRAIN RES, V216, P281, DOI 10.1016/j.bbr.2010.08.009
   Robinson MJF, 2010, BEHAV BRAIN RES, V213, P201, DOI 10.1016/j.bbr.2010.04.056
   Robinson MJF, 2011, FRONT BEHAV NEUROSCI, V5, DOI 10.3389/fnbeh.2011.00042
   Sadler R, 2007, BEHAV PHARMACOL, V18, P699, DOI 10.1097/FBP.0b013e3282effb81
   Sakurai S, 2007, BEHAV PHARMACOL, V18, P497, DOI 10.1097/FBP.0b013e3282ee7b62
   Sanchez H, 2010, J NEUROSCI, V30, P4401, DOI 10.1523/JNEUROSCI.3149-09.2010
   Schiller D, 2010, NATURE, V463, P49, DOI 10.1038/nature08637
   Schroeder JP, 2004, LEARN MEMORY, V11, P641, DOI 10.1101/lm.78504
   Schroeder JP, 2003, EUR J NEUROSCI, V17, P1482, DOI 10.1046/j.1460-9568.2003.02578.x
   See RE, 2002, PHARMACOL BIOCHEM BE, V71, P517, DOI 10.1016/S0091-3057(01)00682-7
   Self DW, 2004, STRESS, V7, P145, DOI 10.1080/10253890400012677
   Shabashov D, 2012, J MOL NEUROSCI, V47, P546, DOI 10.1007/s12031-011-9671-7
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   Shalev U, 2002, PHARMACOL REV, V54, P1, DOI 10.1124/pr.54.1.1
   Shema R, 2007, SCIENCE, V317, P951, DOI 10.1126/science.1144334
   Sorg BA, 2012, NEUROSCI BIOBEHAV R, V36, P1400, DOI 10.1016/j.neubiorev.2012.02.004
   Sutton MA, 2003, NATURE, V421, P70, DOI 10.1038/nature01249
   Suzuki A, 2004, J NEUROSCI, V24, P4787, DOI 10.1523/JNEUROSCI.5491-03.2004
   Taylor JR, 2009, NEUROPHARMACOLOGY, V56, P186, DOI 10.1016/j.neuropharm.2008.07.027
   TERWILLIGER RZ, 1991, BRAIN RES, V548, P100, DOI 10.1016/0006-8993(91)91111-D
   Torregrossa MM, 2008, PHARMACOL BIOCHEM BE, V90, P261, DOI 10.1016/j.pbb.2007.09.001
   Torregrossa MM, 2011, NEUROBIOL LEARN MEM, V96, P609, DOI 10.1016/j.nlm.2011.02.014
   Torregrossa MM, 2010, J NEUROSCI, V30, P10526, DOI 10.1523/JNEUROSCI.2523-10.2010
   Toyomitsu Y, 2002, EUR J NEUROSCI, V15, P753, DOI 10.1046/j.1460-9568.2002.01889.x
   Tronson NC, 2007, NAT REV NEUROSCI, V8, P262, DOI 10.1038/nrn2090
   Tronson NC, 2006, NAT NEUROSCI, V9, P167, DOI 10.1038/nn1628
   Tzeng WY, 2012, NEUROBIOL LEARN MEM, V97, P241, DOI 10.1016/j.nlm.2012.01.001
   Tzschentke TM, 2007, ADDICT BIOL, V12, P227, DOI 10.1111/j.1369-1600.2007.00070.x
   Valjent E, 2006, P NATL ACAD SCI USA, V103, P2932, DOI 10.1073/pnas.0511030103
   Vansteenwegen D, 2007, BEHAV RES THER, V45, P1169, DOI 10.1016/j.brat.2006.08.023
   von der Goltz C, 2009, PSYCHOPHARMACOLOGY, V205, P389, DOI 10.1007/s00213-009-1544-1
   Vurbic D, 2011, BEHAV NEUROSCI, V125, P551, DOI 10.1037/a0024403
   Wang XY, 2008, J NEUROSCI, V28, P5602, DOI 10.1523/JNEUROSCI.0750-08.2008
   Watson BJ, 2011, PSYCHOPHARMACOLOGY, V216, P121, DOI 10.1007/s00213-011-2199-2
   Weiss F, 2001, NEUROPSYCHOPHARMACOL, V25, P361, DOI 10.1016/S0893-133X(01)00238-X
   Wilensky AE, 2006, J NEUROSCI, V26, P12387, DOI 10.1523/JNEUROSCI.4316-06.2006
   Winters BD, 2009, LEARN MEMORY, V16, P545, DOI 10.1101/lm.1509909
   Woods AM, 2006, BEHAV NEUROSCI, V120, P1159, DOI 10.1037/0735-7044.120.5.1159
   Wouda JA, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00179
   Wu P, 2011, J NEUROCHEM, V118, P113, DOI 10.1111/j.1471-4159.2011.07277.x
   Xue YX, 2012, SCIENCE, V336, P241, DOI 10.1126/science.1215070
   Zhai HF, 2008, BEHAV PHARMACOL, V19, P211, DOI 10.1097/FBP.0b013e3282fe88a0
   Zhao LY, 2011, DRUG ALCOHOL DEPEN, V118, P224, DOI 10.1016/j.drugalcdep.2011.03.025
   Zhao LY, 2009, PSYCHOPHARMACOLOGY, V203, P599, DOI 10.1007/s00213-008-1406-2
   Zhou SJ, 2012, PSYCHOPHARMACOLOGY, V221, P79, DOI 10.1007/s00213-011-2551-6
   Zhou WH, 2008, BIOL PSYCHIAT, V63, P338, DOI 10.1016/j.biopsych.2007.06.008
NR 155
TC 113
Z9 115
U1 1
U2 108
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0033-3158
EI 1432-2072
J9 PSYCHOPHARMACOLOGY
JI Psychopharmacology
PD APR
PY 2013
VL 226
IS 4
BP 659
EP 672
DI 10.1007/s00213-012-2750-9
PG 14
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 122GL
UT WOS:000317306200004
PM 22638814
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Colace, C
AF Colace, Claudio
TI Drug dreams as a signal of drug craving persistence in time
SO HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS
LA English
DT Article
DE heroin; addiction; drug dream; drug craving
ID ADDICTION RECOVERY
AB Drug dreams, that is, dreams in which patients addicted to drugs typically use or make an attempt to use the drugs they are addicted to, are a well-documented clinical phenomenon in various forms of addiction. One clinical function of these dreams is their ability to signal the latent recrudescence of drug craving even long after the patients have resolved their addictive behaviours. The following case is an example of how drug dreams reveal the extraordinary persistence in time of drug craving and the patient's risk of potential relapse, even after as many as 10 years of living in a drug-free state.
C1 [Colace, Claudio] UOC Psychol, Civita Castellana, Italy.
RP Colace, C (通讯作者)，Snc, Via Francesco Petrarca, I-01033 Civita Castellana, VT, Italy.
EM claudio.colace@yahoo.it
RI Colace, Claudio/AAE-3791-2019
OI Colace, Claudio/0000-0002-8779-6640
CR APA, 1994, AM PSYCHIATR ASSOC, V4
   CHOI SY, 1973, AM J PSYCHIAT, V130, P699, DOI 10.1176/ajp.130.6.699
   Christo G, 1996, SUBST USE MISUSE, V31, P1, DOI 10.3109/10826089609045795
   Colace C, 2006, DRUG ALCOHOL REV, V25, P177, DOI 10.1080/09595230500538843
   Colace C, 2014, DRUG DREAMS CLIN RES
   Colace C., 2004, NEUROPSYCHOANALYSIS, V6, P167
   Colace C, 2010, AM J ADDICTION, V19, P192, DOI 10.1111/j.1521-0391.2009.00023.x
   De Cicco T. L., 2009, INT J DREAM RES, V2, P45
   Flowers LK, 1996, J SUBST ABUSE TREAT, V13, P99, DOI 10.1016/0740-5472(96)00033-5
   Flowers LK, 1998, J SUBST ABUSE TREAT, V15, P193, DOI 10.1016/S0740-5472(97)00188-8
   HAJEK P, 1991, J ABNORM PSYCHOL, V100, P487, DOI 10.1037/0021-843X.100.4.487
   Johnson B, 2001, J AM PSYCHOANAL ASS, V49, P75, DOI 10.1177/00030651010490011101
   Johnson B., 2008, SLEEP QUALITY LIFE M
   Parker J., 2009, INT J DREAM RES, V2, P73
   Reid SD, 2001, J NERV MENT DIS, V189, P854, DOI 10.1097/00005053-200112000-00007
   Steinig J, 2011, ALCOHOL ALCOHOLISM, V46, P143, DOI 10.1093/alcalc/agq087
   Undcp & Who, 1992, UNDCP UN INT DRUG CO
   Yee T, 2004, J NERV MENT DIS, V192, P238, DOI 10.1097/01.nmd.0000116466.31133.f1
NR 18
TC 3
Z9 3
U1 0
U2 2
PU PACINI EDITORE
PI PISA
PA VIA DELLA GHERARDESCA-ZONA INDUSTRIALE OSPEDALETTO, 56121 PISA, ITALY
SN 1592-1638
J9 HEROIN ADDICT REL CL
JI Heroin Addict. Relat. Clin. Probl.
PD JUN
PY 2014
VL 16
IS 2
BP 53
EP 55
PG 3
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA AP4HS
UT WOS:000342038400009
DA 2023-06-23
ER

PT J
AU Manzanares, J
   Cabanero, D
   Puente, N
   Garcia-Gutierrez, MS
   Grandes, P
   Maldonado, R
AF Manzanares, Jorge
   Cabanero, David
   Puente, Nagore
   Garcia-Gutierrez, Maria S.
   Grandes, Pedro
   Maldonado, Rafael
TI Role of the endocannabinoid system in drug addiction
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Review
DE Mesolimbic system; Nucleus accumbens; Prefrontal cortex; CB1 receptors;
   CB2 receptors; Rimonabant; CB2R allosteric modulators
ID CANNABINOID CB1 RECEPTOR; VENTRAL TEGMENTAL AREA; CONDITIONED PLACE
   PREFERENCE; DISTINCT NEURONAL SUBPOPULATIONS; DIACYLGLYCEROL
   LIPASE-ALPHA; RAT BASOLATERAL AMYGDALA; ACID AMIDE HYDROLASE; VTA
   DOPAMINE NEURONS; AGONIST WIN 55,212-2; PREFRONTAL CORTEX
AB Drug addiction is a chronic relapsing disorder that produces a dramatic global health burden worldwide. Not effective treatment of drug addiction is currently available probably due to the difficulties to find an appropriate target to manage this complex disease raising the needs for further identification of novel therapeutic approaches. The endocannabinoid system has been found to play a crucial role in the neurobiological substrate underlying drug addiction. Endocannabinoids and cannabinoid receptors are widely expressed in the main areas of the mesocorticolimbic system that participate in the initiation and maintenance of drug consumption and in the development of compulsion and loss of behavioral control occurring during drug addiction. The identification of the important role played by CB1 cannabinoid receptors in drug addiction encouraged the possible used of an early commercialized CB1 receptor antagonist for treating drug addiction. However, the incidence of serious psychiatric adverse events leaded to the sudden withdrawal from the market of this CB1 antagonist and all the research programs developed by pharmaceutical companies to obtain new CB1 antagonists were stopped. Currently, new research strategies are under development to target the endocannabinoid system for drug addiction avoiding these side effects, which include allosteric negative modulators of CB1 receptors and compounds targeting CB2 receptors. Recent studies showing the potential role of CB2 receptors in the addictive properties of different drugs of abuse have open a promising research opportunity to develop novel possible therapeutic approaches.
C1 [Manzanares, Jorge; Garcia-Gutierrez, Maria S.] Miguel Hernandez Univ, CSIC, Neurosci Inst, Ave Ramon y Cajal S-N, Alicante 03550, Spain.
   [Cabanero, David; Maldonado, Rafael] Pompeu Fabra Univ, Dept Expt & Hlth Sci, Lab Neuropharmacol, PRBB, C Doctor Aiguader 88, Barcelona 08003, Spain.
   [Puente, Nagore; Grandes, Pedro] Univ Basque Country, UPV EHU, Fac Med & Nursing, Dept Neurosci, E-48940 Leioa, Vizcaya, Spain.
   [Puente, Nagore; Grandes, Pedro] Univ Basque Country, Achucarro Basque Ctr Neurosci, Sci Pk, Leioa, Vizcaya, Spain.
   [Maldonado, Rafael] Hosp del Mar Med Res Inst IMIM, Barcelona, Spain.
   [Manzanares, Jorge; Cabanero, David; Puente, Nagore; Garcia-Gutierrez, Maria S.; Grandes, Pedro; Maldonado, Rafael] Heatlh Inst Carlos III, Addict Disorders Network, Cooperat Hlth Res Themat Network, MICINN, Madrid, Spain.
   [Manzanares, Jorge; Cabanero, David; Puente, Nagore; Garcia-Gutierrez, Maria S.; Grandes, Pedro; Maldonado, Rafael] FEDER, Madrid, Spain.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); Universidad
   Miguel Hernandez de Elche; Pompeu Fabra University; University of Basque
   Country; University of Basque Country; Institut Hospital del Mar
   d'Investigacions Mediques (IMIM); Hospital del Mar
RP Manzanares, J; Grandes, P; Maldonado, R (通讯作者)，Heatlh Inst Carlos III, Addict Disorders Network, Cooperat Hlth Res Themat Network, MICINN, Madrid, Spain.; Manzanares, J; Grandes, P; Maldonado, R (通讯作者)，FEDER, Madrid, Spain.
EM jmanzanares@goumh.umh.es; pedro.grandes@ehu.eus;
   rafael.maldonado@upf.edu
RI Grandes, Pedro/AAA-1627-2019; Gutiérrez, Maria Salud
   García/AAY-6406-2021; Cabañero, David/T-5814-2019; Grandes,
   Pedro/H-7494-2015
OI Cabañero, David/0000-0002-1133-0908; Grandes, Pedro/0000-0003-3947-4230;
   Manzanares, Jorge/0000-0002-4681-1533
FU Spanish MINECO [SAF2017-84060-R-AEI/FEDER-UE]; Instituto de Salud Carlos
   III-RETICS [RD16/0017/0020]; Ministerio de Sanidad, Servicios Sociales e
   Igualdad-Plan Nacional Sobre Drogas [PNSD-2017I068]; Generalitat de
   Catalunya-AGAUR [2017-SGR-669, ICREA Academia2015]; European
   Commission-DG RTD [FP7-HEALTH-F2-2013-602891-NeuroPain]; FEDER funding;
   Red de Trastornos Adictivos, Instituto de Salud Carlos III (ISC-III);
   European Regional Development Funds-European Union (ERDF-EU)
   [RD16/0017/0012]; Basque Government [BCG IT764-13]; MINECO/FEDER, UE
   [SAF2015-65034-R]; Instituto de Salud Carlos III (RETICS)
   [RD12/0028/0019, RD16/0017/0014, RD06/0001/1004]; Plan Nacional Sobre
   Drogas [PNSD 2016/016, 2007/061]; Ministerio de Economia y
   Competitividad (FIS) [PI14/00438]; Ministerio de Ciencia e Innovacion
   [SAF2008-01106]
FX We acknowledge the financial support of the Spanish MINECO
   (#SAF2017-84060-R-AEI/FEDER-UE), Instituto de Salud Carlos III-RETICS
   (##RD16/0017/0020), Ministerio de Sanidad, Servicios Sociales e
   Igualdad-Plan Nacional Sobre Drogas (#PNSD-2017I068), and the
   Generalitat de Catalunya-AGAUR ((#2017-SGR-669 and #ICREA Academia2015)
   and the European Commission-DG RTD
   (#FP7-HEALTH-F2-2013-602891-NeuroPain) to RM. FEDER funding support is
   also acknowledged. This work was supported by Red de Trastornos
   Adictivos, Instituto de Salud Carlos III (ISC-III) and European Regional
   Development Funds-European Union (ERDF-EU) (RD16/0017/0012), The Basque
   Government (BCG IT764-13) and MINECO/FEDER, UE (SAF2015-65034-R) to PG.
   This research was supported by Instituto de Salud Carlos III (RETICS,
   RD12/0028/0019, RD16/0017/0014 and RD06/0001/1004), Plan Nacional Sobre
   Drogas (PNSD 2016/016 and 2007/061), Ministerio de Economia y
   Competitividad (FIS, PI14/00438) and Ministerio de Ciencia e Innovacion
   (SAF2008-01106) to JM.
CR A.P. Association, 2013, DIAGN STAT MAN MENT
   Abuhasira R, 2018, EUR J INTERN MED, V49, P2, DOI 10.1016/j.ejim.2018.01.001
   Adamczyk P, 2012, BRAIN RES, V1444, P45, DOI 10.1016/j.brainres.2012.01.030
   Al Mansouri S, 2014, PHARMACOL BIOCHEM BE, V124, P260, DOI 10.1016/j.pbb.2014.06.025
   Alvarez-Jaimes L, 2008, NEUROPSYCHOPHARMACOL, V33, P2483, DOI 10.1038/sj.npp.1301630
   Andre VM, 2010, EUR J NEUROSCI, V31, P14, DOI 10.1111/j.1460-9568.2009.07047.x
   [Anonymous], 2018, BIOCH PHARM, V157, P108
   Aracil-Fernandez A, 2012, NEUROPSYCHOPHARMACOL, V37, P1749, DOI 10.1038/npp.2012.22
   Arnone M, 1997, PSYCHOPHARMACOLOGY, V132, P104, DOI 10.1007/s002130050326
   Ashton JC, 2006, NEUROSCI LETT, V396, P113, DOI 10.1016/j.neulet.2005.11.038
   Atwood BK, 2010, BRIT J PHARMACOL, V160, P467, DOI 10.1111/j.1476-5381.2010.00729.x
   Baek JH, 2008, ACTA OTO-LARYNGOL, V128, P961, DOI 10.1080/00016480701796944
   Belin D, 2013, CURR OPIN NEUROBIOL, V23, P564, DOI 10.1016/j.conb.2013.01.025
   Bellocchio L, 2010, NAT NEUROSCI, V13, P281, DOI 10.1038/nn.2494
   Benard G, 2012, NAT NEUROSCI, V15, P558, DOI 10.1038/nn.3053
   Benito C, 2003, J NEUROSCI, V23, P11136
   Bergholm R, 2013, INT J OBESITY, V37, P699, DOI 10.1038/ijo.2012.116
   Billing L, 2015, AM J DRUG ALCOHOL AB, V41, P115, DOI 10.3109/00952990.2014.966196
   Blanco-Calvo E, 2014, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00106
   Bodor AL, 2005, J NEUROSCI, V25, P6845, DOI 10.1523/JNEUROSCI.0442-05.2005
   Bonilla-Del Rio I, 2019, ADDICT BIOL, V24, P182, DOI 10.1111/adb.12585
   Bosier B, 2013, MOL METAB, V2, P393, DOI 10.1016/j.molmet.2013.08.001
   Braida D, 2005, PHARMACOL RES, V51, P177, DOI 10.1016/j.phrs.2004.07.009
   Braida D, 2002, BRIT J PHARMACOL, V136, P1089, DOI 10.1038/sj.bjp.0704825
   Bray GA, 2007, GASTROENTEROLOGY, V132, P2239, DOI 10.1053/j.gastro.2007.03.053
   Brusco A, 2008, SYNAPSE, V62, P944, DOI 10.1002/syn.20569
   Busquets-Garcia A, 2018, NEUROPSYCHOPHARMACOL, V43, P4, DOI 10.1038/npp.2017.206
   Cabral GA, 2008, BRIT J PHARMACOL, V153, P240, DOI 10.1038/sj.bjp.0707584
   Cadas H, 1996, J NEUROSCI, V16, P3934
   Caille S, 2006, NEUROPSYCHOPHARMACOL, V31, P804, DOI 10.1038/sj.npp.1300848
   Campolongo P, 2009, P NATL ACAD SCI USA, V106, P4888, DOI 10.1073/pnas.0900835106
   Carlisle SJ, 2002, INT IMMUNOPHARMACOL, V2, P69, DOI 10.1016/S1567-5769(01)00147-3
   Carr DB, 2000, SYNAPSE, V38, P114, DOI 10.1002/1098-2396(200011)38:2<114::AID-SYN2>3.0.CO;2-R
   Cassano T., 2017, NEUROSCIENCE, V11, P30, DOI [10.3389/fnins.2017.0003028210207, DOI 10.3389/FNINS.2017.0003028210207, DOI 10.3389/FNINS.2017.00030]
   Castane A, 2002, NEUROPHARMACOLOGY, V43, P857, DOI 10.1016/S0028-3908(02)00118-1
   Cohen C, 2002, BEHAV PHARMACOL, V13, P451, DOI 10.1097/00008877-200209000-00018
   Colombo G, 2002, PSYCHOPHARMACOLOGY, V159, P181, DOI 10.1007/s002130100887
   Cossu G, 2001, BEHAV BRAIN RES, V118, P61, DOI 10.1016/S0166-4328(00)00311-9
   Dagon Y, 2007, NEUROBIOL DIS, V27, P174, DOI 10.1016/j.nbd.2007.04.017
   Day JJ, 2007, NAT NEUROSCI, V10, P1020, DOI 10.1038/nn1923
   De Vries TJ, 2003, PSYCHOPHARMACOLOGY, V168, P164, DOI 10.1007/s00213-003-1422-1
   De Vries TJ, 2001, NAT MED, V7, P1151, DOI 10.1038/nm1001-1151
   DEROCQ JM, 1995, FEBS LETT, V369, P177, DOI 10.1016/0014-5793(95)00746-V
   DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919
   Di Chiara G, 2004, NEUROPHARMACOLOGY, V47, P227, DOI 10.1016/j.neuropharm.2004.06.032
   Di Marzo V, 2015, NAT REV NEUROSCI, V16, P30, DOI 10.1038/nrn3876
   Diana M, 1998, EUR J NEUROSCI, V10, P2825, DOI 10.1111/j.1460-9568.1998.00292.x
   Dinh TP, 2002, P NATL ACAD SCI USA, V99, P10819, DOI 10.1073/pnas.152334899
   Dubreucq S, 2013, BIOL PSYCHIAT, V73, P895, DOI 10.1016/j.biopsych.2012.10.025
   Egertova M, 2000, J COMP NEUROL, V422, P159, DOI 10.1002/(SICI)1096-9861(20000626)422:2<159::AID-CNE1>3.0.CO;2-1
   Egertova M, 2003, NEUROSCIENCE, V119, P481, DOI 10.1016/S0306-4522(03)00145-3
   Egertova M, 2008, J COMP NEUROL, V506, P604, DOI 10.1002/cne.21568
   Eggan SM, 2007, CEREB CORTEX, V17, P175, DOI 10.1093/cercor/bhj136
   Elliott MB, 2011, J NEUROTRAUM, V28, P973, DOI 10.1089/neu.2010.1672
   Everitt BJ, 2016, ANNU REV PSYCHOL, V67, P23, DOI 10.1146/annurev-psych-122414-033457
   Fattore L, 1999, BEHAV BRAIN RES, V104, P141, DOI 10.1016/S0166-4328(99)00059-5
   Fattore L, 2011, BRIT J PHARMACOL, V163, P1550, DOI 10.1111/j.1476-5381.2011.01459.x
   Fezza F, 2014, MOLECULES, V19, P17078, DOI 10.3390/molecules191117078
   French ED, 1997, NEUROSCI LETT, V226, P159, DOI 10.1016/S0304-3940(97)00278-4
   French ED, 1997, NEUROREPORT, V8, P649, DOI 10.1097/00001756-199702100-00014
   Gado F, 2019, J MED CHEM, V62, P276, DOI 10.1021/acs.jmedchem.8b00368
   GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x
   Gallate JE, 1999, EUR J PHARMACOL, V370, P233, DOI 10.1016/S0014-2999(99)00170-3
   Gamaleddin I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029900
   Gao Y, 2010, J NEUROSCI, V30, P2017, DOI 10.1523/JNEUROSCI.5693-09.2010
   Garcia-Cabrerizo R, 2016, NEUROSCI LETT, V615, P60, DOI 10.1016/j.neulet.2016.01.018
   Garcia-Gutierrez MS, 2010, BRIT J PHARMACOL, V160, P1773, DOI 10.1111/j.1476-5381.2010.00819.x
   Garcia-Gutierrez MS, 2012, BRIT J PHARMACOL, V165, P951, DOI 10.1111/j.1476-5381.2011.01625.x
   Geisler S, 2007, J NEUROSCI, V27, P5730, DOI 10.1523/JNEUROSCI.0012-07.2007
   Glick SD, 2011, EUR J PHARMACOL, V669, P71, DOI 10.1016/j.ejphar.2011.08.001
   Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119
   Gong JP, 2006, BRAIN RES, V1071, P10, DOI 10.1016/j.brainres.2005.11.035
   Gremel CM, 2016, NEURON, V90, P1312, DOI 10.1016/j.neuron.2016.04.043
   Griffin G, 1999, EUR J PHARMACOL, V377, P117, DOI 10.1016/S0014-2999(99)00402-1
   Gutierrez-Rodriguez A, 2018, GLIA, V66, P1417, DOI 10.1002/glia.23314
   Gutierrez-Rodriguez A, 2017, J COMP NEUROL, V525, P302, DOI 10.1002/cne.24066
   Guzman M, 2001, J MOL MED-JMM, V78, P613, DOI 10.1007/s001090000177
   Haller J, 2002, EUR J NEUROSCI, V16, P1395, DOI 10.1046/j.1460-9568.2002.02192.x
   Han J, 2012, CELL, V148, P1039, DOI 10.1016/j.cell.2012.01.037
   Harris KK, 2016, NAT REV ENDOCRINOL, V12, P299, DOI 10.1038/nrendo.2016.32
   Hayase T, 2005, BEHAV PHARMACOL, V16, P395, DOI 10.1097/00008877-200509000-00012
   Hayase T, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-20
   Hebert-Chatelain E, 2016, NATURE, V539, P555, DOI 10.1038/nature20127
   Hebert-Chatelain E, 2014, MOL METAB, V3, P495, DOI 10.1016/j.molmet.2014.03.007
   Hebert-Chatelain E, 2014, MOL METAB, V3, P339, DOI 10.1016/j.molmet.2014.03.008
   HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932
   Hermann H, 2002, NEUROSCIENCE, V109, P451, DOI 10.1016/S0306-4522(01)00509-7
   Hernandez PJ, 2002, NAT NEUROSCI, V5, P1327, DOI 10.1038/nn973
   Hill EL, 2007, J NEUROPHYSIOL, V97, P2580, DOI 10.1152/jn.00603.2006
   Hollister LE, 1998, INT J NEUROPSYCHOP, V1, P71, DOI 10.1017/S1461145798001060
   Houchi H, 2005, NEUROPSYCHOPHARMACOL, V30, P339, DOI 10.1038/sj.npp.1300568
   HOWLETT AC, 1990, TRENDS NEUROSCI, V13, P420, DOI 10.1016/0166-2236(90)90124-S
   Hu SSJ, 2015, HANDB EXP PHARMACOL, V231, P59, DOI 10.1007/978-3-319-20825-1_3
   Hungund BL, 2003, J NEUROCHEM, V84, P698, DOI 10.1046/j.1471-4159.2003.01576.x
   Ignatowska-Jankowska BM, 2013, PSYCHOPHARMACOLOGY, V229, P591, DOI 10.1007/s00213-013-3117-6
   Ishiguro H, 2007, PHARMACOGENOMICS J, V7, P380, DOI 10.1038/sj.tpj.6500431
   Janssen FJ, 2016, BIOORG MED CHEM LETT, V26, P3831, DOI 10.1016/j.bmcl.2016.06.076
   Jennings JH, 2013, NATURE, V496, P224, DOI 10.1038/nature12041
   Kano M, 2009, PHYSIOL REV, V89, P309, DOI 10.1152/physrev.00019.2008
   Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803
   Katona I, 2001, J NEUROSCI, V21, P9506, DOI 10.1523/JNEUROSCI.21-23-09506.2001
   Katona I, 2006, J NEUROSCI, V26, P5628, DOI 10.1523/JNEUROSCI.0309-06.2006
   Katona I, 2012, ANNU REV NEUROSCI, V35, P529, DOI 10.1146/annurev-neuro-062111-150420
   Kawamura Y, 2006, J NEUROSCI, V26, P2991, DOI 10.1523/JNEUROSCI.4872-05.2006
   Koch M, 2015, NATURE, V519, P45, DOI 10.1038/nature14260
   Koob GF, 2016, LANCET PSYCHIAT, V3, P760, DOI 10.1016/S2215-0366(16)00104-8
   Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442
   Koob GF, 1996, NEURON, V16, P893, DOI 10.1016/S0896-6273(00)80109-9
   Kortleven C, 2011, EUR J NEUROSCI, V33, P1751, DOI 10.1111/j.1460-9568.2011.07648.x
   Lafourcade M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000709
   LaLumiere RT, 2005, LEARN MEMORY, V12, P296, DOI 10.1101/lm.93205
   Lanciego JL, 2011, J PSYCHOPHARMACOL, V25, P97, DOI 10.1177/0269881110367732
   Laviolette SR, 2006, J NEUROSCI, V26, P6458, DOI 10.1523/JNEUROSCI.0707-06.2006
   Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401
   Lesscher HMB, 2005, EUR NEUROPSYCHOPHARM, V15, P31, DOI 10.1016/j.euroneuro.2004.04.003
   Lin HC, 2009, CEREB CORTEX, V19, P165, DOI 10.1093/cercor/bhn075
   Liu LW, 2012, MOL PHARMACOL, V81, P541, DOI 10.1124/mol.111.076661
   Liu QR, 2009, GENES BRAIN BEHAV, V8, P519, DOI 10.1111/j.1601-183X.2009.00498.x
   Lopez A, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1174-9
   Lopez-Moreno JA, 2004, J NEUROSCI, V24, P8245, DOI 10.1523/JNEUROSCI.2179-04.2004
   Lu HC, 2016, BIOL PSYCHIAT, V79, P516, DOI 10.1016/j.biopsych.2015.07.028
   Ludanyi A, 2008, J NEUROSCI, V28, P2976, DOI 10.1523/JNEUROSCI.4465-07.2008
   Lutz B, 2007, MOL NEUROBIOL, V36, P92, DOI 10.1007/s12035-007-8004-x
   Lutz B, 2015, NAT REV NEUROSCI, V16, P705, DOI 10.1038/nrn4036
   Mackie K, 2005, HANDB EXP PHARMACOL, V168, P299
   Maldonado R, 2006, TRENDS NEUROSCI, V29, P225, DOI 10.1016/j.tins.2006.01.008
   Maldonado R, 2011, NEUROSCIENCE, V181, P1, DOI 10.1016/j.neuroscience.2011.02.035
   Maldonado R, 2003, J NEURAL TRANSM-SUPP, P1
   Maldonado R, 2002, PHARMACOL THERAPEUT, V95, P153, DOI 10.1016/S0163-7258(02)00254-1
   Malinen H, 2008, ALCOHOL CLIN EXP RES, V32, P1976, DOI 10.1111/j.1530-0277.2008.00786.x
   Marrs WR, 2010, NAT NEUROSCI, V13, P951, DOI 10.1038/nn.2601
   Marsicano G, 1999, EUR J NEUROSCI, V11, P4213, DOI 10.1046/j.1460-9568.1999.00847.x
   Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208
   Marsicano G, 2002, NATURE, V418, P530, DOI 10.1038/nature00839
   Marsicano Giovanni, 2008, P161, DOI 10.1007/978-0-387-74349-3_10
   Martin M, 2002, PSYCHOPHARMACOLOGY, V159, P379, DOI 10.1007/s00213-001-0946-5
   Martin M, 2000, EUR J NEUROSCI, V12, P4038, DOI 10.1046/j.1460-9568.2000.00287.x
   Martin-Garcia E, 2016, NEUROPSYCHOPHARMACOL, V41, P2192, DOI 10.1038/npp.2015.351
   Massi L, 2008, J NEUROSCI, V28, P10496, DOI 10.1523/JNEUROSCI.2291-08.2008
   Mastinu A, 2018, HORM MOL BIOL CLIN I, V36, DOI 10.1515/hmbci-2018-0013
   Mateo Y, 2017, NEURON, V96, P1112, DOI 10.1016/j.neuron.2017.11.012
   Mato S, 2005, J NEUROSCI, V25, P11619, DOI 10.1523/JNEUROSCI.2294-05.2005
   Matyas F, 2008, NEUROPHARMACOLOGY, V54, P95, DOI 10.1016/j.neuropharm.2007.05.028
   McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248
   MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D
   Metna-Laurent M, 2015, GLIA, V63, P353, DOI 10.1002/glia.22773
   Monory K, 2006, NEURON, V51, P455, DOI 10.1016/j.neuron.2006.07.006
   Monory Krisztina, 2007, PLoS Biol, V5, pe269, DOI 10.1371/journal.pbio.0050269
   Monory K, 2015, J NEUROSCI, V35, P3842, DOI 10.1523/JNEUROSCI.3167-14.2015
   MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0
   Navarrete F, 2013, NEUROPSYCHOPHARMACOL, V38, P2515, DOI 10.1038/npp.2013.157
   Navarro M, 2004, EUR J PHARMACOL, V501, P235, DOI 10.1016/j.ejphar.2004.08.022
   Navarro M, 1997, NEUROREPORT, V8, P491, DOI 10.1097/00001756-199701200-00023
   Navarro M, 2001, J NEUROSCI, V21, P5344, DOI 10.1523/JNEUROSCI.21-14-05344.2001
   Nazzaro C, 2012, NAT NEUROSCI, V15, P284, DOI 10.1038/nn.3022
   Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578
   Novick DM, 2015, J ADDICT DIS, V34, P226, DOI 10.1080/10550887.2015.1059225
   Okamoto Y, 2004, J BIOL CHEM, V279, P5298, DOI 10.1074/jbc.M306642200
   Onaivi ES, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001640
   Onaivi ES, 2006, NEUROPSYCHOBIOLOGY, V54, P231, DOI 10.1159/000100778
   Onaivi ES, 2006, ANN NY ACAD SCI, V1074, P514, DOI 10.1196/annals.1369.052
   Onaivi ES, 2008, ANN NY ACAD SCI, V1139, P434, DOI 10.1196/annals.1432.036
   Ortega-Alvaro A, 2015, ADDICT BIOL, V20, P43, DOI 10.1111/adb.12076
   Ortega-Alvaro A, 2011, NEUROPSYCHOPHARMACOL, V36, P1489, DOI 10.1038/npp.2011.34
   Page ME, 2007, PHARMACOL BIOCHEM BE, V86, P162, DOI 10.1016/j.pbb.2006.12.020
   Pang Z, 2011, OBESITY, V19, P1923, DOI 10.1038/oby.2011.250
   Panlilio LV, 2007, NEUROPSYCHOPHARMACOL, V32, P646, DOI 10.1038/sj.npp.1301109
   Parsons LH, 2015, NAT REV NEUROSCI, V16, P579, DOI 10.1038/nrn4004
   Persidsky Y, 2011, BRAIN BEHAV IMMUN, V25, pS61, DOI 10.1016/j.bbi.2011.03.001
   Pertwee RG, 2010, PHARMACOL REV, V62, P588, DOI 10.1124/pr.110.003004
   Pertwee RG, 2015, HANDB EXP PHARMACOL, V231, P1, DOI 10.1007/978-3-319-20825-1_1
   Pertwee RG, 2012, PHILOS T R SOC B, V367, P3353, DOI 10.1098/rstb.2011.0381
   Piazza PV, 2017, NEURON, V93, P1252, DOI 10.1016/j.neuron.2017.02.002
   Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247
   Piomelli D, 2014, NEUROPHARMACOLOGY, V76, P228, DOI 10.1016/j.neuropharm.2013.07.026
   Pistis M, 2002, BRAIN RES, V948, P155, DOI 10.1016/S0006-8993(02)03055-X
   Pistis M, 2004, NEUROPHARMACOLOGY, V46, P115, DOI 10.1016/j.neuropharm.2003.08.003
   Pradier B, 2015, BEHAV BRAIN RES, V287, P163, DOI 10.1016/j.bbr.2015.03.051
   Puente N, 2011, NAT NEUROSCI, V14, P1542, DOI 10.1038/nn.2974
   Racz I, 2015, BRAIN RES BULL, V114, P42, DOI 10.1016/j.brainresbull.2015.03.005
   Rice OV, 2002, BRAIN RES, V945, P135, DOI 10.1016/S0006-8993(02)02890-1
   Rivera P, 2013, INT J NEUROPSYCHOPH, V16, P1277, DOI 10.1017/S1461145712001186
   Robbe D, 2001, J NEUROSCI, V21, P109, DOI 10.1523/JNEUROSCI.21-01-00109.2001
   Robinson JD, 2018, ADDICT BIOL, V23, P291, DOI 10.1111/adb.12508
   Rodriguez JJ, 2001, J NEUROSCI, V21, P823, DOI 10.1523/JNEUROSCI.21-03-00823.2001
   Rothman RB, 2003, EUR J PHARMACOL, V479, P23, DOI 10.1016/j.ejphar.2003.08.054
   Ruehle S, 2013, J NEUROSCI, V33, P10264, DOI 10.1523/JNEUROSCI.4171-12.2013
   Salamone JD, 2007, PSYCHOPHARMACOLOGY, V191, P389, DOI 10.1007/s00213-006-0623-9
   Sanchez-Marin L, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00015
   Serrano A, 2012, ALCOHOL CLIN EXP RES, V36, P984, DOI 10.1111/j.1530-0277.2011.01686.x
   Sharma MK, 2015, EXPERT OPIN THER PAT, V25, P1093, DOI 10.1517/13543776.2015.1064898
   Sharma MK, 2014, EUR J MED CHEM, V79, P298, DOI 10.1016/j.ejmech.2014.04.011
   Sierra S, 2015, BRAIN STRUCT FUNCT, V220, P2721, DOI 10.1007/s00429-014-0823-8
   Silveira MM, 2017, NEUROSCI BIOBEHAV R, V76, P380, DOI 10.1016/j.neubiorev.2016.09.007
   Silvestri C, 2012, EXPERT OPIN INV DRUG, V21, P1309, DOI 10.1517/13543784.2012.704019
   Soria G, 2005, NEUROPSYCHOPHARMACOL, V30, P1670, DOI 10.1038/sj.npp.1300707
   Soria-Gomez E, 2014, NAT NEUROSCI, V17, P407, DOI 10.1038/nn.3647
   Soyka M, 2008, J CLIN PSYCHOPHARM, V28, P317, DOI 10.1097/JCP.0b013e318172b8bc
   Sperlagh B, 2009, NEUROCHEM INT, V54, P452, DOI 10.1016/j.neuint.2009.01.017
   Steindel F, 2013, J NEUROCHEM, V124, P795, DOI 10.1111/jnc.12137
   Stella N, 2010, GLIA, V58, P1017, DOI 10.1002/glia.20983
   Stempel AV, 2016, NEURON, V90, P795, DOI 10.1016/j.neuron.2016.03.034
   Sugiura T, 2000, J BIOL CHEM, V275, P605, DOI 10.1074/jbc.275.1.605
   Szabo B, 2002, EUR J NEUROSCI, V15, P2057, DOI 10.1046/j.1460-9568.2002.02041.x
   Szabo B, 1999, J NEUROCHEM, V73, P1084, DOI 10.1046/j.1471-4159.1999.0731084.x
   Tanda G, 1997, SCIENCE, V276, P2048, DOI 10.1126/science.276.5321.2048
   Tanimura A, 2010, NEURON, V65, P320, DOI 10.1016/j.neuron.2010.01.021
   Taylor D, 2009, CURR DRUG SAF, V4, P2, DOI 10.2174/157488609787354396
   Tourino C, 2008, BIOL PSYCHIAT, V63, P1030, DOI 10.1016/j.biopsych.2007.09.003
   Tsou K, 1998, NEUROSCIENCE, V83, P393, DOI 10.1016/S0306-4522(97)00436-3
   Tsou K, 1999, NEUROSCIENCE, V93, P969, DOI 10.1016/S0306-4522(99)00086-X
   U. N. O. on D. and Crime, 2017, WORLD DRUG REP 2017
   Uchigashima M, 2007, J NEUROSCI, V27, P3663, DOI 10.1523/JNEUROSCI.0448-07.2007
   Ueda N, 2002, PROSTAG OTH LIPID M, V68-9, P521, DOI 10.1016/S0090-6980(02)00053-9
   Valjent E, 2002, BRIT J PHARMACOL, V135, P564, DOI 10.1038/sj.bjp.0704479
   Vallee M, 2014, SCIENCE, V343, P94, DOI 10.1126/science.1243985
   Van Sickle MD, 2005, SCIENCE, V310, P329, DOI 10.1126/science.1115740
   Volkow ND, 1997, NATURE, V386, P830, DOI 10.1038/386830a0
   Volkow ND, 2017, ANNU REV PHARMACOL, V57, P285, DOI 10.1146/annurev-pharmtox-010716-104615
   Volkow ND, 2016, NEW ENGL J MED, V374, P363, DOI 10.1056/NEJMra1511480
   Volkow ND, 2014, P NATL ACAD SCI USA, V111, pE3149, DOI 10.1073/pnas.1411228111
   Ward SJ, 2009, DRUG ALCOHOL DEPEN, V105, P248, DOI 10.1016/j.drugalcdep.2009.07.002
   Wenger T, 2003, BRAIN RES BULL, V61, P125, DOI 10.1016/S0361-9230(03)00081-9
   Wilcox CS, 2011, J INVEST MED, V59, P1280, DOI 10.2130/JIM.0b013e31823581fa
   Xi ZX, 2006, J NEUROSCI, V26, P8531, DOI 10.1523/JNEUROSCI.0726-06.2006
   Xi ZX, 2011, NAT NEUROSCI, V14, P1160, DOI 10.1038/nn.2874
   Yiangou Y, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-12
   Yoshida T, 2006, J NEUROSCI, V26, P4740, DOI 10.1523/JNEUROSCI.0054-06.2006
   Yoshida T, 2011, P NATL ACAD SCI USA, V108, P3059, DOI 10.1073/pnas.1012875108
   Yu LL, 2011, BEHAV BRAIN RES, V217, P111, DOI 10.1016/j.bbr.2010.10.008
   Zhang HY, 2017, ADDICT BIOL, V22, P752, DOI 10.1111/adb.12367
   Zhang HY, 2015, NEUROPSYCHOPHARMACOL, V40, P1037, DOI 10.1038/npp.2014.297
   Zhang HY, 2014, P NATL ACAD SCI USA, V111, pE5007, DOI 10.1073/pnas.1413210111
   Zhang Y, 2013, NEUROPHARMACOLOGY, V67, P259, DOI 10.1016/j.neuropharm.2012.10.015
   Zou SL, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030833
NR 235
TC 75
Z9 75
U1 1
U2 24
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD NOV
PY 2018
VL 157
SI SI
BP 108
EP 121
DI 10.1016/j.bcp.2018.09.013
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Pharmacology & Pharmacy
GA HC4RF
UT WOS:000451791200010
PM 30217570
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Belin, D
   Balado, E
   Piazza, PV
   Deroche-Gamonet, V
AF Belin, David
   Balado, Eric
   Piazza, Pier Vincenzo
   Deroche-Gamonet, Veronique
TI Pattern of Intake and Drug Craving Predict the Development of Cocaine
   Addiction-like Behavior in Rats
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Addiction; cocaine; pattern; rat; reinstatement; self-administration
ID SENSITIZATION; DEPENDENCE; TRANSITION; DELIVERY; VALIDITY
AB Background: Clinical observations suggest that cocaine addiction often emerges with new patterns of use. Whether these changes are a cause of addiction or its consequence is unknown. We investigated whether the development of an addiction-like behavior in the rat is associated with the pattern of cocaine intake and with cocaine craving, a major feature of cocaine addiction.
   Methods: To determine whether changes in the pattern of cocaine use and enhanced craving precede or parallel the onset of addiction, we used a rat addiction model that incorporates core features of human addiction. For this purpose, the pattern of inter-infusion intervals (a measure of pattern of cocaine intake), sensitivity to cocaine-induced reinstatement (a measure of cocaine craving), and addiction-like behaviour were assessed over several months of intravenous cocaine self-administration.
   Results: We found that, even at early stages of cocaine self-administration, both the pattern of cocaine intake and the intensity of drug-induced reinstatement predict the severity of cocaine use, measured after 75 days of self-administration.
   Conclusions: Our results identify key predictors of cocaine addiction-intensified pattern of drug use and high drug-induced craving-that may help in the identification of subjects at risk for subsequent development of severe cocaine addiction.
C1 [Belin, David; Balado, Eric; Piazza, Pier Vincenzo; Deroche-Gamonet, Veronique] Inst Francois Magendie, U862, CRI, F-33077 Bordeaux, France.
C3 UDICE-French Research Universities; Universite de Bordeaux
RP Deroche-Gamonet, V (通讯作者)，Inst Francois Magendie, U862, CRI, 146 Rue Leo Saignat, F-33077 Bordeaux, France.
EM veronique.deroche@inserm.fr
RI Deroche-Gamonet, Véronique/E-5728-2010; Belin, David/E-1231-2014
OI Belin, David/0000-0002-7383-372X; Deroche-Gamonet,
   Veronique/0000-0002-9704-6624
FU Institut National de la Sante et de la Recherche Medicale; Mission
   Interministerielle de Lutte contre la Drogue et la Toxicomanie; Region
   Aquitaine; Agence Nationale de la Recherche; European Commission grants
   [LHSM-CT-2007-037669]; Ministere de l'Education Nationale; de la
   Recherche et de la Technologie and foundation FYSSEN
FX This work was supported by Institut National de la Sante et de la
   Recherche Medicale. Mission Interministerielle de Lutte contre la Drogue
   et la Toxicomanie, Region Aquitaine, Agence Nationale de la Recherche,
   and European Commission grants (FP6 DC RTD project PHECOMP No.
   LHSM-CT-2007-037669) to PVP. DB was supported by grants from Ministere
   de l'Education Nationale, de la Recherche et de la Technologie and
   foundation FYSSEN. We thank Drs. Tavin Shabam, Mercedes Arroyo, and
   Marcello Solinas for their helpful comments.
CR Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th
   Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244
   Dackis CA, 2001, J SUBST ABUSE TREAT, V21, P111, DOI 10.1016/S0740-5472(01)00192-1
   Deroche V, 1999, EUR J NEUROSCI, V11, P2731, DOI 10.1046/j.1460-9568.1999.00696.x
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Epstein DH, 2006, PSYCHOPHARMACOLOGY, V189, P1, DOI 10.1007/s00213-006-0529-6
   FEINGOLD A, 1995, ADDICTION, V90, P1661, DOI 10.1111/j.1360-0443.1995.tb02836.x
   Gawin F H, 1996, NIDA Res Monogr, V163, P224
   GAWIN FH, 1991, SCIENCE, V251, P1580, DOI 10.1126/science.2011738
   Gunnarsdottir ED, 2000, ADDICT BEHAV, V25, P641, DOI 10.1016/S0306-4603(99)00043-X
   JAFFE JH, 1989, PSYCHOPHARMACOLOGY, V97, P59, DOI 10.1007/BF00443414
   Morgan D, 2005, PSYCHOPHARMACOLOGY, V178, P309, DOI 10.1007/s00213-004-1992-6
   Morgan D, 2004, NEUROSCI BIOBEHAV R, V27, P803, DOI 10.1016/j.neubiorev.2003.11.004
   OBrien CP, 1997, SCIENCE, V278, P66, DOI 10.1126/science.278.5335.66
   Panlilio LV, 1998, PSYCHOPHARMACOLOGY, V137, P253, DOI 10.1007/s002130050618
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Samaha AN, 2005, TRENDS PHARMACOL SCI, V26, P82, DOI 10.1016/j.tips.2004.12.007
   Tornatzky W, 2000, PSYCHOPHARMACOLOGY, V148, P289, DOI 10.1007/s002130050053
NR 19
TC 121
Z9 122
U1 1
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 15
PY 2009
VL 65
IS 10
BP 863
EP 868
DI 10.1016/j.biopsych.2008.05.031
PG 6
WC Neurosciences; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology; Psychiatry
GA 442AE
UT WOS:000265811300008
PM 18639867
DA 2023-06-23
ER

PT J
AU Bell, J
AF Bell, James
TI Speciality recognition of addiction medicine in Australia
SO ADDICTION
LA English
DT Editorial Material
DE addiction; brief intervention; medical education; primary care;
   treatment
ID DRUG
C1 [Bell, James] Kings Coll London, Inst Psychiat, London, England.
   [Bell, James] Univ New S Wales, Natl Drug & Alcohol Res Ctr, Kensington, NSW 2033, Australia.
C3 University of London; RLUK- Research Libraries UK; King's College
   London; University of New South Wales Sydney
RP Bell, J (通讯作者)，Kings Coll London, Inst Psychiat, London, England.
EM james.bell@sesiahs.health.nsw.gov.au
CR Abouyanni G, 2000, DRUG ALCOHOL REV, V19, P165, DOI 10.1080/713659318
   Fiellin DA, 2001, JAMA-J AM MED ASSOC, V286, P1724, DOI 10.1001/jama.286.14.1724
   Fucito LM, 2003, DRUG ALCOHOL REV, V22, P417, DOI 10.1080/09595230310001613930
   Martyres RF, 2004, MED J AUSTRALIA, V180, P211, DOI 10.5694/j.1326-5377.2004.tb05887.x
   Paulozzi LJ, 2006, AM J PUBLIC HEALTH, V96, P1755, DOI 10.2105/AJPH.2005.071647
   RICHMOND R, 1995, ADDICTION, V90, P119, DOI 10.1046/j.1360-0443.1995.90111915.x
   Roche AM, 2002, DRUG ALCOHOL REV, V21, P223, DOI 10.1080/0959523021000002679
NR 7
TC 3
Z9 3
U1 0
U2 2
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0965-2140
J9 ADDICTION
JI Addiction
PD MAY
PY 2008
VL 103
IS 5
BP 701
EP 702
DI 10.1111/j.1360-0443.2007.02121.x
PG 2
WC Substance Abuse; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry
GA 288LQ
UT WOS:000254988300002
PM 18412742
OA Bronze
DA 2023-06-23
ER

PT J
AU Racz, J
   Kassai, S
   Pinter, JN
   Benedeczki, P
   Dobo-Nagy, Z
   Horvath, Z
   Gyarmathy, VA
AF Racz, Jozsef
   Kassai, Szilvia
   Pinter, Judit Nora
   Benedeczki, Piroska
   Dobo-Nagy, Zita
   Horvath, Zsofia
   Gyarmathy, V. Anna
TI The Therapeutic Journeys of Recovering Helpers - an Interpretative
   Phenomenological Analysis
SO INTERNATIONAL JOURNAL OF MENTAL HEALTH AND ADDICTION
LA English
DT Article
DE Therapeutic journey; Interpretative phenomenological analysis; Peer
   helpers; Addiction treatment; Drug addiction; Behavioral addiction
ID DRUG-USE; NARRATIVES; EXPERIENCE; IDENTITY; ADDICTION; STORIES
AB Recovering helpers play an increasing role in addiction treatment. In this study, we assessed the process of how addicts become recovering helpers. Semi-structured interviews were conducted with six recovering helpers, and the transcribed interviews were analyzed using interpretative phenomenological analysis. Four turning points were identified during the interviews: starting using drugs or gambling, becoming an addict, hitting bottom, and becoming a helper. In addition, four themes related to being a helper were identified: the recovering self and the helping self, the wounded helper, the skilled helper and the experience of helping. Understanding the dynamics and background of recovering helpers' work may contribute to their training, to finding the most appropriate place for them in addiction treatment, and in drug and alcohol policy.
C1 [Racz, Jozsef; Kassai, Szilvia] Eotvos Lorand Univ, Inst Psychol, Budapest, Hungary.
   [Racz, Jozsef; Benedeczki, Piroska; Dobo-Nagy, Zita; Horvath, Zsofia; Gyarmathy, V. Anna] Semmelweis Univ, Fac Hlth Sci, H-1085 Budapest, Hungary.
   [Pinter, Judit Nora] Univ Szeged, Inst Psychol, Szeged, Hungary.
   [Gyarmathy, V. Anna] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
C3 Eotvos Lorand University; Semmelweis University; Eotvos Lorand Research
   Network; Hungarian Research Centre for Natural Sciences; Szeged
   University; Johns Hopkins University; Johns Hopkins Bloomberg School of
   Public Health
RP Gyarmathy, VA (通讯作者)，Semmelweis Univ, Fac Hlth Sci, H-1085 Budapest, Hungary.
EM vgyarmat@jhsph.edu
RI Pintér, Judit Nóra/Y-1356-2019; Racz, Jozsef/H-8541-2017
OI Pintér, Judit Nóra/0000-0002-2580-588X; Racz, Jozsef/0000-0003-3354-1738
CR AALTONEN I, 1994, INT J ADDICT, V29, P485, DOI 10.3109/10826089409047394
   Baker PL, 2000, J DRUG ISSUES, V30, P863, DOI 10.1177/002204260003000411
   Barr A., 2006, INVESTIGATION EXTENT
   CAIN C, 1991, ETHOS, V19, P210, DOI 10.1525/eth.1991.19.2.02a00040
   Conti-O'Hare M, 2002, NURSE WOUNDED HEALER
   Curtis SL, 2010, J SUBST ABUSE TREAT, V39, P248, DOI 10.1016/j.jsat.2010.06.006
   Dima G, 2012, PROCD SOC BEHV, V33, P672, DOI 10.1016/j.sbspro.2012.01.206
   Doukas N, 2010, DRUG-EDUC PREV POLIC, V17, P216, DOI 10.3109/09687630802378864
   Foucault M., 2001, J ANAL PSYCHOL, V20, P122
   Hanninen V, 1999, ADDICTION, V94, P1837, DOI 10.1046/j.1360-0443.1999.941218379.x
   Hecksher D., 2004, ADDICTION LIFE COURS, P244
   Jensen GeorgeH, 2000, STORYTELLING ALCOHOL
   Knudsen HK, 2006, J SUBST ABUSE TREAT, V31, P173, DOI 10.1016/j.jsat.2006.04.003
   Koski-Jannes A, 2002, ADDICT RES THEORY, V10, P183, DOI 10.1080/16066350290017266
   Koski-Jannes A., 1998, J SUBSTANCE MISUSE, V3, P226, DOI DOI 10.3109/14659899809053506
   Laudet AB, 2007, J SUBST ABUSE TREAT, V33, P243, DOI 10.1016/j.jsat.2007.04.014
   Madacsy J., 2013, MELYPONT UNNEPELYE A
   Marlatt G. A., 1986, J DRUG ISSUES, V17, P28
   McIntosh J, 2000, SOC SCI MED, V50, P1501, DOI 10.1016/S0277-9536(99)00409-8
   McIntosh J, 2001, DRUG-EDUC PREV POLIC, V8, P47
   McIntosh J, 2002, BEATING DRAGON RECOV
   McNulty TL, 2007, SOCIOL INQ, V77, P166, DOI 10.1111/j.1475-682X.2007.00186.x
   Oteiza V, 2010, COUNS PSYCHOTHER RES, V10, P222, DOI 10.1080/14733140903337300
   Rizq R., 2008, COUNSELING PSYCHOL R, V24, P66
   Shinebourne P, 2011, INT J MENT HEALTH AD, V9, P282, DOI 10.1007/s11469-010-9286-1
   Shinebourne P, 2011, DRUG-EDUC PREV POLIC, V18, P313, DOI 10.3109/09687637.2010.514621
   Smith J.A., 2009, INTERPRETATIVE PHENO
   Smith JA, 2007, QUALITATIVE PSYCHOL, DOI DOI 10.1002/9781119975144.CH9
   Steffen V, 1997, SOC SCI MED, V45, P99, DOI 10.1016/S0277-9536(96)00319-X
   Weegmann M, 2009, HEALTH SOCIOL REV, V18, P273, DOI 10.5172/hesr.2009.18.3.273
   White W. L., 2000, ALCOHOL TREAT Q, V18, P1, DOI [10.1300/J020v18n01_01, DOI 10.1300/J020V18N02_01]
NR 31
TC 5
Z9 5
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1557-1874
EI 1557-1882
J9 INT J MENT HEALTH AD
JI Int. J. Mental Health Addict.
PD DEC
PY 2015
VL 13
IS 6
BP 751
EP 757
DI 10.1007/s11469-015-9560-3
PG 7
WC Psychology, Clinical; Substance Abuse; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology; Substance Abuse; Psychiatry
GA CW5CI
UT WOS:000365012600008
DA 2023-06-23
ER

PT J
AU Shekarchizadeh, H
   Ekhtiari, H
   Khami, MR
   Virtanen, JI
AF Shekarchizadeh, Hajar
   Ekhtiari, Hamed
   Khami, Mohammad R.
   Virtanen, Jorma I.
TI Patterns of pre-treatment drug abuse, drug treatment history and
   characteristics of addicts in methadone maintenance treatment in Iran
SO HARM REDUCTION JOURNAL
LA English
DT Article
DE Addiction; Opiates; Methadone Maintenance; Socioeconomic
ID RETENTION; CHINA
AB Background: Opiates are the main drugs of abuse, and Methadone Maintenance Treatment (MMT) is the most widely administered drug addiction treatment program in Iran. Our study aimed to investigate patterns of pre-treatment drug abuse, addiction treatment history and characteristics of patients in MMT in Tehran.
   Methods: We applied a stratified cluster random sampling technique and conducted a cross-sectional survey utilizing a standard patient characteristic and addiction history form with patients (n = 810) in MMT. The Chi-square test and t-test served for statistical analyses.
   Results: A clear majority of the participants were men (96%), more than 60% of whom were between 25 and 44 years of age, educated (89% had more than elementary education), and employed (>70%). The most commonly reported main drugs of abuse prior to MMT entry were opium (69%) and crystalline heroin (24%). The patients' lifetime drug experience included opium (92%), crystalline heroin (28%), cannabis (16%), amphetamines (15%), and other drugs (33%). Crystalline heroin abusers were younger than opium users, had begun abusing drugs earlier, and reported a shorter history of opiate addiction.
   Conclusion: Opium and crystalline heroin were the main drugs of abuse. A high rate of addiction using more dangerous opiate drugs such as crystalline heroin calls for more preventive efforts, especially among young men.
C1 [Virtanen, Jorma I.] Univ Helsinki, Dept Publ Hlth, Helsinki, Finland.
   [Virtanen, Jorma I.] Univ Oulu, Dept Community Dent, FI-90014 Oulu, Finland.
   [Shekarchizadeh, Hajar; Khami, Mohammad R.] Univ Tehran Med Sci, Sch Dent, Community Oral Hlth Dept, Tehran, Iran.
   [Shekarchizadeh, Hajar] Univ Helsinki, Dept Oral Publ Hlth, Helsinki, Finland.
   [Ekhtiari, Hamed] Inst Cognit Sci Studies, Translat Neurosci Program, Tehran, Iran.
   [Ekhtiari, Hamed] Univ Tehran Med Sci, Neurocognit Lab, Iranian Natl Ctr Addict Studies, Tehran, Iran.
C3 University of Helsinki; University of Oulu; Tehran University of Medical
   Sciences; University of Helsinki; Tehran University of Medical Sciences
RP Virtanen, JI (通讯作者)，Univ Helsinki, Dept Publ Hlth, Helsinki, Finland.
EM jorma.virtanen@oulu.fi
RI Shekarchizadeh, Hajar/AAN-4963-2021; Khami, Mohammad R/M-6781-2018;
   Virtanen, Jorma/AAP-1160-2021; Ekhtiari, Hamed/L-3639-2013
OI Khami, Mohammad R/0000-0002-4810-9537; Virtanen,
   Jorma/0000-0001-6574-9942; Ekhtiari, Hamed/0000-0001-6902-8798;
   shekarchizadeh, hajar/0000-0003-0991-7125
CR Ahmadi J, 2003, SUBST USE MISUSE, V38, P151, DOI 10.1081/JA-120016571
   Ahmadi J, 2007, AM J DRUG ALCOHOL AB, V33, P483, DOI 10.1080/00952990701301293
   Ali H., 2011, Eastern Mediterranean Health Journal, V17, P41
   American Psychiatric Association (APA), 2000, DIAGN STAT MAN MENT, Vfourth
   Bao YP, 2009, AM J DRUG ALCOHOL AB, V35, P28, DOI 10.1080/00952990802342899
   Barrett ME, 2003, SUBST USE MISUSE, V38, P1615, DOI 10.1081/JA-120024233
   Chen CY, 2009, CURR OPIN PSYCHIATR, V22, P287, DOI 10.1097/YCO.0b013e32832a2349
   Day Carolyn, 2006, Harm Reduct J, V3, P2, DOI 10.1186/1477-7517-3-2
   Deng QJ, 2012, ADDICTION, V107, P610, DOI 10.1111/j.1360-0443.2011.03648.x
   Department of Health England, 2007, DRUG MIS DEP UK GUID
   Huang KC, 2011, INT J DRUG POLICY, V22, P128, DOI 10.1016/j.drugpo.2010.09.010
   Ilhan IO, 2009, INT J PUBLIC HEALTH, V54, P40, DOI 10.1007/s00038-009-7049-1
   Iranian Drug Control Headquarters (IDCH), 2007, NAT RAP SIT AN DRUG
   Lu L, 2008, CELL MOL NEUROBIOL, V28, P479, DOI 10.1007/s10571-007-9225-2
   Meysamie A, 2009, East Mediterr Health J, V15, P425
   Mokri A., 2002, ARCH IRAN MED, V5, P184
   Mokri A., 2008, PUBLIC HLTH ASPECTS, P583, DOI DOI 10.1007/978-0-387-72711-0_26
   Shirinbayan P, 2010, SCI RES ESSAYS, V5, P3231
   Siavash M, 2009, J ADDICT DIS, V28, P180, DOI 10.1080/10550880902772928
   United Nations Office on Drugs and Crime (UNODC), 2008, UN PUBL
   UNODC, 2011, UN PUBL
   UNODC, 2011, AMPH ECST 2011 ATS A
   WHO, 2009, GUID PSYCH ASS PHARM
   Zerell U, 2005, Bull Narc, V57, P11
   Ziaaddini H., 2005, J APPL SCI, V5, P380, DOI [10.3923/jas.2005.380.382, DOI 10.3923/JAS.2005.380.382]
NR 25
TC 26
Z9 26
U1 2
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1477-7517
J9 HARM REDUCT J
JI Harm Reduct. J.
PD JUN 7
PY 2012
VL 9
AR 18
DI 10.1186/1477-7517-9-18
PG 7
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA 979BY
UT WOS:000306791100001
PM 22676557
OA Green Published, gold
DA 2023-06-23
ER

PT C
AU Hadjahmadi, A
   Ziyaaddini, MH
   Omid, MM
AF Hadjahmadi, AmirHossein
   Ziyaaddini, Mohammad Hossein
   Omid, Mohammad Mehdi
GP IEEE
TI Using End-to-End Deep Neural Networks for Diagnosing Drug Addiction from
   Speech Signals
SO 2020 6TH IRANIAN CONFERENCE ON SIGNAL PROCESSING AND INTELLIGENT SYSTEMS
   (ICSPIS)
LA English
DT Proceedings Paper
CT 6th International Conference on Signal Processing and Intelligent
   Systems (ICSPIS)
CY DEC 23-24, 2020
CL Sadjad Univ, Mashhad, IRAN
HO Sadjad Univ
DE Drug addiction test; end-to-end deep neural networks; speech signal
   processing
ID CLASSIFICATION
AB In this paper, the idea of automatic drug addiction diagnosis from the speech voices is proposed, which provides a comfortable, secret, and remote test for diagnosis of the drug addiction. Moreover, we present an end-to-end approach for diagnosing drug addiction from speech signals based on a 1D Convolution Neural Network (CNN). The proposed method can deal with speech signals of any length as it splits the signal into overlapped frames using a sliding window. Moreover, to evaluate the proposed idea, a dataset was collected in collaboration with an addiction treatment center. Two different architectures are evaluated considering different input sizes. The performance of the proposed end-to-end approach in classifying sounds was assessed on the collected dataset. The experimental results have shown that the classification accuracy achieves 98.5%. Therefore, the proposed idea is applicable to controlled environments and situations.
C1 [Hadjahmadi, AmirHossein; Ziyaaddini, Mohammad Hossein; Omid, Mohammad Mehdi] Vali e Asr Univ Rafsanjan, Comp Engn Dept, Imam Khomeini Sq, Rafsanjan, Iran.
C3 Vali-e-Asr University of Rafsanjan
RP Hadjahmadi, A (通讯作者)，Vali e Asr Univ Rafsanjan, Comp Engn Dept, Imam Khomeini Sq, Rafsanjan, Iran.
EM hadjahmadi@vru.ac.it; m.h.ziyaaddini@stu.vru.ac.ir;
   m.m.omid@stu.vru.ac.ir
OI Hadjahmadi, Amir Hossein/0000-0001-6421-4647
CR Abdoli S, 2019, EXPERT SYST APPL, V136, P252, DOI 10.1016/j.eswa.2019.06.040
   Acion L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175383
   Al Sukar Mustafa, 2016, IDENTIFYING DRUG ADD, DOI [10.5281/zenodo.1125361, DOI 10.5281/ZENODO.1125361]
   Alakwaa W, 2017, INT J ADV COMPUT SC, V8, P409
   do Carmo Franca H. F, GOOGLENET GOING DEEP
   Dumoulin V., 2018, STAT-US
   Eren L, 2019, J SIGNAL PROCESS SYS, V91, P179, DOI 10.1007/s11265-018-1378-3
   Faisal F., 2019, THESIS
   Gibson J, 2016, INTERSPEECH, P1447, DOI 10.21437/Interspeech.2016-554
   Hinton GE, 2006, NEURAL COMPUT, V18, P1527, DOI 10.1162/neco.2006.18.7.1527
   Hoshen Y, 2015, INT CONF ACOUST SPEE, P4624, DOI 10.1109/ICASSP.2015.7178847
   Krizhevsky A, 2017, COMMUN ACM, V60, P84, DOI 10.1145/3065386
   Li YB, 2020, CHINESE J AERONAUT, V33, P427, DOI 10.1016/j.cja.2019.08.014
   Lowe D. G., 1999, Proceedings of the Seventh IEEE International Conference on Computer Vision, P1150, DOI 10.1109/ICCV.1999.790410
   Olgun M, 2016, COMPUT ELECTRON AGR, V122, P185, DOI 10.1016/j.compag.2016.01.033
   Palaz D, 2015, 16TH ANNUAL CONFERENCE OF THE INTERNATIONAL SPEECH COMMUNICATION ASSOCIATION (INTERSPEECH 2015), VOLS 1-5, P11
   Pons J., 2017, ARXIV171102520
   Pratt H, 2016, PROCEDIA COMPUT SCI, V90, P200, DOI 10.1016/j.procs.2016.07.014
   Ravi D, 2017, IEEE J BIOMED HEALTH, V21, P4, DOI 10.1109/JBHI.2016.2636665
   Razzaghi E., RAPID SITUATION ASSE
   Schindler, 2016, MIREX2016
   Schmitt M, 2019, EUR SIGNAL PR CONF
   Simonyan K, 2015, Arxiv, DOI [arXiv:1409.1556, DOI 10.48550/ARXIV.1409.1556]
   Zhang HY, 2016, IEEE IMAGE PROC, P1, DOI 10.1109/ICIP.2016.7532307
NR 24
TC 0
Z9 0
U1 0
U2 1
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 978-1-7281-8629-0
PY 2020
DI 10.1109/ICSPIS51611.2020.9349595
PG 6
WC Computer Science, Artificial Intelligence; Engineering, Electrical &
   Electronic
WE Conference Proceedings Citation Index - Science (CPCI-S)
SC Computer Science; Engineering
GA BR9FP
UT WOS:000675416100061
DA 2023-06-23
ER

PT J
AU Koob, GF
   Le Moal, M
AF Koob, GF
   Le Moal, M
TI Plasticity of reward neurocircuitry and the 'dark side' of drug
   addiction
SO NATURE NEUROSCIENCE
LA English
DT Editorial Material
ID STRESS; DYSREGULATION; WITHDRAWAL; BEHAVIOR; ETHANOL; RELAPSE; SEEKING;
   BRAIN
AB Drug seeking is associated with activation of reward neural circuitry. Here we argue that drug addiction also involves a 'dark side'-a decrease in the function of normal reward-related neurocircuitry and persistent recruitment of anti-reward systems. Understanding the neuroplasticity of the dark side of this circuitry is the key to understanding vulnerability to addiction.
C1 Scripps Res Inst, Mol & Integrat Neurosci Dept, La Jolla, CA 92037 USA.
   Univ Bordeaux 2, Lab Physiopathol Comportements, INSERM, U588, F-33076 Bordeaux, France.
C3 Scripps Research Institute; Institut National de la Sante et de la
   Recherche Medicale (Inserm); UDICE-French Research Universities;
   Universite de Bordeaux
RP Koob, GF (通讯作者)，Scripps Res Inst, Mol & Integrat Neurosci Dept, La Jolla, CA 92037 USA.
EM gkoob@scripps.edu
RI LE MOAL, Michel/B-5125-2008
CR Ahmed SH, 2002, NAT NEUROSCI, V5, P625, DOI 10.1038/nn872
   Aston-Jones G, 1999, ANN NY ACAD SCI, V877, P486, DOI 10.1111/j.1749-6632.1999.tb09284.x
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Koob GF, 2003, ALCOHOL CLIN EXP RES, V27, P232, DOI 10.1097/01.ALC.0000057122.36127.C2
   KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Kreek MJ, 1998, DRUG ALCOHOL DEPEN, V51, P23, DOI 10.1016/S0376-8716(98)00064-7
   Le Moal Michel, 1995, P283
   MARTIN WR, 1968, ADDICT STATES, P206
   Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   Piazza PV, 1996, ANNU REV PHARMACOL, V36, P359, DOI 10.1146/annurev.pa.36.040196.002043
   Rasmussen DD, 2000, ALCOHOL CLIN EXP RES, V24, P1836, DOI 10.1111/j.1530-0277.2000.tb01988.x
   See RE, 2003, ANN NY ACAD SCI, V985, P294
   Shaham Y, 2000, BRAIN RES REV, V33, P13, DOI 10.1016/S0165-0173(00)00024-2
   SHIPPENBERG TS, 2002, NEUROPSYCHOPHARMACOL, P1381
   SOLOMON RL, 1974, PSYCHOL REV, V81, P119, DOI 10.1037/h0036128
   Valdez GR, 2002, ALCOHOL CLIN EXP RES, V26, P1494, DOI 10.1097/01.ALC.0000033120.51856.F0
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Volkow ND, 2003, J CLIN INVEST, V111, P1444, DOI 10.1172/JCI200318533
   World Health Organization, 1992, INT STAT CLASS DIS R
NR 22
TC 659
Z9 672
U1 4
U2 69
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1097-6256
EI 1546-1726
J9 NAT NEUROSCI
JI Nat. Neurosci.
PD NOV
PY 2005
VL 8
IS 11
BP 1442
EP 1444
DI 10.1038/nn1105-1442
PG 3
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 979TB
UT WOS:000232966600013
PM 16251985
DA 2023-06-23
ER

PT J
AU Yager, LM
   Garcia, AF
   Donckels, EA
   Ferguson, SM
AF Yager, Lindsay M.
   Garcia, Aaron F.
   Donckels, Elizabeth A.
   Ferguson, Susan M.
TI Chemogenetic inhibition of direct pathway striatal neurons normalizes
   pathological, cue-induced reinstatement of drug-seeking in rats
SO ADDICTION BIOLOGY
LA English
DT Article
DE cocaine; DREADDs; rat
ID BASAL GANGLIA; ADDICTION; DOPAMINE; SYSTEMS; HABITS; REWARD; ROLES; D1
AB Addiction to drugs such as cocaine is marked by cycles of compulsive drug-taking and drug-seeking behavior. Although the transition to addiction is thought to recruit neural processes in dorsal striatum, little is known regarding the role of dorsal striatal projections to the substantia nigra (i.e. the direct pathway) in regulating these behaviors. Combining a Cre-recombinase-dependent chemogenetic approach with a cocaine self-administration paradigm that produces both low-risk and high-risk addiction phenotypes, we examined the effect of transiently decreasing direct pathway activity in the dorsomedial striatum on drug-taking and drug-seeking under conditions of normal and pathological drug use. Surprisingly, transient inhibition of direct pathway striatal neurons had no effect on several measures of addictive behavior during ongoing drug use, including loss of control over drug intake, high motivation to obtain drug and drug use despite negative consequences (i.e. drug use paired with foot shock). However, chemogenetic inhibition of these neurons during reinstatement reduced cue-induced drug-seeking, but only in the high-risk addiction phenotype group. Cue-induced reinstatement was relatively normal in the low-risk addiction phenotype group, as well as following reinstatement to cues associated with sucrose pellet consumption. These results demonstrate that dorsomedial direct pathway striatal neurons play a very specific role in addictive behaviors, which is to regulate the pathological drug-seeking that accompanies relapse.
C1 [Yager, Lindsay M.; Garcia, Aaron F.; Donckels, Elizabeth A.; Ferguson, Susan M.] Seattle Childrens Res Inst, Ctr Integrat Brain Res, Seattle, WA 98101 USA.
   [Garcia, Aaron F.; Ferguson, Susan M.] Univ Washington, Grad Program Neurosci, Seattle, WA 98195 USA.
   [Ferguson, Susan M.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
C3 Seattle Children's Hospital; University of Washington; University of
   Washington Seattle; University of Washington; University of Washington
   Seattle
RP Ferguson, SM (通讯作者)，Seattle Childrens Res Inst, Ctr Integrat Brain Res, Seattle, WA 98101 USA.; Ferguson, SM (通讯作者)，Univ Washington, Dept Psychiat & Behav Sci, Grad Program Neurosci, Seattle, WA 98195 USA.
EM smfergus@uw.edu
RI Core, Vector/CAF-4832-2022
FU National Institute on Drug Abuse [T32DA007278, R01DA036582]
FX We thank Dr. John Neumaier and Dr. Michelle Kelly for providing the
   CAV2-Cre virus for this work and Ms. Anna Surowiecki for assistance in
   running the behavioral assays. This work was supported by grants from
   the National Institute on Drug Abuse (T32DA007278 to LMF and AFG and
   R01DA036582 to SMF).
CR ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X
   Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244
   Armbruster BN, 2007, P NATL ACAD SCI USA, V104, P5163, DOI 10.1073/pnas.0700293104
   Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9
   Bock R, 2013, NAT NEUROSCI, V16, P632, DOI 10.1038/nn.3369
   Calabresi P, 2014, NAT NEUROSCI, V17, P1022, DOI 10.1038/nn.3743
   Calipari ES, 2016, P NATL ACAD SCI USA, V113, P2726, DOI 10.1073/pnas.1521238113
   Crombag HS, 2000, BEHAV BRAIN RES, V116, P1, DOI 10.1016/S0166-4328(00)00243-6
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Everitt BJ, 2016, ANNU REV PSYCHOL, V67, P23, DOI 10.1146/annurev-psych-122414-033457
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Ferguson SM, 2011, NAT NEUROSCI, V14, P22, DOI 10.1038/nn.2703
   Gerfen CR, 2011, ANNU REV NEUROSCI, V34, P441, DOI 10.1146/annurev-neuro-061010-113641
   Gomez JL, 2017, SCIENCE, V357, P503, DOI 10.1126/science.aan2475
   Hikida T, 2010, NEURON, V66, P896, DOI 10.1016/j.neuron.2010.05.011
   Kerstetter KA, 2016, NEUROPSYCHOPHARMACOL, V41, P1128, DOI 10.1038/npp.2015.253
   Kremer EJ, 2000, J VIROL, V74, P505, DOI 10.1128/JVI.74.1.505-512.2000
   Lobo MK, 2011, FRONT NEUROANAT, V5, DOI 10.3389/fnana.2011.00041
   Lobo MK, 2010, SCIENCE, V330, P385, DOI 10.1126/science.1188472
   MacLaren D. A., 2016, ENEURO, V3, P1, DOI DOI 10.1523/ENEUR0.0219-16.2016
   Mahler SV, 2014, NAT NEUROSCI, V17, P577, DOI 10.1038/nn.3664
   Moussawi K, 2011, P NATL ACAD SCI USA, V108, P385, DOI 10.1073/pnas.1011265108
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   Parent A, 2000, TRENDS NEUROSCI, V23, pS20, DOI 10.1016/S1471-1931(00)00022-7
   Patel TP, 2015, J NEUROSCI METH, V243, P26, DOI 10.1016/j.jneumeth.2015.01.020
   Penberthy Jennifer K, 2010, Curr Drug Abuse Rev, V3, P49
   Self DW, 2010, RECEPT SER, P479, DOI 10.1007/978-1-60327-333-6_17
   Smith RJ, 2013, CURR OPIN NEUROBIOL, V23, P546, DOI 10.1016/j.conb.2013.01.026
   Stefanik MT, 2013, J NEUROSCI, V33, P13654, DOI 10.1523/JNEUROSCI.1570-13.2013
   Sternson SM, 2014, ANNU REV NEUROSCI, V37, DOI 10.1146/annurev-neuro-071013-014048
   Vogelstein JT, 2010, J NEUROPHYSIOL, V104, P3691, DOI 10.1152/jn.01073.2009
   Volkow ND, 2013, CURR OPIN NEUROBIOL, V23, P639, DOI 10.1016/j.conb.2013.01.002
   Wunsch AM, 2017, EUR J NEUROSCI, V46, P1850, DOI 10.1111/ejn.13631
   Yager LM, 2015, NEUROSCIENCE, V301, P529, DOI 10.1016/j.neuroscience.2015.06.033
   Zimmer BA, 2012, NEUROPSYCHOPHARMACOL, V37, P1901, DOI 10.1038/npp.2012.37
NR 35
TC 17
Z9 17
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1355-6215
EI 1369-1600
J9 ADDICT BIOL
JI Addict. Biol.
PD MAR
PY 2019
VL 24
IS 2
BP 251
EP 264
DI 10.1111/adb.12594
PG 14
WC Biochemistry & Molecular Biology; Substance Abuse
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Substance Abuse
GA HL1EJ
UT WOS:000458437000009
PM 29314464
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Che, XH
   Cai, JL
   Liu, YY
   Xu, TY
   Yang, JY
   Wu, CF
AF Che, Xiaohang
   Cai, Jialing
   Liu, Yueyang
   Xu, Tianyu
   Yang, Jingyu
   Wu, Chunfu
TI Oxytocin signaling in the treatment of drug addiction: Therapeutic
   opportunities and challenges
SO PHARMACOLOGY & THERAPEUTICS
LA English
DT Review
DE Addiction; Dependence; Oxytocin; Reward; Treatment
ID MEDIAL PREFRONTAL CORTEX; METHAMPHETAMINE-SEEKING BEHAVIOR;
   CORTICOTROPIN-RELEASING HORMONE; CONDITIONED PLACE PREFERENCE;
   NUCLEUS-ACCUMBENS CORE; PROLYL-D-LEUCINE; INTRANASAL OXYTOCIN;
   RECEPTOR-BINDING; NEUROHYPOPHYSEAL HORMONES; MORPHINE-TOLERANCE
AB Drug addiction is one of the leading causes of mortality worldwide. Despite great advances were achieved in un-derstanding the neurobiology of drug addiction, the therapeutic options are severely limited, with poor effective-ness and serious side effects. The neuropeptide oxytocin (OXT) is well known for its effects on uterine contraction, sexual/maternal behaviors, social affiliation, stress and learning/memory by interacting with the OXT receptor and other neuromodulators. Emerging evidence suggests that the acute or chronic exposure to drugs can affect the OXT system. Additionally, OXT administration can ameliorate a wide range of abused drug-induced neurobehavioral changes. Overall, OXT not only suppresses drug reward in the binge stage of drug addiction, but also reduces stress responses and social impairments during the withdrawal stage and, fi- nally, prevents drug/cue/stress-induced reinstatement. More importantly, clinical studies have also shown that OXT can exert beneficial effects on reducing substance use disorders of a series of drugs, such as heroin, cocaine, alcohol, cannabis and nicotine. Thus, the present review focuses on the role of OXT in treating drug addiction, in-cluding the preclinical and clinical therapeutic potential of OXT and its analogs on the neurobiological perspec-tives of drugs, to provide a better insight of the efficacy of OXT as a clinical addiction therapeutic agent.
   (c) 2021 Elsevier Inc. All rights reserved.
C1 [Che, Xiaohang; Cai, Jialing; Liu, Yueyang; Xu, Tianyu; Yang, Jingyu; Wu, Chunfu] Shenyang Pharmaceut Univ, Dept Pharmacol, 103 Wenhua Rd, Shenyang, Peoples R China.
   [Che, Xiaohang; Liu, Yueyang; Yang, Jingyu; Wu, Chunfu] Shenyang Pharmaceut Univ, Key Lab New Drug Screening Liaoning Prov, Shenyang, Peoples R China.
   [Che, Xiaohang; Liu, Yueyang; Yang, Jingyu; Wu, Chunfu] Shenyang Pharmaceut Univ, Key Lab New Drug Pharmacodynam Evaluat Liaoning P, Shenyang, Peoples R China.
C3 Shenyang Pharmaceutical University; Shenyang Pharmaceutical University;
   Shenyang Pharmaceutical University
RP Yang, JY; Wu, CF (通讯作者)，Shenyang Pharmaceut Univ, Dept Pharmacol, 103 Wenhua Rd, Shenyang, Peoples R China.
EM yangjingyu2006@gmail.com; wucf@syphu.edu.cn
RI Che, Xiaohang/GWM-6783-2022
OI Che, Xiaohang/0000-0002-8910-0205
CR Acheson D, 2013, PSYCHOPHARMACOLOGY, V229, P199, DOI 10.1007/s00213-013-3099-4
   Akerlund M, 1999, BRIT J OBSTET GYNAEC, V106, P1047, DOI 10.1111/j.1471-0528.1999.tb08112.x
   Althammer F, 2018, J NEUROENDOCRINOL, V30, DOI 10.1111/jne.12549
   Andres M, 2004, EUR J PHARMACOL, V501, P59, DOI 10.1016/j.ejphar.2004.08.026
   Aragona BJ, 2006, NAT NEUROSCI, V9, P133, DOI 10.1038/nn1613
   Argiolas A, 2013, PROG NEUROBIOL, V108, P80, DOI 10.1016/j.pneurobio.2013.06.006
   Arima H, 2000, J NEUROENDOCRINOL, V12, P833, DOI 10.1046/j.1365-2826.2000.00528.x
   Avery SN, 2016, NEUROPSYCHOPHARMACOL, V41, P126, DOI 10.1038/npp.2015.185
   BAGDY G, 1995, EUR J PHARMACOL, V275, P301, DOI 10.1016/0014-2999(95)00051-L
   Bahi A, 2015, PHYSIOL BEHAV, V139, P321, DOI 10.1016/j.physbeh.2014.11.046
   Bai YH, 2002, YONSEI MED J, V43, P567, DOI 10.3349/ymj.2002.43.5.567
   Baik JH, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00152
   Baracz SJ, 2020, NEUROSCI BIOBEHAV R, V110, P114, DOI 10.1016/j.neubiorev.2018.08.014
   Baracz SJ, 2016, ADDICT BIOL, V21, P316, DOI 10.1111/adb.12198
   Baracz SJ, 2012, BEHAV BRAIN RES, V228, P185, DOI 10.1016/j.bbr.2011.11.038
   Baracz SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136132
   Barot SK, 2007, EUR J NEUROSCI, V25, P3125, DOI 10.1111/j.1460-9568.2007.05568.x
   Baskerville TA, 2009, EUR J NEUROSCI, V30, P2151, DOI 10.1111/j.1460-9568.2009.06999.x
   Baskerville TA, 2010, CNS NEUROSCI THER, V16, pe92, DOI 10.1111/j.1755-5949.2010.00154.x
   Beard R, 2018, BIOORGAN MED CHEM, V26, P3039, DOI 10.1016/j.bmc.2018.03.019
   Bentzley BS, 2014, P NATL ACAD SCI USA, V111, P11822, DOI 10.1073/pnas.1406324111
   Bernheim A, 2017, PHARMACOL BIOCHEM BE, V161, P13, DOI 10.1016/j.pbb.2017.08.012
   Bloomfield MAP, 2019, PHARMACOL THERAPEUT, V195, P132, DOI 10.1016/j.pharmthera.2018.10.006
   Boning J, 2009, PHARMACOPSYCHIATRY, V42, pS66, DOI 10.1055/s-0029-1216357
   Borroto-Escuela DO, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00037
   Borthwick AD, 2012, J MED CHEM, V55, P783, DOI 10.1021/jm201287w
   Borycz J, 2008, NEUROPSYCHOPHARMACOL, V33, P619, DOI 10.1038/sj.npp.1301445
   Bosch OJ, 2016, PSYCHONEUROENDOCRINO, V64, P66, DOI 10.1016/j.psyneuen.2015.11.011
   Bowen MT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027237
   Breiter HC, 1997, NEURON, V19, P591, DOI 10.1016/S0896-6273(00)80374-8
   Buisman-Pijlman FTA, 2014, PHARMACOL BIOCHEM BE, V119, P22, DOI 10.1016/j.pbb.2013.09.005
   Busnelli M, 2012, J BIOL CHEM, V287, P3617, DOI 10.1074/jbc.M111.277178
   Carson DS, 2013, J PSYCHOPHARMACOL, V27, P231, DOI 10.1177/0269881112473788
   Carson DS, 2010, NEUROPHARMACOLOGY, V58, P38, DOI 10.1016/j.neuropharm.2009.06.018
   Carter CS, 2014, ANNU REV PSYCHOL, V65, P17, DOI 10.1146/annurev-psych-010213-115110
   Cervo L, 1997, BRAIN RES, V775, P30, DOI 10.1016/S0006-8993(97)00866-4
   Chadman KK, 2019, EXPERT OPIN DRUG DIS, V14, P727, DOI 10.1080/17460441.2019.1621285
   Charlson FJ, 2016, LANCET, V388, P376, DOI 10.1016/S0140-6736(16)30590-6
   Chini B, 2003, BRIT J CANCER, V89, P930, DOI 10.1038/sj.bjc.6601189
   CLARKE G, 1983, NEUROSCI LETT, V39, P175, DOI 10.1016/0304-3940(83)90073-3
   Cox BM, 2017, BIOL PSYCHIAT, V81, P949, DOI 10.1016/j.biopsych.2016.11.011
   Cox BM, 2013, PSYCHONEUROENDOCRINO, V38, P2343, DOI 10.1016/j.psyneuen.2013.05.005
   Dabrowska J, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00156
   Dabrowska J, 2011, PSYCHONEUROENDOCRINO, V36, P1312, DOI 10.1016/j.psyneuen.2011.03.003
   Damien G, 2018, CLIN BIOCHEM, V62, P55, DOI 10.1016/j.clinbiochem.2018.10.016
   de Araujo AD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4165
   De Deurwaerdere P, 2017, PROG NEUROBIOL, V151, P175, DOI 10.1016/j.pneurobio.2016.03.004
   DeMayo MM, 2019, NEUROSCI BIOBEHAV R, V107, P388, DOI 10.1016/j.neubiorev.2019.09.034
   Demiselle J, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-0628-2
   Dong Y, 2017, J NEUROSCI, V37, P10867, DOI 10.1523/JNEUROSCI.1821-17.2017
   Dos Santos RG, 2019, CNS DRUGS, V33, P1031, DOI 10.1007/s40263-019-00669-5
   Eckstrand KL, 2019, FRONT BEHAV NEUROSCI, V13, DOI 10.3389/fnbeh.2019.00209
   Eliava M, 2016, NEURON, V89, P1291, DOI 10.1016/j.neuron.2016.01.041
   Engel S, 2019, NEUROSCI BIOBEHAV R, V107, P560, DOI 10.1016/j.neubiorev.2019.08.003
   Engel S, 2019, PSYCHONEUROENDOCRINO, V101, P138, DOI 10.1016/j.psyneuen.2018.11.011
   Estes MK, 2019, NEUROSCIENCE, V408, P226, DOI 10.1016/j.neuroscience.2019.04.006
   Everett N, 2019, PHARMACOL BIOCHEM BE, V183, P64, DOI 10.1016/j.pbb.2019.06.002
   Everett NA, 2018, NEUROPHARMACOLOGY, V133, P1, DOI 10.1016/j.neuropharm.2017.12.036
   Exton-McGuinness MTJ, 2018, LEARN MEMORY, V25, P492, DOI 10.1101/lm.046771.117
   Fan XY, 2020, ADDICT BIOL, V25, DOI 10.1111/adb.12697
   Febo M, 2005, NEUROPSYCHOPHARMACOL, V30, P936, DOI 10.1038/sj.npp.1300653
   Febo M, 2009, NEUROSCI LETT, V465, P267, DOI 10.1016/j.neulet.2009.07.065
   Ferguson JN, 2000, NAT GENET, V25, P284, DOI 10.1038/77040
   Ferguson JN, 2001, J NEUROSCI, V21, P8278
   Ferrer-Perez C, 2019, NEUROPHARMACOLOGY, V146, P50, DOI 10.1016/j.neuropharm.2018.11.011
   Freeman SM, 2016, PSYCHONEUROENDOCRINO, V66, P185, DOI 10.1016/j.psyneuen.2016.01.014
   Freidinger RM, 1997, MED RES REV, V17, P1, DOI 10.1002/(SICI)1098-1128(199701)17:1<1::AID-MED1>3.0.CO;2-5
   Gajewski PA, 2019, J NEUROSCI, V39, P8305, DOI 10.1523/JNEUROSCI.0800-19.2019
   Geisler S, 2008, REV NEUROSCIENCE, V19, P227
   Georgiou P, 2016, EUR J NEUROSCI, V44, P2446, DOI 10.1111/ejn.13348
   Georgiou P, 2016, NEUROPHARMACOLOGY, V105, P520, DOI 10.1016/j.neuropharm.2016.02.012
   Georgiou P, 2015, EUR NEUROPSYCHOPHARM, V25, P2459, DOI 10.1016/j.euroneuro.2015.09.015
   Georgiou P, 2015, ADDICT BIOL, V20, P902, DOI 10.1111/adb.12208
   GOLUBOW J, 1963, P SOC EXP BIOL MED, V112, P218, DOI 10.3181/00379727-112-27997
   Grieder TE, 2014, NAT NEUROSCI, V17, P1751, DOI 10.1038/nn.3872
   Grinevich V, 2016, BIOL PSYCHIAT, V79, P155, DOI 10.1016/j.biopsych.2015.04.013
   Grund T, 2019, PSYCHONEUROENDOCRINO, V106, P77, DOI 10.1016/j.psyneuen.2019.03.019
   Gulliver D, 2019, TRENDS PHARMACOL SCI, V40, P22, DOI 10.1016/j.tips.2018.11.001
   Han WY, 2014, PHARMACOL BIOCHEM BE, V119, P80, DOI 10.1016/j.pbb.2013.11.014
   Hansson AC, 2018, NEUROPSYCHOPHARMACOL, V43, P1235, DOI 10.1038/npp.2017.257
   Hargreaves GA, 2007, NEUROSCIENCE, V145, P764, DOI 10.1016/j.neuroscience.2006.12.023
   Hasan MT, 2019, NEURON, V103, P133, DOI 10.1016/j.neuron.2019.04.029
   Havranek T, 2015, J NEUROSCI RES, V93, P893, DOI 10.1002/jnr.23559
   Hayes DJ, 2011, NEUROSCI BIOBEHAV R, V35, P1419, DOI 10.1016/j.neubiorev.2011.03.005
   Hew-Butler T, 2010, SPORTS MED, V40, P459, DOI 10.2165/11532070-000000000-00000
   Hicks C, 2016, ADDICT BIOL, V21, P304, DOI 10.1111/adb.12197
   Higashida H, 2016, J PHYSIOL SCI, V66, P275, DOI 10.1007/s12576-015-0425-0
   Higgins GA, 2020, PHARMACOL THERAPEUT, V205, DOI 10.1016/j.pharmthera.2019.107417
   Hoge E, 2019, GEN PSYCHIAT, V32, DOI 10.1136/gpsych-2019-100131
   Holman PJ, 2018, HORM BEHAV, V105, P115, DOI 10.1016/j.yhbeh.2018.08.004
   Holubova A, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00305
   Hu JC, 2019, PSYCHOPHARMACOLOGY, V236, P293, DOI 10.1007/s00213-018-5074-6
   IBRAGIMOV R, 1987, LIFE SCI, V41, P1265, DOI 10.1016/0024-3205(87)90205-0
   Ibragimov R Sh, 1990, Neurosci Behav Physiol, V20, P189, DOI 10.1007/BF01195453
   Izuma K, 2008, NEURON, V58, P284, DOI 10.1016/j.neuron.2008.03.020
   Japundzic-Zigon N, 2020, CURR NEUROPHARMACOL, V18, P14, DOI 10.2174/1570159X17666190717150501
   Jarrett TM, 2006, NEUROPEPTIDES, V40, P161, DOI 10.1016/j.npep.2006.03.002
   JASPER JR, 1995, LIFE SCI, V57, P2253, DOI 10.1016/0024-3205(95)02218-8
   JODOGNE C, 1991, PHARMACOL BIOCHEM BE, V40, P261, DOI 10.1016/0091-3057(91)90549-H
   JOHNS JM, 1993, NEUROPEPTIDES, V24, P165, DOI 10.1016/0143-4179(93)90081-K
   Johns JM, 2010, PSYCHOPHARMACOLOGY, V211, P175, DOI 10.1007/s00213-010-1877-9
   Jorgensen H, 2003, J NEUROENDOCRINOL, V15, P564, DOI 10.1046/j.1365-2826.2003.01032.x
   Jorgensen WT, 2018, EUR J MED CHEM, V143, P1644, DOI 10.1016/j.ejmech.2017.10.059
   Joseph JE, 2019, PSYCHOPHARMACOLOGY, DOI 10.1007/s00213-019-05360-7
   Juif PE, 2013, PAIN, V154, P1449, DOI 10.1016/j.pain.2013.05.003
   Jurek B, 2018, PHYSIOL REV, V98, P1805, DOI 10.1152/physrev.00031.2017
   Jurek B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037060
   Kerstetter KA, 2016, NEUROPSYCHOPHARMACOL, V41, P1128, DOI 10.1038/npp.2015.253
   Kibaly C, 2019, NAT REV NEUROSCI, V20, P5, DOI 10.1038/s41583-018-0092-2
   Kim JH, 2017, NEUROBIOL LEARN MEM, V138, P252, DOI 10.1016/j.nlm.2016.10.018
   Kim S, 2017, ANN NY ACAD SCI, V1394, P74, DOI 10.1111/nyas.13140
   Kimura Y, 2008, EUR J PHARMACOL, V589, P157, DOI 10.1016/j.ejphar.2008.05.022
   King CE, 2017, ALCOHOL CLIN EXP RES, V41, P955, DOI 10.1111/acer.13359
   King LB, 2016, BIOL PSYCHIAT, V80, P160, DOI 10.1016/j.biopsych.2015.12.008
   Kirkpatrick MG, 2014, PSYCHONEUROENDOCRINO, V46, P23, DOI 10.1016/j.psyneuen.2014.04.006
   Knobloch HS, 2012, NEURON, V73, P553, DOI 10.1016/j.neuron.2011.11.030
   Kohtz AS, 2018, PSYCHOPHARMACOLOGY, V235, P2051, DOI 10.1007/s00213-018-4902-z
   Koob GF, 2016, LANCET PSYCHIAT, V3, P760, DOI 10.1016/S2215-0366(16)00104-8
   Koob GF, 2014, NEUROPHARMACOLOGY, V76, P370, DOI 10.1016/j.neuropharm.2013.05.024
   KOVACS GL, 1985, LIFE SCI, V37, P1895, DOI 10.1016/0024-3205(85)90007-4
   KOVACS GL, 1985, PSYCHOPHARMACOLOGY, V86, P377, DOI 10.1007/BF00432233
   KOVACS GL, 1985, BRAIN RES, V328, P158, DOI 10.1016/0006-8993(85)91336-8
   KOVACS GL, 1985, NEUROPHARMACOLOGY, V24, P413, DOI 10.1016/0028-3908(85)90026-7
   KOVACS GL, 1985, LIFE SCI, V37, P17, DOI 10.1016/0024-3205(85)90620-4
   KOVACS GL, 1984, BEHAV BRAIN RES, V14, P1, DOI 10.1016/0166-4328(84)90014-7
   KOVACS GL, 1987, EXP BRAIN RES, V65, P307
   KOVACS GL, 1990, NEUROPHARMACOLOGY, V29, P365, DOI 10.1016/0028-3908(90)90095-9
   KOVACS GL, 1987, J PHARMACOL EXP THER, V241, P569
   KOVACS GL, 1986, DRUG ALCOHOL DEPEN, V17, P369, DOI 10.1016/0376-8716(86)90087-6
   LAMBERT RC, 1993, NEUROSCIENCE, V57, P1027, DOI 10.1016/0306-4522(93)90046-I
   Laorden ML, 1997, NEUROPEPTIDES, V31, P143, DOI 10.1016/S0143-4179(97)90083-4
   Lawson SK, 2016, BEHAV BRAIN RES, V314, P52, DOI 10.1016/j.bbr.2016.07.027
   Lee MR, 2014, EUR NEUROPSYCHOPHARM, V24, P1483, DOI 10.1016/j.euroneuro.2014.06.005
   Leng G, 2019, J NEUROENDOCRINOL, V31, DOI 10.1111/jne.12662
   Leong KC, 2017, INT J NEUROPSYCHOPH, V20, P844, DOI 10.1093/ijnp/pyx058
   Leong KC, 2016, EXP CLIN PSYCHOPHARM, V24, P55, DOI 10.1037/pha0000058
   Li JH, 2001, NEUROSCI LETT, V300, P54, DOI 10.1016/S0304-3940(01)01540-3
   Li K, 2016, CELL, V167, P60, DOI 10.1016/j.cell.2016.08.067
   Liddle J, 2008, BIOORG MED CHEM LETT, V18, P90, DOI 10.1016/j.bmcl.2007.11.008
   Lieber SR, 2018, J HEPATOL, V68, P586, DOI [10.1016/j.jhep.2017.09.013, 10.1016/j.jhep.2017.10.024]
   Light KC, 2004, ADDICT BEHAV, V29, P1541, DOI 10.1016/j.addbeh.2004.02.062
   Lin YT, 2018, PROG NEUROBIOL, V171, P1, DOI 10.1016/j.pneurobio.2018.10.003
   Lindow SW, 1999, GYNECOL OBSTET INVES, V48, P33, DOI 10.1159/000010130
   Litt MD, 2016, DRUG ALCOHOL DEPEN, V165, P203, DOI 10.1016/j.drugalcdep.2016.06.010
   Lloyd RB, 2011, CURR TOP MED CHEM, V11, P609
   Ludwig M, 2002, NATURE, V418, P85, DOI 10.1038/nature00822
   Luthi A, 2014, NAT NEUROSCI, V17, P1635, DOI 10.1038/nn.3849
   Lukas M, 2013, PSYCHONEUROENDOCRINO, V38, P916, DOI 10.1016/j.psyneuen.2012.09.018
   Luscher C, 2016, ANNU REV NEUROSCI, V39, P257, DOI 10.1146/annurev-neuro-070815-013920
   LUTZBUCHER B, 1980, EUR J PHARMACOL, V66, P375, DOI 10.1016/0014-2999(80)90470-7
   MacFadyen K, 2016, PHARMACOL BIOCHEM BE, V140, P27, DOI 10.1016/j.pbb.2015.10.014
   Maejima Y, 2018, NEUROENDOCRINOLOGY, V107, P91, DOI 10.1159/000489263
   Manbeck KE, 2014, PHARMACOL BIOCHEM BE, V116, P84, DOI 10.1016/j.pbb.2013.11.002
   Manning M, 2005, J PEPT SCI, V11, P593, DOI 10.1002/psc.667
   Manning M, 2012, J NEUROENDOCRINOL, V24, P609, DOI 10.1111/j.1365-2826.2012.02303.x
   MANNING M, 1989, J MED CHEM, V32, P382, DOI 10.1021/jm00122a016
   MANNING M, 1995, INT J PEPT PROT RES, V46, P244
   Matsushita H, 2019, NEUROSCIENCE, V417, P1, DOI 10.1016/j.neuroscience.2019.07.046
   McMurray MS, 2008, NEUROTOXICOL TERATOL, V30, P475, DOI 10.1016/j.ntt.2008.07.001
   McMurray MS, 2008, STRESS, V11, P398, DOI 10.1080/10253890701850239
   McMurray MS, 2008, NEUROPEPTIDES, V42, P641, DOI 10.1016/j.npep.2008.05.003
   McRae-Clark AL, 2013, PSYCHOPHARMACOLOGY, V228, P623, DOI 10.1007/s00213-013-3062-4
   Melby K, 2019, DRUG ALCOHOL DEPEN, V197, P95, DOI 10.1016/j.drugalcdep.2019.01.003
   Mendez JA, 2011, J BIOL CHEM, V286, P23928, DOI 10.1074/jbc.M111.218032
   Menon R, 2018, CURR BIOL, V28, P1066, DOI 10.1016/j.cub.2018.02.044
   MENS WBJ, 1983, BRAIN RES, V262, P143, DOI 10.1016/0006-8993(83)90478-X
   Mitchell JM, 2016, J ADDICT MED, V10, P182, DOI 10.1097/ADM.0000000000000213
   Moaddab M, 2015, PSYCHONEUROENDOCRINO, V53, P159, DOI 10.1016/j.psyneuen.2015.01.003
   Moeini M, 2019, EUR ADDICT RES, V25, P41, DOI 10.1159/000496194
   Morales-Rivera A, 2014, PSYCHOPHARMACOLOGY, V231, P4145, DOI 10.1007/s00213-014-3553-y
   Muller CP, 2015, BEHAV BRAIN RES, V277, P146, DOI 10.1016/j.bbr.2014.04.007
   Muttenthaler M, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aan3398
   Muttenthaler M, 2010, J MED CHEM, V53, P8585, DOI 10.1021/jm100989w
   Neumann I, 1996, J NEUROENDOCRINOL, V8, P227, DOI 10.1046/j.1365-2826.1996.04557.x
   Neumann I D, 2001, Prog Brain Res, V133, P143
   Neumann ID, 2016, BIOL PSYCHIAT, V79, P213, DOI 10.1016/j.biopsych.2015.06.004
   Neumann ID, 2013, PSYCHONEUROENDOCRINO, V38, P1985, DOI 10.1016/j.psyneuen.2013.03.003
   Nilsson L, 2003, BJOG-INT J OBSTET GY, V110, P1025, DOI 10.1016/S1470-0328(03)20540-1
   Ninan I, 2011, J NEUROCHEM, V119, P324, DOI 10.1111/j.1471-4159.2011.07430.x
   Ornoy A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051074
   Palacios JM, 2017, PSYCHOPHARMACOLOGY, V234, P1395, DOI 10.1007/s00213-017-4545-5
   Palgi S, 2015, SOC COGN AFFECT NEUR, V10, P311, DOI 10.1093/scan/nsu040
   Pandey GN, 2019, PSYCHONEUROENDOCRINO, V106, P233, DOI 10.1016/j.psyneuen.2019.04.015
   Parsons LH, 1998, J NEUROSCI, V18, P10078
   Passoni I, 2016, J NEUROENDOCRINOL, V28, DOI 10.1111/jne.12363
   Pedersen CA, 2013, ALCOHOL CLIN EXP RES, V37, P484, DOI 10.1111/j.1530-0277.2012.01958.x
   Pelloux Y, 2019, NEUROPHARMACOLOGY, V159, DOI 10.1016/j.neuropharm.2019.02.027
   Peters S, 2014, PSYCHONEUROENDOCRINO, V42, P225, DOI 10.1016/j.psyneuen.2014.01.021
   Peters S, 2013, ADDICT BIOL, V18, P66, DOI 10.1111/adb.12001
   Peters ST, 2017, ADDICT BIOL, V22, P702, DOI 10.1111/adb.12362
   Pistillo F, 2016, PHARMACOL RES, V103, P167, DOI 10.1016/j.phrs.2015.11.016
   PUCILOWSKI O, 1985, PEPTIDES, V6, P7, DOI 10.1016/0196-9781(85)90067-1
   Puder BA, 2001, J NEUROSCI RES, V64, P53, DOI 10.1002/jnr.1053
   Qi J, 2008, N-S ARCH PHARMACOL, V376, P441, DOI 10.1007/s00210-007-0245-8
   Qi J, 2012, ADDICT BIOL, V17, P758, DOI 10.1111/j.1369-1600.2012.00439.x
   Qi J, 2009, NEUROPHARMACOLOGY, V56, P856, DOI 10.1016/j.neuropharm.2009.01.010
   Quintana DS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08503-8
   Raam T, 2020, J NEUROSCI, V40, P1194, DOI 10.1523/JNEUROSCI.1348-19.2019
   Rae M, 2018, NEUROPHARMACOLOGY, V138, P267, DOI 10.1016/j.neuropharm.2018.06.013
   Reversi A, 2005, J BIOL CHEM, V280, P16311, DOI 10.1074/jbc.M409945200
   Rich MT, 2020, J NEUROSCI, V40, P1344, DOI 10.1523/JNEUROSCI.0453-19.2019
   RIGTER H, 1980, PHARMACOL BIOCHEM BE, V13, P285, DOI 10.1016/S0091-3057(80)80043-8
   RYDEN G, 1969, ACTA ENDOCRINOL-COP, V61, P425, DOI 10.1530/acta.0.0610425
   SARNYAI Z, 1992, PHARMACOL BIOCHEM BE, V43, P491, DOI 10.1016/0091-3057(92)90182-F
   SARNYAI Z, 1992, NEUROPEPTIDES, V23, P27, DOI 10.1016/0143-4179(92)90006-I
   SARNYAI Z, 1994, PSYCHONEUROENDOCRINO, V19, P85, DOI 10.1016/0306-4530(94)90062-0
   Sarnyai Z, 1990, Neuroreport, V1, P200, DOI 10.1097/00001756-199011000-00006
   Shahrokh DK, 2010, ENDOCRINOLOGY, V151, P2276, DOI 10.1210/en.2009-1271
   Sharifzadeh M, 2006, PHARMACOL BIOCHEM BE, V85, P705, DOI 10.1016/j.pbb.2006.10.027
   Shi YH, 2020, PSYCHOPHARMACOLOGY, V237, P869, DOI 10.1007/s00213-019-05423-9
   Silva SM, 2002, BRAIN RES, V925, P76, DOI 10.1016/S0006-8993(01)03261-9
   Simpson EA, 2017, PSYCHOPHARMACOLOGY, V234, P497, DOI 10.1007/s00213-016-4480-x
   Singewald N, 2015, PHARMACOL THERAPEUT, V149, P150, DOI 10.1016/j.pharmthera.2014.12.004
   Sivukhina EV, 2006, HORM METAB RES, V38, P382, DOI 10.1055/s-2006-944522
   Smith MA, 2020, DRUG ALCOHOL DEPEN, V206, DOI 10.1016/j.drugalcdep.2019.107733
   SOUSA N, 1995, ALCOHOL CLIN EXP RES, V19, P879, DOI 10.1111/j.1530-0277.1995.tb00962.x
   Stauffer CS, 2016, ADDICT RES THEORY, V24, P490, DOI 10.3109/16066359.2016.1173682
   Steinman MQ, 2019, BIOL PSYCHIAT, V85, P792, DOI 10.1016/j.biopsych.2018.10.008
   Stevenson JR, 2017, PHYSIOL BEHAV, V179, P411, DOI 10.1016/j.physbeh.2017.07.021
   Stevenson JR, 2017, ALCOHOL CLIN EXP RES, V41, P1444, DOI 10.1111/acer.13430
   Strathearn L, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00737
   Strauss GP, 2019, J PSYCHIATR RES, V112, P38, DOI 10.1016/j.jpsychires.2019.02.017
   Stuber GD, 2011, NATURE, V475, P377, DOI 10.1038/nature10194
   Stymiest JL, 2005, J ORG CHEM, V70, P7799, DOI 10.1021/jo050539l
   Subramanian MG, 1999, ALCOHOL, V19, P51, DOI 10.1016/S0741-8329(99)00017-8
   SUMMYLONG JY, 1986, NEUROENDOCRINOLOGY, V44, P157, DOI 10.1159/000124639
   SZABO G, 1987, ALCOHOL ALCOHOLISM, V22, P71
   SZABO G, 1985, ALCOHOL, V2, P567, DOI 10.1016/0741-8329(85)90082-5
   SZABO G, 1989, ACTA PHYSIOL HUNG, V73, P97
   Tanaka A, 2018, MOL PHARMACEUT, V15, P1105, DOI 10.1021/acs.molpharmaceut.7b00991
   Tancin V, 2000, J DAIRY RES, V67, P13, DOI 10.1017/S0022029999003945
   TIRELLI E, 1992, PHARMACOL BIOCHEM BE, V43, P1263, DOI 10.1016/0091-3057(92)90512-E
   Tomizawa K, 2003, NAT NEUROSCI, V6, P384, DOI 10.1038/nn1023
   Triana-Del Rio R, 2019, PSYCHOPHARMACOLOGY, V236, P339, DOI 10.1007/s00213-018-5030-5
   UNODC, 2019, WORLD DRUG REPORT 20
   VANREE JM, 1977, EUR J PHARMACOL, V43, P199, DOI 10.1016/0014-2999(77)90132-7
   Verdejo-Garcia A, 2019, DIALOGUES CLIN NEURO, V21, P281, DOI 10.31887/DCNS.2019.21.3/gdom
   Volkow ND, 2019, PHYSIOL REV, V99, P2115, DOI 10.1152/physrev.00014.2018
   Vorel SR, 2001, SCIENCE, V292, P1175, DOI 10.1126/science.1058043
   Wachman EM, 2019, SEMIN FETAL NEONAT M, V24, P105, DOI 10.1016/j.siny.2019.01.002
   Waldherr M, 2007, P NATL ACAD SCI USA, V104, P16681, DOI 10.1073/pnas.0705860104
   Wang JL, 2017, BEHAV BRAIN RES, V334, P135, DOI 10.1016/j.bbr.2017.07.036
   Wang JL, 2014, NEUROPEPTIDES, V48, P29, DOI 10.1016/j.npep.2013.10.016
   Wang SC, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0514-0
   Weber RA, 2018, INT J NEUROPSYCHOPH, V21, P677, DOI 10.1093/ijnp/pyy025
   WILLIAMS PD, 1995, J MED CHEM, V38, P4634, DOI 10.1021/jm00023a002
   Williams SK, 2009, NEUROTOXICOL TERATOL, V31, P291, DOI 10.1016/j.ntt.2009.06.001
   Winter J, 2019, CELL TISSUE RES, V375, P85, DOI 10.1007/s00441-018-2866-2
   Wisniewski K, 2014, J MED CHEM, V57, P5306, DOI 10.1021/jm500365s
   Woolley JD, 2016, PSYCHOPHARMACOLOGY, V233, P2571, DOI 10.1007/s00213-016-4308-8
   Wu Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038402
   Wyatt PG, 2002, BIOORG MED CHEM LETT, V12, P1399, DOI 10.1016/S0960-894X(02)00159-2
   Xu L, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00056
   Yang JY, 2010, ACTA PHARMACOL SIN, V31, P1071, DOI 10.1038/aps.2010.140
   Yoshida M, 2009, J NEUROSCI, V29, P2259, DOI 10.1523/JNEUROSCI.5593-08.2009
   You ZD, 2000, NEUROREPORT, V11, P3113, DOI 10.1097/00001756-200009280-00015
   Young KA, 2014, J NEUROSCI, V34, P8499, DOI 10.1523/JNEUROSCI.4275-13.2014
   Zanos P, 2019, EUR J NEUROSCI, V50, P2255, DOI 10.1111/ejn.14155
   Zanos P, 2018, BRIT J PHARMACOL, V175, P2809, DOI 10.1111/bph.13757
   Zanos P, 2015, NEUROSCI LETT, V600, P33, DOI 10.1016/j.neulet.2015.05.054
   Zanos P, 2014, PHARMACOL BIOCHEM BE, V119, P72, DOI 10.1016/j.pbb.2013.05.009
   Zanos P, 2014, NEUROPSYCHOPHARMACOL, V39, P855, DOI 10.1038/npp.2013.285
   Zehra A, 2018, J NEUROIMMUNE PHARM, V13, P438, DOI 10.1007/s11481-018-9782-9
   Zeng H, 2018, FRONT BEHAV NEUROSCI, V12, DOI 10.3389/fnbeh.2018.00123
   Zhang KM, 2017, NEUROSCI LETT, V638, P5, DOI 10.1016/j.neulet.2016.12.005
   Zhang YX, 2018, NEUROPHARMACOLOGY, V141, P113, DOI 10.1016/j.neuropharm.2018.08.030
   Zhou LY, 2015, INT J NEUROPSYCHOPH, V18, DOI 10.1093/ijnp/pyu009
NR 267
TC 8
Z9 8
U1 7
U2 38
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0163-7258
EI 1879-016X
J9 PHARMACOL THERAPEUT
JI Pharmacol. Ther.
PD JUL
PY 2021
VL 223
AR 107820
DI 10.1016/j.pharmthera.2021.107820
EA FEB 2021
PG 18
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Pharmacology & Pharmacy
GA SN6KN
UT WOS:000658396700011
PM 33600854
DA 2023-06-23
ER

PT J
AU Quaglio, G
   Lugoboni, F
   Pajusco, B
   Fornasiero, A
   Lechi, A
   Mezzelani, P
   Pattaro, C
   Jarlais, DCD
AF Quaglio, G
   Lugoboni, F
   Pajusco, B
   Fornasiero, A
   Lechi, A
   Mezzelani, P
   Pattaro, C
   Jarlais, DCD
CA Investigators
TI Heterosexual relationships among heroin users in Italy
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE heterosexual relationships; partner; drug users
ID DRUG-USERS; GENDER-DIFFERENCES; SOCIAL RELATIONSHIPS; SEX-DIFFERENCES;
   CONDOM USE; HIV; VACCINATION; ABSTINENCE; INJECTION; ADDICTION
AB This study investigated how many stable partners of drug users (DUs) had a history of drug use or were current DUs. Of 589 DUs interviewed, 41% reported that they had a partner with current or previous experience of drug addiction. A strong gender difference emerged: 77% of female DUs reported a stable relationship with partners with a history of addiction, versus only 30% for male DUs. Partners with a history of drug dependence are more likely to be: male, older, with a lower educational level and a lower rate of stable employment than partners without a history of drug addiction. Logistic regression analysis indicated that the characteristics of heroin users who have current partners with histories of drug use include: female gender, older age, living with a partner, lengthy duration of the relationship and HIV positive status. Fewer subjects are married if the partner has a history of addiction, and there is an association between lengthy drug use and partner without drug addiction history. The high percentage (59%) of subjects who were in stable relationships with partners without histories of heroin addiction and the relatively long duration of these relationships, raises the issue of possible transmission of blood-borne viruses from the DUs to their sexual partners. The study does suggest the need for consideration of sexual partnerships and gender differences in providing drug abuse treatment for heroin users. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
C1 Univ Verona, Med Serv Addict Disorders, Dept Internal Med, Policlin GB Rossi, I-37134 Verona, Italy.
   Univ Verona, Dept Internal Med, I-37100 Verona, Italy.
   Univ Verona, Unit Epidemiol & Med Stat, Dept Med & Publ Hlth, I-37100 Verona, Italy.
   Beth Israel Med Ctr, Edmond De Rothschild Fdn Chem Dependency Inst, New York, NY 10003 USA.
C3 University of Verona; Azienda Ospedaliera Universitaria Integrata
   Verona; University of Verona; University of Verona; Harvard University;
   Beth Israel Deaconess Medical Center
RP Quaglio, G (通讯作者)，Univ Verona, Med Serv Addict Disorders, Dept Internal Med, Policlin GB Rossi, I-37134 Verona, Italy.
EM gianluca.quaglio@azosp.vr.it
RI SESM, SESM/C-1440-2008
CR Amaro H, 1995, J PSYCHOACTIVE DRUGS, V27, P325, DOI 10.1080/02791072.1995.10471698
   BAKER A, 1994, DRUG ALCOHOL DEPEN, V34, P155, DOI 10.1016/0376-8716(94)90136-8
   BECKMAN LJ, 1986, J STUD ALCOHOL, V47, P135, DOI 10.15288/jsa.1986.47.135
   Brancato G, 1997, AM J PUBLIC HEALTH, V87, P1654, DOI 10.2105/AJPH.87.10.1654
   CORDONE MR, 2000, 3 NAT C SPREAD NARC
   Evans JL, 2003, J URBAN HEALTH, V80, P137, DOI 10.1093/jurban/jtg137
   FINNEY JW, 1980, J CONSULT CLIN PSYCH, V48, P17, DOI 10.1037/0022-006X.48.1.17
   Gogineni A, 2001, DRUG ALCOHOL DEPEN, V64, P47, DOI 10.1016/S0376-8716(00)00230-1
   Grella CE, 1999, AM J DRUG ALCOHOL AB, V25, P385, DOI 10.1081/ADA-100101868
   HAVASSY BE, 1995, ADDICTION, V90, P699, DOI 10.1111/j.1360-0443.1995.tb02208.x
   HEARST N, 1988, JAMA-J AM MED ASSOC, V259, P2428, DOI 10.1001/jama.259.16.2428
   HIGGINS ST, 1994, AM J DRUG ALCOHOL AB, V20, P47, DOI 10.3109/00952999409084056
   HSER YI, 1987, AM J DRUG ALCOHOL AB, V13, P231, DOI 10.3109/00952998709001512
   Hurcom C, 2000, SUBST USE MISUSE, V35, P473, DOI 10.3109/10826080009147469
   KANE S, 1991, SOC SCI MED, V32, P1037, DOI 10.1016/0277-9536(91)90161-5
   KINGREE JB, 1995, AM J DRUG ALCOHOL AB, V21, P267, DOI 10.3109/00952999509002694
   Kwiatkowski CF, 1999, DRUG ALCOHOL DEPEN, V54, P57, DOI 10.1016/S0376-8716(98)00145-8
   Lugoboni F, 2002, ADDICTION, V97, P104, DOI 10.1046/j.1360-0443.2002.0050j.x
   Paone D, 1995, J Am Med Womens Assoc (1972), V50, P109
   Quaglio G, 2003, CLIN INFECT DIS, V37, P33, DOI 10.1086/375566
   Quaglio G, 2004, DRUG ALCOHOL DEPEN, V74, P85, DOI 10.1016/j.drugalcdep.2003.12.001
   Quaglio G, 2002, ADDICTION, V97, P985, DOI 10.1046/j.1360-0443.2002.00147.x
   Rhodes T., 2002, INT J DRUG POLICY, V13, P85
   Riehman KS, 2003, DRUG ALCOHOL DEPEN, V70, P1, DOI 10.1016/S0376-8716(02)00332-0
   Sherman SG, 2001, DRUG ALCOHOL DEPEN, V64, P97, DOI 10.1016/S0376-8716(00)00236-2
   THOM B, 1987, BRIT J ADDICT, V82, P989
   VELLEMAN R, 1993, ADDICTION, V88, P1281, DOI 10.1111/j.1360-0443.1993.tb02150.x
   WELLMAN B, 1997, SOC NET, V19, P127
   Westermeyer J, 2000, AM J DRUG ALCOHOL AB, V26, P523, DOI 10.1081/ADA-100101893
NR 29
TC 6
Z9 6
U1 0
U2 3
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND
SN 0376-8716
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD AUG 16
PY 2004
VL 75
IS 2
BP 207
EP 213
DI 10.1016/j.drugalcdep.2004.03.002
PG 7
WC Substance Abuse; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Substance Abuse; Psychiatry
GA 846JW
UT WOS:000223312800011
PM 15276227
DA 2023-06-23
ER

PT J
AU Sagheddu, C
   Melis, M
AF Sagheddu, Claudia
   Melis, Miriam
TI Individual Differences and Vulnerability to Drug Addiction: A Focus on
   the Endocannabinoid System
SO CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS
LA English
DT Article; Proceedings Paper
CT 181st Annual Meeting of the
   American-Association-for-the-Advancement-of-Science (AAAS)
CY FEB 12-16, 2015
CL San Jose, CA
SP Amer Assoc Advancement Sci
DE Dopamine; drug addiction; endocannabinoid; lipids; midbrain;
   vulnerability
ID VENTRAL TEGMENTAL AREA; MIDBRAIN DOPAMINE NEURONS; ACID AMIDE HYDROLASE;
   ENDOGENOUS CANNABINOID SYSTEM; EVOKED SYNAPTIC PLASTICITY; CONDITIONED
   PLACE PREFERENCE; LONG-TERM POTENTIATION; NUCLEUS-ACCUMBENS DOPAMINE;
   NEGATIVE REWARD SIGNALS; MU-OPIOID RECEPTORS
AB Vulnerability to drug addiction depends upon the interactions between the biological makeup of the individual, the environment, and age. These interactions are complex and difficult to tease apart. Since dopamine is involved in the rewarding effects of drugs of abuse, it is postulated that innate differences in mesocorticolimbic pathway can influence the response to drug exposure. In particular, higher and lower expression of dopamine D2 receptors in the ventral striatum (i.e. a marker of dopamine function) has been considered a putative protective and a risk factor, respectively, that can influence one's susceptibility to continued drug abuse as well as the transition to addiction. This phenomenon, which is phylogenetically preserved, appears to be a compensatory change to increased impulse activity of midbrain dopamine neurons. Hence, dopamine neuronal excitability plays a fundamental role in the diverse stages of the drug addiction cycle. In this review, a framework for the evidence that modulation of dopamine neuronal activity plays in the context of vulnerability to drug addiction will be presented. Furthermore, since endogenous cannabinoids serve as retrograde messengers to shape afferent neuronal activity in a short- and long-lasting fashion, their role in individual differences and vulnerability to drug addiction will be discussed.
C1 [Sagheddu, Claudia; Melis, Miriam] Univ Cagliari, Dept Biomed Sci, Div Neurosci & Clin Pharmacol, I-09042 Monserrato, CA, Italy.
C3 University of Cagliari
RP Melis, M (通讯作者)，Univ Cagliari, Dept Biomed Sci, I-09042 Monserrato, CA, Italy.
EM myriam@unica.it
RI SAGHEDDU, CLAUDIA/AIC-9000-2022; Melis, Miriam/AAF-3235-2020
OI SAGHEDDU, CLAUDIA/0000-0002-5315-2898; Melis, Miriam/0000-0001-9631-8651
CR Abbott LF, 2004, NATURE, V431, P796, DOI 10.1038/nature03010
   Abbott LF, 1997, SCIENCE, V275, P220, DOI 10.1126/science.275.5297.221
   Abizaid A, 2006, J CLIN INVEST, V116, P3229, DOI 10.1172/JCI29867
   Alger Bradley E, 2013, Cerebrum, V2013, P14
   Alger BE, 2012, J PHYSIOL-LONDON, V590, P2203, DOI 10.1113/jphysiol.2011.220855
   Anker JJ, 2011, CURR TOP BEHAV NEURO, V8, P73, DOI 10.1007/7854_2010_93
   Lopez-Moreno JA, 2012, J PSYCHOPHARMACOL, V26, P133, DOI 10.1177/0269881111416689
   Argilli E, 2008, J NEUROSCI, V28, P9092, DOI 10.1523/JNEUROSCI.1001-08.2008
   Baik JH, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00152
   Ballon N, 2006, PHARMACOGENOMICS J, V6, P126, DOI 10.1038/sj.tpj.6500352
   Bari M, 2006, MINI-REV MED CHEM, V6, P257, DOI 10.2174/138955706776073466
   Barrot M, 2012, J NEUROSCI, V32, P14094, DOI 10.1523/JNEUROSCI.3370-12.2012
   Basavarajappa BS, 2006, NEUROPHARMACOLOGY, V50, P834, DOI 10.1016/j.neuropharm.2005.12.005
   Battista N, 2012, FRONT BEHAV NEUROSCI, V6, DOI 10.3389/fnbeh.2012.00009
   Becker JB, 2001, ANN NY ACAD SCI, V937, P172, DOI 10.1111/j.1749-6632.2001.tb03564.x
   Becker JB, 2012, BIOL SEX DIFFER, V3, DOI 10.1186/2042-6410-3-14
   Belcher AM, 2014, TRENDS COGN SCI, V18, P211, DOI 10.1016/j.tics.2014.01.010
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   Bellone C, 2006, NAT NEUROSCI, V9, P636, DOI 10.1038/nn1682
   Benyamina A, 2011, ADDICT BIOL, V16, P1, DOI 10.1111/j.1369-1600.2009.00198.x
   Berghuis P, 2005, P NATL ACAD SCI USA, V102, P19115, DOI 10.1073/pnas.0509494102
   Berghuis P, 2007, SCIENCE, V316, P1212, DOI 10.1126/science.1137406
   Bernard C, 2005, P NATL ACAD SCI USA, V102, P9388, DOI 10.1073/pnas.0409641102
   Besson M, 2013, NEUROPSYCHOPHARMACOL, V38, P1963, DOI 10.1038/npp.2013.95
   Bierut LJ, 2011, NEURON, V69, P618, DOI 10.1016/j.neuron.2011.02.015
   Blednov YA, 2007, NEUROPSYCHOPHARMACOL, V32, P1570, DOI 10.1038/sj.npp.1301274
   Bobzean SAM, 2014, EXP NEUROL, V259, P64, DOI 10.1016/j.expneurol.2014.01.022
   Bock R, 2013, NAT NEUROSCI, V16, P632, DOI 10.1038/nn.3369
   Bocklisch C, 2013, SCIENCE, V341, P1521, DOI 10.1126/science.1237059
   Boden JM, 2011, ADDICTION, V106, P906, DOI 10.1111/j.1360-0443.2010.03351.x
   Borgland SL, 2009, J NEUROSCI, V29, P11215, DOI 10.1523/JNEUROSCI.6096-08.2009
   Brischoux F, 2009, P NATL ACAD SCI USA, V106, P4894, DOI 10.1073/pnas.0811507106
   Brodie MS, 2000, ALCOHOL CLIN EXP RES, V24, P1120, DOI 10.1097/00000374-200007000-00025
   Bromberg-Martin ES, 2010, NEURON, V68, P815, DOI 10.1016/j.neuron.2010.11.022
   Burton AC, 2015, NEUROBIOL LEARN MEM, V117, P51, DOI 10.1016/j.nlm.2014.05.003
   Butelman ER, 2012, TRENDS NEUROSCI, V35, P587, DOI 10.1016/j.tins.2012.05.005
   Cachope R, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00188
   Cadoni C, 2015, ADDICT BIOL, V20, P132, DOI 10.1111/adb.12085
   Cani PD, 2014, DIABETES METAB, V40, P246, DOI 10.1016/j.diabet.2014.02.004
   Carroll ME, 2010, HORM BEHAV, V58, P44, DOI 10.1016/j.yhbeh.2009.10.001
   Castane A, 2002, NEUROPHARMACOLOGY, V43, P857, DOI 10.1016/S0028-3908(02)00118-1
   Castelli MP, 2014, CURR PHARM DESIGN, V20, P2100, DOI 10.2174/13816128113199990430
   Castillo PE, 2012, NEURON, V76, P70, DOI 10.1016/j.neuron.2012.09.020
   Chambers R Andrew, 2003, J Gambl Stud, V19, P53, DOI 10.1023/A:1021275130071
   Chambers RA, 2003, AM J PSYCHIAT, V160, P1041, DOI 10.1176/appi.ajp.160.6.1041
   Cheer JF, 2007, J NEUROSCI, V27, P791, DOI 10.1523/JNEUROSCI.4152-06.2007
   Chen BT, 2008, NEURON, V59, P288, DOI 10.1016/j.neuron.2008.05.024
   Chen BT, 2013, NATURE, V496, P359, DOI 10.1038/nature12024
   Chen BT, 2010, ANN NY ACAD SCI, V1187, P129, DOI 10.1111/j.1749-6632.2009.05154.x
   Chiang KP, 2004, HUM MOL GENET, V13, P2113, DOI 10.1093/hmg/ddh216
   Chorlian DB, 2013, BEHAV GENET, V43, P386, DOI 10.1007/s10519-013-9604-z
   Clarke TK, 2013, ADDICT BIOL, V18, P702, DOI 10.1111/j.1369-1600.2011.00346.x
   Comings DE, 1997, MOL PSYCHIATR, V2, P161, DOI 10.1038/sj.mp.4000247
   Cossu G, 2001, BEHAV BRAIN RES, V118, P61, DOI 10.1016/S0166-4328(00)00311-9
   Cota D, 2003, INT J OBESITY, V27, P289, DOI 10.1038/sj.ijo.0802250
   Creed MC, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00008
   Creed MC, 2013, CURR OPIN NEUROBIOL, V23, P553, DOI 10.1016/j.conb.2013.03.005
   Crowe MS, 2014, BRAIN BEHAV IMMUN, V42, P1, DOI 10.1016/j.bbi.2014.06.007
   Dalley JW, 2007, SCIENCE, V315, P1267, DOI 10.1126/science.1137073
   Davis L, 2008, CURR OPIN PSYCHIATR, V21, P14, DOI 10.1097/YCO.0b013e3282f32408
   De Carvalho CR, 2014, PSYCHOPHARMACOLOGY, V231, P1417, DOI 10.1007/s00213-013-3331-2
   de Fonseca FR, 2005, ALCOHOL ALCOHOLISM, V40, P2, DOI 10.1093/alcalc/agh110
   Delis F, 2013, BEHAV NEUROSCI, V127, P95, DOI 10.1037/a0030750
   DEMONTIS MG, 1993, ALCOHOL ALCOHOLISM, V28, P397
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Deroche-Gamonet V, 2014, NEUROPHARMACOLOGY, V76, P437, DOI 10.1016/j.neuropharm.2013.07.014
   DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919
   Di Marzo V, 2008, NAT REV DRUG DISCOV, V7, P438, DOI 10.1038/nrd2553
   DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0
   DiNieri JA, 2011, BIOL PSYCHIAT, V70, P763, DOI 10.1016/j.biopsych.2011.06.027
   DiTomaso E, 1997, ADV EXP MED BIOL, V407, P335
   Dittman JS, 2000, J NEUROSCI, V20, P1374
   Dubreucq S, 2012, NEUROPSYCHOPHARMACOL, V37, P1885, DOI 10.1038/npp.2012.36
   Edwards S, 2010, FUTUR NEUROL, V5, P393, DOI 10.2217/FNL.10.14
   Ernst M, 2009, PHARMACOL BIOCHEM BE, V93, P199, DOI 10.1016/j.pbb.2008.12.013
   Ersche KD, 2012, SCIENCE, V335, P601, DOI 10.1126/science.1214463
   Ersche KD, 2011, BRAIN, V134, P2013, DOI 10.1093/brain/awr138
   Ersche KD, 2010, BIOL PSYCHIAT, V68, P770, DOI 10.1016/j.biopsych.2010.06.015
   Ersche KD, 2010, ARCH GEN PSYCHIAT, V67, P632, DOI 10.1001/archgenpsychiatry.2010.60
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Fattore L, 2007, BRIT J PHARMACOL, V152, P795, DOI 10.1038/sj.bjp.0707465
   Fattore L, 2007, EUR J NEUROSCI, V25, P2191, DOI 10.1111/j.1460-9568.2007.05470.x
   Fattore L, 2014, FRONT NEUROENDOCRIN, V35, P272, DOI 10.1016/j.yfrne.2014.04.003
   Flanagan JM, 2006, HUM GENET, V120, P581, DOI 10.1007/s00439-006-0250-x
   Flores G, 1998, BRAIN RES, V814, P34, DOI 10.1016/S0006-8993(98)01011-7
   Fortune ES, 2001, TRENDS NEUROSCI, V24, P381, DOI 10.1016/S0166-2236(00)01835-X
   Fride E, 2009, VITAM HORM, V81, P139, DOI 10.1016/S0083-6729(09)81006-6
   Geier CF, 2010, CEREB CORTEX, V20, P1613, DOI 10.1093/cercor/bhp225
   George O, 2010, NEUROSCI BIOBEHAV R, V35, P232, DOI 10.1016/j.neubiorev.2010.05.002
   Gillies GE, 2014, NEUROSCIENCE, V282, P69, DOI 10.1016/j.neuroscience.2014.05.033
   Goldman D, 2005, NAT REV GENET, V6, P521, DOI 10.1038/nrg1635
   Gorwood P, 2012, HUM GENET, V131, P803, DOI 10.1007/s00439-012-1145-7
   Grace AA, 2007, TRENDS NEUROSCI, V30, P220, DOI 10.1016/j.tins.2007.03.003
   Guillon MS, 2007, ADDICT BEHAV, V32, P758, DOI 10.1016/j.addbeh.2006.06.018
   Haller J, 2004, EUR J NEUROSCI, V19, P1906, DOI 10.1111/j.1460-9568.2004.03293.x
   Hansson AC, 2007, NEUROPSYCHOPHARMACOL, V32, P117, DOI 10.1038/sj.npp.1301034
   Hariri AR, 2009, BIOL PSYCHIAT, V66, P9, DOI 10.1016/j.biopsych.2008.10.047
   Harkany T, 2008, MOL CELL ENDOCRINOL, V286, pS84, DOI 10.1016/j.mce.2008.02.011
   Heidbreder C, 2008, CNS NEUROL DISORD-DR, V7, P410, DOI 10.2174/187152708786927822
   Heifets BD, 2009, ANNU REV PHYSIOL, V71, P283, DOI 10.1146/annurev.physiol.010908.163149
   Hernandez G, 2014, BIOL PSYCHIAT, V75, P487, DOI 10.1016/j.biopsych.2013.09.005
   Hikosaka O, 2010, NAT REV NEUROSCI, V11, P503, DOI 10.1038/nrn2866
   Hojo M, 2008, J PHARMACOL SCI, V108, P308, DOI 10.1254/jphs.08244FP
   Hong S, 2011, J NEUROSCI, V31, P11457, DOI 10.1523/JNEUROSCI.1384-11.2011
   Houchi H, 2005, NEUROPSYCHOPHARMACOL, V30, P339, DOI 10.1038/sj.npp.1300568
   Hungund BL, 2003, J NEUROCHEM, V84, P698, DOI 10.1046/j.1471-4159.2003.01576.x
   Hurd YL, 2014, NEUROPHARMACOLOGY, V76, P416, DOI 10.1016/j.neuropharm.2013.07.028
   Hurst DP, 2013, CHEM PHYS LIPIDS, V169, P46, DOI 10.1016/j.chemphyslip.2013.01.009
   Hwang J, 2010, LIFE SCI, V86, P615, DOI 10.1016/j.lfs.2009.06.003
   Hyman SE, 2005, AM J PSYCHIAT, V162, P1414, DOI 10.1176/appi.ajp.162.8.1414
   Ikemoto S, 2006, J NEUROSCI, V26, P723, DOI 10.1523/JNEUROSCI.4542-05.2006
   Ikemoto S, 2002, J NEUROSCI, V22, P9895
   Ikemoto S, 2014, NEUROPHARMACOLOGY, V76, P329, DOI 10.1016/j.neuropharm.2013.04.031
   Jhou TC, 2013, J NEUROSCI, V33, P7501, DOI 10.1523/JNEUROSCI.3634-12.2013
   Jhou TC, 2012, PSYCHOPHARMACOLOGY, V224, P303, DOI 10.1007/s00213-012-2753-6
   Jhou TC, 2009, NEURON, V61, P786, DOI 10.1016/j.neuron.2009.02.001
   Jhou TC, 2009, J COMP NEUROL, V513, P566, DOI 10.1002/cne.21891
   Ji HF, 2007, J NEUROSCI, V27, P6923, DOI 10.1523/JNEUROSCI.0958-07.2007
   Jin X, 2010, NATURE, V466, P457, DOI 10.1038/nature09263
   Joffe ME, 2014, WIRES COGN SCI, V5, P151, DOI 10.1002/wcs.1273
   Jutras-Aswad D, 2009, EUR ARCH PSY CLIN N, V259, P395, DOI 10.1007/s00406-009-0027-z
   Kano M, 2009, PHYSIOL REV, V89, P309, DOI 10.1152/physrev.00019.2008
   Karkowski LM, 2000, AM J MED GENET, V96, P665, DOI 10.1002/1096-8628(20001009)96:5<665::AID-AJMG13>3.3.CO;2-F
   Kasanetz F, 2013, MOL PSYCHIATR, V18, P729, DOI 10.1038/mp.2012.59
   Kasanetz F, 2010, SCIENCE, V328, P1709, DOI 10.1126/science.1187801
   Katona I, 2012, ANNU REV NEUROSCI, V35, P529, DOI 10.1146/annurev-neuro-062111-150420
   Kaufling J, 2009, J COMP NEUROL, V513, P597, DOI 10.1002/cne.21983
   Kelley AE, 2004, NEURON, V44, P161, DOI 10.1016/j.neuron.2004.09.016
   Kendler KS, 2000, ARCH GEN PSYCHIAT, V57, P261, DOI 10.1001/archpsyc.57.3.261
   Klyachko VA, 2006, PLOS BIOL, V4, P1187, DOI 10.1371/journal.pbio.0040207
   Kohno M, 2014, JAMA PSYCHIAT, V71, P812, DOI 10.1001/jamapsychiatry.2014.399
   Koob G, 2007, AM J PSYCHIAT, V164, P1149, DOI 10.1176/appi.ajp.2007.05030503
   Koob GF, 2008, NEURON, V59, P11, DOI 10.1016/j.neuron.2008.06.012
   Koob GF, 2006, ADDICTION, V101, P23, DOI 10.1111/j.1360-0443.2006.01586.x
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Kortleven C, 2011, EUR J NEUROSCI, V33, P1751, DOI 10.1111/j.1460-9568.2011.07648.x
   Kreek MJ, 2005, NAT NEUROSCI, V8, P1450, DOI 10.1038/nn1583
   Krishnan V, 2007, CELL, V131, P391, DOI 10.1016/j.cell.2007.09.018
   Labouebe G, 2013, NAT NEUROSCI, V16, P300, DOI 10.1038/nn.3321
   Lammel S, 2014, NEUROPHARMACOLOGY, V76, P351, DOI 10.1016/j.neuropharm.2013.03.019
   Lammel S, 2012, NATURE, V491, P212, DOI 10.1038/nature11527
   Le Foll B, 2005, NEUROPHARMACOLOGY, V49, P525, DOI 10.1016/j.neuropharm.2005.04.022
   Lecca S, 2014, EUR J NEUROSCI, V39, P1170, DOI 10.1111/ejn.12480
   Lecca S, 2012, NEUROPSYCHOPHARMACOL, V37, P1164, DOI 10.1038/npp.2011.302
   Lecca S, 2011, NEUROPSYCHOPHARMACOL, V36, P589, DOI 10.1038/npp.2010.190
   Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401
   Lewis JE, 2002, J NEUROPHYSIOL, V88, P1695, DOI 10.1152/jn.2002.88.4.1695
   Leyton M, 2014, TRENDS PHARMACOL SCI, V35, P268, DOI 10.1016/j.tips.2014.04.002
   Leyton M, 2013, NEUROSCI BIOBEHAV R, V37, P1999, DOI 10.1016/j.neubiorev.2013.01.018
   Logrip ML, 2012, NEUROPHARMACOLOGY, V62, P552, DOI 10.1016/j.neuropharm.2011.07.007
   Luscher C, 2013, J NEUROSCI, V33, P17641, DOI 10.1523/JNEUROSCI.3406-13.2013
   Luscher C, 2011, NEURON, V69, P650, DOI 10.1016/j.neuron.2011.01.017
   Luscher C, 2010, NEURON, V65, P445, DOI 10.1016/j.neuron.2010.01.016
   Mahler SV, 2007, NEUROPSYCHOPHARMACOL, V32, P2267, DOI 10.1038/sj.npp.1301376
   Malinen H, 2008, ALCOHOL CLIN EXP RES, V32, P1976, DOI 10.1111/j.1530-0277.2008.00786.x
   Mameli M, 2007, SCIENCE, V317, P530, DOI 10.1126/science.1142365
   Mameli M, 2011, NEUROPHARMACOLOGY, V61, P1052, DOI 10.1016/j.neuropharm.2011.01.036
   Mameli M, 2009, NAT NEUROSCI, V12, P1036, DOI 10.1038/nn.2367
   Mantsch JR, 2001, PSYCHOPHARMACOLOGY, V157, P31, DOI 10.1007/s002130100744
   Manzanares J, 1999, TRENDS PHARMACOL SCI, V20, P287, DOI 10.1016/S0165-6147(99)01339-5
   Marinelli M, 2003, PSYCHOPHARMACOLOGY, V168, P84, DOI 10.1007/s00213-003-1491-1
   Marinelli M, 2000, J NEUROSCI, V20, P8876
   Marinelli S, 2005, NEUROPSYCHOPHARMACOL, V30, P864, DOI 10.1038/sj.npp.1300615
   Marinelli S, 2007, NEUROPSYCHOPHARMACOL, V32, P298, DOI 10.1038/sj.npp.1301118
   Mark GP, 2011, PHYSIOL BEHAV, V104, P76, DOI 10.1016/j.physbeh.2011.04.052
   Martin M, 2000, EUR J NEUROSCI, V12, P4038, DOI 10.1046/j.1460-9568.2000.00287.x
   Mascia MS, 1999, EUR J PHARMACOL, V383, pR1, DOI 10.1016/S0014-2999(99)00656-1
   Matsui A, 2014, NEURON, V82, P1346, DOI 10.1016/j.neuron.2014.04.030
   Matsumoto M, 2007, NATURE, V447, P1111, DOI 10.1038/nature05860
   Matyas F, 2008, NEUROPHARMACOLOGY, V54, P95, DOI 10.1016/j.neuropharm.2007.05.028
   Maze I, 2011, ANN NY ACAD SCI, V1216, P99, DOI 10.1111/j.1749-6632.2010.05893.x
   Mazei-Robison MS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095962
   Mazei-Robison MS, 2011, NEURON, V72, P977, DOI 10.1016/j.neuron.2011.10.012
   McCutcheon JE, 2012, J NEUROPHYSIOL, V108, P1620, DOI 10.1152/jn.00077.2012
   Mechoulam R, 2013, ANNU REV PSYCHOL, V64, P21, DOI 10.1146/annurev-psych-113011-143739
   Melis M, 2007, CURR NEUROPHARMACOL, V5, P268, DOI 10.2174/157015907782793612
   Melis M, 2006, NEUROBIOL DIS, V24, P15, DOI 10.1016/j.nbd.2006.04.010
   Melis M, 2014, J NEUROSCI, V34, P12716, DOI 10.1523/JNEUROSCI.1844-14.2014
   Melis M, 2014, PHARMACOL RES, V86, P42, DOI 10.1016/j.phrs.2014.03.009
   Melis M, 2014, EUR J NEUROSCI, V39, P1189, DOI 10.1111/ejn.12501
   Melis M, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00093
   Melis M, 2013, J NEUROSCI, V33, P6203, DOI 10.1523/JNEUROSCI.4647-12.2013
   Melis M, 2013, CNS NEUROL DISORD-DR, V12, P70, DOI 10.2174/1871527311312010012
   Melis M, 2012, PHILOS T R SOC B, V367, P3276, DOI 10.1098/rstb.2011.0383
   Melis M, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00007
   Melis M, 2009, PSYCHOPHARMACOLOGY, V201, P471, DOI 10.1007/s00213-008-1309-2
   Merikangas KR, 1998, ARCH GEN PSYCHIAT, V55, P973, DOI 10.1001/archpsyc.55.11.973
   Merritt LL, 2008, J PHARMACOL EXP THER, V326, P483, DOI 10.1124/jpet.108.138321
   Meye FJ, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00860
   MINABE Y, 1995, LIFE SCI, V56, pPL261, DOI 10.1016/0024-3205(95)00075-5
   Montague PR, 1996, J NEUROSCI, V16, P1936, DOI 10.1523/jneurosci.16-05-01936.1996
   Morales M, 2014, NEUROSCIENCE, V282, P60, DOI 10.1016/j.neuroscience.2014.05.032
   Morales M, 2012, ANN NY ACAD SCI, V1248, P71, DOI 10.1111/j.1749-6632.2011.06299.x
   Morris CV, 2011, EUR J NEUROSCI, V34, P1574, DOI 10.1111/j.1460-9568.2011.07884.x
   Morzorati SL, 2006, ALCOHOL CLIN EXP RES, V30, P991, DOI 10.1111/j.1530-0277.2006.00113.x
   Morzorati SL, 1998, ALCOHOL CLIN EXP RES, V22, P854, DOI 10.1111/j.1530-0277.1998.tb03879.x
   Mulder J, 2008, P NATL ACAD SCI USA, V105, P8760, DOI 10.1073/pnas.0803545105
   Nader J, 2012, NEUROPSYCHOPHARMACOL, V37, P1579, DOI 10.1038/npp.2012.2
   Nader MA, 2006, NAT NEUROSCI, V9, P1050, DOI 10.1038/nn1737
   Navarro M, 2001, J NEUROSCI, V21, P5344, DOI 10.1523/JNEUROSCI.21-14-05344.2001
   Nazzaro C, 2012, NAT NEUROSCI, V15, P284, DOI 10.1038/nn.3022
   Nestler EJ, 2002, NEUROBIOL LEARN MEM, V78, P637, DOI 10.1006/nlme.2002.4084
   Niehaus JL, 2009, AM J ADDICTION, V18, P259, DOI 10.1080/10550490902925946
   Oleson EB, 2012, COLD SPRING HARB PER, V2
   Oleson EB, 2014, PROG NEURO-PSYCHOPH, V52, P17, DOI 10.1016/j.pnpbp.2013.07.019
   Oleson EB, 2012, NEURON, V73, P360, DOI 10.1016/j.neuron.2011.11.018
   Oliere Stephanie, 2013, Front Psychiatry, V4, P109, DOI 10.3389/fpsyt.2013.00109
   Pacher P, 2013, FEBS J, V280, P1918, DOI 10.1111/febs.12260
   Padgett CL, 2012, NEURON, V73, P978, DOI 10.1016/j.neuron.2011.12.031
   Park K, 2013, J NEUROSCI, V33, P15827, DOI 10.1523/JNEUROSCI.1935-13.2013
   Parolaro D, 2008, DRUG NEWS PERSPECT, V21, P149, DOI 10.1358/dnp.2008.21.3.1203411
   Parolaro D, 2010, CURR DRUG TARGETS, V11, P393, DOI 10.2174/138945010790980367
   Parolaro D, 2010, EXP NEUROL, V224, P3, DOI 10.1016/j.expneurol.2010.03.018
   Patton MH, 2013, J NEUROSCI, V 33, P16865, DOI 10.1523/JNEUROSCI.2449-13.2013
   Piazza PV, 2013, PSYCHOPHARMACOLOGY, V229, P387, DOI 10.1007/s00213-013-3224-4
   Pickel VM, 2004, NEUROSCIENCE, V127, P101, DOI 10.1016/j.neuroscience.2004.05.015
   Pilla M, 1999, NATURE, V400, P371, DOI 10.1038/43944
   Pingault JB, 2013, MOL PSYCHIATR, V18, P806, DOI 10.1038/mp.2012.87
   Proudnikov D, 2010, PHARMACOGENOMICS J, V10, P232, DOI 10.1038/tpj.2009.59
   Richter A, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00250
   Riegel AC, 2004, J NEUROSCI, V24, P11070, DOI 10.1523/JNEUROSCI.3695-04.2004
   Rivera P, 2013, INT J NEUROPSYCHOPH, V16, P1277, DOI 10.1017/S1461145712001186
   Robbe D, 2002, P NATL ACAD SCI USA, V99, P8384, DOI 10.1073/pnas.122149199
   Robinson SA, 2010, BRAIN RES, V1343, P153, DOI 10.1016/j.brainres.2010.04.031
   Romano-Lopez A, 2012, NEUROSCIENCE, V223, P296, DOI 10.1016/j.neuroscience.2012.07.071
   Roussotte FF, 2014, ARZNEIMITTELFORSCHUN
   Rubino T, 2014, PROG NEURO-PSYCHOPH, V52, P41, DOI 10.1016/j.pnpbp.2013.07.020
   Rubino T, 2015, NEUROBIOL DIS, V73, P60, DOI 10.1016/j.nbd.2014.09.015
   Rubino T, 2012, J PSYCHOPHARMACOL, V26, P177, DOI 10.1177/0269881111405362
   Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-7
   Sadakierska-Chudy A., 2014, PHARM THER
   Saito VM, 2010, REV BRAS PSIQUIATR, V32, pS7
   SALAMONE JD, 1994, PHARMACOL BIOCHEM BE, V49, P25, DOI 10.1016/0091-3057(94)90452-9
   SALAMONE JD, 1994, BEHAV BRAIN RES, V61, P117, DOI 10.1016/0166-4328(94)90153-8
   Salamone JD, 2012, NEURON, V76, P470, DOI 10.1016/j.neuron.2012.10.021
   Saunders BT, 2013, NEUROPSYCHOPHARMACOL, V38, P249, DOI 10.1038/npp.2012.161
   Saunders BT, 2010, BIOL PSYCHIAT, V67, P730, DOI 10.1016/j.biopsych.2009.11.015
   Schmidt HD, 2010, ANN NY ACAD SCI, V1187, P35, DOI 10.1111/j.1749-6632.2009.05144.x
   Schneider M, 2008, ADDICT BIOL, V13, P253, DOI 10.1111/j.1369-1600.2008.00110.x
   Schultz W, 1997, CURR OPIN NEUROBIOL, V7, P191, DOI 10.1016/S0959-4388(97)80007-4
   Seif T, 2013, NAT NEUROSCI, V16, P1094, DOI 10.1038/nn.3445
   Serrano A, 2011, PHARMACOL THERAPEUT, V132, P215, DOI 10.1016/j.pharmthera.2011.06.005
   Sidhpura N, 2011, NEUROPHARMACOLOGY, V61, P1070, DOI 10.1016/j.neuropharm.2011.05.034
   Singh ME, 2006, NEUROPSYCHOPHARMACOL, V31, P58, DOI 10.1038/sj.npp.1300770
   Sinha R, 2008, ANN NY ACAD SCI, V1141, P105, DOI 10.1196/annals.1441.030
   Sipe JC, 2002, P NATL ACAD SCI USA, V99, P8394, DOI 10.1073/pnas.082235799
   Sipe JC, 2005, INT J OBESITY, V29, P755, DOI 10.1038/sj.ijo.0802954
   SklairTavron L, 1996, P NATL ACAD SCI USA, V93, P11202, DOI 10.1073/pnas.93.20.11202
   SOKOLOFF P, 1992, ARZNEIMITTEL-FORSCH, V42-1, P224
   Song R, 2012, P NATL ACAD SCI USA, V109, P17675, DOI 10.1073/pnas.1205297109
   Spear LP, 2011, DEV COGN NEUROS-NETH, V1, P390, DOI 10.1016/j.dcn.2011.08.001
   Spiga S, 2005, EUR J NEUROSCI, V22, P2332, DOI 10.1111/j.1460-9568.2005.04416.x
   Spiga S, 2014, P NATL ACAD SCI USA, V111, pE3745, DOI 10.1073/pnas.1406768111
   Spiga S, 2010, ADDICT BIOL, V15, P266, DOI 10.1111/j.1369-1600.2010.00218.x
   Stamatakis AM, 2012, NAT NEUROSCI, V15, P1105, DOI 10.1038/nn.3145
   STEFANINI E, 1992, ALCOHOL ALCOHOLISM, V27, P127
   Stuber GD, 2008, ALCOHOL CLIN EXP RES, V32, P1714, DOI 10.1111/j.1530-0277.2008.00749.x
   Stuber GD, 2008, SCIENCE, V321, P1690, DOI 10.1126/science.1160873
   Stuber GD, 2012, BIOL PSYCHIAT, V71, P1061, DOI 10.1016/j.biopsych.2011.11.010
   Stuber GD, 2010, CURR TOP BEHAV NEURO, V3, P3, DOI 10.1007/7854_2009_23
   SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437
   Sugiura T, 2002, J BIOCHEM, V132, P7, DOI 10.1093/oxfordjournals.jbchem.a003200
   Svizenska I, 2008, PHARMACOL BIOCHEM BE, V90, P501, DOI 10.1016/j.pbb.2008.05.010
   Swadi H, 1999, DRUG ALCOHOL DEPEN, V55, P209, DOI 10.1016/S0376-8716(99)00017-4
   Sweitzer MM, 2012, DRUG ALCOHOL DEPEN, V123, pS59, DOI 10.1016/j.drugalcdep.2012.01.017
   Szabo B, 2002, EUR J NEUROSCI, V15, P2057, DOI 10.1046/j.1460-9568.2002.02041.x
   Tan KR, 2012, NEURON, V73, P1173, DOI 10.1016/j.neuron.2012.02.015
   Tanda G, 1997, SCIENCE, V276, P2048, DOI 10.1126/science.276.5321.2048
   Tarter RE, 2003, AM J PSYCHIAT, V160, P1078, DOI 10.1176/appi.ajp.160.6.1078
   Taylor SR, 2014, J COMP NEUROL, V522, P3308, DOI 10.1002/cne.23603
   Thanos PK, 2008, SYNAPSE, V62, P481, DOI 10.1002/syn.20523
   Thanos PK, 2005, BEHAV BRAIN RES, V164, P206, DOI 10.1016/j.bbr.2005.06.021
   Thanos PK, 2005, LIFE SCI, V77, P130, DOI 10.1016/j.lfs.2004.10.061
   Thanos PK, 2004, ALCOHOL CLIN EXP RES, V28, P720, DOI 10.1097/01.ALC.0000125270.30501.08
   Thanos PK, 2001, J NEUROCHEM, V78, P1094, DOI 10.1046/j.1471-4159.2001.00492.x
   Thompson JL, 2011, BEHAV BRAIN RES, V217, P446, DOI 10.1016/j.bbr.2010.09.028
   Thompson PM, 2001, NAT NEUROSCI, V4, P1253, DOI 10.1038/nn758
   Tomasiewicz HC, 2012, BIOL PSYCHIAT, V72, P803, DOI 10.1016/j.biopsych.2012.04.026
   Tsuang MT, 1996, AM J MED GENET, V67, P473, DOI 10.1002/(SICI)1096-8628(19960920)67:5<473::AID-AJMG6>3.0.CO;2-L
   Tyndale RF, 2007, AM J MED GENET B, V144B, P660, DOI 10.1002/ajmg.b.30491
   Ungless MA, 2004, TRENDS NEUROSCI, V27, P702, DOI 10.1016/j.tins.2004.10.001
   Ungless MA, 2004, SCIENCE, V303, P2040, DOI 10.1126/science.1093360
   Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077
   Unterwald EM, 2001, BRAIN RES, V900, P103, DOI 10.1016/S0006-8993(01)02269-7
   van Zessen R, 2012, NEURON, V73, P1184, DOI 10.1016/j.neuron.2012.02.016
   Vassoler FM, 2014, NEUROSCIENCE, V264, P198, DOI 10.1016/j.neuroscience.2013.07.064
   Vela G, 1998, BRAIN RES, V807, P101, DOI 10.1016/S0006-8993(98)00766-5
   Vinod KY, 2008, J NEUROCHEM, V104, P233, DOI 10.1111/j.1471-4159.2007.04956.x
   Vinod KY, 2012, ADDICT BIOL, V17, P62, DOI 10.1111/j.1369-1600.2010.00299.x
   Viveros MP, 2012, J PSYCHOPHARMACOL, V26, P164, DOI 10.1177/0269881111408956
   Volkow ND, 2009, NEUROPHARMACOLOGY, V56, P3, DOI 10.1016/j.neuropharm.2008.05.022
   Volkow ND, 1999, AM J PSYCHIAT, V156, P1440
   Volkow ND, 2002, SYNAPSE, V46, P79, DOI 10.1002/syn.10137
   Volkow ND, 2006, ARCH GEN PSYCHIAT, V63, P999, DOI 10.1001/archpsyc.63.9.999
   Volman SF, 2013, J NEUROSCI, V33, P17569, DOI 10.1523/JNEUROSCI.3250-13.2013
   Wanat MJ, 2009, BIOL PSYCHIAT, V65, P646, DOI 10.1016/j.biopsych.2008.10.042
   Wang L, 2003, P NATL ACAD SCI USA, V100, P1393, DOI 10.1073/pnas.0336351100
   Ward SJ, 2005, BEHAV PHARMACOL, V16, P381, DOI 10.1097/00008877-200509000-00010
   Watabe-Uchida M, 2012, NEURON, V74, P858, DOI 10.1016/j.neuron.2012.03.017
   Wenzel JM, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00118
   Whitaker LR, 2013, NEURON, V77, P335, DOI 10.1016/j.neuron.2012.11.022
   Wise RA, 2014, NEUROPSYCHOPHARMACOL, V39, P254, DOI 10.1038/npp.2013.261
   Wise Roy A., 2000, Neuron, V26, P27, DOI 10.1016/S0896-6273(00)81134-4
   Yamaguchi T, 2007, EUR J NEUROSCI, V25, P106, DOI 10.1111/j.1460-9568.2006.05263.x
   Yuferov V, 2009, NEUROPSYCHOPHARMACOL, V34, P1185, DOI 10.1038/npp.2008.187
   Zamberletti E, 2014, NEUROBIOL DIS, V63, P35, DOI 10.1016/j.nbd.2013.10.028
   Zamora-Martinez ER, 2014, FRONT INTEGR NEUROSC, V8, DOI 10.3389/fnint.2014.00024
   Zhang PW, 2004, MOL PSYCHIATR, V9, P916, DOI 10.1038/sj.mp.4001560
   Zhou Y, 2015, PHYSIOL BEHAV, V139, P127, DOI 10.1016/j.physbeh.2014.11.002
NR 311
TC 10
Z9 12
U1 1
U2 20
PU BENTHAM SCIENCE PUBL
PI BUSUM
PA PO BOX 294, BUSUM, 1400 AG, NETHERLANDS
SN 1871-5273
EI 1996-3181
J9 CNS NEUROL DISORD-DR
JI CNS Neurol. Disord.-Drug Targets
PY 2015
VL 14
IS 4
BP 502
EP 517
DI 10.2174/1871527314666150225143748
PG 16
WC Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA CH6XG
UT WOS:000354179100011
PM 25714966
DA 2023-06-23
ER

PT J
AU Fattore, L
   Weinstein, AM
AF Fattore, Liana
   Weinstein, Aviv M.
TI Editorial: Novel Psychoactive Drugs
SO FRONTIERS IN PSYCHIATRY
LA English
DT Editorial Material
DE psychoactive drugs; drug abuse and addiction; intoxications; internet
   drug; legal highs
C1 [Fattore, Liana] Natl Res Council Italy, Inst Neurosci Cagliari, Cagliari, Italy.
   [Weinstein, Aviv M.] Ariel Univ, Dept Behav Sci, Ariel, Israel.
C3 Consiglio Nazionale delle Ricerche (CNR); Ariel University
RP Fattore, L (通讯作者)，Natl Res Council Italy, Inst Neurosci Cagliari, Cagliari, Italy.
EM liana.fattore@in.cnr.it
RI Fattore, Liana/AAC-6996-2021
OI FATTORE, LIANA/0000-0002-2663-666X
NR 0
TC 2
Z9 3
U1 1
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD MAR 11
PY 2019
VL 10
AR 119
DI 10.3389/fpsyt.2019.00119
PG 3
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA HO2ZL
UT WOS:000460786700002
PM 30914980
OA gold, Green Published
DA 2023-06-23
ER

PT J
AU Le, QM
   Yan, B
   Yu, XC
   Li, YQ
   Song, HK
   Zhu, HW
   Hou, WQ
   Ma, DGL
   Wu, FZ
   Zhou, YQ
   Ma, L
AF Le, Qiumin
   Yan, Biao
   Yu, Xiangchen
   Li, Yanqing
   Song, Haikun
   Zhu, Huiwen
   Hou, Weiqing
   Ma, Dingailu
   Wu, Feizhen
   Zhou, Yuqing
   Ma, Lan
TI Drug-seeking motivation level in male rats determines offspring
   susceptibility or resistance to cocaine-seeking behaviour
SO NATURE COMMUNICATIONS
LA English
DT Article
ID TRANSGENERATIONAL EPIGENETIC INHERITANCE; SUBSTANCE USE DISORDERS;
   NONGENETIC INHERITANCE; FAMILIAL TRANSMISSION; BRAIN-DEVELOPMENT;
   IN-UTERO; RNA-SEQ; MECHANISMS; GENE; ADDICTION
AB Liability to develop drug addiction is heritable, but the precise contribution of non-Mendelian factors is not well understood. Here we separate male rats into addiction-like and non-addiction-like groups, based on their incentive motivation to seek cocaine. We find that the high incentive responding of the F0 generation could be transmitted to F1 and F2 generations. Moreover, the inheritance of high incentive response to cocaine is contingent on high motivation, as it is elicited by voluntary cocaine administration, but not high intake of cocaine itself. We also find DNA methylation differences between sperm of addiction-like and non-addiction-like groups that were maintained from F0 to F1, providing an epigenetic link to transcriptomic changes of addiction-related signalling pathways in the nucleus accumbens of offspring. Our data suggest that highly motivated drug seeking experience may increase vulnerability and/or reduce resistance to drug addiction in descendants.
C1 [Le, Qiumin; Yan, Biao; Yu, Xiangchen; Li, Yanqing; Song, Haikun; Zhu, Huiwen; Hou, Weiqing; Zhou, Yuqing; Ma, Lan] Fudan Univ, Dept Neurosurg, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China.
   [Le, Qiumin; Yan, Biao; Yu, Xiangchen; Li, Yanqing; Song, Haikun; Zhu, Huiwen; Hou, Weiqing; Zhou, Yuqing; Ma, Lan] Fudan Univ, Inst Translat Neurosci, Huashan Hosp, State Key Lab Med Neurobiol,Sch Basic Med Sci, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China.
   [Le, Qiumin; Yan, Biao; Yu, Xiangchen; Li, Yanqing; Song, Haikun; Zhu, Huiwen; Hou, Weiqing; Zhou, Yuqing; Ma, Lan] Fudan Univ, Inst Brain Sci, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China.
   [Wu, Feizhen; Zhou, Yuqing] Fudan Univ, Inst Biomed Sci, Lab Epigenet, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China.
C3 Fudan University; Fudan University; Fudan University; Fudan University
RP Ma, L (通讯作者)，Fudan Univ, Dept Neurosurg, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China.; Ma, L (通讯作者)，Fudan Univ, Inst Translat Neurosci, Huashan Hosp, State Key Lab Med Neurobiol,Sch Basic Med Sci, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China.; Ma, L (通讯作者)，Fudan Univ, Inst Brain Sci, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China.
EM lanma@fudan.edu.cn
RI ZHOU, yf/IAO-5497-2023; Hou, Wei/F-4996-2015; Zhou, Yu/HHN-3071-2022;
   Ma, Lan/B-9295-2009; Wu, Feizhen/AGR-5215-2022; Zhou,
   Yujie/HZI-3990-2023; Yan, Biao/AAI-6317-2021; hou, wei/GWM-4800-2022;
   Wu, Feizhen/R-6415-2019; Le, Qiumin/P-6605-2019
OI Yan, Biao/0000-0003-3252-2965; Wu, Feizhen/0000-0002-1265-9887; Le,
   Qiumin/0000-0002-2596-3052; Ma, Lan/0000-0001-9034-5472
FU Ministry of Science and Technology [2015CB553500, 2014CB942801,
   2013CB835102]; National Natural Science Foundation of China [31430033,
   91232307, 31421091, 81272295]
FX We thank Dr Nashat Abumaria from Institutes of Brain Science, Fudan
   University, for critical reading of the manuscript, and Dr Naiqing Zhao
   from School of Public Health, Fudan University, for statistical
   assistance. This work was supported by the Ministry of Science and
   Technology (2015CB553500, 2014CB942801 and 2013CB835102) and the
   National Natural Science Foundation of China (31430033, 91232307,
   31421091 and 81272295).
CR Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244
   Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190
   Assenov Y, 2014, NAT METHODS, V11, P1138, DOI [10.1038/NMETH.3115, 10.1038/nmeth.3115]
   Bale TL, 2015, NAT REV NEUROSCI, V16, P332, DOI 10.1038/nrn3818
   Bellone C, 2011, NAT NEUROSCI, V14, P1439, DOI 10.1038/nn.2930
   Bierut LJ, 1998, ARCH GEN PSYCHIAT, V55, P982, DOI 10.1001/archpsyc.55.11.982
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Bock R, 2013, NAT NEUROSCI, V16, P632, DOI 10.1038/nn.3369
   Bohacek J, 2015, NAT REV GENET, V16, P641, DOI 10.1038/nrg3964
   Bohacek J, 2013, BIOL PSYCHIAT, V73, P313, DOI 10.1016/j.biopsych.2012.08.019
   Calegari F, 2005, J NEUROSCI, V25, P6533, DOI 10.1523/JNEUROSCI.0778-05.2005
   Cami J, 2003, NEW ENGL J MED, V349, P975, DOI 10.1056/NEJMra023160
   Chen YL, 2014, NEURON, V83, P431, DOI 10.1016/j.neuron.2014.05.027
   Crozatier C, 2003, DEV BRAIN RES, V147, P97, DOI 10.1016/j.devbrainres.2003.10.006
   Daxinger L, 2012, NAT REV GENET, V13, P153, DOI 10.1038/nrg3188
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Droit A, 2014, DISCOVERY R PACKAGE
   Dunn GA, 2011, ENDOCRINOLOGY, V152, P2228, DOI 10.1210/en.2010-1461
   Goldman D, 2005, NAT REV GENET, V6, P521, DOI 10.1038/nrg1635
   Griffin Jeanine, 2013, Methods Mol Biol, V927, P379
   He F, 2006, NEUROTOXICOL TERATOL, V28, P198, DOI 10.1016/j.ntt.2005.12.003
   Hebestreit K, 2013, BIOINFORMATICS, V29, P1647, DOI 10.1093/bioinformatics/btt263
   Hu SH, 2013, ELIFE, V2, DOI 10.7554/eLife.00726
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Jablonka E, 2009, Q REV BIOL, V84, P131, DOI 10.1086/598822
   Keller RW, 1996, NEUROSCI LETT, V205, P153, DOI 10.1016/0304-3940(96)12409-5
   Kendler KS, 2003, ARCH GEN PSYCHIAT, V60, P929, DOI 10.1001/archpsyc.60.9.929
   Killinger CE, 2012, SYNAPSE, V66, P902, DOI 10.1002/syn.21582
   Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167
   Lane M, 2014, SCIENCE, V345, P756, DOI 10.1126/science.1254400
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Lassalle B, 2004, DEVELOPMENT, V131, P479, DOI 10.1242/dev.00918
   Li Ming D, 2006, Curr Psychiatry Rep, V8, P158, DOI 10.1007/s11920-006-0016-0
   Manikkam M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055387
   Mayes L, 2007, CHILD NEUROPSYCHOL, V13, P205, DOI 10.1080/09297040600888753
   Merikangas KR, 1998, ARCH GEN PSYCHIAT, V55, P973, DOI 10.1001/archpsyc.55.11.973
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Nielson DA, 2012, PHARMACOGENOMICS, V13, P1149, DOI [10.2217/PGS.12.94, 10.2217/pgs.12.94]
   Richards EJ, 2006, NAT REV GENET, V7, P395, DOI 10.1038/nrg1834
   Robison AJ, 2011, NAT REV NEUROSCI, V12, P623, DOI 10.1038/nrn3111
   Sadler B, 2014, SCI REP-UK, V4, DOI 10.1038/srep04497
   Sasaki A, 2014, BEHAV BRAIN RES, V265, P163, DOI 10.1016/j.bbr.2014.02.017
   Singh DP, 2014, NATURE, V509, P447, DOI 10.1038/nature13318
   Skinner MK, 2011, REPROD TOXICOL, V31, P337, DOI 10.1016/j.reprotox.2010.10.012
   Stewart J.E., 2000, EVOLUTIONS ARROW DIR
   Toth M, 2015, NEUROPSYCHOPHARMACOL, V40, P129, DOI 10.1038/npp.2014.127
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Treutlein J, 2011, CURR PSYCHIAT REP, V13, P147, DOI 10.1007/s11920-011-0176-4
   Tsuang MT, 1998, ARCH GEN PSYCHIAT, V55, P967, DOI 10.1001/archpsyc.55.11.967
   Vassoler FM, 2013, NAT NEUROSCI, V16, P42, DOI 10.1038/nn.3280
   Weiss RB, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000125
   White SL, 2016, ADDICT BIOL, V21, P802, DOI 10.1111/adb.12258
   Yohn NL, 2015, PROG BIOPHYS MOL BIO, V118, P21, DOI 10.1016/j.pbiomolbio.2015.03.002
   Zhang DD, 2007, BIOL PSYCHIAT, V61, P1244, DOI 10.1016/j.biopsych.2006.07.012
NR 54
TC 47
Z9 51
U1 3
U2 30
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAY 30
PY 2017
VL 8
AR 15527
DI 10.1038/ncomms15527
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EW2CW
UT WOS:000402305100001
PM 28556835
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Ghouchani, HT
   Armat, MR
   Akbari, H
   Hojjat, SK
   Lashkardoost, H
   Asghari, D
   Gholizadeh, N
   Saadati, H
AF Ghouchani, Hamid Tavakoli
   Armat, Mohammad Reza
   Akbari, Hadi
   Hojjat, Seyed Kaveh
   Lashkardoost, Hossein
   Asghari, Dordane
   Gholizadeh, Nazanin
   Saadati, Hassan
TI Perceived barriers to addiction treatment: an inductive qualitative
   content analysis
SO JOURNAL OF SUBSTANCE USE
LA English
DT Article
DE Barriers; drug use; addiction treatment; qualitative content analysis
ID SELF-EFFICACY; SUBSTANCE; THERAPY; IMPLEMENTATION; RELIABILITY;
   ADOLESCENTS; VALIDITY; CARE
AB Aims This study aimed to identify the context-specific barriers of addiction treatment. Methods This study followed an inductive qualitative content analysis approach to explore the barriers to drug addiction treatment. The sample consisted of 33 participants including 11 clients who sought addiction treatment, 15 psychologists, 5 general practitioners, an internist, and a psychiatrist; selected from Bojnourd's addiction treatment clinics in 2018. Findings In total, 6 themes, 12 categories and 16 subcategories of barriers to addiction treatment emerged. The themes included treatment barriers, social barriers, family barriers, economic barriers, positive attitudes toward drug use, and lack of self-efficacy. Conclusion Lack of family support and lack of self-efficacy were the major reasons for abandoning addiction treatment. Accordingly, more studies (both qualitative and quantitative) are recommended on the role of self-efficacy and family support in addiction treatment programs in different communities.
C1 [Ghouchani, Hamid Tavakoli; Hojjat, Seyed Kaveh; Lashkardoost, Hossein; Saadati, Hassan] North Khorasan Univ Med Sci, Addict & Behav Sci Res Ctr, Bojnurd, Iran.
   [Ghouchani, Hamid Tavakoli] North Khorasan Univ Med Sci, Sch Hlth, Dept Hlth Educ & Promot, Bojnurd, Iran.
   [Armat, Mohammad Reza] North Khorasan Univ Med Sci, Sch Nursing & Midwifery, Sch Hlth, Dept Geriatr Nursing, Bojnurd, Iran.
   [Akbari, Hadi] North Khorasan Univ Med Sci, Sch Med, Dept Gen Courses & Islamic Studies, Bojnurd, Iran.
   [Hojjat, Seyed Kaveh] North Khorasan Univ Med Sci, Sch Med, Dept Internal Med, Bojnurd, Iran.
   [Lashkardoost, Hossein; Saadati, Hassan] North Khorasan Univ Med Sci, Sch Hlth, Dept Epidemiol & Biostat, Bojnurd, Iran.
   [Asghari, Dordane] Addict & Behav Sci Res Ctr, Measurement & Measurement Field Psychometr Field, Bojnurd, Iran.
   [Gholizadeh, Nazanin] Gen Psychol Addict & Behav Sci Res Ctr, Bojnurd, Iran.
C3 North Khorasan University of Medical Sciences; North Khorasan University
   of Medical Sciences; North Khorasan University of Medical Sciences;
   North Khorasan University of Medical Sciences; North Khorasan University
   of Medical Sciences; North Khorasan University of Medical Sciences
RP Saadati, H (通讯作者)，North Khorasan Univ Med Sci, Sch Publ Hlth, Dept Epidemiol & Biostat, Bojnurd, Iran.
EM hasansaadati1391@gmail.com
OI Tavakoli Ghouchani, Hamid/0000-0003-3289-7767; saadati,
   hassan/0000-0002-8523-3684
FU North Khorasan University Medical Sciences (Research Center for
   Addiction Studies & Behavioral Sciences) [IR.NKUMS.REC.1397.020]
FX This study is part of an approved research project funded by North
   Khorasan University Medical Sciences (Research Center for Addiction
   Studies & Behavioral Sciences); (IR.NKUMS.REC.1397.020).
CR Afzali, 2008, IRANIAN J TOXICOLOGY, V2, P5
   Alexander AC, 2018, DRUG-EDUC PREV POLIC, V25, P241, DOI 10.1080/09687637.2017.1282423
   Bojko MJ, 2015, DRUG-EDUC PREV POLIC, V22, P255, DOI 10.3109/09687637.2015.1016397
   Center for Behavioral Health Statistics and Quality, 2015, HHS PUBL
   Chen LY, 2013, PSYCHIAT SERV, V64, P863, DOI 10.1176/appi.ps.201200289
   CUNNINGHAM JA, 1993, ADDICT BEHAV, V18, P347, DOI 10.1016/0306-4603(93)90036-9
   Fisher DG, 2017, J SUBST ABUSE TREAT, V73, P55, DOI 10.1016/j.jsat.2016.11.004
   Gates P, 2012, DRUG ALCOHOL REV, V31, P311, DOI 10.1111/j.1465-3362.2011.00313.x
   Ghouchani HT, 2016, J RES HEALTH SCI, V16, P147
   Ghouchani HT, 2017, J SUBST USE, V22, P253, DOI 10.1080/14659891.2016.1182592
   Isobell D, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0064-z
   Kenny P, 2011, SUBST ABUSE TREAT PR, V6, DOI 10.1186/1747-597X-6-3
   Khammarnia M., 2018, J RAFSANJAN U MED SC, V17, P523
   Klein JD, 1998, ARCH PEDIAT ADOL MED, V152, P676
   Knudsen HK, 2011, EVAL PROGRAM PLANN, V34, P375, DOI 10.1016/j.evalprogplan.2011.02.004
   Kolind T, 2007, DRUG-EDUC PREV POLIC, V14, P261, DOI 10.1080/09687630601073807
   Lin CQ, 2011, SUBST USE MISUSE, V46, P1190, DOI 10.3109/10826084.2011.561905
   Lundgren L, 2012, J SUBST ABUSE TREAT, V42, P231, DOI 10.1016/j.jsat.2011.08.003
   Mazloum S.R., 2009, J ILAM U MED SCI, V17, P32
   Molaee F., 2012, IRANIAN J HLTH CARE, V12, P23
   Molaie A, 2010, PROCD SOC BEHV, V5, P1180, DOI 10.1016/j.sbspro.2010.07.257
   Nasiri, 2006, Q J LORESTAN U MED S, V2, P80
   ONDCP, 2007, TEENS PRESCR DRUGS A
   Pagano Anna, 2014, J Ethn Subst Abuse, V13, P273, DOI 10.1080/15332640.2014.886320
   Qi C, 2015, DRUG ALCOHOL DEPEN, V148, P143, DOI 10.1016/j.drugalcdep.2014.12.033
   Rapp RC, 2006, J SUBST ABUSE TREAT, V30, P227, DOI 10.1016/j.jsat.2006.01.002
   Rimaz S., 2013, Journal of School of Public Health & Institute of Public Health Research, V10, pPe53
   Saberi Zafarghandi M., 2011, IRAN J PSYCHIAT CLIN, V17, P157
   Saberi Zafarghandi Mohammad Bagher, 2015, Int J High Risk Behav Addict, V4, pe22863, DOI 10.5812/ijhrba.22863
   Samargia Luzette A, 2006, J Sch Nurs, V22, P17
   Smith LR, 2016, DRUG ALCOHOL DEPEN, V162, P34, DOI 10.1016/j.drugalcdep.2016.02.019
   STONE SL, 1992, AM J PREV MED, V8, P221, DOI 10.1016/S0749-3797(18)30809-2
   Strangers, 2008, PROJECTIONS NATL EXP
   UNODC Vienna, 2018, WORLD DRUG REPORT 20
   Zvolensky MJ, 2018, ADDICT BEHAV, V76, P45, DOI 10.1016/j.addbeh.2017.07.011
NR 35
TC 5
Z9 5
U1 4
U2 14
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1465-9891
EI 1475-9942
J9 J SUBST USE
JI J. Subst. Use
PD SEP 3
PY 2022
VL 27
IS 5
BP 550
EP 555
DI 10.1080/14659891.2021.1967482
EA AUG 2021
PG 6
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA 4I7TN
UT WOS:000686811000001
DA 2023-06-23
ER

PT J
AU Fraser, S
   Valentine, K
   Ekendahl, M
AF Fraser, Suzanne
   Valentine, Kylie
   Ekendahl, Mats
TI Drugs, Brains and Other Subalterns: Public Debate and the New
   Materialist Politics of Addiction
SO BODY & SOCIETY
LA English
DT Article
DE addiction; Bennett; the brain; Latour; materiality; public debate;
   qualitative research
ID DISEASE-MODEL; GENDER; POLICY; IDEA
AB Over the last few decades feminists, science and technology studies scholars and others have grappled with how to take materiality into account in understanding social practices, subjectivity and events. One key area for these debates has been drug use and addiction. At the same time, neuroscientific accounts of drug use and addiction have also arisen. This development has attracted criticism as simplistically reinstating material determinism. In this article we draw on 80 interviews with health professionals directly involved in drug-related public policy and service provision in three countries to identify the main ways the neuroscience of addiction (and thus the agency of the brain) is understood. We analyse these understandings using contemporary posthumanist theory to develop new options for conceptualizing matter in public responses to addiction. We close by calling for a new approach to addiction and the brain based on a process model of materiality and public debate.
C1 [Fraser, Suzanne] Curtin Univ, Natl Drug Res Inst, Social Studies Addict Concepts SSAC Res Program, Perth, WA, Australia.
   [Fraser, Suzanne] Univ New South Wales, Ctr Social Res Hlth, Sydney, NSW, Australia.
   [Valentine, Kylie] Univ New South Wales, Social Policy Res Ctr, Sydney, NSW, Australia.
   [Ekendahl, Mats] Stockholms Univ, Dept Social Work, Stockholm, Sweden.
C3 Curtin University; University of New South Wales Sydney; University of
   New South Wales Sydney; Stockholm University
RP Fraser, S (通讯作者)，Curtin Univ, Natl Drug Res Inst, Social Studies Addict Concepts SSAC Res Program, Perth, WA, Australia.; Fraser, S (通讯作者)，Univ New South Wales, Ctr Social Res Hlth, Sydney, NSW, Australia.
EM suzanne.fraser@curtin.edu.au
OI Ekendahl, Mats/0000-0003-2295-4078; Fraser, Suzanne/0000-0003-1018-5865;
   valentine, kylie/0000-0003-4785-484X
FU Australian Research Council [FT120100215]; Centre for Social Research in
   Health, Faculty of Arts, University of NSW; BC Centre for Excellence in
   Research, Canada; SORaD, Stockholm University; Australian Government
   under the Substance Misuse Prevention and Service Improvement Grants
   Fund; Australian Research Council [FT120100215] Funding Source:
   Australian Research Council
FX This article was prepared with the support of an Australian Research
   Council Future Fellowship (#FT120100215), awarded to Suzanne Fraser. It
   also benefited from the support of the Centre for Social Research in
   Health, Faculty of Arts, University of NSW, the BC Centre for Excellence
   in Research, Canada, and SORaD, Stockholm University. Each centre hosted
   Suzanne Fraser for lengthy visits during the course of her fellowship.
   The National Drug Research Institute at Curtin University is supported
   by funding from the Australian Government under the Substance Misuse
   Prevention and Service Improvement Grants Fund.
CR ALEXANDER BK, 1978, PSYCHOPHARMACOLOGY, V58, P175, DOI 10.1007/BF00426903
   [Anonymous], 2014, VIBRANT MATTER POLIT, Vix, P120
   Barad K, 2003, SIGNS, V28, P801, DOI 10.1086/345321
   Barad K., 1998, DIFFERENCES, V10, P87, DOI DOI 10.1215/10407391-10-2-87
   Bell S, 2014, NEUROETHICS-NETH, V7, P19, DOI 10.1007/s12152-013-9177-9
   Blackman L, 2016, BODY SOC, V22, P3, DOI 10.1177/1357034X16662325
   Bourgois P., 2009, RIGHTEOUS DOPEFIEND
   Broadus AD, 2010, J DRUG EDUC, V40, P281, DOI 10.2190/DE.40.3.e
   Campbell Nancy, 2007, DISCOVERING ADDICTIO
   Courtwright DT, 2010, BIOSOCIETIES, V5, P137, DOI 10.1057/biosoc.2009.3
   Derrida J., 1993, DIFFERENCES, V5, P1, DOI DOI 10.1215/10407391-5-1-1
   Duff C., 2014, ASSEMBLAGES HLTH DEL
   Fraser S, 2008, SUBSTANCE AND SUBSTITUTION: METHADONE SUBJECTS IN LIBERAL SOCIETIES, P1, DOI 10.1057/9780230582569
   Fraser S., 2011, DRUG EFFECT HLTH CRI, P1
   Fraser S., 2015, CONTEMP DRUG PROBL, V42, P1
   Fraser S, 2018, CRIT POLICY STUD, V12, P61, DOI 10.1080/19460171.2016.1191365
   Fraser S, 2017, INT J DRUG POLICY, V50, P19, DOI 10.1016/j.drugpo.2017.07.001
   Fraser S, 2013, ADDICT RES THEORY, V21, P496, DOI 10.3109/16066359.2012.749868
   Fraser Suzanne, 2014, HABITS REMAKING ADDI
   Frost Samantha, 2016, BIOCULTURAL CREATURE
   Gomart E, 2002, SOC STUD SCI, V32, P93, DOI 10.1177/0306312702032001005
   Gomart E., 2004, BODY SOC, V10, P85, DOI DOI 10.1177/1357034X04042937
   Hall W, 2015, LANCET PSYCHIAT, V2, P105, DOI 10.1016/S2215-0366(14)00126-6
   Haraway D, 2015, ENVIRON HUMANITIES, V6, P159, DOI 10.1215/22011919-3615934
   Hart C., 2013, HIGH PRICE NEUROSCIE
   Heim D, 2014, NATURE, V507, P40, DOI 10.1038/507040e
   Karasaki M, 2013, DRUG ALCOHOL REV, V32, P195, DOI 10.1111/j.1465-3362.2012.00501.x
   Keane H., 2002, WHATS WRONG ADDICTIO
   Kimber J, 2003, DRUG ALCOHOL REV, V22, P227, DOI 10.1080/095952301000116951
   Latour B, 2002, THEOR CULT SOC, V19, P247, DOI 10.1177/026327602761899246
   Latour B, 2004, CRIT INQUIRY, V30, P225, DOI 10.1086/421123
   Latour B, 2010, NEW LITERARY HIST, V41, P471
   Latour Bruno., 2012, WE HAVE NEVER BEEN M
   Lynch P, 2012, COLL ENGL, V74, P458
   Mackenzie A, 2017, BODY SOC, V23, P130, DOI 10.1177/1357034X17716521
   MARLATT GA, 1988, ANNU REV PSYCHOL, V39, P223, DOI 10.1146/annurev.psych.39.1.223
   Martin E, 2006, BIOSOCIETIES, V1, P273, DOI DOI 10.1017/S1745855206003012
   Martin E, 2010, SUBJECTIVITY, V3, P366, DOI 10.1057/sub.2010.23
   Meurk C, 2013, BIOSOCIETIES, V8, P491, DOI 10.1057/biosoc.2013.24
   Moore D, 2015, INT J DRUG POLICY, V26, P420, DOI 10.1016/j.drugpo.2015.01.011
   Moore D, 2006, SOC SCI MED, V62, P3035, DOI 10.1016/j.socscimed.2005.11.067
   Netherland J., 2012, CRIT PERSPECT
   Penington David, 2010, ANN AUSTR PROF SOC A
   Pienaar K, 2017, HEALTH-LONDON, V21, P519, DOI 10.1177/1363459316674062
   PRICE J, 1999, FEMINIST THEORY BODY
   Riley D., 1983, WAR IN THE NURSERY
   Ritter A, 2011, ASSESSMENT ILLICIT D
   Rose N, 2016, BODY SOC, V22, P140, DOI 10.1177/1357034X15623363
   Social Progress Imperative, 2016, SOC PROGR IND REP
   Stenius K., 2010, CONTEMP DRUG PROBL, V37, P417, DOI DOI 10.1177/009145091003700304
   Treloar C, 2007, DRUG ALCOHOL REV, V26, P355, DOI 10.1080/09595230701373867
   Vitellone Nicole, 2016, SOCIAL SCI SYRINGE
   Vrecko S, 2010, BIOSOCIETIES, V5, P36, DOI 10.1057/biosoc.2009.8
   Vrecko S, 2010, HIST HUM SCI, V23, P52, DOI 10.1177/0952695110371598
   Warin M, 2016, BODY SOC, V22, P53, DOI 10.1177/1357034X15590485
   Watson MC, 2011, THEOR CULT SOC, V28, P55, DOI 10.1177/0263276410396913
   Weinberg D, 2011, SOCIOL COMPASS, V5, P298, DOI 10.1111/j.1751-9020.2011.00363.x
   Weinberg Darin T., 2008, HDB CONSTRUCTIONIST, P13
   Wilson E., 2015, GUT FEMINISM
NR 59
TC 6
Z9 6
U1 0
U2 10
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1357-034X
EI 1460-3632
J9 BODY SOC
JI Body Soc.
PD DEC
PY 2018
VL 24
IS 4
BP 58
EP 86
DI 10.1177/1357034X18781738
PG 29
WC Sociology
WE Social Science Citation Index (SSCI)
SC Sociology
GA HE2GW
UT WOS:000453095500003
OA Bronze
DA 2023-06-23
ER

PT J
AU Le Moal, M
AF Le Moal, Michel
TI Negative affects are parts of the addiction syndrome
SO BEHAVIORAL AND BRAIN SCIENCES
LA English
DT Editorial Material
ID DECISION-MAKING; DRUG-ADDICTION; BRAIN; VULNERABILITY; NEUROBIOLOGY;
   REWARD
AB Decision-making is a complex activity for which emotions and affects are essential. Maladaptive choices depend on negative affects. Vulnerabilities to drug or non-drug objects depend on previous psychopathological comorbidities. Premorbid individual characteristics allow us to understand why some individuals - and not others - enter into the addiction cycle. Moreover, plasticity of reward neurocircuitry is, at least in past, responsible for these vulnerabilities leading to compulsive drug use.
C1 [Le Moal, Michel] Univ Bordeaux 2, Neuroctr Magendie, Inst Francois Magendie, F-33077 Bordeaux, France.
C3 UDICE-French Research Universities; Universite de Bordeaux
RP Le Moal, M (通讯作者)，Univ Bordeaux 2, Neuroctr Magendie, Inst Francois Magendie, F-33077 Bordeaux, France.
EM lemoal@bordeaux.inserm.fr
CR Al'Absi M, 2007, STRESS ADDICTION BIO
   Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244
   Baumeister R. F., 2004, HDB SELF REGULATION
   Baumeister RF., 1994, LOSING CONTROL WHY P
   Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295
   Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584
   Bechara A, 1998, J NEUROSCI, V18, P428
   Damasio AR, 2000, NAT NEUROSCI, V3, P1049, DOI 10.1038/79871
   Everitt BJ, 2002, J NEUROSCI, V22, P3312
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   GOODMAN A, 1990, BRIT J ADDICT, V85, P1403
   Goodman A, 2008, BIOCHEM PHARMACOL, V75, P266, DOI 10.1016/j.bcp.2007.07.030
   Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560
   Kahneman D, 2003, AM PSYCHOL, V58, P697, DOI 10.1037/0003-066X.58.9.697
   Kalivas PW, 2003, PSYCHOPHARMACOLOGY, V168, P44, DOI 10.1007/s00213-003-1393-2
   Koob GF, 2008, ANNU REV PSYCHOL, V59, P29, DOI 10.1146/annurev.psych.59.103006.093548
   Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Koob GF, 2006, NEUR ADD
   Le Moal M, 2007, EUR NEUROPSYCHOPHARM, V17, P377, DOI 10.1016/j.euroneuro.2006.10.006
   PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295
   Piazza PV, 1996, ANNU REV PHARMACOL, V36, P359, DOI 10.1146/annurev.pa.36.040196.002043
   See RE, 2003, ANN NY ACAD SCI, V985, P294
   Shaffer HJ, 2004, HARVARD REV PSYCHIAT, V12, P367, DOI 10.1080/10673220490905705
   *SUBST AB MENT HLT, 2003, RES 2002 NAT SURV DR
NR 26
TC 1
Z9 1
U1 0
U2 4
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0140-525X
EI 1469-1825
J9 BEHAV BRAIN SCI
JI Behav. Brain Sci.
PD AUG
PY 2008
VL 31
IS 4
BP 451
EP +
DI 10.1017/S0140525X08004871
PG 20
WC Psychology, Biological; Behavioral Sciences; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology; Behavioral Sciences; Neurosciences & Neurology
GA 370SP
UT WOS:000260783700042
DA 2023-06-23
ER

PT J
AU Shippenberg, TS
   Zapata, A
   Chefer, VI
AF Shippenberg, T. S.
   Zapata, A.
   Chefer, V. I.
TI Dynorphin and the pathophysiology of drug addiction
SO PHARMACOLOGY & THERAPEUTICS
LA English
DT Review
DE dynorphin; kappa-opioid receptor; glutamate; dopamine; drug and alcohol
   addiction
ID KAPPA-OPIOID-RECEPTOR; RAT NUCLEUS-ACCUMBENS; COCAINE-SEEKING BEHAVIOR;
   VENTRAL TEGMENTAL AREA; MESSENGER-RNA EXPRESSION; INTRACRANIAL
   SELF-STIMULATION; CONDITIONED PLACE PREFERENCE; PRODYNORPHIN SYSTEM
   ACTIVITY; ETHANOL WITHDRAWAL SYNDROME; EVOKED GLUTAMATE RELEASE
AB Drug addiction is a chronic relapsing disease in which drug administration becomes the primary stimulus that drives behavior regardless of the adverse consequence that may ensue. As drug use becomes more compulsive, motivation for natural rewards that normally drive behavior decreases. The discontinuation of drug use is associated with somatic signs of withdrawal, dysphoria, anxiety, and anhedonia. These consequences of drug use are thought to contribute to the maintenance of drug use and to the reinstatement of compulsive drug use that occurs during the early phase of abstinence. Even, however, after prolonged periods of abstinence, 80-90% of human addicts relapse to addiction, suggesting that repeated drug use produces enduring changes in brain circuits that subserve incentive motivation and stimulus-response (habit) learning. A major goal of addiction research is the identification of the neural mechanisms by which drugs of abuse produce these effects. This article will review data showing that the dynorphin/kappa-opioid receptor (KOPr) system serves an essential function in opposing alterations in behavior and brain neurochemistry that occur as a consequence of repeated drug use and that aberrant activity of this system may not only contribute to the dysregulation of behavior that characterizes addiction but to individual differences in vulnerability to the pharmacological actions of cocaine and alcohol. We will provide evidence that the repeated administration of cocaine and alcohol up-regulates the dynorphin/KOPr system and that pharmacological treatments that target this system may prove effective in the treatment of drug addiction. Published by Elsevier Inc.
C1 NIDA, Integrat Neurosci Sect, NIH, Intramural Res Program, Baltimore, MD 21224 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute on
   Aging (NIA); NIH National Institute on Drug Abuse (NIDA)
RP Shippenberg, TS (通讯作者)，NIDA, Integrat Neurosci Sect, NIH, Intramural Res Program, 333 Cassell Dr, Baltimore, MD 21224 USA.
EM tshippen@intra.nida.nih.gov
FU Intramural NIH HHS [Z01 DA000504-01] Funding Source: Medline
CR ALVAREZBOLADO G, 1990, J COMP NEUROL, V300, P287, DOI 10.1002/cne.903000302
   *AM PSYCHIAT ASS, 1994, DIAGN STAT MAN MENT
   Baker DA, 2003, NAT NEUROSCI, V6, P743, DOI 10.1038/nn1069
   BALSKUBIK R, 1989, PSYCHOPHARMACOLOGY, V98, P203, DOI 10.1007/BF00444692
   BALSKUBIK R, 1993, J PHARMACOL EXP THER, V264, P489
   Barr AM, 2002, TRENDS PHARMACOL SCI, V23, P475, DOI 10.1016/S0165-6147(02)02086-2
   Beadles-Bohling AS, 2005, BRAIN RES, V1046, P77, DOI 10.1016/j.brainres.2005.03.043
   Beardsley PM, 2005, PSYCHOPHARMACOLOGY, V183, P118, DOI 10.1007/s00213-005-0167-4
   BERENDSE HW, 1992, J COMP NEUROL, V316, P314, DOI 10.1002/cne.903160305
   Bhushan RG, 2004, J MED CHEM, V47, P2969, DOI 10.1021/jm0342358
   Bodnar RJ, 2005, PEPTIDES, V26, P2629, DOI 10.1016/j.peptides.2005.06.010
   Brandon CL, 2003, EUR J NEUROSCI, V18, P1584, DOI 10.1046/j.1460-9568.2003.02892.x
   Breiter HC, 1997, NEURON, V19, P591, DOI 10.1016/S0896-6273(00)80374-8
   BROADBEAR JH, 1994, PSYCHOPHARMACOLOGY, V115, P311, DOI 10.1007/BF02245071
   Brodie MS, 1999, ALCOHOL CLIN EXP RES, V23, P1848, DOI 10.1111/j.1530-0277.1999.tb04082.x
   Capriles N, 2003, PSYCHOPHARMACOLOGY, V168, P66, DOI 10.1007/s00213-002-1283-z
   Carlezon WA, 1998, SCIENCE, V282, P2272, DOI 10.1126/science.282.5397.2272
   Carlezon WA, 2006, J PHARMACOL EXP THER, V316, P440, DOI 10.1124/jpet.105.092304
   Carroll I, 2004, EUR J PHARMACOL, V501, P111, DOI 10.1016/j.ejphar.2004.08.028
   CENCI MA, 1993, EUR J NEUROSCI, V5, P1062, DOI 10.1111/j.1460-9568.1993.tb00959.x
   CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570
   Chefer VI, 2005, J NEUROSCI, V25, P5029, DOI 10.1523/JNEUROSCI.0854-05.2005
   Chefer VI, 2000, NEUROSCIENCE, V101, P619, DOI 10.1016/S0306-4522(00)00417-6
   Chen ACH, 2002, AM J MED GENET, V114, P429, DOI 10.1002/ajmg.10362
   CHROBAK JJ, 1993, J NEURAL TRANSM-GEN, V93, P123, DOI 10.1007/BF01245342
   COLE RL, 1995, NEURON, V14, P813, DOI 10.1016/0896-6273(95)90225-2
   Collins SL, 2001, EUR J PHARMACOL, V426, P25, DOI 10.1016/S0014-2999(01)01194-3
   CORBETT AD, 1982, NATURE, V299, P79, DOI 10.1038/299079a0
   CRAWFORD CA, 1995, PSYCHOPHARMACOLOGY, V120, P392, DOI 10.1007/BF02245810
   Cryan JF, 2002, TRENDS PHARMACOL SCI, V23, P238, DOI 10.1016/S0165-6147(02)02017-5
   Dahl JP, 2005, AM J MED GENET B, V139B, P106, DOI 10.1002/ajmg.b.30238
   DAUNAIS JB, 1993, NEUROREPORT, V4, P543, DOI 10.1097/00001756-199305000-00020
   De Vries TJ, 1998, EUR J NEUROSCI, V10, P3565, DOI 10.1046/j.1460-9568.1998.00368.x
   Di Benedetto M, 2006, NEUROSCIENCE, V137, P187, DOI 10.1016/j.neuroscience.2005.09.015
   Di Chiara G, 2004, NEUROPHARMACOLOGY, V47, P227, DOI 10.1016/j.neuropharm.2004.06.032
   Di Ciano P, 2005, EUR J PHARMACOL, V526, P186, DOI 10.1016/j.ejphar.2005.09.024
   Di Ciano P, 2004, J NEUROSCI, V24, P7167, DOI 10.1523/JNEUROSCI.1581-04.2004
   DIANA M, 1993, P NATL ACAD SCI USA, V90, P7966, DOI 10.1073/pnas.90.17.7966
   Diana M, 1996, NEUROSCIENCE, V71, P411, DOI 10.1016/0306-4522(95)00482-3
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Doyon WM, 2006, NEUROPHARMACOLOGY, V51, P487, DOI 10.1016/j.neuropharm.2006.04.005
   ENDOH T, 1992, ARCH INT PHARMACOD T, V316, P30
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   EVERITT BJ, 2002, J NEUROSCI, V22, P6247
   Fadda P, 1999, ALCOHOL CLIN EXP RES, V23, P1296, DOI 10.1097/00000374-199908000-00002
   Fagergren P, 2003, EUR J NEUROSCI, V17, P2212, DOI 10.1046/j.1460-9568.2003.02636.x
   GAMBARDELLA A, 2003, EPILEPSIA, V44, P1225
   GAWIN FH, 1991, SCIENCE, V251, P1580, DOI 10.1126/science.2011738
   GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780
   GERFEN CR, 1991, J NEUROSCI, V11, P1016
   GLICK SD, 1995, BRAIN RES, V681, P147, DOI 10.1016/0006-8993(95)00306-B
   Gong WH, 1997, BRAIN RES, V754, P103, DOI 10.1016/S0006-8993(97)00059-0
   Gong WH, 1996, BRAIN RES, V707, P64, DOI 10.1016/0006-8993(95)01222-2
   Gray AM, 1999, J NEUROCHEM, V73, P1066, DOI 10.1046/j.1471-4159.1999.0731066.x
   Graybiel AM, 2005, CURR OPIN NEUROBIOL, V15, P638, DOI 10.1016/j.conb.2005.10.006
   GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I
   GROENEWEGEN HJ, 1993, NEUROSCIENCE, V57, P113, DOI 10.1016/0306-4522(93)90115-V
   GROSS RA, 1987, P NATL ACAD SCI USA, V84, P5469, DOI 10.1073/pnas.84.15.5469
   GRUDT TJ, 1993, P NATL ACAD SCI USA, V90, P11429, DOI 10.1073/pnas.90.23.11429
   GULYA K, 1993, MOL BRAIN RES, V20, P1, DOI 10.1016/0169-328X(93)90105-X
   Haber SN, 2000, J NEUROSCI, V20, P2369
   HEIDBREDER CA, 1994, NEUROREPORT, V5, P1797, DOI 10.1097/00001756-199409080-00028
   HEIDBREDER CA, 1995, J PHARMACOL EXP THER, V275, P150
   HEIDBREDER CA, 1993, BRAIN RES, V616, P335, DOI 10.1016/0006-8993(93)90228-F
   HEIDBREDER CA, 1996, J PHARMACOL EXP THER, V278, P182
   HEIJNA MH, 1992, EUR J PHARMACOL, V229, P197, DOI 10.1016/0014-2999(92)90555-I
   Heimer L, 2006, NEUROSCI BIOBEHAV R, V30, P126, DOI 10.1016/j.neubiorev.2005.06.006
   Herz A, 1997, PSYCHOPHARMACOLOGY, V129, P99, DOI 10.1007/s002130050169
   Heyliger SO, 1999, SYNAPSE, V34, P256, DOI 10.1002/(SICI)1098-2396(19991215)34:4<256::AID-SYN2>3.3.CO;2-Y
   HILL MP, 1995, EUR J PHARMACOL, V281, pR1, DOI 10.1016/0014-2999(95)00385-X
   Hill MP, 1999, BRIT J PHARMACOL, V127, P275, DOI 10.1038/sj.bjp.0702523
   Hjelmstad GO, 2001, J NEUROPHYSIOL, V85, P1153, DOI 10.1152/jn.2001.85.3.1153
   Holter SM, 2000, PSYCHOPHARMACOLOGY, V153, P93, DOI 10.1007/s002130000601
   HORAN PJ, 1993, J PHARMACOL EXP THER, V266, P926
   Hurd YL, 1996, NEUROSCIENCE, V72, P767, DOI 10.1016/0306-4522(96)00002-4
   HURD YL, 1993, SYNAPSE, V13, P357, DOI 10.1002/syn.890130408
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   HYYTIA P, 1993, PHARMACOL BIOCHEM BE, V45, P697, DOI 10.1016/0091-3057(93)90527-Z
   Ito R, 2002, J NEUROSCI, V22, P6247
   Jamensky NT, 1997, ALCOHOL CLIN EXP RES, V21, P1455
   Jones RM, 2000, EUR J PHARMACOL, V396, P49, DOI 10.1016/S0014-2999(00)00208-9
   Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441
   KALIVAS PW, 1993, J NEUROSCI, V13, P266
   Kalivas PW, 2005, NEURON, V45, P647, DOI 10.1016/j.neuron.2005.02.005
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   KLITENICK MA, 1992, NEUROSCIENCE, V50, P371, DOI 10.1016/0306-4522(92)90430-A
   Koob GE, 2004, NEBR SYM MOTIV, V50, P1
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Kosterlitz H W, 1989, NIDA Res Monogr, V95, P159
   Kovacs KM, 2005, ALCOHOL CLIN EXP RES, V29, P730, DOI 10.1097/01.ALC.0000164361.62346.D6
   Kuzmin AV, 1997, EUR J PHARMACOL, V321, P265, DOI 10.1016/S0014-2999(96)00961-2
   LAHTI RA, 1985, EUR J PHARMACOL, V109, P281, DOI 10.1016/0014-2999(85)90431-5
   Lindholm S, 2001, BEHAV BRAIN RES, V120, P137, DOI 10.1016/S0166-4328(00)00368-5
   Lindholm S, 2000, ALCOHOL, V22, P165, DOI 10.1016/S0741-8329(00)00118-X
   Liu-Chen LY, 2004, LIFE SCI, V75, P511, DOI 10.1016/j.lfs.2003.10.041
   Mague SD, 2003, J PHARMACOL EXP THER, V305, P323, DOI 10.1124/jpet.102.046433
   MANEUF YP, 1995, BRAIN RES, V683, P102, DOI 10.1016/0006-8993(95)00358-W
   Mansour A, 1996, NEUROSCIENCE, V71, P671, DOI 10.1016/0306-4522(95)00464-5
   Margolis EB, 2006, P NATL ACAD SCI USA, V103, P2938, DOI 10.1073/pnas.0511159103
   Margolis EB, 2003, J NEUROSCI, V23, P9981
   Marinelli PW, 2000, LIFE SCI, V66, P1915, DOI 10.1016/S0024-3205(00)00517-8
   MARKOU A, 1992, PSYCHOPHARMACOLOGY, V109, P305, DOI 10.1007/BF02245878
   Mateo Y, 2005, NEUROPSYCHOPHARMACOL, V30, P1455, DOI 10.1038/sj.npp.1300687
   Mathieu-Kia AM, 1998, MOL BRAIN RES, V54, P141, DOI 10.1016/S0169-328X(97)00338-0
   Matsuzawa S, 1999, EUR J PHARMACOL, V368, P9, DOI 10.1016/S0014-2999(99)00008-4
   MATTHEWS RT, 1984, NEUROSCIENCE, V11, P617, DOI 10.1016/0306-4522(84)90048-4
   McFarland K, 2004, J NEUROSCI, V24, P1551, DOI 10.1523/JNEUROSCI.4177-03.2004
   McFarland K, 2003, J NEUROSCI, V23, P3531
   MCGEORGE AJ, 1989, NEUROSCIENCE, V29, P503, DOI 10.1016/0306-4522(89)90128-0
   McLaughlin JP, 2006, NEUROPSYCHOPHARMACOL, V31, P787, DOI 10.1038/sj.npp.1300860
   McLaughlin JP, 2003, J NEUROSCI, V23, P5674, DOI 10.1523/jneurosci.23-13-05674.2003
   Meiergerd SM, 1997, BRAIN RES, V773, P203, DOI 10.1016/S0006-8993(97)00926-8
   Melendez RI, 2004, ALCOHOL, V32, P137, DOI 10.1016/j.alcohol.2003.12.002
   Mello NK, 1998, J PHARMACOL EXP THER, V286, P812
   Meshul CK, 2000, NEUROSCIENCE, V96, P91, DOI 10.1016/S0306-4522(99)90481-5
   Metcalf MD, 2005, AAPS J, V7, pE704, DOI 10.1208/aapsj070371
   Mitchell JM, 2005, PSYCHOPHARMACOLOGY, V182, P384, DOI 10.1007/s00213-005-0067-7
   MITROVIC I, 1995, J PHARMACOL EXP THER, V272, P1260
   Mitrovic I, 2002, EUR J NEUROSCI, V15, P257, DOI 10.1046/j.0953-816x.2001.01860.x
   Mitrovic I, 1998, BRAIN RES, V792, P193, DOI 10.1016/S0006-8993(98)00130-9
   MOGENSON GJ, 1991, ADV EXP MED BIOL, V295, P267
   Morgan D, 2006, NEUROPSYCHOPHARMACOL, V31, P121, DOI 10.1038/sj.npp.1300773
   MUCHA RF, 1985, PSYCHOPHARMACOLOGY, V86, P274, DOI 10.1007/BF00432213
   NAPIER TC, 1989, NEUROPHARMACOLOGY, V28, P757, DOI 10.1016/0028-3908(89)90163-9
   Napier TC, 1999, ANN NY ACAD SCI, V877, P176, DOI 10.1111/j.1749-6632.1999.tb09268.x
   Negus SS, 2004, PSYCHOPHARMACOLOGY, V176, P204, DOI 10.1007/s00213-004-1878-7
   Negus SS, 1997, J PHARMACOL EXP THER, V282, P44
   Newton SS, 2002, J NEUROSCI, V22, P10883
   NG JP, 1991, J NEUROCHEM, V56, P1485, DOI 10.1111/j.1471-4159.1991.tb02042.x
   Nicol B, 1996, NEUROSCI LETT, V218, P79, DOI 10.1016/S0304-3940(96)13104-9
   NYLANDER I, 1994, ALCOHOL CLIN EXP RES, V18, P1272, DOI 10.1111/j.1530-0277.1994.tb00118.x
   O'Brien CP, 2005, AM J PSYCHIAT, V162, P1423, DOI 10.1176/appi.ajp.162.8.1423
   OLDS ME, 1981, ANNU REV PSYCHOL, V32, P523, DOI 10.1146/annurev.ps.32.020181.002515
   Olianas MC, 2006, BRIT J PHARMACOL, V147, P360, DOI 10.1038/sj.bjp.0706601
   Oswald LM, 2004, PHYSIOL BEHAV, V81, P339, DOI 10.1016/j.physbeh.2004.02.008
   Packard MG, 2002, ANNU REV NEUROSCI, V25, P563, DOI 10.1146/annurev.neuro.25.112701.142937
   Peckys D, 1999, NEUROSCIENCE, V88, P1093, DOI 10.1016/S0306-4522(98)00251-6
   PFEIFFER A, 1986, SCIENCE, V233, P774, DOI 10.1126/science.3016896
   PICKEL VM, 1993, BRAIN RES, V602, P275, DOI 10.1016/0006-8993(93)90693-H
   Pliakas AM, 2001, J NEUROSCI, V21, P7397, DOI 10.1523/JNEUROSCI.21-18-07397.2001
   Ploj K, 2000, BRAIN RES BULL, V53, P219, DOI 10.1016/S0361-9230(00)00328-2
   PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0
   PORTOGHESE PS, 1994, J MED CHEM, V37, P1495, DOI 10.1021/jm00036a015
   Przewlocka B, 1997, NEUROSCI LETT, V238, P13, DOI 10.1016/S0304-3940(97)00829-X
   PRZEWLOCKI R, 1987, BRAIN RES, V413, P213, DOI 10.1016/0006-8993(87)91012-2
   Ranaldi R, 1999, J NEUROSCI, V19, P4102
   Rawls SM, 1999, J NEUROCHEM, V73, P1058, DOI 10.1046/j.1471-4159.1999.0731058.x
   Rawls SM, 1997, J NEUROCHEM, V68, P1553
   Rebec GV, 2005, J EXP ANAL BEHAV, V84, P653, DOI 10.1901/jeab.2005.105-04
   REID M, 1988, EUR J PHARMACOL, V147, P411, DOI 10.1016/0014-2999(88)90176-8
   RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058
   Robbins TW, 1999, NATURE, V398, P567, DOI 10.1038/19208
   Roberts AJ, 2000, J PHARMACOL EXP THER, V293, P1002
   Robinson TE, 2001, ADDICTION, V96, P103, DOI 10.1046/j.1360-0443.2001.9611038.x
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   ROMUALDI P, 1991, BRAIN RES, V563, P132, DOI 10.1016/0006-8993(91)91525-6
   Rosin A, 1999, NEUROSCI LETT, V275, P1, DOI 10.1016/S0304-3940(99)00675-8
   Roth BL, 2002, P NATL ACAD SCI USA, V99, P11934, DOI 10.1073/pnas.182234399
   Sbrenna S, 1999, J PHARMACOL EXP THER, V291, P1365
   Schenk S, 1999, PSYCHOPHARMACOLOGY, V144, P339, DOI 10.1007/s002130051016
   Schenk S, 2000, PSYCHOPHARMACOLOGY, V151, P85, DOI 10.1007/s002130000476
   Schenk S, 2001, NEUROPSYCHOPHARMACOL, V24, P441, DOI 10.1016/S0893-133X(00)00190-1
   SCHMIDT P, 1994, BRAIN RES, V654, P223, DOI 10.1016/0006-8993(94)90483-9
   Schultz W, 2002, NEURON, V36, P241, DOI 10.1016/S0896-6273(02)00967-4
   SEGAL DS, 1992, BRAIN RES, V577, P351, DOI 10.1016/0006-8993(92)90297-M
   Shippenberg TS, 2001, ANN NY ACAD SCI, V937, P50
   SHIPPENBERG TS, 1987, BRAIN RES, V436, P169, DOI 10.1016/0006-8993(87)91571-X
   SHIPPENBERG TS, 1993, J PHARMACOL EXP THER, V265, P53
   Shippenberg TS, 1996, J PHARMACOL EXP THER, V276, P545
   SHIPPENBERG TS, 1988, PAIN, V35, P179, DOI 10.1016/0304-3959(88)90225-4
   SHIPPENBERG TS, 1991, PSYCHOPHARMACOLOGY, V103, P209, DOI 10.1007/BF02244205
   SHIPPENBERG TS, 1988, EUR J PHARMACOL, V151, P233, DOI 10.1016/0014-2999(88)90803-5
   Shirayama Y, 2004, J NEUROCHEM, V90, P1258, DOI 10.1111/j.1471-4159.2004.02589.x
   Simonato M, 1996, PROG NEUROBIOL, V50, P557, DOI 10.1016/S0301-0082(96)00045-7
   Smith JE, 2004, NEUROSCI BIOBEHAV R, V27, P841, DOI 10.1016/j.neubiorev.2003.11.002
   Solbrig MV, 2006, BRAIN, V129, P642, DOI 10.1093/brain/awl008
   SPANAGEL R, 1992, P NATL ACAD SCI USA, V89, P2046, DOI 10.1073/pnas.89.6.2046
   Spanos PD, 2000, PROBABILIST ENG MECH, V15, P1, DOI 10.1016/S0266-8920(99)00002-8
   STEINER H, 1993, J NEUROSCI, V13, P5066, DOI 10.1523/JNEUROSCI.13-12-05066.1993
   Stogmann E, 2002, ANN NEUROL, V51, P260, DOI 10.1002/ana.10108
   Svensson P, 1998, MOL BRAIN RES, V56, P162, DOI 10.1016/S0169-328X(98)00041-2
   Svingos AL, 2002, BRAIN RES, V946, P262, DOI 10.1016/S0006-8993(02)02894-9
   Svingos AL, 1999, J NEUROSCI, V19, P1804
   Svingos AL, 2001, SYNAPSE, V42, P185, DOI 10.1002/syn.10005
   TANG AH, 1985, PSYCHOPHARMACOLOGY, V85, P309, DOI 10.1007/BF00428193
   Thompson AC, 2000, J NEUROSCI, V20, P9333
   Todtenkopf MS, 2004, PSYCHOPHARMACOLOGY, V172, P463, DOI 10.1007/s00213-003-1680-y
   Turchan J, 1998, NEUROSCIENCE, V85, P1051, DOI 10.1016/S0306-4522(97)00639-8
   van Dongen YC, 2005, NEUROSCIENCE, V136, P1049, DOI 10.1016/j.neuroscience.2005.08.050
   VANBOCKSTAELE EJ, 1994, J COMP NEUROL, V341, P1, DOI 10.1002/cne.903410102
   VANBOCKSTAELE EJ, 1995, J COMP NEUROL, V351, P117, DOI 10.1002/cne.903510111
   Vanderschuren LJMJ, 2005, J NEUROSCI, V25, P8665, DOI 10.1523/JNEUROSCI.0925-05.2005
   VONVOIGTLANDER PF, 1982, PROG NEURO-PSYCHOPH, V157, P151
   WALKER BM, 2007, NEUROPSCHOPHARMACOLO
   Walsh SL, 2001, PSYCHOPHARMACOLOGY, V157, P151, DOI 10.1007/s002130100788
   WANG JQ, 1994, SYNAPSE, V18, P343, DOI 10.1002/syn.890180410
   WEISS F, 1993, J PHARMACOL EXP THER, V267, P250
   Weiss F, 1996, J NEUROSCI, V16, P3474
   WEVERS A, 1995, NEUROSCI LETT, V195, P125, DOI 10.1016/0304-3940(95)11797-Z
   Williams JM, 2005, NEUROPHARMACOLOGY, V48, P51, DOI 10.1016/j.neuropharm.2004.09.004
   Williams KL, 1998, ALCOHOL CLIN EXP RES, V22, P1634, DOI 10.1097/00000374-199811000-00004
   Willner P, 2005, NEUROPSYCHOBIOLOGY, V52, P90, DOI 10.1159/000087097
   Willuhn I, 2003, EUR J NEUROSCI, V17, P1053, DOI 10.1046/j.1460-9568.2003.02525.x
   WISE RA, 1995, PSYCHOPHARMACOLOGY, V117, P130, DOI 10.1007/BF02245178
   Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406
   Wise RA, 1998, DRUG ALCOHOL DEPEN, V51, P13, DOI 10.1016/S0376-8716(98)00063-5
   Xuei X, 2006, MOL PSYCHIATR, V11, P1016, DOI 10.1038/sj.mp.4001882
   Yin HH, 2005, EUR J NEUROSCI, V22, P505, DOI 10.1111/j.1460-9568.2005.04219.x
   Yin JCP, 1996, CURR OPIN NEUROBIOL, V6, P264, DOI 10.1016/S0959-4388(96)80082-1
   YOKOO H, 1992, EUR J PHARMACOL, V222, P43, DOI 10.1016/0014-2999(92)90461-C
   YOSHIMOTO K, 1992, ALCOHOL, V9, P17, DOI 10.1016/0741-8329(92)90004-T
   You ZB, 1999, J PHARMACOL EXP THER, V290, P1307
   YUAN XR, 1992, NEUROSCI LETT, V134, P223, DOI 10.1016/0304-3940(92)90522-9
   Yung KKL, 2000, SYNAPSE, V38, P413, DOI 10.1002/1098-2396(20001215)38:4<413::AID-SYN6>3.0.CO;2-V
   ZABORSZKY L, 1985, J NEUROSCI METH, V14, P255, DOI 10.1016/0165-0270(85)90088-3
   ZAHM DS, 1985, BRAIN RES, V325, P317, DOI 10.1016/0006-8993(85)90331-2
   ZAHM DS, 1993, J COMP NEUROL, V327, P220, DOI 10.1002/cne.903270205
   Zapata A, 2006, ALCOHOL CLIN EXP RES, V30, P592, DOI 10.1111/j.1530-0277.2006.00069.x
   Zapata A, 2003, EUR J NEUROSCI, V17, P590, DOI 10.1046/j.1460-9568.2003.02491.x
   Zhang Y, 2004, PSYCHOPHARMACOLOGY, V172, P422, DOI 10.1007/s00213-003-1688-3
   Zhou L, 2003, NEUROSCIENCE, V120, P783, DOI 10.1016/S0306-4522(03)00326-9
NR 221
TC 269
Z9 284
U1 0
U2 33
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0163-7258
J9 PHARMACOL THERAPEUT
JI Pharmacol. Ther.
PD NOV
PY 2007
VL 116
IS 2
BP 306
EP 321
DI 10.1016/j.pharmthera.2007.06.011
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 227LT
UT WOS:000250658900008
PM 17868902
OA Green Accepted, Green Submitted
DA 2023-06-23
ER

PT J
AU Muller, CP
AF Mueller, Christian P.
TI Drug instrumentalization
SO BEHAVIOURAL BRAIN RESEARCH
LA English
DT Review
DE Drug instrumentalization; Drug use; Drug abuse; Drug addiction;
   Instrumentalization goals
ID NUCLEUS-ACCUMBENS DOPAMINE; CORTICOTROPIN-RELEASING-FACTOR; ANDROGENIC
   STEROID DEPENDENCE; MODERATE ALCOHOL-CONSUMPTION; SELF-MEDICATION
   HYPOTHESIS; ENVIRONMENTAL RISK-FACTORS; SUBSTANCE USE DISORDERS;
   MARIJUANA USE MOTIVES; NONMEDICAL USE; PRESCRIPTION STIMULANTS
AB Psychoactive drugs with addiction potential are widely used by people of virtually all cultures in a non-addictive way. In order to understand this behaviour, its population penetrance, and its persistence, drug instrumentalization was suggested as a driving force for this consumption. Drug instrumentalization theory holds that psychoactive drugs are consumed in a very systematic way in order to make other, non-drug-related behaviours more efficient. Here, we review the evolutionary origin of this behaviour and its psychological mechanisms and explore the neurobiological and neuropharmacological mechanisms underlying them. Instrumentalization goals are discussed, for which an environmentally selective and mental state-dependent consumption of psychoactive drugs can be learned and maintained in a non-addictive way. A small percentage of people who regularly instrumentalize psychoactive drugs make a transition to addiction, which often starts with qualitative and quantitative changes in the instrumentalization goals. As such, addiction is proposed to develop from previously established long-term drug instrumentalization. Thus, preventing and treating drug addiction in an individualized medicine approach may essentially require understanding and supporting personal instrumentalization goals.
C1 [Mueller, Christian P.] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp, Dept Psychiat & Psychotherapy, Schwabachanlage 6, D-91054 Erlangen, Germany.
C3 University of Erlangen Nuremberg
RP Muller, CP (通讯作者)，Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp, Dept Psychiat & Psychotherapy, Schwabachanlage 6, D-91054 Erlangen, Germany.
EM christian.mueller@uk-erlangen.de
OI Muller, Christian/0000-0002-5325-9900
FU Deutsche Forschungsgemeinschaft (DFG) [MU 2789/7-2, MU 2789/8-2]; German
   Federal Ministry for Education and Research (Bundesministerium fur
   Bildung und Forschung [BMBF]) grant e:Med Target-OXY
FX The research of the author is funded by the Deutsche
   Forschungsgemeinschaft (DFG) grants MU 2789/7-2 and MU 2789/8-2, and by
   funding from the German Federal Ministry for Education and Research
   (Bundesministerium fur Bildung und Forschung [BMBF]) grant e:Med
   Target-OXY.
CR ALBOUZ S, 1986, LIFE SCI, V38, P357, DOI 10.1016/0024-3205(86)90083-4
   Alcaro A, 2011, NEUROSCI BIOBEHAV R, V35, P1805, DOI 10.1016/j.neubiorev.2011.03.002
   Allison C, 2003, PHARMACOL THERAPEUT, V98, P171, DOI 10.1016/S0163-7258(03)00029-9
   Amato D, 2011, INT J NEUROPSYCHOPH, V14, P1327, DOI 10.1017/S1461145711000010
   Ameri A, 1999, PROG NEUROBIOL, V58, P315, DOI 10.1016/S0301-0082(98)00087-2
   American Psychiatric Association [APA], 2022, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425787]
   Anders Gunther, 1956, ANTIQUIERTHEIT MENSC
   [Anonymous], 1 12 1000 YEARS
   [Anonymous], 2000, SCI MARIJUANA
   [Anonymous], EATING WILD SIDE PHA
   [Anonymous], PHILOS GLUECKS
   [Anonymous], BEHAV NEUROBIOLOGY S
   [Anonymous], COCAINE UNAUTHORIZED
   [Anonymous], OPIUM KULTURGESCHICH
   [Anonymous], HIST OVERVIEW AMPHET
   [Anonymous], NO DRUGS NO FUTURE D
   [Anonymous], PERSONALITY DR UNPUB
   [Anonymous], NEUROTOX RES
   [Anonymous], NEUROSCI BIOBEHAV RE
   Arria AM, 2006, PEDIATR ANN, V35, P565, DOI 10.3928/0090-4481-20060801-09
   Arroyo M, 1998, PSYCHOPHARMACOLOGY, V140, P331, DOI 10.1007/s002130050774
   Aston-Jones G, 1999, BIOL PSYCHIAT, V46, P1309, DOI 10.1016/S0006-3223(99)00140-7
   Atran S, 2004, BEHAV BRAIN SCI, V27, P713, DOI 10.1017/S0140525X04000172
   BAUMBAICKER C, 1985, DRUG ALCOHOL DEPEN, V15, P305, DOI 10.1016/0376-8716(85)90008-0
   Berridge KC, 2003, TRENDS NEUROSCI, V26, P507, DOI 10.1016/S0166-2236(03)00233-9
   Berridge KC, 2015, NEURON, V86, P646, DOI 10.1016/j.neuron.2015.02.018
   Bierut LJ, 1998, ARCH GEN PSYCHIAT, V55, P982, DOI 10.1001/archpsyc.55.11.982
   Bonn-Miller MO, 2007, ADDICT BEHAV, V32, P49, DOI 10.1016/j.addbeh.2006.03.018
   Booth C, 2009, ADDICT BEHAV, V34, P730, DOI 10.1016/j.addbeh.2009.04.010
   Borota D, 2014, NAT NEUROSCI, V17, P201, DOI 10.1038/nn.3623
   BORSINI F, 1979, RES COMMUN CHEM PATH, V26, P3
   Boyd CJ, 2006, PEDIATRICS, V118, P2472, DOI 10.1542/peds.2006-1644
   Boyd CJ, 2009, J ADDICT DIS, V28, P232, DOI 10.1080/10550880903028452
   Boys A, 1999, ADDICTION, V94, P1043, DOI 10.1046/j.1360-0443.1999.94710439.x
   Boys A, 2003, ADDICTION, V98, P951, DOI 10.1046/j.1360-0443.2003.00394.x
   Boys A, 2001, HEALTH EDUC RES, V16, P457, DOI 10.1093/her/16.4.457
   Bradizza CM, 1999, J STUD ALCOHOL, V60, P491, DOI 10.15288/jsa.1999.60.491
   Brand R, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01226
   Brand R, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00101
   Brischoux F, 2009, P NATL ACAD SCI USA, V106, P4894, DOI 10.1073/pnas.0811507106
   Britt GC, 2005, SUBST USE MISUSE, V40, P1189, DOI 10.1081/JA-200066730
   Bronfenbrenner U, 1994, INT ENCY ED, V3, DOI DOI 10.1111/J.1467-9507.1994.TB00025.X
   Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111
   BROWN SA, 1980, J CONSULT CLIN PSYCH, V48, P419, DOI 10.1037/0022-006X.48.4.419
   BROWN SA, 1995, AM J PSYCHIAT, V152, P45
   BROWN SA, 1985, J CONSULT CLIN PSYCH, V53, P123, DOI 10.1037/0022-006X.53.1.123
   Burnett S, 2011, NEUROSCI BIOBEHAV R, V35, P1654, DOI 10.1016/j.neubiorev.2010.10.011
   Campbell JC, 2009, ALCOHOL, V43, P547, DOI 10.1016/j.alcohol.2009.09.029
   Carrigan MH, 2008, ADDICT BEHAV, V33, P1162, DOI 10.1016/j.addbeh.2008.04.020
   Castren E, 2005, NAT REV NEUROSCI, V6, P241, DOI 10.1038/nrn1629
   CATO BM, 1992, J DRUG EDUC, V22, P293, DOI 10.2190/WP67-9KRF-VJPG-JRQ5
   Cauli O, 2005, BEHAV PHARMACOL, V16, P63, DOI 10.1097/00008877-200503000-00001
   Chick J, 1999, EUR ADDICT RES, V5, P74, DOI 10.1159/000018969
   Chisholm J.S., 1999, DEATH HOPE SEX STEPS
   Ciccocioppo R, 1999, PSYCHOPHARMACOLOGY, V144, P151, DOI 10.1007/s002130050988
   CLAYTON DH, 1993, TRENDS ECOL EVOL, V8, P60, DOI 10.1016/0169-5347(93)90160-Q
   CONGER JJ, 1951, Q J STUD ALCOHOL, V12, P1
   COOPER ML, 1995, J PERS SOC PSYCHOL, V69, P990, DOI 10.1037/0022-3514.69.5.990
   COOPER ML, 1992, J ABNORM PSYCHOL, V101, P139, DOI 10.1037/0021-843X.101.1.139
   COOPER ML, 1988, J ABNORM PSYCHOL, V97, P218, DOI 10.1037/0021-843X.97.2.218
   Cooper SE, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09106-3
   Cosmides L, 1999, J ABNORM PSYCHOL, V108, P453, DOI 10.1037/0021-843X.108.3.453
   COSMIDES L, 1994, MAPPING MIND DOMAIN, P85, DOI DOI 10.1017/CBO9780511752902.005
   Cruz FC, 2011, PSYCHOPHARMACOLOGY, V215, P165, DOI 10.1007/s00213-010-2139-6
   CURRAN HV, 1991, PSYCHOPHARMACOLOGY, V105, P1
   Davey Jeremy, 2007, Traffic Inj Prev, V8, P253, DOI 10.1080/15389580601186034
   DAVIES J. B., 1997, MYTH ADDICTION
   DECKER MW, 1995, LIFE SCI, V56, P545, DOI 10.1016/0024-3205(94)00488-E
   Devineni AV, 2009, CURR BIOL, V19, P2126, DOI 10.1016/j.cub.2009.10.070
   Di Chiara G, 2002, BEHAV BRAIN RES, V137, P75, DOI 10.1016/S0166-4328(02)00286-3
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   DICHIARA G, 1995, DRUG ALCOHOL DEPEN, V38, P95, DOI 10.1016/0376-8716(95)01118-I
   DICHIARA G, 1992, TRENDS PHARMACOL SCI, V13, P185
   Dome P, 2010, NEUROSCI BIOBEHAV R, V34, P295, DOI 10.1016/j.neubiorev.2009.07.013
   Dudley R, 2002, ADDICTION, V97, P381, DOI 10.1046/j.1360-0443.2002.00002.x
   Dudley R, 2000, Q REV BIOL, V75, P3, DOI 10.1086/393255
   Eggeling C, 2009, NATURE, V457, P1159, DOI 10.1038/nature07596
   Eissenberg T, 2000, DRUG ALCOHOL DEPEN, V59, pS41
   EMLEY GS, 1983, PHARMACOL BIOCHEM BE, V19, P5, DOI 10.1016/0091-3057(83)90302-7
   Ersche KD, 2011, BRAIN, V134, P2013, DOI 10.1093/brain/awr138
   Everitt BJ, 2002, J NEUROSCI, V22, P3312
   Fantegrossi WE, 2004, NEUROPSYCHOPHARMACOL, V29, P1270, DOI 10.1038/sj.npp.1300442
   Fantini J, 2009, BBA-BIOMEMBRANES, V1788, P2345, DOI 10.1016/j.bbamem.2009.08.016
   Fanzo JC, 2003, CANCER BIOL THER, V2, P392, DOI 10.4161/cbt.2.4.442
   FISCHMAN MW, 1982, FED PROC, V41, P241
   FISCHMAN MW, 1980, PSYCHOPHARMACOLOGY, V72, P1, DOI 10.1007/BF00433800
   Gable RS, 2004, ADDICTION, V99, P686, DOI 10.1111/j.1360-0443.2004.00744.x
   GARATTINI S, 1978, CENTRAL MECH ANORECT
   Garcia-Keller C, 2016, MOL PSYCHIATR, V21, P1063, DOI 10.1038/mp.2015.151
   GAWIN FH, 1991, SCIENCE, V251, P1580, DOI 10.1126/science.2011738
   GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107
   Geyer MA, 2008, TRENDS PHARMACOL SCI, V29, P445, DOI 10.1016/j.tips.2008.06.006
   GLYNN RJ, 1983, J STUD ALCOHOL, V44, P1011, DOI 10.15288/jsa.1983.44.1011
   Goldstein P J, 1990, NIDA Res Monogr, V102, P74
   Grassme H, 2002, J IMMUNOL, V168, P298, DOI 10.4049/jimmunol.168.1.298
   Grassme Heike, 2015, Neurosignals, V23, P84, DOI 10.1159/000442606
   Green AR, 2003, PHARMACOL REV, V55, P463, DOI 10.1124/pr.55.3.3
   Gulbins A, 2018, MOL PSYCHIATR, V23, P2324, DOI 10.1038/s41380-018-0090-9
   Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146
   Gulbins E, 2015, J NEUROCHEM, V134, P183, DOI 10.1111/jnc.13145
   Gulbins E, 2013, NAT MED, V19, P934, DOI 10.1038/nm.3214
   Hagen EH, 2009, NEUROSCIENCE, V160, P69, DOI 10.1016/j.neuroscience.2009.01.077
   Hahn B, 2002, NEUROPSYCHOPHARMACOL, V27, P712, DOI 10.1016/S0893-133X(02)00348-2
   Halberstadt AL, 2020, HBK BEHAV NEUROSCI, V31, P843, DOI 10.1016/B978-0-444-64125-0.00043-8
   Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0
   Harris RA, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.128re7
   Harrison AA, 2002, PSYCHOPHARMACOLOGY, V160, P56, DOI 10.1007/s00213-001-0953-6
   Hartwell KJ, 2012, ADDICT BEHAV, V37, P373, DOI 10.1016/j.addbeh.2011.11.014
   Hassan Z, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00152
   Hassan Z, 2013, NEUROSCI BIOBEHAV R, V37, P138, DOI 10.1016/j.neubiorev.2012.11.012
   Havranek MM, 2015, NEUROPSYCHOPHARMACOL, V40, P2929, DOI 10.1038/npp.2015.146
   Heath D. B., 2000, DRINKING OCCASIONS C
   Heilig M, 2007, TRENDS NEUROSCI, V30, P399, DOI 10.1016/j.tins.2007.06.006
   Henry Brian, 2013, Handb Exp Pharmacol, P77, DOI 10.1007/978-3-7091-1368-4_4
   HIGGINS ST, 1990, PSYCHOPHARMACOLOGY, V102, P451, DOI 10.1007/BF02247124
   Hill EM, 2002, ADDICTION, V97, P375, DOI 10.1046/j.1360-0443.2002.t01-1-00057.x
   Ho YJ, 2004, BEHAV BRAIN RES, V149, P135, DOI 10.1016/S0166-4328(03)00220-1
   Hollerman JR, 1998, NAT NEUROSCI, V1, P304, DOI 10.1038/1124
   Hong ZY, 2005, J NEUROCHEM, V92, P1542, DOI 10.1111/j.1471-4159.2004.02991.x
   Howell LL, 1995, J PHARMACOL EXP THER, V275, P1551
   Huffman MA, 2003, P NUTR SOC, V62, P371, DOI 10.1079/PNS2003257
   HUGHES JR, 1986, AM J PSYCHIAT, V143, P993
   Huston JP, 2016, J NEUROCHEM, V137, P589, DOI 10.1111/jnc.13537
   Huston JP, 2013, NEUROSCI BIOBEHAV R, V37, P2059, DOI 10.1016/j.neubiorev.2013.02.016
   Huston JP, 1996, NEUROSCIENCE, V73, P99, DOI 10.1016/0306-4522(96)00021-8
   Ikemoto S, 1999, BRAIN RES REV, V31, P6, DOI 10.1016/S0165-0173(99)00023-5
   Ito T, 1996, LIFE SCI, V59, P169, DOI 10.1016/0024-3205(96)00199-3
   Jacobs BL, 2010, HBK BEHAV NEUROSCI, V21, P153, DOI 10.1016/S1569-7339(10)70076-X
   JAVAID JI, 1978, SCIENCE, V202, P227, DOI 10.1126/science.694530
   Jay M., 2010, HIGH SOC MIND ALTERI
   Jo YH, 2002, J NEUROBIOL, V53, P618, DOI 10.1002/neu.10147
   Jocham G, 2012, NAT NEUROSCI, V15, P960, DOI 10.1038/nn.3140
   Jocham G, 2011, J NEUROSCI, V31, P1606, DOI 10.1523/JNEUROSCI.3904-10.2011
   JOHANSON CE, 1976, PHARMACOL BIOCHEM BE, V4, P45, DOI 10.1016/0091-3057(76)90174-X
   JOHANSON CE, 1989, PHARMACOL REV, V41, P3
   JOHNSON C, 1975, PHYSIOL BEHAV, V14, P403, DOI 10.1016/0031-9384(75)90003-7
   Kabbaj M, 2001, PSYCHOPHARMACOLOGY, V158, P382, DOI 10.1007/s002130100918
   Kahneman D., 1999, WELL BEING
   Kalinichenko LS, 2019, FRONT NEUROENDOCRIN, V55, DOI 10.1016/j.yfrne.2019.100783
   Kalinichenko LS, 2018, J NEURAL TRANSM, V125, P651, DOI 10.1007/s00702-018-1840-1
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kanayama G, 2009, ADDICTION, V104, P1966, DOI 10.1111/j.1360-0443.2009.02734.x
   Kapur S, 2003, AM J PSYCHIAT, V160, P13, DOI 10.1176/appi.ajp.160.1.13
   Karch, 2017, SAGE HDB DRUGS ALCOH, P411
   KELLEY AE, 1990, NEUROMETHODS, P95
   Kendler KS, 2003, AM J PSYCHIAT, V160, P687, DOI 10.1176/appi.ajp.160.4.687
   Kendler KS, 2003, ARCH GEN PSYCHIAT, V60, P929, DOI 10.1001/archpsyc.60.9.929
   Kenny PJ, 2006, NEUROPSYCHOPHARMACOL, V31, P1203, DOI 10.1038/sj.npp.1300905
   KESTER KM, 1994, OECOLOGIA, V99, P151, DOI 10.1007/BF00317096
   Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550
   KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259
   Kippin TE, 2011, BEHAV BRAIN SCI, V34, P316, DOI 10.1017/S0140525X11000859
   Kochakian C D, 1990, NIDA Res Monogr, V102, P29
   Koob GF, 1999, ANN NY ACAD SCI, V897, P27, DOI 10.1111/j.1749-6632.1999.tb07876.x
   KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J
   Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7
   Kornhuber J, 2015, BIOL CHEM, V396, P707, DOI 10.1515/hsz-2015-0109
   Kornhuber J, 2014, TRENDS PHARMACOL SCI, V35, P293, DOI 10.1016/j.tips.2014.04.003
   Kornhuber J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023852
   Kornhuber J, 2010, CELL PHYSIOL BIOCHEM, V26, P9, DOI 10.1159/000315101
   Koukouli F, 2017, NAT MED, V23, P347, DOI 10.1038/nm.4274
   KRAMER JC, 1967, J AMER MED ASSOC, V201, P305, DOI 10.1001/jama.201.5.305
   Kreibich AS, 2009, NEUROPSYCHOPHARMACOL, V34, P2609, DOI 10.1038/npp.2009.91
   Krishnan V, 2008, NATURE, V455, P894, DOI 10.1038/nature07455
   Kuiper LB, 2019, NEUROPSYCHOPHARMACOL, V44, P503, DOI 10.1038/s41386-018-0235-1
   Kuntsche E, 2005, CLIN PSYCHOL REV, V25, P841, DOI 10.1016/j.cpr.2005.06.002
   Laland KN, 2010, NAT REV GENET, V11, P137, DOI 10.1038/nrg2734
   Laland KN, 2000, BEHAV BRAIN SCI, V23, P131, DOI 10.1017/S0140525X00002417
   Lavikainen HM, 2009, HEALTH PROMOT INT, V24, P108, DOI 10.1093/heapro/dap007
   Le Foll B, 2006, PSYCHOPHARMACOLOGY, V184, P367, DOI 10.1007/s00213-005-0155-8
   Lende DH, 2007, ADDICT RES THEORY, V15, P465, DOI 10.1080/16066350701284552
   Lende DH, 2002, ADDICTION, V97, P447, DOI 10.1046/j.1360-0443.2002.00022.x
   LENDE DH, 2007, EVOLUTIONARY MED HLT, P277
   LICATA A, 1993, PHARMACOL BIOCHEM BE, V45, P549, DOI 10.1016/0091-3057(93)90504-M
   Lisonbee LD, 2009, BEHAV PROCESS, V82, P184, DOI 10.1016/j.beproc.2009.06.009
   Logrip ML, 2012, NEUROPHARMACOLOGY, V62, P552, DOI 10.1016/j.neuropharm.2011.07.007
   London M, 2004, J BIOL CHEM, V279, P9997, DOI 10.1074/jbc.M309992200
   Lozano GA, 1998, ADV STUD BEHAV, V27, P291
   MAIER HW, 1926, KOKAINISMUS
   MALOFF D, 1981, CONTROL OVER INTOXIC, P5
   Manjoch H, 2016, BEHAV BRAIN RES, V306, P91, DOI 10.1016/j.bbr.2016.03.009
   Mansvelder HD, 2006, PSYCHOPHARMACOLOGY, V184, P292, DOI 10.1007/s00213-005-0070-z
   Manzo L, 2015, BEHAV BRAIN RES, V278, P90, DOI 10.1016/j.bbr.2014.09.017
   Manzo L, 2014, PHYSIOL BEHAV, V123, P86, DOI 10.1016/j.physbeh.2013.10.002
   Markou A, 2008, PHILOS T R SOC B, V363, P3159, DOI 10.1098/rstb.2008.0095
   Marsicano G, 2002, NATURE, V418, P530, DOI 10.1038/nature00839
   Matsumoto M, 2009, NATURE, V459, P837, DOI 10.1038/nature08028
   Matthews TJ, 2005, BEHAV NEUROSCI, V119, P1628, DOI 10.1037/0735-7044.119.6.1628
   McBride WJ, 1999, BEHAV BRAIN RES, V101, P129, DOI 10.1016/S0166-4328(99)00022-4
   McBride WJ, 2002, ALCOHOL CLIN EXP RES, V26, P280, DOI 10.1097/00000374-200202000-00017
   McCabe SE, 2005, ADDICTION, V100, P96, DOI 10.1111/j.1360-0443.2005.00944.x
   McCabe SE, 2007, ADDICT BEHAV, V32, P562, DOI 10.1016/j.addbeh.2006.05.022
   McLaughlin JP, 2003, J NEUROSCI, V23, P5674, DOI 10.1523/jneurosci.23-13-05674.2003
   Mechoulam R, 1998, EUR J PHARMACOL, V359, P1, DOI 10.1016/S0014-2999(98)00649-9
   Megha M, 2006, J BIOL CHEM, V281, P21903, DOI 10.1074/jbc.M600395200
   Miczek KA, 1996, PSYCHOPHARMACOLOGY, V128, P256, DOI 10.1007/s002130050133
   Miczek KA, 2011, BEHAV GENET, V41, P787, DOI 10.1007/s10519-011-9462-5
   Mielenz D, 2018, MOL PSYCHIATR, V23, P1303, DOI 10.1038/mp.2017.63
   MITCHELL SN, 1993, NEUROPHARMACOLOGY, V32, P937, DOI 10.1016/0028-3908(93)90058-B
   Mobascher A, 2008, PHARMACOPSYCHIATRY, V41, pS51, DOI 10.1055/s-2008-1081463
   Mondaini N, 2009, J SEX MED, V6, P2772, DOI 10.1111/j.1743-6109.2009.01393.x
   Morgan CJA, 2013, J PSYCHOPHARMACOL, V27, P497, DOI 10.1177/0269881113477744
   Moro L, 2011, BEHAV BRAIN SCI, V34, P319, DOI 10.1017/S0140525X11000768
   Muller CP, 2007, NEUROPHARMACOLOGY, V52, P854, DOI 10.1016/j.neuropharm.2006.10.002
   Muller CP, 2007, SYNAPSE, V61, P254, DOI 10.1002/syn.20366
   Muller CP, 2020, BEHAV BRAIN RES, V384, DOI 10.1016/j.bbr.2020.112521
   Muller CP, 2019, CEREB CORTEX, V29, P1736, DOI 10.1093/cercor/bhy341
   Muller CP, 2017, TRENDS PHARMACOL SCI, V38, P501, DOI 10.1016/j.tips.2017.03.005
   Muller CP, 2017, ACTA NEUROPATHOL, V133, P463, DOI 10.1007/s00401-016-1658-6
   Muller CP, 2015, BBA-MOL CELL BIOL L, V1851, P1052, DOI 10.1016/j.bbalip.2014.12.014
   Muller CP, 2015, BEHAV BRAIN RES, V277, P146, DOI 10.1016/j.bbr.2014.04.007
   Muller CP, 2011, BEHAV BRAIN SCI, V34, P328, DOI 10.1017/S0140525X1100135X
   Muller CP, 2011, BEHAV BRAIN SCI, V34, P293, DOI 10.1017/S0140525X11000057
   Muller CP, 2011, J NEUROCHEM, V119, P419, DOI 10.1111/j.1471-4159.2011.07445.x
   Muller CP, 2008, PHARMACOL BIOCHEM BE, V89, P218, DOI 10.1016/j.pbb.2007.12.013
   NATHANSON JA, 1993, P NATL ACAD SCI USA, V90, P9645, DOI 10.1073/pnas.90.20.9645
   Nesil T, 2015, PHARMACOL BIOCHEM BE, V138, P156, DOI 10.1016/j.pbb.2015.10.001
   Nesse RM, 1997, SCIENCE, V278, P63, DOI 10.1126/science.278.5335.63
   Nesse RM, 2002, ADDICTION, V97, P470, DOI 10.1046/j.1360-0443.2002.00086.x
   Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58
   Newhouse PA, 2011, BIOCHEM PHARMACOL, V82, P943, DOI 10.1016/j.bcp.2011.06.008
   Newlin DB, 2002, ADDICTION, V97, P427, DOI 10.1046/j.1360-0443.2002.00021.x
   Nichols DE, 2004, PHARMACOL THERAPEUT, V101, P131, DOI 10.1016/j.pharmthera.2003.11.002
   Nikulina EM, 2008, EUR J NEUROSCI, V27, P2272, DOI 10.1111/j.1460-9568.2008.06176.x
   Nothdurfter C, 2010, NEUROPSYCHOPHARMACOL, V35, P1510, DOI 10.1038/npp.2010.20
   Nutt DJ, 2015, NAT REV NEUROSCI, V16, P305, DOI 10.1038/nrn3939
   O'Brien CP, 1998, J PSYCHOPHARMACOL, V12, P15, DOI 10.1177/026988119801200103
   O'Malley P M, 1985, NIDA Res Monogr, V61, P50
   O'Malley PM, 2002, J STUD ALCOHOL, P23, DOI 10.15288/jsas.2002.s14.23
   Oliveira TG, 2016, MOL PSYCHIATR, V21, P80, DOI 10.1038/mp.2015.14
   Padwa H, 2014, SUBST USE MISUSE, V49, P743, DOI 10.3109/10826084.2013.866962
   PAGE JE, 1992, PHYTOCHEMISTRY, V31, P3437, DOI 10.1016/0031-9422(92)83702-Z
   Panksepp J, 2002, ADDICTION, V97, P459, DOI 10.1046/j.1360-0443.2002.00025.x
   Panksepp JB, 2007, GENES BRAIN BEHAV, V6, P661, DOI 10.1111/j.1601-183X.2006.00295.x
   Patrick ME, 2008, J ADOLESCENCE, V31, P307, DOI 10.1016/j.adolescence.2007.06.002
   Peele S, 2000, DRUG ALCOHOL DEPEN, V60, P221, DOI 10.1016/S0376-8716(00)00112-5
   PERKINS KA, 1992, BRIT J ADDICT, V87, P193
   Perrotti LI, 2008, SYNAPSE, V62, P358, DOI 10.1002/syn.20500
   PERRY EK, 1995, BRAIN COGNITION, V28, P240, DOI 10.1006/brcg.1995.1255
   PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295
   Pizzimenti CL, 2017, LEARN MEMORY, V24, P422, DOI 10.1101/lm.044164.116
   Polter AM, 2017, ELIFE, V6, DOI [10.7554/eLife.23785.001, 10.7554/eLife.23785]
   Pontieri FE, 1995, P NATL ACAD SCI USA, V92, P12304, DOI 10.1073/pnas.92.26.12304
   Porkka-Heiskanen T, 1997, SCIENCE, V276, P1265, DOI 10.1126/science.276.5316.1265
   POST RM, 1974, AM J PSYCHIAT, V131, P511
   Potvin S, 2003, ENCEPHALE, V29, P193
   Preuss UW, 2002, J STUD ALCOHOL, V63, P498, DOI 10.15288/jsa.2002.63.498
   Prince MA, 2019, J STUD ALCOHOL DRUGS, V80, P366, DOI 10.15288/jsad.2019.80.366
   Pum M, 2007, PSYCHOPHARMACOLOGY, V193, P375, DOI 10.1007/s00213-007-0791-2
   Quednow BB, 2020, HBK BEHAV NEUROSCI, V31, P711, DOI 10.1016/B978-0-444-64125-0.00039-6
   Ramstedt B, 2006, BBA-BIOMEMBRANES, V1758, P1945, DOI 10.1016/j.bbamem.2006.05.020
   Repantis D, 2010, PHARMACOL RES, V62, P187, DOI 10.1016/j.phrs.2010.04.002
   RESNICK RB, 1977, SCIENCE, V195, P696, DOI 10.1126/science.841307
   Rezvani AH, 2001, BIOL PSYCHIAT, V49, P258, DOI 10.1016/S0006-3223(00)01094-5
   Ripke S, 2014, NATURE, V511, P421, DOI 10.1038/nature13595
   RISNER ME, 1980, PSYCHOPHARMACOLOGY, V71, P83, DOI 10.1007/BF00433258
   RITZ MC, 1989, J PHARMACOL EXP THER, V248, P1010
   RITZ MC, 1990, LIFE SCI, V46, P635, DOI 10.1016/0024-3205(90)90132-B
   Robbins TW, 1999, NATURE, V398, P567, DOI 10.1038/19208
   Roberts NP, 2015, CLIN PSYCHOL REV, V38, P25, DOI 10.1016/j.cpr.2015.02.007
   Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI 10.1146/annurev.psych.54.101601.145237
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   ROBLES M, 1995, PLANTA MED, V61, P199, DOI 10.1055/s-2006-958055
   Rodgers B, 2000, ADDICTION, V95, P1833, DOI 10.1046/j.1360-0443.2000.9512183312.x
   RODRIGUEZ E, 1985, EXPERIENTIA, V41, P419, DOI 10.1007/BF02004537
   RODRIGUEZ E, 1993, RECENT ADV PHYTOCHEM, V27, P89
   Room R, 2000, DRUG ALCOHOL DEPEN, V60, P249, DOI 10.1016/S0376-8716(00)00134-4
   Ross HE, 2009, FRONT NEUROENDOCRIN, V30, P534, DOI 10.1016/j.yfrne.2009.05.004
   Ross MM, 2018, ADDICT BEHAV, V79, P45, DOI 10.1016/j.addbeh.2017.12.002
   ROZIN P, 1971, PSYCHOL REV, V78, P459, DOI 10.1037/h0031878
   RUCK CAP, 1979, J PSYCHEDEL DRUG, V11, P145, DOI 10.1080/02791072.1979.10472098
   Salamone JD, 1997, NEUROSCI BIOBEHAV R, V21, P341, DOI 10.1016/S0149-7634(96)00017-6
   SALAMONE JD, 1994, BEHAV BRAIN RES, V61, P117, DOI 10.1016/0166-4328(94)90153-8
   Samaha AN, 2005, TRENDS PHARMACOL SCI, V26, P82, DOI 10.1016/j.tips.2004.12.007
   SAMANIN R, 1993, PHARMACOL TOXICOL, V73, P63, DOI 10.1111/j.1600-0773.1993.tb01537.x
   Sandhoff R, 2010, FEBS LETT, V584, P1907, DOI 10.1016/j.febslet.2009.12.032
   Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328
   Sarter M, 2005, BRAIN RES REV, V48, P98, DOI 10.1016/j.brainresrev.2004.08.006
   Sarter M, 1997, BRAIN RES REV, V23, P28, DOI 10.1016/S0165-0173(96)00009-4
   Sattler S, 2016, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01971
   Schleim S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00003
   Schneider M, 2017, NEUROSCI BIOBEHAV R, V76, P336, DOI 10.1016/j.neubiorev.2016.06.002
   Schopf I, 2015, NEUROSCI LETT, V591, P65, DOI 10.1016/j.neulet.2015.02.031
   Schuckit MA, 2006, DRUG ALCOHOL DEPEN, V82, P194, DOI 10.1016/j.drugalcdep.2005.09.006
   Schuckit MA, 1997, AM J PSYCHIAT, V154, P948
   Schuckit MA, 2007, J STUD ALCOHOL DRUGS, V68, P805, DOI 10.15288/jsad.2007.68.805
   Schuckit MA, 2013, J STUD ALCOHOL DRUGS, V74, P271, DOI 10.15288/jsad.2013.74.271
   Schultz W, 2000, NAT REV NEUROSCI, V1, P199, DOI 10.1038/35044563
   Schumann G, 2008, ARCH GEN PSYCHIAT, V65, P826, DOI 10.1001/archpsyc.65.7.826
   Schumann G, 2016, P NATL ACAD SCI USA, V113, P14372, DOI 10.1073/pnas.1611243113
   Schumann G, 2011, P NATL ACAD SCI USA, V108, P7119, DOI 10.1073/pnas.1017288108
   Schwarting RKW, 1998, NEUROREPORT, V9, P1025, DOI 10.1097/00001756-199804200-00013
   SEGAL B, 1985, INT J ADDICT, V20, P1649, DOI 10.3109/10826088509047253
   SEIDEN LS, 1993, ANNU REV PHARMACOL, V33, P639, DOI 10.1146/annurev.pharmtox.33.1.639
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   SHAHAM Y, 1994, PSYCHOPHARMACOLOGY, V114, P523, DOI 10.1007/BF02249346
   Sher KJ, 2005, ANNU REV CLIN PSYCHO, V1, P493, DOI 10.1146/annurev.clinpsy.1.102803.144107
   Simons J, 2000, ADDICT BEHAV, V25, P153, DOI 10.1016/S0306-4603(98)00104-X
   Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408
   Singer MS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004796
   Singh D, 2019, J ETHNOPHARMACOL, V233, P34, DOI 10.1016/j.jep.2018.12.038
   Singh D, 2014, DRUG ALCOHOL DEPEN, V139, P132, DOI 10.1016/j.drugalcdep.2014.03.017
   Skog OJ, 2000, ADDICTION, V95, P1309, DOI 10.1046/j.1360-0443.2000.95913091.x
   Skogen JC, 2009, ADDICTION, V104, P1519, DOI 10.1111/j.1360-0443.2009.02659.x
   Spanagel R, 2009, PHYSIOL REV, V89, P649, DOI 10.1152/physrev.00013.2008
   STERIADE M, 1990, J NEUROSCI, V10, P2541
   Stewart SH, 1996, PSYCHOL BULL, V120, P83, DOI 10.1037/0033-2909.120.1.83
   STILLMAN R, 1993, PSYCHOPHARMACOLOGY, V110, P415, DOI 10.1007/BF02244647
   Sullivan RJ, 2002, ADDICTION, V97, P389, DOI 10.1046/j.1360-0443.2002.00024.x
   Sullivan RJ, 2008, P ROY SOC B-BIOL SCI, V275, P1231, DOI 10.1098/rspb.2007.1673
   Sussman S, 2006, SUBST ABUSE TREAT PR, V1, DOI 10.1186/1747-597X-1-15
   Talukdar S, 2016, CELL METAB, V23, P344, DOI 10.1016/j.cmet.2015.12.008
   Tatarkiewicz W., 1976, ANAL HAPPINESS, DOI DOI 10.1007/978-94-010-1380-2
   Taylor B, 2005, DIGEST DIS, V23, P170, DOI 10.1159/000090163
   Teter CJ, 2006, PHARMACOTHERAPY, V26, P1501, DOI 10.1592/phco.26.10.1501
   Thiel CM, 2003, NEUROBIOL LEARN MEM, V80, P234, DOI 10.1016/S1074-7427(03)00076-5
   Thiel CM, 1999, NEUROSCIENCE, V93, P243, DOI 10.1016/S0306-4522(99)00158-X
   Tinbergen N, 2005, ANIM BIOL, V55, P297, DOI 10.1163/157075605774840941
   Tupala E, 2004, PROG NEURO-PSYCHOPH, V28, P1221, DOI 10.1016/j.pnpbp.2004.06.022
   Tupper K., 2003, J DRUG ED AWARENESS, V1, P145
   Tupper K.W., 2002, CANADIAN J ED, V27, P499, DOI DOI 10.2307/1602247
   Tzschentke TM, 2007, ADDICT BIOL, V12, P227, DOI 10.1111/j.1369-1600.2007.00070.x
   Uekermann J, 2008, ADDICTION, V103, P726, DOI 10.1111/j.1360-0443.2008.02157.x
   Usher M, 1999, SCIENCE, V283, P549, DOI 10.1126/science.283.5401.549
   van Erp AMM, 2001, PHYSIOL BEHAV, V73, P301, DOI 10.1016/S0031-9384(01)00458-9
   van Erp AMM, 2001, BEHAV PHARMACOL, V12, P335, DOI 10.1097/00008877-200109000-00004
   Veiga MP, 1999, BIOPHYS J, V76, P342, DOI 10.1016/S0006-3495(99)77201-2
   Villalba JJ, 2010, J ANIM SCI, V88, P2189, DOI 10.2527/jas.2009-2272
   Volkow ND, 1997, NATURE, V386, P827, DOI 10.1038/386827a0
   Vonmoos M, 2013, BRIT J PSYCHIAT, V203, P35, DOI 10.1192/bjp.bp.112.118091
   WACK JT, 1982, AM J CLIN NUTR, V35, P366, DOI 10.1093/ajcn/35.2.366
   Wadley G, 2016, BRAIN RES BULL, V126, P138, DOI 10.1016/j.brainresbull.2016.04.008
   Wagner FA, 2002, NEUROPSYCHOPHARMACOL, V26, P479, DOI 10.1016/S0893-133X(01)00367-0
   Waldorf D., 1991, COCAINE CHANGES EXPE
   Waterhouse U, 2018, ADDICT BIOL, V23, P620, DOI 10.1111/adb.12517
   WEIL AT, 1998, NATURAL MIND
   Weir E, 2000, CAN MED ASSOC J, V162, P1843
   Wells BE, 2010, AM J DRUG ALCOHOL AB, V36, P39, DOI 10.3109/00952990903544836
   White BP, 2006, J AM COLL HEALTH, V54, P261, DOI 10.3200/JACH.54.5.261-268
   White NM, 1996, ADDICTION, V91, P921, DOI 10.1111/j.1360-0443.1996.tb03586.x
   Wiens F, 2008, P NATL ACAD SCI USA, V105, P10426, DOI 10.1073/pnas.0801628105
   Williams M.T., 2007, NEUROPSYCHOPHARMACOL
   Wise RA, 2002, NEURON, V36, P229, DOI 10.1016/S0896-6273(02)00965-0
   WISE RA, 1994, APPETITE NEURAL BEHA, P234
   Witkin JM, 1999, J PHARMACOL EXP THER, V288, P1298
   Wolff K, 2006, CNS DRUGS, V20, P199, DOI 10.2165/00023210-200620030-00003
   Wolff W, 2014, BIOPSYCHOSOC MED, V8, DOI 10.1186/1751-0759-8-12
   Wolff W, 2013, SUBST ABUSE TREAT PR, V8, DOI 10.1186/1747-597X-8-23
   Wonnacott S, 2000, EUR J PHARMACOL, V393, P51, DOI 10.1016/S0014-2999(00)00005-4
   Wonnacott S, 1997, TRENDS NEUROSCI, V20, P92, DOI 10.1016/S0166-2236(96)10073-4
   Wood RI, 2004, PHYSIOL BEHAV, V83, P279, DOI 10.1016/j.physbeh.2004.08.012
   Wood RI, 2008, FRONT NEUROENDOCRIN, V29, P490, DOI 10.1016/j.yfrne.2007.12.002
   WRANGHAM R W, 1983, Primates, V24, P276, DOI 10.1007/BF02381090
   Yap Jasmine J, 2008, Drug Discov Today Dis Models, V5, P259
   YOKEL RA, 1973, J PHARMACOL EXP THER, V187, P27
   YOUNG AMJ, 1993, NEUROSCIENCE, V54, P5, DOI 10.1016/0306-4522(93)90378-S
   Zacny JP, 2008, J PAIN, V9, P473, DOI 10.1016/j.jpain.2007.12.008
   Zinberg NE., 1984, DRUG SET SETTING BAS
   Zoicas I, 2020, ADDICT BIOL, V25, DOI 10.1111/adb.12847
   ZUCKERMAN M, 1990, J PERS, V58, P313, DOI 10.1111/j.1467-6494.1990.tb00918.x
   Zvolensky MJ, 2007, ADDICT BEHAV, V32, P3122, DOI 10.1016/j.addbeh.2007.06.010
NR 361
TC 16
Z9 16
U1 5
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-4328
EI 1872-7549
J9 BEHAV BRAIN RES
JI Behav. Brain Res.
PD JUL 15
PY 2020
VL 390
AR 112672
DI 10.1016/j.bbr.2020.112672
PG 15
WC Behavioral Sciences; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Behavioral Sciences; Neurosciences & Neurology
GA LW7LG
UT WOS:000539324300012
PM 32442549
OA hybrid
DA 2023-06-23
ER

PT J
AU Kutlu, MG
   Gould, TJ
AF Kutlu, Munir Gunes
   Gould, Thomas J.
TI Effects of drugs of abuse on hippocampal plasticity and
   hippocampus-dependent learning and memory: contributions to development
   and maintenance of addiction
SO LEARNING & MEMORY
LA English
DT Review
ID LONG-TERM POTENTIATION; CONDITIONED PLACE PREFERENCE; NICOTINIC
   ACETYLCHOLINE-RECEPTOR; SIGNAL-REGULATED KINASE; IMPAIRS SPATIAL MEMORY;
   MORRIS WATER MAZE; WITHDRAWAL-ASSOCIATED DEFICITS; DORSOMEDIAL
   PREFRONTAL CORTEX; COCAINE-SEEKING BEHAVIOR; NON-KORSAKOFF ALCOHOLICS
AB It has long been hypothesized that conditioning mechanisms play major roles in addiction. Specifically, the associations between rewarding properties of drugs of abuse and the drug context can contribute to future use and facilitate the transition from initial drug use into drug dependency. On the other hand, the self-medication hypothesis of drug abuse suggests that negative consequences of drug withdrawal result in relapse to drug use as an attempt to alleviate the negative symptoms. In this review, we explored these hypotheses and the involvement of the hippocampus in the development and maintenance of addiction to widely abused drugs such as cocaine, amphetamine, nicotine, alcohol, opiates, and cannabis. Studies suggest that initial exposure to stimulants (i.e., cocaine, nicotine, and amphetamine) and alcohol may enhance hippocampal function and, therefore, the formation of augmented drug-context associations that contribute to the development of addiction. In line with the self-medication hypothesis, withdrawal from stimulants, ethanol, and cannabis results in hippocampus-dependent learning and memory deficits, which suggest that an attempt to alleviate these deficits may contribute to relapse to drug use and maintenance of addiction. Interestingly, opiate withdrawal leads to enhancement of hippocampus-dependent learning and memory. Given that a conditioned aversion to drug context develops during opiate withdrawal, the cognitive enhancement in this case may result in the formation of an augmented association between withdrawal-induced aversion and withdrawal context. Therefore, individuals with opiate addiction may return to opiate use to avoid aversive symptoms triggered by the withdrawal context. Overall, the systematic examination of the role of the hippocampus in drug addiction may help to formulate a better understanding of addiction and underlying neural substrates.
C1 [Kutlu, Munir Gunes; Gould, Thomas J.] Penn State Univ, Dept Biobehav Hlth, University Pk, PA 16802 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Pennsylvania State University -
   University Park
RP Gould, TJ (通讯作者)，Penn State Univ, Dept Biobehav Hlth, University Pk, PA 16802 USA.
EM thomas.gould@psu.edu
FU National Institute on Drug Abuse [DA017949]
FX T.J.G. was funded with grant support from the National Institute on Drug
   Abuse (DA017949).
CR Abdulla FA, 1996, RELATIONSHIP UP REGU
   Abel T, 2001, CURR OPIN NEUROBIOL, V11, P180, DOI 10.1016/S0959-4388(00)00194-X
   ADLER LE, 1993, AM J PSYCHIAT, V150, P1856
   Agaku Israel, 2012, Morbidity and Mortality Weekly Report, V61, P889
   AGGLETON JP, 1986, BEHAV BRAIN RES, V19, P133, DOI 10.1016/0166-4328(86)90011-2
   Aguayo LG, 1990, ALCOHOL ALCOHOLISM S, V1, P187
   ALEXANDER BK, 1982, PSYCHOL BULL, V92, P367, DOI 10.1037/0033-2909.92.2.367
   Alkondon M, 2003, J NEUROPHYSIOL, V90, P1613, DOI 10.1152/jn.00214.2003
   ALLAN AM, 1986, LIFE SCI, V39, P2005, DOI 10.1016/0024-3205(86)90324-3
   Allgaier C, 2002, NEUROCHEM INT, V41, P377, DOI 10.1016/S0197-0186(02)00046-3
   AllMA S. S., 2011, DRUG AB WARN NETW 20
   Anderson SM, 2005, PHARMACOL THERAPEUT, V106, P389, DOI 10.1016/j.pharmthera.2004.12.004
   [Anonymous], 2011, RES 2010 NAT SURV DR
   ARDILA A, 1991, INT J NEUROSCI, V57, P73, DOI 10.3109/00207459109150348
   Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836
   Bardo MT, 1998, CRIT REV NEUROBIOL, V12, P37, DOI 10.1615/CritRevNeurobiol.v12.i1-2.30
   BARDO MT, 1995, NEUROSCI BIOBEHAV R, V19, P39, DOI 10.1016/0149-7634(94)00021-R
   Bardo MT, 1999, PSYCHOPHARMACOLOGY, V143, P39, DOI 10.1007/s002130050917
   BARDO MT, 1984, PHARMACOL BIOCHEM BE, V21, P545, DOI 10.1016/S0091-3057(84)80037-4
   Bates ME, 2002, EXP CLIN PSYCHOPHARM, V10, P193, DOI 10.1037//1064-1297.10.3.193
   BATES T, 1995, PSYCHOPHARMACOLOGY, V120, P209, DOI 10.1007/BF02246195
   BEATTY W W, 1984, Alcohol, V1, P465, DOI 10.1016/0741-8329(84)90023-5
   Bell S L, 1999, Nicotine Tob Res, V1, P45, DOI 10.1080/14622299050011141
   Benowitz NL, 2008, CLIN PHARMACOL THER, V83, P531, DOI 10.1038/clpt.2008.3
   Benowitz NL, 2010, NEW ENGL J MED, V362, P2295, DOI 10.1056/NEJMra0809890
   Benowitz NL, 1996, ANNU REV PHARMACOL, V36, P597, DOI 10.1146/annurev.pa.36.040196.003121
   Berke JH, 1974, CANNABIS EXPERIENCE
   Berry RB, 2004, ALCOHOL, V32, P9, DOI 10.1016/j.alcohol.2003.09.005
   Bett Walter Reginald, 1946, POST GRAD MED JOUR, V22, P205
   Beveridge TJR, 2006, EUR J NEUROSCI, V23, P3109, DOI 10.1111/j.1460-9568.2006.04788.x
   Bienkowski P, 1996, ALCOHOL ALCOHOLISM, V31, P547
   Bison S, 2003, ALCOHOL CLIN EXP RES, V27, P1173, DOI 10.1097/01.ALC.0000075827.74538.FE
   Blaiss CA, 2007, NEUROBIOL LEARN MEM, V87, P644, DOI 10.1016/j.nlm.2006.12.007
   Blaiss CA, 2006, BEHAV BRAIN RES, V171, P329, DOI 10.1016/j.bbr.2006.04.018
   BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0
   BLOCK RI, 1993, PSYCHOPHARMACOLOGY, V110, P219, DOI 10.1007/BF02246977
   Blokland A, 1998, BEHAV PHARMACOL, V9, P429, DOI 10.1097/00008877-199809000-00006
   Bohme GA, 2000, NEUROSCIENCE, V95, P5
   Bolla KI, 1999, J NEUROPSYCH CLIN N, V11, P361, DOI 10.1176/jnp.11.3.361
   BOND NW, 1976, PHARMACOL BIOCHEM BE, V5, P85, DOI 10.1016/0091-3057(76)90292-6
   Bozarth MA, 1987, METHODS ASSESSING RE, P241
   Braida D, 2004, EUR J PHARMACOL, V506, P63, DOI 10.1016/j.ejphar.2004.10.043
   Brand M, 2005, NEUROPSYCHOLOGY, V19, P267, DOI 10.1037/0894-4105.19.3.267
   Breiter HC, 1997, NEURON, V19, P591, DOI 10.1016/S0896-6273(00)80374-8
   Brielmaier JM, 2008, PHARMACOL BIOCHEM BE, V89, P94, DOI 10.1016/j.pbb.2007.11.005
   BRODY SL, 1990, AM J MED, V88, P325, DOI 10.1016/0002-9343(90)90484-U
   Brown RW, 2000, BEHAV BRAIN RES, V114, P135, DOI 10.1016/S0166-4328(00)00225-4
   Budney AJ, 1999, ADDICTION, V94, P1311, DOI 10.1046/j.1360-0443.1999.94913114.x
   Budney AJ, 2006, CURR OPIN PSYCHIATR, V19, P233, DOI 10.1097/01.yco.0000218592.00689.e5
   Budney AJ, 2003, J ABNORM PSYCHOL, V112, P393, DOI 10.1037/0021-843X.112.3.393
   Budney AJ, 1998, EXP CLIN PSYCHOPHARM, V6, P419, DOI 10.1037/1064-1297.6.4.419
   Budney AJ, 2008, J SUBST ABUSE TREAT, V35, P362, DOI 10.1016/j.jsat.2008.01.002
   Budney AJ, 2007, DRUG ALCOHOL DEPEN, V86, P22, DOI 10.1016/j.drugalcdep.2006.04.014
   Burgess N, 2002, NEURON, V35, P625, DOI 10.1016/S0896-6273(02)00830-9
   CAMPBELL KA, 1986, J PHARMACOL EXP THER, V239, P936
   CAMPBELL KA, 1986, J PHARMACOL EXP THER, V239, P941
   Cao GF, 2013, NEUROPHARMACOLOGY, V67, P144, DOI 10.1016/j.neuropharm.2012.10.020
   CARBONE D, 1992, AM J MED, V93, pS13, DOI 10.1016/0002-9343(92)90621-H
   CARR GD, 1988, PSYCHOPHARMACOLOGY, V94, P221
   Caulo M, 2005, BRAIN, V128, P1584, DOI 10.1093/brain/awh496
   Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P642
   Centers for Disease Control and Prevention (CDC), 2007, CDC HIV AIDS FACT SH
   CERMAK LS, 1974, BRAIN LANG, V1, P141, DOI 10.1016/0093-934X(74)90030-3
   CERMAK LS, 1973, NEUROPSYCHOLOGIA, V11, P85, DOI 10.1016/0028-3932(73)90068-7
   CERMAK LS, 1988, BRAIN COGNITION, V7, P312, DOI 10.1016/0278-2626(88)90005-X
   Cervo L, 1997, BRAIN RES, V775, P30, DOI 10.1016/S0006-8993(97)00866-4
   Cha YM, 2007, BEHAV PHARMACOL, V18, P563, DOI 10.1097/FBP.0b013e3282ee7b7e
   Chabal C, 1997, CLIN J PAIN, V13, P150, DOI 10.1097/00002508-199706000-00009
   Chandler LJ, 2005, ALCOHOL CLIN EXP RES, V29, P672, DOI 10.1097/01.ALC.0000158935.53360.5F
   CHILDRESS AR, 1986, BRIT J ADDICT, V81, P655
   Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11
   Cippitelli A, 2010, NEUROBIOL LEARN MEM, V94, P538, DOI 10.1016/j.nlm.2010.09.006
   Coffey C, 2002, ADDICTION, V97, P187, DOI 10.1046/j.1360-0443.2002.00029.x
   Collins C, 2014, NEW ENGL J MED, V371, P879, DOI [10.1056/NEJMc1407928, 10.1056/NEJMra1402309]
   COLLINS DR, 1995, BRIT J PHARMACOL, V115, P869, DOI 10.1111/j.1476-5381.1995.tb15889.x
   COLLINS DR, 1994, EUR J PHARMACOL, V259, pR7, DOI 10.1016/0014-2999(94)90666-1
   COLRAIN IM, 1992, PSYCHOPHARMACOLOGY, V108, P448, DOI 10.1007/BF02247419
   Copeland J, 2001, J SUBST ABUSE TREAT, V20, P45, DOI 10.1016/S0740-5472(00)00148-3
   Copersino ML, 2006, AM J ADDICTION, V15, P8, DOI 10.1080/10550490500418997
   Crowley TJ, 1998, DRUG ALCOHOL DEPEN, V50, P27, DOI 10.1016/S0376-8716(98)00003-9
   Cunningham CL, 2000, BEHAV PHARMACOL, V11, P591, DOI 10.1097/00008877-200011000-00006
   Curran HV, 2001, PSYCHOPHARMACOLOGY, V154, P153, DOI 10.1007/s002130000628
   Da Silva GE, 2002, PROG NEURO-PSYCHOPH, V26, P321, DOI 10.1016/S0278-5846(01)00275-5
   Dackis CA, 2001, J SUBST ABUSE TREAT, V21, P111, DOI 10.1016/S0740-5472(01)00192-1
   Dajas-Bailador FA, 2002, J NEUROCHEM, V80, P520, DOI 10.1046/j.0022-3042.2001.00725.x
   Darke S, 2000, ADDICTION, V95, P687, DOI 10.1046/j.1360-0443.2000.9556874.x
   Daumas S, 2005, LEARN MEMORY, V12, P375, DOI 10.1101/lm.81905
   Davis JA, 2006, PSYCHOPHARMACOLOGY, V184, P345, DOI 10.1007/s00213-005-0047-y
   Davis JA, 2006, NEUROSCI LETT, V394, P202, DOI 10.1016/j.neulet.2005.10.026
   Davis JA, 2005, J NEUROSCI, V25, P8708, DOI 10.1523/JNEUROSCI.2853-05.2005
   Davis JA, 2007, J NEUROSCI, V27, P10870, DOI 10.1523/JNEUROSCI.3242-07.2007
   Davis JA, 2007, PSYCHOPHARMACOLOGY, V190, P343, DOI 10.1007/s00213-006-0624-8
   Davis JA, 2009, EUR NEUROPSYCHOPHARM, V19, P551, DOI 10.1016/j.euroneuro.2009.02.003
   Davis PE, 2002, DRUG ALCOHOL DEPEN, V67, P105, DOI 10.1016/S0376-8716(02)00012-1
   de Leon J, 2005, SCHIZOPHR RES, V76, P135, DOI 10.1016/j.schres.2005.02.010
   Del Olmo N, 2007, PSYCHOPHARMACOLOGY, V195, P19, DOI 10.1007/s00213-007-0873-1
   DELANOY RL, 1983, PHARMACOL BIOCHEM BE, V18, P137, DOI 10.1016/0091-3057(83)90263-0
   DENEAU G, 1969, PSYCHOPHARMACOLOGIA, V16, P30, DOI 10.1007/BF00405254
   Diergaarde L, 2008, NEUROPHARMACOLOGY, V55, P712, DOI 10.1016/j.neuropharm.2008.06.003
   Dols M, 2002, ADDICTION, V97, P87, DOI 10.1046/j.1360-0443.2002.00010.x
   Dols M, 2000, ADDICT BEHAV, V25, P103, DOI 10.1016/S0306-4603(98)00115-4
   Dominguez-Escriba L, 2006, EUR J NEUROSCI, V24, P586, DOI 10.1111/j.1460-9568.2006.04924.x
   DOTY BA, 1966, PSYCHOPHARMACOLOGIA, V9, P234, DOI 10.1007/BF02198483
   Dougherty KD, 1996, PHARMACOL BIOCHEM BE, V55, P227, DOI 10.1016/S0091-3057(96)00075-5
   DURAND D, 1984, BRAIN RES, V308, P325, DOI 10.1016/0006-8993(84)91072-2
   Edwards S, 2009, SYNAPSE, V63, P224, DOI 10.1002/syn.20601
   Ehrlich D, 2012, J NEUROL SCI, V322, P92, DOI 10.1016/j.jns.2012.07.002
   Eisch AJ, 2000, P NATL ACAD SCI USA, V97, P7579, DOI 10.1073/pnas.120552597
   Espana RA, 2010, EUR J NEUROSCI, V31, P336, DOI 10.1111/j.1460-9568.2009.07065.x
   Evans DE, 2009, ADDICT BIOL, V14, P32, DOI 10.1111/j.1369-1600.2008.00130.x
   Everitt BJ, 1999, ANN NY ACAD SCI, V877, P412, DOI 10.1111/j.1749-6632.1999.tb09280.x
   Fagrell B, 1999, J INTERN MED, V246, P331, DOI 10.1046/j.1365-2796.1999.00576.x
   Fan N, 2010, J NEUROCHEM, V112, P691, DOI 10.1111/j.1471-4159.2009.06489.x
   Farahmandfar M, 2010, BEHAV BRAIN RES, V211, P156, DOI 10.1016/j.bbr.2010.03.013
   FEIN G, 1990, WESTERN J MED, V152, P531
   Ferraro D P, 1980, NIDA Res Monogr, V31, P98
   Fuchs RA, 2005, NEUROPSYCHOPHARMACOL, V30, P296, DOI 10.1038/sj.npp.1300579
   Fuchs RA, 2007, EUR J NEUROSCI, V26, P487, DOI 10.1111/j.1460-9568.2007.05674.x
   FUDALA PJ, 1985, PHARMACOL BIOCHEM BE, V22, P237, DOI 10.1016/0091-3057(85)90384-3
   Fujii S, 2000, NEUROSCI LETT, V286, P134, DOI 10.1016/S0304-3940(00)01076-4
   Fujii S, 1999, BRAIN RES, V846, P137, DOI 10.1016/S0006-8993(99)01982-4
   Garavan H, 2008, PHILOS T R SOC B, V363, P3267, DOI 10.1098/rstb.2008.0106
   George TP, 2000, CURR OPIN PSYCHIATR, V13, P327, DOI 10.1097/00001504-200005000-00015
   Gerdjikov TV, 2004, BEHAV NEUROSCI, V118, P740, DOI 10.1037/0735-7044.118.4.740
   GESSA GL, 1985, BRAIN RES, V348, P201, DOI 10.1016/0006-8993(85)90381-6
   GOLD PE, 1984, BRAIN RES, V305, P103, DOI 10.1016/0006-8993(84)91124-7
   Goode E., 1970, MARIJUANA SMOKERS, P201
   Goodman J, 2016, FRONT PSYCHIATRY, V7, DOI 10.3389/fpsyt.2016.00024
   Gooney M, 2002, BEHAV NEUROSCI, V116, P455, DOI 10.1037//0735-7044.116.3.455
   Gould TJ, 2014, BRAIN RES, V1559, P1, DOI 10.1016/j.brainres.2014.02.038
   Gould TJ, 2014, NEUROBIOL LEARN MEM, V109, P151, DOI 10.1016/j.nlm.2014.01.009
   Gould TJ, 2012, NEUROPHARMACOLOGY, V62, P2118, DOI 10.1016/j.neuropharm.2012.01.003
   Gould TJ, 1999, BEHAV BRAIN RES, V102, P31, DOI 10.1016/S0166-4328(98)00157-0
   Gould TJ, 2004, BEHAV BRAIN RES, V155, P167, DOI 10.1016/j.bbr.2004.04.009
   Gould TJ, 2003, BEHAV NEUROSCI, V117, P1276, DOI 10.1037/0735-7044.117.6.1276
   Gould TJ, 2003, J PSYCHOPHARMACOL, V17, P77, DOI 10.1177/0269881103017001702
   Gould TJ, 2003, INTEGR PHYS BEH SCI, V38, P124, DOI 10.1007/BF02688830
   Gould TJ, 2003, NEUROBIOL LEARN MEM, V80, P147, DOI 10.1016/S1074-7427(03)00057-1
   Grabus SD, 2006, PSYCHOPHARMACOLOGY, V184, P456, DOI 10.1007/s00213-006-0305-7
   Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040
   Green B, 2003, DRUG ALCOHOL REV, V22, P453, DOI 10.1080/09595230310001613976
   Gu H, 2010, NEUROIMAGE, V53, P593, DOI 10.1016/j.neuroimage.2010.06.066
   Guan X, 2009, NEUROSCIENCE, V161, P665, DOI 10.1016/j.neuroscience.2009.04.035
   Gulick D, 2008, PSYCHOPHARMACOLOGY, V196, P483, DOI 10.1007/s00213-007-0982-x
   Gulick D, 2007, ALCOHOL CLIN EXP RES, V31, P1528, DOI 10.1111/j.1530-0277.2007.00458.x
   Guttmann E, 1937, BMJ-BRIT MED J, V1937, P1013, DOI 10.1136/bmj.1.3984.1013
   Hahn B, 2007, J NEUROSCI, V27, P3477, DOI 10.1523/JNEUROSCI.5129-06.2007
   HAIM DY, 1995, CHEST, V107, P233, DOI 10.1378/chest.107.1.233
   Hall W, 2009, LANCET, V374, P1383, DOI 10.1016/S0140-6736(09)61037-0
   HALLIDAY R, 1994, PSYCHOPHYSIOLOGY, V31, P331, DOI 10.1111/j.1469-8986.1994.tb02441.x
   Hamelink C, 2005, J PHARMACOL EXP THER, V314, P780, DOI 10.1124/jpet.105.085779
   Han WY, 2014, PHARMACOL BIOCHEM BE, V119, P80, DOI 10.1016/j.pbb.2013.11.014
   He J, 2000, ACTA PHARMACOL SIN, V21, P429
   He ST, 2004, DRUG ALCOHOL DEPEN, V75, P215, DOI 10.1016/j.drugalcdep.2004.02.010
   Heal DJ, 2013, J PSYCHOPHARMACOL, V27, P479, DOI 10.1177/0269881113482532
   HEYSER CJ, 1993, J PHARMACOL EXP THER, V264, P294
   Heysieattalab S, 2016, SYNAPSE, V70, P325, DOI 10.1002/syn.21905
   HILL S Y, 1979, American Journal of Psychiatry, V136, P598, DOI 10.1176/ajp.1979.136.4b.598
   Hillig KW, 2005, GENET RESOUR CROP EV, V52, P161, DOI 10.1007/s10722-003-4452-y
   Hirvonen J, 2012, MOL PSYCHIATR, V17, P642, DOI 10.1038/mp.2011.82
   Hoffman AF, 2007, LEARN MEMORY, V14, P63, DOI 10.1101/lm.439007
   HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x
   Hong LE, 2011, SCHIZOPHRENIA BULL, V37, P416, DOI 10.1093/schbul/sbp089
   Hu M, 2002, MOL CELL NEUROSCI, V21, P616, DOI 10.1006/mcne.2002.1202
   Hughes JR, 2004, ADDICTION, V99, P29, DOI 10.1111/j.1360-0443.2004.00540.x
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Isenberg-Grzeda E, 2012, PSYCHOSOMATICS, V53, P507, DOI 10.1016/j.psym.2012.04.008
   Ito R, 2010, NEUROPSYCHOPHARMACOL, V35, P1440, DOI 10.1038/npp.2010.14
   Ito Y, 2001, PHARMACOL BIOCHEM BE, V70, P353, DOI 10.1016/S0091-3057(01)00618-9
   Izumi Y, 2005, NEUROSCIENCE, V136, P509, DOI 10.1016/j.neuroscience.2005.08.002
   Jacobsen LK, 2005, BIOL PSYCHIAT, V57, P56, DOI 10.1016/j.biopsych.2004.10.022
   Jaffe JH, 1990, PHARMACOL BASIS THER, P522
   Ji SP, 2006, NAT MED, V12, P324, DOI 10.1038/nm1349
   Jia YS, 2010, EUR J NEUROSCI, V31, P463, DOI 10.1111/j.1460-9568.2009.07058.x
   Jin C, 2005, BEHAV BRAIN RES, V161, P107, DOI 10.1016/j.bbr.2005.01.012
   Johanson CE, 2006, PSYCHOPHARMACOLOGY, V185, P327, DOI 10.1007/s00213-006-0330-6
   Johnson BA, 2000, NEUROPSYCHOPHARMACOL, V22, P504, DOI 10.1016/S0893-133X(99)00116-5
   JONES BP, 1975, NEUROPSYCHOLOGIA, V13, P173, DOI 10.1016/0028-3932(75)90026-3
   JOYCE EM, 1991, NEUROPSYCHOLOGIA, V29, P709, DOI 10.1016/0028-3932(91)90067-I
   Justinova Z, 2003, PSYCHOPHARMACOLOGY, V169, P135, DOI 10.1007/s00213-003-1484-0
   Kalechstein AD, 2003, J NEUROPSYCH CLIN N, V15, P215, DOI 10.1176/appi.neuropsych.15.2.215
   Kelleher RJ, 2004, CELL, V116, P467, DOI 10.1016/S0092-8674(04)00115-1
   Kelley AE, 2004, NEURON, V44, P161, DOI 10.1016/j.neuron.2004.09.016
   Kelley BJ, 2005, COGN BEHAV NEUROL, V18, P108, DOI 10.1097/01.wnn.0000160823.61201.20
   Kenney JW, 2008, BEHAV NEUROSCI, V122, P1158, DOI 10.1037/a0012807
   Kenney JW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039939
   Kenney JW, 2011, PSYCHOPHARMACOLOGY, V217, P353, DOI 10.1007/s00213-011-2283-7
   Kenny PJ, 2006, J NEUROSCI, V26, P5894, DOI 10.1523/JNEUROSCI.0740-06.2006
   Kerstetter KA, 2012, NEUROPSYCHOPHARMACOL, V37, P2605, DOI 10.1038/npp.2012.99
   KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259
   Kilts CD, 2001, ARCH GEN PSYCHIAT, V58, P334, DOI 10.1001/archpsyc.58.4.334
   Kim J, 2011, HIPPOCAMPUS, V21, P609, DOI 10.1002/hipo.20784
   KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183
   KLEINMAN KM, 1973, PSYCHOL REP, V32, P963, DOI 10.2466/pr0.1973.32.3.963
   KLISZ DK, 1977, J STUD ALCOHOL, V38, P1718, DOI 10.15288/jsa.1977.38.1718
   Koob G F, 1994, NIDA Res Monogr, V145, P1
   KOOB GF, 1989, NEUROSCI BIOBEHAV R, V13, P135, DOI 10.1016/S0149-7634(89)80022-3
   Koob GF, 1998, ALCOHOL CLIN EXP RES, V22, P3, DOI 10.1097/00000374-199802000-00001
   Kouri EM, 2000, EXP CLIN PSYCHOPHARM, V8, P483, DOI 10.1037//1064-1297.8.4.483
   Krasnova IN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008790
   KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G
   Kutlu MG, 2015, BEHAV NEUROSCI, V129, P37, DOI 10.1037/bne0000029
   Kutlu MG, 2016, PHYSIOL BEHAV, V155, P162, DOI 10.1016/j.physbeh.2015.12.008
   Kutlu MG, 2015, INT REV NEUROBIOL, V124, P171, DOI 10.1016/bs.irn.2015.08.004
   Lange RA, 2001, NEW ENGL J MED, V345, P351, DOI 10.1056/NEJM200108023450507
   Le Foll B, 2006, BEHAV PHARMACOL, V17, P195
   Lemos JI, 2010, BEHAV BRAIN RES, V207, P105, DOI 10.1016/j.bbr.2009.09.045
   Lenoir M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000698
   Levin ED, 1998, PHARMACOL BIOCHEM BE, V61, P335, DOI 10.1016/S0091-3057(98)00109-9
   Levin ED, 1997, BEHAV PHARMACOL, V8, P236
   Levin ED, 1996, PSYCHOPHARMACOLOGY, V123, P88, DOI 10.1007/BF02246285
   Li Y, 2007, ADDICT BIOL, V12, P470, DOI 10.1111/j.1369-1600.2007.00059.x
   Li Z, 2001, PHARMACOL BIOCHEM BE, V68, P507, DOI 10.1016/S0091-3057(01)00456-7
   Lichtman AH, 1996, PSYCHOPHARMACOLOGY, V126, P125, DOI 10.1007/BF02246347
   LICHTMAN AH, 1995, PSYCHOPHARMACOLOGY, V119, P282, DOI 10.1007/BF02246292
   Loeber S, 2009, ALCOHOL ALCOHOLISM, V44, P372, DOI 10.1093/alcalc/agp030
   LONDON ED, 1990, ARCH GEN PSYCHIAT, V47, P567
   Loureiro M, 2012, BRAIN STRUCT FUNCT, V217, P93, DOI 10.1007/s00429-011-0332-y
   LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382
   LYNCH G, 1990, PROG BRAIN RES, V83, P233
   LYNESS WH, 1979, PHARMACOL BIOCHEM BE, V11, P553, DOI 10.1016/0091-3057(79)90040-6
   Ma MX, 2007, NEUROSCIENCE, V147, P1059, DOI 10.1016/j.neuroscience.2007.05.020
   Maggio N, 2007, J NEUROSCI, V27, P5757, DOI 10.1523/JNEUROSCI.0155-07.2007
   Maggio N, 2009, J NEUROSCI, V29, P8633, DOI 10.1523/JNEUROSCI.1901-09.2009
   Manchikanti Laxmaiah, 2004, Pain Physician, V7, P431
   Manchikanti Laxmaiah, 2006, Pain Physician, V9, P123
   Mandillo S, 2003, BEHAV PHARMACOL, V14, P533, DOI 10.1097/00008877-200311000-00006
   MANGAN GL, 1983, J PSYCHOL, V115, P65, DOI 10.1080/00223980.1983.9923599
   Mansouri FA, 1997, BRAIN RES, V769, P119, DOI 10.1016/S0006-8993(97)00608-2
   Manwell LA, 2009, PHARMACOL BIOCHEM BE, V94, P154, DOI 10.1016/j.pbb.2009.08.002
   Markwiese BJ, 1998, ALCOHOL CLIN EXP RES, V22, P416, DOI 10.1097/00000374-199804000-00018
   Masaki T, 1956, WHO TECH REP SER, V102, P14
   Matsuyama S, 2003, J PHARMACOL SCI, V93, P180, DOI 10.1254/jphs.93.180
   Matsuyama S, 2000, EUR J NEUROSCI, V12, P3741, DOI 10.1046/j.1460-9568.2000.00259.x
   Mattay VS, 2000, NEUROIMAGE, V12, P268, DOI 10.1006/nimg.2000.0610
   Matthews DB, 1999, NEUROBIOL LEARN MEM, V72, P169, DOI 10.1006/nlme.1998.3900
   MATTHEWS DB, 1995, ALCOHOL CLIN EXP RES, V19, P902, DOI 10.1111/j.1530-0277.1995.tb00965.x
   Matthews DB, 2002, ALCOHOL CLIN EXP RES, V26, P1747, DOI 10.1097/01.ALC.0000037219.79257.17
   Maurice E., 2005, Morbidity and Mortality Weekly Report, V54, P1121
   MCAULIFFE WE, 1985, J DRUG ISSUES, V15, P203, DOI 10.1177/002204268501500204
   MCBRIDE PE, 1992, MED CLIN N AM, V76, P333, DOI 10.1016/S0025-7125(16)30356-X
   McClung J, 2010, PSYCHOPHARMACOLOGY, V210, P75, DOI 10.1007/s00213-010-1818-7
   MCLELLAN A T, 1986, Journal of Substance Abuse Treatment, V3, P33
   Means LW, 1996, NEUROBIOL LEARN MEM, V66, P167, DOI 10.1006/nlme.1996.0057
   Melia KR, 1996, NEUROSCIENCE, V74, P313, DOI 10.1016/0306-4522(96)00138-8
   Melnick SM, 2001, NEUROTOXICOL TERATOL, V23, P445, DOI 10.1016/S0892-0362(01)00157-X
   Mendez IA, 2008, NEUROBIOL LEARN MEM, V89, P185, DOI 10.1016/j.nlm.2007.08.005
   Mendrek A, 2006, ADDICT BEHAV, V31, P833, DOI 10.1016/j.addbeh.2005.06.009
   Meyers RA, 2006, BEHAV NEUROSCI, V120, P401, DOI 10.1037/0735-7044.120.2.401
   Meyers RA, 2003, NEUROREPORT, V14, P2127, DOI 10.1097/00001756-200311140-00023
   Milekic MH, 2006, J NEUROSCI, V26, P3010, DOI 10.1523/JNEUROSCI.4818-05.2006
   Mitsushima D, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3760
   MITTENBERG W, 1993, ARCH CLIN NEUROPSYCH, V8, P477, DOI 10.1016/0887-6177(93)90048-6
   MORIMOTO K, 1987, BRAIN RES, V407, P137, DOI 10.1016/0006-8993(87)91227-3
   Moron JA, 2007, MOL CELL PROTEOMICS, V6, P29, DOI 10.1074/mcp.M600184-MCP200
   Myers KM, 2010, BIOL PSYCHIAT, V67, P85, DOI 10.1016/j.biopsych.2009.08.015
   Nakayama H, 2001, J NEUROCHEM, V79, P489, DOI 10.1046/j.1471-4159.2001.00602.x
   National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health, 2014, HLTH CONS SMOK 50 YE
   Newton TF, 2004, AM J ADDICTION, V13, P248, DOI 10.1080/10550490490459915
   Niikura K, 2013, PHARMACOL BIOCHEM BE, V110, P112, DOI 10.1016/j.pbb.2013.06.010
   Niyuhire F, 2007, J PHARMACOL EXP THER, V322, P1067, DOI 10.1124/jpet.107.119594
   Noonan MA, 2008, J NEUROSCI, V28, P2516, DOI 10.1523/JNEUROSCI.4661-07.2008
   Nordahl TE, 2003, J NEUROPSYCH CLIN N, V15, P317, DOI 10.1176/appi.neuropsych.15.3.317
   North A, 2013, SYNAPSE, V67, P245, DOI 10.1002/syn.21635
   NOWICKY AV, 1987, BRAIN RES BULL, V19, P663, DOI 10.1016/0361-9230(87)90052-9
   O'Keefe JH, 2014, MAYO CLIN PROC, V89, P382, DOI 10.1016/j.mayocp.2013.11.005
   Obernier JA, 2002, ALCOHOL CLIN EXP RES, V26, P547, DOI 10.1111/j.1530-0277.2002.tb02573.x
   OBRIEN CP, 1977, SCIENCE, V195, P1000, DOI 10.1126/science.841320
   OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1
   Ornstein TJ, 2000, NEUROPSYCHOPHARMACOL, V23, P113, DOI 10.1016/S0893-133X(00)00097-X
   Oscar-Berman M, 2004, ALCOHOL CLIN EXP RES, V28, P667, DOI 10.1097/01.ALC.0000122761.09179.B9
   PACKARD MG, 1994, PSYCHOBIOLOGY, V22, P54
   Parikh V, 2016, SCHIZOPHR RES, V171, P1, DOI 10.1016/j.schres.2016.01.020
   Parker LA, 2004, PSYCHOPHARMACOLOGY, V175, P360, DOI 10.1007/s00213-004-1825-7
   PARROTT AC, 1992, NEUROPSYCHOBIOLOGY, V25, P34, DOI 10.1159/000118807
   Pascual MM, 2009, PSYCHOPHARMACOLOGY, V207, P57, DOI 10.1007/s00213-009-1630-4
   Patterson F, 2010, DRUG ALCOHOL DEPEN, V106, P61, DOI 10.1016/j.drugalcdep.2009.07.020
   PEEKE SC, 1984, PSYCHOPHARMACOLOGY, V84, P205, DOI 10.1007/BF00427447
   Perry AN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079465
   PIAZZA PV, 1991, P NATL ACAD SCI USA, V88, P2088, DOI 10.1073/pnas.88.6.2088
   PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295
   PIAZZA PV, 1990, BRAIN RES, V514, P22, DOI 10.1016/0006-8993(90)90431-A
   Pomerleau C S, 2000, Nicotine Tob Res, V2, P275
   POMERLEAU CS, 1992, PSYCHOPHARMACOLOGY, V108, P460, DOI 10.1007/BF02247422
   Pomerleau O F, 1995, J Subst Abuse, V7, P373, DOI 10.1016/0899-3289(95)90030-6
   POMERLEAU OF, 1984, NEUROSCI BIOBEHAV R, V8, P503, DOI 10.1016/0149-7634(84)90007-1
   Pope HG, 1996, JAMA-J AM MED ASSOC, V275, P521, DOI 10.1001/jama.275.7.521
   Portugal GS, 2012, NEUROBIOL LEARN MEM, V97, P482, DOI 10.1016/j.nlm.2012.04.003
   Portugal GS, 2012, BEHAV GENET, V42, P133, DOI 10.1007/s10519-011-9489-7
   Potter AS, 2008, PHARMACOL BIOCHEM BE, V88, P407, DOI 10.1016/j.pbb.2007.09.014
   PROVOST SC, 1991, PSYCHOPHARMACOLOGY, V104, P536, DOI 10.1007/BF02245662
   Pu L, 2002, J NEUROSCI, V22, P1914, DOI 10.1523/JNEUROSCI.22-05-01914.2002
   Puighermanal E, 2009, NAT NEUROSCI, V12, P1152, DOI 10.1038/nn.2369
   Rajendran P, 2004, ANN NY ACAD SCI, V1021, P441, DOI 10.1196/annals.1308.060
   Ramirez DR, 2009, EUR J NEUROSCI, V30, P901, DOI 10.1111/j.1460-9568.2009.06889.x
   Ranganathan M, 2006, PSYCHOPHARMACOLOGY, V188, P425, DOI 10.1007/s00213-006-0508-y
   Raybuck JD, 2009, EUR J NEUROSCI, V29, P377, DOI 10.1111/j.1460-9568.2008.06580.x
   Raybuck JD, 2007, BEHAV NEUROSCI, V121, P1119, DOI 10.1037/0735-7044.121.5.1119
   Rehm J, 2003, ADDICTION, V98, P1209, DOI 10.1046/j.1360-0443.2003.00467.x
   Reichel CM, 2014, DRUG ALCOHOL DEPEN, V134, P115, DOI 10.1016/j.drugalcdep.2013.09.018
   Retailleau A, 2013, NEUROBIOL DIS, V59, P151, DOI 10.1016/j.nbd.2013.07.014
   REYNOLDS JN, 1992, EUR J PHARMACOL, V224, P173, DOI 10.1016/0014-2999(92)90802-B
   Richardson NR, 1996, J NEUROSCI METH, V66, P1, DOI 10.1016/0165-0270(95)00153-0
   RISINGER FO, 1995, PHARMACOL BIOCHEM BE, V51, P457, DOI 10.1016/0091-3057(95)00007-J
   Robbins TW, 2008, ANN NY ACAD SCI, V1141, P1, DOI 10.1196/annals.1441.020
   Roberto M, 2003, EUR J NEUROSCI, V17, P1646, DOI 10.1046/j.1460-9568.2003.02614.x
   Roberto M, 2002, J NEUROPHYSIOL, V87, P2385, DOI 10.1152/jn.2002.87.5.2385
   Robinson TE, 1999, SYNAPSE, V33, P160
   Rogers JL, 2007, NEUROBIOL LEARN MEM, V87, P688, DOI 10.1016/j.nlm.2007.01.003
   Rogers RD, 1999, NEUROPSYCHOPHARMACOL, V20, P322, DOI 10.1016/S0893-133X(98)00091-8
   Rosenthal MZ, 2014, PSYCHOL ADDICT BEHAV, V28, P863, DOI 10.1037/a0037082
   Rukstalis M, 2005, J SUBST ABUSE TREAT, V28, P297, DOI 10.1016/j.jsat.2005.02.002
   Ryan, 1983, BIOL ALCOHOL, P485, DOI DOI 10.1007/978-1-4613-3518-4_12
   Ryan C, 1980, Adv Exp Med Biol, V126, P701
   Salmanzadeh F, 2003, BRAIN RES, V965, P108, DOI 10.1016/S0006-8993(02)04144-6
   Salo R, 2002, PSYCHIAT RES, V111, P65, DOI 10.1016/S0165-1781(02)00111-7
   SANDLER DP, 1985, LANCET, V1, P312, DOI 10.1016/S0140-6736(85)91084-0
   Sanna PP, 2002, BRAIN RES, V948, P186, DOI 10.1016/S0006-8993(02)03191-8
   Santucci AC, 2004, NEUROTOXICOL TERATOL, V26, P651, DOI 10.1016/j.ntt.2004.06.002
   Santucci AC, 2008, EXP CLIN PSYCHOPHARM, V16, P77, DOI 10.1037/1064-1297.16.1.77
   SAUCIER D, 1995, NATURE, V378, P186, DOI 10.1038/378186a0
   Schummers J, 2001, MOL BRAIN RES, V94, P9, DOI 10.1016/S0169-328X(01)00161-9
   SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11
   Segal M, 2010, HIPPOCAMPUS, V20, P1332, DOI 10.1002/hipo.20751
   Sharifzadeh M, 2005, J NEUROCHEM, V95, P1078, DOI 10.1111/j.1471-4159.2005.03454.x
   SHERMAN CB, 1992, MED CLIN N AM, V76, P355, DOI 10.1016/S0025-7125(16)30357-1
   SHERWOOD N, 1993, HUM PSYCHOPHARM CLIN, V8, P155, DOI 10.1002/hup.470080303
   Shimizu K, 1998, NEUROSCIENCE, V83, P701, DOI 10.1016/S0306-4522(97)00339-4
   Silber BY, 2006, PSYCHOPHARMACOLOGY, V187, P154, DOI 10.1007/s00213-006-0410-7
   Simoes PF, 2007, NEUROSCIENCE, V150, P433, DOI 10.1016/j.neuroscience.2007.09.044
   Simon SL, 2002, J ADDICT DIS, V21, P61
   Simon SL, 2000, AM J ADDICTION, V9, P222
   SINDEN JD, 1982, PHARMACOL BIOCHEM BE, V16, P181, DOI 10.1016/0091-3057(82)90033-8
   SMITH DA, 1993, BRAIN RES, V608, P259, DOI 10.1016/0006-8993(93)91466-6
   Smith DM, 2006, HIPPOCAMPUS, V16, P716, DOI 10.1002/hipo.20208
   SNYDER FR, 1989, DRUG ALCOHOL DEPEN, V23, P259, DOI 10.1016/0376-8716(89)90090-2
   SOETENS E, 1993, NEUROSCI LETT, V161, P9, DOI 10.1016/0304-3940(93)90127-7
   SOLOWIJ N, 1995, LIFE SCI, V56, P2119, DOI 10.1016/0024-3205(95)00197-E
   SPAIN JW, 1991, PSYCHOPHARMACOLOGY, V105, P101, DOI 10.1007/BF02316870
   SPYRAKI C, 1982, BRAIN RES, V253, P195, DOI 10.1016/0006-8993(82)90686-2
   Stavro K, 2013, ADDICT BIOL, V18, P203, DOI 10.1111/j.1369-1600.2011.00418.x
   Steinpreis RE, 1996, PHARMACOL BIOCHEM BE, V54, P339, DOI 10.1016/0091-3057(95)02141-8
   Stephens RS, 2002, ADDICTION, V97, P109, DOI 10.1046/j.1360-0443.97.s01.6.x
   Stern CAJ, 2012, NEUROPSYCHOPHARMACOL, V37, P2132, DOI 10.1038/npp.2012.63
   Stinus L, 2005, NEUROPSYCHOPHARMACOL, V30, P90, DOI 10.1038/sj.npp.1300487
   STOLERMAN IP, 1995, PSYCHOPHARMACOLOGY, V117, P2, DOI 10.1007/BF02245088
   Stramiello M, 2010, SYNAPSE, V64, P644, DOI 10.1002/syn.20764
   STRUPP BJ, 1991, BEHAV NEURAL BIOL, V56, P62, DOI 10.1016/0163-1047(91)90291-W
   Substance Abuse and Mental Health Services Administration Office of Applied Studies (SAMHSA), 2005, NSDUH REP METH AB DE
   Substance Abuse and Mental Health Services Administration Office of Applied Studies (SAMHSA), 2006, DASIS REP TRENDS MET
   Substance Abuse and Mental Health Services Administration (SAMHSA), 2014, NSDUH SER H, V49
   Substance Abuse and Mental Health Services Administration (SAMHSA), 2006, OFF APPL STUD NSDUH, V30
   Sullivan EV, 2009, ALCOHOL ALCOHOLISM, V44, P155, DOI 10.1093/alcalc/agn103
   Sullivan EV, 2003, NEUROLOGY, V61, P1716, DOI 10.1212/01.WNL.0000098940.31882.BB
   Sullivan JM, 2000, LEARN MEMORY, V7, P132, DOI 10.1101/lm.7.3.132
   SUTHERLAND RJ, 1989, PSYCHOBIOLOGY, V17, P129
   Swant J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011382
   Takahashi KA, 2006, NEUROSCIENCE, V139, P795, DOI 10.1016/j.neuroscience.2006.01.024
   TAKAHASHI RN, 1979, PHARMACOL BIOCHEM BE, V11, P737, DOI 10.1016/0091-3057(79)90274-0
   TERRANOVA JP, 1995, N-S ARCH PHARMACOL, V352, P576, DOI 10.1007/BF00169393
   TEYLER TJ, 1987, ANNU REV NEUROSCI, V10, P131, DOI 10.1146/annurev.ne.10.030187.001023
   Thewissen R, 2005, ADDICTION, V100, P387, DOI 10.1111/j.1360-0443.2005.00996.x
   Thomas KL, 2003, EUR J NEUROSCI, V17, P1964, DOI 10.1046/j.1460-9568.2003.02617.x
   Thomas KL, 2001, J NEUROSCI, V21, P2526, DOI 10.1523/JNEUROSCI.21-07-02526.2001
   Thomas MJ, 2008, BRIT J PHARMACOL, V154, P327, DOI 10.1038/bjp.2008.77
   Thompson AM, 2005, NEUROPHARMACOLOGY, V49, P185, DOI 10.1016/j.neuropharm.2005.03.005
   Thompson AM, 2004, NEUROSCIENCE, V127, P177, DOI 10.1016/j.neuroscience.2004.05.001
   Thompson AM, 2002, NEUROPHARMACOLOGY, V42, P1039, DOI 10.1016/S0028-3908(02)00059-X
   Thorn DA, 2012, EUR J PHARMACOL, V680, P69, DOI 10.1016/j.ejphar.2012.01.037
   Tian SW, 2011, NEUROSCI LETT, V487, P368, DOI 10.1016/j.neulet.2010.10.058
   Tidy HL, 1938, P ROY SOC MED, V32, P385
   TINKLENBERG JR, 1970, NATURE, V226, P1171, DOI 10.1038/2261171b0
   Tramullas M, 2008, NEUROPHARMACOLOGY, V54, P640, DOI 10.1016/j.neuropharm.2007.11.018
   TREMWEL MF, 1994, SYNAPSE, V17, P141, DOI 10.1002/syn.890170210
   Trifilieff P, 2006, LEARN MEMORY, V13, P349, DOI 10.1101/lm.80206
   Tropea TF, 2008, J NEUROCHEM, V106, P1780, DOI 10.1111/j.1471-4159.2008.05518.x
   Tulving E, 1998, HIPPOCAMPUS, V8, P198, DOI 10.1002/(SICI)1098-1063(1998)8:3<198::AID-HIPO2>3.3.CO;2-J
   TZSCHENTKE TM, 1995, NEUROSCI LETT, V193, P37, DOI 10.1016/0304-3940(95)11662-G
   Valjent E, 2000, PSYCHOPHARMACOLOGY, V147, P436, DOI 10.1007/s002130050013
   Valzachi MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078317
   Vandergriff JL, 1995, ALCOHOL CLIN EXP RES, V19, P64
   Vandrey RG, 2008, DRUG ALCOHOL DEPEN, V92, P48, DOI 10.1016/j.drugalcdep.2007.06.010
   Vandrey RG, 2005, AM J ADDICTION, V14, P54, DOI 10.1080/10550490590899853
   Vastola BJ, 2002, PHYSIOL BEHAV, V77, P107, DOI 10.1016/S0031-9384(02)00818-1
   Vetreno RP, 2011, NEUROBIOL LEARN MEM, V96, P596, DOI 10.1016/j.nlm.2011.01.003
   Vianna MRM, 2000, LEARN MEMORY, V7, P333, DOI 10.1101/lm.34600
   Vidal-Infer A, 2012, PHARMACOL BIOCHEM BE, V102, P124, DOI 10.1016/j.pbb.2012.03.031
   Volkow ND, 1999, J PSYCHOPHARMACOL, V13, P337, DOI 10.1177/026988119901300406
   Vorel SR, 2001, SCIENCE, V292, P1175, DOI 10.1126/science.1058043
   Wang YP, 2012, BRAIN RES BULL, V89, P191, DOI 10.1016/j.brainresbull.2012.08.007
   WARBURTON DM, 1986, PSYCHOPHARMACOLOGY, V89, P55
   Watkins S S, 2000, Nicotine Tob Res, V2, P19
   Wehner JM, 2004, NEUROSCIENCE, V129, P11, DOI 10.1016/j.neuroscience.2004.07.016
   Wells AM, 2011, LEARN MEMORY, V18, P693, DOI 10.1101/lm.2273111
   Welsby PJ, 2007, NEUROPHARMACOLOGY, V53, P188, DOI 10.1016/j.neuropharm.2007.05.013
   Welsby P, 2006, EUR J NEUROSCI, V24, P3109, DOI 10.1111/j.1460-9568.2006.05187.x
   WESNES K, 1983, NEUROPSYCHOBIOLOGY, V9, P223, DOI 10.1159/000117969
   WEST R, 1994, ADDICTION, V89, P1483, DOI 10.1111/j.1360-0443.1994.tb03747.x
   Wexler BE, 2001, AM J PSYCHIAT, V158, P86, DOI 10.1176/appi.ajp.158.1.86
   White AM, 1997, PSYCHOPHARMACOLOGY, V133, P256, DOI 10.1007/s002130050399
   White AM, 1998, ALCOHOL CLIN EXP RES, V22, P2102, DOI 10.1111/j.1530-0277.1998.tb05922.x
   White NM, 1996, ADDICTION, V91, P921, DOI 10.1111/j.1360-0443.1996.tb03586.x
   WIKLER A, 1973, ARCH GEN PSYCHIAT, V28, P611
   Wikler A., 1948, AM J PSYCHIAT, V105, P74
   Wilens TE, 2008, J AM ACAD CHILD PSY, V47, P21, DOI 10.1097/chi.0b013e31815a56f1
   Wilkinson DS, 2013, BEHAV BRAIN RES, V250, P58, DOI 10.1016/j.bbr.2013.04.053
   Wilkinson DS, 2013, PSYCHOPHARMACOLOGY, V225, P201, DOI 10.1007/s00213-012-2808-8
   Winder DG, 1999, NEURON, V24, P715, DOI 10.1016/S0896-6273(00)81124-1
   Wing VC, 2008, PSYCHOPHARMACOLOGY, V200, P357, DOI 10.1007/s00213-008-1211-y
   Wise LE, 2011, PSYCHOPHARMACOLOGY, V217, P485, DOI 10.1007/s00213-011-2305-5
   Wood SC, 2007, BEHAV BRAIN RES, V176, P244, DOI 10.1016/j.bbr.2006.10.008
   World Health Organisation, GLOB STAT REP ALC HL
   Xie XH, 2010, PSYCHOPHARMACOLOGY, V208, P1, DOI 10.1007/s00213-009-1700-7
   Yamaguchi M, 2005, SYNAPSE, V58, P63, DOI 10.1002/syn.20182
   Yamaguchi M, 2004, ANN NY ACAD SCI, V1025, P351, DOI 10.1196/annals.1316.043
   Yamazaki Y, 2006, EUR J NEUROSCI, V24, P2903, DOI 10.1111/j.1460-9568.2006.05160.x
   Yonelinas AP, 2013, BEHAV BRAIN RES, V254, P34, DOI 10.1016/j.bbr.2013.05.030
   Zeeuws I, 2007, HUM PSYCHOPHARM CLIN, V22, P279, DOI 10.1002/hup.848
NR 418
TC 157
Z9 163
U1 3
U2 52
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1072-0502
EI 1549-5485
J9 LEARN MEMORY
JI Learn. Mem.
PD OCT
PY 2016
VL 23
IS 10
BP 515
EP 533
DI 10.1101/lm.042192.116
PG 19
WC Neurosciences; Psychology, Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Psychology
GA DZ6JK
UT WOS:000385968200003
PM 27634143
OA Green Submitted, Green Published, gold
DA 2023-06-23
ER

PT J
AU Robles, E
   Huang, BE
   Simpson, PM
   McMillan, DE
AF Robles, Elias
   Huang, B. Emma
   Simpson, Pippa M.
   McMillan, Donald E.
TI Delay discounting, impulsiveness, and addiction severity in
   opioid-dependent patients
SO JOURNAL OF SUBSTANCE ABUSE TREATMENT
LA English
DT Article
DE Delay discounting; Impulsiveness; Addiction severity; Opioids; Methadone
   maintenance
ID CIGARETTE-SMOKING; DECISION-MAKING; DRUG-USE; INDEX; REWARDS;
   PROBABILITY; ALCOHOLICS; BEHAVIOR; ABUSERS; HEROIN
AB Individuals who abuse drugs show higher delay discounting (DD) rate and impulsiveness scores compared with controls; however, it is unclear if DD rate covaries with severity of the addiction or if an individual's discounting rate can be changed by effective substance abuse treatment. This study compared methadone maintenance treatment (MMT) patients (n = 30) who had not used illegal drugs for 2 years with drug-using MMT patients (n = 30) and controls (n = 25) in terms of addiction severity, DD rate, and impulsiveness. Methadone patients abstinent from illegal drugs scored significantly lower on a number of addiction severity measures than the drug-using methadone patients. In addition, both groups of MMT patients showed significantly higher rates of DD and impulsiveness than the control group; however, no differences in DD rate or impulsiveness were found between the groups of patients. Results suggest that DD rate and impulsiveness may not covary with indicators of addiction severity in MMT patients. Published by Elsevier Inc.
C1 [Robles, Elias] Arizona State Univ, Dept Social & Behav Sci, Div Social & Behav Sci, Glendale, AZ 85306 USA.
   [Huang, B. Emma] Commonwealth Sci & Ind Res Org, St Lucia, Qld, Australia.
   [Simpson, Pippa M.] Translat & Biomed Ctr, Childrens Res Inst, Milwaukee, WI USA.
   [McMillan, Donald E.] Univ Arkansas Med Sci, Dept Pharmacol, Little Rock, AR 72205 USA.
C3 Arizona State University; Commonwealth Scientific & Industrial Research
   Organisation (CSIRO); University of Arkansas System; University of
   Arkansas Medical Sciences
RP Robles, E (通讯作者)，Arizona State Univ, Dept Social & Behav Sci, Div Social & Behav Sci, Glendale, AZ 85306 USA.
EM elias.robles@asu.edu
RI simpson, pippa/AAI-8172-2020; Huang, Bevan/A-5949-2009
OI simpson, pippa/0000-0003-1458-3748; Huang, Bevan/0000-0002-1981-5838
FU NIDA NIH HHS [1R03DA13692-01, R03 DA013692-01] Funding Source: Medline
CR AINSLIE G, 1975, PSYCHOL BULL, V82, P463, DOI 10.1037/h0076860
   AINSLIE GW, 1974, J EXP ANAL BEHAV, V21, P485, DOI 10.1901/jeab.1974.21-485
   Audrain-McGovern J, 2009, DRUG ALCOHOL DEPEN, V103, P99, DOI 10.1016/j.drugalcdep.2008.12.019
   Bechara A, 2004, NEUROPSYCHOLOGY, V18, P152, DOI 10.1037/0894-4105.18.1.152
   Bickel WK, 2011, BIOL PSYCHIAT, V69, P260, DOI 10.1016/j.biopsych.2010.08.017
   Bickel WK, 1999, PSYCHOPHARMACOLOGY, V146, P447, DOI 10.1007/PL00005490
   Bickel WK, 2006, BEHAV ANAL TODAY, V7, P32, DOI DOI 10.1037/H0100148
   Black AC, 2011, ADDICT BEHAV, V36, P125, DOI 10.1016/j.addbeh.2010.08.014
   Bretteville-Jensen AL, 1999, J HEALTH ECON, V18, P393, DOI 10.1016/S0167-6296(98)00057-5
   Butler SF, 2001, PSYCHOL ADDICT BEHAV, V15, P4
   de Wit H, 2009, ADDICT BIOL, V14, P22, DOI 10.1111/j.1369-1600.2008.00129.x
   de Wit H, 2007, PERS INDIV DIFFER, V42, P111, DOI 10.1016/j.paid.2006.06.026
   Eysenck H.J, 1968, EYSENCK PERSONALITY
   EYSENCK SBG, 1985, PERS INDIV DIFFER, V6, P613, DOI 10.1016/0191-8869(85)90011-X
   Eysenck SBG, 1993, IMPULSIVE CLIENT THE, P141, DOI DOI 10.1037/10500-009
   Green L, 2004, PSYCHOL BULL, V130, P769, DOI 10.1037/0033-2909.130.5.769
   Heil SH, 2006, ADDICT BEHAV, V31, P1290, DOI 10.1016/j.addbeh.2005.09.005
   Hinson JM, 2003, J EXP PSYCHOL LEARN, V29, P298, DOI 10.1037/0278-7393.29.2.298
   Johnson MW, 2010, EXP CLIN PSYCHOPHARM, V18, P99, DOI 10.1037/a0018333
   Johnson MW, 2002, J EXP ANAL BEHAV, V77, P129, DOI 10.1901/jeab.2002.77-129
   Killeen PR, 2009, PSYCHOL REV, V116, P602, DOI 10.1037/a0016414
   Kirby KN, 1999, J EXP PSYCHOL GEN, V128, P78, DOI 10.1037/0096-3445.128.1.78
   Kirby KN, 2004, ADDICTION, V99, P461, DOI 10.1111/j.1360-0443.2003.00669.x
   Krishnan-Sarin S, 2007, DRUG ALCOHOL DEPEN, V88, P79, DOI 10.1016/j.drugalcdep.2006.09.006
   MacKillop J, 2009, DRUG ALCOHOL DEPEN, V104, P197, DOI 10.1016/j.drugalcdep.2009.04.020
   Madden GJ, 2003, EXP CLIN PSYCHOPHARM, V11, P139, DOI 10.1037/1064-1297.11.2.139
   Madden GJ, 1997, EXP CLIN PSYCHOPHARM, V5, P256, DOI 10.1037/1064-1297.5.3.256
   Mazur JE, 1987, QUANTITATIVE ANAL BE, V5, P57
   McKerchar TL, 2009, BEHAV PROCESS, V81, P256, DOI 10.1016/j.beproc.2008.12.017
   MCLELLAN AT, 1985, J NERV MENT DIS, V173, P412, DOI 10.1097/00005053-198507000-00005
   Odum A. L., 2010, IMPULSIVITY BEHAV NE
   Perry JL, 2008, PSYCHOPHARMACOLOGY, V200, P1, DOI 10.1007/s00213-008-1173-0
   Petry NM, 1999, DRUG ALCOHOL DEPEN, V56, P25, DOI 10.1016/S0376-8716(99)00010-1
   Petry NM, 2001, PSYCHOPHARMACOLOGY, V154, P243, DOI 10.1007/s002130000638
   RACHLIN H, 1991, J EXP ANAL BEHAV, V55, P233, DOI 10.1901/jeab.1991.55-233
   RACHLIN H, 1972, J EXP ANAL BEHAV, V17, P15, DOI 10.1901/jeab.1972.17-15
   Reynolds B, 2004, BEHAV PROCESS, V67, P343, DOI 10.1016/j.beproc.2004.06.003
   Reynolds B, 2004, BEHAV PROCESS, V65, P35, DOI 10.1016/S0376-6357(03)00109-8
   Reynolds B, 2006, BEHAV PHARMACOL, V17, P651, DOI 10.1097/FBP.0b013e3280115f99
   Reynolds B, 2009, DRUG ALCOHOL DEPEN, V99, P350, DOI 10.1016/j.drugalcdep.2008.07.015
   Richards JB, 1999, J EXP ANAL BEHAV, V71, P121, DOI 10.1901/jeab.1999.71-121
   Robles E, 2001, DRUG ALCOHOL DEPEN S, V63, pS133
   Robles E, 2010, J BEHAV HLTH SOCIAL, V2, P105
   Robles E, 2007, BEHAV PROCESS, V75, P237, DOI 10.1016/j.beproc.2007.02.014
   Rosen CS, 2000, ADDICTION, V95, P419, DOI 10.1046/j.1360-0443.2000.95341912.x
   Shamosh NA, 2008, INTELLIGENCE, V36, P289, DOI 10.1016/j.intell.2007.09.004
   Tucker JA, 2002, EXP CLIN PSYCHOPHARM, V10, P248, DOI 10.1037//1064-1297.10.3.248
   Tucker JA, 2006, J CONSULT CLIN PSYCH, V74, P317, DOI 10.1037/0022-006X.74.2.317
   Tucker JA, 2009, J CONSULT CLIN PSYCH, V77, P219, DOI 10.1037/a0014968
   Upton J., 2010, 33 ANN C SOC QUANT A
   Vuchinich RE, 1998, EXP CLIN PSYCHOPHARM, V6, P292, DOI 10.1037/1064-1297.6.3.292
   Yi R., 2010, IMPULSIVITY BEHAV NE
   Yoon JH, 2007, EXP CLIN PSYCHOPHARM, V15, P176, DOI 10.1037/1064-1297.15.2.186
   Zachary R. A, 1991, SHEPLEY I LIVING SCA
   ZACHARY RA, 1985, J CLIN PSYCHOL, V41, P532, DOI 10.1002/1097-4679(198507)41:4<532::AID-JCLP2270410414>3.0.CO;2-D
NR 55
TC 38
Z9 40
U1 2
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0740-5472
J9 J SUBST ABUSE TREAT
JI J. Subst. Abus. Treat.
PD DEC
PY 2011
VL 41
IS 4
BP 354
EP 362
DI 10.1016/j.jsat.2011.05.003
PG 9
WC Psychology, Clinical; Substance Abuse
WE Social Science Citation Index (SSCI)
SC Psychology; Substance Abuse
GA 843QS
UT WOS:000296687900004
PM 21741198
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Dagher, A
AF Dagher, Alain
TI DOPAMINE IS NOT DOPAMINE
SO ADDICTION
LA English
DT Editorial Material
DE Addiction; dopamine; drug dependence; L-dopa; Parkinson; therapy
ID IMPULSE CONTROL DISORDERS; RECEPTORS; ADDICTION
C1 McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada.
C3 McGill University
RP Dagher, A (通讯作者)，McGill Univ, Montreal Neurol Inst, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.
EM alain@bic.mni.mcgill.ca
CR ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X
   Ambermoon P, 2012, ADDICTION, V107, P241, DOI 10.1111/j.1360-0443.2011.03511.x
   Buckholtz JW, 2010, SCIENCE, V329, P532, DOI 10.1126/science.1185778
   Cohen MX, 2009, BEHAV BRAIN RES, V199, P141, DOI 10.1016/j.bbr.2008.09.029
   Collins GT, 2009, BEHAV PHARMACOL, V20, P492, DOI 10.1097/FBP.0b013e328330ad9b
   Dagher A, 2009, NEURON, V61, P502, DOI 10.1016/j.neuron.2009.01.031
   Dalley JW, 2007, SCIENCE, V315, P1267, DOI 10.1126/science.1137073
   Evans AH, 2006, ANN NEUROL, V59, P852, DOI 10.1002/ana.20822
   Frank MJ, 2009, NEUROSCIENCE, V164, P131, DOI 10.1016/j.neuroscience.2009.04.048
   Johnson PM, 2010, NAT NEUROSCI, V13, P635, DOI 10.1038/nn.2519
   Morgan D, 2002, NAT NEUROSCI, V5, P169, DOI 10.1038/nn798
   Nutt JG, 1997, ANN NEUROL, V42, P349, DOI 10.1002/ana.410420311
   O'Sullivan SS, 2011, PARKINSON'S DISEASE: NON-MOTOR AND NON-DOPAMINERGIC FEATURES, P202
   Pontone G, 2006, NEUROLOGY, V67, P1258, DOI 10.1212/01.wnl.0000238401.76928.45
   Potenza MN, 2006, ADDICTION, V101, P142, DOI 10.1111/j.1360-0443.2006.01591.x
   Self DW, 2010, RECEPT SER, P479, DOI 10.1007/978-1-60327-333-6_17
   Shen WX, 2008, SCIENCE, V321, P848, DOI 10.1126/science.1160575
   VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210
   Weintraub D, 2006, ARCH NEUROL-CHICAGO, V63, P969, DOI 10.1001/archneur.63.7.969
   Weintraub D, 2010, ARCH NEUROL-CHICAGO, V67, P589, DOI 10.1001/archneurol.2010.65
NR 20
TC 2
Z9 2
U1 2
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0965-2140
EI 1360-0443
J9 ADDICTION
JI Addiction
PD FEB
PY 2012
VL 107
IS 2
BP 248
EP 250
DI 10.1111/j.1360-0443.2011.03591.x
PG 3
WC Substance Abuse; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry
GA 877DC
UT WOS:000299156100005
PM 22248132
OA Bronze
DA 2023-06-23
ER

PT J
AU Ali, M
AF Ali, Mansur
TI Perspectives on Drug Addiction in Islamic History and Theology
SO RELIGIONS
LA English
DT Article
DE Islamic theology; drugs; addiction; nafs; ruh; Millati Islami;
   Alcoholics Anonymous
AB How does Islam view substance addiction? What happens to the soul of the person suffering from addictive disorder? What happens to their relationship with God? These are some of the questions that this article tries to answer. Three models on drug addiction from an Islamic theological perspective will be explored here. Two of them are preventative models based on an understanding of society rooted in shame-culture, while the third model, called Millati Islami, practiced in the USA, is founded on the Islamic understanding of tawba (repentance). Furthermore, drugs and addiction in scripture, as well as medieval Muslim society's attitude towards them, are explored. As a whole, the models discussed in the article demonstrate that Islamic theology possesses the intellectual and theoretical tools to develop fully-fledged theological models of addiction. This paper concludes by suggesting that one model should be explored.
C1 Cardiff Univ, Ctr Study Islam UK, Sch Hist Archaeol & Relig, Cardiff CF10 3EU, S Glam, Wales.
C3 Cardiff University
RP Ali, M (通讯作者)，Cardiff Univ, Ctr Study Islam UK, Sch Hist Archaeol & Relig, John Percival Bldg,Colum Dr, Cardiff CF10 3EU, S Glam, Wales.
EM AliMM1@Cardiff.ac.uk
RI Ali, Muhammad Mansur/AAO-4157-2020
OI Ali, Muhammad Mansur/0000-0002-3176-4746
CR Abdel Haleem M.A.S., 2005, QUARN NEW TRANSLATIO
   Abidin Muhammad Ibn, 1992, RADD MUHTAR ALA DURR
   Abu-Raiya H, 2011, MENT HEALTH RELIG CU, V14, P93, DOI 10.1080/13674670903426482
   al-Marghinani Burhan al-Din, 2006, AL HIDAYAH GUIDANCE
   al-Mawsili Abu Ya'la, 1984, MUSNAD ABI YALA
   al-Tabari Muhammad Ibn Jarir, 2000, JAMI BAYAN TAWIL QUR
   Alcoholics Anonymous Great Britain, 12 STEPS ALC AN
   Ali Muhammad Mansur, 2012, MUSLIMS BRITAIN MAKI, P84
   Ali-Northcott L, 2012, COUNSELING MUSLIMS: HANDBOOK OF MENTAL HEALTH ISSUES AND INTERVENTIONS, P355
   Bangstad Sindre, 2009, ISLAM AIDS SCORN PIT, P43
   BOS G, 1996, B SCH ORIENT AFR ST, V59, P229, DOI 10.1017/S0041977X00031542
   Byrnes Chris, 2009, ISLAM AIDS SCORN PIT, P198
   California Department of Corrections and Rehabilitation, PRIS FAC
   Christopher C.H., 2006, ALCOHOL ADDICTON CHR
   Cook Christopher C.H., 2008, CHRISTIAN HDB ABUSE, P83
   Cook Christopher C.H., 2011, DEV SERVICES MENTAL, P171
   Dharamsi S, 2012, COUNSELING MUSLIMS: HANDBOOK OF MENTAL HEALTH ISSUES AND INTERVENTIONS, P135
   Doi Abdur R., 1997, SHARIAH ISLAMIC LAW
   Gilliat-Ray Sophie, 2013, UNDERSTANDING MUSLIM
   Hamarneh S, 1972, Med Hist, V16, P226
   Ibn Hanbal Ahmad, 2001, MUSNAD
   Kamali MH, 2000, PRINCIPLES ISLAMIC J
   KIKIT Pathways to Recovery, 1 ISL 12 STEP ADD SU
   Lewis D., 1994, PROC 3 ANN S DOC ANA, P1
   Malik B, 2009, ISLAM AIDS SCORN PIT, P28
   Marsiglia FF, 2005, AM J ORTHOPSYCHIAT, V75, P585, DOI 10.1037/0002-9432.75.4.585
   Matthee Rudi, 2005, PURSUIT PLEASURE DRU
   Millati Islami World Services, WORK 1 3 STEPS
   Millati Islami World Services, MILL ISL STEP 4
   Millati Islami World Services, WHAT IS MILLATI ISL
   Millati Islami World Services, 12 STEPS RECOVERY
   Mission of Hope, HAY HOUS STREET OUTR
   Muhammad Iia-B, 2001, SAHIH AL BUKHARI
   Muslimas' Oasis, J DAW TEX PRIS DAW P
   Nasr Seyyed Hossein, 2002, HEART ISLAM ENDURING
   OMAR I, 1993, MUSLIM WORLD, V83, P279, DOI 10.1111/j.1478-1913.1993.tb03580.x
   Padela AI, 2011, J RELIG HEALTH, V50, P359, DOI 10.1007/s10943-010-9428-6
   Pittman Jason, 2002, CHRISTIANITY SOCIAL
   Ramadan Tariq, INT CALL MORATORIUM
   Rosenthal F, 1971, HERB HASHISH VERSUS
   Safian Yasmin Hanani Mohd., 2013, INT J ED RES, V1, P1
   Schacht Joseph, 1964, INTRO ISLAMIC LAW
   Taymiyya Taqiuddin Ibn, 1995, MAJMU FATAWA MADINA
   Utz A, 2012, COUNSELING MUSLIMS: HANDBOOK OF MENTAL HEALTH ISSUES AND INTERVENTIONS, P15
   Wong Y., 2007, SELF CONSCIOUS EMOTI, P209
   Yusuf Hamza, 2004, PURIFICATION HEART S
NR 46
TC 14
Z9 14
U1 0
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2077-1444
J9 RELIGIONS
JI Religions
PD SEP
PY 2014
VL 5
IS 3
BP 912
EP 928
DI 10.3390/rel5030912
PG 17
WC Religion
WE Arts &amp; Humanities Citation Index (A&amp;HCI)
SC Religion
GA AQ0ZD
UT WOS:000342510300023
OA Green Published, gold, Green Accepted, Green Submitted
DA 2023-06-23
ER

PT J
AU Lin, SK
   Wu, SH
   Yang, YS
   Pan, WHT
AF Lin, SK
   Wu, SH
   Yang, YS
   Pan, WHT
TI Drug addiction-the neurochemical perspective of brain in drug-seeking
   behavior
SO JOURNAL OF FOOD AND DRUG ANALYSIS
LA English
DT Article
DE addiction; drug-seeking behavior; sensitization; dopamine; glutamate;
   nucleus accumbens; ventral tegmental area; associative learning
ID CONDITIONED PLACE PREFERENCE; VENTRAL TEGMENTAL AREA; D-1
   DOPAMINE-RECEPTOR; COCAINE-SEEKING; INCENTIVE-SENSITIZATION; LOCOMOTOR
   RESPONSE; D2 RECEPTORS; TIME-COURSE; AMPHETAMINE; EXPRESSION
AB A critical challenge of the investigation in the neurobiological mechanism of drug addiction is how acute actions become transformed into chronic effects that underlie the compulsive drug-seeking and craving in addiction. Repeated administrations of psychostimulants can enhance the behavioral response upon reinstatement of the drug, a prominent phenomenon known as behavioral sensitization. It has been implicated that the neuronal changes brought about by sensitization in the mesocorticolimbic pathways have close relationship with compulsive drug seeking in addicts. Dopamine and glutamate are the two major neurotransmitters involved in the sensitization of abused drugs. The authors reviewed literature pertinent to amphetamine and cocaine addiction in order to address the recent important concepts and findings in dopaminergic and glutamatergic neurochemical systems of mesolimbic and mesocortical circuits associated with drug-related behavior. The present review also discusses the role of associative learning as manifested in the relationship between environmental cues of drug administration and intractable drug-seeking behavior.
C1 Natl Yang Ming Univ, Inst Pharmacol, Taipei 112, Taiwan.
   Taipei City Psychiat Ctr, Dept Adult Psychiat, Taipei 110, Taiwan.
C3 National Yang Ming Chiao Tung University
RP Pan, WHT (通讯作者)，Natl Yang Ming Univ, Inst Pharmacol, 155,Sec 2,Linong St, Taipei 112, Taiwan.
EM wynn@ym.edu.tw
CR American Psychiatric Association, 1987, DIAGNOSTIC STAT MANU, V3rd
   Anagnostaras SG, 2002, NEUROPSYCHOPHARMACOL, V26, P703, DOI 10.1016/S0893-133X(01)00402-X
   Anagnostaras SG, 1996, BEHAV NEUROSCI, V110, P1397, DOI 10.1037/0735-7044.110.6.1397
   ANTELMAN SM, 1994, TOXICOL IND HEALTH, V10, P335
   Attarian S, 1997, EUR J NEUROSCI, V9, P809, DOI 10.1111/j.1460-9568.1997.tb01430.x
   Badiani A, 1997, J PHARMACOL EXP THER, V282, P787
   Bardo MT, 1998, CRIT REV NEUROBIOL, V12, P37, DOI 10.1615/CritRevNeurobiol.v12.i1-2.30
   Bardo MT, 2000, PSYCHOPHARMACOLOGY, V153, P31, DOI 10.1007/s002130000569
   Battisti JJ, 2000, BEHAV BRAIN RES, V114, P167, DOI 10.1016/S0166-4328(00)00227-8
   Beninger RJ, 1998, NEUROSCI BIOBEHAV R, V22, P335, DOI 10.1016/S0149-7634(97)00019-5
   Capper-Loup C, 2002, J NEUROSCI, V22, P6218
   Chen NNH, 2000, J NEUROCHEM, V74, P2576, DOI 10.1046/j.1471-4159.2000.0742576.x
   Ciccocioppo R, 2001, P NATL ACAD SCI USA, V98, P1976, DOI 10.1073/pnas.98.4.1976
   Cornish JL, 2001, J ADDICT DIS, V20, P43, DOI 10.1300/J069v20n03_05
   Cornish JL, 1999, NEUROSCIENCE, V93, P1359, DOI 10.1016/S0306-4522(99)00214-6
   Cunningham ST, 1997, NEUROPSYCHOPHARMACOL, V16, P147, DOI 10.1016/S0893-133X(96)00166-2
   Dalia AD, 1998, BRAIN RES, V797, P29, DOI 10.1016/S0006-8993(98)00323-0
   De Vries TJ, 2002, NEUROPSYCHOPHARMACOL, V26, P18, DOI 10.1016/S0893-133X(01)00293-7
   De Vries TJ, 1998, EUR J NEUROSCI, V10, P3565, DOI 10.1046/j.1460-9568.1998.00368.x
   Di Chiara G, 1999, EUR J PHARMACOL, V375, P13, DOI 10.1016/S0014-2999(99)00372-6
   DREW KL, 1990, PSYCHOPHARMACOLOGY, V101, P465, DOI 10.1007/BF02244223
   Duvauchelle CL, 2000, BRAIN RES, V862, P49, DOI 10.1016/S0006-8993(00)02091-6
   Everitt BJ, 1999, ANN NY ACAD SCI, V877, P412, DOI 10.1111/j.1749-6632.1999.tb09280.x
   Everitt BJ, 2002, J NEUROSCI, V22, P3312
   Gardner EL, 2000, AM J ADDICTION, V9, P285, DOI 10.1080/105504900750047355
   HAEFELY W, 1986, PHARMACOPSYCHIATRY, V19, P353, DOI 10.1055/s-2007-1025061
   Hummel M, 2002, J CELL PHYSIOL, V191, P17, DOI 10.1002/jcp.10078
   Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560
   Jolly D., 1997, Society for Neuroscience Abstracts, V23, P1091
   KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U
   KALIVAS PW, 1993, J NEUROSCI, V13, P266
   KALIVAS PW, 1993, BEHAV PHARMACOL, V4, P315
   KALIVAS PW, 1993, J PHARMACOL EXP THER, V267, P486
   KARLER R, 1991, BRAIN RES, V552, P295, DOI 10.1016/0006-8993(91)90095-D
   KARLER R, 1994, PSYCHOPHARMACOLOGY, V115, P305, DOI 10.1007/BF02245070
   KARLER R, 1989, LIFE SCI, V45, P599, DOI 10.1016/0024-3205(89)90045-3
   Kelley AE, 2002, J NEUROSCI, V22, P3306
   Kim JH, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-05-j0003.2001
   Koob GF, 2000, ANN NY ACAD SCI, V909, P170, DOI 10.1111/j.1749-6632.2000.tb06682.x
   KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J
   Kuribara H, 1996, EUR J PHARMACOL, V316, P1, DOI 10.1016/S0014-2999(96)00635-8
   LEWIS MJ, 1976, BRAIN RES, V107, P156, DOI 10.1016/0006-8993(76)90105-0
   Meririnne E, 2001, J PHARMACOL EXP THER, V298, P539
   Nocjar C, 2002, BEHAV BRAIN RES, V128, P189, DOI 10.1016/S0166-4328(01)00321-7
   O'Brien CP, 1998, J PSYCHOPHARMACOL, V12, P15, DOI 10.1177/026988119801200103
   ODONNELL P, 1995, J NEUROSCI, V15, P3622
   PAULSON PE, 1991, PSYCHOPHARMACOLOGY, V103, P480, DOI 10.1007/BF02244248
   Phillips AG, 1996, PSYCHOPHARMACOLOGY, V124, P279, DOI 10.1007/BF02246669
   Pierce RC, 1997, BRAIN RES REV, V25, P192, DOI 10.1016/S0165-0173(97)00021-0
   POST RM, 1980, LIFE SCI, V26, P1275, DOI 10.1016/0024-3205(80)90085-5
   Reid MS, 1996, NEUROREPORT, V7, P1325, DOI 10.1097/00001756-199605170-00022
   Robinson TE, 2001, ADDICTION, V96, P103, DOI 10.1046/j.1360-0443.2001.9611038.x
   Robinson TE, 2000, ADDICTION, V95, pS91
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   ROBINSON TE, 1986, BRAIN RES REV, V11, P157, DOI 10.1016/0165-0173(86)90002-0
   Robinson TE, 1998, NEUROSCI BIOBEHAV R, V22, P347, DOI 10.1016/S0149-7634(97)00020-1
   Segal D S, 1981, Essays Neurochem Neuropharmacol, V5, P95
   Shimosato K, 2000, PHARMACOL BIOCHEM BE, V66, P285, DOI 10.1016/S0091-3057(00)00185-4
   Spanagel R, 1999, TRENDS NEUROSCI, V22, P521, DOI 10.1016/S0166-2236(99)01447-2
   Spealman RD, 1999, PHARMACOL BIOCHEM BE, V64, P327, DOI 10.1016/S0091-3057(99)00049-0
   STEWART J, 1992, ANN NY ACAD SCI, V654, P335, DOI 10.1111/j.1749-6632.1992.tb25979.x
   TERNES J W, 1990, Advances in Alcohol and Substance Abuse, V9, P27
   UJIKE H, 1989, PSYCHOPHARMACOLOGY, V98, P89, DOI 10.1007/BF00442011
   Vanderschuren LJMJ, 2000, PSYCHOPHARMACOLOGY, V151, P99, DOI 10.1007/s002130000493
   VEZINA P, 1989, BRAIN RES, V499, P108, DOI 10.1016/0006-8993(89)91140-2
   Weiss F, 2001, NEUROPSYCHOPHARMACOL, V25, P361, DOI 10.1016/S0893-133X(01)00238-X
   WEISS SRB, 1989, PHARMACOL BIOCHEM BE, V34, P655, DOI 10.1016/S0091-3057(89)80001-2
   White FJ, 1998, DRUG ALCOHOL DEPEN, V51, P141, DOI 10.1016/S0376-8716(98)00072-6
   WIKLER A, 1976, ANN NY ACAD SCI, V282, P126, DOI 10.1111/j.1749-6632.1976.tb49893.x
   WISE RA, 1989, ANNU REV PSYCHOL, V40, P191, DOI 10.1146/annurev.ps.40.020189.001203
   WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469
   WOLF ME, 1993, BRAIN RES, V613, P291, DOI 10.1016/0006-8993(93)90913-8
   WOLF ME, 2002, MOL INTERVENTION, V2, P147
NR 73
TC 0
Z9 0
U1 0
U2 6
PU FOOD & DRUG ADMINSTRATION
PI TAIPEI
PA 161-2 KUNYANG STREET, NANGANG, TAIPEI, 00000, TAIWAN
SN 1021-9498
J9 J FOOD DRUG ANAL
JI J. Food Drug Anal.
PD DEC
PY 2003
VL 11
IS 4
BP 344
EP 352
PG 9
WC Food Science & Technology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Food Science & Technology; Pharmacology & Pharmacy
GA 759ET
UT WOS:000187725900012
DA 2023-06-23
ER

PT J
AU Crist, RC
   Ambrose-Lanci, LM
   Zeng, A
   Yuan, C
   Kampman, KM
   Pettinati, HM
   Oslin, DW
   O'Brien, CP
   Ferraro, TN
   Doyle, GA
   Lohoff, FW
   Berrettini, WH
AF Crist, Richard C.
   Ambrose-Lanci, Lisa M.
   Zeng, Angela
   Yuan, Cindy
   Kampman, Kyle M.
   Pettinati, Helen M.
   Oslin, David W.
   O'Brien, Charles P.
   Ferraro, Thomas N.
   Doyle, Glenn A.
   Lohoff, Falk W.
   Berrettini, Wade H.
TI Case-control association study of WLS variants in opioid and cocaine
   addicted populations
SO PSYCHIATRY RESEARCH
LA English
DT Article
DE Drug addiction; Cocaine addiction; Opioid addiction; Genetics
ID RECEPTOR GENE POLYMORPHISMS; PROTEIN-COUPLED RECEPTORS; SUBSTANCE USE;
   REWARD; DEPENDENCE; SECRETION; ABUSE; DRUG; DESENSITIZATION;
   SENSITIZATION
AB The opioid receptor family is involved in the development and maintenance of drug addiction. The mu-opioid receptor (MOR) mediates the rewarding effects of multiple drugs, including opiates and cocaine. A number of proteins interact with MOR, potentially modulating MOR function and altering the physiological consequences of drug use. These mu-opioid receptor interacting proteins (MORIPs) are potential therapeutic targets for the treatment of addiction. The Wntless (WLS) protein was recently identified as a MORIP in a yeast two-hybrid screen. In this study, we conducted a case-control association analysis of 16 WLS genetic variants in opioid and cocaine addicted individuals of both African-American (opioid n=336, cocaine n=908) and European-American (opioid n=335, cocaine n=336) ancestry. Of the analyzed SNPs, three were nominally associated with opioid addiction and four were nominally associated with cocaine addiction. None of these associations were significant following multiple testing correction. These data suggest that the common variants of WLS analyzed in this study are not associated with opioid or cocaine addiction. However, this study does not exclude the possibilities that rare variants in WLS may affect susceptibility to drug addiction, or that common variants with small effect size may fall below the detection level of our analysis. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Crist, Richard C.; Ambrose-Lanci, Lisa M.; Zeng, Angela; Yuan, Cindy; Ferraro, Thomas N.; Doyle, Glenn A.; Lohoff, Falk W.; Berrettini, Wade H.] Univ Penn, Perelman Sch Med, Dept Psychiat, Ctr Neurobiol & Behav, Philadelphia, PA 19104 USA.
   [Kampman, Kyle M.; Pettinati, Helen M.; Oslin, David W.; O'Brien, Charles P.] Univ Penn, Perelman Sch Med, Dept Psychiat, Treatment Res Ctr, Philadelphia, PA 19104 USA.
   [Oslin, David W.] VA Med Ctr, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; University of
   Pennsylvania; Pennsylvania Medicine
RP Crist, RC (通讯作者)，Univ Penn, Sch Med, Dept Psychiat, Ctr Neurobiol & Behav,Translat Res Labs, 125 South 31st St,Room 2109, Philadelphia, PA 19104 USA.
EM crist@mail.med.upenn.edu
RI Lohoff, Falk W/M-7951-2016
OI Ferraro, Thomas/0000-0003-2250-8772
FU NIDA NIH HHS [P20 DA025995, P50 DA012756, P60 DA005186] Funding Source:
   Medline; NIMH NIH HHS [MH059565, MH059588, R01 MH059587, R01 MH059586,
   T32 MH014654, R01 MH060870, R01 MH067257, MH067257, MH059571, R01
   MH059588, U01MH060879, MH59586, MH60870, MH061675, R01 MH061675,
   MH59587, R01 MH060879, R01 MH059571, R01 MH059566, MH59566, R01
   MH059565] Funding Source: Medline
CR ARVIDSSON U, 1995, J NEUROSCI, V15, P3328
   Banziger C, 2006, CELL, V125, P509, DOI 10.1016/j.cell.2006.02.049
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bart G, 2004, MOL PSYCHIATR, V9, P547, DOI 10.1038/sj.mp.4001504
   Bartscherer K, 2006, CELL, V125, P523, DOI 10.1016/j.cell.2006.04.009
   Becker A, 2002, N-S ARCH PHARMACOL, V365, P296, DOI 10.1007/s00210-002-0533-2
   Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2
   Crist RC, 2013, DRUG ALCOHOL DEPEN, V127, P122, DOI 10.1016/j.drugalcdep.2012.06.023
   Crowley JJ, 2003, PSYCHIAT GENET, V13, P169, DOI 10.1097/00041444-200309000-00006
   DICHIARA G, 1988, J PHARMACOL EXP THER, V244, P1067
   Drgon T, 2011, AM J MED GENET B, V156B, P125, DOI 10.1002/ajmg.b.31143
   Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206
   Gauderman WJ, 2006, QUANTO 1 1 COMPUTER
   Goodman AJ, 2007, CHEMMEDCHEM, V2, P1552, DOI 10.1002/cmdc.200700143
   Guang W, 2004, MOL PHARMACOL, V66, P1285, DOI 10.1124/mol.66.5.
   Hall FS, 2004, MOL BRAIN RES, V121, P123, DOI 10.1016/j.molbrainres.2003.10.024
   Herz A, 1998, CAN J PHYSIOL PHARM, V76, P252, DOI 10.1139/cjpp-76-3-252
   Hoehe MR, 2000, HUM MOL GENET, V9, P2895, DOI 10.1093/hmg/9.19.2895
   Hummel M, 2006, NEUROSCIENCE, V142, P481, DOI 10.1016/j.neuroscience.2006.06.013
   Jin J, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-33
   Karkowski LM, 2000, AM J MED GENET, V96, P665, DOI 10.1002/1096-8628(20001009)96:5<665::AID-AJMG13>3.3.CO;2-F
   Kendler KS, 2003, AM J PSYCHIAT, V160, P687, DOI 10.1176/appi.ajp.160.4.687
   Kendler KS, 1998, BRIT J PSYCHIAT, V173, P345, DOI 10.1192/bjp.173.4.345
   Kendler KS, 2000, ARCH GEN PSYCHIAT, V57, P261, DOI 10.1001/archpsyc.57.3.261
   Law PY, 2004, NEUROPHARMACOLOGY, V47, P300, DOI 10.1016/j.neuropharm.2004.07.013
   Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389
   Le Merrer J, 2009, PHYSIOL REV, V89, P1379, DOI 10.1152/physrev.00005.2009
   Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0
   Merikangas KR, 1998, ARCH GEN PSYCHIAT, V55, P973, DOI 10.1001/archpsyc.55.11.973
   Milligan G, 2005, NEUROMOL MED, V7, P51, DOI 10.1385/NMM:7:1-2:051
   Milligan G, 2004, BIOCHEM SOC T, V32, P878, DOI 10.1042/BST0320878
   Onoprishvili I, 2003, MOL PHARMACOL, V64, P1092, DOI 10.1124/mol.64.5.1092
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Reyes ARS, 2010, BRAIN RES, V1358, P71, DOI 10.1016/j.brainres.2010.08.080
   Smith RJ, 2005, AM J MED GENET B, V133B, P105, DOI 10.1002/ajmg.b.30105
   Soderman AR, 2008, NEUROSCIENCE, V154, P1506, DOI 10.1016/j.neuroscience.2008.04.063
   Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544
   Szeto CYK, 2001, NEUROREPORT, V12, P1103, DOI 10.1097/00001756-200105080-00011
   Tan EC, 2003, NEUROREPORT, V14, P569, DOI 10.1097/00001756-200303240-00008
   Tsuang MT, 1998, ARCH GEN PSYCHIAT, V55, P967, DOI 10.1001/archpsyc.55.11.967
   Wong CCY, 2008, PHILOS T R SOC B, V363, P3213, DOI 10.1098/rstb.2008.0104
   Zhang HP, 2006, HUM MOL GENET, V15, P807, DOI 10.1093/hmg/ddl024
NR 42
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0165-1781
J9 PSYCHIAT RES
JI Psychiatry Res.
PD JUN 30
PY 2013
VL 208
IS 1
BP 62
EP 66
DI 10.1016/j.psychres.2013.03.011
PG 5
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA 169ZQ
UT WOS:000320819700010
PM 23566366
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Seear, K
   Fraser, S
AF Seear, Kate
   Fraser, Suzanne
TI Ben Cousins and the 'double life': exploring citizenship and the
   voluntarity/compulsivity binary through the experiences of a 'drug
   addicted' elite athlete
SO CRITICAL PUBLIC HEALTH
LA English
DT Article
DE drug addiction; Ben Cousins; Eve Sedgwick
ID USERS
AB Contemporary neo-liberal public health discourse is increasingly drawn to the language of 'addiction'. Disease models of addiction are mobilised to account for an expanding array of problematised activities, from the familiar smoking and drinking to newer candidates, such as overeating and gambling. Most models of addiction, including disease models, are underpinned by the idea that, unlike proper citizens of neo-liberal democracies, 'addicts' lack free will or agency. This lack can be attributed to any number of problems or dysfunctions: genetic, neurological, social or moral. One high-profile case, which challenges this approach to addiction, involves the famous Australian Rules football player Ben Cousins, one of Australia's most recognised and accomplished athletes. A highly decorated player in the Australian Football League (AFL), Cousins has publicly declared himself a 'drug addict'. In this article, we present an abridged version of an interview we conducted with Cousins around the end of his first season back in the sport (late 2009) following suspension by the AFL for 'bringing the game into disrepute'. In the interview, we explore Cousins' own understanding of drug 'addiction' and its relation to its apparent antithesis - sporting prowess. We also examine the ramifications of the ostensible paradox between drug 'addiction' and sporting accomplishment for understandings of 'addiction' as compulsivity and lack of free will. Drawing on the work of the cultural studies theorist Sedgwick (1993), we identify in Cousins' own understandings of his drug 'addiction' a resistance to the absolute polarisation of voluntarity and compulsivity underpinning some of the most influential versions of the disease model of addiction. We discuss the implications of this polarisation, and of forms of resistance to it, for public health policies regarding drug addiction, and for the intersection of drug use and citizenship. Thinking through Sedgwick's alternative notion of 'habit', we reconsider concepts of addiction, briefly drawing in other phenomena also increasingly framed as 'epidemics of the will'.
C1 [Seear, Kate] Monash Univ, Sch Polit & Social Inquiry, Sociol Program, Clayton, Vic 3800, Australia.
   [Fraser, Suzanne] Monash Univ, Sch Polit & Social Inquiry, Ctr Womens Studies & Gender Res, Clayton, Vic 3800, Australia.
C3 Monash University; Monash University
RP Seear, K (通讯作者)，Monash Univ, Sch Polit & Social Inquiry, Sociol Program, Clayton, Vic 3800, Australia.
EM kate.Seear@arts.monash.edu.au
RI Seear, Kate/GXV-5265-2022
OI Seear, Kate/0000-0002-0886-7069; Fraser, Suzanne/0000-0003-1018-5865
CR Aronowitz R, 2008, SOC SCI MED, V67, P1, DOI 10.1016/j.socscimed.2008.02.017
   Brook H, 2005, INT J DRUG POLICY, V16, P316, DOI 10.1016/j.drugpo.2005.05.002
   Butler Judith, 1993, BODIES MATTER DISCUR
   Duff Cameron, 2003, J YOUTH STUD, V6, P433, DOI DOI 10.1080/1367626032000162131
   Flyvbjerg B, 2006, QUAL INQ, V12, P219, DOI 10.1177/1077800405284363
   FOUCAULT M, 1982, M FOUCAULT STRUCTURA, P208, DOI DOI 10.1086/448181
   Fox KJ, 1999, DEVIANT BEHAV, V20, P209, DOI 10.1080/016396299266470
   Fraser S, 2004, HEALTH-LONDON, V8, P199, DOI 10.1177/1363459304041070
   Fraser S, 2008, SUBSTANCE AND SUBSTITUTION: METHADONE SUBJECTS IN LIBERAL SOCIETIES, P1, DOI 10.1057/9780230582569
   LEVINE HG, 1978, J STUD ALCOHOL, V39, P143, DOI 10.15288/jsa.1978.39.143
   LEVINE MP, 1988, J SEX RES, V25, P347, DOI 10.1080/00224498809551467
   Measham F., 2001, DANCING DRUGS RISK H
   Miles M. B., 1994, QUALITATIVE DATA ANA, DOI DOI 10.1016/S0272-4944(05)80231-2
   Moore D, 2006, SOC SCI MED, V62, P3035, DOI 10.1016/j.socscimed.2005.11.067
   NYERS P, 2004, CITIZENSHIP STUD, V8, P203, DOI DOI 10.1080/1362102042000256961
   Parker H., 1998, ILLEGAL LEISURE NORM
   Procacci G., 2004, BLACKWELL COMPANION
   Punch K. F., 2005, INTRO SOCIAL RES QUA
   Room R., 2003, JANUS HEAD, V6, P221, DOI DOI 10.5840/JH2003628
   Seddon T, 2007, ADDICT RES THEORY, V15, P333, DOI 10.1080/16066350701350262
   Sedgwick E.K., 1993, TENDENCIES
   Seear K., HLTH SOCIOL IN PRESS
   Valverde M., 1998, DIS WILL ALCOHOL DIL
   West R, 2001, ADDICTION, V96, P3, DOI 10.1046/j.1360-0443.2001.96131.x
   West R., 2006, THEORY ADDICTION
   West R, 2006, DRUGS ALCOHOL TODAY, V6, P28, DOI 10.1108/17459265200600011
   White William L., 1998, SLAYING DRAGON HIST
NR 27
TC 21
Z9 21
U1 0
U2 6
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0958-1596
EI 1469-3682
J9 CRIT PUBLIC HEALTH
JI Crit. Public Heath
PY 2010
VL 20
IS 4
SI SI
BP 439
EP 452
DI 10.1080/09581591003653132
PG 14
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
WE Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA V27FX
UT WOS:000208600200004
DA 2023-06-23
ER

PT J
AU Corrigan, PW
   Kuwabara, SA
   O'Shaughnessy, J
AF Corrigan, Patrick W.
   Kuwabara, Sachiko A.
   O'Shaughnessy, John
TI The Public Stigma of Mental Illness and Drug Addiction Findings from a
   Stratified Random Sample
SO JOURNAL OF SOCIAL WORK
LA English
DT Article
DE dangerousness; drug addiction; mental illness; stigma
ID DANGEROUSNESS
AB Previous research has shown that people labeled with drug addiction are viewed as more blameworthy and dangerous compared to individuals labeled with mental illness who, in turn, are viewed more harshly than those with physical disabilities. Endorsement of such stereotypes often lead to less helping behavior and more avoidance of people with drug addiction compared to those with mental illness. In this study, attribution and dangerousness models are tested on a stratified random sample of the US population. The sample was recruited from a national online research panel (N = 815). Research participants read a vignette about a person with one of the three health conditions (mental illness, drug addiction, or physically handicapped in a wheelchair) and were asked to complete items representing attribution and dangerousness judgments about the person.
   Findings: Results are consistent with our hypotheses. Addicted to drugs was seen as more blameworthy and dangerous compared to mental illness.
   Applications: These findings are important for framing the stigma and stereotypes of mental illness and drug addiction are discussed. In turn, these kinds of basic models will inform stigma change efforts of advocates.
C1 [Corrigan, Patrick W.; Kuwabara, Sachiko A.; O'Shaughnessy, John] IIT, Chicago, IL 60616 USA.
C3 Illinois Institute of Technology
RP Corrigan, PW (通讯作者)，IIT, 3424 S State St, Chicago, IL 60616 USA.
EM corrigan@iit.edu
CR Angermeyer MC, 2006, ACTA PSYCHIAT SCAND, V113, P163, DOI 10.1111/j.1600-0447.2005.00699.x
   Angermeyer MC, 1996, SOC SCI MED, V43, P1721, DOI 10.1016/S0277-9536(96)00065-2
   Corrigan P, 2003, J HEALTH SOC BEHAV, V44, P162, DOI 10.2307/1519806
   Corrigan PW, 2000, J COMMUNITY PSYCHOL, V28, P91, DOI 10.1002/(SICI)1520-6629(200001)28:1<91::AID-JCOP9>3.0.CO;2-M
   Corrigan PW, 2002, SCHIZOPHRENIA BULL, V28, P293, DOI 10.1093/oxfordjournals.schbul.a006939
   Corrigan PW, 2002, CLIN PSYCHOL-SCI PR, V9, P35, DOI 10.1093/clipsy/9.1.35
   Corrigan PW, 1999, AM PSYCHOL, V54, P765, DOI 10.1037/0003-066X.54.9.765
   Goffman E., 1963, STIGMA NOTES MANAGEM
   Link BG, 1999, AM J PUBLIC HEALTH, V89, P1328, DOI 10.2105/AJPH.89.9.1328
   Link BG, 2001, ANNU REV SOCIOL, V27, P363, DOI 10.1146/annurev.soc.27.1.363
   MARTIN JK, 2000, J HLTH SOCIAL BEHAV, V42, P435
   Swindle R, 2000, AM PSYCHOL, V55, P740, DOI 10.1037/0003-066X.55.7.740
   WEINER B, 1988, J PERS SOC PSYCHOL, V55, P738, DOI 10.1037/0022-3514.55.5.738
   Weiner B, 1995, JUDGMENTS RESPONSIBI, DOI DOI 10.1111/0162-895X.00150
NR 14
TC 209
Z9 211
U1 3
U2 74
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1468-0173
J9 J SOC WORK
JI J. Soc. Work
PD APR
PY 2009
VL 9
IS 2
BP 139
EP 147
DI 10.1177/1468017308101818
PG 9
WC Social Work
WE Social Science Citation Index (SSCI)
SC Social Work
GA 636FL
UT WOS:000280716700001
DA 2023-06-23
ER

PT J
AU Darcq, E
   Kieffer, BL
AF Darcq, Emmanuel
   Kieffer, Brigitte Lina
TI Opioid receptors: drivers to addiction?
SO NATURE REVIEWS NEUROSCIENCE
LA English
DT Review
ID PROTEIN-COUPLED RECEPTOR; OPRM1 A118G POLYMORPHISM; NOCICEPTIN/ORPHANIN
   FQ RECEPTOR; CONDITIONED PLACE AVERSION; VENTRAL TEGMENTAL AREA;
   CENTRAL-NERVOUS-SYSTEM; HEALTHY-HUMAN SUBJECTS; DORSAL RAPHE NUCLEUS;
   KNOCK-OUT MICE; DRUG DISCOVERY
AB Drug addiction is a worldwide societal problem and public health burden, and results from recreational drug use that develops into a complex brain disorder. The opioid system, one of the first discovered neuropeptide systems in the history of neuroscience, is central to addiction. Recently, opioid receptors have been propelled back on stage by the rising opioid epidemics, revolutions in G protein-coupled receptor research and fascinating developments in basic neuroscience. This Review discusses rapidly advancing research into the role of opioid receptors in addiction, and addresses the key questions of whether we can kill pain without addiction using mu-opioid-receptor-targeting opiates, how mu-and kappa-opioid receptors operate within the neurocircuitry of addiction and whether we can bridge human and animal opioid research in the field of drug abuse.
C1 [Darcq, Emmanuel; Kieffer, Brigitte Lina] McGill Univ, Douglas Mental Hlth Inst, Dept Psychiat, Montreal, PQ, Canada.
   [Kieffer, Brigitte Lina] INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, Strasbourg, France.
   [Kieffer, Brigitte Lina] Univ Strasbourg, Strasbourg, France.
C3 McGill University; Centre National de la Recherche Scientifique (CNRS);
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universites de Strasbourg
   Etablissements Associes; Universite de Strasbourg; UDICE-French Research
   Universities; Universites de Strasbourg Etablissements Associes;
   Universite de Strasbourg
RP Kieffer, BL (通讯作者)，McGill Univ, Douglas Mental Hlth Inst, Dept Psychiat, Montreal, PQ, Canada.; Kieffer, BL (通讯作者)，INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, Strasbourg, France.; Kieffer, BL (通讯作者)，Univ Strasbourg, Strasbourg, France.
EM brigitte.kieffer@douglas.mcgill.ca
RI Darcq, Emmanuel/AAF-9169-2019
OI Darcq, Emmanuel/0000-0002-8377-8015
FU US National Institutes of Health (National Institute of Drug Abuse)
   [05010]; US National Institutes of Health (National Institute on Alcohol
   Abuse and Alcoholism) [16658]
FX The authors deeply thank the CNRS/INSERM/University of Strasbourg
   (France), the US National Institutes of Health (National Institute of
   Drug Abuse Grant 05010 and National Institute on Alcohol Abuse and
   Alcoholism Grant 16658 to B.L.K.), the Canada Fund for Innovation and
   the Canada Research Chairs (to B.L.K and E.D.), and the Bourgeois family
   (B.L.K. is the Bourgeois Chair for Pervasive Developmental Disorders)
   for continuous support.
CR Aboujaoude E, 2016, CNS DRUGS, V30, P719, DOI 10.1007/s40263-016-0373-0
   Abraham AD, 2018, NEUROPSYCHOPHARMACOL, V43, P362, DOI 10.1038/npp.2017.133
   Al-Hasani R, 2015, NEURON, V87, P1063, DOI 10.1016/j.neuron.2015.08.019
   Al-Hasani R, 2011, ANESTHESIOLOGY, V115, P1363, DOI 10.1097/ALN.0b013e318238bba6
   Altarifi AA, 2017, J PSYCHOPHARMACOL, V31, P730, DOI 10.1177/0269881116689257
   Audet M, 2012, CELL, V151, P14, DOI 10.1016/j.cell.2012.09.003
   Ayanga D, 2016, EXPERT OPIN PHARMACO, V17, P2307, DOI 10.1080/14656566.2016.1244529
   Badiani A, 2011, NAT REV NEUROSCI, V12, P685, DOI 10.1038/nrn3104
   Baler RD, 2006, TRENDS MOL MED, V12, P559, DOI 10.1016/j.molmed.2006.10.005
   BALSKUBIK R, 1993, J PHARMACOL EXP THER, V264, P489
   Bart G, 2005, NEUROPSYCHOPHARMACOL, V30, P417, DOI 10.1038/sj.npp.1300598
   Bart G, 2004, MOL PSYCHIATR, V9, P547, DOI 10.1038/sj.mp.4001504
   Becerra L, 2006, ANESTH ANALG, V103, P208, DOI 10.1213/01.ane.0000221457.71536.e0
   Becerra L, 2013, J PHARMACOL EXP THER, V345, P41, DOI 10.1124/jpet.112.201145
   Becker JAJ, 2017, ADDICT BIOL, V22, P1205, DOI 10.1111/adb.12405
   Becker JAJ, 2014, NEUROPSYCHOPHARMACOL, V39, P2049, DOI 10.1038/npp.2014.59
   Belin D, 2013, CURR OPIN NEUROBIOL, V23, P564, DOI 10.1016/j.conb.2013.01.025
   Belzeaux R, 2018, TRENDS MOL MED, V24, P206, DOI 10.1016/j.molmed.2017.12.004
   Ben Hamida S, 2019, ADDICT BIOL, V24, P28, DOI 10.1111/adb.12576
   Bernardi RE, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.132
   Bilbao A, 2015, BIOL PSYCHIAT, V77, P850, DOI 10.1016/j.biopsych.2014.08.021
   Bodnar RJ, 2017, PEPTIDES, V88, P126, DOI 10.1016/j.peptides.2016.12.004
   Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495
   Borsook D, 2006, NAT REV DRUG DISCOV, V5, P411, DOI 10.1038/nrd2027
   Borsook D, 2007, EUR J PAIN, V11, P7, DOI 10.1016/j.ejpain.2005.12.005
   Boulos L. J., 2016, 7811 SOC NEUR
   Boulos LJ, 2017, BIOL PSYCHIAT, V81, P296, DOI 10.1016/j.biopsych.2016.06.003
   Bradley SJ, 2016, ANNU REV PHARMACOL, V56, P535, DOI 10.1146/annurev-pharmtox-011613-140012
   Briand LA, 2015, J NEUROSCI, V35, P3582, DOI 10.1523/JNEUROSCI.4685-14.2015
   Browne CA, 2017, NEUROPHARMACOLOGY, V117, P401, DOI 10.1016/j.neuropharm.2017.02.005
   BROWNSTEIN MJ, 1993, P NATL ACAD SCI USA, V90, P5391, DOI 10.1073/pnas.90.12.5391
   Bruchas MR, 2010, BRAIN RES, V1314, P44, DOI 10.1016/j.brainres.2009.08.062
   Bruchas MR, 2016, TRENDS PHARMACOL SCI, V37, P279, DOI 10.1016/j.tips.2016.01.001
   Bruchas MR, 2011, NEURON, V71, P498, DOI 10.1016/j.neuron.2011.06.011
   Bruehl S, 2013, J PAIN, V14, P103, DOI 10.1016/j.jpain.2012.10.016
   Burford NT, 2013, P NATL ACAD SCI USA, V110, P10830, DOI 10.1073/pnas.1300393110
   Butelman ER, 2012, TRENDS NEUROSCI, V35, P587, DOI 10.1016/j.tins.2012.05.005
   BUTELMAN ER, 2015, FRONT PHARM, V6
   Cabrera EA, 2016, J NEUROIMMUNE PHARM, V11, P408, DOI 10.1007/s11481-016-9680-y
   Cahill CM, 2016, TRENDS PHARMACOL SCI, V37, P963, DOI 10.1016/j.tips.2016.08.002
   Cai XY, 2016, GENESIS, V54, P29, DOI 10.1002/dvg.22910
   Carlezon WA, 2016, DEPRESS ANXIETY, V33, P895, DOI 10.1002/da.22500
   Charbogne P, 2017, BIOL PSYCHIAT, V81, P778, DOI 10.1016/j.biopsych.2016.12.022
   Charbogne P, 2014, NEUROPHARMACOLOGY, V76, P204, DOI 10.1016/j.neuropharm.2013.08.028
   Chavkin C, 2016, NEUROPSYCHOPHARMACOL, V41, P373, DOI 10.1038/npp.2015.258
   Chefer VI, 2013, NEUROPSYCHOPHARMACOL, V38, P2623, DOI 10.1038/npp.2013.171
   Chung PCS, 2015, BIOL PSYCHIAT, V77, P404, DOI 10.1016/j.biopsych.2014.07.033
   Chung PCS, 2013, PHARMACOL THERAPEUT, V140, P112, DOI 10.1016/j.pharmthera.2013.06.003
   Civelli O, 2013, ANNU REV PHARMACOL, V53, P127, DOI 10.1146/annurev-pharmtox-010611-134548
   Colantuoni C, 2011, NATURE, V478, P519, DOI 10.1038/nature10524
   Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490
   Contet C, 2004, CURR OPIN NEUROBIOL, V14, P370, DOI 10.1016/j.conb.2004.05.005
   Convertino M, 2015, PROG NEURO-PSYCHOPH, V62, P61, DOI 10.1016/j.pnpbp.2014.11.009
   Crist RC, 2014, PHARMACOL BIOCHEM BE, V123, P25, DOI 10.1016/j.pbb.2013.10.018
   Crowley NA, 2016, CELL REP, V14, P2774, DOI 10.1016/j.celrep.2016.02.069
   Crowley NA, 2015, PROG NEURO-PSYCHOPH, V62, P51, DOI 10.1016/j.pnpbp.2015.01.001
   Cruz A, 2017, PHYTOCHEMISTRY, V137, P9, DOI 10.1016/j.phytochem.2017.02.001
   Cui YJ, 2014, NAT NEUROSCI, V17, P254, DOI 10.1038/nn.3622
   Dalley JW, 2017, NAT REV NEUROSCI, V18, P158, DOI 10.1038/nrn.2017.8
   Deb I, 2010, J NEUROCHEM, V112, P486, DOI 10.1111/j.1471-4159.2009.06472.x
   DeWire SM, 2013, J PHARMACOL EXP THER, V344, P708, DOI 10.1124/jpet.112.201616
   Dlugos AM, 2011, GENES BRAIN BEHAV, V10, P199, DOI 10.1111/j.1601-183X.2010.00655.x
   Ehrich JM, 2015, J NEUROSCI, V35, P12917, DOI 10.1523/JNEUROSCI.2444-15.2015
   Eisenberger NI, 2012, NAT REV NEUROSCI, V13, P421, DOI 10.1038/nrn3231
   Erbs E, 2015, BRAIN STRUCT FUNCT, V220, P677, DOI 10.1007/s00429-014-0717-9
   ETTENBERG A, 1982, PSYCHOPHARMACOLOGY, V78, P204, DOI 10.1007/BF00428151
   Fareed A, 2017, J ADDICT DIS, V36, P105, DOI 10.1080/10550887.2017.1280898
   Fields HL, 2015, TRENDS NEUROSCI, V38, P217, DOI 10.1016/j.tins.2015.01.002
   Filliol D, 2000, NAT GENET, V25, P195, DOI 10.1038/76061
   Galandrin S, 2007, TRENDS PHARMACOL SCI, V28, P423, DOI 10.1016/j.tips.2007.06.005
   Gardon O, 2014, NEUROSCIENCE, V277, P595, DOI 10.1016/j.neuroscience.2014.07.053
   Gendron L, 2016, PHARMACOL REV, V68, P631, DOI 10.1124/pr.114.008979
   Gilpin NW, 2014, NEUROPHARMACOLOGY, V77, P294, DOI 10.1016/j.neuropharm.2013.10.005
   Goeldner C, 2011, BIOL PSYCHIAT, V69, P236, DOI 10.1016/j.biopsych.2010.08.021
   Goldman D, 2005, NAT REV GENET, V6, P521, DOI 10.1038/nrg1635
   Granier S, 2012, NATURE, V485, P400, DOI 10.1038/nature11111
   Hancock DB, 2015, BIOL PSYCHIAT, V78, P474, DOI 10.1016/j.biopsych.2015.01.003
   Harris JA, 2014, FRONT NEURAL CIRCUIT, V8, DOI 10.3389/fncir.2014.00076
   Helal MA, 2017, EUR J MED CHEM, V141, P632, DOI 10.1016/j.ejmech.2017.10.012
   Hendershot CS, 2016, ADDICT BIOL, V21, P125, DOI 10.1111/adb.12165
   Henderson-Redmond A. N., BRAIN RES B, V123, P5
   Henriksen G, 2008, BRAIN, V131, P1171, DOI 10.1093/brain/awm255
   Hermann D, 2017, NEUROPSYCHOPHARMACOL, V42, P606, DOI 10.1038/npp.2016.145
   Hikosaka O, 2010, NAT REV NEUROSCI, V11, P503, DOI 10.1038/nrn2866
   Hnasko TS, 2005, NATURE, V438, P854, DOI 10.1038/nature04172
   Hu HL, 2016, ANNU REV NEUROSCI, V39, P297, DOI 10.1146/annurev-neuro-070815-014106
   Huang WJ, 2015, NATURE, V524, P315, DOI 10.1038/nature14886
   Ieong HFH, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00169
   Irannejad R, 2017, NAT CHEM BIOL, V13, P799, DOI 10.1038/nchembio.2389
   JOHNSON SW, 1992, J NEUROSCI, V12, P483
   Kang-Park M, 2015, J PHARMACOL EXP THER, V355, P206, DOI 10.1124/jpet.115.225870
   Kang-Park M, 2013, J PHARMACOL EXP THER, V346, P130, DOI 10.1124/jpet.112.202903
   Kapur Suman, 2007, Journal of Integrative Neuroscience, V6, P511, DOI 10.1142/S0219635207001635
   Karlsson HK, 2015, J NEUROSCI, V35, P3959, DOI 10.1523/JNEUROSCI.4744-14.2015
   Kenakin T, 2015, MOL PHARMACOL, V88, P1055, DOI 10.1124/mol.115.099770
   Kieffer BL, 2002, PROG NEUROBIOL, V66, P285, DOI 10.1016/S0301-0082(02)00008-4
   Kieffer BL, 2016, NATURE, V537, P170, DOI 10.1038/nature19424
   Kim CK, 2017, NAT REV NEUROSCI, V18, P222, DOI 10.1038/nrn.2017.15
   Kissler JL, 2016, NEUROPSYCHOPHARMACOL, V41, P560, DOI 10.1038/npp.2015.183
   Klenowski P, 2015, BRIT J PHARMACOL, V172, P297, DOI 10.1111/bph.12618
   Kobilka B, 2013, ANGEW CHEM INT EDIT, V52, P6380, DOI 10.1002/anie.201302116
   Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957
   Kong XY, 2017, BMC MED GENET, V18, DOI 10.1186/s12881-017-0478-4
   Koob GF, 2008, ANNU REV PSYCHOL, V59, P29, DOI 10.1146/annurev.psych.59.103006.093548
   Koob GF, 2016, LANCET PSYCHIAT, V3, P760, DOI 10.1016/S2215-0366(16)00104-8
   Koob GF, 2016, ANNU REV PHARMACOL, V56, P299, DOI 10.1146/annurev-pharmtox-010715-103143
   Koob GF, 2015, EUR J PHARMACOL, V753, P73, DOI 10.1016/j.ejphar.2014.11.044
   Koob GF, 2014, NEUROPHARMACOLOGY, V76, P370, DOI 10.1016/j.neuropharm.2013.05.024
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Kroslak T, 2007, J NEUROCHEM, V103, P77, DOI 10.1111/j.1471-4159.2007.04738.x
   Kumar D, 2012, PROG NEURO-PSYCHOPH, V36, P225, DOI 10.1016/j.pnpbp.2011.10.018
   Kuwabara H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113694
   Lalanne L, 2017, ADDICT BIOL, V22, P1010, DOI 10.1111/adb.12392
   Lammel S, 2012, NATURE, V491, P212, DOI 10.1038/nature11527
   Land BB, 2008, J NEUROSCI, V28, P407, DOI 10.1523/JNEUROSCI.4458-07.2008
   Land BB, 2009, P NATL ACAD SCI USA, V106, P19168, DOI 10.1073/pnas.0910705106
   Laurent V, 2015, BRIT J PHARMACOL, V172, P449, DOI 10.1111/bph.12818
   Laviolette SR, 2004, EUR J NEUROSCI, V20, P2179, DOI 10.1111/j.1460-9568.2004.03665.x
   Le Merrer J, 2011, BIOL PSYCHIAT, V69, P700, DOI 10.1016/j.biopsych.2010.10.021
   Le Merrer J, 2009, PHYSIOL REV, V89, P1379, DOI 10.1152/physrev.00005.2009
   Levran O, 2012, HUM GENET, V131, P823, DOI 10.1007/s00439-012-1172-4
   Li T, 2000, ADDICT BIOL, V5, P181, DOI 10.1080/13556210050003775
   Livingston KE, 2018, BRIT J PHARMACOL, V175, P2846, DOI 10.1111/bph.13823
   Livingston KE, 2014, P NATL ACAD SCI USA, V111, P18369, DOI 10.1073/pnas.1415013111
   Luo SX, 2017, CURR PSYCHIAT REP, V19, DOI 10.1007/s11920-017-0769-7
   Lutz PE, 2014, NEUROPSYCHOPHARMACOL, V39, P2694, DOI 10.1038/npp.2014.126
   Lutz PE, 2013, CURR OPIN NEUROBIOL, V23, P473, DOI 10.1016/j.conb.2013.02.005
   Lutz PE, 2013, TRENDS NEUROSCI, V36, P195, DOI 10.1016/j.tins.2012.11.002
   Madariaga-Mazon A, 2017, DRUG DISCOV TODAY, V22, P1719, DOI 10.1016/j.drudis.2017.07.002
   Mague SD, 2009, P NATL ACAD SCI USA, V106, P10847, DOI 10.1073/pnas.0901800106
   Majumdar S, 2011, P NATL ACAD SCI USA, V108, P19778, DOI 10.1073/pnas.1115231108
   Majuri J, 2017, NEUROPSYCHOPHARMACOL, V42, P1169, DOI 10.1038/npp.2016.265
   Manglik A, 2016, NATURE, V537, P185, DOI 10.1038/nature19112
   Manglik A, 2012, NATURE, V485, P321, DOI 10.1038/nature10954
   Manninen S, 2017, J NEUROSCI, V37, P6125, DOI 10.1523/JNEUROSCI.0688-16.2017
   Marchant NJ, 2016, J NEUROSCI, V36, P3281, DOI 10.1523/JNEUROSCI.4299-15.2016
   Marchant NJ, 2016, NEUROPSYCHOPHARMACOL, V41, P402, DOI 10.1038/npp.2015.149
   Margolis EB, 2006, P NATL ACAD SCI USA, V103, P2938, DOI 10.1073/pnas.0511159103
   Massaly N, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00480
   Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0
   Mechling AE, 2016, P NATL ACAD SCI USA, V113, P11603, DOI 10.1073/pnas.1601640113
   MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0
   Mick I, 2016, NEUROPSYCHOPHARMACOL, V41, P1742, DOI 10.1038/npp.2015.340
   Moles A, 2004, SCIENCE, V304, P1983, DOI 10.1126/science.1095943
   Moore K, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.004771
   Narayanan S, 2004, NEUROSCIENCE, V124, P241, DOI 10.1016/j.neuroscience.2003.11.011
   Navratilova E, 2015, TRENDS NEUROSCI, V38, P741, DOI 10.1016/j.tins.2015.09.003
   Ng E, 2017, AM J DRUG ALCOHOL AB, V43, P456, DOI 10.1080/00952990.2016.1183020
   Nuechterlein EB, 2016, PROG NEURO-PSYCHOPH, V69, P69, DOI 10.1016/j.pnpbp.2016.04.006
   Nummenmaa L, 2018, BRIT J PHARMACOL, V175, P2737, DOI 10.1111/bph.13812
   Nummenmaa L, 2016, NEUROIMAGE, V138, P242, DOI 10.1016/j.neuroimage.2016.05.063
   Oertel BG, 2009, J BIOL CHEM, V284, P6530, DOI 10.1074/jbc.M807030200
   Olmstead MC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004410
   Olson KM, 2017, YALE J BIOL MED, V90, P97
   Otto JM, 2017, ALCOHOL CLIN EXP RES, V41, P929, DOI 10.1111/acer.13369
   Papaleo F, 2007, EUR J NEUROSCI, V25, P3398, DOI 10.1111/j.1460-9568.2007.05595.x
   Pasternak GW, 2014, NEUROPHARMACOLOGY, V76, P198, DOI 10.1016/j.neuropharm.2013.03.039
   Pellissier LP, 2018, HANDB EXP PHARMACOL, V247, P227, DOI 10.1007/164_2016_89
   PFEIFFER A, 1986, SCIENCE, V233, P774, DOI 10.1126/science.3016896
   Pradhan AA, 2012, BRIT J PHARMACOL, V167, P960, DOI 10.1111/j.1476-5381.2012.02075.x
   Pradhan AA, 2011, TRENDS PHARMACOL SCI, V32, P581, DOI 10.1016/j.tips.2011.06.008
   Pradhan AAA, 2010, J NEUROSCI, V30, P16459, DOI 10.1523/JNEUROSCI.3748-10.2010
   Raehal KM, 2011, PHARMACOL REV, V63, P1001, DOI 10.1124/pr.111.004598
   Raehal KM, 2005, J PHARMACOL EXP THER, V314, P1195, DOI 10.1124/jpet.105.087254
   Ramchandani VA, 2011, MOL PSYCHIATR, V16, P809, DOI 10.1038/mp.2010.56
   Ranganathan M, 2012, BIOL PSYCHIAT, V72, P871, DOI 10.1016/j.biopsych.2012.06.012
   Reed B, 2014, CURR PSYCHIAT REP, V16, DOI 10.1007/s11920-014-0504-6
   REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792
   Robinson JE, 2015, NEUROPSYCHOPHARMACOL, V40, P2614, DOI 10.1038/npp.2015.109
   Roth BL, 2002, P NATL ACAD SCI USA, V99, P11934, DOI 10.1073/pnas.182234399
   Saanijoki T, 2018, NEUROPSYCHOPHARMACOL, V43, P246, DOI 10.1038/npp.2017.148
   Scherrer G, 2006, P NATL ACAD SCI USA, V103, P9691, DOI 10.1073/pnas.0603359103
   Schinka JA, 2002, MOL PSYCHIATR, V7, P224, DOI 10.1038/sj.mp.4000951
   Schmid CL, 2017, CELL, V171, P1165, DOI 10.1016/j.cell.2017.10.035
   Schuck K, 2014, PSYCHOL HEALTH, V29, P698, DOI 10.1080/08870446.2014.884222
   Schuckit MA, 2016, NEW ENGL J MED, V375, P357, DOI 10.1056/NEJMra1604339
   Sheffler DJ, 2003, TRENDS PHARMACOL SCI, V24, P107, DOI 10.1016/S0165-6147(03)00027-0
   Siuda ER, 2017, CURR OPIN PHARMACOL, V32, P77, DOI 10.1016/j.coph.2016.11.007
   Siuda ER, 2015, NEURON, V86, P923, DOI 10.1016/j.neuron.2015.03.066
   Skoubis PD, 2001, NEUROSCIENCE, V106, P757, DOI 10.1016/S0306-4522(01)00333-5
   Smith AH, 2017, MOL PSYCHIATR, V22, P346, DOI 10.1038/mp.2016.257
   Sounier R, 2015, NATURE, V524, P375, DOI 10.1038/nature14680
   Spahn V, 2017, SCIENCE, V355, P966, DOI 10.1126/science.aai8636
   Spahn V, 2017, EXPERT OPIN INV DRUG, V26, P155, DOI 10.1080/13543784.2017.1275562
   SPANAGEL R, 1992, P NATL ACAD SCI USA, V89, P2046, DOI 10.1073/pnas.89.6.2046
   Spangler S, 2017, CELL, V171, P989, DOI 10.1016/j.cell.2017.10.046
   Su DR, 2017, SCI REP-UK, V7, DOI 10.1038/srep44476
   Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033
   Szeto CYK, 2001, NEUROREPORT, V12, P1103, DOI 10.1097/00001756-200105080-00011
   Tao R, 2005, BRAIN RES, V1049, P70, DOI 10.1016/j.brainres.2005.04.076
   Tejeda HA, 2012, CELL MOL LIFE SCI, V69, P857, DOI 10.1007/s00018-011-0844-x
   Tejeda HA, 2017, NEURON, V93, P147, DOI 10.1016/j.neuron.2016.12.005
   Tejeda HA, 2013, NEUROPSYCHOPHARMACOL, V38, P1770, DOI 10.1038/npp.2013.76
   Thompson AA, 2012, NATURE, V485, P395, DOI 10.1038/nature11085
   Toll L, 2016, PHARMACOL REV, V68, P419, DOI 10.1124/pr.114.009209
   Town T, 1999, AM J MED GENET, V88, P458, DOI 10.1002/(SICI)1096-8628(19991015)88:5<458::AID-AJMG3>3.0.CO;2-S
   Urs NM, 2016, P NATL ACAD SCI USA, V113, pE8178, DOI 10.1073/pnas.1614347113
   Van Essen DC, 2013, NEURON, V80, P775, DOI 10.1016/j.neuron.2013.10.027
   Van't Veer A, 2013, NEUROPSYCHOPHARMACOL, V38, P1585, DOI 10.1038/npp.2013.58
   Varadi A, 2016, J MED CHEM, V59, P8381, DOI 10.1021/acs.jmedchem.6b00748
   Volkow ND, 2016, NEW ENGL J MED, V374, P1253, DOI 10.1056/NEJMra1507771
   Volkow ND, 2012, NEUROPSYCHOPHARMACOL, V37, P290, DOI 10.1038/npp.2011.84
   Voon P, 2017, SUBST ABUSE TREAT PR, V12, DOI 10.1186/s13011-017-0120-7
   Williams JT, 2013, PHARMACOL REV, V65, P223, DOI 10.1124/pr.112.005942
   WISE RA, 1989, ANNU REV PSYCHOL, V40, P191, DOI 10.1146/annurev.ps.40.020189.001203
   Witkin JM, 2014, PHARMACOL THERAPEUT, V141, P283, DOI 10.1016/j.pharmthera.2013.10.011
   World Health Organization, 2017, CURB PRESCR OP DEP
   Wu HX, 2012, NATURE, V485, P327, DOI 10.1038/nature10939
   Zaveri NT, 2016, J MED CHEM, V59, P7011, DOI 10.1021/acs.jmedchem.5b01499
   Zhang Y, 2017, ADDICT BIOL, V22, P1068, DOI 10.1111/adb.12390
   Zhang Y, 2015, NEUROPSYCHOPHARMACOL, V40, P1091, DOI 10.1038/npp.2014.286
   Zhou Y, 2014, NEUROPHARMACOLOGY, V87, P51, DOI 10.1016/j.neuropharm.2014.05.044
NR 212
TC 153
Z9 155
U1 5
U2 123
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-003X
EI 1471-0048
J9 NAT REV NEUROSCI
JI Nat. Rev. Neurosci.
PD AUG
PY 2018
VL 19
IS 8
BP 499
EP 514
DI 10.1038/s41583-018-0028-x
PG 16
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology
GA GN5AZ
UT WOS:000439056100009
PM 29934561
DA 2023-06-23
ER

PT J
AU Serrano, A
   Parsons, LH
AF Serrano, Antonia
   Parsons, Loren H.
TI Endocannabinoid influence in drug reinforcement, dependence and
   addiction-related behaviors
SO PHARMACOLOGY & THERAPEUTICS
LA English
DT Review
DE Endocannabinoid; CB1 receptor; Addiction; Craving; Relapse; Synaptic
   plasticity
ID CANNABINOID CB1 RECEPTOR; ACID-AMIDE-HYDROLASE; VENTRAL TEGMENTAL AREA;
   CONDITIONED PLACE PREFERENCE; ANXIETY-LIKE BEHAVIOR; LONG-TERM
   DEPRESSION; DISCRIMINATIVE STIMULUS FUNCTIONS; NICOTINE-SEEKING
   BEHAVIOR; MEDIAL PREFRONTAL CORTEX; INDUCED DOPAMINE RELEASE
AB The endogenous cannabinoid system is an important regulatory system involved in physiological homeostasis. Endocannabinoid signaling is known to modulate neural development, immune function, metabolism, synaptic plasticity and emotional state. Accumulating evidence also implicates brain endocannabinoid signaling in the etiology of drug addiction which is characterized by compulsive drug seeking, loss of control in limiting drug intake, emergence of a negative emotional state in the absence of drug use and a persistent vulnerability toward relapse to drug use during protracted abstinence. In this review we discuss the effects of drug intake on brain endocannabinoid signaling, evidence implicating the endocannabinoid system in the motivation for drug consumption, and drug-induced alterations in endocannabinoid function that may contribute to various aspects of addiction including dysregulated synaptic plasticity, increased stress responsivity, negative affective states, drug craving and relapse to drug taking. Current knowledge of genetic variants in endocannabinoid signaling associated with addiction is also discussed. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Serrano, Antonia; Parsons, Loren H.] Scripps Res Inst, Comm Neurobiol Addict Disorders, La Jolla, CA 92037 USA.
   [Serrano, Antonia] Hosp Reg Univ Carlos Haya, Lab Med Regenerativa, Fdn IMABIS, Malaga 29010, Spain.
C3 Scripps Research Institute; FIMABIS; Hospital Carlos Haya
RP Parsons, LH (通讯作者)，Scripps Res Inst, Comm Neurobiol Addict Disorders, SP30-2003,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.
EM lparsons@scripps.edu
OI Serrano, Antonia/0000-0002-8017-9754
FU NIH [PO1-DA017259, P20-DA024194, P60-AA006420]; Spanish National
   Institute of Health 'Carlos III' Red de Trastornos Adictivos EU-ERDF
   [RD06/0001/0000]; National Plan on Drugs PND [2009/049]
FX This work was supported by NIH grants PO1-DA017259, P20-DA024194 and
   P60-AA006420 and grants from the Spanish National Institute of Health
   'Carlos III' Red de Trastornos Adictivos EU-ERDF (RD06/0001/0000) and
   National Plan on Drugs PND 2009/049. The authors would like to thank Dr.
   Matthew Buczynski for assistance in the preparation of Fig. 1. This is
   publication number 21298 from The Scripps Research Institute.
CR Aceto MD, 1998, J PHARMACOL EXP THER, V287, P598
   Adamczyk P, 2009, J PHYSIOL PHARMACOL, V60, P119
   Adamczyki P, 2008, J PHYSIOL PHARMACOL, V59, P217
   Adams IB, 1998, J PHARMACOL EXP THER, V284, P1209
   Adermark L, 2011, NEUROPHARMACOLOGY
   Adermark L, 2009, J NEUROSCI, V29, P1375, DOI 10.1523/JNEUROSCI.3842-08.2009
   Agrawal A, 2009, AM J MED GENET B, V150B, P736, DOI 10.1002/ajmg.b.30881
   Aguiar DC, 2009, PSYCHOPHARMACOLOGY, V205, P217, DOI 10.1007/s00213-009-1532-5
   Ahn K, 2008, CHEM REV, V108, P1687, DOI 10.1021/cr0782067
   Alen F, 2008, EUR J NEUROSCI, V27, P3292, DOI 10.1111/j.1460-9568.2008.06302.x
   Alger BE, 2002, PROG NEUROBIOL, V68, P247
   Alici T, 2004, PHARMACOL BIOCHEM BE, V79, P431, DOI 10.1016/j.pbb.2004.08.020
   ALLING C, 1982, ACTA PSYCHIAT SCAND, V66, P384, DOI 10.1111/j.1600-0447.1982.tb06720.x
   Alvares LDO, 2008, NEUROSCIENCE, V154, P1648, DOI 10.1016/j.neuroscience.2008.05.005
   Alvarez-Jaimes L, 2008, NEUROPSYCHOPHARMACOL, V33, P2483, DOI 10.1038/sj.npp.1301630
   Alvarez-Jaimes Lily, 2009, Open Neuropsychopharmacol J, V2, P77
   Alvarez-Jaimes L, 2009, J NEUROCHEM, V111, P37, DOI 10.1111/j.1471-4159.2009.06301.x
   Anggadiredja K, 2004, NEUROPSYCHOPHARMACOL, V29, P1470, DOI 10.1038/sj.npp.1300454
   Annis HM, 1998, ADDICT BEHAV, V23, P127, DOI 10.1016/S0306-4603(97)00024-5
   Arevalo C, 2001, PHARMACOL BIOCHEM BE, V70, P123, DOI 10.1016/S0091-3057(01)00578-0
   Arnone M, 1997, PSYCHOPHARMACOLOGY, V132, P104, DOI 10.1007/s002130050326
   Aronne LJ, 2010, INT J OBESITY, V34, P919, DOI 10.1038/ijo.2010.21
   Ashton CH, 2001, BRIT J PSYCHIAT, V178, P101, DOI 10.1192/bjp.178.2.101
   Ashton JC, 2007, CURR NEUROPHARMACOL, V5, P73, DOI 10.2174/157015907780866884
   Aso E, 2008, J NEUROCHEM, V105, P565, DOI 10.1111/j.1471-4159.2007.05149.x
   Atwood BK, 2010, BRIT J PHARMACOL, V160, P467, DOI 10.1111/j.1476-5381.2010.00729.x
   Ballon N, 2006, PHARMACOGENOMICS J, V6, P126, DOI 10.1038/sj.tpj.6500352
   Bambico FR, 2007, J NEUROSCI, V27, P11700, DOI 10.1523/JNEUROSCI.1636-07.2007
   Bardo MT, 1998, CRIT REV NEUROBIOL, V12, P37, DOI 10.1615/CritRevNeurobiol.v12.i1-2.30
   Barna I, 2004, LIFE SCI, V75, P2959, DOI 10.1016/j.lfs.2004.06.006
   Basavarajappa BS, 2006, NEUROPHARMACOLOGY, V50, P834, DOI 10.1016/j.neuropharm.2005.12.005
   Basavarajappa BS, 1998, BRAIN RES, V793, P212, DOI 10.1016/S0006-8993(98)00175-9
   Basavarajappa BS, 1999, J NEUROCHEM, V72, P522, DOI 10.1046/j.1471-4159.1999.0720522.x
   Basavarajappa BS, 2003, EUR J PHARMACOL, V466, P73, DOI 10.1016/S0014-2999(03)01557-7
   Basavarajappa BS, 2000, BBA-MOL BASIS DIS, V1535, P78, DOI 10.1016/S0925-4439(00)00085-5
   Batkai S, 2001, NAT MED, V7, P827, DOI 10.1038/89953
   Beckley JT, 2011, NEUROPSYCHOPHARMACOL, V36, P1531, DOI 10.1038/npp.2011.38
   Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094
   Beltramo M, 2000, NEUROREPORT, V11, P1231, DOI 10.1097/00001756-200004270-00018
   Benyamina A, 2011, ADDICT BIOL, V16, P1, DOI 10.1111/j.1369-1600.2009.00198.x
   Bequet F, 2007, EUR J NEUROSCI, V26, P3458, DOI 10.1111/j.1460-9568.2007.05900.x
   Bergman J, 2008, PHYSIOL BEHAV, V93, P666, DOI 10.1016/j.physbeh.2007.11.007
   Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9
   Berrendero F, 2003, EUR J NEUROSCI, V18, P2197, DOI 10.1046/j.1460-9568.2003.02951.x
   Beyer CE, 2010, NEUROBIOL DIS, V39, P148, DOI 10.1016/j.nbd.2010.03.020
   Biala G, 2008, PHARMACOL BIOCHEM BE, V89, P116, DOI 10.1016/j.pbb.2007.12.005
   Bisogno T, 2003, J CELL BIOL, V163, P463, DOI 10.1083/jcb.200305129
   Bisogno T, 2000, BIOCHEM J, V351, P817, DOI 10.1042/0264-6021:3510817
   Bitencourt RM, 2008, EUR NEUROPSYCHOPHARM, V18, P849, DOI 10.1016/j.euroneuro.2008.07.001
   Blankman JL, 2007, CHEM BIOL, V14, P1347, DOI 10.1016/j.chembiol.2007.11.006
   Blednov YA, 2007, NEUROPSYCHOPHARMACOL, V32, P1570, DOI 10.1038/sj.npp.1301274
   Boctor SY, 2007, EUR J PHARMACOL, V571, P39, DOI 10.1016/j.ejphar.2007.06.004
   Bortolato M, 2006, NEUROPSYCHOPHARMACOL, V31, P2652, DOI 10.1038/sj.npp.1301061
   Braida D, 2001, NEUROSCIENCE, V104, P923, DOI 10.1016/S0306-4522(01)00210-X
   Braida D, 2007, EUR J PHARMACOL, V555, P156, DOI 10.1016/j.ejphar.2006.10.038
   Brodie MS, 1999, ALCOHOL CLIN EXP RES, V23, P1848, DOI 10.1111/j.1530-0277.1999.tb04082.x
   Brusco A, 2008, ANN NY ACAD SCI, V1139, P450, DOI 10.1196/annals.1432.037
   Brusco A, 2008, SYNAPSE, V62, P944, DOI 10.1002/syn.20569
   Buczynski MW, 2010, BRIT J PHARMACOL, V160, P423, DOI 10.1111/j.1476-5381.2010.00787.x
   Burkey RT, 1997, EXP CLIN PSYCHOPHARM, V5, P195, DOI 10.1037/1064-1297.5.3.195
   Cadas H, 1996, J NEUROSCI, V16, P3934
   Caille S, 2006, NEUROPSYCHOPHARMACOL, V31, P804, DOI 10.1038/sj.npp.1300848
   Caille S, 2004, EUR J NEUROSCI, V20, P593, DOI 10.1111/j.1460-9568.2004.03497.x
   Caille S, 2003, EUR J NEUROSCI, V18, P3145, DOI 10.1111/j.1460-9568.2003.02961.x
   Caille S, 2007, J NEUROSCI, V27, P3695, DOI 10.1523/JNEUROSCI.4403-06.2007
   Cannich A, 2004, LEARN MEMORY, V11, P625, DOI 10.1101/lm.77904
   CARMODY TP, 1992, J PSYCHOACTIVE DRUGS, V24, P111, DOI 10.1080/02791072.1992.10471632
   Carter BL, 1999, ADDICTION, V94, P327, DOI 10.1046/j.1360-0443.1999.9433273.x
   Castane A, 2002, NEUROPHARMACOLOGY, V43, P857, DOI 10.1016/S0028-3908(02)00118-1
   Castane A, 2003, EUR J NEUROSCI, V17, P155, DOI 10.1046/j.1460-9568.2003.02409.x
   Castelli MP, 2007, EUR J PHARMACOL, V573, P11, DOI 10.1016/j.ejphar.2007.06.047
   Centonze D, 2004, NEUROPSYCHOPHARMACOL, V29, P1488, DOI 10.1038/sj.npp.1300458
   Chaperon F, 1998, PSYCHOPHARMACOLOGY, V135, P324, DOI 10.1007/s002130050518
   Cheer JF, 2007, J NEUROSCI, V27, P791, DOI 10.1523/JNEUROSCI.4152-06.2007
   Chen BT, 2010, ANN NY ACAD SCI, V1187, P129, DOI 10.1111/j.1749-6632.2009.05154.x
   Chen XN, 2008, ARCH GEN PSYCHIAT, V65, P816, DOI 10.1001/archpsyc.65.7.816
   Chevaleyre V, 2006, ANNU REV NEUROSCI, V29, P37, DOI 10.1146/annurev.neuro.29.051605.112834
   Chhatwal JP, 2006, NAT NEUROSCI, V9, P870, DOI 10.1038/nn1718
   Chhatwal JP, 2009, NEUROPSYCHOPHARMACOL, V34, P509, DOI 10.1038/npp.2008.97
   Chhatwal JP, 2005, NEUROPSYCHOPHARMACOL, V30, P516, DOI 10.1038/sj.npp.1300655
   Chiang KP, 2004, HUM MOL GENET, V13, P2113, DOI 10.1093/hmg/ddh216
   CHILDERS SR, 1992, ANN NY ACAD SCI, V654, P33, DOI 10.1111/j.1749-6632.1992.tb25954.x
   Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11
   Christensen R, 2007, LANCET, V370, P1706, DOI 10.1016/S0140-6736(07)61721-8
   Chutuape MA, 2001, AM J DRUG ALCOHOL AB, V27, P19, DOI 10.1081/ADA-100103117
   Cinar R, 2009, J PHARMACOL EXP THER, V330, P567, DOI 10.1124/jpet.109.152710
   Cippitelli A, 2005, EUR J NEUROSCI, V21, P2243, DOI 10.1111/j.1460-9568.2005.04056.x
   Cippitelli A, 2008, PSYCHOPHARMACOLOGY, V198, P449, DOI 10.1007/s00213-008-1104-0
   Cippitelli A, 2007, EUR J NEUROSCI, V26, P476, DOI 10.1111/j.1460-9568.2007.05665.x
   Clarke RBC, 2010, NEUROPHARMACOLOGY, V58, P799, DOI 10.1016/j.neuropharm.2009.12.006
   Coffey SF, 2000, DRUG ALCOHOL DEPEN, V59, P277, DOI 10.1016/S0376-8716(99)00126-X
   Cohen C, 2002, BEHAV PHARMACOL, V13, P451, DOI 10.1097/00008877-200209000-00018
   Cohen C, 2005, NEUROPSYCHOPHARMACOL, V30, P145, DOI 10.1038/sj.npp.1300541
   Colombo G, 2002, PSYCHOPHARMACOLOGY, V159, P181, DOI 10.1007/s002130100887
   Colombo G, 1998, ALCOHOL ALCOHOLISM, V33, P126
   Comings DE, 1997, MOL PSYCHIATR, V2, P161, DOI 10.1038/sj.mp.4000247
   Cooney NL, 1997, J ABNORM PSYCHOL, V106, P243, DOI 10.1037/0021-843X.106.2.243
   Cooper SJ, 2004, EUR J PHARMACOL, V500, P37, DOI 10.1016/j.ejphar.2004.07.009
   Corchero J, 1997, EUR J PHARMACOL, V323, P193, DOI 10.1016/S0014-2999(97)00144-1
   Corchero Javier, 2004, Critical Reviews in Neurobiology, V16, P159, DOI 10.1615/CritRevNeurobiol.v16.i12.170
   Cossu G, 2001, BEHAV BRAIN RES, V118, P61, DOI 10.1016/S0166-4328(00)00311-9
   Costa B, 2000, PSYCHOPHARMACOLOGY, V149, P121, DOI 10.1007/s002139900360
   Cota D, 2008, J NEUROENDOCRINOL, V20, P35, DOI 10.1111/j.1365-2826.2008.01673.x
   Cota D, 2007, ENDOCRINOLOGY, V148, P1574, DOI 10.1210/en.2005-1649
   Cota D, 2006, BRAIN RES REV, V51, P85, DOI 10.1016/j.brainresrev.2005.10.004
   Covault J, 2001, MOL PSYCHIATR, V6, P501, DOI 10.1038/sj.mp.4000925
   Covey LS, 2000, DRUGS, V59, P17, DOI 10.2165/00003495-200059010-00003
   CRAWLEY JN, 1993, PHARMACOL BIOCHEM BE, V46, P967, DOI 10.1016/0091-3057(93)90230-Q
   Crombag HS, 2008, PHILOS T R SOC B, V363, P3233, DOI 10.1098/rstb.2008.0090
   Dannon PN, 2004, HUM PSYCHOPHARM CLIN, V19, P97, DOI 10.1002/hup.560
   Dawson E, 1995, PSYCHIATR GENET, V5, P177, DOI 10.1097/00041444-199524000-00005
   de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582
   De Petrocellis L, 2001, J BIOL CHEM, V276, P12856, DOI 10.1074/jbc.M008555200
   De Vries TJ, 2005, BEHAV BRAIN RES, V161, P164, DOI 10.1016/j.bbr.2005.02.021
   De Vries TJ, 2003, PSYCHOPHARMACOLOGY, V168, P164, DOI 10.1007/s00213-003-1422-1
   De Vries TJ, 2001, NAT MED, V7, P1151, DOI 10.1038/nm1001-1151
   De Wit H, 2000, ADDICTION, V95, pS165
   DELFS JM, 1994, J COMP NEUROL, V345, P46, DOI 10.1002/cne.903450104
   Delfs JM, 2000, NATURE, V403, P430, DOI 10.1038/35000212
   DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919
   Di Chiara G, 2004, NEUROPHARMACOLOGY, V47, P227, DOI 10.1016/j.neuropharm.2004.06.032
   Di Marzo V, 2000, J NEUROCHEM, V74, P1627, DOI 10.1046/j.1471-4159.2000.0741627.x
   Di Marzo V, 2010, CURR MED CHEM, V17, P1430
   Di Marzo V, 2007, CURR OPIN LIPIDOL, V18, P129, DOI 10.1097/MOL.0b013e32803dbdec
   Di S, 2005, J PHYSIOL-LONDON, V569, P751, DOI 10.1113/jphysiol.2005.097477
   Di S, 2005, ENDOCRINOLOGY, V146, P4292, DOI 10.1210/en.2005-0610
   Di S, 2003, J NEUROSCI, V23, P4850
   Di S, 2009, J NEUROSCI, V29, P393, DOI 10.1523/JNEUROSCI.4546-08.2009
   Diana MA, 2004, BRIT J PHARMACOL, V142, P9, DOI 10.1038/sj.bjp.0705726
   Diergaarde L, 2008, NEUROPHARMACOLOGY, V55, P712, DOI 10.1016/j.neuropharm.2008.06.003
   Dinh TP, 2002, P NATL ACAD SCI USA, V99, P10819, DOI 10.1073/pnas.152334899
   Domschke K, 2008, EUR NEUROPSYCHOPHARM, V18, P751, DOI 10.1016/j.euroneuro.2008.05.003
   Dong HW, 2006, J COMP NEUROL, V494, P75, DOI 10.1002/cne.20790
   Drew Michael R., 2007, CNS & Neurological Disorders-Drug Targets, V6, P205, DOI 10.2174/187152707780619353
   Dumont EC, 2005, NAT NEUROSCI, V8, P413, DOI 10.1038/nn1414
   Economidou D, 2006, PSYCHOPHARMACOLOGY, V183, P394, DOI 10.1007/s00213-005-0199-9
   Ehlers CL, 2007, TWIN RES HUM GENET, V10, P805, DOI 10.1375/twin.10.6.805
   Everitt BJ, 2001, BRAIN RES REV, V36, P129, DOI 10.1016/S0165-0173(01)00088-1
   Everitt BJ, 1999, ANN NY ACAD SCI, V877, P412, DOI 10.1111/j.1749-6632.1999.tb09280.x
   Fattore L, 1999, BEHAV BRAIN RES, V104, P141, DOI 10.1016/S0166-4328(99)00059-5
   Fattore L, 2005, NEUROPHARMACOLOGY, V48, P1097, DOI 10.1016/j.neuropharm.2005.01.022
   Fattore L, 2005, PHARMACOL BIOCHEM BE, V81, P343, DOI 10.1016/j.pbb.2005.01.031
   Fattore L, 2003, EUR J NEUROSCI, V17, P1723, DOI 10.1046/j.1460-9568.2003.02607.x
   Fattore L, 2007, EUR J NEUROSCI, V25, P2191, DOI 10.1111/j.1460-9568.2007.05470.x
   Ferrer B, 2007, BIOCHEM J, V404, P97, DOI 10.1042/BJ20061898
   Filbey FM, 2008, ALCOHOL CLIN EXP RES, V32, P1113, DOI 10.1111/j.1530-0277.2008.00692.x
   Filbey FM, 2010, NEUROPSYCHOPHARMACOL, V35, P967, DOI 10.1038/npp.2009.200
   Filip M, 2006, PHARMACOL REP, V58, P806
   Flanagan JM, 2006, HUM GENET, V120, P581, DOI 10.1007/s00439-006-0250-x
   Forget B, 2005, PSYCHOPHARMACOLOGY, V181, P722, DOI 10.1007/s00213-005-0015-6
   Forget B, 2006, PSYCHOPHARMACOLOGY, V189, P59, DOI 10.1007/s00213-006-0525-x
   Forget B, 2009, PSYCHOPHARMACOLOGY, V205, P613, DOI 10.1007/s00213-009-1569-5
   Fourgeaud L, 2004, J NEUROSCI, V24, P6939, DOI 10.1523/JNEUROSCI.0671-04.2004
   Freedland CS, 2001, ALCOHOL CLIN EXP RES, V25, P277, DOI 10.1097/00000374-200102000-00017
   Fride E, 2008, J NEUROENDOCRINOL, V20, P75, DOI 10.1111/j.1365-2826.2008.01670.x
   FRIDE E, 1993, EUR J PHARMACOL, V231, P313, DOI 10.1016/0014-2999(93)90468-W
   Fu Y, 2007, J NEUROPHYSIOL, V97, P937, DOI 10.1152/jn.00349.2006
   Gadzicki D, 1999, MOL CELL PROBE, V13, P321, DOI 10.1006/mcpr.1999.0249
   Gaetani S, 2009, INT REV NEUROBIOL, V85, P57, DOI 10.1016/S0074-7742(09)85005-8
   Gallate JE, 1999, EUR J PHARMACOL, V370, P233, DOI 10.1016/S0014-2999(99)00170-3
   Garcia-Gutierrez MS, 2010, BRIT J PHARMACOL, V160, P1773, DOI 10.1111/j.1476-5381.2010.00819.x
   Garcia-Gutierrez MS, 2011, J PSYCHOPHARMACOL, V25, P111, DOI 10.1177/0269881110379507
   Gardner EL, 2005, PHARMACOL BIOCHEM BE, V81, P263, DOI 10.1016/j.pbb.2005.01.032
   GATTO GJ, 1994, ALCOHOL, V11, P557, DOI 10.1016/0741-8329(94)90083-3
   Gebremedhin D, 1999, AM J PHYSIOL-HEART C, V276, pH2085, DOI 10.1152/ajpheart.1999.276.6.H2085
   Gerdeman GL, 2008, NEUROPSYCHOPHARMACOL, V33, P2747, DOI 10.1038/sj.npp.1301648
   Gessa GL, 2005, ALCOHOL ALCOHOLISM, V40, P46, DOI 10.1093/alcalc/agh114
   Ghozland S, 2002, J NEUROSCI, V22, P1146, DOI 10.1523/JNEUROSCI.22-03-01146.2002
   Giuffrida A, 2004, NEUROPSYCHOPHARMACOL, V29, P2108, DOI 10.1038/sj.npp.1300558
   Giuffrida A, 1999, NAT NEUROSCI, V2, P358, DOI 10.1038/7268
   Glahn DC, 2007, BIOL PSYCHIAT, V61, P1306, DOI 10.1016/j.biopsych.2006.09.041
   Glass M, 1997, NEUROSCIENCE, V77, P299, DOI 10.1016/S0306-4522(96)00428-9
   Gobbi G, 2005, P NATL ACAD SCI USA, V102, P18620, DOI 10.1073/pnas.0509591102
   Godlewski G, 2009, PROSTAG OTH LIPID M, V89, P105, DOI 10.1016/j.prostaglandins.2009.07.001
   Goeders NE, 1996, NEUROENDOCRINOLOGY, V64, P337, DOI 10.1159/000127137
   Goeders NE, 2002, J PHARMACOL EXP THER, V301, P785, DOI 10.1124/jpet.301.3.785
   Goncalves MB, 2008, MOL CELL NEUROSCI, V38, P526, DOI 10.1016/j.mcn.2008.05.001
   Gonzalez S, 2004, BRIT J PHARMACOL, V143, P455, DOI 10.1038/sj.bjp.0705963
   Gonzalez S, 2004, DRUG ALCOHOL DEPEN, V74, P159, DOI 10.1016/j.drugalcdep.2003.12.011
   Gonzalez S, 2002, BRAIN RES, V954, P73, DOI 10.1016/S0006-8993(02)03344-9
   Gonzalez S, 2002, DRUG ALCOHOL DEPEN, V66, P77, DOI 10.1016/S0376-8716(01)00186-7
   Goparaju SK, 1998, FEBS LETT, V422, P69, DOI 10.1016/S0014-5793(97)01603-7
   Gorzalka BB, 2008, NEUROSCI BIOBEHAV R, V32, P1152, DOI 10.1016/j.neubiorev.2008.03.004
   GOSSOP M, 1989, BRIT J PSYCHIAT, V154, P348, DOI 10.1192/bjp.154.3.348
   Griebel G, 2005, BIOL PSYCHIAT, V57, P261, DOI 10.1016/j.biopsych.2004.10.032
   Grueter BA, 2006, J NEUROSCI, V26, P3210, DOI 10.1523/JNEUROSCI.0170-06.2006
   Guindon J, 2009, CNS NEUROL DISORD-DR, V8, P403, DOI 10.2174/187152709789824660
   GYSLING K, 1983, BRAIN RES, V277, P119, DOI 10.1016/0006-8993(83)90913-7
   Hajos N, 2004, EUR J NEUROSCI, V19, P2991, DOI 10.1111/j.0953-816X.2004.03433.x
   Hajos N, 2002, CHEM PHYS LIPIDS, V121, P73, DOI 10.1016/S0009-3084(02)00149-4
   Hall W, 1998, LANCET, V352, P1611, DOI 10.1016/S0140-6736(98)05021-1
   Haller J, 2004, EUR J NEUROSCI, V19, P1906, DOI 10.1111/j.1460-9568.2004.03293.x
   Haller J, 2002, EUR J NEUROSCI, V16, P1395, DOI 10.1046/j.1460-9568.2002.02192.x
   Haller J, 2009, PSYCHOPHARMACOLOGY, V204, P607, DOI 10.1007/s00213-009-1494-7
   Hansson AC, 2007, NEUROPSYCHOPHARMACOL, V32, P117, DOI 10.1038/sj.npp.1301034
   Hanus L, 2001, P NATL ACAD SCI USA, V98, P3662, DOI 10.1073/pnas.061029898
   HANUS L, 1993, J MED CHEM, V36, P3032, DOI 10.1021/jm00072a026
   Hariri AR, 2009, BIOL PSYCHIAT, V66, P9, DOI 10.1016/j.biopsych.2008.10.047
   Harloe JP, 2008, LEARN MEMORY, V15, P806, DOI 10.1101/lm.1113008
   Hartman CA, 2009, DRUG ALCOHOL DEPEN, V104, P11, DOI 10.1016/j.drugalcdep.2009.01.022
   Haughey HM, 2008, ADDICTION, V103, P1678, DOI 10.1111/j.1360-0443.2008.02292.x
   Heifets BD, 2009, ANNU REV PHYSIOL, V71, P283, DOI 10.1146/annurev.physiol.010908.163149
   Heller D, 2001, ADDICT BIOL, V6, P183, DOI 10.1080/13556210020040271
   Henstridge CM, 2009, FASEB J, V23, P183, DOI 10.1096/fj.08-108670
   HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991
   HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932
   HERKENHAM M, 1991, BRAIN RES, V547, P267, DOI 10.1016/0006-8993(91)90970-7
   Herman AI, 2006, AM J MED GENET B, V141B, P499, DOI 10.1002/ajmg.b.30325
   Hill MN, 2008, PHARMACOPSYCHIATRY, V41, P48, DOI 10.1055/s-2007-993211
   Hill MN, 2008, J NEUROCHEM, V106, P2322, DOI 10.1111/j.1471-4159.2008.05567.x
   Hill MN, 2006, EUR J NEUROSCI, V24, P1845, DOI 10.1111/j.1460-9568.2006.05061.x
   Hill MN, 2010, PSYCHONEUROENDOCRINO, V35, P1333, DOI 10.1016/j.psyneuen.2010.03.005
   Hill MN, 2010, PROG NEURO-PSYCHOPH, V34, P791, DOI 10.1016/j.pnpbp.2009.11.001
   Hill MN, 2009, NEUROPSYCHOPHARMACOL, V34, P2733, DOI 10.1038/npp.2009.114
   Hill MN, 2005, EUR NEUROPSYCHOPHARM, V15, P593, DOI 10.1016/j.euroneuro.2005.03.003
   Hillard CJ, 1999, J PHARMACOL EXP THER, V289, P1427
   Hillard CJ, 2000, CHEM PHYS LIPIDS, V108, P123, DOI 10.1016/S0009-3084(00)00191-2
   HINE B, 1975, LIFE SCI, V17, P851, DOI 10.1016/0024-3205(75)90435-X
   HOEHE MR, 1991, NEW BIOL, V3, P880
   Hoffman AF, 2003, J NEUROSCI, V23, P4815
   Hohmann AG, 2005, NATURE, V435, P1108, DOI 10.1038/nature03658
   Holter SM, 2005, EUR J PHARMACOL, V510, P69, DOI 10.1016/j.ejphar.2005.01.008
   Hopfer CJ, 2006, AM J MED GENET B, V141B, P895, DOI 10.1002/ajmg.b.30378
   Houchi H, 2005, NEUROPSYCHOPHARMACOL, V30, P339, DOI 10.1038/sj.npp.1300568
   Howell LL, 2008, BIOCHEM PHARMACOL, V75, P196, DOI 10.1016/j.bcp.2007.08.003
   Howlett AC, 2005, HANDB EXP PHARMACOL, V168, P53
   HOWLETT AC, 1990, TRENDS NEUROSCI, V13, P420, DOI 10.1016/0166-2236(90)90124-S
   Howlett AC, 2002, PROSTAG OTH LIPID M, V68-9, P619, DOI 10.1016/S0090-6980(02)00060-6
   Hu SSJ, 2009, PROSTAG LEUKOTR ESS, V81, P291, DOI 10.1016/j.plefa.2009.05.026
   Huang SM, 2002, P NATL ACAD SCI USA, V99, P8400, DOI 10.1073/pnas.122196999
   Hungund BL, 2003, J NEUROCHEM, V84, P698, DOI 10.1046/j.1471-4159.2003.01576.x
   Hutchison KE, 2008, ARCH GEN PSYCHIAT, V65, P841, DOI 10.1001/archpsyc.65.7.841
   Hwang J, 2010, LIFE SCI, V86, P615, DOI 10.1016/j.lfs.2009.06.003
   Hyman SE, 2005, AM J PSYCHIAT, V162, P1414, DOI 10.1176/appi.ajp.162.8.1414
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Ishiguro H, 2007, PHARMACOGENOMICS J, V7, P380, DOI 10.1038/sj.tpj.6500431
   Iwasaki S, 2007, PSYCHIAT GENET, V17, P215, DOI 10.1097/YPG.0b013e32809913d8
   JAFFE JH, 1989, PSYCHOPHARMACOLOGY, V97, P59, DOI 10.1007/BF00443414
   JAFFE JH, 1990, BRIT J ADDICT, V85, P1425
   Janero DR, 2009, EXPERT OPIN EMERG DR, V14, P43, DOI [10.1517/14728210902736568 , 10.1517/14728210902736568]
   Janiri L, 2005, NEUROPSYCHOBIOLOGY, V52, P37, DOI 10.1159/000086176
   Jarbe TUC, 2010, PSYCHOPHARMACOLOGY, V208, P87, DOI 10.1007/s00213-009-1708-z
   Jarbe TUC, 2006, PSYCHOPHARMACOLOGY, V188, P315, DOI 10.1007/s00213-006-0517-x
   Jarbe TUC, 2009, PSYCHOPHARMACOLOGY, V203, P229, DOI 10.1007/s00213-008-1199-3
   Jarbe TUC, 2001, PSYCHOPHARMACOLOGY, V156, P369
   Jarbe TUC, 1998, PSYCHOPHARMACOLOGY, V140, P519, DOI 10.1007/s002130050797
   Jarbe TUC, 2000, BEHAV PHARMACOL, V11, P81
   Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483
   Jhaveri MD, 2008, EUR J NEUROSCI, V27, P1722, DOI 10.1111/j.1460-9568.2008.06162.x
   Jiang W, 2005, J CLIN INVEST, V115, P3104, DOI 10.1172/JCI25509
   Johnson JP, 1997, MOL PSYCHIATR, V2, P169, DOI 10.1038/sj.mp.4000246
   Juhasz G, 2009, NEUROPSYCHOPHARMACOL, V34, P2019, DOI 10.1038/npp.2009.19
   Justinova Z, 2005, J NEUROSCI, V25, P5645, DOI 10.1523/JNEUROSCI.0951-05.2005
   Justinova Z, 2004, PSYCHOPHARMACOLOGY, V173, P186, DOI 10.1007/s00213-003-1693-6
   Justinova Z, 2003, PSYCHOPHARMACOLOGY, V169, P135, DOI 10.1007/s00213-003-1484-0
   Justinova Z, 2008, NEUROPSYCHOPHARMACOL, V33, P2870, DOI 10.1038/npp.2008.21
   Justinova Z, 2008, BIOL PSYCHIAT, V64, P930, DOI 10.1016/j.biopsych.2008.08.008
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564
   Kalivas PW, 2009, NAT REV NEUROSCI, V10, P561, DOI 10.1038/nrn2515
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kamprath K, 2006, J NEUROSCI, V26, P6677, DOI 10.1523/JNEUROSCI.0153-06.2006
   Kano M, 2009, PHYSIOL REV, V89, P309, DOI 10.1152/physrev.00019.2008
   Kaplan GB, 2011, PHARMACOL BIOCHEM BE, V97, P619, DOI 10.1016/j.pbb.2010.08.004
   KAPLAN RF, 1985, J STUD ALCOHOL, V46, P267, DOI 10.15288/jsa.1985.46.267
   Kapur A, 2009, J BIOL CHEM, V284, P29817, DOI 10.1074/jbc.M109.050187
   Kathmann M, 2006, N-S ARCH PHARMACOL, V372, P354, DOI 10.1007/s00210-006-0033-x
   Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803
   Katona I, 2001, J NEUROSCI, V21, P9506, DOI 10.1523/JNEUROSCI.21-23-09506.2001
   Kauer JA, 2004, ANNU REV PHYSIOL, V66, P447, DOI 10.1146/annurev.physiol.66.032102.112534
   Kauer JA, 2007, NAT REV NEUROSCI, V8, P844, DOI 10.1038/nrn2234
   Kelley AE, 2004, NEURON, V44, P161, DOI 10.1016/j.neuron.2004.09.016
   Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6
   Kim J, 2002, J NEUROSCI, V22, P10182
   Kinsey SG, 2009, J PHARMACOL EXP THER, V330, P902, DOI 10.1124/jpet.109.155465
   Kinsey SG, 2011, PHARMACOL BIOCHEM BE, V98, P21, DOI 10.1016/j.pbb.2010.12.002
   Kodas E, 2007, PSYCHOPHARMACOLOGY, V194, P161, DOI 10.1007/s00213-007-0813-0
   Koob G, 2007, AM J PSYCHIAT, V164, P1149, DOI 10.1176/appi.ajp.2007.05030503
   Koob GF, 2008, NEURON, V59, P11, DOI 10.1016/j.neuron.2008.06.012
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Koob GF, 2009, NEUROPHARMACOLOGY, V56, P18, DOI 10.1016/j.neuropharm.2008.07.043
   Koob GF, 2004, NEUROSCI BIOBEHAV R, V27, P739, DOI 10.1016/j.neubiorev.2003.11.007
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   KOSTEN TR, 1986, ARCH GEN PSYCHIAT, V43, P733
   Kreek MJ, 1998, DRUG ALCOHOL DEPEN, V51, P23, DOI 10.1016/S0376-8716(98)00064-7
   Krishnamurthy M, 2004, BIOORGAN MED CHEM, V12, P393, DOI 10.1016/j.bmc.2003.10.045
   LABERG JC, 1986, BRIT J ADDICT, V81, P797
   Lallemand F, 2001, ALCOHOL CLIN EXP RES, V25, P1317, DOI 10.1111/j.1530-0277.2001.tb02353.x
   Lan RX, 1999, J MED CHEM, V42, P769, DOI 10.1021/jm980363y
   Lauckner JE, 2008, P NATL ACAD SCI USA, V105, P2699, DOI 10.1073/pnas.0711278105
   Le Foll B, 2004, NEUROREPORT, V15, P2139, DOI 10.1097/00001756-200409150-00028
   Le Moal M, 2009, PHARMACOPSYCHIATRY, V42, pS42, DOI 10.1055/s-0029-1216355
   Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Leung D, 2006, BIOCHEMISTRY-US, V45, P4720, DOI 10.1021/bi060163l
   Leweke FM, 2007, SCHIZOPHR RES, V94, P29, DOI 10.1016/j.schres.2007.04.025
   Li T, 2000, MOL PSYCHIATR, V5, P128, DOI 10.1038/sj.mp.4000670
   Li X, 2009, PSYCHOPHARMACOLOGY, V204, P1, DOI 10.1007/s00213-008-1432-0
   Lichtman AH, 2004, J PHARMACOL EXP THER, V311, P441, DOI 10.1124/jpet.104.069401
   Lisboa SF, 2008, EUR J PHARMACOL, V593, P73, DOI 10.1016/j.ejphar.2008.07.032
   Liu J, 2008, NEUROPHARMACOLOGY, V54, P1, DOI 10.1016/j.neuropharm.2007.05.020
   Liu J, 2006, P NATL ACAD SCI USA, V103, P13345, DOI 10.1073/pnas.0601832103
   Liu QS, 2005, NATURE, V437, P1027, DOI 10.1038/nature04050
   Long JZ, 2009, P NATL ACAD SCI USA, V106, P20270, DOI 10.1073/pnas.0909411106
   Long JZ, 2009, CHEM BIOL, V16, P744, DOI 10.1016/j.chembiol.2009.05.009
   Long JZ, 2009, NAT CHEM BIOL, V5, P37, DOI 10.1038/nchembio.129
   Lopez-Moreno JA, 2004, J NEUROSCI, V24, P8245, DOI 10.1523/JNEUROSCI.2179-04.2004
   Lovinger David M., 2008, V184, P435
   Luchicchi A, 2010, ADDICT BIOL, V15, P277, DOI 10.1111/j.1369-1600.2010.00222.x
   Lutz B, 2004, BIOCHEM PHARMACOL, V68, P1691, DOI 10.1016/j.bcp.2004.07.007
   Lutz B, 2009, CURR OPIN PHARMACOL, V9, P46, DOI 10.1016/j.coph.2008.12.001
   Lynch WJ, 1999, EXP CLIN PSYCHOPHARM, V7, P318, DOI 10.1037/1064-1297.7.4.318
   Maccarrone M, 2010, TRENDS BIOCHEM SCI, V35, P601, DOI 10.1016/j.tibs.2010.05.008
   MACKIE K, 1992, P NATL ACAD SCI USA, V89, P3825, DOI 10.1073/pnas.89.9.3825
   MACKIE K, 1995, J NEUROSCI, V15, P6552
   Malcher-Lopes R, 2006, J NEUROSCI, V26, P6643, DOI 10.1523/JNEUROSCI.5126-05.2006
   Maldonado R, 2003, EUR NEUROPSYCHOPHARM, V13, P401, DOI 10.1016/j.euroneuro.2003.08.001
   Malinen H, 2008, ALCOHOL CLIN EXP RES, V32, P1976, DOI 10.1111/j.1530-0277.2008.00786.x
   Malinen H, 2009, ALCOHOL CLIN EXP RES, V33, P1711, DOI 10.1111/j.1530-0277.2009.01008.x
   Mallet PE, 1998, LIFE SCI, V62, P2431, DOI 10.1016/S0024-3205(98)00226-4
   MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U
   Manzanares J, 2005, ALCOHOL ALCOHOLISM, V40, P25, DOI 10.1093/alcalc/agh112
   Manzanares J, 1999, TRENDS PHARMACOL SCI, V20, P287, DOI 10.1016/S0165-6147(99)01339-5
   Manzanares J, 1999, BRAIN RES, V839, P173, DOI 10.1016/S0006-8993(99)01756-4
   Manzanedo C, 2004, NEUROREPORT, V15, P1373, DOI 10.1097/01.wnr.0000126217.87116.8c
   Marchalant Y, 2009, NEUROBIOL DIS, V34, P300, DOI 10.1016/j.nbd.2009.01.014
   Marco EM, 2007, EUR J PHARMACOL, V557, P37, DOI 10.1016/j.ejphar.2006.11.013
   Marrs W. R., 2010, NAT NEUROSCI
   Marsicano G, 2006, J Endocrinol Invest, V29, P27
   Marsicano G, 2002, NATURE, V418, P530, DOI 10.1038/nature00839
   MARTIN BR, 1991, PHARMACOL BIOCHEM BE, V40, P471, DOI 10.1016/0091-3057(91)90349-7
   Martin M, 2002, PSYCHOPHARMACOLOGY, V159, P379, DOI 10.1007/s00213-001-0946-5
   Martin M, 2000, EUR J NEUROSCI, V12, P4038, DOI 10.1046/j.1460-9568.2000.00287.x
   Martin-Fardon R, 2010, BRAIN RES, V1314, P145, DOI 10.1016/j.brainres.2009.12.027
   Mascia MS, 1999, EUR J PHARMACOL, V383, pR1, DOI 10.1016/S0014-2999(99)00656-1
   Mascia P, 2011, BIOL PSYCHIAT, V69, P633, DOI 10.1016/j.biopsych.2010.07.009
   Massi P, 2001, J NEUROIMMUNOL, V117, P116, DOI 10.1016/S0165-5728(01)00323-X
   Mato S, 2005, J NEUROSCI, V25, P11619, DOI 10.1523/JNEUROSCI.2294-05.2005
   Mato S, 2004, NAT NEUROSCI, V7, P585, DOI 10.1038/nn1251
   MATSUDA LA, 1993, J COMP NEUROL, V327, P535, DOI 10.1002/cne.903270406
   Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0
   MATTHEWS RT, 1984, NEUROSCIENCE, V11, P617, DOI 10.1016/0306-4522(84)90048-4
   McBride WJ, 1999, BEHAV BRAIN RES, V101, P129, DOI 10.1016/S0166-4328(99)00022-4
   McElligott ZA, 2009, PROG NEURO-PSYCHOPH, V33, P1329, DOI 10.1016/j.pnpbp.2009.05.022
   McGregor IS, 2005, ALCOHOL ALCOHOLISM, V40, P35, DOI 10.1093/alcalc/agh113
   McGregor IS, 1996, EUR J PHARMACOL, V313, P43, DOI 10.1016/0014-2999(96)00511-0
   McKinney MK, 2005, ANNU REV BIOCHEM, V74, P411, DOI 10.1146/annurev.biochem.74.082803.133450
   McLaughlin RJ, 2007, BEHAV PHARMACOL, V18, P431, DOI 10.1097/FBP.0b013e3282ee7b44
   McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689
   McMahon LR, 2008, PSYCHOPHARMACOLOGY, V198, P487, DOI 10.1007/s00213-007-0900-2
   McMahon LR, 2006, J PHARMACOL EXP THER, V319, P1211, DOI 10.1124/jpet.106.107110
   MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D
   Melis M, 2010, BIOL PSYCHIAT, V68, P256, DOI 10.1016/j.biopsych.2010.04.016
   Melis M, 2008, J NEUROSCI, V28, P13985, DOI 10.1523/JNEUROSCI.3221-08.2008
   Mendelson JH, 1996, NEW ENGL J MED, V334, P965, DOI 10.1056/NEJM199604113341507
   Merritt LL, 2008, J PHARMACOL EXP THER, V326, P483, DOI 10.1124/jpet.108.138321
   Micale V, 2009, NEUROPSYCHOPHARMACOL, V34, P593, DOI 10.1038/npp.2008.98
   Miller WR, 2000, J STUD ALCOHOL, V61, P759, DOI 10.15288/jsa.2000.61.759
   Moise AM, 2008, PSYCHOPHARMACOLOGY, V200, P333, DOI 10.1007/s00213-008-1209-5
   Moreira FA, 2008, NEUROPHARMACOLOGY, V54, P141, DOI 10.1016/j.neuropharm.2007.07.005
   Moreira FA, 2007, NEUROPHARMACOLOGY, V52, P958, DOI 10.1016/j.neuropharm.2006.10.013
   Morrish AC, 2009, PHYSIOL BEHAV, V98, P118, DOI 10.1016/j.physbeh.2009.04.023
   MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0
   Naassila M, 2004, NEUROPHARMACOLOGY, V46, P243, DOI 10.1016/j.neuropharm.2003.09.002
   Naderi N, 2008, PHARMACOL BIOCHEM BE, V89, P64, DOI 10.1016/j.pbb.2007.11.001
   Naidu PS, 2007, PSYCHOPHARMACOLOGY, V192, P61, DOI 10.1007/s00213-006-0689-4
   Navarro M, 1997, NEUROREPORT, V8, P491, DOI 10.1097/00001756-199701200-00023
   Navarro M, 1998, NEUROREPORT, V9, P3397, DOI 10.1097/00001756-199810260-00012
   Navarro M, 2001, J NEUROSCI, V21, P5344, DOI 10.1523/JNEUROSCI.21-14-05344.2001
   Nestler EJ, 2002, NAT NEUROSCI, V5, P1076, DOI 10.1038/nn945
   Nissen SE, 2008, JAMA-J AM MED ASSOC, V299, P1547, DOI 10.1001/jama.299.13.1547
   Niyuhire F, 2007, PSYCHOPHARMACOLOGY, V191, P223, DOI 10.1007/s00213-006-0650-6
   Nunes EV, 2004, BIOL PSYCHIAT, V56, P793, DOI 10.1016/j.biopsych.2004.06.037
   Nunes EV, 2004, JAMA-J AM MED ASSOC, V291, P1887, DOI 10.1001/jama.291.15.1887
   O'Brien CP, 2008, PHILOS T R SOC B, V363, P3277, DOI 10.1098/rstb.2008.0105
   O'Brien CP, 2005, PHARMACOL THERAPEUT, V108, P18, DOI 10.1016/j.pharmthera.2005.06.018
   O'Brien CP, 1998, J PSYCHOPHARMACOL, V12, P15, DOI 10.1177/026988119801200103
   O'Sullivan SE, 2007, BRIT J PHARMACOL, V152, P576, DOI 10.1038/sj.bjp.0707423
   OBrien CP, 1997, SCIENCE, V278, P66, DOI 10.1126/science.278.5335.66
   OBRIEN CP, 1992, ANN NY ACAD SCI, V654, P400, DOI 10.1111/j.1749-6632.1992.tb25984.x
   OBrien CP, 1996, LANCET, V347, P237, DOI 10.1016/S0140-6736(96)90409-2
   Okamoto Y, 2004, J BIOL CHEM, V279, P5298, DOI 10.1074/jbc.M306642200
   Onaivi ES, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001640
   Onaivi ES, 2006, ANN NY ACAD SCI, V1074, P514, DOI 10.1196/annals.1369.052
   Onaivi ES, 1996, BEHAV BRAIN RES, V72, P115, DOI 10.1016/0166-4328(96)00139-8
   Orio L, 2009, J NEUROSCI, V29, P4846, DOI 10.1523/JNEUROSCI.0563-09.2009
   Overton HA, 2006, CELL METAB, V3, P167, DOI 10.1016/j.cmet.2006.02.004
   OVIEDO A, 1993, BRAIN RES, V616, P293, DOI 10.1016/0006-8993(93)90220-H
   Pamplona FA, 2008, NEUROBIOL LEARN MEM, V90, P290, DOI 10.1016/j.nlm.2008.04.003
   Pamplona FA, 2006, PSYCHOPHARMACOLOGY, V188, P641, DOI 10.1007/s00213-006-0514-0
   Pan B, 2008, J NEUROSCI, V28, P1385, DOI 10.1523/JNEUROSCI.4033-07.2008
   Pandey R, 2009, PHARMACOL RES, V60, P85, DOI 10.1016/j.phrs.2009.03.019
   Patel S, 2005, EUR J NEUROSCI, V21, P1057, DOI 10.1111/j.1460-9568.2005.03916.x
   Patel S, 2005, NEUROPSYCHOPHARMACOL, V30, P497, DOI 10.1038/sj.npp.1300535
   Patel S, 2004, ENDOCRINOLOGY, V145, P5431, DOI 10.1210/en.2004-0638
   Patel S, 2003, J PHARMACOL EXP THER, V306, P880, DOI 10.1124/jpet.103.054270
   Patel S, 2006, J PHARMACOL EXP THER, V318, P304, DOI 10.1124/jpet.106.101287
   Paulus Martin P, 2007, Dialogues Clin Neurosci, V9, P379
   Perera TD, 2008, NEUROSCIENTIST, V14, P326, DOI 10.1177/1073858408317242
   Perra S, 2005, PSYCHOPHARMACOLOGY, V183, P368, DOI 10.1007/s00213-005-0195-0
   PERTWEE R, 1994, EUR J PHARMACOL, V259, P115, DOI 10.1016/0014-2999(94)90499-5
   Pertwee RG, 2010, CURR MED CHEM, V17, P1360, DOI 10.2174/092986710790980050
   Pertwee RG, 2005, LIFE SCI, V76, P1307, DOI 10.1016/j.lfs.2004.10.025
   Petrosino S, 2010, CURR OPIN INVEST DR, V11, P51
   Piazza PV, 1998, TRENDS PHARMACOL SCI, V19, P67, DOI 10.1016/S0165-6147(97)01115-2
   Picciotto MR, 2000, NEUROPSYCHOPHARMACOL, V22, P451, DOI 10.1016/S0893-133X(99)00146-3
   Pierce RC, 2006, NEUROSCI BIOBEHAV R, V30, P215, DOI 10.1016/j.neubiorev.2005.04.016
   Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247
   Ponce G, 2003, MOL PSYCHIATR, V8, P466, DOI 10.1038/sj.mp.4001278
   Porter AC, 2002, J PHARMACOL EXP THER, V301, P1020, DOI 10.1124/jpet.301.3.1020
   Preuss UW, 2003, EUR ARCH PSY CLIN N, V253, P275, DOI 10.1007/s00406-003-0440-7
   Price TJ, 2004, BRIT J PHARMACOL, V141, P1118, DOI 10.1038/sj.bjp.0705711
   Pugh G, 1997, J PHARMACOL EXP THER, V281, P730
   Quirk GJ, 2003, ANN NY ACAD SCI, V985, P263
   Racz I, 2003, J NEUROSCI, V23, P2453
   Rademacher DJ, 2008, NEUROPHARMACOLOGY, V54, P108, DOI 10.1016/j.neuropharm.2007.06.012
   Rademacher DJ, 2007, PROG NEURO-PSYCHOPH, V31, P633, DOI 10.1016/j.pnpbp.2006.12.013
   Re G, 2007, VET J, V173, P21, DOI 10.1016/j.tvjl.2005.10.003
   Reich CG, 2008, J PSYCHOPHARMACOL, V22, P769, DOI 10.1177/0269881107083999
   Reisine T, 1996, ANN NY ACAD SCI, V780, P168, DOI 10.1111/j.1749-6632.1996.tb15121.x
   Rice OV, 2002, BRAIN RES, V945, P135, DOI 10.1016/S0006-8993(02)02890-1
   Richman JA, 1996, ADDICTION, V91, P391, DOI 10.1046/j.1360-0443.1996.9133918.x
   Riddle EL, 2005, AAPS J, V7, pE847, DOI 10.1208/aapsj070481
   RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058
   Rodd ZA, 2004, J NEUROSCI, V24, P1050, DOI 10.1523/JNEUROSCI.1319-03.2004
   Rodd-Henricks ZA, 2000, PSYCHOPHARMACOLOGY, V149, P217, DOI 10.1007/s002139900347
   Rodriguez JJ, 2001, J NEUROSCI, V21, P823, DOI 10.1523/JNEUROSCI.21-03-00823.2001
   Romero J, 1998, J MOL NEUROSCI, V11, P109, DOI 10.1385/JMN:11:2:109
   ROMERO J, 1995, PHARMACOL BIOCHEM BE, V51, P731, DOI 10.1016/0091-3057(95)00023-P
   Roohbakhsh A, 2007, CLIN EXP PHARMACOL P, V34, P223, DOI 10.1111/j.1440-1681.2007.04576.x
   Rospenda KM, 2000, ADDICTION, V95, P1805, DOI 10.1046/j.1360-0443.2000.9512180510.x
   Ross S, 2009, CLIN NEUROPHARMACOL, V32, P269, DOI 10.1097/WNF.0b013e3181a9163c
   Rothman RB, 2003, EUR J PHARMACOL, V479, P23, DOI 10.1016/j.ejphar.2003.08.054
   Rouge-Pont F, 1998, EUR J NEUROSCI, V10, P3903, DOI 10.1046/j.1460-9568.1998.00438.x
   ROUGEPONT F, 1995, J NEUROSCI, V15, P7189
   Rubino T, 2008, CEREB CORTEX, V18, P1292, DOI 10.1093/cercor/bhm161
   Rubino T, 2009, NEUROTOX RES, V15, P291, DOI 10.1007/s12640-009-9031-3
   Rubio M, 2007, NEUROSCI LETT, V421, P270, DOI 10.1016/j.neulet.2007.05.052
   Russo R, 2007, J PHARMACOL EXP THER, V322, P236, DOI 10.1124/jpet.107.119941
   Rutkowska M, 2006, PHARMACOL REP, V58, P200
   Rutkowska Maria, 2004, Acta Pol Pharm, V61, P165
   Ryberg E, 2007, BRIT J PHARMACOL, V152, P1092, DOI 10.1038/sj.bjp.0707460
   Saario SM, 2007, CHEM BIODIVERS, V4, P1903, DOI 10.1002/cbdv.200790158
   San Jose B, 2000, ALCOHOL ALCOHOLISM, V35, P307, DOI 10.1093/alcalc/35.3.307
   Santos CJPA, 2008, BEHAV PHARMACOL, V19, P357, DOI 10.1097/FBP.0b013e3283095234
   Schacht JP, 2009, PSYCHOPHARMACOLOGY, V203, P511, DOI 10.1007/s00213-008-1397-z
   Scherma M, 2008, J PHARMACOL EXP THER, V327, P482, DOI 10.1124/jpet.108.142224
   Scherma M, 2008, NEUROPHARMACOLOGY, V54, P129, DOI 10.1016/j.neuropharm.2007.08.011
   Schlosburg JE, 2010, NAT NEUROSCI, V13, P1113, DOI 10.1038/nn.2616
   Schlosburg JE, 2009, AAPS J, V11, P342, DOI 10.1208/s12248-009-9110-7
   Schmidt LG, 2002, DRUG ALCOHOL DEPEN, V65, P221, DOI 10.1016/S0376-8716(01)00164-8
   See RE, 2005, EUR J PHARMACOL, V526, P140, DOI 10.1016/j.ejphar.2005.09.034
   Serra S, 2002, EUR J PHARMACOL, V443, P95, DOI 10.1016/S0014-2999(02)01594-7
   Serra S, 2001, EUR J PHARMACOL, V430, P369, DOI 10.1016/S0014-2999(01)01379-6
   Shaham Y, 2000, BRAIN RES REV, V33, P13, DOI 10.1016/S0165-0173(00)00024-2
   Shaham Y, 2005, NAT NEUROSCI, V8, P1437, DOI 10.1038/nn1105-1437
   Shalev U, 2002, PHARMACOL REV, V54, P1, DOI 10.1124/pr.54.1.1
   Sharir H, 2010, PHARMACOL THERAPEUT, V126, P301, DOI 10.1016/j.pharmthera.2010.02.004
   Shearman LP, 2003, BEHAV PHARMACOL, V14, P573, DOI 10.1097/00008877-200312000-00001
   Shoaib M, 2008, NEUROPHARMACOLOGY, V54, P438, DOI 10.1016/j.neuropharm.2007.10.011
   Sidhpura N, 2011, NEUROPHARMACOLOGY, V61, P1070, DOI 10.1016/j.neuropharm.2011.05.034
   Simon GM, 2008, J BIOL CHEM, V283, P9341, DOI 10.1074/jbc.M707807200
   Simon GM, 2006, J BIOL CHEM, V281, P26465, DOI 10.1074/jbc.M604660200
   Singh ME, 2004, BRAIN RES, V1026, P244, DOI 10.1016/j.brainres.2004.08.027
   Sinha R, 1999, PSYCHOPHARMACOLOGY, V142, P343, DOI 10.1007/s002130050898
   Sipe JC, 2002, P NATL ACAD SCI USA, V99, P8394, DOI 10.1073/pnas.082235799
   SMITH PB, 1994, J PHARMACOL EXP THER, V270, P219
   Solinas M, 2005, NEUROPSYCHOPHARMACOL, V30, P2046, DOI 10.1038/sj.npp.1300754
   Solinas M, 2003, J PHARMACOL EXP THER, V306, P93, DOI 10.1124/jpet.102.047928
   Solinas M, 2007, J PHARMACOL EXP THER, V321, P370, DOI 10.1124/jpet.106.114124
   Solinas M, 2006, J NEUROCHEM, V98, P408, DOI 10.1111/j.1471-4159.2006.03880.x
   Solinas M, 2010, PSYCHOPHARMACOLOGY, V209, P191, DOI 10.1007/s00213-010-1789-8
   Soria G, 2005, NEUROPSYCHOPHARMACOL, V30, P1670, DOI 10.1038/sj.npp.1300707
   Spanagel R, 2000, J NEURAL TRANSM, V107, P669, DOI 10.1007/s007020070068
   Spano MS, 2004, BRIT J PHARMACOL, V143, P343, DOI 10.1038/sj.bjp.0705932
   Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub3
   Steiner MA, 2008, PHARMACOGENOMICS J, V8, P196, DOI 10.1038/sj.tpj.6500466
   Stella N, 2001, EUR J PHARMACOL, V425, P189, DOI 10.1016/S0014-2999(01)01182-7
   Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015
   Stella N, 2009, NEUROPHARMACOLOGY, V56, P244, DOI 10.1016/j.neuropharm.2008.07.037
   Stewart J, 2000, J PSYCHIATR NEUROSCI, V25, P125
   Stewart SH, 2001, ADDICT BEHAV, V26, P775, DOI 10.1016/S0306-4603(01)00236-2
   SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437
   SULZER D, 1990, NEURON, V5, P797, DOI 10.1016/0896-6273(90)90339-H
   Suzuki A, 2004, J NEUROSCI, V24, P4787, DOI 10.1523/JNEUROSCI.5491-03.2004
   Swanson CJ, 2001, J NEUROSCI, V21, P9043, DOI 10.1523/JNEUROSCI.21-22-09043.2001
   Takahashi E, 2008, EUR J PHARMACOL, V589, P149, DOI 10.1016/j.ejphar.2008.05.020
   Tanda G, 2000, NAT NEUROSCI, V3, P1073, DOI 10.1038/80577
   Tanda G, 1997, SCIENCE, V276, P2048, DOI 10.1126/science.276.5321.2048
   Terzian ALB, 2009, EUR NEUROPSYCHOPHARM, V19, P188, DOI 10.1016/j.euroneuro.2008.11.004
   Thanos PK, 2005, BEHAV BRAIN RES, V164, P206, DOI 10.1016/j.bbr.2005.06.021
   Thomas MJ, 2008, BRIT J PHARMACOL, V154, P327, DOI 10.1038/bjp.2008.77
   Tidey JW, 1997, PSYCHOPHARMACOLOGY, V130, P203, DOI 10.1007/s002130050230
   Torregrossa MM, 2011, NEUROBIOL LEARN MEM, V96, P609, DOI 10.1016/j.nlm.2011.02.014
   Tournier M, 2003, PSYCHIAT RES, V118, P1, DOI 10.1016/S0165-1781(03)00052-0
   Twitchell W, 1997, J NEUROPHYSIOL, V78, P43, DOI 10.1152/jn.1997.78.1.43
   Tyndale RF, 2007, AM J MED GENET B, V144B, P660, DOI 10.1002/ajmg.b.30491
   Tzavara ET, 2003, BRIT J PHARMACOL, V138, P544, DOI 10.1038/sj.bjp.0705100
   Uriguen L, 2005, EUR J NEUROSCI, V22, P2106, DOI 10.1111/j.1460-9568.2005.04372.x
   Uriguen L, 2004, NEUROPHARMACOLOGY, V46, P966, DOI 10.1016/j.neuropharm.2004.01.003
   Valjent E, 2002, BRIT J PHARMACOL, V135, P564, DOI 10.1038/sj.bjp.0704479
   Valverde O, 2000, EUR J NEUROSCI, V12, P533, DOI 10.1046/j.1460-9568.2000.00929.x
   Valverde O, 2006, EUR NEUROPSYCHOPHARM, V16, pS302, DOI 10.1016/S0924-977X(06)70316-9
   Valverde O, 2001, EUR J NEUROSCI, V13, P1816, DOI 10.1046/j.0953-816x.2001.01558.x
   Van Sickle MD, 2005, SCIENCE, V310, P329, DOI 10.1126/science.1115740
   Vann RE, 2009, EUR J PHARMACOL, V615, P102, DOI 10.1016/j.ejphar.2009.05.010
   Varma N, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-24-j0003.2001
   VELA G, 1995, NEUROPHARMACOLOGY, V34, P665, DOI 10.1016/0028-3908(95)00032-2
   Vengeliene V, 2003, ALCOHOL CLIN EXP RES, V27, P1048, DOI 10.1097/01.ALC.0000075829.81211.0C
   Vigano D, 2005, PHARMACOL BIOCHEM BE, V81, P360, DOI 10.1016/j.pbb.2005.01.021
   Vigano D, 2004, EUR J NEUROSCI, V20, P1849, DOI 10.1111/j.1460-9568.2004.03645.x
   Vigano D, 2003, NEUROPSYCHOPHARMACOL, V28, P1160, DOI 10.1038/sj.npp.1300117
   Vinklerova J, 2002, J PSYCHOPHARMACOL, V16, P139, DOI 10.1177/026988110201600204
   Vinod K. Y., 2011, ADDICT BIOL
   Vinod KY, 2008, J NEUROCHEM, V104, P233, DOI 10.1111/j.1471-4159.2007.04956.x
   Vinod KY, 2006, NEUROCHEM INT, V49, P619, DOI 10.1016/j.neuint.2006.05.002
   Viscomi MT, 2009, J NEUROSCI, V29, P4564, DOI 10.1523/JNEUROSCI.0786-09.2009
   Viveros M. P., 2008, Endocrine Metabolic & Immune Disorders-Drug Targets, V8, P220, DOI 10.2174/187153008785700082
   Viveros MP, 2005, PHARMACOL BIOCHEM BE, V81, P331, DOI 10.1016/j.pbb.2005.01.029
   Vlachou S, 2003, BEHAV BRAIN RES, V141, P215, DOI 10.1016/S0166-4328(02)00370-4
   Vlachou S, 2008, INT J NEUROPSYCHOPH, V11, P905, DOI 10.1017/S1461145708008717
   Vlachou S, 2006, PSYCHOPHARMACOLOGY, V188, P293, DOI 10.1007/s00213-006-0506-0
   Volkow ND, 2007, ARCH NEUROL-CHICAGO, V64, P1575, DOI 10.1001/archneur.64.11.1575
   VoltaireCarlsson A, 1996, ALCOHOL, V13, P415, DOI 10.1016/0741-8329(96)81678-8
   Wade MR, 2006, EUR J PHARMACOL, V551, P162, DOI 10.1016/j.ejphar.2006.08.083
   Wang L, 2003, P NATL ACAD SCI USA, V100, P1393, DOI 10.1073/pnas.0336351100
   Ward SJ, 2009, DRUG ALCOHOL DEPEN, V105, P248, DOI 10.1016/j.drugalcdep.2009.07.002
   Weiss F, 2005, CURR OPIN PHARMACOL, V5, P9, DOI 10.1016/j.coph.2004.11.001
   Weitlauf C, 2004, J NEUROSCI, V24, P5741, DOI 10.1523/JNEUROSCI.1181-04.2004
   Werling LL, 2009, INT J DEV NEUROSCI, V27, P263, DOI 10.1016/j.ijdevneu.2008.12.008
   White NM, 1996, ADDICTION, V91, P921, DOI 10.1111/j.1360-0443.1996.tb03586.x
   Whyte LS, 2009, P NATL ACAD SCI USA, V106, P16511, DOI 10.1073/pnas.0902743106
   WILEY JL, 1995, DRUG ALCOHOL DEPEN, V40, P81, DOI 10.1016/0376-8716(95)01193-5
   Wiley JL, 2004, EXP CLIN PSYCHOPHARM, V12, P173, DOI 10.1037/1064-1297.12.3.173
   Wiley JL, 1997, PHARMACOL BIOCHEM BE, V58, P1139, DOI 10.1016/S0091-3057(97)00327-4
   Wiley JL, 1998, EUR J PHARMACOL, V355, P113, DOI 10.1016/S0014-2999(98)00502-0
   Wilson RI, 2002, SCIENCE, V296, P678, DOI 10.1126/science.1063545
   Wise RA, 2010, BRAIN RES, V1314, P38, DOI 10.1016/j.brainres.2009.09.101
   Xi ZX, 2008, NEUROPSYCHOPHARMACOL, V33, P1735, DOI 10.1038/sj.npp.1301552
   Xi ZX, 2006, J NEUROSCI, V26, P8531, DOI 10.1523/JNEUROSCI.0726-06.2006
   Xi ZX, 2000, J PHARMACOL EXP THER, V294, P613
   Xi ZX, 2002, ALCOHOL ALCOHOLISM, V37, P485, DOI 10.1093/alcalc/37.5.485
   Yahyavi-Firouz-Abadi N, 2009, PHARMACOL THERAPEUT, V124, P235, DOI 10.1016/j.pharmthera.2009.06.014
   Yin HH, 2008, EUR J NEUROSCI, V28, P1437, DOI 10.1111/j.1460-9568.2008.06422.x
   Yin H, 2009, J BIOL CHEM, V284, P12328, DOI 10.1074/jbc.M806516200
   Zhang PW, 2004, MOL PSYCHIATR, V9, P916, DOI 10.1038/sj.mp.4001560
   Zuo LJ, 2007, BIOL PSYCHIAT, V62, P616, DOI 10.1016/j.biopsych.2006.12.004
   Zuo L, 2009, NEUROPSYCHOPHARMACOL, V34, P1504, DOI 10.1038/npp.2008.206
   Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761
NR 548
TC 114
Z9 116
U1 1
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0163-7258
EI 1879-016X
J9 PHARMACOL THERAPEUT
JI Pharmacol. Ther.
PD DEC
PY 2011
VL 132
IS 3
BP 215
EP 241
DI 10.1016/j.pharmthera.2011.06.005
PG 27
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 853QG
UT WOS:000297440200001
PM 21798285
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Muller, CP
   Homberg, JR
AF Mueller, Christian P.
   Homberg, Judith R.
TI The role of serotonin in drug use and addiction
SO BEHAVIOURAL BRAIN RESEARCH
LA English
DT Review
DE Serotonin; Psychoactive drug; Abuse; Addiction; Animal model; Genetic
   risk
ID CONDITIONED PLACE PREFERENCE; 5-HT3 RECEPTOR ANTAGONISTS; VENTRAL
   TEGMENTAL AREA; COCAINE-SEEKING BEHAVIOR; ALCOHOL-PREFERRING P;
   DISCRIMINATIVE STIMULUS PROPERTIES; INDUCED LOCOMOTOR-ACTIVITY; DORSAL
   RAPHE NUCLEUS; MESSENGER-RNA EXPRESSION; TRANSPORTER PROMOTER
   POLYMORPHISM
AB The use of psychoactive drugs is a wide spread behaviour in human societies. The systematic use of a drug requires the establishment of different drug use-associated behaviours which need to be learned and controlled. However, controlled drug use may develop into compulsive drug use and addiction, a major psychiatric disorder with severe consequences for the individual and society. Here we review the role of the serotonergic (5-HT) system in the establishment of drug use-associated behaviours on the one hand and the transition and maintenance of addiction on the other hand for the drugs: cocaine, amphetamine, methamphetamine, MDMA (ecstasy), morphine/heroin, cannabis, alcohol, and nicotine. Results show a crucial, but distinct involvement of the 5-HT system in both processes with considerable overlap between psychostimulant and opioidergic drugs and alcohol. A new functional model suggests specific adaptations in the 5-HT system, which coincide with the establishment of controlled drug use-associated behaviours. These serotonergic adaptations render the nervous system susceptible to the transition to compulsive drug use behaviours and often overlap with genetic risk factors for addiction. Altogether we suggest a new trajectory by which serotonergic neuroadaptations induced by first drug exposure pave the way for the establishment of addiction. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Mueller, Christian P.] Univ Erlangen Nurnberg, Univ Clin, Dept Psychiat & Psychotherapy, D-91054 Erlangen, Germany.
   [Homberg, Judith R.] Catholic Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, NL-6525 EZ Nijmegen, Netherlands.
C3 University of Erlangen Nuremberg; Radboud University Nijmegen
RP Muller, CP (通讯作者)，Univ Erlangen Nurnberg, Dept Psychiat & Psychotherapy, Sect Addict Med, Schwabachanlage 6, D-91054 Erlangen, Germany.
EM Christian.Mueller@uk-erlangen.de
RI Homberg, Judith R/D-2473-2010; Homberg, J.R./N-4172-2019
OI Homberg, Judith/0000-0002-7621-1010; Muller,
   Christian/0000-0002-5325-9900
FU Friedrich-Alexander-University of Erlangen-Nuremberg; Dutch Organisation
   for Scientific Research [40-00812-98-11002, 60-60600-97-354]
FX This work was supported by funds of the Friedrich-Alexander-University
   of Erlangen-Nuremberg (to C.P. Muller) and by the Dutch Organisation for
   Scientific Research (grant nrs. 40-00812-98-11002 and 60-60600-97-354
   awarded to J. Homberg).
CR Abdollahian E, 2006, AM J ADDICTION, V15, P100, DOI 10.1080/10550490500419151
   Abel E. L., 1980, MARIHUANA 1 12 1000
   Acosta JI, 2005, PHARMACOL BIOCHEM BE, V80, P297, DOI 10.1016/j.pbb.2004.12.001
   ACQUAS E, 1988, PHARMACOL RES, V20, P1113, DOI 10.1016/S0031-6989(88)80752-5
   Adams W, 2008, NEUROPHARMACOLOGY, V55, P1048, DOI 10.1016/j.neuropharm.2008.06.035
   ADELL A, 1995, BRAIN RES, V693, P70, DOI 10.1016/0006-8993(95)00701-Q
   Adell A, 2010, HBK BEHAV NEUROSCI, V21, P259, DOI 10.1016/B978-0-12-374634-4.00015-0
   Adriaens AM, 2012, J NUCL MED, V53, P1969, DOI 10.2967/jnumed.112.103796
   Agatsuma S, 2006, HUM MOL GENET, V15, P2721, DOI 10.1093/hmg/ddl206
   Ago Y, 2006, PHARMACOL BIOCHEM BE, V85, P198, DOI 10.1016/j.pbb.2006.07.036
   Ago Y, 2006, NEUROPHARMACOLOGY, V51, P914, DOI 10.1016/j.neuropharm.2006.06.001
   Agrawal A, 2011, ALCOHOL CLIN EXP RES, V35, P550, DOI 10.1111/j.1530-0277.2010.01372.x
   Ahmed SH, 2010, NEUROSCI BIOBEHAV R, V35, P172, DOI 10.1016/j.neubiorev.2010.04.005
   Ahmed SH, 2005, PSYCHOPHARMACOLOGY, V180, P473, DOI 10.1007/s00213-005-2180-z
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Ahmed SH, 2002, NAT NEUROSCI, V5, P625, DOI 10.1038/nn872
   AHTEE L, 1989, J PHARMACOL EXP THER, V249, P303
   Ait-Daoud Nassima, 2012, Front Psychiatry, V3, P6, DOI 10.3389/fpsyt.2012.00006
   Alexander GM, 2012, NEUROSCIENCE, V207, P167, DOI 10.1016/j.neuroscience.2012.01.027
   Ali I, 1996, BRIT J PHARMACOL, V119, pP207
   Ali I, 1997, PHARMACOL BIOCHEM BE, V58, P311, DOI 10.1016/S0091-3057(97)00239-6
   Allan AM, 2001, PSYCHOPHARMACOLOGY, V158, P18
   Anastasio NC, 2014, NEUROPSYCHOPHARMACOL, V39, P360, DOI 10.1038/npp.2013.199
   Andrade ALM, 2011, NEUROSCIENCE, V189, P178, DOI 10.1016/j.neuroscience.2011.05.028
   Andrews CM, 2001, PSYCHOPHARMACOLOGY, V155, P221, DOI 10.1007/s002130100704
   Anneken JH, 2012, NEUROPHARMACOLOGY, V63, P1022, DOI 10.1016/j.neuropharm.2012.07.026
   [Anonymous], 2011, RES 2010 NAT SURV DR, VI
   ARNOLD B, 1995, PSYCHOPHARMACOLOGY, V119, P213, DOI 10.1007/BF02246163
   ARONSON SC, 1995, PSYCHOPHARMACOLOGY, V119, P179, DOI 10.1007/BF02246159
   Arpin-Bott MP, 2006, ANN NY ACAD SCI, V1074, P382, DOI 10.1196/annals.1369.038
   Arroyo M, 1998, PSYCHOPHARMACOLOGY, V140, P331, DOI 10.1007/s002130050774
   Auclair A, 2004, EUR J NEUROSCI, V20, P3073, DOI 10.1111/j.1460-9568.2004.03805.x
   Auclair AL, 2010, J NEUROCHEM, V114, P1323, DOI 10.1111/j.1471-4159.2010.06848.x
   Avraham Y, 2004, PHARMACOL BIOCHEM BE, V77, P675, DOI 10.1016/j.pbb.2004.01.015
   Baker DA, 2001, PSYCHOPHARMACOLOGY, V155, P18, DOI 10.1007/s002130000676
   Baker LE, 1997, PHARMACOL BIOCHEM BE, V58, P505, DOI 10.1016/S0091-3057(97)00287-6
   BAKER LE, 1993, BEHAV PHARMACOL, V4, P69
   Ball KT, 2005, PSYCHOPHARMACOLOGY, V181, P676, DOI 10.1007/s00213-005-0038-z
   Bambico FR, 2012, PROG NEURO-PSYCHOPH, V38, P88, DOI 10.1016/j.pnpbp.2012.02.006
   Banks ML, 2008, NEUROPSYCHOPHARMACOL, V33, P219, DOI 10.1038/sj.npp.1301420
   Bankson MG, 2002, NEUROPSYCHOPHARMACOL, V26, P40, DOI 10.1016/S0893-133X(01)00345-1
   Bankson MG, 2001, J PHARMACOL EXP THER, V297, P846
   Baptista-Hon DT, 2012, BRIT J PHARMACOL, V165, P693, DOI 10.1111/j.1476-5381.2011.01582.x
   Bardo MT, 2000, PSYCHOPHARMACOLOGY, V153, P31, DOI 10.1007/s002130000569
   Bare DJ, 1998, ALCOHOL CLIN EXP RES, V22, P1272, DOI 10.1111/j.1530-0277.1998.tb03908.x
   Barot SK, 2007, EUR J NEUROSCI, V25, P3125, DOI 10.1111/j.1460-9568.2007.05568.x
   Barr CS, 2004, ARCH GEN PSYCHIAT, V61, P1146, DOI 10.1001/archpsyc.61.11.1146
   Barr JL, 2011, NEUROSCIENCE, V182, P105, DOI 10.1016/j.neuroscience.2011.03.020
   Barr JL, 2013, EUR J NEUROSCI, V37, P479, DOI 10.1111/ejn.12050
   Barros M, 2013, ADDICT BIOL, V18, P452, DOI 10.1111/j.1369-1600.2011.00409.x
   Batki SL, 1996, DRUG ALCOHOL DEPEN, V41, P137, DOI 10.1016/0376-8716(96)01233-1
   Batman AM, 2005, PSYCHOPHARMACOLOGY, V179, P393, DOI 10.1007/s00213-004-2035-z
   Baumann MH, 1998, BIOL PSYCHIAT, V44, P578, DOI 10.1016/S0006-3223(98)00123-1
   Baumann MH, 2008, PHARMACOL BIOCHEM BE, V90, P208, DOI 10.1016/j.pbb.2008.02.018
   Baumann MH, 2007, PSYCHOPHARMACOLOGY, V189, P407, DOI 10.1007/s00213-006-0322-6
   Baumann MH, 2011, DRUG ALCOHOL DEPEN, V114, P147, DOI 10.1016/j.drugalcdep.2010.09.015
   BEDFORD JA, 1980, PHARMACOL BIOCHEM BE, V13, P69, DOI 10.1016/0091-3057(80)90122-7
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   Belzung C, 2000, PHARMACOL BIOCHEM BE, V66, P221, DOI 10.1016/S0091-3057(00)00238-0
   Bengel D, 1998, MOL PHARMACOL, V53, P649, DOI 10.1124/mol.53.4.649
   Bergman J, 2013, INT J NEUROPSYCHOPH, V16, P445, DOI 10.1017/S1461145712000661
   BERTHOLD H, 1989, EUR J PHARMACOL, V162, P19, DOI 10.1016/0014-2999(89)90599-2
   Besson M, 2013, NEUROPSYCHOPHARMACOL, V38, P1963, DOI 10.1038/npp.2013.95
   BILSKY EJ, 1991, PHARMACOL BIOCHEM BE, V39, P509, DOI 10.1016/0091-3057(91)90217-P
   Bisaga Adam, 1993, Polish Journal of Pharmacology, V45, P513
   Bland ST, 2003, NEUROPSYCHOPHARMACOL, V28, P1589, DOI 10.1038/sj.npp.1300206
   Bleich S, 2007, ALCOHOL ALCOHOLISM, V42, P509, DOI 10.1093/alcalc/agm068
   Boyce-Rustay JM, 2006, ALCOHOL CLIN EXP RES, V30, P1957, DOI 10.1111/j.1530-0277.2006.00241.x
   BRADBERRY CW, 1993, J NEUROCHEM, V60, P1429, DOI 10.1111/j.1471-4159.1993.tb03305.x
   Bradbury S., 2013, ADDICT BIOL
   Braida D, 2005, PHARMACOL RES, V51, P177, DOI 10.1016/j.phrs.2004.07.009
   Brand I, 2013, ALCOHOL CLIN EXP RES, V37, P2048, DOI 10.1111/acer.12207
   Brody CL, 2005, ADDICT BEHAV, V30, P557, DOI 10.1016/j.addbeh.2004.08.005
   Bronsert MR, 2001, BEHAV PHARMACOL, V12, P549, DOI 10.1097/00008877-200111000-00017
   Bubar MJ, 2003, NEUROPHARMACOLOGY, V44, P342, DOI 10.1016/S0028-3908(02)00381-7
   Budygin EA, 2004, P NATL ACAD SCI USA, V101, P7781, DOI 10.1073/pnas.0401418101
   Burbassi S, 2008, PSYCHOPHARMACOLOGY, V196, P15, DOI 10.1007/s00213-007-0916-7
   Burmeister JJ, 2004, NEUROPSYCHOPHARMACOL, V29, P660, DOI 10.1038/sj.npp.1300346
   Burmeister JJ, 2003, PSYCHOPHARMACOLOGY, V168, P146, DOI 10.1007/s00213-002-1307-8
   Burnett E J, 2012, Front Psychiatry, V3, P38, DOI 10.3389/fpsyt.2012.00038
   Burnett EJ, 2014, DRUG ALCOHOL DEPEN, V136, P135, DOI 10.1016/j.drugalcdep.2014.01.002
   Burton CL, 2013, BEHAV BRAIN RES, V240, P171, DOI 10.1016/j.bbr.2012.11.030
   Caille S, 2002, PHARMACOL BIOCHEM BE, V72, P979, DOI 10.1016/S0091-3057(02)00810-9
   CALLAHAN PM, 1995, J PHARMACOL EXP THER, V274, P1414
   Callahan PM, 1997, NEUROPHARMACOLOGY, V36, P373, DOI 10.1016/S0028-3908(97)00010-5
   CALLAWAY CW, 1992, NEUROPSYCHOPHARMACOL, V7, P113
   CALLAWAY CW, 1990, J PHARMACOL EXP THER, V254, P456
   CALLAWAY CW, 1992, J PHARMACOL EXP THER, V263, P318
   CAMP DM, 1994, BRAIN RES, V668, P180, DOI 10.1016/0006-8993(94)90523-1
   Cantin L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011592
   Cao J, 2014, HUM GENET, V133, P357, DOI 10.1007/s00439-013-1388-y
   Cao J, 2013, NEUROPSYCHOPHARMACOL, V38, P1737, DOI 10.1038/npp.2013.73
   Cao J, 2013, AM J MED GENET B, V162B, P169, DOI 10.1002/ajmg.b.32128
   Cao JX, 2011, BRAIN RES, V1376, P1, DOI 10.1016/j.brainres.2010.12.039
   Capriles N, 2012, PSYCHOPHARMACOLOGY, V220, P731, DOI 10.1007/s00213-011-2524-9
   CARBONI E, 1989, PSYCHOPHARMACOLOGY, V97, P175, DOI 10.1007/BF00442245
   CARBONI E, 1988, EUR J PHARMACOL, V151, P159, DOI 10.1016/0014-2999(88)90710-8
   Carey RJ, 2005, PHARMACOL BIOCHEM BE, V82, P353, DOI 10.1016/j.pbb.2005.09.005
   Carey RJ, 2005, BRAIN RES, V1047, P194, DOI 10.1016/j.brainres.2005.04.042
   Carey RJ, 2005, BRAIN RES, V1034, P162, DOI 10.1016/j.brainres.2004.12.012
   Carey RJ, 2004, PSYCHOPHARMACOLOGY, V177, P46, DOI 10.1007/s00213-004-1917-4
   Carey RJ, 2004, BRAIN RES, V1019, P134, DOI 10.1016/j.brainres.2004.05.091
   Carey RJ, 2002, BEHAV BRAIN RES, V132, P37, DOI 10.1016/S0166-4328(01)00383-7
   Carey RJ, 2001, BEHAV BRAIN RES, V126, P127, DOI 10.1016/S0166-4328(01)00253-4
   Carey RJ, 2008, BEHAV PHARMACOL, V19, P361, DOI 10.1097/FBP.0b013e3283096848
   Carey RJ, 2013, BIOLOGICAL RESEARCH ON ADDICTION: COMPREHENSIVE ADDICTIVE BEHAVIORS AND DISORDERS, VOL 2, P231, DOI 10.1016/B978-0-12-398335-0.00024-8
   Carey RJ, 2008, PROG BRAIN RES, V172, P347, DOI 10.1016/S0079-6123(08)00917-5
   Carlsson ML, 1999, J NEURAL TRANSM, V106, P123, DOI 10.1007/s007020050144
   Carpenter KM, 2004, DRUG ALCOHOL DEPEN, V74, P123, DOI 10.1016/j.drugalcdep.2003.11.015
   Carrao JL, 2007, EUR ARCH PSY CLIN N, V257, P383, DOI 10.1007/s00406-007-0726-2
   Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968
   Cassel JC, 2010, HBK BEHAV NEUROSCI, V21, P429, DOI 10.1016/B978-0-12-374634-4.00026-5
   Castanon N, 2000, PHARMACOL BIOCHEM BE, V67, P559, DOI 10.1016/S0091-3057(00)00389-0
   Cervo L, 1996, PHARMACOL BIOCHEM BE, V55, P33, DOI 10.1016/0091-3057(96)00046-9
   Cervo L, 2003, NEUROPSYCHOPHARMACOL, V28, P1150, DOI 10.1038/sj.npp.1300169
   Cervo L, 2002, PSYCHOPHARMACOLOGY, V163, P142, DOI 10.1007/s00213-002-1145-8
   CHADWICK MJ, 1990, AM J DRUG ALCOHOL AB, V16, P275, DOI 10.3109/00952999009001589
   Chaouloff F, 1999, PSYCHOPHARMACOLOGY, V141, P326, DOI 10.1007/s002130050841
   Chen CY, 2004, PSYCHOPHARMACOLOGY, V172, P78, DOI 10.1007/s00213-003-1624-6
   Chen YC, 2011, J STUD ALCOHOL DRUGS, V72, P752, DOI 10.15288/jsad.2011.72.752
   CHISHOLM JS, 1993, CURR ANTHROPOL, V34, P1, DOI 10.1086/204131
   Chu SL, 2009, CHINESE MED J-PEKING, V122, P1365, DOI 10.3760/cma.j.issn.0366-6999.2009.12.002
   Ciccocioppo R, 1997, PSYCHOPHARMACOLOGY, V134, P55, DOI 10.1007/s002130050425
   Cigler T, 2001, AM J MED GENET, V105, P489, DOI 10.1002/ajmg.1473
   Collins CM, 2013, J PSYCHOPHARMACOL, V27, P109, DOI 10.1177/0269881112463123
   Colpaert FC, 2006, J PHARMACOL EXP THER, V316, P892, DOI 10.1124/jpet.105.095109
   Conductier G, 2005, NEUROPSYCHOPHARMACOL, V30, P1056, DOI 10.1038/sj.npp.1300662
   Contini V, 2012, DRUG ALCOHOL DEPEN, V122, P100, DOI 10.1016/j.drugalcdep.2011.09.020
   Cornish JW, 2001, DRUG ALCOHOL DEPEN, V61, P183, DOI 10.1016/S0376-8716(00)00140-X
   CORRIGALL WA, 1994, PHARMACOL BIOCHEM BE, V49, P67, DOI 10.1016/0091-3057(94)90457-X
   Cosgrove KP, 2010, PSYCHIAT RES-NEUROIM, V184, P192, DOI 10.1016/j.pscychresns.2010.08.001
   COSTALL B, 1987, BRIT J PHARMACOL, V92, P881, DOI 10.1111/j.1476-5381.1987.tb11394.x
   COSTALL B, 1990, PHARMACOL BIOCHEM BE, V36, P97, DOI 10.1016/0091-3057(90)90132-2
   COSTALL B, 1990, PHARMACOL BIOCHEM BE, V36, P339, DOI 10.1016/0091-3057(90)90414-D
   Covault J, 2007, BIOL PSYCHIAT, V61, P609, DOI 10.1016/j.biopsych.2006.05.018
   Covey LS, 2002, AM J PSYCHIAT, V159, P1731, DOI 10.1176/appi.ajp.159.10.1731
   COVI L, 1995, AM J DRUG ALCOHOL AB, V21, P327, DOI 10.3109/00952999509002701
   Cox SML, 2011, BRIT J PSYCHIAT, V199, P391, DOI 10.1192/bjp.bp.110.084178
   Craige CP, 2013, BEHAV BRAIN RES, V238, P206, DOI 10.1016/j.bbr.2012.10.034
   CROPP CD, 1995, ANN PHARMACOTHER, V29, P1041, DOI 10.1177/106002809502901016
   CUNNINGHAM KA, 1992, SYNAPSE, V11, P112, DOI 10.1002/syn.890110204
   Cunningham KA, 2014, NEUROPHARMACOLOGY, V76, P460, DOI 10.1016/j.neuropharm.2013.06.030
   Cunningham KA, 2013, ACS CHEM NEUROSCI, V4, P110, DOI 10.1021/cn300072u
   Cunningham KA, 2011, NEUROPHARMACOLOGY, V61, P513, DOI 10.1016/j.neuropharm.2011.04.034
   Czoty PW, 2005, BEHAV PHARMACOL, V16, P187, DOI 10.1097/00008877-200505000-00008
   Czoty PW, 2002, J PHARMACOL EXP THER, V300, P831, DOI 10.1124/jpet.300.3.831
   Dahl JP, 2006, ADDICT BIOL, V11, P76, DOI 10.1111/j.1369-1600.2006.00005.x
   David SP, 2008, DRUG ALCOHOL DEPEN, V98, P77, DOI 10.1016/j.drugalcdep.2008.04.013
   David SP, 2007, NICOTINE TOB RES, V9, P225, DOI 10.1080/14622200601078566
   David V, 2004, PSYCHOPHARMACOLOGY, V174, P367, DOI 10.1007/s00213-003-1767-5
   Davidson C, 2004, EUR J PHARMACOL, V503, P99, DOI 10.1016/j.ejphar.2004.09.041
   Davidson C, 2002, NEUROPSYCHOPHARMACOL, V27, P542
   Davidson C, 2007, EUR J PHARMACOL, V565, P113, DOI 10.1016/j.ejphar.2007.02.056
   Daws LC, 2006, J NEUROSCI, V26, P6431, DOI 10.1523/JNEUROSCI.4050-05.2006
   Dawson LA, 2003, BRAIN RES BULL, V59, P513, DOI 10.1016/S0361-9230(02)00967-X
   de Bruin NMWJ, 2013, BEHAV BRAIN RES, V236, P157, DOI 10.1016/j.bbr.2012.08.048
   de Bruin NMWJ, 2011, NEUROPHARMACOLOGY, V61, P451, DOI 10.1016/j.neuropharm.2011.01.045
   De La Garza R, 1998, PSYCHOPHARMACOLOGY, V137, P1, DOI 10.1007/s002130050586
   De la Garza R, 2000, J PHARMACOL EXP THER, V292, P610
   Degenhardt L, 2012, LANCET, V379, P55, DOI 10.1016/S0140-6736(11)61138-0
   DeLaGarza R, 1996, PHARMACOL BIOCHEM BE, V54, P533, DOI 10.1016/0091-3057(95)02207-4
   DEPOORTERE RY, 1993, PHARMACOL BIOCHEM BE, V45, P539, DOI 10.1016/0091-3057(93)90503-L
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Devoto P, 1998, ALCOHOL ALCOHOLISM, V33, P226
   DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175
   Dhonnchadha BAN, 2009, BEHAV NEUROSCI, V123, P382, DOI 10.1037/a0014592
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   DICHIARA G, 1995, DRUG ALCOHOL DEPEN, V38, P95, DOI 10.1016/0376-8716(95)01118-I
   Ding ZM, 2011, PSYCHOPHARMACOLOGY, V216, P245, DOI 10.1007/s00213-011-2208-5
   Ding ZM, 2009, PSYCHOPHARMACOLOGY, V204, P381, DOI 10.1007/s00213-009-1468-9
   Doly S, 2008, J NEUROSCI, V28, P2933, DOI 10.1523/JNEUROSCI.5723-07.2008
   Doly S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007952
   Dukat M, 2007, PHARMACOL BIOCHEM BE, V87, P203, DOI 10.1016/j.pbb.2007.03.008
   DURAZZO TC, 1994, PHARMACOL BIOCHEM BE, V49, P1001, DOI 10.1016/0091-3057(94)90255-0
   Easton AC, 2013, NEUROPSYCHOPHARMACOL, V38, P1636, DOI 10.1038/npp.2013.60
   Egashira N, 2002, EUR J PHARMACOL, V445, P221, DOI 10.1016/S0014-2999(02)01755-7
   Ehrman RN, 1996, DRUG ALCOHOL DEPEN, V42, P167, DOI 10.1016/S0376-8716(96)01278-1
   ELKADI AOS, 1995, LIFE SCI, V57, P511, DOI 10.1016/0024-3205(95)00284-D
   EMCDDA, 2012, ANN REP 2012 STAT DR
   Enoch MA, 2011, MOL PSYCHIATR, V16, P1139, DOI 10.1038/mp.2010.94
   Enoch MA, 2012, CURR PSYCHIAT REP, V14, P150, DOI 10.1007/s11920-011-0252-9
   Erritzoe D, 2009, NEUROIMAGE, V46, P23, DOI 10.1016/j.neuroimage.2009.01.050
   Ettenberg A, 2007, PHARMACOL BIOCHEM BE, V87, P171, DOI 10.1016/j.pbb.2007.04.014
   Ettenberg A, 2011, PHARMACOL BIOCHEM BE, V97, P632, DOI 10.1016/j.pbb.2010.11.008
   Everitt BJ, 2008, PHILOS T R SOC B, V363, P3125, DOI 10.1098/rstb.2008.0089
   Ewing SWF, 2012, PSYCHIAT RES-NEUROIM, V204, P112, DOI 10.1016/j.pscychresns.2012.10.011
   Ezaki N, 2008, ANN NY ACAD SCI, V1139, P49, DOI 10.1196/annals.1432.011
   FADDA F, 1991, ALCOHOL ALCOHOLISM, V26, P107, DOI 10.1093/oxfordjournals.alcalc.a045088
   Fadda P, 2005, SYNAPSE, V56, P29, DOI 10.1002/syn.20122
   Faleiro LJ, 2004, NEUROPSYCHOPHARMACOL, V29, P2115, DOI 10.1038/sj.npp.1300495
   Fantegrossi WE, 2003, PSYCHOPHARMACOLOGY, V166, P202, DOI 10.1007/s00213-002-1261-5
   Fantegrossi WE, 2002, PSYCHOPHARMACOLOGY, V161, P356, DOI 10.1007/s00213-002-1021-6
   Feinn R, 2005, AM J MED GENET B, V133B, P79, DOI 10.1002/ajmg.b.30132
   Ferguson SM, 2008, BIOL PSYCHIAT, V63, P207, DOI 10.1016/j.biopsych.2007.02.018
   Fernandez-Castillo N, 2013, GENES BRAIN BEHAV, V12, P39, DOI 10.1111/gbb.12013
   FERRE S, 1994, J NEUROSCI, V14, P4839
   Fijal K, 2010, PHARMACOL REP, V62, P1005, DOI 10.1016/S1734-1140(10)70362-5
   Filip M, 2005, PHARMACOL REP, V57, P685
   Filip M, 2006, PSYCHOPHARMACOLOGY, V183, P482, DOI 10.1007/s00213-005-0197-y
   Filip M, 2004, J PHARMACOL EXP THER, V310, P1246, DOI 10.1124/jpet.104.068841
   Filip M, 2003, J PHARMACOL EXP THER, V306, P734, DOI 10.1124/jpet.102.045716
   Filip M, 2003, EUR J PHARMACOL, V459, P239, DOI 10.1016/S0014-2999(02)02873-X
   Filip M, 2002, PHARMACOL BIOCHEM BE, V71, P745, DOI 10.1016/S0091-3057(01)00741-9
   Filip M, 2002, N-S ARCH PHARMACOL, V366, P226, DOI 10.1007/s00210-002-0583-5
   Filip M, 2001, POL J PHARMACOL, V53, P449
   Filip M, 2001, J PHYSIOL PHARMACOL, V52, P249
   Filip M, 2012, BRAIN RES, V1476, P132, DOI 10.1016/j.brainres.2012.03.035
   Filip M, 2010, ADDICT BIOL, V15, P227, DOI 10.1111/j.1369-1600.2010.00214.x
   Fletcher PJ, 2008, NEUROPSYCHOPHARMACOL, V33, P1402, DOI 10.1038/sj.npp.1301509
   Fletcher PJ, 2006, PSYCHOPHARMACOLOGY, V187, P515, DOI 10.1007/s00213-006-0453-9
   Fletcher PJ, 2012, NEUROPHARMACOLOGY, V62, P2288, DOI 10.1016/j.neuropharm.2012.01.023
   Fletcher PJ, 2011, NEUROPHARMACOLOGY, V61, P468, DOI 10.1016/j.neuropharm.2011.02.025
   Fletcher PJ, 2004, PSYCHOPHARMACOLOGY, V174, P406, DOI 10.1007/s00213-003-1747-9
   Fletcher PJ, 2004, NEUROPSYCHOPHARMACOL, V29, P308, DOI 10.1038/sj.npp.1300319
   Fletcher PJ, 2002, PSYCHOPHARMACOLOGY, V162, P282, DOI 10.1007/s00213-002-1104-4
   Fletcher PJ, 2002, PHARMACOL BIOCHEM BE, V71, P717, DOI 10.1016/S0091-3057(01)00717-1
   Fletcher PJ, 2002, NEUROPSYCHOPHARMACOL, V27, P576
   Fletcher PJ, 1999, PSYCHOPHARMACOLOGY, V146, P185, DOI 10.1007/s002130051105
   Fletcher PJ, 1999, BEHAV PHARMACOL, V10, P183, DOI 10.1097/00008877-199903000-00007
   Florez G, 2008, ALCOHOL ALCOHOLISM, V43, P516, DOI 10.1093/alcalc/agn048
   Francis HM, 2011, PSYCHOPHARMACOLOGY, V213, P355, DOI 10.1007/s00213-010-1982-9
   Frankel PS, 2004, BEHAV NEUROSCI, V118, P157, DOI 10.1037/0735-7044.118.1.157
   Franklin JM, 2013, NEUROSCI LETT, V548, P165, DOI 10.1016/j.neulet.2013.05.039
   Frantz KJ, 2002, NEUROPHARMACOLOGY, V42, P170, DOI 10.1016/S0028-3908(01)00165-4
   Furay AR, 2011, ALCOHOL, V45, P19, DOI 10.1016/j.alcohol.2010.07.010
   Gacek P, 2008, ADDICT BIOL, V13, P440, DOI 10.1111/j.1369-1600.2008.00118.x
   Gao F, 2011, BIOCHEM BIOPH RES CO, V412, P450, DOI 10.1016/j.bbrc.2011.07.114
   Garduno J, 2012, J NEUROSCI, V32, P15148, DOI 10.1523/JNEUROSCI.0941-12.2012
   Gartside SE, 1996, J PHARMACOL EXP THER, V279, P277
   Gartside SE, 1997, NEUROPHARMACOLOGY, V36, P1697, DOI 10.1016/S0028-3908(97)00171-8
   GATELY PF, 1985, PSYCHOPHARMACOLOGY, V87, P400, DOI 10.1007/BF00432502
   GAWIN FH, 1991, SCIENCE, V251, P1580, DOI 10.1126/science.2011738
   George AK, 2010, NEUROL RES, V32, P510, DOI 10.1179/174313209X385554
   George DT, 1997, AM J PSYCHIAT, V154, P81
   Gerra G, 2007, AM J MED GENET B, V144B, P52, DOI 10.1002/ajmg.b.30388
   Gerra G, 2005, AM J MED GENET B, V135B, P73, DOI 10.1002/ajmg.b.30173
   Gerra G, 2004, AM J MED GENET B, V126B, P37, DOI 10.1002/ajmg.b.20111
   Gerra G, 2004, J NEURAL TRANSM, V111, P611, DOI 10.1007/s00702-004-0129-8
   GEYER MA, 1987, PHARMACOL BIOCHEM BE, V28, P393, DOI 10.1016/0091-3057(87)90460-6
   Gilbert DG, 2009, J ABNORM PSYCHOL, V118, P322, DOI 10.1037/a0015382
   Gillies DM, 1996, EUR J PHARMACOL, V303, P1, DOI 10.1016/0014-2999(96)00028-3
   GLENNON RA, 1992, PHARMACOL BIOCHEM BE, V43, P1099, DOI 10.1016/0091-3057(92)90488-2
   Glennon RA, 2000, PHARMACOL BIOCHEM BE, V66, P483, DOI 10.1016/S0091-3057(00)00174-X
   Goeldner C, 2011, BIOL PSYCHIAT, V69, P236, DOI 10.1016/j.biopsych.2010.08.021
   Gokturk C, 2008, ARCH WOMEN MENT HLTH, V11, P347, DOI 10.1007/s00737-008-0033-6
   GOLD LH, 1988, J PHARMACOL EXP THER, V247, P547
   GOLD LH, 1992, PSYCHOPHARMACOLOGY, V108, P289, DOI 10.1007/BF02245114
   GONGWER MA, 1989, ALCOHOL, V6, P317, DOI 10.1016/0741-8329(89)90089-X
   GOUGH B, 1991, PHARMACOL BIOCHEM BE, V39, P619, DOI 10.1016/0091-3057(91)90137-Q
   Gould RW, 2011, NEUROPHARMACOLOGY, V61, P245, DOI 10.1016/j.neuropharm.2011.04.007
   GRABOWSKI J, 1995, J CLIN PSYCHOPHARM, V15, P163, DOI 10.1097/00004714-199506000-00004
   Grady TA, 1996, PSYCHIAT RES, V64, P1, DOI 10.1016/0165-1781(96)02884-3
   GRAUER SM, 1992, BRAIN RES, V599, P277, DOI 10.1016/0006-8993(92)90402-U
   Graves SM, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-65
   Gravius A, 2011, BEHAV PHARMACOL, V22, P122, DOI 10.1097/FBP.0b013e328343d804
   Gray AM, 2002, EUR NEUROPSYCHOPHARM, V12, P245, DOI 10.1016/S0924-977X(02)00028-7
   Green AR, 2003, PHARMACOL REV, V55, P463, DOI 10.1124/pr.55.3.3
   Grottick AJ, 2000, J PHARMACOL EXP THER, V295, P1183
   Grottick AJ, 2001, PSYCHOPHARMACOLOGY, V157, P292, DOI 10.1007/s002130100801
   Guindalini C, 2005, PSYCHIAT GENET, V15, P141, DOI 10.1097/00041444-200506000-00011
   GULATI A, 1990, EUR J PHARMACOL, V182, P253, DOI 10.1016/0014-2999(90)90284-D
   GULATI A, 1989, EUR J PHARMACOL, V167, P185, DOI 10.1016/0014-2999(89)90578-5
   GULATI A, 1988, NEUROPHARMACOLOGY, V27, P1231, DOI 10.1016/0028-3908(88)90025-1
   Hagen EH, 2009, NEUROSCIENCE, V160, P69, DOI 10.1016/j.neuroscience.2009.01.077
   Hagino Y, 2011, CURR NEUROPHARMACOL, V9, P91, DOI 10.2174/157015911795017254
   Harris GC, 2001, NEUROPSYCHOPHARMACOL, V24, P75, DOI 10.1016/S0893-133X(00)00184-6
   Harrison AA, 2001, NEUROPSYCHOPHARMACOL, V25, P55, DOI 10.1016/S0893-133X(00)00237-2
   Hayes DJ, 2009, BEHAV BRAIN RES, V197, P323, DOI 10.1016/j.bbr.2008.08.034
   Hayslett RL, 2005, PHARMACOL BIOCHEM BE, V81, P879, DOI 10.1016/j.pbb.2005.06.010
   Heath D. B., 2000, DRINKING OCCASIONS C
   Hedou G, 2000, EUR J PHARMACOL, V390, P127, DOI 10.1016/S0014-2999(00)00038-8
   Heils A, 1996, J NEUROCHEM, V66, P2621
   Heinz A, 1998, AM J PSYCHIAT, V155, P1023, DOI 10.1176/ajp.155.8.1023
   Herges S, 1999, N-S ARCH PHARMACOL, V360, P129, DOI 10.1007/s002109900058
   Herges S, 1998, PHARMACOL BIOCHEM BE, V59, P595, DOI 10.1016/S0091-3057(97)00473-5
   Herges S, 2000, BRIT J PHARMACOL, V131, P1294, DOI 10.1038/sj.bjp.0703687
   Herin David V, 2013, Front Psychiatry, V4, P2, DOI 10.3389/fpsyt.2013.00002
   Herin DV, 2005, PSYCHOPHARMACOLOGY, V178, P505, DOI 10.1007/s00213-004-2030-4
   HERNANDEZ L, 1987, BRAIN RES BULL, V19, P623, DOI 10.1016/0361-9230(87)90047-5
   Hernandez-Lopez S, 2013, REV NEUROSCIENCE, V24, P455, DOI 10.1515/revneuro-2013-0012
   HIGGINS GA, 1994, PSYCHOPHARMACOLOGY, V114, P611, DOI 10.1007/BF02244992
   HIGGINS GA, 1992, NEUROSCI BIOBEHAV R, V16, P535, DOI 10.1016/S0149-7634(05)80195-2
   Higgins GA, 2003, EUR J PHARMACOL, V480, P151, DOI 10.1016/j.ejphar.2003.08.102
   HIGGINS GA, 1993, PHARMACOL BIOCHEM BE, V45, P963, DOI 10.1016/0091-3057(93)90148-M
   HIGGINS GA, 1992, PSYCHOPHARMACOLOGY, V106, P315, DOI 10.1007/BF02245411
   HIGGINS GA, 1991, PSYCHOPHARMACOLOGY, V105, P322, DOI 10.1007/BF02244425
   Higgins GA, 2013, TRENDS PHARMACOL SCI, V34, P560, DOI 10.1016/j.tips.2013.08.001
   Higgins GA, 2012, NEUROPSYCHOPHARMACOL, V37, P1177, DOI 10.1038/npp.2011.303
   Hill EM, 2002, ADDICTION, V97, P401, DOI 10.1046/j.1360-0443.2002.00020.x
   Ho PS, 2011, WORLD J BIOL PSYCHIA, V12, P134, DOI 10.3109/15622975.2010.503813
   Hodge CW, 2008, GENES BRAIN BEHAV, V7, P96, DOI 10.1111/j.1601-183X.2007.00332.x
   Homberg JR, 2007, NEUROSCIENCE, V146, P1662, DOI 10.1016/j.neuroscience.2007.03.030
   Homberg JR, 2012, SFN
   Homberg J, 2010, BMC GENET, V11, DOI 10.1186/1471-2156-11-37
   Homberg JR, 2008, PSYCHOPHARMACOLOGY, V200, P367, DOI 10.1007/s00213-008-1212-x
   Homberg JR, 2011, BIOL PSYCHIAT, V69, P513, DOI 10.1016/j.biopsych.2010.09.024
   Hoplight BJ, 2007, NEUROPHARMACOLOGY, V52, P444, DOI 10.1016/j.neuropharm.2006.08.013
   Hoplight BJ, 2005, PHYSIOL BEHAV, V84, P707, DOI 10.1016/j.physbeh.2005.02.016
   Horner KA, 2011, BRAIN RES, V1390, P10, DOI 10.1016/j.brainres.2011.03.033
   Howell LL, 1995, J PHARMACOL EXP THER, V275, P1551
   Hu J, 2010, BIOL PSYCHIAT, V67, P800, DOI 10.1016/j.biopsych.2009.12.028
   Huang CC, 2013, J NEUROCHEM, V125, P809, DOI 10.1111/jnc.12227
   Huang CC, 2009, NEUROPSYCHOPHARMACOL, V34, P1979, DOI 10.1038/npp.2009.10
   HUI SCG, 1993, BRIT J PHARMACOL, V110, P1341, DOI 10.1111/j.1476-5381.1993.tb13966.x
   Huston JP, 2013, TRENDS PHARMACOL SCI, V34, P162, DOI 10.1016/j.tips.2013.01.004
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   HYNES MD, 1985, LIFE SCI, V36, P2317, DOI 10.1016/0024-3205(85)90321-2
   Ikeda R, 2011, EUR J PHARMACOL, V660, P318, DOI 10.1016/j.ejphar.2011.03.050
   Iordanidou M, 2010, DRUG ALCOHOL DEPEN, V108, P70, DOI 10.1016/j.drugalcdep.2009.11.015
   Ivanova EA, 2002, B EXP BIOL MED+, V133, P603, DOI 10.1023/A:1020254430169
   Ivanova S, 1997, PSYCHOPHARMACOLOGY, V134, P187, DOI 10.1007/s002130050441
   JACKSON DM, 1994, PHARMACOL BIOCHEM BE, V48, P465, DOI 10.1016/0091-3057(94)90554-1
   Jakubczyk A, 2012, J PSYCHIATR RES, V46, P44, DOI 10.1016/j.jpsychires.2011.09.001
   JAVAID JI, 1993, EUR J PHARMACOL, V238, P425, DOI 10.1016/0014-2999(93)90880-Q
   Jean A, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.131
   Ji SP, 2006, NAT MED, V12, P324, DOI 10.1038/nm1349
   JOHANSON CE, 1976, PHARMACOL BIOCHEM BE, V4, P45, DOI 10.1016/0091-3057(76)90174-X
   JOHANSON CE, 1993, J PHARMACOL EXP THER, V267, P1
   JOHARCHI N, 1993, PSYCHOPHARMACOLOGY, V112, P111, DOI 10.1007/BF02247370
   Johnson BA, 2000, JAMA-J AM MED ASSOC, V284, P963, DOI 10.1001/jama.284.8.963
   Johnson BA, 2003, ALCOHOL CLIN EXP RES, V27, P1773, DOI 10.1097/01.ALC.0000095635.46911.5D
   Johnson BA, 2002, PSYCHOPHARMACOLOGY, V160, P408, DOI 10.1007/s00213-002-1002-9
   Johnson BA, 2008, INT J NEUROPSYCHOPH, V11, P1, DOI 10.1017/S1461145707007778
   Johnson BA, 2013, AM J PSYCHIAT, V170, P1020, DOI 10.1176/appi.ajp.2013.12091163
   Johnson Bankole A, 2010, Front Psychiatry, V1, P145, DOI 10.3389/fpsyt.2010.00145
   JOHNSON RG, 1993, PHARMACOL BIOCHEM BE, V46, P289, DOI 10.1016/0091-3057(93)90355-W
   Kalivas PW, 2006, MOL INTERV, V6, P339, DOI 10.1124/mi.6.6.7
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   KALIVAS PW, 1988, J PHARMACOL EXP THER, V245, P485
   Kankaanpaa A, 1998, PHARMACOL BIOCHEM BE, V59, P1003, DOI 10.1016/S0091-3057(97)00527-3
   Kankaanpaa A, 2002, PSYCHOPHARMACOLOGY, V159, P341, DOI 10.1007/s00213-001-0939-4
   Karg K, 2011, ARCH GEN PSYCHIAT, V68, P444, DOI 10.1001/archgenpsychiatry.2010.189
   Kasper J, 2013, EUR J PHARMACOL, V718, P98, DOI 10.1016/j.ejphar.2013.09.008
   Kassai F, 2012, BEHAV PHARMACOL, V23, P397, DOI 10.1097/FBP.0b013e3283565248
   Kehne JH, 1996, NEUROPSYCHOPHARMACOL, V15, P116, DOI 10.1016/0893-133X(95)00160-F
   Kelai S, 2003, ALCOHOL ALCOHOLISM, V38, P386, DOI 10.1093/alcalc/agg095
   Kelley AE, 2004, NEURON, V44, P161, DOI 10.1016/j.neuron.2004.09.016
   Kelley AE, 2002, J NEUROSCI, V22, P3306
   Kenna GA, 2010, CURR PHARM DESIGN, V16, P2126
   Kenny PJ, 2001, EUR J NEUROSCI, V13, P1267, DOI 10.1046/j.0953-816x.2001.01501.x
   KING GR, 1994, PHARMACOL BIOCHEM BE, V47, P399, DOI 10.1016/0091-3057(94)90135-X
   KING GR, 1993, PHARMACOL BIOCHEM BE, V44, P253, DOI 10.1016/0091-3057(93)90459-7
   King GR, 2000, EUR J PHARMACOL, V394, P97, DOI 10.1016/S0014-2999(99)00926-7
   Kitanaka N, 2005, NEUROCHEM RES, V30, P445, DOI 10.1007/s11064-005-2679-z
   Kitanaka N, 2005, NEUROSCIENCE, V130, P295, DOI 10.1016/j.neuroscience.2004.09.026
   Klein DA, 2009, BEHAV PHARMACOL, V20, P67, DOI 10.1097/FBP.0b013e3283242fdd
   Kleven MS, 1998, J PHARMACOL EXP THER, V284, P1015
   KNAPP DJ, 1992, PHARMACOL BIOCHEM BE, V41, P847, DOI 10.1016/0091-3057(92)90237-A
   Koch S, 1997, J NEURAL TRANSM, V104, P135, DOI 10.1007/BF01273176
   KOETZNER L, 1995, PHARMACOL BIOCHEM BE, V52, P815, DOI 10.1016/0091-3057(95)00176-W
   Kohut SJ, 2013, INT J NEUROPSYCHOPH, V16, P1985, DOI 10.1017/S146114571300059X
   Kolb B, 2003, P NATL ACAD SCI USA, V100, P10523, DOI 10.1073/pnas.1834271100
   Koob GF, 2008, ANNU REV PSYCHOL, V59, P29, DOI 10.1146/annurev.psych.59.103006.093548
   Koob George F, 2013, Front Psychiatry, V4, P72, DOI 10.3389/fpsyt.2013.00072
   Koob GF, 2009, NEUROPHARMACOLOGY, V56, P18, DOI 10.1016/j.neuropharm.2008.07.043
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Kotler M, 1999, MOL PSYCHIATR, V4, P313, DOI 10.1038/sj.mp.4000499
   Kranzler HR, 2012, AM J MED GENET B, V159B, P484, DOI 10.1002/ajmg.b.32051
   Kranzler HR, 1996, ALCOHOL CLIN EXP RES, V20, P1534, DOI 10.1111/j.1530-0277.1996.tb01696.x
   KRANZLER HR, 1994, ARCH GEN PSYCHIAT, V51, P720
   Kranzler HR, 2003, ALCOHOL CLIN EXP RES, V27, P1150, DOI 10.1097/01.ALC.0000075547.77464.76
   KRANZLER HR, 1995, AM J PSYCHIAT, V152, P391
   Kristjansson SD, 2012, ALCOHOL CLIN EXP RES, V36, P162, DOI 10.1111/j.1530-0277.2011.01596.x
   KRUSZEWSKA A, 1986, EUR J PHARMACOL, V125, P283, DOI 10.1016/0014-2999(86)90038-5
   Kuczenski R, 1999, J PHARMACOL EXP THER, V288, P699
   KUCZENSKI R, 1995, J NEUROSCI, V15, P1308
   KUCZENSKI R, 1989, J NEUROSCI, V9, P2051
   Kuroki T, 1996, BRAIN RES, V743, P357, DOI 10.1016/S0006-8993(96)01111-0
   Kusljic S, 2006, BEHAV BRAIN RES, V168, P74, DOI 10.1016/j.bbr.2005.10.013
   Kusljic S, 2003, NEUROPSYCHOPHARMACOL, V28, P2138, DOI 10.1038/sj.npp.1300277
   Kweon YS, 2005, J PSYCHIATR RES, V39, P371, DOI 10.1016/j.jpsychires.2004.10.005
   LAKOSKI JM, 1988, TRENDS PHARMACOL SCI, V9, P177, DOI 10.1016/0165-6147(88)90034-X
   Lamb RJ, 2013, GENES BRAIN BEHAV, V12, P741, DOI 10.1111/gbb.12068
   Lamb RJ, 2014, BEHAV PHARMACOL, V25, P92, DOI 10.1097/FBP.0000000000000011
   Landabaso MA, 1998, ADDICTION, V93, P739, DOI 10.1046/j.1360-0443.1998.9357399.x
   LANE JD, 1992, DRUG ALCOHOL DEPEN, V30, P151, DOI 10.1016/0376-8716(92)90020-D
   Langen B, 2002, ALCOHOL, V27, P135, DOI 10.1016/S0741-8329(02)00219-7
   Lanteri C, 2008, NEUROPSYCHOPHARMACOL, V33, P1724, DOI 10.1038/sj.npp.1301548
   Laucht M, 2009, BIOL PSYCHIAT, V66, P102, DOI 10.1016/j.biopsych.2009.02.010
   LAYER RT, 1992, LIFE SCI, V50, P813, DOI 10.1016/0024-3205(92)90187-T
   LECCESE AP, 1984, BRAIN RES, V303, P153, DOI 10.1016/0006-8993(84)90223-3
   Lee MD, 2010, HBK BEHAV NEUROSCI, V21, P331, DOI 10.1016/B978-0-12-374634-4.00020-4
   Lee SY, 2009, ALCOHOL CLIN EXP RES, V33, P1589, DOI 10.1111/j.1530-0277.2009.00990.x
   Lehmann O, 2000, BEHAV BRAIN RES, V114, P213, DOI 10.1016/S0166-4328(00)00246-1
   Lende DH, 2007, ADDICT RES THEORY, V15, P465, DOI 10.1080/16066350701284552
   Lenoir M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000698
   Lerman C, 2001, AM J MED GENET, V105, P518, DOI 10.1002/ajmg.1476
   Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527
   Levin ED, 2011, J PHARMACOL EXP THER, V338, P890, DOI 10.1124/jpet.111.183525
   Levin ED, 2008, EUR J PHARMACOL, V600, P93, DOI 10.1016/j.ejphar.2008.10.016
   Levran O, 2008, GENES BRAIN BEHAV, V7, P720, DOI 10.1111/j.1601-183X.2008.00410.x
   Levran O, 2009, GENES BRAIN BEHAV, V8, P531, DOI 10.1111/j.1601-183X.2009.00501.x
   Li C, 2013, PSYCHOPHARMACOLOGY, V230, P537, DOI 10.1007/s00213-013-3182-x
   Li JX, 2013, PSYCHOPHARMACOLOGY, V225, P791, DOI 10.1007/s00213-012-2870-2
   Li JX, 2011, NEUROPSYCHOPHARMACOL, V36, P940, DOI 10.1038/npp.2010.232
   Li T, 2002, AM J MED GENET, V114, P329, DOI 10.1002/ajmg.10200
   Liang YQ, 2008, BRAIN RES, V1231, P6, DOI 10.1016/j.brainres.2008.07.037
   Liechti ME, 2000, NEUROPSYCHOPHARMACOL, V23, P396, DOI 10.1016/S0893-133X(00)00126-3
   Liechti ME, 2000, NEUROPSYCHOPHARMACOL, V22, P513, DOI 10.1016/S0893-133X(99)00148-7
   Lin SH, 2012, EUR NEUROPSYCHOPHARM, V22, P647, DOI 10.1016/j.euroneuro.2012.01.002
   LIPSKA BK, 1992, PHARMACOL BIOCHEM BE, V43, P1247, DOI 10.1016/0091-3057(92)90510-M
   Little KY, 1998, PROG NEURO-PSYCHOPH, V22, P455, DOI 10.1016/S0278-5846(98)00017-7
   Littlefield D.C., 1967, JAMA-J AM MED ASSOC, V201, P89
   Liu SJ, 2013, J PSYCHOPHARMACOL, V27, P801, DOI 10.1177/0269881113492898
   Liu SJ, 2006, DRUG ALCOHOL DEPEN, V81, P275, DOI 10.1016/j.drugalcdep.2005.07.007
   LOH EA, 1990, PSYCHOPHARMACOLOGY, V101, P262, DOI 10.1007/BF02244137
   Lotfipour S, 2011, NEUROPHARMACOLOGY, V61, P95, DOI 10.1016/j.neuropharm.2011.03.007
   LOVINGER DM, 1991, MOL PHARMACOL, V40, P263
   Lovinger DM, 2000, NEUROPHARMACOLOGY, V39, P561, DOI 10.1016/S0028-3908(99)00164-1
   LU MR, 1994, ALCOHOL CLIN EXP RES, V18, P60, DOI 10.1111/j.1530-0277.1994.tb00881.x
   LU MR, 1993, PHARMACOL BIOCHEM BE, V44, P931, DOI 10.1016/0091-3057(93)90027-Q
   Lunden JW, 2013, NEUROSCIENCE, V254, P160, DOI 10.1016/j.neuroscience.2013.08.071
   Lutz PE, 2011, EUR NEUROPSYCHOPHARM, V21, P835, DOI 10.1016/j.euroneuro.2011.02.002
   LYNESS WH, 1980, PHARMACOL BIOCHEM BE, V12, P937, DOI 10.1016/0091-3057(80)90456-6
   Ma Z, 2005, NEUROSCIENCE, V135, P949, DOI 10.1016/j.neuroscience.2005.06.074
   Maguire DR, 2013, PSYCHOPHARMACOLOGY, V225, P173, DOI 10.1007/s00213-012-2803-0
   Maj J, 1996, J NEURAL TRANSM, V103, P131, DOI 10.1007/BF01292622
   Maleki SA, 2008, BEHAV BRAIN RES, V190, P189, DOI 10.1016/j.bbr.2008.02.027
   Mangiavacchi S, 2001, J NEUROCHEM, V79, P1113, DOI 10.1046/j.1471-4159.2001.00665.x
   Mannelli P, 2005, ADDICT BIOL, V10, P261, DOI 10.1080/13556210500235540
   Mannelli P, 2006, PSYCHIAT RES, V144, P99, DOI 10.1016/j.psychres.2006.01.012
   Mansbach RS, 1998, DRUG ALCOHOL DEPEN, V52, P125, DOI 10.1016/S0376-8716(98)00085-4
   Manvich DF, 2012, J PHARMACOL EXP THER, V342, P761, DOI 10.1124/jpet.112.195156
   Manvich DF, 2012, J PHARMACOL EXP THER, V341, P424, DOI 10.1124/jpet.111.186981
   MARKOU A, 1992, PHYSIOL BEHAV, V51, P111, DOI 10.1016/0031-9384(92)90211-J
   Markou A, 2005, PSYCHOPHARMACOLOGY, V178, P133, DOI 10.1007/s00213-004-2008-2
   Markou A, 1998, NEUROPSYCHOPHARMACOL, V18, P135, DOI 10.1016/S0893-133X(97)00113-9
   Marona-Lewicka D, 2011, BEHAV PHARMACOL, V22, P508, DOI 10.1097/FBP.0b013e328349fc31
   MaronaLewicka D, 1997, NEUROPHARMACOLOGY, V36, P1471, DOI 10.1016/S0028-3908(97)00106-8
   Marques FZC, 2006, PSYCHIAT GENET, V16, P125, DOI 10.1097/01.ypg.0000199449.07786.7d
   Marquis KL, 2007, J PHARMACOL EXP THER, V320, P486, DOI 10.1124/jpet.106.106989
   Martin-Santos R, 2010, ADDICT BIOL, V15, P15, DOI 10.1111/j.1369-1600.2009.00180.x
   Maurel S, 1999, EUR J PHARMACOL, V370, P217, DOI 10.1016/S0014-2999(99)00125-9
   Maurel S, 1999, PHARMACOL BIOCHEM BE, V62, P89, DOI 10.1016/S0091-3057(98)00115-4
   Maurel S, 1999, ALCOHOL, V17, P195, DOI 10.1016/S0741-8329(98)00046-9
   Maurel S, 1998, BEHAV PHARMACOL, V9, P337
   Maurel S, 1997, PSYCHOPHARMACOLOGY, V130, P404, DOI 10.1007/s002130050257
   McBride WJ, 2010, HBK BEHAV NEUROSCI, V21, P399, DOI 10.1016/B978-0-12-374634-4.00024-1
   McBride W. J., 1992, NOVEL PHARM INTERVEN, P59
   MCBRIDE WJ, 1990, ALCOHOL, V7, P199, DOI 10.1016/0741-8329(90)90005-W
   McBride WJ, 1999, BEHAV BRAIN RES, V101, P129, DOI 10.1016/S0166-4328(99)00022-4
   McBride WJ, 1998, CRIT REV NEUROBIOL, V12, P339, DOI 10.1615/CritRevNeurobiol.v12.i4.40
   McBride WJ, 2004, ALCOHOL CLIN EXP RES, V28, P257, DOI 10.1097/01.ALC.0000113419.99915.DA
   MCCANN UD, 1993, J CLIN PSYCHOPHARM, V13, P214
   McClung J, 2010, PSYCHOPHARMACOLOGY, V210, P75, DOI 10.1007/s00213-010-1818-7
   McCorvy JD, 2011, NEUROSCI LETT, V505, P10, DOI 10.1016/j.neulet.2011.07.036
   McCreary AC, 1990, J PHARMACOL EXP THER, V290, P965
   MCGREGOR A, 1993, PHARMACOL BIOCHEM BE, V44, P651, DOI 10.1016/0091-3057(93)90181-R
   McKenzie-Quirk SD, 2003, PSYCHOPHARMACOLOGY, V167, P145, DOI 10.1007/s00213-003-1395-0
   McKinzie DL, 2000, ALCOHOL CLIN EXP RES, V24, P1500, DOI 10.1111/j.1530-0277.2000.tb04567.x
   McKinzie DL, 1998, ALCOHOL, V15, P291, DOI 10.1016/S0741-8329(97)00132-8
   McMahon LR, 2001, J NEUROSCI, V21, P7781, DOI 10.1523/JNEUROSCI.21-19-07781.2001
   McMahon LR, 1999, J PHARMACOL EXP THER, V291, P300
   Mechan AO, 2002, BRIT J PHARMACOL, V135, P170, DOI 10.1038/sj.bjp.0704442
   Mello NK, 2013, NEUROPSYCHOPHARMACOL, V38, P1264, DOI 10.1038/npp.2013.25
   Mello NK, 2013, NEUROPSYCHOPHARMACOL, V38, P455, DOI 10.1038/npp.2012.202
   MICZEK KA, 1982, PSYCHOPHARMACOLOGY, V76, P163, DOI 10.1007/BF00435272
   Millan MJ, 1998, J PHARMACOL EXP THER, V286, P1356
   Millan MJ, 1999, EUR J NEUROSCI, V11, P4419, DOI 10.1046/j.1460-9568.1999.00858.x
   MILLERTUTZAUER C, 1991, J STUD ALCOHOL, V52, P434, DOI 10.15288/jsa.1991.52.434
   Minnix JA, 2011, NICOTINE TOB RES, V13, P699, DOI 10.1093/ntr/ntr061
   Miranda F, 2007, PHARMACOL REP, V59, P517
   Miszkiel J, 2013, PHARMACOL REP, V65, P813, DOI 10.1016/S1734-1140(13)71062-4
   Miszkiel J, 2012, EUR J PHARMACOL, V677, P111, DOI 10.1016/j.ejphar.2011.12.033
   Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006
   Miyamoto K, 2007, HUM PSYCHOPHARM CLIN, V22, P483, DOI 10.1002/hup.871
   Moeller FG, 2007, AM J DRUG ALCOHOL AB, V33, P367, DOI 10.1080/00952990701313686
   Molina PE, 2001, LIFE SCI, V69, P1897, DOI 10.1016/S0024-3205(01)01276-0
   Morrow BA, 1996, SYNAPSE, V23, P174, DOI 10.1002/(SICI)1098-2396(199607)23:3<174::AID-SYN6>3.0.CO;2-5
   Moser PC, 1996, BEHAV BRAIN RES, V73, P163
   MOSER PC, 1992, EUR J PHARMACOL, V212, P271, DOI 10.1016/0014-2999(92)90342-2
   Mosner A, 1997, PHARMACOLOGY, V54, P186, DOI 10.1159/000139486
   Muller CP, 2007, PROG NEUROBIOL, V81, P133, DOI 10.1016/j.pneurobio.2007.01.001
   Muller CP, 2007, NEUROPHARMACOLOGY, V52, P854, DOI 10.1016/j.neuropharm.2006.10.002
   Muller CP, 2006, TRENDS PHARMACOL SCI, V27, P455, DOI 10.1016/j.tips.2006.07.003
   Muller CP, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00034
   Muller CP, 2011, BEHAV BRAIN SCI, V34, P328, DOI 10.1017/S0140525X1100135X
   Muller CP, 2011, BEHAV BRAIN SCI, V34, P293, DOI 10.1017/S0140525X11000057
   Muller CP, 2006, TRENDS PHARMACOL SCI, V27, P105, DOI 10.1016/j.tips.2005.12.003
   Muller CP, 2004, HIPPOCAMPUS, V14, P710, DOI 10.1002/hipo.10209
   Muller CP, 2004, NEUROPHARMACOLOGY, V47, P205, DOI 10.1016/j.neuropharm.2004.03.020
   Muller CP, 2003, NEUROPHARMACOLOGY, V44, P592, DOI 10.1016/S0028-3908(03)00046-7
   Muller CP, 2002, SYNAPSE, V45, P67, DOI 10.1002/syn.10083
   Muller CP, 2002, BEHAV BRAIN RES, V134, P337, DOI 10.1016/S0166-4328(02)00042-6
   Munafo MR, 2009, AM J MED GENET B, V150B, P271, DOI 10.1002/ajmg.b.30808
   Munn EM, 2002, NEUROSCI LETT, V332, P151, DOI 10.1016/S0304-3940(02)00949-7
   Munzar P, 1999, J PHARMACOL EXP THER, V291, P239
   Munzar P, 1999, PSYCHOPHARMACOLOGY, V141, P287, DOI 10.1007/s002130050836
   Munzar P, 2002, EUR J PHARMACOL, V436, P75, DOI 10.1016/S0014-2999(01)01598-9
   Murnane KS, 2013, J SLEEP RES, V22, P581, DOI 10.1111/jsr.12045
   Murnane KS, 2013, J NEUROSCI, V33, P13367, DOI 10.1523/JNEUROSCI.1437-13.2013
   MURPHY JM, 1988, ALCOHOL, V5, P283, DOI 10.1016/0741-8329(88)90066-3
   MURPHY JM, 1985, ALCOHOL, V2, P349, DOI 10.1016/0741-8329(85)90073-4
   MURPHY JM, 1982, PHARMACOL BIOCHEM BE, V16, P145, DOI 10.1016/0091-3057(82)90026-0
   MURPHY JM, 1987, PHARMACOL BIOCHEM BE, V26, P389, DOI 10.1016/0091-3057(87)90134-1
   Murray RC, 2014, NEUROSCI LETT, V559, P44, DOI 10.1016/j.neulet.2013.11.028
   NADER MA, 1994, BEHAV PHARMACOL, V5, P591, DOI 10.1097/00008877-199410000-00004
   Nagata T, 2011, NUTR NEUROSCI, V14, P96, DOI 10.1179/1476830511Y.0000000006
   Nair SG, 2013, PHARMACOL BIOCHEM BE, V112, P89, DOI 10.1016/j.pbb.2013.09.009
   Nakamura S, 2006, SYNAPSE, V60, P479, DOI 10.1002/syn.20323
   Varela MJ, 2011, BEHAV PHARMACOL, V22, P362, DOI 10.1097/FBP.0b013e3283487346
   Orejarena MJ, 2011, INT J NEUROPSYCHOPH, V14, P927, DOI 10.1017/S1461145710001215
   NARANJO CA, 1987, CLIN PHARMACOL THER, V41, P266, DOI 10.1038/clpt.1987.27
   NARANJO CA, 1994, INT CLIN PSYCHOPHARM, V9, P163, DOI 10.1097/00004850-199409000-00004
   NEAL BS, 1986, EUR J PHARMACOL, V132, P299, DOI 10.1016/0014-2999(86)90620-5
   NEAL BS, 1986, J PHARMACOL EXP THER, V236, P157
   Neisewander JL, 2007, BEHAV PHARMACOL, V18, P791, DOI 10.1097/FBP.0b013e3282f1c94b
   Neisewander JL, 2014, NEUROPHARMACOLOGY, V76, P301, DOI 10.1016/j.neuropharm.2013.08.014
   Nestler EJ, 2002, NEUROBIOL LEARN MEM, V78, P637, DOI 10.1006/nlme.2002.4084
   Neumaier JF, 2002, J NEUROSCI, V22, P10856
   Neumaier JF, 2009, J NEUROCHEM, V111, P217, DOI 10.1111/j.1471-4159.2009.06313.x
   Niaura R, 2002, J CONSULT CLIN PSYCH, V70, P887, DOI 10.1037//0022-006X.70.4.887
   Nielsen DA, 2008, BEHAV GENET, V38, P133, DOI 10.1007/s10519-007-9187-7
   NOMIKOS GG, 1988, PHARMACOL BIOCHEM BE, V30, P853, DOI 10.1016/0091-3057(88)90110-4
   Nonkes LJP, 2013, NEUROBIOL LEARN MEM, V100, P48, DOI 10.1016/j.nlm.2012.12.004
   Nonkes LJP, 2012, J PSYCHIATR NEUROSCI, V37, P224, DOI 10.1503/jpn.110116
   Nonkes LJP, 2012, LEARN MEMORY, V19, P190, DOI 10.1101/lm.025908.112
   Nonkes LJP, 2013, ADDICT BIOL, V18, P434, DOI 10.1111/j.1369-1600.2011.00351.x
   Nonkes LJP, 2010, NEUROBIOL LEARN MEM, V94, P65, DOI 10.1016/j.nlm.2010.04.002
   O'Leary OF, 2010, HBK BEHAV NEUROSCI, V21, P749, DOI 10.1016/B978-0-12-374634-4.00041-1
   O'Neill MF, 1999, PHARMACOL BIOCHEM BE, V63, P237, DOI 10.1016/S0091-3057(98)00240-8
   Oakly AC, 2014, MOL PSYCHIATR, V19, P534, DOI 10.1038/mp.2013.75
   Ohmoto M, 2013, NICOTINE TOB RES, V15, P572, DOI 10.1093/ntr/nts149
   Ohmura Y, 2011, J PHARMACOL SCI, V117, P121, DOI 10.1254/jphs.11074SC
   Olausson P, 1999, PSYCHOPHARMACOLOGY, V142, P111, DOI 10.1007/s002130050869
   Olausson P, 2001, PSYCHOPHARMACOLOGY, V155, P348, DOI 10.1007/s002130100710
   Olausson P, 2001, EUR J PHARMACOL, V420, P45, DOI 10.1016/S0014-2999(01)00939-6
   OLDS J, 1954, J COMP PHYSIOL PSYCH, V47, P419, DOI 10.1037/h0058775
   Oliveto A, 2012, ADDICTION, V107, P131, DOI 10.1111/j.1360-0443.2011.03552.x
   Olivier JDA, 2008, NEUROSCIENCE, V152, P573, DOI 10.1016/j.neuroscience.2007.12.032
   Olmstead MC, 2006, Q J EXP PSYCHOL, V59, P625, DOI 10.1080/17470210500356308
   Overstreet DH, 1997, ALCOHOL CLIN EXP RES, V21, P1448
   PANOCKA I, 1995, PHARMACOL BIOCHEM BE, V52, P255, DOI 10.1016/0091-3057(95)00078-B
   Papla I, 2002, POL J PHARMACOL, V54, P351
   Pardo-Lozano R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047599
   PARIS JM, 1991, PSYCHOPHARMACOLOGY, V104, P475, DOI 10.1007/BF02245652
   PARSONS LH, 1993, J NEUROCHEM, V61, P1611, DOI 10.1111/j.1471-4159.1993.tb09794.x
   Parsons LH, 1998, J NEUROSCI, V18, P10078
   PARSONS LH, 1995, J PHARMACOL EXP THER, V274, P1182
   Patkar AA, 2004, PSYCHIAT GENET, V14, P25, DOI 10.1097/00041444-200403000-00004
   Patkar AA, 2002, PSYCHIAT GENET, V12, P161, DOI 10.1097/00041444-200209000-00007
   Patkar AA, 2001, ADDICT BIOL, V6, P337, DOI 10.1080/13556210020077064
   PAULUS MP, 1993, PSYCHOPHARMACOLOGY, V113, P187, DOI 10.1007/BF02245696
   Payer DE, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2011.73
   PEI Q, 1993, EUR J PHARMACOL, V230, P63, DOI 10.1016/0014-2999(93)90410-J
   Pelloux Y, 2007, PSYCHOPHARMACOLOGY, V194, P127, DOI 10.1007/s00213-007-0805-0
   Pelloux Y, 2012, NEUROPSYCHOPHARMACOL, V37, P2505, DOI 10.1038/npp.2012.111
   PELTIER R, 1993, PSYCHOPHARMACOLOGY, V110, P390, DOI 10.1007/BF02244643
   Pentkowski NS, 2012, BIOL PSYCHIAT, V72, P396, DOI 10.1016/j.biopsych.2012.03.024
   Pentkowski NS, 2010, NEUROPSYCHOPHARMACOL, V35, P2037, DOI 10.1038/npp.2010.72
   Pentkowski NS, 2009, ADDICT BIOL, V14, P419, DOI 10.1111/j.1369-1600.2009.00162.x
   Pergamin-Hight L, 2012, BIOL PSYCHIAT, V71, P373, DOI 10.1016/j.biopsych.2011.10.030
   PEROUTKA SJ, 1988, NEUROPSYCHOPHARMACOL, V1, P273
   Perret G, 1998, SYNAPSE, V30, P166, DOI 10.1002/(SICI)1098-2396(199810)30:2<166::AID-SYN6>3.3.CO;2-G
   Perrine SA, 2010, NEUROTOXICOLOGY, V31, P654, DOI 10.1016/j.neuro.2010.08.005
   Pickard Hanna, 2012, AJOB Neurosci, V3, P40
   Pinelli A, 1997, EUR J PHARMACOL, V340, P111, DOI 10.1016/S0014-2999(97)01349-6
   Pinto E, 2008, ALCOHOL ALCOHOLISM, V43, P398, DOI 10.1093/alcalc/agn015
   PITTS DK, 1987, PHARMACOL BIOCHEM BE, V26, P453, DOI 10.1016/0091-3057(87)90147-X
   PITTS DK, 1986, EUR J PHARMACOL, V131, P95, DOI 10.1016/0014-2999(86)90520-0
   Platt DM, 1999, J PHARMACOL EXP THER, V290, P1092
   Pockros LA, 2012, SYNAPSE, V66, P989, DOI 10.1002/syn.21592
   Pockros LA, 2011, PSYCHOPHARMACOLOGY, V213, P307, DOI 10.1007/s00213-010-2071-9
   Polina ER, 2009, DRUG ALCOHOL DEPEN, V101, P128, DOI 10.1016/j.drugalcdep.2008.11.001
   Popova NK, 2000, PHARMACOL BIOCHEM BE, V67, P719, DOI 10.1016/S0091-3057(00)00417-2
   PORRINO LJ, 1989, LIFE SCI, V45, P1529, DOI 10.1016/0024-3205(89)90418-9
   POWELL KR, 1994, BEHAV PHARMACOL, V5, P255
   PRADHAN S, 1978, LIFE SCI, V22, P1737, DOI 10.1016/0024-3205(78)90626-4
   Proudnikov D, 2006, PHARMACOGENET GENOM, V16, P25, DOI 10.1097/01.fpc.0000182782.87932.d6
   Przegalinski E, 2004, EUR NEUROPSYCHOPHARM, V14, P217, DOI 10.1016/S0924-977X(03)00106-8
   Przegalinski E, 2003, NEUROSCI LETT, V351, P169, DOI 10.1016/j.neulet.2003.08.007
   Przegalinski E, 2002, J PHYSIOL PHARMACOL, V53, P383
   Przegalinski E, 1997, BEHAV PHARMACOL, V8, P699, DOI 10.1097/00008877-199712000-00004
   Przegalinski E, 2001, EUR J PHARMACOL, V422, P91, DOI 10.1016/S0014-2999(01)01079-2
   Przegalinski E, 2001, BEHAV PHARMACOL, V12, P109, DOI 10.1097/00008877-200104000-00004
   Przegalinski E, 2000, LIFE SCI, V66, P1011, DOI 10.1016/S0024-3205(99)00666-9
   Przegalinski E, 2007, EUR J PHARMACOL, V559, P165, DOI 10.1016/j.ejphar.2006.12.012
   Pullagurla M, 2004, PHARMACOL BIOCHEM BE, V78, P263, DOI 10.1016/j.pbb.2004.03.017
   Pum M, 2007, PSYCHOPHARMACOLOGY, V193, P375, DOI 10.1007/s00213-007-0791-2
   Pum ME, 2008, NEUROSCIENCE, V153, P361, DOI 10.1016/j.neuroscience.2008.02.029
   Pum ME, 2008, PSYCHOPHARMACOLOGY, V201, P391, DOI 10.1007/s00213-008-1296-3
   Quarta D, 2007, PSYCHOPHARMACOLOGY, V193, P391, DOI 10.1007/s00213-007-0802-3
   Ramos M, 2005, NEUROPSYCHOPHARMACOL, V30, P2180, DOI 10.1038/sj.npp.1300735
   RAPOZA D, 1993, PHARMACOL BIOCHEM BE, V45, P179, DOI 10.1016/0091-3057(93)90102-Y
   Rasmussen H, 2009, AM J MED GENET B, V150B, P575, DOI 10.1002/ajmg.b.30880
   Rasmussen K, 1997, SYNAPSE, V27, P145, DOI 10.1002/(SICI)1098-2396(199710)27:2<145::AID-SYN5>3.0.CO;2-E
   Rasmussen K, 1997, PSYCHOPHARMACOLOGY, V133, P343, DOI 10.1007/s002130050411
   Rasmussen K, 2000, J PHARMACOL EXP THER, V294, P688
   Reavill C, 1998, EUR J PHARMACOL, V357, P115, DOI 10.1016/S0014-2999(98)00564-0
   REITH MEA, 1990, EUR J PHARMACOL, V186, P327, DOI 10.1016/0014-2999(90)90454-E
   Reith MEA, 1997, PSYCHOPHARMACOLOGY, V134, P309, DOI 10.1007/s002130050454
   Reuter M, 2007, NEUROPSYCHOBIOLOGY, V56, P47, DOI 10.1159/000110728
   Reveron ME, 2010, BEHAV BRAIN RES, V207, P500, DOI 10.1016/j.bbr.2009.10.038
   REZVANI AH, 1994, PHARMACOL BIOCHEM BE, V48, P105, DOI 10.1016/0091-3057(94)90505-3
   RIBEIRO EB, 1993, BRAIN RES, V621, P311, DOI 10.1016/0006-8993(93)90121-3
   Ricci LA, 2004, PHARMACOL BIOCHEM BE, V77, P415, DOI 10.1016/j.pbb.2003.10.005
   Richardson NR, 1996, J NEUROSCI METH, V66, P1, DOI 10.1016/0165-0270(95)00153-0
   Risch N, 2009, JAMA-J AM MED ASSOC, V301, P2462, DOI 10.1001/jama.2009.878
   RISNER ME, 1980, PSYCHOPHARMACOLOGY, V71, P83, DOI 10.1007/BF00433258
   RITZ MC, 1989, J PHARMACOL EXP THER, V248, P1010
   Robbins TW, 2008, ANN NY ACAD SCI, V1141, P1, DOI 10.1196/annals.1441.020
   Robbins TW, 1999, NATURE, V398, P567, DOI 10.1038/19208
   Robbins TW, 1996, CURR OPIN NEUROBIOL, V6, P228, DOI 10.1016/S0959-4388(96)80077-8
   Roberts DCS, 2002, DRUG ALCOHOL DEPEN, V67, P291, DOI 10.1016/S0376-8716(02)00083-2
   Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI 10.1146/annurev.psych.54.101601.145237
   Robinson TE, 2004, NEUROPHARMACOLOGY, V47, P33, DOI 10.1016/j.neuropharm.2004.06.025
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Rocha BA, 2002, J NEUROSCI, V22, P10039
   Rocha BA, 1998, NATURE, V393, P175, DOI 10.1038/30259
   Rocher C, 2001, N-S ARCH PHARMACOL, V363, P422
   Rodd ZA, 2005, J PHARMACOL EXP THER, V313, P134, DOI 10.1124/jpet.104.075952
   Rodd ZA, 2010, ALCOHOL, V44, P245, DOI 10.1016/j.alcohol.2010.01.002
   Rodd-Henricks ZA, 2000, ALCOHOL, V21, P73, DOI 10.1016/S0741-8329(00)00083-5
   Rodsiri R, 2011, PSYCHOPHARMACOLOGY, V213, P365, DOI 10.1007/s00213-010-1921-9
   Rose JS, 2003, AM J ADDICTION, V12, P253, DOI 10.1080/10550490390202776
   Rossi S, 2005, NEUROCHEM RES, V30, P541, DOI 10.1007/s11064-005-2689-x
   ROWLAND NE, 1992, ALCOHOL, V9, P559, DOI 10.1016/0741-8329(92)90097-T
   Rowlett JK, 2004, J PHARMACOL EXP THER, V310, P342, DOI 10.1124/jpet.104.065631
   Roychoudhury M, 1996, METHOD FIND EXP CLIN, V18, P677
   Rozeske RR, 2011, BEHAV BRAIN RES, V219, P378, DOI 10.1016/j.bbr.2011.01.030
   Ruedi-Bettschen D, 2010, PSYCHOPHARMACOLOGY, V210, P169, DOI 10.1007/s00213-009-1705-2
   Rueter LE, 1997, REV NEUROSCIENCE, V8, P117
   RUTTER JJ, 1995, SYNAPSE, V20, P225, DOI 10.1002/syn.890200306
   Rutter JJ, 1998, BRAIN RES, V798, P7, DOI 10.1016/S0006-8993(98)00320-5
   Sabol KE, 1998, BRAIN RES, V806, P69, DOI 10.1016/S0006-8993(98)00720-3
   Sachs BD, 2014, NEUROPHARMACOLOGY, V77, P177, DOI 10.1016/j.neuropharm.2013.09.010
   Saiz PA, 2008, EUR ADDICT RES, V14, P47, DOI 10.1159/000110410
   Saiz PA, 2009, PROG NEURO-PSYCHOPH, V33, P695, DOI 10.1016/j.pnpbp.2009.03.016
   Salomon L, 2007, PSYCHOPHARMACOLOGY, V194, P11, DOI 10.1007/s00213-007-0810-3
   Sanchis-Segura C, 2006, ADDICT BIOL, V11, P2, DOI 10.1111/j.1369-1600.2006.00012.x
   Sano K, 2008, NEUROSCIENCE, V151, P320, DOI 10.1016/j.neuroscience.2007.10.026
   Sari Y, 2013, J PSYCHOPHARMACOL, V27, P3, DOI 10.1177/0269881112463126
   SASAKI JE, 1995, PSYCHOPHARMACOLOGY, V120, P303, DOI 10.1007/BF02311178
   Sastre-Coll A, 2002, N-S ARCH PHARMACOL, V365, P210, DOI 10.1007/s00210-001-0508-8
   SATEL SL, 1995, AM J PSYCHIAT, V152, P778
   Saules KK, 2004, AM J ADDICTION, V13, P438, DOI 10.1080/10550490490512762
   Sawyer EK, 2012, NEUROPSYCHOPHARMACOL, V37, P1816, DOI 10.1038/npp.2012.29
   SCANZELLO CR, 1993, J PHARMACOL EXP THER, V264, P1484
   Scearce-Levie K, 1999, PSYCHOPHARMACOLOGY, V141, P154, DOI 10.1007/s002130050819
   Schama KF, 1997, PSYCHOPHARMACOLOGY, V132, P27, DOI 10.1007/s002130050316
   SCHECHTER MD, 1988, PHARMACOL BIOCHEM BE, V31, P817, DOI 10.1016/0091-3057(88)90390-5
   SCHECHTER MD, 1991, GEN PHARMACOL, V22, P889, DOI 10.1016/0306-3623(91)90226-V
   SCHECHTER MD, 1972, PSYCHOPHARMACOLOGIA, V24, P417, DOI 10.1007/BF00402536
   SCHECHTER MD, 1992, PHARMACOL BIOCHEM BE, V41, P807, DOI 10.1016/0091-3057(92)90231-4
   SCHEELKRUGER J, 1977, ADV BEHAV BIOL COCAI, P373
   Schenk S, 2011, BRIT J PHARMACOL, V162, P1770, DOI 10.1111/j.1476-5381.2010.01193.x
   Schenk S, 2000, PHARMACOL BIOCHEM BE, V67, P363, DOI 10.1016/S0091-3057(00)00377-4
   Schenk S, 2013, PSYCHOPHARMACOLOGY, V227, P355, DOI 10.1007/s00213-013-2980-5
   Schiffer WK, 2001, SYNAPSE, V42, P196, DOI 10.1002/syn.10000
   SCHMIDT CJ, 1988, EUR J PHARMACOL, V156, P121, DOI 10.1016/0014-2999(88)90154-9
   SCHMIDT CJ, 1987, BIOCHEM PHARMACOL, V36, P747, DOI 10.1016/0006-2952(87)90729-5
   SCHMIDT CJ, 1987, EUR J PHARMACOL, V136, P81, DOI 10.1016/0014-2999(87)90782-5
   Segal DS, 1997, J PHARMACOL EXP THER, V282, P561
   SEGAL DS, 1975, SCIENCE, V190, P475, DOI 10.1126/science.1166317
   SEIDEN LS, 1993, ANNU REV PHARMACOL, V33, P639, DOI 10.1146/annurev.pharmtox.33.1.639
   Selim M, 1996, BRAIN RES, V716, P157, DOI 10.1016/0006-8993(95)01385-7
   SELLERS EM, 1994, ALCOHOL CLIN EXP RES, V18, P879, DOI 10.1111/j.1530-0277.1994.tb00054.x
   Semba J, 2008, PSYCHIAT CLIN NEUROS, V62, P435, DOI 10.1111/j.1440-1819.2008.01822.x
   Semenova S, 2010, EUR NEUROPSYCHOPHARM, V20, P731, DOI 10.1016/j.euroneuro.2010.05.003
   Seneviratne C, 2013, HUM GENET, V132, P1165, DOI 10.1007/s00439-013-1319-y
   Seneviratne C, 2009, ALCOHOL CLIN EXP RES, V33, P332, DOI 10.1111/j.1530-0277.2008.00837.x
   SERIES HG, 1994, PSYCHOPHARMACOLOGY, V116, P508, DOI 10.1007/BF02247485
   Serretti A, 2009, PSYCHIAT RES, V167, P106, DOI 10.1016/j.psychres.2007.12.006
   Sershen H, 1996, PHARMACOL BIOCHEM BE, V53, P863
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   Shankar Ravi P., 2000, Indian Journal of Physiology and Pharmacology, V44, P355
   Shearman E, 2005, NEUROCHEM RES, V30, P1055, DOI 10.1007/s11064-005-7132-9
   Shelton KL, 2013, DRUG ALCOHOL DEPEN, V129, P210, DOI 10.1016/j.drugalcdep.2013.01.003
   SHIMIZU N, 1992, BRAIN RES BULL, V28, P727, DOI 10.1016/0361-9230(92)90252-S
   Shioe K, 2003, SYNAPSE, V48, P184, DOI 10.1002/syn.10204
   SHUSTER L, 1977, PSYCHOPHARMACOLOGY, V52, P185, DOI 10.1007/BF00439108
   Sills TL, 1999, PSYCHOPHARMACOLOGY, V141, P421, DOI 10.1007/s002130050852
   Sills TL, 1999, PSYCHOPHARMACOLOGY, V143, P426, DOI 10.1007/s002130050968
   Sills TL, 2000, BEHAV PHARMACOL, V11, P109, DOI 10.1097/00008877-200004000-00002
   Sills TL, 1997, EUR J PHARMACOL, V337, P161, DOI 10.1016/S0014-2999(97)01308-3
   SILVERSTONE PH, 1992, INT CLIN PSYCHOPHARM, V7, P37, DOI 10.1097/00004850-199200710-00005
   Singer S, 2004, NEUROCHEM RES, V29, P1779, DOI 10.1023/B:NERE.0000035814.45494.15
   Singh VP, 2003, METHOD FIND EXP CLIN, V25, P273, DOI 10.1358/mf.2003.25.4.769675
   Sizemore GM, 2000, PSYCHOPHARMACOLOGY, V150, P391, DOI 10.1007/s002130000456
   Smith AD, 1999, J PHARMACOL EXP THER, V288, P1223
   SMITH FL, 1986, PHARMACOL BIOCHEM BE, V25, P849, DOI 10.1016/0091-3057(86)90397-7
   SMITH JE, 1987, PHARMACOL BIOCHEM BE, V26, P607, DOI 10.1016/0091-3057(87)90173-0
   Solinas M, 2008, P NATL ACAD SCI USA, V105, P17145, DOI 10.1073/pnas.0806889105
   Sora I, 2001, P NATL ACAD SCI USA, V98, P5300, DOI 10.1073/pnas.091039298
   Sora I, 1998, P NATL ACAD SCI USA, V95, P7699, DOI 10.1073/pnas.95.13.7699
   SORENSEN SM, 1993, J PHARMACOL EXP THER, V266, P684
   Soto PL, 2009, BEHAV PHARMACOL, V20, P759, DOI 10.1097/FBP.0b013e328333a267
   Spanagel R, 2009, PHYSIOL REV, V89, P649, DOI 10.1152/physrev.00013.2008
   SPEALMAN RD, 1993, PSYCHOPHARMACOLOGY, V112, P93, DOI 10.1007/BF02247368
   Sperling R, 2011, EUR J NEUROSCI, V33, P1866, DOI 10.1111/j.1460-9568.2011.07677.x
   SPRING B, 1991, HEALTH PSYCHOL, V10, P216, DOI 10.1037/0278-6133.10.3.216
   SPRING B, 1995, AM J CLIN NUTR, V62, P1181, DOI 10.1093/ajcn/62.6.1181
   Spring B, 2007, J CONSULT CLIN PSYCH, V75, P85, DOI 10.1037/0022-006X.75.1.85
   SPROUSE JS, 1990, EUR J PHARMACOL, V178, P313, DOI 10.1016/0014-2999(90)90110-R
   SPROUSE JS, 1989, EUR J PHARMACOL, V167, P375, DOI 10.1016/0014-2999(89)90446-9
   SPYRAKI C, 1988, BEHAV BRAIN RES, V29, P127, DOI 10.1016/0166-4328(88)90060-5
   SPYRAKI C, 1987, BEHAV BRAIN RES, V26, P57, DOI 10.1016/0166-4328(87)90016-7
   Staiti AM, 2011, NEUROPHARMACOLOGY, V61, P544, DOI 10.1016/j.neuropharm.2011.04.005
   Starr MA, 2008, J PHARMACOL EXP THER, V327, P20, DOI 10.1124/jpet.108.139337
   Starr MA, 2012, J PHARMACOL EXP THER, V340, P73, DOI 10.1124/jpet.111.185728
   Staub DR, 2012, PSYCHONEUROENDOCRINO, V37, P859, DOI 10.1016/j.psyneuen.2011.10.002
   Steed E, 2011, BEHAV BRAIN RES, V220, P9, DOI 10.1016/j.bbr.2011.01.026
   STOLERMAN IP, 1983, NEUROPHARMACOLOGY, V22, P1029, DOI 10.1016/0028-3908(83)90021-7
   Storvik M, 2012, PSYCHIAT RES-NEUROIM, V202, P264, DOI 10.1016/j.pscychresns.2011.11.001
   Subhan F, 2000, EUR J PHARMACOL, V390, P137, DOI 10.1016/S0014-2999(99)00909-7
   Sudakov SK, 2007, B EXP BIOL MED+, V144, P210, DOI 10.1007/s10517-007-0291-8
   Suemaru K, 2001, PSYCHOPHARMACOLOGY, V159, P38, DOI 10.1007/s002130100866
   SUMMERS KL, 1995, NEUROCHEM RES, V20, P753, DOI 10.1007/BF01705545
   Suriyaprom K, 2012, GENET MOL RES, V11, P4360, DOI 10.4238/2012.October.15.2
   Suzuki T, 1992, Yakubutsu Seishin Kodo, V12, P33
   Suzuki T, 1997, LIFE SCI, V61, pPL249, DOI 10.1016/S0024-3205(97)00745-5
   SVENSSON L, 1993, ALCOHOL, V10, P219, DOI 10.1016/0741-8329(93)90039-Q
   SVINGOS AL, 1992, PHARMACOL BIOCHEM BE, V43, P871, DOI 10.1016/0091-3057(92)90420-K
   Szumlinski KK, 2004, NEUROPSYCHOPHARMACOL, V29, P1675, DOI 10.1038/sj.npp.1300473
   Szumlinski KK, 2003, PSYCHOPHARMACOLOGY, V165, P329, DOI 10.1007/s00213-002-1274-0
   Takamatsu Y, 2011, CURR NEUROPHARMACOL, V9, P68, DOI 10.2174/157015911795017236
   Takamatsu Y, 2006, ANN NY ACAD SCI, V1074, P295, DOI 10.1196/annals.1369.026
   Tan EC, 1999, MOL PSYCHIATR, V4, P215, DOI 10.1038/sj.mp.4000541
   TAO R, 1995, NEUROSCIENCE, V68, P553, DOI 10.1016/0306-4522(95)00154-B
   Tao R, 2002, J PHARMACOL EXP THER, V303, P704, DOI 10.1124/jpet.102.038133
   Tao R, 1998, J PHARMACOL EXP THER, V286, P481
   TAO R, 1994, J NEUROCHEM, V63, P517
   Taylor BK, 2003, J NEUROCHEM, V86, P1129, DOI 10.1046/j.1471-4159.2003.01907.x
   Teneud LM, 1996, PHARMACOL BIOCHEM BE, V53, P747, DOI 10.1016/0091-3057(95)02087-X
   Thielen RJ, 2002, PHARMACOL BIOCHEM BE, V71, P111, DOI 10.1016/S0091-3057(01)00633-5
   Thielen RJ, 2001, ALCOHOL, V23, P131, DOI 10.1016/S0741-8329(01)00126-4
   Thompson PM, 2012, ACTA PSYCHIAT SCAND, V126, P165, DOI 10.1111/j.1600-0447.2011.01816.x
   Thomsen M, 2009, J NEUROSCI, V29, P1087, DOI 10.1523/JNEUROSCI.4037-08.2009
   Tizabi Y, 2001, PROG NEURO-PSYCHOPH, V25, P1445, DOI 10.1016/S0278-5846(01)00194-4
   TOMKINS DM, 1994, PSYCHOPHARMACOLOGY, V115, P173, DOI 10.1007/BF02244769
   Tomkins DM, 2002, PHARMACOL BIOCHEM BE, V71, P735, DOI 10.1016/S0091-3057(01)00710-9
   Tomkins DM, 2000, PHARMACOL BIOCHEM BE, V66, P129, DOI 10.1016/S0091-3057(00)00232-X
   TOTH E, 1992, NEUROCHEM RES, V17, P265, DOI 10.1007/BF00966669
   Touiki K, 2008, PHARMACOL BIOCHEM BE, V89, P338, DOI 10.1016/j.pbb.2008.01.005
   Tran-Nguyen LTL, 1999, PSYCHOPHARMACOLOGY, V146, P60, DOI 10.1007/s002130051088
   Tran-Nguyen LTL, 2001, PSYCHOPHARMACOLOGY, V157, P340, DOI 10.1007/s002130100822
   Trigo JM, 2007, BIOL PSYCHIAT, V62, P669, DOI 10.1016/j.biopsych.2006.11.005
   Tristan-Noguero A, 2013, PSYCHIAT RES, V210, P1287, DOI 10.1016/j.psychres.2013.09.004
   Trummer O, 2006, PHARMACOGENOMICS J, V6, P397, DOI 10.1038/sj.tpj.6500389
   Tzschentke TM, 2007, ADDICT BIOL, V12, P227, DOI 10.1111/j.1369-1600.2007.00070.x
   Vaht M, 2014, PSYCHOPHARM IN PRESS
   van den Buuse M, 2011, NEUROPHARMACOLOGY, V61, P209, DOI 10.1016/j.neuropharm.2011.04.001
   van der Zwaluw CS, 2010, DRUG ALCOHOL DEPEN, V112, P134, DOI 10.1016/j.drugalcdep.2010.06.001
   Van Dyck CH, 2004, AM J PSYCHIAT, V161, P525, DOI 10.1176/appi.ajp.161.3.525
   van Gaalen MM, 2010, INT J NEUROPSYCHOPH, V13, P961, DOI 10.1017/S1461145710000428
   van Wel JHP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040187
   Vanderschuren LJMJ, 2000, PSYCHOPHARMACOLOGY, V151, P99, DOI 10.1007/s002130000493
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   VANWIJNGAARDEN I, 1990, EUR J PHARM-MOLEC PH, V188, P301, DOI 10.1016/0922-4106(90)90190-9
   Veletza S, 2009, SYNAPSE, V63, P193, DOI 10.1002/syn.20598
   Villegier AS, 2006, NEUROPSYCHOPHARMACOL, V31, P1704, DOI 10.1038/sj.npp.1300987
   Vollenweider FX, 1998, NEUROPSYCHOPHARMACOL, V19, P241, DOI 10.1038/sj.npp.1395197
   Wagner FA, 2002, NEUROPSYCHOPHARMACOL, V26, P479, DOI 10.1016/S0893-133X(01)00367-0
   Waldorf D., 1991, COCAINE CHANGES EXPE
   WALSH SL, 1994, J CLIN PSYCHOPHARM, V14, P396
   WANG Y, 1995, PSYCHOPHARMACOLOGY, V120, P134, DOI 10.1007/BF02246185
   Watanabe Y, 2013, INT J NEUROPSYCHOPH, P1
   Waters KA, 2012, BEHAV BRAIN RES, V228, P211, DOI 10.1016/j.bbr.2011.12.009
   Weinstein AM, 2014, AM J DRUG ALCOHOL AB, V40, P16, DOI 10.3109/00952990.2013.819362
   West R, 1996, PSYCHOPHARMACOLOGY, V126, P95, DOI 10.1007/BF02246417
   WEST WB, 1995, PHARMACOL BIOCHEM BE, V51, P69, DOI 10.1016/0091-3057(94)00361-L
   White MJ, 2011, DRUG ALCOHOL DEPEN, V114, P140, DOI 10.1016/j.drugalcdep.2010.08.014
   White NM, 1996, ADDICTION, V91, P921, DOI 10.1111/j.1360-0443.1996.tb03586.x
   Whitelaw RB, 1996, PSYCHOPHARMACOLOGY, V127, P213, DOI 10.1007/BF02805996
   Wiens F, 2008, P NATL ACAD SCI USA, V105, P10426, DOI 10.1073/pnas.0801628105
   Will MJ, 2004, PSYCHOPHARMACOLOGY, V171, P191, DOI 10.1007/s00213-003-1572-1
   Wilson AW, 1996, ALCOHOL, V13, P407, DOI 10.1016/0741-8329(95)02110-8
   Winstanley EL, 2011, J SUBST ABUSE TREAT, V40, P255, DOI 10.1016/j.jsat.2010.11.010
   WINTER JC, 1977, PSYCHOPHARMACOLOGY, V53, P159, DOI 10.1007/BF00426486
   Wise RA, 2002, NEURON, V36, P229, DOI 10.1016/S0896-6273(02)00965-0
   Witkin JM, 1999, J PHARMACOL EXP THER, V288, P1298
   Wooters Thomas E, 2009, Curr Drug Abuse Rev, V2, P243
   Wrzosek M, 2012, PHARMACOL REP, V64, P449
   Xiong W, 2011, NEUROSCIENCE, V184, P28, DOI 10.1016/j.neuroscience.2011.03.066
   YAMAMOTO BK, 1995, J PHARMACOL EXP THER, V273, P1063
   Yan QS, 1999, ALCOHOL, V19, P1, DOI 10.1016/S0741-8329(99)00006-3
   Yang KHS, 2010, NEUROSCIENCE, V171, P40, DOI 10.1016/j.neuroscience.2010.08.044
   Yang KH, 2010, J PHARMACOL EXP THER, V333, P547, DOI 10.1124/jpet.109.162594
   Yang ZL, 2013, DRUG ALCOHOL DEPEN, V129, P217, DOI 10.1016/j.drugalcdep.2012.12.007
   Yang ZJ, 1999, PHARMACOL BIOCHEM BE, V64, P155, DOI 10.1016/S0091-3057(99)00111-2
   Yasuda K, 2002, N-S ARCH PHARMACOL, V366, P276, DOI 10.1007/s00210-002-0592-4
   YEH SY, 1991, PHARMACOL BIOCHEM BE, V39, P723, DOI 10.1016/0091-3057(91)90154-T
   YOKEL RA, 1973, J PHARMACOL EXP THER, V187, P27
   Yoo JH, 2006, J NEUROCHEM, V99, P976, DOI 10.1111/j.1471-4159.2006.04137.x
   Yoshimoto K, 2000, NEUROCHEM INT, V37, P369, DOI 10.1016/S0197-0186(00)00037-1
   YOSHIMOTO K, 1992, ALCOHOL, V9, P17, DOI 10.1016/0741-8329(92)90004-T
   YOSHIMOTO K, 1992, ALCOHOL CLIN EXP RES, V16, P781, DOI 10.1111/j.1530-0277.1992.tb00678.x
   YOSHIMOTO K, 1987, PHARMACOL BIOCHEM BE, V27, P317
   Yoshimoto K, 2012, EUR J NEUROSCI, V35, P1368, DOI 10.1111/j.1460-9568.2012.08037.x
   Young R, 2006, PHARMACOL BIOCHEM BE, V85, P170, DOI 10.1016/j.pbb.2006.07.029
   Young R, 2006, PHARMACOL BIOCHEM BE, V83, P612, DOI 10.1016/j.pbb.2006.03.025
   YU DSL, 1986, LIFE SCI, V39, P1383, DOI 10.1016/0024-3205(86)90337-1
   Yubero-Lahoz S, 2012, EUR J PHARMACOL, V674, P337, DOI 10.1016/j.ejphar.2011.10.033
   Zaniewska M, 2007, EUR J PHARMACOL, V571, P156, DOI 10.1016/j.ejphar.2007.05.067
   Zaniewska M, 2010, SYNAPSE, V64, P511, DOI 10.1002/syn.20756
   Zaniewska M, 2010, NEUROPHARMACOLOGY, V58, P1140, DOI 10.1016/j.neuropharm.2010.02.006
   Zavitsanou K, 2010, NEUROSCIENCE, V169, P315, DOI 10.1016/j.neuroscience.2010.04.005
   Zayara AE, 2011, PSYCHOPHARMACOLOGY, V213, P321, DOI 10.1007/s00213-010-1996-3
   Zhang XW, 2007, NEUROPSYCHOPHARMACOL, V32, P377, DOI 10.1038/sj.npp.1301101
   ZHOU FC, 1991, ALCOHOL, V8, P425, DOI 10.1016/S0741-8329(91)90034-T
   ZHOU FC, 1994, ALCOHOL CLIN EXP RES, V18, P571, DOI 10.1111/j.1530-0277.1994.tb00912.x
   Zhou Q, 1998, J PHYSIOL-LONDON, V507, P335, DOI 10.1111/j.1469-7793.1998.335bt.x
   Zorick T, 2011, DRUG ALCOHOL DEPEN, V118, P500, DOI 10.1016/j.drugalcdep.2011.04.015
NR 803
TC 205
Z9 213
U1 1
U2 201
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-4328
EI 1872-7549
J9 BEHAV BRAIN RES
JI Behav. Brain Res.
PD JAN 15
PY 2015
VL 277
SI SI
BP 146
EP 192
DI 10.1016/j.bbr.2014.04.007
PG 47
WC Behavioral Sciences; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Behavioral Sciences; Neurosciences & Neurology
GA AU7UG
UT WOS:000345806000014
PM 24769172
DA 2023-06-23
ER

PT J
AU Laakso, A
   Mohn, AR
   Gainetdinov, RR
   Caron, MG
AF Laakso, A
   Mohn, AR
   Gainetdinov, RR
   Caron, MG
TI Experimental genetic approaches to addiction
SO NEURON
LA English
DT Review
ID RECEPTOR MUTANT MICE; RECOMBINANT INBRED MICE; KNOCK-OUT MICE; INCREASE
   EXTRACELLULAR DOPAMINE; CONDITIONED PLACE PREFERENCE; PROTEIN-COUPLED
   RECEPTORS; MAMMALIAN CIRCADIAN CLOCK; NUCLEUS-ACCUMBENS; BEHAVIORAL
   SENSITIZATION; DEFICIENT MICE
AB Drugs of abuse are able to elicit compulsive drug-seeking behaviors upon repeated administration, which ultimately leads to the phenomenon of addiction. Evidence indicates that the susceptibility to develop addiction is influenced by sources of reinforcement, variable neuroadaptive mechanisms, and neurochemical changes that together lead to altered homeostasis of the brain reward system. Addiction is hypothesized to be a cycle of progressive dysregulation of the brain reward system that results in the compulsive use and loss of control over drug taking and the initiation of behaviors associated with drug seeking (Koob et al., 1998). The view that addiction represents a pathological state of reward provides an approach to identifying the factors that contribute to vulnerability, addiction, and relapse in genetic animal models.
C1 Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Dept Cell Biol, Durham, NC 27710 USA.
C3 Duke University
RP Caron, MG (通讯作者)，Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Dept Cell Biol, Durham, NC 27710 USA.
EM caron002@mc.duke.edu
RI Gainetdinov, Raul R/G-5875-2011
OI Gainetdinov, Raul R/0000-0003-2951-6038; Laakso,
   Aki/0000-0002-5312-4926; Ramsey, Amy/0000-0002-2717-5279
FU NIDA NIH HHS [DA-13511] Funding Source: Medline; NIMH NIH HHS [MH-40159]
   Funding Source: Medline; NINDS NIH HHS [NS-19576] Funding Source:
   Medline
CR Abarca C, 2002, P NATL ACAD SCI USA, V99, P9026, DOI 10.1073/pnas.142039099
   Alexander RC, 1996, NEUROPSYCHOPHARMACOL, V15, P484, DOI 10.1016/S0893-133X(96)00058-9
   AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445
   Andretic R, 1999, SCIENCE, V285, P1066, DOI 10.1126/science.285.5430.1066
   Ang E, 2001, J NEUROCHEM, V79, P221, DOI 10.1046/j.1471-4159.2001.00563.x
   Bainton RJ, 2000, CURR BIOL, V10, P187, DOI 10.1016/S0960-9822(00)00336-5
   BELKNAP JK, 1992, ANN NY ACAD SCI, V654, P311, DOI 10.1111/j.1749-6632.1992.tb25977.x
   Bengel D, 1998, MOL PHARMACOL, V53, P649, DOI 10.1124/mol.53.4.649
   Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9
   Beurrier C, 2002, J NEUROSCI, V22, P5817
   Bibb JA, 2001, NATURE, V410, P376, DOI 10.1038/35066591
   BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055
   Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086
   Brandon EP, 1998, J NEUROSCI, V18, P3639
   Budygin EA, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-10-j0002.2002
   Caine SB, 2002, J NEUROSCI, V22, P2977, DOI 10.1523/JNEUROSCI.22-07-02977.2002
   Caine SB, 1999, PSYCHOPHARMACOLOGY, V147, P22, DOI 10.1007/s002130051134
   Carboni E, 2001, J NEUROSCI, V21
   Carlezon WA, 1998, SCIENCE, V282, P2272, DOI 10.1126/science.282.5397.2272
   CARLSSON A, 1987, ANNU REV NEUROSCI, V10, P19
   Carta AR, 2000, NEUROREPORT, V11, P2395, DOI 10.1097/00001756-200008030-00012
   Cha XY, 1997, J NEUROSCI, V17, P6864
   Chausmer AL, 2002, PSYCHOPHARMACOLOGY, V163, P54, DOI 10.1007/s00213-002-1142-y
   Chen JF, 2000, NEUROSCIENCE, V97, P195, DOI 10.1016/S0306-4522(99)00604-1
   Chiamulera C, 2001, NAT NEUROSCI, V4, P873, DOI 10.1038/nn0901-873
   Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5
   Comings DE, 1998, ALCOHOL, V16, P61, DOI 10.1016/S0741-8329(97)00178-X
   Crabbe JC, 1998, DRUG ALCOHOL DEPEN, V51, P61, DOI 10.1016/S0376-8716(98)00066-0
   Darland T, 2001, P NATL ACAD SCI USA, V98, P11691, DOI 10.1073/pnas.191380698
   Darracq L, 1998, J NEUROSCI, V18, P2729
   Di Chiara G, 1999, ANN NY ACAD SCI, V877, P461
   Diaz J, 2000, J NEUROSCI, V20, P8677
   DICHIARA G, 1992, TRENDS PHARMACOL SCI, V13, P185
   Douglass J, 1996, GENE, V169, P241, DOI 10.1016/0378-1119(96)88651-3
   Drouin C, 2002, J NEUROSCI, V22, P2873, DOI 10.1523/JNEUROSCI.22-07-02873.2002
   Duaux E, 2000, EUR PSYCHIAT, V15, P109, DOI 10.1016/S0924-9338(00)00204-2
   Elmer GI, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-10-j0004.2002
   Fienberg AA, 1998, SCIENCE, V281, P838, DOI 10.1126/science.281.5378.838
   Fon EA, 1997, NEURON, V19, P1271, DOI 10.1016/S0896-6273(00)80418-3
   Gainetdinov Raul R., 1999, Science (Washington D C), V283, P397, DOI 10.1126/science.283.5400.397
   Gainetdinov RR, 2002, TRENDS PHARMACOL SCI, V23, P367, DOI 10.1016/S0165-6147(02)02044-8
   GAINETDINOV RR, 2002, PHARMACOLOGIST, V44
   Gerber DJ, 2001, P NATL ACAD SCI USA, V98, P15312, DOI 10.1073/pnas.261583798
   Gerlai R, 2000, PHARMACOL BIOCHEM BE, V67, P773, DOI 10.1016/S0091-3057(00)00422-6
   Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0
   Greengard P, 2001, SCIENCE, V294, P1024, DOI 10.1126/science.294.5544.1024
   Hall FS, 2002, NEUROSCIENCE, V115, P153, DOI 10.1016/S0306-4522(02)00379-2
   Hiroi N, 1997, P NATL ACAD SCI USA, V94, P10397, DOI 10.1073/pnas.94.19.10397
   HITOTSUMACHI S, 1985, P NATL ACAD SCI USA, V82, P6619, DOI 10.1073/pnas.82.19.6619
   Holmes A, 2001, BEHAV NEUROSCI, V115, P1129, DOI 10.1037//0735-7044.115.5.1129
   Horger BA, 1999, J NEUROSCI, V19, P4110
   Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560
   INADA T, 1992, NEUROPHARMACOLOGY, V31, P701, DOI 10.1016/0028-3908(92)90149-J
   Izenwasser S, 2002, PHARMACOL BIOCHEM BE, V73, P877, DOI 10.1016/S0091-3057(02)00942-5
   Jiang MS, 2001, P NATL ACAD SCI USA, V98, P3577, DOI 10.1073/pnas.051632598
   Jones S, 2000, J NEUROSCI, V20, P5575, DOI 10.1523/JNEUROSCI.20-15-05575.2000
   Jones SR, 1998, J NEUROSCI, V18, P1979
   Joseph JD, 2002, NEUROSCIENCE, V112, P39, DOI 10.1016/S0306-4522(02)00067-2
   Justice MJ, 1999, HUM MOL GENET, V8, P1955, DOI 10.1093/hmg/8.10.1955
   Karper PE, 2002, PSYCHOPHARMACOLOGY, V159, P407, DOI 10.1007/s00213-001-0936-7
   Kelley AE, 2002, J NEUROSCI, V22, P3306
   Kelly MA, 1998, J NEUROSCI, V18, P3470
   Kelz MB, 1999, NATURE, V401, P272, DOI 10.1038/45790
   King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7
   KING GR, 1992, PHARMACOL BIOCHEM BE, V43, P243, DOI 10.1016/0091-3057(92)90664-2
   Koeltzow TE, 1998, J NEUROSCI, V18, P2231
   Koks S, 2001, PSYCHOPHARMACOLOGY, V158, P198, DOI 10.1007/s002130100855
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Krezel W, 1998, SCIENCE, V279, P863, DOI 10.1126/science.279.5352.863
   KUCZENSKI R, 1991, J NEUROSCI, V11, P2703
   KUZMIN A, 1992, PHARMACOL BIOCHEM BE, V41, P497, DOI 10.1016/0091-3057(92)90363-K
   Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401
   Littleton J, 2000, ADDICTION, V95, pS83
   Maldonado R, 1996, SCIENCE, V273, P657, DOI 10.1126/science.273.5275.657
   Maldonado R, 1997, NATURE, V388, P586, DOI 10.1038/41567
   Mao L, 2001, NEUROSCIENCE, V106, P303, DOI 10.1016/S0306-4522(01)00284-6
   Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0
   MCCLEARN GE, 1959, Q J STUD ALCOHOL, V20, P691
   McClung C, 1999, CURR BIOL, V9, P853, DOI 10.1016/S0960-9822(99)80389-3
   McClung C, 1998, CURR BIOL, V8, P109, DOI 10.1016/S0960-9822(98)70041-7
   Messer CJ, 2000, NEURON, V26, P247, DOI 10.1016/S0896-6273(00)81154-X
   Miner LL, 1995, NEUROREPORT, V6, P2314, DOI 10.1097/00001756-199511270-00011
   MINER LL, 1995, PSYCHOPHARMACOLOGY, V122, P209, DOI 10.1007/BF02246541
   Mohn AR, 1999, CELL, V98, P427, DOI 10.1016/S0092-8674(00)81972-8
   Moore MS, 1998, CELL, V93, P997, DOI 10.1016/S0092-8674(00)81205-2
   Moratalla R, 1996, P NATL ACAD SCI USA, V93, P14928, DOI 10.1073/pnas.93.25.14928
   Moron JA, 2002, J NEUROSCI, V22, P389, DOI 10.1523/JNEUROSCI.22-02-00389.2002
   Murtra P, 2000, NATURE, V405, P180, DOI 10.1038/35012069
   Nestler EJ, 2000, NAT GENET, V26, P277, DOI 10.1038/81570
   Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58
   Nestler EJ, 2001, P NATL ACAD SCI USA, V98, P11042, DOI 10.1073/pnas.191352698
   Nestler EJ, 2001, J NEUROSCI, V21, P8324, DOI 10.1523/JNEUROSCI.21-21-08324.2001
   Park SK, 2000, J BIOL CHEM, V275, P20588, DOI 10.1074/jbc.M002460200
   Phillips TJ, 1998, J NEUROSCI, V18, P3023
   Picciotto MR, 1998, NATURE, V391, P173, DOI 10.1038/34413
   Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577
   POLLI JW, 1994, J NEUROSCI, V14, P1251, DOI 10.1523/JNEUROSCI.14-03-01251.1994
   Pontieri FE, 1995, P NATL ACAD SCI USA, V92, P12304, DOI 10.1073/pnas.92.26.12304
   Porrino LJ, 2000, CEREB CORTEX, V10, P326, DOI 10.1093/cercor/10.3.326
   POST RM, 1976, NATURE, V260, P731, DOI 10.1038/260731a0
   Pulvirenti L, 2002, TRENDS PHARMACOL SCI, V23, P151, DOI 10.1016/S0165-6147(00)01991-X
   Reed TM, 2002, J NEUROSCI, V22, P5188, DOI 10.1523/JNEUROSCI.22-12-05188.2002
   Resnick A, 1999, J NEUROCHEM, V73, P1539, DOI 10.1046/j.1471-4159.1999.0731539.x
   Ripley TL, 1999, BRAIN RES, V826, P117, DOI 10.1016/S0006-8993(99)01280-9
   Risinger FO, 2000, PSYCHOPHARMACOLOGY, V152, P343, DOI 10.1007/s002130000548
   Robbins TW, 1999, NATURE, V398, P567, DOI 10.1038/19208
   Rocha BA, 1998, NAT NEUROSCI, V1, P132, DOI 10.1038/381
   Rocha BA, 1998, NATURE, V393, P175, DOI 10.1038/30259
   ROSSETTI ZL, 1991, EUR J PHARMACOL, V201, P243, DOI 10.1016/0014-2999(91)90353-R
   Roth Robert H., 1995, P227
   Rubinstein M, 1997, CELL, V90, P991, DOI 10.1016/S0092-8674(00)80365-7
   Sallinen J, 1998, NEUROSCIENCE, V86, P959, DOI 10.1016/S0306-4522(98)00100-6
   Shalev U, 2002, PHARMACOL REV, V54, P1, DOI 10.1124/pr.54.1.1
   Sora I, 2001, P NATL ACAD SCI USA, V98, P5300, DOI 10.1073/pnas.091039298
   Sora I, 1998, P NATL ACAD SCI USA, V95, P7699, DOI 10.1073/pnas.95.13.7699
   SPYRAKI C, 1981, EUR J PHARMACOL, V74, P195, DOI 10.1016/0014-2999(81)90531-8
   Steckler T, 1999, BEHAV BRAIN RES, V102, P151, DOI 10.1016/S0166-4328(99)00003-0
   Takahashi N, 1997, P NATL ACAD SCI USA, V94, P9938, DOI 10.1073/pnas.94.18.9938
   Thomas MJ, 2001, NAT NEUROSCI, V4, P1217, DOI 10.1038/nn757
   TOLLIVER BK, 1994, J PHARMACOL EXP THER, V270, P1230
   Tzschentke TM, 1998, TRENDS PHARMACOL SCI, V19, P447, DOI 10.1016/S0165-6147(98)01255-3
   Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077
   Vanderschuren LJMJ, 2000, PSYCHOPHARMACOLOGY, V151, P99, DOI 10.1007/s002130000493
   Vekovischeva OY, 2001, J NEUROSCI, V21, P4451, DOI 10.1523/JNEUROSCI.21-12-04451.2001
   VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325
   Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI 10.1093/cercor/10.3.318
   Wang XB, 1997, J NEUROSCI, V17, P5993
   Wang YM, 1997, NEURON, V19, P1285, DOI 10.1016/S0896-6273(00)80419-5
   White FJ, 1998, DRUG ALCOHOL DEPEN, V51, P141, DOI 10.1016/S0376-8716(98)00072-6
   Wise RA, 1996, CURR OPIN NEUROBIOL, V6, P243, DOI 10.1016/S0959-4388(96)80079-1
   Wolf ME, 1998, PROG NEUROBIOL, V54, P679, DOI 10.1016/S0301-0082(97)00090-7
   Wolf ME, 1999, CURR BIOL, V9, pR770, DOI 10.1016/S0960-9822(00)80009-3
   WOOLVERTON WL, 1992, TRENDS PHARMACOL SCI, V13, P193, DOI 10.1016/0165-6147(92)90063-C
   Xu F, 2000, NAT NEUROSCI, V3, P465, DOI 10.1038/74839
   XU M, 1994, CELL, V79, P945, DOI 10.1016/0092-8674(94)90026-4
   Xu M, 1997, NEURON, V19, P837, DOI 10.1016/S0896-6273(00)80965-4
   Xu M, 2000, BRAIN RES, V852, P198, DOI 10.1016/S0006-8993(99)02258-1
   Yang J, 2000, P NATL ACAD SCI USA, V97, P9984, DOI 10.1073/pnas.180194597
   Zachariou V, 2001, NEUROPSYCHOPHARMACOL, V24, P576, DOI 10.1016/S0893-133X(00)00224-4
   Zachariou V, 2002, BIOL PSYCHIAT, V51, P612, DOI 10.1016/S0006-3223(01)01318-X
   Zheng BH, 2001, CELL, V105, P683, DOI 10.1016/S0092-8674(01)00380-4
   Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118
   Zhuang XX, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-16-j0001.2000
NR 143
TC 71
Z9 72
U1 0
U2 4
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0896-6273
EI 1097-4199
J9 NEURON
JI Neuron
PD OCT 10
PY 2002
VL 36
IS 2
BP 213
EP 228
DI 10.1016/S0896-6273(02)00972-8
PG 16
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 603JA
UT WOS:000178554700004
PM 12383778
OA Bronze
DA 2023-06-23
ER

PT J
AU Liu, Y
   Liang, JC
   Zhao, CZ
   Zhou, WH
AF Liu, Yu
   Liang, Juncheng
   Zhao, Chengzheng
   Zhou, Wenhua
TI Looking for a solution for drug addiction in China: Exploring the
   challenges and opportunities in the way of China's new Drug Control Law
SO INTERNATIONAL JOURNAL OF DRUG POLICY
LA English
DT Editorial Material
DE Drug Control; Detoxification; Addiction; Treatment; Community
ID HARM REDUCTION; ABUSE; POLICY; DEPENDENCE; HIV/AIDS; SCIENCE; COCAINE;
   USERS
AB In the wake of the deteriorating situation of drug addiction and related infectious diseases among injecting drug users (IDUs) in China in recent years, the Standing Committee of the National People's Congress of China adopted the new Drug Control Law which came into force in June 1, 2008. This law is part of a broad reform movement in China where drug addiction is no longer understood as simply a legal or moral issue but rather, as a complicated medical condition requiring comprehensive therapeutic strategies. Although the Drug Control Law draws a distinct line from previous Drug Control regulations in the country, there have still been dilemmas along the implementation process. This paper is intended to elaborate on the general principles of China's latest Drug Control Law from the point of view of scholars who are involved in the field of drug addiction research and treatment in China. This paper will also discuss the challenges we are currently facing, based on the observations and practical experiences the authors have obtained in China. It is hoped that by addressing these issues, we will be able to implement the new Drug Control Law more successfully and ensure that we deal more effectively with drug addiction in China. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Zhou, Wenhua] Ningbo Univ, Sch Med, Lab Behav Neurosci, Ningbo Addict Treatment & Res Ctr, Ningbo 315010, Zhejiang, Peoples R China.
   [Liu, Yu; Zhou, Wenhua] Ningbo Univ, Sch Med, Ningbo 315211, Peoples R China.
   [Liang, Juncheng; Zhao, Chengzheng] Peking Univ, Natl Inst Drug Dependence, Beijing 100191, Peoples R China.
C3 Ningbo University; Ningbo University; Peking University
RP Zhou, WH (通讯作者)，Ningbo Univ, Sch Med, Lab Behav Neurosci, Ningbo Addict Treatment & Res Ctr, 42 Xibei Rd, Ningbo 315010, Zhejiang, Peoples R China.
EM whzhou@vip.163.com
CR ALLGULANDER C, 1989, AM J PUBLIC HEALTH, V79, P1006, DOI 10.2105/AJPH.79.8.1006
   Cami J, 2003, NEW ENGL J MED, V349, P975, DOI 10.1056/NEJMra023160
   Caulkins JP, 1997, ADDICTION, V92, P1143
   Devaney M., 2006, SITUATIONAL ANAL DRU
   Dikotter Frank, 2004, NARCOTIC CULTURE HIS
   DUPONT RL, 1995, ANN INTERN MED, V123, P461, DOI 10.7326/0003-4819-123-6-199509150-00011
   ENGELSMAN EL, 1989, BRIT J ADDICT, V84, P211
   Fang YX, 2006, ACTA PHARMACOL SIN, V27, P140, DOI 10.1111/j.1745-7254.2006.00270.x
   Galea S, 2004, EPIDEMIOL REV, V26, P36, DOI 10.1093/epirev/mxh007
   Garten RJ, 2004, INT J EPIDEMIOL, V33, P182, DOI 10.1093/ije/dyh019
   Hammett TM, 2008, ADDICTION, V103, P137, DOI 10.1111/j.1360-0443.2007.02053.x
   He N, 2005, CELL RES, V15, P825, DOI 10.1038/sj.cr.7290354
   Huang Y., 2005, J POLITICAL SCI LAW, V22, P72
   IHRD, 2008, HARM RED DEV 2008
   Jennings JM, 2004, J WORLD HIST, V15, P269, DOI 10.1353/jwh.2004.0022
   LANIEL L, 1999, RELATIONSHIP RES DRU
   Leshner AI, 1999, P ASSOC AM PHYSICIAN, V111, P99, DOI 10.1046/j.1525-1381.1999.09218.x
   Leshner AI, 1999, JAMA-J AM MED ASSOC, V282, P1314, DOI 10.1001/jama.282.14.1314
   Leshner AI, 1999, AM J PSYCHIAT, V156, P1
   LI M, 1991, DRUG USE DRUG DEPEND
   Li XM, 2000, J DRUG ISSUES, V30, P663, DOI 10.1177/002204260003000309
   Liu ZM, 2006, DRUG ALCOHOL REV, V25, P173, DOI 10.1080/09595230500538835
   LOWINGER P, 1977, AM J DRUG ALCOHOL AB, V4, P165, DOI 10.3109/00952997709002758
   LOWINGER P, 1973, American Journal of Chinese Medicine, V1, P275, DOI 10.1142/S0192415X73000292
   Lu L, 2008, ANN NY ACAD SCI, V1141, P304, DOI 10.1196/annals.1441.025
   Lu L, 2008, CELL MOL NEUROBIOL, V28, P479, DOI 10.1007/s10571-007-9225-2
   Lu L, 2008, AM J DRUG ALCOHOL AB, V34, P127, DOI 10.1080/00952990701876989
   [罗健 Luo Jian], 2002, [中国心理卫生杂志, Chinese Mental Health Journal], V16, P112
   *NAT NARC CONTR CO, 2006, ANN REP DRUG CONTR C
   PECK DF, 1986, BRIT MED J, V293, P929, DOI 10.1136/bmj.293.6552.929
   [柔克明 ROU Keming], 2009, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V18, P172
   Ruan YH, 2004, WORLD J GASTROENTERO, V10, P1589, DOI 10.3748/wjg.v10.i11.1589
   Shaffer HJ, 2002, ADDICTION, V97, P543, DOI 10.1046/j.1360-0443.2002.00114.x
   Stimson G V, 2000, Int J Drug Policy, V11, P259, DOI 10.1016/S0955-3959(00)00060-8
   STIMSON GV, 1987, BRIT J ADDICT, V82, P477
   Sullivan SG, 2007, INT J DRUG POLICY, V18, P118, DOI 10.1016/j.drugpo.2006.11.014
   Tang YL, 2006, ADDICTION, V101, P657, DOI 10.1111/j.1360-0443.2006.01367.x
   United Nations Office on Drugs and Crime, 2008, CENT INT DRUG CONTR
   Voth EA, 1996, BRIT MED J, V312, P636
   VOTH EA, 1995, JAMA-J AM MED ASSOC, V273, P459, DOI 10.1001/jama.1995.03520300029027
   Wagner FA, 2002, NEUROPSYCHOPHARMACOL, V26, P479, DOI 10.1016/S0893-133X(01)00367-0
   WANG S, 2001, CHIN J DRUG DEPEND, V10, P218
   Wu Z, 2008, 2008 ANN M PROV AIDS
   Xiao Y, 2007, SOC SCI MED, V64, P665, DOI 10.1016/j.socscimed.2006.09.019
   ZHANG ZB, 2008, CHINESE J HLTH ED, V24, P578
   ZHOU W, 2004, CHINESE J DRUG ABUSE, V10, P1
   Zhou Yongming, 1999, ANTIDRUG CRUSADES 20
NR 47
TC 25
Z9 27
U1 0
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0955-3959
EI 1873-4758
J9 INT J DRUG POLICY
JI Int. J. Drug Policy
PD MAY
PY 2010
VL 21
IS 3
BP 149
EP 154
DI 10.1016/j.drugpo.2009.10.002
PG 6
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA 592NH
UT WOS:000277385600002
PM 19896818
DA 2023-06-23
ER

PT J
AU Robinson, TE
   Berridge, KC
AF Robinson, Terry E.
   Berridge, Kent C.
TI The incentive sensitization theory of addiction: some current issues
SO PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
LA English
DT Article; Proceedings Paper
CT Royal-Society-Discussion Meeting on Neurobiology of Drug Addiction
CY FEB 25-26, 2008
CL London, ENGLAND
SP Royal Soc Discuss
DE sensitization; dopamine; habits; cocaine; amphetamine; motivation
ID D-AMPHETAMINE CHALLENGE; COMPULSIVE DRUG-USE; COCAINE-SEEKING;
   BEHAVIORAL SENSITIZATION; PERSISTENT INCREASE; EMISSION-TOMOGRAPHY;
   NUCLEUS-ACCUMBENS; DOPAMINE RELEASE; VENTRAL STRIATUM; DECISION-MAKING
AB We present a brief overview of the incentive sensitization theory of addiction. This posits that addiction is caused primarily by drug-induced sensitization in the brain mesocorticolimbic systems that attribute incentive salience to reward-associated stimuli. If rendered hypersensitive, these systems cause pathological incentive motivation ('wanting') for drugs. We address some current questions including: what is the role of learning in incentive sensitization and addiction? Does incentive sensitization occur in human addicts? Is the development of addiction-like behaviour in animals associated with sensitization? What is the best way to model addiction symptoms using animal models? And, finally, what are the roles of affective pleasure or withdrawal in addiction?.
C1 [Robinson, Terry E.; Berridge, Kent C.] Univ Michigan, Dept Psychol, Biopsychol Program, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan
RP Robinson, TE (通讯作者)，Univ Michigan, Dept Psychol, Biopsychol Program, East Hall,525 E Univ Ave, Ann Arbor, MI 48109 USA.
EM ter@umich.edu
RI Berridge, Kent/C-1525-2009
OI Berridge, Kent/0000-0002-6031-2626
FU NIDA NIH HHS [R01 DA015188] Funding Source: Medline; NIMH NIH HHS [R01
   MH063649] Funding Source: Medline
CR Ahmed SH, 2006, NEUROPSYCHOPHARMACOL, V31, P563, DOI 10.1038/sj.npp.1300834
   Ahmed SH, 2005, P NATL ACAD SCI USA, V102, P11533, DOI 10.1073/pnas.0504438102
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Ahmed SH, 2000, NEUROPSYCHOPHARMACOL, V22, P413, DOI 10.1016/S0893-133X(99)00133-5
   Anagnostaras SG, 2002, NEUROPSYCHOPHARMACOL, V26, P703, DOI 10.1016/S0893-133X(01)00402-X
   Anagnostaras SG, 1996, BEHAV NEUROSCI, V110, P1397, DOI 10.1037/0735-7044.110.6.1397
   Bechara A, 2002, NEUROPSYCHOLOGIA, V40, P1690, DOI 10.1016/S0028-3932(02)00016-7
   Ben-Shahar O, 2004, BRAIN RES, V995, P46, DOI 10.1016/j.brainres.2003.09.053
   Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9
   Berridge KC, 2001, PSYCHOL LEARN MOTIV, V40, P223, DOI 10.1016/s0079-7421(00)80022-5
   Boileau I, 2007, J NEUROSCI, V27, P3998, DOI 10.1523/JNEUROSCI.4370-06.2007
   Boileau I, 2006, ARCH GEN PSYCHIAT, V63, P1386, DOI 10.1001/archpsyc.63.12.1386
   Briand LA, 2008, NEUROPSYCHOPHARMACOL, V33, P2969, DOI 10.1038/npp.2008.18
   Briand LA, 2008, EUR NEUROPSYCHOPHARM, V18, P551, DOI 10.1016/j.euroneuro.2008.01.002
   Calu DJ, 2007, LEARN MEMORY, V14, P325, DOI 10.1101/lm.534807
   Cardinal RN, 2002, NEUROSCI BIOBEHAV R, V26, P321, DOI 10.1016/S0149-7634(02)00007-6
   Childress AR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001506
   Crombag HS, 1999, BEHAV PHARMACOL, V10, P205, DOI 10.1097/00008877-199903000-00009
   Dalia AD, 1998, BRAIN RES, V797, P29, DOI 10.1016/S0006-8993(98)00323-0
   De Vries TJ, 2002, NEUROPSYCHOPHARMACOL, V26, P18, DOI 10.1016/S0893-133X(01)00293-7
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Di Ciano P, 2008, NEUROPSYCHOPHARMACOL, V33, P1426, DOI 10.1038/sj.npp.1301542
   Duvauchelle CL, 2000, BRAIN RES, V862, P49, DOI 10.1016/S0006-8993(00)02091-6
   Edwards S, 2007, NEUROPSYCHOPHARMACOL, V32, P354, DOI 10.1038/sj.npp.1301062
   Evans AH, 2006, ANN NEUROL, V59, P852, DOI 10.1002/ana.20822
   Everitt BJ, 2001, BRAIN RES REV, V36, P129, DOI 10.1016/S0165-0173(01)00088-1
   Ferrario CR, 2007, EUR NEUROPSYCHOPHARM, V17, P352, DOI 10.1016/j.euroneuro.2006.08.005
   Ferrario CR, 2005, BIOL PSYCHIAT, V58, P751, DOI 10.1016/j.biopsych.2005.04.046
   Fiorino DF, 1999, J NEUROSCI, V19, P456, DOI 10.1523/JNEUROSCI.19-01-00456.1999
   Fiorino DF, 1999, PSYCHOPHARMACOLOGY, V142, P200, DOI 10.1007/s002130050880
   Flagel SB, 2007, BEHAV PHARMACOL, V18, P297, DOI 10.1097/FBP.0b013e3281f522a4
   FONTANA DJ, 1993, BRAIN RES, V629, P31, DOI 10.1016/0006-8993(93)90477-5
   George O, 2008, NEUROPSYCHOPHARMACOL, V33, P2474, DOI 10.1038/sj.npp.1301626
   Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134
   Harmer CJ, 1998, BEHAV PHARMACOL, V9, P299
   Hasin D, 2006, ADDICTION, V101, P59, DOI 10.1111/j.1360-0443.2006.01584.x
   Heyne A, 1998, PSYCHOPHARMACOLOGY, V140, P510, DOI 10.1007/s002130050796
   Hyman SE, 2005, AM J PSYCHIAT, V162, P1414, DOI 10.1176/appi.ajp.162.8.1414
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564
   Kapur S, 2005, SCHIZOPHR RES, V79, P59, DOI 10.1016/j.schres.2005.01.003
   Knackstedt LA, 2007, J PHARMACOL EXP THER, V322, P1103, DOI 10.1124/jpet.107.122861
   Koob GF, 2006, NEUR ADD
   LETT BT, 1989, PSYCHOPHARMACOLOGY, V98, P357, DOI 10.1007/BF00451687
   Leyton M, 2007, PROG NEURO-PSYCHOPH, V31, P1601, DOI 10.1016/j.pnpbp.2007.08.027
   Li YL, 2004, EUR J NEUROSCI, V20, P1647, DOI 10.1111/j.1460-9568.2004.03612.x
   Mantsch JR, 2004, PSYCHOPHARMACOLOGY, V175, P26, DOI 10.1007/s00213-004-1778-x
   Martinez D, 2004, NEUROPSYCHOPHARMACOL, V29, P1190, DOI 10.1038/sj.npp.1300420
   Martinez D, 2007, AM J PSYCHIAT, V164, P622, DOI 10.1176/appi.ajp.164.4.622
   Miles FJ, 2003, BEHAV NEUROSCI, V117, P927, DOI 10.1037/0735-7044.117.5.927
   MITCHELL JB, 1990, PHARMACOL BIOCHEM BE, V35, P643, DOI 10.1016/0091-3057(90)90302-X
   Nelson A, 2006, J NEUROSCI, V26, P3805, DOI 10.1523/JNEUROSCI.4305-05.2006
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   Nocjar C, 2002, BEHAV BRAIN RES, V128, P189, DOI 10.1016/S0166-4328(01)00321-7
   Nordquist RE, 2007, EUR NEUROPSYCHOPHARM, V17, P532, DOI 10.1016/j.euroneuro.2006.12.005
   Paterson NE, 2003, NEUROREPORT, V14, P2229, DOI 10.1097/00001756-200312020-00019
   PAULSON PE, 1995, SYNAPSE, V19, P56, DOI 10.1002/syn.890190108
   Pelloux Y, 2007, PSYCHOPHARMACOLOGY, V194, P127, DOI 10.1007/s00213-007-0805-0
   Pierce RC, 1996, J NEUROSCI, V16, P1550
   Porrino LJ, 2007, PROG NEURO-PSYCHOPH, V31, P1593, DOI 10.1016/j.pnpbp.2007.08.040
   POST RM, 1976, NATURE, V260, P731, DOI 10.1038/260731a0
   POST RM, 1980, LIFE SCI, V26, P1275, DOI 10.1016/0024-3205(80)90085-5
   Robinson TE, 2000, ADDICTION, V95, pS91
   Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI 10.1146/annurev.psych.54.101601.145237
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   ROBINSON TE, 1986, BRAIN RES REV, V11, P157, DOI 10.1016/0165-0173(86)90002-0
   Robinson TE, 1998, NEUROSCI BIOBEHAV R, V22, P347, DOI 10.1016/S0149-7634(97)00020-1
   Rogers RD, 1999, NEUROPSYCHOPHARMACOL, V20, P322, DOI 10.1016/S0893-133X(98)00091-8
   Rogers RD, 2001, CURR OPIN NEUROBIOL, V11, P250, DOI 10.1016/S0959-4388(00)00204-X
   Schoenbaum G, 2008, BIOL PSYCHIAT, V63, P256, DOI 10.1016/j.biopsych.2007.06.003
   Seeman P, 2005, P NATL ACAD SCI USA, V102, P3513, DOI 10.1073/pnas.0409766102
   Seeman P, 2002, SYNAPSE, V46, P235, DOI 10.1002/syn.10139
   Seeman P, 2007, SYNAPSE, V61, P263, DOI 10.1002/syn.20367
   Segal D S, 1975, Adv Biochem Psychopharmacol, V13, P247
   STEWART J, 1991, BEHAV PHARMACOL, V2, P65
   Strakowski SM, 1998, BIOL PSYCHIAT, V44, P1171, DOI 10.1016/S0006-3223(97)00454-X
   Strakowski SM, 1996, BIOL PSYCHIAT, V40, P872, DOI 10.1016/0006-3223(95)00497-1
   Taylor JR, 1999, PSYCHOPHARMACOLOGY, V142, P31, DOI 10.1007/s002130050859
   TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147
   Tindell AJ, 2005, EUR J NEUROSCI, V22, P2617, DOI 10.1111/j.1460-9568.2005.04411.x
   UJIKE H, 1990, PSYCHOPHARMACOLOGY, V102, P459, DOI 10.1007/BF02247125
   Uslaner JM, 2006, BEHAV BRAIN RES, V169, P320, DOI 10.1016/j.bbr.2006.02.001
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Vezina P, 2004, NEUROSCI BIOBEHAV R, V27, P827, DOI 10.1016/j.neubiorev.2003.11.001
   Volkow ND, 2004, MOL PSYCHIATR, V9, P557, DOI 10.1038/sj.mp.4001507
   Volkow ND, 1997, NATURE, V386, P830, DOI 10.1038/386830a0
   VOLKOW ND, 1990, AM J PSYCHIAT, V147, P719
   Ward SJ, 2006, PSYCHOPHARMACOLOGY, V185, P150, DOI 10.1007/s00213-005-0288-9
   Wiers R., 2006, HDB IMPLICIT COGNITI
   WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469
   WOLFFGRAMM J, 1995, BEHAV BRAIN RES, V70, P77, DOI 10.1016/0166-4328(95)00131-C
   Wyvell CL, 2001, J NEUROSCI, V21, P7831, DOI 10.1523/JNEUROSCI.21-19-07831.2001
NR 93
TC 1089
Z9 1108
U1 12
U2 204
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 0962-8436
EI 1471-2970
J9 PHILOS T R SOC B
JI Philos. Trans. R. Soc. B-Biol. Sci.
PD OCT 12
PY 2008
VL 363
IS 1507
BP 3137
EP 3146
DI 10.1098/rstb.2008.0093
PG 10
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Life Sciences & Biomedicine - Other Topics
GA 345AW
UT WOS:000258969400004
PM 18640920
OA Green Published
DA 2023-06-23
ER

PT J
AU Dinis-Oliveira, RJ
AF Dinis-Oliveira, Ricardo Jorge
TI Metabolomics of drugs of abuse: a more realistic view of the
   toxicological complexity
SO BIOANALYSIS
LA English
DT Editorial Material
DE addiction; amphetamines; cannabinoids; cocaine; drugs of abuse; ethanol;
   metabolome; metabolomics; new psychoactive substances; opioids
ID COCAINE METABOLISM; RAT; METHAMPHETAMINE; ADDICTION; MARKERS; SPORTS;
   PLASMA; URINE
C1 [Dinis-Oliveira, Ricardo Jorge] Univ Porto, Dept Legal Med & Forens Sci, Fac Med, P-4100 Oporto, Portugal.
   [Dinis-Oliveira, Ricardo Jorge] Adv Inst Hlth Sci North ISCS N, Dept Sci, Inst Res & Adv Training Hlth Sci & Technol IINFAC, Gandra, Portugal.
   [Dinis-Oliveira, Ricardo Jorge] Univ Porto, Dept Biol Sci, Fac Pharm, Toxicol Lab, P-4100 Oporto, Portugal.
C3 Universidade do Porto; Universidade do Porto
RP Dinis-Oliveira, RJ (通讯作者)，Univ Porto, Dept Legal Med & Forens Sci, Fac Med, Rua Campo Alegre 823, P-4100 Oporto, Portugal.
EM ricardinis@sapo.pt
RI Dinis-Oliveira, Ricardo Jorge/D-9186-2013
OI Dinis-Oliveira, Ricardo Jorge/0000-0001-7430-6297
CR Dettmer K, 2007, MASS SPECTROM REV, V26, P51, DOI 10.1002/mas.20108
   Dinis-Oliveira RJ, 2014, TOXICOL MECH METHOD, V24, P81, DOI 10.3109/15376516.2013.869782
   Dinis-Oliveira Ricardo Jorge, 2012, Curr Drug Abuse Rev, V5, P273
   Hannuksela ML, 2007, CLIN CHEM LAB MED, V45, P953, DOI 10.1515/CCLM.2007.190
   Hazekamp A, 2012, DRUG TEST ANAL, V4, P660, DOI 10.1002/dta.407
   Johnson LA, 2013, J EMERG MED, V44, P1108, DOI 10.1016/j.jemermed.2012.09.147
   Kaddurah-Daouk R, 2008, ANNU REV PHARMACOL, V48, P653, DOI 10.1146/annurev.pharmtox.48.113006.094715
   Kaplan KA, 2013, ANAL BIOANAL CHEM, V405, P1959, DOI 10.1007/s00216-012-6638-7
   Kmietowicz Z, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2930
   Monfort N, 2012, TRANSFUSION, V52, P647, DOI 10.1111/j.1537-2995.2011.03331.x
   Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578
   Nicholson JK, 1999, XENOBIOTICA, V29, P1181, DOI 10.1080/004982599238047
   Patkar AA, 2009, PSYCHOPHARMACOLOGY, V206, P479, DOI 10.1007/s00213-009-1625-1
   Robertson DG, 2011, TOXICOL SCI, V120, pS146, DOI 10.1093/toxsci/kfq358
   Russell C, 2013, THER DELIV, V4, P395, DOI [10.4155/TDE.13.4, 10.4155/tde.13.4]
   Shi XL, 2012, J BIOL CHEM, V287, P6336, DOI 10.1074/jbc.M111.312199
   Shima N, 2011, TOXICOLOGY, V287, P29, DOI 10.1016/j.tox.2011.05.012
   THOMPSON ML, 1979, BIOCHEM PHARMACOL, V28, P2389, DOI 10.1016/0006-2952(79)90705-6
   Xu EY, 2009, CURR OPIN DRUG DISC, V12, P40
   Yao D, 2013, DRUG METAB DISPOS, V41, P79, DOI 10.1124/dmd.112.048678
   Zaitsu K, 2014, ANAL BIOANAL CHEM, V406, P1339, DOI 10.1007/s00216-013-7234-1
   Zheng T, 2013, DRUG ALCOHOL DEPEN, V127, P177, DOI 10.1016/j.drugalcdep.2012.06.031
NR 22
TC 40
Z9 40
U1 2
U2 22
PU FUTURE SCI LTD
PI LONDON
PA UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND
SN 1757-6180
EI 1757-6199
J9 BIOANALYSIS
JI Bioanalysis
PY 2014
VL 6
IS 23
SI SI
BP 3155
EP 3159
DI 10.4155/bio.14.260
PG 5
WC Biochemical Research Methods; Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA CA8QP
UT WOS:000349186300010
PM 25529883
DA 2023-06-23
ER

PT C
AU Jamaluddin, AS
   Rasam, ARA
   Khalid, N
   Halim, MA
AF Jamaluddin, Ahmad Safwan
   Rasam, Abdul Rauf Abdul
   Khalid, Nafisah
   Halim, Maisarah Abdul
GP IEEE
TI Exploring Open Source GIS for Drug Mapping and Analysis in Malaysia
SO 2018 IEEE 8TH INTERNATIONAL CONFERENCE ON SYSTEM ENGINEERING AND
   TECHNOLOGY (ICSET)
SE International Conference on System Engineering and Technology
LA English
DT Proceedings Paper
CT 8th IEEE International Conference on System Engineering and Technology
   (ICSET)
CY OCT 15-16, 2018
CL Bandung, INDONESIA
SP IEEE, Inst Teknologi Bandung, Sch Elect Engn & Informat, Univ Teknologi Mara, Univ Teknologi Mara, Fac Elect Engn, IEEE Indonesia CSS RAS Joint Chapter, IEEE Indonesia Sect, Inst Teknologi Bandung
DE open source; QGIS; mapping; analysis; drug addict
AB Drug addiction or drug abuse is a complex brain disease that will cause the addict is dependent on drugs. The addiction is one of the most major matters in Malaysia. The number of addiction is increasing every year that it will lead to commit a crime and therefore the issue need to develop a creative method to control this social problem. The aim of the study is to examine the capabilities of Open Source Geographical Information System (GIS) in mapping and analysing drug addiction cases in Klang, Selangor. The objectives are i) to create maps and database of the drug addiction, ii) to analyse the distribution pattern of the drug addicts, iii) and to produce a hotspot map of the drug addiction. The methodology consists of four phases; systematic review, data collection, data processing and data analysis. The mapping and analysis of the cases were processed using Nearest Neighbour Analysis tool, Mean Coordinate and population patterns in Quantum GIS (QGIS). The result showed that the pattern and hotspot area of the cases was clustered especially in populous (aged 21-30) urban areas such as rapid housing and road activities. QGIS has demonstrated its capabilities for general GIS operations and the hotspot maps could be utilised by the authority to control the cases at the risk areas of drug in Malaysia.
C1 [Jamaluddin, Ahmad Safwan; Rasam, Abdul Rauf Abdul; Khalid, Nafisah; Halim, Maisarah Abdul] Univ Teknol MARA, Fac Architecture Planning & Surveying, Ctr Studies Surveying Sci & Geomat, Shah Alam, Selangor, Malaysia.
C3 Universiti Teknologi MARA
RP Rasam, ARA (通讯作者)，Univ Teknol MARA, Fac Architecture Planning & Surveying, Ctr Studies Surveying Sci & Geomat, Shah Alam, Selangor, Malaysia.
EM rauf@salam.uitm.edu.my
RI Rasam, Abdul Rauf Abdul/AAP-9658-2020
OI Rasam, Abdul Rauf Abdul/0000-0001-8096-0260
FU Research Management Institute (RMI) in UiTM Shah Alam, Selangor
   [600-IRMI 5/3/LESTARI (006/2018)]; Faculty of Architecture, Planning and
   Surveying
FX The authors thank to Agensi Anti Dadah Kebangsaan (AADK) Klang, Selangor
   for providing the general data of drug cases. Faculty of Architecture,
   Planning and Surveying and Research Management Institute (RMI) in UiTM
   Shah Alam, Selangor are also appreciated for providing research fund
   (600-IRMI 5/3/LESTARI (006/2018) used in this academic paper.
CR Anselin L., 2000, SPATIAL ANAL CRIME
   Boba R., 2001, INTRO GUIDE CRIME AN
   Chang K, 2002, INTRO GEOGRAPHIC INF
   DeGrot Len, 2011, QGIS BASIC JOURNALIS
   Gandhi Ujaval, 2018, QGISTUTORIAL
   Jaffe J.H., 1985, DRUG ADDICTION DRUG
   Johnson C. P., 2000, CRIME MAPPING ANAL U
   Orborne Deborah, 2000, INTRO CRIME ANAL BAS
   Rasam A. R. A., 2011, 2011 Proceedings of IEEE 7th International Colloquium on Signal Processing & its Applications (CSPA 2011), P474, DOI 10.1109/CSPA.2011.5759925
   Rasam ARA, 2016, INT ARCH PHOTOGRAMM, V42-4, P9, DOI 10.5194/isprs-archives-XLII-4-W1-9-2016
NR 10
TC 1
Z9 1
U1 0
U2 2
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
SN 2470-640X
BN 978-1-5386-9180-9
J9 INT CONF SYST ENG
PY 2018
BP 91
EP 96
PG 6
WC Computer Science, Information Systems; Engineering, Electrical &
   Electronic
WE Conference Proceedings Citation Index - Science (CPCI-S)
SC Computer Science; Engineering
GA BM0PN
UT WOS:000458982900017
DA 2023-06-23
ER

PT J
AU Alleva, L
   Tirelli, E
   Brabant, C
AF Alleva, Livia
   Tirelli, Ezio
   Brabant, Christian
TI Therapeutic potential of histaminergic compounds in the treatment of
   addiction and drug-related cognitive disorders
SO BEHAVIOURAL BRAIN RESEARCH
LA English
DT Review
DE Addiction; Memory; Cognition; Histamine; Histamine H-3 receptor;
   Acetylcholine
ID RECEPTOR INVERSE AGONIST; MORRIS WATER MAZE; ABSTINENT COCAINE ABUSERS;
   ETHANOL-INDUCED DEFICITS; LONG-TERM POTENTIATION; CUED FEAR EXTINCTION;
   H-3 RECEPTOR; DECISION-MAKING; MEMORY IMPAIRMENT; H3 RECEPTOR
AB Addiction is a behavioral disorder characterized by the compulsive seeking and taking of drugs despite serious negative consequences. In particular, the chronic use of drugs impairs memory and cognitive functions, which aggravates the loss of control over drug use and complicates treatment outcome. Therefore, cognitive enhancers targeting acetylcholine have been proposed to treat addiction. Interestingly, histamine H-3 receptor (H3R) antagonists/inverse agonists stimulate acetylcholine transmission in different brain areas, facilitate memory in animal models and can reverse learning deficits induced by drugs such as scopolamine, dizocilpine and alcohol. Moreover, several studies found that compounds capable of activating the histaminergic system generally decrease the reinforcing effects of drugs, namely alcohol and opioids, in preclinical models of addiction. Finally, several H3R antagonists/inverse agonists increase histamine in the brain and have proven to be safe in humans. However, no studies have yet investigated the therapeutic potential of cognitive enhancing H3R antagonists/inverse agonists in the treatment of addiction in humans. The present review first describes the impact of addictive drugs on learning processes and cognitive functions that play an important role for addicts to remain abstinent. Second, our work briefly summarizes the relevant literature describing the function of histamine in learning, memory and drug addiction. Finally, the potential therapeutic use of histaminergic agents in the treatment of addiction is discussed. Our review suggests that histaminergic compounds like H3R antagonists/inverse agonists may improve the treatment outcome of addiction by reversing drug-induced cognitive deficits and/or diminishing the reinforcing properties of addictive drugs, especially opioids and alcohol. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Alleva, Livia; Tirelli, Ezio; Brabant, Christian] Univ Liege, Dept Psychol Cognit & Comportement, Liege, Belgium.
C3 University of Liege
RP Alleva, L (通讯作者)，Univ Liege, Dept Psychol Cognit & Comportement, Blvd Rectorat 5-B32, Liege, Belgium.
EM Livia.Alleva@student.ulg.ac.be
RI Brabant, Christian/N-9445-2013
FU Fonds National de la Recherche Scientifique (FNRS); Fonds Speciaux pour
   la Recherche de l'Universite de Liege
FX This work was supported by grants from the Fonds National de la
   Recherche Scientifique (FNRS) and the Fonds Speciaux pour la Recherche
   de l'Universite de Liege obtained by Ezio Tirelli.
CR Adinoff B, 2010, NEUROPSYCHOPHARMACOL, V35, P1485, DOI 10.1038/npp.2010.18
   Aharonovich E, 2006, DRUG ALCOHOL DEPEN, V81, P313, DOI 10.1016/j.drugalcdep.2005.08.003
   Akhtar M, 2006, FUND CLIN PHARMACOL, V20, P373, DOI 10.1111/j.1472-8206.2006.00411.x
   Akine Y, 2007, ALCOHOL CLIN EXP RES, V31, P1589, DOI 10.1111/j.1530-0277.2007.00453.x
   Alreja M, 2000, J NEUROSCI, V20, P1179, DOI 10.1523/JNEUROSCI.20-03-01179.2000
   Arendt T, 1994, J Neural Transm Suppl, V44, P173
   ARRANG JM, 1983, NATURE, V302, P832, DOI 10.1038/302832a0
   Bacciottini L, 2002, EUR J NEUROSCI, V15, P1669, DOI 10.1046/j.1460-9568.2002.02005.x
   Bacciottini L, 2001, BEHAV BRAIN RES, V124, P183, DOI 10.1016/S0166-4328(01)00230-3
   Bakker RA, 2006, MOL PHARMACOL, V69, P1194, DOI 10.1124/mol.105.019299
   Bardgett ME, 2010, NEUROPHARMACOLOGY, V59, P492, DOI 10.1016/j.neuropharm.2010.07.004
   Belcher AM, 2008, NEUROPSYCHOPHARMACOL, V33, P1453, DOI 10.1038/sj.npp.1301510
   Bembenek SD, 2008, BIOORGAN MED CHEM, V16, P2968, DOI 10.1016/j.bmc.2007.12.048
   Bernardino L, 2012, STEM CELLS, V30, P773, DOI 10.1002/stem.1042
   BERRY J, 1993, DRUG ALCOHOL DEPEN, V32, P231, DOI 10.1016/0376-8716(93)90087-7
   Bitner RS, 2011, NEUROPHARMACOLOGY, V60, P460, DOI 10.1016/j.neuropharm.2010.10.026
   Blandina P, 2004, LEARN MEMORY, V11, P1, DOI 10.1101/lm.68004
   Bolla K, 2004, J NEUROPSYCH CLIN N, V16, P456, DOI 10.1176/appi.neuropsych.16.4.456
   Bolla KI, 2003, NEUROIMAGE, V19, P1085, DOI 10.1016/S1053-8119(03)00113-7
   Brabant C, 2005, BEHAV BRAIN RES, V160, P161, DOI 10.1016/j.bbr.2004.11.029
   Brabant C, 2007, PSYCHOPHARMACOLOGY, V190, P251, DOI 10.1007/s00213-006-0603-0
   Brabant C, 2006, PHARMACOL BIOCHEM BE, V83, P561, DOI 10.1016/j.pbb.2006.03.018
   Brabant C, 2010, PROG NEUROBIOL, V92, P421, DOI 10.1016/j.pneurobio.2010.07.002
   Brabant C, 2009, PSYCHOPHARMACOLOGY, V202, P673, DOI 10.1007/s00213-008-1345-y
   Brady KT, 2011, PHARMACOL BIOCHEM BE, V99, P285, DOI 10.1016/j.pbb.2011.04.017
   Brand M, 2008, DRUG ALCOHOL DEPEN, V97, P64, DOI 10.1016/j.drugalcdep.2008.03.017
   Briand LA, 2008, NEUROSCIENCE, V155, P1, DOI 10.1016/j.neuroscience.2008.06.004
   Brioni JD, 2011, J PHARMACOL EXP THER, V336, P38, DOI 10.1124/jpet.110.166876
   Burgess N, 2002, NEURON, V35, P625, DOI 10.1016/S0896-6273(02)00830-9
   Burke KA, 2006, LEARN MEMORY, V13, P416, DOI 10.1101/lm.216206
   Canales JJ, 2007, EUR ARCH PSY CLIN N, V257, P261, DOI 10.1007/s00406-007-0730-6
   Canales JJ, 2010, BEHAV PHARMACOL, V21, P379, DOI 10.1097/FBP.0b013e32833e16b6
   Chanraud S, 2007, NEUROPSYCHOPHARMACOL, V32, P429, DOI 10.1038/sj.npp.1301219
   Charlier Y, 2011, NEUROSCIENCE, V193, P132, DOI 10.1016/j.neuroscience.2011.07.034
   Chester JA, 2001, BEHAV PHARMACOL, V12, P535, DOI 10.1097/00008877-200111000-00015
   Cho W, 2011, PSYCHOPHARMACOLOGY, V218, P513, DOI 10.1007/s00213-011-2344-y
   CLAPHAM J, 1994, EUR J PHARMACOL, V259, P107, DOI 10.1016/0014-2999(94)90498-7
   Cleva RM, 2010, CURR NEUROPHARMACOL, V8, P394, DOI 10.2174/157015910793358169
   Connelly WM, 2009, BRIT J PHARMACOL, V157, P55, DOI 10.1111/j.1476-5381.2009.00227.x
   Connolly CG, 2012, DRUG ALCOHOL DEPEN, V121, P45, DOI 10.1016/j.drugalcdep.2011.08.007
   Dalley JW, 2011, NEURON, V69, P680, DOI 10.1016/j.neuron.2011.01.020
   Dalley JW, 2005, PSYCHOPHARMACOLOGY, V182, P579, DOI 10.1007/s00213-005-0107-3
   Dalley JW, 2005, NEUROPSYCHOPHARMACOL, V30, P525, DOI 10.1038/sj.npp.1300590
   Day M, 2007, BIOCHEM PHARMACOL, V73, P1123, DOI 10.1016/j.bcp.2006.12.004
   DEALMEIDA MAMR, 1986, ARCH INT PHARMACOD T, V283, P193
   Dominguez-Escriba L, 2006, EUR J NEUROSCI, V24, P586, DOI 10.1111/j.1460-9568.2006.04924.x
   Drutel G, 2001, MOL PHARMACOL, V59, P1
   Eisch AJ, 2000, P NATL ACAD SCI USA, V97, P7579, DOI 10.1073/pnas.120552597
   Errico AL, 2002, ALCOHOL CLIN EXP RES, V26, P1198, DOI 10.1097/01.ALC.0000025885.23192.FF
   Ersche KD, 2007, NEUROPSYCHOL REV, V17, P317, DOI 10.1007/s11065-007-9033-y
   Ersche KD, 2006, PSYCHOPHARMACOLOGY, V188, P364, DOI 10.1007/s00213-006-0515-z
   Ersche KD, 2006, NEUROPSYCHOPHARMACOL, V31, P1036, DOI 10.1038/sj.npp.1300889
   Ersche KD, 2005, PSYCHOPHARMACOLOGY, V180, P612, DOI 10.1007/s00213-005-2205-7
   Esbenshade TA, 2008, BRIT J PHARMACOL, V154, P1166, DOI 10.1038/bjp.2008.147
   Feil J, 2010, NEUROSCI BIOBEHAV R, V35, P248, DOI 10.1016/j.neubiorev.2010.03.001
   Fein G, 2006, NEUROIMAGE, V32, P1465, DOI 10.1016/j.neuroimage.2006.06.013
   Fillmore MT, 2002, DRUG ALCOHOL DEPEN, V66, P265, DOI 10.1016/S0376-8716(01)00206-X
   Fishbein DH, 2007, DRUG ALCOHOL DEPEN, V90, P25, DOI 10.1016/j.drugalcdep.2007.02.015
   Florian C, 2004, BEHAV BRAIN RES, V154, P365, DOI 10.1016/j.bbr.2004.03.003
   Foley AG, 2009, NEUROPSYCHOPHARMACOL, V34, P2585, DOI 10.1038/npp.2009.89
   Fox GB, 2005, J PHARMACOL EXP THER, V313, P176, DOI 10.1124/jpet.104.078402
   Fox GB, 2002, BEHAV BRAIN RES, V131, P151, DOI 10.1016/S0166-4328(01)00379-5
   Fuchs RA, 2005, NEUROPSYCHOPHARMACOL, V30, P296, DOI 10.1038/sj.npp.1300579
   Galici R, 2011, PSYCHOPHARMACOLOGY, V214, P829, DOI 10.1007/s00213-010-2092-4
   Galici R, 2009, NEUROPHARMACOLOGY, V56, P1131, DOI 10.1016/j.neuropharm.2009.03.011
   Garavan H, 2005, TRENDS COGN SCI, V9, P195, DOI 10.1016/j.tics.2005.02.008
   Ghahremani DG, 2011, NEUROPSYCHOPHARMACOL, V36, P950, DOI 10.1038/npp.2010.233
   Giannoni P, 2010, J PHARMACOL EXP THER, V332, P164, DOI 10.1124/jpet.109.158444
   Giovannini MG, 1999, BEHAV BRAIN RES, V104, P147, DOI 10.1016/S0166-4328(99)00063-7
   Givens B, 2000, HIPPOCAMPUS, V10, P111, DOI 10.1002/(SICI)1098-1063(2000)10:1<111::AID-HIPO12>3.0.CO;2-1
   Gong YX, 2010, ACTA PHARMACOL SIN, V31, P1431, DOI 10.1038/aps.2010.136
   Gong YX, 2010, NEUROSCI LETT, V468, P115, DOI 10.1016/j.neulet.2009.10.079
   Gorji HM, 2008, PHYSIOL BEHAV, V93, P622, DOI 10.1016/j.physbeh.2007.11.002
   Gould RW, 2012, NEUROPHARMACOLOGY
   Gruber SA, 2007, NEUROPSYCHOL REV, V17, P299, DOI 10.1007/s11065-007-9041-y
   Gu CL, 2008, NEUROPSYCHOPHARMACOL, V33, P666, DOI 10.1038/sj.npp.1301441
   Gulick D, 2008, NEUROBIOL LEARN MEM, V90, P230, DOI 10.1016/j.nlm.2008.03.002
   Haas HL, 2008, PHYSIOL REV, V88, P1183, DOI 10.1152/physrev.00043.2007
   Herrera DG, 2003, P NATL ACAD SCI USA, V100, P7919, DOI 10.1073/pnas.1230907100
   Hester R, 2010, EXP CLIN PSYCHOPHARM, V18, P489, DOI 10.1037/a0021791
   Hoffman W, 2008, PSYCHOPHARMACOLOGY, V201, P183, DOI 10.1007/s00213-008-1261-1
   Horner WE, 2007, EUR J PHARMACOL, V558, P96, DOI 10.1016/j.ejphar.2006.11.048
   Huang YW, 2004, BEHAV BRAIN RES, V151, P287, DOI 10.1016/j.bbr.2003.09.002
   Huston JP, 1997, BEHAV BRAIN RES, V83, P97, DOI 10.1016/S0166-4328(97)86052-4
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Iannone R, 2010, CLIN PHARMACOL THER, V88, P831, DOI 10.1038/clpt.2010.205
   Ito C, 1997, PSYCHOPHARMACOLOGY, V130, P362, DOI 10.1007/s002130050251
   Izquierdo A, 2010, NEUROPSYCHOPHARMACOL, V35, P505, DOI 10.1038/npp.2009.155
   James LM, 2011, PSYCHOPHARMACOLOGY, V215, P643, DOI 10.1007/s00213-010-2158-3
   Jerlhag E, 2010, PSYCHOPHARMACOLOGY, V211, P415, DOI 10.1007/s00213-010-1907-7
   Jerlhag E, 2009, P NATL ACAD SCI USA, V106, P11318, DOI 10.1073/pnas.0812809106
   Johnsen-Soriano S, 2007, ALCOHOL CLIN EXP RES, V31, P486, DOI 10.1111/j.1530-0277.2006.00329.x
   Kahn L, 2005, EUR J NEUROSCI, V21, P493, DOI 10.1111/j.1460-9568.2005.03883.x
   Kalechstein AD, 2009, J NEUROPSYCH CLIN N, V21, P254, DOI 10.1176/appi.neuropsych.21.3.254
   Kitanaka J, 2007, NEUROSCIENCE, V147, P765, DOI 10.1016/j.neuroscience.2007.05.006
   Kitanaka J, 2010, PHARMACOL BIOCHEM BE, V94, P464, DOI 10.1016/j.pbb.2009.10.009
   Knafo S, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001262
   Kobilo T, 2011, LEARN MEMORY, V18, P103, DOI 10.1101/lm.2001611
   Korotkova TM, 2002, NEUROSCI LETT, V320, P133, DOI 10.1016/S0304-3940(02)00050-2
   Le SY, 2008, J PHARMACOL EXP THER, V325, P902, DOI 10.1124/jpet.107.135343
   Li Z, 2001, PHARMACOL BIOCHEM BE, V68, P507, DOI 10.1016/S0091-3057(01)00456-7
   Ligneau X, 2007, J PHARMACOL EXP THER, V320, P365, DOI 10.1124/jpet.106.111039
   Ligneau X, 2007, BIOCHEM PHARMACOL, V73, P1215, DOI 10.1016/j.bcp.2007.01.023
   Lin JC, 2008, LECT NOTES COMPUT SC, V4975, P3
   Lintunen Minnamaija, 2001, FASEB Journal, V15, P1074
   Loeber S, 2009, ALCOHOL ALCOHOLISM, V44, P372, DOI 10.1093/alcalc/agp030
   Loughead J, 2010, BIOL PSYCHIAT, V67, P715, DOI 10.1016/j.biopsych.2010.01.016
   Ma MX, 2007, NEUROSCIENCE, V147, P1059, DOI 10.1016/j.neuroscience.2007.05.020
   Mann K, 1999, ALCOHOL ALCOHOLISM, V34, P567, DOI 10.1093/alcalc/34.4.567
   MARTINEZMIR MI, 1990, BRAIN RES, V526, P322, DOI 10.1016/0006-8993(90)91240-H
   MASUKAWA Y, 1993, PSYCHOPHARMACOLOGY, V111, P139, DOI 10.1007/BF02245515
   Medhurst AD, 2007, J PHARMACOL EXP THER, V321, P1032, DOI 10.1124/jpet.107.120311
   Melis F, 1996, NEUROSCIENCE, V74, P155, DOI 10.1016/0306-4522(96)00109-1
   Mendez IA, 2008, NEUROBIOL LEARN MEM, V89, P185, DOI 10.1016/j.nlm.2007.08.005
   MICKLEY GA, 1986, BEHAV NEUROSCI, V100, P79, DOI 10.1037/0735-7044.100.1.79
   MOCHIZUKI T, 1994, J NEUROCHEM, V62, P2275
   Molina-Hernandez A, 2008, J NEUROCHEM, V106, P706, DOI 10.1111/j.1471-4159.2008.05424.x
   Mori T, 2004, EUR J PHARMACOL, V491, P169, DOI 10.1016/j.ejphar.2004.03.017
   Morisset S, 2002, J PHARMACOL EXP THER, V300, P621, DOI 10.1124/jpet.300.2.621
   Motawaj M, 2011, EUR J NEUROSCI, V33, P1197, DOI 10.1111/j.1460-9568.2011.07618.x
   Munzar P, 2004, NEUROPSYCHOPHARMACOL, V29, P705, DOI 10.1038/sj.npp.1300380
   Munzar P, 1998, EUR J PHARMACOL, V363, P93, DOI 10.1016/S0014-2999(98)00789-4
   Nagai T, 2007, PSYCHOPHARMACOLOGY, V194, P21, DOI 10.1007/s00213-007-0820-1
   Nestor LJ, 2011, PSYCHIAT RES-NEUROIM, V194, P287, DOI 10.1016/j.pscychresns.2011.04.010
   Noel X, 2007, NEUROPSYCHOLOGY, V21, P778, DOI 10.1037/0894-4105.21.6.778
   Nuutinen S, 2011, NEUROPSYCHOPHARMACOL, V36, P2030, DOI 10.1038/npp.2011.90
   Nuutinen S, 2011, NEUROPHARMACOLOGY, V60, P1193, DOI 10.1016/j.neuropharm.2010.10.027
   Nuutinen S, 2010, PSYCHOPHARMACOLOGY, V208, P75, DOI 10.1007/s00213-009-1710-5
   OISHI R, 1994, N-S ARCH PHARMACOL, V349, P140
   Okuda T, 2004, EUR J PHARMACOL, V505, P135, DOI 10.1016/j.ejphar.2004.10.022
   Olive MF, 2002, EUR J PHARMACOL, V437, P55, DOI 10.1016/S0014-2999(02)01272-4
   Oroszi G, 2005, ALCOHOL CLIN EXP RES, V29, P303, DOI 10.1097/01.ALC.0000156128.28257.2E
   Pace-Schott EF, 2008, AM J DRUG ALCOHOL AB, V34, P109, DOI 10.1080/00952990701764821
   PANULA P, 1984, P NATL ACAD SCI-BIOL, V81, P2572, DOI 10.1073/pnas.81.8.2572
   Panula P, 2011, J PHARMACOL EXP THER, V336, P9, DOI 10.1124/jpet.110.170928
   Pascoli V, 2009, PSYCHOPHARMACOLOGY, V202, P141, DOI 10.1007/s00213-008-1171-2
   Passetti F, 2008, DRUG ALCOHOL DEPEN, V94, P82, DOI 10.1016/j.drugalcdep.2007.10.008
   Pau CWH, 2002, ARCH CLIN NEUROPSYCH, V17, P663, DOI 10.1016/S0887-6177(01)00169-X
   Peterson JD, 2003, BEHAV BRAIN RES, V143, P101, DOI 10.1016/S0166-4328(03)00035-4
   Pillot C, 2002, NEUROSCIENCE, V114, P173, DOI 10.1016/S0306-4522(02)00135-5
   Pitel AL, 2009, ALCOHOL CLIN EXP RES, V33, P490, DOI 10.1111/j.1530-0277.2008.00859.x
   POLLARD H, 1993, NEUROSCIENCE, V52, P169, DOI 10.1016/0306-4522(93)90191-H
   Prosser J, 2006, DRUG ALCOHOL DEPEN, V84, P240, DOI 10.1016/j.drugalcdep.2006.02.006
   Pu L, 2002, J NEUROSCI, V22, P1914, DOI 10.1523/JNEUROSCI.22-05-01914.2002
   Rapeli P, 2006, BMC PSYCHIATRY, V6, DOI 10.1186/1471-244X-6-9
   Reichel CM, 2011, NEUROPSYCHOPHARMACOL, V36, P782, DOI 10.1038/npp.2010.212
   Rendell PG, 2009, PSYCHOPHARMACOLOGY, V203, P609, DOI 10.1007/s00213-008-1408-0
   Reuter M, 2007, DRUG ALCOHOL DEPEN, V87, P69, DOI 10.1016/j.drugalcdep.2006.08.006
   Rouleau A, 2002, BRIT J PHARMACOL, V135, P383, DOI 10.1038/sj.bjp.0704490
   Salahpour A, 2008, P NATL ACAD SCI USA, V105, P4405, DOI 10.1073/pnas.0707646105
   Salo R, 2009, BIOL PSYCHIAT, V65, P706, DOI 10.1016/j.biopsych.2008.11.026
   Sander K, 2008, BIOL PHARM BULL, V31, P2163, DOI 10.1248/bpb.31.2163
   Santin LJ, 2000, ALCOHOL, V20, P149, DOI 10.1016/S0741-8329(99)00070-1
   Savage DD, 2010, ALCOHOL CLIN EXP RES, V34, P1793, DOI 10.1111/j.1530-0277.2010.01266.x
   Schroeder JP, 2004, LEARN MEMORY, V11, P641, DOI 10.1101/lm.78504
   Schwartz JC, 2011, BRIT J PHARMACOL, V163, P713, DOI 10.1111/j.1476-5381.2011.01286.x
   Siegel JA, 2011, J NEUROCHEM, V119, P89, DOI 10.1111/j.1471-4159.2011.07418.x
   Siegel JA, 2010, BEHAV PHARMACOL, V21, P602, DOI 10.1097/FBP.0b013e32833e7e44
   Sofuoglu M, 2012, NEUROPHARMACOLOGY
   Sofuoglu M, 2010, ADDICTION, V105, P38, DOI 10.1111/j.1360-0443.2009.02791.x
   Sofuoglu M, 2009, CNS DRUGS, V23, P939, DOI 10.2165/11310920-000000000-00000
   SPAIN JW, 1991, PSYCHOPHARMACOLOGY, V105, P101, DOI 10.1007/BF02316870
   Stevenson JR, 2009, NEUROPSYCHOPHARMACOL, V34, P1209, DOI 10.1038/npp.2008.90
   Stocking EM, 2008, CURR TOP MED CHEM, V8, P988, DOI 10.2174/156802608784936728
   Streeter CC, 2008, NEUROPSYCHOPHARMACOL, V33, P827, DOI 10.1038/sj.npp.1301465
   SUZUKI T, 1995, BRAIN RES, V675, P195, DOI 10.1016/0006-8993(95)00064-W
   Thompson AM, 2004, NEUROSCIENCE, V127, P177, DOI 10.1016/j.neuroscience.2004.05.001
   Tramullas M, 2008, NEUROPHARMACOLOGY, V54, P640, DOI 10.1016/j.neuropharm.2007.11.018
   van Gorp WG, 1999, ARCH GEN PSYCHIAT, V56, P85, DOI 10.1001/archpsyc.56.1.85
   van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a
   Varaschin RK, 2010, J PHARMACOL EXP THER, V334, P191, DOI 10.1124/jpet.109.165027
   Walker SE, 2011, PSYCHOPHARMACOLOGY, V217, P433, DOI 10.1007/s00213-011-2298-0
   Wang Hui-Juan, 2009, Zhejiang Da Xue Xue Bao Yi Xue Ban, V38, P559
   Wang ZX, 2007, EUR J PHARMACOL, V557, P159, DOI 10.1016/j.ejphar.2006.11.056
   Wang ZX, 2009, PHARMACOL BIOCHEM BE, V91, P590, DOI 10.1016/j.pbb.2008.09.013
   Weiss F, 2005, CURR OPIN PHARMACOL, V5, P9, DOI 10.1016/j.coph.2004.11.001
   Wellendorph P, 2002, NEUROPHARMACOLOGY, V42, P929, DOI 10.1016/S0028-3908(02)00041-2
   Williams MJ, 2008, NEUROPSYCHOPHARMACOL, V33, P1779, DOI 10.1038/sj.npp.1301585
   WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469
   Witkin JM, 2004, PHARMACOL THERAPEUT, V103, P1, DOI 10.1016/j.pharmthera.2004.05.001
   Witte DG, 2006, BRIT J PHARMACOL, V148, P657, DOI 10.1038/sj.bjp.0706752
   Wu DF, 1997, BIOCHEM PHARMACOL, V53, P1605, DOI 10.1016/S0006-2952(97)00014-2
   Xu CQ, 2004, J PHYSIOL-LONDON, V561, P657, DOI 10.1113/jphysiol.2004.071712
   Xu LS, 2005, ACTA PHARMACOL SIN, V26, P1448, DOI 10.1111/j.1745-7254.2005.00229.x
   Yamaguchi M, 2005, SYNAPSE, V58, P63, DOI 10.1002/syn.20182
NR 185
TC 12
Z9 14
U1 0
U2 33
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-4328
EI 1872-7549
J9 BEHAV BRAIN RES
JI Behav. Brain Res.
PD JAN 15
PY 2013
VL 237
BP 357
EP 368
DI 10.1016/j.bbr.2012.09.025
PG 12
WC Behavioral Sciences; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Behavioral Sciences; Neurosciences & Neurology
GA 051IG
UT WOS:000312119200049
PM 23000530
DA 2023-06-23
ER

PT J
AU Tevik, K
   Selbaek, G
   Engedal, K
   Seim, A
   Krokstad, S
   Helvik, AS
AF Tevik, Kjerstin
   Selbaek, Geir
   Engedal, Knut
   Seim, Arnfinn
   Krokstad, Steinar
   Helvik, Anne-S
TI Factors associated with alcohol consumption and prescribed drugs with
   addiction potential among older women and men - the Nord-Trondelag
   health study (HUNT2 and HUNT3), Norway, a population-based longitudinal
   study
SO BMC GERIATRICS
LA English
DT Article
DE Addictive drugs; Ageing; Alcohol; Elderly; Drinkers; Drinking; HUNT;
   Longitudinal study; Psychotropic drugs; Substance misuse
ID HEAVY DRINKING; PSYCHOTROPIC-DRUGS; GENDER-DIFFERENCES; BENZODIAZEPINE
   USE; RISK DRINKING; UNITED-STATES; ADULTS; TRENDS; PREVALENCE; MISUSE
AB Background: Little is known about factors associated with alcohol consumption and use of drugs with addiction potential in older adults. The aim of this study was to explore the association between socio-demographic variables, physical and mental health and the later (11 years) use of frequent drinking, prescribed drugs with addiction potential and the possible combination of frequent drinking and being prescribed drugs with addiction potential in older adults (>= 65 years).
   Methods: In this longitudinal study, we used data from two surveys of the Nord-Trondelag Health Study (HUNT2 1995-1997 and HUNT3 2006-2008), a population based study in Norway. We totally included 10,656 individuals (5683 women) aged 54 years and older when they participated in HUNT2. Frequent drinking was defined as drinking alcohol 4 days or more per week. Data on prescribed drugs with addiction potential were drawn from the Norwegian Prescription Database. Drugs with addiction potential were defined as at least one prescription of benzodiazepines, z-hypnotics or opioids during one year for a minimum of two consecutive years between 2005 and 2009.
   Results: The typical frequent drinker in HUNT3 was younger, more educated, lived in urban areas, and reported smoking and drinking frequently in HUNT2 compared to the non-frequent drinker in HUNT3. The typical user of prescribed drugs with addiction potential in HUNT3 was an older woman who smoked and was in poor health, suffered from anxiety, had been hospitalized in the last 5 years and used anxiety or sleep medication every week or more often in HUNT2. The typical individual in HUNT3 with the possible combination of frequent drinking and being prescribed drugs with addiction potential had more education, smoked, drank frequently and used anxiety or sleep medication in HUNT2.
   Conclusion: Individuals who were identified as frequent drinkers in HUNT2 were more likely to be frequent drinkers in HUNT3, and to have the possible combination of frequent drinking and being prescribed drugs with addiction potential in HUNT3. Health care professionals need to be aware of use of alcohol among older adults using drugs with addiction potential.
C1 [Tevik, Kjerstin; Selbaek, Geir; Engedal, Knut; Helvik, Anne-S] Vestfold Hosp Trust, Norwegian Natl Advisory Unit Ageing & Hlth, Tonsberg, Norway.
   [Tevik, Kjerstin; Seim, Arnfinn; Helvik, Anne-S] Norwegian Univ Sci & Technol NTNU, Dept Publ Hlth & Nursing, Gen Practice Res Unit, Fac Med & Hlth Sci, Trondheim, Norway.
   [Selbaek, Geir] Innlandet Hosp Trust, Res Ctr Age Related Funct Decline & Dis, Ottestad, Norway.
   [Selbaek, Geir] Univ Oslo, Inst Hlth & Soc, Fac Med, Oslo, Norway.
   [Engedal, Knut] Oslo Univ Hosp, Dept Geriatr Med, Oslo, Norway.
   [Krokstad, Steinar] Norwegian Univ Sci & Technol NTNU, Dept Publ Hlth & Nursing, HUNT Res Ctr, Fac Med & Hlth Sci, Levanger, Norway.
   [Krokstad, Steinar] Nord Trondelag Hosp Trust, Levanger Hosp, Dept Psychiat, Levanger, Norway.
   [Helvik, Anne-S] St Olavs Univ Hosp, Trondheim, Norway.
C3 Norwegian University of Science & Technology (NTNU); Innlandet Hospital
   Trust; University of Oslo; University of Oslo; Norwegian University of
   Science & Technology (NTNU); Norwegian University of Science &
   Technology (NTNU)
RP Tevik, K (通讯作者)，Vestfold Hosp Trust, Norwegian Natl Advisory Unit Ageing & Hlth, Tonsberg, Norway.; Tevik, K (通讯作者)，Norwegian Univ Sci & Technol NTNU, Dept Publ Hlth & Nursing, Gen Practice Res Unit, Fac Med & Hlth Sci, Trondheim, Norway.
EM kjtev@online.no
OI Selbaek, Geir/0000-0001-6511-8219; Tevik, Kjerstin/0000-0002-9810-8276;
   Krokstad, Steinar/0000-0002-2932-6675
FU Norwegian Extra Foundation for Health and Rehabilitation through the
   Norwegian Council for Mental Health [2015/FO5044]; Norwegian National
   Advisory Unit on Ageing and Health, Vestfold Hospital Trust
FX This project has been made possible by the Norwegian Extra Foundation
   for Health and Rehabilitation (https://www.extrastiftelsen.no/) through
   the Norwegian Council for Mental Health (http://www.psykiskhelse.no/)
   (2015/FO5044). In addition, the project has been funded partly by the
   Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital
   Trust (http://www.aldringoghelse.no/).KT is a PhD fellow in this project
   and she received the funding. The funders had no role in the study
   design, data collection and analyses, decision to publish, or
   preparation of the manuscript.
CR Abdulla A, 2013, AGE AGEING, V42, pI1, DOI 10.1093/ageing/afs200
   Andersen AB, 2011, PHARMACOEPIDEMIOL DR, V20
   Barnes AJ, 2010, J GEN INTERN MED, V25, P840, DOI 10.1007/s11606-010-1341-x
   Bell HT, 2015, SCAND J PRIM HLTH CA, V33
   Bjork C, 2008, ALCOHOL CLIN EXP RES, V32, P120, DOI 10.1111/j.1530-0277.2007.00557.x
   Bratberg GH, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3384-3
   Breslow RA, 2015, ALCOHOL CLIN EXP RES, V39, P371, DOI 10.1111/acer.12633
   Britton A, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0273-z
   Campbell CI, 2010, AM J PUBLIC HEALTH, V100, P2541, DOI 10.2105/AJPH.2009.180646
   Cousins G, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-57
   Crowley K, 2011, NEUROPSYCHOL REV, V21, P41, DOI 10.1007/s11065-010-9154-6
   Daatland SO, 2013, 152013 NOVA NORW I G
   Desai HD, 2001, CNS DRUGS, V15, P469, DOI 10.2165/00023210-200115060-00005
   Dixon MA, 2016, ALCOHOL RES, V38
   Du Y, 2008, PHARMACOPSYCHIATRY, V41, P242, DOI 10.1055/s-0028-1083791
   Du Y, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012182
   Emiliussen J, 2017, SUBST USE MISUSE, V52, P1575, DOI 10.1080/10826084.2017.1293102
   Gavens L, 2016, PUBLIC HEALTH, V139, P79, DOI 10.1016/j.puhe.2016.05.016
   GBD 2016 Alcohol Collaborators, 2018, Lancet (British edition), V392, P1015, DOI 10.1016/s0140-6736(18)31310-2
   Geels LM, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-207
   Gell L, 2015, ALCOHOL ALCOHOLISM, V50, P1, DOI 10.1093/alcalc/agu082
   Grant BF, 2017, JAMA PSYCHIAT, V74, P911, DOI 10.1001/jamapsychiatry.2017.2161
   Gray SL, 2003, AM J GERIATR PSYCHIA, V11
   Greenspan JD, 2007, PAIN, V132
   Hajat S, 2004, AGE AGEING, V33, P170, DOI 10.1093/ageing/afh046
   Han BH, 2017, DRUG ALCOHOL DEPEN, V170, P198, DOI 10.1016/j.drugalcdep.2016.11.003
   Harkonen JT, 2011, ALCOHOL ALCOHOL, V46
   Hartz I, 2011, NORSK FARMACEUTISK T, V4
   Helvik AS, 2011, NORD J PSYCHIAT, V65, P338, DOI 10.3109/08039488.2011.560684
   Hoeck S, 2013, EUR J PUB HLTH, V23
   Holahan CJ, 2014, ALCOHOL CLIN EXP RES, V38, P1432, DOI 10.1111/acer.12381
   Holmen J, 2003, NORSK EPIDEMIOLOGI, V13
   Ilomaki J, 2013, ANN PHARMACOTHER, V47, P257, DOI 10.1345/aph.1R449
   Ilomaki J, 2008, ALCOHOL, V42, P261, DOI 10.1016/j.alcohol.2008.02.002
   Immonen S, 2013, SCAND J PRIM HLTH CA, V31
   Jacob L, 2017, THER ADV PSYCHOPHARM, V7, P191, DOI 10.1177/2045125317696454
   Johannessen A, 2015, QUAL PRIM CARE, V23
   Johannessen A, 2017, NORDIC STUD ALCOHOL, V34
   Johannessen A, 2016, SCAND J CARING SCI, V30, P586, DOI 10.1111/scs.12282
   Johannessen A, 2015, SCAND J CARING SCI, V29, P325, DOI 10.1111/scs.12166
   Johnell K, 2017, INT J GERIATR PSYCH, V32, P414, DOI 10.1002/gps.4483
   Kirchner JE, 2007, J GEN INTERN MED, V22, P92, DOI 10.1007/s11606-006-0017-z
   Krokstad S, 2013, INT J EPIDEMIOL, V42, P968, DOI 10.1093/ije/dys095
   Krokstad S, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-016-3993-x
   Langhammer A, 2000, J EPIDEMIOL COMMUNIT, V54
   Langhammer A, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-143
   Leon-Munoz LM, 2015, J ACAD NUTR DIET, V115, P213, DOI 10.1016/j.jand.2014.08.017
   Li J, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0562-9
   Luijendijk HJ, 2008, BR J CLIN PHARM, V65
   Maust DT, 2016, J AM GERIATR SOC, V64, P2546, DOI 10.1111/jgs.14379
   Moore Alison A, 2007, Am J Geriatr Pharmacother, V5, P64, DOI 10.1016/j.amjopharm.2007.03.006
   Moos RH, 2004, ADDICTION, V99
   Mykletun A, 2001, BR J PSYCHIAT, V179
   Neutel CI, 2012, SLEEP MED, V13, P893, DOI 10.1016/j.sleep.2011.12.014
   NIAAA, UND IMP ALC HUM HLTH
   NIAAA, 2007, ALCOHOL ALERT
   Nordfjaern T, 2015, SUBST USE MISUSE, V50, P1284, DOI 10.3109/10826084.2014.998237
   Nordfjaern T, 2014, NORD J PSYCHIAT, V68, P107, DOI 10.3109/08039488.2013.775342
   Nordfjaern T, 2012, ADDICT BEHAV, V37, P1151, DOI 10.1016/j.addbeh.2012.05.017
   Qato DM, 2015, J AM GERIATR SOC, V63, P2324, DOI 10.1111/jgs.13787
   Reczek C, 2016, J HLTH SOC BEHAV, V57
   Rose JE, 2004, NICOTINE TOB RES, V6
   Sacco P, 2014, SUBST USE MISUSE, V49, P456, DOI 10.3109/10826084.2013.846379
   Satre D, 2015, CLIN PSYCHOL SCI PRA, V22
   Shi Y, 2011, NICOTINE TOB RES, V13, P919, DOI 10.1093/ntr/ntr097
   Skurtveit S, 2008, PHARMACOEPIDEMIOL DR, V17
   Stordal E, 2008, J AFFECT DISORD, V106
   Stowell KR, 2008, J AM GERIATR SOC, V56, P2285, DOI 10.1111/j.1532-5415.2008.02011.x
   Tevik K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184428
   Wadd Sarah, 2014, BMC Res Notes, V7, P741, DOI 10.1186/1756-0500-7-741
   West NA, 2015, DRUG ALCOHOL DEPEN, V149, P117, DOI 10.1016/j.drugalcdep.2015.01.027
   Wilhelm KA, 2009, AUST FAM PHYSICIAN, V38, P102
   Wolf IK, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1254-x
   Xu Y, 2012, J ANXIETY DISORD, V26, P12, DOI 10.1016/j.janxdis.2011.08.006
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 75
TC 9
Z9 9
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2318
J9 BMC GERIATR
JI BMC Geriatr.
PD APR 18
PY 2019
VL 19
AR 113
DI 10.1186/s12877-019-1114-2
PG 15
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA HU0TQ
UT WOS:000464984600001
PM 30999872
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Kroll, S
   Kexel, AK
   Boost, C
   Pahlisch, F
   Rohleder, C
   Leweke, FM
   Quednow, B
AF Kroll, Sara
   Kexel, Ann-Kathrin
   Boost, Carola
   Pahlisch, Franziska
   Rohleder, Cathrin
   Leweke, Franz-Markus
   Quednow, Boris
TI Associations Between the Endocannabinoid System and Drug Craving in
   Chronic Cocaine Users
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the American-College-of-Neuropsychopharmacology
   (ACNP)
CY DEC 04-07, 2022
CL Phoenix, AZ
SP Amer Coll Neuropsychopharmacol
DE Endocannabinoids; Cocaine Addiction; Addiction; Craving
C1 [Kroll, Sara; Kexel, Ann-Kathrin; Boost, Carola; Pahlisch, Franziska; Rohleder, Cathrin; Leweke, Franz-Markus; Quednow, Boris] Univ Zurich, Psychiat Univ Hosp Zurich, Zurich, Switzerland.
C3 University of Zurich
RI Kroll, Sara/ABD-2945-2020; Quednow, Boris B./A-1666-2008
OI Quednow, Boris B./0000-0001-7933-2865
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0893-133X
EI 1740-634X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD DEC
PY 2022
VL 47
SU 1
MA P635
BP 421
EP 422
PG 2
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 6Z7EE
UT WOS:000897934700792
DA 2023-06-23
ER

PT J
AU Herve, D
AF Herve, Denis
TI Addiction: an epigenetic story of histone methylation
SO M S-MEDECINE SCIENCES
LA French
DT News Item
ID COCAINE-INDUCED PLASTICITY; STRUCTURAL PLASTICITY; DRUG-ADDICTION;
   MECHANISMS; DOPAMINE; ABUSE
C1 Univ Paris 06, INSERM, Inst Fer Moulin, UMR S839, F-75005 Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite
RP Herve, D (通讯作者)，Univ Paris 06, INSERM, Inst Fer Moulin, UMR S839, 17 Rue Fer Moulin, F-75005 Paris, France.
EM denis.herve@inserm.fr
RI HERVE, Denis/E-2929-2017
OI HERVE, Denis/0000-0003-1376-1522
CR Bertin A, 2008, M S-MED SCI, V24, P715, DOI 10.1051/medsci/20082489715
   Borrelli E, 2008, NEURON, V60, P961, DOI 10.1016/j.neuron.2008.10.012
   Brami-Cherrier K, 2005, J NEUROSCI, V25, P11444, DOI 10.1523/JNEUROSCI.1711-05.2005
   Brami-Cherrier K, 2009, J NEUROCHEM, V108, P1323, DOI 10.1111/j.1471-4159.2009.05879.x
   Chao J, 2004, ANNU REV MED, V55, P113, DOI 10.1146/annurev.med.55.091902.103730
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Kumar A, 2005, NEURON, V48, P303, DOI 10.1016/j.neuron.2005.09.023
   Maze I, 2010, SCIENCE, V327, P213, DOI 10.1126/science.1179438
   Morange M, 2005, M S-MED SCI, V21, P367, DOI 10.1051/medsci/2005214367
   Nestler EJ, 2008, PHILOS T R SOC B, V363, P3245, DOI 10.1098/rstb.2008.0067
   Renthal W, 2008, TRENDS MOL MED, V14, P341, DOI 10.1016/j.molmed.2008.06.004
   Renthal W, 2009, NEURON, V62, P335, DOI 10.1016/j.neuron.2009.03.026
   Robinson TE, 2004, NEUROPHARMACOLOGY, V47, P33, DOI 10.1016/j.neuropharm.2004.06.025
   Russo SJ, 2009, NEUROPHARMACOLOGY, V56, P73, DOI 10.1016/j.neuropharm.2008.06.059
   Schultz W, 2002, NEURON, V36, P241, DOI 10.1016/S0896-6273(02)00967-4
   Stipanovich A, 2008, NATURE, V453, P879, DOI 10.1038/nature06994
NR 16
TC 3
Z9 3
U1 0
U2 2
PU EDITIONS EDK
PI SEVRES CEDEX
PA 2 RUE TROYON, SEVRES CEDEX, 92316, FRANCE
SN 0767-0974
J9 M S-MED SCI
JI M S-Med. Sci.
PD JUN-JUL
PY 2010
VL 26
IS 6-7
BP 568
EP 571
DI 10.1051/medsci/2010266-7568
PG 4
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 630UV
UT WOS:000280301200005
PM 20619152
OA Bronze
DA 2023-06-23
ER

PT J
AU Rahman, S
   Lopez-Hernandez, GY
   Corrigall, WA
   Papke, RL
AF Rahman, Shafiqur
   Lopez-Hernandez, Gretchen Y.
   Corrigall, William A.
   Papke, Roger L.
TI Neuronal Nicotinic Receptors as Brain Targets for Pharmacotherapy of
   Drug Addiction
SO CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS
LA English
DT Review
DE Drug addiction; nicotinic receptors; nicotine; alcohol; cocaine;
   methamphetamine; opiate; dopamine
ID VENTRAL TEGMENTAL AREA; DIHYDRO-BETA-ERYTHROIDINE; INDUCED DOPAMINE
   RELEASE; RAT NUCLEUS-ACCUMBENS; ALPHA-CONOTOXIN-MII;
   METHAMPHETAMINE-SEEKING BEHAVIOR; BRONCHIAL EPITHELIAL-CELLS; VOLUNTARY
   ETHANOL INTAKE; SINGLE-CHANNEL CURRENTS; SUBUNIT MESSENGER-RNA
AB Nicotine addiction and other forms of drug addiction continue to be significant public health problems in the United States and the rest of the world. Accumulated evidence indicates that brain nicotinic acetylcholine receptors (nAChRs) are a heterogenous family of ion channels expressed in the various parts of the brain. A growing body of preclinical studies suggests that brain nAChRs are critical targets for the development of pharmacotherapies for nicotine and other drug addictions. In this review, we will discuss the nAChR subtypes, their function in response to endogenous brain transmitters, and how their functions are regulated in the presence of nicotine. Furthermore, we will discuss the role of nAChRs in mediating nicotine-induced addictive behavior in animal models. Additionally, we will provide an overview of the effects of nicotine and nicotinic compounds on the mesolimbic dopamine system, part of the reinforcement/reward circuitry of the brain, as an example of the neurochemical basis of nicotine addiction and other drug addictions. An appreciation of the complexity of nicotinic receptors and their regulation will be necessary for the development of nicotinic receptor modulators as potential pharmacotherapy for drug addiction.
C1 [Rahman, Shafiqur] S Dakota State Univ, Coll Pharm, Dept Pharmaceut Sci, Brookings, SD 57007 USA.
   [Lopez-Hernandez, Gretchen Y.; Papke, Roger L.] Univ Florida, Coll Med, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA.
   [Corrigall, William A.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55404 USA.
   [Corrigall, William A.] Minneapolis Med Res Fdn Inc, Minneapolis, MN 55404 USA.
C3 South Dakota State University; State University System of Florida;
   University of Florida; University of Minnesota System; University of
   Minnesota Twin Cities; Minneapolis Medical Research Foundation
RP Rahman, S (通讯作者)，S Dakota State Univ, Coll Pharm, Dept Pharmaceut Sci, Brookings, SD 57007 USA.
EM shafiqur.rahman@sdstate.edu; rlpapke@ufl.edu
RI Rahman, Shafiqur/P-6206-2018
OI Rahman, Shafiqur/0000-0002-6289-5386
FU NIH [DA 09577, T32 AG00196, GM57481]
FX The authors acknowledge support from the NIH grants DA 09577, T32
   AG00196 and GM57481.
CR ADAMS DJ, 1992, J PHYSIOLOGY-PARIS, V86, P67, DOI 10.1016/S0928-4257(05)80009-9
   Albuquerque EX, 1996, PROG BRAIN RES, V109, P111
   Alkondon M, 1998, BRAIN RES, V810, P257, DOI 10.1016/S0006-8993(98)00880-4
   Amos CI, 2008, NAT GENET, V40, P616, DOI 10.1038/ng.109
   ANAND R, 1991, J BIOL CHEM, V266, P11192
   ANTONELLI T, 1986, BRIT J PHARMACOL, V89, P853, DOI 10.1111/j.1476-5381.1986.tb11191.x
   Auerbach A, 1998, J GEN PHYSIOL, V112, P181, DOI 10.1085/jgp.112.2.181
   Balfour DJK, 2004, NICOTINE TOB RES, V6, P899, DOI 10.1080/14622200412331324965
   Benwell MEM, 1998, BRIT J PHARMACOL, V125, P1115, DOI 10.1038/sj.bjp.0702161
   BENWELL MEM, 1992, BRIT J PHARMACOL, V105, P849, DOI 10.1111/j.1476-5381.1992.tb09067.x
   BENWELL MEM, 1995, BRIT J PHARMACOL, V114, P454, DOI 10.1111/j.1476-5381.1995.tb13248.x
   Berrettine W, 2008, MOL PSYCHIATR, V13, P368, DOI 10.1038/sj.mp.4002154
   BERTRAND D, 1992, P NATL ACAD SCI USA, V89, P1261, DOI 10.1073/pnas.89.4.1261
   BERTRAND D, 1990, P NATL ACAD SCI USA, V87, P1993, DOI 10.1073/pnas.87.5.1993
   Bertrand S, 1997, NEUROREPORT, V8, P3591, DOI 10.1097/00001756-199711100-00034
   Bibevski S, 2000, J NEUROSCI, V20, P5076
   BIEN TH, 1990, INT J ADDICT, V25, P1429, DOI 10.3109/10826089009056229
   Blokhina EA, 2005, EUR NEUROPSYCHOPHARM, V15, P219, DOI 10.1016/j.euroneuro.2004.07.005
   BLOMQVIST O, 1993, EUR J PHARMACOL, V249, P207, DOI 10.1016/0014-2999(93)90434-J
   Blomqvist O, 1997, EUR J PHARMACOL, V334, P149, DOI 10.1016/S0014-2999(97)01220-X
   BLOMQVIST O, 1992, BRAIN RES BULL, V29, P173, DOI 10.1016/0361-9230(92)90023-Q
   Blomqvist O, 1996, EUR J PHARMACOL, V314, P257, DOI 10.1016/S0014-2999(96)00583-3
   Blomqvist O, 2002, ALCOHOL CLIN EXP RES, V26, P326, DOI 10.1097/00000374-200203000-00004
   Bondarev ML, 2003, EUR J PHARMACOL, V474, P85, DOI 10.1016/S0014-2999(03)02010-7
   Borsook D, 2006, NAT REV DRUG DISCOV, V5, P411, DOI 10.1038/nrd2027
   BOULTER J, 1987, P NATL ACAD SCI USA, V84, P7763, DOI 10.1073/pnas.84.21.7763
   Bouzat C, 2004, NATURE, V430, P896, DOI 10.1038/nature02753
   BOYD ND, 1987, J PHYSIOL-LONDON, V389, P45, DOI 10.1113/jphysiol.1987.sp016646
   BRAZELL MP, 1990, NEUROPHARMACOLOGY, V29, P1177, DOI 10.1016/0028-3908(90)90042-P
   Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011
   Bruijnzeel AW, 2003, SYNAPSE, V50, P20, DOI 10.1002/syn.10242
   Brunzell D, 2006, PSYCHOPHARMACOLOGY, V184, P328, DOI 10.1007/s00213-005-0099-z
   Buisson B, 2002, TRENDS PHARMACOL SCI, V23, P130, DOI 10.1016/S0165-6147(00)01979-9
   Cadoni C, 2000, EUR J PHARMACOL, V387, pR23, DOI 10.1016/S0014-2999(99)00843-2
   Carlisle DL, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-27
   CARTAUD J, 1973, FEBS LETT, V33, P109, DOI 10.1016/0014-5793(73)80171-1
   Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1
   Champtiaux N, 2006, BEHAV BRAIN RES, V168, P120, DOI 10.1016/j.bbr.2005.10.017
   Changeux J-P., 1981, ACETYLCHOLINE RECEPT
   Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9
   CHANGEUX JP, 1986, J PHYSIOL-LONDON, V378, P497, DOI 10.1113/jphysiol.1986.sp016232
   CHANGEUX JP, 1984, SCIENCE, V225, P1335, DOI 10.1126/science.6382611
   Charpantier E, 1998, NEUROREPORT, V9, P3097, DOI 10.1097/00001756-199809140-00033
   Chi H, 2003, ALCOHOL CLIN EXP RES, V27, P780, DOI 10.1097/01.ALC.0000065435.12068.24
   Christianson JC, 2004, EMBO J, V23, P4156, DOI 10.1038/sj.emboj.7600436
   Coe JW, 2005, BIOORG MED CHEM LETT, V15, P2974, DOI 10.1016/j.bmcl.2005.04.036
   Coe JW, 2005, J MED CHEM, V48, P3474, DOI 10.1021/jm050069n
   Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924
   COLQUHOUN D, 1988, J PHYSIOL-LONDON, V395, P131, DOI 10.1113/jphysiol.1988.sp016912
   COLQUHOUN D, 1981, NATURE, V294, P464, DOI 10.1038/294464a0
   COLQUHOUN D, 1985, J PHYSIOL-LONDON, V369, P501, DOI 10.1113/jphysiol.1985.sp015912
   COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0
   CORRIGALL WA, 1994, BRAIN RES, V653, P278, DOI 10.1016/0006-8993(94)90401-4
   CORRIGALL WA, 1992, PSYCHOPHARMACOLOGY, V107, P285, DOI 10.1007/BF02245149
   CORRIGALL WA, 1989, PSYCHOPHARMACOLOGY, V99, P473, DOI 10.1007/BF00589894
   Corringer PJ, 2006, J PHYSIOL-PARIS, V99, P162, DOI 10.1016/j.jphysparis.2005.12.012
   CORRINGER PJ, 1995, J BIOL CHEM, V270, P11749, DOI 10.1074/jbc.270.20.11749
   COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F
   CROSSLAND J, 1984, NEUROCHEM RES, V9, P351, DOI 10.1007/BF00963983
   Cryan JF, 2003, PSYCHOPHARMACOLOGY, V168, P347, DOI 10.1007/s00213-003-1445-7
   Cui CH, 2003, J NEUROSCI, V23, P11045
   Cunningham CS, 2006, DRUG ALCOHOL DEPEN, V84, P211, DOI 10.1016/j.drugalcdep.2006.01.012
   Dajas-Bailador F, 2004, TRENDS PHARMACOL SCI, V25, P317, DOI 10.1016/j.tips.2004.04.006
   Damaj MI, 1997, J PHARMACOL EXP THER, V282, P410
   Damaj MI, 2004, MOL PHARMACOL, V66, P675, DOI 10.1124/mol.104.001313
   Dani JA, 2005, NAT NEUROSCI, V8, P1465, DOI 10.1038/nn1580
   Dani JA, 2003, MOL PSYCHIATR, V8, P255, DOI 10.1038/sj.mp.4001284
   Dani JA, 2007, ANNU REV PHARMACOL, V47, P699, DOI 10.1146/annurev.pharmtox.47.120505.105214
   Davis TJ, 2006, ALCOHOL RES HEALTH, V29, P179
   De Biasi M, 2000, EUR J PHARMACOL, V393, P137, DOI 10.1016/S0014-2999(00)00008-X
   DEBIASI M, 2002, CURR DRUG TARGETS, V1, P409
   DECKER ER, 1990, J NEUROSCI, V10, P3413
   DENERIS ES, 1989, J BIOL CHEM, V264, P6268
   Desai RI, 2003, PSYCHOPHARMACOLOGY, V167, P335, DOI 10.1007/s00213-003-1426-x
   Di Chiara G, 2004, NEUROPHARMACOLOGY, V47, P227, DOI 10.1016/j.neuropharm.2004.06.032
   Drenan RM, 2008, NEURON, V60, P123, DOI 10.1016/j.neuron.2008.09.009
   Dwoskin LP, 2007, BIOCHEM PHARMACOL, V74, P1271, DOI 10.1016/j.bcp.2007.07.021
   ELDEFRAWI ME, 1980, P NATL ACAD SCI-BIOL, V77, P2309, DOI 10.1073/pnas.77.4.2309
   ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X
   Elgoyhen AB, 2001, P NATL ACAD SCI USA, V98, P3501, DOI 10.1073/pnas.051622798
   Ericson M, 1998, EUR J PHARMACOL, V358, P189, DOI 10.1016/S0014-2999(98)00602-5
   Ericson M, 2003, EUR J PHARMACOL, V467, P85, DOI 10.1016/S0014-2999(03)01564-4
   Ericson M, 2008, J PHARMACOL EXP THER, V326, P76, DOI 10.1124/jpet.108.137489
   FELTZ A, 1982, J PHYSIOL-LONDON, V322, P257, DOI 10.1113/jphysiol.1982.sp014036
   Feng Y, 2004, AM J HUM GENET, V75, P112, DOI 10.1086/422194
   FLORES CM, 1992, MOL PHARMACOL, V41, P31
   Frazier CJ, 1998, J NEUROSCI, V18, P8228
   Freedman R, 2007, AM J PSYCHIAT, V164, P1269, DOI 10.1176/appi.ajp.2007.07020326
   Fu Y, 2000, NEUROSCIENCE, V101, P369, DOI 10.1016/S0306-4522(00)00371-7
   Fuchs PA, 1996, CURR OPIN NEUROBIOL, V6, P514, DOI 10.1016/S0959-4388(96)80058-4
   Fucile S, 1998, EUR J NEUROSCI, V10, P172, DOI 10.1046/j.1460-9568.1998.00001.x
   Gahring LC, 2004, J COMP NEUROL, V468, P322, DOI 10.1002/cne.10942
   Gaimarri A, 2007, BRAIN RES REV, V55, P134, DOI 10.1016/j.brainresrev.2007.02.005
   Gallardo KA, 1998, J NEUROCHEM, V70, P663
   GALZI JL, 1991, P NATL ACAD SCI USA, V88, P5051, DOI 10.1073/pnas.88.11.5051
   Gault J, 2003, AM J MED GENET B, V123B, P39, DOI 10.1002/ajmg.b.20061
   GERZANICH V, 1994, MOL PHARMACOL, V45, P212
   GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003
   Glick SD, 2000, NEUROREPORT, V11, P2013, DOI 10.1097/00001756-200006260-00041
   Glick SD, 1996, BRAIN RES, V719, P29, DOI 10.1016/0006-8993(96)00056-X
   Glick SD, 2002, EUR J PHARMACOL, V438, P99, DOI 10.1016/S0014-2999(02)01284-0
   Goldner FM, 1997, NEUROREPORT, V8, P2739
   Gommans J, 2000, NEUROPHARMACOLOGY, V39, P2840, DOI 10.1016/S0028-3908(00)00130-1
   Gotti C, 2005, MOL PHARMACOL, V67, P2007, DOI 10.1124/mol.105.011940
   GOTTI C, 1994, EUR J NEUROSCI, V6, P1281, DOI 10.1111/j.1460-9568.1994.tb00318.x
   Gotti C, 1997, PROG NEUROBIOL, V53, P199, DOI 10.1016/S0301-0082(97)00034-8
   Gotti C, 2004, PROG NEUROBIOL, V74, P363, DOI 10.1016/j.pneurobio.2004.09.006
   Gotti C, 2007, BIOCHEM PHARMACOL, V74, P1102, DOI 10.1016/j.bcp.2007.05.023
   Gotti C, 2006, TRENDS PHARMACOL SCI, V27, P482, DOI 10.1016/j.tips.2006.07.004
   Grady SR, 1997, J PHARMACOL EXP THER, V282, P32
   Grady SR, 2002, J PHARMACOL EXP THER, V301, P651, DOI 10.1124/jpet.301.2.651
   GRANDO SA, 1995, J INVEST DERMATOL, V105, P774, DOI 10.1111/1523-1747.ep12325606
   Grando SA, 1996, J INVEST DERMATOL, V107, P412, DOI 10.1111/1523-1747.ep12363399
   Gray R, 1996, NATURE, V383, P713, DOI 10.1038/383713a0
   Gronlien JH, 2007, MOL PHARMACOL, V72, P715, DOI 10.1124/mol.107.035410
   Groot-Kormelink PJ, 1998, J BIOL CHEM, V273, P15317, DOI 10.1074/jbc.273.25.15317
   Grottick AJ, 2000, J PHARMACOL EXP THER, V294, P1112
   Grutter T, 2001, TRENDS BIOCHEM SCI, V26, P459, DOI 10.1016/S0968-0004(01)01921-1
   Han ZY, 2000, EUR J NEUROSCI, V12, P3664, DOI 10.1046/j.1460-9568.2000.00262.x
   Hansen SB, 2005, EMBO J, V24, P3635, DOI 10.1038/sj.emboj.7600828
   Hansen ST, 2007, PSYCHOPHARMACOLOGY, V194, P53, DOI 10.1007/s00213-007-0822-z
   Harrison AA, 2002, PSYCHOPHARMACOLOGY, V160, P56, DOI 10.1007/s00213-001-0953-6
   Harrod SB, 2001, J PHARMACOL EXP THER, V298, P172
   Hasselmo ME, 2006, CURR OPIN NEUROBIOL, V16, P710, DOI 10.1016/j.conb.2006.09.002
   Hatton GI, 2002, J NEUROSCI, V22, P29, DOI 10.1523/JNEUROSCI.22-01-00029.2002
   Hefft S, 1999, J PHYSIOL-LONDON, V515, P769, DOI 10.1111/j.1469-7793.1999.769ab.x
   HEIDMANN T, 1978, ANNU REV BIOCHEM, V47, P317, DOI 10.1146/annurev.bi.47.070178.001533
   HEIDMANN T, 1981, FEBS LETT, V131, P239, DOI 10.1016/0014-5793(81)80375-4
   HEINEMANN S, 1991, CLIN NEUROPHARMACOL, V14, pS45, DOI 10.1097/00002826-199114001-00007
   Hiranita T, 2004, ANN NY ACAD SCI, V1025, P504, DOI 10.1196/annals.1316.062
   Hiranita T, 2006, P NATL ACAD SCI USA, V103, P8523, DOI 10.1073/pnas.0600347103
   Hogg RC, 2003, REV PHYSIOL BIOCH P, V147, P1, DOI 10.1007/s10254-003-0005-1
   Horch HLW, 1995, J NEUROSCI, V15, P7778
   Horenstein NA, 2007, J BIOL CHEM, V282, P5899, DOI 10.1074/jbc.M609202200
   HORN R, 1984, J GEN PHYSIOL, V84, P505, DOI 10.1085/jgp.84.4.505
   HUGANIR RL, 1986, NATURE, V321, P774, DOI 10.1038/321774a0
   Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885
   Hutchison KE, 2007, ARCH GEN PSYCHIAT, V64, P1078, DOI 10.1001/archpsyc.64.9.1078
   IMPERATO A, 1986, EUR J PHARMACOL, V132, P337, DOI 10.1016/0014-2999(86)90629-1
   ISTVAN J, 1984, PSYCHOL BULL, V95, P301, DOI 10.1037/0033-2909.95.2.301
   Itier V, 2002, NEUROPHYSIOL CLIN, V32, P99, DOI 10.1016/S0987-7053(02)00294-0
   Jackson KJ, 2008, J PHARMACOL EXP THER, V325, P302, DOI 10.1124/jpet.107.132977
   JACKSON MB, 1990, PFLUG ARCH EUR J PHY, V417, P129, DOI 10.1007/BF00370689
   JAMES JR, 1994, PSYCHOPHARMACOLOGY, V114, P456, DOI 10.1007/BF02249336
   Jones IW, 2001, J COMP NEUROL, V439, P235, DOI 10.1002/cne.1345
   Jones S, 1999, TRENDS NEUROSCI, V22, P555, DOI 10.1016/S0166-2236(99)01471-X
   Kaiser SA, 1998, J NEUROCHEM, V70, P1069
   KAO PN, 1984, J BIOL CHEM, V259, P1662
   KAO PN, 1986, J BIOL CHEM, V261, P8085
   Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7
   KATZ B, 1957, J PHYSIOL-LONDON, V138, P63, DOI 10.1113/jphysiol.1957.sp005838
   KEYSER KT, 1993, J NEUROSCI, V13, P442
   King SL, 2004, NEUROPHARMACOLOGY, V47, P132, DOI 10.1016/j.neuropharm.2004.06.024
   Klink R, 2001, J NEUROSCI, V21, P1452, DOI 10.1523/JNEUROSCI.21-05-01452.2001
   Kohen I, 2007, AM J PSYCHIAT, V164, P1269, DOI 10.1176/appi.ajp.2007.07010173
   Koob G. F., 2005, NEUROBIOLOGY ADDICTI
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Kulak JM, 1997, J NEUROSCI, V17, P5263
   Kuryatov A, 2000, NEUROPHARMACOLOGY, V39, P2570, DOI 10.1016/S0028-3908(00)00144-1
   Larsson A, 2004, NEUROSCI BIOBEHAV R, V27, P713, DOI 10.1016/j.neubiorev.2003.11.010
   Larsson A, 2002, ALCOHOL, V28, P157, DOI 10.1016/S0741-8329(02)00244-6
   Le AD, 2000, ALCOHOL CLIN EXP RES, V24, P155, DOI 10.1111/j.1530-0277.2000.tb04585.x
   Lecca D, 2006, PSYCHOPHARMACOLOGY, V184, P435, DOI 10.1007/s00213-005-0280-4
   Lee MG, 2005, J NEUROSCI, V25, P4365, DOI 10.1523/JNEUROSCI.0178-05.2005
   LeNovere N, 1996, EUR J NEUROSCI, V8, P2428
   LENOVERE N, 1995, J MOL EVOL, V40, P155, DOI 10.1007/BF00167110
   Lerman C, 2007, NAT REV DRUG DISCOV, V6, P746, DOI 10.1038/nrd2361
   LeSage MG, 2006, PSYCHOPHARMACOLOGY, V184, P409, DOI 10.1007/s00213-005-0027-2
   LeSage MG, 2003, PSYCHOPHARMACOLOGY, V170, P278, DOI 10.1007/s00213-003-1539-2
   LeSage MG, 2002, PHARMACOL BIOCHEM BE, V72, P279, DOI 10.1016/S0091-3057(01)00775-4
   LESAGE MG, PHARM BIOCH IN PRESS
   Lester HA, 2003, CURR OPIN DRUG DISC, V6, P633
   Levin ED, 2000, PHYSIOL BEHAV, V71, P565, DOI 10.1016/S0031-9384(00)00382-6
   Li MD, 2005, HUM MOL GENET, V14, P1211, DOI 10.1093/hmg/ddi132
   Lindblom N, 2005, N-S ARCH PHARMACOL, V372, P182, DOI 10.1007/s00210-005-0019-0
   Lindblom N, 2002, RESPIRATION, V69, P254, DOI 10.1159/000063629
   Lindstrom J, 1997, MOL NEUROBIOL, V15, P193, DOI 10.1007/BF02740634
   Lindstrom JM, 2000, MUSCLE NERVE, V23, P453, DOI 10.1002/(SICI)1097-4598(200004)23:4<453::AID-MUS3>3.0.CO;2-O
   Lopez-Hernandez G, 2007, NEUROPHARMACOLOGY, V53, P134, DOI 10.1016/j.neuropharm.2007.04.007
   Lopez-Hernandez GY, 2004, J BIOL CHEM, V279, P38007, DOI 10.1074/jbc.M403537200
   LUETJE CW, 1991, J NEUROSCI, V11, P837
   LUKAS RJ, 1991, J NEUROCHEM, V56, P1134, DOI 10.1111/j.1471-4159.1991.tb11403.x
   Lummis SCR, 2005, NATURE, V438, P248, DOI 10.1038/nature04130
   Luo SQ, 1998, J NEUROSCI, V18, P8571
   Malin DH, 1996, PHARMACOL BIOCHEM BE, V53, P81, DOI 10.1016/0091-3057(95)00202-2
   Malin DH, 2006, PSYCHOPHARMACOLOGY, V184, P494, DOI 10.1007/s00213-005-0135-z
   Mansbach RS, 2000, PSYCHOPHARMACOLOGY, V148, P234, DOI 10.1007/s002130050047
   Mansvelder HD, 2000, NEURON, V27, P349, DOI 10.1016/S0896-6273(00)00042-8
   Mansvelder HD, 2002, NEURON, V33, P905, DOI 10.1016/S0896-6273(02)00625-6
   Markou A, 2001, Nicotine Tob Res, V3, P361, DOI 10.1080/14622200110073380
   MARROSU F, 1995, BRAIN RES, V671, P329, DOI 10.1016/0006-8993(94)01399-3
   Marshall DL, 1997, J NEUROCHEM, V68, P1511
   Matsunaga K, 2001, J IMMUNOL, V167, P6518, DOI 10.4049/jimmunol.167.11.6518
   Maus ADJ, 1998, MOL PHARMACOL, V54, P779, DOI 10.1124/mol.54.5.779
   McCallum SE, 2005, MOL PHARMACOL, V68, P737, DOI 10.1124/mol.105.012773
   MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513
   McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59
   Mihalak KB, 2006, MOL PHARMACOL, V70, P801, DOI 10.1124/mol.106.025130
   Miller DK, 2000, NEUROPHARMACOLOGY, V39, P2654, DOI 10.1016/S0028-3908(00)00140-4
   Miller DK, 2002, J PHARMACOL EXP THER, V302, P1113, DOI 10.1124/jpet.102.033852
   Miller DK, 2001, J PHARMACOL EXP THER, V296, P1023
   Miller NS, 1998, J ADDICT DIS, V17, P55, DOI 10.1300/J069v17n01_06
   MILNE RK, 1986, PROC R SOC SER B-BIO, V227, P83, DOI 10.1098/rspb.1986.0011
   Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748
   MOSS BL, 1989, NEURON, V3, P597, DOI 10.1016/0896-6273(89)90270-5
   Mukhtasimova N, 2005, J GEN PHYSIOL, V126, P23, DOI 10.1085/jgp.200509283
   MULLE C, 1992, NEURON, V8, P135, DOI 10.1016/0896-6273(92)90115-T
   NAKAYAMA H, 1993, MOL BRAIN RES, V20, P171, DOI 10.1016/0169-328X(93)90123-7
   Naylor C, 2005, PSYCHOPHARMACOLOGY, V180, P558, DOI 10.1007/s00213-005-2187-5
   Nelson ME, 2003, MOL PHARMACOL, V63, P332, DOI 10.1124/mol.63.2.332
   Neugebauer NM, 2007, EUR J PHARMACOL, V571, P33, DOI 10.1016/j.ejphar.2007.06.003
   Neugebauer NM, 2006, PSYCHOPHARMACOLOGY, V184, P426, DOI 10.1007/s00213-005-0163-8
   Nicke A, 2004, EUR J BIOCHEM, V271, P2305, DOI 10.1111/j.1432-1033.2004.04145.x
   NISELL M, 1994, SYNAPSE, V16, P36, DOI 10.1002/syn.890160105
   NOMIKOS GG, 1992, NEUROPSYCHOPHARMACOL, V7, P7
   NOMIKOS GG, 1989, NEUROPSYCHOPHARMACOL, V2, P273, DOI 10.1016/0893-133X(89)90031-6
   O'Dell LE, 2007, J PHARMACOL EXP THER, V320, P180, DOI 10.1124/jpet.106.105270
   ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4
   Ostroumov K, 2008, EUR BIOPHYS J BIOPHY, V37, P393, DOI 10.1007/s00249-007-0224-5
   Palma E, 1996, J PHYSIOL-LONDON, V491, P151, DOI 10.1113/jphysiol.1996.sp021203
   Panchal V, 2005, EUR J PHARMACOL, V525, P98, DOI 10.1016/j.ejphar.2005.09.060
   Papke RL, 2000, EUR J PHARMACOL, V393, P179, DOI 10.1016/S0014-2999(00)00009-1
   PAPKE RL, 1993, P ROY SOC B-BIOL SCI, V252, P141, DOI 10.1098/rspb.1993.0058
   PAPKE RL, 1991, J PHYSIOL-LONDON, V440, P95, DOI 10.1113/jphysiol.1991.sp018698
   Papke RL, 1996, NEUROSCI LETT, V213, P201
   PAPKE RL, 1988, BIOPHYS J, V53, P1, DOI 10.1016/S0006-3495(88)83059-5
   PAPKE RL, 1989, NEURON, V3, P589, DOI 10.1016/0896-6273(89)90269-9
   Pascual JM, 1998, J GEN PHYSIOL, V111, P717, DOI 10.1085/jgp.111.6.717
   Paterson D, 2000, PROG NEUROBIOL, V61, P75, DOI 10.1016/S0301-0082(99)00045-3
   PATTON DE, 1993, NEURON, V11, P967
   Peng HS, 2004, LIFE SCI, V76, P263, DOI 10.1016/j.lfs.2004.05.031
   Picciotto MR, 1998, NATURE, V391, P173, DOI 10.1038/34413
   Picciotto MR, 2002, J NEUROSCI, V22, P3338
   Pidoplichko VI, 1997, NATURE, V390, P401, DOI 10.1038/37120
   Portugal GS, 2008, BEHAV BRAIN RES, V193, P1, DOI 10.1016/j.bbr.2008.05.006
   PORTUGAL GS, 2008, BEHAV BRAIN RES PROG, V74, P363
   Quick MW, 1999, NEUROPHARMACOLOGY, V38, P769, DOI 10.1016/S0028-3908(99)00024-6
   Quick MW, 2002, J NEUROBIOL, V53, P457, DOI 10.1002/neu.10109
   RADA P, 1991, BRAIN RES, V561, P354, DOI 10.1016/0006-8993(91)91616-9
   Rahman S, 2008, BRIT J PHARMACOL, V153, P792, DOI 10.1038/sj.bjp.0707612
   Rahman S, 2004, NEUROSCIENCE, V129, P415, DOI 10.1016/j.neuroscience.2004.08.010
   Rahman S, 2004, NEUROCHEM RES, V29, P1687, DOI 10.1023/B:NERE.0000035803.64724.17
   Rahman S, 2004, EUR J PHARMACOL, V494, P31, DOI 10.1016/j.ejphar.2004.04.044
   Rahman S, 2003, NEUROSCI LETT, V348, P61, DOI 10.1016/S0304-3940(03)00723-7
   Rahman S, 2007, NEUROPHARMACOLOGY, V52, P755, DOI 10.1016/j.neuropharm.2006.09.012
   RamirezLatorre J, 1996, NATURE, V380, P347, DOI 10.1038/380347a0
   Rauhut AS, 2005, NICOTINE TOB RES, V7, P901, DOI 10.1080/14622200500381384
   Rauhut AS, 2003, PSYCHOPHARMACOLOGY, V169, P1, DOI 10.1007/s00213-003-1450-x
   Reid MS, 1999, NEUROPSYCHOPHARMACOL, V20, P297, DOI 10.1016/S0893-133X(98)00076-1
   REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0
   REYNOLDS JA, 1978, BIOCHEMISTRY-US, V17, P2035, DOI 10.1021/bi00604a001
   Rezvani AH, 2001, BIOL PSYCHIAT, V49, P258, DOI 10.1016/S0006-3223(00)01094-5
   Rho B, 1998, NEUROREPORT, V9, P1283, DOI 10.1097/00001756-199805110-00004
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Roiko SA, 2008, J PHARMACOL EXP THER, V325, P985, DOI 10.1124/jpet.107.135111
   Role L W, 1992, Curr Opin Neurobiol, V2, P254, DOI 10.1016/0959-4388(92)90112-X
   Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8
   Rollema H, 2007, NEUROPHARMACOLOGY, V52, P985, DOI 10.1016/j.neuropharm.2006.10.016
   Romano SJ, 1997, J NEUROBIOL, V32, P69, DOI 10.1002/(SICI)1097-4695(199701)32:1<69::AID-NEU7>3.3.CO;2-B
   Romano SJ, 1997, J NEUROCHEM, V68, P640
   Rowland NE, 2008, PSYCHOPHARMACOLOGY, V199, P605, DOI 10.1007/s00213-008-1186-8
   Saccone SF, 2007, HUM MOL GENET, V16, P36, DOI 10.1093/hmg/ddl438
   Salas R, 2004, J NEUROSCI, V24, P10035, DOI 10.1523/JNEUROSCI.1939-04.2004
   Salas R, 2003, MOL PHARMACOL, V63, P1059, DOI 10.1124/mol.63.5.1059
   Salas R, 2007, NEUROPHARMACOLOGY, V53, P863, DOI 10.1016/j.neuropharm.2007.08.017
   Salminen O, 2004, MOL PHARMACOL, V65, P1526, DOI 10.1124/mol.65.6.1526
   SANDS SB, 1991, BRAIN RES, V560, P38, DOI 10.1016/0006-8993(91)91211-I
   SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155
   Schnoll Robert A, 2006, Expert Opin Emerg Drugs, V11, P429, DOI 10.1517/14728214.11.3.429
   Scholze P, 2007, BRIT J PHARMACOL, V151, P414, DOI 10.1038/sj.bjp.0707236
   SEGUELA P, 1993, J NEUROSCI, V13, P596
   Sgard F, 2002, MOL PHARMACOL, V61, P150, DOI 10.1124/mol.61.1.150
   Sharma G, 2001, P NATL ACAD SCI USA, V98, P4148, DOI 10.1073/pnas.071540198
   SHARPLES CG, 2001, TOCRIS REV, V1
   Sharples CGV, 2000, J NEUROSCI, V20, P2783
   Shoaib M, 2003, PSYCHOPHARMACOLOGY, V165, P405, DOI 10.1007/s00213-002-1277-x
   Shoaib M, 2000, PSYCHOPHARMACOLOGY, V149, P140, DOI 10.1007/s002139900348
   Shoaib M, 2002, NEUROPHARMACOLOGY, V42, P530, DOI 10.1016/S0028-3908(01)00194-0
   Shoaib M, 2006, PSYCHOPHARMACOLOGY, V188, P252, DOI 10.1007/s00213-006-0498-9
   Shytle RD, 2004, J NEUROCHEM, V89, P337, DOI 10.1046/j.1471-4159.2004.02347.x
   SIMASKO SM, 1986, MOL PHARMACOL, V30, P6
   SINE SM, 1987, J PHYSIOL-LONDON, V385, P325, DOI 10.1113/jphysiol.1987.sp016496
   Sine SM, 2002, J NEUROBIOL, V53, P431, DOI 10.1002/neu.10139
   SINE SM, 1986, J PHYSIOL-LONDON, V370, P357, DOI 10.1113/jphysiol.1986.sp015939
   Sixma T. K., 2003, ANNU REV BIOPH BIOM, V21, P21
   Skok M, 2005, EUR J PHARMACOL, V517, P246, DOI 10.1016/j.ejphar.2005.05.011
   Skok MV, 2003, MOL PHARMACOL, V64, P885, DOI 10.1124/mol.64.4.885
   Slemmer JE, 2000, J PHARMACOL EXP THER, V295, P321
   Smith JW, 2007, PSYCHOPHARMACOLOGY, V190, P157, DOI 10.1007/s00213-006-0596-8
   Soderpalm B, 2000, BEHAV BRAIN RES, V113, P85, DOI 10.1016/S0166-4328(00)00203-5
   Soliakov L, 1996, J NEUROCHEM, V67, P163
   Staley JK, 2006, J NEUROSCI, V26, P8707, DOI 10.1523/JNEUROSCI.0546-06.2006
   Steensland P, 2007, P NATL ACAD SCI USA, V104, P12518, DOI 10.1073/pnas.0705368104
   Steinlein OK, 2008, BIOCHEM PHARMACOL, V76, P1175, DOI 10.1016/j.bcp.2008.07.012
   Stolerman IP, 2004, NEUROPHARMACOLOGY, V46, P363, DOI 10.1016/j.neuropharm.2003.10.002
   Stolerman IP, 1997, PSYCHOPHARMACOLOGY, V129, P390, DOI 10.1007/s002130050205
   Swan GE, 1997, J STUD ALCOHOL, V58, P182, DOI 10.15288/jsa.1997.58.182
   Sziraki I, 2002, NEUROCHEM RES, V27, P253, DOI 10.1023/A:1014844823534
   Tapia L, 2007, MOL PHARMACOL, V71, P769, DOI 10.1124/mol.106.030445
   Tapper AR, 2007, PHYSIOL GENOMICS, V31, P422, DOI 10.1152/physiolgenomics.00063.2007
   Tapper AR, 2004, SCIENCE, V306, P1029, DOI 10.1126/science.1099420
   Taraschenko OD, 2005, EUR J PHARMACOL, V513, P207, DOI 10.1016/j.ejphar.2005.03.005
   Taraschenko OD, 2007, SYNAPSE, V61, P547, DOI 10.1002/syn.20396
   Taylor P, 2000, PFLUG ARCH EUR J PHY, V440, pR115, DOI 10.1007/s004240000028
   Thorgeirsson TE, 2008, NATURE, V452, P638, DOI 10.1038/nature06846
   Tizabi Y, 2002, ALCOHOL CLIN EXP RES, V26, P394, DOI 10.1097/00000374-200203000-00014
   TRAUTMANN A, 1983, J NEURAL TRANSM, P353
   True WR, 1999, ARCH GEN PSYCHIAT, V56, P655, DOI 10.1001/archpsyc.56.7.655
   Ullian EM, 1997, J NEUROSCI, V17, P7210
   Uteshev VV, 2003, J NEUROPHYSIOL, V89, P1797, DOI 10.1152/jn.00943.2002
   Vann RE, 2006, BRAIN RES, V1117, P18, DOI 10.1016/j.brainres.2006.07.110
   VERNALLIS AB, 1993, NEURON, V10, P451, DOI 10.1016/0896-6273(93)90333-M
   VERNINO S, 1994, J NEUROSCI, V14, P5514
   VERNINO S, 1992, NEURON, V8, P127, DOI 10.1016/0896-6273(92)90114-S
   VIJAYARAGHAVAN S, 1990, J NEUROSCI, V10, P3255
   WADA E, 1990, BRAIN RES, V526, P45, DOI 10.1016/0006-8993(90)90248-A
   Walters CL, 2006, PSYCHOPHARMACOLOGY, V184, P339, DOI 10.1007/s00213-005-0295-x
   Wang F, 1996, J BIOL CHEM, V271, P17656, DOI 10.1074/jbc.271.30.17656
   Wang N, 2002, J PHYSIOL-LONDON, V542, P347, DOI 10.1113/jphysiol.2001.013456
   Wang Y, 2001, MOL PHARMACOL, V60, P1201, DOI 10.1124/mol.60.6.1201
   Watkins SS, 1999, PHARMACOL BIOCHEM BE, V62, P743, DOI 10.1016/S0091-3057(98)00226-3
   Wehner JM, 2004, NEUROSCIENCE, V129, P11, DOI 10.1016/j.neuroscience.2004.07.016
   Weiland S, 2000, BEHAV BRAIN RES, V113, P43, DOI 10.1016/S0166-4328(00)00199-6
   Weiss RB, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000125
   Whiteaker P, 2000, EUR J PHARMACOL, V393, P123, DOI 10.1016/S0014-2999(00)00052-2
   WHITING PJ, 1988, J NEUROSCI, V8, P3395
   Wiley JL, 2002, EXP CLIN PSYCHOPHARM, V10, P129, DOI 10.1037//1064-1297.10.2.129
   WONNACOTT S, 1986, J NEUROCHEM, V47, P1706, DOI 10.1111/j.1471-4159.1986.tb13078.x
   Wonnacott S, 2000, EUR J PHARMACOL, V393, P51, DOI 10.1016/S0014-2999(00)00005-4
   Wonnacott S, 1997, TRENDS NEUROSCI, V20, P92, DOI 10.1016/S0166-2236(96)10073-4
   Wonnacott S, 2005, CURR OPIN PHARMACOL, V5, P53, DOI 10.1016/j.coph.2004.12.002
   Wooltorton JRA, 2003, J NEUROSCI, V23, P3176
   Xiu J, 2005, NEUROCHEM INT, V47, P281, DOI 10.1016/j.neuint.2005.04.023
   Young EM, 2005, ALCOHOL CLIN EXP RES, V29, P58, DOI 10.1097/01.ALC.0000150007.34702.16
   Young R, 2002, EUR J PHARMACOL, V443, P113, DOI 10.1016/S0014-2999(02)01554-6
   Zachariou V, 2001, NEUROPSYCHOPHARMACOL, V24, P576, DOI 10.1016/S0893-133X(00)00224-4
   Zanetti L, 2006, PSYCHOPHARMACOLOGY, V187, P181, DOI 10.1007/s00213-006-0419-y
   Zhang ZW, 1996, NEURON, V17, P1231, DOI 10.1016/S0896-6273(00)80253-6
   Zhou FM, 2001, NAT NEUROSCI, V4, P1224, DOI 10.1038/nn769
   Zhou Y, 2003, J NEUROSCI, V23, P9004
   Zia S, 1997, RES COMMUN MOL PATH, V97, P243
   Zoli M, 2002, J NEUROSCI, V22, P8785
   Zwart R, 1998, MOL PHARMACOL, V54, P1124, DOI 10.1124/mol.54.6.1124
NR 343
TC 29
Z9 32
U1 0
U2 14
PU BENTHAM SCIENCE PUBL
PI BUSUM
PA PO BOX 294, BUSUM, 1400 AG, NETHERLANDS
SN 1871-5273
EI 1996-3181
J9 CNS NEUROL DISORD-DR
JI CNS Neurol. Disord.-Drug Targets
PD NOV
PY 2008
VL 7
IS 5
BP 422
EP 441
DI 10.2174/187152708786927831
PG 20
WC Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 397HY
UT WOS:000262654700004
PM 19128201
DA 2023-06-23
ER

PT J
AU Hurd, Y
AF Hurd, Yasmin
TI Unmasking Biological Markers of Addiction Along the Path to Treatment
   Interventions
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 73rd Annual Scientific Convention and Meeting of the
   Society-of-Biological-Psychiatry (SOBP)
CY MAY 10-12, 2018
CL New York, NY
SP Soc Biol Psychiat
DE Cannabis; Drug Addiction; Epigenetics; Psychosis; Glutamate
C1 [Hurd, Yasmin] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai
NR 0
TC 0
Z9 0
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2018
VL 83
IS 9
SU S
MA 177
BP S72
EP S72
DI 10.1016/j.biopsych.2018.02.196
PG 1
WC Neurosciences; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Neurosciences & Neurology; Psychiatry
GA GG1SD
UT WOS:000432466300178
DA 2023-06-23
ER

PT J
AU Feltenstein, MW
   See, RE
AF Feltenstein, Matthew W.
   See, Ronald E.
TI Systems Level Neuroplasticity in Drug Addiction
SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LA English
DT Article
ID COCAINE-SEEKING BEHAVIOR; VENTRAL TEGMENTAL AREA; NUCLEUS-ACCUMBENS
   CORE; STRESS-INDUCED REINSTATEMENT; CORTICOTROPIN-RELEASING-FACTOR;
   CUE-INDUCED REINSTATEMENT; MEDIAL PREFRONTAL CORTEX; CONTEXT-INDUCED
   REINSTATEMENT; MEMORY RECONSOLIDATION PROCESSES; CONDITIONED PLACE
   PREFERENCE
AB Drug addiction is a chronic relapsing disorder for which research has been dedicated to understand the various factors that contribute to development, loss of control, and persistence of compulsive addictive behaviors. In this review, we provide a broad overview of various theories of addiction, drugs of abuse, and the neurobiology involved across the addiction cycle. Specific focus is devoted to the role of the mesolimbic pathway in acute drug reinforcement and occasional drug use, the mesocortical pathway and associated areas (e.g., the dorsal striatum) in escalation/dependence, and the involvement of these pathways and associated circuits in mediating conditioned responses, drug craving, and loss of behavioral control thought to underlie withdrawal and relapse. With a better understanding of the neurobiological factors that underlie drug addiction, continued preclinical and clinical research will aid in the development of novel therapeutic interventions that can serve as effective long-term treatment strategies for drug-dependent individuals.
C1 [Feltenstein, Matthew W.; See, Ronald E.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
C3 Medical University of South Carolina
RP See, RE (通讯作者)，Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
EM seere@musc.edu
FU National Institutes of Health [P50 DA015369, P50 DA016511, P20 DA022658,
   R01 DA010462, R01 DA021690]
FX The work of the authors was supported by National Institutes of Health
   Grants P50 DA015369, P50 DA016511, P20 DA022658, R01 DA010462, and R01
   DA021690.
CR Alderson HL, 2006, EUR J NEUROSCI, V23, P2169, DOI 10.1111/j.1460-9568.2006.04737.x
   ALTSHULER HL, 1980, LIFE SCI, V26, P679, DOI 10.1016/0024-3205(80)90257-X
   Anderson SM, 2003, PSYCHOPHARMACOLOGY, V168, P132, DOI 10.1007/s00213-002-1298-5
   Atkins AL, 2008, PHARMACOL BIOCHEM BE, V90, P481, DOI 10.1016/j.pbb.2008.04.007
   Backstrom P, 2007, PSYCHOPHARMACOLOGY, V192, P571, DOI 10.1007/s00213-007-0753-8
   Belin D, 2008, NEURON, V57, P432, DOI 10.1016/j.neuron.2007.12.019
   Berglind WJ, 2006, NEUROSCIENCE, V137, P699, DOI 10.1016/j.neuroscience.2005.08.064
   Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9
   BERRIDGE KC, 1995, CURR DIR PSYCHOL SCI, V4, P71, DOI 10.1111/1467-8721.ep10772316
   Berridge KC, 2007, PSYCHOPHARMACOLOGY, V191, P391, DOI 10.1007/s00213-006-0578-x
   Bolla KI, 2003, NEUROIMAGE, V19, P1085, DOI 10.1016/S1053-8119(03)00113-7
   Bonson KR, 2002, NEUROPSYCHOPHARMACOL, V26, P376, DOI 10.1016/S0893-133X(01)00371-2
   Bossert JM, 2007, J NEUROSCI, V27, P12655, DOI 10.1523/JNEUROSCI.3926-07.2007
   Boutrel B, 2005, P NATL ACAD SCI USA, V102, P19168, DOI 10.1073/pnas.0507480102
   Bozarth M A, 1982, NIDA Res Monogr, V41, P158
   BOZARTH MA, 1983, PROG NEURO-PSYCHOPH, V7, P569, DOI 10.1016/0278-5846(83)90027-1
   BOZARTH MA, 1981, LIFE SCI, V28, P551, DOI 10.1016/0024-3205(81)90148-X
   Bozarth MA, 1987, METHODS ASSESSING RE, P173, DOI DOI 10.1007/978-1-4612-4812-5_9
   Buffalari DM, 2012, PHYSIOL BEHAV, V105, P209, DOI 10.1016/j.physbeh.2011.08.020
   Buffalari DM, 2009, PHYSIOL BEHAV, V98, P614, DOI 10.1016/j.physbeh.2009.09.013
   BURNS LH, 1993, BEHAV BRAIN RES, V55, P167, DOI 10.1016/0166-4328(93)90113-5
   Caille S, 2003, EUR J NEUROSCI, V18, P3145, DOI 10.1111/j.1460-9568.2003.02961.x
   Calu DJ, 2007, LEARN MEMORY, V14, P325, DOI 10.1101/lm.534807
   Cami J, 2003, NEW ENGL J MED, V349, P975, DOI 10.1056/NEJMra023160
   Canales JJ, 2005, NEUROBIOL LEARN MEM, V83, P93, DOI 10.1016/j.nlm.2004.10.006
   Capriles N, 2003, PSYCHOPHARMACOLOGY, V168, P66, DOI 10.1007/s00213-002-1283-z
   Chevrette J, 2002, PHARMACOL BIOCHEM BE, V71, P501, DOI 10.1016/S0091-3057(01)00686-4
   Childress A R, 1993, NIDA Res Monogr, V137, P73
   Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11
   Ciccocioppo R, 2001, P NATL ACAD SCI USA, V98, P1976, DOI 10.1073/pnas.98.4.1976
   Clark D, 1998, ADDICT BIOL, V3, P109, DOI 10.1080/13556219872191
   Colombo G, 2005, PHARMACOL BIOCHEM BE, V81, P369, DOI 10.1016/j.pbb.2005.01.022
   Cornish JL, 1999, NEUROSCIENCE, V93, P1359, DOI 10.1016/S0306-4522(99)00214-6
   Cornish JL, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-15-j0006.2000
   CORRIGALL WA, 1988, PHARMACOL BIOCHEM BE, V30, P443, DOI 10.1016/0091-3057(88)90478-9
   Corrigall WA, 2002, PSYCHOPHARMACOLOGY, V160, P198, DOI 10.1007/s00213-001-0965-2
   CORRIGALL WA, 1991, PSYCHOPHARMACOLOGY, V104, P171, DOI 10.1007/BF02244174
   CORRIGALL WA, 1992, PSYCHOPHARMACOLOGY, V107, P285, DOI 10.1007/BF02245149
   Corrigall WA, 2001, PSYCHOPHARMACOLOGY, V158, P190, DOI 10.1007/s002130100869
   Cossu G, 2001, BEHAV BRAIN RES, V118, P61, DOI 10.1016/S0166-4328(00)00311-9
   Crombag HS, 2005, CEREB CORTEX, V15, P341, DOI 10.1093/cercor/bhh136
   Dackis CA, 2001, J SUBST ABUSE TREAT, V21, P111, DOI 10.1016/S0740-5472(01)00192-1
   Dalley JW, 2004, NEUROSCI BIOBEHAV R, V28, P771, DOI 10.1016/j.neubiorev.2004.09.006
   Dayas CV, 2007, BIOL PSYCHIAT, V61, P979, DOI 10.1016/j.biopsych.2006.07.034
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175
   Di Chiara G, 2002, BEHAV BRAIN RES, V137, P75, DOI 10.1016/S0166-4328(02)00286-3
   Di Chiara G, 1999, EUR J PHARMACOL, V375, P13, DOI 10.1016/S0014-2999(99)00372-6
   Di Ciano P, 2004, J NEUROSCI, V24, P7167, DOI 10.1523/JNEUROSCI.1581-04.2004
   Di Ciano P, 2004, EUR J NEUROSCI, V19, P1661, DOI 10.1111/j.1460-9568.2004.03232.x
   Di Ciano P, 2001, NEUROPSYCHOPHARMACOL, V25, P341, DOI 10.1016/S0893-133X(01)00235-4
   Di Ciano P, 2008, NEUROPSYCHOPHARMACOL, V33, P1413, DOI 10.1038/sj.npp.1301522
   Di Pietro NC, 2006, EUR J NEUROSCI, V24, P3285, DOI 10.1111/j.1460-9568.2006.05193.x
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   DICIANO P, 1995, BEHAV PHARMACOL, V6, P311
   DWORKIN SI, 1988, PHARMACOL BIOCHEM BE, V30, P1051, DOI 10.1016/0091-3057(88)90138-4
   DWORKIN SI, 1988, PHARMACOL BIOCHEM BE, V29, P175, DOI 10.1016/0091-3057(88)90292-4
   Erb S, 1999, J NEUROSCI, V19, part. no., DOI 10.1523/JNEUROSCI.19-20-j0006.1999
   Erb S, 2000, NEUROPSYCHOPHARMACOL, V23, P138, DOI 10.1016/S0893-133X(99)00158-X
   Erb S, 2001, PSYCHOPHARMACOLOGY, V158, P360, DOI 10.1007/s002130000642
   Erb S, 1996, PSYCHOPHARMACOLOGY, V128, P408, DOI 10.1007/s002130050150
   Erb S, 1998, J NEUROSCI, V18, P5529, DOI 10.1523/JNEUROSCI.18-14-05529.1998
   Ersche KD, 2011, BRAIN, V134, P2013, DOI 10.1093/brain/awr138
   ETTENBERG A, 1982, PSYCHOPHARMACOLOGY, V78, P204, DOI 10.1007/BF00428151
   Everitt BJ, 2008, PHILOS T R SOC B, V363, P3125, DOI 10.1098/rstb.2008.0089
   Everitt BJ, 2007, ANN NY ACAD SCI, V1121, P576, DOI 10.1196/annals.1401.022
   Everitt BJ, 2001, BRAIN RES REV, V36, P129, DOI 10.1016/S0165-0173(01)00088-1
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Fadda P, 2006, NEUROREPORT, V17, P1629, DOI 10.1097/01.wnr.0000236853.40221.8e
   Feltenstein MW, 2007, NEUROBIOL LEARN MEM, V88, P435, DOI 10.1016/j.nlm.2007.05.006
   Franklin TR, 2000, EUR J NEUROSCI, V12, P2097, DOI 10.1046/j.1460-9568.2000.00071.x
   Franklin TR, 2002, BIOL PSYCHIAT, V51, P134, DOI 10.1016/S0006-3223(01)01269-0
   Fuchs RA, 2004, J NEUROSCI, V24, P6600, DOI 10.1523/JNEUROSCI.1924-04.2004
   Fuchs RA, 2006, J NEUROSCI, V26, P3584, DOI 10.1523/JNEUROSCI.5146-05.2006
   Fuchs RA, 2005, NEUROPSYCHOPHARMACOL, V30, P296, DOI 10.1038/sj.npp.1300579
   Fuchs RA, 2004, PSYCHOPHARMACOLOGY, V176, P459, DOI 10.1007/s00213-004-1895-6
   Fuchs RA, 2002, PSYCHOPHARMACOLOGY, V160, P425, DOI 10.1007/s00213-001-0997-7
   Fuchs RA, 2007, EUR J NEUROSCI, V26, P487, DOI 10.1111/j.1460-9568.2007.05674.x
   Fuchs RA, 2006, EUR J NEUROSCI, V23, P2809, DOI 10.1111/j.1460-9568.2006.04806.x
   Fuchs RA, 2009, EUR J NEUROSCI, V30, P889, DOI 10.1111/j.1460-9568.2009.06888.x
   Gabriele A, 2011, BRAIN RES, V1417, P27, DOI 10.1016/j.brainres.2011.08.030
   Gabriele A, 2010, EUR J NEUROSCI, V32, P1024, DOI 10.1111/j.1460-9568.2010.07394.x
   Gallagher M, 1999, J NEUROSCI, V19, P6610
   GATTO GJ, 1994, ALCOHOL, V11, P557, DOI 10.1016/0741-8329(94)90083-3
   GERRITS MAFM, 1994, PSYCHOPHARMACOLOGY, V114, P486, DOI 10.1007/BF02249340
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040
   Grimm JW, 2000, NEUROPSYCHOPHARMACOL, V22, P473, DOI 10.1016/S0893-133X(99)00157-8
   Haber SN, 2000, J NEUROSCI, V20, P2369
   Harris GC, 2005, NATURE, V437, P556, DOI 10.1038/nature04071
   HEMBY SE, 1995, J PHARMACOL EXP THER, V273, P591
   Hester R, 2004, J NEUROSCI, V24, P11017, DOI 10.1523/JNEUROSCI.3321-04.2004
   HIGGINS RL, 1975, J ABNORM PSYCHOL, V84, P644, DOI 10.1037/0021-843X.84.6.644
   Highfield D, 2001, NEUROPSYCHOPHARMACOL, V25, P320, DOI 10.1016/S0893-133X(01)00227-5
   Hiranita T, 2006, P NATL ACAD SCI USA, V103, P8523, DOI 10.1073/pnas.0600347103
   HOEBEL BG, 1983, PSYCHOPHARMACOLOGY, V81, P158, DOI 10.1007/BF00429012
   Hungund BL, 2003, J NEUROCHEM, V84, P698, DOI 10.1046/j.1471-4159.2003.01576.x
   HURD YL, 1989, BRAIN RES, V498, P199, DOI 10.1016/0006-8993(89)90422-8
   Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560
   Ikemoto S, 2007, BRAIN RES REV, V56, P27, DOI 10.1016/j.brainresrev.2007.05.004
   Ito R, 2002, J NEUROSCI, V22, P6247
   Ito R, 2000, J NEUROSCI, V20, P7489
   Izquierdo A, 2010, NEUROPSYCHOPHARMACOL, V35, P505, DOI 10.1038/npp.2009.155
   JAFFE JH, 1989, PSYCHOPHARMACOLOGY, V97, P59, DOI 10.1007/BF00443414
   Jalabert M, 2011, P NATL ACAD SCI USA, V108, P16446, DOI 10.1073/pnas.1105418108
   Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483
   Jhou TC, 2009, NEURON, V61, P786, DOI 10.1016/j.neuron.2009.02.001
   Jog MS, 1999, SCIENCE, V286, P1745, DOI 10.1126/science.286.5445.1745
   JOHNSON SW, 1992, J NEUROSCI, V12, P483
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kalivas PW, 2003, PSYCHOPHARMACOLOGY, V168, P44, DOI 10.1007/s00213-003-1393-2
   Kaufling J, 2009, J COMP NEUROL, V513, P597, DOI 10.1002/cne.21983
   Kaufman JN, 2003, J NEUROSCI, V23, P7839
   Kilts CD, 2004, AM J PSYCHIAT, V161, P233, DOI 10.1176/appi.ajp.161.2.233
   Kilts CD, 2001, ARCH GEN PSYCHIAT, V58, P334, DOI 10.1001/archpsyc.58.4.334
   Kolb B, 2004, BRAIN COGNITION, V55, P104, DOI 10.1016/s0278-2626(03)00278-1
   Koob GE, 2004, NEBR SYM MOTIV, V50, P1
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J
   KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Koob GF, 2006, NEUR ADD
   KORNETSKY C, 1979, ARCH GEN PSYCHIAT, V36, P289
   Kornetsky C, 1990, TESTING EVALUATION D, P211
   Koya E, 2006, J NEUROCHEM, V98, P905, DOI 10.1111/j.1471-4159.2006.03917.x
   Kruzich PJ, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-14-j0002.2001
   Kufahl PR, 2009, SYNAPSE, V63, P823, DOI 10.1002/syn.20666
   LaLumiere RT, 2008, J NEUROSCI, V28, P3170, DOI 10.1523/JNEUROSCI.5129-07.2008
   Lanca AJ, 2000, NEUROSCIENCE, V96, P735, DOI 10.1016/S0306-4522(99)00607-7
   Lasseter HC, 2010, NEUROSCIENCE, V171, P830, DOI 10.1016/j.neuroscience.2010.09.032
   Lasseter HC, 2011, NEUROPSYCHOPHARMACOL, V36, P711, DOI 10.1038/npp.2010.209
   Lasseter HC, 2010, CURR TOP BEHAV NEURO, V3, P101, DOI 10.1007/7854_2009_19
   Lasseter HC, 2009, EUR J NEUROSCI, V30, P1370, DOI 10.1111/j.1460-9568.2009.06906.x
   Lavezzi HN, 2011, BASAL GANGLIA, V1, P191, DOI 10.1016/j.baga.2011.08.003
   Lawrence AJ, 2006, BRIT J PHARMACOL, V148, P752, DOI 10.1038/sj.bjp.0706789
   Le AD, 2005, PSYCHOPHARMACOLOGY, V179, P366, DOI 10.1007/s00213-004-2036-y
   Le AD, 2000, PSYCHOPHARMACOLOGY, V150, P317, DOI 10.1007/s002130000411
   Lecca D, 2006, PSYCHOPHARMACOLOGY, V184, P435, DOI 10.1007/s00213-005-0280-4
   Lecca D, 2006, PSYCHOPHARMACOLOGY, V188, P63, DOI 10.1007/s00213-006-0475-3
   Lecca S, 2011, NEUROPSYCHOPHARMACOL, V36, P589, DOI 10.1038/npp.2010.190
   Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401
   Lee B, 2004, NEUROPSYCHOPHARMACOL, V29, P686, DOI 10.1038/sj.npp.1300391
   Leri F, 2002, J NEUROSCI, V22, P5713
   Letchworth SR, 2001, J NEUROSCI, V21, P2799, DOI 10.1523/JNEUROSCI.21-08-02799.2001
   London ED, 1999, CRIT REV NEUROBIOL, V13, P227, DOI 10.1615/CritRevNeurobiol.v13.i3.10
   Lucantonio F, 2012, NAT NEUROSCI, V15, P358, DOI 10.1038/nn.3014
   LYNESS WH, 1979, PHARMACOL BIOCHEM BE, V11, P553, DOI 10.1016/0091-3057(79)90040-6
   LYNESS WH, 1992, PHARMACOL BIOCHEM BE, V42, P187, DOI 10.1016/0091-3057(92)90465-R
   Maas LC, 1998, AM J PSYCHIAT, V155, P124, DOI 10.1176/ajp.155.1.124
   Mark GP, 2011, PHYSIOL BEHAV, V104, P76, DOI 10.1016/j.physbeh.2011.04.052
   Maskos U, 2008, BRIT J PHARMACOL, V153, pS438, DOI 10.1038/bjp.2008.5
   Matochik JA, 2003, NEUROIMAGE, V19, P1095, DOI 10.1016/S1053-8119(03)00244-1
   McFarland K, 2004, J NEUROSCI, V24, P1551, DOI 10.1523/JNEUROSCI.4177-03.2004
   McFarland K, 2003, J NEUROSCI, V23, P3531
   McFarland K, 2001, J NEUROSCI, V21, P8655
   McGregor IS, 2012, HORM BEHAV, V61, P331, DOI 10.1016/j.yhbeh.2011.12.001
   McLaughlin J, 2003, PSYCHOPHARMACOLOGY, V168, P57, DOI 10.1007/s00213-002-1196-x
   Meil WM, 1997, BEHAV BRAIN RES, V87, P139, DOI 10.1016/S0166-4328(96)02270-X
   MEIL WM, 1995, PSYCHOPHARMACOLOGY, V118, P338, DOI 10.1007/BF02245964
   Melendez RI, 2002, ALCOHOL CLIN EXP RES, V26, P318
   Meyer RE, 1996, LANCET, V347, P162, DOI 10.1016/S0140-6736(96)90345-1
   Meyers RA, 2006, BEHAV NEUROSCI, V120, P401, DOI 10.1037/0735-7044.120.2.401
   Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006
   Monaco AP, 1981, NEUROBIOLOGY NUCLEUS, P338
   MYERS RD, 1974, HDB DRUG CHEM STIMUL
   Nader MA, 2002, NEUROPSYCHOPHARMACOL, V27, P35, DOI 10.1016/S0893-133X(01)00427-4
   Neisewander JL, 2000, J NEUROSCI, V20, P798, DOI 10.1523/JNEUROSCI.20-02-00798.2000
   Nesse RM, 1997, SCIENCE, V278, P63, DOI 10.1126/science.278.5335.63
   Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578
   Olausson P, 2007, ANN NY ACAD SCI, V1121, P610, DOI 10.1196/annals.1401.016
   OLDS J, 1954, J COMP PHYSIOL PSYCH, V47, P419, DOI 10.1037/h0058775
   OLDS ME, 1982, BRAIN RES, V237, P429, DOI 10.1016/0006-8993(82)90454-1
   Park WK, 2002, J NEUROSCI, V22, P2916, DOI 10.1523/JNEUROSCI.22-07-02916.2002
   Parsegian A, 2011, BIOL PSYCHIAT, V69, P253, DOI 10.1016/j.biopsych.2010.09.003
   Peters J, 2008, J NEUROSCI, V28, P6046, DOI 10.1523/JNEUROSCI.1045-08.2008
   PETTIT HO, 1984, PSYCHOPHARMACOLOGY, V84, P167, DOI 10.1007/BF00427441
   PETTIT HO, 1989, PHARMACOL BIOCHEM BE, V34, P899, DOI 10.1016/0091-3057(89)90291-8
   PICKENS R, 1968, PSYCHOL REP, V23, P1267, DOI 10.2466/pr0.1968.23.3f.1267
   Plaza-Zabala A, 2010, J NEUROSCI, V30, P2300, DOI 10.1523/JNEUROSCI.5724-09.2010
   Pontieri FE, 1995, P NATL ACAD SCI USA, V92, P12304, DOI 10.1073/pnas.92.26.12304
   Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0
   Porrino LJ, 2004, J NEUROSCI, V24, P3554, DOI 10.1523/JNEUROSCI.5578-03.2004
   Porter JN, 2011, J NEUROSCI, V31, P4926, DOI 10.1523/JNEUROSCI.5426-10.2011
   Ramirez DR, 2009, EUR J NEUROSCI, V30, P901, DOI 10.1111/j.1460-9568.2009.06889.x
   RASSNICK S, 1993, BRAIN RES, V623, P16, DOI 10.1016/0006-8993(93)90004-7
   RASSNICK S, 1992, PSYCHOPHARMACOLOGY, V109, P92, DOI 10.1007/BF02245485
   Richards JK, 2008, PSYCHOPHARMACOLOGY, V199, P109, DOI 10.1007/s00213-008-1136-5
   RICHARDSON NR, 1994, DRUG ALCOHOL DEPEN, V36, P23, DOI 10.1016/0376-8716(94)90005-1
   Robbins TW, 1996, CURR OPIN NEUROBIOL, V6, P228, DOI 10.1016/S0959-4388(96)80077-8
   ROBERTS DCS, 1977, PHARMACOL BIOCHEM BE, V6, P615, DOI 10.1016/0091-3057(77)90084-3
   ROBERTS DCS, 1980, PHARMACOL BIOCHEM BE, V12, P781, DOI 10.1016/0091-3057(80)90166-5
   ROBERTS DCS, 1982, PHARMACOL BIOCHEM BE, V17, P901, DOI 10.1016/0091-3057(82)90469-5
   Roberts DCS, 1992, COCAINE PHARM PHYSL, P73
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Rodd ZA, 2005, J PHARMACOL EXP THER, V313, P134, DOI 10.1124/jpet.104.075952
   Rodd ZA, 2004, ALCOHOL CLIN EXP RES, V28, P1212, DOI 10.1097/01.ALC.0000134401.30394.7F
   Rodd ZA, 2004, J NEUROSCI, V24, P1050, DOI 10.1523/JNEUROSCI.1319-03.2004
   Rodd-Henricks ZA, 2002, J PHARMACOL EXP THER, V303, P1216, DOI 10.1124/jpet.102.038950
   Roesch MR, 2007, J NEUROSCI, V27, P245, DOI 10.1523/JNEUROSCI.4080-06.2007
   Rogers JL, 2008, NEUROSCIENCE, V151, P579, DOI 10.1016/j.neuroscience.2007.10.012
   Rogers JL, 2007, NEUROBIOL LEARN MEM, V87, P688, DOI 10.1016/j.nlm.2007.01.003
   Rogers RD, 1999, NEUROPSYCHOPHARMACOL, V20, P322, DOI 10.1016/S0893-133X(98)00091-8
   RUSSELL JA, 1975, J STUD ALCOHOL, V36, P1508, DOI 10.15288/jsa.1975.36.1508
   SAMHSA (Substance Abuse and Mental Health Services Administration), 2011, NSDUH SER H
   SAMSON HH, 1985, PHARMACOL BIOCHEM BE, V22, P91, DOI 10.1016/0091-3057(85)90491-5
   Sanchez CJ, 2003, NEUROSCIENCE, V119, P497, DOI 10.1016/S0306-4522(03)00078-2
   Sarnyai Z, 2011, ADDICT BIOL, V16, P199, DOI 10.1111/j.1369-1600.2011.00332.x
   Schoenbaum G, 2006, TRENDS NEUROSCI, V29, P116, DOI 10.1016/j.tins.2005.12.006
   See RE, 2007, PSYCHOPHARMACOLOGY, V194, P321, DOI 10.1007/s00213-007-0850-8
   See RE, 2003, NEUROSCIENCE, V117, P477, DOI 10.1016/S0306-4522(02)00665-6
   See RE, 2005, EUR J PHARMACOL, V526, P140, DOI 10.1016/j.ejphar.2005.09.034
   See RE, 2001, PSYCHOPHARMACOLOGY, V154, P301, DOI 10.1007/s002130000636
   Shaham Y, 2000, BRAIN RES REV, V33, P13, DOI 10.1016/S0165-0173(00)00024-2
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   Shaham Y, 1997, J NEUROSCI, V17, P2605
   Shaham Y, 2000, EUR J NEUROSCI, V12, P292, DOI 10.1046/j.1460-9568.2000.00899.x
   Shepard JD, 2004, BIOL PSYCHIAT, V55, P1082, DOI 10.1016/j.biopsych.2004.02.032
   Shoblock JR, 2011, PSYCHOPHARMACOLOGY, V215, P191, DOI 10.1007/s00213-010-2127-x
   Simon NW, 2007, BEHAV NEUROSCI, V121, P543, DOI 10.1037/0735-7044.121.3.543
   Sinha R, 1999, PSYCHOPHARMACOLOGY, V142, P343, DOI 10.1007/s002130050898
   SMITH JE, 1985, PHARMACOL BIOCHEM BE, V23, P843, DOI 10.1016/0091-3057(85)90080-2
   Smith RJ, 2012, EUR J NEUROSCI, V35, P798, DOI 10.1111/j.1460-9568.2012.08013.x
   Smith RJ, 2010, NEUROPHARMACOLOGY, V58, P179, DOI 10.1016/j.neuropharm.2009.06.042
   Smith RJ, 2009, EUR J NEUROSCI, V30, P493, DOI 10.1111/j.1460-9568.2009.06844.x
   Soria G, 2005, NEUROPSYCHOPHARMACOL, V30, P1670, DOI 10.1038/sj.npp.1300707
   Stewart J, 2000, J PSYCHIATR NEUROSCI, V25, P125
   Sun WL, 2005, PSYCHOPHARMACOLOGY, V177, P315, DOI 10.1007/s00213-004-1956-x
   Thanos PK, 2005, BEHAV BRAIN RES, V164, P206, DOI 10.1016/j.bbr.2005.06.021
   Thompson PM, 2004, J NEUROSCI, V24, P6028, DOI 10.1523/JNEUROSCI.0713-04.2004
   van Erp AMM, 2007, PSYCHOPHARMACOLOGY, V191, P679, DOI 10.1007/s00213-006-0637-3
   Van Ree JM, 1999, PHARMACOL REV, V51, P341
   Vanderschuren LJMJ, 2005, J NEUROSCI, V25, P8665, DOI 10.1523/JNEUROSCI.0925-05.2005
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   VANREE JM, 1980, PHARMACOL BIOCHEM BE, V13, P257, DOI 10.1016/S0091-3057(80)80039-6
   Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI 10.1093/cercor/10.3.318
   Volkow ND, 2003, J CLIN INVEST, V111, P1444, DOI 10.1172/JCI200318533
   VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
   Wagner FA, 2002, NEUROPSYCHOPHARMACOL, V26, P479, DOI 10.1016/S0893-133X(01)00367-0
   Weiss F, 2000, P NATL ACAD SCI USA, V97, P4321, DOI 10.1073/pnas.97.8.4321
   WEISS F, 1992, ANN NY ACAD SCI, V654, P220, DOI 10.1111/j.1749-6632.1992.tb25970.x
   WEISS F, 1993, J PHARMACOL EXP THER, V267, P250
   Weissenborn R, 1997, PSYCHOPHARMACOLOGY, V134, P242, DOI 10.1007/s002130050447
   Wells AM, 2011, LEARN MEMORY, V18, P693, DOI 10.1101/lm.2273111
   Whitelaw RB, 1996, PSYCHOPHARMACOLOGY, V127, P213, DOI 10.1007/BF02805996
   WIKLER A, 1973, ARCH GEN PSYCHIAT, V28, P611
   WILSON MC, 1974, PHARMACOL BIOCHEM BE, V2, P563, DOI 10.1016/0091-3057(74)90021-5
   Winstanley CA, 2007, J NEUROSCI, V27, P10497, DOI 10.1523/JNEUROSCI.2566-07.2007
   WISE RA, 1980, PHARMACOL BIOCHEM BE, V13, P213, DOI 10.1016/S0091-3057(80)80033-5
   WISE RA, 1995, PSYCHOPHARMACOLOGY, V120, P10, DOI 10.1007/BF02246140
   WISE RA, 1995, SYNAPSE, V21, P140, DOI 10.1002/syn.890210207
   Wise RA, 2002, NEURON, V36, P229, DOI 10.1016/S0896-6273(02)00965-0
   WOLFFGRAMM J, 1995, BEHAV BRAIN RES, V70, P77, DOI 10.1016/0166-4328(95)00131-C
   Wong DF, 2006, NEUROPSYCHOPHARMACOL, V31, P2716, DOI 10.1038/sj.npp.1301194
   WOOLVERTON WL, 1986, PHARMACOL BIOCHEM BE, V24, P531, DOI 10.1016/0091-3057(86)90553-8
   Xie XH, 2010, PSYCHOPHARMACOLOGY, V208, P1, DOI 10.1007/s00213-009-1700-7
   YOKEL RA, 1975, SCIENCE, V187, P547, DOI 10.1126/science.1114313
   Zapata A, 2010, J NEUROSCI, V30, P15457, DOI 10.1523/JNEUROSCI.4072-10.2010
   Zavala AR, 2003, BRAIN RES, V990, P157, DOI 10.1016/S0006-8993(03)03452-8
   Zavala AR, 2008, SYNAPSE, V62, P421, DOI 10.1002/syn.20502
   Zhou LY, 2012, J PHARMACOL EXP THER, V340, P801, DOI 10.1124/jpet.111.187567
   Zhou W, 2007, NEUROSCIENCE, V144, P1209, DOI 10.1016/j.neuroscience.2006.11.013
   ZITO KA, 1985, PHARMACOL BIOCHEM BE, V23, P1029, DOI 10.1016/0091-3057(85)90110-8
NR 264
TC 22
Z9 24
U1 1
U2 16
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 2157-1422
J9 CSH PERSPECT MED
JI Cold Spring Harb. Perspect. Med.
PD MAY
PY 2013
VL 3
IS 5
AR a011916
DI 10.1101/cshperspect.a011916
PG 19
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 187ZP
UT WOS:000322161000004
PM 23580792
OA Green Published, Bronze
DA 2023-06-23
ER

PT J
AU Robinson, TE
   Berridge, KC
AF Robinson, TE
   Berridge, KC
TI The psychology and neurobiology of addiction: an incentive-sensitization
   view
SO ADDICTION
LA English
DT Review
ID INDUCED BEHAVIORAL SENSITIZATION; RAT NUCLEUS-ACCUMBENS; REPEATED
   D-AMPHETAMINE; DOPAMINE-RECEPTOR ANTAGONISTS; CONDITIONED PLACE
   PREFERENCE; MESSENGER-RNA EXPRESSION; RECOMBINANT INBRED MICE; C-FOS
   EXPRESSION; LOCOMOTOR-ACTIVITY; ENVIRONMENTAL STIMULI
AB The question of addiction specifically concerns (1), the process by which drug-taking behavior, in certain individuals, evolves into compulsive patterns of drug-seeking and drug-taking behavior that take place at the expense of most other activities and (2), the inability to cease drug-taking; the problem of relapse. In this paper current biopsychological views of addiction are critically evaluated in light of the "incentive-sensitization theory of addiction", which we first proposed in 1993, and new developments in research are incorporated. We argue that traditional negative reinforcement, positive reinforcement, and hedonic accounts of addiction are neither necessary nor sufficient to account for compulsive patterns of drug-seeking and drug-taking behavior. Four major tenets of the incentive-sensitization view are discussed. These are: (1) Potentially addictive drugs share the ability to produce long-lasting adaptations in neural systems. (2) The brain systems that are changed include those normally involved in the process of incentive motivation and reward. (3) The critical neuroadaptations for addiction render these brain reward systems hypersensitive ("sensitized") to drugs and drug-associated stimuli. (4) The brain systems that are sensitized do not mediate the pleasurable or euphoric effects of drugs (drug "liking"), but instead they mediate a subcomponent of reward we have termed incentive salience (drug "wanting"). We also discuss the role that mesolimbic dopamine systems play in reward, evidence that neural sensitization happens in humans, and the implications of incentive-sensitization for the development of therapies in the treatment of addiction.
C1 Univ Michigan, Dept Psychol, Biopsychol Program, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan
RP Robinson, TE (通讯作者)，Univ Michigan, Dept Psychol, Biopsychol Program, 525 E Univ,East Hall, Ann Arbor, MI 48109 USA.
EM ter@umich.edu
RI Berridge, Kent/C-1525-2009
OI Berridge, Kent/0000-0002-6031-2626
CR Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   al Qatari M, 1998, ALCOHOL CLIN EXP RES, V22, P810, DOI 10.1097/00000374-199806000-00006
   Anagnostaras SG, 1996, BEHAV NEUROSCI, V110, P1397, DOI 10.1037/0735-7044.110.6.1397
   ANGRIST B, 1994, AMPHETAMINE ITS ANAL, P387
   [Anonymous], 1997, CONSCIOUSNESS LOST F
   ANTELMAN SM, 1988, DRUG DEVELOP RES, V14, P1, DOI 10.1002/ddr.430140102
   ANTELMAN SM, 1980, SCIENCE, V207, P329, DOI 10.1126/science.7188649
   Badiani A, 1999, BEHAV BRAIN RES, V103, P203, DOI 10.1016/S0166-4328(99)00041-8
   BADIANI A, 1995, BRAIN RES, V674, P291, DOI 10.1016/0006-8993(95)00028-O
   Badiani A, 1997, J PHARMACOL EXP THER, V282, P787
   BADIANI A, 1995, PSYCHOPHARMACOLOGY, V117, P443, DOI 10.1007/BF02246217
   Badiani A, 1998, J NEUROSCI, V18, P10579
   Bartlett E, 1997, NEUROPSYCHOPHARMACOL, V16, P77, DOI 10.1016/S0893-133X(96)00164-9
   Berger SP, 1996, LANCET, V347, P504, DOI 10.1016/S0140-6736(96)91139-3
   Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8
   Berridge KC, 1996, NEUROSCI BIOBEHAV R, V20, P1, DOI 10.1016/0149-7634(95)00033-B
   BERRIDGE KC, 1995, CURR DIR PSYCHOL SCI, V4, P71, DOI 10.1111/1467-8721.ep10772316
   BERRIDGE KC, 1989, BEHAV NEUROSCI, V103, P36, DOI 10.1037/0735-7044.103.1.36
   BERRIDGE KC, 1991, BEHAV NEUROSCI, V105, P3, DOI 10.1037/0735-7044.105.1.3
   BERRIDGE KC, 1999, WELL BEING FDN HEDON, P527
   Besson J, 1998, ALCOHOL CLIN EXP RES, V22, P573, DOI 10.1111/j.1530-0277.1998.tb04295.x
   Biggins CA, 1997, BIOL PSYCHIAT, V42, P472, DOI 10.1016/S0006-3223(96)00425-8
   BINDRA D, 1978, BEHAV BRAIN SCI, V1, P41, DOI 10.1017/S0140525X00059380
   Blackburn JR, 1997, BEHAV BRAIN RES, V89, P99, DOI 10.1016/S0166-4328(97)00050-8
   BLACKBURN JR, 1992, PROG NEUROBIOL, V39, P247, DOI 10.1016/0301-0082(92)90018-A
   Bolla KI, 1998, J NEUROPSYCH CLIN N, V10, P280, DOI 10.1176/jnp.10.3.280
   Brauer LH, 1996, BIOL PSYCHIAT, V39, P26, DOI 10.1016/0006-3223(95)00110-7
   Brauer LH, 1997, PHARMACOL BIOCHEM BE, V56, P265, DOI 10.1016/S0091-3057(96)00240-7
   Breiter HC, 1997, NEURON, V19, P591, DOI 10.1016/S0896-6273(00)80374-8
   Broadbent J, 1999, PSYCHOPHARMACOLOGY, V141, P197, DOI 10.1007/s002130050825
   Browman KE, 1998, PSYCHOPHARMACOLOGY, V137, P90, DOI 10.1007/s002130050597
   Browman KE, 1998, J PHARMACOL EXP THER, V287, P1007
   CAMP DM, 1988, BEHAV BRAIN RES, V30, P69, DOI 10.1016/0166-4328(88)90009-5
   CASTANEDA E, 1988, LIFE SCI, V42, P2447, DOI 10.1016/0024-3205(88)90343-8
   Castner SA, 1999, NEUROPSYCHOPHARMACOL, V20, P10, DOI 10.1016/S0893-133X(98)00050-5
   Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11
   Comer SD, 1999, PSYCHOPHARMACOLOGY, V143, P327, DOI 10.1007/s002130050956
   COOPER BR, 1994, NEUROPSYCHOPHARMACOL, V11, P133, DOI 10.1038/npp.1994.43
   CRABBE JC, 1982, J COMP PHYSIOL PSYCH, V96, P440, DOI 10.1037/h0077898
   Crombag HS, 1999, BEHAV PHARMACOL, V10, P205, DOI 10.1097/00008877-199903000-00009
   CUNNINGHAM CL, 1995, PSYCHOPHARMACOLOGY, V120, P28, DOI 10.1007/BF02246142
   CUNNINGHAM CL, 1992, PHARMACOL BIOCHEM BE, V43, P307, DOI 10.1016/0091-3057(92)90673-4
   DACKIS CA, 1985, NEUROSCI BIOBEHAV R, V9, P469, DOI 10.1016/0149-7634(85)90022-3
   De Vries T. J., 1997, Society for Neuroscience Abstracts, V23, P2147
   De Vries TJ, 1998, EUR J NEUROSCI, V10, P3565, DOI 10.1046/j.1460-9568.1998.00368.x
   De Vries TJ, 1999, PSYCHOPHARMACOLOGY, V143, P254, DOI 10.1007/s002130050944
   Deroche V, 1999, EUR J NEUROSCI, V11, P2731, DOI 10.1046/j.1460-9568.1999.00696.x
   DEWS P, 1977, PREDICTING DEPENDENC, P75
   Di Chiara G, 1997, PSYCHOPHARMACOLOGY, V134, P351, DOI 10.1007/s002130050465
   EDWARDS G, 1981, B WORLD HEALTH ORGAN, V59, P225
   FAHLKE C, 1994, PHARMACOL BIOCHEM BE, V47, P345, DOI 10.1016/0091-3057(94)90020-5
   Fiorino DF, 1999, J NEUROSCI, V19, P456, DOI 10.1523/JNEUROSCI.19-01-00456.1999
   Fiorino DF, 1999, PSYCHOPHARMACOLOGY, V142, P200, DOI 10.1007/s002130050880
   Fischman M W, 1989, NIDA Res Monogr, V92, P211
   FISCHMAN MW, 1992, CIBA F SYMP, V166, P165
   FISCHMAN MW, 1990, J PHARMACOL EXP THER, V253, P760
   Flores C, 2000, J NEUROSCI, V20
   Flores C, 1998, J NEUROSCI, V18, P9547
   FOLTIN RW, 1991, DRUG ALCOHOL DEPEN, V28, P3, DOI 10.1016/0376-8716(91)90052-Z
   Fraioli S, 1999, NEUROPSYCHOPHARMACOL, V20, P533, DOI 10.1016/S0893-133X(98)00079-7
   GAIARDI M, 1991, PSYCHOPHARMACOLOGY, V103, P183, DOI 10.1007/BF02244201
   Galloway GP, 1996, J SUBST ABUSE TREAT, V13, P493, DOI 10.1016/S0740-5472(96)00154-7
   GARDNER EL, 1993, SEMIN NEUROSCI, V5, P359, DOI 10.1016/S1044-5765(05)80044-2
   GLICK SD, 1984, EUR J PHARMACOL, V99, P119, DOI 10.1016/0014-2999(84)90442-4
   GLICK SD, 1986, PHYSIOL BEHAV, V38, P67, DOI 10.1016/0031-9384(86)90133-2
   Goldstein MG, 1998, J CLIN PSYCHIAT, V59, P66
   Gonon F, 1997, J NEUROSCI, V17, P5972
   Gonon F, 1996, NEUROSCIENCE, V75, P13, DOI 10.1016/0306-4522(96)00320-X
   Gorelick DA, 1997, BIOL PSYCHIAT, V42, P230, DOI 10.1016/S0006-3223(97)80005-4
   Goudie A. J., 1986, BEHAVIORAL BASIS DRU, P225
   GOUDIE AJ, 1990, PROG NEURO-PSYCHOPH, V14, P675, DOI 10.1016/0278-5846(90)90038-I
   Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040
   Haney M, 1999, PSYCHOPHARMACOLOGY, V143, P102, DOI 10.1007/s002130050925
   Haney M, 1998, PSYCHOPHARMACOLOGY, V137, P15, DOI 10.1007/s002130050588
   Harmer CJ, 1997, PSYCHOPHARMACOLOGY, V132, P247, DOI 10.1007/s002130050342
   Harmer CJ, 1998, BEHAV PHARMACOL, V9, P299
   Harmer CJ, 1999, PSYCHOPHARMACOLOGY, V142, P120, DOI 10.1007/s002130050870
   Harmer CJ, 1999, NEUROSCIENCE, V90, P119, DOI 10.1016/S0306-4522(98)00464-3
   HENRY DJ, 1995, J NEUROSCI, V15, P6287
   HENRY DJ, 1991, J PHARMACOL EXP THER, V258, P882
   Hilgard E.R., 1986, DIVIDED CONSCIOUSNES
   HOOKS MS, 1994, PSYCHOPHARMACOLOGY, V115, P265
   Horger BA, 1999, J NEUROSCI, V19, P4110
   HORGER BA, 1992, PSYCHOPHARMACOLOGY, V107, P271, DOI 10.1007/BF02245147
   HORGER BA, 1990, PHARMACOL BIOCHEM BE, V37, P707, DOI 10.1016/0091-3057(90)90552-S
   HUNT WA, 1992, ALCOHOL, V9, P327, DOI 10.1016/0741-8329(92)90075-L
   *I MED COMM OPP DR, 1996, PATHW ADD
   Itzhak Y, 1999, BRAIN RES, V818, P204, DOI 10.1016/S0006-8993(98)01260-8
   Jackson A, 1998, BEHAV PHARMACOL, V9, P457, DOI 10.1097/00008877-199809000-00009
   JAFFE JH, 1992, RES P ARNMD, V70, P1
   Jaffe JH, 1990, PHARMACOL BASIS THER, P522
   Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483
   Jorenby DE, 1999, NEW ENGL J MED, V340, P685, DOI 10.1056/NEJM199903043400903
   KAHNEMAN D, 1994, J INST THEOR ECON, V150, P18
   KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U
   Kantor L, 1999, J NEUROSCI, V19, P3801
   Kaufman MJ, 1998, PSYCHOPHARMACOLOGY, V138, P76, DOI 10.1007/s002130050647
   Koob GF, 1997, PHARMACOL BIOCHEM BE, V57, P513, DOI 10.1016/S0091-3057(96)00438-8
   KOOB GF, 1989, NEUROSCI BIOBEHAV R, V13, P135, DOI 10.1016/S0149-7634(89)80022-3
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   KOOB GF, 1997, HOSP PRACT SPECIAL R, P12
   Kratzer U, 1998, NEUROSCI LETT, V252, P53, DOI 10.1016/S0304-3940(98)00550-3
   LAMB RJ, 1991, J PHARMACOL EXP THER, V259, P1165
   LeDoux Joseph, 1999, EMOTIONAL BRAIN MYST
   LEITH NJ, 1982, PSYCHOPHARMACOLOGY, V76, P310, DOI 10.1007/BF00449116
   Lessov CN, 1998, PSYCHOPHARMACOLOGY, V135, P374, DOI 10.1007/s002130050525
   LETT BT, 1989, PSYCHOPHARMACOLOGY, V98, P357, DOI 10.1007/BF00451687
   Little KY, 1999, AM J PSYCHIAT, V156, P238
   Loewenstein G., 1999, GETTING HOOKED RATIO, P235
   Lorrain DS, 2000, BEHAV BRAIN RES, V107, P9, DOI 10.1016/S0166-4328(99)00109-6
   Maas LC, 1998, AM J PSYCHIAT, V155, P124, DOI 10.1176/ajp.155.1.124
   Manley SJ, 1997, J PHARMACOL EXP THER, V281, P1330
   Marinelli M, 1998, PSYCHOPHARMACOLOGY, V139, P281, DOI 10.1007/s002130050717
   MARKOU A, 1991, NEUROPSYCHOPHARMACOL, V4, P17
   MARKOU A, 1993, PSYCHOPHARMACOLOGY, V112, P163, DOI 10.1007/BF02244907
   Markou A, 1998, NEUROPSYCHOPHARMACOL, V18, P135, DOI 10.1016/S0893-133X(97)00113-9
   MASUR J, 1986, PHARMACOL BIOCHEM BE, V24, P1225, DOI 10.1016/0091-3057(86)90175-9
   MASUR J, 1980, PHARMACOL BIOCHEM BE, V13, P777, DOI 10.1016/0091-3057(80)90206-3
   Mead AN, 1998, NEUROPHARMACOLOGY, V37, P1131, DOI 10.1016/S0028-3908(98)00101-4
   Mendrek A, 1998, PSYCHOPHARMACOLOGY, V135, P416, DOI 10.1007/s002130050530
   MEYER RE, 1992, ARCH GEN PSYCHIAT, V49, P900
   MITCHELL JB, 1990, PHARMACOL BIOCHEM BE, V35, P643, DOI 10.1016/0091-3057(90)90302-X
   Naassila M, 1998, ALCOHOL CLIN EXP RES, V22, P802
   NASH MJ, 1997, TIME, P68
   Nestby P, 1997, PSYCHOPHARMACOLOGY, V133, P69, DOI 10.1007/s002130050373
   NEWLIN DB, 1991, ALCOHOL CLIN EXP RES, V15, P399, DOI 10.1111/j.1530-0277.1991.tb00537.x
   NISBETT RE, 1977, PSYCHOL REV, V84, P231, DOI 10.1037/0033-295X.84.3.231
   NOMIKOS GG, 1992, NEUROPSYCHOPHARMACOL, V7, P7
   NOMIKOS GG, 1991, EUR J PHARMACOL, V195, P63, DOI 10.1016/0014-2999(91)90382-Z
   NUNES EV, 1995, DRUG ALCOHOL DEPEN, V39, P185, DOI 10.1016/0376-8716(95)01161-6
   OBrien CP, 1997, SCIENCE, V278, P66, DOI 10.1126/science.278.5335.66
   Ohuoha DC, 1997, J SUBST ABUSE TREAT, V14, P249, DOI 10.1016/S0740-5472(96)00161-4
   PAULSON PE, 1991, PSYCHOPHARMACOLOGY, V103, P480, DOI 10.1007/BF02244248
   Pecina S, 1997, PHARMACOL BIOCHEM BE, V58, P801, DOI 10.1016/S0091-3057(97)00044-0
   PERT A, 1990, NIDA RES MG, V97, P208
   Petrie EC, 1998, PROG NEURO-PSYCHOPH, V22, P845, DOI 10.1016/S0278-5846(98)00044-X
   Phillips AG, 1996, PSYCHOPHARMACOLOGY, V124, P279, DOI 10.1007/BF02246669
   Phillips TJ, 1997, PHARMACOL BIOCHEM BE, V57, P487, DOI 10.1016/S0091-3057(96)00448-0
   PHILLIPS TJ, 1995, ALCOHOL CLIN EXP RES, V19, P269, DOI 10.1111/j.1530-0277.1995.tb01502.x
   PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295
   PIAZZA PV, 1990, BRAIN RES, V514, P22, DOI 10.1016/0006-8993(90)90431-A
   Pierce RC, 1997, BRAIN RES REV, V25, P192, DOI 10.1016/S0165-0173(97)00021-0
   Pierre PJ, 1997, PSYCHOPHARMACOLOGY, V129, P277, DOI 10.1007/s002130050191
   Pierre PJ, 1998, PSYCHOPHARMACOLOGY, V138, P159, DOI 10.1007/s002130050658
   POST RM, 1981, LIFE SCI, V28, P755, DOI 10.1016/0024-3205(81)90157-0
   POST RM, 1983, STIMULANTS NEUROCHEM, P169
   Putzke J, 1996, EUR J PHARMACOL, V317, P39, DOI 10.1016/S0014-2999(96)00696-6
   Robbins TW, 1996, CURR OPIN NEUROBIOL, V6, P228, DOI 10.1016/S0959-4388(96)80077-8
   Robinson T. E., 1988, SENSITIZATION NERVOU, P145
   ROBINSON TE, 1982, EUR J PHARMACOL, V85, P253, DOI 10.1016/0014-2999(82)90478-2
   ROBINSON TE, 1988, BRAIN RES, V462, P211, DOI 10.1016/0006-8993(88)90549-5
   Robinson TE, 1999, EUR J NEUROSCI, V11, P1598, DOI 10.1046/j.1460-9568.1999.00576.x
   Robinson TE, 1997, J NEUROSCI, V17, P8491
   ROBINSON TE, 1984, PSYCHOPHARMACOLOGY, V84, P466, DOI 10.1007/BF00431451
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   ROBINSON TE, 1986, BRAIN RES REV, V11, P157, DOI 10.1016/0165-0173(86)90002-0
   Robinson TE, 1998, NEUROSCI BIOBEHAV R, V22, P347, DOI 10.1016/S0149-7634(97)00020-1
   Rogers RD, 1999, NEUROPSYCHOPHARMACOL, V20, P322, DOI 10.1016/S0893-133X(98)00091-8
   ROSSETTI ZL, 1992, EUR J PHARMACOL, V221, P227, DOI 10.1016/0014-2999(92)90706-A
   ROTHMAN RB, 1995, MOL NEUROBIOL, V11, P1, DOI 10.1007/BF02740680
   ROTHMAN RB, 1994, PHARMACOL BIOCHEM BE, V49, P583, DOI 10.1016/0091-3057(94)90073-6
   Salamone JD, 1997, NEUROSCI BIOBEHAV R, V21, P341, DOI 10.1016/S0149-7634(96)00017-6
   Sarter M, 1999, TRENDS NEUROSCI, V22, P67, DOI 10.1016/S0166-2236(98)01289-2
   SATO M, 1983, BIOL PSYCHIAT, V18, P429
   SATO M, 1986, PSYCHOPHARMACOL BULL, V22, P751
   Schenk S, 1997, PHARMACOL BIOCHEM BE, V57, P543, DOI 10.1016/S0091-3057(96)00447-9
   Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1
   SCHULTZ W, 1992, SEMIN NEUROSCI, V4, P129
   Segal D S, 1981, Essays Neurochem Neuropharmacol, V5, P95
   Segal D. S., 1983, STIMULANTS NEUROCHEM, P131
   Sell LA, 1999, EUR J NEUROSCI, V11, P1042, DOI 10.1046/j.1460-9568.1999.00522.x
   Shaham Y, 1996, J NEUROSCI, V16, P1957
   Shippenberg TS, 1996, EUR J PHARMACOL, V299, P33, DOI 10.1016/0014-2999(95)00852-7
   SHIPPENBERG TS, 1995, J PHARMACOL EXP THER, V273, P808
   Shippenberg TS, 1996, J PHARMACOL EXP THER, V276, P545
   SHUSTER L, 1977, PSYCHOPHARMACOLOGY, V52, P185, DOI 10.1007/BF00439108
   Skinner B. F., 1953, SCI HUMAN BEHAV
   Smith G.P., 1995, PROG PSYCHOB PHYSIOL, P83
   STEELE CM, 1990, AM PSYCHOL, V45, P921, DOI 10.1037/0003-066X.45.8.921
   STEWART J, 1993, BEHAV PHARMACOL, V4, P289
   STEWART J, 1992, PSYCHOPHARMACOLOGY, V108, P79, DOI 10.1007/BF02245289
   Strakowski SM, 1998, BIOL PSYCHIAT, V44, P1171, DOI 10.1016/S0006-3223(97)00454-X
   Strakowski SM, 1996, BIOL PSYCHIAT, V40, P872, DOI 10.1016/0006-3223(95)00497-1
   Strakowski SM, 1997, BIOL PSYCHIAT, V42, P230, DOI 10.1016/S0006-3223(97)00167-4
   STRAKOWSKI SM, 1999, ABSTR AM COLL NEUR, V38, P86
   Taylor JR, 1999, PSYCHOPHARMACOLOGY, V142, P31, DOI 10.1007/s002130050859
   Tella SR, 1997, J PHARMACOL EXP THER, V281, P508
   TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147
   Tirelli E, 1998, BEHAV PHARMACOL, V9, P409, DOI 10.1097/00008877-199809000-00004
   Toates F., 1986, MOTIVATIONAL SYSTEMS
   TOLLIVER BK, 1994, J PHARMACOL EXP THER, V270, P1230
   Utena H, 1966, Prog Brain Res, V21, P192
   VALADEZ A, 1994, PHARMACOL BIOCHEM BE, V47, P203, DOI 10.1016/0091-3057(94)90132-5
   Vanderschuren LJMJ, 1999, J NEUROSCI, V19, P4123
   Vanderschuren LJMJ, 1999, PSYCHOPHARMACOLOGY, V143, P244, DOI 10.1007/s002130050943
   Volkow ND, 1997, NATURE, V386, P830, DOI 10.1038/386830a0
   VOLKOW ND, 1991, AM J PSYCHIAT, V148, P621
   VOLKOW ND, 1992, SYNAPSE, V11, P184, DOI 10.1002/syn.890110303
   Volkow ND, 1997, NATURE, V386, P827, DOI 10.1038/386827a0
   Volkow ND, 1999, J PHARMACOL EXP THER, V288, P14
   Wang GJ, 1999, LIFE SCI, V64, P775, DOI 10.1016/S0024-3205(98)00619-5
   Washton A M, 1993, NIDA Res Monogr, V135, P15
   WEISS F, 1992, BRAIN RES, V593, P314, DOI 10.1016/0006-8993(92)91327-B
   WEISS RD, 1988, JAMA-J AM MED ASSOC, V260, P2545, DOI 10.1001/jama.260.17.2545
   White FJ, 1998, DRUG ALCOHOL DEPEN, V51, P141, DOI 10.1016/S0376-8716(98)00072-6
   White FJ, 1998, NEUROPSYCHOPHARMACOL, V18, P26
   WHITE FJ, 1995, J PHARMACOL EXP THER, V273, P445
   WHITE FJ, 1991, BIOL BASES DRUG TOLE, P153
   Wickelgren I, 1997, SCIENCE, V278, P35, DOI 10.1126/science.278.5335.35
   WIKLER A, 1948, AM J PSYCHIAT, V105, P329, DOI 10.1176/ajp.105.5.329
   WISE RA, 1982, BEHAV BRAIN SCI, V5, P39, DOI 10.1017/S0140525X00010372
   WISE RA, 1989, ANNU REV PSYCHOL, V40, P191, DOI 10.1146/annurev.ps.40.020189.001203
   WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469
   WISE RA, 1994, APPETITE NEURAL BEHA, P140
   Wolf ME, 1998, PROG NEUROBIOL, V54, P679, DOI 10.1016/S0301-0082(97)00090-7
   WOOLVERTON WL, 1984, J PHARMACOL EXP THER, V230, P678
   Zhang L, 1998, MOL BRAIN RES, V59, P66, DOI 10.1016/S0169-328X(98)00138-7
NR 217
TC 985
Z9 1018
U1 1
U2 154
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0965-2140
EI 1360-0443
J9 ADDICTION
JI Addiction
PD AUG
PY 2000
VL 95
IS 8
SU 2
BP S91
EP S117
PG 27
WC Substance Abuse; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry
GA 346FT
UT WOS:000088860700006
PM 11002906
DA 2023-06-23
ER

PT J
AU Mathis, SM
   Hagemeier, N
   Foster, KN
   Baker, K
   Pack, RP
AF Mathis, Stephanie M.
   Hagemeier, Nicholas
   Foster, Kelly N.
   Baker, Katie
   Pack, Robert P.
TI "It's Took Over This Region": Patient Perspectives of Prescription Drug
   Abuse in Appalachia
SO SUBSTANCE USE & MISUSE
LA English
DT Article
DE Prescription drug abuse; prescription drug misuse; opioid; patient;
   qualitative
ID OPIOID ABUSE; DIVERSION; PAIN; DECEPTION; ADDICTION
AB Background: Prescription drug abuse is a public health problem in the United States and the region of Appalachia, specifically. Primary care and addiction medicine-as possible points of access for prescription drugs with abuse potential and points of intervention for prescription drug abuse-are among the medical fields at its forefront. Little is known, however, about perceptions of prescription drug abuse across the two patient populations. Objectives: The objective of this qualitative analysis was to explore perceptions of the scale and context of prescription drug abuse among primary care and addiction medicine patients in Appalachia. Methods: As part of a mixed methods study, semi-structured interviews were conducted with 20 patients from primary care and addiction medicine in Central and South Central Appalachia from 2014 to 2015. The interviews were audio-recorded and transcribed verbatim. Thematic analysis was used to identify themes. Results: Three themes were identified: (1) pervasiveness of prescription drug abuse, describing perceptions of its high prevalence and negative consequences; (2) routes and routine practices for prescription drug acquisition and distribution, describing perceptions of routes of access to prescription drugs and behaviors exhibited to acquire and distribute prescription drugs; and (3) rationales for prescription drug acquisition and distribution, describing perceptions of the two underlying reasons for these processes-tolerance/addiction and revenue source. Conclusions/Importance: Perceptions of prescription drug abuse among primary care and addiction medicine patients in Appalachia are multifaceted, especially regarding prescription drug acquisition and distribution. Clinical practice implications for mitigating prescription drug abuse are discussed.
C1 [Mathis, Stephanie M.; Baker, Katie; Pack, Robert P.] East Tennessee State Univ, Coll Publ Hlth, Dept Community & Behav Hlth, POB 70623, Johnson City, TN 37614 USA.
   [Mathis, Stephanie M.; Hagemeier, Nicholas; Pack, Robert P.] East Tennessee State Univ, Ctr Prescript Drug Abuse Prevent & Treatment, Johnson City, TN 37614 USA.
   [Hagemeier, Nicholas] East Tennessee State Univ, Bill Gatton Coll Pharm, Dept Pharm Practice, Johnson City, TN 37614 USA.
   [Foster, Kelly N.] East Tennessee State Univ, Coll Arts & Sci, Dept Sociol & Anthropol, Johnson City, TN 37614 USA.
   [Foster, Kelly N.] East Tennessee State Univ, Appl Social Res Lab, Johnson City, TN 37614 USA.
C3 East Tennessee State University; East Tennessee State University; East
   Tennessee State University; East Tennessee State University; East
   Tennessee State University
RP Pack, RP (通讯作者)，East Tennessee State Univ, Coll Publ Hlth, Dept Community & Behav Hlth, POB 70623, Johnson City, TN 37614 USA.
EM packr@etsu.edu
FU National Institute on Drug Abuse of the National Institutes of Health
   [R24DA036409]
FX This work was supported by the National Institute on Drug Abuse of the
   National Institutes of Health under award number R24DA036409. The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institutes of
   Health.
CR American Board of Preventative Medicine, ADDICTION MED
   [Anonymous], 2015, HHS PUBLICATION
   [Anonymous], 2008, HLTH BEHAV HLTH ED T
   Appalachian Regional Commission, APP REG
   Arfken CL, 2010, J SUBST ABUSE TREAT, V39, P96, DOI 10.1016/j.jsat.2010.05.004
   Bachhuber M. A., 2016, PRIMARY CARE FRONT L
   Bandura A, 2004, HEALTH EDUC BEHAV, V31, P143, DOI 10.1177/1090198104263660
   Bandura A, 1986, SOCIAL FUNCTIONS THO
   Barrett Sean P, 2008, Curr Drug Abuse Rev, V1, P255, DOI 10.2174/1874473710801030255
   Barry CL, 2016, ADDICTION, V111, P85, DOI 10.1111/add.13077
   Bonhomme J, 2012, J NATL MED ASSOC, V104, P342, DOI 10.1016/S0027-9684(15)30175-9
   Borders TF, 2007, J RURAL HEALTH, V23, P79, DOI 10.1111/j.1748-0361.2007.00128.x
   Boyatzis RE, 1998, TRANSFORMING QUALITA, P144
   Braun V., 2012, APA HDB RES METHODS, V2, P57, DOI [10.1037/13620-004, DOI 10.1037/13620-004]
   Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI DOI 10.1191/1478088706QP063OA
   Center for Behavioral Health Statistics and Quality, 2016, 2015 NAT SURV DRUG U
   Center for Behavioral Health Statistics and Quality (CBHSQ), 2015, HHS PUBL, VSMA 15-4927
   Center for Substance Abuse Treatment [CSAT], 1997, TREATMENT IMPROVEMEN, V24, pxv
   Centers for Disease Control and Prevention, 2017, PRESCR OP
   Centers for Disease Control and Prevention (CDC), 2016, DRUG OV DEATH DAT
   Compton WA, 2006, DRUG ALCOHOL DEPEN, V83, pS4, DOI 10.1016/j.drugalcdep.2005.10.020
   Crosby R., 2013, HLTH BEHAV THEORY PU, P163
   Ctr Dis Control Prevent, 2016, J PAIN PALLIAT CARE, V30, P138, DOI 10.3109/15360288.2016.1173761
   Donaldson MS, 1996, PRIMARY CARE AMERICA, P27
   Frank JW, 2016, PAIN MED, V17, P1838, DOI 10.1093/pm/pnw078
   Hancock C, 2017, TREATING RURAL OPIOI
   Hughes A., 2016, PRESCRIPTION DRUG US
   Hurstak EE, 2017, SUBST ABUS, V38, P213, DOI 10.1080/08897077.2017.1296524
   Inciardi JA, 2007, PAIN MED, V8, P171, DOI 10.1111/j.1526-4637.2006.00255.x
   Inciardi JA, 2009, J ADDICT DIS, V28, P332, DOI 10.1080/10550880903182986
   Inciardi JA, 2009, PAIN MED, V10, P537, DOI 10.1111/j.1526-4637.2009.00603.x
   Kaye AD, 2017, PAIN PHYSICIAN, V20, pS93
   Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957
   Levy B, 2015, AM J PREV MED, V49, P409, DOI 10.1016/j.amepre.2015.02.020
   Lipari R. N., 2016, AMERICAS NEED RECEIP
   McCabe SE, 2008, ADDICT BEHAV, V33, P713, DOI 10.1016/j.addbeh.2007.12.008
   McCroskey J. C., 1997, AVOIDING COMMUNICATI, P75
   McHugh RK, 2015, J SUBST ABUSE TREAT, V48, P1, DOI 10.1016/j.jsat.2014.08.004
   Mueller SR, 2017, J GEN INTERN MED, V32, P277, DOI 10.1007/s11606-016-3895-8
   NIDA, 2012, SCREEN DRUG US GEN M
   O'Connor PG, 2014, JAMA INTERN MED, V174, P1717, DOI 10.1001/jamainternmed.2014.4211
   Paulozzi LJ, 2014, MMWR-MORBID MORTAL W, V63, P563
   Paulozzi LJ, 2012, J SAFETY RES, V43, P283, DOI 10.1016/j.jsr.2012.08.009
   Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487
   Pollard K., 2017, CO1866216 POP REF BU
   Prescription Drug Monitoring Program Center of Excellence at Brandeis University, 2014, BRIEF PDMP EFF
   Pullen E, 2014, SUBST USE MISUSE, V49, P891, DOI 10.3109/10826084.2014.891615
   QSR International, 2014, NVIVO QUAL DAT AN SO
   QSR International, 1999, NVIVO QUAL DAT AN SO
   Rigg KK, 2012, DRUG-EDUC PREV POLIC, V19, P145, DOI 10.3109/09687637.2011.631197
   Sanders AN, 2016, J PRIM CARE COMMUNIT, V7, P175, DOI 10.1177/2150131916628462
   Shapiro B, 2013, AM FAM PHYSICIAN, V88, P113
   Silvestri MM, 2016, PSYCHOL ADDICT BEHAV, V30, P516, DOI 10.1037/adb0000182
   Stogner JM, 2014, J AM BOARD FAM MED, V27, P583, DOI 10.3122/jabfm.2014.05.140107
   Substance Abuse and Mental Health Services Administration (SAMHSA), 2016, RIS PRESCR DRUG MIS
   Substance Abuse and Mental Health Services Administration (SAMHSA), 2014, NSDUH SER H, P13
   Twillman RK, 2014, CA-CANCER J CLIN, V64, P369, DOI 10.3322/caac.21243
   U. S. Department of Health and Human Services, 2013, PRESCR DRUG MON PROG, P3
   Xierali IM, 2013, J AM BOARD FAM MED, V26, P114, DOI 10.3122/jabfm.2013.02.120219
NR 59
TC 1
Z9 1
U1 1
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1082-6084
EI 1532-2491
J9 SUBST USE MISUSE
JI Subst. Use Misuse
PD JAN 1
PY 2020
VL 55
IS 1
BP 37
EP 47
DI 10.1080/10826084.2019.1654514
EA SEP 2019
PG 11
WC Substance Abuse; Psychiatry; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry; Psychology
GA OP1ZP
UT WOS:000486857900001
PM 31526177
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Varghese, SP
AF Varghese, Sajoy P.
TI Stress and Drug Addiction. "A Focus on Corticotropin-Releasing Factor"
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE Addiction; Stress; Opiate Withdrawal; FbCRHOE mice; CRF receptors
C1 [Varghese, Sajoy P.] Captain James A Lovell FHCC, Dept Mental Hlth, N Chicago, IL USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 814
BP 260S
EP 260S
PG 1
WC Neurosciences; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801124
DA 2023-06-23
ER

PT J
AU Ghitza, UE
AF Ghitza, Udi E.
TI Commentary: rewriting the Valuation and Salience of alcohol-related
   Stimuli via memory reconsolidation
SO FRONTIERS IN PSYCHIATRY
LA English
DT Editorial Material
DE alcohol drinking; memory retrieval; alcohol use disorder; drug use
   disorder; substance use disorder; addiction; alcohol abuse; drug abuse
ID NEURONAL ENSEMBLES; PREFRONTAL CORTEX; ADDICTION; RELAPSE
C1 [Ghitza, Udi E.] NIDA, Ctr Clin Trials Network, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute on
   Drug Abuse (NIDA)
RP Ghitza, UE (通讯作者)，NIDA, Ctr Clin Trials Network, NIH, Bethesda, MD 20892 USA.
EM ghitzau@nida.nih.gov
CR Bossert JM, 2011, NAT NEUROSCI, V14, P420, DOI 10.1038/nn.2758
   Buhler M, 2010, BIOL PSYCHIAT, V67, P745, DOI 10.1016/j.biopsych.2009.10.029
   Cruz FC, 2014, J NEUROSCI, V34, P7437, DOI 10.1523/JNEUROSCI.0238-14.2014
   Das RK, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.132
   Exton-McGuinness MTJ, 2015, BEHAV BRAIN RES, V278, P375, DOI 10.1016/j.bbr.2014.10.011
   Ghitza UE, 2015, FRONT PSYCHIATRY, V6, DOI 10.3389/fpsyt.2015.00037
   Ghitza UE, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00180
   Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119
   Lonergan M, 2016, J BEHAV THER EXP PSY, V50, P245, DOI 10.1016/j.jbtep.2015.09.012
   Nestler Eric J, 2013, Dialogues Clin Neurosci, V15, P431
   Otis JM, 2015, NEUROPSYCHOPHARMACOL, V40, P793, DOI 10.1038/npp.2014.243
   Reichelt AC, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00118
   Tronson NC, 2013, CURR OPIN NEUROBIOL, V23, P573, DOI 10.1016/j.conb.2013.01.022
   Zhang J, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000437
NR 14
TC 0
Z9 0
U1 0
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD MAR 17
PY 2016
VL 7
AR 41
DI 10.3389/fpsyt.2016.00041
PG 3
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA DG5WL
UT WOS:000372150000001
PM 27014104
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU ACKER, CJ
AF ACKER, CJ
TI ADDICTION AND THE LABORATORY - THE WORK OF THE
   NATIONAL-RESEARCH-COUNCILS COMMITTEE ON DRUG-ADDICTION, 1928-1939
SO ISIS
LA English
DT Article
RP ACKER, CJ (通讯作者)，CARNEGIE MELLON UNIV,DEPT HIST,PITTSBURGH,PA 15213, USA.
CR ABEL JJ, 1921, FUTURE INDEPENDENCE
   ACKER CJ, 1995, DRUGS NARCOTICS HIST
   [Anonymous], DISCOVERIES PHARM
   BAYNEJONES S, 1933, COMMUNICATION   0324
   BUGOS GE, 1989, HIST STUD PHYS BIOL, V20, P1
   Burrow J, 1963, AMA VOICE AM MED
   BYNUM W F, 1970, Bulletin of the History of Medicine, V44, P518
   CLARKE, 1985, THESIS U CALIFORNIA
   Clarke Adele, 1992, RIGHT TOOLS JOB WORK, P3, DOI DOI 10.1515/9781400863136.3
   CLARKE AE, 1990, SOC PROBL, V37, P18, DOI 10.1525/sp.1990.37.1.03a00020
   *COMM DRUG ADD, 1973, NAT RES COUNC INV OP
   COUNCILMAN WT, 1915, AM MED ASS B, V10, P338
   Courtwright David, 1982, DARK PARADISE OPIATE, P35
   DUNHAM L, 1928, COMMUNICATION   1123
   EDDY NB, 1967, SCIENCE, V181, P407
   EDDY NB, 1936, PUB HLTH REP S, V118, P2
   Geison G. L., 1979, THERAPEUTIC REVOLUTI, P67
   Goodman L, 1941, PHARM BASIS THERAPEU
   HARDEN VA, 1986, INVENTING NIH FEDERA, P71
   HATCHER R, 1930, REPORT COMMITTEE DRU
   HIMMELSBACH, 1938, COMMUNICATION   1701
   Himmelsbach CK, 1939, J PHARMACOL EXP THER, V67, P239
   HUNT, 1928, COMMUNICATION   1217
   HUNT, 1922, COMMUNICATION   0710
   JACOBSON AE, 1991, PROBLEMS DRUG DEPEND
   KING MR, 1935, PUB HLTH REP, V113
   KOHLER RE, 1991, PARTNERS SCI F NATUR
   Kohler Robert E., 1982, MED CHEM BIOCH MAKIN, DOI [10.1017/CBO9780511897313, DOI 10.1017/CBO9780511897313]
   Kolb L, 1924, PUBLIC HEALTH REP, V39, P1179, DOI 10.2307/4577168
   Lee LF, 1942, J PHARMACOL EXP THER, V75, P161
   LENOIR T, 1988, MINERVA, V26, P66, DOI 10.1007/BF01096701
   Liebenau Jonathan, 1987, MED SCI MED IND FORM
   LILLY E, 1936, COMMUNICATION   1116
   LUDMERER KM, 1985, LEARNING HEAL
   MARSHALL EK, 1951, BIOGR MEM NAT ACAD S, V26, P25
   Maulitz R. C., 1979, THERAPEUTIC REVOLUTI, P91
   MCCLUNG CE, 1989, BIOGRAPHICAL MEMOIRS, V20, P245
   MERCK G, 1934, COMMUNICATION   0424
   MEYERTHUROW G, 1982, ISIS, V73, P363, DOI 10.1086/353039
   MUSTO DF, 1987, AM DISEASE ORIGINS N, P134
   NICHOLAS P, 1935, COMMUNICATION   0320
   PARASCANDOLA J, 1983, CHEM MODERN SOC HIST, P85
   Parascandola J., 1992, DEV AM PHARM JJ ABEL
   Rosenberg Charles, 1979, ORG KNOWLEDGE MODERN, P440
   ROSIN, 1933, COMMUNICATION   0628
   ROTHSTEIN WG, 1987, AM MED SCH PARACTICE
   SMALL, 1936, COMMUNICATION   0511
   SMALL, 1935, COMMUNICATION   0325
   SMALL, 1933, COMMUNICATION   0621
   SMALL, 1934, COMMUNICATION   0614
   SMALL LF, 1959, BIOGR MEM NAT ACAD S, V33, P397
   SMALL LF, 1936, COMMUNICATION   1207
   STAR SL, 1989, SOC STUD SCI, V19, P387, DOI 10.1177/030631289019003001
   SWANN JP, 1988, ACADEMIC SCI PHARMAC
   TERRY C, 1928, OPIUM PROBLEM
   WEINER C, 1989, OWNING SCI TECHNICAL, P87
   WHITE, 1936, COMMUNICATION   1224
   WHITE, 1928, COMMUNICATION   1126
   WHITE, 1929, COMMUNICATION   0610
   WHITE, 1929, COMMUNICATION   1205
   WHITE, 1930, COMMUNICATION   0105
   WHITE WC, 1993, REPORT COMMITTEE DRU
   WHITE WC, 1933, PRELIMINARY ANN REPO
   WHITE WC, 1929, COMMUNICATION   0114
   YOUNG, 1967, MED MESSIAHS SOCIAL
   Young James Harvey, 1961, TOADSTOOL MILLIONAIR
   1925, MENT HYG, V9, P300
   1928, ARCH NEUROLOGY PSYCH, V20, P171
   AM J PSYCHIAT, V5, P163
   1936, WASHINGTON POST 1109
NR 70
TC 6
Z9 6
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0021-1753
J9 ISIS
JI Isis
PD JUN
PY 1995
VL 86
IS 2
BP 167
EP 193
DI 10.1086/357152
PG 27
WC History & Philosophy Of Science
WE Arts &amp; Humanities Citation Index (A&amp;HCI); Social Science Citation Index (SSCI)
SC History & Philosophy of Science
GA RP895
UT WOS:A1995RP89500001
PM 7558752
DA 2023-06-23
ER

PT J
AU Maffly-Kipp, J
   Flanagan, PN
   Schlegel, RJ
   Vess, M
AF Maffly-Kipp, Joseph
   Flanagan, Patricia N.
   Schlegel, Rebecca J.
   Vess, Matthew
TI True self-attributions shape judgments of blame in the context of
   addiction-relevant crime
SO ADDICTIVE BEHAVIORS
LA English
DT Article
AB In three studies, we examined how attributing the criminal actions of a drug-addicted offender to their "true self " influences perceptions of their blameworthiness. Study 1 revealed that attributing a drug-addicted offender's crime (theft) to his true self positively predicted judgments of the offender's blameworthiness for the crime. Study 2 employed an experimental design and revealed that information connecting a crime (vs. not connecting) to an addicted offender's true self led to greater judgments of blame, whereas learning that the offender had (vs. did not have) a genetic predisposition to addiction mitigated blame. In Study 3, participants read a vignette about a drug-addicted thief whose addiction began with a doctor's prescription, a drug-addicted thief whose addiction began with recreational drug use, or a thief with no mention of addiction. Participants in the prescription condition, but not the recreational use condition, attributed theft to the offender's true self less and ascribed less blame for the crime, relative to the no addiction condition. Furthermore, participants attributed the addiction less to the offender's true self and assigned less blame to the offender for his addiction in the prescription (vs. recreation) condition. Overall, our studies suggest that lay intuitions about true selves robustly guide people's judgments about blame in the context of crimes involving drug-addicted offenders.
C1 [Maffly-Kipp, Joseph; Flanagan, Patricia N.; Schlegel, Rebecca J.; Vess, Matthew] Texas A&M Univ, Dept Psychol & Brain Sci, College Stn, TX 77843 USA.
C3 Texas A&M University System; Texas A&M University College Station
RP Vess, M (通讯作者)，Texas A&M Univ, Dept Psychol & Brain Sci, College Stn, TX 77843 USA.
EM vess@tamu.edu
RI Vess, Matthew/C-7362-2014
OI Maffly-Kipp, Joseph/0000-0002-7178-3570
CR [Anonymous], 2013, COURT REV, V49, P40
   Aust F, 2013, BEHAV RES METHODS, V45, P527, DOI 10.3758/s13428-012-0265-2
   Bench SW, 2015, SOC COGNITION, V33, P169
   Bennett T, 2008, AGGRESS VIOLENT BEH, V13, P107, DOI 10.1016/j.avb.2008.02.001
   BRADBURY TN, 1990, PSYCHOL BULL, V107, P3, DOI 10.1037/0033-2909.107.1.3
   Christy AG, 2019, J PERS SOC PSYCHOL, V117, P386, DOI 10.1037/pspp0000254
   Dar-Nimrod I, 2011, PSYCHOL BULL, V137, P800, DOI 10.1037/a0021860
   Felson RB, 2017, CRIME DELINQUENCY, V63, P375, DOI 10.1177/0011128715591696
   Gallagher J. R., 2018, J ADV JUSTICE, V1, P89
   Gallucci M., 2020, JAMM JAMOVI ADV MEDI
   GOLDSTEIN PJ, 1985, J DRUG ISSUES, V15, P493, DOI 10.1177/002204268501500406
   Hansen H, 2016, AM J PUBLIC HEALTH, V106, P2127, DOI 10.2105/AJPH.2016.303483
   Hayhurst KP, 2017, INT J DRUG POLICY, V39, P1, DOI 10.1016/j.drugpo.2016.08.015
   Hester N, 2020, PERSPECT PSYCHOL SCI, V15, P216, DOI 10.1177/1745691619885840
   Krebs CP, 2007, DRUG ALCOHOL DEPEN, V91, P57, DOI 10.1016/j.drugalcdep.2007.05.011
   Lacey N, 2013, OXFORD J LEGAL STUD, V33, P1, DOI 10.1093/ojls/gqs028
   Landau MJ, 2011, J EXP SOC PSYCHOL, V47, P79, DOI 10.1016/j.jesp.2010.08.012
   Lebowitz MS, 2017, INT J SOC PSYCHIATR, V63, P717, DOI 10.1177/0020764017737573
   Newman GE, 2015, COGNITIVE SCI, V39, P96, DOI 10.1111/cogs.12134
   Newman GE, 2014, PERS SOC PSYCHOL B, V40, P203, DOI 10.1177/0146167213508791
   Pickard H, 2017, NEUROETHICS-NETH, V10, P169, DOI 10.1007/s12152-016-9295-2
   Pizarro DA, 2003, PSYCHOL REV, V110, P193, DOI 10.1037/0033-295X.110.1.193
   Pletcher MJ, 2008, JAMA-J AM MED ASSOC, V299, P70, DOI 10.1001/jama.2007.64
   Strohminger N, 2017, PERSPECT PSYCHOL SCI, V12, P551, DOI 10.1177/1745691616689495
   Strohminger N, 2014, COGNITION, V131, P159, DOI 10.1016/j.cognition.2013.12.005
   Tabb K, 2019, BEHAV GENET, V49, P128, DOI 10.1007/s10519-018-9916-0
   The jamovi project, 2020, JAM
   Vonasch Andrew J, 2017, Addict Behav Rep, V5, P56, DOI 10.1016/j.abrep.2017.01.002
NR 28
TC 0
Z9 0
U1 1
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4603
EI 1873-6327
J9 ADDICT BEHAV
JI Addict. Behav.
PD JUL
PY 2022
VL 130
AR 107287
DI 10.1016/j.addbeh.2022.107287
EA FEB 2022
PG 8
WC Psychology, Clinical; Substance Abuse
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology; Substance Abuse
GA 1N0KE
UT WOS:000800352300012
PM 35220152
DA 2023-06-23
ER

PT J
AU Morikawa, H
   Young, CC
   Smits, JA
AF Morikawa, Hitoshi
   Young, Cara C.
   Smits, Jasper A.
TI Usage of L-type calcium channel blockers to suppress drug reward and
   memory driving addiction: Past, present, and future
SO NEUROPHARMACOLOGY
LA English
DT Article
DE L -type calcium channels; Dopaminergic system; Addiction; Cue exposure
   therapy; Isradipine
ID CONDITIONED PLACE PREFERENCE; VENTRAL TEGMENTAL AREA; CA2+ CHANNELS;
   DOPAMINERGIC MODULATION; REINFORCING PROPERTIES; SYNAPTIC-TRANSMISSION;
   NUCLEUS-ACCUMBENS; BLOOD-FLOW; COCAINE; ISRADIPINE
AB Over the past three decades, L-type Ca2+ channel (LTCC) blockers have been considered a potential therapeutic drug to alleviate the symptoms of drug addiction. This idea has been supported, in part, by 1) expression of LTCCs in the brain dopaminergic circuits that are thought to play critical roles in the development and expression of addictive behaviors and 2) common usage of LTCC blockers in treating hypertension, which may enable off -label use of these drugs with good brain penetration as therapeutics for brain disorders. Addiction can be viewed as a maladaptive form of learning where powerful memories of drug-associated stimuli and actions drive compulsive drug intake. Largely under this framework, we will focus on the dopaminergic system that is thought be critically involved in drug-associated learning and memory and provide a brief overview of the past and recent studies testing the therapeutic potential of LTCC blockers for addictive disorders in animal models and humans and offer a future perspective on the use of LTCC blockers in drug addiction and, possibly, addiction to other non -drug rewards (e.g., gambling, eating, shopping). Interested readers can refer to other related articles in this issue and a comprehensive review available elsewhere (Little, 2021) to gain further insights into the roles of LTCCs in drug addiction and withdrawal symptoms associated with dependence.
C1 [Morikawa, Hitoshi] Dept Neurosci, Austin, TX USA.
   [Morikawa, Hitoshi] Waggoner Ctr Alcohol & Addict Res, Austin, TX USA.
   [Young, Cara C.] Sch Nursing, Austin, TX USA.
   [Smits, Jasper A.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA.
C3 University of Texas System; University of Texas Austin
RP Morikawa, H (通讯作者)，2400 Speedway, Austin, TX 78712 USA.
EM morikawa@utexas.edu
OI Smits, Jasper/0000-0003-1633-9693
FU NIH;  [DA054274];  [DA049539]
FX Acknowledgements This work was supported by NIH grants DA054274 to H.M.
   and DA049539 to C.C.Y. and J.A.S.
CR Adermark L, 2007, J NEUROSCI, V27, P6781, DOI 10.1523/JNEUROSCI.0280-07.2007
   Anderson SM, 2008, NAT NEUROSCI, V11, P344, DOI 10.1038/nn2054
   Bavley CC, 2020, MOL PSYCHIATR, V25, P2373, DOI 10.1038/s41380-019-0513-2
   Biala G, 2008, PHARMACOL BIOCHEM BE, V89, P116, DOI 10.1016/j.pbb.2007.12.005
   Biala G, 1996, J PHYSIOL PHARMACOL, V47, P497
   Biala G, 2006, EUR J PHARMACOL, V537, P85, DOI 10.1016/j.ejphar.2006.03.017
   Bromberg-Martin ES, 2010, NEURON, V68, P815, DOI 10.1016/j.neuron.2010.11.022
   Carter AG, 2004, NEURON, V44, P483, DOI 10.1016/j.neuron.2004.10.013
   Cepeda C, 1998, J NEUROPHYSIOL, V79, P82, DOI 10.1152/jn.1998.79.1.82
   Chan CS, 2007, NATURE, V447, P1081, DOI 10.1038/nature05865
   Chartoff EH, 2006, BIOL PSYCHIAT, V59, P1236, DOI 10.1016/j.biopsych.2005.09.024
   Clark JJ, 2012, CURR OPIN NEUROBIOL, V22, P1054, DOI 10.1016/j.conb.2012.06.004
   Covey DP, 2014, TRENDS NEUROSCI, V37, P200, DOI 10.1016/j.tins.2014.02.002
   Degoulet M, 2016, MOL PSYCHIATR, V21, P394, DOI 10.1038/mp.2015.84
   Everitt BJ, 2013, NEUROSCI BIOBEHAV R, V37, P1946, DOI 10.1016/j.neubiorev.2013.02.010
   Galarraga E, 1997, NEUROREPORT, V8, P2183, DOI 10.1097/00001756-199707070-00019
   Gottschalk PCH, 2002, AM J ADDICTION, V11, P200, DOI 10.1080/10550490290087983
   Guzman JN, 2010, NATURE, V468, P696, DOI 10.1038/nature09536
   Guzman JN, 2009, J NEUROSCI, V29, P11011, DOI 10.1523/JNEUROSCI.2519-09.2009
   Harnett MT, 2009, NEURON, V62, P826, DOI 10.1016/j.neuron.2009.05.011
   HernandezLopez S, 1997, J NEUROSCI, V17, P3334
   Huang H, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5481
   Hyland BI, 2002, NEUROSCIENCE, V114, P475, DOI 10.1016/S0306-4522(02)00267-1
   Johnson B, 1998, PSYCHOPHARMACOLOGY, V136, P335, DOI 10.1007/s002130050575
   Johnson BA, 2000, NEUROPSYCHOPHARMACOL, V22, P504, DOI 10.1016/S0893-133X(99)00116-5
   Johnson BA, 2005, AM J HYPERTENS, V18, P813, DOI 10.1016/j.amjhyper.2005.01.020
   Johnson BA, 2005, INT J NEUROPSYCHOPH, V8, P203, DOI 10.1017/S1461145704005036
   Johnson BA, 2005, PROG NEURO-PSYCHOPH, V29, P15, DOI 10.1016/j.pnpbp.2004.08.014
   Johnson BA, 1999, PSYCHOPHARMACOLOGY, V144, P295, DOI 10.1007/s002130051007
   Kang S, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2149
   Keiflin R, 2015, NEURON, V88, P247, DOI 10.1016/j.neuron.2015.08.037
   KUZMIN A, 1992, PHARMACOL BIOCHEM BE, V41, P497, DOI 10.1016/0091-3057(92)90363-K
   Licata SC, 2004, EUR J NEUROSCI, V19, P405, DOI 10.1111/j.0953-816X.2003.03110.x
   Lipscombe D, 2004, J NEUROPHYSIOL, V92, P2633, DOI 10.1152/jn.00486.2004
   Liss B, 2019, ANNU REV PHARMACOL, V59, P263, DOI 10.1146/annurev-pharmtox-010818-021214
   Little HJ, 2021, PHARMACOL REV, V73, P127, DOI 10.1124/pharmrev.120.000245
   Liu YD, 2014, J NEUROPHYSIOL, V112, P1119, DOI 10.1152/jn.00757.2013
   LJUNGBERG T, 1992, J NEUROPHYSIOL, V67, P145, DOI 10.1152/jn.1992.67.1.145
   MERCURI NB, 1994, BRIT J PHARMACOL, V113, P831, DOI 10.1111/j.1476-5381.1994.tb17068.x
   Montague PR, 2004, NATURE, V431, P760, DOI 10.1038/nature03015
   MUNTANER C, 1991, PSYCHOPHARMACOLOGY, V105, P37, DOI 10.1007/BF02316861
   NEDERGAARD S, 1993, J PHYSIOL-LONDON, V466, P727
   Oliveto A, 2004, EUR J PHARMACOL, V491, P157, DOI 10.1016/j.ejphar.2004.03.024
   Olsen CM, 2011, NEUROPHARMACOLOGY, V61, P1109, DOI 10.1016/j.neuropharm.2011.03.010
   Olson PA, 2005, J NEUROSCI, V25, P1050, DOI 10.1523/JNEUROSCI.3327-04.2005
   Overton PG, 1997, BRAIN RES REV, V25, P312, DOI 10.1016/S0165-0173(97)00039-8
   Paladini CA, 2014, NEUROSCIENCE, V282, P109, DOI 10.1016/j.neuroscience.2014.07.032
   Pan WX, 2005, J NEUROSCI, V25, P6235, DOI 10.1523/JNEUROSCI.1478-05.2005
   PANI L, 1990, EUR J PHARMACOL, V190, P217, DOI 10.1016/0014-2999(90)94128-K
   PANI L, 1990, EUR J PHARMACOL, V176, P245, DOI 10.1016/0014-2999(90)90537-G
   PANI L, 1991, BRAIN RES BULL, V26, P445, DOI 10.1016/0361-9230(91)90022-C
   Papini S, 2020, CONTEMP CLIN TRIALS, V94, DOI 10.1016/j.cct.2020.106013
   PUCILOWSKI O, 1993, EUR J PHARMACOL, V240, P89, DOI 10.1016/0014-2999(93)90551-R
   PUCILOWSKI O, 1995, NEUROPSYCHOPHARMACOL, V12, P239, DOI 10.1016/0893-133X(94)00080-J
   Rajadhyaksha A, 2004, J NEUROSCI, V24, P7464, DOI 10.1523/JNEUROSCI.0612-04.2004
   Rajadhyaksha A, 1999, J NEUROSCI, V19, P6348
   Redish AD, 2004, SCIENCE, V306, P1944, DOI 10.1126/science.1102384
   Roache JD, 2005, EXP CLIN PSYCHOPHARM, V13, P319, DOI 10.1037/1064-1297.13.4.319
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   ROSSE RB, 1994, CLIN NEUROPHARMACOL, V17, P348, DOI 10.1097/00002826-199408000-00007
   ROWBOTHAM MC, 1987, PSYCHOPHARMACOLOGY, V93, P152
   Rush CR, 1998, ALCOHOL CLIN EXP RES, V22, P539, DOI 10.1111/j.1530-0277.1998.tb03686.x
   Saunders BT, 2018, NAT NEUROSCI, V21, P1072, DOI 10.1038/s41593-018-0191-4
   Schierberl K, 2011, J NEUROSCI, V31, P13562, DOI 10.1523/JNEUROSCI.2315-11.2011
   Schultz W, 2015, PHYSIOL REV, V95, P853, DOI 10.1152/physrev.00023.2014
   Shen F, 2018, NEUROSCIENCE, V370, P139, DOI 10.1016/j.neuroscience.2017.07.049
   Shepard PD, 1999, BRAIN RES, V817, P104, DOI 10.1016/S0006-8993(98)01231-1
   Sinnegger-Brauns MJ, 2009, MOL PHARMACOL, V75, P407, DOI 10.1124/mol.108.049981
   Stephenson-Jones M, 2016, NATURE, V539, P289, DOI 10.1038/nature19845
   Stuber GD, 2008, SCIENCE, V321, P1690, DOI 10.1126/science.1160873
   Tenti G, 2014, J MED CHEM, V57, P4313, DOI 10.1021/jm500263v
   Tritsch NX, 2012, NEURON, V76, P33, DOI 10.1016/j.neuron.2012.09.023
   Vafaie N, 2022, JAMA PSYCHIAT, V79, P641, DOI 10.1001/jamapsychiatry.2022.1240
   Venniro M, 2016, PROG BRAIN RES, V224, P25, DOI 10.1016/bs.pbr.2015.08.004
   Wang B, 2013, NEUROPSYCHOPHARMACOL, V38, P1763, DOI 10.1038/npp.2013.75
   Watabe-Uchida M, 2017, ANNU REV NEUROSCI, V40, P373, DOI 10.1146/annurev-neuro-072116-031109
   Wickens JR, 2009, BEHAV BRAIN RES, V199, P119, DOI 10.1016/j.bbr.2008.10.030
   Zampese E, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092045
NR 78
TC 0
Z9 0
U1 1
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3908
EI 1873-7064
J9 NEUROPHARMACOLOGY
JI Neuropharmacology
PD DEC 15
PY 2022
VL 221
AR 109290
DI 10.1016/j.neuropharm.2022.109290
EA OCT 2022
PG 5
WC Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 5T0AO
UT WOS:000875541300005
PM 36241085
DA 2023-06-23
ER

PT J
AU Luscher, C
   Robbins, TW
   Everitt, BJ
AF Luscher, Christian
   Robbins, Trevor W.
   Everitt, Barry J.
TI The transition to compulsion in addiction
SO NATURE REVIEWS NEUROSCIENCE
LA English
DT Review
ID COCAINE-SEEKING BEHAVIOR; NUCLEUS-ACCUMBENS CORE; PAVLOVIAN-INSTRUMENTAL
   TRANSFER; AMYGDALA CENTRAL NUCLEUS; PREFRONTAL CORTEX; DRUG-ADDICTION;
   DORSAL STRIATUM; ORBITOFRONTAL CORTEX; BASOLATERAL AMYGDALA; HABIT
   FORMATION
AB Compulsion is a key symptom of drug addiction. In this Review, Luscher, Robbins and Everitt integrate the neural and psychological mechanisms that underlie the transition to compulsion within a learning theory framework, highlighting the distinctions between compulsive drug taking and compulsive drug seeking.
   Compulsion is a cardinal symptom of drug addiction (severe substance use disorder). However, compulsion is observed in only a small proportion of individuals who repeatedly seek and use addictive substances. Here, we integrate accounts of the neuropharmacological mechanisms that underlie the transition to compulsion with overarching learning theories, to outline how compulsion develops in addiction. Importantly, we emphasize the conceptual distinctions between compulsive drug-seeking behaviour and compulsive drug-taking behaviour (that is, use). In the latter, an individual cannot stop using a drug despite major negative consequences, possibly reflecting an imbalance in frontostriatal circuits that encode reward and aversion. By contrast, an individual may compulsively seek drugs (that is, persist in seeking drugs despite the negative consequences of doing so) when the neural systems that underlie habitual behaviour dominate goal-directed behavioural systems, and when executive control over this maladaptive behaviour is diminished. This distinction between different aspects of addiction may help to identify its neural substrates and new treatment strategies.
C1 [Luscher, Christian] Univ Geneva, Dept Basic Neurosci, Geneva, Switzerland.
   [Luscher, Christian] Geneva Univ Hosp, Dept Clin Neurosci, Div Neurol, Geneva, Switzerland.
   [Robbins, Trevor W.; Everitt, Barry J.] Univ Cambridge, Dept Psychol, Behav & Clin Neurosci Inst, Cambridge, England.
C3 University of Geneva; University of Geneva; University of Cambridge
RP Luscher, C (通讯作者)，Univ Geneva, Dept Basic Neurosci, Geneva, Switzerland.; Luscher, C (通讯作者)，Geneva Univ Hosp, Dept Clin Neurosci, Div Neurol, Geneva, Switzerland.; Robbins, TW; Everitt, BJ (通讯作者)，Univ Cambridge, Dept Psychol, Behav & Clin Neurosci Inst, Cambridge, England.
EM christian.luscher@unige.ch; twr2@cam.ac.uk; bje10@cam.ac.uk
RI Lüscher, Christian/A-2496-2011; Robbins, Trevor W/A-7551-2008
OI Lüscher, Christian/0000-0001-7917-4596; Robbins,
   Trevor/0000-0003-0642-5977; Everitt, Barry/0000-0003-4431-6536
FU Swiss National Science Foundation; European Research Council; UK Medical
   Research Council [MR/N02530X/1]; Wellcome Trust [WT 104631/Z/14/Z/]; MRC
   [MR/N02530X/1] Funding Source: UKRI
FX The authors acknowledge the Swiss National Science Foundation and the
   European Research Council (C.L.) as well as the UK Medical Research
   Council (grant MR/N02530X/1) and the Wellcome Trust (Investigator Award
   WT 104631/Z/14/Z/) for financial support (B.J.E., T.W.R.). The authors
   thank D. Belin and M. Loureiro for help with the figures.
CR Abrahao KP, 2017, NEURON, V96, P1223, DOI 10.1016/j.neuron.2017.10.032
   Ahmed SH, 2018, PROG NEURO-PSYCHOPH, V87, P3, DOI 10.1016/j.pnpbp.2017.09.027
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Ahmed SH, 1999, PSYCHOPHARMACOLOGY, V146, P303, DOI 10.1007/s002130051121
   American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5th, DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]
   Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244
   Augier E, 2018, SCIENCE, V360, P1321, DOI 10.1126/science.aao1157
   Balleine BW, 2011, ANN NY ACAD SCI, V1239, P43, DOI 10.1111/j.1749-6632.2011.06270.x
   Balleine BW, 2010, NEUROPSYCHOPHARMACOL, V35, P48, DOI 10.1038/npp.2009.131
   Balleine BW, 2009, BEHAV BRAIN RES, V199, P43, DOI 10.1016/j.bbr.2008.10.034
   Balleine BW, 2005, PHYSIOL BEHAV, V86, P717, DOI 10.1016/j.physbeh.2005.08.061
   Bechara A, 2001, NEUROPSYCHOLOGIA, V39, P376, DOI 10.1016/S0028-3932(00)00136-6
   Belin D, 2007, PSYCHOPHARMACOLOGY, V193, P567, DOI 10.1007/s00213-007-0790-3
   Belin D, 2016, GENES BRAIN BEHAV, V15, P74, DOI 10.1111/gbb.12265
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   Belin D, 2008, NEURON, V57, P432, DOI 10.1016/j.neuron.2007.12.019
   Belin D, 2013, CURR OPIN NEUROBIOL, V23, P564, DOI 10.1016/j.conb.2013.01.025
   Belin D, 2009, BIOL PSYCHIAT, V65, P863, DOI 10.1016/j.biopsych.2008.05.031
   Bocklisch C, 2013, SCIENCE, V341, P1521, DOI 10.1126/science.1237059
   Boileau I, 2006, ARCH GEN PSYCHIAT, V63, P1386, DOI 10.1001/archpsyc.63.12.1386
   Boulos LJ, 2020, NEUROPSYCHOPHARMACOL, V45, P247, DOI 10.1038/s41386-019-0395-7
   Bradfield LA, 2015, NEURON, V88, P1268, DOI 10.1016/j.neuron.2015.10.044
   Brown ME, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011373
   CADOR M, 1989, NEUROSCIENCE, V30, P77, DOI 10.1016/0306-4522(89)90354-0
   Cantin L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011592
   Cardinal RN, 2002, NEUROSCI BIOBEHAV R, V26, P321, DOI 10.1016/S0149-7634(02)00007-6
   Cardinal RN, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-9
   Cardinal RN, 2003, INT CONGR SER, V1250, P347, DOI 10.1016/S0531-5131(03)01013-6
   Carlson VCC, 2011, NEUROPSYCHOPHARMACOL, V36, P2513, DOI 10.1038/npp.2011.140
   Chen BT, 2013, NATURE, V496, P359, DOI 10.1038/nature12024
   Clemens KJ, 2014, NEUROPSYCHOPHARMACOL, V39, P2584, DOI 10.1038/npp.2014.111
   COLWILL RM, 1986, PSYCHOL LEARN MOTIV, V20, P55
   Corbit LH, 2012, BIOL PSYCHIAT, V72, P389, DOI 10.1016/j.biopsych.2012.02.024
   Corbit LH, 2011, J NEUROSCI, V31, P11786, DOI 10.1523/JNEUROSCI.2711-11.2011
   Corre J, 2018, ELIFE, V7, DOI 10.7554/eLife.39945
   Crombag HS, 2005, CEREB CORTEX, V15, P341, DOI 10.1093/cercor/bhh136
   Daglish MRC, 2008, BRIT J PSYCHIAT, V193, P65, DOI 10.1192/bjp.bp.107.041228
   Davis DR, 2016, PREV MED, V92, P36, DOI 10.1016/j.ypmed.2016.08.008
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Di Ciano P, 2004, J NEUROSCI, V24, P7167, DOI 10.1523/JNEUROSCI.1581-04.2004
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   DICKINSON A, 1981, BRIT MED BULL, V37, P165, DOI 10.1093/oxfordjournals.bmb.a071695
   Dickinson A, 2002, Q J EXP PSYCHOL-B, V55, P331, DOI 10.1080/0272499024400016
   DICKINSON A, 1985, PHILOS T ROY SOC B, V308, P67, DOI 10.1098/rstb.1985.0010
   El-Amamy H, 2007, EUR J NEUROSCI, V25, P1557, DOI 10.1111/j.1460-9568.2007.05402.x
   Ersche KD, 2016, SCIENCE, V352, P1468, DOI 10.1126/science.aaf3700
   Ersche KD, 2013, CURR OPIN NEUROBIOL, V23, P615, DOI 10.1016/j.conb.2013.02.017
   Ersche KD, 2012, SCIENCE, V335, P601, DOI 10.1126/science.1214463
   Ersche KD, 2011, BRAIN, V134, P2013, DOI 10.1093/brain/awr138
   ETTENBERG A, 1982, PSYCHOPHARMACOLOGY, V78, P204, DOI 10.1007/BF00428151
   Everitt BJ, 2016, ANNU REV PSYCHOL, V67, P23, DOI 10.1146/annurev-psych-122414-033457
   Everitt BJ, 2014, EUR J NEUROSCI, V40, P2163, DOI 10.1111/ejn.12644
   Everitt BJ, 2000, PSYCHOPHARMACOLOGY, V153, P17, DOI 10.1007/s002130000566
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Everitt BJ, 2013, NEUROSCI BIOBEHAV RE
   Fan XC, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00085
   Giuliano C, 2019, J NEUROSCI, V39, P1744, DOI 10.1523/JNEUROSCI.2615-18.2018
   Giuliano C, 2018, NEUROPSYCHOPHARMACOL, V43, P728, DOI 10.1038/npp.2017.105
   GOLDBERG SR, 1973, J PHARMACOL EXP THER, V186, P18
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Gremel CM, 2016, NEURON, V90, P1312, DOI 10.1016/j.neuron.2016.04.043
   Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134
   Haber SN, 2000, J NEUROSCI, V20, P2369
   Hampson RE, 2011, PSYCHOPHARMACOLOGY, V213, P105, DOI 10.1007/s00213-010-2017-2
   Harada M, 2019, CORTICO STRIATAL SYN
   Hardwick RM, 2019, NAT HUM BEHAV, V3, P1252, DOI 10.1038/s41562-019-0725-0
   Hart G, 2018, CURR BIOL, V28, P2218, DOI 10.1016/j.cub.2018.05.028
   Hellard ER, 2019, NEUROPHARMACOLOGY, V155, P89, DOI 10.1016/j.neuropharm.2019.05.022
   Heymann G, 2020, NEURON, V105, P909, DOI 10.1016/j.neuron.2019.11.024
   Higgins ST, 2004, ANNU REV PSYCHOL, V55, P431, DOI 10.1146/annurev.psych.55.090902.142033
   Hilario MRF, 2008, FRONT NEUROSCI-SWITZ, V2, P208, DOI 10.3389/neuro.01.030.2008
   Hirokawa J, 2019, NATURE, V576, P446, DOI 10.1038/s41586-019-1816-9
   Hodebourg R, 2019, EUR J NEUROSCI, V50, P2036, DOI 10.1111/ejn.13894
   Hogarth L, 2019, EUR J NEUROSCI, V50, P2513, DOI 10.1111/ejn.13961
   Hogarth L, 2013, ANN NY ACAD SCI, V1282, P12, DOI 10.1111/j.1749-6632.2012.06768.x
   Holland PC, 2004, J EXP PSYCHOL-ANIM B, V30, P104, DOI 10.1037/0097-7403.30.2.104
   Hu YZ, 2019, P NATL ACAD SCI USA, V116, P9066, DOI 10.1073/pnas.1819978116
   Ikemoto S, 2007, BRAIN RES REV, V56, P27, DOI 10.1016/j.brainresrev.2007.05.004
   Ito R, 2004, NAT NEUROSCI, V7, P389, DOI 10.1038/nn1217
   Ito R, 2002, J NEUROSCI, V22, P6247
   JOHNSON SW, 1992, J NEUROSCI, V12, P483
   Jonkman S, 2012, NEUROPSYCHOPHARMACOL, V37, P1612, DOI 10.1038/npp.2012.6
   Jonkman S, 2012, J NEUROSCI, V32, P4645, DOI 10.1523/JNEUROSCI.0348-12.2012
   Kalivas PW, 2009, NAT REV NEUROSCI, V10, P561, DOI 10.1038/nrn2515
   Kalivas PW, 2003, PSYCHOPHARMACOLOGY, V168, P44, DOI 10.1007/s00213-003-1393-2
   Kasanetz F, 2010, SCIENCE, V328, P1709, DOI 10.1126/science.1187801
   Kawa AB, 2016, PSYCHOPHARMACOLOGY, V233, P3587, DOI 10.1007/s00213-016-4393-8
   Kelley AE, 2002, J NEUROSCI, V22, P3306
   Killcross S, 2003, CEREB CORTEX, V13, P400, DOI 10.1093/cercor/13.4.400
   Kim J, 2016, NAT NEUROSCI, V19, P1636, DOI 10.1038/nn.4414
   Koob GF, 2016, LANCET PSYCHIAT, V3, P760, DOI 10.1016/S2215-0366(16)00104-8
   Koob GF, 2013, CURR OPIN NEUROBIOL, V23, P559, DOI 10.1016/j.conb.2013.03.011
   Koob GF, 2009, NEUROPHARMACOLOGY, V56, P18, DOI 10.1016/j.neuropharm.2008.07.043
   Koob GF, 2009, ADDICT BIOL, V14, P1, DOI 10.1111/j.1369-1600.2008.00127.x
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Kosaki Y, 2010, J EXP PSYCHOL-ANIM B, V36, P334, DOI 10.1037/a0016887
   Kuhn B.N., 2018, NEUROBIOLOGICAL MECH
   Lammel S, 2012, NATURE, V491, P212, DOI 10.1038/nature11527
   Lee Hongjoo J, 2010, Learn Mem, V17, P531, DOI 10.1101/lm.1889510
   Lesscher HMB, 2012, REV NEUROSCIENCE, V23, P731, DOI 10.1515/revneuro-2012-0066
   Lingawi NW, 2012, J NEUROSCI, V32, P1073, DOI 10.1523/JNEUROSCI.4806-11.2012
   Luscher C, 2006, PLOS MED, V3, P2005, DOI 10.1371/journal.pmed.0030437
   Malvaez M, 2018, CURR OPIN BEHAV SCI, V20, P67, DOI 10.1016/j.cobeha.2017.11.005
   Mameli M, 2009, NAT NEUROSCI, V12, P1036, DOI 10.1038/nn.2367
   Marchant NJ, 2018, PROG NEURO-PSYCHOPH, V87, P68, DOI 10.1016/j.pnpbp.2017.07.020
   Mateo Y, 2005, NEUROPSYCHOPHARMACOL, V30, P1455, DOI 10.1038/sj.npp.1300687
   Matsumoto M, 2007, NATURE, V447, P1111, DOI 10.1038/nature05860
   McFarland K, 2001, J NEUROSCI, V21, P8655
   Miles FJ, 2003, BEHAV NEUROSCI, V117, P927, DOI 10.1037/0735-7044.117.5.927
   Momennejad I, 2017, NAT HUM BEHAV, V1, P680, DOI 10.1038/s41562-017-0180-8
   Morein-Zamir S, 2014, BRAIN RES, V21, P488
   Murray EA, 2018, NAT REV NEUROSCI, V19, P404, DOI 10.1038/s41583-018-0013-4
   Murray JE, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10088
   Murray JE, 2012, NEUROPSYCHOPHARMACOL, V37, P2456, DOI 10.1038/npp.2012.104
   Naqvi NH, 2007, SCIENCE, V315, P531, DOI 10.1126/science.1135926
   Nelson A, 2006, J NEUROSCI, V26, P3805, DOI 10.1523/JNEUROSCI.4305-05.2006
   Nutt DJ, 2015, NAT REV NEUROSCI, V16, P305, DOI 10.1038/nrn3939
   O'Dell LE, 2004, ALCOHOL CLIN EXP RES, V28, P1676, DOI 10.1097/01.ALC.0000145781.11923.4E
   Olmstead MC, 2000, PSYCHOPHARMACOLOGY, V152, P123, DOI 10.1007/s002130000498
   Olmstead MC, 2001, BEHAV NEUROSCI, V115, P394, DOI 10.1037/0735-7044.115.2.394
   Ostlund SB, 2008, J NEUROSCI, V28, P4398, DOI 10.1523/JNEUROSCI.5472-07.2008
   Ostlund Sean B, 2008, Drug Discov Today Dis Models, V5, P235
   Parkes SL, 2018, CEREB CORTEX, V28, P2313, DOI 10.1093/cercor/bhx132
   Parkinson JA, 1999, J NEUROSCI, V19, P2401
   Pascoli V, 2018, NATURE, V564, P366, DOI 10.1038/s41586-018-0789-4
   Pascoli V, 2015, NEURON, V88, DOI 10.1016/j.neuron.2015.10.017
   Pascoli V, 2014, NATURE, V509, P459, DOI 10.1038/nature13257
   Pascoli V, 2012, NATURE, V481, P71, DOI 10.1038/nature10709
   Paterson NE, 2003, NEUROREPORT, V14, P2229, DOI 10.1097/00001756-200312020-00019
   Patriarchi T, 2018, SCIENCE, V360, P1420, DOI 10.1126/science.aat4422
   Pelloux Y, 2007, PSYCHOPHARMACOLOGY, V194, P127, DOI 10.1007/s00213-007-0805-0
   Pelloux Y, 2013, EUR J NEUROSCI, V38, P3018, DOI 10.1111/ejn.12289
   Pelloux Y, 2013, CURR OPIN NEUROBIOL, V23, P713, DOI 10.1016/j.conb.2013.02.016
   PETTIT HO, 1984, PSYCHOPHARMACOLOGY, V84, P167, DOI 10.1007/BF00427441
   Pickens CL, 2011, TRENDS NEUROSCI, V34, P411, DOI 10.1016/j.tins.2011.06.001
   Renteria R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02615-9
   Rogers RD, 1999, NEUROPSYCHOPHARMACOL, V20, P322, DOI 10.1016/S0893-133X(98)00091-8
   Rogers RD, 2001, CURR OPIN NEUROBIOL, V11, P250, DOI 10.1016/S0959-4388(00)00204-X
   Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-7
   Sanchis-Segura C, 2006, ADDICT BIOL, V11, P2, DOI 10.1111/j.1369-1600.2006.00012.x
   Schmitzer-Torbert N, 2015, NEUROBIOL LEARN MEM, V118, P105, DOI 10.1016/j.nlm.2014.11.007
   Schoenbaum G, 2008, BIOL PSYCHIAT, V63, P256, DOI 10.1016/j.biopsych.2007.06.003
   Seif T, 2013, NAT NEUROSCI, V16, P1094, DOI 10.1038/nn.3445
   Shen CJ, 2019, NAT MED, V25, P337, DOI 10.1038/s41591-018-0299-9
   Siciliano CA, 2019, SCIENCE, V366, P1008, DOI 10.1126/science.aay1186
   Singer BF, 2018, J NEUROSCI, V38, P60, DOI 10.1523/JNEUROSCI.2458-17.2017
   Sjoerds Z, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.107
   Smith KS, 2013, NEURON, V79, P361, DOI 10.1016/j.neuron.2013.05.038
   Smith KS, 2012, P NATL ACAD SCI USA, V109, P18932, DOI 10.1073/pnas.1216264109
   Smith RJ, 2018, PROG NEURO-PSYCHOPH, V87, P11, DOI 10.1016/j.pnpbp.2017.09.003
   Stuber GD, 2016, NAT NEUROSCI, V19, P198, DOI 10.1038/nn.4220
   Szumlinski KK, 2006, NEUROPSYCHOPHARMACOL, V31, P768, DOI 10.1038/sj.npp.1300890
   Terraneo A, 2016, EUR NEUROPSYCHOPHARM, V26, P37, DOI 10.1016/j.euroneuro.2015.11.011
   Terrier J, 2016, NEUROPSYCHOPHARMACOL, V41, P1779, DOI 10.1038/npp.2015.345
   Ting AKR, 2012, COLD SPRING HARB PER
   Tornatzky W, 2000, PSYCHOPHARMACOLOGY, V148, P289, DOI 10.1007/s002130050053
   Torres OV, 2017, BEHAV BRAIN RES, V326, P265, DOI 10.1016/j.bbr.2017.03.009
   Trifilieff P, 2017, SEMIN NUCL MED, V47, P64, DOI 10.1053/j.semnuclmed.2016.09.003
   Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077
   Urcelay GP, 2019, J EXP PSYCHOL-ANIM L, V45, P413, DOI 10.1037/xan0000221
   Vanderschuren LJMJ, 2005, J NEUROSCI, V25, P8665, DOI 10.1523/JNEUROSCI.0925-05.2005
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Vengeliene V, 2009, ADDICT BIOL, V14, P384, DOI 10.1111/j.1369-1600.2009.00177.x
   Venniro M, 2016, PROG BRAIN RES, V224, P25, DOI 10.1016/bs.pbr.2015.08.004
   Volkow ND, 2014, MOL PSYCHIATR, V19, P1037, DOI 10.1038/mp.2014.58
   Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI 10.1093/cercor/10.3.318
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
   Vollstadt-Klein S, 2010, ADDICTION, V105, P1741, DOI 10.1111/j.1360-0443.2010.03022.x
   Voon V, 2015, MOL PSYCHIATR, V20, P345, DOI 10.1038/mp.2014.44
   Wall NR, 2019, NEURON, V104, P916, DOI 10.1016/j.neuron.2019.10.032
   WEEKS JR, 1962, SCIENCE, V138, P143, DOI 10.1126/science.138.3537.143
   WEISS F, 1992, BRAIN RES, V593, P314, DOI 10.1016/0006-8993(92)91327-B
   Whitelaw RB, 1996, PSYCHOPHARMACOLOGY, V127, P213, DOI 10.1007/BF02805996
   Willuhn I, 2012, P NATL ACAD SCI USA, V109, P20703, DOI 10.1073/pnas.1213460109
   Wise RA, 2006, PHILOS T R SOC B, V361, P1149, DOI 10.1098/rstb.2006.1854
   Wolf ME, 2016, NAT REV NEUROSCI, V17, P351, DOI 10.1038/nrn.2016.39
   WOLFFGRAMM J, 1991, NEUROSCI BIOBEHAV R, V15, P515, DOI 10.1016/S0149-7634(05)80142-3
   Wong DF, 2006, NEUROPSYCHOPHARMACOL, V31, P2716, DOI 10.1038/sj.npp.1301194
   Wood W, 2016, ANNU REV PSYCHOL, V67, P289, DOI 10.1146/annurev-psych-122414-033417
   Wouterlood FG, 2018, J NEUROSCI RES, V96, P1518, DOI 10.1002/jnr.24242
   Yang HB, 2018, NEURON, V97, P434, DOI 10.1016/j.neuron.2017.12.022
   Yin HH, 2005, EUR J NEUROSCI, V22, P513, DOI 10.1111/j.1460-9568.2005.04218.x
   Yin HH, 2004, EUR J NEUROSCI, V19, P181, DOI 10.1111/j.1460-9568.2004.03095.x
   Zapata A, 2017, NEUROPSYCHOPHARMACOL, V42, P1103, DOI 10.1038/npp.2016.286
   Zapata A, 2010, J NEUROSCI, V30, P15457, DOI 10.1523/JNEUROSCI.4072-10.2010
   Zhou XQ, 2019, BIOL PSYCHIAT-COGN N, V4, P751, DOI 10.1016/j.bpsc.2019.04.006
   Zhu YJ, 2016, NATURE, V530, P219, DOI 10.1038/nature16954
   [No title captured]
NR 188
TC 147
Z9 149
U1 29
U2 149
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1471-003X
EI 1471-0048
J9 NAT REV NEUROSCI
JI Nat. Rev. Neurosci.
PD MAY
PY 2020
VL 21
IS 5
BP 247
EP 263
DI 10.1038/s41583-020-0289-z
EA MAR 2020
PG 17
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology
GA QF6BA
UT WOS:000522381000001
PM 32231315
OA Green Accepted
HC Y
HP N
DA 2023-06-23
ER

PT J
AU Weinstein, A
   Lejoyeux, M
AF Weinstein, Aviv
   Lejoyeux, Michel
TI New Developments on the Neurobiological and Pharmaco-Genetic Mechanisms
   Underlying Internet and Videogame Addiction
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Article
ID STRIATAL DOPAMINE RELEASE; BRAIN ACTIVITY; PREFRONTAL CORTEX;
   DRUG-ABUSE; RECEPTOR AVAILABILITY; REGIONAL HOMOGENEITY; LIMBIC
   ACTIVATION; GAMING ADDICTION; GAME ADDICTION; SMOKING CUES
AB BackgroundThere is emerging evidence that the psychobiological mechanisms underlying behavioral addictions such as internet and videogame addiction resemble those of addiction for substances of abuse.
   ObjectivesReview of brain imaging, treatment and genetic studies on videogame and internet addiction.
   MethodsLiterature search of published articles between 2009 and 2013 in Pubmed using internet addiction and videogame addiction as the search word. Twenty-nine studies have been selected and evaluated under the criteria of brain imaging, treatment, and genetics.
   ResultsBrain imaging studies of the resting state have shown that long-term internet game playing affected brain regions responsible for reward, impulse control and sensory-motor coordination. Brain activation studies have shown that videogame playing involved changes in reward and loss of control and that gaming pictures have activated regions similarly to those activated by cue-exposure to drugs. Structural studies have shown alterations in the volume of the ventral striatum possible as result of changes in reward. Furthermore, videogame playing was associated with dopamine release similar in magnitude to those of drugs of abuse and that there were faulty inhibitory control and reward mechanisms videogame addicted individuals. Finally, treatment studies using fMRI have shown reduction in craving for videogames and reduced associated brain activity.
   Conclusions and Scientific SignificanceVideogame playing may be supported by similar neural mechanisms underlying drug abuse. Similar to drug and alcohol abuse, internet addiction results in sub-sensitivity of dopamine reward mechanisms. Given the fact that this research is in its early stage it is premature to conclude that internet addiction is equivalent to substance addictions. (Am J Addict 2015;24:117-125)
C1 [Weinstein, Aviv] Med Ctr Nucl Med, Tel Aviv Sourasky, Israel.
   [Lejoyeux, Michel] Hop Xavier Bichat, AP HP, Dept Psychiat & Addict Med, Paris, France.
   [Lejoyeux, Michel] Maison Blanche Hosp, Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Paul-Brousse - APHP; UDICE-French Research Universities; Sorbonne
   Universite; Hopital Universitaire Saint-Antoine - APHP; Universite Paris
   Cite; Hopital Universitaire Bichat-Claude Bernard - APHP; Hopital
   Universitaire Hotel-Dieu - APHP; Hopital Universitaire Saint-Louis -
   APHP; UDICE-French Research Universities; Universite Paris Cite; GHU
   PARIS Psychiatrie Neurosciences
RP Weinstein, A (通讯作者)，Med Ctr Nucl Med, Tel Aviv Sourasky, Israel.
EM avivweinstein@yahoo.com
RI Weinstein, Aviv/I-9941-2017
OI Weinstein, Aviv/0000-0002-9465-9943
FU National Institute for Psychobiology in Israel; Israeli anti-drug
   authority
FX Dr. Weinstein is supported by grants from the National Institute for
   Psychobiology in Israel and the Israeli anti-drug authority.
CR American Psychiatric Association, 2013, DIAGN STAT MAN MENYT
   BECK AT, 1978, DEPRESSION INVENTORY
   Bernardi S, 2009, COMPR PSYCHIAT, V50, P510, DOI 10.1016/j.comppsych.2008.11.011
   Birmaher B, 1997, J AM ACAD CHILD PSY, V36, P545, DOI 10.1097/00004583-199704000-00018
   Blum Kenneth, 2008, Neuropsychiatr Dis Treat, V4, P893
   Boileau I, 2003, SYNAPSE, V49, P226, DOI 10.1002/syn.10226
   Breiter HC, 1997, NEURON, V19, P591, DOI 10.1016/S0896-6273(00)80374-8
   Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11
   Crews FT, 2009, PHARMACOL BIOCHEM BE, V93, P237, DOI 10.1016/j.pbb.2009.04.018
   Dagher A, 2009, NEURON, V61, P502, DOI 10.1016/j.neuron.2009.01.031
   Daglish MRC, 2001, AM J PSYCHIAT, V158, P1680, DOI 10.1176/appi.ajp.158.10.1680
   David SP, 2005, BIOL PSYCHIAT, V58, P488, DOI 10.1016/j.biopsych.2005.04.028
   De Berardis D, 2009, CYBERPSYCHOL BEHAV, V12, P67, DOI 10.1089/cpb.2008.0108
   Dong GH, 2012, BEHAV BRAIN FUNCT, V8, DOI 10.1186/1744-9081-8-41
   Dong GH, 2012, PSYCHIAT RES-NEUROIM, V203, P153, DOI 10.1016/j.pscychresns.2012.02.001
   Dong GH, 2011, J PSYCHIATR RES, V45, P1525, DOI 10.1016/j.jpsychires.2011.06.017
   Dong GH, 2011, NEUROSCI LETT, V499, P114, DOI 10.1016/j.neulet.2011.05.047
   Dong GH, 2010, NEUROSCI LETT, V485, P138, DOI 10.1016/j.neulet.2010.09.002
   Due DL, 2002, AM J PSYCHIAT, V159, P954, DOI 10.1176/appi.ajp.159.6.954
   Durkee T, 2012, ADDICTION, V107, P2210, DOI 10.1111/j.1360-0443.2012.03946.x
   Elkashef AM, 2008, NEUROPSYCHOPHARMACOL, V33, P1162, DOI 10.1038/sj.npp.1301481
   Franklin TR, 2007, NEUROPSYCHOPHARMACOL, V32, P2301, DOI 10.1038/sj.npp.1301371
   George MS, 2001, ARCH GEN PSYCHIAT, V58, P345, DOI 10.1001/archpsyc.58.4.345
   Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040
   Han DH, 2007, J ADDICT MED, V1, P133, DOI 10.1097/ADM.0b013e31811f465f
   Han DH, 2012, J PSYCHOPHARMACOL, V26, P689, DOI 10.1177/0269881111400647
   Han DH, 2012, J PSYCHIATR RES, V46, P507, DOI 10.1016/j.jpsychires.2012.01.004
   Han DH, 2010, CYBERPSYCH BEH SOC N, V13, P655, DOI 10.1089/cyber.2009.0327
   Han DH, 2010, EXP CLIN PSYCHOPHARM, V18, P297, DOI 10.1037/a0020023
   Han DH, 2011, COMPR PSYCHIAT, V52, P88, DOI 10.1016/j.comppsych.2010.04.004
   Hoeft F, 2008, J PSYCHIATR RES, V42, P253, DOI 10.1016/j.jpsychires.2007.11.010
   Hong SB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057831
   Hou HF, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/854524
   Hurt RD, 1997, NEW ENGL J MED, V337, P1195, DOI 10.1056/NEJM199710233371703
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Kim SH, 2011, NEUROREPORT, V22, P407, DOI 10.1097/WNR.0b013e328346e16e
   King DL, 2011, CLIN PSYCHOL REV, V31, P1110, DOI 10.1016/j.cpr.2011.06.009
   Ko CH, 2013, J PSYCHIATR RES, V47, P486, DOI 10.1016/j.jpsychires.2012.11.008
   Ko CH, 2013, ADDICT BIOL, V18, P559, DOI 10.1111/j.1369-1600.2011.00405.x
   Ko CH, 2009, J PSYCHIATR RES, V43, P739, DOI 10.1016/j.jpsychires.2008.09.012
   Koepp MJ, 1998, NATURE, V393, P266, DOI 10.1038/30498
   Kratzer S, 2008, PSYCHIAT PRAX, V35, P80, DOI 10.1055/s-2007-970888
   Kreek MJ, 2005, NAT NEUROSCI, V8, P1450, DOI 10.1038/nn1583
   Kuhn S, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.53
   Kuss DJ, 2012, BRAIN SCI, V2, P347, DOI 10.3390/brainsci2030347
   Lee YS, 2008, J AFFECT DISORDERS, V109, P165, DOI 10.1016/j.jad.2007.10.020
   Lin FC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030253
   Linnet J, 2010, ACTA PSYCHIAT SCAND, V122, P326, DOI 10.1111/j.1600-0447.2010.01591.x
   Liu J, 2010, CHINESE MED J-PEKING, V123, P1904, DOI 10.3760/cma.j.issn.0366-6999.2010.14.014
   London ED, 2000, CEREB CORTEX, V10, P334, DOI 10.1093/cercor/10.3.334
   Maas LC, 1998, AM J PSYCHIAT, V155, P124, DOI 10.1176/ajp.155.1.124
   Montag C, 2012, J ADDICT MED, V6, P191, DOI 10.1097/ADM.0b013e31825ba7e7
   Morrison CM, 2010, PSYCHOPATHOLOGY, V43, P121, DOI 10.1159/000277001
   Myrick H, 2004, NEUROPSYCHOPHARMACOL, V29, P393, DOI 10.1038/sj.npp.1300295
   Park HS, 2010, CNS SPECTRUMS, V15, P159, DOI 10.1017/S1092852900027437
   Pawlikowski M, 2011, PSYCHIAT RES, V188, P428, DOI 10.1016/j.psychres.2011.05.017
   Steeves TDL, 2009, BRAIN, V132, P1376, DOI 10.1093/brain/awp054
   Sun YJ, 2012, BEHAV BRAIN RES, V233, P563, DOI 10.1016/j.bbr.2012.05.005
   van Holst RJ, 2012, DRUG ALCOHOL DEPEN, V124, P142, DOI 10.1016/j.drugalcdep.2011.12.025
   Volkow ND, 2004, MOL PSYCHIATR, V9, P557, DOI 10.1038/sj.mp.4001507
   Volkow ND, 1996, ALCOHOL CLIN EXP RES, V20, P1594, DOI 10.1111/j.1530-0277.1996.tb05936.x
   VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210
   Volkow ND, 2001, AM J PSYCHIAT, V158, P2015, DOI 10.1176/appi.ajp.158.12.2015
   Wang GJ, 2011, OBESITY, V19, P1601, DOI 10.1038/oby.2011.27
   Wang GJ, 1999, LIFE SCI, V64, P775, DOI 10.1016/S0024-3205(98)00619-5
   Wang GJ, 1997, NEUROPSYCHOPHARMACOL, V16, P174, DOI 10.1016/S0893-133X(96)00184-4
   Weinstein A, 2010, J PSYCHOPHARMACOL, V24, P829, DOI 10.1177/0269881109105456
   Weinstein A, 2012, CURR PSYCHIAT REP, V14, P590, DOI 10.1007/s11920-012-0311-x
   Weinstein A, 2010, AM J DRUG ALCOHOL AB, V36, P277, DOI 10.3109/00952990.2010.491880
   Wildt BTT, 2007, PSYCHIAT PRAX, V34, pS318, DOI 10.1055/s-2007-970973
   Winkler A, 2013, CLIN PSYCHOL REV, V33, P317, DOI 10.1016/j.cpr.2012.12.005
   Yen JY, 2011, PSYCHIAT RES, V190, P282, DOI 10.1016/j.psychres.2011.07.003
   Yuan Kai, 2011, Commun Integr Biol, V4, P637
   Yuan K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020708
   Zald DH, 2004, J NEUROSCI, V24, P4105, DOI 10.1523/JNEUROSCI.4643-03.2004
   Zhou Y, 2011, EUR J RADIOL, V79, P92, DOI 10.1016/j.ejrad.2009.10.025
NR 78
TC 67
Z9 71
U1 2
U2 57
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
EI 1521-0391
J9 AM J ADDICTION
JI Am. J. Addict.
PD MAR
PY 2015
VL 24
IS 2
BP 117
EP 125
DI 10.1111/ajad.12110
PG 9
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA CF8KI
UT WOS:000352807600004
PM 25864599
DA 2023-06-23
ER

PT J
AU Belin, D
   Mar, AC
   Dalley, JW
   Robbins, TW
   Everitt, BJ
AF Belin, David
   Mar, Adam C.
   Dalley, Jeffrey W.
   Robbins, Trevor W.
   Everitt, Barry J.
TI High impulsivity predicts the switch to compulsive cocaine-taking
SO SCIENCE
LA English
DT Article
ID SUBSTANCE USE DISORDERS; DRUG-ADDICTION; PERSONALITY; BEHAVIOR;
   REINFORCEMENT; VULNERABILITY; AMPHETAMINE; STRIATUM; STIMULI; SEEKING
AB Both impulsivity and novelty- seeking have been suggested to be behavioral markers of the propensity to take addictive drugs. However, their relevance for the vulnerability to compulsively seek and take drugs, which is a hallmark feature of addiction, is unknown. We report here that, whereas high reactivity to novelty predicts the propensity to initiate cocaine self- administration, high impulsivity predicts the development of addiction- like behavior in rats, including persistent or compulsive drug- taking in the face of aversive outcomes. This study shows experimental evidence that a shift from impulsivity to compulsivity occurs during the development of addictive behavior, which provides insights into the genesis and neural mechanisms of drug addiction.
C1 [Belin, David; Mar, Adam C.; Dalley, Jeffrey W.; Robbins, Trevor W.; Everitt, Barry J.] Univ Cambridge, Behav & Clin Neurosci Inst, Cambridge CB2 3EB, England.
   [Belin, David; Mar, Adam C.; Dalley, Jeffrey W.; Robbins, Trevor W.; Everitt, Barry J.] Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England.
   [Dalley, Jeffrey W.] Univ Cambridge, Addenbrookes Hosp, Dept Psychiat, Cambridge CB2 2QQ, England.
C3 University of Cambridge; University of Cambridge; Cambridge University
   Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of
   Cambridge
RP Belin, D (通讯作者)，Univ Cambridge, Behav & Clin Neurosci Inst, Downing St, Cambridge CB2 3EB, England.
EM bdb26@cam.ac.uk; bje10@cam.ac.uk
RI Robbins, Trevor W/A-7551-2008; Belin, David/E-1231-2014; Mar, Adam
   C/A-3455-2013
OI Belin, David/0000-0002-7383-372X; Robbins, Trevor/0000-0003-0642-5977;
   Everitt, Barry/0000-0003-4431-6536; Mar, Adam/0000-0002-2095-2936;
   Dalley, Jeffrey/0000-0002-2282-3660
FU Medical Research Council [G0600196, G0600196(77608), G0001354] Funding
   Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0600196]
   Funding Source: UKRI; Medical Research Council [G0001354, G0600196,
   G0001354B] Funding Source: researchfish
CR American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th
   Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244
   Dalley JW, 2007, SCIENCE, V315, P1267, DOI 10.1126/science.1137073
   Dawe S, 2004, NEUROSCI BIOBEHAV R, V28, P343, DOI 10.1016/j.neubiorev.2004.03.007
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Dom G, 2006, ADDICTION, V101, P50, DOI 10.1111/j.1360-0443.2005.01270.x
   Evenden J, 1999, PSYCHOPHARMACOLOGY, V143, P111, DOI 10.1007/s002130050926
   Evenden JL, 1999, PSYCHOPHARMACOLOGY, V146, P348, DOI 10.1007/PL00005481
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Haber SN, 2000, J NEUROSCI, V20, P2369
   Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Kreek MJ, 2005, NAT NEUROSCI, V8, P1450, DOI 10.1038/nn1583
   Nader MA, 2006, NAT NEUROSCI, V9, P1050, DOI 10.1038/nn1737
   Nigg JT, 2006, J AM ACAD CHILD PSY, V45, P468, DOI 10.1097/01.chi.0000199028.76452.a9
   Perry JL, 2005, PSYCHOPHARMACOLOGY, V178, P193, DOI 10.1007/s00213-004-1994-4
   PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295
   Poulos CX, 1995, BEHAV PHARMACOL, V6, P810
   Rikoon SH, 2006, J SUBST ABUSE TREAT, V31, P17, DOI 10.1016/j.jsat.2006.03.003
   Sher KJ, 2000, J CONSULT CLIN PSYCH, V68, P818, DOI 10.1037/0022-006X.68.5.818
   Vanderschuren LJMJ, 2005, J NEUROSCI, V25, P8665, DOI 10.1523/JNEUROSCI.0925-05.2005
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210
   White TL, 2006, NEUROPSYCHOPHARMACOL, V31, P1064, DOI 10.1038/sj.npp.1300939
   Wills T A, 1994, J Subst Abuse, V6, P1, DOI 10.1016/S0899-3289(94)90039-6
   Zilberman ML, 2007, J ADDICT DIS, V26, P79, DOI 10.1300/J069v26n01_10
NR 26
TC 705
Z9 720
U1 0
U2 91
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD JUN 6
PY 2008
VL 320
IS 5881
BP 1352
EP 1355
DI 10.1126/science.1158136
PG 4
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 309DO
UT WOS:000256441100048
PM 18535246
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Yao, YW
   Liu, L
   Worhunsky, PD
   Lichenstein, S
   Ma, SS
   Zhu, L
   Shi, XH
   Yang, SS
   Zhang, JT
   Yip, SW
AF Yao, Yuan-Wei
   Liu, Lu
   Worhunsky, Patrick D.
   Lichenstein, Sarah
   Ma, Shan-Shan
   Zhu, Lei
   Shi, Xin-Hui
   Yang, Songshan
   Zhang, Jin-Tao
   Yip, Sarah W.
TI Is monetary reward processing altered in drug-naive youth with a
   behavioral addiction? Findings from internet gaming disorder
SO NEUROIMAGE-CLINICAL
LA English
DT Article
DE Behavioral addiction; Reward processing; Loss aversion; Monetary
   incentive delay task; Internet gaming disorder
ID IMPAIRED DECISION-MAKING; RISKY DECISION; BRAIN; INDIVIDUALS;
   METAANALYSIS; RESPONSES; FMRI
AB Current models of addiction biology highlight altered neural responses to non-drug rewards as a central feature of addiction. However, given that drugs of abuse can directly impact reward-related dopamine circuitry, it is difficult to determine the extent to which reward processing alterations are a trait feature of individuals with addictions, or primarily a consequence of exogenous drug exposure. Examining individuals with behavioral addictions is one promising approach for disentangling neural features of addiction from the direct effects of substance exposure. The current fMRI study compared neural responses during monetary reward processing between drug naive young adults with a behavioral addiction, internet gaming disorder (IGD; n = 22), and healthy controls (n = 27) using a monetary incentive delay task. Relative to controls, individuals with IGD exhibited blunted caudate activity associated with loss magnitude at the outcome stage, but did not differ from controls in neural activity at other stages. These findings suggest that decreased loss sensitivity might be a critical feature of IGD, whereas alterations in gain processing may be less characteristic of individuals with IGD, relative to those with substance use disorders. Therefore, classic theories of altered reward processing in substance use disorders should be translated to behavioral addictions with caution.
C1 [Yao, Yuan-Wei; Ma, Shan-Shan; Zhu, Lei; Shi, Xin-Hui; Zhang, Jin-Tao] Beijing Normal Univ, State Key Lab Cognit Neurosci & Learning, Xinjiekouwai St 19, Beijing 100875, Peoples R China.
   [Yao, Yuan-Wei; Ma, Shan-Shan; Zhu, Lei; Shi, Xin-Hui; Zhang, Jin-Tao] Beijing Normal Univ, IDG McGovern Inst Brain Res, Xinjiekouwai St 19, Beijing 100875, Peoples R China.
   [Yao, Yuan-Wei] Free Univ Berlin, Dept Educ & Psychol, D-14195 Berlin, Germany.
   [Yao, Yuan-Wei] Charite Univ Med Berlin, Einstein Ctr Neurosci Berlin, D-10117 Berlin, Germany.
   [Yao, Yuan-Wei] Humboldt Univ, Berlin Sch Mind & Brain, D-10117 Berlin, Germany.
   [Liu, Lu] German Inst Human Nutr Potsdam Rehbrucke, D-14558 Nuthetal, Germany.
   [Worhunsky, Patrick D.; Yip, Sarah W.] Yale Sch Med, Dept Psychiat, New Haven, CT 06519 USA.
   [Lichenstein, Sarah] Yale Sch Med, Radiol & Biomed Engn, New Haven, CT 06519 USA.
   [Ma, Shan-Shan] Beijing Normal Univ, Inst Dev Psychol, Beijing 100875, Peoples R China.
   [Yang, Songshan] Penn State Univ, Dept Stat, University Pk, PA 16802 USA.
   [Yip, Sarah W.] Yale Sch Med, Child Study Ctr, New Haven, CT 06519 USA.
C3 Beijing Normal University; Beijing Normal University; Free University of
   Berlin; Free University of Berlin; Humboldt University of Berlin;
   Charite Universitatsmedizin Berlin; Humboldt University of Berlin;
   Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE);
   Yale University; Yale University; Beijing Normal University;
   Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Pennsylvania State University -
   University Park; Yale University
RP Zhang, JT (通讯作者)，Beijing Normal Univ, State Key Lab Cognit Neurosci & Learning, Xinjiekouwai St 19, Beijing 100875, Peoples R China.; Zhang, JT (通讯作者)，Beijing Normal Univ, IDG McGovern Inst Brain Res, Xinjiekouwai St 19, Beijing 100875, Peoples R China.
EM zhangjintao@bnu.edu.cn
RI Yao, Yuan-Wei/J-7368-2019
OI Yao, Yuan-Wei/0000-0002-9635-7826; Zhang, Jin-Tao/0000-0002-4807-1196;
   Worhunsky, Patrick/0000-0001-9629-1428
FU National Natural Science Foundation of China [31871122]; Einstein Center
   for Neurosciences Berlin; NIDA [K01DA039299, K12DA000167]; National
   Center on Addiction and Substance Abuse (CASA); State Key Laboratory of
   Cognitive Neuroscience and Learning of Beijing Normal University
FX This study was supported by the National Natural Science Foundation of
   China (No. 31871122). YWY's involvement was supported by the PhD
   Fellowship from the Einstein Center for Neurosciences Berlin. SWY's
   involvement was supported by NIDA grants (K01DA039299 and K12DA000167),
   the National Center on Addiction and Substance Abuse (CASA) and an Open
   Project grant from the State Key Laboratory of Cognitive Neuroscience
   and Learning of Beijing Normal University. The funders had no role in
   the study design, collection and analysis of the data, or preparation of
   the manuscript.
CR Alexander WH, 2015, NEUROIMAGE-CLIN, V8, P59, DOI 10.1016/j.nicl.2015.02.025
   American Psychiatric Association [APA], 2022, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425787]
   Andrews MM, 2011, BIOL PSYCHIAT, V69, P675, DOI 10.1016/j.biopsych.2010.09.049
   [Anonymous], NEUROSC BIOBEHAV REV
   Balodis IM, 2015, BIOL PSYCHIAT, V77, P434, DOI 10.1016/j.biopsych.2014.08.020
   Balodis IM, 2013, BIOL PSYCHIAT, V73, P877, DOI 10.1016/j.biopsych.2013.01.014
   Balodis IM, 2012, BIOL PSYCHIAT, V71, P749, DOI 10.1016/j.biopsych.2012.01.006
   Bartra O, 2013, NEUROIMAGE, V76, P412, DOI 10.1016/j.neuroimage.2013.02.063
   Blum K, 2000, J PSYCHOACTIVE DRUGS, V32
   Clark L, 2019, MOL PSYCHIATR, V24, P674, DOI 10.1038/s41380-018-0230-2
   Clithero JA, 2014, SOC COGN AFFECT NEUR, V9, P1289, DOI 10.1093/scan/nst106
   Cohen MX, 2009, J NEUROSCI, V29, P7591, DOI 10.1523/JNEUROSCI.5335-08.2009
   Dong GH, 2013, PROG NEURO-PSYCHOPH, V46, P139, DOI 10.1016/j.pnpbp.2013.07.007
   Dong GH, 2011, J PSYCHIATR RES, V45, P1525, DOI 10.1016/j.jpsychires.2011.06.017
   Ersche KD, 2016, SCIENCE, V352, P1468, DOI 10.1126/science.aaf3700
   Fauth-Buhler M, 2017, ADDICT BEHAV, V64, P349, DOI 10.1016/j.addbeh.2015.11.004
   Hommer DW, 2011, ANN NY ACAD SCI, V1216, P50, DOI 10.1111/j.1749-6632.2010.05898.x
   Keiflin R, 2015, NEURON, V88, P247, DOI 10.1016/j.neuron.2015.08.037
   Kim JE, 2014, PSYCHIAT CLIN NEUROS, V68, P463, DOI 10.1111/pcn.12154
   Knutson B, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-16-j0002.2001
   Ko CH, 2017, EUR PSYCHIAT, V44, P189, DOI 10.1016/j.eurpsy.2017.05.020
   Ko CH, 2014, J PSYCHIATR RES, V53, P103, DOI 10.1016/j.jpsychires.2014.02.008
   Ko CH, 2013, ADDICT BIOL, V18, P559, DOI 10.1111/j.1369-1600.2011.00405.x
   Liu L, 2017, NEUROIMAGE-CLIN, V14, P741, DOI 10.1016/j.nicl.2017.03.010
   Liu L, 2017, ADDICT BIOL, V22, P791, DOI 10.1111/adb.12338
   Luijten M, 2017, JAMA PSYCHIAT, V74, P387, DOI 10.1001/jamapsychiatry.2016.3084
   Nutt DJ, 2015, NAT REV NEUROSCI, V16, P305, DOI 10.1038/nrn3939
   Qi X, 2016, NEUROIMAGE-CLIN, V12, P845, DOI 10.1016/j.nicl.2016.10.024
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Seok JW, 2015, AUST NZ J PSYCHIAT, V49, P923, DOI 10.1177/0004867415598009
   Sescousse G, 2013, NEUROSCI BIOBEHAV R, V37, P681, DOI 10.1016/j.neubiorev.2013.02.002
   Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi
   Volkow ND, 2015, CELL, V162, P712, DOI 10.1016/j.cell.2015.07.046
   Wagenmakers EJ, 2018, PSYCHON B REV, V25, P35, DOI 10.3758/s13423-017-1343-3
   Wang YF, 2017, ADDICT BIOL, V22, P1610, DOI 10.1111/adb.12458
   Wei L, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00285
   Weinstein A, 2017, NEUROSCI BIOBEHAV R, V75, P314, DOI 10.1016/j.neubiorev.2017.01.040
   Wilson SJ, 2008, J ABNORM PSYCHOL, V117, P428, DOI 10.1037/0021-843X.117.2.428
   Yan CG, 2016, NEUROINFORMATICS, V14, P339, DOI 10.1007/s12021-016-9299-4
   Yao YW, 2017, NEUROSCI BIOBEHAV R, V83, P313, DOI 10.1016/j.neubiorev.2017.10.029
   Yao YW, 2015, PSYCHIAT RES, V229, P302, DOI 10.1016/j.psychres.2015.07.004
   Yip SW, 2018, NEUROPSYCHOPHARMACOL, V43, P1364, DOI 10.1038/npp.2017.283
   Yip SW, 2016, DRUG ALCOHOL DEPEN, V166, P134, DOI 10.1016/j.drugalcdep.2016.07.006
   Young K, 2009, J CONTEMP PSYCHOTHER, V39, P241, DOI 10.1007/s10879-009-9120-x
NR 44
TC 12
Z9 12
U1 3
U2 21
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-1582
J9 NEUROIMAGE-CLIN
JI NeuroImage-Clin.
PY 2020
VL 26
AR 102202
DI 10.1016/j.nicl.2020.102202
PG 7
WC Neuroimaging
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology
GA LN7YO
UT WOS:000533149400020
PM 32045732
OA gold, Green Published
DA 2023-06-23
ER

PT J
AU Pierce, RC
   Vanderschuren, LJMJ
AF Pierce, R. Christopher
   Vanderschuren, Louk J. M. J.
TI Kicking the habit: The neural basis of ingrained behaviors in cocaine
   addiction
SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
LA English
DT Review
DE Cocaine; Habits; Addiction; Striatum; Accumbens; Circuitry
ID MEDIAL PREFRONTAL CORTEX; NUCLEUS-ACCUMBENS CORE; MESOLIMBIC DOPAMINE
   SYSTEM; VENTRAL TEGMENTAL AREA; SEEKING BEHAVIOR; DORSAL STRIATUM;
   DRUG-SEEKING; DORSOLATERAL STRIATUM; BASAL GANGLIA; INDUCED
   REINSTATEMENT
AB Cocaine addiction is a complex and multifaceted process encompassing a number of forms of behavioral plasticity. The process of acquiring and consuming drugs can be sufficiently risky and complicated that the casual drug user may choose not to act on every motivation to use drugs. The repetition of drug seeking and taking, however, often results in the gradual development of drug craving and compulsive drug seeking associated with addiction. Moreover, the complex sets of behaviors associated with drug addiction can become ingrained to such an extent that, when activated by drug-associated stimuli or exposure to the drug itself, the processes underlying drug seeking and taking are automatically engaged and very difficult to suppress. Here, we examine the hypothesis that aspects of cocaine seeking and taking become ingrained with repetition, thereby contributing to continued drug use despite a conscious desire to abstain. We also review emerging evidence indicating that neuronal circuits including the dorsolateral striatum play a particularly important role in the habitual aspects of drug seeking and taking. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Pierce, R. Christopher] Univ Penn, Sch Med, Dept Psychiat, Ctr Neurobiol & Behav, Philadelphia, PA 19104 USA.
   [Vanderschuren, Louk J. M. J.] Univ Med Ctr Utrecht, Dept Neurosci & Pharmacol, Rudolf Magnus Inst Neurosci, NL-3584 CG Utrecht, Netherlands.
C3 University of Pennsylvania; Pennsylvania Medicine; Utrecht University;
   Utrecht University Medical Center
RP Pierce, RC (通讯作者)，Univ Penn, Sch Med, Dept Psychiat, Ctr Neurobiol & Behav, 125 S 31st St, Philadelphia, PA 19104 USA.
EM rcpierce@mail.med.upenn.edu
RI Pierce, Chris/HJO-9791-2023; Vanderschuren, Louk/AAS-4391-2020
OI Vanderschuren, Louk/0000-0002-5379-0363
FU NIDA NIH HHS [R01 DA015214, K02 DA018678, R01 DA022339] Funding Source:
   Medline
CR ADAMS CD, 1982, PSYCHO, V34, P77
   ALEXANDER GE, 1990, PROG BRAIN RES, V85, P119
   American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th
   Anderson SM, 2005, PHARMACOL THERAPEUT, V106, P389, DOI 10.1016/j.pharmthera.2004.12.004
   Arroyo M, 1998, PSYCHOPHARMACOLOGY, V140, P331, DOI 10.1007/s002130050774
   ASHER IM, 1974, BRAIN RES, V82, P1, DOI 10.1016/0006-8993(74)90888-9
   Baker DA, 2003, NAT NEUROSCI, V6, P743, DOI 10.1038/nn1069
   Bari AA, 2005, NEUROSCIENCE, V135, P959, DOI 10.1016/j.neuroscience.2005.06.048
   Belin D, 2008, NEURON, V57, P432, DOI 10.1016/j.neuron.2007.12.019
   Belin D, 2009, BIOL PSYCHIAT, V65, P863, DOI 10.1016/j.biopsych.2008.05.031
   BERENDSE HW, 1992, J COMP NEUROL, V316, P314, DOI 10.1002/cne.903160305
   Beveridge TJR, 2006, EUR J NEUROSCI, V23, P3109, DOI 10.1111/j.1460-9568.2006.04788.x
   Bossert JM, 2009, PSYCHOPHARMACOLOGY, V206, P51, DOI 10.1007/s00213-009-1580-x
   CAINE SB, 1995, BRAIN RES, V692, P47
   Carlezon WA, 1996, J NEUROSCI, V16, P3112
   Chevrette J, 2002, PHARMACOL BIOCHEM BE, V71, P501, DOI 10.1016/S0091-3057(01)00686-4
   Corbit LH, 2007, J NEUROSCI, V27, P13977, DOI 10.1523/JNEUROSCI.4097-07.2007
   Coutureau E, 2003, BEHAV BRAIN RES, V146, P167, DOI 10.1016/j.bbr.2003.09.025
   Cox SML, 2009, BIOL PSYCHIAT, V65, P846, DOI 10.1016/j.biopsych.2009.01.021
   CREESE I, 1975, BRAIN RES, V83, P419, DOI 10.1016/0006-8993(75)90834-3
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Di Ciano P, 2004, NEUROPHARMACOLOGY, V47, P202, DOI 10.1016/j.neuropharm.2004.06.005
   Di Ciano P, 2004, J NEUROSCI, V24, P7167, DOI 10.1523/JNEUROSCI.1581-04.2004
   Di Ciano P, 2001, NEUROPSYCHOPHARMACOL, V25, P341, DOI 10.1016/S0893-133X(01)00235-4
   Di Ciano P, 2008, NEUROPSYCHOPHARMACOL, V33, P1413, DOI 10.1038/sj.npp.1301522
   Dickinson A, 2002, Q J EXP PSYCHOL-B, V55, P331, DOI 10.1080/0272499024400016
   DICKINSON A, 1985, PHILOS T ROY SOC B, V308, P67, DOI 10.1098/rstb.1985.0010
   Eagle DM, 2003, BEHAV NEUROSCI, V117, P1302, DOI 10.1037/0735-7044.117.6.1302
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Everitt BJ, 1999, ANN NY ACAD SCI, V877, P412, DOI 10.1111/j.1749-6632.1999.tb09280.x
   Faure A, 2005, J NEUROSCI, V25, P2771, DOI 10.1523/JNEUROSCI.3894-04.2005
   Fuchs RA, 2006, J NEUROSCI, V26, P3584, DOI 10.1523/JNEUROSCI.5146-05.2006
   Galli G, 2004, DRUG ALCOHOL DEPEN, V73, P51, DOI 10.1016/j.drugalcdep.2003.09.003
   Garavan H, 2000, AM J PSYCHIAT, V157, P1789, DOI 10.1176/appi.ajp.157.11.1789
   Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134
   Grusser SM, 2004, PSYCHOPHARMACOLOGY, V175, P296, DOI 10.1007/s00213-004-1828-4
   Haber SN, 2000, J NEUROSCI, V20, P2369
   Haber SN, 2003, J CHEM NEUROANAT, V26, P317, DOI 10.1016/j.jchemneu.2003.10.003
   Heidbreder CA, 2003, NEUROSCI BIOBEHAV R, V27, P555, DOI 10.1016/j.neubiorev.2003.09.003
   Heimer L, 1997, J NEUROPSYCH CLIN N, V9, P354
   HEIMER L, 1991, NEUROSCIENCE, V41, P89, DOI 10.1016/0306-4522(91)90202-Y
   Iaria G, 2003, J NEUROSCI, V23, P5945
   Ikemoto S, 2003, J NEUROSCI, V23, P9305
   Ito R, 2004, NAT NEUROSCI, V7, P389, DOI 10.1038/nn1217
   Ito R, 2002, J NEUROSCI, V22, P6247
   Ito R, 2000, J NEUROSCI, V20, P7489
   Kalivas PW, 1998, J NEUROCHEM, V70, P1497
   Kalivas PW, 2005, NEURON, V45, P647, DOI 10.1016/j.neuron.2005.02.005
   Kantak KM, 2002, PSYCHOPHARMACOLOGY, V161, P278, DOI 10.1007/s00213-002-1036-z
   Kawagoe R, 1998, NAT NEUROSCI, V1, P411, DOI 10.1038/1625
   KELLY PH, 1975, BRAIN RES, V94, P507, DOI 10.1016/0006-8993(75)90233-4
   Killcross S, 2003, CEREB CORTEX, V13, P400, DOI 10.1093/cercor/13.4.400
   Kimchi EY, 2009, J NEUROSCI, V29, P3148, DOI 10.1523/JNEUROSCI.5206-08.2009
   KOLTA MG, 1985, NEUROPHARMACOLOGY, V24, P823, DOI 10.1016/0028-3908(85)90032-2
   Letchworth SR, 2001, J NEUROSCI, V21, P2799, DOI 10.1523/JNEUROSCI.21-08-02799.2001
   Lu L, 2004, NEUROPHARMACOLOGY, V47, P214, DOI 10.1016/j.neuropharm.2004.06.027
   Luo S, 2009, J NEUROSCI, V29, P14820, DOI 10.1523/JNEUROSCI.4261-09.2009
   Martinez D, 2004, NEUROPSYCHOPHARMACOL, V29, P1190, DOI 10.1038/sj.npp.1300420
   McClernon FJ, 2009, PSYCHOPHARMACOLOGY, V204, P25, DOI 10.1007/s00213-008-1436-9
   McFarland K, 2003, J NEUROSCI, V23, P3531
   MCGEORGE AJ, 1989, NEUROSCIENCE, V29, P503, DOI 10.1016/0306-4522(89)90128-0
   MCGREGOR A, 1995, BEHAV BRAIN RES, V67, P75, DOI 10.1016/0166-4328(94)00106-P
   Miles FJ, 2003, BEHAV NEUROSCI, V117, P927, DOI 10.1037/0735-7044.117.5.927
   Moore RJ, 1998, SYNAPSE, V30, P88, DOI 10.1002/(SICI)1098-2396(199809)30:1<88::AID-SYN11>3.0.CO;2-L
   Nader MA, 2002, NEUROPSYCHOPHARMACOL, V27, P35, DOI 10.1016/S0893-133X(01)00427-4
   Nelson A, 2006, J NEUROSCI, V26, P3805, DOI 10.1523/JNEUROSCI.4305-05.2006
   Nordquist RE, 2007, EUR NEUROPSYCHOPHARM, V17, P532, DOI 10.1016/j.euroneuro.2006.12.005
   Nutt D, 2007, LANCET, V369, P1047, DOI 10.1016/S0140-6736(07)60464-4
   O'Brien C. P., 2001, GOODMAN GILMANS PHAR, P621
   Packard MG, 2002, ANNU REV NEUROSCI, V25, P563, DOI 10.1146/annurev.neuro.25.112701.142937
   Panlilio LV, 2005, NEUROPSYCHOPHARMACOL, V30, P433, DOI 10.1038/sj.npp.1300599
   Park WK, 2002, J NEUROSCI, V22, P2916, DOI 10.1523/JNEUROSCI.22-07-02916.2002
   Parsons LH, 1996, BEHAV BRAIN RES, V73, P225
   PAULSON PE, 1995, SYNAPSE, V19, P56, DOI 10.1002/syn.890190108
   Pelloux Y, 2007, PSYCHOPHARMACOLOGY, V194, P127, DOI 10.1007/s00213-007-0805-0
   Pierce RC, 1997, BRAIN RES REV, V25, P192, DOI 10.1016/S0165-0173(97)00021-0
   Pierce RC, 2006, NEUROSCI BIOBEHAV R, V30, P215, DOI 10.1016/j.neubiorev.2005.04.016
   PIERCE RC, 1996, NEUROSCIENCE, V16, P1550
   Porrino LJ, 2007, PROG NEURO-PSYCHOPH, V31, P1593, DOI 10.1016/j.pnpbp.2007.08.040
   Porrino LJ, 2004, NEUROSCI BIOBEHAV R, V27, P813, DOI 10.1016/j.neubiorev.2003.11.013
   Porrino LJ, 2004, J NEUROSCI, V24, P3554, DOI 10.1523/JNEUROSCI.5578-03.2004
   Porrino LJ, 2002, J NEUROSCI, V22, P7687
   Risinger RC, 2005, NEUROIMAGE, V26, P1097, DOI 10.1016/j.neuroimage.2005.03.030
   RITZ MC, 1988, PROG NEURO-PSYCHOPH, V12, P233, DOI 10.1016/0278-5846(88)90040-1
   Robbins TW, 1999, NATURE, V398, P567, DOI 10.1038/19208
   Robbins TW, 2002, NEUROBIOL LEARN MEM, V78, P625, DOI 10.1006/nlme.2002.4103
   Rodd-Henricks ZA, 2002, J PHARMACOL EXP THER, V303, P1216, DOI 10.1124/jpet.102.038950
   Samaha AN, 2004, J NEUROSCI, V24, P6362, DOI 10.1523/JNEUROSCI.1205-04.2004
   Samaha AN, 2005, TRENDS PHARMACOL SCI, V26, P82, DOI 10.1016/j.tips.2004.12.007
   Schilman EA, 2008, NEUROSCI LETT, V432, P40, DOI 10.1016/j.neulet.2007.12.024
   Schmidt HD, 2005, EUR J PHARMACOL, V526, P65, DOI 10.1016/j.ejphar.2005.09.068
   Schmidt HD, 2006, BEHAV BRAIN RES, V175, P189, DOI 10.1016/j.bbr.2006.08.009
   See RE, 2007, PSYCHOPHARMACOLOGY, V194, P321, DOI 10.1007/s00213-007-0850-8
   Shalev U, 2002, PHARMACOL REV, V54, P1, DOI 10.1124/pr.54.1.1
   Spealman RD, 1999, PHARMACOL BIOCHEM BE, V64, P327, DOI 10.1016/S0091-3057(99)00049-0
   Thomas MJ, 2008, BRIT J PHARMACOL, V154, P327, DOI 10.1038/bjp.2008.77
   TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147
   Tran-Tu-Yen DAS, 2009, EUR J NEUROSCI, V30, P464, DOI 10.1111/j.1460-9568.2009.06834.x
   TRICOMI E, 2009, EUR J NEUROSCI
   Vanderschuren LJMJ, 2005, J NEUROSCI, V25, P8665, DOI 10.1523/JNEUROSCI.0925-05.2005
   Vanderschuren LJMJ, 2000, PSYCHOPHARMACOLOGY, V151, P99, DOI 10.1007/s002130000493
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
   Voorn P, 2004, TRENDS NEUROSCI, V27, P468, DOI 10.1016/j.tins.2004.06.006
   Wang B, 2005, J NEUROSCI, V25, P5389, DOI 10.1523/JNEUROSCI.0955-05.2005
   Wassum KM, 2009, NEUROSCIENCE, V163, P770, DOI 10.1016/j.neuroscience.2009.06.071
   Weiss F, 2001, NEUROPSYCHOPHARMACOL, V25, P361, DOI 10.1016/S0893-133X(01)00238-X
   White NM, 2002, NEUROBIOL LEARN MEM, V77, P125, DOI 10.1006/nlme.2001.4008
   WISE RA, 1995, PSYCHOPHARMACOLOGY, V120, P10, DOI 10.1007/BF02246140
   Wolf ME, 2004, NEUROPHARMACOLOGY, V47, P61, DOI 10.1016/j.neuropharm.2004.07.006
   WOLFFGRAMM J, 1991, NEUROSCI BIOBEHAV R, V15, P515, DOI 10.1016/S0149-7634(05)80142-3
   Wong DF, 2006, NEUROPSYCHOPHARMACOL, V31, P2716, DOI 10.1038/sj.npp.1301194
   Yin HH, 2006, NAT REV NEUROSCI, V7, P464, DOI 10.1038/nrn1919
   Yin HH, 2009, NAT NEUROSCI, V12, P333, DOI 10.1038/nn.2261
   Yin HH, 2006, BEHAV BRAIN RES, V166, P189, DOI 10.1016/j.bbr.2005.07.012
   Yin HH, 2005, EUR J NEUROSCI, V22, P513, DOI 10.1111/j.1460-9568.2005.04218.x
   Yin HH, 2004, EUR J NEUROSCI, V19, P181, DOI 10.1111/j.1460-9568.2004.03095.x
   You ZB, 2007, J NEUROSCI, V27, P10546, DOI 10.1523/JNEUROSCI.2967-07.2007
   ZAHM DS, 1992, NEUROSCIENCE, V50, P751, DOI 10.1016/0306-4522(92)90202-D
   Zahm DS, 2000, NEUROSCI BIOBEHAV R, V24, P85, DOI 10.1016/S0149-7634(99)00065-2
   Zhang XF, 1997, J PHARMACOL EXP THER, V281, P699
NR 121
TC 81
Z9 83
U1 0
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0149-7634
EI 1873-7528
J9 NEUROSCI BIOBEHAV R
JI Neurosci. Biobehav. Rev.
PD NOV
PY 2010
VL 35
IS 2
SI SI
BP 212
EP 219
DI 10.1016/j.neubiorev.2010.01.007
PG 8
WC Behavioral Sciences; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Behavioral Sciences; Neurosciences & Neurology
GA 681UG
UT WOS:000284344900007
PM 20097224
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Bornstein, AM
   Pickard, H
AF Bornstein, Aaron M.
   Pickard, Hanna
TI "Chasing the first high": memory sampling in drug choice
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Review
ID EPISODIC MEMORY; NEURAL MECHANISMS; NATURAL RECOVERY; OPIATE ADDICTION;
   DECISION-MAKING; LEARNING-MODELS; CUE-EXPOSURE; REINFORCEMENT; RELAPSE;
   COCAINE
AB Although vivid memories of drug experiences are prevalent within clinical contexts and addiction folklore ("chasing the first high"), little is known about the relevance of cognitive processes governing memory retrieval to substance use disorder. Drawing on recent work that identifies episodic memory's influence on decisions for reward, we propose a framework in which drug choices are biased by selective sampling of individual memories during two phases of addiction: (i) downward spiral into persistent use and (ii) relapse. Consideration of how memory retrieval influences the addiction process suggests novel treatment strategies. Rather than try to break learned associations between drug cues and drug rewards, treatment should aim to strengthen existing and/or create new associations between drug cues and drug-inconsistent rewards.
C1 [Bornstein, Aaron M.] Univ Calif Irvine, Dept Cognit Sci, Irvine, CA 92617 USA.
   [Bornstein, Aaron M.] Univ Calif Irvine, Ctr Neurobiol Learning & Memory, Irvine, CA 92697 USA.
   [Bornstein, Aaron M.] Univ Calif Irvine, Inst Math Behav Sci, Irvine, CA 92697 USA.
   [Pickard, Hanna] Johns Hopkins Univ, Dept Philosophy, Baltimore, MD 21218 USA.
   [Pickard, Hanna] Johns Hopkins Univ, Berman Inst Bioeth, Baltimore, MD 21205 USA.
C3 University of California System; University of California Irvine;
   University of California System; University of California Irvine;
   University of California System; University of California Irvine; Johns
   Hopkins University; Johns Hopkins University
RP Bornstein, AM (通讯作者)，Univ Calif Irvine, Dept Cognit Sci, Irvine, CA 92617 USA.; Bornstein, AM (通讯作者)，Univ Calif Irvine, Ctr Neurobiol Learning & Memory, Irvine, CA 92697 USA.; Bornstein, AM (通讯作者)，Univ Calif Irvine, Inst Math Behav Sci, Irvine, CA 92697 USA.; Pickard, H (通讯作者)，Johns Hopkins Univ, Dept Philosophy, Baltimore, MD 21218 USA.; Pickard, H (通讯作者)，Johns Hopkins Univ, Berman Inst Bioeth, Baltimore, MD 21205 USA.
EM aaron.bornstein@uci.edu; h.pickard@jhu.edu
OI Pickard, Hanna/0000-0001-5926-1377; Bornstein, Aaron/0000-0001-6251-6000
CR Ahmed SH, 2013, CURR OPIN NEUROBIOL, V23, P581, DOI 10.1016/j.conb.2013.01.028
   Ahmed SH, 2010, NEUROSCI BIOBEHAV R, V35, P172, DOI 10.1016/j.neubiorev.2010.04.005
   Ahmed SH, 2018, NEUROSCI BIOBEHAV R, DOI [10.1016/j.neubiorev.2018.08.015, DOI 10.1016/J.NEUBI0REV.2018.08.015]
   Ainslie G, 2000, LAW PHILOS, V19, P77
   Allen TA, 2013, P NATL ACAD SCI USA, V110, P10379, DOI 10.1073/pnas.1301199110
   Andrews K, 2017, ROUTLEDGE HDB PHILOS
   [Anonymous], 2001, ALC AN LARG PRINT
   Barto A. G., 1995, MODELS INFORM PROCES, P215
   Bickel WK, 2014, ANNU REV CLIN PSYCHO, V10, P641, DOI 10.1146/annurev-clinpsy-032813-153724
   Bickel WK, 2001, ADDICTION, V96, P73, DOI 10.1046/j.1360-0443.2001.961736.x
   Biele G, 2009, J MATH PSYCHOL, V53, P155, DOI 10.1016/j.jmp.2008.05.006
   Bornstein AM, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15958
   Bornstein AM, 2017, NAT NEUROSCI, V20, P997, DOI 10.1038/nn.4573
   Bornstein AM, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003387
   Bornstein AM, 2018, PERCEPTUAL DECISIONS, V10, DOI [10.1101/186817, DOI 10.1101/186817]
   Bossert JM, 2013, PSYCHOPHARMACOLOGY, V229, P453, DOI 10.1007/s00213-013-3120-y
   Bouton ME, 2002, BIOL PSYCHIAT, V52, P976, DOI 10.1016/S0006-3223(02)01546-9
   Buckner RL, 2007, TRENDS COGN SCI, V11, P49, DOI 10.1016/j.tics.2006.11.004
   Buzsaki G, 2018, TRENDS COGN SCI, V22, P853, DOI 10.1016/j.tics.2018.07.006
   Carr VA, 2010, NEURON, V65, P298, DOI 10.1016/j.neuron.2009.12.022
   Chan JCK., 2012, PSYCEXTRA DATASET, DOI [10.1037/e502412013-124, DOI 10.1037/E502412013-124]
   Chan Wan Yee Macy, 2010, Learn Mem, V17, P512, DOI 10.1101/lm.1912510
   Charland Louis C., 2002, American Journal of Bioethics, V2, P37, DOI 10.1162/152651602317533686
   Colin A, 2017, STANFORD ENCY PHILOS
   Conklin CA, 2002, ADDICTION, V97, P155, DOI 10.1046/j.1360-0443.2002.00014.x
   CRICK F, 1983, NATURE, V304, P111, DOI 10.1038/304111a0
   Daw ND, 2006, NATURE, V441, P876, DOI 10.1038/nature04766
   Daw ND, 2011, NEURON, V69, P1204, DOI 10.1016/j.neuron.2011.02.027
   Daw ND, 2005, NAT NEUROSCI, V8, P1704, DOI 10.1038/nn1560
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Duncan KD, 2016, J EXP PSYCHOL GEN, V145, P1420, DOI 10.1037/xge0000231
   Eichenbaum H, 2005, J EXP ANAL BEHAV, V84, P619, DOI 10.1901/jeab.2005.80-04
   Epstein DH, 2009, ARCH GEN PSYCHIAT, V66, P88, DOI 10.1001/archgenpsychiatry.2008.509
   Everitt BJ, 2001, BRAIN RES REV, V36, P129, DOI 10.1016/S0165-0173(01)00088-1
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Fernandez J, 2018, POWER ADDICTION HARM
   Flaherty CF, 1985, ANIMAL LEARNING COGN
   Folkerts S, 2018, J NEUROSCI, V38, P4200, DOI 10.1523/JNEUROSCI.2312-17.2018
   Franken IHA, 2003, COGNITIVE THER RES, V27, P481, DOI 10.1023/A:1025480615623
   Fridrici C, 2014, PSYCHIAT RES, V218, P311, DOI 10.1016/j.psychres.2014.03.041
   Frings D, 2015, ADDICT BEHAV, V44, P35, DOI 10.1016/j.addbeh.2014.10.023
   Gabaix X, 2017, W23254 NAT BUR EC RE, DOI [10.3386/w23254, DOI 10.3386/W23254]
   Gershman SJ, 2017, ANNU REV PSYCHOL, V68, P101, DOI 10.1146/annurev-psych-122414-033625
   Gershman SJ, 2012, NEURAL COMPUT, V24, P1553, DOI 10.1162/NECO_a_00282
   Girardeau P, 2019, NEUROPHARMACOLOGY, V155, P185, DOI 10.1016/j.neuropharm.2019.05.036
   Glascher J, 2010, NEURON, V66, P585, DOI 10.1016/j.neuron.2010.04.016
   Goldfarb EV, 2019, J EXP PSYCHOL GEN, V148, P13, DOI 10.1037/xge0000472
   Goldfarb EV, 2018, TRENDS NEUROSCI, V41, P853, DOI 10.1016/j.tins.2018.08.005
   GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P501, DOI 10.1037/0278-7393.11.3.501
   Hammer RR, 2012, CULT MED PSYCHIAT, V36, P712, DOI 10.1007/s11013-012-9283-x
   Hart CL, 2008, BEHAV BRAIN SCI, V31, P448, DOI 10.1017/S0140525X08004846
   Hart CL, 2000, BEHAV PHARMACOL, V11, P87, DOI 10.1097/00008877-200002000-00010
   Hasin DS, 2013, AM J PSYCHIAT, V170, P834, DOI 10.1176/appi.ajp.2013.12060782
   Hassabis D, 2007, P NATL ACAD SCI USA, V104, P1726, DOI 10.1073/pnas.0610561104
   Hawken A., 2009, MANAGING DRUG INVOLV
   Henson RN, 2010, HIPPOCAMPUS, V20, P1315, DOI 10.1002/hipo.20857
   Heyman Gene M., 2009, ADDICTION DISORDER C, DOI [10.4159/9780674053991, DOI 10.4159/9780674053991]
   Hogarth L, 2018, PSYCHOL HABIT, P325, DOI [10.1007/978-3-319-97529-0_18, DOI 10.1007/978-3-319-97529-0_18]
   Holton R, 2013, ADDICTION SELF CONTR, P239, DOI [10.1093/acprof:oso/9780199862580.003.0012, DOI 10.1093/ACPROF:OSO/9780199862580.003.0012]
   Howard MW, 2002, J MATH PSYCHOL, V46, P269, DOI 10.1006/jmps.2001.1388
   Hunter LE, 2018, COMMON DELIBERATIVE, DOI [10.1101/499707, DOI 10.1101/499707]
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Jang AI, 2019, NAT HUM BEHAV, V3, P719, DOI 10.1038/s41562-019-0597-3
   Johansson P, 2005, SCIENCE, V310, P116, DOI 10.1126/science.1111709
   Kelly JF, 2018, BRIEF INTERVENTIONS
   Kennedy PJ, 2004, J NEUROSCI, V24, P6979, DOI 10.1523/JNEUROSCI.1388-04.2004
   Kirouac M, 2015, ALCOHOL TREAT Q, V33, P312, DOI 10.1080/07347324.2015.1050934
   Klein AA, 2013, ADDICT BEHAV, V38, P1687, DOI 10.1016/j.addbeh.2012.10.006
   Krank M. D., 2006, HDB IMPLICIT COGNITI, P281, DOI DOI 10.4135/9781412976237.N19
   Kuhl BA, 2010, NAT NEUROSCI, V13, P501, DOI 10.1038/nn.2498
   LANE RD, 2015, BEHAV BRAIN SCI, V38, DOI DOI 10.1017/S0140525X14000041
   Lengyel M., 2008, ADV NEURAL INFORM PR, V20, P889
   Lohnas LJ, 2015, PSYCHOL REV, V122, P337, DOI 10.1037/a0039036
   Ludvig EA, 2015, J EXP PSYCHOL GEN, V144, P24, DOI 10.1037/xge0000046
   Mackintosh V, 2012, QUAL HEALTH RES, V22, P1094, DOI 10.1177/1049732312450325
   MARR D, 1971, PHILOS T ROY SOC B, V262, P23, DOI 10.1098/rstb.1971.0078
   Martin CS, 2014, ADDICTION, V109, P1773, DOI 10.1111/add.12615
   McIntosh J, 2001, DRUG-EDUC PREV POLIC, V8, P47
   McNamara CG, 2017, TRENDS NEUROSCI, V40, P383, DOI 10.1016/j.tins.2017.05.005
   Mikolov Tomas, 2013, PROC 1 INT C LEARN R, DOI DOI 10.48550/ARXIV.1301.3781
   Milton AL, 2012, NEUROSCI BIOBEHAV R, V36, P1119, DOI 10.1016/j.neubiorev.2012.01.002
   Moeller SJ, 2014, TRENDS COGN SCI, V18, P635, DOI 10.1016/j.tics.2014.09.003
   Montague PR, 1996, J NEUROSCI, V16, P1936, DOI 10.1523/jneurosci.16-05-01936.1996
   Muller CP, 2011, BEHAV BRAIN SCI, V34, P293, DOI 10.1017/S0140525X11000057
   Murty VP, 2016, J EXP PSYCHOL GEN, V145, P548, DOI 10.1037/xge0000158
   Nestler EJ, 2002, NEUROBIOL LEARN MEM, V78, P637, DOI 10.1006/nlme.2002.4084
   NEVIN JA, 1988, PSYCHOL BULL, V103, P44, DOI 10.1037/0033-2909.103.1.44
   O'Doherty JP, 2003, NEURON, V38, P329, DOI 10.1016/S0896-6273(03)00169-7
   Ostafin BD, 2019, ADDICT BEHAV, V90, P107, DOI 10.1016/j.addbeh.2018.10.035
   Otto AR, 2013, P NATL ACAD SCI USA, V110, P20941, DOI 10.1073/pnas.1312011110
   Palombo DJ, 2015, HIPPOCAMPUS, V25, P345, DOI 10.1002/hipo.22376
   Peters J, 2010, NEURON, V66, P138, DOI 10.1016/j.neuron.2010.03.026
   Peters Megan A K, 2017, Neurosci Conscious, V2017, pnix015, DOI 10.1093/nc/nix015
   PETTIT HO, 1984, PSYCHOPHARMACOLOGY, V84, P167, DOI 10.1007/BF00427441
   Pezzulo G, 2019, CURR OPIN BEHAV SCI, V29, P69, DOI 10.1016/j.cobeha.2019.04.009
   Pickard H, ADDICTION SELF
   Pickard H, 2018, PHILOS SCI ADDICTION, P29
   Pickard H, 2016, MIND LANG, V31, P277, DOI 10.1111/mila.12106
   Pickard Hanna, 2012, AJOB Neurosci, V3, P40
   Preston KL, 2009, PSYCHOPHARMACOLOGY, V207, P291, DOI 10.1007/s00213-009-1655-8
   Raio CM, 2014, NEUROBIOL LEARN MEM, V112, P212, DOI 10.1016/j.nlm.2014.01.015
   Redish AD, 2008, BEHAV BRAIN SCI, V31, P461, DOI 10.1017/S0140525X08004986
   Redish AD, 2007, PSYCHOL REV, V114, P784, DOI 10.1037/0033-295X.114.3.784
   Redish AD, 2016, NAT REV NEUROSCI, V17, P147, DOI 10.1038/nrn.2015.30
   Redish AD, 2004, SCIENCE, V306, P1944, DOI 10.1126/science.1102384
   Reiner DJ, 2019, NEUROPSYCHOPHARMACOL, V44, P465, DOI 10.1038/s41386-018-0234-2
   Ritter S, 2018, EPISODIC CONTROL MET, DOI DOI 10.1101/360537
   ROBBINS SJ, 1990, J EXP PSYCHOL ANIM B, V16, P235, DOI 10.1037/0097-7403.16.3.235
   Robinson MJF, 2018, PHILOS SCI ADDICTION, P351
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Rouhani N, 2019, COGNITION
   Rouhani N, 2018, J EXP PSYCHOL LEARN, V44, P1430, DOI 10.1037/xlm0000518
   Schacter D. L., 1989, VARIETIES MEMORY CON, P355
   Schoenbaum G, 2016, NEUROPSYCHOPHARMACOL, V41, P2966, DOI 10.1038/npp.2016.147
   Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593
   Schwabe L, 2011, EXP CLIN PSYCHOPHARM, V19, P53, DOI 10.1037/a0022212
   Schwabe L, 2009, J NEUROSCI, V29, P7191, DOI 10.1523/JNEUROSCI.0979-09.2009
   Schwabe L, 2009, LEARN MEMORY, V16, P110, DOI 10.1101/lm.1257509
   Sederberg PB, 2008, PSYCHOL REV, V115, P893, DOI 10.1037/a0013396
   Serre F, 2015, DRUG ALCOHOL DEPEN, V148, P1, DOI 10.1016/j.drugalcdep.2014.12.024
   Shadlen MN, 2016, NEURON, V90, P927, DOI 10.1016/j.neuron.2016.04.036
   Shalev U, 2002, PHARMACOL REV, V54, P1, DOI 10.1124/pr.54.1.1
   Sharot T, 2011, CURR BIOL, V21, pR941, DOI 10.1016/j.cub.2011.10.030
   Shenhav A, 2013, NEURON, V79, P217, DOI 10.1016/j.neuron.2013.07.007
   Shohamy D, 2015, CURR OPIN BEHAV SCI, V5, P85, DOI 10.1016/j.cobeha.2015.08.010
   Shteingart H, 2013, J EXP PSYCHOL GEN, V142, P476, DOI 10.1037/a0029550
   Sidani JE, 2019, DRUG ALCOHOL DEPEN, V204, DOI 10.1016/j.drugalcdep.2019.06.005
   Silverman Kenneth, 2016, Transl Issues Psychol Sci, V2, P203
   Simon DA, 2012, SPR SER COMPUT NEURO, V10, P145, DOI 10.1007/978-1-4614-0751-5_5
   Sinha R, 2005, PSYCHOPHARMACOLOGY, V183, P171, DOI 10.1007/s00213-005-0147-8
   Sinha R, 2007, DRUG ALCOHOL REV, V26, P25, DOI 10.1080/09595230601036960
   Slotnick SD, 2010, COGN NEUROSCI-UK, V1, P8, DOI 10.1080/17588920903474263
   Soeter M, 2011, LEARN MEMORY, V18, P357, DOI 10.1101/lm.2148511
   Sripada C, 2018, J PHILOS, V115, P569, DOI 10.5840/jphil20181151133
   Stein JS, 2018, J BEHAV MED, V41, P269, DOI 10.1007/s10865-017-9908-1
   Stein JS, 2016, PSYCHOPHARMACOLOGY, V233, P3771, DOI 10.1007/s00213-016-4410-y
   Substance Abuse Mental Health Services Administration, 2006, RES 2005 NAT SURV DR
   Suddendorf T, 2007, BEHAV BRAIN SCI, V30, P299, DOI 10.1017/S0140525X07001975
   Takeuchi T, 2016, NATURE, V537, P357, DOI 10.1038/nature19325
   Talmi D, 2019, PSYCHOL REV, V126, P455, DOI 10.1037/rev0000132
   Templer VL, 2013, CURR BIOL, V23, pR801, DOI 10.1016/j.cub.2013.07.016
   Nguyen T, 2017, INT J MED INFORM, V102, P130, DOI 10.1016/j.ijmedinf.2017.03.013
   Tiffany ST, 1998, J PSYCHOPHARMACOL, V12, P23, DOI 10.1177/026988119801200104
   Torregrossa MM, 2013, PSYCHOPHARMACOLOGY, V226, P659, DOI 10.1007/s00213-012-2750-9
   Tulving E., 1972, ORG MEMORY, DOI DOI 10.1007/978-1-4419-0463-8_37
   Venniro M, 2018, NAT NEUROSCI, V21, P1520, DOI 10.1038/s41593-018-0246-6
   Verdejo-Garcia A, 2018, PHILOS SCI ADDICTION, P339, DOI DOI 10.4324/9781315689197-28
   WAISBERG JL, 1994, BRIT J CLIN PSYCHOL, V33, P49, DOI 10.1111/j.2044-8260.1994.tb01093.x
   WALDORF D, 1981, J DRUG ISSUES, V11, P61, DOI 10.1177/002204268101100104
   WALDORF D, 1983, J DRUG ISSUES, V13, P237, DOI 10.1177/002204268301300205
   Waldorf D, 1992, COCAINE CHANGES EXPE
   Wang JX, 2015, NEUROBIOL LEARN MEM, V117, P22, DOI 10.1016/j.nlm.2014.04.003
   Wang S, 2019, WILEY INTERDISCIP RE
   Warren BL, 2019, J NEUROSCI, V39, P7394, DOI 10.1523/JNEUROSCI.0918-19.2019
   Warren BL, 2016, J NEUROSCI, V36, P6691, DOI 10.1523/JNEUROSCI.0140-16.2016
   Wemm SE, 2019, NEUROBIOL STRESS, V10, DOI 10.1016/j.ynstr.2019.100148
   Wray JM, 2013, NICOTINE TOB RES, V15, P1167, DOI 10.1093/ntr/nts268
   Zajac K, 2018, PHILOS SCI ADDICTION, P455
   Zernig G, 2008, ADDICTION, V103, P2024, DOI 10.1111/j.1360-0443.2008.02348.x
   Zhou WY, 2009, P NATL ACAD SCI USA, V106, P9525, DOI 10.1073/pnas.0904360106
   Zinberg NE., 1984, DRUG SET SETTING BAS
NR 161
TC 16
Z9 16
U1 1
U2 3
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0893-133X
EI 1740-634X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD MAY
PY 2020
VL 45
IS 6
BP 907
EP 915
DI 10.1038/s41386-019-0594-2
EA JAN 2020
PG 9
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA LE0BO
UT WOS:000508147400001
PM 31896119
OA Green Published, Bronze
DA 2023-06-23
ER

PT J
AU Alatawi, KKZ
   Albalawi, KSD
   Aljuhani, AAM
   Albalawi, NSD
   Alalawy, AI
   Oyouni, AAA
AF Alatawi, Khaled Khader Z.
   Albalawi, Khalid Saleh D.
   Aljuhani, Abdulrhman Abdulaziz M.
   Albalawi, Nader Salem D.
   Alalawy, Adel Ibrahim
   Oyouni, Atif Abdulwahab A.
TI Drug detection tests and the important factors and effects of the
   development of addiction
SO JOURNAL OF KING SAUD UNIVERSITY SCIENCE
LA English
DT Article
DE Methamphetamine; Drug; Addiction; Dopamine; Environment
ID ILLICIT DRUGS; RISK BEHAVIORS; SLEEP; METHAMPHETAMINE; AMPHETAMINE;
   ADOLESCENTS; BRAIN; BLOOD
AB Drug addiction is a serious issue. A lot of psychopathic drugs are in use, but mainly methamphetamine. Addiction is a problem not only for the addicted person but also affected family and the entire society. Addicted persons lose control of their actions and so commit different crimes such as stealing, raping and killing. They may end up committing suicide. In this review article, we analyze the causes of addiction, absorption of methamphetamine into the body, its effects on cells and the analytical tool to detect the chemicals.(c) 2022 The Authors. Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Alatawi, Khaled Khader Z.; Albalawi, Khalid Saleh D.; Aljuhani, Abdulrhman Abdulaziz M.; Albalawi, Nader Salem D.; Alalawy, Adel Ibrahim] Univ Tabuk, Fac Sci, Dept Biochem, Tabuk, Saudi Arabia.
   [Oyouni, Atif Abdulwahab A.] Univ Tabuk, Fac Sci, Dept Biol, Tabuk, Saudi Arabia.
   [Oyouni, Atif Abdulwahab A.] Univ Tabuk, Fac Sci, Genome & Biotechnol Unit, Tabuk, Saudi Arabia.
   [Oyouni, Atif Abdulwahab A.] Fac Sci Univ Tabuk, Dept Biol, Med Mol Biol Genet, Tabuk, Saudi Arabia.
C3 University of Tabuk; University of Tabuk; University of Tabuk
RP Oyouni, AAA (通讯作者)，Fac Sci Univ Tabuk, Dept Biol, Med Mol Biol Genet, Tabuk, Saudi Arabia.
EM a.oyouni@ut.edu.sa
RI Oyouni, Atif Abdulwahab A./GSE-1275-2022; ALALAWY, ADEL/HSE-5556-2023
OI Oyouni, Atif Abdulwahab A./0000-0001-8762-4999; ALALAWY,
   ADEL/0000-0002-5880-973X
CR Adcock JL, 2011, DRUG TEST ANAL, V3, P145, DOI 10.1002/dta.236
   Ahmed SR, 2020, TRAC-TREND ANAL CHEM, V131, DOI 10.1016/j.trac.2020.116006
   Albers DS, 1995, J PHARMACOL EXP THER, V275, P1104
   Basch CE, 2014, PREV CHRONIC DIS, V11, DOI 10.5888/pcd11.140383
   Campobasso CP, 2001, FORENSIC SCI INT, V120, P18, DOI 10.1016/S0379-0738(01)00411-X
   Concheiro M, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01210
   Cumba LR, 2015, ANALYST, V140, P5536, DOI 10.1039/c5an00858a
   De Rycke E, 2020, BIOSENS BIOELECTRON, V169, DOI 10.1016/j.bios.2020.112579
   Dobroiu A, 2007, P IEEE, V95, P1566, DOI 10.1109/JPROC.2007.898840
   Gamouras GA, 2000, AM J MED SCI, V320, P9, DOI 10.1097/00000441-200007000-00002
   Garrido E, 2018, CHEMISTRYOPEN, V7, P401, DOI 10.1002/open.201800034
   Gjerde H, 2015, FORENSIC SCI INT, V256, P42, DOI 10.1016/j.forsciint.2015.06.027
   Guinan T, 2012, TALANTA, V99, P791, DOI 10.1016/j.talanta.2012.07.029
   Hao PL, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.O111.009381
   Hasler BP, 2015, ALCOHOL, V49, P377, DOI 10.1016/j.alcohol.2014.06.010
   Huang JQ, 2019, INT J CANCER, V145, P3231, DOI 10.1002/ijc.32218
   Johansson AEE, 2016, J PEDIATR NURS, V31, P498, DOI 10.1016/j.pedn.2016.04.004
   Kang Yi-Rae, 2012, Journal of Pharmaceutical Investigation, V42, P41, DOI 10.1007/s40005-012-0006-7
   Kintz P, 2017, CURR PHARM DESIGN, V23, P5480, DOI 10.2174/1381612823666170929155628
   Kiyatkin EA, 2019, INT REV NEUROBIOL, V146, P189, DOI 10.1016/bs.irn.2019.06.010
   LEBISH P, 1970, CLIN CHEM, V16, P195
   Makino Y, 2012, BIOMED CHROMATOGR, V26, P327, DOI 10.1002/bmc.1661
   Mao K, 2019, SCI TOTAL ENVIRON, V688, P771, DOI 10.1016/j.scitotenv.2019.06.325
   McKnight-Eily LR, 2011, PREV MED, V53, P271, DOI 10.1016/j.ypmed.2011.06.020
   Metcalf JL, 2019, FORENSIC SCI INT-GEN, V38, P211, DOI 10.1016/j.fsigen.2018.11.004
   Mizukami H, 2020, J PROTEOME RES, V19, P2122, DOI 10.1021/acs.jproteome.0c00060
   Mustafa NS, 2020, BASIC CLIN NEUROSCI, V11, P381, DOI 10.32598/bcn.9.10.485
   Oonk S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34791-z
   Park S, 2019, J CLIN MONIT COMPUT, V33, P95, DOI 10.1007/s10877-018-0132-5
   Parker GJ, 2021, FORENSIC SCI INT-GEN, V54, DOI 10.1016/j.fsigen.2021.102529
   Parker GJ, 2019, J ARCHAEOL SCI, V101, P169, DOI 10.1016/j.jas.2018.08.011
   Parrilla M, 2021, SENSOR ACTUAT B-CHEM, V348, DOI 10.1016/j.snb.2021.130659
   Pasch KE, 2012, J YOUTH ADOLESCENCE, V41, P1184, DOI 10.1007/s10964-012-9784-5
   Pechal JL, 2014, INT J LEGAL MED, V128, P193, DOI 10.1007/s00414-013-0872-1
   Phillips KA, 2014, NEUROPHARMACOLOGY, V87, P150, DOI 10.1016/j.neuropharm.2014.04.002
   Prieto-Bonete G, 2019, J PROTEOMICS, V192, P54, DOI 10.1016/j.jprot.2018.08.008
   Pujol ML, 2007, FORENSIC SCI INT, V170, P189, DOI 10.1016/j.forsciint.2007.02.032
   Ramsoe A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-87125-x
   Randler C, 2008, CHRONOBIOL INT, V25, P1017, DOI 10.1080/07420520802551519
   Roberts RE, 2009, J ADOLESCENCE, V32, P1045, DOI 10.1016/j.adolescence.2009.03.007
   Robinson NE, 2001, P NATL ACAD SCI USA, V98, P12409, DOI 10.1073/pnas.221463198
   Roenneberg T, 2004, CURR BIOL, V14, pR1038, DOI 10.1016/j.cub.2004.11.039
   Sanchez-Fernandez C, 2017, ADV EXP MED BIOL, V964, P109, DOI 10.1007/978-3-319-50174-1_9
   Schott M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128528
   Shah A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.374
   Shedge R., 2020, POSTMORTEM CHANGES
   Sivertsen B, 2015, DRUG ALCOHOL DEPEN, V149, P180, DOI 10.1016/j.drugalcdep.2015.01.045
   Stojanovska N, 2013, FORENSIC SCI INT, V224, P8, DOI 10.1016/j.forsciint.2012.10.040
   Strowbridge BW, 2009, ANN NY ACAD SCI, V1170, P270, DOI 10.1111/j.1749-6632.2009.04018.x
   Szeremeta M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22063010
   Thomas AG, 2015, J YOUTH ADOLESCENCE, V44, P447, DOI 10.1007/s10964-014-0179-7
   Tsujikawa K, 2012, FORENSIC TOXICOL, V30, P70, DOI 10.1007/s11419-011-0119-0
   Ussher JR, 2016, J AM COLL CARDIOL, V68, P2850, DOI 10.1016/j.jacc.2016.09.972
   Wasserman DA, 1999, AM J DRUG ALCOHOL AB, V25, P561, DOI 10.1081/ADA-100101879
   Wheaton AG, 2016, MMWR-MORBID MORTAL W, V65, P337, DOI 10.15585/mmwr.mm6513a1
   Zhang QJ, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.2.026006
NR 56
TC 0
Z9 0
U1 5
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1018-3647
EI 2213-686X
J9 J KING SAUD UNIV SCI
JI J. King Saud Univ. Sci.
PD JUL
PY 2022
VL 34
IS 5
AR 102093
DI 10.1016/j.jksus.2022.102093
EA MAY 2022
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 2A9SN
UT WOS:000809836200020
OA gold
DA 2023-06-23
ER

PT J
AU Jackson, DS
   Tiako, MJN
   Jordan, A
AF Jackson, Danielle S.
   Tiako, Max Jordan Nguemeni
   Jordan, Ayana
TI Disparities in Addiction Treatment Learning from the Past to Forge an
   Equitable Future
SO MEDICAL CLINICS OF NORTH AMERICA
LA English
DT Article
DE Addiction; Treatment; Disparities; Inequity; Drug policy; Structural
   competency; Structural racism
ID SUBSTANCE USE DISORDERS; SOCIAL DETERMINANTS; PRIMARY-CARE; HEALTH;
   RACE; WAR; BUPRENORPHINE; BLACK; PSYCHIATRY; DRUGS
C1 [Jackson, Danielle S.] Rutgers Robert Wood Johnson Med Sch, Dept Psychiat, 671 Hoes Lane West,2nd Floor, Piscataway, NJ 08854 USA.
   [Tiako, Max Jordan Nguemeni] Brigham & Womens Hosp, Dept Internal Med, Boston, MA 02115 USA.
   [Tiako, Max Jordan Nguemeni] Harvard Med Sch, Boston, MA 02115 USA.
   [Jordan, Ayana] NYU Grossman Sch Med, Dept Psychiat, New York, NY USA.
   [Tiako, Max Jordan Nguemeni; Jordan, Ayana] 300 George St,Suite 901, New Haven, CT 06461 USA.
C3 Rutgers State University New Brunswick; Rutgers State University Medical
   Center; Harvard University; Brigham & Women's Hospital; Harvard
   University; Harvard Medical School
RP Jackson, DS (通讯作者)，Rutgers Robert Wood Johnson Med Sch, Dept Psychiat, 671 Hoes Lane West,2nd Floor, Piscataway, NJ 08854 USA.
EM danielle.jackson@yale.edu
RI Nguemeni Tiako, Max Jordan/AAZ-7373-2020
OI Nguemeni Tiako, Max Jordan/0000-0002-5468-8926
CR Abraham AJ, 2013, J STUD ALCOHOL DRUGS, V74, P258, DOI 10.15288/jsad.2013.74.258
   Alexander M., 2010, RACE POVERTY ENV, V17, P75
   Andraka-Christou B, 2019, J SUBST ABUSE TREAT, V104, P72, DOI 10.1016/j.jsat.2019.06.011
   [Anonymous], 2016, RACIAL EQUITY
   Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E
   Barenie RE, 2021, DRUG ALCOHOL DEPEN, V219, DOI 10.1016/j.drugalcdep.2020.108491
   Baum Dan., 2016, HARPERS
   Bobo LD, 2006, SOC RES, V73, P445
   Campbell ND, 2012, ANN NY ACAD SCI, V1248, P124, DOI 10.1111/j.1749-6632.2011.06352.x
   Cobbina Jennifer, 2008, J CRIMINAL JUSTICE P, V15, P145
   Cohen MM, 2006, SOUTH CULT, V12, P55, DOI 10.1353/scu.2006.0031
   Corrigan P, 2017, AM J ADDICTION, V26, P59, DOI 10.1111/ajad.12458
   Courtwright DT, 2004, DRUG ALCOHOL DEPEN, V76, P9, DOI 10.1016/j.drugalcdep.2004.04.012
   Drucker E, 2002, J URBAN HEALTH, V79, P434, DOI 10.1093/jurban/79.3.434
   Ducharme LJ, 2008, SUBST ABUSE TREAT PR, V3, DOI 10.1186/1747-597X-3-17
   Fiscella K, 2019, JAMA PSYCHIAT, V76, P229, DOI 10.1001/jamapsychiatry.2018.3685
   Frontz AJ, 2020, OPIOID TREATMENT PRO
   Furr-Holden D, 2021, ADDICTION, V116, P677, DOI 10.1111/add.15233
   Ginther DK, 2011, SCIENCE, V333, P1015, DOI 10.1126/science.1196783
   Goedel WC, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3711
   Greenwald MK, 2003, NEUROPSYCHOPHARMACOL, V28, P2000, DOI 10.1038/sj.npp.1300251
   Hansen H, 2012, 2 TIERS BIOMEDICALIZ, V14
   Hansen H, 2018, JAMA PSYCHIAT, V75, P117, DOI 10.1001/jamapsychiatry.2017.3894
   Hansen H, 2017, ACAD MED, V92, P279, DOI 10.1097/ACM.0000000000001542
   Hansen HB, 2013, J BEHAV HEALTH SER R, V40, P367, DOI 10.1007/s11414-013-9341-3
   Hart C, 2014, MYTH NEGRO COCAINE F
   Hedegaard Holly, 2018, Natl Vital Stat Rep, V67, P1
   Heimer R, 2019, CLIN INFECT DIS, V69, P546, DOI 10.1093/cid/ciy977
   Hickman TA, 2007, SECRET LEPROSY MODER, P59
   Hoppe TA, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw7238
   Jackson JR, 2020, J SUBST ABUSE TREAT, V115, DOI 10.1016/j.jsat.2020.108008
   James K, 2018, J LAW MED ETHICS, V46, P404, DOI 10.1177/1073110518782949
   Jordan A, 2021, J SUBST ABUSE TREAT, V124, DOI 10.1016/j.jsat.2020.108218
   Jordan A, 2021, HARVARD REV PSYCHIAT, V29, P108, DOI 10.1097/HRP.0000000000000285
   Jordan A, 2021, LANCET PSYCHIAT, V8, P8, DOI 10.1016/S2215-0366(20)30519-8
   Jordan A, 2020, AM J ADDICTION, V29, P413, DOI 10.1111/ajad.13097
   Jordan A, 2020, PSYCHIAT CLIN N AM, V43, P487, DOI 10.1016/j.psc.2020.05.007
   Joseph H, 2000, MT SINAI J MED, V67, P347
   Joudrey PJ, 2020, JAMA PSYCHIAT, V77, P1105, DOI 10.1001/jamapsychiatry.2020.1511
   Joudrey PJ, 2020, DRUG ALCOHOL DEPEN, V211, DOI 10.1016/j.drugalcdep.2020.107968
   Krystal H, 2018, J AM ACAD PSYCHIATRY, V46, P472, DOI 10.29158/JAAPL.003790-18
   Lagisetty PA, 2019, JAMA PSYCHIAT, V76, P979, DOI 10.1001/jamapsychiatry.2019.0876
   Marino R, 2019, J MED TOXICOL, V15, P307, DOI 10.1007/s13181-019-00728-9
   Marmot M, 2005, LANCET, V365, P1099, DOI 10.1016/S0140-6736(05)74234-3
   McBournie Alaina, 2019, HLTH AFFAIRS BLOG SE, DOI [10.1377/hblog20190920.981503/full/, DOI 10.1377/HBLOG20190920.981503/FULL]
   Metzl JM, 2014, SOC SCI MED, V103, P126, DOI 10.1016/j.socscimed.2013.06.032
   Morgan JR, 2019, DRUG ALCOHOL DEPEN, V200, P34, DOI 10.1016/j.drugalcdep.2019.02.031
   Murch D, 2015, J AM HIST, V102, P162, DOI 10.1093/jahist/jav260
   Musto DF, 1999, AM DIS ORIGINS NARCO, V3rd, P91
   Netherland J, 2017, BIOSOCIETIES, V12, P217, DOI 10.1057/biosoc.2015.46
   Netherland J, 2016, CULT MED PSYCHIAT, V40, P664, DOI 10.1007/s11013-016-9496-5
   Tiako MJN, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.29043
   Olfson M, 2020, JAMA-J AM MED ASSOC, V323, P276, DOI 10.1001/jama.2019.18913
   Pettit B, 2004, AM SOCIOL REV, V69, P151, DOI 10.1177/000312240406900201
   Redford A, 2016, INDEP REV, V20, P509
   RETTIG RA, 1995, FEDERAL REGULATION M
   Roberts AW, 2018, PSYCHIAT SERV, V69, P832, DOI 10.1176/appi.ps.201700315
   Rundle SM, 2021, DRUG ALCOHOL REV, V40, P842, DOI 10.1111/dar.13244
   Sacco LN, 2014, DRUG ENFORCEMENT US
   Spillane J, 2003, DRUG ALCOHOL DEPEN, V70, pS5, DOI 10.1016/S0376-8716(03)00096-6
   Tetrault JM, 2017, J GEN INTERN MED, V32, P1387, DOI 10.1007/s11606-017-4140-9
   Vagins D, 2005, CRACKS SYSTEM 20 YEA
   van Boekel LC, 2014, DRUG ALCOHOL DEPEN, V134, P92, DOI 10.1016/j.drugalcdep.2013.09.012
   Volkow ND, 2016, NEW ENGL J MED, V374, P363, DOI 10.1056/NEJMra1511480
   Wakeman SE, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2019.20622
   Wakeman SE, 2017, J ADDICT MED, V11, P308, DOI 10.1097/ADM.0000000000000314
   Watkins KE, 2017, JAMA INTERN MED, V177, P1480, DOI 10.1001/jamainternmed.2017.3947
   Whitebread BRI, 1999, MARIJUANA CONVICTION
   Wood E, 2009, LANCET, V373, P989, DOI 10.1016/S0140-6736(09)60455-4
NR 69
TC 7
Z9 7
U1 1
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0025-7125
EI 1557-9859
J9 MED CLIN N AM
JI Med. Clin. N. Am.
PD JAN
PY 2022
VL 106
IS 1
BP 29
EP 41
DI 10.1016/j.mcna.2021.08.008
EA NOV 2021
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine
GA XD7NI
UT WOS:000722890800005
PM 34823733
DA 2023-06-23
ER

PT J
AU Stover, H
AF Stoever, H.
TI Man, intoxication, addiction: Construction and crisis of masculinity
SO SUCHTTHERAPIE
LA German
DT Article
DE intoxication; drugs; gender; men specific drug services; masculinity;
   prevention; therapy
AB Intoxication, drug use and addiction are phenomenon, which are closely associated with the construction of male identities. Drug use therefore can be understood within general health risk behaviour of men, which is meant to demonstrate or permanently (re-)construct masculinity. The interrelation of gender and drug use/addiction has mainly been studied and implemented into practice along the relationship of "women and addiction" since 25 years. The "discovery of masculinity" [1] in drug research and drug services is of a much younger date. On the background of an increasing perception of gender theories and health behaviour and a growing necessity to work gender specifically in prevention, counselling, and treatment of drug using patients transfers into the practice have to be developed. This contribution gives first indications for this implementation process of men specific services for men at risk or dependent.
C1 [Stoever, H.] Univ Bremen, ARCHIDO eV Informat, D-28334 Bremen, Germany.
   [Stoever, H.] Univ Bremen, Forsch Zentrum Tabak Alkohol Drogen Medikamente &, D-28334 Bremen, Germany.
C3 University of Bremen; University of Bremen
RP Stover, H (通讯作者)，Univ Bremen, ARCHIDO eV Informat, FB 11 Publ Hlth,Postfach 330 440, D-28334 Bremen, Germany.
EM heino.stoever@uni-bremen.de
CR ALTGELD T, 2006, SUCHT MANNLICHKEITEN, P79
   Apter M., 1992, RAUSCH GEFAHR WARUM
   *BUND GES AUFKL BZ, 2002, STAT GRUNDL 2001
   CONNEL RW, 2000, GEMACHTE MANN KONSTR
   *DROG BUND, 2002, FRAUEN SUCHT DOK BUN
   Kolip P, 2002, GESCHLECHT GESUNDHEI, P13
   KUHLMANN E, GESCHLECHT GESUNDHEI, P104
   MULLER J, 1996, ABHANGIGKEITEN, V2, P38
   Neubauer G., 2001, DIES VARIABLENMODELL
   SCHWARTUNG F, 2003, BINAD INFO LANDESFAC, V24, P46
   SIEBER M, 1996, ABHANGIGKEITEN, V2, P27
   TRINKLER J, 2002, HDB DROGENBENUTZER E, P87
   VOGT I, 2007, SOZIALWISSENSCHAFTLI, P235
   VOSSHAGEN A, 2002, ABHANGIGKEITEN, P21
   VOSSHAGEN A, 2006, SUCHT MANNLICHKEITEN, P129
   Wulf H., 2006, SUCHT MANNLICHKEITEN, P119
NR 16
TC 2
Z9 2
U1 0
U2 8
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 1439-9903
J9 SUCHTTHERAPIE
JI Suchttherapie
PD SEP
PY 2007
VL 8
IS 3
BP 89
EP 94
DI 10.1055/s-2007-985397
PG 6
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Psychiatry
GA 326SJ
UT WOS:000257678900002
DA 2023-06-23
ER

PT S
AU Everitt, BJ
   Robbins, TW
AF Everitt, Barry J.
   Robbins, Trevor W.
BE Fiske, ST
TI Drug Addiction: Updating Actions to Habits to Compulsions Ten Years On
SO ANNUAL REVIEW OF PSYCHOLOGY, VOL 67
SE Annual Review of Psychology
LA English
DT Review; Book Chapter
DE striatum; prefrontal cortex; insula; inhibitory control; endophenotype;
   vulnerability
ID VENTROMEDIAL PREFRONTAL CORTEX; NUCLEUS-ACCUMBENS CORE;
   REACTION-TIME-TASK; COCAINE-SEEKING; DORSAL STRIATUM; CHRONIC
   AMPHETAMINE; HIGH IMPULSIVITY; DECISION-MAKING; ALCOHOL SEEKING; NMDA
   RECEPTORS
AB A decade ago, we hypothesized that drug addiction can be viewed as a transition from voluntary, recreational drug use to compulsive drug-seeking habits, neurally underpinned by a transition from prefrontal cortical to striatal control over drug seeking and taking as well as a progression from the ventral to the dorsal striatum. Here, in the light of burgeoning, supportive evidence, we reconsider and elaborate this hypothesis, in particular the refinements in our understanding of ventral and dorsal striatal mechanisms underlying goal-directed and habitual drug seeking, the influence of drug-associated Pavlovian-conditioned stimuli on drug seeking and relapse, and evidence for impairments in top-down prefrontal cortical inhibitory control over this behavior. We further review animal and human studies that have begun to define etiological factors and individual differences in the propensity to become addicted to drugs, leading to the description of addiction endophenotypes, especially for cocaine addiction. We consider the prospect of novel treatments for addiction that promote abstinence from and relapse to drug use.
C1 [Everitt, Barry J.; Robbins, Trevor W.] Univ Cambridge, Dept Psychol, Cambridge CB2 3EB, England.
   [Everitt, Barry J.; Robbins, Trevor W.] Univ Cambridge, Behav & Clin Neurosci Inst, Cambridge CB2 3EB, England.
C3 University of Cambridge; University of Cambridge
RP Everitt, BJ; Robbins, TW (通讯作者)，Univ Cambridge, Dept Psychol, Cambridge CB2 3EB, England.; Everitt, BJ; Robbins, TW (通讯作者)，Univ Cambridge, Behav & Clin Neurosci Inst, Cambridge CB2 3EB, England.
EM bje10@cam.ac.uk; twr2@cam.ac.uk
RI Robbins, Trevor W/A-7551-2008
OI Robbins, Trevor/0000-0003-0642-5977
FU MRC [G9537855, G0802729, G1000183, G0701497, G0701500, G1002231] Funding
   Source: UKRI; Medical Research Council [G0001354B, G1002231, G0600196,
   G1000183, G0802729, G9537855, G1000183B, G0701497, G0001354, G0701500]
   Funding Source: researchfish
CR American Psychiatric Association [APA], 2022, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425787]
   Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244
   Aron AR, 2014, TRENDS COGN SCI, V18, P177, DOI 10.1016/j.tics.2013.12.003
   Arroyo M, 1998, PSYCHOPHARMACOLOGY, V140, P331, DOI 10.1007/s002130050774
   Balleine BW, 2010, NEUROPSYCHOPHARMACOL, V35, P48, DOI 10.1038/npp.2009.131
   Barak S, 2014, ALCOHOL, V48, P176
   Barker JM, 2014, NEUROSCI BIOBEHAV R, V47, P281, DOI 10.1016/j.neubiorev.2014.08.012
   Bechara A, 2001, NEUROPSYCHOLOGIA, V39, P376, DOI 10.1016/S0028-3932(00)00136-6
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   Belin D, 2008, NEURON, V57, P432, DOI 10.1016/j.neuron.2007.12.019
   Belin D, 2013, CURR OPIN NEUROBIOL, V23, P564, DOI 10.1016/j.conb.2013.01.025
   Belin D, 2011, NEUROPSYCHOPHARMACOL, V36, P569, DOI 10.1038/npp.2010.188
   Belin D, 2009, BEHAV BRAIN RES, V199, P89, DOI 10.1016/j.bbr.2008.09.027
   Belin-Rauscent A, 2013, BEHAV PHARMACOL, V24, P14
   Bohbot VD, 2013, HIPPOCAMPUS, V23, P973, DOI 10.1002/hipo.22187
   Brody AL, 2004, BIOL PSYCHIAT, V55, P77, DOI 10.1016/S0006-3223(03)00610-3
   Cannella N, 2013, NEUROPSYCHOPHARMACOL, V38, P2048, DOI 10.1038/npp.2013.106
   Caprioli D, 2014, BIOL PSYCHIAT, V75, P115, DOI 10.1016/j.biopsych.2013.07.013
   Cardinal RN, 2004, CURR OPIN NEUROBIOL, V14, P156, DOI 10.1016/j.conb.2004.03.004
   Cardinal RN, 2002, NEUROSCI BIOBEHAV R, V26, P321, DOI 10.1016/S0149-7634(02)00007-6
   Castane A, 2010, BEHAV BRAIN RES, V210, P74, DOI 10.1016/j.bbr.2010.02.017
   Chen BT, 2013, NATURE, V496, P359, DOI 10.1038/nature12024
   Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11
   Clark L, 2008, BRAIN, V131, P1311, DOI 10.1093/brain/awn066
   Clarke HF, 2008, J NEUROSCI, V28, P10972, DOI 10.1523/JNEUROSCI.1521-08.2008
   Clemens KJ, 2014, NEUROPSYCHOPHARMACOL, V39, P2584, DOI 10.1038/npp.2014.111
   Conklin CA, 2002, ADDICTION, V97, P155, DOI 10.1046/j.1360-0443.2002.00014.x
   Contreras M, 2007, SCIENCE, V318, P655, DOI 10.1126/science.1145590
   Corbit LH, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00301
   Corbit LH, 2012, BIOL PSYCHIAT, V72, P389, DOI 10.1016/j.biopsych.2012.02.024
   Corbit LH, 2005, J NEUROSCI, V25, P962, DOI 10.1523/JNEUROSCI.4507-04.2005
   Covington HE, 2005, PSYCHOPHARMACOLOGY, V183, P331, DOI 10.1007/s00213-005-0190-5
   Cuthbert BN, 2014, WORLD PSYCHIATRY, V13, P28, DOI 10.1002/wps.20087
   Dalley JW, 2007, SCIENCE, V315, P1267, DOI 10.1126/science.1137073
   Dalley JW, 2011, NEURON, V69, P680, DOI 10.1016/j.neuron.2011.01.020
   Davis M, 2002, EUR J NEUROSCI, V16, P395, DOI 10.1046/j.1460-9568.2002.02138.x
   de Wit H, 2000, BEHAV NEUROSCI, V114, P830, DOI 10.1037//0735-7044.114.4.830
   Debiec J, 2004, NEUROSCIENCE, V129, P267, DOI 10.1016/j.neuroscience.2004.08.018
   Depoy L, 2013, P NATL ACAD SCI USA, V110, P14783, DOI 10.1073/pnas.1308198110
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Dezfouli A, 2009, NEURAL COMPUT, V21, P2869, DOI 10.1162/neco.2009.10-08-882
   Dias R, 1996, NATURE, V380, P69, DOI 10.1038/380069a0
   Dias-Ferreira E, 2009, SCIENCE, V325, P621, DOI 10.1126/science.1171203
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Dickinson A, 2002, Q J EXP PSYCHOL-B, V55, P331, DOI 10.1080/0272499024400016
   DICKINSON A, 1985, PHILOS T ROY SOC B, V308, P67, DOI 10.1098/rstb.1985.0010
   DICKINSON A, 1994, ANIM LEARN BEHAV, V22, P1, DOI 10.3758/BF03199951
   Diergaarde L, 2008, BIOL PSYCHIAT, V63, P301, DOI 10.1016/j.biopsych.2007.07.011
   Donnelly NA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111300
   Economidou D, 2012, NEUROPSYCHOPHARMACOL, V37, P2057, DOI 10.1038/npp.2012.53
   Economidou D, 2009, BIOL PSYCHIAT, V65, P851, DOI 10.1016/j.biopsych.2008.12.008
   Ersche KD, 2008, PSYCHOPHARMACOLOGY, V197, P421, DOI 10.1007/s00213-007-1051-1
   Ersche KD, 2013, CURR OPIN NEUROBIOL, V23, P615, DOI 10.1016/j.conb.2013.02.017
   Ersche KD, 2013, BIOL PSYCHIAT, V74, P137, DOI 10.1016/j.biopsych.2012.11.016
   Ersche KD, 2012, AM J PSYCHIAT, V169, P926, DOI 10.1176/appi.ajp.2012.11091421
   Ersche KD, 2012, SCIENCE, V335, P601, DOI 10.1126/science.1214463
   Ersche KD, 2011, BIOL PSYCHIAT, V70, P754, DOI 10.1016/j.biopsych.2011.06.033
   Ersche KD, 2011, BRAIN, V134, P2013, DOI 10.1093/brain/awr138
   Ersche KD, 2010, ARCH GEN PSYCHIAT, V67, P632, DOI 10.1001/archgenpsychiatry.2010.60
   Ersche KD, 2005, PSYCHOPHARMACOLOGY, V180, P612, DOI 10.1007/s00213-005-2205-7
   Everitt BJ, 2014, EUR J NEUROSCI, V40, P2163, DOI 10.1111/ejn.12644
   Everitt BJ, 2013, NEUROSCI BIOBEHAV R, V37, P1946, DOI 10.1016/j.neubiorev.2013.02.010
   Everitt BJ, 2001, BRAIN RES REV, V36, P129, DOI 10.1016/S0165-0173(01)00088-1
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Fein G, 2002, ALCOHOL CLIN EXP RES, V26, P558, DOI 10.1111/j.1530-0277.2002.tb02574.x
   Fernando ABP, 2012, PSYCHOPHARMACOLOGY, V219, P341, DOI 10.1007/s00213-011-2408-z
   Fillmore MT, 2005, EXP CLIN PSYCHOPHARM, V13, P327, DOI 10.1037/1064-1297.13.4.327
   Flagel SB, 2011, NATURE, V469, P53, DOI 10.1038/nature09588
   Friedman NP, 2006, PSYCHOL SCI, V17, P172, DOI 10.1111/j.1467-9280.2006.01681.x
   Gallinat J, 2006, EUR J NEUROSCI, V24, P1744, DOI 10.1111/j.1460-9568.2006.05050.x
   Garavan H, 2000, AM J PSYCHIAT, V157, P1789, DOI 10.1176/appi.ajp.157.11.1789
   Garavan H, 2013, CURR OPIN NEUROBIOL, V23, P668, DOI 10.1016/j.conb.2013.01.029
   Garavan H, 2008, PHILOS T R SOC B, V363, P3267, DOI 10.1098/rstb.2008.0106
   GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107
   Gillan CM, 2015, AM J PSYCHIAT, V172, P284, DOI 10.1176/appi.ajp.2014.14040525
   GLAUTIER S, 1994, PSYCHOPHARMACOLOGY, V116, P360, DOI 10.1007/BF02245341
   GOLDBERG SR, 1973, J PHARMACOL EXP THER, V186, P18
   Goldstein RZ, 2009, TRENDS COGN SCI, V13, P372, DOI 10.1016/j.tics.2009.06.004
   Gottesman II, 2003, AM J PSYCHIAT, V160, P636, DOI 10.1176/appi.ajp.160.4.636
   Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040
   Groman SM, 2013, BIOL PSYCHIAT, V73, P756, DOI 10.1016/j.biopsych.2012.12.002
   Grueter BA, 2012, CURR OPIN NEUROBIOL, V22, P545, DOI 10.1016/j.conb.2011.09.009
   Haber SN, 2000, J NEUROSCI, V20, P2369
   Hall J, 2001, EUR J NEUROSCI, V13, P1984, DOI 10.1046/j.0953-816x.2001.01577.x
   Han JS, 1997, J NEUROSCI, V17, P3913
   Hellemans KGC, 2006, J NEUROSCI, V26, P12694, DOI 10.1523/JNEUROSCI.3101-06.2006
   Hogarth Lee, 2013, Ann N Y Acad Sci, V1282, P12, DOI 10.1111/j.1749-6632.2012.06768.x
   Hogarth L, 2010, PSYCHOPHARMACOLOGY, V208, P337, DOI 10.1007/s00213-009-1735-9
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Ikemoto S, 2004, NEUROPHARMACOLOGY, V47, P190, DOI 10.1016/j.neuropharm.2004.07.012
   Ito R, 2002, J NEUROSCI, V22, P6247
   Jang DP, 2007, NEUROSCI LETT, V428, P21, DOI 10.1016/j.neulet.2007.09.047
   Jentsch JD, 2002, NEUROPSYCHOPHARMACOL, V26, P183, DOI 10.1016/S0893-133X(01)00355-4
   Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483
   Jonkman S, 2013, NEUROPSYCHOPHARMACOL, V38, P198, DOI 10.1038/npp.2012.120
   Jonkman S, 2012, NEUROPSYCHOPHARMACOL, V37, P1612, DOI 10.1038/npp.2012.6
   Jonkman S, 2012, J NEUROSCI, V32, P4645, DOI 10.1523/JNEUROSCI.0348-12.2012
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kalivas PW, 2003, PSYCHOPHARMACOLOGY, V168, P44, DOI 10.1007/s00213-003-1393-2
   Kasanetz F, 2010, SCIENCE, V328, P1709, DOI 10.1126/science.1187801
   Kauer JA, 2007, NAT REV NEUROSCI, V8, P844, DOI 10.1038/nrn2234
   KELLY PH, 1975, BRAIN RES, V94, P507, DOI 10.1016/0006-8993(75)90233-4
   Koob GF, 2008, NEURON, V59, P11, DOI 10.1016/j.neuron.2008.06.012
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Lee JLC, 2006, J NEUROSCI, V26, P5881, DOI 10.1523/JNEUROSCI.0323-06.2006
   Lee JLC, 2005, NEURON, V47, P795, DOI 10.1016/j.neuron.2005.08.007
   Lee JLC, 2004, SCIENCE, V304, P839, DOI 10.1126/science.1095760
   Lee JLC, 2007, RES PER NEUROSCI, P83, DOI 10.1007/978-3-540-45702-2_6
   Lee JLC, 2006, J NEUROSCI, V26, P10051, DOI 10.1523/JNEUROSCI.2466-06.2006
   Lee JLC, 2009, LEARN MEMORY, V16, P82, DOI 10.1101/lm.1186609
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Letchworth SR, 2001, J NEUROSCI, V21, P2799, DOI 10.1523/JNEUROSCI.21-08-02799.2001
   LEWIS DJ, 1979, PSYCHOL BULL, V86, P1054, DOI 10.1037/0033-2909.86.5.1054
   Leyton M, 2007, PROG NEURO-PSYCHOPH, V31, P1601, DOI 10.1016/j.pnpbp.2007.08.027
   Leyton M, 2014, TRENDS PHARMACOL SCI, V35, P268, DOI 10.1016/j.tips.2014.04.002
   Lingawi NW, 2012, J NEUROSCI, V32, P1073, DOI 10.1523/JNEUROSCI.4806-11.2012
   Luscher C, 2011, NEURON, V69, P650, DOI 10.1016/j.neuron.2011.01.017
   McNamara R, 2010, PSYCHOPHARMACOLOGY, V212, P453, DOI 10.1007/s00213-010-1974-9
   Mechtcheriakov S, 2007, J NEUROL NEUROSUR PS, V78, P610, DOI 10.1136/jnnp.2006.095869
   Merlo E, 2014, J NEUROSCI, V34, P2422, DOI 10.1523/JNEUROSCI.4001-13.2014
   Meunier D, 2012, NEUROIMAGE, V59, P1461, DOI 10.1016/j.neuroimage.2011.08.003
   Miles FJ, 2003, BEHAV NEUROSCI, V117, P927, DOI 10.1037/0735-7044.117.5.927
   Miller CA, 2005, NEURON, V47, P873, DOI 10.1016/j.neuron.2005.08.006
   Milton AL, 2013, CURR OPIN NEUROBIOL, V23, P706, DOI 10.1016/j.conb.2012.11.008
   Milton AL, 2008, J NEUROSCI, V28, P8230, DOI 10.1523/JNEUROSCI.1723-08.2008
   Milton AL, 2008, LEARN MEMORY, V15, P88, DOI 10.1101/lm.825008
   Milton AL, 2012, PSYCHOPHARMACOLOGY, V219, P751, DOI 10.1007/s00213-011-2399-9
   Milton AL, 2010, EUR J NEUROSCI, V31, P2308, DOI 10.1111/j.1460-9568.2010.07249.x
   Mitchell MR, 2014, NEUROPSYCHOPHARMACOL, V39, P955, DOI 10.1038/npp.2013.295
   Molander AC, 2011, PSYCHOPHARMACOLOGY, V215, P721, DOI 10.1007/s00213-011-2167-x
   Monfils MH, 2009, SCIENCE, V324, P951, DOI 10.1126/science.1167975
   Morein-Zamir Sharon, 2015, Brain Res, V1628, P117, DOI 10.1016/j.brainres.2014.09.012
   Morein-Zamir S, 2013, NEUROPSYCHOPHARMACOL, V38, P1945, DOI 10.1038/npp.2013.90
   Morgan D, 2002, NAT NEUROSCI, V5, P169, DOI 10.1038/nn798
   Murray JE, 2013, 51 ANN M AM COLL NEU
   Murray JE, 2012, NEUROPSYCHOPHARMACOL, V37, P2456, DOI 10.1038/npp.2012.104
   Myers KM, 2012, BIOL PSYCHIAT, V71, P947, DOI 10.1016/j.biopsych.2012.02.030
   Nader K, 2000, NATURE, V406, P722, DOI 10.1038/35021052
   Naqvi NH, 2007, SCIENCE, V315, P531, DOI 10.1126/science.1135926
   Naqvi NH, 2010, BRAIN STRUCT FUNCT, V214, P435, DOI 10.1007/s00429-010-0268-7
   Naqvi NH, 2009, TRENDS NEUROSCI, V32, P56, DOI 10.1016/j.tins.2008.09.009
   Nelson A, 2006, J NEUROSCI, V26, P3805, DOI 10.1523/JNEUROSCI.4305-05.2006
   Nestler EJ, 2004, NEUROPHARMACOLOGY, V47, P24, DOI 10.1016/j.neuropharm.2004.06.031
   O'Brien CP, 1998, J PSYCHOPHARMACOL, V12, P15, DOI 10.1177/026988119801200103
   O'Doherty J, 2004, SCIENCE, V304, P452, DOI 10.1126/science.1094285
   Olmstead MC, 2001, BEHAV NEUROSCI, V115, P394, DOI 10.1037/0735-7044.115.2.394
   Ornstein TJ, 2000, NEUROPSYCHOPHARMACOL, V23, P113, DOI 10.1016/S0893-133X(00)00097-X
   Paulus MP, 2014, NEUROPHARMACOLOGY, V76, P342, DOI 10.1016/j.neuropharm.2013.07.002
   Pelloux Y, 2007, PSYCHOPHARMACOLOGY, V194, P127, DOI 10.1007/s00213-007-0805-0
   Pelloux Y, 2013, EUR J NEUROSCI, V38, P3018, DOI 10.1111/ejn.12289
   Pelloux Y, 2012, NEUROPSYCHOPHARMACOL, V37, P2505, DOI 10.1038/npp.2012.111
   Perry JL, 2008, PSYCHOPHARMACOLOGY, V200, P1, DOI 10.1007/s00213-008-1173-0
   PIAZZA PV, 1993, P NATL ACAD SCI USA, V90, P11738, DOI 10.1073/pnas.90.24.11738
   PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295
   Piray P, 2010, NEURAL COMPUT, V22, P2334, DOI 10.1162/NECO_a_00009
   Porrino LJ, 2010, NEUROBIOLOGY ADDICTI, P241
   Price KL, 2013, PSYCHOPHARMACOLOGY, V226, P739, DOI 10.1007/s00213-011-2592-x
   Robbins TW, 2008, ANN NY ACAD SCI, V1141, P1, DOI 10.1196/annals.1441.020
   Robbins TW, 2012, TRENDS COGN SCI, V16, P81, DOI 10.1016/j.tics.2011.11.009
   Robbins TW, 1999, NATURE, V398, P567, DOI 10.1038/19208
   ROBERTS DCS, 1982, PHARMACOL BIOCHEM BE, V17, P901, DOI 10.1016/0091-3057(82)90469-5
   Robinson ESJ, 2009, BEHAV BRAIN RES, V196, P310, DOI 10.1016/j.bbr.2008.09.021
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Rogers RD, 1999, NEUROPSYCHOPHARMACOL, V20, P322, DOI 10.1016/S0893-133X(98)00091-8
   Rogers RD, 2001, CURR OPIN NEUROBIOL, V11, P250, DOI 10.1016/S0959-4388(00)00204-X
   Sanchez-Roige S, 2014, NEUROPSYCHOPHARMACOL, V39, P2919, DOI 10.1038/npp.2014.151
   Saunders BT, 2013, NEUROSCI BIOBEHAV R, V37, P1955, DOI 10.1016/j.neubiorev.2013.02.008
   Schiller D, 2010, NATURE, V463, P49, DOI 10.1038/nature08637
   Schmitzer-Torbert N, 2015, NEUROBIOL LEARN MEM, V118, P105, DOI 10.1016/j.nlm.2014.11.007
   Shiflett MW, 2010, J NEUROSCI, V30, P2951, DOI 10.1523/JNEUROSCI.1778-09.2010
   Sjoerds Z, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.107
   Stasiewicz PR, 2007, PSYCHOL ADDICT BEHAV, V21, P244, DOI 10.1037/0893-164X.21.2.244
   STEWART J, 1984, PSYCHOL REV, V91, P251, DOI 10.1037/0033-295X.91.2.251
   Sullivan EV, 2005, BIOL PSYCHIAT, V57, P768, DOI 10.1016/j.biopsych.2004.12.012
   TAYLOR JR, 1984, PSYCHOPHARMACOLOGY, V84, P405, DOI 10.1007/BF00555222
   Thorn CA, 2010, NEURON, V66, P781, DOI 10.1016/j.neuron.2010.04.036
   TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147
   Tronson NC, 2007, NAT REV NEUROSCI, V8, P262, DOI 10.1038/nrn2090
   Vanderschuren LJMJ, 2005, J NEUROSCI, V25, P8665, DOI 10.1523/JNEUROSCI.0925-05.2005
   Verdejo-Garcia A, 2006, CURR NEUROPHARMACOL, V4, P17, DOI 10.2174/157015906775203057
   Verdejo-Garcia A, 2009, NEUROPHARMACOLOGY, V56, P48, DOI 10.1016/j.neuropharm.2008.07.035
   Vezina P, 2009, NEUROPHARMACOLOGY, V56, P160, DOI 10.1016/j.neuropharm.2008.06.070
   Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI 10.1093/cercor/10.3.318
   Volkow ND, 2007, ARCH NEUROL-CHICAGO, V64, P1575, DOI 10.1001/archneur.64.11.1575
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
   Whelan R, 2012, NAT NEUROSCI, V15, P920, DOI 10.1038/nn.3092
   Wikler A., 1965, NARCOTICS, P7
   Willuhn I, 2012, P NATL ACAD SCI USA, V109, P20703, DOI 10.1073/pnas.1213460109
   Wise RA, 2008, NEUROTOX RES, V14, P169, DOI 10.1007/BF03033808
   Xie C, 2014, MOL PSYCHIATR, V19, P10, DOI 10.1038/mp.2012.169
   Xue YX, 2012, SCIENCE, V336, P241, DOI 10.1126/science.1215070
   Yin HH, 2005, EUR J NEUROSCI, V22, P513, DOI 10.1111/j.1460-9568.2005.04218.x
   Yin HH, 2004, EUR J NEUROSCI, V19, P181, DOI 10.1111/j.1460-9568.2004.03095.x
   Zapata A, 2010, J NEUROSCI, V30, P15457, DOI 10.1523/JNEUROSCI.4072-10.2010
NR 195
TC 611
Z9 623
U1 13
U2 226
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA
SN 0066-4308
EI 1545-2085
BN 978-0-8243-0267-2
J9 ANNU REV PSYCHOL
JI Annu. Rev. Psychol
PY 2016
VL 67
BP 23
EP 50
DI 10.1146/annurev-psych-122414-033457
PG 28
WC Psychology; Psychology, Multidisciplinary
WE Book Citation Index– Social Sciences & Humanities (BKCI-SSH); Book Citation Index– Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology
GA BE1PH
UT WOS:000368344500003
PM 26253543
HC Y
HP N
DA 2023-06-23
ER

PT C
AU Hani, AFM
   Ul Haq, N
   Kumar, D
   Wei, EHT
AF Hani, Ahmad Fadzil M.
   Ul Haq, Nuhman
   Kumar, Dileep
   Wei, Eric Ho Tatt
GP IEEE
TI Brain circuit model for drug addiction
SO 2014 5TH INTERNATIONAL CONFERENCE ON INTELLIGENT AND ADVANCED SYSTEMS
   (ICIAS 2014)
SE International Conference on Advanced Robotics and Intelligent Systems
LA English
DT Proceedings Paper
CT 5th International Conference on Intelligent and Advanced Systems (ICIAS)
CY JUN 03-05, 2014
CL Kuala Lumpur, MALAYSIA
SP Univ Teknologi Petronas, Lembaga Jurutera, IEEE Signal Proc Soc, IEEE Consumer Elect Soc, CAS
ID COCAINE; PLASTICITY
AB Drug addiction is one of the chronic mental disorders that results in a compulsive behavior to seek and consume drug. Recent statistics show that about 15% of world population is addicted with some sort of drug. It has been reported that drug addiction causes structural such as change in volume of gray and/or white matter, and functional neuroplasticity such as changes in the concentration of neurotransmitter (dopamine, glutamate, GABA etc.). Functional neuroplasticity can either block or excite neurotransmission among the neurons, hence altering the functionality of neurons and disrupt the control mechanism in the reward pathway and finally leading to an uncontrolled behavior. In drug addiction, the occurrence of uncontrolled behaviors in the different regions of reward pathways can be modeled using brain circuit to map directly the neural activities. This paper discusses the biological & chemical processes and control mechanisms involved in drug addiction develops a model of brain circuit under the influence of drug. It is observed that reduced inhibitory neurotransmission of GABA and increased excitatory neurotransmission of Glutamate in different regions of brain circuit contributes to reorganization of control mechanism by impaired encoding in control regions (PFC and Cigulate Gyrus). As a result, the drug related reward is considered as reinforcement of drug taking. Furthermore, it is also argued that estimation and quantification of GABA and Glutamate may provide significant differences between normal and drug addict brain that will lead to development of drug addiction severity monitoring system.
C1 [Hani, Ahmad Fadzil M.; Ul Haq, Nuhman; Kumar, Dileep; Wei, Eric Ho Tatt] Univ Teknol PETRONAS, Ctr Intelligent Signal & Imaging Res, Tronoh, Perak, Malaysia.
C3 Universiti Teknologi Petronas
RP Hani, AFM (通讯作者)，Univ Teknol PETRONAS, Ctr Intelligent Signal & Imaging Res, Tronoh, Perak, Malaysia.
EM fadzamo@petronas.com.my
RI Kumar, Dileep/AAV-3611-2020; Ul Haq, Nuhman/AGY-8616-2022
OI Kumar, Dileep/0000-0002-6220-475X
CR Adinoff B, 2011, NEUROIMAGING ADDICTI
   Breiter HC, 1997, NEURON, V19, P591, DOI 10.1016/S0896-6273(00)80374-8
   Chawla S., 2012, WORLD DRUG REPORT
   Clarke J., 2007, DRUGS FACING FACTS R
   Corominas M., 2009, SYNAPTIC PLASTICITY, P177
   Daglish MRC, 2008, BRIT J PSYCHIAT, V193, P65, DOI 10.1192/bjp.bp.107.041228
   Feltenstein MW, 2008, BRIT J PHARMACOL, V154, P261, DOI 10.1038/bjp.2008.51
   Hibell B., 2003, CONDUCTING SCH SURVE
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Karoly HC, 2013, ANN NY ACAD SCI, V1282, P71, DOI 10.1111/nyas.12074
   Koob GF, 2008, NEURON, V59, P11, DOI 10.1016/j.neuron.2008.06.012
   Kourrich S, 2007, J NEUROSCI, V27, P7921, DOI 10.1523/JNEUROSCI.1859-07.2007
   Kuroda R., 2013, EUROPEAN J NEUROSCIE, P1
   Luscher C, 2011, NEURON, V69, P650, DOI 10.1016/j.neuron.2011.01.017
   Ma N, 2010, NEUROIMAGE, V49, P738, DOI 10.1016/j.neuroimage.2009.08.037
   Ouwerkerk R, 2011, METHODS MOL BIOL, V711, P175, DOI 10.1007/978-1-61737-992-5_8
   Shen HW, 2009, J NEUROSCI, V29, P2876, DOI 10.1523/JNEUROSCI.5638-08.2009
   Shen LH, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/259349
   Volkow ND, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016573
NR 19
TC 0
Z9 0
U1 0
U2 6
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
SN 2374-3255
BN 978-1-4799-4653-2
J9 INT CONF ADV ROBOT
PY 2014
PG 5
WC Computer Science, Artificial Intelligence; Computer Science, Information
   Systems; Robotics
WE Conference Proceedings Citation Index - Science (CPCI-S)
SC Computer Science; Robotics
GA BB7MA
UT WOS:000345738000082
DA 2023-06-23
ER

PT J
AU Snow, D
   Lu, JH
AF Snow, Diane
   Lu, Julie Hue
TI Genetics and Genomics: Unraveling New Opportunities for Addiction
   Treatment and Education
SO JOURNAL OF ADDICTIONS NURSING
LA English
DT Editorial Material
ID ALCOHOL DEPENDENCE; DRUG-ADDICTION; RECEPTOR; POLYMORPHISM; THERAPY
C1 [Snow, Diane; Lu, Julie Hue] Univ Texas Arlington, Coll Nursing, Arlington, TX 76019 USA.
C3 University of Texas System; University of Texas Arlington
RP Snow, D (通讯作者)，Univ Texas Arlington, Coll Nursing, Arlington, TX 76019 USA.
CR [Anonymous], ESS GEN GEN NURS COM
   Anton RF, 2008, ARCH GEN PSYCHIAT, V65, P135, DOI 10.1001/archpsyc.65.2.135
   Arias AJ, 2008, ALCOHOL CLIN EXP RES, V32, P1159, DOI 10.1111/j.1530-0277.2008.00735.x
   Bart G, 2005, NEUROPSYCHOPHARMACOL, V30, P417, DOI 10.1038/sj.npp.1300598
   Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608
   Bonoiu AC, 2009, P NATL ACAD SCI USA, V106, P5546, DOI 10.1073/pnas.0901715106
   Chi KR, 2011, NAT MED, V17, P146, DOI 10.1038/nm0211-146
   Doehring A, 2011, EUR J PAIN, V15, P11, DOI 10.1016/j.ejpain.2010.06.004
   Garcia SPQ, 2011, J NURS EDUC, V50, P612, DOI 10.3928/01484834-20110715-04
   Green ED, 2011, NATURE, V470, P204, DOI 10.1038/nature09764
   Ito H, 2006, PREV MED, V42, P102, DOI 10.1016/j.ypmed.2005.10.006
   Kang TS, 2009, J CLIN PHARM THER, V34, P225, DOI 10.1111/j.1365-2710.2008.00986.x
   Malaiyandi V, 2006, MOL PSYCHIATR, V11, P400, DOI 10.1038/sj.mp.4001794
   Mroziewicz Margaret, 2010, Addict Sci Clin Pract, V5, P17
   National Institute on Drug Abuse, 2011, NIDA INFOFACTS NAT T
   Ray R, 2009, J NEUROGENET, V23, P252, DOI 10.1080/01677060802572887
   Renthal W, 2008, TRENDS MOL MED, V14, P341, DOI 10.1016/j.molmed.2008.06.004
   Volkow N. D., 2010, RES REPORT SERIES
NR 18
TC 0
Z9 0
U1 0
U2 3
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1088-4602
J9 J ADDICT NURS
JI J. Addict. Nurs.
PD MAY
PY 2012
VL 23
IS 2
BP 93
EP 96
DI 10.3109/10884602.2012.669914
PG 4
WC Substance Abuse; Nursing
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Nursing
GA 951WW
UT WOS:000304751800001
PM 22548614
DA 2023-06-23
ER

PT J
AU Cheron, J
   d'Exaerde, AD
AF Cheron, Julian
   d'Exaerde, Alban de Kerchove
TI Drug addiction: from bench to bedside
SO TRANSLATIONAL PSYCHIATRY
LA English
DT Review
ID DEEP BRAIN-STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; CONDITIONED
   PLACE PREFERENCE; INDUCED BEHAVIORAL SENSITIZATION; COCAINE-INDUCED
   PLASTICITY; MEDIAL PREFRONTAL CORTEX; VENTRAL TEGMENTAL AREA;
   NUCLEUS-ACCUMBENS; SYNAPTIC PLASTICITY; AMPA RECEPTOR
AB Drug addiction is responsible for millions of deaths per year around the world. Still, its management as a chronic disease is shadowed by misconceptions from the general public. Indeed, drug consumers are often labelled as "weak", "immoral" or "depraved". Consequently, drug addiction is often perceived as an individual problem and not societal. In technical terms, drug addiction is defined as a chronic, relapsing disease resulting from sustained effects of drugs on the brain. Through a better characterisation of the cerebral circuits involved, and the long-term modifications of the brain induced by addictive drugs administrations, first, we might be able to change the way the general public see the patient who is suffering from drug addiction, and second, we might be able to find new treatments to normalise the altered brain homeostasis. In this review, we synthetise the contribution of fundamental research to the understanding drug addiction and its contribution to potential novel therapeutics. Mostly based on drug-induced modifications of synaptic plasticity and epigenetic mechanisms (and their behavioural correlates) and after demonstration of their reversibility, we tried to highlight promising therapeutics. We also underline the specific temporal dynamics and psychosocial aspects of this complex psychiatric disease adding parameters to be considered in clinical trials and paving the way to test new therapeutic venues.
C1 [Cheron, Julian; d'Exaerde, Alban de Kerchove] Univ Libre Bruxelles ULB, ULB Neurosci Inst, Lab Neurophysiol, B-1070 Brussels, Belgium.
C3 Universite Libre de Bruxelles
RP d'Exaerde, AD (通讯作者)，Univ Libre Bruxelles ULB, ULB Neurosci Inst, Lab Neurophysiol, B-1070 Brussels, Belgium.
EM alban.de.kerchove@ulb.be
OI de Kerchove d'Exaerde, Alban/0000-0002-0682-5877
FU FRS-FNRS (Belgium); Fondation Simone et Pierre Clerdent; Fondation ULB
FX We thank Michele Zoli, Romain Icick and Daniel Rial for helpful comments
   and corrections on the manuscript. Julian Cheron is supported by a
   fellowship of the FRS-FNRS (Belgium). Alban de Kerchove dExaerde is a
   Research Director of the FRS-FNRS. FRS-FNRS (Belgium). Fondation Simone
   et Pierre Clerdent, Fondation ULB, supported this study.
CR Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X
   Abulseoud OA, 2014, NEUROPSYCHOPHARMACOL, V39, P1674, DOI 10.1038/npp.2014.14
   Achuta VS, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aan8784
   Addolorato G, 2012, NEUROPSYCHOPHARMACOL, V37, P163, DOI 10.1038/npp.2011.216
   Allis CD, 2016, NAT REV GENET, V17, P487, DOI 10.1038/nrg.2016.59
   Amiaz R, 2009, ADDICTION, V104, P653, DOI 10.1111/j.1360-0443.2008.02448.x
   Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244
   Authement ME, 2016, J NEUROPHYSIOL, V116, P1093, DOI 10.1152/jn.00238.2016
   Baptista MAS, 2004, J NEUROSCI, V24, P4723, DOI 10.1523/JNEUROSCI.0176-04.2004
   Bardo MT, 2000, PSYCHOPHARMACOLOGY, V153, P31, DOI 10.1007/s002130000569
   Barker JS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124445
   Barrett AC, 2005, J PHARMACOL EXP THER, V315, P858, DOI 10.1124/jpet.105.086033
   Barrett RM, 2008, LEARN MEMORY, V15, P460, DOI 10.1101/lm.917508
   Batra V, 2017, J NEUROSURG, V126, P1339, DOI 10.3171/2016.4.JNS152524
   BAYER VE, 1991, BRAIN RES, V559, P44, DOI 10.1016/0006-8993(91)90285-4
   Belin D, 2008, NEURON, V57, P432, DOI 10.1016/j.neuron.2007.12.019
   Belin-Rauscent A, 2016, BIOL PSYCHIAT, V79, P39, DOI 10.1016/j.biopsych.2015.01.004
   Bellone C, 2006, NAT NEUROSCI, V9, P636, DOI 10.1038/nn1682
   BENABID AL, 1991, LANCET, V337, P403, DOI 10.1016/0140-6736(91)91175-T
   BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638
   Bertran-Gonzalez J, 2008, J NEUROSCI, V28, P5671, DOI 10.1523/JNEUROSCI.1039-08.2008
   BOLAM JP, 1990, BRAIN RES, V529, P57, DOI 10.1016/0006-8993(90)90811-O
   Boudreau AC, 2005, J NEUROSCI, V25, P9144, DOI 10.1523/JNEUROSCI.2252-05.2005
   Brami-Cherrier K, 2005, J NEUROSCI, V25, P11444, DOI 10.1523/JNEUROSCI.1711-05.2005
   Brami-Cherrier K, 2009, J NEUROCHEM, V108, P1323, DOI 10.1111/j.1471-4159.2009.05879.x
   Brands B, 2008, J ADDICT DIS, V27, P37, DOI 10.1080/10550880802122620
   Brebner K, 2000, PHARMACOL BIOCHEM BE, V66, P857, DOI 10.1016/S0091-3057(00)00286-0
   Brodie JD, 2003, SYNAPSE, V50, P261, DOI 10.1002/syn.10278
   Brown TE, 2008, SYNAPSE, V62, P886, DOI 10.1002/syn.20562
   Caprioli D, 2018, BIOL PSYCHIAT, V84, P180, DOI 10.1016/j.biopsych.2017.08.018
   Chahrour M, 2008, SCIENCE, V320, P1224, DOI 10.1126/science.1153252
   Chen SA, 2006, NEUROPSYCHOPHARMACOL, V31, P2692, DOI 10.1038/sj.npp.1301008
   Chiamulera C, 2001, NAT NEUROSCI, V4, P873, DOI 10.1038/nn0901-873
   Chiamulera C, 2021, CURR OPIN PHARMACOL, V56, P39, DOI 10.1016/j.coph.2020.09.005
   Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11
   Chisholm A, 2021, J NEUROSCI, V41, P354, DOI 10.1523/JNEUROSCI.2103-20.2020
   Cho SS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006725
   Clark AM, 2017, ENEURO, V4, DOI 10.1523/ENEURO.0227-17.2017
   Conrad KL, 2008, NATURE, V454, P118, DOI 10.1038/nature06995
   Cox J, 2019, NAT REV NEUROSCI, V20, P482, DOI 10.1038/s41583-019-0189-2
   Creed M, 2015, SCIENCE, V347, P659, DOI 10.1126/science.1260776
   Dacher M, 2011, NEUROPHARMACOLOGY, V61, P1166, DOI 10.1016/j.neuropharm.2010.11.012
   Dackis C, 2005, NAT NEUROSCI, V8, P1431, DOI 10.1038/nn1105-1431
   Dackis CA, 2012, J SUBST ABUSE TREAT, V43, P303, DOI 10.1016/j.jsat.2011.12.014
   Darke S, 2016, ADDICTION, V111, P767, DOI 10.1111/add.13158
   De Backer JF, 2018, EMBO REP, V19, DOI 10.15252/embr.201745089
   De Crescenzo F, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002715
   De Groote A, 2021, FRONT SYST NEUROSCI, V15, DOI 10.3389/fnsys.2021.711350
   De Vries TJ, 1998, EUR J NEUROSCI, V10, P3565, DOI 10.1046/j.1460-9568.1998.00368.x
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Dobbs LK, 2019, NEUROPSYCHOPHARMACOL, V44, P805, DOI 10.1038/s41386-018-0286-3
   Dobbs LK, 2016, NEURON, V90, P1100, DOI 10.1016/j.neuron.2016.04.031
   Dong XW, 2017, BRAIN STRUCT FUNCT, V222, P3927, DOI 10.1007/s00429-017-1445-8
   Dong Y, 2006, NAT NEUROSCI, V9, P475, DOI 10.1038/nn1661
   Dore GM, 2011, ALCOHOL ALCOHOLISM, V46, P714, DOI 10.1093/alcalc/agr131
   Dos Santos M, 2018, BRAIN STRUCT FUNCT, V223, P913, DOI 10.1007/s00429-017-1532-x
   Durieux PF, 2012, EMBO J, V31, P640, DOI 10.1038/emboj.2011.400
   Edwards NJ, 2017, NAT NEUROSCI, V20, P438, DOI 10.1038/nn.4482
   Egervari G, 2018, NEUROSCI BIOBEHAV R, V85, P117, DOI 10.1016/j.neubiorev.2017.05.019
   Ekhtiari H, 2019, NEUROSCI BIOBEHAV R, V104, P118, DOI 10.1016/j.neubiorev.2019.06.007
   Ena SL, 2013, J NEUROSCI, V33, P8794, DOI 10.1523/JNEUROSCI.2989-12.2013
   Everitt BJ, 2016, ANNU REV PSYCHOL, V67, P23, DOI 10.1146/annurev-psych-122414-033457
   Ferrario CR, 2010, NEUROPSYCHOPHARMACOL, V35, P818, DOI 10.1038/npp.2009.190
   Freeze BS, 2013, J NEUROSCI, V33, P18531, DOI 10.1523/JNEUROSCI.1278-13.2013
   Garbutt JC, 2010, ALCOHOL CLIN EXP RES, V34, P1849, DOI 10.1111/j.1530-0277.2010.01273.x
   Gavin DP, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00346
   GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107
   Gerfen CR, 2011, ANNU REV NEUROSCI, V34, P441, DOI 10.1146/annurev-neuro-061010-113641
   GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780
   GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C
   Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0
   Goldberg LR, 2019, EUR J NEUROSCI, V50, P2453, DOI 10.1111/ejn.14060
   Greenberg BD, 2006, NEUROPSYCHOPHARMACOL, V31, P2384, DOI 10.1038/sj.npp.1301165
   Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134
   Grueter BA, 2013, P NATL ACAD SCI USA, V110, P1923, DOI 10.1073/pnas.1221742110
   Hamilton PJ, 2019, CURR OPIN NEUROBIOL, V59, P128, DOI 10.1016/j.conb.2019.05.005
   Handel AE, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-73
   Hartmann-Boyce J, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub5
   Heinze HJ, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.022.2009
   Heller EA, 2016, J NEUROSCI, V36, P4690, DOI 10.1523/JNEUROSCI.0013-16.2016
   Heller EA, 2014, NAT NEUROSCI, V17, P1720, DOI 10.1038/nn.3871
   Henny P, 2012, NAT NEUROSCI, V15, P613, DOI 10.1038/nn.3048
   Holley D., 2013, INTRO ZOOLOGY INVEST
   Hossain MK, 2020, EXPERT REV VACCINES, V19, P1105, DOI 10.1080/14760584.2020.1857738
   Hotsenpiller G, 2003, NEUROSCIENCE, V118, P123, DOI 10.1016/S0306-4522(02)00951-X
   Huang AS, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2017.0028
   Huntley GW, 2012, NAT REV NEUROSCI, V13, P743, DOI 10.1038/nrn3320
   Iida N, 2004, METHOD ENZYMOL, V390, P475
   Itzhak Y, 2002, NEUROPSYCHOPHARMACOL, V26, P130, DOI 10.1016/S0893-133X(01)00303-7
   Jablonka E, 1999, EPIGENETIC INHERITAN
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Johansen-Berg H, 2008, CEREB CORTEX, V18, P1374, DOI 10.1093/cercor/bhm167
   JOHNSON SW, 1992, J PHYSIOL-LONDON, V450, P455, DOI 10.1113/jphysiol.1992.sp019136
   Jordi E, 2013, P NATL ACAD SCI USA, V110, P9511, DOI 10.1073/pnas.1307116110
   Kahn R, 2009, DRUG ALCOHOL DEPEN, V103, P59, DOI 10.1016/j.drugalcdep.2009.03.011
   Kalda A, 2007, BEHAV BRAIN RES, V181, P76, DOI 10.1016/j.bbr.2007.03.027
   Kalivas PW, 2005, NEURON, V45, P647, DOI 10.1016/j.neuron.2005.02.005
   Kandel D.B., 2002, STAGES PATHWAYS DRUG, DOI DOI 10.1017/CBO9780511499777.003
   Karadurmus D, 2019, J NEUROSCI, V39, P7513, DOI 10.1523/JNEUROSCI.2454-18.2019
   Kasanetz F, 2013, MOL PSYCHIATR, V18, P729, DOI 10.1038/mp.2012.59
   Kauer JA, 2007, NAT REV NEUROSCI, V8, P844, DOI 10.1038/nrn2234
   Kelley AE, 2005, J COMP NEUROL, V493, P72, DOI 10.1002/cne.20769
   Kennedy PJ, 2013, NAT NEUROSCI, V16, P434, DOI 10.1038/nn.3354
   Knackstedt LA, 2010, BIOL PSYCHIAT, V67, P81, DOI 10.1016/j.biopsych.2009.07.018
   Kobylecki C, 2010, J NEUROCHEM, V114, P499, DOI 10.1111/j.1471-4159.2010.06776.x
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Kosten TR, 2014, DRUG ALCOHOL DEPEN, V140, P42, DOI 10.1016/j.drugalcdep.2014.04.003
   Kreek MJ, 2005, NAT NEUROSCI, V8, P1450, DOI 10.1038/nn1583
   Kroener S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037541
   Kuhn J, 2014, MOL PSYCHIATR, V19, P145, DOI 10.1038/mp.2012.196
   Kuhn J, 2007, J NEUROL NEUROSUR PS, V78, P1152, DOI 10.1136/jnnp.2006.113092
   Kuhn J, 2011, ADDICT BIOL, V16, P620, DOI 10.1111/j.1369-1600.2011.00337.x
   Kumar A, 2005, NEURON, V48, P303, DOI 10.1016/j.neuron.2005.09.023
   Kyzar EJ, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00222
   Kyzar EJ, 2015, NEUROSCI LETT, V601, P11, DOI 10.1016/j.neulet.2015.01.051
   Lalchandani RR, 2013, J NEUROSCI, V33, P14075, DOI 10.1523/JNEUROSCI.0692-13.2013
   LaPlant Q, 2010, NAT NEUROSCI, V13, P1137, DOI 10.1038/nn.2619
   Laviolette SR, 2002, J NEUROSCI, V22, P8653
   Le Moal M, 2007, EUR NEUROPSYCHOPHARM, V17, P377, DOI 10.1016/j.euroneuro.2006.10.006
   Lepack AE, 2020, SCIENCE, V368, P197, DOI 10.1126/science.aaw8806
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Levine AA, 2005, P NATL ACAD SCI USA, V102, P19186, DOI 10.1073/pnas.0509735102
   Levy D, 2007, J NEUROSCI, V27, P14179, DOI 10.1523/JNEUROSCI.4477-07.2007
   Li MD, 2009, NAT REV GENET, V10, P225, DOI 10.1038/nrg2536
   Liao HK, 2017, CELL, V171, P1495, DOI 10.1016/j.cell.2017.10.025
   LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4
   Ling W, 1998, NEUROPSYCHOPHARMACOL, V18, P403
   Lippman-Bell JJ, 2016, MOL CELL NEUROSCI, V76, P11, DOI 10.1016/j.mcn.2016.08.002
   Liu HY, 2008, ADDICT BIOL, V13, P40, DOI 10.1111/j.1369-1600.2007.00088.x
   Liu QS, 2005, NATURE, V437, P1027, DOI 10.1038/nature04050
   Liu XS, 2016, CELL, V167, P233, DOI 10.1016/j.cell.2016.08.056
   Lobo MK, 2013, J NEUROSCI, V33, P18381, DOI 10.1523/JNEUROSCI.1875-13.2013
   Loweth JA, 2014, NAT NEUROSCI, V17, P73, DOI 10.1038/nn.3590
   Lu L, 2007, BIOL PSYCHIAT, V61, P591, DOI 10.1016/j.biopsych.2006.04.011
   Luigjes J, 2019, NEUROPSYCHOL REV, V29, P116, DOI 10.1007/s11065-018-9393-5
   Ma TF, 2018, NAT NEUROSCI, V21, P373, DOI 10.1038/s41593-018-0081-9
   MacAskill AF, 2014, NAT NEUROSCI, V17, P1198, DOI 10.1038/nn.3783
   Mahoney JJ, 2020, J NEUROL SCI, V418, DOI 10.1016/j.jns.2020.117149
   Malvaez M, 2011, J NEUROSCI, V31, P16941, DOI 10.1523/JNEUROSCI.2747-11.2011
   Mameli M, 2007, SCIENCE, V317, P530, DOI 10.1126/science.1142365
   Mantione M, 2010, NEUROSURGERY, V66, P218, DOI 10.1227/01.NEU.0000360570.40339.64
   Martin M, 2006, NAT NEUROSCI, V9, P868, DOI 10.1038/nn1713
   Massart R, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2013.120
   Massart R, 2015, J NEUROSCI, V35, P8042, DOI 10.1523/JNEUROSCI.3053-14.2015
   Mattick RP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002209.pub2
   Maze I, 2011, P NATL ACAD SCI USA, V108, P3035, DOI 10.1073/pnas.1015483108
   Maze I, 2010, SCIENCE, V327, P213, DOI 10.1126/science.1179438
   Meinhardt MW, 2013, J NEUROSCI, V33, P2794, DOI 10.1523/JNEUROSCI.4062-12.2013
   Menegas W, 2015, ELIFE, V4, DOI 10.7554/eLife.10032
   Mizoguchi H, 2007, J NEUROCHEM, V102, P1548, DOI 10.1111/j.1471-4159.2007.04623.x
   Monsey MS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019958
   Mototani Y, 2018, PFLUG ARCH EUR J PHY, V470, P937, DOI 10.1007/s00424-018-2124-1
   Moussawi K, 2011, P NATL ACAD SCI USA, V108, P385, DOI 10.1073/pnas.1011265108
   Moussawi K, 2009, NAT NEUROSCI, V12, P182, DOI 10.1038/nn.2250
   Mulholland PJ, 2016, TRENDS NEUROSCI, V39, P472, DOI 10.1016/j.tins.2016.04.007
   Murphy DD, 1997, P NATL ACAD SCI USA, V94, P1482, DOI 10.1073/pnas.94.4.1482
   Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   Nestler EJ, 2019, NEURON, V102, P48, DOI 10.1016/j.neuron.2019.01.016
   Nestler Eric J, 2005, Sci Pract Perspect, V3, P4
   Nestler Eric J, 2013, Dialogues Clin Neurosci, V15, P431
   Nestler EJ, 2014, NEUROPHARMACOLOGY, V76, P259, DOI 10.1016/j.neuropharm.2013.04.004
   Nielsen DA, 2014, METHODS MOL BIOL, V1175, P589, DOI 10.1007/978-1-4939-0956-8_15
   Nimitvilai S, 2016, NEUROPSYCHOPHARMACOL, V41, P1112, DOI 10.1038/npp.2015.250
   Nudelman AS, 2010, HIPPOCAMPUS, V20, P492, DOI 10.1002/hipo.20646
   Nugent FS, 2007, NATURE, V446, P1086, DOI 10.1038/nature05726
   Otis JM, 2019, NEURON, V103, P423, DOI 10.1016/j.neuron.2019.05.018
   Parvaz MA, 2016, JAMA PSYCHIAT, V73, P1127, DOI 10.1001/jamapsychiatry.2016.2181
   Pascoli V, 2018, NATURE, V564, P366, DOI 10.1038/s41586-018-0789-4
   Pascoli V, 2014, NATURE, V509, P459, DOI 10.1038/nature13257
   Pascoli V, 2012, NATURE, V481, P71, DOI 10.1038/nature10709
   PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303
   Penzo MA, 2021, TRENDS NEUROSCI, V44, P538, DOI 10.1016/j.tins.2021.03.001
   Perez SM, 2018, J NEUROSCI, V38, P10607, DOI 10.1523/JNEUROSCI.2629-16.2018
   Peters J, 2006, PSYCHOPHARMACOLOGY, V186, P143, DOI 10.1007/s00213-006-0372-9
   Pettorruso M, 2019, ADDICT BEHAV, V93, P246, DOI 10.1016/j.addbeh.2019.02.013
   Phillips KA, 2014, NEUROPHARMACOLOGY, V87, P150, DOI 10.1016/j.neuropharm.2014.04.002
   Piazza PV, 2013, PSYCHOPHARMACOLOGY, V229, P387, DOI 10.1007/s00213-013-3224-4
   Pierce RC, 2006, NEUROSCI BIOBEHAV R, V30, P215, DOI 10.1016/j.neubiorev.2005.04.016
   Pignatelli M, 2015, NEURON, V86, P1145, DOI 10.1016/j.neuron.2015.04.015
   Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0
   Porta M, 2009, NEUROLOGY, V73, P1375, DOI 10.1212/WNL.0b013e3181bd809b
   Renthal W, 2009, NEURON, V62, P335, DOI 10.1016/j.neuron.2009.03.026
   Reynoard J, 2020, EXPERT OPIN DRUG MET, V16, P309, DOI 10.1080/17425255.2020.1740681
   Roberts DCS, 1996, NEUROPSYCHOPHARMACOL, V15, P417, DOI 10.1016/0893-133X(96)00002-4
   Robinson TE, 1999, EUR J NEUROSCI, V11, P1598, DOI 10.1046/j.1460-9568.1999.00576.x
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Robison AJ, 2011, NAT REV NEUROSCI, V12, P623, DOI 10.1038/nrn3111
   Rogge GA, 2013, NEUROPSYCHOPHARMACOL, V38, P94, DOI 10.1038/npp.2012.154
   Romieu P, 2008, J NEUROSCI, V28, P9342, DOI 10.1523/JNEUROSCI.0379-08.2008
   Roth GA, 2018, LANCET, V392, P1736, DOI [10.1016/S0140-6736(18)32203-7, 10.1016/s0140-6736(18)32203-7]
   Sadakierska-Chudy A, 2017, NEUROTOX RES, V32, P141, DOI 10.1007/s12640-017-9728-7
   Sadler-Smith E, 2015, CREATIVITY RES J, V27, P342, DOI 10.1080/10400419.2015.1087277
   Sadri-Vakili G, 2010, J NEUROSCI, V30, P11735, DOI 10.1523/JNEUROSCI.2328-10.2010
   Sammaraiee Y, 2019, MULT SCLER RELAT DIS, V27, P95, DOI 10.1016/j.msard.2018.10.009
   Sanna A, 2021, CURR OPIN PHARMACOL, V56, P61, DOI 10.1016/j.coph.2020.11.001
   Schenk S, 1997, PHARMACOL BIOCHEM BE, V57, P543, DOI 10.1016/S0091-3057(96)00447-9
   Scheyer AF, 2016, BIOL PSYCHIAT, V80, P661, DOI 10.1016/j.biopsych.2016.04.003
   Schiffmann SN, 2007, PROG NEUROBIOL, V83, P277, DOI 10.1016/j.pneurobio.2007.05.001
   Schmidt HD, 2012, J NEUROCHEM, V120, P202, DOI 10.1111/j.1471-4159.2011.07571.x
   Scobie KN, 2014, P NATL ACAD SCI USA, V111, P2005, DOI 10.1073/pnas.1319703111
   Selvaraj BT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02729-0
   Shearer J, 2009, ADDICTION, V104, P224, DOI 10.1111/j.1360-0443.2008.02437.x
   Shen WX, 2008, SCIENCE, V321, P848, DOI 10.1126/science.1160575
   Shen Y, 2020, FRONT NEURAL CIRCUIT, V14, DOI 10.3389/fncir.2020.00041
   Shohat S, 2021, BIOL PSYCHIAT, V89, P32, DOI 10.1016/j.biopsych.2020.05.019
   Slattery DA, 2005, NEUROPSYCHOPHARMACOL, V30, P2065, DOI 10.1038/sj.npp.1300734
   Smith ACW, 2018, GENES BRAIN BEHAV, V17, DOI 10.1111/gbb.12424
   SMITH AD, 1990, TRENDS NEUROSCI, V13, P259
   Smith ACW, 2014, NAT NEUROSCI, V17, P1655, DOI 10.1038/nn.3846
   Sora I, 2001, P NATL ACAD SCI USA, V98, P5300, DOI 10.1073/pnas.091039298
   Spencer S, 2017, BIOL PSYCHIAT, V81, P616, DOI 10.1016/j.biopsych.2016.08.033
   Strafella AP, 2003, BRAIN, V126, P2609, DOI 10.1093/brain/awg268
   Stuber GD, 2008, SCIENCE, V321, P1690, DOI 10.1126/science.1160873
   Sun HS, 2012, J NEUROSCI, V32, P17454, DOI 10.1523/JNEUROSCI.1357-12.2012
   Sun J, 2008, NEUROSCI LETT, V441, P72, DOI 10.1016/j.neulet.2008.05.010
   Suto N, 2004, NEUROPSYCHOPHARMACOL, V29, P2149, DOI 10.1038/sj.npp.1300533
   Tan KR, 2011, TRENDS NEUROSCI, V34, P188, DOI 10.1016/j.tins.2011.01.004
   Tanda G, 1997, SCIENCE, V276, P2048, DOI 10.1126/science.276.5321.2048
   Tardelli VS, 2020, PSYCHOPHARMACOLOGY, V237, P2233, DOI 10.1007/s00213-020-05563-3
   Tecuapetla F, 2009, J NEUROSCI, V29, P8977, DOI 10.1523/JNEUROSCI.6145-08.2009
   Thomas MJ, 2001, NAT NEUROSCI, V4, P1217, DOI 10.1038/nn757
   Tsankova NM, 2006, NAT NEUROSCI, V9, P519, DOI 10.1038/nn1659
   Twomey EC, 2018, NEURON, V99, P956, DOI 10.1016/j.neuron.2018.07.027
   Tzschentke TM, 2007, ADDICT BIOL, V12, P227, DOI 10.1111/j.1369-1600.2007.00070.x
   Valencia-Alfonso CE, 2012, BIOL PSYCHIAT, V71, pE35, DOI 10.1016/j.biopsych.2011.12.013
   Valjent E, 2010, NEUROPSYCHOPHARMACOL, V35, P401, DOI 10.1038/npp.2009.143
   Vanderschuren LJMJ, 2000, PSYCHOPHARMACOLOGY, V151, P99, DOI 10.1007/s002130000493
   Vassoler FM, 2008, J NEUROSCI, V28, P8735, DOI 10.1523/JNEUROSCI.5277-07.2008
   Vassoler FM, 2013, NAT NEUROSCI, V16, P42, DOI 10.1038/nn.3280
   Ventura A, 2004, P NATL ACAD SCI USA, V101, P10380, DOI 10.1073/pnas.0403954101
   Verrico CD, 2013, EXPERT OPIN INV DRUG, V22, P1549, DOI 10.1517/13543784.2013.836488
   Vezina P, 2002, J NEUROSCI, V22, P4654, DOI 10.1523/JNEUROSCI.22-11-04654.2002
   Vezina P, 2009, NEUROPHARMACOLOGY, V56, P160, DOI 10.1016/j.neuropharm.2008.06.070
   Vicente AM, 2016, CURR BIOL, V26, pR267, DOI 10.1016/j.cub.2016.02.036
   Vocci FJ, 2005, CURR OPIN PSYCHIATR, V18, P265, DOI 10.1097/01.yco.0000165596.98552.02
   Voges J, 2013, WORLD NEUROSURG, V80, DOI 10.1016/j.wneu.2012.07.011
   Volkow ND, 2004, MOL PSYCHIATR, V9, P557, DOI 10.1038/sj.mp.4001507
   Vorspan F, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-01050-7
   Vorspan F, 2020, PSYCHOPHARMACOLOGY, V237, P3399, DOI 10.1007/s00213-020-05620-x
   Vorspan F, 2011, ADDICTION, V106, P1535, DOI 10.1111/j.1360-0443.2011.03450.x
   Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985
   Wang L, 2010, NEUROPSYCHOPHARMACOL, V35, P913, DOI 10.1038/npp.2009.193
   Wang TR, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.5.FOCUS18163
   Whitehead G, 2017, NEUROPHARMACOLOGY, V112, P221, DOI 10.1016/j.neuropharm.2016.08.022
   Wolf ME, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00072
   Wu XQ, 2018, BEHAV BRAIN RES, V353, P129, DOI 10.1016/j.bbr.2018.07.004
   Yamini D, 2014, ALCOHOL ALCOHOLISM, V49, P453, DOI 10.1093/alcalc/agu028
   Yang HJ, 2017, CELL REP, V20, P319, DOI 10.1016/j.celrep.2017.06.046
   Yasui DH, 2007, P NATL ACAD SCI USA, V104, P19416, DOI 10.1073/pnas.0707442104
   Young KA, 2014, J NEUROSCI, V34, P5038, DOI 10.1523/JNEUROSCI.4977-13.2014
   Zhu YJ, 2016, NATURE, V530, P219, DOI 10.1038/nature16954
NR 252
TC 7
Z9 7
U1 2
U2 10
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2158-3188
J9 TRANSL PSYCHIAT
JI Transl. Psychiatr.
PD AUG 12
PY 2021
VL 11
IS 1
AR 424
DI 10.1038/s41398-021-01542-0
PG 14
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA UA6YF
UT WOS:000685305100002
PM 34385417
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Olsen, Y
AF Olsen, Yngvild
TI What Is Addiction? History, Terminology, and Core Concepts
SO MEDICAL CLINICS OF NORTH AMERICA
LA English
DT Article
DE Addiction; Substance use disorders; Definition; Terminology
ID DRUG-USE; ALCOHOL; HEALTH
C1 [Olsen, Yngvild] Inst Behav Resources Inc, REACH Hlth Serv, 2104 Maryland Ave, Baltimore, MD 21218 USA.
RP Olsen, Y (通讯作者)，Inst Behav Resources Inc, REACH Hlth Serv, 2104 Maryland Ave, Baltimore, MD 21218 USA.
EM Yngvild.olsen@gmail.com
CR Aliferis L., 2017, STYLEBOOK AP DIRECTS
   American Society of Addiction Medicine, 2019, DEF ADD
   [Anonymous], 2016, ABMS OFFICIALLY RECO
   [Anonymous], 2007, AM HERITAGE MED DICT
   [Anonymous], 2012, FARLEX PARTNER MED D
   [Anonymous], 2004, COLLINS DICT MED
   APA, 2013, DIAGNOSTIC STAT MANU, DOI 10.5555/appi.books.9780890425596.x00pre
   Ashford RD, 2019, SUBST USE MISUSE, V54, P1376, DOI 10.1080/10826084.2019.1581221
   Biondich AS, 2016, EMERG MED INT, V2016, DOI 10.1155/2016/4048764
   Botticelli MP, 2017, CHANGING LANGUAGE AD
   Burlacu A, 2019, INT UROL NEPHROL, V51, P839, DOI 10.1007/s11255-019-02129-x
   Cadet JL, 2016, MOL NEUROBIOL, V53, P545, DOI 10.1007/s12035-014-9040-y
   Commission on Accreditation of Rehabilitation Facilities, 2019, NEW CARF STAND ADDR
   Crothers TD, 1902, DRUG HABITS THEIR TR, P61
   Dube SR, 2003, PEDIATRICS, V111, P564, DOI 10.1542/peds.111.3.564
   Foddy B, 2011, ADDICTION, V106, P25, DOI 10.1111/j.1360-0443.2010.03158.x
   Gerrard M, 2012, PSYCHOL ADDICT BEHAV, V26, P550, DOI 10.1037/a0027711
   Gussow L., 2013, EMERG MED NEWS, V35, P25
   Gutierrez J, 2014, DIABETES EDUCATOR, V40, P214, DOI 10.1177/0145721714521872
   Hemmati R, 2019, J RELIG HEALTH, V58, P1203, DOI 10.1007/s10943-018-0722-z
   Juster RP, 2016, DEV PSYCHOPATHOL, V28, P1117, DOI 10.1017/S0954579416000730
   Kerr WC, 2017, AM J PREV MED, V52, P469, DOI 10.1016/j.amepre.2016.09.021
   Kranzler HR, 2008, ALCOHOL RES HEALTH, V31, P93
   Manhica H, 2021, ADDICTION, V116, P1747, DOI 10.1111/add.15336
   Mendoza S, 2019, MED ANTHROPOL Q, V33, P242, DOI 10.1111/maq.12449
   Musto DF, 1999, ORIGINS NARCOTIC CON, V3rd
   Nathan PE, 2016, ANNU REV CLIN PSYCHO, V12, P29, DOI 10.1146/annurev-clinpsy-021815-093546
   National Academies of Sciences Engineering and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Medication-Assisted Treatment for Opioid Use Disorder, 2019, MED OP US DIS SAV LI
   National Institute on Drug Abuse (NIDA), 2020, DRUG MIS ADD
   O'Brien CP., 2018, GOODMAN GILMANS PHAR
   Office of the Surgeon General, 2016, TEEN INS DRUGS ALC
   Olsen Y, 2019, OPIOID EPIDEMIC WHAT, P3
   Restar AJ, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.1015
   Rosenthal RJ, 2019, ADDICT RES THEORY, V27, P437, DOI 10.1080/16066359.2018.1543412
   Scully JL, 2004, EMBO REP, V5, P650, DOI 10.1038/sj.embor.7400195
   Slutske WS, 2019, ADDICTION, V114, P815, DOI 10.1111/add.14534
   Substance Abuse and Mental Health Services Administration, 2010, REC OR SYST CAR ROSC
   Substance Abuse and Mental Health Services Administration, 2018, TREATMENT IMPROVEMEN
   U.S. Department of health and human services (HHS) office of the surgeon general, 2016, FAC ADD AM SURG GEN, P1
   Volkow ND, 2019, ASAM PRINCIPLES ADDI, P11
   Vu M, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6430-0
   White W., 2014, SLAYING DRAGON HIST, V2nd, P1
   White W., 2014, SLAYING DRAGON HIST, V2nd, P33
   White W., SLAYING DRAGON HIST, V2nd
   Winstanley EL, 2008, DRUG ALCOHOL DEPEN, V92, P173, DOI 10.1016/j.drugalcdep.2007.07.012
NR 45
TC 4
Z9 4
U1 2
U2 19
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0025-7125
EI 1557-9859
J9 MED CLIN N AM
JI Med. Clin. N. Am.
PD JAN
PY 2022
VL 106
IS 1
BP 1
EP 12
DI 10.1016/j.mcna.2021.08.001
EA NOV 2021
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine
GA XD7NI
UT WOS:000722890800003
PM 34823724
DA 2023-06-23
ER

PT J
AU Nemati, Z
   Matlabi, H
AF Nemati, Zeinab
   Matlabi, Hossein
TI Assessing behavioral patterns of Internet addiction and drug abuse among
   high school students
SO PSYCHOLOGY RESEARCH AND BEHAVIOR MANAGEMENT
LA English
DT Article
DE Internet; drug abuse; adolescence; addiction; behavior
ID TAIWANESE
AB Background: Internet addiction and drug abuse isolate adolescents from their family and friends and cause damage to their health, relations, emotions, and spirit. In the society, adolescents' addiction extracts high cost on health care, educational failure and mental health services.
   Objectives: The aim of this study was to assess the behavioral patterns of Internet and drug addiction among urban and rural students in Urmia, Iran.
   Methods: A sectional and descriptive-analytical approach with stratified sampling method was employed to recruit 385 high school students from urban and rural areas. The Internet Addiction Test (IAT) and the Addiction Acknowledgement Scale (AAS) were used for data collection.
   Results: The total score of Internet addiction among the students was 41.72 +/- 17.41. Approximately two-third of the students were not addicted to the Internet. The mean score of the AAS was 1.87 +/- 1.23 among boys and 1.75 +/- 1.31 among girls. Moreover, 8.31% of the students were prone to abusing substances. A statistically significant relationship was found between mother's literacy level and Internet addiction behavior of students (p=0.009).
   Conclusion: Concentrating on adolescents' behavioral patterns and their tendency toward misusing Internet and drugs is a notable procedure. Therefore, focusing on adolescents' health and institutionalizing appropriate training programs for adolescents and their families are vital.
C1 [Nemati, Zeinab; Matlabi, Hossein] Tabriz Univ Med Sci, Fac Hlth Sci, Dept Hlth Educ & Promot, Attar Neishabouri St, Tabriz 5165665811, Iran.
C3 Tabriz University of Medical Science
RP Matlabi, H (通讯作者)，Tabriz Univ Med Sci, Fac Hlth Sci, Dept Hlth Educ & Promot, Attar Neishabouri St, Tabriz 5165665811, Iran.
EM hm1349@gmail.com
RI Matlabi, Hossein/M-2932-2017
OI Matlabi, Hossein/0000-0001-6922-692X
FU Tabriz University of Medical Sciences [5/53/3183-31/08/2014]
FX The study was financed by a grant from the Tabriz University of Medical
   Sciences (grant number: 5/53/3183-31/08/2014). We really appreciate
   Deputy of Research and Technology for their valuable supports. We also
   are most grateful for the assistance given by Mrs. Ghalichi, the
   facilitators, and the participants. Last, but not the least, we would
   like to show our gratitude to Professor Hamid Allahverdipour and Doctor
   Kousha who provided insight and expertise that greatly assisted the
   research.
CR Aghamolaei Teamur, 2013, Int J High Risk Behav Addict, V2, P34, DOI 10.5812/ijhrba.8842
   Aubi E., 2012, PAJOOHANDEH J, V17, P114
   Babaei Heydarabadi A., 2015, INT J HIGH RISK BEHA, V4, DOI 10.5812/ijhrba.22350v2
   Bahri N, 2011, MOD CARE J, V8, P166
   Bashirian S., 2012, J FASA U MED SCI, V2, P156
   Brook JS, 2006, J ADOLESCENT HEALTH, V38, P26, DOI 10.1016/j.jadohealth.2004.08.004
   Chen MY, 2007, INT J NURS STUD, V44, P59, DOI 10.1016/j.ijnurstu.2005.11.015
   Chen MY, 2003, PUBLIC HEALTH NURS, V20, P104, DOI 10.1046/j.1525-1446.2003.20204.x
   Ghahremani L, 2013, MEDIA, V4, P44
   Golmakani N, 2013, J MIDWIFERY REPROD H, V1, P42
   Guo L, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007569
   Hasanzadeh R, 2010, Q J ED PSYCHOL, V1, P69
   HAWKINS JD, 1992, PSYCHOL BULL, V112, P64, DOI 10.1037/0033-2909.112.1.64
   Khagemogahi N, 2010, AHVAZ MED J, V9, P360
   Khazaie H., 2013, Journal of Kermanshah University of Medical Sciences, V17, P197
   Ko CH, 2005, J NERV MENT DIS, V193, P273, DOI 10.1097/01.nmd.0000158373.85150.57
   Lam LT, 2009, CYBERPSYCHOL BEHAV, V12, P551, DOI 10.1089/cpb.2009.0036
   Masoudnia E., 2013, Iranian Journal of Epidemiology, V8, P15
   Mohamadian H, 2013, INT J PREVENTIVE MED, V4, P42
   Nikmanesh Z, 2012, INT J HIGH RISK BEHA, V1, P20
   Patrick M. E., 2016, OXFORD HDB SUBSTANCE
   Pourshahbaz A, 2006, SOC WELFARE, V5, P31
   Rostami R, 2007, PSCHOLOGICAL RES, V10, P11
   Safari Hajat Aghaii Saideh, 2012, Int J High Risk Behav Addict, V1, P92, DOI 10.5812/ijhrba.5330
   Tamanaeifar MR, 2014, BIMONTHLY HORMOZGAN, V17, P69
   WEED NC, 1992, J PERS ASSESS, V58, P389, DOI 10.1207/s15327752jpa5802_15
   WHO, MAT NEW BORN CHILD A
   Young K. S., 2009, CYBERPSYCHOL BEHAV, V11, P237, DOI DOI 10.1089/CPB.1998.1.237
   Zareipour M., 2012, J NURS RES, V9, P84
NR 29
TC 11
Z9 13
U1 5
U2 20
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1179-1578
J9 PSYCHOL RES BEHAV MA
JI Psychol. Res. Behav. Manag.
PY 2017
VL 10
BP 39
EP 45
DI 10.2147/PRBM.S123224
PG 7
WC Psychology, Clinical; Psychiatry; Psychology, Multidisciplinary
WE Social Science Citation Index (SSCI)
SC Psychology; Psychiatry
GA EJ5UE
UT WOS:000393283100001
PM 28182139
OA gold, Green Published, Green Submitted
DA 2023-06-23
ER

PT J
AU Sussman, S
   Reynaud, M
   Aubin, HJ
   Leventhal, AM
AF Sussman, Steve
   Reynaud, Michel
   Aubin, Henri-Jean
   Leventhal, Adam M.
TI Drug Addiction, Love, and the Higher Power
SO EVALUATION & THE HEALTH PROFESSIONS
LA English
DT Article
DE addiction; love; higher power
ID REWARD; RELIGION
AB This discussion piece suggests that reliance on a Higher Power in drug abuse recovery programs is entertained among some addicts for its psychobiological effects. Prayer, meditation, early romantic love, and drug abuse may have in common activation of mesolimbic dopaminergic pathways of the brain and the generation of intense emotional states. In this sense, reliance on a Higher Power may operate as a substitute addiction, which replaces the psychobiological functions formerly served by drug use. Implications of this perspective are discussed.
C1 [Sussman, Steve] Univ So Calif, Inst Hlth Promot & Dis Prevent Res, Dept Prevent Med, Alhambra, CA 91803 USA.
   [Sussman, Steve; Leventhal, Adam M.] Univ So Calif, Dept Psychol, Alhambra, CA 91803 USA.
   [Reynaud, Michel; Aubin, Henri-Jean] Univ Paris Sud, Hop Paul Brousse, Dept Addict & Psychiat, INSERM U699, Villejuif, France.
C3 University of Southern California; University of Southern California;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Paul-Brousse - APHP; Institut National de la Sante et de la Recherche
   Medicale (Inserm); UDICE-French Research Universities; Universite Paris
   Saclay
RP Sussman, S (通讯作者)，Univ So Calif, Inst Hlth Promot & Dis Prevent Res, Dept Prevent Med, 1000 S Fremont Ave,Unit 8,Bldg A-6,Room 6129, Alhambra, CA 91803 USA.
EM ssussma@usc.edu
RI Aubin, Henri-Jean/AAP-8605-2021; , Aubin/AAT-9739-2021
FU National Institute on Drug Abuse [DA020138, K08-DA025041]
FX The author(s) disclosed receipt of the following financial support for
   the research and/or authorship of this article: grants from National
   Institute on Drug Abuse (#DA020138 and #K08-DA025041).
CR Alcoholics Anonymous, 1981, 12 STEPS 12 TRADITIO
   Aron A, 2005, J NEUROPHYSIOL, V94, P327, DOI 10.1152/jn.00838.2004
   Borras L, 2010, SUBST USE MISUSE, V45, P2357, DOI 10.3109/10826081003747611
   Fisher HE, 2010, J NEUROPHYSIOL, V104, P51, DOI 10.1152/jn.00784.2009
   HERRNSTEIN RJ, 1991, J ECON PERSPECT, V5, P137, DOI 10.1257/jep.5.3.137
   Kjaer TW, 2002, COGNITIVE BRAIN RES, V13, P255, DOI 10.1016/S0926-6410(01)00106-9
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Krause N, 2011, J RELIG HEALTH, V50, P20, DOI 10.1007/s10943-010-9373-4
   Lesieur Henry R., 1993, Journal of Addictive Diseases, V12, P89, DOI 10.1300/J069v12n03_08
   Leventhal AM, 2008, AM J ADDICTION, V17, P218, DOI 10.1080/10550490802019774
   Markou A, 1998, NEUROPSYCHOPHARMACOL, V18, P135, DOI 10.1016/S0893-133X(97)00113-9
   Reynaud M, 2010, AM J DRUG ALCOHOL AB, V36, P261, DOI 10.3109/00952990.2010.495183
   Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI 10.1146/annurev.psych.54.101601.145237
   Schjodt U, 2008, NEUROSCI LETT, V443, P165, DOI 10.1016/j.neulet.2008.07.068
   Schjoedt U, 2009, SOC COGN AFFECT NEUR, V4, P199, DOI 10.1093/scan/nsn050
   Shariff AF, 2007, PSYCHOL SCI, V18, P803, DOI 10.1111/j.1467-9280.2007.01983.x
   Sussman S, 2008, DRUG ABUSE: CONCEPTS, PREVENTION, AND CESSATION, P1
   Sussman S, 2008, J DRUG EDUC, V38, P167, DOI 10.2190/DE.38.2.e
   Sussman S, 2010, SEX ADDICT COMPULS, V17, P31, DOI 10.1080/10720161003604095
   Sussman S, 2011, EVAL HEALTH PROF, V34, P3, DOI 10.1177/0163278710380124
   Sussman S, 2010, SUBST USE MISUSE, V45, P2383
   Taylor C. Z., 2002, PASTORAL PSYCHOL, V50, P291
   Tonigan JS, 2002, J STUD ALCOHOL, V63, P534, DOI 10.15288/jsa.2002.63.534
   Younger J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013309
   1976, ALCOHOLICS ANONYMOUS
NR 25
TC 11
Z9 12
U1 2
U2 31
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0163-2787
EI 1552-3918
J9 EVAL HEALTH PROF
JI Eval. Health Prof.
PD SEP
PY 2011
VL 34
IS 3
SI SI
BP 362
EP 370
DI 10.1177/0163278711401002
PG 9
WC Health Care Sciences & Services; Health Policy & Services
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services
GA 826BJ
UT WOS:000295326100008
PM 21411471
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Luongo, NM
   Dong, HR
   Kerr, TH
   Milloy, MJS
   Hayashi, K
   Richardson, LA
AF Luongo, Nicole M.
   Dong, Huiru
   Kerr, Thomas H.
   Milloy, M-J S.
   Hayashi, Kanna
   Richardson, Lindsey A.
TI Income generation and attitudes towards addiction treatment among people
   who use illicit drugs in a Canadian setting
SO ADDICTIVE BEHAVIORS
LA English
DT Article
DE Drug use; Addiction treatment; Income generation; Homelessness;
   Addiction treatment
ID SEX WORK; INJECT DRUGS; TREATMENT READINESS; USE PATTERNS; COHORT;
   INCARCERATION; EMPLOYMENT; VANCOUVER; IMPACT; STIGMA
AB Introduction: Socioeconomically marginalized people who use illicit drugs (PWUD) often engage in alternative income generating activities to meet their basic needs. These activities commonly carry a number of health and social risks, which may prompt some PWUD to consider addiction treatment to reduce their drug use or drug-related expenses. We sought to determine whether engaging in certain forms of income generation was independently associated with self-reported need for addiction treatment among a cohort of PWUD in Vancouver, Canada.
   Methods: Data from two prospective cohorts of PWUD in Vancouver were used in generalized estimating equations to identify factors associated with self-reported need for addiction treatment, with a focus on income generating activities.
   Results: Between June 2013 and May 2014, 1285 respondents participated in the study of whom 483 (34.1%) were female and 396 (30.8%) indicated that they needed addiction treatment. In final multivariate analyses, key factors significantly and positively associated with self-reported need for addiction treatment included engaging in illegal income generating activities (adjusted odds ratio [AOR] = 1.96, 95% confidence interval [CI]: 1.11-3.46); sex work (AOR = 1.61, 95% CI: 1.05-2.47), homelessness (AOR = 1.65, 95% CI: 1.22-2.25); and recent engagement in counselling (AOR = 1.85, 95% CI: 1.40-2.44).
   Discussion: Our results suggest that key markers of socioeconomic marginalization are strongly linked with a stated need for addiction treatment. These findings underscore the need to provide appropriate and accessible addiction treatment access to marginalized PWUD and to consider alternative approaches to reduce socioeconomic disadvantage. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Luongo, Nicole M.; Richardson, Lindsey A.] Univ British Columbia, Dept Sociol, 6303 NW Marine Dr, Vancouver, BC V6T 1Z1, Canada.
   [Dong, Huiru; Kerr, Thomas H.; Milloy, M-J S.; Hayashi, Kanna; Richardson, Lindsey A.] St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
   [Kerr, Thomas H.; Milloy, M-J S.; Hayashi, Kanna] Univ British Columbia, St Pauls Hosp, Div Aids, Fac Med, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
C3 University of British Columbia; B.C. Centre for Excellence in HIV/AIDS;
   St. Paul's Hospital; St. Paul's Hospital; University of British Columbia
RP Richardson, LA (通讯作者)，St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
EM uhri-lr@cfenet.ubc.ca
RI Milloy, M-J/AAY-3618-2020; Richardson, Lindsey/AAU-3753-2021
FU NIDA NIH HHS [U01 DA038886, R01 DA011591, R01 DA021525, U01 DA021525]
   Funding Source: Medline
CR Alley ES, 2014, SUBST USE MISUSE, V49, P253, DOI 10.3109/10826084.2013.825920
   Arunachalam R, 2013, J HUM RESOUR, V48, P345
   Bauer IE, 2015, AM J ADDICTION, V24, P15, DOI 10.1111/ajad.12172
   Bennett T, 2008, AGGRESS VIOLENT BEH, V13, P107, DOI 10.1016/j.avb.2008.02.001
   Benoit C, 2015, SOCIOL HEALTH ILL, V37, P437, DOI 10.1111/1467-9566.12201
   Bogenschutz MP, 2016, PROG NEURO-PSYCHOPH, V64, P250, DOI 10.1016/j.pnpbp.2015.03.002
   Braine N, 2013, SEXUALITY RES SOCIAL, V11, P199
   Brubaker MD, 2013, J ADDICT OFFENDER CO, V34, P81, DOI 10.1002/j.2161-1874.2013.00017.x
   de Vet R, 2013, AM J PUBLIC HEALTH, V103, pE13, DOI 10.2105/AJPH.2013.301491
   DeBeck K, 2007, DRUG ALCOHOL DEPEN, V91, P50, DOI 10.1016/j.drugalcdep.2007.05.003
   DeBeck K, 2011, INT J DRUG POLICY, V22, P376, DOI 10.1016/j.drugpo.2011.05.012
   DeBeck K, 2011, DRUG ALCOHOL DEPEN, V113, P172, DOI 10.1016/j.drugalcdep.2010.07.023
   DeBeck K, 2009, ADDICTION, V104, P69, DOI 10.1111/j.1360-0443.2008.02387.x
   Deering KN, 2011, DRUG ALCOHOL DEPEN, V118, P430, DOI 10.1016/j.drugalcdep.2011.05.005
   Degenhardt L, 2012, LANCET, V379, P55, DOI 10.1016/S0140-6736(11)61138-0
   Draus PJ, 2010, J DRUG ISSUES, V40, P841, DOI 10.1177/002204261004000405
   Fischer B, 2001, CAN J CRIMINOL, V43, P197
   Goodyear MDE, 2007, BMJ-BRIT MED J, V334, P52, DOI 10.1136/bmj.39087.642801.BE
   Kerr T, 2008, J PSYCHOACTIVE DRUGS, V40, P147, DOI 10.1080/02791072.2008.10400624
   Koehn JD, 2015, ADDICT BEHAV, V46, P1, DOI 10.1016/j.addbeh.2015.01.038
   Levy JA, 2005, ADDICT RES THEORY, V13, P245, DOI 10.1080/16066350500053554
   Link BG, 2014, SOC SCI MED, V103, P24, DOI 10.1016/j.socscimed.2013.07.035
   Livingston JD, 2010, SOC SCI MED, V71, P2150, DOI 10.1016/j.socscimed.2010.09.030
   Long C, 2014, INT J DRUG POLICY, V25, P458, DOI 10.1016/j.drugpo.2013.11.011
   Mak WWS, 2007, SOC SCI MED, V65, P245, DOI 10.1016/j.socscimed.2007.03.015
   McEachern J., 2016, J ADDICTION MED, V1
   Milloy MJ, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-565
   Nwakeze PC, 2002, SUBST USE MISUSE, V37, P291, DOI 10.1081/JA-120002480
   Pager D, 2003, AM J SOCIOL, V108, P937, DOI 10.1086/374403
   Pan W, 2001, BIOMETRICS, V57, P120, DOI 10.1111/j.0006-341X.2001.00120.x
   Pani P. P., 2011, COCHRANE SYSTEMATIC
   Rapp Richard C, 2007, Subst Abus, V28, P11, DOI 10.1300/J465v28n01_03
   Richardson L, 2013, SOC SCI MED, V76, P126, DOI 10.1016/j.socscimed.2012.10.015
   Richardson L, 2012, J SUBST ABUSE TREAT, V43, P276, DOI 10.1016/j.jsat.2011.12.008
   Richardson L, 2010, DRUG ALCOHOL REV, V29, P293, DOI 10.1111/j.1465-3362.2009.00141.x
   Richardson LA, 2015, J EPIDEMIOL COMMUN H, V69, P686, DOI 10.1136/jech-2014-205079
   Rosenthal D, 2008, J ADOLESCENT HEALTH, V43, P296, DOI 10.1016/j.jadohealth.2008.06.002
   Seffrin PM, 2014, J DRUG ISSUES, V44, P394, DOI 10.1177/0022042614526994
   Shannon K, 2007, CAN J PUBLIC HEALTH, V98, P465, DOI 10.1007/BF03405440
   Sherman SG, 2006, AIDS CARE, V18, P1, DOI 10.1080/09540120500101625
   Small W, 2005, SUBST USE MISUSE, V40, P831, DOI 10.1081/JA-200030795
   Small W, 2013, INT J DRUG POLICY, V24, P479, DOI 10.1016/j.drugpo.2013.03.006
   Strang J, 2015, BRIT J PSYCHIAT, V207, P5, DOI 10.1192/bjp.bp.114.149195
   Sztramko R, 2014, CAN GERIATR J, V17, P5, DOI 10.5770/cgj.17.83
   Ti LP, 2014, DRUG ALCOHOL DEPEN, V141, P58, DOI 10.1016/j.drugalcdep.2014.05.003
   Tunnell Kenneth, 2004, PISSING DEMAND WORKP
   Uhlmann S, 2015, AM J ADDICTION, V24, P368, DOI 10.1111/ajad.12200
   Werb D, 2008, INT J DRUG POLICY, V19, P332, DOI 10.1016/j.drugpo.2007.08.004
   Wood E, 2005, LANCET, V366, P1834, DOI 10.1016/S0140-6736(05)67737-9
   Wood E, 2001, CAN MED ASSOC J, V165, P405
   Wood E., 2003, BRIT COLUMBIA MED J, V45, P128
   Wood E, 2008, INT J DRUG POLICY, V19, P220, DOI 10.1016/j.drugpo.2007.11.001
   Zule WA, 2003, J PSYCHOACTIVE DRUGS, V35, P503, DOI 10.1080/02791072.2003.10400498
NR 53
TC 4
Z9 4
U1 1
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4603
EI 1873-6327
J9 ADDICT BEHAV
JI Addict. Behav.
PD JAN
PY 2017
VL 64
BP 159
EP 164
DI 10.1016/j.addbeh.2016.08.041
PG 6
WC Psychology, Clinical; Substance Abuse
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology; Substance Abuse
GA EC3TA
UT WOS:000388048000027
PM 27614055
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Du, HY
   Cao, DN
   Chen, Y
   Wang, L
   Wu, N
   Li, J
AF Du, Hao-Yue
   Cao, Dan-Ni
   Chen, Ying
   Wang, Lv
   Wu, Ning
   Li, Jin
TI Alterations of prefrontal cortical microRNAs in methamphetamine
   self-administering rats: From controlled drug intake to escalated drug
   intake
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE Methamphetamine addiction; Escalated drug use; Controlled drug use;
   Prefrontal cortex; microRNAs
ID ACTIN CYTOSKELETON; COCAINE INTAKE; EXPRESSION; CORTEX; P53;
   ABNORMALITIES; REINSTATEMENT; MOTIVATION; APOPTOSIS; MIR-24
AB Drug addiction is a process that transits from recreative and regular drug use into compulsive drug use. The two patterns of drug use, controlled drug intake and escalated drug intake, represent different stages in the development of drug addiction; and escalation of drug use is a hallmark of addiction. Accumulating studies indicate that microRNAs (miRNAs) play key regulatory roles in drug addiction. However, the molecular adaptations in escalation of drug use, as well as the difference in the adaptations between escalated and controlled drug use, remain unclear. In the present study, 28 altered miRNAs in the prefrontal cortex (PFC) were found in the groups of controlled methamphetamine self-administration (1 h/session) and escalated self-administration (6 h/session), and some of them were validated. Compared with saline control group, miR-186 was verified to be up-regulated while miR-195 and miR-329 were down-regulated in the rats with controlled methamphetamine use. In the rats with escalated drug use, miR-127, miR-186, miR-222 and miR-24 were verified to be up-regulated while miR-329 was down regulated compared with controls. Furthermore, bioinformatic analysis indicated that the predicted targets of these verified miRNAs involved in the processes of neuronal apoptosis and synaptic plasticity. However, the putative regulated molecules may be different between controlled and escalated drug use groups. Taken together, we detected the altered miRNAs in rat PFC under the conditions of controlled methamphetamine use and escalated use respectively, which may extend our understanding of the molecular adaptations underlying the transition from controlled drug use to addiction. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Du, Hao-Yue; Cao, Dan-Ni; Chen, Ying; Wang, Lv; Wu, Ning; Li, Jin] Beijing Inst Pharmacol & Toxicol, State Key Lab Toxicol & Med Countermeasures, Beijing Key Lab Neuropsychopharmacol, 27th Taiping Rd, Beijing 100850, Peoples R China.
C3 Academy of Military Medical Sciences - China
RP Wu, N; Li, J (通讯作者)，Beijing Inst Pharmacol & Toxicol, State Key Lab Toxicol & Med Countermeasures, Beijing Key Lab Neuropsychopharmacol, 27th Taiping Rd, Beijing 100850, Peoples R China.
EM wuning7671@126.com; jinli9802@163.com
FU National Basic Research Program of China [2015CB553504]; China
   Postdoctoral Science Foundation [57, 2015M572688]; National Science and
   Technology Support Program in China [2012BAI01B07]
FX This work was supported by National Basic Research Program of China
   (2015CB553504), No.57 China Postdoctoral Science Foundation Funded
   Project (2015M572688) and Project of National Science and Technology
   Support Program in China (2012BAI01B07).
CR Ahmed SH, 2012, NEUROSCIENCE, V211, P107, DOI 10.1016/j.neuroscience.2011.08.014
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Ahmed SH, 2000, NEUROPSYCHOPHARMACOL, V22, P413, DOI 10.1016/S0893-133X(99)00133-5
   Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X
   Chandrasekar V, 2011, NEUROPSYCHOPHARMACOL, V36, P1149, DOI 10.1038/npp.2010.250
   Chandrasekar V, 2009, MOL CELL NEUROSCI, V42, P350, DOI 10.1016/j.mcn.2009.08.009
   Darcq E, 2014, MOL PSYCHIAT
   Golden SA, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a011957
   Halpin LE, 2014, LIFE SCI, V97, P37, DOI 10.1016/j.lfs.2013.07.014
   Hollander JA, 2010, NATURE, V466, P197, DOI 10.1038/nature09202
   Imam SZ, 2001, MOL BRAIN RES, V91, P174, DOI 10.1016/S0169-328X(01)00139-5
   Kalivas PW, 2008, NEUROTOX RES, V14, P185, DOI 10.1007/BF03033809
   Kitamura O, 2006, PSYCHOPHARMACOLOGY, V186, P48, DOI 10.1007/s00213-006-0353-z
   Knackstedt LA, 2007, J PHARMACOL EXP THER, V322, P1103, DOI 10.1124/jpet.107.122861
   Mandyam CD, 2007, J NEUROSCI, V27, P11442, DOI 10.1523/JNEUROSCI.2505-07.2007
   Mellios N, 2008, HUM MOL GENET, V17, P3030, DOI 10.1093/hmg/ddn201
   Meng YH, 2003, REV NEUROSCIENCE, V14, P233
   Meredith GE, 2002, BRAIN RES, V949, P218, DOI 10.1016/S0006-8993(02)03160-8
   Mishra PJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008445
   Puerta-Gil P, 2012, AM J PATHOL, V180, P1808, DOI 10.1016/j.ajpath.2012.01.034
   Singh R, 2012, J CELL SCI, V125, P1568, DOI 10.1242/jcs.095976
   Srivastava N, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2861
   Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519
   Tanabe J, 2009, BIOL PSYCHIAT, V65, P160, DOI 10.1016/j.biopsych.2008.07.030
   Tapocik JD, 2014, J NEUROSCI, V34, P4581, DOI 10.1523/JNEUROSCI.0445-14.2014
   Thompson PM, 2004, J NEUROSCI, V24, P6028, DOI 10.1523/JNEUROSCI.0713-04.2004
   To KH, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-69
   Tobias MC, 2010, PSYCHOPHARMACOLOGY, V209, P13, DOI 10.1007/s00213-009-1761-7
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Wee S, 2008, EUR NEUROPSYCHOPHARM, V18, P303, DOI 10.1016/j.euroneuro.2007.08.003
   Yu SB, 2015, BEHAV NEUROL, V2015, DOI 10.1155/2015/103969
   Zhou QB, 2014, MOL THER, V22, P378, DOI 10.1038/mt.2013.243
NR 32
TC 19
Z9 24
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3940
EI 1872-7972
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD JAN 12
PY 2016
VL 611
BP 21
EP 27
DI 10.1016/j.neulet.2015.11.016
PG 7
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA DC1BO
UT WOS:000368952000004
PM 26592480
DA 2023-06-23
ER

PT J
AU Holden, C
AF Holden, C
TI Drug addiction - Zapping memory center triggers drug craving
SO SCIENCE
LA English
DT News Item
NR 0
TC 8
Z9 11
U1 0
U2 8
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD MAY 11
PY 2001
VL 292
IS 5519
BP 1039
EP 1039
PG 1
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 431AF
UT WOS:000168609200007
PM 11352038
DA 2023-06-23
ER

PT J
AU Du, WJ
   Liu, Y
   Meng, YM
   Yan, YM
   Jin, LT
   Zhang, JJ
   Liang, J
   Li, YH
   Shen, F
AF Du, Wenjie
   Liu, Ying
   Meng, Yiming
   Yan, Yimin
   Jin, Lingtong
   Zhang, Jianjun
   Liang, Jing
   Li, Yonghui
   Shen, Fang
TI A Translation from Goal-Directed to Habitual Control: the Striatum in
   Drug Addiction
SO CURRENT ADDICTION REPORTS
LA English
DT Article
DE Goal-directed behaviour; Habitual behaviour; Compulsive drug seeking;
   Striatum; The nucleus accumbens; Pavlovian conditioning; Instrumental
   conditioning
ID COCAINE-SEEKING BEHAVIOR; MEDIAL PREFRONTAL CORTEX; NUCLEUS-ACCUMBENS
   CORE; BASAL GANGLIA; DOPAMINE RELEASE; PLASTICITY; DEFICITS;
   REINFORCEMENT; COGNITION; ALCOHOL
AB Purpose of Review Drug addiction starts from recreational drug use, gradually becomes habitual or even compulsive. However, after exposure to addictive drugs, only 20% of individuals finally fall into a vicious cycle of addiction. As the number of addicts worldwide increases year by year, the need for understanding the neural basis underlying addiction is in high demand. Recent Findings The intrastriatal functional shifts have been widely recognized to contribute to addiction development, where the nucleus accumbens permits the devolution of its control over behaviour to the dorsal striatum. In addition, compulsive drug seeking and taking have been taken as maladaptive habits, coupling with impaired goal-directed behaviour, thus habitual system dominant behaviour in spite of punishment. However, this hypothesis has not fully been proven at the level of neural mechanisms. Here we elaborated the function of the striatum at the different stages of addiction within the associative learning theory framework to highlight the potentially vulnerable targets of addictive drugs. Furthermore, based on current findings, we proposed new possibilities to explain compulsive drug-seeking behaviour.
C1 [Du, Wenjie; Liu, Ying; Meng, Yiming; Yan, Yimin; Jin, Lingtong; Zhang, Jianjun; Liang, Jing; Li, Yonghui; Shen, Fang] Chinese Acad Sci, Inst Psychol, Key Lab Mental Hlth, 16 Lin Cui Rd, Beijing 100101, Peoples R China.
   [Du, Wenjie; Liu, Ying; Meng, Yiming; Yan, Yimin; Jin, Lingtong; Zhang, Jianjun; Liang, Jing; Li, Yonghui; Shen, Fang] Univ Chinese Acad Sci, Dept Psychol, Beijing, Peoples R China.
C3 Chinese Academy of Sciences; Institute of Psychology, CAS; Chinese
   Academy of Sciences; University of Chinese Academy of Sciences, CAS
RP Shen, F (通讯作者)，Chinese Acad Sci, Inst Psychol, Key Lab Mental Hlth, 16 Lin Cui Rd, Beijing 100101, Peoples R China.; Shen, F (通讯作者)，Univ Chinese Acad Sci, Dept Psychol, Beijing, Peoples R China.
EM shenf@psych.ac.cn
RI Li, Yonghui/G-8539-2012; 梁, 璟/IQV-8737-2023
FU National Natural Science Foundation of China [3197070674]; National
   Natural Science Foundation of Beijing [7202128]; CAS Key Laboratory of
   Mental Health, Institute of Psychology [GJHZ202129]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No.3197070674) and the National Natural Science Foundation
   of Beijing (Grant No. 7202128) to F.S., and CAS Key Laboratory of Mental
   Health, Institute of Psychology. The CASVPST Silk Road Science Fund 2021
   to N.S.(Grant No. GJHZ202129).
CR Alaghband Y, 2018, J NEUROSCI, V38, P9514, DOI 10.1523/JNEUROSCI.2911-17.2018
   Balleine BW, 2009, BEHAV BRAIN RES, V199, P43, DOI 10.1016/j.bbr.2008.10.034
   Bechara A, 2001, NEUROPSYCHOLOGIA, V39, P376, DOI 10.1016/S0028-3932(00)00136-6
   Bergstrom HC, 2018, CELL REP, V23, P2264, DOI 10.1016/j.celrep.2018.04.081
   Capuzzo G, 2020, J NEUROSCI, V40, P4773, DOI 10.1523/JNEUROSCI.0414-20.2020
   Cartoni E, 2016, NEUROSCI BIOBEHAV R, V71, P829, DOI 10.1016/j.neubiorev.2016.09.020
   Chen BT, 2013, NATURE, V496, P359, DOI 10.1038/nature12024
   Corbit LH, 2016, CURR TOP BEHAV NEURO, V27, P259, DOI 10.1007/7854_2015_388
   Corbit LH, 2012, BIOL PSYCHIAT, V72, P389, DOI 10.1016/j.biopsych.2012.02.024
   Corre J, 2018, ELIFE, V7, DOI 10.7554/eLife.39945
   Dalley JW, 2011, NEURON, V69, P680, DOI 10.1016/j.neuron.2011.01.020
   de Jong JW, 2019, NEURON, V101, P133, DOI 10.1016/j.neuron.2018.11.005
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Ersche KD, 2013, CURR OPIN NEUROBIOL, V23, P615, DOI 10.1016/j.conb.2013.02.017
   Everitt BJ, 2016, ANNU REV PSYCHOL, V67, P23, DOI 10.1146/annurev-psych-122414-033457
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Furlong TM, 2017, ADDICT BIOL, V22, P172, DOI 10.1111/adb.12316
   Garbusow M, 2016, ADDICT BIOL, V21, P719, DOI 10.1111/adb.12243
   Gremel CM, 2016, NEURON, V90, P1312, DOI 10.1016/j.neuron.2016.04.043
   Heymann G, 2020, NEURON, V105, P909, DOI 10.1016/j.neuron.2019.11.024
   Hilario MRF, 2008, FRONT NEUROSCI-SWITZ, V2, P208, DOI 10.3389/neuro.01.030.2008
   Hintiryan H, 2016, NAT NEUROSCI, V19, P1100, DOI 10.1038/nn.4332
   Hirokawa J, 2019, NATURE, V576, P446, DOI 10.1038/s41586-019-1816-9
   Hu YZ, 2019, P NATL ACAD SCI USA, V116, P9066, DOI 10.1073/pnas.1819978116
   Ito R, 2002, J NEUROSCI, V22, P6247
   Ito R, 2000, J NEUROSCI, V20, P7489
   Jedynak J, 2016, NEUROPSYCHOPHARMACOL, V41, P464, DOI 10.1038/npp.2015.168
   JOHNSON SW, 1992, J NEUROSCI, V12, P483
   Kreitzer AC, 2008, NEURON, V60, P543, DOI 10.1016/j.neuron.2008.11.005
   Li Y, 2016, NEUROPSYCHOPHARMACOL, V41, P1003, DOI 10.1038/npp.2015.227
   Loos M, 2014, BIOL PSYCHIAT, V76, P648, DOI 10.1016/j.biopsych.2014.02.011
   Luscher C, 2020, NAT REV NEUROSCI, V21, P247, DOI 10.1038/s41583-020-0289-z
   Mameli M, 2011, NEUROPHARMACOLOGY, V61, P1052, DOI 10.1016/j.neuropharm.2011.01.036
   Maskos U, 2005, NATURE, V436, P103, DOI 10.1038/nature03694
   MCGEORGE AJ, 1989, NEUROSCIENCE, V29, P503, DOI 10.1016/0306-4522(89)90128-0
   Mendelsohn A, 2014, NEURON, V81, P207, DOI 10.1016/j.neuron.2013.10.019
   Mihindou C, 2013, BIOL PSYCHIAT, V73, P271, DOI 10.1016/j.biopsych.2012.08.011
   Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228
   Montague PR, 1996, J NEUROSCI, V16, P1936, DOI 10.1523/jneurosci.16-05-01936.1996
   Morse AK, 2020, NEURON, V106, P855, DOI 10.1016/j.neuron.2020.03.007
   Narayananl NS, 2017, CURR BIOL, V27, pR148, DOI 10.1016/j.cub.2017.01.010
   Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578
   O'Hare JK, 2016, NEURON, V89, P472, DOI 10.1016/j.neuron.2015.12.032
   Paine TA, 2015, PSYCHOPHARMACOLOGY, V232, P1755, DOI 10.1007/s00213-014-3816-7
   Pascoli V, 2018, NATURE, V564, P366, DOI 10.1038/s41586-018-0789-4
   Pascoli V, 2015, NEURON, V88, DOI 10.1016/j.neuron.2015.10.017
   Pontieri FE, 1995, P NATL ACAD SCI USA, V92, P12304, DOI 10.1073/pnas.92.26.12304
   Puaud M, 2021, BIOL PSYCHIAT, V89, P356, DOI 10.1016/j.biopsych.2020.07.022
   RESCORLA RA, 1967, PSYCHOL REV, V74, P151, DOI 10.1037/h0024475
   Rocha A, 2010, EUR J NEUROSCI, V31, P903, DOI 10.1111/j.1460-9568.2010.07134.x
   Rogers RD, 1999, NEUROPSYCHOPHARMACOL, V20, P322, DOI 10.1016/S0893-133X(98)00091-8
   Schmidt R, 2013, NAT NEUROSCI, V16, P1118, DOI 10.1038/nn.3456
   Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1
   Sjoerds Z, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.107
   Stuber GD, 2011, NATURE, V475, P377, DOI 10.1038/nature10194
   Sul JH, 2010, NEURON, V66, P449, DOI 10.1016/j.neuron.2010.03.033
   Vandaele Y, 2019, ELIFE, V8, DOI [10.7554/elife.49536, 10.7554/eLife.49536]
   Vicente AM, 2016, CURR BIOL, V26, pR267, DOI 10.1016/j.cub.2016.02.036
   Wolf ME, 2016, NAT REV NEUROSCI, V17, P351, DOI 10.1038/nrn.2016.39
   Yin HH, 2008, EUR J NEUROSCI, V28, P1437, DOI 10.1111/j.1460-9568.2008.06422.x
   Zhou YM, 2019, NAT NEUROSCI, V22, P1986, DOI 10.1038/s41593-019-0524-y
   Zinsmaier AK, 2022, MOL PSYCHIATR, V27, P669, DOI 10.1038/s41380-021-01112-2
NR 62
TC 1
Z9 1
U1 1
U2 13
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
EI 2196-2952
J9 CURR ADDICT REP
JI Curr. Addict. Rep.
PD DEC
PY 2021
VL 8
IS 4
BP 530
EP 537
DI 10.1007/s40429-021-00392-6
EA SEP 2021
PG 8
WC Substance Abuse; Psychiatry
WE Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry
GA WV0MH
UT WOS:000691923300001
DA 2023-06-23
ER

PT J
AU Kircher, S
   Zacny, J
   Apfelbaum, SM
   Passik, S
   Kirsch, K
   Burbage, M
   Lofwall, M
AF Kircher, Sheetal
   Zacny, James
   Apfelbaum, Sean M.
   Passik, Steve
   Kirsch, Ken
   Burbage, Maureen
   Lofwall, Michelle
TI Understanding and Treating Opioid Addiction in a Patient With Cancer
   Pain
SO JOURNAL OF PAIN
LA English
DT Review
DE Addiction; heroin; cancer; pain; universal precautions
ID DRUG-ADDICTION; RECEPTOR AVAILABILITY; INDUCED REINSTATEMENT; NEURAL
   MECHANISMS; GLUTAMATE RELEASE; HEROIN; BRAIN; COCAINE; REWARD; NUCLEUS
C1 [Kircher, Sheetal] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA.
   [Zacny, James; Apfelbaum, Sean M.] Univ Chicago, Dept Anesthesia & Crit Care, Chicago, IL 60637 USA.
   [Passik, Steve] Vanderbilt Univ, Med Ctr, Dept Psychiat & Anesthesiol, Nashville, TN USA.
   [Kirsch, Ken] Univ Kentucky, Coll Pharm, Pain Treatment Ctr Bluegrass, Dept Pharm Practice & Sci, Lexington, KY USA.
   [Burbage, Maureen; Lofwall, Michelle] Univ Kentucky, Dept Psychiat, Ctr Drug & Alcohol Res, Lexington, KY USA.
C3 Northwestern University; Feinberg School of Medicine; University of
   Chicago; Vanderbilt University; University of Kentucky; University of
   Kentucky
RP Kircher, S (通讯作者)，Care of Paice JA, Northwestern Univ, Sch Med, 676 N St Clair St,Suite 850, Chicago, IL 60611 USA.
OI Lofwall, Michelle/0000-0002-5911-0752
CR Alford DP, 2006, ANN INTERN MED, V144, P127, DOI 10.7326/0003-4819-144-2-200601170-00010
   Bassareo V, 2011, PSYCHOPHARMACOLOGY, V214, P687, DOI 10.1007/s00213-010-2072-8
   Botelho MF, 2006, ANN NY ACAD SCI, V1074, P466, DOI 10.1196/annals.1369.047
   Carlezon WA, 2009, NEUROPHARMACOLOGY, V56, P122, DOI 10.1016/j.neuropharm.2008.06.075
   Clapp P, 2008, ALCOHOL RES HEALTH, V31, P310
   COLLIVER JD, 1991, PUBLIC HEALTH REP, V106, P59
   Daglish MRC, 2001, AM J PSYCHIAT, V158, P1680, DOI 10.1176/appi.ajp.158.10.1680
   Everitt BJ, 2008, PHILOS T R SOC B, V363, P3125, DOI 10.1098/rstb.2008.0089
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Forman SD, 2004, BIOL PSYCHIAT, V55, P531, DOI 10.1016/j.biopsych.2003.09.011
   Fuentealba JA, 2000, J NEUROCHEM, V75, P741, DOI 10.1046/j.1471-4159.2000.0750741.x
   Gass JT, 2008, BIOCHEM PHARMACOL, V75, P218, DOI 10.1016/j.bcp.2007.06.039
   GFROERER J, 1992, BRIT J ADDICT, V87, P1345
   Goldstein RZ, 2009, TRENDS COGN SCI, V13, P372, DOI 10.1016/j.tics.2009.06.004
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Gourlay DL, 2005, PAIN MED, V6, P107, DOI 10.1111/j.1526-4637.2005.05031.x
   Gourlay DL, 2008, J ADDICT DIS, V27, P23, DOI 10.1080/10550880802122570
   Hyman SE, 2005, AM J PSYCHIAT, V162, P1414, DOI 10.1176/appi.ajp.162.8.1414
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Katz Nathaniel P, 2010, J Pain Palliat Care Pharmacother, V24, P141, DOI 10.3109/15360281003799098
   Kirsh KL, 2006, CANCER INVEST, V24, P425, DOI 10.1080/07357900600705565
   Koob G, 2007, AM J PSYCHIAT, V164, P1149, DOI 10.1176/appi.ajp.2007.05030503
   Koob GF, 2008, NEURON, V59, P11, DOI 10.1016/j.neuron.2008.06.012
   Koob GF, 2010, BRAIN RES, V1314, P3, DOI 10.1016/j.brainres.2009.11.008
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Koob GF, 2009, BRAIN RES, V1293, P61, DOI 10.1016/j.brainres.2009.03.038
   Koob GF, 2009, J DRUG ISSUES, V39, P115, DOI 10.1177/002204260903900110
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Koob GF, 1997, J NEUROPSYCH CLIN N, V9, P482
   Kreek MJ, 1997, PHARMACOL BIOCHEM BE, V57, P551, DOI 10.1016/S0091-3057(96)00440-6
   Kreek MJ, 1998, DRUG ALCOHOL DEPEN, V51, P23, DOI 10.1016/S0376-8716(98)00064-7
   KREEK MJ, 2002, NEUROPSYCHOPHARMACOL, P1491
   LaLumiere RT, 2008, J NEUROSCI, V28, P3170, DOI 10.1523/JNEUROSCI.5129-07.2008
   Le Moal M, 2007, EUR NEUROPSYCHOPHARM, V17, P377, DOI 10.1016/j.euroneuro.2006.10.006
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   MARTIN WR, 1961, J PHARMACOL EXP THER, V133, P388
   McClernon FJ, 2009, PSYCHOPHARMACOLOGY, V204, P25, DOI 10.1007/s00213-008-1436-9
   McFarland K, 2003, J NEUROSCI, V23, P3531
   McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689
   Passik SD, 2008, EXP CLIN PSYCHOPHARM, V16, P400, DOI 10.1037/a0013634
   Passik SD, 2008, PAIN MED, V9, pS145, DOI 10.1111/j.1526-4637.2008.00486.x
   REGIER DA, 1984, ARCH GEN PSYCHIAT, V41, P934
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Rogers Peter D, 2009, Adolesc Med State Art Rev, V20, P1
   Ross S, 2009, CLIN NEUROPHARMACOL, V32, P269, DOI 10.1097/WNF.0b013e3181a9163c
   Savage SR, 2003, J PAIN SYMPTOM MANAG, V26, P655, DOI 10.1016/S0885-3924(03)00219-7
   Shaham Y, 1998, PSYCHOPHARMACOLOGY, V137, P184, DOI 10.1007/s002130050608
   Shalev U, 2006, PSYCHOPHARMACOLOGY, V187, P376, DOI 10.1007/s00213-006-0427-y
   Smith Sean M, 2006, Dialogues Clin Neurosci, V8, P383
   Tenore PL, 2010, J ADDICT DIS, V29, P436, DOI 10.1080/10550887.2010.509277
   Volkow ND, 2004, MOL PSYCHIATR, V9, P557, DOI 10.1038/sj.mp.4001507
   VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210
   Volkow ND, 2001, AM J PSYCHIAT, V158, P2015, DOI 10.1176/appi.ajp.158.12.2015
   Volkow ND, 2010, BIOESSAYS, V32, P748, DOI 10.1002/bies.201000042
   Wang GJ, 1997, NEUROPSYCHOPHARMACOL, V16, P174, DOI 10.1016/S0893-133X(96)00184-4
   Watanabe T, 2003, PSYCHOPHARMACOLOGY, V170, P80, DOI 10.1007/s00213-003-1504-0
   Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406
   Zhou WH, 2008, BIOL PSYCHIAT, V63, P338, DOI 10.1016/j.biopsych.2007.06.008
   Zorrilla EP, 2010, DRUG DISCOV TODAY, V15, P371, DOI 10.1016/j.drudis.2010.02.011
NR 62
TC 12
Z9 13
U1 0
U2 8
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526-5900
J9 J PAIN
JI J. Pain
PD OCT
PY 2011
VL 12
IS 10
BP 1025
EP 1031
DI 10.1016/j.jpain.2011.07.006
PG 7
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology
GA 834GH
UT WOS:000295947300001
PM 21968264
DA 2023-06-23
ER

PT J
AU Wong, J
   Marshall, BDL
   Kerr, T
   Lai, C
   Wood, E
AF Wong, Jellena
   Marshall, Brandon D. L.
   Kerr, Thomas
   Lai, Calvin
   Wood, Evan
TI Addiction Treatment Experience among a Cohort of Street-Involved Youths
   and Young Adults
SO JOURNAL OF CHILD & ADOLESCENT SUBSTANCE ABUSE
LA English
DT Article
DE drug treatment; homeless; initiation; injection drug use; youth
ID INJECTION-DRUG USERS; NEEDLE EXCHANGE PROGRAM; SUBSTANCE USE; RISK
   BEHAVIOR; SAN-FRANCISCO; FOLLOW-UP; HOMELESS; HIV; ADOLESCENTS; SERVICES
AB Very little is known about the accessibility and potential barriers to addiction treatment among street youths and young adults. We sought to examine the prevalence and correlates of enrollment in addiction treatment among a cohort of street-involved youths and young adults in Vancouver, Canada. Street-involved youths and young adults who use illicit drugs were enrolled in a prospective cohort study known as the At Risk Youth Study (ARYS). We examined the prevalence of addiction treatment experience and identified the factors associated with this outcome using multivariate logistic regression. Among 478 participants, 243 (50.8%) had previously been enrolled in some form of addiction treatment program. In multivariate analysis, history of overdose, previous incarceration, crack use, cocaine use, and history of injection drug use were positively and independently associated with enrollment in addiction treatment. These findings may assist health authorities in identifying and assisting youths who may have barriers to accessing treatment, and further suggest that efforts may be needed to scale up addiction treatment programming for high-risk youths and young adults.
C1 [Wood, Evan] St Pauls Hosp, BC Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada.
   [Wong, Jellena] Univ Victoria, Victoria, BC V8W 2Y2, Canada.
   [Marshall, Brandon D. L.; Kerr, Thomas; Lai, Calvin; Wood, Evan] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
C3 B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University
   of Victoria; University of British Columbia
RP Wood, E (通讯作者)，St Pauls Hosp, BC Ctr Excellence HIV AIDS, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
EM uhri@cfenet.ubc.ca
RI Marshall, Brandon DL/B-4895-2010
OI Marshall, Brandon DL/0000-0002-0134-7052
CR Baron SW, 1999, YOUTH SOC, V31, P3, DOI 10.1177/0044118X99031001001
   Brands B, 2005, ADDICT RES THEORY, V13, P477, DOI 10.1080/16066350500150624
   Bungay V, 2006, ADDICT RES THEORY, V14, P235, DOI 10.1080/16066350500270901
   Copeland Jan, 2003, Drug Alcohol Rev, V22, P15, DOI 10.1080/0959523021000059785
   Davidson PJ, 2002, ADDICTION, V97, P1511, DOI 10.1046/j.1360-0443.2002.00210.x
   Des Jarlais DC, 1999, LANCET, V353, P1657, DOI 10.1016/S0140-6736(98)07026-3
   Erickson PG, 2005, SUBST USE MISUSE, V40, P953, DOI 10.1081/JA-200058855
   Gleghorn AA, 1998, DRUG ALCOHOL DEPEN, V51, P219, DOI 10.1016/S0376-8716(98)00042-8
   Hagan H, 2000, J SUBST ABUSE TREAT, V19, P247, DOI 10.1016/S0740-5472(00)00104-5
   Hser YI, 2004, PSYCHIAT SERV, V55, P767, DOI 10.1176/appi.ps.55.7.767
   Hubbard RL, 2003, J SUBST ABUSE TREAT, V25, P125, DOI 10.1016/S0740-5472(03)00130-2
   Jainchill N, 2000, SUBST USE MISUSE, V35, P2031, DOI 10.3109/10826080009148249
   Kerr T, 2005, DRUG ALCOHOL DEPEN, V80, P329, DOI 10.1016/j.drugalcdep.2005.05.002
   Kinlock TW, 2004, J PSYCHOACTIVE DRUGS, V36, P5, DOI 10.1080/02791072.2004.10399719
   Kral AH, 1997, INT J STD AIDS, V8, P109, DOI 10.1258/0956462971919651
   Laudet A, 2007, EVALUATION REV, V31, P613, DOI 10.1177/0193841X07306745
   MACDONALD NE, 1994, PEDIATR INFECT DIS J, V13, P690, DOI 10.1097/00006454-199408000-00003
   Martin I, 2006, CAN J PUBLIC HEALTH, V97, P320, DOI 10.1007/BF03405613
   Martinez TE, 1998, J PSYCHOACTIVE DRUGS, V30, P1
   Miller CL, 2006, J ADOLESCENT HEALTH, V38, P462, DOI 10.1016/j.jadohealth.2005.03.004
   Ochnio JJ, 2001, CAN MED ASSOC J, V165, P293
   Pollini RA, 2006, DRUG ALCOHOL DEPEN, V83, P104, DOI 10.1016/j.drugalcdep.2005.10.015
   Porter J, 2002, SUBST USE MISUSE, V37, P1305, DOI 10.1081/JA-120014080
   Riley ED, 2002, AM J DRUG ALCOHOL AB, V28, P497, DOI 10.1081/ADA-120006738
   Rounds-Bryant JL, 1999, AM J DRUG ALCOHOL AB, V25, P573, DOI 10.1081/ADA-100101880
   Roy E, 2002, ADDICTION, V97, P1003, DOI 10.1046/j.1360-0443.2002.00161.x
   Roy E, 2004, JAMA-J AM MED ASSOC, V292, P624
   SCHUTZ CG, 1994, DRUG ALCOHOL DEPEN, V36, P129, DOI 10.1016/0376-8716(94)90095-7
   Shoptaw S, 2000, AIDS BEHAV, V4, P193, DOI DOI 10.1023/A:1009568725510
   Slesnick N, 2007, ADDICT BEHAV, V32, P1237, DOI 10.1016/j.addbeh.2006.08.010
   Strathdee SA, 1999, J URBAN HEALTH, V76, P448, DOI 10.1007/BF02351502
   Vourakis C, 2005, J CHILD ADOL PS NURS, V18, P161, DOI 10.1111/j.1744-6171.2005.00031.x
   Weber AE, 2004, J URBAN HEALTH, V81, P584, DOI 10.1093/jurban/jth142
   Wood E, 2002, AIDS, V16, P941, DOI 10.1097/00002030-200204120-00021
   Wood Evan, 2006, Harm Reduct J, V3, P18, DOI 10.1186/1477-7517-3-18
   Zador D, 2001, ADDICT RES THEORY, V9, P407, DOI 10.3109/16066350109141761
NR 36
TC 6
Z9 6
U1 0
U2 9
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1067-828X
EI 1547-0652
J9 J CHILD ADOLES SUBST
JI J. Child Adolesc. Subst. Abus.
PY 2009
VL 18
IS 4
BP 398
EP 409
DI 10.1080/10678280903185567
PG 12
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA 509JV
UT WOS:000271013100005
DA 2023-06-23
ER

PT J
AU Moussawi, K
   Ortiz, MM
   Gantz, SC
   Tunstall, BJ
   Marchette, RCN
   Bonci, A
   Koob, GF
   Vendruscolo, LF
AF Moussawi, K.
   Ortiz, M. M.
   Gantz, S. C.
   Tunstall, B. J.
   Marchette, R. C. N.
   Bonci, A.
   Koob, G. F.
   Vendruscolo, L. F.
TI Fentanyl vapor self-administration model in mice to study opioid
   addiction
SO SCIENCE ADVANCES
LA English
DT Article
ID VENTRAL TEGMENTAL AREA; DOPAMINE TRANSMISSION; NUCLEUS-ACCUMBENS;
   MORPHINE; SENSITIZATION; MODULATION; EXPRESSION; NEURONS; RATS;
   SUFENTANIL
AB Intravenous drug self-administration is considered the "gold standard" model to investigate the neurobiology of drug addiction in rodents. However, its use in mice is limited by frequent complications of intravenous catheterization. Given the many advantages of using mice in biomedical research, we developed a noninvasive mouse model of opioid self-administration using vaporized fentanyl. Mice readily self-administered fentanyl vapor, titrated their drug intake, and exhibited addiction-like behaviors, including escalation of drug intake, somatic signs of withdrawal, drug intake despite punishment, and reinstatement of drug seeking. Electrophysiological recordings from ventral tegmental area dopamine neurons showed a lower amplitude of GABA B receptor-dependent currents during protracted abstinence from fentanyl vapor self-administration. This mouse model of fentanyl self-administration recapitulates key features of opioid addiction, overcomes limitations of the intravenous model, and allows investigation of the neurobiology of opioid addiction in unprecedented ways.
C1 [Moussawi, K.; Ortiz, M. M.; Gantz, S. C.; Tunstall, B. J.; Marchette, R. C. N.; Koob, G. F.; Vendruscolo, L. F.] NIDA, Intramural Res Program, NIH, Baltimore, MD 20852 USA.
   [Moussawi, K.] Johns Hopkins Med, Neurol Dept, Baltimore, MD 21287 USA.
   [Gantz, S. C.] Univ Iowa, Dept Mol Physiol & Biophys, Iowa City, IA USA.
   [Bonci, A.] Global Inst Addict, Miami, FL USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute on
   Aging (NIA); NIH National Institute on Drug Abuse (NIDA); Johns Hopkins
   University; Johns Hopkins Medicine; University of Iowa
RP Moussawi, K; Vendruscolo, LF (通讯作者)，NIDA, Intramural Res Program, NIH, Baltimore, MD 20852 USA.; Moussawi, K (通讯作者)，Johns Hopkins Med, Neurol Dept, Baltimore, MD 21287 USA.
EM moussawi.khaled@gmail.com; leandro.vendruscolo@nih.gov
RI Tunstall, Brendan J/T-4055-2019; Gantz, Stephanie/AAF-4473-2021;
   Marchete, Renata/AAC-3693-2022
OI Tunstall, Brendan J/0000-0001-9430-9612; Marchete,
   Renata/0000-0001-5040-7966; /0000-0002-8829-8627; Moussawi,
   Khaled/0000-0001-6378-0428; Gantz, Stephanie/0000-0002-1800-4400
FU Intramural Research Program at the National Institute on Drug Abuse
   [DA048530, DA048085]; Center on Compulsive Behaviors at the NIH
FX This project was supported by the Intramural Research Program at the
   National Institute on Drug Abuse (DA048530 to B.J.T. and DA048085 to
   K.M.). S.C.G. and R.C.N.M. were supported by a fellowship from the
   Center on Compulsive Behaviors at the NIH.
CR ACQUAS E, 1992, J NEUROCHEM, V58, P1620, DOI 10.1111/j.1471-4159.1992.tb10033.x
   Ahmed SH, 2000, NEUROPSYCHOPHARMACOL, V22, P413, DOI 10.1016/S0893-133X(99)00133-5
   Arena DT, 2019, PSYCHOPHARMACOLOGY, V236, P2027, DOI 10.1007/s00213-019-05191-6
   Back SE, 2011, AM J DRUG ALCOHOL AB, V37, P313, DOI 10.3109/00952990.2011.596982
   Becker JB, 2016, PHARMACOL REV, V68, P242, DOI 10.1124/pr.115.011163
   Beckstead MJ, 2007, EUR J NEUROSCI, V26, P1479, DOI 10.1111/j.1460-9568.2007.05775.x
   Belin-Rauscent A, 2016, BIOL PSYCHIAT, V79, P39, DOI 10.1016/j.biopsych.2015.01.004
   Bonci A, 1996, NEURON, V16, P631, DOI 10.1016/S0896-6273(00)80082-3
   Bryant CD, 2009, DRUG ALCOHOL DEPEN, V103, P74, DOI 10.1016/j.drugalcdep.2009.03.016
   Carmack SA, 2019, J CLIN INVEST, V129, P2480, DOI 10.1172/JCI125534
   Chieng B, 2011, J PHYSIOL-LONDON, V589, P3775, DOI 10.1113/jphysiol.2011.210807
   Degenhardt L, 2018, LANCET PSYCHIAT, V5, P987, DOI 10.1016/S2215-0366(18)30337-7
   Dershwitz M, 2000, ANESTHESIOLOGY, V93, P619, DOI 10.1097/00000542-200009000-00009
   Diana M, 1999, EUR J NEUROSCI, V11, P1037, DOI 10.1046/j.1460-9568.1999.00488.x
   Erhardt S, 2002, N-S ARCH PHARMACOL, V365, P173, DOI 10.1007/s00210-001-0519-5
   European Monitoring Centre for Drugs and Drug Addiction, 2015, FENT DRUG PROF
   Filip M, 2008, PHARMACOL REP, V60, P755
   Fiorillo CD, 1998, NATURE, V394, P78, DOI 10.1038/27919
   FOLTIN RW, 1992, J PHARMACOL EXP THER, V261, P841
   Freels TG, 2020, J NEUROSCI, V40, P1897, DOI 10.1523/JNEUROSCI.2416-19.2020
   GOLDSTEI.DB, 1971, SCIENCE, V172, P288, DOI 10.1126/science.172.3980.288
   Gutierrez A., 2020, BIORXIV, P1, DOI [10.1101/2020.03.30.016725, DOI 10.1101/2020.03.30.016725]
   JAFFE AB, 1989, PSYCHOPHARMACOLOGY, V99, P289, DOI 10.1007/BF00445545
   JOHNSON DW, 1993, PHARMACOL BIOCHEM BE, V46, P341, DOI 10.1016/0091-3057(93)90362-W
   JOHNSON SW, 1992, J PHYSIOL-LONDON, V450, P455, DOI 10.1113/jphysiol.1992.sp019136
   Jones CM, 2018, JAMA-J AM MED ASSOC, V319, P1819, DOI 10.1001/jama.2018.2844
   KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U
   KALIVAS PW, 1990, J PHARMACOL EXP THER, V253, P858
   Kantak KM, 2007, DRUG ALCOHOL DEPEN, V86, P123, DOI 10.1016/j.drugalcdep.2006.05.020
   KISH GB, 1955, J COMP PHYSIOL PSYCH, V48, P261, DOI 10.1037/h0040782
   Koob GF, 2020, BIOL PSYCHIAT, V87, P44, DOI 10.1016/j.biopsych.2019.05.023
   Kuczynska K, 2018, FORENSIC SCI INT, V289, P207, DOI 10.1016/j.forsciint.2018.05.042
   LACEY MG, 1988, J PHYSIOL-LONDON, V401, P437, DOI 10.1113/jphysiol.1988.sp017171
   Lammel S, 2011, NEURON, V70, P855, DOI 10.1016/j.neuron.2011.03.025
   Larney S., 2019, JAMA PSYCHIAT, V77, P1
   Lopez A. J., 2019, 786616 BIORXIV, DOI [10.1101/786616, DOI 10.1101/786616]
   Marsch LA, 2001, J PHARMACOL EXP THER, V299, P1056
   Olsen CM, 2009, NEUROPSYCHOPHARMACOL, V34, P1685, DOI 10.1038/npp.2008.226
   POTHOS E, 1991, BRAIN RES, V566, P348, DOI 10.1016/0006-8993(91)91724-F
   Reiner DJ, 2019, NEUROPSYCHOPHARMACOL, V44, P465, DOI 10.1038/s41386-018-0234-2
   Shoji Y, 1999, J NEUROSCI, V19, P2347
   Thomsen M, 2011, BEHAV PHARMACOL, V22, P239, DOI 10.1097/FBP.0b013e328345f8f2
   Towers EB, 2019, NEUROPHARMACOLOGY, V151, P189, DOI 10.1016/j.neuropharm.2019.03.019
   Vanderschuren LJMJ, 2000, PSYCHOPHARMACOLOGY, V151, P99, DOI 10.1007/s002130000493
   Vendruscolo JCM, 2018, NEUROPSYCHOPHARMACOL, V43, P801, DOI 10.1038/npp.2017.172
   Vendruscolo LF, 2014, ALCOHOL, V48, P277, DOI 10.1016/j.alcohol.2013.08.006
   Volkow ND, 2000, LIFE SCI, V67, pPL1507
   Xi ZX, 1999, J PHARMACOL EXP THER, V290, P1369
   Zhang Y, 2018, NEUROSCIENCE, V393, P333, DOI 10.1016/j.neuroscience.2018.07.032
   Zhang Y, 2014, PSYCHOPHARMACOLOGY, V231, P1277, DOI 10.1007/s00213-013-3306-3
   Zijistra F, 2008, EUR NEUROPSYCHOPHARM, V18, P262, DOI 10.1016/j.euroneuro.2007.11.002
NR 51
TC 20
Z9 20
U1 3
U2 23
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375-2548
J9 SCI ADV
JI Sci. Adv.
PD AUG
PY 2020
VL 6
IS 32
AR eabc0413
DI 10.1126/sciadv.abc0413
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NB3YQ
UT WOS:000560452300034
PM 32821843
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Goldstein, RZ
   Barrot, M
   Everitt, BJ
   Foxe, JJ
AF Goldstein, Rita Z.
   Barrot, Michel
   Everitt, Barry J.
   Foxe, John J.
TI Addiction in focus: molecular mechanisms, model systems, circuit maps,
   risk prediction and the quest for effective interventions
SO EUROPEAN JOURNAL OF NEUROSCIENCE
LA English
DT Editorial Material
ID INHIBITORY CONTROL PROCESSES; COCAINE ADDICTION; DRUG-ADDICTION; FORMER
   COCAINE; METHYLPHENIDATE; DEPENDENCE; ABUSERS; CONSEQUENCES; IMPAIRMENT;
   RETENTION
C1 [Goldstein, Rita Z.] Icahn Sch Med Mt Sinai, Leon & Norma Hess Ctr Sci & Med, Dept Psychiat & Neurosci, New York, NY 10029 USA.
   [Barrot, Michel] Univ Strasbourg, CNRS, Inst Neurosci Cellulaires & Integrat, Strasbourg, France.
   [Everitt, Barry J.] Univ Cambridge, Behav & Clin Neurosci Inst, Cambridge, England.
   [Everitt, Barry J.] Univ Cambridge, Dept Psychol, Cambridge, England.
   [Foxe, John J.] Univ Rochester, Sch Med & Dent, Ernest J Del Monte Inst Neurosci, Dept Neurosci,Cognit Neurophysiol Lab, Rochester, NY USA.
C3 Icahn School of Medicine at Mount Sinai; Centre National de la Recherche
   Scientifique (CNRS); UDICE-French Research Universities; Universites de
   Strasbourg Etablissements Associes; Universite de Strasbourg; University
   of Cambridge; University of Cambridge; University of Rochester
RP Goldstein, RZ (通讯作者)，Icahn Sch Med Mt Sinai, Leon & Norma Hess Ctr Sci & Med, Dept Psychiat & Neurosci, New York, NY 10029 USA.
EM rita.goldstein@mssm.edu
FU Medical Research Council [MR/N02530X/1] Funding Source: Medline; NCCIH
   NIH HHS [R01 AT010627] Funding Source: Medline; NIDA NIH HHS [R01
   DA041528] Funding Source: Medline; MRC [MR/N02530X/1] Funding Source:
   UKRI
CR Aharonovich E, 2006, DRUG ALCOHOL DEPEN, V81, P313, DOI 10.1016/j.drugalcdep.2005.08.003
   Aharonovich E, 2003, DRUG ALCOHOL DEPEN, V71, P207, DOI 10.1016/S0376-8716(03)00092-9
   Alia-Klein N, 2011, ARCH GEN PSYCHIAT, V68, P283, DOI 10.1001/archgenpsychiatry.2011.10
   Anand KJS, 2015, ACTA PAEDIATR, V104, P1066, DOI 10.1111/apa.13121
   Anderson EM, 2019, EUR J NEUROSCI, V50, P2477, DOI 10.1111/ejn.14170
   Angioletti L, 2019, EUR J NEUROSCI, V50, P2392, DOI 10.1111/ejn.13993
   Balodis IM, 2016, NEUROPSYCHOPHARMACOL, V41, P2112, DOI 10.1038/npp.2016.11
   Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215
   Bechara Antoine, 2003, J Gambl Stud, V19, P23, DOI 10.1023/A:1021223113233
   Bell RP, 2014, NEUROPHARMACOLOGY, V82, P143, DOI 10.1016/j.neuropharm.2013.02.018
   Bossert J.M., 2019, EUR J NEUROSCI, V50, P2475
   Cannella LA, 2019, EXP NEUROL, V317, P191, DOI 10.1016/j.expneurol.2019.03.003
   Caritis SN, 2019, AM J OBSTET GYNECOL, V221, P602, DOI 10.1016/j.ajog.2019.07.022
   Cocker PJ, 2019, EUR J NEUROSCI, V50, P2401, DOI 10.1111/ejn.14070
   Cohen K, 2019, EUR J NEUROSCI, V50, P2322, DOI 10.1111/ejn.14407
   Curtis K., 2019, EUR J NEUROSCI, V50, P2466
   Damasio AR, 1996, PHILOS T R SOC B, V351, P1413, DOI 10.1098/rstb.1996.0125
   di Volo M, 2019, EUR J NEUROSCI, V50, P2282, DOI 10.1111/ejn.14147
   Even-Chen O, 2019, EUR J NEUROSCI, V50, P2552, DOI 10.1111/ejn.14133
   Everitt BJ, 2014, EUR J NEUROSCI, V40, P2163, DOI 10.1111/ejn.12644
   Ewald A, 2016, EUR J NEUROSCI, V43, P98, DOI 10.1111/ejn.13118
   First LR, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-3344
   Garcia-Pardo MP, 2019, EUR J NEUROSCI, V50, P2623, DOI 10.1111/ejn.14190
   Gibson GD, 2019, EUR J NEUROSCI, V50, P2014, DOI 10.1111/ejn.14084
   Gil-Miravet I, 2019, EUR J NEUROSCI, V50, P2613, DOI 10.1111/ejn.14187
   Goldberg LR, 2019, EUR J NEUROSCI, V50, P2453, DOI 10.1111/ejn.14060
   Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119
   Goldstein RZ, 2010, P NATL ACAD SCI USA, V107, P16667, DOI 10.1073/pnas.1011455107
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Goldstein RZ, 2004, NEUROPSYCHOLOGIA, V42, P1447, DOI 10.1016/j.neuropsychologia.2004.04.002
   Gregoriou GC, 2019, EUR J NEUROSCI, V50, P2065, DOI 10.1111/ejn.14107
   Harley M, 2010, PSYCHOL MED, V40, P1627, DOI 10.1017/S0033291709991966
   Herman AM, 2019, EUR J NEUROSCI, V50, P2297, DOI 10.1111/ejn.14108
   Hester R, 2009, PHARMACOL BIOCHEM BE, V93, P270, DOI 10.1016/j.pbb.2008.12.009
   Hodebourg R, 2019, EUR J NEUROSCI, V50, P2036, DOI 10.1111/ejn.13894
   Hofford RS, 2019, EUR J NEUROSCI, V50, P2562, DOI 10.1111/ejn.14143
   Hogarth L, 2019, EUR J NEUROSCI, V50, P2513, DOI 10.1111/ejn.13961
   Jadhav KS, 2019, EUR J NEUROSCI, V50, P2274, DOI 10.1111/ejn.14316
   James MH, 2019, EUR J NEUROSCI, V50, P2602, DOI 10.1111/ejn.14166
   Kaag AM, 2019, EUR J NEUROSCI, V50, P2264, DOI 10.1111/ejn.13991
   Kaneda K, 2019, EUR J NEUROSCI, V50, P2239, DOI 10.1111/ejn.13962
   Keighron JD, 2019, EUR J NEUROSCI, V50, P2045, DOI 10.1111/ejn.14256
   Konova AB, 2013, JAMA PSYCHIAT, V70, P857, DOI 10.1001/jamapsychiatry.2013.1129
   Linker KE, 2019, EUR J NEUROSCI, V50, P2574, DOI 10.1111/ejn.14163
   Liu JF, 2019, EUR J NEUROSCI, V50, P2503, DOI 10.1111/ejn.14072
   Loweth JA, 2019, EUR J NEUROSCI, V50, P2590, DOI 10.1111/ejn.14151
   Mackey S, 2019, AM J PSYCHIAT, V176, P119, DOI 10.1176/appi.ajp.2018.17040415
   Martinez D, 2011, AM J PSYCHIAT, V168, P634, DOI 10.1176/appi.ajp.2010.10050748
   Minogianis EA, 2019, EUR J NEUROSCI, V50, P2054, DOI 10.1111/ejn.13941
   Moeller SJ, 2014, CEREB CORTEX, V24, P643, DOI 10.1093/cercor/bhs345
   Moeller SJ, 2010, BRAIN, V133, P1484, DOI 10.1093/brain/awq066
   Morel C, 2019, EUR J NEUROSCI, V50, P2180, DOI 10.1111/ejn.14160
   Morie KP, 2014, NEUROPHARMACOLOGY, V82, P151, DOI 10.1016/j.neuropharm.2013.02.023
   Myles D, 2019, EUR J NEUROSCI, V50, P2384, DOI 10.1111/ejn.14191
   Naef L, 2019, EUR J NEUROSCI, V50, P2146, DOI 10.1111/ejn.14291
   Naish KR, 2019, EUR J NEUROSCI, V50, P2415, DOI 10.1111/ejn.14110
   Napier TC, 2019, EUR J NEUROSCI, V50, P2492, DOI 10.1111/ejn.14177
   Nawarawong NN, 2019, EUR J NEUROSCI, V50, P2101, DOI 10.1111/ejn.14281
   Nestor LJ, 2019, EUR J NEUROSCI, V50, P2311, DOI 10.1111/ejn.14262
   Parvaz MA, 2012, PSYCHIAT RES-NEUROIM, V203, P75, DOI 10.1016/j.pscychresns.2012.01.001
   Peng C, 2019, EUR J NEUROSCI, V50, P2224, DOI 10.1111/ejn.13957
   Potenza MN, 2012, AM J PSYCHIAT, V169, P406, DOI 10.1176/appi.ajp.2011.11020289
   Prashad S, 2019, EUR J NEUROSCI, V50, P2357, DOI 10.1111/ejn.14194
   Radke AK, 2019, EUR J NEUROSCI, V50, P2023, DOI 10.1111/ejn.14152
   Ross EJ, 2015, NEUROPSYCHOPHARMACOL, V40, P61, DOI 10.1038/npp.2014.147
   Runegaard AH, 2019, EUR J NEUROSCI, V50, P2156, DOI 10.1111/ejn.14082
   Sargeant TJ, 2008, EUR J NEUROSCI, V28, P1060, DOI 10.1111/j.1460-9568.2008.06412.x
   Sharp BM, 2019, EUR J NEUROSCI, V50, P2164, DOI 10.1111/ejn.14171
   Sharp BM, 2019, EUR J NEUROSCI, V50, P2247, DOI 10.1111/ejn.13970
   Shen ZJ, 2019, EUR J NEUROSCI, V50, P2201, DOI 10.1111/ejn.14282
   Spagnolo PA, 2019, EUR J NEUROSCI, V50, P2370, DOI 10.1111/ejn.14313
   Spechler PA, 2019, EUR J NEUROSCI, V50, P2346, DOI 10.1111/ejn.13989
   Sullivan RM, 2019, EUR J NEUROSCI, V50, P2467, DOI 10.1111/ejn.14229
   Tan D, 2019, EUR J NEUROSCI, V50, P2124, DOI 10.1111/ejn.14120
   Tom RL, 2019, EUR J NEUROSCI, V50, P2086, DOI 10.1111/ejn.13967
   Toyoda H, 2019, EUR J NEUROSCI, V50, P2211, DOI 10.1111/ejn.13857
   Vainik U, 2019, EUR J NEUROSCI, V50, P2430, DOI 10.1111/ejn.14352
   Vaucher J, 2018, MOL PSYCHIATR, V23, P1287, DOI 10.1038/mp.2016.252
   Verdejo-Garcia A, 2006, CURR NEUROPHARMACOL, V4, P17, DOI 10.2174/157015906775203057
   Verdejo-Garcia A, 2009, NEUROPHARMACOLOGY, V56, P48, DOI 10.1016/j.neuropharm.2008.07.035
   Viohl L, 2019, EUR J NEUROSCI, V50, P2526, DOI 10.1111/ejn.14340
   Violante-Soria V, 2019, EUR J NEUROSCI, V50, P2113, DOI 10.1111/ejn.13969
   Volkow ND, 2012, ANNU REV PHARMACOL, V52, P321, DOI 10.1146/annurev-pharmtox-010611-134625
   Vonder Haar C, 2019, EUR J NEUROSCI, V50, P2134, DOI 10.1111/ejn.14123
   Woicik PA, 2009, NEUROPSYCHOPHARMACOL, V34, P1112, DOI 10.1038/npp.2008.60
   Womersley JS, 2019, EUR J NEUROSCI, V50, P2538, DOI 10.1111/ejn.14130
   Zanos P, 2019, EUR J NEUROSCI, V50, P2255, DOI 10.1111/ejn.14155
   Zilverstand A, 2018, NEURON, V98, P886, DOI 10.1016/j.neuron.2018.03.048
NR 88
TC 2
Z9 2
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0953-816X
EI 1460-9568
J9 EUR J NEUROSCI
JI Eur. J. Neurosci.
PD AUG
PY 2019
VL 50
IS 3
SI SI
BP 2007
EP 2013
DI 10.1111/ejn.14544
PG 7
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology
GA IY1UN
UT WOS:000486177300001
PM 31502353
OA Green Accepted, Bronze
DA 2023-06-23
ER

PT J
AU Moore, D
   Pienaar, K
   Dilkes-Frayne, E
   Fraser, S
AF Moore, David
   Pienaar, Kiran
   Dilkes-Frayne, Ella
   Fraser, Suzanne
TI Challenging the addiction/health binary with assemblage thinking: An
   analysis of consumer accounts
SO INTERNATIONAL JOURNAL OF DRUG POLICY
LA English
DT Article
DE Addiction; Health; Assemblage; Critical analysis; Qualitative research;
   Australia
ID INJECTING DRUG-USERS; HEALTH; HIV
AB Critical analyses of drug use and 'addiction' have identified a series of binary oppositions between addiction and free will, independence, self-control, responsibility, productivity and autonomy. This critical work has also examined how science, policy and popular discourses frequently characterise addiction as antithetical to health and well-being. Furthermore, those diagnosed with addiction are often understood as indifferent to health and well-being, or as lacking the knowledge or desire required to maintain them. In this article, we draw on data from 60 qualitative interviews with people who self identify as living with an 'addiction', 'dependence' or 'habit', to argue that the binary opposition between addiction and health struggles to attend to their rich and varied health perspectives and experiences. We explore three themes in the interview data: reinscribing the binary opposition between addiction and health/well-being; strategies for maintaining health and well-being alongside addiction; and alcohol and other drug consumption as aiding health and well-being. Perhaps because addiction and health have been so thoroughly understood as antithetical, such perspectives and experiences have received surprisingly little research and policy attention. Yet they offer fertile ground for rethinking the strengths and capacities of those who self-identity as living with an addiction, dependence or habit, as well as untapped resources for responding to the harm sometimes associated with alcohol and other drug use. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Moore, David] Curtin Univ, NDRI Melbourne Off, Fac Hlth Sci, Ethnog Res Program,Natl Drug Res Inst, 6-19-35 Gertrude St, Fitzroy, Vic 3065, Australia.
   [Pienaar, Kiran; Fraser, Suzanne] Curtin Univ, NDRI Melbourne Off, Fac Hlth Sci, Social Studies Addict Concepts Res Program,Natl D, 6-19-35 Gertrude St, Fitzroy, Vic 3065, Australia.
   [Dilkes-Frayne, Ella] Monash Univ, Arts, Social Studies Hlth & Med Res Program, Menzies Bldg,20 Chancellors Walk,Clayton Campus, Clayton, Vic 3800, Australia.
C3 Curtin University; Curtin University; Monash University
RP Moore, D (通讯作者)，Curtin Univ, NDRI Melbourne Off, Fac Hlth Sci, Ethnog Res Program,Natl Drug Res Inst, 6-19-35 Gertrude St, Fitzroy, Vic 3065, Australia.
EM d.moore@curtin.edu.au
RI Moore, David/GXV-9667-2022; Pienaar, Kiran/AAB-1206-2020
OI Moore, David/0000-0002-5860-3109; Fraser, Suzanne/0000-0003-1018-5865;
   Pienaar, Kiran/0000-0003-4770-7882
FU Australian Research Council [DP140100996]; Australian Research Council
   Future Fellowship [FT120100215]; Australian Government under the
   Substance Misuse Prevention and Service Improvement Grants Fund;
   Australian Department of Health
FX The research reported in this article was conducted in the Social
   Studies of Addiction Concepts (SSAC) Research Program, based in the
   National Drug Research Institute, Faculty of Health Sciences, Curtin
   University, in collaboration with Healthtalk Australia, Monash
   University, the University of New South Wales' Centre for Social
   Research in Health and the Hunter New England Local Health District. The
   research was funded by the Australian Research Council (Discovery
   Project DP140100996). Suzanne Fraser was funded by an Australian
   Research Council Future Fellowship (FT120100215). The National Drug
   Research Institute is supported by funding from the Australian
   Government under the Substance Misuse Prevention and Service Improvement
   Grants Fund. The Centre for Social Research in Health is supported by a
   grant from the Australian Department of Health. The interviews were
   conducted by Kiran Pienaar, Ella Dilkes-Frayne, Jeanne Ellard and Jamee
   Newland. The authors thank the participants for generously sharing their
   stories. They also thank the reviewers and associate editor for their
   comments on an earlier version of the article.
CR American Psychiatric Association [APA], 2022, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425787]
   [Anonymous], RES HDB PROD HEALTHT
   Burrows R., 2005, SOCIOLOGY HLTH PROMO, P1
   CRAWFORD R, 1977, INT J HEALTH SERV, V7, P663, DOI 10.2190/YU77-T7B1-EN9X-G0PN
   CRAWFORD R, 1994, SOC SCI MED, V38, P1347, DOI 10.1016/0277-9536(94)90273-9
   Crawford R, 2006, HEALTH, V10, P401, DOI 10.1177/1363459306067310
   Duff C., 2014, ASSEMBLAGES HLTH DEL
   Dumit J., 2004, PICTURING PERSONHOOD
   Dwyer R, 2016, HEALTH SOCIOL REV, V25, P223, DOI 10.1080/14461242.2016.1184581
   Dwyer R, 2015, INT J DRUG POLICY, V26, P1189, DOI 10.1016/j.drugpo.2015.08.016
   Farrugia A., 2015, CONTEMP DRUG PROBL, V42, P240, DOI DOI 10.1177/0091450915601520
   Fraser S, 2008, SUBSTANCE AND SUBSTITUTION: METHADONE SUBJECTS IN LIBERAL SOCIETIES, P1, DOI 10.1057/9780230582569
   Fraser S, 2011, MAKING DIS MAKING CI
   Fraser S, 2008, SOC SCI MED, V66, P740, DOI 10.1016/j.socscimed.2007.10.012
   Fraser S, 2011, INT J DRUG POLICY, V22, P498, DOI 10.1016/j.drugpo.2011.09.004
   Fraser Suzanne, 2014, HABITS REMAKING ADDI
   Fry C, 2001, ADDICTION, V96, P1319, DOI 10.1046/j.1360-0443.2001.969131911.x
   Hart A., 2015, CONTEMP DRUG PROBL, V42, P148, DOI [10.1177/0091450915583828, DOI 10.1177/0091450915583828]
   Keane H., 2002, WHATS WRONG ADDICTIO
   Keane H., 2000, HEALTH, V4, P324, DOI DOI 10.1177/136345930000400305
   Kirkland A, 2010, HLTH HLTH BECAME NEW, P195
   LEVINE HG, 1978, J STUD ALCOHOL, V39, P143, DOI 10.15288/jsa.1978.39.143
   Lupton D, 1997, SOC SCI MED, V45, P373, DOI 10.1016/S0277-9536(96)00353-X
   McLeod K., 2014, CONTEMP DRUG PROBL, V41, P109, DOI DOI 10.1177/009145091404100106
   Metzl Jonathan M., 2010, HLTH HLTH BECAME NEW
   Moore D, 2004, SOC SCI MED, V59, P1547, DOI 10.1016/j.socscimed.2004.01.029
   Moore D, 2006, SOC SCI MED, V62, P3035, DOI 10.1016/j.socscimed.2005.11.067
   OMalley Pat, 1999, GOVERNABLE PLACES RE, P191, DOI DOI 10.4324/9780429427114-8
   PETERSEN A, 1997, FOUCAULT HLTH MED, P188
   Petersen A., 1996, NEW PUBLIC HLTH HLTH
   Petersen Alan, 1997, FOUCAULT HLTH MED
   Pienaar K, 2016, SOC THEOR HEALTH, V14, P149, DOI 10.1057/sth.2015.26
   Race K, 2014, CONTEMP DRUG PROBL, V41, P301, DOI DOI 10.1177/009145091404100303
   Redfield M, 2002, HIGH ANXIETIES CULTU, P1
   Reinarman C, 2005, ADDICT RES THEORY, V13, P307, DOI 10.1080/16066350500077728
   Reith G, 2004, BRIT J SOCIOL, V55, P283, DOI 10.1111/j.1468-4446.2004.00019.x
   ROOM R, 1985, BRIT J ADDICT, V80, P133
   Room R., 2003, JANUS HEAD, V6, P221, DOI DOI 10.5840/JH2003628
   Seddon T., 2010, HIST DRUGS DRUGS FRE
   SEDGWICK EK, 1993, TENDENCIES, P130
   Squire C, 2010, CRIT PUBLIC HEALTH, V20, P401, DOI 10.1080/09581596.2010.517828
   Tesh S., 1990, HIDDEN ARGUMENTS POL
   Valverde M., 1998, DIS WILL ALCOHOL DIL
   Weinberg D, 2011, SOCIOL COMPASS, V5, P298, DOI 10.1111/j.1751-9020.2011.00363.x
   World Health Organization, 1992, ICD 10 CLASS DIS REL
NR 45
TC 30
Z9 30
U1 0
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0955-3959
EI 1873-4758
J9 INT J DRUG POLICY
JI Int. J. Drug Policy
PD JUN
PY 2017
VL 44
BP 155
EP 163
DI 10.1016/j.drugpo.2017.01.013
PG 9
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA FD9VR
UT WOS:000407870700018
PM 28431794
OA Green Submitted
DA 2023-06-23
ER

PT J
AU Polcin, DL
AF Polcin, Douglas L.
TI Addiction science advocacy: Mobilizing political support to influence
   public policy
SO INTERNATIONAL JOURNAL OF DRUG POLICY
LA English
DT Editorial Material
DE Addiction; Drug use; Policy; Advocacy; Training
ID SOBER LIVING HOUSES
C1 Inst Publ Hlth, Alcohol Res Grp, Emeryville, CA 94608 USA.
C3 Alcohol Research Group; Public Health Institute
RP Polcin, DL (通讯作者)，Inst Publ Hlth, Alcohol Res Grp, 6475 Christie Ave,Suite 400, Emeryville, CA 94608 USA.
EM DPolcin@arg.org
OI Polcin, Douglas/0000-0002-6518-8628
FU NIDA NIH HHS [R21 DA025208] Funding Source: Medline
CR Cook C., 2010, DIFFUSION HARM REDUC
   Grattet R., 2009, FED PROBAT, V73, P2
   Gwynne K, 2011, NEW POLL MOST AM CON
   Hedrich D., 2010, HARM REDUCTION EVIDE
   Kaskutas LA, 2007, SUBST USE MISUSE, V42, P1767, DOI 10.1080/10826080701208608
   Kubi R, 2012, YALE J MED LAW UNDER, V8
   National Institute on Drug Abuse, 2012, NIH PUBLICATION
   Petersilia Joan, 2003, PRISONERS COME HOME
   Petteruti Amanda, 2008, JAILING COMMUNITIES
   Pew Charitable Trusts, 2009, PEW CTR STAT ON 31 L
   Polcin DL, 2012, ADDICT RES THEORY, V20, P480, DOI 10.3109/16066359.2012.665967
   Polcin DL, 2010, J PSYCHOACTIVE DRUGS, V42, P425
   Sober Living Network, 2013, HOUS RIGHTS VERS CIT
   Tulchin Research, 2012, NEW CAL STAT POLL FI
   Walmsley R., 2006, WORLD PRISON POPULAT, P1
   White W., 2010, RECOVERY CITIZENSHIP
NR 16
TC 7
Z9 7
U1 1
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0955-3959
EI 1873-4758
J9 INT J DRUG POLICY
JI Int. J. Drug Policy
PD MAR
PY 2014
VL 25
IS 2
BP 329
EP 331
DI 10.1016/j.drugpo.2013.11.002
PG 3
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA AE6WR
UT WOS:000334139200020
PM 24331761
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Whistler, JL
   Chuang, HH
   Chu, P
   Jan, LY
   von Zastrow, M
AF Whistler, JL
   Chuang, HH
   Chu, P
   Jan, LY
   von Zastrow, M
TI Functional dissociation of mu opioid receptor signaling and endocytosis:
   Implications for the biology of opiate tolerance and addiction
SO NEURON
LA English
DT Article
ID DOWN-REGULATION; BETA-ARRESTIN; BRAIN-CELLS; DESENSITIZATION; MORPHINE;
   PHOSPHORYLATION; EFFICACY; INTERNALIZATION; RESENSITIZATION; EXPRESSION
AB Opiate analgesia, tolerance, and addiction are mediated by drug-induced activation of the mu opioid receptor. A fundamental question in addiction biology is why exogenous opiate drugs have a high liability for inducing tolerance and addiction while native ligands do not. Studies indicate that highly addictive opiate drugs such as morphine are deficient in their ability to induce the desensitization and endocytosis of receptors. Here, we demonstrate that this regulatory mechanism reveals an independent functional property of opiate drugs that can be distinguished from previously established agonist properties. Moreover, this property correlates with agonist propensity to promote physiological tolerance, suggesting a fundamental revision of our understanding of the role of receptor endocytosis in the biology of opiate drug action and addiction.
C1 Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA.
C3 University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   University of California System; University of California San Francisco
RP von Zastrow, M (通讯作者)，Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.
OI Jan, Lily/0000-0003-3938-8498
CR Afify EA, 1998, MOL BRAIN RES, V54, P24, DOI 10.1016/S0169-328X(97)00315-X
   Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497
   CHAKRABARTI S, 1995, J NEUROCHEM, V64, P2534
   CHAVKIN C, 1984, P NATL ACAD SCI-BIOL, V81, P7253, DOI 10.1073/pnas.81.22.7253
   Chuang HH, 1998, P NATL ACAD SCI USA, V95, P11727, DOI 10.1073/pnas.95.20.11727
   COSTA T, 1992, MOL PHARMACOL, V41, P549
   DUTTAROY A, 1995, ANESTHESIOLOGY, V82, P1226, DOI 10.1097/00000542-199505000-00018
   Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6
   Keith DE, 1998, MOL PHARMACOL, V53, P377, DOI 10.1124/mol.53.3.377
   Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021
   Kovoor A, 1998, MOL PHARMACOL, V54, P704
   Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605
   Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289
   Lefkowitz R J, 1998, Adv Pharmacol, V42, P416
   LENOIR D, 1984, BRAIN RES, V304, P285, DOI 10.1016/0006-8993(84)90332-9
   Lissin DV, 1998, P NATL ACAD SCI USA, V95, P7097, DOI 10.1073/pnas.95.12.7097
   Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0
   Mercadante S, 1998, J CLIN ONCOL, V16, P3656, DOI 10.1200/JCO.1998.16.11.3656
   Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987
   PEI G, 1995, MOL PHARMACOL, V48, P173
   RAYNOR K, 1994, MOL PHARMACOL, V45, P330
   REZVANI A, 1983, J PHARMACOL EXP THER, V225, P251
   SIMANTOV R, 1984, NEUROPEPTIDES, V5, P197, DOI 10.1016/0143-4179(84)90061-1
   Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241
   Szekeres PG, 1998, MOL PHARMACOL, V53, P759, DOI 10.1124/mol.53.4.759
   Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279
   TRAYNOR JR, 1995, MOL PHARMACOL, V47, P848
   Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914
   Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869
   Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157
   Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449
NR 31
TC 358
Z9 376
U1 0
U2 19
PU CELL PRESS
PI CAMBRIDGE
PA 1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA
SN 0896-6273
J9 NEURON
JI Neuron
PD AUG
PY 1999
VL 23
IS 4
BP 737
EP 746
DI 10.1016/S0896-6273(01)80032-5
PG 10
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 230ZE
UT WOS:000082280900017
PM 10482240
OA Bronze
DA 2023-06-23
ER

PT J
AU Nagaya, D
   Ramanathan, S
   Ravichandran, M
   Navaratnam, V
AF Nagaya, Devaki
   Ramanathan, Surash
   Ravichandran, Manickam
   Navaratnam, Visweswaran
TI A118G mu opioid receptor polymorphism among drug addicts in Malaysia
SO JOURNAL OF INTEGRATIVE NEUROSCIENCE
LA English
DT Article
DE mu-opioid receptor; polymorphism; A118G; drug addicts; Malaysia
ID GENE; ASSOCIATION; ENVIRONMENT; ALCOHOL; DEPENDENCE
AB Drug addiction is an important social problem in many countries. Genetic and environmental factors contribute to the predisposition of drug addiction. Genetic variations at the mu opioid receptor (OPRM1) gene locus have been associated with opiate addiction. The present study aims to delineate the frequency of A118G allele of OPRM1 among Malaysian subjects. The frequency of A allele and G allele were 51% and 49%, respectively for addicts and about 73% and 27% respectively for healthy volunteers. The frequency of G allele was 1.77-fold higher in addicts by odds ratio calculation at 95% Cl, which indicate the G allele to be strongly associated with addiction X-2 = 15.31; P < 0.0001; odds ratio 2.51; 95% Cl (1.575-3.994), compared to healthy volunteers. A significant association was observed between A118G polymorphism in mu opioid receptor gene and drug addiction.
C1 [Nagaya, Devaki; Ravichandran, Manickam] AIMST Univ, Fac Sci Appl, Kedah, Malaysia.
   [Ramanathan, Surash; Navaratnam, Visweswaran] Univ Sci Malaysia, Ctr Drug Res, George Town, Malaysia.
C3 AIMST University; Universiti Sains Malaysia
RP Nagaya, D (通讯作者)，AIMST Univ, Fac Sci Appl, Kedah, Malaysia.
EM devakisen121@yahoo.com
RI RAVICHANDRAN, MANICKAM/A-7128-2011
OI RAVICHANDRAN, MANICKAM/0000-0001-5321-1344; Nagaya,
   Devaki/0000-0002-0930-3249
FU Centre for Drug Research, University Science Malaysia; AIMST University
   Malaysia
FX We are grateful to all the subjects from Rehabilitation Centre, Penang
   Malaysia for their participation in this study. We also thank the staff
   at Centre for Drug Research, University Science Malaysia and AIMST
   University Malaysia for their support during sample collection and the
   lab work.
CR Bart G, 2004, MOL PSYCHIATR, V9, P547, DOI 10.1038/sj.mp.4001504
   Becker A, 2000, N-S ARCH PHARMACOL, V361, P584, DOI 10.1007/s002100000244
   Bergen AW, 1997, MOL PSYCHIATR, V2, P490, DOI 10.1038/sj.mp.4000331
   Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608
   Franke P., 2008, AM J MED GENET, V8, P462
   Gelernter J, 1999, MOL PSYCHIATR, V4, P476, DOI 10.1038/sj.mp.4000556
   Kapur Suman, 2007, Journal of Integrative Neuroscience, V6, P511, DOI 10.1142/S0219635207001635
   Kendler KS, 2007, PSYCHOL MED, V37, P615, DOI 10.1017/S0033291706009524
   Li CY, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.0040002
   Li T, 2000, ADDICT BIOL, V5, P181, DOI 10.1080/13556210050003775
   Li T, 1997, MOL PSYCHIATR, V2, P413, DOI 10.1038/sj.mp.4000310
   Rutter M, 2007, DEVELOPMENTAL SCI, V10, P12, DOI 10.1111/j.1467-7687.2007.00557.x
   Tan EC, 2003, NEUROREPORT, V14, P569, DOI 10.1097/00001756-200303240-00008
   van der Zwaluw CS, 2009, ADDICTION, V104, P907, DOI 10.1111/j.1360-0443.2009.02563.x
   Zhang DD, 2007, BIOL PSYCHIAT, V61, P1244, DOI 10.1016/j.biopsych.2006.07.012
NR 15
TC 12
Z9 12
U1 0
U2 10
PU IMR PRESS
PI WAN CHAI
PA RM 19C, LOCKHART CTR, 301-307 LOCKHART RD, WAN CHAI, 00000, HONG KONG
SN 0219-6352
EI 1757-448X
J9 J INTEGR NEUROSCI
JI J. Integr. Neurosci.
PD MAR
PY 2012
VL 11
IS 1
BP 117
EP 122
DI 10.1142/S0219635212500082
PG 6
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 909CL
UT WOS:000301539600008
PM 22744787
DA 2023-06-23
ER

PT J
AU Moll, MF
   Santos, VO
   Duarte, CF
   Silva, PS
   Ventura, CAA
AF Moll, Marciana F.
   Santos, Vanessa O.
   Duarte, Cleudiane F.
   Silva, Paulline S.
   Ventura, Carla A. A.
TI Situations That Lead Women to Seek Treatment for Drug Addiction
SO JOURNAL OF ADDICTIONS NURSING
LA English
DT Article
DE Illicit Drugs; Substance-Related Disorders; Therapy; Women
AB Introduction
   Investigating the situations that lead women to seek treatment for drug addiction is necessary, as women experience the organic, social, and family damage caused by addiction intensely. Objective
   The aim of this study was to describe situations that lead women to seek treatment for drug addiction. Method
   This is an exploratory, descriptive study, with a qualitative approach, carried out in a CAPS Ad service in the state of Minas Gerais (CAAE: 92864518.4.0000.5145). Open interviews were conducted in September 2018 with 24 of 28 women assisted by the service. The discourse of the collective subject was the basis of the data analysis. Results
   Social, family, and health problems were the main damaging impact of drug addiction among the women and were represented by the following: death of loved ones, violence from partners, theft, cognitive problems, hypertension, and diabetes. Specifically, it was affective and material losses experienced during the period of addiction that led the women to seek treatment. Final Considerations
   It is necessary to facilitate women's access to treatment for drug addiction and to incorporate their families into the treatment through activities that will reinforce the former's commitment to any proposed therapeutics; in addition, goals to reconstruct bonds within the family environment should be established.
C1 [Moll, Marciana F.; Ventura, Carla A. A.] Univ Sao Paulo, Ribeirao Preto Coll Nursing, PAHO WHO Collaborating Ctr Nursing Res Dev, Ribeirao Preto, Brazil.
   [Moll, Marciana F.; Santos, Vanessa O.; Duarte, Cleudiane F.; Silva, Paulline S.] Univ Uberaba, Uberaba, MG, Brazil.
C3 Universidade de Sao Paulo; Universidade de Uberaba (Uniube)
RP Ventura, CAA (通讯作者)，Univ Sao Paulo, Ribeirao Preto Coll Nursing, Dept Psychiat Nursing & Human Sci, Av Bandeirantes 3900,Cidade Univ, BR-14040902 Ribeirao Preto, SP, Brazil.
EM caaventu@eerp.usp.br
RI Ventura, Carla/B-2609-2014
OI Ventura, Carla/0000-0003-0379-913X
CR Alvarez S.Q., 2014, REV ENFERMAGEM UFPE, V8, P641, DOI [10.5205/reuol.5149-42141-1-SM.0803201419, DOI 10.5205/REUOL.5149-42141-1-SM.0803201419]
   Assis D., 2010, REV TEXTOS CONTEXTO, V9, P358
   Assis E.X., 2016, REV DIVULGACAO INTER, V4, P1
   Baharudin DF, 2014, J SUBST USE, V19, P301, DOI 10.3109/14659891.2013.799239
   Brasil, 2013, NAT POL PLAN WOM 201
   Brasil, 2015, MIN HLTH POL COMPR C
   Brasil, 2014, EFF PSYCH SUBST
   Brasil, 2018, CIT UB
   Carlini E.A., 2007, HOME SURVEY PSYCHOTR
   Carvalho Marta Cristina Silva, 2018, Rev. Ambient. Água, V13, pe2078, DOI 10.4136/ambi-agua.2078
   Oliveira Graciele Cadahaiane de, 2012, Rev. Gaúcha Enferm., V33, P60
   Donato E.C.S.G., 2014, WOMEN DRUGS VIOLENCE, P149
   Ferreira A.C.Z., 2015, REV MIN ENFERM, V19, P150, DOI [10.5935/1415-2762.20150032, DOI 10.5935/1415-2762.20150032]
   Fertig Adriana, 2016, Esc. Anna Nery, V20, P310, DOI 10.5935/1414-8145.20160042
   Gomes R.R., 2015, REV TERAPIA OCUPACIO, V26, P326, DOI [10.11606/issn.2238-6149.v26i3p326-335, DOI 10.11606/ISSN.2238-6149.V26I3P326-335]
   Kessler Felix, 2010, Rev. psiquiatr. Rio Gd. Sul, V32, P48, DOI 10.1590/S0101-81082010000200005
   Lefevre Fernando, 2014, Texto contexto - enferm., V23, P502, DOI 10.1590/0104-07072014000000014
   Limberger J., 2015, PSICOL PESQ, V9, P13, DOI [10.5327/Z1982-1247201500020004, DOI 10.5327/Z1982-1247201500020004]
   Marangoni Sônia Regina, 2013, Texto contexto - enferm., V22, P662, DOI 10.1590/S0104-07072013000300012
   Meireles A.C.A., 2018, REV CIENTIFICA MULTI, V3, P125
   Nacoes Unidas Sobre Drogas  Crime, 2018, WORLD DRUG REPORT 20
   Nimtz M.A., 2016, REV ELETRONICA SAUDE, V12, P68, DOI [10.11606/issn.1806-6976.v12i2p65-74, DOI 10.11606/ISSN.1806-6976.V12I2P65-74]
   Noori R, 2019, J SUBST USE, V24, P280, DOI 10.1080/14659891.2018.1562573
   Oliveira M.M., 2014, REV ELETRONICA SAUDE, V10, P119, DOI [10.11606/issn.1806-6976.v10i3p119-125, DOI 10.11606/ISSN.1806-6976.V10I3P119]
   Prefeitura Municipal de Uberaba, 2017, MUN HLTH PLAN 2018 2
   Reis L.M., 2015, REV ELETRONICA ENFER, V17, P1, DOI [10.5216/ree.v17i3.28663, DOI 10.5216/REE.V17I3.28663]
   Seleghim MR, 2013, ACTA PAUL ENFERM, V26, P263, DOI 10.1590/S0103-21002013000300010
   Soares Iracil, 2017, Psic., Saúde & Doenças, V18, P567, DOI 10.15309/17psd180223
   Souza Márcia Rebeca Rocha de, 2014, Texto contexto - enferm., V23, P92, DOI 10.1590/S0104-07072014000100011
   Stefanelli M.C., 2017, PSYCHIAT NURSING, V2nd ed, P586
   United Nations Office of Drugs and Crime, 2015, WORLD DRUG REPORT 20
   van Boekel LC, 2015, INT J SOC PSYCHIATR, V61, P539, DOI 10.1177/0020764014562051
   Vargas Divane de, 2015, Saúde debate, V39, P782, DOI 10.1590/0103-1104201510600030018
   World Health Organization (WHO), 2010, GLOB STRAT RED HARMF
NR 34
TC 0
Z9 0
U1 3
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1088-4602
EI 1548-7148
J9 J ADDICT NURS
JI J. Addict. Nurs.
PD APR-JUN
PY 2021
VL 32
IS 2
BP 126
EP 131
DI 10.1097/JAN.0000000000000399
PG 6
WC Substance Abuse; Nursing
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Nursing
GA SP9LJ
UT WOS:000659984000008
PM 34060764
DA 2023-06-23
ER

PT J
AU Wu, RY
   Li, JX
AF Wu, Ruyan
   Li, Jun-Xu
TI Toll-Like Receptor 4 Signaling and Drug Addiction
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE toll-like receptor 4; opioids; alcohol; psychostimulants; drug reward;
   reinstatement; withdrawal
ID ENHANCES INFLAMMATORY MEDIATORS; MICE LACKING CD14; INDUCED
   NEUROINFLAMMATION; INTESTINAL PERMEABILITY; ETHANOL-CONSUMPTION;
   ALCOHOL-DEPENDENCE; PREFRONTAL CORTEX; GABA(A) RECEPTOR; CELL-DEATH;
   TNF-ALPHA
AB The emphasis of neuronal alterations and adaptations have long been the main focus of the studies of the mechanistic underpinnings of drug addiction. Recent studies have begun to appreciate the role of innate immune system, especially toll-like receptor 4 (TLR4) signaling in drug reward-associated behaviors and physiology. Drugs like opioids, alcohol and psychostimulants activate TLR4 signaling and subsequently induce proinflammatory responses, which in turn contributes to the development of drug addiction. Inhibition of TLR4 or its downstream effectors attenuated the reinforcing effects of opioids, alcohol and psychostimulants, and this effect is also involved in the withdrawal and relapse-like behaviors of different drug classes. However, conflicting results also argue that TLR4-related immune response may play a minimal part in drug addiction. This review discussed the preclinical evidence that whether TLR4 signaling is involved in multiple drug classes action and the possible mechanisms underlying this effect. Moreover, clinical studies which examined the potential efficacy of immune-base pharmacotherapies in treating drug addiction are also discussed.
C1 [Wu, Ruyan] Yangzhou Univ, Sch Med, Yangzhou, Jiangsu, Peoples R China.
   [Wu, Ruyan; Li, Jun-Xu] SUNY Buffalo, Dept Pharmacol & Toxicol, Buffalo, NY 14260 USA.
C3 Yangzhou University; State University of New York (SUNY) System; State
   University of New York (SUNY) Buffalo
RP Wu, RY (通讯作者)，Yangzhou Univ, Sch Med, Yangzhou, Jiangsu, Peoples R China.; Wu, RY (通讯作者)，SUNY Buffalo, Dept Pharmacol & Toxicol, Buffalo, NY 14260 USA.
EM ruyanwu0908@gmail.com
RI Li, Jun-Xu/K-9192-2013
OI Li, Jun-Xu/0000-0003-4749-0767
FU National Natural Science Foundation of China [81701340]; Natural Science
   Foundation of Jiangsu Province [BK 20170517]
FX RW was partially supported by the National Natural Science Foundation of
   China (Grant 81701340) and Natural Science Foundation of Jiangsu
   Province (Grant BK 20170517).
CR Alfonso-Loeches S, 2012, GLIA, V60, P948, DOI 10.1002/glia.22327
   Alfonso-Loeches S, 2010, J NEUROSCI, V30, P8285, DOI 10.1523/JNEUROSCI.0976-10.2010
   Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622
   Arout CA, 2019, PSYCHOPHARMACOLOGY, V236, P2857, DOI 10.1007/s00213-018-5146-7
   Aurelian L, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.72
   Bachtell R, 2015, CNS NEUROL DISORD-DR, V14, P692, DOI 10.2174/1871527314666150529132503
   Bajo M, 2016, ALCOHOL ALCOHOLISM, V51, P541, DOI 10.1093/alcalc/agw026
   Balan I, 2018, BRAIN SCI, V8, DOI 10.3390/brainsci8040072
   Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490
   Birath JB, 2017, DRUG ALCOHOL DEPEN, V178, P386, DOI 10.1016/j.drugalcdep.2017.05.016
   Blanco AM, 2005, J IMMUNOL, V175, P6893, DOI 10.4049/jimmunol.175.10.6893
   Blanco AM, 2004, NEUROREPORT, V15, P681, DOI 10.1097/00001756-200403220-00021
   Blanco AM, 2008, J NEUROCHEM, V106, P625, DOI 10.1111/j.1471-4159.2008.05425.x
   Blanco AM, 2007, FRONT BIOSCI-LANDMRK, V12, P2616, DOI 10.2741/2259
   Blednov YA, 2017, ALCOHOL CLIN EXP RES, V41, P531, DOI 10.1111/acer.13314
   Blednov YA, 2017, ALCOHOL CLIN EXP RES, V41, P516, DOI 10.1111/acer.13316
   Brown KT, 2018, BRAIN BEHAV IMMUN, V67, P130, DOI 10.1016/j.bbi.2017.08.012
   Burns Lindsay H, 2010, Recent Pat CNS Drug Discov, V5, P210
   Caron G, 2005, J IMMUNOL, V175, P1551, DOI 10.4049/jimmunol.175.3.1551
   Chaplin DD, 2010, J ALLERGY CLIN IMMUN, V125, pS3, DOI 10.1016/j.jaci.2009.12.980
   Chikritzhs TN, 2001, MED J AUSTRALIA, V174, P281, DOI 10.5694/j.1326-5377.2001.tb143269.x
   Coller JK, 2012, PHARMACOL THERAPEUT, V134, P219, DOI 10.1016/j.pharmthera.2012.01.008
   Cooper ZD, 2017, DRUG ALCOHOL DEPEN, V178, P340, DOI 10.1016/j.drugalcdep.2017.04.029
   Cooper ZD, 2016, ADDICT BIOL, V21, P895, DOI 10.1111/adb.12261
   Crews FT, 2011, BRAIN BEHAV IMMUN, V25, pS4, DOI 10.1016/j.bbi.2011.03.003
   Crews FT, 2017, NEUROPHARMACOLOGY, V122, P56, DOI 10.1016/j.neuropharm.2017.01.031
   Crews FT, 2017, PSYCHOPHARMACOLOGY, V234, P1483, DOI 10.1007/s00213-017-4560-6
   Crews FT, 2015, ALCOHOL RES-CURR REV, V37, P331, DOI 10.17615/kbjf-fa93
   Cummings JR, 2018, J ADDICT MED, V12, P410, DOI 10.1097/ADM.0000000000000416
   Domercq M, 2006, J BIOL CHEM, V281, P30684, DOI 10.1074/jbc.M606429200
   Du SH, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00409
   Ducci F, 2007, ALCOHOL, V41, P3, DOI 10.1016/j.alcohol.2007.02.005
   Dunne A, 2011, CURR OPIN PHARMACOL, V11, P404, DOI 10.1016/j.coph.2011.03.004
   Edenberg HJ, 2004, AM J HUM GENET, V74, P705, DOI 10.1086/383283
   Eidson LN, 2017, NEUROPSYCHOPHARMACOL, V42, P661, DOI 10.1038/npp.2016.131
   Eidson LN, 2013, J NEUROSCI, V33, P15952, DOI 10.1523/JNEUROSCI.1609-13.2013
   Erickson EK, 2019, PHARMACOL BIOCHEM BE, V177, P34, DOI 10.1016/j.pbb.2018.12.007
   Feldmann M, 2009, ANNU REV IMMUNOL, V27, P1, DOI 10.1146/annurev-immunol-082708-100732
   Fernandez-Lizarbe S, 2009, J IMMUNOL, V183, P4733, DOI 10.4049/jimmunol.0803590
   Fields HL, 2015, TRENDS NEUROSCI, V38, P217, DOI 10.1016/j.tins.2015.01.002
   Flores-Bastias O, 2018, NEUROPHARMACOLOGY, V128, P401, DOI 10.1016/j.neuropharm.2017.11.003
   Foster KL, 2004, NEUROPSYCHOPHARMACOL, V29, P269, DOI 10.1038/sj.npp.1300306
   Bueno BG, 2016, NEUROSCI BIOBEHAV R, V64, P134, DOI 10.1016/j.neubiorev.2016.02.013
   Gasiorowski K, 2018, MOL NEUROBIOL, V55, P1463, DOI 10.1007/s12035-017-0419-4
   Gaudino SJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00360
   Gesuete R, 2014, J NEUROPATH EXP NEUR, V73, P378, DOI 10.1097/NEN.0000000000000068
   Gibson LCD, 2006, EUR J PHARMACOL, V538, P39, DOI 10.1016/j.ejphar.2006.02.053
   Hall FS, 2004, ANN NY ACAD SCI, V1025, P47, DOI 10.1196/annals.1316.006
   Harris RA, 2017, J NEUROSCI, V37, P1139, DOI 10.1523/JNEUROSCI.2002-16.2016
   Heinzerling KG, 2020, J NEUROIMMUNE PHARM, V15, P238, DOI 10.1007/s11481-019-09883-w
   Hennessy EJ, 2010, NAT REV DRUG DISCOV, V9, P293, DOI 10.1038/nrd3203
   Hurd YL, 2019, AM J PSYCHIAT, V176, P911, DOI 10.1176/appi.ajp.2019.18101191
   Hurd YL, 2015, NEUROTHERAPEUTICS, V12, P807, DOI 10.1007/s13311-015-0373-7
   Hutchinson MR, 2012, J NEUROSCI, V32, P11187, DOI 10.1523/JNEUROSCI.0684-12.2012
   Jacobsen JHW, 2014, INT REV NEUROBIOL, V118, P129, DOI 10.1016/B978-0-12-801284-0.00006-3
   June HL, 2015, NEUROPSYCHOPHARMACOL, V40, P1549, DOI 10.1038/npp.2015.4
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564
   Kashima DT, 2017, P NATL ACAD SCI USA, V114, P8865, DOI 10.1073/pnas.1705974114
   Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Klareskog L, 2004, LANCET, V363, P675, DOI 10.1016/S0140-6736(04)15640-7
   Koropatnick TA, 2004, SCIENCE, V306, P1186, DOI 10.1126/science.1102218
   Kronenberger B, 2009, ANN HEPATOL, V8, P103, DOI 10.1016/S1665-2681(19)31786-7
   Lacagnina MJ, 2017, NEUROPSYCHOPHARMACOL, V42, P156, DOI 10.1038/npp.2016.121
   Landreth GE, 2009, CURR TOP MICROBIOL, V336, P137, DOI 10.1007/978-3-642-00549-7_8
   Langlois LD, 2017, ACS CHEM NEUROSCI, V8, P1830, DOI 10.1021/acschemneuro.7b00281
   Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452
   Leclercq S, 2014, P NATL ACAD SCI USA, V111, pE4485, DOI 10.1073/pnas.1415174111
   Leclercq S, 2012, BRAIN BEHAV IMMUN, V26, P911, DOI 10.1016/j.bbi.2012.04.001
   Lee BR, 2013, NAT NEUROSCI, V16, P1644, DOI 10.1038/nn.3533
   Lewitus GM, 2016, NEURON, V90, P483, DOI 10.1016/j.neuron.2016.03.030
   Lewitus GM, 2014, J NEUROSCI, V34, P6146, DOI 10.1523/JNEUROSCI.3481-13.2014
   Li MJ, 2020, DRUG ALCOHOL DEPEN, V206, DOI 10.1016/j.drugalcdep.2019.107776
   Liu G, 2010, CLIN EXP IMMUNOL, V160, P168, DOI 10.1111/j.1365-2249.2010.04091.x
   Liu JF, 2019, NEUROSCI BULL, V35, P771, DOI 10.1007/s12264-018-00335-8
   Liu JA, 2011, P NATL ACAD SCI USA, V108, P4465, DOI 10.1073/pnas.1019020108
   Loftis JM, 2014, INT REV NEUROBIOL, V118, P165, DOI 10.1016/B978-0-12-801284-0.00007-5
   Ma YY, 2014, NEURON, V83, P1453, DOI 10.1016/j.neuron.2014.08.023
   Mattioli TA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097361
   Metz VE, 2017, NEUROPSYCHOPHARMACOL, V42, P1825, DOI 10.1038/npp.2017.70
   Montesinos J, 2016, ALCOHOL CLIN EXP RES, V40, P2260, DOI 10.1111/acer.13208
   Naimi TS, 2003, JAMA-J AM MED ASSOC, V289, P70, DOI 10.1001/jama.289.1.70
   Narita M, 2006, NEUROPSYCHOPHARMACOL, V31, P2476, DOI 10.1038/sj.npp.1301007
   Nie X, 2018, NEURON, V99, P464, DOI 10.1016/j.neuron.2018.06.035
   Northcutt AL, 2015, MOL PSYCHIATR, V20, P1525, DOI 10.1038/mp.2014.177
   Otis JM, 2017, NEUROPSYCHOPHARMACOL, V42, P2000, DOI 10.1038/npp.2017.90
   Pandey SC, 2012, BRIT J PHARMACOL, V165, P1316, DOI 10.1111/j.1476-5381.2011.01695.x
   Parlesak A, 2000, J HEPATOL, V32, P742, DOI 10.1016/S0168-8278(00)80242-1
   Pascual M, 2015, NEUROPHARMACOLOGY, V89, P352, DOI 10.1016/j.neuropharm.2014.10.014
   Pascual M, 2011, BRAIN BEHAV IMMUN, V25, pS80, DOI 10.1016/j.bbi.2011.02.012
   Pascual O, 2012, P NATL ACAD SCI USA, V109, pE197, DOI 10.1073/pnas.1111098109
   Periyasamy P, 2018, MOL NEUROBIOL, V55, P3196, DOI 10.1007/s12035-017-0584-5
   Ray LA, 2017, NEUROPSYCHOPHARMACOL, V42, P1776, DOI 10.1038/npp.2017.10
   Reyes-Gibby CC, 2008, CANCER EPIDEM BIOMAR, V17, P3262, DOI 10.1158/1055-9965.EPI-08-0125
   Rizzo FR, 2018, NEURAL PLAST, V2018, DOI 10.1155/2018/8430123
   Roberts AJ, 1996, ALCOHOL CLIN EXP RES, V20, P1289, DOI 10.1111/j.1530-0277.1996.tb01125.x
   Roh YS, 2013, J GASTROEN HEPATOL, V28, P38, DOI 10.1111/jgh.12019
   Rolan P, 2008, BRIT J CLIN PHARMACO, V66, P792, DOI 10.1111/j.1365-2125.2008.03270.x
   Ruiz-Perez D, 2016, ANESTH ANALG, V122, P1370, DOI 10.1213/ANE.0000000000001171
   Sesack SR, 2010, NEUROPSYCHOPHARMACOL, V35, P27, DOI 10.1038/npp.2009.93
   Sfondrini L, 2006, J IMMUNOL, V176, P6624, DOI 10.4049/jimmunol.176.11.6624
   Shah M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00642
   Shah M, 2016, SCI REP-UK, V6, DOI 10.1038/srep39271
   Skolnick P, 2014, TRENDS PHARMACOL SCI, V35, P431, DOI 10.1016/j.tips.2014.06.008
   Song C, 2006, PHARMACOPSYCHIATRY, V39, P88, DOI 10.1055/s-2006-941557
   Spanagel R, 1995, PSYCHOPHARMACOLOGY, V122, P369, DOI 10.1007/BF02246268
   Stellwagen D, 2006, NATURE, V440, P1054, DOI 10.1038/nature04671
   Stellwagen D, 2005, J NEUROSCI, V25, P3219, DOI 10.1523/JNEUROSCI.4486-04.2005
   Stevens CW, 2013, BRIT J PHARMACOL, V168, P1421, DOI 10.1111/bph.12028
   Stopponi S, 2013, ALCOHOL CLIN EXP RES, V37, P1351, DOI 10.1111/acer.12091
   Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003
   Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186
   Tanda G, 2016, NEUROPSYCHOPHARMACOL, V41, P2772, DOI 10.1038/npp.2016.91
   Tanibuchi Y., 2010, GEN HOSP PSYCHIAT, V32, p559., DOI [10.1016/j.genhosppsych.2009.12.005, DOI 10.1016/j.genhosppsych.2009.12.005, DOI 10.1016/J.GENHOSPPSYCH.2009.12.005]
   Theberge FR, 2013, BIOL PSYCHIAT, V73, P729, DOI 10.1016/j.biopsych.2012.12.019
   Valles SL, 2004, BRAIN PATHOL, V14, P365
   Vaure C, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00316
   Vetreno R P, 2014, Handb Clin Neurol, V125, P477, DOI 10.1016/B978-0-444-62619-6.00027-6
   Volkow ND, 2015, CELL, V162, P712, DOI 10.1016/j.cell.2015.07.046
   Wang HY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004282
   Wang QS, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-32
   Wang S, 2000, J PHARMACOL EXP THER, V292, P497
   Wang XH, 2019, ACS CHEM NEUROSCI, V10, P3622, DOI 10.1021/acschemneuro.9b00225
   Wang XH, 2012, P NATL ACAD SCI USA, V109, P6325, DOI 10.1073/pnas.1200130109
   Watkins LR, 2014, TRENDS PHARMACOL SCI, V35, P432, DOI 10.1016/j.tips.2014.07.002
   Worley MJ, 2016, DRUG ALCOHOL DEPEN, V162, P245, DOI 10.1016/j.drugalcdep.2016.02.036
   Wu Y, 2012, BRIT J PHARMACOL, V165, P1319, DOI 10.1111/j.1476-5381.2011.01572.x
   Yang HA, 2010, P NATL ACAD SCI USA, V107, P11942, DOI 10.1073/pnas.1003893107
   Yu JC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01759
   Yue K, 2020, BEHAV PHARMACOL, V31, P186, DOI 10.1097/FBP.0000000000000474
   Zhang H, 2020, BRAIN RES BULL, V155, P102, DOI 10.1016/j.brainresbull.2019.11.012
   Zhang S, 2016, NEUROIMAGE-CLIN, V12, P348, DOI 10.1016/j.nicl.2016.08.006
NR 132
TC 11
Z9 11
U1 1
U2 11
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 24
PY 2020
VL 11
AR 603445
DI 10.3389/fphar.2020.603445
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA PB8GM
UT WOS:000596553000001
PM 33424612
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Olive, MF
   Gass, JT
AF Olive, M. Foster
   Gass, Justin T.
TI Editorial: structural plasticity induced by drugs of abuse
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Editorial Material
DE addiction; plasticity; glutamate; neurotrophin; GABA; homer;
   oligodendrocyte; cytoskeleton
ID SYNAPTIC PLASTICITY; ADDICTION
C1 [Olive, M. Foster] Arizona State Univ, Dept Psychol, Behav Neurosci Area, Tempe, AZ 85287 USA.
   [Gass, Justin T.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
C3 Arizona State University; Arizona State University-Tempe; Medical
   University of South Carolina
RP Olive, MF (通讯作者)，Arizona State Univ, Dept Psychol, Behav Neurosci Area, Tempe, AZ 85287 USA.
EM foster.olive@asu.edu
OI Olive, Foster/0000-0002-2517-0351
FU NIAAA NIH HHS [K99 AA020537, R01 AA013852, R00 AA020537] Funding Source:
   Medline; NIDA NIH HHS [R21 DA037741, R01 DA024355, R01 DA025606] Funding
   Source: Medline
CR Bajo M, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00049
   Collo G, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00259
   DePoy LM, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00228
   Gipson CD, 2014, NEUROPHARMACOLOGY, V76, P276, DOI 10.1016/j.neuropharm.2013.04.032
   Griffin WC, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00027
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564
   Luscher C, 2011, NEURON, V69, P650, DOI 10.1016/j.neuron.2011.01.017
   McGuier NS, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00028
   Olive MF, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00204
   Somkuwar SS, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00279
   Vashchinkina E, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00256
   Weiland A, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00044
NR 12
TC 4
Z9 4
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAY 15
PY 2015
VL 6
AR 88
DI 10.3389/fphar.2015.00088
PG 2
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CW5ME
UT WOS:000365038700001
PM 26029104
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Wakeman, SE
   Metlay, JP
   Chang, Y
   Herman, GE
   Rigotti, NA
AF Wakeman, Sarah E.
   Metlay, Joshua P.
   Chang, Yuchiao
   Herman, Grace E.
   Rigotti, Nancy A.
TI Inpatient Addiction Consultation for Hospitalized Patients Increases
   Post-Discharge Abstinence and Reduces Addiction Severity
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE addiction; substance use disorder; addiction consultation; hospitalized
   patients; post-discharge abstinence
ID RANDOMIZED CLINICAL-TRIAL; DRUG-TREATMENT; SCREENING-TEST; PRIMARY-CARE;
   DEPENDENCE; ALCOHOL; INTERVENTION; ASSOCIATION; RELIABILITY; DISCHARGE
AB Alcohol and drug use results in substantial morbidity, mortality, and cost. Individuals with alcohol and drug use disorders are overrepresented in general medical settings. Hospital-based interventions offer an opportunity to engage with a vulnerable population that may not otherwise seek treatment.
   To determine whether inpatient addiction consultation improves substance use outcomes 1 month after discharge.
   Prospective quasi-experimental evaluation comparing 30-day post-discharge outcomes between participants who were and were not seen by an addiction consult team during hospitalization at an urban academic hospital.
   Three hundred ninety-nine hospitalized adults who screened as high risk for having an alcohol or drug use disorder or who were clinically identified by the primary nurse as having a substance use disorder.
   Addiction consultation from a multidisciplinary specialty team offering pharmacotherapy initiation, motivational counseling, treatment planning, and direct linkage to ongoing addiction treatment.
   Addiction Severity Index (ASI) composite score for alcohol and drug use and self-reported abstinence at 30 days post-discharge. Secondary outcomes included 90-day substance use measures and self-reported hospital and ED utilization.
   Among 265 participants with 30-day follow-up, a greater reduction in the ASI composite score for drug or alcohol use was seen in the intervention group than in the control group (mean ASI-alcohol decreased by 0.24 vs. 0.08, p < 0.001; mean ASI-drug decreased by 0.05 vs. 0.02, p = 0.003.) There was also a greater increase in the number of days of abstinence in the intervention group versus the control group (+12.7 days vs. +5.6, p < 0.001). The differences in ASI-alcohol, ASI-drug, and days abstinent all remained statistically significant after controlling for age, gender, employment status, smoking status, and baseline addiction severity (p = 0.018, 0.018, and 0.02, respectively). In a sensitivity analysis, assuming that patients who were lost to follow-up had no change from baseline severity, the differences remained statistically significant.
   In a non-randomized cohort of medical inpatients, addiction consultation reduced addiction severity for alcohol and drug use and increased the number of days of abstinence in the first month after hospital discharge.
C1 [Wakeman, Sarah E.; Metlay, Joshua P.; Chang, Yuchiao; Rigotti, Nancy A.] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA.
   [Wakeman, Sarah E.; Metlay, Joshua P.; Chang, Yuchiao; Rigotti, Nancy A.] Harvard Med Sch, Boston, MA USA.
   [Herman, Grace E.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
C3 Harvard University; Massachusetts General Hospital; Harvard University;
   Harvard Medical School; Harvard University; Massachusetts General
   Hospital
RP Wakeman, SE (通讯作者)，Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA.
EM swakeman@partners.org
OI Herman, Grace/0000-0002-1987-5611
CR Brown RL, 1998, PREV MED, V27, P101, DOI 10.1006/pmed.1997.0250
   Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789
   Carey KB, 1997, PSYCHOL ASSESSMENT, V9, P422, DOI 10.1037/1040-3590.9.4.422
   Center for Health Information and Analysis, 2016, BEH HLTH READM MASS
   D'Onofrio G, 2015, JAMA-J AM MED ASSOC, V313, P1636, DOI 10.1001/jama.2015.3474
   Ford JD, 2009, DRUG ALCOHOL DEPEN, V99, P193, DOI 10.1016/j.drugalcdep.2008.07.004
   Hjorthoj CR, 2012, ADDICT BEHAV, V37, P225, DOI 10.1016/j.addbeh.2011.11.025
   Hoeppner BB, 2011, J SUBST ABUSE TREAT, V41, P305, DOI 10.1016/j.jsat.2011.04.005
   Houck JM, 2013, SUBST USE MISUSE, V48, P99, DOI 10.3109/10826084.2012.731674
   Liebschutz JM, 2014, JAMA INTERN MED, V174, P1369, DOI 10.1001/jamainternmed.2014.2556
   Massachusetts Department of Public Health, 2016, ASS OP DEATHS MASS 2
   McGahan PL, 1986, ADDICTION SEVERITY C
   MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006
   McQueen J, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD005191.pub3, 10.1002/14651858.CD005191]
   Merralll ELC, 2013, ADDICTION, V108, P377, DOI 10.1111/j.1360-0443.2012.04066.x
   Parthasarathy S, 2001, J STUD ALCOHOL, V62, P89, DOI 10.15288/jsa.2001.62.89
   Paulozzi Leonard, 2012, Morbidity and Mortality Weekly Report, V61, P10
   Pecoraro A, 2012, ADDICT SCI CLIN PRAC, V7, DOI 10.1186/1940-0640-7-20
   Rigotti NA, 2014, JAMA-J AM MED ASSOC, V312, P719, DOI 10.1001/jama.2014.9237
   Roy-Byrne P, 2014, JAMA-J AM MED ASSOC, V312, P492, DOI 10.1001/jama.2014.7860
   Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3
   Shanahan CW, 2010, J GEN INTERN MED, V25, P803, DOI 10.1007/s11606-010-1311-3
   Smith PC, 2010, ARCH INTERN MED, V170, P1155, DOI 10.1001/archinternmed.2010.140
   Substance Abuse and Mental Health Services Administration, 2014, RES 2014 NAT SURV DR
   Wei J, 2015, J GEN INTERN MED, V30, P365, DOI 10.1007/s11606-014-2968-9
NR 25
TC 142
Z9 142
U1 0
U2 18
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD AUG
PY 2017
VL 32
IS 8
BP 909
EP 916
DI 10.1007/s11606-017-4077-z
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services; General & Internal Medicine
GA FB1OV
UT WOS:000405914000011
PM 28526932
OA Green Published, Bronze
DA 2023-06-23
ER

PT J
AU Babaci, A
   Jafari, H
   Liya, A
AF Babaci, Afshin
   Jafari, Hossein
   Liya, Atena
TI Mathematical models of HIV/AIDS and drug addiction in prisons
SO EUROPEAN PHYSICAL JOURNAL PLUS
LA English
DT Article
ID EPIDEMIC MODEL; HIV
AB In this study, we examine the interaction between drug addiction and the contagion of HIV/AIDS in Iranian prisons. We provide a simple mathematical model for such an interaction. The stability of drug addiction and HIV/AIDS models are analyzed separately with no medical treatment. Then, we present an improved model describing the effect of treatment of drug users on the spread of HIV/AIDS. This fully extended model is obtained by adding some new parameters for the treatment of drug addiction. The impact of rehabilitating treatments on the control of HIV/AIDS spread in prisons is investigated, and finally, the reproduction numbers are compared in cases where there is no cure or some treatment methods are available.
C1 [Babaci, Afshin; Jafari, Hossein; Liya, Atena] Univ Mazandaran, Dept Math, POB 47416-95447, Babol Sar, Iran.
   [Jafari, Hossein] Univ South Africa, Dept Math Sci, UNISA, ZA-0003 Pretoria, South Africa.
C3 University of Mazandaran; University of South Africa
RP Jafari, H (通讯作者)，Univ Mazandaran, Dept Math, POB 47416-95447, Babol Sar, Iran.; Jafari, H (通讯作者)，Univ South Africa, Dept Math Sci, UNISA, ZA-0003 Pretoria, South Africa.
EM jafari.usern@gmail.com
RI Jafari, Hossein/E-9912-2016; BABAEI, AFSHIN/J-9085-2019
OI Jafari, Hossein/0000-0001-6807-6675; BABAEI, AFSHIN/0000-0002-6980-9786
CR Akgul EK, 2019, CHAOS, V29, DOI 10.1063/1.5084035
   AlAgha AD, 2019, EUR PHYS J PLUS, V134, DOI 10.1140/epjp/i2019-12740-9
   Aliyu AL, 2019, ADV DIFFER EQU-NY, V2019, DOI 10.1186/s13662-019-2336-5
   ANDERSON R M, 1986, IMA Journal of Mathematics Applied in Medicine and Biology, V3, P229
   Arshad S, 2017, ADV DIFFER EQU, V2017, P1
   Atangana A, 2020, ALEXANDRIA ENG J
   Babaei A, 2016, J ADV MATH MODEL, V5, P91
   Babaei A, 2019, MATH METHOD APPL SCI, V42, P2334, DOI 10.1002/mma.5511
   Babaei A, 2018, IRAN J SCI TECHNOL A, V42, P2225, DOI 10.1007/s40995-017-0360-4
   Bacaer N, 2008, J MATH BIOL, V57, P557, DOI 10.1007/s00285-008-0177-z
   Beg M, 2017, UPDATE HIV PRISONS O
   Bhunu CP, 2009, B MATH BIOL, V71, P1745, DOI 10.1007/s11538-009-9423-9
   Carvalho ARM, 2018, ADV DIFFER EQU-NY, DOI 10.1186/s13662-017-1456-z
   Gupta PK, 2019, EUR PHYS J PLUS, V134, DOI 10.1140/epjp/i2019-12599-8
   Ingalls B., 2013, MATH MODELING SYSTEM
   Jafari H, 2019, J OPTIMIZ THEORY APP, V183, P688, DOI 10.1007/s10957-019-01576-x
   Jajarmi A, 2018, CHAOS SOLITON FRACT, V113, P221, DOI 10.1016/j.chaos.2018.06.009
   Kumar S, 2018, EUR PHYS J PLUS, V133, DOI 10.1140/epjp/i2018-12117-8
   Misra JC, 2006, BIOMATHEMATICS: MODELLING AND SIMULATION, P1
   Mukandavire Z, 2009, MATH BIOSCI ENG, V6, P333, DOI 10.3934/mbe.2009.6.333
   Nieduszynski CA, 2002, GENOME BIOL, V3
   Okosun KO, 2017, EUR PHYS J PLUS, V132, DOI 10.1140/epjp/i2017-11625-3
   Pinto CMA, 2019, MATHEMATICS-BASEL, V7, DOI 10.3390/math7060515
   Raza A, 2019, IET SYST BIOL, V13, P305, DOI 10.1049/iet-syb.2019.0051
   Sowndarrajan PT, 2019, EUR PHYS J PLUS, V134, DOI 10.1140/epjp/i2019-12866-8
   Stilianakis NI, 1997, MATH BIOSCI, V145, P27, DOI 10.1016/S0025-5564(97)00018-7
   Stone J, 2018, LANCET INFECT DIS, V18, P1397, DOI 10.1016/S1473-3099(18)30469-9
   Tabassum MF, 2020, CHAOS SOLITON FRACT, V134, DOI 10.1016/j.chaos.2020.109686
   van den Driessche P, 2002, MATH BIOSCI, V180, P29, DOI 10.1016/S0025-5564(02)00108-6
NR 29
TC 31
Z9 31
U1 2
U2 7
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 2190-5444
J9 EUR PHYS J PLUS
JI Eur. Phys. J. Plus
PD MAY 3
PY 2020
VL 135
IS 5
AR 395
DI 10.1140/epjp/s13360-020-00400-0
PG 12
WC Physics, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physics
GA LL5GM
UT WOS:000531586000002
DA 2023-06-23
ER

PT J
AU Briand, LA
   Blendy, JA
AF Briand, Lisa A.
   Blendy, Julie A.
TI Molecular and genetic substrates linking stress and addiction
SO BRAIN RESEARCH
LA English
DT Article
DE Addiction; Stress; CREB; BDNF; Dynorphin; CRF
ID CORTICOTROPIN-RELEASING-FACTOR; ELEMENT-BINDING PROTEIN; CAMP RESPONSE
   ELEMENT; CONDITIONED-PLACE PREFERENCE; KAPPA-OPIOID RECEPTOR; MEDIAL
   PREFRONTAL CORTEX; FACTOR-LIKE IMMUNOREACTIVITY; VENTRAL TEGMENTAL AREA;
   COCAINE-INDUCED REINSTATEMENT; MESSENGER-RNA EXPRESSION
AB Drug addiction is one of the top three health concerns in the United States in terms of economic and health care costs. Despite this, there are very few effective treatment options available. Therefore, understanding the causes and molecular mechanisms underlying the transition from casual drug use to compulsive drug addiction could aid in the development of treatment options. Studies in humans and animal models indicate that stress can lead to both vulnerability to develop addiction, and increased drug taking and relapse in addicted individuals. Exposure to stress or drugs of abuse results in long-term adaptations in the brain that are likely to involve persistent alterations in gene expression or activation of transcription factors, such as the cAMP Response Element Binding (CREB) protein. The signaling pathways controlled by CREB have been strongly implicated in drug addiction and stress. Many potential CREB target genes have been identified based on the presence of a CRE element in promoter DNA sequences. These include, but are not limited to CRF, BDNF, and dynorphin. These genes have been associated with initiation or reinstatement of drug reward and are altered in one direction or the other following stress. While many reviews have examined the interactions between stress and addiction, the goal of this review was to focus on specific molecules that play key roles in both stress and addiction and are therefore posed to mediate the interaction between the two. Focus on these molecules could provide us with new targets for pharmacological treatments for addiction. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Briand, Lisa A.; Blendy, Julie A.] Univ Penn, Dept Pharmacol, Sch Med, TRL, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Blendy, JA (通讯作者)，Univ Penn, Dept Pharmacol, Sch Med, TRL, 125 S 31st St, Philadelphia, PA 19104 USA.
EM blendy@mail.med.upenn.edu
RI Briand, Lisa A/P-4877-2018
OI Briand, Lisa A/0000-0002-1228-5061; Blendy, Julie/0000-0003-1705-9001
FU National Institute on Drug Abuse [DA-11649]
FX This work was supported by National Institute on Drug Abuse grant
   DA-11649.
CR ABERCROMBIE ED, 1989, J NEUROCHEM, V52, P1655, DOI 10.1111/j.1471-4159.1989.tb09224.x
   Adamec RE, 2003, PROG NEURO-PSYCHOPH, V27, P1243, DOI 10.1016/j.pnpbp.2003.09.017
   ADVANI T, 2009, INT J NEUROPSYCHOPH, P1
   Ahmed SH, 1997, PSYCHOPHARMACOLOGY, V132, P289, DOI 10.1007/s002130050347
   Aid T, 2007, J NEUROSCI RES, V85, P525, DOI 10.1002/jnr.21139
   ANTELMAN SM, 1980, SCIENCE, V207, P329, DOI 10.1126/science.7188649
   Ardayfio P, 2006, BEHAV NEUROSCI, V120, P249, DOI 10.1037/0735-7044.120.2.249
   Arunrut T, 2009, LIFE SCI, V84, P584, DOI 10.1016/j.lfs.2009.02.005
   Bahi A, 2008, PSYCHOPHARMACOLOGY, V199, P169, DOI 10.1007/s00213-008-1164-1
   Bakshi VP, 2002, J NEUROSCI, V22, P2926, DOI 10.1523/JNEUROSCI.22-07-02926.2002
   Barrot M, 2002, P NATL ACAD SCI USA, V99, P11435, DOI 10.1073/pnas.172091899
   Barrot M, 2005, P NATL ACAD SCI USA, V102, P8357, DOI 10.1073/pnas.0500587102
   Baxter GT, 1997, J NEUROSCI, V17, P2683
   Belcheva MM, 2005, J BIOL CHEM, V280, P27662, DOI 10.1074/jbc.M502593200
   Berglind WJ, 2007, EUR J NEUROSCI, V26, P757, DOI 10.1111/j.1460-9568.2007.05692.x
   Berglind WJ, 2009, J NEUROSCI, V29, P3715, DOI 10.1523/JNEUROSCI.5457-08.2009
   BERRIDGE CW, 1989, J NEUROSCI, V9, P3513
   BERRIDGE CW, 1986, REGUL PEPTIDES, V16, P83, DOI 10.1016/0167-0115(86)90196-5
   Bhushan RG, 2004, J MED CHEM, V47, P2969, DOI 10.1021/jm0342358
   Bilang-Bleuel A, 2002, EUR J NEUROSCI, V15, P1048, DOI 10.1046/j.1460-9568.2002.01934.x
   Bland ST, 2005, BRAIN RES, V1051, P90, DOI 10.1016/j.brainres.2005.05.065
   Blank T, 2003, J NEUROSCI, V23, P700, DOI 10.1523/JNEUROSCI.23-02-00700.2003
   Blednov YA, 2006, ALCOHOL, V40, P73, DOI 10.1016/j.alcohol.2006.12.002
   Boer U, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000431
   Bohn LM, 2000, J NEUROCHEM, V74, P564, DOI 10.1046/j.1471-4159.2000.740564.x
   BORSOOK D, 1994, MOL ENDOCRINOL, V8, P240, DOI 10.1210/me.8.2.240
   Brandon CL, 2003, EUR J NEUROSCI, V18, P1584, DOI 10.1046/j.1460-9568.2003.02892.x
   BROWN SA, 1995, J STUD ALCOHOL, V56, P538, DOI 10.15288/jsa.1995.56.538
   BROWN SA, 1990, J ABNORM PSYCHOL, V99, P344, DOI 10.1037/0021-843X.99.4.344
   Bruijnzeel AW, 2009, BIOL PSYCHIAT, V66, P110, DOI 10.1016/j.biopsych.2009.01.010
   Bruijnzeel AW, 2001, BRAIN RES, V908, P187, DOI 10.1016/S0006-8993(01)02646-4
   Brunzell DH, 2009, NEUROPSYCHOPHARMACOL, V34, P1993, DOI 10.1038/npp.2009.11
   BUCKINGHAM JC, 1982, NEUROENDOCRINOLOGY, V35, P111, DOI 10.1159/000123364
   BUCKINGHAM JC, 1986, NEUROENDOCRINOLOGY, V44, P36, DOI 10.1159/000124618
   Buczek Y, 1999, PSYCHOPHARMACOLOGY, V144, P183, DOI 10.1007/s002130050992
   Carey AN, 2009, J NEUROSCI, V29, P4293, DOI 10.1523/JNEUROSCI.6146-08.2009
   Carlezon WA, 1998, SCIENCE, V282, P2272, DOI 10.1126/science.282.5397.2272
   CHAPPELL PB, 1986, J NEUROSCI, V6, P2908
   Chartoff EH, 2003, J NEUROCHEM, V87, P107, DOI 10.1046/j.1471-4159.2003.01992.x
   CHAVKIN C, 1983, LIFE SCI, V33, P13, DOI 10.1016/0024-3205(83)90432-0
   CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570
   Chefer VI, 2006, EUR J NEUROSCI, V23, P229, DOI 10.1111/j.1460-9568.2005.04525.x
   Chefer VI, 2005, J NEUROSCI, V25, P5029, DOI 10.1523/JNEUROSCI.0854-05.2005
   Chen ACH, 2001, BIOL PSYCHIAT, V49, P753, DOI 10.1016/S0006-3223(00)01114-8
   Chen JX, 2004, WORLD J GASTROENTERO, V10, P2547, DOI 10.3748/wjg.v10.i17.2547
   Clarke TK, 2009, ADDICT BIOL, V14, P366, DOI 10.1111/j.1369-1600.2009.00151.x
   Cleck JN, 2008, PSYCHOPHARMACOLOGY, V201, P15, DOI 10.1007/s00213-008-1243-3
   COLE BJ, 1988, J PHARMACOL EXP THER, V247, P902
   COLE BJ, 1990, BRAIN RES, V512, P343, DOI 10.1016/0006-8993(90)90646-S
   COLE RL, 1995, NEURON, V14, P813, DOI 10.1016/0896-6273(95)90225-2
   Conti AC, 2002, J NEUROSCI, V22, P3262, DOI 10.1523/JNEUROSCI.22-08-03262.2002
   Cryan JF, 2005, NAT REV DRUG DISCOV, V4, P775, DOI 10.1038/nrd1825
   Cryan JF, 2004, MOL PSYCHIATR, V9, P326, DOI 10.1038/sj.mp.4001457
   Czoty PW, 2005, J PHARMACOL EXP THER, V312, P96, DOI 10.1124/jpet.104.073411
   DAUNAIS JB, 1995, BRAIN RES BULL, V37, P523, DOI 10.1016/0361-9230(95)00049-K
   DAUNAIS JB, 1993, NEUROREPORT, V4, P543, DOI 10.1097/00001756-199305000-00020
   deFonseca FR, 1997, SCIENCE, V276, P2050, DOI 10.1126/science.276.5321.2050
   deFonseca FR, 1996, J PHARMACOL EXP THER, V276, P56
   Der-Avakian A, 2007, PSYCHOPHARMACOLOGY, V191, P909, DOI 10.1007/s00213-006-0678-7
   Dewart T, 2006, AM J DRUG ALCOHOL AB, V32, P665, DOI 10.1080/00952990600919435
   DeWit DJ, 1999, AM J ORTHOPSYCHIAT, V69, P61, DOI 10.1037/h0080382
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   DiNieri JA, 2009, J NEUROSCI, V29, P1855, DOI 10.1523/JNEUROSCI.5104-08.2009
   Do Couto BR, 2006, PSYCHOPHARMACOLOGY, V185, P459, DOI 10.1007/s00213-006-0345-z
   Donovan B, 2001, J TRAUMA STRESS, V14, P757, DOI 10.1023/A:1013094206154
   DOUGLASS J, 1994, MOL ENDOCRINOL, V8, P333, DOI 10.1210/me.8.3.333
   DUNN AJ, 1987, PHARMACOL BIOCHEM BE, V27, P685, DOI 10.1016/0091-3057(87)90195-X
   DUNN AJ, 1990, BRAIN RES REV, V15, P71, DOI 10.1016/0165-0173(90)90012-D
   Edwards S, 2007, EUR J NEUROSCI, V25, P2201, DOI 10.1111/j.1460-9568.2007.05473.x
   Edwards S, 2009, SYNAPSE, V63, P224, DOI 10.1002/syn.20601
   Eide FF, 1996, J NEUROSCI, V16, P3123
   ElDaly ES, 1996, LIFE SCI, V59, P1881, DOI 10.1016/S0024-3205(96)00535-8
   Erb S, 1999, J NEUROSCI, V19, part. no., DOI 10.1523/JNEUROSCI.19-20-j0006.1999
   Erb S, 2001, PSYCHOPHARMACOLOGY, V158, P360, DOI 10.1007/s002130000642
   Erb S, 1996, PSYCHOPHARMACOLOGY, V128, P408, DOI 10.1007/s002130050150
   Erb S, 1998, J NEUROSCI, V18, P5529, DOI 10.1523/JNEUROSCI.18-14-05529.1998
   Erb S, 2006, PSYCHOPHARMACOLOGY, V187, P112, DOI 10.1007/s00213-006-0392-5
   Erickson JT, 1996, J NEUROSCI, V16, P5361
   ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0
   Euskirchen G, 2004, MOL CELL BIOL, V24, P3804, DOI 10.1128/MCB.24.9.3804-3814.2004
   Filip M, 2006, BRAIN RES, V1071, P218, DOI 10.1016/j.brainres.2005.11.099
   Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5
   Ford JD, 2009, DRUG ALCOHOL DEPEN, V99, P193, DOI 10.1016/j.drugalcdep.2008.07.004
   Frankel PS, 2008, NEUROPHARMACOLOGY, V55, P41, DOI 10.1016/j.neuropharm.2008.04.019
   Fumagalli F, 2007, EUR J NEUROSCI, V26, P2756, DOI 10.1111/j.1460-9568.2007.05918.x
   Fumagalli F, 2009, EUR NEUROPSYCHOPHARM, V19, P402, DOI 10.1016/j.euroneuro.2009.01.003
   Gardi J, 1997, NEUROPEPTIDES, V31, P15, DOI 10.1016/S0143-4179(97)90013-5
   Geisler S, 2005, J COMP NEUROL, V490, P270, DOI 10.1002/cne.20668
   George O, 2007, P NATL ACAD SCI USA, V104, P17198, DOI 10.1073/pnas.0707585104
   GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306
   GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5
   Gooney M, 2004, NEUROBIOL AGING, V25, P1323, DOI 10.1016/j.neurobiolaging.2004.01.003
   Gordon NS, 2003, NEUROSCI LETT, V341, P17, DOI 10.1016/S0304-3940(03)00158-7
   Graham DL, 2007, NAT NEUROSCI, V10, P1029, DOI 10.1038/nn1929
   Grammatopoulos DK, 2001, J NEUROCHEM, V76, P509, DOI 10.1046/j.1471-4159.2001.00067.x
   Graves L, 2002, HIPPOCAMPUS, V12, P18, DOI 10.1002/hipo.10003
   Greenwell TN, 2009, ADDICT BIOL, V14, P130, DOI 10.1111/j.1369-1600.2008.00142.x
   Greisen MH, 2005, J NEUROSCI RES, V79, P772, DOI 10.1002/jnr.20418
   Grimm JW, 2003, J NEUROSCI, V23, P742
   GUARDIOLADIAZ HM, 1994, J BIOL CHEM, V269, P14784
   GUITART X, 1992, J NEUROCHEM, V58, P1168, DOI 10.1111/j.1471-4159.1992.tb09377.x
   Gur TL, 2007, J NEUROSCI, V27, P7860, DOI 10.1523/JNEUROSCI.2051-07.2007
   Haapasalo A, 2001, BIOCHEM BIOPH RES CO, V280, P1352, DOI 10.1006/bbrc.2001.4296
   HAHN B, 1986, PHARMACOL BIOCHEM BE, V25, P29, DOI 10.1016/0091-3057(86)90225-X
   Hall FS, 2003, NEUROPSYCHOPHARMACOL, V28, P1485, DOI 10.1038/sj.npp.1300192
   HAMAMURA T, 1993, EUR J PHARMACOL, V237, P65, DOI 10.1016/0014-2999(93)90094-X
   HANEY M, 1995, BRAIN RES, V698, P46, DOI 10.1016/0006-8993(95)00788-R
   Hartmann M, 2004, J CELL SCI, V117, P5803, DOI 10.1242/jcs.01511
   HASHIMOTO K, 1989, ACTA MED OKAYAMA, V43, P161
   Hashimoto K, 2004, BRAIN RES REV, V45, P104, DOI 10.1016/j.brainresrev.2004.02.003
   Hebda-Bauer EK, 2004, EUR J NEUROSCI, V20, P503, DOI 10.1111/j.1460-9568.2004.03487.x
   Hebert MA, 2005, J NEUROCHEM, V95, P484, DOI 10.1111/j.1471-4159.2005.03386.x
   Heilig M, 2007, TRENDS NEUROSCI, V30, P399, DOI 10.1016/j.tins.2007.06.006
   HENRY DJ, 1995, MOL PHARMACOL, V47, P551
   HERMAN JP, 1984, PSYCHOPHARMACOLOGY, V84, P431, DOI 10.1007/BF00555227
   HERMAN JP, 1992, MOL ENDOCRINOL, V6, P1061, DOI 10.1210/me.6.7.1061
   Herrero MJ, 2008, ADDICTION, V103, P284, DOI 10.1111/j.1360-0443.2007.02076.x
   Heyliger SO, 1999, SYNAPSE, V34, P256, DOI 10.1002/(SICI)1098-2396(19991215)34:4<256::AID-SYN2>3.3.CO;2-Y
   HORAN PJ, 1993, J PHARMACOL EXP THER, V266, P926
   Horger BA, 1999, J NEUROSCI, V19, P4110
   Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677
   Huang LT, 2002, EPILEPSIA, V43, P1141, DOI 10.1046/j.1528-1157.2002.14602.x
   HURD YL, 1993, SYNAPSE, V13, P357, DOI 10.1002/syn.890130408
   HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0
   HYMAN SE, 1995, CHEM SENSES, V20, P257, DOI 10.1093/chemse/20.2.257
   Itoi K, 1996, ENDOCRINOLOGY, V137, P2389, DOI 10.1210/en.137.6.2389
   JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8
   Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441
   Kabbaj M, 2001, PSYCHOPHARMACOLOGY, V158, P382, DOI 10.1007/s002130100918
   KALIVAS PW, 1989, BIOL PSYCHIAT, V25, P913, DOI 10.1016/0006-3223(89)90271-0
   KANO T, 1995, NEUROREPORT, V6, P2197, DOI 10.1097/00001756-199511000-00023
   Karasinska JM, 2005, EUR J NEUROSCI, V22, P1741, DOI 10.1111/j.1460-9568.2005.04353.x
   Kawahara H, 2000, EUR J PHARMACOL, V387, P279, DOI 10.1016/S0014-2999(99)00793-1
   Kenny PJ, 2000, MOL BRAIN RES, V85, P234, DOI 10.1016/S0169-328X(00)00246-1
   KIM KS, 1993, J BIOL CHEM, V268, P15689
   KONRADI C, 1994, J NEUROSCI, V14, P5623
   Koob GF, 2008, PHILOS T R SOC B, V363, P3113, DOI 10.1098/rstb.2008.0094
   Koob GF, 1999, ANN NY ACAD SCI, V897, P27, DOI 10.1111/j.1749-6632.1999.tb07876.x
   Kornhauser JM, 2002, NEURON, V34, P221, DOI 10.1016/S0896-6273(02)00655-4
   Kovacs KM, 2005, ALCOHOL CLIN EXP RES, V29, P730, DOI 10.1097/01.ALC.0000164361.62346.D6
   Kreibich AS, 2009, NEUROPSYCHOPHARMACOL, V34, P2609, DOI 10.1038/npp.2009.91
   Kreibich AS, 2004, J NEUROSCI, V24, P6686, DOI 10.1523/JNEUROSCI.1706-04.2004
   Kudo K, 2004, BRAIN RES, V1024, P233, DOI 10.1016/j.brainres.2004.08.007
   Kufahl PR, 2005, NEUROIMAGE, V28, P904, DOI 10.1016/j.neuroimage.2005.06.039
   Kwon MS, 2006, NEUROSCIENCE, V142, P1281, DOI 10.1016/j.neuroscience.2006.07.027
   Laifenfeld D, 2005, NEUROBIOL DIS, V20, P432, DOI 10.1016/j.nbd.2005.03.023
   Le AD, 1998, PSYCHOPHARMACOLOGY, V135, P169, DOI 10.1007/s002130050498
   Le AD, 2002, J NEUROSCI, V22, P7844
   Le Foll B, 2005, NEUROREPORT, V16, P175, DOI 10.1097/00001756-200502080-00022
   Leao RM, 2009, BEHAV PHARMACOL, V20, P109, DOI 10.1097/FBP.0b013e3283242f41
   Lee DK, 2008, EUR J PHARMACOL, V590, P157, DOI 10.1016/j.ejphar.2008.06.048
   Leri F, 2002, J NEUROSCI, V22, P5713
   LEYTON M, 1990, PHARMACOL BIOCHEM BE, V37, P303, DOI 10.1016/0091-3057(90)90339-J
   Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0
   Lu L, 2004, J NEUROSCI, V24, P1604, DOI 10.1523/JNEUROSCI.5124-03.2004
   Lu L, 2004, NEUROPHARMACOLOGY, V47, P214, DOI 10.1016/j.neuropharm.2004.06.027
   Lu L, 2002, BRAIN RES, V954, P132, DOI 10.1016/S0006-8993(02)03359-0
   MACLENNAN AJ, 1983, SCIENCE, V219, P1091, DOI 10.1126/science.6681679
   Maj M, 2003, NEUROPEPTIDES, V37, P105, DOI 10.1016/S0143-4179(03)00021-0
   Maldonado R, 1996, SCIENCE, V273, P657, DOI 10.1126/science.273.5275.657
   Mathews IZ, 2008, DEV PSYCHOBIOL, V50, P451, DOI 10.1002/dev.20299
   Mathieu-Kia AM, 1998, MOL BRAIN RES, V54, P141, DOI 10.1016/S0169-328X(97)00338-0
   Matsushita Y, 2009, NEUROREPORT, V20, P63, DOI 10.1097/WNR.0b013e328314decb
   MATTA SG, 1987, J PHARMACOL EXP THER, V243, P217
   MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107
   Mattson BJ, 2005, J NEUROCHEM, V95, P1481, DOI 10.1111/j.1471-4159.2005.03500.x
   Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068
   McClung CA, 2003, NAT NEUROSCI, V6, P1208, DOI 10.1038/nn1143
   MCFALL ME, 1992, J STUD ALCOHOL, V53, P357, DOI 10.15288/jsa.1992.53.357
   McLaughlin JP, 2006, NEUROPSYCHOPHARMACOL, V31, P1241, DOI 10.1038/sj.npp.1300872
   McLaughlin JP, 2006, NEUROPSYCHOPHARMACOL, V31, P787, DOI 10.1038/sj.npp.1300860
   McLaughlin JP, 2003, J NEUROSCI, V23, P5674, DOI 10.1523/jneurosci.23-13-05674.2003
   MELIA KR, 1991, P NATL ACAD SCI USA, V88, P8382, DOI 10.1073/pnas.88.19.8382
   Miller JC, 2007, INT J NEUROPSYCHOPH, V10, P609, DOI 10.1017/S1461145706007279
   Monteggia LM, 2007, BIOL PSYCHIAT, V61, P187, DOI 10.1016/j.biopsych.2006.03.021
   Morgan D, 2002, NAT NEUROSCI, V5, P169, DOI 10.1038/nn798
   MORLEY JE, 1982, PEPTIDES, V3, P901, DOI 10.1016/0196-9781(82)90058-4
   MUCHA RF, 1985, PSYCHOPHARMACOLOGY, V86, P274, DOI 10.1007/BF00432213
   Murakami S, 2005, NEUROSCI RES, V53, P129, DOI 10.1016/j.neures.2005.06.008
   Nazarian A, 2009, PSYCHOPHARMACOLOGY, V203, P641, DOI 10.1007/s00213-008-1411-5
   Newton SS, 2002, J NEUROSCI, V22, P10883
   Nibuya M, 1999, NEUROSCI LETT, V267, P81, DOI 10.1016/S0304-3940(99)00335-3
   Numan S, 1999, J COMP NEUROL, V403, P295, DOI 10.1002/(SICI)1096-9861(19990118)403:3<295::AID-CNE2>3.0.CO;2-L
   Olianas MC, 2006, BRIT J PHARMACOL, V147, P360, DOI 10.1038/sj.bjp.0706601
   Olson VG, 2005, J NEUROSCI, V25, P5553, DOI 10.1523/JNEUROSCI.0345-05.2005
   Ouimette P, 2007, ADDICT BEHAV, V32, P1719, DOI 10.1016/j.addbeh.2006.11.020
   Pacchioni AM, 2002, ANN NY ACAD SCI, V965, P233
   Pandey SC, 2005, ALCOHOL CLIN EXP RES, V29, P176, DOI 10.1097/01.ALC.0000153550.31168.1D
   Pandey SC, 2005, J CLIN INVEST, V115, P2762, DOI 10.1172/JCI24381
   Pandey SC, 2004, J NEUROSCI, V24, P5022, DOI 10.1523/JNEUROSCI.5557-03.2004
   Pandey SC, 2006, J NEUROSCI, V26, P8320, DOI 10.1523/JNEUROSCI.4988-05.2006
   Penk W E, 1988, Recent Dev Alcohol, V6, P69
   Petraglia F, 1996, HORM RES, V45, P187, DOI 10.1159/000184785
   PFEIFFER A, 1986, SCIENCE, V233, P774, DOI 10.1126/science.3016896
   PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295
   PIAZZA PV, 1990, BRAIN RES, V514, P22, DOI 10.1016/0006-8993(90)90431-A
   PICH EM, 1995, J NEUROSCI, V15, P5439
   Pizarro JM, 2004, BRAIN RES, V1025, P10, DOI 10.1016/j.brainres.2004.06.085
   Pliakas AM, 2001, J NEUROSCI, V21, P7397, DOI 10.1523/JNEUROSCI.21-18-07397.2001
   Price ML, 2002, PSYCHOPHARMACOLOGY, V162, P406, DOI 10.1007/s00213-002-1114-2
   PUDER M, 1982, EXP BRAIN RES, V46, P85
   Radecki DT, 2005, HIPPOCAMPUS, V15, P246, DOI 10.1002/hipo.20048
   Rattiner LM, 2004, J NEUROSCI, V24, P4796, DOI 10.1523/JNEUROSCI.5654-03.2004
   Ren-Patterson RF, 2006, CELL MOL NEUROBIOL, V26, P755, DOI 10.1007/s10571-006-9048-6
   Renthal W, 2009, NEURON, V62, P335, DOI 10.1016/j.neuron.2009.03.026
   Restivo L, 2009, HIPPOCAMPUS, V19, P228, DOI 10.1002/hipo.20527
   RICHTER RM, 1995, NEUROSCI LETT, V187, P169, DOI 10.1016/0304-3940(95)11365-4
   Richter RM, 1999, SYNAPSE, V32, P254, DOI 10.1002/(SICI)1098-2396(19990615)32:4<254::AID-SYN2>3.0.CO;2-H
   RIVIER C, 1984, J PHARMACOL EXP THER, V229, P127
   RIVIER C, 1987, BRAIN RES, V422, P403, DOI 10.1016/0006-8993(87)90953-X
   Rose CR, 2003, NATURE, V426, P74, DOI 10.1038/nature01983
   Rossant CJ, 1999, ENDOCRINOLOGY, V140, P1525, DOI 10.1210/en.140.4.1525
   Rozeske RR, 2009, NEUROPSYCHOPHARMACOL, V34, P834, DOI 10.1038/npp.2008.34
   Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-7
   Sabban EL, 2004, ANN NY ACAD SCI, V1032, P130, DOI 10.1196/annals.1314.010
   Sanchez CJ, 2003, NEUROSCIENCE, V119, P497, DOI 10.1016/S0306-4522(03)00078-2
   SARNYAI Z, 1992, BRAIN RES, V589, P154, DOI 10.1016/0006-8993(92)91176-F
   SARNYAI Z, 1995, BRAIN RES, V675, P89, DOI 10.1016/0006-8993(95)00043-P
   SARNYAI Z, 1993, BRAIN RES, V616, P315, DOI 10.1016/0006-8993(93)90224-B
   SARNYAI Z, 1992, LIFE SCI, V51, P2019, DOI 10.1016/0024-3205(92)90151-E
   SAWCHENKO PE, 1985, FED PROC, V44, P221
   Shaffer HJ, 2002, ADDICTION, V97, P543, DOI 10.1046/j.1360-0443.2002.00114.x
   Shaham Y, 1996, J NEUROSCI, V16, P1957
   SHAHAM Y, 1995, PSYCHOPHARMACOLOGY, V119, P334, DOI 10.1007/BF02246300
   Shaham Y, 1997, J NEUROSCI, V17, P2605
   Shaham Y, 1996, ANN BEHAV MED, V18, P255, DOI 10.1007/BF02895287
   Shaw-Lutchman TZ, 2002, J NEUROSCI, V22, P3663
   Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821
   Shen CP, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-36
   Shimizu YS, 2004, NEUROSCIENCE, V129, P831, DOI 10.1016/j.neuroscience.2004.08.024
   Shirayama Y, 2004, J NEUROCHEM, V90, P1258, DOI 10.1111/j.1471-4159.2004.02589.x
   SIMPSON JN, 1995, SYNAPSE, V19, P151, DOI 10.1002/syn.890190302
   Sinha R, 2007, DRUG ALCOHOL REV, V26, P25, DOI 10.1080/09595230601036960
   SMITH MA, 1995, ENDOCRINOLOGY, V136, P3743, DOI 10.1210/en.136.9.3743
   SMITH MA, 1995, J NEUROSCI, V15, P1768, DOI 10.1523/JNEUROSCI.15-03-01768.1995
   Sofuoglu Mehmet, 2006, Expert Opin Emerg Drugs, V11, P91, DOI 10.1517/14728214.11.1.91
   Song L, 2006, PHARMACOL BIOCHEM BE, V83, P186, DOI 10.1016/j.pbb.2006.01.004
   SORG BA, 1993, NEUROSCIENCE, V53, P695, DOI 10.1016/0306-4522(93)90617-O
   Specio SE, 2008, PSYCHOPHARMACOLOGY, V196, P473, DOI 10.1007/s00213-007-0983-9
   Stanciu M, 2001, MOL BRAIN RES, V94, P15, DOI 10.1016/S0169-328X(01)00174-7
   Steinbeck JA, 2004, GENE EXPRESSION, V12, P99, DOI 10.3727/000000005783992142
   Stoilov P, 2002, BIOCHEM BIOPH RES CO, V290, P1054, DOI 10.1006/bbrc.2001.6301
   SWERDLOW NR, 1986, PSYCHOPHARMACOLOGY, V88, P147, DOI 10.1007/BF00652231
   SWIERGIEL AH, 1992, BRAIN RES, V587, P263, DOI 10.1016/0006-8993(92)91006-Z
   TALLENT M, 1994, NEUROSCIENCE, V63, P1033, DOI 10.1016/0306-4522(94)90570-3
   Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7
   Tapia-Arancibia L, 2001, J NEUROSCI RES, V63, P200, DOI 10.1002/1097-4547(20010115)63:2<200::AID-JNR1012>3.0.CO;2-Q
   Tervonen TA, 2006, EUR J NEUROSCI, V24, P1277, DOI 10.1111/j.1460-9568.2006.05010.x
   Teusch R, 2001, PSYCHIATR SERV, V52, P1530, DOI 10.1176/appi.ps.52.11.1530
   THIERRY AM, 1976, NATURE, V263, P242, DOI 10.1038/263242a0
   THIERRY B, 1984, BEHAV NEURAL BIOL, V41, P180, DOI 10.1016/S0163-1047(84)90555-7
   Tidey JW, 1997, PSYCHOPHARMACOLOGY, V130, P203, DOI 10.1007/s002130050230
   Trentani A, 2002, EUR J NEUROSCI, V15, P1681, DOI 10.1046/j.1460-9568.2002.02000.x
   TRIFFLEMAN EG, 1995, J NERV MENT DIS, V183, P172, DOI 10.1097/00005053-199503000-00008
   Turchan J, 2002, POL J PHARMACOL, V54, P367
   Turchan J, 1998, NEUROSCIENCE, V85, P1051, DOI 10.1016/S0306-4522(97)00639-8
   Turgeon SM, 1997, BRAIN RES, V749, P120, DOI 10.1016/S0006-8993(96)01316-9
   Valdez GR, 2007, J PHARMACOL EXP THER, V323, P525, DOI 10.1124/jpet.107.125484
   VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699
   Valverde O, 2004, NEUROPSYCHOPHARMACOL, V29, P1122, DOI 10.1038/sj.npp.1300416
   Van Pett K, 2000, J COMP NEUROL, V428, P191, DOI 10.1002/1096-9861(20001211)428:2<191::AID-CNE1>3.0.CO;2-U
   Walker G C, 1998, J Psychosoc Nurs Ment Health Serv, V36, P10
   Wallace DL, 2009, NAT NEUROSCI, V12, P200, DOI 10.1038/nn.2257
   Wallace TL, 2004, BIOL PSYCHIAT, V56, P151, DOI 10.1016/j.biopsych.2004.04.010
   Walters CL, 2005, NEURON, V46, P933, DOI 10.1016/j.neuron.2005.05.005
   Walters CL, 2001, J NEUROSCI, V21, P9438, DOI 10.1523/JNEUROSCI.21-23-09438.2001
   Wang B, 2007, PSYCHOPHARMACOLOGY, V193, P283, DOI 10.1007/s00213-007-0782-3
   Wang JS, 2006, PSYCHOPHARMACOLOGY, V185, P19, DOI 10.1007/s00213-005-0262-6
   Wang XM, 1999, MOL BRAIN RES, V66, P184, DOI 10.1016/S0169-328X(99)00021-2
   Wang XY, 2001, EUR J PHARMACOL, V432, P153, DOI 10.1016/S0014-2999(01)01487-X
   Widnell KL, 1996, J PHARMACOL EXP THER, V276, P306
   Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959
   Xu HY, 2006, HIPPOCAMPUS, V16, P551, DOI 10.1002/hipo.20184
   Yang HY, 2009, EUR J PHARMACOL, V609, P51, DOI 10.1016/j.ejphar.2009.03.028
   Yang XJ, 1996, J PHARMACOL EXP THER, V278, P338
   Yang XO, 1998, ALCOHOL CLIN EXP RES, V22, P382, DOI 10.1111/j.1530-0277.1998.tb03664.x
   Yin HS, 2006, SYNAPSE, V60, P573, DOI 10.1002/syn.20334
   Yurek DM, 1996, EXP NEUROL, V137, P105, DOI 10.1006/exnr.1996.0011
   ZASLAV MR, 1994, J PSYCHOACTIVE DRUGS, V26, P393, DOI 10.1080/02791072.1994.10472459
   Zorrilla EP, 2001, PSYCHOPHARMACOLOGY, V158, P374, DOI 10.1007/s002130100773
NR 280
TC 89
Z9 97
U1 1
U2 21
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
EI 1872-6240
J9 BRAIN RES
JI Brain Res.
PD FEB 16
PY 2010
VL 1314
SI SI
BP 219
EP 234
DI 10.1016/j.brainres.2009.11.002
PG 16
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 565RQ
UT WOS:000275312400021
PM 19900417
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Siddiqui, H
   Rutherford, MD
AF Siddiqui, Hasan
   Rutherford, M. D.
TI Belief that addiction is a discrete category is a stronger correlate
   with stigma than the belief that addiction is biologically based
SO SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY
LA English
DT Article
DE Essentialism; Stigma; Addiction
ID PSYCHOLOGICAL ESSENTIALISM; DRUG-ADDICTION; SELF-STIGMA; OPIOID USE;
   POWER; RACE
AB Background Drug addiction is stigmatized, and this stigma contributes to poor outcomes for individuals with addiction. Researchers have argued that providing genetic explanations of addiction will reduce stigma, but there has been limited research testing this prediction.Methods We presented participants (N = 252) with news articles that either provided genetic or anti-genetic explanations of addiction.Results There was no effect of article condition on stigma. Participants' biological essentialism correlated with stigma in the context of both opioid and methamphetamine addiction. However, participants' non-biological essentialism was a significantly stronger correlate with stigma.Conclusions This suggests that other essentialist beliefs, like belief that categories are discrete, may be more useful than biological essentialism for understanding addiction stigma.
C1 [Siddiqui, Hasan; Rutherford, M. D.] McMaster Univ, 1280 Main St West, Hamilton, ON L8S 4L8, Canada.
C3 McMaster University
RP Siddiqui, H (通讯作者)，McMaster Univ, 1280 Main St West, Hamilton, ON L8S 4L8, Canada.
EM siddih6@mcmaster.ca
FU Social Sciences & Humanities Research Council of Canada (SSHRC)
FX Funding for this experiment was acquired by Dr. M.D. Rutherford from the
   Social Sciences & Humanities Research Council of Canada (SSHRC).
CR Akrami N, 2009, J RES PERS, V43, P890, DOI 10.1016/j.jrp.2009.04.007
   Barry CL, 2014, PSYCHIAT SERV, V65, P1269, DOI 10.1176/appi.ps.201400140
   Bastian B, 2006, J EXP SOC PSYCHOL, V42, P228, DOI 10.1016/j.jesp.2005.03.003
   Battle DE, 2013, CODAS, V25, P191
   Ben-Zeev D, 2010, J MENT HEALTH, V19, P318, DOI 10.3109/09638237.2010.492484
   Bruneau E, 2021, PERS SOC PSYCHOL B, V47, P906, DOI 10.1177/0146167220949004
   Cohn A, 2020, DRUG-EDUC PREV POLIC, V27, P261, DOI 10.1080/09687637.2019.1679089
   Corrigan PW, 2016, J MENT HEALTH, V25, P10, DOI 10.3109/09638237.2015.1021902
   Crocetti E, 2021, DEV REV, V60, DOI 10.1016/j.dr.2021.100959
   Deen H, 2021, INT J DRUG POLICY, V87, DOI 10.1016/j.drugpo.2020.102982
   Difallah D, 2018, WSDM'18: PROCEEDINGS OF THE ELEVENTH ACM INTERNATIONAL CONFERENCE ON WEB SEARCH AND DATA MINING, P135, DOI 10.1145/3159652.3159661
   Dobson KS, 2022, STIGMA HEALTH, V7, P27, DOI 10.1037/sah0000323
   Earnshaw V, 2013, INT J MENT HEALTH AD, V11, P110, DOI 10.1007/s11469-012-9402-5
   Gelman SA, 2004, TRENDS COGN SCI, V8, P404, DOI 10.1016/j.tics.2004.07.001
   GELMAN SA, 2003, ESSENTIAL CHILD ORIG
   Goodyear K, 2018, DRUG ALCOHOL DEPEN, V185, P339, DOI 10.1016/j.drugalcdep.2017.12.037
   Haque OS, 2012, PERSPECT PSYCHOL SCI, V7, P176, DOI 10.1177/1745691611429706
   Haslam N, 2002, BRIT J SOC PSYCHOL, V41, P87, DOI 10.1348/014466602165072
   Haslam N, 2000, BRIT J SOC PSYCHOL, V39, P113, DOI 10.1348/014466600164363
   Haslam N, 2022, CURR OPIN PSYCHOL, V43, P312, DOI 10.1016/j.copsyc.2021.08.013
   Haslam N, 2011, PSYCHOL BULL, V137, P819, DOI 10.1037/a0022386
   Henry PJ, 2009, POLIT PSYCHOL, V30, P569, DOI 10.1111/j.1467-9221.2009.00715.x
   Jackson JS, 2010, AM J PUBLIC HEALTH, V100, P933, DOI 10.2105/AJPH.2008.143446
   Kennedy-Hendricks A, 2017, PSYCHIAT SERV, V68, P462, DOI 10.1176/appi.ps.201600056
   Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7
   Li MD, 2009, NAT REV GENET, V10, P225, DOI 10.1038/nrg2536
   Link BG, 2001, ANNU REV SOCIOL, V27, P363, DOI 10.1146/annurev.soc.27.1.363
   Mahalingam R, 2003, J SOC ISSUES, V59, P733, DOI 10.1046/j.0022-4537.2003.00087.x
   Mahalingam R, 2007, HUM DEV, V50, P300, DOI 10.1159/000109832
   Matthews S, 2017, J BIOETHIC INQ, V14, P275, DOI 10.1007/s11673-017-9784-y
   Matto HC, 2016, J SOC WORK PRACT ADD, V16, P7, DOI 10.1080/1533256X.2016.1165113
   McDonald M, 2017, GROUP PROCESS INTERG, V20, P125, DOI 10.1177/1368430215595107
   McGinty E. E., 2019, STIGMA ADDICTION, P201
   MEDIN D, 1989, SIMILARITY AND ANALOGICAL REASONING, P179, DOI 10.1017/CBO9780511529863.009
   Meurk C, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0373-x
   Moss AJ, 2020, TRENDS COGN SCI, V24, P678, DOI 10.1016/j.tics.2020.05.014
   Naeim M, 2021, ADDICT DISORD TREAT, V20, P479, DOI 10.1097/ADT.0000000000000277
   Phelan JC, 2002, TRENDS NEUROSCI, V25, P430, DOI 10.1016/S0166-2236(02)02209-9
   Prati F, 2015, GROUP PROCESS INTERG, V18, P801, DOI 10.1177/1368430214567762
   Richter L, 2019, STIGMA ADDICTION, P93
   Ross J., 2010, CHI 10 HUM FACT COMP, V10, P2863, DOI DOI 10.1145/1753846.1753873
   Tajfel H., 1986, PSYCHOL INTERGROUP R, P7, DOI DOI 10.4324/9780203505984-16
   Vrieze SI, 2012, HUM GENET, V131, P791, DOI 10.1007/s00439-012-1167-1
   Williams MJ, 2008, J PERS SOC PSYCHOL, V94, P1033, DOI 10.1037/0022-3514.94.6.1033
NR 44
TC 2
Z9 2
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1747-597X
J9 SUBST ABUSE TREAT PR
JI Subst/ Abus. Treatment Prev. Pol.
PD JAN 10
PY 2023
VL 18
IS 1
AR 3
DI 10.1186/s13011-022-00512-z
PG 11
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA 7U2EW
UT WOS:000911948500001
PM 36627629
OA gold, Green Submitted, Green Published
DA 2023-06-23
ER

PT S
AU Chen, ML
   Sun, Y
   Lu, L
   Shi, J
AF Chen, Manli
   Sun, Yan
   Lu, Lin
   Shi, Jie
BE Zhang, X
   Shi, J
   Tao, R
TI Similarities and Differences in Neurobiology
SO SUBSTANCE AND NON-SUBSTANCE ADDICTION
SE Advances in Experimental Medicine and Biology
LA English
DT Article; Book Chapter
DE Substance addiction; Non-substance addiction; Neurobiology
ID COCAINE-INDUCED REINSTATEMENT; ENDOGENOUS OPIOID SYSTEMS; N-ACETYL
   CYSTEINE; DOUBLE-BLIND; DOPAMINE-D-2 RECEPTORS; PATHOLOGICAL GAMBLERS;
   ALCOHOL-DEPENDENCE; DRUG-ADDICTION; TRYPTOPHAN DEPLETION; SEEKING
   BEHAVIOR
AB Substance addiction is a chronic, relapsing brain disease characterized by compulsive drug seeking and use despite harmful consequences. Non-substance addiction is defined recently that people may compulsively engage in an activity despite any negative consequences to their lives. Despite differences with respect to their addictive object, substance addiction and non-substance addiction may share similarities with respect to biological, epidemiological, clinical, genetic and other features. Here we review the similarities and differences in neurobiology between these two addictions with a focus on dopamine, serotonin, opioid, glutamate and norepinephrine systems. Studies suggest the involvement of all these systems in both substance addiction and non-substance addiction while differences may exist with respect to their contributions.
C1 [Chen, Manli] Peking Univ Hlth Sci Ctr, Sch Basic Med Sci, Dept Pharmacol, Beijing 100191, Peoples R China.
   [Chen, Manli; Lu, Lin; Shi, Jie] Peking Univ, Natl Inst Drug Dependence, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
   [Lu, Lin] Peking Univ, Inst Mental Health, Peking Univ Sixth Hosp, Beijing 100191, Peoples R China.
   [Lu, Lin] Peking Univ, Natl Clin Res Ctr Mental Disorders, Key Lab Mental Hlth, Beijing 100191, Peoples R China.
C3 Peking University; Peking University; Peking University; Peking
   University
RP Shi, J (通讯作者)，Peking Univ, Natl Inst Drug Dependence, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
EM shijie@bjmu.edu.cn
RI SHI, JIE/GXG-3394-2022
CR Amato L, 2007, COCHRANE DB SYST REV, V3
   Baker DA, 2003, ANN NY ACAD SCI, V1003, P349, DOI 10.1196/annals.1300.023
   Barbano MF, 2007, PSYCHOPHARMACOLOGY, V191, P497, DOI 10.1007/s00213-006-0521-1
   Boileau I, 2014, MOL PSYCHIATR, V19, P1305, DOI 10.1038/mp.2013.163
   Boileau I, 2013, ADDICTION, V108, P953, DOI 10.1111/add.12066
   Brewer JA, 2008, BIOCHEM PHARMACOL, V75, P63, DOI 10.1016/j.bcp.2007.06.043
   Bullock Scott A, 2012, Curr Psychopharmacol, V1, DOI 10.2174/2211556011201010067
   Campbell-Meiklejohn D, 2011, NEUROPSYCHOPHARMACOL, V36, P402, DOI 10.1038/npp.2010.170
   Carroll KM, 2004, ARCH GEN PSYCHIAT, V61, P264, DOI 10.1001/archpsyc.61.3.264
   Carroll KM, 1998, ADDICTION, V93, P713, DOI 10.1046/j.1360-0443.1998.9357137.x
   Clark L, 2013, J NEUROSCI, V33, P17617, DOI 10.1523/JNEUROSCI.3231-13.2013
   Clark L, 2012, NEUROIMAGE, V63, P40, DOI 10.1016/j.neuroimage.2012.06.067
   Crean J, 2002, BEHAV BRAIN RES, V136, P349, DOI 10.1016/S0166-4328(02)00132-8
   De Vries TJ, 2002, NEUROPSYCHOPHARMACOL, V26, P18, DOI 10.1016/S0893-133X(01)00293-7
   Drouin C, 2002, J NEUROSCI, V22, P2873, DOI 10.1523/JNEUROSCI.22-07-02873.2002
   Erb S, 2000, NEUROPSYCHOPHARMACOL, V23, P138, DOI 10.1016/S0893-133X(99)00158-X
   FilsAime ML, 1996, ARCH GEN PSYCHIAT, V53, P211
   Fong T, 2008, PHARMACOL BIOCHEM BE, V89, P298, DOI 10.1016/j.pbb.2007.12.025
   George TP, 2000, BIOL PSYCHIAT, V47, P1080, DOI 10.1016/S0006-3223(99)00310-8
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Goudriaan AE, 2004, NEUROSCI BIOBEHAV R, V28, P123, DOI 10.1016/j.neubiorev.2004.03.001
   Grant JE, 2006, AM J PSYCHIAT, V163, P303, DOI 10.1176/appi.ajp.163.2.303
   Grant JE, 2003, INT CLIN PSYCHOPHARM, V18, P243, DOI 10.1097/00004850-200307000-00007
   Grant JE, 2008, PSYCHOPHARMACOLOGY, V200, P521, DOI 10.1007/s00213-008-1235-3
   Grant JE, 2008, J CLIN PSYCHIAT, V69, P783, DOI 10.4088/JCP.v69n0511
   Grant JE, 2007, BIOL PSYCHIAT, V62, P652, DOI 10.1016/j.biopsych.2006.11.021
   Grant JE, 2010, PSYCHOPHARMACOLOGY, V212, P603, DOI 10.1007/s00213-010-1994-5
   Grant JE, 2010, BRIT J PSYCHIAT, V197, P330, DOI 10.1192/bjp.bp.110.078105
   Gray KM, 2010, AM J ADDICTION, V19, P187, DOI 10.1111/j.1521-0391.2009.00027.x
   Guardia J, 2004, ALCOHOL CLIN EXP RES, V28, P736, DOI 10.1097/01.ALC.0000125352.06688.F7
   Heinz A, 2004, AM J PSYCHIAT, V161, P1783, DOI 10.1176/appi.ajp.161.10.1783
   Herz A, 1997, PSYCHOPHARMACOLOGY, V129, P99, DOI 10.1007/s002130050169
   HIETALA J, 1994, PSYCHOPHARMACOLOGY, V116, P285, DOI 10.1007/BF02245330
   Highfield D, 2001, NEUROPSYCHOPHARMACOL, V25, P320, DOI 10.1016/S0893-133X(01)00227-5
   Hollander E, 2000, BIOL PSYCHIAT, V47, P813, DOI 10.1016/S0006-3223(00)00241-9
   Hu J, 2010, BIOL PSYCHIAT, V67, P800, DOI 10.1016/j.biopsych.2009.12.028
   Jobes ML, 2011, PSYCHOPHARMACOLOGY, V218, P83, DOI 10.1007/s00213-011-2230-7
   Kalivas PW, 2011, MOL PSYCHIATR, V16, P974, DOI 10.1038/mp.2011.46
   Kalivas PW, 2009, NAT REV NEUROSCI, V10, P561, DOI 10.1038/nrn2515
   Kalivas PW, 2001, AM J PSYCHIAT, V158, P349, DOI 10.1176/appi.ajp.158.3.349
   Khroyan TV, 2000, J PHARMACOL EXP THER, V294, P680
   Kim SW, 2002, J CLIN PSYCHIAT, V63, P501, DOI 10.4088/JCP.v63n0606
   Kim SW, 2001, BIOL PSYCHIAT, V49, P914, DOI 10.1016/S0006-3223(01)01079-4
   Knackstedt LA, 2009, BIOL PSYCHIAT, V65, P841, DOI 10.1016/j.biopsych.2008.10.040
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Krishnan-Sarin S, 2007, BIOL PSYCHIAT, V62, P694, DOI 10.1016/j.biopsych.2006.11.018
   Krupitsky EM, 2007, AM J PSYCHIAT, V164, P519, DOI 10.1176/appi.ajp.164.3.519
   KRYSTAL JH, 1994, ARCH GEN PSYCHIAT, V51, P898
   Lee B, 2009, J NEUROSCI, V29, P14734, DOI 10.1523/JNEUROSCI.3765-09.2009
   LeMarquand DG, 1999, AM J PSYCHIAT, V156, P1771
   Leri F, 2002, J NEUROSCI, V22, P5713
   Lobo DSS, 2009, ADDICTION, V104, P1454, DOI 10.1111/j.1360-0443.2009.02671.x
   Lutz PE, 2013, CURR OPIN NEUROBIOL, V23, P473, DOI 10.1016/j.conb.2013.02.005
   Marazziti D, 2008, NEUROPSYCHOBIOLOGY, V57, P38, DOI 10.1159/000129665
   Martinez D, 2005, BIOL PSYCHIAT, V58, P779, DOI 10.1016/j.biopsych.2005.04.044
   Martinez D, 2007, AM J PSYCHIAT, V164, P622, DOI 10.1176/appi.ajp.164.4.622
   Martinez D, 2012, BIOL PSYCHIAT, V71, P192, DOI 10.1016/j.biopsych.2011.08.024
   Martinez D, 2011, AM J PSYCHIAT, V168, P634, DOI 10.1176/appi.ajp.2010.10050748
   Martinez D, 2009, AM J PSYCHIAT, V166, P1170, DOI 10.1176/appi.ajp.2009.08121801
   McElroy SL, 2008, J CLIN PSYCHIAT, V69, P433, DOI 10.4088/JCP.v69n0314
   Monti PM, 1999, ALCOHOL CLIN EXP RES, V23, P1386, DOI 10.1111/j.1530-0277.1999.tb04361.x
   MOORE RY, 1979, ANNU REV NEUROSCI, V2, P113, DOI 10.1146/annurev.ne.02.030179.000553
   Narendran R, 2011, SYNAPSE, V65, P1344, DOI 10.1002/syn.20970
   Niciu MJ, 2013, CNS DRUGS, V27, P777, DOI 10.1007/s40263-013-0096-4
   Nordin C, 1999, CNS Spectr, V4, P25
   Nordin C, 2007, NEUROPSYCHOBIOLOGY, V56, P152, DOI 10.1159/000115782
   Nussbaum D, 2011, J GAMBL STUD, V27, P523, DOI 10.1007/s10899-010-9219-8
   Olsen CM, 2011, NEUROPHARMACOLOGY, V61, P1109, DOI 10.1016/j.neuropharm.2011.03.010
   Padgett DA, 2003, TRENDS IMMUNOL, V24, P444, DOI 10.1016/S1471-4906(03)00173-X
   Palfai T, 1999, EXP CLIN PSYCHOPHARM, V7, P266, DOI 10.1037/1064-1297.7.3.266
   Pallanti S, 2010, J PSYCHOPHARMACOL, V24, P847, DOI 10.1177/0269881108099419
   Pallanti S, 2006, CNS SPECTRUMS, V11, P956, DOI 10.1017/S1092852900015145
   Pecina S, 2006, NEUROSCIENTIST, V12, P500, DOI 10.1177/1073858406293154
   Perry CJ, 2013, EUR J NEUROSCI, V38, P2762, DOI 10.1111/ejn.12283
   Petrovic P, 2008, J NEUROSCI, V28, P10509, DOI 10.1523/JNEUROSCI.2807-08.2008
   Potenza M.N., 2008, PHILOS T R SOC B, V363, P1507
   Potenza MN, 2013, WORLD J BIOL PSYCHIA, V14, P139, DOI 10.3109/15622975.2011.598559
   Potenza MN, 2012, AM J PSYCHIAT, V169, P406, DOI 10.1176/appi.ajp.2011.11020289
   Potenza MN, 2001, AM J PSYCHIAT, V158, P1500, DOI 10.1176/appi.ajp.158.9.1500
   Ratsma JE, 2002, ALCOHOL ALCOHOLISM, V37, P522, DOI 10.1093/alcalc/37.6.522
   RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058
   Rosner S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001867.pub3
   ROY A, 1989, PSYCHIAT RES, V30, P137, DOI 10.1016/0165-1781(89)90155-8
   Saiz-Ruiz J, 2005, J CLIN PSYCHIAT, V66, P28, DOI 10.4088/JCP.v66n0104
   Shaham Y, 2000, BRAIN RES REV, V33, P13, DOI 10.1016/S0165-0173(00)00024-2
   Shinohara Kikunori, 1999, Applied Human Science, V18, P37, DOI 10.2114/jpa.18.37
   Simmons D, 2009, NEUROPSYCHOPHARMACOL, V34, P1946, DOI 10.1038/npp.2009.28
   Sinha R, 2007, PSYCHOPHARMACOLOGY, V190, P569, DOI 10.1007/s00213-006-0640-8
   Sofuoglu M, 2009, ADDICT BIOL, V14, P119, DOI 10.1111/j.1369-1600.2008.00138.x
   SPANAGEL R, 1992, P NATL ACAD SCI USA, V89, P2046, DOI 10.1073/pnas.89.6.2046
   Tang XC, 2005, J NEUROSCI, V25, P4512, DOI 10.1523/JNEUROSCI.0685-05.2005
   Torrens M, 2005, DRUG ALCOHOL DEPEN, V78, P1, DOI 10.1016/j.drugalcdep.2004.09.004
   Tremblay AM, 2011, ADDICT BIOL, V16, P467, DOI 10.1111/j.1369-1600.2010.00208.x
   Urban NBL, 2010, BIOL PSYCHIAT, V68, P689, DOI 10.1016/j.biopsych.2010.06.005
   van Wageningen H, 2010, CEREB CORTEX, V20, P798, DOI 10.1093/cercor/bhp145
   Vescovi PP, 1997, ALCOHOL ALCOHOLISM, V32, P85
   Volkow ND, 2005, J NEUROSCI, V25, P3932, DOI 10.1523/JNEUROSCI.0433-05.2005
   Volkow ND, 1997, NATURE, V386, P830, DOI 10.1038/386830a0
   Volkow ND, 1996, ALCOHOL CLIN EXP RES, V20, P1594, DOI 10.1111/j.1530-0277.1996.tb05936.x
   VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210
   Volkow ND, 2001, AM J PSYCHIAT, V158, P2015, DOI 10.1176/appi.ajp.158.12.2015
   VOLKOW ND, 1990, AM J PSYCHIAT, V147, P719
   Volkow ND, 2007, J NEUROSCI, V27, P12700, DOI 10.1523/JNEUROSCI.3371-07.2007
   Volkow ND, 2006, ARCH GEN PSYCHIAT, V63, P999, DOI 10.1001/archpsyc.63.9.999
   Volkow ND, 2011, P NATL ACAD SCI USA, V108, P15037, DOI 10.1073/pnas.1010654108
   Wang GJ, 2012, MOL PSYCHIATR, V17, P918, DOI 10.1038/mp.2011.86
   Weinshenker D, 2007, NEUROPSYCHOPHARMACOL, V32, P1433, DOI 10.1038/sj.npp.1301263
   Welberg L, 2011, NAT REV NEUROSCI, V12, P621, DOI 10.1038/nrn3131
   Zack M, 2004, NEUROPSYCHOPHARMACOL, V29, P195, DOI 10.1038/sj.npp.1300333
   Zhou WH, 2008, BIOL PSYCHIAT, V63, P338, DOI 10.1016/j.biopsych.2007.06.008
NR 110
TC 3
Z9 3
U1 3
U2 11
PU SPRINGER-VERLAG SINGAPORE PTE LTD
PI SINGAPORE
PA 152 BEACH ROAD, #21-01/04 GATEWAY EAST, SINGAPORE, 189721, SINGAPORE
SN 0065-2598
EI 2214-8019
BN 978-981-10-5562-1; 978-981-10-5561-4
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2017
VL 1010
BP 45
EP 58
DI 10.1007/978-981-10-5562-1_3
D2 10.1007/978-981-10-5562-1
PG 14
WC Substance Abuse; Medicine, Research & Experimental
WE Book Citation Index– Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Substance Abuse; Research & Experimental Medicine
GA BJ9IE
UT WOS:000429224300004
PM 29098667
DA 2023-06-23
ER

PT J
AU Droutman, V
   Read, SJ
   Bechara, A
AF Droutman, Vita
   Read, Stephen J.
   Bechara, Antoine
TI Revisiting the role of the insula in addiction
SO TRENDS IN COGNITIVE SCIENCES
LA English
DT Review
DE insular cortex; drug dependence; smoking; decision-making
ID FUNCTIONAL CONNECTIVITY; CUE REACTIVITY; METHAMPHETAMINE USERS;
   SMOKING-CESSATION; DECISION-MAKING; IMPULSE CONTROL; DRUG-ADDICTION;
   NEURAL BASIS; CORTEX; COCAINE
AB Brain lesions that damage the insular cortex (IC) interrupt addictive behaviors, suggesting that drug addiction sensitizes the insula. However, neuroimaging studies seem to lead to an opposite picture: structural neuroimaging studies show reduced gray matter volume of the IC of drug users, and functional neuroimaging studies show reduced IC activity when drug users perform decision-making tasks. These results have been interpreted as indicating that addictive behaviors are associated with reduced interoceptive signaling within the IC. Here, we use this apparent contradiction to examine the possible roles of the insula in addiction, identify open questions, and explore ways to address them.
C1 [Droutman, Vita; Read, Stephen J.; Bechara, Antoine] Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA.
   [Bechara, Antoine] Univ So Calif, Brain & Creat Inst, Los Angeles, CA USA.
C3 University of Southern California; University of Southern California
RP Droutman, V (通讯作者)，Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA.
EM vdroutman@gmail.com
RI Droutman, Vita/AAA-3379-2020
OI Bechara, Antoine/0000-0001-5127-2549
FU NCI [R01CA152062]; NIDA [R01DA031626]
FX This manuscript was supported in part by NIDA Grant Number R01DA031626
   to S.J.R. and NCI Grant Number R01CA152062 to A.B.
CR Barros-Loscertales A, 2011, NEUROIMAGE, V56, P1021, DOI 10.1016/j.neuroimage.2011.02.035
   Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584
   Bechara A, 2005, GAME ECON BEHAV, V52, P336, DOI 10.1016/j.geb.2004.06.010
   Bienkowski P, 2010, NEUROSCI LETT, V478, P161, DOI 10.1016/j.neulet.2010.05.008
   Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475
   Cauda F, 2012, NEUROIMAGE, V62, P343, DOI 10.1016/j.neuroimage.2012.04.012
   Chang LJ, 2013, CEREB CORTEX, V23, P739, DOI 10.1093/cercor/bhs065
   Clark L, 2014, P NATL ACAD SCI USA, V111, P6098, DOI 10.1073/pnas.1322295111
   Contreras M, 2007, SCIENCE, V318, P655, DOI 10.1126/science.1145590
   Contreras M, 2012, NEUROPSYCHOPHARMACOL, V37, P2101, DOI 10.1038/npp.2012.59
   Craig A. D. B., 1996, SOMESTHESIS NEUROBIO, P27, DOI [10.1007/978-3-0348-9016-8_3, DOI 10.1007/978-3-0348-9016-8_3]
   Craig AD, 2010, BRAIN STRUCT FUNCT, V214, P563, DOI 10.1007/s00429-010-0248-y
   Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555
   Craig AD, 2002, NAT REV NEUROSCI, V3, P655, DOI 10.1038/nrn894
   David SP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070104
   Dosenbach NUF, 2006, NEURON, V50, P799, DOI 10.1016/j.neuron.2006.04.031
   Durazzo TC, 2014, ADDICT BIOL, V19, P132, DOI 10.1111/j.1369-1600.2012.00492.x
   Eckert MA, 2009, HUM BRAIN MAPP, V30, P2530, DOI 10.1002/hbm.20688
   Engelmann JM, 2012, NEUROIMAGE, V60, P252, DOI 10.1016/j.neuroimage.2011.12.024
   Ersche KD, 2011, BRAIN, V134, P2013, DOI 10.1093/brain/awr138
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Forget B, 2010, BIOL PSYCHIAT, V68, P265, DOI 10.1016/j.biopsych.2010.01.029
   Gardini S, 2012, BRAIN RES BULL, V87, P205, DOI 10.1016/j.brainresbull.2011.11.021
   Gaznick N, 2014, NICOTINE TOB RES, V16, P445, DOI 10.1093/ntr/ntt172
   Gilman JM, 2008, ADDICT BIOL, V13, P423, DOI 10.1111/j.1369-1600.2008.00111.x
   Gowin JL, 2014, ADDICTION, V109, P237, DOI 10.1111/add.12354
   Gu H, 2010, NEUROIMAGE, V53, P593, DOI 10.1016/j.neuroimage.2010.06.066
   Hanlon CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067917
   Kim YT, 2011, NMR BIOMED, V24, P1392, DOI 10.1002/nbm.1702
   Kuhnen CM, 2005, NEURON, V47, P763, DOI 10.1016/j.neuron.2005.08.008
   Kurth F, 2010, BRAIN STRUCT FUNCT, V214, P519, DOI 10.1007/s00429-010-0255-z
   Lau B, 2008, NEURON, V58, P451, DOI 10.1016/j.neuron.2008.02.021
   Lawrence NS, 2009, CEREB CORTEX, V19, P1134, DOI 10.1093/cercor/bhn154
   Li CSR, 2009, ALCOHOL CLIN EXP RES, V33, P740, DOI 10.1111/j.1530-0277.2008.00891.x
   Li CL, 2013, J PSYCHOPHARMACOL, V27, P837, DOI 10.1177/0269881113492028
   Li XR, 2010, HUM BRAIN MAPP, V31, P410, DOI 10.1002/hbm.20875
   Lopez-Larson MP, 2011, BEHAV BRAIN RES, V220, P164, DOI 10.1016/j.bbr.2011.02.001
   Luijten M, 2013, ADDICTION, V108, P1969, DOI 10.1111/add.12276
   Luo X, 2013, BRAIN, V136, P1231, DOI 10.1093/brain/awt040
   Mackey S, 2013, NEUROSCI BIOBEHAV R, V37, P300, DOI 10.1016/j.neubiorev.2012.12.003
   May A., 2014, DRUG ALCOHOL DEPEN, V140, pe138, DOI [10.1016/j.drugalcdep.2014.02.391, DOI 10.1016/J.DRUGALCDEP.2014.02.391]
   Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0
   Morales AM, 2014, NEUROPSYCHOPHARMACOL, V39, P1816, DOI 10.1038/npp.2014.48
   Morel A, 2013, NEUROSCIENCE, V236, P117, DOI 10.1016/j.neuroscience.2012.12.076
   Munoz-Cuevas FJ, 2013, NAT NEUROSCI, V16, P1367, DOI 10.1038/nn.3498
   Mutschler I, 2009, NEUROSCI LETT, V457, P66, DOI 10.1016/j.neulet.2009.03.101
   Nakama H, 2011, ADDICTION, V106, P1474, DOI 10.1111/j.1360-0443.2011.03433.x
   Naqvi NH, 2007, SCIENCE, V315, P531, DOI 10.1126/science.1135926
   Naqvi NH, 2014, ANN NY ACAD SCI, V1316, P53, DOI 10.1111/nyas.12415
   Naqvi NH, 2010, BRAIN STRUCT FUNCT, V214, P435, DOI 10.1007/s00429-010-0268-7
   Naqvi NH, 2009, TRENDS NEUROSCI, V32, P56, DOI 10.1016/j.tins.2008.09.009
   Nestor L, 2010, NEUROIMAGE, V49, P1133, DOI 10.1016/j.neuroimage.2009.07.022
   Noel X, 2013, CURR OPIN NEUROBIOL, V23, P632, DOI 10.1016/j.conb.2013.01.018
   Paulus MP, 2014, NEUROPHARMACOLOGY, V76, P342, DOI 10.1016/j.neuropharm.2013.07.002
   Pushparaj A, 2013, NEUROPSYCHOPHARMACOL, V38, P690, DOI 10.1038/npp.2012.235
   Rubinstein ML, 2011, NICOTINE TOB RES, V13, P751, DOI 10.1093/ntr/ntr046
   Sanfey AG, 2003, SCIENCE, V300, P1755, DOI 10.1126/science.1082976
   Schacht JP, 2013, ADDICT BIOL, V18, P121, DOI 10.1111/j.1369-1600.2012.00464.x
   Schwartz DL, 2010, NEUROIMAGE, V50, P1392, DOI 10.1016/j.neuroimage.2010.01.056
   Scott D, 2011, BIOL PSYCHIAT, V69, P1052, DOI 10.1016/j.biopsych.2011.01.023
   Sinha R, 2011, CURR PSYCHIAT REP, V13, P398, DOI 10.1007/s11920-011-0224-0
   Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105
   Stewart JL, 2014, DRUG ALCOHOL DEPEN, V142, P110, DOI 10.1016/j.drugalcdep.2014.06.003
   Stewart JL, 2014, ADDICTION, V109, P460, DOI 10.1111/add.12403
   Suner-Soler R, 2012, STROKE, V43, P131, DOI 10.1161/STROKEAHA.111.630004
   Sutherland MT, 2013, BIOL PSYCHIAT, V74, P538, DOI 10.1016/j.biopsych.2013.01.035
   Sutherland MT, 2013, PSYCHOPHARMACOLOGY, V228, P143, DOI 10.1007/s00213-013-3018-8
   Sutherland MT, 2012, NEUROIMAGE, V62, P2281, DOI 10.1016/j.neuroimage.2012.01.117
   Uddin LQ, 2011, J NEUROSCI, V31, P18578, DOI 10.1523/JNEUROSCI.4465-11.2011
   Upadhyay J, 2010, BRAIN, V133, P2098, DOI 10.1093/brain/awq138
   van den Heuvel MP, 2010, EUR NEUROPSYCHOPHARM, V20, P519, DOI 10.1016/j.euroneuro.2010.03.008
   Van Dijk KRA, 2012, NEUROIMAGE, V59, P431, DOI 10.1016/j.neuroimage.2011.07.044
   Wager T. D., 2004, EMOTION, V129, P2865
   Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065
   Xie CM, 2011, BEHAV BRAIN RES, V216, P639, DOI 10.1016/j.bbr.2010.09.004
   Yarkoni T, 2011, NAT METHODS, V8, P665, DOI [10.1038/NMETH.1635, 10.1038/nmeth.1635]
NR 76
TC 173
Z9 175
U1 2
U2 48
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 1364-6613
EI 1879-307X
J9 TRENDS COGN SCI
JI TRENDS COGN. SCI.
PD JUL
PY 2015
VL 19
IS 7
BP 414
EP 420
DI 10.1016/j.tics.2015.05.005
PG 7
WC Behavioral Sciences; Neurosciences; Psychology, Experimental
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Behavioral Sciences; Neurosciences & Neurology; Psychology
GA CM7XP
UT WOS:000357910100009
PM 26066588
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Ivlieva, NY
AF Ivlieva, N. Yu.
TI Neurobiology of Addictive Behavior
SO ZHURNAL VYSSHEI NERVNOI DEYATELNOSTI IMENI I P PAVLOVA
LA Russian
DT Article
DE addictive behavior; addiction; drugs of abuse; dopamine; reinforcement;
   mesocorticolimbic system; ventral tegmental area; vulnerability
ID VENTRAL TEGMENTAL AREA; CORTICOTROPIN-RELEASING-FACTOR; LONG-TERM
   POTENTIATION; NUCLEUS-ACCUMBENS; DOPAMINE NEURONS; PREFRONTAL CORTEX;
   NEURAL MECHANISMS; INCENTIVE SENSITIZATION; AMPHETAMINE EXPOSURE;
   COCAINE ADDICTION
AB Addictive behavior developes after repeated substance use and it typically include a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful consequences, a higher priority given to the drug use than to other activities. Relapse, the resumption of drug taking after periods of abstinence, remains the major problem for the treatment of addiction. The process of drug addiction shares striking commonalities with neural plasticity associated with natural reward learning and memory and is caused primarily by drug-induced sensitization in the brain mesocorticolimbic systems that attribute incentive salience to reward-associated stimuli. The switch from controlled to compulsive drug seeking represents a transition at the neural level from prefrontal cortical to striatal control. Current neurophysiologic evidence suggests that the development of addiction is to some extent due to neurochemical stimulation of the midbrain dopaminergic system that is traditionally considered as a 'common neural currency' for rewards of most kinds. Addictions are a result of the interplay of multiple genetic and environmental factors. They are characterized by phenotypic and genetic heterogeneity as well as polygenicity. Environmental factors are crucial in addiction vulnerability and resistese too.
C1 Moscow Stale Univ Psychol & Educ, Dept Social Pedag, Moscow, Russia.
RP Ivlieva, NY (通讯作者)，Moscow Stale Univ Psychol & Educ, Dept Social Pedag, Moscow, Russia.
EM nivlieva@mail.ru
RI Ивлиева, Наталья/AAC-2636-2022
OI Natalia, Ivlieva/0000-0002-4194-8952
CR Ahmed SH, 2005, EUR J PHARMACOL, V526, P9, DOI 10.1016/j.ejphar.2005.09.036
   ALEXANDER BK, 1981, PHARMACOL BIOCHEM BE, V15, P571, DOI 10.1016/0091-3057(81)90211-2
   ANOKHINA IP, 2008, OSNOVNYE BIOLOGICHES, P71
   ANOKHINA IP, 2008, VOPR NARKOLOGII, P23
   ANOKHINA IP, 2008, GENETIKA ZAVISIMOSTI, P80
   Bechara A, 2001, NEUROPSYCHOLOGIA, V39, P376, DOI 10.1016/S0028-3932(00)00136-6
   Beveridge TJR, 2008, PHILOS T R SOC B, V363, P3257, DOI 10.1098/rstb.2008.0102
   Borgland SL, 2004, J NEUROSCI, V24, P7482, DOI 10.1523/JNEUROSCI.1312-04.2004
   Bowirrat A, 2005, AM J MED GENET B, V132B, P29, DOI 10.1002/ajmg.b.30080
   Briand LA, 2010, BRAIN RES, V1314, P219, DOI 10.1016/j.brainres.2009.11.002
   Buckland PR, 2008, ADDICTION, V103, P1768, DOI 10.1111/j.1360-0443.2008.02285.x
   Caille S, 2009, J NEUROSCI, V29, P10410, DOI 10.1523/JNEUROSCI.2950-09.2009
   Caprioli D, 2007, PROG NEURO-PSYCHOPH, V31, P1639, DOI 10.1016/j.pnpbp.2007.08.029
   Caprioli D, 2009, BIOL PSYCHIAT, V65, P893, DOI 10.1016/j.biopsych.2008.12.009
   Carroll ME, 2009, DRUG ALCOHOL DEPEN, V104, pS70, DOI 10.1016/j.drugalcdep.2008.11.011
   Chambers RA, 2003, AM J PSYCHIAT, V160, P1041, DOI 10.1176/appi.ajp.160.6.1041
   Chen BT, 2008, NEURON, V59, P288, DOI 10.1016/j.neuron.2008.05.024
   Clark L, 2004, BRAIN COGNITION, V55, P41, DOI 10.1016/s0278-2626(03)00284-7
   Czoty PW, 2004, PSYCHOPHARMACOLOGY, V174, P381, DOI 10.1007/s00213-003-1752-z
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   DEVINE DP, 1994, J NEUROSCI, V14, P1978
   DEVRIES TJ, 2002, J NEUROSCI, V22, P9
   Diana M, 2006, ANN NY ACAD SCI, V1074, P446, DOI 10.1196/annals.1369.045
   Dick DM, 2006, BEHAV GENET, V36, P112, DOI 10.1007/s10519-005-9001-3
   Duan JB, 2003, HUM MOL GENET, V12, P205, DOI 10.1093/hmg/ddg055
   Enck P, 2008, NEURON, V59, P195, DOI 10.1016/j.neuron.2008.06.030
   Everitt BJ, 2008, PHILOS T R SOC B, V363, P3125, DOI 10.1098/rstb.2008.0089
   Feltenstein MW, 2008, BRIT J PHARMACOL, V154, P261, DOI 10.1038/bjp.2008.51
   FERSTL R, 2003, RASSTROYSTVA BYZVANN, P968
   Funk CK, 2006, J NEUROSCI, V26, P11324, DOI 10.1523/JNEUROSCI.3096-06.2006
   GALANKIN GA, 2008, VOPR NARKOLOGII, P66
   Gallagher JP, 2008, EUR J PHARMACOL, V583, P215, DOI 10.1016/j.ejphar.2007.11.075
   Goeders NE, 2002, J PHARMACOL EXP THER, V301, P785, DOI 10.1124/jpet.301.3.785
   Haber SN, 2000, J NEUROSCI, V20, P2369
   Hahn J, 2009, J NEUROSCI, V29, P6535, DOI 10.1523/JNEUROSCI.4773-08.2009
   Hansson AC, 2006, P NATL ACAD SCI USA, V103, P15236, DOI 10.1073/pnas.0604419103
   Harris GC, 2003, NEUROPSYCHOPHARMACOL, V28, P73, DOI 10.1038/sj.npp.1300011
   Hinrichs AL, 2006, AM J HUM GENET, V78, P103, DOI 10.1086/499253
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Ito R, 2004, NAT NEUROSCI, V7, P389, DOI 10.1038/nn1217
   Ivlieva NY, 2010, ZH VYSSH NERV DEYAT+, V60, P259
   Jacobs EH, 2005, ADDICT BIOL, V10, P91, DOI 10.1080/13556210412331284748
   Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483
   Jones S, 2000, J NEUROSCI, V20, P5575, DOI 10.1523/JNEUROSCI.20-15-05575.2000
   Kauer JA, 2007, NAT REV NEUROSCI, V8, P844, DOI 10.1038/nrn2234
   Kelley AE, 2004, NEURON, V44, P161, DOI 10.1016/j.neuron.2004.09.016
   Kenny PJ, 2006, J NEUROSCI, V26, P5894, DOI 10.1523/JNEUROSCI.0740-06.2006
   KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259
   KIBIMOV AO, 2009, VOPR NARKOLOGII, P13
   KIBIMOV AO, 2009, NARKOLOGIYA, P53
   Kim Y, 2009, P NATL ACAD SCI USA, V106, P2915, DOI 10.1073/pnas.0813179106
   Kim Y, 2009, NEUROSCI LETT, V465, P31, DOI 10.1016/j.neulet.2009.08.066
   Koob GF, 2008, ANNU REV PSYCHOL, V59, P29, DOI 10.1146/annurev.psych.59.103006.093548
   KRAEMER GW, 1985, PSYCHOPHARMACOLOGY, V86, P182, DOI 10.1007/BF00431706
   Kreek MJ, 2009, CURR OPIN PHARMACOL, V9, P74, DOI 10.1016/j.coph.2008.12.016
   Lane DA, 2008, J NEUROSCI, V28, P9670, DOI 10.1523/JNEUROSCI.2151-08.2008
   Lecca D, 2007, PSYCHOPHARMACOLOGY, V194, P103, DOI 10.1007/s00213-007-0815-y
   Liu X, 1998, NEUROPSYCHOPHARMACOL, V18, P243
   Lovic V, 2006, PHARMACOL BIOCHEM BE, V84, P497, DOI 10.1016/j.pbb.2006.06.013
   Lu L, 2004, NEUROPHARMACOLOGY, V47, P214, DOI 10.1016/j.neuropharm.2004.06.027
   Miczek KA, 2008, PHARMACOL THERAPEUT, V120, P102, DOI 10.1016/j.pharmthera.2008.07.006
   Nader MA, 2008, PHILOS T R SOC B, V363, P3223, DOI 10.1098/rstb.2008.0092
   Nelson A, 2006, J NEUROSCI, V26, P3805, DOI 10.1523/JNEUROSCI.4305-05.2006
   Nestler EJ, 2008, PHILOS T R SOC B, V363, P3245, DOI 10.1098/rstb.2008.0067
   Nikolaeva V.V., 2009, VOPR NARKOLOGII, P57
   Nocjar C, 2007, BEHAV BRAIN RES, V181, P191, DOI 10.1016/j.bbr.2007.04.004
   Nugent FS, 2007, NATURE, V446, P1086, DOI 10.1038/nature05726
   O'Brien CP, 2008, PHILOS T R SOC B, V363, P3277, DOI 10.1098/rstb.2008.0105
   PIAZZA PV, 1991, P NATL ACAD SCI USA, V88, P2088, DOI 10.1073/pnas.88.6.2088
   PIAZZA PV, 1991, BRAIN RES, V567, P169, DOI 10.1016/0006-8993(91)91452-7
   Pierce RC, 2006, NEUROSCI BIOBEHAV R, V30, P215, DOI 10.1016/j.neubiorev.2005.04.016
   Porrino LJ, 2004, J NEUROSCI, V24, P3554, DOI 10.1523/JNEUROSCI.5578-03.2004
   Potenza MN, 2008, PHILOS T R SOC B, V363, P3181, DOI 10.1098/rstb.2008.0100
   Robinson TE, 2001, SYNAPSE, V39, P257
   Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI 10.1146/annurev.psych.54.101601.145237
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   ROTHMAN RB, 1994, PHARMACOL BIOCHEM BE, V49, P583, DOI 10.1016/0091-3057(94)90073-6
   Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-7
   Savage SR, 2003, J PAIN SYMPTOM MANAG, V26, P655, DOI 10.1016/S0885-3924(03)00219-7
   Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1
   Shalev U, 2010, BRAIN RES, V1314, P15, DOI 10.1016/j.brainres.2009.07.028
   Sinha R, 2008, ANN NY ACAD SCI, V1141, P105, DOI 10.1196/annals.1441.030
   SOLOMON RL, 1973, J ABNORM PSYCHOL, V81, P158, DOI 10.1037/h0034534
   Spanagel R, 2005, ADDICTION, V100, P1813, DOI 10.1111/j.1360-0443.2005.01260.x
   Stewart J, 2008, PHILOS T R SOC B, V363, P3147, DOI 10.1098/rstb.2008.0084
   TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147
   Tzschentke TM, 2001, PROG NEUROBIOL, V63, P241, DOI 10.1016/S0301-0082(00)00033-2
   Ungless MA, 2003, NEURON, V39, P401, DOI 10.1016/S0896-6273(03)00461-6
   Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077
   Vanderschuren LJMJ, 2005, J NEUROSCI, V25, P8665, DOI 10.1523/JNEUROSCI.0925-05.2005
   Vargas-Perez H, 2009, SCIENCE, V324, P1732, DOI 10.1126/science.1168501
   Volkow ND, 2008, PHILOS T R SOC B, V363, P3191, DOI 10.1098/rstb.2008.0107
   White FJ, 1998, DRUG ALCOHOL DEPEN, V51, P141, DOI 10.1016/S0376-8716(98)00072-6
   Wise RA, 2002, NEURON, V36, P229, DOI 10.1016/S0896-6273(02)00965-0
   Wise RA, 2010, BRAIN RES, V1314, P38, DOI 10.1016/j.brainres.2009.09.101
   Wong CCY, 2008, PHILOS T R SOC B, V363, P3213, DOI 10.1098/rstb.2008.0104
   Wyvell CL, 2001, J NEUROSCI, V21, P7831, DOI 10.1523/JNEUROSCI.21-19-07831.2001
   Zhang Y, 2007, P NATL ACAD SCI USA, V104, P20552, DOI 10.1073/pnas.0707106104
NR 98
TC 1
Z9 2
U1 0
U2 13
PU MEZHDUNARODNAYA KNIGA
PI MOSCOW
PA 39 DIMITROVA UL., MOSCOW, 113095, RUSSIA
SN 0044-4677
J9 ZH VYSSH NERV DEYAT+
JI Zhurnal Vyss. Nervn. Deyatelnosti Im. I P Pavlov.
PD MAR-APR
PY 2011
VL 61
IS 2
BP 133
EP 150
PG 18
WC Neurosciences; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Physiology
GA 798HH
UT WOS:000293192900001
PM 21675220
DA 2023-06-23
ER

PT J
AU Nutt, D
AF Nutt, David
TI Addiction: lifestyle choice or medical diagnosis?
SO JOURNAL OF EVALUATION IN CLINICAL PRACTICE
LA English
DT Article
DE abstinence; addiction; buprenorphine; heroin; recovery; treatment
ID DRUG-ABUSE; DEPENDENCE; MORTALITY
AB The concept of addiction is under threat from the current UK government's attempt to define it as a lifestyle choice rather than an illness. This overturns the previous government's rational policy on drug treatment and is both dishonest and damaging. It is dishonest because addiction fulfils all the criteria for an illness. It is damaging because proven treatments for many addictions exist and the failure to optimize these means that more patients will die, get blood-borne viruses, and encourage others into drug use. In this paper, I detail these issues and suggest ways to avoid irreparable damage to the current care provisions that are proving effective.
C1 Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Med, Ctr Neuropsychopharmacol,Div Brain Sci, London W12 0NN, England.
C3 Imperial College London
RP Nutt, D (通讯作者)，Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Med, Ctr Neuropsychopharmacol,Div Brain Sci, London Burlington Danes Bldg, London W12 0NN, England.
EM d.nutt@imperial.ac.uk
OI nutt, david/0000-0002-1286-1401
FU MRC [G1002226] Funding Source: UKRI; Medical Research Council [G1002226]
   Funding Source: researchfish; Medical Research Council [G1002226]
   Funding Source: Medline
CR Advisory Council on the Misuse of Drugs, 2010, CONS US FOIL INT RED
   Aitkenhead D., 2012, GUARDIAN
   [Anonymous], 2012, BBC NEWS
   BBC News, 2010, BBC NEWS
   BMA Board of Science, 2013, DRUGS DEP ROL MED PR
   Cabinet Office Behavioural Insights Team, 2011, BEH INS TEAM ANN UPD
   Campbell Denis, 2009, OBSERVER
   Christensen PB, 2006, INT J PRISON HEALTH, V2, P13, DOI 10.1080/17449200600743644
   Dawar A., 2008, GUARDIAN
   Dick Danielle M, 2006, Curr Psychiatry Rep, V8, P151, DOI 10.1007/s11920-006-0015-1
   Edenberg HJ, 2006, HUM MOL GENET, V15, P1539, DOI 10.1093/hmg/ddl073
   GOODWIN DW, 1973, ARCH GEN PSYCHIAT, V28, P238
   Gordon H., 2012, ESTIMATES PREVALENCE
   Hickman M, 2011, J PUBLIC HEALTH-UK, V33, P332, DOI 10.1093/pubmed/fdr055
   Home Office, 2012, PUTT FULL REC 1 REC
   Hunt N., 2003, FORWARD THINKING DRU
   Kendler KS, 1998, AM J PSYCHIAT, V155, P1016, DOI 10.1176/ajp.155.8.1016
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442
   Kreek MJ, 2005, NAT NEUROSCI, V8, P1450, DOI 10.1038/nn1583
   May T., 2012, HOME SECRETARY REQUE
   McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689
   Messina ES, 1997, J PHARMACOL EXP THER, V282, P1608
   Mori I., 2013, DRUG LEGALISATION OM
   Nutt DJ, 2012, J PSYCHOPHARMACOL, V26, P199, DOI 10.1177/0269881111410899
   Volkow ND, 2007, ARCH NEUROL-CHICAGO, V64, P1575, DOI 10.1001/archneur.64.11.1575
NR 26
TC 7
Z9 9
U1 2
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1356-1294
EI 1365-2753
J9 J EVAL CLIN PRACT
JI J. Eval. Clin. Pract.
PD JUN
PY 2013
VL 19
IS 3
SI SI
BP 493
EP 496
DI 10.1111/jep.12045
PG 4
WC Health Care Sciences & Services; Medical Informatics; Medicine, General
   & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; Medical Informatics; General & Internal
   Medicine
GA 149DP
UT WOS:000319298500013
PM 23692233
DA 2023-06-23
ER

PT J
AU Kordi-Tamandani, DM
   Tajoddini, S
   Salimi, F
AF Kordi-Tamandani, Dor Mohammad
   Tajoddini, Shahrad
   Salimi, Farzaneh
TI Promoter Methylation and BDNF and DAT1 Gene Expression Profiles in
   Patients with Drug Addiction
SO PATHOBIOLOGY
LA English
DT Article
DE Brain-derived neurotrophic factor; Dopamine transporter 1; Expression;
   Gene; Methylation; Dopamine; Drug addiction
ID DOPAMINE TRANSPORTER; NEUROTROPHIC FACTOR; EPIGENETIC MECHANISMS; DNA
   METHYLATION; ANIMAL-MODELS; COCAINE; TRANSCRIPTION; PATHWAYS; NEURONS;
   ABUSE
AB Background: Drug addiction is a brain disorder that has negative consequences for individuals and society. Addictions are chronic relapsing diseases of the brain that are caused by direct drug-induced effects and persevering neuro-adaptations at the epigenetic, neuropeptide and neurotransmitter levels. Because the dopaminergic system has a significant role in drug abuse, the purpose of this study was to analyze the methylation and expression profile of brain-derived neurotrophic factor (BDNF) and dopamine transporter (DAT1) genes in individuals with drug addiction. Materials and Methods: BDNF and DAT1 promoter methylation were investigated with a methylation-specific polymerase chain reaction (PCR) technique in blood samples from 75 individuals with drug addiction and 65 healthy controls. The expression levels of BDNF and DAT1 were assessed in 12 mRNA samples from the blood of patients and compared to the samples of healthy controls (n = 12) with real-time quantitative reverse transcription PCR. Results: No significant differences were found in the methylation of BDNF and DAT1 between patients and controls, but the relative levels of expression of BDNF and DAT1 mRNA differed significantly in the patients compared to controls (p < 0.0001). Conclusion: These results showed that the methylation status of the BDNF and DAT1 genes had no significant function in the processes of drug addiction. (C) 2015 S. Karger AG, Basel
C1 [Kordi-Tamandani, Dor Mohammad; Salimi, Farzaneh] Univ Sistan & Baluchestan, Dept Biol, Zahedan, Iran.
   [Tajoddini, Shahrad] Kerman Univ Med Sci, Kerman Neurosci Res Ctr, Kerman, Iran.
C3 University of Sistan & Baluchestan; Kerman University of Medical
   Sciences
RP Kordi-Tamandani, DM (通讯作者)，Univ Sistan & Baluchestan, Dept Biol, POB 98155-987, Zahedan, Iran.
EM dor_kordi@yahoo.com
RI Mohammad, Dor/AGT-2048-2022
OI Mohammad, Dor/0000-0002-4358-4785
FU Institute of Neuroscience, Kerman University of Medical Sciences,
   Kerman; Department of Biology, University of Sistan and Baluchestan,
   Zahedan, Iran
FX We thank the Institute of Neuroscience, Kerman University of Medical
   Sciences, Kerman, and the Department of Biology, University of Sistan
   and Baluchestan, Zahedan, Iran, for supporting this project financially.
CR Baquet ZC, 2005, J NEUROSCI, V25, P6251, DOI 10.1523/JNEUROSCI.4601-04.2005
   Berton O, 2006, SCIENCE, V311, P864, DOI 10.1126/science.1120972
   Cami J, 2003, NEW ENGL J MED, V349, P975, DOI 10.1056/NEJMra023160
   Corominas M, 2007, NEUROPSYCHOBIOLOGY, V55, P2, DOI 10.1159/000103570
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Di Chiara G, 2007, CURR OPIN PHARMACOL, V7, P69, DOI 10.1016/j.coph.2006.11.003
   Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7
   Fisch GS, 2007, BEHAV GENET, V37, P1, DOI 10.1007/s10519-006-9117-0
   Frieling H, 2010, INT J EAT DISORDER, V43, P577, DOI 10.1002/eat.20745
   Fumagalli F, 2003, MOL PSYCHIATR, V8, P898, DOI 10.1038/sj.mp.4001370
   Gorwood P, 2012, HUM GENET, V131, P803, DOI 10.1007/s00439-012-1145-7
   Jeanblanc J, 2009, J NEUROSCI, V29, P13494, DOI 10.1523/JNEUROSCI.2243-09.2009
   Justinova Z, 2009, CURR TOP BEHAV NEURO, V1, P309, DOI 10.1007/978-3-540-88955-7_13
   Kalueff AV, 2008, BEHAV BRAIN RES, V188, P243, DOI 10.1016/j.bbr.2007.11.011
   Khodayari N, 2004, AM J MED GENET B, V129B, P10, DOI 10.1002/ajmg.b.30067
   Kordi-Tamandani DM, 2012, MOL BIOL REP, V39, P10889, DOI 10.1007/s11033-012-1986-0
   Kreek MJ, 2004, NEUROMOL MED, V5, P85, DOI 10.1385/NMM:5:1:085
   Liu JC, 2005, MOL ENDOCRINOL, V19, P1904, DOI 10.1210/me.2004-0111
   Lubin FD, 2008, J NEUROSCI, V28, P10576, DOI 10.1523/JNEUROSCI.1786-08.2008
   Merchant BA, 2012, J MOL GRAPH MODEL, V38, P1, DOI 10.1016/j.jmgm.2012.05.007
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   Norregaard L, 2001, Curr Opin Drug Discov Devel, V4, P591
   O'Loughlin J, 2004, TOB CONTROL, V13, P422, DOI 10.1136/tc.2003.007070
   Renthal W, 2008, TRENDS MOL MED, V14, P341, DOI 10.1016/j.molmed.2008.06.004
   Robison AJ, 2011, NAT REV NEUROSCI, V12, P623, DOI 10.1038/nrn3111
   Russo SJ, 2010, TRENDS NEUROSCI, V33, P267, DOI 10.1016/j.tins.2010.02.002
   SEROOGY KB, 1994, J COMP NEUROL, V342, P321, DOI 10.1002/cne.903420302
   Song YX, 2014, AM J MED GENET B, V165, P357, DOI 10.1002/ajmg.b.32238
   Sullivan D, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2012.146
   Tzschentke TM, 2003, MOL PSYCHIATR, V8, P373, DOI 10.1038/sj.mp.4001269
   Vassoler FM, 2014, NEUROSCIENCE, V264, P198, DOI 10.1016/j.neuroscience.2013.07.064
   Volkow ND, 2004, MOL PSYCHIATR, V9, P557, DOI 10.1038/sj.mp.4001507
   Waddington CH, 2012, INT J EPIDEMIOL, V41, P10, DOI 10.1093/ije/dyr184
   Wang Y, 2004, BIOINFORMATICS, V20, P1170, DOI 10.1093/bioinformatics/bth059
   Zhang HP, 2009, MOL BRAIN, V2, DOI 10.1186/1756-6606-2-10
   Zhou ZF, 2011, P NATL ACAD SCI USA, V108, P6626, DOI 10.1073/pnas.1018514108
NR 36
TC 10
Z9 10
U1 0
U2 9
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-2008
EI 1423-0291
J9 PATHOBIOLOGY
JI Pathobiology
PY 2015
VL 82
IS 2
BP 94
EP 99
DI 10.1159/000430465
PG 6
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Pathology
GA CN5AQ
UT WOS:000358442200007
PM 26160290
OA Bronze
DA 2023-06-23
ER

PT J
AU Moeller, SJ
   London, ED
   Northoff, G
AF Moeller, Scott J.
   London, Edythe D.
   Northoff, Georg
TI Neuroimaging markers of glutamatergic and GABAergic systems in drug
   addiction: Relationships to resting-state functional connectivity
SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
LA English
DT Article
DE Drug addiction; Glutamate; GABA; Neurochemistry; Magnetic resonance
   spectroscopy; Positron emission tomography; Resting-state; fMRI
ID MAGNETIC-RESONANCE-SPECTROSCOPY; ANTERIOR CINGULATE CORTEX;
   GAMMA-AMINOBUTYRIC-ACID; HEROIN-DEPENDENT INDIVIDUALS;
   POSITRON-EMISSION-TOMOGRAPHY; DEFAULT MODE NETWORK; GABA-BENZODIAZEPINE
   RECEPTOR; MEDIAL PREFRONTAL CORTEX; CIGARETTE-SMOKING; ALCOHOL
   DEPENDENCE
AB Drug addiction is characterized by widespread abnormalities in brain function and neurochemistry, including drug-associated effects on concentrations of the excitatory and inhibitory neurotransmitters glutamate and gamma-aminobutyric acid (GABA), respectively. In healthy individuals, these neurotransmitters drive the resting state, a default condition of brain function also disrupted in addiction. Here, our primary goal was to review in vivo magnetic resonance spectroscopy and positron emission tomography studies that examined markers of glutamate and GABA abnormalities in human drug addiction. Addicted individuals tended to show decreases in these markers compared with healthy controls, but findings also varied by individual characteristics (e.g., abstinence length). Interestingly, select corticolimbic brain regions showing glutamatergic and/or GABAergic abnormalities have been similarly implicated in resting-state functional connectivity deficits in drug addiction. Thus, our secondary goals were to provide a brief review of this resting-state literature, and an initial rationale for the hypothesis that abnormalities in glutamatergic and/or GABAergic neurotransmission may underlie resting-state functional deficits in drug addiction. In doing so, we suggest future research directions and possible treatment implications. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Moeller, Scott J.; London, Edythe D.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
   [Moeller, Scott J.; London, Edythe D.] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA.
   [London, Edythe D.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
   [London, Edythe D.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA.
   [Northoff, Georg] Mental Hlth Res Inst, Brain Imaging & Neuroeth Res Unit, Ottawa, ON, Canada.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; University of California System; University of California
   Los Angeles; University of California System; University of California
   Los Angeles; University of Ottawa
RP Moeller, SJ (通讯作者)，One Gustave L Levy Pl,Box 1230, New York, NY 10029 USA.; Northoff, G (通讯作者)，1145 Carling Ave, Ottawa, ON, Canada.
EM scott.moeller@mssm.edu; georg.northoff@theroyal.ca
RI Moeller, Scott J/L-5549-2016; Moeller, Scott J/AAV-1861-2021
OI Moeller, Scott J/0000-0002-4449-0844; 
FU National Institute on Drug Abuse [K01DA037452, R21DA040046]; Brain
   Imaging Center (BIC) pilot funds from the Icahn School of Medicine at
   Mount Sinai; Canadian Institutes of Health (CIHR) [465]; Michael Smith
   Chair for Neuroscience and Mental Health
FX This work was supported by grants from the National Institute on Drug
   Abuse (K01DA037452; R21DA040046) (to SJM). The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health. Additional support
   came from: Brain Imaging Center (BIC) pilot funds from the Icahn School
   of Medicine at Mount Sinai (to SJM); endowments from the Thomas P. and
   Katherine K. Pike Chair of Addiction Studies and the Marjorie Greene
   Trust (to EDL); grants from the Canadian Institutes of Health (CIHR 465
   and CIHR-EJLB) (to GN); and the Michael Smith Chair for Neuroscience and
   Mental Health (to GN).
CR Abe C, 2013, DRUG ALCOHOL DEPEN, V130, P30, DOI 10.1016/j.drugalcdep.2012.10.004
   Abi-Dargham A, 1998, AM J PSYCHIAT, V155, P1550, DOI 10.1176/ajp.155.11.1550
   Abraham A, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00341
   Akkus F., 2015, BIOL PSYCHI IN PRESS
   Akkus F, 2013, P NATL ACAD SCI USA, V110, P737, DOI 10.1073/pnas.1210984110
   Bagga D, 2014, J STUD ALCOHOL DRUGS, V75, P817, DOI 10.15288/jsad.2014.75.817
   Barkhof F, 2014, RADIOLOGY, V272, P28, DOI 10.1148/radiol.14132388
   Bauer J, 2013, NEUROPSYCHOPHARMACOL, V38, P1401, DOI 10.1038/npp.2013.45
   Behar KL, 1999, AM J PSYCHIAT, V156, P952, DOI 10.1176/ajp.156.6.952
   Bolo N, 1998, PSYCHIAT RES-NEUROIM, V82, P115, DOI 10.1016/S0925-4927(98)00017-1
   Brier MR, 2014, BRAIN CONNECT, V4, P299, DOI 10.1089/brain.2014.0236
   Bu Q, 2013, NEUROTOXICOLOGY, V36, P17, DOI 10.1016/j.neuro.2013.02.007
   Burnett E.J., 2015, BIOL PSYCHI IN PRESS
   Cabral J, 2014, PROG NEUROBIOL, V114, P102, DOI 10.1016/j.pneurobio.2013.12.005
   Camchong J, 2011, BIOL PSYCHIAT, V69, P1117, DOI 10.1016/j.biopsych.2011.01.008
   Chang L, 2006, J NEUROIMMUNE PHARM, V1, P65, DOI 10.1007/s11481-005-9005-z
   Chang L, 1997, BIOL PSYCHIAT, V42, P1105, DOI 10.1016/S0006-3223(97)00135-2
   Clark L, 2013, CURR OPIN NEUROBIOL, V23, P655, DOI 10.1016/j.conb.2013.01.004
   Contreras-Rodriguez O, 2015, ADDICTION, V110, P1953, DOI 10.1111/add.13076
   Contreras-Rodriguez O, 2016, ADDICT BIOL, V21, P709, DOI 10.1111/adb.12242
   Cook JB, 2005, ALCOHOL CLIN EXP RES, V29, P1390, DOI 10.1097/01.alc.0000175073.94575.86
   Cosgrove KP, 2014, P NATL ACAD SCI USA, V111, P18031, DOI 10.1073/pnas.1413947111
   Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555
   Crocker CE, 2014, SCHIZOPHR RES, V157, P231, DOI 10.1016/j.schres.2014.05.004
   D'Argembeau A, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00372
   Damoiseaux JS, 2009, BRAIN STRUCT FUNCT, V213, P525, DOI 10.1007/s00429-009-0208-6
   de Greck M, 2008, NEUROIMAGE, V39, P2066, DOI 10.1016/j.neuroimage.2007.11.006
   de Greck M, 2009, HUM BRAIN MAPP, V30, P1691, DOI 10.1002/hbm.20634
   Deco G, 2014, J NEUROSCI, V34, P7886, DOI 10.1523/JNEUROSCI.5068-13.2014
   Demertzi A, 2014, CORTEX, V52, P35, DOI 10.1016/j.cortex.2013.11.005
   Doucet G, 2012, NEUROIMAGE, V59, P3194, DOI 10.1016/j.neuroimage.2011.11.059
   Duncan NW, 2014, NEUROSCI BIOBEHAV R, V47, P36, DOI 10.1016/j.neubiorev.2014.07.016
   Duncan NW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060312
   Duncan NW, 2011, HUM BRAIN MAPP, V32, P2172, DOI 10.1002/hbm.21179
   Durazzo T. C., 2015, BIOL PSYCHI IN PRESS
   Ende G, 2013, ALCOHOL CLIN EXP RES, V37, P1643, DOI 10.1111/acer.12149
   Engel AK, 2013, NEURON, V80, P867, DOI 10.1016/j.neuron.2013.09.038
   Epperson CN, 2005, BIOL PSYCHIAT, V57, P44, DOI 10.1016/j.biopsych.2004.09.021
   Ernst T, 2008, J NEUROIMMUNE PHARM, V3, P165, DOI 10.1007/s11481-008-9108-4
   Fedota JR, 2015, ANN NY ACAD SCI, V1349, P64, DOI 10.1111/nyas.12882
   Fox KCR, 2015, NEUROIMAGE, V111, P611, DOI 10.1016/j.neuroimage.2015.02.039
   Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201
   Frankle WG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032443
   Frankle WG, 2009, NEUROPSYCHOPHARMACOL, V34, P624, DOI 10.1038/npp.2008.104
   Franklin TR, 2012, DRUG ALCOHOL DEPEN, V125, P60, DOI 10.1016/j.drugalcdep.2012.03.016
   Franklin TR, 2011, DRUG ALCOHOL DEPEN, V117, P176, DOI 10.1016/j.drugalcdep.2011.01.015
   Gallinat J, 2007, PHARMACOPSYCHIATRY, V40, P64, DOI 10.1055/s-2007-970144
   Garland EL, 2014, FRONT PSYCHIATRY, V4, DOI 10.3389/fpsyt.2013.00173
   Gilman S, 1996, ANN NEUROL, V40, P163, DOI 10.1002/ana.410400207
   Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119
   Gomez R, 2012, BIOL PSYCHIAT, V71, P239, DOI 10.1016/j.biopsych.2011.06.026
   Gonzalez G, 2003, ADDICTION, V98, P1625, DOI 10.1046/j.1360-0443.2003.00544.x
   Greenwald MK, 2015, PSYCHIAT RES-NEUROIM, V233, P218, DOI 10.1016/j.pscychresns.2015.07.002
   Gu H, 2010, NEUROIMAGE, V53, P593, DOI 10.1016/j.neuroimage.2010.06.066
   Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098
   Gutzeit A, 2013, EUR ADDICT RES, V19, P184, DOI 10.1159/000345915
   Hampson M, 2006, J NEUROSCI, V26, P13338, DOI 10.1523/JNEUROSCI.3408-06.2006
   Hermann D, 2012, BIOL PSYCHIAT, V71, P1015, DOI 10.1016/j.biopsych.2011.07.034
   Hermann D, 2012, ADDICT BIOL, V17, P659, DOI 10.1111/j.1369-1600.2010.00290.x
   Hinton DJ, 2012, NEUROPHARMACOLOGY, V62, P2480, DOI 10.1016/j.neuropharm.2012.02.022
   Howells FM, 2014, SCHIZOPHR RES, V153, P122, DOI 10.1016/j.schres.2014.01.029
   Hu YZ, 2015, JAMA PSYCHIAT, V72, P584, DOI 10.1001/jamapsychiatry.2015.1
   Hu YZ, 2013, J NEUROSCI, V33, P18566, DOI 10.1523/JNEUROSCI.1973-13.2013
   Huang W, 2014, BRAIN BEHAV, V4, P408, DOI 10.1002/brb3.227
   Hulka LM, 2014, MOL PSYCHIATR, V19, P625, DOI 10.1038/mp.2013.51
   Hulka L.M., 2014, ADDICT BIOL IN PRESS
   Hyder F, 2006, J CEREBR BLOOD F MET, V26, P865, DOI 10.1038/sj.jcbfm.9600263
   Hyder F, 2013, J CEREBR BLOOD F MET, V33, P339, DOI 10.1038/jcbfm.2012.207
   Jalan R, 2000, GUT, V46, P546, DOI 10.1136/gut.46.4.546
   Janes AC, 2012, DRUG ALCOHOL DEPEN, V125, P252, DOI 10.1016/j.drugalcdep.2012.02.020
   Jasinska AJ, 2014, NEUROSCI BIOBEHAV R, V38, P1, DOI 10.1016/j.neubiorev.2013.10.013
   Kalivas Peter W, 2007, Dialogues Clin Neurosci, V9, P389
   Kalivas PW, 2009, NAT REV NEUROSCI, V10, P561, DOI 10.1038/nrn2515
   Kapogiannis D, 2013, NEUROIMAGE, V64, P112, DOI 10.1016/j.neuroimage.2012.09.029
   Ke Y, 2004, PSYCHIAT RES-NEUROIM, V130, P283, DOI 10.1016/j.pscychresns.2003.12.001
   Kelly AMC, 2008, NEUROIMAGE, V39, P527, DOI 10.1016/j.neuroimage.2007.08.008
   Kim H, 2015, PROG NEURO-PSYCHOPH, V60, P104, DOI 10.1016/j.pnpbp.2015.02.004
   Kohno M, 2014, JAMA PSYCHIAT, V71, P812, DOI 10.1001/jamapsychiatry.2014.399
   Konova AB, 2015, BRAIN RES, V1628, P147, DOI 10.1016/j.brainres.2015.02.002
   Konova AB, 2013, JAMA PSYCHIAT, V70, P857, DOI 10.1001/jamapsychiatry.2013.1129
   Lee DW, 2014, NEUROSCIENCE, V262, P107, DOI 10.1016/j.neuroscience.2013.12.061
   Lee E, 2007, NEUROREPORT, V18, P1511, DOI 10.1097/WNR.0b013e3282ef7625
   Li Y, 2012, NEUROSCIENCE, V218, P196, DOI 10.1016/j.neuroscience.2012.05.019
   Licata SC, 2010, ANN NY ACAD SCI, V1187, P148, DOI 10.1111/j.1749-6632.2009.05143.x
   Lingford-Hughes A, 2012, J PSYCHOPHARMACOL, V26, P273, DOI 10.1177/0269881110379509
   Lingford-Hughes AR, 2000, ALCOHOL CLIN EXP RES, V24, P1449, DOI 10.1097/00000374-200009000-00018
   Lingford-Hughes AR, 2005, PSYCHOPHARMACOLOGY, V180, P595, DOI 10.1007/s00213-005-2271-x
   Lingford-Hughes AR, 1998, BRIT J PSYCHIAT, V173, P116, DOI 10.1192/bjp.173.2.116
   LITTON JE, 1993, PSYCHIAT RES-NEUROIM, V50, P1
   Liu JX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023098
   Liu JX, 2009, NEUROSCI LETT, V460, P72, DOI 10.1016/j.neulet.2009.05.038
   Liu XX, 2011, PSYCHOPHARMACOLOGY, V217, P367, DOI 10.1007/s00213-011-2292-6
   Logothetis NK, 2009, NEUROIMAGE, V45, P1080, DOI 10.1016/j.neuroimage.2009.01.010
   Lu HB, 2014, BRAIN CONNECT, V4, P499, DOI 10.1089/brain.2014.0264
   Lu HB, 2014, NEUROPHARMACOLOGY, V84, P79, DOI 10.1016/j.neuropharm.2013.08.023
   Luscher B, 2011, NEURON, V70, P385, DOI 10.1016/j.neuron.2011.03.024
   Ma N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016560
   Ma N, 2010, NEUROIMAGE, V49, P738, DOI 10.1016/j.neuroimage.2009.08.037
   Ma XF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120861
   Mantini D, 2013, J NEUROSCI, V33, P3259, DOI 10.1523/JNEUROSCI.4392-12.2013
   Margulies DS, 2007, NEUROIMAGE, V37, P579, DOI 10.1016/j.neuroimage.2007.05.019
   Martinez D, 2014, BIOL PSYCHIAT, V75, P165, DOI 10.1016/j.biopsych.2013.06.026
   Mashhoon Y, 2011, PROG NEURO-PSYCHOPH, V35, P1709, DOI 10.1016/j.pnpbp.2011.05.006
   Mason GF, 2006, BIOL PSYCHIAT, V59, P85, DOI 10.1016/j.biopsych.2005.06.009
   McHugh MJ, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00016
   McHugh MJ, 2013, AM J DRUG ALCOHOL AB, V39, P424, DOI 10.3109/00952990.2013.847446
   McKay PF, 2004, PSYCHOPHARMACOLOGY, V172, P455, DOI 10.1007/s00213-003-1671-z
   Mennecke A, 2014, J NEURAL TRANSM, V121, P1211, DOI 10.1007/s00702-014-1190-6
   Miese F, 2006, AM J NEURORADIOL, V27, P1019
   Milella MS, 2014, NEUROIMAGE, V98, P195, DOI 10.1016/j.neuroimage.2014.04.061
   Moeller SJ, 2014, TRENDS COGN SCI, V18, P635, DOI 10.1016/j.tics.2014.09.003
   Moeller SJ, 2009, BIOL PSYCHIAT, V66, P169, DOI 10.1016/j.biopsych.2009.02.015
   Molnar-Szakacs I, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00571
   Mon A, 2012, DRUG ALCOHOL DEPEN, V125, P27, DOI 10.1016/j.drugalcdep.2012.03.012
   Morcom AM, 2007, NEUROIMAGE, V37, P1073, DOI 10.1016/j.neuroimage.2006.09.013
   Morris L.S., 2015, BIOL PSYCHI IN PRESS
   Muetzel RL, 2013, NEUROIMAGE-CLIN, V2, P581, DOI 10.1016/j.nicl.2013.04.011
   Naqvi NH, 2007, SCIENCE, V315, P531, DOI 10.1126/science.1135926
   Nery FG, 2010, J PSYCHIATR RES, V44, P278, DOI 10.1016/j.jpsychires.2009.09.006
   Northoff G, 2014, UNLOCKING BRAIN, V1
   O'Neill J, 2015, INT J NEUROPSYCHOPH, V18, DOI 10.1093/ijnp/pyu059
   O'Neill J, 2014, PSYCHOPHARMACOLOGY, V231, P2717, DOI 10.1007/s00213-014-3441-5
   Pennington DL, 2014, PSYCHIAT RES-NEUROIM, V224, P281, DOI 10.1016/j.pscychresns.2014.09.004
   Porrino LJ, 2013, PSYCHOPHARMACOLOGY, V225, P105, DOI 10.1007/s00213-012-2798-6
   Prescot AP, 2011, NEUROIMAGE, V57, P69, DOI 10.1016/j.neuroimage.2011.02.044
   Pujol J, 2014, J PSYCHIATR RES, V51, P68, DOI 10.1016/j.jpsychires.2013.12.008
   Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676
   Ravan Shervin, 2014, Handb Clin Neurol, V125, P293, DOI 10.1016/B978-0-444-62619-6.00018-5
   Rosazza C, 2011, NEUROL SCI, V32, P773, DOI 10.1007/s10072-011-0636-y
   Rothman DL, 2011, NMR BIOMED, V24, P943, DOI 10.1002/nbm.1772
   Sailasuta N, 2010, SUBST ABUS-RES TREAT, V4, P9, DOI 10.4137/SART.S4625
   Satterthwaite TD, 2015, CURR OPIN NEUROBIOL, V30, P85, DOI 10.1016/j.conb.2014.10.005
   Schmidt A, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.28
   Seitz D, 1999, ALCOHOL CLIN EXP RES, V23, P158, DOI 10.1097/00000374-199901000-00023
   Shmuel A, 2008, HUM BRAIN MAPP, V29, P751, DOI 10.1002/hbm.20580
   Smallwood J, 2015, ANNU REV PSYCHOL, V66, P487, DOI 10.1146/annurev-psych-010814-015331
   Staley JK, 2005, ARCH GEN PSYCHIAT, V62, P877, DOI 10.1001/archpsyc.62.8.877
   Stephens DN, 2005, EUR J PHARMACOL, V526, P240, DOI 10.1016/j.ejphar.2005.09.031
   Stokes PRA, 2014, NEUROIMAGE, V99, P158, DOI 10.1016/j.neuroimage.2014.05.035
   Stokes PRA, 2013, NEUROIMAGE, V69, P70, DOI 10.1016/j.neuroimage.2012.12.010
   STUHRMANN A, 2011, BIOL MOOD ANXIETY DI, V1
   Sullivan EV, 2013, BIOL PSYCHIAT, V74, P547, DOI 10.1016/j.biopsych.2013.02.026
   Sutherland MT, 2013, BIOL PSYCHIAT, V74, P538, DOI 10.1016/j.biopsych.2013.01.035
   Sutherland MT, 2012, NEUROIMAGE, V62, P2281, DOI 10.1016/j.neuroimage.2012.01.117
   Terbeck S, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00086
   Thoma R, 2011, NEUROPSYCHOPHARMACOL, V36, P1359, DOI 10.1038/npp.2011.20
   Uddin LQ, 2015, NAT REV NEUROSCI, V16, P55, DOI 10.1038/nrn3857
   Uddin LQ, 2009, HUM BRAIN MAPP, V30, P625, DOI 10.1002/hbm.20531
   Umhau JC, 2010, ARCH GEN PSYCHIAT, V67, P1069, DOI 10.1001/archgenpsychiatry.2010.125
   Upadhyay J, 2010, BRAIN, V133, P2098, DOI 10.1093/brain/awq138
   van der Meer L, 2010, NEUROSCI BIOBEHAV R, V34, P935, DOI 10.1016/j.neubiorev.2009.12.004
   Verdejo-Garcia A, 2014, ADDICT BIOL, V19, P272, DOI 10.1111/j.1369-1600.2012.00472.x
   Verdejo-Garcia A, 2013, AUST NZ J PSYCHIAT, V47, P244, DOI 10.1177/0004867412463088
   Verdejo-Garcia A, 2012, NEUROSCI BIOBEHAV R, V36, P1857, DOI 10.1016/j.neubiorev.2012.05.007
   Walls AB, 2015, NEUROCHEM RES, V40, P402, DOI 10.1007/s11064-014-1473-1
   Wang KC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102828
   Wang YR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058098
   Weinberger D. R., 2015, AM J PSYCHI IN PRESS
   Wheelock MD, 2014, FRONT PHARMACOL, V5, DOI [10.3389/fphar.2014.00158, 10.3389/fphar.2014.00518]
   Wiebking C, 2014, NEUROIMAGE, V86, P10, DOI 10.1016/j.neuroimage.2013.04.042
   Wilcox CE, 2011, DRUG ALCOHOL DEPEN, V115, P137, DOI 10.1016/j.drugalcdep.2011.01.009
   Xie CM, 2011, BEHAV BRAIN RES, V216, P639, DOI 10.1016/j.bbr.2010.09.004
   Xu CJ, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00012
   Yang SL, 2015, ADDICT BIOL, V20, P69, DOI 10.1111/adb.12078
   Yang SL, 2009, PSYCHIAT RES-NEUROIM, V174, P171, DOI 10.1016/j.pscychresns.2009.05.004
   Yeo RA, 2013, PSYCHIAT RES-NEUROIM, V211, P141, DOI 10.1016/j.pscychresns.2012.05.005
   Yuan K, 2010, NEUROSCI LETT, V475, P20, DOI 10.1016/j.neulet.2010.03.033
   Yucel M, 2007, MOL PSYCHIATR, V12, P691, DOI 10.1038/sj.mp.4001955
   Zahr N. M., 2015, ADDICT BIOL IN PRESS
   Zhang Y, 2015, NEUROSCIENCE, V284, P998, DOI 10.1016/j.neuroscience.2014.11.007
   Zhu J.C., 2015, ADDICT BIOL IN PRESS
NR 171
TC 29
Z9 30
U1 1
U2 42
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0149-7634
EI 1873-7528
J9 NEUROSCI BIOBEHAV R
JI Neurosci. Biobehav. Rev.
PD FEB
PY 2016
VL 61
BP 35
EP 52
DI 10.1016/j.neubiorev.2015.11.010
PG 18
WC Behavioral Sciences; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Behavioral Sciences; Neurosciences & Neurology
GA DD7IP
UT WOS:000370097200004
PM 26657968
OA Green Accepted
DA 2023-06-23
ER

PT S
AU Rezapour, T
   DeVito, EE
   Sofuoglu, M
   Ekhtiari, H
AF Rezapour, Tara
   DeVito, Elise E.
   Sofuoglu, Mehmet
   Ekhtiari, Hamed
BE Ekhtiari, H
   Paulus, MP
TI Perspectives on neurocognitive rehabilitation as an adjunct treatment
   for addictive disorders: From cognitive improvement to relapse
   prevention
SO NEUROSCIENCE FOR ADDICTION MEDICINE: FROM PREVENTION TO REHABILITATION -
   METHODS AND INTERVENTIONS
SE Progress in Brain Research
LA English
DT Review; Book Chapter
DE Addiction; Neurocognitive rehabilitation; Neuroplasticity
ID DECISION-MAKING; SUBSTANCE-ABUSE; WORKING-MEMORY; NEUROPSYCHOLOGICAL
   FUNCTION; CONTINGENCY MANAGEMENT; EXECUTIVE FUNCTIONS; ATTENTIONAL BIAS;
   EPISODIC MEMORY; ALCOHOL; ABSTINENT
AB Addiction, as a brain disorder, can be defined with two distinct but interacting components: drug dependency and neurocognitive deficits. Most of the therapeutic interventions in addiction medicine, including pharmacological or psychosocial therapies, that are in clinical use have been mainly focused on directly addressing addictive behaviors, especially drug use and urges to use drugs. In the field of addiction treatment, it is often presumed that drug users' neurocognitive deficits will reverse following abstinence. However, in many cases, neurocognitive deficits are not fully ameliorated following sustained abstinence, and neurocognitive function may further deteriorate in early abstinence. It can be argued that many cognitive functions, such as sustained attention and executive control, are essential for full recovery and long-term abstinence from addiction. Recent advances in cognitive neuroscience have provided scientific foundations for neurocognitive rehabilitation as a means of facilitating recovery from drug addiction. Neurocognitive rehabilitation for drug addicted individuals could be implemented as part of addiction treatment, with highly flexible delivery methods including traditional "paper and pencil" testing, or computer-based technology via laptops, web-based, or smartphones in inpatient and outpatient settings. Despite this promise, there has been limited research into the potential efficacy of neurocognitive rehabilitation as a treatment for drug addiction. Further, many questions including the optimum treatment length, session duration, and necessary treatment adherence for treatment efficacy remain to be addressed. In this chapter, we first introduce cognitive rehabilitation as one of the potential areas to bridge the gap between cognitive neuroscience and addiction medicine, followed by an overview of current challenges and future directions.
C1 [Rezapour, Tara; Ekhtiari, Hamed] Univ Tehran Med Sci, Res Ctr Mol & Cellular Imaging, Tehran, Iran.
   [Rezapour, Tara; Ekhtiari, Hamed] Inst Cognit Sci Studies, Translat Neurosci Program, Tehran, Iran.
   [DeVito, Elise E.; Sofuoglu, Mehmet] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
   [Sofuoglu, Mehmet] VA Connecticut Healthcare Syst, West Haven, CT USA.
C3 Tehran University of Medical Sciences; Yale University; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut
   Healthcare System
RP Ekhtiari, H (通讯作者)，Univ Tehran Med Sci, Res Ctr Mol & Cellular Imaging, Tehran, Iran.; Ekhtiari, H (通讯作者)，Inst Cognit Sci Studies, Translat Neurosci Program, Tehran, Iran.
EM H_Ekhtiari@razi.tums.ac.ir
RI Ekhtiari, Hamed/L-3639-2013; Rezapour, Tara/S-2976-2018
OI Ekhtiari, Hamed/0000-0001-6902-8798; 
FU Cognitive Science and Technologies Council of Iran; Tehran University of
   Medical Sciences; Veterans Administration (VA) Mental Illness Research,
   Education and Clinical Center (MIRECC); NIH [DA030794, P50 DA09241]
FX The authors would like to acknowledge the invaluable contributions and
   helpful suggestions provided by Professor Barbara A. Wilson from Oliver
   Zangwill Centre. We would also like to thank Dr. Ali Farhoudian and Dr.
   Reza Daneshmand for their useful comments over the final draft. T.R. and
   H.E. have received supports from Cognitive Science and Technologies
   Council of Iran and Tehran University of Medical Sciences for this
   chapter. This research was supported by the Veterans Administration (VA)
   Mental Illness Research, Education and Clinical Center (MIRECC), and NIH
   grants DA030794 and P50 DA09241.
CR Alfonso JP, 2011, DRUG ALCOHOL DEPEN, V117, P78, DOI 10.1016/j.drugalcdep.2010.12.025
   Bahar-Fuchs A, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt189
   Bahar-Fuchs A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003260.pub2
   Baldacchino A, 2012, NEUROSCI BIOBEHAV R, V36, P2056, DOI 10.1016/j.neubiorev.2012.06.006
   Barr AM, 2006, J PSYCHIATR NEUROSCI, V31, P301
   Bayley MT, 2014, J HEAD TRAUMA REHAB, V29, P290, DOI 10.1097/HTR.0000000000000070
   Bickel WK, 2014, NEUROPHARMACOLOGY, V76, P518, DOI 10.1016/j.neuropharm.2013.06.013
   Bickel WK, 2011, BIOL PSYCHIAT, V69, P260, DOI 10.1016/j.biopsych.2010.08.017
   Bolla KI, 2002, NEUROLOGY, V59, P1337, DOI 10.1212/01.WNL.0000031422.66442.49
   Bolla KI, 1999, J NEUROPSYCH CLIN N, V11, P361, DOI 10.1176/jnp.11.3.361
   Brand M, 2008, DRUG ALCOHOL DEPEN, V97, P64, DOI 10.1016/j.drugalcdep.2008.03.017
   Budney Alan J, 2007, Addict Sci Clin Pract, V4, P4
   Calkins Amanda W, 2015, Behav Cogn Psychother, V43, P578, DOI 10.1017/S1352465814000046
   Carroll KM, 2006, J CONSULT CLIN PSYCH, V74, P955, DOI 10.1037/0022-006X.74.5.955
   Carroll KM, 2006, DRUG ALCOHOL DEPEN, V81, P301, DOI 10.1016/j.drugalcdep.2005.08.002
   Cherner M, 2010, DRUG ALCOHOL DEPEN, V106, P154, DOI 10.1016/j.drugalcdep.2009.08.010
   Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240
   Colzato LS, 2009, PSYCHOPHARMACOLOGY, V207, P225, DOI 10.1007/s00213-009-1650-0
   Cramer SC, 2011, BRAIN, V134, P1591, DOI 10.1093/brain/awr039
   Crean RD, 2011, J ADDICT MED, V5, P1, DOI 10.1097/ADM.0b013e31820c23fa
   Crews FT, 2009, PHARMACOL BIOCHEM BE, V93, P237, DOI 10.1016/j.pbb.2009.04.018
   Davies SJC, 2005, ALCOHOL ALCOHOLISM, V40, P498, DOI 10.1093/alcalc/agh203
   LLopis SD, 2008, J PSYCHOPHARMACOL, V22, P498, DOI 10.1177/0269881107081545
   de Wit H, 2009, ADDICT BIOL, V14, P22, DOI 10.1111/j.1369-1600.2008.00129.x
   Eack SM, 2012, SOC WORK, V57, P235, DOI 10.1093/sw/sws008
   Ersche KD, 2012, AM J PSYCHIAT, V169, P926, DOI 10.1176/appi.ajp.2012.11091421
   Fals-Stewart W, 2010, EXP CLIN PSYCHOPHARM, V18, P87, DOI 10.1037/a0018058
   FALSSTEWART W, 1994, REHABIL PSYCHOL, V39, P75, DOI 10.1037/0090-5550.39.2.75
   Fein G, 2006, ALCOHOL CLIN EXP RES, V30, P1538, DOI 10.1111/j.1530-0277.2006.00185.x
   Fox HC, 2009, PSYCHONEUROENDOCRINO, V34, P1198, DOI 10.1016/j.psyneuen.2009.03.007
   Garland EL, 2014, FRONT PSYCHIATRY, V4, DOI 10.3389/fpsyt.2013.00173
   Goldstein G, 2005, J REHABIL RES DEV, V42, P225, DOI 10.1682/JRRD.2004.03.0040
   Gould Thomas J, 2010, Addict Sci Clin Pract, V5, P4
   Griffiths A, 2012, ADDICTION, V107, P1809, DOI 10.1111/j.1360-0443.2012.03941.x
   Grohman K, 2006, BRAIN COGNITION, V60, P203
   Grohman K, 2003, J COGNITIVE REHABILI, V21, P10
   Gutchess A, 2014, SCIENCE, V346, P579, DOI 10.1126/science.1254604
   Harrell M., 2004, COGNITIVE REHABILITA
   Hoffman WF, 2006, PSYCHOPHARMACOLOGY, V188, P162, DOI 10.1007/s00213-006-0494-0
   Hoshi R, 2007, PSYCHOPHARMACOLOGY, V194, P371, DOI 10.1007/s00213-007-0837-5
   Hosseinbor Mohsen, 2014, Int J High Risk Behav Addict, V3, pe22688, DOI 10.5812/ijhrba.22688
   Houben K, 2011, PSYCHOL SCI, V22, P968, DOI 10.1177/0956797611412392
   Hubener M, 2014, CELL, V159, P727, DOI 10.1016/j.cell.2014.10.035
   Iudicello JE, 2010, J CLIN EXP NEUROPSYC, V32, P704, DOI 10.1080/13803390903512637
   James BD, 2011, J INT NEUROPSYCH SOC, V17, P998, DOI 10.1017/S1355617711000531
   Jovanovski D, 2005, J CLIN EXP NEUROPSYC, V27, P189, DOI 10.1080/13803390490515694
   Kenney JW, 2008, MOL NEUROBIOL, V38, P101, DOI 10.1007/s12035-008-8037-9
   Knudsen HK, 2011, J ADDICT MED, V5, P21, DOI 10.1097/ADM.0b013e3181d41ddb
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Kopera M, 2015, ALCOHOL ALCOHOLISM, V50, P173, DOI 10.1093/alcalc/agu099
   Kornreich C, 2003, PSYCHIAT RES, V119, P251, DOI 10.1016/S0165-1781(03)00130-6
   Kramer AF, 2007, TRENDS COGN SCI, V11, P342, DOI 10.1016/j.tics.2007.06.009
   Kreek MJ, 2010, J ADDICT DIS, V29, P200, DOI 10.1080/10550881003684798
   Lamers CTJ, 2006, J PSYCHOPHARMACOL, V20, P302, DOI 10.1177/0269881106059495
   Ledgerwood DM, 2008, J APPL BEHAV ANAL, V41, P517, DOI 10.1901/jaba.2008.41-517
   Leeman RF, 2014, EXP CLIN PSYCHOPHARM, V22, P469, DOI 10.1037/a0037806
   Loeber S, 2009, ALCOHOL ALCOHOLISM, V44, P372, DOI 10.1093/alcalc/agp030
   London ED, 2004, ARCH GEN PSYCHIAT, V61, P73, DOI 10.1001/archpsyc.61.1.73
   Ma WJ, 2014, NAT NEUROSCI, V17, P347, DOI 10.1038/nn.3655
   MAGURA S, 1988, ADDICT BEHAV, V13, P113, DOI 10.1016/0306-4603(88)90035-4
   Mathai G, 1998, Indian J Psychiatry, V40, P280
   Mathis GM, 2009, J GROUPS ADDICT RECO, V4, P42, DOI 10.1080/15560350802712389
   McHugh RK, 2010, PSYCHIAT CLIN N AM, V33, P511, DOI 10.1016/j.psc.2010.04.012
   Mehta MA, 2004, J CHILD PSYCHOL PSYC, V45, P293, DOI 10.1111/j.1469-7610.2004.00221.x
   Mik-Meyer N, 2012, SOCIOL HEALTH ILL, V34, P1025, DOI 10.1111/j.1467-9566.2011.01448.x
   Miranda R, 2009, ALCOHOL CLIN EXP RES, V33, P817, DOI 10.1111/j.1530-0277.2009.00901.x
   Mishra J, 2012, GAMES HEALTH J, V1, P192, DOI 10.1089/g4h.2011.0033
   Moon M, 2007, INT J NEUROSCI, V117, P1, DOI 10.1080/00207450500535503
   Moriyama Y, 2006, PSYCHIAT CLIN NEUROS, V60, P85, DOI 10.1111/j.1440-1819.2006.01464.x
   Noel Xavier, 2006, Psychiatry (Edgmont), V3, P30
   Nombela Cristina, 2011, Front Neurol, V2, P82, DOI 10.3389/fneur.2011.00082
   O'Brien AR, 2008, ARCH PHYS MED REHAB, V89, P761, DOI 10.1016/j.apmr.2007.10.019
   O'Farrell TJ, 2000, J SUBST ABUSE TREAT, V18, P51, DOI 10.1016/S0740-5472(99)00026-4
   Paquin K, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-139
   Paulus Martin P, 2013, Front Psychiatry, V4, P137, DOI 10.3389/fpsyt.2013.00137
   Peterson MA, 2002, NEUROPSYCHOL REHABIL, V12, P63, DOI 10.1080/09602010143000167
   Pitel AL, 2007, ALCOHOL CLIN EXP RES, V31, P1169, DOI 10.1111/j.1530-0277.2007.00418.x
   Pitel AL, 2009, ALCOHOL CLIN EXP RES, V33, P490, DOI 10.1111/j.1530-0277.2008.00859.x
   Prosser JM, 2008, SUBST ABUSE TREAT PR, V3, DOI 10.1186/1747-597X-3-23
   Quednow BB, 2007, PSYCHOPHARMACOLOGY, V189, P517, DOI 10.1007/s00213-005-0256-4
   Rezapour T, 2015, BASIC CLIN NEUROSCI, V6, P291
   RICHARDSON JTE, 1992, NEUROLOGY, V42, P283, DOI 10.1212/WNL.42.2.283
   Rupp CI, 2012, J STUD ALCOHOL DRUGS, V73, P625, DOI 10.15288/jsad.2012.73.625
   Samuel Ravi, 2008, Indian J Psychiatry, V50, P282, DOI 10.4103/0019-5545.44752
   Schoenmakers TM, 2010, DRUG ALCOHOL DEPEN, V109, P30, DOI 10.1016/j.drugalcdep.2009.11.022
   Sewell RA, 2009, AM J ADDICTION, V18, P185, DOI 10.1080/10550490902786934
   Shapiro C., 1999, INTEGRATING FAMILY F
   Smith Gwenn S, 2013, Dialogues Clin Neurosci, V15, P3
   Sofuoglu M, 2013, NEUROPHARMACOLOGY, V64, P452, DOI 10.1016/j.neuropharm.2012.06.021
   STEINGASS HP, 1994, NEUROPSYCHOL REHABIL, V4, P49, DOI 10.1080/09602019408401455
   Stotts AL, 2009, EXPERT OPIN PHARMACO, V10, P1727, DOI 10.1517/14656560903037168
   Sutherland MT, 2012, NEUROIMAGE, V62, P2281, DOI 10.1016/j.neuroimage.2012.01.117
   Thomasius R, 2006, J PSYCHOPHARMACOL, V20, P211, DOI 10.1177/0269881106059486
   Thorsen AL, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00103
   Timmers C, 2014, APPL NEUROPSYCH-ADUL, V21, P136, DOI 10.1080/09084282.2013.778261
   Uekermann J, 2007, ADDICTION, V102, P232, DOI 10.1111/j.1360-0443.2006.01656.x
   van Holst Ruth Janke, 2011, Curr Drug Abuse Rev, V4, P42
   Verdejo-Garcia A, 2007, PSYCHOPHARMACOLOGY, V190, P517, DOI 10.1007/s00213-006-0632-8
   Wagner M, 2013, ADDICT BIOL, V18, P752, DOI 10.1111/j.1369-1600.2011.00429.x
   Williams KN, 2010, J PSYCHOSOC NURS MEN, V48, P42, DOI 10.3928/02793695-20100331-03
   Willis SL, 2006, JAMA-J AM MED ASSOC, V296, P2805, DOI 10.1001/jama.296.23.2805
   Woicik PA, 2009, NEUROPSYCHOPHARMACOL, V34, P1112, DOI 10.1038/npp.2008.60
   Yang SL, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-290
   Yip JTH, 2005, PSYCHOPHARMACOLOGY, V179, P620, DOI 10.1007/s00213-004-2083-4
NR 104
TC 44
Z9 45
U1 1
U2 11
PU ELSEVIER
PI AMSTERDAM
PA Radarweg 29, PO Box 211, AMSTERDAM, NETHERLANDS
SN 0079-6123
BN 978-0-444-63716-1
J9 PROG BRAIN RES
JI Prog. Brain Res.
PY 2016
VL 224
BP 345
EP 369
DI 10.1016/bs.pbr.2015.07.022
PG 25
WC Substance Abuse; Neurosciences; Psychiatry
WE Book Citation Index– Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Substance Abuse; Neurosciences & Neurology; Psychiatry
GA BS3EA
UT WOS:000709859000017
PM 26822366
DA 2023-06-23
ER

PT C
AU Krahulcova, K
   Chrastina, J
AF Krahulcova, Kristyna
   Chrastina, Jan
GP SGEM
TI SPECIFICS OF DRAMA THERAPY FOR PEOPLE WITH DRUG ADDICTION IN THE COMPLEX
   THERAPEUTIC PROCESS IN DETOXICAL DEPARTMENT
SO PSYCHOLOGY AND PSYCHIATRY, SOCIOLOGY AND HEALTHCARE, EDUCATION, VOL II
SE International Multidisciplinary Scientific Conferences on Social
   Sciences and Arts
LA English
DT Proceedings Paper
CT International Multidisciplinary Scientific Conferences on Social
   Sciences and Arts (SGEM 2014)
CY SEP 01-10, 2014
CL Albena, BULGARIA
SP Bulgarian Acad Sci, Acad Sci Czech Republ, Latvian Acad Sci, Polish Acad Sci, Russian Acad Sci, Serbian Acad Sci & Arts, Slovak Acad Sci Intro, Natl Acad Sci Ukraine, Natl Acad Sci Armenia, Sci Counc Japan, World Acad Sci TWAS, European Acad Sci, Arts & Lett, Acad Fine Arts Zagreb Croatia, Croatian Acad Sci & Arts, Acad Sci Moldova, Montenegrin Acad Sci & Arts, Georgian Acad Sci, Acad Fine Arts & Design Bratislava, Russian Acad Arts, Turkish Acad Sci, SGEM
DE drama therapy; drug addiction; therapeutical proces; detoxical
   department
AB The paper describes the authors metodics of drama therapy for people with drug addiction.To begin all paper is targeted to the specifics of approach used on detoxifical department. Consequently the article points out the complex therapy, incidentally this expressive therapy and its methods. The author discusses her five-year practical experience of drama therapeutical procces with drug addicted people, in addiction presents her methodology of approach, demonstrations of techniques and examples work of client's. This applied methodic of the author can be used as a general valid model for specific attitude of the work with drug addicted people in detoxifical department.
C1 [Krahulcova, Kristyna; Chrastina, Jan] Palacky Univ, Inst Special Educ Studies, CR-77147 Olomouc, Czech Republic.
C3 Palacky University Olomouc
RP Krahulcova, K (通讯作者)，Palacky Univ, Inst Special Educ Studies, CR-77147 Olomouc, Czech Republic.
RI Chrastina, Jan/C-6957-2018; Chrastina, Jan/Q-7688-2019
OI Chrastina, Jan/0000-0003-2114-1083; 
CR Krahulcova K., 2010, SBORN 6 MEZ DRAM K U
   Valenta M., 2009, RUKOVET DRAMATERAPIE, V1
   VALENTA M., 2001, DRAMATERAPIE, V2
NR 3
TC 0
Z9 0
U1 1
U2 4
PU STEF92 TECHNOLOGY LTD
PI SOFIA
PA 1 ANDREY LYAPCHEV BLVD, SOFIA, 1797, BULGARIA
SN 2367-5659
BN 978-619-7105-23-0
J9 INT MULTIDDISCIP SCI
PY 2014
BP 855
EP 860
PG 6
WC Public, Environmental & Occupational Health; Sociology
WE Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)
SC Public, Environmental & Occupational Health; Sociology
GA BD0YK
UT WOS:000357835100109
DA 2023-06-23
ER

PT J
AU Delaporte, PS
AF Delaporte, Pablo Seward
TI "We Will Revive': addiction, spiritual warfare, and recovery in Latin
   America's cocaine production zone
SO THIRD WORLD QUARTERLY
LA English
DT Article
DE Addiction; Peru; Christianity; Urban Poverty; War on Drugs
AB Once a key site in the War on Drugs against cocaine, the Upper Amazon in northeastern Peru has lately seen an increase in addiction to coca paste, a toxic by-product of the cocaine manufacturing process. Unregulated and coercive Pentecostal ministries, founded and administered by recovered pastors, constitute the main form of addiction treatment in the Upper Amazon today. Based on ethnographic research in nine ministries and using the example of the ministry We Will Revive,' this article suggests that Pentecostal ministries re-articulate addiction as demonic possession. Accordingly, ministries treat addiction through spiritual warfare against the Devil. In so doing, Pentecostal ministries change the locus of the War on Drugs from trade networks to sinful bodies.
C1 [Delaporte, Pablo Seward] Stanford Univ, Dept Anthropol, Palo Alto, CA 94304 USA.
C3 Stanford University
RP Delaporte, PS (通讯作者)，Stanford Univ, Dept Anthropol, Palo Alto, CA 94304 USA.
EM pseward@stanford.edu
FU Society for Psychological Anthropology / Robert Lemelson Foundation
   Fellowship; Department of Anthropology at Stanford University; National
   Science Foundation's Graduate Research Fellowship Programme
   [DGE-1656518]
FX This research was supported by the Society for Psychological
   Anthropology / Robert Lemelson Foundation Fellowship, made possible by a
   generous donation from The Robert Lemelson Foundation. This research was
   also supported by the Department of Anthropology at Stanford University.
   The training for this research was supported by the National Science
   Foundation's Graduate Research Fellowship Programme under Grant
   DGE-1656518.
CR Agamben Giorgio, 1998, HOMO SACER SOVEREIGN
   Becerra Beatriz, 1999, DIAGNOSTICO SITUACIO
   Biehl Joao Guilherme, 2005, VITA LIFE ZONE SOCIA
   Browder John, 1997, RAINFOREST CITIES
   Caldeira Teresa PR, 2000, CITY WALLS CRIME SEG
   Chesnut A, 1997, BORN AGAIN BRAZIL PE
   CIDDH, 2010, EX MOD EC PER CAMB F
   Csordas TJ, 2013, CURR ANTHROPOL, V54, P523, DOI 10.1086/672210
   CVR (Comision de la Verdad y Reconciliacion), 2003, INF FIN
   Davis M, 2004, NEW LEFT REV, P5
   De Leon G, 2000, THERAPEUTIC COMMUNIT
   Douglas M., 1966, PURITY DANGER, DOI [10.4324/9780203361832, DOI 10.4324/9780203361832]
   Foucault M., 2007, SECURITY TERRITORY P
   Franco J., 2013, CRUEL MODERNITY
   Galli Enrique, 2012, IDEELE REV       JUN
   Garcia A, 2015, MED ANTHROPOL Q, V29, P455, DOI 10.1111/maq.12208
   Gooren Henri, 2014, OXFORD HDB RELIG CON
   Gootenberg P, 2008, ANDEAN COCAINE: THE MAKING OF A GLOBAL DRUG, P1
   Han C., 2012, LIFE DEBT
   Hansen H, 2012, SOC SCI MED, V74, P1721, DOI 10.1016/j.socscimed.2011.06.048
   Hansen TB, 2012, MELANCHOLIA OF FREEDOM: SOCIAL LIFE IN AN INDIAN TOWNSHIP IN SOUTH AFRICA, P1
   Hartch Todd, 2014, REBIRTH LATIN AM CHR, DOI [10.1093/acprof:oso/9780199844593.001.0001, DOI 10.1093/ACPROF:OSO/9780199844593.001.0001]
   Herlinghaus Hermann, 2009, VIOLENCE GUILT ETHIC, DOI [10.1007/978-0-230-61793-3, DOI 10.1007/978-0-230-61793-3]
   IDPC, 2014, COMP REH LAT AM UN I
   Jurgens R, 2012, ADDICTION, V107, P689, DOI 10.1111/j.1360-0443.2011.03738.x
   Kernaghan Richard., 2009, COCAS GONE MIGHT RIG
   Kling David, 2014, OXFORD HDB RELIG CON
   Lewis I. M., 1971, ECSTATIC RELIG STUDY
   Luhrmann T. M, 2012, GOD TALKS BACK UNDER
   Mangelinckx Jerome, 2013, COMUNIDADES TERAPEUT
   Meyer B, 2010, S ATL Q, V109, P741, DOI 10.1215/00382876-2010-015
   Miles Jack, 2002, CHRIST CRISIS LIFE G
   O'Neill K. L., 2015, SECURE SOUL CHRISTIA
   O'Neill KL, 2014, SOC TEXT, V32, P11, DOI 10.1215/01642472-2703833
   O'Neill KL, 2017, CRIT INQUIRY, V43, P697, DOI 10.1086/691004
   Paucar Felipe Mariluz, 2006, GUERRA OCULTA HUALLA
   Robbins J, 2004, ANNU REV ANTHROPOL, V33, P117, DOI 10.1146/annurev.anthro.32.061002.093421
   Robbins J, 2010, S ATL Q, V109, P633, DOI 10.1215/00382876-2010-010
   Robbins Joel, 2010, STUDYING GLOBAL PENT
   Taussig Michael T., 1980, DEVIL COMMODITY FETI
   UNODC, 2013, PAST BAS COC CUATR D
   UNODC, 2015, WORLD DRUG REP 2015
   Wilkinson Annie Kathryn, 2013, THESIS
   Wynter S, 2003, CR-NEW CENTEN REV, V3, P257, DOI 10.1353/ncr.2004.0015
   Zeiderman A, 2016, ENDANGERED CITY POLI
NR 45
TC 1
Z9 1
U1 0
U2 4
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0143-6597
EI 1360-2241
J9 THIRD WORLD Q
JI Third World Q.
PY 2018
VL 39
IS 2
SI SI
BP 298
EP 313
DI 10.1080/01436597.2017.1328275
PG 16
WC Development Studies
WE Social Science Citation Index (SSCI)
SC Development Studies
GA FW1ON
UT WOS:000425069300008
DA 2023-06-23
ER

PT J
AU Vassileva, J
   Shahidi, R
   Taylor, B
   Moeller, FG
   Ahn, WY
AF Vassileva, Jasmin
   Shahidi, Ryan
   Taylor, Brian
   Moeller, F. G.
   Ahn, Woo-Young
TI Machine Learning Identifies Common and Specific Markers of Addiction to
   Five Different Classes of Drugs
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 74th Annual Meeting of the Society-of-Biological-Psychiatry (SOBP)
CY MAY 16-18, 2019
CL Chicago, IL
SP Soc Biol Psychiat
DE Addiction; Risk Factors; Machine Learning
C1 [Vassileva, Jasmin; Shahidi, Ryan; Taylor, Brian; Moeller, F. G.] Virginia Commonwealth Univ, Richmond, VA 23284 USA.
   [Ahn, Woo-Young] Seoul Natl Univ, Seoul, South Korea.
C3 Virginia Commonwealth University; Seoul National University (SNU)
RI Vassileva, Jasmin/AAF-8356-2019
OI Vassileva, Jasmin/0000-0003-2397-2657
FU National Institute on Drug Abuse; Fogarty International Center
   [R01DA021421]
FX Supported By: This research was supported by the National Institute on
   Drug Abuse and the Fogarty International Center under award number
   R01DA021421 to Jasmin Vassileva.
NR 0
TC 4
Z9 4
U1 3
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 15
PY 2019
VL 85
IS 10
SU S
MA S209
BP S378
EP S378
DI 10.1016/j.biopsych.2019.03.960
PG 1
WC Neurosciences; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Neurosciences & Neurology; Psychiatry
GA IE8YX
UT WOS:000472661000925
DA 2023-06-23
ER

PT J
AU Perkins, FN
   Freeman, KB
AF Perkins, Frank N.
   Freeman, Kevin B.
TI Pharmacotherapies for decreasing maladaptive choice in drug addiction:
   Targeting the behavior and the drug
SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
LA English
DT Review
ID IMPULSIVE DECISION-MAKING; FOOD-COCAINE CHOICE; D-AMPHETAMINE;
   RHESUS-MONKEYS; ENVIRONMENTAL MANIPULATIONS; DELAYED REINFORCEMENT;
   DOPAMINERGIC DRUGS; NUCLEUS-ACCUMBENS; AGONIST REPLACEMENT;
   PROGRESSIVE-RATIO
AB Drug addiction can be conceptualized as a disorder of maladaptive decision making in which drugs are chosen at the expense of pro-social, nondrug alternatives. The study of decision making in drug addiction has focused largely on the role of impulsivity as a facilitator of addiction, in particular the tendency for drug abusers to choose small, immediate gains over larger but delayed outcomes (i.e., delay discounting). A parallel line of work, also focused on decision making in drug addiction, has focused on identifying the determinants underlying the choice to take drugs over nondrug alternatives (i.e., drug vs. nondrug choice). Both tracks of research have been valuable tools in the development of pharmacotherapies for treating maladaptive decision making in drug addiction, and a number of common drugs have been studied in both designs. However, we have observed that there is little uniformity in the administration regimens of potential treatments between the designs, which hinders congruence in the development of single treatment strategies to reduce both impulsive behavior and drug choice. The current review provides an overview of the drugs that have been tested in both delay-discounting and drug-choice designs, and focuses on drugs that reduced the maladaptive choice in both designs. Suggestions to enhance congruence between the findings in future studies are provided. Finally, we propose the use of a hybridized, experimental approach that may enable researchers to test the effectiveness of therapeutics at decreasing impulsive and drug choice in a single design.
C1 [Perkins, Frank N.; Freeman, Kevin B.] Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, Div Neurobiol & Behav Res, Jackson, MS 39216 USA.
C3 University of Mississippi; University of Mississippi Medical Center
RP Freeman, KB (通讯作者)，Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, 2500 N State St, Jackson, MS 39216 USA.
EM kfreeman@umc.edu
FU NIDA [R01-DA027666, R01-DA039167]; Department of Psychiatry and Human
   Behavior at the University of Mississippi Medical Center
FX Preparation of this manuscript was supported by NIDA grants R01-DA027666
   and R01-DA039167 to K.B.F and the Residency Program of the Department of
   Psychiatry and Human Behavior at the University of Mississippi Medical
   Center.
CR Aboujaoude E, 2016, CNS DRUGS, V30, P719, DOI 10.1007/s40263-016-0373-0
   Acheson A, 2008, EXP CLIN PSYCHOPHARM, V16, P113, DOI 10.1037/1064-1297.16.2.113
   Acheson A, 2006, EXP CLIN PSYCHOPHARM, V14, P190, DOI 10.1037/1064-1297.14.2.190
   Adriani Walter, 2012, Curr Top Behav Neurosci, V9, P113, DOI 10.1007/7854_2011_156
   Ashare RL, 2012, EXP CLIN PSYCHOPHARM, V20, P63, DOI 10.1037/a0025594
   Augier E, 2012, ADDICT BIOL, V17, P378, DOI 10.1111/j.1369-1600.2011.00368.x
   Ballard ME, 2015, INT J NEUROPSYCHOPH, V18, DOI 10.1093/ijnp/pyu119
   Banks ML, 2017, NEUROPSYCHOPHARMACOL, V42, P1082, DOI 10.1038/npp.2016.259
   Banks ML, 2017, TRENDS PHARMACOL SCI, V38, P181, DOI 10.1016/j.tips.2016.11.002
   Banks ML, 2015, NEUROPSYCHOPHARMACOL, V40, P2198, DOI 10.1038/npp.2015.63
   Banks ML, 2012, ADV PHARMACOL SCI, V2012, DOI 10.1155/2012/281768
   Banks ML, 2013, DRUG ALCOHOL DEPEN, V131, P204, DOI 10.1016/j.drugalcdep.2013.05.005
   Barbelivien A, 2008, BEHAV BRAIN RES, V187, P273, DOI 10.1016/j.bbr.2007.09.020
   Bickel WK, 2016, PSYCHOPHARMACOLOGY, V233, P1, DOI 10.1007/s00213-015-4148-y
   Bickel WK, 2012, PHARMACOL THERAPEUT, V134, P287, DOI 10.1016/j.pharmthera.2012.02.004
   Bickel WK, 2011, PSYCHOPHARMACOLOGY, V217, P177, DOI 10.1007/s00213-011-2272-x
   Bizot JC, 1999, PSYCHOPHARMACOLOGY, V146, P400, DOI 10.1007/PL00005485
   Bolin BL, 2016, EXP CLIN PSYCHOPHARM, V24, P162, DOI 10.1037/pha0000076
   Boomhower SR, 2014, BEHAV PHARMACOL, V25, P705, DOI 10.1097/FBP.0000000000000058
   Briars Leslie, 2016, J Pediatr Pharmacol Ther, V21, P192, DOI 10.5863/1551-6776-21.3.192
   Broos N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036781
   Broos N, 2012, NEUROPSYCHOPHARMACOL, V37, P1377, DOI 10.1038/npp.2011.323
   Cardinal RN, 2000, PSYCHOPHARMACOLOGY, V152, P362, DOI 10.1007/s002130000536
   CARROLL ME, 1989, PSYCHOPHARMACOLOGY, V97, P23, DOI 10.1007/BF00443407
   Collins ED, 2006, PHARMACOL BIOCHEM BE, V83, P47, DOI 10.1016/j.pbb.2005.12.003
   Collins ED, 1998, BEHAV PHARMACOL, V9, P587, DOI 10.1097/00008877-199811000-00014
   Collins ED, 2007, EXP CLIN PSYCHOPHARM, V15, P228, DOI 10.1037/1064-1297.15.3.228
   Collins SL, 2006, DRUG ALCOHOL DEPEN, V82, P158, DOI 10.1016/j.drugalcdep.2005.09.003
   Comer SD, 2005, PSYCHOPHARMACOLOGY, V181, P664, DOI 10.1007/s00213-005-0023-6
   Czoty PW, 2015, NEUROPSYCHOPHARMACOL, V40, P1072, DOI 10.1038/npp.2014.300
   Czoty PW, 2013, J PHARMACOL EXP THER, V344, P329, DOI 10.1124/jpet.112.201012
   Czoty PW, 2005, BEHAV PHARMACOL, V16, P187, DOI 10.1097/00008877-200505000-00008
   Dakwar E, 2017, MOL PSYCHIATR, V22, P76, DOI 10.1038/mp.2016.39
   De la Garza R, 2010, DRUG ALCOHOL DEPEN, V106, P173, DOI 10.1016/j.drugalcdep.2009.08.013
   de Wit H, 2002, NEUROPSYCHOPHARMACOL, V27, P813, DOI 10.1016/S0893-133X(02)00343-3
   Dursteler KM, 2015, SUBST ABUSE REHABIL, V6, P61, DOI 10.2147/SAR.S50807
   Eubig PA, 2014, PHARMACOL BIOCHEM BE, V118, P1, DOI 10.1016/j.pbb.2013.12.021
   Evenden JL, 1996, PSYCHOPHARMACOLOGY, V128, P161, DOI 10.1007/s002130050121
   Evenden JL, 1999, PSYCHOPHARMACOLOGY, V146, P413, DOI 10.1007/PL00005486
   Floresco SB, 2008, NEUROPSYCHOPHARMACOL, V33, P1966, DOI 10.1038/sj.npp.1301565
   Foltin RW, 2016, PHARMACOL BIOCHEM BE, V150, P8, DOI 10.1016/j.pbb.2016.08.009
   Freeman KB, 2012, LEARN BEHAV, V40, P54, DOI 10.3758/s13420-011-0045-3
   Freeman KB, 2009, BEHAV PROCESS, V82, P214, DOI 10.1016/j.beproc.2009.06.002
   Gasior M, 2004, J PHARMACOL EXP THER, V308, P249, DOI 10.1124/jpet.103.052795
   GERBER GJ, 1985, PHARMACOL BIOCHEM BE, V23, P837, DOI 10.1016/0091-3057(85)90079-6
   Gipson CD, 2009, PSYCHOPHARMACOLOGY, V207, P391, DOI 10.1007/s00213-009-1667-4
   Gondre-Lewis MC, 2016, STRESS, V19, P235, DOI 10.3109/10253890.2016.1160280
   Grabowski J, 1997, J CLIN PSYCHOPHARM, V17, P485, DOI 10.1097/00004714-199712000-00008
   Green L, 2004, PSYCHOL BULL, V130, P769, DOI 10.1037/0033-2909.130.5.769
   Greenwald MK, 2010, NEUROPSYCHOPHARMACOL, V35, P2624, DOI 10.1038/npp.2010.175
   GRIFFITHS RR, 1975, PHARMACOL REV, V27, P357
   GRIFFITHS RR, 1981, J EXP ANAL BEHAV, V35, P335, DOI 10.1901/jeab.1981.35-335
   Hart CL, 2008, NEUROPSYCHOPHARMACOL, V33, P761, DOI 10.1038/sj.npp.1301472
   Harvey-Lewis C, 2015, BEHAV PHARMACOL, V26, P326, DOI 10.1097/FBP.0000000000000106
   Heal DJ, 2013, J PSYCHOPHARMACOL, V27, P479, DOI 10.1177/0269881113482532
   Helms CM, 2006, PSYCHOPHARMACOLOGY, V188, P144, DOI 10.1007/s00213-006-0478-0
   Higgins GA, 2016, PSYCHOPHARMACOLOGY, V233, P2841, DOI 10.1007/s00213-016-4329-3
   Hursh SR, 2008, PSYCHOL REV, V115, P186, DOI 10.1037/0033-295X.115.1.186
   Huskinson SL, 2016, EXP CLIN PSYCHOPHARM, V24, P456, DOI 10.1037/pha0000098
   Huskinson SL, 2015, EXP CLIN PSYCHOPHARM, V23, P184, DOI 10.1037/pha0000015
   Huskinson SL, 2014, NEUROPHARMACOLOGY, V87, P66, DOI 10.1016/j.neuropharm.2014.03.009
   Huskinson SL, 2012, BEHAV PHARMACOL, V23, P315, DOI 10.1097/FBP.0b013e3283564da4
   Huskinson SL, 2012, PHARMACOL BIOCHEM BE, V101, P403, DOI 10.1016/j.pbb.2012.02.005
   Hutsell BA, 2016, DRUG ALCOHOL DEPEN, V168, P36, DOI 10.1016/j.drugalcdep.2016.08.637
   Isles AR, 2003, PSYCHOPHARMACOLOGY, V170, P376, DOI 10.1007/s00213-003-1551-6
   John WS, 2015, PSYCHOPHARMACOLOGY, V232, P1279, DOI 10.1007/s00213-014-3760-6
   Jones JD, 2013, BEHAV PHARMACOL, V24, P384, DOI 10.1097/FBP.0b013e3283641c3d
   Joos L, 2013, EUR NEUROPSYCHOPHARM, V23, P948, DOI 10.1016/j.euroneuro.2012.10.004
   Joutsa J, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2014.133
   Juarez J, 2015, BEHAV NEUROSCI, V129, P756, DOI 10.1037/bne0000109
   Kieres AK, 2004, PSYCHOPHARMACOLOGY, V173, P167, DOI 10.1007/s00213-003-1697-2
   Koffarnus MN, 2011, BEHAV PHARMACOL, V22, P300, DOI 10.1097/FBP.0b013e3283473bcb
   Krebs CA, 2016, BEHAV PROCESS, V130, P39, DOI 10.1016/j.beproc.2016.07.004
   Krebs CA, 2012, BEHAV PHARMACOL, V23, P228, DOI 10.1097/FBP.0b013e32835342ed
   Lamb RJ, 2016, BEHAV PROCESS, V127, P35, DOI 10.1016/j.beproc.2016.04.001
   Leeman Robert F, 2014, Curr Addict Rep, V1, P41
   Leung D, 2017, DRUG ALCOHOL DEPEN, V172, P21, DOI 10.1016/j.drugalcdep.2016.11.034
   Liu YP, 2004, PSYCHOPHARMACOLOGY, V173, P175, DOI 10.1007/s00213-003-1726-1
   Maguire DR, 2016, BEHAV PHARMACOL, V27, P148, DOI 10.1097/FBP.0000000000000193
   Maguire DR, 2014, NEUROPHARMACOLOGY, V87, P173, DOI 10.1016/j.neuropharm.2014.04.012
   Maguire DR, 2013, PSYCHOPHARMACOLOGY, V229, P323, DOI 10.1007/s00213-013-3121-x
   Maguire DR, 2012, J PHARMACOL TOX MET, V66, P264, DOI 10.1016/j.vascn.2012.08.168
   McCreary AC, 2015, INT REV NEUROBIOL, V120, P41, DOI 10.1016/bs.irn.2015.02.008
   Mihalak KB, 2006, MOL PHARMACOL, V70, P801, DOI 10.1124/mol.106.025130
   Minzenberg MJ, 2008, NEUROPSYCHOPHARMACOL, V33, P1477, DOI 10.1038/sj.npp.1301534
   Mitchell JM, 2007, NEUROPSYCHOPHARMACOL, V32, P439, DOI 10.1038/sj.npp.1301226
   NADER MA, 1992, PSYCHOPHARMACOLOGY, V108, P295, DOI 10.1007/BF02245115
   NADER MA, 1991, PSYCHOPHARMACOLOGY, V105, P169, DOI 10.1007/BF02244304
   Negus SS, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a012104
   Negus SS, 2009, NEUROPSYCHOPHARMACOL, V34, P899, DOI 10.1038/npp.2008.127
   Negus SS, 2006, J PHARMACOL EXP THER, V317, P711, DOI 10.1124/jpet.105.095380
   Negus SS, 2004, DRUG ALCOHOL DEPEN, V74, P297, DOI 10.1016/j.drugalcdep.2004.01.006
   Negus SS, 2003, NEUROPSYCHOPHARMACOL, V28, P919, DOI 10.1038/sj.npp.1300096
   Oberlin BG, 2010, ALCOHOL CLIN EXP RES, V34, P1363, DOI 10.1111/j.1530-0277.2010.01220.x
   Orsini CA, 2017, BEHAV BRAIN RES, V321, P130, DOI 10.1016/j.bbr.2017.01.001
   Panlilio LV, 2007, ADDICTION, V102, P1863, DOI 10.1111/j.1360-0443.2007.02011.x
   Panlilio LV, 2015, PSYCHOPHARMACOLOGY, V232, P1451, DOI 10.1007/s00213-014-3787-8
   Patel K, 2016, THER ADV PSYCHOPHARM, V6, P99, DOI 10.1177/2045125316629071
   Pattij T, 2009, PSYCHOPHARMACOLOGY, V205, P489, DOI 10.1007/s00213-009-1558-8
   Perry AN, 2015, NEUROPSYCHOPHARMACOL, V40, P2696, DOI 10.1038/npp.2015.116
   Perry JL, 2008, PSYCHOPHARMACOLOGY, V200, P1, DOI 10.1007/s00213-008-1173-0
   Pietras CJ, 2003, PSYCHOPHARMACOLOGY, V170, P390, DOI 10.1007/s00213-003-1547-2
   Pitts RC, 2005, J EXP ANAL BEHAV, V83, P297, DOI 10.1901/jeab.2005.47-04
   Rajala AZ, 2015, J NEUROPHYSIOL, V114, P70, DOI 10.1152/jn.00278.2015
   Reed SC, 2016, DRUG ALCOHOL DEPEN, V163, P141, DOI 10.1016/j.drugalcdep.2016.04.013
   Reynolds B, 2004, PHARMACOL BIOCHEM BE, V79, P17, DOI 10.1016/j.pbb.2004.06.011
   Richardson NR, 1996, J NEUROSCI METH, V66, P1, DOI 10.1016/0165-0270(95)00153-0
   Robles E, 2011, J SUBST ABUSE TREAT, V41, P354, DOI 10.1016/j.jsat.2011.05.003
   Rush CR, 2012, FUTURE MED CHEM, V4, P245, DOI [10.4155/FMC.11.184, 10.4155/fmc.11.184]
   Schmaal L, 2014, PSYCHOL MED, V44, P2787, DOI 10.1017/S0033291714000312
   Schwager AL, 2014, PSYCHOPHARMACOLOGY, V231, P3941, DOI 10.1007/s00213-014-3529-y
   Schwienteck KL, 2015, DRUG ALCOHOL DEPEN, V155, P16, DOI 10.1016/j.drugalcdep.2015.08.022
   Shiels K, 2009, EXP CLIN PSYCHOPHARM, V17, P291, DOI 10.1037/a0017259
   Slezak JM, 2014, PSYCHOPHARMACOLOGY, V231, P191, DOI 10.1007/s00213-013-3220-8
   Slezak JM, 2011, PHARMACOL BIOCHEM BE, V99, P545, DOI 10.1016/j.pbb.2011.05.027
   Slezak JM, 2009, BEHAV PHARMACOL, V20, P424, DOI 10.1097/FBP.0b013e3283305ef9
   Stahl Stephen M., 2004, Prim Care Companion J Clin Psychiatry, V6, P159
   Stanis JJ, 2008, DRUG ALCOHOL DEPEN, V98, P54, DOI 10.1016/j.drugalcdep.2008.04.009
   Stanis JJ, 2008, PSYCHOPHARMACOLOGY, V199, P539, DOI 10.1007/s00213-008-1182-z
   STITZER ML, 1983, CLIN PHARMACOL THER, V34, P29, DOI 10.1038/clpt.1983.124
   STITZER ML, 1980, ADDICT BEHAV, V5, P333, DOI 10.1016/0306-4603(80)90007-6
   Stoops WW, 2013, CURR PHARM DESIGN, V19, P7026, DOI 10.2174/138161281940131209142843
   Stoops WW, 2012, ADDICTION, V107, P1140, DOI 10.1111/j.1360-0443.2011.03766.x
   Strickland JC, 2017, HUM PSYCHOPHARM CLIN, V32, DOI 10.1002/hup.2567
   Sullivan MA, 2006, PSYCHOPHARMACOLOGY, V189, P37, DOI 10.1007/s00213-006-0509-x
   Tanno T, 2014, PSYCHOPHARMACOLOGY, V231, P85, DOI 10.1007/s00213-013-3209-3
   THIEBOT MH, 1985, PSYCHOPHARMACOLOGY, V86, P147, DOI 10.1007/BF00431700
   Thomsen M, 2013, J EXP ANAL BEHAV, V99, P211, DOI 10.1002/jeab.15
   van Gaalen MM, 2006, BIOL PSYCHIAT, V60, P66, DOI 10.1016/j.biopsych.2005.06.005
   Verrico CD, 2014, DRUG ALCOHOL DEPEN, V141, P72, DOI 10.1016/j.drugalcdep.2014.05.008
   Wade TR, 2000, PSYCHOPHARMACOLOGY, V150, P90
   Weber SC, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.113
   Weintraub SJ, 2017, CNS DRUGS, V31, P87, DOI 10.1007/s40263-016-0403-y
   Winstanley CA, 2005, NEUROPSYCHOPHARMACOL, V30, P669, DOI 10.1038/sj.npp.1300610
   Winstanley CA, 2003, PSYCHOPHARMACOLOGY, V170, P320, DOI 10.1007/s00213-003-1546-3
   Winstanley CA, 2011, BRIT J PHARMACOL, V164, P1301, DOI 10.1111/j.1476-5381.2011.01323.x
   Woolverton WL, 2007, EXP CLIN PSYCHOPHARM, V15, P238, DOI 10.1037/1064-1297.15.3.238
   WOOLVERTON WL, 1981, DRUG ALCOHOL DEPEN, V8, P69, DOI 10.1016/0376-8716(81)90088-0
   Wooters TE, 2011, BRAIN RES, V1396, P45, DOI 10.1016/j.brainres.2011.04.040
   Yates JR, 2017, PSYCHOPHARMACOLOGY, V234, P461, DOI 10.1007/s00213-016-4469-5
   Yates JR, 2014, BRAIN RES, V1574, P26, DOI 10.1016/j.brainres.2014.06.004
   Zeeb FD, 2016, NEUROPSYCHOPHARMACOL, V41, P2091, DOI 10.1038/npp.2016.9
NR 142
TC 11
Z9 11
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0091-3057
J9 PHARMACOL BIOCHEM BE
JI Pharmacol. Biochem. Behav.
PD JAN
PY 2018
VL 164
SI SI
BP 40
EP 49
DI 10.1016/j.pbb.2017.06.015
PG 10
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA FU1VN
UT WOS:000423637700005
PM 28666892
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Stoltman, JJ
   Marra, A
   Uppercue, K
   Terplan, M
AF Stoltman, Jonathan JK.
   Marra, Ashton
   Uppercue, Kristen
   Terplan, Mishka
TI Reporting on Addiction: An Innovative, Collaborative Approach to Reduce
   Stigma by Improving Media Coverage and Public Messaging about Addiction
   Treatment and Recovery
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Editorial Material
DE Stigma; Media; Addiction; Lived experience; People who use drugs;
   Communication
ID LANGUAGE
C1 [Stoltman, Jonathan JK.; Terplan, Mishka] Opioid Policy Inst, 2262 Boston St SE, East Grand Rapids, MI USA.
   [Stoltman, Jonathan JK.; Marra, Ashton; Uppercue, Kristen; Terplan, Mishka] Reporting Addict, 364 Patteson Dr 218, Morgantown, WV USA.
   [Marra, Ashton; Uppercue, Kristen] West Virginia Univ, Reed Coll Media, Morgantown, WV USA.
   [Terplan, Mishka] Friends Res Inst, 1040 Pk Ave Suite 103, Baltimore, MD USA.
   [Stoltman, Jonathan JK.] 2262 Boston St SE, East Grand Rapids, MI 49506 USA.
C3 West Virginia University; Friends Research Institute, Inc.
RP Stoltman, JJ (通讯作者)，2262 Boston St SE, East Grand Rapids, MI 49506 USA.
EM jonathan.stoltman@opioidpolicy.org
CR Associated Press, 2017, ASS PRESS
   Atayde AMP, 2021, ADDICT RES THEORY, V29, P359, DOI 10.1080/16066359.2021.1875215
   Bessette L.G., 2020, SUBST ABUSE, P1
   Botticelli MP, 2016, JAMA-J AM MED ASSOC, V316, P1361, DOI 10.1001/jama.2016.11874
   Earnshaw VA, 2020, AM PSYCHOL, V75, P1300, DOI 10.1037/amp0000744
   Kelly JF, 2010, INT J DRUG POLICY, V21, P202, DOI 10.1016/j.drugpo.2009.10.010
   Mann B, 2020, MED PROFESSIONALS ST
   McGinty EE, 2020, NEW ENGL J MED, V382, P1291, DOI 10.1056/NEJMp2000227
   McGinty EE, 2019, PREV MED, V124, P110, DOI 10.1016/j.ypmed.2019.03.018
   NIDA,, 2021, WORDS MATT TERMS US
   ONDCP, 2016, WHITE HOUSE OFFICE
   Socia KM, 2021, CRIMINOL PUBLIC POL, V20, P729, DOI 10.1111/1745-9133.12566
   Tsuda-McCaie F, 2022, DRUG ALCOHOL REV, V41, P851, DOI 10.1111/dar.13421
   White B., 2020, PERSONAL PRIVACY PUB
   Wolfson L, 2021, HEALTH SOC CARE COMM, V29, P589, DOI 10.1111/hsc.13335
   Yu Y, 2022, PSYCHIATR REHABIL J, V45, P183, DOI 10.1037/prj0000507
NR 16
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0376-8716
EI 1879-0046
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD DEC 1
PY 2022
VL 241
AR 109648
DI 10.1016/j.drugalcdep.2022.109648
EA DEC 2022
PG 3
WC Substance Abuse; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry
GA 6X5HB
UT WOS:000896442900012
DA 2023-06-23
ER

PT J
AU ARLACCHI, P
AF ARLACCHI, P
TI HEROIN IN VERONA + DRUG-ADDICTION AND THE DRUG-TRADE
SO TLS-THE TIMES LITERARY SUPPLEMENT
LA English
DT Discussion
C1 COLUMBIA UNIV,NEW YORK,NY 10027.
C3 Columbia University
RP ARLACCHI, P (通讯作者)，UNIV FLORENCE,I-50121 FLORENCE,ITALY.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU TIMES NEWSPAPERS LTD
PI LONDON
PA PO BOX 479 VIRGINIA ST, LONDON, ENGLAND E1 9XU
SN 0307-661X
J9 TLS-TIMES LIT SUPPL
JI TLS-Times Lit. Suppl.
PD JUN 8
PY 1990
IS 4549
BP S15
EP S15
PG 1
WC Humanities, Multidisciplinary
WE Arts &amp; Humanities Citation Index (A&amp;HCI)
SC Arts & Humanities - Other Topics
GA DJ741
UT WOS:A1990DJ74100066
DA 2023-06-23
ER

PT J
AU Sokhadze, T
   Singh, S
   Stewart, C
   Hollifield, M
   Tasman, A
AF Sokhadze, Tato
   Singh, Shraddha
   Stewart, Christopher
   Hollifield, Michael
   Tasman, Allan
TI Psychophysiological reactivity to drug and trauma cues in cocaine
   addiction co-occurring with PTSD
SO APPLIED PSYCHOPHYSIOLOGY AND BIOFEEDBACK
LA English
DT Meeting Abstract
DE cocaine addiction; PTSD; cue reactivity
C1 [Sokhadze, Tato] Univ Louisville, Hosp Affiliat, Dept Psychiat, Louisville, KY 40292 USA.
C3 University of Louisville
EM tato.sokhadze@louisville.edu
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-0586
J9 APPL PSYCHOPHYS BIOF
JI Appl. Psychophysiol. Biofeedback
PD SEP
PY 2008
VL 33
IS 3
BP 176
EP 176
PG 1
WC Psychology, Clinical
WE Social Science Citation Index (SSCI)
SC Psychology
GA 351GC
UT WOS:000259411600016
DA 2023-06-23
ER

PT J
AU Groman, S
   Carlyle, B
   Wilson, R
   Nairn, A
   Taylor, J
AF Groman, Stephanie
   Carlyle, Becky
   Wilson, Rashaun
   Nairn, Angus
   Taylor, Jane
TI Dissociating the Signaling Mechanisms Underlying Addiction Vulnerability
   From the Consequences of Drug Use
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Meeting Abstract
DE Reinforcement-Based Decision-Making; Vulnerability; Addiction;
   Proteomics
C1 [Groman, Stephanie; Carlyle, Becky; Wilson, Rashaun; Nairn, Angus; Taylor, Jane] Yale Univ, New Haven, CT USA.
C3 Yale University
RI Carlyle, Becky/HGD-4177-2022
OI Carlyle, Becky/0000-0003-1491-3217
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
EI 1740-634X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD DEC
PY 2018
VL 43
SU S
MA W238
BP S503
EP S503
PG 1
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA VI6YX
UT WOS:000509546600915
DA 2023-06-23
ER

PT J
AU Wood, E
   Li, K
   Palepu, A
   Marsh, DC
   Schechter, MT
   Hogg, RS
   Montaner, JSG
   Kerr, T
AF Wood, E
   Li, K
   Palepu, A
   Marsh, DC
   Schechter, MT
   Hogg, RS
   Montaner, JSG
   Kerr, T
TI Sociodemographic disparities in access to addiction treatment among a
   cohort of Vancouver injection drug users
SO SUBSTANCE USE & MISUSE
LA English
DT Article
DE addiction treatment; injection drug use; HIV/AIDS
ID NEEDLE EXCHANGE PROGRAMS; OPIOID DEPENDENCE; RISK-FACTORS; HIV; COCAINE;
   EPIDEMIOLOGY; INFECTION; METHADONE; EFFICACY; POLITICS
AB Vancouver's explosive HIV epidemic among injection drug users (IDUs) has received international attention due to the presence of a large needle exchange program. The role of addiction treatment bras not been evaluated in this setting. We evaluated factors associated with use of addiction treatment among a prospective cohort of Vancouver IDUs. Addiction treatment was negatively associated with Aboriginal ethnicity and unstable housing, both of which have been associated with HIV infection in previous studies. These findings demonstrate low levels of addiction treatment among Vancouver IDUs and suggest that programs may need to be targeted towards specific populations with poor access.
C1 St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada.
   Univ British Columbia, Fac Med, Dept Hlth Care & Epidemiol, Vancouver, BC V5Z 1M9, Canada.
   Univ British Columbia, Fac Med, Dept Med, Vancouver, BC V5Z 1M9, Canada.
   Vancouver Coastal Hlth, Vancouver, BC, Canada.
C3 B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University
   of British Columbia; University of British Columbia; Vancouver Coastal
   Health Research Institute
RP Wood, E (通讯作者)，BC Ctr Excellence HIV AIDS, Div Epidemiol & Populat Hlth, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
EM ewood@hivnet.ubc.ca
RI Montaner, Julio/K-7621-2012; Marsh, David C./AAU-7184-2020; Hogg, Robert
   S/B-2783-2012
OI Marsh, David C./0000-0002-8769-1785; Hogg, Robert S/0000-0003-3463-5488;
   Palepu, Anita/0000-0002-7881-4800; Schechter, Martin/0000-0001-6063-2155
FU NIDA NIH HHS [R01 DA 011591-04A1] Funding Source: Medline
CR ALFORD GS, 1991, J STUD ALCOHOL, V52, P118, DOI 10.15288/jsa.1991.52.118
   Bellm J, 1999, LANCET, V353, P930, DOI 10.1016/S0140-6736(05)75044-3
   Cartwright WS, 1998, EVALUATION REV, V22, P609, DOI 10.1177/0193841X9802200503
   Collins C, 2000, AM J PUBLIC HEALTH, V90, P1389, DOI 10.2105/AJPH.90.9.1389
   Coutinho RA, 2000, AM J PUBLIC HEALTH, V90, P1387, DOI 10.2105/AJPH.90.9.1387
   COX DR, 1972, J R STAT SOC B, V34, P187
   Craib KJP, 2003, CAN MED ASSOC J, V168, P19
   Crits-Christoph P, 1999, ARCH GEN PSYCHIAT, V56, P493, DOI 10.1001/archpsyc.56.6.493
   Darke S, 1998, DRUG ALCOHOL DEPEN, V51, P253, DOI 10.1016/S0376-8716(98)00028-3
   Des Jarlais DC, 2000, AM J PUBLIC HEALTH, V90, P1392, DOI 10.2105/AJPH.90.9.1392
   Des Jarlais DC, 1999, LANCET, V353, P1657, DOI 10.1016/S0140-6736(98)07026-3
   Hartel D M, 1998, Public Health Rep, V113 Suppl 1, P107
   Jarlais DCD, 1996, LANCET, V348, P987, DOI 10.1016/S0140-6736(96)02536-6
   Johnson RE, 2000, NEW ENGL J MED, V343, P1290, DOI 10.1056/NEJM200011023431802
   Magura S, 2000, SUBST USE MISUSE, V35, P1617, DOI 10.3109/10826080009148234
   Miller CL, 2002, J URBAN HEALTH, V79, P257, DOI 10.1093/jurban/79.2.257
   Millsap BA, 2002, J RAPTOR RES, V36, P3
   Moss AR, 2000, AM J PUBLIC HEALTH, V90, P1385, DOI 10.2105/AJPH.90.9.1385
   OSHAUGHNESSY MV, 1998, INT C AIDS, V12, P982
   Palepu A, 1999, J URBAN HEALTH, V76, P409, DOI 10.1007/BF02351499
   Palepu A, 2001, CAN MED ASSOC J, V165, P415
   Rehm J, 2001, LANCET, V358, P1417, DOI 10.1016/S0140-6736(01)06529-1
   Rydell CP, 1996, OPER RES, V44, P687, DOI 10.1287/opre.44.5.687
   Schechter MT, 1999, AIDS, V13, pF45, DOI 10.1097/00002030-199904160-00002
   Schechter MT, 2002, ANN AM ACAD POLIT SS, V582, P94
   Sees KL, 2000, JAMA-J AM MED ASSOC, V283, P1303, DOI 10.1001/jama.283.10.1303
   Strathdee SA, 2001, ARCH INTERN MED, V161, P1281, DOI 10.1001/archinte.161.10.1281
   Strathdee SA, 1997, AIDS, V11, pF59, DOI 10.1097/00002030-199708000-00001
   Tyndall MW, 2003, AIDS, V17, P887, DOI 10.1097/00002030-200304110-00014
   Vlahov D, 2000, AM J PUBLIC HEALTH, V90, P1390
   Wall R, 2000, J URBAN HEALTH, V77, P688, DOI 10.1007/BF02344032
   WENGER LD, 1994, J PSYCHOACTIVE DRUGS, V26, P1
   Wood E, 2003, CAN MED ASSOC J, V168, P165
   Wood E, 2004, LANCET INFECT DIS, V4, P301, DOI 10.1016/S1473-3099(04)01006-0
   Wood E, 2003, CAN J PUBLIC HEALTH, V94, P355, DOI 10.1007/BF03403560
   Wood E, 2003, J INFECT DIS, V188, P1164, DOI 10.1086/378703
   Wood E., 2002, International Journal of Drug Policy, V13, P95, DOI 10.1016/S0955-3959(02)00008-7
   Wood E, 2003, JAIDS-J ACQ IMM DEF, V32, P2, DOI 10.1097/00126334-200301010-00002
   Wood E, 2002, AIDS, V16, P941, DOI 10.1097/00002030-200204120-00021
   Wood E, 2003, BC MED J, V45, P130
   2001, REPORT AUDITOR GEN
   1994, J ADDICT DIS, V13, P231
NR 42
TC 32
Z9 33
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1082-6084
EI 1532-2491
J9 SUBST USE MISUSE
JI Subst. Use Misuse
PY 2005
VL 40
IS 8
BP 1153
EP 1167
DI 10.1081/JA-200042287
PG 15
WC Substance Abuse; Psychiatry; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry; Psychology
GA 952AT
UT WOS:000230974300010
PM 16040375
DA 2023-06-23
ER

PT J
AU Lundin, RM
   Hill, H
AF Lundin, Robert M.
   Hill, Harry
TI The worrying, current state of addictions training in medicine
SO FRONTIERS IN MEDICINE
LA English
DT Editorial Material
DE addictions; drugs; alcohol; training; dual diagnosis; competency;
   curriculum
ID PSYCHIATRY; DISORDERS
C1 [Lundin, Robert M.; Hill, Harry] Deakin Univ, Inst Mental & Phys Hlth & Clin Translat IMPACT, Geelong, Vic, Australia.
   [Lundin, Robert M.; Hill, Harry] Barwon Hlth, Change Improve Mental Hlth CHIME, MHDAS, Geelong, Vic, Australia.
   [Hill, Harry] Albury Wodonga Hlth, Dept Mental Hlth, Wangaratta, Vic, Australia.
C3 Deakin University
RP Lundin, RM (通讯作者)，Deakin Univ, Inst Mental & Phys Hlth & Clin Translat IMPACT, Geelong, Vic, Australia.; Lundin, RM (通讯作者)，Barwon Hlth, Change Improve Mental Hlth CHIME, MHDAS, Geelong, Vic, Australia.
EM Robert@lundin.no
RI Lundin, Robert/Q-5362-2018
OI Lundin, Robert/0000-0002-5992-2822
CR Ayu AP, 2017, SUBST ABUS, V38, P483, DOI 10.1080/08897077.2017.1355868
   Ayu AP, 2015, EUR ADDICT RES, V21, P223, DOI 10.1159/000381671
   Balhara YPS, 2021, ASIA-PAC PSYCHIAT, V13, DOI 10.1111/appy.12492
   Berkovitch L, 2021, ENCEPHALE, V47, P376, DOI 10.1016/j.encep.2020.12.002
   Butler K, 2016, PUBLIC HEALTH RES PR, V26, DOI 10.17061/phrp2641642
   Christison GW, 2003, TEACH LEARN MED, V15, P93, DOI 10.1207/S15328015TLM1502_04
   Clancy C, 2019, J ADDICT NURS, V30, P149, DOI 10.1097/JAN.0000000000000295
   Eyre HA, 2021, NEURON, V109, P1430, DOI 10.1016/j.neuron.2021.04.007
   Haque LY, 2022, DIGEST DIS SCI, V67, P2721, DOI 10.1007/s10620-022-07478-9
   International Narcotics Control Board, 2013, EC CONS DRUG AB
   King Ryan S, 2006, Harm Reduct J, V3, P6, DOI 10.1186/1477-7517-3-6
   Klimas J, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4027
   Lubman DI, 2007, AUST NZ J PSYCHIAT, V41, P830, DOI 10.1080/00048670701579090
   Nunes EV, 2020, AM J ADDICTION, V29, P390, DOI 10.1111/ajad.13068
   Orsolini L, 2021, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.585607
   Rasyidi E, 2012, PSYCHIAT CLIN N AM, V35, P461, DOI 10.1016/j.psc.2012.04.001
   Segawa T, 2020, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01409
   Shulman M, 2019, CNS DRUGS, V33, P567, DOI 10.1007/s40263-019-00637-z
   State of Victoria, 2021, 202 STAT VICT, P120
   United Nation Office on Drugs and Crime, 2011, WORLD DRUG REP
   Wakeman SE, 2013, SUBST ABUS, V34, P363, DOI 10.1080/08897077.2013.797540
   Zajac K, 2020, EXPERT REV NEUROTHER, V20, P85, DOI 10.1080/14737175.2020.1671824
NR 22
TC 1
Z9 1
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD NOV 24
PY 2022
VL 9
AR 1062096
DI 10.3389/fmed.2022.1062096
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 6V1HB
UT WOS:000894807000001
PM 36507515
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Husak, DN
AF Husak, DN
TI The moral relevance of addiction
SO SUBSTANCE USE & MISUSE
LA English
DT Article
DE addiction; blame; compulsion; craving; virtue; voluntariness
ID DRUG; DISEASE; RISK
AB I attempt to understand and assess, the widespread, belief that addiction is relevant to morality. I examine several accounts of how addiction might be significant from a moral point of view. Although I briefly discuss theories of virtue, I focus on three possible ways addiction might be relevant to moral blame. First, blame might be imposed for the act of using addictive drugs. Second, blame might be imposed for the condition of being addicted. Third, blame might be imposed for further risks persons are likely to undertake once they have become addicts. I conclude that each of-these accounts has some plausibility, but none is entirely unproblematic. Addiction probably is relevant to morality, although its degree of importance is not as great as some commentators appear to believe. The moral relevance of addiction does not appear to rise to whatever level would justify a punitive response to addictive drug users.
C1 Rutgers State Univ, Dept Philosophy, New Brunswick, NJ 08903 USA.
C3 Rutgers State University New Brunswick
RP Husak, DN (通讯作者)，Rutgers State Univ, Dept Philosophy, 26 Nichol Ave, New Brunswick, NJ 08903 USA.
EM husak@rci.rutgers.edu
CR Ainslie G., 1992, PICOECONOMICS
   AKERS RL, 1991, J DRUG ISSUES, V21, P777, DOI 10.1177/002204269102100407
   *AM PSYCH ASS, DIAGN STAT MAN, V4, P175
   Annas GJ, 1997, NEW ENGL J MED, V337, P435, DOI 10.1056/NEJM199708073370621
   BENNETT W, 1998, DRUGS SHOULD WE LEGA, P63
   Bilionis LD, 1998, MICH LAW REV, V96, P1269, DOI 10.2307/1290179
   Blendon RJ, 1998, JAMA-J AM MED ASSOC, V279, P827, DOI 10.1001/jama.279.11.827
   Bluthenthal RN, 1999, J DRUG ISSUES, V29, P1
   Boyum D., 2001, DRUG ADDICTION DRUG, P239
   BROWN JH, 1977, EDUC EVAL POLICY AN, V19, P65
   *BUR JUST STAT, 2000, SOURC CRIM JUST STAT
   CAULKINS J, 1988, J DRUG ISSUES, V28, P593
   Chaffin M, 1996, CHILD ABUSE NEGLECT, V20, P191, DOI 10.1016/S0145-2134(95)00144-1
   CHAIKEN JM, 1990, DRUGS CRIME, P203
   Churchland PS, 1996, RES PER NEUROSCI, P181
   COHEN JS, 2001, OVERDOSE CASE DRUG C
   Courtwright D., 2001, FORCES HABIT DRUGS M, P190
   Duff A., 2002, BUFFALO CRIMINAL LAW, V6, P147
   EDWARDS R, 1994, DRUGS MORALITY LAW, P183
   EISER JR, 1978, ADDICT BEHAV, V3, P99
   ELSTER J, 1984, ULYSSES SIRENS
   Elster Jon, 1999, STRONG FEELINGS
   FAGAN, 1990, DRUGS CRIME, P241
   FAGAN JA, 1994, DRUGS CRIME EVALUATI
   Feinberg Joel., 1986, HARM SELF
   GOLDSTEIN PJ, 1985, J DRUG ISSUES, V15, P493, DOI 10.1177/002204268501500406
   Goodin R. E., 1989, NO SMOKING
   HEATHER N, 1993, PSYCHOACTIVE DRUGS H
   HEYMAN GM, 2001, DRUG ADDICTION DRUG
   Holden C, 2001, SCIENCE, V294, P980, DOI 10.1126/science.294.5544.980
   Husak D., 2002, CRIMINAL LAW THEORY, P13
   HUSAK D, 2002, HDB PRACTICAL ETHICS, P653
   HUSAK D, 1987, PHILOS CRIMINAL LAW, P100
   Husak D. N, 1992, DRUGS AND RIGHTS
   Husak DN, 1999, LAW PHILOS, V18, P655
   Husak Douglas, 2002, LEGALIZE THIS CASE D
   Husak Douglas N., 1998, FUNDAMENTALS SENTENC, p[187, 217]
   Jencks C., 1994, HOMELESS
   KAPLAN J, 1983, HARDEST DRUG HEROIN
   Kleiman M. A. R., 1992, EXCESS DRUG POLICY R
   Klingemann H. K., 2001, SUBST USE MISUSE, V36, P11
   Kubey R, 2002, SCI AM, V286, P74, DOI 10.1038/scientificamerican0202-74
   LATROU J, 1998, JAMA-J AM MED ASSOC, V279, P1200
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   LUNGREN D, 2000, PROHIBITION, P179
   MacCoun R., 1998, HDB CRIME PUNISHMENT, P207
   MacCoun RJ, 2001, DRUG WAR HERESIES LE
   Meier KJ, 1997, AM J PUBLIC HEALTH, V87, P1126, DOI 10.2105/AJPH.87.7.1126
   Moore Michael, 1993, ACT AND CRIME
   MORRIS H, 1968, MONIST, V52, P475, DOI 10.5840/monist196852436
   Morse SJ, 2000, LAW PHILOS, V19, P3
   NADELMANN EA, 1989, SCIENCE, V245, P939, DOI 10.1126/science.2772647
   *NAT CTR ADD SUBST, 1997, BARS SUBST AB AM PRI
   Nolan James, 2001, REINVENTING JUSTICE
   *OFF JUST PROGR, 2000, DRUG US FOR ANN REP
   OLEARY J, 2001, DRUGS DOPING SPORT
   Packer Herbert L., 1968, LIMITS CRIMINAL SANC
   Parker H., 1998, ILLEGAL LEISURE
   PEELE S, 1975, LOV ADDICTION
   PEELE S, 1995, DIS AM
   RICHARDS DAJ, 1982, SEX DRUGS DEATH LAW
   Roberts DE, 1997, MICH LAW REV, V95, P938, DOI 10.2307/1290050
   ROBINSON PH, 1985, VA LAW REV, V71, P1, DOI 10.2307/1072934
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   SHEDLER J, 1990, AM PSYCHOL, V45, P612, DOI 10.1037/0003-066X.45.5.612
   Stuntz WJ, 1998, COLUMBIA LAW REV, V98, P1795, DOI 10.2307/1123466
   Szasz, 1992, OUR RIGHT DRUGS
   THOMBS DL, 1994, INTRO ADDICTIVE BEHA
   Tiffany ST, 1998, J PSYCHOPHARMACOL, V12, P23, DOI 10.1177/026988119801200104
   URBAN L, 1978, POWER GOD
   VAILLANT GE, DRUG ADDICTION DRUG
   von Hirsch A., 1996, HARM CULPABILITY, P259
   WALDORF D, 1983, J DRUG ISSUES, V13, P237, DOI 10.1177/002204268301300205
   Waldorf D., 1991, COCAINE CHANGES EXPE
   Watson G, 1999, ADDICTION, P3
   Watson G, 1999, LAW PHILOS, V18, P589
   Wilson James Q., 1993, MORAL SENSE
   WILSON JQ, 1990, COMMENTARY, V89, P21
   WILSON JQ, 1990, DRUGS CRIME, P521
   Yaffe G, 2001, PHILOS PUBLIC AFF, V30, P178, DOI 10.1111/j.1088-4963.2001.00178.x
   Zimmer LE, 1997, MARIJUANA MYTHS MARI
   Zimmerman M, 1988, ESSAY MORAL RESPONSI
   2001, NY TIMES        1214, P1
   2001, NY TIMES        1214, pA26
NR 84
TC 11
Z9 11
U1 1
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1082-6084
EI 1532-2491
J9 SUBST USE MISUSE
JI Subst. Use Misuse
PY 2004
VL 39
IS 3
BP 399
EP 436
DI 10.1081/JA-120029984
PG 38
WC Substance Abuse; Psychiatry; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry; Psychology
GA 809BZ
UT WOS:000220613500003
PM 15088808
DA 2023-06-23
ER

PT J
AU Ghitza, UE
AF Ghitza, Udi E.
TI ASPIRE model for treating cannabis and other substance use disorders: a
   novel personalized-medicine framework
SO FRONTIERS IN PSYCHIATRY
LA English
DT Editorial Material
DE substance use disorder; drug abuse; substance abuse; addiction;
   dependence; addiction treatment; substance abuse treatment; drug abuse
   treatment
ID SHARED DECISION-MAKING; WITHDRAWAL; ABSTINENCE; DEPENDENCE; CARE
C1 [Ghitza, Udi E.] NIDA, Ctr Clin Trials Network, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute on
   Drug Abuse (NIDA)
RP Ghitza, UE (通讯作者)，NIDA, Ctr Clin Trials Network, NIH, Bethesda, MD 20892 USA.
EM ghitzau@nida.nih.gov
CR Allsop DJ, 2011, DRUG ALCOHOL DEPEN, V119, P123, DOI 10.1016/j.drugalcdep.2011.06.003
   [Anonymous], 2014, EV BAS APPR DRUG ADD
   Babson KA, 2013, ADDICT BEHAV, V38, P2707, DOI 10.1016/j.addbeh.2013.06.012
   Balter Rebecca E, 2014, Curr Addict Rep, V1, P137
   Blum K, 2012, CURR PHARM DESIGN, V18, P113, DOI 10.2174/138161212798919110
   Bradley KA, 2014, JAMA-J AM MED ASSOC, V311, P1861, DOI 10.1001/jama.2014.3629
   Brooks AT, 2014, SUBST ABUS-RES TREAT, V8, P55, DOI 10.4137/SART.S18446
   Degenhardt L, 2013, LANCET, V382, P1564, DOI 10.1016/S0140-6736(13)61530-5
   Elwyn G, 2012, J GEN INTERN MED, V27, P1361, DOI 10.1007/s11606-012-2077-6
   Fox H, 2014, ADV PHARMACOL, V69, P217, DOI 10.1016/B978-0-12-420118-7.00006-8
   Ghitza UE, 2014, J HEALTH CARE POOR U, V25, P36, DOI 10.1353/hpu.2014.0067
   Haney M, 2013, NEUROPSYCHOPHARMACOL, V38, P1557, DOI 10.1038/npp.2013.54
   Hughes JR, 2007, NICOTINE TOB RES, V9, P315, DOI 10.1080/14622200701188919
   Jobes ML, 2011, PSYCHOPHARMACOLOGY, V218, P83, DOI 10.1007/s00213-011-2230-7
   Keramati M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061489
   Lee D, 2014, AM J ADDICTION, V23, P234, DOI 10.1111/j.1521-0391.2014.12088.x
   Legare F, 2013, HEALTH AFFAIR, V32, P276, DOI 10.1377/hlthaff.2012.1078
   Mason BJ, 2014, JAMA INTERN MED, V174, P70, DOI 10.1001/jamainternmed.2013.11950
   Mason BJ, 2012, NEUROPSYCHOPHARMACOL, V37, P1689, DOI 10.1038/npp.2012.14
   Matuskey D, 2011, DRUG ALCOHOL DEPEN, V115, P62, DOI 10.1016/j.drugalcdep.2010.10.015
   McClure EA, 2014, CONTEMP CLIN TRIALS, V39, P211, DOI 10.1016/j.cct.2014.08.011
   Oyefeso A, 1997, DRUG ALCOHOL DEPEN, V48, P9, DOI 10.1016/S0376-8716(97)00097-5
   Sinha R, 2007, PSYCHOPHARMACOLOGY, V190, P569, DOI 10.1007/s00213-006-0640-8
   Substance Abuse and Mental Health Services Administration, 2014, RES 2013 NAT SURV DR
   U. S. Food and Drug Administration, 2012, GUID IND ENR STRAT C
   Volkow ND, 2013, CURR OPIN NEUROBIOL, V23, P639, DOI 10.1016/j.conb.2013.01.002
   Wise RA, 2014, NEUROPSYCHOPHARMACOL, V39, P254, DOI 10.1038/npp.2013.261
NR 27
TC 8
Z9 8
U1 5
U2 12
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD DEC 8
PY 2014
VL 5
AR 180
DI 10.3389/fpsyt.2014.00180
PG 4
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA V46XP
UT WOS:000209917200001
PM 25538635
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Kwok, HS
   Freedy, AM
   Siegenfeld, AP
   Morriss, JW
   Waterbury, AL
   Kissler, SM
   Liau, BB
AF Kwok, Hui Si
   Freedy, Allyson M.
   Siegenfeld, Allison P.
   Morriss, Julia W.
   Waterbury, Amanda L.
   Kissler, Stephen M.
   Liau, Brian B.
TI Drug addiction unveils a repressive methylation ceiling in EZH2-mutant
   lymphoma
SO NATURE CHEMICAL BIOLOGY
LA English
DT Article; Early Access
ID EZH2 MUTATIONS; PRC2; CHROMATIN; RESISTANCE; REVEALS; BINDING;
   RECRUITMENT; MECHANISMS; INHIBITOR; DYNAMICS
AB Drug addiction, a phenomenon where cancer cells paradoxically depend on continuous drug treatment for survival, has uncovered cell signaling mechanisms and cancer codependencies. Here we discover mutations that confer drug addiction to inhibitors of the transcriptional repressor polycomb repressive complex 2 (PRC2) in diffuse large B-cell lymphoma. Drug addiction is mediated by hypermorphic mutations in the CXC domain of the catalytic subunit EZH2, which maintain H3K27me3 levels even in the presence of PRC2 inhibitors. Discontinuation of inhibitor treatment leads to overspreading of H3K27me3, surpassing a repressive methylation ceiling compatible with lymphoma cell survival. Exploiting this vulnerability, we show that inhibition of SETD2 similarly induces the spread of H3K27me3 and blocks lymphoma growth. Collectively, our findings demonstrate that constraints on chromatin landscapes can yield biphasic dependencies in epigenetic signaling in cancer cells. More broadly, we highlight how approaches to identify drug addiction mutations can be leveraged to discover cancer vulnerabilities.
C1 [Kwok, Hui Si; Freedy, Allyson M.; Siegenfeld, Allison P.; Morriss, Julia W.; Waterbury, Amanda L.; Liau, Brian B.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.
   [Kwok, Hui Si; Freedy, Allyson M.; Siegenfeld, Allison P.; Morriss, Julia W.; Waterbury, Amanda L.; Liau, Brian B.] Broad Inst & Harvard, Cambridge, MA 02142 USA.
   [Kissler, Stephen M.] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA USA.
C3 Harvard University; Harvard University; Massachusetts Institute of
   Technology (MIT); Broad Institute; Harvard University; Harvard T.H. Chan
   School of Public Health
RP Liau, BB (通讯作者)，Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.; Liau, BB (通讯作者)，Broad Inst & Harvard, Cambridge, MA 02142 USA.
EM liau@chemistry.harvard.edu
OI Siegenfeld, Allison/0000-0001-8599-577X; Waterbury,
   Amanda/0000-0002-4473-2866; Liau, Brian/0000-0002-2985-462X; Morriss,
   Julia/0000-0002-7337-8712
FU National Institute of General Medical Sciences [1DP2GM137494]; American
   Cancer Society Research Scholar Grant [RSG-22-083-01-DMC]; Harvard
   University; National Institute of General Medical Sciences
   [T32GM007753]; Charles A. King Trust Postdoctoral Research Fellowship
   (H.S.K.) from Sara Elizabeth O'Brien Trust/Simeon J. Fortin Charitable
   Foundation; Bank of America Private Bank and co-trustees
FX We thank members of T. Cech Laboratory (University of Colorado Boulder),
   especially A. Gooding and Y. Long, and members of B. Kingston Laboratory
   (Massachusetts General Hospital) especially S. Marr and T. Oei for
   guidance on protein biochemistry experiments; P. Cole (Harvard Medical
   School) for providing the nucleosomal DNA sequence for binding studies;
   K. Ngan for guidance on computational analysis of CRISPR-suppressor
   scans; S. Araten for aiding in protein conservation analysis; M. Quezada
   for aiding in genomics analysis; D. Youmans, D. Narducci and A. Hansen
   for guidance on live-cell imaging experiments; R. Ryan for providing
   cell lines for SETD2 inhibitor studies; and the Bauer Core Facility at
   Harvard University, particularly Z. Nizioleck and J. Nelson for their
   assistance with cell sorting. We thank members of the Liau Laboratory,
   especially P. Gosavi, for helpful discussions and comments on the paper.
   This work was supported by the award 1DP2GM137494 (B.B.L.) from the
   National Institute of General Medical Sciences, American Cancer Society
   Research Scholar Grant RSG-22-083-01-DMC (B.B.L.), startup funds from
   Harvard University (B.B.L), award T32GM007753 (A.M.F.) from the National
   Institute of General Medical Sciences, Charles A. King Trust
   Postdoctoral Research Fellowship (H.S.K.) from Sara Elizabeth O'Brien
   Trust/Simeon J. Fortin Charitable Foundation, Bank of America Private
   Bank and co-trustees.
CR Baker T, 2015, ONCOTARGET, V6, P32646, DOI 10.18632/oncotarget.5066
   Beguelin W, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01029-x
   Beguelin W, 2013, CANCER CELL, V23, P677, DOI 10.1016/j.ccr.2013.04.011
   Ben Chorin A, 2020, PROTEIN SCI, V29, P258, DOI 10.1002/pro.3779
   Bodor C, 2013, BLOOD, V122, P3165, DOI 10.1182/blood-2013-04-496893
   Boettiger AN, 2016, NATURE, V529, P418, DOI 10.1038/nature16496
   Brooun A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11384
   Caganova M, 2013, J CLIN INVEST, V123, P5009, DOI 10.1172/JCI70626
   Calebiro D, 2016, J CLIN INVEST, V126, P3383, DOI 10.1172/JCI84894
   Carvalho S, 2014, ELIFE, V3, DOI 10.7554/eLife.02482
   Carvalho S, 2013, NUCLEIC ACIDS RES, V41, P2881, DOI 10.1093/nar/gks1472
   Chen ZS, 2015, NATURE, V521, P357, DOI 10.1038/nature14231
   Choi J, 2017, NAT STRUCT MOL BIOL, V24, P1039, DOI 10.1038/nsmb.3488
   Clapier CR, 2001, MOL CELL BIOL, V21, P875, DOI 10.1128/MCB.21.3.875-883.2001
   Clement K, 2019, NAT BIOTECHNOL, V37, P224, DOI 10.1038/s41587-019-0032-3
   Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814
   Davidovich C, 2014, NUCLEIC ACIDS RES, V42, P9236, DOI 10.1093/nar/gku540
   Dyer PN, 2004, METHOD ENZYMOL, V375, P23
   Ecker V, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23752-2
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621
   Fellmann C, 2013, CELL REP, V5, P1704, DOI 10.1016/j.celrep.2013.11.020
   Freedy AM, 2021, NAT CHEM BIOL, V17, P1219, DOI 10.1038/s41589-021-00865-9
   Gibaja V, 2016, ONCOGENE, V35, P558, DOI 10.1038/onc.2015.114
   Gosavi PM, 2022, ACS CENTRAL SCI, V8, P417, DOI 10.1021/acscentsci.1c01603
   Hsu PD, 2013, NAT BIOTECHNOL, V31, P827, DOI 10.1038/nbt.2647
   Joung J, 2017, NAT PROTOC, V12, P828, DOI 10.1038/nprot.2017.016
   Kasinath V, 2021, SCIENCE, V371, P362, DOI 10.1126/science.abc3393
   Kasinath V, 2018, SCIENCE, V359, P940, DOI 10.1126/science.aar5700
   Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036
   Kong XJ, 2017, NATURE, V550, P270, DOI 10.1038/nature24037
   Lampe J., 2020, SUBSTITUTED INDOLES
   Lampe JW, 2021, ACS MED CHEM LETT, V12, P1539, DOI 10.1021/acsmedchemlett.1c00272
   Laugesen A, 2019, MOL CELL, V74, P8, DOI 10.1016/j.molcel.2019.03.011
   Lee CH, 2018, MOL CELL, V70, P435, DOI 10.1016/j.molcel.2018.03.019
   Leung W, 2022, CANCER DISCOV, V12, P1782, DOI 10.1158/2159-8290.CD-21-1514
   Luger K, 1999, METHOD ENZYMOL, V304, P3
   Margueron R, 2008, MOL CELL, V32, P503, DOI 10.1016/j.molcel.2008.11.004
   McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606
   Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890
   Murray J. D., 2002, MATH BIOL, DOI DOI 10.1086/421587
   Nemazee D, 2017, NAT REV IMMUNOL, V17, P281, DOI 10.1038/nri.2017.19
   Ngan Kevin C, 2022, Curr Protoc, V2, pe614, DOI 10.1002/cpz1.614
   Orlando DA, 2014, CELL REP, V9, P1163, DOI 10.1016/j.celrep.2014.10.018
   Pfister SX, 2014, CELL REP, V7, P2006, DOI 10.1016/j.celrep.2014.05.026
   Poepsel S, 2018, NAT STRUCT MOL BIOL, V25, P154, DOI 10.1038/s41594-018-0023-y
   Qi W, 2017, NAT CHEM BIOL, V13, P381, DOI 10.1038/nchembio.2304
   Rajan SS, 2020, ONCOGENE, V39, P2103, DOI 10.1038/s41388-019-1136-4
   Reddy A, 2017, CELL, V171, P481, DOI 10.1016/j.cell.2017.09.027
   Reimann M, 2010, CANCER CELL, V17, P262, DOI 10.1016/j.ccr.2009.12.043
   Schmitges FW, 2011, MOL CELL, V42, P330, DOI 10.1016/j.molcel.2011.03.025
   Schmitz R, 2018, NEW ENGL J MED, V378, P1396, DOI 10.1056/NEJMoa1801445
   Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9
   Son J, 2013, GENE DEV, V27, P2663, DOI 10.1101/gad.225888.113
   Velichutina I, 2010, BLOOD, V116, P5247, DOI 10.1182/blood-2010-04-280149
   Verma SK, 2012, ACS MED CHEM LETT, V3, P1091, DOI 10.1021/ml3003346
   Vinyard ME, 2019, NAT CHEM BIOL, V15, P529, DOI 10.1038/s41589-019-0263-0
   Wu Di, 2021, STAR Protoc, V2, P100681, DOI 10.1016/j.xpro.2021.100681
   Youmans DT, 2021, MOL CELL, V81, P488, DOI 10.1016/j.molcel.2020.11.044
   Yuan W, 2011, J BIOL CHEM, V286, P7983, DOI 10.1074/jbc.M110.194027
NR 60
TC 0
Z9 0
U1 3
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1552-4450
EI 1552-4469
J9 NAT CHEM BIOL
JI Nat. Chem. Biol.
PD 2023 MAR 27
PY 2023
DI 10.1038/s41589-023-01299-1
EA MAR 2023
PG 31
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA C2TL8
UT WOS:000960502500003
PM 36973442
OA Green Submitted
DA 2023-06-23
ER

PT J
AU Fraser, S
AF Fraser, Suzanne
TI Junk: Overeating and obesity and the neuroscience of addiction
SO ADDICTION RESEARCH & THEORY
LA English
DT Article
DE Obesity; addiction; science and technology studies; feminist research
ID PUBLIC-HEALTH CRISIS; FOOD ADDICTION; DRUG-ADDICTION; FEMINIST; DISEASE;
   MORALITY; SCIENCE; BODIES; POLICY
AB Over the past decade intense concern has developed in the West about what has been characterised as an obesity epidemic. This concern is producing a range of effects, including changing attitudes towards food. Some foods are no longer just foods; they are increasingly framed as illicit substances. At the same time, overeating is coming to be seen as a form of addictive behaviour. How do new concerns about junk food, health and overeating impact on notions of drug use and addiction? In this article, I explore food and obesity as a case study of changing ideas about addiction. Drawing on an analysis of scientific journal articles that link obesity and addiction, the article examines the assumptions that drive such linkages, and their implications and effects. Wherever obesity is linked to addiction, this link is increasingly explained via neuroscientific theories of behaviour. The brain's hedonic and reward systems are cited to frame 'excessive' eating as addictive behaviour, and 'highly palatable' or junk foods as akin to conventional drugs. In the process, a range of phenomena are enacted. In science studies theorist John Law's [(2011). Collateral realities. In P. Baert & F. Rubio (Eds.), The politics of knowledge (pp. 156-178). London and New York: Routledge] terms, numerous important 'collateral realities' are produced. 'Drug addiction' is referred to as though no controversy exists over its interpretation. Likewise, 'drugs' are produced as a homogeneous group with no differentiating features. The article concludes by considering the limitations of such accounts of food, the body, health and well-being, and their reciprocal effects on the field of drug addiction.
C1 [Fraser, Suzanne] Monash Univ, Ctr Womens Studies & Gender Res, Clayton, Vic 3800, Australia.
   [Fraser, Suzanne] Curtin Univ, Natl Drug Res Inst, Shenton Pk 6008, Australia.
C3 Monash University; Curtin University
RP Fraser, S (通讯作者)，Monash Univ, Ctr Womens Studies & Gender Res, Wellington Rd, Clayton, Vic 3800, Australia.
EM suzanne.fraser@monash.edu
OI Fraser, Suzanne/0000-0003-1018-5865
CR Bordo Susan, 2004, UNBEARABLE WEIGHT FE
   Campbell ND, 2010, BIOSOCIETIES, V5, P89, DOI 10.1057/biosoc.2009.2
   Campos P, 2006, INT J EPIDEMIOL, V35, P55, DOI 10.1093/ije/dyi254
   Courtwright DT, 2010, BIOSOCIETIES, V5, P137, DOI 10.1057/biosoc.2009.3
   Davis C, 2011, INT J OBESITY, V35, P1347, DOI 10.1038/ijo.2010.276
   Davis C, 2009, INT J OBESITY, V33, pS49, DOI 10.1038/ijo.2009.72
   Davis C, 2009, APPETITE, V53, P1, DOI 10.1016/j.appet.2009.05.018
   Derrida J., 1993, DIFFERENCES, V5, P1, DOI DOI 10.1215/10407391-5-1-1
   Evans B, 2006, AREA, V38, P259, DOI 10.1111/j.1475-4762.2006.00692.x
   Fraser S., HABITS REMA IN PRESS
   Fraser S, 2010, SOC THEOR HEALTH, V8, P192, DOI 10.1057/sth.2009.28
   Gard M, 2001, STUD PHILOS EDUC, V20, P535, DOI DOI 10.1023/A:1012238617836
   Gearhardt AN, 2011, ADDICTION, V106, P1208, DOI 10.1111/j.1360-0443.2010.03301.x
   Hyman SE, 2005, AM J PSYCHIAT, V162, P1414, DOI 10.1176/appi.ajp.162.8.1414
   Ifland JR, 2009, MED HYPOTHESES, V72, P518, DOI 10.1016/j.mehy.2008.11.035
   Keane H., 2002, WHATS WRONG ADDICTIO
   Kirkland A, 2011, SIGNS, V36, P463, DOI 10.1086/655916
   Law John, 2011, POLITICS KNOWLEDGE, P156
   LeBesco Kathleen, 2001, BODIES OUT BOUNDS FA, P1
   Lintzeris N, 2004, DRUG USE AUSTR PREVE, P221
   Liu YJ, 2010, J PSYCHOACTIVE DRUGS, V42, P133, DOI 10.1080/02791072.2010.10400686
   Lobstein T, 2006, INT J EPIDEMIOL, V35, P74, DOI 10.1093/ije/dyi257
   MARKS I, 1990, BRIT J ADDICT, V85, P1389
   MONAGHAN LF, 2005, SOC THEORY HLTH, V3, P302, DOI DOI 10.1057/PALGRAVE.STH.8700058
   Murray S., 2005, WOMEN STUD, V34, P213
   Orford J, 2001, ADDICTION, V96, P15, DOI 10.1046/j.1360-0443.2001.961152.x
   Pelchat ML, 2009, J NUTR, V139, P620, DOI 10.3945/jn.108.097816
   Probyn E, 2008, FEM PSYCHOL, V18, P401, DOI 10.1177/0959353508092095
   Rich E., 2005, SOCIAL THEORY HLTH, V3, P341, DOI DOI 10.1057/PALGRAVE.STH.8700057
   Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI 10.1146/annurev.psych.54.101601.145237
   Rogers PJ, 2000, PHARMACOL BIOCHEM BE, V66, P3, DOI 10.1016/S0091-3057(00)00197-0
   Saguy AC, 2005, J HEALTH POLIT POLIC, V30, P869, DOI 10.1215/03616878-30-5-869
   SEDGWICK EK, 1993, TENDENCIES, P130
   Stephenson RH, 2007, LEA COMMUN SER, P277
   Volkow ND, 2004, NAT REV NEUROSCI, V5, P963, DOI 10.1038/nrn1539
   Volkow ND, 2005, NAT NEUROSCI, V8, P555, DOI 10.1038/nn1452
   Vrecko S, 2010, HIST HUM SCI, V23, P52, DOI 10.1177/0952695110371598
   Weaver M., 2010, CLIN ADDICTION PSYCH, P23
   Yancey AK, 2006, SIGNS, V31, P425, DOI 10.1086/491682
NR 39
TC 17
Z9 17
U1 0
U2 29
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1606-6359
EI 1476-7392
J9 ADDICT RES THEORY
JI Addict. Res. Theory
PY 2013
VL 21
IS 6
BP 496
EP 506
DI 10.3109/16066359.2012.749868
PG 11
WC Substance Abuse; Social Issues
WE Social Science Citation Index (SSCI)
SC Substance Abuse; Social Issues
GA 239RR
UT WOS:000326043600008
OA Green Submitted
DA 2023-06-23
ER

PT J
AU Chen, G
   Gueta, K
AF Chen, Gila
   Gueta, Keren
TI Childhood Abuse and Drug Addiction Among Israeli Male Inmates
SO PRISON JOURNAL
LA English
DT Article
DE incarcerated men; childhood abuse; drug addiction; crime
ID SEXUAL-ABUSE; RELATIONSHIP QUALITY; INCARCERATED MALES; ATTACHMENT
   THEORY; EARLY DEPRIVATION; PARTNER VIOLENCE; SUBSTANCE-ABUSE; TRAUMA
   EXPOSURE; NEGLECT; VICTIMIZATION
AB The purpose of the study was to investigate types of childhood abuse in a sample of 60 inmates and to explore the relationships between childhood abuse, criminality, and drug addiction. Overall, the sample inmates came from risky families with a high prevalence of crime, drug addiction, and mental health problems. The results showed that a history of child abuse was common, and emotional neglect was more prevalent than physical, emotional, or sexual abuse. The odds for childhood abuse were higher among inmates whose fathers had been addicted to drugs and involved in crime, and whose siblings suffered from mental health problems.
C1 [Chen, Gila] Ashkelon Acad Coll, Dept Criminol, 12 Ben Tzvi St, IL-78109 Ashqelon, Israel.
   [Gueta, Keren] Bar Ilan Univ, Dept Criminol, Ramat Gan, Israel.
C3 Bar Ilan University
RP Chen, G (通讯作者)，Ashkelon Acad Coll, Dept Criminol, 12 Ben Tzvi St, IL-78109 Ashqelon, Israel.
EM chengila6@gmail.com
RI Chen, Gila/I-7934-2019
OI Chen, Gila/0000-0003-4283-3361
CR Aguilar B, 2001, J ABNORM CHILD PSYCH, V29, P479, DOI 10.1023/A:1012273024211
   Alexander, 1987, BIOL MORAL SYSTEMS
   ALEXANDER PC, 1992, J CONSULT CLIN PSYCH, V60, P185, DOI 10.1037/0022-006X.60.2.185
   ALTERMAN AI, 1985, J STUD ALCOHOL, V46, P256, DOI 10.15288/jsa.1985.46.256
   Anderson KL, 2002, J MARRIAGE FAM, V64, P851, DOI 10.1111/j.1741-3737.2002.00851.x
   Bandura A., 1997, SOCIAL LEARNING THEO
   BERNSTEIN DP, 1994, AM J PSYCHIAT, V151, P1132, DOI 10.1176/ajp.151.8.1132
   Bowlby J., 1973, ATTACHMENT LOSS
   Bradley RH, 2001, CHILD DEV, V72, P1844, DOI 10.1111/1467-8624.t01-1-00382
   BRETHERTON I, 1985, MONOGR SOC RES CHILD, V50, P3, DOI 10.2307/3333824
   Buist KL, 2013, CLIN PSYCHOL REV, V33, P97, DOI 10.1016/j.cpr.2012.10.007
   Burton DL, 2002, CHILD ABUSE NEGLECT, V26, P893, DOI 10.1016/S0145-2134(02)00360-5
   Carlson BE, 2010, PRISON J, V90, P494, DOI 10.1177/0032885510382226
   Chapple Constance L, 2005, Violence Vict, V20, P39
   Chen GL, 2006, INT J OFFENDER THER, V50, P306, DOI 10.1177/0306624X05279038
   Chesney-Lind M., 2004, FEMALE OFFENDERS GIR
   Chesney-Lind M., 2004, GIRLS DELINQUENCY JU
   Chugani HT, 2001, NEUROIMAGE, V14, P1290, DOI 10.1006/nimg.2001.0917
   Colvert E, 2008, DEV PSYCHOPATHOL, V20, P547, DOI 10.1017/S0954579408000278
   CONTE JR, 1987, CHILD ABUSE NEGLECT, V11, P201, DOI 10.1016/0145-2134(87)90059-7
   CONTE JR, 1988, LASTING EFFECTS CHIL, P157
   Coviello DM, 2004, J SUBST ABUSE TREAT, V26, P303, DOI 10.1016/S0740-5472(03)00143-0
   Creigton S, 2004, PREVALENCE INCIDENCE
   CRITTENDEN PM, 1992, DEV PSYCHOPATHOL, V4, P209, DOI 10.1017/S0954579400000110
   DILALLA LF, 1991, PSYCHOL BULL, V109, P125, DOI 10.1037/0033-2909.109.1.125
   Dube SR, 2003, PEDIATRICS, V111, P564, DOI 10.1542/peds.111.3.564
   DUBOWITZ H, 1994, J INTERPERS VIOLENCE, V9, P556, DOI 10.1177/088626094009004010
   DUTTON DG, 1992, INT J OFFENDER THER, V36, P129, DOI 10.1177/0306624X9203600205
   Ehrensaft MK, 2003, J CONSULT CLIN PSYCH, V71, P741, DOI 10.1037/0022-006X.71.4.741
   Emery RE, 1998, AM PSYCHOL, V53, P121, DOI 10.1037/0003-066X.53.2.121
   Euser EM, 2010, CHILD MALTREATMENT, V15, P5, DOI 10.1177/1077559509345904
   Falshaw L, 1996, AGGRESS VIOLENT BEH, V1, P389, DOI 10.1016/S1359-1789(96)00005-5
   Feinberg ME, 2013, J ADOLESCENT HEALTH, V53, P166, DOI 10.1016/j.jadohealth.2012.10.004
   Felson RB, 2009, AGGRESSIVE BEHAV, V35, P489, DOI 10.1002/ab.20322
   FINKELHOR D, 1990, CHILD ABUSE NEGLECT, V14, P19, DOI 10.1016/0145-2134(90)90077-7
   Finzi R, 2001, J YOUTH ADOLESCENCE, V30, P769, DOI 10.1023/A:1012237813771
   Fondacaro KM, 1999, CHILD ABUSE NEGLECT, V23, P361, DOI 10.1016/S0145-2134(99)00004-6
   Garland R., 1994, PEDOPHILIA BIOSOCIAL, P488
   Glaser D, 2002, CHILD ABUSE NEGLECT, V26, P697, DOI 10.1016/S0145-2134(02)00342-3
   Green BL, 2005, CRIME DELINQUENCY, V51, P133, DOI 10.1177/0011128704267477
   Grella CE, 2005, PSYCHOL ADDICT BEHAV, V19, P43, DOI 10.1037/0893-164X.19.1.43
   Haapasalo J, 1999, AGGRESS VIOLENT BEH, V4, P107, DOI 10.1016/S1359-1789(97)00027-X
   Haapasalo J, 2004, CRIM JUSTICE BEHAV, V31, P127, DOI 10.1177/0093854803261328
   HELZER JE, 1981, ARCH GEN PSYCHIAT, V38, P393
   Hildyard KL, 2002, CHILD ABUSE NEGLECT, V26, P679, DOI 10.1016/S0145-2134(02)00341-1
   Hyman SM, 2006, AM J DRUG ALCOHOL AB, V32, P655, DOI 10.1080/10623320600919193
   Inciardi J. A., 1996, DRUG CONTROL COURT
   Irish Prison Service (IPS), 2013, ANN REPORT
   Israel Prison Service (IPS), 2013, DRUGS ALC US ISR PRI
   James D. J., 2006, 213600 NCJ US DEP JU
   Jennings WG, 2012, AGGRESS VIOLENT BEH, V17, P16, DOI 10.1016/j.avb.2011.09.003
   Jewkes RK, 2010, CHILD ABUSE NEGLECT, V34, P833, DOI 10.1016/j.chiabu.2010.05.002
   Johnson JG, 2000, J PERS DISORD, V14, P171, DOI 10.1521/pedi.2000.14.2.171
   Johnson Renee M, 2002, Child Maltreat, V7, P179, DOI 10.1177/1077559502007003001
   Johnson RJ, 2006, CHILD ABUSE NEGLECT, V30, P75, DOI 10.1016/j.chiabu.2005.08.013
   Johnson RJ, 2005, SUBST USE MISUSE, V40, P211, DOI 10.1081/JA-200048457
   KENDALLTACKETT KA, 1993, PSYCHOL BULL, V113, P164, DOI 10.1037/0033-2909.113.1.164
   Kennedy DE, 2008, FAM RELAT, V57, P567, DOI 10.1111/j.1741-3729.2008.00523.x
   Komarovskaya IA, 2011, J FORENSIC PSYCHI PS, V22, P395, DOI 10.1080/14789949.2011.572989
   Lee V, 2007, CHILD MALTREATMENT, V12, P281, DOI 10.1177/1077559507303778
   Lipschitz DS, 1999, J NERV MENT DIS, V187, P32, DOI 10.1097/00005053-199901000-00006
   Madu SN, 2003, J ADOLESCENCE, V26, P121, DOI 10.1016/S0140-1971(02)00120-3
   McGrath SA, 2011, AGGRESS VIOLENT BEH, V16, P485, DOI 10.1016/j.avb.2011.03.008
   MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199, DOI 10.1016/0740-5472(92)90062-S
   Mehrabian A, 2001, J PSYCHOL, V135, P71, DOI 10.1080/00223980109603681
   Messina N, 2007, CRIM JUSTICE BEHAV, V34, P1385, DOI 10.1177/0093854807305150
   Messina N, 2006, AM J PUBLIC HEALTH, V96, P1842, DOI 10.2105/AJPH.2005.082016
   Mikaeili N, 2013, J INTERPERS VIOLENCE, V28, P975, DOI 10.1177/0886260512459377
   Moloney KP, 2009, PUBLIC HEALTH, V123, P426, DOI 10.1016/j.puhe.2009.04.002
   Neller DJ, 2006, J INTERPERS VIOLENCE, V21, P1234, DOI 10.1177/0886260506290663
   Noller P, 2005, PERS RELATIONSHIP, V12, P1, DOI 10.1111/j.1350-4126.2005.00099.x
   Norman RE, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001349
   Pike A, 1996, DEV PSYCHOL, V32, P590, DOI 10.1037/0012-1649.32.4.590
   Rosler M, 2004, EUR ARCH PSY CLIN N, V254, P365, DOI 10.1007/S00406-004-0516-Z
   Sanders R., 2004, SIBLING RELATIONSHIP
   SMALL SA, 1994, J MARRIAGE FAM, V56, P181, DOI 10.2307/352712
   Snyder SM, 2014, CHILD YOUTH SERV REV, V46, P64, DOI 10.1016/j.childyouth.2014.08.007
   van der Vegt EJM, 2009, J ABNORM CHILD PSYCH, V37, P239, DOI 10.1007/s10802-008-9272-2
   Widom C. S., 1997, CRIM BEHAV MENT HEAL, V7, P287, DOI [10.1002/cbm.191, DOI 10.1002/CBM.191]
   WIDOM CS, 1989, CRIMINOLOGY, V27, P251, DOI 10.1111/j.1745-9125.1989.tb01032.x
   Widom CS, 1996, SOCIETY, V33, P47, DOI 10.1007/BF02700307
   Wise LA, 2001, LANCET, V358, P881, DOI 10.1016/S0140-6736(01)06072-X
   Wolff N, 2012, INT J ENV RES PUB HE, V9, P1908, DOI 10.3390/ijerph9051908
   Wolff N, 2009, VIOLENCE VICTIMS, V24, P469, DOI 10.1891/0886-6708.24.4.469
   Young R, 2011, J CHILD PSYCHOL PSYC, V52, P889, DOI 10.1111/j.1469-7610.2011.02390.x
NR 85
TC 4
Z9 4
U1 0
U2 35
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0032-8855
EI 1552-7522
J9 PRISON J
JI Prison J.
PD NOV
PY 2016
VL 96
IS 5
BP 709
EP 730
DI 10.1177/0032885516662637
PG 22
WC Criminology & Penology
WE Social Science Citation Index (SSCI)
SC Criminology & Penology
GA DY1DW
UT WOS:000384836100005
DA 2023-06-23
ER

PT J
AU Weber, R
   Logan, C
   Peris, J
   Knackstedt, L
   Reichel, C
AF Weber, Rachel
   Logan, Carly
   Peris, Joanna
   Knackstedt, Lori
   Reichel, Carmela
TI Oxytocin Increases Glutamate in the Nucleus Accumbens Core and Decreases
   Drug Seeking
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-College-of-Neuropsychopharmacology
   (ACNP) and Cognitive-Neuroscience-Society
CY DEC 03-07, 2017
CL Palm Springs, CA
SP Amer Coll Neuropsychopharmacol, Cognit Neuroscience Soc
DE Cue Reinstatement; Oxytocin and Addiction; Addiction Circuitry
C1 [Weber, Rachel; Logan, Carly; Peris, Joanna; Knackstedt, Lori; Reichel, Carmela] Med Univ South Carolina, Charleston, SC USA.
C3 Medical University of South Carolina
RI REichel, Carmela M/E-8067-2016
OI REichel, Carmela M/0000-0003-3508-8754
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
EI 1740-634X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD NOV
PY 2017
VL 42
SU 1
MA W278
BP S650
EP S651
PG 2
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA FO4VU
UT WOS:000416846303274
DA 2023-06-23
ER

PT J
AU Volkow, ND
   Wang, GJ
   Fowler, JS
   Telang, F
AF Volkow, Nora D.
   Wang, Gene-Jack
   Fowler, Joanna S.
   Telang, Frank
TI Overlapping neuronal circuits in addiction and obesity: evidence of
   systems pathology
SO PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
LA English
DT Article; Proceedings Paper
CT Royal-Society-Discussion Meeting on Neurobiology of Drug Addiction
CY FEB 25-26, 2008
CL London, ENGLAND
SP Royal Soc Discuss
DE dopamine; positron emission tomography; imaging; self-control;
   compulsion
ID DOPAMINE-D-2 RECEPTORS; DRUG-ADDICTION; DORSAL STRIATUM; BRAIN DOPAMINE;
   FOOD STIMULI; COCAINE; ACTIVATION; METABOLISM; METHYLPHENIDATE;
   AMPHETAMINE
AB Drugs and food exert their reinforcing effects in part by increasing dopamine (DA) in limbic regions, which has generated interest in understanding how drug abuse/addiction relates to obesity. Here, we integrate findings from positron emission tomography imaging studies on DA's role in drug abuse/addiction and in obesity and propose a common model for these two conditions. Both in abuse/addiction and in obesity, there is an enhanced value of one type of reinforcer (drugs and food, respectively) at the expense of other reinforcers, which is a consequence of conditioned learning and resetting of reward thresholds secondary to repeated stimulation by drugs (abuse/addiction) and by large quantities of palatable food (obesity) in vulnerable individuals (i.e. genetic factors). In this model, during exposure to the reinforcer or to conditioned cues, the expected reward (processed by memory circuits) overactivates the reward and motivation circuits while inhibiting the cognitive control circuit, resulting in an inability to inhibit the drive to consume the drug or food despite attempts to do so. These neuronal circuits, which are modulated by DA, interact with one another so that disruption in one circuit can be buffered by another, which highlights the need of multiprong approaches in the treatment of addiction and obesity.
C1 [Volkow, Nora D.] NIDA, Bethesda, MD 20892 USA.
   [Volkow, Nora D.; Telang, Frank] NIAAA, Bethesda, MD 20892 USA.
   [Wang, Gene-Jack; Fowler, Joanna S.] Brookhaven Natl Lab, Dept Med, Upton, NY 11973 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute on
   Drug Abuse (NIDA); National Institutes of Health (NIH) - USA; NIH
   National Institute on Alcohol Abuse & Alcoholism (NIAAA); United States
   Department of Energy (DOE); Brookhaven National Laboratory
RP Volkow, ND (通讯作者)，NIDA, Bethesda, MD 20892 USA.
EM nvolkow@nida.nih.gov
FU Intramural NIH HHS [Z99 DA999999] Funding Source: Medline
CR Allison DB, 1999, AM J PSYCHIAT, V156, P1686
   Avena NM, 2008, NEUROSCI BIOBEHAV R, V32, P20, DOI 10.1016/j.neubiorev.2007.04.019
   Berthoud HR, 2007, PHYSIOL BEHAV, V91, P486, DOI 10.1016/j.physbeh.2006.12.016
   Garavan H, 2000, AM J PSYCHIAT, V157, P1789, DOI 10.1176/appi.ajp.157.11.1789
   Gautier JF, 2000, DIABETES, V49, P838, DOI 10.2337/diabetes.49.5.838
   Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040
   Haltia LT, 2007, SYNAPSE, V61, P748, DOI 10.1002/syn.20418
   Heinz A, 2004, AM J PSYCHIAT, V161, P1783, DOI 10.1176/appi.ajp.161.10.1783
   INSEL TR, 1992, ARCH GEN PSYCHIAT, V49, P739
   Kalivas PW, 2005, NEURON, V45, P647, DOI 10.1016/j.neuron.2005.02.005
   KIYATKIN EA, 1994, BRAIN RES, V652, P225, DOI 10.1016/0006-8993(94)90231-3
   Levine AS, 2003, AM J CLIN NUTR, V78, p834S, DOI 10.1093/ajcn/78.4.834S
   MARK GP, 1994, PHARMACOL BIOCHEM BE, V48, P651, DOI 10.1016/0091-3057(94)90327-1
   Martel P, 1996, PHARMACOL BIOCHEM BE, V53, P221, DOI 10.1016/0091-3057(95)00187-5
   Martin-Solch C, 2001, EXP BRAIN RES, V139, P278, DOI 10.1007/s002210100751
   Martinez D, 2005, BIOL PSYCHIAT, V58, P779, DOI 10.1016/j.biopsych.2005.04.044
   Martinez D, 2007, AM J PSYCHIAT, V164, P622, DOI 10.1176/appi.ajp.164.4.622
   Miller JL, 2007, J NEUROL NEUROSUR PS, V78, P615, DOI 10.1136/jnnp.2006.099044
   MINTUN MA, 2003, AM COLL NEUR 42 ANN
   Phan KL, 2002, NEUROIMAGE, V16, P331, DOI 10.1006/nimg.2002.1087
   PIAZZA PV, 1991, P NATL ACAD SCI USA, V88, P2088, DOI 10.1073/pnas.88.6.2088
   Roitman MF, 2004, J NEUROSCI, V24, P1265, DOI 10.1523/JNEUROSCI.3823-03.2004
   Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284
   Rolls ET, 2004, BRAIN COGNITION, V55, P11, DOI 10.1016/s0278-2626(03)00277-x
   Schultz W, 2002, NEURON, V36, P241, DOI 10.1016/S0896-6273(02)00967-4
   Thanos PK, 2001, J NEUROCHEM, V78, P1094, DOI 10.1046/j.1471-4159.2001.00492.x
   Vanderschuren LJMJ, 2005, EUR J PHARMACOL, V526, P77, DOI 10.1016/j.ejphar.2005.09.037
   Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI 10.1093/cercor/10.3.318
   Volkow ND, 1999, AM J PSYCHIAT, V156, P1440
   Volkow ND, 2005, J NEUROSCI, V25, P3932, DOI 10.1523/JNEUROSCI.0433-05.2005
   Volkow ND, 2004, NAT REV NEUROSCI, V5, P963, DOI 10.1038/nrn1539
   Volkow ND, 2004, MOL PSYCHIATR, V9, P557, DOI 10.1038/sj.mp.4001507
   Volkow ND, 2003, J CLIN INVEST, V111, P1444, DOI 10.1172/JCI200318533
   Volkow ND, 2003, INT J EAT DISORDER, V33, P136, DOI 10.1002/eat.10118
   Volkow ND, 2005, NAT NEUROSCI, V8, P555, DOI 10.1038/nn1452
   Volkow ND, 2002, SYNAPSE, V44, P175, DOI 10.1002/syn.10075
   Volkow ND, 2002, SYNAPSE, V46, P79, DOI 10.1002/syn.10137
   Volkow ND, 1997, NATURE, V386, P830, DOI 10.1038/386830a0
   VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210
   VOLKOW ND, 1991, AM J PSYCHIAT, V148, P621
   Volkow ND, 1999, AM J PSYCHIAT, V156, P19, DOI 10.1176/ajp.156.1.19
   Volkow ND, 2001, AM J PSYCHIAT, V158, P2015, DOI 10.1176/appi.ajp.158.12.2015
   Volkow ND, 2008, NEUROIMAGE, V42, P1537, DOI 10.1016/j.neuroimage.2008.06.002
   Volkow ND, 2007, ARCH NEUROL-CHICAGO, V64, P1575, DOI 10.1001/archneur.64.11.1575
   Volkow ND, 2007, J NEUROSCI, V27, P12700, DOI 10.1523/JNEUROSCI.3371-07.2007
   Volkow ND, 2007, AM J PSYCHIAT, V164, P708, DOI 10.1176/appi.ajp.164.5.708
   Volkow ND, 2006, ARCH GEN PSYCHIAT, V63, P999, DOI 10.1001/archpsyc.63.9.999
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
   Wang GJ, 1999, LIFE SCI, V64, P775, DOI 10.1016/S0024-3205(98)00619-5
   Wang GJ, 2004, NEUROIMAGE, V21, P1790, DOI 10.1016/j.neuroimage.2003.11.026
   Wang GJ, 2001, LANCET, V357, P354, DOI 10.1016/S0140-6736(00)03643-6
   Wardle J, 2007, OBES REV, V8, P73, DOI 10.1111/j.1467-789X.2007.00322.x
   Wong DF, 2006, NEUROPSYCHOPHARMACOL, V31, P2716, DOI 10.1038/sj.npp.1301194
NR 55
TC 539
Z9 550
U1 0
U2 89
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 0962-8436
EI 1471-2970
J9 PHILOS T R SOC B
JI Philos. Trans. R. Soc. B-Biol. Sci.
PD OCT 12
PY 2008
VL 363
IS 1507
BP 3191
EP 3200
DI 10.1098/rstb.2008.0107
PG 10
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Life Sciences & Biomedicine - Other Topics
GA 345AW
UT WOS:000258969400009
PM 18640912
OA Green Published
DA 2023-06-23
ER

PT J
AU Heather, N
AF Heather, N
TI A conceptual framework for explaining drug addiction
SO JOURNAL OF PSYCHOPHARMACOLOGY
LA English
DT Article
DE compulsive drug use; definition; drug addiction; reductionism; theory
ID ALCOHOL
AB The aim of this paper is to describe a conceptual framework of questions which an adequate theory of drug addiction must attempt to answer. First, a satisfactory definition of addiction is sought and it is concluded that it is best defined by repeated failures to refrain from drug use despite prior resolutions to do so. This definition is consistent with views of addiction that see decision-making, ambivalence and conflict as central features of the addict's behaviour and experience. On this basis, a three-level framework of required explanation is set out, consisting of (1) the level of neuroadaptation, (2) the level of desire for drugs and (3) the level of 'akrasia' or failures of resolve. The crucial argument is made that explanatory concepts used at the 'lower' levels in this framework can never be held to be sufficient as explanations at higher levels, i.e. the postulation of additional determinants is always required at Levels 2 and 3. In particular, it is a failure to address problems at the highest level in the framework that marks the inadequacy of most existing theories of addiction. The paper concludes by considering the relevance of the ideas presented to the concept of 'compulsive drug use' and concludes that this concept is no longer useful in the explanation of addiction.
C1 Ctr Alcohol & Drug Studies, Newcastle Upon Tyne NE1 6UR, Tyne & Wear, England.
C3 N8 Research Partnership; Newcastle University - UK
RP Heather, N (通讯作者)，Ctr Alcohol & Drug Studies, Plummer Court,Cariol Pl, Newcastle Upon Tyne NE1 6UR, Tyne & Wear, England.
CR AINSLIE G, 1975, PSYCHOL BULL, V82, P463, DOI 10.1037/h0076860
   Ainslie G., 1992, PICOECONOMICS STRATE
   Allen JP, 1997, J STUD ALCOHOL, V58, P7
   [Anonymous], 1969, WHO TECHN REP SER, V407
   BEGLEITER H, 1995, GENETICS ALCOHOLISM
   DAVIDSON D, 1969, MORAL CONCEPTS
   Davies J. B, 1997, MYTH ADDICTION
   EDDY NB, 1965, B WORLD HEALTH ORGAN, V32, P721
   EDWARDS G, 1982, BRIT J ADDICT, V77, P3
   HEATHER N, 1994, ADDICT RES, V2, P135, DOI 10.3109/16066359409109138
   JELLINEK EM, 1960, DIS CONCEPT ALCOHOLI
   KOZLOWSKI LT, 1987, BRIT J ADDICT, V82, P31
   Lindesmith AR., 1968, ADDICTION OPIATES
   Miller W., 1991, MOTIVATIONAL INTERVI, V1, DOI DOI 10.1002/CASP.2450020410
   Orford J., 1985, EXCESSIVE APPETITES
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Russell M. A. H., 1976, DRUGS DRUG DEPENDENC
   TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147
   *WHO, 1979, WHO OFFS PUBL, V32
   Zinberg NE., 1984, DRUG SET SETTING BAS
   ZINBERG NE, 1974, ADDICTION
NR 21
TC 67
Z9 69
U1 4
U2 18
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0269-8811
EI 1461-7285
J9 J PSYCHOPHARMACOL
JI J. Psychopharmacol.
PD MAR
PY 1998
VL 12
IS 1
BP 3
EP 7
DI 10.1177/026988119801200101
PG 5
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA ZH321
UT WOS:000073096300001
PM 9584962
DA 2023-06-23
ER

PT J
AU Nestler, EJ
AF Nestler, EJ
TI New treatments for drug addiction: Intracellular targets for drug
   discovery
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-College-of-Neuropsychopharmacology
CY DEC 12-16, 2004
CL San Juan, PR
SP Vanderbilt Univ, Sch Med, Dept Psychiaty, Amer Coll Neuropsychopharmacol
C1 UT Southwestern, Dallas, TX USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center Dallas
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD DEC
PY 2004
VL 29
SU 1
BP S60
EP S61
PG 2
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 877RO
UT WOS:000225588000180
DA 2023-06-23
ER

PT J
AU Karrari, P
   Mehrpour, O
   Afshari, R
   Keyler, D
AF Karrari, Parissa
   Mehrpour, Omid
   Afshari, Reza
   Keyler, Daniel
TI Pattern of illicit drug use in patients referred to addiction treatment
   centres in Birjand, Eastern Iran
SO JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION
LA English
DT Article
DE Iran; Birjand; Substance abuse; Epidemiological research; Drugs
ID HIGH-SCHOOL-STUDENTS; WOMEN
AB Objective: To evaluate the pattern of use of opioid and other illegal drugs in patients seeking addiction treatment in Birjand, eastern Iran.
   Methods: The prospective study was conducted from March 21, 2009 to March 21, 2010, and comprised all patients referred to the seven addiction treatment centres in Birjand. Data was obtained through pre-designed questionnaires and it was analysed using SPSS 16.
   Results: Of the 700 substance users referred to the 7 centres and who volunteered to participate, 632 (90.3%) were males and 68(9.7%) were females. The male/female ratio was similar to 9.3/1. Mean age was 34 +/- 10.2 (range: 10-75) years. The type of drugs used included traditional drugs (n=342; 48.9%) and newer modern drugs (n=314; 44.9 %). The mean age of the first experience with drugs was 21.91 +/- 7.1 (range=0-60) years. There was significant different between the type of drugs used and the place of residence (p<0.019), age (p<0.0001), martial status (p<0.0001), occupation (p<0.006) and education (p<0.017).
   Conclusion: The prevalence of illicit drug addiction was quite high. There seemed to have been a change in the pattern of drug use and in the type of illegal drugs used in the study area, from traditional drugs to new and modern drugs. As such, identifying risk factors related to addiction and the prevention of addiction should be one of the most important health priorities for the authorities.
C1 [Karrari, Parissa; Mehrpour, Omid] BUMS, Dept Clin Toxicol, Med Toxicol & Drug Abuse Res Ctr MTDRC, Birjand, Iran.
   [Afshari, Reza] Mashhad Univ Med Sci, Med Toxicol Res Ctr, Mashhad, Iran.
   [Keyler, Daniel] Univ Minnesota, Dept Expt & Clin Pharmacol, Minneapolis, MN USA.
C3 Mashhad University Medical Science; University of Minnesota System;
   University of Minnesota Twin Cities
RP Mehrpour, O (通讯作者)，BUMS, Dept Clin Toxicol, Med Toxicol & Drug Abuse Res Ctr MTDRC, Birjand, Iran.
EM omid.mehrpour@yahoo.com.au
RI Darmian, Faezeh Vahedi/AAF-7755-2019; amiri, omolbanin/G-4425-2017;
   mehrpour, omid/O-3399-2017; Mehrpour, Omid/E-9554-2011
OI amiri, omolbanin/0000-0002-3815-5716; Mehrpour, Omid/0000-0002-1070-8841
FU Birjand University of Medical Sciences, Iran
FX The study is based on the MD thesis of Dr. Parissa Karrari. We are
   grateful to Birjand University of Medical Sciences, Iran, for funding
   the study, and to Dr. Siavash Jafari for editorial assistance.
CR Ahmadi J, 2003, ADDICT BEHAV, V28, P375, DOI 10.1016/S0306-4603(01)00246-5
   Ahmadi J, 2000, PSYCHOL REP, V87, P1158, DOI 10.2466/PR0.87.7.1158-1164
   Ayatollahi V., 2011, IRAN J TOXICOL, V4, P362
   BARNARD MA, 1993, ADDICTION, V88, P805, DOI 10.1111/j.1360-0443.1993.tb02094.x
   Day Carolyn, 2006, Harm Reduct J, V3, P2, DOI 10.1186/1477-7517-3-2
   de Kort G, 2006, YOUNG PEOPLE DRUGS C
   Ghodse H, 1995, Health Serv J, V105, P31
   Goodarzi F, 2011, INDIAN J FORENSIC ME, V5, P66
   Heinz AJ, 2009, ADDICT BEHAV, V34, P258, DOI 10.1016/j.addbeh.2008.10.020
   Jafari S., 2009, INT J MENT HEALTH AD, V7, P376, DOI DOI 10.1007/S11469-008-9176-Y
   Jafari S, 2010, ADDICT RES THEORY, V18, P59, DOI 10.3109/16066350902825930
   Jazayeri A, 2003, SOCIAL WELFARE, V2, P217
   Kadri AM, 2003, INDIAN J COMMUNITY M, V28, P74
   Karrari P, 2012, J RES MED SCI, V17, P203
   Mehrpour O, 2012, HUM EXP TOXICOL, V31, P1188, DOI 10.1177/0960327112446814
   Meysamie A, 2009, East Mediterr Health J, V15, P425
   Mokri A., 2002, ARCH IRAN MED, V5, P184
   Momtazi S, 2010, CURR OPIN PSYCHIATR, V23, P221, DOI 10.1097/YCO.0b013e328338630d
   Movaghar AR, 2005, J URBAN HEALTH, V82, P370, DOI 10.1093/jurban/jti089
   PECK DF, 1986, BRIT MED J, V293, P929, DOI 10.1136/bmj.293.6552.929
   Rasouli-Azad M, 2011, ZAHEDAN J RES MED SC, V13, P36
   Razzaghi EM., 1999, RAPID SITUATION ASSE, P1998
   Razzaghi EM, 1999, RAPID SITUATION ASSE, P38
   Samiei M, 2002, J REHABIL, V3, P56
   Swift W, 1998, DRUG ALCOHOL REV, V17, P59, DOI 10.1080/09595239800187601
   Taghaddosinejad F, 2011, J MED TOXICOL, V7, P183, DOI 10.1007/s13181-011-0168-0
   United Nations International Drug Control Programme, 2002, ANN REP ADD YEAR 200
   UNODC, 2008, WORLD DRUG REP 2008, V2008, P173, DOI [10.18356/4713aa6f-en, DOI 10.18356/4713AA6F-EN]
   Ziaaddini H., 2005, J APPL SCI, V5, P380, DOI [10.3923/jas.2005.380.382, DOI 10.3923/JAS.2005.380.382]
NR 29
TC 25
Z9 27
U1 0
U2 3
PU PAKISTAN MEDICAL ASSOC
PI KARACHI
PA PMA HOUSE, AGA KHAN III RD, KARACHI, 00000, PAKISTAN
SN 0030-9982
J9 J PAK MED ASSOC
JI J. Pak. Med. Assoc.
PD JUN
PY 2013
VL 63
IS 6
BP 711
EP 716
PG 6
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA 147ON
UT WOS:000319177000010
PM 23901670
DA 2023-06-23
ER

PT J
AU Hall, W
   Carter, A
   Forlini, C
AF Hall, Wayne
   Carter, Adrian
   Forlini, Cynthia
TI The brain disease model of addiction: is it supported by the evidence
   and has it delivered on its promises?
SO LANCET PSYCHIATRY
LA English
DT Article
ID DRUG-ADDICTION; NEUROBIOLOGY; SCIENCE; DEPENDENCE; GENETICS; COCAINE;
   ABUSE; STIMULATION; PREVALENCE; ALCOHOL
AB Since 1997 the US National Institute on Drug Abuse has advocated a brain disease model of addiction (BDMA). We assess the strength of evidence for the BDMA in animals, neuroimaging studies of people with addiction, and current research on the role of genetics in addiction. We critically assess claims about the medical and social benefits of use of the BDMA because the social implications are often implied as a reason to accept this model. Furthermore, we argue that the BDMA is not supported by animal and neuroimaging evidence to the extent its advocates suggest; it has not helped to deliver more effective treatments for addiction; and its effect on public policies toward drugs and people with addiction has been modest. The focus of the BDMA is on disordered neurobiology in a minority of severely addicted individuals, which undermines the implementation of effective and cost-effective policies at the population level to discourage people from smoking tobacco and drinking heavily. The pursuit of high technology direct brain interventions to cure addiction when most individuals with addiction do not have access to effective psychosocial and drug treatments is questionable.
C1 [Hall, Wayne] Univ Queensland, Ctr Youth Subst Abuse Res, Brisbane, Qld 4029, Australia.
   [Hall, Wayne; Carter, Adrian; Forlini, Cynthia] Univ Queensland, Ctr Clin Res, Brisbane, Qld 4029, Australia.
   [Hall, Wayne] Kings Coll London, Natl Addict Ctr, London WC2R 2LS, England.
   [Carter, Adrian] Monash Univ, Sch Psychol Sci, Melbourne, Vic 3004, Australia.
C3 University of Queensland; University of Queensland; University of
   London; King's College London; Monash University
RP Hall, W (通讯作者)，Univ Queensland, Ctr Youth Subst Abuse Res, Mental Hlth Ctr, K Floor,Royal Brisbane & Womens Hosp Site, Brisbane, Qld 4029, Australia.
EM w.hall@uq.edu.au
RI Carter, Adrian/AAG-2830-2020; Forlini, Cynthia E/K-2864-2013; Hall,
   Wayne D/A-3283-2008
OI Carter, Adrian/0000-0002-3593-0772; Hall, Wayne D/0000-0003-1984-0096;
   Forlini, Cynthia/0000-0003-3809-8229
FU National Health and Medical Research Council Australia; National Health
   and Medical Research Council
FX We thank Sarah Yeates for comments on an earlier draft of this
   manuscript and her assistance in literature searches for the article. WH
   and CF were funded by an National Health and Medical Research Council
   Australia Fellowship awarded to WH. AC was supported by an National
   Health and Medical Research Council postdoctoral fellowship.
CR Ahmed SH, 2012, NEUROSCIENCE, V211, P107, DOI 10.1016/j.neuroscience.2011.08.014
   Ahmed SH, 2013, CURR OPIN NEUROBIOL, V23, P581, DOI 10.1016/j.conb.2013.01.028
   ALEXANDER BK, 1978, PSYCHOPHARMACOLOGY, V58, P175, DOI 10.1007/BF00426903
   American Society of Addiction Medicine, 2011, PUBL POL STAT DEF AD
   [Anonymous], 2014, NATURE, V506, P5, DOI 10.1038/506005a
   BACHMAN JG, 1997, SMOKING DRINKING DRU
   Ball D, 2008, ADDICTION, V103, P360, DOI 10.1111/j.1360-0443.2007.02061.x
   Baltuch G. H., 2007, DEEP BRAIN STIMULATI
   Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475
   Cahill K, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006103.pub2
   Carter A, 2012, ADDICTION NEUROETHICS: THE ETHICS OF ADDICTION NEUROSCIENCE RESEARCH AND TREATMENT, P1
   Carter A, 2011, ADDICTION, V106, P235, DOI 10.1111/j.1360-0443.2010.03245.x
   Courtwright DT, 2010, BIOSOCIETIES, V5, P137, DOI 10.1057/biosoc.2009.3
   Dackis C, 2005, NAT NEUROSCI, V8, P1431, DOI 10.1038/nn1105-1431
   Djulbegovic B, 2014, JAMA-J AM MED ASSOC, V311, P355, DOI 10.1001/jama.2013.283742
   Doran CM, 2010, MED J AUSTRALIA, V192, P468, DOI 10.5694/j.1326-5377.2010.tb03589.x
   Ersche KD, 2013, CURR OPIN NEUROBIOL, V23, P615, DOI 10.1016/j.conb.2013.02.017
   Feltenstein MW, 2008, BRIT J PHARMACOL, V154, P261, DOI 10.1038/bjp.2008.51
   Gartner CE, 2009, ADDICTION, V104, P118, DOI 10.1111/j.1360-0443.2008.02392.x
   Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119
   Hall W, 2006, ADDICTION, V101, P1, DOI 10.1111/j.1360-0443.2005.01363.x
   Hall W, 2002, TOB CONTROL, V11, P119, DOI 10.1136/tc.11.2.119
   Hall W, 2011, CURR OPIN PSYCHIATR, V24, P191, DOI 10.1097/YCO.0b013e328345922b
   Hall WD, 2008, ADDICTION, V103, P350, DOI 10.1111/j.1360-0443.2007.02070.x
   Hall WD, 2012, ADDICTION NEUROETHICS: THE ETHICS OF ADDICTION NEUROSCIENCE RESEARCH AND TREATMENT, P115
   Hartmann-Boyce J, 2012, COCHRANE DB SYST REV, V8, DOI DOI 10.1002/14651858.CD007072.PUB2]
   Heim D, 2014, NATURE, V507, P40, DOI 10.1038/507040e
   Heyman Gene M., 2009, ADDICTION DISORDER C, DOI [10.4159/9780674053991, DOI 10.4159/9780674053991]
   Hyman S, 2011, OXFORD HDB NEUROETHI, P203
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Ioannidis JPA, 2014, TRENDS COGN SCI, V18, P235, DOI 10.1016/j.tics.2014.02.010
   Ioannidis JPA, 2011, ARCH GEN PSYCHIAT, V68, P773, DOI 10.1001/archgenpsychiatry.2011.28
   Kalant H, 2010, ADDICTION, V105, P780, DOI 10.1111/j.1360-0443.2009.02739.x
   Kendler KS, 2012, NAT NEUROSCI, V15, P181, DOI 10.1038/nn.3018
   Kincaid H., 2010, WHAT IS ADDICTION, P353
   Kleiman M. A. R., 2009, BRUTE FORCE FAILS HA
   Koob GF, 2006, ADDICTION, V101, P23, DOI 10.1111/j.1360-0443.2006.01586.x
   Koob GF, 2009, NAT REV DRUG DISCOV, V8, P500, DOI 10.1038/nrd2828
   Koob GF, 2006, NEUR ADD
   Kosten TR, 2014, DRUG ALCOHOL DEPEN, V140, P42, DOI 10.1016/j.drugalcdep.2014.04.003
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Lingford-Hughes AR, 2012, J PSYCHOPHARMACOL, V26, P899, DOI 10.1177/0269881112444324
   Lingford-Hughes A, 2010, BRIT MED BULL, V96, P93, DOI 10.1093/bmb/ldq032
   Luigjes J, 2012, MOL PSYCHIATR, V17, P572, DOI 10.1038/mp.2011.114
   Miller P, 2012, ADDICTION NEUROETHICS: THE ETHICS OF ADDICTION NEUROSCIENCE RESEARCH AND TREATMENT, P277
   Minozzi S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001333.pub4
   National Institute on Drug Abuse, 2014, FISC YEAR 2015 BUDG
   National Institute on Drug Abuse, 2007, DRUGS BRAINS BEH SCI
   Nutt D, 2008, BRIT J PHARMACOL, V154, P397, DOI 10.1038/bjp.2008.101
   Nutt D, 2007, LANCET, V369, P1047, DOI 10.1016/S0140-6736(07)60464-4
   Panlilio LV, 2007, ADDICTION, V102, P1863, DOI 10.1111/j.1360-0443.2007.02011.x
   Paul SM, 2010, NAT REV DRUG DISCOV, V9, P203, DOI 10.1038/nrd3078
   Pierce JP, 1998, JAMA-J AM MED ASSOC, V280, P893, DOI 10.1001/jama.280.10.893
   Prinz F, 2011, NAT REV DRUG DISCOV, V10, P712, DOI 10.1038/nrd3439-c1
   Reske M, 2011, OXFORD HDB NEUROETHI, P177
   Roberts NJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003380
   Robins LN, 2010, AM J ADDICTION, V19, P203, DOI 10.1111/j.1521-0391.2010.00046.x
   Rosner S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004332.pub2
   ROSE G., 1992, STRATEGY PREVENTIVE
   Rouaud T, 2010, P NATL ACAD SCI USA, V107, P1196, DOI 10.1073/pnas.0908189107
   Satel Sally, 2013, BRAINWASHED SEDUCTIV
   Stephen JH, 2012, ADDICTION, V107, P624, DOI 10.1111/j.1360-0443.2011.03656.x
   Tsilidis KK, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001609
   Vanderschuren LJMJ, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a011932
   Volkow N, 2010, DOPAMINE HDB, P407
   Volkow ND, 2014, NEUROPHARMACOLOGY, V76, P235, DOI 10.1016/j.neuropharm.2013.05.007
   Volkow ND, 2009, NEUROPHARMACOLOGY, V56, P3, DOI 10.1016/j.neuropharm.2008.05.022
   Volkow N.D., 2014, IMAGING HUMAN BRAIN, P1, DOI [10.1016/B978-0-12-418677-4.00001-4, DOI 10.1016/B978-0-12-418677-4.00001-4]
   Volkow ND, 2005, PHARMACOL THERAPEUT, V108, P3, DOI 10.1016/j.pharmthera.2005.06.021
   Volkow ND, 2004, NAT REV NEUROSCI, V5, P963, DOI 10.1038/nrn1539
   Volkow ND, 2012, ANNU REV PHARMACOL, V52, P321, DOI 10.1146/annurev-pharmtox-010611-134625
   White V, 2003, TOB CONTROL, V12, P67, DOI 10.1136/tc.12.suppl_2.ii67
NR 72
TC 127
Z9 132
U1 3
U2 60
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2215-0374
J9 LANCET PSYCHIAT
JI Lancet Psychiatry
PD JAN
PY 2015
VL 2
IS 1
BP 105
EP 110
DI 10.1016/S2215-0366(14)00126-6
PG 6
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA CF6ZM
UT WOS:000352705600028
PM 26359616
DA 2023-06-23
ER

PT J
AU Liu, CJ
AF Liu, Chang-Jiang
TI Development and Validation of the Volitional Components Inventory for
   Drug Rehabilitation
SO JOURNAL OF DRUG ISSUES
LA English
DT Article
DE volition; drug addiction abstinence; self-regulation; action control;
   inventory development
ID RELAPSE PREVENTION; ATTENTIONAL BIAS; ADDICTION; HEALTH; IMPULSIVITY;
   MODEL; USERS
AB Long-term recovery from drug abuse is a volitional process. Until now, no measure has been available for assessment of executive functioning capacity in this process. This study aims to identify a volitional process for drug addiction rehabilitation and to develop the Volitional Components Inventory for Drug Rehabilitation (VCI-DR). An item pool was constructed, based on theory construction, individual- and group-focused interviews, and expert feedback. Results of exploratory and confirmatory factor analyses suggested a structure with five factors: motivation control, impulse control, arousal control, self-discipline, and action management. The VCI-DR displayed promising convergent and discriminant validity with theoretically predicted criterion variables (sense of control, indecisiveness, impulsiveness, motivation of drug addiction rehabilitation, and emotion regulation). In addition, results showed good test-retest reliability, with excellent internal consistencies. Taken together, this research offers promising support for the VCI-DR, potentially advancing both basic and applied addiction research.
C1 [Liu, Chang-Jiang] Nanjing Normal Univ, Sch Psychol, 122 Ninghai Rd, Nanjing 210097, Jiangsu, Peoples R China.
   [Liu, Chang-Jiang] Nanjing Normal Univ, Res Inst Moral Educ, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing Normal University; Nanjing Normal University
RP Liu, CJ (通讯作者)，Nanjing Normal Univ, Sch Psychol, 122 Ninghai Rd, Nanjing 210097, Jiangsu, Peoples R China.
EM chjliu@njnu.edu.cn
OI /0000-0003-1906-4808
CR Baumeister R.F., 2014, DUAL PROCESS ORIE, P35
   Baumeister RF, 2015, ADDICT BEHAV, V44, P3, DOI 10.1016/j.addbeh.2014.09.011
   Carter A, 2014, NEUROETHICS-NETH, V7, P205, DOI 10.1007/s12152-013-9196-6
   Constantinou N, 2010, DRUG ALCOHOL DEPEN, V109, P220, DOI 10.1016/j.drugalcdep.2010.01.012
   Cousijn J, 2011, ADDICTION, V106, P1667, DOI 10.1111/j.1360-0443.2011.03475.x
   Duckworth AL, 2015, CHILD DEV PERSPECT, V9, P32, DOI 10.1111/cdep.12107
   Ersche KD, 2010, BIOL PSYCHIAT, V68, P770, DOI 10.1016/j.biopsych.2010.06.015
   Foddy B, 2006, BIOETHICS, V20, P1, DOI 10.1111/j.1467-8519.2006.00470.x
   FROST RO, 1993, BEHAV RES THER, V31, P683, DOI 10.1016/0005-7967(93)90121-A
   Fudala Paul J, 2004, Curr Psychiatry Rep, V6, P339, DOI 10.1007/s11920-004-0020-1
   Giordano AL, 2014, J ADDICT OFFENDER CO, V35, P114, DOI 10.1002/j.2161-1874.2014.00030.x
   Gollwitzer P.M., 1990, HDB MOTIVATION COGNI
   Gross JJ, 2003, J PERS SOC PSYCHOL, V85, P348, DOI 10.1037/0022-3514.85.2.348
   Hammerbacher M, 2006, J SUBST USE, V11, P387, DOI DOI 10.1080/14659890600708266
   Hendershot CS, 2011, SUBST ABUSE TREAT PR, V6, DOI 10.1186/1747-597X-6-17
   Heppner P.P., 2004, WRITING PUBLISHING Y
   Hester R, 2006, DRUG ALCOHOL DEPEN, V81, P251, DOI 10.1016/j.drugalcdep.2005.07.002
   Hodgins DC, 2015, INT J MENT HEALTH AD, V13, P699, DOI 10.1007/s11469-015-9572-z
   Hser YI, 1997, J SUBST ABUSE TREAT, V14, P543, DOI 10.1016/S0740-5472(97)00016-0
   Kuhl J., 1998, MOTIVATION SELF REGU, P15, DOI DOI 10.1017/CBO9780511527869.003
   Lachman ME, 1998, J PERS SOC PSYCHOL, V74, P763, DOI 10.1037/0022-3514.74.3.763
   Lundqvist T, 2010, CURR TOP BEHAV NEURO, V3, P247, DOI 10.1007/7854_2009_26
   Marhe R, 2013, J CONSULT CLIN PSYCH, V81, P1, DOI 10.1037/a0030754
   MARLATT GA, 1984, BRIT J ADDICT, V79, P261
   McCabe CJ, 2015, PSYCHOL ADDICT BEHAV, V29, P753, DOI 10.1037/adb0000075
   Min Z, 2011, AM J DRUG ALCOHOL AB, V37, P141, DOI 10.3109/00952990.2010.538943
   Mooi E, 2011, CONCISE GUIDE TO MARKET RESEARCH: THE PROCESS, DATA, AND METHODS USING IBM SPSS STATISTICS, P1, DOI 10.1007/978-3-642-12541-6
   Racine E, 2017, BIOETHICS, V31, P349, DOI 10.1111/bioe.12356
   Ryan F., 2013, COGNITIVE THERAPY AD
   Ryba TV, 2009, INT J SPORT EXERC PS, V7, P275, DOI 10.1080/1612197X.2009.9671910
   SCHALER JA, 1995, INT J ADDICT, V30, P117, DOI 10.3109/10826089509060737
   Schwarzer R, 2011, REHABIL PSYCHOL, V56, P161, DOI 10.1037/a0024509
   Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012
   Tripp JC, 2015, ADDICT BEHAV, V47, P55, DOI 10.1016/j.addbeh.2015.03.013
   VATZ RE, 1990, J MIND BEHAV, V11, P531
   Whiteside SP, 2001, PERS INDIV DIFFER, V30, P669, DOI 10.1016/S0191-8869(00)00064-7
   Yang M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130711
   [张琪 Zhang Qi], 2013, [西南师范大学学报. 自然科学版, Journal of Southwest China Normal University. Natural Science Edition], V38, P163
NR 38
TC 1
Z9 1
U1 0
U2 10
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022-0426
EI 1945-1369
J9 J DRUG ISSUES
JI J. Drug Issues
PD JAN
PY 2020
VL 50
IS 1
BP 89
EP 102
DI 10.1177/0022042619890839
PG 14
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA JU8CQ
UT WOS:000501898600007
OA Bronze
DA 2023-06-23
ER

PT J
AU [Anonymous]
AF [Anonymous]
TI Battling the biology of opioid addiction
SO NATURE MEDICINE
LA English
DT Editorial Material
AB Deaths from drug overdose are rising worldwide, in part owing to the growing epidemic of opioid addiction. Efforts to combat opioid addiction will benefit from stronger collaboration between preclinical researchers who are studying addiction and those studying chronic pain.
CR 2016, MMWR MORB MORTAL WKL, V65, P1445
NR 1
TC 2
Z9 2
U1 2
U2 12
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD JUL
PY 2017
VL 23
IS 7
BP 790
EP 790
DI 10.1038/nm.4374
PG 1
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA FA1DS
UT WOS:000405180100002
PM 28697181
OA Bronze
DA 2023-06-23
ER

PT J
AU Miller, PG
   Staiger, PK
   Hutchinson, D
AF Miller, Peter G.
   Staiger, Petra K.
   Hutchinson, Delyse
TI THE DEAKIN CENTRE FOR DRUG, ALCOHOL AND ADDICTION RESEARCH: EXPLORING
   ADDICTION AND SUBSTANCE USE FROM DEVELOPMENTAL AND INTERGENERATIONAL
   PERSPECTIVES
SO DRUG AND ALCOHOL REVIEW
LA English
DT Meeting Abstract
C1 [Miller, Peter G.; Staiger, Petra K.; Hutchinson, Delyse] Deakin Univ, Deakin Ctr Drug Alcohol & Addict Res, Geelong, Vic, Australia.
   [Hutchinson, Delyse] Deakin Univ, Ctr Social & Early Emot Dev, Fac Hlth, Sch Psychol, Melbourne, Vic, Australia.
   [Hutchinson, Delyse] Royal Childrens Hosp Melbourne, Murdoch Childrens Res Inst, Melbourne, Vic, Australia.
   [Hutchinson, Delyse] Univ Melbourne Paediat, Melbourne, Vic, Australia.
   [Hutchinson, Delyse] UNSW Sydney, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia.
C3 Deakin University; Deakin University; Murdoch Children's Research
   Institute; Royal Children's Hospital Melbourne; University of New South
   Wales Sydney
EM peter.miller@deakin.edu.au
RI Hutchinson, Delyse May/I-8574-2017
OI Hutchinson, Delyse May/0000-0003-3221-7143
NR 0
TC 0
Z9 0
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0959-5236
EI 1465-3362
J9 DRUG ALCOHOL REV
JI Drug Alcohol Rev.
PD NOV
PY 2017
VL 36
SU 1
SI SI
BP 52
EP 52
PG 1
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA FU6ZB
UT WOS:000424000500135
DA 2023-06-23
ER

PT J
AU Perez, JM
   Orellana, G
AF Perez F, Juan Manuel
   Orellana, Gricel, V
TI Update in the clinic of addictions: learning and dopamine
SO REVISTA MEDICA DE CHILE
LA Spanish
DT Review
DE dopamine; drug addiction; learning; substance addiction
ID MOLECULAR-MECHANISMS; DRUG; ALCOHOL; REINFORCEMENT; REWARD; BRAIN;
   RELAPSE; ABUSE; CUES; SENSITIZATION
AB There are two parallel explanatory models for addictions. One is the homeostatic model, that explains tolerance and The abstinence syndrome. Tolerance and abstinence are reversible phenomena that mask, sensitization. These appear more commonly with the continued use of drugs, and are based in the up-regulation of cyclic AMP. The other is the plasticity model, that explains sensitization and compulsive use of drugs or addiction. Addiction is probably irreversible, underlies tolerance, appears more frequently with intermittent use of drugs, and is based in learning and memory mechanisms, Both are boldly linked to environmental and behavioral elements. in the plasticity model, dopamine (DA) has at an outstanding role. Its phasic discharge is a temporal re-ward prediction error marker It is the prediction error that generates learning. All the addictive drugs provoke a very strong increase of phasic DA discharge in some cerebral nuclei by direct or indirect paths. This increase is interpreted by cerebral circuits as prediction errors that generate learning behaviors. Pavlovian and operating type learning is involved. It is clinically observed as The prominence of environmental cues that are related to drug consumption, and the appearance of behaviors directed to the search and use of drugs, that are mainly involuntary and triggered by these cites. Pleasure (primary reinforcement) plays a role in ibis model, only in the initial stages of addiction. Understanding ibis double parallel model allows to design therapeutic interventions directed towards a conscious control of involuntary, environmental and affective cues that trigger drug search and use.
C1 Univ Chile, Fac Med, Dept Psiquiatria Sur, Santiago, Chile.
C3 Universidad de Chile
RP Orellana, G (通讯作者)，Univ Chile, Fac Med, Dept Psiquiatria Sur, Gran Ave 3100, Santiago, Chile.
EM gorellana@med.uchile.cl
RI orellana, gricel p/O-7013-2017
OI orellana, gricel p/0000-0003-2503-1535
CR Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9
   Bernheim BD, 2004, AM ECON REV, V94, P1558, DOI 10.1257/0002828043052222
   Berridge KC, 2003, TRENDS NEUROSCI, V26, P507, DOI 10.1016/S0166-2236(03)00233-9
   CEPEDA C, 1993, P NATL ACAD SCI USA, V90, P9576, DOI 10.1073/pnas.90.20.9576
   Charpier S, 1997, P NATL ACAD SCI USA, V94, P7036, DOI 10.1073/pnas.94.13.7036
   CHICK J, 1993, ADDICTION, V88, P1481, DOI 10.1111/j.1360-0443.1993.tb03134.x
   Crits-Christoph P, 1999, ARCH GEN PSYCHIAT, V56, P493, DOI 10.1001/archpsyc.56.6.493
   Crombag HS, 2000, BEHAV BRAIN RES, V116, P1, DOI 10.1016/S0166-4328(00)00243-6
   Dayan P, 2002, NEURON, V36, P285, DOI 10.1016/S0896-6273(02)00963-7
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   DRUMMOND DC, 1990, BRIT J ADDICT, V85, P725
   Flannery BA, 2003, J STUD ALCOHOL, V64, P120, DOI 10.15288/jsa.2003.64.120
   FRANKEN IGH, 2003, COGNITIVE THER RES, V27, P48
   Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0
   HEATHER N, 1991, ADDICT BEHAV, V16, P41, DOI 10.1016/0306-4603(91)90038-J
   Hyman SE, 1996, AM J PSYCHIAT, V153, P151
   Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560
   KALANT H, 1981, ALCOHOLISMO
   Kauer JA, 2004, ANNU REV PHYSIOL, V66, P447, DOI 10.1146/annurev.physiol.66.032102.112534
   Kelley AE, 1997, P NATL ACAD SCI USA, V94, P12174, DOI 10.1073/pnas.94.22.12174
   KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Kranzler HR, 1999, PSYCHIAT CLIN N AM, V22, P401, DOI 10.1016/S0193-953X(05)70084-8
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   LEVIN FR, 2002, PSIQUIATRIA SALUD IN, V2, P35
   LITMAN GK, 1983, BRIT J ADDICT, V78, P269
   Litt MD, 2003, J CONSULT CLIN PSYCH, V71, P118, DOI 10.1037/0022-006X.71.1.118
   Longabaugh R, 1996, ADDICTION, V91, pS73, DOI 10.1111/j.1360-0443.1996.tb02328.x
   Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870
   Marlatt GA, 1996, ADDICTION, V91, pS37, DOI 10.1111/j.1360-0443.1996.tb02326.x
   Mason BJ, 2001, J CLIN PSYCHIAT, V62, P42
   McKay JR, 1999, J STUD ALCOHOL, V60, P566, DOI 10.15288/jsa.1999.60.566
   Miller WR, 1996, ADDICTION, V91, pS155, DOI 10.1046/j.1360-0443.91.12s1.7.x
   MILLER WR, 1996, ADDICTION S, V91
   Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006
   Montague PR, 2002, NEURON, V36, P265, DOI 10.1016/S0896-6273(02)00974-1
   Naranjo CA, 2001, J CLIN PSYCHIAT, V62, P18
   Nestler EJ, 2004, TRENDS PHARMACOL SCI, V25, P210, DOI 10.1016/j.tips.2004.02.005
   Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58
   Nestler EJ, 1996, NEURON, V16, P897, DOI 10.1016/S0896-6273(00)80110-5
   OBrien CP, 1996, LANCET, V347, P237, DOI 10.1016/S0140-6736(96)90409-2
   OLDS J, 1954, J COMP PHYSIOL PSYCH, V47, P419, DOI 10.1037/h0058775
   *ORG MUND SAL, 1995, CLAS INT ENF
   Pérez Juan, 2003, Rev. chil. neuro-psiquiatr., V41, P55
   Redish AD, 2004, SCIENCE, V306, P1944, DOI 10.1126/science.1102384
   Robinson TE, 2000, ADDICTION, V95, pS91
   ROLLNICK S, 1982, ADDICT BEHAV, V7, P243, DOI 10.1016/0306-4603(82)90051-X
   Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593
   Schultz W, 2002, NEURON, V36, P241, DOI 10.1016/S0896-6273(02)00967-4
   Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1
   SELF DW, 1995, ANNU REV NEUROSCI, V18, P463, DOI 10.1146/annurev.ne.18.030195.002335
   Sitharthan T, 2003, J CLIN PSYCHOL, V59, P351, DOI 10.1002/jclp.10127
   Spanagel R, 1999, TRENDS NEUROSCI, V22, P521, DOI 10.1016/S0166-2236(99)01447-2
   Tiffany ST, 2000, ADDICTION, V95, pS145, DOI 10.1046/j.1360-0443.95.8s2.3.x
   TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147
   Townshend JM, 2001, PSYCHOPHARMACOLOGY, V157, P67, DOI 10.1007/s002130100764
   Valjent E, 2005, P NATL ACAD SCI USA, V102, P491, DOI 10.1073/pnas.0408305102
   Volpicelli JR, 2001, J CLIN PSYCHIAT, V62, P4
   Waelti P, 2001, NATURE, V412, P43, DOI 10.1038/35083500
   WENGER JR, 1981, SCIENCE, V213, P575
   Wickelgren I, 1997, SCIENCE, V278, P35, DOI 10.1126/science.278.5335.35
   Wise RA, 1996, ANNU REV NEUROSCI, V19, P319, DOI 10.1146/annurev.ne.19.030196.001535
   Wise RA, 2002, NEURON, V36, P229, DOI 10.1016/S0896-6273(02)00965-0
   Wise Roy A., 2000, Neuron, V26, P27, DOI 10.1016/S0896-6273(00)81134-4
NR 65
TC 2
Z9 2
U1 2
U2 13
PU SOC MEDICA SANTIAGO
PI SANTIAGO 9
PA BERNARDA MORIN 488 PROVIDENCIA, CASILLA 168 CORREO 55, SANTIAGO 9,
   00000, CHILE
SN 0034-9887
EI 0717-6163
J9 REV MED CHILE
JI Rev. Medica Chile
PD MAR
PY 2007
VL 135
IS 3
BP 384
EP 391
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine
GA 164FN
UT WOS:000246219100015
PM 17505586
DA 2023-06-23
ER

PT J
AU Pienaar, K
   Moore, D
   Fraser, S
   Kokanovic, R
   Treloar, C
   Dilkes-Frayne, E
AF Pienaar, Kiran
   Moore, David
   Fraser, Suzanne
   Kokanovic, Renata
   Treloar, Carla
   Dilkes-Frayne, Ella
TI Diffracting addicting binaries: An analysis of personal accounts of
   alcohol and other drug "addiction'
SO HEALTH
LA English
DT Article
DE discourse analysis; experiencing illness and narratives; theory
ID PLEASURE; USERS
AB Associated with social and individual harm, loss of control and destructive behaviour, addiction is widely considered to be a major social problem. Most models of addiction, including the influential disease model, rely on the volition/compulsion binary, conceptualising addiction as a disorder of compulsion. In order to interrogate this prevailing view, this article draws on qualitative data from interviews with people who describe themselves as having an alcohol or other drug addiction', dependence' or habit'. Applying the concept of diffraction' elaborated by science studies scholar Karen Barad, we examine the process of addicting', or the various ways in which addiction is constituted, in accounts of daily life with regular alcohol and other drug use. Our analysis suggests not only that personal accounts of addiction exceed the absolute opposition of volition/compulsion but also that the polarising assumptions of existing addicting discourses produce many of the negative effects typically attributed to the disease of addiction'.
C1 [Pienaar, Kiran] Curtin Univ, Melbourne Off, NDRI, Bentley, WA, Australia.
   [Moore, David; Fraser, Suzanne] Curtin Univ, NDRI, Bentley, WA, Australia.
   [Kokanovic, Renata] Monash Univ, Clayton, Vic, Australia.
   [Treloar, Carla] Univ New South Wales, Ctr Social Res Hlth, Sydney, NSW, Australia.
   [Dilkes-Frayne, Ella] Monash Univ, Social Studies Hlth & Med Res Program, Clayton, Vic, Australia.
C3 Curtin University; Curtin University; Monash University; University of
   New South Wales Sydney; Monash University
RP Pienaar, K (通讯作者)，Curtin Univ, Fac Hlth Sci, Social Studies Addict Concepts Res Program, Natl Drug Res Inst,Melbourne Off, Suite 6,19-35 Gertrude St, Fitzroy, Vic 3065, Australia.
EM Kiran.pienaar@curtin.edu.au
RI Pienaar, Kiran/AAB-1206-2020; Moore, David/GXV-9667-2022
OI Moore, David/0000-0002-5860-3109; Fraser, Suzanne/0000-0003-1018-5865;
   Treloar, Carla/0000-0002-8230-0386; Kokanovic,
   Renata/0000-0002-4308-3403; Pienaar, Kiran/0000-0003-4770-7882
FU Australian Research Council [DP140100996]; Australian Government;
   Australian Department of Health; Australian Research Council Future
   Fellowship [FT120100215]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: The
   research on which this article draws is funded by an Australian Research
   Council Discovery Project grant (DP140100996). The project is based at
   Curtin University's National Drug Research Institute (NDRI), which is
   supported by funding from the Australian Government, under the Substance
   Misuse Prevention and Service Improvements Grants Fund. The study is a
   collaboration with Healthtalk Australia, Monash University and the
   University of New South Wales' Centre for Social Research in Health
   (CSRH). CSRH is supported by a grant from the Australian Department of
   Health. Suzanne Fraser is funded by an Australian Research Council
   Future Fellowship (FT120100215).
CR Allen L, 2015, SEXUALITIES, V18, P941, DOI 10.1177/1363460714550920
   [Anonymous], 2001, CONTEMP DRUG PROBL, DOI DOI 10.1177/009145090102800404
   [Anonymous], RES HDB PROD HEALTHT
   APA, 2013, DIAGNOSTIC STAT MANU, V5th edition, DOI DOI 10.5555/APPI.BOOKS.9780890425596
   Barad K., 2007, M UNIVERSE HALFWAY Q
   Barad K, 2014, PARALLAX, V20, P168, DOI 10.1080/13534645.2014.927623
   Berridge V., 2013, DEMONS OUR CHANGING
   Brook H, 2005, INT J DRUG POLICY, V16, P316, DOI 10.1016/j.drugpo.2005.05.002
   Carr ES, 2011, SCRIPTING ADDICTION
   Covington S, 2011, J PSYCHOACTIVE DRUGS, V40, P377
   Dobbin Robert, 2012, INTRO SOCIOLOGY ORG, pxi
   Duff C, 2015, J SOCIOL, V51, P81, DOI 10.1177/1440783314562502
   Fox NJ, 2016, HEALTH-LONDON, V20, P62, DOI 10.1177/1363459315615393
   Fraser S, 2008, SUBSTANCE AND SUBSTITUTION: METHADONE SUBJECTS IN LIBERAL SOCIETIES, P1, DOI 10.1057/9780230582569
   Fraser Suzanne, 2014, HABITS REMAKING ADDI
   Fry C, 2001, ADDICTION, V96, P1319, DOI 10.1046/j.1360-0443.2001.969131911.x
   Haraway Donna, 1992, CULT STUD, P295
   Kaiser BM, 2014, PARALLAX, V20, P165, DOI 10.1080/13534645.2014.927621
   Karasaki M, 2013, DRUG ALCOHOL REV, V32, P195, DOI 10.1111/j.1465-3362.2012.00501.x
   Keane H., 2002, WHATS WRONG ADDICTIO
   Keane H., 2003, INT J DRUG POLICY, V14, P227, DOI 10.1016/S0955-3959(02)00151-2
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Mol A., 2002, BODY MULTIPLE ONTOLO
   Moore D, 2008, INT J DRUG POLICY, V19, P353, DOI 10.1016/j.drugpo.2007.07.004
   Moore D, 2006, SOC SCI MED, V62, P3035, DOI 10.1016/j.socscimed.2005.11.067
   Netherland J, 2011, SOCIOLOGICAL REFLECT, P153
   Palmer A., 2011, ED RES METHODOLOGY, V1, P3, DOI DOI 10.7577/rerm.173
   ROOM R, 1985, BRIT J ADDICT, V80, P133
   Seddon T., 2010, HIST DRUGS DRUGS FRE
   SEDGWICK EK, 1993, TENDENCIES, P130
   Seear K, 2010, CRIT PUBLIC HEALTH, V20, P439, DOI 10.1080/09581591003653132
   Valentine K, 2008, INT J DRUG POLICY, V19, P410, DOI 10.1016/j.drugpo.2007.08.001
   Weinberg D., 2002, BODY SOC, V8, P1, DOI [10.1177/1357034X02008004001, DOI 10.1177/1357034X02008004001]
NR 33
TC 23
Z9 23
U1 0
U2 11
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1363-4593
EI 1461-7196
J9 HEALTH-LONDON
JI Health
PD SEP
PY 2017
VL 21
IS 5
BP 519
EP 537
DI 10.1177/1363459316674062
PG 19
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
WE Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA FD6NR
UT WOS:000407645700004
PM 28805150
OA Green Published
DA 2023-06-23
ER

PT J
AU Clemente-Suarez, VJ
   Ruisoto, P
   Isorna-Folgar, M
   Cancelo-Martinez, J
   Beltran-Velasco, AI
   Tornero-Aguilera, JF
AF Javier Clemente-Suarez, Vicente
   Ruisoto, Pablo
   Isorna-Folgar, Manuel
   Cancelo-Martinez, Jesus
   Isabel Beltran-Velasco, Ana
   Francisco Tornero-Aguilera, Jose
TI Psychophysiological and Psychosocial Profile of Patients Attending Drug
   Addiction Centers
SO APPLIED PSYCHOPHYSIOLOGY AND BIOFEEDBACK
LA English
DT Article
DE Drug addiction; Heart rate variability; Stress; Psychosocial;
   Psychological trait
ID HEART-RATE-VARIABILITY; PHYSICAL-ACTIVITY; USERS; METAANALYSIS;
   PERSONALITY; DISORDERS; ABUSE; TIME
AB Drug treatment centres provide the highest level of rehab services for patients diagnosed with drug addictions. Most inpatient drug rehab programs focus on medical detox and mental health interventions. However, how to optimize the later remains a challenge. The aim of this study was to examine the psychophysiological and psychosocial profile of patients attending drug addiction centres in comparation with the general population. A total of 105 inpatient drug rehab patients and 50 participants from the general population were compared based on standardized psychophysiological and psychosocial measures. Results of this study suggest that patients attending drug addiction centers differ from general population in several different psychophysiological and psychosocial factors. Patients reported significantly lower levels of physical activity and increased sympathetic responsiveness, and significantly higher levels in loneliness, psychologically inflexibility and neuroticism. The results of this study highlight the importance of address healthy lifestyle behaviors such as sport practice and psychological variables such as loneliness, psychological (in)flexibility and neuroticism to improve current programs aim to prevent or reduce problematic drug consumptions.
C1 [Javier Clemente-Suarez, Vicente; Francisco Tornero-Aguilera, Jose] Univ Europea Madrid, Fac Sports Sci, Tajo St S-N, Madrid 28670, Spain.
   [Javier Clemente-Suarez, Vicente; Francisco Tornero-Aguilera, Jose] Studies Ctr Appl Combat CESCA, Toledo, Spain.
   [Javier Clemente-Suarez, Vicente] Univ Costa, Grp Invest Cultura Educ & Soc, Barranquilla, Colombia.
   [Ruisoto, Pablo] Univ Publ Navarra, Dept Hlth Sci, Pamplona, Spain.
   [Isorna-Folgar, Manuel] Univ Vigo, Fac Ciencias Educ & Trabajo Social, Orense, Spain.
   [Cancelo-Martinez, Jesus] Unidad Asistencial Alborada, Vigo, Pontevedra, Spain.
   [Isabel Beltran-Velasco, Ana] Univ Antonio Nebrija, Psychol Dept, Madrid, Spain.
C3 European University of Madrid; Universidad de la Costa; Universidad
   Publica de Navarra; Universidade de Vigo; Universidad Antonio de Nebrija
RP Clemente-Suarez, VJ (通讯作者)，Univ Europea Madrid, Fac Sports Sci, Tajo St S-N, Madrid 28670, Spain.; Clemente-Suarez, VJ (通讯作者)，Studies Ctr Appl Combat CESCA, Toledo, Spain.; Clemente-Suarez, VJ (通讯作者)，Univ Costa, Grp Invest Cultura Educ & Soc, Barranquilla, Colombia.
EM vctxente@yahoo.es
RI Isorna Folgar, Manuel/AAK-9304-2020; Ruisoto, Pablo/J-3170-2019;
   Clemente-Suarez, Vicente Javier/K-7980-2014
OI Isorna Folgar, Manuel/0000-0002-3398-8882; Ruisoto,
   Pablo/0000-0003-1252-0479; Clemente-Suarez, Vicente
   Javier/0000-0002-2397-2801
FU CRUE-CSIC; Springer Nature
FX Open Access funding provided thanks to the CRUE-CSIC agreement with
   Springer Nature. None.
CR Acharya UR, 2004, BIOMED ENG ONLINE, V3, DOI 10.1186/1475-925X-3-24
   [Anonymous], DRUG SITUATION EUROP
   Bardo MT, 2015, DRUG ALCOHOL DEPEN, V153, P3, DOI 10.1016/j.drugalcdep.2015.05.037
   Billman GE, 2015, J APPL PHYSIOL, V118, P1344, DOI 10.1152/japplphysiol.01111.2014
   Bond FW, 2011, BEHAV THER, V42, P676, DOI 10.1016/j.beth.2011.03.007
   Bustamante-Sanchez L, 2020, CARDIOL RES PRACT, V2020, DOI 10.1155/2020/7986249
   Clemente-Suarez VJ, 2017, J MED SYST, V41, DOI 10.1007/s10916-017-0741-4
   Clemente-Suarez VJ, 2015, ACTA PHYSIOL HUNG, V102, P105, DOI 10.1556/APhysiol.102.2015.1.11
   Delgado-Moreno R, 2017, J MED SYST, V41, DOI 10.1007/s10916-017-0772-x
   Drumm RD, 2005, J DRUG ISSUES, V35, P607, DOI 10.1177/002204260503500311
   Elghozi JL, 2001, AUTON NEUROSCI-BASIC, V90, P116, DOI 10.1016/S1566-0702(01)00276-4
   Fehrman E., 2019, PERSONALITY TRAITS D, P5
   Fischer J, 2012, BRIT J SPORT MED, V46, P1142, DOI 10.1136/bjsports-2011-090724
   Fiskum C, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00561
   Hughes ME, 2004, RES AGING, V26, P655, DOI 10.1177/0164027504268574
   Clemente-Suarez VJ, 2020, PHYSIOL BEHAV, V214, DOI 10.1016/j.physbeh.2019.112761
   Clemente-Suarez VJ, 2018, J MED SYST, V42, DOI 10.1007/s10916-018-0907-8
   Clemente-Suarez VJ, 2017, J MED SYST, V41, DOI 10.1007/s10916-017-0779-3
   Jeronimus BF, 2016, PSYCHOL MED, V46, P2883, DOI 10.1017/S0033291716001653
   Kotov R, 2010, PSYCHOL BULL, V136, P768, DOI 10.1037/a0020327
   Krstacic G, 2007, ANN NONINVAS ELECTRO, V12, P130, DOI 10.1111/j.1542-474X.2007.00151.x
   Kumar N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057824
   Lahey BB, 2009, AM PSYCHOL, V64, P241, DOI 10.1037/a0015309
   Lin IM, 2016, CLIN PSYCHOPHARM NEU, V14, P168, DOI 10.9758/cpn.2016.14.2.168
   Liu I, 2020, TELEMED E-HEALTH, V26, P1483, DOI 10.1089/tmj.2019.0283
   Luoma J, 2011, ADDICT RES THEORY, V19, P3, DOI 10.3109/16066359.2010.524956
   Meyer M, 2018, HEART FAIL REV, V23, P499, DOI 10.1007/s10741-017-9660-1
   Polcin Douglas L, 2017, J Alcohol Drug Educ, V61, P51
   Quintana DS, 2013, ALCOHOL CLIN EXP RES, V37, pE23, DOI 10.1111/j.1530-0277.2012.01913.x
   Rammstedt B, 2007, J RES PERS, V41, P203, DOI 10.1016/j.jrp.2006.02.001
   Rennie KL, 2003, AM J EPIDEMIOL, V158, P135, DOI 10.1093/aje/kwg120
   Ruiz FJ, 2016, PSYCHOL REC, V66, P429, DOI 10.1007/s40732-016-0183-2
   Shanahan MJ, 2014, DEV PSYCHOL, V50, P1407, DOI 10.1037/a0031130
   Smith Mark A, 2011, Front Psychiatry, V2, P82, DOI 10.3389/fpsyt.2011.00082
   Stephan Y, 2019, J PSYCHOSOM RES, V116, P1, DOI 10.1016/j.jpsychores.2018.11.002
   Stewart SH, 2008, SER ANXIETY RELAT DI, P1, DOI 10.1007/978-0-387-74290-8
   World Health Organization, 2010, SOCIAL DETERMINANTS, DOI DOI 10.13016/17CR-AQB9
   Zilberman N, 2018, ADDICT BEHAV, V82, P174, DOI 10.1016/j.addbeh.2018.03.007
NR 38
TC 3
Z9 3
U1 10
U2 14
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-0586
EI 1573-3270
J9 APPL PSYCHOPHYS BIOF
JI Appl. Psychophysiol. Biofeedback
PD JUN
PY 2022
VL 47
IS 2
BP 77
EP 84
DI 10.1007/s10484-021-09531-1
EA DEC 2021
PG 8
WC Psychology, Clinical
WE Social Science Citation Index (SSCI)
SC Psychology
GA 1F1DH
UT WOS:000734696500001
PM 34958443
OA hybrid, Green Published
DA 2023-06-23
ER

PT J
AU Chou, TM
   D'Orsogna, MR
AF Chou, Tom
   D'Orsogna, Maria R.
TI A mathematical model of reward-mediated learning in drug addiction
SO CHAOS
LA English
DT Article
ID DOPAMINE NEURONS; PREDICTION; COCAINE; ERROR; ABUSE; POTENTIATION;
   PERSONALITY; ADAPTATION; MECHANISMS; BEHAVIOR
AB Substances of abuse are known to activate and disrupt neuronal circuits in the brain reward system. We propose a simple and easily interpretable dynamical systems model to describe the neurobiology of drug addiction that incorporates the psychiatric concepts of reward prediction error, drug-induced incentive salience, and opponent process theory. Drug-induced dopamine releases activate a biphasic reward response with pleasurable, positive "a-processes " (euphoria, rush) followed by unpleasant, negative "b-processes " (cravings, withdrawal). Neuroadaptive processes triggered by successive intakes enhance the negative component of the reward response, which the user compensates for by increasing drug dose and/or intake frequency. This positive feedback between physiological changes and drug self-administration leads to habituation, tolerance, and, eventually, to full addiction. Our model gives rise to qualitatively different pathways to addiction that can represent a diverse set of user profiles (genetics, age) and drug potencies. We find that users who have, or neuroadaptively develop, a strong b-process response to drug consumption are most at risk for addiction. Finally, we include possible mechanisms to mitigate withdrawal symptoms, such as through the use of methadone or other auxiliary drugs used in detoxification.
C1 [Chou, Tom] Univ Calif Los Angeles, Dept Computat Med, Los Angeles, CA 90095 USA.
   [D'Orsogna, Maria R.] Calif State Univ Northridge, Dept Math, Los Angeles, CA 91130 USA.
   [Chou, Tom] Univ Calif Los Angeles, Dept Math, Los Angeles, CA 90095 USA.
   [D'Orsogna, Maria R.] Univ Calif Los Angeles, Dept Computat Med, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   California State University System; California State University
   Northridge; University of California System; University of California
   Los Angeles; University of California System; University of California
   Los Angeles
RP D'Orsogna, MR (通讯作者)，Calif State Univ Northridge, Dept Math, Los Angeles, CA 91130 USA.
EM dorsogna@csun.edu
FU Army Research Office [W911NF-18-1-0345]; NIH [R01HL146552]; NSF
   [DMS-1814090]
FX The authors thank Sayun Mao and Xiaoou Cheng for insightful comments.
   This research was supported by the Army Research Office through Grant
   No. W911NF-18-1-0345, the NIH through Grant No. R01HL146552 (T.C.), and
   the NSF through Grant No. DMS-1814090 (M.R.D.).
CR Ahmad F., 2020, PROVISIONAL DRUG OVE
   Berridge KC, 2003, TRENDS NEUROSCI, V26, P507, DOI 10.1016/S0166-2236(03)00233-9
   Berridge KC, 2007, PSYCHOPHARMACOLOGY, V191, P391, DOI 10.1007/s00213-006-0578-x
   Blum K, 2012, J PSYCHOACTIVE DRUGS, V44, P134, DOI 10.1080/02791072.2012.685407
   Cohen JY, 2012, NATURE, V482, P85, DOI 10.1038/nature10754
   Cosgrove KP, 2010, CURR TOP BEHAV NEURO, V3, P199, DOI 10.1007/7854_2009_24
   Counterman ED, 2022, B MATH BIOL, V84, DOI 10.1007/s11538-021-00976-3
   Diana Marco, 2011, Front Psychiatry, V2, P64, DOI 10.3389/fpsyt.2011.00064
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Dong Y, 2004, P NATL ACAD SCI USA, V101, P14282, DOI 10.1073/pnas.0401553101
   Duncan JP, 2019, SIAM J APPL DYN SYST, V18, P881, DOI 10.1137/18M121410X
   Fowler JS, 2008, NEUROIMAGE, V43, P756, DOI 10.1016/j.neuroimage.2008.07.020
   George O, 2017, DIALOGUES CLIN NEURO, V19, P217
   Grasman J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158323
   Graupner M, 2012, SPR SER COMPUT NEURO, V10, P111, DOI 10.1007/978-1-4614-0751-5_4
   GROSSBERG S, 1987, PSYCHOL REV, V94, P300, DOI 10.1037/0033-295X.94.3.300
   Guerri C, 2019, INT J DEV NEUROSCI, V77, P89, DOI 10.1016/j.ijdevneu.2018.11.006
   Gutkin BS, 2006, P NATL ACAD SCI USA, V103, P1106, DOI 10.1073/pnas.0510220103
   Hawkins R. C, 1998, CLIN CHAOS THERAPIST, P89
   HEINRICHS SC, 1995, BEHAV PHARMACOL, V6, P74
   Hollerman JR, 1998, NAT NEUROSCI, V1, P304, DOI 10.1038/1124
   Hu HL, 2016, ANNU REV NEUROSCI, V39, P297, DOI 10.1146/annurev-neuro-070815-014106
   Huys QJM, 2014, PROG BRAIN RES, V211, P31, DOI 10.1016/B978-0-444-63425-2.00003-9
   JACKSON AH, 1973, DIS NERV SYST, V34, P162
   Jones S, 2005, CURR OPIN PHARMACOL, V5, P20, DOI 10.1016/j.coph.2004.08.011
   Kelley AE, 2004, NEUROSCI BIOBEHAV R, V27, P765, DOI 10.1016/j.neubiorev.2003.11.015
   Keramati M, 2014, ELIFE, V3, DOI 10.7554/eLife.04811
   Keramati M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061489
   Koob GF, 2008, PHILOS T R SOC B, V363, P3113, DOI 10.1098/rstb.2008.0094
   Koob GF, 2015, EUR J PHARMACOL, V753, P73, DOI 10.1016/j.ejphar.2014.11.044
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   LI TY, 1975, AM MATH MON, V82, P985, DOI 10.2307/2318254
   Luhmann M., 2018, HDB WELL BEING
   Martinez D, 2010, CURR TOP BEHAV NEURO, V3, P219, DOI 10.1007/7854_2009_34
   McEwen BS, 1998, ANN NY ACAD SCI, V840, P33, DOI 10.1111/j.1749-6632.1998.tb09546.x
   National Institute on Drug Abuse, 2018, TRENDS STAT COSTS SU
   Oyama K, 2010, J NEUROSCI, V30, P11447, DOI 10.1523/JNEUROSCI.1719-10.2010
   Pando-Naude V, 2021, TRANSL PSYCHIAT, V11, DOI 10.1038/s41398-020-01128-2
   Peper A, 2012, SPR SER COMPUT NEURO, V10, P19, DOI 10.1007/978-1-4614-0751-5_2
   Radulescu A, 2017, J THEOR BIOL, V414, P165, DOI 10.1016/j.jtbi.2016.11.025
   Redish AD, 2008, BEHAV BRAIN SCI, V31, P415, DOI 10.1017/S0140525X0800472X
   Redish AD, 2004, SCIENCE, V306, P1944, DOI 10.1126/science.1102384
   Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI 10.1146/annurev.psych.54.101601.145237
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Schultz W, 2006, ANNU REV PSYCHOL, V57, P87, DOI 10.1146/annurev.psych.56.091103.070229
   Schultz W, 2016, DIALOGUES CLIN NEURO, V18, P23
   Seger D, 2010, TOXICOL LETT, V196, pS15, DOI 10.1016/j.toxlet.2010.03.080
   Seger D, 2010, CLIN TOXICOL, V48, P695, DOI 10.3109/15563650.2010.516263
   SELF DW, 1995, ANNU REV NEUROSCI, V18, P463, DOI 10.1146/annurev.ne.18.030195.002335
   Shippenberg TS, 2007, PHARMACOL THERAPEUT, V116, P306, DOI 10.1016/j.pharmthera.2007.06.011
   SKINNER HA, 1989, BRIT J ADDICT, V84, P353
   Sulzer D, 2011, NEURON, V69, P628, DOI 10.1016/j.neuron.2011.02.010
   Sweis BM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04967-2
   Szalavitz M., 2017, UNBROKEN BRAIN REVOL
   Tsibulsky VL, 2012, SPR SER COMPUT NEURO, V10, P3, DOI 10.1007/978-1-4614-0751-5_1
   Turiano NA, 2012, J RES PERS, V46, P295, DOI 10.1016/j.jrp.2012.02.009
   Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077
   Volkow ND, 2009, NEUROPHARMACOLOGY, V56, P3, DOI 10.1016/j.neuropharm.2008.05.022
   Volkow ND, 2011, P NATL ACAD SCI USA, V108, P15037, DOI 10.1073/pnas.1010654108
   Volkow Nora D., 2000, Life Sciences, V67, P1507, DOI 10.1016/S0024-3205(00)00731-1
   Warren K, 2003, ADDICT BEHAV, V28, P369, DOI 10.1016/S0306-4603(01)00234-9
   WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063
   Werner CT, 2019, NEURAL MECHANISMS OF ADDICTION, P137, DOI 10.1016/B978-0-12-812202-0.00010-5
   Widiger TA, 2017, WORLD PSYCHIATRY, V16, P144, DOI 10.1002/wps.20411
   World Health Organization, 2009, CLIN GUID WITHDR MAN
   Zhang J, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000437
NR 66
TC 4
Z9 4
U1 3
U2 3
PU AIP Publishing
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 1054-1500
EI 1089-7682
J9 CHAOS
JI Chaos
PD FEB
PY 2022
VL 32
IS 2
AR 021102
DI 10.1063/5.0082997
PG 12
WC Mathematics, Applied; Physics, Mathematical
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Mathematics; Physics
GA YU1QU
UT WOS:000751824900001
PM 35232044
OA Green Submitted, Green Published
DA 2023-06-23
ER

PT J
AU Milton, AL
   Everitt, BJ
AF Milton, Amy L.
   Everitt, Barry J.
TI The persistence of maladaptive memory: Addiction, drug memories and
   anti-relapse treatments
SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
LA English
DT Review
DE Addiction; Drug; Memory; Reconsolidation; Pavlovian; Instrumental
ID NUCLEUS-ACCUMBENS CORE; COCAINE-SEEKING BEHAVIOR; CONDITIONED PLACE
   PREFERENCE; PAVLOVIAN APPROACH BEHAVIOR; CYCLOSERINE FACILITATES
   EXTINCTION; MK-801 DISRUPTS RECONSOLIDATION; FOOTSHOCK-INDUCED
   REINSTATEMENT; CORTICOTROPIN-RELEASING-FACTOR; DORSOMEDIAL PREFRONTAL
   CORTEX; STRESS-INDUCED REINSTATEMENT
AB Addiction is a chronic, relapsing disorder, characterised by the long-term propensity of addicted individuals to relapse. A major factor that obstructs the attainment of abstinence is the persistence of maladaptive drug-associated memories, which can maintain drug-seeking and taking behaviour and promote unconscious relapse of these habits. Thus, addiction can be conceptualised as a disorder of aberrant learning of the formation of strong instrumental memories linking actions to drug-seeking and taking outcomes that ultimately are expressed as persistent stimulus-response habits; of previously neutral environmental stimuli that become associated with drug highs (and/or withdrawal states) through pavlovian conditioning, and of the subsequent interactions between pavlovian and instrumental memories to influence relapse behaviour. Understanding the psychological, neurobiological and molecular basis of these drug memories may produce new methods of pro-abstinence, anti-relapse treatments for addiction. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Milton, Amy L.; Everitt, Barry J.] Univ Cambridge, Dept Expt Psychol, Behav & Clin Neurosci Inst, Cambridge CB2 3EB, England.
C3 University of Cambridge
RP Milton, AL (通讯作者)，Univ Cambridge, Dept Expt Psychol, Behav & Clin Neurosci Inst, Downing Site, Cambridge CB2 3EB, England.
EM alm46@cam.ac.uk
RI Milton, Amy L/B-6839-2009
OI Milton, Amy L/0000-0003-0175-9417; Everitt, Barry/0000-0003-4431-6536
FU UK Medical Research Council [9536855]; MRC; Wellcome Trust; MRC
   [G1002231] Funding Source: UKRI; Medical Research Council [G1002231]
   Funding Source: researchfish
FX This work was supported by a UK Medical Research Council grant (no.
   9536855) to BJE, and was conducted in the Behavioural and Clinical
   Neuroscience Institute, funded by a joint award from the MRC and the
   Wellcome Trust. Matej Macak and Brian Kelleher provided technical
   assistance in the collection of the data shown in Fig. 2.
CR ADAMS WJ, 1969, J PHARMACOL EXP THER, V168, P251
   Ahmed SH, 2006, NEUROPSYCHOPHARMACOL, V31, P563, DOI 10.1038/sj.npp.1300834
   Alheid GF, 1998, NEUROSCIENCE, V84, P967, DOI 10.1016/S0306-4522(97)00560-5
   ALHEID GF, 1988, NEUROSCIENCE, V27, P1, DOI 10.1016/0306-4522(88)90217-5
   Ana EJS, 2009, DRUG ALCOHOL DEPEN, V104, P220, DOI 10.1016/j.drugalcdep.2009.04.023
   Anagnostaras SG, 2002, NEUROPSYCHOPHARMACOL, V26, P703, DOI 10.1016/S0893-133X(01)00402-X
   Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244
   Arroyo M, 1998, PSYCHOPHARMACOLOGY, V140, P331, DOI 10.1007/s002130050774
   Badiani A, 2000, PSYCHOPHARMACOLOGY, V151, P273, DOI 10.1007/s002130000447
   Badiani A, 1997, J PHARMACOL EXP THER, V282, P787
   BAKER TB, 1985, PSYCHOL REV, V92, P78, DOI 10.1037/0033-295X.92.1.78
   Balleine BW, 2009, BEHAV BRAIN RES, V199, P43, DOI 10.1016/j.bbr.2008.10.034
   Balleine BW, 2006, TRENDS NEUROSCI, V29, P272, DOI 10.1016/j.tins.2006.03.002
   Balleine BW, 1998, NEUROPHARMACOLOGY, V37, P407, DOI 10.1016/S0028-3908(98)00033-1
   Baxter MG, 2000, J NEUROSCI, V20, P4311
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   Belin D, 2008, NEURON, V57, P432, DOI 10.1016/j.neuron.2007.12.019
   Belin D, 2011, NEUROPSYCHOPHARMACOL, V36, P569, DOI 10.1038/npp.2010.188
   Belin D, 2009, BEHAV BRAIN RES, V199, P89, DOI 10.1016/j.bbr.2008.09.027
   Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9
   Bernardi RE, 2007, BEHAV NEUROSCI, V121, P156, DOI 10.1037/0735-7044.121.1.156
   Bernardi RE, 2006, NEUROREPORT, V17, P1443, DOI 10.1097/01.wnr.0000233098.20655.26
   Bernardi RE, 2009, LEARN MEMORY, V16, P777, DOI 10.1101/lm.1648509
   BINDRA D, 1968, PSYCHOL REV, V75, P1, DOI 10.1037/h0025306
   Blundell P, 2001, J NEUROSCI, V21, P9018, DOI 10.1523/JNEUROSCI.21-22-09018.2001
   Bonson KR, 2002, NEUROPSYCHOPHARMACOL, V26, P376, DOI 10.1016/S0893-133X(01)00371-2
   Bossert J.M., 2006, EUR J PHARMACOL, V526, P36
   Bossert JM, 2007, J NEUROSCI, V27, P12655, DOI 10.1523/JNEUROSCI.3926-07.2007
   Bossert JM, 2004, J NEUROSCI, V24, P10726, DOI 10.1523/JNEUROSCI.3207-04.2004
   Boujabit M, 2003, NEUROBIOL LEARN MEM, V79, P57, DOI 10.1016/S1074-7427(02)00010-2
   BOUTON ME, 1979, LEARN MOTIV, V10, P445, DOI 10.1016/0023-9690(79)90057-2
   BOUTON ME, 1991, CLIN PSYCHOL REV, V11, P123, DOI 10.1016/0272-7358(91)90091-8
   Bouton ME, 2002, BIOL PSYCHIAT, V52, P976, DOI 10.1016/S0006-3223(02)01546-9
   Bozon B, 2003, NEURON, V40, P695, DOI 10.1016/S0896-6273(03)00674-3
   Brebner K, 2002, ALCOHOL ALCOHOLISM, V37, P478, DOI 10.1093/alcalc/37.5.478
   BROOKS DC, 1993, J EXP PSYCHOL ANIM B, V19, P77, DOI 10.1037/0097-7403.19.1.77
   BROWN PL, 1968, J EXP ANAL BEHAV, V11, P1, DOI 10.1901/jeab.1968.11-1
   Brown TE, 2008, LEARN MEMORY, V15, P857, DOI 10.1101/lm.1152808
   Budney AJ, 2000, J CONSULT CLIN PSYCH, V68, P1051, DOI 10.1037/0022-006X.68.6.1051
   Burattini C, 2008, INT J NEUROPSYCHOPH, V11, P103, DOI 10.1017/S1461145707007705
   CADOR M, 1989, NEUROSCIENCE, V30, P77, DOI 10.1016/0306-4522(89)90354-0
   CAMP DM, 1988, BEHAV BRAIN RES, V30, P55, DOI 10.1016/0166-4328(88)90008-3
   CARBONI E, 1989, NEUROSCIENCE, V28, P653, DOI 10.1016/0306-4522(89)90012-2
   Cardinal RN, 2002, NEUROSCI BIOBEHAV R, V26, P321, DOI 10.1016/S0149-7634(02)00007-6
   Cardinal RN, 2003, INT CONGR SER, V1250, P347, DOI 10.1016/S0531-5131(03)01013-6
   Carroll KM, 2005, AM J PSYCHIAT, V162, P1452, DOI 10.1176/appi.ajp.162.8.1452
   Cave J., 2006, EC ADDICTION DRUGS
   Chan Wan Yee Macy, 2010, Learn Mem, V17, P512, DOI 10.1101/lm.1912510
   Childress A R, 1984, NIDA Res Monogr, V55, P202
   Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11
   CLARKE PBS, 1983, BRIT J PHARMACOL, V78, P329, DOI 10.1111/j.1476-5381.1983.tb09398.x
   Conklin CA, 2002, ADDICTION, V97, P155, DOI 10.1046/j.1360-0443.2002.00014.x
   Corbit LH, 2003, BEHAV BRAIN RES, V146, P145, DOI 10.1016/j.bbr.2003.09.023
   Corbit LH, 2001, J NEUROSCI, V21, P3251, DOI 10.1523/JNEUROSCI.21-09-03251.2001
   CORRIGALL WA, 1991, PSYCHOPHARMACOLOGY, V104, P167, DOI 10.1007/BF02244173
   Crombag HS, 2002, NEUROPSYCHOPHARMACOL, V27, P1006, DOI 10.1016/S0893-133X(02)00356-1
   Crombag HS, 2002, BEHAV NEUROSCI, V116, P169, DOI 10.1037//0735-7044.116.1.169
   Davis M, 2006, BIOL PSYCHIAT, V60, P369, DOI 10.1016/j.biopsych.2006.03.084
   DAWSON RG, 1969, SCIENCE, V166, P525, DOI 10.1126/science.166.3904.525
   De Vries TJ, 1998, EUR J NEUROSCI, V10, P3565, DOI 10.1046/j.1460-9568.1998.00368.x
   Debiec J, 2006, P NATL ACAD SCI USA, V103, P3428, DOI 10.1073/pnas.0507168103
   DEITRICH RA, 1971, MOL PHARMACOL, V7, P301
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175
   Dhonnchadha BAN, 2011, PHARMACOL BIOCHEM BE, V99, P229, DOI 10.1016/j.pbb.2011.01.018
   Di Chiara G, 1999, ANN NY ACAD SCI, V877, P461
   Di Chiara G, 2002, BEHAV BRAIN RES, V137, P75, DOI 10.1016/S0166-4328(02)00286-3
   Di Ciano P, 2003, NEUROPSYCHOPHARMACOL, V28, P329, DOI 10.1038/sj.npp.1300148
   Di Ciano P, 2004, NEUROPHARMACOLOGY, V47, P202, DOI 10.1016/j.neuropharm.2004.06.005
   Di Ciano P, 2004, J NEUROSCI, V24, P7167, DOI 10.1523/JNEUROSCI.1581-04.2004
   Di Ciano P, 2001, NEUROPSYCHOPHARMACOL, V25, P341, DOI 10.1016/S0893-133X(01)00235-4
   Di Ciano P, 2008, NEUROPSYCHOPHARMACOL, V33, P1413, DOI 10.1038/sj.npp.1301522
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Dickinson A, 2002, Q J EXP PSYCHOL-B, V55, P331, DOI 10.1080/0272499024400016
   DICKINSON A, 1985, PHILOS T ROY SOC B, V308, P67, DOI 10.1098/rstb.1985.0010
   DICKINSON A, 1994, ANIM LEARN BEHAV, V22, P1, DOI 10.3758/BF03199951
   Economidou D, 2011, BIOL PSYCHIAT, V69, P266, DOI 10.1016/j.biopsych.2010.09.040
   Economidou D, 2009, BIOL PSYCHIAT, V65, P851, DOI 10.1016/j.biopsych.2008.12.008
   Erb S, 2000, NEUROPSYCHOPHARMACOL, V23, P138, DOI 10.1016/S0893-133X(99)00158-X
   Erb S, 2001, PSYCHOPHARMACOLOGY, V158, P360, DOI 10.1007/s002130000642
   Estes WK, 1943, J EXP PSYCHOL, V32, P150, DOI 10.1037/h0058316
   Everitt BJ, 2008, PHILOS T R SOC B, V363, P3125, DOI 10.1098/rstb.2008.0089
   Everitt BJ, 2001, BRAIN RES REV, V36, P129, DOI 10.1016/S0165-0173(01)00088-1
   Everitt BJ, 2000, PSYCHOPHARMACOLOGY, V153, P17, DOI 10.1007/s002130000566
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   FERGUSON RK, 1969, EUR J PHARMACOL, V8, P83
   Ferrario CR, 2007, EUR NEUROPSYCHOPHARM, V17, P352, DOI 10.1016/j.euroneuro.2006.08.005
   Foulds J, 2006, DRUG ALCOHOL REV, V25, P59, DOI 10.1080/09595230500459529
   Frenois F, 2005, J NEUROSCI, V25, P1366, DOI 10.1523/JNEUROSCI.3090-04.2005
   Fricks-Gleason AN, 2008, LEARN MEMORY, V15, P643, DOI 10.1101/lm.1054608
   Fuchs RA, 2005, NEUROPSYCHOPHARMACOL, V30, P296, DOI 10.1038/sj.npp.1300579
   Fuchs RA, 2004, PSYCHOPHARMACOLOGY, V176, P459, DOI 10.1007/s00213-004-1895-6
   Fuchs RA, 2002, PSYCHOPHARMACOLOGY, V160, P425, DOI 10.1007/s00213-001-0997-7
   Fuchs RA, 2007, EUR J NEUROSCI, V26, P487, DOI 10.1111/j.1460-9568.2007.05674.x
   Fuchs RA, 2006, EUR J NEUROSCI, V23, P2809, DOI 10.1111/j.1460-9568.2006.04806.x
   Gallagher M, 1999, J NEUROSCI, V19, P6610
   Garavan H, 2000, AM J PSYCHIAT, V157, P1789, DOI 10.1176/appi.ajp.157.11.1789
   Gawin F.H., 1992, EVOLVING CONCEPTUALI, P33
   Gerrits MAFM, 2005, EUR NEUROPSYCHOPHARM, V15, P297, DOI 10.1016/j.euroneuro.2004.11.004
   Glasner SV, 2005, J STUD ALCOHOL, V66, P53, DOI 10.15288/jsa.2005.66.53
   Glautier Steven, 1994, APPETITE NEURAL BEHA, P165
   GOEDERS NE, 1994, PSYCHOPHARMACOLOGY, V114, P63, DOI 10.1007/BF02245445
   GOLD PE, 1972, PHYSIOL BEHAV, V8, P797, DOI 10.1016/0031-9384(72)90286-7
   Goldapple K, 2004, ARCH GEN PSYCHIAT, V61, P34, DOI 10.1001/archpsyc.61.1.34
   GOLDBERG SR, 1967, J EXP ANAL BEHAV, V10, P235, DOI 10.1901/jeab.1967.10-235
   GOLDBERG SR, 1971, J PHARMACOL EXP THER, V179, P268
   Gordon L., 2006, EC SOCIAL COSTS CLAS
   Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040
   Graybiel AM, 1998, NEUROBIOL LEARN MEM, V70, P119, DOI 10.1006/nlme.1998.3843
   Grillner S, 2005, TRENDS NEUROSCI, V28, P364, DOI 10.1016/j.tins.2005.05.004
   Groblewski PA, 2009, ALCOHOL CLIN EXP RES, V33, P772, DOI 10.1111/j.1530-0277.2009.00895.x
   Haber SN, 2000, J NEUROSCI, V20, P2369
   HAKAN RL, 1988, PHARMACOL BIOCHEM BE, V29, P661, DOI 10.1016/0091-3057(88)90184-0
   Hall J, 2001, EUR J NEUROSCI, V13, P1984, DOI 10.1046/j.0953-816x.2001.01577.x
   Hall J, 2001, J NEUROSCI, V21, P2186, DOI 10.1523/JNEUROSCI.21-06-02186.2001
   Hatfield T, 1996, J NEUROSCI, V16, P5256
   Heidbreder CA, 2010, ANN NY ACAD SCI, V1187, P4, DOI 10.1111/j.1749-6632.2009.05149.x
   Heimer L, 1997, J NEUROPSYCH CLIN N, V9, P354
   HEIMER L, 1991, NEUROSCIENCE, V41, P89, DOI 10.1016/0306-4522(91)90202-Y
   Hellemans KGC, 2006, J NEUROSCI, V26, P12694, DOI 10.1523/JNEUROSCI.3101-06.2006
   Hernandez PJ, 2004, LEARN MEMORY, V11, P748, DOI 10.1101/lm.84904
   HIGGINS ST, 1991, AM J PSYCHIAT, V148, P1218
   Hitchcott PK, 1997, PSYCHOPHARMACOLOGY, V131, P187, DOI 10.1007/s002130050283
   Holland PC, 2003, EUR J NEUROSCI, V17, P1680, DOI 10.1046/j.1460-9568.2003.02585.x
   HURD YL, 1989, SYNAPSE, V3, P48, DOI 10.1002/syn.890030107
   Hutcheson DM, 2001, NAT NEUROSCI, V4, P943, DOI 10.1038/nn0901-943
   HYDE TS, 1976, LEARN MOTIV, V7, P223, DOI 10.1016/0023-9690(76)90030-8
   Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Ito R, 2004, NAT NEUROSCI, V7, P389, DOI 10.1038/nn1217
   Ito R, 2006, EUR J NEUROSCI, V23, P3071, DOI 10.1111/j.1460-9568.2006.04883.x
   Itzhak Y, 2007, SYNAPSE, V61, P1002, DOI 10.1002/syn.20446
   Itzhak Y, 2008, ANN NY ACAD SCI, V1139, P350, DOI 10.1196/annals.1432.051
   Ji D, 2008, BEHAV PHARMACOL, V19, P1, DOI 10.1097/FBP.0b013e3282f3cf70
   Jones S, 2005, CURR OPIN PHARMACOL, V5, P20, DOI 10.1016/j.coph.2004.08.011
   Joseph MH, 2003, NEUROSCI BIOBEHAV R, V27, P527, DOI 10.1016/j.neubiorev.2003.09.001
   Kalivas PW, 2004, CURR OPIN PHARMACOL, V4, P23, DOI 10.1016/j.coph.2003.11.002
   Kalivas PW, 2003, ANN NY ACAD SCI, V1003, P169, DOI 10.1196/annals.1300.009
   Kalivas PW, 2003, PSYCHOPHARMACOLOGY, V168, P44, DOI 10.1007/s00213-003-1393-2
   KALIVAS PW, 1990, SYNAPSE, V5, P48, DOI 10.1002/syn.890050104
   Kampman KM, 2006, DRUG ALCOHOL DEPEN, V85, P129, DOI 10.1016/j.drugalcdep.2006.04.002
   Kantak KM, 2002, J NEUROSCI, V22, P1126, DOI 10.1523/JNEUROSCI.22-03-01126.2002
   Kauer JA, 2004, ANNU REV PHYSIOL, V66, P447, DOI 10.1146/annurev.physiol.66.032102.112534
   KAYAN S, 1969, EUR J PHARMACOL, V6, P333, DOI 10.1016/0014-2999(69)90193-9
   Kearns DN, 2007, DRUG ALCOHOL DEPEN, V90, P193, DOI 10.1016/j.drugalcdep.2007.03.006
   Kelley AE, 2005, PHYSIOL BEHAV, V86, P773, DOI 10.1016/j.physbeh.2005.08.066
   Kelley AE, 2002, J NEUROSCI, V22, P3306
   Kenny PJ, 2006, J NEUROSCI, V26, P5894, DOI 10.1523/JNEUROSCI.0740-06.2006
   Killcross S, 1997, NATURE, V388, P377, DOI 10.1038/41097
   Knowlton BJ, 1996, SCIENCE, V273, P1399, DOI 10.1126/science.273.5280.1399
   Koob G., 2008, FUNDAMENTAL NEUROSCI
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Krampe H, 2006, ALCOHOL CLIN EXP RES, V30, P86, DOI 10.1111/j.1530-0277.2006.00013.x
   Kropotov JD, 1999, INT J PSYCHOPHYSIOL, V31, P197, DOI 10.1016/S0167-8760(98)00051-8
   KUCZENSKI R, 1989, J NEUROSCI, V9, P2051
   Ledgerwood L, 2003, BEHAV NEUROSCI, V117, P341, DOI 10.1037/0735-7044.117.2.341
   Ledgerwood L, 2005, BIOL PSYCHIAT, V57, P841, DOI 10.1016/j.biopsych.2005.01.023
   LEDOUX JE, 1986, NEUROSCIENCE, V17, P615, DOI 10.1016/0306-4522(86)90034-5
   Lee JLC, 2006, J NEUROSCI, V26, P5881, DOI 10.1523/JNEUROSCI.0323-06.2006
   Lee JLC, 2005, NEURON, V47, P795, DOI 10.1016/j.neuron.2005.08.007
   Lee JLC, 2004, SCIENCE, V304, P839, DOI 10.1126/science.1095760
   Lee JLC, 2008, NAT NEUROSCI, V11, P1264, DOI 10.1038/nn.2205
   Lee JLC, 2008, LEARN MEMORY, V15, P390, DOI 10.1101/lm.976108
   Lee JLC, 2006, J NEUROSCI, V26, P10051, DOI 10.1523/JNEUROSCI.2466-06.2006
   Lee JLC, 2009, LEARN MEMORY, V16, P82, DOI 10.1101/lm.1186609
   LEWIS DJ, 1979, PSYCHOL BULL, V86, P1054, DOI 10.1037/0033-2909.86.5.1054
   Li XF, 1996, LEARN MEMORY, V3, P229, DOI 10.1101/lm.3.2-3.229
   Lindgren JL, 2003, EUR J NEUROSCI, V17, P160, DOI 10.1046/j.1460-9568.2003.02421.x
   Liu X, 2002, J NEUROSCI, V22, P7856
   LOVIBOND PF, 1983, J EXP PSYCHOL ANIM B, V9, P225, DOI 10.1037/0097-7403.9.3.225
   Lu L, 2005, NAT NEUROSCI, V8, P212, DOI 10.1038/nn1383
   Lubman DI, 2000, PSYCHOL MED, V30, P169, DOI 10.1017/S0033291799001269
   Lucas M, 2008, NEUROSCIENCE, V154, P1021, DOI 10.1016/j.neuroscience.2008.04.006
   Lyvers M, 1998, EXP CLIN PSYCHOPHARM, V6, P107
   Ma DY, 2008, J INT MED RES, V36, P992, DOI 10.1177/147323000803600516
   Mackintosh N.J., 1974, PSYCHOL ANIMAL LEARN, P484
   Maren S, 1996, BEHAV NEUROSCI, V110, P718, DOI 10.1037/0735-7044.110.4.718
   Marinelli M, 1998, PSYCHOPHARMACOLOGY, V139, P281, DOI 10.1007/s002130050717
   Matus-Amat P, 2007, BEHAV NEUROSCI, V121, P721, DOI 10.1037/0735-7044.121.4.721
   MCAULIFFE WE, 1982, INT J ADDICT, V17, P19, DOI 10.3109/10826088209054607
   McCrae F., 2007, DAILY MAIL      0126
   McDonald AJ, 1999, ANN NY ACAD SCI, V877, P309, DOI 10.1111/j.1749-6632.1999.tb09275.x
   McElroy S L, 1989, NIDA Res Monogr, V95, P57
   McFarland K, 2004, J NEUROSCI, V24, P1551, DOI 10.1523/JNEUROSCI.4177-03.2004
   MCGAUGH JL, 1966, SCIENCE, V153, P1351, DOI 10.1126/science.153.3742.1351
   McNamara R, 2010, PSYCHOPHARMACOLOGY, V212, P453, DOI 10.1007/s00213-010-1974-9
   Meil WM, 1997, BEHAV BRAIN RES, V87, P139, DOI 10.1016/S0166-4328(96)02270-X
   MELLO NK, 1990, J PHARMACOL EXP THER, V254, P926
   Meredith GE, 2008, BRAIN STRUCT FUNCT, V213, P17, DOI 10.1007/s00429-008-0175-3
   Milekic MH, 2006, J NEUROSCI, V26, P3010, DOI 10.1523/JNEUROSCI.4818-05.2006
   Miles FJ, 2003, BEHAV NEUROSCI, V117, P927, DOI 10.1037/0735-7044.117.5.927
   Miller CA, 2005, NEURON, V47, P873, DOI 10.1016/j.neuron.2005.08.006
   MILLER DB, 1979, PAVLOVIAN J BIOL SCI, V14, P170
   Milton AL, 2009, EUR NEUROPSYCHOPHARM, V19, pS86, DOI 10.1016/S0924-977X(09)70099-9
   Milton A.L., REACTIVATION D UNPUB
   Milton AL, 2008, J NEUROSCI, V28, P8230, DOI 10.1523/JNEUROSCI.1723-08.2008
   Milton AL, 2008, LEARN MEMORY, V15, P88, DOI 10.1101/lm.825008
   Milton AL, 2012, PSYCHOPHARMACOLOGY, V219, P751, DOI 10.1007/s00213-011-2399-9
   Milton AL, 2010, EUR J NEUROSCI, V31, P2308, DOI 10.1111/j.1460-9568.2010.07249.x
   MINK JW, 1991, J NEUROPHYSIOL, V65, P273, DOI 10.1152/jn.1991.65.2.273
   MISANIN JR, 1968, SCIENCE, V160, P554, DOI 10.1126/science.160.3827.554
   Mishkin M, 1984, NEUROBIOLOGY LEARNIN, P65
   MOGENSON GJ, 1980, PROG NEUROBIOL, V14, P69, DOI 10.1016/0301-0082(80)90018-0
   Molander AC, 2011, PSYCHOPHARMACOLOGY, V215, P721, DOI 10.1007/s00213-011-2167-x
   Monfils MH, 2009, SCIENCE, V324, P951, DOI 10.1126/science.1167975
   Moran MM, 2005, J NEUROSCI, V25, P6389, DOI 10.1523/JNEUROSCI.1007-05.2005
   Morgan D, 2004, NEUROSCI BIOBEHAV R, V27, P803, DOI 10.1016/j.neubiorev.2003.11.004
   MUCHA RF, 1979, PHARMACOL BIOCHEM BE, V10, P397, DOI 10.1016/0091-3057(79)90204-1
   Murray JE, 2011, BEHAV PHARMACOL, V22, pE28
   Nader K, 2003, TRENDS NEUROSCI, V26, P65, DOI 10.1016/S0166-2236(02)00042-5
   Nader K, 2000, NATURE, V406, P722, DOI 10.1038/35021052
   Nelson A, 2006, J NEUROSCI, V26, P3805, DOI 10.1523/JNEUROSCI.4305-05.2006
   Nordquist RE, 2007, EUR NEUROPSYCHOPHARM, V17, P532, DOI 10.1016/j.euroneuro.2006.12.005
   OBRIEN CP, 1976, PAVLOVIAN J BIOL SCI, V11, P195
   OBRIEN CP, 1992, ANN NY ACAD SCI, V654, P400, DOI 10.1111/j.1749-6632.1992.tb25984.x
   OBRIEN CP, 1990, ADDICT BEHAV, V15, P355, DOI 10.1016/0306-4603(90)90045-Y
   Olmstead MC, 2001, BEHAV NEUROSCI, V115, P394, DOI 10.1037/0735-7044.115.2.394
   Packard MG, 1996, NEUROBIOL LEARN MEM, V65, P65, DOI 10.1006/nlme.1996.0007
   Parkinson JA, 2002, BEHAV BRAIN RES, V137, P149, DOI 10.1016/S0166-4328(02)00291-7
   Parkinson JA, 1999, J NEUROSCI, V19, P2401
   Parkinson JA, 2000, BEHAV NEUROSCI, V114, P42, DOI 10.1037/0735-7044.114.1.42
   Pavlov I, 1927, CONDITIONED REFLEXES
   Pelloux Y, 2007, PSYCHOPHARMACOLOGY, V194, P127, DOI 10.1007/s00213-007-0805-0
   PERT A, 1990, NIDA RES MG, V97, P208
   Petry NM, 2004, ADDICTION, V99, P349, DOI 10.1111/j.1360-0443.2003.00642.x
   PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274
   PIAZZA PV, 1990, BRAIN RES, V514, P22, DOI 10.1016/0006-8993(90)90431-A
   Pilla M, 1999, NATURE, V400, P371, DOI 10.1038/43944
   Pitkanen A, 1997, TRENDS NEUROSCI, V20, P517, DOI 10.1016/S0166-2236(97)01125-9
   POST RM, 1981, LIFE SCI, V28, P755, DOI 10.1016/0024-3205(81)90157-0
   Price KL, 2009, AM J DRUG ALCOHOL AB, V35, P434, DOI 10.3109/00952990903384332
   RAMSEY NF, 1993, BRAIN RES, V608, P216, DOI 10.1016/0006-8993(93)91461-Z
   Redish AD, 2008, BEHAV BRAIN SCI, V31, P415, DOI 10.1017/S0140525X0800472X
   Redish AD, 2007, PSYCHOL REV, V114, P784, DOI 10.1037/0033-295X.114.3.784
   REITH MEA, 1986, EUR J PHARMACOL, V130, P65, DOI 10.1016/0014-2999(86)90184-6
   RIZVI TA, 1991, J COMP NEUROL, V303, P121, DOI 10.1002/cne.903030111
   Robbins TW, 1996, CURR OPIN NEUROBIOL, V6, P228, DOI 10.1016/S0959-4388(96)80077-8
   ROBINS LN, 1974, AM J EPIDEMIOL, V99, P235, DOI 10.1093/oxfordjournals.aje.a121608
   Robinson MJF, 2007, BEHAV BRAIN RES, V182, P129, DOI 10.1016/j.bbr.2007.05.023
   Robinson MJF, 2007, BEHAV BRAIN RES, V178, P146, DOI 10.1016/j.bbr.2006.12.013
   Robinson MJF, 2010, BEHAV BRAIN RES, V213, P201, DOI 10.1016/j.bbr.2010.04.056
   Robinson TE, 2000, ADDICTION, V95, pS91
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Rosner S, 2008, J PSYCHOPHARMACOL, V22, P11, DOI 10.1177/0269881107078308
   Sadler R, 2007, BEHAV PHARMACOL, V18, P699, DOI 10.1097/FBP.0b013e3282effb81
   Sanchez H, 2010, J NEUROSCI, V30, P4401, DOI 10.1523/JNEUROSCI.3149-09.2010
   Sanchis-Segura C, 2006, ADDICT BIOL, V11, P2, DOI 10.1111/j.1369-1600.2006.00012.x
   Schiffer WK, 2009, J NEUROSCI, V29, P6176, DOI 10.1523/JNEUROSCI.5221-08.2009
   Schiller D, 2010, NATURE, V463, P49, DOI 10.1038/nature08637
   SCHNEIDER AM, 1968, SCIENCE, V159, P219, DOI 10.1126/science.159.3811.219
   SCHNUR P, 1992, PSYCHOPHARMACOLOGY, V107, P517, DOI 10.1007/BF02245265
   Schoenbaum G, 1998, NAT NEUROSCI, V1, P155, DOI 10.1038/407
   Schoenbaum G, 2010, CURR OPIN NEUROBIOL, V20, P205, DOI 10.1016/j.conb.2010.01.009
   Schramm M.J.W., BETA ADRENERGI UNPUB
   Schulteis G, 2000, NATURE, V405, P1013, DOI 10.1038/35016630
   Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593
   SELDEN NRW, 1991, NEUROSCIENCE, V42, P335, DOI 10.1016/0306-4522(91)90379-3
   Setlow B, 2002, EUR J NEUROSCI, V15, P1841, DOI 10.1046/j.1460-9568.2002.02010.x
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   SHIPPENBERG TS, 1995, J PHARMACOL EXP THER, V273, P808
   SIEGEL S, 1975, J COMP PHYSIOL PSYCH, V89, P498, DOI 10.1037/h0077058
   SIEGEL S, 1977, J EXP PSYCHOL ANIM B, V3, P1, DOI 10.1037/0097-7403.3.1.1
   Silverman K, 1996, DRUG ALCOHOL DEPEN, V41, P157, DOI 10.1016/0376-8716(96)01246-X
   Simms JA, 2008, ALCOHOL CLIN EXP RES, V32, P1816, DOI 10.1111/j.1530-0277.2008.00753.x
   Sinha R, 2000, PSYCHOPHARMACOLOGY, V152, P140, DOI 10.1007/s002130000499
   Skinner BF, 1938, BEHAV ORGANISMS
   SOLOMON RL, 1974, PSYCHOL REV, V81, P119, DOI 10.1037/h0036128
   STEWART J, 1984, PSYCHOL REV, V91, P251, DOI 10.1037/0033-295X.91.2.251
   STOLERMAN IP, 1973, PSYCHOPHARMACOLOGIA, V30, P329, DOI 10.1007/BF00429192
   Streatfeild D., 2007, COCAINE DEFINITIVE H
   Thanos PK, 2009, BEHAV BRAIN RES, V199, P345, DOI 10.1016/j.bbr.2008.12.025
   Theberge FRM, 2010, LEARN MEMORY, V17, P444, DOI 10.1101/lm.1757410
   Thomas KL, 2003, EUR J NEUROSCI, V17, P1964, DOI 10.1046/j.1460-9568.2003.02617.x
   Thomas KL, 2002, EUR J NEUROSCI, V16, P1789, DOI 10.1046/j.1460-9568.2002.02247.x
   Thomas KL, 2001, J NEUROSCI, V21, P2526, DOI 10.1523/JNEUROSCI.21-07-02526.2001
   Thorndike Edward L., 1911, INDIVIDUALITY
   TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147
   Tomie A, 1996, NEUROSCI BIOBEHAV R, V20, P505, DOI 10.1016/0149-7634(95)00023-2
   Torregrossa MM, 2010, J NEUROSCI, V30, P10526, DOI 10.1523/JNEUROSCI.2523-10.2010
   Tronson NC, 2007, NAT REV NEUROSCI, V8, P262, DOI 10.1038/nrn2090
   TRUJILLO KA, 1991, SCIENCE, V251, P85, DOI 10.1126/science.1824728
   TURNER BH, 1991, J COMP NEUROL, V313, P295, DOI 10.1002/cne.903130208
   Tyacke RJ, 2010, ADV PHARMACOL, V58, P373, DOI 10.1016/S1054-3589(10)58014-1
   Valjent E, 2006, P NATL ACAD SCI USA, V103, P2932, DOI 10.1073/pnas.0511030103
   van Dongen YC, 2005, NEUROSCIENCE, V136, P1049, DOI 10.1016/j.neuroscience.2005.08.050
   Vanderschuren LJMJ, 2005, EUR J PHARMACOL, V526, P77, DOI 10.1016/j.ejphar.2005.09.037
   Vanderschuren LJMJ, 2005, J NEUROSCI, V25, P8665, DOI 10.1523/JNEUROSCI.0925-05.2005
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Veeneman MMJ, 2012, NEUROPSYCHOPHARMACOL, V37, P487, DOI 10.1038/npp.2011.209
   Vengeliene V, 2008, ALCOHOL ALCOHOLISM, V43, P626, DOI 10.1093/alcalc/agn067
   Vezina P, 2009, NEUROPHARMACOLOGY, V56, P160, DOI 10.1016/j.neuropharm.2008.06.070
   VOLKOW ND, 1991, AM J PSYCHIAT, V148, P621
   von der Goltz C, 2009, PSYCHOPHARMACOLOGY, V205, P389, DOI 10.1007/s00213-009-1544-1
   Walker DL, 2002, J NEUROSCI, V22, P2343, DOI 10.1523/JNEUROSCI.22-06-02343.2002
   Wang SH, 2005, J NEUROSCI, V25, P830, DOI 10.1523/JNEUROSCI.4716-04.2005
   Whitelaw RB, 1996, PSYCHOPHARMACOLOGY, V127, P213, DOI 10.1007/BF02805996
   WIKLER A, 1967, PSYCHOPHARMACOLOGIA, V10, P255, DOI 10.1007/BF00401386
   WIKLER A, 1948, AM J PSYCHIAT, V105, P329, DOI 10.1176/ajp.105.5.329
   WISE RA, 1993, BEHAV PHARMACOL, V4, P339
   Wise RA, 2002, NEURON, V36, P229, DOI 10.1016/S0896-6273(02)00965-0
   Wouda JA, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00179
   Yamada H, 2011, NEUROPHARMACOLOGY, V60, P303, DOI 10.1016/j.neuropharm.2010.09.013
   Yim AJ, 2006, BEHAV BRAIN RES, V171, P162, DOI 10.1016/j.bbr.2006.03.031
   Yin HH, 2006, BEHAV BRAIN RES, V166, P189, DOI 10.1016/j.bbr.2005.07.012
   Yin HH, 2005, EUR J NEUROSCI, V22, P513, DOI 10.1111/j.1460-9568.2005.04218.x
   Yin HH, 2004, EUR J NEUROSCI, V19, P181, DOI 10.1111/j.1460-9568.2004.03095.x
   Yun IA, 2003, NEUROSCIENCE, V121, P747, DOI 10.1016/S0306-4522(03)00531-1
   ZAHM DS, 1992, NEUROSCIENCE, V50, P751, DOI 10.1016/0306-4522(92)90202-D
   Zahm DS, 1999, ANN NY ACAD SCI, V877, P113, DOI 10.1111/j.1749-6632.1999.tb09264.x
   Zapata A, 2010, J NEUROSCI, V30, P15457, DOI 10.1523/JNEUROSCI.4072-10.2010
   Zhai HF, 2008, BEHAV PHARMACOL, V19, P211, DOI 10.1097/FBP.0b013e3282fe88a0
NR 311
TC 169
Z9 175
U1 1
U2 68
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0149-7634
EI 1873-7528
J9 NEUROSCI BIOBEHAV R
JI Neurosci. Biobehav. Rev.
PD APR
PY 2012
VL 36
IS 4
BP 1119
EP 1139
DI 10.1016/j.neubiorev.2012.01.002
PG 21
WC Behavioral Sciences; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Behavioral Sciences; Neurosciences & Neurology
GA 928GJ
UT WOS:000302970900003
PM 22285426
OA Green Submitted
DA 2023-06-23
ER

PT J
AU Chiappetta, S
   Stier, C
   Hadid, MA
   Malo, N
   Theodoridou, S
   Weiner, R
   Weiner, S
AF Chiappetta, Sonja
   Stier, Christine
   Hadid, Mohamed Ajan
   Malo, Nina
   Theodoridou, Sophia
   Weiner, Rudolf
   Weiner, Sylvia
TI Remission of Food Addiction Does Not Induce Cross-Addiction after Sleeve
   Gastrectomy and Gastric Bypass: A Prospective Cohort Study
SO OBESITY FACTS
LA English
DT Article
DE Addiction; Sleeve gastrectomy; Gastric bypass; Food addiction;
   Cross-addiction; Addiction remission; Addiction transfer; Food; Alcohol;
   Nicotine; Exercise; Sport; Drug
ID ALCOHOL-USE DISORDERS; BARIATRIC SURGERY; SUBSTANCE USE; PREVALENCE;
   ASSOCIATION; CANDIDATES; CRAVINGS
AB Background:The hypothesis of "cross-addiction" has never been validated, and numerous aspects speak against it.Objectives:To compare the differences between sleeve gastrectomy (SG) and gastric bypass (GB) procedures concerning cross-addiction.Setting:Center for maximum care in Germany.Methods:We performed a prospective analysis of patients undergoing SG or GB as the first surgical treatment for severe obesity. All patients completed validated questionnaires to evaluate food intake (Yale Food Addiction Scale, YFAS), alcohol intake (Alcohol Use Disorders Identification Test), nicotine use (Fagerstrom Test for Nicotine Dependence), exercise (Exercise Addiction Inventory), drug addiction (20-item Drug Abuse Screening Test), and Internet use disorder (Internet Addiction Test) before the operation (T0) and 6 (T6) and 24 (T24) months postoperatively (ClinicalTrials.gov identifier: NCT02757716).Results:One hundred thirteen patients underwent SG (n= 68) or GB (n= 45). At the follow-up, 61% completed the questionnaires at T6 and 44% at T24. In the YFAS, the percentage of patients diagnosed with food addiction decreased from 69 to 10%, and the mean symptom count decreased from 3.52 +/- 1.95 to 1.26 +/- 0.99 at T24 (p< 0.0001); these values did not differ between the surgical groups (p= 0.784). No significant evidence of cross-addiction was observed for use of alcohol, nicotine, drugs, the Internet, or exercise in either surgical group. The percentage of patients with moderate nicotine dependence increased in the SG group (+8.9%) at T24, but this was not significant.Conclusion:In this single-center cohort study, surgery for obesity caused significant addiction remission regarding food but without inducing cross-addiction after 2 years. Importantly, no significant differences were seen between the SG and GB procedures.
C1 [Chiappetta, Sonja] Osped Evangel Betania, Dept Obes & Metab Surg, Via Argine 604, IT-80147 Naples, Italy.
   [Chiappetta, Sonja; Stier, Christine; Hadid, Mohamed Ajan; Malo, Nina; Theodoridou, Sophia; Weiner, Rudolf; Weiner, Sylvia] Sana Klinikum Offenbach, Dept Obes & Metab Surg, Offenbach, Germany.
   [Stier, Christine] Sana Kliniken Germany, Obes Ctr NRW, Hurth, Germany.
   [Weiner, Sylvia] Krankenhaus NW Frankfurt, Dept Obes & Metab Surg, Frankfurt, Germany.
C3 Sana Klinikum Offenbach; Krankenhaus Nordwest
RP Chiappetta, S (通讯作者)，Osped Evangel Betania, Dept Obes & Metab Surg, Via Argine 604, IT-80147 Naples, Italy.
EM drschiappetta@gmail.com
RI Chiappetta, Sonja/ABE-3340-2020
OI Chiappetta, Sonja/0000-0002-1964-416X; Stier,
   Christine/0000-0002-7508-7775
CR Beard E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209442
   Bianciardi E, 2019, RIV PSICHIATR, V54, P127, DOI 10.1708/3181.31602
   Brath H, 2019, WIEN KLIN WOCHENSCHR, V131, P67, DOI 10.1007/s00508-019-1455-z
   Chao AM, 2017, COMPR PSYCHIAT, V73, P97, DOI 10.1016/j.comppsych.2016.11.009
   Chiappetta S, 2016, SURG OBES RELAT DIS, V12, P1847, DOI 10.1016/j.soard.2016.02.042
   Cushing CC, 2015, SURG OBES RELAT DIS, V11, P14, DOI 10.1016/j.soard.2014.05.035
   Emous M, 2018, SURG OBES RELAT DIS, V14, P1173, DOI 10.1016/j.soard.2018.04.011
   Griffiths MD, 2005, BRIT J SPORT MED, V39, DOI 10.1136/bjsm.2004.017020
   Ivezaj V, 2017, OBES REV, V18, P1386, DOI 10.1111/obr.12600
   Ivezaj V, 2019, CURR PSYCHIAT REP, V21, DOI 10.1007/s11920-019-1070-8
   Ivezaj V, 2017, SURG OBES RELAT DIS, V13, P392, DOI 10.1016/j.soard.2016.09.028
   Jakobsen GS, 2018, JAMA-J AM MED ASSOC, V319, P291, DOI 10.1001/jama.2017.21055
   Jelenchick LA, 2012, PSYCHIAT RES, V196, P296, DOI 10.1016/j.psychres.2011.09.007
   Jeynes KD, 2017, DRUG ALCOHOL DEPEN, V179, P229, DOI 10.1016/j.drugalcdep.2017.07.006
   King WC, 2017, SURG OBES RELAT DIS, V13, P1392, DOI 10.1016/j.soard.2017.03.021
   King WC, 2012, JAMA-J AM MED ASSOC, V307, P2516, DOI 10.1001/jama.2012.6147
   Li GM, 2019, ADDICT BEHAV, V90, P421, DOI 10.1016/j.addbeh.2018.12.009
   Meule A, 2012, EUR EAT DISORD REV, V20, P419, DOI 10.1002/erv.2189
   Muller A, 2018, EUR EAT DISORD REV, V26, P585, DOI 10.1002/erv.2629
   Murray SM, 2019, OBES SURG, V29, P2700, DOI 10.1007/s11695-019-03915-3
   Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578
   Pepino MY, 2014, OBESITY, V22, P1792, DOI 10.1002/oby.20797
   Rios-Bedoya CF, 2008, ADDICT BEHAV, V33, P1086, DOI 10.1016/j.addbeh.2008.04.005
   SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x
   Scheffel O, 2011, OBESITY FACTS, V4, P39, DOI 10.1159/000327340
   Sengor G, 2019, EAT WEIGHT DISORD-ST, V24, P1031, DOI 10.1007/s40519-019-00662-3
   Sevincer GM, 2016, PSYCHIAT RES, V244, P159, DOI 10.1016/j.psychres.2016.07.022
   Shimane Takuya, 2015, Nihon Arukoru Yakubutsu Igakkai Zasshi, V50, P310
   Sinclair P, 2018, NAT REV GASTRO HEPAT, V15, P606, DOI 10.1038/s41575-018-0057-y
   Steptoe A, 2019, BRAIN BEHAV IMMUN, V77, P16, DOI 10.1016/j.bbi.2018.11.019
   Strong DR, 2015, NICOTINE TOB RES, V17, P855, DOI 10.1093/ntr/ntu256
   Sudan R, 2017, SURG OBES RELAT DIS, V13, P220, DOI 10.1016/j.soard.2016.09.001
   Svane MS, 2019, GASTROENTEROLOGY, V156, P1627, DOI 10.1053/j.gastro.2019.01.262
   Testino G, 2018, OBES SURG, V28, P3304, DOI 10.1007/s11695-018-3424-4
   Torres-Fuentes C, 2017, LANCET GASTROENTEROL, V2, P747, DOI 10.1016/S2468-1253(17)30147-4
   Volkow ND, 2013, BIOL PSYCHIAT, V73, P811, DOI 10.1016/j.biopsych.2012.12.020
NR 36
TC 6
Z9 6
U1 1
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1662-4025
EI 1662-4033
J9 OBESITY FACTS
JI Obes. Facts
PD JUL
PY 2020
VL 13
IS 3
BP 307
EP 320
DI 10.1159/000506838
PG 14
WC Endocrinology & Metabolism; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA MK3LD
UT WOS:000548684000002
PM 32369811
OA gold, Green Published
DA 2023-06-23
ER

PT J
AU Gass, JT
   Olive, MF
AF Gass, Justin T.
   Olive, M. Foster
TI Glutamatergic substrates of drug addiction and alcoholism
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Review
DE drug addiction; alcoholism; glutamate; synaptic plasticity;
   pharmacotherapeutics; relapse
ID METHYL-D-ASPARTATE; VENTRAL TEGMENTAL AREA; CONDITIONED PLACE
   PREFERENCE; LONG-TERM POTENTIATION; CHRONIC ETHANOL TREATMENT;
   MESSENGER-RNA EXPRESSION; NMDA-RECEPTOR ANTAGONIST; EXCITATORY
   SYNAPTIC-TRANSMISSION; LOCUS-COERULEUS NEURONS; COCAINE-SEEKING BEHAVIOR
AB The past two decades have witnessed a dramatic accumulation of evidence indicating that the excitatory amino acid glutamate plays an important role in drug addiction and alcoholism. The purpose of this review is to summarize findings on glutamatergic substrates of addiction, surveying data from both human and animal studies. The effects of various drugs of abuse on glutamatergic neurotransmission are discussed, as are the effects of pharmacological or genetic manipulation of various components of glutamate transmission on drug reinforcement, conditioned reward, extinction, and relapse-like behavior. In addition, glutamatergic agents that are currently in use or are undergoing testing in clinical trials for the treatment of addiction are discussed, including acamprosate, N-acetylcysteine, modafinil, topiramate, lamotrigine, gabapentin and memantine. All drugs of abuse appear to modulate glutamatergic transmission, albeit by different mechanisms, and this modulation of glutamate transmission is believed to result in long-lasting neuroplastic changes in the brain that may contribute to the perseveration of drug-seeking behavior and drug-associated memories. In general, attenuation of glutamatergic transmission reduces drug reward, reinforcement, and relapse-like behavior. On the other hand, potentiation of glutamatergic transmission appears to facilitate the extinction of drug-seeking behavior. However, attempts at identifying genetic polymorphisms in components of glutamate transmission in humans have yielded only a limited number of candidate genes that may serve as risk factors for the development of addiction. Nonetheless, manipulation of glutamatergic neurotransmission appears to be a promising avenue of research in developing improved therapeutic agents for the treatment of drug addiction and alcoholism. (C) 2007 Elsevier Inc. All rights reserved.
C1 [Gass, Justin T.; Olive, M. Foster] Med Univ S Carolina, Dept Psychiat & Behav Sci, Ctr Drug & Alcohol Programs, Charleston, SC 29425 USA.
C3 Medical University of South Carolina
RP Olive, MF (通讯作者)，Med Univ S Carolina, Dept Psychiat & Behav Sci, Ctr Drug & Alcohol Programs, 67 President St,POB 250861, Charleston, SC 29425 USA.
EM olive@musc.edu
OI Olive, Foster/0000-0002-2517-0351
CR ABEKAWA T, 1994, BRAIN RES, V643, P276, DOI 10.1016/0006-8993(94)90033-7
   Adewale AS, 2006, J PHARMACOL EXP THER, V318, P922, DOI 10.1124/jpet.106.105387
   Adriani W, 2004, NEUROPSYCHOPHARMACOL, V29, P869, DOI 10.1038/sj.npp.1300366
   AGHAJANIAN GK, 1994, BRAIN RES, V636, P126, DOI 10.1016/0006-8993(94)90186-4
   AHERN KV, 1994, NEUROSCI LETT, V165, P211
   Ahmad S, 2004, BRAIN RES, V1029, P41, DOI 10.1016/j.brainres.2004.09.016
   AKAOKA H, 1991, J NEUROSCI, V11, P3830
   Akhondzadeh S, 2005, FUND CLIN PHARMACOL, V19, P601, DOI 10.1111/j.1472-8206.2005.00355.x
   Akinshola BE, 2003, ALCOHOL CLIN EXP RES, V27, P1876, DOI 10.1097/01.ALC.0000098874.65490.52
   Akinshola BE, 2001, BRIT J PHARMACOL, V133, P651, DOI 10.1038/sj.bjp.0704112
   al Qatari M, 1998, ALCOHOL CLIN EXP RES, V22, P810, DOI 10.1097/00000374-199806000-00006
   Allgaier C, 2000, N-S ARCH PHARMACOL, V362, P440, DOI 10.1007/s002100000285
   Allgaier C, 1999, BRIT J PHARMACOL, V126, P121, DOI 10.1038/sj.bjp.0702284
   Anders DL, 1999, J NEUROCHEM, V72, P1389, DOI 10.1046/j.1471-4159.1999.721389.x
   Anderson CE, 2003, AM FAM PHYSICIAN, V68, P869
   Anderson N, 2003, J FAM PRACTICE, V52, P682
   Anderzhanova E, 2001, EUR J PHARMACOL, V428, P87, DOI 10.1016/S0014-2999(01)01285-7
   Anton RF, 2006, JAMA-J AM MED ASSOC, V295, P2003, DOI 10.1001/jama.295.17.2003
   Aoki T, 2004, EUR J NEUROSCI, V20, P1633, DOI 10.1111/j.1460-9568.2004.03609.x
   Aramakis VB, 1998, J NEUROSCI, V18, P8485
   Arias AJ, 2007, ADDICT DISORD TREAT, V6, P77, DOI 10.1097/01.adt.0000210724.41187.4a
   Ariwodola OJ, 2003, ALCOHOL CLIN EXP RES, V27, P1632, DOI 10.1097/01.ALC.0000089956.43262.17
   Armstrong V, 2004, EUR J PHARMACOL, V488, P111, DOI 10.1016/j.ejphar.2004.02.001
   Auclair N, 2000, J NEUROPHYSIOL, V83, P3287, DOI 10.1152/jn.2000.83.6.3287
   Azad SC, 2003, LEARN MEMORY, V10, P116, DOI 10.1101/lm.53303
   Bachteler D, 2005, NEUROPSYCHOPHARMACOL, V30, P1104, DOI 10.1038/sj.npp.1300657
   Backes E, 2003, J PHARMACOL EXP THER, V307, P450, DOI 10.1124/jpet.103.054965
   Backstrom P, 2005, EUR J PHARMACOL, V528, P110, DOI 10.1016/j.ejphar.2005.10.051
   Backstrom P, 2004, ALCOHOL CLIN EXP RES, V28, P558, DOI 10.1097/01.ALC.0000122101.13164.21
   Backstrom P, 2004, NEUROPSYCHOPHARMACOL, V29, P921, DOI 10.1038/sj.npp.1300381
   Backstrom P, 2006, NEUROPSYCHOPHARMACOL, V31, P778, DOI 10.1038/sj.npp.1300845
   Backstrom P, 2007, PSYCHOPHARMACOLOGY, V192, P571, DOI 10.1007/s00213-007-0753-8
   Badiani A, 2000, PSYCHOPHARMACOLOGY, V151, P166, DOI 10.1007/s002139900359
   Bailey CP, 1998, BRIT J PHARMACOL, V123, P215, DOI 10.1038/sj.bjp.0701596
   Baker DA, 2002, AMINO ACIDS, V23, P161, DOI 10.1007/s00726-001-0122-6
   Baker DA, 2002, J NEUROSCI, V22, P9134
   Baker DA, 2003, NAT NEUROSCI, V6, P743, DOI 10.1038/nn1069
   Bale AS, 2005, NEUROSCIENCE, V130, P197, DOI 10.1016/j.neuroscience.2004.08.040
   Ballon JS, 2006, J CLIN PSYCHIAT, V67, P554, DOI 10.4088/JCP.v67n0406
   Balster RL, 1998, DRUG ALCOHOL DEPEN, V51, P207, DOI 10.1016/S0376-8716(98)00078-7
   BALSTER RL, 1992, EUR J PHARMACOL, V222, P39, DOI 10.1016/0014-2999(92)90460-L
   Bao XD, 2001, NEUROSCI LETT, V315, P5, DOI 10.1016/S0304-3940(01)02317-5
   Baptista MAS, 2004, J NEUROSCI, V24, P4723, DOI 10.1523/JNEUROSCI.0176-04.2004
   Barazangi N, 2001, J NEUROPHYSIOL, V86, P463, DOI 10.1152/jn.2001.86.1.463
   Bardo MT, 2000, PSYCHOPHARMACOLOGY, V153, P31, DOI 10.1007/s002130000569
   Bardo MT, 2001, NEUROSCI LETT, V302, P133, DOI 10.1016/S0304-3940(01)01681-0
   Barron Susan, 2005, Alcohol Clin Exp Res, V29, P1720, DOI 10.1097/01.alc.0000179220.79356.e5
   Baum SS, 2006, ALCOHOL CLIN EXP RES, V30, P1414, DOI 10.1111/j.1530-0277.2006.00169.x
   Becker H. C., 1999, CNS SPECTRUMS, V4, P38
   Beleslin DB, 1997, ALCOHOL, V14, P167, DOI 10.1016/S0741-8329(96)00140-1
   Bell K, 2000, NEUROPSYCHOPHARMACOL, V23, P335, DOI 10.1016/S0893-133X(00)00100-7
   Bellone C, 2006, NAT NEUROSCI, V9, P636, DOI 10.1038/nn1682
   Berger SP, 2005, ADDICTION, V100, P58, DOI 10.1111/j.1360-0443.2005.00983.x
   Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9
   Berton F, 1998, ALCOHOL CLIN EXP RES, V22, P183, DOI 10.1097/00000374-199802000-00025
   Besheer J, 2006, EUR J PHARMACOL, V551, P71, DOI 10.1016/j.ejphar.2006.08.071
   Bespalov AY, 1998, PHARMACOL BIOCHEM BE, V60, P507, DOI 10.1016/S0091-3057(98)00006-9
   Bespalov AY, 2005, NEUROPHARMACOLOGY, V49, P167, DOI 10.1016/j.neuropharm.2005.06.007
   BHARGAVA HN, 1995, GEN PHARMACOL, V26, P131, DOI 10.1016/0306-3623(94)00147-F
   Biala G, 1999, ALCOHOL ALCOHOLISM, V34, P175, DOI 10.1093/alcalc/34.2.175
   Bienkowski P, 1999, ALCOHOL, V18, P131, DOI 10.1016/S0741-8329(98)00075-5
   Bienkowski P, 1997, PHARMACOL BIOCHEM BE, V58, P1159, DOI 10.1016/S0091-3057(97)00317-1
   Bienkowski P, 2001, EUR J PHARMACOL, V413, P81, DOI 10.1016/S0014-2999(01)00743-9
   Bienkowski P, 1998, PHARMACOL BIOCHEM BE, V60, P61, DOI 10.1016/S0091-3057(97)00469-3
   Bienkowski P, 1996, EUR J PHARMACOL, V314, P277, DOI 10.1016/S0014-2999(96)00658-9
   BIOULAC B, 1975, CAN J PHYSIOL PHARM, V53, P683, DOI 10.1139/y75-096
   Bisaga A, 2006, DRUG ALCOHOL DEPEN, V81, P267, DOI 10.1016/j.drugalcdep.2005.07.009
   Bisaga A, 2004, PSYCHOPHARMACOLOGY, V172, P16, DOI 10.1007/s00213-003-1617-5
   Bisaga A, 2001, PSYCHOPHARMACOLOGY, V157, P1, DOI 10.1007/s002130100739
   Bisaga A, 2006, DRUG ALCOHOL DEPEN, V83, P25, DOI 10.1016/j.drugalcdep.2005.10.008
   Bjorklund A, 2007, TRENDS NEUROSCI, V30, P194, DOI 10.1016/j.tins.2007.03.006
   BJORNAES S, 1988, TOXICOLOGY, V49, P367, DOI 10.1016/0300-483X(88)90020-0
   BLAGOEVA P, 1972, PHYSIOL BEHAV, V9, P307, DOI 10.1016/0031-9384(72)90150-3
   Blednov YA, 2004, ALCOHOL, V34, P251, DOI 10.1016/j.alcohol.2004.10.003
   Blevins T, 1995, NEUROSCI LETT, V200, P214, DOI 10.1016/0304-3940(95)12086-J
   BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0
   BLITZER RD, 1990, BRAIN RES, V537, P203, DOI 10.1016/0006-8993(90)90359-J
   Blokhina EA, 2005, EUR NEUROPSYCHOPHARM, V15, P219, DOI 10.1016/j.euroneuro.2004.07.005
   Boehm SL, 2003, ALCOHOL CLIN EXP RES, V27, P1033, DOI 10.1097/01.ALC.0000075822.80583.71
   Bogen IL, 2003, NEUROCHEM INT, V43, P393, DOI 10.1016/S0197-0186(03)00027-5
   BOISMARE F, 1984, PHARMACOL BIOCHEM BE, V21, P787, DOI 10.1016/S0091-3057(84)80020-9
   Bonci A, 2003, TRENDS PHARMACOL SCI, V24, P172, DOI 10.1016/S0165-6147(03)00068-3
   Bonnet U, 1999, PHARMACOPSYCHIATRY, V32, P107, DOI 10.1055/s-2007-979203
   Bontempi B, 1997, J NEUROSCI, V17, P8596
   Boothby LA, 2005, CLIN THER, V27, P695, DOI 10.1016/j.clinthera.2005.06.015
   Bossert JM, 2006, NEUROPSYCHOPHARMACOL, V31, P2197, DOI 10.1038/sj.npp.1300977
   Bossert JM, 2005, NEUROREPORT, V16, P1013, DOI 10.1097/00001756-200506210-00026
   Bossert JM, 2004, J NEUROSCI, V24, P10726, DOI 10.1523/JNEUROSCI.3207-04.2004
   Botreau F, 2006, BEHAV BRAIN RES, V172, P173, DOI 10.1016/j.bbr.2006.05.012
   Boudreau AC, 2005, J NEUROSCI, V25, P9144, DOI 10.1523/JNEUROSCI.2252-05.2005
   BOUTON ME, 1991, CLIN PSYCHOL REV, V11, P123, DOI 10.1016/0272-7358(91)90091-8
   Bouton ME, 2004, LEARN MEMORY, V11, P485, DOI 10.1101/lm.78804
   Bouton ME, 2002, BIOL PSYCHIAT, V52, P976, DOI 10.1016/S0006-3223(02)01546-9
   Bowers MS, 2004, NEURON, V42, P269, DOI 10.1016/S0896-6273(04)00159-X
   BOWERS MS, IN PRESS PSYCHOPHARM
   Boyce-Rustay JM, 2006, PSYCHOPHARMACOLOGY, V187, P455, DOI 10.1007/s00213-006-0448-6
   Boyce-Rustay JM, 2005, SYNAPSE, V56, P222, DOI 10.1002/syn.20143
   Boyce-Rustay JM, 2004, BEHAV NEUROSCI, V118, P822, DOI 10.1037/0735-7044.118.4.822
   Bozikas V, 2002, PROG NEURO-PSYCHOPH, V26, P197, DOI 10.1016/S0278-5846(01)00234-2
   Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0
   Bredt DS, 2003, NEURON, V40, P361, DOI 10.1016/S0896-6273(03)00640-8
   Breivogel CS, 2004, NEUROPHARMACOLOGY, V47, P81, DOI 10.1016/j.neuropharm.2004.02.017
   Broadbent J, 2003, PSYCHOPHARMACOLOGY, V167, P225, DOI 10.1007/s00213-003-1404-3
   Broadbent J, 1999, ALCOHOL ALCOHOLISM, V34, P283, DOI 10.1093/alcalc/34.3.283
   Brouette T, 2001, AM J ADDICTION, V10, P79
   Brown ES, 2006, J AFFECT DISORDERS, V93, P219, DOI 10.1016/j.jad.2006.02.001
   Brown ES, 2003, J CLIN PSYCHIAT, V64, P197, DOI 10.4088/JCP.v64n0213
   Brown TM, 2003, J NEUROSCI, V23, P11073
   Bruckner MK, 1997, J BRAIN RES, V38, P369
   Burrows KB, 1999, NEUROSCIENCE, V90, P833, DOI 10.1016/S0306-4522(98)00506-5
   Burrows KB, 1997, SYNAPSE, V27, P133, DOI 10.1002/(SICI)1098-2396(199710)27:2<133::AID-SYN4>3.3.CO;2-F
   Bustamante D, 2002, J NEUROCHEM, V83, P645, DOI 10.1046/j.1471-4159.2002.01171.x
   Cadet JL, 2007, NEUROTOX RES, V11, P183, DOI 10.1007/BF03033567
   Caille S, 2004, EUR J NEUROSCI, V20, P593, DOI 10.1111/j.1460-9568.2004.03497.x
   Camarini R, 2000, ALCOHOL CLIN EXP RES, V24, P285, DOI 10.1097/00000374-200003000-00005
   Cannizzaro C, 2006, NEUROCHEM INT, V48, P159, DOI 10.1016/j.neuint.2005.10.009
   Cappendijk S L, 1993, Eur Neuropsychopharmacol, V3, P111, DOI 10.1016/0924-977X(93)90262-K
   Carlezon WA, 2000, J NEUROSCI, V20
   Carlezon WA, 1997, SCIENCE, V277, P812, DOI 10.1126/science.277.5327.812
   Carmen B, 2004, ADDICTION, V99, P811, DOI 10.1111/j.1360-0443.2004.00763.x
   Carpenter-Hyland EP, 2004, J NEUROSCI, V24, P7859, DOI 10.1523/JNEUROSCI.1902-04.2004
   Carta M, 2003, P NATL ACAD SCI USA, V100, P6813, DOI 10.1073/pnas.1137276100
   Castellano C, 2001, CURR DRUG TARGETS, V2, P273, DOI 10.2174/1389450013348515
   Chandler LJ, 1999, ALCOHOL CLIN EXP RES, V23, P363, DOI 10.1097/00000374-199902000-00025
   Chao SZ, 2002, J NEUROCHEM, V81, P984, DOI 10.1046/j.1471-4159.2002.00877.x
   Chao SZ, 2002, J NEUROCHEM, V83, P704, DOI 10.1046/j.1471-4159.2002.01164.x
   Chen XY, 1997, J NEUROCHEM, V69, P1559
   Chen XY, 1999, J NEUROCHEM, V72, P1969, DOI 10.1046/j.1471-4159.1999.0721969.x
   Chiamulera C, 2001, NAT NEUROSCI, V4, P873, DOI 10.1038/nn0901-873
   Childress A R, 1993, NIDA Res Monogr, V137, P73
   Childress A R, 1988, NIDA Res Monogr, V84, P25
   Choe ES, 2002, NEUROPSYCHOPHARMACOL, V27, P565
   Choi KH, 2003, ANN NY ACAD SCI, V1003, P372, DOI 10.1196/annals.1300.029
   CHU B, 1995, J NEUROCHEM, V65, P140
   Churchill L, 1999, J NEUROCHEM, V72, P2397, DOI 10.1046/j.1471-4159.1999.0722397.x
   Clark D, 1998, ADDICT BIOL, V3, P109, DOI 10.1080/13556219872191
   Coderre TJ, 2007, J NEUROCHEM, V100, P1289, DOI 10.1111/j.1471-4159.2006.04304.x
   Collins ED, 1998, BEHAV PHARMACOL, V9, P587, DOI 10.1097/00008877-199811000-00014
   Collins ED, 2007, EXP CLIN PSYCHOPHARM, V15, P228, DOI 10.1037/1064-1297.15.3.228
   Colombo G, 2005, PHARMACOL BIOCHEM BE, V81, P369, DOI 10.1016/j.pbb.2005.01.022
   COLOMBO G, 1992, ANN NY ACAD SCI, V654, P421, DOI 10.1111/j.1749-6632.1992.tb25986.x
   Conklin CA, 2002, ADDICTION, V97, P155, DOI 10.1046/j.1360-0443.2002.00014.x
   Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205
   Cooke SF, 2006, BRAIN, V129, P1659, DOI 10.1093/brain/awl082
   Cornish JL, 1999, NEUROSCIENCE, V93, P1359, DOI 10.1016/S0306-4522(99)00214-6
   Cornish JL, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-15-j0006.2000
   Costa ET, 2000, ALCOHOL CLIN EXP RES, V24, P220, DOI 10.1097/00000374-200002000-00013
   Coutinho V, 2002, NEUROSCIENTIST, V8, P551, DOI 10.1177/1073858402238514
   COUTINHONETTO J, 1982, BIOCHEM PHARMACOL, V31, P1019, DOI 10.1016/0006-2952(82)90337-9
   COUTINHONETTO J, 1980, BIOCHEM PHARMACOL, V29, P2777, DOI 10.1016/0006-2952(80)90011-8
   Cowen MS, 2007, PSYCHOPHARMACOLOGY, V190, P21, DOI 10.1007/s00213-006-0583-0
   Cowen MS, 2005, J PHARMACOL EXP THER, V315, P590, DOI 10.1124/jpet.105.090449
   Cowen MS, 2003, NEUROPHARMACOLOGY, V45, P325, DOI 10.1016/S0028-3908(03)00174-6
   Cowen MS, 2003, ALCOHOL CLIN EXP RES, V27, P1213, DOI 10.1097/01.ALC.0000081630.14159.02
   Crabbe JC, 2006, ADDICT BIOL, V11, P195, DOI 10.1111/j.1369-1600.2006.00038.x
   Criswell HE, 2003, J PHARMACOL EXP THER, V304, P192, DOI 10.1124/jpet.102.041590
   Crowder TL, 2002, J PHARMACOL EXP THER, V303, P937, DOI 10.1124/jpet.102.038471
   Cruz SL, 1998, J PHARMACOL EXP THER, V286, P334
   Cull-Candy S, 2006, CURR OPIN NEUROBIOL, V16, P288, DOI 10.1016/j.conb.2006.05.012
   CUMMINS JT, 1975, PSYCHOPHARMACOL COMM, V1, P383
   Cunningham MO, 2000, NEUROPHARMACOLOGY, V39, P2139, DOI 10.1016/S0028-3908(00)00051-4
   Cunningham MO, 2004, EUR J NEUROSCI, V20, P1566, DOI 10.1111/j.1460-9568.2004.03625.x
   Dackis CA, 2005, NEUROPSYCHOPHARMACOL, V30, P205, DOI 10.1038/sj.npp.1300600
   Dackis CA, 2003, DRUG ALCOHOL DEPEN, V70, P29, DOI 10.1016/S0376-8716(02)00335-6
   Dahchour A, 1996, BRAIN RES, V735, P9
   DAHCHOUR A, 1994, ALCOHOL ALCOHOLISM, V29, P485
   Dahchour A, 2000, PROG NEUROBIOL, V60, P343, DOI 10.1016/S0301-0082(99)00031-3
   Dahchour A, 2003, ALCOHOL CLIN EXP RES, V27, P465, DOI 10.1097/01.ALC.0000056617.68874.18
   Dahchour A, 2003, EUR J PHARMACOL, V459, P171, DOI 10.1016/S0014-2999(02)02851-0
   Dahchour A, 1999, ALCOHOL CLIN EXP RES, V23, P1698, DOI 10.1111/j.1530-0277.1999.tb04063.x
   Dahchour A, 2000, ALCOHOL ALCOHOLISM, V35, P548, DOI 10.1093/alcalc/35.6.548
   Dahchour A, 2000, PHARMACOL BIOCHEM BE, V65, P345, DOI 10.1016/S0091-3057(99)00197-5
   DAHCHOUR A, 1995, ALCOHOL ALCOHOLISM, V30, P483
   Dahl JR, 2005, PSYCHIAT GENET, V15, P277, DOI 10.1097/00041444-200512000-00010
   DALIA A, 1995, BRAIN RES, V694, P299, DOI 10.1016/0006-8993(95)00794-Q
   Dalia A, 1998, BRAIN RES, V788, P111, DOI 10.1016/S0006-8993(97)01518-7
   Dallimore JE, 2006, BEHAV NEUROSCI, V120, P1103, DOI 10.1037/0735-7044.120.5.1103
   Danysz W, 2005, NEUROPHARMACOLOGY, V48, P360, DOI 10.1016/j.neuropharm.2004.11.005
   DANYSZ W, 1992, ALCOHOL CLIN EXP RES, V16, P499, DOI 10.1111/j.1530-0277.1992.tb01407.x
   DAOUST M, 1985, J PHARMACOL-PARIS, V16, P521
   Davis M, 2006, BIOL PSYCHIAT, V60, P369, DOI 10.1016/j.biopsych.2006.03.084
   Davis Michael, 2006, NeuroRx, V3, P82, DOI 10.1016/j.nurx.2005.12.008
   de Bartolomeis Andrea, 2003, Psychopharmacol Bull, V37, P51
   de la Mora MP, 1999, NEUROSCI LETT, V259, P181, DOI 10.1016/S0304-3940(98)00905-7
   De Vries TJ, 1998, NEUROREPORT, V9, P637, DOI 10.1097/00001756-199803090-00014
   De Witte P, 2005, CNS DRUGS, V19, P517, DOI 10.2165/00023210-200519060-00004
   De Witte P, 1994, Alcohol Alcohol Suppl, V2, P229
   Deas D, 2006, J CLIN PSYCHIAT, V67, P18, DOI 10.4088/JCP.0706e02
   Del Arco A, 1999, NEUROPHARMACOLOGY, V38, P943, DOI 10.1016/S0028-3908(99)00043-X
   Del Arco A, 1998, NEUROCHEM RES, V23, P1153, DOI 10.1023/A:1020769816332
   Del Re AM, 2006, BRAIN RES, V1087, P75, DOI 10.1016/j.brainres.2006.03.031
   DELAMORA MP, 1991, ACTA PHYSIOL SCAND, V141, P241
   Derkach VA, 2007, NAT REV NEUROSCI, V8, P101, DOI 10.1038/nrn2055
   Desole MS, 1996, BRAIN RES, V723, P154, DOI 10.1016/0006-8993(96)00235-1
   Devaud LL, 1999, EUR J PHARMACOL, V369, P331, DOI 10.1016/S0014-2999(99)00103-X
   Devaud LL, 2004, ALCOHOL CLIN EXP RES, V28, P957, DOI 10.1097/01.ALC.0000128225.83916.40
   Di Chiara G, 1998, J PSYCHOPHARMACOL, V12, P54, DOI 10.1177/026988119801200108
   Di Chiara G, 1999, EUR J PHARMACOL, V375, P13, DOI 10.1016/S0014-2999(99)00372-6
   Di Ciano P, 2004, J NEUROSCI, V24, P7167, DOI 10.1523/JNEUROSCI.1581-04.2004
   Di Ciano P, 2001, NEUROPSYCHOPHARMACOL, V25, P341, DOI 10.1016/S0893-133X(01)00235-4
   Di S, 2005, J PHYSIOL-LONDON, V569, P751, DOI 10.1113/jphysiol.2005.097477
   Dickenson A H, 2007, Handb Exp Pharmacol, P145
   DILDY JE, 1989, BRAIN RES, V499, P383, DOI 10.1016/0006-8993(89)90789-0
   DILDYMAYFIELD JE, 1992, J PHARMACOL EXP THER, V262, P487
   DILDYMAYFIELD JE, 1991, J NEUROCHEM, V56, P1536, DOI 10.1111/j.1471-4159.1991.tb02048.x
   DILDYMAYFIELD JE, 1995, J NEUROSCI, V15, P3162
   Dingledine R, 1999, PHARMACOL REV, V51, P7
   DINWIDDIE SH, 1994, ADDICTION, V89, P925, DOI 10.1111/j.1360-0443.1994.tb03348.x
   Do Couto BR, 2005, BRAIN RES BULL, V64, P493, DOI 10.1016/j.brainresbull.2004.10.005
   Doherty J, 2003, CURR OPIN PHARMACOL, V3, P46, DOI 10.1016/S1471-4892(02)00014-0
   Domenici MR, 2006, J NEUROSCI, V26, P5794, DOI 10.1523/JNEUROSCI.0372-06.2006
   Dong Y, 2004, P NATL ACAD SCI USA, V101, P14282, DOI 10.1073/pnas.0401553101
   Donovan JL, 2005, CLIN PHARMACOKINET, V44, P753, DOI 10.2165/00003088-200544070-00006
   Dooley DJ, 2000, NEUROSCI LETT, V280, P107, DOI 10.1016/S0304-3940(00)00769-2
   Dravolina OA, 2007, NEUROPHARMACOLOGY, V52, P263, DOI 10.1016/j.neuropharm.2006.07.023
   DWORKIN SI, 1995, BRAIN RES, V682, P116, DOI 10.1016/0006-8993(95)00327-M
   EARLE ML, 1991, J NEURAL TRANSM-GEN, V86, P217, DOI 10.1007/BF01250707
   ENGBERG G, 1989, LIFE SCI, V44, P1535, DOI 10.1016/0024-3205(89)90446-3
   ENGBERG G, 1992, N-S ARCH PHARMACOL, V345, P222, DOI 10.1007/BF00165740
   Engblom AC, 1997, J NEUROCHEM, V69, P2162
   Enrico P, 1998, BRAIN RES, V797, P94, DOI 10.1016/S0006-8993(98)00371-0
   Epstein DH, 2006, PSYCHOPHARMACOLOGY, V189, P1, DOI 10.1007/s00213-006-0529-6
   Erden BF, 1999, PHARMACOL BIOCHEM BE, V62, P537, DOI 10.1016/S0091-3057(98)00175-0
   Erhardt S, 2000, SYNAPSE, V37, P104, DOI 10.1002/1098-2396(200008)37:2<104::AID-SYN4>3.0.CO;2-L
   Erhardt S, 2002, SYNAPSE, V43, P227, DOI 10.1002/syn.10044
   Escher T, 2006, PSYCHOPHARMACOLOGY, V187, P424, DOI 10.1007/s00213-006-0465-5
   Esteban Jose A, 2003, Mol Interv, V3, P375, DOI 10.1124/mi.3.7.375
   Evans SM, 2007, ALCOHOL CLIN EXP RES, V31, P775, DOI 10.1111/j.1530-0277.2007.00360.x
   Fagen ZM, 2003, ANN NY ACAD SCI, V1003, P185, DOI 10.1196/annals.1300.011
   Faleiro LJ, 2004, NEUROPSYCHOPHARMACOL, V29, P2115, DOI 10.1038/sj.npp.1300495
   Famous KR, 2007, NEUROSCI LETT, V420, P169, DOI 10.1016/j.neulet.2007.04.063
   Fedele E, 1998, BRIT J PHARMACOL, V125, P1042, DOI 10.1038/sj.bjp.0702130
   Ferguson SM, 2003, J NEUROCHEM, V86, P33, DOI 10.1046/j.1471-4159.2003.01815.x
   Ferrani-Kile K, 2003, MOL BRAIN RES, V115, P78, DOI 10.1016/S0169-328X(03)00186-4
   Ferraro L, 2001, CEREB CORTEX, V11, P728, DOI 10.1093/cercor/11.8.728
   Ferraro L, 1998, NEUROSCI LETT, V253, P135, DOI 10.1016/S0304-3940(98)00629-6
   Ferraro L, 1997, NEUROREPORT, V8, P2883, DOI 10.1097/00001756-199709080-00016
   Ferraro L, 1999, NEUROPSYCHOPHARMACOL, V20, P346, DOI 10.1016/S0893-133X(98)00085-2
   Fink K, 2000, BRIT J PHARMACOL, V130, P900, DOI 10.1038/sj.bjp.0703380
   Fischer W, 2003, ALCOHOL ALCOHOLISM, V38, P394, DOI 10.1093/alcalc/agg108
   Fisher JL, 2000, NEUROPHARMACOLOGY, V39, P2756, DOI 10.1016/S0028-3908(00)00102-7
   Fitzgerald LW, 1996, J NEUROSCI, V16, P274
   Floyd DW, 2003, J PHARMACOL EXP THER, V307, P1020, DOI 10.1124/jpet.103.057505
   Foley PF, 2004, ANN NY ACAD SCI, V1025, P39, DOI 10.1196/annals.1316.005
   FOLLESA P, 1995, MOL BRAIN RES, V29, P99, DOI 10.1016/0169-328X(94)00235-7
   Follesa P, 1996, J BIOL CHEM, V271, P13297, DOI 10.1074/jbc.271.23.13297
   Fournier ME, 2006, CURR OPIN PEDIATR, V18, P352, DOI 10.1097/01.mop.0000236381.33907.9d
   Freeman WM, 2001, NEUROSCIENCE, V108, P371, DOI 10.1016/S0306-4522(01)00432-8
   Freiman I, 2005, NEUROSCIENCE, V133, P305, DOI 10.1016/j.neuroscience.2005.01.058
   FREY JM, 1985, BRAIN RES BULL, V14, P251, DOI 10.1016/0361-9230(85)90090-5
   FROHLICH R, 1994, N-S ARCH PHARMACOL, V350, P626
   FRY JP, 1980, BRIT J PHARMACOL, V68, P585, DOI 10.1111/j.1476-5381.1980.tb14574.x
   Frye GD, 2000, BRIT J PHARMACOL, V129, P87, DOI 10.1038/sj.bjp.0703039
   Fu YT, 2000, J PHARMACOL EXP THER, V294, P458
   Fujii S, 1999, BRAIN RES, V846, P137, DOI 10.1016/S0006-8993(99)01982-4
   Fujio M, 2005, EUR J NEUROSCI, V22, P2744, DOI 10.1111/j.1460-9568.2005.04467.x
   FUNDYTUS ME, 1994, BRIT J PHARMACOL, V113, P1215, DOI 10.1111/j.1476-5381.1994.tb17127.x
   Fundytus ME, 1997, BRIT J PHARMACOL, V121, P511, DOI 10.1038/sj.bjp.0701174
   Gallinat J, 2007, PHARMACOPSYCHIATRY, V40, P64, DOI 10.1055/s-2007-970144
   Gao C, 2006, J NEUROCHEM, V98, P1664, DOI 10.1111/j.1471-4159.2006.03999.x
   Garcia MM, 2003, NEUROSCIENCE, V119, P787, DOI 10.1016/S0306-4522(02)00975-2
   Garcia-Junco-Clemente P, 2005, MOL PSYCHIATR, V10, P185, DOI 10.1038/sj.mp.4001628
   GarciaMunoz M, 1996, J PHARMACOL EXP THER, V277, P1685
   Geisler S, 2007, J NEUROSCI, V27, P5730, DOI 10.1523/JNEUROSCI.0012-07.2007
   Gerdeman G, 2001, J NEUROPHYSIOL, V85, P468, DOI 10.1152/jn.2001.85.1.468
   Gerdjikov TV, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-43
   Ghasemzadeh MB, 2003, ANN NY ACAD SCI, V1003, P395, DOI 10.1196/annals.1300.034
   Ghasemzadeh MB, 1999, J NEUROCHEM, V72, P157, DOI 10.1046/j.1471-4159.1999.0720157.x
   Giacchino JL, 1998, PROG NEURO-PSYCHOPH, V22, P1157, DOI 10.1016/S0278-5846(98)00053-0
   Gioanni Y, 1999, EUR J NEUROSCI, V11, P18, DOI 10.1046/j.1460-9568.1999.00403.x
   Giocomo LM, 2005, EUR J NEUROSCI, V22, P1349, DOI 10.1111/j.1460-9568.2005.04316.x
   Giorgetti M, 2001, J NEUROSCI, V21, P6362, DOI 10.1523/JNEUROSCI.21-16-06362.2001
   GIVENS B, 1995, BRAIN RES, V688, P27, DOI 10.1016/0006-8993(95)00499-G
   Glass MJ, 2005, SYNAPSE, V58, P1, DOI 10.1002/syn.20176
   Glick SD, 2000, ANN NY ACAD SCI, V914, P369, DOI 10.1111/j.1749-6632.2000.tb05211.x
   Glick SD, 2001, EUR J PHARMACOL, V422, P87, DOI 10.1016/S0014-2999(01)01066-4
   Glick SD, 2000, ANN NY ACAD SCI, V909, P88
   Gonzalez G, 2007, DRUG ALCOHOL DEPEN, V87, P1, DOI 10.1016/j.drugalcdep.2006.07.003
   Gonzalez P, 1997, EUR J PHARMACOL, V332, P257, DOI 10.1016/S0014-2999(97)01099-6
   Gordey M, 2001, NEUROSCIENCE, V105, P987, DOI 10.1016/S0306-4522(01)00234-2
   GRANT KA, 1991, BEHAV PHARMACOL, V2, P87
   GRANT KA, 1990, EUR J PHARMACOL, V176, P289, DOI 10.1016/0014-2999(90)90022-X
   GRANT KA, 1992, J PHARMACOL EXP THER, V260, P1017
   GRANT KA, 1993, J PHARMACOL EXP THER, V264, P1241
   Gray R, 1996, NATURE, V383, P713, DOI 10.1038/383713a0
   Grignaschi G, 2004, EUR J NEUROSCI, V20, P2833, DOI 10.1111/j.1460-9568.2004.03712.x
   Grillner P, 2000, SYNAPSE, V38, P1
   Groenewegen HJ, 1999, ANN NY ACAD SCI, V877, P49, DOI 10.1111/j.1749-6632.1999.tb09260.x
   Grover CA, 1998, BRAIN RES, V782, P43, DOI 10.1016/S0006-8993(97)01001-9
   Gryder DS, 2003, J NEUROSCI, V23, P7069, DOI 10.1523/JNEUROSCI.23-18-07069.2003
   GUDEHITHLU KP, 1994, BRAIN RES, V639, P269, DOI 10.1016/0006-8993(94)91740-X
   Gudehithlu KP, 1996, GEN PHARMACOL, V27, P91, DOI 10.1016/0306-3623(95)00110-7
   Guo M, 2005, NEUROSCI LETT, V381, P12, DOI 10.1016/j.neulet.2005.01.071
   HABERNY KA, 1994, EUR J PHARMACOL, V261, P1, DOI 10.1016/0014-2999(94)90293-3
   Hajos N, 2001, NEUROSCIENCE, V106, P1, DOI 10.1016/S0306-4522(01)00287-1
   Haney M, 2005, DRUG ALCOHOL DEPEN, V80, P53, DOI 10.1016/j.drugalcdep.2005.03.006
   HANSON GR, 1995, DRUG ALCOHOL DEPEN, V37, P107, DOI 10.1016/0376-8716(94)01065-S
   Hao Y, 2005, BRAIN RES, V1040, P191, DOI 10.1016/j.brainres.2005.01.072
   Hardy PA, 1999, BRAIN RES, V819, P33, DOI 10.1016/S0006-8993(98)01340-7
   Harris BR, 2003, ALCOHOL CLIN EXP RES, V27, P1724, DOI 10.1097/01.ALC.0000093601.33119.E3
   Harris BR, 2002, ALCOHOL CLIN EXP RES, V26, P1779, DOI 10.1097/01.ALC.0000042011.99580.98
   Harris GC, 2004, NEUROSCIENCE, V129, P841, DOI 10.1016/j.neuroscience.2004.09.018
   Harris GC, 2003, NEUROPSYCHOPHARMACOL, V28, P73, DOI 10.1038/sj.npp.1300011
   Harrison AA, 2002, PSYCHOPHARMACOLOGY, V160, P56, DOI 10.1007/s00213-001-0953-6
   Harrison JM, 2002, J NEUROPHYSIOL, V87, P2464, DOI 10.1152/jn.2002.87.5.2464
   Hayes RJ, 2003, PSYCHOPHARMACOLOGY, V168, P75, DOI 10.1007/s00213-002-1328-3
   Heimer L, 1997, J NEUROPSYCH CLIN N, V9, P354
   Heinzerling KG, 2006, DRUG ALCOHOL DEPEN, V85, P177, DOI 10.1016/j.drugalcdep.2006.03.019
   Helton DR, 1997, NEUROPHARMACOLOGY, V36, P1511, DOI 10.1016/S0028-3908(97)00170-6
   Hemby SE, 2005, J NEUROCHEM, V95, P1785, DOI 10.1111/j.1471-4159.2005.03517.x
   Hemby SE, 2005, BRAIN RES, V1064, P75, DOI 10.1016/j.brainres.2005.09.051
   Hendricson AW, 2002, J PHARMACOL EXP THER, V301, P938, DOI 10.1124/jpet.301.3.938
   Henniger MSH, 2003, EUR J PHARMACOL, V470, P33, DOI 10.1016/S0014-2999(03)01787-4
   Hentges ST, 2005, J NEUROSCI, V25, P9746, DOI 10.1523/JNEUROSCI.2769-05.2005
   Hermans E, 2001, BIOCHEM J, V359, P465, DOI 10.1042/0264-6021:3590465
   Herzig V, 2005, ADDICT BIOL, V10, P243, DOI 10.1080/13556210500223272
   Herzig V, 2004, NEUROPHARMACOLOGY, V47, P973, DOI 10.1016/j.neuropharm.2004.07.037
   Heusner CL, 2005, J NEUROSCI, V25, P6651, DOI 10.1523/JNEUROSCI.1474-05.2005
   Hodge CW, 2001, PSYCHOPHARMACOLOGY, V154, P13, DOI 10.1007/s002130000619
   Hodge CW, 2006, PSYCHOPHARMACOLOGY, V183, P429, DOI 10.1007/s00213-005-0217-y
   Hodge CW, 1998, PSYCHOPHARMACOLOGY, V139, P95, DOI 10.1007/s002130050694
   Hoffman AF, 2003, EUR J NEUROSCI, V18, P524, DOI 10.1046/j.1460-9568.2003.02773.x
   Hoffman AF, 2001, J NEUROPHYSIOL, V85, P72, DOI 10.1152/jn.2001.85.1.72
   Hoffman AF, 2007, LEARN MEMORY, V14, P63, DOI 10.1101/lm.439007
   Hoffman P L, 1994, Alcohol Alcohol Suppl, V2, P199
   HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x
   Holter SM, 2000, J PHARMACOL EXP THER, V292, P545
   HONG M, 1993, BRAIN RES, V623, P131, DOI 10.1016/0006-8993(93)90020-N
   Hoshi K, 2000, INFLAMM RES, V49, P36, DOI 10.1007/PL00000201
   Hotsenpiller G, 2002, NEUROPHARMACOLOGY, V43, P1218, DOI 10.1016/S0028-3908(02)00308-8
   Hotsenpiller G, 2001, EUR J NEUROSCI, V14, P1843, DOI 10.1046/j.0953-816x.2001.01804.x
   Howes SR, 2000, PSYCHOPHARMACOLOGY, V151, P55, DOI 10.1007/s002130000451
   Howlett AC, 2004, NEUROPHARMACOLOGY, V47, P345, DOI 10.1016/j.neuropharm.2004.07.030
   Hsiao SH, 2003, DEV BRAIN RES, V142, P89, DOI 10.1016/S0165-3806(03)00034-8
   Hu XJ, 1996, MOL BRAIN RES, V36, P211, DOI 10.1016/0169-328X(95)00223-F
   Huang CC, 2001, J PHYSIOL-LONDON, V532, P731, DOI 10.1111/j.1469-7793.2001.0731e.x
   Huang CC, 2007, J NEUROSCI, V27, P2958, DOI 10.1523/JNEUROSCI.4247-06.2007
   Huang NK, 1997, PHARMACOL BIOCHEM BE, V56, P363, DOI 10.1016/S0091-3057(96)00236-5
   HUBNER CB, 1990, BRAIN RES, V508, P20, DOI 10.1016/0006-8993(90)91112-T
   Huettner JE, 2003, PROG NEUROBIOL, V70, P387, DOI 10.1016/S0301-0082(03)00122-9
   HUFFMAN RD, 1981, NEUROSCI LETT, V22, P195, DOI 10.1016/0304-3940(81)90087-2
   HUFFMAN RD, 1989, EUR J PHARMACOL, V170, P179, DOI 10.1016/0014-2999(89)90538-4
   Hundt W, 1998, PSYCHOPHARMACOLOGY, V135, P44, DOI 10.1007/s002130050484
   Hyman SE, 2005, AM J PSYCHIAT, V162, P1414, DOI 10.1176/appi.ajp.162.8.1414
   Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Hyytia P, 1999, EUR J PHARMACOL, V378, P9, DOI 10.1016/S0014-2999(99)00446-X
   Ibbotson T, 1997, BRIT J PHARMACOL, V122, P956, DOI 10.1038/sj.bjp.0701471
   Inoue M, 2003, J NEUROSCI, V23, P6529
   IORIO KR, 1992, MOL PHARMACOL, V41, P1142
   Iso Y, 2006, J MED CHEM, V49, P1080, DOI 10.1021/jm050570f
   Ito K, 2006, PSYCHOPHARMACOLOGY, V187, P293, DOI 10.1007/s00213-006-0423-2
   ITZHAK Y, 1992, J PHARMACOL EXP THER, V262, P464
   Itzhak Y, 2000, NEUROPHARMACOLOGY, V39, P32, DOI 10.1016/S0028-3908(99)00073-8
   ITZHAK Y, 1994, NEUROTOXICOL TERATOL, V16, P363, DOI 10.1016/0892-0362(94)90024-8
   Jackson A, 1996, PSYCHOPHARMACOLOGY, V128, P320, DOI 10.1007/s002130050140
   Jacobs EH, 2005, EUR J PHARMACOL, V511, P27, DOI 10.1016/j.ejphar.2005.02.009
   Jay TM, 2003, PROG NEUROBIOL, V69, P375, DOI 10.1016/S0301-0082(03)00085-6
   Jenab S, 2005, MOL BRAIN RES, V142, P134, DOI 10.1016/j.molbrainres.2005.08.015
   JIMENEZRIVERA CA, 1991, BRAIN RES, V546, P287, DOI 10.1016/0006-8993(91)91493-K
   Jin C, 2006, ALCOHOL CLIN EXP RES, V30, P673, DOI 10.1111/j.1530-0277.2006.00079.x
   Jin C, 2006, BRAIN RES, V1069, P120, DOI 10.1016/j.brainres.2005.11.058
   Johnson BA, 2005, ARCH INTERN MED, V165, P1600, DOI 10.1001/archinte.165.14.1600
   Johnson BA, 2004, ARCH GEN PSYCHIAT, V61, P905, DOI 10.1001/archpsyc.61.9.905
   Johnson PI, 1997, NEUROSCIENCE, V77, P187, DOI 10.1016/S0306-4522(96)00482-4
   Jones IW, 2004, J NEUROSCI, V24, P11244, DOI 10.1523/JNEUROSCI.3009-04.2004
   Jones S, 2005, CURR OPIN PHARMACOL, V5, P20, DOI 10.1016/j.coph.2004.08.011
   Jones S, 2000, J NEUROSCI, V20, P5575, DOI 10.1523/JNEUROSCI.20-15-05575.2000
   Jones S, 1999, J NEUROSCI, V19, P9780
   Justinova Z, 2005, PHARMACOL BIOCHEM BE, V81, P285, DOI 10.1016/j.pbb.2005.01.026
   Kalivas PW, 2004, CURR OPIN PHARMACOL, V4, P23, DOI 10.1016/j.coph.2003.11.002
   Kalivas PW, 1998, J NEUROCHEM, V70, P1497
   Kalivas PW, 2005, NEURON, V45, P647, DOI 10.1016/j.neuron.2005.02.005
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   KALIVAS PW, 1995, J NEUROSCI, V15, P5379, DOI 10.1523/jneurosci.15-07-05379.1995
   Kalivas PW, 1997, BRAIN RES, V761, P173, DOI 10.1016/S0006-8993(97)00464-2
   Kalluri HSG, 1998, MOL BRAIN RES, V58, P221, DOI 10.1016/S0169-328X(98)00112-0
   Kaminski RM, 2004, NEUROPHARMACOLOGY, V46, P1097, DOI 10.1016/j.neuropharm.2004.02.010
   Kampman KM, 2004, DRUG ALCOHOL DEPEN, V75, P233, DOI 10.1016/j.drugalcdep.2004.03.008
   Kane JK, 2005, EUR J NEUROSCI, V21, P1145, DOI 10.1111/j.1460-9568.2005.03945.x
   KARLER R, 1989, LIFE SCI, V45, P599, DOI 10.1016/0024-3205(89)90045-3
   Kashkin VA, 2005, EUR NEUROPSYCHOPHARM, V15, P625, DOI 10.1016/j.euroneuro.2005.03.004
   Katona I, 2006, J NEUROSCI, V26, P5628, DOI 10.1523/JNEUROSCI.0309-06.2006
   Kauer JA, 2004, ANNU REV PHYSIOL, V66, P447, DOI 10.1146/annurev.physiol.66.032102.112534
   Kawa K, 2002, J PHYSIOL-LONDON, V538, P87, DOI 10.1113/jphysiol.2001.012885
   Kawasaki Y, 2005, BRIT J PHARMACOL, V145, P751, DOI 10.1038/sj.bjp.0706228
   Kelley AE, 2004, NEURON, V44, P161, DOI 10.1016/j.neuron.2004.09.016
   Kelley JB, 2007, NEUROREPORT, V18, P777, DOI 10.1097/WNR.0b013e3280c1e2e7
   Kelsey JE, 2002, PSYCHOPHARMACOLOGY, V161, P370, DOI 10.1007/s00213-002-1015-4
   Kenny PJ, 2007, TRENDS PHARMACOL SCI, V28, P135, DOI 10.1016/j.tips.2007.01.008
   Kenny PJ, 2005, PSYCHOPHARMACOLOGY, V179, P247, DOI 10.1007/s00213-004-2069-2
   Kenny PJ, 2003, J PHARMACOL EXP THER, V306, P1068, DOI 10.1124/jpet.103.052027
   Kenny PJ, 2003, ANN NY ACAD SCI, V1003, P415, DOI 10.1196/annals.1300.040
   Keys AS, 1998, SYNAPSE, V30, P393, DOI 10.1002/(SICI)1098-2396(199812)30:4<393::AID-SYN6>3.0.CO;2-H
   Khazaal Y, 2006, PSYCHIAT CLIN NEUROS, V60, P384, DOI 10.1111/j.1440-1819.2006.01518.x
   KIBA H, 1994, MOL BRAIN RES, V23, P1, DOI 10.1016/0169-328X(94)90205-4
   Kiefer F, 2003, BIOL PSYCHIAT, V53, P345, DOI 10.1016/S0006-3223(02)01486-5
   Kim JH, 2005, EUR J NEUROSCI, V21, P295, DOI 10.1111/j.1460-9568.2004.03822.x
   KIM JS, 1981, NEUROSCI LETT, V24, P93, DOI 10.1016/0304-3940(81)90365-7
   Kiyatkin EA, 2000, EUR J NEUROSCI, V12, P1789, DOI 10.1046/j.1460-9568.2000.00066.x
   Klodzinska A, 1999, NEUROPHARMACOLOGY, V38, P1831, DOI 10.1016/S0028-3908(99)00066-0
   Kofalvi A, 2005, J NEUROSCI, V25, P2874, DOI 10.1523/JNEUROSCI.4232-04.2005
   Kofalvi A, 2003, EUR J NEUROSCI, V18, P1973, DOI 10.1046/j.1460-9568.2003.02897.x
   Kokoshka JM, 1998, BRAIN RES, V799, P78, DOI 10.1016/S0006-8993(98)00472-7
   Komanduri R, 2003, J CLIN PSYCHIAT, V64, P612, DOI 10.4088/JCP.v64n0518d
   Konradi C, 1996, J NEUROSCI, V16, P4231
   Kosowski AR, 2004, J PHARMACOL EXP THER, V311, P560, DOI 10.1124/jpet.104.070235
   Kosowski AR, 2004, PSYCHOPHARMACOLOGY, V175, P114, DOI 10.1007/s00213-004-1797-7
   Kotlinska J, 2000, POL J PHARMACOL, V52, P179
   Kotlinska J, 2004, EUR J PHARMACOL, V503, P95, DOI 10.1016/j.ejphar.2004.09.036
   Kotlinska J, 2001, POL J PHARMACOL, V53, P47
   Kotlinska J, 1997, EUR J PHARMACOL, V332, P1, DOI 10.1016/S0014-2999(97)01069-8
   Kotlinska J, 2006, BEHAV PHARMACOL, V17, P1, DOI 10.1097/01.fbp.0000181600.95405.c7
   Koyuncuoglu H, 1999, PHARMACOL RES, V39, P311, DOI 10.1006/phrs.1998.0443
   Kozela E, 2005, PSYCHOPHARMACOLOGY, V183, P275, DOI 10.1007/s00213-005-0182-5
   Kozela E, 2003, PSYCHOPHARMACOLOGY, V165, P245, DOI 10.1007/s00213-002-1287-8
   Kozell LB, 2004, SYNAPSE, V51, P224, DOI 10.1002/syn.10304
   Kozell LB, 2003, PSYCHOPHARMACOLOGY, V165, P337, DOI 10.1007/s00213-002-1296-7
   KRUPITSKY EM, 2007, AM J PSYCHIAT, V164, P519
   Krupitsky EM, 2007, ALCOHOL CLIN EXP RES, V31, P604, DOI 10.1111/j.1530-0277.2007.00344.x
   Krystal JH, 1998, ARCH GEN PSYCHIAT, V55, P354, DOI 10.1001/archpsyc.55.4.354
   Kumari M, 1998, J NEUROCHEM, V70, P1467
   Kumari M, 2001, J BIOL CHEM, V276, P29764, DOI 10.1074/jbc.M100317200
   KUNER T, 1993, NEUROREPORT, V5, P297, DOI 10.1097/00001756-199312000-00029
   LABARCA R, 1995, PROG NEURO-PSYCHOPH, V19, P467, DOI 10.1016/0278-5846(94)00027-F
   Lallemand F, 2006, BRAIN RES, V1111, P48, DOI 10.1016/j.brainres.2006.06.083
   Lambe EK, 2003, NEUROPSYCHOPHARMACOL, V28, P216, DOI 10.1038/sj.npp.1300032
   Landmark CJ, 2007, MED SCI MONITOR, V13, pRA1
   Lapish CC, 2006, ALCOHOL CLIN EXP RES, V30, P1451, DOI 10.1111/j.1530-0277.2006.00176.x
   LaRowe SD, 2006, AM J ADDICTION, V15, P105, DOI 10.1080/10550490500419169
   Laviolette SR, 2004, NAT REV NEUROSCI, V5, P55, DOI 10.1038/nrn1298
   LAYER RT, 1993, BRAIN RES, V617, P267, DOI 10.1016/0006-8993(93)91094-9
   Le Greves P, 1998, EUR J PHARMACOL, V341, P161, DOI 10.1016/S0014-2999(97)01400-3
   LEACH MJ, 1986, EPILEPSIA, V27, P490, DOI 10.1111/j.1528-1157.1986.tb03573.x
   Leal MB, 2003, PROG NEURO-PSYCHOPH, V27, P781, DOI 10.1016/S0278-5846(03)00109-X
   Lee B, 2005, J PHARMACOL EXP THER, V312, P1232, DOI 10.1124/jpet.104.078733
   Lee JLC, 2006, J NEUROSCI, V26, P10051, DOI 10.1523/JNEUROSCI.2466-06.2006
   LEES G, 1993, BRAIN RES, V612, P190, DOI 10.1016/0006-8993(93)91660-K
   Levenes C, 1998, J PHYSIOL-LONDON, V510, P867, DOI 10.1111/j.1469-7793.1998.867bj.x
   LHUINTRE JP, 1985, LANCET, V1, P1014, DOI 10.1016/S0140-6736(85)91615-0
   Li Y, 2004, SYNAPSE, V51, P1, DOI 10.1002/syn.10270
   Liechti ME, 2007, EUR J PHARMACOL, V554, P164, DOI 10.1016/j.ejphar.2006.10.011
   LILJEQUIST S, 1991, EUR J PHARMACOL, V192, P197, DOI 10.1016/0014-2999(91)90092-5
   Lim DK, 2000, ARCH PHARM RES, V23, P488, DOI 10.1007/BF02976578
   Lim DK, 2003, ARCH PHARM RES, V26, P321, DOI 10.1007/BF02976963
   LIMALANDMAN MTR, 1989, FEBS LETT, V247, P61, DOI 10.1016/0014-5793(89)81241-4
   LIN NL, 1995, BRAIN RES BULL, V36, P421, DOI 10.1016/0361-9230(94)00215-M
   Lingamaneni R, 1999, NEUROSCI LETT, V276, P127, DOI 10.1016/S0304-3940(99)00810-1
   LIU JL, 1994, P NATL ACAD SCI USA, V91, P8537, DOI 10.1073/pnas.91.18.8537
   Liu QS, 2005, NATURE, V437, P1027, DOI 10.1038/nature04050
   Liu SJ, 2007, TRENDS NEUROSCI, V30, P126, DOI 10.1016/j.tins.2007.01.006
   Liu XY, 2006, NEURON, V52, P897, DOI 10.1016/j.neuron.2006.10.011
   Loftis JM, 2000, J NEUROCHEM, V75, P2040, DOI 10.1046/j.1471-4159.2000.0752040.x
   Loftis JM, 2002, PSYCHOPHARMACOLOGY, V164, P349, DOI 10.1007/s00213-002-1209-9
   Lominac KD, 2005, J NEUROSCI, V25, P11586, DOI 10.1523/JNEUROSCI.3764-05.2005
   Lominac KD, 2006, DRUG ALCOHOL DEPEN, V85, P142, DOI 10.1016/j.drugalcdep.2006.04.003
   Lopez E, 2001, CEREB CORTEX, V11, P158, DOI 10.1093/cercor/11.2.158
   LOVINGER DM, 1990, ANN MED, V22, P247, DOI 10.3109/07853899009148935
   LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382
   LOVINGER DM, 1990, J NEUROSCI, V10, P1372
   LOVINGER DM, 1993, NEUROSCI LETT, V159, P83, DOI 10.1016/0304-3940(93)90804-T
   Lu L, 2005, J NEUROCHEM, V94, P161, DOI 10.1111/j.1471-4159.2005.03178.x
   Lu L, 2003, J NEUROCHEM, V85, P1604, DOI 10.1046/j.1471-4159.2003.01824.x
   Lu L, 2007, BIOL PSYCHIAT, V61, P591, DOI 10.1016/j.biopsych.2006.04.011
   Lu SM, 1999, NEUROCHEM INT, V35, P175, DOI 10.1016/S0197-0186(99)00059-5
   Lu WX, 2002, NEUROPSYCHOPHARMACOL, V26, P1, DOI 10.1016/S0893-133X(01)00272-X
   Lu WX, 1997, SYNAPSE, V26, P269, DOI 10.1002/(SICI)1098-2396(199707)26:3<269::AID-SYN8>3.0.CO;2-5
   Lu WX, 1999, SYNAPSE, V32, P119, DOI 10.1002/(SICI)1098-2396(199905)32:2<119::AID-SYN5>3.0.CO;2-F
   Lu WX, 1999, EUR J NEUROSCI, V11, P3167, DOI 10.1046/j.1460-9568.1999.00736.x
   Lue WM, 2007, SYNAPSE, V61, P420, DOI 10.1002/syn.20391
   Ma YY, 2007, EXP NEUROL, V203, P309, DOI 10.1016/j.expneurol.2006.08.014
   Madamba SG, 1996, ALCOHOL CLIN EXP RES, V20, P651, DOI 10.1111/j.1530-0277.1996.tb01667.x
   Mair RD, 2007, NEUROPHARMACOLOGY, V52, P193, DOI 10.1016/j.neuropharm.2006.07.004
   Malcolm R, 2006, AM J DRUG ALCOHOL AB, V32, P577, DOI 10.1080/00952990600920425
   Maldonado C, 2007, PROG NEURO-PSYCHOPH, V31, P932, DOI 10.1016/j.pnpbp.2007.02.012
   Maldonado R, 2006, TRENDS NEUROSCI, V29, P225, DOI 10.1016/j.tins.2006.01.008
   Maldve RE, 2002, NAT NEUROSCI, V5, P641, DOI 10.1038/nn877
   Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012
   Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870
   Malenka RC, 2003, ANN NY ACAD SCI, V1003, P1, DOI 10.1196/annals.1300.001
   Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758
   Malinowska B, 1999, EUR J PHARMACOL, V377, P13, DOI 10.1016/S0014-2999(99)00393-3
   Maneuf YP, 2004, BRIT J PHARMACOL, V141, P574, DOI 10.1038/sj.bjp.0705579
   Maneuf YP, 2001, BRIT J PHARMACOL, V134, P237, DOI 10.1038/sj.bjp.0704227
   Mangiavacchi S, 2004, J NEUROCHEM, V88, P1261, DOI 10.1046/j.1471-4159.2003.02248.x
   Mann K, 2004, ALCOHOL CLIN EXP RES, V28, P51, DOI 10.1097/01.ALC.0000108656.81563.05
   Mansvelder HD, 2000, NEURON, V27, P349, DOI 10.1016/S0896-6273(00)00042-8
   Mansvelder HD, 2002, NEURON, V33, P905, DOI 10.1016/S0896-6273(02)00625-6
   Manzoni OJ, 1999, J NEUROSCI, V19, P6629
   Mao LM, 2003, NEUROSCI LETT, V346, P17, DOI 10.1016/S0304-3940(03)00542-1
   Mao LM, 2002, BRAIN RES, V924, P167, DOI 10.1016/S0006-8993(01)03230-9
   Mao LM, 2001, SYNAPSE, V41, P230, DOI 10.1002/syn.1080
   Mao SC, 2006, J NEUROSCI, V26, P8892, DOI 10.1523/JNEUROSCI.0365-06.2006
   Marcaggi P, 2005, NAT NEUROSCI, V8, P776, DOI 10.1038/nn1458
   Marchi M, 2002, J NEUROCHEM, V80, P1071, DOI 10.1046/j.0022-3042.2002.00805.x
   Mardikian PN, 2007, PROG NEURO-PSYCHOPH, V31, P389, DOI 10.1016/j.pnpbp.2006.10.001
   MAREK P, 1991, BRAIN RES, V547, P77
   Margolin A, 1998, AM J DRUG ALCOHOL AB, V24, P85, DOI 10.3109/00952999809001700
   Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006
   Paxinos G., 2001, MOUSE BRAIN STEREOTA
   Li YH, 2006, J PSYCHOPHARMACOL, V20, P40, DOI [10.1177/02698881105057250, 10.1177/0269881105057250]
   Mariani JJ, 2006, AM J ADDICTION, V15, P76, DOI 10.1080/10550490500419110
   Mark KA, 2004, J NEUROSCI, V24, P11449, DOI 10.1523/JNEUROSCI.3597-04.2004
   Mark KA, 2007, J NEUROSCI, V27, P6823, DOI 10.1523/JNEUROSCI.0013-07.2007
   Markou A, 2007, BIOL PSYCHIAT, V61, P17, DOI 10.1016/j.biopsych.2006.03.053
   MARTIN D, 1995, ALCOHOL CLIN EXP RES, V19, P1312, DOI 10.1111/j.1530-0277.1995.tb01617.x
   MARTIN D, 1991, BRAIN RES, V546, P227, DOI 10.1016/0006-8993(91)91486-K
   Martin G, 1999, J PHARMACOL EXP THER, V288, P30
   Martin G, 2004, J PHARMACOL EXP THER, V311, P265, DOI 10.1124/jpet.104.067504
   Martin M, 2006, NAT NEUROSCI, V9, P868, DOI 10.1038/nn1713
   Martinez-Raga J, 2004, PROG NEURO-PSYCHOPH, V28, P599, DOI 10.1016/j.pnpbp.2003.11.020
   Mason BJ, 2005, EXPERT OPIN PHARMACO, V6, P2103, DOI 10.1517/14656566.6.12.2103
   MASOOD K, 1994, MOL PHARMACOL, V45, P324
   Mato S, 2005, J NEUROSCI, V25, P11619, DOI 10.1523/JNEUROSCI.2294-05.2005
   Matsubayashi H, 2001, JPN J PHARMACOL, V86, P429, DOI 10.1254/jjp.86.429
   McBean GJ, 2002, TRENDS PHARMACOL SCI, V23, P299, DOI 10.1016/S0165-6147(02)02060-6
   McDaid J, 2006, NEUROPSYCHOPHARMACOL, V31, P1212, DOI 10.1038/sj.npp.1300854
   McFarland K, 2003, J NEUROSCI, V23, P3531
   Mcgeehan AJ, 2003, BRIT J PHARMACOL, V138, P9, DOI 10.1038/sj.bjp.0705059
   McGeehan AJ, 2003, SYNAPSE, V47, P240, DOI 10.1002/syn.10166
   Mcgeehan AJ, 2006, BEHAV PHARMACOL, V17, P363, DOI 10.1097/01.fbp.0000224384.01863.5f
   MCGEHEE DS, 1995, SCIENCE, V269, P1692, DOI 10.1126/science.7569895
   Mckee NL, 2005, NEUROSCIENCE, V133, P605, DOI 10.1016/j.neuroscience.2005.02.020
   McMillen BA, 2005, ALCOHOL ALCOHOLISM, V40, P494, DOI 10.1093/alcalc/agh200
   McMillen BA, 2004, BRAIN RES BULL, V64, P279, DOI 10.1016/j.brainresbull.2004.08.001
   Mead AN, 2005, PSYCHOPHARMACOLOGY, V179, P164, DOI 10.1007/s00213-004-2071-8
   Mead AN, 2007, NEUROPSYCHOPHARMACOL, V32, P343, DOI 10.1038/sj.npp.1301045
   Melendez RI, 2005, ALCOHOL CLIN EXP RES, V29, P326, DOI 10.1097/01.ALC.0000156086.65665.4D
   Melendez RI, 2005, J PHARMACOL EXP THER, V314, P139, DOI 10.1124/jpet.104.081521
   Melis M, 2004, J NEUROSCI, V24, P53, DOI 10.1523/JNEUROSCI.4503-03.2004
   Mendiguren A, 2007, NEUROPHARMACOLOGY, V52, P617, DOI 10.1016/j.neuropharm.2006.09.004
   Meshul CK, 1998, SYNAPSE, V30, P211, DOI 10.1002/(SICI)1098-2396(199810)30:2<211::AID-SYN11>3.0.CO;2-4
   Meshul CK, 2002, EXP NEUROL, V175, P257, DOI 10.1006/exnr.2002.7900
   Mexal S, 2005, MOL BRAIN RES, V139, P317, DOI 10.1016/j.molbrainres.2005.06.006
   Meyer PJ, 2003, BEHAV NEUROSCI, V117, P641, DOI 10.1037/0735-7044.117.3.641
   Miele M, 2000, BRIT J PHARMACOL, V129, P582, DOI 10.1038/sj.bjp.0703066
   Miller CA, 2005, NEURON, V47, P873, DOI 10.1016/j.neuron.2005.08.006
   Minami K, 1998, MOL PHARMACOL, V53, P148, DOI 10.1124/mol.53.1.148
   MIRSHAHI T, 1995, NEUROPHARMACOLOGY, V34, P347, DOI 10.1016/0028-3908(94)00155-L
   Mirshahi T, 1998, J NEUROCHEM, V71, P1095
   Misner DL, 1999, J NEUROSCI, V19, P6795, DOI 10.1523/JNEUROSCI.19-16-06795.1999
   Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698
   Miyamoto Y, 2004, EUR J NEUROSCI, V19, P151, DOI 10.1111/j.1460-9568.2004.03086.x
   MOGHADDAM B, 1994, NEUROSCI LETT, V178, P99, DOI 10.1016/0304-3940(94)90299-2
   MOLLEMAN A, 1995, J PHARMACOL EXP THER, V274, P1035
   MORA F, 1993, CAN J PHYSIOL PHARM, V71, P348, DOI 10.1139/y93-054
   Moran MM, 2005, J NEUROSCI, V25, P6389, DOI 10.1523/JNEUROSCI.1007-05.2005
   Morishima Y, 2005, P NATL ACAD SCI USA, V102, P4170, DOI 10.1073/pnas.0500914102
   Moron JA, 2007, MOL CELL PROTEOMICS, V6, P29, DOI 10.1074/mcp.M600184-MCP200
   MORONI F, 1981, N-S ARCH PHARMACOL, V316, P235, DOI 10.1007/BF00505655
   Moroz I, 1997, EXP CLIN PSYCHOPHARM, V5, P119, DOI 10.1037/1064-1297.5.2.119
   MORRISETT RA, 1991, NEUROPHARMACOLOGY, V30, P1173, DOI 10.1016/0028-3908(91)90162-5
   MORRISETT RA, 1993, J NEUROSCI, V13, P2264
   MORRISETT RA, 1990, EUR J PHARMACOL, V176, P103, DOI 10.1016/0014-2999(90)90138-V
   Morrow A L, 1994, Alcohol Alcohol Suppl, V2, P89
   Moykkynen T, 2003, J PHARMACOL EXP THER, V306, P546, DOI 10.1124/jpet.103.050666
   Mudo G, 2007, BRAIN RES, V1149, P1, DOI 10.1016/j.brainres.2007.02.041
   Murray F, 2007, EUR J PHARMACOL, V562, P191, DOI 10.1016/j.ejphar.2007.01.027
   Myrick H, 2001, J CLIN PSYCHIAT, V62, P19, DOI 10.4088/JCP.v62n0105
   Myrick H, 1998, AM J PSYCHIAT, V155, P1632
   Myrick H, 2007, ALCOHOL CLIN EXP RES, V31, P221, DOI 10.1111/j.1530-0277.2006.00299.x
   Naassila M, 1998, ALCOHOL CLIN EXP RES, V22, P802
   Nagy J, 2003, NEUROCHEM INT, V42, P35, DOI 10.1016/S0197-0186(02)00062-1
   NAH SY, 1993, EUR J PHARM-MOLEC PH, V246, P19, DOI 10.1016/0922-4106(93)90004-S
   Nakagawa T, 2005, BEHAV BRAIN RES, V156, P233, DOI 10.1016/j.bbr.2004.05.029
   Nakagawa T, 2001, EUR J PHARMACOL, V419, P39, DOI 10.1016/S0014-2999(01)00965-7
   Narita M, 2000, EUR J PHARMACOL, V401, P191, DOI 10.1016/S0014-2999(00)00428-3
   Narushima M, 2006, NEUROSCI RES, V54, P159, DOI 10.1016/j.neures.2005.12.004
   NASH JF, 1993, BRAIN RES, V627, P1
   NASH JF, 1992, BRAIN RES, V581, P237, DOI 10.1016/0006-8993(92)90713-J
   Nelson TE, 2005, BRAIN RES, V1048, P69, DOI 10.1016/j.brainres.2005.04.041
   Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578
   Netzeband JG, 1999, NEUROCHEM INT, V35, P163, DOI 10.1016/S0197-0186(99)00058-3
   Netzeband JG, 1999, BRAIN RES, V826, P270, DOI 10.1016/S0006-8993(99)01309-8
   Neugebauer V, 2000, J NEUROPHYSIOL, V84, P759, DOI 10.1152/jn.2000.84.2.759
   Nicol B, 1996, NEUROSCI LETT, V218, P79, DOI 10.1016/S0304-3940(96)13104-9
   Nicola SM, 2000, ANNU REV NEUROSCI, V23, P185, DOI 10.1146/annurev.neuro.23.1.185
   Nicola SM, 1997, J NEUROSCI, V17, P5697
   Nicola SM, 1996, J NEUROSCI, V16, P1591
   NIE ZG, 1994, J PHARMACOL EXP THER, V271, P1566
   Nieber K, 1998, N-S ARCH PHARMACOL, V357, P299, DOI 10.1007/PL00005171
   Nugent FS, 2007, NATURE, V446, P1086, DOI 10.1038/nature05726
   O'Brien CP, 1998, J PSYCHOPHARMACOL, V12, P15, DOI 10.1177/026988119801200103
   O'Donnell P, 2003, EUR J NEUROSCI, V17, P429, DOI 10.1046/j.1460-9568.2003.02463.x
   OBRIEN CP, 1992, RES P ARNMD, V70, P157
   Ohno-Shosaku T, 2002, J NEUROSCI, V22, P3864, DOI 10.1523/JNEUROSCI.22-10-03864.2002
   Ojanen SP, 2007, EUR J PHARMACOL, V559, P38, DOI 10.1016/j.ejphar.2006.11.046
   Olive MF, 2005, MOL PHARMACOL, V67, P349, DOI 10.1124/mol.104.003319
   Omelchenko N, 2007, NEUROSCIENCE, V146, P1259, DOI 10.1016/j.neuroscience.2007.02.016
   ORTIZ J, 1995, SYNAPSE, V21, P289, DOI 10.1002/syn.890210403
   Othman T, 2002, NEUROCHEM RES, V27, P289, DOI 10.1023/A:1014955111742
   Ozawa T, 2004, EUR J NEUROSCI, V19, P221, DOI 10.1111/j.1460-9568.2004.03101.x
   Ozawa T, 2001, BRAIN RES, V905, P254, DOI 10.1016/S0006-8993(01)02536-7
   Pace CJ, 2004, EUR J PHARMACOL, V492, P159, DOI 10.1016/j.ejphar.2004.03.062
   Paladini CA, 2001, NAT NEUROSCI, V4, P275, DOI 10.1038/85124
   Palucha A, 2004, POL J PHARMACOL, V56, P863
   Paoletti P, 2007, CURR OPIN PHARMACOL, V7, P39, DOI 10.1016/j.coph.2006.08.011
   Papp M, 2002, NEUROPSYCHOPHARMACOL, V27, P727, DOI 10.1016/S0893-133X(02)00349-4
   Parelkar NK, 2004, MOL BRAIN RES, V122, P151, DOI 10.1016/j.molbrainres.2003.12.010
   Park WK, 2002, J NEUROSCI, V22, P2916, DOI 10.1523/JNEUROSCI.22-07-02916.2002
   Parolaro D, 2005, CNS NEUROL DISORD-DR, V4, P643, DOI 10.2174/156800705774933014
   Paterson NE, 2003, PSYCHOPHARMACOLOGY, V167, P257, DOI 10.1007/s00213-003-1432-z
   Paterson NE, 2005, PSYCHOPHARMACOLOGY, V179, P255, DOI 10.1007/s00213-004-2070-9
   Peoples RW, 1997, BRIT J PHARMACOL, V122, P1035, DOI 10.1038/sj.bjp.0701483
   Perez-Otano I, 2005, TRENDS NEUROSCI, V28, P229, DOI 10.1016/j.tins.2005.03.004
   Peters J, 2006, PSYCHOPHARMACOLOGY, V186, P143, DOI 10.1007/s00213-006-0372-9
   Peterson JD, 2000, SYNAPSE, V36, P342, DOI 10.1002/(SICI)1098-2396(20000615)36:4<342::AID-SYN11>3.0.CO;2-9
   Petrakis IL, 2004, AM J PSYCHIAT, V161, P1776, DOI 10.1176/appi.ajp.161.10.1776
   Piasecki J, 1998, EUR J PHARMACOL, V354, P135, DOI 10.1016/S0014-2999(98)00442-7
   Picciotto MR, 2002, J NEUROSCI, V22, P3338
   Piepponen TP, 2002, PHARMACOL BIOCHEM BE, V74, P21, DOI 10.1016/S0091-3057(02)00937-1
   Pierce RC, 1997, BRAIN RES REV, V25, P192, DOI 10.1016/S0165-0173(97)00021-0
   Pierce RC, 1996, J NEUROSCI, V16, P1550
   Pistis M, 2002, BRAIN RES, V948, P155, DOI 10.1016/S0006-8993(02)03055-X
   Pistis M, 2002, EUR J NEUROSCI, V15, P1795, DOI 10.1046/j.1460-9568.2002.02019.x
   Popik P, 2000, BRIT J PHARMACOL, V130, P1425, DOI 10.1038/sj.bjp.0703438
   Popik P, 2006, NEUROPSYCHOPHARMACOL, V31, P160, DOI 10.1038/sj.npp.1300760
   Popik P, 1999, N-S ARCH PHARMACOL, V359, P288, DOI 10.1007/PL00005354
   Popik P, 1996, PHARMACOL BIOCHEM BE, V53, P791, DOI 10.1016/0091-3057(95)02163-9
   Popik P, 2003, NEUROPSYCHOPHARMACOL, V28, P457, DOI 10.1038/sj.npp.1300048
   Popik P, 2002, NEUROPHARMACOLOGY, V43, P1210, DOI 10.1016/S0028-3908(02)00309-X
   Popp RL, 1998, NEUROPHARMACOLOGY, V37, P45, DOI 10.1016/S0028-3908(97)00186-X
   Popp RL, 2000, EUR J PHARMACOL, V394, P221, DOI 10.1016/S0014-2999(00)00195-3
   Popp RL, 1999, J PHARMACOL EXP THER, V289, P1564
   Preuss UW, 2006, PHARMACOGENOMICS J, V6, P34, DOI 10.1038/sj.tpj.6500343
   Preuss UW, 2002, ALCOHOL ALCOHOLISM, V37, P174, DOI 10.1093/alcalc/37.2.174
   Prieto-Gomez B, 2005, LIFE SCI, V77, P635, DOI 10.1016/j.lfs.2004.10.076
   PULVIRENTI L, 1992, BRAIN RES, V594, P327, DOI 10.1016/0006-8993(92)91145-5
   Pulvirenti L, 1997, EUR J PHARMACOL, V321, P279, DOI 10.1016/S0014-2999(96)00970-3
   PULVIRENTI L, 1991, PHARMACOL BIOCHEM BE, V40, P841, DOI 10.1016/0091-3057(91)90095-J
   PULVIRENTI L, 1994, BRAIN RES, V664, P231, DOI 10.1016/0006-8993(94)91977-1
   PULVIRENTI L, 1989, NEUROSCI LETT, V103, P213, DOI 10.1016/0304-3940(89)90578-8
   Pulvirenti L, 2001, REV NEUROSCIENCE, V12, P141
   PUTZKE J, 1996, J NEURAL TRANSM, V103, P10
   Pyapali GK, 1999, ALCOHOL, V19, P107, DOI 10.1016/S0741-8329(99)00021-X
   Quertemont E, 1998, PSYCHOPHARMACOLOGY, V139, P71, DOI 10.1007/s002130050691
   Quertemont E, 2002, EUR J PHARMACOL, V444, P143, DOI 10.1016/S0014-2999(02)01648-5
   RABE CS, 1990, MOL PHARMACOL, V38, P753
   Raby WN, 2000, AM J PSYCHIAT, V157, P2058, DOI 10.1176/appi.ajp.157.12.2058-a
   Raby WN, 2004, J CLIN PSYCHIAT, V65, P84
   Radcliffe KA, 1999, ANN NY ACAD SCI, V868, P591, DOI 10.1111/j.1749-6632.1999.tb11332.x
   Radcliffe KA, 1998, J NEUROSCI, V18, P7075
   Rammes G, 2001, NEUROPHARMACOLOGY, V40, P749, DOI 10.1016/S0028-3908(01)00008-9
   Randoll LA, 1996, ALCOHOL CLIN EXP RES, V20, P197, DOI 10.1111/j.1530-0277.1996.tb01629.x
   Rani CSS, 2006, ALCOHOL, V38, P89, DOI 10.1016/j.alcohol.2006.05.002
   Rao VR, 2007, TRENDS NEUROSCI, V30, P284, DOI 10.1016/j.tins.2007.03.012
   Rasmussen K, 2005, NEUROPHARMACOLOGY, V48, P173, DOI 10.1016/j.neuropharm.2004.09.010
   Rasmussen K, 2004, NEUROPHARMACOLOGY, V46, P620, DOI 10.1016/j.neuropharm.2003.11.013
   Rasmussen K, 1996, NEUROPSYCHOPHARMACOL, V15, P497, DOI 10.1016/S0893-133X(96)00094-2
   RASSNICK S, 1992, PSYCHOPHARMACOLOGY, V109, P92, DOI 10.1007/BF02245485
   Raudensky J, 2007, BRAIN RES, V1135, P129, DOI 10.1016/j.brainres.2006.12.002
   Ravindran CRM, 2005, NEUROCHEM INT, V46, P313, DOI 10.1016/j.neuint.2004.10.004
   Ravindran CRM, 2004, MOL BRAIN RES, V121, P19, DOI 10.1016/j.molbrainres.2003.10.025
   RAYNOR K, 1994, MOL PHARMACOL, V45, P330
   Reid MS, 2000, SYNAPSE, V35, P129, DOI 10.1002/(SICI)1098-2396(200002)35:2<129::AID-SYN5>3.0.CO;2-D
   Reid MS, 1997, SYNAPSE, V27, P95, DOI 10.1002/(SICI)1098-2396(199710)27:2<95::AID-SYN1>3.0.CO;2-6
   Reid MS, 1996, NEUROREPORT, V7, P1325, DOI 10.1097/00001756-199605170-00022
   Reno LAC, 2004, NEUROSCIENCE, V124, P647, DOI 10.1016/j.neuroscience.2003.12.023
   Rescorla RA, 1996, Q J EXP PSYCHOL-B, V49, P245
   Rezayof A, 2007, BRAIN RES, V1133, P34, DOI 10.1016/j.brainres.2006.11.049
   Riddle EL, 2006, AAPS J, V8, pE413, DOI 10.1007/BF02854914
   Riedel G, 2005, HANDB EXP PHARMACOL, V168, P445
   Riedel G, 2003, BEHAV BRAIN RES, V140, P1, DOI 10.1016/S0166-4328(02)00272-3
   Riegel AC, 2002, ANN NY ACAD SCI, V965, P281
   Riegel AC, 2007, NEUROPSYCHOPHARMACOL, V32, P1558, DOI 10.1038/sj.npp.1301273
   Robbe D, 2003, ANN NY ACAD SCI, V1003, P212, DOI 10.1196/annals.1300.013
   Robbe D, 2002, EUR J NEUROSCI, V16, P2231, DOI 10.1046/j.1460-9568.2002.02273.x
   Robbe D, 2001, J NEUROSCI, V21, P109, DOI 10.1523/JNEUROSCI.21-01-00109.2001
   Robbins TW, 2002, NEUROBIOL LEARN MEM, V78, P625, DOI 10.1006/nlme.2002.4103
   Roberto M, 2006, NEUROPSYCHOPHARMACOL, V31, P988, DOI 10.1038/sj.npp.1300840
   Roberto M, 2004, J NEUROSCI, V24, P1594, DOI 10.1523/JNEUROSCI.5077-03.2004
   ROBINSON SE, 1995, PHARMACOL BIOCHEM BE, V50, P627, DOI 10.1016/0091-3057(94)00355-6
   Robinson SE, 1997, EUR J PHARMACOL, V319, P31, DOI 10.1016/S0014-2999(96)00923-5
   ROBLEDO P, 1991, PHARMACOL BIOCHEM BE, V39, P513, DOI 10.1016/0091-3057(91)90218-Q
   Rocher C, 2001, N-S ARCH PHARMACOL, V363, P422
   Rockhold RW, 1998, PROG DRUG RES, V50, P155
   Rogawski MA, 2004, NAT REV NEUROSCI, V5, P553, DOI 10.1038/nrn1430
   RON D, 2005, SCI STKE, pRE14
   RONNBACK L, 1986, NEUROCHEM RES, V11, P317, DOI 10.1007/BF00967978
   Rosenthal RN, 2006, J CLIN PSYCHOPHARM, V26, pS20, DOI 10.1097/01.jcp.000246223.94119.cd
   Rossetti ZL, 1999, NEUROSCIENCE, V93, P1135, DOI 10.1016/S0306-4522(99)00250-X
   ROSSETTI ZL, 1995, EUR J PHARMACOL, V283, P177, DOI 10.1016/0014-2999(95)00344-K
   Rubio G, 2004, PHARMACOPSYCHIATRY, V37, P37, DOI 10.1055/s-2004-815473
   Rubio G, 2006, BIPOLAR DISORD, V8, P289, DOI 10.1111/j.1399-5618.2006.00292.x
   Rujescu D, 2005, AM J MED GENET B, V133B, P85, DOI 10.1002/ajmg.b.30112
   Rustembegovic Avdo, 2004, Med Arh, V58, P5
   Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-7
   Samochowiec J, 2006, NEUROSCI LETT, V396, P159, DOI 10.1016/j.neulet.2005.11.030
   Sanchis-Segura C, 2006, J NEUROSCI, V26, P1231, DOI 10.1523/JNEUROSCI.4237-05.2006
   Sanchis-Segura C, 2006, ADDICT BIOL, V11, P2, DOI 10.1111/j.1369-1600.2006.00012.x
   Sander T, 2000, PSYCHIATR GENET, V10, P103, DOI 10.1097/00041444-200010030-00001
   SANGER DJ, 1993, BEHAV PHARMACOL, V4, P523
   SANNA E, 1993, ALCOHOL CLIN EXP RES, V17, P115, DOI 10.1111/j.1530-0277.1993.tb00735.x
   Sansig G, 2001, J NEUROSCI, V21, P8734, DOI 10.1523/JNEUROSCI.21-22-08734.2001
   Sato Y, 2006, ANESTH ANALG, V103, P117, DOI 10.1213/01.ane.0000220944.27963.b1
   SATOH M, 1975, LIFE SCI, V17, P75, DOI 10.1016/0024-3205(75)90239-8
   SATOH M, 1976, N-S ARCH PHARMACOL, V293, P101, DOI 10.1007/BF00498877
   SATOH M, 1976, BRAIN RES, V115, P99, DOI 10.1016/0006-8993(76)90825-8
   SCHECHTER MD, 1993, ALCOHOL, V10, P197, DOI 10.1016/0741-8329(93)90035-M
   Scheggi S, 2002, NEUROSCIENCE, V109, P267, DOI 10.1016/S0306-4522(01)00483-3
   Schilstrom B, 2000, SYNAPSE, V38, P375, DOI 10.1002/1098-2396(20001215)38:4<375::AID-SYN2>3.0.CO;2-Y
   Schilstrom B, 1998, NEUROSCIENCE, V85, P1005, DOI 10.1016/S0306-4522(98)00114-6
   Schilstrom B, 2000, SYNAPSE, V36, P314, DOI 10.1002/(SICI)1098-2396(20000615)36:4<314::AID-SYN8>3.0.CO;2-U
   Schilstrom B, 2003, INT J NEUROPSYCHOPH, V6, P1, DOI 10.1017/S1461145702003188
   Schilstrom B, 1998, NEUROSCIENCE, V82, P781
   Schilstrom B, 2006, J NEUROSCI, V26, P8549, DOI 10.1523/JNEUROSCI.5179-05.2006
   Schmidt EF, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-07-j0003.2001
   Schoffelmeer ANM, 2006, NEUROPHARMACOLOGY, V51, P773, DOI 10.1016/j.neuropharm.2006.05.019
   Schramm-Sapyta NL, 2006, NEUROPSYCHOPHARMACOL, V31, P1444, DOI 10.1038/sj.npp.1300918
   Schroeder JP, 2005, PSYCHOPHARMACOLOGY, V179, P262, DOI 10.1007/s00213-005-2175-9
   Schumann G, 2003, MOL PSYCHIATR, V8, P11, DOI 10.1038/sj.mp.4001245
   See RE, 2005, EUR J PHARMACOL, V526, P140, DOI 10.1016/j.ejphar.2005.09.034
   See RE, 2001, PSYCHOPHARMACOLOGY, V154, P301, DOI 10.1007/s002130000636
   Sekiya Y, 2004, EUR J PHARMACOL, V485, P201, DOI 10.1016/j.ejphar.2003.11.062
   Self DW, 2004, LEARN MEMORY, V11, P648, DOI 10.1101/lm.81404
   Selim M, 1996, BRAIN RES, V716, P157, DOI 10.1016/0006-8993(95)01385-7
   Sepulveda J, 2004, EUR J PHARMACOL, V483, P249, DOI 10.1016/j.ejphar.2003.10.037
   Sepulveda MJ, 1998, PHARMACOL BIOCHEM BE, V60, P255, DOI 10.1016/S0091-3057(97)00550-9
   Sesack SR, 2003, ANN NY ACAD SCI, V1003, P36, DOI 10.1196/annals.1300.066
   Shelton KL, 2004, ALCOHOL, V34, P165, DOI 10.1016/j.alcohol.2004.07.014
   Shelton KL, 2002, ALCOHOL CLIN EXP RES, V26, P747, DOI 10.1097/00000374-200206000-00002
   Shelton KL, 1997, J PHARMACOL EXP THER, V280, P1250
   SHELTON KL, 1994, BEHAV PHARMACOL, V5, P441
   Shen EH, 1998, PHARMACOL BIOCHEM BE, V59, P135, DOI 10.1016/S0091-3057(97)00389-4
   Shen MX, 1996, J NEUROSCI, V16, P4322
   Shen MX, 1999, MOL PHARMACOL, V55, P8, DOI 10.1124/mol.55.1.8
   SHEN YC, 2006, BIOL PSYCHIAT, V31, P769
   Shigeri Y, 2004, BRAIN RES REV, V45, P250, DOI 10.1016/j.brainresrev.2004.04.004
   Shimoyama M, 2000, PAIN, V85, P405, DOI 10.1016/S0304-3959(99)00283-3
   Shirai Y, 1996, PSYCHIAT CLIN NEUROS, V50, P161, DOI 10.1111/j.1440-1819.1996.tb01682.x
   Shoblock JR, 2003, PSYCHOPHARMACOLOGY, V165, P359, DOI 10.1007/s00213-002-1288-7
   Shoji S, 1997, J PHARMACOL EXP THER, V280, P129
   Sidiropoulou K, 2001, MOL BRAIN RES, V90, P187, DOI 10.1016/S0169-328X(01)00110-3
   Silveri MM, 2002, ALCOHOL CLIN EXP RES, V26, P449, DOI 10.1097/00000374-200204000-00003
   Simonyi A, 2004, ALCOHOL CLIN EXP RES, V28, P1419, DOI 10.1097/01.ALC.0000139825.35438.A4
   SIMSON PE, 1993, BRAIN RES, V607, P9, DOI 10.1016/0006-8993(93)91483-9
   Sircar R, 2006, ALCOHOL, V39, P51, DOI 10.1016/j.alcohol.2006.07.002
   Sitges M, 2007, NEUROPHARMACOLOGY, V52, P598, DOI 10.1016/j.neuropharm.2006.09.002
   Sizemore GM, 2000, PSYCHOPHARMACOLOGY, V150, P391, DOI 10.1007/s002130000456
   Slusher BS, 2001, SYNAPSE, V41, P22, DOI 10.1002/syn.1056
   Smith A, 2004, ALCOHOL CLIN EXP RES, V28, P1028, DOI 10.1097/01.ALC.0000131979.78003.34
   SMITH JA, 1995, BRAIN RES, V683, P264, DOI 10.1016/0006-8993(95)00383-2
   Smith JE, 2003, NEUROSCIENCE, V117, P461, DOI 10.1016/S0306-4522(02)00819-9
   SMITH JE, 1982, PHARMACOL BIOCHEM BE, V16, P509, DOI 10.1016/0091-3057(82)90460-9
   SMITH TL, 1994, ALCOHOL, V11, P405, DOI 10.1016/0741-8329(94)90025-6
   Smith TL, 1997, LIFE SCI, V61, P2499, DOI 10.1016/S0024-3205(97)00985-5
   Smothers CT, 2003, BRAIN RES, V987, P117, DOI 10.1016/S0006-8993(03)03315-8
   Smothers CT, 2001, NEUROCHEM INT, V38, P333, DOI 10.1016/S0197-0186(00)00094-2
   Snell LD, 1996, MOL BRAIN RES, V40, P71
   SNELL LD, 1994, ALCOHOL CLIN EXP RES, V18, P81, DOI 10.1111/j.1530-0277.1994.tb00884.x
   Snyder GL, 2000, J NEUROSCI, V20, P4480, DOI 10.1523/JNEUROSCI.20-12-04480.2000
   Song I, 2002, TRENDS NEUROSCI, V25, P578, DOI 10.1016/S0166-2236(02)02270-1
   SONSALLA PK, 1989, SCIENCE, V243, P398, DOI 10.1126/science.2563176
   Soyka M, 2000, J NEURAL TRANSM, V107, P701, DOI 10.1007/s007020070071
   Soyka M, 2006, EXPERT OPIN PHARMACO, V7, P2341, DOI 10.1517/14656566.7.17.2341
   Spanagel R, 2005, NAT MED, V11, P35, DOI 10.1038/nm1163
   Spanagel R, 1998, PSYCHOPHARMACOLOGY, V139, P391, DOI 10.1007/s002130050730
   Sprengel R, 2006, CELL TISSUE RES, V326, P447, DOI 10.1007/s00441-006-0275-4
   Steffensen SC, 2000, J PHARMACOL EXP THER, V294, P637
   Steketee JD, 2003, BRAIN RES REV, V41, P203, DOI 10.1016/S0165-0173(02)00233-3
   Steketee Jeffery D., 2005, Critical Reviews in Neurobiology, V17, P69
   STEPHANS SE, 1995, BRAIN RES, V700, P99, DOI 10.1016/0006-8993(95)00938-M
   STEPHANS SE, 1994, SYNAPSE, V17, P203, DOI 10.1002/syn.890170310
   Stephens DN, 1999, ALCOHOL CLIN EXP RES, V23, P1914
   Stephenson FA, 2006, BIOCHEM SOC T, V34, P877, DOI 10.1042/BST0340877
   Stobbs SH, 2004, J PHARMACOL EXP THER, V311, P282, DOI 10.1124/jpet.104.071860
   Stolerman IP, 2001, NEUROPHARMACOLOGY, V40, P123, DOI 10.1016/S0028-3908(00)00100-3
   Sullivan JM, 1999, J NEUROPHYSIOL, V82, P1286, DOI 10.1152/jn.1999.82.3.1286
   Sun WL, 2005, NEUROPSYCHOPHARMACOL, V30, P2073, DOI 10.1038/sj.npp.1300744
   Sun X, 2005, J NEUROSCI, V25, P7342, DOI 10.1523/JNEUROSCI.4603-04.2005
   Suto N, 2004, NEUROPSYCHOPHARMACOL, V29, P2149, DOI 10.1038/sj.npp.1300533
   Sutton MA, 2003, NATURE, V421, P70, DOI 10.1038/nature01249
   Suvarna N, 2005, J BIOL CHEM, V280, P31450, DOI 10.1074/jbc.M504120200
   Svensson TH, 1998, AMINO ACIDS, V14, P51, DOI 10.1007/BF01345242
   Swanson CJ, 2001, J NEUROSCI, V21, P9043, DOI 10.1523/JNEUROSCI.21-22-09043.2001
   Szabo B, 2000, NEUROSCIENCE, V97, P89, DOI 10.1016/S0306-4522(00)00036-1
   Sziraki I, 2002, NEUROCHEM RES, V27, P253, DOI 10.1023/A:1014844823534
   Szumlinski KK, 2007, PSYCHOPHARMACOLOGY, V190, P415, DOI 10.1007/s00213-006-0641-7
   Szumlinski KK, 2006, CURR OPIN NEUROBIOL, V16, P251, DOI 10.1016/j.conb.2006.05.002
   Szumlinski KK, 2005, J NEUROSCI, V25, P7054, DOI 10.1523/JNEUROSCI.1529-05.2005
   Szumlinski KK, 2003, ANN NY ACAD SCI, V1003, P468, DOI 10.1196/annals.1300.055
   Szumlinski KK, 2000, NEUROREPORT, V11, P2785, DOI 10.1097/00001756-200008210-00035
   Szumlinski KK, 2004, NEURON, V43, P401, DOI 10.1016/j.neuron.2004.07.019
   Takahashi KA, 2006, NEUROSCIENCE, V139, P795, DOI 10.1016/j.neuroscience.2006.01.024
   Tang WX, 2004, J NEUROCHEM, V89, P1021, DOI 10.1111/j.1471-4159.2004.02392.x
   Tang WX, 2003, J NEUROCHEM, V85, P911, DOI 10.1046/j.1471-4159.2003.01740.x
   TANGANELLI S, 1991, NEUROSCI LETT, V122, P270, DOI 10.1016/0304-3940(91)90875-T
   Taylor JR, 1998, PSYCHOPHARMACOLOGY, V138, P133, DOI 10.1007/s002130050655
   Teo MY, 2004, ACTA NEUROBIOL EXP, V64, P119
   TEOH H, 1995, NEUROPHARMACOLOGY, V34, P1273, DOI 10.1016/0028-3908(95)00104-E
   Tessari M, 2004, EUR J PHARMACOL, V499, P121, DOI 10.1016/j.ejphar.2004.07.056
   Thomas MJ, 2003, PHILOS T ROY SOC B, V358, P815, DOI 10.1098/rstb.2002.1236
   Thomas MJ, 2001, NAT NEUROSCI, V4, P1217, DOI 10.1038/nn757
   TISEO PJ, 1993, J PHARMACOL EXP THER, V264, P1090
   Toda S, 2002, J NEUROCHEM, V82, P1290, DOI 10.1046/j.1471-4159.2002.01083.x
   Todtenkopf MS, 2006, J NEUROSCI, V26, P11665, DOI 10.1523/JNEUROSCI.3070-06.2006
   Tokuyama S, 1996, EUR J PHARMACOL, V295, P123, DOI 10.1016/0014-2999(95)00645-1
   Tokuyama S, 2001, NEUROCHEM INT, V39, P103, DOI 10.1016/S0197-0186(01)00019-5
   Tokuyama S, 1998, J BIOMED SCI, V5, P45, DOI 10.1159/000025311
   Tonini R, 2006, J NEUROSCI, V26, P5810, DOI 10.1523/JNEUROSCI.5469-05.2006
   TOTH E, 1993, NEUROPHARMACOLOGY, V32, P827, DOI 10.1016/0028-3908(93)90192-6
   TOTH E, 1992, NEUROCHEM RES, V17, P265, DOI 10.1007/BF00966669
   TREVISAN L, 1994, J NEUROCHEM, V62, P1635
   TRUJILLO KA, 1991, SCIENCE, V251, P85, DOI 10.1126/science.1824728
   TSAI GC, 1995, AM J PSYCHIAT, V152, P332
   Tsai GC, 1998, ANNU REV MED, V49, P173
   Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7
   Turchan J, 2003, DRUG ALCOHOL DEPEN, V72, P193, DOI 10.1016/S0376-8716(03)00193-5
   Tzschentke TM, 1998, NEUROSCI LETT, V242, P114, DOI 10.1016/S0304-3940(98)00023-8
   Tzschentke TM, 2003, MOL PSYCHIATR, V8, P373, DOI 10.1038/sj.mp.4001269
   Tzschentke TM, 1998, PROG NEUROBIOL, V56, P613, DOI 10.1016/S0301-0082(98)00060-4
   Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077
   Valenzuela CF, 1998, J NEUROCHEM, V71, P1777
   Valenzuela CF, 1999, J PHARMACOL EXP THER, V288, P1199
   Valjent E, 2000, J NEUROSCI, V20, P8701
   Vandergriff J, 1999, NEUROPHARMACOLOGY, V38, P217, DOI 10.1016/S0028-3908(98)00196-8
   Vanderschuren LJMJ, 2005, J NEUROSCI, V25, P8665, DOI 10.1523/JNEUROSCI.0925-05.2005
   Vanderschuren LJMJ, 2000, PSYCHOPHARMACOLOGY, V151, P99, DOI 10.1007/s002130000493
   Vaughan CW, 2005, HANDB EXP PHARMACOL, V168, P367
   Veatch LM, 2005, BRAIN RES, V1065, P92, DOI 10.1016/j.brainres.2005.10.047
   Vekovischeva OY, 2001, J NEUROSCI, V21, P4451, DOI 10.1523/JNEUROSCI.21-12-04451.2001
   Vengeliene V, 2005, NEUROPHARMACOLOGY, V48, P822, DOI 10.1016/j.neuropharm.2005.01.002
   VIDAL C, 1993, NEUROSCIENCE, V56, P23, DOI 10.1016/0306-4522(93)90558-W
   Vivian JA, 2002, PSYCHOPHARMACOLOGY, V162, P273, DOI 10.1007/s00213-002-1086-2
   Vlaskovska M, 1997, J NEUROCHEM, V68, P517
   Volkow ND, 2002, NEUROBIOL LEARN MEM, V78, P610, DOI 10.1006/nlme.2002.4099
   Vorel SR, 2001, SCIENCE, V292, P1175, DOI 10.1126/science.1058043
   Voris John, 2003, Subst Abus, V24, P129, DOI 10.1023/A:1023740800907
   Vosburg SK, 2005, DRUG ALCOHOL DEPEN, V79, P257, DOI 10.1016/j.drugalcdep.2005.01.020
   Vosler PS, 2001, LIFE SCI, V69, P591, DOI 10.1016/S0024-3205(01)01150-X
   Waldmeier PC, 1996, N-S ARCH PHARMACOL, V354, P164
   WALDMEIER PC, 1995, NEUROLOGY, V45, P1907, DOI 10.1212/WNL.45.10.1907
   Walker DL, 2002, J NEUROSCI, V22, P2343, DOI 10.1523/JNEUROSCI.22-06-02343.2002
   Wang BW, 2006, SYNAPSE, V59, P491, DOI 10.1002/syn.20267
   Wang F, 2007, NEUROPSYCHOPHARMACOL, V32, P103, DOI 10.1038/sj.npp.1301033
   Wang HL, 2005, EUR J PHARMACOL, V527, P94, DOI 10.1016/j.ejphar.2005.10.017
   Wang HL, 2004, PROG NEURO-PSYCHOPH, V28, P1079, DOI 10.1016/j.pnpbp.2004.05.043
   Wang JQ, 1996, NEUROSCI LETT, V218, P13
   WANG JQ, 1994, SYNAPSE, V18, P343, DOI 10.1002/syn.890180410
   WANG JQ, 1994, MOL BRAIN RES, V27, P118, DOI 10.1016/0169-328X(94)90192-9
   Wang J, 2007, J NEUROSCI, V27, P3593, DOI 10.1523/JNEUROSCI.4749-06.2007
   Wang MY, 1999, J PHARMACOL EXP THER, V290, P362
   Wang SJ, 2003, EUR J PHARMACOL, V469, P47, DOI 10.1016/S0014-2999(03)01734-5
   Wang SJ, 2001, NEUROREPORT, V12, P2255, DOI 10.1097/00001756-200107200-00042
   Watanabe T, 2002, JPN J PHARMACOL, V88, P399, DOI 10.1254/jjp.88.399
   Watkins S S, 2000, Nicotine Tob Res, V2, P19
   Watson WP, 1997, NEUROPHARMACOLOGY, V36, P1369, DOI 10.1016/S0028-3908(97)00118-4
   Weiner JL, 1999, MOL PHARMACOL, V56, P85, DOI 10.1124/mol.56.1.85
   Weitlauf C, 2004, J NEUROSCI, V24, P5741, DOI 10.1523/JNEUROSCI.1181-04.2004
   Wernicke C, 2003, BIOL PSYCHIAT, V54, P922, DOI 10.1016/S0006-3223(03)00072-6
   White FJ, 1998, DRUG ALCOHOL DEPEN, V51, P141, DOI 10.1016/S0376-8716(98)00072-6
   WHITE FJ, 1995, J PHARMACOL EXP THER, V273, P445
   WHITE G, 1990, BRAIN RES, V507, P332, DOI 10.1016/0006-8993(90)90292-J
   White NM, 1996, ADDICTION, V91, P921, DOI 10.1111/j.1360-0443.1996.tb03586.x
   WHITE SR, 1994, NEUROSCIENCE, V62, P41, DOI 10.1016/0306-4522(94)90313-1
   White WD, 2005, NICOTINE TOB RES, V7, P809, DOI 10.1080/14622200500259887
   Williams JM, 2005, NEUROCHEM INT, V46, P1, DOI 10.1016/j.neuint.2004.07.006
   Williams JM, 2004, EUR J NEUROSCI, V20, P1639, DOI 10.1111/j.1460-9568.2004.03618.x
   WILSON WR, 1990, ALCOHOL, V7, P389, DOI 10.1016/0741-8329(90)90021-4
   Win-Shwe TT, 2007, TOXICOL LETT, V168, P75, DOI 10.1016/j.toxlet.2006.10.017
   Winder Danny G., 2002, Current Molecular Medicine (Hilversum), V2, P667, DOI 10.2174/1566524023361961
   Winther LC, 2000, AM J DRUG ALCOHOL AB, V26, P47, DOI 10.1081/ADA-100100590
   Wirkner K, 2000, N-S ARCH PHARMACOL, V362, P568
   Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406
   WITKIN JM, 1993, LIFE SCI, V53, pPL405
   Wolf ME, 2000, J NEUROCHEM, V75, P1634, DOI 10.1046/j.1471-4159.2000.0751634.x
   Wolf ME, 1999, J NEUROCHEM, V73, P1529, DOI 10.1046/j.1471-4159.1999.0731529.x
   Wolf ME, 1998, PROG NEUROBIOL, V54, P679, DOI 10.1016/S0301-0082(97)00090-7
   Wolf ME, 1998, J NEUROCHEM, V70, P198
   Wolf ME, 2004, NEUROPHARMACOLOGY, V47, P61, DOI 10.1016/j.neuropharm.2004.07.006
   Wonnacott S, 2005, CURR OPIN PHARMACOL, V5, P53, DOI 10.1016/j.coph.2004.12.002
   Wu M, 2003, EUR J NEUROSCI, V18, P1155, DOI 10.1046/j.1460-9568.2003.02847.x
   Xi ZX, 2002, PSYCHOPHARMACOLOGY, V164, P144, DOI 10.1007/s00213-002-1190-3
   Xi ZX, 2002, J PHARMACOL EXP THER, V303, P608, DOI 10.1124/jpet.102.039735
   Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8
   Xu MF, 2006, J NEUROCHEM, V96, P1760, DOI 10.1111/j.1471-4159.2006.03703.x
   Xu NJ, 2003, J NEUROSCI, V23, P4775
   Xue CJ, 1996, J NEUROCHEM, V67, P352
   Yaka R, 2003, ALCOHOL CLIN EXP RES, V27, P1736, DOI 10.1097/01.ALC.0000095924.87729.D8
   Yaka R, 2003, J NEUROSCI, V23, P3623
   Yamaguchi M, 2002, SYNAPSE, V46, P157, DOI 10.1002/SYN.10132
   Yamaguchi T, 2007, EUR J NEUROSCI, V25, P106, DOI 10.1111/j.1460-9568.2006.05263.x
   Yamamoto Bryan K., 2005, Critical Reviews in Neurobiology, V17, P87
   Yamamoto H, 1999, INT J NEUROPSYCHOP, V2, P155, DOI 10.1017/S1461145799001480
   Yamazaki Y, 2006, EUR J NEUROSCI, V23, P1819, DOI 10.1111/j.1460-9568.2006.04714.x
   Yamazaki Y, 2005, EUR J NEUROSCI, V22, P845, DOI 10.1111/j.1460-9568.2005.04259.x
   Yan QS, 1998, NEUROSCI LETT, V258, P29, DOI 10.1016/S0304-3940(98)00840-4
   Yang TT, 2004, SYNAPSE, V51, P83, DOI 10.1002/syn.10290
   Yang XH, 1996, J PHARMACOL EXP THER, V278, P114
   Yin HH, 2007, EUR J NEUROSCI, V25, P3226, DOI 10.1111/j.1460-9568.2007.05606.x
   Yu MF, 2003, SYNAPSE, V50, P334, DOI 10.1002/syn.10275
   Yu MF, 2001, J MOL NEUROSCI, V17, P13, DOI 10.1385/JMN:17:1:13
   Yuferov V, 2003, SYNAPSE, V48, P157, DOI 10.1002/syn.10198
   Zavala AR, 2007, NEUROSCIENCE, V145, P438, DOI 10.1016/j.neuroscience.2006.12.038
   ZEISE ML, 1993, EUR J PHARMACOL, V231, P47, DOI 10.1016/0014-2999(93)90682-8
   ZEISE ML, 1990, PROG CLIN BIOL RES, V351, P237
   Zhang GC, 2007, MOL PHARMACOL, V71, P1148, DOI 10.1124/mol.106.028399
   Zhang XF, 1997, J PHARMACOL EXP THER, V281, P699
   Zhang XW, 2007, NEUROPSYCHOPHARMACOL, V32, P377, DOI 10.1038/sj.npp.1301101
   Zhao Y, 2006, J NEUROSCI, V26, P9967, DOI 10.1523/JNEUROSCI.2384-06.2006
   Zhong WX, 2006, LIFE SCI, V79, P861, DOI 10.1016/j.lfs.2006.02.040
   Zhu H, 1999, EUR J PHARMACOL, V365, P47, DOI 10.1016/S0014-2999(98)00861-9
   Zhu W, 2007, J NEUROSCI, V27, P289, DOI 10.1523/JNEUROSCI.3912-06.2007
   ZIEGLGANSBERGER.W, 2003, GLUTAMATE ADDICTION, P399
   Zullino DF, 2004, DRUG TODAY, V40, P603, DOI 10.1358/dot.2004.40.7.850478
   Zuo GC, 2007, TOXICOL LETT, V169, P253, DOI 10.1016/j.toxlet.2006.09.016
NR 906
TC 353
Z9 366
U1 2
U2 73
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD JAN 1
PY 2008
VL 75
IS 1
BP 218
EP 265
DI 10.1016/j.bcp.2007.06.039
PG 48
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 252YU
UT WOS:000252484800015
PM 17706608
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Humphreys, K
AF Humphreys, Keith
TI Federal Policy on Criminal Offenders Who Have Substance Use Disorders:
   How Can We Maximize Public Health and Public Safety?
SO SUBSTANCE ABUSE
LA English
DT Article
DE Drug policy; addiction; crime; incarceration; opiate addiction
ID ABUSE
AB The Obama Administration is striving to promote both public health and public safety by improving the public policy response to criminal offenders who have substance use disorders. This includes supporting drug courts, evidence-based probation and parole programs, addiction treatment and re-entry programs. Scientists and clinicians in the addiction field have a critical role to play in this much-needed effort to break the cycle of addiction, crime and incarceration.
C1 [Humphreys, Keith] Stanford Univ, Sch Med, Dept Psychiat, Stanford, CA 94305 USA.
   [Humphreys, Keith] White House Off Natl Drug Control Policy, Washington, DC USA.
   [Humphreys, Keith] Dept Vet Affairs, Washington, DC USA.
C3 Stanford University
RP Humphreys, K (通讯作者)，Stanford Univ, Sch Med, Dept Psychiat, 401 N Quarry Rd,MC 5717, Stanford, CA 94305 USA.
EM knh@stanford.edu
CR Babor T, 2010, DRUG POLICY PUBLIC G
   Bird SM, 2003, ADDICTION, V98, P185, DOI 10.1046/j.1360-0443.2003.00264.x
   Chandler RK, 2009, JAMA-J AM MED ASSOC, V301, P183, DOI 10.1001/jama.2008.976
   Finney JW, 1999, ALCOHOL CLIN EXP RES, V23, P537, DOI 10.1097/00000374-199903000-00023
   Fletcher B., 2006, PRINCIPLES DRUG ABUS
   Gottfredson D. C., 2003, CRIMINOL PUBLIC POL, V2, P171, DOI DOI 10.1111/J.1745-9133.2003.TB00117.X
   Greenfield LA, 1998, NCJ168632 US DEP JUS
   Hawken A, 2009, MANAGING DRUG IINVOL
   Humphreys K, 2004, J SUBST ABUSE TREAT, V26, P151, DOI 10.1016/S0740-5472(03)00212-5
   Humphreys K, 2010, PSYCHOL SERV, V7, P275, DOI 10.1037/a0020390
   Karberg Jennifer C., 2005, NCJ209588 US DEP JUS
   Kleiman M. A. R., 2009, BRUTE FORCE FAILS HA
   McKay J. R., 2009, TREATING SUBSTANCE U
   Mumola C. J., 2006, NCJ213530 US DEP JUS
   Office of National Drug Control Policy, 2010, NAT DRUG CONTR STRAT
   Office of National Drug Control Policy, 2009, ADAM 2 2008 ANN REP
   Strang J, LANCET IN PRESS
NR 17
TC 4
Z9 4
U1 0
U2 8
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0889-7077
J9 SUBST ABUS
JI Subst. Abus.
PY 2012
VL 33
IS 1
SI SI
BP 5
EP 8
DI 10.1080/08897077.2011.616805
PG 4
WC Substance Abuse
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse
GA 923HE
UT WOS:000302609500002
PM 22263708
DA 2023-06-23
ER

PT J
AU Carinci, AJ
   Mao, JR
AF Carinci, Adam J.
   Mao, Jianren
TI Pain and Opioid Addiction: What is the Connection?
SO CURRENT PAIN AND HEADACHE REPORTS
LA English
DT Review
DE Opioids; Abuse; Addiction; Aberrant drug related behavior (ADRB);
   Chronic pain; Epidemiology; Neurobiology; Cellular mechanisms
ID ACTIVATED PROTEIN-KINASE; CHRONIC NONCANCER PAIN; DRUG-ABUSE; MORPHINE;
   THERAPY; PREVALENCE; EXPRESSION; BEHAVIORS; MICROGLIA; PATHWAY
AB Addiction to opioid analgesics is an important and yet underinvestigated clinical issue, which has substantial implications in opioid therapy for chronic pain management. Problematic opioid use, including compulsive opioid seeking and addiction, arises in some fraction of opioid-treated chronic pain patients. The connection between chronic pain and opioid addiction is a complex interplay between psychological, epidemiological, and neurobiological factors. Herein, we explore this critical relationship.
C1 [Carinci, Adam J.; Mao, Jianren] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia & Crit Care,Div Pain Med, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts General
   Hospital
RP Carinci, AJ (通讯作者)，Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia & Crit Care,Div Pain Med, 15 Parkman St, Boston, MA 02114 USA.
EM acarinci@partners.org; jmao@partners.org
CR Alonso E, 2007, NEUROSCI LETT, V412, P163, DOI 10.1016/j.neulet.2006.11.002
   Asensio VJ, 2006, EUR J PHARMACOL, V539, P49, DOI 10.1016/j.ejphar.2006.04.001
   Back SE, 2009, CLIN J PAIN, V25, P477, DOI 10.1097/AJP.0b013e31819c2c2f
   Ballantyne JC, 2007, PAIN, V131, P350, DOI 10.1016/j.pain.2007.07.021
   Ballantyne JC, 2003, NEW ENGL J MED, V349, P1943, DOI 10.1056/NEJMra025411
   Bowers MS, 2003, EUR J NEUROSCI, V17, P1273, DOI 10.1046/j.1460-9568.2003.02537.x
   Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008
   Cui Y, 2006, BRAIN RES, V1069, P235, DOI 10.1016/j.brainres.2005.11.066
   DeLeo JA, 1996, J INTERF CYTOK RES, V16, P695, DOI 10.1089/jir.1996.16.695
   FERRELL BR, 1992, J PAIN SYMPTOM MANAG, V7, P117, DOI 10.1016/0885-3924(92)90123-Y
   Festa ED, 2002, BRAIN RES BULL, V58, P285, DOI 10.1016/S0361-9230(02)00791-8
   FISHBAIN DA, 1992, CLIN J PAIN, V8, P77, DOI 10.1097/00002508-199206000-00003
   Fishbain DA, 2008, PAIN MED, V9, P444, DOI 10.1111/j.1526-4637.2007.00370.x
   Furlan AD, 2006, CAN MED ASSOC J, V174, P1589, DOI 10.1503/cmaj.051528
   Hauser KF, 2005, NEUROTOX RES, V8, P63, DOI 10.1007/BF03033820
   Hauser KF, 2007, J NEUROCHEM, V100, P567, DOI 10.1111/j.1471-4159.2006.04227.x
   Herber DL, 2006, GLIA, V53, P382, DOI 10.1002/glia.20272
   HOFFMANN NG, 1995, INT J ADDICT, V30, P919, DOI 10.3109/10826089509055820
   Hutchinson Mark R, 2007, ScientificWorldJournal, V7, P98
   Kalso E, 2004, PAIN, V112, P372, DOI 10.1016/j.pain.2004.09.019
   Katz NP, 2003, ANESTH ANALG, V97, P1097, DOI 10.1213/01.ANE.0000080159.83342.B5
   Lu L, 2005, NAT NEUROSCI, V8, P212, DOI 10.1038/nn1383
   Manchilkanti L, 2008, PAIN PHYSICIAN, V11, P13
   Mao JR, 2002, PAIN, V100, P213, DOI 10.1016/S0304-3959(02)00422-0
   Martin BI, 2008, JAMA-J AM MED ASSOC, V299, P656, DOI 10.1001/jama.299.6.656
   Narita M, 2006, J NEUROCHEM, V97, P1369, DOI 10.1111/j.1471-4159.2006.03824.x
   Passik SD, 2004, CLIN THER, V26, P552, DOI 10.1016/S0149-2918(04)90057-4
   Passik SD, 2009, MAYO CLIN PROC, V84, P593, DOI 10.1016/S0025-6196(11)60748-9
   PATT RB, 1998, EVALUATION TREATMENT, P337
   Rosenblum A, 2008, EXP CLIN PSYCHOPHARM, V16, P405, DOI 10.1037/a0013628
   Song P, 2001, NEUROSCI RES, V39, P281, DOI 10.1016/S0168-0102(00)00226-1
   Sproule B, 2009, CAN FAM PHYS, V55
   Stewart WF, 2003, JAMA-J AM MED ASSOC, V290, P2443, DOI 10.1001/jama.290.18.2443
   Tawfik VL, 2005, J PHARMACOL EXP THER, V313, P1239, DOI 10.1124/jpet.104.082420
   Tomlinson GS, 1999, NEUROPATH APPL NEURO, V25, P369
   Turk DC, 2008, CLIN J PAIN, V24, P497, DOI 10.1097/AJP.0b013e31816b1070
   Valjent E, 2006, P NATL ACAD SCI USA, V103, P2932, DOI 10.1073/pnas.0511030103
   Verhaak PFM, 1998, PAIN, V77, P231, DOI 10.1016/S0304-3959(98)00117-1
   Watkins LR, 2003, NAT REV DRUG DISCOV, V2, P973, DOI 10.1038/nrd1251
   Yang YL, 2005, NEUROSCIENCE, V134, P247, DOI 10.1016/j.neuroscience.2005.04.003
NR 40
TC 6
Z9 6
U1 2
U2 18
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1531-3433
EI 1534-3081
J9 CURR PAIN HEADACHE R
JI Curr. Pain Headache Rep.
PD FEB
PY 2010
VL 14
IS 1
BP 17
EP 21
DI 10.1007/s11916-009-0086-x
PG 5
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 559SC
UT WOS:000274845900003
PM 20425210
DA 2023-06-23
ER

PT J
AU Engels, RCME
AF Engels, Rutger C. M. E.
TI WHAT WE DO AND DO NOT KNOW ABOUT ADDICTION
SO ADDICTION
LA English
DT Editorial Material
DE Addiction; adolescence; adulthood; alcohol; drugs; smoking
ID ADOLESCENT SMOKERS; SMOKING; MOVIES; ASSOCIATIONS; DEPENDENCE
C1 Radboud Univ Nijmegen, Inst Behav Sci, NL-6500 HE Nijmegen, Netherlands.
C3 Radboud University Nijmegen
RP Engels, RCME (通讯作者)，Radboud Univ Nijmegen, Inst Behav Sci, POB 9104, NL-6500 HE Nijmegen, Netherlands.
EM r.engels@bsi.ru.nl
OI Engels, Rutger/0000-0003-1944-9126
CR Chambers RA, 2003, AM J PSYCHIAT, V160, P1041, DOI 10.1176/appi.ajp.160.6.1041
   Dal Cin S, 2007, PSYCHOL SCI, V18, P559, DOI 10.1111/j.1467-9280.2007.01939.x
   Dalton MA, 2003, LANCET, V362, P281, DOI 10.1016/S0140-6736(03)13970-0
   DiFranza JR, 2002, TOB CONTROL, V11, P228, DOI 10.1136/tc.11.3.228
   Engels RCME, 2004, J ADOLESCENCE, V27, P531, DOI 10.1016/j.adolescence.2004.06.006
   Gwaltney CJ, 2008, NICOTINE TOB RES, V10, P1185, DOI 10.1080/14622200802163118
   Hanson K, 2003, NICOTINE TOB RES, V5, P515, DOI 10.1080/1462220031000118559
   Kandel DB, 2007, DRUG ALCOHOL DEPEN, V91, P26, DOI 10.1016/j.drugalcdep.2007.04.011
   Kleinjan M, 2008, ADDICTION, V103, P331, DOI 10.1111/j.1360-0443.2007.02068.x
   Lochbuehler K, 2009, ADDICTION, V104, P2102, DOI 10.1111/j.1360-0443.2009.02712.x
   Moolchan ET, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1894
   Sargent JD, 2007, PEDIATRICS, V119, pE1167, DOI 10.1542/peds.2006-2897
   Sellman D, 2010, ADDICTION, V105, P6, DOI 10.1111/j.1360-0443.2009.02673.x
   Steinberg L, 1996, LAW HUMAN BEHAV, V20, P249, DOI 10.1007/BF01499023
NR 14
TC 1
Z9 1
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0965-2140
EI 1360-0443
J9 ADDICTION
JI Addiction
PD JAN
PY 2010
VL 105
IS 1
BP 14
EP 15
DI 10.1111/j.1360-0443.2009.02745.x
PG 2
WC Substance Abuse; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry
GA 532SK
UT WOS:000272769800004
PM 20078454
OA Bronze
DA 2023-06-23
ER

PT J
AU Bachi, K
   Sierra, S
   Volkow, ND
   Goldstein, RZ
   Alia-Klein, N
AF Bachi, Keren
   Sierra, Salvador
   Volkow, Nora D.
   Goldstein, Rita Z.
   Alia-Klein, Nelly
TI Is biological aging accelerated in drug addiction?
SO CURRENT OPINION IN BEHAVIORAL SCIENCES
LA English
DT Review
ID LEUKOCYTE TELOMERE LENGTH; OXIDATIVE STRESS; MICROGLIAL ACTIVATION;
   COCAINE DEPENDENCE; PERIPHERAL ORGANS; BRAIN; TOXICITY; DISEASE; ABUSE;
   AGE
AB Drug-addiction may trigger early onset of age-related disease, due to drug-induced multi-system toxicity and perilous lifestyle, which remains mostly undetected and untreated. We present the literature on pathophysiological processes that may hasten aging and its relevance to addiction, including: oxidative stress and cellular aging, inflammation in periphery and brain, decline in brain volume and function, and early onset of cardiac, cerebrovascular, kidney, and liver disease. Timely detection of accelerated aging in addiction is crucial for the prevention of premature morbidity and mortality.
C1 [Bachi, Keren; Goldstein, Rita Z.; Alia-Klein, Nelly] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
   [Bachi, Keren; Goldstein, Rita Z.; Alia-Klein, Nelly] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA.
   [Sierra, Salvador] Icahn Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA.
   [Volkow, Nora D.] Natl Inst Drug Abuse, Bethesda, MD USA.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; Icahn School of Medicine at Mount Sinai; National
   Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse
   (NIDA)
RP Alia-Klein, N (通讯作者)，Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.; Alia-Klein, N (通讯作者)，Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA.
EM nelly.alia-klein@mssm.edu
RI Alia-Klein, Nelly/C-3154-2013; Bachi, Keren/O-9024-2017; San Nicolás,
   Salvador Sierra/O-4280-2019
OI Bachi, Keren/0000-0001-9817-5957; San Nicolás, Salvador
   Sierra/0000-0003-2758-8265
FU National Institute on Drug Abuse [T32-DA007135-31, 1U01DA041174,
   R01DA041528]; National Institutes of Health [R01MH090134]; Department of
   Preventive Medicine, Icahn School of Medicine at Mount Sinai; Social
   Work Services support, Icahn School of Medicine at Mount Sinai; Alfonso
   Martin Escudero Foundation
FX This work was supported by: the National Institute on Drug Abuse: [KB:
   T32-DA007135-31; NDV: Intramural funding; RZG: 1U01DA041174,
   R01DA041528]; the National Institutes of Health [NAK: R01MH090134];
   Department of Preventive Medicine, and Social Work Services support,
   Icahn School of Medicine at Mount Sinai [KB]; Grant from Alfonso Martin
   Escudero Foundation [SS].
CR Abraham HMA, 2016, J CEREBR BLOOD F MET, V36, P132, DOI 10.1038/jcbfm.2015.121
   Afonso L, 2007, AM J CARDIOL, V100, P1040, DOI 10.1016/j.amjcard.2007.04.049
   AMES BN, 1992, ANN NY ACAD SCI, V663, P85, DOI 10.1111/j.1749-6632.1992.tb38652.x
   Battistella G, 2014, NEUROPSYCHOPHARMACOL, V39, P2041, DOI 10.1038/npp.2014.67
   Bazuaye-Ekwuyasi EA, 2015, TOXICOL MECH METHOD, V25, P604, DOI 10.3109/15376516.2015.1045658
   Beggs S, 2016, CELL, V165, P1294, DOI 10.1016/j.cell.2016.05.036
   Belsky DW, 2015, P NATL ACAD SCI USA, V112, pE4104, DOI 10.1073/pnas.1506264112
   Benoilid A, 2013, NEUROCASE, V19, P313, DOI 10.1080/13554794.2012.667125
   Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003
   Cunha-Oliveira T, 2013, MINI-REV ORG CHEM, V10, P321, DOI 10.2174/1570193X113106660026
   Cunha-Oliveira T, 2010, TOXICOLOGY, V276, P11, DOI 10.1016/j.tox.2010.06.009
   Diercks DB, 2008, AM J CARDIOL, V102, P1216, DOI 10.1016/j.amjcard.2008.06.045
   Drachman DA, 2006, NEUROLOGY, V67, P1340, DOI 10.1212/01.wnl.0000240127.89601.83
   Effros RB, 2011, EXP GERONTOL, V46, P135, DOI 10.1016/j.exger.2010.08.027
   Elobeid A, 2016, J NEUROPATH EXP NEUR, V75, P316, DOI 10.1093/jnen/nlw002
   Ersche KD, 2013, MOL PSYCHIATR, V18, P134, DOI 10.1038/mp.2012.31
   Ersche KD, 2006, NEUROPSYCHOPHARMACOL, V31, P1036, DOI 10.1038/sj.npp.1300889
   Fowler JS, 2003, P NATL ACAD SCI USA, V100, P11600, DOI 10.1073/pnas.1833106100
   Fox HC, 2012, HUM PSYCHOPHARM CLIN, V27, P156, DOI 10.1002/hup.1251
   Gasiorowski J, 2013, POSTEP HIG MED DOSW, V67, P1214
   Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119
   Guollo F, 2015, J CLIN GASTROENTEROL, V49, P250, DOI 10.1097/MCG.0000000000000056
   Ho EL, 2009, NEUROCRIT CARE, V10, P295, DOI 10.1007/s12028-008-9177-5
   Irwin M, 2004, BRAIN BEHAV IMMUN, V18, P349, DOI 10.1016/j.bbi.2004.02.001
   Irwin MR, 2016, ADDICTION, V111, P1084, DOI 10.1111/add.13300
   Jankovic S, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005222
   Kiecolt-Glaser JK, 2011, PSYCHOSOM MED, V73, P16, DOI 10.1097/PSY.0b013e31820573b6
   Kousik SM, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00121
   Kovacs GG, 2015, NEUROBIOL AGING, V36, P3100, DOI 10.1016/j.neurobiolaging.2015.07.018
   Kovacs KJ, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00074
   Liao K, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0501-2
   Lindqvist D, 2015, NEUROSCI BIOBEHAV R, V55, P333, DOI 10.1016/j.neubiorev.2015.05.007
   Margolick JB, 2015, EXP GERONTOL, V64, P78, DOI 10.1016/j.exger.2015.02.009
   Massardo T, 2015, J ADDICT MED, V9, P139, DOI 10.1097/ADM.0000000000000109
   Molofsky AV, 2006, NATURE, V443, P448, DOI 10.1038/nature05091
   Muezzinler A, 2013, AGEING RES REV, V12, P509, DOI 10.1016/j.arr.2013.01.003
   Mysels David J, 2010, J Opioid Manag, V6, P445
   Nakama H, 2011, ADDICTION, V106, P1474, DOI 10.1111/j.1360-0443.2011.03433.x
   Narvaez JCM, 2013, NEUROSCI LETT, V544, P80, DOI 10.1016/j.neulet.2013.03.045
   Partridge L, 2005, CELL, V120, P461, DOI 10.1016/j.cell.2005.01.026
   Pomierny-Chamiolo L, 2013, NEUROTOX RES, V23, P92, DOI 10.1007/s12640-012-9335-6
   Pontes H, 2008, TOXICOLOGY, V254, P42, DOI 10.1016/j.tox.2008.09.009
   Radunski UK., 2013, J CARDIOVASC MAGN R, V15, pE101
   Rawdin BJ, 2013, BRAIN BEHAV IMMUN, V31, P143, DOI 10.1016/j.bbi.2012.11.011
   Reece Albert Stuart, 2007, Immun Ageing, V4, P6, DOI 10.1186/1742-4933-4-6
   Reece AS, 2013, CARDIOVASC TOXICOL, V13, P55, DOI 10.1007/s12012-012-9186-7
   Ren H, 2012, MOL PSYCHIATR, V17, P1017, DOI 10.1038/mp.2011.160
   Rosso T, 2016, EUR J CANC PREVENT
   Sanvicente-Vieira B, 2016, REV BRAS PSIQUIATR, V38, P58, DOI 10.1590/1516-4446-2015-1708
   Sarafian TA, 2006, AM J PHYSIOL-LUNG C, V290, pL1202, DOI 10.1152/ajplung.00371.2005
   Schon EA, 2011, NEURON, V70, P1033, DOI 10.1016/j.neuron.2011.06.003
   Scott KM, 2016, JAMA PSYCHIAT, V73, P150, DOI 10.1001/jamapsychiatry.2015.2688
   Sekine Y, 2008, J NEUROSCI, V28, P5756, DOI 10.1523/JNEUROSCI.1179-08.2008
   Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025
   Shalev C, 2013, PSYCHONEUROENDOCRINO, V38, P1835, DOI 10.1016/j.psyneuen.2013.03.010
   Shenkin SD, 2010, STROKE, V41, P2083, DOI 10.1161/STROKEAHA.110.590505
   Shvartsbeyn M, 2010, J FORENSIC SCI, V55, P1389, DOI 10.1111/j.1556-4029.2010.01410.x
   Skrabalova J, 2013, MINI-REV ORG CHEM, V10, P367, DOI 10.2174/1570193X113106660031
   Sordo L, 2014, DRUG ALCOHOL DEPEN, V142, P1, DOI 10.1016/j.drugalcdep.2014.06.041
   Substance Abuse and Mental Health Services Administration, 2011, HHS PUBL, V(SMA) 11-4658
   Virmani A, 2010, ANN NY ACAD SCI, V1199, P52, DOI 10.1111/j.1749-6632.2009.05171.x
   Volkow ND, 2016, NEW ENGL J MED, V374, P363, DOI 10.1056/NEJMra1511480
   Volkow ND, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015269
   Wallace TL, 2003, NEUROSCIENCE, V116, P1063, DOI 10.1016/S0306-4522(02)00795-9
   Yan LJ, 2014, REDOX BIOL, V2, P165, DOI 10.1016/j.redox.2014.01.002
   Yang ZY, 2013, SCI REP-UK, V3, DOI 10.1038/srep01542
   Zhang G, 2013, NATURE, V497, P211, DOI 10.1038/nature12143
NR 67
TC 42
Z9 43
U1 1
U2 24
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352-1546
EI 2352-1554
J9 CURR OPIN BEHAV SCI
JI Curr. Opin. Behav. Sci.
PD FEB
PY 2017
VL 13
BP 34
EP 39
DI 10.1016/j.cobeha.2016.09.007
PG 6
WC Behavioral Sciences; Neurosciences; Psychology, Experimental
WE Social Science Citation Index (SSCI)
SC Behavioral Sciences; Neurosciences & Neurology; Psychology
GA EM5AL
UT WOS:000395324200007
PM 27774503
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Phillips, R
AF Phillips, Rod
TI The Age of Addiction: How Bad Habits Became Big Business
SO JOURNAL OF THE HISTORY OF MEDICINE AND ALLIED SCIENCES
LA English
DT Book Review
DE Addiction; Alcoholism; Drug Abuse; Substance Abuse; Gambling; Social
   Media; Tobacco
C1 [Phillips, Rod] Carleton Univ, Ottawa, ON, Canada.
C3 Carleton University
RP Phillips, R (通讯作者)，Carleton Univ, Ottawa, ON, Canada.
CR Courtwright DT., 2019, AGE ADDICTION BAD HA
NR 1
TC 0
Z9 0
U1 1
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-5045
EI 1468-4373
J9 J HIST MED ALL SCI
JI J. Hist. Med. Allied Sci.
PD JUL 8
PY 2022
VL 77
IS 3
BP 386
EP 388
DI 10.1093/jhmas/jrac017
EA JUN 2022
PG 3
WC Health Care Sciences & Services; History & Philosophy Of Science
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)
SC Health Care Sciences & Services; History & Philosophy of Science
GA 2X8WD
UT WOS:000807650500001
DA 2023-06-23
ER

PT J
AU Gamble, K
   Businelle, M
   Ra, CK
   Cropsey, K
AF Gamble, Karen
   Businelle, Michael
   Ra, Chaelin Karen
   Cropsey, Karen
TI Assessment of Symptoms Around the Clock: Implications for Addiction and
   Other Neuropsychiatric Diseases
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
DE Circadian Rhythms; Sleep; Drug Addiction; Smoking; ADHD
C1 [Gamble, Karen; Cropsey, Karen] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA.
   [Businelle, Michael; Ra, Chaelin Karen] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Oklahoma System; University of Oklahoma Health Sciences
   Center
RI Ra, Karen/GZA-9513-2022
FU NIH NIDA [R01DA047297]
FX NIH NIDA R01DA047297
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2021
VL 89
IS 9
SU S
BP S72
EP S72
PG 1
WC Neurosciences; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Psychiatry
GA RV2QO
UT WOS:000645683800174
DA 2023-06-23
ER

PT J
AU Badiani, A
   Belin, D
   Epstein, D
   Calu, D
   Shaham, Y
AF Badiani, Aldo
   Belin, David
   Epstein, David
   Calu, Donna
   Shaham, Yavin
TI Opiate versus psychostimulant addiction: the differences do matter
SO NATURE REVIEWS NEUROSCIENCE
LA English
DT Review
ID VENTRAL TEGMENTAL AREA; MESOLIMBIC DOPAMINE SYSTEM; CONDITIONED PLACE
   PREFERENCE; STRESS-INDUCED REINSTATEMENT; NUCLEUS-ACCUMBENS DOPAMINE;
   SELF-ADMINISTERED COCAINE; MEDIAL PREFRONTAL CORTEX; HEROIN-SEEKING
   BEHAVIOR; FREELY MOVING RATS; CONTEXT-INDUCED REINSTATEMENT
AB The publication of the psychomotor stimulant theory of addiction in 1987 and the finding that addictive drugs increase dopamine concentrations in the rat mesolimbic system in 1988 have led to a predominance of psychobiological theories that consider addiction to opiates and addiction to psychostimulants as essentially identical phenomena. Indeed, current theories of addiction - hedonic allostasis, incentive sensitization, aberrant learning and frontostriatal dysfunction - all argue for a unitary account of drug addiction. This view is challenged by behavioural, cognitive and neurobiological findings in laboratory animals and humans. Here, we argue that opiate addiction and psychostimulant addiction are behaviourally and neurobiologically distinct and that the differences have important implications for addiction treatment, addiction theories and future research.
C1 [Badiani, Aldo] Univ Roma La Sapienza, Dept Physiol & Pharmacol Vittorio Erspamer, I-00185 Rome, Italy.
   [Badiani, Aldo] Univ Roma La Sapienza, Drug Addict & Clin Pharmacol Unit, Univ Hosp Umberto I, I-00185 Rome, Italy.
   [Belin, David] Univ Poitiers, AVENIR Team Psychobiol Compuls Disorders, INSERM, Expt & Clin Neurosci Lab, F-86000 Poitiers, France.
   [Epstein, David; Calu, Donna; Shaham, Yavin] NIDA, Intramural Res Program, NIH, Baltimore, MD 21224 USA.
C3 Sapienza University Rome; Sapienza University Rome; University Hospital
   Sapienza Rome; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite de Poitiers; National Institutes of Health (NIH) -
   USA; NIH National Institute on Aging (NIA); NIH National Institute on
   Drug Abuse (NIDA)
RP Badiani, A (通讯作者)，Univ Roma La Sapienza, Dept Physiol & Pharmacol Vittorio Erspamer, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
EM aldo.badiani@uniroma1.it; yshaham@intra.nida.nih.gov
RI Belin, David/E-1231-2014; shaham, yavin/G-1306-2014
OI Belin, David/0000-0002-7383-372X; Calu, Donna/0000-0003-2377-9494;
   Badiani, Aldo/0000-0001-6885-369X
FU Sapienza University of Rome, Italy; Institut National de la Sante et de
   la Recherche Medicale (INSERM); US National Institutes of Health (NIH)
   National Institute on Drug Abuse (NIDA)
FX This Perspective was written with financial support from the Ricerche di
   Universita Program of the Sapienza University of Rome, Italy (A. B.),
   the Institut National de la Sante et de la Recherche Medicale (INSERM)
   (D. B.) and the Intramural Research Program of the US National
   Institutes of Health (NIH) National Institute on Drug Abuse (NIDA) (D.
   C., D. E. and Y.S.). We thank R. See for sharing with us unpublished
   data that are included in the summary diagram in FIG. 4, A. Ettenberg
   for sharing historical data with us, and M. Heilig and E. Koya for very
   helpful comments.
CR Ahmed SH, 2011, NEUROMETHODS, V53, P267, DOI 10.1007/978-1-60761-934-5_10
   Ahmed SH, 2006, NEUROPSYCHOPHARMACOL, V31, P563, DOI 10.1038/sj.npp.1300834
   Ahmed SH, 2005, PSYCHOPHARMACOLOGY, V180, P473, DOI 10.1007/s00213-005-2180-z
   Airavaara M, 2011, ADDICT BIOL, V16, P261, DOI 10.1111/j.1369-1600.2010.00281.x
   Albertson DN, 2006, NEUROPSYCHOPHARMACOL, V31, P2304, DOI 10.1038/sj.npp.1301089
   Alderson HL, 2000, PSYCHOPHARMACOLOGY, V153, P111, DOI 10.1007/s002130000527
   Ambroggi F, 2009, NAT NEUROSCI, V12, P247, DOI 10.1038/nn.2282
   American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th
   AMIT Z, 1982, PHARMACOL BIOCHEM BE, V17, P233, DOI 10.1016/0091-3057(82)90075-2
   Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244
   ANTHONY JC, 1989, AM J EPIDEMIOL, V129, P543, DOI 10.1093/oxfordjournals.aje.a115166
   Badiani A, 1999, BEHAV BRAIN RES, V103, P203, DOI 10.1016/S0166-4328(99)00041-8
   Badiani A, 2004, BEHAV PHARMACOL, V15, P327, DOI 10.1097/00008877-200409000-00004
   BEACH HD, 1957, CAN J PSYCHOLOGY, V11, P104, DOI 10.1037/h0083703
   Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584
   Bechara A, 1998, PHARMACOL BIOCHEM BE, V59, P1, DOI 10.1016/S0091-3057(97)00047-6
   Becker JB, 2008, FRONT NEUROENDOCRIN, V29, P36, DOI 10.1016/j.yfrne.2007.07.003
   Bedi G, 2011, BIOL PSYCHIAT, V69, P708, DOI 10.1016/j.biopsych.2010.07.014
   Belin D, 2011, NEUROMETHODS, V53, P337, DOI 10.1007/978-1-60761-934-5_13
   Belin D, 2009, BEHAV BRAIN RES, V199, P89, DOI 10.1016/j.bbr.2008.09.027
   Bonci A, 1996, NEURON, V16, P631, DOI 10.1016/S0896-6273(00)80082-3
   Bossert JM, 2007, J NEUROSCI, V27, P12655, DOI 10.1523/JNEUROSCI.3926-07.2007
   Bossert JM, 2006, BEHAV BRAIN RES, V173, P148, DOI 10.1016/j.bbr.2006.06.008
   Bossert JM, 2011, NAT NEUROSCI, V14, P420, DOI 10.1038/nn.2758
   Bossert JM, 2009, PSYCHOPHARMACOLOGY, V206, P51, DOI 10.1007/s00213-009-1580-x
   Bossert JM, 2005, EUR J PHARMACOL, V526, P36, DOI 10.1016/j.ejphar.2005.09.030
   Bowers MS, 2010, NEURON, V67, P11, DOI 10.1016/j.neuron.2010.06.004
   BOZARTH MA, 1981, LIFE SCI, V28, P551, DOI 10.1016/0024-3205(81)90148-X
   BOZARTH MA, 1985, JAMA-J AM MED ASSOC, V254, P81, DOI 10.1001/jama.254.1.81
   BRADY JV, 1991, NEUROSCI BIOBEHAV R, V15, P35, DOI 10.1016/S0149-7634(05)80089-2
   Breiter HC, 1997, NEURON, V19, P591, DOI 10.1016/S0896-6273(00)80374-8
   Cain ME, 2004, PSYCHOPHARMACOLOGY, V176, P129, DOI 10.1007/s00213-004-1870-2
   Caprioli D, 2007, PROG NEURO-PSYCHOPH, V31, P1639, DOI 10.1016/j.pnpbp.2007.08.029
   Caprioli D, 2008, PSYCHOPHARMACOLOGY, V198, P395, DOI 10.1007/s00213-008-1154-3
   Caprioli D, 2007, PSYCHOPHARMACOLOGY, V192, P397, DOI 10.1007/s00213-007-0717-z
   Caprioli D, 2009, BIOL PSYCHIAT, V65, P893, DOI 10.1016/j.biopsych.2008.12.009
   CARELLI RM, 1993, BRAIN RES, V626, P14, DOI 10.1016/0006-8993(93)90557-4
   Carroll ME, 2002, PSYCHOPHARMACOLOGY, V161, P304, DOI 10.1007/s00213-002-1030-5
   CARROLL ME, 1984, ADV BEHAV PHARMACOL, V4, P47
   Celentano M, 2009, PSYCHOPHARMACOLOGY, V204, P349, DOI 10.1007/s00213-009-1467-x
   Chang JY, 1997, BRAIN RES, V754, P12, DOI 10.1016/S0006-8993(97)00012-7
   Chang JY, 1998, J NEUROSCI, V18, P3098
   Childress A R, 1993, NIDA Res Monogr, V137, P73
   COLLIER HOJ, 1968, NATURE, V220, P228, DOI 10.1038/220228a0
   COLLIER HOJ, 1968, NATURE, V220, P1327, DOI 10.1038/2201327a0
   COLPAERT FC, 1975, LIFE SCI, V16, P705, DOI 10.1016/0024-3205(75)90347-1
   COMPTON PA, 1995, J ADDICT DIS, V14, P97, DOI 10.1300/J069v14n03_07
   Cooper A, 2007, PSYCHOPHARMACOLOGY, V194, P117, DOI 10.1007/s00213-007-0827-7
   Cornish JL, 2003, EUR J PHARMACOL, V482, P339, DOI 10.1016/j.ejphar.2003.09.060
   Covington HE, 2001, PSYCHOPHARMACOLOGY, V158, P388, DOI 10.1007/s002130100858
   Covington HE, 2008, PSYCHOPHARMACOLOGY, V197, P203, DOI 10.1007/s00213-007-1024-4
   CRAIG RJ, 1990, J CLIN PSYCHOL, V46, P230, DOI 10.1002/1097-4679(199003)46:2<230::AID-JCLP2270460217>3.0.CO;2-7
   Crombag HS, 2008, PHILOS T R SOC B, V363, P3233, DOI 10.1098/rstb.2008.0090
   Cruz FC, 2011, PSYCHOPHARMACOLOGY, V215, P165, DOI 10.1007/s00213-010-2139-6
   Dacher M, 2011, NEUROPHARMACOLOGY, V61, P1166, DOI 10.1016/j.neuropharm.2010.11.012
   Dalley JW, 2007, SCIENCE, V315, P1267, DOI 10.1126/science.1137073
   Dalley JW, 2011, NEURON, V69, P680, DOI 10.1016/j.neuron.2011.01.020
   Dalley JW, 2005, PSYCHOPHARMACOLOGY, V182, P579, DOI 10.1007/s00213-005-0107-3
   De Luca MT, 2011, PSYCHOPHARMACOLOGY, V214, P549, DOI 10.1007/s00213-010-2062-x
   de Wit H, 2009, ADDICT BIOL, V14, P22, DOI 10.1111/j.1369-1600.2008.00129.x
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175
   deWit H, 1996, EXP CLIN PSYCHOPHARM, V4, P5, DOI 10.1037/1064-1297.4.1.5
   Di Chiara G, 1999, EUR J PHARMACOL, V375, P13, DOI 10.1016/S0014-2999(99)00372-6
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   DOLE VP, 1966, ARCH INTERN MED, V118, P304, DOI 10.1001/archinte.118.4.304
   Dutra L, 2008, AM J PSYCHIAT, V165, P179, DOI 10.1176/appi.ajp.2007.06111851
   DWORKIN SI, 1988, PHARMACOL BIOCHEM BE, V30, P1051, DOI 10.1016/0091-3057(88)90138-4
   EDDY NB, 1959, PUBLIC HEALTH REP, V74, P755, DOI 10.2307/4590569
   Epstein DH, 2009, DRUG ALCOHOL DEPEN, V101, P92, DOI 10.1016/j.drugalcdep.2008.11.006
   Epstein DH, 2009, ARCH GEN PSYCHIAT, V66, P88, DOI 10.1001/archgenpsychiatry.2008.509
   Ersche KD, 2008, PSYCHOPHARMACOLOGY, V197, P421, DOI 10.1007/s00213-007-1051-1
   Ersche KD, 2006, NEUROPSYCHOPHARMACOL, V31, P1036, DOI 10.1038/sj.npp.1300889
   Ersche KD, 2005, PSYCHOPHARMACOLOGY, V180, P612, DOI 10.1007/s00213-005-2205-7
   Ettenberg A, 2004, NEUROSCI BIOBEHAV R, V27, P721, DOI 10.1016/j.neubiorev.2003.11.009
   ETTENBERG A, 1993, PHARMACOL BIOCHEM BE, V44, P191, DOI 10.1016/0091-3057(93)90298-8
   ETTENBERG A, 1982, PSYCHOPHARMACOLOGY, V78, P204, DOI 10.1007/BF00428151
   Ettenberg A, 1999, PHARMACOL BIOCHEM BE, V64, P507, DOI 10.1016/S0091-3057(99)00109-4
   Ettenberg A, 2009, PHARMACOL BIOCHEM BE, V91, P271, DOI 10.1016/j.pbb.2008.11.003
   Everitt BJ, 2000, PSYCHOPHARMACOLOGY, V153, P17, DOI 10.1007/s002130000566
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Everitt BJ, 1999, ANN NY ACAD SCI, V877, P412, DOI 10.1111/j.1749-6632.1999.tb09280.x
   Feltenstein MW, 2008, BRIT J PHARMACOL, V154, P261, DOI 10.1038/bjp.2008.51
   Ferguson SM, 2004, J NEUROCHEM, V91, P337, DOI 10.1111/j.1471-4159.2004.02712.x
   Fletcher PJ, 2011, NEUROPHARMACOLOGY, V61, P468, DOI 10.1016/j.neuropharm.2011.02.025
   Fole A, 2011, NEUROBIOL LEARN MEM, V95, P491, DOI 10.1016/j.nlm.2011.02.012
   Francesconi W, 2009, J NEUROSCI, V29, P5389, DOI 10.1523/JNEUROSCI.5129-08.2009
   Fu LP, 2008, NEUROSCI LETT, V438, P322, DOI 10.1016/j.neulet.2008.04.033
   Fuchs RA, 2006, J NEUROSCI, V26, P3584, DOI 10.1523/JNEUROSCI.5146-05.2006
   Fuchs RA, 2005, NEUROPSYCHOPHARMACOL, V30, P296, DOI 10.1038/sj.npp.1300579
   Fuchs RA, 2002, PSYCHOPHARMACOLOGY, V160, P425, DOI 10.1007/s00213-001-0997-7
   Fuchs RA, 2008, PSYCHOPHARMACOLOGY, V200, P545, DOI 10.1007/s00213-008-1234-4
   Geist TD, 1997, PHARMACOL BIOCHEM BE, V57, P145, DOI 10.1016/S0091-3057(96)00300-0
   GERACIOTI TD, 1991, BIOL PSYCHIAT, V29, P403, DOI 10.1016/0006-3223(91)90227-D
   GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C
   Gerrits MAFM, 1996, BRAIN RES, V713, P114, DOI 10.1016/0006-8993(95)01491-8
   GERRITS MAFM, 1994, PSYCHOPHARMACOLOGY, V114, P486, DOI 10.1007/BF02249340
   Girault JA, 2007, CURR OPIN PHARMACOL, V7, P77, DOI 10.1016/j.coph.2006.08.012
   Glantz M. D., 1992, VULNERABILITY DRUG A
   GLICKMAN SE, 1967, PSYCHOL REV, V74, P81, DOI 10.1037/h0024290
   Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134
   GYSLING K, 1983, BRAIN RES, V277, P119, DOI 10.1016/0006-8993(83)90913-7
   HARDING WM, 1984, J PSYCHOACTIVE DRUGS, V16, P101, DOI 10.1080/02791072.1984.10471811
   HARRIS JE, 1973, NEUROPHARMACOLOGY, V12, P669, DOI 10.1016/0028-3908(73)90120-2
   Harty SC, 2011, PHARMACOL BIOCHEM BE, V98, P337, DOI 10.1016/j.pbb.2011.02.004
   HEATHER N, 1991, ADDICT BEHAV, V16, P41, DOI 10.1016/0306-4603(91)90038-J
   Heilig M, 2010, NEUROSCI BIOBEHAV R, V35, P334, DOI 10.1016/j.neubiorev.2009.11.018
   Heyne A, 1998, PSYCHOPHARMACOLOGY, V140, P510, DOI 10.1007/s002130050796
   Higgins ST, 2004, ANNU REV PSYCHOL, V55, P431, DOI 10.1146/annurev.psych.55.090902.142033
   HOPE BT, 1994, NEURON, V13, P1235, DOI 10.1016/0896-6273(94)90061-2
   Huang CC, 2007, CEREB CORTEX, V17, P1877, DOI 10.1093/cercor/bhl096
   Hubbard R L, 1986, NIDA Res Monogr, V72, P157
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483
   JOHNSON SW, 1992, J NEUROSCI, V12, P483
   Fernandez-Serrano MJ, 2010, J PSYCHOPHARMACOL, V24, P1317, DOI 10.1177/0269881109349841
   Kalivas PW, 2009, NAT REV NEUROSCI, V10, P561, DOI 10.1038/nrn2515
   KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U
   Kalivas PW, 2005, NEURON, V45, P647, DOI 10.1016/j.neuron.2005.02.005
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kelley AE, 2002, J NEUROSCI, V22, P3306
   Kendler KS, 2003, AM J PSYCHIAT, V160, P687, DOI 10.1176/appi.ajp.160.4.687
   KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259
   Klebaur JE, 2001, EXP CLIN PSYCHOPHARM, V9, P372, DOI 10.1037/1064-1297.9.4.372
   Knackstedt LA, 2002, PHARMACOL BIOCHEM BE, V72, P931, DOI 10.1016/S0091-3057(02)00764-5
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   KOSTEN TR, 1987, ARCH GEN PSYCHIAT, V44, P281
   LaLumiere RT, 2008, J NEUROSCI, V28, P3170, DOI 10.1523/JNEUROSCI.5129-07.2008
   Laviolette SR, 2004, NAT REV NEUROSCI, V5, P55, DOI 10.1038/nrn1298
   Laviolette SR, 2003, MOL PSYCHIATR, V8, P50, DOI 10.1038/sj.mp.4001197
   Lee KW, 2006, P NATL ACAD SCI USA, V103, P3399, DOI 10.1073/pnas.0511244103
   Lenoir M., ADDICTION B IN PRESS
   Lenoir M, 2007, NEUROPSYCHOPHARMACOL, V32, P616, DOI 10.1038/sj.npp.1301083
   LETT BT, 1989, PSYCHOPHARMACOLOGY, V98, P357, DOI 10.1007/BF00451687
   Liu SJ, 2009, J NEUROSCI METH, V177, P67, DOI 10.1016/j.jneumeth.2008.09.020
   London ED, 2005, BIOL PSYCHIAT, V58, P770, DOI 10.1016/j.biopsych.2005.04.039
   Lu H, 2010, NEURON, V67, P821, DOI 10.1016/j.neuron.2010.08.012
   Lu L, 2003, NEUROSCI BIOBEHAV R, V27, P457, DOI 10.1016/S0149-7634(03)00073-3
   Lu L, 2009, BIOL PSYCHIAT, V66, P137, DOI 10.1016/j.biopsych.2009.02.009
   Lundqvist T, 2005, PHARMACOL BIOCHEM BE, V81, P319, DOI 10.1016/j.pbb.2005.02.017
   Lynch WJ, 1999, PSYCHOPHARMACOLOGY, V144, P77, DOI 10.1007/s002130050979
   MACKEY WB, 1985, PHARMACOL BIOCHEM BE, V22, P101, DOI 10.1016/0091-3057(85)90492-7
   Marinelli M, 1998, P NATL ACAD SCI USA, V95, P7742, DOI 10.1073/pnas.95.13.7742
   Marinelli M, 2002, EUR J NEUROSCI, V16, P387, DOI 10.1046/j.1460-9568.2002.02089.x
   MARLATT GA, 1985, RELAPSE PREVENTION M
   Maze I, 2010, SCIENCE, V327, P213, DOI 10.1126/science.1179438
   McBride WJ, 1999, BEHAV BRAIN RES, V101, P129, DOI 10.1016/S0166-4328(99)00022-4
   McFarland K, 2001, J NEUROSCI, V21, P8655
   McLaughlin J, 2003, PSYCHOPHARMACOLOGY, V168, P57, DOI 10.1007/s00213-002-1196-x
   McNamara R, 2010, PSYCHOPHARMACOLOGY, V212, P453, DOI 10.1007/s00213-010-1974-9
   Meil WM, 1996, BEHAV PHARMACOL, V7, P754
   Mello NK, 1996, NEUROPSYCHOPHARMACOL, V14, P375, DOI 10.1016/0893-133X(95)00274-H
   Miczek KA, 2008, PHARMACOL THERAPEUT, V120, P102, DOI 10.1016/j.pharmthera.2008.07.006
   Montanari C, 2011, BEHAV PHARMACOL, V22, pE21
   Montoya ID, 2004, CLIN PHARMACOL THER, V75, P34, DOI 10.1016/j.clpt.2003.09.004
   Muriach M, 2010, J NEUROCHEM, V114, P675, DOI 10.1111/j.1471-4159.2010.06794.x
   NADER K, 1994, BEHAV NEUROSCI, V108, P1128, DOI 10.1037/0735-7044.108.6.1128
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   NESTLER EJ, 1992, J NEUROSCI, V12, P2439
   Niehaus JL, 2010, EUR J NEUROSCI, V32, P108, DOI 10.1111/j.1460-9568.2010.07256.x
   Nielsen DA, 2010, PSYCHIAT GENET, V20, P207, DOI 10.1097/YPG.0b013e32833a2106
   Nutt DJ, 2010, LANCET, V376, P1558, DOI 10.1016/S0140-6736(10)61462-6
   OCONNOR L, 1990, J PSYCHOACTIVE DRUGS, V22, P305, DOI 10.1080/02791072.1990.10472553
   OLDS J, 1954, J COMP PHYSIOL PSYCH, V47, P419, DOI 10.1037/h0058775
   OLDS ME, 1982, BRAIN RES, V237, P429, DOI 10.1016/0006-8993(82)90454-1
   Olmstead MC, 1997, BEHAV NEUROSCI, V111, P1313, DOI 10.1037/0735-7044.111.6.1313
   Ornstein TJ, 2000, NEUROPSYCHOPHARMACOL, V23, P113, DOI 10.1016/S0893-133X(00)00097-X
   Pan B, 2008, J NEUROSCI, V28, P1385, DOI 10.1523/JNEUROSCI.4033-07.2008
   Paolone G, 2004, BEHAV BRAIN RES, V152, P149, DOI 10.1016/j.bbr.2003.10.003
   Paolone G, 2007, NEUROPSYCHOPHARMACOL, V32, P2611, DOI 10.1038/sj.npp.1301388
   Paxinos G, 2005, RAT BRAIN STEREOTAXI
   Pelloux Y, 2007, PSYCHOPHARMACOLOGY, V194, P127, DOI 10.1007/s00213-007-0805-0
   Peters J, 2008, J NEUROSCI, V28, P6046, DOI 10.1523/JNEUROSCI.1045-08.2008
   Peters J, 2009, LEARN MEMORY, V16, P279, DOI 10.1101/lm.1041309
   PETTIT HO, 1984, PSYCHOPHARMACOLOGY, V84, P167, DOI 10.1007/BF00427441
   PHILLIPS AG, 1980, PHARMACOL BIOCHEM BE, V12, P965, DOI 10.1016/0091-3057(80)90460-8
   Piazza PV, 1998, TRENDS PHARMACOL SCI, V19, P67, DOI 10.1016/S0165-6147(97)01115-2
   Piazza PV, 1996, ANNU REV PHARMACOL, V36, P359, DOI 10.1146/annurev.pa.36.040196.002043
   Pickens CL, 2011, TRENDS NEUROSCI, V34, P411, DOI 10.1016/j.tins.2011.06.001
   PICKENS R, 1968, PSYCHOPHARMACOLOGIA, V12, P158, DOI 10.1007/BF00401545
   Pierce RC, 2006, NEUROSCI BIOBEHAV R, V30, P215, DOI 10.1016/j.neubiorev.2005.04.016
   RASSNICK S, 1993, BRAIN RES, V623, P16, DOI 10.1016/0006-8993(93)90004-7
   ROBERTS DCS, 1980, PHARMACOL BIOCHEM BE, V12, P781, DOI 10.1016/0091-3057(80)90166-5
   ROBINS LN, 1974, AM J EPIDEMIOL, V99, P235, DOI 10.1093/oxfordjournals.aje.a121608
   Robinson TE, 1997, J NEUROSCI, V17, P8491
   Robinson TE, 2004, NEUROPHARMACOLOGY, V47, P33, DOI 10.1016/j.neuropharm.2004.06.025
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   ROBINSON TE, 1986, BRAIN RES REV, V11, P157, DOI 10.1016/0165-0173(86)90002-0
   Rogers JL, 2008, NEUROSCIENCE, V151, P579, DOI 10.1016/j.neuroscience.2007.10.012
   ROSSETTI ZL, 1992, EUR J PHARMACOL, V221, P227, DOI 10.1016/0014-2999(92)90706-A
   Roth ME, 2004, NEUROSCI BIOBEHAV R, V28, P533, DOI 10.1016/j.neubiorev.2004.08.001
   Russo SJ, 2010, TRENDS NEUROSCI, V33, P267, DOI 10.1016/j.tins.2010.02.002
   Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-7
   Schindler CW, 2002, PSYCHOPHARMACOLOGY, V163, P327, DOI 10.1007/s00213-002-1157-4
   Schmidt HD, 2005, EUR J PHARMACOL, V526, P65, DOI 10.1016/j.ejphar.2005.09.068
   Schottenfeld RS, 1997, ARCH GEN PSYCHIAT, V54, P713
   SCHUSTER CR, 1969, ANNU REV PHARMACOLOG, V9, P483, DOI 10.1146/annurev.pa.09.040169.002411
   Self DW, 1998, J NEUROSCI, V18, P1848
   Sellings LHL, 2003, J NEUROSCI, V23, P6295
   Shaham Y, 2000, BRAIN RES REV, V33, P13, DOI 10.1016/S0165-0173(00)00024-2
   SHAHAM Y, 1995, PSYCHOPHARMACOLOGY, V119, P334, DOI 10.1007/BF02246300
   Shaham Y, 2000, EUR J NEUROSCI, V12, P292, DOI 10.1046/j.1460-9568.2000.00899.x
   Shalev U, 2002, PHARMACOL REV, V54, P1, DOI 10.1124/pr.54.1.1
   Shalev U, 2001, PSYCHOPHARMACOLOGY, V156, P98, DOI 10.1007/s002130100748
   Shalev U, 2010, BRAIN RES, V1314, P15, DOI 10.1016/j.brainres.2009.07.028
   Shearer J, 2008, DRUG ALCOHOL REV, V27, P301, DOI 10.1080/09595230801927372
   Shepard JD, 2004, BIOL PSYCHIAT, V55, P1082, DOI 10.1016/j.biopsych.2004.02.032
   Shippenberg TS, 1998, CRIT REV NEUROBIOL, V12, P267, DOI 10.1615/CritRevNeurobiol.v12.i4.10
   SHIPPENBERG TS, 1993, J PHARMACOL EXP THER, V265, P53
   Sinha R, 2001, PSYCHOPHARMACOLOGY, V158, P343, DOI 10.1007/s002130100917
   SOLOMON RL, 1973, J ABNORM PSYCHOL, V81, P158, DOI 10.1037/h0034534
   Spagnolo PA, 2011, BEHAV PHARMACOL, V22, pE21
   STEWART J, 1984, PSYCHOL REV, V91, P251, DOI 10.1037/0033-295X.91.2.251
   Stewart J, 1999, BEHAV BRAIN RES, V102, P89, DOI 10.1016/S0166-4328(99)00002-9
   Stewart J, 1996, PSYCHOBIOLOGY, V24, P154
   STINUS L, 1989, BIOL PSYCHIAT, V26, P363, DOI 10.1016/0006-3223(89)90052-8
   STOLERMAN I, 1992, TRENDS PHARMACOL SCI, V13, P170, DOI 10.1016/0165-6147(92)90059-F
   STRETCH R, 1973, CAN J PSYCHOL, V27, P168, DOI 10.1037/h0082466
   Suh JJ, 2008, PSYCHOANAL PSYCHOL, V25, P518, DOI 10.1037/0736-9735.25.3.518
   TARTER RE, 1992, VULNERABILITY TO DRUG ABUSE, P149, DOI 10.1037/10107-007
   Testa A, 2011, PSYCHOPHARMACOLOGY, V215, P749, DOI 10.1007/s00213-011-2176-9
   Thomas MJ, 2008, BRIT J PHARMACOL, V154, P327, DOI 10.1038/bjp.2008.77
   Thomsen M, 2007, BEHAV GENET, V37, P101, DOI 10.1007/s10519-006-9097-0
   Tramullas M, 2008, NEUROPHARMACOLOGY, V54, P640, DOI 10.1016/j.neuropharm.2007.11.018
   Tsuang MT, 1998, ARCH GEN PSYCHIAT, V55, P967, DOI 10.1001/archpsyc.55.11.967
   Tzschentke TM, 1998, PROG NEUROBIOL, V56, P613, DOI 10.1016/S0301-0082(98)00060-4
   Uslaner J, 2001, EUR J NEUROSCI, V13, P1977, DOI 10.1046/j.0953-816x.2001.01574.x
   Van den Oever MC, 2008, NAT NEUROSCI, V11, P1053, DOI 10.1038/nn.2165
   VANDERKOOY D, 1982, BRAIN RES, V243, P107, DOI 10.1016/0006-8993(82)91124-6
   Vanderschuren LJMJ, 2005, J NEUROSCI, V25, P8665, DOI 10.1523/JNEUROSCI.0925-05.2005
   Vanderschuren LJMJ, 2000, PSYCHOPHARMACOLOGY, V151, P99, DOI 10.1007/s002130000493
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   VANREE JM, 1987, EUR J PHARMACOL, V134, P239, DOI 10.1016/0014-2999(87)90172-5
   Verdejo-Garcia A, 2007, REV NEUROLOGIA, V44, P432, DOI 10.33588/rn.4407.2006356
   Vezina P, 2004, NEUROSCI BIOBEHAV R, V27, P827, DOI 10.1016/j.neubiorev.2003.11.001
   Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI 10.1093/cercor/10.3.318
   WARNER LA, 1995, ARCH GEN PSYCHIAT, V52, P219
   Weeks J R, 1968, Res Publ Assoc Res Nerv Ment Dis, V46, P288
   WEEKS JR, 1962, SCIENCE, V138, P143, DOI 10.1126/science.138.3537.143
   Weiss F, 2005, CURR OPIN PHARMACOL, V5, P9, DOI 10.1016/j.coph.2004.11.001
   Westerink BHC, 1996, J NEUROSCI, V16, P2605
   White NM, 1996, ADDICTION, V91, P921, DOI 10.1111/j.1360-0443.1996.tb03586.x
   Whitelaw RB, 1996, PSYCHOPHARMACOLOGY, V127, P213, DOI 10.1007/BF02805996
   WIKLER A, 1973, ARCH GEN PSYCHIAT, V28, P611
   Wills T A, 1994, J Subst Abuse, V6, P1, DOI 10.1016/S0899-3289(94)90039-6
   WINGER G, 1994, BEHAV PHARMACOL, V5, P141, DOI 10.1097/00008877-199404000-00005
   Winstanley CA, 2009, CEREB CORTEX, V19, P435, DOI 10.1093/cercor/bhn094
   WISE RA, 1989, ANNU REV PSYCHOL, V40, P191, DOI 10.1146/annurev.ps.40.020189.001203
   Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406
   WISE RA, 1978, BRAIN RES, V152, P215, DOI 10.1016/0006-8993(78)90253-6
   WISE RA, 1995, SYNAPSE, V21, P140, DOI 10.1002/syn.890210207
   WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469
   Wolf ME, 1998, PROG NEUROBIOL, V54, P679, DOI 10.1016/S0301-0082(97)00090-7
   Wolf ME, 2004, NEUROPHARMACOLOGY, V47, P61, DOI 10.1016/j.neuropharm.2004.07.006
   WOLFFGRAMM J, 1995, BEHAV BRAIN RES, V70, P77, DOI 10.1016/0166-4328(95)00131-C
   Yuferov V, 2010, ANN NY ACAD SCI, V1187, P184, DOI 10.1111/j.1749-6632.2009.05275.x
NR 256
TC 336
Z9 343
U1 0
U2 81
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-003X
EI 1471-0048
J9 NAT REV NEUROSCI
JI Nat. Rev. Neurosci.
PD NOV
PY 2011
VL 12
IS 11
BP 685
EP 700
DI 10.1038/nrn3104
PG 16
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 842GU
UT WOS:000296584400013
PM 21971065
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Hostetler, CM
   Ryabinin, AE
AF Hostetler, Caroline M.
   Ryabinin, Andrey E.
TI Love and addiction: the devil is in the differences: a commentary on
   "The behavioral, anatomical and pharmacological parallels between social
   attachment, love and addiction."
SO PSYCHOPHARMACOLOGY
LA English
DT Editorial Material
ID DRUG-ADDICTION; ALCOHOL; COCAINE; MODEL; AMPHETAMINE; PREDICTORS;
   MECHANISMS; SUPPORT; RELAPSE
C1 [Hostetler, Caroline M.; Ryabinin, Andrey E.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA.
C3 Oregon Health & Science University
RP Hostetler, CM (通讯作者)，Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA.
EM caroline.hostetler@gmail.com
OI Ryabinin, Andrey/0000-0003-4662-3775
FU NIAAA NIH HHS [5T32AA007468-24, U01 AA016647, P60 AA10760, R01 AA019793]
   Funding Source: Medline
CR Ahmed SH, 2005, PSYCHOPHARMACOLOGY, V180, P473, DOI 10.1007/s00213-005-2180-z
   Anacker AMJ, 2011, ALCOHOL CLIN EXP RES, V35, P1884, DOI 10.1111/j.1530-0277.2011.01533.x
   Anacker AMJ, 2011, ADDICT BIOL, V16, P92, DOI 10.1111/j.1369-1600.2010.00234.x
   Aragona BJ, 2006, NAT NEUROSCI, V9, P133, DOI 10.1038/nn1613
   Buckner JD, 2008, J PSYCHIATR RES, V42, P230, DOI 10.1016/j.jpsychires.2007.01.002
   Burkett JP, 2012, PSYCHOPHARMACOLOGY B
   Carter CS, 1998, PSYCHONEUROENDOCRINO, V23, P779
   Charney DA, 2010, J SUBST ABUSE TREAT, V38, P42, DOI 10.1016/j.jsat.2009.06.002
   Ducharme JK, 2012, J HOMOSEXUAL, V59, P580, DOI 10.1080/00918369.2012.665689
   Ferris CF, 2005, J NEUROSCI, V25, P149, DOI 10.1523/JNEUROSCI.3156-04.2005
   Fleckenstein AE, 2000, EUR J PHARMACOL, V406, P1, DOI 10.1016/S0014-2999(00)00639-7
   Garmendia ML, 2008, REV MED CHILE, V136, P169, DOI /S0034-98872008000200005
   Gubernick DJ, 2000, P ROY SOC B-BIOL SCI, V267, P147, DOI 10.1098/rspb.2000.0979
   Hajema KJ, 1998, ADDICTION, V93, P1717, DOI 10.1046/j.1360-0443.1998.931117179.x
   Heilig M, 2006, PHARMACOL THERAPEUT, V111, P855, DOI 10.1016/j.pharmthera.2006.02.001
   Homish GG, 2008, J STUD ALCOHOL DRUGS, V69, P906, DOI 10.15288/jsad.2008.69.906
   Hostetler CM, 2012, ALCOHOL CLIN EXP RES, V36, p108A
   Hostetler CM, 2012, NEUROSCIENCE
   Hunter-Reel D, 2009, ADDICTION, V104, P1281, DOI 10.1111/j.1360-0443.2009.02611.x
   Insel TR, 2003, PHYSIOL BEHAV, V79, P351, DOI 10.1016/S0031-9384(03)00148-3
   Kelly JF, 2008, ALCOHOL CLIN EXP RES, V32, P1468, DOI 10.1111/j.1530-0277.2008.00712.x
   Liu Y, 2011, J NEUROSCI, V31, P7960, DOI 10.1523/JNEUROSCI.1006-11.2011
   Liu Y, 2010, P NATL ACAD SCI USA, V107, P1217, DOI 10.1073/pnas.0911998107
   MacLean Paul, 1990, TRIUNE BRAIN EVOLUTI
   Mark TL, 2001, DRUG ALCOHOL DEPEN, V61, P195, DOI 10.1016/S0376-8716(00)00162-9
   Mattson BJ, 2001, BEHAV NEUROSCI, V115, P683, DOI 10.1037/0735-7044.115.3.683
   McCrady BS, 2006, ALCOHOL CLIN EXP RES, V30, P688, DOI 10.1111/j.1530-0277.2006.00080.x
   McGeehan AJ, 2003, SYNAPSE, V47, P240, DOI 10.1002/syn.10166
   Mcguire B, 1992, EFFECTS MATE REMOVAL, P37
   McKay JR, 2005, J SUBST ABUSE TREAT, V28, pS73, DOI 10.1016/j.jsat.2004.10.010
   National Institute on Drug Abuse (NIDA), 2012, MED CONS DRUG AB
   Nestler EJ, 2008, PHILOS T R SOC B, V363, P3245, DOI 10.1098/rstb.2008.0067
   NUMAN M, 2003, HORM BR BEHAV, P1
   *OFF NAT DRUG CONT, 2004, EC COSTS DRUG AB US
   Ragen BJ, 2012, AM J PRIMATOL, DOI ajp.22026/ajp.22026
   Ramsey AJ, 2008, NEUROPSYCHOPHARMACOL, V33, P2701, DOI 10.1038/sj.npp.1301663
   Rehm J, 2009, LANCET, V373, P2223, DOI 10.1016/S0140-6736(09)60746-7
   Schaeffer B., 2009, IS IT LOVE IS IT ADD
   Uchino BN, 1996, PSYCHOL BULL, V119, P488, DOI 10.1037/0033-2909.119.3.488
NR 39
TC 8
Z9 9
U1 2
U2 29
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0033-3158
EI 1432-2072
J9 PSYCHOPHARMACOLOGY
JI Psychopharmacology
PD NOV
PY 2012
VL 224
IS 1
BP 27
EP 29
DI 10.1007/s00213-012-2858-y
PG 3
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 018SB
UT WOS:000309681900002
PM 22948669
OA Bronze
DA 2023-06-23
ER

PT J
AU Davis, M
AF Davis, Michael
TI Addiction, Criminalization, and Character Evidence
SO TEXAS LAW REVIEW
LA English
DT Article
ID DRUG-ADDICTION; CRIME; LAW; PERSPECTIVE; PUNISHMENT; DOCTRINE; DEFENSE;
   DISEASE; STIGMA; SEARCH
AB A drug addict's addiction is no defense to drug crimes. Criminal law rejects the disease model of addiction, at least insofar as the model would inform the Eighth Amendment, the voluntary act doctrine, or the insanity defense. This Note does not take issue with the criminalization of addiction, arguing merely that it should preclude evidence law's treatment of addiction as something other than immoral.
   The rule against character evidence precludes evidence of an immoral propensity when offered to prove action in conformity with that propensity. But in prosecutions for property crimes, courts routinely admit evidence of a defendant's addiction on the theory that it proves a motive, not an immoral propensity. The law's rejection of the disease model, though, teaches that an addict will only decide to acquire and use drugs if she succumbs not to an irresistible compulsion, but to a temptation to do wrong.
   Criminal law's treatment of addiction should have force in the law of evidence because, right or wrong, and among other reasons, criminalization teaches jurors that action in accordance with addiction is immoral. And the prejudice that arises from a perception of the defendant as prone to immorality is precisely the reason we have a rule against character evidence.
CR Anderson BJ, 2012, YALE LAW J, V121, P1912
   Anderson Barrett J., 2012, YALE LAW J, V121, P1912
   [Anonymous], 2014, RESULTS 2013 NATL SU
   [Anonymous], 2013, DIAGN STAT MAN MENT, P541
   Bennett T, 2008, AGGRESS VIOLENT BEH, V13, P107, DOI 10.1016/j.avb.2008.02.001
   BOLDT RC, 1992, U PENN LAW REV, V140, P2245, DOI 10.2307/3312415
   Boldt Richard C., 1992, U PENN LAW REV, V140, P2245
   Bone RG, 1998, CALIF LAW REV, V86, P241, DOI 10.2307/3481134
   BROUN KENNETH S., 2013, MCCORMICK EVIDENCE, P1080
   Cole John O., 1988, MERCER L REV, V39, P907
   Cole John O., 1988, MERCER LAW REV, V39, P907
   Corrado Michael Louis, 2007, QUINNIPIAC L REV, V25, P117
   Corrado Michael Louis, 2007, QUINNIPIAC L REV, V25, P117
   Corrigan PW, 2009, J SOC WORK, V9, P139, DOI 10.1177/1468017308101818
   Crabbe JC, 2002, ANNU REV PSYCHOL, V53, P435, DOI 10.1146/annurev.psych.53.100901.135142
   Denno DW, 2002, MINN LAW REV, V87, P269
   Duff R.A., 2000, MELBOURNE U L REV, V24, P411
   DUFF RA, 2000, MELB UNIV LAW REV, V24, P411
   FEINBERG J, 1965, MONIST, V49, P397, DOI 10.5840/monist196549326
   Feix J, 2007, J AM ACAD PSYCHIATRY, V35, P172
   FINGARETTE H, 1970, HARVARD LAW REV, V83, P793, DOI 10.2307/1339839
   Fingarette Herbert, 1970, HARVARD LAW REV, V83, P802
   Goldstein Paul J., 1985, J DRUG ISSUES, V15, P493
   GOLDSTEIN PJ, 1985, J DRUG ISSUES, V15, P493, DOI 10.1177/002204268501500406
   Grant E, 2000, U ILLINOIS LAW REV, P997
   Grasmick Harold G., 1980, J CRIM LAW CRIM, V71, P325
   GRASMICK HG, 1980, J CRIM LAW CRIM, V71, P325, DOI 10.2307/1142704
   HAMMERSLEY R, 1989, BRIT J ADDICT, V84, P1029
   Hammersley Richard, 1989, BRIT J ADDICT, V84, P1029
   Hanna N, 2008, LAW PHILOS, V27, P123, DOI 10.1007/s10982-007-9014-6
   HART H.L.A., 1968, PUNISHMENT RESPONSIB, V28, P35
   Heyman Gene M., 2009, ADDICTION DISORDER C, DOI [10.4159/9780674053991, DOI 10.4159/9780674053991]
   Hollander-Blumoff Rebecca, 2012, EMORY LJ, V61, P501
   Hollander-Blumoff Rebecca, 2012, EMORY LJ, V61, P501
   Imwinkelried EJ, 2010, CATHOL U LAW REV, V59, P719
   Imwinkelried Edward J., 1990, OHIO ST L J, V51, P575
   IMWINKELRIED EJ, 1999, UNCHARGED MISCONDUCT, V1
   KADISH SH, 1987, CALIF LAW REV, V75, P257, DOI 10.2307/3480580
   Kahan Dan M., 1996, U CHICAGO LAW REV, V63, P602
   Kahan DM, 1996, U CHICAGO LAW REV, V63, P591, DOI 10.2307/1600237
   KUHNS RB, 1981, IOWA LAW REV, V66, P777
   LAFAVE WAYNE R., 2003, CRIMINAL LAW, P481
   Landis Debra T., 1980, A L R
   Leonard David P., 1998, IND LJ, V73, P1161
   Leonard David P., 2001, LOYOLA L REV, V34, P439
   Leonard DP, 1998, INDIANA LAW J, V73, P1161
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   MCCORMICK CHARLES T., 1954, MCCORMICKS HDB LAW E, P340
   Menard S, 2001, JUSTICE Q, V18, P269, DOI 10.1080/07418820100094901
   Mendez MA, 1998, HASTINGS LAW J, V49, P871
   Mendez Miguel A., 1998, HASTINGS LAW J, V49, P881
   Morris Andrew J., 1998, REV LITIG, V17, P181
   MORSE SJ, 1994, U PENN LAW REV, V142, P1587, DOI 10.2307/3312464
   Morse Stephen J., 2017, ADDICTION CHOICE, P426
   Murray PE, 2013, UCLA LAW REV, V60, P1006
   Nordstrom BR, 2011, J PSYCHIAT LAW, V39, P663, DOI DOI 10.1177/009318531103900407
   Reed Thomas J., TEMP L REV, V78, P201
   Reed Thomas J., TEMP L REV, V78, P201
   Robinson Paul H., 2018, MAPPING AMCRIMINAL L
   Room R, 2005, DRUG ALCOHOL REV, V24, P143, DOI 10.1080/09595230500102434
   Rothstein Paul F., 1995, LOY LA L REV, V28, P1259
   Rothstein Paul F., 1995, LOY L REV, V28, P1259
   Seddon T, 2000, J SOC POLICY, V29, P95, DOI 10.1017/S0047279400005833
   Seddon Toby, 2000, J SOCIAL POLY, V29, P95
   Simpson M, 2003, INT J DRUG POLICY, V14, P307, DOI DOI 10.1016/S0955-3959(03)00081-1
   Simpson Mark, 2003, INT J DRUG POLY, V14, P307
   SLOUGH MC, 1956, IOWA LAW REV, V41, P325
   Stuntz William J., 1997, YALE LAW J, V107, P1
   Stuntz WJ, 1997, YALE LAW J, V107, P1, DOI 10.2307/797276
   SUTHERLAND EDWIN H., 1992, PRINCIPLES CRIMINOLO, P90
   Teitelbaum E., 1983, NM L REV, V13, P423
   Teitelbaum Lee E., 1983, NM L REV, V13, P423
   Uviller H. Richard, 1982, U PENN LAW REV, V130, P846
   UVILLER HR, 1982, U PENN LAW REV, V130, P845, DOI 10.2307/3311930
   WEISSENBERGER G, 1985, IOWA LAW REV, V70, P579
   WORLD HEALTH ORG, 1993, ICD CLASS MENT BEH D, P57
   WRIGHT CHARLES ALAN, 2014, FEDERAL PRACTICE PRO, P97
   WRIGHT CHARLES ALAN, 2017, FEDERAL PRACTICE PRO
   WROTH LK, 1985, VILL L REV, V30, P1329
   WROTH LK, 1985, VILL L REV, V30, P1315
   ZWEBEN JE, 1990, WESTERN J MED, V152, P588
   Zweben Joan Ellen, 1990, W J MED, V152, P588
NR 82
TC 2
Z9 2
U1 0
U2 5
PU TEXAS LAW REVIEW PUBL INC
PI AUSTIN
PA 727 E 26TH ST, AUSTIN, TX 78705 USA
SN 0040-4411
J9 TEX LAW REV
JI Tex. Law Rev.
PD FEB
PY 2018
VL 96
IS 3
BP 619
EP 652
PG 34
WC Law
WE Social Science Citation Index (SSCI)
SC Government & Law
GA FY0XO
UT WOS:000426536200004
DA 2023-06-23
ER

PT J
AU Ziegler, PP
AF Ziegler, PP
TI Addiction and the treatment of pain
SO SUBSTANCE USE & MISUSE
LA English
DT Article
DE pain; addiction; opioids; relapse; tolerance
ID CHRONIC NONMALIGNANT PAIN; METHADONE-MAINTENANCE; ABUSE
AB Persons experiencing pain, whether acute or chronic, seek and deserve relief from their discomfort and loss of function. However, opioid analgesics have the capacity to induce tolerance, physical dependence, and addiction. Furthermore, persons with a history of opioid use disorders or other substance misuse problems are at "high risk" when they acquire painful conditions requiring aggressive treatment. Prescription of opioids could trigger a relapse to the original drug of choice or could initiate a new bout of addiction with the prescribed drug. This article explores the relationship between addiction and pain, including signs of developing addiction and approaches to managing pain in those with addiction.
C1 Williamsburg Pl & William J Farley Ctr, Williamsburg, VA 23188 USA.
RP Ziegler, PP (通讯作者)，Williamsburg Pl & William J Farley Ctr, 5477 Mooretown Rd, Williamsburg, VA 23188 USA.
EM penzig@aol.com
CR ANDERSSON S, 1995, MED HYPOTHESES, V45, P271, DOI 10.1016/0306-9877(95)90117-5
   Campbell J., 1995, PAIN 5 VITAL SIGN
   Ciccone DS, 2000, J PAIN SYMPTOM MANAG, V20, P180, DOI 10.1016/S0885-3924(00)00177-9
   Doverty M, 2001, PAIN, V90, P91, DOI 10.1016/S0304-3959(00)00391-2
   FERNANDEZ E, 1995, PAIN, V61, P165, DOI 10.1016/0304-3959(95)00192-U
   FIELDS H, 1994, ANN NEUROL, V35, pS42, DOI 10.1002/ana.410350713
   FLOR H, 1992, PAIN, V49, P221, DOI 10.1016/0304-3959(92)90145-2
   GRINSTEAD SF, 1999, ADDICTION FREE PAIN
   Kouyanou K, 1997, J PSYCHOSOM RES, V43, P497, DOI 10.1016/S0022-3999(97)00171-2
   MCQUAY H, 1995, BRIT MED J, V311, P1047, DOI 10.1136/bmj.311.7012.1047
   Portenoy RK, 1996, J PAIN SYMPTOM MANAG, V11, P203, DOI 10.1016/0885-3924(95)00187-5
   Rosenblum A, 2003, JAMA-J AM MED ASSOC, V289, P2370, DOI 10.1001/jama.289.18.2370
   SAVAGE SR, 2003, PRINCIPLES ADDICTION, P1405
   Schnoll SH, 2003, AM J ADDICTION, V12, pS27, DOI 10.1080/10550490390210218
   Toomey TC, 1995, CLIN J PAIN, V11, P307, DOI 10.1097/00002508-199512000-00008
   WEISSMAN DE, 1989, PAIN, V36, P363, DOI 10.1016/0304-3959(89)90097-3
NR 16
TC 19
Z9 19
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1082-6084
EI 1532-2491
J9 SUBST USE MISUSE
JI Subst. Use Misuse
PY 2005
VL 40
IS 13-14
BP 1945
EP 1954
DI 10.1080/10826080500294841
PG 10
WC Substance Abuse; Psychiatry; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry; Psychology
GA 990YR
UT WOS:000233779800004
PM 16282087
DA 2023-06-23
ER

PT J
AU Foddy, B
AF Foddy, Bennett
TI Addicted to Food, Hungry for Drugs
SO NEUROETHICS
LA English
DT Article
DE Addiction; Obesity; Binge-eating; Drugs; Neuroscience
ID OBESITY; BRAIN; CONSCIOUSNESS; SIMILARITY; SATIATION; APPETITE;
   COERCION; DISEASE; NERVOSA; HUMANS
AB There is a growing consensus among neuroscientists that people can become addicted to food, and that at least some cases of obesity have addiction as their cause. By contrast, the rest of the world continues to see obesity as either a disease of the metabolism, or as a reckless case of self-harm. Among obesity researchers, there has been a lively debate on the issue of whether obesity ought to be considered a disease. Few researchers, however, have suggested that obesity is a disease in the same sense as addiction is usually claimed to be a disease-that is, a disease of behaviour with a neurological cause. In this piece, I review what is now a compelling body of evidence for food addiction, to establish that many or most cases of obesity have addiction at their foundation. I then argue that in spite of this, obesity ought not to be considered a neurobehavioural disease in the sense usually attributed to drug addiction. Given the link between addiction and obesity, this implies that the disease conception of addiction must be abandoned. I conclude by assessing some of the implications this move has for policy and ethics, with regard to both obesity and drug addiction.
C1 Princeton Univ, Univ Ctr Human Values, Princeton, NJ 08544 USA.
C3 Princeton University
RP Foddy, B (通讯作者)，Princeton Univ, Univ Ctr Human Values, 5 Ivy Lane, Princeton, NJ 08544 USA.
EM bfoddy@princeton.edu
CR Ahima RS, 2008, J CLIN INVEST, V118, P2380, DOI 10.1172/JCI36284
   Ahituv N, 2006, HUM MOL GENET, V15, P387, DOI 10.1093/hmg/ddi455
   American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th
   [Anonymous], 1996, Nutrition, V12, P397
   AVENA NM, 2007, NEUROSCI BIOBEHAV RE
   Bash KW, 1939, J COMP PSYCHOL, V28, P137, DOI 10.1037/h0060670
   Batterham RL, 2003, ANN NY ACAD SCI, V994, P162, DOI 10.1111/j.1749-6632.2003.tb03176.x
   BOORSE C, 1977, PHILOS SCI, V44, P542, DOI 10.1086/288768
   Bruch H., 1973, EATING DISORDERS OBE
   Caplan AL, 2006, J SUBST ABUSE TREAT, V31, P117, DOI 10.1016/j.jsat.2006.06.009
   Chang GQ, 2008, J NEUROSCI, V28, P12107, DOI 10.1523/JNEUROSCI.2642-08.2008
   Colantuoni C, 2002, OBES RES, V10, P478, DOI 10.1038/oby.2002.66
   Colantuoni C, 2001, NEUROREPORT, V12, P3549, DOI 10.1097/00001756-200111160-00035
   Conway B, 2004, Obes Rev, V5, P145, DOI 10.1111/j.1467-789X.2004.00144.x
   Dakin CL, 2004, ENDOCRINOLOGY, V145, P2687, DOI 10.1210/en.2003-1338
   Denton D, 1999, P NATL ACAD SCI USA, V96, P5304, DOI 10.1073/pnas.96.9.5304
   FODDY B, 2010, PHILOS PSYC IN PRESS, V17
   Gabel JR, 2007, HEALTH AFFAIR, V26, pW474, DOI 10.1377/hlthaff.26.4.w474
   GARFINKEL PE, 1995, AM J PSYCHIAT, V152, P1052
   Gold MS, 2003, PSYCHIAT ANN, V33, P117, DOI 10.3928/0048-5713-20030201-08
   GORTZEN A, 2007, DTSCH ARZTEBL, V104, P1166
   Hebb D.O., 1949, WILEY BOOK CLIN PSYC
   Heshka S, 2001, INT J OBESITY, V25, P1401, DOI 10.1038/sj.ijo.0801790
   Holst B, 2004, TRENDS PHARMACOL SCI, V25, P113, DOI 10.1016/j.tips.2004.01.010
   Hu F, 2008, OBESITY EPIDEMIOLOGY, P216
   Hyman SE, 2007, AM J BIOETHICS, V7, P8, DOI 10.1080/15265160601063969
   Klag S, 2005, SUBST USE MISUSE, V40, P1777, DOI 10.1080/10826080500260891
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Liotti M, 2001, P NATL ACAD SCI USA, V98, P2035, DOI 10.1073/pnas.98.4.2035
   MERSKEY H, 1986, J MED PHILOS, V11, P215, DOI 10.1093/jmp/11.3.215
   Mitchell J. E., 2008, BINGE EATING DISORDE
   Nace EP, 2007, AM J ADDICTION, V16, P15, DOI 10.1080/10550490601077783
   National Institute on Drug Abuse, 2009, PRINC DRUG ADD TREAT
   Nordenfelt Lennart, 2007, Med Health Care Philos, V10, P5, DOI 10.1007/s11019-006-9017-3
   Pelchat ML, 2009, J NUTR, V139, P620, DOI 10.3945/jn.108.097816
   Pelchat ML, 2004, NEUROIMAGE, V23, P1486, DOI 10.1016/j.neuroimage.2004.08.023
   *SAMSHA, 2007, RES 2006 SURV DRUG U
   Santel S, 2006, BRAIN RES, V1114, P138, DOI 10.1016/j.brainres.2006.07.045
   Sidney S, 1997, AM J PUBLIC HEALTH, V87, P585, DOI 10.2105/AJPH.87.4.585
   Striegel-Moore RH, 2000, EUR EAT DISORD REV, V8, P344, DOI 10.1002/1099-0968(200010)8:5<344::AID-ERV380>3.0.CO;2-0
   Tataranni PA, 1999, P NATL ACAD SCI USA, V96, P4569, DOI 10.1073/pnas.96.8.4569
   Tsai AG, 2006, J AM DIET ASSOC, V106, P1651, DOI 10.1016/j.jada.2006.07.012
   Volkow ND, 2008, PHILOS T R SOC B, V363, P3191, DOI 10.1098/rstb.2008.0107
   Wall Tamara L, 2007, Nicotine Tob Res, V9 Suppl 3, pS459
   Wang GJ, 2004, J ADDICT DIS, V23, P39, DOI 10.1300/J069v23n03_04
   Wang GJ, 2003, PSYCHIAT ANN, V33, P104, DOI 10.3928/0048-5713-20030201-06
   WHO, 2004, NEUR PSYCH SUBST US
NR 47
TC 7
Z9 7
U1 0
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1874-5490
EI 1874-5504
J9 NEUROETHICS-NETH
JI Neuroethics
PD JUL
PY 2011
VL 4
IS 2
SI SI
BP 79
EP 89
DI 10.1007/s12152-010-9069-1
PG 11
WC Ethics; Medical Ethics; Social Sciences, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Social Sciences - Other Topics; Medical Ethics; Biomedical Social
   Sciences
GA 777WS
UT WOS:000291656400002
DA 2023-06-23
ER

PT J
AU Estevez, A
   Jauregui, P
   Sanchez-Marcos, I
   Lopez-Gonzalez, H
   Griffiths, MD
AF Estevez, Ana
   Jauregui, Paula
   Sanchez-Marcos, Inmaculada
   Lopez-Gonzalez, Hibai
   Griffiths, Mark D.
TI Attachment and emotion regulation in substance addictions and behavioral
   addictions
SO JOURNAL OF BEHAVIORAL ADDICTIONS
LA English
DT Article
DE addiction; emotion regulation; attachment; behavioral addictions;
   substance addictions; alcohol
ID GENDER-DIFFERENCES; INDIVIDUAL-DIFFERENCES; PSYCHIATRIC-DISORDERS;
   PROBLEMATIC INTERNET; AGE-DIFFERENCES; VIDEO GAMES; ADOLESCENTS;
   IMPULSIVITY; DRUG; CONSEQUENCES
AB Background: Risky behaviors have been related to emotional regulation and attachment, which may constitute risk factors for developing an addictive behavior. However, there may also be differences between substance and non-substance-related addictions. Aims: This study aimed to examine the relationship of emotional regulation and attachment, with substance (alcohol and drug abuse), and non-substance-related addictions (gambling disorder, video game addiction, and problematic Internet use) in adolescents and emerging adults. The study also aimed to examine gender differences for such predictors. Methods: The sample comprised 472 students aged 13-21 years recruited from high schools and vocational education centers. Results: Findings demonstrated that emotion regulation was predictive of all addictive behaviors assessed in this study (alcohol and drug abuse, gambling disorder, video game addiction, and problematic Internet use), whereas attachment predicted non-substance-related addictions (gambling disorder, video game addiction, and problematic Internet use). In addition, gender differences were found, with females scoring significantly higher in maternal and peer attachment, whereas males scored significantly higher in gambling disorder and video game addiction. Conclusion: The findings may be useful for preventive and clinical interventions conducted with youth regarding addictive behaviors.
C1 [Estevez, Ana; Jauregui, Paula; Sanchez-Marcos, Inmaculada; Lopez-Gonzalez, Hibai] Univ Deusto, Dept Personal Psychol Assessment & Psychol Treatm, Bilbao, Spain.
   [Lopez-Gonzalez, Hibai; Griffiths, Mark D.] Nottingham Trent Univ, Int Gaming Res Unit, Nottingham, England.
C3 University of Deusto; Nottingham Trent University
RP Estevez, A (通讯作者)，Univ Deusto, Dept Psychol, Apartado 1, Bilbao 48080, Spain.
EM aestevez@deusto.es
RI Lopez-Gonzalez, Hibai/H-5753-2015; Jauregui, Paula/U-6465-2019;
   Griffiths, Mark D./AAY-3546-2021; Estevez, Ana/V-1236-2019
OI Lopez-Gonzalez, Hibai/0000-0003-1249-2623; Jauregui,
   Paula/0000-0002-9706-0274; Griffiths, Mark D./0000-0001-8880-6524;
   Estevez, Ana/0000-0003-0314-7086
CR AINSWORT.MD, 1970, CHILD DEV, V41, P49, DOI 10.2307/1127388
   Al-Kubaisy W, 2012, PROCD SOC BEHV, V38, P59, DOI 10.1016/j.sbspro.2012.03.324
   Aldao A, 2010, CLIN PSYCHOL REV, V30, P217, DOI 10.1016/j.cpr.2009.11.004
   American Psychiatric Association [APA], 2022, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425787]
   Andreassen CS, 2016, PSYCHOL ADDICT BEHAV, V30, P252, DOI 10.1037/adb0000160
   ARMSDEN GC, 1987, J YOUTH ADOLESCENCE, V16, P427, DOI 10.1007/BF02202939
   Banyai F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169839
   Baysinger Amber, 2015, Yale J Biol Med, V88, P203
   Fargues MB, 2009, PSICOTHEMA, V21, P480
   Berking M, 2011, J CONSULT CLIN PSYCH, V79, P307, DOI 10.1037/a0023421
   Blanchard-Fields F, 2008, DEV PSYCHOL, V44, P1547, DOI 10.1037/a0013915
   Bowlby J., 1973, ATTACHMENT LOSS
   Calado F, 2017, J GAMBL STUD, V33, P397, DOI 10.1007/s10899-016-9627-5
   Calvete E, 2005, J ABNORM CHILD PSYCH, V33, P179, DOI 10.1007/s10802-005-1826-y
   Calvete E, 2009, ADICCIONES, V21, P49, DOI 10.20882/adicciones.251
   Canale N, 2016, COMPUT HUM BEHAV, V57, P99, DOI 10.1016/j.chb.2015.12.020
   Carbonell X, 2012, AN PSICOL-SPAIN, V28, P789, DOI 10.6018/analesps.28.3.156061
   Miguez MC, 2015, ADICCIONES, V27, P8
   Chamarro A, 2014, ADICCIONES, V26, P303, DOI 10.20882/adicciones.31
   Cleveland MJ, 2010, J YOUTH ADOLESCENCE, V39, P114, DOI 10.1007/s10964-009-9395-y
   Coffey KA, 2008, J EVID-BASED INTEGR, V13, P79, DOI 10.1177/1533210108316307
   De Rick A, 2009, SUBST USE MISUSE, V44, P99, DOI 10.1080/10826080802525744
   Demetrovics Z, 2012, J BEHAV ADDICT, V1, P1, DOI 10.1556/JBA.1.2012.1.0
   DONOVAN JE, 1985, J CONSULT CLIN PSYCH, V53, P890, DOI 10.1037/0022-006X.53.6.890
   Elmas HG, 2017, TURK PSIKIYATR DERG, V28, DOI 10.5080/u13779
   Esmaeilinasab M., 2014, RES ADDICTION Q J DR, V8, P41
   Estevez A, 2017, AN PSICOL-SPAIN, V33, P260, DOI 10.6018/analesps.33.2.255111
   Gutierrez AE, 2014, ADICCIONES, V26, P282, DOI 10.20882/adicciones.26
   Estevez L., 2009, ADICCION NUEVAS TECN
   Fletcher K, 2015, CLIN SOC WORK J, V43, P109, DOI 10.1007/s10615-014-0502-5
   Gainsbury Sally M, 2015, Curr Addict Rep, V2, P185
   Gallarin M, 2013, SPAN J PSYCHOL, V16, DOI 10.1017/sjp.2013.47
   Garcia Ruiz P, 2016, POLITICA SOC, V53, P551, DOI 10.5209/rev_POSO.2016.v53.n2.47921
   Gardner TW, 2008, J ABNORM CHILD PSYCH, V36, P273, DOI 10.1007/s10802-007-9176-6
   Gonzalez-Alcaide G, 2014, ADICCIONES, V26, P168, DOI 10.20882/adicciones.20
   Grant JE, 2010, AM J DRUG ALCOHOL AB, V36, P233, DOI 10.3109/00952990.2010.491884
   Gratz KL, 2004, J PSYCHOPATHOL BEHAV, V26, P41, DOI 10.1023/B:JOBA.0000007455.08539.94
   Griffiths M, 1998, J COMMUNITY APPL SOC, V8, P423, DOI 10.1002/(SICI)1099-1298(199811/12)8:6<423::AID-CASP499>3.0.CO;2-B
   Griffiths M. D., 2005, J SUBST USE, V10, P191, DOI [10.1080/14659890500114359, DOI 10.1080/14659890500114359]
   Griffiths MD, 2017, ADDICTION, V112, P1718, DOI 10.1111/add.13828
   Griffiths MD, 2016, ADDICTA, V3, P151, DOI 10.15805/addicta.2016.3.0101
   Griffiths MD, 2015, ALOMA, V33, P31
   Griffiths MD, 2014, NEUROPSYCHIATRY-LOND, V4, P1, DOI 10.2217/NPY.13.82
   Griffiths MD, 2012, CURR PSYCHIATRY REV, V8, P308, DOI 10.2174/157340012803520414
   Gross JJ, 2002, PSYCHOPHYSIOLOGY, V39, P281, DOI 10.1017/S0048577201393198
   HAZAN C, 1987, J PERS SOC PSYCHOL, V52, P511, DOI 10.1037/0022-3514.52.3.511
   Herrera H, 2010, PSICOLOGIA IBEROAMER, V18, P6, DOI DOI 10.17162/RCCS.V7I1.985
   Hervás Gonzalo, 2008, Clínica y Salud, V19, P139
   Janfaza M., 2015, RES ADDICTION Q J DR, V9, P45
   Jauregui P, 2016, J BEHAV ADDICT, V5, P251, DOI 10.1556/2006.5.2016.038
   Kausch O, 2003, J SUBST ABUSE TREAT, V25, P263, DOI 10.1016/S0740-5472(03)00117-X
   Kobak R, 2009, DEV PSYCHOPATHOL, V21, P839, DOI 10.1017/S0954579409000455
   Kun B, 2010, SUBST USE MISUSE, V45, P1131, DOI 10.3109/10826080903567855
   Kuss DJ, 2012, INT J MENT HEALTH AD, V10, P278, DOI 10.1007/s11469-011-9318-5
   Ladouceur R, 2000, J Gambl Stud, V16, P1, DOI 10.1023/A:1009443516329
   Langhinrichsen-Rohling J, 2004, J GAMBL STUD, V20, P259, DOI 10.1023/B:JOGS.0000040279.26711.ef
   Laursen B, 1996, CO THEY KEEP FRIENDS, P186
   Lee JM, 2003, J ADOLESCENCE, V26, P347, DOI 10.1016/S0140-1971(03)00018-6
   Li X, 2013, CYBERPSYCH BEH SOC N, V16, P442, DOI 10.1089/cyber.2012.0293
   Malbergier A, 2012, REV BRAS PSIQUIATR, V34, P16, DOI 10.1590/S1516-44462012000100005
   Malik S, 2015, J AFFECT DISORDERS, V172, P428, DOI 10.1016/j.jad.2014.10.007
   Markus D. R., 2003, THESIS
   Martinez J. L., 2003, PSICOTHEMA, V13, P161
   MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121
   Mihajlov M, 2017, PSYCHIAT DANUB, V29, P260, DOI 10.24869/psyd.2017.260
   Mikulincer M, 2003, MOTIV EMOTION, V27, P77, DOI 10.1023/A:1024515519160
   Mikulincer M., 2007, ATTACHMENT ADULTHOOD
   Mikulincer M, 2009, J PERS SOC PSYCHOL, V97, P615, DOI 10.1037/a0015649
   Molinaro S, 2014, ADDICTION, V109, P2089, DOI 10.1111/add.12719
   Monacis L, 2017, INT J MENT HEALTH AD, V15, P853, DOI 10.1007/s11469-017-9768-5
   Mullin B. C., 2007, HDB EMOTION REGULATI, P523, DOI DOI 10.1037/A0015760
   Observatorio Espanol sobre Drogas [National Drugs Plan], 2016, ENC EST US DROG ENS
   Pace U, 2013, CLIN NEUROPSYCHIATR, V10, P253
   Pedrero Perez E., 2007, TRASTORNOS ADICTIVOS, V9, P269, DOI [10.1016/S1575-0973(07)75656-8, DOI 10.1016/S1575-0973(07)75656-8]
   Quigley BM, 2000, AGGRESSION AND VIOLENCE, P259
   Richardson CG, 2011, ADDICTION, V106, P1846, DOI 10.1111/j.1360-0443.2011.03496.x
   Ricketts T, 2004, ADDICT RES THEORY, V12, P77, DOI 10.1080/1606635031000112546
   Sarabia I, 2016, COMPUT HUM BEHAV, V61, P219, DOI 10.1016/j.chb.2016.03.037
   Sayette M. A., 2004, HDB SELF REGULATION, P447
   Schimmenti A, 2015, CHILD ADOL MENT H-UK, V20, P41, DOI 10.1111/camh.12051
   Schmitt N, 2008, HUM PERFORM, V21, P49, DOI 10.1080/08959280701522197
   Schreiber LRN, 2012, J PSYCHIATR RES, V46, P651, DOI 10.1016/j.jpsychires.2012.02.005
   Secades R., 1998, EL JUEGO PATOLOGICO
   Shaffer HJ, 1999, AM J PUBLIC HEALTH, V89, P1369, DOI 10.2105/AJPH.89.9.1369
   Steinberg L, 2005, TRENDS COGN SCI, V9, P69, DOI 10.1016/j.tics.2004.12.005
   Stucki S, 2007, J GAMBL STUD, V23, P245, DOI 10.1007/s10899-006-9031-7
   Vacaru MA, 2014, INT J MENT HEALTH AD, V12, P572, DOI 10.1007/s11469-014-9488-z
   van Rooij AJ, 2014, J BEHAV ADDICT, V3, P157, DOI 10.1556/JBA.3.2014.013
   Vierhaus M, 2007, ANXIETY STRESS COPIN, V20, P267, DOI 10.1080/10615800701330242
   Vollmer C, 2014, SAGE OPEN, V4, DOI 10.1177/2158244013518054
   Wallin D. J., 2015, SAGE OPEN
   Weatherly JN, 2013, INT GAMBL STUD, V13, P52, DOI 10.1080/14459795.2012.703214
   WHO, 2014, GLOBAL STATUS REPORT ON VIOLENCE PREVENTION 2014, P1
   Williams AD, 2012, COGNITIVE THER RES, V36, P451, DOI 10.1007/s10608-011-9384-9
   Williams AD, 2012, BRIT J CLIN PSYCHOL, V51, P223, DOI 10.1111/j.2044-8260.2011.02022.x
   Winters K.C., 1993, J GAMBL STUD, V9, P63, DOI DOI 10.1007/BF01019925
   Xu J, 2014, BMC CANCER, V14, DOI [10.1186/1471-2229-14-83, 10.1186/1471-2407-14-75]
   Zimmermann P, 2014, INT J BEHAV DEV, V38, P182, DOI 10.1177/0165025413515405
NR 98
TC 156
Z9 160
U1 16
U2 103
PU AKADEMIAI KIADO ZRT
PI BUDAPEST
PA BUDAFOKI UT 187-189-A-3, H-1117 BUDAPEST, HUNGARY
SN 2062-5871
EI 2063-5303
J9 J BEHAV ADDICT
JI J. Behav. Addict.
PD DEC
PY 2017
VL 6
IS 4
BP 534
EP 544
DI 10.1556/2006.6.2017.086
PG 11
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA FR0ZC
UT WOS:000418792800008
PM 29280395
OA Green Published, gold, Green Accepted
DA 2023-06-23
ER

PT J
AU Sjoerds, Z
   Luigjes, J
   van den Brink, W
   Denys, D
   Yucel, M
AF Sjoerds, Zsuzsika
   Luigjes, Judy
   van den Brink, Wim
   Denys, Damiaan
   Yucel, Murat
TI The role of habits and motivation in human drug addiction: a reflection
SO FRONTIERS IN PSYCHIATRY
LA English
DT Editorial Material
DE habits; habit formation; motivation; addiction; goal-directed behavior
C1 [Sjoerds, Zsuzsika] Vrije Univ Amsterdam, Med Ctr, Dept Psychiat, Amsterdam, Netherlands.
   [Sjoerds, Zsuzsika; Luigjes, Judy; van den Brink, Wim; Denys, Damiaan] Univ Amsterdam, Acad Med Ctr, Dept Psychiat, Amsterdam, Netherlands.
   [Sjoerds, Zsuzsika; Luigjes, Judy] Univ Amsterdam, Acad Med Ctr, Brain Imaging Ctr, Amsterdam, Netherlands.
   [Sjoerds, Zsuzsika] Max Planck Inst Human Cognit & Brain Sci, Leipzig, Germany.
   [Denys, Damiaan] Inst Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci, Amsterdam, Netherlands.
   [Yucel, Murat] Monash Univ, Sch Psychol Sci, Monash Biomed Imaging Facil, Monash Clin & Imaging Neurosci, Melbourne, Vic, Australia.
C3 Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical
   Center Amsterdam; University of Amsterdam; Academic Medical Center
   Amsterdam; Max Planck Society; Royal Netherlands Academy of Arts &
   Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Monash
   University
RP Sjoerds, Z (通讯作者)，Vrije Univ Amsterdam, Med Ctr, Dept Psychiat, Amsterdam, Netherlands.
EM sjoerds.zs@gmail.com
RI luigjes, judy/P-5161-2014; Yücel, Murat/AAY-8124-2020; Yucel,
   Murat/I-3004-2014; Sjoerds, Zsuzsika/E-9311-2012
OI Yücel, Murat/0000-0002-4705-452X; Yucel, Murat/0000-0002-4705-452X;
   Sjoerds, Zsuzsika/0000-0001-9467-3772; Denys,
   Damiaan/0000-0002-3191-3844; Luigjes, Judy/0000-0002-9395-9426
CR Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Bayley PJ, 2005, NATURE, V436, P550, DOI 10.1038/nature03857
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   Breiner MJ, 1999, ALCOHOL RES HEALTH, V23, P197
   Chein I, 1964, ROAD H NARCOTICS DEL
   Corbit LH, 2012, BIOL PSYCHIAT, V72, P389, DOI 10.1016/j.biopsych.2012.02.024
   COX WM, 1988, J ABNORM PSYCHOL, V97, P168, DOI 10.1037/0021-843X.97.2.168
   Daw ND, 2011, NEURON, V69, P1204, DOI 10.1016/j.neuron.2011.02.027
   de Wit S, 2012, J NEUROSCI, V32, P12066, DOI 10.1523/JNEUROSCI.1088-12.2012
   de Wit S, 2009, J NEUROSCI, V29, P11330, DOI 10.1523/JNEUROSCI.1639-09.2009
   de Wit S, 2009, PSYCHOL RES-PSYCH FO, V73, P463, DOI 10.1007/s00426-009-0230-6
   Denys D, 2014, CNS SPECTRUMS, V19, P8, DOI 10.1017/S1092852913000412
   Dickinson A, 2002, Q J EXP PSYCHOL-B, V55, P331, DOI 10.1080/0272499024400016
   Dolan RJ, 2013, NEURON, V80, P312, DOI 10.1016/j.neuron.2013.09.007
   Everitt BJ, 2008, PHILOS T R SOC B, V363, P3125, DOI 10.1098/rstb.2008.0089
   Everitt BJ, 2013, NEUROSCI BIOBEHAV R, V37, P1946, DOI 10.1016/j.neubiorev.2013.02.010
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Foerde K, 2006, P NATL ACAD SCI USA, V103, P11778, DOI 10.1073/pnas.0602659103
   Fontenelle LF, 2011, DRUGS, V71, P827, DOI 10.2165/11591790-000000000-00000
   Gillan CM, 2014, BIOL PSYCHIAT, V75, P631, DOI 10.1016/j.biopsych.2013.02.002
   Gillan CM, 2011, AM J PSYCHIAT, V168, P718, DOI 10.1176/appi.ajp.2011.10071062
   Glascher J, 2010, NEURON, V66, P585, DOI 10.1016/j.neuron.2010.04.016
   GLUCK MA, 1988, J EXP PSYCHOL GEN, V117, P227, DOI 10.1037/0096-3445.117.3.227
   Hogarth L, 2012, BIOL PSYCHOL, V90, P154, DOI 10.1016/j.biopsycho.2012.02.016
   Kennett Jeanette, 2013, Front Psychiatry, V4, P117, DOI 10.3389/fpsyt.2013.00117
   Knowlton B J, 1994, Learn Mem, V1, P106
   Knowlton BJ, 1996, SCIENCE, V273, P1399, DOI 10.1126/science.273.5280.1399
   Koob GF, 2008, PHILOS T R SOC B, V363, P3113, DOI 10.1098/rstb.2008.0094
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Robbins TW, 1999, NATURE, V398, P567, DOI 10.1038/19208
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Schulteis G, 1993, SEMIN NEUROSCI, V5, P351
   Schwabe L, 2012, J NEUROSCI, V32, P10146, DOI 10.1523/JNEUROSCI.1304-12.2012
   Schwabe L, 2009, J NEUROSCI, V29, P7191, DOI 10.1523/JNEUROSCI.0979-09.2009
   Sjoerds Z, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.107
   Skinner MD, 2010, NEUROSCI BIOBEHAV R, V34, P606, DOI 10.1016/j.neubiorev.2009.11.024
   Smittenaar P, 2013, NEURON, V80, P914, DOI 10.1016/j.neuron.2013.08.009
   SOLOMON RL, 1980, AM PSYCHOL, V35, P691, DOI 10.1037/0003-066X.35.8.691
   SOLOMON RL, 1973, J ABNORM PSYCHOL, V81, P158, DOI 10.1037/h0034534
   TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147
   Tricomi E, 2009, EUR J NEUROSCI, V29, P2225, DOI 10.1111/j.1460-9568.2009.06796.x
   Valentin VV, 2007, J NEUROSCI, V27, P4019, DOI 10.1523/JNEUROSCI.0564-07.2007
   van den Brink W, 2012, Tijdschr Psychiatr, V54, P941
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Vollstadt-Klein S, 2010, ADDICTION, V105, P1741, DOI 10.1111/j.1360-0443.2010.03022.x
   West R., 2006, THEORY ADDICTION
   Wunderlich K, 2012, NEURON, V75, P418, DOI 10.1016/j.neuron.2012.03.042
   Zapata A, 2010, J NEUROSCI, V30, P15457, DOI 10.1523/JNEUROSCI.4072-10.2010
NR 48
TC 26
Z9 27
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD JAN 29
PY 2014
VL 5
AR 8
DI 10.3389/fpsyt.2014.00008
PG 5
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA V46QK
UT WOS:000209898500002
PM 24523702
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Skidelsky, E
AF Skidelsky, E
TI Drug addiction and drug policy - The struggle to control dependence
SO TLS-THE TIMES LITERARY SUPPLEMENT
LA English
DT Book Review
CR HEYMANN PB, DRUG ADDICTION DRUG
NR 1
TC 0
Z9 0
U1 0
U2 0
PU TIMES SUPPLEMENTS LIMITED
PI MARKET HARBOROUGH
PA TOWER HOUSE, SOVEREIGN PARK, MARKET HARBOROUGH LE87 4JJ, ENGLAND
SN 0307-661X
EI 1366-7211
J9 TLS-TIMES LIT SUPPL
JI TLS-Times Lit. Suppl.
PD SEP 14
PY 2001
IS 5137
BP 5
EP 7
PG 3
WC Humanities, Multidisciplinary
WE Arts &amp; Humanities Citation Index (A&amp;HCI)
SC Arts & Humanities - Other Topics
GA 472PP
UT WOS:000170993000006
DA 2023-06-23
ER

PT J
AU Fatseas, M
AF Fatseas, M.
TI ADHD and addictive disorders: What links?
SO EUROPEAN PSYCHIATRY
LA English
DT Meeting Abstract
DE Attention-deficit/hyperactive disorder; Addiction; Addiction severity;
   Psychiatric comorbidity; Diagnostic accuracy
ID DEPENDENCE; PREVALENCE; DRUG
C1 [Fatseas, M.] Ctr Hosp Charles Perrens, Pole Addictol, CNRS USR Sanpsy 3413, Bordeaux, France.
EM melina.fatseas@u-bordeaux2.fr
CR Arias AJ, 2008, ADDICT BEHAV, V33, P1199, DOI 10.1016/j.addbeh.2008.05.003
   Biederman J, 1998, BIOL PSYCHIAT, V44, P269, DOI 10.1016/S0006-3223(97)00406-X
   Fatseas M, 2012, CURR OPIN PSYCHIATR, V25, P219, DOI 10.1097/YCO.0b013e3283523d7c
   van de Glind G, 2014, DRUG ALCOHOL DEPEN, V134, P158, DOI 10.1016/j.drugalcdep.2013.09.026
NR 4
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0924-9338
EI 1778-3585
J9 EUR PSYCHIAT
JI Eur. Psychiat.
PD NOV
PY 2015
VL 30
IS 8
SU S
MA S13B
BP S28
EP S28
DI 10.1016/j.eurpsy.2015.09.085
PG 1
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA DA5OA
UT WOS:000367851200068
OA Bronze
DA 2023-06-23
ER

PT J
AU Taylor, D
AF Taylor, D
TI Drugs on the brain (The neurochemical bases of drug addiction)
SO MEANJIN
LA English
DT Article
C1 Monash Univ, Victorian Coll Pharmacy, Dept Pharmaceut Biol & Pharmmacol, Clayton, Vic 3168, Australia.
C3 Monash University
RP Taylor, D (通讯作者)，Monash Univ, Victorian Coll Pharmacy, Dept Pharmaceut Biol & Pharmmacol, Clayton, Vic 3168, Australia.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MEANJIN
PI PARKVILLE
PA UNIV MELBOURNE, PARKVILLE, VICTORIA 3052, AUSTRALIA
SN 0025-6293
J9 MEANJIN
JI Meanjin
PY 2002
VL 61
IS 2
BP 138
EP 144
PG 7
WC Literary Reviews
WE Arts &amp; Humanities Citation Index (A&amp;HCI)
SC Literature
GA 560ZG
UT WOS:000176110800028
DA 2023-06-23
ER

PT J
AU Kpelly, E
   Schauder, S
   Masson, J
   Kokou-Kpolou, CK
   Moukouta, C
AF Kpelly, Eli
   Schauder, Silke
   Masson, Joanic
   Kokou-Kpolou, Cyrille Kossigan
   Moukouta, Charlemagne
TI Influence of attachment and psychotrauma in drug addiction
SO ANNALES MEDICO-PSYCHOLOGIQUES
LA French
DT Article
DE Attachment; Psychotrauma; Addiction to psychoactive substances; Young
   adults; Siblings; Addiction; Drug; Psychic trauma
ID POSTTRAUMATIC-STRESS-DISORDER; ALCOHOL-USE DISORDERS; ADULT ATTACHMENT;
   DEPENDENCE; CHILDHOOD; TRAUMA; NICOTINE; SECURITY; SMOKING; INFANCY
AB Introduction. - Many researches are developed to support theorizations of drug addiction. Among the tracks, the attachment paradigm and the psychotrauma thesis shed more light on the problem.
   Objective. - This study aims to examine the influence of attachment and psychotrauma in the etiology of the addictions of psychoactive substances.
   Methods. - It involved 120 participants including 60 drug dependent subjects (average age = 33.67 years and standard deviation = 13.47) and 60 of their brothers and/or sisters (average age = 25.37 years and standard deviation = 5.79) with no addictive history, including drug-free addictions.
   Results. - The results show that subjects, who develop disorders linked to the use of psychoactive substances, have styles of insecure avoidance and disorganized attachment. In addition, the number of psychotraumas seems to influence the use of drugs (other than tobacco and alcohol).
   Conclusion. - These results corroborate the contribution of attachmentist and psychotraumatic perspectives of addictive problem. However, we must beware of contextual generalizations and open up to other models of explanations. (C) 2020 Elsevier Masson SAS. All rights reserved.
C1 [Kpelly, Eli; Schauder, Silke; Masson, Joanic; Kokou-Kpolou, Cyrille Kossigan; Moukouta, Charlemagne] Univ Reims, Reims, France.
C3 Universite de Reims Champagne-Ardenne
RP Kpelly, E (通讯作者)，Univ Reims, Reims, France.
EM eli.kpelly1@gmail.com
CR Ainsworth M.D., 1969, DETERMINANTS INFANT
   American Psychiatric Association, 2013, MAN DIAGN STAT TROUB
   Auxemery Y, 2019, EUR J TRAUMA DISSOC, V3, P245, DOI 10.1016/j.ejtd.2019.02.002
   Auxemery Y, 2018, PRESSE MED, V47, P423, DOI 10.1016/j.lpm.2017.12.006
   BARTHOLOMEW K, 1991, J PERS SOC PSYCHOL, V61, P226, DOI 10.1037/0022-3514.61.2.226
   Bellet P, 2019, ALCOOLOGIE ADDICTOLO, V41, P22
   BOWLBY J, 1978, ATTACHEMENT PERTE
   Breslau N, 2003, ARCH GEN PSYCHIAT, V60, P289, DOI 10.1001/archpsyc.60.3.289
   Brochu S, 2001, DOCUMENTS CESAMES, V9
   Caspers KM, 2006, SUBST ABUSE TREAT PR, V1, DOI 10.1186/1747-597X-1-32
   Cottencin O, 2009, ANN MED-PSYCHOL, V167, P537, DOI 10.1016/j.amp.2009.07.009
   Dassa KS, 2013, PERSPECT PSY, V52, P371
   Doumas DM, 2008, J INTERPERS VIOLENCE, V23, P616, DOI 10.1177/0886260507313526
   Driessen M, 2008, ALCOHOL CLIN EXP RES, V32, P481, DOI 10.1111/j.1530-0277.2007.00591.x
   FAGERSTROM KO, 1978, ADDICT BEHAV, V3, P235, DOI 10.1016/0306-4603(78)90024-2
   Farley M, 2004, J SUBST ABUSE TREAT, V27, P161, DOI 10.1016/j.jsat.2004.06.006
   Fidelle G, 2009, STRESS TRAUMA, V9, P45
   Flores PJ, 2004, ADDICTION ATTACHMENT
   Galaif ER, 2001, J STUD ALCOHOL, V62, P486, DOI 10.15288/jsa.2001.62.486
   Guedeney N, 2010, ENCEPHALE, V36, P69, DOI 10.1016/j.encep.2008.12.006
   Hapke U, 2005, J NERV MENT DIS, V193, P843, DOI 10.1097/01.nmd.0000188964.83476.e0
   Jeammet P., 2000, ADDICTIONS, P93
   Kassel JD, 2007, ADDICT BEHAV, V32, P1164, DOI 10.1016/j.addbeh.2006.08.005
   KHANTZIAN E J, 1985, Journal of Substance Abuse Treatment, V2, P83, DOI 10.1016/0740-5472(85)90031-5
   Kpelly E., 2020, REV QU B COISE PSYCH, V41, P61, DOI [10.7202/1070663ar, DOI 10.7202/1070663AR]
   MAIN M, 1985, MONOGR SOC RES CHILD, V50, P66, DOI 10.2307/3333827
   Masson J, 2016, OPEN J PSYCHIAT, V6, P262
   Miljkovitch R., 2013, TROUBLE PERSONNALITE, P227
   Miljkovitch R, 2001, ATTACHEMENT COURS VI
   Molnar DS, 2010, CAN J BEHAV SCI, V42, P1, DOI 10.1037/a0016759
   Olsson CA, 2013, ADDICT BIOL, V18, P717, DOI 10.1111/j.1369-1600.2011.00413.x
   ONUDC, 2019, RAPP MOND DROG 2019
   Peele S., 1985, MEANING ADDICTION CO
   Rosenstein DS, 1996, J CONSULT CLIN PSYCH, V64, P244, DOI 10.1037/0022-006X.64.2.244
   SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x
   Schindler A, 2005, ATTACH HUM DEV, V7, P207, DOI 10.1080/14616730500173918
   Sinnasse P, 2017, ANN MED-PSYCHOL, V175, P370
   SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3
   SPITZER RL, 1980, J AM ACAD CHILD PSY, V19, P356, DOI 10.1016/S0002-7138(09)61059-1
   Thorberg FA, 2006, ADDICT BEHAV, V31, P732, DOI 10.1016/j.addbeh.2005.05.050
   Tupker E., 2001, JEUNES DROGUES SANTE
   Varescon I, 2005, ALCOOLOGIE ADDICTOLO, V27, P85
   Varescon I., 2011, TRAITE RESILIENCE AS, P361
   Venisse JL, 2013, ADDICTOLOGIE SECTION
   Vungkhanching M, 2004, DRUG ALCOHOL DEPEN, V75, P47, DOI 10.1016/j.drugalcdep.2004.01.013
   Wedekind D, 2013, SUBST ABUSE TREAT PR, V8, DOI 10.1186/1747-597X-8-1
NR 46
TC 0
Z9 0
U1 6
U2 10
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0003-4487
EI 1769-6631
J9 ANN MED-PSYCHOL
JI Ann. Med.-Psychol.
PD JUN
PY 2022
VL 180
IS 6
SU S
BP S81
EP S87
DI 10.1016/j.amp.2020.11.019
PG 7
WC Pharmacology & Pharmacy; Psychiatry; Psychology; Psychology,
   Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Psychiatry; Psychology
GA 2R2FO
UT WOS:000820925500011
OA Green Submitted
DA 2023-06-23
ER

PT B
AU Koob, GF
AF Koob, GF
BE Glick, SD
   Maisonneuve, IM
TI Neurobiology of addiction - Toward the development of new therapies
SO NEW MEDICATIONS FOR DRUG ABUSE
SE Annals of the New York Academy of Sciences-Series
LA English
DT Article; Proceedings Paper
CT Archer Conference on Drug Abuse - New Medications
CY SEP 29-OCT 01, 1999
CL RENSSELAERVILLE, NY
SP Natl Inst Drug Abuse
ID CORTICOTROPIN-RELEASING FACTOR; NICOTINE ABSTINENCE SYNDROME; FREELY
   MOVING RATS; NUCLEUS-ACCUMBENS; COCAINE WITHDRAWAL; EXTRACELLULAR
   DOPAMINE; 6-HYDROXYDOPAMINE LESIONS; INTRAVENOUS COCAINE; ETHANOL
   WITHDRAWAL; OPIATE WITHDRAWAL
AB Drug addiction is a chronic relapsing brain disorder characterized by neurobiological changes that lead to a compulsion to take a drug with loss of control over drug intake. The hypothesis outlined here is that knowledge of the neurochemical systems involved in the transition from drug use to the compulsive use of addiction will provide the rational basis for development of pharmacotherapies for drug addiction. Much evidence has been obtained in identifying the midbrain-basal forebrain neural elements involved in the positive reinforcing effects of drugs of abuse and more recently in the neural elements involved in the negative reinforcement associated with drug addiction, Key elements for the acute reinforcing effects of drugs of abuse include a macrostructure in the basal forebrain called the extended amygdala that contains parts of the nucleus accumbens and amgydala and involves keg neurotransmitters such as dopamine, opioid peptides, serotonin, GABA, and glutamate, Withdrawal from drugs of abuse is associated with subjective symptoms of negative affect, such as dysphoria, depression, irritability and anxiety, and dysregulation of brain reward systems involving some of the same neurochemical systems implicated in the acute reinforcing effects of drugs of abuse, In addition, acute withdrawal is accompanied by recruitment of the brain stress neurotransmitter system, corticotropin-releasing factor. Animal models of craving involve not only conditioning models but also models of excessive drug intake during prolonged abstinence, post-acute withdrawal, that may reflect continued dysregulation of drug reinforcement that could lead to vulnerability to relapse and represent an important focus for pharmacotherapy. Such changes have been hypothesized to involve a change in set point for drug reward that may represent an allostatic state contributing to vulnerability to relapse and re-entry into the addiction cycle. Elucidation of the specific neuropharmacological changes contributing to this prolonged functional dysregulation will be the challenge of future research on the neurobiology of drug addiction.
C1 Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA.
C3 Scripps Research Institute
RP Koob, GF (通讯作者)，Scripps Res Inst, Dept Neuropharmacol, CVN-7,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.
EM gkoob@scripps.edu
CR Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Ahmed SH, 1999, PSYCHOPHARMACOLOGY, V146, P303, DOI 10.1007/s002130051121
   ALHEID GF, 1988, NEUROSCIENCE, V27, P1, DOI 10.1016/0306-4522(88)90217-5
   Bergman J., 1990, Behav Pharmacol, V1, P355
   BRITT MD, 1983, BRAIN RES, V258, P105, DOI 10.1016/0006-8993(83)91232-5
   CAINE SB, 1993, SCIENCE, V260, P1814, DOI 10.1126/science.8099761
   CAINE SB, 1995, BRAIN RES, V692, P47
   Carr G.D., 1989, TOPICS EXPT PSYCHOPH, P264
   COLLINS AC, 1990, CIBA F SYMP, V152, P68
   COLLINS RJ, 1984, PSYCHOPHARMACOLOGY, V82, P6
   Dani JA, 1996, NEURON, V16, P905, DOI 10.1016/S0896-6273(00)80112-9
   DAVIS WM, 1975, J PHARM PHARMACOL, V27, P540, DOI 10.1111/j.2042-7158.1975.tb09502.x
   deFonseca FR, 1997, SCIENCE, V276, P2050, DOI 10.1126/science.276.5321.2050
   DEWIT H, 1977, CAN J PSYCHOL, V31, P195, DOI 10.1037/h0081662
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   DICHIARA G, 1988, J PHARMACOL EXP THER, V244, P1067
   DICHIARA G, 1992, TRENDS PHARMACOL SCI, V13, P185
   Edwards G, 1976, DRUGS DRUG DEPENDENC, P182
   ENGEL JA, 1992, NOVEL PHARM INTERVEN, P68
   Epping-Jordan MP, 1998, BRAIN RES, V784, P105, DOI 10.1016/S0006-8993(97)01190-6
   ETTENBERG A, 1982, PSYCHOPHARMACOLOGY, V78, P204, DOI 10.1007/BF00428151
   EVERITT BJ, 1991, NEUROSCIENCE, V42, P1, DOI 10.1016/0306-4522(91)90145-E
   FITZGERALD LW, 1995, CLIN NEUROSCI, V3, P165
   FRYE GD, 1982, J PHARMACOL EXP THER, V223, P750
   GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107
   GILL K, 1988, ALCOHOL, V5, P349, DOI 10.1016/0741-8329(88)90019-5
   GOEDERS NE, 1984, PHARMACOL BIOCHEM BE, V20, P451, DOI 10.1016/0091-3057(84)90284-3
   GOLDBERG SR, 1971, J PHARMACOL EXP THER, V176, P464
   GRANT KA, 1993, J PHARMACOL EXP THER, V264, P1241
   HEIMER L, 1991, ADV EXP MED BIOL, V295, P1
   HEIMER L, 1991, NEUROSCIENCE, V41, P89, DOI 10.1016/0306-4522(91)90202-Y
   HEINRICHS SC, 1995, BEHAV PHARMACOL, V6, P74
   HEMBY SE, 1995, J PHARMACOL EXP THER, V273, P591
   Heyser CJ, 1999, ALCOHOL CLIN EXP RES, V23, P1468, DOI 10.1111/j.1530-0277.1999.tb04669.x
   HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x
   HUBBELL CL, 1991, ALCOHOL, V8, P355, DOI 10.1016/0741-8329(91)90573-F
   HURD YL, 1989, BRAIN RES, V498, P199, DOI 10.1016/0006-8993(89)90422-8
   HYYTIA P, 1995, EUR J PHARMACOL, V283, P151, DOI 10.1016/0014-2999(95)00314-B
   HYYTIA P, 1993, PHARMACOL BIOCHEM BE, V45, P697, DOI 10.1016/0091-3057(93)90527-Z
   JOHANSON CE, 1978, B NARCOTICS, V30, P43
   Johnston JB, 1923, J COMP NEUROL, V35, P337, DOI 10.1002/cne.900350502
   Koob G. F., 1987, BRAIN REWARD SYSTEMS, P35
   KOOB GF, 1984, J PHARMACOL EXP THER, V229, P481
   Koob GF, 1999, ANN NY ACAD SCI, V877, P445, DOI 10.1111/j.1749-6632.1999.tb09282.x
   KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   KOOB GF, 1987, NEUROSCI LETT, V79, P315, DOI 10.1016/0304-3940(87)90451-4
   KOOB GF, 1996, PHARM ALCOHOL ALCOHO, P477
   KOOB GF, 1994, SEMIN NEUROSCI, V6, P221
   KORNETSKY C, 1979, FED PROC, V38, P2473
   Kreek M. J., 1987, PSYCHOPHARMACOLOGY 3, P1597
   KREEK MJ, 1984, NEUROPEPTIDES, V5, P277, DOI 10.1016/0143-4179(84)90081-7
   Legault M., 1994, Society for Neuroscience Abstracts, V20, P1032
   LEITH NJ, 1976, PSYCHOPHARMACOLOGIA, V46, P19, DOI 10.1007/BF00421544
   LILJEQUIST S, 1982, PSYCHOPHARMACOLOGY, V78, P71, DOI 10.1007/BF00470592
   LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382
   LYNESS WH, 1979, PHARMACOL BIOCHEM BE, V11, P553, DOI 10.1016/0091-3057(79)90040-6
   MALIN DH, 1993, PSYCHOPHARMACOLOGY, V112, P339, DOI 10.1007/BF02244930
   MALIN DH, 1994, PSYCHOPHARMACOLOGY, V115, P180, DOI 10.1007/BF02244770
   MARKOU A, 1992, PHYSIOL BEHAV, V51, P111, DOI 10.1016/0031-9384(92)90211-J
   MARKOU A, 1991, NEUROPSYCHOPHARMACOL, V4, P17
   MARKOU A, 1993, PSYCHOPHARMACOLOGY, V112, P163, DOI 10.1007/BF02244907
   Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0
   Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006
   MYERS RD, 1991, PHARMACOL BIOCHEM BE, V40, P923, DOI 10.1016/0091-3057(91)90107-D
   NEGUS SS, 1993, J PHARMACOL EXP THER, V265, P1245
   OBRIEN CP, 1975, PHARMACOL REV, V27, P533
   PARSONS LH, 1995, J PHARMACOL EXP THER, V274, P1182
   PETTIT HO, 1984, PSYCHOPHARMACOLOGY, V84, P167, DOI 10.1007/BF00427441
   PFEFFER AO, 1988, PHARMACOL BIOCHEM BE, V29, P343, DOI 10.1016/0091-3057(88)90167-0
   PICH EM, 1995, J NEUROSCI, V15, P5439
   Pilla M, 1999, NATURE, V400, P371, DOI 10.1038/43944
   Pontieri FE, 1995, P NATL ACAD SCI USA, V92, P12304, DOI 10.1073/pnas.92.26.12304
   Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0
   RASSNICK S, 1993, BRAIN RES, V605, P25, DOI 10.1016/0006-8993(93)91352-S
   RASSNICK S, 1993, BRAIN RES, V623, P16, DOI 10.1016/0006-8993(93)90004-7
   Richards G., 1991, SEMIN NEUROSCI, V3, P191
   Richter RM, 1999, SYNAPSE, V32, P254, DOI 10.1002/(SICI)1098-2396(19990615)32:4<254::AID-SYN2>3.0.CO;2-H
   Roberts AJ, 1996, ALCOHOL CLIN EXP RES, V20, P1289, DOI 10.1111/j.1530-0277.1996.tb01125.x
   Roberts AJ, 2000, NEUROPSYCHOPHARMACOL, V22, P581, DOI 10.1016/S0893-133X(99)00167-0
   ROBERTS DCS, 1980, PHARMACOL BIOCHEM BE, V12, P781, DOI 10.1016/0091-3057(80)90166-5
   SAMSON HH, 1993, BRAIN RES BULL, V30, P133, DOI 10.1016/0361-9230(93)90049-H
   SARNYAI Z, 1995, BRAIN RES, V675, P89, DOI 10.1016/0006-8993(95)00043-P
   SCHULTEIS G, 1995, P NATL ACAD SCI USA, V92, P5880, DOI 10.1073/pnas.92.13.5880
   SCHULTEIS G, 1994, J PHARMACOL EXP THER, V271, P1391
   SCHULTEIS G, 2000, IN PRESS NATURE
   Schuster C R, 1988, Psychopharmacol Ser, V4, P161
   SCHUSTER CR, 1969, ANNU REV PHARMACOLOG, V9, P483, DOI 10.1146/annurev.pa.09.040169.002411
   SELLERS EM, 1992, TRENDS PHARMACOL SCI, V13, P69, DOI 10.1016/0165-6147(92)90026-3
   SHIPPENBERG TS, 1992, ANN NY ACAD SCI, V654, P347, DOI 10.1111/j.1749-6632.1992.tb25980.x
   Solomon R.L, 1977, PSYCHOPATHOLOGY EXPT, P124
   SOLOMON RL, 1980, AM PSYCHOL, V35, P691, DOI 10.1037/0003-066X.35.8.691
   Spanagel R, 1999, TRENDS NEUROSCI, V22, P521, DOI 10.1016/S0166-2236(99)01447-2
   STINUS L, 1990, NEUROSCIENCE, V37, P767, DOI 10.1016/0306-4522(90)90106-E
   STINUS L, 1989, BIOL PSYCHIAT, V26, P363, DOI 10.1016/0006-3223(89)90052-8
   Tabakoff B., 1992, SUBSTANCE ABUSE COMP, P152
   Tanda G, 1997, SCIENCE, V276, P2048, DOI 10.1126/science.276.5321.2048
   VACCARINO FJ, 1985, PSYCHOPHARMACOLOGY, V86, P37, DOI 10.1007/BF00431681
   VACCARINO FJ, 1985, PHARMACOL BIOCHEM BE, V23, P495, DOI 10.1016/0091-3057(85)90027-9
   WEEKS JR, 1976, PROSTAGLANDINS, V12, P11, DOI 10.1016/S0090-6980(76)80003-2
   WEISS F, 1992, BRAIN RES, V593, P314, DOI 10.1016/0006-8993(92)91327-B
   WEISS F, 1992, ANN NY ACAD SCI, V654, P220, DOI 10.1111/j.1749-6632.1992.tb25970.x
   WEISS F, 1992, J NEUROSCI, V12, P4372
   Weiss F, 1996, J NEUROSCI, V16, P3474
   *WHO UN INT DRUG P, 1992, INF EXP GROUP M CRAV
   WIKLER A, 1973, ARCH GEN PSYCHIAT, V28, P611
   WOOLVERTON WL, 1989, PHARMACOL BIOCHEM BE, V32, P691, DOI 10.1016/0091-3057(89)90019-1
   WOOLVERTON WL, 1992, TRENDS PHARMACOL SCI, V13, P193, DOI 10.1016/0165-6147(92)90063-C
   World Health Organization, 1992, INT STAT CLASS DIS R
NR 109
TC 255
Z9 264
U1 1
U2 21
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA
BN 1-57331-276-2; 1-57331-275-4
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2000
VL 909
BP 170
EP 185
DI 10.1111/j.1749-6632.2000.tb06682.x
PG 16
WC Substance Abuse; Pharmacology & Pharmacy
WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Substance Abuse; Pharmacology & Pharmacy
GA BQ52D
UT WOS:000088609300011
PM 10911930
DA 2023-06-23
ER

PT J
AU Eisch, AJ
   Mandyam, CD
AF Eisch, AJ
   Mandyam, CD
TI Drug Dependence and Addiction, II - Adult neurogenesis and drug abuse
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Editorial Material
C1 Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75390 USA.
C3 University of Texas System; University of Texas Dallas; University of
   Texas Southwestern Medical Center Dallas
RP Eisch, AJ (通讯作者)，Univ Texas, SW Med Ctr, Dept Psychiat, 5323 Harry Hines Blvd,NC5-914, Dallas, TX 75390 USA.
RI mandyam, chitra D/C-9189-2013
OI mandyam, chitra D/0000-0002-7354-205X; Eisch, Amelia/0000-0001-6476-5385
NR 0
TC 33
Z9 35
U1 0
U2 2
PU AMER PSYCHIATRIC PRESS, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD MAR
PY 2004
VL 161
IS 3
BP 426
EP 426
DI 10.1176/appi.ajp.161.3.426
PG 1
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA 818WU
UT WOS:000221276000004
PM 14992964
DA 2023-06-23
ER

PT J
AU Robbins, TW
AF Robbins, TW
TI ADHD and addiction
SO NATURE MEDICINE
LA English
DT Editorial Material
AB Attention deficit/hyperactivity disorder is often treated with stimulant drugs such as methylphenidate. However, this treatment remains controversial, as some studies have suggested that sensitization to these drugs of abuse predispose towards adult drug addiction. A new study, using juvenile rats, now shows that chronic treatment with methylphenidate during adolescence actually reduces drug-seeking behavior during adulthood.
C1 Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England.
C3 University of Cambridge
RP Robbins, TW (通讯作者)，Univ Cambridge, Dept Expt Psychol, Downing St, Cambridge CB2 3EB, England.
EM twr2@cam.ac.uk
RI Robbins, Trevor W/A-7551-2008
OI Robbins, Trevor/0000-0003-0642-5977
CR Andersen SL, 2002, NAT NEUROSCI, V5, P13, DOI 10.1038/nn777
   Biederman J, 1997, J AM ACAD CHILD PSY, V36, P21, DOI 10.1097/00004583-199701000-00013
   Biederman J, 1999, PEDIATRICS, V104, part. no., DOI 10.1542/peds.104.2.e20
   Brandon CL, 2001, NEUROPSYCHOPHARMACOL, V25, P651, DOI 10.1016/S0893-133X(01)00281-0
   FERGUSON SA, 2001, STIMULANT DRUGS ADHD, P209
   Grace A., 2001, STIMULANT DRUGS ADHD, P134
   Lambert NM, 1998, J LEARN DISABIL-US, V31, P533, DOI 10.1177/002221949803100603
   RAPOPORT J, 1978, ARCH GEN PSYCHIAT, V37, P933
   ROBBINS TW, 1979, NEUROPHARMACOLOGY, V18, P931, DOI 10.1016/0028-3908(79)90157-6
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
NR 10
TC 35
Z9 36
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD JAN
PY 2002
VL 8
IS 1
BP 24
EP 25
DI 10.1038/nm0102-24
PG 2
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 507XQ
UT WOS:000173056900021
PM 11786901
DA 2023-06-23
ER

PT J
AU Ahmed, SH
AF Ahmed, S. H.
TI THE SCIENCE OF MAKING DRUG-ADDICTED ANIMALS
SO NEUROSCIENCE
LA English
DT Review
DE addiction; abstinence; choice; prefrontal cortex; cocaine; heroin
ID SUBSTANCE USE DISORDERS; COCAINE-INDUCED REINSTATEMENT;
   SELF-ADMINISTERED COCAINE; MEDIAL PREFRONTAL CORTEX; LONG-LASTING
   INCREASE; BRAIN REWARD FUNCTION; EXTENDED DAILY ACCESS; INCREASED
   MOTIVATION; RECEPTOR ANTAGONIST; MENTAL-DISORDERS
AB Research involving animal models of drug addiction can be viewed as a sort of reverse psychiatry. Contrary to clinicians who seek to treat addicted people to become and remain abstinent, researchers seek to make drug-naive animals addicted to a drug with known addictive properties in humans. The goals of this research are to better understand the neuroscience of drug addiction and, ultimately, to translate this knowledge into effective treatments for people with addiction. The present review will not cover the vast literature that has accumulated over the past 50 years on animal models of drug addiction. It is instead more modestly devoted to recent research spanning the past decade on drug self-administration based models of addiction in the rat (the animal species most frequently used in the field), with a special focus on current efforts to model compulsive cocaine use as opposed to nonaddictive use. Surprisingly, it turns out that modeling compulsive cocaine use in rats is possible but more difficult than previously thought In fact, it appears that resilience to cocaine addiction is the norm in rats. As in human cocaine users, only few individual rats would be vulnerable. This conclusion has several important implications for future research on the neuroscience of cocaine addiction and on preclinical medication development.
   This article is part of a Special Issue entitled: Neuroscience Disease Models. (c) 2012 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 Univ Bordeaux, Inst Malad Neurodegenerat, CNRS, UMR 5293, F-33000 Bordeaux, France.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS - National
   Institute for Biology (INSB); UDICE-French Research Universities;
   Universite de Bordeaux
RP Ahmed, SH (通讯作者)，Univ Bordeaux, Inst Malad Neurodegenerat, CNRS, UMR 5293, F-33000 Bordeaux, France.
EM sahmed@u-bordeaux2.fr
RI AHMED, Serge H/D-5236-2014
OI Ahmed, Serge/0000-0002-1225-9234
FU French Research Council (CNRS); Universite Bordeaux-Segalen; National
   Research Agency (ANR); Mission Interministerielle de Lutte contre les
   Drogues et la Toxicomanie (MILDT); Conseil Regional d'Aquitaine (CRA);
   Fondation pour la Recherche Medicate (FRM)
FX This work was supported by the French Research Council (CNRS), the
   Universite Bordeaux-Segalen, the National Research Agency (ANR), the
   Mission Interministerielle de Lutte contre les Drogues et la Toxicomanie
   (MILDT), the Conseil Regional d'Aquitaine (CRA), and the Fondation pour
   la Recherche Medicate (FRM). I thank Dr. Karyn Guillem for her comments
   on a previous version of this article. Finally, I thank the reviewers
   for their constructive and insightful comments.
CR Ahmed SH, 2011, NEUROMETHODS, V53, P267, DOI 10.1007/978-1-60761-934-5_10
   Ahmed SH, 2010, NEUROSCI BIOBEHAV R, V35, P172, DOI 10.1016/j.neubiorev.2010.04.005
   Ahmed SH, 2006, NEUROPSYCHOPHARMACOL, V31, P563, DOI 10.1038/sj.npp.1300834
   Ahmed SH, 2005, EUR J PHARMACOL, V526, P9, DOI 10.1016/j.ejphar.2005.09.036
   Ahmed SH, 2005, PSYCHOPHARMACOLOGY, V180, P473, DOI 10.1007/s00213-005-2180-z
   Ahmed SH, 2005, P NATL ACAD SCI USA, V102, P11533, DOI 10.1073/pnas.0504438102
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Ahmed SH, 1999, PSYCHOPHARMACOLOGY, V146, P303, DOI 10.1007/s002130051121
   Ahmed SH, 2003, J NEUROCHEM, V86, P102, DOI 10.1046/j.1471-4159.2003.01833.x
   Ahmed SH, 2002, NAT NEUROSCI, V5, P625, DOI 10.1038/nn872
   Ahmed SH, 2000, NEUROPSYCHOPHARMACOL, V22, P413, DOI 10.1016/S0893-133X(99)00133-5
   Ahmed SH, BEHAV BRAIN IN PRESS
   Ahmed SH, I ANIM LAB IN PRESS
   AIGNER TG, 1978, SCIENCE, V201, P534, DOI 10.1126/science.96531
   Ainslie G, 2000, LAW PHILOS, V19, P77
   Alexander B., 2010, GLOBALIZATION ADDICT
   Allen RM, 2007, PSYCHOPHARMACOLOGY, V191, P341, DOI 10.1007/s00213-006-0661-3
   Allen RM, 2007, PHARMACOL BIOCHEM BE, V88, P82, DOI 10.1016/j.pbb.2007.07.009
   Anker JJ, 2009, PHARMACOL BIOCHEM BE, V93, P343, DOI 10.1016/j.pbb.2009.05.013
   ANTHONY JC, 2002, NEUROPSYCHOPHARMACOL, P1557
   Anthony JC, 2011, ANN NY ACAD SCI, V1187, P353
   Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P224
   Augier E, ADDICT BIOL IN PRESS
   Aujla H, 2008, NEUROPSYCHOPHARMACOL, V33, P1818, DOI 10.1038/sj.npp.1301588
   Banks ML, 2010, NEUROPSYCHOPHARMACOL, V35, P493, DOI 10.1038/npp.2009.154
   Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584
   BECKER GS, 1988, J POLIT ECON, V96, P675, DOI 10.1086/261558
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   Ben-Shahar O, 2004, BRAIN RES, V995, P46, DOI 10.1016/j.brainres.2003.09.053
   Ben-Shahar O, 2008, PROG NEURO-PSYCHOPH, V32, P863, DOI 10.1016/j.pnpbp.2008.01.002
   Ben-Shahar O, 2006, BRAIN RES, V1095, P148, DOI 10.1016/j.brainres.2006.04.002
   Ben-Shahar O, 2009, SYNAPSE, V63, P598, DOI 10.1002/syn.20640
   BENOWITZ NL, 1994, NEW ENGL J MED, V331, P123, DOI 10.1056/NEJM199407143310212
   BERRIDGE KC, 1986, PHARMACOL BIOCHEM BE, V24, P217, DOI 10.1016/0091-3057(86)90341-2
   BERRIDGE KC, 1995, NEUROSCI BIOBEHAV R, V19, P121, DOI 10.1016/0149-7634(94)00026-W
   Briand LA, 2008, NEUROSCIENCE, V155, P1, DOI 10.1016/j.neuroscience.2008.06.004
   Briand LA, 2008, NEUROPSYCHOPHARMACOL, V33, P2969, DOI 10.1038/npp.2008.18
   Briand LA, 2008, EUR NEUROPSYCHOPHARM, V18, P551, DOI 10.1016/j.euroneuro.2008.01.002
   Cantin L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011592
   CARROLL ME, 1989, PSYCHOPHARMACOLOGY, V97, P23, DOI 10.1007/BF00443407
   CARROLL ME, 1993, PSYCHOPHARMACOLOGY, V110, P5, DOI 10.1007/BF02246944
   Chambers CD, 2009, NEUROSCI BIOBEHAV R, V33, P631, DOI 10.1016/j.neubiorev.2008.08.016
   Chib VS, 2009, J NEUROSCI, V29, P12315, DOI 10.1523/JNEUROSCI.2575-09.2009
   Christensen CJ, 2008, PSYCHOPHARMACOLOGY, V198, P221, DOI 10.1007/s00213-008-1120-0
   Christensen CJ, 2008, PHARMACOL BIOCHEM BE, V91, P209, DOI 10.1016/j.pbb.2008.07.009
   Collier G, 1997, APPETITE, V29, P159, DOI 10.1006/appe.1997.0124
   Dalley JW, 2007, SCIENCE, V315, P1267, DOI 10.1126/science.1137073
   Dalley JW, 2005, PSYCHOPHARMACOLOGY, V182, P579, DOI 10.1007/s00213-005-0107-3
   Degenhardt L, 2008, DRUG ALCOHOL DEPEN, V93, P227, DOI 10.1016/j.drugalcdep.2007.09.024
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Doherty J, 2009, PHARMACOL BIOCHEM BE, V92, P164, DOI 10.1016/j.pbb.2008.11.009
   EDWARDS G, 1976, BRIT MED J, V1, P1058, DOI 10.1136/bmj.1.6017.1058
   Edwards S, 2007, EUR J NEUROSCI, V25, P2201, DOI 10.1111/j.1460-9568.2007.05473.x
   Epstein DH, 2003, PSYCHOPHARMACOLOGY, V168, P31, DOI 10.1007/s00213-003-1470-6
   ETTENBERG A, 1991, PSYCHOPHARMACOLOGY, V103, P455, DOI 10.1007/BF02244244
   FALK JL, 1983, PHARMACOL BIOCHEM BE, V19, P385, DOI 10.1016/0091-3057(83)90106-5
   Ferrario CR, 2007, EUR NEUROPSYCHOPHARM, V17, P352, DOI 10.1016/j.euroneuro.2006.08.005
   Ferrario CR, 2005, BIOL PSYCHIAT, V58, P751, DOI 10.1016/j.biopsych.2005.04.046
   FitzGerald THB, 2009, J NEUROSCI, V29, P8388, DOI 10.1523/JNEUROSCI.0717-09.2009
   Foddy B, 2006, BIOETHICS, V20, P1, DOI 10.1111/j.1467-8519.2006.00470.x
   Fowler CD, 2011, NATURE, V471, P597, DOI 10.1038/nature09797
   Fritz M, 2011, ADDICT BIOL, V16, P273, DOI 10.1111/j.1369-1600.2010.00285.x
   Garavan H, 2005, TRENDS COGN SCI, V9, P195, DOI 10.1016/j.tics.2005.02.008
   George O, 2008, NEUROPSYCHOPHARMACOL, V33, P2474, DOI 10.1038/sj.npp.1301626
   Gipson CD, 2011, PSYCHOPHARMACOLOGY, V214, P557, DOI 10.1007/s00213-010-2060-z
   Goldstein RZ, 2009, TRENDS COGN SCI, V13, P372, DOI 10.1016/j.tics.2009.06.004
   GOODMAN A, 1990, BRIT J ADDICT, V85, P1403
   Goodman A, 2008, BIOCHEM PHARMACOL, V75, P266, DOI 10.1016/j.bcp.2007.07.030
   Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134
   Hancock SD, 2011, NEUROMETHODS, V53, P207, DOI 10.1007/978-1-60761-934-5_8
   Haney M, 2009, ADDICT BIOL, V14, P9, DOI 10.1111/j.1369-1600.2008.00121.x
   Hansen ST, 2007, PSYCHOPHARMACOLOGY, V194, P53, DOI 10.1007/s00213-007-0822-z
   Hao Y, 2010, BIOL PSYCHIAT, V68, P240, DOI 10.1016/j.biopsych.2010.02.011
   Hare TA, 2009, SCIENCE, V324, P646, DOI 10.1126/science.1168450
   Heather N, 1998, J PSYCHOPHARMACOL, V12, P3, DOI 10.1177/026988119801200101
   Helmuth L, 2003, SCIENCE, V302, P808, DOI 10.1126/science.302.5646.808
   Heyman GM, 1996, BEHAV BRAIN SCI, V19, P561, DOI 10.1017/S0140525X00042990
   HODOS W, 1961, SCIENCE, V134, P943, DOI 10.1126/science.134.3483.943
   Hogarth L, 2011, PSYCHOPHARMACOLOGY, V215, P567, DOI 10.1007/s00213-011-2172-0
   Hollander JA, 2010, NATURE, V466, P197, DOI 10.1038/nature09202
   HURSH SR, 1980, J EXP ANAL BEHAV, V34, P219, DOI 10.1901/jeab.1980.34-219
   Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560
   Hyman SE, 2007, NAT REV NEUROSCI, V8, P725, DOI 10.1038/nrn2218
   Hyman SE, 2007, AM J BIOETHICS, V7, P8, DOI 10.1080/15265160601063969
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Im HI, 2010, NAT NEUROSCI, V13, P1120, DOI 10.1038/nn.2615
   JAFFE JH, 1989, PSYCHOPHARMACOLOGY, V97, P59, DOI 10.1007/BF00443414
   Jin XC, 2010, NEUROPSYCHOPHARMACOL, V35, P2021, DOI 10.1038/npp.2010.82
   Kalivas PW, 2005, NEURON, V45, P647, DOI 10.1016/j.neuron.2005.02.005
   Kenny PJ, 2006, J NEUROSCI, V26, P5894, DOI 10.1523/JNEUROSCI.0740-06.2006
   Kenny PJ, 2006, NEUROPSYCHOPHARMACOL, V31, P1203, DOI 10.1038/sj.npp.1300905
   Kenny PJ, 2005, PSYCHOPHARMACOLOGY, V179, P247, DOI 10.1007/s00213-004-2069-2
   Kippin TE, 2006, PSYCHOPHARMACOLOGY, V187, P60, DOI 10.1007/s00213-006-0386-3
   Kitamura O, 2006, PSYCHOPHARMACOLOGY, V186, P48, DOI 10.1007/s00213-006-0353-z
   Knackstedt LA, 2007, J PHARMACOL EXP THER, V322, P1103, DOI 10.1124/jpet.107.122861
   Koob GF, 2006, ADDICTION, V101, P23, DOI 10.1111/j.1360-0443.2006.01586.x
   Koob GF, 2009, NAT REV DRUG DISCOV, V8, P500, DOI 10.1038/nrd2828
   KOZLOWSKI LT, 1987, BRIT J ADDICT, V82, P31
   Larson EB, 2007, EXP CLIN PSYCHOPHARM, V15, P461, DOI 10.1037/1064-1297.15.5.461
   LASAGNA L, 1955, JAMA-J AM MED ASSOC, V157, P1006, DOI 10.1001/jama.1955.02950290026009
   Lebreton M, 2009, NEURON, V64, P431, DOI 10.1016/j.neuron.2009.09.040
   Lenoir M, 2008, NEUROPSYCHOPHARMACOL, V33, P2272, DOI 10.1038/sj.npp.1301602
   Lenoir M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000698
   Lenoir M, 2007, NEUROPSYCHOPHARMACOL, V32, P616, DOI 10.1038/sj.npp.1301083
   LI DH, 1994, PSYCHOPHARMACOLOGY, V116, P326, DOI 10.1007/BF02245336
   Liu C, 2005, BRAIN RES, V1049, P128, DOI 10.1016/j.brainres.2005.05.013
   Liu Y, 2005, PSYCHOPHARMACOLOGY, V179, P644, DOI 10.1007/s00213-004-2089-y
   Madayag A, 2007, J NEUROSCI, V27, P13968, DOI 10.1523/JNEUROSCI.2808-07.2007
   Madayag A, 2010, J NEUROSCI, V30, P210, DOI 10.1523/JNEUROSCI.1342-09.2010
   Maddux JF, 2000, ADDICTION, V95, P661, DOI 10.1046/j.1360-0443.2000.9556611.x
   Mandyam CD, 2007, J NEUROSCI, V27, P11442, DOI 10.1523/JNEUROSCI.2505-07.2007
   Mantsch JR, 2008, NEUROPSYCHOPHARMACOL, V33, P814, DOI 10.1038/sj.npp.1301464
   Mantsch JR, 2008, PSYCHOPHARMACOLOGY, V195, P591, DOI 10.1007/s00213-007-0950-5
   Mantsch JR, 2004, PSYCHOPHARMACOLOGY, V175, P26, DOI 10.1007/s00213-004-1778-x
   Martin CS, 2008, J ABNORM PSYCHOL, V117, P561, DOI 10.1037/0021-843X.117.3.561
   Marusich JA, 2010, EXP CLIN PSYCHOPHARM, V18, P257, DOI 10.1037/a0019814
   McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689
   McNamara R, 2010, PSYCHOPHARMACOLOGY, V212, P453, DOI 10.1007/s00213-010-1974-9
   Miller G, 2010, SCIENCE, V327, P770, DOI 10.1126/science.327.5967.770-a
   Muller CP, BEHAV BRAIN IN PRESS
   NADER MA, 1991, PSYCHOPHARMACOLOGY, V105, P169, DOI 10.1007/BF02244304
   Negus SS, 2003, NEUROPSYCHOPHARMACOL, V28, P919, DOI 10.1038/sj.npp.1300096
   Nutt D, 2007, LANCET, V369, P1047, DOI 10.1016/S0140-6736(07)60464-4
   O'Brien C, 2011, ADDICTION, V106, P866, DOI 10.1111/j.1360-0443.2010.03144.x
   O'Brien CP, 2008, PHILOS T R SOC B, V363, P3277, DOI 10.1098/rstb.2008.0105
   O'Brien CP, 2006, AM J PSYCHIAT, V163, P764, DOI 10.1176/appi.ajp.163.5.764
   Oleson EB, 2009, NEUROPSYCHOPHARMACOL, V34, P796, DOI 10.1038/npp.2008.195
   Orford J, 2001, ADDICTION, V96, P15, DOI 10.1046/j.1360-0443.2001.961152.x
   Orio L, 2009, J NEUROSCI, V29, P4846, DOI 10.1523/JNEUROSCI.0563-09.2009
   Paronis CA, 2002, PSYCHOPHARMACOLOGY, V163, P283, DOI 10.1007/s00213-002-1180-5
   Paterson NE, 2003, NEUROREPORT, V14, P2229, DOI 10.1097/00001756-200312020-00019
   Paterson NE, 2004, PSYCHOPHARMACOLOGY, V173, P64, DOI 10.1007/s00213-003-1692-7
   Paulus MP, 2007, SCIENCE, V318, P602, DOI 10.1126/science.1142997
   Pecina S, 1996, BRAIN RES, V727, P22
   Perry JL, 2006, PSYCHOPHARMACOLOGY, V186, P235, DOI 10.1007/s00213-006-0371-x
   Picetti R, 2010, PSYCHOPHARMACOLOGY, V211, P313, DOI 10.1007/s00213-010-1899-3
   Pollan Michael, 2001, BOT DESIRE PLANTS EY
   Potenza MN, 2011, NEURON, V69, P695, DOI 10.1016/j.neuron.2011.02.009
   Quadros IMH, 2009, PSYCHOPHARMACOLOGY, V206, P109, DOI 10.1007/s00213-009-1584-6
   Quick SL, 2011, NEUROPSYCHOPHARMACOL, V36, P1015, DOI 10.1038/npp.2010.239
   Redish AD, 2008, BEHAV BRAIN SCI, V31, P415, DOI 10.1017/S0140525X0800472X
   Richardson DK, 2005, PHARMACOL BIOCHEM BE, V81, P657, DOI 10.1016/j.pbb.2005.05.006
   Richardson NR, 1996, J NEUROSCI METH, V66, P1, DOI 10.1016/0165-0270(95)00153-0
   Riley AL, 2011, PHYSIOL BEHAV, V103, P69, DOI 10.1016/j.physbeh.2010.11.021
   Robbins TW, 2008, ANN NY ACAD SCI, V1141, P1, DOI 10.1196/annals.1441.020
   Roberts DCS, 2007, PROG NEURO-PSYCHOPH, V31, P1614, DOI 10.1016/j.pnpbp.2007.08.028
   Roberts WA, 2002, PSYCHOL BULL, V128, P473, DOI 10.1037//0033-2909.128.3.473
   Robins LN, 1998, SOC PSYCH PSYCH EPID, V33, P393, DOI 10.1007/s001270050071
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Rogers JL, 2008, PSYCHOPHARMACOLOGY, V199, P615, DOI 10.1007/s00213-008-1187-7
   Roth ME, 2004, PHARMACOL BIOCHEM BE, V78, P199, DOI 10.1016/j.pbb.2004.03.018
   Saunders JB, 2006, ADDICTION, V101, P48, DOI 10.1111/j.1360-0443.2006.01589.x
   Saunders JB, 2006, ADDICTION, V101, P1, DOI 10.1111/j.1360-0443.2006.01612.x
   Schuckit MA, 2006, ADDICTION, V101, P170, DOI 10.1111/j.1360-0443.2006.01611.x
   Schwendt M, 2009, J PHARMACOL EXP THER, V331, P555, DOI 10.1124/jpet.109.155770
   Setlow B, 2009, BEHAV PHARMACOL, V20, P380, DOI 10.1097/FBP.0b013e3283305eb4
   Skog OJ, 2003, CHOICE, BEHAVIOURAL ECONOMICS AND ADDICTION, P157, DOI 10.1016/B978-008044056-9/50047-6
   Sorge RE, 2005, PSYCHOPHARMACOLOGY, V183, P210, DOI 10.1007/s00213-005-0160-y
   Stein DJ, 2010, PSYCHOL MED, V40, P1759, DOI 10.1017/S0033291709992261
   Suddendorf T, 2007, BEHAV BRAIN SCI, V30, P299, DOI 10.1017/S0140525X07001975
   Sullivan RJ, 2002, ADDICTION, V97, P389, DOI 10.1046/j.1360-0443.2002.00024.x
   Swendsen J, 2011, ANN NY ACAD SCI, V1216, P73, DOI 10.1111/j.1749-6632.2010.05894.x
   TREIT D, 1990, PHARMACOL BIOCHEM BE, V37, P451, DOI 10.1016/0091-3057(90)90011-6
   TREIT D, 1987, PHARMACOL BIOCHEM BE, V26, P709, DOI 10.1016/0091-3057(87)90601-0
   Uhl GR, 2004, ARCH GEN PSYCHIAT, V61, P223, DOI 10.1001/archpsyc.61.3.223
   Vanderschuren LJMJ, 2000, PSYCHOPHARMACOLOGY, V151, P99, DOI 10.1007/s002130000493
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Vendruscolo LF, 2011, PHARMACOL BIOCHEM BE, V98, P570, DOI 10.1016/j.pbb.2011.03.004
   Vendruscolo LF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009296
   Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI 10.1093/cercor/10.3.318
   Volkow ND, 2005, J NEUROSCI, V25, P3932, DOI 10.1523/JNEUROSCI.0433-05.2005
   VOLKOW ND, 1991, AM J PSYCHIAT, V148, P621
   Volkow ND, 2011, NEURON, V69, P599, DOI 10.1016/j.neuron.2011.01.027
   Wakabayashi KT, 2010, J NEUROSCI, V30, P11346, DOI 10.1523/JNEUROSCI.2524-10.2010
   WAKEFIELD JC, 1992, AM PSYCHOL, V47, P373, DOI 10.1037/0003-066X.47.3.373
   Walsh SL, 2010, DRUG ALCOHOL DEPEN, V106, P28, DOI 10.1016/j.drugalcdep.2009.07.011
   Wee S, 2008, EUR NEUROPSYCHOPHARM, V18, P303, DOI 10.1016/j.euroneuro.2007.08.003
   Wee S, 2007, NEUROPSYCHOPHARMACOL, V32, P2238, DOI 10.1038/sj.npp.1301353
   Wee S, 2007, J PHARMACOL EXP THER, V320, P1134, DOI 10.1124/jpet.106.113340
   Wee S, 2009, PSYCHOPHARMACOLOGY, V205, P565, DOI 10.1007/s00213-009-1563-y
   Welberg Leonie, 2010, Nat Rev Neurosci, V11, P668
   Wheeler RA, 2011, BIOL PSYCHIAT, V69, P1067, DOI 10.1016/j.biopsych.2011.02.014
   Wikler A, 1952, PSYCHIAT QUART, V26, P270, DOI 10.1007/BF01568465
   WOLFFGRAMM J, 1995, BEHAV BRAIN RES, V70, P77, DOI 10.1016/0166-4328(95)00131-C
   Wolgin DL, 2000, NEUROSCI BIOBEHAV R, V24, P279, DOI 10.1016/S0149-7634(99)00070-6
   WOOLVERTON WL, 1979, COMMUN PSYCHOPHARMAC, V3, P309
   Zhou WH, 2009, PSYCHOPHARMACOLOGY, V203, P677, DOI 10.1007/s00213-008-1414-2
NR 187
TC 131
Z9 130
U1 0
U2 166
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD JUN 1
PY 2012
VL 211
SI SI
BP 107
EP 125
DI 10.1016/j.neuroscience.2011.08.014
PG 19
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 955WA
UT WOS:000305050400009
PM 21864653
DA 2023-06-23
ER

PT J
AU Gorun, GS
AF Gorun, Gabriel Stefan
TI Cinematography - pull factor in drug addiction
SO ROMANIAN JOURNAL OF LEGAL MEDICINE
LA Unspecified
DT Article
DE drugs; addiction; pull factor; traffic
AB Inside of multiple faces of drugs addiction's etiology, the exogenous factors have a major inductive and a releaser trigger roles for this disease. The inveiglements factors, so called pull factors, includes too the symbolic, informative and cultural pressure of mass media. Movies, through the copiousness and diversity of specific arsenal with the powerful force in public impact, become the real message-carrying agent focus on audience. Drug-movies, the movie with the core built up on drugs presence and the whole implicitly life style - production, traffic, getting, use, abuse, clinical manifestation, withdrawn, recovery etc. - are more often presence on the screens, and are obviously the change of templates towards breaking the moral precepts about evilly of chemical addiction. It's imperative to assess with more attention the content and the message of them and in this manner to be possible to prevent the dissemination of distortion images about addictions and eventually to try to capitalize the power of messages. This article surveys and suggests the outlines of the drug-movie's pattern and presents the role inside of etiopathogeny of addiction, with some examples from movies with large audience.
C1 Inst Natl Med Legala Mina Minovici Bucuresti, Bucharest, Romania.
RP Gorun, GS (通讯作者)，Inst Natl Med Legala Mina Minovici Bucuresti, Str Vitan Barzesti 9,Sector 4, Bucharest, Romania.
EM gabriel.gorun@legmed.ro
CR FEDLER F, 1994, J DRUG EDUC, V24, P291, DOI 10.2190/TWWQ-JT4D-VX8P-H33E
   Gunasekera H, 2005, J ROY SOC MED, V98, P464, DOI 10.1258/jrsm.98.10.464
   TERRE L, 1991, J APPL SOC PSYCHOL, V21, P1303, DOI 10.1111/j.1559-1816.1991.tb00472.x
NR 3
TC 1
Z9 1
U1 0
U2 3
PU ROMANIAN LEGAL MED SOC
PI BUCHAREST
PA SOS VITAN-BIRZESTI 9, BUCHAREST, 75669, ROMANIA
SN 1221-8618
J9 ROM J LEG MED
JI Rom. J. Leg. Med.
PD MAR
PY 2007
VL 15
IS 1
BP 55
EP 62
PG 8
WC Medicine, Legal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Legal Medicine
GA 309YB
UT WOS:000256495000009
DA 2023-06-23
ER

PT J
AU Haque, MI
   Rani, V
   Chowdhury, ABMA
   Akter, T
   Hasan, I
   Harun, MGD
   Ullah, AZ
AF Haque, Md Imdadul
   Rani, Varoti
   Chowdhury, A. B. M. Alauddin
   Akter, Tasnim
   Hasan, Istiaque
   Harun, Md Golam Dostogir
   Ullah, Abu Naser Zafar
TI Drug Addiction and Substance Use Among the Dalit Married Adolescent
   Girls in Bangladesh: a Cross-Sectional Survey
SO INTERNATIONAL JOURNAL OF MENTAL HEALTH AND ADDICTION
LA English
DT Article
DE Married adolescent girls; Dalit community; Drug addiction; Substance
   use; Smoking; Risky behaviors
ID SOCIOECONOMIC-STATUS; CIGARETTE-SMOKING; RISK-FACTORS; ASSOCIATION;
   INITIATION; HEALTH; MARIJUANA; BEHAVIOR; CHILDREN; ALCOHOL
AB Dalits are referred to "shattered," "outcasts," and socially marginalized community in Bangladesh. In particular, Dalit adolescent girls are the most vulnerable owing to their caste and gender. Prior studies have looked at the prevalence and effects of drug addiction among the youths in mainstream population, but the Dalit adolescents were excluded from the samples. The study aimed to investigate the prevalence of drug addiction and substance use among the Dalit married adolescent girls (MAGs), and to identify the significant predictors associated with this addiction. A cross-sectional survey was carried out among 300 MAGs in the Dalit community. Involving systematic random sampling, participants were selected from both urban and rural settings located in Dhaka and Gaibandha districts. Bivariate and multivariate logistic regressions were performed to explore the significant factors associated with drug addiction. The prevalence of drug addiction was 11.3% among married Dalit adolescent girls. Multivariate analysis identified that participants' habit of smoking (AOR=5.210, 95% CI=2.413-11.250), participant's husband's habit of smoking (AOR=10.415, 95% CI=3.911-27.739), and habit of using alcohol/highly risky substances (AOR=19.030, 95% CI=6.481-55.875) were significant associated with drug addiction. An alarming proportion of Dalit adolescent girls were recorded to be habituated in various forms of drugs use. Therefore, immediate policy measures focusing intensive campaigns, targeted counseling, and health education programs need to design to get over the risky health behaviors.
C1 [Haque, Md Imdadul; Rani, Varoti; Chowdhury, A. B. M. Alauddin; Akter, Tasnim; Harun, Md Golam Dostogir; Ullah, Abu Naser Zafar] Daffodil Int Univ, Fac Allied Hlth Sci, Dept Publ Hlth, 102-1 Shukrabad,Mirpur Rd, Dhaka 1207, Bangladesh.
   [Rani, Varoti] Dhaka Med Coll Hosp, Dhaka, Bangladesh.
   [Akter, Tasnim] SQ Coll Nursing, Dhaka 1205, Bangladesh.
   [Hasan, Istiaque] Queens Univ Belfast, Fac Med Dent & Biomed Sci, Dept Publ Hlth, Belfast, Antrim, North Ireland.
   [Ullah, Abu Naser Zafar] KIT Royal Trop Inst, Amsterdam, Netherlands.
C3 Daffodil International University; Dhaka Medical College; RLUK- Research
   Libraries UK; Queens University Belfast
RP Ullah, AZ (通讯作者)，Daffodil Int Univ, Fac Allied Hlth Sci, Dept Publ Hlth, 102-1 Shukrabad,Mirpur Rd, Dhaka 1207, Bangladesh.; Ullah, AZ (通讯作者)，KIT Royal Trop Inst, Amsterdam, Netherlands.
EM a.zafar@diu.edu.bd
OI Haque, Md. Imdadul/0000-0003-4822-9157
CR Ali M, 2016, J ARMED FORCES MED C, V12, P15, DOI [10.3329/jafmc.v12i2.41079, DOI 10.3329/JAFMC.V12I2.41079]
   AMARO H, 1989, PEDIATRICS, V84, P144
   Center on Addiction and Substance Abuse, 2011, FETT AAR
   Cherry, 2016, DOES CROSS SECTIONAL
   Dalit Community, 2015, BANGLAPEDIA NATL ENC
   DiClemente RJ, 2001, PEDIATRICS, V107, P1363, DOI 10.1542/peds.107.6.1363
   Erskine HE, 2015, PSYCHOL MED, V45, P1551, DOI 10.1017/S0033291714002888
   Fernando Dulitha N, 2014, Int J Adolesc Med Health, V26, P39, DOI 10.1515/ijamh-2012-0110
   Fettes DL, 2013, J STUD ALCOHOL DRUGS, V74, P825, DOI 10.15288/jsad.2013.74.825
   Hanchett, 2018, INT UN ANTHR ETHN SC
   Hanson MD, 2007, J BEHAV MED, V30, P263, DOI 10.1007/s10865-007-9098-3
   Hasan K, 2018, DHAKA TRIBUNE
   Homish GG, 2007, DRUG ALCOHOL DEPEN, V91, P121, DOI 10.1016/j.drugalcdep.2007.05.014
   HSER YI, 1987, AM J DRUG ALCOHOL AB, V13, P33, DOI 10.3109/00952998709001499
   Islam F., 2011, DALIT WOMEN BANGLADE
   Islam M., 2013, DALIT INITIATIVES BA
   Jackson JM, 2015, AM J PUBLIC HEALTH, V105, P2137, DOI 10.2105/AJPH.2014.302493
   Joel S. J. A, 2006, DALIT WOMEN SPEAK OU
   Johnston LD, 2007, MONITORING FUTURE NA
   KANDEL D, 1975, SCIENCE, V190, P912, DOI 10.1126/science.1188374
   KANDEL DB, 1984, AM J PUBLIC HEALTH, V74, P660, DOI 10.2105/AJPH.74.7.660
   Kastbom AA, 2015, ACTA PAEDIATR, V104, P91, DOI 10.1111/apa.12803
   Khan MMA, 2020, SOC PSYCH PSYCH EPID, V55, P1491, DOI 10.1007/s00127-020-01867-z
   Kiesner J, 2010, MERRILL PALMER QUART, V56, P529
   Killen JD, 1997, J CONSULT CLIN PSYCH, V65, P1011, DOI 10.1037/0022-006X.65.6.1011
   Lai SH, 2000, J ADDICT DIS, V19, P11, DOI 10.1300/J069v19n04_02
   Laws of Bangladesh, 1974, GUARD MARR BANGL MUS
   Lemstra M, 2008, CAN J PUBLIC HEALTH, V99, P172, DOI 10.1007/BF03405467
   MACFARLANE A, 1987, ARCH DIS CHILD, V62, P1125, DOI 10.1136/adc.62.11.1125
   Martin SL, 1996, AM J PUBLIC HEALTH, V86, P991, DOI 10.2105/AJPH.86.7.991
   Mishra RR., 2018, AJIRSET
   Mushahid, 2017, ASIA PACIFIC J MULTI, V5, P1
   One World Action and Nagorik Uddyog, 2011, DALIT WOM BANGL MULT
   ROHRBACH LA, 2002, HDB DRUG USE THEORY, P343
   Rosenbaum M., 1981, WOMEN HEROIN
   Sayem AM, 2011, REPROD HEALTH, V8, DOI 10.1186/1742-4755-8-16
   Sedgwick P, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1286
   Shazzad M.N., 2013, MED TODAY, V25, P84
   Shivkumar V, 2013, LANGUAGE INDIA, V13, P3
   Shrivastava J, 2015, ASIAN J WOMEN STUD, V21, P180, DOI 10.1080/12259276.2015.1062273
   Silberg J, 2003, J CHILD PSYCHOL PSYC, V44, P664, DOI 10.1111/1469-7610.00153
   Sultana H, 2016, INT J POLITICS CULT, V29, P19, DOI 10.1007/s10767-015-9202-6
   Theme-Filha MM, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0227-8
   TORABI MR, 1993, J SCHOOL HEALTH, V63, P302, DOI 10.1111/j.1746-1561.1993.tb06150.x
   TSCHANN JM, 1994, HEALTH PSYCHOL, V13, P326, DOI 10.1037/0278-6133.13.4.326
   Uddyog N, 2016, BRINGING DALIT WOMEN
   Vazquez-Nava F, 2014, J URBAN HEALTH, V91, P176, DOI 10.1007/s11524-013-9819-6
   von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X
   World Health Organization, 2004, ADOLESCENT PREGNANCY
   World Health Organization, 2016, RISK PROTECTIVE FACT
NR 50
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1557-1874
EI 1557-1882
J9 INT J MENT HEALTH AD
JI Int. J. Mental Health Addict.
PD OCT
PY 2022
VL 20
IS 5
BP 3145
EP 3161
DI 10.1007/s11469-021-00570-7
EA AUG 2021
PG 17
WC Psychology, Clinical; Substance Abuse; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology; Substance Abuse; Psychiatry
GA 5F7HB
UT WOS:000687947500001
DA 2023-06-23
ER

PT J
AU el-Guebaly, N
AF el-Guebaly, N
TI Drug addiction and drug policy: The struggle to control dependence.
SO CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
LA English
DT Book Review
C1 FRCPC, Calgary, AB, Canada.
RP el-Guebaly, N (通讯作者)，FRCPC, Calgary, AB, Canada.
CR Brownsberger W.N., 2001, DRUG ADDICTION DRUG, P51
NR 1
TC 0
Z9 0
U1 0
U2 0
PU CANADIAN PSYCHIATRIC ASSOC
PI OTTAWA
PA 260-441 MACLAREN ST, OTTAWA, ONTARIO K2H 2P3, CANADA
SN 0706-7437
J9 CAN J PSYCHIAT
JI Can. J. Psychiat.-Rev. Can. Psychiat.
PD JUN
PY 2002
VL 47
IS 5
BP 478
EP 479
DI 10.1177/070674370204700511
PG 2
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA 565JE
UT WOS:000176365600011
OA Bronze
DA 2023-06-23
ER

PT J
AU Milton, AL
AF Milton, A. L.
TI Drink, drugs and disruption: memory manipulation for the treatment of
   addiction
SO CURRENT OPINION IN NEUROBIOLOGY
LA English
DT Review
ID CONDITIONED PLACE PREFERENCE; BETA-ADRENERGIC-RECEPTORS; NMDA RECEPTORS;
   D-CYCLOSERINE; PROTEIN-SYNTHESIS; COCAINE-SEEKING; FEAR MEMORIES;
   RECONSOLIDATION; EXTINCTION; CONSOLIDATION
AB Addiction is a complex disorder, and one characterised by the acquisition of maladaptive instrumental (drug-seeking and drug-taking) and pavlovian (cue-drug associations) memories. These memories markedly contribute to the long-term risk of relapse, so reduction of the impact of these memories on behaviour could potentially be an important addition to current therapies for addiction. Memory reconsolidation may provide such a target for disrupting well-consolidated pavlovian cue-drug memories following an extensive drug history. Reconsolidation can be disrupted either by administering amnestic drugs in conjunction with a memory reactivation session, or by updating the memory adaptively through the induction of 'superextinction'. More work is needed before these therapies are ready for translation to the clinic, but if found clinically effective memory manipulation promises a radical new way of treating addiction.
C1 Univ Cambridge, Dept Psychol, Behav & Clin Neurosci Inst, Cambridge CB2 3EB, England.
C3 University of Cambridge
RP Milton, AL (通讯作者)，Univ Cambridge, Dept Psychol, Behav & Clin Neurosci Inst, Downing Site, Cambridge CB2 3EB, England.
EM alm46@cam.ac.uk
RI Milton, Amy L/B-6839-2009
OI Milton, Amy L/0000-0003-0175-9417
FU UK Medical Research Council [1002231]; Medical Research Council;
   Wellcome Trust; Medical Research Council [G0001354B, G1000183B,
   G0001354] Funding Source: researchfish
FX This work was supported by a UK Medical Research Council Programme Grant
   (no. 1002231) and was conducted in the Behavioural and Clinical
   Neuroscience Institute, funded by a joint award from the Medical
   Research Council and the Wellcome Trust.
CR Bernardi RE, 2007, BEHAV NEUROSCI, V121, P156, DOI 10.1037/0735-7044.121.1.156
   Bernardi RE, 2006, NEUROREPORT, V17, P1443, DOI 10.1097/01.wnr.0000233098.20655.26
   Bernardi RE, 2009, LEARN MEMORY, V16, P777, DOI 10.1101/lm.1648509
   BOUTON ME, 1979, LEARN MOTIV, V10, P445, DOI 10.1016/0023-9690(79)90057-2
   Bouton ME, 2002, BIOL PSYCHIAT, V52, P976, DOI 10.1016/S0006-3223(02)01546-9
   Chan Wan Yee Macy, 2010, Learn Mem, V17, P512, DOI 10.1101/lm.1912510
   COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478
   Debiec J, 2006, P NATL ACAD SCI USA, V103, P3428, DOI 10.1073/pnas.0507168103
   Debiec J, 2004, NEUROSCIENCE, V129, P267, DOI 10.1016/j.neuroscience.2004.08.018
   DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175
   Dhonnchadha BAN, 2011, PHARMACOL BIOCHEM BE, V99, P229, DOI 10.1016/j.pbb.2011.01.018
   Di Ciano P, 2004, NEUROPHARMACOLOGY, V47, P202, DOI 10.1016/j.neuropharm.2004.06.005
   Doyere V, 2007, NAT NEUROSCI, V10, P414, DOI 10.1038/nn1871
   Everitt BJ, 2001, BRAIN RES REV, V36, P129, DOI 10.1016/S0165-0173(01)00088-1
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Font L, 2012, PHARMACOL BIOCHEM BE, V101, P222, DOI 10.1016/j.pbb.2012.01.009
   Fricks-Gleason AN, 2008, LEARN MEMORY, V15, P643, DOI 10.1101/lm.1054608
   Itzhak Y, 2008, ANN NY ACAD SCI, V1139, P350, DOI 10.1196/annals.1432.051
   Lee JLC, 2006, J NEUROSCI, V26, P5881, DOI 10.1523/JNEUROSCI.0323-06.2006
   Lee JLC, 2005, NEURON, V47, P795, DOI 10.1016/j.neuron.2005.08.007
   Lee JLC, 2004, SCIENCE, V304, P839, DOI 10.1126/science.1095760
   Lee JLC, 2006, J NEUROSCI, V26, P10051, DOI 10.1523/JNEUROSCI.2466-06.2006
   Lee JLC, 2009, TRENDS NEUROSCI, V32, P413, DOI 10.1016/j.tins.2009.05.002
   Lee JLC, 2009, LEARN MEMORY, V16, P82, DOI 10.1101/lm.1186609
   Lee SH, 2008, SCIENCE, V319, P1253, DOI 10.1126/science.1150541
   Merlo E, 2012, NMDAR DEPENDENT INCR
   Milton AL, 2009, EUR NEUROPSYCHOPHARM, V19, pS86, DOI 10.1016/S0924-977X(09)70099-9
   Milton AL, 2008, J NEUROSCI, V28, P8230, DOI 10.1523/JNEUROSCI.1723-08.2008
   Milton AL, 2008, LEARN MEMORY, V15, P88, DOI 10.1101/lm.825008
   Milton AL, 2013, J NEUROSCI, V33, P1109, DOI 10.1523/JNEUROSCI.3273-12.2013
   Milton AL, 2012, PSYCHOPHARMACOLOGY, V219, P751, DOI 10.1007/s00213-011-2399-9
   Milton AL, 2010, EUR J NEUROSCI, V31, P2308, DOI 10.1111/j.1460-9568.2010.07249.x
   MISANIN JR, 1968, SCIENCE, V160, P554, DOI 10.1126/science.160.3827.554
   Monfils MH, 2009, SCIENCE, V324, P951, DOI 10.1126/science.1167975
   MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0
   Nader K, 2000, NATURE, V406, P722, DOI 10.1038/35021052
   Price KL, 2009, AM J DRUG ALCOHOL AB, V35, P434, DOI 10.3109/00952990903384332
   Sanchez H, 2010, J NEUROSCI, V30, P4401, DOI 10.1523/JNEUROSCI.3149-09.2010
   SCHNEIDER AM, 1968, SCIENCE, V159, P219, DOI 10.1126/science.159.3811.219
   Theberge FRM, 2010, LEARN MEMORY, V17, P444, DOI 10.1101/lm.1757410
   TOMIE A, 1995, CLIN PSYCHOL REV, V15, P145, DOI 10.1016/0272-7358(95)00005-A
   Torregrossa MM, 2010, J NEUROSCI, V30, P10526, DOI 10.1523/JNEUROSCI.2523-10.2010
   Tzeng WY, 2012, NEUROBIOL LEARN MEM, V97, P241, DOI 10.1016/j.nlm.2012.01.001
   Valjent E, 2006, P NATL ACAD SCI USA, V103, P2932, DOI 10.1073/pnas.0511030103
   von der Goltz C, 2009, PSYCHOPHARMACOLOGY, V205, P389, DOI 10.1007/s00213-009-1544-1
   WILSON DA, 1994, BEHAV NEUROSCI, V108, P1053, DOI 10.1037/0735-7044.108.6.1053
   Wouda JA, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00179
   Xue YX, 2012, SCIENCE, V336, P241, DOI 10.1126/science.1215070
NR 48
TC 29
Z9 29
U1 0
U2 30
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0959-4388
EI 1873-6882
J9 CURR OPIN NEUROBIOL
JI Curr. Opin. Neurobiol.
PD AUG
PY 2013
VL 23
IS 4
BP 706
EP 712
DI 10.1016/j.conb.2012.11.008
PG 7
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 204XJ
UT WOS:000323404300035
PM 23265965
DA 2023-06-23
ER

PT J
AU Aston-Jones, GS
   Baunez, C
   Grant, SJ
   Insel, TR
   Napier, TC
   Winn, P
AF Aston-Jones, GS
   Baunez, C
   Grant, SJ
   Insel, TR
   Napier, TC
   Winn, P
TI Is consideration of a wider brain circuitry needed to account for drug
   abuse? Implications for psychiatry of addiction and addiction therapy
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-College-of-Neuropsychopharmacology
CY DEC 12-16, 2004
CL San Juan, PR
SP Vanderbilt Univ, Sch Med, Dept Psychiaty, Amer Coll Neuropsychopharmacol
C1 Loyola Univ, Chicago Med CtrMed, Maywood, IL 60153 USA.
C3 Loyola University Chicago
RI Baunez, Christelle/J-6664-2019; Baunez, Christelle/L-9989-2019
OI Baunez, Christelle/0000-0002-4368-652X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD DEC
PY 2004
VL 29
SU 1
BP S10
EP S10
PG 1
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 877RO
UT WOS:000225588000031
DA 2023-06-23
ER

PT J
AU Shippenberg, TS
   LeFevour, A
   Chefer, VI
AF Shippenberg, T. S.
   LeFevour, A.
   Chefer, V. I.
TI Targeting Endogenous Mu- and Delta-Opioid Receptor Systems for the
   Treatment of Drug Addiction
SO CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS
LA English
DT Review
DE Opioid receptors; drug self-administration; enkephalin; endorphin;
   cocaine; ethanol; morphine
ID NUCLEUS-ACCUMBENS SHELL; EXTRACELLULAR DOPAMINE LEVELS; COCAINE-INDUCED
   REINSTATEMENT; CONDITIONED PLACE PREFERENCE; ANTERIOR CINGULATE CORTEX;
   MEDIAL PREFRONTAL CORTEX; VENTRAL TEGMENTAL AREA; GENE-EXPRESSION;
   BETA-ENDORPHIN; SEEKING BEHAVIOR
AB Drug addiction is a chronic, relapsing disorder that is characterized by a compulsion to take drug regardless of the adverse consequences that may ensue. Although the involvement of mesoaccumbal dopamine neurons in the initiation of drug abuse is well-established, neuroadaptations within the limbic cortical-striatopallidal circuit that occur as a consequence of repeated drug use are thought to lead to the behavioral dysregulation that characterizes addiction. Opioid receptors and their endogenous ligands are enriched in brain regions comprising this system and are, thus, strategically located to modulate neurotransmission therein. This article will review data suggesting an important role of mu-opioid receptor (MOPr) and delta opioid receptor (DOPr) systems in mediating the rewarding effects of several classes of abused drugs and that aberrant activity of these opioid systems may not only contribute to the behavioral dysregulation that characterizes addiction but to individual differences in addiction vulnerability.
C1 [Shippenberg, T. S.; LeFevour, A.; Chefer, V. I.] NIH NIDA Intramural Res Program, Integrat Neurosci Sect, Baltimore, MD 21224 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute on
   Drug Abuse (NIDA)
RP Shippenberg, TS (通讯作者)，NIH NIDA Intramural Res Program, Integrat Neurosci Sect, 333 Cassell Dr, Baltimore, MD 21224 USA.
EM tshippen@intra.nida.nih.gov
CR ALTSHULER HL, 1980, LIFE SCI, V26, P679, DOI 10.1016/0024-3205(80)90257-X
   BALSKUBIK R, 1989, PSYCHOPHARMACOLOGY, V98, P203, DOI 10.1007/BF00444692
   BALSKUBIK R, 1993, J PHARMACOL EXP THER, V264, P489
   Bassareo V, 1996, PSYCHOPHARMACOLOGY, V124, P293, DOI 10.1007/BF02247433
   BAUSCH SB, 1995, J CHEM NEUROANAT, V8, P175, DOI 10.1016/0891-0618(94)00044-T
   BECKETT AH, 1954, NATURE, V173, P1231, DOI 10.1038/1731231a0
   BERENDSE HW, 1992, J COMP NEUROL, V316, P314, DOI 10.1002/cne.903160305
   Bhushan RG, 2004, J MED CHEM, V47, P2969, DOI 10.1021/jm0342358
   Bossert JM, 2007, J NEUROSCI, V27, P12655, DOI 10.1523/JNEUROSCI.3926-07.2007
   Cahill CM, 2001, J COMP NEUROL, V440, P65, DOI 10.1002/cne.1370
   CHEFER VI, 2008, 39 ANN M INT NARC RE
   CHEFER VI, 2008, NEUROPSYCHOPHARMACOL
   CHESSELET MF, 1981, NATURE, V291, P320, DOI 10.1038/291320a0
   Ciccocioppo R, 2002, NEUROPSYCHOPHARMACOL, V27, P391, DOI 10.1016/S0893-133X(02)00302-0
   Cornish JL, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-15-j0006.2000
   COX B, 2005, PHARM REV
   Crespo JA, 2001, NEUROPSYCHOPHARMACOL, V25, P185, DOI 10.1016/S0893-133X(01)00221-4
   Crombag HS, 2008, PHILOS T R SOC B, V363, P3233, DOI 10.1098/rstb.2008.0090
   Daglish MRC, 2003, NEUROIMAGE, V20, P1964, DOI 10.1016/j.neuroimage.2003.07.025
   Daniels DJ, 2005, P NATL ACAD SCI USA, V102, P19208, DOI 10.1073/pnas.0506627102
   Daniels DJ, 2005, J MED CHEM, V48, P1713, DOI 10.1021/jm034234f
   de Gortari P, 2000, NEUROCHEM INT, V37, P483, DOI 10.1016/S0197-0186(00)00059-0
   DEVINE DP, 1994, J NEUROSCI, V14, P1978
   DEVRIES TJ, 1995, PSYCHOPHARMACOLOGY, V120, P442, DOI 10.1007/BF02245816
   DEWAELE JP, 1994, ALCOHOL CLIN EXP RES, V18, P1468
   DEYEBENES EG, 1993, NEUROPEPTIDES, V25, P91, DOI 10.1016/0143-4179(93)90087-Q
   Di Chiara G, 2004, NEUROPHARMACOLOGY, V47, P227, DOI 10.1016/j.neuropharm.2004.06.032
   Di Ciano P, 2005, EUR J PHARMACOL, V526, P186, DOI 10.1016/j.ejphar.2005.09.024
   Di Ciano P, 2001, NEUROPSYCHOPHARMACOL, V25, P341, DOI 10.1016/S0893-133X(01)00235-4
   Diana M, 1996, NEUROSCIENCE, V71, P411, DOI 10.1016/0306-4522(95)00482-3
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Do Carmo GP, 2006, EUR J PHARMACOL, V547, P92, DOI 10.1016/j.ejphar.2006.06.075
   DOURMAP N, 1990, BRAIN RES, V524, P153, DOI 10.1016/0006-8993(90)90505-6
   DOURMAP N, 1992, J NEUROCHEM, V58, P709, DOI 10.1111/j.1471-4159.1992.tb09775.x
   DOURMAP N, 1994, EUR J PHARMACOL, V253, pR9, DOI 10.1016/0014-2999(94)90210-0
   Drakenberg K, 2006, P NATL ACAD SCI USA, V103, P7883, DOI 10.1073/pnas.0600871103
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Everitt BJ, 2002, J NEUROSCI, V22, P3312
   Feltenstein MW, 2008, BRIT J PHARMACOL, V154, P261, DOI 10.1038/bjp.2008.51
   Filliol D, 2000, NAT GENET, V25, P195, DOI 10.1038/76061
   Finnegan TF, 2006, J NEUROPHYSIOL, V95, P2032, DOI 10.1152/jn.01004.2005
   Foster KL, 2004, NEUROPSYCHOPHARMACOL, V29, P269, DOI 10.1038/sj.npp.1300306
   Franklin TR, 2007, NEUROPSYCHOPHARMACOL, V32, P2301, DOI 10.1038/sj.npp.1301371
   FROEHLICH JC, 1990, PHARMACOL BIOCHEM BE, V35, P385, DOI 10.1016/0091-3057(90)90174-G
   FROEHLICH JC, 1994, ANN NY ACAD SCI, V739, P156, DOI 10.1111/j.1749-6632.1994.tb19817.x
   FULLER TA, 1987, J COMP NEUROL, V258, P317, DOI 10.1002/cne.902580302
   Funada M, 1996, EUR J PHARMACOL, V300, P17, DOI 10.1016/0014-2999(95)00860-8
   FUNDYTUS ME, 1995, EUR J PHARMACOL, V286, P105, DOI 10.1016/0014-2999(95)00554-X
   Garzon M, 2002, NEUROSCIENCE, V114, P461, DOI 10.1016/S0306-4522(02)00249-X
   Gaveriaux-Ruff C, 2001, J PHARMACOL EXP THER, V298, P1193
   GAWIN FH, 1991, SCIENCE, V251, P1580, DOI 10.1126/science.2011738
   George MS, 2001, ARCH GEN PSYCHIAT, V58, P345, DOI 10.1001/archpsyc.58.4.345
   GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780
   Gerrits MAFM, 2005, EUR NEUROPSYCHOPHARM, V15, P297, DOI 10.1016/j.euroneuro.2004.11.004
   Giacchino JL, 1998, PROG NEURO-PSYCHOPH, V22, P1157, DOI 10.1016/S0278-5846(98)00053-0
   GLIMCHER PW, 1984, BEHAV NEUROSCI, V98, P262, DOI 10.1037/0735-7044.98.2.262
   GOEDERS NE, 1984, PHARMACOL BIOCHEM BE, V20, P451, DOI 10.1016/0091-3057(84)90284-3
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Gomes I, 2004, P NATL ACAD SCI USA, V101, P5135, DOI 10.1073/pnas.0307601101
   Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000
   Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040
   Graybiel AM, 2005, CURR OPIN NEUROBIOL, V15, P638, DOI 10.1016/j.conb.2005.10.006
   GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I
   GREVERT P, 1977, P NATL ACAD SCI USA, V74, P1291, DOI 10.1073/pnas.74.3.1291
   Grisel JE, 1999, BRAIN RES, V835, P62, DOI 10.1016/S0006-8993(99)01384-0
   GROENEWEGEN HJ, 1993, NEUROSCIENCE, V57, P113, DOI 10.1016/0306-4522(93)90115-V
   Hao Y, 2005, BRAIN RES, V1040, P191, DOI 10.1016/j.brainres.2005.01.072
   HEIDBREDER CA, 1996, J PHARMACOL EXP THER, V278, P182
   Heimer L, 2006, NEUROSCI BIOBEHAV R, V30, P126, DOI 10.1016/j.neubiorev.2005.06.006
   Heyser CJ, 1999, ALCOHOL CLIN EXP RES, V23, P1468, DOI 10.1111/j.1530-0277.1999.tb04669.x
   Hyytia P, 2001, ALCOHOL CLIN EXP RES, V25, P25, DOI 10.1097/00000374-200101000-00005
   Ito R, 2002, J NEUROSCI, V22, P6247
   Jayaram-Lindstrom N, 2008, NEUROPSYCHOPHARMACOL, V33, P1856, DOI 10.1038/sj.npp.1301572
   JAYARAMLINDSTRO.N, 2008, AM J PSYCHIAT
   JOHNSON SW, 1992, J NEUROSCI, V12, P483
   June HL, 1999, PSYCHOPHARMACOLOGY, V147, P81, DOI 10.1007/s002130051145
   June HL, 2004, NEUROPSYCHOPHARMACOL, V29, P285, DOI 10.1038/sj.npp.1300338
   Jutkiewicz EM, 2003, BEHAV PHARMACOL, V14, P509, DOI 10.1097/00008877-200311000-00003
   KALIVAS PW, 1993, J NEUROSCI, V13, P266
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Katner SN, 1999, ALCOHOL CLIN EXP RES, V23, P1751, DOI 10.1097/00000374-199911000-00007
   Kest B, 1996, BRAIN RES BULL, V39, P185, DOI 10.1016/0361-9230(95)02092-6
   KHACHATURIAN H, 1983, J NEUROSCI, V3, P844
   KHACHATURIAN H, 1993, HDB EXPT PHARM, P471
   KRISHNANSARIN S, 1995, PHARMACOL BIOCHEM BE, V52, P153, DOI 10.1016/0091-3057(95)00080-G
   KRISHNANSARIN S, 1995, PSYCHOPHARMACOLOGY, V120, P177, DOI 10.1007/BF02246191
   LaLumiere RT, 2008, J NEUROSCI, V28, P3170, DOI 10.1523/JNEUROSCI.5129-07.2008
   LAM MP, 2008, PSYCHOPHARMACOLOGY
   Lenard NR, 2007, EUR J PHARMACOL, V566, P75, DOI 10.1016/j.ejphar.2007.02.040
   LHEREAULT S, 1991, MOL BRAIN RES, V9, P327, DOI 10.1016/0169-328X(91)90080-H
   Loh EW, 2004, ALCOHOL CLIN EXP RES, V28, P15, DOI 10.1097/01.ALC.0000106303.41755.B8
   Longoni R, 1998, BEHAV PHARMACOL, V9, P9
   LONGONI R, 1991, J NEUROSCI, V11, P1565
   LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0
   MANSOUR A, 1995, J CHEM NEUROANAT, V8, P283, DOI 10.1016/0891-0618(95)00055-C
   Marinelli PW, 2003, PSYCHOPHARMACOLOGY, V169, P60, DOI 10.1007/s00213-003-1490-2
   Marquez P, 2008, PSYCHOPHARMACOLOGY, V197, P443, DOI 10.1007/s00213-007-1053-z
   Martin TJ, 1998, DRUG ALCOHOL DEPEN, V52, P135, DOI 10.1016/S0376-8716(98)00082-9
   Martin TJ, 2002, PSYCHOPHARMACOLOGY, V161, P152, DOI 10.1007/s00213-002-1008-3
   MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517
   Mateo Y, 2005, NEUROPSYCHOPHARMACOL, V30, P1455, DOI 10.1038/sj.npp.1300687
   Mathieu-Kia AM, 1998, MOL BRAIN RES, V54, P141, DOI 10.1016/S0169-328X(97)00338-0
   McFarland K, 2001, J NEUROSCI, V21, P8655
   MCGEORGE AJ, 1989, NEUROSCIENCE, V29, P503, DOI 10.1016/0306-4522(89)90128-0
   Mendez M, 2001, MOL BRAIN RES, V94, P148, DOI 10.1016/S0169-328X(01)00232-7
   Middaugh LD, 2000, PHARMACOL BIOCHEM BE, V65, P145, DOI 10.1016/S0091-3057(99)00184-7
   MITROVIC I, 1995, J PHARMACOL EXP THER, V272, P1260
   Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006
   MIYAMOTO Y, 1993, J PHARMACOL EXP THER, V264, P1141
   MOGENSON GJ, 1993, LIMBIC MOTOR CIRCUIT, P193
   Monti PM, 1999, ALCOHOL CLIN EXP RES, V23, P1386, DOI 10.1111/j.1530-0277.1999.tb04361.x
   MUCHA RF, 1985, PSYCHOPHARMACOLOGY, V86, P281, DOI 10.1007/BF00432214
   NAPIER TC, 1991, ADV EXP MED BIOL, V295, P183
   Napier TC, 1999, ANN NY ACAD SCI, V877, P176, DOI 10.1111/j.1749-6632.1999.tb09268.x
   NEGUS SS, 1995, J PHARMACOL EXP THER, V273, P1245
   NG JP, 1991, J NEUROCHEM, V56, P1485, DOI 10.1111/j.1471-4159.1991.tb02042.x
   Nieto MM, 2002, J NEUROSCI, V22, P1034, DOI 10.1523/JNEUROSCI.22-03-01034.2002
   Nikoshkov A, 2008, P NATL ACAD SCI USA, V105, P786, DOI 10.1073/pnas.0710902105
   Oliva JM, 2008, EUR NEUROPSYCHOPHARM, V18, P373, DOI 10.1016/j.euroneuro.2007.09.001
   Olive MF, 1998, J PHARMACOL EXP THER, V285, P1310
   Olive MF, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-23-j0002.2001
   Olive MF, 1998, PSYCHOPHARMACOLOGY, V139, P251, DOI 10.1007/s002130050712
   Ongur D, 2000, CEREB CORTEX, V10, P206, DOI 10.1093/cercor/10.3.206
   Ostermeier AM, 2000, ANESTHESIOLOGY, V93, P1053, DOI 10.1097/00000542-200010000-00029
   Packard MG, 2002, ANNU REV NEUROSCI, V25, P563, DOI 10.1146/annurev.neuro.25.112701.142937
   Perrine SA, 2006, BRIT J PHARMACOL, V147, P864, DOI 10.1038/sj.bjp.0706686
   Perrine SA, 2008, NEUROPHARMACOLOGY, V54, P355, DOI 10.1016/j.neuropharm.2007.10.007
   PERT CB, 1973, SCIENCE, V182, P1359, DOI 10.1126/science.182.4119.1359
   PETIT F, 1986, EUR J PHARMACOL, V126, P1, DOI 10.1016/0014-2999(86)90731-4
   PHILLIPS AG, 1982, BEHAV BRAIN RES, V5, P225, DOI 10.1016/0166-4328(82)90057-2
   Pierce RC, 1997, BRAIN RES REV, V25, P192, DOI 10.1016/S0165-0173(97)00021-0
   Poulin JF, 2008, J COMP NEUROL, V506, P943, DOI 10.1002/cne.21587
   Ramsey NF, 1999, EUR NEUROPSYCHOPHARM, V9, P93, DOI 10.1016/S0924-977X(98)00009-1
   Rasmussen DD, 2002, ALCOHOL CLIN EXP RES, V26, P535, DOI 10.1111/j.1530-0277.2002.tb02572.x
   REID LD, 1995, NEUROREPORT, V6, P1409, DOI 10.1097/00001756-199507100-00012
   Robbins TW, 1999, NATURE, V398, P567, DOI 10.1038/19208
   Robinson TE, 2001, ADDICTION, V96, P103, DOI 10.1046/j.1360-0443.2001.9611038.x
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Rosin A, 2003, BRAIN RES, V978, P1, DOI 10.1016/S0006-8993(03)02674-X
   Roth-Deri I, 2003, J NEUROCHEM, V84, P930, DOI 10.1046/j.1471-4159.2003.01584.x
   Sah P, 2003, PHYSIOL REV, V83, P803, DOI 10.1152/physrev.00002.2003
   Saland LC, 2005, NEUROSCI LETT, V381, P163, DOI 10.1016/j.neulet.2005.02.016
   Schad CA, 2002, J PHARMACOL EXP THER, V300, P932, DOI 10.1124/jpet.300.3.932
   Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593
   Schultz W, 2002, NEURON, V36, P241, DOI 10.1016/S0896-6273(02)00967-4
   Shippenberg TS, 2007, PHARMACOL THERAPEUT, V116, P306, DOI 10.1016/j.pharmthera.2007.06.011
   Shippenberg TS, 1998, CRIT REV NEUROBIOL, V12, P267, DOI 10.1615/CritRevNeurobiol.v12.i4.10
   SHIPPENBERG TS, 1995, BEHAV PHARMACOL, V6, P99
   SHIPPENBERG TS, 1987, BRAIN RES, V436, P234, DOI 10.1016/0006-8993(87)91667-2
   SHIPPENBERG TS, 2008, BIOL PSYCHI IN PRESS
   SIMON EJ, 1973, P NATL ACAD SCI USA, V70, P1947, DOI 10.1073/pnas.70.7.1947
   Skoubis PD, 2005, EUR J NEUROSCI, V21, P1379, DOI 10.1111/j.1460-9568.2005.03956.x
   Skoubis PD, 2003, NEUROSCIENCE, V119, P241, DOI 10.1016/S0306-4522(03)00121-0
   Skoubis PD, 2001, NEUROSCIENCE, V106, P757, DOI 10.1016/S0306-4522(01)00333-5
   Soderman AR, 2008, NEUROSCIENCE, V154, P1506, DOI 10.1016/j.neuroscience.2008.04.063
   SPANAGEL R, 1993, SYNAPSE, V14, P243, DOI 10.1002/syn.890140307
   SPANAGEL R, 1990, J NEUROCHEM, V55, P1734, DOI 10.1111/j.1471-4159.1990.tb04963.x
   SPANAGEL R, 1992, P NATL ACAD SCI USA, V89, P2046, DOI 10.1073/pnas.89.6.2046
   SPANAGEL R, 1991, PSYCHOPHARMACOLOGY, V104, P51, DOI 10.1007/BF02244553
   Spangler R, 1997, MOL BRAIN RES, V44, P139, DOI 10.1016/S0169-328X(96)00249-5
   STAPELFELD A, 1992, EUR J PHARMACOL, V214, P273, DOI 10.1016/0014-2999(92)90129-R
   Stromberg MF, 1998, ALCOHOL, V15, P281, DOI 10.1016/S0741-8329(97)00131-6
   Suzuki T, 1997, PHARMACOL BIOCHEM BE, V57, P293, DOI 10.1016/S0091-3057(96)00319-X
   SUZUKI T, 1994, LIFE SCI, V55, pPL339, DOI 10.1016/0024-3205(94)00774-8
   Svingos AL, 1999, SYNAPSE, V34, P1
   Svingos AL, 1998, J NEUROSCI, V18, P1923
   TAKEMORI AE, 1992, LIFE SCI, V50, P1491, DOI 10.1016/0024-3205(92)90138-F
   TANAKA E, 1994, J NEUROSCI, V14, P1106, DOI 10.1523/JNEUROSCI.14-03-01106.1994
   Tang XC, 2005, J NEUROSCI, V25, P4512, DOI 10.1523/JNEUROSCI.0685-05.2005
   Thompson AC, 2000, J NEUROSCI, V20, P9333
   Turchan J, 1999, NEUROSCIENCE, V91, P971, DOI 10.1016/S0306-4522(98)00637-X
   Turchan J, 1997, NEUROPEPTIDES, V31, P24, DOI 10.1016/S0143-4179(97)90015-9
   ULM RR, 1995, J CLIN PSYCHIAT, V56, P5
   UNTERWALD EM, 1992, BRAIN RES, V584, P314, DOI 10.1016/0006-8993(92)90912-S
   UNTERWALD EM, 1994, NEUROREPORT, V5, P1613, DOI 10.1097/00001756-199408150-00018
   van Dongen YC, 2005, NEUROSCIENCE, V136, P1049, DOI 10.1016/j.neuroscience.2005.08.050
   VAUGHT JL, 1979, J PHARMACOL EXP THER, V208, P86
   VOGT BA, 1995, EXP NEUROL, V135, P83, DOI 10.1006/exnr.1995.1069
   Waldhoer M, 2005, P NATL ACAD SCI USA, V102, P9050, DOI 10.1073/pnas.0501112102
   Waldhoer M, 2004, ANNU REV BIOCHEM, V73, P953, DOI 10.1146/annurev.biochem.73.011303.073940
   Ward SJ, 2003, PHARMACOL BIOCHEM BE, V75, P301, DOI 10.1016/S0091-3057(03)00087-X
   Weiss F, 1996, J NEUROSCI, V16, P3474
   Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406
   Xuei XL, 2007, AM J MED GENET B, V144B, P877, DOI 10.1002/ajmg.b.30531
   Yin HH, 2005, EUR J NEUROSCI, V22, P513, DOI 10.1111/j.1460-9568.2005.04218.x
   Yung KKL, 2000, SYNAPSE, V38, P413, DOI 10.1002/1098-2396(20001215)38:4<413::AID-SYN6>3.0.CO;2-V
   Zadina JE, 1997, NATURE, V386, P499, DOI 10.1038/386499a0
   ZAHM DS, 1985, BRAIN RES, V325, P317, DOI 10.1016/0006-8993(85)90331-2
   ZAHM DS, 1993, J COMP NEUROL, V327, P220, DOI 10.1002/cne.903270205
   Zaki PA, 1996, ANNU REV PHARMACOL, V36, P379
   Zhang Y, 2005, J BIOL CHEM, V280, P32618, DOI 10.1074/jbc.M504942200
   Zhou Y, 2003, BRAIN RES, V964, P187, DOI 10.1016/S0006-8993(02)03929-X
   Zhu W, 2005, NEUROSCIENCE, V133, P97, DOI 10.1016/j.neuroscience.2005.02.004
   Zhu W, 2004, NEUROSCIENCE, V127, P871, DOI 10.1016/j.neuroscience.2004.05.043
   Zubieta JK, 1996, NAT MED, V2, P1225, DOI 10.1038/nm1196-1225
NR 195
TC 47
Z9 48
U1 1
U2 10
PU BENTHAM SCIENCE PUBL
PI BUSUM
PA PO BOX 294, BUSUM, 1400 AG, NETHERLANDS
SN 1871-5273
EI 1996-3181
J9 CNS NEUROL DISORD-DR
JI CNS Neurol. Disord.-Drug Targets
PD NOV
PY 2008
VL 7
IS 5
BP 442
EP 453
DI 10.2174/187152708786927813
PG 12
WC Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 397HY
UT WOS:000262654700005
PM 19128202
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Amirabadizadeh, A
   Nakhaee, S
   Ghasemi, S
   Benito, M
   Torbati, VB
   Mehrpour, O
AF Amirabadizadeh, Alireza
   Nakhaee, Samaneh
   Ghasemi, Saeedeh
   Benito, Maria
   Torbati, Vahideh Bazzazadeh
   Mehrpour, Omid
TI Evaluating drug use relapse event rate and its associated factors using
   Poisson model
SO JOURNAL OF SUBSTANCE USE
LA English
DT Article
DE Relapse; addiction; drug use; Poisson regression model
ID COUNT DATA; REGRESSION; ADDICTION; CENTERS
AB Background: Drug use is a chronic and recurrent disease, and many individuals return to using drugs a short time after rehabilitation treatment. This study investigated factors involved in increasing the number of times individuals with drug addiction problems relapse. Methods: In this descriptive-analytic study, 700 individuals referred to seven drug rehabilitation centers in Birjand City, Iran were selected based on the date of referral to the center. Checklists and interviews with the patients were used to gather the required information; data were analyzed using Poisson model distributions. Results: Age increases the odds of a higher number of relapses to drug addictions by 1.02 times per year of age (p< .001). Compared to those who smoke cigarettes, the odds of stopping drug use for those with no history of smoking cigarettes decreases by 0.13 with every year of age. Additionally, for every year of delay in age of initiating smoking, the number of drug addiction relapses decreases 0.96 times (p< .001). Modern drugs increase the odds of relapse compared to traditional drugs (p< .05). Individuals with university education undergo a higher number of drug rehabilitations compared to those with only an elementary school education. For every year of age delay in starting the use of drugs, the number of relapses decreases significantly by 0.97 times (p< .001). Conclusion: This study revealed that the current age and the age when first starting drug use, education level, type of substance used, and previous history of smoking cigarettes significantly influence the number of relapses of drug addiction.
C1 [Amirabadizadeh, Alireza; Nakhaee, Samaneh] Birjand Univ Med Sci, Med Toxicol & Drug Abuse Res Ctr MTDRC, Birjand, Iran.
   [Ghasemi, Saeedeh] Birjand Univ Med Sci, Student Res Comm, Birjand, Iran.
   [Benito, Maria] CMB Counselling Clin, Dublin, Ireland.
   [Benito, Maria] Hosp Pharm News, IPN Commun, Dublin, Ireland.
   [Torbati, Vahideh Bazzazadeh] Mashhad Univ Med Sci, Dept Biostat, Mashhad, Razavi Khorasan, Iran.
   [Mehrpour, Omid] Denver Hlth & Hosp Author, Rocky Mt Poison & Drug Ctr, Denver, CO 80204 USA.
C3 Mashhad University Medical Science; Denver Health Medical Center
RP Mehrpour, O (通讯作者)，Denver Hlth & Hosp Author, Rocky Mt Poison & Drug Ctr, Denver, CO 80204 USA.
EM omid.mehrpour@yahoo.com.au
RI Mehrpour, Omid/E-9554-2011
OI Mehrpour, Omid/0000-0002-1070-8841
FU Medical Toxicology and Drug Abuse Research Centre (MTDRC) of Birjand
   University of Medical Sciences
FX This study was supported by the Medical Toxicology and Drug Abuse
   Research Centre (MTDRC) of Birjand University of Medical Sciences. We
   are grateful to all patients, staff, and managers of addiction treatment
   centers in Birjand city who helped us conduct this research
CR Abdul-Aziz A., 2013, AM INT J CONT RES, V3, P148
   Allison PD, 1999, SOCIOL METHOD RES, V28, P186, DOI 10.1177/0049124199028002003
   Amirabadizadeh A, 2018, SUBST USE MISUSE, V53, P1030, DOI 10.1080/10826084.2017.1392981
   Atadokht Akbar, 2015, Int J High Risk Behav Addict, V4, pe21250, DOI 10.5812/ijhrba.21250
   Atkins DC, 2007, J FAM PSYCHOL, V21, P726, DOI 10.1037/0893-3200.21.4.726
   Bazzazzadeh V., 2017, BIOSTATISTICS BIOMET, V3, DOI 10.19080/BBOAJ.2017.03.555620
   Esmaili A., 2002, IRANIAN J PSYCHIAT C, V8, P29
   Goodarzi F., 2011, IRAN J TOXICOL, V4, P377
   Greene W. H., 1994, EC9410 NYU LN STERN
   Hayatbakhsh MM, 2017, SUBST ABUSE TREAT PR, V12, DOI 10.1186/s13011-017-0127-0
   Hosseini Somaye, 2014, Osong Public Health Res Perspect, V5, P92, DOI 10.1016/j.phrp.2014.02.003
   Huls A, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00071
   IBRAHIM F, 2009, EUR J SOC SCI, V11, P471
   Islam MA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178153
   Johnson, 2010, ADDICTION MED, P765, DOI DOI 10.1007/978-1-4419-0338-9_38
   Karrari P, 2013, J PAK MED ASSOC, V63, P711
   Kassani A, 2015, HEALTH SCOPE, V4
   LAMBERT D, 1992, TECHNOMETRICS, V34, P1, DOI 10.2307/1269547
   Lim HK, 2014, COMPUT STAT DATA AN, V71, P151, DOI 10.1016/j.csda.2013.06.021
   Loeys T, 2012, BRIT J MATH STAT PSY, V65, P163, DOI 10.1111/j.2044-8317.2011.02031.x
   Margoob M A, 1993, Indian J Psychiatry, V35, P163
   Martina R, 2015, PHARM STAT, V14, P151, DOI 10.1002/pst.1664
   Mehrpour Omid, 2016, Addict Health, V8, P76
   Mohammadpoorasl A, 2012, J ADDICT RES THER, V3, P1
   MULLAHY J, 1986, J ECONOMETRICS, V33, P341, DOI 10.1016/0304-4076(86)90002-3
   Nazari I, 2016, INT J PHARM RES ALLI, V5, P174
   Okoffo ED, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2561-2
   Rahman MM, 2016, J SUBST USE, V21, P627, DOI 10.3109/14659891.2015.1122099
   Ridout M, 2001, BIOMETRICS, V57, P219, DOI 10.1111/j.0006-341X.2001.00219.x
   Rimaz Shahnaz, 2013, J SCH PUBLIC HLTH I, V10, P53
   Roshani B., 2014, LIFE SCI J, V11, P66
   Saffari SE, 2011, MATEMATIKA, V27, P21
   Sapkota S., 2016, J CHITWAN MED COLL, V6, P20, DOI [10.3126/jcmc.v6i3.16695, DOI 10.3126/JCMC.V6I3.16695]
   Sharma A., 2012, INDIAN J LIFE SCI, V2, P31
   Xie HY, 2013, J SUBST ABUSE TREAT, V45, P99, DOI 10.1016/j.jsat.2013.01.005
   Yau KKW, 2003, BIOMETRICAL J, V45, P437, DOI 10.1002/bimj.200390024
NR 36
TC 6
Z9 6
U1 1
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1465-9891
EI 1475-9942
J9 J SUBST USE
JI J. Subst. Use
PD JAN 2
PY 2021
VL 26
IS 1
BP 60
EP 66
DI 10.1080/14659891.2020.1779359
EA JUN 2020
PG 7
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA PR5YL
UT WOS:000546039700001
DA 2023-06-23
ER

PT J
AU Karim, R
   Chaudhri, P
AF Karim, Reef
   Chaudhri, Priya
TI Behavioral Addictions: An Overview
SO JOURNAL OF PSYCHOACTIVE DRUGS
LA English
DT Article
DE behavioral addictions; binge eating; impulse control disorders;
   pathological gambling; process addictions; sex addiction
ID PROBLEMATIC INTERNET USE; BINGE-EATING DISORDER; DRUG-ADDICTION;
   MESOLIMBIC DOPAMINE; IMPULSE CONTROL; PREVALENCE; SUBSTANCE; ALCOHOL;
   NEUROBIOLOGY; COMORBIDITY
AB The legitimacy of nonsubstance addictions has received increased attention from clinicians, researchers and the general population as more and more individuals report symptoms consistent with impairment of impulse control. The clinical presentation of these disorders is varied, as compulsive activities may include: gambling, eating, sex, shopping, use of the Internet or videogames or even exercising, working or falling in love. As such, there is great controversy in diagnosing, treating or even naming these conditions, as many of these behaviors are daily rituals instrumental to our ultimate survival. Historically, the phrase "impulse control disorders" described these conditions but many researchers and clinicians also use the term "behavioral addictions," "process addictions" or "impulsive-compulsive behaviors" to report behavioral pathology. This review summarizes the data of each of these behavioral addictions from epidemiology to neurobiology to treatment options. Research suggests similarities between natural and drug reward processing but clinical evidence supports the utilization of treatment modalities for these behavioral conditions that can sometimes differ from traditional drug treatment.
C1 [Karim, Reef] UCLA Semel Inst Neurosci & Human Behav, Dept Psychiat, Los Angeles, CA USA.
   [Chaudhri, Priya] Univ Calif San Diego, San Diego, CA 92103 USA.
C3 University of California System; University of California San Diego
RP Karim, R (通讯作者)，Control Ctr, 9777 Wilshire Blvd,Suite 704, Beverly Hills, CA 90210 USA.
EM Reef@doctorreef.com
CR Alcock J., 2005, ANIMAL BEHAV EVOLUTI
   Allison SE, 2006, AM J PSYCHIAT, V163, P381, DOI 10.1176/appi.ajp.163.3.381
   American Psychiatric Association (APA), 2000, DIAGN STAT MAN MENT, Vfourth
   American Psychiatric Association DSM-5 Development, 2010, HYP DIS
   [Anonymous], 2002, NEURON, V36, P189
   Appolinario JC, 2004, CURR DRUG TARGETS, V5, P301, DOI 10.2174/1389450043490488
   Bassareo V, 1999, EUR J NEUROSCI, V11, P4389, DOI 10.1046/j.1460-9568.1999.00843.x
   Beard KW, 2005, CYBERPSYCHOL BEHAV, V8, P7, DOI 10.1089/cpb.2005.8.7
   Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584
   Berridge KC, 2007, PSYCHOPHARMACOLOGY, V191, P391, DOI 10.1007/s00213-006-0578-x
   Black DW, 2007, CNS SPECTRUMS, V12, P124, DOI 10.1017/S1092852900020630
   Black DW, 2000, CNS SPECTRUMS, V5, P40, DOI 10.1017/S1092852900025037
   Black DW, 2001, J NERV MENT DIS, V189, P123, DOI 10.1097/00005053-200102000-00010
   Blum K, 1996, J ROY SOC MED, V89, P396, DOI 10.1177/014107689608900711
   BLUNDELL JE, 1984, NEUROPHARMACOLOGY, V23, P1537, DOI 10.1016/0028-3908(84)90098-4
   Bostwick JM, 2008, MAYO CLIN PROC, V83, P226, DOI 10.4065/83.2.226
   Breiter HC, 2001, NEURON, V30, P619, DOI 10.1016/S0896-6273(01)00303-8
   Brewer JA, 2008, BIOCHEM PHARMACOL, V75, P63, DOI 10.1016/j.bcp.2007.06.043
   Carnes P.J., 2002, CLIN MANAGEMENT SEX
   Carter WP, 2003, INT J EAT DISORDER, V34, pS74, DOI 10.1002/eat.10207
   Chak K, 2004, CYBERPSYCHOL BEHAV, V7, P559, DOI 10.1089/1094931042403073
   Chamberlain SR, 2007, CURR OPIN PSYCHIATR, V20, P255, DOI 10.1097/yco.0b013e3280ba4989
   Chan Philip A, 2006, Ann Gen Psychiatry, V5, P16, DOI 10.1186/1744-859X-5-16
   Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11
   Claes L, 2011, COMPR PSYCHIAT, V52, P50, DOI 10.1016/j.comppsych.2010.05.003
   Coleman Eli, 2003, Minn Med, V86, P42
   Council on Science and Public Health (CSAPH), 2006, EM BEH EFF INCL ADD
   Davis C, 2009, APPETITE, V53, P1, DOI 10.1016/j.appet.2009.05.018
   Davis RA, 2001, COMPUT HUM BEHAV, V17, P187, DOI 10.1016/S0747-5632(00)00041-8
   Deadwyler SA, 2010, ANN NY ACAD SCI, V1187, P140, DOI 10.1111/j.1749-6632.2009.05155.x
   Di Chiara G, 1998, J PSYCHOPHARMACOL, V12, P54, DOI 10.1177/026988119801200108
   Djamshidian A, 2010, MOVEMENT DISORD, V25, P2203, DOI 10.1002/mds.23247
   Entertainment Software Association (ESA), 2005, SAL DEM USAG DAT ESS
   ESA, 2006, ESS FACTS COMP VID G
   Evans AH, 2006, ANN NEUROL, V59, P852, DOI 10.1002/ana.20822
   Filip M, 2005, PHARMACOL REP, V57, P685
   GOLDBERG I, 1995, INTERNET ADDICTIVE D
   Goodman A, 2008, BIOCHEM PHARMACOL, V75, P266, DOI 10.1016/j.bcp.2007.07.030
   Grant J E, 2001, Ann Clin Psychiatry, V13, P229, DOI 10.1023/A:1014626102110
   Grant JE, 2006, AM J PSYCHIAT, V163, P303, DOI 10.1176/appi.ajp.163.2.303
   Grant JE, 2007, BIOL PSYCHIAT, V62, P652, DOI 10.1016/j.biopsych.2006.11.021
   Grant JE, 2006, CNS SPECTRUMS, V11, P924, DOI 10.1017/S109285290001511X
   Griffiths M, 2000, CYBERPSYCHOL BEHAV, V3, P211, DOI 10.1089/109493100316067
   Grusser SM, 2007, CYBERPSYCHOL BEHAV, V10, P290, DOI 10.1089/cpb.2006.9956
   Halford J C, 2000, Prog Drug Res, V54, P25
   Halford JCG, 1998, PHARMACOL BIOCHEM BE, V61, P159, DOI 10.1016/S0091-3057(98)00032-X
   Hammersley R., 1995, E COMMUNICATION
   Hodgins DC, 2011, LANCET, V378, P1874, DOI 10.1016/S0140-6736(10)62185-X
   Hodgins DC, 1999, J GAMBL STUD, V15, P93, DOI DOI 10.1023/A:1022237807310
   Hoeft F, 2008, J PSYCHIATR RES, V42, P253, DOI 10.1016/j.jpsychires.2007.11.010
   Holden C, 2001, SCIENCE, V294, P980, DOI 10.1126/science.294.5544.980
   Hudson JI, 2007, BIOL PSYCHIAT, V61, P348, DOI 10.1016/j.biopsych.2006.03.040
   Hyman SE, 2005, AM J PSYCHIAT, V162, P1414, DOI 10.1176/appi.ajp.162.8.1414
   Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483
   Kafka MP, 2010, ARCH SEX BEHAV, V39, P377, DOI 10.1007/s10508-009-9574-7
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564
   Kalivas PW, 2006, MOL INTERV, V6, P339, DOI 10.1124/mi.6.6.7
   Kaplan MS, 2010, J SEX RES, V47, P181, DOI 10.1080/00224491003592863
   Kelley AE, 2005, PHYSIOL BEHAV, V86, P773, DOI 10.1016/j.physbeh.2005.08.066
   Kenna GA, 2009, ALCOHOL CLIN EXP RES, V33, P315, DOI 10.1111/j.1530-0277.2008.00835.x
   Knutson B, 2007, NEURON, V53, P147, DOI 10.1016/j.neuron.2006.11.010
   Koepp MJ, 1998, NATURE, V393, P266, DOI 10.1038/30498
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Koran LM, 2006, AM J PSYCHIAT, V163, P1806, DOI 10.1176/appi.ajp.163.10.1806
   KRUESI MJP, 1992, ARCH SEX BEHAV, V21, P587, DOI 10.1007/BF01542257
   Langenbucher J, 2001, PSYCHOL ADDICT BEHAV, V15, P77, DOI 10.1037/0893-164X.15.1.77
   Langstrom N, 2006, ARCH SEX BEHAV, V35, P37, DOI 10.1007/s10508-006-8993-y
   Lee MI, 1997, BEHAV MODIF, V21, P159, DOI 10.1177/01454455970212002
   LINNOILA M, 1983, LIFE SCI, V33, P2609, DOI 10.1016/0024-3205(83)90344-2
   Marazziti D, 2011, CURR MED CHEM, V18, P5159, DOI 10.2174/092986711797636045
   Martin PR, 2005, AM J ADDICTION, V14, P1, DOI 10.1080/10550490590899808
   MCELROY SL, 1991, AM J PSYCHIAT, V148, P652
   MCELROY SL, 1995, J CLIN PSYCHIAT, V56, P14
   McElroy SL, 2007, BIOL PSYCHIAT, V61, P1039, DOI 10.1016/j.biopsych.2006.08.008
   Miner MH, 2009, PSYCHIAT RES-NEUROIM, V174, P146, DOI 10.1016/j.pscychresns.2009.04.008
   Mitchell P, 2000, LANCET, V355, P632, DOI 10.1016/S0140-6736(05)72500-9
   MONEY J, 1994, HARVARD REV PSYCHIAT, V2, P41, DOI 10.3109/10673229409017113
   Morahan-Martin J, 2005, SOC SCI COMPUT REV, V23, P39, DOI 10.1177/0894439304271533
   Mueller A, 2010, PSYCHIAT RES, V178, P348, DOI 10.1016/j.psychres.2010.04.021
   Nirenberg MJ, 2006, MOVEMENT DISORD, V21, P524, DOI 10.1002/mds.20757
   Olsen CM, 2011, NEUROPHARMACOLOGY, V61, P1109, DOI 10.1016/j.neuropharm.2011.03.010
   Pessiglione M, 2006, NATURE, V442, P1042, DOI 10.1038/nature05051
   Petry NA, 2009, COGN BEHAV PRACT, V16, P457, DOI 10.1016/j.cbpra.2009.02.005
   Petry NM, 2006, ADDICTION, V101, P152, DOI 10.1111/j.1360-0443.2006.01593.x
   Petry NM, 2001, DRUG ALCOHOL DEPEN, V63, P29, DOI 10.1016/S0376-8716(00)00188-5
   Petry NM, 2005, J CLIN PSYCHIAT, V66, P564, DOI 10.4088/JCP.v66n0504
   Potenza MN, 2006, ADDICTION, V101, P142, DOI 10.1111/j.1360-0443.2006.01591.x
   Potenza MN, 2008, PHILOS T R SOC B, V363, P3181, DOI 10.1098/rstb.2008.0100
   Potenza MN, 2003, ARCH GEN PSYCHIAT, V60, P828, DOI 10.1001/archpsyc.60.8.828
   Potenza MN, 2001, JAMA-J AM MED ASSOC, V286, P141, DOI 10.1001/jama.286.2.141
   Raymond NC, 2003, COMPR PSYCHIAT, V44, P370, DOI 10.1016/S0010-440X(03)00110-X
   Reid RC, 2010, INT J NEUROSCI, V120, P120, DOI 10.3109/00207450903165577
   Reuter J, 2005, NAT NEUROSCI, V8, P147, DOI 10.1038/nn1378
   Ruiz-Mafe C, 2006, INTERNET RES, V16, P380, DOI 10.1108/10662240610690016
   Salguero RAT, 2002, ADDICTION, V97, P1601
   Shapira NA, 2003, DEPRESS ANXIETY, V17, P207, DOI 10.1002/da.10094
   Sharf R, 2005, BRAIN RES, V1033, P179, DOI 10.1016/j.brainres.2004.11.041
   Sheese BE, 2005, PSYCHOL SCI, V16, P354, DOI 10.1111/j.0956-7976.2005.01539.x
   Slutske WS, 2000, ARCH GEN PSYCHIAT, V57, P666, DOI 10.1001/archpsyc.57.7.666
   Smith DE, 1998, ANN BEHAV MED, V20, P227, DOI 10.1007/BF02884965
   Soule LC, 2003, J COMPUT INFORM SYST, V44, P64
   Vastag B, 2004, JAMA-J AM MED ASSOC, V291, P1822, DOI 10.1001/jama.291.15.1822
   Vilas Dolores, 2012, Parkinsonism Relat Disord, V18 Suppl 1, pS80, DOI 10.1016/S1353-8020(11)70026-8
   Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI 10.1093/cercor/10.3.318
   Volkow ND, 2005, NAT NEUROSCI, V8, P555, DOI 10.1038/nn1452
   Volkow ND, 2008, NEUROIMAGE, V42, P1537, DOI 10.1016/j.neuroimage.2008.06.002
   Wainberg ML, 2006, J CLIN PSYCHIAT, V67, P1968, DOI 10.4088/JCP.v67n1218
   Wang GJ, 2009, J ADDICT MED, V3, P8, DOI 10.1097/ADM.0b013e31819a86f7
   Wang GJ, 2004, J ADDICT DIS, V23, P39, DOI 10.1300/J069v23n03_04
   Wang GJ, 2004, NEUROIMAGE, V21, P1790, DOI 10.1016/j.neuroimage.2003.11.026
   Welte J, 2001, J STUD ALCOHOL, V62, P706, DOI 10.15288/jsa.2001.62.706
   Whang LSM, 2003, CYBERPSYCHOL BEHAV, V6, P143, DOI 10.1089/109493103321640338
   Widyanto L, 2011, CYBERPSYCH BEH SOC N, V14, P141, DOI 10.1089/cyber.2010.0151
   Yellowlees PM, 2007, COMPUT HUM BEHAV, V23, P1447, DOI 10.1016/j.chb.2005.05.004
   Young K. S., 2009, CYBERPSYCHOL BEHAV, V11, P237, DOI DOI 10.1089/CPB.1998.1.237
   YOUNG K. S., 1999, INNOVATIONS CLIN PRA, V17, P1, DOI DOI 10.1007/S10879-009-9120-X
   Young KS, 2007, CYBERPSYCHOL BEHAV, V10, P671, DOI 10.1089/cpb.2007.9971
   Young KS, 1996, PSYCHOL REP, V79, P899, DOI 10.2466/pr0.1996.79.3.899
NR 118
TC 121
Z9 123
U1 12
U2 196
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0279-1072
EI 2159-9777
J9 J PSYCHOACTIVE DRUGS
JI J. Psychoact. Drugs
PD JAN-MAR
PY 2012
VL 44
IS 1
BP 5
EP 17
DI 10.1080/02791072.2012.662859
PG 13
WC Psychology, Clinical; Substance Abuse
WE Social Science Citation Index (SSCI)
SC Psychology; Substance Abuse
GA 917VR
UT WOS:000302207200002
PM 22641961
DA 2023-06-23
ER

PT J
AU Naqvi, NH
   Bechara, A
AF Naqvi, Nasir H.
   Bechara, Antoine
TI The insula and drug addiction: an interoceptive view of pleasure, urges,
   and decision-making
SO BRAIN STRUCTURE & FUNCTION
LA English
DT Review
DE Insula; Drug addiction; Emotion; Reward; Interoception; Learning;
   Motivation; Lesion effects; Neuropsychology
ID BRAIN ACTIVATION; ORBITOFRONTAL CORTEX; NICOTINE REPLACEMENT;
   SMOKING-CESSATION; NEURAL SYSTEMS; SEXUAL AROUSAL; ABSTINENCE;
   RESPONSES; PROJECTIONS; DEPENDENCE
AB We have recently shown that damage to the insula leads to a profound disruption of addiction to cigarette smoking (Naqvi et al., Science 315:531-534, 2007). Yet, there is little understanding of why the insula should play such an important role in an addictive behavior. A broad literature (much of it reviewed in this issue) has addressed the role of the insula in processes related to conscious interoception, emotional experience, and decision-making. Here, we review evidence for the role of the insula in drug addiction, and propose a novel theoretical framework for addiction in which the insula represents the interoceptive effects of drug taking, making this information available to conscious awareness, memory and executive functions. A central theme of this framework is that a primary goal for the addicted individual is to obtain the effects of the drug use ritual upon the body, and representations of this goal in interoceptive terms by the insula contribute to how addicted individuals feel, remember, and decide about taking drugs. This makes drug addiction like naturally motivated behaviors, such as eating and sex, for which an embodied ritual is the primary goal.
C1 [Naqvi, Nasir H.] Columbia Univ, Dept Psychiat, New York, NY 10032 USA.
   [Naqvi, Nasir H.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA.
   [Bechara, Antoine] McGill Univ, Dept Psychiat, Montreal, PQ H3A 2T5, Canada.
   [Bechara, Antoine] McGill Univ, Desautels Fac Management, Montreal, PQ H3A 2T5, Canada.
   [Bechara, Antoine] Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA.
C3 Columbia University; New York State Psychiatry Institute; McGill
   University; McGill University; University of Southern California
RP Naqvi, NH (通讯作者)，Columbia Univ, Dept Psychiat, New York, NY 10032 USA.
EM nhn2102@columbia.edu
RI Naqvi, Nasir/AAW-7933-2021
OI Bechara, Antoine/0000-0001-5127-2549
FU National Institute on Drug Abuse (NIDA) [R01 DA023051]; National
   Institute of Mental Health (NIMH) [R25 MH086466]; Leon Levy Resident
   Fellowship
FX The research described in this article was supported by a grant from the
   National Institute on Drug Abuse (NIDA) R01 DA023051 (A. B.). The
   writing of this article was supported by grants from the National
   Institute of Mental Health (NIMH) R25 MH086466 (N.H.N.), and by the Leon
   Levy Resident Fellowship (N.H.N.).
CR ALLEN GV, 1991, J COMP NEUROL, V311, P1, DOI 10.1002/cne.903110102
   Allman JM, 2010, BRAIN STRUCT FUNCT, V214, P495, DOI 10.1007/s00429-010-0254-0
   Arnow BA, 2002, BRAIN, V125, P1014, DOI 10.1093/brain/awf108
   Balleine BW, 2000, J NEUROSCI, V20, P8954
   Bechara A, 2004, NAT NEUROSCI, V7, P102, DOI 10.1038/nn0204-102
   Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584
   BECHARA A, 1985, NATURE, V314, P533, DOI 10.1038/314533a0
   Bechara A, 2002, NEUROPSYCHOLOGIA, V40, P1675, DOI 10.1016/S0028-3932(02)00015-5
   Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293
   Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9
   Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8
   Berridge KC, 2003, TRENDS NEUROSCI, V26, P507, DOI 10.1016/S0166-2236(03)00233-9
   BERTHIER M, 1988, ANN NEUROL, V24, P41, DOI 10.1002/ana.410240109
   Bonson KR, 2002, NEUROPSYCHOPHARMACOL, V26, P376, DOI 10.1016/S0893-133X(01)00371-2
   Brody AL, 2002, ARCH GEN PSYCHIAT, V59, P1162, DOI 10.1001/archpsyc.59.12.1162
   Brody AL, 2007, BIOL PSYCHIAT, V62, P642, DOI 10.1016/j.biopsych.2006.10.026
   Calder AJ, 2000, NAT NEUROSCI, V3, P1077, DOI 10.1038/80586
   Carter BL, 1999, ADDICTION, V94, P327, DOI 10.1046/j.1360-0443.1999.9433273.x
   Chikama M, 1997, J NEUROSCI, V17, P9686
   Contreras M, 2007, SCIENCE, V318, P655, DOI 10.1126/science.1145590
   Cox L S, 2001, Nicotine Tob Res, V3, P7, DOI 10.1080/14622200020032051
   Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555
   Craig AD, 2002, NAT REV NEUROSCI, V3, P655, DOI 10.1038/nrn894
   Critchley HD, 2002, NEURON, V33, P653, DOI 10.1016/S0896-6273(02)00588-3
   Crockford DN, 2005, BIOL PSYCHIAT, V58, P787, DOI 10.1016/j.biopsych.2005.04.037
   Cubero I, 1999, BRAIN RES, V839, P323, DOI 10.1016/S0006-8993(99)01745-X
   Damasio A., 2000, PSYCHE
   Damasio A. R., 2000, DESCARTES ERROR EMOT
   Dar R, 2004, PSYCHOPHARMACOLOGY, V173, P18, DOI 10.1007/s00213-004-1781-2
   Dar R, 2002, ADDICT RES THEORY, V10, P545, DOI 10.1080/1606635021000041753
   de Araujo IET, 2003, J NEUROPHYSIOL, V90, P1865, DOI 10.1152/jn.00297.2003
   Del Parigi A, 2002, ANN NY ACAD SCI, V967, P389
   Egan G, 2003, P NATL ACAD SCI USA, V100, P15241, DOI 10.1073/pnas.2136650100
   Etter JF, 2006, TOB CONTROL, V15, DOI 10.1136/tc.2005.015487
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Farrell MJ, 2006, P NATL ACAD SCI USA, V103, P2416, DOI 10.1073/pnas.0511019103
   Franklin TR, 2007, NEUROPSYCHOPHARMACOL, V32, P2301, DOI 10.1038/sj.npp.1301371
   Garavan H, 2000, AM J PSYCHIAT, V157, P1789, DOI 10.1176/appi.ajp.157.11.1789
   Georgiadis JR, 2005, J COMP NEUROL, V493, P33, DOI 10.1002/cne.20735
   Goldstein RZ, 2009, TRENDS COGN SCI, V13, P372, DOI 10.1016/j.tics.2009.06.004
   GOWING L, 2003, COCHRANE DB SYST REV
   GOWING L, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002024.PUB2
   Gowing L, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002024.pub3
   HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119
   Hudmon KS, 2005, ADDICT BEHAV, V30, P613, DOI 10.1016/j.addbeh.2004.08.006
   Hurd YL, 2001, J CHEM NEUROANAT, V22, P127, DOI 10.1016/S0891-0618(01)00122-3
   HURLEY KM, 1991, J COMP NEUROL, V308, P249, DOI 10.1002/cne.903080210
   Ibanez A, 2010, BRAIN STRUCT FUNCT, V214, P397, DOI 10.1007/s00429-010-0256-y
   JAMES W, 1884, MIND, V9, P188, DOI DOI 10.1093/MIND/OS-IX.34.188
   Kampman KM, 2001, DRUG ALCOHOL DEPEN, V63, P69, DOI 10.1016/S0376-8716(00)00193-9
   Karama S, 2002, HUM BRAIN MAPP, V16, P1, DOI 10.1002/hbm.10014
   Kilts CD, 2004, AM J PSYCHIAT, V161, P233, DOI 10.1176/appi.ajp.161.2.233
   Koob GF, 2004, NEUROSCI BIOBEHAV R, V27, P739, DOI 10.1016/j.neubiorev.2003.11.007
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   KRETTEK JE, 1978, J COMP NEUROL, V178, P225, DOI 10.1002/cne.901780204
   Lee JH, 2005, APPL PSYCHOPHYS BIOF, V30, P195, DOI 10.1007/s10484-005-6377-z
   LEVIN ED, 1993, DRUG ALCOHOL DEPEN, V33, P211, DOI 10.1016/0376-8716(93)90108-3
   Lovero KL, 2009, NEUROIMAGE, V45, P976, DOI 10.1016/j.neuroimage.2008.12.070
   Manes F, 1999, J NERV MENT DIS, V187, P707, DOI 10.1097/00005053-199912000-00001
   McBride D, 2006, NEUROPSYCHOPHARMACOL, V31, P2728, DOI 10.1038/sj.npp.1301075
   McClernon FJ, 2005, NEUROPSYCHOPHARMACOL, V30, P1940, DOI 10.1038/sj.npp.1300780
   MORECRAFT RJ, 1992, J COMP NEUROL, V323, P341, DOI 10.1002/cne.903230304
   Myrick H, 2004, NEUROPSYCHOPHARMACOL, V29, P393, DOI 10.1038/sj.npp.1300295
   NAQVI N, 2006, ORBITOFRONTAOL CORTE
   Naqvi NH, 2007, SCIENCE, V315, P531, DOI 10.1126/science.1135926
   Naqvi NH, 2005, PHARMACOL BIOCHEM BE, V81, P821, DOI 10.1016/j.pbb.2005.06.005
   NAQVI NH, 2006, NEUROSCIENCE, V211
   O'Brien CP, 1998, J PSYCHOPHARMACOL, V12, P15, DOI 10.1177/026988119801200103
   Olausson H, 2002, NAT NEUROSCI, V5, P900, DOI 10.1038/nn896
   Paulozzi LJ, 2008, TRENDS UNINTENTIONAL
   Paulus MP, 2005, ARCH GEN PSYCHIAT, V62, P761, DOI 10.1001/archpsyc.62.7.761
   Pelchat ML, 2004, NEUROIMAGE, V23, P1486, DOI 10.1016/j.neuroimage.2004.08.023
   PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D
   Phan KL, 2002, NEUROIMAGE, V16, P331, DOI 10.1006/nimg.2002.1087
   Potenza MN, 2003, ARCH GEN PSYCHIAT, V60, P828, DOI 10.1001/archpsyc.60.8.828
   Rezaishiraz H, 2007, NICOTINE TOB RES, V9, P1139, DOI 10.1080/14622200701684172
   Robinson TE, 2001, ADDICTION, V96, P103, DOI 10.1046/j.1360-0443.2001.9611038.x
   Rolls ET, 2005, CHEM SENSES, V30, pI76, DOI 10.1093/chemse/bjh121
   ROLLS ET, 1989, EUR J NEUROSCI, V1, P53, DOI 10.1111/j.1460-9568.1989.tb00774.x
   ROSE JE, 1991, BRIT J ADDICT, V86, P605
   ROSENBLUM K, 1993, BEHAV NEURAL BIOL, V59, P49, DOI 10.1016/0163-1047(93)91145-D
   ROSENBLUM K, 1995, P NATL ACAD SCI USA, V92, P1157, DOI 10.1073/pnas.92.4.1157
   Sanchez MM, 1999, J COMP NEUROL, V408, P365
   Sehlmeyer C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005865
   Sell LA, 1999, EUR J NEUROSCI, V11, P1042, DOI 10.1046/j.1460-9568.1999.00522.x
   Small DM, 2010, BRAIN STRUCT FUNCT, V214, P551, DOI 10.1007/s00429-010-0266-9
   SPIESS M, 2000, DRUG RELATED CRIME R
   STINSON FS, 1992, BRIT J ADDICT, V87, P777
   Stoleru S, 1999, ARCH SEX BEHAV, V28, P1, DOI 10.1023/A:1018733420467
   Tapert SF, 2004, ADDICT BEHAV, V29, P33, DOI 10.1016/j.addbeh.2003.07.003
   Tiffany ST, 2000, ADDICTION, V95, pS145, DOI 10.1046/j.1360-0443.95.8s2.3.x
   TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147
   Tiffany ST, 2000, J CONSULT CLIN PSYCH, V68, P233, DOI 10.1037//0022-006X.68.2.233
   Vorel SR, 2007, SCIENCE, V317, P318
   Wang GJ, 2008, NEUROIMAGE, V39, P1824, DOI 10.1016/j.neuroimage.2007.11.008
   Wang GJ, 1999, LIFE SCI, V64, P775, DOI 10.1016/S0024-3205(98)00619-5
   Wang GJ, 2004, NEUROIMAGE, V21, P1790, DOI 10.1016/j.neuroimage.2003.11.026
   Wang Z, 2007, J NEUROSCI, V27, P14035, DOI 10.1523/JNEUROSCI.2966-07.2007
   Westman EC, 1996, PHARMACOL BIOCHEM BE, V53, P309, DOI 10.1016/0091-3057(95)02027-6
   WESTMAN EC, 1995, CHEST, V107, P1358, DOI 10.1378/chest.107.5.1358
   Wexler BE, 2001, AM J PSYCHIAT, V158, P86, DOI 10.1176/appi.ajp.158.1.86
   WIKLER A, 1948, AM J PSYCHIAT, V105, P329, DOI 10.1176/ajp.105.5.329
   WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469
   YAXLEY S, 1988, PHYSIOL BEHAV, V42, P223, DOI 10.1016/0031-9384(88)90074-1
   ZITO KA, 1988, PHARMACOL BIOCHEM BE, V30, P693, DOI 10.1016/0091-3057(88)90086-X
NR 105
TC 373
Z9 382
U1 2
U2 95
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1863-2653
EI 1863-2661
J9 BRAIN STRUCT FUNCT
JI Brain Struct. Funct.
PD JUN
PY 2010
VL 214
IS 5-6
SI SI
BP 435
EP 450
DI 10.1007/s00429-010-0268-7
PG 16
WC Anatomy & Morphology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Anatomy & Morphology; Neurosciences & Neurology
GA 612KX
UT WOS:000278898300005
PM 20512364
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Fletcher, PC
   Kenny, PJ
AF Fletcher, Paul C.
   Kenny, Paul J.
TI Food addiction: a valid concept?
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
ID GASTRIC BYPASS-SURGERY; BODY-MASS INDEX; STRIATAL RESPONSE; RECEPTOR
   AVAILABILITY; NUCLEUS-ACCUMBENS; EATING ADDICTION; SUGAR ADDICTION;
   BULIMIA-NERVOSA; OBESE-PATIENTS; HIGH-CALORIE
AB Can food be addictive? What does it mean to be a food addict? Do common underlying neurobiological mechanisms contribute to drug and food addiction? These vexing questions have been the subject of considerable interest and debate in recent years, driven in large part by the major health concerns associated with dramatically increasing body weights and rates of obesity in the United States, Europe, and other regions with developed economies. No dear consensus has yet emerged on the validity of the concept of food addiction and whether some individuals who struggle to control their food intake can be considered food addicts. Some, including Fletcher, have argued that the concept of food addiction is unsupported, as many of the defining features of drug addiction are not seen in the context of feeding behaviors. Others, Kenny included, have argued that food and drug addiction share similar features that may reflect common underlying neural mechanisms. Here, Fletcher and Kenny argue the merits of these opposing positions on the concept of food addiction.
C1 [Fletcher, Paul C.] Univ Cambridge, Dept Psychiat, Cambridge CB2 8AH, England.
   [Fletcher, Paul C.] Cambridgeshire & Peterborough NHS Fdn Trust, Cambridge CB21 5EF, England.
   [Kenny, Paul J.] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA.
C3 University of Cambridge; Icahn School of Medicine at Mount Sinai
RP Fletcher, PC (通讯作者)，Univ Cambridge, Dept Psychiat, Cambridge CB2 8AH, England.; Fletcher, PC (通讯作者)，Cambridgeshire & Peterborough NHS Fdn Trust, Cambridge CB21 5EF, England.
EM paul.kenny@mssm.edu
RI Fletcher, Paul/HZK-7358-2023; Fletcher, Paul/F-5380-2011
OI Fletcher, Paul/0000-0001-8257-1517
FU Wellcome Trust; Bernard Wolfe Health Neuroscience Fund; National
   Institutes of Health
FX PCF is supported by the Wellcome Trust and the Bernard Wolfe Health
   Neuroscience Fund. He is grateful to Hisham Ziauddeen and Margaret
   Westwater for their erudite discussion and suggestions around this
   topic. PJK was supported by the National Institutes of Health and is
   grateful to Drs. Alexandra DiFeliceantonio and Richard O'Connor for
   helpful discussions.
CR Ahmed SH, 2013, CURR OPIN CLIN NUTR, V16, P434, DOI 10.1097/MCO.0b013e328361c8b8
   American Psychiatric Association [APA], 2022, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425787]
   Augier E, 2018, SCIENCE, V360, P1321, DOI 10.1126/science.aao1157
   Avena NM, 2012, NAT REV NEUROSCI, V13, DOI 10.1038/nrn3212-c1
   Bassareo V, 1999, EUR J NEUROSCI, V11, P4389, DOI 10.1046/j.1460-9568.1999.00843.x
   BLACKBURN JR, 1986, PHARMACOL BIOCHEM BE, V25, P1095, DOI 10.1016/0091-3057(86)90091-2
   Booth ML, 2008, J PAEDIATR CHILD H, V44, P248, DOI 10.1111/j.1440-1754.2007.01267.x
   CAHILL K, 2007, COCHRANE DATABASE SY
   Cantin L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011592
   Chen BT, 2013, NATURE, V496, P359, DOI 10.1038/nature12024
   Colantuoni C, 2002, OBES RES, V10, P478, DOI 10.1038/oby.2002.66
   Corwin Rebecca L W, 2011, Curr Drug Abuse Rev, V4, P174
   Dang LC, 2016, NEUROIMAGE, V138, P176, DOI 10.1016/j.neuroimage.2016.05.044
   Davis C, 2014, SUBST ABUSE REHABIL, V5, P129, DOI 10.2147/SAR.S56835
   de Vries SK, 2016, EUR EAT DISORD REV, V24, P518, DOI 10.1002/erv.2470
   Decorte T, 2001, EUR ADDICT RES, V7, P161, DOI 10.1159/000050737
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Diana M, 2017, NAT REV NEUROSCI, V18, P685, DOI 10.1038/nrn.2017.113
   DiFeliceantonio AG, 2018, CELL METAB, V28, P33, DOI 10.1016/j.cmet.2018.05.018
   Eisenstein SA, 2015, SCI REP-UK, V5, DOI 10.1038/srep11283
   Ersche KD, 2016, SCIENCE, V352, P1468, DOI 10.1126/science.aaf3700
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Farooqi IS, 2007, SCIENCE, V317, P1355, DOI 10.1126/science.1144599
   Finlayson G, 2017, NAT REV ENDOCRINOL, V13, P493, DOI 10.1038/nrendo.2017.61
   Freese L, 2018, PHARMACOL BIOCHEM BE, V173, P65, DOI 10.1016/j.pbb.2018.07.010
   Furlong TM, 2014, J NEUROSCI, V34, P5012, DOI 10.1523/JNEUROSCI.3707-13.2014
   GAWIN FH, 1991, SCIENCE, V251, P1580, DOI 10.1126/science.2011738
   Gearhardt AN, 2012, INT J EAT DISORDER, V45, P657, DOI 10.1002/eat.20957
   Gearhardt AN, 2009, APPETITE, V52, P430, DOI 10.1016/j.appet.2008.12.003
   Geiger BM, 2009, NEUROSCIENCE, V159, P1193, DOI 10.1016/j.neuroscience.2009.02.007
   Hebebrand J, 2014, NEUROSCI BIOBEHAV R, V47, P295, DOI 10.1016/j.neubiorev.2014.08.016
   Hilker I, 2016, EUR EAT DISORD REV, V24, P482, DOI 10.1002/erv.2473
   Holsen LM, 2005, NEUROIMAGE, V27, P669, DOI 10.1016/j.neuroimage.2005.04.043
   Huynh C, 2017, ADDICT BIOL, V22, P142, DOI 10.1111/adb.12306
   Jaspers Karl, 1963, GEN PSYCHOPATHOLOGY
   Johnson PM, 2010, NAT NEUROSCI, V13, P635, DOI 10.1038/nn.2519
   Kalivas PW, 2004, CURR OPIN PHARMACOL, V4, P23, DOI 10.1016/j.coph.2003.11.002
   Karlsson HK, 2015, J NEUROSCI, V35, P3959, DOI 10.1523/JNEUROSCI.4744-14.2015
   Kenny PJ, 2018, BIOL PSYCHIAT, V83, P940, DOI 10.1016/j.biopsych.2018.02.009
   Killgore WDS, 2013, INT J OBESITY, V37, P1435, DOI 10.1038/ijo.2013.26
   Killgore WDS, 2003, NEUROIMAGE, V19, P1381, DOI 10.1016/S1053-8119(03)00191-5
   Koob GF, 2008, ANNU REV PSYCHOL, V59, P29, DOI 10.1146/annurev.psych.59.103006.093548
   Lenoir M, 2013, NEUROPSYCHOPHARMACOL, V38, P1209, DOI 10.1038/npp.2013.17
   Locke AE, 2015, NATURE, V518, P197, DOI 10.1038/nature14177
   Long CG, 2015, OBESITY FACTS, V8, P386, DOI 10.1159/000442403
   Madsen HB, 2015, ADDICT BIOL, V20, P433, DOI 10.1111/adb.12134
   Martel P, 1996, PHARMACOL BIOCHEM BE, V55, P297, DOI 10.1016/S0091-3057(96)00087-1
   Medic N, 2016, INT J OBESITY, V40, P1177, DOI 10.1038/ijo.2016.42
   Meule A, 2014, EUR EAT DISORD REV, V22, P331, DOI 10.1002/erv.2306
   Meule A, 2012, EUR EAT DISORD REV, V20, P419, DOI 10.1002/erv.2189
   Morris L.S., 2018, ALCOHOL CLIN EXP RES
   Munafo MR, 2007, MOL PSYCHIATR, V12, P454, DOI 10.1038/sj.mp.4001938
   [National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health (US) CfDCaP], 2014, HLTH CONSMOK 50 YE
   O'Rahilly S, 2008, DIABETES, V57, P2905, DOI 10.2337/db08-0210
   Owens AP, 2018, NEUROSCI BIOBEHAV R, V90, P174, DOI 10.1016/j.neubiorev.2018.04.017
   Pedram P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074832
   Puhl RM, 2008, HEALTH EDUC RES, V23, P347, DOI 10.1093/her/cym052
   RUSSELL MAH, 1974, PRACTITIONER, V212, P791
   Russo SJ, 2010, TRENDS NEUROSCI, V33, P267, DOI 10.1016/j.tins.2010.02.002
   Sanchez-Roige S, 2018, GENES BRAIN BEHAV, V17, DOI 10.1111/gbb.12439
   Saunders R, 2001, OBES SURG, V11, P757, DOI 10.1381/09608920160558731
   Scholtz S, 2014, GUT, V63, P891, DOI 10.1136/gutjnl-2013-305008
   Schulte EM, 2017, APPETITE, V115, P9, DOI 10.1016/j.appet.2016.10.033
   Scofield MD, 2016, PHARMACOL REV, V68, P816, DOI 10.1124/pr.116.012484
   Shanahan WR, 2017, NICOTINE TOB RES, V19, P944, DOI 10.1093/ntr/ntw301
   Siep N, 2009, BEHAV BRAIN RES, V198, P149, DOI 10.1016/j.bbr.2008.10.035
   Small DM, 2001, BRAIN, V124, P1720, DOI 10.1093/brain/124.9.1720
   Stice E, 2008, SCIENCE, V322, P449, DOI 10.1126/science.1161550
   Stice E, 2016, J NEUROSCI, V36, P6949, DOI 10.1523/JNEUROSCI.4365-15.2016
   Stice E, 2011, J NEUROSCI, V31, P4360, DOI 10.1523/JNEUROSCI.6604-10.2011
   Stice E, 2010, J NEUROSCI, V30, P13105, DOI 10.1523/JNEUROSCI.2105-10.2010
   Tallon-Baudry C, 2018, CORTEX, V102, P139, DOI 10.1016/j.cortex.2017.05.019
   Tantot F, 2017, APPETITE, V108, P203, DOI 10.1016/j.appet.2016.10.001
   Terraneo A, 2016, EUR NEUROPSYCHOPHARM, V26, P37, DOI 10.1016/j.euroneuro.2015.11.011
   Teufel C, 2016, BRAIN, V139, P2600, DOI 10.1093/brain/aww209
   Thompson JL, 2017, NEUROPSYCHOPHARMACOL, V42, P1480, DOI 10.1038/npp.2016.284
   Thorgeirsson TE, 2008, NATURE, V452, P638, DOI 10.1038/nature06846
   van Bloemendaal L, 2014, DIABETES, V63, P4186, DOI 10.2337/db14-0849
   van der Klaauw AA, 2014, J CLIN ENDOCR METAB, V99, pE2101, DOI 10.1210/jc.2014-1651
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Volkow ND, 2013, OBES REV, V14, P2, DOI 10.1111/j.1467-789X.2012.01031.x
   Wang GJ, 2001, LANCET, V357, P354, DOI 10.1016/S0140-6736(00)03643-6
   Warburton DM, 1989, PSYCHOLOGIST, V4, P166
   Wee S, 2010, PSYCHOPHARMACOLOGY, V210, P121, DOI 10.1007/s00213-010-1825-8
   Westwater ML, 2016, EUR J NUTR, V55, pS55, DOI 10.1007/s00394-016-1229-6
   WILSON C, 1995, J NEUROSCI, V15, P5169
   Wilson GT, 2010, EUR EAT DISORD REV, V18, P341, DOI 10.1002/erv.1048
   Yokum S, 2014, OBESITY, V22, P2544, DOI 10.1002/oby.20882
   Ziauddeen H, 2013, OBES REV, V14, P19, DOI 10.1111/j.1467-789X.2012.01046.x
   Ziauddeen H, 2012, NAT REV NEUROSCI, V13, P279, DOI 10.1038/nrn3212
NR 90
TC 98
Z9 99
U1 1
U2 10
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0893-133X
EI 1740-634X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD DEC
PY 2018
VL 43
IS 13
BP 2506
EP 2513
DI 10.1038/s41386-018-0203-9
PG 8
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA GZ6QZ
UT WOS:000449567500004
PM 30188514
OA Green Published, hybrid, Green Submitted
DA 2023-06-23
ER

PT S
AU Maze, I
   Nestler, EJ
AF Maze, Ian
   Nestler, Eric J.
BE Uhl, GR
TI The epigenetic landscape of addiction
SO ADDICTION REVIEWS
SE Annals of the New York Academy of Sciences
LA English
DT Article; Book Chapter
DE histone; chromatin; plasticity; histone deacetylase (HDAC); histone
   methyltransferase (HMT); drug addiction
ID COCAINE-INDUCED PLASTICITY; MEDIUM SPINY NEURONS; GENOME-WIDE ANALYSIS;
   HISTONE DEACETYLASE; NUCLEUS-ACCUMBENS; GENE-EXPRESSION; TRANSCRIPTIONAL
   MECHANISMS; BEHAVIORAL SENSITIZATION; CHROMATIN MODIFICATIONS; SYNAPTIC
   PLASTICITY
AB Drug-induced alterations in gene expression throughout the reward circuitry of the brain are likely components of the persistence of the drug-addicted state. Recent studies examining the molecular mechanisms controlling drug-induced transcriptional, behavioral, and synaptic plasticity have indicated a direct role for chromatin remodeling in the regulation and stability of drug-mediated neuronal gene programs, and the subsequent promulgation of addictive behaviors. In this review, we discuss recent advances in our understanding of chromatin phenomena-or epigenetics, by one definition-that contribute to drug addiction, with the hope that such mechanistic insights may aid in the development of novel therapeutics for future treatments of addiction.
C1 [Maze, Ian; Nestler, Eric J.] Mt Sinai Sch Med, Fishberg Dept Neurosci, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai
RP Nestler, EJ (通讯作者)，Mt Sinai Sch Med, Fishberg Dept Neurosci, 1 Gustave L Levy Pl,Box 1065, New York, NY 10029 USA.
EM eric.nestler@mssm.edu
RI Maze, Ian/P-8077-2018
OI Maze, Ian/0000-0003-1490-7781
FU NIDA NIH HHS [R01 DA007359-24, P01 DA008227-19, R01 DA007359, R01
   DA007359-23, P01 DA008227, P01 DA008227-20] Funding Source: Medline
CR Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810
   Balemans MCM, 2010, BEHAV BRAIN RES, V208, P47, DOI 10.1016/j.bbr.2009.11.008
   Barski A, 2009, J CELL BIOCHEM, V107, P11, DOI 10.1002/jcb.22077
   Benavides DR, 2007, J NEUROSCI, V27, P12967, DOI 10.1523/JNEUROSCI.4061-07.2007
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Berglind WJ, 2009, J NEUROSCI, V29, P3715, DOI 10.1523/JNEUROSCI.5457-08.2009
   Bernstein E, 2006, MOL CELL BIOL, V26, P2560, DOI 10.1128/MCB.26.7.2560-2569.2006
   Bibb JA, 2001, NATURE, V410, P376, DOI 10.1038/35066591
   Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913
   Black YD, 2006, J NEUROSCI, V26, P9656, DOI 10.1523/JNEUROSCI.2391-06.2006
   Borrelli E, 2008, NEURON, V60, P961, DOI 10.1016/j.neuron.2008.10.012
   Brami-Cherrier K, 2005, J NEUROSCI, V25, P11444, DOI 10.1523/JNEUROSCI.1711-05.2005
   Brami-Cherrier K, 2007, J NEUROCHEM, V101, P697, DOI 10.1111/j.1471-4159.2006.04352.x
   Chahrour M, 2008, SCIENCE, V320, P1224, DOI 10.1126/science.1153252
   CHAMBON P, 1977, COLD SPRING HARB SYM, V42, P1209, DOI 10.1101/SQB.1978.042.01.122
   Chen BT, 2010, ANN NY ACAD SCI, V1187, P129, DOI 10.1111/j.1749-6632.2009.05154.x
   Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5
   Ding N, 2008, MOL CELL, V31, P347, DOI 10.1016/j.molcel.2008.05.023
   Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197
   Freeman WM, 2008, NEUROPSYCHOPHARMACOL, V33, P1807, DOI 10.1038/sj.npp.1301577
   Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006
   Grimm JW, 2003, J NEUROSCI, V23, P742
   Guan JS, 2009, NATURE, V459, P55, DOI 10.1038/nature07925
   Heiman M, 2008, CELL, V135, P738, DOI 10.1016/j.cell.2008.10.028
   HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098
   Host L, 2011, J PSYCHOPHARMACOL, V25, P222, DOI 10.1177/0269881109348173
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Kalda A, 2007, BEHAV BRAIN RES, V181, P76, DOI 10.1016/j.bbr.2007.03.027
   Kalivas PW, 2005, NEURON, V45, P647, DOI 10.1016/j.neuron.2005.02.005
   Koob G, 2007, AM J PSYCHIAT, V164, P1149, DOI 10.1176/appi.ajp.2007.05030503
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kumar A, 2005, NEURON, V48, P303, DOI 10.1016/j.neuron.2005.09.023
   LaPlant Q, 2010, NAT NEUROSCI, V13, P1137, DOI 10.1038/nn.2619
   Levine AA, 2005, P NATL ACAD SCI USA, V102, P19186, DOI 10.1073/pnas.0509735102
   Li JH, 2004, J NEUROCHEM, V90, P1117, DOI 10.1111/j.1471-4159.2004.02569.x
   Lobo MK, 2009, INT REV NEUROBIOL, V89, P1, DOI 10.1016/S0074-7742(09)89001-6
   Lu L, 2006, TRENDS NEUROSCI, V29, P695, DOI 10.1016/j.tins.2006.10.005
   Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444
   Malvaez M, 2010, BIOL PSYCHIAT, V67, P36, DOI 10.1016/j.biopsych.2009.07.032
   Maze I, 2010, MOL INTERV, V10, P219, DOI 10.1124/mi.10.4.5
   Maze I, 2010, SCIENCE, V327, P213, DOI 10.1126/science.1179438
   McQuown SC, 2010, CURR PSYCHIAT REP, V12, P145, DOI 10.1007/s11920-010-0099-5
   Nestler EJ, 2008, PHILOS T R SOC B, V363, P3245, DOI 10.1098/rstb.2008.0067
   Norrholm SD, 2003, NEUROSCIENCE, V116, P19, DOI 10.1016/S0306-4522(02)00560-2
   Novikova SI, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001919
   Park PJ, 2009, NAT REV GENET, V10, P669, DOI 10.1038/nrg2641
   Pinskaya M, 2009, EPIGENETICS-US, V4, P302, DOI 10.4161/epi.4.5.9369
   Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026
   Pulipparacharuvil S, 2008, NEURON, V59, P621, DOI 10.1016/j.neuron.2008.06.020
   Renthal W, 2008, TRENDS MOL MED, V14, P341, DOI 10.1016/j.molmed.2008.06.004
   Renthal W, 2008, J NEUROSCI, V28, P7344, DOI 10.1523/JNEUROSCI.1043-08.2008
   Renthal W, 2007, NEURON, V56, P517, DOI 10.1016/j.neuron.2007.09.032
   Renthal W, 2009, NEURON, V62, P335, DOI 10.1016/j.neuron.2009.03.026
   Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8
   Robinson TE, 1997, J NEUROSCI, V17, P8491
   Romieu P, 2008, J NEUROSCI, V28, P9342, DOI 10.1523/JNEUROSCI.0379-08.2008
   Russo SJ, 2009, J NEUROSCI, V29, P3529, DOI 10.1523/JNEUROSCI.6173-08.2009
   Ruthenburg AJ, 2007, NAT REV MOL CELL BIO, V8, P983, DOI 10.1038/nrm2298
   Sanchis-Segura C, 2009, NEUROPSYCHOPHARMACOL, V34, P2642, DOI 10.1038/npp.2009.125
   Schaefer A, 2009, NEURON, V64, P678, DOI 10.1016/j.neuron.2009.11.019
   Schroeder FA, 2008, NEUROPSYCHOPHARMACOL, V33, P2981, DOI 10.1038/npp.2008.15
   Self DW, 1996, SCIENCE, V271, P1586, DOI 10.1126/science.271.5255.1586
   Skene PJ, 2010, MOL CELL, V37, P457, DOI 10.1016/j.molcel.2010.01.030
   Stipanovich A, 2008, NATURE, V453, P879, DOI 10.1038/nature06994
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Sun J, 2008, NEUROSCI LETT, V441, P72, DOI 10.1016/j.neulet.2008.05.010
   Surani MA, 2007, CELL, V128, P747, DOI 10.1016/j.cell.2007.02.010
   Surmeier DJ, 2007, TRENDS NEUROSCI, V30, P228, DOI 10.1016/j.tins.2007.03.008
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005
   Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200
   Taverna SD, 2007, NAT STRUCT MOL BIOL, V14, P1025, DOI 10.1038/nsmb1338
   Thomas MJ, 2001, NAT NEUROSCI, V4, P1217, DOI 10.1038/nn757
   Tsankova NM, 2004, J NEUROSCI, V24, P5603, DOI 10.1523/JNEUROSCI.0589-04.2004
   Waddington C. H., 1957, STRATEGY GENES DISCU
   Wang L, 2010, NEUROPSYCHOPHARMACOL, V35, P913, DOI 10.1038/npp.2009.193
   Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102
NR 80
TC 148
Z9 153
U1 0
U2 46
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA
SN 0077-8923
BN 978-1-57331-812-9
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2011
VL 1216
BP 99
EP 113
DI 10.1111/j.1749-6632.2010.05893.x
PG 15
WC Substance Abuse; Multidisciplinary Sciences
WE Book Citation Index– Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Substance Abuse; Science & Technology - Other Topics
GA BTN80
UT WOS:000287434400008
PM 21272014
OA Green Accepted
DA 2023-06-23
ER

PT S
AU Kim, HD
   Call, T
   Magazu, S
   Ferguson, D
AF Kim, Hee-Dae
   Call, Tanessa
   Magazu, Samantha
   Ferguson, Deveroux
BE DelgadoMorales, R
TI Drug Addiction and Histone Code Alterations
SO NEUROEPIGENOMICS IN AGING AND DISEASE
SE Advances in Experimental Medicine and Biology
LA English
DT Article; Book Chapter
DE Addiction; Drug of abuse; Epigenetics; Histone modification; Reward
   circuitry
ID COCAINE-INDUCED PLASTICITY; VENTRAL TEGMENTAL AREA; NUCLEUS-ACCUMBENS;
   EPIGENETIC MECHANISMS; ARGININE METHYLATION; METHAMPHETAMINE ADDICTION;
   SYNAPTIC PLASTICITY; NEGATIVE REGULATOR; STRIATAL NEURONS; MEMORY
   FORMATION
AB Acute and prolonged exposure to drugs of abuse induces changes in gene expression, synaptic function, and neural plasticity in brain regions involved in reward. Numerous genes are involved in this process, and persistent changes in gene expression coincide with epigenetic histone modifications and DNA methylation. Histone modifications are attractive regulatory mechanisms, which can encode complex environmental signals in the genome of postmitotic cells, like neurons. Recently, it has been demonstrated that specific histone modifications are involved in addiction-related gene regulatory mechanisms, by a diverse set of histone-modifying enzymes and readers. These histone modifiers and readers may prove to be valuable pharmacological targets for effective treatments for drug addiction.
C1 [Kim, Hee-Dae; Call, Tanessa; Magazu, Samantha; Ferguson, Deveroux] Univ Arizona, Coll Med Phoenix, Dept Basic Med Sci, Phoenix, AZ 85004 USA.
C3 University of Arizona
RP Ferguson, D (通讯作者)，Univ Arizona, Coll Med Phoenix, Dept Basic Med Sci, Phoenix, AZ 85004 USA.
EM heedaekim@email.arizona.edu; tcall1@asu.edu; smagazu@email.arizona.edu;
   dferguson@email.arizona.edu
OI Ferguson, Deveroux/0000-0001-9302-5992
CR Aguilar-Valles A, 2014, BIOL PSYCHIAT, V76, P57, DOI 10.1016/j.biopsych.2013.09.014
   Alam H, 2015, CELL MOL LIFE SCI, V72, P4577, DOI 10.1007/s00018-015-2023-y
   Bibb JA, 2001, NATURE, V410, P376, DOI 10.1038/35066591
   Brami-Cherrier K, 2005, J NEUROSCI, V25, P11444, DOI 10.1523/JNEUROSCI.1711-05.2005
   Cahill ME, 2016, NEURON, V89, P566, DOI 10.1016/j.neuron.2016.01.031
   Chandra R, 2015, J NEUROSCI, V35, P7927, DOI 10.1523/JNEUROSCI.0548-15.2015
   Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7
   Cohen-Armon M, 2007, MOL CELL, V25, P297, DOI 10.1016/j.molcel.2006.12.012
   Creed MC, 2013, CURR OPIN NEUROBIOL, V23, P553, DOI 10.1016/j.conb.2013.03.005
   Cuthbert GL, 2004, CELL, V118, P545, DOI 10.1016/j.cell.2004.08.020
   D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249
   Damez-Werno DM, 2016, P NATL ACAD SCI USA, V113, P9623, DOI 10.1073/pnas.1605045113
   Dong Y, 2014, TRENDS PHARMACOL SCI, V35, P374, DOI 10.1016/j.tips.2014.05.005
   Drazic A, 2016, BBA-PROTEINS PROTEOM, V1864, P1372, DOI 10.1016/j.bbapap.2016.06.007
   Du JM, 2015, NAT REV MOL CELL BIO, V16, P519, DOI 10.1038/nrm4043
   Engel GL, 2016, J NEUROSCI, V36, P5241, DOI 10.1523/JNEUROSCI.0499-16.2016
   Feng J, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-4-r65
   Feng J, 2013, CURR OPIN NEUROBIOL, V23, P521, DOI 10.1016/j.conb.2013.01.001
   Ferguson D, 2015, J NEUROSCI, V35, P3100, DOI 10.1523/JNEUROSCI.4012-14.2015
   Ferguson D, 2013, J NEUROSCI, V33, P16088, DOI 10.1523/JNEUROSCI.1284-13.2013
   Fontan-Lozano A, 2010, J NEUROSCI, V30, P13305, DOI 10.1523/JNEUROSCI.3010-10.2010
   Gambetta MC, 2015, CHROMOSOMA, V124, P429, DOI 10.1007/s00412-015-0513-1
   Godino A, 2015, EPIGENETICS-US, V10, P574, DOI 10.1080/15592294.2015.1055441
   Graff J, 2013, NAT REV NEUROSCI, V14, P97, DOI 10.1038/nrn3427
   Grimm JW, 2003, J NEUROSCI, V23, P742
   Guez-Barber D, 2011, J NEUROSCI, V31, P4251, DOI 10.1523/JNEUROSCI.6195-10.2011
   Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324
   Heller EA, 2016, J NEUROSCI, V36, P4690, DOI 10.1523/JNEUROSCI.0013-16.2016
   Heller EA, 2014, NAT NEUROSCI, V17, P1720, DOI 10.1038/nn.3871
   Hilton IB, 2015, NAT BIOTECHNOL, V33, P510, DOI 10.1038/nbt.3199
   Huang YY, 2014, LEARN MEMORY, V21, P153, DOI 10.1101/lm.032292.113
   Huang YY, 2013, NEUROPHARMACOLOGY, V74, P126, DOI 10.1016/j.neuropharm.2013.03.031
   Izzo A, 2016, BBA-GENE REGUL MECH, V1859, P486, DOI 10.1016/j.bbagrm.2015.09.003
   Jayanthi S, 2014, BIOL PSYCHIAT, V76, P47, DOI 10.1016/j.biopsych.2013.09.034
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jordi E, 2013, P NATL ACAD SCI USA, V110, P9511, DOI 10.1073/pnas.1307116110
   Kennedy PJ, 2013, NAT NEUROSCI, V16, P434, DOI 10.1038/nn.3354
   Kim J, 2009, CELL, V137, P459, DOI 10.1016/j.cell.2009.02.027
   Koo JW, 2014, NEUROPSYCHOPHARMACOL, V39, P2646, DOI 10.1038/npp.2014.118
   Koo JW, 2015, NAT NEUROSCI, V18, P415, DOI 10.1038/nn.3932
   Krasnova IN, 2013, NEUROBIOL DIS, V58, P132, DOI 10.1016/j.nbd.2013.05.009
   Kraus WL, 2008, CURR OPIN CELL BIOL, V20, P294, DOI 10.1016/j.ceb.2008.03.006
   Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1
   Kumar A, 2005, NEURON, V48, P303, DOI 10.1016/j.neuron.2005.09.023
   Levine AA, 2005, P NATL ACAD SCI USA, V102, P19186, DOI 10.1073/pnas.0509735102
   Levine A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003062
   Li Y, 2015, J NEUROSCI, V35, P12890, DOI 10.1523/JNEUROSCI.0246-15.2015
   Lobo MK, 2010, SCIENCE, V330, P385, DOI 10.1126/science.1188472
   Malvaez M, 2013, P NATL ACAD SCI USA, V110, P2647, DOI 10.1073/pnas.1213364110
   Malvaez M, 2011, J NEUROSCI, V31, P16941, DOI 10.1523/JNEUROSCI.2747-11.2011
   Malvaez M, 2010, BIOL PSYCHIAT, V67, P36, DOI 10.1016/j.biopsych.2009.07.032
   Maze I, 2014, NAT NEUROSCI, V17, P1476, DOI 10.1038/nn.3816
   Maze I, 2014, NAT NEUROSCI, V17, P533, DOI 10.1038/nn.3670
   Maze I, 2011, P NATL ACAD SCI USA, V108, P3035, DOI 10.1073/pnas.1015483108
   Maze I, 2010, SCIENCE, V327, P213, DOI 10.1126/science.1179438
   Miller CA, 2008, NEUROBIOL LEARN MEM, V89, P599, DOI 10.1016/j.nlm.2007.07.016
   Nathan D, 2006, GENE DEV, V20, P966, DOI 10.1101/gad.1404206
   Nestler EJ, 2002, NEUROBIOL LEARN MEM, V78, P637, DOI 10.1006/nlme.2002.4084
   Pena CJ, 2014, J MOL BIOL, V426, P3389, DOI 10.1016/j.jmb.2014.03.016
   Renthal W, 2007, NEURON, V56, P517, DOI 10.1016/j.neuron.2007.09.032
   Renthal W, 2009, NEURON, V62, P335, DOI 10.1016/j.neuron.2009.03.026
   Robison AJ, 2011, NAT REV NEUROSCI, V12, P623, DOI 10.1038/nrn3111
   Rogge GA, 2013, J NEUROSCI, V33, P6623, DOI 10.1523/JNEUROSCI.4472-12.2013
   Rossetto D, 2012, EPIGENETICS-US, V7, P1098, DOI 10.4161/epi.21975
   Russo SJ, 2013, NAT REV NEUROSCI, V14, P609, DOI 10.1038/nrn3381
   Sanchis-Segura C, 2009, NEUROPSYCHOPHARMACOL, V34, P2642, DOI 10.1038/npp.2009.125
   Sartor GC, 2015, J NEUROSCI, V35, P15062, DOI 10.1523/JNEUROSCI.0826-15.2015
   Schmidt HD, 2012, J NEUROCHEM, V120, P202, DOI 10.1111/j.1471-4159.2011.07571.x
   Scobie KN, 2014, P NATL ACAD SCI USA, V111, P2005, DOI 10.1073/pnas.1319703111
   Stipanovich A, 2008, NATURE, V453, P879, DOI 10.1038/nature06994
   Sun HS, 2012, J NEUROSCI, V32, P17454, DOI 10.1523/JNEUROSCI.1357-12.2012
   Thakore PI, 2016, NAT METHODS, V13, P127, DOI [10.1038/NMETH.3733, 10.1038/nmeth.3733]
   Tsai SYA, 2015, P NATL ACAD SCI USA, V112, pE6562, DOI 10.1073/pnas.1518894112
   Tweedie-Cullen RY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036980
   Walker DM, 2015, CURR OPIN NEUROBIOL, V30, P112, DOI 10.1016/j.conb.2014.11.002
   Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985
   Wang L, 2010, NEUROPSYCHOPHARMACOL, V35, P913, DOI 10.1038/npp.2009.193
   Wang Y, 2004, SCIENCE, V306, P279, DOI 10.1126/science.1101400
NR 78
TC 5
Z9 5
U1 1
U2 14
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 0065-2598
EI 2214-8019
BN 978-3-319-53889-1; 978-3-319-53888-4
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2017
VL 978
BP 127
EP 143
DI 10.1007/978-3-319-53889-1_7
D2 10.1007/978-3-319-53889-1
PG 17
WC Genetics & Heredity; Medicine, Research & Experimental; Neurosciences
WE Book Citation Index– Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Research & Experimental Medicine; Neurosciences &
   Neurology
GA BK5BJ
UT WOS:000438240500007
PM 28523544
DA 2023-06-23
ER

PT J
AU Rasmussen, N
AF Rasmussen, Nicolas
TI Maurice Seevers, the stimulants and the political economy of addiction
   in American biomedicine
SO BIOSOCIETIES
LA English
DT Article
DE Maurice Seevers; addiction theory; amphetamine addiction; nicotine
   addiction; pharmaceuticals regulation; World Health Organization
ID MORPHINE ADDICTION; OPIATE ADDICTION; INTERWAR AMERICA; DRUG DEPENDENCE;
   BRITISH DOCTORS; MONKEY; TOLERANCE; MORTALITY; NICOTINE; INDUSTRY
AB From about 1930 to the late 1960s a definition of addiction dominated in the United States that made opiate-style abstinence reactions essential, and distinguished sharply between true addiction and merely psychological drug habituation. This definition was so narrow that it left all stimulants out of the addictive category, and it was not uncontested. By looking at the postwar efforts of one of the chief architects of this definition, pharmacologist Maurice Seevers, to defend his conception of addiction in both scientific and policy realms, I demonstrate the contingency of this construction of addiction upon methodological commitments and industrial interests related to amphetamines and tobacco. BioSocieties (2010) 5, 105-123. doi:10.1057/biosoc.2009.7
C1 Univ New S Wales, Sch Hist & Philosophy, Sydney, NSW 2052, Australia.
C3 University of New South Wales Sydney
RP Rasmussen, N (通讯作者)，Univ New S Wales, Sch Hist & Philosophy, Sydney, NSW 2052, Australia.
EM n.rasmussen@unsw.edu.au
RI Rasmussen, Nicolas/GXH-6643-2022; Rasmussen, Nicolas/B-3333-2009
OI Rasmussen, Nicolas/0000-0002-9498-0921
CR Acker C. J., 2002, CREATING AM JUNKIE A
   *AMA COMM ALC ADD, 1966, JAMA-J AM MED ASSOC, V197, P1023
   [Anonymous], 1969, WHO TECHN REP SER, V407
   Becker Howard S, 1973, OUTSIDERS STUDIES SO
   BERRIDGE V, 1979, ANN SCI, V36, P67, DOI 10.1080/00033797900200131
   BERRIDGE V, 2009, C ADD BRAIN SOC FEBR
   Berridge V, 2007, B HIST MED, V81, P286, DOI 10.1353/bhm.2007.0000
   Blasingame Francis, 1964, JAMA AM MED ASS, V188, P31
   BRANDON S, 1962, J Coll Gen Pract, V5, P603
   Brandt A., 2007, CIGARETTE CENTURY RI
   Campbell Nancy, 2007, DISCOVERING ADDICTIO
   COCHIN J, 1970, U MICH MED CENT J, V36, P225
   Cosgrove L, 2006, PSYCHOTHER PSYCHOSOM, V75, P154, DOI 10.1159/000091772
   COURTWRIGHT D, 1982, DARK PARADISE OPIATE
   COURTWRIGHT D, 1989, ADDICTS SURVIVED ORA, P1
   DENEAU G, 1969, PSYCHOPHARMACOLOGIA, V16, P30, DOI 10.1007/BF00405254
   DENEAU GA, 1970, U MICHIGAN MEDICAL 2, V36, P212
   DOLL R, 1956, BRIT MED J, V2, P1071, DOI 10.1136/bmj.2.5001.1071
   Doll R, 2004, BMJ-BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE
   DOLL R, 1954, BRIT MED J, V1, P1541
   EDDY NB, 1965, B WORLD HEALTH ORGAN, V32, P721
   Eddy NB, 1934, J PHARMACOL EXP THER, V52, P468
   Goffman E., 1963, STIGMA NOTES MANAGEM
   HAMMOND EC, 1954, JAMA-J AM MED ASSOC, V155, P1316, DOI 10.1001/jama.1954.03690330020006
   Himmelsbach, 1943, FED PROC, V2, P201
   Himmelsbach CK, 1935, J PHARMACOL EXP THER, V53, P179
   HIRSCHHORN N, EVOLUTION T IN PRESS
   JONNES J, 1995, AM J PUBLIC HEALTH, V85, P1157, DOI 10.2105/AJPH.85.8_Pt_1.1157
   KILOH LG, 1962, BRIT MED J, V2, P40, DOI 10.1136/bmj.2.5296.40
   Kluger R, 1996, ASHES ASHES AM 100 Y
   KOLB L, 1939, SCI MONTHLY      MAY, P391
   Kolb L, 1924, PUBLIC HEALTH REP, V39, P1179, DOI 10.2307/4577168
   Kolb L, 1931, PUBLIC HEALTH REP, V46, P698, DOI 10.2307/4579992
   Levine HarryG, 1978, J STUD ALCOHOL, V15, P493
   Lindesmith AR, 1940, AM SOCIOL REV, V5, P914, DOI 10.2307/2084525
   Mars SG, 2008, AM J PUBLIC HEALTH, V98, P1793, DOI 10.2105/AJPH.2007.114124
   Musto D.F., 1973, AM DIS ORIGINS NARCO
   OSWALD I, 1963, BMJ-BRIT MED J, P427
   PARASCANDOLA M, 2009, ADD BRAIN SOC C EM U
   PEELE S, 1977, INT J HEALTH SERV, V7, P103, DOI 10.2190/A7JM-3YQ7-NPAK-MWTL
   Pieters T, 2007, CAN BULL MED HIST, V24, P93, DOI 10.3138/cbmh.24.1.93
   Rasmussen N, 2005, B HIST MED, V79, P50, DOI 10.1353/bhm.2005.0036
   Rasmussen N, 2004, SOC STUD SCI, V34, P161, DOI 10.1177/0306312704042623
   Rasmussen N., 2008, SPEED MANY LIVEAMP, pIx
   Rasmussen N, 2008, AM J PUBLIC HEALTH, V98, P974, DOI 10.2105/AJPH.2007.110593
   Rose N, 2004, BIOTECHNOLOGY COMMER
   Royal College of Physicians of London, 1962, SMOK HLTH
   SCHMIDT C R, 1961, Am Pract Dig Treat, V12, P863
   SEDGWICK EK, 1993, TENDENCIES, P130
   SEEVERS M, 1941, J PHARM EXPT THERAPE, V71, P383
   SEEVERS M, 1969, MICHIGAN QUARTERLY R, V8, P3
   SEEVERS M H, 1954, Fed Proc, V13, P672
   SEEVERS M. H., 1941, JOUR PHARMACOL AND EXP THERAP, V71, P373
   Seevers M H, 1968, Res Publ Assoc Res Nerv Ment Dis, V46, P199
   SEEVERS MH, 1948, ANN NY ACAD SCI, V51, P98, DOI 10.1111/j.1749-6632.1948.tb27253.x
   SEEVERS MH, 1968, J AMER MED ASSOC, V206, P1263, DOI 10.1001/jama.206.6.1263
   Seevers MH, 1936, J PHARMACOL EXP THER, V56, P147
   Seevers MH, 1931, J PHARMACOL EXP THER, V42, P217
   SEEVERS MH, 1958, FED PROC, V17, P1175
   Seevers MH, 1936, J PHARMACOL EXP THER, V56, P157
   SEEVERS MH, 1953, AM J MED, V14, P546, DOI 10.1016/0002-9343(53)90370-2
   SEEVERS MH, 1953, JAMA-J AM MED ASSOC, V153, P1329, DOI 10.1001/jama.1953.02940320001001
   SEEVERS MH, 1967, SCIENCE, V158, P535, DOI 10.1126/science.158.3800.535
   SEEVERS MH, 1962, JAMA-J AM MED ASSOC, V181, P112
   Shideman FE, 1942, J PHARMACOL EXP THER, V74, P88
   SLADE J, 1995, JAMA-J AM MED ASSOC, V274, P225, DOI 10.1001/jama.274.3.225
   Stevenson T, 2008, AM J PUBLIC HEALTH, V98, P1184, DOI 10.2105/AJPH.2007.121657
   *SURG GEN ADV COMM, 1964, PUBL HLTH SERV PUBL, V1103
   Swann John Patrick, 1988, ACAD SCIENTISTS PHAR
   Tatum AL, 1929, J PHARMACOL EXP THER, V36, P401
   Tatum AL, 1929, J PHARMACOL EXP THER, V36, P447
   Tatum AL, 1931, PHYSIOL REV, V11, P107, DOI 10.1152/physrev.1931.11.2.107
   WEEKS JR, 1962, SCIENCE, V138, P143, DOI 10.1126/science.138.3537.143
   Weinberg D, 1997, SOCIOL THEOR, V15, P150, DOI 10.1111/0735-2751.00029
   *WHO, 1957, WHO TECHN REP SER, V116
   *WHO, 1965, WHO TECHN REP SER, V312
   WHO, 1950, WHO TECHN REP SER, V21
   WIKLER A, 1950, PHARMACOL REV, V2, P435
   WILSON CWM, 1964, BRIT J ADDICT, V60, P81, DOI 10.1111/j.1360-0443.1964.tb00050.x
   Wolinsky H, 1994, SERPENT STAFF UNHEAL
   WOODS LA, 1951, J PHARMACOL EXP THER, V101, P188
   World Health Organization, 1952, WHO TECHN REP SER, V57
NR 82
TC 15
Z9 15
U1 0
U2 6
PU PALGRAVE MACMILLAN LTD
PI BASINGSTOKE
PA BRUNEL RD BLDG, HOUNDMILLS, BASINGSTOKE RG21 6XS, HANTS, ENGLAND
SN 1745-8552
EI 1745-8560
J9 BIOSOCIETIES
JI BioSocieties
PD MAR
PY 2010
VL 5
IS 1
SI SI
BP 105
EP 123
DI 10.1057/biosoc.2009.7
PG 19
WC Social Sciences, Biomedical
WE Social Science Citation Index (SSCI)
SC Biomedical Social Sciences
GA 688TX
UT WOS:000284877900009
DA 2023-06-23
ER

PT J
AU Smith, ACW
   Kenny, PJ
AF Smith, A. C. W.
   Kenny, P. J.
TI MicroRNAs regulate synaptic plasticity underlying drug addiction
SO GENES BRAIN AND BEHAVIOR
LA English
DT Review
DE Addiction; alcohol; circulating RNA; epigenetics; microRNA;
   neuroplasticity; opiates; psychostimulants; synaptic plasticity
ID CONDITIONED-PLACE PREFERENCE; LONG-TERM POTENTIATION; NUCLEUS-ACCUMBENS;
   COCAINE-SEEKING; BDNF EXPRESSION; MESSENGER-RNA; ARGONAUTE 2; C-FOS;
   DOPAMINE-RECEPTOR; DORSAL STRIATUM
AB Chronic use of drugs of abuse results in neurochemical, morphological and behavioral plasticity that underlies the emergence of compulsive drug seeking and vulnerability to relapse during periods of attempted abstinence. Identifying and reversing addiction-relevant plasticity is seen as a potential point of pharmacotherapeutic intervention in drug-addicted individuals. Despite considerable advances in our understanding of the actions of drugs of abuse in the brain, this information has thus far yielded few novel treatment options addicted individuals. MicroRNAs are small noncoding RNAs that can each regulate the translation of hundreds to thousands of messenger RNAs. The highly pleiotropic nature of miRNAs has focused attention on their contribution to addiction-relevant structural and functional plasticity in the brain and their potential utility as targets for medications development. In this review, we discuss the roles of miRNAs in synaptic plasticity underlying the development of addiction and then briefly discuss the possibility of using circulating miRNA as biomarkers for addiction.
C1 [Smith, A. C. W.; Kenny, P. J.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, One Gustave L Levy Pl, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai
RP Kenny, PJ (通讯作者)，Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, One Gustave L Levy Pl, New York, NY 10029 USA.
EM paul.kenny@mssm.edu
OI Smith, Alexander/0000-0001-7724-6234
FU NIDA NIH HHS [F32 DA043315] Funding Source: Medline
CR Anderson SM, 2008, NAT NEUROSCI, V11, P344, DOI 10.1038/nn2054
   Bahi A, 2013, EUR J NEUROSCI, V38, P2328, DOI 10.1111/ejn.12228
   Banerjee A, 2015, BIOMARKERS, V20, P123, DOI 10.3109/1354750X.2014.1000970
   Bastle R.M., 2017, MOL PSYCHIAT, DOI 10. 1038/mp. 2016. 238
   Berglind WJ, 2009, J NEUROSCI, V29, P3715, DOI 10.1523/JNEUROSCI.5457-08.2009
   Bienvenu T, 2000, HUM MOL GENET, V9, P1377, DOI 10.1093/hmg/9.9.1377
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Borges VM, 2010, J NEUROSCI RES, V88, P2610, DOI 10.1002/jnr.22428
   Boudreau AC, 2005, J NEUROSCI, V25, P9144, DOI 10.1523/JNEUROSCI.2252-05.2005
   Bozarth M A, 1986, NIDA Res Monogr, V67, P190
   CAINE SB, 1995, BRAIN RES, V692, P47
   Cassel S, 2006, MOL PHARMACOL, V70, P487, DOI 10.1124/mol.106.022301
   Chahrour M, 2008, SCIENCE, V320, P1224, DOI 10.1126/science.1153252
   Chandrasekar V, 2011, NEUROPSYCHOPHARMACOL, V36, P1149, DOI 10.1038/npp.2010.250
   Chandrasekar V, 2009, MOL CELL NEUROSCI, V42, P350, DOI 10.1016/j.mcn.2009.08.009
   Chen BT, 2013, NATURE, V496, P359, DOI 10.1038/nature12024
   Chen DY, 2012, NAT NEUROSCI, V15, P1707, DOI 10.1038/nn.3266
   Conrad KL, 2008, NATURE, V454, P118, DOI 10.1038/nature06995
   Dreyer JL, 2010, GENOME MED, V2, DOI 10.1186/gm213
   Dziembowska M, 2013, AM J MED GENET A, V161, P1897, DOI 10.1002/ajmg.a.36023
   Dziembowska M, 2012, J NEUROSCI, V32, P14538, DOI 10.1523/JNEUROSCI.6028-11.2012
   Edbauer D, 2010, NEURON, V65, P373, DOI 10.1016/j.neuron.2010.01.005
   Etheridge A, 2011, MUTAT RES-FUND MOL M, V717, P85, DOI 10.1016/j.mrfmmm.2011.03.004
   Everitt BJ, 2016, ANNU REV PSYCHOL, V67, P23, DOI 10.1146/annurev-psych-122414-033457
   Gao C, 2011, J NEUROSCI, V31, P8533, DOI 10.1523/JNEUROSCI.1300-11.2011
   Gao J, 2010, NATURE, V466, P1105, DOI 10.1038/nature09271
   Garcia-Perez D, 2015, ADDICT BIOL, V20, P104, DOI 10.1111/adb.12083
   Gardiner AS, 2016, ALCOHOL CLIN EXP RES, V40, P826, DOI 10.1111/acer.13026
   Gipson CD, 2013, P NATL ACAD SCI USA, V110, P9124, DOI 10.1073/pnas.1220591110
   Gipson CD, 2013, NEURON, V77, P867, DOI 10.1016/j.neuron.2013.01.005
   Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0
   Goldie BJ, 2014, NUCLEIC ACIDS RES, V42, P9195, DOI 10.1093/nar/gku594
   Graybiel A M, 1991, Curr Opin Neurobiol, V1, P644, DOI 10.1016/S0959-4388(05)80043-1
   Guo J, 2014, INT J CLIN EXP MED, V7, P1297
   He Ying, 2012, Frontiers in Genetics, V3, P110, DOI 10.3389/fgene.2012.00110
   He Y, 2010, J NEUROSCI, V30, P10251, DOI 10.1523/JNEUROSCI.2419-10.2010
   Hearing MC, 2011, INT J NEUROPSYCHOPH, V14, P784, DOI 10.1017/S1461145710001173
   Heller EA, 2016, J NEUROSCI, V36, P4690, DOI 10.1523/JNEUROSCI.0013-16.2016
   HERSCH SM, 1995, J NEUROSCI, V15, P5222
   Ho VM, 2014, MOL CELL NEUROSCI, V61, P1, DOI 10.1016/j.mcn.2014.04.006
   Hollander JA, 2010, NATURE, V466, P197, DOI 10.1038/nature09202
   Horman SR, 2013, MOL CELL, V50, P356, DOI 10.1016/j.molcel.2013.03.015
   Huang WH, 2009, INT J NEUROPSYCHOPH, V12, P537, DOI 10.1017/S1461145708009528
   Huang WH, 2009, BIOL PSYCHIAT, V65, P702, DOI 10.1016/j.biopsych.2008.11.024
   Im HI, 2010, NAT NEUROSCI, V13, P1120, DOI 10.1038/nn.2615
   Janusz A, 2013, J NEUROSCI, V33, P18234, DOI 10.1523/JNEUROSCI.2207-13.2013
   Jasinska M, 2016, MOL NEUROBIOL, V53, P4701, DOI 10.1007/s12035-015-9383-z
   Kalivas PW, 2011, MOL PSYCHIATR, V16, P974, DOI 10.1038/mp.2011.46
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   KANO T, 1995, NEUROREPORT, V6, P2197, DOI 10.1097/00001756-199511000-00023
   Kawashima H, 2010, NEUROSCIENCE, V165, P1301, DOI 10.1016/j.neuroscience.2009.11.057
   Kenny PJ, 2007, TRENDS PHARMACOL SCI, V28, P135, DOI 10.1016/j.tips.2007.01.008
   Kenny PJ, 2014, DIALOGUES CLIN NEURO, V16, P335
   Kourrich S, 2007, J NEUROSCI, V27, P7921, DOI 10.1523/JNEUROSCI.1859-07.2007
   Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921
   Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865
   Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062
   Leung AKL, 2015, TRENDS CELL BIOL, V25, P601, DOI 10.1016/j.tcb.2015.07.005
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li M, 2012, BEHAV BRAIN RES, V231, P146, DOI 10.1016/j.bbr.2012.03.010
   Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513
   Magill ST, 2010, P NATL ACAD SCI USA, V107, P20382, DOI 10.1073/pnas.1015691107
   Makeyev EV, 2007, MOL CELL, V27, P435, DOI 10.1016/j.molcel.2007.07.015
   Mattson M.E., 2013, MED PRESCRIBING BEHA
   McCrae JC, 2016, CLIN TOXICOL, V54, P53, DOI 10.3109/15563650.2015.1112015
   Mellios N, 2011, NAT NEUROSCI, V14, P1240, DOI 10.1038/nn.2909
   Moretti P, 2006, J NEUROSCI, V26, P319, DOI 10.1523/JNEUROSCI.2623-05.2006
   Moussawi K, 2009, NAT NEUROSCI, V12, P182, DOI 10.1038/nn.2250
   Muller WA, 2014, AM J PATHOL, V184, P886, DOI 10.1016/j.ajpath.2013.12.033
   Nagy V, 2006, J NEUROSCI, V26, P1923, DOI 10.1523/JNEUROSCI.4359-05.2006
   Nudelman AS, 2010, HIPPOCAMPUS, V20, P492, DOI 10.1002/hipo.20646
   Numakawa T, 2009, P NATL ACAD SCI USA, V106, P647, DOI 10.1073/pnas.0800888106
   Ouellet DL, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/69616
   Panayotis N, 2011, NEUROBIOL DIS, V41, P385, DOI 10.1016/j.nbd.2010.10.006
   Pietrzykowski AZ, 2008, NEURON, V59, P274, DOI 10.1016/j.neuron.2008.05.032
   Quinn RK, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2014.144
   Quinn RK, 2018, ADDICT BIOL, V23, P631, DOI 10.1111/adb.12520
   Rajasethupathy P, 2009, NEURON, V63, P803, DOI 10.1016/j.neuron.2009.05.029
   Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607
   Remenyi J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062509
   Robinson TE, 2004, NEUROPHARMACOLOGY, V47, P33, DOI 10.1016/j.neuropharm.2004.06.025
   Robison AJ, 2011, NAT REV NEUROSCI, V12, P623, DOI 10.1038/nrn3111
   Rodriguez-Ortiz CJ, 2014, J ALZHEIMERS DIS, V42, P1229, DOI 10.3233/JAD-140204
   Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246
   Sadakierska-Chudy A, 2017, MOL NEUROBIOL, V54, P2241, DOI 10.1007/s12035-016-9817-2
   Schaefer A, 2010, J EXP MED, V207, P1843, DOI 10.1084/jem.20100451
   Scheyer AF, 2014, J NEUROSCI, V34, P3095, DOI 10.1523/JNEUROSCI.4940-13.2014
   Schmidt WJ, 1995, J NEURAL TRANSM-SUPP, P67
   Self DW, 1998, J NEUROSCI, V18, P1848
   Shen HW, 2011, P NATL ACAD SCI USA, V108, P19407, DOI 10.1073/pnas.1112052108
   Smith ACW, 2017, J NEUROSCI, V37, P742, DOI 10.1523/JNEUROSCI.2673-16.2016
   Smith ACW, 2015, BRAIN RES, V1628, P29, DOI 10.1016/j.brainres.2015.03.027
   Smith ACW, 2014, NAT NEUROSCI, V17, P1655, DOI 10.1038/nn.3846
   Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514
   Sweatt JD, 2016, J NEUROCHEM, V139, P179, DOI 10.1111/jnc.13580
   Takahashi K, 2013, TOXICOL APPL PHARM, V272, P154, DOI 10.1016/j.taap.2013.05.018
   Tang YM, 2008, ALCOHOL CLIN EXP RES, V32, P355, DOI 10.1111/j.1530-0277.2007.00584.x
   Tapocik JD, 2016, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00020
   Tapocik JD, 2014, J NEUROSCI, V34, P4581, DOI 10.1523/JNEUROSCI.0445-14.2014
   Tapocik JD, 2013, ADDICT BIOL, V18, P480, DOI 10.1111/j.1369-1600.2012.00470.x
   Tognini P, 2012, INT J BIOCHEM CELL B, V44, P6, DOI 10.1016/j.biocel.2011.10.015
   Vaquero L, 2017, ADDICT BIOL, V22, P844, DOI 10.1111/adb.12356
   Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460
   Viola TW, 2016, PSYCHOPHARMACOLOGY, V233, P3279, DOI 10.1007/s00213-016-4373-z
   Vo N, 2005, P NATL ACAD SCI USA, V102, P16426, DOI 10.1073/pnas.0508448102
   Volkow ND, 2012, NEUROPSYCHOPHARMACOL, V37, P290, DOI 10.1038/npp.2011.84
   Wiggins A, 2011, J NEUROSCI, V31, P16177, DOI 10.1523/JNEUROSCI.3816-11.2011
   Wright JW, 2003, BRAIN RES, V963, P252, DOI 10.1016/S0006-8993(02)04036-2
   Wright KN, 2015, J NEUROSCI, V35, P8948, DOI 10.1523/JNEUROSCI.5227-14.2015
   Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441
   Yan BA, 2017, SCI REP-UK, V7, DOI 10.1038/srep40413
   Yang L.X., 2014, ABSTR APPL ANAL, V2014, P1, DOI DOI 10.1186/S13568-014-0054-7
   YE Y, 2016, NEURAL PLAST, V2016, DOI DOI 10.1155/2016/4959523
   Yung KKL, 1996, EUR J NEUROSCI, V8, P861, DOI 10.1111/j.1460-9568.1996.tb01573.x
   Zapata A, 2010, J NEUROSCI, V30, P15457, DOI 10.1523/JNEUROSCI.4072-10.2010
   Zeng Y, 2008, BIOCHEM J, V413, P429, DOI 10.1042/BJ20080599
   Zhang J, 2015, GENOM PROTEOM BIOINF, V13, P17, DOI 10.1016/j.gpb.2015.02.001
   Zhang LW, 2014, CARDIOVASC DRUG THER, V28, P303, DOI 10.1007/s10557-014-6533-x
   Zhao Y, 2016, J NEUROIMMUNE PHARM, V11, P542, DOI 10.1007/s11481-016-9671-z
   Zheng H, 2010, J BIOL CHEM, V285, P21994, DOI 10.1074/jbc.M110.112607
NR 120
TC 54
Z9 56
U1 0
U2 30
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1601-1848
EI 1601-183X
J9 GENES BRAIN BEHAV
JI Genes Brain Behav.
PD MAR
PY 2018
VL 17
IS 3
AR e12424
DI 10.1111/gbb.12424
PG 11
WC Behavioral Sciences; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Behavioral Sciences; Neurosciences & Neurology
GA GB1EU
UT WOS:000428794800004
PM 28873276
OA Bronze, Green Accepted
DA 2023-06-23
ER

PT J
AU Thompson, S
   Jun, J
   Bender, K
   Ferguson, KM
   Pollio, DE
AF Thompson, Sanna
   Jun, Jina
   Bender, Kimberly
   Ferguson, Kristin M.
   Pollio, David E.
TI Estrangement factors associated with addiction to alcohol and drugs
   among homeless youth in three US cities
SO EVALUATION AND PROGRAM PLANNING
LA English
DT Article
DE Homeless youth; Street youth; Societal estrangement; Substance abuse;
   Addiction; Alcohol abuse; Drug abuse
ID SUBSTANCE-ABUSE DISORDERS; RUNAWAY; DISAFFILIATION; VICTIMIZATION;
   ADOLESCENTS; HEALTH; ADULTS; PTSD; PERSPECTIVES; PREVALENCE
AB Substance use is highly prevalent among homeless, street-involved young people. Societal estrangement is often associated with substance use, particularly among this population. The current study sought to identify four domains of social estrangement (disaffiliation, human capital, identification with homeless culture, and psychological dysfunction) in relation to alcohol and drug addiction. Homeless young adults were recruited from three disparate urban areas: Los Angeles, CA (n = 50), Austin, TX (n = 50) and St. Louis, MO (n = 46) using comparable research methods and measurement instruments. Findings demonstrated that variables measuring psychological dysfunction and homeless culture predicted alcohol addiction, while institutional disaffiliation and homeless culture predicted drug addiction. Findings affirm distinct patterns of estrangement related to alcohol compared to drug addiction. Understanding these features and the heterogeneity of this population has strong potential for assisting development of programs targeting substance use among this underserved population. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Thompson, Sanna] Univ Texas Austin, Sch Social Work, Austin, TX 78703 USA.
   [Bender, Kimberly] Univ Denver, Sch Social Work, Denver, CO 80208 USA.
   [Ferguson, Kristin M.] Univ S Carolina, Sch Social Work, Columbia, SC 29208 USA.
   [Pollio, David E.] Univ Alabama, Sch Social Work, Tuscaloosa, AL 35487 USA.
C3 University of Texas System; University of Texas Austin; University of
   Denver; University of South Carolina System; University of South
   Carolina Columbia; University of Alabama System; University of Alabama
   Tuscaloosa
RP Thompson, S (通讯作者)，Univ Texas Austin, Sch Social Work, 1717 W 6th St Suite 295, Austin, TX 78703 USA.
EM sannathompson@mail.utexas.edu; jina@mail.utexas.edu;
   kimberly.bender@du.edu; kmfergus@usc.edu; depollio@sw.ua.edu
CR ARNOLD RA, 1990, SOCIAL JUSTICE, V17, P153
   Auerswald CL, 2002, SOC SCI MED, V54, P1497, DOI 10.1016/S0277-9536(01)00128-9
   Aviles A, 2004, J YOUTH ADOLESCENCE, V33, P331, DOI 10.1023/B:JOYO.0000032641.82942.22
   Bao WN, 2000, J HEALTH SOC BEHAV, V41, P408, DOI 10.2307/2676294
   Baron SW, 1999, YOUTH SOC, V31, P3, DOI 10.1177/0044118X99031001001
   Bender Kimberly, 2007, Child Youth Care Forum, V36, P25, DOI 10.1007/s10566-006-9029-4
   BULLOCK A, 1988, FONTANA DICT MODERN
   Caplow T., 1973, OLD MEN DRUNK SOBER
   Castel R, 2000, INT J URBAN REGIONAL, V24, P519, DOI 10.1111/1468-2427.00262
   Chassin L, 2008, FUTURE CHILD, V18, P165
   Chen XJ, 2006, J RES ADOLESCENCE, V16, P379, DOI 10.1111/j.1532-7795.2006.00499.x
   Dalton MM, 2002, J YOUTH ADOLESCENCE, V31, P79, DOI 10.1023/A:1014041201490
   De Rosa CJ, 1999, J ADOLESCENT HEALTH, V24, P190, DOI 10.1016/S1054-139X(98)00081-0
   Farabee D, 2001, J ADOLESCENT RES, V16, P679, DOI 10.1177/0743558401166009
   Fest Jerry, 2003, School Nurse News, V20, P16
   Flanzer J, 2005, SUBST USE MISUSE, V40, P887, DOI 10.1081/JA-200058862
   Gaetz S, 2004, CAN J CRIMINOL CRIM, V46, P423, DOI 10.3138/cjccj.46.4.423
   GOMEZ R, 2010, SUBSTANCE ABUSE, V31, P1
   GRIGSBY C, 1990, J SOC ISSUES, V46, P141, DOI 10.1111/j.1540-4560.1990.tb01803.x
   Haley N, 2004, J Pediatr Adolesc Gynecol, V17, P313, DOI 10.1016/j.jpag.2004.06.006
   Johnson KD, 2005, J DRUG ISSUES, V35, P799, DOI 10.1177/002204260503500407
   KANDEL DB, 1992, J STUD ALCOHOL, V53, P447, DOI 10.15288/jsa.1992.53.447
   Kidd S. A., 2003, CHILD ADOLESCENT SOC, V20, P235, DOI [DOI 10.1023/A:1024552808179, 10.1023/A:1024552808179]
   Kipke MD, 1997, SUBST USE MISUSE, V32, P969, DOI 10.3109/10826089709055866
   Kipke MD, 1997, ADOLESCENCE, V32, P655
   Lankenau SE, 2005, INT J DRUG POLICY, V16, P10, DOI 10.1016/j.drugpo.2004.07.006
   Lecrubier Y, 1997, EUR PSYCHIAT, V12, P224, DOI 10.1016/S0924-9338(97)83296-8
   Lindsey E. W., 2000, CHILD ADOLESC SOC WO, V17, P115, DOI DOI 10.1023/A:1007558323191
   Little M, 2006, J RES CRIME DELINQ, V43, P357, DOI 10.1177/0022427806291260
   Mallett S, 2004, J ADOLESCENCE, V27, P337, DOI 10.1016/j.adolescence.2003.11.014
   Malloy C, 1990, J Community Health Nurs, V7, P25, DOI 10.1207/s15327655jchn0701_3
   Martijn C, 2006, SOC SCI MED, V62, P1, DOI 10.1016/j.socscimed.2005.05.007
   McMorris BJ, 2002, J STUD ALCOHOL, V63, P34
   MUNDY P, 1990, J AM ACAD CHILD PSY, V29, P724, DOI 10.1097/00004583-199009000-00008
   Najavits LM, 2007, J STUD ALCOHOL DRUGS, V68, P353, DOI 10.15288/jsad.2007.68.353
   Najavits LM, 2006, J BEHAV HEALTH SER R, V33, P453, DOI 10.1007/s11414-006-9034-2
   Noell JW, 2001, J ADOLESCENT HEALTH, V29, P31, DOI 10.1016/S1054-139X(01)00205-1
   Piliavin I, 1996, SOC SERV REV, V70, P33, DOI 10.1086/604164
   PILIAVIN I, 1993, SOC SERV REV, V67, P576, DOI 10.1086/604012
   Ramirez BL, 1996, PARASITE IMMUNOL, V18, P49, DOI 10.1046/j.1365-3024.1996.d01-4.x
   Rew L, 2001, Issues Compr Pediatr Nurs, V24, P225
   Rew L, 2002, J NURS SCHOLARSHIP, V34, P139, DOI 10.1111/j.1547-5069.2002.00139.x
   Rounds-Bryant JL, 1999, AM J DRUG ALCOHOL AB, V25, P573, DOI 10.1081/ADA-100101880
   Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi
   Shinn M, 2007, J HEALTH PSYCHOL, V12, P696, DOI 10.1177/1359105307080581
   Sosin MR, 2000, SOC WORK RES, V24, P16, DOI 10.1093/swr/24.1.16
   Stewart AJ, 2004, J AM ACAD CHILD PSY, V43, P325, DOI 10.1097/00004583-200403000-00015
   Sullivan TP, 2008, J TRAUMA STRESS, V21, P173, DOI 10.1002/jts.20318
   Thompson Sanna J, 2004, Subst Abus, V25, P13, DOI 10.1300/J465v25n03_02
   Thompson SJ, 2006, SOC WORK RES, V30, P245, DOI 10.1093/swr/30.4.245
   Thompson SJ, 2010, J ADOLESCENT RES, V25, P231, DOI 10.1177/0743558409350502
   Thompson SJ, 2001, SOC WORK RES, V25, P163, DOI 10.1093/swr/25.3.163
   THOMPSON SJ, 2006, BRIEF TREATMENT CRIS, V6, P1
   Tyler KA, 2006, J ADOLESCENT RES, V21, P133, DOI 10.1177/0743558405285494
   Unger JB, 1997, AM J COMMUN PSYCHOL, V25, P371, DOI 10.1023/A:1024680727864
   Warr M, 2002, COMPANIONS CRIME SOC
   Whitbeck LB, 2000, CHILD DEV, V71, P721, DOI 10.1111/1467-8624.00181
   Whitbeck LB, 2004, J SEX RES, V41, P329, DOI 10.1080/00224490409552240
   Zlotnick C, 2003, SUBST USE MISUSE, V38, P577, DOI 10.1081/JA-120017386
NR 59
TC 26
Z9 26
U1 1
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0149-7189
EI 1873-7870
J9 EVAL PROGRAM PLANN
JI Eval. Program Plan.
PD NOV
PY 2010
VL 33
IS 4
BP 418
EP 427
DI 10.1016/j.evalprogplan.2010.02.002
PG 10
WC Social Sciences, Interdisciplinary
WE Social Science Citation Index (SSCI)
SC Social Sciences - Other Topics
GA 628KF
UT WOS:000280117700012
PM 20299098
DA 2023-06-23
ER

PT J
AU Planeta, CS
AF Planeta, Cleopatra S.
TI Animal models of alcohol and drug dependence
SO REVISTA BRASILEIRA DE PSIQUIATRIA
LA English
DT Article
DE Animal model; dependence; addiction; drugs of abuse
ID CONDITIONED PLACE PREFERENCE; STRESS-INDUCED REINSTATEMENT;
   NICOTINE-SEEKING BEHAVIOR; SOCIAL-DEFEAT STRESS; NUCLEUS-ACCUMBENS;
   REINFORCING EFFICACY; ETHANOL-CONSUMPTION; COCAINE SEEKING; SET-POINT;
   RATS
AB Drug addiction has serious health and social consequences. In the last 50 years, a wide range of techniques have been developed to model specific aspects of drug-taking behaviors and have greatly contributed to the understanding of the neurobiological basis of drug abuse and addiction. In the last two decades, new models have been proposed in an attempt to capture the more genuine aspects of addiction-like behaviors in laboratory animals. The goal of the present review is to provide an overview of the preclinical procedures used to study drug abuse and dependence and describe recent progress that has been made in studying more specific aspects of addictive behavior in animals.
C1 [Planeta, Cleopatra S.] Univ Estadual Paulista, UNESP, Sch Pharmaceut Sci, Araraquara, SP, Brazil.
C3 Universidade Estadual Paulista
RP Planeta, CS (通讯作者)，Rodovia Araraquara Jau Km 01, BR-14801902 Araraquara, SP, Brazil.
EM cplaneta@fcfar.unesp.br
RI Scavone, Cristoforo/C-1580-2012; Planeta, Cleopatra/Z-5255-2019
OI Scavone, Cristoforo/0000-0002-1206-0882; Planeta,
   Cleopatra/0000-0002-1378-6327
CR Aguilar MA, 2009, BRAIN RES REV, V59, P253, DOI 10.1016/j.brainresrev.2008.08.002
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Ahmed SH, 1999, PSYCHOPHARMACOLOGY, V146, P303, DOI 10.1007/s002130051121
   Ahmed SH, 2000, NEUROPSYCHOPHARMACOL, V22, P413, DOI 10.1016/S0893-133X(99)00133-5
   Bardo MT, 2000, PSYCHOPHARMACOLOGY, V153, P31, DOI 10.1007/s002130000569
   Bell RL, 2006, ADDICT BIOL, V11, P270, DOI 10.1111/j.1369-1600.2005.00029.x
   Ben-Shahar O, 2008, PROG NEURO-PSYCHOPH, V32, P863, DOI 10.1016/j.pnpbp.2008.01.002
   BONESE KF, 1974, NATURE, V252, P708, DOI 10.1038/252708a0
   BOYLE AEL, 1994, BEHAV PHARMACOL, V5, P502, DOI 10.1097/00008877-199408000-00011
   Buczek Y, 1999, PSYCHOPHARMACOLOGY, V144, P183, DOI 10.1007/s002130050992
   Chiamulera C, 1996, PSYCHOPHARMACOLOGY, V127, P102, DOI 10.1007/BF02805981
   Covington HE, 2001, PSYCHOPHARMACOLOGY, V158, P388, DOI 10.1007/s002130100858
   Crabbe JC, 2011, ANN NY ACAD SCI, V1216, P24, DOI 10.1111/j.1749-6632.2010.05895.x
   Crabbe JC, 2010, BEHAV GENET, V40, P737, DOI 10.1007/s10519-010-9371-z
   Crabbe JC, 2009, BIOL PSYCHIAT, V65, P662, DOI 10.1016/j.biopsych.2008.11.002
   Cruz FC, 2008, NEUROSCIENCE, V151, P313, DOI 10.1016/j.neuroscience.2007.10.019
   Cruz FC, 2011, PSYCHOPHARMACOLOGY, V215, P165, DOI 10.1007/s00213-010-2139-6
   Cruz FC, 2010, PHARMACOL BIOCHEM BE, V96, P160, DOI 10.1016/j.pbb.2010.05.001
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175
   Do Couto BR, 2006, PSYCHOPHARMACOLOGY, V185, P459, DOI 10.1007/s00213-006-0345-z
   FRYE GD, 1981, J PHARMACOL EXP THER, V216, P306
   Funk CK, 2007, BIOL PSYCHIAT, V61, P78, DOI 10.1016/j.biopsych.2006.03.063
   Gilpin N.W., 2008, CURR PROTOC NEUROSCI, V9
   Gilpin NW, 2009, ALCOHOL CLIN EXP RES, V33, P2113, DOI 10.1111/j.1530-0277.2009.01051.x
   GOLDBERG SR, 1981, SCIENCE, V214, P573
   GOLDSTEI.DB, 1971, SCIENCE, V172, P288, DOI 10.1126/science.172.3980.288
   GRANT KA, 1985, ALCOHOL, V2, P317, DOI 10.1016/0741-8329(85)90067-9
   Hao Y, 2010, BIOL PSYCHIAT, V68, P240, DOI 10.1016/j.biopsych.2010.02.011
   HILL SY, 1976, PHARMACOL BIOCHEM BE, V5, P701, DOI 10.1016/0091-3057(76)90315-4
   Hopf FW, 2010, ALCOHOL CLIN EXP RES, V34, P1565, DOI 10.1111/j.1530-0277.2010.01241.x
   Justinova Z, 2003, PSYCHOPHARMACOLOGY, V169, P135, DOI 10.1007/s00213-003-1484-0
   Katz JL, 2003, PSYCHOPHARMACOLOGY, V168, P21, DOI 10.1007/s00213-003-1441-y
   Leao RM, 2013, PHARMACOL BIOCHEM BE, V104, P169, DOI 10.1016/j.pbb.2013.01.007
   Leao RM, 2009, BEHAV PHARMACOL, V20, P109, DOI 10.1097/FBP.0b013e3283242f41
   Leao RM, 2012, PHARMACOL BIOCHEM BE, V101, P434, DOI 10.1016/j.pbb.2012.01.025
   Leeman RF, 2010, ADDICT BIOL, V15, P109, DOI 10.1111/j.1369-1600.2009.00192.x
   LEMAGNEN J, 1987, ALCOHOL, V4, P97, DOI 10.1016/0741-8329(87)90005-X
   Lesscher HMB, 2010, ALCOHOL CLIN EXP RES, V34, P1219, DOI 10.1111/j.1530-0277.2010.01199.x
   LIEBER CS, 1973, RES COMMUN CHEM PATH, V6, P983
   LIEBER CS, 1989, J NUTR, V119, P2038, DOI 10.1093/jn/119.12.2038
   Liu Y, 2005, PSYCHOPHARMACOLOGY, V179, P644, DOI 10.1007/s00213-004-2089-y
   MAJCHROWICZ E, 1975, PSYCHOPHARMACOLOGIA, V43, P245, DOI 10.1007/BF00429258
   McBride WJ, 1998, CRIT REV NEUROBIOL, V12, P339, DOI 10.1615/CritRevNeurobiol.v12.i4.40
   Miczek KA, 1996, PSYCHOPHARMACOLOGY, V128, P256, DOI 10.1007/s002130050133
   Mueller D, 2000, BEHAV BRAIN RES, V115, P39, DOI 10.1016/S0166-4328(00)00239-4
   O'Dell LE, 2004, ALCOHOL CLIN EXP RES, V28, P1676, DOI 10.1097/01.ALC.0000145781.11923.4E
   Panlilio LV, 2007, ADDICTION, V102, P1863, DOI 10.1111/j.1360-0443.2007.02011.x
   Pattison LP, 2012, J NEUROCHEM, V122, P138, DOI 10.1111/j.1471-4159.2012.07738.x
   PICKENS R, 1968, PSYCHOPHARMACOLOGIA, V12, P158, DOI 10.1007/BF00401545
   Quadros IMH, 2009, PSYCHOPHARMACOLOGY, V206, P109, DOI 10.1007/s00213-009-1584-6
   Redila VA, 2008, PSYCHOPHARMACOLOGY, V200, P59, DOI 10.1007/s00213-008-1122-y
   Richardson NR, 1996, J NEUROSCI METH, V66, P1, DOI 10.1016/0165-0270(95)00153-0
   Richter CP, 1940, SCIENCE, V91, P507, DOI 10.1126/science.91.2369.507
   Roberts AJ, 1999, ALCOHOL CLIN EXP RES, V23, P1151, DOI 10.1097/00000374-199907000-00003
   Roberts AJ, 1996, ALCOHOL CLIN EXP RES, V20, P1289, DOI 10.1111/j.1530-0277.1996.tb01125.x
   ROGERS J, 1979, BEHAV NEURAL BIOL, V27, P466, DOI 10.1016/S0163-1047(79)92061-2
   Sanchis-Segura C, 2006, ADDICT BIOL, V11, P2, DOI 10.1111/j.1369-1600.2006.00012.x
   Schank JR, 2011, PSYCHOPHARMACOLOGY, V218, P111, DOI 10.1007/s00213-011-2201-z
   Shaham Y, 2000, BRAIN RES REV, V33, P13, DOI 10.1016/S0165-0173(00)00024-2
   Shaham Y, 1997, PSYCHOPHARMACOLOGY, V130, P396, DOI 10.1007/s002130050256
   SHAHAM Y, 1994, PSYCHOPHARMACOLOGY, V114, P523, DOI 10.1007/BF02249346
   Shaham Y, 1996, J NEUROSCI, V16, P1957
   Sinha R, 2001, PSYCHOPHARMACOLOGY, V158, P343, DOI 10.1007/s002130100917
   Sinha R, 2006, ARCH GEN PSYCHIAT, V63, P324, DOI 10.1001/archpsyc.63.3.324
   Smith S G, 1974, Pharmacol Res Commun, V6, P379
   Spanagel R, 1997, TRENDS PHARMACOL SCI, V18, P54, DOI 10.1016/S0165-6147(97)89800-8
   Tordoff MG, 2003, ALCOHOL CLIN EXP RES, V27, P600, DOI 10.1097/01.ALC.0000060529.30157.38
   Valdez GR, 2002, ALCOHOL CLIN EXP RES, V26, P1494, DOI 10.1097/01.ALC.0000033120.51856.F0
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Vanderschuren LJMJ, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a011932
   WEEKS JR, 1962, SCIENCE, V138, P143, DOI 10.1126/science.138.3537.143
   WISE RA, 1973, PSYCHOPHARMACOLOGIA, V29, P203, DOI 10.1007/BF00414034
   WOLFFGRAMM J, 1991, NEUROSCI BIOBEHAV R, V15, P515, DOI 10.1016/S0149-7634(05)80142-3
NR 74
TC 21
Z9 21
U1 0
U2 9
PU ASSOC BRASILEIRA PSIQUIATRIA
PI SAO PAULO
PA SUBSCRIPTION DEPARTMENT, RUA PEDRO DE TOLEDO, 967 - CASA 01, SAO PAULO,
   SP 04039-032  A, BRAZIL
SN 1516-4446
J9 REV BRAS PSIQUIATR
JI Rev. Bras. Psiquiatr.
PY 2013
VL 35
SU 2
BP S140
EP S146
DI 10.1590/1516-4446-2013-1149
PG 7
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA 277CF
UT WOS:000328795300010
PM 24271226
OA Green Submitted, Green Published, gold
DA 2023-06-23
ER

PT J
AU Singer, BF
   Fadanelli, M
   Kawa, AB
   Robinson, TE
AF Singer, Bryan F.
   Fadanelli, Monica
   Kawa, Alex B.
   Robinson, Terry E.
TI Are Cocaine-Seeking "Habits" Necessary for the Development of
   Addiction-Like Behavior in Rats?
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE accumbens; addiction; cocaine; DLS; habit; motivation
ID SELF-ADMINISTRATION INCREASES; NUCLEUS-ACCUMBENS CORE; DORSAL STRIATUM;
   DRUG-USE; PSYCHOMOTOR SENSITIZATION; INCENTIVE-SENSITIZATION; DOPAMINE
   RELEASE; CUE; MODEL; METHAMPHETAMINE
AB Drug self-administration models of addiction typically require animals to make the same response (e.g., a lever-press or nose-poke) over and over to procure and take drugs. Bytheir design, such procedures often produce behavior controlled by stimulus-response (S-R) habits. This has supported the notion of addiction as a "drug habit," and has led to considerable advances in our understanding of the neurobiological basis of such behavior. However, to procure such drugs as cocaine, addicts often require considerable ingenuity and flexibility in seeking behavior, which, by definition, precludes the development of habits. To better model drug-seeking behavior in addicts, we first developed a novel cocaine self-administration procedure [puzzle self-administration procedure (PSAP)] that required rats to solve anewpuzzle every day to gain access to cocaine, which they then self-administeredonan intermittent access (IntA) schedule. Such daily problem-solving precluded the development of S-R seeking habits. We then asked whether prolonged PSAP/ IntA experience would nevertheless produce "symptoms of addiction." It did, including escalation of intake, sensitized motivation for drug, continued drug use in the face of adverse consequences, and very robust cueinduced reinstatement of drug seeking, especially in a subset of "addiction-prone" rats. Furthermore, drug-seeking behavior continued to require dopamine neurotransmission in the core of the nucleus accumbens (but not the dorsolateral striatum). We conclude that the development of S-R seeking habits is not necessary for the development of cocaine addiction-like behavior in rats.
C1 [Singer, Bryan F.; Fadanelli, Monica; Kawa, Alex B.; Robinson, Terry E.] Univ Michigan, Dept Psychol, Biopsychol Area, Ann Arbor, MI 48109 USA.
   [Singer, Bryan F.] Open Univ, Fac Sci Technol Engn & Math, Sch Life Hlth & Chem Sci, Milton Keynes MK7 6AA, Bucks, England.
C3 University of Michigan System; University of Michigan; Open University -
   UK
RP Singer, BF (通讯作者)，Open Univ, Fac Sci Technol Engn & Math, Sch Life Hlth & Chem Sci, Milton Keynes MK7 6AA, Bucks, England.
EM bryan.singer@open.ac.uk
RI Singer, Bryan F./H-7961-2013
OI Singer, Bryan F./0000-0003-3474-6137; Robinson,
   Terry/0000-0001-7861-3737
FU National Institute on Drug Abuse [F32 DA038383-01, T32 DA007268-21, P01
   DA031656]
FX This work was supported by grants from the National Institute on Drug
   Abuse to B.F.S. (F32 DA038383-01, T32 DA007268-21) and T.E.R. (P01
   DA031656). We thank Dr. Aldo Badiani (University of Sussex), Dr. Kent
   Berridge (University of Michigan), Dr. Hans Crombag (University of
   Sussex), and Dr. Anna Samaha (Universite de Montreal) for their comments
   on an earlier version of the manuscript. Wethank several undergraduate
   students for their help with the project, including Sarah Burke, Cody
   Carter, Yazmyn Cross, Jeffrey Hoshal, Sarah Lopez, Melanie Schweir,
   Brett Wietecha, Erin Wright, and Joyce Xia.
CR Ahmed SH, 1999, PSYCHOPHARMACOLOGY, V146, P303, DOI 10.1007/s002130051121
   Allain F, 2017, NEUROPHARMACOLOGY, V117, P227, DOI 10.1016/j.neuropharm.2017.01.026
   Allain F, 2015, NEUROSCI BIOBEHAV R, V56, P166, DOI 10.1016/j.neubiorev.2015.06.012
   American Psychiatric Association [APA], 2022, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425787]
   Anggadiredja K, 2004, BRAIN RES, V1021, P272, DOI 10.1016/j.brainres.2004.06.051
   [Anonymous], 2017, OED ONLINE
   Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244
   Belin D, 2008, NEURON, V57, P432, DOI 10.1016/j.neuron.2007.12.019
   Bentzley BS, 2014, P NATL ACAD SCI USA, V111, P11822, DOI 10.1073/pnas.1406324111
   Bentzley BS, 2013, PSYCHOPHARMACOLOGY, V226, P113, DOI 10.1007/s00213-012-2899-2
   Beveridge T. J., 2012, ANAL HUMAN COCAINE U
   Boileau I, 2007, J NEUROSCI, V27, P3998, DOI 10.1523/JNEUROSCI.4370-06.2007
   Burton AC, 2017, J NEUROSCI, V37, P7737, DOI 10.1523/JNEUROSCI.0897-17.2017
   Calipari ES, 2014, J PHARMACOL EXP THER, V349, P192, DOI 10.1124/jpet.114.212993
   Crombag HS, 2000, BEHAV BRAIN RES, V116, P1, DOI 10.1016/S0166-4328(00)00243-6
   Dalley JW, 2011, NEURON, V69, P680, DOI 10.1016/j.neuron.2011.01.020
   Deroche V, 1999, EUR J NEUROSCI, V11, P2731, DOI 10.1046/j.1460-9568.1999.00696.x
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Di Ciano P, 2004, J NEUROSCI, V24, P7167, DOI 10.1523/JNEUROSCI.1581-04.2004
   DICKINSON A, 1995, ANIM LEARN BEHAV, V23, P197, DOI 10.3758/BF03199935
   DICKINSON A, 1985, PHILOS T ROY SOC B, V308, P67, DOI 10.1098/rstb.1985.0010
   DiFeliceantonio AG, 2016, EUR J NEUROSCI, V43, P1203, DOI 10.1111/ejn.13220
   Epstein DH, 2006, PSYCHOPHARMACOLOGY, V189, P1, DOI 10.1007/s00213-006-0529-6
   Everitt BJ, 2016, ANNU REV PSYCHOL, V67, P23, DOI 10.1146/annurev-psych-122414-033457
   Everitt BJ, 2014, EUR J NEUROSCI, V40, P2163, DOI 10.1111/ejn.12644
   Everitt BJ, 2000, PSYCHOPHARMACOLOGY, V153, P17, DOI 10.1007/s002130000566
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Gasbarri A, 2014, NEUROBIOL LEARN MEM, V114, P198, DOI 10.1016/j.nlm.2014.06.010
   Gillan CM, 2015, COGN AFFECT BEHAV NE, V15, P523, DOI 10.3758/s13415-015-0347-6
   Gollwitzer P M, 1998, Pers Soc Psychol Rev, V2, P124, DOI 10.1207/s15327957pspr0202_5
   Graybiel AM, 2008, ANNU REV NEUROSCI, V31, P359, DOI 10.1146/annurev.neuro.29.051605.112851
   Grimm JW, 2003, J NEUROSCI, V23, P742
   Halbout B, 2016, FRONT PSYCHIATRY, V7, DOI 10.3389/fpsyt.2016.00044
   Heather Nick, 2017, Addict Behav Rep, V6, P15, DOI 10.1016/j.abrep.2017.05.002
   Higgins ST, 1997, PHARMACOL BIOCHEM BE, V57, P419, DOI 10.1016/S0091-3057(96)00446-7
   Ito R, 2004, NAT NEUROSCI, V7, P389, DOI 10.1038/nn1217
   Ito R, 2002, J NEUROSCI, V22, P6247
   Kawa AB, 2016, PSYCHOPHARMACOLOGY, V233, P3587, DOI 10.1007/s00213-016-4393-8
   Lewis M., 2015, BIOL DESIRE WHY ADDI
   Leyton M, 2012, BIOL PSYCHIAT, V72, pE21, DOI 10.1016/j.biopsych.2012.04.036
   MacKillop J, 2016, ALCOHOL CLIN EXP RES, V40, P672, DOI 10.1111/acer.13004
   Miles FJ, 2003, BEHAV NEUROSCI, V117, P927, DOI 10.1037/0735-7044.117.5.927
   Murray JE, 2014, BIOL PSYCHIAT, V76, P15, DOI 10.1016/j.biopsych.2013.09.011
   Neale J, 2002, DRUG USERS SOC
   Oleson EB, 2011, PSYCHOPHARMACOLOGY, V214, P567, DOI 10.1007/s00213-010-2058-6
   Oleson EB, 2009, NEUROPSYCHOPHARMACOL, V34, P796, DOI 10.1038/npp.2008.195
   Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix
   Pitchers KK, 2017, BEHAV BRAIN RES, V320, P302, DOI 10.1016/j.bbr.2016.11.024
   PREBLE E, 1969, INT J ADDICT, V4, P1, DOI 10.3109/10826086909061998
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   ROBLEDO P, 1992, ANN NY ACAD SCI, V654, P509, DOI 10.1111/j.1749-6632.1992.tb26015.x
   Sakano E, 2014, BRAZ J OTORHINOLAR, V80, P1, DOI 10.1002/0471142700.nc0909s57
   Saunders BT, 2010, BIOL PSYCHIAT, V67, P730, DOI 10.1016/j.biopsych.2009.11.015
   Schneck N, 2012, BEHAV BRAIN RES, V235, P136, DOI 10.1016/j.bbr.2012.07.042
   Sheeran P, 2005, PERS SOC PSYCHOL B, V31, P87, DOI 10.1177/0146167204271308
   Singer BF, 2016, EUR J NEUROSCI, V43, P662, DOI 10.1111/ejn.13134
   Skinner B. F., 1971, FREEDOM DIGNITY
   Smith RJ, 2017, PROG NEUROPSYCHOPHAR
   Suto N, 2011, NEUROSCI LETT, V493, P29, DOI 10.1016/j.neulet.2011.02.011
   TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147
   Vandaele Y, 2017, PROG NEUROPSYCHOPHAR
   Vanderschuren LJMJ, 2005, J NEUROSCI, V25, P8665, DOI 10.1523/JNEUROSCI.0925-05.2005
   Venniro M, 2017, NEUROPSYCHOPHARMACOL, V42, P1126, DOI 10.1038/npp.2016.287
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
   Vollstadt-Klein S, 2010, ADDICTION, V105, P1741, DOI 10.1111/j.1360-0443.2010.03022.x
   WEEKS JR, 1962, SCIENCE, V138, P143, DOI 10.1126/science.138.3537.143
   Willuhn I, 2014, NAT NEUROSCI, V17, P704, DOI 10.1038/nn.3694
   Willuhn I, 2012, P NATL ACAD SCI USA, V109, P20703, DOI 10.1073/pnas.1213460109
   Wood W, 2016, ANNU REV PSYCHOL, V67, P289, DOI 10.1146/annurev-psych-122414-033417
   Zapata A, 2010, J NEUROSCI, V30, P15457, DOI 10.1523/JNEUROSCI.4072-10.2010
   Zimmer BA, 2012, NEUROPSYCHOPHARMACOL, V37, P1901, DOI 10.1038/npp.2012.37
NR 71
TC 54
Z9 54
U1 2
U2 25
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
EI 1529-2401
J9 J NEUROSCI
JI J. Neurosci.
PD JAN 3
PY 2018
VL 38
IS 1
BP 60
EP 73
DI 10.1523/JNEUROSCI.2458-17.2017
PG 14
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA FS4CE
UT WOS:000419734200008
PM 29158359
OA Green Accepted, Green Published, hybrid
DA 2023-06-23
ER

PT J
AU Kalivas, PW
AF Kalivas, Peter W.
TI Neurobiology of cocaine addiction: Implications for new pharmacotherapy
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Article
ID PLACEBO-CONTROLLED TRIAL; DRUG-SEEKING BEHAVIOR; NUCLEUS-ACCUMBENS;
   INDUCED REINSTATEMENT; RELAPSE PREVENTION; VENTRAL PALLIDUM; GABA
   TRANSMISSION; GLUTAMATE RELEASE; RECEPTOR AGONIST; DOPAMINE
AB The development of pharmacotherapies for cocaine addiction has been disappointingly slow. However, new neurobiological knowledge of how the brain is changed by chronic pharmacological insult with cocaine is revealing novel targets for drug development. Certain drugs currently being tested in clinical trials tap into the underlying cocaine-induced neuroplasticity, including drugs promoting GABA or inhibiting glutamate transmission. Armed with rationales derived from a neurobiological perspective that cocaine addiction is a pharmacologically induced disease of neuroplasticity in brain circuits mediating normal reward learning, one can expect novel pharmacotherapies to emerge that directly target the biological pathology of addiction.
C1 Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
C3 Medical University of South Carolina
RP Kalivas, PW (通讯作者)，Med Univ S Carolina, Dept Neurosci, 173 Ashley Ave,BSB403, Charleston, SC 29425 USA.
EM kalivasp@musc.edu
FU NIDA NIH HHS [DA05369, DA12513, DA03906] Funding Source: Medline
CR Backstrom P, 2006, NEUROPSYCHOPHARMACOL, V31, P778, DOI 10.1038/sj.npp.1300845
   Baker DA, 2003, NAT NEUROSCI, V6, P743, DOI 10.1038/nn1069
   Ballon JS, 2006, J CLIN PSYCHIAT, V67, P554, DOI 10.4088/JCP.v67n0406
   Baptista MAS, 2004, J NEUROSCI, V24, P4723, DOI 10.1523/JNEUROSCI.0176-04.2004
   Botreau F, 2006, BEHAV BRAIN RES, V172, P173, DOI 10.1016/j.bbr.2006.05.012
   Bradberry CW, 2000, J NEUROSCI, V20, P7109, DOI 10.1523/JNEUROSCI.20-18-07109.2000
   Brebner K, 2005, SCIENCE, V310, P1340, DOI 10.1126/science.1116894
   Brebner K, 2002, ALCOHOL ALCOHOLISM, V37, P478, DOI 10.1093/alcalc/37.5.478
   Caille S, 2004, EUR J NEUROSCI, V20, P593, DOI 10.1111/j.1460-9568.2004.03497.x
   Chiamulera C, 2001, NAT NEUROSCI, V4, P873, DOI 10.1038/nn0901-873
   CHILDRESS AR, 2002, COLL  PROBL DRUG DEP
   Couceyro PR, 2005, J PHARMACOL EXP THER, V315, P1091, DOI 10.1124/jpet.105.091678
   Dackis CA, 2005, NEUROPSYCHOPHARMACOL, V30, P205, DOI 10.1038/sj.npp.1300600
   Everitt BJ, 2002, J NEUROSCI, V22, P3312
   Ferraro L, 1998, NEUROSCI LETT, V253, P135, DOI 10.1016/S0304-3940(98)00629-6
   FLANAGAN RJ, 1991, AM J MED, V91, pS131, DOI 10.1016/0002-9343(91)90296-A
   Garavan H, 2000, AM J PSYCHIAT, V157, P1789, DOI 10.1176/appi.ajp.157.11.1789
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Haney M, 2006, NEUROPSYCHOPHARMACOL, V31, P1814, DOI 10.1038/sj.npp.1300999
   Hubert GW, 2005, BRAIN RES, V1050, P8, DOI 10.1016/j.brainres.2005.05.025
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Jaworski JN, 2006, PEPTIDES, V27, P1993, DOI 10.1016/j.peptides.2006.03.034
   Jay TM, 2003, PROG NEUROBIOL, V69, P375, DOI 10.1016/S0301-0082(03)00085-6
   Kalivas PW, 2005, NEURON, V45, P647, DOI 10.1016/j.neuron.2005.02.005
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kelley AE, 2004, NEURON, V44, P161, DOI 10.1016/j.neuron.2004.09.016
   LaRowe SD, 2006, AM J ADDICTION, V15, P105, DOI 10.1080/10550490500419169
   Lindsey KP, 2004, J PHARMACOL EXP THER, V309, P959, DOI 10.1124/jpet.103.060293
   Ling W, 1998, NEUROPSYCHOPHARMACOL, V18, P403
   Lynch G, 2006, TRENDS NEUROSCI, V29, P554, DOI 10.1016/j.tins.2006.07.007
   McFarland K, 2003, J NEUROSCI, V23, P3531
   McGeehan AJ, 2003, SYNAPSE, V47, P240, DOI 10.1002/syn.10166
   Modesto-Lowe V, 1997, DRUG ALCOHOL DEPEN, V49, P9, DOI 10.1016/S0376-8716(97)00134-8
   Moran MM, 2005, J NEUROSCI, V25, P6389, DOI 10.1523/JNEUROSCI.1007-05.2005
   O'Brien CP, 2005, AM J PSYCHIAT, V162, P1423, DOI 10.1176/appi.ajp.162.8.1423
   Oslin DW, 1999, J SUBST ABUSE TREAT, V16, P163, DOI 10.1016/S0740-5472(98)00039-7
   Peters J, 2006, PSYCHOPHARMACOLOGY, V186, P143, DOI 10.1007/s00213-006-0372-9
   Schmitz JM, 2004, AM J ADDICTION, V13, P333, DOI 10.1080/10550490490480982
   Schmitz JM, 2001, ADDICT BEHAV, V26, P167, DOI 10.1016/S0306-4603(00)00098-8
   SCHULTZ W, 1998, AM J PHYSIOL, V80, P1
   SEIDEN LS, 1993, ANNU REV PHARMACOL, V33, P639, DOI 10.1146/annurev.pharmtox.33.1.639
   Shoptaw S, 2003, J CLIN PSYCHIAT, V64, P1440, DOI 10.4088/JCP.v64n1207
   Sofuoglu M, 2005, CNS DRUGS, V19, P13, DOI 10.2165/00023210-200519010-00002
   Sofuoglu M, 2003, PHARMACOL BIOCHEM BE, V75, P801, DOI 10.1016/S0091-3057(03)00157-6
   Steiner RC, 2006, BEHAV BRAIN RES, V171, P56, DOI 10.1016/j.bbr.2006.03.022
   Tang XC, 2005, J NEUROSCI, V25, P4512, DOI 10.1523/JNEUROSCI.0685-05.2005
   Toda S, 2006, J NEUROSCI, V26, P1579, DOI 10.1523/JNEUROSCI.4132-05.2006
   van Nimwegen L, 2005, ACTA PSYCHIAT SCAND, V111, P35
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Vocci F, 2005, PHARMACOL THERAPEUT, V108, P94, DOI 10.1016/j.pharmthera.2005.06.010
   Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406
   Xi ZX, 2006, NEUROPSYCHOPHARMACOL, V31, P1393, DOI 10.1038/sj.npp.1300912
   Xi ZX, 2003, J NEUROSCI, V23, P3498
   Yao WD, 2004, NEURON, V41, P625, DOI 10.1016/S0896-6273(04)00048-0
   Zahm DS, 1996, J COMP NEUROL, V364, P340, DOI 10.1002/(SICI)1096-9861(19960108)364:2<340::AID-CNE11>3.0.CO;2-T
NR 55
TC 87
Z9 89
U1 1
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
EI 1521-0391
J9 AM J ADDICTION
JI Am. J. Addict.
PY 2007
VL 16
IS 2
BP 71
EP 78
DI 10.1080/10550490601184142
PG 8
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA 165HY
UT WOS:000246296400001
PM 17453607
DA 2023-06-23
ER

PT J
AU Canabarro, RDD
   D'Agord, MRL
AF dos Santos Canabarro, Rita de Cassia
   de Leao D'Agord, Marta Regina
TI Drug Addiction and Social Discourses
SO REVISTA LATINOAMERICANA DE PSICOPATOLOGIA FUNDAMENTAL
LA English
DT Article
DE Addiction; psychoanalysis; discourse; symptom
AB This article analyzes the various discursive positions found in the phenomenon of addiction. The relations these discursive positions establish with the discourses of the master, the hysteric, the university and the capitalist are discussed. By analyzing material from clinical listening at a public outpatient drug and alcohol rehab center, it was seen that addiction can be described in different discourses. This article shows that the shift of focus from the symptom to the discursive position of the subject is an indicator for the clinical treatment of addiction.
C1 [dos Santos Canabarro, Rita de Cassia] Univ Fed Rio Grande do Sul, Grad Program Social & Inst Psychol, Porto Alegre, RS, Brazil.
   [de Leao D'Agord, Marta Regina] Univ Fed Rio Grande do Sul, Psychoanal & Psychopathol Dept, Porto Alegre, RS, Brazil.
   [de Leao D'Agord, Marta Regina] Univ Fed Rio Grande do Sul, Grad Program Social & Inst Psychol, Inst Psychol, Porto Alegre, RS, Brazil.
C3 Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio
   Grande do Sul; Universidade Federal do Rio Grande do Sul
RP Canabarro, RDD (通讯作者)，Rua Sao Jose 1971-313, BR-96845751 Santa Cruz Do Sul, RS, Brazil.
EM ritinha.sc@hotmail.com; mdagord@terra.com.br
OI D'Agord, Marta/0000-0003-0379-5323
CR ALBERTI S., 2003, REV LATINOAMERICANA, V6, P11
   CONTE M., 2003, REV ASS PSICANALITIC, P41
   CONTE M., 2001, REV ASS PSICANALITIC, P91
   Conte M., 2003, CLIN PSICANALITICA C
   CONTE M., 2002, REV LATINOAMERICANA, V5, P28
   Eidelsztein A., 2008, ESTRUCTURAS CLIN PAR, V1
   FREUD S., 1925, ESCRITOS PSICOL, VIII, P145
   FREUD S., 1930, EDICAO STANDARD BRAS, VXXI, P73
   Hegel G., 1966, FENOMENOLOGIA ESPIRI
   HEGEL GWF, PHENOMENOLOGY SPIRIT
   LACAN J., 1997, SABER PSICANALISTA S
   LACAN J., 1992, SEMINARIO
   Lacan J, 1972, C LUNIVERSITE MILAN
   LACAN J., 1974, CHE VUOI PSICANALISE, P14
   LACAN J., 2005, TRIUNFO RELIG
   Lacan Jacques, 2009, SEMINARIO
   LE POULICHET S., 1996, TEMPO PSICANALISE, P105
   Le Poulichet Sylvie, 2005, TOXICOMANIAS PSICOAN
   PETIT P., 1989, CLIN TOXICOMANAO, P52
   SANTIAGO J., 2001, DROGA TOXICOMANA PAR
   SAURET M.-J., 2009, REV ELETRONICA PSYCO
NR 21
TC 0
Z9 0
U1 0
U2 7
PU ASSOC UNIV PEQUISA PSICOPATOLOGIA FUNDAMENTAL
PI SAO PAOLO SP
PA RUA TUPI, 397-10- CJ 104, SAO PAOLO SP, 01233-001, BRAZIL
SN 1415-4714
J9 REV LATINOAM PSICOPA
JI Rev. Latinoam. Psicopatol. Funda.
PD SEP
PY 2012
VL 15
IS 3
BP 482
EP 496
PG 15
WC Psychology, Multidisciplinary
WE Social Science Citation Index (SSCI)
SC Psychology
GA V30SA
UT WOS:000208834500003
DA 2023-06-23
ER

PT J
AU Everitt, BJ
AF Everitt, Barry J.
TI Neural and psychological mechanisms underlying compulsive drug seeking
   habits and drug memories - indications for novel treatments of addiction
SO EUROPEAN JOURNAL OF NEUROSCIENCE
LA English
DT Review
DE cocaine; compulsion; habits; reconsolidation; relapse; striatum
ID NUCLEUS-ACCUMBENS CORE; DOPAMINE D-3 RECEPTOR; INCENTIVE-SENSITIZATION
   THEORY; MEDIAL PREFRONTAL CORTEX; COCAINE-SEEKING; ORBITOFRONTAL CORTEX;
   BASOLATERAL AMYGDALA; DORSAL STRIATUM; NMDA RECEPTORS; D-CYCLOSERINE
AB This review discusses the evidence for the hypothesis that the development of drug addiction can be understood in terms of interactions between Pavlovian and instrumental learning and memory mechanisms in the brain that underlie the seeking and taking of drugs. It is argued that these behaviours initially are goal-directed, but increasingly become elicited as stimulus-response habits by drug-associated conditioned stimuli that are established by Pavlovian conditioning. It is further argued that compulsive drug use emerges as the result of a loss of prefrontal cortical inhibitory control over drug seeking habits. Data are reviewed that indicate these transitions from use to abuse to addiction depend upon shifts from ventral to dorsal striatal control over behaviour, mediated in part by serial connectivity between the striatum and midbrain dopamine systems. Only some individuals lose control over their drug use, and the importance of behavioural impulsivity as a vulnerability trait predicting stimulant abuse and addiction in animals and humans, together with consideration of an emerging neuroendophenotype for addiction are discussed. Finally, the potential for developing treatments for addiction is considered in light of the neuropsychological advances that are reviewed, including the possibility of targeting drug memory reconsolidation and extinction to reduce Pavlovian influences on drug seeking as a means of promoting abstinence and preventing relapse.
C1 Univ Cambridge, Dept Psychol, Behav & Clin Neurosci Inst, Cambridge CB2 3EB, England.
C3 University of Cambridge
RP Everitt, BJ (通讯作者)，Univ Cambridge, Dept Psychol, Behav & Clin Neurosci Inst, Downing St, Cambridge CB2 3EB, England.
EM bje10@cam.ac.uk
OI Everitt, Barry/0000-0003-4431-6536
FU Medical Research Council; Wellcome Trust; European Union; Human Frontier
   Science Programme; Medical Research Council [G0001354, G1000183B,
   G0001354B, G1002231] Funding Source: researchfish; MRC [G1002231]
   Funding Source: UKRI
FX I would like to acknowledge the immense contributions of my
   collaborators Trevor Robbins and Tony Dickinson, with whom the
   theoretical framework of the summarized research was initially
   developed, Jeff Dalley, David Belin and Amy Milton. I further thank
   David Belin for criticism of the manuscript and for providing Figs 1 and
   2. Many postdoctoral researchers, graduate students and visiting
   scientists have made major contributions and they include currently in
   alphabetical order: Johan Alsjo, Emma Cahill, Kristin Feltmann, Chiara
   Giuliano, Charley Goodlett, Zara Goozee, Emiliano Merlo, Yolanda
   Pena-Oliver, Adam Mar, Jennifer Murray, Mark Renshaw and George Vousden.
   Former graduate students and postdoctoral researchers and visitors:
   Mercedes Arroyo, Martine Cador, Daniele Caprioli, Morgane Besson, Barak
   Caine, Rudolf Cardinal, Pat DiCiano, Liana Fattore, Jeremy Hall, Kim
   Hellemans, Dan Hutcheson, Rutsuko Ito, Sietse Jonkman, Joff Lee, Athina
   Markou, Ruth McNamara, Cella Olmstead, John Parkinson, Maria Pilla,
   Patricia Robledo, Moritz Schramm, Florence Theberge, Kerrie Thomas, Louk
   Vanderschuren, Ruth Weissenborn, Rachel Whitelaw and Melissa Woods. I
   also thank my collaborators: Eric Nestler, Paul Phillips, Jean-Charles
   Schwarcz, Pierre Sokoloff and Ingo Willuhn. I have been fortunate to
   have received grant support from the Medical Research Council
   continuously since I was a graduate student, but especially for the
   research on addiction summarized here. The Wellcome Trust (with my
   collaborators Trevor Robbins and Jeff Dalley), the European Union and
   Human Frontier Science Programme have also supported this work. Finally,
   I dedicate this review to Daina Economidou, who died in December 2012
   when she was contributing in a major way to the research in my
   laboratory - we all remember Daina as an enthusiastic, supportive and
   devoted member of the laboratory in Cambridge and she is deeply missed.
CR ADAMS CD, 1981, Q J EXP PSYCHOL-B, V33, P109, DOI 10.1080/14640748108400816
   Ahmed SH, 2003, J NEUROCHEM, V86, P102, DOI 10.1046/j.1471-4159.2003.01833.x
   Ahmed SH, 2002, NAT NEUROSCI, V5, P625, DOI 10.1038/nn872
   Alderson HL, 2001, PSYCHOPHARMACOLOGY, V153, P455, DOI 10.1007/s002130000634
   American Psychiatric Association [APA], 2022, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425787]
   Ansquer S, 2014, BIOL PSYCHIAT, V75, P825, DOI 10.1016/j.biopsych.2013.09.031
   Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244
   ARNETT J, 1994, PERS INDIV DIFFER, V16, P289, DOI 10.1016/0191-8869(94)90165-1
   Arroyo M, 1998, PSYCHOPHARMACOLOGY, V140, P331, DOI 10.1007/s002130050774
   Badiani A, 2013, CURR OPIN NEUROBIOL, V23, P588, DOI 10.1016/j.conb.2013.03.010
   Baler RD, 2006, TRENDS MOL MED, V12, P559, DOI 10.1016/j.molmed.2006.10.005
   Bassareo V, 1999, EUR J NEUROSCI, V11, P4389, DOI 10.1046/j.1460-9568.1999.00843.x
   Batki SL, 1996, DRUG ALCOHOL DEPEN, V41, P137, DOI 10.1016/0376-8716(96)01233-1
   Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   Belin D, 2008, NEURON, V57, P432, DOI 10.1016/j.neuron.2007.12.019
   Belin D, 2013, CURR OPIN NEUROBIOL, V23, P564, DOI 10.1016/j.conb.2013.01.025
   Belin D, 2011, NEUROPSYCHOPHARMACOL, V36, P569, DOI 10.1038/npp.2010.188
   Belin-Rauscent A, 2013, BEHAV PHARMACOL, V24, P14
   Bernardi RE, 2006, NEUROREPORT, V17, P1443, DOI 10.1097/01.wnr.0000233098.20655.26
   Besson M, 2013, NEUROPSYCHOPHARMACOL, V38, P1963, DOI 10.1038/npp.2013.95
   BLACKBURN JR, 1986, PHARMACOL BIOCHEM BE, V25, P1095, DOI 10.1016/0091-3057(86)90091-2
   BLACKBURN JR, 1989, BEHAV NEUROSCI, V103, P15, DOI 10.1037/0735-7044.103.1.15
   BLACKBURN JR, 1987, BEHAV NEUROSCI, V101, P352, DOI 10.1037/0735-7044.101.3.352
   Bohbot VD, 2013, HIPPOCAMPUS, V23, P973, DOI 10.1002/hipo.22187
   Bossert JM, 2013, PSYCHOPHARMACOLOGY, V229, P453, DOI 10.1007/s00213-013-3120-y
   Bossert JM, 2005, EUR J PHARMACOL, V526, P36, DOI 10.1016/j.ejphar.2005.09.030
   Burke KA, 2008, NATURE, V454, P340, DOI 10.1038/nature06993
   CADOR M, 1989, NEUROSCIENCE, V30, P77, DOI 10.1016/0306-4522(89)90354-0
   Calu DJ, 2007, LEARN MEMORY, V14, P325, DOI 10.1101/lm.534807
   Cannella N, 2013, NEUROPSYCHOPHARMACOL, V38, P2048, DOI 10.1038/npp.2013.106
   Caprioli D, 2014, NAT NEUROSCI, V17, P644, DOI 10.1038/nn.3699
   Caprioli D, 2014, BIOL PSYCHIAT, V75, P115, DOI 10.1016/j.biopsych.2013.07.013
   Caprioli D, 2013, NEUROPSYCHOPHARMACOL, V38, P1460, DOI 10.1038/npp.2013.44
   Cardinal RN, 2004, CURR OPIN NEUROBIOL, V14, P156, DOI 10.1016/j.conb.2004.03.004
   Cardinal RN, 2004, ANN NY ACAD SCI, V1021, P33, DOI 10.1196/annals.1308.004
   Cardinal RN, 2002, NEUROSCI BIOBEHAV R, V26, P321, DOI 10.1016/S0149-7634(02)00007-6
   Cardinal RN, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-9
   Chen BT, 2013, NATURE, V496, P359, DOI 10.1038/nature12024
   Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11
   Clarke HF, 2004, SCIENCE, V304, P878, DOI 10.1126/science.1094987
   Conklin CA, 2002, ADDICTION, V97, P155, DOI 10.1046/j.1360-0443.2002.00014.x
   Corbit LH, 2012, BIOL PSYCHIAT, V72, P389, DOI 10.1016/j.biopsych.2012.02.024
   Corbit LH, 2005, J NEUROSCI, V25, P962, DOI 10.1523/JNEUROSCI.4507-04.2005
   COVI L, 1995, AM J DRUG ALCOHOL AB, V21, P327, DOI 10.3109/00952999509002701
   Crombag HS, 2008, PHILOS T R SOC B, V363, P3233, DOI 10.1098/rstb.2008.0090
   Dalley JW, 2007, SCIENCE, V315, P1267, DOI 10.1126/science.1137073
   Dalley JW, 2011, NEURON, V69, P680, DOI 10.1016/j.neuron.2011.01.020
   Davidson D, 1999, ALCOHOL CLIN EXP RES, V23, P195, DOI 10.1111/j.1530-0277.1999.tb04099.x
   Davis M, 2002, EUR J NEUROSCI, V16, P395, DOI 10.1046/j.1460-9568.2002.02138.x
   de Wit H, 2004, NEBR SYM MOTIV, V50, P19
   Depoy L, 2013, P NATL ACAD SCI USA, V110, P14783, DOI 10.1073/pnas.1308198110
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Dezfouli A, 2009, NEURAL COMPUT, V21, P2869, DOI 10.1162/neco.2009.10-08-882
   Di Ciano P, 2003, NEUROPSYCHOPHARMACOL, V28, P329, DOI 10.1038/sj.npp.1300148
   Di Ciano P, 2004, J NEUROSCI, V24, P7167, DOI 10.1523/JNEUROSCI.1581-04.2004
   Di Ciano P, 2003, BEHAV NEUROSCI, V117, P952, DOI 10.1037/0735-7044.117.5.952
   Di Ciano P, 2003, NEUROPSYCHOPHARMACOL, V28, P510, DOI 10.1038/sj.npp.1300088
   Dias-Ferreira E, 2009, SCIENCE, V325, P621, DOI 10.1126/science.1171203
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   DICKINSON A, 1995, ANIM LEARN BEHAV, V23, P197, DOI 10.3758/BF03199935
   Dickinson A, 2002, Q J EXP PSYCHOL-B, V55, P331, DOI 10.1080/0272499024400016
   DICKINSON A, 1985, PHILOS T ROY SOC B, V308, P67, DOI 10.1098/rstb.1985.0010
   DICKINSON A, 1994, ANIM LEARN BEHAV, V22, P1, DOI 10.3758/BF03199951
   Diergaarde L, 2008, BIOL PSYCHIAT, V63, P301, DOI 10.1016/j.biopsych.2007.07.011
   Diergaarde L, 2009, BEHAV NEUROSCI, V123, P794, DOI 10.1037/a0016504
   Dilleen R, 2012, PSYCHOPHARMACOLOGY, V222, P89, DOI 10.1007/s00213-011-2626-4
   Dom G, 2006, ADDICTION, V101, P50, DOI 10.1111/j.1360-0443.2005.01270.x
   Economidou D, 2011, BIOL PSYCHIAT, V69, P266, DOI 10.1016/j.biopsych.2010.09.040
   Economidou D, 2009, BIOL PSYCHIAT, V65, P851, DOI 10.1016/j.biopsych.2008.12.008
   Ehrman RN, 1998, J SUBST ABUSE TREAT, V15, P431, DOI 10.1016/S0740-5472(97)00290-0
   Epstein DH, 2006, PSYCHOPHARMACOLOGY, V189, P1, DOI 10.1007/s00213-006-0529-6
   Ersche KD, 2008, PSYCHOPHARMACOLOGY, V197, P421, DOI 10.1007/s00213-007-1051-1
   Ersche KD, 2013, CURR OPIN NEUROBIOL, V23, P615, DOI 10.1016/j.conb.2013.02.017
   Ersche KD, 2013, BIOL PSYCHIAT, V74, P137, DOI 10.1016/j.biopsych.2012.11.016
   Ersche KD, 2012, AM J PSYCHIAT, V169, P926, DOI 10.1176/appi.ajp.2012.11091421
   Ersche KD, 2012, SCIENCE, V335, P601, DOI 10.1126/science.1214463
   Ersche KD, 2011, BIOL PSYCHIAT, V70, P754, DOI 10.1016/j.biopsych.2011.06.033
   Ersche KD, 2011, BRAIN, V134, P2013, DOI 10.1093/brain/awr138
   Ersche KD, 2010, BIOL PSYCHIAT, V68, P770, DOI 10.1016/j.biopsych.2010.06.015
   Ersche KD, 2005, PSYCHOPHARMACOLOGY, V180, P612, DOI 10.1007/s00213-005-2205-7
   Everitt B.J., 2011, SOC NEUR ABS, V471, P16
   Everitt BJ, 2007, ANN NY ACAD SCI, V1121, P576, DOI 10.1196/annals.1401.022
   Everitt BJ, 2013, NEUROSCI BIOBEHAV R, V37, P1946, DOI 10.1016/j.neubiorev.2013.02.010
   Everitt BJ, 2001, BRAIN RES REV, V36, P129, DOI 10.1016/S0165-0173(01)00088-1
   Everitt BJ, 2000, PSYCHOPHARMACOLOGY, V153, P17, DOI 10.1007/s002130000566
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Everitt BJ, 1999, ANN NY ACAD SCI, V877, P412, DOI 10.1111/j.1749-6632.1999.tb09280.x
   EVERITT BJ, 1990, NEUROSCI BIOBEHAV R, V14, P217, DOI 10.1016/S0149-7634(05)80222-2
   Ferrario CR, 2005, BIOL PSYCHIAT, V58, P751, DOI 10.1016/j.biopsych.2005.04.046
   Flagel SB, 2011, NATURE, V469, P53, DOI 10.1038/nature09588
   Font L, 2012, PHARMACOL BIOCHEM BE, V101, P222, DOI 10.1016/j.pbb.2012.01.009
   Franck J, 2008, INT J NEUROPSYCHOPH, V11, P21
   Fricks-Gleason AN, 2008, LEARN MEMORY, V15, P643, DOI 10.1101/lm.1054608
   Garavan H, 2000, AM J PSYCHIAT, V157, P1789, DOI 10.1176/appi.ajp.157.11.1789
   GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107
   Gilpin NW, 2008, ALCOHOL RES HEALTH, V31, P185
   Giuliano C, 2013, PSYCHOPHARMACOLOGY, V227, P137, DOI 10.1007/s00213-012-2949-9
   Giuliano C, 2012, NEUROPSYCHOPHARMACOL, V37, P2643, DOI 10.1038/npp.2012.128
   Goldstein RZ, 2004, NEUROPSYCHOLOGIA, V42, P1447, DOI 10.1016/j.neuropsychologia.2004.04.002
   Goto Y, 2005, NAT NEUROSCI, V8, P805, DOI 10.1038/nn1471
   GRABOWSKI J, 1995, J CLIN PSYCHOPHARM, V15, P163, DOI 10.1097/00004714-199506000-00004
   Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040
   Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134
   Haber SN, 2000, J NEUROSCI, V20, P2369
   Hall J, 2001, EUR J NEUROSCI, V13, P1984, DOI 10.1046/j.0953-816x.2001.01577.x
   Han JS, 1997, J NEUROSCI, V17, P3913
   Hao Y, 2010, BIOL PSYCHIAT, V68, P240, DOI 10.1016/j.biopsych.2010.02.011
   Heidbreder C, 2013, N-S ARCH PHARMACOL, V386, P167, DOI 10.1007/s00210-012-0803-6
   Hellemans KGC, 2006, J NEUROSCI, V26, P12694, DOI 10.1523/JNEUROSCI.3101-06.2006
   Hester R, 2004, J NEUROSCI, V24, P11017, DOI 10.1523/JNEUROSCI.3321-04.2004
   Hutton-Bedbrook Kate, 2013, Front Psychiatry, V4, P14, DOI 10.3389/fpsyt.2013.00014
   Ikemoto S, 2005, J NEUROSCI, V25, P5061, DOI 10.1523/JNEUROSCI.0892-05.2005
   Ikemoto S, 2004, NEUROPHARMACOLOGY, V47, P190, DOI 10.1016/j.neuropharm.2004.07.012
   Im HI, 2010, NAT NEUROSCI, V13, P1120, DOI 10.1038/nn.2615
   Ito R, 2004, NAT NEUROSCI, V7, P389, DOI 10.1038/nn1217
   Ito R, 2002, J NEUROSCI, V22, P6247
   Janak PH, 2012, NEUROPSYCHOPHARMACOL, V37, P975, DOI 10.1038/npp.2011.281
   Jayaram-Lindstrom N, 2008, AM J PSYCHIAT, V165, P1442, DOI 10.1176/appi.ajp.2008.08020304
   Jedynak JP, 2007, EUR J NEUROSCI, V25, P847, DOI 10.1111/j.1460-9568.2007.05316.x
   Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483
   Jonkman S, 2013, NEUROPSYCHOPHARMACOL, V38, P198, DOI 10.1038/npp.2012.120
   Jonkman S, 2012, NEUROPSYCHOPHARMACOL, V37, P1612, DOI 10.1038/npp.2012.6
   Jonkman S, 2012, J NEUROSCI, V32, P4645, DOI 10.1523/JNEUROSCI.0348-12.2012
   Kalivas PW, 2006, MOL INTERV, V6, P339, DOI 10.1124/mi.6.6.7
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kasanetz F, 2010, SCIENCE, V328, P1709, DOI 10.1126/science.1187801
   Kaufman JN, 2003, J NEUROSCI, V23, P7839
   Killcross S, 2003, CEREB CORTEX, V13, P400, DOI 10.1093/cercor/13.4.400
   Kindt M, 2009, NAT NEUROSCI, V12, P256, DOI 10.1038/nn.2271
   Koob G. F., 2005, NEUROBIOLOGY ADDICTI
   Koob GF, 2008, NEURON, V59, P11, DOI 10.1016/j.neuron.2008.06.012
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442
   Koob GF, 2004, NEUROSCI BIOBEHAV R, V27, P739, DOI 10.1016/j.neubiorev.2003.11.007
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Koob GF, 1996, NEURON, V16, P893, DOI 10.1016/S0896-6273(00)80109-9
   Kreek MJ, 2005, NAT NEUROSCI, V8, P1450, DOI 10.1038/nn1583
   Le Foll B, 2002, EUR J NEUROSCI, V15, P2016, DOI 10.1046/j.1460-9568.2002.02049.x
   Lee J.L.C., 2007, SCIENCE, V304, P839
   Lee JLC, 2006, J NEUROSCI, V26, P5881, DOI 10.1523/JNEUROSCI.0323-06.2006
   Lee JLC, 2005, NEURON, V47, P795, DOI 10.1016/j.neuron.2005.08.007
   Lee JLC, 2006, J NEUROSCI, V26, P10051, DOI 10.1523/JNEUROSCI.2466-06.2006
   Lee JLC, 2009, LEARN MEMORY, V16, P82, DOI 10.1101/lm.1186609
   Letchworth SR, 2001, J NEUROSCI, V21, P2799, DOI 10.1523/JNEUROSCI.21-08-02799.2001
   Letchworth SR, 1997, BRAIN RES, V750, P214, DOI 10.1016/S0006-8993(96)01384-4
   Lu L, 2004, NEUROPHARMACOLOGY, V47, P214, DOI 10.1016/j.neuropharm.2004.06.027
   Lu L, 2005, NAT NEUROSCI, V8, P212, DOI 10.1038/nn1383
   Marchant NJ, 2013, CURR OPIN NEUROBIOL, V23, P675, DOI 10.1016/j.conb.2013.01.003
   Martin-Fardon R, 2014, NEUROREPORT, V25, P485, DOI 10.1097/WNR.0000000000000120
   McClure EA, 2014, CNS DRUGS, V28, P95, DOI 10.1007/s40263-014-0142-x
   McFarland K, 2001, J NEUROSCI, V21, P8655
   McNally GP, 2014, NEUROPHARMACOLOGY, V76, P528, DOI 10.1016/j.neuropharm.2013.06.007
   McNamara R, 2010, PSYCHOPHARMACOLOGY, V212, P453, DOI 10.1007/s00213-010-1974-9
   Meunier D, 2012, NEUROIMAGE, V59, P1461, DOI 10.1016/j.neuroimage.2011.08.003
   Miles FJ, 2003, BEHAV NEUROSCI, V117, P927, DOI 10.1037/0735-7044.117.5.927
   Miller CA, 2005, NEURON, V47, P873, DOI 10.1016/j.neuron.2005.08.006
   Milton AL, 2013, CURR OPIN NEUROBIOL, V23, P706, DOI 10.1016/j.conb.2012.11.008
   Milton A.L., 2010, PSYCHOPHARMACOLOGY, V219, P751
   Milton AL, 2008, J NEUROSCI, V28, P8230, DOI 10.1523/JNEUROSCI.1723-08.2008
   Milton AL, 2008, LEARN MEMORY, V15, P88, DOI 10.1101/lm.825008
   Milton AL, 2012, SCIENCE, V336, P167, DOI 10.1126/science.1221691
   Milton AL, 2012, NEUROSCI BIOBEHAV R, V36, P1119, DOI 10.1016/j.neubiorev.2012.01.002
   Milton AL, 2012, PSYCHOPHARMACOLOGY, V219, P751, DOI 10.1007/s00213-011-2399-9
   Milton AL, 2010, EUR J NEUROSCI, V31, P2308, DOI 10.1111/j.1460-9568.2010.07249.x
   Mishkin M, 1984, NEUROBIOLOGY LEARNIN, P65
   Moeller FG, 2007, AM J DRUG ALCOHOL AB, V33, P367, DOI 10.1080/00952990701313686
   Mogenson G., 1984, PROG NEUROBIOL, V14, P69
   Monfils MH, 2009, SCIENCE, V324, P951, DOI 10.1126/science.1167975
   Moore RJ, 1998, SYNAPSE, V30, P88, DOI 10.1002/(SICI)1098-2396(199809)30:1<88::AID-SYN11>3.0.CO;2-L
   Murray J.E., 2013, 51 ANN M AM COLL NEU, pM5
   Murray JE, 2014, BIOL PSYCHIAT, V76, P15, DOI 10.1016/j.biopsych.2013.09.011
   Murray JE, 2012, NEUROPSYCHOPHARMACOL, V37, P2456, DOI 10.1038/npp.2012.104
   Murray JE, 2012, ADDICT BIOL, V17, P437, DOI 10.1111/j.1369-1600.2011.00330.x
   Myers KM, 2012, BIOL PSYCHIAT, V71, P947, DOI 10.1016/j.biopsych.2012.02.030
   Nader K, 2000, NAT REV NEUROSCI, V1, P216, DOI 10.1038/35044580
   Nader K, 2000, NATURE, V406, P722, DOI 10.1038/35021052
   Nader MA, 2002, NEUROPSYCHOPHARMACOL, V27, P35, DOI 10.1016/S0893-133X(01)00427-4
   Nelson A, 2006, J NEUROSCI, V26, P3805, DOI 10.1523/JNEUROSCI.4305-05.2006
   Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578
   Nestler EJ, 2014, NEUROPHARMACOLOGY, V76, P259, DOI 10.1016/j.neuropharm.2013.04.004
   O'Brien CP, 1998, J PSYCHOPHARMACOL, V12, P15, DOI 10.1177/026988119801200103
   O'Doherty J, 2004, SCIENCE, V304, P452, DOI 10.1126/science.1094285
   OBrien CP, 1996, LANCET, V347, P237, DOI 10.1016/S0140-6736(96)90409-2
   Olmstead MC, 2000, PSYCHOPHARMACOLOGY, V152, P123, DOI 10.1007/s002130000498
   Olmstead MC, 2001, BEHAV NEUROSCI, V115, P394, DOI 10.1037/0735-7044.115.2.394
   Ostlund SB, 2005, J NEUROSCI, V25, P7763, DOI 10.1523/JNEUROSCI.1921-05.2005
   Ostlund SB, 2007, ANN NY ACAD SCI, V1121, P174, DOI 10.1196/annals.1401.033
   Palfai T, 1999, EXP CLIN PSYCHOPHARM, V7, P266, DOI 10.1037/1064-1297.7.3.266
   Park CB, 2014, CYBERPSYCH BEH SOC N, V17, P262, DOI 10.1089/cyber.2013.0253
   Parkinson JA, 2000, EUR J NEUROSCI, V12, P405, DOI 10.1046/j.1460-9568.2000.00960.x
   Parkinson JA, 2001, BRAIN COGNITION, V47, P40
   Parkinson JA, 1999, J NEUROSCI, V19, P2401
   Paterson NE, 2014, AM J DRUG ALCOHOL AB, V40, P1, DOI 10.3109/00952990.2013.858723
   Pelloux Y, 2007, PSYCHOPHARMACOLOGY, V194, P127, DOI 10.1007/s00213-007-0805-0
   Pelloux Y, 2013, EUR J NEUROSCI, V38, P3018, DOI 10.1111/ejn.12289
   Pelloux Y, 2012, NEUROPSYCHOPHARMACOL, V37, P2505, DOI 10.1038/npp.2012.111
   PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295
   Pickens CL, 2011, TRENDS NEUROSCI, V34, P411, DOI 10.1016/j.tins.2011.06.001
   Pilla M, 1999, NATURE, V400, P371, DOI 10.1038/43944
   Piray P, 2010, NEURAL COMPUT, V22, P2334, DOI 10.1162/NECO_a_00009
   Porrino LJ, 2004, J NEUROSCI, V24, P3554, DOI 10.1523/JNEUROSCI.5578-03.2004
   Price KL, 2013, PSYCHOPHARMACOLOGY, V226, P739, DOI 10.1007/s00213-011-2592-x
   Reissner KJ, 2010, BEHAV PHARMACOL, V21, P514, DOI 10.1097/FBP.0b013e32833d41b2
   Robbins TW, 2008, ANN NY ACAD SCI, V1141, P1, DOI 10.1196/annals.1441.020
   Robbins TW, 2012, TRENDS COGN SCI, V16, P81, DOI 10.1016/j.tics.2011.11.009
   Robbins TW, 1999, NATURE, V398, P567, DOI 10.1038/19208
   Robbins TW, 2002, NEUROBIOL LEARN MEM, V78, P625, DOI 10.1006/nlme.2002.4103
   ROBBINS TW, 1989, NEUROSCI BIOBEHAV R, V13, P155, DOI 10.1016/S0149-7634(89)80025-9
   ROBERTS DCS, 1982, PHARMACOL BIOCHEM BE, V17, P901, DOI 10.1016/0091-3057(82)90469-5
   Robinson MJF, 2007, BEHAV BRAIN RES, V182, P129, DOI 10.1016/j.bbr.2007.05.023
   ROBINSON TE, 1988, BRAIN RES, V462, P211, DOI 10.1016/0006-8993(88)90549-5
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Rogers RD, 1999, NEUROPSYCHOPHARMACOL, V20, P322, DOI 10.1016/S0893-133X(98)00091-8
   Russo SJ, 2010, TRENDS NEUROSCI, V33, P267, DOI 10.1016/j.tins.2010.02.002
   Sanchez H, 2010, J NEUROSCI, V30, P4401, DOI 10.1523/JNEUROSCI.3149-09.2010
   Schiller D, 2010, NATURE, V463, P49, DOI 10.1038/nature08637
   Schoenbaum G, 2005, NEURON, V47, P633, DOI 10.1016/j.neuron.2005.07.018
   Schoenbaum G, 2008, BIOL PSYCHIAT, V63, P256, DOI 10.1016/j.biopsych.2007.06.003
   Schulteis G, 2000, NATURE, V405, P1013, DOI 10.1038/35016630
   See RE, 2003, ANN NY ACAD SCI, V985, P294
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P1, DOI 10.1007/s00213-003-1469-z
   Shalev U, 2002, PHARMACOL REV, V54, P1, DOI 10.1124/pr.54.1.1
   Shiflett MW, 2010, J NEUROSCI, V30, P2951, DOI 10.1523/JNEUROSCI.1778-09.2010
   Soyka M, 2014, INT J NEUROPSYCHOPH, V17, P675, DOI 10.1017/S1461145713001284
   Stewart J, 2004, NEBR SYM MOTIV, V50, P197
   STEWART J, 1984, PSYCHOL REV, V91, P251, DOI 10.1037/0033-295X.91.2.251
   Takahashi Y, 2007, FRONT INTEGR NEUROSC, V1, DOI 10.3389/neuro.07.011.2007
   Taylor JR, 2009, NEUROPHARMACOLOGY, V56, P186, DOI 10.1016/j.neuropharm.2008.07.027
   Thorn CA, 2010, NEURON, V66, P781, DOI 10.1016/j.neuron.2010.04.036
   Tiffany ST, 2000, ADDICTION, V95, P1106, DOI 10.1046/j.1360-0443.2000.957110613.x
   TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147
   Torregrossa MM, 2008, BIOL PSYCHIAT, V63, P253, DOI 10.1016/j.biopsych.2007.11.014
   Torregrossa MM, 2013, PSYCHOPHARMACOLOGY, V226, P659, DOI 10.1007/s00213-012-2750-9
   Torregrossa MM, 2010, J NEUROSCI, V30, P10526, DOI 10.1523/JNEUROSCI.2523-10.2010
   Valjent E, 2006, P NATL ACAD SCI USA, V103, P2932, DOI 10.1073/pnas.0511030103
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Vayalapalli S, 2011, AM J ADDICTION, V20, P485, DOI 10.1111/j.1521-0391.2011.00162.x
   Velazquez-Sanchez C, 2014, NEUROPSYCHOPHARMACOL, V39, P2463, DOI 10.1038/npp.2014.98
   Verdejo-Garcia A, 2006, J INT NEUROPSYCH SOC, V12, P405, DOI 10.1017/S1355617706060486
   Volkow N, 2005, NAT NEUROSCI, V8, P1429, DOI 10.1038/nn1105-1429
   Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI 10.1093/cercor/10.3.318
   VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210
   Volkow ND, 2001, AM J PSYCHIAT, V158, P2015, DOI 10.1176/appi.ajp.158.12.2015
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
   Vollstadt-Klein S, 2010, ADDICTION, V105, P1741, DOI 10.1111/j.1360-0443.2010.03022.x
   VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876
   Waters RP, 2014, PSYCHOPHARMACOLOGY, V231, P3197, DOI 10.1007/s00213-014-3497-2
   WEEKS JR, 1962, SCIENCE, V138, P143, DOI 10.1126/science.138.3537.143
   Whitelaw RB, 1996, PSYCHOPHARMACOLOGY, V127, P213, DOI 10.1007/BF02805996
   WIKLER A, 1973, ARCH GEN PSYCHIAT, V28, P611
   Wikler A., 1965, NARCOTICS, P7
   Willuhn I, 2014, NAT NEUROSCI, V17, P704, DOI 10.1038/nn.3694
   Willuhn I, 2012, P NATL ACAD SCI USA, V109, P20703, DOI 10.1073/pnas.1213460109
   Winstanley CA, 2004, J NEUROSCI, V24, P4718, DOI 10.1523/JNEUROSCI.5606-03.2004
   Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406
   Wise RA, 2008, NEUROTOX RES, V14, P169, DOI 10.1007/BF03033808
   Wright CI, 1996, J NEUROSCI, V16, P1877
   Xie C, 2014, MOL PSYCHIATR, V19, P10, DOI 10.1038/mp.2012.169
   Xue YX, 2012, SCIENCE, V336, P241, DOI 10.1126/science.1215070
   Yahyavi-Firouz-Abadi N, 2009, PHARMACOL THERAPEUT, V124, P235, DOI 10.1016/j.pharmthera.2009.06.014
   Yin HH, 2006, BEHAV BRAIN RES, V166, P189, DOI 10.1016/j.bbr.2005.07.012
   Yin HH, 2005, EUR J NEUROSCI, V22, P505, DOI 10.1111/j.1460-9568.2005.04219.x
   Yin HH, 2005, EUR J NEUROSCI, V22, P513, DOI 10.1111/j.1460-9568.2005.04218.x
   Yin HH, 2004, EUR J NEUROSCI, V19, P181, DOI 10.1111/j.1460-9568.2004.03095.x
   Young KA, 2014, J NEUROSCI, V34, P5038, DOI 10.1523/JNEUROSCI.4977-13.2014
   Zapata A, 2010, J NEUROSCI, V30, P15457, DOI 10.1523/JNEUROSCI.4072-10.2010
   Zhou WH, 2008, BIOL PSYCHIAT, V63, P338, DOI 10.1016/j.biopsych.2007.06.008
   Zilberman ML, 2007, J ADDICT DIS, V26, P79, DOI 10.1300/J069v26n01_10
NR 270
TC 217
Z9 221
U1 5
U2 107
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0953-816X
EI 1460-9568
J9 EUR J NEUROSCI
JI Eur. J. Neurosci.
PD JUL
PY 2014
VL 40
IS 1
BP 2163
EP 2182
DI 10.1111/ejn.12644
PG 20
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology
GA AL6QJ
UT WOS:000339257400001
PM 24935353
OA Green Published, hybrid
DA 2023-06-23
ER

PT C
AU Bonfilgio, NS
   Renati, R
   Pessa, E
   Penna, MP
AF Bonfilgio, Natale Salvatore
   Renati, Roberta
   Pessa, Eliano
   Penna, Maria Pietronilla
GP IEEE
TI The influence of resilience factors in the treatment of substances
   addiction A Multylayer Perceptron Predictive Model
SO 2018 IEEE INTERNATIONAL SYMPOSIUM ON MEDICAL MEASUREMENTS AND
   APPLICATIONS (MEMEA)
SE IEEE International Symposium on Medical Measurements and Applications
   Proceedings-MeMeA
LA English
DT Proceedings Paper
CT 13th IEEE International Symposium on Medical Measurements and
   Applications (MeMeA)
CY JUN 11-13, 2018
CL Engn Sch, Rome, ITALY
SP IEEE, IEEE Instrumentat & Measurement Soc
HO Engn Sch
DE neural network; addiction; stress; resilience; coping
ID DRUG-ADDICTION; STRESS; ADOLESCENCE; ALCOHOL; REWARD
AB Scientific literature gives more and more importance to the stress-coping model in the framework of drug addiction. Recently, studies have highlighted resilience as a crucial element of the stress-coping model. In this work stress-coping-resilience is presented as an elective model to treat addictions. Through the use of neural networks, a Multilayer Perceptron is simulated with the aim of understanding the importance that stress-copingresilience model variables have in influencing the seriousness of addiction. Results show the correctness of the model underlining the importance of resilience factors and coping strategies in the treatment of addiction.
C1 [Bonfilgio, Natale Salvatore; Renati, Roberta; Pessa, Eliano] Univ Pavia, Dept Brain & Behav Sci, Pavia, Italy.
   [Penna, Maria Pietronilla] Univ Cagliari, Dept Pedag, Psychol, Philosophy, Cagliari, Italy.
C3 University of Pavia; University of Cagliari
RP Bonfilgio, NS (通讯作者)，Univ Pavia, Dept Brain & Behav Sci, Pavia, Italy.
EM salvo.bonfiglio@unipv.it; roberta.renati@unipv.it; pessa@unipv.it;
   penna@unica.it
RI salvatore, bonfiglio/AEG-9820-2022
CR Bonfiglio Natale S., 2012, RESILIENZA TRA RISCH
   Bonfiglio NS, 2014, SECOND WORLD CONGRESS ON RESILIENCE: FROM PERSON TO SOCIETY, P41
   Bonfiglio NS, 2016, PSYCHOL ADDICT BEHAV, V30, P509, DOI 10.1037/adb0000176
   COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404
   Compas BE, 2001, PSYCHOL BULL, V127, P87, DOI 10.1037//0033-2909.127.1.87
   Crabbe JC, 2002, ANNU REV PSYCHOL, V53, P435, DOI 10.1146/annurev.psych.53.100901.135142
   Folkman S, 2004, ANNU REV PSYCHOL, V55, P745, DOI 10.1146/annurev.psych.55.090902.141456
   Friborg O, 2005, INT J METH PSYCH RES, V14, P29, DOI 10.1002/mpr.15
   Hiroi N, 2005, MOL PSYCHIATR, V10, P336, DOI 10.1038/sj.mp.4001622
   Kaufman J, 2007, BIOL PSYCHIAT, V61, P1228, DOI 10.1016/j.biopsych.2006.06.039
   Konopka A, 2013, PROG NEURO-PSYCHOPH, V40, P229, DOI 10.1016/j.pnpbp.2012.09.001
   Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Lee EH, 2012, ASIAN NURS RES, V6, P121, DOI 10.1016/j.anr.2012.08.004
   Leshner AI, 1999, JAMA-J AM MED ASSOC, V282, P1314, DOI 10.1001/jama.282.14.1314
   Lopez-Goni JJ, 2008, INT J SOC WELF, V17, P374, DOI 10.1111/j.1468-2397.2008.00584.x
   Lopez-Quintero C, 2011, ADDICTION, V106, P657, DOI 10.1111/j.1360-0443.2010.03194.x
   Luthar S. S., 1997, DEV PSYCHOPATHOLOGY
   Luthar SS, 2000, CHILD DEV, V71, P543, DOI 10.1111/1467-8624.00164
   McLellan AT, 2006, AM J ADDICTION, V15, P113, DOI 10.1080/10550490500528316
   MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006
   Nibuya M., 2012, POSTTRAUMATIC STRESS, P141
   Rutter M, 2006, J CHILD PSYCHOL PSYC, V47, P226, DOI 10.1111/j.1469-7610.2005.01557.x
   RUTTER M, 1987, AM J ORTHOPSYCHIAT, V57, P316, DOI 10.1111/j.1939-0025.1987.tb03541.x
   Scherbaum N., 2008, INT J METHODS PSYCHI, V17
   Sica C., PERSONALITY INDIVIDU, V23, P1025
   Simpson DD, 1997, J SUBST ABUSE TREAT, V14, P565, DOI 10.1016/S0740-5472(97)00181-5
   Skinner Ellen A, 2007, Annu Rev Psychol, V58, P119, DOI 10.1146/annurev.psych.58.110405.085705
   Trucco EM, 2011, ADDICT BEHAV, V36, P729, DOI 10.1016/j.addbeh.2011.02.008
   Uhl GR, 2004, ARCH GEN PSYCHIAT, V61, P223, DOI 10.1001/archpsyc.61.3.223
   Ungar M, 2011, AM J ORTHOPSYCHIAT, V81, P1, DOI 10.1111/j.1939-0025.2010.01067.x
   Wagner EF, 1999, ADDICT BEHAV, V24, P769, DOI 10.1016/S0306-4603(99)00058-1
   WERNER EE, 1989, SCI AM, V260, P106, DOI 10.1038/scientificamerican0489-106
   WILLS TA, 1986, HEALTH PSYCHOL, V5, P503, DOI 10.1037/0278-6133.5.6.503
NR 34
TC 3
Z9 3
U1 0
U2 0
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 978-1-5386-3392-2
J9 IEEE INT SYM MED MEA
PY 2018
BP 809
EP 813
PG 5
WC Engineering, Biomedical
WE Conference Proceedings Citation Index - Science (CPCI-S)
SC Engineering
GA BO2FP
UT WOS:000505594000141
DA 2023-06-23
ER

PT J
AU Edwards, G
AF Edwards, G
TI Drug addiction and drug policy: the struggle to control dependence
SO ADDICTION
LA English
DT Book Review
CR Brownsberger W.N., 2001, DRUG ADDICTION DRUG, P51
   MACCOUN RJ, 2001, DRUG WAR HERESIES LE
NR 2
TC 0
Z9 0
U1 0
U2 0
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 0965-2140
J9 ADDICTION
JI Addiction
PD MAR
PY 2002
VL 97
IS 3
BP 365
EP 366
PG 2
WC Substance Abuse; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry
GA 532GF
UT WOS:000174465400024
DA 2023-06-23
ER

PT J
AU Muller, CP
   Schumann, G
AF Mueller, Christian P.
   Schumann, Gunter
TI To use or not to use: Expanding the view on non-addictive psychoactive
   drug consumption and its implications
SO BEHAVIORAL AND BRAIN SCIENCES
LA English
DT Article
ID ETHANOL DRINKING; ALCOHOL-USE; PERCEIVED FUNCTIONS; SOCIAL OPPORTUNITY;
   INTERNET ADDICTION; NICHE CONSTRUCTION; SUBSTANCE USE; SELF-ESTEEM;
   EXERCISE; COCAINE
AB Proposing a change to the view on psychoactive drug use in non-addicts touches a sensitive issue because of its potential implications to addiction prevention, therapeutic practice, and drug policy. Commentators raised nine questions that ranged from clarifications, suggested extensions of the model to supporting data previously not regarded, to assumptions on the implications of the model. Here, we take up the suggestions of the commentators to expand the model to behavioral addictions, discuss additional instrumentalization goals, and review the evidence from laboratory animal studies on drug instrumentalization. We consider further the role of sociocultural factors and individual development in the establishment in drug instrumentalization and addiction. Finally, we clarify which implications we think this model may have. We conclude that drug instrumentalization theory can be further applied to other behaviors but will require a sensitive debate when used for drug and addiction policy that directly affects prevention and treatment.
C1 [Mueller, Christian P.] Univ Erlangen Nurnberg, Dept Psychiat & Psychotherapy, Sect Addict Med, D-91054 Erlangen, Germany.
   [Mueller, Christian P.; Schumann, Gunter] Kings Coll London, Inst Psychiat, MRC SGDP Ctr, London SE5 8AF, England.
C3 University of Erlangen Nuremberg; University of London; King's College
   London
RP Muller, CP (通讯作者)，Univ Erlangen Nurnberg, Dept Psychiat & Psychotherapy, Sect Addict Med, D-91054 Erlangen, Germany.
EM christian.mueller@uk-erlangen.de; Gunter.Schumann@kcl.ac.uk
RI Schumann, Gunter/H-1013-2013
OI Muller, Christian/0000-0002-5325-9900
CR Abel EL., 1980, MARIHUANA 1 12000 YE
   Ahmed SH, 2010, NEUROSCI BIOBEHAV R, V35, P172, DOI 10.1016/j.neubiorev.2010.04.005
   ALEXANDER BK, 1987, J DRUG ISSUES, V17, P47, DOI 10.1177/002204268701700104
   ALEXANDER BK, 1990, J DRUG ISSUES, V20, P29
   Allegre B, 2006, ADDICT RES THEORY, V14, P631, DOI 10.1080/16066350600903302
   Andersen SL, 2009, NEUROSCI BIOBEHAV R, V33, P516, DOI 10.1016/j.neubiorev.2008.09.009
   ANDREASSON S, 1987, LANCET, V2, P1483, DOI 10.1016/s0140-6736(87)92620-1
   ANDREASSON S, 1989, ACTA PSYCHIAT SCAND, V79, P505, DOI 10.1111/j.1600-0447.1989.tb10296.x
   Atran S, 2004, BEHAV BRAIN SCI, V27, P713, DOI 10.1017/S0140525X04000172
   Behrendt S, 2009, DRUG ALCOHOL DEPEN, V99, P68, DOI 10.1016/j.drugalcdep.2008.06.014
   Black DW, 1997, AM J PSYCHIAT, V154, P243
   Blomeyer D, 2008, BIOL PSYCHIAT, V63, P146, DOI 10.1016/j.biopsych.2007.04.026
   Boys A, 1999, ADDICTION, V94, P1043, DOI 10.1046/j.1360-0443.1999.94710439.x
   Boys A, 2003, ADDICTION, V98, P951, DOI 10.1046/j.1360-0443.2003.00394.x
   Bray GA, 2000, NUTRITION, V16, P953, DOI 10.1016/S0899-9007(00)00424-X
   Burke RJ, 2004, PSYCHOL REP, V94, P457
   Cantin L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011592
   DAVIES J. B., 1997, MYTH ADDICTION
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   DONOVAN JE, 1985, J CONSULT CLIN PSYCH, V53, P890, DOI 10.1037/0022-006X.53.6.890
   Garcia FD, 2010, AM J DRUG ALCOHOL AB, V36, P254, DOI 10.3109/00952990.2010.503823
   Geyer MA, 2008, TRENDS PHARMACOL SCI, V29, P445, DOI 10.1016/j.tips.2008.06.006
   GOODMAN A, 1992, J SEX MARITAL THER, V18, P303, DOI 10.1080/00926239208412855
   Gouzoulis-Mayfrank Euphrosyne, 2009, Dialogues Clin Neurosci, V11, P305
   Grant BF, 1997, J SUBST ABUSE, V9, P103, DOI 10.1016/S0899-3289(97)90009-2
   Griffiths M, 2001, J SEX RES, V38, P333, DOI 10.1080/00224490109552104
   Griffiths M, 1993, J GAMBL STUD, V9, P133
   Griffiths M. D., 2005, J SUBST USE, V10, P191, DOI [10.1080/14659890500114359, DOI 10.1080/14659890500114359]
   Griffiths M.D., 1996, J WORKPLACE LEARNING, V8, P19, DOI 10.1108/13665629610116872
   GRILO CM, 2011, INT J EATING DISORDE
   GUCCIARDI E, 2004, BMC WOMENS HLTH S1, V4, pS21, DOI DOI 10.1186/1472-6874-4-S1-S21
   Hale BD, 2010, BODY IMAGE, V7, P234, DOI 10.1016/j.bodyim.2010.02.001
   HARDING W M, 1977, P111
   Harper C, 2007, HUM EXP TOXICOL, V26, P251, DOI 10.1177/0960327107070499
   Hatcher A S, 1989, Nurse Pract, V14, P13
   Hausenblas HA, 2002, PSYCHOL SPORT EXERC, V3, P89, DOI 10.1016/S1469-0292(00)00015-7
   Heath D. B., 2000, DRINKING OCCASIONS C
   Hesse M, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-50
   Hill EM, 2002, ADDICTION, V97, P401, DOI 10.1046/j.1360-0443.2002.00020.x
   Hodge CW, 2006, ALCOHOL CLIN EXP RES, V30, P203, DOI 10.1111/j.1530-0277.2006.00024.x
   Husain M, 2011, TRENDS COGN SCI, V15, P28, DOI 10.1016/j.tics.2010.11.002
   JAY M, 2010, HIGH SOCIETY
   Kalman Thomas P, 2008, J Am Acad Psychoanal Dyn Psychiatry, V36, P593, DOI 10.1521/jaap.2008.36.4.593
   Kendal J, 2011, PHILOS T R SOC B, V366, P785, DOI 10.1098/rstb.2010.0306
   Laland KN, 2010, NAT REV GENET, V11, P137, DOI 10.1038/nrg2734
   Laland KN, 2000, BEHAV BRAIN SCI, V23, P131, DOI 10.1017/S0140525X00002417
   Laucht M, 2009, BIOL PSYCHIAT, V66, P102, DOI 10.1016/j.biopsych.2009.02.010
   Leigh BC, 2004, ADDICTION, V99, P215, DOI 10.1111/j.1360-0443.2003.00641.x
   Lende DH, 2007, ADDICT RES THEORY, V15, P465, DOI 10.1080/16066350701284552
   Lenoir M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000698
   Leonard KE, 1999, J STUD ALCOHOL, P130, DOI 10.15288/jsas.1999.s13.130
   MALOFF D, 1981, CONTROL OVER INTOXIC, P5
   MARKS I, 1990, BRIT J ADDICT, V85, P1389
   MARTINSEN EW, 1990, SPORTS MED, V9, P380, DOI 10.2165/00007256-199009060-00006
   Matthews TJ, 2005, BEHAV NEUROSCI, V119, P1628, DOI 10.1037/0735-7044.119.6.1628
   MILLERTUTZAUER C, 1991, J STUD ALCOHOL, V52, P434, DOI 10.15288/jsa.1991.52.434
   Moreira T., 2009, COCHRANE DB SYST REV, V3, DOI [10.1002/14651858.CD006748.pub2, 10.1002/14651858, DOI 10.1002/14651858]
   Mumenthaler MS, 1998, PSYCHOPHARMACOLOGY, V140, P38, DOI 10.1007/s002130050736
   NATHANSON JA, 1993, P NATL ACAD SCI USA, V90, P9645, DOI 10.1073/pnas.90.20.9645
   NEGRETE JC, 1993, CANNABIS: PHYSIOPATHOLOGY, EPIDEMIOLOGY, DETECTION, P105
   Nichols DE, 2004, PHARMACOL THERAPEUT, V101, P131, DOI 10.1016/j.pharmthera.2003.11.002
   Niemz K, 2005, CYBERPSYCHOL BEHAV, V8, P562, DOI 10.1089/cpb.2005.8.562
   Nilsen P, 2008, ACTA OBSTET GYN SCAN, V87, P768, DOI 10.1080/00016340802179830
   Paluska SA, 2000, SPORTS MED, V29, P167, DOI 10.2165/00007256-200029030-00003
   Panksepp JB, 2007, GENES BRAIN BEHAV, V6, P661, DOI 10.1111/j.1601-183X.2006.00295.x
   Parsons OA, 1998, ALCOHOL CLIN EXP RES, V22, P954, DOI 10.1097/00000374-199806000-00029
   PASCUALLEONE A, 1991, NEUROTOXICOLOGY, V12, P393
   PEYNAULD E, 1995, HOHE SCHULE WEINKENN
   PRESTON KL, 1991, BEHAV PHARMACOL, V2, P293
   Ray R, 2009, ANNU REV MED, V60, P247, DOI 10.1146/annurev.med.60.041707.160511
   Rehbein F, 2010, CYBERPSYCH BEH SOC N, V13, P269, DOI 10.1089/cyber.2009.0227
   Rehm J, 2003, EUR ADDICT RES, V9, P147, DOI 10.1159/000072221
   Richardson NR, 1996, J NEUROSCI METH, V66, P1, DOI 10.1016/0165-0270(95)00153-0
   Robbins TW, 1999, NATURE, V398, P567, DOI 10.1038/19208
   Roessler KK, 2010, SCAND J PUBLIC HEALT, V38, P664, DOI 10.1177/1403494810371249
   RUCK CAP, 1979, J PSYCHEDEL DRUG, V11, P145, DOI 10.1080/02791072.1979.10472098
   RUSSELL MAH, 1974, J ROY STAT SOC A STA, V137, P313, DOI 10.2307/2344953
   Ryan DH, 2000, CURR OPIN GASTROEN, V16, P166, DOI 10.1097/00001574-200003000-00012
   Sahakian B, 2007, NATURE, V450, P1157, DOI 10.1038/4501157a
   Seiden L S, 1996, NIDA Res Monogr, V163, P251
   Shaffer HJ, 2004, HARVARD REV PSYCHIAT, V12, P367, DOI 10.1080/10673220490905705
   Shaw M, 2008, CNS DRUGS, V22, P353, DOI 10.2165/00023210-200822050-00001
   Skog OJ, 2000, ADDICTION, V95, P1309, DOI 10.1046/j.1360-0443.2000.95913091.x
   SLATER PE, 1980, WEALTH ADDICTION
   SNAITH P, 1993, PSYCHOL MED, V23, P957, DOI 10.1017/S0033291700026428
   SOLOWIJ N, 1998, CANNABIS COGNITIVE F
   SPEALMAN RD, 1978, ANNU REV PHARMACOL, V18, P313, DOI 10.1146/annurev.pa.18.040178.001525
   SPENCE JT, 1992, J PERS ASSESS, V58, P160, DOI 10.1207/s15327752jpa5801_15
   STREATFEILD D, 2001, COCAINE
   Sullivan RJ, 2002, ADDICTION, V97, P389, DOI 10.1046/j.1360-0443.2002.00024.x
   Tomie A, 2006, PHARMACOL BIOCHEM BE, V83, P307, DOI 10.1016/j.pbb.2006.02.012
   Tomie A, 2005, ALCOHOL, V35, P43, DOI 10.1016/j.alcohol.2004.11.005
   Tomie A, 2004, PROG NEURO-PSYCHOPH, V28, P1089, DOI 10.1016/j.pnpbp.2004.05.044
   Tomie A, 2004, ALCOHOL ALCOHOLISM, V39, P197, DOI 10.1093/alcalc/agh055
   Ussher MH, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002295.pub3
   van Erp AMM, 2001, PHYSIOL BEHAV, V73, P301, DOI 10.1016/S0031-9384(01)00458-9
   van Erp AMM, 2001, BEHAV PHARMACOL, V12, P335, DOI 10.1097/00008877-200109000-00004
   Van Leijenhorst L, 2010, CEREB CORTEX, V20, P61, DOI 10.1093/cercor/bhp078
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   VOLKOW ND, 1992, SYNAPSE, V11, P184, DOI 10.1002/syn.890110303
   Ward RJ, 2009, ALCOHOL ALCOHOLISM, V44, P128, DOI 10.1093/alcalc/agn100
   Weinstein A, 2010, AM J DRUG ALCOHOL AB, V36, P277, DOI 10.3109/00952990.2010.491880
   Wiens F, 2008, P NATL ACAD SCI USA, V105, P10426, DOI 10.1073/pnas.0801628105
   Wood RI, 2004, PHYSIOL BEHAV, V83, P279, DOI 10.1016/j.physbeh.2004.08.012
   Zinberg N E, 1978, Ann N Y Acad Sci, V311, P10, DOI 10.1111/j.1749-6632.1978.tb16759.x
   Zinberg NE., 1984, DRUG SET SETTING BAS
NR 106
TC 38
Z9 38
U1 0
U2 31
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0140-525X
EI 1469-1825
J9 BEHAV BRAIN SCI
JI Behav. Brain Sci.
PD DEC
PY 2011
VL 34
IS 6
BP 328
EP 347
DI 10.1017/S0140525X1100135X
PG 20
WC Psychology, Biological; Behavioral Sciences; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology; Behavioral Sciences; Neurosciences & Neurology
GA 857UT
UT WOS:000297748500021
PM 22379623
DA 2023-06-23
ER

PT C
AU Mews, P
   Walker, DM
   Nestler, EJ
AF Mews, Philipp
   Walker, Deena M.
   Nestler, Eric J.
BE Stewart, D
   Stillman, B
TI Epigenetic Priming in Drug Addiction
SO BRAINS AND BEHAVIOR: ORDER AND DISORDER IN THE NERVOUS SYSTEM
SE Cold Spring Harbor Symposia on Quantitative Biology
LA English
DT Proceedings Paper
CT 83rd Cold Spring Harbor Symposium on Quantitative Biology
CY MAY 30-JUN 03, 2018
CL Cold Spring Harbor Lab, Cold Spring Harbor, NY
SP Agilent Technologies, Bristol Myers Squibb Co, Calico Labs, Celgene, Genentech Inc, Thermo Fisher Sci, Merck, Monsanto Co, New England BioLabs, Pfizer
HO Cold Spring Harbor Lab
ID COCAINE-INDUCED PLASTICITY; NUCLEUS-ACCUMBENS; HISTONE ACETYLATION;
   CHROMATIN REGULATION; MECHANISMS; BRAIN; INHIBITION; INDUCTION; LTP; D1
AB Drug addiction is a chronic relapsing brain disorder that is characterized by compulsive drug seeking and continued use despite negative outcomes. Current pharmacological therapies target neuronal receptors or transporters upon which drugs of abuse act initially, yet these treatments remain ineffective for most individuals and do not prevent disease relapse after abstinence. Drugs of abuse, in addition to their acute effects, cause persistent plasticity after repeated use, involving dysregulated gene expression in the brain's reward regions, which are thought to mediate the persistent behavioral abnormalities that characterize addiction. Emerging evidence implicates epigenetic priming as a key mechanism that underlies the long-lasting alterations in neuronal gene regulation, which can remain latent until triggered by re-exposure to drug-associated stimuli or the drug itself. Thus, to effectively treat drug addiction, we must identify the precise epigenetic mechanisms that establish and preserve the drug-induced pathology of the brain reward circuitry.
C1 [Mews, Philipp; Walker, Deena M.; Nestler, Eric J.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, Dept Neurosci, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai
RP Mews, P; Nestler, EJ (通讯作者)，Icahn Sch Med Mt Sinai, Friedman Brain Inst, Dept Neurosci, New York, NY 10029 USA.
EM philipp.mews@mssm.edu; eric.nestler@mssm.edu
RI Walker, Deena/GOE-5789-2022
OI Mews, Philipp/0000-0003-2052-1578
FU NIDA NIH HHS [R01 DA007359, R37 DA007359, K99 DA042100] Funding Source:
   Medline
CR Baker DA, 2003, NAT NEUROSCI, V6, P743, DOI 10.1038/nn1069
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Bastle RM, 2019, CURR OPIN BEHAV SCI, V25, P57, DOI 10.1016/j.cobeha.2018.07.004
   Berndsen CE, 2008, CURR OPIN STRUC BIOL, V18, P682, DOI 10.1016/j.sbi.2008.11.004
   Bibb JA, 2001, NATURE, V410, P376, DOI 10.1038/35066591
   Bose J, 2018, HHS PUBL, VSMA 18-5068
   Bridi MS, 2017, NEUROPSYCHOPHARMACOL, V42, P1243, DOI 10.1038/npp.2016.253
   Buenrostro Jason D, 2015, Curr Protoc Mol Biol, V109, DOI 10.1002/0471142727.mb2129s109
   Calipari ES, 2016, P NATL ACAD SCI USA, V113, P2726, DOI 10.1073/pnas.1521238113
   Cates HM, 2018, BIOL PSYCHIAT, V84, P167, DOI 10.1016/j.biopsych.2017.11.027
   Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876
   Conrad KL, 2008, NATURE, V454, P118, DOI 10.1038/nature06995
   Day JJ, 2011, NEURON, V70, P813, DOI 10.1016/j.neuron.2011.05.019
   Dong Y, 2014, TRENDS PHARMACOL SCI, V35, P374, DOI 10.1016/j.tips.2014.05.005
   Feng J, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-4-r65
   Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286
   Graff J, 2013, NAT REV NEUROSCI, V14, P97, DOI 10.1038/nrn3427
   Graham DL, 2007, NAT NEUROSCI, V10, P1029, DOI 10.1038/nn1929
   Grueter BA, 2013, P NATL ACAD SCI USA, V110, P1923, DOI 10.1073/pnas.1221742110
   Hamilton PJ, 2018, METHODS MOL BIOL, V1767, P113, DOI 10.1007/978-1-4939-7774-1_5
   HOPE BT, 1994, NEURON, V13, P1235, DOI 10.1016/0896-6273(94)90061-2
   Huang YY, 2013, NEUROPHARMACOLOGY, V74, P126, DOI 10.1016/j.neuropharm.2013.03.031
   Kau KS, 2008, NEUROSCIENCE, V155, P530, DOI 10.1016/j.neuroscience.2008.06.010
   Kennedy PJ, 2013, NAT NEUROSCI, V16, P434, DOI 10.1038/nn.3354
   Koob GF, 2016, LANCET PSYCHIAT, V3, P760, DOI 10.1016/S2215-0366(16)00104-8
   Kourrich S, 2007, J NEUROSCI, V27, P7921, DOI 10.1523/JNEUROSCI.1859-07.2007
   Kreek MJ, 2005, NAT NEUROSCI, V8, P1450, DOI 10.1038/nn1583
   Kumar A, 2005, NEURON, V48, P303, DOI 10.1016/j.neuron.2005.09.023
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Levine A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003062
   Lobo MK, 2010, SCIENCE, V330, P385, DOI 10.1126/science.1188472
   Maze I, 2011, P NATL ACAD SCI USA, V108, P3035, DOI 10.1073/pnas.1015483108
   Maze I, 2010, SCIENCE, V327, P213, DOI 10.1126/science.1179438
   Mews P, 2018, SOC NEUR ABS, V161, P04
   Mews P, 2017, PROG BRAIN RES, V235, P19, DOI 10.1016/bs.pbr.2017.08.012
   Mews P, 2017, NATURE, V546, P381, DOI 10.1038/nature22405
   Nestler EJ, 2014, NEUROPHARMACOLOGY, V76, P259, DOI 10.1016/j.neuropharm.2013.04.004
   Pierce RC, 1996, J NEUROSCI, V16, P1550
   Reid MS, 1996, NEUROREPORT, V7, P1325, DOI 10.1097/00001756-199605170-00022
   Renthal W, 2009, NEURON, V62, P335, DOI 10.1016/j.neuron.2009.03.026
   Rivera CM, 2013, CELL, V155, P39, DOI 10.1016/j.cell.2013.09.011
   Robison AJ, 2011, NAT REV NEUROSCI, V12, P623, DOI 10.1038/nrn3111
   Rogge GA, 2013, NEUROPSYCHOPHARMACOL, V38, P94, DOI 10.1038/npp.2012.154
   Schroeder FA, 2008, NEUROPSYCHOPHARMACOL, V33, P2981, DOI 10.1038/npp.2008.15
   Sheng J, 2011, NEUROREPORT, V22, P575, DOI 10.1097/WNR.0b013e328348e6aa
   Surmeier DJ, 2007, TRENDS NEUROSCI, V30, P228, DOI 10.1016/j.tins.2007.03.008
   Walker DM, 2018, BIOL PSYCHIAT, V84, P867, DOI 10.1016/j.biopsych.2018.04.009
   Walker DM, 2015, CURR OPIN NEUROBIOL, V30, P112, DOI 10.1016/j.conb.2014.11.002
   Whitaker LR, 2018, LEARN MEMORY, V25, P455, DOI 10.1101/lm.046698.117
   Zhang JY, 2014, J MOL NEUROSCI, V52, P261, DOI [10.1007/s12031-013-0134-1, 10.1007/s12031-014-0317-4]
NR 50
TC 9
Z9 9
U1 1
U2 3
PU COLD SPRING HARBOR LABORATORY PRESS
PI PLAINVIEW
PA 10 SKYLINE DRIVE, PLAINVIEW, NY 11803-2500 USA
SN 0091-7451
EI 1943-4456
BN 978-1-621823-35-3
J9 COLD SH Q B
JI Cold Spring Harbor Symp. Quant. Biol.
PY 2018
VL 83
BP 131
EP 139
DI 10.1101/sqb.2018.83.037663
PG 9
WC Behavioral Sciences; Neurosciences
WE Conference Proceedings Citation Index - Science (CPCI-S)
SC Behavioral Sciences; Neurosciences & Neurology
GA BQ2LX
UT WOS:000582302800015
PM 30936392
OA gold, Green Accepted
DA 2023-06-23
ER

PT C
AU Liba, J
   Portik, M
AF Liba, Jozef
   Portik, Milan
BE Rehulka, E
TI TEACHER PROFESSION IN THE CONTEXT OF PRIMARY PREVENTION TO DRUG
   ADDDICTION
SO UCITELE A ZDRAVI 6 - 6TH CONFERENCE TEACHERS AND HEALTH
LA English
DT Proceedings Paper
CT 6th Conference on Teachers and Health
CY 2004
CL Brno, CZECH REPUBLIC
DE Healthy life style; primary prevention; drug addiction; professional
   competence of teacher; formative authority of school
AB The abstract presents the indispensable role of school, especially its forming influence in the process if initiating, forming, and acceptance of healthy life-style principles. The emphasis is on the preventive possibilities and the growing responsibility of school in relation to socially undesirable phenomena, primarily the drug addiction. In addition, the authors outline the properties and the expected competence of an effective teacher in the context of primary prevention of drug addiction.
C1 [Liba, Jozef; Portik, Milan] Presovska Univ, Fak Humanitnych & Prirodnych Vied, Katedra Pedagog, Presov 08001, Slovakia.
C3 University of Presov
EM libajo@unipo.sk; portik@unipo.sk
NR 0
TC 0
Z9 0
U1 0
U2 2
PU PAIDO
PI BRNO
PA SRBSKA 35, BRNO, 612 00, CZECH REPUBLIC
BN 978-80-7315-093-8
PY 2004
BP 515
EP 521
PG 7
WC Education & Educational Research; Public, Environmental & Occupational
   Health; Psychology, Social
WE Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)
SC Education & Educational Research; Public, Environmental & Occupational
   Health; Psychology
GA BJC39
UT WOS:000264734800038
DA 2023-06-23
ER

PT J
AU Rodrigues, LCM
   Gobira, PH
   de Oliveira, AC
   Pelicao, R
   Teixeira, AL
   Moreira, FA
   Campos, AC
AF Rodrigues, Livia C. M.
   Gobira, Pedro H.
   de Oliveira, Antonio Carlos
   Pelicao, Renan
   Teixeira, Antonio Lucio
   Moreira, Fabricio A.
   Campos, Alline Cristina
TI Neuroinflammation as a possible link between cannabinoids and addiction
SO ACTA NEUROPSYCHIATRICA
LA English
DT Review
DE addiction; alcohol; cannabinoids; cocaine; neuroinflammation
ID CB1 RECEPTOR ANTAGONIST; CONDITIONED PLACE PREFERENCE; BRAIN-STIMULATION
   REWARD; TUMOR-NECROSIS-FACTOR; KAPPA-B BINDING; ENDOCANNABINOID SYSTEM;
   ALCOHOL DEPENDENCE; NUCLEUS-ACCUMBENS; AMPHETAMINE SENSITIZATION;
   INFLAMMATORY RESPONSES
AB Rodrigues LCM, Gobira PH, de Oliveira AC, Pelicao R, Teixeira AL, Moreira FA, Campos AC. Neuroinflammation as a possible link between cannabinoids and addiction.
   Objective: Substance dependence disorder is a chronically relapsing condition characterised by neurobiological changes leading to loss of control in restricting a substance intake, compulsion and withdrawal syndrome. In the past few years, (endo) cannabinoids have been raised as a possible target in the aetiology of drug addiction. On the other hand, although the exact mechanisms of the genesis of addiction remain poorly understood, it is possible that neuroinflammation might also play a role in the pathophysiology of this condition. Studies demonstrated that (endo) cannabinoids act as immunomodulators by inhibiting cytokines production and microglial cell activation. Thus, in the present review, we explore the possible role of neuroinflammation on the therapeutic effects of cannabinoids on drug addiction.
   Methods: We conducted an evidence-based review of the literature in order to assess the role of cannabinoids on the neuroinflammatory hypothesis of addiction (terms: addiction, cannabinoids and inflammation). We searched PubMed and BioMedCentral databases up to April 2014 with no date restrictions.
   Results: In all, 165 eligible articles were included in the present review. Existing evidence suggests that disruption in cannabinoid signalling during the drug addiction process leads to microglial activation and neuroinflammation.
   Conclusion: The literature showed that inflammation and changes in endocannabinod signalling occur in drug abuse; however, it remains uncertain whether these changes are causally or coincidentally associated with addiction. Additional studies, therefore, are needed to elucidate the contribution of neuroinflammation on the behavioural and neuroprotective effects of cannabinoids on drug addiction.
C1 [Rodrigues, Livia C. M.; Pelicao, Renan] Univ Fed Espirito Santo, Dept Physiol Sci, Hlth Sci Ctr, Vitoria, Brazil.
   [Gobira, Pedro H.; de Oliveira, Antonio Carlos; Moreira, Fabricio A.] Univ Fed Minas Gerais, Dept Pharmacol, Inst Biol Sci, Belo Horizonte, MG, Brazil.
   [Teixeira, Antonio Lucio; Campos, Alline Cristina] Univ Fed Minas Gerais, Grp Neuroimmunol, Lab Immunopharmacol, Inst Biol Sci, Belo Horizonte, MG, Brazil.
   [Teixeira, Antonio Lucio; Campos, Alline Cristina] Univ Fed Minas Gerais, Infect Dis & Trop Med Program, Sch Med, Belo Horizonte, MG, Brazil.
C3 Universidade Federal do Espirito Santo; Universidade Federal de Minas
   Gerais; Universidade Federal de Minas Gerais; Universidade Federal de
   Minas Gerais
RP de Oliveira, AC (通讯作者)，Univ Fed Minas Gerais, Interdisciplinary Lab Med Invest, Dept Internal Med, Infect Dis & Trop Med Grad Program,Sch Med, Av Alfredo Balena, Belo Horizonte, MG, Brazil.
EM allinecampos@usp.br
RI Campos, Alline Cristina/A-8343-2013; Gobira, Pedro/ABD-2653-2020;
   Gobira, Pedro/P-3067-2015; de Oliveira, Antonio CP/F-1661-2013;
   Teixeira, Antonio L/N-3315-2014
OI Campos, Alline Cristina/0000-0003-4258-3198; de Oliveira, Antonio
   CP/0000-0003-3217-4294; Teixeira, Antonio L/0000-0002-9621-5422;
   Moreira, Fabricio/0000-0002-0824-7302
FU CNPq; CAPES; FAPES [53630408/2011]; FAPEMIG [CBB-APQ-04389-10,
   CBB-APQ-04625-10]; Pro-Reitoria de Pesquisa da UFMG (PRPq), Brazil
FX The authors thank Radael Junior for his technical support in relation to
   design and graphic art. This work was supported by grants from CNPq,
   CAPES, FAPES (Programa Primeiros Projetos (PPP) number 53630408/2011)
   and FAPEMIG (Programa Primeiros Projetos (PPP), number CBB-APQ-04389-10;
   Programa de Apoio a Nucleos Emergentes de Pesquisa (PRONEM), number
   CBB-APQ-04625-10) and Pro-Reitoria de Pesquisa da UFMG (PRPq), Brazil.
   FAM and ALT are recipients of productivity research fellowships (level 2
   and 1C, respectively) from CNPq. ACC is a recipient of CAPES fellowship.
CR Adamczyk P, 2009, J PHYSIOL PHARMACOL, V60, P119
   AGRAWAL RG, 2001, BRAIN BEHAV IMMUN S1, V25, pS165
   Albayram O, 2011, P NATL ACAD SCI USA, V108, P11256, DOI 10.1073/pnas.1016442108
   Alvaro-Bartolome M, 2013, NEUROSCIENCE, V247, P294, DOI 10.1016/j.neuroscience.2013.05.035
   American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th
   Anggadiredja K, 2004, NEUROPSYCHOPHARMACOL, V29, P1470, DOI 10.1038/sj.npp.1300454
   Aracil-Fernandez A, 2012, NEUROPSYCHOPHARMACOL, V37, P1749, DOI 10.1038/npp.2012.22
   Arnold JC, 2005, PHARMACOL BIOCHEM BE, V81, P396, DOI 10.1016/j.pbb.2005.02.015
   Ashton JC, 2007, CURR OPIN INVEST DR, V8, P373
   Atwood BK, 2010, BRIT J PHARMACOL, V160, P467, DOI 10.1111/j.1476-5381.2010.00729.x
   Avila AH, 2003, J PHARMACOL EXP THER, V305, P290, DOI 10.1124/jpet.102.045989
   Basavarajappa BS, 2006, NEUROPHARMACOLOGY, V50, P834, DOI 10.1016/j.neuropharm.2005.12.005
   BLANK SE, 1991, ALCOHOL CLIN EXP RES, V15, P16, DOI 10.1111/j.1530-0277.1991.tb00514.x
   Bloomfield MAP, 2014, BIOL PSYCHIAT, V75, P470, DOI 10.1016/j.biopsych.2013.05.027
   BOGDAL J, 1976, Archivum Immunologiae et Therapiae Experimentalis, V24, P799
   Caille S, 2007, J NEUROSCI, V27, P3695, DOI 10.1523/JNEUROSCI.4403-06.2007
   Castane A, 2002, NEUROPHARMACOLOGY, V43, P857, DOI 10.1016/S0028-3908(02)00118-1
   Centonze D, 2004, NEUROPSYCHOPHARMACOL, V29, P1488, DOI 10.1038/sj.npp.1300458
   Chaperon F, 1998, PSYCHOPHARMACOLOGY, V135, P324, DOI 10.1007/s002130050518
   CHEN JP, 1990, PSYCHOPHARMACOLOGY, V102, P156, DOI 10.1007/BF02245916
   Chiva-Blanch G, 2012, AM J CLIN NUTR, V95, P326, DOI 10.3945/ajcn.111.022889
   Clark KH, 2013, NEUROTOX RES, V23, P174, DOI 10.1007/s12640-012-9334-7
   Cohen C, 2002, BEHAV PHARMACOL, V13, P451, DOI 10.1097/00008877-200209000-00018
   Cohen C, 2005, PHARMACOL BIOCHEM BE, V81, P387, DOI 10.1016/j.pbb.2005.01.024
   COHEN PR, 1993, PEDIATR DERMATOL, V10, P245, DOI 10.1111/j.1525-1470.1993.tb00369.x
   Collino M, 2006, EUR J PHARMACOL, V530, P70, DOI 10.1016/j.ejphar.2005.11.049
   Colombo G, 2007, MOL NEUROBIOL, V36, P102, DOI 10.1007/s12035-007-0017-y
   Combs CK, 2000, J NEUROSCI, V20, P558, DOI 10.1523/JNEUROSCI.20-02-00558.2000
   Cook RT, 2000, ALCOHOL CLIN EXP RES, V24, P241
   Corbille AG, 2007, J NEUROSCI, V27, P6937, DOI 10.1523/JNEUROSCI.3936-06.2007
   Correa F, 2005, BRIT J PHARMACOL, V145, P441, DOI 10.1038/sj.bjp.0706215
   Cossu G, 2001, BEHAV BRAIN RES, V118, P61, DOI 10.1016/S0166-4328(00)00311-9
   Croxford JL, 2003, J CLIN INVEST, V111, P1231, DOI 10.1172/JCI200317652
   De Vries TJ, 2005, TRENDS PHARMACOL SCI, V26, P420, DOI 10.1016/j.tips.2005.06.002
   DEVANE WA, 1988, MOL PHARMACOL, V34, P605
   Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495
   Ehrhart J, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-29
   Eisenstein SA, 2009, SYNAPSE, V63, P941, DOI 10.1002/syn.20679
   Eljaschewitsch E, 2006, NEURON, V49, P67, DOI 10.1016/j.neuron.2005.11.027
   Enayatfard L, 2013, NEUROMOL MED, V15, P523, DOI 10.1007/s12017-013-8238-x
   Espinosa-Oliva AM, 2014, NEUROTOXICOLOGY, V41, P89, DOI 10.1016/j.neuro.2014.01.006
   Fang H, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-27
   Fattore L, 2003, EUR J NEUROSCI, V17, P1723, DOI 10.1046/j.1460-9568.2003.02607.x
   Filip M, 2006, PHARMACOL REP, V58, P806
   Fitzgerald ML, 2012, PROG NEURO-PSYCHOPH, V38, P21, DOI 10.1016/j.pnpbp.2011.12.004
   FOLL LE, 2004, NEUROREPORT, V15, P2139
   Freund TF, 2003, PHYSIOL REV, V83, P1017, DOI 10.1152/physrev.00004.2003
   GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x
   Gallate JE, 1999, EUR J PHARMACOL, V370, P233, DOI 10.1016/S0014-2999(99)00170-3
   Gan XH, 1998, CLIN IMMUNOL IMMUNOP, V89, P181, DOI 10.1006/clin.1998.4607
   GARDNER EL, 1988, PSYCHOPHARMACOLOGY, V96, P142, DOI 10.1007/BF02431546
   GARDNER EL, 1991, PHARMACOL BIOCHEM BE, V40, P571, DOI 10.1016/0091-3057(91)90365-9
   Gardner EL, 1998, NEUROBIOL DIS, V5, P502, DOI 10.1006/nbdi.1998.0219
   Gelfandt EV, 2006, EXPERT OPIN INV DRUG, V15, P307, DOI 10.1517/13543784.15.3.307
   George DT, 2010, PSYCHOPHARMACOLOGY, V208, P37, DOI 10.1007/s00213-009-1704-3
   Gessa GL, 2005, ALCOHOL ALCOHOLISM, V40, P46, DOI 10.1093/alcalc/agh114
   Gonzalez S, 2004, BRIT J PHARMACOL, V143, P455, DOI 10.1038/sj.bjp.0705963
   Gonzalez S, 2002, DRUG ALCOHOL DEPEN, V66, P77, DOI 10.1016/S0376-8716(01)00186-7
   Gutierrez-Lopez MD, 2010, BRIT J PHARMACOL, V160, P772, DOI 10.1111/j.1476-5381.2010.00720.x
   HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991
   Hermann H, 2002, NEUROSCIENCE, V109, P451, DOI 10.1016/S0306-4522(01)00509-7
   HILLARD CJ, 1986, BIOCHEM PHARMACOL, V35, P2797, DOI 10.1016/0006-2952(86)90192-9
   HO BT, 1994, CYTOKINE, V6, P365, DOI 10.1016/1043-4666(94)90059-0
   Hungund BL, 2003, J NEUROCHEM, V84, P698, DOI 10.1046/j.1471-4159.2003.01576.x
   Hutchinson MR, 2008, BRAIN BEHAV IMMUN, V22, P1248, DOI 10.1016/j.bbi.2008.07.008
   Ignatowska-Jankowska BM, 2013, PSYCHOPHARMACOLOGY, V229, P591, DOI 10.1007/s00213-013-3117-6
   Iversen L, 2003, BRAIN, V126, P1252, DOI 10.1093/brain/awg143
   Luque-Rojas MJ, 2013, INT J NEUROPSYCHOPH, V16, P661, DOI 10.1017/S1461145712000569
   Justinova Z, 2005, J NEUROSCI, V25, P5645, DOI 10.1523/JNEUROSCI.0951-05.2005
   Justinova Z, 2003, PSYCHOPHARMACOLOGY, V169, P135, DOI 10.1007/s00213-003-1484-0
   Justinova Z, 2011, J NEUROSCI, V31, P7043, DOI 10.1523/JNEUROSCI.6058-10.2011
   Justinova Z, 2009, CURR TOP BEHAV NEURO, V1, P309, DOI 10.1007/978-3-540-88955-7_13
   Katona I, 2008, NAT MED, V14, P923, DOI 10.1038/nm.f.1869
   Kerr DM, 2013, BRIT J PHARMACOL, V169, P808, DOI 10.1111/j.1476-5381.2012.02237.x
   KHORUTS A, 1991, HEPATOLOGY, V13, P267, DOI 10.1002/hep.1840130211
   Klein TW, 1998, J NEUROIMMUNOL, V83, P102, DOI 10.1016/S0165-5728(97)00226-9
   Klein TW, 2003, J LEUKOCYTE BIOL, V74, P486, DOI 10.1189/jlb.0303101
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Kovacs KJ, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00074
   Le Foll B, 2013, CURR DRUG TARGETS, V14, P768
   Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401
   Lee YW, 2001, J NEUROSCI RES, V66, P583, DOI 10.1002/jnr.1248
   Liu PCC, 2003, J STEROID BIOCHEM, V85, P71, DOI 10.1016/S0960-0760(03)00135-3
   Llorente-Garcia E, 2009, J PHYSIOL BIOCHEM, V65, P61, DOI 10.1007/BF03165970
   Maldonado R, 2006, TRENDS NEUROSCI, V29, P225, DOI 10.1016/j.tins.2006.01.008
   Mandrekar P, 2002, ALCOHOL CLIN EXP RES, V26, P1872, DOI 10.1097/01.ALC.0000042220.48841.9E
   MANSBACH RS, 1994, BEHAV PHARMACOL, V5, P219, DOI 10.1097/00008877-199404000-00014
   MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0
   Matute C, 2002, EUR J PHARMACOL, V447, P239, DOI 10.1016/S0014-2999(02)01847-2
   Mechoulam R, 2000, CHEM PHYS LIPIDS, V108, P1, DOI 10.1016/S0009-3084(00)00184-5
   Merighi S, 2012, BRIT J PHARMACOL, V166, P2371, DOI 10.1111/j.1476-5381.2012.01948.x
   Merighi S, 2012, BRIT J PHARMACOL, V165, P1773, DOI 10.1111/j.1476-5381.2011.01673.x
   Mestre L, 2005, J NEUROCHEM, V92, P1327, DOI 10.1111/j.1471-4159.2004.02979.x
   Mnich SJ, 2010, J PHARMACOL EXP THER, V333, P445, DOI 10.1124/jpet.109.163998
   Morales M, 2012, NAT MED, V18, P504, DOI 10.1038/nm.2722
   Muldoon PP, 2013, LIFE SCI, V92, P458, DOI 10.1016/j.lfs.2012.05.015
   Murray RM, 2007, NAT REV NEUROSCI, V8, P885, DOI 10.1038/nrn2253
   Nakajima A, 2004, J NEUROSCI, V24, P2212, DOI 10.1523/JNEUROSCI.4847-03.2004
   Navarrete CM, 2009, J NEUROCHEM, V109, P452, DOI 10.1111/j.1471-4159.2009.05966.x
   Navarro M, 2001, J NEUROSCI, V21, P5344, DOI 10.1523/JNEUROSCI.21-14-05344.2001
   Nicolaou C, 2004, ALCOHOL, V32, P243, DOI 10.1016/j.alcohol.2004.02.004
   Nomura DK, 2011, SCIENCE, V334, P809, DOI 10.1126/science.1209200
   O'SULLIVAN S, 2006, P INT CANN RES SOC I, P59
   Onaivi ES, 2011, CURR NEUROPHARMACOL, V9, P205, DOI 10.2174/157015911795017416
   Onaivi ES, 2008, ANN NY ACAD SCI, V1139, P412, DOI 10.1196/annals.1432.056
   Ortega-Alvaro A, 2015, ADDICT BIOL, V20, P43, DOI 10.1111/adb.12076
   Ortega-Gutierrez S, 2005, CNS NEUROL DISORD-DR, V4, P697, DOI 10.2174/156800705774933032
   Pascual M, 2011, IMMUNOL CELL BIOL, V89, P716, DOI 10.1038/icb.2010.163
   Pava MJ, 2012, ALCOHOL, V46, P185, DOI 10.1016/j.alcohol.2012.01.002
   Peters EN, 2014, DRUG ALCOHOL DEPEN, V134, P228, DOI 10.1016/j.drugalcdep.2013.10.003
   Pettinati HM, 2013, AM J PSYCHIAT, V170, P23, DOI 10.1176/appi.ajp.2012.12010112
   Raby WN, 2009, AM J ADDICTION, V18, P301, DOI 10.1080/10550490902927785
   RAMAMOORTHY S, 1995, BIOCHEM BIOPH RES CO, V216, P560, DOI 10.1006/bbrc.1995.2659
   Ramesh D, 2013, NEUROPSYCHOPHARMACOL, V38, P1039, DOI 10.1038/npp.2012.269
   Redwine L, 2003, PSYCHOSOM MED, V65, P75, DOI 10.1097/01.PSY.0000038943.33335.D2
   Rigotti NA, 2009, ADDICTION, V104, P266, DOI 10.1111/j.1360-0443.2008.02454.x
   Rockwell CE, 2004, J PHARMACOL EXP THER, V311, P683, DOI 10.1124/jpet.104.065524
   Rockwell CE, 2006, MOL PHARMACOL, V70, P101, DOI 10.1124/mol.105.019117
   Runkorg K, 2012, BEHAV BRAIN RES, V226, P335, DOI 10.1016/j.bbr.2011.09.005
   Sadasivan S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033693
   Sanchis-Segura C, 2006, ADDICT BIOL, V11, P2, DOI 10.1111/j.1369-1600.2006.00012.x
   Sancho R, 2003, MOL PHARMACOL, V63, P429, DOI 10.1124/mol.63.2.429
   Scavone JL, 2013, NEUROSCIENCE, V248, P637, DOI 10.1016/j.neuroscience.2013.04.034
   Schleifer SJ, 2006, BRAIN BEHAV IMMUN, V20, P80, DOI 10.1016/j.bbi.2005.05.006
   Schlosburg JE, 2009, AAPS J, V11, P342, DOI 10.1208/s12248-009-9110-7
   Serra S, 2001, EUR J PHARMACOL, V430, P369, DOI 10.1016/S0014-2999(01)01379-6
   Serrano A, 2011, PHARMACOL THERAPEUT, V132, P215, DOI 10.1016/j.pharmthera.2011.06.005
   Shah A, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-52
   Shi J, 2010, J IMMUNOL, V184, P7207, DOI 10.4049/jimmunol.0903487
   Solinas M, 2004, EUR J NEUROSCI, V19, P3183, DOI 10.1111/j.0953-816X.2004.03420.x
   Solinas M, 2007, PHARMACOL RES, V56, P393, DOI 10.1016/j.phrs.2007.09.005
   Solinas M, 2006, J NEUROCHEM, V98, P408, DOI 10.1111/j.1471-4159.2006.03880.x
   Soria G, 2005, NEUROPSYCHOPHARMACOL, V30, P1670, DOI 10.1038/sj.npp.1300707
   Soyka M, 2008, J CLIN PSYCHOPHARM, V28, P317, DOI 10.1097/JCP.0b013e318172b8bc
   Stahel PF, 2008, PPAR RES, V2008, DOI 10.1155/2008/538141
   Sun Y, 2007, PPAR RES, V2007, DOI 10.1155/2007/23513
   Szabo G, 2011, ALCOHOL CLIN EXP RES, V35, P782, DOI 10.1111/j.1530-0277.2010.01398.x
   Szabo G, 2007, PANCREATOLOGY, V7, P115, DOI 10.1159/000104236
   Tanda G, 2000, NAT NEUROSCI, V3, P1073, DOI 10.1038/80577
   Tanda G, 2003, PSYCHOPHARMACOLOGY, V169, P115, DOI 10.1007/s00213-003-1485-z
   Tanda G, 1997, SCIENCE, V276, P2048, DOI 10.1126/science.276.5321.2048
   Thanos PK, 2005, BEHAV BRAIN RES, V164, P206, DOI 10.1016/j.bbr.2005.06.021
   Thiemann G, 2008, BEHAV BRAIN RES, V187, P289, DOI 10.1016/j.bbr.2007.09.022
   Thomas DM, 2008, J NEUROCHEM, V106, P696, DOI 10.1111/j.1471-4159.2008.05421.x
   Tucci S, 2010, CURR DRUG TARGETS, V11, P392, DOI 10.2174/138945010790980286
   Ueda Natsuo, 1998, Journal of Medical Investigation, V45, P27
   UNODOC, 2013, WORLD DRUG REP
   Valjent E, 2002, BRIT J PHARMACOL, V135, P564, DOI 10.1038/sj.bjp.0704479
   Vaughn LK, 2012, NEUROSCIENCE, V204, P117, DOI 10.1016/j.neuroscience.2011.08.021
   Vinklerova J, 2002, J PSYCHOPHARMACOL, V16, P139, DOI 10.1177/026988110201600204
   Wiley JL, 1999, PHARMACOL BIOCHEM BE, V64, P257, DOI 10.1016/S0091-3057(99)00059-3
   Wiskerke J, 2008, ADDICT BIOL, V13, P225, DOI 10.1111/j.1369-1600.2008.00109.x
   Xi ZX, 2008, NEUROPSYCHOPHARMACOL, V33, P1735, DOI 10.1038/sj.npp.1301552
   Xi ZX, 2011, NAT NEUROSCI, V14, P1160, DOI 10.1038/nn.2874
   Xi ZX, 2009, ACTA PHARMACOL SIN, V30, P723, DOI 10.1038/aps.2009.46
   Xi ZX, 2004, PSYCHOPHARMACOLOGY, V176, P57, DOI 10.1007/s00213-004-1858-y
   Yamada K, 2004, ANN NY ACAD SCI, V1025, P198, DOI 10.1196/annals.1316.025
   Zalcman S, 1999, BRAIN RES, V847, P276, DOI 10.1016/S0006-8993(99)02063-6
   Zalcman SS, 2001, BRAIN RES, V899, P1, DOI 10.1016/S0006-8993(01)02090-X
   Zhang J, 2008, J BIOL CHEM, V283, P22601, DOI 10.1074/jbc.M800524200
   Zhao YN, 2013, BEHAV BRAIN RES, V236, P270, DOI 10.1016/j.bbr.2012.08.052
NR 161
TC 17
Z9 18
U1 0
U2 14
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1601-5215
J9 ACTA NEUROPSYCHIATR
JI Acta Neuropsychiatr.
PD DEC
PY 2014
VL 26
IS 6
BP 334
EP 346
DI 10.1017/neu.2014.24
PG 13
WC Neurosciences; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Psychiatry
GA AW5RM
UT WOS:000346331700003
PM 25455257
DA 2023-06-23
ER

PT J
AU Ersche, KD
   Jones, PS
   Williams, GB
   Turton, AJ
   Robbins, TW
   Bullmore, ET
AF Ersche, Karen D.
   Jones, P. Simon
   Williams, Guy B.
   Turton, Abigail J.
   Robbins, Trevor W.
   Bullmore, Edward T.
TI Abnormal Brain Structure Implicated in Stimulant Drug Addiction
SO SCIENCE
LA English
DT Article
ID SUBSTANCE USE DISORDERS; BASAL GANGLIA; RESPONSE-INHIBITION; COCAINE
   DEPENDENCE; PREFRONTAL CORTEX; TEMPORAL-LOBE; IMPULSIVITY; MEMORY;
   REINFORCEMENT; SYSTEMS
AB Addiction to drugs is a major contemporary public health issue, characterized by maladaptive behavior to obtain and consume an increasing amount of drugs at the expense of the individual's health and social and personal life. We discovered abnormalities in fronto-striatal brain systems implicated in self-control in both stimulant-dependent individuals and their biological siblings who have no history of chronic drug abuse; these findings support the idea of an underlying neurocognitive endophenotype for stimulant drug addiction.
C1 [Ersche, Karen D.; Jones, P. Simon; Williams, Guy B.; Turton, Abigail J.; Robbins, Trevor W.; Bullmore, Edward T.] Univ Cambridge, Behav & Clin Neurosci Inst, Cambridge CB2 3EB, England.
   [Ersche, Karen D.; Jones, P. Simon; Williams, Guy B.; Turton, Abigail J.; Robbins, Trevor W.; Bullmore, Edward T.] Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England.
   [Ersche, Karen D.; Jones, P. Simon; Williams, Guy B.; Turton, Abigail J.; Robbins, Trevor W.; Bullmore, Edward T.] Univ Cambridge, Dept Psychiat, Cambridge CB2 3EB, England.
   [Williams, Guy B.] Univ Cambridge, Wolfson Brain Imaging Ctr, Dept Clin Neurosci, Cambridge CB2 0QQ, England.
   [Bullmore, Edward T.] GlaxoSmithKline Inc, Clin Unit Cambridge, Addenbrookes Ctr Clin Invest, Cambridge CB2 2GG, England.
   [Bullmore, Edward T.] Natl Hlth Serv Trust, Cambridgeshire & Peterborough Fdn, Cambridge CB21 5EF, England.
C3 University of Cambridge; University of Cambridge; University of
   Cambridge; University of Cambridge; GlaxoSmithKline
RP Ersche, KD (通讯作者)，Univ Cambridge, Behav & Clin Neurosci Inst, Cambridge CB2 3EB, England.
EM ke220@cam.ac.uk
RI Robbins, Trevor W/A-7551-2008; Bullmore, Ed/C-1706-2012
OI Bullmore, Ed/0000-0002-8955-8283; Robbins, Trevor/0000-0003-0642-5977;
   Williams, Guy/0000-0001-5223-6654
FU Wellcome Trust Clinical Research Facility at Addenbrooke's Hospital;
   Wolfson Brain Imaging Centre; U.K. Medical Research Council (MRC); MRC;
   Wellcome Trust; Medical Research Council [G0001354, G0001354B,
   G1000183B, G0701497] Funding Source: researchfish; MRC [G0701497]
   Funding Source: UKRI
FX The authors thank all volunteers for their participation in this study
   and the clinical study officers at the Mental Health Research Network
   for their dedicated support with volunteer recruitment. The authors are
   grateful to the staff at the Wellcome Trust Clinical Research Facility
   at Addenbrooke's Hospital and the Wolfson Brain Imaging Centre for their
   help and support throughout the study. This work was funded by the U.K.
   Medical Research Council (MRC) and conducted within the Behavioral and
   Clinical Neuroscience Institute at the University of Cambridge, which is
   jointly funded by the MRC and the Wellcome Trust. K. D. E., P.S.J., and
   A.J.T. are supported by a research grant of the MRC. T. W. R. and A.J.T.
   consult for Cambridge Cognition. E. T. B. is employed 50% by
   GlaxoSmithKline and 50% by the University of Cambridge. K. D. E.,
   P.S.J., and G. B. W. declare that they have no conflicts of interest.
CR Aron AR, 2007, J NEUROSCI, V27, P3743, DOI 10.1523/JNEUROSCI.0519-07.2007
   Belin D, 2009, BEHAV BRAIN RES, V199, P89, DOI 10.1016/j.bbr.2008.09.027
   Breiter HC, 1997, NEURON, V19, P591, DOI 10.1016/S0896-6273(00)80374-8
   Casey BJ, 2010, J AM ACAD CHILD PSY, V49, P1189, DOI 10.1016/j.jaac.2010.08.017
   Dalley JW, 2007, SCIENCE, V315, P1267, DOI 10.1126/science.1137073
   Ersche KD, 2011, BRAIN, V134, P2013, DOI 10.1093/brain/awr138
   Ersche KD, 2010, BIOL PSYCHIAT, V68, P770, DOI 10.1016/j.biopsych.2010.06.015
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   George O, 2010, NEUROSCI BIOBEHAV R, V35, P232, DOI 10.1016/j.neubiorev.2010.05.002
   Gottesman II, 2003, AM J PSYCHIAT, V160, P636, DOI 10.1176/appi.ajp.160.4.636
   Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040
   Graybiel AM, 1995, CURR OPIN NEUROBIOL, V5, P733, DOI 10.1016/0959-4388(95)80100-6
   Hammers A, 2003, HUM BRAIN MAPP, V19, P224, DOI 10.1002/hbm.10123
   Kroener S, 2010, NEUROPSYCHOPHARMACOL, V35, P2292, DOI 10.1038/npp.2010.107
   Kwon JS, 2003, J NEUROL NEUROSUR PS, V74, P962, DOI 10.1136/jnnp.74.7.962
   Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Li CSR, 2006, DRUG ALCOHOL DEPEN, V85, P205, DOI 10.1016/j.drugalcdep.2006.04.008
   Logan GD, 1997, PSYCHOL SCI, V8, P60, DOI 10.1111/j.1467-9280.1997.tb00545.x
   Madsen KS, 2010, NEUROPSYCHOLOGIA, V48, P854, DOI 10.1016/j.neuropsychologia.2009.11.001
   Merikangas KR, 1998, ARCH GEN PSYCHIAT, V55, P973, DOI 10.1001/archpsyc.55.11.973
   Nigg JT, 2006, J AM ACAD CHILD PSY, V45, P468, DOI 10.1097/01.chi.0000199028.76452.a9
   Padmala S, 2010, NEUROPSYCHOLOGIA, V48, P558, DOI 10.1016/j.neuropsychologia.2009.10.017
   Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024
   SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849
   Tabibnia G, 2011, J NEUROSCI, V31, P4805, DOI 10.1523/JNEUROSCI.2859-10.2011
   Tarter RE, 2003, AM J PSYCHIAT, V160, P1078, DOI 10.1176/appi.ajp.160.6.1078
   Wright IC, 2002, NEUROIMAGE, V17, P256, DOI 10.1006/nimg.2002.1163
   Yin HH, 2006, NAT REV NEUROSCI, V7, P464, DOI 10.1038/nrn1919
NR 29
TC 385
Z9 401
U1 9
U2 154
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD FEB 3
PY 2012
VL 335
IS 6068
BP 601
EP 604
DI 10.1126/science.1214463
PG 4
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 885HI
UT WOS:000299769200048
PM 22301321
DA 2023-06-23
ER

PT J
AU Shurtleff, D
   Sasek, C
   Kautz, M
AF Shurtleff, David
   Sasek, Cathrine
   Kautz, Mary
TI Sponsor's foreword: NIDA at forty Foreword
SO NEUROPHARMACOLOGY
LA English
DT Editorial Material
ID DRUG-ADDICTION; NEUROBIOLOGICAL MECHANISMS; SMOKING-CESSATION; COCAINE
   ADDICTION; REWARD; VULNERABILITY; RECEPTOR; FUTURE; ABUSE; MODEL
C1 [Shurtleff, David; Sasek, Cathrine; Kautz, Mary] NIDA, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute on
   Drug Abuse (NIDA)
RP Sasek, C (通讯作者)，NIDA, Off Sci Policy & Commun, 6001 Execut Blvd,Rm 5230,MSC 9991, Bethesda, MD 20892 USA.
EM csasek@nih.gov
CR Ashare RL, 2014, NEUROPHARMACOLOGY, V76, P581, DOI 10.1016/j.neuropharm.2013.04.034
   Bickel WK, 2014, NEUROPHARMACOLOGY, V76, P518, DOI 10.1016/j.neuropharm.2013.06.013
   Bierut LJ, 2014, NEUROPHARMACOLOGY, V76, P592, DOI 10.1016/j.neuropharm.2013.09.009
   Calu DJ, 2014, NEUROPHARMACOLOGY, V76, P395, DOI 10.1016/j.neuropharm.2013.04.030
   Carelli RM, 2014, NEUROPHARMACOLOGY, V76, P360, DOI 10.1016/j.neuropharm.2013.04.025
   Charbogne P, 2014, NEUROPHARMACOLOGY, V76, P204, DOI 10.1016/j.neuropharm.2013.08.028
   Cunningham KA, 2014, NEUROPHARMACOLOGY, V76, P460, DOI 10.1016/j.neuropharm.2013.06.030
   Deroche-Gamonet V, 2014, NEUROPHARMACOLOGY, V76, P437, DOI 10.1016/j.neuropharm.2013.07.014
   Flagel SB, 2014, NEUROPHARMACOLOGY, V76, P425, DOI 10.1016/j.neuropharm.2013.04.033
   Fowler CD, 2014, NEUROPHARMACOLOGY, V76, P533, DOI 10.1016/j.neuropharm.2013.09.008
   Gipson CD, 2014, NEUROPHARMACOLOGY, V76, P276, DOI 10.1016/j.neuropharm.2013.04.032
   Hurd YL, 2014, NEUROPHARMACOLOGY, V76, P416, DOI 10.1016/j.neuropharm.2013.07.028
   Hutchinson MR, 2014, NEUROPHARMACOLOGY, V76, P218, DOI 10.1016/j.neuropharm.2013.05.039
   Ikemoto S, 2014, NEUROPHARMACOLOGY, V76, P329, DOI 10.1016/j.neuropharm.2013.04.031
   Jentsch JD, 2014, NEUROPHARMACOLOGY, V76, P479, DOI 10.1016/j.neuropharm.2013.05.022
   Jupp B, 2014, NEUROPHARMACOLOGY, V76, P487, DOI 10.1016/j.neuropharm.2013.05.041
   Koob GF, 2014, NEUROPHARMACOLOGY, V76, P370, DOI 10.1016/j.neuropharm.2013.05.024
   Lammel S, 2014, NEUROPHARMACOLOGY, V76, P351, DOI 10.1016/j.neuropharm.2013.03.019
   Li X, 2014, NEUROPHARMACOLOGY, V76, P554, DOI 10.1016/j.neuropharm.2013.05.042
   Loweth JA, 2014, NEUROPHARMACOLOGY, V76, P287, DOI 10.1016/j.neuropharm.2013.04.061
   Lucantonio F, 2014, NEUROPHARMACOLOGY, V76, P407, DOI 10.1016/j.neuropharm.2013.05.033
   Mantsch JR, 2014, NEUROPHARMACOLOGY, V76, P383, DOI 10.1016/j.neuropharm.2013.07.021
   McNally GP, 2014, NEUROPHARMACOLOGY, V76, P528, DOI 10.1016/j.neuropharm.2013.06.007
   Nader MA, 2014, NEUROPHARMACOLOGY, V76, P510, DOI 10.1016/j.neuropharm.2013.05.044
   Neisewander JL, 2014, NEUROPHARMACOLOGY, V76, P301, DOI 10.1016/j.neuropharm.2013.08.014
   Nestler EJ, 2014, NEUROPHARMACOLOGY, V76, P259, DOI 10.1016/j.neuropharm.2013.04.004
   O'Dell LE, 2014, NEUROPHARMACOLOGY, V76, P566, DOI 10.1016/j.neuropharm.2013.04.055
   Parker CC, 2014, NEUROPHARMACOLOGY, V76, P250, DOI 10.1016/j.neuropharm.2013.05.047
   Pasternak GW, 2014, NEUROPHARMACOLOGY, V76, P198, DOI 10.1016/j.neuropharm.2013.03.039
   Paulus MP, 2014, NEUROPHARMACOLOGY, V76, P342, DOI 10.1016/j.neuropharm.2013.07.002
   Picciotto MR, 2014, NEUROPHARMACOLOGY, V76, P545, DOI 10.1016/j.neuropharm.2013.04.028
   Piomelli D, 2014, NEUROPHARMACOLOGY, V76, P228, DOI 10.1016/j.neuropharm.2013.07.026
   Robinson TE, 2014, NEUROPHARMACOLOGY, V76, P450, DOI 10.1016/j.neuropharm.2013.05.040
   Stamatakis AM, 2014, NEUROPHARMACOLOGY, V76, P320, DOI 10.1016/j.neuropharm.2013.05.046
   Trifilieff P, 2014, NEUROPHARMACOLOGY, V76, P498, DOI 10.1016/j.neuropharm.2013.06.031
   Vassoler FM, 2014, NEUROPHARMACOLOGY, V76, P269, DOI 10.1016/j.neuropharm.2013.06.016
   Volkow ND, 2014, NEUROPHARMACOLOGY, V76, P235, DOI 10.1016/j.neuropharm.2013.05.007
NR 37
TC 0
Z9 0
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3908
EI 1873-7064
J9 NEUROPHARMACOLOGY
JI Neuropharmacology
PD JAN
PY 2014
VL 76
SI SI
BP 195
EP 197
DI 10.1016/j.neuropharm.2013.08.020
PN B
PG 3
WC Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 294YK
UT WOS:000330083600001
PM 23994442
DA 2023-06-23
ER

PT J
AU Piray, P
   Keramati, MM
   Dezfouli, A
   Lucas, C
   Mokri, A
AF Piray, Payam
   Keramati, Mohammad Mahdi
   Dezfouli, Amir
   Lucas, Caro
   Mokri, Azarakhsh
TI Individual Differences in Nucleus Accumbens Dopamine Receptors Predict
   Development of Addiction-Like Behavior: A Computational Approach
SO NEURAL COMPUTATION
LA English
DT Article
ID VENTRAL TEGMENTAL AREA; POSITRON-EMISSION-TOMOGRAPHY; TRIAL PLACE
   PREFERENCE; DORSAL STRIATUM; DRUG-ADDICTION; NEURONS ENCODE; OLFACTORY
   TUBERCLE; D2 RECEPTORS; ORBITOFRONTAL CORTEX; SYNAPTIC PLASTICITY
AB Clinical and experimental observations show individual differences in the development of addiction. Increasing evidence supports the hypothesis that dopamine receptor availability in the nucleus accumbens (NAc) predisposes drug reinforcement. Here, modeling striatal-midbrain dopaminergic circuit, we propose a reinforcement learning model for addiction based on the actor-critic model of striatum. Modeling dopamine receptors in the NAc as modulators of learning rate for appetitive-but not aversive-stimuli in the critic-but not the actor-we define vulnerability to addiction as a relatively lower learning rate for the appetitive stimuli, compared to aversive stimuli, in the critic. We hypothesize that an imbalance in this learning parameter used by appetitive and aversive learning systems can result in addiction. We elucidate that the interaction between the degree of individual vulnerability and the duration of exposure to drug has two progressive consequences: deterioration of the imbalance and establishment of an abnormal habitual response in the actor. Using computational language, the proposed model describes how development of compulsive behavior can be a function of both degree of drug exposure and individual vulnerability. Moreover, the model describes how involvement of the dorsal striatum in addiction can be augmented progressively. The model also interprets other forms of addiction, such as obesity and pathological gambling, in a common mechanism with drug addiction. Finally, the model provides an answer for the question of why behavioral addictions are triggered in Parkinson's disease patients by D2 dopamine agonist treatments.
C1 [Piray, Payam; Dezfouli, Amir; Lucas, Caro] Univ Tehran, Sch Elect & Comp Engn, Control & Intelligent Proc Ctr Excellence, Tehran, Iran.
   [Keramati, Mohammad Mahdi] Sharif Univ Technol, Sch Management & Econ, Tehran, Iran.
   [Mokri, Azarakhsh] Univ Tehran Med Sci, Roozbeh Hosp, Dept Psychiat, Tehran, Iran.
   [Mokri, Azarakhsh] Univ Tehran Med Sci, Iranian Natl Ctr Addict Studies, Dept Clin Sci, Tehran, Iran.
C3 University of Tehran; Sharif University of Technology; Tehran University
   of Medical Sciences; Tehran University of Medical Sciences
RP Piray, P (通讯作者)，Univ Tehran, Sch Elect & Comp Engn, Control & Intelligent Proc Ctr Excellence, Tehran, Iran.
EM piray@ut.ac.ir; keramati_mm@alum.sharif.edu; a.dezfouli@ut.ac.ir;
   lucas@ut.ac.ir; mokriazr@sina.tums.ac.ir
RI Piray, Payam/F-6620-2013
OI Piray, Payam/0000-0002-8100-6628
CR Ahmed SH, 2008, BEHAV BRAIN SCI, V31, P437, DOI 10.1017/S0140525X08004731
   Ahmed SH, 2005, PSYCHOPHARMACOLOGY, V180, P473, DOI 10.1007/s00213-005-2180-z
   Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298
   Ahmed SH, 2004, SCIENCE, V306, P1901, DOI 10.1126/science.1107071
   American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th
   Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244
   Atallah HE, 2007, NAT NEUROSCI, V10, P126, DOI 10.1038/nn1817
   Bachtell RK, 2005, PSYCHOPHARMACOLOGY, V183, P41, DOI 10.1007/s00213-005-0133-1
   Balleine BW, 2007, J NEUROSCI, V27, P8161, DOI 10.1523/JNEUROSCI.1554-07.2007
   Bayer HM, 2005, NEURON, V47, P129, DOI 10.1016/j.neuron.2005.05.020
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   Belin D, 2008, NEURON, V57, P432, DOI 10.1016/j.neuron.2007.12.019
   Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9
   Beveridge TJR, 2009, NEUROPSYCHOPHARMACOL, V34, P1162, DOI 10.1038/npp.2008.135
   Bolanos CA, 2003, J NEUROSCI, V23, P7569
   BRISCHOUX F, 2009, NATL ACAD SCI UNITED, V106, P4894
   Caine SB, 1999, J PHARMACOL EXP THER, V291, P353
   Cardinal RN, 2002, NEUROSCI BIOBEHAV R, V26, P321, DOI 10.1016/S0149-7634(02)00007-6
   Carelli RM, 2002, PHYSIOL BEHAV, V76, P379, DOI 10.1016/S0031-9384(02)00760-6
   Carlezon WA, 2000, J NEUROSCI, V20
   Carlezon WA, 1997, SCIENCE, V277, P812, DOI 10.1126/science.277.5327.812
   CARLEZON WA, 1995, PSYCHOPHARMACOLOGY, V122, P194, DOI 10.1007/BF02246095
   Conrad KL, 2008, NATURE, V454, P118, DOI 10.1038/nature06995
   CORRIGALL WA, 1991, PHARMACOL BIOCHEM BE, V39, P799, DOI 10.1016/0091-3057(91)90168-2
   Dagher A, 2009, NEURON, V61, P502, DOI 10.1016/j.neuron.2009.01.031
   DALLEY JW, 2007, SCIENCE, V1270, pD2
   Daw ND, 2005, NAT NEUROSCI, V8, P1704, DOI 10.1038/nn1560
   Daw ND, 2002, NEURAL NETWORKS, V15, P603, DOI 10.1016/S0893-6080(02)00052-7
   Dayan P, 2009, PHARMACOPSYCHIATRY, V42, pS56, DOI 10.1055/s-0028-1124107
   Dayan P, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.0040004
   DE WITH, 1986, DRUG ALCOHOL DEPEN, V16, P341
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   Dezfouli A, 2009, NEURAL COMPUT, V21, P2869, DOI 10.1162/neco.2009.10-08-882
   Di Chiara G, 2004, NEUROPHARMACOLOGY, V47, P227, DOI 10.1016/j.neuropharm.2004.06.032
   Edwards S, 2007, NEUROPSYCHOPHARMACOL, V32, P354, DOI 10.1038/sj.npp.1301062
   Everitt BJ, 2008, PHILOS T R SOC B, V363, P3125, DOI 10.1098/rstb.2008.0089
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Fenu S, 2006, PSYCHOPHARMACOLOGY, V187, P143, DOI 10.1007/s00213-006-0415-2
   Ford CP, 2006, J NEUROSCI, V26, P2788, DOI 10.1523/JNEUROSCI.4331-05.2006
   Frank MJ, 2007, P NATL ACAD SCI USA, V104, P16311, DOI 10.1073/pnas.0706111104
   Frank MJ, 2009, J MOL CELL BIOL, V1, P15, DOI 10.1093/jmcb/mjp010
   Frank MJ, 2009, NAT NEUROSCI, V12, P1062, DOI 10.1038/nn.2342
   Frank MJ, 2004, SCIENCE, V306, P1940, DOI 10.1126/science.1102941
   Garavan H, 2000, AM J PSYCHIAT, V157, P1789, DOI 10.1176/appi.ajp.157.11.1789
   Goldstein RZ, 2007, AM J PSYCHIAT, V164, P43, DOI 10.1176/appi.ajp.164.1.43
   Goto Y, 2005, NAT NEUROSCI, V8, P805, DOI 10.1038/nn1471
   Gutkin BS, 2006, P NATL ACAD SCI USA, V103, P1106, DOI 10.1073/pnas.0510220103
   Haber SN, 2000, J NEUROSCI, V20, P2369
   Haber SN, 2010, NEUROPSYCHOPHARMACOL, V35, P4, DOI 10.1038/npp.2009.129
   Hazy TE, 2007, PHILOS T R SOC B, V362, P1601, DOI 10.1098/rstb.2007.2055
   Hopf FW, 2003, J NEUROSCI, V23, P5079
   Hyman SE, 2005, AM J PSYCHIAT, V162, P1414, DOI 10.1176/appi.ajp.162.8.1414
   HYMAN SE, 2006, ANN REV OF NEUROSCIE, V565, P598
   Ikemoto S, 1997, J NEUROSCI, V17, P8580
   Ikemoto S, 1998, PHARMACOL BIOCHEM BE, V61, P87, DOI 10.1016/S0091-3057(98)00086-0
   Ikemoto S, 2002, J NEUROSCI, V22, P9895
   Ikemoto S, 2005, J NEUROSCI, V25, P5061, DOI 10.1523/JNEUROSCI.0892-05.2005
   Ikemoto S, 2003, J NEUROSCI, V23, P9305
   Ikemoto S, 2007, BRAIN RES REV, V56, P27, DOI 10.1016/j.brainresrev.2007.05.004
   Inoue Y, 2007, J PHARMACOL EXP THER, V322, P23, DOI 10.1124/jpet.107.120675
   Ito M, 2009, J NEUROSCI, V29, P9861, DOI 10.1523/JNEUROSCI.6157-08.2009
   Ito R, 2002, J NEUROSCI, V22, P6247
   Janak PH, 2004, BEHAV BRAIN RES, V154, P125, DOI 10.1016/j.bbr.2004.02.003
   Jentsch JD, 2002, NEUROPSYCHOPHARMACOL, V26, P183, DOI 10.1016/S0893-133X(01)00355-4
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564
   Kalivas PW, 2009, NAT REV NEUROSCI, V10, P561, DOI 10.1038/nrn2515
   Kauer JA, 2007, NAT REV NEUROSCI, V8, P844, DOI 10.1038/nrn2234
   Kim H, 2009, J NEUROSCI, V29, P14701, DOI 10.1523/JNEUROSCI.2728-09.2009
   Kim YB, 2007, J NEUROPHYSIOL, V98, P3548, DOI 10.1152/jn.00310.2007
   Klein TA, 2007, SCIENCE, V318, P1642, DOI 10.1126/science.1145044
   Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442
   Laruelle M, 1997, NEUROPSYCHOPHARMACOL, V17, P162, DOI 10.1016/S0893-133X(97)00043-2
   Lau B, 2008, NEURON, V58, P451, DOI 10.1016/j.neuron.2008.02.021
   Lauwereyns J, 2002, NATURE, V418, P413, DOI 10.1038/nature00892
   Mach RH, 1997, PHARMACOL BIOCHEM BE, V57, P477, DOI 10.1016/S0091-3057(96)00449-2
   Mameli M, 2009, NAT NEUROSCI, V12, P1036, DOI 10.1038/nn.2367
   Martinez D, 2009, NEUROPSYCHOPHARMACOL, V34, P1774, DOI 10.1038/npp.2008.235
   Matsumoto M, 2009, NATURE, V459, P837, DOI 10.1038/nature08028
   McClure SM, 2003, TRENDS NEUROSCI, V26, P423, DOI 10.1016/S0166-2236(03)00177-2
   Montague PR, 2004, NATURE, V431, P760, DOI 10.1038/nature03015
   Montague PR, 1996, J NEUROSCI, V16, P1936, DOI 10.1523/jneurosci.16-05-01936.1996
   Moore RJ, 1998, SYNAPSE, V28, P1
   Morgan M, 2002, QUALITATIVE RES, V2, P5, DOI DOI 10.1177/1468794102002001636
   Morris G, 2006, NAT NEUROSCI, V9, P1057, DOI 10.1038/nn1743
   Moustafa AA, 2008, J NEUROSCI, V28, P12294, DOI 10.1523/JNEUROSCI.3116-08.2008
   Nader MA, 2002, NEUROPSYCHOPHARMACOL, V27, P35, DOI 10.1016/S0893-133X(01)00427-4
   Nader MA, 2008, PHILOS T R SOC B, V363, P3223, DOI 10.1098/rstb.2008.0092
   Nader MA, 2006, NAT NEUROSCI, V9, P1050, DOI 10.1038/nn1737
   Nelson A, 2006, J NEUROSCI, V26, P3805, DOI 10.1523/JNEUROSCI.4305-05.2006
   Nicola SM, 2007, PSYCHOPHARMACOLOGY, V191, P521, DOI 10.1007/s00213-006-0510-4
   Noble EP, 2003, AM J MED GENET B, V116B, P103, DOI 10.1002/ajmg.b.10005
   O'Doherty J, 2004, SCIENCE, V304, P452, DOI 10.1126/science.1094285
   OBRIEN CP, 1986, BEHAV ANAL DRUG DEPE, P329
   Olson VG, 2005, J NEUROSCI, V25, P5553, DOI 10.1523/JNEUROSCI.0345-05.2005
   Packard MG, 2002, ANNU REV NEUROSCI, V25, P563, DOI 10.1146/annurev.neuro.25.112701.142937
   Pasquereau B, 2007, J NEUROSCI, V27, P1176, DOI 10.1523/JNEUROSCI.3745-06.2007
   Peterson DA, 2009, NEUROSCIENCE, V163, P1092, DOI 10.1016/j.neuroscience.2009.07.033
   Pezze MA, 2007, NEUROPSYCHOPHARMACOL, V32, P273, DOI 10.1038/sj.npp.1301073
   PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295
   Porrino LJ, 2004, NEUROSCI BIOBEHAV R, V27, P813, DOI 10.1016/j.neubiorev.2003.11.013
   Porrino LJ, 2004, J NEUROSCI, V24, P3554, DOI 10.1523/JNEUROSCI.5578-03.2004
   Potenza MN, 2008, PHILOS T R SOC B, V363, P3181, DOI 10.1098/rstb.2008.0100
   Redish AD, 2008, BEHAV BRAIN SCI, V31, P415, DOI 10.1017/S0140525X0800472X
   Redish AD, 2007, ANN NY ACAD SCI, V1104, P324, DOI 10.1196/annals.1390.014
   Redish AD, 2007, PSYCHOL REV, V114, P784, DOI 10.1037/0033-295X.114.3.784
   Redish AD, 2004, SCIENCE, V306, P1944, DOI 10.1126/science.1102384
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Rodd ZA, 2005, NEUROPSYCHOPHARMACOL, V30, P330, DOI 10.1038/sj.npp.1300561
   Rodd ZA, 2004, J NEUROSCI, V24, P1050, DOI 10.1523/JNEUROSCI.1319-03.2004
   Rodd-Henricks ZA, 2002, J PHARMACOL EXP THER, V303, P1216, DOI 10.1124/jpet.102.038950
   Roesch MR, 2007, NAT NEUROSCI, V10, P1615, DOI 10.1038/nn2013
   Roesch MR, 2007, J NEUROSCI, V27, P245, DOI 10.1523/JNEUROSCI.4080-06.2007
   Roesch MR, 2009, J NEUROSCI, V29, P13365, DOI 10.1523/JNEUROSCI.2572-09.2009
   Samejima K, 2005, SCIENCE, V310, P1337, DOI 10.1126/science.1115270
   Schoenbaum G, 2005, CEREB CORTEX, V15, P1162, DOI 10.1093/cercor/bhh216
   Schoenbaum G, 2004, EUR J NEUROSCI, V19, P1997, DOI 10.1111/j.1460-9568.2004.03274.x
   Schoenbaum G, 2009, NAT REV NEUROSCI, V10, P885, DOI 10.1038/nrn2753
   Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593
   Self DW, 2004, NEUROPHARMACOLOGY, V47, P242, DOI 10.1016/j.neuropharm.2004.07.005
   Sellings LHL, 2006, NEUROSCIENCE, V141, P1457, DOI 10.1016/j.neuroscience.2006.04.040
   Sellings LHL, 2006, J PHARMACOL EXP THER, V317, P1178, DOI 10.1124/jpet.105.100339
   Sellings LHL, 2003, J NEUROSCI, V23, P6295
   Shin R, 2008, PSYCHOPHARMACOLOGY, V198, P261, DOI 10.1007/s00213-008-1131-x
   Spina L, 2006, PSYCHOPHARMACOLOGY, V184, P447, DOI 10.1007/s00213-005-0211-4
   Steeves TDL, 2009, BRAIN, V132, P1376, DOI 10.1093/brain/awp054
   Sutton R. S., 1998, REINFORCEMENT LEARNI
   Taha SA, 2005, J NEUROSCI, V25, P1193, DOI 10.1523/JNEUROSCI.3975-04.2005
   Takahashi Y, 2008, FRONT NEUROSCI-SWITZ, V2, P86, DOI 10.3389/neuro.01.014.2008
   Takahashi Y, 2007, FRONT INTEGR NEUROSC, V1, DOI 10.3389/neuro.07.011.2007
   Thanos PK, 2001, J NEUROCHEM, V78, P1094, DOI 10.1046/j.1471-4159.2001.00492.x
   van der Meer MAA, 2009, FRONT INTEGR NEUROSC, V3, DOI 10.3389/neuro.07.001.2009
   Vanderschuren LJMJ, 2005, J NEUROSCI, V25, P8665, DOI 10.1523/JNEUROSCI.0925-05.2005
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Volkow ND, 1999, AM J PSYCHIAT, V156, P1440
   Volkow ND, 2004, MOL PSYCHIATR, V9, P557, DOI 10.1038/sj.mp.4001507
   Volkow ND, 2005, NAT NEUROSCI, V8, P555, DOI 10.1038/nn1452
   Volkow ND, 2008, PHILOS T R SOC B, V363, P3191, DOI 10.1098/rstb.2008.0107
   Volkow ND, 2006, ARCH GEN PSYCHIAT, V63, P999, DOI 10.1001/archpsyc.63.9.999
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
   Wong DF, 2006, NEUROPSYCHOPHARMACOL, V31, P2716, DOI 10.1038/sj.npp.1301194
   Zangen A, 2006, J NEUROSCI, V26, P4901, DOI 10.1523/JNEUROSCI.3554-05.2006
   Zangen A, 2002, J NEUROSCI, V22, P7225
   Zhang J, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000437
NR 143
TC 25
Z9 26
U1 2
U2 15
PU MIT PRESS
PI CAMBRIDGE
PA ONE ROGERS ST, CAMBRIDGE, MA 02142-1209 USA
SN 0899-7667
EI 1530-888X
J9 NEURAL COMPUT
JI Neural Comput.
PD SEP
PY 2010
VL 22
IS 9
BP 2334
EP 2368
DI 10.1162/NECO_a_00009
PG 35
WC Computer Science, Artificial Intelligence; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Neurosciences & Neurology
GA 634EX
UT WOS:000280563600004
PM 20569176
DA 2023-06-23
ER

PT J
AU Babor, TF
AF Babor, Thomas F.
TI Addictionology as biography: one hundred ways to have a successful
   career in addiction science
SO ADDICTION
LA English
DT Editorial Material
DE Addiction; alcohol; careers; drugs; history; professional training
C1 Univ Connecticut, Dept Community Med & Hlth Care, Sch Med, Farmington, CT 06030 USA.
C3 University of Connecticut
RP Babor, TF (通讯作者)，Univ Connecticut, Dept Community Med & Hlth Care, Sch Med, 263 Farmington Ave, Farmington, CT 06030 USA.
EM babor@nso.uchc.edu
OI Babor, Thomas/0000-0002-2580-0835
CR Edwards G., 2012, ADDICTION M IN PRESS
   Edwards G, 2002, ADDICTION EVOLUTION
   Edwards Griffith, 1991, ADDICTIONS PERSONAL
   Levine R, 2004, MILLIONS SAVED PROVE
   Taylor P., 2010, MILLENNIALS PORTRAIT
   Warner K E, 2006, Glob Public Health, V1, P65, DOI 10.1080/17441690500430771
   Zeigler DW, 2011, WORLD MED HEALTH POL, V3, DOI 10.2202/1948-4682.1199
NR 7
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0965-2140
J9 ADDICTION
JI Addiction
PD MAR
PY 2012
VL 107
IS 3
BP 464
EP 466
DI 10.1111/j.1360-0443.2012.03788.x
PG 3
WC Substance Abuse; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse; Psychiatry
GA 888IL
UT WOS:000299997000002
PM 22313100
OA Bronze
DA 2023-06-23
ER

PT S
AU Luscher, C
AF Luscher, Christian
BE Hyman, SE
TI The Emergence of a Circuit Model for Addiction
SO ANNUAL REVIEW OF NEUROSCIENCE, VOL 39
SE Annual Review of Neuroscience
LA English
DT Review; Book Chapter
DE cocaine; synaptic plasticity; metabotropic glutamate receptors;
   calcium-permeable AMPA receptors; deep brain stimulation; optogenetics
ID VENTRAL TEGMENTAL AREA; EVOKED SYNAPTIC PLASTICITY; MIDBRAIN DOPAMINE
   NEURONS; LONG-TERM DEPRESSION; NUCLEUS-ACCUMBENS SYNAPSES; PERMEABLE
   AMPA RECEPTORS; PREFRONTAL CORTEX; LATERAL HABENULA; COCAINE EXPOSURE;
   IN-VIVO
AB Addiction is a disease of altered behavior. Addicts use drugs compulsively and will continue to do so despite negative consequences. Even after prolonged periods of abstinence, addicts are at risk of relapse, particularly when cues evoke memories that are associated with drug use. Rodent models mimic many of the core components of addiction, from the initial drug reinforcement to cue-associated relapse and continued drug intake despite negative consequences. Rodent models have also enabled unprecedented mechanistic insight into addiction, revealing plasticity of glutamatergic synaptic transmission evoked by the strong activation of mesolimbic dopamine-a defining feature of all addictive drugs-as a neural substrate for these drug-adaptive behaviors. Cell type-specific optogenetic manipulations have allowed both identification of the relevant circuits and design of protocols to reverse drug-evoked plasticity and to establish links of causality with drug-adaptive behaviors. The emergence of a circuit model for addiction will open the door for novel therapies, such as deep brain stimulation.
C1 [Luscher, Christian] Univ Geneva, Fac Med, Dept Basic Neurosci, CH-1211 Geneva, Switzerland.
   [Luscher, Christian] Univ Hosp Geneva, Dept Clin Neurosci, Neurol Clin, CH-1211 Geneva, Switzerland.
C3 University of Geneva; University of Geneva
RP Luscher, C (通讯作者)，Univ Geneva, Fac Med, Dept Basic Neurosci, CH-1211 Geneva, Switzerland.; Luscher, C (通讯作者)，Univ Hosp Geneva, Dept Clin Neurosci, Neurol Clin, CH-1211 Geneva, Switzerland.
EM Christian.Luscher@unige.ch
RI Lüscher, Christian/A-2496-2011
OI Lüscher, Christian/0000-0001-7917-4596
CR Adamantidis AR, 2011, J NEUROSCI, V31, P10829, DOI 10.1523/JNEUROSCI.2246-11.2011
   American Society of Addiction Medicine, 2011, PUBL POL STAT DEF AD
   Baimel C, 2015, BRIT J PHARMACOL, V172, P334, DOI 10.1111/bph.12639
   BECHARA A, 1992, PHARMACOL BIOCHEM BE, V42, P9, DOI 10.1016/0091-3057(92)90438-L
   Bellone C, 2006, NAT NEUROSCI, V9, P636, DOI 10.1038/nn1682
   Bocklisch C, 2013, SCIENCE, V341, P1521, DOI 10.1126/science.1237059
   Borgland SL, 2006, NEURON, V49, P589, DOI 10.1016/j.neuron.2006.01.016
   Boudreau AC, 2007, J NEUROSCI, V27, P10621, DOI 10.1523/JNEUROSCI.2163-07.2007
   Brown MTC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015870
   Brown TE, 2011, J NEUROSCI, V31, P8163, DOI 10.1523/JNEUROSCI.0016-11.2011
   Buchta WC, 2015, BRAIN RES, V1628, P88, DOI 10.1016/j.brainres.2015.02.003
   Chen BT, 2013, NATURE, V496, P359, DOI 10.1038/nature12024
   Chen R, 2006, P NATL ACAD SCI USA, V103, P9333, DOI 10.1073/pnas.0600905103
   Cohen JY, 2012, NATURE, V482, P85, DOI 10.1038/nature10754
   Conrad KL, 2008, NATURE, V454, P118, DOI 10.1038/nature06995
   Creed M, 2015, SCIENCE, V347, P659, DOI 10.1126/science.1260776
   Creed MC, 2013, CURR OPIN NEUROBIOL, V23, P553, DOI 10.1016/j.conb.2013.03.005
   Cruz HG, 2004, NAT NEUROSCI, V7, P153, DOI 10.1038/nn1181
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Engblom D, 2008, NEURON, V59, P497, DOI 10.1016/j.neuron.2008.07.010
   Everitt BJ, 2013, NEUROSCI BIOBEHAV R, V37, P1946, DOI 10.1016/j.neubiorev.2013.02.010
   GESSA GL, 1985, BRAIN RES, V348, P201, DOI 10.1016/0006-8993(85)90381-6
   Good CH, 2010, J NEUROSCI, V30, P7900, DOI 10.1523/JNEUROSCI.1507-10.2010
   Gremel CM, 2013, FRONT COMPUT NEUROSC, V7, DOI 10.3389/fncom.2013.00110
   Gremel CM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3264
   Hearing MC, 2016, P NATL ACAD SCI USA, V113, P757, DOI 10.1073/pnas.1519248113
   Heikkinen AE, 2009, NEUROPSYCHOPHARMACOL, V34, P290, DOI 10.1038/npp.2008.89
   Hnasko TS, 2005, NATURE, V438, P854, DOI 10.1038/nature04172
   Jhou TC, 2013, J NEUROSCI, V33, P7501, DOI 10.1523/JNEUROSCI.3634-12.2013
   Jhou TC, 2009, NEURON, V61, P786, DOI 10.1016/j.neuron.2009.02.001
   JOHNSON SW, 1992, J NEUROSCI, V12, P483
   Kalivas PW, 2005, NEURON, V45, P647, DOI 10.1016/j.neuron.2005.02.005
   Kasanetz F, 2013, MOL PSYCHIATR, V18, P729, DOI 10.1038/mp.2012.59
   Keiflin R, 2015, NEURON, V88, P247, DOI 10.1016/j.neuron.2015.08.037
   Kenny PJ, 2014, DIALOGUES CLIN NEURO, V16, P335
   Kessler RC, 2004, INT J METH PSYCH RES, V13, P69, DOI 10.1002/mpr.167
   Koob GF, 2009, BRAIN RES, V1293, P61, DOI 10.1016/j.brainres.2009.03.038
   Kourrich S, 2007, J NEUROSCI, V27, P7921, DOI 10.1523/JNEUROSCI.1859-07.2007
   Labouebe G, 2007, NAT NEUROSCI, V10, P1559, DOI 10.1038/nn2006
   Lammel S, 2014, NEUROPHARMACOLOGY, V76, P351, DOI 10.1016/j.neuropharm.2013.03.019
   Lammel S, 2012, NATURE, V491, P212, DOI 10.1038/nature11527
   Laviolette SR, 2002, BEHAV BRAIN RES, V129, P17, DOI 10.1016/S0166-4328(01)00327-8
   Lee BR, 2013, NAT NEUROSCI, V16, P1644, DOI 10.1038/nn.3533
   Liu QS, 2005, NATURE, V437, P1027, DOI 10.1038/nature04050
   Liu SJ, 2007, TRENDS NEUROSCI, V30, P126, DOI 10.1016/j.tins.2007.01.006
   Loweth JA, 2014, NAT NEUROSCI, V17, P73, DOI 10.1038/nn.3590
   Luscher C, 2006, PLOS MED, V3, P2005, DOI 10.1371/journal.pmed.0030437
   Luscher C, 2013, J NEUROSCI, V33, P17641, DOI 10.1523/JNEUROSCI.3406-13.2013
   Luscher C, 2011, NEURON, V69, P650, DOI 10.1016/j.neuron.2011.01.017
   Luthi A, 2014, NAT NEUROSCI, V17, P1635, DOI 10.1038/nn.3849
   Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5
   Luscher C, 2010, NEURON, V65, P445, DOI 10.1016/j.neuron.2010.01.016
   Ma YY, 2014, NEURON, V83, P1453, DOI 10.1016/j.neuron.2014.08.023
   Mameli M, 2007, SCIENCE, V317, P530, DOI 10.1126/science.1142365
   Mameli M, 2011, NAT NEUROSCI, V14, P414, DOI 10.1038/nn.2763
   Mameli M, 2009, NAT NEUROSCI, V12, P1036, DOI 10.1038/nn.2367
   Maroteaux M, 2012, J NEUROSCI, V32, P12641, DOI 10.1523/JNEUROSCI.2405-12.2012
   Matsumoto M, 2009, NAT NEUROSCI, V12, P77, DOI 10.1038/nn.2233
   McCutcheon JE, 2011, J NEUROSCI, V31, P5737, DOI 10.1523/JNEUROSCI.0350-11.2011
   Melis M, 2005, INT REV NEUROBIOL, V63, P101, DOI 10.1016/S0074-7742(05)63005-X
   Meye FJ, 2015, NAT NEUROSCI, V18, P376, DOI 10.1038/nn.3923
   Nugent FS, 2008, J PHYSIOL-LONDON, V586, P1487, DOI 10.1113/jphysiol.2007.148098
   Nutt DJ, 2015, NAT REV NEUROSCI, V16, P305, DOI 10.1038/nrn3939
   Padgett CL, 2012, NEURON, V73, P978, DOI 10.1016/j.neuron.2011.12.031
   Paoletti P, 2013, NAT REV NEUROSCI, V14, P383, DOI 10.1038/nrn3504
   Pascoli V, 2015, NEURON, V88, DOI 10.1016/j.neuron.2015.10.017
   Pascoli V, 2014, NATURE, V509, P459, DOI 10.1038/nature13257
   Pascoli V, 2012, NATURE, V481, P71, DOI 10.1038/nature10709
   Pascoli V, 2011, BIOL PSYCHIAT, V69, P218, DOI 10.1016/j.biopsych.2010.08.031
   Perez-Otano I, 2001, J NEUROSCI, V21, P1228
   Peters J, 2008, J NEUROSCI, V28, P6046, DOI 10.1523/JNEUROSCI.1045-08.2008
   Piazza PV, 2014, PSYCHOPHARMACOLOGY, V231, P3929, DOI 10.1007/s00213-014-3628-9
   Proulx CD, 2014, NAT NEUROSCI, V17, P1146, DOI 10.1038/nn.3779
   Rehm J, 2015, EUR ADDICT RES, V21, P6, DOI 10.1159/000365284
   ROBERTS DCS, 1977, PHARMACOL BIOCHEM BE, V6, P615, DOI 10.1016/0091-3057(77)90084-3
   Robison AJ, 2011, NAT REV NEUROSCI, V12, P623, DOI 10.1038/nrn3111
   Rocha BA, 1998, NAT NEUROSCI, V1, P132, DOI 10.1038/381
   Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3
   Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-7
   Scheyer AF, 2014, J NEUROSCI, V34, P3095, DOI 10.1523/JNEUROSCI.4940-13.2014
   Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593
   Schultz W, 2011, NEURON, V69, P603, DOI 10.1016/j.neuron.2011.02.014
   Shen WX, 2008, SCIENCE, V321, P848, DOI 10.1126/science.1160575
   Sora I, 2001, P NATL ACAD SCI USA, V98, P5300, DOI 10.1073/pnas.091039298
   Tan KR, 2010, NATURE, V463, P769, DOI 10.1038/nature08758
   Terraneo A, 2016, EUR NEUROPSYCHOPHARM, V26, P37, DOI 10.1016/j.euroneuro.2015.11.011
   Terrier J, 2015, NEUROPSYCHO IN PRESS, DOI [10.1038/npp.2015.345, DOI 10.1038/NPP.2015.345]
   Thomas MJ, 2001, NAT NEUROSCI, V4, P1217, DOI 10.1038/nn757
   Threlfell S, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00011
   Tsai HC, 2009, SCIENCE, V324, P1080, DOI 10.1126/science.1168878
   Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077
   Volkow N. D., 2014, NIH PUB, V14-5605
   Volkow ND, 2005, J NEUROSCI, V25, P3932, DOI 10.1523/JNEUROSCI.0433-05.2005
   Wagner FA, 2002, NEUROPSYCHOPHARMACOL, V26, P479, DOI 10.1016/S0893-133X(01)00367-0
   Waung MW, 2008, NEURON, V59, P84, DOI 10.1016/j.neuron.2008.05.014
   Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406
   Wolf ME, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00072
   Wolf ME, 2010, NEUROSCI BIOBEHAV R, V35, P185, DOI 10.1016/j.neubiorev.2010.01.013
   World Health Organization [WHO ], 2010, ATLAS SUBST US 2010
   Yang YL, 2015, ELIFE, V4, DOI 10.7554/eLife.10206
   Yuan TF, 2013, NEURON, V80, P1025, DOI 10.1016/j.neuron.2013.07.050
   Zhu YJ, 2016, NATURE, V530, P219, DOI 10.1038/nature16954
   Zinberg N., 1986, DRUG SET SETTING BAS
NR 103
TC 135
Z9 143
U1 5
U2 55
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA
SN 0147-006X
BN 978-0-8243-2439-1
J9 ANNU REV NEUROSCI
JI Annu. Rev. Neurosci.
PY 2016
VL 39
BP 257
EP 276
DI 10.1146/annurev-neuro-070815-013920
PG 20
WC Neurosciences
WE Book Citation Index– Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA BF4RQ
UT WOS:000381633400013
PM 27145911
DA 2023-06-23
ER

PT J
AU Zhang, XX
   Zeng, XQ
AF Zhang, Xinxin
   Zeng, Xiaoqing
TI Effects of family functioning on relapse among individuals with drug
   addiction in compulsory isolation: a chained mediation model
SO CURRENT PSYCHOLOGY
LA English
DT Article
DE Family adaptability and cohesion; Relapse tendency; Self-efficacy;
   Positive trait coping style; Individuals with drug addiction
ID SUBSTANCE USE DISORDER; GENERAL SELF-EFFICACY; COPING STRATEGIES; SOCIAL
   SUPPORT; STRESS; ABUSE; ADAPTATION; PREVENTION; MOTIVATION; PEOPLE
AB Drug addiction is considered one of the most important issues related to the overall health of society. Previous studies have shown that family functioning has an important influence on drug relapse among individuals with drug addiction, but the social psychological mechanism of the effect of family functioning on drug relapse needs to be further explored. This study explored how family adaptation and cohesion, as components of family functioning, affect drug relapse by examining the mediating role of self-efficacy and trait coping style. A total of 957 (mean age = 34.51, 63.63% males) individuals with drug addiction were surveyed with the self-report measurements. Structural equation modeling was used to examine the direct link between family adaptability and cohesion and relapse as well as indirect links through self-efficacy and trait coping style. (1) Family adaptability and cohesion were negatively correlated with relapse tendency (beta = -0.035, p < 0.001). (2) Self-efficacy and positive coping style mediated this relationship through two mediating pathways - the separate mediating effect of positive trait coping style (beta = -0.045, p < 0.001) and the sequential chain mediating effect of self-efficacy and positive trait coping style (beta = -0.014, p < 0.001). The self-efficacy and positive trait coping styles of individuals with drug addiction have a chain mediating effect on the relationship between family adaptability and cohesion and relapse tendency. This study is helpful for understanding the social-psychological mechanisms of drug addiction and provides new ideas for developing effective treatment methods.
C1 [Zhang, Xinxin; Zeng, Xiaoqing] Jiangxi Normal Univ, Sch Psychol, Nanchang, Jiangxi, Peoples R China.
   [Zhang, Xinxin; Zeng, Xiaoqing] Jiangxi Key Lab Psychol & Cognit Sci, Nanchang, Jiangxi, Peoples R China.
   [Zhang, Xinxin; Zeng, Xiaoqing] Jiangxi Normal Univ, Inst Psychol, Nanchang, Jiangxi, Peoples R China.
C3 Jiangxi Normal University; Jiangxi Normal University
RP Zeng, XQ (通讯作者)，Jiangxi Normal Univ, Sch Psychol, Nanchang, Jiangxi, Peoples R China.; Zeng, XQ (通讯作者)，Jiangxi Key Lab Psychol & Cognit Sci, Nanchang, Jiangxi, Peoples R China.; Zeng, XQ (通讯作者)，Jiangxi Normal Univ, Inst Psychol, Nanchang, Jiangxi, Peoples R China.
EM zxq3701@163.com
FU National Social Science Foundation of China [19BGL230]; "13th Five-Year
   Plan" Project of Educational Science in Jiangxi Province [20YB19]
FX This research was supported by grants from the National Social Science
   Foundation of China (19BGL230), and from the "13th Five-Year Plan"
   Project of Educational Science in Jiangxi Province (20YB19).
CR Altiere MJ, 2009, J CHILD FAM STUD, V18, P83, DOI 10.1007/s10826-008-9209-y
   Azmi A.A., 2018, MATEC WEB C, V150, DOI [10.1051/matecconf/201815005097, DOI 10.1051/MATECCONF/201815005097]
   BANDURA A, 1982, AM PSYCHOL, V37, P122, DOI 10.1037/0003-066X.37.2.122
   Baptista Makilim Nunes, 2008, Psicol. cienc. prof., V28, P260
   Bowen S, 2014, JAMA PSYCHIAT, V71, P547, DOI 10.1001/jamapsychiatry.2013.4546
   Boyraz G, 2011, AM J MENS HEALTH, V5, P286, DOI 10.1177/1557988310372538
   Brandon TH, 2007, ANNU REV CLIN PSYCHO, V3, P257, DOI 10.1146/annurev.clinpsy.3.022806.091455
   Budney AJ, 2000, J CONSULT CLIN PSYCH, V68, P1051, DOI 10.1037/0022-006X.68.6.1051
   Chen MR, 2020, SOC BEHAV PERSONAL, V48, DOI 10.2224/sbp.9334
   Chen Q., 2019, CHINESE J DRUG DEPEN, V28, P408, DOI [10.13936/j.cnki.cjdd1992.2019.06.001, DOI 10.13936/J.CNKI.CJDD1992.2019.06.001]
   Chilcoat HD, 1996, J AM ACAD CHILD PSY, V35, P91, DOI 10.1097/00004583-199601000-00017
   Chudzicka-Czupala A, 2020, HEALTH QUAL LIFE OUT, V18, DOI 10.1186/s12955-020-01348-6
   Cohen GL, 2006, SCIENCE, V313, P1307, DOI 10.1126/science.1128317
   Cordova D, 2014, SUBST USE MISUSE, V49, P1908, DOI 10.3109/10826084.2014.935792
   D'Alessio M, 2006, ADDICT BEHAV, V31, P2328, DOI 10.1016/j.addbeh.2006.03.002
   Daley, 1989, J CHEM DEPENDENCY TR, V2, P3
   DiClemente CC, 1999, PSYCHOL SCI, V10, P209, DOI 10.1111/1467-9280.00137
   Dolan SL, 2008, ADDICT BEHAV, V33, P675, DOI 10.1016/j.addbeh.2007.12.001
   Fei L., 1991, CHIN J MENTAL HLTH, V5, P198
   Fiorentine R, 2003, AM J ADDICTION, V12, P346, DOI 10.1080/10550490390226932
   Geng LN, 2011, SOC BEHAV PERSONAL, V39, P797, DOI 10.2224/sbp.2011.39.6.797
   Gorall, 2007, F ACES 4 CIRCUMPLEX
   Gorgulu T, 2019, DUSUNEN ADAM, V32, P33, DOI 10.14744/DAJPNS.2019.00005
   Graber R, 2016, BRIT J PSYCHOL, V107, P338, DOI 10.1111/bjop.12135
   Guo Rui, 2009, Wei Sheng Yan Jiu, V38, P320
   HALIM MA, 2013, PROCEDIA SOCIAL BEHA, V84, P1829
   Harmer ALM, 1999, CHILD ABUSE NEGLECT, V23, P421, DOI 10.1016/S0145-2134(99)00020-4
   Hruska B, 2011, PSYCHOL ADDICT BEHAV, V25, P405, DOI 10.1037/a0022439
   Hunter-Reel D, 2009, ADDICTION, V104, P1281, DOI 10.1111/j.1360-0443.2009.02611.x
   Hyman SM, 2009, PSYCHOL ADDICT BEHAV, V23, P613, DOI 10.1037/a0017324
   Johnson K, 2010, AM J ADDICTION, V19, P277, DOI 10.1111/j.1521-0391.2010.00041.x
   Kadden RM, 2011, ADDICT BEHAV, V36, P1120, DOI 10.1016/j.addbeh.2011.07.032
   Kandel DB, 1996, ARCH GEN PSYCHIAT, V53, P71
   Lakey B., 2000, SOCIAL SUPPORT MEASU, P29, DOI [DOI 10.1093/MED:PSYCH/9780195126709.003.0002, 10.1093/med:psych/9780195126709.003.0002]
   Lavee Y, 2001, CONTEMP FAM THER, V23, P513, DOI 10.1023/A:1013061230698
   Litt MD, 2005, J CONSULT CLIN PSYCH, V73, P1015, DOI 10.1037/0022-006X.73.6.1015
   Liu WL, 2016, PERS INDIV DIFFER, V88, P35, DOI 10.1016/j.paid.2015.08.044
   Lucas R.E., 2006, HDB MULTIMETHOD ASSE, DOI [10.1037/11383-003, DOI 10.1037/11383-003]
   MARLATT GA, 1985, RELAPSE PREVENTION M
   Miller WR, 1996, PSYCHOL ADDICT BEHAV, V10, P81, DOI 10.1037/0893-164X.10.2.81
   Moran CM, 2013, MOTIV EMOTION, V37, P323, DOI 10.1007/s11031-012-9301-x
   Rey GN, 2010, DRUG-EDUC PREV POLIC, V17, P193, DOI 10.3109/09687637.2010.514787
   Olson D, 2011, J MARITAL FAM THER, V37, P64, DOI 10.1111/j.1752-0606.2009.00175.x
   Panebianco D, 2016, INT J DRUG POLICY, V27, P146, DOI 10.1016/j.drugpo.2015.09.009
   Podsakoff PM, 2012, ANNU REV PSYCHOL, V63, P539, DOI 10.1146/annurev-psych-120710-100452
   Reitz AK, 2014, DEV PSYCHOL, V50, P754, DOI 10.1037/a0033889
   Rowe CL, 2012, J MARITAL FAM THER, V38, P59, DOI 10.1111/j.1752-0606.2011.00280.x
   Sanchez-Queija I, 2016, J CHILD FAM STUD, V25, P232, DOI 10.1007/s10826-015-0212-9
   Sbicigo JB, 2012, PSICOL-REFLEX CRIT, V25, P615, DOI 10.1590/S0102-79722012000300022
   Schmitt MT, 2014, PSYCHOL BULL, V140, P921, DOI 10.1037/a0035754
   Shen, 2002, J PSYCHOL SCI, V25, P755, DOI [10.16719/j.cnki.1671-6981.2002.06.040, DOI 10.16719/J.CNKI.1671-6981.2002.06.040]
   Smyth NJ, 2005, J SOC WORK PRACT ADD, V5, P63, DOI 10.1300/J160v05n04_05
   STEPHENS RS, 1994, J CONSULT CLIN PSYCH, V62, P92, DOI 10.1037/0022-006X.62.1.92
   Tafa M, 2009, AM J FAM THER, V37, P388, DOI 10.1080/01926180902754745
   [汤丹丹 Tang Dandan], 2020, [心理科学, Journal of Psychological Science], V43, P215
   Tanguay P, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0071-0
   Thomas AC, 2011, PSYCHOL ADDICT BEHAV, V25, P738, DOI 10.1037/a0024865
   Thorberg FA, 2010, ADDICT RES THEORY, V18, P464, DOI 10.3109/16066350903254783
   Tomori C, 2014, INT J DRUG POLICY, V25, P897, DOI 10.1016/j.drugpo.2014.04.012
   Van Gundy KT, 2015, SUBST USE MISUSE, V50, P1459, DOI 10.3109/10826084.2015.1018544
   Vogel DL, 2009, J COUNS PSYCHOL, V56, P301, DOI 10.1037/a0014903
   Wahler EA, 2014, SUBST USE MISUSE, V49, P1820, DOI 10.3109/10826084.2014.935789
   Walton GM, 2007, J PERS SOC PSYCHOL, V92, P82, DOI 10.1037/0022-3514.92.1.82
   Wang, 2001, STUDY MENTAL HLTH RE
   [温忠麟 Wen Zhonglin], 2014, [心理学报, Acta Psychologica Sinica], V46, P714
   Witkiewitz K, 2004, AM PSYCHOL, V59, P224, DOI 10.1037/0003-066X.59.4.224
   Woodhead EL, 2014, J CLIN PSYCHOL, V70, P1183, DOI 10.1002/jclp.21924
   Wu SY, 2020, J EDUC COMPUT RES, V58, P249, DOI 10.1177/0735633119828044
   Xiong HY, 2019, INT J OFFENDER THER, V63, P1202, DOI 10.1177/0306624X18815243
   Zeng X. Q., 2019, PSYCHOL EXPLOR, V39, P83
   Zeng XQ, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18020625
   Zeng XQ, 2022, J ETHN SUBST ABUSE, V21, P402, DOI 10.1080/15332640.2020.1777608
   Zeng XQ, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.00948
   [曾晓青 Zeng Xiaoqing], 2018, [中国临床心理学杂志, Chinese Journal of Clinical Psychology], V26, P947
   ZHANG JX, 1995, PSYCHOLOGIA, V38, P174
   Zhang ZY., 2004, J PSYCHOL SCI, V27, P739, DOI [10.16719/j.cnki.1671-6981.2004.03.061, DOI 10.16719/J.CNKI.1671-6981.2004.03.061]
   Zheng J., 2019, HLTH RES, V39, P368, DOI [10.3969/j.issn.1674-6449.2019.04.002, DOI 10.3969/J.ISSN.1674-6449.2019.04.002]
   [钟伟芳 Zhong Weifang], 2018, [中国临床心理学杂志, Chinese Journal of Clinical Psychology], V26, P1096
   Zhu Y., 1999, CHIN J BEHAV MED, V8, P167, DOI DOI 10.3760/CMA.J.ISSN.1674-6554.1999.03.003
NR 79
TC 17
Z9 17
U1 4
U2 49
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1046-1310
EI 1936-4733
J9 CURR PSYCHOL
JI Curr. Psychol.
PD JAN
PY 2023
VL 42
IS 3
BP 1701
EP 1711
DI 10.1007/s12144-021-01561-6
EA MAR 2021
PG 11
WC Psychology, Multidisciplinary
WE Social Science Citation Index (SSCI)
SC Psychology
GA F7PI6
UT WOS:000626801400001
DA 2023-06-23
ER

PT J
AU Cheng, J
   Wang, SY
   Lin, WW
   Wu, N
   Wang, YQ
   Chen, MZ
   Xie, XQ
   Feng, ZW
AF Cheng, Jin
   Wang, Siyi
   Lin, Weiwei
   Wu, Nan
   Wang, Yuanqiang
   Chen, Maozi
   Xie, Xiang-Qun
   Feng, Zhiwei
TI Computational Systems Pharmacology-Target Mapping for Fentanyl-Laced
   Cocaine Overdose
SO ACS CHEMICAL NEUROSCIENCE
LA English
DT Article
DE fentanyl; cocaine; fentanyl-laced cocaine; overdose; polydrug addiction;
   computational systems pharmacology-target mapping
ID POSITIVE ALLOSTERIC MODULATOR; MOLECULAR-DYNAMICS SIMULATION; D-3
   RECEPTOR ANTAGONISM; HUMAN LIVER-MICROSOMES; BRAIN REWARD FUNCTION;
   PARTICLE MESH EWALD; SEEKING BEHAVIOR; GABA(B) RECEPTOR; FREE-ENERGIES;
   INDUCED REINSTATEMENT
AB The United States of America is fighting against one of its worst-ever drug crises. Over 900 people a week die from opioid- or heroin-related overdoses, while millions more suffer from opioid prescription addiction. Recently, drug overdoses caused by fentanyl-laced cocaine specifically are on the rise. Due to drug synergy and an increase in side effects, polydrug addiction can cause more risk than addiction to a single drug. In the present work, we systematically analyzed the overdose and addiction mechanism of cocaine and fentanyl. First, we applied our established chemogenomics knowledgebase and machine-learning-based methods to map out the potential and known proteins, transporters, and metabolic enzymes and the potential therapeutic target(s) for cocaine and fentanyl. Sequentially, we looked into the detail of (1) the addiction to cocaine and fentanyl by binding to the dopamine transporter and the mu opioid receptor (DAT and mu OR, respectively), (2) the potential drug-drug interaction of cocaine and fentanyl via p-glycoprotein (P-gp) efflux, (3) the metabolism of cocaine and fentanyl in CYP3A4, and (4) the physiologically based pharmacokinetic (PBPK) model for two drugs and their drug-drug interaction at the absorption, distribution, metabolism, and excretion (ADME) level. Finally, we looked into the detail of JWH133, an agonist of cannabinoid 2-receptor (CB2) with potential as a therapy for cocaine and fentanyl overdose. All these results provide a better understanding of fentanyl and cocaine polydrug addiction and future drug abuse prevention.
C1 [Cheng, Jin; Wang, Siyi; Lin, Weiwei; Wu, Nan; Wang, Yuanqiang; Chen, Maozi; Xie, Xiang-Qun; Feng, Zhiwei] Univ Pittsburgh, Sch Med, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA.
   [Cheng, Jin; Wang, Siyi; Lin, Weiwei; Wu, Nan; Wang, Yuanqiang; Chen, Maozi; Xie, Xiang-Qun; Feng, Zhiwei] Univ Pittsburgh, Natl Ctr Excellence Computat Drug Abuse Res, Sch Pharm,Dept Computat Biol,Sch Med, Computat Chem Genom Screening Ctr,Drug Discovery, Pittsburgh, PA 15261 USA.
   [Cheng, Jin; Wang, Siyi; Lin, Weiwei; Wu, Nan; Wang, Yuanqiang; Chen, Maozi; Xie, Xiang-Qun; Feng, Zhiwei] Univ Pittsburgh, Natl Ctr Excellence Computat Drug Abuse Res, Sch Pharm,Sch Med,Dept Struct Biol, Computat Chem Genom Screening Ctr,Drug Discovery, Pittsburgh, PA 15261 USA.
   [Cheng, Jin] Jiangsu Vocat Coll Med, Dept Pharm, Yancheng 224005, Jiangsu, Peoples R China.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Jiangsu Vocational
   College of Medicine
RP Xie, XQ; Feng, ZW (通讯作者)，Univ Pittsburgh, Sch Med, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA.; Xie, XQ; Feng, ZW (通讯作者)，Univ Pittsburgh, Natl Ctr Excellence Computat Drug Abuse Res, Sch Pharm,Dept Computat Biol,Sch Med, Computat Chem Genom Screening Ctr,Drug Discovery, Pittsburgh, PA 15261 USA.; Xie, XQ; Feng, ZW (通讯作者)，Univ Pittsburgh, Natl Ctr Excellence Computat Drug Abuse Res, Sch Pharm,Sch Med,Dept Struct Biol, Computat Chem Genom Screening Ctr,Drug Discovery, Pittsburgh, PA 15261 USA.
EM xix15@pitt.edu; zhf11@pitt.edu
RI FENG, ZHIWEI/L-5072-2014
OI FENG, ZHIWEI/0000-0001-6533-8932; wu, nan/0000-0002-1475-4503; Chen,
   Maozi/0000-0002-0763-6963
FU NIH NIDA [P30 DA035778A1]; Jiangsu Overseas Visiting Scholar Program for
   University Prominent Young & Middle-aged Teachers and Presidents
FX Authors acknowledge funding support to the Xie laboratory from the NIH
   NIDA (Grant P30 DA035778A1). Authors acknowledge the sponsorship of
   Jiangsu Overseas Visiting Scholar Program for University Prominent Young
   & Middle-aged Teachers and Presidents.
CR Adamczyk P, 2012, BRAIN RES, V1444, P45, DOI 10.1016/j.brainres.2012.01.030
   Agarwala R, 2016, NUCLEIC ACIDS RES, V44, pD7, DOI [10.1093/nar/gkv1290, 10.1093/nar/gku1130]
   Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI [10.1093/nar/gkw1099, 10.1093/nar/gkh131]
   Aracil-Fernandez A, 2012, NEUROPSYCHOPHARMACOL, V37, P1749, DOI 10.1038/npp.2012.22
   Ariano RE, 2001, J CLIN PHARMACOL, V41, P757, DOI 10.1177/00912700122010663
   Barutta F, 2011, DIABETES, V60, P2386, DOI 10.2337/db10-1809
   Bashford D, 2000, ANNU REV PHYS CHEM, V51, P129, DOI 10.1146/annurev.physchem.51.1.129
   Bergstrom KA, 1998, SYNAPSE, V29, P413, DOI 10.1002/(SICI)1098-2396(199808)29:4<413::AID-SYN13>3.0.CO;2-R
   Bespalov AY, 2005, NEUROPHARMACOLOGY, V49, P167, DOI 10.1016/j.neuropharm.2005.06.007
   Beuming T, 2008, NAT NEUROSCI, V11, P780, DOI 10.1038/nn.2146
   Bjorkman S, 2003, J PHARMACOKINET PHAR, V30, P285, DOI 10.1023/A:1026194618660
   Bonate PL, 1996, J PHARM SCI, V85, P878, DOI 10.1021/js950437i
   Carrigan KA, 2007, PSYCHOPHARMACOLOGY, V191, P985, DOI 10.1007/s00213-006-0671-1
   Case D. A., 2016, AMBER, DOI DOI 10.13140/RG.2.2.27958.70729
   Chen F, 2016, PHYS CHEM CHEM PHYS, V18, P22129, DOI 10.1039/c6cp03670h
   Chen JF, 2003, NEUROPSYCHOPHARMACOL, V28, P1086, DOI 10.1038/sj.npp.1300152
   Chen JZ, 2007, J CHEM INF MODEL, V47, P1626, DOI 10.1021/ci7000814
   Chen MZ, 2019, J CHEM INF MODEL, V59, P1283, DOI 10.1021/acs.jcim.8b00623
   Chiamulera C, 2017, PSYCHOPHARMACOLOGY, V234, P1357, DOI 10.1007/s00213-016-4487-3
   CHOW MJ, 1985, CLIN PHARMACOL THER, V38, P318, DOI 10.1038/clpt.1985.179
   Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001
   Cone EJ, 2003, J ANAL TOXICOL, V27, P386, DOI 10.1093/jat/27.7.386
   Cotter R, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00039
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   De Vries TJ, 2001, NAT MED, V7, P1151, DOI 10.1038/nm1001-1151
   Dencker D, 2012, PSYCHOPHARMACOLOGY, V224, P277, DOI 10.1007/s00213-012-2751-8
   Deng LT, 2015, BIOL PSYCHIAT, V77, P475, DOI 10.1016/j.biopsych.2014.04.009
   Dhanya RP, 2011, J MED CHEM, V54, P342, DOI 10.1021/jm1012165
   Dhopeshwarkar A, 2014, MOL PHARMACOL, V86, P430, DOI 10.1124/mol.114.094649
   Ehrhart J, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-29
   Ertl P, 2010, J CHEMINFORMATICS, V2, DOI 10.1186/1758-2946-2-1
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Webb Benjamin, 2016, Curr Protoc Bioinformatics, V54, DOI [10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s15, 10.1002/cpps.20, 10.1002/cpbi.3]
   Feierman DE, 1996, DRUG METAB DISPOS, V24, P932
   Feng Zhiwei, 2015, Journal of Chemical Biology, V8, P79, DOI 10.1007/s12154-015-0131-7
   Feng ZW, 2015, J CHEM INF MODEL, V55, P572, DOI 10.1021/ci5007189
   Feng ZW, 2014, J CHEM INF MODEL, V54, P2483, DOI 10.1021/ci5002718
   Gallelli L., 2018, CURR DRUG ABUSE REV, V10, P25
   Gardner EL, 2006, NEUROPHARMACOLOGY, V51, P993, DOI 10.1016/j.neuropharm.2006.06.009
   Gotz AW, 2012, J CHEM THEORY COMPUT, V8, P1542, DOI 10.1021/ct200909j
   Gorelick DA, 2004, DRUGS, V64, P1547, DOI 10.2165/00003495-200464140-00004
   Grabowski J, 2004, ADDICT BEHAV, V29, P1439, DOI 10.1016/j.addbeh.2004.06.018
   Gutstein H, 2001, GOODMAN GILMANS PHAR, P569
   Hammad AM, 2019, MOL NEUROBIOL, V56, P1921, DOI 10.1007/s12035-018-1153-2
   Hanley S., 2010, SYBYL X V1 3, P1699
   Hart CL, 2000, PSYCHOPHARMACOLOGY, V149, P153, DOI 10.1007/s002139900363
   Hawkins GD, 1996, J PHYS CHEM-US, V100, P19824, DOI 10.1021/jp961710n
   Hilger D, 2018, NAT STRUCT MOL BIOL, V25, P4, DOI 10.1038/s41594-017-0011-7
   Hongjian Li, 2012, 2012 IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB), P77, DOI 10.1109/CIBCB.2012.6217214
   Hu JP, 2016, J CHEM INF MODEL, V56, P1152, DOI 10.1021/acs.jcim.5b00739
   HUSTVEIT O, 1994, JPN J PHARMACOL, V64, P57, DOI 10.1254/jjp.64.57
   Isberg V, 2017, NUCLEIC ACIDS RES, V45, P2936, DOI 10.1093/nar/gkw1218
   Izaguirre JA, 2001, J CHEM PHYS, V114, P2090, DOI 10.1063/1.1332996
   Jain AN, 1996, J COMPUT AID MOL DES, V10, P427, DOI 10.1007/BF00124474
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   JAVAID JI, 1983, BIOPHARM DRUG DISPOS, V4, P9, DOI 10.1002/bdd.2510040104
   JEFFCOAT AR, 1989, DRUG METAB DISPOS, V17, P153
   Jin XC, 2010, NEUROPSYCHOPHARMACOL, V35, P2021, DOI 10.1038/npp.2010.82
   Jing L, 2015, INT J NEUROPSYCHOPH, V18, DOI 10.1093/ijnp/pyu060
   Jones CM, 2018, JAMA-J AM MED ASSOC, V319, P1819, DOI 10.1001/jama.2018.2844
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Keck TM, 2014, ADDICT BIOL, V19, P195, DOI 10.1111/adb.12086
   Kenny PJ, 2005, PSYCHOPHARMACOLOGY, V179, P247, DOI 10.1007/s00213-004-2069-2
   Kolbrich EA, 2006, J ANAL TOXICOL, V30, P501, DOI 10.1093/jat/30.8.501
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G
   Kumaresan V, 2009, BEHAV BRAIN RES, V202, P238, DOI 10.1016/j.bbr.2009.03.039
   Ladona MG, 2000, LIFE SCI, V68, P431, DOI 10.1016/S0024-3205(00)00952-8
   Lam VM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00953
   LEDUC BW, 1993, PHARMACOLOGY, V46, P294, DOI 10.1159/000139058
   Li AL, 2019, MOL PHARMACOL, V95, P155, DOI 10.1124/mol.118.113233
   Li X, 2017, PSYCHOPHARMACOLOGY, V234, P1633, DOI 10.1007/s00213-017-4594-9
   Li X, 2016, PSYCHOPHARMACOLOGY, V233, P1801, DOI 10.1007/s00213-016-4220-2
   Li XT, 2019, CELL, V176, P459, DOI 10.1016/j.cell.2018.12.011
   Lin JH, 2003, ADV DRUG DELIVER REV, V55, P53, DOI 10.1016/S0169-409X(02)00171-0
   Lin XY, 2018, MOL PHARMACOL, V93, P49, DOI 10.1124/mol.117.109355
   Liu HB, 2014, J CHEM INF MODEL, V54, P1050, DOI 10.1021/ci500004h
   Liu JF, 2017, J NEUROSCI, V37, P882, DOI 10.1523/JNEUROSCI.2006-16.2016
   LONCHARICH RJ, 1992, BIOPOLYMERS, V32, P523, DOI 10.1002/bip.360320508
   Maccioni P, 2008, ALCOHOL CLIN EXP RES, V32, P1558, DOI 10.1111/j.1530-0277.2008.00725.x
   Maccioni P, 2007, PSYCHOPHARMACOLOGY, V193, P171, DOI 10.1007/s00213-007-0776-1
   Maccioni P, 2009, ALCOHOL CLIN EXP RES, V33, P1749, DOI 10.1111/j.1530-0277.2009.01012.x
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Malan TP, 2001, PAIN, V93, P239, DOI 10.1016/S0304-3959(01)00321-9
   MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004
   McCance-Katz EF, 2010, AM J ADDICTION, V19, P38, DOI 10.1111/j.1521-0391.2009.00001.x
   Neant N., 2018, INT J ANTIMICROB AG, V13, P14
   Oda Y, 1999, BRIT J ANAESTH, V82, P900, DOI 10.1093/bja/82.6.900
   Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29
   Pal D, 2006, J NEUROIMMUNE PHARM, V1, P323, DOI 10.1007/s11481-006-9034-2
   Pawar P. P., 2017, ASIAN J PHARM SCI TE, V7, P61
   Pei Y, 2015, PROG NEURO-PSYCHOPH, V63, P70, DOI 10.1016/j.pnpbp.2015.05.014
   Pertwee RG, 2002, PHARMACOL THERAPEUT, V95, P165, DOI 10.1016/S0163-7258(02)00255-3
   Poleszak E, 2000, POL J PHARMACOL, V52, P423
   Runyon SP, 2006, CURR TOP MED CHEM, V6, P1825, DOI 10.2174/156802606778249775
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   Salomon-Ferrer R, 2013, J CHEM THEORY COMPUT, V9, P3878, DOI 10.1021/ct400314y
   Shabani S, 2010, NEUROSCIENCE, V170, P559, DOI 10.1016/j.neuroscience.2010.07.028
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   SITKOFF D, 1994, J PHYS CHEM-US, V98, P1978, DOI 10.1021/j100058a043
   Spreafico M, 2013, CURR TOP MED CHEM, V13, P813, DOI 10.2174/1568026611313070004
   STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038
   Sun HY, 2018, PHYS CHEM CHEM PHYS, V20, P14450, DOI 10.1039/c7cp07623a
   Sun HY, 2014, PHYS CHEM CHEM PHYS, V16, P22035, DOI 10.1039/c4cp03179b
   Sun HY, 2014, PHYS CHEM CHEM PHYS, V16, P16719, DOI 10.1039/c4cp01388c
   Tanda G, 2007, J PHARMACOL EXP THER, V321, P334, DOI 10.1124/jpet.106.118067
   Thorn DA, 2014, NEUROPSYCHOPHARMACOL, V39, P2309, DOI 10.1038/npp.2014.91
   Tournier N, 2010, INT J NEUROPSYCHOPH, V13, P905, DOI 10.1017/S1461145709990848
   Tsui V, 2001, BIOPOLYMERS, V56, P275, DOI 10.1002/1097-0282(2000)56:4<275::AID-BIP10024>3.0.CO;2-E
   Verma V, 2015, CLIN PSYCHOPHARM NEU, V13, P227, DOI 10.9758/cpn.2015.13.3.227
   Volkow ND, 2017, NAT REV NEUROSCI, V18, P741, DOI 10.1038/nrn.2017.130
   Vorel SR, 2002, J NEUROSCI, V22, P9595
   Wandel C, 2002, ANESTHESIOLOGY, V96, P913, DOI 10.1097/00000542-200204000-00019
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang JM, 2012, J CHEM INF MODEL, V52, P1199, DOI 10.1021/ci300064d
   Wang L, 2013, AAPS J, V15, P53, DOI 10.1208/s12248-012-9413-y
   Weiser J, 1999, J COMPUT CHEM, V20, P217, DOI 10.1002/(SICI)1096-987X(19990130)20:2<217::AID-JCC4>3.0.CO;2-A
   Xi ZX, 2008, NEUROPSYCHOPHARMACOL, V33, P1735, DOI 10.1038/sj.npp.1301552
   Xi ZX, 2006, NEUROPSYCHOPHARMACOL, V31, P1393, DOI 10.1038/sj.npp.1300912
   Xi ZX, 2017, NEUROPSYCHOPHARMACOL, V42, P682, DOI 10.1038/npp.2016.155
   Xi ZX, 2011, NAT NEUROSCI, V14, P1160, DOI 10.1038/nn.2874
   Xi ZX, 2005, EUR J NEUROSCI, V21, P3427, DOI 10.1111/j.1460-9568.2005.04159.x
   Xie JD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143701
   Xu XM, 2016, J MOL GRAPH MODEL, V70, P284, DOI 10.1016/j.jmgm.2016.08.001
   Xue Y, 2018, ACTA PHARMACOL SIN, V39, P205, DOI 10.1038/aps.2017.85
   Yao LN, 2006, P NATL ACAD SCI USA, V103, P7877, DOI 10.1073/pnas.0602661103
   Yoshida Y, 1999, NEUROSCIENCE, V92, P1357, DOI 10.1016/S0306-4522(99)00046-9
   Zerbino DR, 2018, NUCLEIC ACIDS RES, V46, pD754, DOI 10.1093/nar/gkx1098
   Zhang H, 2016, SCI REP-UK, V6, DOI 10.1038/srep33963
   Zhang HY, 2017, ADDICT BIOL, V22, P752, DOI 10.1111/adb.12367
   Zhang HY, 2015, NEUROPSYCHOPHARMACOL, V40, P1037, DOI 10.1038/npp.2014.297
   Zhang HY, 2014, P NATL ACAD SCI USA, V111, pE5007, DOI 10.1073/pnas.1413210111
   Zhang Y, 2016, J CHEM INF MODEL, V56, P1995, DOI 10.1021/acs.jcim.5b00748
NR 133
TC 15
Z9 15
U1 0
U2 37
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-7193
J9 ACS CHEM NEUROSCI
JI ACS Chem. Neurosci.
PD AUG
PY 2019
VL 10
IS 8
BP 3486
EP 3499
DI 10.1021/acschemneuro.9b00109
PG 27
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences
   & Neurology
GA IT0OS
UT WOS:000482546100022
PM 31257858
OA Green Accepted
DA 2023-06-23
ER

PT J
AU McConnell, PA
   Froeliger, B
AF McConnell, Patrick A.
   Froeliger, Brett
TI Mindfulness, Mechanisms and Meaning: Perspectives From the Cognitive
   Neuroscience of Addiction
SO PSYCHOLOGICAL INQUIRY
LA English
DT Editorial Material
ID STATE FUNCTIONAL CONNECTIVITY; DEFAULT-MODE NETWORK; ANTERIOR CINGULATE
   CORTEX; ORIENTED RECOVERY ENHANCEMENT; DECISION-MAKING; DRUG-ADDICTION;
   CIGARETTE-SMOKING; PREFRONTAL CORTEX; COCAINE ADDICTION; NEURAL RESPONSE
C1 [McConnell, Patrick A.; Froeliger, Brett] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
   [Froeliger, Brett] Med Univ S Carolina, Dept & Psychiat, Charleston, SC 29425 USA.
   [Froeliger, Brett] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.
C3 Medical University of South Carolina; Medical University of South
   Carolina; Medical University of South Carolina
RP Froeliger, B (通讯作者)，Med Univ S Carolina, Neurosci Res, 96 Jonathan Lucas St,MSC 606, Charleston, SC 29425 USA.
EM froelige@musc.edu
RI McConnell, Patrick A./AAE-8342-2020; McConnell, Patrick A./P-9391-2019
OI Froeliger, Brett/0000-0001-9451-9900; McConnell, Patrick
   A./0000-0002-6367-7065
FU NCI NIH HHS [P30 CA138313] Funding Source: Medline; NIDA NIH HHS [R01
   DA033459] Funding Source: Medline
CR Alcaro A, 2011, NEUROSCI BIOBEHAV R, V35, P1805, DOI 10.1016/j.neubiorev.2011.03.002
   Asensio S, 2010, ADDICT BIOL, V15, P504, DOI 10.1111/j.1369-1600.2010.00230.x
   Azizian A, 2010, NEUROPSYCHOPHARMACOL, V35, P775, DOI 10.1038/npp.2009.186
   Barros-Loscertales A, 2011, PSYCHIAT RES-NEUROIM, V194, P111, DOI 10.1016/j.pscychresns.2011.05.001
   Beauregard M, 2006, NEUROSCI LETT, V405, P186, DOI 10.1016/j.neulet.2006.06.060
   Beck AT, 2009, DEPRESSION: CAUSES AND TREATMENT, SECOND EDITION, P1
   Berridge KC, 2009, CURR OPIN PHARMACOL, V9, P65, DOI 10.1016/j.coph.2008.12.014
   BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409
   Brewer JA, 2011, P NATL ACAD SCI USA, V108, P20254, DOI 10.1073/pnas.1112029108
   Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2
   Bush G, 2002, P NATL ACAD SCI USA, V99, P523, DOI 10.1073/pnas.012470999
   Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P300
   Cole DM, 2010, NEUROIMAGE, V52, P590, DOI 10.1016/j.neuroimage.2010.04.251
   Craig AD, 2011, ANN NY ACAD SCI, V1225, P72, DOI 10.1111/j.1749-6632.2011.05990.x
   Delle Fave A, 2011, CROSS CULT ADV POSIT, V2, P39, DOI 10.1007/978-90-481-9876-4_3
   Diekhof EK, 2008, BRAIN RES REV, V59, P164, DOI 10.1016/j.brainresrev.2008.07.004
   Diggs HA, 2013, PSYCHIAT RES-NEUROIM, V211, P85, DOI 10.1016/j.pscychresns.2012.06.009
   Duncan NW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060312
   Fox MD, 2010, FRONT SYST NEUROSCI, V4, DOI [10.3389/fnsys.2010.00019, 10.3389/fnsys.2010.0001]
   Fredrickson BL, 2004, PHILOS T R SOC B, V359, P1367, DOI 10.1098/rstb.2004.1512
   Froeliger B, 2015, DRUG ALCOHOL DEPEN, V156, P234, DOI 10.1016/j.drugalcdep.2015.09.021
   Froeliger B, 2013, PSYCHIAT RES-NEUROIM, V211, P57, DOI 10.1016/j.pscychresns.2012.05.002
   Froeliger B, 2012, ADDICT BIOL, V17, P668, DOI 10.1111/j.1369-1600.2011.00410.x
   Froeliger B, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/680407
   Froeliger B, 2012, PSYCHOPHARMACOLOGY, V220, P707, DOI 10.1007/s00213-011-2522-y
   Froeliger BE, 2012, FRONT INTEGR NEUROSC, V6, DOI 10.3389/fnint.2012.00048
   Garavan H, 2008, PHILOS T R SOC B, V363, P3267, DOI 10.1098/rstb.2008.0106
   Garland EL, 2015, J BEHAV MED, V38, P327, DOI 10.1007/s10865-014-9607-0
   Garland EL, 2014, PSYCHOPHARMACOLOGY, V231, P3229, DOI 10.1007/s00213-014-3504-7
   Garland EL, 2014, FRONT PSYCHIATRY, V4, DOI 10.3389/fpsyt.2013.00173
   Garland EL, 2011, MED HYPOTHESES, V76, P745, DOI 10.1016/j.mehy.2011.02.014
   Garland EL, 2010, CLIN PSYCHOL REV, V30, P849, DOI 10.1016/j.cpr.2010.03.002
   Garrison KA, 2015, COGN AFFECT BEHAV NE, V15, P712, DOI 10.3758/s13415-015-0358-3
   George O, 2010, NEUROSCI BIOBEHAV R, V35, P232, DOI 10.1016/j.neubiorev.2010.05.002
   Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119
   Goldstein RZ, 2009, P NATL ACAD SCI USA, V106, P9453, DOI 10.1073/pnas.0900491106
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Greicius M, 2008, CURR OPIN NEUROL, V21, P424, DOI 10.1097/WCO.0b013e328306f2c5
   Greicius MD, 2007, BIOL PSYCHIAT, V62, P429, DOI 10.1016/j.biopsych.2006.09.020
   Gu H, 2010, NEUROIMAGE, V53, P593, DOI 10.1016/j.neuroimage.2010.06.066
   Hamilton JP, 2015, BIOL PSYCHIAT, V78, P224, DOI 10.1016/j.biopsych.2015.02.020
   Hampshire A, 2010, NEUROIMAGE, V50, P1313, DOI 10.1016/j.neuroimage.2009.12.109
   Hasenkamp W, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00038
   Hester R, 2009, PHARMACOL BIOCHEM BE, V93, P270, DOI 10.1016/j.pbb.2008.12.009
   Holzel BK, 2011, PERSPECT PSYCHOL SCI, V6, P537, DOI 10.1177/1745691611419671
   Holzel B., 2006, J TRANSPERSONAL PSYC, V38, P179, DOI DOI 10.1002/pola.20555
   Hong LE, 2009, ARCH GEN PSYCHIAT, V66, P431, DOI 10.1001/archgenpsychiatry.2009.2
   Jamal A, 2014, MMWR-MORBID MORTAL W, V63, P1108
   Jang JH, 2011, NEUROSCI LETT, V487, P358, DOI 10.1016/j.neulet.2010.10.056
   Jao T, 2016, BRAIN CONNECT, V6, P9, DOI 10.1089/brain.2014.0318
   Josipovic Z, 2014, ANN NY ACAD SCI, V1307, P9, DOI 10.1111/nyas.12261
   Josipovic Z, 2012, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00183
   Kalisch R, 2009, NEUROSCI BIOBEHAV R, V33, P1215, DOI 10.1016/j.neubiorev.2009.06.003
   Kalivas PW, 2009, NAT REV NEUROSCI, V10, P561, DOI 10.1038/nrn2515
   Kang Y, 2013, EMOT REV, V5, P192, DOI 10.1177/1754073912451629
   Kiken LG, 2011, SOC PSYCHOL PERS SCI, V2, P425, DOI 10.1177/1948550610396585
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Kozink RV, 2010, ADDICT BIOL, V15, P480, DOI 10.1111/j.1369-1600.2010.00252.x
   Kringelbach ML, 2009, TRENDS COGN SCI, V13, P479, DOI 10.1016/j.tics.2009.08.006
   Ma N, 2010, NEUROIMAGE, V49, P738, DOI 10.1016/j.neuroimage.2009.08.037
   Motzkin JC, 2014, HUM BRAIN MAPP, V35, P4282, DOI 10.1002/hbm.22474
   Naqvi NH, 2007, SCIENCE, V315, P531, DOI 10.1126/science.1135926
   Naqvi NH, 2010, BRAIN STRUCT FUNCT, V214, P435, DOI 10.1007/s00429-010-0268-7
   National Institute on Drug Abuse, 2015, NAT TRENDS
   Payer D. E., 2010, ARCH GEN PSYCHIAT, V2010, P2154
   Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676
   Richiardi J, 2015, SCIENCE, V348, P1241, DOI 10.1126/science.1255905
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Shallcross AJ, 2015, J CONSULT CLIN PSYCH, V83, P964, DOI 10.1037/ccp0000050
   Shmuel A, 2008, HUM BRAIN MAPP, V29, P751, DOI 10.1002/hbm.20580
   Simon R, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00776
   Sinha R, 2005, PSYCHOPHARMACOLOGY, V183, P171, DOI 10.1007/s00213-005-0147-8
   Sperduti M, 2012, CONSCIOUS COGN, V21, P269, DOI 10.1016/j.concog.2011.09.019
   Spreng RN, 2012, CEREB CORTEX, V22, P2610, DOI 10.1093/cercor/bhr339
   Sutherland MT, 2012, NEUROIMAGE, V62, P2281, DOI 10.1016/j.neuroimage.2012.01.117
   Tang YY, 2015, NAT REV NEUROSCI, V16, P213, DOI 10.1038/nrn3916
   Tang YY, 2012, TRENDS COGN SCI, V16, P330, DOI 10.1016/j.tics.2012.05.001
   Taylor VA, 2013, SOC COGN AFFECT NEUR, V8, P4, DOI 10.1093/scan/nsr087
   Vago DR, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00296
   Verdejo-Garcia A, 2009, NEUROPHARMACOLOGY, V56, P48, DOI 10.1016/j.neuropharm.2008.07.035
NR 82
TC 26
Z9 28
U1 5
U2 42
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1047-840X
EI 1532-7965
J9 PSYCHOL INQ
JI Psychol. Inq.
PD OCT 2
PY 2015
VL 26
IS 4
BP 349
EP 357
DI 10.1080/1047840X.2015.1076701
PG 9
WC Psychology, Multidisciplinary
WE Social Science Citation Index (SSCI)
SC Psychology
GA CX3KQ
UT WOS:000365598100007
PM 26924915
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Walsh, A
   Johnson, H
   Bolen, JD
AF Walsh, Anthony
   Johnson, Hailey
   Bolen, Jonathan D.
TI Drugs, Crime, and the Epigenetics of Hedonic Allostasis
SO JOURNAL OF CONTEMPORARY CRIMINAL JUSTICE
LA English
DT Article
DE drug abuse; epigenetics; allostasis; reward dominance; opponent process
ID NEUROBIOLOGY; ADDICTION; STRESS
AB Given the relationship between drug abuse and criminal behavior, it is important for criminologists to understand what drug addiction is and how it occurs. This article examines the process of becoming addicted to drugs (specifically, cocaine) via epigenetic processes. Frequent drug usage leads to an allostatic (the changing of a physiological system by the calibration its set points) brain changes in its pleasure centers. We first examine the reward dominance theory of approach-avoidance behavior, and then explore epigenetic processes in the context of the opponent process and the incentive-sensitization models of drug addiction, and in terms of environmental stress.
C1 [Walsh, Anthony; Bolen, Jonathan D.] Boise State Univ, Boise, ID 83725 USA.
   [Walsh, Anthony; Johnson, Hailey] Boise State Univ, Dept Criminal Justice, Boise, ID 83725 USA.
C3 Idaho; Boise State University; Idaho; Boise State University
RP Walsh, A (通讯作者)，Boise State Univ, Dept Criminal Justice, Boise, ID 83725 USA.
EM twalsh@boisestate.edu
CR Ahmed SH, 2009, PHARMACOPSYCHIATRY, V42, pS144, DOI 10.1055/s-0029-1216345
   Anderson E., 1999, CODE STREETS DECENCY
   Bevilacqua L, 2009, CLIN PHARMACOL THER, V85, P359, DOI 10.1038/clpt.2009.6
   Chao J, 2004, ANNU REV MED, V55, P113, DOI 10.1146/annurev.med.55.091902.103730
   Corr PJ, 2004, NEUROSCI BIOBEHAV R, V28, P317, DOI 10.1016/j.neubiorev.2004.01.005
   Corwin Elizabeth J, 2004, Biol Res Nurs, V6, P11, DOI 10.1177/1099800404264779
   Cullen FT, 2009, CRIMINOL JUST STUD, pXV
   Day JJ, 2007, NEUROSCIENTIST, V13, P148, DOI 10.1177/1073858406295854
   Enoch MA, 2006, ANN NY ACAD SCI, V1094, P193, DOI 10.1196/annals.1376.019
   Fishbein D., 2001, BIOBEHAVIORAL PERSPE
   Goeders N., 2002, PERSPECTIVES PHARM, V301, P885
   Goldsmith HH, 2004, CHILD DEV, V75, P361, DOI 10.1111/j.1467-8624.2004.00678.x
   Gottlieb G, 2007, DEVELOPMENTAL SCI, V10, P1, DOI 10.1111/j.1467-7687.2007.00556.x
   Gunnar M, 2007, ANNU REV PSYCHOL, V58, P145, DOI 10.1146/annurev.psych.58.110405.085605
   Hyman SE, 2007, AM J BIOETHICS, V7, P8, DOI 10.1080/15265160601063969
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564
   Koob GF, 2008, ANNU REV PSYCHOL, V59, P29, DOI 10.1146/annurev.psych.59.103006.093548
   Kubota T, 2010, J PHARMACOL SCI, V113, P3, DOI 10.1254/jphs.09R20FM
   Lopez-Rangel E, 2006, CLIN GENET, V69, P21, DOI 10.1111/j.1399-0004.2006.00543a.x
   Madras B., 2006, HARVARD MAHONEY NEUR, V12, P1
   Massey D., 2004, DU BOIS REV, V1, P7, DOI DOI 10.1017/S1742058X04040032
   McDermott PA, 2000, J CONSULT CLIN PSYCH, V68, P181, DOI 10.1037/0022-006X.68.1.181
   Menard S, 2001, JUSTICE Q, V18, P269, DOI 10.1080/07418820100094901
   Narvaez D, 2008, J MORAL EDUC, V37, P289, DOI 10.1080/03057240802227478
   Nestler EJ, 2001, P NATL ACAD SCI USA, V98, P11042, DOI 10.1073/pnas.191352698
   Office of Drug Control Policy, 2010, ADAM 2 2009 ANN REP
   Oh G, 2008, SCHIZOPHRENIA BULL, V34, P1122, DOI 10.1093/schbul/sbn105
   Powledge TM, 2009, BIOSCIENCE, V59, P736, DOI 10.1525/bio.2009.59.9.3
   Quinn J., 2008, J TEACHING ADDICTION, V70, P16, DOI DOI 10.1080/15332700802072258
   Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI 10.1146/annurev.psych.54.101601.145237
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   SOLOMON RL, 1980, AM PSYCHOL, V35, P691, DOI 10.1037/0003-066X.35.8.691
   Tsai HC, 2009, SCIENCE, V324, P1080, DOI 10.1126/science.1168878
   Tsankova N, 2007, NAT REV NEUROSCI, V8, P355, DOI 10.1038/nrn2132
   van Goozen SHM, 2007, PSYCHOL BULL, V133, P149, DOI 10.1037/0033-2909.133.1.149
   Van Voorhees Elizabeth, 2004, Trauma Violence Abuse, V5, P333, DOI 10.1177/1524838004269486
   Vaughn MG, 2009, CRIMINOL JUST STUD, P176
   Walsh A, 2009, CRIMINOL JUST STUD, P1
   Walsh A., 2003, BIOSOCIAL CRIMINOLOG, P185
   Wand G, 2008, ALCOHOL RES HEALTH, V31, P119
   Weinhold B., 2006, ENVIRON HEALTH PERSP, V114, P161
   Wright JP, 2009, CRIM JUSTICE BEHAV, V36, P1228, DOI 10.1177/0093854809343140
NR 42
TC 10
Z9 10
U1 1
U2 13
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1043-9862
EI 1552-5406
J9 J CONTEMP CRIM JUST
JI J. Contemp. Crim. Justice
PD AUG
PY 2012
VL 28
IS 3
SI SI
BP 314
EP 328
DI 10.1177/1043986212450226
PG 15
WC Criminology & Penology
WE Social Science Citation Index (SSCI)
SC Criminology & Penology
GA V35SH
UT WOS:000209168000006
OA Green Submitted
DA 2023-06-23
ER

PT J
AU Piacentine, LB
AF Piacentine, Linda B.
TI Spirituality, Religiosity, Depression, Anxiety, and Drug-Use
   Consequences During Methadone Maintenance Therapy
SO WESTERN JOURNAL OF NURSING RESEARCH
LA English
DT Article
DE spirituality; religiosity; substance addiction; anxiety; depression
ID ADDICTION; INVENTORY; SEVERITY; HEALTH; INDUC; PHQ-9
AB Substance addiction is damaging to the health of persons, families, and society. Often the person with addiction has decreased spirituality and religiosity and suffers from anxiety, depression, or both, increasing the risk for continued substance use and its concomitant negative consequences. The study purpose was to describe spirituality and religiosity, among persons enrolled in methadone maintenance therapy and to examine associations between spirituality, religiosity, anxiety, depression, and drug-use consequences. Using a descriptive and cross-sectional correlational design, 108 participants completed questionnaires assessing the study variables. Spiritual well-being was similar to other addiction samples and lower than healthy person samples. Most participants described themselves as spiritual or religious though religious participation was lower than in their past. The analysis indicated that spirituality, religiosity, depression, anxiety, and negative drug-use consequences are interrelated in the person with addiction. Higher anxiety was predictive of negative drug-use consequences.
C1 Marquette Univ, Coll Nursing, Milwaukee, WI 53201 USA.
C3 Marquette University
RP Piacentine, LB (通讯作者)，Marquette Univ, Coll Nursing, POB 1881, Milwaukee, WI 53201 USA.
EM linda.piacentine@marquette.edu
RI Piacentine, Linda/L-8779-2019
OI Piacentine, Linda/0000-0003-3844-7142
CR *AM PSYCHIAT ASS, 1994, DIAGN STAT MAN MENT
   [Anonymous], 2000, J BLACK PSYCHOL, DOI DOI 10.1177/0095798400026004008
   BRIZER DA, 1993, AM J DRUG ALCOHOL AB, V19, P337, DOI 10.3109/00952999309001623
   BUFFORD RK, 1991, J PSYCHOL THEOL, V19, P56, DOI 10.1177/009164719101900106
   Center for Substance Abuse Treatment, 2005, DHHS PUBL, V43
   Conner KR, 2009, J PSYCHOACTIVE DRUGS, V41, P93, DOI 10.1080/02791072.2009.10400678
   Connors GJ, 1996, PSYCHOL ADDICT BEHAV, V10, P90, DOI 10.1037/0893-164X.10.2.90
   DARKE S, 1994, ADDICTION, V89, P211, DOI 10.1111/j.1360-0443.1994.tb00880.x
   Dum M, 2008, ADDICT BEHAV, V33, P381, DOI 10.1016/j.addbeh.2007.09.017
   ELLISON CW, 1991, J PSYCHOL THEOL, V19, P35, DOI 10.1177/009164719101900104
   ELLISON CW, 1983, J PSYCHOL THEOL, V11, P330, DOI 10.1177/009164718301100406
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Fehring R J, 1997, Oncol Nurs Forum, V24, P663
   Ghitza UE, 2007, DRUG ALCOHOL DEPEN, V91, P169, DOI 10.1016/j.drugalcdep.2007.05.018
   Green LL, 1998, J SUBST ABUSE TREAT, V15, P325, DOI 10.1016/S0740-5472(97)00211-0
   Hartz G. W., 2005, SPIRITUALITY MENTAL
   Heinz AJ, 2010, SUBST USE MISUSE, V45, P134, DOI 10.3109/10826080903035130
   Hill PC, 1999, MEASURES RELIG
   Koenig HG, 2008, J NERV MENT DIS, V196, P349, DOI 10.1097/NMD.0b013e31816ff796
   Koenig HG, 2009, CAN J PSYCHIAT, V54, P283, DOI 10.1177/070674370905400502
   KOENIG HG, 2001, HDB RELIG HLTH
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   McCoubrie R, 2006, SUPPORT CARE CANCER, V14, P379, DOI 10.1007/s00520-005-0892-6
   Miller WR, 2008, J SUBST ABUSE TREAT, V35, P434, DOI 10.1016/j.jsat.2008.02.004
   Miller WR, 2007, SOUTH MED J, V100, P433, DOI 10.1097/SMJ.0b013e3180316fbf
   Neuman B., 2002, NEUMAN SYSTEMS MODEL
   OBrien M. E., 2011, SPIRITUALITY NURSING
   Piderman M. A. K., 2005, THESIS WALDEN U MINN
   Spielberger CD., 1983, APA PSYCTESTS, DOI [10.1039/t06496-000, DOI 10.1037/T06496-000]
   States J. A., 2001, THESIS W VIRGINIA U
   Stimmel B, 2009, FAM COURT REV, V47, P265, DOI 10.1111/j.1744-1617.2009.01253.x
   Substance Abuse and Mental Health Services Administration, 2012, RES 2010 NAT SURV DR
   Tonigan JS, 2007, SOUTH MED J, V100, P437, DOI 10.1097/SMJ.0b013e31803171ef
   Tonigan JS, 2002, PSYCHOL ADDICT BEHAV, V16, P165, DOI 10.1037//0893-164X.16.2.165
   Verthein U, 2005, EUR ADDICT RES, V11, P15, DOI 10.1159/000081412
   White W, 2010, RECOVERY ORIENTED ME
NR 36
TC 6
Z9 6
U1 1
U2 13
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0193-9459
EI 1552-8456
J9 WESTERN J NURS RES
JI West. J. Nurs. Res.
PD JUL
PY 2013
VL 35
IS 6
BP 795
EP 814
DI 10.1177/0193945913479452
PG 20
WC Nursing
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Nursing
GA 191FH
UT WOS:000322397900007
PM 23446494
OA Green Submitted
DA 2023-06-23
ER

PT C
AU Kabiri, MN
   Paracha, S
AF Kabiri, Mohammad Nazim
   Paracha, Samiullah
BE Meen, TH
   Prior, SD
   Lam, ADKT
TI Virtual Reality Intervention: A Promising Deterrent to Children's Drug
   Addiction
SO PROCEEDINGS OF THE IEEE INTERNATIONAL CONFERENCE ON ADVANCED MATERIALS
   FOR SCIENCE AND ENGINEERING (IEEE-ICAMSE 2016)
LA English
DT Proceedings Paper
CT IEEE International Conference on Advanced Materials for Science and
   Engineering (IEEE-ICAMSE)
CY NOV 12-13, 2016
CL Tainan, TAIWAN
SP IEEE, IEEE Tainan Sect Sensors Council, Taiwanese Inst Knowledge Innovat, Natl Formosa Univ, Kun Shan Univ, So Taiwan Univ Sci & Technol, Natl United Univ, Kongju Natl Univ, Hannam Univ, Chia Nan Univ Pharmacy & Sci, St Johns Univ
DE ICT in Education; Artificial Intelligence; Virtual Learning Environment;
   Intelligent Virtual Agents
AB Drug addiction amongst Afghan children is a major social menace. This paper proposes an innovative virtual learning environment that will offer a promising deterrent against drug abuse at schools. The system comprises of an intelligent tutoring layer and a story generator. The former offers a customized learning on drug addiction to children and the later engages them in a coherent story generation. To measure success, usability and pedagogical evaluations will be carried out in lab and at Afghan schools consecutively.
C1 [Kabiri, Mohammad Nazim; Paracha, Samiullah] Kobe Inst Comp, Grad Sch Informat Technol, Dept Informat Syst, Kobe, Hyogo, Japan.
RP Kabiri, MN (通讯作者)，Kobe Inst Comp, Grad Sch Informat Technol, Dept Informat Syst, Kobe, Hyogo, Japan.
EM nazimkabiri@gmail.com; paracha@kic.ac.jp
RI kabiri, Mohammad taghi/AAE-7413-2022
OI kabiri, Mohammad taghi/0000-0001-9498-7712
FU Japan International Cooperation Agency (JICA)
FX The authors are grateful for the generous financial sponsor provided by
   Japan International Cooperation Agency (JICA). Further thanks should be
   extended to Kobe Institute of Computing for its assistance in carrying
   out this project at P-Lab.
CR [Anonymous], 2015, VOICE OF AM
   [Anonymous], 1995, WHAT IS EV
   delTufo Sarah, 2002, WHAT IS EV
   Framingham J., 2011, WHAT IS PSYCHOL ASSE
   Ministry of Counter Narcotics, 2013, AFGH DRUG REP MCN 20
   Parachal Samiullah, 2009, VIRTUAL REALITY INTE
   Psotka J., 1988, INTELLIGENT TUTORING
   Rubin J., 2011, HDB USABILITY TESTIN
   SHUTE V, 1989, LEARN INDIVID DIFFER, P279
   Tapscott D., 1998, GROWING DIGITAL RISE
   Thayer R. H., 1997, SOFTWARE REQUIREMENT
   Zoll C., EVALUATION METHODOLO
NR 12
TC 1
Z9 1
U1 0
U2 10
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 978-1-5090-3869-5
PY 2016
BP 530
EP 533
PG 4
WC Engineering, Multidisciplinary
WE Conference Proceedings Citation Index - Science (CPCI-S)
SC Engineering
GA BH6QD
UT WOS:000402015500149
DA 2023-06-23
ER

PT J
AU van Huijstee, AN
   Mansvelder, HD
AF van Huijstee, Aile N.
   Mansvelder, Huibert D.
TI Glutamatergic synaptic plasticity in the mesocorticolimbic system in
   addiction
SO FRONTIERS IN CELLULAR NEUROSCIENCE
LA English
DT Review
DE addiction; drugs of abuse; synaptic plasticity; glutamate; dopamine;
   ventral tegmental area; nucleus accumbens; prefrontal cortex
ID VENTRAL TEGMENTAL AREA; TIMING-DEPENDENT PLASTICITY; LONG-TERM
   POTENTIATION; MEDIAL PREFRONTAL CORTEX; ADOLESCENT NICOTINE EXPOSURE;
   AMPA RECEPTOR PLASTICITY; HUMAN MOTOR CORTEX; NUCLEUS-ACCUMBENS;
   IN-VIVO; DOPAMINE NEURONS
AB Addictive drugs remodel the brain's reward circuitry, the mesocorticolimbic dopamine (DA) system, by inducing widespread adaptations of glutamatergic synapses. This drug-induced synaptic plasticity is thought to contribute to both the development and the persistence of addiction. This review highlights the synaptic modifications that are induced by in vivo exposure to addictive drugs and describes how these drug-induced synaptic changes may contribute to the different components of addictive behavior, such as compulsive drug use despite negative consequences and relapse. Initially, exposure to an addictive drug induces synaptic changes in the ventral tegmental area (VTA). This drug-induced synaptic potentiation in the VTA subsequently triggers synaptic changes in downstream areas of the mesocorticolimbic system, such as the nucleus accumbens (NAc) and the prefrontal cortex (PFC), with further drug exposure. These glutamatergic synaptic alterations are then thought to mediate many of the behavioral symptoms that characterize addiction. The later stages of glutamatergic synaptic plasticity in the NAc and in particular in the PFC play a role in maintaining addiction and drive relapse to drug-taking induced by drug-associated cues. Remodeling of PFC glutamatergic circuits can persist into adulthood, causing a lasting vulnerability to relapse. We will discuss how these neurobiological changes produced by drugs of abuse may provide novel targets for potential treatment strategies for addiction.
C1 [van Huijstee, Aile N.; Mansvelder, Huibert D.] Vrije Univ Amsterdam, Ctr Neurogenom & Cognit Res, Dept Integrat Neurophysiol, NL-1081 HV Amsterdam, Netherlands.
C3 Vrije Universiteit Amsterdam
RP Mansvelder, HD (通讯作者)，Vrije Univ Amsterdam, Ctr Neurogenom & Cognit Res, Dept Integrat Neurophysiol, Neurosci Campus Amsterdam,Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands.
EM h.d.mansvelder@vu.nl
RI Mansvelder, Huibert/N-6138-2018
OI Mansvelder, Huibert/0000-0003-1365-5340
CR Abrahao KP, 2013, J NEUROSCI, V33, P4834, DOI 10.1523/JNEUROSCI.5839-11.2013
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425596
   Argilli E, 2008, J NEUROSCI, V28, P9092, DOI 10.1523/JNEUROSCI.1001-08.2008
   Bellone C, 2006, NAT NEUROSCI, V9, P636, DOI 10.1038/nn1682
   Bellone C, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00075
   Ben-Shahar O, 2009, SYNAPSE, V63, P598, DOI 10.1002/syn.20640
   Bocklisch C, 2013, SCIENCE, V341, P1521, DOI 10.1126/science.1237059
   Borgland SL, 2004, J NEUROSCI, V24, P7482, DOI 10.1523/JNEUROSCI.1312-04.2004
   Boudreau AC, 2005, J NEUROSCI, V25, P9144, DOI 10.1523/JNEUROSCI.2252-05.2005
   Brebner K, 2005, SCIENCE, V310, P1340, DOI 10.1126/science.1116894
   Cahill E, 2014, MOL PSYCHIATR, V19, P1295, DOI 10.1038/mp.2014.73
   Chen BT, 2008, NEURON, V59, P288, DOI 10.1016/j.neuron.2008.05.024
   Conde V, 2013, J NEUROPHYSIOL, V109, P2260, DOI 10.1152/jn.01004.2012
   Conrad KL, 2008, NATURE, V454, P118, DOI 10.1038/nature06995
   Cornish JL, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-15-j0006.2000
   Couey JJ, 2007, NEURON, V54, P73, DOI 10.1016/j.neuron.2007.03.006
   Counotte DS, 2012, FASEB J, V26, P1810, DOI 10.1096/fj.11-198994
   Counotte DS, 2011, NAT NEUROSCI, V14, P417, DOI 10.1038/nn.2770
   Counotte DS, 2009, NEUROPSYCHOPHARMACOL, V34, P299, DOI 10.1038/npp.2008.96
   Creed MC, 2013, CURR OPIN NEUROBIOL, V23, P553, DOI 10.1016/j.conb.2013.03.005
   Curcio L, 2013, BRAIN, V136, P1216, DOI 10.1093/brain/awt036
   D'Ascenzo Marcello, 2014, Front Synaptic Neurosci, V6, P16, DOI 10.3389/fnsyn.2014.00016
   De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Dong Y, 2014, TRENDS PHARMACOL SCI, V35, P374, DOI 10.1016/j.tips.2014.05.005
   EMCDDA, 2013, EUR DRUG REP 2013
   Engblom D, 2008, NEURON, V59, P497, DOI 10.1016/j.neuron.2008.07.010
   Fitzgerald LW, 1996, J NEUROSCI, V16, P274
   Gabbott PLA, 2005, J COMP NEUROL, V492, P145, DOI 10.1002/cne.20738
   Gipson CD, 2014, NEUROPHARMACOLOGY, V76, P276, DOI 10.1016/j.neuropharm.2013.04.032
   Gipson CD, 2013, P NATL ACAD SCI USA, V110, P9124, DOI 10.1073/pnas.1220591110
   Gipson CD, 2013, NEURON, V77, P867, DOI 10.1016/j.neuron.2013.01.005
   Goriounova NA, 2012, J NEUROSCI, V32, P10484, DOI 10.1523/JNEUROSCI.5502-11.2012
   Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134
   Groenewegen HJ, 1999, ANN NY ACAD SCI, V877, P49, DOI 10.1111/j.1749-6632.1999.tb09260.x
   Grundey J, 2012, J NEUROSCI, V32, P4156, DOI 10.1523/JNEUROSCI.3660-11.2012
   Heidbreder CA, 2003, NEUROSCI BIOBEHAV R, V27, P555, DOI 10.1016/j.neubiorev.2003.09.003
   Hoover WB, 2007, BRAIN STRUCT FUNCT, V212, P149, DOI 10.1007/s00429-007-0150-4
   Huang YHH, 2009, NEURON, V63, P40, DOI 10.1016/j.neuron.2009.06.007
   Isaac JTR, 2007, NEURON, V54, P859, DOI 10.1016/j.neuron.2007.06.001
   ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2
   JOHNSON SW, 1992, J NEUROSCI, V12, P483
   Kalivas PW, 2009, NAT REV NEUROSCI, V10, P561, DOI 10.1038/nrn2515
   KALIVAS PW, 1993, NEUROSCIENCE, V57, P1047, DOI 10.1016/0306-4522(93)90048-K
   Kasanetz F, 2010, SCIENCE, V328, P1709, DOI 10.1126/science.1187801
   Knackstedt LA, 2010, BIOL PSYCHIAT, V67, P81, DOI 10.1016/j.biopsych.2009.07.018
   Koch G, 2013, J NEUROSCI, V33, P9725, DOI 10.1523/JNEUROSCI.4988-12.2013
   Kourrich S, 2007, J NEUROSCI, V27, P7921, DOI 10.1523/JNEUROSCI.1859-07.2007
   Koya E, 2012, NAT NEUROSCI, V15, P1556, DOI 10.1038/nn.3232
   Koya E, 2009, NAT NEUROSCI, V12, P1069, DOI 10.1038/nn.2364
   Kreple CJ, 2014, NAT NEUROSCI, V17, P1083, DOI 10.1038/nn.3750
   LaLumiere RT, 2012, EUR J NEUROSCI, V35, P614, DOI 10.1111/j.1460-9568.2012.07991.x
   Lammel S, 2014, NEUROPHARMACOLOGY, V76, P351, DOI 10.1016/j.neuropharm.2013.03.019
   Lammel S, 2012, NATURE, V491, P212, DOI 10.1038/nature11527
   Lammel S, 2011, NEURON, V70, P855, DOI 10.1016/j.neuron.2011.03.025
   LaRowe SD, 2007, AM J PSYCHIAT, V164, P1115, DOI 10.1176/appi.ajp.164.7.1115
   Lecca S, 2014, EUR J NEUROSCI, V39, P1170, DOI 10.1111/ejn.12480
   Lee BR, 2013, NAT NEUROSCI, V16, P1644, DOI 10.1038/nn.3533
   Liu QS, 2005, NATURE, V437, P1027, DOI 10.1038/nature04050
   Lu H, 2010, NEURON, V67, P821, DOI 10.1016/j.neuron.2010.08.012
   Lu MK, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00260
   Luscher C, 2013, J NEUROSCI, V33, P17641, DOI 10.1523/JNEUROSCI.3406-13.2013
   Luscher C, 2011, NEURON, V69, P650, DOI 10.1016/j.neuron.2011.01.017
   Luu P, 2008, J NEUROPHYSIOL, V100, P533, DOI 10.1152/jn.01384.2007
   Mameli M, 2007, SCIENCE, V317, P530, DOI 10.1126/science.1142365
   Mameli M, 2011, NAT NEUROSCI, V14, P414, DOI 10.1038/nn.2763
   Mameli M, 2009, NAT NEUROSCI, V12, P1036, DOI 10.1038/nn.2367
   Mansvelder HD, 2000, NEURON, V27, P349, DOI 10.1016/S0896-6273(00)00042-8
   Mansvelder HD, 2002, NEURON, V33, P905, DOI 10.1016/S0896-6273(02)00625-6
   Mao DY, 2011, J NEUROSCI, V31, P6710, DOI 10.1523/JNEUROSCI.5671-10.2011
   Mardikian PN, 2007, PROG NEURO-PSYCHOPH, V31, P389, DOI 10.1016/j.pnpbp.2006.10.001
   Maroteaux M, 2012, J NEUROSCI, V32, P12641, DOI 10.1523/JNEUROSCI.2405-12.2012
   Martin M, 2006, NAT NEUROSCI, V9, P868, DOI 10.1038/nn1713
   Maskos U, 2005, NATURE, V436, P103, DOI 10.1038/nature03694
   Mato S, 2004, NAT NEUROSCI, V7, P585, DOI 10.1038/nn1251
   Moussawi K, 2009, NAT NEUROSCI, V12, P182, DOI 10.1038/nn.2250
   Niehaus JL, 2010, EUR J NEUROSCI, V32, P108, DOI 10.1111/j.1460-9568.2010.07256.x
   Pascoli V, 2014, NATURE, V509, P459, DOI 10.1038/nature13257
   Pascoli V, 2012, NATURE, V481, P71, DOI 10.1038/nature10709
   Peters J, 2008, J NEUROSCI, V28, P6046, DOI 10.1523/JNEUROSCI.1045-08.2008
   Ping AS, 2008, BRAIN RES, V1215, P173, DOI 10.1016/j.brainres.2008.03.088
   Robinson TE, 2004, NEUROPHARMACOLOGY, V47, P33, DOI 10.1016/j.neuropharm.2004.06.025
   Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-7
   Schramm-Sapyta NL, 2006, NEUROPSYCHOPHARMACOL, V31, P1444, DOI 10.1038/sj.npp.1300918
   Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1
   Shen HW, 2014, J NEUROSCI, V34, P5649, DOI 10.1523/JNEUROSCI.4564-13.2014
   Stefan K, 2002, J PHYSIOL-LONDON, V543, P699, DOI 10.1113/jphysiol.2002.023317
   Stefan K, 2000, BRAIN, V123, P572, DOI 10.1093/brain/123.3.572
   Steffensen SC, 1998, J NEUROSCI, V18, P8003
   Sun WL, 2006, J NEUROSCI, V26, P8004, DOI 10.1523/JNEUROSCI.1413-06.2006
   SWANSON LW, 1982, BRAIN RES BULL, V9, P321, DOI 10.1016/0361-9230(82)90145-9
   Szabo B, 2002, EUR J NEUROSCI, V15, P2057, DOI 10.1046/j.1460-9568.2002.02041.x
   Tan KR, 2010, NATURE, V463, P769, DOI 10.1038/nature08758
   Tang WX, 2004, J NEUROCHEM, V89, P1021, DOI 10.1111/j.1471-4159.2004.02392.x
   Testa-Silva G, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1002007
   Testa-Silva Guilherme, 2010, Front Synaptic Neurosci, V2, P12, DOI 10.3389/fnsyn.2010.00012
   Thabit MN, 2010, J NEUROSCI, V30, P11529, DOI 10.1523/JNEUROSCI.1829-10.2010
   Thomas MJ, 2001, NAT NEUROSCI, V4, P1217, DOI 10.1038/nn757
   Tolu S, 2013, MOL PSYCHIATR, V18, P382, DOI 10.1038/mp.2012.83
   Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077
   United Nations Office on Drugs and Crime, 2014, WORLD DRUG REP 2014
   Van den Oever MC, 2008, NAT NEUROSCI, V11, P1053, DOI 10.1038/nn.2165
   Van den Oever MC, 2012, ADV EXP MED BIOL, V970, P469, DOI 10.1007/978-3-7091-0932-8_21
   Van den Oever MC, 2010, NEUROPSYCHOPHARMACOL, V35, P2120, DOI 10.1038/npp.2010.90
   Verhoog MB, 2013, J NEUROSCI, V 33, P17197, DOI 10.1523/JNEUROSCI.3158-13.2013
   Volkow N, 2005, NAT NEUROSCI, V8, P1429, DOI 10.1038/nn1105-1429
   Volkow ND, 2003, J CLIN INVEST, V111, P1444, DOI 10.1172/JCI200318533
   Washburn MS, 1996, J PHARMACOL EXP THER, V278, P669
   Williams JM, 2006, HANDB EXP PHARM, V175, P215
   Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406
   Wolf ME, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00072
   Wolf ME, 2010, NEUROSCI BIOBEHAV R, V35, P185, DOI 10.1016/j.neubiorev.2010.01.013
   Wolters A, 2005, J PHYSIOL-LONDON, V565, P1039, DOI 10.1113/jphysiol.2005.084954
   Wolters A, 2003, J NEUROPHYSIOL, V89, P2339, DOI 10.1152/jn.00900.2002
   World Health Organization, 2008, The global burden of disease: 2004 update
   Yuan TF, 2013, NEURON, V80, P1025, DOI 10.1016/j.neuron.2013.07.050
   Zweifel LS, 2008, NEURON, V59, P486, DOI 10.1016/j.neuron.2008.05.028
NR 117
TC 92
Z9 93
U1 1
U2 36
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1662-5102
J9 FRONT CELL NEUROSCI
JI Front. Cell. Neurosci.
PD JAN 20
PY 2015
VL 8
AR 466
DI 10.3389/fncel.2014.00466
PG 13
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA CA7CC
UT WOS:000349073800001
PM 25653591
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Niehaus, JL
   Cruz-Bermudez, ND
   Kauer, JA
AF Niehaus, Jason L.
   Cruz-Bermudez, Nelson D.
   Kauer, Julie A.
TI Plasticity of Addiction: A Mesolimbic Dopamine Short-Circuit?
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Review
ID VENTRAL TEGMENTAL AREA; LONG-TERM POTENTIATION; VOLUNTARY ETHANOL
   INTAKE; EXCITATORY SYNAPTIC STRENGTH; COCAINE-INDUCED POTENTIATION;
   NUCLEUS-ACCUMBENS DOPAMINE; IN-VIVO; BEHAVIORAL SENSITIZATION; RECEPTOR
   SUBUNITS; AMINO-ACIDS
AB The development of drug addiction progresses along a continuum from acute drug use to compulsive use and drug seeking behavior. Many researchers have focused on identifying the physiological mechanisms involved in drug addiction in order to develop effective pharmacotherapies. Neuroplasticity, the putative mechanism underlying learning and memory, is modified by drugs of abuse and may contribute to the development of the eventual addicted state. Innovative treatments directly targeting these drug-induced changes in brain reward components and circuits may be efficacious in reducing drug use and relapse.
C1 [Niehaus, Jason L.; Cruz-Bermudez, Nelson D.; Kauer, Julie A.] Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA.
   [Kauer, Julie A.] Brown Univ, Dept Neurosci, Providence, RI 02912 USA.
C3 Brown University; Brown University
RP Kauer, JA (通讯作者)，Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Box G-B4, Providence, RI 02912 USA.
EM Julie_Kauer@Brown.edu
OI Kauer, Julie/0000-0002-3362-1642
CR Addolorato G, 2006, INT J CLIN PRACT, V60, P1003, DOI 10.1111/j.1742-1241.2006.01065.x
   Backes EN, 2008, NEUROCHEM RES, V33, P459, DOI 10.1007/s11064-007-9454-2
   Baker DA, 2002, J NEUROSCI, V22, P9134
   Baker DA, 2003, NAT NEUROSCI, V6, P743, DOI 10.1038/nn1069
   Bayer HM, 2005, NEURON, V47, P129, DOI 10.1016/j.neuron.2005.05.020
   Bellone C, 2006, NAT NEUROSCI, V9, P636, DOI 10.1038/nn1682
   Bellone C, 2005, EUR J NEUROSCI, V21, P1280, DOI 10.1111/j.1460-9568.2005.03979.x
   Bonci A, 1999, J NEUROSCI, V19, P3723
   Borgland SL, 2006, NEURON, V49, P589, DOI 10.1016/j.neuron.2006.01.016
   Borgland SL, 2004, J NEUROSCI, V24, P7482, DOI 10.1523/JNEUROSCI.1312-04.2004
   Boudreau AC, 2005, J NEUROSCI, V25, P9144, DOI 10.1523/JNEUROSCI.2252-05.2005
   Boudreau AC, 2007, J NEUROSCI, V27, P10621, DOI 10.1523/JNEUROSCI.2163-07.2007
   Boyce-Rustay JM, 2006, PSYCHOPHARMACOLOGY, V187, P455, DOI 10.1007/s00213-006-0448-6
   BOYLE AE, 1993, PHARMACOL BIOCHEM BE, V46, P179, DOI 10.1016/0091-3057(93)90338-T
   Brodie JD, 2003, SYNAPSE, V50, P261, DOI 10.1002/syn.10278
   Brodie MS, 1999, ALCOHOL CLIN EXP RES, V23, P1848, DOI 10.1111/j.1530-0277.1999.tb04082.x
   BUNNEY BS, 1973, J PHARMACOL EXP THER, V185, P560
   CALABRESI P, 1989, BRIT J PHARMACOL, V98, P135, DOI 10.1111/j.1476-5381.1989.tb16873.x
   CAMERON DL, 1994, J NEUROSCI, V14, P6763
   Carlezon WA, 1997, SCIENCE, V277, P812, DOI 10.1126/science.277.5327.812
   Carlezon WA, 2009, NEUROPHARMACOLOGY, V56, P122, DOI 10.1016/j.neuropharm.2008.06.075
   CHARLETY PJ, 1991, ACTA PHYSIOL SCAND, V142, P105, DOI 10.1111/j.1748-1716.1991.tb09134.x
   Chen BT, 2008, NEURON, V59, P288, DOI 10.1016/j.neuron.2008.05.024
   CHERGUI K, 1994, NEUROSCIENCE, V62, P641, DOI 10.1016/0306-4522(94)90465-0
   Chergui K, 1996, NEUROSCIENCE, V72, P141, DOI 10.1016/0306-4522(95)00513-7
   CHERGUI K, 1993, EUR J NEUROSCI, V5, P137, DOI 10.1111/j.1460-9568.1993.tb00479.x
   Cho DI, 2007, BIOCHEM BIOPH RES CO, V357, P1113, DOI 10.1016/j.bbrc.2007.04.066
   COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478
   Conrad KL, 2008, NATURE, V454, P118, DOI 10.1038/nature06995
   Cooper DC, 2002, NEUROCHEM INT, V41, P333, DOI 10.1016/S0197-0186(02)00068-2
   Di Matteo V, 2007, CURR PHARM DESIGN, V13, P1269, DOI 10.2174/138161207780618920
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Dong Y, 2004, P NATL ACAD SCI USA, V101, P14282, DOI 10.1073/pnas.0401553101
   Dong Z, 2007, NEUROSCIENCE, V144, P845, DOI 10.1016/j.neuroscience.2006.10.018
   Engblom D, 2008, NEURON, V59, P497, DOI 10.1016/j.neuron.2008.07.010
   Fagerstrom Karl, 2008, Neuropsychiatr Dis Treat, V4, P353
   Faleiro LJ, 2004, NEUROPSYCHOPHARMACOL, V29, P2115, DOI 10.1038/sj.npp.1300495
   FALLON JH, 1978, J COMP NEUROL, V180, P545, DOI 10.1002/cne.901800310
   Feltenstein MW, 2008, BRIT J PHARMACOL, V154, P261, DOI 10.1038/bjp.2008.51
   Fields HL, 2007, ANNU REV NEUROSCI, V30, P289, DOI 10.1146/annurev.neuro.30.051606.094341
   Fitzgerald LW, 1996, J NEUROSCI, V16, P274
   FREEMAN AS, 1987, BRAIN RES, V405, P46, DOI 10.1016/0006-8993(87)90988-7
   Gallegos RA, 1999, J PHARMACOL EXP THER, V291, P1045
   GARIANO RF, 1988, BRAIN RES, V462, P194, DOI 10.1016/0006-8993(88)90606-3
   Georges F, 2002, J NEUROSCI, V22, P5173, DOI 10.1523/JNEUROSCI.22-12-05173.2002
   Glass MJ, 2008, EXP NEUROL, V210, P750, DOI 10.1016/j.expneurol.2008.01.012
   GONON FG, 1988, NEUROSCIENCE, V24, P19, DOI 10.1016/0306-4522(88)90307-7
   GRACE AA, 1989, J NEUROSCI, V9, P3463
   Gremel CM, 2008, J NEUROSCI, V28, P1076, DOI 10.1523/JNEUROSCI.4520-07.2008
   GRENHOFF J, 1988, ACTA PHYSIOL SCAND, V134, P127, DOI 10.1111/j.1748-1716.1988.tb08468.x
   GRENHOFF J, 1986, ACTA PHYSIOL SCAND, V128, P351, DOI 10.1111/j.1748-1716.1986.tb07988.x
   Grillner P, 2000, SYNAPSE, V38, P1
   Grillner P, 2002, BEHAV BRAIN RES, V130, P149, DOI 10.1016/S0166-4328(01)00418-1
   Gronier B, 1998, BRIT J PHARMACOL, V124, P455, DOI 10.1038/sj.bjp.0701850
   Gutlerner JL, 2002, NEURON, V36, P921, DOI 10.1016/S0896-6273(02)01051-6
   Haney M, 2006, NEUROPSYCHOPHARMACOL, V31, P1814, DOI 10.1038/sj.npp.1300999
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Ingersoll KS, 2005, SUBST USE MISUSE, V40, P1923, DOI 10.1080/10826080500294817
   Isaac JTR, 2007, NEURON, V54, P859, DOI 10.1016/j.neuron.2007.06.001
   Ji SP, 2006, NAT MED, V12, P324, DOI 10.1038/nm1349
   JOHNSON SW, 1992, J NEUROSCI, V12, P483
   JOHNSON SW, 1992, J PHYSIOL-LONDON, V450, P455, DOI 10.1113/jphysiol.1992.sp019136
   JONES SR, 1995, J PHARMACOL EXP THER, V274, P396
   Kalivas PW, 2006, TRENDS NEUROSCI, V29, P610, DOI 10.1016/j.tins.2006.08.008
   Kauer JA, 2004, ANNU REV PHYSIOL, V66, P447, DOI 10.1146/annurev.physiol.66.032102.112534
   Kauer JA, 2007, NAT REV NEUROSCI, V8, P844, DOI 10.1038/nrn2234
   Kelley AE, 2002, J NEUROSCI, V22, P3306
   KOMBIAN SB, 1994, NATURE, V368, P242, DOI 10.1038/368242a0
   Kourrich S, 2007, J NEUROSCI, V27, P7921, DOI 10.1523/JNEUROSCI.1859-07.2007
   Kushner SA, 1999, J PHARMACOL EXP THER, V290, P797
   LEONE P, 1991, PHARMACOL BIOCHEM BE, V39, P469, DOI 10.1016/0091-3057(91)90210-S
   Lisman JE, 1997, TRENDS NEUROSCI, V20, P38, DOI 10.1016/S0166-2236(96)10070-9
   Liu QS, 2005, NATURE, V437, P1027, DOI 10.1038/nature04050
   LJUNGBERG T, 1992, J NEUROPHYSIOL, V67, P145, DOI 10.1152/jn.1992.67.1.145
   Lodge DJ, 2006, NEUROPSYCHOPHARMACOL, V31, P1356, DOI 10.1038/sj.npp.1300963
   Loftis JM, 2000, J NEUROCHEM, V75, P2040, DOI 10.1046/j.1471-4159.2000.0752040.x
   Luthi A, 1998, NEURON, V21, P9, DOI 10.1016/S0896-6273(00)80509-7
   Luu P, 2008, J NEUROPHYSIOL, V100, P533, DOI 10.1152/jn.01384.2007
   LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0
   Madayag A, 2007, J NEUROSCI, V27, P13968, DOI 10.1523/JNEUROSCI.2808-07.2007
   Maillet JC, 2008, PROG BRAIN RES, V172, P407, DOI 10.1016/S0079-6123(08)00920-5
   Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012
   Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870
   Mameli M, 2007, SCIENCE, V317, P530, DOI 10.1126/science.1142365
   Mansvelder HD, 2000, NEURON, V27, P349, DOI 10.1016/S0896-6273(00)00042-8
   Mansvelder HD, 2002, NEURON, V33, P905, DOI 10.1016/S0896-6273(02)00625-6
   Mardikian PN, 2007, PROG NEURO-PSYCHOPH, V31, P389, DOI 10.1016/j.pnpbp.2006.10.001
   Marinelli M., 2006, CNS & Neurological Disorders-Drug Targets, V5, P79, DOI 10.2174/187152706784111542
   Marinelli M, 2000, J NEUROSCI, V20, P8876
   Martin M, 2006, NAT NEUROSCI, V9, P868, DOI 10.1038/nn1713
   McFarland K, 2003, J NEUROSCI, V23, P3531
   Mead AN, 2005, PSYCHOPHARMACOLOGY, V179, P164, DOI 10.1007/s00213-004-2071-8
   Mead AN, 2007, NEUROPSYCHOPHARMACOL, V32, P343, DOI 10.1038/sj.npp.1301045
   MEISTER A, 1985, METHOD ENZYMOL, V113, P571
   Melis M, 2002, J NEUROSCI, V22, P2074, DOI 10.1523/JNEUROSCI.22-06-02074.2002
   Meltzer LT, 1997, NEUROSCI BIOBEHAV R, V21, P511, DOI 10.1016/S0149-7634(96)00030-9
   Mereu G, 1997, NEUROSCIENCE, V77, P1029, DOI 10.1016/S0306-4522(96)00474-5
   Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006
   Montague PR, 2002, NEURON, V36, P265, DOI 10.1016/S0896-6273(02)00974-1
   Moran MM, 2005, J NEUROSCI, V25, P6389, DOI 10.1523/JNEUROSCI.1007-05.2005
   MUELLER AL, 1989, J NEUROSCI METH, V28, P15, DOI 10.1016/0165-0270(89)90005-8
   MURASE S, 1993, NEUROSCI LETT, V157, P53, DOI 10.1016/0304-3940(93)90641-W
   Murray F, 2007, EUR J PHARMACOL, V562, P191, DOI 10.1016/j.ejphar.2007.01.027
   Nicola SM, 2000, ANNU REV NEUROSCI, V23, P185, DOI 10.1146/annurev.neuro.23.1.185
   Nowak KL, 1998, PSYCHOPHARMACOLOGY, V139, P108, DOI 10.1007/s002130050695
   Nugent FS, 2007, NATURE, V446, P1086, DOI 10.1038/nature05726
   Overton PG, 1997, BRAIN RES REV, V25, P312, DOI 10.1016/S0165-0173(97)00039-8
   Overton PG, 1999, NEUROREPORT, V10, P221, DOI 10.1097/00001756-199902050-00004
   Pan B, 2008, J NEUROSCI, V28, P1385, DOI 10.1523/JNEUROSCI.4033-07.2008
   Peng XQ, 2008, DRUG ALCOHOL DEPEN, V97, P216, DOI 10.1016/j.drugalcdep.2007.10.004
   Pierce RC, 1996, J NEUROSCI, V16, P1550
   Ramsey AJ, 2008, NEUROPSYCHOPHARMACOL, V33, P2701, DOI 10.1038/sj.npp.1301663
   Reid MS, 1996, NEUROREPORT, V7, P1325, DOI 10.1097/00001756-199605170-00022
   Robinson RB, 2003, ANNU REV PHYSIOL, V65, P453, DOI 10.1146/annurev.physiol.65.092101.142734
   Rollema H, 2007, TRENDS PHARMACOL SCI, V28, P316, DOI 10.1016/j.tips.2007.05.003
   Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-7
   Sarti F, 2007, EUR J NEUROSCI, V26, P749, DOI 10.1111/j.1460-9568.2007.05689.x
   Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593
   Schultz W, 1997, CURR OPIN NEUROBIOL, V7, P191, DOI 10.1016/S0959-4388(97)80007-4
   SCHULTZ W, 1993, J NEUROSCI, V13, P900
   Shi WX, 2004, NEUROPSYCHOPHARMACOL, V29, P2160, DOI 10.1038/sj.npp.1300534
   SMITH BR, 1992, ALCOHOL ALCOHOLISM, V27, P227
   Stuber GD, 2008, ALCOHOL CLIN EXP RES, V32, P1714, DOI 10.1111/j.1530-0277.2008.00749.x
   Stuber GD, 2008, SCIENCE, V321, P1690, DOI 10.1126/science.1160873
   SUAUDCHAGNY MF, 1992, NEUROSCIENCE, V49, P63, DOI 10.1016/0306-4522(92)90076-E
   Swanson CJ, 2001, J NEUROSCI, V21, P9043, DOI 10.1523/JNEUROSCI.21-22-09043.2001
   Szumlinski KK, 2005, J NEUROSCI, V25, P7054, DOI 10.1523/JNEUROSCI.1529-05.2005
   Szumlinski KK, 2004, NEURON, V43, P401, DOI 10.1016/j.neuron.2004.07.019
   Thomas MJ, 2008, BRIT J PHARMACOL, V154, P327, DOI 10.1038/bjp.2008.77
   Thomas MJ, 2003, PHILOS T ROY SOC B, V358, P815, DOI 10.1098/rstb.2002.1236
   Thomas MJ, 2001, NAT NEUROSCI, V4, P1217, DOI 10.1038/nn757
   Tong ZY, 1996, SYNAPSE, V22, P195, DOI 10.1002/(SICI)1098-2396(199603)22:3<195::AID-SYN1>3.3.CO;2-P
   Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077
   Vanderschuren LJMJ, 2001, EUR J NEUROSCI, V14, P1533, DOI 10.1046/j.0953-816x.2001.01775.x
   Venton BJ, 2006, J NEUROSCI, V26, P3206, DOI 10.1523/JNEUROSCI.4901-04.2006
   Volkow ND, 2007, ARCH NEUROL-CHICAGO, V64, P1575, DOI 10.1001/archneur.64.11.1575
   Voorn P, 2004, TRENDS NEUROSCI, V27, P468, DOI 10.1016/j.tins.2004.06.006
   WANG RY, 1981, BRAIN RES REV, V3, P123, DOI 10.1016/0165-0173(81)90002-3
   White FJ, 1996, ANNU REV NEUROSCI, V19, P405, DOI 10.1146/annurev.ne.19.030196.002201
   WISE RA, 1989, ANNU REV PSYCHOL, V40, P191, DOI 10.1146/annurev.ps.40.020189.001203
   Wise RA, 1996, CURR OPIN NEUROBIOL, V6, P243, DOI 10.1016/S0959-4388(96)80079-1
   Wise RA, 1998, DRUG ALCOHOL DEPEN, V51, P13, DOI 10.1016/S0376-8716(98)00063-5
   Wolf ME, 1998, PROG NEUROBIOL, V54, P679, DOI 10.1016/S0301-0082(97)00090-7
   Wu Q, 2001, J NEUROSCI, V21, P6338, DOI 10.1523/JNEUROSCI.21-16-06338.2001
   Xiao C, 2007, ALCOHOL CLIN EXP RES, V31, P1106, DOI 10.1111/j.1530-0277.2007.00405.x
   Yamada H, 2007, BRAIN RES, V1131, P88, DOI 10.1016/j.brainres.2006.11.011
   Zhang XF, 1997, J PHARMACOL EXP THER, V281, P699
   Zweifel LS, 2008, NEURON, V59, P486, DOI 10.1016/j.neuron.2008.05.028
NR 148
TC 26
Z9 26
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
EI 1521-0391
J9 AM J ADDICTION
JI Am. J. Addict.
PY 2009
VL 18
IS 4
BP 259
EP 271
AR PII 911212537
DI 10.1080/10550490902925946
PG 13
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA 446FJ
UT WOS:000266105800001
PM 19444729
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Aguilar, MA
   Garcia-Pardo, MP
   Montagud-Romero, S
   Minarro, J
   Do Couto, BR
AF Aguilar, Maria A.
   Garcia-Pardo, Maria P.
   Montagud-Romero, Sandra
   Minarro, Jose
   Ribeiro Do Couto, Bruno
TI Impact of Social Stress in Addiction to Psychostimulants: What we know
   from Animal Models
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Psychostimulants; addiction; social stress; animal model; reinstatement
ID CONDITIONED PLACE PREFERENCE; CORTICOTROPIN-RELEASING-FACTOR;
   COCAINE-INDUCED REINSTATEMENT; ENVIRONMENTAL ENRICHMENT DECREASES;
   VENTRAL TEGMENTAL AREA; DEPRIVATION-INDUCED REINSTATEMENT;
   GLUTAMATE-DOPAMINE INTERACTION; DRUG-INDUCED REINSTATEMENT; MEDIAL
   PREFRONTAL CORTEX; MESSENGER-RNA EXPRESSION
AB Psychostimulant addiction, most notably cocaine and amphetamine - type stimulants are an important public health problem worldwide. It appears that social factors may influence the initiation, maintenance and recovery from addictions. Several animal models have been developed to study addiction, highlighting drug self-administration (SA) and the conditioned place preference (CPP) paradigms. These models have been modified to accurately reflect the characteristics of drug addiction in its different stages. One factor that clearly plays a major role in addiction is stress, which is a risk factor not only for the initiation, maintenance and escalation of drug consumption, but also for relapse. In animal models, stress for itself can provoke reinstatement of self-administration or CPP. The relationship between stress and addiction is very tight. One example is the close anatomical relationship of some areas that share these two phenomena. It seems obvious to think that the main source of stress in humans is social interaction. The aim of the present review is to gather the current information regarding the role of social stress in the addiction to psychostimulant drugs in animal models. First, we briefly describe the mechanisms by which stress exerts its effects and the basic concepts of addiction. We will try to establish common pathways of stress and addiction, to address later social stress effects on different stages of addiction. Then, we will address pharmacological therapies and preventive factors that counteract the enhancing effects of social stress in addiction. Finally, we will analyze how negative environmental conditions may induce individuals to increased vulnerability to drugs, and how favorable environmental conditions may have protective and curative effects against addiction. In this sense, we also analyze the importance of social interactions and their ability to modulate the different stages of addiction. As a conclusion, and despite the scarcity of the research, social stress exposure increases the initiation of psychostimulant consumption and the vulnerability to relapse in animal models of addiction. Studies on the mechanisms underlying the effects of social stress and how it can be counteracted pharmacologically, are research areas that should be explored in the future. At the same time, translational research on the effects of environmental conditions and positive social interactions, which have been shown to have a critical role in addictions, should be encouraged.
C1 [Aguilar, Maria A.; Garcia-Pardo, Maria P.; Montagud-Romero, Sandra; Minarro, Jose] Univ Valencia, Fac Psychol, Dept Psychobiol, Unidad Invest Psicobiol Drogodependencias, Valencia 46010, Spain.
   [Ribeiro Do Couto, Bruno] Univ Murcia, Dept Human Anat & Psychobiol, E-30100 Murcia, Spain.
   [Ribeiro Do Couto, Bruno] Murcia Inst Biomed Res IMIB, Murcia 30100, Spain.
C3 University of Valencia; University of Murcia
RP Do Couto, BR (通讯作者)，Univ Murcia, Dept Human Anat & Psychobiol, Campus Univ Espinardo, E-30100 Murcia, Spain.
EM bruno.ribeiro@um.es
RI Do Couto, Bruno R/B-5066-2009; Romero, Sandra Montagud/AAF-9408-2021;
   Montagud-Romero, Sandra/E-6537-2017; Aguilar, Maria A/D-3416-2011;
   Minarro, Jose/B-4414-2011; PARDO, MARIA PILAR GARCIA/B-3352-2017
OI Romero, Sandra Montagud/0000-0002-3380-7252; Montagud-Romero,
   Sandra/0000-0002-3380-7252; Aguilar, Maria A/0000-0002-1935-6619;
   Minarro, Jose/0000-0002-5731-7821; PARDO, MARIA PILAR
   GARCIA/0000-0003-2730-0145
FU Ministerio de Economia y Competitividad: Direccion General de
   Investigacion [PSI2011-24762]; Instituto de Salud "Carlos III" (FIS);
   RETICS; Red de Trastornos Adictivos [RD06/001/0016, RD12/0028/0005];
   Generalitat Valenciana, Conselleria de Educacion [PRO-METEO/2009/072]
FX This work was supported by the following grants: Ministerio de Economia
   y Competitividad: Direccion General de Investigacion (PSI2011-24762),
   Instituto de Salud "Carlos III" (FIS), RETICS, Red de Trastornos
   Adictivos (RD06/001/0016) and (RD12/0028/0005). Generalitat Valenciana,
   Conselleria de Educacion (PRO-METEO/2009/072 and Programa VALi+d for MP
   G-P), Spain.
CR Aguilar MA, 2009, BRAIN RES REV, V59, P253, DOI 10.1016/j.brainresrev.2008.08.002
   Ahmed SH, 2010, NEUROSCI BIOBEHAV R, V35, P172, DOI 10.1016/j.neubiorev.2010.04.005
   AHMED SH, 1995, PSYCHOPHARMACOLOGY, V117, P116, DOI 10.1007/BF02245106
   ALHEID GF, 1988, NEUROSCIENCE, V27, P1, DOI 10.1016/0306-4522(88)90217-5
   [Anonymous], 2012, WORLD DRUG REP
   Anstrom KK, 2009, NEUROSCIENCE, V161, P3, DOI 10.1016/j.neuroscience.2009.03.023
   Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244
   ARMARIO A, 1984, NEUROENDOCRINOLOGY, V39, P330, DOI 10.1159/000124000
   AstonJones G, 1996, PROG BRAIN RES, V107, P379
   BADIANI A, 1995, BRAIN RES, V673, P13, DOI 10.1016/0006-8993(94)01365-O
   BARDO MT, 1995, PHARMACOL BIOCHEM BE, V51, P397, DOI 10.1016/0091-3057(94)00413-D
   Bardo MT, 2000, PSYCHOPHARMACOLOGY, V153, P31, DOI 10.1007/s002130000569
   Bardo MT, 2001, PSYCHOPHARMACOLOGY, V155, P278
   Baumans V, 2005, ILAR J, V46, P162, DOI 10.1093/ilar.46.2.162
   Belujon P, 2011, ANN NY ACAD SCI, V1216, P114, DOI 10.1111/j.1749-6632.2010.05896.x
   Bolanos CA, 1998, DEV BRAIN RES, V111, P25, DOI 10.1016/S0165-3806(98)00116-3
   Boutrel B, 2005, P NATL ACAD SCI USA, V102, P19168, DOI 10.1073/pnas.0507480102
   BOWLING SL, 1994, PHARMACOL BIOCHEM BE, V48, P459, DOI 10.1016/0091-3057(94)90553-3
   BOWLING SL, 1993, NEUROPHARMACOLOGY, V32, P885, DOI 10.1016/0028-3908(93)90144-R
   Boyson CO, 2011, PSYCHOPHARMACOLOGY, V218, P257, DOI 10.1007/s00213-011-2266-8
   Brady KT, 1998, AM J ADDICTION, V7, P128
   Brady KT, 2005, AM J PSYCHIAT, V162, P1483, DOI 10.1176/appi.ajp.162.8.1483
   Briand LA, 2010, J NEUROSCI, V30, P16149, DOI 10.1523/JNEUROSCI.2827-10.2010
   Brown G, 1998, BEHAV PHARMACOL, V9, P149
   BROWN KJ, 1995, PHYSIOL BEHAV, V58, P1085, DOI 10.1016/0031-9384(95)02043-8
   Bruchas MR, 2010, BRAIN RES, V1314, P44, DOI 10.1016/j.brainres.2009.08.062
   Buffalari DM, 2009, INT J NEUROPSYCHOPH, V12, P95, DOI 10.1017/S1461145708009140
   Burke AR, 2011, NEUROSCIENCE, V197, P269, DOI 10.1016/j.neuroscience.2011.09.008
   Campbell J, 1999, PSYCHOPHARMACOLOGY, V143, P183, DOI 10.1007/s002130050934
   Capriles N, 2003, PSYCHOPHARMACOLOGY, V168, P66, DOI 10.1007/s00213-002-1283-z
   Capriles ND, 2002, BEHAV BRAIN RES, V132, P159, DOI 10.1016/S0166-4328(01)00414-4
   Caprioli D, 2007, PROG NEURO-PSYCHOPH, V31, P1639, DOI 10.1016/j.pnpbp.2007.08.029
   Caprioli D, 2009, BIOL PSYCHIAT, V65, P893, DOI 10.1016/j.biopsych.2008.12.009
   Capuron L, 2011, PHARMACOL THERAPEUT, V130, P226, DOI 10.1016/j.pharmthera.2011.01.014
   Carlezon WA, 2009, NEUROPHARMACOLOGY, V56, P122, DOI 10.1016/j.neuropharm.2008.06.075
   Carroll ME, 2009, DRUG ALCOHOL DEPEN, V104, pS70, DOI 10.1016/j.drugalcdep.2008.11.011
   Chauvet C, 2011, NEUROSCIENCE, V184, P88, DOI 10.1016/j.neuroscience.2011.03.068
   Chauvet C, 2009, NEUROPSYCHOPHARMACOL, V34, P2767, DOI 10.1038/npp.2009.127
   CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244
   COLLINS RJ, 1984, PSYCHOPHARMACOLOGY, V82, P6
   Collins SL, 2002, DEV BRAIN RES, V138, P27, DOI 10.1016/S0165-3806(02)00471-6
   Costa-Pinto FA, 2010, NEUROIMMUNOMODULAT, V17, P196, DOI 10.1159/000258722
   Covington HE, 2005, PSYCHOPHARMACOLOGY, V183, P331, DOI 10.1007/s00213-005-0190-5
   Covington HE, 2005, NEUROPSYCHOPHARMACOL, V30, P310, DOI 10.1038/sj.npp.1300587
   Covington HE, 2001, PSYCHOPHARMACOLOGY, V158, P388, DOI 10.1007/s002130100858
   Covington HE, 2008, PSYCHOPHARMACOLOGY, V197, P203, DOI 10.1007/s00213-007-1024-4
   Cruz FC, 2011, PSYCHOPHARMACOLOGY, V215, P165, DOI 10.1007/s00213-010-2139-6
   Dalley JW, 2009, SEMIN CELL DEV BIOL, V20, P403, DOI 10.1016/j.semcdb.2009.01.002
   de Guglielmo G, 2012, ADDICT BIOL IN PRESS
   de Kloet ER, 2005, NAT REV NEUROSCI, V6, P463, DOI 10.1038/nrn1683
   de Olmos JS, 1999, ANN NY ACAD SCI, V877, P1
   De Vries TJ, 1998, EUR J NEUROSCI, V10, P3565, DOI 10.1046/j.1460-9568.1998.00368.x
   Der-Avakian A, 2010, NEUROSCIENCE, V170, P1189, DOI 10.1016/j.neuroscience.2010.08.002
   Der-Avakian A, 2007, PSYCHOPHARMACOLOGY, V191, P909, DOI 10.1007/s00213-006-0678-7
   DEROCHE V, 1995, J NEUROSCI, V15, P7181
   DEROCHE V, 1992, BRAIN RES, V598, P343, DOI 10.1016/0006-8993(92)90205-N
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Ding YJ, 2005, PHARMACOL BIOCHEM BE, V82, P673, DOI 10.1016/j.pbb.2005.11.007
   Do Couto BR, 2006, PSYCHOPHARMACOLOGY, V185, P459, DOI 10.1007/s00213-006-0345-z
   Edwards S, 2012, METHODS MOL BIOL, V829, P31, DOI 10.1007/978-1-61779-458-2_2
   El Rawas R, 2012, FRONT BEHAV NEUROSCI, V6, DOI 10.3389/fnbeh.2012.00063
   El Rawas R, 2011, BRAIN RES, V1390, P80, DOI 10.1016/j.brainres.2011.03.025
   El Rawas R, 2009, PSYCHOPHARMACOLOGY, V203, P561, DOI 10.1007/s00213-008-1402-6
   Eliava M, 2003, HISTOCHEM CELL BIOL, V120, P183, DOI 10.1007/s00418-003-0557-9
   Ellenbroek BA, 2005, EUR J PHARMACOL, V526, P251, DOI 10.1016/j.ejphar.2005.09.032
   Enoch MA, 2006, ANN NY ACAD SCI, V1094, P193, DOI 10.1196/annals.1376.019
   Enoch MA, 2010, BIOL PSYCHIAT, V67, P20, DOI 10.1016/j.biopsych.2009.08.019
   Epstein DH, 2006, PSYCHOPHARMACOLOGY, V189, P1, DOI 10.1007/s00213-006-0529-6
   Erb S, 2000, NEUROPSYCHOPHARMACOL, V23, P138, DOI 10.1016/S0893-133X(99)00158-X
   Erb S, 2001, PSYCHOPHARMACOLOGY, V158, P360, DOI 10.1007/s002130000642
   Ettenberg A, 1996, PSYCHOPHARMACOLOGY, V124, P205, DOI 10.1007/BF02246658
   Everitt BJ, 2008, PHILOS T R SOC B, V363, P3125, DOI 10.1098/rstb.2008.0089
   Faure J, 2009, METAB BRAIN DIS, V24, P541, DOI 10.1007/s11011-009-9158-1
   Filip M, 2005, PHARMACOL REP, V57, P685
   Fish EW, 1999, PSYCHOPHARMACOLOGY, V146, P391, DOI 10.1007/PL00005484
   Fleckenstein AE, 2007, ANNU REV PHARMACOL, V47, P681, DOI 10.1146/annurev.pharmtox.47.120505.105140
   Fritz M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026761
   Fritz M, 2011, ADDICT BIOL, V16, P273, DOI 10.1111/j.1369-1600.2010.00285.x
   Fritz M, 2011, PHARMACOLOGY, V87, P45, DOI 10.1159/000322534
   Fuchs E, 2004, BEHAV PHARMACOL, V15, P315, DOI 10.1097/00008877-200409000-00003
   Fuchs RA, 2008, PSYCHOPHARMACOLOGY, V200, P545, DOI 10.1007/s00213-008-1234-4
   Fuchs RA, 2006, EUR J NEUROSCI, V23, P2809, DOI 10.1111/j.1460-9568.2006.04806.x
   GERBER GJ, 1975, PHARMACOL BIOCHEM BE, V3, P1055, DOI 10.1016/0091-3057(75)90016-7
   Goeders NE, 2003, EUR NEUROPSYCHOPHARM, V13, P435, DOI 10.1016/j.euroneuro.2003.08.004
   Goeders NE, 2002, PSYCHONEUROENDOCRINO, V27, P13, DOI 10.1016/S0306-4530(01)00034-8
   Goeders NE, 2002, J PHARMACOL EXP THER, V301, P785, DOI 10.1124/jpet.301.3.785
   GOEDERS NE, 1994, PSYCHOPHARMACOLOGY, V114, P63, DOI 10.1007/BF02245445
   Graf EN, 2011, NEUROPSYCHOPHARMACOL, V36, P1444, DOI 10.1038/npp.2011.28
   Green TA, 2002, PSYCHOPHARMACOLOGY, V162, P373, DOI 10.1007/s00213-002-1134-y
   Green TA, 2010, BIOL PSYCHIAT, V67, P28, DOI 10.1016/j.biopsych.2009.06.022
   Grimm JW, 2003, J NEUROSCI, V23, P742
   Gysling K, 2012, BIOCHEM PHARMACOL, V83, P1, DOI 10.1016/j.bcp.2011.07.101
   Hall FS, 1998, PHARMACOL BIOCHEM BE, V59, P859, DOI 10.1016/S0091-3057(97)00510-8
   HANEY M, 1995, BRAIN RES, V698, P46, DOI 10.1016/0006-8993(95)00788-R
   Hasue RH, 2002, J COMP NEUROL, V454, P15, DOI 10.1002/cne.10420
   Higgins ST, 1997, PHARMACOL BIOCHEM BE, V57, P419, DOI 10.1016/S0091-3057(96)00446-7
   Howell LL, 2008, BIOCHEM PHARMACOL, V75, P196, DOI 10.1016/j.bcp.2007.08.003
   Howes SR, 2000, PSYCHOPHARMACOLOGY, V151, P55, DOI 10.1007/s002130000451
   HUCKLEBR.FH, 1974, PHYSIOL BEHAV, V13, P35, DOI 10.1016/0031-9384(74)90303-5
   HUNT WA, 1971, J CLIN PSYCHOL, V27, P455, DOI 10.1002/1097-4679(197110)27:4<455::AID-JCLP2270270412>3.0.CO;2-R
   Hutchinson E, 2005, ILAR J, V46, P148, DOI 10.1093/ilar.46.2.148
   Jessor R, 1980, NIDA Res Monogr, V30, P102
   Kabbaj M, 2001, PSYCHOPHARMACOLOGY, V158, P382, DOI 10.1007/s002130100918
   Kabbaj M, 2002, NEUROSCIENCE, V113, P395, DOI 10.1016/S0306-4522(02)00188-4
   Kelley AE, 2002, J NEUROSCI, V22, P3306
   Koob G, 2007, AM J PSYCHIAT, V164, P1149, DOI 10.1176/appi.ajp.2007.05030503
   Koob GF, 2008, NEURON, V59, P11, DOI 10.1016/j.neuron.2008.06.012
   Koob GF, 2010, BRAIN RES, V1314, P3, DOI 10.1016/j.brainres.2009.11.008
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Koob GF, 2009, BRAIN RES, V1293, P61, DOI 10.1016/j.brainres.2009.03.038
   Kosten TA, 2000, BRAIN RES, V875, P44, DOI 10.1016/S0006-8993(00)02595-6
   Kozorovitskiy Y, 2004, J NEUROSCI, V24, P6755, DOI 10.1523/JNEUROSCI.0345-04.2004
   Kupferschmidt DA, 2012, BRIT J PHARMACOL, V167, P196, DOI 10.1111/j.1476-5381.2012.01983.x
   Land BB, 2009, P NATL ACAD SCI USA, V106, P19168, DOI 10.1073/pnas.0910705106
   LANIER LP, 1977, BRAIN RES, V126, P567
   Laviola G, 2002, BEHAV BRAIN RES, V130, P117, DOI 10.1016/S0166-4328(01)00420-X
   Laviola G, 2008, NEUROBIOL DIS, V31, P159, DOI 10.1016/j.nbd.2008.05.001
   LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155
   LEYTON M, 1990, PHARMACOL BIOCHEM BE, V37, P303, DOI 10.1016/0091-3057(90)90339-J
   Logrip ML, 2012, NEUROPHARMACOLOGY, V62, P552, DOI 10.1016/j.neuropharm.2011.07.007
   Logrip ML, 2011, CNS DRUGS, V25, P271, DOI 10.2165/11587790-000000000-00000
   Lu L, 2003, NEUROSCI BIOBEHAV R, V27, P457, DOI 10.1016/S0149-7634(03)00073-3
   Lu L, 2002, BRAIN RES, V954, P132, DOI 10.1016/S0006-8993(02)03359-0
   Lynch WJ, 2005, NEUROPSYCHOPHARMACOL, V30, P322, DOI 10.1038/sj.npp.1300594
   Macedo CE, 2007, BEHAV BRAIN RES, V177, P100, DOI 10.1016/j.bbr.2006.10.031
   Mantsch JR, 2010, NEUROPSYCHOPHARMACOL, V35, P2165, DOI 10.1038/npp.2010.86
   Manzanedo C, 2001, NEUROSCI RES COMMUN, V28, P23, DOI 10.1002/1520-6769(200101/02)28:1<23::AID-NRC3>3.0.CO;2-D
   Manzanedo C, 2001, BEHAV BRAIN RES, V121, P189, DOI 10.1016/S0166-4328(01)00164-4
   Marinelli M, 2002, EUR J NEUROSCI, V16, P387, DOI 10.1046/j.1460-9568.2002.02089.x
   Martin-Fardon R, 2012, ADDICT BIOL, V17, P557, DOI 10.1111/j.1369-1600.2011.00345.x
   Martini M, 2012, PSYCHOPHARMACOLOGY, V219, P149, DOI 10.1007/s00213-011-2385-2
   Mathews IZ, 2008, DEV PSYCHOBIOL, V50, P451, DOI 10.1002/dev.20299
   Matthews K, 1999, PSYCHOPHARMACOLOGY, V141, P123, DOI 10.1007/s002130050816
   McBride WJ, 1999, BEHAV BRAIN RES, V101, P129, DOI 10.1016/S0166-4328(99)00022-4
   McEwen BS, 2003, BIOL PSYCHIAT, V54, P200, DOI 10.1016/S0006-3223(03)00177-X
   McFarland K, 2004, J NEUROSCI, V24, P1551, DOI 10.1523/JNEUROSCI.4177-03.2004
   McFarland K, 1997, PSYCHOPHARMACOLOGY, V131, P86, DOI 10.1007/s002130050269
   McGregor IS, 2012, HORM BEHAV, V61, P331, DOI 10.1016/j.yhbeh.2011.12.001
   McLaughlin JP, 2006, NEUROPSYCHOPHARMACOL, V31, P1241, DOI 10.1038/sj.npp.1300872
   McLaughlin JP, 2006, NEUROPSYCHOPHARMACOL, V31, P787, DOI 10.1038/sj.npp.1300860
   McLaughlin JP, 2003, J NEUROSCI, V23, P5674, DOI 10.1523/jneurosci.23-13-05674.2003
   MICZEK KA, 1982, SCIENCE, V215, P1520, DOI 10.1126/science.7199758
   Miczek KA, 1999, PSYCHOPHARMACOLOGY, V141, P225, DOI 10.1007/s002130050829
   Miczek KA, 2004, NEUROSCI BIOBEHAV R, V27, P787, DOI 10.1016/j.neubiorev.2003.11.005
   Miczek KA, 1996, PSYCHOPHARMACOLOGY, V128, P256, DOI 10.1007/s002130050133
   Miczek KA, 1999, PSYCHOPHARMACOLOGY, V147, P190, DOI 10.1007/s002130051160
   Miczek KA, 2011, J NEUROSCI, V31, P9848, DOI 10.1523/JNEUROSCI.0637-11.2011
   Miczek KA, 2008, PHARMACOL THERAPEUT, V120, P102, DOI 10.1016/j.pharmthera.2008.07.006
   Milton AL, 2012, NEUROSCI BIOBEHAV R, V36, P1119, DOI 10.1016/j.neubiorev.2012.01.002
   Moeller FG, 2007, AM J DRUG ALCOHOL AB, V33, P367, DOI 10.1080/00952990701313686
   Moffett MC, 2007, BIOCHEM PHARMACOL, V73, P321, DOI 10.1016/j.bcp.2006.08.003
   Moffett MC, 2006, J PHARMACOL EXP THER, V317, P1210, DOI 10.1124/jpet.106.101139
   MOORE RY, 1979, ANNU REV NEUROSCI, V2, P113, DOI 10.1146/annurev.ne.02.030179.000553
   Mora F, 2007, BRAIN RES REV, V55, P78, DOI 10.1016/j.brainresrev.2007.03.011
   Moser P, 2011, J PHARMACOL EXP THER, V336, P588, DOI 10.1124/jpet.110.169979
   Nader J, 2012, NEUROPSYCHOPHARMACOL, V37, P1579, DOI 10.1038/npp.2012.2
   Nawata Y, 2012, PHARMACOL BIOCHEM BE, V101, P297, DOI 10.1016/j.pbb.2012.01.003
   Nestler EJ, 2004, NEUROPHARMACOLOGY, V47, P24, DOI 10.1016/j.neuropharm.2004.06.031
   Nikulina EM, 2012, NEUROSCIENCE, V212, P38, DOI 10.1016/j.neuroscience.2012.04.012
   Nikulina EM, 2005, NEUROPSYCHOPHARMACOL, V30, P1096, DOI 10.1038/sj.npp.1300658
   Nikulina EM, 2004, NEUROSCIENCE, V123, P857, DOI 10.1016/j.neuroscience.2003.10.029
   Nikulina EM, 1998, BRAIN RES, V810, P200, DOI 10.1016/S0006-8993(98)00925-1
   Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970
   OBrien CP, 1997, SCIENCE, V278, P66, DOI 10.1126/science.278.5335.66
   Pacchioni AM, 2007, NEUROPSYCHOPHARMACOL, V32, P682, DOI 10.1038/sj.npp.1301080
   Pacchioni AM, 2002, ANN NY ACAD SCI, V965, P233
   Panksepp JB, 2007, GENES BRAIN BEHAV, V6, P661, DOI 10.1111/j.1601-183X.2006.00295.x
   Pavlov I, 1927, CONDITIONED REFLEXES
   Pezze MA, 2004, PROG NEUROBIOL, V74, P301, DOI 10.1016/j.pneurobio.2004.09.004
   PHELIX CF, 1994, BRAIN RES BULL, V33, P109
   Piazza PV, 1998, TRENDS PHARMACOL SCI, V19, P67, DOI 10.1016/S0165-6147(97)01115-2
   PIAZZA PV, 1990, BRAIN RES, V514, P22, DOI 10.1016/0006-8993(90)90431-A
   Poling J, 2006, ARCH GEN PSYCHIAT, V63, P219, DOI 10.1001/archpsyc.63.2.219
   Qi J, 2009, NEUROPHARMACOLOGY, V56, P856, DOI 10.1016/j.neuropharm.2009.01.010
   Quadros IMH, 2009, PSYCHOPHARMACOLOGY, V206, P109, DOI 10.1007/s00213-009-1584-6
   Rampon C, 2000, P NATL ACAD SCI USA, V97, P12880, DOI 10.1073/pnas.97.23.12880
   RAMSEY NF, 1993, BRAIN RES, V608, P216, DOI 10.1016/0006-8993(93)91461-Z
   Razzoli M, 2007, PHYSIOL BEHAV, V92, P734, DOI 10.1016/j.physbeh.2007.05.063
   Reis FLV, 2004, PHARMACOL BIOCHEM BE, V79, P359, DOI 10.1016/j.pbb.2004.08.006
   Do Couto BR, 2009, PSYCHOPHARMACOLOGY, V207, P485, DOI 10.1007/s00213-009-1678-1
   ROBBINS TW, 1978, PSYCHOPHARMACOLOGY, V58, P79, DOI 10.1007/BF00426794
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Rodaros D, 2007, NEUROSCIENCE, V150, P8, DOI 10.1016/j.neuroscience.2007.09.043
   Rodriguez-Arias M, 1998, EUR NEUROPSYCHOPHARM, V8, P95, DOI 10.1016/S0924-977X(97)00051-5
   Rosenkranz JA, 2003, J NEUROSCI, V23, P11054
   Rosenkranz JA, 2002, NATURE, V417, P282, DOI 10.1038/417282a
   Rosenkranz JA, 2002, J NEUROSCI, V22, P324, DOI 10.1523/JNEUROSCI.22-01-00324.2002
   ROSENZWEIG MR, 1978, BRAIN RES, V153, P563, DOI 10.1016/0006-8993(78)90340-2
   Rosenzweig MR, 1996, BEHAV BRAIN RES, V78, P57, DOI 10.1016/0166-4328(95)00216-2
   Rothman RB, 2001, SYNAPSE, V39, P32, DOI 10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3
   ROUGEPONT F, 1995, J NEUROSCI, V15, P7189
   SAKANAKA M, 1986, BRAIN RES, V382, P213, DOI 10.1016/0006-8993(86)91332-6
   Sanchez CJ, 2003, NEUROSCIENCE, V119, P497, DOI 10.1016/S0306-4522(03)00078-2
   Sanchez CJ, 2001, BRAIN RES, V908, P86, DOI 10.1016/S0006-8993(01)02638-5
   Sanchis-Segura C, 2006, ADDICT BIOL, V11, P2, DOI 10.1111/j.1369-1600.2006.00012.x
   Sarnyai Z, 2001, PHARMACOL REV, V53, P209
   SCHENK S, 1987, NEUROSCI LETT, V81, P227, DOI 10.1016/0304-3940(87)91003-2
   Schindler AG, 2010, NEUROPSYCHOPHARMACOL, V35, P1932, DOI 10.1038/npp.2010.67
   Schramm-Sapyta NL, 2009, PSYCHOPHARMACOLOGY, V206, P1, DOI 10.1007/s00213-009-1585-5
   See RE, 2003, ANN NY ACAD SCI, V985, P294
   See RE, 2011, AM J TRANSL RES, V3, P81
   Segovia G, 2009, J NEURAL TRANSM, V116, P1007, DOI 10.1007/s00702-009-0214-0
   Selye H, 1975, STRESS DISTRESS
   Sgoifo A, 2001, PHYSIOL BEHAV, V73, P253, DOI 10.1016/S0031-9384(01)00544-3
   Shaham Y, 2000, BRAIN RES REV, V33, P13, DOI 10.1016/S0165-0173(00)00024-2
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   Shaham Y, 1998, PSYCHOPHARMACOLOGY, V137, P184, DOI 10.1007/s002130050608
   SHAHAM Y, 1994, PSYCHOPHARMACOLOGY, V114, P523, DOI 10.1007/BF02249346
   Shaham Y, 1996, J NEUROSCI, V16, P1957
   Shaham Y, 1997, PHYSIOL BEHAV, V61, P337, DOI 10.1016/S0031-9384(96)00446-5
   Shalev U, 2002, PHARMACOL REV, V54, P1, DOI 10.1124/pr.54.1.1
   Shalev U, 2003, PSYCHOPHARMACOLOGY, V168, P170, DOI 10.1007/s00213-002-1200-5
   Shalev U, 2006, PSYCHOPHARMACOLOGY, V187, P376, DOI 10.1007/s00213-006-0427-y
   Shalev U, 2010, BRAIN RES, V1314, P15, DOI 10.1016/j.brainres.2009.07.028
   Shalev Z, 2000, PSYCHOPHARMACOLOGY, V150, P337, DOI 10.1007/s002130000441
   SHIPPENBERG TS, 2002, NEUROPSYCHOPHARMACOL, P1381
   Sinha R, 2001, PSYCHOPHARMACOLOGY, V158, P343, DOI 10.1007/s002130100917
   Sinha R, 2006, ARCH GEN PSYCHIAT, V63, P324, DOI 10.1001/archpsyc.63.3.324
   Sinha R, 2008, ANN NY ACAD SCI, V1141, P105, DOI 10.1196/annals.1441.030
   Sinha Rajita, 2007, Curr Psychiatry Rep, V9, P388, DOI 10.1007/s11920-007-0050-6
   Sinha R, 2011, PSYCHOPHARMACOLOGY, V218, P69, DOI 10.1007/s00213-011-2263-y
   Sinha R, 2011, CURR PSYCHIAT REP, V13, P398, DOI 10.1007/s11920-011-0224-0
   Smith JK, 1997, PSYCHOPHARMACOLOGY, V131, P23, DOI 10.1007/s002130050261
   Smith RJ, 2008, BRAIN STRUCT FUNCT, V213, P43, DOI 10.1007/s00429-008-0191-3
   SMOOTHY R, 1986, PHYSIOL BEHAV, V37, P689, DOI 10.1016/0031-9384(86)90173-3
   Solinas M, 2009, NEUROPSYCHOPHARMACOL, V34, P1102, DOI 10.1038/npp.2008.51
   Solinas M, 2008, P NATL ACAD SCI USA, V105, P17145, DOI 10.1073/pnas.0806889105
   Solinas M, 2010, PROG NEUROBIOL, V92, P572, DOI 10.1016/j.pneurobio.2010.08.002
   Stairs DJ, 2006, BEHAV PHARMACOL, V17, P597, DOI 10.1097/01.fbp.0000236271.72300.0e
   Stairs DJ, 2011, PSYCHOPHARMACOLOGY, V218, P293, DOI 10.1007/s00213-011-2448-4
   Stairs DJ, 2009, PHARMACOL BIOCHEM BE, V92, P377, DOI 10.1016/j.pbb.2009.01.016
   Stalnaker TA, 2009, NEUROPHARMACOLOGY, V56, P63, DOI 10.1016/j.neuropharm.2008.07.019
   Stewart J, 2000, J PSYCHIATR NEUROSCI, V25, P125
   Stohr T, 1999, BEHAV BRAIN RES, V103, P85, DOI 10.1016/S0166-4328(99)00027-3
   Stratakis CA, 1995, ANN NY ACAD SCI, V771, P1, DOI 10.1111/j.1749-6632.1995.tb44666.x
   Sun WenLin, 2011, Curr Drug Abuse Rev, V4, P270
   Swadi H, 1999, DRUG ALCOHOL DEPEN, V55, P209, DOI 10.1016/S0376-8716(99)00017-4
   Thiel KJ, 2008, DRUG ALCOHOL DEPEN, V96, P202, DOI 10.1016/j.drugalcdep.2008.02.013
   Thiel KJ, 2009, INT J NEUROPSYCHOPH, V12, P1151, DOI 10.1017/S1461145709990472
   Thiriet N, 2011, NEUROTOX RES, V19, P172, DOI 10.1007/s12640-010-9158-2
   Tidey JW, 1997, PSYCHOPHARMACOLOGY, V130, P203, DOI 10.1007/s002130050230
   Titomanlio F, EFFECTS RHODIO UNPUB
   TORNATZKY W, 1993, PHYSIOL BEHAV, V53, P983, DOI 10.1016/0031-9384(93)90278-N
   TRIFFLEMAN EG, 1995, J NERV MENT DIS, V183, P172, DOI 10.1097/00005053-199503000-00008
   Trzcinska M, 2002, PHYSIOL BEHAV, V76, P457, DOI 10.1016/S0031-9384(02)00727-8
   Turnbull AV, 1997, P SOC EXP BIOL MED, V215, P1
   Tzschentke TM, 2007, ADDICT BIOL, V12, P227, DOI 10.1111/j.1369-1600.2007.00070.x
   Tzschentke TM, 1998, PROG NEUROBIOL, V56, P613, DOI 10.1016/S0301-0082(98)00060-4
   Ungless MA, 2010, NEUROSCI BIOBEHAV R, V35, P151, DOI 10.1016/j.neubiorev.2010.04.006
   Van den Oever MC, 2010, NEUROSCI BIOBEHAV R, V35, P276, DOI 10.1016/j.neubiorev.2009.11.016
   van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558
   Vaughn LK, 2012, NEUROSCIENCE, V204, P117, DOI 10.1016/j.neuroscience.2011.08.021
   Verdejo-Garcia A, 2009, NEUROPHARMACOLOGY, V56, P48, DOI 10.1016/j.neuropharm.2008.07.035
   Wang B, 2007, PSYCHOPHARMACOLOGY, V193, P283, DOI 10.1007/s00213-007-0782-3
   Wang B, 2009, BIOL PSYCHIAT, V65, P857, DOI 10.1016/j.biopsych.2009.01.018
   Wang XY, 2001, EUR J PHARMACOL, V432, P153, DOI 10.1016/S0014-2999(01)01487-X
   Wee S, 2010, PSYCHOPHARMACOLOGY, V210, P121, DOI 10.1007/s00213-010-1825-8
   Weiss F, 2005, CURR OPIN PHARMACOL, V5, P9, DOI 10.1016/j.coph.2004.11.001
   Weiss F, 2010, FRONT NEUROSCI, P1
   Wise RA, 1998, DRUG ALCOHOL DEPEN, V51, P13, DOI 10.1016/S0376-8716(98)00063-5
   Wise RA, 2010, BRAIN RES, V1314, P38, DOI 10.1016/j.brainres.2009.09.101
   Wise RA, 2008, NEUROTOX RES, V14, P169, DOI 10.1007/BF03033808
   Wise RA, 2009, NEUROPHARMACOLOGY, V56, P174, DOI 10.1016/j.neuropharm.2008.06.008
   WOODY GE, 1993, ADDICTION, V88, P1573, DOI 10.1111/j.1360-0443.1993.tb03144.x
   Xu ZW, 2007, EXP NEUROL, V204, P714, DOI 10.1016/j.expneurol.2006.12.027
   Yahyavi-Firouz-Abadi N, 2009, PHARMACOL THERAPEUT, V124, P235, DOI 10.1016/j.pharmthera.2009.06.014
   Yan Y, 2009, BEHAV BRAIN RES, V196, P1, DOI 10.1016/j.bbr.2008.08.017
   Yap JJ, 2007, PSYCHOPHARMACOLOGY, V192, P261, DOI 10.1007/s00213-007-0712-4
   Yap Jasmine J, 2008, Drug Discov Today Dis Models, V5, P259
   Zhang XY, 2005, PSYCHOPHARMACOLOGY, V177, P391, DOI 10.1007/s00213-004-1963-y
NR 271
TC 22
Z9 22
U1 0
U2 36
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD DEC
PY 2013
VL 19
IS 40
BP 7009
EP 7025
DI 10.2174/138161281940131209124708
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 274YH
UT WOS:000328641600003
PM 23574439
DA 2023-06-23
ER

PT J
AU Abazid, H
   Abu-Farha, R
   Alsayed, AR
   Barakat, M
   Al-Qudah, R
AF Abazid, Husam
   Abu-Farha, Rana
   Alsayed, Ahmad R.
   Barakat, Muna
   Al-Qudah, Raja 'a
TI A comprehensive overview of substance abuse amongst Syrian individuals
   in an addiction rehabilitation center
SO HELIYON
LA English
DT Article
DE Addiction; Syria; Perception; Abuse; Rehabilitation
ID SOCIOECONOMIC-STATUS; YOUNG-ADULTS; DRUGS
AB Objectives: This study aims to provide a comprehensive overview of substance abuse amongst Syrian individuals in an addiction rehabilitation center.Methods: This is a descriptive cross-sectional survey-based study, from patients receiving treatment in an addiction rehabilitation center in Damascus. Syria. The study was conducted over a period of nine months.Results: A total of 82 participants were recruited, the majority of them were males (n = 78.95.1%). More than half of those investigated reported multi-level failure (n = 46, 56.1%) during their education. Most of the participants (n = 44, 53.7%) started to use drugs at a friend's home. The family was shown to play a positive role in stopping the initial drug taking trials at early stages (33/56, 58.9%). Again, friends' effect was the main reason for the return of abusing drugs (20/56, 35.7%). Sources of drugs were mainly from drug promoters for most of the participants (n = 58, 70.7%) followed by friends (n = 28, 34.1%). Participants revealed that taking drugs were mostly accompanied by additional habits such as cigarette smoking before using their drugs (n = 65, 79.3%), or drinking alcohol (57.3%). Surprisingly, participants believed that drug abuse does not lead to addiction (n = 52, 63.4%). The most common experienced feeling was depressed, desperate, or sad (n = 47, 57.3%), followed by anxiety and the desire to escape reality and resort to imaginations (n = 44, 53.7%). Conclusions: The findings of this study indicate the need of policymakers to give more attention, in developing preventive strategies, to friends, as a main cause of addiction, in addition to the family influences on individual's drug abuse, addiction behaviors, and mindsets. Understanding the influencing factors could spot the light on the key to solve the addiction problem. A realist rehabilitation programs must be well designed and implemented as the level of individuals, institutions and communities to face this problematic addiction disaster.
C1 [Abazid, Husam; Abu-Farha, Rana; Alsayed, Ahmad R.; Barakat, Muna; Al-Qudah, Raja 'a] Appl Sci Private Univ, Fac Pharm, Dept Clin Pharm & Therapeut, Amman 11931, Jordan.
RP Abazid, H (通讯作者)，Appl Sci Private Univ, Fac Pharm, Dept Clin Pharm & Therapeut, Amman 11931, Jordan.
EM h_abazid@asu.edu.jo
RI Abazid, Husam/Z-5116-2019; Barakat, Muna/AAN-8778-2020
OI Abazid, Husam/0000-0002-4333-9712; Barakat, Muna/0000-0002-7966-1172;
   Alsayed, Ahmad R./0000-0002-1324-7884
CR Abazid H, 2020, J PHARM HEALTH SERV, V11, P183, DOI 10.1111/jphs.12345
   Abel T, 2013, SWISS MED WKLY, V143, DOI 10.4414/smw.2013.13901
   Ahad M., 2017, IOSR J HUMANIT SOC S, V22, P84
   Alsayed AR, 2022, SAUDI PHARM J, V30, P317, DOI 10.1016/j.jsps.2022.01.013
   Buchman AL, 2001, J CLIN GASTROENTEROL, V33, P289, DOI 10.1097/00004836-200110000-00006
   Calafat A, 2011, PSICOTHEMA, V23, P544
   Center of disease control and prevention (CDC), 2015, TOD HER EP
   Charitonidi E, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2949-5
   Coffield F., 1994, DRUGS YOUNG PEOPLE
   Eric P., 2017, J CAN SOC SCI, V13, P49
   Goodman E, 2002, ARCH PEDIAT ADOL MED, V156, P448, DOI 10.1001/archpedi.156.5.448
   Grim BJ, 2019, J RELIG HEALTH, V58, P1713, DOI 10.1007/s10943-019-00876-w
   Hall W, 2009, LANCET, V374, P1383, DOI 10.1016/S0140-6736(09)61037-0
   Hanan F., 2018, DOES PSYCHOL CAUSES, P4
   Hetherington C.S., 2005, SOCIAL DETERMINANTS
   Horvath A., ADDICTION SOCIOLOGIC
   Humensky JL, 2010, SUBST ABUSE TREAT PR, V5, DOI 10.1186/1747-597X-5-19
   Janicijevic KM, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00366
   Kopetz CE, 2013, PERSPECT PSYCHOL SCI, V8, P3, DOI 10.1177/1745691612457575
   Kolind T, 2016, DRUG-EDUC PREV POLIC, V23, P89, DOI 10.3109/09687637.2016.1153604
   Massad SG, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3472-4
   N.i.o.d. abuse, 2020, SEX GENDER DIFFERENC
   National Institutes of Health (NIH), 2022, COR DIS 2019 COVID 1
   Padhy G.K., 2014, INDIAN MED GAZ, V148, P276
   Patrick ME, 2012, J STUD ALCOHOL DRUGS, V73, P772, DOI 10.15288/jsad.2012.73.772
   Perkonigg A, 1998, EUR ADDICT RES, V4, P58, DOI 10.1159/000018923
   Rabie M, 2020, MIDDLE EAST CURR PSY, V27, DOI 10.1186/s43045-019-0013-8
   Raeisei Ahmadali, 2014, Glob J Health Sci, V7, P194, DOI 10.5539/gjhs.v7n3p194
   Shadur JM, 2014, J SOC PERS RELAT, V31, P997, DOI 10.1177/0265407513516889
   Smith SM, 2013, PAIN, V154, P2287, DOI 10.1016/j.pain.2013.05.053
   U.N.O.o.D.A.C. (UNODC), 2010, WORLD DRUG REP
   UNICEF, 2021, SYR CRIS
   United Nations Office on Drugs And Crime (UNODC), 2018, AN DRUG MARK OP COC
NR 33
TC 0
Z9 0
U1 2
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2405-8440
J9 HELIYON
JI Heliyon
PD APR
PY 2023
VL 9
IS 4
AR e14731
DI 10.1016/j.heliyon.2023.e14731
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA I0JJ9
UT WOS:000999721300001
PM 37025821
OA gold, Green Published
DA 2023-06-23
ER

PT J
AU Rushing, AM
AF Rushing, Alison M.
TI The unitary life pattern of persons experiencing serenity in recovery
   from alcohol and drug addiction
SO ADVANCES IN NURSING SCIENCE
LA English
DT Article
DE addiction; healing; serenity; 12-step programs; unitary appreciative
   inquiry; unitary life pattern
ID PERSPECTIVES
AB People recovering from addiction to alcohol or drugs often acknowledge the need for complete change in life pattern orientation in a journey toward healing. Serenity is the hallmark of recovery according to the tenets of 12-step programs, but little is known about the actual experience of serenity in healing from addiction. From a perspective of unitary pattern appreciation and a method of unitary appreciative inquiry, this study explored the experience of serenity among 9 people recovering from alcohol and/or drug addiction. Results are portrayed in both individual and group profiles, depicted in a format that integrates empirical findings as poetry.
C1 Georgia So Univ, Sch Nursing, Statesboro, GA 30460 USA.
C3 University System of Georgia; Georgia Southern University
RP Rushing, AM (通讯作者)，Georgia So Univ, Sch Nursing, Box 8158, Statesboro, GA 30460 USA.
EM alison_r0022@yahoo.com
CR [Anonymous], 2001, ALCOHOLICS ANONYMOUS
   BEANBAYOG M, 1984, RES ALCOHOLICS ANONY, P99
   Broad C. D., 1953, RELIG PHILOS PSYCHIC
   Brush BL, 2000, APPL NURS RES, V13, P181, DOI 10.1053/apnr.2000.9227
   Caldwell PE, 1998, J SUBST ABUSE TREAT, V15, P221, DOI 10.1016/S0740-5472(97)00191-8
   Cooperrider D.L., 1987, RES ORG CHANGE DEV
   Cowling W R 3rd, 1990, NLN Publ, P45
   Cowling W R 3rd, 1993, Nurs Sci Q, V6, P201, DOI 10.1177/089431849300600409
   Cowling W R 3rd, 2001, ANS Adv Nurs Sci, V23, P32
   Cowling WR, 1998, NURS SCI QUART, V11, P139, DOI 10.1177/089431849801100403
   Cowling WR, 2000, ADV NURS SCI, V22, P16
   COWLING WR, 1996, ADV NURS SCI, V23, P32
   COWLING WR, 2004, ADV NURS SCI, V27
   COWLING WR, 1997, PATTERNS ROGERIAN KN, P129
   Deevey S, 1992, Health Care Women Int, V13, P199
   DuPont R.L, 1997, SELFISH BRAIN LEARNI
   GRAPEVINE AA, 1992, ALCOHOLICS ANONYMOUS
   HERRON J, 1996, COOPERATIVE INQUIRY
   Kruse BG, 1999, NURS SCI QUART, V12, P143, DOI 10.1177/08943189922106576
   Messenger T, 1994, J Gerontol Nurs, V20, P17
   Murphy M, 1992, FUTURE BODY EXPLORAT
   Newman M., 1982, NURS OUTLOOK, V40, P10
   NEWMAN MA, 1990, NURS SCI QUART, V3, P37, DOI DOI 10.1177/089431849000300109
   Parse R R, 1992, Nurs Sci Q, V5, P35, DOI 10.1177/089431849200500109
   PARSE RR, 1981, MAN LIVING HLTH THEO
   PARSE RR, 1995, ILLUNIMATIONS HUMAN
   POLKINGHORNE DE, 1996, AGING BIOGRAPHY EXPL, P77
   Reason P., 2001, HDB ACTION RES PARTI
   ROBERTS JM, 1990, J MATH SOCIOL, V16, P77, DOI 10.1080/0022250X.1990.9990079
   Roberts K T, 1996, Image J Nurs Sch, V28, P359
   Roberts K T, 1993, Geriatr Nurs, V14, P317, DOI 10.1016/S0197-4572(06)80059-5
   Roberts K T, 1993, J Nurs Meas, V1, P145
   Roberts K T, 1991, Sch Inq Nurs Pract, V5, P127
   Rogers M E, 1990, NLN Publ, P5
   Rogers M E, 1992, Nurs Sci Q, V5, P27
   Rogers M E, 1988, Nurs Sci Q, V1, P99, DOI 10.1177/089431848800100304
   ROGERS ME, 1994, NURS SCI QUART, V7, P33, DOI 10.1177/089431849400700111
   ROGERS ME, 1986, EXPLORATIONS M ROGER, P3
   Rogers ME, 1980, CONCEPTUAL MODELS NU, P329
   RUSHING AM, 2005, THESIS VIRGINIA COMM
   Sandelowski M, 1991, Image J Nurs Sch, V23, P161, DOI 10.1111/j.1547-5069.1991.tb00662.x
   Sandelowski M, 1994, J Holist Nurs, V12, P23, DOI 10.1177/089801019401200105
   Steigerwald F, 1999, J SUBST ABUSE TREAT, V16, P321, DOI 10.1016/S0740-5472(98)00052-X
   Taylor EJ, 1999, APPL NURS RES, V12, P30, DOI 10.1016/S0897-1897(99)80156-6
   Vourakis C., 1989, PROCESS RECOVERY WOM
NR 45
TC 4
Z9 5
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0161-9268
EI 1550-5014
J9 ADV NURS SCI
JI Adv. Nurs. Sci.
PD JUL-SEP
PY 2008
VL 31
IS 3
BP 198
EP 210
DI 10.1097/01.ANS.0000334284.73730.75
PG 13
WC Nursing
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Nursing
GA 341QF
UT WOS:000258729000004
PM 18724110
DA 2023-06-23
ER

PT J
AU Rinker, K
AF Rinker, Katelyn
TI Drug Use and Abuse
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Book Review
DE methylphenidate; attention; ADHD; pediatric; drug use; addiction
C1 [Rinker, Katelyn] Washington State Univ, Dept Psychol, Pullman, WA 99164 USA.
C3 Washington State University
RP Rinker, K (通讯作者)，Washington State Univ, Dept Psychol, Pullman, WA 99164 USA.
EM katelyn.rinker@wsu.edu
CR Jones HA, 2015, J ATTEN DISORD, V19, P251, DOI 10.1177/1087054712473181
   Mahone EM, 2017, J INT NEUROPSYCH SOC, V23, P916, DOI 10.1017/S1355617717000807
   MAISTO S, 2017, DRUG USE ABUSE
   Sugrue D, 2014, AM J HEALTH-SYST PH, V71, P1163, DOI 10.2146/ajhp130638
NR 4
TC 1
Z9 1
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD AUG 7
PY 2019
VL 10
AR 1817
DI 10.3389/fpsyg.2019.01817
PG 2
WC Psychology, Multidisciplinary
WE Social Science Citation Index (SSCI)
SC Psychology
GA IO1WL
UT WOS:000479172500003
OA Green Published, gold
DA 2023-06-23
ER

PT J
AU Torregrossa, MM
   Kalivas, PW
AF Torregrossa, Mary M.
   Kalivas, Peter W.
TI Microdialysis and the neurochemistry of addiction
SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
LA English
DT Review
DE microdialysis; neuroplasticity; addiction; glutamate; GABA; dopamine;
   neuropeptide
ID VENTRAL TEGMENTAL AREA; RAT NUCLEUS-ACCUMBENS; IN-VIVO MICRODIALYSIS;
   FREELY MOVING RATS; COCAINE-INDUCED REINSTATEMENT; INDUCED BEHAVIORAL
   SENSITIZATION; CORTICOTROPIN-RELEASING-FACTOR; EXTRACELLULAR DOPAMINE
   LEVELS; SEEKING BEHAVIOR; ACETYLCHOLINE-RELEASE
AB Drug addiction is a process beginning with the initial exposure to a drug of abuse, and leading, in some individuals, to chronic habitual use, and high rates of relapse. Microdialysis allows researchers to monitor the neurochemical changes that occur in the brain after the initial exposure to a drug, and the neurochemical changes that occur with repeated exposure. These changes in the brain are often referred to as drug-induced neuroplasticity, and the aim of this article is to review studies that have utilized microdialysis to increase our understanding of the neuroplasticity that occurs in the process of addiction. We will review how several neurotransmitter systems, including glutamate, GABA, the monoamines, and others, are altered after chronic drug exposure, and how microdialysis can be used to determine if putative treatments for addiction can reverse the drug-induced neuroplasticity in these systems. We will also briefly discuss our recent research using a known change in GABA neurotransmission that occurs during reinstatement of drug-seeking to screen for possible novel treatments to prevent relapse. Overall, rnicrodialysis in combination with other behavioral and pharmacological techniques has greatly increased our understanding of addiction-related neuroplasticity, and provides a means for discovering new ways to prevent these changes and treat addiction. (c) 2007 Elsevier Inc. All rights reserved.
C1 [Torregrossa, Mary M.; Kalivas, Peter W.] Med Univ S Carolina, Charleston, SC 29425 USA.
C3 Medical University of South Carolina
RP Torregrossa, MM (通讯作者)，Med Univ S Carolina, Suite 403 Basic Sci Bldg,173 Ashley Ave, Charleston, SC 29425 USA.
EM mary.torregrossa@yale.edu; kalivasp@musc.edu
RI Torregrossa, Mary/N-6053-2017; Torregrossa, Mary/AAW-6740-2020
OI Torregrossa, Mary/0000-0003-2083-0231; Torregrossa,
   Mary/0000-0003-2083-0231
FU NIDA NIH HHS [T32 DA007288-15, R01 DA003906-09, P50 DA015369, R01
   DA012513-09, DA03906, F32 DA022812, R01 DA003906, R01 DA015851, T32
   DA007288, T32 DA07288-15, R01 DA012513, F32 DA022812-01A1, R37 DA003906,
   R01 DA015851-05, DA12513] Funding Source: Medline
CR Arnold HM, 2003, PSYCHOPHARMACOLOGY, V165, P346, DOI 10.1007/s00213-002-1260-6
   Baker DA, 2002, AMINO ACIDS, V23, P161, DOI 10.1007/s00726-001-0122-6
   Baker DA, 2003, NAT NEUROSCI, V6, P743, DOI 10.1038/nn1069
   Bassareo V, 2007, PSYCHOPHARMACOLOGY, V191, P689, DOI 10.1007/s00213-006-0560-7
   Beinfeld MC, 2002, J NEUROCHEM, V81, P1021, DOI 10.1046/j.1471-4159.2002.00894.x
   Bell K, 2000, NEUROPSYCHOPHARMACOL, V23, P335, DOI 10.1016/S0893-133X(00)00100-7
   Bickerdike MJ, 1997, J PHARMACOL EXP THER, V282, P818
   Bossert JM, 2005, EUR J PHARMACOL, V526, P36, DOI 10.1016/j.ejphar.2005.09.030
   BOURDELAIS A, 1990, BRAIN RES, V516, P132, DOI 10.1016/0006-8993(90)90907-S
   Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0
   Cadoni C, 2000, EUR J PHARMACOL, V388, P69, DOI 10.1016/S0014-2999(99)00824-9
   Cadoni C, 1999, NEUROSCIENCE, V90, P447, DOI 10.1016/S0306-4522(98)00466-7
   Caille S, 2006, NEUROPSYCHOPHARMACOL, V31, P804, DOI 10.1038/sj.npp.1300848
   Caille S, 2004, EUR J NEUROSCI, V20, P593, DOI 10.1111/j.1460-9568.2004.03497.x
   Chefer VI, 2002, NEUROSCIENCE, V112, P907, DOI 10.1016/S0306-4522(02)00099-4
   Chen Jianping, 1996, Life Sciences, V58, P139
   Cowen M, 1998, PHARMACOL BIOCHEM BE, V59, P51, DOI 10.1016/S0091-3057(97)00390-0
   deFonseca FR, 1997, SCIENCE, V276, P2050, DOI 10.1126/science.276.5321.2050
   Dewey SL, 1997, SYNAPSE, V25, P393, DOI 10.1002/(SICI)1098-2396(199704)25:4<393::AID-SYN11>3.0.CO;2-W
   Duvauchelle CL, 2000, BEHAV NEUROSCI, V114, P1156, DOI 10.1037/0735-7044.114.6.1156
   Fadda P, 2003, SYNAPSE, V50, P1, DOI 10.1002/syn.10238
   Fiserova M, 1999, PSYCHOPHARMACOLOGY, V142, P85, DOI 10.1007/s002130050866
   Giorgetti M, 2002, NEUROSCIENCE, V109, P585, DOI 10.1016/S0306-4522(01)00510-3
   Hao Y, 2005, BRAIN RES, V1040, P191, DOI 10.1016/j.brainres.2005.01.072
   HEIDBREDER CA, 1994, NEUROREPORT, V5, P1797, DOI 10.1097/00001756-199409080-00028
   Heidbreder CA, 1996, J PHARMACOL EXP THER, V278, P490
   HOOKS MS, 1994, PSYCHOPHARMACOLOGY, V115, P265
   Hotsenpiller G, 2003, NEUROSCIENCE, V118, P123, DOI 10.1016/S0306-4522(02)00951-X
   Hotsenpiller G, 2001, EUR J NEUROSCI, V14, P1843, DOI 10.1046/j.0953-816x.2001.01804.x
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Ikegami A, 2007, BEHAV NEUROSCI, V121, P389, DOI 10.1037/0735-7044.121.2.389
   Ito R, 2000, J NEUROSCI, V20, P7489
   Jayaram P, 2005, EUR J NEUROSCI, V21, P2035, DOI 10.1111/j.1460-9568.2005.04000.x
   Jayaram P, 2004, J NEUROCHEM, V90, P839, DOI 10.1111/j.1471-4159.2004.02525.x
   JOHNSON DW, 1993, PHARMACOL BIOCHEM BE, V46, P341, DOI 10.1016/0091-3057(93)90362-W
   Kalivas PW, 1998, NEUROPSYCHOPHARMACOL, V18, P469, DOI 10.1016/S0893-133X(97)00195-4
   KALIVAS PW, 1993, J NEUROSCI, V13, P266
   Kalivas PW, 1998, J NEUROCHEM, V70, P1497
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kalivas PW, 1998, J PSYCHOPHARMACOL, V12, P49, DOI 10.1177/026988119801200107
   Katner SN, 1999, ALCOHOL CLIN EXP RES, V23, P1751, DOI 10.1097/00000374-199911000-00007
   Kelley AE, 2004, NEURON, V44, P161, DOI 10.1016/j.neuron.2004.09.016
   KOLTA MG, 1985, NEUROPHARMACOLOGY, V24, P823, DOI 10.1016/0028-3908(85)90032-2
   Lin SK, 2007, BRAIN RES BULL, V71, P365, DOI 10.1016/j.brainresbull.2006.10.001
   Marinelli PW, 2005, ALCOHOL CLIN EXP RES, V29, P1821, DOI 10.1097/01.alc.0000183008.62955.2e
   McFarland K, 2004, J NEUROSCI, V24, P1551, DOI 10.1523/JNEUROSCI.4177-03.2004
   McFarland K, 2003, J NEUROSCI, V23, P3531
   McFarland K, 2001, J NEUROSCI, V21, P8655
   MEIL WM, 1995, PSYCHOPHARMACOLOGY, V118, P338, DOI 10.1007/BF02245964
   Neisewander JL, 1996, NEUROPSYCHOPHARMACOL, V15, P506, DOI 10.1016/S0893-133X(96)00097-8
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   Nieto MM, 2002, J NEUROSCI, V22, P1034, DOI 10.1523/JNEUROSCI.22-03-01034.2002
   Olive MF, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-23-j0002.2001
   Olive MF, 1998, PSYCHOPHARMACOLOGY, V139, P251, DOI 10.1007/s002130050712
   Parent M, 2001, METHODS, V23, P11, DOI 10.1006/meth.2000.1102
   PARSONS LH, 1993, J NEUROCHEM, V61, P1611, DOI 10.1111/j.1471-4159.1993.tb09794.x
   PARSONS LH, 1991, SYNAPSE, V9, P60, DOI 10.1002/syn.890090109
   PAULSON PE, 1995, SYNAPSE, V19, P56, DOI 10.1002/syn.890190108
   PIERCE RC, 1995, J PHARMACOL EXP THER, V275, P1019
   Pierce RC, 1996, J NEUROSCI, V16, P1550
   Ranaldi R, 1999, J NEUROSCI, V19, P4102
   Reid MS, 1998, BEHAV PHARMACOL, V9, P137
   Reid MS, 1996, NEUROREPORT, V7, P1325, DOI 10.1097/00001756-199605170-00022
   RICHTER RM, 1995, NEUROSCI LETT, V187, P169, DOI 10.1016/0304-3940(95)11365-4
   Richter RM, 1999, SYNAPSE, V32, P254, DOI 10.1002/(SICI)1098-2396(19990615)32:4<254::AID-SYN2>3.0.CO;2-H
   Roberts DCS, 2005, PHYSIOL BEHAV, V86, P18, DOI 10.1016/j.physbeh.2005.06.017
   Robinson SE, 1997, EUR J PHARMACOL, V319, P31, DOI 10.1016/S0014-2999(96)00923-5
   ROBINSON TE, 1988, BRAIN RES, V462, P211, DOI 10.1016/0006-8993(88)90549-5
   Sanchis-Segura C, 2006, ADDICT BIOL, V11, P2, DOI 10.1111/j.1369-1600.2006.00012.x
   SEGAL DS, 1992, BRAIN RES, V571, P330, DOI 10.1016/0006-8993(92)90672-V
   SEGAL DS, 1992, BRAIN RES, V577, P351, DOI 10.1016/0006-8993(92)90297-M
   Shaham Y, 1996, J NEUROSCI, V16, P1957
   Shim I, 2001, BEHAV BRAIN RES, V121, P137, DOI 10.1016/S0166-4328(01)00161-9
   Sizemore GM, 2000, PSYCHOPHARMACOLOGY, V150, P391, DOI 10.1007/s002130000456
   Swanson CJ, 2001, J NEUROSCI, V21, P9043, DOI 10.1523/JNEUROSCI.21-22-09043.2001
   Szumlinski KK, 2007, PSYCHOPHARMACOLOGY, V190, P415, DOI 10.1007/s00213-006-0641-7
   Szumlinski KK, 2006, NEUROPSYCHOPHARMACOL, V31, P768, DOI 10.1038/sj.npp.1300890
   Tang XC, 2005, J NEUROSCI, V25, P4512, DOI 10.1523/JNEUROSCI.0685-05.2005
   Tran-Nguyen LTL, 1998, NEUROPSYCHOPHARMACOL, V19, P48
   Valverde O, 2001, EUR J NEUROSCI, V13, P1816, DOI 10.1046/j.0953-816x.2001.01558.x
   Ventura R, 2005, CEREB CORTEX, V15, P1877, DOI 10.1093/cercor/bhi066
   VEZINA P, 1993, BRAIN RES, V605, P332, DOI 10.1016/0006-8993(93)91761-G
   Williams JM, 2004, EUR J NEUROSCI, V20, P1639, DOI 10.1111/j.1460-9568.2004.03618.x
   WOLF ME, 1993, J PHARMACOL EXP THER, V264, P249
   Xi ZX, 2006, J NEUROSCI, V26, P8531, DOI 10.1523/JNEUROSCI.0726-06.2006
   Xi ZX, 2000, J PHARMACOL EXP THER, V294, P613
   Xi ZX, 2003, J NEUROSCI, V23, P3498
   Xue CJ, 1996, J NEUROCHEM, V67, P352
   Zahm DS, 1996, J COMP NEUROL, V364, P340, DOI 10.1002/(SICI)1096-9861(19960108)364:2<340::AID-CNE11>3.0.CO;2-T
   Zapata A, 2003, EUR J NEUROSCI, V17, P590, DOI 10.1046/j.1460-9568.2003.02491.x
NR 90
TC 43
Z9 44
U1 0
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0091-3057
J9 PHARMACOL BIOCHEM BE
JI Pharmacol. Biochem. Behav.
PD AUG
PY 2008
VL 90
IS 2
BP 261
EP 272
DI 10.1016/j.pbb.2007.09.001
PG 12
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA 323ZW
UT WOS:000257488300015
PM 17928041
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Lynch, WJ
   Peterson, AB
   Sanchez, V
   Abel, J
   Smith, MA
AF Lynch, Wendy J.
   Peterson, Alexis B.
   Sanchez, Victoria
   Abel, Jean
   Smith, Mark A.
TI Exercise as a novel treatment for drug addiction: A neurobiological and
   stage-dependent hypothesis
SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
LA English
DT Review
DE Addiction; Animal models; Chromatin; Clinical; Dopamine; Epigenetic;
   Exercise; Glutamate; Neurobiological mechanisms
ID MEDIAL PREFRONTAL CORTEX; VENTRAL TEGMENTAL AREA; CONDITIONED PLACE
   PREFERENCE; INCREASE EXTRACELLULAR DOPAMINE; MGLUR(2/3) AGONIST
   LY379268; CUE-INDUCED REINSTATEMENT; PERMEABLE AMPA RECEPTORS;
   NUCLEUS-ACCUMBENS CORE; PHYSICAL-ACTIVITY; NEUROTROPHIC FACTOR
AB Physical activity, and specifically exercise, has been suggested as a potential treatment for drug addiction. In this review, we discuss clinical and preclinical evidence for the efficacy of exercise at different phases of the addiction process. Potential neurobiological mechanisms are also discussed focusing on interactions with dopaminergic and glutamatergic signaling and chromatin remodeling in the reward pathway. While exercise generally produces an efficacious response, certain exercise conditions may be either ineffective or lead to detrimental effects depending on the level/type/timing of exercise exposure, the stage of addiction, the drug involved, and the subject population. During drug use initiation and withdrawal, its efficacy may be related to its ability to facilitate dopaminergic transmission, and once addiction develops, its efficacy may be related to its ability to normalize glutamatergic and dopaminergic signaling and reverse drug-induced changes in chromatin via epigenetic interactions with brain-derived neurotrophic factor (BDNF) in the reward pathway. We conclude with future directions, including the development of exercise-based interventions alone or as an adjunct to other strategies for treating drug addiction. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Lynch, Wendy J.; Peterson, Alexis B.; Sanchez, Victoria] Univ Virginia, Dept Psychiat & Neurobehav Sci, Charlottesville, VA 22911 USA.
   [Abel, Jean] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22911 USA.
   [Smith, Mark A.] Davidson Coll, Dept Psychol, Davidson, NC 28036 USA.
C3 University of Virginia; University of Virginia; Davidson College
RP Lynch, WJ (通讯作者)，Univ Virginia, Dept Psychiat & Neurobehav Sci, 1670 Discovery Dr, Charlottesville, VA 22911 USA.
EM wlynch@virginia.edu
RI Smith, Mark/C-9793-2014
OI Smith, Mark/0000-0002-0429-2798
FU National Institute on Drug Abuse [R01-DA024716, R01-DA024716-S1,
   R01-DA027485]; National Institute on Alcohol Abuse and Alcoholism
   [R01-AA016554]; Virginia Youth Tobacco Projects Research Coalition
   (Darlene Brunzell, PI)
FX This work was supported by grants from the National Institute on Drug
   Abuse (R01-DA024716 to WJL; R01-DA024716-S1 to WJL; R01-DA027485 to
   MAS), the National Institute on Alcohol Abuse and Alcoholism
   (R01-AA016554 to WJL) and the Virginia Youth Tobacco Projects Research
   Coalition (Darlene Brunzell, PI; WJL).
CR AARON DJ, 1995, MED SCI SPORT EXER, V27, P1639
   Ahmed SH, 2012, NEUROSCIENCE, V211, P107, DOI 10.1016/j.neuroscience.2011.08.014
   Ahmed SH, 2004, PSYCHOPHARMACOLOGY, V172, P450, DOI 10.1007/s00213-003-1682-9
   Allen RM, 2007, PSYCHOPHARMACOLOGY, V191, P341, DOI 10.1007/s00213-006-0661-3
   Angelucci F, 2007, J PSYCHOPHARMACOL, V21, P820, DOI 10.1177/0269881107078491
   ARAVICH PF, 1993, BRAIN RES, V622, P1, DOI 10.1016/0006-8993(93)90794-N
   ART T, 1994, VET REC, V135, P499, DOI 10.1136/vr.135.21.499
   Baker DA, 2003, NAT NEUROSCI, V6, P743, DOI 10.1038/nn1069
   Balter RE, 2012, PSYCHOPHARMACOLOGY, V224, P91, DOI 10.1007/s00213-012-2826-6
   Barbour KA, 2007, J CARDIOPULM REHABIL, V27, P359, DOI 10.1097/01.HCR.0000300262.69645.95
   Bauer J., 2013, NEUROPSYCHOPHARMACOL
   Ben-Shahar O, 2013, J NEUROSCI, V33, P495, DOI 10.1523/JNEUROSCI.3710-12.2013
   Ben-Shahar O, 2009, SYNAPSE, V63, P598, DOI 10.1002/syn.20640
   Ben-Shahar OM, 2012, ADDICT BIOL, V17, P746, DOI 10.1111/j.1369-1600.2011.00428.x
   Berczik K, 2012, SUBST USE MISUSE, V47, P403, DOI 10.3109/10826084.2011.639120
   Berg CJ, 2012, HEALTH EDUC BEHAV, V39, P191, DOI 10.1177/1090198111432252
   Berglind WJ, 2007, EUR J NEUROSCI, V26, P757, DOI 10.1111/j.1460-9568.2007.05692.x
   Berglind WJ, 2009, J NEUROSCI, V29, P3715, DOI 10.1523/JNEUROSCI.5457-08.2009
   Biedermann S, 2012, NEUROIMAGE, V61, P1206, DOI 10.1016/j.neuroimage.2012.04.010
   Bilinski P, 2012, ANN AGR ENV MED, V19, P491
   Bock BC, 1999, ADDICT BEHAV, V24, P399, DOI 10.1016/S0306-4603(98)00088-4
   Bossert JM, 2012, J NEUROSCI, V32, P4982, DOI 10.1523/JNEUROSCI.0005-12.2012
   Botia B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047527
   Brager AJ, 2012, PHYSIOL BEHAV, V107, P418, DOI 10.1016/j.physbeh.2012.09.011
   Brocardo PS, 2012, NEUROPHARMACOLOGY, V62, P1607, DOI 10.1016/j.neuropharm.2011.10.006
   BROWN BS, 1979, J APPL PHYSIOL, V46, P19, DOI 10.1152/jappl.1979.46.1.19
   Brown Richard A, 2010, Ment Health Phys Act, V3, P27
   Buchowski MS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017465
   CARBONI E, 1989, NEUROSCIENCE, V28, P653, DOI 10.1016/0306-4522(89)90012-2
   Carroll ME, 1997, PSYCHOPHARMACOLOGY, V129, P206, DOI 10.1007/s002130050182
   Castrucci BC, 2004, AM J HEALTH BEHAV, V28, P63, DOI 10.5993/AJHB.28.1.7
   CHANG JY, 1994, J NEUROSCI, V14, P1224, DOI 10.1523/JNEUROSCI.14-03-01224.1994
   Chase K.A., 2013, INT J NEUROPSYCHOPH, P1
   Chen HI, 2008, BEHAV BRAIN RES, V187, P185, DOI 10.1016/j.bbr.2007.09.014
   Chen JX, 2007, CELL MOL NEUROBIOL, V27, P1, DOI 10.1007/s10571-006-9110-4
   CHEN JP, 1990, PSYCHOPHARMACOLOGY, V102, P156, DOI 10.1007/BF02245916
   Chen P.H., 2013, ADDICT BIOL
   Cohen A, 2012, NEUROPSYCHOPHARMACOL, V37, P2153, DOI 10.1038/npp.2012.67
   Collingwood TR, 2000, J DRUG EDUC, V30, P435, DOI 10.2190/RVUE-9XW7-TYRQ-EJR8
   Corominas-Roso M., 2012, EUR NEUROPSYCHOPHARM
   Correia CJ, 2005, ADDICT BEHAV, V30, P19, DOI 10.1016/j.addbeh.2004.04.006
   CORRIGALL WA, 1992, PSYCHOPHARMACOLOGY, V107, P285, DOI 10.1007/BF02245149
   Cosgrove KP, 2003, PSYCHOPHARMACOLOGY, V170, P9, DOI 10.1007/s00213-003-1487-x
   Cosgrove KP, 2002, PHARMACOL BIOCHEM BE, V73, P663, DOI 10.1016/S0091-3057(02)00853-5
   Costa MA, 2011, ALCOHOL CLIN EXP RES, V35, P1966, DOI 10.1111/j.1530-0277.2011.01548.x
   D'Sa C, 2011, BIOL PSYCHIAT, V70, P706, DOI 10.1016/j.biopsych.2011.05.013
   Dalley JW, 2007, SCIENCE, V315, P1267, DOI 10.1126/science.1137073
   Damez-Werno D, 2012, J NEUROSCI, V32, P10267, DOI 10.1523/JNEUROSCI.1290-12.2012
   DAMSMA G, 1989, EUR J PHARMACOL, V168, P363, DOI 10.1016/0014-2999(89)90798-X
   Debruille C, 1999, PHYSIOL RES, V48, P129
   Devaud LL, 2012, PHARMACOL BIOCHEM BE, V103, P18, DOI 10.1016/j.pbb.2012.07.012
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Dishman RK, 1997, MED SCI SPORT EXER, V29, P63, DOI 10.1097/00005768-199701000-00010
   Droste SK, 2006, J NEUROENDOCRINOL, V18, P915, DOI 10.1111/j.1365-2826.2006.01489.x
   Duman CH, 2008, BRAIN RES, V1199, P148, DOI 10.1016/j.brainres.2007.12.047
   Dunn AL, 1996, MED SCI SPORT EXER, V28, P204, DOI 10.1097/00005768-199602000-00008
   Ehringer MA, 2009, ALCOHOL, V43, P443, DOI 10.1016/j.alcohol.2009.06.003
   Eisenstein SA, 2007, PHARMACOL BIOCHEM BE, V86, P607, DOI 10.1016/j.pbb.2007.02.002
   Ekkekakis P, 2011, SPORTS MED, V41, P641, DOI 10.2165/11590680-000000000-00000
   El Rawas R, 2009, PSYCHOPHARMACOLOGY, V203, P561, DOI 10.1007/s00213-008-1402-6
   Engelmann A.J., 2013, BRAIN STRUCT FUNCT
   ESCOBEDO LG, 1993, JAMA-J AM MED ASSOC, V269, P1391, DOI 10.1001/jama.269.11.1391
   Feng J., 2013, CURR OPIN NEUROBIOL
   Field T, 2001, ADOLESCENCE, V36, P105
   Fischer-Smith KD, 2012, NEUROSCIENCE, V210, P333, DOI 10.1016/j.neuroscience.2012.02.049
   Foley TE, 2008, NEUROMOL MED, V10, P67, DOI 10.1007/s12017-008-8032-3
   FONTANA F, 1994, J HYPERTENS, V12, P1285
   Fontes-Ribeiro CA, 2011, CURR NEUROPHARMACOL, V9, P45, DOI 10.2174/157015911795017380
   Freeman WM, 2008, NEUROPSYCHOPHARMACOL, V33, P1807, DOI 10.1038/sj.npp.1301577
   Gardner EL, 2011, ADV PSYCHOSOM MED, V30, P22, DOI 10.1159/000324065
   Gerrits MAFM, 1996, BRAIN RES, V713, P114, DOI 10.1016/0006-8993(95)01491-8
   Ghasemzadeh MB, 2011, BRAIN RES, V1413, P60, DOI 10.1016/j.brainres.2011.06.041
   Gomez-Pinilla F, 2011, EUR J NEUROSCI, V33, P383, DOI 10.1111/j.1460-9568.2010.07508.x
   Gozen O., 2013, SYNAPSE
   Greenwald M.K., 2012, ADDICT BIOL
   Greenwood BN, 2008, NEUROMOL MED, V10, P81, DOI 10.1007/s12017-008-8029-y
   Greenwood BN, 2007, BEHAV NEUROSCI, V121, P992, DOI 10.1037/0735-7044.121.5.992
   Greenwood BN, 2011, BEHAV BRAIN RES, V217, P354, DOI 10.1016/j.bbr.2010.11.005
   Grimm JW, 2003, J NEUROSCI, V23, P742
   Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134
   Guezennec CY, 1998, INT J SPORTS MED, V19, P323, DOI 10.1055/s-2007-971925
   Haasova M, 2013, ADDICTION, V108, P26, DOI 10.1111/j.1360-0443.2012.04034.x
   Hammer SB, 2010, ALCOHOL CLIN EXP RES, V34, P1651, DOI 10.1111/j.1530-0277.2010.01251.x
   Hao Y, 2010, BIOL PSYCHIAT, V68, P240, DOI 10.1016/j.biopsych.2010.02.011
   Hatzigiakoumis D.S., 2011, FRONT PSYCHIATRY, V17, P2
   Henry DJ, 1998, PSYCHOPHARMACOLOGY, V140, P233, DOI 10.1007/s002130050762
   HERNANDEZ L, 1988, LIFE SCI, V42, P1705, DOI 10.1016/0024-3205(88)90036-7
   Herz A, 1998, CAN J PHYSIOL PHARM, V76, P252, DOI 10.1139/cjpp-76-3-252
   Hilburn C, 2011, NEUROPSYCH DIS TREAT, V7, P357, DOI 10.2147/NDT.S18953
   HOFFMANN P, 1990, REGUL PEPTIDES, V28, P233, DOI 10.1016/0167-0115(90)90021-N
   Horn K, 2011, PEDIATRICS, V128, pE801, DOI 10.1542/peds.2010-2599
   Hosseini Mahmoud, 2009, Pathophysiology, V16, P3, DOI 10.1016/j.pathophys.2008.11.001
   Hotsenpiller G, 2001, EUR J NEUROSCI, V14, P1843, DOI 10.1046/j.0953-816x.2001.01804.x
   Houghten R A, 1986, NIDA Res Monogr, V75, P505
   Im HI, 2010, NAT NEUROSCI, V13, P1120, DOI 10.1038/nn.2615
   IVERSEN IH, 1993, J EXP ANAL BEHAV, V60, P219, DOI 10.1901/jeab.1993.60-219
   Jia J, 2009, LIFE SCI, V84, P505, DOI 10.1016/j.lfs.2009.01.015
   Jia W, 2011, NEUROSCI LETT, V495, P221, DOI 10.1016/j.neulet.2011.03.072
   Kalivas PW, 2011, MOL PSYCHIATR, V16, P974, DOI 10.1038/mp.2011.46
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kanarek RB, 1998, PHARMACOL BIOCHEM BE, V61, P19, DOI 10.1016/S0091-3057(98)00059-8
   Kenford SL, 2005, ADDICT BEHAV, V30, P285, DOI 10.1016/j.addbeh.2004.05.017
   Kirkcaldy BD, 2002, SOC PSYCH PSYCH EPID, V37, P544, DOI 10.1007/s00127-002-0554-7
   Knab AM, 2010, INT J BIOL SCI, V6, P133
   Koeltzow TE, 2003, BEHAV NEUROSCI, V117, P860, DOI 10.1037/0735-7044.117.4.860
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Korhonen T, 2009, TWIN RES HUM GENET, V12, P261, DOI 10.1375/twin.12.3.261
   Kovatsi L, 2011, CURR MED CHEM, V18, P1765, DOI 10.2174/092986711795496836
   Kufahl PR, 2013, NEUROPHARMACOLOGY, V66, P290, DOI 10.1016/j.neuropharm.2012.05.037
   Kufahl PR, 2011, NEUROPSYCHOPHARMACOL, V36, P2762, DOI 10.1038/npp.2011.174
   Kujala UM, 2007, ADDICTION, V102, P1151, DOI 10.1111/j.1360-0443.2007.01858.x
   Kulig K, 2003, ARCH PEDIAT ADOL MED, V157, P905, DOI 10.1001/archpedi.157.9.905
   Kumar A, 2005, NEURON, V48, P303, DOI 10.1016/j.neuron.2005.09.023
   Landers D. M., 2007, HDB SPORT PSYCHOL, P469, DOI [DOI 10.1002/9781118270011.CH21, 10.1002/9781118270011.]
   LaPlant Q, 2011, HORM BEHAV, V59, P321, DOI 10.1016/j.yhbeh.2010.05.015
   Lavie CJ, 2011, PROG CARDIOVASC DIS, V53, P464, DOI 10.1016/j.pcad.2011.03.007
   Leasure JL, 2008, NEUROSCIENCE, V156, P456, DOI 10.1016/j.neuroscience.2008.07.041
   Leasure JL, 2010, ALCOHOL CLIN EXP RES, V34, P404, DOI 10.1111/j.1530-0277.2009.01105.x
   Lett BT, 2002, PHARMACOL BIOCHEM BE, V72, P101, DOI 10.1016/S0091-3057(01)00722-5
   Li X, 2013, J NEUROSCI, V33, P1130, DOI 10.1523/JNEUROSCI.3082-12.2013
   Lisha NE, 2010, ADDICT BEHAV, V35, P399, DOI 10.1016/j.addbeh.2009.12.032
   Liste I, 1997, EXP BRAIN RES, V115, P458, DOI 10.1007/PL00005715
   Loweth J.A., 2013, CURR OPIN NEUROBIOL, VS0959-4388
   Lu H, 2010, NEURON, V67, P821, DOI 10.1016/j.neuron.2010.08.012
   Lu L, 2004, J NEUROSCI, V24, P1604, DOI 10.1523/JNEUROSCI.5124-03.2004
   Lu L, 2007, BIOL PSYCHIAT, V61, P591, DOI 10.1016/j.biopsych.2006.04.011
   Lynch WJ, 2007, PSYCHOPHARMACOLOGY, V191, P263, DOI 10.1007/s00213-006-0656-0
   Lynch WJ, 2010, BIOL PSYCHIAT, V68, P774, DOI 10.1016/j.biopsych.2010.06.022
   Lynch WJ, 2004, NEUROPSYCHOPHARMACOL, V29, P943, DOI 10.1038/sj.npp.1300389
   LYNESS WH, 1979, PHARMACOL BIOCHEM BE, V11, P553, DOI 10.1016/0091-3057(79)90040-6
   LYNESS WH, 1992, PHARMACOL BIOCHEM BE, V42, P187, DOI 10.1016/0091-3057(92)90465-R
   MACRAE PG, 1987, NEUROSCI LETT, V79, P138, DOI 10.1016/0304-3940(87)90686-0
   Madayag A, 2007, J NEUROSCI, V27, P13968, DOI 10.1523/JNEUROSCI.2808-07.2007
   MAISONNEUVE IM, 1991, EUR J PHARMACOL, V199, P35, DOI 10.1016/0014-2999(91)90634-3
   MAISONNEUVE IM, 1995, J PHARMACOL EXP THER, V272, P652
   Marques E, 2008, ANN NY ACAD SCI, V1139, P222, DOI 10.1196/annals.1432.041
   Martens MP, 2006, J SUBST ABUSE TREAT, V31, P305, DOI 10.1016/j.jsat.2006.05.004
   Martinez D, 2004, NEUROPSYCHOPHARMACOL, V29, P1190, DOI 10.1038/sj.npp.1300420
   Martinez D, 2012, BIOL PSYCHIAT, V71, P192, DOI 10.1016/j.biopsych.2011.08.024
   Martinsen M., 2012, SCAND J MED SCI SPOR
   Mathes WF, 2010, BEHAV BRAIN RES, V210, P155, DOI 10.1016/j.bbr.2010.02.016
   Mathes WF, 2001, PHYSIOL BEHAV, V74, P245, DOI 10.1016/S0031-9384(01)00577-7
   Mattila VM, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-230
   McCulley WD, 2012, PHARMACOL BIOCHEM BE, V100, P485, DOI 10.1016/j.pbb.2011.10.009
   McCutcheon JE, 2011, J NEUROSCI, V31, P14536, DOI 10.1523/JNEUROSCI.3625-11.2011
   McFarland K, 2003, J NEUROSCI, V23, P3531
   McGinty JF, 2010, BRAIN RES, V1314, P183, DOI 10.1016/j.brainres.2009.08.078
   McGough NNH, 2004, J NEUROSCI, V24, P10542, DOI 10.1523/JNEUROSCI.3714-04.2004
   Meinhardt MW, 2013, J NEUROSCI, V33, P2794, DOI 10.1523/JNEUROSCI.4062-12.2013
   Melis M, 2005, INT REV NEUROBIOL, V63, P101, DOI 10.1016/S0074-7742(05)63005-X
   Mello NK, 2000, ANN NY ACAD SCI, V909, P104
   Melnick M.J., 1997, ADOLESCENCE, V236, P727
   Meng C, 2012, GENET TEST MOL BIOMA, V16, P1044, DOI 10.1089/gtmb.2012.0016
   Miladi-Gorji H, 2012, PHYSIOL BEHAV, V105, P195, DOI 10.1016/j.physbeh.2011.08.010
   Miller ML, 2012, DRUG ALCOHOL DEPEN, V121, P90, DOI 10.1016/j.drugalcdep.2011.08.013
   Mokdad AH, 2004, JAMA-J AM MED ASSOC, V291, P1238, DOI 10.1001/jama.291.10.1238
   Moore MJ, 2005, J ADOLESCENT HEALTH, V36, P486, DOI 10.1016/j.jadohealth.2004.02.031
   Morgan D, 2002, NAT NEUROSCI, V5, P169, DOI 10.1038/nn798
   Mustroph ML, 2011, EUR J NEUROSCI, V34, P1161, DOI 10.1111/j.1460-9568.2011.07828.x
   Nader MA, 2005, AM J PSYCHIAT, V162, P1473, DOI 10.1176/appi.ajp.162.8.1473
   Nelson MC, 2006, PEDIATRICS, V117, P1281, DOI 10.1542/peds.2005-1692
   Nielson DA, 2012, PHARMACOGENOMICS, V13, P1149, DOI [10.2217/PGS.12.94, 10.2217/pgs.12.94]
   O'Dell SJ, 2012, SYNAPSE, V66, P71, DOI 10.1002/syn.20989
   Okvist A, 2011, BIOL PSYCHIAT, V69, P245, DOI 10.1016/j.biopsych.2010.09.037
   Orsini C, 2001, NEUROPSYCHOPHARMACOL, V25, P789, DOI 10.1016/S0893-133X(01)00270-6
   Pascual M, 2012, NEUROPHARMACOLOGY, V62, P2309, DOI 10.1016/j.neuropharm.2012.01.011
   Pastor Y, 2003, J ADOLESCENCE, V26, P717, DOI 10.1016/j.adolescence.2003.07.001
   Pate RR, 1996, AM J PUBLIC HEALTH, V86, P1577, DOI 10.2105/AJPH.86.11.1577
   Pate RR, 2000, ARCH PEDIAT ADOL MED, V154, P904, DOI 10.1001/archpedi.154.9.904
   Casanova JP, 2013, BEHAV BRAIN RES, V237, P313, DOI 10.1016/j.bbr.2012.09.052
   PAULSON PE, 1991, PSYCHOPHARMACOLOGY, V103, P480, DOI 10.1007/BF02244248
   Peretti-Watel P, 2003, ADDICTION, V98, P1249, DOI 10.1046/j.1360-0443.2003.00490.x
   Peterson A., 2013, COLL PROBL IN PRESS
   Pichard C, 2009, ALCOHOL, V43, P593, DOI 10.1016/j.alcohol.2009.10.007
   Pickens CL, 2011, TRENDS NEUROSCI, V34, P411, DOI 10.1016/j.tins.2011.06.001
   Pierce RC, 2006, NEUROSCI BIOBEHAV R, V30, P215, DOI 10.1016/j.neubiorev.2005.04.016
   Pierce RC, 1996, J NEUROSCI, V16, P1550
   Puig S, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.103
   Raichlen DA, 2012, J EXP BIOL, V215, P1331, DOI 10.1242/jeb.063677
   Rainey CJ, 1996, J SCHOOL HEALTH, V66, P27, DOI 10.1111/j.1746-1561.1996.tb06254.x
   Ramoa C.P., 2013, NEUROPSYCHO IN PRESS
   Real CC, 2010, BRAIN RES, V1363, P63, DOI 10.1016/j.brainres.2010.09.060
   Repunte-Canonigo V., 2013, ADDICT BIOL
   Roberts AJ, 2001, ALCOHOL CLIN EXP RES, V25, P1249, DOI 10.1111/j.1530-0277.2001.tb02344.x
   Roberts AJ, 2000, J PHARMACOL EXP THER, V293, P1002
   Roberts DCS, 2007, PROG NEURO-PSYCHOPH, V31, P1614, DOI 10.1016/j.pnpbp.2007.08.028
   Roberts MD, 2012, PHYSIOL BEHAV, V105, P661, DOI 10.1016/j.physbeh.2011.09.024
   Roberts V, 2012, PSYCHOPHARMACOLOGY, V222, P1, DOI 10.1007/s00213-012-2731-z
   Robison AJ, 2011, NAT REV NEUROSCI, V12, P623, DOI 10.1038/nrn3111
   ROBLEDO P, 1992, ANN NY ACAD SCI, V654, P509, DOI 10.1111/j.1749-6632.1992.tb26015.x
   de Oliveira MSR, 2010, BRAIN RES BULL, V83, P278, DOI 10.1016/j.brainresbull.2010.07.009
   Roessler KK, 2010, SCAND J PUBLIC HEALT, V38, P664, DOI 10.1177/1403494810371249
   Rogers JL, 2008, PSYCHOPHARMACOLOGY, V199, P615, DOI 10.1007/s00213-008-1187-7
   Rossetti ZL, 1999, NEUROSCIENCE, V93, P1135, DOI 10.1016/S0306-4522(99)00250-X
   ROSSETTI ZL, 1992, EUR J PHARMACOL, V221, P227, DOI 10.1016/0014-2999(92)90706-A
   Rozeske RR, 2011, BEHAV BRAIN RES, V219, P378, DOI 10.1016/j.bbr.2011.01.030
   Sadri-Vakili G, 2010, J NEUROSCI, V30, P11735, DOI 10.1523/JNEUROSCI.2328-10.2010
   Sanchez V., 2013, PSYCHOPHARMACOLOGY
   Schmidt H.D., 2013, COLD SPRING HARB PER
   Schmidt HD, 2012, J NEUROCHEM, V120, P202, DOI 10.1111/j.1471-4159.2011.07571.x
   Schmidt HD, 2010, ANN NY ACAD SCI, V1187, P35, DOI 10.1111/j.1749-6632.2009.05144.x
   Schmidt LG, 1996, BIOL PSYCHIAT, V39, P193, DOI 10.1016/0006-3223(95)00078-X
   Schwarz JM, 2011, J NEUROSCI, V31, P17835, DOI 10.1523/JNEUROSCI.3297-11.2011
   Schwendt M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034299
   Sidhpura N, 2010, BIOL PSYCHIAT, V67, P804, DOI 10.1016/j.biopsych.2010.01.005
   SINGER G, 1982, PHARMACOL BIOCHEM BE, V17, P579, DOI 10.1016/0091-3057(82)90321-5
   SINGER G, 1984, PHARMACOL BIOCHEM BE, V20, P807, DOI 10.1016/0091-3057(84)90204-1
   Smith MA, 2003, PSYCHOPHARMACOLOGY, V168, P426, DOI 10.1007/s00213-003-1471-5
   Smith MA, 2008, DRUG ALCOHOL DEPEN, V98, P129, DOI 10.1016/j.drugalcdep.2008.05.006
   Smith MA, 2006, PHARMACOL BIOCHEM BE, V85, P12, DOI 10.1016/j.pbb.2006.06.020
   Smith MA, 2012, EXP CLIN PSYCHOPHARM, V20, P437, DOI 10.1037/a0029724
   Smith MA, 2012, PHARMACOL REP, V64, P960, DOI 10.1016/S1734-1140(12)70891-5
   Smith MA, 2012, DRUG ALCOHOL DEPEN, V121, P54, DOI 10.1016/j.drugalcdep.2011.08.006
   Smith MA, 2011, PSYCHOPHARMACOLOGY, V218, P357, DOI 10.1007/s00213-011-2321-5
   Smith MA, 2011, PHARMACOL BIOCHEM BE, V100, P237, DOI 10.1016/j.pbb.2011.08.025
   Solinas M, 2008, P NATL ACAD SCI USA, V105, P17145, DOI 10.1073/pnas.0806889105
   Strohle A, 2007, PSYCHOL MED, V37, P1657, DOI 10.1017/S003329170700089X
   Sutoo D, 1996, PHYSIOL BEHAV, V60, P177, DOI 10.1016/0031-9384(96)00011-X
   Sutoo D, 2003, NEUROBIOL DIS, V13, P1, DOI 10.1016/S0969-9961(03)00030-5
   Takizawa T, 2008, TRENDS NEUROSCI, V31, P343, DOI 10.1016/j.tins.2008.03.005
   Taylor AH, 2007, ADDICTION, V102, P534, DOI 10.1111/j.1360-0443.2006.01739.x
   Terry-McElrath YM, 2011, ADDICTION, V106, P1855, DOI 10.1111/j.1360-0443.2011.03489.x
   Terry-McElrath YM, 2011, AM J PREV MED, V40, P530, DOI 10.1016/j.amepre.2010.12.021
   Thanos PK, 2013, BEHAV BRAIN RES, V239, P8, DOI 10.1016/j.bbr.2012.10.035
   Thanos PK, 2010, BEHAV BRAIN RES, V215, P77, DOI 10.1016/j.bbr.2010.06.033
   Theberge FRM, 2012, PSYCHOPHARMACOLOGY, V224, P559, DOI 10.1007/s00213-012-2784-z
   Tomasiewicz HC, 2012, BIOL PSYCHIAT, V72, P803, DOI 10.1016/j.biopsych.2012.04.026
   UNTERWALD EM, 1994, J PHARMACOL EXP THER, V270, P1387
   Ussher M, 2004, ADDICTION, V99, P1542, DOI 10.1111/j.1360-0443.2004.00919.x
   Ussher MH, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002295.pub4
   Van den Oever MC, 2012, ADV EXP MED BIOL, V970, P469, DOI 10.1007/978-3-7091-0932-8_21
   Vassoler FM, 2013, NAT NEUROSCI, V16, P42, DOI 10.1038/nn.3280
   Vendruscolo LF, 2011, PHARMACOL BIOCHEM BE, V98, P570, DOI 10.1016/j.pbb.2011.03.004
   Voisey J, 2012, PSYCHIAT RES, V196, P285, DOI 10.1016/j.psychres.2011.09.024
   Volkow ND, 1999, J PHARMACOL EXP THER, V288, P14
   Volkow ND, 2011, P NATL ACAD SCI USA, V108, P15037, DOI 10.1073/pnas.1010654108
   Walker BM, 2011, ADDICT BIOL, V16, P116, DOI 10.1111/j.1369-1600.2010.00226.x
   Wan LH, 2011, BRAIN RES, V1416, P26, DOI 10.1016/j.brainres.2011.07.045
   Wang DV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016528
   Wee S, 2010, PSYCHOPHARMACOLOGY, V210, P121, DOI 10.1007/s00213-010-1825-8
   Weinstock J, 2008, ADDICT BEHAV, V33, P1072, DOI 10.1016/j.addbeh.2008.03.011
   WEISS F, 1992, BRAIN RES, V593, P314, DOI 10.1016/0006-8993(92)91327-B
   Weiss F, 1996, J NEUROSCI, V16, P3474
   Werch CC, 2005, PREV SCI, V6, P213, DOI 10.1007/s11121-005-0012-3
   Werme M, 2002, BEHAV BRAIN RES, V133, P301, DOI 10.1016/S0166-4328(02)00027-X
   Whitfield TW, 2011, J NEUROSCI, V31, P834, DOI 10.1523/JNEUROSCI.4986-10.2011
   Wichstrom T, 2009, ADDICTION, V104, P138, DOI 10.1111/j.1360-0443.2008.02422.x
   Willuhn I, 2010, CURR TOP BEHAV NEURO, V3, P29, DOI 10.1007/7854_2009_27
   Wolf ME, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00072
   Worsley JN, 2000, MOL PSYCHIATR, V5, P664, DOI 10.1038/sj.mp.4000760
   Yang XJ, 2012, INT J MOL SCI, V13, P9447, DOI 10.3390/ijms13089447
   YOSHIMOTO K, 1992, ALCOHOL, V9, P17, DOI 10.1016/0741-8329(92)90004-T
   Zhang F, 2010, MOLECULES, V15, P5246, DOI 10.3390/molecules15085246
   Zhang Y, 2006, J NEUROSCI, V26, P2645, DOI 10.1523/JNEUROSCI.3923-05.2006
   Zlebnik NE, 2012, PSYCHOPHARMACOLOGY, V224, P387, DOI 10.1007/s00213-012-2760-7
   Zlebnik NE, 2010, PSYCHOPHARMACOLOGY, V209, P113, DOI 10.1007/s00213-010-1776-0
   Zoladz JA, 2010, J PHYSIOL PHARMACOL, V61, P533
   Zschucke E, 2012, SCI WORLD J, DOI 10.1100/2012/901741
NR 258
TC 190
Z9 200
U1 3
U2 113
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0149-7634
EI 1873-7528
J9 NEUROSCI BIOBEHAV R
JI Neurosci. Biobehav. Rev.
PD SEP
PY 2013
VL 37
IS 8
BP 1622
EP 1644
DI 10.1016/j.neubiorev.2013.06.011
PG 23
WC Behavioral Sciences; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Behavioral Sciences; Neurosciences & Neurology
GA 251BK
UT WOS:000326902600024
PM 23806439
OA Green Accepted
DA 2023-06-23
ER

PT J
AU Page, G
AF Page, Geoff
TI Illness or deviance: Drug courts, drug treatment and the ambiguity of
   addiction
SO DRUGS-EDUCATION PREVENTION AND POLICY
LA English
DT Book Review
C1 [Page, Geoff] Univ York, Mental Hlth & Addict Res Grp, York, N Yorkshire, England.
C3 N8 Research Partnership; White Rose University Consortium; University of
   York - UK
RP Page, G (通讯作者)，Univ York, Mental Hlth & Addict Res Grp, York, N Yorkshire, England.
EM geoff.page@york.ac.uk
CR Andrews D., 1989, FORUM CORRECTIONS RE, V1, P1
   Hannah-Moffat K, 2005, PUNISHM SOC, V7, P29, DOI 10.1177/1462474505048132
   Lloyd C, 2010, SINNING SINNED STIGM
   Maden T., 2010, TREATING VIOLENCE GU
   McSweeney T, 2007, BRIT J CRIMINOL, V47, P470, DOI 10.1093/bjc/azl087
   Murphy J, 2015, ILLNESS OR DEVIANCE?: DRUG COURTS, DRUG TREATMENT, AND THE AMBIGUITY OF ADDICTION, P1
   PRINS H, 2005, OFFENDERS DEVIANTS P
   Scott P.D., 1975, HAS PSYCHIAT FAILED
   Seddon T., 2012, RISK SECURITY CRIMIN
   Stevens A, 2005, INT J DRUG POLICY, V16, P207, DOI 10.1016/j.drugpo.2005.04.004
   Stone AA, 2008, J AM ACAD PSYCHIATRY, V36, P167
   Stone Alan A., 1984, LAW PSYCHIAT MORALIT
   Wild TC, 2002, EUR ADDICT RES, V8, P84, DOI 10.1159/000052059
NR 13
TC 0
Z9 0
U1 0
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0968-7637
EI 1465-3370
J9 DRUG-EDUC PREV POLIC
JI Drug-Educ. Prev. Policy
PY 2018
VL 25
IS 1
BP 102
EP 103
DI 10.1080/09687637.2016.1248053
PG 2
WC Substance Abuse
WE Social Science Citation Index (SSCI)
SC Substance Abuse
GA FP6VE
UT WOS:000417763800013
OA Bronze
DA 2023-06-23
ER

PT J
AU Henckes, N
AF Henckes, Nicolas
TI Illness or Deviance? Drug Courts, Drug Treatment, and the Ambiguity of
   Addiction
SO SOCIOLOGY OF HEALTH & ILLNESS
LA English
DT Book Review
C1 [Henckes, Nicolas] CNRS, Ctr Rech Med Sci Sante Sante Mentale & Soc CERMES, Paris, France.
C3 Centre National de la Recherche Scientifique (CNRS); UDICE-French
   Research Universities; Universite Paris Cite
RP Henckes, N (通讯作者)，CNRS, Ctr Rech Med Sci Sante Sante Mentale & Soc CERMES, Paris, France.
CR Murphy J, 2015, ILLNESS OR DEVIANCE?: DRUG COURTS, DRUG TREATMENT, AND THE AMBIGUITY OF ADDICTION, P1
NR 1
TC 0
Z9 0
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0141-9889
EI 1467-9566
J9 SOCIOL HEALTH ILL
JI Sociol. Health Ill.
PD MAY
PY 2017
VL 39
IS 4
BP 645
EP 647
DI 10.1111/1467-9566.12444
PG 4
WC Public, Environmental & Occupational Health; Social Sciences,
   Biomedical; Sociology
WE Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health; Biomedical Social Sciences;
   Sociology
GA EY2PQ
UT WOS:000403811500012
OA Bronze
DA 2023-06-23
ER

PT J
AU Branch, MN
AF Branch, Marc N.
TI DRUG ADDICTION. IS IT A DISEASE OR IS TT BASED ON CHOICE? A REVIEW OF
   GENE HEYMAN'S ADDICTION: A DISORDER OF CHOICE
SO JOURNAL OF THE EXPERIMENTAL ANALYSIS OF BEHAVIOR
LA English
DT Review
DE drug addiction; chronic disease; operant choice; framing
ID NATIONAL EPIDEMIOLOGIC SURVEY; DSM-IV ALCOHOL; UNITED-STATES;
   COMORBIDITY; ABUSE
AB In Addiction: A disorder of choice, Gene Heyman surveys a broad array of evidence historical, anthropological, survey, clinical, and laboratory-based to build an argument about the role of basic choice processes in the phenomena that comprise drug addiction. He makes a compelling, multifaceted argument that conceptualizing drug addiction as a chronic disease (like schizophrenia or diabetes) is both misleading and erroneous. In developing his argument, he points out that the best survey data available indicate that most drug addicts quit their addiction, a fact inconsistent with a chronic-disease model. He illustrates how basic, normal choice processes can lead to addiction, arguing that people do not choose to be addicts, but that normal choice dynamics can lead them to that condition. He points to a variety, of factors that keep most from becoming addicted, with a focus on the role of choice governed by choice-by-choice contingencies versus choice governed by the outcome of sequences of choices, a difference in an under-described activity called framing. His view is consistent with the most effective treatments currently available, and provides a basis for continued basic research on choice as well as research on treatment and prevention.
C1 Univ Florida, Dept Psychol, Gainesville, FL 32611 USA.
C3 State University System of Florida; University of Florida
RP Branch, MN (通讯作者)，Univ Florida, Dept Psychol, Gainesville, FL 32611 USA.
EM branch@ufl.edu
FU National Institute on Drug Abuse [DA004074]
FX Preparation of this review was supported by USPHS Grant No. DA004074
   from the National Institute on Drug Abuse.
CR Hasin DS, 2007, ARCH GEN PSYCHIAT, V64, P830, DOI 10.1001/archpsyc.64.7.830
   Heyman Gene M., 2009, ADDICTION DISORDER C, DOI [10.4159/9780674053991, DOI 10.4159/9780674053991]
   Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45
   Lynam DR, 1999, J CONSULT CLIN PSYCH, V67, P590, DOI 10.1037/0022-006X.67.4.590
   McLellan AT, 2005, ADDICTION, V100, P447, DOI 10.1111/j.1360-0443.2005.01012.x
   NIDA, 2008, NIDA INFOFACTS UND D
   REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511
   Robins L. N., 1980, YB SUBSTANCE ABUSE, P214
   ROBINS LN, 1993, ADDICTION, V88, P1041, DOI 10.1111/j.1360-0443.1993.tb02123.x
   ROBINS LN, 1991, PSYCHIAT DISORDERS A
   Rosenbaum D. P., 2010, CRIMINOL PUBLIC POL, V6, P815
   Rosenbaum DP, 1998, J RES CRIME DELINQ, V35, P381, DOI 10.1177/0022427898035004002
   Stinson FS, 2005, DRUG ALCOHOL DEPEN, V80, P105, DOI 10.1016/j.drugalcdep.2005.03.009
   VOLKOW ND, 1990, AM J PSYCHIAT, V147, P719
   WALLER NG, 1990, PSYCHOL SCI, V1, P138, DOI 10.1111/j.1467-9280.1990.tb00083.x
NR 15
TC 6
Z9 6
U1 2
U2 34
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-5002
EI 1938-3711
J9 J EXP ANAL BEHAV
JI J. Exp. Anal. Behav.
PD MAR
PY 2011
VL 95
IS 2
BP 263
EP 267
DI 10.1901/jeab.2011.95-263
PG 5
WC Psychology, Biological; Behavioral Sciences; Psychology, Experimental
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology; Behavioral Sciences
GA 739MB
UT WOS:000288720700008
OA Green Published
DA 2023-06-23
ER

PT J
AU [Anonymous]
AF [Anonymous]
TI APPREHENDING THE DIFFERENCES BETWEEN NON-DRUG AND DRUG REINFORCEMENT TO
   BETTER UNDERSTAND THE PATHOLOGY OF DRUG ADDICTION
SO BEHAVIOURAL PHARMACOLOGY
LA English
DT Meeting Abstract
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0955-8810
EI 1473-5849
J9 BEHAV PHARMACOL
JI Behav. Pharmacol.
PD OCT
PY 2013
VL 24
SU S
BP E13
EP E13
DI 10.1097/01.fbp.0000434728.62034.aa
PG 1
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA VI4GM
UT WOS:000484761300049
DA 2023-06-23
ER

PT J
AU Lev-Ran, S
   Adler, L
   Nitzan, U
   Fennig, S
AF Lev-Ran, Shaul
   Adler, Limor
   Nitzan, Uri
   Fennig, Shmuel
TI Attitudes towards nicotine, alcohol and drug dependence among physicians
   in Israel
SO JOURNAL OF SUBSTANCE ABUSE TREATMENT
LA English
DT Article
DE Attitudes; Physicians; Addictions; Israel; Alcohol; Drug; Nicotine;
   Substance use
ID RESPONSE RATES; SUBSTANCE ABUSE; ILLICIT DRUG; CONSUMPTION; PREVALENCE;
   ADDICTION; KNOWLEDGE; PHARMACOTHERAPY; INTERVENTIONS; EPIDEMIOLOGY
AB Prevalence of substance use and substance use disorders in Israel is similar to those in other developed countries. The aim of this study was to examine attitudes of physicians in Israel towards nicotine, alcohol and drug use and dependence. A national sample of physicians from different fields of medical specialty (n = 208, response rate 26%) responded to a 50-item questionnaire. Questions included general questions regarding substance use and addictions, as well as specific questions focusing on nicotine, alcohol, cannabis and heroin use. The poor response rate in this survey dictates caution in interpretation the results. However, they suggest that among medical specialties, psychiatrists had higher levels of self-reported competency in treating addictions and lower rates of moralism towards addictions. Across substances, the highest rates of moralism and lowest ratings of treatment efficacy were directed towards individuals with alcohol dependence. Physicians generally reported experiencing lower levels of satisfaction and higher levels of aggression when treating individuals with alcohol or drug dependence compared with other patients. Physicians' attitudes towards addictions have a significant role in the care that clients with addictions receive. Medical education programs in Israel should devote provisions towards educating physicians about addictions. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Lev-Ran, Shaul; Nitzan, Uri; Fennig, Shmuel] Shalvata Mental Hlth Ctr, Hod Hasharon, Israel.
   [Lev-Ran, Shaul; Adler, Limor; Nitzan, Uri; Fennig, Shmuel] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
   [Lev-Ran, Shaul] Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON M5S 2S1, Canada.
C3 Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine;
   University of Toronto; Centre for Addiction & Mental Health - Canada
RP Lev-Ran, S (通讯作者)，Shalvata Mental Hlth Ctr, POB 94, Hod Hasharon, Israel.
EM shauli.levran@gmail.com
OI Adler, Limor/0000-0002-9335-6596
CR Abu-Hammad T, 2008, MED SCI MONITOR, V14, pCR262
   Alonso J, 2004, ACTA PSYCHIAT SCAND, V109, P21
   American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4th, DOI [DOI 10.1176/DSM10.1176/APPI.BOOKS.9780890420249.DSM-IV-TR, DOI 10.1016/B978-1-4377-2242-0.00016-X]
   Andlin-Sobocki P, 2005, EUR J NEUROL, V12, P28, DOI 10.1111/j.1468-1331.2005.01194.x
   Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1
   BABOR TF, 1990, BEHAV ASSESS, V12, P5
   Baliunas Dolly, 2007, Chronic Dis Can, V27, P154
   Bar-Hamburger R, 2009, ILLEGAL USE DRUGS AL
   Bloomfield K, 2006, ALCOHOL ALCOHOLISM, V41, pI26, DOI 10.1093/alcalc/agl073
   Bowling A., 1997, DATA COLLECTION METH
   BREWSTER JM, 1990, CAN MED ASSOC J, V143, P1076
   CHAPPEL JN, 1977, JAMA-J AM MED ASSOC, V237, P2318, DOI 10.1001/jama.237.21.2318
   CHAPPEL JN, 1985, J STUD ALCOHOL, V46, P48, DOI 10.15288/jsa.1985.46.48
   Cummings SM, 2001, HEALTH SERV RES, V35, P1347
   D'Onofrio G, 2008, ANN EMERG MED, V51, P742, DOI 10.1016/j.annemergmed.2007.11.028
   Delos Reyes CM, 2002, JAMA-J AM MED ASSOC, V287, P1857, DOI 10.1001/jama.287.14.1857
   Endevelt Ronit, 2009, Journal of Nutrition for the Elderly, V28, P96, DOI 10.1080/01639360802634100
   EWAN CE, 1982, INT J ADDICT, V17, P1211, DOI 10.3109/10826088209056350
   Friedmann PD, 2001, ARCH INTERN MED, V161, P248, DOI 10.1001/archinte.161.2.248
   GALANTER M, 1999, TXB SUBSTANCE ABUSE
   Garbutt JC, 2009, J SUBST ABUSE TREAT, V36, pS15, DOI 10.1016/j.jsat.2008.08.008
   GELLER G, 1989, JAMA-J AM MED ASSOC, V261, P3115, DOI 10.1001/jama.261.21.3115
   Grava-Gubins I, 2008, CAN FAM PHYSICIAN, V54, P1424
   Humeniuk R, 2008, ADDICTION, V103, P1039, DOI 10.1111/j.1360-0443.2007.02114.x
   Israel Medical Association, 2012, LIST PROF ASS
   Kaner EFS, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004148.pub3, 10.1002/14651858.CD004148.pub4]
   Link BG, 2001, ANNU REV SOCIOL, V27, P363, DOI 10.1146/annurev.soc.27.1.363
   Link BG, 1997, J HEALTH SOC BEHAV, V38, P177, DOI 10.2307/2955424
   Madras BK, 2009, DRUG ALCOHOL DEPEN, V99, P280, DOI 10.1016/j.drugalcdep.2008.08.003
   Marcus A., 1963, ALCOHOLISM QUESTIONN
   Mark TL, 2009, DRUG ALCOHOL DEPEN, V99, P345, DOI 10.1016/j.drugalcdep.2008.07.018
   Mattick RP, 2014, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002207.pub4, 10.1002/14651858.CD002207.pub3]
   May JA, 2002, J CLIN ANESTH, V14, P284, DOI 10.1016/S0952-8180(02)00359-8
   MILLER WR, 1993, J CONSULT CLIN PSYCH, V61, P455, DOI 10.1037/0022-006X.61.3.455
   Miller WR, 2000, PSYCHOL ADDICT BEHAV, V14, P6, DOI 10.1037/0893-164X.14.1.6
   Neumark YD, 2007, ISR J PSYCHIATR REL, V44, P126
   Nordstrom Benjamin R, 2007, Am J Addict, V16, P331, DOI 10.1080/10550490701525665
   Nutt DJ, 2010, LANCET, V376, P1558, DOI 10.1016/S0140-6736(10)61462-6
   Oreskovich MR, 2012, ARCH SURG-CHICAGO, V147, P168, DOI 10.1001/archsurg.2011.1481
   Parry CD, 2011, ADDICTION, V106, P1718, DOI 10.1111/j.1360-0443.2011.03605.x
   Penberthy Jennifer K, 2010, Curr Drug Abuse Rev, V3, P49
   Popova S, 2007, DRUG ALCOHOL REV, V26, P251, DOI 10.1080/09595230701247673
   Pouletty P, 2002, NAT REV DRUG DISCOV, V1, P731, DOI 10.1038/nrd896
   Raupach T, 2011, CNS DRUGS, V25, P371, DOI 10.2165/11590620-000000000-00000
   Rehm J, 2006, ADDICTION, V101, P373, DOI 10.1111/j.1360-0443.2005.01338.x
   Rehm J, 2010, ADDICTION, V105, P817, DOI 10.1111/j.1360-0443.2010.02899.x
   Rehm J, 2006, DRUG ALCOHOL REV, V25, P503, DOI 10.1080/09595230600944453
   ROCHE AM, 1995, ADDICTION, V90, P1357, DOI 10.1111/j.1360-0443.1995.tb03553.x
   Ronzani TM, 2009, SOC SCI MED, V69, P1080, DOI 10.1016/j.socscimed.2009.07.026
   Saitz R, 2002, J GEN INTERN MED, V17, P373, DOI 10.1007/s11606-002-0043-4
   SOVEROW G, 1972, BRIT J ADDICT, V67, P195
   Werner P, 2000, ISRAEL MED ASSOC J, V2, P361
NR 52
TC 10
Z9 11
U1 0
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0740-5472
EI 1873-6483
J9 J SUBST ABUSE TREAT
JI J. Subst. Abus. Treat.
PD JAN
PY 2013
VL 44
IS 1
BP 84
EP 89
DI 10.1016/j.jsat.2012.04.001
PG 6
WC Psychology, Clinical; Substance Abuse
WE Social Science Citation Index (SSCI)
SC Psychology; Substance Abuse
GA 050JV
UT WOS:000312050500013
PM 22579033
DA 2023-06-23
ER

PT C
AU Alam, KMR
   Ahammed, K
   Rony, MA
   Ferdousi, Z
AF Alam, K. M. Rashedul
   Ahammed, Khair
   Rony, Mohammad Abu Tareq
   Ferdousi, Zannatul
GP IEEE
TI A Comparative Machine Learning Study to Predict Drug Addiction in
   Bangladesh
SO 2021 IEEE 15TH INTERNATIONAL CONFERENCE ON APPLICATION OF INFORMATION
   AND COMMUNICATION TECHNOLOGIES (AICT2021)
SE International Conference on Application of Information and Communication
   Technologies
LA English
DT Proceedings Paper
CT IEEE 15th International Conference on Application of Information and
   Communication Technologies (AICT)
CY OCT 13-15, 2021
CL ELECTR NETWORK
SP IEEE, ADA Univ, George Washington Univ, Inst Informat Sci & Technologies Alessandro Faedo
DE Drug; Machine Learning; Statistical Analysis
ID CLASSIFICATION
AB Drug Addiction is one of the growing threats all over the world. According to Dhaka Tribune, more than 7.5 million people are addicted to drugs in Bangladesh. There are a lot of differences between a drug-addicted and a nonaddicted person on health condition, social life, personal life, and familial life behaviors. So, steps should be taken to prevent drug addiction with proper curative issues. In this paper, we dig for the influential factors behind drug addiction and possible solutions to reduce the drug addiction rate. The research is held on the people of Dhaka, Bangladesh. Most of the data of drug-addicted people are collected from 'Drug Rehab' and for non-addicted person data we have collected from different schools, colleges, and universities in Dhaka, Bangladesh. All are male and the age group of 17 to 45 years. Our primary data set is constructed including only 188 qualitative data. A total of 5 algorithms have been employed including Logistic Regression, Decision Tree, Random Forest, Naive Bayes, Support Vector Machine (SVM) and their results are compared. Among the algorithms Random Forest comes up with the highest accuracy of 97.3484%, XGBoost & Decision Tree Classifier delivers the accuracy of 96.2768% and 94.68 %.
C1 [Ahammed, Khair] FAU Erlangen NUrnberg, Dept Data Sci, Erlangen, Germany.
   Noakhali Sci & Technol Univ, Dept Software Engn, Noakhali, Bangladesh.
   [Alam, K. M. Rashedul; Rony, Mohammad Abu Tareq] Noakhali Sci & Technol Univ, Dept Stat, Noakhali, Bangladesh.
   [Ferdousi, Zannatul] Southeast Univ, Dept Comp Sci Engn, Dhaka, Bangladesh.
C3 University of Erlangen Nuremberg; Noakhali Science & Technology
   University (NSTU); Noakhali Science & Technology University (NSTU)
RP Alam, KMR (通讯作者)，Noakhali Sci & Technol Univ, Dept Stat, Noakhali, Bangladesh.
EM rashedulalam.km@gmail.com; khairahmad6@gmail.com; abutareqrony@gmail.com
CR Acion L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175383
   Ahammed K, 2020, IEEE REGION 10 SYMP, P1371
   Arif Md, 2020, DISS
   El Naqa I., 2015, MACHINE LEARNING RAD, P3, DOI [DOI 10.1007/978-3-319-18305-3_1, DOI 10.1007/978-3-319-18305-3]
   Hammann F, 2010, CLIN PHARMACOL THER, V88, P52, DOI 10.1038/clpt.2009.248
   Handelman GS, 2019, AM J ROENTGENOL, V212, P38, DOI 10.2214/AJR.18.20224
   Heather N, 1998, J PSYCHOPHARMACOL, V12, P3, DOI 10.1177/026988119801200101
   Islam Azizul, 2017, INT J SOCIOLOGY ANTH, V9, P143
   Kinreich S., 2019, MOL PSYCHIATR, V66, P1
   Koizumi Y, 2019, INT CONF ACOUST SPEE, P915, DOI 10.1109/ICASSP.2019.8683667
   Kotsiantis SB, 2007, INFORM-J COMPUT INFO, V31, P249
   Maxwell AE, 2018, INT J REMOTE SENS, V39, P2784, DOI 10.1080/01431161.2018.1433343
   Mitrpanont J., 2017, 2017 2 INT C INF TEC, P1, DOI DOI 10.1109/INCIT.2017.8257883
   Myers MG, 2006, ALCOHOL RES HEALTH, V29, P221
   Nath P., 2018, INT J INF TECHNOL, V10, P233, DOI [10.1007/s41870-018-0094-3, DOI 10.1007/S41870-018-0094-3]
   Palomba F, 2021, J SYST SOFTWARE, V171, DOI 10.1016/j.jss.2020.110847
   Peng HC, 2005, IEEE T PATTERN ANAL, V27, P1226, DOI 10.1109/TPAMI.2005.159
   Picek S., 2019, IACR T CRYPTOGRAPHIC, V2019, P1
   Pisutaporn Auth, 2018, 2018 IEEE INT C INN, P1
   Rahman MM, 2016, J SUBST USE, V21, P627, DOI 10.3109/14659891.2015.1122099
   SAFAVIAN SR, 1991, IEEE T SYST MAN CYB, V21, P660, DOI 10.1109/21.97458
   Sahker E, 2015, J AM COLL HEALTH, V63, P118, DOI 10.1080/07448481.2014.990970
   Shahriar Arif, 2019, 2019 22 INT C COMPUT
   Sharma H., 2016, SURVEY DECISION TREE
   Tatbul N., 2018, ARXIV
   Trivedi Tanvi, EXPLORING PREDICTION
   Viloria Amelec, 2020, INT S DISTRIBUTED CO
   Zhang L, 2018, CURR TOP MED CHEM, V18, P987, DOI 10.2174/1568026618666180727152557
NR 28
TC 0
Z9 0
U1 1
U2 1
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
SN 2378-8232
EI 2472-8586
BN 978-1-6654-3640-3
J9 I C APPL INF COMM TE
PY 2021
DI 10.1109/AICT52784.2021.9620453
PG 6
WC Computer Science, Information Systems; Telecommunications
WE Conference Proceedings Citation Index - Science (CPCI-S)
SC Computer Science; Telecommunications
GA BT8GH
UT WOS:000853096900043
DA 2023-06-23
ER

PT J
AU Gu, XL
   Yang, BH
   Gao, SW
   Yan, LF
   Xu, D
   Wang, W
AF Gu, Xuelin
   Yang, Banghua
   Gao, Shouwei
   Yan, Lin Feng
   Xu, Ding
   Wang, Wen
TI Application of bi-modal signal in the classification and recognition of
   drug addiction degree based on machine learning
SO MATHEMATICAL BIOSCIENCES AND ENGINEERING
LA English
DT Article
DE drug addiction; bi-modal signal; EEG-NIRS; machine learning; 3-class
   accuracy; degree of drug addiction
ID NEAR-INFRARED SPECTROSCOPY; EEG-NIRS; FNIRS; NETWORK; SYSTEM
AB Most studies on drug addiction degree are made based on statistical scales, addicts' account, and subjective judgement of rehabilitation doctors. No objective, quantified evaluation has been made. This paper uses devises the synchronous bimodal signal collection and experimentation paradigm with electroencephalogram (EEG) and forehead high-density near-infrared spectroscopy (NIRS) device. The drug addicts are classified into mild, moderate and severe groups with reference to the suggestions of researchers and medical experts. Data of 45 drug addicts (mild: 15; moderate: 15; and severe: 15) is collected, and then used to design an addiction degree testing algorithm based on decision fusion. The algorithm is used to classify mild, moderate and severe addiction. This paper pioneers to use two types of Convolutional Neural Network (CNN) to abstract the EEG and NIR data of drug addicts, and introduces batch normalization to CNN, thus accelerating training process, reducing parameter sensitivity, and enhancing system robustness. The characteristics output by two CNNs are transformed into dimensions. Two new characteristics are assigned with a weight of 50% each. The data is used for decision fusion. In the networks, 27 subjects are used as training sets, 9 as validation sets, and 9 as testing sets. The 3-class accuracy remains to be 63.15%, preliminarily justifying this method as an effective approach to measure drug addiction degree. And the method is ready to use, objective, and offers results in real time.
C1 [Gu, Xuelin; Yang, Banghua; Gao, Shouwei] Shanghai Univ, Sch Mech & Elect Engn & Automat, Shanghai 200444, Peoples R China.
   [Xu, Ding] Shanghai Drug Rehabil Adm Bur, Shanghai 200080, Peoples R China.
   [Yan, Lin Feng; Wang, Wen] Fourth Mil Med Univ, Tangdu Hosp, Dept Radiol, Xian 710038, Shaanxi, Peoples R China.
   [Yan, Lin Feng; Wang, Wen] Fourth Mil Med Univ, Tangdu Hosp, Funct & Mol Imaging Key Lab Shaanxi Prov, Xian 710038, Shaanxi, Peoples R China.
C3 Shanghai University; Air Force Military Medical University; Air Force
   Military Medical University
RP Yang, BH; Gao, SW (通讯作者)，Shanghai Univ, Sch Mech & Elect Engn & Automat, Shanghai 200444, Peoples R China.; Wang, W (通讯作者)，Fourth Mil Med Univ, Tangdu Hosp, Dept Radiol, Xian 710038, Shaanxi, Peoples R China.; Wang, W (通讯作者)，Fourth Mil Med Univ, Tangdu Hosp, Funct & Mol Imaging Key Lab Shaanxi Prov, Xian 710038, Shaanxi, Peoples R China.
EM yangbanghua@shu.edu.cn; swgao@shu.edu.cn; wangwen@fmmu.edu.cn
FU Key Research & Development Project of National Science and Technique
   Ministry of China [2018YFC0807405, 2018YFC1312903]; Defense Industrial
   Technology Development Program [JCKY2019413D002]; National Natural
   Science Foundation of China [61976133]
FX This project was supported by Key Research & Development Project of
   National Science and Technique Ministry of China (No. 2018YFC0807405,
   No. 2018YFC1312903), Defense Industrial Technology Development Program
   (JCKY2019413D002), National Natural Science Foundation of China (No.
   61976133).
CR Abibullaev B, 2017, MEASUREMENT, V98, P250, DOI 10.1016/j.measurement.2016.12.001
   Al-Shargie F, 2017, BIOMED OPT EXPRESS, V8, P2583, DOI 10.1364/BOE.8.002583
   Almajidy RK, 2015, IEEE ENG MED BIO, P1067, DOI 10.1109/EMBC.2015.7318549
   Balconi M, 2015, BRAIN COGNITION, V95, P67, DOI 10.1016/j.bandc.2015.02.001
   Buccino AP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146610
   Chen L, 2019, COMPUT STRUCT BIOTEC, V17, P49, DOI 10.1016/j.csbj.2018.12.002
   Chen XB, 2021, MATH BIOSCI ENG, V18, P4341, DOI 10.3934/mbe.2021218
   Croce P, 2019, IEEE T BIO-MED ENG, V66, P2372, DOI 10.1109/TBME.2018.2889512
   Das A, 2016, INT J STROKE, V11, P271
   Fazli S, 2012, NEUROIMAGE, V59, P519, DOI 10.1016/j.neuroimage.2011.07.084
   Ferrari M, 2012, NEUROIMAGE, V63, P921, DOI 10.1016/j.neuroimage.2012.03.049
   Guo D, 2019, NANJING U POSTS TELE
   Huang L, 2019, MATH BIOSCI ENG, V16, P3003, DOI 10.3934/mbe.2019149
   Huhn AS, 2019, DRUG ALCOHOL DEPEN, V205, DOI 10.1016/j.drugalcdep.2019.107650
   Jindal U, 2015, IEEE J TRANSL ENG HE, V3, DOI [10.1109/JTEHM.2015.2389230, 10.1109/ITEHM.2015.2389230]
   Kassab A, 2018, HUM BRAIN MAPP, V39, P7, DOI 10.1002/hbm.23849
   Khan MJ, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00244
   Kim JM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31685-y
   Kroczek AM, 2017, ADDICT BIOL, V22, P513, DOI 10.1111/adb.12344
   Li JY, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00766
   Liu CL, 2017, COMB CHEM HIGH T SCR, V20, P603, DOI 10.2174/1386207320666170417144937
   Liu T, 2019, NEUROIMAGE, V185, P955, DOI 10.1016/j.neuroimage.2017.09.044
   Madanu R, 2021, MATH BIOSCI ENG, V18, P5047, DOI 10.3934/mbe.2021257
   Mohammed BA, 2020, MATH BIOSCI ENG, V18, P851, DOI 10.3934/mbe.2021045
   Pan XY, 2022, IEEE ACM T COMPUT BI, V19, P666, DOI 10.1109/TCBB.2021.3080386
   Pouliot P, 2014, EPILEPSY RES, V108, P883, DOI 10.1016/j.eplepsyres.2014.03.007
   Putze F, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00373
   Raghu S, 2020, NEURAL NETWORKS, V124, P202, DOI 10.1016/j.neunet.2020.01.017
   Safaie J, 2013, J NEURAL ENG, V10, DOI 10.1088/1741-2560/10/5/056001
   Sawan M, 2013, IEEE T BIOMED CIRC S, V7, P186, DOI 10.1109/TBCAS.2013.2255595
   Shin J, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18061827
   Shin J, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.3
   Shin J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16639-0
   Song HF, 2020, MATH BIOSCI ENG, V17, P3450, DOI 10.3934/mbe.2020195
   Tomita Y, 2014, IEEE T BIO-MED ENG, V61, P1274, DOI 10.1109/TBME.2014.2300492
   von Luhmann A, 2017, I IEEE EMBS C NEUR E, P349, DOI 10.1109/NER.2017.8008362
   Wallois F, 2012, BRAIN LANG, V121, P110, DOI 10.1016/j.bandl.2011.03.010
   Xia YF, 2018, IEEE ACCESS, V6, P16529, DOI 10.1109/ACCESS.2018.2807700
   Xing S F, 1987, Zhonghua Bing Li Xue Za Zhi, V16, P174
   Zhang T, 2012, CEREB CORTEX, V22, P854, DOI 10.1093/cercor/bhr152
   Zich C, 2017, NEUROBIOL AGING, V49, P183, DOI 10.1016/j.neurobiolaging.2016.10.011
NR 41
TC 3
Z9 3
U1 4
U2 50
PU AMER INST MATHEMATICAL SCIENCES-AIMS
PI SPRINGFIELD
PA PO BOX 2604, SPRINGFIELD, MO 65801-2604, UNITED STATES
SN 1547-1063
EI 1551-0018
J9 MATH BIOSCI ENG
JI Math. Biosci. Eng.
PY 2021
VL 18
IS 5
BP 6926
EP 6940
DI 10.3934/mbe.2021344
PG 15
WC Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematical & Computational Biology
GA UF1NG
UT WOS:000688347400012
PM 34517564
OA gold
DA 2023-06-23
ER

PT J
AU Florez, KR
   Derose, KP
   Breslau, J
   Griffin, BA
   Haas, AC
   Kanouse, DE
   Stucky, BD
   Williams, MV
AF Florez, Karen R.
   Derose, Kathryn Pitkin
   Breslau, Joshua
   Griffin, Beth Ann
   Haas, Ann C.
   Kanouse, David E.
   Stucky, Brian D.
   Williams, Malcolm V.
TI Acculturation and Drug Use Stigma Among Latinos and African Americans:
   An Examination of a Church-Based Sample
SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH
LA English
DT Article
DE Drug addiction stigma; Acculturation; Church-based sample; Latinos;
   African Americans
ID SUBSTANCE USE; LINGUISTIC ACCULTURATION; GENDER-DIFFERENCES;
   UNITED-STATES; USE DISORDERS; HIV; HEALTH; RISK; ALCOHOL; ABUSE
AB Substance use patterns among Latinos likely reflect changes in attitudes resulting from acculturation, but little is known about Latinos' attitudes regarding drug addiction. We surveyed a church-based sample of Latinos and African Americans (N = 1,235) about attitudes toward drug addiction and socio-demographics. Linear regression models compared Latino subgroups with African-Americans. In adjusted models, Latinos had significantly higher drug addiction stigma scores compared to African Americans across all subgroups (US-born Latinos, beta = 0.22, p < .05; foreign-born Latinos with high English proficiency, beta = 0.30, p < .05; and foreign-born Latinos with low English proficiency, beta = 0.49, p < .001). Additionally, Latinos with low English proficiency had significantly higher mean levels of drug use stigma compared Latinos with high proficiency (both foreign-born and US-born). In this church-affiliated sample, Latinos' drug addiction stigma decreases with acculturation, but remains higher among the most acculturated Latinos compared to African-Americans. These attitudes may pose a barrier to treatment for Latino drug users.
C1 [Florez, Karen R.; Derose, Kathryn Pitkin; Kanouse, David E.; Stucky, Brian D.; Williams, Malcolm V.] RAND Corp, Hlth Program, Santa Monica, CA 90407 USA.
   [Breslau, Joshua; Haas, Ann C.] RAND Corp, Pittsburgh, PA USA.
   [Griffin, Beth Ann] RAND Corp, Arlington, VA USA.
C3 RAND Corporation; RAND Corporation; RAND Corporation
RP Florez, KR (通讯作者)，RAND Corp, Hlth Program, 1776 Main St, Santa Monica, CA 90407 USA.
EM kflorez@rand.org
RI Florez, Karen/AAG-4036-2021
OI Florez, Karen/0000-0002-5758-433X
FU Eunice Kennedy Shriver National Institute of Child Health and Human
   Development [1 R01 HD050150]
FX This study was supported by Grant 1 R01 HD050150 (Derose) from the
   Eunice Kennedy Shriver National Institute of Child Health and Human
   Development. Its contents are solely the responsibility of the authors
   and do not represent the official views of NICHD. The authors thank all
   FAITH Project participants; Laura Bogart for guidance in developing
   study instruments; Jennifer Hawes-Dawson, Frances Aunon, Alexandria
   Felton, and Blanca Dominguez for recruiting participants and collecting
   survey data.
CR Abraido-Lanza AF, 2006, AM J PUBLIC HEALTH, V96, P1342, DOI 10.2105/AJPH.2005.064980
   Adlaf EM, 2009, ADDICT BEHAV, V34, P360, DOI 10.1016/j.addbeh.2008.11.012
   AMARO H, 2003, NATL STRATEGIC PLAN
   Anstice S, 2009, SUBST USE MISUSE, V44, P794, DOI 10.1080/10826080802483936
   BABOR TF, 1986, ANN NY ACAD SCI, V472, P98, DOI 10.1111/j.1749-6632.1986.tb29613.x
   Basanez T, 2013, ETHNIC HEALTH, V18, P244, DOI 10.1080/13557858.2012.713093
   Blanco C, 2013, J PSYCHIATR RES, V47, P226, DOI 10.1016/j.jpsychires.2012.09.019
   Borges G, 2007, AM J PUBLIC HEALTH, V97, P1847, DOI 10.2105/AJPH.2006.097915
   Borges G, 2012, DRUG ALCOHOL DEPEN, V125, pS4, DOI 10.1016/j.drugalcdep.2012.05.007
   Borges G, 2011, DRUG ALCOHOL DEPEN, V117, P16, DOI 10.1016/j.drugalcdep.2010.12.022
   Briceno-Leon R, 2012, CURR SOCIOL, V50, P19
   Brocato J, 2013, J ETHN CRIM JUSTICE, V11, P150, DOI 10.1080/15377938.2012.756845
   Cabassa LJ, 2003, HISPANIC J BEHAV SCI, V25, P127, DOI 10.1177/0739986303025002001
   Cabriales JA, 2013, EXP CLIN PSYCHOPHARM, V21, P235, DOI 10.1037/a0031973
   Capitanio JP, 1999, AM BEHAV SCI, V42, P1148, DOI 10.1177/00027649921954813
   Center PR, 2014, SHIFT REL ID LAT US
   Center PR, 2009, REL PORTR AFR AM
   Cepeda A, 2012, DRUG ALCOHOL DEPEN, V125, pS12, DOI 10.1016/j.drugalcdep.2012.05.035
   CHAPPEL JN, 1985, J STUD ALCOHOL, V46, P48, DOI 10.15288/jsa.1985.46.48
   Chesney MA, 1999, AM BEHAV SCI, V42, P1162, DOI 10.1177/00027649921954822
   Conner KO, 2008, J SOC WORK PRACT ADD, V8, P244, DOI 10.1080/15332560802157065
   Conway KP, 2007, AM J PREV MED, V32, pS219, DOI 10.1016/j.amepre.2007.02.033
   Goffman E., 1963, STIGMA NOTES MANAGEM, P168
   Gonzalez-Guarda RM, 2012, ANN ANTHROPL PRACT, V36, P212, DOI 10.1111/napa.12001
   Herek GM, 1997, J APPL SOC PSYCHOL, V27, P1, DOI 10.1111/j.1559-1816.1997.tb00621.x
   Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118
   International Harm Reduction Association, 2014, LAT AM HARM RED PROG
   Jimenez Julio, 2011, Qual Res Psychol, V8, P26
   Lara M, 2005, ANNU REV PUBL HEALTH, V26, P367, DOI 10.1146/annurev.publhealth.26.021304.144615
   Lau JTF, 2007, AIDS CARE, V19, P1230, DOI 10.1080/09540120701402848
   Mall S, 2013, AIDS CARE, V25, P194, DOI 10.1080/09540121.2012.689810
   Marsiglia FF, 2005, AM J ORTHOPSYCHIAT, V75, P585, DOI 10.1037/0002-9432.75.4.585
   Marsiglia Flavio F, 2012, J Ethn Subst Abuse, V11, P226, DOI 10.1080/15332640.2012.701566
   Marsiglia Flavio F, 2010, J Ethn Subst Abuse, V9, P40, DOI 10.1080/15332640903539252
   McBride DC, 1996, RELIG BELIEF INITIAT
   Miller Jean Kearns, 2003, HEALING TRAUMA ATTAC, pxvii
   Mizuno Y, 2015, J IMMIGR MINOR HEALT, V17, P47, DOI 10.1007/s10903-013-9894-5
   Morris Stephen D., 2012, BROWN J WORLD AFFAIR, V18, P29
   Muthen L. K., 1998, MPLUS USERS GUIDE, V8th
   Nambiar D, 2012, AIDS CARE, V24, P1384, DOI 10.1080/09540121.2011.648597
   O'Connor K, 2015, J IMMIGR MINOR HEALT, V17, P198, DOI 10.1007/s10903-013-9859-8
   Ojeda VD, 2008, AM J PUBLIC HEALTH, V98, P862, DOI 10.2105/AJPH.2006.108142
   Pinedo M, 2014, J IMMIGR MINOR HEALT, V16, P348, DOI 10.1007/s10903-013-9964-8
   Reidpath DD, 2005, AIDS CARE, V17, P425, DOI 10.1080/09540120412331319769
   Rodriguez Rosemarie A, 2007, J Ethn Subst Abuse, V6, P97, DOI 10.1300/J233v06n02_07
   Ronzani Telmo Mota, 2009, Rev. Saúde Pública, V43, P51
   Ronzani TM, 2009, SOC SCI MED, V69, P1080, DOI 10.1016/j.socscimed.2009.07.026
   Rote SM, 2013, J ADDICT DIS, V32, P354, DOI 10.1080/10550887.2013.859452
   Saint-Jean Gilbert, 2011, J Int Assoc Physicians AIDS Care (Chic), V10, P326, DOI 10.1177/1545109711401749
   Saint-Jean G, 2008, J IMMIGR MINOR HEALT, V10, P187, DOI 10.1007/s10903-007-9060-z
   Simmonds L, 2009, INT J DRUG POLICY, V20, P121, DOI 10.1016/j.drugpo.2007.09.002
   Suarez-Orozco MM, 2000, DAEDALUS, V129, P1
   Substance Abuse and Mental Health Services Administration, 2014, SUBST EST SUBST US M
   SURO R, 2002, LATINO GROWTH METROP
   United Nations Office on Drugs and Crime, 2014, WORLD DRUG REP
   Varas-Diaz N, 2010, P R HEALTH SCI J, V29, P109
   Vasquez Elias Provencio, 2011, Issues Ment Health Nurs, V32, P90, DOI 10.3109/01612840.2010.528169
   Warner LA, 2006, DRUG ALCOHOL DEPEN, V84, pS8, DOI 10.1016/j.drugalcdep.2006.05.003
   Yang LH, 2007, SOC SCI MED, V64, P1524, DOI 10.1016/j.socscimed.2006.11.013
NR 59
TC 16
Z9 16
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1557-1912
EI 1557-1920
J9 J IMMIGR MINOR HEALT
JI J. Immigr. Minor. Health
PD DEC
PY 2015
VL 17
IS 6
SI SI
BP 1607
EP 1614
DI 10.1007/s10903-015-0161-9
PG 8
WC Public, Environmental & Occupational Health
WE Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA CV0YS
UT WOS:000363980500003
PM 25612923
OA Green Accepted
DA 2023-06-23
ER

EF